{"PMC4704671": [["Animal work was performed by certified staff in an Association for Assessment and Accreditation of Laboratory Animal Care\u2013approved facility.", [["Assessment", "TEST", 67, 77]]], ["Animal housing, care, and experimental protocols were in accordance with National Institutes of Health guidelines.Viruses ::: MATERIALS AND METHODSHeV, NiV strain Malaysia (NIV-M), and NiV strain Bangladesh (NiV-B) were kindly provided by the Special Pathogens Branch (Centers for Disease Control and Prevention, Atlanta, Georgia).", [["NiV-B", "CHEMICAL", 208, 213], ["NiV strain Malaysia", "ORGANISM", 152, 171], ["NiV strain Bangladesh", "ORGANISM", 185, 206], ["NiV-B", "ORGANISM", 208, 213], ["NiV strain Malaysia (NIV-M)", "SPECIES", 152, 179], ["NiV-B", "SPECIES", 208, 213], ["experimental protocols", "TREATMENT", 26, 48], ["Disease Control", "TREATMENT", 281, 296]]], ["The viruses were propagated on Vero cells (CCL-81; ATCC) as described previously [13].Monoclonal Antibodies and Escape Mutants ::: MATERIALS AND METHODSA panel of 6 HNV G\u2013specific mAbs were used in this study. mAbs against HNVs were generated as described previously [9, 14].", [["Vero cells", "ANATOMY", 31, 41], ["CCL-81", "ANATOMY", 43, 49], ["ATCC", "ANATOMY", 51, 55], ["Vero cells", "CELL", 31, 41], ["CCL-81; ATCC", "CELL", 43, 55], ["mAbs", "GENE_OR_GENE_PRODUCT", 210, 214], ["HNVs", "GENE_OR_GENE_PRODUCT", 223, 227], ["Vero cells", "CELL_LINE", 31, 41], ["Monoclonal Antibodies", "PROTEIN", 86, 107], ["HNV G\u2013specific mAbs", "PROTEIN", 165, 184], ["mAbs", "PROTEIN", 210, 214], ["HNVs", "PROTEIN", 223, 227], ["HNV", "SPECIES", 165, 168], ["The viruses", "PROBLEM", 0, 11], ["Vero cells", "TEST", 31, 41], ["CCL", "TEST", 43, 46], ["ATCC", "TEST", 51, 55], ["Monoclonal Antibodies", "TEST", 86, 107], ["METHODSA panel", "TEST", 145, 159], ["HNV G\u2013specific mAbs", "TREATMENT", 165, 184], ["this study", "TEST", 198, 208], ["HNVs", "PROBLEM", 223, 227], ["viruses", "OBSERVATION", 4, 11]]], ["Mouse mAbs nAH1.3 and 213 were generated against NiV-M, while mouse mAbs hAH14.2, hAH1.3, and hAH5.1 and human mAb m102.4 were generated against HeV.", [["Mouse", "ORGANISM", 0, 5], ["NiV", "ORGANISM", 49, 52], ["mouse", "ORGANISM", 62, 67], ["hAH14.2", "GENE_OR_GENE_PRODUCT", 73, 80], ["hAH1.3", "GENE_OR_GENE_PRODUCT", 82, 88], ["hAH5.1", "GENE_OR_GENE_PRODUCT", 94, 100], ["human", "ORGANISM", 105, 110], ["Mouse mAbs nAH1.3", "PROTEIN", 0, 17], ["mouse mAbs", "PROTEIN", 62, 72], ["hAH14.2", "PROTEIN", 73, 80], ["hAH1.3", "PROTEIN", 82, 88], ["hAH5.1", "PROTEIN", 94, 100], ["human mAb m102.4", "PROTEIN", 105, 121], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 62, 67], ["human", "SPECIES", 105, 110], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 62, 67], ["human", "SPECIES", 105, 110], ["HeV.", "SPECIES", 145, 149], ["Mouse mAbs", "TEST", 0, 10], ["human mAb m", "TEST", 105, 116]]], ["Neutralization-resistant NiV-M and HeV mutants were generated as described previously [12].Neutralization Assay ::: MATERIALS AND METHODSNeutralizing titers were determined by a plaque reduction neutralization titer (PRNT) assay.", [["plaque", "ANATOMY", 178, 184], ["NiV-M", "GENE_OR_GENE_PRODUCT", 25, 30], ["HeV", "ORGANISM", 35, 38], ["HeV", "SPECIES", 35, 38], ["Neutralization", "TEST", 0, 14], ["HeV mutants", "TREATMENT", 35, 46], ["Neutralization Assay", "TEST", 91, 111], ["METHODSNeutralizing titers", "TREATMENT", 130, 156], ["a plaque reduction neutralization titer", "TREATMENT", 176, 215], ["plaque", "OBSERVATION", 178, 184]]], ["For the PRNT, mAbs were serially diluted 2-fold and incubated with 100 plaque-forming units (PFU) of NiV-M, NiV-B, or HeV for 1 hour at 37\u00b0C. The virus and antibody mixture was then added to a 6-well plate with 5 \u00d7 105 Vero cells/well in triplicate.", [["cells", "ANATOMY", 224, 229], ["NiV-B", "CHEMICAL", 108, 113], ["mAbs", "GENE_OR_GENE_PRODUCT", 14, 18], ["NiV", "ORGANISM", 101, 104], ["NiV-B", "SIMPLE_CHEMICAL", 108, 113], ["HeV", "ORGANISM", 118, 121], ["Vero cells", "CELL", 219, 229], ["PRNT", "PROTEIN", 8, 12], ["mAbs", "PROTEIN", 14, 18], ["NiV", "PROTEIN", 108, 111], ["Vero cells", "CELL_LINE", 219, 229], ["the PRNT, mAbs", "TREATMENT", 4, 18], ["NiV", "TREATMENT", 101, 104], ["NiV", "TREATMENT", 108, 111], ["The virus and antibody mixture", "TREATMENT", 142, 172], ["a 6-well plate", "TREATMENT", 191, 205], ["virus", "OBSERVATION", 146, 151]]], ["After incubation for 1 hour at 37\u00b0C, cells were overlaid with 3 mL of 0.8% agarose in medium.", [["cells", "ANATOMY", 37, 42], ["cells", "CELL", 37, 42], ["agarose", "SIMPLE_CHEMICAL", 75, 82], ["0.8% agarose in medium", "TREATMENT", 70, 92]]], ["Plates were incubated for 3 days at 37\u00b0C and stained with crystal violet in 10% formalin, and plaques were counted.", [["plaques", "ANATOMY", 94, 101], ["formalin", "CHEMICAL", 80, 88], ["formalin", "CHEMICAL", 80, 88], ["C", "SIMPLE_CHEMICAL", 39, 40], ["formalin", "SIMPLE_CHEMICAL", 80, 88], ["plaques", "PATHOLOGICAL_FORMATION", 94, 101], ["crystal violet", "TEST", 58, 72], ["plaques", "PROBLEM", 94, 101], ["crystal", "OBSERVATION_MODIFIER", 58, 65], ["violet", "OBSERVATION_MODIFIER", 66, 72], ["plaques", "OBSERVATION", 94, 101]]], ["The percentage of neutralization was calculated as [1 \u2212 (number of plaques with antibody/number of plaques without antibody)] \u00d7 100.", [["plaques", "ANATOMY", 67, 74], ["plaques", "ANATOMY", 99, 106], ["plaques", "PATHOLOGICAL_FORMATION", 67, 74], ["antibody", "PROTEIN", 80, 88], ["plaques", "PROBLEM", 67, 74], ["antibody", "TEST", 80, 88], ["plaques", "PROBLEM", 99, 106], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["neutralization", "OBSERVATION", 18, 32], ["plaques", "OBSERVATION", 67, 74]]], ["All assays were performed in triplicate.Structural Mapping of Neutralization-Escape Mutations ::: MATERIALS AND METHODSThe crystal structure coordinates of the HeV and NiV-M attachment proteins G interacting with their receptor the human Ephrin B2 (PDB code 2VSK and 2VSM2, respectively) were used to determine the locations of amino acid residues associated with neutralization escape [15].", [["amino acid", "CHEMICAL", 328, 338], ["amino acid", "CHEMICAL", 328, 338], ["HeV", "ORGANISM", 160, 163], ["NiV-M attachment proteins G", "GENE_OR_GENE_PRODUCT", 168, 195], ["human", "ORGANISM", 232, 237], ["Ephrin B2", "GENE_OR_GENE_PRODUCT", 238, 247], ["PDB code 2VSK", "GENE_OR_GENE_PRODUCT", 249, 262], ["2VSM2", "GENE_OR_GENE_PRODUCT", 267, 272], ["amino acid", "AMINO_ACID", 328, 338], ["HeV and NiV-M attachment proteins G", "PROTEIN", 160, 195], ["human Ephrin B2", "PROTEIN", 232, 247], ["PDB code 2VSK", "PROTEIN", 249, 262], ["2VSM2", "PROTEIN", 267, 272], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["All assays", "TEST", 0, 10], ["their receptor the human Ephrin B2 (PDB code 2VSK", "TREATMENT", 213, 262], ["amino acid residues", "TREATMENT", 328, 347], ["neutralization escape", "PROBLEM", 364, 385], ["Neutralization", "OBSERVATION", 62, 76], ["Escape Mutations", "OBSERVATION", 77, 93], ["HeV", "OBSERVATION", 160, 163], ["amino acid", "OBSERVATION", 328, 338], ["neutralization escape", "OBSERVATION", 364, 385]]], ["All molecular representations were produced with PyMOL (Delano Scientific).Virus Growth Curves ::: MATERIALS AND METHODSGrowth curves were performed by inoculating Vero cell cultures with NiV-M, HeV, and their escape mutants at a low multiplicity of infection (MOI) of 0.01 for 1 hour, after which the cells were washed 3 times with phosphate-buffered saline and overlaid with medium.", [["Vero cell cultures", "ANATOMY", 164, 182], ["cells", "ANATOMY", 302, 307], ["low multiplicity of infection", "DISEASE", 230, 259], ["phosphate", "CHEMICAL", 333, 342], ["phosphate", "CHEMICAL", 333, 342], ["Vero cell cultures", "CELL", 164, 182], ["NiV-M", "GENE_OR_GENE_PRODUCT", 188, 193], ["HeV", "ORGANISM", 195, 198], ["cells", "CELL", 302, 307], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 333, 358], ["Vero cell cultures", "CELL_LINE", 164, 182], ["METHODSGrowth curves", "TEST", 113, 133], ["inoculating Vero cell cultures", "TEST", 152, 182], ["HeV", "TREATMENT", 195, 198], ["their escape mutants", "PROBLEM", 204, 224], ["infection", "PROBLEM", 250, 259], ["phosphate-buffered saline", "TREATMENT", 333, 358], ["low multiplicity", "OBSERVATION_MODIFIER", 230, 246], ["infection", "OBSERVATION", 250, 259]]], ["Virus samples were obtained at various time points after infection and stored at \u221280\u00b0C until viral titers were determined by a 50% tissue infective culture dose (TCID50) assay, as previously described [16].Animal Studies ::: MATERIALS AND METHODSFemale Syrian golden hamsters (Mesocricetus auratus; 6-week-old HsdHan:AURA hamsters from Harlan Laboratories) were inoculated with 105 TCID50 of HeV, NiV-M, or their respective neutralization-escape mutants in a 100-\u00b5L volume via the intraperitoneal route and were monitored as described previously [16].", [["samples", "ANATOMY", 6, 13], ["tissue", "ANATOMY", 131, 137], ["intraperitoneal", "ANATOMY", 481, 496], ["infection", "DISEASE", 57, 66], ["Virus", "ORGANISM", 0, 5], ["C", "GENE_OR_GENE_PRODUCT", 85, 86], ["tissue", "TISSUE", 131, 137], ["Syrian golden hamsters", "ORGANISM", 253, 275], ["Mesocricetus auratus", "ORGANISM", 277, 297], ["Hsd", "ORGANISM", 310, 313], ["Han", "ORGANISM", 313, 316], ["AURA hamsters", "ORGANISM", 317, 330], ["Harlan Laboratories", "ORGANISM", 336, 355], ["HeV", "ORGANISM", 392, 395], ["NiV", "ORGANISM", 397, 400], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 481, 496], ["Syrian golden hamsters", "SPECIES", 253, 275], ["Mesocricetus auratus", "SPECIES", 277, 297], ["hamsters", "SPECIES", 322, 330], ["Syrian golden hamsters", "SPECIES", 253, 275], ["Mesocricetus auratus", "SPECIES", 277, 297], ["HeV", "SPECIES", 392, 395], ["Virus samples", "TEST", 0, 13], ["infection", "PROBLEM", 57, 66], ["viral titers", "TEST", 93, 105], ["NiV", "TREATMENT", 397, 400], ["escape mutants", "PROBLEM", 439, 453], ["neutralization", "OBSERVATION", 424, 438], ["intraperitoneal", "ANATOMY", 481, 496]]], ["For the pathogenesis study, groups of 5 animals were euthanized on day 3 after infection or when moribund, and whole-blood samples (collected in Vacutainer tubes containing ethylenediaminetetraacetic acid), as well as spleen, kidney, lung, and brain, were removed for virus isolation.", [["whole-blood samples", "ANATOMY", 111, 130], ["spleen", "ANATOMY", 218, 224], ["kidney", "ANATOMY", 226, 232], ["lung", "ANATOMY", 234, 238], ["brain", "ANATOMY", 244, 249], ["infection", "DISEASE", 79, 88], ["ethylenediaminetetraacetic acid", "CHEMICAL", 173, 204], ["ethylenediaminetetraacetic acid", "CHEMICAL", 173, 204], ["animals", "ORGANISM", 40, 47], ["blood samples", "ORGANISM_SUBSTANCE", 117, 130], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 173, 204], ["spleen", "ORGAN", 218, 224], ["kidney", "ORGAN", 226, 232], ["lung", "ORGAN", 234, 238], ["brain", "ORGAN", 244, 249], ["the pathogenesis study", "TEST", 4, 26], ["infection", "PROBLEM", 79, 88], ["moribund", "PROBLEM", 97, 105], ["whole-blood samples", "TEST", 111, 130], ["Vacutainer tubes", "TREATMENT", 145, 161], ["ethylenediaminetetraacetic acid", "TREATMENT", 173, 204], ["virus isolation", "TREATMENT", 268, 283], ["spleen", "ANATOMY", 218, 224], ["kidney", "ANATOMY", 226, 232], ["lung", "ANATOMY", 234, 238], ["brain", "ANATOMY", 244, 249]]], ["Virus titration of tissue samples was performed as described previously [16].Identification of Amino Acids That Are Critical for HNV Neutralization ::: RESULTSmAbs hAH14.2 and hAH1.3 were used for selection of neutralization-escape mutants of HeV, mAbs nAH1.3, hAH5.1 and 213 were used for selection of neutralization-escape mutants of NiV-M, and mAb m102.4 was previously used to generate a neutralization-escape mutant of both HeV and NiV-M [12].Identification of Amino Acids That Are Critical for HNV Neutralization ::: RESULTSFive of 7 escape mutants contained a single amino acid change in G, while escape mutants generated by using mAbs hAH5.1 and 213 resulted in 2 amino acid changes each in G (Supplemental Table 1).", [["tissue samples", "ANATOMY", 19, 33], ["hAH1.3", "CHEMICAL", 176, 182], ["amino acid", "CHEMICAL", 574, 584], ["amino acid", "CHEMICAL", 672, 682], ["Amino Acids", "CHEMICAL", 95, 106], ["Amino Acids", "CHEMICAL", 466, 477], ["amino acid", "CHEMICAL", 574, 584], ["amino acid", "CHEMICAL", 672, 682], ["Virus", "ORGANISM", 0, 5], ["tissue samples", "CANCER", 19, 33], ["Amino Acids", "SIMPLE_CHEMICAL", 95, 106], ["hAH1.3", "SIMPLE_CHEMICAL", 176, 182], ["HeV", "ORGANISM", 243, 246], ["NiV", "ORGANISM", 336, 339], ["mAb m102.4", "SIMPLE_CHEMICAL", 347, 357], ["HeV", "ORGANISM", 429, 432], ["NiV", "ORGANISM", 437, 440], ["amino acid", "AMINO_ACID", 574, 584], ["amino acid", "AMINO_ACID", 672, 682], ["hAH1.3", "PROTEIN", 176, 182], ["mAbs nAH1.3", "PROTEIN", 248, 259], ["hAH5.1", "PROTEIN", 261, 267], ["NiV", "PROTEIN", 336, 339], ["mAb m102.4", "PROTEIN", 347, 357], ["mAbs hAH5.1", "PROTEIN", 638, 649], ["HeV", "SPECIES", 243, 246], ["HeV", "SPECIES", 429, 432], ["tissue samples", "TEST", 19, 33], ["Amino Acids", "TREATMENT", 95, 106], ["RESULTSmAbs", "TEST", 152, 163], ["neutralization", "TEST", 210, 224], ["HeV", "TEST", 243, 246], ["mAbs", "TEST", 248, 252], ["neutralization", "TEST", 303, 317], ["mAb m", "TEST", 347, 352], ["a neutralization", "TEST", 390, 406], ["Amino Acids", "TREATMENT", 466, 477], ["a single amino acid change in G", "TREATMENT", 565, 596], ["mAbs hAH5.1", "TEST", 638, 649], ["2 amino acid changes each in G (Supplemental Table", "TREATMENT", 670, 720], ["Amino Acids", "OBSERVATION", 95, 106], ["Amino Acids", "OBSERVATION", 466, 477]]], ["We previously showed that the m102.4 escape mutants resulted in an amino acid change in NiV-M G at position V507I and in HeV G at position D582N [12].", [["amino acid", "CHEMICAL", 67, 77], ["amino acid", "CHEMICAL", 67, 77], ["m102.4", "GENE_OR_GENE_PRODUCT", 30, 36], ["amino acid", "AMINO_ACID", 67, 77], ["NiV-M G", "GENE_OR_GENE_PRODUCT", 88, 95], ["V507I", "AMINO_ACID", 108, 113], ["HeV G", "GENE_OR_GENE_PRODUCT", 121, 126], ["NiV-M G", "PROTEIN", 88, 95], ["position V507I", "PROTEIN", 99, 113], ["an amino acid change", "TREATMENT", 64, 84], ["NiV", "TREATMENT", 88, 91], ["amino acid", "OBSERVATION", 67, 77]]], ["The nAH1.3 escape mutant contained a single amino acid change at position Q450K in NiV-M G. Interestingly, both mAb hAH5.1 and 213 neutralization-escape mutants contained an amino acid change at position N159D.", [["amino acid", "CHEMICAL", 44, 54], ["hAH5.1", "CHEMICAL", 116, 122], ["amino acid", "CHEMICAL", 174, 184], ["amino acid", "CHEMICAL", 44, 54], ["amino acid", "CHEMICAL", 174, 184], ["nAH1.3", "GENE_OR_GENE_PRODUCT", 4, 10], ["amino acid", "AMINO_ACID", 44, 54], ["mAb", "GENE_OR_GENE_PRODUCT", 112, 115], ["amino acid", "AMINO_ACID", 174, 184], ["nAH1.3 escape mutant", "PROTEIN", 4, 24], ["position Q450K", "PROTEIN", 65, 79], ["mAb hAH5.1", "PROTEIN", 112, 122], ["position N159D", "PROTEIN", 195, 209], ["The nAH1.3 escape mutant", "PROBLEM", 0, 24], ["a single amino acid change", "TREATMENT", 35, 61], ["escape mutants", "TREATMENT", 146, 160], ["an amino acid change", "TREATMENT", 171, 191], ["amino acid", "OBSERVATION", 174, 184]]], ["In addition to this N159D change, the hAH5.1 neutralization-escape mutant contained a mutation at position R516K, whereas the mAb 213 mutant contained a mutation at Q388R.", [["hAH5.1", "GENE_OR_GENE_PRODUCT", 38, 44], ["N159D", "DNA", 20, 25], ["hAH5.1", "PROTEIN", 38, 44], ["position R516K", "PROTEIN", 98, 112], ["mAb 213 mutant", "PROTEIN", 126, 140], ["Q388R", "PROTEIN", 165, 170], ["this N159D change", "TREATMENT", 15, 32], ["the hAH5.1 neutralization", "TREATMENT", 34, 59], ["escape mutant", "PROBLEM", 60, 73], ["the mAb", "TEST", 122, 129], ["a mutation", "PROBLEM", 151, 161]]], ["In HeV G, an amino acid change was present at position H406Y in the hAH14.2 escape mutant.", [["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["HeV G", "GENE_OR_GENE_PRODUCT", 3, 8], ["amino acid", "AMINO_ACID", 13, 23], ["H406Y", "AMINO_ACID", 55, 60], ["hAH14.2", "GENE_OR_GENE_PRODUCT", 68, 75], ["position H406Y", "PROTEIN", 46, 60], ["hAH14.2 escape mutant", "PROTEIN", 68, 89], ["HeV", "SPECIES", 3, 6], ["HeV G", "TREATMENT", 3, 8], ["an amino acid change", "TREATMENT", 10, 30]]], ["Finally, generation of neutralization-escape mutants by using the mAb hAH1.3 resulted in an amino acid change at position S134F in HeV G.Cross-neutralization of Escape Mutants ::: RESULTSUnfortunately, hybridomas producing mAbs hAH5.1 and hAH14.2 used in generating escape mutants were lost owing to a technical failure during storage.", [["hAH1.3", "CHEMICAL", 70, 76], ["amino acid", "CHEMICAL", 92, 102], ["hAH5.1", "CHEMICAL", 228, 234], ["hAH14.2", "CHEMICAL", 239, 246], ["amino acid", "CHEMICAL", 92, 102], ["mAb", "GENE_OR_GENE_PRODUCT", 66, 69], ["amino acid", "AMINO_ACID", 92, 102], ["hybridomas", "CELL", 202, 212], ["hAH5.1", "GENE_OR_GENE_PRODUCT", 228, 234], ["mAb hAH1.3", "PROTEIN", 66, 76], ["position S134F", "PROTEIN", 113, 127], ["mAbs hAH5.1", "PROTEIN", 223, 234], ["hAH14.2", "PROTEIN", 239, 246], ["the mAb", "TREATMENT", 62, 69], ["an amino acid change", "TREATMENT", 89, 109], ["hybridomas", "PROBLEM", 202, 212], ["hAH14.2", "PROBLEM", 239, 246], ["a technical failure", "PROBLEM", 300, 319], ["amino acid", "OBSERVATION", 92, 102], ["failure", "OBSERVATION", 312, 319]]], ["Thus, all further analyses were performed with mAbs m102.4, nAH1.3, 213, and hAH1.3.Cross-neutralization of Escape Mutants ::: RESULTSFirst, the neutralizing antibody titers for each of the mAbs against HeV, NiV-M, and NiV-B were determined (Figure 1). mAbs m102.4 and nAH1.3 were able to neutralize HeV and both NiV-M and NiV-B efficiently (Figure 1A and 1B). mAb 213 neutralized NiV-M but not NiV-B or HeV (Figure 1C). mAb hAH1.3 efficiently neutralized HeV but none of the 2 NiV strains (Figure 1D).", [["hAH1.3", "CHEMICAL", 425, 431], ["mAbs m102.4", "GENE_OR_GENE_PRODUCT", 47, 58], ["nAH1.3", "GENE_OR_GENE_PRODUCT", 60, 66], ["hAH1", "GENE_OR_GENE_PRODUCT", 77, 81], ["HeV", "ORGANISM", 203, 206], ["NiV-M", "GENE_OR_GENE_PRODUCT", 208, 213], ["NiV-B", "GENE_OR_GENE_PRODUCT", 219, 224], ["nAH1.3", "GENE_OR_GENE_PRODUCT", 269, 275], ["HeV", "ORGANISM", 300, 303], ["NiV-B", "GENE_OR_GENE_PRODUCT", 323, 328], ["NiV-M", "GENE_OR_GENE_PRODUCT", 381, 386], ["NiV-B", "GENE_OR_GENE_PRODUCT", 395, 400], ["HeV", "ORGANISM", 404, 407], ["mAb", "GENE_OR_GENE_PRODUCT", 421, 424], ["NiV", "ORGANISM", 478, 481], ["mAbs", "PROTEIN", 47, 51], ["hAH1", "PROTEIN", 77, 81], ["mAbs", "PROTEIN", 190, 194], ["NiV", "PROTEIN", 208, 211], ["NiV", "PROTEIN", 219, 222], ["nAH1.3", "PROTEIN", 269, 275], ["NiV-B", "PROTEIN", 323, 328], ["mAb 213", "PROTEIN", 361, 368], ["NiV", "PROTEIN", 395, 398], ["B", "PROTEIN", 399, 400], ["mAb hAH1.3", "PROTEIN", 421, 431], ["HeV", "SPECIES", 203, 206], ["NiV-B", "SPECIES", 219, 224], ["HeV", "SPECIES", 300, 303], ["HeV", "SPECIES", 456, 459], ["all further analyses", "TEST", 6, 26], ["mAbs m", "TEST", 47, 53], ["nAH1.3", "TEST", 60, 66], ["hAH1", "TEST", 77, 81], ["the neutralizing antibody titers", "TEST", 141, 173], ["the mAbs", "TEST", 186, 194], ["HeV", "TEST", 203, 206], ["NiV", "TREATMENT", 208, 211], ["NiV", "TREATMENT", 219, 222], ["mAbs m", "TEST", 253, 259], ["NiV", "TREATMENT", 323, 326], ["mAb", "TEST", 361, 364], ["NiV", "TREATMENT", 395, 398], ["the 2 NiV strains", "TREATMENT", 472, 489]]]], "731b26ceffb7b60b94ca8ded21a774e46b2e8eca": [["Standard proteomics techniques are unable to describe the stoichiometry, subunit interactions and organisation of assemblies since many are heterogeneous, present at low cellular abundance and frequently difficult to isolate.", [["cellular", "ANATOMY", 170, 178], ["cellular", "CELL", 170, 178], ["Standard proteomics techniques", "TREATMENT", 0, 30], ["heterogeneous", "OBSERVATION_MODIFIER", 140, 153], ["low cellular", "OBSERVATION_MODIFIER", 166, 178]]], ["We have combined two existing methodologies to tackle these challenges: tandem affinity purification (TAP) and nanoflow ESI-MS.", [["TAP", "PROTEIN", 102, 105], ["tandem affinity purification", "TREATMENT", 72, 100]]], ["We use methods designed to maintain non-covalent complexes within the mass spectrometer to provide definitive evidence of interacting subunits based on the masses of complexes and subcomplexes generated by perturbation both in solution and gas phases.", [["non-covalent complexes", "PROTEIN", 36, 58], ["interacting subunits", "PROTEIN", 122, 142], ["subcomplexes", "PROTEIN", 180, 192], ["methods", "TREATMENT", 7, 14], ["the mass spectrometer", "TREATMENT", 66, 87], ["interacting subunits", "PROBLEM", 122, 142], ["masses", "OBSERVATION", 156, 162]]], ["Structural models will be presented for three oligomeric protein complexes of unknown structure: the yeast exosome and the human U1snRNP and eIF3 complexes.", [["exosome", "ANATOMY", 107, 114], ["human", "ORGANISM", 123, 128], ["U1snRNP", "GENE_OR_GENE_PRODUCT", 129, 136], ["eIF3", "GENE_OR_GENE_PRODUCT", 141, 145], ["oligomeric protein complexes", "PROTEIN", 46, 74], ["yeast exosome", "PROTEIN", 101, 114], ["human U1snRNP and eIF3 complexes", "PROTEIN", 123, 155], ["yeast", "SPECIES", 101, 106], ["human", "SPECIES", 123, 128], ["yeast", "SPECIES", 101, 106], ["human", "SPECIES", 123, 128], ["three oligomeric protein complexes", "TEST", 40, 74], ["the yeast exosome", "PROBLEM", 97, 114], ["eIF3 complexes", "TREATMENT", 141, 155], ["yeast exosome", "OBSERVATION", 101, 114], ["eIF3 complexes", "OBSERVATION", 141, 155]]], ["Recent developments in mass spectrometry have added a further dimension to our studies of protein complexes: that of their collision cross-section.", [["protein complexes", "PROTEIN", 90, 107], ["Recent developments in mass spectrometry", "PROBLEM", 0, 40], ["mass", "OBSERVATION", 23, 27]]], ["Using ion mobility mass spectrometry we have been able to add spatial restraints to our models validating our models with measurements of collision cross-sections.", [["ion mobility mass spectrometry", "TREATMENT", 6, 36], ["spatial restraints", "TREATMENT", 62, 80]]], ["Very recently we have had a considerable breakthrough which has enabled us to preserve intact membrane complexes in the gas phase .", [["membrane", "ANATOMY", 94, 102], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["membrane complexes", "PROTEIN", 94, 112], ["a considerable breakthrough", "PROBLEM", 26, 53], ["intact membrane complexes", "OBSERVATION", 87, 112], ["gas phase", "OBSERVATION", 120, 129]]], ["This enables us to establish lipid and nucleotide binding and to define the stoichiometry and post translational modifications within the intact transmembrane regions of a number of complexes.O-3In vivo molecular sensing: fluorescence beyond labeling F. Beltram Scuola Normale Superiore, I-56126 Pisa, Italy Fluorescent molecules are powerful reporter tools that have much extended the impact of optical microscopy, particularly thanks to the flexibility of genetically encoded tags.", [["transmembrane", "ANATOMY", 145, 158], ["nucleotide", "CHEMICAL", 39, 49], ["nucleotide", "CHEMICAL", 39, 49], ["O-3In", "CHEMICAL", 192, 197], ["lipid", "SIMPLE_CHEMICAL", 29, 34], ["nucleotide", "SIMPLE_CHEMICAL", 39, 49], ["transmembrane", "CELLULAR_COMPONENT", 145, 158], ["O-3In", "SIMPLE_CHEMICAL", 192, 197], ["transmembrane regions", "PROTEIN", 145, 166], ["genetically encoded tags", "DNA", 458, 482], ["lipid and nucleotide binding", "PROBLEM", 29, 57], ["the stoichiometry", "PROBLEM", 72, 89], ["post translational modifications", "PROBLEM", 94, 126], ["optical microscopy", "TEST", 396, 414], ["post translational modifications", "OBSERVATION", 94, 126]]], ["Detection can now target single molecules even in the complex environment of intact live cells offering unprecedented insight on biological processes in real time in live cells and tissues.", [["cells", "ANATOMY", 89, 94], ["cells", "ANATOMY", 171, 176], ["tissues", "ANATOMY", 181, 188], ["cells", "CELL", 89, 94], ["cells", "CELL", 171, 176], ["tissues", "TISSUE", 181, 188], ["intact live cells", "CELL_TYPE", 77, 94], ["live cells", "CELL_TYPE", 166, 176], ["tissues", "ANATOMY", 181, 188]]], ["Fluorescent labels, however, can do more that this.", [["Fluorescent labels", "TEST", 0, 18]]], ["Our increased ability to tailor molecule and, more in general, nanosystem properties allows us to design, produce and exploit intelligent tags that can actually analyze the cellular environment.", [["cellular", "ANATOMY", 173, 181], ["cellular", "CELL", 173, 181], ["intelligent tags", "PROBLEM", 126, 142]]], ["Importantly these nanosystems can target specific subcellular domains and have the ability to be used also in the case of live organisms.", [["subcellular", "ANATOMY", 50, 61], ["subcellular domains", "PROTEIN", 50, 69], ["live organisms", "PROBLEM", 122, 136]]], ["Recent results will be discussed that highlight the impact of nanobiotechnology in this context with a particular emphasis given to methods suitable for in vivo studies that can be transferred to the biomedical world.O-2Far-field optical nanoscopy S. W. Hell Max Planck Institute, G\u00f6ttingen, GermanyO-2The resolution of a far-field optical microscope is usually limited to d = \u03bb/ (2 n sin \u03b1) > 200 nm, with n sin \u03b1 denoting the numerical aperture of the lens and \u03bb the wavelength of light.", [["lens", "ANATOMY", 454, 458], ["wavelength", "OBSERVATION_MODIFIER", 469, 479]]], ["We will discuss lens-based fluorescence microscopy concepts that feature a resolving power on the nanoscale.", [["lens-based fluorescence microscopy", "TEST", 16, 50]]], ["All these concepts share a common basis: exploiting selected (pairs of) states and transitions of the fluorescent marker to neutralize the limiting role of diffraction.", [["the fluorescent marker", "TREATMENT", 98, 120]]], ["Specifically, the fluorophore is switched on and off, that is, between a bright and a dark state, to detect the emission of adjacent features sequentially in time.", [["the fluorophore", "TREATMENT", 14, 29]]], ["The first viable concept of this kind was Stimulated Emission Depletion (STED) microscopy in which the fluorescence ability of the dye is switched off by stimulated emission.", [["Stimulated Emission Depletion", "TREATMENT", 42, 71], ["microscopy", "TEST", 79, 89], ["the dye", "TREATMENT", 127, 134]]], ["In the STED microscope, the extent of the region in which the molecule is able to fluoresce follows d \u2248 \u03bb/ 2 n sin \u03b1 1 + I/I s , meaning that fluorophores that are further away than d can be separated.", [["meaning that fluorophores", "PROBLEM", 129, 154], ["region", "ANATOMY_MODIFIER", 42, 48]]], ["I is the intensity that drives a fluorophore from the bright fluorescent state to the dark ground state by stimulated emission.", [["a fluorophore", "PROBLEM", 31, 44]]], ["For I/I s \u2192 \u221e, it follows that d \u2192 0, meaning that the resolution can be molecular).", [["\u221e", "PROTEIN", 12, 13]]], ["Since it has already been a key to answering important questions in biology, and owing to its simplicity and commercial availability, we expect far-field fluorescence 'nanoscopes' to enter most cell biology and many nanoscience laboratories in the near future.O-2Grabbing the cat by the tail: Discrete steps by a DNA packaging motor and the inter-subunit coordination in a ring-ATPase C. Bustamante, J. Moffitt University of California, Berkeley, California, U.S.A.O-2As part of their infection cycle, many viruses must package their newly replicated genomes inside a protein capsid.", [["cell", "ANATOMY", 194, 198], ["O-2Grabbing", "CHEMICAL", 260, 271], ["infection", "DISEASE", 485, 494], ["O-2Grabbing", "CHEMICAL", 260, 271], ["cell", "CELL", 194, 198], ["cat", "ORGANISM", 276, 279], ["DNA", "CELLULAR_COMPONENT", 313, 316], ["protein capsid", "PROTEIN", 568, 582], ["a DNA packaging", "TREATMENT", 311, 326], ["their infection cycle", "PROBLEM", 479, 500], ["many viruses", "PROBLEM", 502, 514], ["infection", "OBSERVATION", 485, 494], ["protein capsid", "OBSERVATION", 568, 582]]], ["Bacteriophage \u03d529 packages its 6.6 mm long double-stranded DNA into a 42 nm dia. x 54 nm high capsid using a multimeric ring motor that belongs to the ASCE (Additional Strand, Conserved E) superfamily of ATPases.", [["DNA", "CELLULAR_COMPONENT", 59, 62], ["Bacteriophage \u03d529", "DNA", 0, 17], ["6.6 mm long double-stranded DNA", "DNA", 31, 62], ["multimeric ring motor", "PROTEIN", 109, 130], ["ASCE (Additional Strand, Conserved E) superfamily", "PROTEIN", 151, 200], ["ATPases", "PROTEIN", 204, 211], ["Bacteriophage", "TEST", 0, 13], ["long double-stranded DNA", "TREATMENT", 38, 62], ["a multimeric ring motor", "TREATMENT", 107, 130], ["6.6 mm", "OBSERVATION_MODIFIER", 31, 37], ["42 nm", "OBSERVATION_MODIFIER", 70, 75]]], ["A number of fundamental questions remain as to the coordination of the various subunits in these multimeric rings.", [["these multimeric rings", "TREATMENT", 91, 113], ["multimeric rings", "OBSERVATION", 97, 113]]], ["The portal motor in bacteriophage phi29 is ideal to investigate these questions and is a remarkable machine that must overcome entropic, electrostatic, and DNA bending energies to package its genome to near-crystalline density inside the capsid.", [["portal", "MULTI-TISSUE_STRUCTURE", 4, 10], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["capsid", "CELLULAR_COMPONENT", 238, 244], ["bacteriophage phi29", "PROTEIN", 20, 39], ["bacteriophage phi29", "TREATMENT", 20, 39], ["DNA bending energies", "TREATMENT", 156, 176], ["portal motor", "ANATOMY", 4, 16], ["crystalline density", "OBSERVATION", 207, 226], ["capsid", "ANATOMY_MODIFIER", 238, 244]]], ["Interestingly, the packaging rate decreases as the prohead fills, indicating that an internal pressure builds up due to DNA compression attaining the value of \u223c6 MegaPascals at the end of the packaging.", [["DNA", "CELLULAR_COMPONENT", 120, 123], ["the packaging rate", "TEST", 15, 33], ["an internal pressure", "TEST", 82, 102], ["DNA compression", "PROBLEM", 120, 135], ["the packaging", "TREATMENT", 188, 201], ["rate", "OBSERVATION_MODIFIER", 29, 33], ["decreases", "OBSERVATION_MODIFIER", 34, 43], ["internal pressure", "OBSERVATION", 85, 102], ["compression", "OBSERVATION", 124, 135]]], ["We show that the chemical energy of ATP is converted into mechanical work during phosphate release.", [["ATP", "CHEMICAL", 36, 39], ["phosphate", "CHEMICAL", 81, 90], ["ATP", "CHEMICAL", 36, 39], ["phosphate", "CHEMICAL", 81, 90], ["ATP", "SIMPLE_CHEMICAL", 36, 39], ["phosphate", "SIMPLE_CHEMICAL", 81, 90], ["mechanical work during phosphate release", "TREATMENT", 58, 98]]], ["Using ultra-high resolution optical tweezers, we determined the step size of the motor and established the coordination of the polymerases around the ring.", [["ring", "ANATOMY", 150, 154], ["polymerases", "PROTEIN", 127, 138], ["size", "OBSERVATION_MODIFIER", 69, 73], ["ring", "ANATOMY_MODIFIER", 150, 154]]], ["We propose a comprehensive model of the operation of this motor.O-7Watching proteins function in real time via timeresolved X-ray diffraction and solution scattering P. A. Anfinrud Laboratory of Chemical Physics/NIDDK, NIH, Bethesda, Maryland, U.S.A.O-7To generate a deeper understanding into the relations between protein structure, dynamics, and function, we have developed X-ray methods capable of probing changes in protein structure on time scales as short as 150 ps.", [["O-7Watching", "GENE_OR_GENE_PRODUCT", 64, 75], ["O-7Watching proteins", "PROTEIN", 64, 84], ["the operation", "TREATMENT", 36, 49], ["probing changes in protein structure", "PROBLEM", 401, 437]]], ["In studies of ligand-binding heme proteins, a picosecond laser pulse first photolyzes CO from the heme, then a suitably delayed picosecond X-ray pulse passes through the protein and the scattered X-rays are imaged on a 2D detector.", [["CO", "CHEMICAL", 86, 88], ["heme", "CHEMICAL", 98, 102], ["CO", "SIMPLE_CHEMICAL", 86, 88], ["heme", "SIMPLE_CHEMICAL", 98, 102], ["ligand-binding heme proteins", "PROTEIN", 14, 42], ["CO", "PROTEIN", 86, 88], ["heme", "PROTEIN", 98, 102], ["scattered X-rays", "DNA", 186, 202], ["a picosecond laser pulse", "TREATMENT", 44, 68], ["a suitably delayed picosecond X-ray pulse", "TEST", 109, 150], ["the protein", "TEST", 166, 177], ["a 2D detector", "TEST", 217, 230], ["heme", "ANATOMY", 98, 102], ["scattered", "OBSERVATION_MODIFIER", 186, 195]]], ["When the sample is a protein crystal, this \"pump-probe\" approach recovers time-resolved diffraction \"snapshots\" whose corresponding electron density maps can be stitched together into movies that unveil the correlated protein motions that accompany and/or mediate ligand migration within the hydrophobic interior of the protein.", [["electron", "SIMPLE_CHEMICAL", 132, 140], ["a protein crystal", "PROBLEM", 19, 36], ["this \"pump", "TREATMENT", 38, 48]]], ["When the sample is a protein solution, we recover timeresolved small-and wide-angle X-ray scattering patterns that are sensitive to changes in the size, shape, and structure of the protein.", [["a protein solution", "TREATMENT", 19, 37], ["small", "OBSERVATION_MODIFIER", 63, 68], ["size", "OBSERVATION_MODIFIER", 147, 151], ["shape", "OBSERVATION_MODIFIER", 153, 158]]], ["Scattering studies of proteins in solution unveil structural dynamics without the constraints imposed by crystal contacts; thus, these scattering \"fingerprints\" complement results obtained from diffraction studies.", [["Scattering studies", "TEST", 0, 18], ["these scattering \"fingerprints", "TEST", 129, 159], ["diffraction studies", "TEST", 194, 213]]], ["This research was supported in part by the Intramural Research Program of the NIH, NIDDK DC-SIGN is a trans-membrane protein expressed on antigen presenting cells and recognizes pathogens like HIV-1, Hepatitis C virus and Ebola.", [["membrane", "ANATOMY", 108, 116], ["antigen presenting cells", "ANATOMY", 138, 162], ["Hepatitis C virus", "DISEASE", 200, 217], ["Ebola", "DISEASE", 222, 227], ["cells", "CELL", 157, 162], ["HIV-1", "ORGANISM", 193, 198], ["Hepatitis C virus", "ORGANISM", 200, 217], ["Ebola", "ORGANISM", 222, 227], ["SIGN", "DNA", 92, 96], ["trans-membrane protein", "PROTEIN", 102, 124], ["antigen presenting cells", "CELL_TYPE", 138, 162], ["HIV-1", "SPECIES", 193, 198], ["Hepatitis C virus", "SPECIES", 200, 217], ["HIV-1", "SPECIES", 193, 198], ["Hepatitis C virus", "SPECIES", 200, 217], ["HIV", "TEST", 193, 196], ["Hepatitis C virus", "PROBLEM", 200, 217], ["Ebola", "PROBLEM", 222, 227]]], ["By electron microscopy and near-field optical nanoscopy, we demonstrated that at the plasma membrane DC-SIGN is organized in well-defined nanodomains of 100-180 nm in diameter.", [["plasma membrane DC", "ANATOMY", 85, 103], ["plasma membrane", "CELLULAR_COMPONENT", 85, 100], ["DC", "CELL_TYPE", 101, 103], ["SIGN", "PROTEIN", 104, 108], ["electron microscopy", "TEST", 3, 22], ["near-field optical nanoscopy", "TEST", 27, 55], ["the plasma membrane DC", "TEST", 81, 103], ["diameter", "OBSERVATION_MODIFIER", 167, 175]]], ["Intensity-size correlation analysis revealed remarkable heterogeneity in the nanodomains molecular packing density.", [["Intensity-size correlation analysis", "TEST", 0, 35], ["remarkable heterogeneity in the nanodomains molecular packing density", "PROBLEM", 45, 114], ["size", "OBSERVATION_MODIFIER", 10, 14], ["remarkable", "OBSERVATION_MODIFIER", 45, 55], ["heterogeneity", "OBSERVATION", 56, 69], ["nanodomains", "OBSERVATION_MODIFIER", 77, 88], ["molecular", "OBSERVATION_MODIFIER", 89, 98], ["packing density", "OBSERVATION", 99, 114]]], ["We constructed and characterized several DC-SIGN mutated forms lacking specific molecular domains.", [["DC", "ANATOMY", 41, 43], ["DC", "CELL_TYPE", 41, 43], ["molecular domains", "PROTEIN", 80, 97]]], ["By immunogold labeling and spatial point pattern analysis, we show that the extracellular neck domain is essential for DC-SIGN nanoclustering.", [["extracellular neck domain", "ANATOMY", 76, 101], ["DC", "ANATOMY", 119, 121], ["SIGN", "GENE_OR_GENE_PRODUCT", 122, 126], ["extracellular neck domain", "PROTEIN", 76, 101], ["DC", "CELL_TYPE", 119, 121], ["SIGN", "PROTEIN", 122, 126], ["immunogold labeling", "TEST", 3, 22], ["spatial point pattern analysis", "TEST", 27, 57], ["the extracellular neck domain", "PROBLEM", 72, 101], ["neck", "ANATOMY", 90, 94]]], ["Finally, we present a model that describes the probability of a cell to have a certain number of receptors joining the contact site in the initial encounter with an external object.", [["cell", "ANATOMY", 64, 68], ["cell", "CELL", 64, 68], ["receptors", "PROTEIN", 97, 106], ["a cell", "PROBLEM", 62, 68], ["external object", "OBSERVATION", 165, 180]]], ["Monte Carlo simulations subsequently define the parameters that are determinant in the object-cell encounter.", [["object-cell", "ANATOMY", 87, 98], ["cell", "CELL", 94, 98], ["Monte Carlo simulations", "TEST", 0, 23]]], ["Our results show that receptor nanoclustering is of particular importance for binding objects of sizes comparable to the nanocluster size, indicating that the nanoscale spatial organization of DC-SIGN is optimized for binding to virus-sized objects.P-11Imaging of mobile stable lipid rafts in the live cell plasma membrane M. Brameshuber 1 , J. Weghuber 1 , V. Ruprecht 1 , H. Stockinger 2 , G. J. Schuetz 1 1 Johannes Kepler University Linz, Austria, 2 Medical University of Vienna, AustriaP-11The organization of the cellular plasma membrane at a nanoscopic length scale is believed to affect the association of distinct sets of membrane proteins for the regulation of multiple signaling pathways.", [["DC", "ANATOMY", 193, 195], ["lipid rafts", "ANATOMY", 278, 289], ["cell plasma membrane", "ANATOMY", 302, 322], ["cellular plasma membrane", "ANATOMY", 519, 543], ["membrane", "ANATOMY", 631, 639], ["cell", "CELL", 302, 306], ["cellular", "CELLULAR_COMPONENT", 519, 527], ["plasma membrane", "CELLULAR_COMPONENT", 528, 543], ["membrane", "CELLULAR_COMPONENT", 631, 639], ["DC", "CELL_TYPE", 193, 195], ["SIGN", "PROTEIN", 196, 200], ["P", "DNA", 249, 250], ["membrane proteins", "PROTEIN", 631, 648], ["binding objects of sizes", "PROBLEM", 78, 102], ["mobile stable lipid rafts", "TREATMENT", 264, 289], ["AustriaP", "TEST", 484, 492], ["a nanoscopic length scale", "TEST", 547, 572], ["membrane proteins", "TREATMENT", 631, 648], ["sizes", "OBSERVATION_MODIFIER", 97, 102], ["nanocluster size", "OBSERVATION_MODIFIER", 121, 137], ["sized", "OBSERVATION_MODIFIER", 235, 240], ["objects", "OBSERVATION", 241, 248], ["lipid rafts", "OBSERVATION", 278, 289], ["cellular plasma membrane", "OBSERVATION", 519, 543]]], ["Based on in vitro results, conflicting models have been proposed which postulate the existence of stable or highly dynamic platforms of membrane lipids and proteins.", [["membrane", "ANATOMY", 136, 144], ["membrane lipids", "CELLULAR_COMPONENT", 136, 151], ["membrane lipids", "TREATMENT", 136, 151], ["stable", "OBSERVATION_MODIFIER", 98, 104]]], ["Here we directly imaged and further characterized lipid rafts in the plasma membrane of living CHO cells by single molecule TIRF microscopy.", [["lipid rafts", "ANATOMY", 50, 61], ["plasma membrane", "ANATOMY", 69, 84], ["CHO cells", "ANATOMY", 95, 104], ["lipid rafts", "CELLULAR_COMPONENT", 50, 61], ["plasma membrane", "CELLULAR_COMPONENT", 69, 84], ["CHO cells", "CELL", 95, 104], ["CHO cells", "CELL_LINE", 95, 104], ["single molecule TIRF microscopy", "TEST", 108, 139], ["lipid rafts", "OBSERVATION", 50, 61]]], ["Using a novel recording scheme for \"Thinning Out Clusters while Conserving Stoichiometry of Labeling\" 1 , molecular homo-association of GPI-anchored mGFP was detected at 37 \u2022 C and ascribed to specific enrichment in lipid platforms.", [["GPI-anchored mGFP", "SIMPLE_CHEMICAL", 136, 153], ["GPI", "PROTEIN", 136, 139], ["mGFP", "PROTEIN", 149, 153], ["a novel recording scheme", "TREATMENT", 6, 30], ["Thinning Out Clusters", "PROBLEM", 36, 57], ["GPI", "PROBLEM", 136, 139]]], ["The mobile mGFP-GPI homo-associates were found to be stable on a seconds timescale and dissolved after cholesterol depletion.", [["cholesterol", "CHEMICAL", 103, 114], ["cholesterol", "CHEMICAL", 103, 114], ["mGFP-GPI", "GENE_OR_GENE_PRODUCT", 11, 19], ["cholesterol", "SIMPLE_CHEMICAL", 103, 114], ["mobile mGFP-GPI homo-associates", "PROTEIN", 4, 35], ["The mobile mGFP", "TEST", 0, 15], ["cholesterol depletion", "PROBLEM", 103, 124], ["stable", "OBSERVATION_MODIFIER", 53, 59], ["cholesterol depletion", "OBSERVATION", 103, 124]]], ["Having confirmed the association of mGFP-GPI to stable membrane rafts, we attempted to use an externally applied marker to test this hypothesis.", [["membrane rafts", "ANATOMY", 55, 69], ["mGFP-GPI", "GENE_OR_GENE_PRODUCT", 36, 44], ["membrane rafts", "CELLULAR_COMPONENT", 55, 69], ["mGFP", "PROTEIN", 36, 40], ["GPI", "PROTEIN", 41, 44], ["mGFP", "TEST", 36, 40], ["an externally applied marker", "TREATMENT", 91, 119], ["stable", "OBSERVATION_MODIFIER", 48, 54], ["membrane rafts", "OBSERVATION", 55, 69]]], ["We used Bodipy-GM1, a probe that was recently reported to be enriched in the liquid-ordered phase of plasma membrane vesicles.", [["plasma membrane vesicles", "ANATOMY", 101, 125], ["Bodipy-GM1", "GENE_OR_GENE_PRODUCT", 8, 18], ["plasma", "CELLULAR_COMPONENT", 101, 107], ["membrane vesicles", "CELLULAR_COMPONENT", 108, 125], ["Bodipy", "DNA", 8, 14], ["GM1", "DNA", 15, 18], ["Bodipy-GM1", "TREATMENT", 8, 18], ["a probe", "TREATMENT", 20, 27], ["plasma membrane vesicles", "TREATMENT", 101, 125], ["membrane vesicles", "OBSERVATION", 108, 125]]], ["When applied to CHO cells at different surface staining, we found that also Bodipy-GM1 homo-associated in a cholesterol-dependent manner, thus providing further evidence for the existence of membrane rafts.", [["CHO cells", "ANATOMY", 16, 25], ["surface", "ANATOMY", 39, 46], ["membrane rafts", "ANATOMY", 191, 205], ["cholesterol", "CHEMICAL", 108, 119], ["cholesterol", "CHEMICAL", 108, 119], ["CHO cells", "CELL", 16, 25], ["Bodipy-GM1", "GENE_OR_GENE_PRODUCT", 76, 86], ["cholesterol", "SIMPLE_CHEMICAL", 108, 119], ["membrane rafts", "CELLULAR_COMPONENT", 191, 205], ["CHO cells", "CELL_LINE", 16, 25], ["CHO cells", "TREATMENT", 16, 25], ["Bodipy", "TEST", 76, 82], ["GM1 homo", "TEST", 83, 91], ["membrane rafts", "PROBLEM", 191, 205], ["membrane rafts", "OBSERVATION", 191, 205]]], ["[1] Appl Phys Lett 87, 263903 (2005) .O-10Synapsin Knock-Out mice as an in vitro model of human epilepsy studied with Multi-Electrode Arrays D. F. Boido, P. Farisello, P. Baldelli, F. Benfenati Department of Neuroscience and Brain Technologies, Italian Institute of Technology, Genova, Italy Mutant mice lacking synapsins (Syn), a family of synaptic vesicles (SV) proteins implicated in the regulation of neurotransmitter release and synapse formation, are epileptic.", [["synaptic vesicles", "ANATOMY", 341, 358], ["synapse", "ANATOMY", 434, 441], ["epilepsy", "DISEASE", 96, 104], ["epileptic", "DISEASE", 457, 466], ["mice", "ORGANISM", 61, 65], ["human", "ORGANISM", 90, 95], ["mice", "ORGANISM", 299, 303], ["synapsins", "GENE_OR_GENE_PRODUCT", 312, 321], ["Syn", "GENE_OR_GENE_PRODUCT", 323, 326], ["synaptic vesicles (SV) proteins", "GENE_OR_GENE_PRODUCT", 341, 372], ["synapse", "CELLULAR_COMPONENT", 434, 441], ["synapsins", "PROTEIN", 312, 321], ["Syn", "PROTEIN", 323, 326], ["synaptic vesicles (SV) proteins", "PROTEIN", 341, 372], ["mice", "SPECIES", 61, 65], ["human", "SPECIES", 90, 95], ["mice", "SPECIES", 299, 303], ["human", "SPECIES", 90, 95], ["mice", "SPECIES", 299, 303], ["human epilepsy", "PROBLEM", 90, 104], ["Genova", "TREATMENT", 278, 284], ["neurotransmitter release", "TREATMENT", 405, 429], ["epileptic", "PROBLEM", 457, 466], ["Brain", "ANATOMY", 225, 230]]], ["Several mutations of Syn genes have been found in families of patients with epilepsy.", [["epilepsy", "DISEASE", 76, 84], ["Syn", "GENE_OR_GENE_PRODUCT", 21, 24], ["patients", "ORGANISM", 62, 70], ["Syn genes", "DNA", 21, 30], ["patients", "SPECIES", 62, 70], ["Several mutations of Syn genes", "PROBLEM", 0, 30], ["epilepsy", "PROBLEM", 76, 84], ["epilepsy", "OBSERVATION", 76, 84]]], ["We used Micro-Electrode Arrays (MEAs) to study spontaneous and chemically evoked epileptiform activities in cortico-hippocampal brain slices obtained from wild-type (WT) and SynKO mice.", [["epileptiform", "ANATOMY", 81, 93], ["cortico-hippocampal brain slices", "ANATOMY", 108, 140], ["cortico-hippocampal brain slices", "MULTI-TISSUE_STRUCTURE", 108, 140], ["SynKO mice", "ORGANISM", 174, 184], ["mice", "SPECIES", 180, 184], ["mice", "SPECIES", 180, 184], ["Micro-Electrode Arrays (MEAs", "TREATMENT", 8, 36], ["spontaneous and chemically evoked epileptiform activities", "PROBLEM", 47, 104], ["epileptiform activities", "OBSERVATION", 81, 104], ["hippocampal brain", "ANATOMY", 116, 133]]], ["6-months old SynKO mice show sporadic ictal (IC) events in the entorhinal cortex.", [["entorhinal cortex", "ANATOMY", 63, 80], ["SynKO", "ORGANISM", 13, 18], ["mice", "ORGANISM", 19, 23], ["entorhinal cortex", "MULTI-TISSUE_STRUCTURE", 63, 80], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["sporadic ictal (IC) events in the entorhinal cortex", "PROBLEM", 29, 80], ["entorhinal cortex", "ANATOMY", 63, 80]]], ["A potassium channel blocker, 4aminopyridine (4AP), elicits IC and inter-ictal (I-IC) events in both WT and SynKO slices.", [["SynKO slices", "ANATOMY", 107, 119], ["potassium", "CHEMICAL", 2, 11], ["4aminopyridine", "CHEMICAL", 29, 43], ["4AP", "CHEMICAL", 45, 48], ["potassium", "CHEMICAL", 2, 11], ["4aminopyridine", "CHEMICAL", 29, 43], ["4AP", "CHEMICAL", 45, 48], ["potassium channel blocker", "SIMPLE_CHEMICAL", 2, 27], ["4aminopyridine", "SIMPLE_CHEMICAL", 29, 43], ["4AP", "SIMPLE_CHEMICAL", 45, 48], ["A potassium channel blocker", "TREATMENT", 0, 27], ["4aminopyridine (4AP)", "TREATMENT", 29, 49], ["IC and inter-ictal (I-IC)", "TREATMENT", 59, 84]]], ["In the hippocampus of young SynKO (15-days old) mice, 4AP induces I-IC events at higher frequencies than in WT mice.", [["hippocampus", "ANATOMY", 7, 18], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 7, 18], ["SynKO", "GENE_OR_GENE_PRODUCT", 28, 33], ["mice", "ORGANISM", 48, 52], ["4AP", "GENE_OR_GENE_PRODUCT", 54, 57], ["I-IC", "GENE_OR_GENE_PRODUCT", 66, 70], ["WT mice", "ORGANISM", 108, 115], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 111, 115], ["hippocampus", "ANATOMY", 7, 18]]], ["Also the frequency of IC events, mainly observed in the cortex, is higher in SynKO.", [["cortex", "ANATOMY", 56, 62], ["cortex", "CANCER", 56, 62], ["SynKO", "GENE_OR_GENE_PRODUCT", 77, 82], ["IC events", "PROBLEM", 22, 31], ["cortex", "ANATOMY_MODIFIER", 56, 62], ["higher", "OBSERVATION_MODIFIER", 67, 73]]], ["The analysis of adult (1-year old) mice, revealed a clear age-related aggravation, which paralleled the increase in the severity of the epileptic phenotype observed in vivo.", [["epileptic", "DISEASE", 136, 145], ["mice", "ORGANISM", 35, 39], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["The analysis", "TEST", 0, 12], ["related aggravation", "PROBLEM", 62, 81], ["the epileptic phenotype", "PROBLEM", 132, 155], ["aggravation", "OBSERVATION", 70, 81], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["epileptic phenotype", "OBSERVATION", 136, 155]]], ["Many slices from adult SynKO mice showed an IC event, while WT slices were refractory at this age to experience IC activity.", [["slices", "ANATOMY", 5, 11], ["slices", "ANATOMY", 63, 69], ["slices", "MULTI-TISSUE_STRUCTURE", 5, 11], ["SynKO mice", "ORGANISM", 23, 33], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["an IC event", "PROBLEM", 41, 52], ["WT slices", "PROBLEM", 60, 69]]], ["SynKO mice are useful to study how neuronal network hyperexcitabilty due to mutations in SV proteins leads to the development of epileptiform activity.", [["neuronal network", "ANATOMY", 35, 51], ["epileptiform", "ANATOMY", 129, 141], ["hyperexcitabilty", "DISEASE", 52, 68], ["SynKO mice", "ORGANISM", 0, 10], ["neuronal network", "MULTI-TISSUE_STRUCTURE", 35, 51], ["SV proteins", "GENE_OR_GENE_PRODUCT", 89, 100], ["epileptiform", "CANCER", 129, 141], ["SV proteins", "PROTEIN", 89, 100], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["mutations in SV proteins", "PROBLEM", 76, 100], ["epileptiform activity", "PROBLEM", 129, 150], ["epileptiform activity", "OBSERVATION", 129, 150]]], ["MEAs proved themselves to be useful tools to characterize the epileptic signals foci and patterns of propagation.O-10High Electron Mobility Transistor (HEMT) structures were used to bridge the gap between the analysis of biological reactions and biophysical characterization.", [["foci", "ANATOMY", 80, 84], ["epileptic", "DISEASE", 62, 71], ["O-10High", "CHEMICAL", 113, 121], ["the epileptic signals foci", "PROBLEM", 58, 84], ["Electron Mobility Transistor (HEMT) structures", "TREATMENT", 122, 168], ["the analysis", "TEST", 205, 217], ["biological reactions", "TREATMENT", 221, 241], ["biophysical characterization", "TEST", 246, 274], ["epileptic", "OBSERVATION", 62, 71], ["foci", "OBSERVATION", 80, 84], ["propagation", "OBSERVATION_MODIFIER", 101, 112]]], ["The combination of nanotechnological measurement approaches with biological reactions provides new possibilities for living cell examinations after exposure to ionizing radiation and basically during the irradiation experiments itself.", [["cell", "ANATOMY", 124, 128], ["cell", "CELL", 124, 128], ["nanotechnological measurement approaches", "TREATMENT", 19, 59], ["biological reactions", "PROBLEM", 65, 85], ["living cell examinations", "TEST", 117, 141], ["ionizing radiation", "TREATMENT", 160, 178], ["the irradiation experiments", "TREATMENT", 200, 227]]], ["In this transdisciplinary approach experimental data and handling of biological material enables the identification and specification of systems properties of biological responses to ionizing radiation at different hierarchical levels.", [["ionizing radiation", "TREATMENT", 183, 201]]], ["GaN/AlGaN-heterostructures form a HEMT with a gate very sensitive to pH-value changes and potential changes in general.", [["GaN", "CHEMICAL", 0, 3], ["GaN", "CHEMICAL", 0, 3], ["pH", "TEST", 69, 71], ["value changes", "PROBLEM", 72, 85]]], ["To record cell membrane potentials and ion fluxes during and after irradiation experiments living cells are cultivated on the functionalised biocompatible chip surface.", [["cell membrane", "ANATOMY", 10, 23], ["cells", "ANATOMY", 98, 103], ["surface", "ANATOMY", 160, 167], ["cell", "CELL", 10, 14], ["cells", "CELL", 98, 103], ["record cell membrane potentials", "TEST", 3, 34], ["ion fluxes", "PROBLEM", 39, 49], ["irradiation experiments living cells", "TREATMENT", 67, 103], ["the functionalised biocompatible chip surface", "TREATMENT", 122, 167], ["cell membrane potentials", "OBSERVATION", 10, 34], ["ion fluxes", "OBSERVATION", 39, 49]]], ["Here, we present results of X-ray stimulated cell responses grown on GaN-chip surfaces.", [["cell", "ANATOMY", 45, 49], ["GaN-", "CHEMICAL", 69, 73], ["cell", "CELL", 45, 49], ["X-ray stimulated cell responses", "TEST", 28, 59]]], ["We recorded transistor signal changes of 0.13 \u00b5A within 60 s caused by an irradiated cell monolayer.", [["cell monolayer", "ANATOMY", 85, 99], ["cell monolayer", "CELL", 85, 99], ["irradiated cell monolayer", "CELL_LINE", 74, 99], ["transistor signal changes", "TEST", 12, 37], ["an irradiated cell monolayer", "PROBLEM", 71, 99], ["irradiated cell monolayer", "OBSERVATION", 74, 99]]], ["To measure cell potentials, not only after irradiation experiments but also during the irradiation itself expands the examination restrictions in an enormous way.P-15Measuring diffusion by spatial-cross-correlation E. Gratton, M. A. Digman Laboratory for Fluorescence Dynamics, University of California, Irvine, U.S.A.P-15Fluorescence correlation spectroscopy (FCS) has emerged as a very powerful method to study the motions of proteins both in the interior and exterior of the cell.", [["cell", "ANATOMY", 11, 15], ["cell", "ANATOMY", 478, 482], ["cell", "CELL", 11, 15], ["cell", "CELL", 478, 482], ["P", "DNA", 162, 163], ["irradiation experiments", "TREATMENT", 43, 66], ["the irradiation", "TREATMENT", 83, 98], ["the examination", "TEST", 114, 129], ["U.S.A.P", "TEST", 312, 319], ["cell potentials", "OBSERVATION", 11, 26], ["interior", "ANATOMY_MODIFIER", 449, 457], ["exterior", "ANATOMY_MODIFIER", 462, 470], ["cell", "ANATOMY", 478, 482]]], ["Single particle tracking (SPT) is also a highly sensitive technique to measure particle movement.", [["particle", "OBSERVATION_MODIFIER", 7, 15], ["particle movement", "OBSERVATION", 79, 96]]], ["However, the FCS method suffers in spatial resolution while the SPT technique only allows for the tracking of isolated molecules.", [["the FCS method", "TEST", 9, 23], ["the SPT technique", "TEST", 60, 77], ["isolated molecules", "PROBLEM", 110, 128], ["spatial", "OBSERVATION_MODIFIER", 35, 42], ["resolution", "OBSERVATION_MODIFIER", 43, 53], ["isolated molecules", "OBSERVATION", 110, 128]]], ["Here we propose a change of paradigm in which using spatial pair cross-correlation functions we can overcome this limitation.", [["a change of paradigm", "TREATMENT", 16, 36]]], ["Therefore we can trace the average path of the particles.", [["average", "OBSERVATION_MODIFIER", 27, 34], ["particles", "OBSERVATION_MODIFIER", 47, 56]]], ["For example, our method could be used to detect when a protein passes the nuclear barrier and the location of the passage.P-15This information cannot be obtained with the FRAP (fluorescence recovery after photobleaching) technique or the image correlation spectroscopy method.O-14The interaction of the Bax C-terminal domain with membranes J. C. Gomez-Fernandez, S. Sanchez-Bautista, A. Perez-Lara, S. Corbalan-Garc\u00eda Departamento de Bioquimica y Biologia Molecular.", [["nuclear", "ANATOMY", 74, 81], ["C", "CHEMICAL", 307, 308], ["Bax", "GENE_OR_GENE_PRODUCT", 303, 306], ["P", "DNA", 122, 123], ["Bax C-terminal domain", "PROTEIN", 303, 324], ["the FRAP", "TEST", 167, 175], ["the image correlation spectroscopy method", "TEST", 234, 275], ["Gomez", "TEST", 346, 351], ["Sanchez", "TEST", 366, 373], ["Perez", "TEST", 387, 392], ["Corbalan", "TEST", 402, 410]]], ["Universidad de Murcia, Murcia, SpainO-14The C-terminal domain of the pro-apoptotic protein Bax (Bax-C) acts as a membrane anchor during the translocation to the membrane of this protein leading to programmed cell death.", [["membrane", "ANATOMY", 113, 121], ["membrane", "ANATOMY", 161, 169], ["cell", "ANATOMY", 208, 212], ["death", "DISEASE", 213, 218], ["Bax", "GENE_OR_GENE_PRODUCT", 91, 94], ["Bax-C", "GENE_OR_GENE_PRODUCT", 96, 101], ["membrane", "CELLULAR_COMPONENT", 113, 121], ["membrane", "CELLULAR_COMPONENT", 161, 169], ["cell", "CELL", 208, 212], ["C-terminal domain", "PROTEIN", 44, 61], ["pro-apoptotic protein Bax (Bax-C", "PROTEIN", 69, 101], ["membrane anchor", "PROTEIN", 113, 128], ["SpainO", "TEST", 31, 37], ["the pro-apoptotic protein Bax", "TREATMENT", 65, 94], ["a membrane anchor", "TREATMENT", 111, 128], ["this protein", "PROBLEM", 173, 185], ["programmed cell death", "PROBLEM", 197, 218], ["programmed cell death", "OBSERVATION", 197, 218]]], ["We have used static and MAS-NMR techniques to show that the interaction of Bax-C with membranes is modulated by the presence of a negatively charged phosphatidylglycerol.", [["membranes", "ANATOMY", 86, 95], ["phosphatidylglycerol", "CHEMICAL", 149, 169], ["phosphatidylglycerol", "CHEMICAL", 149, 169], ["Bax-C", "GENE_OR_GENE_PRODUCT", 75, 80], ["membranes", "CELLULAR_COMPONENT", 86, 95], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 149, 169], ["Bax", "PROTEIN", 75, 78], ["static and MAS-NMR techniques", "TEST", 13, 42], ["membranes", "TREATMENT", 86, 95], ["a negatively charged phosphatidylglycerol", "TREATMENT", 128, 169]]], ["The width of the resonance peaks were considerably more increased by Bax-C, in the presence of phosphatidylglycerol.", [["phosphatidylglycerol", "CHEMICAL", 95, 115], ["phosphatidylglycerol", "CHEMICAL", 95, 115], ["Bax-C", "SIMPLE_CHEMICAL", 69, 74], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 95, 115], ["Bax", "PROTEIN", 69, 72], ["the resonance peaks", "TEST", 13, 32], ["phosphatidylglycerol", "TREATMENT", 95, 115], ["width", "OBSERVATION_MODIFIER", 4, 9], ["increased", "OBSERVATION_MODIFIER", 56, 65]]], ["Bax-C substantially decreased the T 1 relaxation times of phosphatidylglycerol and those of phosphatidylcholine when mixtured with phosphatidylglycerol but they were not decreased when phosphatidylcholine was the only phospholipid present in the membrane.", [["membrane", "ANATOMY", 246, 254], ["phosphatidylglycerol", "CHEMICAL", 58, 78], ["phosphatidylcholine", "CHEMICAL", 92, 111], ["phosphatidylglycerol", "CHEMICAL", 131, 151], ["phosphatidylcholine", "CHEMICAL", 185, 204], ["phosphatidylglycerol", "CHEMICAL", 58, 78], ["phosphatidylcholine", "CHEMICAL", 92, 111], ["phosphatidylglycerol", "CHEMICAL", 131, 151], ["phosphatidylcholine", "CHEMICAL", 185, 204], ["Bax-C", "SIMPLE_CHEMICAL", 0, 5], ["T 1", "GENE_OR_GENE_PRODUCT", 34, 37], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 58, 78], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 92, 111], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 131, 151], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 185, 204], ["phospholipid", "SIMPLE_CHEMICAL", 218, 230], ["membrane", "CELLULAR_COMPONENT", 246, 254], ["Bax", "PROTEIN", 0, 3], ["Bax", "TEST", 0, 3], ["the T 1 relaxation", "TREATMENT", 30, 48], ["phosphatidylglycerol", "TREATMENT", 58, 78], ["phosphatidylcholine", "TREATMENT", 92, 111], ["phosphatidylglycerol", "TREATMENT", 131, 151], ["phosphatidylcholine", "TREATMENT", 185, 204], ["substantially", "OBSERVATION_MODIFIER", 6, 19], ["decreased", "OBSERVATION_MODIFIER", 20, 29]]], ["13 C-MAS-NMR showed that T 1 values were decreased when Bax-C was incorporated and, when phosphatidylglycerol was also present, the decrease in T 1 affected considerably more to some carbons in the polar region.", [["phosphatidylglycerol", "CHEMICAL", 89, 109], ["phosphatidylglycerol", "CHEMICAL", 89, 109], ["carbons", "CHEMICAL", 183, 190], ["T 1", "GENE_OR_GENE_PRODUCT", 25, 28], ["Bax-C", "SIMPLE_CHEMICAL", 56, 61], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 89, 109], ["T 1", "GENE_OR_GENE_PRODUCT", 144, 147], ["carbons", "SIMPLE_CHEMICAL", 183, 190], ["Bax", "PROTEIN", 56, 59], ["NMR", "TEST", 9, 12], ["T 1 values", "TEST", 25, 35], ["Bax", "TEST", 56, 59], ["phosphatidylglycerol", "TEST", 89, 109], ["decrease", "OBSERVATION_MODIFIER", 132, 140], ["polar", "ANATOMY_MODIFIER", 198, 203], ["region", "ANATOMY_MODIFIER", 204, 210]]], ["These results indicate that Bax-C interacts differently with the polar part of the membrane depending on whether phosphatidylglycerol is present or not, suggesting that an electrostatic interaction of Bax-C with the membrane determines the membrane disposition of this domain.", [["membrane", "ANATOMY", 83, 91], ["membrane", "ANATOMY", 216, 224], ["membrane", "ANATOMY", 240, 248], ["phosphatidylglycerol", "CHEMICAL", 113, 133], ["phosphatidylglycerol", "CHEMICAL", 113, 133], ["Bax-C", "GENE_OR_GENE_PRODUCT", 28, 33], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 113, 133], ["Bax-C", "GENE_OR_GENE_PRODUCT", 201, 206], ["membrane", "CELLULAR_COMPONENT", 216, 224], ["membrane", "CELLULAR_COMPONENT", 240, 248], ["Bax-C", "PROTEIN", 28, 33], ["Bax-C", "PROTEIN", 201, 206], ["Bax-C interacts", "PROBLEM", 28, 43], ["phosphatidylglycerol", "PROBLEM", 113, 133], ["an electrostatic interaction of Bax", "PROBLEM", 169, 204], ["the membrane", "TREATMENT", 212, 224], ["polar", "ANATOMY_MODIFIER", 65, 70], ["electrostatic", "OBSERVATION", 172, 185]]], ["Fluorescence spectroscopy showed that the Trp residues of Bax-C were located in a microenvironment more hydrophobic when phosphatidylglycerol was present.Specificity of a HIV fusion inhibitor towards phosphatidylcholine gel phase membranesH.", [["Trp", "CHEMICAL", 42, 45], ["phosphatidylglycerol", "CHEMICAL", 121, 141], ["phosphatidylcholine gel", "CHEMICAL", 200, 223], ["Trp", "CHEMICAL", 42, 45], ["phosphatidylglycerol", "CHEMICAL", 121, 141], ["phosphatidylcholine", "CHEMICAL", 200, 219], ["Bax-C", "GENE_OR_GENE_PRODUCT", 58, 63], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 121, 141], ["HIV", "ORGANISM", 171, 174], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 200, 219], ["Bax", "PROTEIN", 58, 61], ["C", "PROTEIN", 62, 63], ["HIV", "SPECIES", 171, 174], ["Fluorescence spectroscopy", "TEST", 0, 25], ["the Trp residues of Bax", "PROBLEM", 38, 61], ["phosphatidylglycerol", "TREATMENT", 121, 141], ["a HIV fusion inhibitor", "TREATMENT", 169, 191], ["phosphatidylcholine gel phase membranesH", "TREATMENT", 200, 240]]], ["Coimbra, PortugalSpecificity of a HIV fusion inhibitor towards phosphatidylcholine gel phase membranesSince the efficacy of HIV fusion inhibitors was previously reported to be related to an ability to interact with membranes, we studied the interaction of the HIV fusion inhibitor sifuvirtide, a 36 aa negatively charged peptide, with lipid vesicles.", [["membranes", "ANATOMY", 215, 224], ["lipid vesicles", "ANATOMY", 335, 349], ["phosphatidylcholine gel", "CHEMICAL", 63, 86], ["sifuvirtide", "CHEMICAL", 281, 292], ["phosphatidylcholine", "CHEMICAL", 63, 82], ["sifuvirtide", "CHEMICAL", 281, 292], ["HIV", "ORGANISM", 34, 37], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 63, 82], ["HIV", "ORGANISM", 124, 127], ["membranes", "CELLULAR_COMPONENT", 215, 224], ["HIV", "ORGANISM", 260, 263], ["sifuvirtide", "SIMPLE_CHEMICAL", 281, 292], ["lipid vesicles", "CELLULAR_COMPONENT", 335, 349], ["HIV", "SPECIES", 34, 37], ["HIV", "SPECIES", 124, 127], ["HIV", "SPECIES", 260, 263], ["Coimbra", "TREATMENT", 0, 7], ["a HIV fusion inhibitor", "TREATMENT", 32, 54], ["phosphatidylcholine gel phase membranes", "TREATMENT", 63, 102], ["HIV fusion inhibitors", "TREATMENT", 124, 145], ["the HIV fusion inhibitor sifuvirtide", "TREATMENT", 256, 292], ["lipid vesicles", "PROBLEM", 335, 349], ["HIV fusion", "OBSERVATION", 124, 134], ["lipid vesicles", "OBSERVATION", 335, 349]]], ["Since this peptide has aromatic residues, fluorescence spectroscopy techniques were used with no need for attached probes.", [["aromatic residues", "PROBLEM", 23, 40], ["fluorescence spectroscopy techniques", "TEST", 42, 78], ["attached probes", "TREATMENT", 106, 121], ["aromatic residues", "OBSERVATION", 23, 40]]], ["Results showed no significant interaction with both zwitterionic fluid phase and cholesterol-enriched membranes; however extensive partition to fluid phase cationic membranes were observed.", [["membranes", "ANATOMY", 102, 111], ["fluid phase cationic membranes", "ANATOMY", 144, 174], ["cholesterol", "CHEMICAL", 81, 92], ["cholesterol", "CHEMICAL", 81, 92], ["cholesterol", "SIMPLE_CHEMICAL", 81, 92], ["membranes", "CELLULAR_COMPONENT", 102, 111], ["membranes", "CELLULAR_COMPONENT", 165, 174], ["significant interaction", "PROBLEM", 18, 41], ["both zwitterionic fluid phase", "TEST", 47, 76], ["extensive partition to fluid phase cationic membranes", "TREATMENT", 121, 174], ["no", "UNCERTAINTY", 15, 17], ["fluid phase", "OBSERVATION", 65, 76], ["enriched membranes", "OBSERVATION", 93, 111]]], ["In the DPPC gel phase, however, an adsorption at the surface of these membranes was detected by using a differential quenching approach with lipophilic probes, as well as by FRET.", [["surface", "ANATOMY", 53, 60], ["membranes", "ANATOMY", 70, 79], ["DPPC gel", "CHEMICAL", 7, 15], ["DPPC", "CHEMICAL", 7, 11], ["DPPC", "SIMPLE_CHEMICAL", 7, 11], ["surface", "CELLULAR_COMPONENT", 53, 60], ["membranes", "CELLULAR_COMPONENT", 70, 79], ["the DPPC gel phase", "TEST", 3, 21], ["an adsorption", "PROBLEM", 32, 45], ["a differential quenching approach", "TREATMENT", 102, 135], ["lipophilic probes", "TREATMENT", 141, 158]]], ["Moreover, the interaction with gel phase membranes seems to be specific towards PC vesicles, since no significant interaction was retrieved for membranes composed by shingomyelin and ceramide.", [["gel phase membranes", "ANATOMY", 31, 50], ["PC vesicles", "ANATOMY", 80, 91], ["membranes", "ANATOMY", 144, 153], ["shingomyelin", "CHEMICAL", 166, 178], ["ceramide", "CHEMICAL", 183, 191], ["shingomyelin", "CHEMICAL", 166, 178], ["ceramide", "CHEMICAL", 183, 191], ["membranes", "CELLULAR_COMPONENT", 41, 50], ["PC vesicles", "MULTI-TISSUE_STRUCTURE", 80, 91], ["membranes", "CELLULAR_COMPONENT", 144, 153], ["shingomyelin", "SIMPLE_CHEMICAL", 166, 178], ["ceramide", "SIMPLE_CHEMICAL", 183, 191], ["gel phase membranes", "TREATMENT", 31, 50], ["membranes", "PROBLEM", 144, 153], ["ceramide", "TREATMENT", 183, 191], ["no", "UNCERTAINTY", 99, 101], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["interaction", "OBSERVATION", 114, 125]]], ["Besides fluorescence, atomic force microscopy and zeta-potential were used to further investigate this issue.", [["atomic force microscopy", "TEST", 22, 45], ["zeta-potential", "TREATMENT", 50, 64]]], ["Our results show a selectivity and specificity of the peptide towards rigid domains, where most of the receptors are found, and help explain the importance of the interaction with membranes in the improved efficacy of sifuvirtide compared to other fusion inhibitors, by providing a local increased concentration of the peptide near the fusion site on both cellular and viral membranes.Specificity of a HIV fusion inhibitor towards phosphatidylcholine gel phase membranesThe study of molecular dynamics at the single-molecule level with fluorescence far-field optics offers new detailed insights into scientific problems, especially in living cells.", [["membranes", "ANATOMY", 180, 189], ["cellular", "ANATOMY", 356, 364], ["membranes", "ANATOMY", 375, 384], ["cells", "ANATOMY", 642, 647], ["sifuvirtide", "CHEMICAL", 218, 229], ["phosphatidylcholine gel", "CHEMICAL", 431, 454], ["sifuvirtide", "CHEMICAL", 218, 229], ["phosphatidylcholine", "CHEMICAL", 431, 450], ["membranes", "CELLULAR_COMPONENT", 180, 189], ["sifuvirtide", "SIMPLE_CHEMICAL", 218, 229], ["cellular", "CELL", 356, 364], ["viral membranes", "CELLULAR_COMPONENT", 369, 384], ["HIV", "ORGANISM", 402, 405], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 431, 450], ["cells", "CELL", 642, 647], ["fusion site", "DNA", 336, 347], ["HIV", "SPECIES", 402, 405], ["the peptide towards rigid domains", "PROBLEM", 50, 83], ["membranes", "TREATMENT", 180, 189], ["sifuvirtide", "TREATMENT", 218, 229], ["other fusion inhibitors", "TREATMENT", 242, 265], ["a local increased concentration of the peptide", "TREATMENT", 280, 326], ["a HIV fusion inhibitor", "TREATMENT", 400, 422], ["phosphatidylcholine gel phase membranes", "TREATMENT", 431, 470], ["The study", "TEST", 470, 479], ["fusion", "OBSERVATION", 336, 342], ["viral membranes", "OBSERVATION", 369, 384]]], ["Unfortunately, the resolution of common far-field techniques is limited to about 200nm in the lateral direction by diffraction.", [["resolution", "OBSERVATION_MODIFIER", 19, 29], ["common", "OBSERVATION_MODIFIER", 33, 39], ["lateral", "ANATOMY_MODIFIER", 94, 101]]], ["In recent years, several concepts such as stimulated emission depletion microscopy (STED) have been successfully applied to overcome the diffraction barrier by exploiting the photophysical properties of fluorescent labels.", [["stimulated emission depletion microscopy", "TREATMENT", 42, 82], ["the diffraction barrier", "TREATMENT", 133, 156]]], ["We present the combination of high resolution STED microscopy with different fluorescence fluctuation techniques providing the unique ability to study molecular dynamics with high spatial (<40nm) and temporal resolution (<1ms) in living cells.", [["cells", "ANATOMY", 237, 242], ["cells", "CELL", 237, 242], ["different fluorescence fluctuation techniques", "TREATMENT", 67, 112], ["high spatial (<40nm) and temporal resolution (<1ms) in living cells", "PROBLEM", 175, 242]]], ["Using fluorescence correlation spectroscopy (FCS) and general single-molecule analysis, we were able to explore single-molecule dynamics in up to 70-fold reduced focal volumes on two-dimensional samples such as lipid membranes with excellent signal-to-noise ratios.", [["samples", "ANATOMY", 195, 202], ["lipid membranes", "ANATOMY", 211, 226], ["lipid membranes", "MULTI-TISSUE_STRUCTURE", 211, 226], ["fluorescence correlation spectroscopy", "TEST", 6, 43], ["FCS", "TEST", 45, 48], ["general single-molecule analysis", "TEST", 54, 86], ["single-molecule dynamics", "TEST", 112, 136], ["reduced focal volumes", "PROBLEM", 154, 175], ["lipid membranes", "TREATMENT", 211, 226], ["reduced", "OBSERVATION_MODIFIER", 154, 161], ["focal", "OBSERVATION_MODIFIER", 162, 167], ["volumes", "OBSERVATION_MODIFIER", 168, 175], ["lipid membranes", "ANATOMY", 211, 226]]], ["Special attention is drawn to inhomogeneous lipid diffusion on the plasma membrane of living cells 1 .", [["plasma membrane", "ANATOMY", 67, 82], ["cells", "ANATOMY", 93, 98], ["lipid", "SIMPLE_CHEMICAL", 44, 49], ["plasma membrane", "CELLULAR_COMPONENT", 67, 82], ["cells", "CELL", 93, 98], ["inhomogeneous lipid diffusion", "PROBLEM", 30, 59]]], ["By extending the available spatial scale of standard single-molecule fluorescence far-field spectroscopy techniques, our experiments outline a new way of approaching scientific problems.O-19Modulation of the properties of membrane microdomains as a control mechanism in cellular physiology P. O'Shea Cell Biophysics Group, Institute of Biophysics, Imaging & Optical Science, School of Biology, University of Nottingham, Nottingham NG7 2RD, U.K. This presentation will outline the molecular-physical rationale of how membrane microdomains may modulate the behaviour of membrane receptor systems as a controlling mechanism in cell signaling.", [["membrane microdomains", "ANATOMY", 222, 243], ["cellular", "ANATOMY", 270, 278], ["membrane microdomains", "ANATOMY", 516, 537], ["membrane", "ANATOMY", 568, 576], ["cell", "ANATOMY", 624, 628], ["membrane microdomains", "CELLULAR_COMPONENT", 222, 243], ["cellular", "CELL", 270, 278], ["membrane microdomains", "CELLULAR_COMPONENT", 516, 537], ["membrane", "CELLULAR_COMPONENT", 568, 576], ["cell", "CELL", 624, 628], ["membrane microdomains", "TREATMENT", 222, 243], ["membrane receptor systems", "TREATMENT", 568, 593], ["membrane microdomains", "OBSERVATION", 222, 243], ["cell signaling", "OBSERVATION", 624, 638]]], ["A number of external factors that modulate these properties will be indicated that have a bearing on controlling cellular behaviour.", [["cellular", "ANATOMY", 113, 121], ["cellular", "CELL", 113, 121], ["external factors", "PROTEIN", 12, 28], ["external factors", "PROBLEM", 12, 28]]], ["Some of key questions will be considered such as the factors that control the assembly and disassembly of microdomains, the size and numberdensity of the microdomains and the lifetime that they exist within the membrane.", [["microdomains", "ANATOMY", 106, 118], ["microdomains", "ANATOMY", 154, 166], ["membrane", "ANATOMY", 211, 219], ["microdomains", "CELLULAR_COMPONENT", 106, 118], ["microdomains", "CELLULAR_COMPONENT", 154, 166], ["membrane", "CELLULAR_COMPONENT", 211, 219], ["size", "OBSERVATION_MODIFIER", 124, 128]]], ["Throughout this presentation, correlations will be made between theory and experiment as well as between model membrane systems and real cellular systems.O-18Structural and dynamic properties of caveolin-1 and -2 fragments at the membrane interface C. Le Lan 1 , J. Gallay 2 , M. Vincent 2 , J.-M. Neumann 1 , B. de Foresta 1 , N. Jamin 1 1 CEA, iBiTecs, SB2SM, & URA CNRS 2096, Gif-sur-Yvette, France, 2 IBBMC, Universit\u00e9 Paris-Sud, UMR8619-CNRS, IFR115, Orsay, France Caveolins are major protein components of caveolae, microdomains of the plasma membrane involved in a large number of biological functions, including signal transduction, cholesterol homeostasis and transport.", [["membrane systems", "ANATOMY", 111, 127], ["cellular", "ANATOMY", 137, 145], ["membrane", "ANATOMY", 230, 238], ["caveolae", "ANATOMY", 512, 520], ["microdomains", "ANATOMY", 522, 534], ["plasma membrane", "ANATOMY", 542, 557], ["cholesterol", "CHEMICAL", 641, 652], ["cholesterol", "CHEMICAL", 641, 652], ["cellular", "CELL", 137, 145], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 195, 205], ["-2", "GENE_OR_GENE_PRODUCT", 210, 212], ["membrane", "CELLULAR_COMPONENT", 230, 238], ["CEA", "GENE_OR_GENE_PRODUCT", 341, 344], ["caveolae", "CELLULAR_COMPONENT", 512, 520], ["microdomains", "CELLULAR_COMPONENT", 522, 534], ["plasma membrane", "CELLULAR_COMPONENT", 542, 557], ["cholesterol", "SIMPLE_CHEMICAL", 641, 652], ["caveolin-1 and -2 fragments", "DNA", 195, 222], ["caveolin", "TEST", 195, 203], ["CEA", "TEST", 341, 344], ["iBiTecs", "TEST", 346, 353], ["SB2SM", "TEST", 355, 360], ["URA CNRS", "TEST", 364, 372], ["Gif", "TEST", 379, 382], ["CNRS", "TEST", 442, 446], ["the plasma membrane", "TREATMENT", 538, 557], ["signal transduction", "TREATMENT", 620, 639], ["caveolin", "ANATOMY", 195, 203], ["membrane", "ANATOMY_MODIFIER", 230, 238], ["interface", "ANATOMY_MODIFIER", 239, 248], ["Le Lan", "ANATOMY", 252, 258], ["CEA", "ANATOMY", 341, 344], ["large", "OBSERVATION_MODIFIER", 572, 577], ["biological functions", "OBSERVATION", 588, 608]]], ["The consensus topological model of caveolin-1 includes a small central intramembrane region (102-134) flanked by two cytosolic amphiphilic domains (82-101 and 135-150) which probably constitute in-plane membrane anchors.", [["cytosolic", "ANATOMY", 117, 126], ["membrane", "ANATOMY", 203, 211], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 35, 45], ["caveolin-1", "PROTEIN", 35, 45], ["intramembrane region", "PROTEIN", 71, 91], ["cytosolic amphiphilic domains", "PROTEIN", 117, 146], ["a small central intramembrane region", "PROBLEM", 55, 91], ["two cytosolic amphiphilic domains", "TEST", 113, 146], ["small", "OBSERVATION_MODIFIER", 57, 62], ["central", "ANATOMY_MODIFIER", 63, 70], ["intramembrane", "ANATOMY_MODIFIER", 71, 84], ["region", "ANATOMY_MODIFIER", 85, 91], ["cytosolic", "OBSERVATION_MODIFIER", 117, 126], ["amphiphilic domains", "OBSERVATION", 127, 146]]], ["We investigated the interaction of the cav-1(94-102) juxta-membrane segment with various membrane mimics, using fluorescence, CD and NMR.", [["membrane", "ANATOMY", 59, 67], ["membrane", "ANATOMY", 89, 97], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["cav-1(94-102) juxta-membrane segment", "PROTEIN", 39, 75], ["juxta-membrane segment", "TREATMENT", 53, 75], ["various membrane mimics", "PROBLEM", 81, 104], ["NMR", "TEST", 133, 136], ["membrane segment", "ANATOMY_MODIFIER", 59, 75], ["various membrane mimics", "OBSERVATION", 81, 104]]], ["This segment partitioned better in DPC and in DM/anionic lipids micelles than in DM micelles and this partitioning was coupled with the formation of an amphipathic \u03b1-helix.", [["DPC", "CHEMICAL", 35, 38], ["DPC", "SIMPLE_CHEMICAL", 35, 38], ["DM/anionic lipids micelles", "SIMPLE_CHEMICAL", 46, 72], ["DM micelles", "SIMPLE_CHEMICAL", 81, 92], ["amphipathic \u03b1-helix", "PROTEIN", 152, 171], ["DM/anionic lipids micelles", "TREATMENT", 46, 72], ["DM micelles", "PROBLEM", 81, 92], ["an amphipathic \u03b1-helix", "TREATMENT", 149, 171], ["segment", "OBSERVATION_MODIFIER", 5, 12], ["partitioned", "OBSERVATION_MODIFIER", 13, 24], ["better", "OBSERVATION_MODIFIER", 25, 31], ["amphipathic \u03b1-helix", "OBSERVATION", 152, 171]]], ["This amphipathic helix was located in an average shallow position, in the polar head group region of the DPC micelle, as shown by fluorescence data and intermolecular NOEs, with the aromatic doublet W98-F99 probably pointing towards the inside of the micelle on average.", [["head", "ANATOMY", 80, 84], ["DPC", "CHEMICAL", 105, 108], ["W98-F99", "CHEMICAL", 199, 206], ["DPC", "SIMPLE_CHEMICAL", 105, 108], ["amphipathic helix", "PROTEIN", 5, 22], ["polar head group region", "PROTEIN", 74, 97], ["This amphipathic helix", "PROBLEM", 0, 22], ["fluorescence data", "TEST", 130, 147], ["the aromatic doublet W98", "TEST", 178, 202], ["amphipathic helix", "OBSERVATION", 5, 22], ["average", "OBSERVATION_MODIFIER", 41, 48], ["shallow", "OBSERVATION_MODIFIER", 49, 56], ["position", "OBSERVATION_MODIFIER", 57, 65], ["polar", "ANATOMY_MODIFIER", 74, 79], ["head", "ANATOMY", 80, 84], ["micelle", "ANATOMY_MODIFIER", 251, 258]]], ["The peptide encompassing the homologous sequence of cav-2 was also localized to the DPC micelle polar head group region, in which it adopted a more stable helical conformation than cav- 1(94-102) .", [["cav- 1(94-102", "CHEMICAL", 181, 194], ["cav-2", "GENE_OR_GENE_PRODUCT", 52, 57], ["cav-2", "DNA", 52, 57], ["DPC micelle polar head group region", "PROTEIN", 84, 119], ["The peptide", "TREATMENT", 0, 11], ["cav", "TEST", 181, 184], ["cav", "ANATOMY", 52, 55], ["DPC", "ANATOMY_MODIFIER", 84, 87], ["micelle", "ANATOMY_MODIFIER", 88, 95], ["polar", "ANATOMY_MODIFIER", 96, 101], ["head", "ANATOMY", 102, 106], ["stable", "OBSERVATION_MODIFIER", 148, 154]]], ["These data brings experimental support for the role of this segment as an interfacial membrane anchor.O-18Resveratrol (trans-3,4',5-trihydroxystilbene) , a phytoalexin present in grapes and its analogue piceatannol (trans-3,4,3',5'-tetrahydroxystilbene) are biologically active compounds and possess potential chemopreventive and anticancer properties.", [["membrane", "ANATOMY", 86, 94], ["grapes", "ANATOMY", 179, 185], ["anticancer", "ANATOMY", 330, 340], ["O-18Resveratrol", "CHEMICAL", 102, 117], ["trans-3,4',5-trihydroxystilbene", "CHEMICAL", 119, 150], ["phytoalexin", "CHEMICAL", 156, 167], ["piceatannol", "CHEMICAL", 203, 214], ["trans-3,4,3',5'-tetrahydroxystilbene", "CHEMICAL", 216, 252], ["O-18Resveratrol", "CHEMICAL", 102, 117], ["trans-3,4',5-trihydroxystilbene", "CHEMICAL", 119, 150], ["phytoalexin", "CHEMICAL", 156, 167], ["piceatannol", "CHEMICAL", 203, 214], ["trans-3,4,3',5'-tetrahydroxystilbene", "CHEMICAL", 216, 252], ["membrane anchor", "CELLULAR_COMPONENT", 86, 101], ["O-18Resveratrol", "SIMPLE_CHEMICAL", 102, 117], ["trans-3,4',5-trihydroxystilbene", "SIMPLE_CHEMICAL", 119, 150], ["phytoalexin", "SIMPLE_CHEMICAL", 156, 167], ["grapes", "ORGANISM_SUBDIVISION", 179, 185], ["piceatannol", "SIMPLE_CHEMICAL", 203, 214], ["trans-3,4,3',5'-tetrahydroxystilbene", "SIMPLE_CHEMICAL", 216, 252], ["anticancer", "CANCER", 330, 340], ["experimental support", "TREATMENT", 18, 38], ["an interfacial membrane anchor", "TREATMENT", 71, 101], ["trihydroxystilbene", "TREATMENT", 132, 150], ["a phytoalexin", "TREATMENT", 154, 167], ["its analogue piceatannol (trans", "TREATMENT", 190, 221], ["tetrahydroxystilbene", "TREATMENT", 232, 252], ["interfacial membrane", "OBSERVATION", 74, 94], ["anticancer properties", "OBSERVATION", 330, 351]]], ["The activity of resveratrol and piceatannol can be mediated by membrane effects since structure of lipid membrane domains may play an important role in cell signalling pathways.", [["membrane", "ANATOMY", 63, 71], ["lipid membrane", "ANATOMY", 99, 113], ["cell", "ANATOMY", 152, 156], ["resveratrol", "CHEMICAL", 16, 27], ["piceatannol", "CHEMICAL", 32, 43], ["resveratrol", "CHEMICAL", 16, 27], ["piceatannol", "CHEMICAL", 32, 43], ["resveratrol", "SIMPLE_CHEMICAL", 16, 27], ["piceatannol", "SIMPLE_CHEMICAL", 32, 43], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["lipid membrane", "CELLULAR_COMPONENT", 99, 113], ["cell", "CELL", 152, 156], ["lipid membrane domains", "PROTEIN", 99, 121], ["resveratrol", "TREATMENT", 16, 27], ["piceatannol", "TREATMENT", 32, 43], ["lipid membrane domains", "TREATMENT", 99, 121], ["lipid membrane", "OBSERVATION", 99, 113]]], ["Drugs interactions with DMPC bilayers was investigated using a combination of ESR spectroscopy and differential scanning calorimetry.", [["DMPC", "CHEMICAL", 24, 28], ["DMPC", "CHEMICAL", 24, 28], ["DMPC bilayers", "SIMPLE_CHEMICAL", 24, 37], ["DMPC bilayers", "TREATMENT", 24, 37], ["ESR spectroscopy", "TEST", 78, 94], ["differential scanning calorimetry", "TEST", 99, 132]]], ["Spin probes used in EPR experiment were located in different part of lipid bilayer.", [["lipid bilayer", "ANATOMY", 69, 82], ["lipid bilayer", "CELLULAR_COMPONENT", 69, 82], ["Spin probes", "TREATMENT", 0, 11]]], ["Study was performed at temperatures below and above phase transition temperature (T m ).", [["Study", "TEST", 0, 5]]], ["EPR spectra were simulated and displayed with GHOST condensation method.", [["EPR spectra", "TEST", 0, 11], ["GHOST condensation method", "PROBLEM", 46, 71]]], ["The values of \u03d1 and \u03d5 (the main and asymmetry cone angles of wobbling spin probe, respectively) were taken for free rotational space parameter (\u2126) calculation.", [["The values", "TEST", 0, 10], ["spin probe", "TEST", 70, 80], ["free rotational space parameter", "TEST", 111, 142], ["main", "OBSERVATION_MODIFIER", 27, 31]]], ["The decrease of \u2126 values was observed in the presence of both compounds and the effect was more pronounced in lipid gel phase.", [["lipid", "SIMPLE_CHEMICAL", 110, 115], ["The decrease of \u2126 values", "PROBLEM", 0, 24], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["compounds", "OBSERVATION", 62, 71]]], ["Order parameter and correlation time were also determined and presented in form of GHOST patterns.", [["GHOST", "PROTEIN", 83, 88]]], ["Using this approach the differential influence of studied compounds on membrane heterogenity was revealed.O-18Separating hydrostatic pressure from cellular strain: development of an in vitro model system R. Sulley 1 , J. Whatmore 1 , C. P. Winlove 2 , A. Shore 1 , J. Tooke 1 , R. Ellis 2 , K. Gooding 1 1 Peninsula Medical School, 2 School of Physics, University of Exeter, UK Endothelial cells (ECs) line blood vessels & are constantly subjected to haemodynamic and mechanical stresses and strains.", [["membrane", "ANATOMY", 71, 79], ["cellular", "ANATOMY", 147, 155], ["Endothelial cells", "ANATOMY", 378, 395], ["ECs", "ANATOMY", 397, 400], ["blood vessels", "ANATOMY", 407, 420], ["O-18Separating", "CHEMICAL", 106, 120], ["O-18Separating", "CHEMICAL", 106, 120], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["O-18Separating", "SIMPLE_CHEMICAL", 106, 120], ["cellular", "CELL", 147, 155], ["Endothelial cells", "CELL", 378, 395], ["ECs", "CELL", 397, 400], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 407, 420], ["ECs", "CELL_TYPE", 397, 400], ["this approach", "TREATMENT", 6, 19], ["membrane heterogenity", "TEST", 71, 92], ["hydrostatic pressure", "PROBLEM", 121, 141], ["cellular strain", "PROBLEM", 147, 162], ["mechanical stresses", "PROBLEM", 468, 487], ["strains", "PROBLEM", 492, 499], ["hydrostatic pressure", "OBSERVATION", 121, 141], ["cellular strain", "OBSERVATION", 147, 162], ["Exeter", "ANATOMY_MODIFIER", 367, 373], ["Endothelial cells", "OBSERVATION", 378, 395], ["vessels", "ANATOMY", 413, 420], ["mechanical stresses", "OBSERVATION", 468, 487]]], ["These stimuli are known to influence ECs, modifying their morphology, intracellular signalling & gene expression.", [["ECs", "ANATOMY", 37, 40], ["intracellular", "ANATOMY", 70, 83], ["ECs", "CELL", 37, 40], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 83], ["ECs", "CELL_TYPE", 37, 40]]], ["Most reported systems exposing EC to mechanical forces in vitro alter pressure & strain simultaneously, making it impossible to distinguish the two potentially independent stimuli.", [["EC", "ANATOMY", 31, 33], ["EC", "CELL", 31, 33], ["EC", "CELL_TYPE", 31, 33]]], ["This distinction is particularly relevant when examining the interaction of haemodynamic forces on microvascular ECs, which are exposed to low hydrostatic pressure but significant strains.", [["microvascular ECs", "ANATOMY", 99, 116], ["microvascular ECs", "CELL", 99, 116], ["microvascular ECs", "CELL_TYPE", 99, 116], ["microvascular ECs", "TEST", 99, 116], ["low hydrostatic pressure", "PROBLEM", 139, 163], ["significant strains", "PROBLEM", 168, 187], ["haemodynamic forces", "OBSERVATION", 76, 95], ["microvascular ECs", "ANATOMY", 99, 116], ["low hydrostatic", "OBSERVATION_MODIFIER", 139, 154], ["pressure", "OBSERVATION_MODIFIER", 155, 163], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["strains", "OBSERVATION", 180, 187]]], ["This research aims to create an in vitro system that can independently examine the effects of pressure and strain, over a range experienced by ECs in the microvasculature.", [["ECs", "ANATOMY", 143, 146], ["microvasculature", "ANATOMY", 154, 170], ["ECs", "CELL", 143, 146], ["microvasculature", "TISSUE", 154, 170], ["ECs", "CELL_TYPE", 143, 146], ["pressure and strain", "PROBLEM", 94, 113], ["pressure", "OBSERVATION_MODIFIER", 94, 102], ["microvasculature", "ANATOMY", 154, 170]]], ["Human ECs are seeded (12x10\u02c64cells/cm\u02c62) on to the inner surface of compliant 4mm diameter tubing.", [["ECs", "ANATOMY", 6, 9], ["cells", "ANATOMY", 29, 34], ["inner surface", "ANATOMY", 51, 64], ["Human", "ORGANISM", 0, 5], ["ECs", "CELL", 6, 9], ["12x10\u02c64cells", "CELL", 22, 34], ["Human ECs", "CELL_TYPE", 0, 9], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human ECs", "TEST", 0, 9], ["compliant 4mm diameter tubing", "TREATMENT", 68, 97], ["inner", "ANATOMY_MODIFIER", 51, 56], ["surface", "ANATOMY_MODIFIER", 57, 64], ["compliant", "OBSERVATION", 68, 77], ["4mm", "OBSERVATION_MODIFIER", 78, 81], ["diameter tubing", "OBSERVATION", 82, 97]]], ["Which is mounted on a perfusion rig inside a sealed, fluid-filled chamber.", [["a perfusion rig", "TREATMENT", 20, 35], ["sealed", "OBSERVATION_MODIFIER", 45, 51], ["fluid", "OBSERVATION", 53, 58], ["filled chamber", "OBSERVATION", 59, 73]]], ["A continuous sinusoidal cyclical strain of 5-10% is created by a pump attached to the external chamber.", [["A continuous sinusoidal cyclical strain", "TREATMENT", 0, 39], ["a pump", "TREATMENT", 63, 69], ["continuous", "OBSERVATION_MODIFIER", 2, 12], ["sinusoidal", "OBSERVATION_MODIFIER", 13, 23], ["cyclical", "OBSERVATION_MODIFIER", 24, 32], ["strain", "OBSERVATION_MODIFIER", 33, 39], ["external", "ANATOMY_MODIFIER", 86, 94], ["chamber", "ANATOMY_MODIFIER", 95, 102]]], ["Lumenal pressure is generated using two hydrostatic pressure heads.", [["Lumenal", "ANATOMY", 0, 7], ["Lumenal", "MULTI-TISSUE_STRUCTURE", 0, 7], ["Lumenal pressure", "TEST", 0, 16], ["two hydrostatic pressure heads", "TREATMENT", 36, 66], ["pressure", "OBSERVATION_MODIFIER", 8, 16], ["hydrostatic", "OBSERVATION_MODIFIER", 40, 51], ["pressure heads", "OBSERVATION", 52, 66]]], ["Validation experiments show that pressure & substrate strain can be independently varied & controlled over a physiological range.", [["Validation experiments", "TEST", 0, 22], ["pressure & substrate strain", "PROBLEM", 33, 60], ["pressure", "OBSERVATION_MODIFIER", 33, 41]]], ["The system is now being used to investigate the effects of pathophysiological haemodynamic abnormalities on EC function.P-23Membrane potential dynamics of living cells in response to femtosecond laser irradiation N. I. Smith 1 , J. Ando 2 , K. Fujita 2 , S. Kawata 2 1 Photonics Advanced Research Center, Osaka University, Suita, Osaka 565-0871, Japan, 2 Dept of Applied Physics, Osaka University, Suita, Osaka 565-0871, JapanP-23The ultrashort pulsed near-infrared femtosecond laser has had a large impact in biomedical research fields and in microscopy, where it has enabled new imaging methodologies.", [["EC", "ANATOMY", 108, 110], ["cells", "ANATOMY", 162, 167], ["P-23Membrane", "CHEMICAL", 120, 132], ["JapanP-23", "CHEMICAL", 421, 430], ["EC", "CELL", 108, 110], ["cells", "CELL", 162, 167], ["EC", "CELL_TYPE", 108, 110], ["P", "DNA", 120, 121], ["living cells", "CELL_TYPE", 155, 167], ["pathophysiological haemodynamic abnormalities", "PROBLEM", 59, 104], ["EC function", "TEST", 108, 119], ["living cells", "PROBLEM", 155, 167], ["femtosecond laser irradiation", "TREATMENT", 183, 212], ["JapanP", "TEST", 421, 427], ["The ultrashort pulsed near-infrared femtosecond laser", "TREATMENT", 430, 483], ["microscopy", "TEST", 544, 554], ["new imaging methodologies", "TEST", 577, 602], ["large", "OBSERVATION_MODIFIER", 494, 499], ["impact", "OBSERVATION_MODIFIER", 500, 506]]], ["At high intensities, the focused beam of a femtosecond laser has been used to irradiate specific locations inside a cell, often beneath the cell membrane, exploiting the inherent penetration and localized absorption that comes from the multiphoton absorption physics.", [["cell", "ANATOMY", 116, 120], ["cell membrane", "ANATOMY", 140, 153], ["cell", "CELL", 116, 120], ["cell membrane", "CELLULAR_COMPONENT", 140, 153], ["a femtosecond laser", "TREATMENT", 41, 60], ["the inherent penetration", "PROBLEM", 166, 190], ["localized absorption", "PROBLEM", 195, 215], ["high intensities", "OBSERVATION_MODIFIER", 3, 19], ["cell", "OBSERVATION", 116, 120], ["cell membrane", "OBSERVATION", 140, 153], ["inherent", "OBSERVATION_MODIFIER", 170, 178], ["penetration", "OBSERVATION", 179, 190]]], ["This has been applied in photobleaching, photouncaging, laser surgery and other experiments where the light is used not merely for observation but is instead an integral tool to interact with the dynamics of cells, to probe and perturb the cell condition.", [["cells", "ANATOMY", 208, 213], ["cell", "ANATOMY", 240, 244], ["cells", "CELL", 208, 213], ["cell", "CELL", 240, 244], ["photobleaching", "TREATMENT", 25, 39], ["photouncaging", "TREATMENT", 41, 54], ["laser surgery", "TREATMENT", 56, 69], ["cell condition", "OBSERVATION", 240, 254]]], ["In this talk I will discuss biological and mechanical effects that can be generated by short exposures to femtosecond laser irradiation, such as calcium waves, membrane hyperpolarization, and cell contraction.", [["membrane", "ANATOMY", 160, 168], ["cell", "ANATOMY", 192, 196], ["calcium", "CHEMICAL", 145, 152], ["calcium", "CHEMICAL", 145, 152], ["calcium", "SIMPLE_CHEMICAL", 145, 152], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["cell", "CELL", 192, 196], ["biological and mechanical effects", "TREATMENT", 28, 61], ["femtosecond laser irradiation", "TREATMENT", 106, 135], ["calcium waves", "TEST", 145, 158], ["membrane hyperpolarization", "TREATMENT", 160, 186], ["cell contraction", "PROBLEM", 192, 208], ["membrane hyperpolarization", "OBSERVATION", 160, 186], ["cell contraction", "OBSERVATION", 192, 208]]], ["This talk will concentrate on the changes in membrane potential that can occur when the cell is subjected to focused femtosecond laser beams.", [["membrane", "ANATOMY", 45, 53], ["cell", "ANATOMY", 88, 92], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["cell", "CELL", 88, 92]]], ["Both depolarization and hyperpolarization of the membrane potential could be evoked, depending on the laser parameters and on the position of the laser focus.", [["membrane", "ANATOMY", 49, 57], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["the laser parameters", "TEST", 98, 118], ["depolarization", "OBSERVATION", 5, 19], ["hyperpolarization", "OBSERVATION_MODIFIER", 24, 41], ["laser", "OBSERVATION_MODIFIER", 146, 151], ["focus", "OBSERVATION", 152, 157]]], ["These results have implications for the use of laser beams in microscopy, optical gene transfection, and laser nanosurgery.", [["laser beams", "TREATMENT", 47, 58], ["microscopy", "TEST", 62, 72], ["optical gene transfection", "TREATMENT", 74, 99], ["laser nanosurgery", "TREATMENT", 105, 122]]], ["In a recent study we showed that the melting behavior of Supported Lipid Bilayers (SLBs) on mica can be influenced by the solution ionic strength and by the SLB preparation temperature [1] .", [["SLB", "CHEMICAL", 157, 160], ["Lipid Bilayers", "SIMPLE_CHEMICAL", 67, 81], ["SLBs", "SIMPLE_CHEMICAL", 83, 87], ["a recent study", "TEST", 3, 17], ["the melting behavior", "PROBLEM", 33, 53], ["the solution ionic strength", "TREATMENT", 118, 145]]], ["By changing these parameters we could control the coupling between the two bilayer leaflets obtaining a coupled or decoupled melting behavior.", [["decoupled melting behavior", "PROBLEM", 115, 141]]], ["Thus, we could provide evidence that the SLB model system is also suited for the study of lipid/protein interactions which had been questioned in the past.", [["SLB", "CHEMICAL", 41, 44], ["lipid", "SIMPLE_CHEMICAL", 90, 95], ["the SLB model system", "PROBLEM", 37, 57], ["the study", "TEST", 77, 86], ["lipid/protein interactions", "PROBLEM", 90, 116]]], ["Then we investigated the mutual interactions between the membrane lipids (POPE:POPG 3:1) and the KcsA potassium ion channel by studying KcsA proteins reconstituted in SLBs.", [["membrane lipids", "ANATOMY", 57, 72], ["SLBs", "ANATOMY", 167, 171], ["potassium", "CHEMICAL", 102, 111], ["potassium", "CHEMICAL", 102, 111], ["membrane lipids", "CELLULAR_COMPONENT", 57, 72], ["POPE", "SIMPLE_CHEMICAL", 74, 78], ["KcsA", "GENE_OR_GENE_PRODUCT", 136, 140], ["SLBs", "PATHOLOGICAL_FORMATION", 167, 171], ["KcsA potassium ion channel", "PROTEIN", 97, 123], ["KcsA proteins", "PROTEIN", 136, 149], ["SLBs", "CELL_TYPE", 167, 171], ["the KcsA potassium ion channel", "TREATMENT", 93, 123], ["KcsA proteins", "TEST", 136, 149]]], ["In particular, we studied the melting behavior of the SLB and the ion channel distribution relative to the different membrane phases by temperature controlled atomic force microscopy (AFM).", [["membrane", "ANATOMY", 117, 125], ["SLB", "CHEMICAL", 54, 57], ["SLB", "SIMPLE_CHEMICAL", 54, 57], ["SLB", "ANATOMY", 54, 57], ["ion channel", "OBSERVATION_MODIFIER", 66, 77]]], ["By decreasing the temperature we found that the proteins underwent diffusion so to be excluded from the growing solid ordered regions.", [["the temperature", "TEST", 14, 29], ["the proteins underwent diffusion", "PROBLEM", 44, 76]]], ["Further, the ion channels tended to accumulate at the domain boundaries or they aggregated in the liquid disordered phase.", [["the ion channels", "TREATMENT", 9, 25]]], ["When we started from a low temperature at which the membrane was mainly in the solid ordered phase the membrane melting processes started in the vicinity of the included ion channels.", [["membrane", "ANATOMY", 52, 60], ["membrane", "ANATOMY", 103, 111], ["membrane", "CELLULAR_COMPONENT", 52, 60], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["a low temperature", "PROBLEM", 21, 38], ["the membrane melting processes", "TREATMENT", 99, 129], ["low temperature", "OBSERVATION_MODIFIER", 23, 38], ["membrane melting", "OBSERVATION", 103, 119]]], ["We report fluorescence recovery after photobleaching (FRAP) measurements performed at variable spot radius for T7-EGFP-hMOP receptors on SH-SY5Y neuroblastoma cells in the presence of ligands.", [["SH-SY5Y neuroblastoma cells", "ANATOMY", 137, 164], ["SH-SY5Y neuroblastoma cells", "CELL", 137, 164], ["T7-EGFP-hMOP receptors", "PROTEIN", 111, 133], ["SH-SY5Y neuroblastoma cells", "CELL_LINE", 137, 164], ["photobleaching (FRAP) measurements", "TEST", 38, 72], ["variable spot radius", "TEST", 86, 106], ["T7", "TEST", 111, 113], ["neuroblastoma cells", "PROBLEM", 145, 164], ["neuroblastoma cells", "OBSERVATION", 145, 164]]], ["Two different agonists, DAMGO and morphine, caused markedly different changes to receptor diffusion as compared to the basal state.", [["DAMGO", "CHEMICAL", 24, 29], ["morphine", "CHEMICAL", 34, 42], ["DAMGO", "CHEMICAL", 24, 29], ["morphine", "CHEMICAL", 34, 42], ["DAMGO", "SIMPLE_CHEMICAL", 24, 29], ["morphine", "SIMPLE_CHEMICAL", 34, 42], ["Two different agonists", "TREATMENT", 0, 22], ["DAMGO", "TREATMENT", 24, 29], ["morphine", "TREATMENT", 34, 42], ["markedly different changes to receptor diffusion", "PROBLEM", 51, 99], ["markedly", "OBSERVATION_MODIFIER", 51, 59], ["different", "OBSERVATION_MODIFIER", 60, 69]]], ["Like receptors in the absence of ligand, receptors bound to morphine exhibited diffusion confined to joint semi-permeable domains, but with smaller domain size and diffusion coefficient.", [["morphine", "CHEMICAL", 60, 68], ["morphine", "CHEMICAL", 60, 68], ["morphine", "SIMPLE_CHEMICAL", 60, 68], ["joint semi-permeable domains", "PROTEIN", 101, 129], ["morphine", "TREATMENT", 60, 68], ["smaller domain size", "PROBLEM", 140, 159], ["diffusion coefficient", "TEST", 164, 185], ["joint", "ANATOMY", 101, 106], ["smaller", "OBSERVATION_MODIFIER", 140, 147], ["size", "OBSERVATION_MODIFIER", 155, 159], ["diffusion coefficient", "OBSERVATION", 164, 185]]], ["This effect was inhibited by pertussis toxin, suggesting that this dynamic behaviour is associated with early steps of signaling.", [["pertussis toxin", "CHEMICAL", 29, 44], ["pertussis toxin", "SIMPLE_CHEMICAL", 29, 44], ["pertussis toxin", "PROTEIN", 29, 44], ["pertussis toxin", "PROBLEM", 29, 44], ["this dynamic behaviour", "PROBLEM", 62, 84]]], ["In the presence of DAMGO, half of the receptors displayed free long-range diffusion and the other half were confined to smaller isolated domains.", [["DAMGO", "CHEMICAL", 19, 24], ["DAMGO", "CHEMICAL", 19, 24], ["DAMGO", "SIMPLE_CHEMICAL", 19, 24], ["the receptors", "TEST", 34, 47], ["smaller", "OBSERVATION_MODIFIER", 120, 127], ["isolated domains", "OBSERVATION", 128, 144]]], ["Hypertonic sucrose buffer suppressed this effect which we attribute to receptor entry into clathrin-coated pits.", [["sucrose", "CHEMICAL", 11, 18], ["sucrose", "CHEMICAL", 11, 18], ["clathrin", "GENE_OR_GENE_PRODUCT", 91, 99], ["clathrin", "PROTEIN", 91, 99], ["Hypertonic sucrose buffer", "TREATMENT", 0, 25]]], ["It is likely that the observation of distinct receptor dynamics in the presence of DAMGO and morphine involves the agonist-selective phosphorylation of the receptor.AFM Study of Protein Redistribution upon Lipid Domain Formation in Supported Lipid BilayersThe alteration of the physiological transcriptional program is one of the constant features of cancer cells.", [["cancer cells", "ANATOMY", 351, 363], ["DAMGO", "CHEMICAL", 83, 88], ["morphine", "CHEMICAL", 93, 101], ["cancer", "DISEASE", 351, 357], ["DAMGO", "CHEMICAL", 83, 88], ["morphine", "CHEMICAL", 93, 101], ["DAMGO", "SIMPLE_CHEMICAL", 83, 88], ["morphine", "SIMPLE_CHEMICAL", 93, 101], ["cancer cells", "CELL", 351, 363], ["cancer cells", "CELL_TYPE", 351, 363], ["DAMGO", "TREATMENT", 83, 88], ["morphine", "TREATMENT", 93, 101], ["selective phosphorylation of the receptor", "TREATMENT", 123, 164], ["AFM Study", "TEST", 165, 174], ["Protein Redistribution", "PROBLEM", 178, 200], ["Lipid Domain Formation", "TREATMENT", 206, 228], ["Supported Lipid Bilayers", "TREATMENT", 232, 256], ["cancer cells", "PROBLEM", 351, 363], ["is likely", "UNCERTAINTY", 3, 12], ["Protein Redistribution", "OBSERVATION", 178, 200], ["Lipid Domain", "OBSERVATION", 206, 218], ["Lipid Bilayers", "OBSERVATION", 242, 256], ["cancer cells", "OBSERVATION", 351, 363]]], ["However, the characterization of the chromatin changes at single-gene level requires going beyond the diffraction limit affecting conventional fluorescence microscopy.", [["chromatin", "ANATOMY", 37, 46], ["chromatin", "CELLULAR_COMPONENT", 37, 46], ["chromatin", "DNA", 37, 46], ["the chromatin changes", "PROBLEM", 33, 54], ["conventional fluorescence microscopy", "TEST", 130, 166], ["chromatin", "OBSERVATION", 37, 46]]], ["The ability of molecular biology techniques to obtain a detailed view of the chromatin status at a sub-promoter resolution has to pay instead the price of averaging over a cell population.", [["chromatin", "ANATOMY", 77, 86], ["cell", "ANATOMY", 172, 176], ["chromatin", "CELLULAR_COMPONENT", 77, 86], ["cell", "CELL", 172, 176], ["chromatin", "DNA", 77, 86], ["a cell population", "TREATMENT", 170, 187]]], ["We report here the application of an approach based on high-resolution cytometry, chromatin immuno-precipitation and transcriptional profiling (DNA microarray) for the characterization of the transcriptional and chromatin changes induced by the oncogenic transcription factor PML/RAR\u03b1.", [["chromatin", "ANATOMY", 82, 91], ["chromatin", "ANATOMY", 212, 221], ["chromatin", "CELLULAR_COMPONENT", 82, 91], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["chromatin", "CELLULAR_COMPONENT", 212, 221], ["PML", "GENE_OR_GENE_PRODUCT", 276, 279], ["RAR", "GENE_OR_GENE_PRODUCT", 280, 283], ["chromatin", "DNA", 82, 91], ["oncogenic transcription factor", "PROTEIN", 245, 275], ["PML", "PROTEIN", 276, 279], ["RAR", "PROTEIN", 280, 283], ["an approach", "TREATMENT", 34, 45], ["chromatin immuno-precipitation", "TREATMENT", 82, 112], ["transcriptional profiling (DNA microarray", "TREATMENT", 117, 158], ["the characterization", "TEST", 164, 184], ["the transcriptional and chromatin changes", "PROBLEM", 188, 229]]], ["The presentation will focus on the imaging protocol employed to observe the effects on the chromatin status and the extent of the deregulation induced on transcriptional activity in Acute Promyelocytic Leukemia cells.", [["chromatin", "ANATOMY", 91, 100], ["Acute Promyelocytic Leukemia cells", "ANATOMY", 182, 216], ["Acute Promyelocytic Leukemia", "DISEASE", 182, 210], ["chromatin", "CELLULAR_COMPONENT", 91, 100], ["Acute Promyelocytic Leukemia cells", "CELL", 182, 216], ["chromatin", "DNA", 91, 100], ["Acute Promyelocytic Leukemia cells", "CELL_LINE", 182, 216], ["the imaging protocol", "TEST", 31, 51], ["the deregulation", "PROBLEM", 126, 142], ["Acute Promyelocytic Leukemia cells", "PROBLEM", 182, 216], ["transcriptional activity", "OBSERVATION", 154, 178], ["Acute", "OBSERVATION_MODIFIER", 182, 187], ["Promyelocytic Leukemia cells", "OBSERVATION", 188, 216]]], ["This multiple-approach examination provides a further step towards the comprehension of the hierarchy of chromatin modifications leading to the establishment of a malignant transcriptional program.AFM Study of Protein Redistribution upon Lipid Domain Formation in Supported Lipid BilayersDNA is rigid negatively charged polymer and in solution exists in extended conformation.", [["chromatin", "ANATOMY", 105, 114], ["BilayersDNA", "CHEMICAL", 280, 291], ["chromatin", "CELLULAR_COMPONENT", 105, 114], ["Lipid BilayersDNA", "SIMPLE_CHEMICAL", 274, 291], ["chromatin", "DNA", 105, 114], ["approach examination", "TEST", 14, 34], ["a malignant transcriptional program", "TREATMENT", 161, 196], ["AFM Study", "TEST", 197, 206], ["Protein Redistribution", "PROBLEM", 210, 232], ["Lipid Domain Formation", "TREATMENT", 238, 260], ["rigid negatively charged polymer", "PROBLEM", 295, 327], ["chromatin modifications", "OBSERVATION", 105, 128], ["Protein Redistribution", "OBSERVATION", 210, 232], ["Lipid Domain", "OBSERVATION", 238, 250], ["Lipid BilayersDNA", "OBSERVATION", 274, 291], ["rigid", "OBSERVATION", 295, 300]]], ["I n vivo, volume occupied by DNA must be reduced to fit to tiny space of cell nucleus.", [["cell nucleus", "ANATOMY", 73, 85], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["cell nucleus", "CELLULAR_COMPONENT", 73, 85], ["tiny", "OBSERVATION_MODIFIER", 59, 63], ["cell nucleus", "OBSERVATION", 73, 85]]], ["To condense DNA, DNA-DNA electrostatic repulsion must be cut off that is achieved by interaction with cationic ligands.", [["DNA", "CELLULAR_COMPONENT", 12, 15], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["DNA electrostatic repulsion", "TREATMENT", 21, 48]]], ["In binding to DNA, oligocations compete with salt cations (K + , Na + , Mg 2+ ).", [["K", "CHEMICAL", 59, 60], ["Na", "CHEMICAL", 65, 67], ["Mg", "CHEMICAL", 72, 74], ["K +", "CHEMICAL", 59, 62], ["Na +", "CHEMICAL", 65, 69], ["Mg 2+", "CHEMICAL", 72, 77], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["oligocations", "SIMPLE_CHEMICAL", 19, 31], ["salt cations", "SIMPLE_CHEMICAL", 45, 57], ["K +", "SIMPLE_CHEMICAL", 59, 62], ["Na +", "SIMPLE_CHEMICAL", 65, 69], ["Mg 2+", "SIMPLE_CHEMICAL", 72, 77], ["salt cations", "TREATMENT", 45, 57], ["K", "TEST", 59, 60], ["Na", "TEST", 65, 67], ["Mg", "TEST", 72, 74]]], ["Description of salt dependence of oligocation-induced DNA condensation is still lacking.", [["oligocation", "CHEMICAL", 34, 45], ["oligocation", "SIMPLE_CHEMICAL", 34, 45], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["salt dependence of oligocation", "PROBLEM", 15, 45], ["DNA condensation", "PROBLEM", 54, 70], ["salt dependence", "OBSERVATION", 15, 30]]], ["We studied DNA condensation by model oligocations, \u03b5-oligo(L-lysines), with variation of charge from +3 to +31.", [["L-lysines", "CHEMICAL", 59, 68], ["\u03b5-oligo(L-lysines", "CHEMICAL", 51, 68], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["\u03b5-oligo", "SIMPLE_CHEMICAL", 51, 58], ["L-lysines", "SIMPLE_CHEMICAL", 59, 68], ["DNA condensation", "PROBLEM", 11, 27], ["\u03b5-oligo(L-lysines)", "TREATMENT", 51, 69]]], ["Combination of light scattering, UV-monitored precipitation assay and isothermal titration calorimetry allowed covering wide range of DNA (C DNA ) and salt (C KCl ) concentrations.", [["KCl", "CHEMICAL", 159, 162], ["KCl", "CHEMICAL", 159, 162], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["salt", "SIMPLE_CHEMICAL", 151, 155], ["C KCl", "SIMPLE_CHEMICAL", 157, 162], ["light scattering", "TEST", 15, 31], ["UV", "TEST", 33, 35], ["monitored precipitation assay", "TEST", 36, 65], ["isothermal titration calorimetry", "TEST", 70, 102], ["DNA (C DNA )", "TREATMENT", 134, 146], ["salt (C KCl ) concentrations", "TREATMENT", 151, 179]]], ["Salt dependence of DNA condensation efficiency of the ligand, EC 50 (ligand concentration at the transition midpoint) displays two regimes: salt-independent at low C KCl and salt-dependent at higher C KCl (steep increase of EC 50 with C KCl ).", [["EC", "CHEMICAL", 62, 64], ["KCl", "CHEMICAL", 166, 169], ["salt", "CHEMICAL", 174, 178], ["KCl", "CHEMICAL", 201, 204], ["KCl", "CHEMICAL", 237, 240], ["KCl", "CHEMICAL", 166, 169], ["KCl", "CHEMICAL", 201, 204], ["KCl", "CHEMICAL", 237, 240], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["salt", "SIMPLE_CHEMICAL", 140, 144], ["C KCl", "SIMPLE_CHEMICAL", 164, 169], ["salt", "SIMPLE_CHEMICAL", 174, 178], ["Salt dependence", "PROBLEM", 0, 15], ["DNA condensation efficiency of the ligand", "PROBLEM", 19, 60], ["EC 50 (ligand concentration at the transition midpoint)", "TREATMENT", 62, 117], ["low C KCl", "TREATMENT", 160, 169], ["salt-dependent at higher C KCl", "TREATMENT", 174, 204], ["steep increase of EC", "TREATMENT", 206, 226], ["C KCl", "TREATMENT", 235, 240], ["dependence", "OBSERVATION", 5, 15], ["DNA condensation efficiency", "OBSERVATION", 19, 46], ["ligand", "ANATOMY", 54, 60]]], ["Simple formula describing EC 50 as function of ligand charge, C DNA and dissociation constant of ligand-DNA complex (K d ), was proposed.AFM Study of Protein Redistribution upon Lipid Domain Formation in Supported Lipid BilayersIn the salt-independent regime EC 50 is defined by C DNA .", [["EC", "ANATOMY", 26, 28], ["EC", "CELL", 26, 28], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["EC", "CELL", 259, 261], ["DNA", "CELLULAR_COMPONENT", 281, 284], ["ligand-DNA complex", "PROTEIN", 97, 115], ["EC 50", "CELL_LINE", 259, 264], ["C DNA", "DNA", 279, 284], ["EC", "TEST", 26, 28], ["ligand charge", "TEST", 47, 60], ["C DNA", "PROBLEM", 62, 67], ["dissociation", "PROBLEM", 72, 84], ["AFM Study", "TEST", 137, 146], ["Protein Redistribution", "PROBLEM", 150, 172], ["Lipid Domain Formation", "TREATMENT", 178, 200], ["Supported Lipid Bilayers", "TREATMENT", 204, 228], ["Protein Redistribution", "OBSERVATION", 150, 172], ["Lipid Domain", "OBSERVATION", 178, 190], ["Lipid Bilayers", "OBSERVATION", 214, 228]]], ["Salt-dependence of EC 50 is rooted in the variation of K d with C KCl earlier described in ligand-DNA binding studies.", [["EC", "ANATOMY", 19, 21], ["EC", "CHEMICAL", 19, 21], ["K", "CHEMICAL", 55, 56], ["KCl", "CHEMICAL", 66, 69], ["KCl", "CHEMICAL", 66, 69], ["EC", "CELL", 19, 21], ["K d", "GENE_OR_GENE_PRODUCT", 55, 58], ["C KCl", "SIMPLE_CHEMICAL", 64, 69], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["C KCl", "TREATMENT", 64, 69], ["DNA binding studies", "TEST", 98, 117]]], ["Importance of our findings for description of chromatin is discussed.O-32Interaction between proteins from linker region of nucleosome in presence/absence of DNA in solution I. B. Kipenko 1 , E. V. Chikhirzhina 2 , A. M. Polyanichko 1 1 Faculty of Physics, Saint-Petersburg State University, Russia, 2 Laboratory of Cell Biochemistry, Institute of Cytology, RAS, Saint-Petersburg, RussiaO-32Interactions in the linker region of the nucleosome play a key role in the structural organization of the chromatin.", [["chromatin", "ANATOMY", 46, 55], ["nucleosome", "ANATOMY", 124, 134], ["Cell", "ANATOMY", 316, 320], ["nucleosome", "ANATOMY", 432, 442], ["chromatin", "ANATOMY", 497, 506], ["chromatin", "CELLULAR_COMPONENT", 46, 55], ["O-32Interaction", "GENE_OR_GENE_PRODUCT", 69, 84], ["nucleosome", "CELLULAR_COMPONENT", 124, 134], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["Cell", "CELL", 316, 320], ["nucleosome", "CELLULAR_COMPONENT", 432, 442], ["chromatin", "CELLULAR_COMPONENT", 497, 506], ["chromatin", "DNA", 46, 55], ["linker region", "PROTEIN", 107, 120], ["nucleosome", "PROTEIN", 124, 134], ["linker region", "PROTEIN", 411, 424], ["chromatin", "DNA", 497, 506], ["Cytology", "TEST", 348, 356], ["nucleosome", "ANATOMY", 124, 134], ["nucleosome", "ANATOMY", 432, 442]]], ["The most fascinating and least understood is the interplay between non-histone chromatin protein HMGB1 and a linker histone H1.", [["chromatin", "ANATOMY", 79, 88], ["chromatin", "CELLULAR_COMPONENT", 79, 88], ["HMGB1", "GENE_OR_GENE_PRODUCT", 97, 102], ["histone H1", "GENE_OR_GENE_PRODUCT", 116, 126], ["non-histone chromatin protein", "PROTEIN", 67, 96], ["HMGB1", "PROTEIN", 97, 102], ["linker histone H1", "PROTEIN", 109, 126], ["non-histone chromatin protein HMGB1", "TREATMENT", 67, 102], ["a linker histone H1", "TREATMENT", 107, 126], ["chromatin protein HMGB1", "OBSERVATION", 79, 102]]], ["It is known that both H1 and HMGB1 bind the linker region of the DNA in vivo.", [["H1", "GENE_OR_GENE_PRODUCT", 22, 24], ["HMGB1", "GENE_OR_GENE_PRODUCT", 29, 34], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["H1", "PROTEIN", 22, 24], ["HMGB1", "PROTEIN", 29, 34], ["linker region", "PROTEIN", 44, 57], ["linker", "OBSERVATION_MODIFIER", 44, 50], ["DNA", "OBSERVATION", 65, 68]]], ["The main attention in this work is paid to the investigation of the interactions between the HMGB1 and H1 proteins in physiological environment.", [["HMGB1", "GENE_OR_GENE_PRODUCT", 93, 98], ["H1 proteins", "GENE_OR_GENE_PRODUCT", 103, 114], ["HMGB1", "PROTEIN", 93, 98], ["H1 proteins", "PROTEIN", 103, 114], ["the HMGB1", "TREATMENT", 89, 98], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Using circular dichroism (CD) spectroscopy we have studied the interactions between HMGB1 and H1 at various HMGB1/H1 ratios (R).", [["HMGB1", "GENE_OR_GENE_PRODUCT", 84, 89], ["H1", "GENE_OR_GENE_PRODUCT", 94, 96], ["HMGB1", "GENE_OR_GENE_PRODUCT", 108, 113], ["H1", "GENE_OR_GENE_PRODUCT", 114, 116], ["HMGB1", "PROTEIN", 84, 89], ["H1", "PROTEIN", 94, 96], ["HMGB1", "PROTEIN", 108, 113], ["H1", "PROTEIN", 114, 116], ["circular dichroism (CD) spectroscopy", "TEST", 6, 42], ["HMGB1", "TEST", 84, 89], ["H1", "PROBLEM", 94, 96]]], ["It has been shown that there is a CDdetectable interaction between the proteins H1 and HMGB1 at R < 1.", [["H1", "GENE_OR_GENE_PRODUCT", 80, 82], ["HMGB1", "GENE_OR_GENE_PRODUCT", 87, 92], ["H1", "PROTEIN", 80, 82], ["HMGB1", "PROTEIN", 87, 92], ["the proteins H1", "TREATMENT", 67, 82], ["HMGB1", "TEST", 87, 92]]], ["We have demonstrated that the interaction between these proteins results in changes of their secondary structure.", [["these proteins", "TEST", 50, 64], ["secondary structure", "OBSERVATION", 93, 112]]], ["CD indicates that the structural impact of the unordered fragments decreases while the net \u03b1-helicity of the proteins increases upon the interaction.", [["fragments", "ANATOMY", 57, 66], ["the unordered fragments", "PROBLEM", 43, 66], ["structural", "OBSERVATION_MODIFIER", 22, 32], ["impact", "OBSERVATION_MODIFIER", 33, 39], ["unordered", "OBSERVATION_MODIFIER", 47, 56], ["fragments", "OBSERVATION_MODIFIER", 57, 66], ["decreases", "OBSERVATION_MODIFIER", 67, 76], ["net", "OBSERVATION_MODIFIER", 87, 90]]], ["We have also shown that large higher order structures are formed in solution.", [["large", "OBSERVATION_MODIFIER", 24, 29], ["higher", "OBSERVATION_MODIFIER", 30, 36], ["order structures", "OBSERVATION_MODIFIER", 37, 53]]], ["In this work we have also discussed the DNA-binding properties of the HMGB1 and H1 proteins.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["HMGB1", "GENE_OR_GENE_PRODUCT", 70, 75], ["H1 proteins", "GENE_OR_GENE_PRODUCT", 80, 91], ["HMGB1", "PROTEIN", 70, 75], ["H1 proteins", "PROTEIN", 80, 91], ["the HMGB1 and H1 proteins", "PROBLEM", 66, 91], ["HMGB1", "ANATOMY", 70, 75]]], ["The work was supported by a RFBR grant (09-08-01119) and the Government of Staint-Petersburg.Structural changes of HMGB1 chromosomal protein upon binding to DNAT.", [["chromosomal", "ANATOMY", 121, 132], ["HMGB1", "GENE_OR_GENE_PRODUCT", 115, 120], ["chromosomal", "CELLULAR_COMPONENT", 121, 132], ["DNAT", "GENE_OR_GENE_PRODUCT", 157, 161], ["HMGB1 chromosomal protein", "PROTEIN", 115, 140], ["DNAT", "PROTEIN", 157, 161], ["Structural changes of HMGB1 chromosomal protein", "PROBLEM", 93, 140], ["HMGB1 chromosomal protein", "OBSERVATION", 115, 140]]], ["U. Rodionova 1 , A. M. Polyanichko 1 , V. I. Vorob'ev 2 1 Faculty of Physics, Saint-Petersburg State University, Russia, 2 Institute of Cytology of the Russian Academy of Sciences, Saint-Petersburg, Russia HMGB1 is a nonhistone chromosomal protein.", [["chromosomal", "ANATOMY", 228, 239], ["HMGB1", "GENE_OR_GENE_PRODUCT", 206, 211], ["nonhistone", "CELLULAR_COMPONENT", 217, 227], ["chromosomal", "CELLULAR_COMPONENT", 228, 239], ["HMGB1", "PROTEIN", 206, 211], ["nonhistone chromosomal protein", "PROTEIN", 217, 247], ["Polyanichko", "TEST", 23, 34], ["a nonhistone chromosomal protein", "PROBLEM", 215, 247]]], ["Data regarding the structure of the HMGB-proteins obtained so far are rather different.", [["HMGB", "GENE_OR_GENE_PRODUCT", 36, 40], ["HMGB-proteins", "PROTEIN", 36, 49], ["the HMGB-proteins", "TEST", 32, 49]]], ["Thermodynamic experiments reveal predominant \u03b1-helical structure of the proteins only at temperatures below +5 \u2022 C, i.e. under physiological conditions they are mainly disordered.", [["\u03b1-helical structure", "PROTEIN", 45, 64], ["Thermodynamic experiments", "TEST", 0, 25], ["predominant", "OBSERVATION_MODIFIER", 33, 44], ["\u03b1-helical structure", "OBSERVATION", 45, 64]]], ["Despite a lot of experimental data biological role of HMGB1 still remains unclear.", [["HMGB1", "GENE_OR_GENE_PRODUCT", 54, 59], ["HMGB1", "PROTEIN", 54, 59], ["HMGB1", "PROBLEM", 54, 59]]], ["It is believed that the proteins perform structural functions in chromatin and participate in various regulatory processes in cell.", [["chromatin", "ANATOMY", 65, 74], ["cell", "ANATOMY", 126, 130], ["chromatin", "CELLULAR_COMPONENT", 65, 74], ["cell", "CELL", 126, 130], ["chromatin", "DNA", 65, 74], ["the proteins", "PROBLEM", 20, 32]]], ["Using circular dichroism spectroscopy and DNA melting analysis we have shown that HMGB1 changes its structure upon binding to DNA.", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["HMGB1", "GENE_OR_GENE_PRODUCT", 82, 87], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["HMGB1", "PROTEIN", 82, 87], ["circular dichroism spectroscopy", "TEST", 6, 37], ["DNA melting analysis", "TEST", 42, 62], ["HMGB1", "PROBLEM", 82, 87], ["HMGB1", "OBSERVATION", 82, 87]]], ["It was shown that at room temperature only about 25% of amino acid residues form \u03b1-helices, while in DNA-HMGB1complex the degree of the \u03b1-helicity of the protein increases to approximately 50%.", [["amino acid", "CHEMICAL", 56, 66], ["amino acid", "CHEMICAL", 56, 66], ["amino acid", "AMINO_ACID", 56, 66], ["\u03b1-helices", "SIMPLE_CHEMICAL", 81, 90], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["-HMGB1", "GENE_OR_GENE_PRODUCT", 104, 110], ["\u03b1-helices", "PROTEIN", 81, 90], ["DNA-HMGB1complex", "PROTEIN", 101, 117], ["amino acid residues form \u03b1-helices", "PROBLEM", 56, 90], ["DNA", "TEST", 101, 104]]], ["Based on the data obtained we estimate the size of HMGB1 binding site as 80-100 b.p.", [["HMGB1", "GENE_OR_GENE_PRODUCT", 51, 56], ["HMGB1 binding site", "DNA", 51, 69], ["the data", "TEST", 9, 17], ["HMGB1 binding site", "PROBLEM", 51, 69], ["size", "OBSERVATION_MODIFIER", 43, 47], ["HMGB1 binding", "OBSERVATION", 51, 64]]], ["We have also demonstrated that despite of strong DNA-bending properties of HMGB1 its binding to DNA results in increase of the double helix termostability.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["HMGB1", "GENE_OR_GENE_PRODUCT", 75, 80], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["HMGB1", "PROTEIN", 75, 80], ["strong DNA", "PROBLEM", 42, 52], ["HMGB1", "PROBLEM", 75, 80], ["the double helix termostability", "TREATMENT", 123, 154], ["increase", "OBSERVATION_MODIFIER", 111, 119], ["double helix termostability", "OBSERVATION", 127, 154]]], ["The authors are grateful for the financial support from the Russian Foundation for Basic Research (grants 09-08-01119, 07-04-01072) and the Government of Saint-Petersburg.P-38Structural organization of supramolecular complexes of DNA with chromosomal proteins HMGB1 and H1P-38A.", [["chromosomal", "ANATOMY", 239, 250], ["H1P-38A", "CHEMICAL", 270, 277], ["DNA", "CELLULAR_COMPONENT", 230, 233], ["chromosomal", "CELLULAR_COMPONENT", 239, 250], ["HMGB1", "GENE_OR_GENE_PRODUCT", 260, 265], ["H1P-38A", "GENE_OR_GENE_PRODUCT", 270, 277], ["P", "DNA", 171, 172], ["supramolecular complexes", "PROTEIN", 202, 226], ["chromosomal proteins", "PROTEIN", 239, 259], ["HMGB1", "PROTEIN", 260, 265], ["H1P", "PROTEIN", 270, 273], ["38A", "PROTEIN", 274, 277], ["supramolecular complexes of DNA", "PROBLEM", 202, 233], ["chromosomal proteins HMGB1", "TEST", 239, 265], ["H1P", "TEST", 270, 273], ["supramolecular complexes", "OBSERVATION", 202, 226]]], ["M. Polyanichko 1 , H. Wieser 2 1 Faculty of Physics, Saint-Petersburg State University, Russia, 2 Dept. of Chemistry, University of Calgary, Canada A combination of UV and IR absorption and circular dichroism spectroscopy together with atomic Force Microscopy was applied to investigate the structure and formation of large supramolecular DNA-protein complexes.", [["DNA", "CELLULAR_COMPONENT", 339, 342], ["large supramolecular DNA-protein complexes", "PROTEIN", 318, 360], ["UV and IR absorption", "TREATMENT", 165, 185], ["circular dichroism spectroscopy", "TEST", 190, 221], ["atomic Force Microscopy", "TEST", 236, 259], ["large supramolecular DNA-protein complexes", "PROBLEM", 318, 360], ["large", "OBSERVATION_MODIFIER", 318, 323], ["supramolecular DNA", "OBSERVATION", 324, 342], ["protein complexes", "OBSERVATION", 343, 360]]], ["This combination of techniques was used to overcome limitations of UV-CD spectroscopy due to considerable light scattering in such solutions.", [["UV", "TREATMENT", 67, 69], ["CD spectroscopy", "TEST", 70, 85], ["considerable light scattering in such solutions", "PROBLEM", 93, 140]]], ["Based on the analysis of FTIR and UV circular dichroism spectra and AFM data the interaction of DNA with highmobility group non-histone chromatin protein HMGB1 and linker histone H1 was studied.", [["DNA", "CELLULAR_COMPONENT", 96, 99], ["HMGB1", "GENE_OR_GENE_PRODUCT", 154, 159], ["linker histone H1", "GENE_OR_GENE_PRODUCT", 164, 181], ["highmobility group non-histone chromatin protein", "PROTEIN", 105, 153], ["HMGB1", "PROTEIN", 154, 159], ["linker histone H1", "PROTEIN", 164, 181], ["the analysis", "TEST", 9, 21], ["FTIR", "TEST", 25, 29], ["UV circular dichroism spectra", "TEST", 34, 63], ["AFM data", "TEST", 68, 76], ["DNA", "PROBLEM", 96, 99], ["highmobility group non-histone chromatin protein HMGB1", "TREATMENT", 105, 159], ["linker histone H1", "TREATMENT", 164, 181]]], ["It is believed, that HMGB-domain proteins perform both structural and regulatory functions in chromatin.", [["chromatin", "ANATOMY", 94, 103], ["HMGB-domain", "GENE_OR_GENE_PRODUCT", 21, 32], ["chromatin", "CELLULAR_COMPONENT", 94, 103], ["HMGB-domain proteins", "PROTEIN", 21, 41], ["chromatin", "DNA", 94, 103], ["HMGB-domain proteins", "PROBLEM", 21, 41]]], ["However, the particular mechanisms of it functioning remain unclear/ Our data show that histone H1 facilitated binding of HMGB1 to DNA by interacting with the sugar-phosphate backbone and binding of Aspamino acid residues of HMGB1.", [["phosphate", "CHEMICAL", 165, 174], ["Aspamino acid", "CHEMICAL", 199, 212], ["sugar", "CHEMICAL", 159, 164], ["phosphate", "CHEMICAL", 165, 174], ["Aspamino acid", "CHEMICAL", 199, 212], ["histone H1", "GENE_OR_GENE_PRODUCT", 88, 98], ["HMGB1", "GENE_OR_GENE_PRODUCT", 122, 127], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["sugar", "SIMPLE_CHEMICAL", 159, 164], ["Aspamino acid", "SIMPLE_CHEMICAL", 199, 212], ["HMGB1", "GENE_OR_GENE_PRODUCT", 225, 230], ["histone H1", "PROTEIN", 88, 98], ["HMGB1", "PROTEIN", 122, 127], ["HMGB1", "PROTEIN", 225, 230], ["Our data", "TEST", 69, 77], ["histone H1", "PROBLEM", 88, 98], ["the sugar-phosphate backbone", "TREATMENT", 155, 183], ["Aspamino acid residues", "TREATMENT", 199, 221], ["HMGB1", "PROBLEM", 225, 230]]], ["Acting together, HMGB1 and H1 stimulated the assemblage of supramolecular DNA-protein structures.", [["HMGB1", "GENE_OR_GENE_PRODUCT", 17, 22], ["H1", "GENE_OR_GENE_PRODUCT", 27, 29], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["HMGB1", "PROTEIN", 17, 22], ["H1", "PROTEIN", 27, 29], ["HMGB1", "TEST", 17, 22], ["supramolecular DNA", "OBSERVATION", 59, 77]]], ["The organization of the ternary complexes is modulated by the interactions between HMGB1 and H1 molecules.", [["HMGB1", "GENE_OR_GENE_PRODUCT", 83, 88], ["H1 molecules", "GENE_OR_GENE_PRODUCT", 93, 105], ["ternary complexes", "PROTEIN", 24, 41], ["HMGB1", "PROTEIN", 83, 88], ["H1 molecules", "PROTEIN", 93, 105], ["the interactions between HMGB1 and H1 molecules", "PROBLEM", 58, 105], ["ternary complexes", "OBSERVATION", 24, 41], ["H1 molecules", "OBSERVATION", 93, 105]]], ["The DNA-proteins interactions in the presence of metal ions were different, causing prominent DNA compaction and formation of large intermolecular complexes.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["metal ions", "SIMPLE_CHEMICAL", 49, 59], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["DNA-proteins", "PROTEIN", 4, 16], ["intermolecular complexes", "PROTEIN", 132, 156], ["metal ions", "PROBLEM", 49, 59], ["prominent DNA compaction", "PROBLEM", 84, 108], ["large intermolecular complexes", "PROBLEM", 126, 156], ["proteins interactions", "OBSERVATION", 8, 29], ["metal ions", "OBSERVATION", 49, 59], ["prominent", "OBSERVATION_MODIFIER", 84, 93], ["DNA compaction", "OBSERVATION", 94, 108], ["large", "OBSERVATION_MODIFIER", 126, 131], ["intermolecular complexes", "OBSERVATION", 132, 156]]], ["The work was supported by RFBR (grant 09-08-01119).O-37Biophysical properties and mechanisms of phage DNA ejection T. Mdzinarashvili 1 , M. Khvedelidze 2 , A. Ivanova 1 , T. Partskhaladze 1 , N. Shengelia 1 1 I. Javakhishvili Tbilisi State University, Tbilisi, Georgia, 2 Institute of Molecular Biology and Biophysics, Tbilisi, GeorgiaO-37To determine the requirements for phage adsorption on bacterial cell and for the realizing resources of following DNA ejection thermodynamic and hydrodynamic methods were employed.", [["cell", "ANATOMY", 403, 407], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["bacterial cell", "CELL", 393, 407], ["DNA", "CELLULAR_COMPONENT", 453, 456], ["bacterial cell", "CELL_TYPE", 393, 407], ["T. Partskhaladze 1", "SPECIES", 171, 189], ["phage DNA ejection T. Mdzinarashvili", "TREATMENT", 96, 132], ["GeorgiaO", "TEST", 328, 336], ["phage adsorption", "TREATMENT", 373, 389], ["bacterial cell", "TREATMENT", 393, 407], ["hydrodynamic methods", "TREATMENT", 484, 504], ["bacterial cell", "OBSERVATION", 393, 407]]], ["The temperature, bacterial membrane fragments and receptors had been chosen as such external factors.", [["membrane fragments", "ANATOMY", 27, 45], ["bacterial membrane fragments", "PROTEIN", 17, 45], ["The temperature", "TEST", 0, 15], ["bacterial membrane fragments", "PROBLEM", 17, 45], ["receptors", "TREATMENT", 50, 59], ["bacterial membrane fragments", "OBSERVATION", 17, 45]]], ["The phages with short and long tail, both contractile and noncontractile have been studied.", [["tail", "ANATOMY", 31, 35], ["long tail", "CELLULAR_COMPONENT", 26, 35], ["short and long tail", "PROBLEM", 16, 35]]], ["Our viscometric studies of the phage DNA ejection induced by receptor by the example of T5 phage and its receptor FhuA have shown that the minimum protein-to-phage ratio necessary for complete DNA release is 300 to 1.", [["DNA", "CELLULAR_COMPONENT", 37, 40], ["T5 phage", "GENE_OR_GENE_PRODUCT", 88, 96], ["FhuA", "GENE_OR_GENE_PRODUCT", 114, 118], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["T5 phage", "PROTEIN", 88, 96], ["FhuA", "PROTEIN", 114, 118], ["Our viscometric studies", "TEST", 0, 23], ["the phage DNA ejection", "TREATMENT", 27, 49], ["T5 phage", "TREATMENT", 88, 96], ["its receptor FhuA", "TEST", 101, 118], ["the minimum protein", "TEST", 135, 154], ["complete DNA release", "TEST", 184, 204]]], ["The viscometric study of DDVI phage DNA ejection induced by membrane fragments obtained from its host cells has shown that the environmental conditions play significant role in ejection process.", [["membrane fragments", "ANATOMY", 60, 78], ["cells", "ANATOMY", 102, 107], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["membrane fragments", "CELLULAR_COMPONENT", 60, 78], ["host cells", "CELL", 97, 107], ["host cells", "CELL_TYPE", 97, 107], ["The viscometric study", "TEST", 0, 21], ["DDVI phage DNA ejection", "TREATMENT", 25, 48], ["membrane fragments", "PROBLEM", 60, 78], ["the environmental conditions", "PROBLEM", 123, 151], ["membrane fragments", "OBSERVATION", 60, 78]]], ["Both methods show that the thermally induced phage DNA ejection for all investigated by us phages have shown that this process is nonenthalpic.", [["DNA", "CELLULAR_COMPONENT", 51, 54], ["the thermally induced phage DNA ejection", "TREATMENT", 23, 63]]], ["Finally from our experimental results we conclude that the start of the DNA ejection process from the phage particle occurs without additional energy from either a physical or chemical source.", [["DNA", "CELLULAR_COMPONENT", 72, 75], ["the DNA ejection process", "PROBLEM", 68, 92], ["the phage particle", "PROBLEM", 98, 116]]], ["We thank GNSF for the financial support.P-36Nitroxides induce apoptosis through caspase-3 activation and collapse of mitochondrial potential K. Matczak 1 , A. Koceva-Chyla 1 , K. Gwozdzinski 2 , Z. Jozwiak 1 1 Department of Thermobiology, 2 Department of Molecular Biophysics, University of Lodz, Lodz, PolandP-36Nitroxides are new class of antioxidants that have been proved to show high reactivity toward free radicals.", [["mitochondrial", "ANATOMY", 117, 130], ["P-36Nitroxides", "CHEMICAL", 40, 54], ["PolandP-36Nitroxides", "CHEMICAL", 303, 323], ["P-36Nitroxides", "CHEMICAL", 40, 54], ["P-36Nitroxides", "SIMPLE_CHEMICAL", 40, 54], ["caspase-3", "GENE_OR_GENE_PRODUCT", 80, 89], ["mitochondrial", "CELLULAR_COMPONENT", 117, 130], ["PolandP-36Nitroxides", "SIMPLE_CHEMICAL", 303, 323], ["free radicals", "SIMPLE_CHEMICAL", 407, 420], ["caspase-3", "PROTEIN", 80, 89], ["36Nitroxides", "TREATMENT", 42, 54], ["caspase", "TREATMENT", 80, 87], ["PolandP", "TREATMENT", 303, 310], ["36Nitroxides", "TREATMENT", 311, 323], ["antioxidants", "TREATMENT", 341, 353], ["high reactivity toward free radicals", "PROBLEM", 384, 420]]], ["They act as superoxide dismutase mimics dismutating superoxide anions, but can also exert pro-oxidative properties.", [["superoxide", "CHEMICAL", 12, 22], ["superoxide", "CHEMICAL", 52, 62], ["superoxide", "CHEMICAL", 12, 22], ["superoxide", "CHEMICAL", 52, 62], ["superoxide dismutase", "SIMPLE_CHEMICAL", 12, 32], ["superoxide anions", "SIMPLE_CHEMICAL", 52, 69], ["superoxide dismutase", "PROTEIN", 12, 32], ["superoxide dismutase mimics dismutating superoxide anions", "TREATMENT", 12, 69]]], ["In view of their possible dual activity nitroxides could be of great importance in medicine.", [["nitroxides", "CHEMICAL", 40, 50], ["nitroxides", "CHEMICAL", 40, 50], ["nitroxides", "SIMPLE_CHEMICAL", 40, 50], ["dual activity nitroxides", "TREATMENT", 26, 50]]], ["We have investigated pro-apoptotic activity of pyrroline and pyrrolidine nitroxides Pirolid (PD) and Pirolin (PL) in human breast cancer cells.", [["breast cancer cells", "ANATOMY", 123, 142], ["pyrroline", "CHEMICAL", 47, 56], ["pyrrolidine nitroxides", "CHEMICAL", 61, 83], ["Pirolin", "CHEMICAL", 101, 108], ["breast cancer", "DISEASE", 123, 136], ["pyrroline", "CHEMICAL", 47, 56], ["pyrrolidine nitroxides", "CHEMICAL", 61, 83], ["Pirolid", "CHEMICAL", 84, 91], ["Pirolin", "CHEMICAL", 101, 108], ["pyrroline", "SIMPLE_CHEMICAL", 47, 56], ["pyrrolidine nitroxides Pirolid", "SIMPLE_CHEMICAL", 61, 91], ["PD", "SIMPLE_CHEMICAL", 93, 95], ["Pirolin", "SIMPLE_CHEMICAL", 101, 108], ["PL", "SIMPLE_CHEMICAL", 110, 112], ["human", "ORGANISM", 117, 122], ["breast cancer cells", "CELL", 123, 142], ["human breast cancer cells", "CELL_TYPE", 117, 142], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["pyrroline", "TREATMENT", 47, 56], ["pyrrolidine nitroxides Pirolid (PD)", "TREATMENT", 61, 96], ["Pirolin (PL) in human breast cancer cells", "TREATMENT", 101, 142], ["breast", "ANATOMY", 123, 129], ["cancer cells", "OBSERVATION", 130, 142]]], ["In cancer, it is the failure of malignant cells to undergo apoptosis that is crucial.", [["cancer", "ANATOMY", 3, 9], ["malignant cells", "ANATOMY", 32, 47], ["cancer", "DISEASE", 3, 9], ["cancer", "CANCER", 3, 9], ["malignant cells", "CELL", 32, 47], ["malignant cells", "CELL_TYPE", 32, 47], ["malignant cells", "PROBLEM", 32, 47], ["apoptosis", "PROBLEM", 59, 68], ["cancer", "OBSERVATION", 3, 9], ["failure", "OBSERVATION_MODIFIER", 21, 28], ["malignant cells", "OBSERVATION", 32, 47], ["apoptosis", "OBSERVATION", 59, 68]]], ["Using microplate fluorescence methods, we estimated kinetics of changes in mitochondrial transmembrane potential and caspase-3 activity in breast cancer cells MCF-7 treated with Pirolin or Pirolid.", [["mitochondrial transmembrane", "ANATOMY", 75, 102], ["breast cancer cells MCF-7", "ANATOMY", 139, 164], ["breast cancer", "DISEASE", 139, 152], ["Pirolin", "CHEMICAL", 178, 185], ["Pirolid", "CHEMICAL", 189, 196], ["Pirolin", "CHEMICAL", 178, 185], ["Pirolid", "CHEMICAL", 189, 196], ["mitochondrial", "CELLULAR_COMPONENT", 75, 88], ["caspase-3", "GENE_OR_GENE_PRODUCT", 117, 126], ["breast cancer cells MCF-7", "CELL", 139, 164], ["Pirolin", "SIMPLE_CHEMICAL", 178, 185], ["Pirolid", "SIMPLE_CHEMICAL", 189, 196], ["caspase-3", "PROTEIN", 117, 126], ["breast cancer cells MCF-7", "CELL_LINE", 139, 164], ["microplate fluorescence methods", "TEST", 6, 37], ["mitochondrial transmembrane potential", "TREATMENT", 75, 112], ["caspase-3 activity in breast cancer cells", "TREATMENT", 117, 158], ["MCF", "TEST", 159, 162], ["Pirolin", "TREATMENT", 178, 185], ["Pirolid", "TREATMENT", 189, 196], ["breast", "ANATOMY", 139, 145], ["cancer", "OBSERVATION", 146, 152]]], ["These features are connected with induction of apoptosis in some type of cancer cells.", [["cancer cells", "ANATOMY", 73, 85], ["cancer", "DISEASE", 73, 79], ["cancer cells", "CELL", 73, 85], ["cancer cells", "CELL_TYPE", 73, 85], ["apoptosis", "PROBLEM", 47, 56], ["cancer cells", "PROBLEM", 73, 85], ["some type", "OBSERVATION_MODIFIER", 60, 69], ["cancer cells", "OBSERVATION", 73, 85]]], ["We observed steady-state increase in caspase-3 activity up to 12 h of postincubation that was followed by a decrease in the enzyme activity at 24 h.", [["caspase-3", "GENE_OR_GENE_PRODUCT", 37, 46], ["caspase-3", "PROTEIN", 37, 46], ["caspase", "TREATMENT", 37, 44], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["Caspase-3 activation was considerably greater in cells treated with Pirolid.", [["cells", "ANATOMY", 49, 54], ["Pirolid", "CHEMICAL", 68, 75], ["Pirolid", "CHEMICAL", 68, 75], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 0, 9], ["cells", "CELL", 49, 54], ["Pirolid", "SIMPLE_CHEMICAL", 68, 75], ["Caspase-3", "PROTEIN", 0, 9], ["Caspase-3 activation", "TREATMENT", 0, 20], ["Pirolid", "TREATMENT", 68, 75]]], ["Both nitroxides also caused notable decrease in mitochondrial transmembrane potential, which suggest that they can induce apoptosis in breast cancer cells through mitochondrial pathway.In vivo study of mouse experimental melanoma by combination of confocal and nonlinear microscopyO.", [["mitochondrial transmembrane", "ANATOMY", 48, 75], ["breast cancer cells", "ANATOMY", 135, 154], ["mitochondrial", "ANATOMY", 163, 176], ["melanoma", "ANATOMY", 221, 229], ["nitroxides", "CHEMICAL", 5, 15], ["breast cancer", "DISEASE", 135, 148], ["melanoma", "DISEASE", 221, 229], ["nitroxides", "CHEMICAL", 5, 15], ["nitroxides", "SIMPLE_CHEMICAL", 5, 15], ["mitochondrial", "CELLULAR_COMPONENT", 48, 61], ["breast cancer cells", "CELL", 135, 154], ["mitochondrial", "CELLULAR_COMPONENT", 163, 176], ["mouse", "ORGANISM", 202, 207], ["melanoma", "CANCER", 221, 229], ["breast cancer cells", "CELL_TYPE", 135, 154], ["mouse", "SPECIES", 202, 207], ["mouse", "SPECIES", 202, 207], ["Both nitroxides", "TREATMENT", 0, 15], ["notable decrease in mitochondrial transmembrane potential", "PROBLEM", 28, 85], ["apoptosis in breast cancer cells", "PROBLEM", 122, 154], ["mouse experimental melanoma", "PROBLEM", 202, 229], ["confocal and nonlinear microscopyO", "TREATMENT", 248, 282], ["notable", "OBSERVATION_MODIFIER", 28, 35], ["decrease", "OBSERVATION_MODIFIER", 36, 44], ["mitochondrial transmembrane potential", "OBSERVATION", 48, 85], ["breast", "ANATOMY", 135, 141], ["cancer", "OBSERVATION", 142, 148], ["experimental melanoma", "OBSERVATION", 208, 229]]], ["Chernyavskiy 1 , L. Vannucci 2 , P. Bianchini 3 , F. Difato 4 , L. Kub\u00ednov\u00e1 1 1 Dept. of Biomathematics, Inst. of Physiology, AS CR, Prague, Czech Republic, 2 Dept. of Immunology, Inst. of Microbiology, AS CR, Prague, Czech Republic, 3 LAMBS, Dept. of Physics, University of Genoa, Italy, 4 Dept. of Neuroscience and Brain Technologies, The Italian Institute of Technology, Genoa, ItalyIn vivo study of mouse experimental melanoma by combination of confocal and nonlinear microscopyThe second harmonic generation (SHG) imaging along with confocal laser scanning microscopy in reflectance mode can be applied to imaging unstained tissues in vivo, so it can be considered as a fast and non-invasive tool for in vivo studies.", [["melanoma", "ANATOMY", 422, 430], ["tissues", "ANATOMY", 629, 636], ["melanoma", "DISEASE", 422, 430], ["mouse", "ORGANISM", 403, 408], ["melanoma", "CANCER", 422, 430], ["tissues", "TISSUE", 629, 636], ["mouse", "SPECIES", 403, 408], ["mouse", "SPECIES", 403, 408], ["mouse experimental melanoma", "PROBLEM", 403, 430], ["nonlinear microscopy", "TEST", 462, 482], ["The second harmonic generation (SHG) imaging", "TEST", 482, 526], ["confocal laser scanning microscopy", "TEST", 538, 572], ["imaging unstained tissues", "TEST", 611, 636], ["vivo studies", "TEST", 709, 721], ["Brain", "ANATOMY", 317, 322], ["melanoma", "OBSERVATION", 422, 430]]], ["Murine B16F10 melanoma cells after subcutaneous inoculation in syngeneic mice were let to develop into tumor up to 15-20 mm in diameter.", [["B16F10 melanoma cells", "ANATOMY", 7, 28], ["subcutaneous", "ANATOMY", 35, 47], ["tumor", "ANATOMY", 103, 108], ["melanoma", "DISEASE", 14, 22], ["tumor", "DISEASE", 103, 108], ["Murine", "ORGANISM", 0, 6], ["B16F10 melanoma cells", "CELL", 7, 28], ["syngeneic", "ORGANISM", 63, 72], ["mice", "ORGANISM", 73, 77], ["tumor", "CANCER", 103, 108], ["Murine B16F10 melanoma cells", "CELL_LINE", 0, 28], ["Murine", "SPECIES", 0, 6], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["Murine B16F10 melanoma cells", "TREATMENT", 0, 28], ["subcutaneous inoculation in syngeneic mice", "TREATMENT", 35, 77], ["tumor", "PROBLEM", 103, 108], ["B16F10 melanoma cells", "OBSERVATION", 7, 28], ["subcutaneous", "OBSERVATION_MODIFIER", 35, 47], ["inoculation", "OBSERVATION_MODIFIER", 48, 59], ["tumor", "OBSERVATION", 103, 108], ["15-20 mm", "OBSERVATION_MODIFIER", 115, 123]]], ["Microscopic images were taken before and after microwave hyperthermia treatment (MWHT).", [["hyperthermia", "DISEASE", 57, 69], ["Microscopic images", "TEST", 0, 18], ["microwave hyperthermia treatment", "TREATMENT", 47, 79]]], ["The microscopic images were acquired by 1-photon imaging in reflectance mode, SHG imaging and 2-photon imaging of tissue autofluorescence.", [["tissue", "ANATOMY", 114, 120], ["tissue", "TISSUE", 114, 120], ["The microscopic images", "TEST", 0, 22], ["photon imaging", "TEST", 42, 56], ["SHG imaging", "TEST", 78, 89], ["tissue autofluorescence", "TEST", 114, 137]]], ["The evaluation of changes in the images after MWHT of the tumor demonstrated changes in the architecture and organization in both the tumor capsule and tumor mass.", [["tumor", "ANATOMY", 58, 63], ["tumor capsule", "ANATOMY", 134, 147], ["tumor mass", "ANATOMY", 152, 162], ["tumor", "DISEASE", 58, 63], ["tumor", "DISEASE", 134, 139], ["tumor", "DISEASE", 152, 157], ["tumor", "CANCER", 58, 63], ["tumor capsule", "CANCER", 134, 147], ["tumor", "CANCER", 152, 157], ["The evaluation", "TEST", 0, 14], ["the images", "TEST", 29, 39], ["the tumor", "PROBLEM", 54, 63], ["changes in the architecture", "PROBLEM", 77, 104], ["tumor mass", "PROBLEM", 152, 162], ["tumor", "OBSERVATION", 58, 63], ["both", "ANATOMY_MODIFIER", 125, 129], ["tumor", "OBSERVATION", 134, 139], ["capsule", "OBSERVATION_MODIFIER", 140, 147], ["tumor", "OBSERVATION_MODIFIER", 152, 157], ["mass", "OBSERVATION", 158, 162]]], ["The presented study was supported by the Academy of Sciences of the Czech Republic (grant IAA500200510, InstitutionalIn vivo study of mouse experimental melanoma by combination of confocal and nonlinear microscopyResearch Concepts No.AV0Z50200510, AV0Z50110509), and Ministry of Education, Youth and Sports of the Czech Republic (research program LC06063).P-44Intracellular delivery and fate of peptide-capped gold nanoparticles: towards cellular biosensors Y. Cesbron 1 , V. S\u00e9e 1 , P. Free 1 , P. Nativo 1 , D. G. Spiller 1 , M. R. H. White 1 , M. Brust 1 , B. Lounis 2 , R. L\u00e9vy 1 1 Liverpool Institute for Nanoscale Science, Engineering and Technology, Liverpool, UK, 2 Universit\u00e9 Bordeaux I / CNRS, Bordeaux, France Gold nanoparticles (NPs) have extraordinary optical properties that make them very attractive single molecule labels.", [["melanoma", "ANATOMY", 153, 161], ["cellular", "ANATOMY", 438, 446], ["melanoma", "DISEASE", 153, 161], ["P-44Intracellular", "CHEMICAL", 356, 373], ["gold nanoparticles", "CHEMICAL", 410, 428], ["mouse", "ORGANISM", 134, 139], ["melanoma", "CANCER", 153, 161], ["peptide-capped gold nanoparticles", "SIMPLE_CHEMICAL", 395, 428], ["cellular", "CELL", 438, 446], ["Gold nanoparticles", "SIMPLE_CHEMICAL", 721, 739], ["mouse", "SPECIES", 134, 139], ["mouse", "SPECIES", 134, 139], ["The presented study", "TEST", 0, 19], ["mouse experimental melanoma", "PROBLEM", 134, 161], ["nonlinear microscopy", "TEST", 193, 213], ["44Intracellular delivery", "TREATMENT", 358, 382], ["fate of peptide", "TREATMENT", 387, 402], ["capped gold nanoparticles", "TREATMENT", 403, 428], ["Cesbron", "TEST", 461, 468], ["France Gold nanoparticles (NPs", "TREATMENT", 714, 744], ["extraordinary optical properties", "TREATMENT", 751, 783], ["melanoma", "OBSERVATION", 153, 161]]], ["Although understanding their dynamic interactions with biomolecules, living cells and organisms is a prerequisite for their use as in situ sensors or actuators.", [["cells", "ANATOMY", 76, 81], ["cells", "CELL", 76, 81]]], ["While recent research has provided indications on the effect of size, shape, and surface properties of NPs on their internalization by living cells, the biochemical fate of NPs after internalization has been essentially unknown.", [["surface", "ANATOMY", 81, 88], ["cells", "ANATOMY", 142, 147], ["NPs", "CHEMICAL", 173, 176], ["NPs", "SIMPLE_CHEMICAL", 103, 106], ["cells", "CELL", 142, 147], ["NPs", "SIMPLE_CHEMICAL", 173, 176], ["NPs", "TREATMENT", 103, 106], ["size", "OBSERVATION_MODIFIER", 64, 68], ["shape", "OBSERVATION_MODIFIER", 70, 75]]], ["Here we show that peptide-capped gold NPs enter mammalian cells by endocytosis.", [["cells", "ANATOMY", 58, 63], ["gold NPs", "SIMPLE_CHEMICAL", 33, 41], ["mammalian cells", "CELL", 48, 63], ["mammalian cells", "CELL_TYPE", 48, 63], ["peptide", "TEST", 18, 25], ["capped gold NPs", "TREATMENT", 26, 41], ["mammalian cells", "OBSERVATION", 48, 63], ["endocytosis", "OBSERVATION_MODIFIER", 67, 78]]], ["We demonstrate that the peptide layer is subsequently degraded within the endosomal compartments through peptide cleavage by the ubiquitous endosomal protease cathepsin L. Preservation of the peptide layer integrity and cytosolic delivery of NPs can be achieved by a combination of cathepsin inhibition and endosome disruption.", [["endosomal compartments", "ANATOMY", 74, 96], ["endosomal", "ANATOMY", 140, 149], ["cytosolic", "ANATOMY", 220, 229], ["endosome", "ANATOMY", 307, 315], ["endosomal compartments", "CELLULAR_COMPONENT", 74, 96], ["endosomal", "CELLULAR_COMPONENT", 140, 149], ["cathepsin L.", "GENE_OR_GENE_PRODUCT", 159, 171], ["NPs", "SIMPLE_CHEMICAL", 242, 245], ["cathepsin", "GENE_OR_GENE_PRODUCT", 282, 291], ["endosome", "CELLULAR_COMPONENT", 307, 315], ["ubiquitous endosomal protease cathepsin", "PROTEIN", 129, 168], ["cathepsin", "PROTEIN", 282, 291], ["the peptide layer", "PROBLEM", 20, 37], ["peptide cleavage", "TREATMENT", 105, 121], ["the ubiquitous endosomal protease cathepsin L.", "TREATMENT", 125, 171], ["the peptide layer integrity", "TREATMENT", 188, 215], ["cytosolic delivery of NPs", "TREATMENT", 220, 245], ["cathepsin inhibition", "TREATMENT", 282, 302], ["endosome disruption", "PROBLEM", 307, 326], ["layer", "OBSERVATION_MODIFIER", 32, 37], ["endosomal compartments", "OBSERVATION", 74, 96], ["layer", "OBSERVATION_MODIFIER", 200, 205], ["integrity", "OBSERVATION_MODIFIER", 206, 215], ["endosome disruption", "OBSERVATION", 307, 326]]], ["This is demonstrated using a combination of distance-dependant fluorescence unquenching and photothermal heterodyne imaging.", [["distance-dependant fluorescence unquenching", "TREATMENT", 44, 87], ["photothermal heterodyne imaging", "TEST", 92, 123]]], ["These results prove the potential of peptide-capped gold NPs as cellular biosensors.", [["cellular", "ANATOMY", 64, 72], ["gold NPs", "SIMPLE_CHEMICAL", 52, 60], ["cellular", "CELL", 64, 72], ["peptide-capped gold NPs", "TREATMENT", 37, 60], ["cellular biosensors", "TREATMENT", 64, 83], ["cellular biosensors", "OBSERVATION", 64, 83]]], ["Current efforts focus on in-vivo labeling of NPs, nanoparticle-based real-time sensing of enzyme activity in living cells, and the development of photothermal microscopy for single nanoparticle imaging in living cells.P-43Towards intravital two photon microscopy study of lymphocytes mobility in lymphonodes M. Caccia 1 , L. Sironi 1 , M. Collini 1 , I. Zanoni 2 , T. Gorletta 2 , M. Di Gioia 2 , G. Francesca 2 1 Dipartimento di Fisica, Universit\u00e0 di Milano Bicocca, Italy, 2 Dipartimento di Biotecnologie e Bioscienze, Universit\u00e0 di Milano Bicocca, Italy During the last 30 years the edge between optical fluorescence based microscopy and the world of bio-medical research has become thinner and thinner and Two Photon Laser Scanning Microscopy (TPLSM) is one of the most powerful tool for immunological and medical research.", [["cells", "ANATOMY", 116, 121], ["cells", "ANATOMY", 212, 217], ["lymphocytes", "ANATOMY", 272, 283], ["NPs", "SIMPLE_CHEMICAL", 45, 48], ["nanoparticle", "SIMPLE_CHEMICAL", 50, 62], ["cells", "CELL", 116, 121], ["cells", "CELL", 212, 217], ["lymphocytes", "CELL", 272, 283], ["living cells", "CELL_TYPE", 109, 121], ["P", "DNA", 218, 219], ["lymphocytes", "CELL_TYPE", 272, 283], ["L. Sironi", "SPECIES", 322, 331], ["enzyme activity in living cells", "PROBLEM", 90, 121], ["photothermal microscopy", "TEST", 146, 169], ["single nanoparticle imaging", "TEST", 174, 201], ["intravital two photon microscopy study", "TEST", 230, 268], ["lymphocytes mobility", "PROBLEM", 272, 292], ["Caccia", "TEST", 311, 317], ["Zanoni", "TREATMENT", 354, 360], ["optical fluorescence based microscopy", "TEST", 599, 636], ["Two Photon Laser Scanning Microscopy", "TEST", 710, 746]]], ["One of the most limiting step in intravital microscopy is the preparation of the animal model and the number of animals to be sacrificed to get good statistics.", [["intravital microscopy", "TEST", 33, 54]]], ["We employ TPLSM to explanted lymphnodes.", [["lymphnodes", "ANATOMY", 29, 39], ["lymphnodes", "CANCER", 29, 39], ["explanted lymphnodes", "PROBLEM", 19, 39], ["lymphnodes", "OBSERVATION", 29, 39]]], ["Two photon excitation and a non descanned detection mode allow to increase, respectively, the excitation and detection efficiency while the explanted organs are kept very close to the condition they experience in live animals by means of an home-made temperature controlled box surrounding the microscope and a system for the flux of physiological fluids.", [["organs", "ANATOMY", 150, 156], ["organs", "ORGAN", 150, 156], ["Two photon excitation", "TREATMENT", 0, 21], ["a non descanned detection mode", "TREATMENT", 26, 56], ["temperature controlled box", "TREATMENT", 251, 277], ["the flux of physiological fluids", "TREATMENT", 322, 354]]], ["Experiments performed on explanted lymphonodes, kept under constant flux of CO 2 -O 2 saturated buffers and at 36 o C, agree with literature for what concern T-cell homing and motility.", [["lymphonodes", "ANATOMY", 35, 46], ["T-cell", "ANATOMY", 158, 164], ["CO 2 -O", "CHEMICAL", 76, 83], ["CO 2 -O 2 saturated buffers", "SIMPLE_CHEMICAL", 76, 103], ["T-cell", "CELL", 158, 164]]], ["This seems to confirm that T-cells behavior in explanted organs mantained in physiological conditions is very similar to that observed in live animals.", [["T-cells", "ANATOMY", 27, 34], ["organs", "ANATOMY", 57, 63], ["T-cells", "CELL", 27, 34], ["organs", "ORGAN", 57, 63], ["T-cells", "CELL_TYPE", 27, 34], ["T-cells behavior", "PROBLEM", 27, 43], ["organs", "ANATOMY", 57, 63]]], ["We then believe that our TPLSM microscope would allow to study cell behaviors in in-vivo with high efficiency and a little technical effort.P-42A generalized quantitative FRAP method with no restriction on the size of the photobleached area Heterochromatin protein 1 in DNA damage response -recruitment or dissociation from repair sites?", [["cell", "ANATOMY", 63, 67], ["cell", "CELL", 63, 67], ["Heterochromatin protein 1", "GENE_OR_GENE_PRODUCT", 241, 266], ["DNA", "CELLULAR_COMPONENT", 270, 273], ["Heterochromatin protein 1", "PROTEIN", 241, 266], ["our TPLSM microscope", "TEST", 21, 41], ["high efficiency", "PROBLEM", 94, 109], ["generalized quantitative FRAP method", "TREATMENT", 146, 182], ["Heterochromatin protein", "PROBLEM", 241, 264], ["DNA damage response", "PROBLEM", 270, 289], ["dissociation", "PROBLEM", 306, 318], ["repair sites", "TREATMENT", 324, 336], ["size", "OBSERVATION_MODIFIER", 210, 214], ["recruitment", "OBSERVATION_MODIFIER", 291, 302]]], ["J. W. Dobrucki Division of Cell Biophysics, Faculty of Biochem.", [["Cell", "ANATOMY", 27, 31], ["Cell", "CELL", 27, 31], ["Cell Biophysics", "OBSERVATION", 27, 42], ["Biochem", "ANATOMY", 55, 62]]], ["Biophys. and Biotechnol., Jagiellonian University, Krak\u00f3w, PolandP-42We studied recruitment of DNA repair proteins to damage sites in live cells, by microscopy approaches, using a new method of inflicting local, sublethal damage in nuclei of live cells.", [["cells", "ANATOMY", 139, 144], ["nuclei", "ANATOMY", 232, 238], ["cells", "ANATOMY", 247, 252], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["cells", "CELL", 139, 144], ["nuclei", "CELLULAR_COMPONENT", 232, 238], ["cells", "CELL", 247, 252], ["DNA repair proteins", "PROTEIN", 95, 114], ["live cells", "CELL_TYPE", 134, 144], ["live cells", "CELL_TYPE", 242, 252], ["Biotechnol", "TREATMENT", 13, 23], ["PolandP", "TREATMENT", 59, 66], ["DNA repair proteins", "TREATMENT", 95, 114], ["damage sites", "PROBLEM", 118, 130], ["sublethal damage in nuclei of live cells", "PROBLEM", 212, 252], ["live cells", "ANATOMY", 134, 144], ["sublethal damage", "OBSERVATION", 212, 228], ["live cells", "OBSERVATION", 242, 252]]], ["Oxidative damage, which was inflicted by exciting DNA-intercalated ethidium with focused green light, triggered recruitment of base excision repair enzymes.", [["ethidium", "CHEMICAL", 67, 75], ["ethidium", "CHEMICAL", 67, 75], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["ethidium", "SIMPLE_CHEMICAL", 67, 75], ["base excision repair enzymes", "PROTEIN", 127, 155], ["Oxidative damage", "PROBLEM", 0, 16], ["exciting DNA", "PROBLEM", 41, 53], ["intercalated ethidium", "PROBLEM", 54, 75], ["base excision repair enzymes", "TREATMENT", 127, 155], ["damage", "OBSERVATION", 10, 16], ["base", "ANATOMY_MODIFIER", 127, 131], ["excision", "OBSERVATION", 132, 140]]], ["Surprisingly, an epigenetic regulator, heterochromatin protein 1 (HP1) (Zarebski et al., 2009 ) was recruited to damage as well.", [["heterochromatin protein 1", "GENE_OR_GENE_PRODUCT", 39, 64], ["HP1", "GENE_OR_GENE_PRODUCT", 66, 69], ["epigenetic regulator", "PROTEIN", 17, 37], ["heterochromatin protein 1", "PROTEIN", 39, 64], ["HP1", "PROTEIN", 66, 69], ["an epigenetic regulator", "PROBLEM", 14, 37], ["heterochromatin protein", "PROBLEM", 39, 62]]], ["HP1 is a constitutive component of heterochromatin, and plays an important role in transcriptional repression and regulation of euchromatic genes, however it was not known to be required for repair of oxidative damage.", [["heterochromatin", "ANATOMY", 35, 50], ["HP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["heterochromatin", "CELLULAR_COMPONENT", 35, 50], ["euchromatic", "CELLULAR_COMPONENT", 128, 139], ["HP1", "PROTEIN", 0, 3], ["heterochromatin", "DNA", 35, 50], ["euchromatic genes", "DNA", 128, 145], ["HP1", "PROBLEM", 0, 3], ["heterochromatin", "PROBLEM", 35, 50], ["transcriptional repression", "TREATMENT", 83, 109], ["euchromatic genes", "PROBLEM", 128, 145], ["repair", "TREATMENT", 191, 197], ["oxidative damage", "PROBLEM", 201, 217], ["constitutive", "OBSERVATION_MODIFIER", 9, 21], ["component", "OBSERVATION_MODIFIER", 22, 31], ["heterochromatin", "OBSERVATION", 35, 50], ["euchromatic genes", "OBSERVATION", 128, 145], ["oxidative damage", "OBSERVATION", 201, 217]]], ["The finding of HP1 recruitment is particularly puzzling, since in another study HP1 was shown to dissociate from chromatin as a result of DNA damage (Ayoub et al. 2008) .", [["chromatin", "ANATOMY", 113, 122], ["HP1", "GENE_OR_GENE_PRODUCT", 15, 18], ["HP1", "GENE_OR_GENE_PRODUCT", 80, 83], ["chromatin", "CELLULAR_COMPONENT", 113, 122], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["HP1", "PROTEIN", 15, 18], ["HP1", "PROTEIN", 80, 83], ["chromatin", "DNA", 113, 122], ["HP1 recruitment", "PROBLEM", 15, 30], ["another study HP1", "TEST", 66, 83], ["DNA damage", "PROBLEM", 138, 148], ["HP1 recruitment", "OBSERVATION", 15, 30]]], ["Technical aspects of live cell imaging that may explain these contradictory results will be discussed.", [["cell", "ANATOMY", 26, 30], ["cell", "CELL", 26, 30], ["live cell imaging", "TEST", 21, 38]]], ["In this presentation, we report a method for determining both the presence and the stoichiometry of protein complexes at pixel resolution and apply it to disassembling focal adhesions.", [["focal adhesions", "ANATOMY", 168, 183], ["focal adhesions", "CELLULAR_COMPONENT", 168, 183], ["protein complexes", "PROTEIN", 100, 117], ["protein complexes", "PROBLEM", 100, 117], ["focal adhesions", "PROBLEM", 168, 183], ["focal", "OBSERVATION_MODIFIER", 168, 173], ["adhesions", "OBSERVATION", 174, 183]]], ["The method is derived from fluorescence fluctuation methods that have single molecule sensitivity and is based on our previously described N&B (Number and Brightness) method that measures the number and brightness (aggregation state) of fluorescent molecules in every pixel of a confocal microscope image.", [["fluorescent molecules", "PROTEIN", 237, 258], ["fluorescence fluctuation methods", "TEST", 27, 59], ["single molecule sensitivity", "PROBLEM", 70, 97], ["a confocal microscope image", "TEST", 277, 304]]], ["The new method exploits the correlation of fluorescence amplitude fluctuations for two colors and detects the presence of molecular complexes and their stoichiometry.", [["molecular complexes", "PROTEIN", 122, 141], ["fluorescence amplitude fluctuations", "TEST", 43, 78], ["new", "OBSERVATION_MODIFIER", 4, 7], ["molecular complexes", "OBSERVATION", 122, 141]]], ["While the original N&B method was developed for one color, i.e., a single molecular species, the new method, ccN&B, extends the analysis to two colors and introduces the concept of cross-variance.", [["N&B", "DNA", 19, 22], ["ccN&B", "PROTEIN", 109, 114], ["the original N&B method", "TEST", 6, 29], ["a single molecular species", "PROBLEM", 65, 91], ["species", "OBSERVATION", 84, 91]]], ["This method is similar in concept to the two-color PCH analysis.", [["the two-color PCH analysis", "TEST", 37, 63]]], ["However, the covariancebased ccN&B method also generates pixel resolution maps of protein complexes and can be used on commercial confocal microscopes.", [["protein complexes", "PROTEIN", 82, 99], ["the covariancebased ccN&B method", "TREATMENT", 9, 41], ["commercial confocal microscopes", "TEST", 119, 150]]], ["The method is highly sensitive and has relatively high temporal resolution.", [["The method", "TEST", 0, 10], ["high", "OBSERVATION_MODIFIER", 50, 54], ["temporal", "OBSERVATION_MODIFIER", 55, 63], ["resolution", "OBSERVATION_MODIFIER", 64, 74]]], ["We have applied this method to adhesion complexes in cells.", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["adhesion complexes", "PROTEIN", 31, 49], ["this method to adhesion complexes in cells", "TREATMENT", 16, 58]]], ["In addition of their structural role, to link the extracellular substratum to actin filaments, they also serve as signaling centers that regulate many cellular processes including their own assembly and turnover, migration, gene expression, apoptosis, and proliferation.O-47Spatio-temporal analysis of membrane lipid remodeling during phagocytosis S. de Keijzer 1 , D. Kilic 1 , C. G. Figdor 1 , S. Grinstein 2 , A. Cambi 1 1 Department of Tumor Immunology, Radboud University of Nijmegen, Nijmegen, The Netherlands, 2 Department of Biochemistry, University of Toronto, Toronto, CanadaO-47The constant threat posed by pathogens and cell debris is tackled by phagocytosis, the process through which cells engulf and destroy dangerous material.", [["extracellular substratum", "ANATOMY", 50, 74], ["filaments", "ANATOMY", 84, 93], ["cellular", "ANATOMY", 151, 159], ["membrane", "ANATOMY", 302, 310], ["Tumor", "ANATOMY", 440, 445], ["cell", "ANATOMY", 632, 636], ["cells", "ANATOMY", 698, 703], ["extracellular substratum", "CELLULAR_COMPONENT", 50, 74], ["actin", "GENE_OR_GENE_PRODUCT", 78, 83], ["cellular", "CELL", 151, 159], ["membrane", "CELLULAR_COMPONENT", 302, 310], ["cell", "CELL", 632, 636], ["cells", "CELL", 698, 703], ["many cellular processes", "PROBLEM", 146, 169], ["apoptosis", "PROBLEM", 241, 250], ["proliferation", "PROBLEM", 256, 269], ["membrane lipid remodeling", "PROBLEM", 302, 327], ["CanadaO", "TREATMENT", 579, 586], ["cell debris", "PROBLEM", 632, 643], ["many", "OBSERVATION_MODIFIER", 146, 150], ["cellular processes", "OBSERVATION", 151, 169], ["apoptosis", "OBSERVATION_MODIFIER", 241, 250], ["proliferation", "OBSERVATION_MODIFIER", 256, 269], ["Tumor", "OBSERVATION", 440, 445], ["cell debris", "OBSERVATION", 632, 643]]], ["The signaling, targeting and trafficking during phagocytosis is dependent on cytoskeleton rearrangements and membrane remodeling.", [["cytoskeleton", "ANATOMY", 77, 89], ["membrane", "ANATOMY", 109, 117], ["cytoskeleton", "CELLULAR_COMPONENT", 77, 89], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["trafficking during phagocytosis", "PROBLEM", 29, 60], ["membrane remodeling", "PROBLEM", 109, 128], ["cytoskeleton rearrangements", "OBSERVATION", 77, 104], ["membrane remodeling", "OBSERVATION", 109, 128]]], ["It is becoming increasingly evident that lipids play an important role and can affect the phagocytic response.", [["lipids", "SIMPLE_CHEMICAL", 41, 47]]], ["They assemble microdomains which can act as signaling platforms and confer charge and curvature to the membrane surface promoting electrostatic attraction and retention of proteins.", [["microdomains", "ANATOMY", 14, 26], ["membrane surface", "ANATOMY", 103, 119], ["membrane surface", "CELLULAR_COMPONENT", 103, 119], ["electrostatic attraction", "PROBLEM", 130, 154], ["retention of proteins", "PROBLEM", 159, 180], ["microdomains", "OBSERVATION", 14, 26], ["electrostatic attraction", "OBSERVATION", 130, 154]]], ["Little is known about the mechanism(s) regulating membrane lipid remodeling during phagocytosis.", [["membrane", "ANATOMY", 50, 58], ["membrane lipid", "CELLULAR_COMPONENT", 50, 64], ["regulating membrane lipid remodeling during phagocytosis", "PROBLEM", 39, 95], ["lipid remodeling", "OBSERVATION", 59, 75]]], ["Here we used fluorescently labeled biosensors based on K-ras and H-ras proteins to obtain spatio-temporal information on phagosomal membrane lipid remodeling during FcReceptormediated phagocytosis.", [["phagosomal membrane", "ANATOMY", 121, 140], ["K-ras", "GENE_OR_GENE_PRODUCT", 55, 60], ["H-ras", "GENE_OR_GENE_PRODUCT", 65, 70], ["phagosomal", "CELLULAR_COMPONENT", 121, 131], ["membrane lipid", "CELLULAR_COMPONENT", 132, 146], ["K-ras and H-ras proteins", "PROTEIN", 55, 79], ["fluorescently labeled biosensors", "TREATMENT", 13, 45], ["K-ras", "TEST", 55, 60], ["H-ras proteins", "TEST", 65, 79], ["spatio", "TEST", 90, 96], ["phagosomal membrane lipid remodeling", "TREATMENT", 121, 157], ["FcReceptormediated phagocytosis", "TREATMENT", 165, 196], ["phagosomal membrane", "OBSERVATION", 121, 140], ["lipid remodeling", "OBSERVATION", 141, 157], ["FcReceptormediated phagocytosis", "OBSERVATION", 165, 196]]], ["The results show that cell activation by cytokines modulates the kinetics of anionic lipids thus affecting the membrane charge and the recruitment of cytosolic proteins to the phagosomal membrane.", [["cell", "ANATOMY", 22, 26], ["membrane", "ANATOMY", 111, 119], ["cytosolic", "ANATOMY", 150, 159], ["phagosomal membrane", "ANATOMY", 176, 195], ["cell", "CELL", 22, 26], ["lipids", "SIMPLE_CHEMICAL", 85, 91], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["phagosomal membrane", "CELLULAR_COMPONENT", 176, 195], ["cytokines", "PROTEIN", 41, 50], ["cytosolic proteins", "PROTEIN", 150, 168], ["cell activation", "PROBLEM", 22, 37], ["anionic lipids", "TREATMENT", 77, 91], ["the membrane charge", "TREATMENT", 107, 126], ["cell activation", "OBSERVATION", 22, 37], ["membrane charge", "OBSERVATION", 111, 126], ["phagosomal membrane", "OBSERVATION", 176, 195]]], ["Our data emphasize the fundamental role of lipids in the generation and transduction of signals in phagocytosis, and we believe this can be extrapolated to many important processes in a cell.Local BDNF delivery by means of laser tweezers to stimulate hippocampal neurons signallingFluorescence correlation spectroscopy (FCS) is a useful technique for characterizing the mobility and concentration of fluorescent molecules both in vitro and in vivo.", [["cell", "ANATOMY", 186, 190], ["hippocampal neurons", "ANATOMY", 251, 270], ["lipids", "SIMPLE_CHEMICAL", 43, 49], ["cell", "CELL", 186, 190], ["BDNF", "GENE_OR_GENE_PRODUCT", 197, 201], ["hippocampal neurons", "CELL", 251, 270], ["BDNF", "PROTEIN", 197, 201], ["Our data", "TEST", 0, 8], ["lipids", "TREATMENT", 43, 49], ["phagocytosis", "PROBLEM", 99, 111], ["Local BDNF delivery", "TREATMENT", 191, 210], ["laser tweezers", "TREATMENT", 223, 237], ["Fluorescence correlation spectroscopy", "TEST", 281, 318], ["fluorescent molecules", "PROBLEM", 400, 421]]], ["We utilize two-photon FCS to characterize the concentration and mobility of fluorescent molecules within living cells of Bacillus subtilis.", [["cells", "ANATOMY", 112, 117], ["cells", "CELL", 112, 117], ["Bacillus subtilis", "ORGANISM", 121, 138], ["fluorescent molecules", "PROTEIN", 76, 97], ["Bacillus subtilis", "SPECIES", 121, 138], ["Bacillus subtilis", "SPECIES", 121, 138], ["two-photon FCS", "TREATMENT", 11, 25], ["fluorescent molecules", "PROBLEM", 76, 97], ["Bacillus subtilis", "PROBLEM", 121, 138], ["Bacillus subtilis", "OBSERVATION", 121, 138]]], ["Autocorrelation functions were measured in bacteria expressing green fluorescent protein (GFP) under the lac promoter in both nutrient rich and nutrient poor culture medium.", [["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 63, 88], ["GFP", "GENE_OR_GENE_PRODUCT", 90, 93], ["lac", "GENE_OR_GENE_PRODUCT", 105, 108], ["green fluorescent protein", "PROTEIN", 63, 88], ["GFP", "PROTEIN", 90, 93], ["lac promoter", "DNA", 105, 117], ["Autocorrelation functions", "TEST", 0, 25], ["bacteria", "PROBLEM", 43, 51], ["green fluorescent protein (GFP", "PROBLEM", 63, 93], ["the lac promoter", "TREATMENT", 101, 117], ["nutrient rich", "OBSERVATION", 126, 139]]], ["Although considerable heterogeneity was evident from cell to cell, on average, both intracellular concentration and mobility were found to be dependent upon culture medium.", [["cell", "ANATOMY", 53, 57], ["cell", "ANATOMY", 61, 65], ["intracellular", "ANATOMY", 84, 97], ["cell", "CELL", 53, 57], ["cell", "CELL", 61, 65], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["considerable heterogeneity", "PROBLEM", 9, 35], ["culture medium", "TEST", 157, 171], ["considerable", "OBSERVATION_MODIFIER", 9, 21], ["heterogeneity", "OBSERVATION", 22, 35], ["cell to cell", "OBSERVATION", 53, 65], ["concentration", "OBSERVATION_MODIFIER", 98, 111]]], ["We also investigated bacteria expressing GFP under control of native promoters for involved in the regulation of the carbon metabolic cycle in Bacillus subtilis.", [["carbon", "CHEMICAL", 117, 123], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["carbon", "SIMPLE_CHEMICAL", 117, 123], ["Bacillus subtilis", "ORGANISM", 143, 160], ["GFP", "PROTEIN", 41, 44], ["native promoters", "DNA", 62, 78], ["Bacillus subtilis", "SPECIES", 143, 160], ["Bacillus subtilis", "SPECIES", 143, 160], ["bacteria", "PROBLEM", 21, 29], ["the carbon metabolic cycle", "TREATMENT", 113, 139], ["Bacillus subtilis", "PROBLEM", 143, 160], ["carbon metabolic cycle", "OBSERVATION", 117, 139], ["Bacillus subtilis", "OBSERVATION", 143, 160]]], ["The GFP concentration, which should be related to promoter activity, was investigated for single cells and cell populations under different metabolic conditions.", [["cells", "ANATOMY", 97, 102], ["cell", "ANATOMY", 107, 111], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 97, 102], ["cell populations", "CELL", 107, 123], ["GFP", "PROTEIN", 4, 7], ["The GFP concentration", "TEST", 0, 21], ["single cells", "PROBLEM", 90, 102], ["cell populations", "TREATMENT", 107, 123], ["metabolic conditions", "OBSERVATION", 140, 160]]], ["Some photobleaching was observed during the course of the measurements as a decrease in the average fluorescence intensity.", [["Some photobleaching", "PROBLEM", 0, 19], ["photobleaching", "OBSERVATION", 5, 19], ["decrease", "OBSERVATION_MODIFIER", 76, 84]]], ["This is due to the small size of the bacteria (\u223c1 fL) and low basal expression levels of GFP (\u223c100 nM) in the absence of IPTG.", [["IPTG", "CHEMICAL", 121, 125], ["IPTG", "CHEMICAL", 121, 125], ["GFP", "GENE_OR_GENE_PRODUCT", 89, 92], ["GFP", "PROTEIN", 89, 92], ["the bacteria", "PROBLEM", 33, 45], ["low basal expression levels of GFP", "PROBLEM", 58, 92], ["IPTG", "PROBLEM", 121, 125], ["small", "OBSERVATION_MODIFIER", 19, 24], ["size", "OBSERVATION_MODIFIER", 25, 29], ["bacteria", "OBSERVATION", 37, 45], ["low basal", "OBSERVATION_MODIFIER", 58, 67], ["IPTG", "OBSERVATION", 121, 125]]], ["Methods to take this into account during data analysis are discussed.Evaluation of synaptic vesicle pools at synapse expressing human epileptogenic synapsin mutationsA.", [["synaptic vesicle", "ANATOMY", 83, 99], ["synapse", "ANATOMY", 109, 116], ["synaptic vesicle", "CELLULAR_COMPONENT", 83, 99], ["synapse", "CELLULAR_COMPONENT", 109, 116], ["human", "ORGANISM", 128, 133], ["synapsin", "GENE_OR_GENE_PRODUCT", 148, 156], ["human epileptogenic synapsin mutationsA", "PROTEIN", 128, 167], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["Methods", "TREATMENT", 0, 7], ["data analysis", "TEST", 41, 54], ["Evaluation", "TEST", 69, 79], ["synaptic vesicle pools", "PROBLEM", 83, 105], ["synaptic vesicle pools", "OBSERVATION", 83, 105], ["epileptogenic synapsin", "OBSERVATION", 134, 156]]], ["Fassio 1 , S. Congia 2 , P. Baldelli 2 , F. Benfenati 2 1 DIMES, University of Genoa, Genoa, Italy, 2 DNBT , IIT, Genoa, Italy Several mutations have been discovered in the Synapsin I (Syn) gene in families with epilepsy, but the mechanism inducing the epileptic phenotype is unknown.", [["epilepsy", "DISEASE", 212, 220], ["epileptic", "DISEASE", 253, 262], ["Synapsin I", "GENE_OR_GENE_PRODUCT", 173, 183], ["Syn", "GENE_OR_GENE_PRODUCT", 185, 188], ["Synapsin I (Syn) gene", "DNA", 173, 194], ["Fassio", "TEST", 0, 6], ["epilepsy", "PROBLEM", 212, 220], ["the epileptic phenotype", "PROBLEM", 249, 272], ["epilepsy", "OBSERVATION", 212, 220], ["epileptic phenotype", "OBSERVATION", 253, 272]]], ["Syn is a protein associated with synaptic vesicles (SVs) that control SV trafficking and neurotransmitter release.", [["synaptic vesicles", "ANATOMY", 33, 50], ["SVs", "ANATOMY", 52, 55], ["SV", "ANATOMY", 70, 72], ["Syn", "GENE_OR_GENE_PRODUCT", 0, 3], ["synaptic vesicles", "CELLULAR_COMPONENT", 33, 50], ["SVs", "CELLULAR_COMPONENT", 52, 55], ["SV", "GENE_OR_GENE_PRODUCT", 70, 72], ["Syn", "PROTEIN", 0, 3], ["a protein", "PROBLEM", 7, 16], ["synaptic vesicles", "PROBLEM", 33, 50], ["synaptic vesicles", "OBSERVATION", 33, 50]]], ["The Syn mutations subject of this study are a non sense (ns-1) and of two missense (ms-2, ms-3) .", [["Syn", "GENE_OR_GENE_PRODUCT", 4, 7], ["this study", "TEST", 29, 39], ["ns", "TEST", 57, 59], ["two missense", "PROBLEM", 70, 82], ["ms", "TEST", 84, 86], ["ms", "TEST", 90, 92]]], ["Syn knockout (KO) hippocampal neurons were transfected with the either wild type (WT) or mutated Syns.", [["hippocampal neurons", "ANATOMY", 18, 37], ["Syn", "GENE_OR_GENE_PRODUCT", 0, 3], ["wild type (WT)", "ORGANISM", 71, 85], ["Syns", "GENE_OR_GENE_PRODUCT", 97, 101], ["Syn knockout (KO) hippocampal neurons", "CELL_LINE", 0, 37], ["wild type (WT) or mutated Syns", "PROTEIN", 71, 101]]], ["All Syns presented a common punctate pattern of expression at the level of axonal arborizations but, while ns-1 Syn targeted to synapses as WT-Syn, ms-2 and ms-3 Syns reached the presynaptic terminal less efficiently.", [["axonal arborizations", "ANATOMY", 75, 95], ["synapses", "ANATOMY", 128, 136], ["presynaptic terminal", "ANATOMY", 179, 199], ["Syns", "GENE_OR_GENE_PRODUCT", 4, 8], ["axonal arborizations", "CELLULAR_COMPONENT", 75, 95], ["ns-1 Syn", "GENE_OR_GENE_PRODUCT", 107, 115], ["WT-Syn", "GENE_OR_GENE_PRODUCT", 140, 146], ["ms-2", "GENE_OR_GENE_PRODUCT", 148, 152], ["ms-3", "GENE_OR_GENE_PRODUCT", 157, 161], ["Syns", "GENE_OR_GENE_PRODUCT", 162, 166], ["Syns", "PROTEIN", 4, 8], ["1 Syn", "PROTEIN", 110, 115], ["WT-Syn, ms-2 and ms-3 Syns", "PROTEIN", 140, 166], ["WT", "TEST", 140, 142], ["ms", "TEST", 148, 150], ["ms", "TEST", 157, 159], ["axonal arborizations", "ANATOMY", 75, 95]]], ["We next set up a live cell imaging experiment using synaptophysin-pHluorin and evaluated the effects of ns-1, ms-2 and ms-3 Syns on the size of SV pools.", [["cell", "ANATOMY", 22, 26], ["Hluorin", "CHEMICAL", 67, 74], ["Hluorin", "CHEMICAL", 67, 74], ["cell", "CELL", 22, 26], ["synaptophysin-p", "GENE_OR_GENE_PRODUCT", 52, 67], ["Hluorin", "SIMPLE_CHEMICAL", 67, 74], ["ms-3 Syns", "SIMPLE_CHEMICAL", 119, 128], ["synaptophysin", "PROTEIN", 52, 65], ["Hluorin", "TREATMENT", 67, 74], ["ns", "TREATMENT", 104, 106], ["ms", "TEST", 110, 112]]], ["Restoring WT-Syn in Syn I KO terminals led to a increase of all SV pools.", [["WT-Syn", "GENE_OR_GENE_PRODUCT", 10, 16], ["Syn I", "GENE_OR_GENE_PRODUCT", 20, 25], ["Syn", "PROTEIN", 13, 16], ["Syn I", "PROTEIN", 20, 25], ["increase", "OBSERVATION_MODIFIER", 48, 56]]], ["Restoring ms-2 and ms-3 Syns resulted in a phenotype not significatively different from Syn I KO background whereas restoring ns-1 Syn caused a decrease of all SV pools as compared either with WT-Syn or Syn I KO background.", [["ms-2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ms-3", "GENE_OR_GENE_PRODUCT", 19, 23], ["Syn I", "GENE_OR_GENE_PRODUCT", 88, 93], ["Syn", "GENE_OR_GENE_PRODUCT", 131, 134], ["WT-Syn", "GENE_OR_GENE_PRODUCT", 193, 199], ["Syn I", "GENE_OR_GENE_PRODUCT", 203, 208], ["ms-2 and ms-3 Syns", "DNA", 10, 28], ["Syn I", "PROTEIN", 88, 93], ["Syn", "PROTEIN", 131, 134], ["Syn", "PROTEIN", 196, 199], ["Syn I", "PROTEIN", 203, 208], ["Restoring ms", "TEST", 0, 12], ["a phenotype", "PROBLEM", 41, 52], ["a decrease of all SV pools", "PROBLEM", 142, 168], ["WT", "TEST", 193, 195], ["decrease", "OBSERVATION_MODIFIER", 144, 152]]], ["These data suggest an alteration in the subcellular distribution and function of Syn in patients carrying ms-2 e ms-3 mutation and a more severe effect on synaptic activity in patient carrying ns-1 mutation.P-51Imaging dynamics of DC-SIGN at the plasma membrane of HIV-1-stimulated dendritic cells O Understanding how viruses interact with host receptors is essential for developing new antiviral strategies.", [["subcellular", "ANATOMY", 40, 51], ["synaptic", "ANATOMY", 155, 163], ["DC", "ANATOMY", 231, 233], ["plasma membrane", "ANATOMY", 246, 261], ["dendritic cells", "ANATOMY", 282, 297], ["Syn", "GENE_OR_GENE_PRODUCT", 81, 84], ["patients", "ORGANISM", 88, 96], ["ms-3", "GENE_OR_GENE_PRODUCT", 113, 117], ["patient", "ORGANISM", 176, 183], ["ns-1", "GENE_OR_GENE_PRODUCT", 193, 197], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 231, 238], ["plasma membrane", "CELLULAR_COMPONENT", 246, 261], ["HIV-1", "ORGANISM", 265, 270], ["dendritic cells O", "CELL", 282, 299], ["Syn", "PROTEIN", 81, 84], ["P", "DNA", 207, 208], ["DC", "CELL_TYPE", 231, 233], ["SIGN", "PROTEIN", 234, 238], ["dendritic cells", "CELL_TYPE", 282, 297], ["host receptors", "PROTEIN", 340, 354], ["patients", "SPECIES", 88, 96], ["patient", "SPECIES", 176, 183], ["HIV-1", "SPECIES", 265, 270], ["HIV-1", "SPECIES", 265, 270], ["These data", "TEST", 0, 10], ["an alteration in the subcellular distribution", "PROBLEM", 19, 64], ["ms", "TEST", 106, 108], ["3 mutation", "PROBLEM", 116, 126], ["a more severe effect", "PROBLEM", 131, 151], ["HIV", "PROBLEM", 265, 268], ["new antiviral strategies", "TREATMENT", 383, 407], ["alteration", "OBSERVATION", 22, 32], ["subcellular distribution", "OBSERVATION", 40, 64], ["more severe", "OBSERVATION_MODIFIER", 133, 144], ["antiviral strategies", "OBSERVATION", 387, 407]]], ["Dendritic cells (DCs) can efficiently capture and take up HIV-1 through multiple attachment factors, such as the C-type lectin DC-SIGN.", [["Dendritic cells", "ANATOMY", 0, 15], ["DCs", "ANATOMY", 17, 20], ["Dendritic cells", "CELL", 0, 15], ["DCs", "CELL", 17, 20], ["HIV-1", "ORGANISM", 58, 63], ["C-type lectin DC-SIGN", "GENE_OR_GENE_PRODUCT", 113, 134], ["Dendritic cells", "CELL_TYPE", 0, 15], ["DCs", "CELL_TYPE", 17, 20], ["attachment factors", "PROTEIN", 81, 99], ["C-type lectin DC", "PROTEIN", 113, 129], ["SIGN", "PROTEIN", 130, 134], ["HIV-1", "SPECIES", 58, 63], ["HIV-1", "SPECIES", 58, 63], ["Dendritic cells", "PROBLEM", 0, 15], ["multiple attachment factors", "PROBLEM", 72, 99]]], ["However, the initial interactions between HIV-1 and this receptor on DCs are not fully understood yet.", [["DCs", "ANATOMY", 69, 72], ["HIV-1", "ORGANISM", 42, 47], ["DCs", "CELL", 69, 72], ["DCs", "CELL_TYPE", 69, 72], ["HIV-1", "SPECIES", 42, 47], ["HIV-1", "SPECIES", 42, 47]]], ["In this work, we have used single-molecule EPI-TIRF microscopy in combination with fluorescently labelled HIV-1 virus like particles (VLPs) and DC-SIGN-specific antibodies to image the dynamic interaction between HIV-1 and DC-SIGN nanoclusters at the plasma membrane of DCs.", [["DC", "ANATOMY", 144, 146], ["DC", "ANATOMY", 223, 225], ["plasma membrane", "ANATOMY", 251, 266], ["DCs", "ANATOMY", 270, 273], ["HIV-1 virus", "ORGANISM", 106, 117], ["VLPs", "ORGANISM", 134, 138], ["HIV-1", "ORGANISM", 213, 218], ["DC", "CELL", 223, 225], ["SIGN", "GENE_OR_GENE_PRODUCT", 226, 230], ["plasma membrane", "CELLULAR_COMPONENT", 251, 266], ["DCs", "CELL", 270, 273], ["DC", "CELL_TYPE", 144, 146], ["SIGN", "PROTEIN", 147, 151], ["DC", "CELL_TYPE", 223, 225], ["DCs", "CELL_TYPE", 270, 273], ["HIV-1 virus", "SPECIES", 106, 117], ["HIV-1", "SPECIES", 213, 218], ["HIV-1 virus", "SPECIES", 106, 117], ["HIV-1", "SPECIES", 213, 218], ["single-molecule EPI", "TREATMENT", 27, 46], ["TIRF microscopy", "TEST", 47, 62], ["fluorescently labelled HIV", "TEST", 83, 109], ["VLPs", "TEST", 134, 138], ["specific antibodies", "TEST", 152, 171], ["HIV", "TEST", 213, 216]]], ["By tracking individual trajectories of DC-SIGN on the cell surface of living DCs we have found heterogeneity in the modes of motion of DC-SIGN: some clusters are immobile whereas others move very quickly, with a few ones showing a directed motion on the cell membrane.", [["DC", "ANATOMY", 39, 41], ["cell surface", "ANATOMY", 54, 66], ["DCs", "ANATOMY", 77, 80], ["DC", "ANATOMY", 135, 137], ["cell membrane", "ANATOMY", 254, 267], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 39, 46], ["cell surface", "CELLULAR_COMPONENT", 54, 66], ["DCs", "CELL", 77, 80], ["cell membrane", "CELLULAR_COMPONENT", 254, 267], ["DC", "CELL_TYPE", 39, 41], ["SIGN", "PROTEIN", 42, 46], ["DCs", "CELL_TYPE", 77, 80], ["DC", "CELL_TYPE", 135, 137], ["SIGN", "PROTEIN", 138, 142], ["immobile", "OBSERVATION", 162, 170], ["cell membrane", "OBSERVATION", 254, 267]]], ["To investigate how such motion might be correlated to DC-SIGN function as virus attachment factor, we have developed glass platforms functionalized with HIV-1 VLPs to locally stimulate living DCs.", [["DC", "ANATOMY", 54, 56], ["DCs", "ANATOMY", 192, 195], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 54, 61], ["HIV-1 VLPs", "ORGANISM", 153, 163], ["DCs", "CELL", 192, 195], ["DC", "CELL_TYPE", 54, 56], ["SIGN", "PROTEIN", 57, 61], ["virus attachment factor", "PROTEIN", 74, 97], ["DCs", "CELL_TYPE", 192, 195], ["HIV-1", "SPECIES", 153, 158], ["HIV-1", "SPECIES", 153, 158], ["virus attachment factor", "PROBLEM", 74, 97], ["HIV-1 VLPs", "TREATMENT", 153, 163]]], ["These virus platforms have allowed us to measure DC-SIGN diffusion rates and motion modes over the cell surface of stimulated DCs and represent a powerful tool for studying the dynamic interactions between HIV-1 and the DC membrane.Quantitative imaging and the homeostasis of Plasmodium falciparum infected erythrocytesA.", [["DC", "ANATOMY", 49, 51], ["cell surface", "ANATOMY", 99, 111], ["DCs", "ANATOMY", 126, 129], ["DC membrane", "ANATOMY", 220, 231], ["Plasmodium falciparum", "DISEASE", 276, 297], ["SIGN", "SIMPLE_CHEMICAL", 52, 56], ["cell surface", "CELLULAR_COMPONENT", 99, 111], ["DCs", "CELL", 126, 129], ["HIV-1", "ORGANISM", 206, 211], ["DC membrane", "CELLULAR_COMPONENT", 220, 231], ["Plasmodium falciparum", "ORGANISM", 276, 297], ["erythrocytesA", "CELL", 307, 320], ["DC", "CELL_TYPE", 49, 51], ["DCs", "CELL_TYPE", 126, 129], ["HIV-1", "SPECIES", 206, 211], ["Plasmodium falciparum", "SPECIES", 276, 297], ["HIV-1", "SPECIES", 206, 211], ["Plasmodium falciparum", "SPECIES", 276, 297], ["These virus platforms", "TEST", 0, 21], ["stimulated DCs", "TREATMENT", 115, 129], ["HIV", "TEST", 206, 209], ["the DC membrane", "TREATMENT", 216, 231], ["Quantitative imaging", "TEST", 232, 252], ["the homeostasis", "TEST", 257, 272], ["Plasmodium falciparum infected erythrocytesA", "PROBLEM", 276, 320], ["Plasmodium falciparum", "OBSERVATION", 276, 297]]], ["Esposito 1 , T. Tiffert 2 , J. Mauritz 1 , S. Schlachter 1 , J. N. Skepper 2 , V. L. Lew 2 , C. F. Kaminski 1 1 Dept. of Chemical Engineering and Biotechnology, Univ. of Cambridge, U.K., 2 Dept. of Physiology, Development and Neuroscience, Univ. of Cambridge, U.K.Quantitative imaging and the homeostasis of Plasmodium falciparum infected erythrocytesPlasmodium falciparum (Pf ) causes the most lethal form of malaria in humans.", [["erythrocytes", "ANATOMY", 339, 351], ["Plasmodium falciparum", "DISEASE", 308, 329], ["Plasmodium falciparum", "DISEASE", 351, 372], ["malaria", "DISEASE", 410, 417], ["Plasmodium falciparum", "ORGANISM", 308, 329], ["erythrocytesPlasmodium falciparum", "ORGANISM", 339, 372], ["Pf )", "ORGANISM", 374, 378], ["humans", "ORGANISM", 421, 427], ["Plasmodium falciparum", "SPECIES", 308, 329], ["Plasmodium falciparum", "SPECIES", 351, 372], ["humans", "SPECIES", 421, 427], ["Plasmodium falciparum", "SPECIES", 308, 329], ["Plasmodium falciparum", "SPECIES", 351, 372], ["humans", "SPECIES", 421, 427], ["Quantitative imaging", "TEST", 264, 284], ["the homeostasis", "TEST", 289, 304], ["Plasmodium falciparum infected erythrocytes", "PROBLEM", 308, 351], ["Plasmodium falciparum (Pf )", "TREATMENT", 351, 378], ["malaria in humans", "PROBLEM", 410, 427], ["most lethal", "OBSERVATION_MODIFIER", 390, 401], ["malaria", "OBSERVATION", 410, 417]]], ["Early research exposed two paradoxes: 1) during its intraerythrocytic cycle Pf permeabilizes the host cell so much that a comparably permeabilized healthy red blood cell (RBC) would lyse prematurely, and 2) Pf digests far more hemoglobin than needed for its metabolism.", [["cell", "ANATOMY", 102, 106], ["red blood cell", "ANATOMY", 155, 169], ["RBC", "ANATOMY", 171, 174], ["Pf", "GENE_OR_GENE_PRODUCT", 76, 78], ["host cell", "CELL", 97, 106], ["red blood cell", "CELL", 155, 169], ["RBC", "CELL", 171, 174], ["Pf", "GENE_OR_GENE_PRODUCT", 207, 209], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 227, 237], ["Pf", "PROTEIN", 76, 78], ["healthy red blood cell", "CELL_TYPE", 147, 169], ["RBC", "CELL_TYPE", 171, 174], ["Pf", "PROTEIN", 207, 209], ["hemoglobin", "PROTEIN", 227, 237], ["its intraerythrocytic cycle", "TREATMENT", 48, 75], ["red blood cell", "TEST", 155, 169], ["RBC", "TEST", 171, 174], ["Pf digests far more hemoglobin", "PROBLEM", 207, 237], ["host cell", "OBSERVATION", 97, 106]]], ["A model of the homeostasis of a Pf infected RBC suggested a common explanation of both puzzles: excess hemoglobin digestion is required to reduce the colloidosmotic pressure within the host cell thus ensuring its osmotic stability to the end of the Pf asexual cycle.", [["RBC", "ANATOMY", 44, 47], ["cell", "ANATOMY", 190, 194], ["Pf", "GENE_OR_GENE_PRODUCT", 32, 34], ["RBC", "CELL", 44, 47], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 103, 113], ["host cell", "CELL", 185, 194], ["Pf infected RBC", "CELL_TYPE", 32, 47], ["hemoglobin", "PROTEIN", 103, 113], ["a Pf infected RBC", "PROBLEM", 30, 47], ["excess hemoglobin digestion", "PROBLEM", 96, 123], ["the colloidosmotic pressure within the host cell", "PROBLEM", 146, 194], ["hemoglobin digestion", "OBSERVATION", 103, 123], ["colloidosmotic pressure", "OBSERVATION", 150, 173], ["host cell", "OBSERVATION", 185, 194], ["osmotic stability", "OBSERVATION", 213, 230]]], ["We investigated these predictions with direct measurements of [Hb] and volumes of parasitized RBCs.", [["RBCs", "ANATOMY", 94, 98], ["[Hb", "SIMPLE_CHEMICAL", 62, 65], ["RBCs", "CELL", 94, 98], ["parasitized RBCs", "CELL_TYPE", 82, 98], ["direct measurements", "TEST", 39, 58], ["Hb", "TEST", 63, 65], ["parasitized RBCs", "PROBLEM", 82, 98], ["parasitized RBCs", "OBSERVATION", 82, 98]]], ["Reliable volume and morphological data was obtained by confocal microscopy and quantitative surface reconstruction.", [["surface", "ANATOMY", 92, 99], ["morphological data", "TEST", 20, 38], ["confocal microscopy", "TEST", 55, 74], ["quantitative surface reconstruction", "TREATMENT", 79, 114]]], ["Furthermore, we developed a new FRET-based method to measure hemoglobin molecular crowding by exploiting the reduction in fluorescence lifetime of a donor fluorophore loaded in the RBC cytosol.", [["RBC cytosol", "ANATOMY", 181, 192], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 61, 71], ["RBC cytosol", "CELLULAR_COMPONENT", 181, 192], ["hemoglobin", "PROTEIN", 61, 71], ["a new FRET-based method", "PROBLEM", 26, 49], ["hemoglobin molecular crowding", "PROBLEM", 61, 90], ["a donor fluorophore", "TREATMENT", 147, 166], ["the RBC cytosol", "TREATMENT", 177, 192], ["crowding", "OBSERVATION_MODIFIER", 82, 90], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["RBC cytosol", "OBSERVATION", 181, 192]]], ["FRET imaging techniques are powerful tools for probing the biophysics of living cells.", [["cells", "ANATOMY", 80, 85], ["cells", "CELL", 80, 85], ["living cells", "CELL_TYPE", 73, 85], ["FRET imaging techniques", "TEST", 0, 23]]], ["These tools provided a first validation of the colloidosmotic hypothesis and a deeper understanding of the homeostasis of the intraerythrocytic stage of Pf.Quantitative imaging and the homeostasis of Plasmodium falciparum infected erythrocytesHIV-1 assembly and release occur at the plasma membrane of infected cells and are driven by the Gag polyprotein.", [["erythrocytes", "ANATOMY", 231, 243], ["plasma membrane", "ANATOMY", 283, 298], ["cells", "ANATOMY", 311, 316], ["Plasmodium falciparum", "DISEASE", 200, 221], ["Pf", "GENE_OR_GENE_PRODUCT", 153, 155], ["Plasmodium falciparum", "ORGANISM", 200, 221], ["erythrocytesHIV-1", "ORGANISM", 231, 248], ["plasma membrane", "CELLULAR_COMPONENT", 283, 298], ["cells", "CELL", 311, 316], ["Gag", "GENE_OR_GENE_PRODUCT", 339, 342], ["infected cells", "CELL_TYPE", 302, 316], ["Gag polyprotein", "PROTEIN", 339, 354], ["Plasmodium falciparum", "SPECIES", 200, 221], ["HIV-1", "SPECIES", 243, 248], ["Plasmodium falciparum", "SPECIES", 200, 221], ["HIV-1", "SPECIES", 243, 248], ["the colloidosmotic hypothesis", "PROBLEM", 43, 72], ["Pf", "PROBLEM", 153, 155], ["Quantitative imaging", "TEST", 156, 176], ["the homeostasis", "TEST", 181, 196], ["Plasmodium falciparum infected erythrocytesHIV", "PROBLEM", 200, 246], ["infected cells", "PROBLEM", 302, 316], ["the Gag polyprotein", "TREATMENT", 335, 354], ["infected cells", "OBSERVATION", 302, 316], ["Gag polyprotein", "OBSERVATION", 339, 354]]], ["Using a combination of wide-field and total internal reflection fluorescence microscopy, we have investigated assembly of fluorescently labeled HIV-1 at the plasma membrane of living cells with high time resolution.", [["plasma membrane", "ANATOMY", 157, 172], ["cells", "ANATOMY", 183, 188], ["HIV-1", "GENE_OR_GENE_PRODUCT", 144, 149], ["plasma membrane", "CELLULAR_COMPONENT", 157, 172], ["cells", "CELL", 183, 188], ["living cells", "CELL_TYPE", 176, 188], ["HIV-1", "SPECIES", 144, 149], ["HIV-1", "SPECIES", 144, 149], ["wide-field", "TREATMENT", 23, 33], ["total internal reflection fluorescence microscopy", "TEST", 38, 87], ["fluorescently labeled HIV", "PROBLEM", 122, 147], ["high time", "OBSERVATION_MODIFIER", 194, 203]]], ["Gag assembled into discrete clusters corresponding to single virions.", [["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["Gag", "PROTEIN", 0, 3], ["discrete", "OBSERVATION_MODIFIER", 19, 27], ["clusters", "OBSERVATION_MODIFIER", 28, 36]]], ["After their initial appearance, assembly sites accumulated at the plasma membrane of individual cells over 1-2 hours.", [["plasma membrane", "ANATOMY", 66, 81], ["cells", "ANATOMY", 96, 101], ["plasma membrane", "CELLULAR_COMPONENT", 66, 81], ["cells", "CELL", 96, 101], ["plasma membrane", "ANATOMY", 66, 81], ["individual cells", "OBSERVATION", 85, 101]]], ["Using a photoconvertible fluorescent protein, we determined that assembly was nucleated by membrane bound Gag molecules, while both membrane-bound and cytosol derived Gag polyproteins contributed to the growing bud.", [["membrane", "ANATOMY", 91, 99], ["membrane", "ANATOMY", 132, 140], ["cytosol", "ANATOMY", 151, 158], ["bud", "ANATOMY", 211, 214], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["Gag", "GENE_OR_GENE_PRODUCT", 106, 109], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["cytosol", "CELLULAR_COMPONENT", 151, 158], ["Gag", "GENE_OR_GENE_PRODUCT", 167, 170], ["bud", "DEVELOPING_ANATOMICAL_STRUCTURE", 211, 214], ["photoconvertible fluorescent protein", "PROTEIN", 8, 44], ["membrane bound Gag molecules", "PROTEIN", 91, 119], ["membrane-bound and cytosol derived Gag polyproteins", "PROTEIN", 132, 183], ["a photoconvertible fluorescent protein", "TEST", 6, 44], ["membrane bound Gag molecules", "PROBLEM", 91, 119], ["cytosol derived Gag polyproteins", "PROBLEM", 151, 183], ["the growing bud", "PROBLEM", 199, 214], ["Gag polyproteins", "OBSERVATION", 167, 183]]], ["Assembly kinetics were rapid and three phases are observed.", [["kinetics", "OBSERVATION_MODIFIER", 9, 17]]], ["In phase I, the number of Gag molecules at a budding site increases following a saturating exponential with a rate constant of \u223c 5 x 10 \u22123 s \u22121 .", [["Gag molecules", "PROTEIN", 26, 39], ["budding site", "PROTEIN", 45, 57], ["Gag molecules", "PROBLEM", 26, 39], ["a budding site", "PROBLEM", 43, 57], ["Gag molecules", "OBSERVATION", 26, 39]]], ["Hence, Gag assembly is complete in \u223c 200 s.", [["Gag", "GENE_OR_GENE_PRODUCT", 7, 10], ["Gag", "PROTEIN", 7, 10]]], ["In Phase II, a plateau in fluorescence intensity is observed with no exchange of Gag protein.", [["Gag", "GENE_OR_GENE_PRODUCT", 81, 84], ["Phase II", "PROTEIN", 3, 11], ["Gag protein", "PROTEIN", 81, 92], ["a plateau in fluorescence intensity", "PROBLEM", 13, 48], ["Gag protein", "TREATMENT", 81, 92], ["plateau", "OBSERVATION", 15, 22]]], ["The fluorescence intensity decays in phase III.", [["The fluorescence intensity", "TEST", 0, 26]]], ["This decay, in some cases, corresponds to the release of a virion.", [["virion", "CELLULAR_COMPONENT", 59, 65], ["a virion", "TREATMENT", 57, 65]]], ["The time scale from the onset of assembly to release of extracellular particles was measured to be \u223c1,500+/-700 s.O-56Fast 3D chromatin dynamics studied in living yeasts using a novel lab on chip technology H. Hajjoul 1 , M. Dilhan 1 , I. Lassadi 2 , K. Bystricky 2 , A. Bancaud 1 1 LAAS-CNRS, Universit\u00e9 de Toulouse, France, 2 LBME, CNRS UMR 5099, Toulouse, FranceO-56We present a novel Lab-on-Chip technology for 3D particle tracking yeast abased on V-shaped mirrors, which are used to observe fluorescent specimens from multiple vantage points, providing stereo-images that can be recombined for 3D reconstruction.", [["extracellular particles", "ANATOMY", 56, 79], ["chromatin", "ANATOMY", 126, 135], ["specimens", "ANATOMY", 508, 517], ["extracellular particles", "CELLULAR_COMPONENT", 56, 79], ["yeast", "SPECIES", 436, 441], ["yeast", "SPECIES", 436, 441], ["The time scale", "TEST", 0, 14], ["extracellular particles", "TEST", 56, 79], ["3D particle tracking yeast", "PROBLEM", 415, 441], ["fluorescent specimens", "TEST", 496, 517], ["stereo-images", "TEST", 558, 571], ["3D reconstruction", "TREATMENT", 599, 616]]], ["Our technology is based on V-shaped mirrors, which are fabricated by wet etching of silicon wafers, and used as optical and fluidic components.", [["silicon", "CHEMICAL", 84, 91], ["wet etching of silicon wafers", "TREATMENT", 69, 98], ["silicon wafers", "OBSERVATION", 84, 98], ["fluidic components", "OBSERVATION", 124, 142]]], ["After rigorous optical optimization of the device in vitro, the Lab-on-Chip is applied to study chromatin dynamics in vivo using budding yeasts as a model system.", [["chromatin", "ANATOMY", 96, 105], ["chromatin", "CELLULAR_COMPONENT", 96, 105], ["Lab-on", "PROTEIN", 64, 70], ["chromatin", "DNA", 96, 105], ["the device in vitro", "TREATMENT", 39, 58], ["the Lab-on-Chip", "TREATMENT", 60, 75], ["budding yeasts", "PROBLEM", 129, 143]]], ["Yeasts cells are visualized using GFP fused to the associated repressor protein.", [["Yeasts cells", "ANATOMY", 0, 12], ["Yeasts cells", "CELL", 0, 12], ["GFP", "GENE_OR_GENE_PRODUCT", 34, 37], ["GFP", "PROTEIN", 34, 37], ["repressor protein", "PROTEIN", 62, 79], ["Yeasts cells", "PROBLEM", 0, 12]]], ["We confirm earlier observations that telomeric sequences, i.e. located close to chromosome ends, accumulate at the nuclear periphery, whereas genes found midway along chromosome arms are mostly present in the nuclear lumen.", [["chromosome ends", "ANATOMY", 80, 95], ["nuclear periphery", "ANATOMY", 115, 132], ["chromosome arms", "ANATOMY", 167, 182], ["nuclear lumen", "ANATOMY", 209, 222], ["telomeric", "CELLULAR_COMPONENT", 37, 46], ["chromosome ends", "CELLULAR_COMPONENT", 80, 95], ["nuclear periphery", "CELLULAR_COMPONENT", 115, 132], ["chromosome arms", "CELLULAR_COMPONENT", 167, 182], ["nuclear lumen", "CELLULAR_COMPONENT", 209, 222], ["telomeric sequences", "DNA", 37, 56], ["chromosome ends", "DNA", 80, 95], ["chromosome arms", "DNA", 167, 182], ["telomeric sequences", "TEST", 37, 56], ["nuclear", "ANATOMY_MODIFIER", 115, 122], ["periphery", "ANATOMY_MODIFIER", 123, 132], ["midway", "OBSERVATION_MODIFIER", 154, 160], ["chromosome arms", "OBSERVATION", 167, 182], ["nuclear", "ANATOMY_MODIFIER", 209, 216], ["lumen", "ANATOMY_MODIFIER", 217, 222]]], ["The dynamics of these sequences is followed in 3D with an unpreceded temporal resolution of 10 ms, showing that chromosome dynamics is non linear in the short time regime and switches to a linear regime at larger timescales.", [["chromosome", "ANATOMY", 112, 122], ["chromosome", "CELLULAR_COMPONENT", 112, 122], ["these sequences", "TEST", 16, 31], ["chromosome dynamics", "PROBLEM", 112, 131], ["a linear regime", "TREATMENT", 187, 202], ["non linear", "OBSERVATION_MODIFIER", 135, 145], ["short time", "OBSERVATION_MODIFIER", 153, 163], ["linear", "OBSERVATION_MODIFIER", 189, 195], ["regime", "OBSERVATION_MODIFIER", 196, 202], ["larger", "OBSERVATION_MODIFIER", 206, 212], ["timescales", "OBSERVATION_MODIFIER", 213, 223]]], ["Notably, this behavior is reminiscent of universal responses observed in polymer solutions, and is related to the confinement and the structure of chromosomes.", [["chromosomes", "ANATOMY", 147, 158], ["chromosomes", "CELLULAR_COMPONENT", 147, 158], ["chromosomes", "DNA", 147, 158], ["universal responses", "PROBLEM", 41, 60]]], ["This technique shows a great potential for studying dynamic processes in small living organisms.O-55Retrovirus induced remodeling of the host cell actin architecture M. Gladnikoff, I. Rousso Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel Retrovirus budding is a key step in the virus replication cycle.", [["cell", "ANATOMY", 142, 146], ["O-55Retrovirus", "CHEMICAL", 96, 110], ["O-55Retrovirus", "CHEMICAL", 96, 110], ["O-55Retrovirus", "SIMPLE_CHEMICAL", 96, 110], ["cell", "CELL", 142, 146], ["This technique", "TEST", 0, 14], ["small living organisms", "PROBLEM", 73, 95], ["Israel Retrovirus budding", "TREATMENT", 265, 290], ["small", "OBSERVATION_MODIFIER", 73, 78], ["host cell", "OBSERVATION", 137, 146]]], ["Yet, despite substantial progress in the structural and biochemical characterization of retroviral budding, the underlying physical mechanism remains poorly understood, primarily due to technical limitations preventing visualization of bud formation in real time.", [["bud", "ANATOMY", 236, 239], ["retroviral", "ORGANISM", 88, 98], ["bud", "ORGANISM_SUBDIVISION", 236, 239], ["retroviral budding", "PROBLEM", 88, 106], ["substantial", "OBSERVATION_MODIFIER", 13, 24], ["retroviral budding", "OBSERVATION", 88, 106], ["bud formation", "OBSERVATION", 236, 249]]], ["Using atomic force-, fluorescence-and transmission electron microscopy we find that both HIV and Moloney murine leukemia virus (MLV) remodel the actin cytoskeleton of their host cells and utilize the forces it generates to drive their assembly and budding.", [["cytoskeleton", "ANATOMY", 151, 163], ["cells", "ANATOMY", 178, 183], ["HIV and Moloney murine leukemia", "DISEASE", 89, 120], ["HIV", "ORGANISM", 89, 92], ["Moloney murine leukemia virus", "ORGANISM", 97, 126], ["MLV", "ORGANISM", 128, 131], ["actin", "GENE_OR_GENE_PRODUCT", 145, 150], ["cytoskeleton", "CELLULAR_COMPONENT", 151, 163], ["host cells", "CELL", 173, 183], ["actin", "PROTEIN", 145, 150], ["host cells", "CELL_TYPE", 173, 183], ["HIV", "SPECIES", 89, 92], ["murine", "SPECIES", 105, 111], ["leukemia virus", "SPECIES", 112, 126], ["HIV", "SPECIES", 89, 92], ["Moloney murine leukemia virus", "SPECIES", 97, 126], ["MLV", "SPECIES", 128, 131], ["atomic force", "TEST", 6, 18], ["transmission electron microscopy", "TEST", 38, 70], ["both HIV and Moloney murine leukemia virus", "PROBLEM", 84, 126], ["Moloney murine leukemia virus", "OBSERVATION", 97, 126], ["actin cytoskeleton", "OBSERVATION", 145, 163]]], ["Highly dynamic actin-filamentous structures which varied in size over the duration of budding appeared to emanate from the assembled virion.", [["-filamentous structures", "ANATOMY", 20, 43], ["virion", "ANATOMY", 133, 139], ["actin", "GENE_OR_GENE_PRODUCT", 15, 20], ["virion", "CELLULAR_COMPONENT", 133, 139], ["actin", "PROTEIN", 15, 20], ["Highly dynamic actin-filamentous structures", "PROBLEM", 0, 43], ["dynamic", "OBSERVATION_MODIFIER", 7, 14], ["actin-filamentous", "OBSERVATION", 15, 32], ["varied", "OBSERVATION_MODIFIER", 50, 56], ["size", "OBSERVATION_MODIFIER", 60, 64], ["virion", "OBSERVATION", 133, 139]]], ["These actin structures assemble simultaneously or immediately after the beginning of budding, and disappear as soon as the nascent virus is released from the cell membrane.", [["actin structures", "ANATOMY", 6, 22], ["cell membrane", "ANATOMY", 158, 171], ["actin", "GENE_OR_GENE_PRODUCT", 6, 11], ["cell membrane", "CELLULAR_COMPONENT", 158, 171], ["actin", "PROTEIN", 6, 11], ["the nascent virus", "PROBLEM", 119, 136], ["virus", "OBSERVATION", 131, 136], ["cell membrane", "OBSERVATION", 158, 171]]], ["Analysis of sections of cryo-preserved virus infected cells by TEM reveals similar actin filaments structures emerging from every nascent virus.", [["sections", "ANATOMY", 12, 20], ["cells", "ANATOMY", 54, 59], ["filaments structures", "ANATOMY", 89, 109], ["cells", "CELL", 54, 59], ["actin", "GENE_OR_GENE_PRODUCT", 83, 88], ["cryo-preserved virus infected cells", "CELL_TYPE", 24, 59], ["actin", "PROTEIN", 83, 88], ["cryo-preserved virus", "SPECIES", 24, 44], ["Analysis of sections", "TEST", 0, 20], ["cryo-preserved virus infected cells", "PROBLEM", 24, 59], ["similar actin filaments structures", "PROBLEM", 75, 109], ["every nascent virus", "PROBLEM", 124, 143], ["actin filaments", "OBSERVATION", 83, 98], ["nascent virus", "OBSERVATION", 130, 143]]], ["Substitution of the nucleocapsid domain implicated in actin binding by a leucine-zipper domain resulted in budding of virus-like particles that was not accompanied by remodeling of the cell's cytoskeleton.", [["cell", "ANATOMY", 185, 189], ["cytoskeleton", "ANATOMY", 192, 204], ["leucine", "CHEMICAL", 73, 80], ["leucine", "CHEMICAL", 73, 80], ["actin", "GENE_OR_GENE_PRODUCT", 54, 59], ["cell", "CELL", 185, 189], ["cytoskeleton", "CELLULAR_COMPONENT", 192, 204], ["nucleocapsid domain", "PROTEIN", 20, 39], ["actin", "PROTEIN", 54, 59], ["leucine-zipper domain", "PROTEIN", 73, 94], ["the nucleocapsid domain", "PROBLEM", 16, 39], ["a leucine-zipper domain", "TREATMENT", 71, 94], ["budding of virus-like particles", "PROBLEM", 107, 138], ["nucleocapsid domain", "OBSERVATION", 20, 39], ["virus", "OBSERVATION", 118, 123], ["not accompanied", "UNCERTAINTY", 148, 163], ["remodeling", "OBSERVATION", 167, 177], ["cell's cytoskeleton", "OBSERVATION", 185, 204]]], ["Notably, budding of viruses carrying the modified nucleocapsid domains was an order of magnitude slower than that of the wild type.", [["modified nucleocapsid domains", "PROTEIN", 41, 70], ["viruses", "PROBLEM", 20, 27], ["the modified nucleocapsid domains", "PROBLEM", 37, 70], ["viruses", "OBSERVATION", 20, 27]]], ["The results of this study show that retroviruses utilize the cell cytoskeleton to expedite their assembly and budding.Intracellular calcium and chloride concentrations in neuronal cells -a Fluorescence Lifetime Imaging (FLIM) approachT.", [["cell cytoskeleton", "ANATOMY", 61, 78], ["Intracellular", "ANATOMY", 118, 131], ["neuronal cells", "ANATOMY", 171, 185], ["calcium", "CHEMICAL", 132, 139], ["chloride", "CHEMICAL", 144, 152], ["calcium", "CHEMICAL", 132, 139], ["chloride", "CHEMICAL", 144, 152], ["retroviruses", "ORGANISM", 36, 48], ["cell", "CELL", 61, 65], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["calcium", "SIMPLE_CHEMICAL", 132, 139], ["chloride", "SIMPLE_CHEMICAL", 144, 152], ["neuronal cells", "CELL", 171, 185], ["neuronal cells", "CELL_TYPE", 171, 185], ["this study", "TEST", 15, 25], ["retroviruses", "TREATMENT", 36, 48], ["the cell cytoskeleton", "TREATMENT", 57, 78], ["Intracellular calcium", "TEST", 118, 139], ["chloride concentrations", "TEST", 144, 167], ["neuronal cells", "TEST", 171, 185], ["Lifetime Imaging", "TEST", 202, 218], ["neuronal cells", "OBSERVATION", 171, 185]]], ["Gensch Institute of Structural Biology and Biophysics (ISB-1) Cellular Biophysics, Research Centre J\u00fclich, GermanyIntracellular calcium and chloride concentrations in neuronal cells -a Fluorescence Lifetime Imaging (FLIM) approachThe determination of ion concentrations in cells -in particular in neurons -is very important for understanding cell function and life.", [["Intracellular", "ANATOMY", 114, 127], ["neuronal cells", "ANATOMY", 167, 181], ["cells", "ANATOMY", 273, 278], ["neurons", "ANATOMY", 297, 304], ["cell", "ANATOMY", 342, 346], ["calcium", "CHEMICAL", 128, 135], ["chloride", "CHEMICAL", 140, 148], ["calcium", "CHEMICAL", 128, 135], ["chloride", "CHEMICAL", 140, 148], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["calcium", "SIMPLE_CHEMICAL", 128, 135], ["chloride", "SIMPLE_CHEMICAL", 140, 148], ["neuronal cells", "CELL", 167, 181], ["ion", "SIMPLE_CHEMICAL", 251, 254], ["cells", "CELL", 273, 278], ["neurons", "CELL", 297, 304], ["cell", "CELL", 342, 346], ["neuronal cells", "CELL_TYPE", 167, 181], ["Intracellular calcium", "TEST", 114, 135], ["chloride concentrations", "TEST", 140, 163], ["Lifetime Imaging", "TEST", 198, 214], ["ion concentrations in cells", "PROBLEM", 251, 278], ["neuronal cells", "OBSERVATION", 167, 181], ["ion concentrations", "OBSERVATION_MODIFIER", 251, 269], ["neurons", "ANATOMY", 297, 304]]], ["Ca 2+ is an ubiquitous messenger in almost all cell types, Cl \u2212 has several roles, e.g. plays an important role in some neuronal signaling pathways including olfaction, nociception and vision.", [["cell", "ANATOMY", 47, 51], ["neuronal", "ANATOMY", 120, 128], ["Ca", "CHEMICAL", 0, 2], ["Cl", "CHEMICAL", 59, 61], ["Ca 2+", "CHEMICAL", 0, 5], ["Cl", "CHEMICAL", 59, 61], ["Ca 2+", "SIMPLE_CHEMICAL", 0, 5], ["cell", "CELL", 47, 51], ["Cl \u2212", "GENE_OR_GENE_PRODUCT", 59, 63], ["neuronal", "CELL", 120, 128], ["Cl \u2212", "PROTEIN", 59, 63], ["Ca", "TEST", 0, 2], ["ubiquitous", "OBSERVATION_MODIFIER", 12, 22], ["messenger", "OBSERVATION", 23, 32], ["almost all cell types", "OBSERVATION", 36, 57]]], ["Fluorescence lifetime imaging (FLIM) is of advantage over intensity based fluorescence microscopy, when comparisons between micro-domains of one cell or between different cells of one cell type are performed.", [["cell", "ANATOMY", 145, 149], ["cells", "ANATOMY", 171, 176], ["cell", "ANATOMY", 184, 188], ["cell", "CELL", 145, 149], ["cells", "CELL", 171, 176], ["cell type", "CELL", 184, 193], ["Fluorescence lifetime imaging", "TEST", 0, 29], ["fluorescence microscopy", "TEST", 74, 97], ["one cell", "PROBLEM", 141, 149], ["one cell type", "OBSERVATION", 180, 193]]], ["Several (organic chromophores and fluorescent protein based) Ca 2+ -and Cl \u2212 -sensors have been tested in culture cells with respect to their applicability in FLIM studies.", [["culture cells", "ANATOMY", 106, 119], ["Ca", "CHEMICAL", 61, 63], ["Cl", "CHEMICAL", 72, 74], ["Ca 2+", "CHEMICAL", 61, 66], ["Cl", "CHEMICAL", 72, 74], ["Ca 2+", "SIMPLE_CHEMICAL", 61, 66], ["Cl \u2212", "SIMPLE_CHEMICAL", 72, 76], ["culture cells", "CELL", 106, 119], ["culture cells", "CELL_LINE", 106, 119], ["Several (organic chromophores", "TREATMENT", 0, 29], ["fluorescent protein based", "TREATMENT", 34, 59], ["Ca", "TEST", 61, 63], ["Cl", "TEST", 72, 74], ["culture cells", "TEST", 106, 119], ["FLIM studies", "TEST", 159, 171]]], ["The Ca 2+ -and Cl \u2212 concentration in rodent olfactory sensory neurons, dorsal root ganglion neurons and neurons of the retina is investigated by time-resolved FLIM with two-photon excitation.Intracellular calcium and chloride concentrations in neuronal cells -a Fluorescence Lifetime Imaging (FLIM) approachViscosity is one of the main factors which influence diffusion in condensed media.", [["olfactory sensory neurons", "ANATOMY", 44, 69], ["dorsal root ganglion neurons", "ANATOMY", 71, 99], ["neurons", "ANATOMY", 104, 111], ["retina", "ANATOMY", 119, 125], ["Intracellular", "ANATOMY", 191, 204], ["neuronal cells", "ANATOMY", 244, 258], ["Ca", "CHEMICAL", 4, 6], ["Cl", "CHEMICAL", 15, 17], ["calcium", "CHEMICAL", 205, 212], ["chloride", "CHEMICAL", 217, 225], ["Ca 2+", "CHEMICAL", 4, 9], ["Cl", "CHEMICAL", 15, 17], ["calcium", "CHEMICAL", 205, 212], ["chloride", "CHEMICAL", 217, 225], ["Ca 2+", "SIMPLE_CHEMICAL", 4, 9], ["Cl \u2212", "SIMPLE_CHEMICAL", 15, 19], ["olfactory sensory neurons", "CELL", 44, 69], ["dorsal root ganglion neurons", "CELL", 71, 99], ["neurons", "CELL", 104, 111], ["retina", "MULTI-TISSUE_STRUCTURE", 119, 125], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 191, 204], ["calcium", "SIMPLE_CHEMICAL", 205, 212], ["chloride", "SIMPLE_CHEMICAL", 217, 225], ["neuronal cells", "CELL", 244, 258], ["rodent olfactory sensory neurons", "CELL_TYPE", 37, 69], ["dorsal root ganglion neurons", "CELL_TYPE", 71, 99], ["neuronal cells", "CELL_TYPE", 244, 258], ["rodent", "SPECIES", 37, 43], ["The Ca", "TEST", 0, 6], ["two-photon excitation", "TREATMENT", 169, 190], ["Intracellular calcium", "TEST", 191, 212], ["chloride concentrations", "TEST", 217, 240], ["neuronal cells", "TEST", 244, 258], ["Imaging (FLIM) approachViscosity", "TEST", 284, 316], ["concentration", "OBSERVATION_MODIFIER", 20, 33], ["olfactory", "ANATOMY_MODIFIER", 44, 53], ["sensory neurons", "ANATOMY", 54, 69], ["dorsal", "ANATOMY_MODIFIER", 71, 77], ["root ganglion", "ANATOMY", 78, 91], ["retina", "ANATOMY", 119, 125], ["neuronal cells", "OBSERVATION", 244, 258], ["condensed media", "OBSERVATION", 373, 388]]], ["In a cell viscosity can play a role in several diffusion mediated processes, such as drug delivery and signalling.", [["cell", "ANATOMY", 5, 9], ["cell", "CELL", 5, 9], ["drug delivery", "TREATMENT", 85, 98], ["cell viscosity", "OBSERVATION", 5, 19]]], ["Previously, alterations in viscosity in cells and organs have been linked to malfunction; however, mapping viscosity on a single-cell scale remains a challenge.", [["cells", "ANATOMY", 40, 45], ["organs", "ANATOMY", 50, 56], ["cell", "ANATOMY", 129, 133], ["cells", "CELL", 40, 45], ["organs", "ORGAN", 50, 56], ["alterations in viscosity in cells", "PROBLEM", 12, 45], ["mapping viscosity", "TEST", 99, 116], ["a single-cell scale", "TREATMENT", 120, 139], ["viscosity", "OBSERVATION_MODIFIER", 27, 36]]], ["We have imaged viscosity inside individual cells using novel fluorescent probes, called molecular rotors, in which the speed of rotation about a sterically hindered bond is viscosity-dependent.", [["cells", "ANATOMY", 43, 48], ["cells", "CELL", 43, 48], ["novel fluorescent probes", "TREATMENT", 55, 79]]], ["1, 2 This approach enabled us to demonstrate that viscosity distribution in a cell is highly heterogeneous and that the local microviscosity in hydrophobic cell domains can be up to 100\u00d7 higher than that of water.", [["cell", "ANATOMY", 78, 82], ["cell", "ANATOMY", 156, 160], ["cell", "CELL", 78, 82], ["cell", "CELL", 156, 160], ["water", "SIMPLE_CHEMICAL", 207, 212], ["viscosity distribution in a cell", "PROBLEM", 50, 82], ["the local microviscosity in hydrophobic cell domains", "PROBLEM", 116, 168], ["viscosity", "OBSERVATION", 50, 59], ["highly", "OBSERVATION_MODIFIER", 86, 92], ["heterogeneous", "OBSERVATION_MODIFIER", 93, 106], ["local", "OBSERVATION_MODIFIER", 120, 125], ["microviscosity", "OBSERVATION_MODIFIER", 126, 140], ["hydrophobic cell", "OBSERVATION", 144, 160]]], ["1 We have also shown that the intracellular viscosity increases dramatically during light activated cancer treatment, called Photodynamic therapy (PDT).", [["intracellular", "ANATOMY", 30, 43], ["cancer", "ANATOMY", 100, 106], ["cancer", "DISEASE", 100, 106], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["cancer", "CANCER", 100, 106], ["the intracellular viscosity", "PROBLEM", 26, 53], ["light activated cancer treatment", "TREATMENT", 84, 116], ["Photodynamic therapy", "TREATMENT", 125, 145], ["PDT", "TREATMENT", 147, 150], ["intracellular", "OBSERVATION_MODIFIER", 30, 43], ["viscosity", "OBSERVATION_MODIFIER", 44, 53], ["increases", "OBSERVATION_MODIFIER", 54, 63], ["dramatically", "OBSERVATION_MODIFIER", 64, 76], ["cancer", "OBSERVATION", 100, 106]]], ["2 We have demonstrated the effect of such viscosity increase on intracellular reactions by directly monitoring the rates of formation and decay of a short lived toxic intermediate, crucial in PDT, called singlet molecular oxygen, in light perturbed cells.", [["intracellular", "ANATOMY", 64, 77], ["cells", "ANATOMY", 249, 254], ["oxygen", "CHEMICAL", 222, 228], ["oxygen", "CHEMICAL", 222, 228], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["oxygen", "SIMPLE_CHEMICAL", 222, 228], ["cells", "CELL", 249, 254], ["light perturbed cells", "CELL_LINE", 233, 254], ["such viscosity", "PROBLEM", 37, 51], ["intracellular reactions", "TREATMENT", 64, 87], ["a short lived toxic intermediate", "PROBLEM", 147, 179], ["singlet molecular oxygen", "TREATMENT", 204, 228]]], ["Characean algae, close relatives of higher plants, represent a convenient model for studying the effect of propagating electrical signals, action potentials (AP) on photosynthesis.", [["Characean algae", "CELL", 0, 15], ["propagating electrical signals", "PROBLEM", 107, 137]]], ["Illuminated Chara corallina cells produce coordinated spatial patterns of chlorophyll fluorescence (Chl Fl) and extracellular pH.", [["Chara corallina cells", "ANATOMY", 12, 33], ["extracellular", "ANATOMY", 112, 125], ["chlorophyll", "CHEMICAL", 74, 85], ["Chara corallina cells", "CELL", 12, 33], ["chlorophyll", "SIMPLE_CHEMICAL", 74, 85], ["Chl Fl", "GENE_OR_GENE_PRODUCT", 100, 106], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["Illuminated Chara corallina cells", "CELL_LINE", 0, 33], ["Chara corallina", "SPECIES", 12, 27], ["Illuminated Chara corallina cells", "TREATMENT", 0, 33], ["chlorophyll fluorescence", "TEST", 74, 98], ["extracellular pH", "TEST", 112, 128], ["corallina cells", "OBSERVATION", 18, 33]]], ["Photosynthesis is higher in the cell regions adjacent to acid zones compared to alkaline zones.", [["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36], ["Photosynthesis", "TREATMENT", 0, 14], ["acid zones", "PROBLEM", 57, 67], ["higher", "OBSERVATION_MODIFIER", 18, 24], ["cell", "ANATOMY_MODIFIER", 32, 36], ["regions", "ANATOMY_MODIFIER", 37, 44], ["acid zones", "OBSERVATION", 57, 67], ["alkaline zones", "OBSERVATION", 80, 94]]], ["Under physiological conditions, the electrically induced AP differentially and reversibly suppresses photosynthesis in the alkaline and acid regions.", [["AP", "GENE_OR_GENE_PRODUCT", 57, 59], ["alkaline", "SIMPLE_CHEMICAL", 123, 131], ["AP", "PROTEIN", 57, 59], ["alkaline and acid regions", "PROTEIN", 123, 148], ["reversibly suppresses photosynthesis in the alkaline and acid regions", "PROBLEM", 79, 148]]], ["In this work we examined the effects of an artificial PSI acceptor, methyl viologen (MV), on Chl Fl with Imaging-PAM technique.", [["methyl viologen", "CHEMICAL", 68, 83], ["methyl viologen", "CHEMICAL", 68, 83], ["Chl Fl", "CHEMICAL", 93, 99], ["methyl viologen", "SIMPLE_CHEMICAL", 68, 83], ["MV", "SIMPLE_CHEMICAL", 85, 87], ["Chl Fl", "SIMPLE_CHEMICAL", 93, 99], ["an artificial PSI acceptor", "TREATMENT", 40, 66], ["methyl viologen (MV)", "TREATMENT", 68, 88], ["Imaging", "TEST", 105, 112]]], ["MV is a divalent cation and poorly permeates through biological membranes.", [["membranes", "ANATOMY", 64, 73], ["cation", "SIMPLE_CHEMICAL", 17, 23], ["membranes", "CELLULAR_COMPONENT", 64, 73], ["MV", "SPECIES", 0, 2], ["a divalent cation", "TREATMENT", 6, 23], ["divalent cation", "OBSERVATION", 8, 23]]], ["The presence in the medium of MV had no effect on Fl as well as on P700 + absorbance signals until the application of a single excitatory stimulus.", [["P700 +", "SIMPLE_CHEMICAL", 67, 73], ["P700", "PROTEIN", 67, 71], ["MV", "SPECIES", 30, 32], ["absorbance signals", "TEST", 74, 92], ["a single excitatory stimulus", "TREATMENT", 118, 146], ["no", "UNCERTAINTY", 37, 39], ["effect", "OBSERVATION_MODIFIER", 40, 46]]], ["Once an AP was generated in the presence of MV, it induced irreversible inhibition of native (NADPdependent) electron flow and a strong non-photochemical Fl quenching all over the cell.", [["cell", "ANATOMY", 180, 184], ["electron", "SIMPLE_CHEMICAL", 109, 117], ["cell", "CELL", 180, 184], ["MV", "SPECIES", 44, 46], ["electron flow", "TEST", 109, 122], ["irreversible", "OBSERVATION_MODIFIER", 59, 71]]], ["This indicates that AP redirects electron flow from the main pathway to the artificial acceptor.", [["AP", "SIMPLE_CHEMICAL", 20, 22], ["electron", "SIMPLE_CHEMICAL", 33, 41]]], ["We concluded that AP generation opens access for permeation of MV from the medium to the chloroplast stroma across two membrane barriers, plasmalemma and chloroplast inner membrane.", [["chloroplast stroma", "ANATOMY", 89, 107], ["membrane", "ANATOMY", 119, 127], ["plasmalemma", "ANATOMY", 138, 149], ["chloroplast inner membrane", "ANATOMY", 154, 180], ["AP", "SIMPLE_CHEMICAL", 18, 20], ["chloroplast stroma", "CELLULAR_COMPONENT", 89, 107], ["membrane barriers", "CELLULAR_COMPONENT", 119, 136], ["plasmalemma", "CELLULAR_COMPONENT", 138, 149], ["chloroplast", "CELLULAR_COMPONENT", 154, 165], ["inner membrane", "CELLULAR_COMPONENT", 166, 180], ["MV", "SPECIES", 63, 65], ["AP generation opens access", "TREATMENT", 18, 44], ["permeation of MV", "TREATMENT", 49, 65], ["the chloroplast stroma", "PROBLEM", 85, 107], ["two membrane barriers", "TREATMENT", 115, 136], ["plasmalemma and chloroplast inner membrane", "TREATMENT", 138, 180], ["chloroplast stroma", "OBSERVATION", 89, 107], ["membrane barriers", "OBSERVATION", 119, 136], ["inner membrane", "OBSERVATION", 166, 180]]], ["We suggested that MV might enter Chara cell via plasmalemma Ca 2+ -channels activated during AP.P-59Evaluation of cell damage after photodynamic and sonodynamic treatment H. Kolarova, K. Tomankova, S. Binder, P. Kolar, R. Bajgar, M. Strnad Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic Photodynamic therapy (PDT) and sonodynamic therapy (SDT) is a new, combined therapy for treating cancer.", [["Chara cell", "ANATOMY", 33, 43], ["plasmalemma", "ANATOMY", 48, 59], ["cell", "ANATOMY", 114, 118], ["cancer", "ANATOMY", 472, 478], ["Ca", "CHEMICAL", 60, 62], ["P-59Evaluation", "CHEMICAL", 96, 110], ["cancer", "DISEASE", 472, 478], ["Ca 2+", "CHEMICAL", 60, 65], ["Chara cell", "CELL", 33, 43], ["plasmalemma", "CELLULAR_COMPONENT", 48, 59], ["cell", "CELL", 114, 118], ["cancer", "CANCER", 472, 478], ["Chara cell", "CELL_TYPE", 33, 43], ["plasmalemma Ca 2+ -channels", "PROTEIN", 48, 75], ["MV", "SPECIES", 18, 20], ["MV", "TREATMENT", 18, 20], ["P", "TEST", 96, 97], ["cell damage", "PROBLEM", 114, 125], ["photodynamic and sonodynamic treatment", "TREATMENT", 132, 170], ["Czech Republic Photodynamic therapy (PDT", "TREATMENT", 360, 400], ["sonodynamic therapy", "TREATMENT", 406, 425], ["combined therapy", "TREATMENT", 442, 458], ["treating cancer", "PROBLEM", 463, 478], ["cell damage", "OBSERVATION", 114, 125], ["cancer", "OBSERVATION", 472, 478]]], ["The basis of the therapy is to administer a small amount of photosensitizer and sonosensitizer, which are selectively taken up by cancer cells, and then expose the body to light and ultrasound to activate these sensitizers.", [["cancer cells", "ANATOMY", 130, 142], ["body", "ANATOMY", 164, 168], ["cancer", "DISEASE", 130, 136], ["photosensitizer", "SIMPLE_CHEMICAL", 60, 75], ["cancer cells", "CELL", 130, 142], ["body", "ORGANISM_SUBDIVISION", 164, 168], ["cancer cells", "CELL_TYPE", 130, 142], ["the therapy", "TREATMENT", 13, 24], ["a small amount of photosensitizer", "TREATMENT", 42, 75], ["sonosensitizer", "TREATMENT", 80, 94], ["ultrasound", "TEST", 182, 192]]], ["When the sensitizers absorb light of an appropriate wavelength, it may cause their excitation with subsequent energy transfer to oxygen; the oxygen then becomes highly reactive in cancer cells and produces reactive oxygen species (ROS).", [["cancer cells", "ANATOMY", 180, 192], ["oxygen", "CHEMICAL", 129, 135], ["oxygen", "CHEMICAL", 141, 147], ["cancer", "DISEASE", 180, 186], ["oxygen", "CHEMICAL", 215, 221], ["ROS", "CHEMICAL", 231, 234], ["oxygen", "CHEMICAL", 129, 135], ["oxygen", "CHEMICAL", 141, 147], ["oxygen", "CHEMICAL", 215, 221], ["oxygen", "SIMPLE_CHEMICAL", 129, 135], ["oxygen", "SIMPLE_CHEMICAL", 141, 147], ["cancer cells", "CELL", 180, 192], ["reactive oxygen species", "SIMPLE_CHEMICAL", 206, 229], ["ROS", "SIMPLE_CHEMICAL", 231, 234], ["cancer cells", "CELL_TYPE", 180, 192], ["oxygen", "TREATMENT", 129, 135], ["highly reactive in cancer cells", "PROBLEM", 161, 192], ["reactive oxygen species", "PROBLEM", 206, 229], ["reactive", "OBSERVATION_MODIFIER", 168, 176], ["cancer cells", "OBSERVATION", 180, 192], ["reactive", "OBSERVATION_MODIFIER", 206, 214], ["oxygen species", "OBSERVATION", 215, 229]]], ["The resulting damage to organelles within malignant cells leads to tumor ablation.", [["organelles", "ANATOMY", 24, 34], ["malignant cells", "ANATOMY", 42, 57], ["tumor", "ANATOMY", 67, 72], ["tumor", "DISEASE", 67, 72], ["organelles", "CELLULAR_COMPONENT", 24, 34], ["malignant cells", "CELL", 42, 57], ["tumor", "CANCER", 67, 72], ["malignant cells", "CELL_TYPE", 42, 57], ["The resulting damage to organelles within malignant cells", "PROBLEM", 0, 57], ["tumor ablation", "TREATMENT", 67, 81], ["malignant cells", "OBSERVATION", 42, 57], ["tumor ablation", "OBSERVATION", 67, 81]]], ["SDT uses an agent that is sensitive to ultrasound, allowing deeper penetration and destruction of abnormal cells.", [["cells", "ANATOMY", 107, 112], ["cells", "CELL", 107, 112], ["abnormal cells", "CELL_TYPE", 98, 112], ["an agent", "TREATMENT", 9, 17], ["ultrasound", "TEST", 39, 49], ["deeper penetration", "PROBLEM", 60, 78], ["destruction of abnormal cells", "PROBLEM", 83, 112], ["abnormal cells", "OBSERVATION", 98, 112]]], ["Changes in human melanoma cells were evaluated using fluorescence microscope and atomic force microscopy.We focused on obtaining pictures of the topography and pictures involving elastic properties of cell surface.", [["melanoma cells", "ANATOMY", 17, 31], ["cell surface", "ANATOMY", 201, 213], ["melanoma", "DISEASE", 17, 25], ["human", "ORGANISM", 11, 16], ["melanoma cells", "CELL", 17, 31], ["cell surface", "CELLULAR_COMPONENT", 201, 213], ["human melanoma cells", "CELL_TYPE", 11, 31], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["Changes in human melanoma cells", "PROBLEM", 0, 31], ["fluorescence microscope", "TEST", 53, 76], ["atomic force microscopy", "TEST", 81, 104], ["the topography", "TEST", 141, 155], ["human", "ANATOMY", 11, 16], ["melanoma cells", "OBSERVATION", 17, 31], ["elastic properties", "OBSERVATION", 179, 197], ["cell surface", "OBSERVATION", 201, 213]]], ["The production of ROS was investigated with the molecular probe CM-H2DCFDA, and morphological changes in cells were evaluated using fluorescence microscope.", [["cells", "ANATOMY", 105, 110], ["ROS", "CHEMICAL", 18, 21], ["ROS", "SIMPLE_CHEMICAL", 18, 21], ["cells", "CELL", 105, 110], ["morphological changes in cells", "PROBLEM", 80, 110], ["fluorescence microscope", "TEST", 132, 155]]], ["The quantitative ROS production changes in relation to phthalocyanine concentration, irradiation doses and ultrasound intensity were measured by a fluororeader.P-58Activity correlation imaging: visualizing function and structure of neuronal populations S. Junek 1 , T.-W. Chen 1 , M. Alevra 1 , D. Schild 2 1 Department of Neurophysiology and Cellular Biophysics, University of G\u00f6ttingen, Germany, 2 DFG Research Center for Molecular Physiology of the Brain (CMPB), University of G\u00f6ttingen, GermanyP-58Understanding a neuronal network relies on knowledge about both the function and the structure of its neurons.", [["neuronal", "ANATOMY", 232, 240], ["neuronal network", "ANATOMY", 518, 534], ["neurons", "ANATOMY", 604, 611], ["ROS", "CHEMICAL", 17, 20], ["phthalocyanine", "CHEMICAL", 55, 69], ["phthalocyanine", "CHEMICAL", 55, 69], ["ROS", "SIMPLE_CHEMICAL", 17, 20], ["phthalocyanine", "SIMPLE_CHEMICAL", 55, 69], ["neuronal", "CELL", 232, 240], ["neuronal network", "MULTI-TISSUE_STRUCTURE", 518, 534], ["neurons", "CELL", 604, 611], ["P", "DNA", 160, 161], ["The quantitative ROS production changes", "PROBLEM", 0, 39], ["phthalocyanine concentration", "TREATMENT", 55, 83], ["irradiation doses", "TREATMENT", 85, 102], ["ultrasound intensity", "TEST", 107, 127], ["correlation imaging", "TEST", 173, 192], ["GermanyP", "TEST", 491, 499], ["ROS production", "OBSERVATION", 17, 31], ["Brain", "ANATOMY", 452, 457], ["neurons", "ANATOMY", 604, 611]]], ["While he simultaneous observation of hundreds of neurons is possible by densely staining brain tissue with functional dyes, the low contrast of these stainings does not allow the identification of neuronal processes from the raw fluorescent images.", [["neurons", "ANATOMY", 49, 56], ["brain tissue", "ANATOMY", 89, 101], ["neuronal", "ANATOMY", 197, 205], ["neurons", "CELL", 49, 56], ["brain tissue", "TISSUE", 89, 101], ["neuronal", "CELL", 197, 205], ["densely staining brain tissue", "PROBLEM", 72, 101], ["functional dyes", "PROBLEM", 107, 122], ["these stainings", "TEST", 144, 159], ["the raw fluorescent images", "TEST", 221, 247], ["brain tissue", "ANATOMY", 89, 101]]], ["However, as neurons are known to exhibit complex temporal patterns of activity, fluctuations in signal intensity over time could be exploited to generate contrast in densely stained tissue.", [["neurons", "ANATOMY", 12, 19], ["tissue", "ANATOMY", 182, 188], ["neurons", "CELL", 12, 19], ["tissue", "TISSUE", 182, 188], ["fluctuations in signal intensity", "PROBLEM", 80, 112], ["contrast in densely stained tissue", "PROBLEM", 154, 188], ["complex", "OBSERVATION_MODIFIER", 41, 48], ["temporal", "OBSERVATION_MODIFIER", 49, 57], ["activity", "OBSERVATION_MODIFIER", 70, 78], ["fluctuations", "OBSERVATION_MODIFIER", 80, 92], ["intensity", "OBSERVATION_MODIFIER", 103, 112], ["densely", "OBSERVATION_MODIFIER", 166, 173], ["stained tissue", "OBSERVATION", 174, 188]]], ["We demonstrate that the uniform calcium signals within individual neurons of the olfactory bulb can be exploited to visualize the morphology and projection patterns of these cells in tissue slices.", [["neurons", "ANATOMY", 66, 73], ["olfactory bulb", "ANATOMY", 81, 95], ["cells", "ANATOMY", 174, 179], ["tissue slices", "ANATOMY", 183, 196], ["calcium", "CHEMICAL", 32, 39], ["calcium", "CHEMICAL", 32, 39], ["calcium", "SIMPLE_CHEMICAL", 32, 39], ["neurons", "CELL", 66, 73], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 81, 95], ["cells", "CELL", 174, 179], ["tissue slices", "MULTI-TISSUE_STRUCTURE", 183, 196], ["the uniform calcium signals", "TEST", 20, 47], ["uniform", "OBSERVATION_MODIFIER", 24, 31], ["calcium signals", "OBSERVATION", 32, 47], ["olfactory bulb", "ANATOMY", 81, 95]]], ["As different neurons exhibit distinct time patterns, it is possible to generate a highcontrast multi-color visualization of the network's active neurons, solely based on the specificity of temporal fluctuations of a single-color calcium dye.", [["neurons", "ANATOMY", 13, 20], ["neurons", "ANATOMY", 145, 152], ["calcium", "CHEMICAL", 229, 236], ["calcium", "CHEMICAL", 229, 236], ["neurons", "CELL", 13, 20], ["neurons", "CELL", 145, 152], ["calcium dye", "SIMPLE_CHEMICAL", 229, 240], ["active neurons", "CELL_TYPE", 138, 152], ["a single-color calcium dye", "TREATMENT", 214, 240]]], ["It is thus possible to use other spectral channels for additional labelling, for example using cell-type or protein specific markers.", [["cell", "ANATOMY", 95, 99], ["cell", "CELL", 95, 99], ["protein specific markers", "PROTEIN", 108, 132], ["thus possible", "UNCERTAINTY", 6, 19]]], ["The ability to map function and structure of neuronal populations online opens up a number of intriguing applications, such as selecting cells or cell pairs with certain functional or projection profiles for targeted recordings, ablation or stimulation.O-57-Live cell imaging -123Investigation of the dynamics of redox elements in live cells by using fluorescence ratio microscopy G. Maulucci 1 , G. Pani 2 , V. Labate 2 , M. Mele 2 , E. Panieri 2 , M. Papi 1 , G. Arcovito 1 , T. Galeotti 2 , M. de Spirito 1 1 Istituto di Fisica, Universit\u00e0 Cattolica S. Cuore, Roma, Italy, 2 Istituto di Patologia Generale, Universit\u00e0 Cattolica S. Cuore, Roma, Italy123Oxidative stress or signaling events can affect cellular redox environment, which act simultaneously as regulator and indicator of key cellular functions in both physiological and pathological settings.", [["neuronal populations", "ANATOMY", 45, 65], ["cells", "ANATOMY", 137, 142], ["cell", "ANATOMY", 146, 150], ["cell", "ANATOMY", 263, 267], ["cells", "ANATOMY", 336, 341], ["cellular", "ANATOMY", 703, 711], ["cellular", "ANATOMY", 790, 798], ["neuronal populations", "CELL", 45, 65], ["cells", "CELL", 137, 142], ["cell", "CELL", 146, 150], ["cells", "CELL", 336, 341], ["cellular", "CELL", 703, 711], ["cellular", "CELL", 790, 798], ["neuronal populations", "CELL_TYPE", 45, 65], ["redox elements", "DNA", 313, 327], ["live cells", "CELL_TYPE", 331, 341], ["map function", "TEST", 15, 27], ["intriguing applications", "TREATMENT", 94, 117], ["cell pairs", "PROBLEM", 146, 156], ["targeted recordings", "TEST", 208, 227], ["ablation", "TREATMENT", 229, 237], ["stimulation", "TREATMENT", 241, 252], ["Live cell imaging", "TEST", 258, 275], ["fluorescence ratio microscopy", "TEST", 351, 380], ["Maulucci", "TEST", 384, 392], ["signaling events", "PROBLEM", 675, 691]]], ["By using a redox-sensitive protein (rxYFP), employed ratiometrically, it is possible to generate high resolution redox maps of cells.", [["cells", "ANATOMY", 127, 132], ["cells", "CELL", 127, 132], ["redox-sensitive protein", "PROTEIN", 11, 34], ["rxYFP", "PROTEIN", 36, 41], ["a redox", "TEST", 9, 16]]], ["The spatial distributions of oxidized and reduced elements have been discriminated in human embryonic kidney cells by the deconvolution of the histograms of redox maps.", [["embryonic kidney cells", "ANATOMY", 92, 114], ["human", "ORGANISM", 86, 91], ["embryonic kidney cells", "CELL", 92, 114], ["human embryonic kidney cells", "CELL_TYPE", 86, 114], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["oxidized and reduced elements", "PROBLEM", 29, 58], ["human embryonic kidney cells", "PROBLEM", 86, 114], ["redox maps", "TEST", 157, 167], ["spatial", "OBSERVATION_MODIFIER", 4, 11], ["distributions", "OBSERVATION_MODIFIER", 12, 25], ["oxidized", "OBSERVATION_MODIFIER", 29, 37], ["reduced elements", "OBSERVATION", 42, 58], ["human embryonic kidney cells", "OBSERVATION", 86, 114]]], ["By transfecting cell with Glutaredoxin V (GRX-V), a significant shift towards more reduced state with respect to that recovered from non-transfected cells is observed.", [["cell", "ANATOMY", 16, 20], ["cells", "ANATOMY", 149, 154], ["cell", "CELL", 16, 20], ["Glutaredoxin V", "GENE_OR_GENE_PRODUCT", 26, 40], ["GRX-V", "GENE_OR_GENE_PRODUCT", 42, 47], ["cells", "CELL", 149, 154], ["Glutaredoxin V", "PROTEIN", 26, 40], ["GRX-V", "PROTEIN", 42, 47], ["non-transfected cells", "CELL_LINE", 133, 154], ["Glutaredoxin V", "TREATMENT", 26, 40], ["a significant shift", "PROBLEM", 50, 69], ["non-transfected cells", "PROBLEM", 133, 154], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["shift", "OBSERVATION", 64, 69], ["more reduced", "OBSERVATION_MODIFIER", 78, 90], ["non-transfected cells", "OBSERVATION", 133, 154]]], ["Despite such large differences, a common behaviour in the spatial distribution of reduced and oxidized couples can still be observed: oxidized population shows a pronounced localization on the cell borders, near the plasma membrane, while reduced population appears as a collection of well separated spots homogeneuosly distributed thoroughly the inner part of the cell with a mean dimension of 2 um.", [["cell borders", "ANATOMY", 193, 205], ["plasma membrane", "ANATOMY", 216, 231], ["inner part", "ANATOMY", 347, 357], ["cell", "ANATOMY", 365, 369], ["cell borders", "CELLULAR_COMPONENT", 193, 205], ["plasma membrane", "CELLULAR_COMPONENT", 216, 231], ["cell", "CELL", 365, 369], ["such large differences", "PROBLEM", 8, 30], ["a pronounced localization on the cell borders", "PROBLEM", 160, 205], ["reduced population", "PROBLEM", 239, 257], ["a collection of well separated spots", "PROBLEM", 269, 305], ["large", "OBSERVATION_MODIFIER", 13, 18], ["differences", "OBSERVATION_MODIFIER", 19, 30], ["common", "OBSERVATION_MODIFIER", 34, 40], ["reduced", "OBSERVATION_MODIFIER", 82, 89], ["pronounced", "OBSERVATION_MODIFIER", 162, 172], ["plasma membrane", "ANATOMY", 216, 231], ["reduced", "OBSERVATION_MODIFIER", 239, 246], ["population", "OBSERVATION", 247, 257], ["collection", "OBSERVATION_MODIFIER", 271, 281], ["inner", "ANATOMY_MODIFIER", 347, 352], ["cell", "ANATOMY", 365, 369], ["mean dimension", "OBSERVATION_MODIFIER", 377, 391]]], ["Furthermore we observe that the role of GRX-V consists in causing a shift towards reduced values of the highly reduced region, while leaving unaltered the redox-balance of the intracellular side of the plasma membrane.", [["intracellular", "ANATOMY", 176, 189], ["plasma membrane", "ANATOMY", 202, 217], ["GRX-V", "GENE_OR_GENE_PRODUCT", 40, 45], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 176, 189], ["plasma membrane", "CELLULAR_COMPONENT", 202, 217], ["GRX-V", "PROTEIN", 40, 45], ["a shift", "PROBLEM", 66, 73], ["reduced values of the highly reduced region", "PROBLEM", 82, 125], ["highly", "OBSERVATION_MODIFIER", 104, 110], ["reduced", "OBSERVATION", 111, 118], ["plasma membrane", "ANATOMY", 202, 217]]], ["Fluorescence lifetime imaging (FLIM) provides a robust read-out of FRET but has largely been restricted to fixed cells owing to relatively long acquisition times.", [["cells", "ANATOMY", 113, 118], ["cells", "CELL", 113, 118], ["fixed cells", "CELL_TYPE", 107, 118], ["Fluorescence lifetime imaging", "TEST", 0, 29], ["fixed cells", "PROBLEM", 107, 118]]], ["We present a highspeed wide-field multidimensional fluorescence microscope for FLIM FRET in live cells on second timescales for high content analysis and studying fast dynamics.", [["cells", "ANATOMY", 97, 102], ["cells", "CELL", 97, 102], ["FLIM FRET in live cells", "PROBLEM", 79, 102], ["high content analysis", "PROBLEM", 128, 149]]], ["The system uses a Nipkow disc for optical sectioning and a time-gated image intensifier for wide-field FLIM.", [["a Nipkow disc", "TREATMENT", 16, 29], ["optical sectioning", "TREATMENT", 34, 52], ["wide-field FLIM", "TEST", 92, 107]]], ["A spectrally selected supercontinuum excitation source facilitates versatile realtime FLIM of live cells transfected with fluorescent proteins.", [["cells", "ANATOMY", 99, 104], ["cells", "CELL", 99, 104], ["live cells", "CELL_TYPE", 94, 104], ["fluorescent proteins", "PROTEIN", 122, 142], ["A spectrally selected supercontinuum excitation source", "TREATMENT", 0, 54], ["fluorescent proteins", "TEST", 122, 142]]], ["For cell signalling studies we have developed a multiplexed FRET approach.", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["cell signalling studies", "TEST", 4, 27], ["a multiplexed FRET approach", "TREATMENT", 46, 73]]], ["Ras activation at the plasma membrane is demonstrated using FLIM to read out TagRFP-Raf RBD interaction with mPlum-H-Ras.", [["plasma membrane", "ANATOMY", 22, 37], ["Ras", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma membrane", "CELLULAR_COMPONENT", 22, 37], ["TagRFP-Raf", "GENE_OR_GENE_PRODUCT", 77, 87], ["mPlum-H-Ras", "GENE_OR_GENE_PRODUCT", 109, 120], ["Ras", "PROTEIN", 0, 3], ["TagRFP", "PROTEIN", 77, 83], ["Raf", "PROTEIN", 84, 87], ["RBD", "PROTEIN", 88, 91], ["mPlum", "PROTEIN", 109, 114], ["H-Ras", "PROTEIN", 115, 120], ["Ras activation", "PROBLEM", 0, 14], ["TagRFP", "TEST", 77, 83]]], ["Simultaneously, a spectral ratiometric read-out is used for a second FRET (CFP/YFP Cameleon) probe to monitor the downstream calcium flux.", [["calcium", "CHEMICAL", 125, 132], ["calcium", "CHEMICAL", 125, 132], ["calcium", "SIMPLE_CHEMICAL", 125, 132], ["YFP", "PROTEIN", 79, 82], ["a spectral ratiometric", "TEST", 16, 38], ["a second FRET (CFP/YFP Cameleon)", "TREATMENT", 60, 92], ["the downstream calcium flux", "TEST", 110, 137], ["calcium flux", "OBSERVATION", 125, 137]]], ["To further develop multiplexed FRET as a tool for imaging multiple components of cell signalling networks, we are working to include polarisation-resolved imaging for steady-state and time resolved fluorescence anisotropy measurements.P-63Monitoring gene expression via novel nucleic acid and delivery methods K. Lymperopoulos 1 , C. Spassova 1 , A. Seefeld 1 , H. S. Parekh 2 , D. P. Herten 1 1 BioQuant Institute,Heidelberg University, Germany, 2 School of Pharmacy, University of Queensland, Australia Application of single-molecule and high-resolution fluorescence methods to monitor gene expression in living cells increase the demand on novel probes and delivery methods.They require fluorophores with high photostability and quantum yield and highly-efficient delivery methods that ensure the minimum interference with cell processes such as metabolism and signal transduction.", [["cell", "ANATOMY", 81, 85], ["cells", "ANATOMY", 614, 619], ["cell", "ANATOMY", 826, 830], ["nucleic acid", "CHEMICAL", 276, 288], ["cell", "CELL", 81, 85], ["cells", "CELL", 614, 619], ["cell", "CELL", 826, 830], ["P-63Monitoring gene", "DNA", 235, 254], ["living cells", "CELL_TYPE", 607, 619], ["imaging", "TEST", 50, 57], ["cell signalling networks", "PROBLEM", 81, 105], ["imaging", "TEST", 155, 162], ["fluorescence anisotropy measurements", "TEST", 198, 234], ["P", "TEST", 235, 236], ["novel nucleic acid", "TREATMENT", 270, 288], ["single-molecule", "TREATMENT", 520, 535], ["high-resolution fluorescence methods", "TREATMENT", 540, 576], ["gene expression in living cells", "PROBLEM", 588, 619], ["novel probes and delivery methods", "TREATMENT", 643, 676], ["fluorophores", "TREATMENT", 690, 702], ["high photostability", "TREATMENT", 708, 727], ["quantum yield", "TEST", 732, 745], ["efficient delivery methods", "TREATMENT", 757, 783], ["cell processes", "TREATMENT", 826, 840], ["metabolism and signal transduction", "TREATMENT", 849, 883]]], ["We used a novel class of dendrimers with varying generations and branching factors and different number of positive charges due to different moieties and functional groups.These different properties were tested for their efficiency to transfect eukaryotic cells with fluorescent oligonucleotides (ODNs).Different parameters (temperature,concentration of dendrimers, ratio of dendrimers and ODNs) were evaluated and optimised.We utilised these established optimal conditions to deliver a modified concept of SmartProbes to mammalian cells targeting mRNAs involved in signal pathways.We tested different mRNA targets and we optimised the fluorescence signal by varying a range of parameters,namely the fluorescent label and the intrinsic properties of the SmartProbe (length of the loop and stem, conformation and number of guanosines).In the near future,we plan to use these probes for monitoring gene expression levels using Diffusion Imaging Microscopy.", [["cells", "ANATOMY", 256, 261], ["cells", "ANATOMY", 532, 537], ["guanosines", "CHEMICAL", 822, 832], ["cells", "CELL", 256, 261], ["fluorescent oligonucleotides", "SIMPLE_CHEMICAL", 267, 295], ["dendrimers", "SIMPLE_CHEMICAL", 375, 385], ["SmartProbes", "SIMPLE_CHEMICAL", 507, 518], ["mammalian cells", "CELL", 522, 537], ["guanosines", "GENE_OR_GENE_PRODUCT", 822, 832], ["branching factors", "PROTEIN", 65, 82], ["eukaryotic cells", "CELL_TYPE", 245, 261], ["SmartProbes", "PROTEIN", 507, 518], ["mammalian cells", "CELL_TYPE", 522, 537], ["mRNAs", "RNA", 548, 553], ["mRNA targets", "RNA", 602, 614], ["SmartProbe", "PROTEIN", 754, 764], ["guanosines", "PROTEIN", 822, 832], ["a novel class of dendrimers", "TREATMENT", 8, 35], ["varying generations", "TREATMENT", 41, 60], ["branching factors", "PROBLEM", 65, 82], ["positive charges", "PROBLEM", 107, 123], ["fluorescent oligonucleotides (ODNs", "TREATMENT", 267, 301], ["Different parameters", "TEST", 303, 323], ["temperature", "TEST", 325, 336], ["concentration of dendrimers, ratio of dendrimers and ODNs", "TREATMENT", 337, 394], ["a modified concept of SmartProbes", "TREATMENT", 485, 518], ["mammalian cells", "TREATMENT", 522, 537], ["the fluorescence signal", "TEST", 632, 655], ["the loop and stem", "TREATMENT", 776, 793], ["guanosines", "TREATMENT", 822, 832], ["these probes", "TREATMENT", 868, 880], ["monitoring gene expression levels", "TEST", 885, 918], ["Diffusion Imaging Microscopy", "TEST", 925, 953], ["branching", "OBSERVATION_MODIFIER", 65, 74], ["positive charges", "OBSERVATION", 107, 123], ["intrinsic properties", "OBSERVATION", 726, 746], ["stem", "OBSERVATION_MODIFIER", 789, 793]]], ["We present a novel near-field scanning microwave microscope (SMM) capable of providing surface impedance measurements of samples with nanometric resolution.", [["surface", "ANATOMY", 87, 94], ["samples", "ANATOMY", 121, 128], ["surface impedance measurements", "TEST", 87, 117], ["nanometric resolution", "OBSERVATION", 134, 155]]], ["The instrument is the integration of a microwave Vector Network Analyzer (VNA) and a scanning probe microscope (AFM/STM).A novel scanning microwave microscope for investigating living cells at the nanometric scaleA key point is that our software, controlling and synchronizing both the instruments, creates simultaneously images of the sample at several frequency points.", [["cells", "ANATOMY", 184, 189], ["cells", "CELL", 184, 189], ["a scanning probe microscope", "TEST", 83, 110], ["A novel scanning microwave microscope", "TEST", 121, 158]]], ["This can be used to extract several features of the sample depending on the frequency.", [["the sample", "TEST", 48, 58]]], ["We have been working on the optimization of this system for biological applications, to detect functional characteristics of cells generating a variation of their dielectric properties.", [["cells", "ANATOMY", 125, 130], ["cells", "CELL", 125, 130], ["biological applications", "TREATMENT", 60, 83], ["functional characteristics of cells", "PROBLEM", 95, 130]]], ["This instrument offers the possibility of performing local impedance measurements on a single live cell and, if correctly calibrated, it provides also quantitative information (e.g. absolute measurements of membrane permittivity).", [["cell", "ANATOMY", 99, 103], ["membrane", "ANATOMY", 207, 215], ["cell", "CELL", 99, 103], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["local impedance measurements", "TEST", 53, 81], ["membrane permittivity", "TREATMENT", 207, 228]]], ["The system was demonstrated to work on Saccharomyces Cerevisiae.", [["Saccharomyces Cerevisiae", "ORGANISM", 39, 63], ["Saccharomyces Cerevisiae", "SPECIES", 39, 63], ["Saccharomyces Cerevisiae", "SPECIES", 39, 63], ["Saccharomyces Cerevisiae", "TREATMENT", 39, 63]]], ["A better model for a full test of the potentialities of the new technique is given by excitable cells, characterized by a greater variability of dielectric properties.", [["cells", "ANATOMY", 96, 101], ["cells", "CELL", 96, 101], ["excitable cells", "CELL_TYPE", 86, 101], ["a full test", "TEST", 19, 30], ["new", "OBSERVATION_MODIFIER", 60, 63], ["greater", "OBSERVATION_MODIFIER", 122, 129], ["dielectric properties", "OBSERVATION", 145, 166]]], ["A challenging objective could be directly imaging ion channels.A novel scanning microwave microscope for investigating living cells at the nanometric scaleHIV-1 to efficiently complete a replication cycle has to integrate its genome into the host cellular DNA.After HIV-1 enters target cells,neosynthesized viral DNA forms along with other proteins the pre-integration complex (PIC).PICs are then transported into the nucleus where integration,catalyzed by the viral integrase,takes place.HIV-1 viral particles engineered to incorporate integrase fused to EGFP have proven effective to study PICs within nuclei of infected cells.In this study we report the live imaging analysis of nuclear PIC dynamics obtained by time-lapse microscopy.Intranuclear trajectories of IN-EGFP-labeled PIC were collected in three dimensions and examined by both mean squared displacement (MSD) and cage diameter (CD) analysis.In CD the maximum distances measured between two positions occupied by a PIC in a time window of 2 minutes were calculated while in our MSD analysis 5-minute long trajectory segments were considered.Remarkably,MSD revealed the presence of an underlying active transport mechanism.To test the possible role of actin filaments,PIC nuclear trafficking was analyzed in cells treated with latrunculin B (actin polymerization inhibitor).Preliminary results suggest that the disruption of actin function impairs the active nuclear movement of PICs.P-68Second harmonic generation microscopy reveals sarcomere contractile dynamics of cardiomyocytes N. Prent 1 , C. A. Greenhalgh 1 , R. O. Cisek 1 , J. Aus Der Au 2 , S. Elmore 3 , J. H. van Beek 3 , J. Squier 2 , V. Barzda 1 1 Department of Physics and Institute for Optical Sciences, University of Toronto, Toronto, Canada, 2 Department of Physics, Colorado School of Mines, Golden, USA, 3 Department of Molecular Cell Physiology, Vrije Universiteit, Amsterdam, Netherlands Cardiomyocytes, like other striated muscles, exhibit strong inherent second-order nonlinear optical properties that make them exemplar for live cell dynamic studies with second harmonic generation (SHG) microscopy.", [["cells", "ANATOMY", 126, 131], ["cellular", "ANATOMY", 247, 255], ["cells", "ANATOMY", 286, 291], ["nucleus", "ANATOMY", 418, 425], ["nuclei", "ANATOMY", 604, 610], ["cells", "ANATOMY", 623, 628], ["nuclear", "ANATOMY", 682, 689], ["filaments", "ANATOMY", 1221, 1230], ["nuclear", "ANATOMY", 1235, 1242], ["cells", "ANATOMY", 1271, 1276], ["nuclear", "ANATOMY", 1422, 1429], ["PICs", "ANATOMY", 1442, 1446], ["sarcomere", "ANATOMY", 1497, 1506], ["cardiomyocytes", "ANATOMY", 1531, 1545], ["Cell", "ANATOMY", 1863, 1867], ["Cardiomyocytes", "ANATOMY", 1923, 1937], ["striated muscles", "ANATOMY", 1950, 1966], ["cell", "ANATOMY", 2067, 2071], ["latrunculin B", "CHEMICAL", 1290, 1303], ["PIC", "CHEMICAL", 782, 785], ["latrunculin B", "CHEMICAL", 1290, 1303], ["cells", "CELL", 126, 131], ["cellular DNA", "CELLULAR_COMPONENT", 247, 259], ["HIV-1", "ORGANISM", 266, 271], ["cells", "CELL", 286, 291], ["DNA", "CELLULAR_COMPONENT", 313, 316], ["PIC", "CELLULAR_COMPONENT", 378, 381], ["nucleus", "CELLULAR_COMPONENT", 418, 425], ["HIV-1", "ORGANISM", 489, 494], ["EGFP", "GENE_OR_GENE_PRODUCT", 556, 560], ["nuclei", "CELLULAR_COMPONENT", 604, 610], ["cells", "CELL", 623, 628], ["IN", "GENE_OR_GENE_PRODUCT", 766, 768], ["EGFP", "GENE_OR_GENE_PRODUCT", 769, 773], ["PIC", "CELLULAR_COMPONENT", 782, 785], ["actin", "GENE_OR_GENE_PRODUCT", 1215, 1220], ["filaments", "CELLULAR_COMPONENT", 1221, 1230], ["PIC", "CELLULAR_COMPONENT", 1231, 1234], ["nuclear", "CELLULAR_COMPONENT", 1235, 1242], ["cells", "CELL", 1271, 1276], ["latrunculin B", "SIMPLE_CHEMICAL", 1290, 1303], ["actin", "GENE_OR_GENE_PRODUCT", 1305, 1310], ["actin", "GENE_OR_GENE_PRODUCT", 1388, 1393], ["nuclear", "CELLULAR_COMPONENT", 1422, 1429], ["PICs", "CELLULAR_COMPONENT", 1442, 1446], ["muscles", "ORGAN", 1959, 1966], ["cell", "CELL", 2067, 2071], ["nanometric scaleHIV-1", "DNA", 139, 160], ["host cellular DNA", "DNA", 242, 259], ["target cells", "CELL_TYPE", 279, 291], ["neosynthesized viral DNA", "DNA", 292, 316], ["pre-integration complex", "PROTEIN", 353, 376], ["PIC", "PROTEIN", 378, 381], ["PICs", "PROTEIN", 383, 387], ["viral integrase", "PROTEIN", 461, 476], ["EGFP", "DNA", 556, 560], ["PICs", "PROTEIN", 592, 596], ["infected cells", "CELL_TYPE", 614, 628], ["IN-EGFP-labeled PIC", "DNA", 766, 785], ["PIC", "DNA", 979, 982], ["actin filaments", "PROTEIN", 1215, 1230], ["PIC", "PROTEIN", 1231, 1234], ["actin", "PROTEIN", 1305, 1310], ["actin", "PROTEIN", 1388, 1393], ["PICs", "PROTEIN", 1442, 1446], ["HIV-", "SPECIES", 266, 270], ["HIV-1", "SPECIES", 489, 494], ["HIV-1", "SPECIES", 266, 271], ["HIV-1", "SPECIES", 489, 494], ["A novel scanning microwave microscope", "TEST", 63, 100], ["a replication cycle", "TREATMENT", 185, 204], ["HIV", "TEST", 266, 269], ["target cells", "PROBLEM", 279, 291], ["neosynthesized viral DNA forms", "PROBLEM", 292, 322], ["PICs", "TREATMENT", 383, 387], ["the viral integrase", "TREATMENT", 457, 476], ["HIV", "PROBLEM", 489, 492], ["1 viral particles", "PROBLEM", 493, 510], ["integrase fused to EGFP", "TREATMENT", 537, 560], ["infected cells", "PROBLEM", 614, 628], ["this study", "TEST", 632, 642], ["the live imaging analysis", "TEST", 653, 678], ["nuclear PIC dynamics", "TEST", 682, 702], ["labeled PIC", "TREATMENT", 774, 785], ["cage diameter (CD) analysis", "TEST", 878, 905], ["a PIC", "TREATMENT", 977, 982], ["our MSD analysis", "TEST", 1038, 1054], ["actin filaments", "PROBLEM", 1215, 1230], ["PIC nuclear trafficking", "TREATMENT", 1231, 1254], ["latrunculin B (actin polymerization inhibitor", "TREATMENT", 1290, 1335], ["the disruption of actin function", "PROBLEM", 1370, 1402], ["P", "TEST", 1447, 1448], ["harmonic generation microscopy", "TEST", 1458, 1488], ["sarcomere contractile dynamics of cardiomyocytes", "PROBLEM", 1497, 1545], ["other striated muscles", "PROBLEM", 1944, 1966], ["live cell dynamic studies", "TEST", 2062, 2087], ["second harmonic generation (SHG) microscopy", "TEST", 2093, 2136], ["host cellular DNA", "OBSERVATION", 242, 259], ["nucleus", "ANATOMY", 418, 425], ["viral integrase", "OBSERVATION", 461, 476], ["infected cells", "OBSERVATION", 614, 628], ["trajectories", "OBSERVATION_MODIFIER", 750, 762], ["mean squared", "OBSERVATION", 842, 854], ["displacement", "OBSERVATION_MODIFIER", 855, 867], ["CD", "OBSERVATION", 909, 911], ["maximum", "OBSERVATION_MODIFIER", 916, 923], ["distances", "OBSERVATION_MODIFIER", 924, 933], ["positions", "OBSERVATION_MODIFIER", 955, 964], ["PIC", "OBSERVATION_MODIFIER", 979, 982], ["active", "OBSERVATION_MODIFIER", 1159, 1165], ["transport mechanism", "OBSERVATION", 1166, 1185], ["possible", "UNCERTAINTY", 1198, 1206], ["actin filaments", "OBSERVATION", 1215, 1230], ["actin function", "OBSERVATION", 1388, 1402], ["active", "OBSERVATION_MODIFIER", 1415, 1421], ["nuclear movement", "OBSERVATION", 1422, 1438], ["sarcomere contractile dynamics", "OBSERVATION", 1497, 1527], ["cardiomyocytes", "ANATOMY", 1531, 1545], ["Molecular Cell Physiology", "OBSERVATION", 1853, 1878], ["striated muscles", "ANATOMY", 1950, 1966]]], ["Laser scanning SHG microscopy with an incident wavelength around 1\u00b5m, enables fast imaging for extended periods of time with negligible tissue damage.", [["tissue", "ANATOMY", 136, 142], ["tissue", "TISSUE", 136, 142], ["Laser scanning SHG microscopy", "TEST", 0, 29], ["fast imaging", "TEST", 78, 90], ["negligible tissue damage", "PROBLEM", 125, 149], ["negligible tissue", "OBSERVATION_MODIFIER", 125, 142], ["damage", "OBSERVATION", 143, 149]]], ["Strong SHG signal originates from the anisotropic (A-) bands which are comprised of regularly arranged myosin molecules, while actin molecules, the main constituent of the isotropic (I-) bands, produce negligible SHG.", [["myosin", "GENE_OR_GENE_PRODUCT", 103, 109], ["actin", "GENE_OR_GENE_PRODUCT", 127, 132], ["SHG", "PROTEIN", 7, 10], ["myosin molecules", "PROTEIN", 103, 119], ["actin molecules", "PROTEIN", 127, 142], ["isotropic (I-) bands", "PROTEIN", 172, 192], ["SHG", "PROTEIN", 213, 216], ["the anisotropic (A-) bands", "PROBLEM", 34, 60], ["negligible SHG", "PROBLEM", 202, 216], ["main", "OBSERVATION_MODIFIER", 148, 152]]], ["Consequently, the alternating bands along the myofibril are clearly visualized, therefore, enabling the determination of individual sarcomere lengths and the study of sarcomere length dynamics during macro-scale contractions.", [["myofibril", "ANATOMY", 46, 55], ["sarcomere", "ANATOMY", 132, 141], ["sarcomere", "ANATOMY", 167, 176], ["myofibril", "CELLULAR_COMPONENT", 46, 55], ["the alternating bands", "PROBLEM", 14, 35], ["the study", "TEST", 154, 163], ["macro-scale contractions", "PROBLEM", 200, 224], ["myofibril", "ANATOMY", 46, 55]]], ["SHG intensity is shown to positively correlate to sarcomere length, which leads to the development of real-time inherent force sensors for in vivo myocytes.", [["sarcomere", "ANATOMY", 50, 59], ["myocytes", "ANATOMY", 147, 155], ["myocytes", "CELL", 147, 155], ["SHG", "PROTEIN", 0, 3], ["sarcomere length", "TEST", 50, 66], ["sarcomere length", "OBSERVATION_MODIFIER", 50, 66]]], ["Rich sarcomere dynamics can be observed during myocyte contraction, which can be used for medical diagnostic purpose of muscular degenerative diseases.P-67Imaging cellular communication in insulin secretion ex vivo and in vivo D. W. Piston Vanderbilt University, Nashville, Tennessee, U.S.A.P-67The islet of Langerhans is the functional unit responsible for glucose-stimulated insulin secretion (GSIS), and thus plays a key role in blood glucose homeostasis.", [["sarcomere", "ANATOMY", 5, 14], ["myocyte", "ANATOMY", 47, 54], ["muscular", "ANATOMY", 120, 128], ["cellular", "ANATOMY", 163, 171], ["islet", "ANATOMY", 299, 304], ["Langerhans", "ANATOMY", 308, 318], ["blood", "ANATOMY", 432, 437], ["muscular degenerative diseases", "DISEASE", 120, 150], ["glucose", "CHEMICAL", 358, 365], ["glucose", "CHEMICAL", 438, 445], ["glucose", "CHEMICAL", 358, 365], ["glucose", "CHEMICAL", 438, 445], ["myocyte", "CELL", 47, 54], ["cellular", "CELL", 163, 171], ["insulin", "GENE_OR_GENE_PRODUCT", 189, 196], ["islet", "MULTI-TISSUE_STRUCTURE", 299, 304], ["Langerhans", "MULTI-TISSUE_STRUCTURE", 308, 318], ["glucose", "SIMPLE_CHEMICAL", 358, 365], ["insulin", "GENE_OR_GENE_PRODUCT", 377, 384], ["GSIS", "GENE_OR_GENE_PRODUCT", 396, 400], ["blood", "ORGANISM_SUBSTANCE", 432, 437], ["glucose", "SIMPLE_CHEMICAL", 438, 445], ["P", "DNA", 151, 152], ["Rich sarcomere dynamics", "PROBLEM", 0, 23], ["muscular degenerative diseases", "PROBLEM", 120, 150], ["insulin secretion", "TREATMENT", 189, 206], ["glucose", "TEST", 358, 365], ["blood glucose homeostasis", "TEST", 432, 457], ["muscular", "ANATOMY", 120, 128], ["degenerative diseases", "OBSERVATION", 129, 150]]], ["The importance of the islet is demonstrated by the proven ability of islet transplants to reverse Type I diabetes pathologies in human patients.", [["islet", "ANATOMY", 22, 27], ["islet", "ANATOMY", 69, 74], ["Type I diabetes pathologies", "DISEASE", 98, 125], ["islet", "MULTI-TISSUE_STRUCTURE", 22, 27], ["islet", "MULTI-TISSUE_STRUCTURE", 69, 74], ["human", "ORGANISM", 129, 134], ["patients", "ORGANISM", 135, 143], ["human", "SPECIES", 129, 134], ["patients", "SPECIES", 135, 143], ["human", "SPECIES", 129, 134], ["islet transplants", "TREATMENT", 69, 86], ["Type I diabetes pathologies in human patients", "PROBLEM", 98, 143]]], ["We are interested in understanding the multicellular mechanisms of islet function, and their role in the regulation of blood glucose under normal and pathological conditions.", [["islet", "ANATOMY", 67, 72], ["blood", "ANATOMY", 119, 124], ["glucose", "CHEMICAL", 125, 132], ["glucose", "CHEMICAL", 125, 132], ["islet", "MULTI-TISSUE_STRUCTURE", 67, 72], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["glucose", "SIMPLE_CHEMICAL", 125, 132], ["blood glucose", "TEST", 119, 132]]], ["In many ways, the islet appears to function as a syncytium, which exhibits synchronous behavior of membrane action potentials, Ca 2+ oscillations, and pulsatile insulin secretion across all \u03b2-cells in the islet.", [["islet", "ANATOMY", 18, 23], ["syncytium", "ANATOMY", 49, 58], ["membrane", "ANATOMY", 99, 107], ["\u03b2-cells", "ANATOMY", 190, 197], ["islet", "ANATOMY", 205, 210], ["Ca", "CHEMICAL", 127, 129], ["Ca 2+", "CHEMICAL", 127, 132], ["islet", "MULTI-TISSUE_STRUCTURE", 18, 23], ["syncytium", "CELLULAR_COMPONENT", 49, 58], ["membrane", "CELLULAR_COMPONENT", 99, 107], ["Ca 2+", "SIMPLE_CHEMICAL", 127, 132], ["insulin", "GENE_OR_GENE_PRODUCT", 161, 168], ["islet", "MULTI-TISSUE_STRUCTURE", 205, 210], ["\u03b2-cells", "CELL_TYPE", 190, 197], ["a syncytium", "PROBLEM", 47, 58], ["synchronous behavior of membrane action potentials", "PROBLEM", 75, 125], ["Ca", "TEST", 127, 129], ["pulsatile insulin secretion", "PROBLEM", 151, 178], ["synchronous", "OBSERVATION_MODIFIER", 75, 86], ["islet", "ANATOMY", 205, 210]]], ["In other ways, the islet works as individual cells, especially in the regulation of gene transcription.", [["islet", "ANATOMY", 19, 24], ["cells", "ANATOMY", 45, 50], ["islet", "MULTI-TISSUE_STRUCTURE", 19, 24], ["cells", "CELL", 45, 50], ["gene transcription", "TREATMENT", 84, 102]]], ["Using our unique quantitative optical imaging methods and novel microfluidic devices, the dynamics of these molecular mechanisms can be followed quantitatively in living cells within intact islets.", [["cells", "ANATOMY", 170, 175], ["islets", "ANATOMY", 190, 196], ["cells", "CELL", 170, 175], ["islets", "MULTI-TISSUE_STRUCTURE", 190, 196], ["novel microfluidic devices", "TREATMENT", 58, 84], ["microfluidic devices", "OBSERVATION", 64, 84]]], ["These investigations utilize transgenic and tissue-specific knock-out mouse models with demonstrated phenotypes, as well as traditional biochemical and molecular biological approaches.O-66Do retinal rod outer segments carry out oxydative phosphorylation?O-66I.", [["tissue", "ANATOMY", 44, 50], ["retinal rod outer segments", "ANATOMY", 191, 217], ["O-66I", "CHEMICAL", 254, 259], ["O-66Do", "CHEMICAL", 184, 190], ["O-66I", "CHEMICAL", 254, 259], ["tissue", "TISSUE", 44, 50], ["mouse", "ORGANISM", 70, 75], ["O-66I", "SIMPLE_CHEMICAL", 254, 259], ["mouse", "SPECIES", 70, 75], ["mouse", "SPECIES", 70, 75], ["These investigations", "TEST", 0, 20], ["transgenic and tissue", "TEST", 29, 50], ["phenotypes", "PROBLEM", 101, 111], ["retinal rod outer segments", "TREATMENT", 191, 217], ["oxydative phosphorylation", "TREATMENT", 228, 253], ["rod", "OBSERVATION_MODIFIER", 199, 202], ["outer", "ANATOMY_MODIFIER", 203, 208], ["segments", "ANATOMY_MODIFIER", 209, 217]]], ["Panfoli 1 , P. Bianchini 2 , D. Calzia 1 , S. Ravera 1 , A. Morelli 1 , A. Diaspro 3 1 Biology Dept., University of Genova, Italy, 2 LAMBS-MicroScoBiO Res.Centre, University of Genova, Italy, 3 Neuroscience and Brain Technology Dept., I.I.T. Genova, Italy Visual transduction in vertebrate retinal rod Outer Segments (OS) is very energy demanding.", [["retinal rod Outer Segments", "ANATOMY", 290, 316], ["retinal", "MULTI-TISSUE_STRUCTURE", 290, 297], ["Outer Segments", "MULTI-TISSUE_STRUCTURE", 302, 316], ["Panfoli", "TREATMENT", 0, 7], ["Brain", "ANATOMY", 211, 216], ["vertebrate", "ANATOMY_MODIFIER", 279, 289], ["retinal", "ANATOMY", 290, 297], ["rod", "ANATOMY_MODIFIER", 298, 301], ["Outer", "ANATOMY_MODIFIER", 302, 307], ["Segments", "ANATOMY_MODIFIER", 308, 316]]], ["However, ATP supply in OS, that are devoid of mitochondria, is still puzzling.", [["mitochondria", "ANATOMY", 46, 58], ["ATP", "CHEMICAL", 9, 12], ["ATP", "CHEMICAL", 9, 12], ["ATP", "SIMPLE_CHEMICAL", 9, 12], ["mitochondria", "CELLULAR_COMPONENT", 46, 58], ["ATP supply in OS", "PROBLEM", 9, 25], ["mitochondria", "PROBLEM", 46, 58]]], ["By a proteomic analysis we identified in purified bovine OS disks, proteins involved in vision, as well as the respiratory chain complexes I to IV and F 1 F o -ATP synthase, whose activity was comparable to that of mitochondria and sensitive to specific inhibitors.", [["mitochondria", "ANATOMY", 215, 227], ["ATP", "CHEMICAL", 160, 163], ["ATP", "CHEMICAL", 160, 163], ["bovine", "ORGANISM", 50, 56], ["F 1 F o -ATP synthase", "GENE_OR_GENE_PRODUCT", 151, 172], ["mitochondria", "CELLULAR_COMPONENT", 215, 227], ["respiratory chain complexes", "PROTEIN", 111, 138], ["I to IV and F 1 F o -ATP synthase", "PROTEIN", 139, 172], ["bovine", "SPECIES", 50, 56], ["a proteomic analysis", "TEST", 3, 23], ["purified bovine OS disks", "TREATMENT", 41, 65], ["ATP synthase", "TREATMENT", 160, 172], ["mitochondria", "PROBLEM", 215, 227], ["specific inhibitors", "TREATMENT", 245, 264], ["OS disks", "OBSERVATION", 57, 65]]], ["Rhodamine 123 fluorescence quenching experiments showed the presence of a proton potential difference across disks.", [["Rhodamine 123", "CHEMICAL", 0, 13], ["Rhodamine 123", "CHEMICAL", 0, 13], ["Rhodamine 123", "SIMPLE_CHEMICAL", 0, 13], ["Rhodamine", "TREATMENT", 0, 9], ["fluorescence quenching experiments", "TEST", 14, 48], ["a proton potential difference across disks", "PROBLEM", 72, 114]]], ["Disks consumed oxygen.", [["oxygen", "CHEMICAL", 15, 21], ["oxygen", "CHEMICAL", 15, 21], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["oxygen", "TREATMENT", 15, 21], ["oxygen", "OBSERVATION_MODIFIER", 15, 21]]], ["Confocal laser scanning and transmission electron microscopy showed that Cytochrome c Oxydase and ATP synthase are localized on disks.", [["ATP", "CHEMICAL", 98, 101], ["ATP", "CHEMICAL", 98, 101], ["Cytochrome c Oxydase", "GENE_OR_GENE_PRODUCT", 73, 93], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 98, 110], ["Cytochrome c Oxydase", "PROTEIN", 73, 93], ["ATP synthase", "PROTEIN", 98, 110], ["Confocal laser scanning", "TEST", 0, 23], ["transmission electron microscopy", "TEST", 28, 60], ["Cytochrome c Oxydase", "TREATMENT", 73, 93], ["ATP synthase", "TREATMENT", 98, 110]]], ["Mitochondrial vital dyes stained OS ex vivo, and disks.", [["Mitochondrial", "ANATOMY", 0, 13], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["Mitochondrial vital dyes", "TEST", 0, 24], ["disks", "PROBLEM", 49, 54]]], ["Rhodopsin and MitoTracker fluorescence co-localized in OS.", [["Rhodopsin", "GENE_OR_GENE_PRODUCT", 0, 9], ["MitoTracker", "SIMPLE_CHEMICAL", 14, 25], ["Rhodopsin and MitoTracker fluorescence", "TREATMENT", 0, 38]]], ["Data, suggestive of an aerobic metabolism in OS, point to the existence of \"mitochondrial inner membrane-like membranes\" ectopically producing ATP through oxidative phosphorylation, with respect to mitochondria.", [["mitochondrial inner membrane-like membranes", "ANATOMY", 76, 119], ["mitochondria", "ANATOMY", 198, 210], ["ATP", "CHEMICAL", 143, 146], ["ATP", "CHEMICAL", 143, 146], ["mitochondrial", "CELLULAR_COMPONENT", 76, 89], ["inner membrane", "CELLULAR_COMPONENT", 90, 104], ["like membranes", "CELLULAR_COMPONENT", 105, 119], ["ATP", "SIMPLE_CHEMICAL", 143, 146], ["mitochondria", "CELLULAR_COMPONENT", 198, 210], ["an aerobic metabolism in OS", "PROBLEM", 20, 47], ["\"mitochondrial inner membrane", "PROBLEM", 75, 104], ["ATP through oxidative phosphorylation", "TREATMENT", 143, 180], ["suggestive of", "UNCERTAINTY", 6, 19], ["aerobic metabolism", "OBSERVATION", 23, 41]]], ["New scenarios open on the patho-physiology of many retinal diseases associated to mitochondrial dysfunction.O-65-Live cell imaging -Abstracts 123 Unmixing using lifetime-excitation multidimensional confocal fluorescence microscopy data S. Schlachter 1 , S. Schwedler 2 , A. Esposito 1 , A. D. Elder 1 , G. S. Kaminski Schierle 1 , C. F. Kaminski 1 1 Cambridge University, U.K., 2 Universit\u00e4t Bielefeld, Germany Fluorescence imaging provides a powerful tool to probe biological systems, enabling the high resolution investigation of the localization, interaction and biochemical modification of biomolecules.", [["retinal", "ANATOMY", 51, 58], ["mitochondrial", "ANATOMY", 82, 95], ["cell", "ANATOMY", 118, 122], ["retinal diseases", "DISEASE", 51, 67], ["mitochondrial dysfunction", "DISEASE", 82, 107], ["retinal", "MULTI-TISSUE_STRUCTURE", 51, 58], ["mitochondrial", "CELLULAR_COMPONENT", 82, 95], ["New scenarios", "PROBLEM", 0, 13], ["many retinal diseases", "PROBLEM", 46, 67], ["mitochondrial dysfunction", "PROBLEM", 82, 107], ["Live cell imaging", "TEST", 113, 130], ["Germany Fluorescence imaging", "TEST", 403, 431], ["biochemical modification of biomolecules", "TREATMENT", 566, 606], ["scenarios", "OBSERVATION", 4, 13], ["many", "OBSERVATION_MODIFIER", 46, 50], ["retinal", "ANATOMY", 51, 58], ["diseases", "OBSERVATION", 59, 67], ["mitochondrial dysfunction", "OBSERVATION", 82, 107]]], ["Multidimensional imaging, in particular, is a growing application of confocal and other forms of fluorescence microscopy.", [["Multidimensional imaging", "TEST", 0, 24], ["fluorescence microscopy", "TEST", 97, 120]]], ["It seeks to measure not only fluorescence intensity in three spatial dimensions, but also other features of fluorescence emission, such as lifetime and fluorescence spectra.", [["fluorescence emission", "PROBLEM", 108, 129], ["three spatial dimensions", "OBSERVATION_MODIFIER", 55, 79]]], ["Although multi-dimensional fluorescence microscopy has been demonstrated before, little attention has so far been paid to the problem of data interpretation and representation when dealing with such large datasets.", [["multi-dimensional fluorescence microscopy", "TEST", 9, 50], ["such large datasets", "PROBLEM", 194, 213]]], ["We present here an instrument capable of recording fluorescence lifetime and excitation data by combining TCSPC for lifetime determination and a supercontinuum excitation source for extracting excitation spectra.", [["excitation data", "TEST", 77, 92], ["a supercontinuum excitation source", "TREATMENT", 143, 177]]], ["These technologies permit the acquisition of 2D and 3D images with lifetime and excitation spectrum information at every pixel.", [["3D images", "TEST", 52, 61]]], ["We demonstrate a method whereby the multidimensional datasets acquired with this instrument are processed to yield biologically relevant parameters, (e.g. unmix fluorophores in a multiply labelled sample).", [["this instrument", "TREATMENT", 76, 91]]], ["Our method relies on a global analysis approach and uses AB plots for displaying multidimensional data.", [["AB plots", "TEST", 57, 65], ["multidimensional data", "TEST", 81, 102]]], ["We demonstrate the instrument & processing method on dye and multiply labelled biological samples.P-72Advanced neuroimaging with diffractive optical elements P. Saggau Baylor College of Medicine, Houston, Texas, USA Studying neural systems is complicated by the large number and small size of its cellular elements.", [["samples", "ANATOMY", 90, 97], ["neural systems", "ANATOMY", 225, 239], ["cellular", "ANATOMY", 297, 305], ["dye", "SIMPLE_CHEMICAL", 53, 56], ["cellular", "CELL", 297, 305], ["P", "DNA", 98, 99], ["cellular elements", "DNA", 297, 314], ["dye", "TREATMENT", 53, 56], ["neuroimaging", "TEST", 111, 123], ["large", "OBSERVATION_MODIFIER", 262, 267], ["number", "OBSERVATION_MODIFIER", 268, 274], ["small", "OBSERVATION_MODIFIER", 279, 284], ["size", "OBSERVATION_MODIFIER", 285, 289], ["cellular elements", "OBSERVATION", 297, 314]]], ["The traditional way of exploring neuronal function by electrical monitoring with micropipettes is increasingly replaced by molecular imaging.", [["neuronal", "ANATOMY", 33, 41], ["neuronal", "CELL", 33, 41], ["electrical monitoring", "TEST", 54, 75], ["micropipettes", "TREATMENT", 81, 94], ["molecular imaging", "TEST", 123, 140]]], ["Fluorescent molecules allow optical monitoring of neuronal signaling with cellular and often subcellular resolution.", [["neuronal", "ANATOMY", 50, 58], ["cellular", "ANATOMY", 74, 82], ["subcellular", "ANATOMY", 93, 104], ["neuronal", "CELL", 50, 58], ["cellular", "CELL", 74, 82], ["Fluorescent molecules", "TEST", 0, 21], ["optical monitoring", "TEST", 28, 46], ["resolution", "OBSERVATION_MODIFIER", 105, 115]]], ["In addition to monitoring activity, analyzing the functional properties of individual neurons or neuronal populations requires their controlled activation.", [["neurons", "ANATOMY", 86, 93], ["neuronal populations", "ANATOMY", 97, 117], ["neurons", "CELL", 86, 93], ["neuronal populations", "CELL", 97, 117], ["neuronal populations", "CELL_TYPE", 97, 117], ["monitoring activity", "TEST", 15, 34], ["individual neurons", "PROBLEM", 75, 93], ["neuronal populations", "PROBLEM", 97, 117]]], ["Optical approaches are well-suited, including molecular photolysis of inert precursors and light activation of engineered proteins that control ionic membrane currents.", [["membrane", "ANATOMY", 150, 158], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["engineered proteins", "PROTEIN", 111, 130], ["molecular photolysis of inert precursors", "TREATMENT", 46, 86], ["light activation of engineered proteins", "TREATMENT", 91, 130], ["inert precursors", "OBSERVATION", 70, 86]]], ["To fully utilize optical techniques for exploring neural systems requires more than adequate spatial resolution to distinguish neuronal elements and sufficient temporal resolution to induce and/or monitor neuronal signaling.", [["neural systems", "ANATOMY", 50, 64], ["neuronal", "ANATOMY", 127, 135], ["neuronal", "ANATOMY", 205, 213], ["neuronal", "CELL", 127, 135], ["neuronal", "CELL", 205, 213], ["optical techniques", "TREATMENT", 17, 35], ["exploring neural systems", "TREATMENT", 40, 64], ["neuronal elements", "PROBLEM", 127, 144]]], ["Because of the non-linear and non-stationary nature of the studied system it is necessary to access many neuronal sites simultaneously.", [["neuronal sites", "ANATOMY", 105, 119], ["neuronal sites", "MULTI-TISSUE_STRUCTURE", 105, 119], ["neuronal sites", "OBSERVATION", 105, 119]]], ["In modern imaging, wide-field illumination and imageformation are often replaced by patterned excitation and nonimaging photon collection.", [["modern imaging", "TEST", 3, 17], ["nonimaging photon collection", "TEST", 109, 137]]], ["In many instants, diffractive illumination schemes can substitute for conventional reflective or refractive designs.", [["diffractive illumination schemes", "TREATMENT", 18, 50], ["refractive designs", "TREATMENT", 97, 115], ["refractive designs", "OBSERVATION", 97, 115]]], ["In particular, the availability of programmable diffractive optical elements has made this an attractive alternative, since they permit highly versatile microscope designs and support a significant increase in the overall spatio-temporal resolution.", [["diffractive optical elements", "DNA", 48, 76], ["a significant increase", "PROBLEM", 184, 206], ["the overall spatio", "PROBLEM", 210, 228], ["significant", "OBSERVATION_MODIFIER", 186, 197], ["increase", "OBSERVATION_MODIFIER", 198, 206], ["overall", "OBSERVATION_MODIFIER", 214, 221], ["spatio", "OBSERVATION_MODIFIER", 222, 228], ["temporal", "OBSERVATION_MODIFIER", 229, 237], ["resolution", "OBSERVATION_MODIFIER", 238, 248]]], ["I will present an advanced imaging approach using diffractive optical elements to analyze structure and function of live neurons in brain slices and intact cortex.P-71Efficient evaluation of FRET in image cytometry with acceptor photobleaching and ratiometric methods J. Roszik, D. Lisboa, J. Sz\u00f6ll\u0151si, G. Vereb Department of Biophysics and Cell Biology, University of Debrecen, Debrecen, Hungary Fluorescence resonance energy transfer (FRET) is a powerful technique that can be applied to study nanoscale intra-and intermolecular events and interactions of molecules in situ in biological systems.", [["neurons", "ANATOMY", 121, 128], ["brain slices", "ANATOMY", 132, 144], ["cortex", "ANATOMY", 156, 162], ["Cell", "ANATOMY", 341, 345], ["neurons", "CELL", 121, 128], ["brain slices", "MULTI-TISSUE_STRUCTURE", 132, 144], ["cortex", "MULTI-TISSUE_STRUCTURE", 156, 162], ["Cell", "CELL", 341, 345], ["diffractive optical elements", "DNA", 50, 78], ["live neurons", "CELL_TYPE", 116, 128], ["P", "DNA", 163, 164], ["an advanced imaging approach", "TEST", 15, 43], ["diffractive optical elements", "TREATMENT", 50, 78], ["71Efficient evaluation", "TEST", 165, 187], ["FRET in image cytometry", "TEST", 191, 214], ["acceptor photobleaching", "TREATMENT", 220, 243], ["a powerful technique", "TREATMENT", 446, 466], ["nanoscale intra-and intermolecular events", "PROBLEM", 496, 537], ["brain", "ANATOMY", 132, 137], ["intact cortex", "OBSERVATION", 149, 162]]], ["A robust, easy to use, self-controlled FRET method, independent of donor and acceptor concentration and stochiometry, is acceptor photobleaching FRET, which requires only simple image mathematics.", [["self-controlled FRET method", "PROBLEM", 23, 50], ["donor and acceptor concentration", "TREATMENT", 67, 99], ["acceptor photobleaching FRET", "PROBLEM", 121, 149], ["photobleaching FRET", "OBSERVATION", 130, 149]]], ["Another approach with more complicated calculations is the intensitybased ratiometric method, which is not based on destroying the acceptor fluorophores, making it applicable for following molecular interactions in live cells.", [["cells", "ANATOMY", 220, 225], ["cells", "CELL", 220, 225], ["live cells", "CELL_TYPE", 215, 225], ["the intensitybased ratiometric method", "TEST", 55, 92], ["the acceptor fluorophores", "TREATMENT", 127, 152]]], ["As the need for using FRET in image cytometry for evaluating molecular interactions increases, we have undertaken to develop softwares for these methods involving the calculation and usage of all correction factors needed to obtain reliable energy transfer efficiencies.", [["correction factors", "PROTEIN", 196, 214], ["FRET in image cytometry", "TEST", 22, 45], ["these methods", "TEST", 139, 152], ["the calculation", "TEST", 163, 178], ["all correction factors", "TREATMENT", 192, 214]]], ["Correction possibilities of the acceptor photobleaching method include unwanted photobleaching of the donor, fluorescent photoproduct of the acceptor after photobleaching, cross-talk of unbleached acceptor into the donor channel and partial photobleaching of the acceptor.", [["the acceptor photobleaching method", "TREATMENT", 28, 62], ["the donor", "TREATMENT", 98, 107], ["fluorescent photoproduct of the acceptor", "TREATMENT", 109, 149], ["the donor channel", "TREATMENT", 211, 228], ["partial photobleaching of the acceptor", "TREATMENT", 233, 271], ["partial photobleaching", "OBSERVATION", 233, 255]]], ["In the case of intensity-based ratiometric FRET, we can correct for all channel cross-talks and calibrate the FRET efficiency calculations.", [["the FRET efficiency calculations", "TREATMENT", 106, 138]]], ["Both programs provide registration and semiautomatic processing, and they are freely available.Involvement of pendrin in volume and pH control analyzed through the fluorescence properties of EYFPThe pendrin (SLC26A4) gene is responsible, when mutated, for the Pendred syndrome, a recessive disorder characterized by sensorineural hearing loss often accompanied by thyroid disfunctions.", [["thyroid", "ANATOMY", 364, 371], ["Pendred syndrome", "DISEASE", 260, 276], ["recessive disorder", "DISEASE", 280, 298], ["sensorineural hearing loss", "DISEASE", 316, 342], ["thyroid disfunctions", "DISEASE", 364, 384], ["pendrin", "GENE_OR_GENE_PRODUCT", 110, 117], ["EYFPThe pendrin", "GENE_OR_GENE_PRODUCT", 191, 206], ["SLC26A4", "GENE_OR_GENE_PRODUCT", 208, 215], ["thyroid", "ORGAN", 364, 371], ["pendrin", "PROTEIN", 110, 117], ["EYFPThe pendrin (SLC26A4) gene", "DNA", 191, 221], ["semiautomatic processing", "TEST", 39, 63], ["pendrin in volume and pH control", "TREATMENT", 110, 142], ["the Pendred syndrome", "PROBLEM", 256, 276], ["a recessive disorder", "PROBLEM", 278, 298], ["sensorineural hearing loss", "PROBLEM", 316, 342], ["thyroid disfunctions", "PROBLEM", 364, 384], ["sensorineural hearing loss", "OBSERVATION", 316, 342], ["thyroid", "ANATOMY", 364, 371], ["disfunctions", "OBSERVATION", 372, 384]]], ["Pendrin is an anion exchanger.", [["Pendrin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Pendrin", "PROTEIN", 0, 7], ["anion exchanger", "PROTEIN", 14, 29], ["an anion exchanger", "TREATMENT", 11, 29], ["anion exchanger", "OBSERVATION", 14, 29]]], ["The way it works and its role in different tissues, owing to the lack of known isoforms, is matter of wide research and debate.", [["tissues", "ANATOMY", 43, 50], ["tissues", "TISSUE", 43, 50]]], ["We focused on a still unexplored pendrin function, that is most important in the inner ear: cellular volume control and Cl \u2212 fluxes regulation.", [["inner ear", "ANATOMY", 81, 90], ["cellular", "ANATOMY", 92, 100], ["Cl", "CHEMICAL", 120, 122], ["Cl", "CHEMICAL", 120, 122], ["pendrin", "GENE_OR_GENE_PRODUCT", 33, 40], ["inner ear", "TISSUE", 81, 90], ["cellular", "CELL", 92, 100], ["Cl \u2212", "SIMPLE_CHEMICAL", 120, 124], ["pendrin", "PROTEIN", 33, 40], ["cellular volume control", "TREATMENT", 92, 115], ["Cl \u2212 fluxes regulation", "TEST", 120, 142], ["ear", "ANATOMY", 87, 90], ["cellular volume", "OBSERVATION", 92, 107]]], ["We used HEK cells over-expressing wild type pendrin or a mutated isoform together with the EYFP.", [["HEK cells", "ANATOMY", 8, 17], ["HEK cells", "CELL", 8, 17], ["pendrin", "GENE_OR_GENE_PRODUCT", 44, 51], ["EYFP", "GENE_OR_GENE_PRODUCT", 91, 95], ["HEK cells", "CELL_LINE", 8, 17], ["wild type pendrin", "PROTEIN", 34, 51], ["EYFP", "PROTEIN", 91, 95], ["HEK cells", "TREATMENT", 8, 17]]], ["We challenged cells with hypo-osmolar solutions and followed their volume variations in time.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["hypo-osmolar solutions", "TREATMENT", 25, 47]]], ["Taking advantage of the confocal optical sectioning we independently measured cell volume and fluorescence intensity.", [["cell", "ANATOMY", 78, 82], ["cell", "CELL", 78, 82], ["the confocal optical sectioning", "TREATMENT", 20, 51], ["fluorescence intensity", "TEST", 94, 116]]], ["In this way, given the dependence of EYFP fluorescence from [Cl \u2212 ] and pH (measured with SNARF5) we could estimate at the same time Cl \u2212 fluxes, volume and pH variations.", [["Cl", "CHEMICAL", 61, 63], ["Cl", "CHEMICAL", 133, 135], ["Cl", "CHEMICAL", 61, 63], ["Cl", "CHEMICAL", 133, 135], ["EYFP", "GENE_OR_GENE_PRODUCT", 37, 41], ["[Cl \u2212", "SIMPLE_CHEMICAL", 60, 65], ["Cl \u2212", "SIMPLE_CHEMICAL", 133, 137], ["EYFP", "PROTEIN", 37, 41], ["EYFP fluorescence", "TEST", 37, 54], ["pH", "TEST", 72, 74], ["volume", "TEST", 146, 152], ["pH variations", "TEST", 157, 170], ["pH variations", "OBSERVATION", 157, 170]]], ["The contemporary measurements of the three variables, not yet reported in living cells, allowed to assess the role of pendrin in volume regulation and evidenced its participation to Cl \u2212 fluxes as compared to the mutated isoform or controls.", [["cells", "ANATOMY", 81, 86], ["Cl", "CHEMICAL", 182, 184], ["Cl", "CHEMICAL", 182, 184], ["cells", "CELL", 81, 86], ["pendrin", "GENE_OR_GENE_PRODUCT", 118, 125], ["Cl \u2212", "SIMPLE_CHEMICAL", 182, 186], ["pendrin", "PROTEIN", 118, 125], ["mutated isoform", "PROTEIN", 213, 228], ["The contemporary measurements", "TEST", 0, 29], ["pendrin in volume regulation", "TREATMENT", 118, 146]]], ["Particle tracking inside the cell largely benefits of the ability to spatially and temporally mark specific structures to follow their \"signalling\" over a \"dark\" background as made possible since the advent of the photo-activatable markers.", [["cell", "ANATOMY", 29, 33], ["cell", "CELL", 29, 33], ["photo-activatable markers", "PROTEIN", 214, 239]]], ["In terms of spatial confinement of the photo-activation process, the use of multiphoton excitation provides several favourable aspects compared to single photon confocal microscopy in photomarking biological structures to be tracked: the confined excitation volumes, of the order of magnitude of subfemtoliter, due to the non-linear requirements provide a unique control of the excitation and consequently photoactivation in the 3D space.", [["the photo-activation process", "PROBLEM", 35, 63], ["multiphoton excitation", "TREATMENT", 76, 98], ["single photon confocal microscopy", "TEST", 147, 180], ["subfemtoliter", "TREATMENT", 296, 309], ["the non-linear requirements", "PROBLEM", 318, 345], ["the excitation", "TREATMENT", 374, 388], ["spatial confinement", "OBSERVATION", 12, 31], ["photo-activation process", "OBSERVATION", 39, 63]]], ["In this context photoactivation experiments can be used to assess quantitative information about the binding kinetics of a macromolecule expressed in different cellular compartments.", [["cellular compartments", "ANATOMY", 160, 181], ["cellular", "CELL", 160, 168], ["the binding kinetics", "PROBLEM", 97, 117], ["a macromolecule", "PROBLEM", 121, 136], ["cellular compartments", "OBSERVATION", 160, 181]]], ["In this work we extended to photoactivation procedures and models originally developed for the quantitative analysis of FRAP experiments and we evaluated, for different proteins of medical interest (Rac-paGFP), the diffusive behaviour in the cytoplasm and the binding kinetics at the large endosomes.", [["cytoplasm", "ANATOMY", 242, 251], ["endosomes", "ANATOMY", 290, 299], ["Rac-paGFP", "GENE_OR_GENE_PRODUCT", 199, 208], ["cytoplasm", "ORGANISM_SUBSTANCE", 242, 251], ["endosomes", "CELLULAR_COMPONENT", 290, 299], ["Rac", "PROTEIN", 199, 202], ["paGFP", "PROTEIN", 203, 208], ["photoactivation procedures", "TREATMENT", 28, 54], ["FRAP experiments", "TEST", 120, 136], ["the diffusive behaviour in the cytoplasm", "PROBLEM", 211, 251], ["large", "OBSERVATION_MODIFIER", 284, 289], ["endosomes", "OBSERVATION", 290, 299]]], ["The results are compared with standard photobleaching experiments, in order to evidence the gained sensitivity obtained with photo-activatable proteins.O-76Motile plaques involved in stress fiber assembly revealed by high-speed SPM for living cells K. Tamura, T. Mizutani, H. Haga, K. Kawabata Division of Biological Sciences, Graduate School of Science, Hokkaido University, Kita-ku, Sapporo, Japan Stress fibers, which are contractile actin cables aligned in a highly-ordered manner, are important for cell migration, mechanical support of plasma membranes and extracellular matrix organization.", [["stress fiber", "ANATOMY", 183, 195], ["cells", "ANATOMY", 243, 248], ["cell", "ANATOMY", 504, 508], ["plasma membranes", "ANATOMY", 542, 558], ["extracellular matrix", "ANATOMY", 563, 583], ["O-76Motile", "CHEMICAL", 152, 162], ["O-76Motile", "GENE_OR_GENE_PRODUCT", 152, 162], ["stress fiber", "CELLULAR_COMPONENT", 183, 195], ["cells", "CELL", 243, 248], ["actin", "GENE_OR_GENE_PRODUCT", 437, 442], ["cell", "CELL", 504, 508], ["plasma membranes", "CELLULAR_COMPONENT", 542, 558], ["extracellular matrix", "CELLULAR_COMPONENT", 563, 583], ["photo-activatable proteins", "PROTEIN", 125, 151], ["standard photobleaching experiments", "TEST", 30, 65], ["photo-activatable proteins", "TREATMENT", 125, 151], ["plaques", "PROBLEM", 163, 170], ["Japan Stress fibers", "PROBLEM", 394, 413], ["contractile actin cables", "TREATMENT", 425, 449], ["cell migration", "TREATMENT", 504, 518], ["mechanical support of plasma membranes", "TREATMENT", 520, 558], ["extracellular matrix organization", "TREATMENT", 563, 596], ["plaques", "OBSERVATION", 163, 170], ["contractile", "OBSERVATION", 425, 436], ["actin cables", "OBSERVATION", 437, 449], ["extracellular matrix", "OBSERVATION", 563, 583]]], ["Although stress fibers are dynamically disassembled and assembled again in cells, it is poorly understood how actin filaments are organized into cables with highly-ordered alignment for stress fiber assembly.", [["stress fibers", "ANATOMY", 9, 22], ["cells", "ANATOMY", 75, 80], ["filaments", "ANATOMY", 116, 125], ["stress fiber", "ANATOMY", 186, 198], ["stress fibers", "CELLULAR_COMPONENT", 9, 22], ["cells", "CELL", 75, 80], ["actin", "GENE_OR_GENE_PRODUCT", 110, 115], ["filaments", "CELLULAR_COMPONENT", 116, 125], ["stress fiber", "CELLULAR_COMPONENT", 186, 198], ["actin", "PROTEIN", 110, 115], ["stress fibers", "PROBLEM", 9, 22], ["stress fiber", "TREATMENT", 186, 198], ["stress fibers", "OBSERVATION", 9, 22]]], ["For investigation of actin cytoskeletal dynamics during actin cable formation, we performed time-lapse observation of actin cytoskeleton in lamella of living fibroblasts by using scanning probe microscopy (SPM).", [["cytoskeletal", "ANATOMY", 27, 39], ["actin cable", "ANATOMY", 56, 67], ["cytoskeleton", "ANATOMY", 124, 136], ["lamella", "ANATOMY", 140, 147], ["fibroblasts", "ANATOMY", 158, 169], ["actin", "GENE_OR_GENE_PRODUCT", 21, 26], ["actin", "GENE_OR_GENE_PRODUCT", 56, 61], ["actin", "GENE_OR_GENE_PRODUCT", 118, 123], ["cytoskeleton", "CELLULAR_COMPONENT", 124, 136], ["lamella", "CELLULAR_COMPONENT", 140, 147], ["fibroblasts", "CELL", 158, 169], ["actin", "PROTEIN", 21, 26], ["actin", "PROTEIN", 56, 61], ["actin", "PROTEIN", 118, 123], ["living fibroblasts", "CELL_TYPE", 151, 169], ["actin cytoskeletal dynamics", "PROBLEM", 21, 48], ["scanning probe microscopy", "TEST", 179, 204], ["actin cytoskeletal dynamics", "OBSERVATION", 21, 48], ["actin cytoskeleton", "OBSERVATION", 118, 136]]], ["High-speed SPM observation revealed that motile plaques defined front-side ends of new actin cables and that preexisting mesh-form actin networks were remodeled into new actin cables.", [["plaques", "ANATOMY", 48, 55], ["actin", "GENE_OR_GENE_PRODUCT", 87, 92], ["actin", "GENE_OR_GENE_PRODUCT", 131, 136], ["actin", "GENE_OR_GENE_PRODUCT", 170, 175], ["actin", "PROTEIN", 87, 92], ["actin networks", "PROTEIN", 131, 145], ["actin", "PROTEIN", 170, 175], ["High-speed SPM observation", "TEST", 0, 26], ["motile plaques", "PROBLEM", 41, 55], ["new actin cables", "TREATMENT", 83, 99], ["preexisting mesh-form actin networks", "TREATMENT", 109, 145], ["new actin cables", "TREATMENT", 166, 182], ["motile", "OBSERVATION_MODIFIER", 41, 47], ["plaques", "OBSERVATION", 48, 55], ["new", "OBSERVATION_MODIFIER", 83, 86], ["actin cables", "OBSERVATION", 87, 99], ["mesh", "OBSERVATION", 121, 125], ["new", "OBSERVATION_MODIFIER", 166, 169], ["actin cables", "OBSERVATION", 170, 182]]], ["Directional order analysis of movement of plaques and pharmacological experiments clarified that plaques were driven by myosin-II-based retrograde actin flow, indicating that plaques are associated with actin cytoskeleton.", [["plaques", "ANATOMY", 42, 49], ["plaques", "ANATOMY", 97, 104], ["plaques", "ANATOMY", 175, 182], ["cytoskeleton", "ANATOMY", 209, 221], ["plaques", "DISEASE", 97, 104], ["plaques", "PATHOLOGICAL_FORMATION", 97, 104], ["myosin-II", "GENE_OR_GENE_PRODUCT", 120, 129], ["retrograde actin", "GENE_OR_GENE_PRODUCT", 136, 152], ["plaques", "PATHOLOGICAL_FORMATION", 175, 182], ["actin", "GENE_OR_GENE_PRODUCT", 203, 208], ["cytoskeleton", "CELLULAR_COMPONENT", 209, 221], ["myosin-II", "PROTEIN", 120, 129], ["actin", "PROTEIN", 147, 152], ["actin", "PROTEIN", 203, 208], ["plaques", "PROBLEM", 42, 49], ["pharmacological experiments", "TEST", 54, 81], ["plaques", "PROBLEM", 97, 104], ["plaques", "PROBLEM", 175, 182], ["actin cytoskeleton", "PROBLEM", 203, 221], ["plaques", "OBSERVATION", 42, 49], ["plaques", "OBSERVATION", 97, 104], ["actin flow", "OBSERVATION", 147, 157], ["plaques", "OBSERVATION", 175, 182], ["associated with", "UNCERTAINTY", 187, 202], ["actin cytoskeleton", "OBSERVATION", 203, 221]]], ["Immunofluorescence experiments showed that plaques were localized on foci of vinculin, a component of cell-substratum adhesions, suggesting that plaques can bind to extracellular substrata via vinculin.", [["plaques", "ANATOMY", 43, 50], ["foci", "ANATOMY", 69, 73], ["cell-substratum adhesions", "ANATOMY", 102, 127], ["plaques", "ANATOMY", 145, 152], ["extracellular substrata", "ANATOMY", 165, 188], ["vinculin", "GENE_OR_GENE_PRODUCT", 77, 85], ["cell", "CELL", 102, 106], ["substratum adhesions", "CELLULAR_COMPONENT", 107, 127], ["extracellular substrata", "CELLULAR_COMPONENT", 165, 188], ["vinculin", "GENE_OR_GENE_PRODUCT", 193, 201], ["vinculin", "PROTEIN", 77, 85], ["vinculin", "PROTEIN", 193, 201], ["Immunofluorescence experiments", "TEST", 0, 30], ["plaques", "PROBLEM", 43, 50], ["foci of vinculin", "PROBLEM", 69, 85], ["cell-substratum adhesions", "PROBLEM", 102, 127], ["plaques", "PROBLEM", 145, 152], ["extracellular substrata via vinculin", "TREATMENT", 165, 201], ["plaques", "OBSERVATION", 43, 50], ["foci", "OBSERVATION_MODIFIER", 69, 73], ["component", "OBSERVATION_MODIFIER", 89, 98], ["cell", "OBSERVATION", 102, 106], ["substratum adhesions", "OBSERVATION", 107, 127], ["plaques", "OBSERVATION", 145, 152]]], ["Based on these results, we propose a model for actin cable formation that motile plaques initiate remodeling of preexisting actin networks into actin cables aligned in a direction of actin flow by associating with extracellular substrata.", [["plaques", "ANATOMY", 81, 88], ["extracellular substrata", "ANATOMY", 214, 237], ["actin", "GENE_OR_GENE_PRODUCT", 47, 52], ["plaques", "PATHOLOGICAL_FORMATION", 81, 88], ["actin", "GENE_OR_GENE_PRODUCT", 124, 129], ["actin", "GENE_OR_GENE_PRODUCT", 144, 149], ["actin", "GENE_OR_GENE_PRODUCT", 183, 188], ["extracellular substrata", "CELLULAR_COMPONENT", 214, 237], ["actin", "PROTEIN", 47, 52], ["actin networks", "PROTEIN", 124, 138], ["actin", "PROTEIN", 144, 149], ["actin", "PROTEIN", 183, 188], ["a model for actin cable formation", "TREATMENT", 35, 68], ["motile plaques", "PROBLEM", 74, 88], ["actin cables", "TREATMENT", 144, 156], ["extracellular substrata", "TREATMENT", 214, 237], ["motile", "OBSERVATION_MODIFIER", 74, 80], ["plaques", "OBSERVATION", 81, 88], ["actin networks", "OBSERVATION", 124, 138], ["actin cables", "OBSERVATION", 144, 156], ["actin flow", "OBSERVATION", 183, 193]]], ["Abscisic acid (ABA) is a plant hormone regulating fundamental physiological functions in plants, such as response to abiotic stress.", [["Abscisic acid", "CHEMICAL", 0, 13], ["ABA", "CHEMICAL", 15, 18], ["Abscisic acid", "CHEMICAL", 0, 13], ["Abscisic acid", "SIMPLE_CHEMICAL", 0, 13], ["ABA", "SIMPLE_CHEMICAL", 15, 18], ["Abscisic acid (ABA)", "PROBLEM", 0, 19], ["a plant hormone", "TREATMENT", 23, 38], ["abiotic stress", "PROBLEM", 117, 131], ["abiotic stress", "OBSERVATION", 117, 131]]], ["Recently, ABA was shown to be produced and released by human granulocytes, by insulin-producing rat insulinoma cells and by human and murine pancreatic \u03b2 cells.", [["granulocytes", "ANATOMY", 61, 73], ["insulinoma cells", "ANATOMY", 100, 116], ["pancreatic \u03b2 cells", "ANATOMY", 141, 159], ["ABA", "CHEMICAL", 10, 13], ["ABA", "SIMPLE_CHEMICAL", 10, 13], ["human", "ORGANISM", 55, 60], ["granulocytes", "CELL", 61, 73], ["insulin", "GENE_OR_GENE_PRODUCT", 78, 85], ["rat", "ORGANISM", 96, 99], ["insulinoma cells", "CELL", 100, 116], ["human", "ORGANISM", 124, 129], ["murine", "ORGANISM", 134, 140], ["pancreatic \u03b2 cells", "CELL", 141, 159], ["human granulocytes", "CELL_TYPE", 55, 73], ["insulin-producing rat insulinoma cells", "CELL_TYPE", 78, 116], ["human and murine pancreatic \u03b2 cells", "CELL_TYPE", 124, 159], ["human", "SPECIES", 55, 60], ["rat", "SPECIES", 96, 99], ["human", "SPECIES", 124, 129], ["murine", "SPECIES", 134, 140], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 124, 129], ["human granulocytes", "TEST", 55, 73], ["insulin", "TEST", 78, 85], ["insulinoma cells", "OBSERVATION", 100, 116], ["pancreatic", "ANATOMY", 141, 151], ["\u03b2 cells", "OBSERVATION", 152, 159]]], ["ABA autocrinally stimulates the functional activities specific for each cell type through a receptor-operated signal transduction pathway, sequentially involving a pertussis toxin (PTX)-sensitive receptor/G-protein complex, cyclic AMP, CD38-produced cyclic ADP-ribose and intracellular calcium.", [["cell", "ANATOMY", 72, 76], ["intracellular", "ANATOMY", 272, 285], ["ABA", "CHEMICAL", 0, 3], ["PTX", "CHEMICAL", 181, 184], ["AMP", "CHEMICAL", 231, 234], ["cyclic ADP-ribose", "CHEMICAL", 250, 267], ["calcium", "CHEMICAL", 286, 293], ["PTX", "CHEMICAL", 181, 184], ["cyclic AMP", "CHEMICAL", 224, 234], ["ADP", "CHEMICAL", 257, 260], ["ribose", "CHEMICAL", 261, 267], ["calcium", "CHEMICAL", 286, 293], ["ABA", "SIMPLE_CHEMICAL", 0, 3], ["cell type", "CELL", 72, 81], ["pertussis toxin", "SIMPLE_CHEMICAL", 164, 179], ["PTX", "SIMPLE_CHEMICAL", 181, 184], ["G-protein", "GENE_OR_GENE_PRODUCT", 205, 214], ["cyclic AMP", "SIMPLE_CHEMICAL", 224, 234], ["CD38", "GENE_OR_GENE_PRODUCT", 236, 240], ["cyclic ADP-ribose", "SIMPLE_CHEMICAL", 250, 267], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 272, 285], ["calcium", "SIMPLE_CHEMICAL", 286, 293], ["pertussis toxin (PTX)-sensitive receptor", "PROTEIN", 164, 204], ["G-protein complex", "PROTEIN", 205, 222], ["CD38", "PROTEIN", 236, 240], ["a pertussis toxin", "TEST", 162, 179], ["PTX", "TEST", 181, 184], ["cyclic AMP", "TEST", 224, 234], ["CD38", "TEST", 236, 240], ["cyclic ADP", "TEST", 250, 260], ["intracellular calcium", "TREATMENT", 272, 293]]], ["Here, the ABA receptor on human granulocytes and on rat insulinoma cells is identified as the lanthionine synthetase C-like protein LANCL2.", [["granulocytes", "ANATOMY", 32, 44], ["insulinoma cells", "ANATOMY", 56, 72], ["ABA", "CHEMICAL", 10, 13], ["lanthionine", "CHEMICAL", 94, 105], ["ABA receptor", "GENE_OR_GENE_PRODUCT", 10, 22], ["human", "ORGANISM", 26, 31], ["granulocytes", "CELL", 32, 44], ["rat", "ORGANISM", 52, 55], ["insulinoma cells", "CELL", 56, 72], ["LANCL2", "GENE_OR_GENE_PRODUCT", 132, 138], ["ABA receptor", "PROTEIN", 10, 22], ["human granulocytes", "CELL_TYPE", 26, 44], ["rat insulinoma cells", "CELL_TYPE", 52, 72], ["lanthionine synthetase C-like protein", "PROTEIN", 94, 131], ["LANCL2", "PROTEIN", 132, 138], ["human", "SPECIES", 26, 31], ["rat", "SPECIES", 52, 55], ["human", "SPECIES", 26, 31], ["rat", "SPECIES", 52, 55], ["the ABA receptor", "TEST", 6, 22], ["human granulocytes", "TEST", 26, 44], ["rat insulinoma cells", "PROBLEM", 52, 72], ["the lanthionine synthetase C", "TEST", 90, 118], ["protein LANCL2", "TREATMENT", 124, 138], ["insulinoma cells", "OBSERVATION", 56, 72]]], ["Co-expression of LANCL2 and CD38 in the human HeLa cell line reproduces the ABA-signaling pathway.", [["HeLa cell line", "ANATOMY", 46, 60], ["ABA", "CHEMICAL", 76, 79], ["LANCL2", "GENE_OR_GENE_PRODUCT", 17, 23], ["CD38", "GENE_OR_GENE_PRODUCT", 28, 32], ["human", "ORGANISM", 40, 45], ["HeLa cell line", "CELL", 46, 60], ["ABA", "GENE_OR_GENE_PRODUCT", 76, 79], ["LANCL2", "PROTEIN", 17, 23], ["CD38", "PROTEIN", 28, 32], ["human HeLa cell line", "CELL_LINE", 40, 60], ["ABA", "PROTEIN", 76, 79], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["LANCL2", "TEST", 17, 23], ["CD38", "TEST", 28, 32], ["the human HeLa cell line", "TREATMENT", 36, 60], ["the ABA", "TEST", 72, 79], ["CD38", "ANATOMY", 28, 32], ["human", "ANATOMY", 40, 45], ["HeLa cell line", "OBSERVATION", 46, 60]]], ["The PTX-sensitive G protein coupled to LANCL2 is identified as G i by transfection of CD38 + /LANCL2 + HeLa with a chimeric G protein (G\u03b1 q/i ).", [["CD38 + /LANCL2 + HeLa", "ANATOMY", 86, 107], ["PTX", "CHEMICAL", 4, 7], ["PTX", "CHEMICAL", 4, 7], ["PTX", "SIMPLE_CHEMICAL", 4, 7], ["G protein", "GENE_OR_GENE_PRODUCT", 18, 27], ["LANCL2", "GENE_OR_GENE_PRODUCT", 39, 45], ["G i", "GENE_OR_GENE_PRODUCT", 63, 66], ["CD38", "GENE_OR_GENE_PRODUCT", 86, 90], ["LANCL2", "GENE_OR_GENE_PRODUCT", 94, 100], ["chimeric G protein", "GENE_OR_GENE_PRODUCT", 115, 133], ["G protein", "PROTEIN", 18, 27], ["LANCL2", "DNA", 39, 45], ["CD38", "PROTEIN", 86, 90], ["LANCL2", "PROTEIN", 94, 100], ["HeLa", "CELL_LINE", 103, 107], ["chimeric G protein", "PROTEIN", 115, 133], ["G\u03b1 q/i", "PROTEIN", 135, 141], ["The PTX", "TEST", 0, 7], ["sensitive G protein", "PROBLEM", 8, 27], ["LANCL2", "TEST", 39, 45], ["CD38", "TEST", 86, 90], ["LANCL2", "TEST", 94, 100], ["HeLa", "PROBLEM", 103, 107], ["a chimeric G protein", "TEST", 113, 133], ["PTX", "OBSERVATION", 4, 7]]], ["Identification of the mammalian ABA receptor will enable the screening of synthetic ABA antagonists as prospective new anti-inflammatory and anti-diabetic agents.P-74Investigation of post-thaw damage of S.cerevisiae yeasts using fluorescent dyes 2-DAB and 3-DABP-74T.", [["ABA", "CHEMICAL", 84, 87], ["P-74Investigation", "CHEMICAL", 162, 179], ["2-DAB", "CHEMICAL", 246, 251], ["3-DABP-74T", "CHEMICAL", 256, 266], ["2-DAB", "CHEMICAL", 246, 251], ["3-DABP-74T", "CHEMICAL", 256, 266], ["ABA receptor", "GENE_OR_GENE_PRODUCT", 32, 44], ["ABA", "SIMPLE_CHEMICAL", 84, 87], ["2-DAB", "SIMPLE_CHEMICAL", 246, 251], ["3-DABP-74T", "SIMPLE_CHEMICAL", 256, 266], ["mammalian ABA receptor", "PROTEIN", 22, 44], ["P", "DNA", 162, 163], ["the mammalian ABA receptor", "TREATMENT", 18, 44], ["the screening", "TEST", 57, 70], ["synthetic ABA antagonists", "TREATMENT", 74, 99], ["prospective new anti-inflammatory", "TREATMENT", 103, 136], ["anti-diabetic agents", "TREATMENT", 141, 161], ["S.cerevisiae yeasts", "PROBLEM", 203, 222], ["fluorescent dyes", "TEST", 229, 245], ["DABP", "TEST", 258, 262]]], ["S. Dyubko 1 , I. A. Buriak 2 , V. D. Zinchenko 2 , I. F. Kovalenko 2 1 State Scientific Institution \"Institute for Single Crystals\", National Acadey of Sciences of Ukraine, Kharkov, Ukraine, 2 Institute for Problems of Cryobiology and Cryomedicine, National Academy of Sciences of Ukraine, Kharkov, UkraineP-74We investigate applicability of the fluorescent probes 2-DAB and 3-DAB available from SETA BioMedicals (www.setabiomedicals.com) to study the post-thaw damage of Saccharomyces Cerevisiae yeast cells.", [["cells", "ANATOMY", 503, 508], ["2-DAB", "CHEMICAL", 365, 370], ["2-DAB", "CHEMICAL", 365, 370], ["3-DAB", "CHEMICAL", 375, 380], ["2-DAB", "SIMPLE_CHEMICAL", 365, 370], ["3-DAB", "SIMPLE_CHEMICAL", 375, 380], ["Saccharomyces Cerevisiae yeast cells", "CELL", 472, 508], ["Saccharomyces Cerevisiae yeast cells", "CELL_LINE", 472, 508], ["Saccharomyces Cerevisiae", "SPECIES", 472, 496], ["yeast", "SPECIES", 497, 502], ["Saccharomyces Cerevisiae", "SPECIES", 472, 496], ["the fluorescent probes", "TEST", 342, 364], ["Saccharomyces Cerevisiae yeast cells", "TREATMENT", 472, 508], ["yeast cells", "OBSERVATION", 497, 508]]], ["The leaving cells stained with these dyes have bright fluorescence in the yellow and red region, respectively.", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["these dyes", "PROBLEM", 31, 41], ["bright fluorescence in the yellow and red region", "PROBLEM", 47, 95], ["bright fluorescence", "OBSERVATION", 47, 66], ["yellow", "OBSERVATION_MODIFIER", 74, 80], ["region", "ANATOMY_MODIFIER", 89, 95]]], ["However, the freezing followed by post-thawing causes cell damage, which results in a change of fluorescence intensity.", [["cell", "ANATOMY", 54, 58], ["cell", "CELL", 54, 58], ["cell damage", "PROBLEM", 54, 65], ["a change of fluorescence intensity", "PROBLEM", 84, 118], ["cell damage", "OBSERVATION", 54, 65], ["fluorescence intensity", "OBSERVATION", 96, 118]]], ["In the native living cells the dyes are preferably localized in the cell membranes and organelles which are highly fluorescent.", [["cells", "ANATOMY", 21, 26], ["cell membranes", "ANATOMY", 68, 82], ["organelles", "ANATOMY", 87, 97], ["cells", "CELL", 21, 26], ["dyes", "SIMPLE_CHEMICAL", 31, 35], ["cell membranes", "CELLULAR_COMPONENT", 68, 82], ["organelles", "CELLULAR_COMPONENT", 87, 97], ["cell membranes", "OBSERVATION", 68, 82]]], ["Partially damaged cells have even brighter fluorescence as compared to the living cells.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 82, 87], ["cells", "CELL", 18, 23], ["cells", "CELL", 82, 87], ["living cells", "CELL_TYPE", 75, 87], ["Partially damaged cells", "PROBLEM", 0, 23], ["brighter fluorescence", "PROBLEM", 34, 55], ["damaged cells", "OBSERVATION", 10, 23], ["brighter fluorescence", "OBSERVATION", 34, 55]]], ["However, their cell ultra-structure is not well-distinguished in the fluorescence mode.", [["cell", "ANATOMY", 15, 19], ["cell", "CELL", 15, 19], ["cell ultra-structure", "OBSERVATION", 15, 35]]], ["Ultimately destroyed cells are almost non-fluorescent: the cell membranes are not visible in the fluorescent mode and their organelles are only weakly fluorescent.", [["cells", "ANATOMY", 21, 26], ["cell membranes", "ANATOMY", 59, 73], ["organelles", "ANATOMY", 124, 134], ["cells", "CELL", 21, 26], ["cell membranes", "CELLULAR_COMPONENT", 59, 73], ["organelles", "CELLULAR_COMPONENT", 124, 134], ["destroyed cells", "CELL_TYPE", 11, 26], ["the cell membranes", "TEST", 55, 73], ["the fluorescent mode", "TEST", 93, 113], ["destroyed cells", "OBSERVATION", 11, 26], ["cell membranes", "OBSERVATION", 59, 73], ["not visible", "UNCERTAINTY", 78, 89]]], ["The number of intensively fluorescing cells with partially destroyed membranes, which were obtained by freezing to -20 \u2022 C, is lower compared to those frozen at -196 \u2022 C. 2-DAB and 3-DAB enable not only to distinguish damaged and undamaged cells, but also allow quantitative estimation of the extent of damage in membranes by cryogenic effects.P-74The thylakoid membrane is a structured network in higher plants which is organised into stacked granal thylakoids that are interconnected by single 'stromal' lamellae.", [["cells", "ANATOMY", 38, 43], ["membranes", "ANATOMY", 69, 78], ["cells", "ANATOMY", 240, 245], ["membranes", "ANATOMY", 313, 322], ["thylakoid membrane", "ANATOMY", 352, 370], ["thylakoids", "ANATOMY", 451, 461], ["stromal' lamellae", "ANATOMY", 497, 514], ["2-DAB", "CHEMICAL", 171, 176], ["3-DAB", "CHEMICAL", 181, 186], ["P-74", "CHEMICAL", 344, 348], ["2-DAB", "CHEMICAL", 171, 176], ["3-DAB", "CHEMICAL", 181, 186], ["cells", "CELL", 38, 43], ["membranes", "CELLULAR_COMPONENT", 69, 78], ["2-DAB", "SIMPLE_CHEMICAL", 171, 176], ["3-DAB", "SIMPLE_CHEMICAL", 181, 186], ["cells", "CELL", 240, 245], ["membranes", "CELLULAR_COMPONENT", 313, 322], ["thylakoid membrane", "CELLULAR_COMPONENT", 352, 370], ["thylakoids", "GENE_OR_GENE_PRODUCT", 451, 461], ["stromal' lamellae", "CELLULAR_COMPONENT", 497, 514], ["intensively fluorescing cells", "CELL_TYPE", 14, 43], ["damaged and undamaged cells", "CELL_TYPE", 218, 245], ["P-74", "DNA", 344, 348], ["intensively fluorescing cells", "PROBLEM", 14, 43], ["partially destroyed membranes", "PROBLEM", 49, 78], ["damage in membranes", "PROBLEM", 303, 322], ["P", "TEST", 344, 345], ["stacked granal thylakoids", "PROBLEM", 436, 461], ["single 'stromal' lamellae", "TREATMENT", 489, 514], ["fluorescing cells", "OBSERVATION", 26, 43], ["destroyed membranes", "OBSERVATION", 59, 78], ["undamaged cells", "OBSERVATION", 230, 245], ["damage", "OBSERVATION", 303, 309], ["cryogenic effects", "OBSERVATION", 326, 343], ["higher plants", "OBSERVATION", 398, 411], ["granal thylakoids", "OBSERVATION", 444, 461], ["stromal' lamellae", "OBSERVATION", 497, 514]]], ["We have studied the mobility of a resident protein of the stromal lamellae, Hcf106, part of the Tat protein translocase.", [["stromal lamellae", "ANATOMY", 58, 74], ["stromal lamellae", "TISSUE", 58, 74], ["Hcf106", "CELL", 76, 82], ["Tat", "GENE_OR_GENE_PRODUCT", 96, 99], ["resident protein", "PROTEIN", 34, 50], ["Hcf106", "PROTEIN", 76, 82], ["Tat protein translocase", "PROTEIN", 96, 119], ["the Tat protein translocase", "TREATMENT", 92, 119], ["stromal lamellae", "OBSERVATION", 58, 74]]], ["Hcf106-green fluorescent protein fusion (GFP) was targeted into thylakoids and studied using photobleaching approaches.", [["thylakoids", "ANATOMY", 64, 74], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 7, 32], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["Hcf106", "PROTEIN", 0, 6], ["green fluorescent protein fusion", "PROTEIN", 7, 39], ["GFP", "PROTEIN", 41, 44], ["Hcf", "TEST", 0, 3], ["green fluorescent protein fusion", "TREATMENT", 7, 39], ["photobleaching approaches", "TREATMENT", 93, 118], ["protein fusion", "OBSERVATION", 25, 39]]], ["We show that small regions fail to recover significant levels of Hcf106-GFP fluorescence within 3 minutes after photobleaching.", [["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["small regions", "PROBLEM", 13, 26], ["Hcf", "TEST", 65, 68], ["GFP fluorescence", "TEST", 72, 88], ["small", "OBSERVATION_MODIFIER", 13, 18], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["levels", "OBSERVATION_MODIFIER", 55, 61]]], ["Autofluorescence from the photosystem II light-harvesting complex (LHCII) in granal stacks likewise fails to recover over this time scale.", [["photosystem II light-harvesting complex", "GENE_OR_GENE_PRODUCT", 26, 65], ["photosystem II light-harvesting complex", "PROTEIN", 26, 65], ["LHCII", "PROTEIN", 67, 72], ["Autofluorescence", "TEST", 0, 16], ["the photosystem II light-harvesting complex", "TREATMENT", 22, 65]]], ["Although the thylakoid membrane is a single continuous entity, these data show that both Hcf106-GFP and LHCII are constrained within this network.", [["thylakoid membrane", "ANATOMY", 13, 31], ["thylakoid membrane", "CELLULAR_COMPONENT", 13, 31], ["Hcf106", "GENE_OR_GENE_PRODUCT", 89, 95], ["GFP", "GENE_OR_GENE_PRODUCT", 96, 99], ["LHCII", "GENE_OR_GENE_PRODUCT", 104, 109], ["Hcf106", "PROTEIN", 89, 95], ["GFP", "PROTEIN", 96, 99], ["LHCII", "PROTEIN", 104, 109], ["these data", "TEST", 63, 73], ["Hcf", "TEST", 89, 92], ["thylakoid membrane", "OBSERVATION", 13, 31]]], ["Since the Hcf106 homologue, TatB, is highly mobile in the Escherichia coli plasma membrane, we believe that the stromal lamellae take the form of distinct domains that are effectively constrained by boundaries within the thylakoid network.P-80Cytomechanical modifications induced by drugloaded carriers uptake by breast cancer cells The novel opportunities offered by the nanotechnologies have attracted great interest in the development of novel biomaterials for targeted drug delivery in cancer research.", [["plasma membrane", "ANATOMY", 75, 90], ["stromal lamellae", "ANATOMY", 112, 128], ["thylakoid network", "ANATOMY", 221, 238], ["breast cancer cells", "ANATOMY", 313, 332], ["cancer", "ANATOMY", 490, 496], ["breast cancer", "DISEASE", 313, 326], ["cancer", "DISEASE", 490, 496], ["Hcf106", "GENE_OR_GENE_PRODUCT", 10, 16], ["TatB", "GENE_OR_GENE_PRODUCT", 28, 32], ["Escherichia coli", "ORGANISM", 58, 74], ["plasma membrane", "CELLULAR_COMPONENT", 75, 90], ["stromal lamellae", "CELLULAR_COMPONENT", 112, 128], ["thylakoid network", "MULTI-TISSUE_STRUCTURE", 221, 238], ["breast cancer cells", "CELL", 313, 332], ["cancer", "CANCER", 490, 496], ["Hcf106 homologue", "PROTEIN", 10, 26], ["TatB", "PROTEIN", 28, 32], ["P", "DNA", 239, 240], ["breast cancer cells", "CELL_TYPE", 313, 332], ["Escherichia coli", "SPECIES", 58, 74], ["Escherichia coli", "SPECIES", 58, 74], ["the Escherichia coli plasma membrane", "TREATMENT", 54, 90], ["the stromal lamellae", "PROBLEM", 108, 128], ["distinct domains", "PROBLEM", 146, 162], ["drugloaded carriers uptake", "PROBLEM", 283, 309], ["breast cancer cells", "PROBLEM", 313, 332], ["novel biomaterials", "TREATMENT", 441, 459], ["targeted drug delivery", "TREATMENT", 464, 486], ["highly", "OBSERVATION_MODIFIER", 37, 43], ["mobile", "OBSERVATION", 44, 50], ["Escherichia coli", "ANATOMY", 58, 74], ["stromal lamellae", "OBSERVATION", 112, 128], ["thylakoid network", "OBSERVATION", 221, 238], ["breast", "ANATOMY", 313, 319], ["cancer cells", "OBSERVATION", 320, 332], ["cancer", "OBSERVATION", 490, 496]]], ["The desired features of pharmaceutical drug delivery for intravenous administration are their small size, biodegradability, high drug content, prolonged circulation in the blood and the ability to target required areas.", [["intravenous", "ANATOMY", 57, 68], ["blood", "ANATOMY", 172, 177], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 68], ["blood", "ORGANISM_SUBSTANCE", 172, 177], ["pharmaceutical drug delivery", "TREATMENT", 24, 52], ["intravenous administration", "TREATMENT", 57, 83], ["high drug content", "PROBLEM", 124, 141], ["prolonged circulation in the blood", "PROBLEM", 143, 177], ["pharmaceutical drug", "OBSERVATION", 24, 43], ["small", "OBSERVATION_MODIFIER", 94, 99], ["size", "OBSERVATION_MODIFIER", 100, 104], ["high drug content", "OBSERVATION", 124, 141], ["prolonged", "OBSERVATION_MODIFIER", 143, 152], ["circulation", "OBSERVATION_MODIFIER", 153, 164]]], ["In this work we have compared efficacy of different type of carriers having complementary properties for pharmaceutical delivery in cancer therapy.", [["cancer", "ANATOMY", 132, 138], ["cancer", "DISEASE", 132, 138], ["cancer", "CANCER", 132, 138], ["pharmaceutical delivery", "TREATMENT", 105, 128], ["cancer therapy", "TREATMENT", 132, 146], ["cancer", "OBSERVATION", 132, 138]]], ["Drug nano-colloids encapsulated by combination of layer by layer (LbL) techniques and ultrasonication, phytochemical encapsulated artificial oleosomes and drug-loading clay/carbon nanotubes have been used for uptake into breast cancer cells.", [["breast cancer cells", "ANATOMY", 221, 240], ["carbon nanotubes", "CHEMICAL", 173, 189], ["breast cancer", "DISEASE", 221, 234], ["carbon", "CHEMICAL", 173, 179], ["Drug nano-colloids", "SIMPLE_CHEMICAL", 0, 18], ["oleosomes", "SIMPLE_CHEMICAL", 141, 150], ["clay/carbon nanotubes", "SIMPLE_CHEMICAL", 168, 189], ["breast cancer cells", "CELL", 221, 240], ["breast cancer cells", "CELL_TYPE", 221, 240], ["Drug nano-colloids", "TREATMENT", 0, 18], ["layer by layer (LbL) techniques", "TREATMENT", 50, 81], ["ultrasonication", "TREATMENT", 86, 101], ["phytochemical encapsulated artificial oleosomes", "TREATMENT", 103, 150], ["drug-loading clay/carbon nanotubes", "TREATMENT", 155, 189], ["uptake into breast cancer cells", "PROBLEM", 209, 240], ["breast", "ANATOMY", 221, 227], ["cancer cells", "OBSERVATION", 228, 240]]], ["Analysis of viscoelastic response of neoplastic cells induced by cargo-carriers uptake has been carried out by a combination of high resolution optical and scanning force microscopy techniques.", [["neoplastic cells", "ANATOMY", 37, 53], ["neoplastic cells", "CELL", 37, 53], ["neoplastic cells", "CELL_TYPE", 37, 53], ["neoplastic cells", "PROBLEM", 37, 53], ["scanning force microscopy techniques", "TEST", 156, 192], ["viscoelastic response", "OBSERVATION", 12, 33], ["neoplastic cells", "OBSERVATION", 37, 53]]], ["Furthermore, the effects of drug-reservoir carriers on the cytoskeleton (re)organisation of neoplastic cells were further investigated by confocal microscopy using different fluorescent probes.P-79Mapping diffusion by raster image correlation spectroscopy (RICS) with analog detectionP-78Time lapse and flow cytometry data integrated in a common cell cycle proliferation model P. Ubezio, V. Colombo, M. Lupi, F. Falcetta Istituto di Ricerche Farmacologiche \"Mario Negri\", Milano, ItalyP-78We present a cell cycle simulation tool, connecting the basic proliferation process to the cell population data obtained by time lapse and flow cytometry.", [["cytoskeleton", "ANATOMY", 59, 71], ["neoplastic cells", "ANATOMY", 92, 108], ["cell", "ANATOMY", 346, 350], ["cell", "ANATOMY", 502, 506], ["cell", "ANATOMY", 580, 584], ["cytoskeleton", "CELLULAR_COMPONENT", 59, 71], ["neoplastic cells", "CELL", 92, 108], ["cell", "CELL", 346, 350], ["cell", "CELL", 502, 506], ["cell", "CELL", 580, 584], ["neoplastic cells", "CELL_TYPE", 92, 108], ["P", "DNA", 193, 194], ["drug-reservoir carriers", "TREATMENT", 28, 51], ["neoplastic cells", "PROBLEM", 92, 108], ["confocal microscopy", "TEST", 138, 157], ["different fluorescent probes", "TREATMENT", 164, 192], ["P", "TEST", 193, 194], ["raster image correlation spectroscopy", "TEST", 218, 255], ["RICS", "TEST", 257, 261], ["analog detectionP", "TEST", 268, 285], ["flow cytometry data", "TEST", 303, 322], ["a common cell cycle proliferation", "TREATMENT", 337, 370], ["flow cytometry", "TEST", 628, 642], ["neoplastic cells", "OBSERVATION", 92, 108], ["common cell", "ANATOMY", 339, 350], ["flow cytometry", "OBSERVATION", 628, 642]]], ["The computer program is a general framework within which cell cycle progression can be interactively modeled at the desired level of complexity, including G1/S/G2M cell cycle phases with variable duration, G0 phase, cell subpopulations belonging to different generations or differentiation stages, distinct block and cell death parameters for each phase.", [["cell", "ANATOMY", 57, 61], ["cell", "ANATOMY", 164, 168], ["cell", "ANATOMY", 216, 220], ["cell", "ANATOMY", 317, 321], ["death", "DISEASE", 322, 327], ["cell", "CELL", 57, 61], ["cell", "CELL", 216, 220], ["cell", "CELL", 317, 321], ["G1/S/G2M cell cycle phases", "TEST", 155, 181], ["differentiation stages", "PROBLEM", 274, 296], ["distinct block", "PROBLEM", 298, 312], ["cell death parameters", "TEST", 317, 338], ["cell death", "OBSERVATION", 317, 327]]], ["In this way, we achieved a detailed rendering of cell proliferation of normal or tumor cell populations, additionally including cytostatic and cytotoxic effects of treatments.", [["cell", "ANATOMY", 49, 53], ["tumor cell populations", "ANATOMY", 81, 103], ["tumor", "DISEASE", 81, 86], ["cell", "CELL", 49, 53], ["tumor cell populations", "CELL", 81, 103], ["normal or tumor cell populations", "CELL_TYPE", 71, 103], ["cell proliferation", "TEST", 49, 67], ["tumor cell populations", "PROBLEM", 81, 103], ["cytostatic and cytotoxic effects of treatments", "TREATMENT", 128, 174], ["cell proliferation", "OBSERVATION", 49, 67], ["normal", "OBSERVATION", 71, 77], ["tumor cell populations", "OBSERVATION", 81, 103], ["cytostatic", "OBSERVATION_MODIFIER", 128, 138], ["cytotoxic effects", "OBSERVATION", 143, 160]]], ["The program gives as output simulated measures, reproducing those obtained by absolute cell counting, growth inhibition tests, flow cytometric DNA histograms and cell cycle percentages, pulse continuous-labeling studies, time-lapse intermitotic times and generation-wise analyses.", [["cell", "ANATOMY", 87, 91], ["cell", "ANATOMY", 162, 166], ["cell", "CELL", 87, 91], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["cell", "CELL", 162, 166], ["absolute cell counting", "TEST", 78, 100], ["growth inhibition tests", "TEST", 102, 125], ["flow cytometric DNA histograms", "TEST", 127, 157], ["cell cycle percentages", "TEST", 162, 184], ["pulse", "TEST", 186, 191], ["labeling studies", "TEST", 203, 219]]], ["Each technique provides a piece of information related to the underlying proliferation process, catching only some of the phenomena in play, and the measures often cannot be univocally interpreted.", [["the underlying proliferation process", "PROBLEM", 58, 94], ["proliferation", "OBSERVATION", 73, 86]]], ["We used the cell cycle simulator to fit together time lapse and flow cytometry time courses measures, to achieve a detailed reconstruction of the cell cycle proliferation of an ovarian cancer cell line in vitro after X-ray exposure.P-77-Live cell imaging -123Detection of functional modes in protein dynamics J. S. Hub 1 , B. L. de Groot 2 1 Deptartment of Cell & Molecular Biology, Uppsala University, Sweden, 2 Computational biomolecular dynamics group, Max-Planck-Institute for Biophysical Chemistry, G\u00f6ttingen, Germany Proteins frequently accomplish their biological function by collective atomic motions.", [["cell", "ANATOMY", 12, 16], ["cell", "ANATOMY", 146, 150], ["ovarian cancer cell line", "ANATOMY", 177, 201], ["cell", "ANATOMY", 242, 246], ["ovarian cancer", "DISEASE", 177, 191], ["cell", "CELL", 12, 16], ["cell", "CELL", 146, 150], ["ovarian cancer cell line", "CELL", 177, 201], ["Cell", "CELL", 357, 361], ["ovarian cancer cell line", "CELL_LINE", 177, 201], ["the cell cycle simulator", "TREATMENT", 8, 32], ["flow cytometry", "TEST", 64, 78], ["a detailed reconstruction", "TREATMENT", 113, 138], ["the cell cycle proliferation", "TREATMENT", 142, 170], ["an ovarian cancer", "PROBLEM", 174, 191], ["P", "TEST", 232, 233], ["Live cell imaging", "TEST", 237, 254], ["Biophysical Chemistry", "TEST", 481, 502], ["ovarian", "ANATOMY", 177, 184], ["cancer", "OBSERVATION", 185, 191], ["cell line", "OBSERVATION", 192, 201]]], ["Yet the identification of a collective motions related to a specific protein function from, e.g. a molecular dynamics trajectory, is often non-trivial.", [["a collective motions", "PROBLEM", 26, 46], ["a specific protein function", "TEST", 58, 85], ["a molecular dynamics trajectory", "PROBLEM", 97, 128]]], ["Here, we propose a novel technique termedfunctional quantity' that quantifies the functional state of the protein, the method detects the collective motion that is maximally correlated to the functional quantity.", [["a novel technique termedfunctional quantity", "TREATMENT", 17, 60], ["the method", "TEST", 115, 125], ["collective motion", "OBSERVATION", 138, 155]]], ["The functional quantity could, e.g., correspond to a geometric, electrostatic, or chemical observable, or any other variable that is relevant to the function of the protein.", [["a geometric, electrostatic, or chemical observable", "PROBLEM", 51, 101], ["functional", "OBSERVATION_MODIFIER", 4, 14], ["quantity", "OBSERVATION_MODIFIER", 15, 23]]], ["First, the Pearson correlation coefficient that measures linear correlation only; and second, the mutual information that can assess any kind of interdependence.", [["interdependence", "OBSERVATION", 145, 160]]], ["The new method is illustrated using various biomolecules, including a polyalanine-helix, T4 lysozyme, Trp-cage, and Leucine-binding protein.P-84Logic estimation of the optimum source neutron energy for BNCT of brain tumors Boron Neutron Capture Therapy (BNCT) is a promising method for treating the highly fatal brain tumor; glioblastoma multiform.", [["brain tumors", "ANATOMY", 210, 222], ["brain tumor", "ANATOMY", 312, 323], ["glioblastoma", "ANATOMY", 325, 337], ["Leucine", "CHEMICAL", 116, 123], ["brain tumors", "DISEASE", 210, 222], ["Boron Neutron", "CHEMICAL", 223, 236], ["brain tumor", "DISEASE", 312, 323], ["glioblastoma", "DISEASE", 325, 337], ["Trp", "CHEMICAL", 102, 105], ["Leucine", "CHEMICAL", 116, 123], ["Boron", "CHEMICAL", 223, 228], ["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 89, 100], ["Trp", "AMINO_ACID", 102, 105], ["Leucine-binding protein", "GENE_OR_GENE_PRODUCT", 116, 139], ["brain tumors", "CANCER", 210, 222], ["brain tumor", "CANCER", 312, 323], ["glioblastoma multiform", "CANCER", 325, 347], ["polyalanine-helix", "PROTEIN", 70, 87], ["T4 lysozyme", "PROTEIN", 89, 100], ["Trp-cage, and Leucine-binding protein", "PROTEIN", 102, 139], ["P", "DNA", 140, 141], ["various biomolecules", "TREATMENT", 36, 56], ["a polyalanine-helix", "TREATMENT", 68, 87], ["T4 lysozyme", "TREATMENT", 89, 100], ["Trp-cage", "TREATMENT", 102, 110], ["Leucine-binding protein", "TREATMENT", 116, 139], ["neutron energy", "PROBLEM", 183, 197], ["BNCT of brain tumors", "TREATMENT", 202, 222], ["Boron Neutron Capture Therapy", "TREATMENT", 223, 252], ["a promising method", "TREATMENT", 263, 281], ["the highly fatal brain tumor", "PROBLEM", 295, 323], ["glioblastoma multiform", "PROBLEM", 325, 347], ["new", "OBSERVATION_MODIFIER", 4, 7], ["brain", "ANATOMY", 210, 215], ["tumors", "OBSERVATION", 216, 222], ["highly", "OBSERVATION_MODIFIER", 299, 305], ["fatal", "OBSERVATION_MODIFIER", 306, 311], ["brain", "ANATOMY", 312, 317], ["tumor", "OBSERVATION", 318, 323], ["glioblastoma", "OBSERVATION", 325, 337]]], ["It is a binary modality; in which use is made of two components simultaneously; viz. thermal neutrons and Boron-10.", [["Boron-10", "CHEMICAL", 106, 114], ["Boron-10", "CHEMICAL", 106, 114], ["thermal neutrons", "TREATMENT", 85, 101], ["Boron", "TREATMENT", 106, 111]]], ["A new concept was adopted for estimating the optimum source neutrons energy appropriate for different circumstances of BNCT.", [["BNCT", "CANCER", 119, 123], ["BNCT", "PROBLEM", 119, 123]]], ["An energy escalation study was carried out investigating 65 different source neutron energies, between 0.01 eV and 13.2 MeV.", [["An energy escalation study", "TEST", 0, 26]]], ["MCNP4B Monte Carlo neutron transport code was utilized to study the behavior of these neutrons in the brain.", [["brain", "ANATOMY", 102, 107], ["brain", "ORGAN", 102, 107], ["brain", "ANATOMY", 102, 107]]], ["The deduced four conditions were applied to the results.", [["The deduced four conditions", "PROBLEM", 0, 27]]], ["A source neutron energy range of few electron volts (eV) to about 30 keV was estimated to be optimum for BNCT of brain tumors located at different depths in brain.", [["brain tumors", "ANATOMY", 113, 125], ["brain", "ANATOMY", 157, 162], ["tumors", "DISEASE", 119, 125], ["brain tumors", "CANCER", 113, 125], ["brain", "ORGAN", 157, 162], ["A source neutron energy", "PROBLEM", 0, 23], ["brain tumors", "PROBLEM", 113, 125], ["brain", "ANATOMY", 113, 118], ["tumors", "OBSERVATION", 119, 125], ["different", "OBSERVATION_MODIFIER", 137, 146], ["depths", "OBSERVATION_MODIFIER", 147, 153], ["brain", "ANATOMY", 157, 162]]], ["The results were discussed.Molecular dynamics simulation of CB1 and CB2 cannabinoid receptors in solutionV.", [["CB1", "GENE_OR_GENE_PRODUCT", 60, 63], ["CB2 cannabinoid receptors", "GENE_OR_GENE_PRODUCT", 68, 93], ["CB1 and CB2 cannabinoid receptors", "PROTEIN", 60, 93], ["CB1", "TEST", 60, 63]]], ["CSIC Cannabinoid receptors are an important class of G protein coupled receptors.", [["Cannabinoid", "CHEMICAL", 5, 16], ["Cannabinoid receptors", "GENE_OR_GENE_PRODUCT", 5, 26], ["G protein coupled receptors", "GENE_OR_GENE_PRODUCT", 53, 80], ["CSIC", "PROTEIN", 0, 4], ["Cannabinoid receptors", "PROTEIN", 5, 26], ["G protein coupled receptors", "PROTEIN", 53, 80], ["CSIC Cannabinoid receptors", "TREATMENT", 0, 26], ["G protein coupled receptors", "TREATMENT", 53, 80]]], ["In particular CB1 and CB2 have received considerable interest because they mediate a variety of physiological responses in the Central Nervous and Immune Systems.", [["CB2", "CHEMICAL", 22, 25], ["CB1", "GENE_OR_GENE_PRODUCT", 14, 17], ["CB2", "GENE_OR_GENE_PRODUCT", 22, 25], ["Nervous", "ANATOMICAL_SYSTEM", 135, 142], ["CB1", "PROTEIN", 14, 17], ["CB2", "PROTEIN", 22, 25], ["CB2", "TEST", 22, 25], ["Central", "ANATOMY_MODIFIER", 127, 134], ["Nervous", "ANATOMY", 135, 142]]], ["Experimental information suggests the presence of both, an active and an inactive conformation.", [["active", "OBSERVATION", 59, 65], ["inactive", "OBSERVATION", 73, 81]]], ["CB1 and CB2 share a common structural framework consisting in a seven transmembrane \u03b1-helix bundle connected by three extracellular and three intracellular loops.", [["transmembrane", "ANATOMY", 70, 83], ["extracellular", "ANATOMY", 118, 131], ["intracellular", "ANATOMY", 142, 155], ["CB1", "GENE_OR_GENE_PRODUCT", 0, 3], ["CB2", "GENE_OR_GENE_PRODUCT", 8, 11], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["intracellular loops", "CELLULAR_COMPONENT", 142, 161], ["CB1", "PROTEIN", 0, 3], ["CB2", "PROTEIN", 8, 11], ["transmembrane \u03b1-helix bundle", "PROTEIN", 70, 98], ["extracellular and three intracellular loops", "PROTEIN", 118, 161], ["CB1", "TEST", 0, 3], ["CB2", "TEST", 8, 11], ["a seven transmembrane \u03b1-helix bundle", "TREATMENT", 62, 98], ["three", "OBSERVATION_MODIFIER", 112, 117], ["extracellular", "OBSERVATION_MODIFIER", 118, 131], ["intracellular loops", "OBSERVATION", 142, 161]]], ["However, the knowledge of structural differences between both receptors may serve to design new ligands to activate/deactivate selectively only one of those receptors.", [["structural differences", "PROBLEM", 26, 48]]], ["In the present research, we report a multi-nanosecond Molecular Dynamics simulation of both receptors in solution, starting from a structure obtained by homology modelling using the X-ray determined bovine rhodopsin protein.Molecular dynamics simulation of CB1 and CB2 cannabinoid receptors in solutionWe look for differences in the behaviour of CB1 and CB2 during the simulation process to shed light about those structural features which can be important for ligand selectivity.", [["CB2", "CHEMICAL", 354, 357], ["bovine", "ORGANISM", 199, 205], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 206, 215], ["CB1", "GENE_OR_GENE_PRODUCT", 257, 260], ["CB2 cannabinoid receptors", "GENE_OR_GENE_PRODUCT", 265, 290], ["CB1", "SIMPLE_CHEMICAL", 346, 349], ["CB2", "GENE_OR_GENE_PRODUCT", 354, 357], ["X-ray determined bovine rhodopsin protein", "PROTEIN", 182, 223], ["CB1 and CB2 cannabinoid receptors", "PROTEIN", 257, 290], ["bovine", "SPECIES", 199, 205], ["the X-ray", "TEST", 178, 187], ["bovine rhodopsin protein", "TREATMENT", 199, 223], ["CB1", "TEST", 257, 260], ["the simulation process", "TREATMENT", 365, 387]]], ["In this sense, we observed that CB1 tend to present a more flexible and opened helix bundle than CB2.", [["CB1", "GENE_OR_GENE_PRODUCT", 32, 35], ["CB2", "GENE_OR_GENE_PRODUCT", 97, 100], ["CB1", "PROTEIN", 32, 35], ["CB2", "PROTEIN", 97, 100], ["CB1", "TEST", 32, 35], ["CB2", "TEST", 97, 100]]], ["We expect these results will be useful to design more selective ligands.P-82Self-assembly and equilibration of bola-lipids membranes studied by molecular dynamics M. Bulacu, S. J. Marrink Groningen University, The Netherlands Bola-lipids consist of two monopolar, twin-tailed lipids that are held together by chemical linkage between one or both ends of the tails from one lipid and the corresponding ends from the other one.", [["bola-lipids membranes", "ANATOMY", 111, 132], ["P-82Self", "CHEMICAL", 72, 80], ["P", "DNA", 72, 73], ["P", "TEST", 72, 73], ["equilibration of bola-lipids membranes", "TREATMENT", 94, 132], ["The Netherlands Bola-lipids", "TREATMENT", 210, 237], ["two monopolar, twin-tailed lipids", "TREATMENT", 249, 282], ["tails", "ANATOMY_MODIFIER", 358, 363]]], ["Membranes formed by these lipids or by their mixtures with monopolar lipids are known to have additional mechanical stability while retaining membrane fluidity.", [["Membranes", "ANATOMY", 0, 9], ["membrane", "ANATOMY", 142, 150], ["lipids", "SIMPLE_CHEMICAL", 26, 32], ["monopolar lipids", "SIMPLE_CHEMICAL", 59, 75], ["membrane", "CELLULAR_COMPONENT", 142, 150], ["these lipids", "TREATMENT", 20, 32], ["monopolar lipids", "TREATMENT", 59, 75], ["mechanical stability", "OBSERVATION", 105, 125], ["membrane fluidity", "OBSERVATION", 142, 159]]], ["This is traditionally attributed to the fact that, in the membrane phase, the bola-lipids have predominantly spanning configuration (the two polar heads are positioned at opposite membrane-water interfaces) in detriment to looping configuration (both head groups are located in the same membrane-water interface).", [["membrane", "ANATOMY", 58, 66], ["membrane", "ANATOMY", 180, 188], ["head", "ANATOMY", 251, 255], ["membrane", "ANATOMY", 287, 295], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["membrane", "CELLULAR_COMPONENT", 287, 295], ["predominantly", "OBSERVATION_MODIFIER", 95, 108], ["spanning", "OBSERVATION_MODIFIER", 109, 117], ["configuration", "OBSERVATION_MODIFIER", 118, 131], ["polar", "OBSERVATION_MODIFIER", 141, 146], ["water interfaces", "OBSERVATION", 189, 205], ["looping configuration", "OBSERVATION", 223, 244]]], ["We start with self-assembly simulations of bola-lipids followed by bilayer equilibration.", [["bola-lipids", "CHEMICAL", 43, 54], ["bola-lipids", "SIMPLE_CHEMICAL", 43, 54], ["self-assembly simulations of bola-lipids", "TREATMENT", 14, 54]]], ["An artificial pore is created in the membrane that significantly increases the flip-flop mobility of the lipids and hasten equilibration.", [["pore", "ANATOMY", 14, 18], ["membrane", "ANATOMY", 37, 45], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["lipids", "SIMPLE_CHEMICAL", 105, 111], ["An artificial pore", "TREATMENT", 0, 18], ["the lipids", "TREATMENT", 101, 111], ["artificial pore", "OBSERVATION", 3, 18], ["membrane", "ANATOMY_MODIFIER", 37, 45], ["significantly", "OBSERVATION_MODIFIER", 51, 64], ["increases", "OBSERVATION_MODIFIER", 65, 74], ["flip", "OBSERVATION_MODIFIER", 79, 83]]], ["The membrane properties are characterized (area per lipid, thickness, order parameter, pressure profile) with emphasis on the spanning/looping ratio.", [["membrane", "ANATOMY", 4, 12], ["pressure profile", "TEST", 87, 103], ["the spanning/looping ratio", "TEST", 122, 148], ["membrane properties", "OBSERVATION", 4, 23]]], ["Our study can help designing new artificial membranes, with higher stability under extreme conditions.P-81-Multiscale simulation -AbstractsEvidence for proton shuffling in a thioredoxinlike protein during catalysis D. Narzi 1 , S. W. Siu 1 , C. U. Stirnimann 3 , J. P. Grimshaw 2 , R. Glockshuber 2 , G. Capitani 4 , R. A. B\u00f6ckmann 1 1 Theoretical and Computational Membrane Biology, Center for Bioinformatics, Saarland University, Germany, 2 Institute of Molecular Biology and Biophysics, ETH Z\u00fcrich, Switzerland, 3 Structural and Computational Unit, EMBL, Heidelberg, Germany, 4 Paul Scherrer Institute, Villigen PSI, Switzerland Proteins of the thioredoxin (Trx) superfamily catalyze disulfide-bond formation, reduction and isomerization in substrate proteins both in prokaryotic and in eukaryotic cells.", [["membranes", "ANATOMY", 44, 53], ["cells", "ANATOMY", 801, 806], ["disulfide", "CHEMICAL", 687, 696], ["membranes", "CELLULAR_COMPONENT", 44, 53], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 648, 659], ["Trx", "GENE_OR_GENE_PRODUCT", 661, 664], ["cells", "CELL", 801, 806], ["thioredoxinlike protein", "PROTEIN", 174, 197], ["thioredoxin (Trx) superfamily", "PROTEIN", 648, 677], ["substrate proteins", "PROTEIN", 744, 762], ["prokaryotic and in eukaryotic cells", "CELL_TYPE", 771, 806], ["Our study", "TEST", 0, 9], ["new artificial membranes", "TREATMENT", 29, 53], ["P", "TEST", 102, 103], ["proton shuffling", "PROBLEM", 152, 168], ["Villigen PSI", "TREATMENT", 606, 618], ["the thioredoxin (Trx) superfamily catalyze disulfide-bond formation", "TREATMENT", 644, 711], ["reduction and isomerization in substrate proteins", "TREATMENT", 713, 762], ["artificial membranes", "OBSERVATION", 33, 53], ["higher stability", "OBSERVATION_MODIFIER", 60, 76], ["eukaryotic cells", "OBSERVATION", 790, 806]]], ["All members of the Trx family with thioldisulfide oxidoreductase activity contain the characteristic Cys-X-X-Cys motif in their active site.", [["thioldisulfide", "CHEMICAL", 35, 49], ["thioldisulfide", "CHEMICAL", 35, 49], ["Cys", "CHEMICAL", 101, 104], ["Cys", "CHEMICAL", 109, 112], ["Trx", "GENE_OR_GENE_PRODUCT", 19, 22], ["thioldisulfide oxidoreductase", "GENE_OR_GENE_PRODUCT", 35, 64], ["Trx family", "PROTEIN", 19, 29], ["thioldisulfide oxidoreductase", "PROTEIN", 35, 64], ["Cys-X-X-Cys motif", "PROTEIN", 101, 118], ["thioldisulfide oxidoreductase activity", "TREATMENT", 35, 73], ["Cys motif", "TREATMENT", 109, 118]]], ["Here, using Poisson-Boltzmann-based protonation-state calculations based on 100-ns Molecular Dynamics simulations, we investigated the catalytic mechanism of DsbL, the most oxidizing protein known to date.", [["DsbL", "CHEMICAL", 158, 162], ["DsbL", "SIMPLE_CHEMICAL", 158, 162], ["DsbL", "PROTEIN", 158, 162], ["Boltzmann", "TREATMENT", 20, 29], ["DsbL", "TREATMENT", 158, 162]]], ["We observed several correlated transitions in the protonation states of the buried active-site cysteine and a neighboring lysine coupled to the exposure of the active-site thiolate.", [["lysine", "CHEMICAL", 122, 128], ["cysteine", "CHEMICAL", 95, 103], ["lysine", "CHEMICAL", 122, 128], ["thiolate", "CHEMICAL", 172, 180], ["cysteine", "AMINO_ACID", 95, 103], ["lysine", "AMINO_ACID", 122, 128], ["the buried active-site cysteine", "PROBLEM", 72, 103], ["a neighboring lysine", "TREATMENT", 108, 128], ["several", "OBSERVATION_MODIFIER", 12, 19], ["correlated", "OBSERVATION_MODIFIER", 20, 30], ["transitions", "OBSERVATION_MODIFIER", 31, 42], ["active", "OBSERVATION_MODIFIER", 160, 166]]], ["These results support the view of an internal proton shuffling mechanism during oxidation crucial for the uptake of two electrons from the substrate protein.", [["substrate protein", "PROTEIN", 139, 156], ["an internal proton shuffling mechanism", "TREATMENT", 34, 72], ["the substrate protein", "TEST", 135, 156]]], ["Intramolecular disulfide-bond formation is probably steered by the conformational switch facilitating interaction with the active-site thiolate.", [["disulfide", "CHEMICAL", 15, 24], ["thiolate", "CHEMICAL", 135, 143], ["Intramolecular disulfide-bond formation", "PROBLEM", 0, 39], ["disulfide", "OBSERVATION", 15, 24], ["bond formation", "OBSERVATION", 25, 39]]], ["A consistent catalytic mechanism for DsbL, probably conferrable to other proteins of the same class, is presented.", [["DsbL", "CHEMICAL", 37, 41], ["DsbL", "SIMPLE_CHEMICAL", 37, 41], ["DsbL", "PROTEIN", 37, 41], ["DsbL", "PROBLEM", 37, 41], ["catalytic mechanism", "OBSERVATION", 13, 32]]], ["Our results suggest a functional role of hydration entropy of active-site groups .P-88The role of water in Zn(II)-Abeta(1-16) complexes Beta-amyloid (A\u03b2) peptides are the main component of amyloid fibrils detected in the brain of Alzheimer patients.", [["brain", "ANATOMY", 221, 226], ["P-88The", "CHEMICAL", 82, 89], ["Zn", "CHEMICAL", 107, 109], ["1-16)", "CHEMICAL", 120, 125], ["Alzheimer", "DISEASE", 230, 239], ["Zn(II)", "CHEMICAL", 107, 113], ["water", "SIMPLE_CHEMICAL", 98, 103], ["Zn(II)-Abeta(1-16) complexes", "SIMPLE_CHEMICAL", 107, 135], ["Beta-amyloid (A\u03b2) peptides", "SIMPLE_CHEMICAL", 136, 162], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 189, 204], ["brain", "ORGAN", 221, 226], ["patients", "ORGANISM", 240, 248], ["Zn(II)-Abeta(1-16) complexes", "PROTEIN", 107, 135], ["amyloid fibrils", "PROTEIN", 189, 204], ["patients", "SPECIES", 240, 248], ["hydration entropy", "TREATMENT", 41, 58], ["Abeta(1-16) complexes Beta-amyloid (A\u03b2) peptides", "TREATMENT", 114, 162], ["amyloid fibrils", "PROBLEM", 189, 204], ["active", "OBSERVATION_MODIFIER", 62, 68], ["main", "OBSERVATION_MODIFIER", 171, 175], ["amyloid fibrils", "OBSERVATION", 189, 204], ["brain", "ANATOMY", 221, 226]]], ["Fibrils display an abnormal content of Cu and Zn ions whose binding to A\u03b2-peptides has been recently studied by X-ray Absorption Spectroscopy [1] and interpreted in terms of ab initio simulations.", [["Cu", "CHEMICAL", 39, 41], ["Zn", "CHEMICAL", 46, 48], ["Cu", "CHEMICAL", 39, 41], ["Zn", "CHEMICAL", 46, 48], ["Cu", "SIMPLE_CHEMICAL", 39, 41], ["Zn ions", "SIMPLE_CHEMICAL", 46, 53], ["A\u03b2-peptides", "GENE_OR_GENE_PRODUCT", 71, 82], ["A\u03b2", "PROTEIN", 71, 73], ["an abnormal content", "PROBLEM", 16, 35], ["Cu and Zn ions", "TREATMENT", 39, 53], ["Absorption Spectroscopy", "TEST", 118, 141], ["ab initio simulations", "TEST", 174, 195], ["abnormal content", "OBSERVATION", 19, 35]]], ["In order to perform such simulations it is of the utmost importance to find a compromise between the need of having a realistic description of the actual physical system and the difficulty of dealing with too many atoms and electrons.", [["such simulations", "TREATMENT", 20, 36]]], ["In this work we investigate the relevance of water in the Zn-A\u03b2 1\u221216 coordination mode.", [["Zn", "CHEMICAL", 58, 60], ["A\u03b2", "CHEMICAL", 61, 63], ["Zn", "CHEMICAL", 58, 60], ["A\u03b2", "CHEMICAL", 61, 63], ["water", "SIMPLE_CHEMICAL", 45, 50], ["Zn-A\u03b2", "SIMPLE_CHEMICAL", 58, 63]]], ["Relying on a combination of Classical [2] and Quantum Chemistry [3] methods we find a significant difference in the Zn coordination geometry depending on whether water is present or not.", [["Zn", "CHEMICAL", 116, 118], ["Zn", "CHEMICAL", 116, 118], ["Zn", "SIMPLE_CHEMICAL", 116, 118], ["water", "SIMPLE_CHEMICAL", 162, 167], ["Quantum Chemistry", "TEST", 46, 63], ["methods", "TREATMENT", 68, 75], ["the Zn coordination geometry", "TREATMENT", 112, 140]]], ["This information is exploited in building a full model system for subsequent Car-Parrinello simulations where two A\u03b2 peptides in water are in interaction in the presence of Zn.", [["Zn.", "CHEMICAL", 173, 176], ["Zn.", "CHEMICAL", 173, 176], ["A\u03b2 peptides", "GENE_OR_GENE_PRODUCT", 114, 125], ["water", "SIMPLE_CHEMICAL", 129, 134], ["Zn.", "SIMPLE_CHEMICAL", 173, 176], ["subsequent Car-Parrinello simulations", "TREATMENT", 66, 103], ["Zn.", "OBSERVATION", 173, 176]]], ["[ Although experiments which can directly probe the mechanical properties of proteins have only been performed recently, it is clear that the complex folds of polypeptide backbones lead to very heterogeneous mechanical behavior.", [["polypeptide backbones", "TREATMENT", 159, 180], ["very heterogeneous mechanical behavior", "PROBLEM", 189, 227], ["very", "OBSERVATION_MODIFIER", 189, 193], ["heterogeneous", "OBSERVATION_MODIFIER", 194, 207], ["mechanical behavior", "OBSERVATION", 208, 227]]], ["This heterogeneity is likely to play an important role in protein function and interaction and it would be useful to be able to predict what mechanical (and dynamical) properties will result from a given structure.", [["is likely to", "UNCERTAINTY", 19, 31]]], ["We have been using coarse-grain elastic network models to investigate this question and have found that these models are able to link specific mechanical properties to a number of functional features including enzymatic active sites, folding nuclei and changes in behavior due to point mutations.", [["nuclei", "ANATOMY", 242, 248], ["elastic network", "MULTI-TISSUE_STRUCTURE", 32, 47], ["nuclei", "CELLULAR_COMPONENT", 242, 248], ["enzymatic active sites", "PROTEIN", 210, 232], ["functional features", "PROBLEM", 180, 199], ["enzymatic active sites", "PROBLEM", 210, 232], ["folding nuclei", "PROBLEM", 234, 248], ["changes in behavior", "PROBLEM", 253, 272], ["point mutations", "PROBLEM", 280, 295], ["active sites", "OBSERVATION", 220, 232]]], ["These models are also adapted to looking at complex formation between proteins and how specific recognition is achieved, while being fast enough to be applied to very large numbers of interactions.O-86Refinement of protein model structures using biasing potential replica exchange simulations S. Kannan, M. Zacharias School of Engineering and Science, Jacobs University Bremen, D-28759 Bremen, GermanyO-86Comparative protein modeling of a target protein based on sequence similarity to a protein with known structure is widely used to provide structural models of proteins.", [["target protein", "PROTEIN", 439, 453], ["protein model structures", "TREATMENT", 215, 239], ["GermanyO", "TEST", 394, 402], ["a target protein", "TEST", 437, 453], ["known structure", "PROBLEM", 501, 516], ["large", "OBSERVATION_MODIFIER", 167, 172], ["numbers", "OBSERVATION", 173, 180]]], ["Frequently, the quality of the target-template sequence alignment is non-uniform along the sequence: parts can be modeled with a high confidence, whereas other parts differ strongly from the template.", [["a high confidence", "PROBLEM", 127, 144]]], ["We have used a recently developed biasing potential replica exchange (BP-Rex) MD method (Kannan, S. Zacharias, M. Proteins 2007, 66, 697-70) to refine homology modeled protein structure at atomic resolution including explicit solvent.", [["explicit solvent", "TREATMENT", 217, 233]]], ["In standard Rex-MD simulations several replicas of a system are run in parallel at different temperatures allowing exchanges at preset time intervals.", [["Rex", "PROTEIN", 12, 15]]], ["In a BP-RexMD simulation replicas are controlled by various levels of a biasing potential to reduce the energy barriers associated with peptide backbone dihedral transitions.", [["a BP", "TEST", 3, 7], ["the energy barriers", "TREATMENT", 100, 119], ["peptide backbone dihedral transitions", "TREATMENT", 136, 173]]], ["The method requires much fewer replicas for efficient sampling compared with standard temperature RexMD.", [["standard temperature RexMD", "TREATMENT", 77, 103]]], ["BP-RexMD simulations on several test cases starting from decoy structures deviating significantly from the native structure resulted in final structures in much closer agreement with experiment compared to conventional MD simulations.Multiscale simulations of membrane proteinsM.", [["membrane", "ANATOMY", 260, 268], ["membrane", "CELLULAR_COMPONENT", 260, 268], ["BP", "PROTEIN", 0, 2], ["membrane proteinsM", "PROTEIN", 260, 278], ["BP", "TEST", 0, 2], ["several test cases", "TEST", 24, 42], ["decoy structures", "PROBLEM", 57, 73], ["membrane proteinsM", "PROBLEM", 260, 278], ["membrane proteinsM", "OBSERVATION", 260, 278]]], ["S. P. Sansom, P. J. Stansfeld, C. L. Wee, K. Balali-Mood Department of Biochemistry, University of Oxford, U.K.Multiscale simulations of membrane proteinsCoarse-grained molecular dynamics simulations may be used to probe the interactions of membrane proteins with bilayers and their component lipids on an extended (\u223c1 \u00b5s) timescale (1 ) .", [["membrane", "ANATOMY", 137, 145], ["membrane", "ANATOMY", 241, 249], ["membrane", "CELLULAR_COMPONENT", 137, 145], ["membrane", "CELLULAR_COMPONENT", 241, 249], ["membrane proteins", "PROTEIN", 137, 154], ["membrane proteins", "PROTEIN", 241, 258], ["C. L. Wee", "SPECIES", 31, 40], ["membrane proteinsCoarse", "PROBLEM", 137, 160], ["grained molecular dynamics simulations", "PROBLEM", 161, 199], ["membrane proteins", "TREATMENT", 241, 258], ["their component lipids", "TREATMENT", 277, 299]]], ["Conversion to atomistic resolution allows more detailed protein/lipid interactions to be examined.", [["lipid", "SIMPLE_CHEMICAL", 64, 69], ["detailed protein/lipid interactions", "TREATMENT", 47, 82]]], ["This multiscale approach will be examined via three examples: (i) interactions of a small ion channel toxin (VsTx1) We present a new competitive approach for the treatment of biomolecular flexibility to provide an alternative to the limitations of current methodologies such as molecular dynamics and normal mode analysis.", [["small ion channel toxin", "PROTEIN", 84, 107], ["VsTx1", "PROTEIN", 109, 114], ["a small ion channel toxin", "TREATMENT", 82, 107], ["the treatment of biomolecular flexibility", "TREATMENT", 158, 199], ["current methodologies", "TREATMENT", 248, 269]]], ["The algorithm allows obtaining a set of deformations, each one corresponding to a specific interaction on a specific molecular site, in terms of force constants contained in the energy model.", [["deformations", "DISEASE", 40, 52]]], ["Such a process can be used to explore the properties of single molecular intrinsic flexibility, as well as to predict molecular docking or molecule/surface interactions.", [["surface", "ANATOMY", 148, 155], ["single molecular intrinsic flexibility", "PROBLEM", 56, 94], ["intrinsic flexibility", "OBSERVATION", 73, 94]]], ["From a modelling point of view, the interaction problem can be expressed in terms of reactive sites between the interacting entities, the molecular deformations being extracted from the pre-calculated Static Modes of each separated ones.", [["the interaction problem", "PROBLEM", 32, 55], ["the molecular deformations", "PROBLEM", 134, 160], ["reactive", "OBSERVATION_MODIFIER", 85, 93], ["interacting entities", "OBSERVATION", 112, 132], ["molecular deformations", "OBSERVATION", 138, 160]]], ["The first applications of our method have focused on the intrinsic flexibility of biomolecules like nucleic acids and proteins.", [["nucleic acids", "CHEMICAL", 100, 113], ["nucleic acids", "SIMPLE_CHEMICAL", 100, 113], ["our method", "TREATMENT", 26, 36], ["nucleic acids", "TEST", 100, 113], ["nucleic acids", "OBSERVATION", 100, 113]]], ["More recently, this new methodology allowed us to investigate the folding of the region 1-16 of the Amyloid \u03b2-peptide, via the docking of a zinc ion on the reactive sites of the molecule.P-91Conformational study on a Myelin Basic Protein fragment: molecular dynamics simulations in membrane E. Polverini 1 , G. Harauz 2 1 Dipartimento di Fisica, Universit\u00e0 di Parma, Parma, Italy, 2 Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada Myelin basic protein (MBP) is a multifunctional protein of the central nervous system whose principal role is in maintaining the compactness and integrity of the myelin sheath, the multilamellar membrane wrapped around nerve axons.", [["membrane", "ANATOMY", 282, 290], ["central nervous system", "ANATOMY", 538, 560], ["myelin sheath", "ANATOMY", 637, 650], ["multilamellar membrane", "ANATOMY", 656, 678], ["nerve axons", "ANATOMY", 694, 705], ["zinc", "CHEMICAL", 140, 144], ["zinc", "CHEMICAL", 140, 144], ["Amyloid \u03b2-peptide", "GENE_OR_GENE_PRODUCT", 100, 117], ["zinc", "SIMPLE_CHEMICAL", 140, 144], ["Myelin basic protein (MBP)", "GENE_OR_GENE_PRODUCT", 475, 501], ["central nervous system", "ANATOMICAL_SYSTEM", 538, 560], ["myelin sheath", "CELLULAR_COMPONENT", 637, 650], ["multilamellar membrane", "CELLULAR_COMPONENT", 656, 678], ["nerve axons", "CELLULAR_COMPONENT", 694, 705], ["P", "DNA", 187, 188], ["Myelin Basic Protein fragment", "PROTEIN", 217, 246], ["Myelin basic protein", "PROTEIN", 475, 495], ["MBP", "PROTEIN", 497, 500], ["multifunctional protein", "PROTEIN", 507, 530], ["the Amyloid \u03b2-peptide", "TREATMENT", 96, 117], ["a zinc ion", "TREATMENT", 138, 148], ["a Myelin Basic Protein fragment", "PROBLEM", 215, 246], ["Guelph", "TEST", 443, 449], ["Guelph", "TEST", 451, 457], ["MBP", "TEST", 497, 500], ["the myelin sheath", "TREATMENT", 633, 650], ["the multilamellar membrane", "TREATMENT", 652, 678], ["reactive sites", "OBSERVATION", 156, 170], ["molecule", "ANATOMY", 178, 186], ["central", "ANATOMY_MODIFIER", 538, 545], ["nervous system", "ANATOMY", 546, 560], ["myelin sheath", "OBSERVATION", 637, 650], ["multilamellar membrane", "OBSERVATION", 656, 678], ["nerve", "ANATOMY", 694, 699], ["axons", "ANATOMY_MODIFIER", 700, 705]]], ["However, MBP also interacts with other proteins such as cytoskeletal and signalling proteins, adapting its structure to the different roles.", [["cytoskeletal", "ANATOMY", 56, 68], ["MBP", "GENE_OR_GENE_PRODUCT", 9, 12], ["cytoskeletal", "CELLULAR_COMPONENT", 56, 68], ["MBP", "PROTEIN", 9, 12], ["cytoskeletal and signalling proteins", "PROTEIN", 56, 92], ["MBP", "TEST", 9, 12], ["other proteins", "PROBLEM", 33, 47], ["cytoskeletal and signalling proteins", "PROBLEM", 56, 92]]], ["MBP is a candidate autoantigen in the human demyelinating disease multiple sclerosis.", [["demyelinating disease multiple sclerosis", "DISEASE", 44, 84], ["MBP", "GENE_OR_GENE_PRODUCT", 0, 3], ["human", "ORGANISM", 38, 43], ["MBP", "PROTEIN", 0, 3], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["MBP", "TEST", 0, 3], ["the human demyelinating disease multiple sclerosis", "PROBLEM", 34, 84], ["demyelinating", "OBSERVATION_MODIFIER", 44, 57], ["sclerosis", "OBSERVATION", 75, 84]]], ["This study investigated at atomic detail the conformation of a highly conserved central fragment of MBP, constisting of two consecutive regions with different relevant functionalities.", [["MBP", "GENE_OR_GENE_PRODUCT", 100, 103], ["MBP", "PROTEIN", 100, 103], ["This study", "TEST", 0, 10], ["a highly conserved central fragment of MBP", "PROBLEM", 61, 103], ["central", "OBSERVATION_MODIFIER", 80, 87], ["fragment", "OBSERVATION", 88, 96], ["two", "OBSERVATION_MODIFIER", 120, 123], ["consecutive", "OBSERVATION_MODIFIER", 124, 135], ["different", "OBSERVATION_MODIFIER", 149, 158], ["relevant functionalities", "OBSERVATION", 159, 183]]], ["The first one is associated with the membrane and comprises the primary immunodominant epitope in multiple sclerosis; the second one was predicted to be a ligand for SH3-domains of signalling proteins.", [["membrane", "ANATOMY", 37, 45], ["multiple sclerosis", "DISEASE", 98, 116], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["SH3", "GENE_OR_GENE_PRODUCT", 166, 169], ["primary immunodominant epitope", "PROTEIN", 64, 94], ["SH3", "PROTEIN", 166, 169], ["signalling proteins", "PROTEIN", 181, 200], ["the primary immunodominant epitope in multiple sclerosis", "PROBLEM", 60, 116], ["signalling proteins", "PROBLEM", 181, 200], ["immunodominant epitope", "OBSERVATION", 72, 94], ["multiple", "OBSERVATION_MODIFIER", 98, 106], ["sclerosis", "OBSERVATION", 107, 116]]], ["Molecular dynamics simulations were perfomed in the presence of dodecylphosphocholine micelle, starting from a structure extrapolated from experimental data (Harauz and Libich, Curr.", [["dodecylphosphocholine", "CHEMICAL", 64, 85], ["dodecylphosphocholine", "CHEMICAL", 64, 85], ["dodecylphosphocholine micelle", "SIMPLE_CHEMICAL", 64, 93], ["Molecular dynamics simulations", "TEST", 0, 30], ["dodecylphosphocholine micelle", "TREATMENT", 64, 93], ["experimental data", "TEST", 139, 156]]], ["Protein Pept.", [["Protein Pept.", "TEST", 0, 13]]], ["The results confirm the experimetal hypothesis, showing, in the micelle, a stable alpha-helix anchored to the membrane for the first region and, for the proline-rich second one, a poly-proline type II helix pointing outwards, ready to interact with the signalling proteins.P-90Multiresolution modelling of drug and hormone permeability through a lipid bilayer Traditional atomic-level (AL) modelling of biomembranes is time-consuming, and hence limited in the range of systems and phenomena that can be simulated.", [["membrane", "ANATOMY", 110, 118], ["proline", "CHEMICAL", 153, 160], ["poly-proline", "CHEMICAL", 180, 192], ["P-90Multiresolution", "CHEMICAL", 273, 292], ["proline", "CHEMICAL", 153, 160], ["poly-proline", "CHEMICAL", 180, 192], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["poly-proline type II helix", "PROTEIN", 180, 206], ["signalling proteins", "PROTEIN", 253, 272], ["the experimetal hypothesis", "PROBLEM", 20, 46], ["a poly-proline type II helix", "TREATMENT", 178, 206], ["P", "TEST", 273, 274], ["drug and hormone permeability", "TREATMENT", 306, 335], ["a lipid bilayer", "TREATMENT", 344, 359], ["stable", "OBSERVATION_MODIFIER", 75, 81], ["alpha-helix", "OBSERVATION", 82, 93], ["membrane", "ANATOMY_MODIFIER", 110, 118]]], ["To alleviate this problem, we designed a coarse-grain (CG) representation where each lipid molecule, in reality consisting of more than 100 atoms, is modelled with only 10 CG sites.", [["this problem", "PROBLEM", 13, 25], ["each lipid molecule", "PROBLEM", 80, 99], ["lipid molecule", "OBSERVATION", 85, 99]]], ["Our CG technique proves two orders of magnitude less demanding of computational resources than traditional AL methodology.", [["traditional AL methodology", "TREATMENT", 95, 121]]], ["A unique feature of our approach is that the CG potentials are directly compatible with standard AL models, thus facilitating the simulation of multiresolution systems, where the \"chemically-sensitive\" components (e.g., the solutes in membrane permeation studies) are modelled atomistically, while the surrounding environment is coarse-grained.", [["membrane", "ANATOMY", 235, 243], ["membrane", "CELLULAR_COMPONENT", 235, 243], ["the CG potentials", "TEST", 41, 58], ["the \"chemically-sensitive\" components", "PROBLEM", 175, 212], ["the solutes in membrane permeation studies", "TEST", 220, 262], ["coarse", "OBSERVATION", 329, 335]]], ["In this contribution, we present a summary of our multiscale methodology, together with its application to the permeation of large molecules -drugs and steroid hormones.", [["steroid", "CHEMICAL", 152, 159], ["steroid", "CHEMICAL", 152, 159], ["steroid hormones", "GENE_OR_GENE_PRODUCT", 152, 168], ["large molecules", "PROBLEM", 125, 140], ["drugs", "TREATMENT", 142, 147], ["steroid hormones", "TREATMENT", 152, 168], ["large", "OBSERVATION_MODIFIER", 125, 130], ["molecules", "OBSERVATION", 131, 140], ["steroid hormones", "OBSERVATION", 152, 168]]], ["The calculated permeabilities are compared to the available experimental measurements and AL simulation data.", [["The calculated permeabilities", "TEST", 0, 29], ["AL simulation data", "TEST", 90, 108], ["permeabilities", "OBSERVATION_MODIFIER", 15, 29]]], ["Molecularlevel insights regarding the permeation mechanism are obtained and rationalised.P-89-Multiscale simulation -123The processes of life involve a variety of events that occur on different scales, ranging from a few\u00c5/ps of the triggering steps of the biochemical reactions, up to their macroscopic effects in cells and organs.", [["cells", "ANATOMY", 314, 319], ["organs", "ANATOMY", 324, 330], ["cells", "CELL", 314, 319], ["organs", "ORGAN", 324, 330], ["the permeation mechanism", "TEST", 34, 58], ["P", "TEST", 89, 90], ["Multiscale simulation", "TEST", 94, 115], ["a few\u00c5/ps", "TREATMENT", 215, 224], ["the biochemical reactions", "PROBLEM", 252, 277], ["organs", "ANATOMY", 324, 330]]], ["Intermediate steps involve the structural rearrangement of the bio-molecules (\u223cnm/10-100ns), their aggregation, folding (\u223c10nm-\u00b5m/ \u00b5s-ms), internal cell diffusion and dynamics (\u00b5m-mm/ms-hours), evidently requiring a multi-scale modeling approach.", [["cell", "ANATOMY", 148, 152], ["cell", "CELL", 148, 152], ["the bio-molecules", "TEST", 59, 76], ["their aggregation", "PROBLEM", 93, 110], ["folding", "TEST", 112, 119], ["internal cell diffusion", "TEST", 139, 162], ["a multi-scale modeling approach", "TREATMENT", 214, 245], ["internal cell", "ANATOMY", 139, 152]]], ["Here the multi-scale approaches are first briefly illustrated with a particular attention to the issue of matching the different resolutions, which is essential to achieve a coherent descripition.", [["the multi-scale approaches", "TREATMENT", 5, 31]]], ["The focus is then fixed on the Coarse Grained (CG) models, typically spanning the nm-\u00b5m and \u00b5s-ms scale, and in particular on their minimalist -simplest and computationally cheapest -versions [1, 2] .", [["the nm", "TEST", 78, 84]]], ["A parameterization strategy that combines accuracy and predictive power within these models is presented here and applications are shown to relevant cases including the proteins involved in the HIV replication, the Green Fluorescent Proteins and examples of macromolecular complexes.", [["Green Fluorescent Proteins", "PROTEIN", 215, 241], ["macromolecular complexes", "PROTEIN", 258, 282], ["HIV", "SPECIES", 194, 197], ["A parameterization strategy", "TREATMENT", 0, 27], ["the HIV replication", "TREATMENT", 190, 209], ["Green Fluorescent Proteins", "TEST", 215, 241], ["macromolecular complexes", "OBSERVATION", 258, 282]]], ["[1] Controlled degradation of collagen is an important process in tissue remodeling and wound healing.", [["tissue", "ANATOMY", 66, 72], ["wound", "ANATOMY", 88, 93], ["collagen", "GENE_OR_GENE_PRODUCT", 30, 38], ["tissue", "TISSUE", 66, 72], ["wound", "PATHOLOGICAL_FORMATION", 88, 93], ["collagen", "PROTEIN", 30, 38], ["Controlled degradation of collagen", "TREATMENT", 4, 38], ["tissue remodeling", "TREATMENT", 66, 83], ["wound healing", "PROBLEM", 88, 101], ["tissue remodeling", "OBSERVATION_MODIFIER", 66, 83], ["wound", "OBSERVATION_MODIFIER", 88, 93], ["healing", "OBSERVATION_MODIFIER", 94, 101]]], ["Collagenase cleaves fibrillar collagens about three quarters of the distance from the amino-terminus.", [["amino-terminus", "CHEMICAL", 86, 100], ["amino", "CHEMICAL", 86, 91], ["Collagenase", "GENE_OR_GENE_PRODUCT", 0, 11], ["fibrillar collagens", "GENE_OR_GENE_PRODUCT", 20, 39], ["amino-terminus", "AMINO_ACID", 86, 100], ["Collagenase", "PROTEIN", 0, 11], ["fibrillar collagens", "PROTEIN", 20, 39], ["amino-terminus", "PROTEIN", 86, 100], ["Collagenase cleaves fibrillar collagens", "TREATMENT", 0, 39], ["amino-terminus", "OBSERVATION", 86, 100]]], ["Even though the determination of the cleavage site and the collagenase structure took place decades ago, the mode of action of collagenase on collagen is not clear.", [["collagenase", "GENE_OR_GENE_PRODUCT", 59, 70], ["collagenase", "GENE_OR_GENE_PRODUCT", 127, 138], ["collagen", "GENE_OR_GENE_PRODUCT", 142, 150], ["collagenase", "PROTEIN", 59, 70], ["collagenase", "PROTEIN", 127, 138], ["collagen", "PROTEIN", 142, 150], ["the cleavage site", "PROBLEM", 33, 50], ["collagenase on collagen", "TREATMENT", 127, 150], ["clear", "OBSERVATION", 158, 163]]], ["To understand the mechanism of collagenase activity on collagen, the structure, stability and dynamics of collagen, its conformation around the cleavage site and the possibilities of conformational rearrangements between the two domains in collagenase was explored using MD simulation.", [["collagenase", "GENE_OR_GENE_PRODUCT", 31, 42], ["collagen", "GENE_OR_GENE_PRODUCT", 55, 63], ["collagen", "GENE_OR_GENE_PRODUCT", 106, 114], ["collagenase", "GENE_OR_GENE_PRODUCT", 240, 251], ["collagenase", "PROTEIN", 31, 42], ["collagen", "PROTEIN", 55, 63], ["collagen", "PROTEIN", 106, 114], ["cleavage site", "PROTEIN", 144, 157], ["collagenase", "PROTEIN", 240, 251], ["collagenase activity", "PROBLEM", 31, 51], ["the cleavage site", "PROBLEM", 140, 157], ["conformational rearrangements", "PROBLEM", 183, 212], ["stability", "OBSERVATION_MODIFIER", 80, 89]]], ["The results of principal component (PCA) and normal mode (NM) analysis of the collagen and collagenase suggests that the C-terminal domain of collagenase recognizes the collagen, and then the N-terminal catalytic domain undergoes rearrangement on the substrate (with the help of linker regions).", [["C", "CHEMICAL", 121, 122], ["N", "CHEMICAL", 192, 193], ["collagen", "GENE_OR_GENE_PRODUCT", 78, 86], ["collagenase", "GENE_OR_GENE_PRODUCT", 91, 102], ["collagenase", "GENE_OR_GENE_PRODUCT", 142, 153], ["collagen", "GENE_OR_GENE_PRODUCT", 169, 177], ["collagen", "PROTEIN", 78, 86], ["collagenase", "PROTEIN", 91, 102], ["C-terminal domain", "PROTEIN", 121, 138], ["collagenase", "PROTEIN", 142, 153], ["collagen", "PROTEIN", 169, 177], ["N-terminal catalytic domain", "PROTEIN", 192, 219], ["linker regions", "PROTEIN", 279, 293], ["the collagen and collagenase", "TREATMENT", 74, 102], ["the C-terminal domain of collagenase", "TREATMENT", 117, 153], ["the substrate", "TREATMENT", 247, 260]]], ["The SDA software for carrying out Brownian dynamics simulations of protein-protein diffusional association with the help of biochemical constraints is being used to predict the mode of interaction of collagen and collagenase.", [["collagen", "GENE_OR_GENE_PRODUCT", 200, 208], ["collagenase", "GENE_OR_GENE_PRODUCT", 213, 224], ["collagen", "PROTEIN", 200, 208], ["collagenase", "PROTEIN", 213, 224], ["The SDA software", "TEST", 0, 16], ["protein", "TEST", 67, 74], ["protein diffusional association", "PROBLEM", 75, 106], ["biochemical constraints", "TREATMENT", 124, 147], ["collagen and collagenase", "TREATMENT", 200, 224]]], ["Different conformations obtained from PCA and NM analysis are being used for the docking.", [["PCA", "TREATMENT", 38, 41], ["NM analysis", "TEST", 46, 57]]], ["The predicted structures of the complex will help us to understand how collagenase recognizes and binds collagen specifically.", [["collagenase", "GENE_OR_GENE_PRODUCT", 71, 82], ["collagen", "GENE_OR_GENE_PRODUCT", 104, 112], ["collagenase", "PROTEIN", 71, 82], ["collagen", "PROTEIN", 104, 112]]], ["Acknowledgment: DAAD, Germany, CSIR-SRF India, and the Klaus Tschira Foundation.O-94Membrane aoration by antimicrobial peptides combining atomistic and coarse-grained descriptions D. Sengupta, A. J. Rzepiela, N. Goga, S. J. Marrink University of Groningen, The Netherlands Antimicrobial peptides (AMPs) comprise a large family of peptides that include small cationic peptides, such as magainins, which permeabilize lipid membranes.", [["lipid membranes", "ANATOMY", 415, 430], ["O-94Membrane", "CHEMICAL", 80, 92], ["O-94Membrane", "CHEMICAL", 80, 92], ["O-94Membrane", "SIMPLE_CHEMICAL", 80, 92], ["magainins", "GENE_OR_GENE_PRODUCT", 385, 394], ["lipid membranes", "CELLULAR_COMPONENT", 415, 430], ["94Membrane aoration", "TREATMENT", 82, 101], ["antimicrobial peptides", "TREATMENT", 105, 127], ["a large family of peptides", "TREATMENT", 312, 338], ["small cationic peptides", "TREATMENT", 352, 375], ["magainins", "TREATMENT", 385, 394], ["small", "OBSERVATION_MODIFIER", 352, 357], ["cationic peptides", "OBSERVATION", 358, 375], ["lipid membranes", "OBSERVATION", 415, 430]]], ["Previous atomistic level simulations of magainin-H2 peptides show that they act by forming toroidal transmembrane pores.", [["transmembrane pores", "ANATOMY", 100, 119], ["magainin-H2", "CHEMICAL", 40, 51], ["magainin-H2", "GENE_OR_GENE_PRODUCT", 40, 51], ["magainin-H2 peptides", "TREATMENT", 40, 60], ["toroidal", "OBSERVATION_MODIFIER", 91, 99], ["transmembrane pores", "OBSERVATION", 100, 119]]], ["However, due to the atomistic level of description, these simulations were necessarily limited to small system sizes and sub-microsecond time scales.", [["these simulations", "TEST", 52, 69], ["sizes", "OBSERVATION_MODIFIER", 111, 116]]], ["The peptides sample different orientations but at any given time, only a few peptides insert into the pore.", [["pore", "ANATOMY", 102, 106], ["pore", "CELLULAR_COMPONENT", 102, 106], ["a few peptides insert", "TREATMENT", 71, 92], ["different", "OBSERVATION_MODIFIER", 20, 29], ["orientations", "OBSERVATION_MODIFIER", 30, 42]]], ["Key states observed at the CG level are subsequently back-transformed to the atomistic level using a resolutionexchange protocol.", [["a resolutionexchange protocol", "TREATMENT", 99, 128]]], ["The configurations sampled at the CG level are stable in the atomistic simulation.", [["configurations", "OBSERVATION_MODIFIER", 4, 18], ["stable", "OBSERVATION_MODIFIER", 47, 53]]], ["The effect of helicity on pore stability is investigated at the CG level and we find that partial helicity is required to form stable pores.", [["pore", "ANATOMY", 26, 30], ["stable", "OBSERVATION_MODIFIER", 127, 133]]], ["We also show that the current CG scheme can be used to study spontaneous poration by magainin-H2 peptides.", [["magainin-H2", "CHEMICAL", 85, 96], ["H2", "CHEMICAL", 94, 96], ["magainin-H2 peptides", "GENE_OR_GENE_PRODUCT", 85, 105], ["magainin-H2 peptides", "TREATMENT", 85, 105]]], ["Over-all, our simulations provide a multi-scale view of a fundamental biophysical membrane process involving a complex interplay between peptides and lipids.", [["membrane", "ANATOMY", 82, 90], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["lipids", "SIMPLE_CHEMICAL", 150, 156], ["a fundamental biophysical membrane process", "TREATMENT", 56, 98], ["a complex interplay between peptides", "TREATMENT", 109, 145], ["lipids", "TREATMENT", 150, 156], ["biophysical membrane", "OBSERVATION", 70, 90]]], ["The Varkud Satellite (VS) ribozyme is the largest of the nucleolytic ribozymes, and the only one for which there is no crystal structure.", [["Varkud Satellite (VS) ribozyme", "DNA", 4, 34], ["The Varkud Satellite (VS) ribozyme", "PROBLEM", 0, 34], ["crystal structure", "PROBLEM", 119, 136], ["Satellite", "OBSERVATION_MODIFIER", 11, 20], ["largest", "OBSERVATION_MODIFIER", 42, 49], ["nucleolytic ribozymes", "OBSERVATION", 57, 78], ["no", "UNCERTAINTY", 116, 118], ["crystal structure", "OBSERVATION", 119, 136]]], ["We have determined the overall architecture of the complete VS ribozyme using small-angle X-ray scattering in solution.", [["VS ribozyme", "DNA", 60, 71], ["small-angle X-ray scattering in solution", "TREATMENT", 78, 118], ["small", "OBSERVATION_MODIFIER", 78, 83]]], ["The substrate stem-loop docks into the tertiary fold of the ribozyme, allowing an intimate loop-loop interaction to occur.", [["The substrate stem-loop docks", "TREATMENT", 0, 29], ["the ribozyme", "TREATMENT", 56, 68], ["substrate stem", "OBSERVATION", 4, 18]]], ["This brings two key nucleobases A756 and G638 into close proximity of the scissile phosphate, and we believe that these nucleobases are involved in general acid-base catalysis of the phosphoryl transfer reactions.", [["G638", "CHEMICAL", 41, 45], ["phosphate", "CHEMICAL", 83, 92], ["phosphoryl", "CHEMICAL", 183, 193], ["A756", "CHEMICAL", 32, 36], ["G638", "CHEMICAL", 41, 45], ["scissile phosphate", "CHEMICAL", 74, 92], ["nucleobases", "CHEMICAL", 120, 131], ["phosphoryl", "CHEMICAL", 183, 193], ["A756", "SIMPLE_CHEMICAL", 32, 36], ["G638", "SIMPLE_CHEMICAL", 41, 45], ["phosphate", "SIMPLE_CHEMICAL", 83, 92], ["phosphoryl", "SIMPLE_CHEMICAL", 183, 193], ["the scissile phosphate", "TEST", 70, 92], ["these nucleobases", "PROBLEM", 114, 131], ["general acid-base catalysis", "TREATMENT", 148, 175], ["the phosphoryl transfer reactions", "TREATMENT", 179, 212]]], ["This is supported by functional group substitution, and the pH dependence of the reaction rate for the natural and modified RNA.", [["natural and modified RNA", "RNA", 103, 127], ["functional group substitution", "PROBLEM", 21, 50], ["the pH dependence", "PROBLEM", 56, 73], ["the reaction rate", "TEST", 77, 94], ["the natural and modified RNA", "PROBLEM", 99, 127], ["functional group substitution", "OBSERVATION", 21, 50]]], ["Although possessing totally different folds, the functional elements of the VS and hairpin ribozymes are topologically and mechanistically very similar if not identical.", [["functional elements", "DNA", 49, 68], ["VS and hairpin ribozymes", "DNA", 76, 100], ["possessing totally different folds", "PROBLEM", 9, 43], ["the VS", "TEST", 72, 78], ["hairpin ribozymes", "TREATMENT", 83, 100], ["totally different", "OBSERVATION_MODIFIER", 20, 37], ["folds", "OBSERVATION_MODIFIER", 38, 43], ["functional elements", "OBSERVATION", 49, 68], ["hairpin ribozymes", "OBSERVATION", 83, 100]]], ["This has probably arisen by convergent evolution.", [["probably arisen", "UNCERTAINTY", 9, 24], ["convergent", "OBSERVATION_MODIFIER", 28, 38], ["evolution", "OBSERVATION_MODIFIER", 39, 48]]], ["Other nucleolytic ribozymes have diversified to employ hydrated metal ions and even small molecules to participate in genera acid-base catalysis.", [["hydrated metal ions", "SIMPLE_CHEMICAL", 55, 74], ["Other nucleolytic ribozymes", "PROBLEM", 0, 27], ["hydrated metal ions", "TREATMENT", 55, 74], ["small molecules", "PROBLEM", 84, 99], ["genera acid-base catalysis", "TREATMENT", 118, 144], ["nucleolytic ribozymes", "OBSERVATION", 6, 27], ["small", "OBSERVATION_MODIFIER", 84, 89], ["molecules", "OBSERVATION", 90, 99], ["base", "ANATOMY_MODIFIER", 130, 134]]], ["By contrast, the larger ribozymes seem to have adopted a different, metalloenzyme, catalytic strategy.", [["metalloenzyme", "PROTEIN", 68, 81], ["the larger ribozymes", "PROBLEM", 13, 33], ["metalloenzyme, catalytic strategy", "TREATMENT", 68, 101]]], ["Why these different groups have evolved different catalytic chemistries is an interesting challenge to our understanding of biocatalysis.O-100Comparison of DNA and siRNA binding and nuclease protection by non-viral vectors for gene delivery J. Lam, K. Witt, A. J. Mason, L. Kudsiova, M. J. Lawrence Pharmaceutical Science Division, King's College London, UK The biggest obstacle for the success of gene therapy is delivery.", [["DNA", "CELLULAR_COMPONENT", 156, 159], ["nuclease", "PROTEIN", 182, 190], ["DNA", "PROBLEM", 156, 159], ["siRNA binding", "PROBLEM", 164, 177], ["nuclease protection", "TREATMENT", 182, 201], ["non-viral vectors", "TREATMENT", 205, 222], ["gene therapy", "TREATMENT", 398, 410], ["delivery", "TREATMENT", 414, 422], ["siRNA binding", "OBSERVATION", 164, 177], ["biggest", "OBSERVATION_MODIFIER", 362, 369], ["obstacle", "OBSERVATION", 370, 378]]], ["With the discovery of RNAi, the use of siRNA to regulate gene expression as potential therapy has attracted much attention recently.", [["siRNA", "TREATMENT", 39, 44], ["potential therapy", "TREATMENT", 76, 93]]], ["In contrast to DNA, siRNA delivery does not require nuclear entry.", [["nuclear", "ANATOMY", 52, 59], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["nuclear", "CELLULAR_COMPONENT", 52, 59], ["siRNA delivery", "TREATMENT", 20, 34]]], ["With one less barrier to overcome, the delivery of siRNA seems to be easier.", [["the delivery of siRNA", "TREATMENT", 35, 56]]], ["It is frequently assumed that comparable delivery strategy could be used for both DNA and siRNA.", [["DNA", "CELLULAR_COMPONENT", 82, 85], ["comparable delivery strategy", "TREATMENT", 30, 58], ["both DNA and siRNA", "PROBLEM", 77, 95], ["siRNA", "OBSERVATION", 90, 95]]], ["In fact the two types of nucleic acids are fundamentally different with distinct properties, which impact their delivery strategies.", [["nucleic acids", "CHEMICAL", 25, 38], ["nucleic acids", "SIMPLE_CHEMICAL", 25, 38], ["nucleic acids", "TREATMENT", 25, 38], ["their delivery strategies", "TREATMENT", 106, 131], ["nucleic acids", "OBSERVATION", 25, 38], ["distinct properties", "OBSERVATION_MODIFIER", 72, 91]]], ["In the present study it was found that most non-viral delivery vectors including polymers, peptides and lipids were generally more efficient in binding with DNA than siRNA as shown in gel retardation assay.", [["lipids", "SIMPLE_CHEMICAL", 104, 110], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["the present study", "TEST", 3, 20], ["non-viral delivery vectors", "TREATMENT", 44, 70], ["polymers, peptides", "TREATMENT", 81, 99], ["lipids", "TREATMENT", 104, 110], ["DNA than siRNA", "TREATMENT", 157, 171], ["gel retardation assay", "PROBLEM", 184, 205]]], ["The inferior siRNA binding is possibly due to the rigid structure of siRNA, resulting in weaker electrostatic interaction with the cationic vectors.", [["The inferior siRNA binding", "PROBLEM", 0, 26], ["the rigid structure of siRNA", "PROBLEM", 46, 74], ["the cationic vectors", "TREATMENT", 127, 147], ["inferior", "ANATOMY_MODIFIER", 4, 12], ["siRNA binding", "OBSERVATION", 13, 26], ["possibly due to", "UNCERTAINTY", 30, 45], ["rigid structure", "OBSERVATION", 50, 65], ["siRNA", "OBSERVATION", 69, 74], ["weaker", "OBSERVATION_MODIFIER", 89, 95], ["electrostatic interaction", "OBSERVATION", 96, 121]]], ["Surprisingly, it was observed that all the vectors studied offered better nuclease protection for siRNA than DNA despite poorer siRNA binding.", [["DNA", "CELLULAR_COMPONENT", 109, 112], ["nuclease", "PROTEIN", 74, 82], ["all the vectors", "TREATMENT", 35, 50], ["nuclease protection", "TREATMENT", 74, 93], ["siRNA", "PROBLEM", 98, 103], ["DNA", "PROBLEM", 109, 112], ["poorer siRNA binding", "PROBLEM", 121, 141], ["siRNA binding", "OBSERVATION", 128, 141]]], ["Either the nuclease protection for siRNA is easier to achieve due to its small size, or the gel retardation assay did not truly reflect the binding efficiency as the weaker siRNA complexes may dissociate during electrophoresis.", [["nuclease", "PROTEIN", 11, 19], ["siRNA complexes", "PROTEIN", 173, 188], ["the nuclease protection", "TREATMENT", 7, 30], ["siRNA", "PROBLEM", 35, 40], ["its small size", "PROBLEM", 69, 83], ["the gel retardation assay", "TEST", 88, 113], ["the binding efficiency", "PROBLEM", 136, 158], ["the weaker siRNA complexes", "PROBLEM", 162, 188], ["small", "OBSERVATION_MODIFIER", 73, 78], ["size", "OBSERVATION_MODIFIER", 79, 83], ["binding efficiency", "OBSERVATION", 140, 158]]], ["Not only the delivery strategy, the results between DNA and siRNA study must also be carefully adapted and interpreted.P-99Single molecule studies of spliceosomal RNAs U2 and U6 Z. Guo, D. Rueda Department of Chemistry, Wayne State University, Detroit, Michigan, U.S.A.P-99Splicing is an essential step in the maturation reaction of mRNA, in which intervening introns from exons.", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["P", "DNA", 119, 120], ["U2", "DNA", 168, 170], ["mRNA", "RNA", 333, 337], ["introns", "DNA", 360, 367], ["exons", "DNA", 373, 378], ["the delivery strategy", "TREATMENT", 9, 30], ["siRNA study", "TEST", 60, 71], ["P", "TEST", 119, 120], ["spliceosomal RNAs U2", "OBSERVATION", 150, 170]]], ["The spliceosome is a dynamic assembly of 5 small nuclear RNAs and >150 proteins that catalyzes splicing.", [["nuclear", "ANATOMY", 49, 56], ["5 small nuclear RNAs", "RNA", 41, 61], ["5 small nuclear RNAs", "PROBLEM", 41, 61], ["spliceosome", "OBSERVATION", 4, 15], ["nuclear RNAs", "OBSERVATION", 49, 61]]], ["U2 and U6 are the only 2 snRNAs strictly required for splicing.", [["U2", "GENE_OR_GENE_PRODUCT", 0, 2], ["U6", "GENE_OR_GENE_PRODUCT", 7, 9], ["U2", "DNA", 0, 2], ["U6", "DNA", 7, 9], ["U2 and U6", "TREATMENT", 0, 9], ["splicing", "PROBLEM", 54, 62], ["U6", "ANATOMY_MODIFIER", 7, 9]]], ["Major conformational changes are expected to take place during spliceosomal assembly and catalysis.", [["spliceosomal", "ANATOMY", 63, 75], ["Major conformational changes", "PROBLEM", 0, 28]]], ["We have developed a single-molecule fluorescence assay to study the structural dynamics of a protein-free U2-U6 complex from yeast.", [["U6", "GENE_OR_GENE_PRODUCT", 109, 111], ["U2", "DNA", 106, 108], ["U6 complex", "PROTEIN", 109, 119], ["yeast", "SPECIES", 125, 130], ["yeast", "SPECIES", 125, 130], ["a protein", "TEST", 91, 100], ["U6 complex", "PROBLEM", 109, 119], ["yeast", "PROBLEM", 125, 130]]], ["Our previous data have revealed a 2-step large amplitude conformational change of the U2-U6 complex.", [["U2-U6", "GENE_OR_GENE_PRODUCT", 86, 91], ["U2", "DNA", 86, 88], ["U6 complex", "PROTEIN", 89, 99], ["Our previous data", "TEST", 0, 17], ["a 2-step large amplitude conformational change of the U2-U6 complex", "PROBLEM", 32, 99], ["large", "OBSERVATION_MODIFIER", 41, 46], ["amplitude", "OBSERVATION_MODIFIER", 47, 56], ["conformational change", "OBSERVATION", 57, 78], ["U2-", "OBSERVATION", 86, 89], ["U6 complex", "OBSERVATION", 89, 99]]], ["The 1 st step is a Mg 2+ -induced conformational change where helix III and the U6-ISL are in close proximity in low Mg 2+ and separated in high Mg 2+ .", [["Mg", "CHEMICAL", 19, 21], ["Mg", "CHEMICAL", 117, 119], ["Mg", "CHEMICAL", 145, 147], ["Mg 2+", "CHEMICAL", 19, 24], ["Mg 2+", "CHEMICAL", 117, 122], ["Mg 2+", "CHEMICAL", 145, 150], ["Mg 2+", "SIMPLE_CHEMICAL", 19, 24], ["U6-ISL", "GENE_OR_GENE_PRODUCT", 80, 86], ["Mg 2+", "SIMPLE_CHEMICAL", 117, 122], ["Mg 2+", "SIMPLE_CHEMICAL", 145, 150], ["helix III", "PROTEIN", 62, 71], ["U6", "PROTEIN", 80, 82], ["ISL", "PROTEIN", 83, 86], ["helix III", "TREATMENT", 62, 71], ["the U6", "TREATMENT", 76, 82]]], ["The 2 nd step corresponds to the formation of the highly conserved helix IB.", [["highly conserved helix IB", "PROTEIN", 50, 75], ["helix IB", "OBSERVATION", 67, 75]]], ["We now examine the role of the highly conserved bases in the folding dynamics of the U2-U6 complex.", [["U2-U6", "GENE_OR_GENE_PRODUCT", 85, 90], ["U2", "DNA", 85, 87], ["U6 complex", "PROTEIN", 88, 98], ["bases", "ANATOMY_MODIFIER", 48, 53], ["U6 complex", "OBSERVATION", 88, 98]]], ["The data show that U80 and the ACAGAG loop play an important role in stabilizing the interaction between helix III and the U6-ISL.", [["U80", "GENE_OR_GENE_PRODUCT", 19, 22], ["ACAGAG", "GENE_OR_GENE_PRODUCT", 31, 37], ["helix III", "GENE_OR_GENE_PRODUCT", 105, 114], ["U6-ISL", "GENE_OR_GENE_PRODUCT", 123, 129], ["U80", "PROTEIN", 19, 22], ["ACAGAG loop", "PROTEIN", 31, 42], ["helix III", "PROTEIN", 105, 114], ["U6", "PROTEIN", 123, 125], ["ISL", "PROTEIN", 126, 129], ["The data", "TEST", 0, 8], ["U80", "TEST", 19, 22], ["the ACAGAG loop", "TREATMENT", 27, 42], ["ISL", "ANATOMY", 126, 129]]], ["We hypothesize that U80 flips out of the U6-ISL and interacts with the ACAGAG loop to bring them in close proximity.", [["U6-ISL", "GENE_OR_GENE_PRODUCT", 41, 47], ["U80", "DNA", 20, 23], ["U6", "DNA", 41, 43], ["ISL", "PROTEIN", 44, 47], ["ACAGAG loop", "PROTEIN", 71, 82], ["the ACAGAG loop", "TREATMENT", 67, 82]]], ["Our results raise the interesting possibility that this interaction plays an important role in bringing the 5' splice site and the branched A into close proximity of U80, which may be critical for catalysis.O-98A structure-based approach for targeting HIV-1 genomic RNA Dimerization Initiation Site S. Freisz, S. Bernacchi, P. Dumas, E. Ennifar IBMC -CNRS, Strasbourg, France All retroviral genomes consist in two homologous single stranded RNAs.", [["O-98A", "CHEMICAL", 207, 212], ["O-98A", "CHEMICAL", 207, 212], ["U80", "GENE_OR_GENE_PRODUCT", 166, 169], ["HIV-1", "ORGANISM", 252, 257], ["retroviral", "ORGANISM", 380, 390], ["5' splice site", "DNA", 108, 122], ["U80", "DNA", 166, 169], ["retroviral genomes", "DNA", 380, 398], ["homologous single stranded RNAs", "RNA", 414, 445], ["HIV-1", "SPECIES", 252, 257], ["the 5' splice site", "TREATMENT", 104, 122], ["targeting HIV-1 genomic RNA Dimerization", "TREATMENT", 242, 282], ["All retroviral genomes", "TREATMENT", 376, 398], ["retroviral genomes", "OBSERVATION", 380, 398], ["stranded RNAs", "OBSERVATION", 432, 445]]], ["HIV-1 Dimerization Initiation Site (DIS) is a conserved hairpin in the 5' non-coding region of the genomic RNA and essential for viral infectivity.", [["HIV-1", "ORGANISM", 0, 5], ["HIV-1 Dimerization Initiation Site", "DNA", 0, 34], ["DIS", "DNA", 36, 39], ["5' non-coding region", "DNA", 71, 91], ["genomic RNA", "RNA", 99, 110], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["a conserved hairpin", "PROBLEM", 44, 63], ["viral infectivity", "PROBLEM", 129, 146], ["hairpin", "OBSERVATION", 56, 63], ["genomic RNA", "ANATOMY", 99, 110], ["essential for", "UNCERTAINTY", 115, 128], ["viral infectivity", "OBSERVATION", 129, 146]]], ["The DIS initiates genome dimerization by forming a kissing-loop complex, further stabilized into an extended duplex upon interaction with the NCp7 nucleocapsid protein.", [["genome", "CELLULAR_COMPONENT", 18, 24], ["DIS", "DNA", 4, 7], ["kissing-loop complex", "PROTEIN", 51, 71], ["NCp7 nucleocapsid protein", "PROTEIN", 142, 167], ["a kissing-loop complex", "TREATMENT", 49, 71], ["the NCp7 nucleocapsid protein", "TREATMENT", 138, 167], ["genome dimerization", "OBSERVATION", 18, 37]]], ["X-ray structures of the DIS kissing-loop and extended duplex revealed similarities with the bacterial 16S ribosomal RNA A-site, which is the target of aminoglycoside antibiotics.", [["ribosomal", "ANATOMY", 106, 115], ["aminoglycoside", "CHEMICAL", 151, 165], ["aminoglycoside", "CHEMICAL", 151, 165], ["ribosomal", "CELLULAR_COMPONENT", 106, 115], ["aminoglycoside antibiotics", "SIMPLE_CHEMICAL", 151, 177], ["DIS kissing-loop", "DNA", 24, 40], ["bacterial 16S ribosomal RNA A-site", "DNA", 92, 126], ["extended duplex", "TEST", 45, 60], ["the bacterial 16S ribosomal RNA A-site", "PROBLEM", 88, 126], ["aminoglycoside antibiotics", "TREATMENT", 151, 177], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["16S", "OBSERVATION_MODIFIER", 102, 105], ["ribosomal RNA", "OBSERVATION", 106, 119]]], ["As a result, aminoglycosides also bind the HIV-1 DIS as shown by our X-ray structures of the DIS kissingloop bound to aminoglycosides.", [["aminoglycosides", "CHEMICAL", 13, 28], ["aminoglycosides", "CHEMICAL", 118, 133], ["aminoglycosides", "CHEMICAL", 13, 28], ["aminoglycosides", "CHEMICAL", 118, 133], ["aminoglycosides", "SIMPLE_CHEMICAL", 13, 28], ["HIV-1", "ORGANISM", 43, 48], ["DIS", "ORGANISM", 49, 52], ["aminoglycosides", "SIMPLE_CHEMICAL", 118, 133], ["DIS kissingloop", "DNA", 93, 108], ["HIV-1", "SPECIES", 43, 48], ["HIV-1", "SPECIES", 43, 48], ["aminoglycosides", "TREATMENT", 13, 28], ["aminoglycosides", "TREATMENT", 118, 133]]], ["Using fluorescence, UVspectroscopy and microcalorimetry, we further characterized HIV-1 DIS/aminoglycosides interactions.", [["aminoglycosides", "CHEMICAL", 92, 107], ["aminoglycosides", "CHEMICAL", 92, 107], ["HIV-1", "ORGANISM", 82, 87], ["aminoglycosides", "SIMPLE_CHEMICAL", 92, 107], ["HIV-1", "SPECIES", 82, 87], ["HIV-1", "SPECIES", 82, 87], ["UVspectroscopy", "TEST", 20, 34], ["microcalorimetry", "TEST", 39, 55], ["HIV", "PROBLEM", 82, 85], ["aminoglycosides interactions", "TREATMENT", 92, 120]]], ["We found that the affinity of aminoglycosides for the DIS was higher than for their natural target, the 16S A site.", [["aminoglycosides", "CHEMICAL", 30, 45], ["aminoglycosides", "CHEMICAL", 30, 45], ["aminoglycosides", "SIMPLE_CHEMICAL", 30, 45], ["16S A site", "DNA", 104, 114], ["aminoglycosides", "TREATMENT", 30, 45], ["the DIS", "PROBLEM", 50, 57]]], ["They strongly stabilize the DIS kissing-loop, blocking its conversion into the duplex form.", [["loop", "TREATMENT", 40, 44], ["DIS", "OBSERVATION", 28, 31]]], ["Finally, we also solved X-ray structures of the DIS duplex bound to aminoglycosides, revealing an important conformational change following drug binding.", [["aminoglycosides", "CHEMICAL", 68, 83], ["aminoglycosides", "CHEMICAL", 68, 83], ["aminoglycosides", "SIMPLE_CHEMICAL", 68, 83], ["DIS duplex", "DNA", 48, 58], ["aminoglycosides", "TREATMENT", 68, 83], ["drug binding", "PROBLEM", 140, 152]]], ["These structures show that it is possible to target the HIV-1 DIS dimer before and after the NCp7-assisted RNA maturation with the same molecule.", [["HIV-1", "ORGANISM", 56, 61], ["NCp7", "GENE_OR_GENE_PRODUCT", 93, 97], ["HIV-1 DIS dimer", "PROTEIN", 56, 71], ["NCp7", "PROTEIN", 93, 97], ["HIV-1", "SPECIES", 56, 61], ["HIV-1", "SPECIES", 56, 61], ["the NCp7-assisted RNA maturation", "TREATMENT", 89, 121]]], ["Altogether, our studies create the basis for a rationally driven design of novel potential drugs targeting the HIV-1 genome.O-98The core protein of Hepatitis C virus is a multifunctional protein of 179 aa, consisting of a hydrophilic N-terminal domain with three basic domains (BD1-BD3) responsible for the interactions with RNA and a hydrophobic C-terminal domain.", [["O-98", "CHEMICAL", 124, 128], ["Hepatitis C", "DISEASE", 148, 159], ["N", "CHEMICAL", 234, 235], ["C", "CHEMICAL", 347, 348], ["HIV-1", "ORGANISM", 111, 116], ["O-98", "GENE_OR_GENE_PRODUCT", 124, 128], ["Hepatitis C virus", "ORGANISM", 148, 165], ["HIV-1 genome", "DNA", 111, 123], ["multifunctional protein", "PROTEIN", 171, 194], ["179 aa", "PROTEIN", 198, 204], ["hydrophilic N-terminal domain", "PROTEIN", 222, 251], ["basic domains", "PROTEIN", 263, 276], ["BD1", "PROTEIN", 278, 281], ["BD3", "PROTEIN", 282, 285], ["RNA", "RNA", 325, 328], ["hydrophobic C-terminal domain", "PROTEIN", 335, 364], ["HIV-1", "SPECIES", 111, 116], ["Hepatitis C virus", "SPECIES", 148, 165], ["HIV-1", "SPECIES", 111, 116], ["Hepatitis C virus", "SPECIES", 148, 165], ["our studies", "TEST", 12, 23], ["novel potential drugs", "TREATMENT", 75, 96], ["The core protein", "TEST", 128, 144], ["Hepatitis C virus", "PROBLEM", 148, 165], ["a multifunctional protein", "TEST", 169, 194], ["a hydrophilic N-terminal domain", "PROBLEM", 220, 251], ["a hydrophobic C-terminal domain", "PROBLEM", 333, 364], ["Hepatitis", "OBSERVATION", 148, 157]]], ["The N-terminal domain exhibits nucleic acid chaperone properties similar to those of the nucleocapsid protein from HIV.", [["nucleic acid", "CHEMICAL", 31, 43], ["N", "CHEMICAL", 4, 5], ["N-terminal domain", "PROTEIN", 4, 21], ["nucleocapsid protein", "PROTEIN", 89, 109], ["HIV", "SPECIES", 115, 118], ["HIV", "SPECIES", 115, 118], ["The N-terminal domain", "TEST", 0, 21], ["nucleic acid chaperone properties", "PROBLEM", 31, 64], ["the nucleocapsid protein", "PROBLEM", 85, 109], ["HIV", "PROBLEM", 115, 118], ["nucleic acid", "OBSERVATION", 31, 43]]], ["Here, we characterized the mechanism of the chaperone properties of a peptide E corresponding to the BD2 and BD3 clusters of the N-terminal domain.", [["BD2", "GENE_OR_GENE_PRODUCT", 101, 104], ["BD2", "PROTEIN", 101, 104], ["BD3", "PROTEIN", 109, 112], ["N-terminal domain", "PROTEIN", 129, 146], ["a peptide E", "PROBLEM", 68, 79], ["N-terminal domain", "OBSERVATION", 129, 146]]], ["To this end, we monitored the promotion by this peptide of the annealing of dTAR, the DNA analogue of the transactivation response element to its complementary sequence, cTAR DNA, taken as models.", [["dTAR", "GENE_OR_GENE_PRODUCT", 76, 80], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["dTAR", "PROTEIN", 76, 80], ["transactivation response element", "DNA", 106, 138], ["complementary sequence", "DNA", 146, 168], ["cTAR DNA", "DNA", 170, 178], ["the annealing of dTAR", "TREATMENT", 59, 80], ["cTAR DNA", "TEST", 170, 178]]], ["The annealing involves two second-order kinetic components that are activated by at least three orders of magnitude by peptide E. This activation was correlated with the ability of peptide E to destabilize the lower half of dTAR stem.", [["dTAR stem", "ANATOMY", 224, 233], ["dTAR stem", "CELL", 224, 233], ["dTAR stem", "CELL_LINE", 224, 233], ["The annealing", "TREATMENT", 0, 13], ["peptide E", "TREATMENT", 181, 190], ["order kinetic", "OBSERVATION_MODIFIER", 34, 47], ["lower", "ANATOMY_MODIFIER", 210, 215], ["dTAR stem", "ANATOMY", 224, 233]]], ["Using, cTAR and dTAR mutants, the two kinetic components were assigned to two pathways which are connected with the fast annealing of the terminal bases of cTAR to dTAR and slow extended duplex formation, limited kinetically by the nucleation of central segments of cTAR and dTAR stems.P-104Structure and conformational dynamics of a unique DEAD box helicase M. Rudolph 1 , M. Linden 2 , R. Hartmann 3 , D. Klostermeier 2 1 Hoffmann-La Roche, Basel, Switzerland, 2 Biozentrum, Univ. of Basel, Switzerland, 3 Univ. of Marburg, Germany DEAD box helicases couple ATP hydrolysis to RNA structural rearrangements.", [["ATP", "CHEMICAL", 560, 563], ["ATP", "CHEMICAL", 560, 563], ["cTAR", "GENE_OR_GENE_PRODUCT", 7, 11], ["dTAR", "GENE_OR_GENE_PRODUCT", 16, 20], ["cTAR", "SIMPLE_CHEMICAL", 156, 160], ["dTAR", "SIMPLE_CHEMICAL", 164, 168], ["cTAR", "GENE_OR_GENE_PRODUCT", 266, 270], ["dTAR", "GENE_OR_GENE_PRODUCT", 275, 279], ["ATP", "SIMPLE_CHEMICAL", 560, 563], ["cTAR", "PROTEIN", 7, 11], ["dTAR mutants", "PROTEIN", 16, 28], ["cTAR", "PROTEIN", 156, 160], ["dTAR", "PROTEIN", 164, 168], ["central segments", "PROTEIN", 246, 262], ["cTAR", "PROTEIN", 266, 270], ["dTAR", "PROTEIN", 275, 279], ["P", "DNA", 286, 287], ["DEAD box helicase", "PROTEIN", 341, 358], ["DEAD box helicases", "PROTEIN", 534, 552], ["cTAR and dTAR mutants", "TREATMENT", 7, 28], ["slow extended duplex formation", "PROBLEM", 173, 203], ["Rudolph", "TEST", 362, 369], ["Klostermeier", "TEST", 407, 419], ["Germany DEAD box helicases", "TREATMENT", 526, 552], ["ATP hydrolysis", "TREATMENT", 560, 574], ["fast annealing", "OBSERVATION", 116, 130], ["terminal", "ANATOMY_MODIFIER", 138, 146], ["bases", "ANATOMY_MODIFIER", 147, 152], ["slow", "OBSERVATION_MODIFIER", 173, 177], ["duplex formation", "OBSERVATION", 187, 203], ["central segments", "ANATOMY_MODIFIER", 246, 262], ["dTAR stems", "OBSERVATION", 275, 285], ["Hartmann", "ANATOMY", 391, 399]]], ["T. thermophilus Hera consists of a helicase core and a C-terminal extension (CTE) with a putative RNase P motif.", [["C", "CHEMICAL", 55, 56], ["T. thermophilus", "ORGANISM", 0, 15], ["RNase", "GENE_OR_GENE_PRODUCT", 98, 103], ["helicase core", "DNA", 35, 48], ["C-terminal extension", "DNA", 55, 75], ["CTE", "PROTEIN", 77, 80], ["RNase P motif", "PROTEIN", 98, 111], ["T. thermophilus", "SPECIES", 0, 15], ["T. thermophilus", "SPECIES", 0, 15], ["a helicase core", "PROBLEM", 33, 48], ["a C-terminal extension", "PROBLEM", 53, 75], ["a putative RNase P motif", "TREATMENT", 87, 111]]], ["Crystal structures show that the CTE is bipartite, forming a highly flexible dimerization motif with a novel fold and an additional RNA-binding module.", [["CTE", "DNA", 33, 36], ["dimerization motif", "PROTEIN", 77, 95], ["RNA-binding module", "PROTEIN", 132, 150], ["Crystal structures", "TEST", 0, 18], ["a highly flexible dimerization motif", "TREATMENT", 59, 95], ["a novel fold", "PROBLEM", 101, 113], ["an additional RNA-binding module", "PROBLEM", 118, 150], ["highly", "OBSERVATION_MODIFIER", 61, 67], ["flexible dimerization", "OBSERVATION", 68, 89], ["binding module", "OBSERVATION", 136, 150]]], ["We provide a first glimpse on the orientation of an RNA-binding domain outside the helicase core.", [["RNA-binding domain", "PROTEIN", 52, 70], ["helicase core", "PROTEIN", 83, 96]]], ["In a structure-based model for the complete Hera dimer, the RNA-binding sites of the helicase cores face each other, allowing for inter-subunit communication.", [["Hera dimer", "PROTEIN", 44, 54], ["RNA-binding sites", "DNA", 60, 77], ["helicase cores", "DNA", 85, 99]]], ["The plasticity of the dimerization motif allows for drastic changes in the juxtaposition of the helicase cores within the dimer.", [["dimerization motif", "PROTEIN", 22, 40], ["helicase cores", "PROTEIN", 96, 110], ["dimer", "PROTEIN", 122, 127], ["the dimerization motif", "TREATMENT", 18, 40], ["drastic changes", "PROBLEM", 52, 67]]], ["In single molecule FRET experiments we identified fragments of the 23S rRNA and RNase P RNA as substrates for Hera.", [["23S", "GENE_OR_GENE_PRODUCT", 67, 70], ["rRNA", "CELLULAR_COMPONENT", 71, 75], ["RNase P", "GENE_OR_GENE_PRODUCT", 80, 87], ["23S rRNA", "RNA", 67, 75], ["RNase P RNA", "RNA", 80, 91], ["single molecule FRET experiments", "TREATMENT", 3, 35], ["fragments of the 23S rRNA", "PROBLEM", 50, 75], ["RNase P RNA", "TREATMENT", 80, 91], ["Hera", "PROBLEM", 110, 114], ["FRET experiments", "OBSERVATION", 19, 35], ["fragments", "OBSERVATION_MODIFIER", 50, 59], ["23S rRNA", "OBSERVATION", 67, 75]]], ["Both substrates switch the Hera core to the closed conformation and stimulate the intrinsic ATPase activity.", [["ATPase", "GENE_OR_GENE_PRODUCT", 92, 98], ["Hera core", "DNA", 27, 36], ["ATPase", "PROTEIN", 92, 98], ["the closed conformation", "TREATMENT", 40, 63], ["ATPase activity", "OBSERVATION", 92, 107]]], ["RNA binding is mediated by the CTE, but does not require the putative RNase P motif.", [["RNase", "GENE_OR_GENE_PRODUCT", 70, 75], ["CTE", "DNA", 31, 34], ["RNase P motif", "DNA", 70, 83], ["the putative RNase P motif", "TREATMENT", 57, 83]]], ["ATP-dependent unwinding of a short helix in 23S rRNA suggests a specific role for Hera in ribosome assembly, in analogy to the E. coli and B. subtilis helicases DbpA and YxiN.", [["ribosome", "ANATOMY", 90, 98], ["ATP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["23S", "GENE_OR_GENE_PRODUCT", 44, 47], ["rRNA", "CELLULAR_COMPONENT", 48, 52], ["Hera", "GENE_OR_GENE_PRODUCT", 82, 86], ["ribosome", "CELLULAR_COMPONENT", 90, 98], ["E. coli", "ORGANISM", 127, 134], ["B. subtilis", "ORGANISM", 139, 150], ["DbpA", "GENE_OR_GENE_PRODUCT", 161, 165], ["YxiN", "GENE_OR_GENE_PRODUCT", 170, 174], ["23S rRNA", "RNA", 44, 52], ["Hera", "PROTEIN", 82, 86], ["E. coli and B. subtilis helicases", "PROTEIN", 127, 160], ["DbpA", "PROTEIN", 161, 165], ["YxiN", "PROTEIN", 170, 174], ["E. coli", "SPECIES", 127, 134], ["B. subtilis", "SPECIES", 139, 150], ["E. coli", "SPECIES", 127, 134], ["B. subtilis", "SPECIES", 139, 150], ["ATP", "PROBLEM", 0, 3], ["dependent unwinding", "PROBLEM", 4, 23], ["a short helix in 23S rRNA", "PROBLEM", 27, 52], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["unwinding", "OBSERVATION_MODIFIER", 14, 23], ["short helix", "OBSERVATION_MODIFIER", 29, 40]]], ["In addition, the specificity of Hera for RNase P RNA may be required for RNase P RNA folding or RNase P assembly.", [["RNase P", "GENE_OR_GENE_PRODUCT", 41, 48], ["RNase P", "GENE_OR_GENE_PRODUCT", 73, 80], ["RNase P", "GENE_OR_GENE_PRODUCT", 96, 103], ["RNase P RNA", "RNA", 41, 52], ["RNase P RNA", "RNA", 73, 84], ["RNase P", "PROTEIN", 96, 103], ["RNase P RNA", "TREATMENT", 41, 52], ["RNase P RNA folding", "TREATMENT", 73, 92]]], ["Simultaneous action of two Hera subunits on the same RNA molecule may be important for efficient RNA remodeling in vivo.P-103Structural basis for the encapsidation process of turnip yellow mosaic virus M. Petersen 1 , J. Hansen 1 , S. S. Wijmenga 2 1 Nucleic Acid Center, Department of Physics and Chemistry, University of Southern Denmark, Odense, Denmark, 2 Physical Chemistry/Biophysical Chemistry, Radboud University, Nijmegen, The Netherlands Formation of hairpins with internal loops with C C and C A mismatches in the 5' untranslated region is a common characteristic among the plant viruses belonging to the Tymovirus genus.", [["turnip", "ORGANISM", 175, 181], ["C C", "GENE_OR_GENE_PRODUCT", 495, 498], ["C A", "GENE_OR_GENE_PRODUCT", 503, 506], ["Tymovirus genus", "ORGANISM", 616, 631], ["Hera subunits", "PROTEIN", 27, 40], ["RNA molecule", "PROTEIN", 53, 65], ["P", "DNA", 120, 121], ["C C and C A mismatches", "DNA", 495, 517], ["5' untranslated region", "DNA", 525, 547], ["turnip", "SPECIES", 175, 181], ["mosaic virus M.", "SPECIES", 189, 204], ["turnip yellow mosaic virus", "SPECIES", 175, 201], ["two Hera subunits", "TREATMENT", 23, 40], ["the same RNA molecule", "TREATMENT", 44, 65], ["the encapsidation process", "TREATMENT", 146, 171], ["Physical Chemistry", "TEST", 360, 378], ["Biophysical Chemistry", "TEST", 379, 400], ["hairpins", "PROBLEM", 461, 469], ["internal loops", "TREATMENT", 475, 489], ["C C and C A mismatches in the 5' untranslated region", "TREATMENT", 495, 547], ["hairpins", "OBSERVATION", 461, 469], ["internal loops", "ANATOMY", 475, 489], ["mismatches", "OBSERVATION", 507, 517], ["plant viruses", "OBSERVATION", 585, 598]]], ["Turnip yellow mosaic virus possesses two such hairpins, HP1 and HP2.", [["Turnip yellow mosaic virus", "ORGANISM", 0, 26], ["HP1", "GENE_OR_GENE_PRODUCT", 56, 59], ["HP2", "GENE_OR_GENE_PRODUCT", 64, 67], ["HP1", "PROTEIN", 56, 59], ["HP2", "DNA", 64, 67], ["yellow mosaic virus", "SPECIES", 7, 26], ["Turnip yellow mosaic virus", "SPECIES", 0, 26], ["Turnip yellow mosaic virus", "PROBLEM", 0, 26], ["HP1", "PROBLEM", 56, 59], ["mosaic virus", "OBSERVATION", 14, 26]]], ["HP1, and in particular the presence of the C C and C A mismatches in its internal loop, is important for initiation of the encapsidation of the viral genome.", [["HP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["C C", "GENE_OR_GENE_PRODUCT", 43, 46], ["C A", "GENE_OR_GENE_PRODUCT", 51, 54], ["HP1", "PROTEIN", 0, 3], ["C C and C A mismatches", "DNA", 43, 65], ["viral genome", "DNA", 144, 156], ["HP1", "PROBLEM", 0, 3], ["the C C and C A mismatches in its internal loop", "PROBLEM", 39, 86], ["the encapsidation", "TREATMENT", 119, 136], ["the viral genome", "TREATMENT", 140, 156], ["mismatches", "OBSERVATION", 55, 65], ["internal loop", "ANATOMY", 73, 86], ["viral genome", "OBSERVATION", 144, 156]]], ["The encapsidation occurs under acidic conditions at the neck of invaginations of the chloroplast membrane.", [["neck", "ANATOMY", 56, 60], ["chloroplast membrane", "ANATOMY", 85, 105], ["neck", "ORGANISM_SUBDIVISION", 56, 60], ["chloroplast membrane", "CELLULAR_COMPONENT", 85, 105], ["The encapsidation", "TREATMENT", 0, 17], ["the chloroplast membrane", "TREATMENT", 81, 105], ["encapsidation", "OBSERVATION", 4, 17], ["acidic conditions", "OBSERVATION", 31, 48], ["neck", "ANATOMY", 56, 60], ["chloroplast membrane", "OBSERVATION", 85, 105]]], ["We have now determined the 3D structures of revertants involved in the evolutionary pathway using NMR spectroscopy.", [["NMR spectroscopy", "TEST", 98, 114]]], ["These structures reveal how the grooves in the hairpin become increasingly positively charged in successive generations of evolution.", [["the grooves in the hairpin", "PROBLEM", 28, 54], ["grooves", "OBSERVATION_MODIFIER", 32, 39], ["hairpin", "OBSERVATION", 47, 54], ["positively", "OBSERVATION_MODIFIER", 75, 85], ["charged", "OBSERVATION_MODIFIER", 86, 93], ["successive", "OBSERVATION_MODIFIER", 97, 107], ["generations", "OBSERVATION_MODIFIER", 108, 119], ["evolution", "OBSERVATION_MODIFIER", 123, 132]]], ["The similarity between the CCCA mutant and the wild-type hairpin (HP1) is striking and explains why this mutant gives rise to a viable virus.", [["CCCA", "GENE_OR_GENE_PRODUCT", 27, 31], ["HP1", "GENE_OR_GENE_PRODUCT", 66, 69], ["CCCA mutant", "PROTEIN", 27, 38], ["wild-type hairpin", "DNA", 47, 64], ["HP1", "PROTEIN", 66, 69], ["this mutant", "PROBLEM", 100, 111], ["a viable virus", "PROBLEM", 126, 140], ["virus", "OBSERVATION", 135, 140]]], ["In addition, a characteristic tilt of the backbone is observed upon occurrence of a protonated C C base pair.", [["C C", "CHEMICAL", 95, 98], ["C C", "SIMPLE_CHEMICAL", 95, 98], ["a protonated C C base pair", "TREATMENT", 82, 108], ["characteristic", "OBSERVATION_MODIFIER", 15, 29], ["tilt", "OBSERVATION", 30, 34], ["backbone", "ANATOMY", 42, 50]]], ["Both the positively charged major groove and the kink in the RNA backbone appear to be crucial for interactions with the viral capsid.", [["viral capsid", "PROTEIN", 121, 133], ["the kink in the RNA backbone", "PROBLEM", 45, 73], ["the viral capsid", "PROBLEM", 117, 133], ["positively", "OBSERVATION_MODIFIER", 9, 19], ["charged", "OBSERVATION", 20, 27], ["major", "OBSERVATION_MODIFIER", 28, 33], ["groove", "OBSERVATION_MODIFIER", 34, 40], ["kink", "OBSERVATION", 49, 53], ["RNA backbone", "OBSERVATION", 61, 73], ["viral capsid", "OBSERVATION", 121, 133]]], ["At neutral pH, the structure of HP1 resembles the Watson-Crick base paired mutant which explains why encapsidation only occurs under acidic conditions.Surface-Enhanced Raman Scattering to probe Hairpin Ribozyme CatalysisA.", [["HP1", "GENE_OR_GENE_PRODUCT", 32, 35], ["HP1", "PROTEIN", 32, 35], ["Watson-Crick base paired mutant", "PROTEIN", 50, 81], ["Surface", "TEST", 151, 158], ["Enhanced Raman Scattering", "TREATMENT", 159, 184], ["Hairpin Ribozyme CatalysisA", "TREATMENT", 194, 221], ["acidic conditions", "OBSERVATION", 133, 150], ["Hairpin Ribozyme", "OBSERVATION", 194, 210]]], ["Percot 1 , J. Vergne 2 , M.-C. Maurel 2 , S. Lecomte 3 1 LADIR, UMR7075, 94320 Thiais, France, 2 LBEAM, UPMC, 75005 Paris, France, 3 CBMN, UMR5248, 33607 Pessac, FranceSurface-Enhanced Raman Scattering to probe Hairpin Ribozyme CatalysisThe existence of \"RNA world\" as an early step in the history of life increases the interest for the characterization of these biomolecules.", [["Percot", "TREATMENT", 0, 6], ["UPMC", "TEST", 104, 108], ["CBMN", "TEST", 133, 137], ["UMR5248", "TEST", 139, 146], ["Pessac", "TEST", 154, 160], ["FranceSurface", "TEST", 162, 175], ["Hairpin Ribozyme Catalysis", "TREATMENT", 211, 237], ["Hairpin Ribozyme", "OBSERVATION", 211, 227]]], ["The studied hairpin ribozyme is a self-cleaving/ligating motif found in the minus strand of the satellite RNA associated with tobacco ringspot virus.", [["tobacco ringspot virus", "ORGANISM", 126, 148], ["satellite RNA", "RNA", 96, 109], ["tobacco", "SPECIES", 126, 133], ["tobacco ringspot virus", "SPECIES", 126, 148], ["The studied hairpin ribozyme", "TREATMENT", 0, 28], ["a self-cleaving/ligating motif", "TREATMENT", 32, 62], ["the satellite RNA", "PROBLEM", 92, 109], ["tobacco ringspot virus", "PROBLEM", 126, 148], ["hairpin ribozyme", "OBSERVATION", 12, 28], ["minus strand", "OBSERVATION", 76, 88], ["satellite RNA", "OBSERVATION", 96, 109], ["tobacco ringspot virus", "OBSERVATION", 126, 148]]], ["Surface-enhanced Raman spectroscopy (SERS) was successfully used to detect sub-picomole quantities of nucleic acids.", [["nucleic acids", "CHEMICAL", 102, 115], ["nucleic acids", "SIMPLE_CHEMICAL", 102, 115], ["Surface-enhanced Raman spectroscopy (SERS)", "TREATMENT", 0, 42], ["nucleic acids", "TREATMENT", 102, 115], ["nucleic acids", "OBSERVATION", 102, 115]]], ["SERS takes advantage of the strongly increased Raman signals generated by local field enhancement near metallic (typically Au and Ag) nanostructures.", [["Au", "CHEMICAL", 123, 125], ["Au", "CHEMICAL", 123, 125], ["Ag", "CHEMICAL", 130, 132], ["the strongly increased Raman signals", "PROBLEM", 24, 60], ["local field enhancement near metallic (typically Au and Ag) nanostructures", "TREATMENT", 74, 148], ["metallic", "OBSERVATION_MODIFIER", 103, 111]]], ["SERS spectra of DNA or RNA are strongly dominated by Stockes modes of adenine.", [["adenine", "CHEMICAL", 70, 77], ["adenine", "CHEMICAL", 70, 77], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["adenine", "SIMPLE_CHEMICAL", 70, 77], ["DNA or RNA", "PROBLEM", 16, 26]]], ["Through an interaction of adenyl residues with silver colloid, adenyl Raman signal is 10 6 times increased compared to Raman scattering.", [["silver", "CHEMICAL", 47, 53], ["adenyl", "CHEMICAL", 26, 32], ["silver", "CHEMICAL", 47, 53], ["adenyl", "CHEMICAL", 63, 69], ["adenyl", "SIMPLE_CHEMICAL", 26, 32], ["silver colloid", "SIMPLE_CHEMICAL", 47, 61], ["adenyl Raman", "SIMPLE_CHEMICAL", 63, 75], ["adenyl residues", "TREATMENT", 26, 41], ["silver colloid", "TREATMENT", 47, 61], ["adenyl Raman signal", "TEST", 63, 82]]], ["In controlled conditions, SERS signal is proportional to the amount of free residues adsorbed on the metal surface.", [["free residues", "PROBLEM", 71, 84], ["amount", "OBSERVATION_MODIFIER", 61, 67], ["free residues", "OBSERVATION", 71, 84], ["metal", "ANATOMY_MODIFIER", 101, 106], ["surface", "ANATOMY_MODIFIER", 107, 114]]], ["Upon RNA cleavage, residues are unpaired and free to interact with metal.", [["RNA cleavage", "OBSERVATION", 5, 17]]], ["In the present study, we proposed to follow the cleavage reaction of hairpin ribozyme (HPR85) using the SERS signal of the liberate adenyl residues.", [["adenyl", "CHEMICAL", 132, 138], ["the present study", "TEST", 3, 20], ["the cleavage reaction of hairpin ribozyme", "TREATMENT", 44, 85], ["the liberate adenyl residues", "TREATMENT", 119, 147], ["adenyl residues", "OBSERVATION", 132, 147]]], ["As the SERS signal is proportional to the adenyl residues, reactivity of HR85 was monitored by measuring the Raman intensity of the fragment liberated during the cleavage of hairpin.", [["adenyl", "CHEMICAL", 42, 48], ["HR85", "SIMPLE_CHEMICAL", 73, 77], ["HR85", "PROTEIN", 73, 77], ["the SERS signal", "TEST", 3, 18], ["the adenyl residues", "PROBLEM", 38, 57], ["the fragment", "PROBLEM", 128, 140], ["the cleavage of hairpin", "TREATMENT", 158, 181], ["adenyl residues", "OBSERVATION", 42, 57], ["fragment", "OBSERVATION", 132, 140]]], ["The results obtained were compared with the electrophoresis method performed on the same sample and similar results were obtained.P-101-RNA world - Eur Biophys J (2009) The development of arrays for biomolecular recognition for a broad range of applications in biomedical diagnostics is receiving a constantly increasing attention.", [["the electrophoresis method", "TEST", 40, 66], ["P", "TEST", 130, 131], ["biomolecular recognition", "PROBLEM", 199, 223], ["a constantly increasing attention", "TREATMENT", 297, 330]]], ["The design of efficient protein biochips, however, requires the optimization of protein immobilization protocols for improving the device sensitivity.", [["efficient protein biochips", "TREATMENT", 14, 40], ["protein immobilization protocols", "TREATMENT", 80, 112], ["the device sensitivity", "TEST", 127, 149], ["protein biochips", "OBSERVATION", 24, 40]]], ["Moreover, innovative platforms for in-vitro detection in highly diluted, small volume samples need to be developed, for which standard micro-fabrication techniques are not suitable.", [["innovative platforms", "TEST", 10, 30], ["vitro detection", "TEST", 38, 53], ["small volume samples", "PROBLEM", 73, 93], ["standard micro-fabrication techniques", "TREATMENT", 126, 163], ["small", "OBSERVATION_MODIFIER", 73, 78]]], ["Therefore, the development of nano-scale platforms for protein and antibody detection is essential.", [["protein and antibody detection", "TEST", 55, 85]]], ["We report here on a novel approach for the fabrication of multiple protein nanosensors using Atomic Force Microscopy based Nanografting and DNA-directed immobilization (DDI), which takes advantage of the specific Watson-Crick hybridization of oligonucleotide-modified proteins to surfacebound complementary oligomers.S62Using Nanografting, single-stranded DNA nano-structures with well defined local environments were fabricated on a flat surface.", [["surface", "ANATOMY", 439, 446], ["DNA", "CELLULAR_COMPONENT", 140, 143], ["DNA", "CELLULAR_COMPONENT", 356, 359], ["a novel approach", "TREATMENT", 18, 34], ["the fabrication of multiple protein nanosensors", "TREATMENT", 39, 86], ["Atomic Force Microscopy", "TEST", 93, 116], ["DNA-directed immobilization", "TREATMENT", 140, 167], ["oligonucleotide", "TREATMENT", 243, 258], ["modified proteins", "TREATMENT", 259, 276], ["single-stranded DNA nano-structures", "TREATMENT", 340, 375], ["well defined", "OBSERVATION_MODIFIER", 381, 393], ["local environments", "OBSERVATION", 394, 412], ["flat surface", "OBSERVATION_MODIFIER", 434, 446]]], ["DNA-protein conjugates were then anchored on the engineered binding sites by DDI in a single chemical operation and detected by the corresponding topographic height increase of the relevant patches.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["engineered binding sites", "DNA", 49, 73], ["DNA-protein conjugates", "TREATMENT", 0, 22], ["a single chemical operation", "TREATMENT", 84, 111]]], ["Immunological assay were used to demonstrate the biochemical functionality of the immobilized proteins, proving the specificity of biomolecular recognition of our nanodevices, in the micro-molar to pico-molar concentration range.O-108DNA accessible surface area and indirect protein-DNA recognition: study by bioinformatical approach O. P. Boryskina 1 , M. Y. Tkachenko 1 , A. V. Shestopalova 1 , M. Y. Tolstorukov 2 1 Institute of Radiophysics and Electronics NAS of Ukraine, 2 Harvard-Partners Center for Genetics and Genomics, USA Revealing the mechanisms of protein-DNA recognition is essential for understanding the regulation of many cellular processes.", [["surface area", "ANATOMY", 249, 261], ["cellular", "ANATOMY", 640, 648], ["O-108DNA", "CHEMICAL", 229, 237], ["O-108DNA", "CHEMICAL", 229, 237], ["pico-molar", "SIMPLE_CHEMICAL", 198, 208], ["DNA", "CELLULAR_COMPONENT", 283, 286], ["DNA", "CELLULAR_COMPONENT", 570, 573], ["cellular", "CELL", 640, 648], ["immobilized proteins", "PROTEIN", 82, 102], ["Immunological assay", "TEST", 0, 19], ["our nanodevices", "TREATMENT", 159, 174], ["DNA recognition", "PROBLEM", 570, 585], ["many", "OBSERVATION_MODIFIER", 635, 639], ["cellular processes", "OBSERVATION", 640, 658]]], ["There is growing evidence that recognition through sequence-specific contacts (direct readout) can be enhanced by recognition via DNA sequence-dependent deformability (indirect readout).", [["DNA", "CELLULAR_COMPONENT", 130, 133], ["DNA sequence", "TEST", 130, 142], ["dependent deformability", "PROBLEM", 143, 166]]], ["The role of changes in DNA accessible surface area (ASA) in distorted DNA configurations in complexes with proteins is not fully understood yet, even though such changes and related changes in polarity of DNA surface are among key factors of indirect readout.", [["surface area", "ANATOMY", 38, 50], ["surface", "ANATOMY", 209, 216], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["surface area", "CELLULAR_COMPONENT", 38, 50], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["DNA surface", "CELLULAR_COMPONENT", 205, 216], ["DNA accessible surface area (ASA", "TREATMENT", 23, 55], ["distorted DNA configurations in complexes with proteins", "PROBLEM", 60, 115], ["such changes", "PROBLEM", 157, 169], ["DNA surface", "PROBLEM", 205, 216], ["surface", "OBSERVATION_MODIFIER", 38, 45]]], ["To fill this gap we have developed a publicly-available Internet database of protein-DNA complexes, which integrates the data on DNA conformational parameters with information on ASA of DNA atoms in the minor and major grooves, ProtNA-ASA.", [["ProtNA-ASA", "CHEMICAL", 228, 238], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["ProtNA-ASA", "GENE_OR_GENE_PRODUCT", 228, 238], ["protein-DNA complexes", "PROTEIN", 77, 98], ["ProtNA", "PROTEIN", 228, 234], ["DNA complexes", "PROBLEM", 85, 98], ["ASA of DNA atoms", "TREATMENT", 179, 195], ["ASA", "TREATMENT", 235, 238], ["major grooves", "ANATOMY", 213, 226]]], ["The database has been used to analyze the effect of changes in DNA backbone configuration on ASA of DNA atoms in major and minor grooves.", [["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["DNA backbone configuration", "TREATMENT", 63, 89], ["ASA of DNA atoms", "TREATMENT", 93, 109], ["minor grooves", "ANATOMY", 123, 136]]], ["We observe that sugar puckering and conformation of torsion angle \u03b3 affect the accessibility of DNA atoms in both grooves to a noticeable extent.", [["sugar", "CHEMICAL", 16, 21], ["sugar", "SIMPLE_CHEMICAL", 16, 21], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["sugar puckering", "PROBLEM", 16, 31], ["torsion angle", "PROBLEM", 52, 65], ["DNA atoms", "PROBLEM", 96, 105], ["sugar puckering", "OBSERVATION", 16, 31], ["noticeable extent", "OBSERVATION_MODIFIER", 127, 144]]], ["We also report sequence specific preferences of the nucleotides for structural domains of \u03b3.", [["nucleotides", "CHEMICAL", 52, 63], ["the nucleotides", "TREATMENT", 48, 63]]], ["These results can shed new light on the mechanisms of indirect protein-DNA recognition.Modeling of the joint binding of different types of ligands with DNAA.", [["DNAA", "CHEMICAL", 152, 156], ["DNAA", "CHEMICAL", 152, 156], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNAA", "SIMPLE_CHEMICAL", 152, 156], ["DNAA", "PROTEIN", 152, 156], ["DNAA", "PROBLEM", 152, 156], ["joint", "ANATOMY", 103, 108], ["DNAA", "OBSERVATION", 152, 156]]], ["Arakelyan Biology dpt., Yerevan State University, Yerevan, ArmeniaModeling of the joint binding of different types of ligands with DNAThe influence of ligand, irreversibly binding with DNA, on the isotherm of adsorption of ligand binding with DNA reversibly has been modeled theoretically.", [["DNA", "CELLULAR_COMPONENT", 131, 134], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["Yerevan", "TREATMENT", 50, 57], ["DNA", "PROBLEM", 185, 188], ["the isotherm of adsorption of ligand binding", "TREATMENT", 193, 237], ["joint", "ANATOMY", 82, 87]]], ["The isotherm of adsorption of EtBr on DNA in presence of cis-DDPt has been considered at low concentrations of cis-DDPt and EtBr..", [["EtBr", "CHEMICAL", 30, 34], ["cis-DDPt", "CHEMICAL", 57, 65], ["cis-DDPt", "CHEMICAL", 111, 119], ["EtBr", "CHEMICAL", 124, 128], ["EtBr", "CHEMICAL", 30, 34], ["cis-DDPt", "CHEMICAL", 57, 65], ["cis-DDPt", "CHEMICAL", 111, 119], ["EtBr", "CHEMICAL", 124, 128], ["EtBr", "SIMPLE_CHEMICAL", 30, 34], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["cis-DDPt", "SIMPLE_CHEMICAL", 57, 65], ["cis-DDPt", "SIMPLE_CHEMICAL", 111, 119], ["EtBr", "SIMPLE_CHEMICAL", 124, 128], ["EtBr", "PROBLEM", 30, 34], ["cis-DDPt", "PROBLEM", 57, 65], ["EtBr", "OBSERVATION", 30, 34]]], ["The isotherm of adsorption of EtBr on DNA has linear form in Scatchard coordinates at low degrees of occupation.", [["EtBr", "CHEMICAL", 30, 34], ["EtBr", "CHEMICAL", 30, 34], ["EtBr", "SIMPLE_CHEMICAL", 30, 34], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["EtBr", "OBSERVATION", 30, 34], ["linear", "OBSERVATION_MODIFIER", 46, 52], ["low degrees", "OBSERVATION_MODIFIER", 86, 97]]], ["The comparison with experimental isotherm permits to estimate the parameters of EtBr binding with DNA.", [["EtBr", "CHEMICAL", 80, 84], ["EtBr", "CHEMICAL", 80, 84], ["EtBr", "SIMPLE_CHEMICAL", 80, 84], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["DNA", "PROBLEM", 98, 101]]], ["With taking into account the pseudo-ring structures formation with partially molten regions we consider two types of binding regions, linear and ring at low degrees of occupation.", [["binding regions", "PROTEIN", 117, 132], ["partially molten regions", "PROBLEM", 67, 91], ["binding regions", "PROBLEM", 117, 132], ["ring structures", "OBSERVATION", 36, 51], ["partially molten", "OBSERVATION", 67, 83], ["two types", "OBSERVATION_MODIFIER", 104, 113], ["binding regions", "OBSERVATION", 117, 132], ["linear", "OBSERVATION_MODIFIER", 134, 140], ["ring", "OBSERVATION_MODIFIER", 145, 149], ["low degrees", "OBSERVATION_MODIFIER", 153, 164]]], ["The isotherm of adsorption of EtBr on DNA and also variation of the number of bounded EtBr molecules are calculated with taking into account these two types of binding regions.", [["EtBr", "CHEMICAL", 30, 34], ["EtBr", "CHEMICAL", 86, 90], ["EtBr", "CHEMICAL", 30, 34], ["EtBr", "CHEMICAL", 86, 90], ["EtBr", "SIMPLE_CHEMICAL", 30, 34], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["EtBr molecules", "SIMPLE_CHEMICAL", 86, 100], ["EtBr molecules", "PROTEIN", 86, 100], ["binding regions", "PROTEIN", 160, 175], ["EtBr", "PROBLEM", 30, 34], ["DNA", "TREATMENT", 38, 41], ["bounded EtBr molecules", "PROBLEM", 78, 100], ["adsorption", "OBSERVATION_MODIFIER", 16, 26], ["EtBr", "OBSERVATION", 30, 34], ["EtBr molecules", "OBSERVATION", 86, 100], ["binding regions", "OBSERVATION", 160, 175]]], ["It was shown that at low concentrations cis-DDP, bounding with DNA, changes the isotherm of ligands adsorption.", [["cis-", "CHEMICAL", 40, 44], ["DDP", "CHEMICAL", 44, 47], ["cis-DDP", "CHEMICAL", 40, 47], ["cis-DDP", "SIMPLE_CHEMICAL", 40, 47], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["the isotherm of ligands adsorption", "TREATMENT", 76, 110]]], ["The linear in Scathcard coordinates isotherm of adsorption transforms into non-linear isotherm.", [["linear", "OBSERVATION_MODIFIER", 4, 10], ["isotherm", "OBSERVATION_MODIFIER", 36, 44], ["non-linear isotherm", "OBSERVATION", 75, 94]]], ["The degree of transformation depends on the fraction of DNA in the ring regions, on the ratio between number of EtBr binding cites in the ring and linear regions, and also on the binding constants for these regions.", [["EtBr", "CHEMICAL", 112, 116], ["EtBr", "CHEMICAL", 112, 116], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["EtBr", "SIMPLE_CHEMICAL", 112, 116], ["ring and linear regions", "PROTEIN", 138, 161], ["transformation", "PROBLEM", 14, 28], ["EtBr binding cites", "PROBLEM", 112, 130], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["transformation", "OBSERVATION", 14, 28], ["fraction", "OBSERVATION_MODIFIER", 44, 52], ["DNA", "OBSERVATION", 56, 59], ["ring", "ANATOMY_MODIFIER", 67, 71], ["regions", "ANATOMY_MODIFIER", 72, 79], ["EtBr binding cites", "OBSERVATION", 112, 130], ["ring", "ANATOMY_MODIFIER", 138, 142], ["linear", "OBSERVATION_MODIFIER", 147, 153], ["regions", "OBSERVATION_MODIFIER", 154, 161]]], ["It was shown that low concentrations of cis-DDP affect the dependence of dispersion on the concentration of ligands, changing both the magnitude of maximum and its position.P-106Tunable nanoconfinement structures for DNA manipulation E. Angeli, L. Repetto, G. Firpo, C. Boragno, U. Valbusa NanoMed Labs, Advanced Biotechnology Center and Physics Department, University of Genoa, Italy Nanostructures, such as nanochannels [1] or nanoslits [2] , have been successfully used to confine and stretch DNA molecules, offering interesting opportunities of investigation on conformational changes induced by confinement, physical and biological properties, etc. The integration of these nanostructures on lab-on-chip systems has shown their great potential for applications such as DNA sieving or single molecule manipulation [3] , [4] .", [["cis-DDP", "CHEMICAL", 40, 47], ["cis-DDP", "CHEMICAL", 40, 47], ["cis-DDP", "SIMPLE_CHEMICAL", 40, 47], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["nanoslits [2]", "SIMPLE_CHEMICAL", 429, 442], ["DNA", "CELLULAR_COMPONENT", 496, 499], ["DNA", "CELLULAR_COMPONENT", 774, 777], ["P", "DNA", 173, 174], ["stretch DNA molecules", "PROTEIN", 488, 509], ["low concentrations of cis-DDP", "PROBLEM", 18, 47], ["the concentration of ligands", "TREATMENT", 87, 115], ["P", "TEST", 173, 174], ["DNA sieving", "TREATMENT", 774, 785], ["single molecule manipulation", "TREATMENT", 789, 817], ["low concentrations", "OBSERVATION_MODIFIER", 18, 36], ["dependence", "OBSERVATION_MODIFIER", 59, 69], ["dispersion", "OBSERVATION_MODIFIER", 73, 83], ["magnitude", "OBSERVATION_MODIFIER", 135, 144], ["maximum", "OBSERVATION_MODIFIER", 148, 155], ["position", "OBSERVATION_MODIFIER", 164, 172]]], ["Arrays of nanochannels fabricated, using a Focused Ion Beam (FIB) on a silicon master, are replicated using elastomeric materials, such as poly(dimethylsiloxane) (PDMS), and soft-lithography techniques.P-106The cross-section of these flexible polymeric nanoconfinement structures can be reversibly and dynamically tuned, in order to vary biomolecules transport characteristics and confinement conditions of trapped DNA molecules.P-106Moreover, these nanochannels, with tunable cross-section, are used to study and exploit the sieving mechanism of \"entropic recoil\" [5] for the separation of long DNA chains.", [["poly(dimethylsiloxane", "CHEMICAL", 139, 160], ["silicon", "CHEMICAL", 71, 78], ["poly(dimethylsiloxane)", "CHEMICAL", 139, 161], ["PDMS", "CHEMICAL", 163, 167], ["poly(dimethylsiloxane)", "SIMPLE_CHEMICAL", 139, 161], ["DNA", "CELLULAR_COMPONENT", 415, 418], ["DNA", "CELLULAR_COMPONENT", 596, 599], ["trapped DNA molecules", "PROTEIN", 407, 428], ["long DNA chains", "PROTEIN", 591, 606], ["a Focused Ion Beam (FIB", "TREATMENT", 41, 64], ["a silicon master", "TREATMENT", 69, 85], ["elastomeric materials", "TREATMENT", 108, 129], ["poly(dimethylsiloxane) (PDMS)", "TREATMENT", 139, 168], ["soft-lithography techniques", "TREATMENT", 174, 201], ["P", "TEST", 202, 203], ["these flexible polymeric nanoconfinement structures", "TREATMENT", 228, 279], ["trapped DNA molecules", "PROBLEM", 407, 428], ["P", "TEST", 429, 430], ["tunable cross-section", "TREATMENT", 469, 490], ["\"entropic recoil\"", "TREATMENT", 547, 564], ["the separation of long DNA chains", "TREATMENT", 573, 606], ["nanochannels fabricated", "OBSERVATION", 10, 33], ["trapped DNA molecules", "OBSERVATION", 407, 428]]], ["[2] Jo K, et al., (2007 ) PNAS, 104, 8: 2673 -2678 .", [["PNAS", "TEST", 26, 30]]], ["The nucleocapsid protein NCp7 of HIV-1 is characterized by two conserved zinc fingers and plays crucial roles in the virus, through its binding to nucleic acids.", [["nucleic acids", "CHEMICAL", 147, 160], ["zinc", "CHEMICAL", 73, 77], ["NCp7", "GENE_OR_GENE_PRODUCT", 25, 29], ["HIV-1", "ORGANISM", 33, 38], ["nucleic acids", "SIMPLE_CHEMICAL", 147, 160], ["nucleocapsid protein", "PROTEIN", 4, 24], ["NCp7", "PROTEIN", 25, 29], ["zinc fingers", "PROTEIN", 73, 85], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["The nucleocapsid protein NCp7", "TEST", 0, 29], ["HIV", "TEST", 33, 36], ["two conserved zinc fingers", "PROBLEM", 59, 85], ["the virus", "PROBLEM", 113, 122], ["nucleic acids", "TREATMENT", 147, 160], ["protein NCp7", "OBSERVATION", 17, 29], ["zinc fingers", "OBSERVATION", 73, 85]]], ["NCp7 is required for efficient proviral DNA synthesis, by promoting the initiation of reverse transcription and the two obligatory strand transfers.", [["NCp7", "GENE_OR_GENE_PRODUCT", 0, 4], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["NCp7", "PROTEIN", 0, 4], ["NCp7", "PROBLEM", 0, 4], ["efficient proviral DNA synthesis", "TREATMENT", 21, 53], ["reverse transcription", "TREATMENT", 86, 107]]], ["Using fluorescence techniques as well as FCS and NMR, we investigated the chaperone properties of NCp7 on the primer binding sites (PBS) and transactivation response elements (TAR) sequences involved in the two obligatory strand transfers.", [["NCp7", "GENE_OR_GENE_PRODUCT", 98, 102], ["NCp7", "PROTEIN", 98, 102], ["primer binding sites", "DNA", 110, 130], ["transactivation response elements", "DNA", 141, 174], ["TAR", "DNA", 176, 179], ["fluorescence techniques", "TEST", 6, 29], ["NMR", "TEST", 49, 52], ["NCp7", "TREATMENT", 98, 102], ["transactivation response elements (TAR) sequences", "TREATMENT", 141, 190]]], ["We showed that NCp7 binds mainly to the (-)PBS loop, which results in an extension of the loop and a destabilization of the upper base pair of the stem.", [["stem", "ANATOMY", 147, 151], ["NCp7", "GENE_OR_GENE_PRODUCT", 15, 19], ["stem", "TISSUE", 147, 151], ["NCp7", "PROTEIN", 15, 19], ["NCp7 binds", "PROBLEM", 15, 25], ["an extension of the loop", "PROBLEM", 70, 94], ["a destabilization of the upper base pair of the stem", "TREATMENT", 99, 151], ["loop", "OBSERVATION", 90, 94], ["destabilization", "OBSERVATION", 101, 116], ["upper", "ANATOMY_MODIFIER", 124, 129], ["base", "ANATOMY_MODIFIER", 130, 134], ["pair", "ANATOMY_MODIFIER", 135, 139], ["stem", "ANATOMY", 147, 151]]], ["These structural changes chaperone a kissing complex with the complementary (+)PBS loop and its further conversion into an extended duplex.", [["kissing complex", "PROTEIN", 37, 52], ["the complementary (+)PBS loop", "TREATMENT", 58, 87], ["an extended duplex", "TEST", 120, 138]]], ["In contrast, the NCp7-promoted annealing of cTAR-TAR results from the destabilization of the bottom of cTAR stem, which favors the invasion of the TAR stem.", [["cTAR stem", "ANATOMY", 103, 112], ["stem", "ANATOMY", 151, 155], ["NCp7", "GENE_OR_GENE_PRODUCT", 17, 21], ["cTAR", "GENE_OR_GENE_PRODUCT", 44, 48], ["NCp7", "PROTEIN", 17, 21], ["cTAR", "PROTEIN", 44, 48], ["TAR", "DNA", 49, 52], ["cTAR stem", "CELL_LINE", 103, 112], ["TAR stem", "DNA", 147, 155], ["the NCp7", "TEST", 13, 21], ["cTAR", "TEST", 44, 48], ["the invasion of the TAR stem", "PROBLEM", 127, 155], ["destabilization", "OBSERVATION", 70, 85], ["bottom", "ANATOMY_MODIFIER", 93, 99], ["cTAR stem", "ANATOMY", 103, 112], ["invasion", "OBSERVATION_MODIFIER", 131, 139], ["TAR stem", "OBSERVATION", 147, 155]]], ["By developing new fluorescence methodologies to site-specifically characterize these interactions, we further showed that NCp7 slows down the ps to ns conformational fluctuations of its nucleic acid targets and freezes the local mobility of the bases contacted by the zinc fingers.O-112Exploring DNA orientation in flow E. L. Gilroy, M. R. Hicks, A. Rodger Department of Chemistry, University of Warwick, UK DNA is one of the most important biomolecules.", [["nucleic acid", "CHEMICAL", 186, 198], ["zinc", "CHEMICAL", 268, 272], ["NCp7", "GENE_OR_GENE_PRODUCT", 122, 126], ["DNA", "CELLULAR_COMPONENT", 296, 299], ["DNA", "CELLULAR_COMPONENT", 408, 411], ["NCp7", "PROTEIN", 122, 126], ["zinc fingers", "PROTEIN", 268, 280], ["new fluorescence methodologies to site", "PROBLEM", 14, 52], ["NCp7", "TEST", 122, 126], ["its nucleic acid targets", "PROBLEM", 182, 206], ["local", "OBSERVATION_MODIFIER", 223, 228], ["mobility", "OBSERVATION_MODIFIER", 229, 237], ["bases", "ANATOMY_MODIFIER", 245, 250], ["zinc fingers", "ANATOMY", 268, 280]]], ["In order to undertake its biological role the DNA needs to fold and unfold for which its structure and flexibility are crucially important.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["the DNA", "PROBLEM", 42, 49]]], ["We have studied the characteristics of DNA in flow to probe its structure.", [["DNA", "CELLULAR_COMPONENT", 39, 42], ["DNA", "PROBLEM", 39, 42], ["DNA", "OBSERVATION", 39, 42], ["flow", "OBSERVATION", 46, 50]]], ["Flow aligned Linear Dichroism (LD) is a technique that uses light polarised parallel and perpendicular to an orientated sample.", [["sample", "ANATOMY", 120, 126], ["a technique", "TREATMENT", 38, 49], ["Linear", "OBSERVATION_MODIFIER", 13, 19], ["Dichroism", "OBSERVATION_MODIFIER", 20, 29]]], ["It can be used to measure how aligned a sample is, and the orientation of any interacting molecules.", [["interacting molecules", "PROTEIN", 78, 99], ["any interacting molecules", "PROBLEM", 74, 99]]], ["To create this alignment, the sample is placed between two concentric cylinders where one is spun to create a shear flow.", [["two concentric cylinders", "TREATMENT", 55, 79], ["a shear flow", "TEST", 108, 120], ["shear flow", "OBSERVATION", 110, 120]]], ["The longer and more rigid the molecule is the better the orientation and the signal.", [["The longer and more rigid the molecule", "PROBLEM", 0, 38], ["more rigid", "OBSERVATION_MODIFIER", 15, 25], ["molecule", "OBSERVATION", 30, 38]]], ["There are many methods to measure the viscosity of a sample of DNA at varying temperatures.", [["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA", "PROBLEM", 63, 66]]], ["These include viscometer, rheometer and dynamic light scattering.", [["viscometer", "TEST", 14, 24]]], ["The effects temperature has on viscosity and the sample itself need also to be considered.", [["The effects temperature", "PROBLEM", 0, 23]]], ["The findings of all these studies have been reported and show the significance that viscosity and temperature have on DNA LD measurements.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["all these studies", "TEST", 16, 33], ["DNA LD measurements", "TEST", 118, 137]]], ["Possible applications of using LD to study DNA have also been discussed, showing the importance of the use of LD and in the results shown.Description of non-specific DNA/protein interaction and facilitated diffusionA.-M. Florescu, M. Joyeux Laboratoire de Spectrom\u00e9trie Physique, Universit\u00e9 Joseph Fourier Grenoble 1, France We present a dynamical model for simulating non-specific DNA protein interactions, which is based on the \"beadspring\" model for DNA with elastic, bending and Debye-H\u00fcckel electrostatic interactions, and where the protein interacts with the DNA chain through electrostatic and excluded-volume forces.", [["DNA", "CELLULAR_COMPONENT", 43, 46], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["DNA", "CELLULAR_COMPONENT", 382, 385], ["DNA", "CELLULAR_COMPONENT", 453, 456], ["DNA", "CELLULAR_COMPONENT", 565, 568], ["DNA chain", "PROTEIN", 565, 574], ["non-specific DNA/protein interaction", "PROBLEM", 153, 189], ["simulating non-specific DNA protein interactions", "PROBLEM", 358, 406], ["DNA", "PROBLEM", 453, 456], ["electrostatic interactions", "OBSERVATION", 496, 522], ["volume forces", "OBSERVATION", 610, 623]]], ["We study the properties of this model using a Brownian dynamics algorithm that takes hydrodynamic interactions into account and obtain results that partially agree with experiments and predictions of kinetic models.", [["this model", "TREATMENT", 27, 37], ["a Brownian dynamics algorithm", "TREATMENT", 44, 73]]], ["For example, we show that the protein samples DNA by a combination of three-dimensional diffusion in the solvent and one-dimensional sliding along the DNA chain.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["DNA chain", "PROTEIN", 151, 160], ["the protein samples DNA", "PROBLEM", 26, 49], ["the solvent", "TREATMENT", 101, 112], ["one-dimensional sliding along the DNA chain", "TREATMENT", 117, 160], ["DNA", "ANATOMY", 151, 154], ["chain", "ANATOMY_MODIFIER", 155, 160]]], ["This model evidences the presence, in a certain range of values of the effective protein charge, of facilitated diffusion, i.e. a combination of the two types of diffusion that leads to faster than 3-dimensional diffusion sampling of DNA.", [["DNA", "CELLULAR_COMPONENT", 234, 237], ["the effective protein charge", "PROBLEM", 67, 95], ["facilitated diffusion", "PROBLEM", 100, 121], ["the two types of diffusion", "PROBLEM", 145, 171], ["DNA", "PROBLEM", 234, 237], ["protein charge", "OBSERVATION", 81, 95], ["faster", "OBSERVATION_MODIFIER", 186, 192]]], ["Moreover, the analysis of single sliding events shows that the number of base pairs visited during sliding is comparable to those deduced from single molecule experiments.", [["the analysis", "TEST", 10, 22], ["single sliding events", "PROBLEM", 26, 47]]], ["In contrast to kinetic models, which predict an increase of the number of different base pairs visited by the protein proportional to the square root of time, our model however suggests that this number increases linearly with time until it reaches a value that is close to the total number of DNA base pairs in the cell (published in J. Chem.", [["cell", "ANATOMY", 316, 320], ["DNA", "CELLULAR_COMPONENT", 294, 297], ["cell", "CELL", 316, 320], ["increase", "OBSERVATION_MODIFIER", 48, 56], ["cell", "ANATOMY", 316, 320]]], ["130, 015103 (2009)).P-110Use of MD simulation to identify the critical radiation-induced lesions of a DNA binding protein N. Chalabi, S. Goffinont, N. Garnier, D. Genest, 45071 Orl\u00e9ans cedex 2, France A key step in the regulation of gene expression, DNA structuring and DNA repair is the binding of some proteins to specific DNA sequences.", [["lesions", "ANATOMY", 89, 96], ["lesions", "PATHOLOGICAL_FORMATION", 89, 96], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["45071 Orl\u00e9ans cedex 2", "CELL", 171, 192], ["DNA", "CELLULAR_COMPONENT", 250, 253], ["DNA", "CELLULAR_COMPONENT", 270, 273], ["DNA", "CELLULAR_COMPONENT", 325, 328], ["P", "DNA", 20, 21], ["DNA binding protein", "PROTEIN", 102, 121], ["DNA sequences", "DNA", 325, 338], ["induced lesions", "PROBLEM", 81, 96], ["gene expression", "TREATMENT", 233, 248], ["DNA structuring", "TREATMENT", 250, 265], ["DNA repair", "TREATMENT", 270, 280], ["specific DNA sequences", "TEST", 316, 338], ["lesions", "OBSERVATION", 89, 96], ["DNA repair", "OBSERVATION", 270, 280]]], ["We have shown previously that ionizing radiation destabilizes such DNA-protein complexes mainly through damage to the protein.", [["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA-protein complexes", "PROTEIN", 67, 88], ["ionizing radiation", "TREATMENT", 30, 48], ["such DNA-protein complexes", "PROBLEM", 62, 88]]], ["For the typical lactose operator -repressor system we have shown by fluorescence measurement and mass spectrometry that upon irradiation, all the four tyrosine residues of the DNA binding domain (called headpiece) are oxidized into 3,4dihydroxyphenylalanine (DOPA).", [["lactose", "CHEMICAL", 16, 23], ["tyrosine", "CHEMICAL", 151, 159], ["3,4dihydroxyphenylalanine", "CHEMICAL", 232, 257], ["DOPA", "CHEMICAL", 259, 263], ["lactose", "CHEMICAL", 16, 23], ["tyrosine", "CHEMICAL", 151, 159], ["3,4dihydroxyphenylalanine", "CHEMICAL", 232, 257], ["DOPA", "CHEMICAL", 259, 263], ["lactose", "SIMPLE_CHEMICAL", 16, 23], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["3,4dihydroxyphenylalanine", "SIMPLE_CHEMICAL", 232, 257], ["DOPA", "SIMPLE_CHEMICAL", 259, 263], ["DNA binding domain", "PROTEIN", 176, 194], ["headpiece", "PROTEIN", 203, 212], ["fluorescence measurement", "TEST", 68, 92], ["mass spectrometry", "PROBLEM", 97, 114], ["irradiation", "TREATMENT", 125, 136], ["dihydroxyphenylalanine (DOPA", "TREATMENT", 235, 263]]], ["A circular dichroism study revealed a global conformational change and the destabilization of the headpiece.", [["headpiece", "PROTEIN", 98, 107], ["A circular dichroism study", "TEST", 0, 26], ["a global conformational change", "PROBLEM", 36, 66], ["global", "OBSERVATION_MODIFIER", 38, 44], ["conformational change", "OBSERVATION", 45, 66]]], ["To decide which lesion is critical for the induction of these effects, a molecular dynamics simulation study was undertaken in parallel with a site-directed mutagenesis one.", [["lesion", "ANATOMY", 16, 22], ["a molecular dynamics simulation study", "TEST", 71, 108], ["a site-directed mutagenesis", "TREATMENT", 141, 168], ["lesion", "OBSERVATION", 16, 22]]], ["Each tyrosine residue of the headpiece was replaced by another amino-acid that mimics the damaged tyrosine.", [["tyrosine", "CHEMICAL", 5, 13], ["amino-acid", "CHEMICAL", 63, 73], ["tyrosine", "CHEMICAL", 98, 106], ["tyrosine", "CHEMICAL", 5, 13], ["amino-acid", "CHEMICAL", 63, 73], ["tyrosine", "CHEMICAL", 98, 106], ["tyrosine", "AMINO_ACID", 5, 13], ["headpiece", "CELLULAR_COMPONENT", 29, 38], ["amino-acid", "SIMPLE_CHEMICAL", 63, 73], ["tyrosine", "AMINO_ACID", 98, 106], ["headpiece", "PROTEIN", 29, 38], ["Each tyrosine residue of the headpiece", "TREATMENT", 0, 38], ["another amino-acid", "TREATMENT", 55, 73], ["damaged tyrosine", "OBSERVATION", 90, 106]]], ["The most common amino-acid used in site-directed mutagenesis being alanine, we have replaced one tyrosine (7, 12, 17 or 47) in the NMR-based structure of the headpiece from PDB databank (1LQC) by an alanine.", [["amino-acid", "CHEMICAL", 16, 26], ["alanine", "CHEMICAL", 67, 74], ["tyrosine", "CHEMICAL", 97, 105], ["alanine", "CHEMICAL", 199, 206], ["amino-acid", "CHEMICAL", 16, 26], ["alanine", "CHEMICAL", 67, 74], ["tyrosine", "CHEMICAL", 97, 105], ["alanine", "CHEMICAL", 199, 206], ["amino-acid", "SIMPLE_CHEMICAL", 16, 26], ["alanine", "AMINO_ACID", 67, 74], ["tyrosine", "AMINO_ACID", 97, 105], ["alanine", "AMINO_ACID", 199, 206], ["headpiece", "PROTEIN", 158, 167], ["PDB databank", "PROTEIN", 173, 185], ["The most common amino-acid", "TREATMENT", 0, 26], ["alanine", "TREATMENT", 67, 74], ["one tyrosine", "TREATMENT", 93, 105], ["an alanine", "TEST", 196, 206]]], ["The conformational stability of each Tyr\u2192Ala mutant has been studied by Molecular Dynamics simulation (MD) and compared to that of the native sequence and of the different Tyr\u2192DOPA mutants.", [["Tyr\u2192Ala", "CHEMICAL", 37, 44], ["Ala", "CHEMICAL", 41, 44], ["Tyr\u2192", "GENE_OR_GENE_PRODUCT", 37, 41], ["Tyr\u2192DOPA", "GENE_OR_GENE_PRODUCT", 172, 180], ["Tyr\u2192Ala mutant", "PROTEIN", 37, 51], ["Tyr\u2192DOPA mutants", "PROTEIN", 172, 188], ["stability", "OBSERVATION_MODIFIER", 19, 28]]], ["The mammalian high mobility group protein AT-hook 2 (HMGA2) is a nuclear protein associated with mensenchymal cell development and differentiation.", [["nuclear", "ANATOMY", 65, 72], ["mensenchymal cell", "ANATOMY", 97, 114], ["high mobility group protein AT-hook 2", "GENE_OR_GENE_PRODUCT", 14, 51], ["HMGA2", "GENE_OR_GENE_PRODUCT", 53, 58], ["mensenchymal cell", "CELL", 97, 114], ["mammalian high mobility group protein AT-hook 2", "PROTEIN", 4, 51], ["HMGA2", "PROTEIN", 53, 58], ["nuclear protein", "PROTEIN", 65, 80], ["a nuclear protein", "PROBLEM", 63, 80], ["mensenchymal cell development", "PROBLEM", 97, 126], ["high mobility", "OBSERVATION_MODIFIER", 14, 27], ["mensenchymal cell", "OBSERVATION", 97, 114]]], ["Disruption of its normal expression pattern is directly linked to oncogenesis and obesity.", [["obesity", "DISEASE", 82, 89], ["obesity", "PROBLEM", 82, 89], ["normal expression", "OBSERVATION", 18, 35], ["obesity", "OBSERVATION", 82, 89]]], ["Our laboratory has utilized a variety of biochemical and biophysical methods to investigate the molecular mechanisms of HMGA2 recognizing AT-rich DNA.", [["HMGA2", "GENE_OR_GENE_PRODUCT", 120, 125], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["HMGA2", "PROTEIN", 120, 125], ["AT-rich DNA", "DNA", 138, 149], ["biochemical and biophysical methods", "TREATMENT", 41, 76], ["HMGA2", "PROBLEM", 120, 125], ["HMGA2", "OBSERVATION", 120, 125]]], ["Using a PCR-based SELEX procedure, we discovered that HMGA2 is a sequence-specific DNA-binding protein and recognizes the following two sequences: 5'-ATATTCGCGAWWATT-3' and 5'ATATTGCGCAWWATT-3', where W is A or T. Using a double-label EMSA assay, we found that HMGA2 binds to AT-rich DNA as a monomer.", [["HMGA2", "GENE_OR_GENE_PRODUCT", 54, 59], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["HMGA2", "GENE_OR_GENE_PRODUCT", 261, 266], ["DNA", "CELLULAR_COMPONENT", 284, 287], ["HMGA2", "DNA", 54, 59], ["DNA-binding protein", "PROTEIN", 83, 102], ["HMGA2", "PROTEIN", 261, 266], ["AT-rich DNA", "DNA", 276, 287], ["a PCR-based SELEX procedure", "TREATMENT", 6, 33], ["HMGA2", "PROBLEM", 54, 59], ["a sequence", "TEST", 63, 73], ["ATATTCGCGAWWATT", "TEST", 150, 165], ["a double-label EMSA assay", "TEST", 220, 245], ["HMGA2 binds", "PROBLEM", 261, 272], ["HMGA2", "OBSERVATION", 54, 59]]], ["Using isothermal-titrationcalorimetry, we demonstrated that HMGA2 binds to AT-rich DNA with very high binding affinity whereby the binding of HMGA2 to A-tracts is entropy-driven and to alternate AT sequences is enthalpy-driven.", [["HMGA2", "GENE_OR_GENE_PRODUCT", 60, 65], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["HMGA2", "GENE_OR_GENE_PRODUCT", 142, 147], ["A-tracts", "GENE_OR_GENE_PRODUCT", 151, 159], ["HMGA2", "PROTEIN", 60, 65], ["AT-rich DNA", "DNA", 75, 86], ["HMGA2", "PROTEIN", 142, 147], ["A-tracts", "DNA", 151, 159], ["AT sequences", "DNA", 195, 207], ["isothermal-titrationcalorimetry", "TREATMENT", 6, 37], ["HMGA2 binds", "PROBLEM", 60, 71], ["very high binding affinity", "PROBLEM", 92, 118], ["HMGA2", "PROBLEM", 142, 147], ["entropy", "TEST", 163, 170], ["HMGA2", "OBSERVATION", 142, 147]]], ["This is a typical example of enthalpy-entropy compensation in which the hydration difference between HMGA2-DNA complexes is a main reason for the compensation.", [["HMGA2", "GENE_OR_GENE_PRODUCT", 101, 106], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["HMGA2", "PROTEIN", 101, 106], ["DNA complexes", "PROTEIN", 107, 120], ["enthalpy-entropy compensation", "TREATMENT", 29, 58], ["the hydration difference between HMGA2", "PROBLEM", 68, 106], ["entropy compensation", "OBSERVATION", 38, 58]]], ["Interestingly, the binding of HMGA2 to different AT-rich sequences is accompanied with a large negative heat capacity change indicating an important role of solvent displacement and charge-charge interaction in the linked folding/binding processes.O-116Partition of Gibb\u00b4s free energy of drug-DNA complexation We report a computation methodology, which leads to the ability to partition the Gibb's free energy for the complexation reaction of aromatic drug molecules with DNA.", [["O-116Partition", "CHEMICAL", 248, 262], ["O-116Partition", "CHEMICAL", 248, 262], ["HMGA2", "GENE_OR_GENE_PRODUCT", 30, 35], ["DNA", "CELLULAR_COMPONENT", 293, 296], ["DNA", "CELLULAR_COMPONENT", 472, 475], ["HMGA2", "PROTEIN", 30, 35], ["AT-rich sequences", "DNA", 49, 66], ["Gibb", "PROTEIN", 391, 395], ["a large negative heat capacity change", "PROBLEM", 87, 124], ["solvent displacement", "PROBLEM", 157, 177], ["the linked folding/binding processes", "PROBLEM", 211, 247], ["drug-DNA complexation", "PROBLEM", 288, 309], ["a computation methodology", "TEST", 320, 345], ["the complexation reaction", "PROBLEM", 414, 439], ["DNA", "PROBLEM", 472, 475], ["large", "OBSERVATION_MODIFIER", 89, 94], ["negative", "OBSERVATION", 95, 103], ["heat capacity", "OBSERVATION", 104, 117], ["solvent displacement", "OBSERVATION", 157, 177], ["aromatic drug molecules", "OBSERVATION", 443, 466]]], ["Using this approach it is now possible to calculate the absolute values of the energy contributions of various physical factors to the DNA binding process, whose summation gives a value that is reasonably close to the experimentallymeasured Gibb's free energy of binding.", [["DNA", "CELLULAR_COMPONENT", 135, 138], ["physical factors", "PROTEIN", 111, 127], ["Gibb", "PROTEIN", 241, 245], ["this approach", "TREATMENT", 6, 19], ["various physical factors", "PROBLEM", 103, 127], ["the DNA binding process", "PROBLEM", 131, 154]]], ["Application of the methodology to binding of various aromatic drugs with DNA provides an answer to the question 'What forces are the main contributors to the stabilization of aromatic ligand-DNA complexes' ?", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["DNA", "CELLULAR_COMPONENT", 191, 194], ["aromatic ligand-DNA complexes", "PROTEIN", 175, 204], ["various aromatic drugs", "TREATMENT", 45, 67]]], ["We report the effects of 22 kHz ultrasound irradiation of double-stranded DNA solutions under conditions of transient cavitation.", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["22 kHz ultrasound irradiation", "TREATMENT", 25, 54], ["double-stranded DNA solutions", "TREATMENT", 58, 87], ["transient cavitation", "PROBLEM", 108, 128], ["transient", "OBSERVATION_MODIFIER", 108, 117], ["cavitation", "OBSERVATION", 118, 128]]], ["A new method was developed for studying these effects which is based on combination of two procedures: ultrasound irradiation of the solutions of double-stranded DNA fragments and subsequent analysis of the high resolution denaturing gel electrophoresis data.", [["DNA", "CELLULAR_COMPONENT", 162, 165], ["double-stranded DNA fragments", "DNA", 146, 175], ["A new method", "TREATMENT", 0, 12], ["two procedures", "TREATMENT", 87, 101], ["ultrasound irradiation", "TREATMENT", 103, 125], ["the solutions", "TREATMENT", 129, 142], ["double-stranded DNA fragments", "TREATMENT", 146, 175], ["subsequent analysis", "TEST", 180, 199], ["the high resolution denaturing gel electrophoresis data", "TEST", 203, 258], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["Statistical treatment of the data on the mobility of 3'-end-labelled restriction fragments with known sequence allowed us to discover the phenomenon of sequence specific ultrasonic cleavage of DNA.", [["DNA", "CELLULAR_COMPONENT", 193, 196], ["3'-end-labelled restriction fragments", "DNA", 53, 90], ["the data", "TEST", 25, 33], ["3'-end-labelled restriction fragments", "TREATMENT", 53, 90], ["DNA", "PROBLEM", 193, 196]]], ["Our analysis results in the following conclusions: 1) all steps with 5'-ward cytosine [5'-d(CpN)-3'] have significantly higher cleavage rates than others; the intensity of cleavage diminishes in the order CpG > CpA \u2248 CpT > CpC; 2) the cleavage rates of all 16 steps depend on the type of flanking base pairs; 3) the cleavage rates of the complementary base pair steps are not identical.", [["cytosine", "CHEMICAL", 77, 85], ["cytosine", "CHEMICAL", 77, 85], ["CpG", "CHEMICAL", 205, 208], ["CpA", "CHEMICAL", 211, 214], ["CpC", "CHEMICAL", 223, 226], ["5'-d(CpN)-3']", "SIMPLE_CHEMICAL", 87, 100], ["CpT", "PROTEIN", 217, 220], ["CpC", "PROTEIN", 223, 226], ["Our analysis", "TEST", 0, 12], ["ward cytosine", "TREATMENT", 72, 85], ["d(CpN)", "TREATMENT", 90, 96], ["significantly higher cleavage rates", "PROBLEM", 106, 141], ["cleavage diminishes", "PROBLEM", 172, 191], ["CpT > CpC", "TREATMENT", 217, 226], ["the cleavage rates", "TREATMENT", 231, 249], ["flanking base pairs", "PROBLEM", 288, 307], ["the cleavage rates", "TREATMENT", 312, 330]]], ["Thus, subtle sequence specific conformational and physical-chemical variations modulate the reaction of sugar-phosphate single bonds on the ultrasound exposure.P-114A theory of the mechanisms on the simultaneous binding of two aromatic drugs to DNA It has long been recognized that certain combinations of DNA-binding aromatic drugs, X +Y, lead to synergistic biological effects.", [["sugar-phosphate", "CHEMICAL", 104, 119], ["sugar-phosphate", "CHEMICAL", 104, 119], ["sugar-phosphate single bonds", "SIMPLE_CHEMICAL", 104, 132], ["DNA", "CELLULAR_COMPONENT", 245, 248], ["DNA", "CELLULAR_COMPONENT", 306, 309], ["X +Y", "SIMPLE_CHEMICAL", 334, 338], ["subtle sequence specific conformational and physical-chemical variations", "PROBLEM", 6, 78], ["the ultrasound exposure", "TEST", 136, 159], ["DNA", "PROBLEM", 306, 309], ["binding aromatic drugs", "TREATMENT", 310, 332], ["aromatic drugs", "OBSERVATION", 318, 332]]], ["Considering X as a basic ligand and Y as an added ligand, the change of the integral biological response of X in the presence of Y has been interpreted in terms of two mechanisms: the interceptor and protector action of Y on X. This mechanisms have been characterized by two criteria, R D and A D , reflecting the removal of X from DNA by Y (Biophys.", [["R D", "SIMPLE_CHEMICAL", 285, 288], ["A D", "SIMPLE_CHEMICAL", 293, 296], ["DNA", "CELLULAR_COMPONENT", 332, 335], ["the interceptor and protector action", "TREATMENT", 180, 216], ["the removal", "TREATMENT", 310, 321]]], ["Chem., 2008, Vol.132, pages 148-158 ) .", [["Chem.", "TEST", 0, 5]]], ["In this work we develop the theory of the interceptor-protector action of a mixture of two biologically-active DNA-binding aromatic drugs.", [["DNA", "CELLULAR_COMPONENT", 111, 114], ["-binding aromatic drugs", "SIMPLE_CHEMICAL", 114, 137], ["aromatic drugs", "OBSERVATION", 123, 137]]], ["The theory is based on solution of a general system of mass balance equations in the three-component system X -Y -DNA with respect to the two factors, R D and A D .", [["DNA", "CELLULAR_COMPONENT", 114, 117], ["R D", "GENE_OR_GENE_PRODUCT", 151, 154], ["A D", "SIMPLE_CHEMICAL", 159, 162], ["X -Y -DNA", "DNA", 108, 117], ["R D and A D", "PROTEIN", 151, 162], ["mass balance equations", "PROBLEM", 55, 77], ["mass", "OBSERVATION", 55, 59]]], ["The outcome is a set of expressions enabling estimation of the change in biological response of X on addition of Y as a function of equilibrium parameters under different restrictions.", [["the change", "PROBLEM", 59, 69]]], ["The results are in good agreement with known in vitro data on Caffeine+Antibiotic action in leukemia cell lines.", [["leukemia cell lines", "ANATOMY", 92, 111], ["Caffeine", "CHEMICAL", 62, 70], ["leukemia", "DISEASE", 92, 100], ["Caffeine", "CHEMICAL", 62, 70], ["Caffeine+Antibiotic", "SIMPLE_CHEMICAL", 62, 81], ["leukemia cell lines", "CELL", 92, 111], ["leukemia cell lines", "CELL_LINE", 92, 111], ["Caffeine", "TREATMENT", 62, 70], ["Antibiotic action", "TREATMENT", 71, 88], ["leukemia cell lines", "TREATMENT", 92, 111], ["leukemia cell lines", "OBSERVATION", 92, 111]]], ["The influence of Mn 2+ ions on the structure of natural calf thymus DNA was studied by Raman spectroscopy.", [["calf thymus", "ANATOMY", 56, 67], ["Mn", "CHEMICAL", 17, 19], ["Mn 2+", "CHEMICAL", 17, 22], ["Mn 2+ ions", "SIMPLE_CHEMICAL", 17, 27], ["calf", "ORGANISM", 56, 60], ["thymus DNA", "ORGANISM_SUBSTANCE", 61, 71], ["calf", "SPECIES", 56, 60], ["natural calf thymus DNA", "TREATMENT", 48, 71], ["Raman spectroscopy", "TEST", 87, 105], ["natural", "ANATOMY_MODIFIER", 48, 55], ["calf thymus", "ANATOMY", 56, 67]]], ["Measurements were done at room temperature and pH 6.2 \u00b1 0.2, in the presence of the physiological concentration of 150 mM Na + ions, and in the presence of Mn 2+ concentrations that varied between 0 and 600 mM.", [["Na", "CHEMICAL", 122, 124], ["Mn", "CHEMICAL", 156, 158], ["Na +", "CHEMICAL", 122, 126], ["Mn 2+", "CHEMICAL", 156, 161], ["Na + ions", "SIMPLE_CHEMICAL", 122, 131], ["Mn 2+", "SIMPLE_CHEMICAL", 156, 161], ["Measurements", "TEST", 0, 12], ["room temperature", "TEST", 26, 42], ["pH", "TEST", 47, 49], ["Mn", "TEST", 156, 158], ["600 mM", "OBSERVATION_MODIFIER", 203, 209]]], ["No condensation of DNA was observed.", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["condensation of DNA", "PROBLEM", 3, 22], ["condensation", "OBSERVATION", 3, 15], ["DNA", "OBSERVATION", 19, 22]]], ["DNA backbone conformational changes were not detected in the whole concentration range of Mn 2+ ions as judging from the Raman spectra.", [["Mn", "CHEMICAL", 90, 92], ["Mn 2+", "CHEMICAL", 90, 95], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["Mn 2+ ions", "SIMPLE_CHEMICAL", 90, 100], ["DNA backbone conformational changes", "PROBLEM", 0, 35]]], ["No evidence for DNA melting was identified.", [["DNA", "CELLULAR_COMPONENT", 16, 19], ["DNA melting", "PROBLEM", 16, 27], ["evidence for", "UNCERTAINTY", 3, 15], ["DNA melting", "OBSERVATION", 16, 27]]], ["Binding of manganese(II) ions to the charged phosphate groups of DNA, stabilizing the double helical structure, is indicated in the spectra.", [["manganese", "CHEMICAL", 11, 20], ["phosphate", "CHEMICAL", 45, 54], ["manganese(II)", "CHEMICAL", 11, 24], ["phosphate", "CHEMICAL", 45, 54], ["manganese(II) ions", "SIMPLE_CHEMICAL", 11, 29], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["double helical structure", "PROTEIN", 86, 110], ["the charged phosphate groups", "TREATMENT", 33, 61], ["DNA", "PROBLEM", 65, 68], ["DNA", "OBSERVATION", 65, 68], ["double helical", "OBSERVATION_MODIFIER", 86, 100]]], ["As judged from the marker band of dC near 785 cm \u22121 , altered nucleoside conformations in dC residues are supposed to occur, in the Mn 2+ concentration range of 400-600 mM.", [["nucleoside", "CHEMICAL", 62, 72], ["dC", "CHEMICAL", 90, 92], ["Mn", "CHEMICAL", 132, 134], ["dC", "CHEMICAL", 34, 36], ["nucleoside", "CHEMICAL", 62, 72], ["dC", "CHEMICAL", 90, 92], ["Mn 2+", "CHEMICAL", 132, 137], ["nucleoside", "SIMPLE_CHEMICAL", 62, 72], ["dC", "SIMPLE_CHEMICAL", 90, 92], ["Mn 2+", "SIMPLE_CHEMICAL", 132, 137], ["altered nucleoside conformations in dC residues", "PROBLEM", 54, 101], ["concentration range", "TEST", 138, 157], ["nucleoside conformations", "OBSERVATION", 62, 86]]], ["Binding of divalent ions to N7 of guanine and, possibly, in a lesser extent to adenine was observed as judging from the Raman marker bands at 1336, 1376, 1490 and 1578 cm \u22121 .P-120Toward rapid DNA sequencing -ab initio study of nucleotide sandwiched between Au(111) plates C. Morari, D. Bogdan, I. Turcu National Institute for Research and Development of Isotopic and Molecular Technologies, Cluj-Napoca, RomaniaP-120Recently a new technique for DNA sequencing based on measurement of transversal conductive properties of a single strained DNA molecule has been proposed.", [["N7", "CHEMICAL", 28, 30], ["guanine", "CHEMICAL", 34, 41], ["adenine", "CHEMICAL", 79, 86], ["nucleotide", "CHEMICAL", 228, 238], ["Au", "CHEMICAL", 258, 260], ["N7", "CHEMICAL", 28, 30], ["guanine", "CHEMICAL", 34, 41], ["adenine", "CHEMICAL", 79, 86], ["nucleotide", "CHEMICAL", 228, 238], ["Au(111)", "CHEMICAL", 258, 265], ["guanine", "SIMPLE_CHEMICAL", 34, 41], ["adenine", "SIMPLE_CHEMICAL", 79, 86], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["DNA", "CELLULAR_COMPONENT", 446, 449], ["DNA", "CELLULAR_COMPONENT", 540, 543], ["strained DNA molecule", "PROTEIN", 531, 552], [".P", "TEST", 174, 176], ["rapid DNA sequencing", "TEST", 187, 207], ["ab initio study", "TEST", 209, 224], ["nucleotide sandwiched", "TREATMENT", 228, 249], ["Isotopic", "TEST", 355, 363], ["a new technique", "TREATMENT", 426, 441], ["DNA sequencing", "TEST", 446, 460], ["transversal conductive properties", "TREATMENT", 485, 518], ["a single strained DNA molecule", "TREATMENT", 522, 552]]], ["Such a method would allow single-base resolution by measuring the electrical current perpendicular to the DNA backbone.", [["DNA", "CELLULAR_COMPONENT", 106, 109], ["a method", "TREATMENT", 5, 13], ["single-base resolution", "TREATMENT", 26, 48], ["the DNA backbone", "TREATMENT", 102, 118]]], ["Until now, it is still not clear if the electrical signals obtained for the four nucleotide can be clearly distinguished by a hypothetical experimental setup.", [["nucleotide", "CHEMICAL", 81, 91], ["nucleotide", "CHEMICAL", 81, 91], ["the electrical signals", "TEST", 36, 58]]], ["Several factors -like the influence of the pentose group or the presence of water -may influence quite strongly the electrical signatures of the four bases.", [["pentose", "CHEMICAL", 43, 50], ["pentose", "CHEMICAL", 43, 50], ["pentose", "SIMPLE_CHEMICAL", 43, 50], ["water", "SIMPLE_CHEMICAL", 76, 81], ["Several factors", "PROBLEM", 0, 15], ["the pentose group", "TREATMENT", 39, 56], ["bases", "ANATOMY_MODIFIER", 150, 155]]], ["Therefore, in order to obtain a working device, the understanding and detailed description of the conduction mechanisms through DNA bases connected to a metallic electrode is essential.", [["DNA", "CELLULAR_COMPONENT", 128, 131], ["a working device", "TREATMENT", 30, 46], ["DNA bases", "TREATMENT", 128, 137], ["a metallic electrode", "TREATMENT", 151, 171], ["metallic electrode", "OBSERVATION", 153, 171]]], ["The goal of theoretical studies in this field is to describe the electric signatures of DNA bases from a theoretical point of view.", [["DNA", "CELLULAR_COMPONENT", 88, 91], ["theoretical studies", "TEST", 12, 31]]], ["Our study is focused on the detailed description of the electronic structure of DNA's base pairs \"squeezed\" between two Au plates.", [["Au", "CHEMICAL", 120, 122], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["Our study", "TEST", 0, 9], ["two Au plates", "TREATMENT", 116, 129], ["Au plates", "OBSERVATION", 120, 129]]], ["While such a geometrical model closely mimic the sequencing devices proposed in the literature, it allows us to compute meaningful physical properties such as density of states, charge transfer and orbital localizationby using \"ab initio\" methods.", [["the sequencing devices", "TREATMENT", 45, 67], ["\"ab initio\" methods", "TREATMENT", 227, 246], ["orbital", "ANATOMY", 198, 205]]], ["The results allow us to give qualitative prediction over the potential use of such a device in the DNA's sequencing technology.", [["DNA", "CELLULAR_COMPONENT", 99, 102], ["a device", "TREATMENT", 83, 91]]], ["Multinuclear platinum complexes represent a new class of anticancer agents, distinct in DNA binding and antitumor activity from their mononuclear counterparts.", [["anticancer", "ANATOMY", 57, 67], ["antitumor", "ANATOMY", 104, 113], ["platinum", "CHEMICAL", 13, 21], ["platinum", "CHEMICAL", 13, 21], ["anticancer", "CANCER", 57, 67], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["antitumor", "CANCER", 104, 113], ["mononuclear counterparts", "CELL", 134, 158], ["mononuclear counterparts", "CELL_TYPE", 134, 158], ["Multinuclear platinum complexes", "PROBLEM", 0, 31], ["anticancer agents", "TREATMENT", 57, 74], ["DNA binding", "PROBLEM", 88, 99], ["platinum complexes", "OBSERVATION", 13, 31], ["new", "OBSERVATION_MODIFIER", 44, 47], ["anticancer agents", "OBSERVATION", 57, 74], ["DNA binding", "OBSERVATION", 88, 99], ["antitumor activity", "OBSERVATION", 104, 122]]], ["BBR3464 as a first representative of this class has undergone Phase II clinical trials for treatment of ovarian and lung cancers.P-119The structure of this trinuclear Pt drug consists of two trans-PtCl(NH 3 ) 2 units bridged by a trans-P-119The main lesions formed by multinuclear Pt complexes in DNA are long-range intra-and interstrand cross-links (CLs) bridging two guanines separated by up to four base pairs.", [["ovarian", "ANATOMY", 104, 111], ["lung cancers", "ANATOMY", 116, 128], ["lesions", "ANATOMY", 250, 257], ["BBR3464", "CHEMICAL", 0, 7], ["ovarian and lung cancers", "DISEASE", 104, 128], ["P-119", "CHEMICAL", 129, 134], ["Pt", "CHEMICAL", 167, 169], ["trans-P-119", "CHEMICAL", 230, 241], ["interstrand", "CHEMICAL", 326, 337], ["BBR3464", "CHEMICAL", 0, 7], ["Pt", "CHEMICAL", 167, 169], ["trans-PtCl(NH 3 ) 2", "CHEMICAL", 191, 210], ["Pt", "CHEMICAL", 281, 283], ["guanines", "CHEMICAL", 369, 377], ["BBR3464", "SIMPLE_CHEMICAL", 0, 7], ["ovarian", "CANCER", 104, 111], ["lung cancers", "CANCER", 116, 128], ["trinuclear Pt", "SIMPLE_CHEMICAL", 156, 169], ["trans-PtCl(NH 3 ) 2 units", "SIMPLE_CHEMICAL", 191, 216], ["lesions", "CANCER", 250, 257], ["DNA", "CELLULAR_COMPONENT", 297, 300], ["multinuclear Pt complexes", "PROTEIN", 268, 293], ["Phase II clinical trials", "TREATMENT", 62, 86], ["treatment", "TREATMENT", 91, 100], ["ovarian and lung cancers", "PROBLEM", 104, 128], ["P", "TEST", 129, 130], ["this trinuclear Pt drug", "TREATMENT", 151, 174], ["two trans-PtCl(NH", "TREATMENT", 187, 204], ["The main lesions", "PROBLEM", 241, 257], ["multinuclear Pt complexes in DNA", "PROBLEM", 268, 300], ["bridging two guanines", "PROBLEM", 356, 377], ["ovarian", "ANATOMY", 104, 111], ["lung", "ANATOMY", 116, 120], ["cancers", "OBSERVATION", 121, 128], ["main", "OBSERVATION_MODIFIER", 245, 249], ["lesions", "OBSERVATION", 250, 257], ["multinuclear", "OBSERVATION_MODIFIER", 268, 280], ["Pt complexes", "OBSERVATION_MODIFIER", 281, 293], ["long", "OBSERVATION_MODIFIER", 305, 309], ["base", "ANATOMY_MODIFIER", 402, 406]]], ["Since interstrand CLs can prevent DNA strand separation interfering with critical cellular events they represent a serious obstacle in cell survival.", [["cellular", "ANATOMY", 82, 90], ["cell", "ANATOMY", 135, 139], ["interstrand", "CHEMICAL", 6, 17], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["cellular", "CELL", 82, 90], ["cell", "CELL", 135, 139], ["interstrand CLs", "TREATMENT", 6, 21], ["DNA strand separation", "PROBLEM", 34, 55], ["critical cellular events", "PROBLEM", 73, 97], ["a serious obstacle in cell survival", "PROBLEM", 113, 148], ["interstrand CLs", "OBSERVATION", 6, 21], ["strand separation", "OBSERVATION", 38, 55], ["serious", "OBSERVATION_MODIFIER", 115, 122], ["cell survival", "OBSERVATION", 135, 148]]], ["In order to contribute to understanding the biological effects of DNA interstrand CLs of BBR3464, we analyzed the effect of the single, site-specific 1,4-interstrand CL formed by this metallodrug between two guanine bases on opposite strands in the 3'-3' and 5'-5' direction on the thermal stability and energetics of short DNA duplexes.", [["interstrand", "CHEMICAL", 70, 81], ["BBR3464", "CHEMICAL", 89, 96], ["interstrand", "CHEMICAL", 154, 165], ["guanine", "CHEMICAL", 208, 215], ["BBR3464", "CHEMICAL", 89, 96], ["guanine", "CHEMICAL", 208, 215], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["BBR3464", "SIMPLE_CHEMICAL", 89, 96], ["1,4-interstrand CL", "SIMPLE_CHEMICAL", 150, 168], ["metallodrug", "SIMPLE_CHEMICAL", 184, 195], ["guanine", "SIMPLE_CHEMICAL", 208, 215], ["DNA", "CELLULAR_COMPONENT", 324, 327], ["3'-3' and 5'-5' direction", "DNA", 249, 274], ["DNA interstrand CLs of BBR3464", "TREATMENT", 66, 96], ["short DNA duplexes", "PROBLEM", 318, 336], ["bases", "ANATOMY_MODIFIER", 216, 221], ["thermal stability", "OBSERVATION_MODIFIER", 282, 299], ["short DNA", "OBSERVATION_MODIFIER", 318, 327], ["duplexes", "OBSERVATION", 328, 336]]], ["The results demonstrate that 1,4-interstrand CLs of BBR3464 in both 3'-3' and 5'-5' directions exist as two distinct conformers that are not interconvertible and affect thermodynamic stability of the DNA differently.P-118Side-by-side and end-to-end attraction of doublestranded DNA C. Maffeo 1 , B. Luan 2 , A. Aksimentiev 1 1 University of Illinois at Urbana-Champaign, Urbana, USA, 2 IBM Watson Research Center, Yorktown Heights, USA Genomic DNA is densely packed inside cell nuclei and viral capsids.", [["cell nuclei", "ANATOMY", 473, 484], ["1,4-interstrand", "CHEMICAL", 29, 44], ["BBR3464", "CHEMICAL", 52, 59], ["P-118Side", "CHEMICAL", 216, 225], ["BBR3464", "CHEMICAL", 52, 59], ["1,4-interstrand CLs", "SIMPLE_CHEMICAL", 29, 48], ["BBR3464", "SIMPLE_CHEMICAL", 52, 59], ["DNA", "CELLULAR_COMPONENT", 200, 203], ["DNA", "CELLULAR_COMPONENT", 278, 281], ["DNA", "CELLULAR_COMPONENT", 444, 447], ["cell nuclei", "CELLULAR_COMPONENT", 473, 484], ["P", "DNA", 216, 217], ["P", "TEST", 216, 217], ["Urbana", "TEST", 353, 359], ["viral capsids", "TREATMENT", 489, 502], ["densely packed", "OBSERVATION_MODIFIER", 451, 465], ["cell nuclei", "OBSERVATION", 473, 484], ["viral capsids", "OBSERVATION", 489, 502]]], ["Such close packing suggests that electrostatic repulsion between negatively charged DNA in the condensed states is balanced by counterion-induced attraction.", [["DNA", "CELLULAR_COMPONENT", 84, 87], ["counterion", "SIMPLE_CHEMICAL", 127, 137], ["Such close packing", "TREATMENT", 0, 18], ["electrostatic repulsion", "PROBLEM", 33, 56], ["electrostatic repulsion", "OBSERVATION", 33, 56]]], ["Several theoretical models have been proposed to explain DNA attraction, however, specific microscopic mechanisms are not known.", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["DNA attraction", "PROBLEM", 57, 71]]], ["Here, we report all-atom molecular dynamics simulations of the effective force between double-stranded DNA in side-by-side and end-to-end orientations.", [["DNA", "CELLULAR_COMPONENT", 103, 106], ["double-stranded DNA", "TREATMENT", 87, 106]]], ["In the side-by-side orientation, the DNA molecules were found to form a bond state in the presence of magnesium ions.", [["magnesium", "CHEMICAL", 102, 111], ["magnesium", "CHEMICAL", 102, 111], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["magnesium ions", "SIMPLE_CHEMICAL", 102, 116], ["DNA molecules", "PROTEIN", 37, 50], ["the DNA molecules", "PROBLEM", 33, 50], ["magnesium ions", "TREATMENT", 102, 116]]], ["In the bond state, the DNA molecules contact each other via their negatively charged phosphate groups, bridged by magnesium ions.", [["phosphate", "CHEMICAL", 85, 94], ["magnesium", "CHEMICAL", 114, 123], ["phosphate", "CHEMICAL", 85, 94], ["magnesium", "CHEMICAL", 114, 123], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["phosphate groups", "SIMPLE_CHEMICAL", 85, 101], ["magnesium ions", "SIMPLE_CHEMICAL", 114, 128], ["DNA molecules", "PROTEIN", 23, 36], ["their negatively charged phosphate groups", "TREATMENT", 60, 101], ["magnesium ions", "TREATMENT", 114, 128]]], ["The maximum attractive force in the side-by-side orientation is about 40 pN per DNA turn.", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["attractive", "OBSERVATION_MODIFIER", 12, 22], ["force", "OBSERVATION_MODIFIER", 23, 28]]], ["In the end-to-end orientation, a strong ( > 60 pN) attractive force was observed at short (< 0.8 nm) end-to-end distances regardless of the electrolyte concentration.", [["electrolyte", "SIMPLE_CHEMICAL", 140, 151], ["the electrolyte concentration", "TREATMENT", 136, 165]]], ["The presence of a phosphate group at the 5'ends of the fragments was found to direct DNA end-to-end self-assembly and produce bound states resembling a continuous DNA molecule.", [["phosphate", "CHEMICAL", 18, 27], ["phosphate", "CHEMICAL", 18, 27], ["phosphate", "SIMPLE_CHEMICAL", 18, 27], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["DNA", "CELLULAR_COMPONENT", 163, 166], ["continuous DNA molecule", "PROTEIN", 152, 175], ["a phosphate group", "TREATMENT", 16, 33], ["the fragments", "PROBLEM", 51, 64], ["a continuous DNA molecule", "PROBLEM", 150, 175], ["phosphate group", "OBSERVATION_MODIFIER", 18, 33], ["fragments", "OBSERVATION", 55, 64]]], ["The computed potentials of the mean force suggest that the end-to-end attraction, rather than being mediated by counterions, is likely caused by hydrophobic and van der Waals interactions between terminal nucleobases of the fragments.", [["fragments", "ANATOMY", 224, 233], ["nucleobases", "CHEMICAL", 205, 216], ["hydrophobic and van der Waals interactions", "PROBLEM", 145, 187], ["the fragments", "PROBLEM", 220, 233], ["likely caused", "UNCERTAINTY", 128, 141], ["terminal", "OBSERVATION_MODIFIER", 196, 204], ["nucleobases", "OBSERVATION_MODIFIER", 205, 216], ["fragments", "OBSERVATION_MODIFIER", 224, 233]]], ["Doxorubicin (DOX) is an anticancer antibiotics with a four-membered ring system containing an anthraquinone chromophore, and an aminoglycoside.", [["anticancer", "ANATOMY", 24, 34], ["Doxorubicin", "CHEMICAL", 0, 11], ["DOX", "CHEMICAL", 13, 16], ["anthraquinone", "CHEMICAL", 94, 107], ["aminoglycoside", "CHEMICAL", 128, 142], ["Doxorubicin", "CHEMICAL", 0, 11], ["DOX", "CHEMICAL", 13, 16], ["anthraquinone", "CHEMICAL", 94, 107], ["aminoglycoside", "CHEMICAL", 128, 142], ["Doxorubicin", "SIMPLE_CHEMICAL", 0, 11], ["DOX", "SIMPLE_CHEMICAL", 13, 16], ["anticancer", "CANCER", 24, 34], ["anthraquinone chromophore", "SIMPLE_CHEMICAL", 94, 119], ["aminoglycoside", "SIMPLE_CHEMICAL", 128, 142], ["Doxorubicin (DOX)", "TREATMENT", 0, 17], ["an anticancer antibiotics", "TREATMENT", 21, 46], ["a four-membered ring system", "TREATMENT", 52, 79], ["an anthraquinone chromophore", "TREATMENT", 91, 119], ["an aminoglycoside", "TREATMENT", 125, 142]]], ["It has good anticancer activity against a wide spectrum of tumors and is one of the most extensively used antitumor chemotherapeutic compounds currently in clinical use.", [["anticancer", "ANATOMY", 12, 22], ["tumors", "ANATOMY", 59, 65], ["antitumor", "ANATOMY", 106, 115], ["tumors", "DISEASE", 59, 65], ["anticancer", "CANCER", 12, 22], ["tumors", "CANCER", 59, 65], ["antitumor", "CANCER", 106, 115], ["a wide spectrum of tumors", "PROBLEM", 40, 65], ["antitumor chemotherapeutic compounds", "TREATMENT", 106, 142], ["good", "OBSERVATION_MODIFIER", 7, 11], ["anticancer activity", "OBSERVATION", 12, 31], ["wide spectrum", "OBSERVATION_MODIFIER", 42, 55], ["tumors", "OBSERVATION", 59, 65]]], ["Interestingly, conversion of DOX to 2pyrrolinodoxorubicin analog (p-DOX) exhibits 500-1000 times higher toxic effects in human breast cancer cell line (Nagy, A. et al., PNAS, 93 (1996 ) 2464 .", [["breast cancer cell line", "ANATOMY", 127, 150], ["DOX", "CHEMICAL", 29, 32], ["2pyrrolinodoxorubicin", "CHEMICAL", 36, 57], ["p-DOX", "CHEMICAL", 66, 71], ["breast cancer", "DISEASE", 127, 140], ["DOX", "CHEMICAL", 29, 32], ["2pyrrolinodoxorubicin", "CHEMICAL", 36, 57], ["p-DOX", "CHEMICAL", 66, 71], ["DOX", "SIMPLE_CHEMICAL", 29, 32], ["2pyrrolinodoxorubicin analog", "SIMPLE_CHEMICAL", 36, 64], ["p-DOX", "SIMPLE_CHEMICAL", 66, 71], ["human", "ORGANISM", 121, 126], ["breast cancer cell line", "CELL", 127, 150], ["human breast cancer cell line", "CELL_LINE", 121, 150], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["DOX", "TREATMENT", 29, 32], ["2pyrrolinodoxorubicin analog (p-DOX)", "TREATMENT", 36, 72], ["higher toxic effects in human breast cancer", "PROBLEM", 97, 140], ["cell line", "TREATMENT", 141, 150], ["breast", "ANATOMY", 127, 133], ["cancer", "OBSERVATION", 134, 140], ["cell line", "OBSERVATION", 141, 150]]], ["Molecular mechanisms responsible for this enormously enhanced cytotoxicity have not been entirely clarified.", [["Molecular mechanisms", "PROBLEM", 0, 20], ["this enormously enhanced cytotoxicity", "PROBLEM", 37, 74]]], ["There is good evidence that a key component of the mechanism of action of DOX is its intercalation into DNA and the formation of DOX-DNA adducts.", [["DOX", "CHEMICAL", 74, 77], ["DOX", "CHEMICAL", 129, 132], ["DOX", "CHEMICAL", 74, 77], ["DOX", "CHEMICAL", 129, 132], ["DOX", "SIMPLE_CHEMICAL", 74, 77], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["DOX", "SIMPLE_CHEMICAL", 129, 132], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["DOX", "TREATMENT", 74, 77], ["its intercalation into DNA", "PROBLEM", 81, 107], ["DNA adducts", "PROBLEM", 133, 144], ["good", "OBSERVATION_MODIFIER", 9, 13], ["DNA adducts", "OBSERVATION", 133, 144]]], ["Therefore, we have examined in detail, using the methods of molecular biophysics, DNA interactions of p-DOX in cell-free media and compared these results with the same studies focused on the parental DOX.", [["cell", "ANATOMY", 111, 115], ["p-DOX", "CHEMICAL", 102, 107], ["DOX", "CHEMICAL", 200, 203], ["p-DOX", "CHEMICAL", 102, 107], ["DOX", "CHEMICAL", 200, 203], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["p-DOX", "SIMPLE_CHEMICAL", 102, 107], ["cell", "CELL", 111, 115], ["DOX", "SIMPLE_CHEMICAL", 200, 203], ["p-DOX in cell-free media", "TREATMENT", 102, 126], ["the same studies", "TEST", 159, 175], ["the parental DOX", "TREATMENT", 187, 203]]], ["We find distinct differences between DNA interactions of DOX and p-DOX and suggest that these differences are responsible at least in part for different biological effects of these two anticancer drugs.P-124Design of a microfluidic devices for the detection of oligonucl\u00e9otides by SERS Designing fast and efficient analytical tools allowing the detection of free DNA or RNA at very low concentration within small volumes, without specific molecular labeling, remains a major issue of significance to perform diagnostic or to detect pathogen agents.", [["anticancer", "ANATOMY", 185, 195], ["DOX", "CHEMICAL", 57, 60], ["p-DOX", "CHEMICAL", 65, 70], ["DOX", "CHEMICAL", 57, 60], ["p-DOX", "CHEMICAL", 65, 70], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["DOX", "SIMPLE_CHEMICAL", 57, 60], ["p-DOX", "SIMPLE_CHEMICAL", 65, 70], ["anticancer", "CANCER", 185, 195], ["DNA", "CELLULAR_COMPONENT", 363, 366], ["P", "DNA", 202, 203], ["DOX", "TREATMENT", 57, 60], ["p-DOX", "TREATMENT", 65, 70], ["these two anticancer drugs", "TREATMENT", 175, 201], ["a microfluidic devices", "TREATMENT", 217, 239], ["oligonucl\u00e9otides", "TREATMENT", 261, 277], ["free DNA", "PROBLEM", 358, 366], ["RNA at very low concentration within small volumes", "PROBLEM", 370, 420], ["pathogen agents", "TREATMENT", 532, 547], ["distinct", "OBSERVATION_MODIFIER", 8, 16], ["small", "OBSERVATION_MODIFIER", 407, 412], ["volumes", "OBSERVATION_MODIFIER", 413, 420]]], ["Our strategy is to use Surface-Enhanced Raman Scattering (SERS) to probe selectively the spectral signature of each base in polynucleotides.", [["Surface-Enhanced Raman Scattering (SERS)", "TREATMENT", 23, 63], ["base", "ANATOMY_MODIFIER", 116, 120], ["polynucleotides", "OBSERVATION", 124, 139]]], ["SERS takes advantage of the strongly increased Raman signals of species when adsorbed on adapted silver colloids.", [["silver", "CHEMICAL", 97, 103], ["silver", "CHEMICAL", 97, 103], ["silver colloids", "SIMPLE_CHEMICAL", 97, 112], ["the strongly increased Raman signals of species", "PROBLEM", 24, 71], ["adapted silver colloids", "TREATMENT", 89, 112]]], ["We already demonstrated that adenyl Raman signal of pA in presence of silver colloids is 10 6 times enhanced compared to bulk signal.", [["silver", "CHEMICAL", 70, 76], ["adenyl", "CHEMICAL", 29, 35], ["silver", "CHEMICAL", 70, 76], ["adenyl Raman", "GENE_OR_GENE_PRODUCT", 29, 41], ["silver colloids", "SIMPLE_CHEMICAL", 70, 85], ["adenyl Raman signal", "TEST", 29, 48], ["silver colloids", "TREATMENT", 70, 85], ["bulk signal", "TEST", 121, 132], ["silver colloids", "OBSERVATION", 70, 85]]], ["We plan to use nanoliter droplets of uniformed size that form spontaneously in microchannels when two immiscible fluid streams merge.", [["nanoliter droplets of uniformed size", "TREATMENT", 15, 51], ["two immiscible fluid streams", "TREATMENT", 98, 126], ["size", "OBSERVATION_MODIFIER", 47, 51], ["fluid streams", "OBSERVATION", 113, 126]]], ["These tiny droplets are almost ideal reactors as they create homogeneous control condition.", [["These tiny droplets", "PROBLEM", 0, 19], ["tiny", "OBSERVATION_MODIFIER", 6, 10], ["droplets", "OBSERVATION", 11, 19], ["homogeneous", "OBSERVATION_MODIFIER", 61, 72]]], ["We will design an optimized channels network platform that result in droplets production hosting both nucleotides and silver colloids: internal fluids recirculation provide fast and efficient mixing, favoring base adsorption on silver nanoparticles.", [["silver", "CHEMICAL", 118, 124], ["silver nanoparticles", "CHEMICAL", 228, 248], ["nucleotides", "CHEMICAL", 102, 113], ["silver", "CHEMICAL", 118, 124], ["silver", "CHEMICAL", 228, 234], ["silver colloids", "SIMPLE_CHEMICAL", 118, 133], ["silver nanoparticles", "SIMPLE_CHEMICAL", 228, 248], ["droplets production", "PROBLEM", 69, 88], ["nucleotides and silver colloids", "TREATMENT", 102, 133], ["internal fluids recirculation", "TREATMENT", 135, 164], ["base adsorption on silver nanoparticles", "TREATMENT", 209, 248]]], ["Nicks represent the most common damage in DNA which occurs naturally in living cells.", [["cells", "ANATOMY", 79, 84], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["cells", "CELL", 79, 84], ["living cells", "CELL_TYPE", 72, 84], ["Nicks", "TREATMENT", 0, 5], ["the most common damage in DNA", "PROBLEM", 16, 45], ["most common", "OBSERVATION_MODIFIER", 20, 31], ["damage", "OBSERVATION", 32, 38], ["DNA", "OBSERVATION", 42, 45]]], ["Structural properties of nicked DNA fragments have been an object of numerous studies due to its special role in reparation processes.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["nicked DNA fragments", "DNA", 25, 45], ["nicked DNA fragments", "PROBLEM", 25, 45], ["numerous studies", "TEST", 69, 85], ["nicked", "OBSERVATION_MODIFIER", 25, 31], ["DNA fragments", "OBSERVATION", 32, 45]]], ["Here we report experimental results covering ultrasound irradiation of nicked DNA solutions.", [["DNA", "CELLULAR_COMPONENT", 78, 81], ["ultrasound irradiation", "TREATMENT", 45, 67], ["nicked DNA solutions", "TREATMENT", 71, 91]]], ["Several single-stranded nicks were produced into one strand of dsDNA fragments by the nicking enzyme Bst9I.", [["Bst9I", "GENE_OR_GENE_PRODUCT", 101, 106], ["dsDNA fragments", "DNA", 63, 78], ["nicking enzyme", "PROTEIN", 86, 100], ["Bst9I", "PROTEIN", 101, 106], ["Several single-stranded nicks", "TREATMENT", 0, 29], ["dsDNA fragments", "PROBLEM", 63, 78], ["the nicking enzyme Bst9I", "TEST", 82, 106], ["stranded nicks", "OBSERVATION_MODIFIER", 15, 29], ["one strand", "OBSERVATION_MODIFIER", 49, 59], ["dsDNA fragments", "OBSERVATION", 63, 78]]], ["We have quantitatively estimated the ultrasonic cleavage rates in nicked DNA fragments with known sequences using the polyacrylamide gel electrophoresis.", [["fragments", "ANATOMY", 77, 86], ["polyacrylamide", "CHEMICAL", 118, 132], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["nicked DNA fragments", "DNA", 66, 86], ["the ultrasonic cleavage rates", "TREATMENT", 33, 62], ["nicked DNA fragments", "PROBLEM", 66, 86], ["the polyacrylamide gel electrophoresis", "TREATMENT", 114, 152]]], ["Computer analysis of the cleavage pattern in the 3'-end labeled and primarily intact strand reveal cleavage enhancement in the regions of about 10 b. p. up and down the nicks which were initially produced into complementary strand.", [["3'-end", "DNA", 49, 55], ["Computer analysis", "TEST", 0, 17], ["the cleavage pattern", "TEST", 21, 41], ["cleavage enhancement in the regions", "PROBLEM", 99, 134], ["cleavage enhancement", "OBSERVATION", 99, 119], ["regions", "ANATOMY_MODIFIER", 127, 134]]], ["The intensity of cleavage near the nicks is (in average) about 20 times higher than cleavage in the same sites of the intact dsDNA fragments.", [["fragments", "ANATOMY", 131, 140], ["dsDNA fragments", "DNA", 125, 140], ["cleavage near the nicks", "PROBLEM", 17, 40], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["cleavage", "OBSERVATION", 17, 25], ["nicks", "OBSERVATION_MODIFIER", 35, 40], ["intact", "OBSERVATION", 118, 124], ["dsDNA fragments", "OBSERVATION", 125, 140]]], ["At the same time, the cleavage rates in positions beyond the regions of the nick markedly grow weak even comparing to the sequence-specific cleavage of intact double-stranded DNA fragments.", [["DNA", "CELLULAR_COMPONENT", 175, 178], ["double-stranded DNA fragments", "DNA", 159, 188], ["the cleavage rates", "TREATMENT", 18, 36], ["the sequence", "TEST", 118, 130], ["intact double-stranded DNA fragments", "TREATMENT", 152, 188], ["intact", "OBSERVATION_MODIFIER", 152, 158], ["double", "OBSERVATION_MODIFIER", 159, 165], ["stranded", "OBSERVATION_MODIFIER", 166, 174], ["DNA fragments", "OBSERVATION", 175, 188]]], ["Thus, the presence of the nick serves as an expressive structural indignation, which exceeds modulation of the structure caused by the base-pair sequence and is capable of absorbing mechanical stresses applied to the nearby sites of the molecule.P-122Comparing the native and an irradiated lactose repressor-operateur complex by MD simulation G. Naudin, N. Garnier, D. Genest, rue Charles Sadron, 45071 Orl\u00e9ans cedex 02, FranceP-122The function of the E. Coli lactose operon requires the binding of a protein, the tetrameric repressor, to a specific DNA sequence, the operator.", [["P-122Comparing", "CHEMICAL", 246, 260], ["lactose", "CHEMICAL", 290, 297], ["FranceP-122", "CHEMICAL", 421, 432], ["lactose", "CHEMICAL", 290, 297], ["lactose", "CHEMICAL", 460, 467], ["lactose", "SIMPLE_CHEMICAL", 290, 297], ["E. Coli lactose", "GENE_OR_GENE_PRODUCT", 452, 467], ["DNA", "CELLULAR_COMPONENT", 550, 553], ["base-pair sequence", "DNA", 135, 153], ["P", "DNA", 246, 247], ["irradiated lactose repressor", "PROTEIN", 279, 307], ["operateur complex", "PROTEIN", 308, 325], ["E. Coli lactose operon", "DNA", 452, 474], ["tetrameric repressor", "PROTEIN", 514, 534], ["DNA sequence", "DNA", 550, 562], ["E. Coli", "SPECIES", 452, 459], ["E. Coli", "SPECIES", 452, 459], ["the nick serves", "PROBLEM", 22, 37], ["an expressive structural indignation", "PROBLEM", 41, 77], ["the base-pair sequence", "TEST", 131, 153], ["mechanical stresses", "TREATMENT", 182, 201], ["P", "TEST", 246, 247], ["an irradiated lactose repressor", "TREATMENT", 276, 307], ["FranceP", "TEST", 421, 428], ["the E. Coli lactose operon", "TREATMENT", 448, 474], ["the tetrameric repressor", "TREATMENT", 510, 534], ["nick", "OBSERVATION", 26, 30], ["expressive", "OBSERVATION_MODIFIER", 44, 54], ["structural indignation", "OBSERVATION", 55, 77], ["molecule", "ANATOMY", 237, 245]]], ["The formation of this complex involves the interaction of at least one protein dimer with the operator sequence.", [["protein dimer", "PROTEIN", 71, 84], ["operator sequence", "DNA", 94, 111], ["the operator sequence", "TEST", 90, 111]]], ["This occurs via the DNA-binding domains (called headpieces) of the two constitutive monomers.", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["DNA-binding domains", "PROTEIN", 20, 39]]], ["We have previously shown that upon irradiation with gamma rays the complex is destabilised mainly because the repressor losses its DNA binding ability.", [["DNA", "CELLULAR_COMPONENT", 131, 134], ["irradiation with gamma rays", "TREATMENT", 35, 62], ["the repressor losses its DNA binding ability", "PROBLEM", 106, 150]]], ["Radiation-induced lesions were identified that may be responsible for this deleterious effect: all tyrosine residues of the headpieces are oxidized into 3,4-dihydroxyphenylalanine (DOPA).", [["lesions", "ANATOMY", 18, 25], ["tyrosine", "CHEMICAL", 99, 107], ["3,4-dihydroxyphenylalanine", "CHEMICAL", 153, 179], ["DOPA", "CHEMICAL", 181, 185], ["tyrosine", "CHEMICAL", 99, 107], ["3,4-dihydroxyphenylalanine", "CHEMICAL", 153, 179], ["DOPA", "CHEMICAL", 181, 185], ["lesions", "PATHOLOGICAL_FORMATION", 18, 25], ["tyrosine", "AMINO_ACID", 99, 107], ["3,4-dihydroxyphenylalanine", "SIMPLE_CHEMICAL", 153, 179], ["DOPA", "SIMPLE_CHEMICAL", 181, 185], ["Radiation-induced lesions", "PROBLEM", 0, 25], ["this deleterious effect", "PROBLEM", 70, 93], ["all tyrosine residues", "TREATMENT", 95, 116], ["dihydroxyphenylalanine (DOPA", "TREATMENT", 157, 185], ["lesions", "OBSERVATION", 18, 25], ["may be responsible for", "UNCERTAINTY", 47, 69]]], ["In order to unravel the mechanisms leading to the observed destabilization of the operator-repressor complex, we compare by MD simulations two complexes: 1-the native complex formed by a dimer of two headpieces and a fragment of DNA with the operator sequence and 2-the damaged complex in which all tyrosines are replaced by DOPA.", [["DOPA", "CHEMICAL", 325, 329], ["tyrosines", "CHEMICAL", 299, 308], ["DOPA", "CHEMICAL", 325, 329], ["DNA", "CELLULAR_COMPONENT", 229, 232], ["tyrosines", "SIMPLE_CHEMICAL", 299, 308], ["DOPA", "SIMPLE_CHEMICAL", 325, 329], ["repressor complex", "PROTEIN", 91, 108], ["native complex", "PROTEIN", 160, 174], ["dimer", "PROTEIN", 187, 192], ["headpieces", "PROTEIN", 200, 210], ["damaged complex", "PROTEIN", 270, 285], ["a fragment of DNA", "PROBLEM", 215, 232], ["the operator sequence", "TEST", 238, 259], ["all tyrosines", "TREATMENT", 295, 308], ["DOPA", "TREATMENT", 325, 329], ["all tyrosines", "OBSERVATION", 295, 308]]], ["Analysis of these trajectories shows a loss of stability and binding energy as well as changes in the structure of the damaged complex with respect to the native one.", [["damaged complex", "PROTEIN", 119, 134], ["these trajectories", "TEST", 12, 30], ["a loss of stability", "PROBLEM", 37, 56], ["binding energy", "PROBLEM", 61, 75], ["loss", "OBSERVATION_MODIFIER", 39, 43], ["stability", "OBSERVATION_MODIFIER", 47, 56], ["binding energy", "OBSERVATION", 61, 75]]], ["By comparing precisely the evolution of the two complexes we can explain how the oxidation of the tyrosine residues of the headpieces into DOPA may trigger the destabilization of the complex.P-122Local conformation of confined DNA studied using emission polarization anisotropy In nanochannels with dimensions smaller than the DNA radius of gyration, DNA will extend along the channel.", [["tyrosine", "CHEMICAL", 98, 106], ["DOPA", "CHEMICAL", 139, 143], ["tyrosine", "CHEMICAL", 98, 106], ["DOPA", "CHEMICAL", 139, 143], ["tyrosine", "AMINO_ACID", 98, 106], ["DOPA", "SIMPLE_CHEMICAL", 139, 143], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["DNA", "CELLULAR_COMPONENT", 327, 330], ["DNA", "CELLULAR_COMPONENT", 351, 354], ["P", "DNA", 191, 192], ["the tyrosine residues", "TREATMENT", 94, 115], ["DOPA", "TREATMENT", 139, 143], ["emission polarization anisotropy", "TREATMENT", 245, 277], ["DNA", "PROBLEM", 351, 354], ["destabilization", "OBSERVATION", 160, 175], ["complex", "OBSERVATION_MODIFIER", 183, 190], ["nanochannels", "OBSERVATION_MODIFIER", 281, 293], ["dimensions", "OBSERVATION_MODIFIER", 299, 309], ["smaller", "OBSERVATION_MODIFIER", 310, 317], ["DNA radius", "OBSERVATION", 327, 337], ["gyration", "OBSERVATION", 341, 349]]], ["We investigate long DNA confined in nanochannels with dimensions down to 50 weighted imaging CD4+ lymphocyte infiltration was observed in the brainstem-midbrain region while the CD8+ cells were more confined to the brainstem region.", [["nanochannels", "ANATOMY", 36, 48], ["CD4+ lymphocyte", "ANATOMY", 93, 108], ["brainstem-midbrain region", "ANATOMY", 142, 167], ["CD8+ cells", "ANATOMY", 178, 188], ["brainstem region", "ANATOMY", 215, 231], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["lymphocyte", "CELL", 98, 108], ["brainstem-midbrain", "ANATOMICAL_SYSTEM", 142, 160], ["CD8", "GENE_OR_GENE_PRODUCT", 178, 181], ["brainstem", "ORGAN", 215, 224], ["CD4", "PROTEIN", 93, 96], ["CD8+ cells", "CELL_TYPE", 178, 188], ["long DNA", "PROBLEM", 15, 23], ["weighted imaging CD4", "TEST", 76, 96], ["lymphocyte infiltration", "PROBLEM", 98, 121], ["the CD8+ cells", "TEST", 174, 188], ["long DNA", "OBSERVATION_MODIFIER", 15, 23], ["lymphocyte infiltration", "OBSERVATION", 98, 121], ["brainstem", "ANATOMY", 142, 151], ["midbrain", "ANATOMY", 152, 160], ["region", "ANATOMY_MODIFIER", 161, 167], ["CD8+ cells", "OBSERVATION", 178, 188], ["brainstem", "ANATOMY", 215, 224], ["region", "ANATOMY_MODIFIER", 225, 231]]], ["Comparison of MRI of labelled CD4+ vs. CD8+ lymphocytes reveals the relevant cellular inflammatory mechanism in ALS.", [["CD4+ vs. CD8+ lymphocytes", "ANATOMY", 30, 55], ["cellular", "ANATOMY", 77, 85], ["ALS", "DISEASE", 112, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 30, 33], ["CD8", "GENE_OR_GENE_PRODUCT", 39, 42], ["cellular", "CELL", 77, 85], ["CD4", "PROTEIN", 30, 33], ["CD8+ lymphocytes", "CELL_TYPE", 39, 55], ["MRI of labelled CD4", "TEST", 14, 33], ["CD8", "TEST", 39, 42], ["lymphocytes", "PROBLEM", 44, 55], ["the relevant cellular inflammatory mechanism in ALS", "PROBLEM", 64, 115], ["cellular", "OBSERVATION_MODIFIER", 77, 85], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98]]], ["The appearance of the MRI signal from the latter T cell type points to the mechanism of BBB disruption as suggested from a recent study on the role of CD8+ T cells in a model of multiple sclerosis.P-132Emodin uptake study in U-87MG cells using optically trapped surface-enhanced Raman scattering probes S. Balint 1 , S. Rao 1 , P. Miskovsky 2 , D. Petrov 1 1 ICFO -The Institute of Photonic Sciences, Barcelona, Spain, 2 Department of Biophysics, University of P.J.\u0160af\u00e1rik, Ko\u0161ice, Slovakia Emodin (1,3,8-trihydroxy-6-methylantraquinone) is a photosensitizing pigment present in plants of herbal laxatives.", [["T cell", "ANATOMY", 49, 55], ["BBB", "ANATOMY", 88, 91], ["T cells", "ANATOMY", 156, 163], ["U-87MG cells", "ANATOMY", 225, 237], ["multiple sclerosis", "DISEASE", 178, 196], ["P-132Emodin", "CHEMICAL", 197, 208], ["U-87MG", "CHEMICAL", 225, 231], ["Emodin", "CHEMICAL", 491, 497], ["1,3,8-trihydroxy-6-methylantraquinone", "CHEMICAL", 499, 536], ["1,3,8-trihydroxy-6-methylantraquinone", "CHEMICAL", 499, 536], ["T cell", "CELL", 49, 55], ["BBB", "MULTI-TISSUE_STRUCTURE", 88, 91], ["CD8", "GENE_OR_GENE_PRODUCT", 151, 154], ["T cells", "CELL", 156, 163], ["P-132Emodin", "SIMPLE_CHEMICAL", 197, 208], ["U-87MG cells", "CELL", 225, 237], ["1,3,8-trihydroxy-6-methylantraquinone", "SIMPLE_CHEMICAL", 499, 536], ["CD8", "PROTEIN", 151, 154], ["T cells", "CELL_TYPE", 156, 163], ["P", "DNA", 197, 198], ["U-87MG cells", "CELL_LINE", 225, 237], ["the MRI signal", "TEST", 18, 32], ["BBB disruption", "PROBLEM", 88, 102], ["a recent study", "TEST", 121, 135], ["multiple sclerosis", "PROBLEM", 178, 196], ["132Emodin uptake study", "TEST", 199, 221], ["P.J.\u0160af\u00e1rik", "TREATMENT", 461, 472], ["Ko\u0161ice", "TREATMENT", 474, 480], ["Slovakia Emodin", "TREATMENT", 482, 497], ["trihydroxy", "TREATMENT", 505, 515], ["methylantraquinone", "TREATMENT", 518, 536], ["a photosensitizing pigment", "TREATMENT", 541, 567], ["herbal laxatives", "TREATMENT", 589, 605], ["BBB", "ANATOMY", 88, 91], ["disruption", "OBSERVATION", 92, 102], ["multiple", "OBSERVATION_MODIFIER", 178, 186], ["sclerosis", "OBSERVATION", 187, 196], ["herbal laxatives", "OBSERVATION", 589, 605]]], ["Emodin inhibits nuclear transcription factor-\u03baB activation and induces free radical production in human mononuclear cells resulting in its antiviral and anti-cancer activity.", [["nuclear", "ANATOMY", 16, 23], ["mononuclear cells", "ANATOMY", 104, 121], ["Emodin", "CHEMICAL", 0, 6], ["Emodin", "CHEMICAL", 0, 6], ["Emodin", "SIMPLE_CHEMICAL", 0, 6], ["nuclear", "CELLULAR_COMPONENT", 16, 23], ["factor-\u03ba", "GENE_OR_GENE_PRODUCT", 38, 46], ["B", "GENE_OR_GENE_PRODUCT", 46, 47], ["free radical", "SIMPLE_CHEMICAL", 71, 83], ["human", "ORGANISM", 98, 103], ["mononuclear cells", "CELL", 104, 121], ["anti-cancer", "CANCER", 153, 164], ["nuclear transcription factor", "PROTEIN", 16, 44], ["\u03ba", "PROTEIN", 45, 46], ["human mononuclear cells", "CELL_TYPE", 98, 121], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["Emodin", "TREATMENT", 0, 6], ["nuclear transcription factor", "TEST", 16, 44], ["B activation", "PROBLEM", 46, 58], ["free radical production in human mononuclear cells", "TREATMENT", 71, 121], ["its antiviral and anti-cancer activity", "TREATMENT", 135, 173], ["free", "OBSERVATION_MODIFIER", 71, 75], ["radical production", "OBSERVATION", 76, 94], ["human mononuclear cells", "OBSERVATION", 98, 121], ["antiviral", "OBSERVATION_MODIFIER", 139, 148], ["anti-cancer activity", "OBSERVATION", 153, 173]]], ["The uptake and distribution of emodin inside the U-87 MG cell line is studied by combining optical tweezers and surfaceenhanced Raman spectroscopy (SERS).", [["U-87 MG cell line", "ANATOMY", 49, 66], ["emodin", "CHEMICAL", 31, 37], ["U-87 MG", "CHEMICAL", 49, 56], ["emodin", "CHEMICAL", 31, 37], ["emodin", "SIMPLE_CHEMICAL", 31, 37], ["U-87 MG cell line", "CELL", 49, 66], ["U-87 MG cell line", "CELL_LINE", 49, 66], ["emodin", "TREATMENT", 31, 37], ["surfaceenhanced Raman spectroscopy", "TEST", 112, 146], ["uptake", "OBSERVATION_MODIFIER", 4, 10], ["distribution", "OBSERVATION_MODIFIER", 15, 27], ["emodin", "OBSERVATION_MODIFIER", 31, 37], ["cell line", "OBSERVATION", 57, 66]]], ["SERS greatly enhances the spectrum of an otherwise weakly scattering material which is achieved by attaching nano-sized silver colloids to micron-sized dielectric beads.", [["silver", "CHEMICAL", 120, 126], ["silver colloids", "SIMPLE_CHEMICAL", 120, 135], ["weakly scattering material", "PROBLEM", 51, 77], ["attaching nano-sized silver colloids to micron-sized dielectric beads", "TREATMENT", 99, 168], ["otherwise", "OBSERVATION_MODIFIER", 41, 50], ["weakly", "OBSERVATION_MODIFIER", 51, 57], ["scattering material", "OBSERVATION", 58, 77], ["silver colloids", "OBSERVATION", 120, 135], ["sized", "OBSERVATION_MODIFIER", 146, 151], ["dielectric beads", "OBSERVATION", 152, 168]]], ["The distribution of emodin in the cell is studied by simultaneously trapping and exciting the SERS bead and scanning it across the membrane while recording the emitted light.", [["cell", "ANATOMY", 34, 38], ["membrane", "ANATOMY", 131, 139], ["emodin", "CHEMICAL", 20, 26], ["emodin", "CHEMICAL", 20, 26], ["emodin", "SIMPLE_CHEMICAL", 20, 26], ["cell", "CELL", 34, 38], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["emodin in the cell", "PROBLEM", 20, 38], ["the SERS bead", "TREATMENT", 90, 103], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["emodin", "OBSERVATION", 20, 26], ["cell", "OBSERVATION", 34, 38]]], ["Secondly, the beads are statically placed inside the cell and excited at certain intervals in order to track the migration of emodin through the membrane.", [["beads", "ANATOMY", 14, 19], ["cell", "ANATOMY", 53, 57], ["membrane", "ANATOMY", 145, 153], ["emodin", "CHEMICAL", 126, 132], ["emodin", "CHEMICAL", 126, 132], ["cell", "CELL", 53, 57], ["emodin", "SIMPLE_CHEMICAL", 126, 132], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["the beads", "TREATMENT", 10, 19], ["beads", "OBSERVATION_MODIFIER", 14, 19], ["cell", "ANATOMY", 53, 57], ["membrane", "ANATOMY", 145, 153]]], ["The results give new insight in to the metabolic pathways of emodin and demonstrate a new imaging and detection technique that is fast and less invasive than current standards.", [["emodin", "CHEMICAL", 61, 67], ["emodin", "CHEMICAL", 61, 67], ["emodin", "SIMPLE_CHEMICAL", 61, 67], ["emodin", "TREATMENT", 61, 67], ["a new imaging", "TEST", 84, 97], ["detection technique", "TEST", 102, 121]]], ["Acknowledgement: MIIN FIS2008-00114 (Spain), Fundaci\u00f3 Cellex Barcelona, Nadacia SPP (Slovakia), APVV-0449-07 (Slovakia) Amphotericin B (AmB) is a polyene antibiotic that has been widely used for treatment of systemic fungal infections.", [["MIIN FIS2008-00114", "CHEMICAL", 17, 35], ["APVV-0449-07", "CHEMICAL", 96, 108], ["Amphotericin B", "CHEMICAL", 120, 134], ["AmB", "CHEMICAL", 136, 139], ["polyene", "CHEMICAL", 146, 153], ["fungal infections", "DISEASE", 217, 234], ["Amphotericin B", "CHEMICAL", 120, 134], ["AmB", "CHEMICAL", 136, 139], ["polyene", "CHEMICAL", 146, 153], ["APVV-0449-07", "SIMPLE_CHEMICAL", 96, 108], ["Amphotericin B", "SIMPLE_CHEMICAL", 120, 134], ["AmB", "SIMPLE_CHEMICAL", 136, 139], ["polyene", "SIMPLE_CHEMICAL", 146, 153], ["APVV-0449", "TREATMENT", 96, 105], ["Amphotericin B (AmB)", "TREATMENT", 120, 140], ["a polyene antibiotic", "TREATMENT", 144, 164], ["systemic fungal infections", "PROBLEM", 208, 234], ["systemic", "OBSERVATION_MODIFIER", 208, 216], ["fungal infections", "OBSERVATION", 217, 234]]], ["The main mechanism of biological mode of action of AmB is considered to be associated with formation of ionic membrane pores or channels in the lipid membranes.", [["membrane pores", "ANATOMY", 110, 124], ["lipid membranes", "ANATOMY", 144, 159], ["AmB", "CHEMICAL", 51, 54], ["AmB", "CHEMICAL", 51, 54], ["AmB", "SIMPLE_CHEMICAL", 51, 54], ["membrane pores", "CELLULAR_COMPONENT", 110, 124], ["lipid membranes", "CELLULAR_COMPONENT", 144, 159], ["AmB", "TREATMENT", 51, 54], ["ionic membrane pores", "PROBLEM", 104, 124], ["main", "OBSERVATION_MODIFIER", 4, 8], ["ionic membrane pores", "OBSERVATION", 104, 124], ["lipid membranes", "OBSERVATION", 144, 159]]], ["The aim of this work was to study the influence of the K + and Na + ions on the aggregation process of AmB in aqueous medium.", [["K", "CHEMICAL", 55, 56], ["Na", "CHEMICAL", 63, 65], ["AmB", "CHEMICAL", 103, 106], ["K +", "CHEMICAL", 55, 58], ["Na +", "CHEMICAL", 63, 67], ["AmB", "CHEMICAL", 103, 106], ["K +", "SIMPLE_CHEMICAL", 55, 58], ["Na + ions", "SIMPLE_CHEMICAL", 63, 72], ["AmB", "SIMPLE_CHEMICAL", 103, 106], ["the K", "TEST", 51, 56], ["Na", "TEST", 63, 65]]], ["The analysis of electronic absorption and fluorescence spectra of AmB shows that the increasing K + concentration have influence on the level of aggregation of the drug much more than the same amount of Na + ions.", [["AmB", "CHEMICAL", 66, 69], ["K", "CHEMICAL", 96, 97], ["Na", "CHEMICAL", 203, 205], ["AmB", "CHEMICAL", 66, 69], ["K +", "CHEMICAL", 96, 99], ["Na +", "CHEMICAL", 203, 207], ["AmB", "SIMPLE_CHEMICAL", 66, 69], ["K +", "SIMPLE_CHEMICAL", 96, 99], ["Na + ions", "SIMPLE_CHEMICAL", 203, 212], ["electronic absorption", "TEST", 16, 37], ["fluorescence spectra of AmB", "TEST", 42, 69], ["the increasing K + concentration", "PROBLEM", 81, 113]]], ["The RLS technique was used to study aggregation of AmB in solution, in the environment of the K + and Na + ions.", [["RLS", "DISEASE", 4, 7], ["AmB", "CHEMICAL", 51, 54], ["K", "CHEMICAL", 94, 95], ["Na", "CHEMICAL", 102, 104], ["AmB", "CHEMICAL", 51, 54], ["K +", "CHEMICAL", 94, 97], ["Na +", "CHEMICAL", 102, 106], ["AmB", "SIMPLE_CHEMICAL", 51, 54], ["K +", "SIMPLE_CHEMICAL", 94, 97], ["Na + ions", "SIMPLE_CHEMICAL", 102, 111], ["The RLS technique", "TREATMENT", 0, 17], ["AmB in solution", "TREATMENT", 51, 66], ["the K", "TEST", 90, 95]]], ["The application of this technique makes it possible to study the electronically coupled chromophores, especially molecular aggregates.", [["this technique", "TREATMENT", 19, 33]]], ["The results of the ATR-FTIR and Raman spectroscopic studies also support this conclusion.", [["the ATR", "TEST", 15, 22], ["Raman spectroscopic studies", "TEST", 32, 59]]], ["These results provide a better understanding of the interaction between K + and Na + ions and antibiotic which has not been previously considered to be significant for biological action of AmB.P-130G-quadruplexes: combining theory with experimental spectroscopic methods Guanine-rich oligonucleotides can form unique tetrameric structures with four coplanar guanine bases, known as Gquadruplex motifs.", [["K", "CHEMICAL", 72, 73], ["Na", "CHEMICAL", 80, 82], ["AmB.P-130G-quadruplexes", "CHEMICAL", 189, 212], ["Guanine", "CHEMICAL", 271, 278], ["guanine", "CHEMICAL", 358, 365], ["K +", "CHEMICAL", 72, 75], ["Na +", "CHEMICAL", 80, 84], ["AmB", "CHEMICAL", 189, 192], ["Guanine", "CHEMICAL", 271, 278], ["guanine", "CHEMICAL", 358, 365], ["K +", "SIMPLE_CHEMICAL", 72, 75], ["Na + ions", "SIMPLE_CHEMICAL", 80, 89], ["AmB.P-130G-quadruplexes", "SIMPLE_CHEMICAL", 189, 212], ["Guanine-rich oligonucleotides", "SIMPLE_CHEMICAL", 271, 300], ["Gquadruplex motifs", "PROTEIN", 382, 400], ["K", "TEST", 72, 73], ["Na + ions", "TREATMENT", 80, 89], ["antibiotic", "TREATMENT", 94, 104], ["experimental spectroscopic methods Guanine-rich oligonucleotides", "TREATMENT", 236, 300], ["four coplanar guanine bases", "TREATMENT", 344, 371]]], ["The G-quadruplexes have been found in vivo in the terminal parts of telomeres and other genomic regions.", [["telomeres", "ANATOMY", 68, 77], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 4, 18], ["telomeres", "CELLULAR_COMPONENT", 68, 77], ["genomic regions", "DNA", 88, 103], ["The G-quadruplexes", "TREATMENT", 0, 18], ["terminal", "ANATOMY_MODIFIER", 50, 58], ["parts", "ANATOMY_MODIFIER", 59, 64], ["telomeres", "ANATOMY_MODIFIER", 68, 77], ["genomic regions", "OBSERVATION", 88, 103]]], ["Ligands, specifically binding to the G-quadruplex regions inhibit telomerase activity and thus can play an important role in the cancer therapy.", [["cancer", "ANATOMY", 129, 135], ["cancer", "DISEASE", 129, 135], ["telomerase", "GENE_OR_GENE_PRODUCT", 66, 76], ["cancer", "CANCER", 129, 135], ["G-quadruplex regions", "DNA", 37, 57], ["telomerase", "PROTEIN", 66, 76], ["the cancer therapy", "TREATMENT", 125, 143], ["telomerase activity", "OBSERVATION", 66, 85], ["cancer", "OBSERVATION", 129, 135]]], ["In the present work we use the infrared spectroscopy, including the relatively novel technique of the vibrational circular dichroism (VCD), in a combination with molecular dynamics and quantum chemistry computational methods to investigate the structure and spectroscopic response of the quadruplexes formed by the d(G) 8 and selfassociated dGMP.", [["dGMP", "CHEMICAL", 341, 345], ["dGMP", "SIMPLE_CHEMICAL", 341, 345], ["selfassociated dGMP", "PROTEIN", 326, 345], ["the infrared spectroscopy", "TEST", 27, 52], ["the vibrational circular dichroism", "PROBLEM", 98, 132], ["vibrational", "OBSERVATION", 102, 113], ["circular dichroism", "OBSERVATION", 114, 132]]], ["We obtained a good agreement between the computed and experimental spectra, confirming that the proposed geometrical models are realistic.", [["geometrical models", "OBSERVATION", 105, 123]]], ["The VCD technique appears especially convenient for the studies as it can detect the liquid-crystalline phases of the G-quadruplexes by an anomalous enhancement of the signal.Role of fructose in the seasonal adaptation of Picea omorika (Pan\u010di\u0107) Purkinye to coldJ.", [["fructose", "CHEMICAL", 183, 191], ["fructose", "CHEMICAL", 183, 191], ["G-quadruplexes", "SIMPLE_CHEMICAL", 118, 132], ["fructose", "SIMPLE_CHEMICAL", 183, 191], ["Picea omorika", "ORGANISM", 222, 235], ["Picea omorika", "SPECIES", 222, 235], ["Picea omorika", "SPECIES", 222, 235], ["The VCD technique", "TREATMENT", 0, 17], ["the studies", "TEST", 52, 63], ["an anomalous enhancement of the signal", "PROBLEM", 136, 174], ["anomalous", "OBSERVATION_MODIFIER", 139, 148], ["enhancement", "OBSERVATION", 149, 160], ["Picea omorika", "OBSERVATION", 222, 235]]], ["Bogdanovic Pristov, A. Mitrovic, K. Radotic, I. Spasojevic Institute for multidisciplinary research, Belgrade, Serbia Fructose, due to its high antioxidative capacity, represents a significant component of non-enzymatic defense of some plants against cold-provoked oxidative stress.", [["Fructose", "CHEMICAL", 118, 126], ["Fructose", "CHEMICAL", 118, 126], ["Fructose", "SIMPLE_CHEMICAL", 118, 126], ["its high antioxidative capacity", "PROBLEM", 135, 166], ["cold-provoked oxidative stress", "PROBLEM", 251, 281], ["significant", "OBSERVATION_MODIFIER", 181, 192], ["non-enzymatic defense", "OBSERVATION", 206, 227], ["oxidative stress", "OBSERVATION", 265, 281]]], ["In the present study, we have investigated role of fructose in seasonal adaptation of Picea omorika (Pan\u010di\u0107) Purkinye to cold.", [["fructose", "CHEMICAL", 51, 59], ["fructose", "CHEMICAL", 51, 59], ["fructose", "SIMPLE_CHEMICAL", 51, 59], ["Picea omorika", "ORGANISM", 86, 99], ["Picea omorika", "SPECIES", 86, 99], ["Picea omorika", "SPECIES", 86, 99], ["the present study", "TEST", 3, 20], ["Picea omorika", "OBSERVATION", 86, 99]]], ["This endemic coniferous species is exposed to subfreezing temperatures that range from -10 to -30 \u2022 C during the autumn/winter and high temperatures exceeding 30 \u2022 C during the summer.", [["This endemic coniferous species", "PROBLEM", 0, 31], ["subfreezing temperatures", "PROBLEM", 46, 70], ["high temperatures", "PROBLEM", 131, 148], ["endemic", "OBSERVATION_MODIFIER", 5, 12], ["coniferous species", "OBSERVATION", 13, 31]]], ["Characteristic EPR signal of free or weakly bound Mn 2+ was used as an indicator of oxidative status of needles, since coldrelated oxidative damage leads to Mn 2+ release from photosystem II.", [["Mn", "CHEMICAL", 50, 52], ["Mn", "CHEMICAL", 157, 159], ["Mn 2+", "CHEMICAL", 50, 55], ["Mn 2+", "CHEMICAL", 157, 162], ["Mn 2+", "SIMPLE_CHEMICAL", 50, 55], ["Mn 2+", "SIMPLE_CHEMICAL", 157, 162], ["photosystem II", "GENE_OR_GENE_PRODUCT", 176, 190], ["photosystem II", "PROTEIN", 176, 190], ["Characteristic EPR signal", "TEST", 0, 25], ["weakly bound Mn", "PROBLEM", 37, 52], ["oxidative status of needles", "PROBLEM", 84, 111], ["coldrelated oxidative damage leads", "TREATMENT", 119, 153], ["free", "OBSERVATION_MODIFIER", 29, 33]]], ["It was observed that prooxidative conditions developed in the autumn, at the beginning of cold season, which corresponded to significant increase of fructose level.", [["fructose", "CHEMICAL", 149, 157], ["fructose", "CHEMICAL", 149, 157], ["fructose", "SIMPLE_CHEMICAL", 149, 157], ["prooxidative conditions", "PROBLEM", 21, 44], ["significant increase of fructose level", "PROBLEM", 125, 163], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["increase", "OBSERVATION_MODIFIER", 137, 145], ["fructose level", "OBSERVATION", 149, 163]]], ["Total SOD, as well as MnSOD activity also rose significantly higher in the autumn.", [["SOD", "GENE_OR_GENE_PRODUCT", 6, 9], ["MnSOD", "GENE_OR_GENE_PRODUCT", 22, 27], ["SOD", "PROTEIN", 6, 9], ["MnSOD", "PROTEIN", 22, 27], ["Total SOD", "TREATMENT", 0, 9], ["MnSOD activity", "TEST", 22, 36]]], ["Observed activation of antioxidative system (non-enzymatic and enzymatic) led to adaptation of needles to cold, as oxidative status during winter was decreased and similar to the status of needles in cold-free seasons.P-136Calyx of Held: STED nanoscopy of a glutamatergic terminal P. Bingen 1 , T. M. Staudt 2 , C. Kempf 3 , H. Horstmann 3 , J. Engelhardt 1 , T. Kuner 3 , S. W. Hell 2 1 German Cancer Research Center / BioQuant, 69120 Heidelberg, Germany, 2 Max Planck Institute for Biophysical Chemistry, 37077 G\u00f6ttingen, Germany, 3 Institute for Anatomy and Cell Biology, University of Heidelberg, 69120 Heidelberg, GermanyP-136The calyx of Held, a large glutamatergic synaptic terminal in the auditory brainstem circuit has been increasingly employed to study presynaptic mechanisms of neurotransmission in the central nervous system.", [["Cell", "ANATOMY", 561, 565], ["calyx", "ANATOMY", 635, 640], ["glutamatergic synaptic terminal", "ANATOMY", 658, 689], ["auditory brainstem", "ANATOMY", 697, 715], ["central nervous system", "ANATOMY", 815, 837], ["Cancer", "DISEASE", 395, 401], ["GermanyP-136", "CHEMICAL", 619, 631], ["glutamatergic synaptic terminal", "CELLULAR_COMPONENT", 658, 689], ["brainstem circuit", "MULTI-TISSUE_STRUCTURE", 706, 723], ["central nervous system", "ANATOMICAL_SYSTEM", 815, 837], ["P", "DNA", 218, 219], ["antioxidative system", "TREATMENT", 23, 43], ["adaptation of needles", "TREATMENT", 81, 102], ["Biophysical Chemistry", "TEST", 484, 505], ["GermanyP", "TEST", 619, 627], ["a large glutamatergic synaptic terminal in the auditory brainstem circuit", "TREATMENT", 650, 723], ["Cancer", "OBSERVATION", 395, 401], ["calyx", "ANATOMY_MODIFIER", 635, 640], ["large", "OBSERVATION_MODIFIER", 652, 657], ["glutamatergic synaptic", "OBSERVATION", 658, 680], ["terminal", "OBSERVATION_MODIFIER", 681, 689], ["auditory brainstem", "ANATOMY", 697, 715], ["central", "ANATOMY_MODIFIER", 815, 822], ["nervous system", "ANATOMY", 823, 837]]], ["A highly detailed model of the morphology and distribution of cytoskeleton, synapsin, synaptic vesicles, calcium sensors, mitochondria, the presynaptic membrane and its active zones is derived by colocalization analysis of these different key elements of synaptic transmission in the rat brain.", [["cytoskeleton", "ANATOMY", 62, 74], ["synaptic vesicles", "ANATOMY", 86, 103], ["mitochondria", "ANATOMY", 122, 134], ["presynaptic membrane", "ANATOMY", 140, 160], ["synaptic", "ANATOMY", 255, 263], ["brain", "ANATOMY", 288, 293], ["calcium", "CHEMICAL", 105, 112], ["calcium", "CHEMICAL", 105, 112], ["cytoskeleton", "CELLULAR_COMPONENT", 62, 74], ["synapsin", "GENE_OR_GENE_PRODUCT", 76, 84], ["synaptic vesicles", "CELLULAR_COMPONENT", 86, 103], ["calcium", "SIMPLE_CHEMICAL", 105, 112], ["mitochondria", "CELLULAR_COMPONENT", 122, 134], ["presynaptic membrane", "CELLULAR_COMPONENT", 140, 160], ["synaptic", "MULTI-TISSUE_STRUCTURE", 255, 263], ["rat", "ORGANISM", 284, 287], ["brain", "ORGAN", 288, 293], ["synapsin", "PROTEIN", 76, 84], ["rat", "SPECIES", 284, 287], ["rat", "SPECIES", 284, 287], ["calcium sensors", "TEST", 105, 120], ["mitochondria", "PROBLEM", 122, 134], ["the presynaptic membrane", "PROBLEM", 136, 160], ["colocalization analysis", "TEST", 196, 219], ["synaptic transmission in the rat brain", "PROBLEM", 255, 293], ["synaptic vesicles", "OBSERVATION", 86, 103], ["presynaptic membrane", "OBSERVATION", 140, 160], ["active", "OBSERVATION_MODIFIER", 169, 175], ["synaptic transmission", "OBSERVATION", 255, 276], ["rat", "ANATOMY_MODIFIER", 284, 287], ["brain", "ANATOMY", 288, 293]]], ["The various cellular components are visualized with subdiffraction resolution by stimulated emission depletion (STED) microscopy.", [["cellular", "ANATOMY", 12, 20], ["cellular", "CELL", 12, 20], ["stimulated emission depletion", "TREATMENT", 81, 110], ["microscopy", "TEST", 118, 128], ["various", "OBSERVATION_MODIFIER", 4, 11], ["cellular components", "OBSERVATION", 12, 31], ["resolution", "OBSERVATION_MODIFIER", 67, 77], ["emission depletion", "OBSERVATION", 92, 110]]], ["Imaging individual structural elements exhibit a focal plane resolution of <50 nm inside 3 \u00b5m thick tissue sections.P-135Three-dimensional SHIM and 2PEM to study collagen arrangement and crimping pattern P. Bianchini 1 , M. Franchi 3 , L. Leonardi 3 , A. Diaspro 2 1 LAMBS-IFOM MicroSCoBio Research Centre and Department of Physics, University of Genova, Genova, Italy., 2 Italian Institute of Technology (IIT), Genova, Italy, 3 Department of Human Anatomical Sciences and Physiopathology of the LocomotorApparatus, University of Bologna, Italy Ligaments have been generally described as multifascicular structures with collagen fibre bundles cross-connecting to each other or running straight and parallel with crimps.", [["tissue sections", "ANATOMY", 100, 115], ["multifascicular structures", "ANATOMY", 588, 614], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 100, 115], ["collagen", "GENE_OR_GENE_PRODUCT", 162, 170], ["Human", "ORGANISM", 443, 448], ["collagen", "GENE_OR_GENE_PRODUCT", 620, 628], ["P-135Three-dimensional SHIM", "DNA", 116, 143], ["Human", "SPECIES", 443, 448], ["Imaging", "TEST", 0, 7], ["a focal plane resolution", "PROBLEM", 47, 71], ["thick tissue sections", "PROBLEM", 94, 115], ["P", "TEST", 116, 117], ["study collagen arrangement", "TREATMENT", 156, 182], ["Bianchini", "TEST", 207, 216], ["focal", "OBSERVATION_MODIFIER", 49, 54], ["plane", "OBSERVATION_MODIFIER", 55, 60], ["resolution", "OBSERVATION_MODIFIER", 61, 71], ["Italy Ligaments", "ANATOMY", 539, 554]]], ["A different collagen array and crimping pattern in different ligaments may reflect a different mechanical role.", [["ligaments", "ANATOMY", 61, 70], ["collagen", "GENE_OR_GENE_PRODUCT", 12, 20], ["ligaments", "TISSUE", 61, 70], ["collagen", "PROTEIN", 12, 20], ["A different collagen array and crimping pattern in different ligaments", "PROBLEM", 0, 70], ["different", "OBSERVATION_MODIFIER", 2, 11], ["collagen array", "OBSERVATION_MODIFIER", 12, 26], ["ligaments", "ANATOMY", 61, 70], ["may reflect", "UNCERTAINTY", 71, 82], ["different mechanical", "OBSERVATION_MODIFIER", 85, 105]]], ["Aim of this study was to relate the 3D collagen arrangement and crimping pattern by backward and forward second harmonic imaging microscopy (SHIM) and 2-photon excitation microscopy (2PEM).", [["collagen", "GENE_OR_GENE_PRODUCT", 39, 47], ["this study", "TEST", 7, 17], ["the 3D collagen arrangement", "TREATMENT", 32, 59], ["forward second harmonic imaging microscopy", "TEST", 97, 139], ["photon excitation microscopy", "TEST", 153, 181]]], ["SHIM on a laser-scanning system is a powerful and unique tool for high-resolution, high-contrast, three-dimensional studies of tissue architecture.", [["tissue", "ANATOMY", 127, 133], ["tissue", "TISSUE", 127, 133], ["SHIM", "PROTEIN", 0, 4], ["a laser-scanning system", "TEST", 8, 31]]], ["Although it is a coherent process the multiple scattering through the tissue give us the capability to acquire signal in both backward and forward direction [1] .", [["tissue", "ANATOMY", 70, 76], ["tissue", "TISSUE", 70, 76], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["scattering", "OBSERVATION_MODIFIER", 47, 57]]], ["SHIM and 2PEM were combined in a dual-mode nonlinear microscopy to find out collagen fibre arrangement and crimping pattern.", [["2PEM", "SIMPLE_CHEMICAL", 9, 13], ["collagen", "GENE_OR_GENE_PRODUCT", 76, 84], ["2PEM", "DNA", 9, 13], ["collagen", "PROTEIN", 76, 84], ["nonlinear microscopy", "TEST", 43, 63], ["collagen fibre arrangement", "PROBLEM", 76, 102]]], ["Both polarization dependence and differences between forward and backward signals allowed to yield information on local structure [2] .", [["Both polarization dependence", "PROBLEM", 0, 28], ["polarization", "OBSERVATION_MODIFIER", 5, 17], ["dependence", "OBSERVATION_MODIFIER", 18, 28]]], ["Currently used TCSPC FLIM systems are characterised by high counting efficiency, high time resolution, and multiwavelength capability.", [["TCSPC FLIM systems", "TREATMENT", 15, 33], ["high counting efficiency", "PROBLEM", 55, 79], ["high", "OBSERVATION_MODIFIER", 55, 59], ["counting efficiency", "OBSERVATION", 60, 79]]], ["The systems are, however, restricted to count rates on the order of a few MHz.", [["count rates", "TEST", 40, 51]]], ["In the majority of applications, such as FRET or autofluorescence, the photostability of the samples limits the count rate to much lower values.", [["samples", "ANATOMY", 93, 100], ["the samples", "TEST", 89, 100], ["the count rate", "TEST", 108, 122]]], ["The limitation of the count rate is therefore no problem.", [["the count rate", "TEST", 18, 32], ["problem", "PROBLEM", 49, 56], ["no problem", "UNCERTAINTY", 46, 56]]], ["However, if FLIM is used for ion concentration measurements or imaging of chlorophyll in plants the available count rates can exceed the counting capability of a single TCSPC channel.", [["chlorophyll", "CHEMICAL", 74, 85], ["chlorophyll", "SIMPLE_CHEMICAL", 74, 85], ["TCSPC", "GENE_OR_GENE_PRODUCT", 169, 174], ["TCSPC channel", "PROTEIN", 169, 182], ["FLIM", "TEST", 12, 16], ["ion concentration measurements", "TEST", 29, 59], ["imaging", "TEST", 63, 70], ["chlorophyll", "TREATMENT", 74, 85], ["count rates", "TEST", 110, 121], ["a single TCSPC channel", "TREATMENT", 160, 182]]], ["We therefore developed a FLIM system that uses eight fully parallel TCSPC channels.", [["TCSPC", "GENE_OR_GENE_PRODUCT", 68, 73], ["TCSPC channels", "PROTEIN", 68, 82], ["a FLIM system", "PROBLEM", 23, 36], ["FLIM system", "OBSERVATION", 25, 36]]], ["By using a polychromator for spectral dispersion and a multichannel PMT for detection we obtain multi-spectral FLIM data at a rate of several frames per second.", [["multi-spectral FLIM data", "TEST", 96, 120]]], ["We will demonstrate the application of the system to dyamic changes of the fluorescence lifetime of chlorophyll in living plants.O-133-Imaging and spectroscopy -123Scattering effects on non linear imaging of thick biological samples F. Cella 1 , Z. Lavagnino 1 , A. Diaspro 2 1 LAMBS-IFOM, MicroScoBio Research Center, University of Genoa, Italy, 2 IIT, Italian Institute of Technology, Genoa, Italy Non linear optical scanning microscopy became a useful tool for living tissue imaging.", [["tissue", "ANATOMY", 471, 477], ["chlorophyll", "CHEMICAL", 100, 111], ["chlorophyll", "CHEMICAL", 100, 111], ["O-133", "CHEMICAL", 129, 134], ["chlorophyll", "SIMPLE_CHEMICAL", 100, 111], ["O-133", "SIMPLE_CHEMICAL", 129, 134], ["tissue", "TISSUE", 471, 477], ["chlorophyll in living plants", "TREATMENT", 100, 128], ["Imaging", "TEST", 135, 142], ["spectroscopy", "TEST", 147, 159], ["linear imaging", "TEST", 190, 204], ["Cella", "TEST", 236, 241], ["linear optical scanning microscopy", "TEST", 404, 438], ["living tissue imaging", "TEST", 464, 485]]], ["Biological tissues are highly scattering media and this leads to an exponential attenuation of the excitation intensity as the light travels into the sample.", [["tissues", "ANATOMY", 11, 18], ["sample", "ANATOMY", 150, 156], ["tissues", "TISSUE", 11, 18], ["highly scattering media", "PROBLEM", 23, 46], ["tissues", "ANATOMY", 11, 18], ["highly", "OBSERVATION_MODIFIER", 23, 29], ["scattering media", "OBSERVATION", 30, 46], ["exponential", "OBSERVATION_MODIFIER", 68, 79], ["attenuation", "OBSERVATION_MODIFIER", 80, 91], ["excitation", "OBSERVATION_MODIFIER", 99, 109], ["intensity", "OBSERVATION_MODIFIER", 110, 119]]], ["While performing imaging of biological scattering tissues in two photon excitation (2PE) regime, the localization of the maximum 2PE intensity was found to shift closer to the surface 1 and the imaging depth limit appears strongly limited by near surface fluorescence 2 .", [["tissues", "ANATOMY", 50, 57], ["surface", "ANATOMY", 176, 183], ["surface", "ANATOMY", 247, 254], ["tissues", "TISSUE", 50, 57], ["imaging", "TEST", 17, 24], ["two photon excitation (2PE) regime", "TREATMENT", 61, 95], ["the maximum 2PE intensity", "PROBLEM", 117, 142], ["the imaging depth limit", "TEST", 190, 213]]], ["In this work we computed illumination and photobleaching intensity distribution 3 in order to characterize the effects induced by scattering.", [["computed illumination", "TEST", 16, 37], ["photobleaching intensity distribution", "TEST", 42, 79]]], ["Simulations of 2PE illumination and photobleaching intensity profiles have been performed for different scattering coefficients and at different focus depth.", [["2PE illumination", "TREATMENT", 15, 31], ["photobleaching intensity profiles", "TEST", 36, 69], ["different scattering coefficients", "PROBLEM", 94, 127]]], ["Furthermore imaging of fluorescent immobile sample (polyelectrolyte gel) allowed to perform an experimental test on thick turbid media.", [["sample", "ANATOMY", 44, 50], ["Furthermore imaging", "TEST", 0, 19], ["fluorescent immobile sample (polyelectrolyte gel", "TREATMENT", 23, 71], ["an experimental test", "TEST", 92, 112], ["thick turbid media", "TREATMENT", 116, 134]]], ["Results confirm that under these conditions no photobleaching effects due to scattering occur close to the surface.", [["surface", "ANATOMY", 107, 114], ["surface", "CELLULAR_COMPONENT", 107, 114], ["photobleaching effects", "PROBLEM", 47, 69]]], ["46 (2007) .P-140Biospectroscopic probes for real time measurement of hydrogen-deuterium exchange P. Carmona 1 , M. Molina 2 1 Instituto de Estructura de la Materia (CSIC), Madrid, Spain, 2 Escuela Universitaria de\u00d3ptica, Madrid, Spain Isotopic exchange has long been used for the analysis of biomolecular structure and dynamics.", [["hydrogen-deuterium", "CHEMICAL", 69, 87], ["hydrogen", "CHEMICAL", 69, 77], ["hydrogen", "SIMPLE_CHEMICAL", 69, 77], ["hydrogen-deuterium exchange", "TREATMENT", 69, 96], ["Spain Isotopic exchange", "TREATMENT", 229, 252], ["the analysis", "TEST", 276, 288], ["biomolecular structure", "OBSERVATION", 292, 314]]], ["Hydrogen-deuterium exchange rates depend on pH, temperature and biomolecular environment.", [["Hydrogen-deuterium", "CHEMICAL", 0, 18], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen-deuterium", "SIMPLE_CHEMICAL", 0, 18], ["Hydrogen-deuterium exchange", "TREATMENT", 0, 27], ["pH", "TEST", 44, 46]]], ["This is due to hydrogen bonding, low solvent accessibility, and steric blocking.", [["hydrogen", "CHEMICAL", 15, 23], ["hydrogen", "SIMPLE_CHEMICAL", 15, 23], ["hydrogen bonding", "PROBLEM", 15, 31], ["steric blocking", "TREATMENT", 64, 79], ["hydrogen bonding", "OBSERVATION", 15, 31], ["low", "OBSERVATION_MODIFIER", 33, 36], ["solvent accessibility", "OBSERVATION", 37, 58], ["steric blocking", "OBSERVATION", 64, 79]]], ["Time resolved measurement of hydrogen-deuterium exchange for subsequent 2D correlation spectroscopic analysis can, then, be very useful to obtain structural information from the said viewpoint.", [["hydrogen-deuterium", "CHEMICAL", 29, 47], ["hydrogen", "CHEMICAL", 29, 37], ["deuterium", "CHEMICAL", 38, 47], ["hydrogen-deuterium", "SIMPLE_CHEMICAL", 29, 47], ["hydrogen-deuterium exchange", "TREATMENT", 29, 56], ["subsequent 2D correlation spectroscopic analysis", "TEST", 61, 109]]], ["We have developed a microdialysis quartz cell for use in conjunction with Raman spectroscopy to investigate hydrogen-isotope exchange reactions of biomolecules.", [["quartz cell", "ANATOMY", 34, 45], ["hydrogen-isotope", "CHEMICAL", 108, 124], ["quartz", "CHEMICAL", 34, 40], ["hydrogen", "CHEMICAL", 108, 116], ["quartz cell", "CELL", 34, 45], ["a microdialysis quartz cell", "TREATMENT", 18, 45], ["Raman spectroscopy", "TEST", 74, 92], ["hydrogen-isotope exchange reactions", "TREATMENT", 108, 143], ["microdialysis quartz cell", "OBSERVATION", 20, 45], ["isotope exchange", "OBSERVATION", 117, 133]]], ["The system requires only 40 \u00b5l volumes of the initial substrate and perturbing effluent solutions.", [["the initial substrate", "TREATMENT", 42, 63], ["perturbing effluent solutions", "TREATMENT", 68, 97]]], ["We have obtained a D 2 O efflux rate of k d = 0.38 \u00b1 0.008 min \u22121 with the greatest MWCO (18 kDa) used here, which involves that an exchange rate of 2.5 min \u22121 is the limiting rate that could be resolved with the said cell system.", [["cell", "ANATOMY", 218, 222], ["D 2 O", "CHEMICAL", 19, 24], ["cell", "CELL", 218, 222], ["efflux rate", "TEST", 25, 36], ["k d", "TEST", 40, 43], ["an exchange rate", "TEST", 129, 145]]], ["Analogous results have been obtained using an infrared biospectroscopic microdialysis probe.", [["an infrared biospectroscopic microdialysis probe", "TREATMENT", 43, 91]]], ["The use of the method described here has the advantage of avoiding sample dilution (and subsequent signal loss) involved in the known stop flow methods.", [["sample", "ANATOMY", 67, 73], ["avoiding sample dilution", "TREATMENT", 58, 82], ["subsequent signal loss)", "PROBLEM", 88, 111]]], ["Acknowledgements: The authors gratefully acknowledge financial support from the Spanish Ministerio de Ciencia e Innovaci\u00f3n (Project CTQ2006-04161/BQU).P-139Polarized transient absorption to resolve electron transfer between tryptophans in DNA photolyase Photoactivation of DNA photolyase comprises electron transfer through the chain FADH \u2022 -W382-W359-W306.", [["CTQ2006-04161", "CHEMICAL", 132, 145], ["P-139", "CHEMICAL", 151, 156], ["tryptophans", "CHEMICAL", 224, 235], ["FADH \u2022 -W382-W359-W306", "CHEMICAL", 334, 356], ["electron", "SIMPLE_CHEMICAL", 198, 206], ["DNA", "CELLULAR_COMPONENT", 239, 242], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["electron", "SIMPLE_CHEMICAL", 298, 306], ["DNA photolyase", "PROTEIN", 239, 253], ["DNA photolyase", "PROTEIN", 273, 287], ["W382-W359", "PROTEIN", 342, 351], ["W306", "PROTEIN", 352, 356], ["Polarized transient absorption", "PROBLEM", 156, 186], ["electron transfer between tryptophans", "TREATMENT", 198, 235], ["DNA photolyase", "TREATMENT", 239, 253], ["DNA photolyase", "TREATMENT", 273, 287]]], ["Photo-excited FADH \u2022 abstracts an electron from the tryptophan residue W382 in \u223c30 ps (monitored by transient absorption spectroscopy).", [["FADH", "CHEMICAL", 14, 18], ["tryptophan", "CHEMICAL", 52, 62], ["W382", "CHEMICAL", 71, 75], ["FADH", "CHEMICAL", 14, 18], ["tryptophan", "CHEMICAL", 52, 62], ["W382", "CHEMICAL", 71, 75], ["tryptophan", "AMINO_ACID", 52, 62], ["the tryptophan residue", "TEST", 48, 70], ["transient absorption spectroscopy", "TEST", 100, 133]]], ["The subsequent electron transfer steps (from W359 to W382 \u2022+ and from W306 to W359 \u2022+ ) are difficult to resolve experimentally, because electron transfer between chemically identical species does not give rise to net absorption changes.", [["W359", "CHEMICAL", 78, 82], ["electron", "SIMPLE_CHEMICAL", 15, 23], ["electron", "SIMPLE_CHEMICAL", 137, 145], ["chemically identical species", "PROBLEM", 163, 191], ["net absorption changes", "PROBLEM", 214, 236]]], ["To overcome this difficulty, we make use of the fact that polarized excitation (pulse laser) induces a preferential axis (that of the excited flavin transition) in the system (photoselection), and that W359 and W306 form different angles with that axis (known from the crystal structure).", [["flavin", "CHEMICAL", 142, 148], ["flavin", "CHEMICAL", 142, 148], ["W306", "CHEMICAL", 211, 215], ["flavin", "SIMPLE_CHEMICAL", 142, 148], ["W359", "PROTEIN", 202, 206], ["W306", "PROTEIN", 211, 215], ["polarized excitation (pulse laser", "TREATMENT", 58, 91], ["the excited flavin transition", "PROBLEM", 130, 159]]], ["Thus, polarized detection should allow distinguishing between them.", [["polarized detection", "TEST", 6, 25]]], ["Using polarized \"classical\" transient absorption on a nanosecond time scale and the pump-probe technique on a picosecond scale, we demonstrate the feasibility of the method and provide evidence that electron transfer from W306 to W359 \u2022+ is faster than the 30 ps time constant of the initial electron transfer from W382 to excited FADH \u2022 .A synchrotron based IR spectroscopy detection of apoptosis in U-87 MG cells induced by hypericinSynchrotron based Fourier transform infrared (SR-FTIR) microspectroscopy was applied to investigate apoptotic death of U-87 MG cells induced by the photosensitizer hypericin (Hyp), in using different transport systems (Hyp alone vs. Hyp/LDL complexes) and incubation protocols.", [["U-87 MG cells", "ANATOMY", 401, 414], ["U-87 MG cells", "ANATOMY", 554, 567], ["W359", "CHEMICAL", 230, 234], ["U-87 MG", "CHEMICAL", 401, 408], ["death", "DISEASE", 545, 550], ["U-87 MG", "CHEMICAL", 554, 561], ["hypericin", "CHEMICAL", 599, 608], ["W306", "CHEMICAL", 222, 226], ["W359 \u2022+", "CHEMICAL", 230, 237], ["W382", "CHEMICAL", 315, 319], ["FADH", "CHEMICAL", 331, 335], ["hypericin", "CHEMICAL", 599, 608], ["Hyp", "CHEMICAL", 610, 613], ["electron", "SIMPLE_CHEMICAL", 199, 207], ["W306", "SIMPLE_CHEMICAL", 222, 226], ["W359 \u2022+", "SIMPLE_CHEMICAL", 230, 237], ["electron", "SIMPLE_CHEMICAL", 292, 300], ["W382", "SIMPLE_CHEMICAL", 315, 319], ["U-87 MG cells", "CELL", 401, 414], ["U-87 MG cells", "CELL", 554, 567], ["hypericin", "SIMPLE_CHEMICAL", 599, 608], ["Hyp", "SIMPLE_CHEMICAL", 610, 613], ["Hyp", "SIMPLE_CHEMICAL", 654, 657], ["Hyp", "SIMPLE_CHEMICAL", 668, 671], ["LDL", "GENE_OR_GENE_PRODUCT", 672, 675], ["FADH", "PROTEIN", 331, 335], ["U-87 MG cells", "CELL_LINE", 401, 414], ["U-87 MG cells", "CELL_LINE", 554, 567], ["Hyp", "PROTEIN", 668, 671], ["LDL complexes", "PROTEIN", 672, 685], ["a nanosecond time scale", "TREATMENT", 52, 75], ["the pump-probe technique", "TREATMENT", 80, 104], ["a picosecond scale", "TREATMENT", 108, 126], ["A synchrotron based IR spectroscopy", "TEST", 339, 374], ["apoptosis", "PROBLEM", 388, 397], ["U", "TEST", 401, 402], ["hypericinSynchrotron", "TEST", 426, 446], ["Fourier transform", "TEST", 453, 470], ["microspectroscopy", "TEST", 490, 507], ["apoptotic death", "PROBLEM", 535, 550], ["U", "TEST", 554, 555], ["the photosensitizer hypericin", "TREATMENT", 579, 608], ["Hyp/LDL complexes", "TREATMENT", 668, 685], ["incubation protocols", "TREATMENT", 691, 711]]], ["The differences between IR spectra of non-treated and Hyp treated cells are mainly manifested in the positions of amide I and amide II vibrational bands of proteins.", [["cells", "ANATOMY", 66, 71], ["amide II", "CHEMICAL", 126, 134], ["amide I", "CHEMICAL", 114, 121], ["amide II", "CHEMICAL", 126, 134], ["Hyp", "SIMPLE_CHEMICAL", 54, 57], ["cells", "CELL", 66, 71], ["Hyp treated cells", "CELL_LINE", 54, 71], ["amide I", "PROTEIN", 114, 121], ["non-treated and Hyp treated cells", "PROBLEM", 38, 71], ["amide II vibrational bands of proteins", "PROBLEM", 126, 164]]], ["These vibrational shifts are attributed to the protein structure changes from dominantly alfa-helix, in the non-treated cells, to beta-sheets and random coil structures, which prevail 4h and 24h after photodynamic treatment, respectively.", [["cells", "ANATOMY", 120, 125], ["alfa-helix", "SIMPLE_CHEMICAL", 89, 99], ["cells", "CELL", 120, 125], ["non-treated cells", "CELL_LINE", 108, 125], ["the protein structure changes", "PROBLEM", 43, 72], ["dominantly alfa-helix", "PROBLEM", 78, 99], ["photodynamic treatment", "TREATMENT", 201, 223], ["vibrational shifts", "OBSERVATION", 6, 24], ["protein structure", "OBSERVATION", 47, 64], ["dominantly", "OBSERVATION_MODIFIER", 78, 88], ["alfa-helix", "OBSERVATION_MODIFIER", 89, 99], ["non-treated cells", "OBSERVATION", 108, 125]]], ["The observed conformational changes of proteins can be explained as the consequences of the processes leading to apoptosis as was verified by flow cytometry experiments.", [["The observed conformational changes of proteins", "PROBLEM", 0, 47], ["apoptosis", "PROBLEM", 113, 122], ["flow cytometry experiments", "TEST", 142, 168], ["flow cytometry", "OBSERVATION", 142, 156]]], ["The results confirm suggestion that IR spectroscopy can be successfully applied for the detection of early apoptotic processes.Controlling molecular fluorescence in laserscanning microscopyA.", [["IR spectroscopy", "TEST", 36, 51], ["early apoptotic processes", "PROBLEM", 101, 126], ["early", "OBSERVATION_MODIFIER", 101, 106], ["apoptotic processes", "OBSERVATION", 107, 126], ["molecular fluorescence", "OBSERVATION", 139, 161]]], ["K. De, D. Goswami Indian Institute of Technology Kanpur, India Molecular fluorescence has been an indispensable tool in modern day optical imaging.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["K", "TEST", 0, 1], ["optical imaging", "TEST", 131, 146]]], ["One of the state-of the-art challenges in fluorescence microscopy is having better depth resolution as embodied by the confocal and multi-photon laser-scanning microscopic techniques.Controlling molecular fluorescence in laserscanning microscopyHowever, each technique bears its own limitation in having sufficient out-of-focus signal for the former while the low non-linear photon absorption cross-section for the latter.", [["fluorescence microscopy", "TEST", 42, 65], ["scanning microscopic techniques", "TEST", 151, 182], ["laserscanning microscopy", "TEST", 221, 245], ["the low non-linear photon absorption cross-section", "TREATMENT", 356, 406]]], ["For confocal microscopy using one-photon excitation, we have shown how the clever choice of pulsed illumination instead of continuous-wave excitation leads to a gigantic enhancement in fluorescence that also has immediate applications in microscopy.Controlling molecular fluorescence in laserscanning microscopyMoreover, single-photon illumination with ultrafast pulses leads to a novel way of achieving axial resolution along with numerous other advantageous applications e.g. reduced photo-bleaching of the chromophore.", [["confocal microscopy", "TEST", 4, 23], ["one-photon excitation", "TREATMENT", 30, 51], ["pulsed illumination", "TREATMENT", 92, 111], ["continuous-wave excitation", "TREATMENT", 123, 149], ["a gigantic enhancement in fluorescence", "PROBLEM", 159, 197], ["microscopy", "TEST", 238, 248], ["laserscanning microscopy", "TEST", 287, 311], ["single-photon illumination", "TREATMENT", 321, 347], ["ultrafast pulses", "TREATMENT", 353, 369], ["numerous other advantageous applications", "TREATMENT", 432, 472], ["reduced photo", "TREATMENT", 478, 491], ["the chromophore", "TREATMENT", 505, 520], ["gigantic", "OBSERVATION_MODIFIER", 161, 169], ["enhancement", "OBSERVATION_MODIFIER", 170, 181]]], ["On the other hand we have thrown new insight demonstrating that the use of mode-locked laser pulses in multi-photon microscopy induces severe solvent-induced photo-thermal damage and prescribed methods to get rid of it.", [["mode-locked laser pulses", "TREATMENT", 75, 99], ["multi-photon microscopy", "TEST", 103, 126], ["severe solvent", "PROBLEM", 135, 149], ["thermal damage", "PROBLEM", 164, 178], ["severe", "OBSERVATION_MODIFIER", 135, 141]]], ["Besides, the use of pulse pair excitation in multi-photon microscopy leads to probe and control the dynamics of fluorophores which has crucial role in selective excitation of fluorophores from quantum control perspectives.", [["pulse pair excitation", "TREATMENT", 20, 41], ["multi-photon microscopy", "TEST", 45, 68], ["fluorophores", "TREATMENT", 112, 124], ["selective excitation of fluorophores from quantum control perspectives", "TREATMENT", 151, 221]]], ["All these cutting edge research works will be presented in addition to our recent work on application of laser pulse shaping in multi-photon microscopy.P-144Interkingdom signalling in pseudomonas aeruginosa B. Davis 1 , R. Jenson 2 , P. Williams 2 , P. O'Shea 1 1 Institute of Biophysics, Imaging and Optical Science, University of Nottingham, U.K., 2 Institute of Infection, Immunity and Inflamation, University of Nottingham, U.K.P-144Quorum sensing is the process through which some bacterial species coordinate cell-cell communication.", [["cell", "ANATOMY", 515, 519], ["cell", "ANATOMY", 520, 524], ["Infection", "DISEASE", 365, 374], ["Immunity and Inflamation", "DISEASE", 376, 400], ["U.K.P-144Quorum", "CHEMICAL", 428, 443], ["pseudomonas aeruginosa", "ORGANISM", 184, 206], ["cell", "CELL", 515, 519], ["cell", "CELL", 520, 524], ["pseudomonas aeruginosa", "SPECIES", 184, 206], ["pseudomonas aeruginosa", "SPECIES", 184, 206], ["laser pulse shaping", "TREATMENT", 105, 124], ["multi-photon microscopy", "TEST", 128, 151], ["P", "TEST", 152, 153], ["Interkingdom signalling in pseudomonas aeruginosa", "PROBLEM", 157, 206], ["Imaging", "TEST", 289, 296], ["Infection", "PROBLEM", 365, 374], ["U.K.P", "TEST", 428, 433], ["some bacterial species", "PROBLEM", 481, 503], ["Infection", "OBSERVATION", 365, 374], ["bacterial species", "OBSERVATION", 486, 503], ["coordinate cell", "OBSERVATION", 504, 519], ["cell communication", "OBSERVATION", 520, 538]]], ["Pseudomonas aeruginosa; the pathogen responsible for over 90% of chronic lung infections and the leading cause of mortality in cystic fibrosis patients, expresses two major classes of quorum sensing molecules characterized as N-acyl homoserine lactones and 2-alkyl-4-quinolones.", [["lung", "ANATOMY", 73, 77], ["Pseudomonas aeruginosa", "DISEASE", 0, 22], ["lung infections", "DISEASE", 73, 88], ["cystic fibrosis", "DISEASE", 127, 142], ["N-acyl homoserine lactones", "CHEMICAL", 226, 252], ["2-alkyl-4-quinolones", "CHEMICAL", 257, 277], ["N-acyl homoserine lactones", "CHEMICAL", 226, 252], ["2-alkyl-4-quinolones", "CHEMICAL", 257, 277], ["Pseudomonas aeruginosa", "ORGANISM", 0, 22], ["lung", "ORGAN", 73, 77], ["patients", "ORGANISM", 143, 151], ["N-acyl homoserine lactones", "SIMPLE_CHEMICAL", 226, 252], ["2-alkyl-4-quinolones", "SIMPLE_CHEMICAL", 257, 277], ["quorum sensing molecules", "PROTEIN", 184, 208], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["patients", "SPECIES", 143, 151], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["Pseudomonas aeruginosa", "PROBLEM", 0, 22], ["the pathogen", "PROBLEM", 24, 36], ["chronic lung infections", "PROBLEM", 65, 88], ["cystic fibrosis", "PROBLEM", 127, 142], ["quorum sensing molecules", "TREATMENT", 184, 208], ["N-acyl homoserine lactones", "TREATMENT", 226, 252], ["alkyl", "TREATMENT", 259, 264], ["quinolones", "TREATMENT", 267, 277], ["aeruginosa", "OBSERVATION", 12, 22], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["lung", "ANATOMY", 73, 77], ["infections", "OBSERVATION", 78, 88], ["cystic", "OBSERVATION_MODIFIER", 127, 133], ["fibrosis", "OBSERVATION", 134, 142]]], ["These compounds, in addition to their signalling roles have also been found to possess virulent properties, not only against competing species of bacteria such as Staphylococcus aureus but also eukaryotic cells such as T-lymphocytes.", [["cells", "ANATOMY", 205, 210], ["T-lymphocytes", "ANATOMY", 219, 232], ["Staphylococcus aureus", "ORGANISM", 163, 184], ["cells", "CELL", 205, 210], ["T-lymphocytes", "CELL", 219, 232], ["eukaryotic cells", "CELL_TYPE", 194, 210], ["T-lymphocytes", "CELL_TYPE", 219, 232], ["Staphylococcus aureus", "SPECIES", 163, 184], ["Staphylococcus aureus", "SPECIES", 163, 184], ["bacteria", "PROBLEM", 146, 154], ["Staphylococcus aureus", "PROBLEM", 163, 184], ["eukaryotic cells", "PROBLEM", 194, 210], ["Staphylococcus aureus", "OBSERVATION", 163, 184], ["eukaryotic cells", "OBSERVATION", 194, 210]]], ["The process of bacterial quorum signalling molecules influencing eukaryotic cell activity is termed 'interkingdom signalling'.", [["cell", "ANATOMY", 76, 80], ["eukaryotic cell", "CELL", 65, 80], ["interkingdom", "GENE_OR_GENE_PRODUCT", 101, 113], ["bacterial quorum signalling molecules", "PROTEIN", 15, 52], ["bacterial quorum signalling molecules", "PROBLEM", 15, 52], ["eukaryotic cell activity", "PROBLEM", 65, 89], ["bacterial quorum", "OBSERVATION", 15, 31], ["signalling molecules", "OBSERVATION", 32, 52], ["eukaryotic cell activity", "OBSERVATION", 65, 89]]], ["To date it has been suggested that the Quorum sensing molecules outlined above act on eukaryotic cells through interactions with an as yet unidentified plasma membrane or cytosolic receptors.", [["cells", "ANATOMY", 97, 102], ["plasma membrane", "ANATOMY", 152, 167], ["cytosolic", "ANATOMY", 171, 180], ["eukaryotic cells", "CELL", 86, 102], ["plasma membrane", "CELLULAR_COMPONENT", 152, 167], ["cytosolic", "CELLULAR_COMPONENT", 171, 180], ["Quorum sensing molecules", "PROTEIN", 39, 63], ["eukaryotic cells", "CELL_TYPE", 86, 102], ["cytosolic receptors", "PROTEIN", 171, 190], ["the Quorum sensing molecules", "PROBLEM", 35, 63], ["cytosolic receptors", "PROBLEM", 171, 190], ["cytosolic receptors", "OBSERVATION", 171, 190]]], ["This project is directed towards developing an understanding of how these compounds elicit eukaryotic response through a combination of membrane based interactions at physiologically relevant concentrations.", [["membrane", "ANATOMY", 136, 144], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["membrane based interactions", "PROBLEM", 136, 163]]], ["Particular emphasis is placed on studies of ligand binding with membrane microdomains in and the consequent downstream signalling are also considered.", [["membrane microdomains", "ANATOMY", 64, 85], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["membrane microdomains", "TREATMENT", 64, 85]]], ["This work is significant as it will not only lead to a better understanding of Pseudomonas infection, but may also lead to the discovery of new classes of agents for the treatment of infective diseases.P-143A XAS study of the sulphur environment in human neuromelanin and its synthetic analogues Neuromelanin is a complex molecule accumulating in the catecholaminergic neurons that undergo a degenerative process in Parkinson's Disease.", [["catecholaminergic neurons", "ANATOMY", 351, 376], ["Pseudomonas infection", "DISEASE", 79, 100], ["infective diseases", "DISEASE", 183, 201], ["sulphur", "CHEMICAL", 226, 233], ["neuromelanin", "CHEMICAL", 255, 267], ["Neuromelanin", "CHEMICAL", 296, 308], ["Parkinson's Disease", "DISEASE", 416, 435], ["sulphur", "CHEMICAL", 226, 233], ["Neuromelanin", "CHEMICAL", 296, 308], ["sulphur", "SIMPLE_CHEMICAL", 226, 233], ["human", "ORGANISM", 249, 254], ["neuromelanin", "CANCER", 255, 267], ["Neuromelanin", "SIMPLE_CHEMICAL", 296, 308], ["catecholaminergic neurons", "CELL", 351, 376], ["P", "DNA", 202, 203], ["catecholaminergic neurons", "CELL_TYPE", 351, 376], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["Pseudomonas infection", "PROBLEM", 79, 100], ["agents", "TREATMENT", 155, 161], ["infective diseases", "PROBLEM", 183, 201], ["XAS study", "TEST", 209, 218], ["human neuromelanin", "TREATMENT", 249, 267], ["a complex molecule", "PROBLEM", 312, 330], ["the catecholaminergic neurons", "PROBLEM", 347, 376], ["a degenerative process", "PROBLEM", 390, 412], ["Parkinson's Disease", "PROBLEM", 416, 435], ["Pseudomonas", "OBSERVATION_MODIFIER", 79, 90], ["infection", "OBSERVATION", 91, 100], ["infective", "OBSERVATION", 183, 192], ["catecholaminergic neurons", "ANATOMY", 351, 376], ["degenerative", "OBSERVATION_MODIFIER", 392, 404], ["Parkinson", "OBSERVATION", 416, 425]]], ["It was shown to play an either protective or toxic role depending on whether it is present in the intraneuronal or extraneuronal milieu.", [["intraneuronal", "ANATOMY", 98, 111], ["intraneuronal", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 111], ["extraneuronal milieu", "CELLULAR_COMPONENT", 115, 135]]], ["In the present study X-ray Absorption Spectroscopy is employed to investigate the sulphur binding mode in natural human neuromelanin, synthetic neuromelanins and in certain structurally known model compounds, namely cysteine and trichochrome C. Based on comparative fits of human and synthetic neuromelanin spectra in terms of those of model compounds, the occurrence of both cysteine-and trichochrome-like sulphur coordination modes is recognized and the relative abundance of these two types of structural arrangement is determined.", [["sulphur", "CHEMICAL", 82, 89], ["neuromelanins", "CHEMICAL", 144, 157], ["cysteine", "CHEMICAL", 216, 224], ["cysteine", "CHEMICAL", 376, 384], ["trichochrome", "CHEMICAL", 389, 401], ["sulphur", "CHEMICAL", 407, 414], ["sulphur", "CHEMICAL", 82, 89], ["neuromelanins", "CHEMICAL", 144, 157], ["cysteine", "CHEMICAL", 216, 224], ["cysteine", "CHEMICAL", 376, 384], ["trichochrome", "CHEMICAL", 389, 401], ["sulphur", "CHEMICAL", 407, 414], ["sulphur", "SIMPLE_CHEMICAL", 82, 89], ["human", "ORGANISM", 114, 119], ["neuromelanin", "SIMPLE_CHEMICAL", 120, 132], ["neuromelanins", "SIMPLE_CHEMICAL", 144, 157], ["cysteine", "SIMPLE_CHEMICAL", 216, 224], ["human", "ORGANISM", 274, 279], ["cysteine", "AMINO_ACID", 376, 384], ["trichochrome", "SIMPLE_CHEMICAL", 389, 401], ["sulphur", "SIMPLE_CHEMICAL", 407, 414], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 274, 279], ["the sulphur binding mode", "PROBLEM", 78, 102], ["trichochrome C.", "PROBLEM", 229, 244], ["both cysteine", "TREATMENT", 371, 384], ["trichochrome", "TREATMENT", 389, 401], ["sulphur coordination modes", "PROBLEM", 407, 433], ["sulphur coordination", "OBSERVATION", 407, 427]]], ["Data on the amount of cysteine-and trichochrome-like sulphur measured in this way indicate that among the synthetic neuromelanins those produced by enzymatic oxidation are the most similar ones to natural neuromelanin.Spectrally Assigned Localization Microscopy (SALM): A new approach in nuclear genome biophysicsC.", [["nuclear", "ANATOMY", 288, 295], ["cysteine", "CHEMICAL", 22, 30], ["trichochrome", "CHEMICAL", 35, 47], ["sulphur", "CHEMICAL", 53, 60], ["cysteine", "CHEMICAL", 22, 30], ["trichochrome", "CHEMICAL", 35, 47], ["sulphur", "CHEMICAL", 53, 60], ["neuromelanin", "CHEMICAL", 205, 217], ["cysteine", "AMINO_ACID", 22, 30], ["trichochrome", "SIMPLE_CHEMICAL", 35, 47], ["sulphur", "SIMPLE_CHEMICAL", 53, 60], ["neuromelanins", "GENE_OR_GENE_PRODUCT", 116, 129], ["neuromelanin", "GENE_OR_GENE_PRODUCT", 205, 217], ["nuclear", "CELLULAR_COMPONENT", 288, 295], ["cysteine", "TEST", 22, 30], ["trichochrome-like sulphur", "PROBLEM", 35, 60], ["enzymatic oxidation", "TREATMENT", 148, 167], ["Localization Microscopy", "TEST", 238, 261], ["A new approach", "TREATMENT", 270, 284], ["enzymatic oxidation", "OBSERVATION", 148, 167], ["new", "OBSERVATION_MODIFIER", 272, 275], ["nuclear genome biophysicsC", "OBSERVATION", 288, 314]]], ["Cremer Kirchhoff-Institute for Physics, University of Heidelberg, GermanySpectrally Assigned Localization Microscopy (SALM): A new approach in nuclear genome biophysicsHere we report on \"Spectral Precision Distance/Position Determination Microscopy (SPDM) with Physically Modifiable Fluorochromes (SPDM Phymod ) to analyse the spatial distribution of single nuclear proteins and DNA sequences at the macromolecular optical resolution level.", [["nuclear", "ANATOMY", 143, 150], ["nuclear", "ANATOMY", 358, 365], ["DNA", "CELLULAR_COMPONENT", 379, 382], ["nuclear proteins", "PROTEIN", 358, 374], ["DNA sequences", "DNA", 379, 392], ["A new approach", "TREATMENT", 125, 139], ["Determination Microscopy", "TEST", 224, 248], ["Physically Modifiable Fluorochromes (SPDM Phymod )", "PROBLEM", 261, 311], ["single nuclear proteins", "TEST", 351, 374], ["DNA sequences", "TEST", 379, 392], ["nuclear genome", "OBSERVATION", 143, 157]]], ["Like other methods of \"Spectrally Assigned Localization Microscopy\" (SALM), SPDM Phymod is based on labelling 'point like' objects (single molecules) with different spectral signatures, spectrally selective registration and high precision localization monitoring by far field fluorescence microscopy.", [["SPDM Phymod", "DNA", 76, 87], ["Localization Microscopy", "TEST", 43, 66], ["SPDM Phymod", "PROBLEM", 76, 87], ["spectrally selective registration", "TEST", 186, 219], ["high precision localization monitoring", "TEST", 224, 262], ["far field fluorescence microscopy", "TEST", 266, 299]]], ["The intranuclear spatial location of single molecules was determined up to a density up to ca.", [["intranuclear", "OBSERVATION_MODIFIER", 4, 16], ["spatial", "OBSERVATION_MODIFIER", 17, 24], ["location", "OBSERVATION_MODIFIER", 25, 33], ["density", "OBSERVATION", 77, 84]]], ["Quantum dots (QDs) are semiconductor nanoparticles with increasing application as fluorescent markers in biology.We investigated structure of the cell walls of different species complexed with CdSe QDs using fluorescence microscopy, fluorescence spectroscopy and FTIR techniques.", [["cell walls", "ANATOMY", 146, 156], ["CdSe QDs", "CHEMICAL", 193, 201], ["CdSe", "CHEMICAL", 193, 197], ["Quantum dots", "SIMPLE_CHEMICAL", 0, 12], ["QDs", "SIMPLE_CHEMICAL", 14, 17], ["cell", "CELL", 146, 150], ["CdSe QDs", "SIMPLE_CHEMICAL", 193, 201], ["Quantum dots (QDs)", "TREATMENT", 0, 18], ["semiconductor nanoparticles", "TREATMENT", 23, 50], ["increasing application", "TREATMENT", 56, 78], ["fluorescent markers", "TEST", 82, 101], ["different species", "PROBLEM", 160, 177], ["CdSe QDs", "TREATMENT", 193, 201], ["fluorescence microscopy", "TEST", 208, 231], ["fluorescence spectroscopy", "TEST", 233, 258], ["FTIR techniques", "TEST", 263, 278], ["cell", "OBSERVATION", 146, 150], ["walls", "ANATOMY_MODIFIER", 151, 156], ["different species", "OBSERVATION", 160, 177]]], ["In the experiments we used the cell walls isolated from three distinct plant species: Arabidopsis thaliana, Acer sp. and Picea omorika.", [["cell walls", "ANATOMY", 31, 41], ["cell", "CELL", 31, 35], ["Arabidopsis thaliana", "ORGANISM", 86, 106], ["Acer sp", "ORGANISM", 108, 115], ["Picea omorika", "ORGANISM", 121, 134], ["Arabidopsis thaliana", "SPECIES", 86, 106], ["Arabidopsis thaliana", "SPECIES", 86, 106], ["Picea omorika", "SPECIES", 121, 134], ["the cell walls", "TREATMENT", 27, 41], ["Acer sp", "TREATMENT", 108, 115], ["plant species", "OBSERVATION", 71, 84], ["Arabidopsis thaliana", "OBSERVATION", 86, 106], ["Picea omorika", "OBSERVATION", 121, 134]]], ["We studied both unlabeled and CdSe-labeled cell walls.", [["cell walls", "ANATOMY", 43, 53], ["CdSe-", "CHEMICAL", 30, 35], ["CdSe-", "SIMPLE_CHEMICAL", 30, 35], ["cell", "CELL", 43, 47], ["cell", "OBSERVATION", 43, 47], ["walls", "ANATOMY_MODIFIER", 48, 53]]], ["Fluorescence spectroscopy and microscopy were used for detection of QDs alone or complexed to the cell walls.", [["cell walls", "ANATOMY", 98, 108], ["QDs", "SIMPLE_CHEMICAL", 68, 71], ["cell", "CELL", 98, 102], ["Fluorescence spectroscopy", "TEST", 0, 25], ["microscopy", "TEST", 30, 40], ["QDs", "PROBLEM", 68, 71], ["cell walls", "OBSERVATION", 98, 108]]], ["Emission spectra were deconvolved using the Nelder-Mead algorithm in Matlab 6.5.", [["Emission spectra", "TEST", 0, 16], ["Matlab", "TEST", 69, 75]]], ["We calculated approximate probability distribution (APD) for positions of spectral component maxima.", [["spectral component maxima", "PROBLEM", 74, 99], ["component", "OBSERVATION_MODIFIER", 83, 92], ["maxima", "OBSERVATION_MODIFIER", 93, 99]]], ["There was certain difference between unlabeled cell walls and those complexed with QDs.", [["cell walls", "ANATOMY", 47, 57], ["cell", "CELL", 47, 51], ["unlabeled cell walls", "OBSERVATION", 37, 57]]], ["The FTIR spectra also show some difference between the complexed and pure cell walls.", [["cell walls", "ANATOMY", 74, 84], ["cell", "CELL", 74, 78], ["The FTIR spectra", "TEST", 0, 16], ["some difference between the complexed and pure cell walls", "PROBLEM", 27, 84], ["some", "OBSERVATION_MODIFIER", 27, 31], ["difference", "OBSERVATION_MODIFIER", 32, 42], ["complexed", "OBSERVATION_MODIFIER", 55, 64], ["pure cell walls", "OBSERVATION", 69, 84]]], ["The results show that structure was changed, but not significantly in reaction with CdSe QDs.", [["CdSe QDs", "CHEMICAL", 84, 92], ["CdSe", "CHEMICAL", 84, 88], ["CdSe QDs", "SIMPLE_CHEMICAL", 84, 92], ["CdSe QDs", "TREATMENT", 84, 92], ["structure", "OBSERVATION", 22, 31]]], ["These results are promising in context of use of QDs as labels in cell wall studies.", [["cell wall", "ANATOMY", 66, 75], ["QDs", "SIMPLE_CHEMICAL", 49, 52], ["cell wall", "MULTI-TISSUE_STRUCTURE", 66, 75], ["QDs", "TREATMENT", 49, 52], ["labels in cell wall studies", "TEST", 56, 83]]], ["The characterization of the complex of cell wall structure with QDs is a part of the study of nanoparticles application in investigations of plant materials.P-148Modulating the response of single neurons and neuronal networks with biophysical stimuli F. Difato, A. Maccione, L. Berdondini, F. Benfenati, A. Blau Italian Institute of Technology, Department of Neuroscience and Brain Technologies, Genoa, Italy During differentiation, cell processes create connections with other cells to form tissue capable of performing complex tasks.", [["cell wall", "ANATOMY", 39, 48], ["neurons", "ANATOMY", 196, 203], ["neuronal networks", "ANATOMY", 208, 225], ["cell", "ANATOMY", 433, 437], ["cells", "ANATOMY", 478, 483], ["tissue", "ANATOMY", 492, 498], ["P-148", "CHEMICAL", 157, 162], ["cell wall", "MULTI-TISSUE_STRUCTURE", 39, 48], ["neurons", "CELL", 196, 203], ["neuronal networks", "MULTI-TISSUE_STRUCTURE", 208, 225], ["cell", "CELL", 433, 437], ["cells", "CELL", 478, 483], ["tissue", "TISSUE", 492, 498], ["P-148", "DNA", 157, 162], ["the study", "TEST", 81, 90], ["nanoparticles application", "TREATMENT", 94, 119], ["cell processes", "TREATMENT", 433, 447], ["complex", "OBSERVATION_MODIFIER", 28, 35], ["cell", "OBSERVATION", 39, 43], ["wall", "ANATOMY_MODIFIER", 44, 48], ["plant materials", "OBSERVATION", 141, 156], ["Brain", "ANATOMY", 376, 381]]], ["Biophysical constraints provide necessary inputs for cellular organization in living organism 1 .", [["cellular", "ANATOMY", 53, 61], ["cellular", "CELL", 53, 61], ["Biophysical constraints", "TREATMENT", 0, 23], ["cellular organization in living organism", "PROBLEM", 53, 93]]], ["To better understand how biophysical conditions influence tissue development, it is necessary to bridge the gap between experiments on single cells and complex tissues 2,3 .", [["tissue", "ANATOMY", 58, 64], ["cells", "ANATOMY", 142, 147], ["tissues", "ANATOMY", 160, 167], ["tissue", "TISSUE", 58, 64], ["cells", "CELL", 142, 147], ["tissues", "TISSUE", 160, 167]]], ["To achieve this goal we pair optical tweezers with electrophysiology measurements 4 .", [["electrophysiology measurements", "TEST", 51, 81]]], ["By adopting neuronal networks as a biological model, neuronal signal transmission can be recorded either by patchclamp electrophysiology or microelectrode arrays (MEAs).", [["neuronal networks", "ANATOMY", 12, 29], ["neuronal", "ANATOMY", 53, 61], ["neuronal networks", "MULTI-TISSUE_STRUCTURE", 12, 29], ["neuronal", "CELL", 53, 61]]], ["Dissociated neurons will be cultured on MEAs to record neuronal network activity at different sites of the network while applying spatio-temporally defined biophysical stimuli to individual neurons.3D Correlative Light-Electron Microscopy approach to study cellular and molecular eventsA.", [["neurons", "ANATOMY", 12, 19], ["neuronal network", "ANATOMY", 55, 71], ["neurons", "ANATOMY", 190, 197], ["cellular", "ANATOMY", 257, 265], ["Dissociated neurons", "CELL", 0, 19], ["MEAs", "CELL", 40, 44], ["neuronal network", "MULTI-TISSUE_STRUCTURE", 55, 71], ["neurons", "CELL", 190, 197], ["cellular", "CELL", 257, 265], ["Dissociated neurons", "PROBLEM", 0, 19], ["neurons", "ANATOMY", 12, 19]]], ["Diaspro 1 , K. Cortese 2 , P. Bianchini 2 , C. Gagliani 2 , C. Tacchetti 2 1 IIT -Italian Institute of Technology, Morego, Genova, Italy, 2 MICROSCOBIO, University of Genoa, Italy Correlative light/electron microscopy (CLEM) is becoming increasingly frequent in molecular and cellular biophysics.", [["cellular", "ANATOMY", 276, 284], ["cellular", "CELL", 276, 284], ["Diaspro", "TREATMENT", 0, 7], ["light/electron microscopy", "TEST", 192, 217], ["increasingly", "OBSERVATION_MODIFIER", 237, 249], ["frequent", "OBSERVATION_MODIFIER", 250, 258], ["cellular biophysics", "OBSERVATION", 276, 295]]], ["We successfully applied the method to analyze the 3D structure of rough and smooth Russell bodies used as model systems.", [["the method", "TREATMENT", 24, 34], ["smooth", "OBSERVATION", 76, 82], ["Russell bodies", "OBSERVATION", 83, 97]]], ["The major advantages of this approach are the following: (i) the ability to correlate several hundreds of events at the same time, (ii) the possibilit\u02c6to perform 3D correlation, (iii) the potential to immunolabel both endogenous and recombinantly expressed proteins at the same time and (iv) the effective combination of the high data analysis capability of FLM with the high precisionaccuracy of transmission electron microscopy in a CLEM hybrid morphometry analysis.", [["endogenous and recombinantly expressed proteins", "PROTEIN", 218, 265], ["transmission electron microscopy", "TEST", 397, 429], ["a CLEM hybrid morphometry analysis", "TEST", 433, 467]]], ["We have identified and optimized critical steps in sample preparation, defined routines for sample analysis and retracing of regions of interest, developed software for semi/fully automatic 3D reconstruction and defined preliminary conditions for an hybrid light/electron microscopy morphometry approach.", [["sample", "ANATOMY", 51, 57], ["sample analysis", "TEST", 92, 107], ["semi/fully automatic 3D reconstruction", "TREATMENT", 169, 207], ["an hybrid light/electron microscopy", "TEST", 247, 282]]], ["The relevance of the presented approach lies in two important key elements, namely: the development of optical nanoscopy methods and the potentiality for exploring different correlative frameworks like optical nanoscopy vs. optical microscopy adding scanning force microscopy techniques.", [["optical nanoscopy methods", "TREATMENT", 103, 128], ["optical nanoscopy", "TEST", 202, 219], ["optical microscopy", "TEST", 224, 242], ["scanning force microscopy techniques", "TEST", 250, 286]]], ["Multidrug resistance is a well known phenomenon which limits effectiveness in treating malignancy with chemotherapy by modifying the internalization and/or externalization flow of the drugs through the cancerous cells.", [["cancerous cells", "ANATOMY", 202, 217], ["malignancy", "DISEASE", 87, 97], ["malignancy", "CANCER", 87, 97], ["cancerous cells", "CELL", 202, 217], ["cancerous cells", "CELL_TYPE", 202, 217], ["Multidrug resistance", "PROBLEM", 0, 20], ["a well known phenomenon", "PROBLEM", 24, 47], ["treating malignancy", "PROBLEM", 78, 97], ["chemotherapy", "TREATMENT", 103, 115], ["the internalization", "TREATMENT", 129, 148], ["the drugs", "TREATMENT", 180, 189], ["the cancerous cells", "PROBLEM", 198, 217], ["malignancy", "OBSERVATION", 87, 97], ["cancerous cells", "OBSERVATION", 202, 217]]], ["Combined chemotherapies, such as MVAC, are therefore currently used in bladder cancer treatment.", [["bladder cancer", "ANATOMY", 71, 85], ["MVAC", "CHEMICAL", 33, 37], ["bladder cancer", "DISEASE", 71, 85], ["MVAC", "CHEMICAL", 33, 37], ["MVAC", "SIMPLE_CHEMICAL", 33, 37], ["bladder cancer", "CANCER", 71, 85], ["Combined chemotherapies", "TREATMENT", 0, 23], ["MVAC", "TREATMENT", 33, 37], ["bladder cancer treatment", "TREATMENT", 71, 95], ["chemotherapies", "OBSERVATION", 9, 23], ["bladder", "ANATOMY", 71, 78], ["cancer", "OBSERVATION", 79, 85]]], ["However, about 30% of patients do not respond this chemotherapy because of inherent or acquired drug resistance.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["this chemotherapy", "TREATMENT", 46, 63], ["inherent or acquired drug resistance", "PROBLEM", 75, 111], ["drug resistance", "OBSERVATION", 96, 111]]], ["We developed a non invasive predicative test on urinary cells to estimate the chemotherapy effectiveness before treatment, based on the fluorescence emission of MVAC.", [["urinary cells", "ANATOMY", 48, 61], ["urinary cells", "CELL", 48, 61], ["MVAC", "SIMPLE_CHEMICAL", 161, 165], ["urinary cells", "CELL_TYPE", 48, 61], ["a non invasive predicative test", "PROBLEM", 13, 44], ["urinary cells", "TREATMENT", 48, 61], ["the chemotherapy effectiveness", "TREATMENT", 74, 104], ["treatment", "TREATMENT", 112, 121], ["the fluorescence emission", "TEST", 132, 157], ["MVAC", "TREATMENT", 161, 165]]], ["We first studied the MVAC photophysical properties in solution and using five cell lines: a drug sensitive cancer cell line MGH-u1S, its multidrug resistant subline MGH-u1R, a not tumorigenic cell line SV-HUC-1, its tumorigenic counterpart MC-SV-HUC T-2 and a cell line from transitional cell carcinoma T24.", [["cell lines", "ANATOMY", 78, 88], ["cancer cell line MGH-u1S", "ANATOMY", 107, 131], ["subline MGH-u1R", "ANATOMY", 157, 172], ["cell line SV-HUC-1", "ANATOMY", 192, 210], ["MC-SV-HUC T-2", "ANATOMY", 240, 253], ["cell line", "ANATOMY", 260, 269], ["transitional cell carcinoma T24", "ANATOMY", 275, 306], ["cancer", "DISEASE", 107, 113], ["transitional cell carcinoma", "DISEASE", 275, 302], ["MVAC", "SIMPLE_CHEMICAL", 21, 25], ["cell lines", "CELL", 78, 88], ["cancer cell line MGH-u1S", "CELL", 107, 131], ["subline MGH-u1R", "CELL", 157, 172], ["cell line SV-HUC-1", "CELL", 192, 210], ["MC-SV-HUC T-2", "CELL", 240, 253], ["cell line", "CELL", 260, 269], ["transitional cell carcinoma T24", "CELL", 275, 306], ["cell lines", "CELL_LINE", 78, 88], ["drug sensitive cancer cell line", "CELL_LINE", 92, 123], ["MGH-u1S", "CELL_LINE", 124, 131], ["multidrug resistant subline MGH-u1R", "CELL_LINE", 137, 172], ["tumorigenic cell line SV", "CELL_LINE", 180, 204], ["HUC-1", "CELL_LINE", 205, 210], ["tumorigenic counterpart MC", "CELL_LINE", 216, 242], ["SV", "CELL_LINE", 243, 245], ["HUC T-2", "CELL_LINE", 246, 253], ["cell line", "CELL_LINE", 260, 269], ["transitional cell carcinoma T24", "CELL_LINE", 275, 306], ["the MVAC photophysical properties in solution", "TREATMENT", 17, 62], ["five cell lines", "TREATMENT", 73, 88], ["a drug sensitive cancer", "PROBLEM", 90, 113], ["its multidrug resistant subline MGH", "PROBLEM", 133, 168], ["SV", "TEST", 202, 204], ["HUC", "TEST", 205, 208], ["MC", "TEST", 240, 242], ["SV", "TEST", 243, 245], ["HUC", "TEST", 246, 249], ["T", "TEST", 250, 251], ["a cell line", "TREATMENT", 258, 269], ["transitional cell carcinoma T24", "PROBLEM", 275, 306], ["cell lines", "OBSERVATION", 78, 88], ["tumorigenic cell line", "OBSERVATION", 180, 201], ["SV", "ANATOMY", 243, 245], ["cell line", "OBSERVATION", 260, 269], ["transitional cell carcinoma", "OBSERVATION", 275, 302], ["T24", "OBSERVATION", 303, 306]]], ["The results revealed a penetration and localization of the drug depending of the cell line type, allowing us to find a specific fluorescence signature for the identification of MVAC resistant cells.", [["cell line type", "ANATOMY", 81, 95], ["cells", "ANATOMY", 192, 197], ["cell line type", "CELL", 81, 95], ["MVAC resistant cells", "CELL", 177, 197], ["cell line type", "CELL_LINE", 81, 95], ["MVAC resistant cells", "CELL_LINE", 177, 197], ["a penetration", "PROBLEM", 21, 34], ["a specific fluorescence signature", "PROBLEM", 117, 150], ["MVAC resistant cells", "PROBLEM", 177, 197], ["penetration", "OBSERVATION", 23, 34], ["cell line", "OBSERVATION", 81, 90], ["MVAC resistant cells", "OBSERVATION", 177, 197]]], ["Similar data have been obtained for cytospined fixed culture cells and patients urinary cells.O-145-Imaging and spectroscopy -Abstracts Multilayered photoresist system as a ghost model for biological samples in confocal microscopy.O-145L.", [["culture cells", "ANATOMY", 53, 66], ["urinary cells", "ANATOMY", 80, 93], ["samples", "ANATOMY", 200, 207], ["O-145", "CHEMICAL", 94, 99], ["O-145L", "CHEMICAL", 231, 237], ["O-145L", "CHEMICAL", 231, 237], ["cells", "CELL", 61, 66], ["patients", "ORGANISM", 71, 79], ["urinary cells", "CELL", 80, 93], ["O-145L", "GENE_OR_GENE_PRODUCT", 231, 237], ["cytospined fixed culture cells", "CELL_LINE", 36, 66], ["urinary cells", "CELL_TYPE", 80, 93], ["patients", "SPECIES", 71, 79], ["cytospined fixed culture cells", "PROBLEM", 36, 66], ["patients urinary cells", "PROBLEM", 71, 93], ["Imaging", "TEST", 100, 107], ["spectroscopy", "TEST", 112, 124], ["biological samples", "TEST", 189, 207], ["confocal microscopy", "TEST", 211, 230], ["urinary cells", "ANATOMY", 80, 93]]], ["Ferrari, F. Cilloco, F. R. Bertani, S. Selci Istituto dei Sistemi Complessi CNR RomeO-145We have realized a bilayer photoresist system as a model to perform optical characterization in the VIS-IR range of multilayered complex biological specimen.", [["specimen", "ANATOMY", 237, 245], ["S. Selci Istituto dei Sistemi Complessi CNR RomeO-145We", "SPECIES", 36, 91], ["a bilayer photoresist system", "TREATMENT", 106, 134], ["optical characterization", "TEST", 157, 181]]], ["Our goal is to obtain structural and spectroscopic reference parameters from the identification of reflectance pattern features within a novel project granted by MIUR (SKINTARGET, IDEAS FIRB).", [["MIUR", "PROTEIN", 162, 166], ["SKINTARGET", "PROTEIN", 168, 178]]], ["Our model is composed by a 1300 nm thick layer (Shipley photoresist 1813) with a refractive index n= 1.6-1.8, wavelength dependent, and a 600 nm tick HSQ (hydrogen silsesquioxane) layer with a refractive index n around 1.38, both spin-coated over a glass substrate.", [["hydrogen silsesquioxane", "CHEMICAL", 155, 178], ["HSQ", "CHEMICAL", 150, 153], ["hydrogen silsesquioxane", "CHEMICAL", 155, 178], ["hydrogen silsesquioxane", "SIMPLE_CHEMICAL", 155, 178], ["a 1300 nm thick layer (Shipley photoresist", "TREATMENT", 25, 67], ["a refractive index n", "TEST", 79, 99], ["wavelength dependent", "PROBLEM", 110, 130], ["a 600 nm tick HSQ (hydrogen silsesquioxane)", "TREATMENT", 136, 179], ["a refractive index n", "TEST", 191, 211], ["refractive index", "OBSERVATION", 193, 209], ["glass substrate", "OBSERVATION", 249, 264]]], ["We present the analysis of reflectance pattern that can be obtained by a confocal laser reflective system as compared to the expected values as coming from analytical calculations, using a matrix approach, or a microscopic electromagnetic finite element analysis.", [["analytical calculations", "TEST", 156, 179], ["a matrix approach", "TREATMENT", 187, 204], ["a microscopic electromagnetic finite element analysis", "TEST", 209, 262]]], ["Interfacial roughness and consequent optical scattering are analyzed using a neural network approach.P-152Translational biophysics: multimode imaging for preclinical and clinical applications D. L. Farkas Cedars-Sinai Medical Center, Los Angeles, USA Our focus is where light and patient meet, and improvements yielding better outcomes.", [["neural network", "ANATOMY", 77, 91], ["neural network", "MULTI-TISSUE_STRUCTURE", 77, 91], ["patient", "ORGANISM", 280, 287], ["P", "DNA", 101, 102], ["patient", "SPECIES", 280, 287], ["Interfacial roughness", "PROBLEM", 0, 21], ["a neural network approach", "TREATMENT", 75, 100], ["multimode imaging", "TEST", 132, 149], ["roughness", "OBSERVATION_MODIFIER", 12, 21], ["consequent", "OBSERVATION_MODIFIER", 26, 36], ["optical scattering", "OBSERVATION", 37, 55]]], ["Surgery is moving towards minimally invasive intervention, where biophotonics represents a major area of hope and growth.", [["Surgery", "TREATMENT", 0, 7], ["minimally invasive intervention", "TREATMENT", 26, 57]]], ["The translation of useful laboratory-derived knowledge into clinical practice has been hampered by the difficulty of detecting, characterizing and monitoring molecules and cells in the human body, especially dynamically.", [["cells", "ANATOMY", 172, 177], ["body", "ANATOMY", 191, 195], ["cells", "CELL", 172, 177], ["human", "ORGANISM", 185, 190], ["body", "ORGANISM_SUBDIVISION", 191, 195], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 185, 190], ["cells in the human body", "PROBLEM", 172, 195], ["human", "ANATOMY", 185, 190], ["body", "ANATOMY_MODIFIER", 191, 195]]], ["Advanced bi ophotonic imaging is best suited for studying such entities, but has been lagging in clinical acceptance, in spite of major advances, and a clear need for the kind of resolution (spatial, temporal, spectral) and specificity that it alone can offer.", [["Advanced bi ophotonic imaging", "TEST", 0, 29]]], ["Biophysics-based new strategies are needed to address this challenge.", [["new strategies", "TREATMENT", 17, 31], ["this challenge", "TREATMENT", 54, 68]]], ["The development of biophysical methods for translational medicine will be reviewed, with emphasis on our recent advances.", [["translational medicine", "TREATMENT", 43, 65]]], ["Our approach is a multimode one -combining methods to achieve early, quantitative detection of abnormalities.", [["abnormalities", "PROBLEM", 95, 108], ["abnormalities", "OBSERVATION", 95, 108]]], ["With imaging fulfilling its dual role of better describing anatomy and physiology, intrasurgical histopathologyequivalent molecular and cellular imaging is achievable in vivo, as is a closer spatio-temporal connection between imaging and intervention.", [["cellular", "ANATOMY", 136, 144], ["cellular", "CELL", 136, 144], ["imaging", "TEST", 5, 12], ["cellular imaging", "TEST", 136, 152], ["imaging", "TEST", 226, 233], ["intervention", "TREATMENT", 238, 250]]], ["Some application areas to be covered: cancer (early detection by spectral reflectance/autofluorescence; progression quantitation by OCT; nano-and targeted chemotherapy assessment in vivo); neurobiology (imaging fast calcium transients and Alzheimer's plaques); hyperspectral Mie scattering imaging for in situ displasia; design and use of an advanced multimode imaging endoscope with in vivo delineation of Hirschsprung's disease for better intervention; monitoring of stem cell fate in vivo.O-151Immobilization of liposomes in a sol-gel matrix: a fluorescence confocal microscopy study R. Esquembre 1 , S. N. Pinto 2 , J. A. Poveda 1 , M. Prieto 2 , C. R. Mateo 1 1 IBMC, Universidad Miguel Hern\u00e1ndez, Elche, Spain, 2 CQFM, Instituto Superior T\u00e9cnico, Lisbon, Portugal Immobilization of liposomes shows interesting applications in protein biology, membrane biophysics and biosensor technology.", [["cancer", "ANATOMY", 38, 44], ["stem cell", "ANATOMY", 469, 478], ["membrane", "ANATOMY", 849, 857], ["cancer", "DISEASE", 38, 44], ["calcium", "CHEMICAL", 216, 223], ["Alzheimer's plaques", "DISEASE", 239, 258], ["displasia", "DISEASE", 310, 319], ["Hirschsprung's disease", "DISEASE", 407, 429], ["O-151Immobilization", "CHEMICAL", 492, 511], ["calcium", "CHEMICAL", 216, 223], ["cancer", "CANCER", 38, 44], ["calcium", "SIMPLE_CHEMICAL", 216, 223], ["stem cell", "CELL", 469, 478], ["O-151Immobilization", "SIMPLE_CHEMICAL", 492, 511], ["liposomes", "SIMPLE_CHEMICAL", 515, 524], ["membrane", "CELLULAR_COMPONENT", 849, 857], ["cancer", "PROBLEM", 38, 44], ["spectral reflectance", "TEST", 65, 85], ["autofluorescence", "PROBLEM", 86, 102], ["progression quantitation", "PROBLEM", 104, 128], ["OCT", "TEST", 132, 135], ["nano", "TEST", 137, 141], ["targeted chemotherapy assessment", "TEST", 146, 178], ["neurobiology (imaging fast calcium transients", "TEST", 189, 234], ["Alzheimer's plaques", "PROBLEM", 239, 258], ["hyperspectral Mie scattering imaging", "TEST", 261, 297], ["an advanced multimode imaging endoscope", "TREATMENT", 339, 378], ["Hirschsprung's disease", "PROBLEM", 407, 429], ["better intervention", "TREATMENT", 434, 453], ["stem cell fate in vivo", "TREATMENT", 469, 491], ["a fluorescence confocal microscopy study", "TEST", 546, 586], ["Portugal Immobilization of liposomes", "TREATMENT", 761, 797], ["cancer", "OBSERVATION", 38, 44], ["Hirschsprung", "OBSERVATION", 407, 419], ["stem cell", "OBSERVATION", 469, 478], ["liposomes", "ANATOMY", 515, 524]]], ["Previous fluorescence spectroscopy works revealed that the entrappement of zwitterionic phospholipid liposomes in a silica sol-gel matrix alters the thermodynamic properties as well as the fluidity of the lipid bilayer.", [["lipid bilayer", "ANATOMY", 205, 218], ["silica sol-gel", "CHEMICAL", 116, 130], ["silica", "CHEMICAL", 116, 122], ["zwitterionic phospholipid liposomes", "SIMPLE_CHEMICAL", 75, 110], ["lipid bilayer", "CELLULAR_COMPONENT", 205, 218], ["Previous fluorescence spectroscopy", "TEST", 0, 34], ["zwitterionic phospholipid liposomes", "TREATMENT", 75, 110], ["a silica sol-gel matrix", "TREATMENT", 114, 137], ["zwitterionic phospholipid liposomes", "OBSERVATION", 75, 110], ["thermodynamic properties", "OBSERVATION", 149, 173]]], ["Interactions between the polar head of phospholipids and the porous surface of the host matrix could be responsible of such behaviour.", [["head", "ANATOMY", 31, 35], ["porous surface", "ANATOMY", 61, 75], ["matrix", "ANATOMY", 88, 94], ["head", "ORGANISM_SUBDIVISION", 31, 35], ["phospholipids", "SIMPLE_CHEMICAL", 39, 52], ["porous surface", "CELLULAR_COMPONENT", 61, 75], ["host matrix", "CELLULAR_COMPONENT", 83, 94], ["phospholipids", "TREATMENT", 39, 52], ["polar", "ANATOMY_MODIFIER", 25, 30], ["host matrix", "ANATOMY", 83, 94]]], ["In order to get more insight into this possibility we have immobilized, for the first time, giant unilamelar vesicles (GUVs) and the shape and size of these structures as well as the possible existence of lipid domains have been visualized through fluorescence confocal microscopy.", [["giant unilamelar vesicles", "ANATOMY", 92, 117], ["GUVs", "ANATOMY", 119, 123], ["unilamelar vesicles", "CELLULAR_COMPONENT", 98, 117], ["GUVs", "CELLULAR_COMPONENT", 119, 123], ["lipid domains", "PROTEIN", 205, 218], ["lipid domains", "PROBLEM", 205, 218], ["fluorescence confocal microscopy", "TEST", 248, 280], ["shape", "OBSERVATION_MODIFIER", 133, 138], ["size", "OBSERVATION_MODIFIER", 143, 147]]], ["This technique allows for direct observation of the effect of encapsulation on an individual liposome, in contrast to the averaged information given by macroscopic spectroscopic techniques.", [["liposome", "SIMPLE_CHEMICAL", 93, 101], ["direct observation", "TEST", 26, 44], ["encapsulation", "TREATMENT", 62, 75], ["an individual liposome", "TREATMENT", 79, 101], ["macroscopic spectroscopic techniques", "TEST", 152, 188]]], ["Liposomes composed of pure POPC or DOPC as well as mixtures DOPC/DPPC were labelled with the fluorescent probes Bodipy, Rhd-PE and Rhd-DOPE.", [["POPC", "CHEMICAL", 27, 31], ["DOPC", "CHEMICAL", 35, 39], ["DOPC", "CHEMICAL", 60, 64], ["DPPC", "CHEMICAL", 65, 69], ["Rhd-PE", "CHEMICAL", 120, 126], ["POPC", "CHEMICAL", 27, 31], ["DOPC", "CHEMICAL", 35, 39], ["DOPC", "CHEMICAL", 60, 64], ["DPPC", "CHEMICAL", 65, 69], ["DOPE", "CHEMICAL", 135, 139], ["Liposomes", "SIMPLE_CHEMICAL", 0, 9], ["POPC", "SIMPLE_CHEMICAL", 27, 31], ["DOPC", "SIMPLE_CHEMICAL", 35, 39], ["DOPC/DPPC", "SIMPLE_CHEMICAL", 60, 69], ["Bodipy", "SIMPLE_CHEMICAL", 112, 118], ["Rhd-PE", "SIMPLE_CHEMICAL", 120, 126], ["Rhd-DOPE", "SIMPLE_CHEMICAL", 131, 139], ["Liposomes", "TREATMENT", 0, 9], ["pure POPC", "PROBLEM", 22, 31], ["DOPC", "TREATMENT", 35, 39], ["mixtures DOPC/DPPC", "TREATMENT", 51, 69], ["the fluorescent probes Bodipy", "TEST", 89, 118], ["Rhd", "PROBLEM", 120, 123], ["PE", "PROBLEM", 124, 126], ["Rhd-DOPE", "TREATMENT", 131, 139], ["PE", "OBSERVATION", 124, 126]]], ["Preliminary results shows that only the smallest GUVs (6-10\u00b5m) survive to the encapsulation process but often with a slight loss of its sphericity, probably due to pressures suffered during the matrix gelation.", [["GUVs", "ANATOMY", 49, 53], ["matrix", "ANATOMY", 194, 200], ["matrix", "CELLULAR_COMPONENT", 194, 200], ["the smallest GUVs", "TEST", 36, 53], ["a slight loss of its sphericity", "PROBLEM", 115, 146], ["pressures", "PROBLEM", 164, 173], ["the matrix gelation", "TREATMENT", 190, 209], ["smallest", "OBSERVATION_MODIFIER", 40, 48], ["GUVs", "OBSERVATION_MODIFIER", 49, 53], ["encapsulation", "OBSERVATION", 78, 91], ["slight", "OBSERVATION_MODIFIER", 117, 123], ["loss", "OBSERVATION_MODIFIER", 124, 128], ["sphericity", "OBSERVATION_MODIFIER", 136, 146], ["probably due to", "UNCERTAINTY", 148, 163], ["pressures", "OBSERVATION_MODIFIER", 164, 173]]], ["However no change in the gel/fluid phase proportion has been observed for immobilized DOPC/DPPC GUVs, regarding to solution.", [["DPPC GUVs", "CHEMICAL", 91, 100], ["DOPC", "CHEMICAL", 86, 90], ["DPPC", "CHEMICAL", 91, 95], ["DOPC/DPPC GUVs", "SIMPLE_CHEMICAL", 86, 100], ["the gel/fluid phase", "TEST", 21, 40], ["immobilized DOPC/DPPC GUVs", "TREATMENT", 74, 100], ["no", "UNCERTAINTY", 8, 10], ["change", "OBSERVATION_MODIFIER", 11, 17], ["fluid phase", "OBSERVATION", 29, 40]]], ["Here, we have studied how the reaction catalyzed by the light-activated enzyme protochlorophyllide oxidoreductase (POR) couple with solvent dynamics (G. Durin et al, Biophysical J. (2009 ) 96, 1902 .", [["protochlorophyllide", "CHEMICAL", 79, 98], ["protochlorophyllide", "CHEMICAL", 79, 98], ["protochlorophyllide oxidoreductase", "GENE_OR_GENE_PRODUCT", 79, 113], ["POR", "SIMPLE_CHEMICAL", 115, 118], ["light-activated enzyme", "PROTEIN", 56, 78], ["protochlorophyllide oxidoreductase", "PROTEIN", 79, 113], ["POR", "PROTEIN", 115, 118], ["the reaction", "PROBLEM", 26, 38], ["activated enzyme protochlorophyllide oxidoreductase", "TREATMENT", 62, 113]]], ["To simultaneously monitor the catalytic cycle of the enzyme and the solvent dynamics, we designed temperature-dependent UV-visible microspectrophotometry experiments, using flash-cooled nano-droplets of POR.", [["enzyme", "PROTEIN", 53, 59], ["POR", "PROTEIN", 203, 206], ["the enzyme", "TEST", 49, 59], ["the solvent dynamics", "TEST", 64, 84], ["temperature", "TEST", 98, 109], ["visible microspectrophotometry experiments", "PROBLEM", 123, 165], ["flash-cooled nano-droplets of POR", "TREATMENT", 173, 206]]], ["The temperature-dependant formation of the first two intermediates in the POR reaction were measured, together with the solvent glass transition temperature (T g ) and the build-up of crystalline ice.", [["POR", "SIMPLE_CHEMICAL", 74, 77], ["The temperature", "TEST", 0, 15], ["the POR reaction", "PROBLEM", 70, 86], ["crystalline ice", "TREATMENT", 184, 199], ["dependant", "OBSERVATION_MODIFIER", 16, 25]]], ["These results suggest that internal protein motions drive the first step of the POR reaction whereas solvent slaved motions control the second step.", [["internal protein motions", "PROBLEM", 27, 51], ["the POR reaction", "PROBLEM", 76, 92], ["protein motions", "OBSERVATION", 36, 51]]], ["We propose that the concept of solvent slaving applies to complex enzymes such as POR.", [["POR", "GENE_OR_GENE_PRODUCT", 82, 85], ["complex enzymes", "PROTEIN", 58, 73], ["POR", "PROTEIN", 82, 85], ["solvent slaving", "TREATMENT", 31, 46], ["complex enzymes", "TEST", 58, 73]]], ["Amphotericin B (AmB) is one of the main polyene antibiotics widely used to treat deep-seated fungal infections.", [["Amphotericin B", "CHEMICAL", 0, 14], ["AmB", "CHEMICAL", 16, 19], ["fungal infections", "DISEASE", 93, 110], ["Amphotericin B", "CHEMICAL", 0, 14], ["AmB", "CHEMICAL", 16, 19], ["polyene", "CHEMICAL", 40, 47], ["Amphotericin B", "SIMPLE_CHEMICAL", 0, 14], ["AmB", "SIMPLE_CHEMICAL", 16, 19], ["Amphotericin B (AmB)", "TREATMENT", 0, 20], ["the main polyene antibiotics", "TREATMENT", 31, 59], ["deep-seated fungal infections", "PROBLEM", 81, 110], ["fungal infections", "OBSERVATION", 93, 110]]], ["The mechanism of biological action of AmB is most probably directly related to the ability of the drug to form hydrophilic pores in the membrane core, thus affecting physiological transport of ions.", [["membrane", "ANATOMY", 136, 144], ["AmB", "CHEMICAL", 38, 41], ["AmB", "CHEMICAL", 38, 41], ["AmB", "SIMPLE_CHEMICAL", 38, 41], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["hydrophilic pores in the membrane core", "PROBLEM", 111, 149], ["hydrophilic pores", "OBSERVATION", 111, 128], ["membrane", "ANATOMY_MODIFIER", 136, 144]]], ["The effects of AmB-Cu 2+ complexation are demonstrated by the electronic absorption and fluorescence spectra.", [["AmB", "CHEMICAL", 15, 18], ["Cu", "CHEMICAL", 19, 21], ["AmB", "CHEMICAL", 15, 18], ["Cu 2+", "CHEMICAL", 19, 24], ["AmB", "SIMPLE_CHEMICAL", 15, 18], ["Cu 2+", "SIMPLE_CHEMICAL", 19, 24], ["fluorescence spectra", "TEST", 88, 108]]], ["The absorption spectra of AmB in water (pH=7) after the injection of water solution of copper(II)sulfate display a complex structure with hypsochromic-and bathochromic-shifted bands indicative of formation of molecular aggregates of the drug.", [["AmB", "CHEMICAL", 26, 29], ["copper(II)sulfate", "CHEMICAL", 87, 104], ["AmB", "CHEMICAL", 26, 29], ["copper(II)sulfate", "CHEMICAL", 87, 104], ["AmB", "SIMPLE_CHEMICAL", 26, 29], ["water", "SIMPLE_CHEMICAL", 33, 38], ["copper(II)sulfate", "SIMPLE_CHEMICAL", 87, 104], ["The absorption spectra of AmB in water (pH", "TEST", 0, 42], ["the injection of water solution of copper(II)sulfate", "TREATMENT", 52, 104], ["a complex structure", "PROBLEM", 113, 132], ["hypsochromic-and bathochromic-shifted bands", "TREATMENT", 138, 181], ["molecular aggregates", "OBSERVATION", 209, 229]]], ["Formation of the electronically coupled chromophores of AmB, especially aggregates, was analyzed at different Cu 2+ concentrations by the RLS (Resonance Light Scattering) technique.", [["AmB", "CHEMICAL", 56, 59], ["Cu", "CHEMICAL", 110, 112], ["RLS", "DISEASE", 138, 141], ["AmB", "CHEMICAL", 56, 59], ["Cu 2+", "CHEMICAL", 110, 115], ["AmB", "SIMPLE_CHEMICAL", 56, 59], ["Cu 2+", "SIMPLE_CHEMICAL", 110, 115]]], ["Intensity of the fluorescence emission spectrum (characteristic of the dimeric form of AmB) decreases after the AmB-Cu 2+ complex formation.", [["AmB", "CHEMICAL", 87, 90], ["AmB", "CHEMICAL", 112, 115], ["Cu", "CHEMICAL", 116, 118], ["AmB", "CHEMICAL", 87, 90], ["AmB", "CHEMICAL", 112, 115], ["Cu 2+", "CHEMICAL", 116, 121], ["AmB", "SIMPLE_CHEMICAL", 87, 90], ["AmB", "SIMPLE_CHEMICAL", 112, 115], ["Cu 2+ complex", "SIMPLE_CHEMICAL", 116, 129], ["the fluorescence emission spectrum", "TEST", 13, 47], ["the AmB", "TREATMENT", 108, 115]]], ["This effect of the formation of the AmB aggregated structures by AmB-Cu 2+ are different from the spontaneous molecular aggregation process, as deduced from the spectroscopic analysis.P-156Morfo-functional asymmetry of the olfactory receptors of the honeybee Apis mellifera L E. Frasnelli 1 , G. Anfora 2 , F. Trona 2 , F. Tessarolo 3 , R. Antolini 3 , G. Vallortigara 1 1 CiMeC, Centre for Mind/Brain Sciences, University of Trento, Italy, 2 IASMA Research and Innovation Center, Fondazione E. Mach, S. Michele all\u00b4Adige (TN), Italy, 3 Biophysics and Biosignals Lab., Dept. of Physics, University of Trento, Italy Lateralization, i.e. the different functional specialisation of the left and right side of the brain, has been documented in many vertebrate and, recently, invertebrates species.", [["olfactory", "ANATOMY", 223, 232], ["left", "ANATOMY", 683, 687], ["brain", "ANATOMY", 710, 715], ["AmB", "CHEMICAL", 36, 39], ["AmB", "CHEMICAL", 65, 68], ["Cu", "CHEMICAL", 69, 71], ["AmB", "CHEMICAL", 36, 39], ["AmB", "CHEMICAL", 65, 68], ["Cu 2+", "CHEMICAL", 69, 74], ["AmB", "SIMPLE_CHEMICAL", 36, 39], ["AmB-Cu 2+", "SIMPLE_CHEMICAL", 65, 74], ["brain", "ORGAN", 710, 715], ["olfactory receptors", "PROTEIN", 223, 242], ["Apis mellifera", "SPECIES", 259, 273], ["Apis mellifera", "SPECIES", 259, 273], ["the AmB aggregated structures", "PROBLEM", 32, 61], ["the spontaneous molecular aggregation process", "PROBLEM", 94, 139], ["the spectroscopic analysis", "TEST", 157, 183], ["P", "TEST", 184, 185], ["Frasnelli", "TEST", 279, 288], ["Anfora", "TEST", 296, 302], ["Trona", "TEST", 310, 315], ["Tessarolo", "TEST", 323, 332], ["Vallortigara", "TREATMENT", 356, 368], ["spontaneous molecular", "OBSERVATION", 98, 119], ["aggregation process", "OBSERVATION", 120, 139], ["olfactory receptors", "ANATOMY", 223, 242], ["Brain", "ANATOMY", 396, 401], ["different", "OBSERVATION_MODIFIER", 640, 649], ["functional specialisation", "OBSERVATION", 650, 675], ["left", "ANATOMY_MODIFIER", 683, 687], ["right", "ANATOMY_MODIFIER", 692, 697], ["brain", "ANATOMY", 710, 715]]], ["In the Honeybee Apis mellifera L. olfactory memory seems to involve at first the use of the right antenna.", [["right antenna", "ANATOMY", 92, 105], ["Honeybee Apis mellifera", "ORGANISM", 7, 30], ["Apis mellifera L.", "SPECIES", 16, 33], ["Apis mellifera", "SPECIES", 16, 30], ["olfactory memory", "OBSERVATION", 34, 50], ["right", "ANATOMY_MODIFIER", 92, 97]]], ["The present study investigated physiological and anatomical differences between left and right antennae of honeybees.", [["left", "ANATOMY", 80, 84], ["right antennae", "ANATOMY", 89, 103], ["The present study", "TEST", 0, 17], ["left", "ANATOMY_MODIFIER", 80, 84], ["right", "ANATOMY_MODIFIER", 89, 94], ["antennae", "ANATOMY_MODIFIER", 95, 103]]], ["Electroantennographic responses (EAG) were recorded from the left and right antennae of 16 honeybees to Linalool, a floral volatile compound, and IsoAmyl Acetate, an alarm pheromone, at 5 doses (from 0,25 to 2500 \u00b5g).", [["left", "ANATOMY", 61, 65], ["right antennae", "ANATOMY", 70, 84], ["Linalool", "CHEMICAL", 104, 112], ["IsoAmyl Acetate", "CHEMICAL", 146, 161], ["Linalool", "CHEMICAL", 104, 112], ["IsoAmyl Acetate", "CHEMICAL", 146, 161], ["Linalool", "SIMPLE_CHEMICAL", 104, 112], ["IsoAmyl Acetate", "SIMPLE_CHEMICAL", 146, 161], ["EAG", "TEST", 33, 36], ["Linalool", "TREATMENT", 104, 112], ["a floral volatile compound", "TREATMENT", 114, 140], ["IsoAmyl Acetate", "TREATMENT", 146, 161], ["an alarm pheromone", "TREATMENT", 163, 181], ["left", "ANATOMY_MODIFIER", 61, 65], ["right", "ANATOMY_MODIFIER", 70, 75]]], ["The number of sensilla on the left and right antennae was recorded by Scanning Electron Microscopy (SEM).", [["sensilla", "ANATOMY", 14, 22], ["left", "ANATOMY", 30, 34], ["right antennae", "ANATOMY", 39, 53], ["sensilla", "TISSUE", 14, 22], ["antennae", "ORGAN", 45, 53], ["Scanning Electron Microscopy", "TEST", 70, 98], ["sensilla", "ANATOMY_MODIFIER", 14, 22], ["left", "ANATOMY_MODIFIER", 30, 34], ["right", "ANATOMY_MODIFIER", 39, 44]]], ["Each antenna segment, from 14 insects, was observed from 4 different viewpoints in order to image the whole antenna surface and compute the number of sensilla.", [["antenna surface", "ANATOMY", 108, 123], ["sensilla", "ANATOMY", 150, 158], ["antenna segment", "MULTI-TISSUE_STRUCTURE", 5, 20], ["sensilla", "TISSUE", 150, 158], ["antenna segment", "DNA", 5, 20], ["antenna", "ANATOMY_MODIFIER", 5, 12], ["segment", "ANATOMY_MODIFIER", 13, 20], ["sensilla", "ANATOMY_MODIFIER", 150, 158]]], ["The tested compounds induced higher EAG responses on the right than on the left antenna at every dose.", [["left antenna", "ANATOMY", 75, 87], ["EAG", "SIMPLE_CHEMICAL", 36, 39], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["EAG responses", "OBSERVATION", 36, 49], ["right", "ANATOMY_MODIFIER", 57, 62], ["left", "ANATOMY_MODIFIER", 75, 79]]], ["SEM showed that the placoidea olfactory sensilla were slightly more abundant on the right antenna surface than on the left one.", [["olfactory sensilla", "ANATOMY", 30, 48], ["right antenna surface", "ANATOMY", 84, 105], ["olfactory sensilla", "ORGAN", 30, 48], ["the placoidea olfactory sensilla", "PROBLEM", 16, 48], ["olfactory", "ANATOMY_MODIFIER", 30, 39], ["sensilla", "ANATOMY_MODIFIER", 40, 48], ["slightly", "OBSERVATION_MODIFIER", 54, 62], ["more", "OBSERVATION_MODIFIER", 63, 67], ["abundant", "OBSERVATION_MODIFIER", 68, 76], ["right", "ANATOMY_MODIFIER", 84, 89], ["antenna", "ANATOMY_MODIFIER", 90, 97], ["surface", "ANATOMY_MODIFIER", 98, 105], ["left", "ANATOMY_MODIFIER", 118, 122]]], ["Results suggest an asymmetry in the peripheral odour perception mechanism in the honeybee A. mellifera.P-155Super-resolution imaging of DNA through single molecule switching of intercalating cyanine dyes C. Flors, C. N. J. Ravarani, D. T. F. Dryden School of Chemistry, University of Edinburgh, U.K.P-155A growing trend in far-field super resolution fluorescence microscopy involves the replacement of photoactivatable fluorophores by common dyes such as Cy, Atto or Alexa [1] .", [["intercalating cyanine", "CHEMICAL", 177, 198], ["Cy", "CHEMICAL", 455, 457], ["cyanine", "CHEMICAL", 191, 198], ["Cy", "CHEMICAL", 455, 457], ["Atto", "CHEMICAL", 459, 463], ["Alexa", "CHEMICAL", 467, 472], ["honeybee", "ORGANISM", 81, 89], ["A. mellifera", "ORGANISM", 90, 102], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["cyanine", "SIMPLE_CHEMICAL", 191, 198], ["Cy", "SIMPLE_CHEMICAL", 455, 457], ["Atto", "SIMPLE_CHEMICAL", 459, 463], ["Alexa [1]", "SIMPLE_CHEMICAL", 467, 476], ["P", "DNA", 103, 104], ["A. mellifera", "SPECIES", 90, 102], ["A. mellifera", "SPECIES", 90, 102], ["an asymmetry", "PROBLEM", 16, 28], ["the peripheral odour perception mechanism", "PROBLEM", 32, 73], ["P", "TEST", 103, 104], ["resolution imaging", "TEST", 114, 132], ["DNA", "PROBLEM", 136, 139], ["intercalating cyanine dyes", "TREATMENT", 177, 203], ["U.K.P", "TEST", 295, 300], ["fluorescence microscopy", "TEST", 350, 373], ["the replacement of photoactivatable fluorophores", "TREATMENT", 383, 431], ["common dyes", "TREATMENT", 435, 446], ["asymmetry", "OBSERVATION", 19, 28], ["peripheral", "ANATOMY_MODIFIER", 36, 46], ["odour perception", "OBSERVATION", 47, 63], ["mellifera", "OBSERVATION", 93, 102]]], ["It has been shown that these dyes can blink in useful timescales for single-molecule based imaging by adding suitable buffers.", [["these dyes", "PROBLEM", 23, 33], ["single-molecule based imaging", "TEST", 69, 98], ["suitable buffers", "TREATMENT", 109, 125]]], ["This strategy greatly simplifies the sample preparation and imaging scheme, enabling its application to a wider range of biological systems.", [["sample", "ANATOMY", 37, 43], ["the sample preparation", "TREATMENT", 33, 55], ["imaging scheme", "TEST", 60, 74]]], ["We have explored if a similar approach might be useful to study DNA topology using intercalating cyanine dyes such as YOYO-1.", [["intercalating cyanine", "CHEMICAL", 83, 104], ["cyanine", "CHEMICAL", 97, 104], ["YOYO-1", "CHEMICAL", 118, 124], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["cyanine dyes", "SIMPLE_CHEMICAL", 97, 109], ["YOYO-1", "GENE_OR_GENE_PRODUCT", 118, 124], ["intercalating cyanine dyes", "TREATMENT", 83, 109]]], ["There are two main advantages of this approach: i) DNA labelling with intercalating dyes is straightforward, and ii) the free dye in solution is essentially non-fluorescent, greatly reducing the fluorescence background.", [["DNA", "CELLULAR_COMPONENT", 51, 54], ["free dye", "SIMPLE_CHEMICAL", 121, 129], ["intercalating dyes", "TREATMENT", 70, 88], ["main", "OBSERVATION_MODIFIER", 14, 18], ["free dye", "OBSERVATION", 121, 129], ["essentially", "OBSERVATION_MODIFIER", 145, 156], ["non-fluorescent", "OBSERVATION", 157, 172]]], ["We show that YOYO-1 can blink in the absence of oxygen and in the presence of cysteamine, which allows its application to nanoscale imaging.", [["oxygen", "CHEMICAL", 48, 54], ["cysteamine", "CHEMICAL", 78, 88], ["oxygen", "CHEMICAL", 48, 54], ["cysteamine", "CHEMICAL", 78, 88], ["YOYO-1", "GENE_OR_GENE_PRODUCT", 13, 19], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["cysteamine", "SIMPLE_CHEMICAL", 78, 88], ["YOYO", "PROTEIN", 13, 17], ["oxygen", "TREATMENT", 48, 54], ["cysteamine", "TREATMENT", 78, 88], ["nanoscale imaging", "TEST", 122, 139]]], ["We exemplify its use by imaging \u03bb-DNA and a pUC19 plasmid.", [["DNA", "CELLULAR_COMPONENT", 34, 37], ["pUC19", "GENE_OR_GENE_PRODUCT", 44, 49], ["\u03bb-DNA", "DNA", 32, 37], ["pUC19 plasmid", "DNA", 44, 57], ["imaging", "TEST", 24, 31], ["a pUC19 plasmid", "TREATMENT", 42, 57]]], ["We also explore the compatibility of several intercalating dyes with biological systems such as enzymes or cells.", [["cells", "ANATOMY", 107, 112], ["cells", "CELL", 107, 112], ["enzymes", "PROTEIN", 96, 103], ["several intercalating dyes with biological systems", "PROBLEM", 37, 87], ["enzymes", "TEST", 96, 103]]], ["Our results suggest that DNA intercalating dyes are a promising option for fluorescence super-resolution studies of DNA topology.P-154Seeing more in total internal reflection fluorescence (TIRF) microscopy R. Fiolka, A. Stemmer Nanotechnology Group, ETH Z\u00fcrich, Z\u00fcrich, Switzerland Total internal reflection fluorescence (TIRF) microscopy is an effective widefield imaging tool that selectively excites a very thin sample layer within the evanescent excitation field at the glass-water interface.", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["P-154Seeing", "DNA", 129, 140], ["DNA intercalating dyes", "PROBLEM", 25, 47], ["P", "TEST", 129, 130], ["Z\u00fcrich", "TREATMENT", 262, 268], ["an effective widefield imaging tool", "TEST", 342, 377], ["a very thin sample layer", "PROBLEM", 403, 427]]], ["Lateral resolution of standard TIRF microscopy is limited to approx.", [["standard TIRF microscopy", "TEST", 22, 46], ["standard TIRF", "OBSERVATION", 22, 35]]], ["240nm using green emission, which can be insufficient for a large class of biological investigations.", [["biological investigations", "TEST", 75, 100]]], ["Additionally, the evanescent excitation field is prone to light scattering, creating out of focus blur in the final image.", [["the evanescent excitation field", "TEST", 14, 45], ["evanescent", "OBSERVATION_MODIFIER", 18, 28], ["excitation", "OBSERVATION_MODIFIER", 29, 39], ["focus blur", "OBSERVATION", 92, 102]]], ["We present several techniques that address these mentioned shortcomings of standard TIRF microscopy.", [["standard TIRF microscopy", "TEST", 75, 99]]], ["Using evanescent standing waves, the lateral resolution in TIRF microscopy can be extended by a factor of 2.5, reaching 90nm.", [["evanescent standing waves", "TEST", 6, 31], ["TIRF microscopy", "TEST", 59, 74], ["a factor", "TEST", 94, 102]]], ["We further show techniques to reduce the blur induced by light scattering of the evanescent field.", [["the blur", "PROBLEM", 37, 45], ["light", "OBSERVATION_MODIFIER", 57, 62], ["scattering", "OBSERVATION_MODIFIER", 63, 73]]], ["Finally, we demonstrate optical sub-sectioning capabilities in TIRF microscopy by acquiring several images with different penetration depth of the evanescent field and applying suitable post processing algorithms.", [["TIRF microscopy", "TEST", 63, 78], ["several images", "TEST", 92, 106]]], ["Thereby the obtainable z-resolution exceeds the classical limit of widefield microscopy, and object structures lying within the evanescent field can be reconstructed.", [["widefield microscopy", "TEST", 67, 87]]], ["The natural photosentizer hypericine (Hyp) exhibits potent properties for tumor diagnosis and photodynamic therapy.", [["tumor", "ANATOMY", 74, 79], ["hypericine", "CHEMICAL", 26, 36], ["Hyp", "CHEMICAL", 38, 41], ["tumor", "DISEASE", 74, 79], ["hypericine", "CHEMICAL", 26, 36], ["photosentizer hypericine", "SIMPLE_CHEMICAL", 12, 36], ["Hyp", "SIMPLE_CHEMICAL", 38, 41], ["tumor", "CANCER", 74, 79], ["The natural photosentizer hypericine", "TREATMENT", 0, 36], ["tumor diagnosis", "TEST", 74, 89], ["photodynamic therapy", "TREATMENT", 94, 114], ["potent properties", "OBSERVATION_MODIFIER", 52, 69], ["tumor", "OBSERVATION", 74, 79]]], ["Evidences of Hyp release from LDLs prior to passive diffusion within cells are addressed in this study.", [["cells", "ANATOMY", 69, 74], ["LDLs", "CHEMICAL", 30, 34], ["Hyp", "SIMPLE_CHEMICAL", 13, 16], ["LDLs", "SIMPLE_CHEMICAL", 30, 34], ["cells", "CELL", 69, 74], ["Hyp release", "PROBLEM", 13, 24], ["passive diffusion within cells", "PROBLEM", 44, 74], ["this study", "TEST", 92, 102], ["Hyp", "OBSERVATION", 13, 16]]], ["Fluorescent properties of Hyp have been used for dynamic studies of its interaction with low-density lipoproteins (LDLs) and U87 glioma cells.", [["LDLs", "ANATOMY", 115, 119], ["U87 glioma cells", "ANATOMY", 125, 141], ["Hyp", "SIMPLE_CHEMICAL", 26, 29], ["low-density lipoproteins", "SIMPLE_CHEMICAL", 89, 113], ["LDLs", "CELL", 115, 119], ["U87 glioma cells", "CELL", 125, 141], ["Hyp", "PROTEIN", 26, 29], ["low-density lipoproteins", "PROTEIN", 89, 113], ["LDLs", "CELL_TYPE", 115, 119], ["U87 glioma cells", "CELL_LINE", 125, 141], ["dynamic studies", "TEST", 49, 64], ["U87 glioma cells", "PROBLEM", 125, 141], ["Hyp", "OBSERVATION", 26, 29], ["U87 glioma cells", "OBSERVATION", 125, 141]]], ["Subsequent non-specific staining of intracellular membranes compartment were observed by mean of colocalization fluorescent imaging studies.", [["intracellular membranes compartment", "ANATOMY", 36, 71], ["intracellular", "CELLULAR_COMPONENT", 36, 49], ["membranes compartment", "CELLULAR_COMPONENT", 50, 71], ["Subsequent non-specific staining of intracellular membranes compartment", "PROBLEM", 0, 71], ["colocalization fluorescent imaging studies", "TEST", 97, 139], ["non-specific", "OBSERVATION_MODIFIER", 11, 23], ["staining", "OBSERVATION", 24, 32], ["intracellular membranes", "ANATOMY", 36, 59]]], ["It was shown, that monomers of Hyp are only redistributive forms.", [["Hyp", "CHEMICAL", 31, 34], ["Hyp", "SIMPLE_CHEMICAL", 31, 34], ["Hyp", "OBSERVATION", 31, 34], ["redistributive", "OBSERVATION_MODIFIER", 44, 58]]], ["Increasing of Hyp concentration leads to the formation of non-fluorescent aggregates within LDLs as well as within the U87 cells, and can preclude its photosensitizing activities.", [["LDLs", "ANATOMY", 92, 96], ["U87 cells", "ANATOMY", 119, 128], ["Hyp", "SIMPLE_CHEMICAL", 14, 17], ["LDLs", "SIMPLE_CHEMICAL", 92, 96], ["U87 cells", "CELL", 119, 128], ["U87 cells", "CELL_LINE", 119, 128], ["Hyp concentration", "PROBLEM", 14, 31], ["non-fluorescent aggregates within LDLs", "PROBLEM", 58, 96], ["Hyp concentration", "OBSERVATION", 14, 31], ["non-fluorescent aggregates", "OBSERVATION", 58, 84], ["U87 cells", "OBSERVATION", 119, 128]]], ["In all experiments, hydrophobic character of the molecules appears as the driving force of its redistribution process.", [["hydrophobic character", "OBSERVATION_MODIFIER", 20, 41], ["molecules", "OBSERVATION", 49, 58], ["redistribution process", "OBSERVATION", 95, 117]]], ["LPP-0337-06.", [["LPP-0337-06", "CHEMICAL", 0, 11], ["LPP-0337-06", "CHEMICAL", 0, 11], ["LPP-0337-06", "SIMPLE_CHEMICAL", 0, 11]]], ["We also kindly thank the synchrotron SOLEIL for using the detection system of the disco beamline.P-160LEDGF/p75 switches from a dynamic to a tight chromatin interaction upon binding to HIV-1 integrase J. Hendrix 1 , Z. Debyser 2 , Y. Engelborghs 1 1 Laboratory of Biomolecular Dynamics, Katholieke Universiteit Leuven, Belgium, 2 Laboratory of Molecular Virology and Gene Therapy, Katholieke Universiteit Leuven, Belgium Human transcriptional co-activator LEDGF/p75 is hijacked by HIV-1 integrase (IN) during the replication of HIV.", [["chromatin", "ANATOMY", 147, 156], ["P-160LEDGF", "GENE_OR_GENE_PRODUCT", 97, 107], ["p75", "GENE_OR_GENE_PRODUCT", 108, 111], ["chromatin", "CELLULAR_COMPONENT", 147, 156], ["Human", "ORGANISM", 421, 426], ["LEDGF", "GENE_OR_GENE_PRODUCT", 456, 461], ["p75", "GENE_OR_GENE_PRODUCT", 462, 465], ["HIV-1", "ORGANISM", 481, 486], ["IN", "GENE_OR_GENE_PRODUCT", 498, 500], ["HIV", "ORGANISM", 528, 531], ["synchrotron SOLEIL", "PROTEIN", 25, 43], ["P", "DNA", 97, 98], ["160LEDGF", "PROTEIN", 99, 107], ["p75", "PROTEIN", 108, 111], ["chromatin", "DNA", 147, 156], ["Human transcriptional co-activator", "PROTEIN", 421, 455], ["LEDGF", "PROTEIN", 456, 461], ["p75", "PROTEIN", 462, 465], ["IN", "PROTEIN", 498, 500], ["HIV-1", "SPECIES", 185, 190], ["Human", "SPECIES", 421, 426], ["HIV-1", "SPECIES", 481, 486], ["HIV", "SPECIES", 528, 531], ["HIV-1", "SPECIES", 185, 190], ["HIV-1", "SPECIES", 481, 486], ["HIV", "SPECIES", 528, 531], ["the disco beamline", "TREATMENT", 78, 96], ["a tight chromatin interaction", "PROBLEM", 139, 168], ["HIV", "TREATMENT", 185, 188], ["Molecular Virology", "TREATMENT", 344, 362], ["Gene Therapy", "TREATMENT", 367, 379], ["Katholieke Universiteit Leuven", "TREATMENT", 381, 411], ["Belgium Human transcriptional co-activator LEDGF", "TREATMENT", 413, 461], ["HIV", "PROBLEM", 528, 531]]], ["Little is still known about the molecular complex of these two proteins in the living cell.", [["cell", "ANATOMY", 86, 90], ["cell", "CELL", 86, 90], ["proteins", "OBSERVATION", 63, 71], ["living cell", "OBSERVATION", 79, 90]]], ["In this work we first studied the cellular chromatin interaction of eGFP-tagged LEDGF/p75 with tunable-focus fluorescence correlation spectroscopy (TF-FCS) and show that LEDGF/p75 is in equilibrium between a free Brownian motion and a very slow movement on the chromatin.", [["cellular", "ANATOMY", 34, 42], ["chromatin", "ANATOMY", 43, 52], ["chromatin", "ANATOMY", 261, 270], ["cellular", "CELL", 34, 42], ["eGFP", "GENE_OR_GENE_PRODUCT", 68, 72], ["LEDGF", "GENE_OR_GENE_PRODUCT", 80, 85], ["p75", "GENE_OR_GENE_PRODUCT", 86, 89], ["LEDGF", "GENE_OR_GENE_PRODUCT", 170, 175], ["p75", "GENE_OR_GENE_PRODUCT", 176, 179], ["chromatin", "CELLULAR_COMPONENT", 261, 270], ["eGFP", "PROTEIN", 68, 72], ["LEDGF", "PROTEIN", 80, 85], ["p75", "PROTEIN", 86, 89], ["LEDGF", "PROTEIN", 170, 175], ["p75", "PROTEIN", 176, 179], ["chromatin", "DNA", 261, 270], ["eGFP", "TEST", 68, 72], ["fluorescence correlation spectroscopy", "TEST", 109, 146], ["TF-FCS", "TEST", 148, 154], ["LEDGF", "TEST", 170, 175], ["a very slow movement on the chromatin", "PROBLEM", 233, 270], ["Brownian motion", "OBSERVATION", 213, 228], ["very", "OBSERVATION_MODIFIER", 235, 239], ["slow", "OBSERVATION_MODIFIER", 240, 244], ["movement", "OBSERVATION", 245, 253]]], ["Being dependent on the size of the laser focus, this slow movement represents a continuous associationdissociation-reassociation process that is governed by diffusion.", [["this slow movement", "PROBLEM", 48, 66], ["a continuous associationdissociation-reassociation process", "PROBLEM", 78, 136], ["dependent", "OBSERVATION_MODIFIER", 6, 15], ["size", "OBSERVATION_MODIFIER", 23, 27], ["laser", "OBSERVATION_MODIFIER", 35, 40], ["focus", "OBSERVATION", 41, 46], ["continuous", "OBSERVATION_MODIFIER", 80, 90], ["associationdissociation", "OBSERVATION", 91, 114], ["reassociation process", "OBSERVATION", 115, 136]]], ["Concentration-dependent continuous photobleaching measurements (CP) furthermore revealed the existence of high-affinity chromatin binding sites.", [["chromatin", "ANATOMY", 120, 129], ["chromatin", "CELLULAR_COMPONENT", 120, 129], ["chromatin binding sites", "DNA", 120, 143], ["Concentration", "TEST", 0, 13], ["continuous photobleaching measurements (CP) furthermore", "TEST", 24, 79], ["high-affinity chromatin binding sites", "PROBLEM", 106, 143], ["affinity chromatin", "OBSERVATION", 111, 129], ["binding sites", "OBSERVATION", 130, 143]]], ["Next, we co-expressed mRFP-tagged IN and confirmed its intracellular interaction with LEDGF/p75 by fluorescence cross-correlation spectroscopy (FCCS).", [["intracellular", "ANATOMY", 55, 68], ["mRFP", "GENE_OR_GENE_PRODUCT", 22, 26], ["IN", "GENE_OR_GENE_PRODUCT", 34, 36], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 68], ["LEDGF", "GENE_OR_GENE_PRODUCT", 86, 91], ["p75", "GENE_OR_GENE_PRODUCT", 92, 95], ["mRFP", "PROTEIN", 22, 26], ["tagged IN", "PROTEIN", 27, 36], ["LEDGF", "PROTEIN", 86, 91], ["p75", "PROTEIN", 92, 95], ["mRFP", "TEST", 22, 26], ["fluorescence cross-correlation spectroscopy", "TEST", 99, 142]]], ["Interestingly, CP and fluorescence recovery after photobleaching (FRAP) indicated that the affinity of this complex for chromatin is exceptionally high.", [["chromatin", "ANATOMY", 120, 129], ["chromatin", "CELLULAR_COMPONENT", 120, 129], ["chromatin", "DNA", 120, 129], ["CP", "PROBLEM", 15, 17], ["photobleaching (FRAP", "TREATMENT", 50, 70]]], ["By twophoton fluorescence lifetime imaging (2P-FLIM) we verified if the cellular stoichiometry was altered when the proteins were expressed together.", [["cellular", "ANATOMY", 72, 80], ["cellular", "CELL", 72, 80], ["imaging", "TEST", 35, 42], ["the cellular stoichiometry", "PROBLEM", 68, 94], ["stoichiometry", "OBSERVATION", 81, 94]]], ["We believe that this work is useful for the understanding and targeting of HIV-replication.O-159Biophysical identification of orf10 from clavulanic acid biosynthesis cluster as a CYP450 L. S. Goto 2 , C. O. Hokka 1 , J. F. Lima 2 , O. R. Nascimento 2 , A. P. U. Ara\u00fajo 2 1 Grupo de Engenharia Bioqu\u00edmica, UFSCar, BR, 2 Grupo de Biof\u00edsica Molecular \"S\u00e9rgio Mascarenhas\", USP, BR Streptomyces clavuligerus produces the clinically important \u03b2-lactamase inhibitor clavulanic acid.", [["clavulanic acid", "CHEMICAL", 137, 152], ["clavulanic acid", "CHEMICAL", 460, 475], ["clavulanic acid", "CHEMICAL", 137, 152], ["clavulanic acid", "CHEMICAL", 460, 475], ["HIV", "ORGANISM", 75, 78], ["orf10", "GENE_OR_GENE_PRODUCT", 126, 131], ["clavulanic acid", "SIMPLE_CHEMICAL", 137, 152], ["BR Streptomyces clavuligerus", "ORGANISM", 375, 403], ["\u03b2-lactamase", "SIMPLE_CHEMICAL", 438, 449], ["clavulanic acid", "SIMPLE_CHEMICAL", 460, 475], ["orf10", "PROTEIN", 126, 131], ["Streptomyces clavuligerus", "SPECIES", 378, 403], ["HIV", "SPECIES", 75, 78], ["Streptomyces clavuligerus", "SPECIES", 378, 403], ["HIV-replication", "TREATMENT", 75, 90], ["Biophysical identification", "TEST", 96, 122], ["clavulanic acid biosynthesis", "TREATMENT", 137, 165], ["BR Streptomyces clavuligerus", "TREATMENT", 375, 403], ["clavulanic acid", "TREATMENT", 460, 475]]], ["Biosynthesis related genes reside in three gene clusters, one of these, named clavulanic acid gene cluster, includes most of the known clavulanic acid biosynthetic enzymes.", [["clavulanic acid", "CHEMICAL", 78, 93], ["clavulanic acid", "CHEMICAL", 135, 150], ["clavulanic acid", "CHEMICAL", 78, 93], ["clavulanic acid", "CHEMICAL", 135, 150], ["clavulanic acid", "SIMPLE_CHEMICAL", 78, 93], ["clavulanic acid", "SIMPLE_CHEMICAL", 135, 150], ["clavulanic acid gene cluster", "DNA", 78, 106], ["clavulanic acid biosynthetic enzymes", "PROTEIN", 135, 171], ["Biosynthesis related genes", "PROBLEM", 0, 26], ["clavulanic acid gene cluster", "TREATMENT", 78, 106], ["the known clavulanic acid biosynthetic enzymes", "PROBLEM", 125, 171]]], ["The penultimate step along clavulanic acid biosynthesis remains unclear.", [["clavulanic acid", "CHEMICAL", 27, 42], ["clavulanic acid", "CHEMICAL", 27, 42], ["clavulanic acid", "SIMPLE_CHEMICAL", 27, 42], ["The penultimate step along clavulanic acid biosynthesis", "PROBLEM", 0, 55], ["clavulanic", "OBSERVATION_MODIFIER", 27, 37], ["acid biosynthesis", "OBSERVATION", 38, 55]]], ["Required transformation involves at least two events: oxidative deamination and double epimerization of (3S , 5S )-clavaminic acid into (3R, 5R)-clavaldehyde.", [["(3S , 5S )-clavaminic acid", "CHEMICAL", 104, 130], ["(3R, 5R)-clavaldehyde", "CHEMICAL", 136, 157], ["(3S , 5S )-clavaminic acid", "CHEMICAL", 104, 130], ["(3R, 5R)-clavaldehyde", "CHEMICAL", 136, 157], ["(3S , 5S )-clavaminic acid", "SIMPLE_CHEMICAL", 104, 130], ["(3R, 5R)-clavaldehyde", "SIMPLE_CHEMICAL", 136, 157], ["oxidative deamination", "TREATMENT", 54, 75], ["double epimerization", "TREATMENT", 80, 100], ["clavaminic acid", "TREATMENT", 115, 130], ["clavaldehyde", "TREATMENT", 145, 157]]], ["Downstream the known part of clavulanic acid cluster lays orf10 , a putative gene encoding a tentative cytochrome P450-like protein which knockout has been proven deleterious to clavulanic acid biosynthesis.", [["clavulanic acid", "CHEMICAL", 29, 44], ["clavulanic acid", "CHEMICAL", 178, 193], ["clavulanic acid", "CHEMICAL", 29, 44], ["clavulanic acid", "CHEMICAL", 178, 193], ["clavulanic acid", "SIMPLE_CHEMICAL", 29, 44], ["orf10", "GENE_OR_GENE_PRODUCT", 58, 63], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 103, 118], ["clavulanic acid", "SIMPLE_CHEMICAL", 178, 193], ["clavulanic acid cluster", "PROTEIN", 29, 52], ["orf10", "DNA", 58, 63], ["cytochrome P450-like protein", "PROTEIN", 103, 131], ["clavulanic acid cluster lays orf", "PROBLEM", 29, 61], ["a tentative cytochrome P450", "TEST", 91, 118], ["clavulanic acid biosynthesis", "TREATMENT", 178, 206], ["clavulanic", "OBSERVATION_MODIFIER", 29, 39], ["acid", "OBSERVATION_MODIFIER", 40, 44], ["clavulanic acid biosynthesis", "OBSERVATION", 178, 206]]], ["Should such protein exist, it would be candidate to fulfill the clavulanic acid pathway missing step.", [["clavulanic acid", "CHEMICAL", 64, 79], ["clavulanic acid", "CHEMICAL", 64, 79], ["clavulanic acid", "SIMPLE_CHEMICAL", 64, 79], ["the clavulanic acid pathway", "TREATMENT", 60, 87]]], ["In this work, orf10 encoded protein is characterized aiming to place it as a real P450.", [["orf10", "GENE_OR_GENE_PRODUCT", 14, 19], ["P450", "GENE_OR_GENE_PRODUCT", 82, 86], ["orf10 encoded protein", "PROTEIN", 14, 35], ["P450", "PROTEIN", 82, 86]]], ["For this task, molecular cloning and recombinant expression of orf10 were accomplished.", [["this task", "TEST", 4, 13], ["molecular cloning", "TREATMENT", 15, 32]]], ["Purified protein was submitted to spectroscopic measurements such as circular dichroism and electron paramagnetic resonance which indicate P450 features, including catalytic relevant heme iron redox states and homolytic peroxide scission mechanisms.", [["iron", "CHEMICAL", 188, 192], ["peroxide", "CHEMICAL", 220, 228], ["heme", "CHEMICAL", 183, 187], ["iron", "CHEMICAL", 188, 192], ["peroxide", "CHEMICAL", 220, 228], ["P450", "GENE_OR_GENE_PRODUCT", 139, 143], ["heme iron", "SIMPLE_CHEMICAL", 183, 192], ["peroxide", "SIMPLE_CHEMICAL", 220, 228], ["Purified protein", "TEST", 0, 16], ["spectroscopic measurements", "TEST", 34, 60], ["circular dichroism", "TEST", 69, 87], ["electron paramagnetic resonance", "TEST", 92, 123], ["P450 features", "PROBLEM", 139, 152], ["catalytic relevant heme iron redox states", "PROBLEM", 164, 205], ["homolytic peroxide scission mechanisms", "TREATMENT", 210, 248], ["peroxide scission", "OBSERVATION", 220, 237]]], ["Further, peroxide reaction adducts were characterized by spin trapping.", [["peroxide", "CHEMICAL", 9, 17], ["peroxide", "CHEMICAL", 9, 17], ["peroxide", "SIMPLE_CHEMICAL", 9, 17], ["spin", "SIMPLE_CHEMICAL", 57, 61], ["peroxide reaction adducts", "PROBLEM", 9, 34], ["spin trapping", "OBSERVATION", 57, 70]]], ["This work is supported by FAPESP.P-158Muscle structure and GABAergic innervations in the limbs of barnacle cyprid L. Gallus 1 , S. Ferrando 1 , C. Gambardella 1 , A. Diaspro 2 , P. Bianchini 2 , P. Ramoino 3 , V. Piazza 4 , G. Tagliafierro 1 1 LIBiOM, DIBIO, Universit\u00e0 di Genova, Italy, 2 IFOM-LAMBS/microscobio, DIFI, Universit\u00e0 di Genova, Italy, 3 DIPTERIS, Universit\u00e0 di Genova, Italy, 4 ISMAR CNR, Venezia, Veneto, Italy Balanus amphitrite is a sessile crustacean that settles at the larval stage of cyprid.", [["GABAergic innervations", "ANATOMY", 59, 81], ["limbs", "ANATOMY", 89, 94], ["GABAergic innervations", "MULTI-TISSUE_STRUCTURE", 59, 81], ["limbs", "ORGANISM_SUBDIVISION", 89, 94], ["P", "DNA", 33, 34], ["L. Gallus", "SPECIES", 114, 123], ["L. Gallus", "SPECIES", 114, 123], ["P", "TEST", 33, 34], ["GABAergic innervations", "PROBLEM", 59, 81], ["barnacle cyprid", "TEST", 98, 113], ["Ferrando", "TEST", 131, 139], ["Piazza", "TREATMENT", 213, 219], ["Tagliafierro", "TREATMENT", 227, 239], ["Venezia", "TREATMENT", 403, 410], ["Balanus amphitrite", "TREATMENT", 426, 444], ["a sessile crustacean", "TREATMENT", 448, 468], ["GABAergic innervations", "OBSERVATION", 59, 81], ["limbs", "ANATOMY", 89, 94], ["barnacle", "ANATOMY", 98, 106], ["Gallus", "ANATOMY", 117, 123]]], ["In this stage we studied the GABAergic innervation of limb striated muscular fibers, by immunohistochemistry.", [["limb striated muscular fibers", "ANATOMY", 54, 83], ["limb striated muscular fibers", "TISSUE", 54, 83], ["limb striated muscular fibers", "PROBLEM", 54, 83], ["GABAergic innervation", "OBSERVATION", 29, 50], ["limb", "ANATOMY_MODIFIER", 54, 58], ["muscular fibers", "ANATOMY", 68, 83]]], ["The second harmonic generation (SHG) and 2-photon excitation (2PE) microscopy were used to set out the muscle structure and its relationship with nerve terminal.", [["muscle", "ANATOMY", 103, 109], ["nerve terminal", "ANATOMY", 146, 160], ["muscle", "ORGAN", 103, 109], ["nerve terminal", "MULTI-TISSUE_STRUCTURE", 146, 160], ["The second harmonic generation (SHG)", "TREATMENT", 0, 36], ["2-photon excitation (2PE)", "TREATMENT", 41, 66], ["microscopy", "TEST", 67, 77], ["muscle", "ANATOMY", 103, 109], ["nerve", "ANATOMY", 146, 151]]], ["The laser system used is a Ti:Sapphire Chameleon-Ultra (Coherent Inc, Santa Clara, CA, USA), tunable between 690 nm and 1040 nm and characterized by a pulse width of 140 fs delivered at a repetition rate of 90 MHz by means of a homebuilt set-up (Bianchini P. and Diaspro A. J Biophotonics 2008 1:443-50).", [["Ti", "CHEMICAL", 27, 29], ["a pulse width", "TEST", 149, 162], ["a repetition rate", "TEST", 186, 203]]], ["The z-stacks were performed in order to obtain the 3-dimensional distribution of the muscular fibers.", [["muscular fibers", "ANATOMY", 85, 100], ["muscular fibers", "TISSUE", 85, 100], ["The z-stacks", "TEST", 0, 12], ["muscular fibers", "ANATOMY", 85, 100]]], ["In the posterior ganglion GAD immunoreactive (IR) motor neurons were arranged in 12 clusters near the emergence of the limb nerves.", [["posterior ganglion", "ANATOMY", 7, 25], ["IR) motor neurons", "ANATOMY", 46, 63], ["limb nerves", "ANATOMY", 119, 130], ["posterior ganglion GAD immunoreactive", "GENE_OR_GENE_PRODUCT", 7, 44], ["limb nerves", "MULTI-TISSUE_STRUCTURE", 119, 130], ["posterior ganglion GAD immunoreactive (IR) motor neurons", "CELL_TYPE", 7, 63], ["posterior", "ANATOMY_MODIFIER", 7, 16], ["ganglion", "ANATOMY", 17, 25], ["limb nerves", "ANATOMY", 119, 130]]], ["GABA and GABAbR1 IR neuromuscular junctions (NJ) were localized in the limb muscle fibers; VGAT IR cells surrounded each limb muscles.", [["neuromuscular junctions", "ANATOMY", 20, 43], ["limb muscle fibers", "ANATOMY", 71, 89], ["VGAT IR cells", "ANATOMY", 91, 104], ["limb muscles", "ANATOMY", 121, 133], ["GABA", "CHEMICAL", 0, 4], ["GABA", "CHEMICAL", 0, 4], ["GABA", "SIMPLE_CHEMICAL", 0, 4], ["GABAbR1", "GENE_OR_GENE_PRODUCT", 9, 16], ["neuromuscular junctions", "CELLULAR_COMPONENT", 20, 43], ["NJ", "GENE_OR_GENE_PRODUCT", 45, 47], ["limb muscle fibers", "CELL", 71, 89], ["VGAT IR cells", "CELL", 91, 104], ["limb muscles", "ORGANISM_SUBDIVISION", 121, 133], ["GABAbR1", "PROTEIN", 9, 16], ["VGAT IR cells", "CELL_TYPE", 91, 104], ["GABA and GABAbR1 IR neuromuscular junctions", "TREATMENT", 0, 43], ["neuromuscular junctions", "ANATOMY", 20, 43], ["limb muscle", "ANATOMY", 71, 82], ["limb muscles", "ANATOMY", 121, 133]]], ["These results suggest that GABA plays a key role in the regulation of limbs movement.", [["limbs", "ANATOMY", 70, 75], ["GABA", "CHEMICAL", 27, 31], ["GABA", "CHEMICAL", 27, 31], ["GABA", "SIMPLE_CHEMICAL", 27, 31], ["limbs", "ORGANISM_SUBDIVISION", 70, 75], ["limbs", "ANATOMY", 70, 75]]], ["The SHG was very useful to outline the relationship between nerve terminals and limbs muscle fibers.", [["nerve terminals", "ANATOMY", 60, 75], ["limbs muscle fibers", "ANATOMY", 80, 99], ["nerve terminals", "MULTI-TISSUE_STRUCTURE", 60, 75], ["limbs muscle fibers", "TISSUE", 80, 99], ["nerve", "ANATOMY", 60, 65], ["limbs muscle", "ANATOMY", 80, 92]]], ["Giant unilamellar vesicles (GUVs) are very useful model membrane systems to study many aspects of lipid-lipid and lipid protein interactions, particularly employing fluorescence microscopy related techniques (Bagatolli 2006) .", [["Giant unilamellar vesicles", "ANATOMY", 0, 26], ["GUVs", "ANATOMY", 28, 32], ["membrane systems", "ANATOMY", 56, 72], ["unilamellar vesicles", "CELLULAR_COMPONENT", 6, 26], ["GUVs", "CELLULAR_COMPONENT", 28, 32], ["lipid", "SIMPLE_CHEMICAL", 98, 103], ["lipid", "SIMPLE_CHEMICAL", 104, 109], ["lipid", "SIMPLE_CHEMICAL", 114, 119], ["Giant unilamellar vesicles", "PROBLEM", 0, 26], ["lipid-lipid", "TREATMENT", 98, 109], ["lipid protein interactions", "TREATMENT", 114, 140], ["fluorescence microscopy", "TEST", 165, 188], ["unilamellar vesicles", "OBSERVATION", 6, 26]]], ["The use of this model system can be particularly useful to study aspects related with the lateral structure of bacterial membranes using the aforementioned approach (i.e. fluorescence microscopy).", [["membranes", "ANATOMY", 121, 130], ["bacterial membranes", "CELLULAR_COMPONENT", 111, 130], ["this model system", "TREATMENT", 11, 28], ["bacterial membranes", "PROBLEM", 111, 130], ["fluorescence microscopy", "TEST", 171, 194], ["lateral", "ANATOMY_MODIFIER", 90, 97], ["bacterial membranes", "OBSERVATION", 111, 130]]], ["Bacterial cells have a size close to the resolution limit of optical microscopy and details about the organization of their membranes are not easy to achieve using such technique.", [["Bacterial cells", "ANATOMY", 0, 15], ["membranes", "ANATOMY", 124, 133], ["Bacterial cells", "CELL", 0, 15], ["membranes", "CELLULAR_COMPONENT", 124, 133], ["Bacterial cells", "PROBLEM", 0, 15], ["optical microscopy", "TEST", 61, 79], ["such technique", "TREATMENT", 164, 178], ["cells", "OBSERVATION", 10, 15], ["size", "OBSERVATION_MODIFIER", 23, 27]]], ["Recently a new electroformation method to prepare GUVs composed of compositionally complex mixtures under physiological conditions was developed in our laboratory (Montes 2007).", [["a new electroformation method", "TREATMENT", 9, 38], ["new", "OBSERVATION_MODIFIER", 11, 14]]], ["In the present work we further extended this electroformation method to prepare GUVs composed of bacterial lipid extracts and lipopolysaccharide (LPS).", [["extracts", "ANATOMY", 113, 121], ["lipopolysaccharide", "CHEMICAL", 126, 144], ["LPS", "CHEMICAL", 146, 149], ["GUVs", "SIMPLE_CHEMICAL", 80, 84], ["lipid extracts", "ORGANISM_SUBSTANCE", 107, 121], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 126, 144], ["LPS", "SIMPLE_CHEMICAL", 146, 149], ["this electroformation method", "TREATMENT", 40, 68], ["bacterial lipid extracts", "TREATMENT", 97, 121], ["lipopolysaccharide (LPS", "TREATMENT", 126, 149]]], ["In our experiments we used E.coli lipid extract to prepare small vesicles containing various LPS species, from smooth strains and rough mutants.", [["vesicles", "ANATOMY", 65, 73], ["smooth strains", "ANATOMY", 111, 125], ["LPS", "CHEMICAL", 93, 96], ["E.coli", "SPECIES", 27, 33], ["E.coli lipid extract", "TREATMENT", 27, 47], ["small vesicles", "PROBLEM", 59, 73], ["various LPS species", "PROBLEM", 85, 104], ["smooth strains", "PROBLEM", 111, 125], ["rough mutants", "PROBLEM", 130, 143], ["small vesicles", "OBSERVATION", 59, 73], ["various LPS species", "OBSERVATION", 85, 104], ["smooth strains", "OBSERVATION", 111, 125], ["rough mutants", "OBSERVATION", 130, 143]]], ["SUVs were used as starting point to electroform GUVs using various types of buffers with high ionic strength.", [["SUVs", "SIMPLE_CHEMICAL", 0, 4], ["SUVs", "TREATMENT", 0, 4], ["high ionic strength", "TREATMENT", 89, 108], ["ionic strength", "OBSERVATION", 94, 108]]], ["The successfully obtained bacterial-GUVs were used to study the interaction of these membranes with known LPS-binging proteins (lung surfactant protein D, SP-D) and peptides (polymyxin B).", [["membranes", "ANATOMY", 85, 94], ["lung", "ANATOMY", 128, 132], ["LPS", "CHEMICAL", 106, 109], ["polymyxin B", "CHEMICAL", 175, 186], ["polymyxin B", "CHEMICAL", 175, 186], ["membranes", "CELLULAR_COMPONENT", 85, 94], ["LPS", "SIMPLE_CHEMICAL", 106, 109], ["lung", "ORGAN", 128, 132], ["SP-D", "SIMPLE_CHEMICAL", 155, 159], ["polymyxin B", "SIMPLE_CHEMICAL", 175, 186], ["LPS-binging proteins", "PROTEIN", 106, 126], ["lung surfactant protein D", "PROTEIN", 128, 153], ["SP", "PROTEIN", 155, 157], ["bacterial-GUVs", "TREATMENT", 26, 40], ["known LPS", "PROBLEM", 100, 109], ["binging proteins", "PROBLEM", 110, 126], ["lung surfactant protein D", "TEST", 128, 153], ["peptides (polymyxin B", "TREATMENT", 165, 186], ["lung", "ANATOMY", 128, 132]]], ["Our results remark the usefulness of this particular bilayer models to perform studies mimicking bacterial membranes.P-164Mechanical properties of polymeric membranes probed by AFM M. Kocun 1 , I. Mey 1 , W. M\u00fcller 2 , M. Maskos 2 , A. Janshoff 1 1 Georg-August Universit\u00e4t, Institute for Physical Chemistry, G\u00f6ttingen, Germany, 2 Johannes Gutenberg Universit\u00e4t, Institute for Physical Chemistry, Mainz, Germany Many biological cell functions are dependent on the mechanical properties of the membrane.", [["membranes", "ANATOMY", 107, 116], ["membranes", "ANATOMY", 157, 166], ["cell", "ANATOMY", 428, 432], ["membrane", "ANATOMY", 493, 501], ["bacterial membranes", "CELLULAR_COMPONENT", 97, 116], ["cell", "CELL", 428, 432], ["membrane", "CELLULAR_COMPONENT", 493, 501], ["mimicking bacterial membranes", "PROBLEM", 87, 116], ["polymeric membranes", "TREATMENT", 147, 166], ["bacterial membranes", "OBSERVATION", 97, 116], ["polymeric membranes", "OBSERVATION", 147, 166], ["biological cell functions", "OBSERVATION", 417, 442], ["membrane", "ANATOMY_MODIFIER", 493, 501]]], ["Polymeric membranes that mimic native cell membranes are valuable research tools which can be used to better understand the physics of biological membranes.", [["membranes", "ANATOMY", 10, 19], ["cell membranes", "ANATOMY", 38, 52], ["membranes", "ANATOMY", 146, 155], ["membranes", "CELLULAR_COMPONENT", 10, 19], ["cell membranes", "CELLULAR_COMPONENT", 38, 52], ["membranes", "CELLULAR_COMPONENT", 146, 155], ["Polymeric membranes", "TREATMENT", 0, 19], ["membranes", "OBSERVATION", 10, 19], ["native cell membranes", "OBSERVATION", 31, 52]]], ["We have investigated free standing artificial membranes prepared from polybutadiene-b-polyethylene oxide (PB-b-PEO).", [["membranes", "ANATOMY", 46, 55], ["polybutadiene-b-polyethylene oxide", "CHEMICAL", 70, 104], ["PB-b-PEO", "CHEMICAL", 106, 114], ["polybutadiene", "CHEMICAL", 70, 83], ["polyethylene oxide", "CHEMICAL", 86, 104], ["PEO", "CHEMICAL", 111, 114], ["polybutadiene-b-polyethylene oxide", "SIMPLE_CHEMICAL", 70, 104], ["PB-b-PEO", "SIMPLE_CHEMICAL", 106, 114], ["free standing artificial membranes", "TREATMENT", 21, 55], ["polybutadiene-b-polyethylene oxide", "TREATMENT", 70, 104], ["PB-b-PEO)", "TREATMENT", 106, 115]]], ["The membranes were prepared from vesicles ruptured on porous silicon substrates.", [["membranes", "ANATOMY", 4, 13], ["vesicles", "ANATOMY", 33, 41], ["silicon", "CHEMICAL", 61, 68], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["vesicles", "ORGANISM_SUBSTANCE", 33, 41], ["porous silicon substrates", "TREATMENT", 54, 79], ["ruptured", "OBSERVATION", 42, 50], ["porous silicon substrates", "OBSERVATION", 54, 79]]], ["These polymeric membranes were studied by confocal laser scanning microscopy (CLSM) and atomic force microscopy (AFM).", [["polymeric membranes", "ANATOMY", 6, 25], ["confocal laser scanning microscopy", "TEST", 42, 76], ["atomic force microscopy", "TEST", 88, 111], ["polymeric membranes", "OBSERVATION", 6, 25]]], ["Force indentation curves were performed on the membranes and theoretical models were used to extract elasticity constants from the results.", [["membranes", "ANATOMY", 47, 56], ["membranes", "CELLULAR_COMPONENT", 47, 56], ["Force indentation curves", "TEST", 0, 24]]], ["The study of polymeric membranes can give insight to the function of biological membranes, furthermore polymeric membranes can be used to create new hybrid systems by incorporating biological (lipids, proteins), artificial (polymers, dyes) and inorganic (nanoparticles) components.P-163Site-directed spin labeling study of the lightharvesting complex CP29 The topology of the long N-terminal domain of the photosynthetic light-harvesting complex CP29 was studied using electron spin resonance (ESR).", [["membranes", "ANATOMY", 23, 32], ["membranes", "ANATOMY", 80, 89], ["membranes", "ANATOMY", 113, 122], ["inorganic", "CHEMICAL", 244, 253], ["P-163Site", "CHEMICAL", 281, 290], ["CP29", "CHEMICAL", 351, 355], ["CP29", "CHEMICAL", 351, 355], ["N", "CHEMICAL", 381, 382], ["membranes", "CELLULAR_COMPONENT", 80, 89], ["membranes", "CELLULAR_COMPONENT", 113, 122], ["lipids", "SIMPLE_CHEMICAL", 193, 199], ["inorganic", "SIMPLE_CHEMICAL", 244, 253], ["CP29", "SIMPLE_CHEMICAL", 446, 450], ["electron", "SIMPLE_CHEMICAL", 469, 477], ["lightharvesting complex", "PROTEIN", 327, 350], ["CP29", "PROTEIN", 351, 355], ["long N-terminal domain", "PROTEIN", 376, 398], ["photosynthetic light-harvesting complex CP29", "PROTEIN", 406, 450], ["The study", "TEST", 0, 9], ["polymeric membranes", "TREATMENT", 13, 32], ["furthermore polymeric membranes", "TREATMENT", 91, 122], ["new hybrid systems", "PROBLEM", 145, 163], ["incorporating biological (lipids, proteins", "TREATMENT", 167, 209], ["artificial (polymers, dyes", "TREATMENT", 212, 238], ["inorganic (nanoparticles) components", "TREATMENT", 244, 280], ["P", "TEST", 281, 282], ["the photosynthetic light", "TREATMENT", 402, 426], ["electron spin resonance", "TEST", 469, 492]]], ["CP29 is a minor antenna complex of the Photosystem II (PSII), a multisubunit protein complex.", [["CP29", "CHEMICAL", 0, 4], ["CP29", "GENE_OR_GENE_PRODUCT", 0, 4], ["Photosystem II", "GENE_OR_GENE_PRODUCT", 39, 53], ["PSII", "GENE_OR_GENE_PRODUCT", 55, 59], ["CP29", "PROTEIN", 0, 4], ["minor antenna complex", "PROTEIN", 10, 31], ["Photosystem II", "PROTEIN", 39, 53], ["PSII", "PROTEIN", 55, 59], ["multisubunit protein complex", "PROTEIN", 64, 92], ["a multisubunit protein complex", "PROBLEM", 62, 92], ["protein complex", "OBSERVATION", 77, 92]]], ["Wild-type CP29 protein containing a single cysteine at position 108 and nine single cysteine mutants were produced, allowing to label different parts of the domain with a nitroxide spin label.", [["cysteine", "CHEMICAL", 43, 51], ["nitroxide", "CHEMICAL", 171, 180], ["cysteine", "CHEMICAL", 43, 51], ["cysteine", "CHEMICAL", 84, 92], ["nitroxide", "CHEMICAL", 171, 180], ["CP29", "GENE_OR_GENE_PRODUCT", 10, 14], ["cysteine", "AMINO_ACID", 43, 51], ["cysteine", "AMINO_ACID", 84, 92], ["nitroxide", "SIMPLE_CHEMICAL", 171, 180], ["Wild-type CP29 protein", "PROTEIN", 0, 22], ["a single cysteine at position", "TREATMENT", 34, 63], ["nine single cysteine mutants", "TREATMENT", 72, 100], ["a nitroxide spin label", "TREATMENT", 169, 191]]], ["In all cases the apoproteins were either solubilized in detergent or they were reconstituted with their native pigments (holoproteins) in vitro.", [["apoproteins", "GENE_OR_GENE_PRODUCT", 17, 28], ["holoproteins", "SIMPLE_CHEMICAL", 121, 133]]], ["The spin label ESR spectra were analyzed in terms of a multi-component spectral simulation approach, based on hybrid evolutionary optimization and solution condensation.", [["The spin label ESR spectra", "TEST", 0, 26], ["a multi-component spectral simulation approach", "TREATMENT", 53, 99], ["hybrid evolutionary optimization", "TREATMENT", 110, 142], ["solution condensation", "PROBLEM", 147, 168]]], ["These results permit to trace the structural organization of the long N-terminal domain of CP29.", [["N", "CHEMICAL", 70, 71], ["CP29", "GENE_OR_GENE_PRODUCT", 91, 95], ["long N-terminal domain", "PROTEIN", 65, 87], ["CP29", "PROTEIN", 91, 95]]], ["We took the crystal structure of light-harvesting complex II (LHCII), major antenna complex of PSII available in PDB as a starting point and constructed a model for CP29 based on ESR data.P-162Present opportunities and future developments in soft x-ray transmission and emission microscopy B. Kaulich, A. Gianoncelli, V. Babin, M. Kiskinova Elettra -Sincrotrone Trieste, S.S. 14 km 163.5 in Area Science Park, I-34012 Trieste-Basovizza, Italy Soft X-ray transmission and emission imaging and spectromicroscopy are bridging the gap to other microscopy techniques in terms of lateral resolution, penetration depth and chemical sensitivity.", [["light-harvesting complex II", "GENE_OR_GENE_PRODUCT", 33, 60], ["LHCII", "GENE_OR_GENE_PRODUCT", 62, 67], ["PSII", "GENE_OR_GENE_PRODUCT", 95, 99], ["CP29", "SIMPLE_CHEMICAL", 165, 169], ["light-harvesting complex II", "PROTEIN", 33, 60], ["LHCII", "PROTEIN", 62, 67], ["major antenna complex", "PROTEIN", 70, 91], ["PSII", "PROTEIN", 95, 99], ["CP29", "PROTEIN", 165, 169], ["light-harvesting complex II (LHCII", "TREATMENT", 33, 67], ["ESR data", "TEST", 179, 187], ["soft x-ray transmission", "TEST", 242, 265], ["emission microscopy", "TEST", 270, 289], ["Soft X-ray transmission", "TEST", 443, 466], ["emission imaging", "TEST", 471, 487], ["spectromicroscopy", "TREATMENT", 492, 509], ["other microscopy techniques", "TEST", 534, 561], ["lateral resolution", "TEST", 574, 592], ["penetration depth", "TEST", 594, 611], ["chemical sensitivity", "TEST", 616, 636]]], ["The novel soft X-ray spectromicroscopy approach of the TwinMic instrument at the Elettra synchrotron radiation facility is combining several imaging modes for morphology characterization, such as scanning, projection and full-field imaging with several contrast techniques including brightfield, darkfield, differential phase and interference contrast at sub-100 nm lateral resolution.", [["The novel soft X-ray spectromicroscopy approach", "TREATMENT", 0, 47], ["morphology characterization", "TEST", 159, 186], ["scanning, projection and full-field imaging", "TEST", 196, 239], ["brightfield, darkfield, differential phase", "TEST", 283, 325], ["interference contrast", "TEST", 330, 351]]], ["Complementary chemical information is provided by chemical imaging and micro-spectroscopy using the photon-in/photon-out Xray absorption and X-ray fluorescence.", [["Xray", "SIMPLE_CHEMICAL", 121, 125], ["chemical imaging", "TEST", 50, 66], ["micro-spectroscopy", "TEST", 71, 89], ["the photon", "TEST", 96, 106], ["Xray absorption", "TEST", 121, 136], ["X-ray fluorescence", "TEST", 141, 159]]], ["Unique for TwinMic is the low-energy X-ray fluorescence setup operated at 280 -2200 eV photon energies, which allows simultaneous analysis of the morphology, and the distribution of light elements on cellular and sub-cellular level.", [["cellular", "ANATOMY", 200, 208], ["cellular", "ANATOMY", 217, 225], ["cellular", "CELL", 200, 208], ["cellular", "CELL", 217, 225], ["light elements", "DNA", 182, 196], ["morphology", "OBSERVATION_MODIFIER", 146, 156], ["light elements", "OBSERVATION", 182, 196]]], ["In the presentation the principles of the methods used in the TwinMic instruments the performance and potentials of the instrument will be demonstrated by several examples of applications in the field of human, animal and plant biology, biophysics and chemistry, physiology and genetics.", [["human", "ORGANISM", 204, 209], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["the methods", "TREATMENT", 38, 49]]], ["The potential impact of microscopy techniques using free-electron X-ray lasers on biophysics will be illustrated by the DiProI project at Fermi@Elettra.P-161-Imaging and spectroscopy -AbstractsFluorescence anisotropy and AFM used as tools to characterized porin\u00b4s reconstituion in LUV\u00b4s S. C. Lopes, I. Sousa, P. Eaton, P. Gameiro Requimte, Faculdade de Ci\u00eancias, Universidade do Porto, Rua do Campo Alegre, 4169-007 Porto, Portugal A major requirement to perform structural studies with membrane proteins is to define efficient reconstitution protocols that assure, not only, a high incorporation degree in preformed liposomes, but also a protein directionality and topology that mimics its in vivo conditions.", [["membrane", "ANATOMY", 488, 496], ["membrane", "CELLULAR_COMPONENT", 488, 496], ["liposomes", "SIMPLE_CHEMICAL", 618, 627], ["membrane proteins", "PROTEIN", 488, 505], ["microscopy techniques", "TEST", 24, 45], ["free-electron X-ray lasers", "TREATMENT", 52, 78], ["P", "TEST", 152, 153], ["Imaging and spectroscopy", "TEST", 158, 182], ["Fluorescence anisotropy", "TEST", 193, 216], ["AFM", "TEST", 221, 224], ["structural studies", "TEST", 464, 482], ["membrane proteins", "TREATMENT", 488, 505], ["efficient reconstitution protocols", "TREATMENT", 519, 553], ["a high incorporation degree in preformed liposomes", "PROBLEM", 577, 627], ["high", "OBSERVATION_MODIFIER", 579, 583], ["incorporation degree", "OBSERVATION_MODIFIER", 584, 604]]], ["For this kind of studies, protein reconstitution in membranes systems via a detergent-mediated pathway is usually successfully adopted, since detergents are generally used in the initial isolation and purification of membrane proteins.", [["membranes", "ANATOMY", 52, 61], ["membrane", "ANATOMY", 217, 225], ["membranes", "CELLULAR_COMPONENT", 52, 61], ["membrane", "CELLULAR_COMPONENT", 217, 225], ["membrane proteins", "PROTEIN", 217, 234], ["studies", "TEST", 17, 24], ["protein reconstitution in membranes systems", "TREATMENT", 26, 69], ["a detergent-mediated pathway", "TREATMENT", 74, 102], ["the initial isolation", "TREATMENT", 175, 196], ["membrane proteins", "PROBLEM", 217, 234], ["membrane proteins", "OBSERVATION", 217, 234]]], ["In this study we report the reconstitution of OmpF in preformed DMPC and E. coli liposomes using two different techniques for detergent removal: (1) exclusion chromatography and (2) incubation with detergent adsorbing beads.", [["DMPC", "CHEMICAL", 64, 68], ["DMPC", "CHEMICAL", 64, 68], ["OmpF", "GENE_OR_GENE_PRODUCT", 46, 50], ["DMPC", "SIMPLE_CHEMICAL", 64, 68], ["E. coli", "ORGANISM", 73, 80], ["liposomes", "SIMPLE_CHEMICAL", 81, 90], ["OmpF", "PROTEIN", 46, 50], ["E. coli", "SPECIES", 73, 80], ["E. coli", "SPECIES", 73, 80], ["this study", "TEST", 3, 13], ["the reconstitution of OmpF in preformed DMPC and E. coli liposomes", "TREATMENT", 24, 90], ["detergent removal", "TREATMENT", 126, 143], ["exclusion chromatography", "TEST", 149, 173], ["detergent adsorbing beads", "TREATMENT", 198, 223], ["coli liposomes", "OBSERVATION", 76, 90]]], ["The incorporation degree was determined by bicinchoninic acid assay and fluorescence anisotropy was used to determine OmpF effect on the structural order of membrane lipids.", [["membrane lipids", "ANATOMY", 157, 172], ["bicinchoninic acid", "CHEMICAL", 43, 61], ["bicinchoninic acid", "CHEMICAL", 43, 61], ["bicinchoninic acid", "SIMPLE_CHEMICAL", 43, 61], ["OmpF", "GENE_OR_GENE_PRODUCT", 118, 122], ["membrane lipids", "CELLULAR_COMPONENT", 157, 172], ["OmpF", "PROTEIN", 118, 122], ["bicinchoninic acid assay", "TEST", 43, 67], ["fluorescence anisotropy", "TEST", 72, 95], ["membrane lipids", "TREATMENT", 157, 172], ["incorporation degree", "OBSERVATION", 4, 24]]], ["These results show that protein insertion in membranes depends both on the technique used to remove detergent and on the lipids used to prepare the liposomes.", [["membranes", "ANATOMY", 45, 54], ["membranes", "CELLULAR_COMPONENT", 45, 54], ["liposomes", "SIMPLE_CHEMICAL", 148, 157], ["protein insertion in membranes", "TREATMENT", 24, 54], ["the technique", "TREATMENT", 71, 84], ["detergent", "TREATMENT", 100, 109], ["the lipids", "TREATMENT", 117, 127], ["the liposomes", "TREATMENT", 144, 157], ["protein insertion", "OBSERVATION", 24, 41]]], ["Moreover more anisotropy and atomic force microscopy studies will allow a better characterization of bacterial model system membranes.P-168The wavelength dependence of the luminescence for different sized AuNP by 2-photon CLSM K. Li, M. Schneider Pharmaceutical Nanotechnology, Saarland University, Campus A4 1, D-66123 Saarbr\u00fccken, Germany Gold nanoparticles (AuNP) with different sizes can exhibit original luminescent properties if excited with pulsed nearinfrared laser light which makes them a suitable object to be detected in biological tissues.", [["system membranes", "ANATOMY", 117, 133], ["tissues", "ANATOMY", 544, 551], ["AuNP", "CHEMICAL", 205, 209], ["AuNP", "CHEMICAL", 361, 365], ["membranes", "CELLULAR_COMPONENT", 124, 133], ["AuNP", "SIMPLE_CHEMICAL", 205, 209], ["Gold nanoparticles", "SIMPLE_CHEMICAL", 341, 359], ["AuNP", "SIMPLE_CHEMICAL", 361, 365], ["tissues", "TISSUE", 544, 551], ["atomic force microscopy studies", "TEST", 29, 60], ["bacterial model system membranes", "PROBLEM", 101, 133], ["The wavelength dependence of the luminescence", "TREATMENT", 139, 184], ["different sized AuNP", "TREATMENT", 189, 209], ["Germany Gold nanoparticles (AuNP) with different sizes", "TREATMENT", 333, 387], ["pulsed nearinfrared laser light", "TREATMENT", 448, 479], ["bacterial model system membranes", "OBSERVATION", 101, 133]]], ["The main obstacle is to distinguish between the object of interest (emitted light) and the autofluorescence from the sample which limits the scope of application of AuNP.", [["sample", "ANATOMY", 117, 123], ["AuNP", "CHEMICAL", 165, 169], ["AuNP", "SIMPLE_CHEMICAL", 165, 169], ["the autofluorescence", "TEST", 87, 107], ["the sample", "TEST", 113, 123], ["application of AuNP", "TREATMENT", 150, 169], ["main", "OBSERVATION_MODIFIER", 4, 8], ["obstacle", "OBSERVATION", 9, 17]]], ["Therefore, our aim is to characterize the luminescent properties of such nanoparticles regarding their excitation and emission.", [["such nanoparticles", "TREATMENT", 68, 86]]], ["In this study, the excitation and emission spectra of AuNP with different sizes below 50 nm in an excitation range of 720 nm to 900 nm were investigated.", [["AuNP", "CHEMICAL", 54, 58], ["AuNP", "SIMPLE_CHEMICAL", 54, 58], ["this study", "TEST", 3, 13], ["sizes", "OBSERVATION_MODIFIER", 74, 79]]], ["Our study shows the emission spectra curves of AuNP are broadband spectrum and vary with the changing of excitation wavelength from 720 nm to 900 nm.", [["AuNP", "CHEMICAL", 47, 51], ["AuNP", "SIMPLE_CHEMICAL", 47, 51], ["Our study", "TEST", 0, 9], ["excitation wavelength", "TREATMENT", 105, 126]]], ["The results also suggest the minimum laser power necessary to trap the AuNP depends on particle size and excitation light wavelength and a maximum power above which the particles are destroyed.", [["AuNP", "CHEMICAL", 71, 75], ["AuNP", "SIMPLE_CHEMICAL", 71, 75], ["particle size", "OBSERVATION_MODIFIER", 87, 100]]], ["In all the experiment above, to avoid the simultaneous effects from slide and cover slip is a must.P-167Rocking, tumbling, and sliding:P-167Real-time nanomotion of a membrane-bound virus P. Kukura 1 , H. Ewers 2 , C. Mueller 1 , A. Renn 1 , A. Helenius 2 , V. Sandoghdar 1 1 Laboratory of Physical Chemistry, ETH Zurich, CH-8093 Zurich, Switzerland, 2 Institute of Biochemistry, ETH Zurich, CH-8093 Zurich, SwitzerlandP-167The interaction of a virus with its receptors in the plasma membrane is decisive for its infection of cells.", [["membrane", "ANATOMY", 166, 174], ["plasma membrane", "ANATOMY", 476, 491], ["cells", "ANATOMY", 525, 530], ["P-167Rocking", "CHEMICAL", 99, 111], ["CH-8093", "CHEMICAL", 391, 398], ["SwitzerlandP-167", "CHEMICAL", 407, 423], ["infection", "DISEASE", 512, 521], ["membrane", "CELLULAR_COMPONENT", 166, 174], ["plasma membrane", "CELLULAR_COMPONENT", 476, 491], ["cells", "CELL", 525, 530], ["P", "DNA", 99, 100], ["P", "TEST", 99, 100], ["a membrane", "TREATMENT", 164, 174], ["a virus", "PROBLEM", 442, 449], ["its infection of cells", "PROBLEM", 508, 530], ["infection", "OBSERVATION", 512, 521]]], ["Optical studies have revealed that after binding, virus particles move laterally on the membrane, but the complexity of the cellular environment and the drawbacks of fluorescence microscopy have prevented access to the molecular dynamics of early virus-host couplings.", [["membrane", "ANATOMY", 88, 96], ["cellular", "ANATOMY", 124, 132], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["cellular", "CELL", 124, 132], ["Optical studies", "TEST", 0, 15], ["virus particles", "PROBLEM", 50, 65], ["fluorescence microscopy", "TEST", 166, 189], ["early virus", "PROBLEM", 241, 252], ["cellular environment", "OBSERVATION", 124, 144]]], ["Here, we examine a model system, in which single Simian viruses (SV40) interact with their GM1 ganglioside receptors in supported lipid bilayers.", [["lipid bilayers", "ANATOMY", 130, 144], ["ganglioside", "CHEMICAL", 95, 106], ["Simian viruses", "ORGANISM", 49, 63], ["SV40", "ORGANISM", 65, 69], ["GM1 ganglioside receptors", "GENE_OR_GENE_PRODUCT", 91, 116], ["lipid bilayers", "CELLULAR_COMPONENT", 130, 144], ["GM1 ganglioside receptors", "PROTEIN", 91, 116], ["Simian viruses", "SPECIES", 49, 63], ["a model system", "TEST", 17, 31], ["single Simian viruses (SV40)", "TREATMENT", 42, 70], ["their GM1 ganglioside receptors", "TREATMENT", 85, 116], ["lipid bilayers", "OBSERVATION", 130, 144]]], ["We employed scattering interferometry and single molecule fluorescence localization to visualize the vectorial rotational motion of virions.", [["virions", "ANATOMY", 132, 139], ["single molecule fluorescence localization", "TEST", 42, 83]]], ["At low receptor concentration, we observed sliding and tumbling of single virions during rapid lateral diffusion.", [["virions", "ANATOMY", 74, 81], ["single virions", "TREATMENT", 67, 81], ["rapid lateral diffusion", "TEST", 89, 112]]], ["In contrast, at increased receptor concentration the virions repeatedly underwent periods of standstill, reminiscent of their behavior prior to endocytosis.", [["virions", "ANATOMY", 53, 60], ["increased receptor concentration the virions", "TREATMENT", 16, 60], ["endocytosis", "PROBLEM", 144, 155]]], ["By an unprecedented combination of millisecond time and nanometer spatial resolutions, we revealed that during these immobile periods, the virions rock back and forth among nanoscopic spots separated by 9 nm.", [["the virions rock", "TREATMENT", 135, 151], ["9 nm", "OBSERVATION_MODIFIER", 203, 207]]], ["Our insights, together with the structure of the viral capsid, suggest aggregation of receptors in nanodomains and recurrent swap of binding between receptor molecules and neighboring viral protein pentamers.", [["viral capsid", "PROTEIN", 49, 61], ["receptor molecules", "PROTEIN", 149, 167], ["neighboring viral protein pentamers", "PROTEIN", 172, 207], ["the viral capsid", "PROBLEM", 45, 61], ["aggregation of receptors in nanodomains", "PROBLEM", 71, 110], ["recurrent swap of binding between receptor molecules", "PROBLEM", 115, 167], ["neighboring viral protein pentamers", "TREATMENT", 172, 207], ["viral capsid", "OBSERVATION", 49, 61], ["viral protein pentamers", "OBSERVATION", 184, 207]]], ["Herein, we have developed different membrane probes binding spontaneously to the outer plasma membrane leaflet and showing sensitivity to membrane properties such as surface charge and phase state.", [["membrane", "ANATOMY", 36, 44], ["plasma membrane leaflet", "ANATOMY", 87, 110], ["membrane", "ANATOMY", 138, 146], ["surface", "ANATOMY", 166, 173], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["outer", "CELLULAR_COMPONENT", 81, 86], ["plasma", "CELLULAR_COMPONENT", 87, 93], ["membrane leaflet", "CELLULAR_COMPONENT", 94, 110], ["membrane", "CELLULAR_COMPONENT", 138, 146], ["different membrane probes binding", "PROBLEM", 26, 59], ["sensitivity to membrane properties", "PROBLEM", 123, 157]]], ["The first two types of probes were based on 3-hydroxyflavone fluorophore.", [["3-hydroxyflavone", "CHEMICAL", 44, 60], ["3-hydroxyflavone", "CHEMICAL", 44, 60], ["3-hydroxyflavone fluorophore", "SIMPLE_CHEMICAL", 44, 72], ["hydroxyflavone fluorophore", "TREATMENT", 46, 72]]], ["One of them showed a high sensitivity to the surface charge and to the phase state of lipid bilayers, while the other was only sensitive to the surface charge.", [["surface", "ANATOMY", 45, 52], ["surface", "ANATOMY", 144, 151], ["lipid bilayers", "SIMPLE_CHEMICAL", 86, 100], ["a high sensitivity", "PROBLEM", 19, 37]]], ["The third type, which was based on Nile Red fluorophore, was sensitive only to the phase state.", [["Nile Red", "CHEMICAL", 35, 43], ["Nile Red fluorophore", "SIMPLE_CHEMICAL", 35, 55], ["Nile Red fluorophore", "TEST", 35, 55], ["third type", "OBSERVATION_MODIFIER", 4, 14]]], ["Surprisingly, the probes that were sensitive only to the surface charge did not respond to apoptosis, while the other two types of probes showed significant spectroscopic response to it.", [["surface", "ANATOMY", 57, 64], ["the probes", "TEST", 14, 24], ["apoptosis", "PROBLEM", 91, 100], ["significant spectroscopic response", "PROBLEM", 145, 179], ["apoptosis", "OBSERVATION", 91, 100], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["spectroscopic response", "OBSERVATION", 157, 179]]], ["Moreover, the latter exhibited response to cholesterol depletion, which was similar to that observed on apoptosis.", [["cholesterol", "CHEMICAL", 43, 54], ["cholesterol", "CHEMICAL", 43, 54], ["cholesterol", "SIMPLE_CHEMICAL", 43, 54], ["cholesterol depletion", "PROBLEM", 43, 64], ["apoptosis", "PROBLEM", 104, 113], ["cholesterol depletion", "OBSERVATION", 43, 64], ["apoptosis", "OBSERVATION", 104, 113]]], ["Thus, according to our data, the intact living cells present a remarkable fraction of the cholesterol-rich domains, while apoptotic loss of the transmembrane asymmetry decreases it dramatically.", [["cells", "ANATOMY", 47, 52], ["transmembrane", "ANATOMY", 144, 157], ["cholesterol", "CHEMICAL", 90, 101], ["cholesterol", "CHEMICAL", 90, 101], ["cells", "CELL", 47, 52], ["cholesterol", "SIMPLE_CHEMICAL", 90, 101], ["transmembrane", "CELLULAR_COMPONENT", 144, 157], ["cholesterol-rich domains", "PROTEIN", 90, 114], ["apoptotic loss", "PROBLEM", 122, 136], ["the transmembrane asymmetry", "PROBLEM", 140, 167], ["apoptotic loss", "OBSERVATION", 122, 136], ["transmembrane asymmetry", "OBSERVATION", 144, 167], ["decreases", "OBSERVATION_MODIFIER", 168, 177]]], ["These probes represent a new tool for quantification of surface charge and cholesterol-rich domains in cell membranes.P-165-Imaging and spectroscopy - Due to its porosity and unique optical properties porous silicon (PSi) is an attractive template to develop biomaterials and biosensors.", [["surface", "ANATOMY", 56, 63], ["cell membranes", "ANATOMY", 103, 117], ["cholesterol", "CHEMICAL", 75, 86], ["P-165", "CHEMICAL", 118, 123], ["silicon", "CHEMICAL", 208, 215], ["PSi", "CHEMICAL", 217, 220], ["cholesterol", "CHEMICAL", 75, 86], ["silicon", "CHEMICAL", 208, 215], ["PSi", "CHEMICAL", 217, 220], ["cholesterol", "SIMPLE_CHEMICAL", 75, 86], ["cell membranes", "CELLULAR_COMPONENT", 103, 117], ["PSi", "SIMPLE_CHEMICAL", 217, 220], ["cholesterol-rich domains", "PROTEIN", 75, 99], ["surface charge", "PROBLEM", 56, 70], ["cholesterol-rich domains in cell membranes", "PROBLEM", 75, 117], ["P", "TEST", 118, 119], ["Imaging and spectroscopy", "TEST", 124, 148], ["its porosity", "PROBLEM", 158, 170], ["unique optical properties porous silicon (PSi)", "TREATMENT", 175, 221], ["an attractive template", "TREATMENT", 225, 247], ["biomaterials and biosensors", "TREATMENT", 259, 286], ["new", "OBSERVATION_MODIFIER", 25, 28], ["cell membranes", "OBSERVATION", 103, 117], ["porous silicon", "OBSERVATION", 201, 215]]], ["Porous silicon microcavity (PSiMc) structures were prepared then functionalized for covalent protein attachment of glucose oxidase (GOX) or solubilized bacteriorhodopsin (BR).", [["glucose", "CHEMICAL", 115, 122], ["silicon", "CHEMICAL", 7, 14], ["glucose", "CHEMICAL", 115, 122], ["Porous silicon microcavity", "SIMPLE_CHEMICAL", 0, 26], ["glucose oxidase", "SIMPLE_CHEMICAL", 115, 130], ["GOX", "SIMPLE_CHEMICAL", 132, 135], ["solubilized bacteriorhodopsin", "SIMPLE_CHEMICAL", 140, 169], ["glucose oxidase", "PROTEIN", 115, 130], ["GOX", "PROTEIN", 132, 135], ["BR", "PROTEIN", 171, 173], ["Porous silicon microcavity (PSiMc) structures", "TREATMENT", 0, 45], ["covalent protein attachment of glucose oxidase (GOX", "TREATMENT", 84, 135], ["solubilized bacteriorhodopsin (BR", "TREATMENT", 140, 173], ["silicon microcavity", "OBSERVATION", 7, 26]]], ["Functionalization and protein infiltration was monitored by specular reflectometry sensitive to change in refractive index, when a molecule is attached to the large internal surface of PSi.", [["surface", "ANATOMY", 174, 181], ["PSi", "CHEMICAL", 185, 188], ["PSi", "SIMPLE_CHEMICAL", 185, 188], ["PSi", "PROTEIN", 185, 188], ["Functionalization", "TREATMENT", 0, 17], ["protein infiltration", "PROBLEM", 22, 42], ["specular reflectometry", "TEST", 60, 82], ["refractive index", "TEST", 106, 122], ["the large internal surface of PSi", "TREATMENT", 155, 188], ["protein infiltration", "OBSERVATION", 22, 42], ["refractive index", "OBSERVATION", 106, 122], ["large", "OBSERVATION_MODIFIER", 159, 164], ["internal", "OBSERVATION_MODIFIER", 165, 173], ["surface", "OBSERVATION_MODIFIER", 174, 181]]], ["Protein infiltration into the porous scaffold was confirmed by EDX spectroscopy and the structures were imaged by biphoton microscopy.", [["Protein infiltration into the porous scaffold", "PROBLEM", 0, 45], ["EDX spectroscopy", "TEST", 63, 79], ["biphoton microscopy", "TEST", 114, 133], ["infiltration", "OBSERVATION", 8, 20], ["porous scaffold", "OBSERVATION", 30, 45]]], ["Second harmonic generation and enhanced two-photon excited fluorescence emission from porous silicon was observed when resonantly exciting the structures.", [["silicon", "CHEMICAL", 93, 100], ["Second harmonic generation", "PROBLEM", 0, 26], ["enhanced two-photon excited fluorescence emission from porous silicon", "TREATMENT", 31, 100], ["porous silicon", "OBSERVATION", 86, 100]]], ["In addition, when the microcavities were infiltrated with GOX or BR, the proteins acted as a very efficient internal two-photon-excited fluorescence emitter, hence protein infiltration enabled the in-depth visualization of the porous structure by taking advantage of the optical sectioning capacity inherent to the non linear optical microscopy technique.P-171Patterning of bio-molecules: methods for characterization of neuron-substrate interfaces We investigated how to use and improve micro printing techniques to obtain molecules patterns on cell culture substrates.", [["microcavities", "ANATOMY", 22, 35], ["neuron", "ANATOMY", 421, 427], ["cell culture", "ANATOMY", 546, 558], ["GOX", "SIMPLE_CHEMICAL", 58, 61], ["BR", "GENE_OR_GENE_PRODUCT", 65, 67], ["neuron", "CELL", 421, 427], ["cell", "CELL", 546, 550], ["GOX", "PROTEIN", 58, 61], ["BR", "PROTEIN", 65, 67], ["P", "DNA", 355, 356], ["excited fluorescence emitter", "TREATMENT", 128, 156], ["protein infiltration", "PROBLEM", 164, 184], ["the optical sectioning capacity", "TEST", 267, 298], ["micro printing techniques", "TREATMENT", 488, 513], ["cell culture substrates", "TEST", 546, 569], ["porous structure", "OBSERVATION", 227, 243], ["neuron", "ANATOMY", 421, 427]]], ["With micro contact printing (\u00b5CP), we generated geometrically defined depositions of Poly-D-Lysine (PDL) using poly-dimethylsiloxane stamps and optimized neuronal culturing conditions.", [["neuronal", "ANATOMY", 154, 162], ["Poly-D-Lysine", "CHEMICAL", 85, 98], ["poly-dimethylsiloxane", "CHEMICAL", 111, 132], ["Poly-D-Lysine", "CHEMICAL", 85, 98], ["PDL", "CHEMICAL", 100, 103], ["poly-dimethylsiloxane", "CHEMICAL", 111, 132], ["Poly-D-Lysine", "SIMPLE_CHEMICAL", 85, 98], ["poly-dimethylsiloxane", "SIMPLE_CHEMICAL", 111, 132], ["neuronal", "CELL", 154, 162], ["Poly-D-Lysine (PDL)", "TREATMENT", 85, 104], ["poly-dimethylsiloxane stamps", "TREATMENT", 111, 139]]], ["Rat and mice hippocampal neurons grown on those patterns showed to be alive and functional.", [["hippocampal neurons", "ANATOMY", 13, 32], ["mice", "ORGANISM", 8, 12], ["hippocampal neurons", "CELL", 13, 32], ["hippocampal neurons", "CELL_TYPE", 13, 32], ["Rat", "SPECIES", 0, 3], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["alive", "OBSERVATION", 70, 75]]], ["We then applied \u00b5CP to study axonal development by combining cell culture assays with Atomic Force Microscopy (AFM) to investigate in more detail the molecule deposition on the surface and to measure morphological changes in the growth cone (GC) during the early phases of neurite development.", [["axonal", "ANATOMY", 29, 35], ["cell", "ANATOMY", 61, 65], ["surface", "ANATOMY", 177, 184], ["GC", "ANATOMY", 242, 244], ["neurite", "ANATOMY", 273, 280], ["axonal", "MULTI-TISSUE_STRUCTURE", 29, 35], ["cell", "CELL", 61, 65], ["surface", "CELLULAR_COMPONENT", 177, 184], ["neurite", "CELL", 273, 280], ["combining cell culture assays", "TEST", 51, 80], ["Atomic Force Microscopy", "TEST", 86, 109], ["morphological changes", "PROBLEM", 200, 221], ["molecule deposition", "OBSERVATION", 150, 169]]], ["We found distinct shapes of the GCs depending on whether they were growing on L1 adhesion molecule patterned by indirect-\u00b5CP or on PDL coated surfaces.", [["GCs", "ANATOMY", 32, 35], ["L1 adhesion molecule", "PROTEIN", 78, 98], ["L1 adhesion molecule", "PROBLEM", 78, 98], ["\u00b5CP", "PROBLEM", 121, 124], ["PDL coated surfaces", "TREATMENT", 131, 150], ["distinct", "OBSERVATION_MODIFIER", 9, 17], ["shapes", "OBSERVATION_MODIFIER", 18, 24], ["L1 adhesion", "OBSERVATION_MODIFIER", 78, 89]]], ["We also attempted to transfer such patterns on Multi Electrode Arrays in order to constrain neuronal cell bodies on the electrode area and to improve electrophysiological recordings from neuronal networks.P-171Other patterning techniques were therefore explored using a nano-drop printing system.", [["neuronal cell bodies", "ANATOMY", 92, 112], ["electrode area", "ANATOMY", 120, 134], ["neuronal networks", "ANATOMY", 187, 204], ["neuronal cell", "CELL", 92, 105], ["neuronal networks", "MULTI-TISSUE_STRUCTURE", 187, 204], ["Multi Electrode Arrays", "TREATMENT", 47, 69], ["the electrode area", "TREATMENT", 116, 134], ["electrophysiological recordings", "TEST", 150, 181], ["Other patterning techniques", "TEST", 210, 237], ["a nano-drop printing system", "TREATMENT", 268, 295], ["neuronal cell bodies", "OBSERVATION", 92, 112]]], ["Patterned surfaces were analyzed with AFM and Scanning Electron Microscopy to combine different approaches aimed to the improvement and characterization of the printing techniques.P-170Insights on the mechanism of electron transfer in Complex I A. L. Maniero 1 , C. Bergamini 2 , M. Bortolus 1 , R. Fato 2 , S. Leoni 2 , G. Lenaz 2 1 Universit\u00e0 degli Studi di Padova, Padova, Italy, 2 Universit\u00e0 degli studi di Bologna, Bologna, Italy Complex I (NADH Dehydrogenase) plays a central role in cellular energy production, transferring two electrons from NADH through a series of iron-sulfur clusters (FeS) to ubiquinone (coenzyme Q); the electron transfer is coupled to the translocation of protons across the membrane.", [["cellular", "ANATOMY", 490, 498], ["membrane", "ANATOMY", 706, 714], ["NADH", "CHEMICAL", 446, 450], ["NADH", "CHEMICAL", 550, 554], ["ubiquinone", "CHEMICAL", 605, 615], ["NADH", "CHEMICAL", 446, 450], ["NADH", "CHEMICAL", 550, 554], ["iron-sulfur", "CHEMICAL", 575, 586], ["FeS", "CHEMICAL", 597, 600], ["ubiquinone", "CHEMICAL", 605, 615], ["electron", "SIMPLE_CHEMICAL", 214, 222], ["NADH Dehydrogenase", "GENE_OR_GENE_PRODUCT", 446, 464], ["cellular", "CELL", 490, 498], ["NADH", "SIMPLE_CHEMICAL", 550, 554], ["iron-sulfur clusters", "SIMPLE_CHEMICAL", 575, 595], ["FeS", "SIMPLE_CHEMICAL", 597, 600], ["ubiquinone", "SIMPLE_CHEMICAL", 605, 615], ["coenzyme Q", "SIMPLE_CHEMICAL", 617, 627], ["electron", "SIMPLE_CHEMICAL", 634, 642], ["protons", "SIMPLE_CHEMICAL", 687, 694], ["membrane", "CELLULAR_COMPONENT", 706, 714], ["P-170Insights", "DNA", 180, 193], ["NADH Dehydrogenase", "PROTEIN", 446, 464], ["FeS", "PROTEIN", 597, 600], ["AFM", "TEST", 38, 41], ["Scanning Electron Microscopy", "TEST", 46, 74], ["the printing techniques", "TEST", 156, 179], ["Bergamini", "TEST", 266, 275], ["Leoni", "TEST", 311, 316], ["Lenaz", "TEST", 324, 329], ["(NADH Dehydrogenase)", "TREATMENT", 445, 465], ["a series of iron-sulfur clusters (FeS)", "TREATMENT", 563, 601], ["ubiquinone (coenzyme Q)", "TREATMENT", 605, 628], ["energy production", "OBSERVATION", 499, 516], ["membrane", "ANATOMY", 706, 714]]], ["The FeS center N2 is the last acceptor in the electron-transfer chain, but the mechanism through which the enzyme couples the 1e \u2212 reduction of the FeS centers to the 2e \u2212 reduction of ubiquinone (Q\u2192SQ\u2192QH 2 ) is unclear [1] .", [["ubiquinone", "CHEMICAL", 185, 195], ["FeS", "CHEMICAL", 4, 7], ["N2", "CHEMICAL", 15, 17], ["FeS", "CHEMICAL", 148, 151], ["ubiquinone", "CHEMICAL", 185, 195], ["Q\u2192SQ\u2192QH 2", "CHEMICAL", 197, 206], ["FeS center N2", "SIMPLE_CHEMICAL", 4, 17], ["electron", "SIMPLE_CHEMICAL", 46, 54], ["FeS centers", "SIMPLE_CHEMICAL", 148, 159], ["2e \u2212", "SIMPLE_CHEMICAL", 167, 171], ["ubiquinone", "SIMPLE_CHEMICAL", 185, 195], ["Q\u2192SQ\u2192QH 2", "SIMPLE_CHEMICAL", 197, 206], ["FeS centers", "PROTEIN", 148, 159], ["the FeS centers", "TREATMENT", 144, 159], ["the 2e \u2212 reduction of ubiquinone (Q\u2192SQ\u2192QH", "TREATMENT", 163, 204]]], ["In our experiments, submitochondrial particles were treated with different inhibitors, in the absence or in the presence of different quinone analogues, and NADH addition initiated the electron transfer.", [["submitochondrial particles", "ANATOMY", 20, 46], ["quinone", "CHEMICAL", 134, 141], ["NADH", "CHEMICAL", 157, 161], ["quinone", "CHEMICAL", 134, 141], ["NADH", "CHEMICAL", 157, 161], ["quinone", "SIMPLE_CHEMICAL", 134, 141], ["NADH", "SIMPLE_CHEMICAL", 157, 161], ["electron", "SIMPLE_CHEMICAL", 185, 193], ["submitochondrial particles", "PROBLEM", 20, 46], ["different inhibitors", "TREATMENT", 65, 85], ["different quinone analogues", "TREATMENT", 124, 151], ["submitochondrial particles", "OBSERVATION", 20, 46], ["quinone analogues", "OBSERVATION", 134, 151]]], ["We assess by EPR (Electron Paramagnetic Resonance) spectroscopy the relative abundance of the reduced N2 center and of the semiquinone radical, and coupled EPR data to enzymatic activity assays and to fluorescence measurements on the effect of inhibitors on Reactive Oxygen Species (ROS) production.", [["semiquinone", "CHEMICAL", 123, 134], ["ROS", "CHEMICAL", 283, 286], ["N2", "CHEMICAL", 102, 104], ["semiquinone", "CHEMICAL", 123, 134], ["Oxygen", "CHEMICAL", 267, 273], ["semiquinone", "SIMPLE_CHEMICAL", 123, 134], ["Reactive Oxygen Species", "SIMPLE_CHEMICAL", 258, 281], ["ROS", "SIMPLE_CHEMICAL", 283, 286], ["the semiquinone radical", "TREATMENT", 119, 142], ["coupled EPR data", "TEST", 148, 164], ["enzymatic activity assays", "TEST", 168, 193], ["fluorescence measurements", "TEST", 201, 226], ["inhibitors", "TREATMENT", 244, 254], ["Reactive Oxygen Species", "TREATMENT", 258, 281], ["Reactive", "OBSERVATION_MODIFIER", 258, 266], ["Oxygen Species", "OBSERVATION", 267, 281]]], ["We identify two different classes of inhibitors showing different effects on ROS production.", [["ROS", "CHEMICAL", 77, 80], ["ROS", "SIMPLE_CHEMICAL", 77, 80], ["inhibitors", "TREATMENT", 37, 47], ["ROS production", "PROBLEM", 77, 91]]], ["Moreover the redox state of the complex has shown to depend both on the inhibitors and on the quinone analogues.", [["quinone", "CHEMICAL", 94, 101], ["quinone", "CHEMICAL", 94, 101], ["quinone", "SIMPLE_CHEMICAL", 94, 101], ["the inhibitors", "TREATMENT", 68, 82], ["the quinone analogues", "TREATMENT", 90, 111]]], ["A possible mechanism of the electron transfer, that can explain the experimental findings, will be presented.", [["electron", "SIMPLE_CHEMICAL", 28, 36], ["possible", "UNCERTAINTY", 2, 10]]], ["Conventional fluorescence microscopy suffers from a resolution limit imposed by the diffraction of light.", [["Conventional fluorescence microscopy", "TEST", 0, 36]]], ["Stimulated emission depletion (STED) microscopy overcomes this resolution barrier without being limited by the wavelength by taking advantage of the photophysics of the observed sample into the image formation process, and has proven to be a powerful approach for exploring relevant biological issues.", [["Stimulated emission depletion", "TREATMENT", 0, 29], ["microscopy", "TEST", 37, 47], ["this resolution barrier", "TREATMENT", 58, 81], ["relevant biological issues", "PROBLEM", 274, 300]]], ["The outstanding resolution of STED microscopy is achieved by drastically minimizing the spatial extent of the focal region from which fluorescent molecules can emit signal in the sample.", [["sample", "ANATOMY", 179, 185], ["STED microscopy", "TEST", 30, 45], ["the focal region", "PROBLEM", 106, 122], ["spatial", "OBSERVATION_MODIFIER", 88, 95], ["extent", "OBSERVATION_MODIFIER", 96, 102], ["focal", "OBSERVATION_MODIFIER", 110, 115], ["fluorescent molecules", "OBSERVATION", 134, 155]]], ["So far, mainly complex and relatively expensive lasers systems providing pulsed beams have been used to inhibit the fluorescence in the outer area of the focal region.", [["outer area", "ANATOMY", 136, 146], ["focal region", "ANATOMY", 154, 166], ["focal region", "CELLULAR_COMPONENT", 154, 166], ["relatively expensive lasers systems", "TREATMENT", 27, 62], ["pulsed beams", "TREATMENT", 73, 85], ["complex", "OBSERVATION_MODIFIER", 15, 22], ["outer", "ANATOMY_MODIFIER", 136, 141], ["area", "ANATOMY_MODIFIER", 142, 146], ["focal", "OBSERVATION_MODIFIER", 154, 159]]], ["Here we report on the development of a new setup based on a fast beam scanning confocal microscope using compact turn-key and inexpensive continuous wave lasers.", [["inexpensive continuous wave lasers", "TREATMENT", 126, 160]]], ["The great potential of this simple configuration is demonstrated for a selection of commonly used fluorescent markers.O-176Characterization of Hepatitis B antigen particles by atomic force microscopy Each year, over one million people die from hepatitis B virusrelated chronic liver disease, including cirrhosis and hepatocellular carcinoma.", [["liver", "ANATOMY", 277, 282], ["hepatocellular carcinoma", "ANATOMY", 316, 340], ["Hepatitis B antigen", "CHEMICAL", 143, 162], ["hepatitis B", "DISEASE", 244, 255], ["chronic liver disease", "DISEASE", 269, 290], ["cirrhosis", "DISEASE", 302, 311], ["hepatocellular carcinoma", "DISEASE", 316, 340], ["Hepatitis B antigen", "GENE_OR_GENE_PRODUCT", 143, 162], ["people", "ORGANISM", 228, 234], ["liver", "ORGAN", 277, 282], ["hepatocellular carcinoma", "CANCER", 316, 340], ["fluorescent markers", "PROTEIN", 98, 117], ["people", "SPECIES", 228, 234], ["fluorescent markers", "TEST", 98, 117], ["Hepatitis B antigen particles", "PROBLEM", 143, 172], ["hepatitis B virusrelated chronic liver disease", "PROBLEM", 244, 290], ["cirrhosis", "PROBLEM", 302, 311], ["hepatocellular carcinoma", "PROBLEM", 316, 340], ["great", "OBSERVATION_MODIFIER", 4, 9], ["simple configuration", "OBSERVATION", 28, 48], ["Hepatitis", "OBSERVATION", 143, 152], ["hepatitis", "OBSERVATION", 244, 253], ["chronic", "OBSERVATION_MODIFIER", 269, 276], ["liver", "ANATOMY", 277, 282], ["disease", "OBSERVATION", 283, 290], ["cirrhosis", "OBSERVATION", 302, 311], ["hepatocellular", "ANATOMY", 316, 330], ["carcinoma", "OBSERVATION", 331, 340]]], ["The major surface antigen of Hepatitis B virus (HBsAg) is a cysteine-rich, lipid-bound protein with 226 amino acids.", [["surface", "ANATOMY", 10, 17], ["Hepatitis B", "DISEASE", 29, 40], ["HBsAg", "CHEMICAL", 48, 53], ["cysteine", "CHEMICAL", 60, 68], ["amino acids", "CHEMICAL", 104, 115], ["cysteine", "CHEMICAL", 60, 68], ["amino acids", "CHEMICAL", 104, 115], ["Hepatitis B virus", "ORGANISM", 29, 46], ["HBsAg", "GENE_OR_GENE_PRODUCT", 48, 53], ["cysteine", "AMINO_ACID", 60, 68], ["lipid", "SIMPLE_CHEMICAL", 75, 80], ["amino acids", "AMINO_ACID", 104, 115], ["HBsAg", "PROTEIN", 48, 53], ["cysteine-rich, lipid-bound protein", "PROTEIN", 60, 94], ["Hepatitis B virus", "SPECIES", 29, 46], ["Hepatitis B virus", "SPECIES", 29, 46], ["The major surface antigen", "TEST", 0, 25], ["Hepatitis B virus (HBsAg", "TEST", 29, 53], ["a cysteine", "TEST", 58, 68], ["lipid-bound protein", "TEST", 75, 94], ["amino acids", "TEST", 104, 115], ["Hepatitis", "OBSERVATION", 29, 38]]], ["Recombinant HBsAg produced in yeast can self-assemble into 22-nm immunogenic spherical particles that are used in licensed Hepatitis B vaccines (protein/lipid ratio is 60/40 in mass).", [["HBsAg", "CHEMICAL", 12, 17], ["Hepatitis B", "DISEASE", 123, 134], ["HBsAg", "GENE_OR_GENE_PRODUCT", 12, 17], ["Hepatitis B vaccines", "ORGANISM", 123, 143], ["lipid", "SIMPLE_CHEMICAL", 153, 158], ["HBsAg", "PROTEIN", 12, 17], ["yeast", "SPECIES", 30, 35], ["yeast", "SPECIES", 30, 35], ["Hepatitis B", "SPECIES", 123, 134], ["Recombinant HBsAg", "TEST", 0, 17], ["nm immunogenic spherical particles", "TREATMENT", 62, 96], ["Hepatitis B vaccines", "TREATMENT", 123, 143], ["protein/lipid ratio", "TEST", 145, 164], ["mass", "PROBLEM", 177, 181], ["HBsAg", "OBSERVATION", 12, 17], ["spherical particles", "OBSERVATION", 77, 96], ["mass", "OBSERVATION", 177, 181]]], ["HBsAg size and shape have been mainly investigated by transmission electron microscopy after negative staining of the particles.", [["HBsAg", "CHEMICAL", 0, 5], ["HBsAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBsAg", "PROTEIN", 0, 5], ["HBsAg size", "TEST", 0, 10], ["transmission electron microscopy", "TEST", 54, 86], ["size", "OBSERVATION_MODIFIER", 6, 10], ["shape", "OBSERVATION_MODIFIER", 15, 20]]], ["However, under these conditions, no details of the particle surface can be obtained because of the shadowing effect due to the uranium salts.", [["surface", "ANATOMY", 60, 67], ["uranium salts", "CHEMICAL", 127, 140], ["uranium", "CHEMICAL", 127, 134], ["uranium salts", "SIMPLE_CHEMICAL", 127, 140], ["the shadowing effect", "PROBLEM", 95, 115], ["the uranium salts", "PROBLEM", 123, 140], ["shadowing", "OBSERVATION", 99, 108], ["uranium salts", "OBSERVATION", 127, 140]]], ["Here we describe new structural insights of HBsAg particles using Atomic Force Microscopy (AFM) performed under physiological conditions.", [["HBsAg", "CHEMICAL", 44, 49], ["HBsAg", "ORGANISM", 44, 49], ["HBsAg particles", "TREATMENT", 44, 59], ["Atomic Force Microscopy", "TEST", 66, 89]]], ["We applied atomic force microscopy to define structural details of the surface organization with a resolution in the nanometer range.", [["surface", "ANATOMY", 71, 78], ["atomic force microscopy", "TEST", 11, 34], ["surface", "OBSERVATION_MODIFIER", 71, 78]]], ["As expected, the diameter of HBsAg particles is 26,8 \u00b1 2,5 nm in average.", [["HBsAg", "CHEMICAL", 29, 34], ["the diameter of HBsAg particles", "TEST", 13, 44], ["diameter", "OBSERVATION_MODIFIER", 17, 25], ["HBsAg particles", "OBSERVATION", 29, 44]]], ["The surface of these particles clearly shows the presence of protuberances that most probably correspond to proteins.", [["surface", "ANATOMY", 4, 11], ["surface", "CELLULAR_COMPONENT", 4, 11], ["protuberances", "PROBLEM", 61, 74], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["particles", "OBSERVATION", 21, 30], ["protuberances", "OBSERVATION", 61, 74], ["most probably correspond to", "UNCERTAINTY", 80, 107], ["proteins", "OBSERVATION", 108, 116]]], ["Indeed, reduction and alkylation induces the disappearance of the protuberances.", [["alkylation", "TREATMENT", 22, 32], ["the protuberances", "PROBLEM", 62, 79], ["reduction", "OBSERVATION_MODIFIER", 8, 17], ["alkylation", "OBSERVATION", 22, 32], ["protuberances", "OBSERVATION_MODIFIER", 66, 79]]], ["The number of the protuberances estimated from AFM micrographs is about 70 per spherical particles.P-175A biophysical study of equine herpesvirus-1 entry into cells G. Mckenzie 1 , P. O'Shea 2 , J. Kydd 1 , C. Rauch 1 1 School of Veterinary Medicine and Science, University of Nottingham, UK, 2 Institute of Biophysics, imaging and optical science, University of Nottingham, UK Equine herpesvirus-1 (EHV-1) can cause respiratory disease in young horses, varying degrees of paralysis and abortion during the later stages of pregnancy.", [["cells", "ANATOMY", 159, 164], ["respiratory", "ANATOMY", 417, 428], ["Equine herpesvirus-1 (EHV-1", "CHEMICAL", 378, 405], ["respiratory disease", "DISEASE", 417, 436], ["paralysis", "DISEASE", 473, 482], ["abortion", "DISEASE", 487, 495], ["equine herpesvirus-1", "ORGANISM", 127, 147], ["cells", "CELL", 159, 164], ["UK", "ORGANISM", 375, 377], ["Equine herpesvirus-1", "ORGANISM", 378, 398], ["EHV-1", "ORGANISM", 400, 405], ["horses", "ORGANISM_SUBDIVISION", 446, 452], ["equine herpesvirus", "SPECIES", 127, 145], ["Equine herpesvirus-1", "SPECIES", 378, 398], ["equine herpesvirus-1", "SPECIES", 127, 147], ["Equine herpesvirus-1", "SPECIES", 378, 398], ["EHV-1", "SPECIES", 400, 405], ["AFM micrographs", "TEST", 47, 62], ["A biophysical study", "TEST", 104, 123], ["equine herpesvirus", "TEST", 127, 145], ["imaging", "TEST", 320, 327], ["UK Equine herpesvirus", "TEST", 375, 396], ["EHV", "TEST", 400, 403], ["respiratory disease", "PROBLEM", 417, 436], ["paralysis", "PROBLEM", 473, 482], ["abortion", "TREATMENT", 487, 495], ["pregnancy", "PROBLEM", 523, 532], ["number", "OBSERVATION_MODIFIER", 4, 10], ["protuberances", "OBSERVATION_MODIFIER", 18, 31], ["respiratory disease", "OBSERVATION", 417, 436], ["varying degrees", "OBSERVATION_MODIFIER", 454, 469], ["paralysis", "OBSERVATION", 473, 482]]], ["Furthermore, there has been a recent increase in the number of outbreaks involving paralysis of Thoroughbred horses in training.", [["paralysis", "DISEASE", 83, 92], ["paralysis", "PROBLEM", 83, 92], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["number", "OBSERVATION_MODIFIER", 53, 59]]], ["Virus disseminates rapidly after initial infection via cell associated viraemia.", [["cell", "ANATOMY", 55, 59], ["infection", "DISEASE", 41, 50], ["viraemia", "DISEASE", 71, 79], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 55, 59], ["Virus", "PROBLEM", 0, 5], ["initial infection", "PROBLEM", 33, 50], ["cell associated viraemia", "PROBLEM", 55, 79], ["infection", "OBSERVATION", 41, 50], ["cell associated viraemia", "OBSERVATION", 55, 79]]], ["Controlling this may prove crucial in combating the pathogenicity of the disease.", [["the disease", "PROBLEM", 69, 80], ["may prove", "UNCERTAINTY", 17, 26], ["disease", "OBSERVATION", 73, 80]]], ["We have investigated the cellular interactions of EHV-1.P-175Initially, binding of EHV-1 to fluorescein phosphatidylethanolamine (FPE)-labelled phospholipid vesicles of various compositions was examined.", [["cellular", "ANATOMY", 25, 33], ["phospholipid vesicles", "ANATOMY", 144, 165], ["EHV-1.P-175Initially", "CHEMICAL", 50, 70], ["fluorescein phosphatidylethanolamine", "CHEMICAL", 92, 128], ["FPE", "CHEMICAL", 130, 133], ["fluorescein phosphatidylethanolamine", "CHEMICAL", 92, 128], ["FPE", "CHEMICAL", 130, 133], ["cellular", "CELL", 25, 33], ["EHV-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["fluorescein phosphatidylethanolamine", "SIMPLE_CHEMICAL", 92, 128], ["FPE", "SIMPLE_CHEMICAL", 130, 133], ["phospholipid vesicles", "SIMPLE_CHEMICAL", 144, 165], ["EHV", "PROTEIN", 50, 53], ["EHV", "PROTEIN", 83, 86], ["EHV", "TEST", 50, 53], ["EHV", "TEST", 83, 86], ["fluorescein phosphatidylethanolamine", "TEST", 92, 128], ["FPE", "TEST", 130, 133]]], ["A variety of microscopy techniques were then employed to study the events surrounding the binding of virus to equine peripheral blood mononuclear cell (PBMC) membranes.", [["peripheral blood mononuclear cell", "ANATOMY", 117, 150], ["PBMC", "ANATOMY", 152, 156], ["membranes", "ANATOMY", 158, 167], ["equine", "ORGANISM", 110, 116], ["peripheral blood mononuclear cell", "CELL", 117, 150], ["PBMC", "CELL", 152, 156], ["membranes", "CELLULAR_COMPONENT", 158, 167], ["equine peripheral blood mononuclear cell", "CELL_TYPE", 110, 150], ["PBMC", "CELL_TYPE", 152, 156], ["equine", "SPECIES", 110, 116], ["equine", "SPECIES", 110, 116], ["microscopy techniques", "TEST", 13, 34], ["the binding of virus", "PROBLEM", 86, 106], ["peripheral", "ANATOMY_MODIFIER", 117, 127], ["blood", "ANATOMY", 128, 133], ["mononuclear cell", "OBSERVATION", 134, 150]]], ["Confocal microscopy images have highlighted possible colocalisation of EHV-1 with membrane 'rafts'.", [["membrane 'rafts", "ANATOMY", 82, 97], ["EHV-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["'rafts", "CELLULAR_COMPONENT", 91, 97], ["EHV", "PROTEIN", 71, 74], ["Confocal microscopy images", "TEST", 0, 26], ["colocalisation of EHV", "PROBLEM", 53, 74], ["membrane 'rafts", "TREATMENT", 82, 97]]], ["Total Internal Reflection Fluorescent microscopy was then used to identify viral binding at the membrane with high contrast images, able to observe single virus particles.", [["membrane", "ANATOMY", 96, 104], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["Total Internal Reflection Fluorescent microscopy", "TEST", 0, 48], ["viral binding", "PROBLEM", 75, 88], ["high contrast images", "TEST", 110, 130], ["single virus particles", "PROBLEM", 148, 170]]], ["Establishing the viral entry pathway into PBMCs would allow drugs that target this process to be employed, reducing clinical viraemia.", [["PBMCs", "ANATOMY", 42, 47], ["viraemia", "DISEASE", 125, 133], ["PBMCs", "CELL", 42, 47], ["PBMCs", "CELL_TYPE", 42, 47], ["drugs", "TREATMENT", 60, 65], ["clinical viraemia", "PROBLEM", 116, 133]]], ["The interpretation of in-vivo binding rate measurements allows inferring the molecular interactions that regulate cellular functions.", [["cellular", "ANATOMY", 114, 122], ["cellular", "CELL", 114, 122], ["cellular functions", "OBSERVATION", 114, 132]]], ["Fluorescence Recovery After Photobleaching (FRAP) is a widely used tool to quantify binding reactions in vivo.", [["Photobleaching (FRAP", "TREATMENT", 28, 48]]], ["However the lack of \"golden standards\" for these measurements requires the measured binding rates to be validated with other techniques.", [["these measurements", "TEST", 43, 61]]], ["We present a new Fluorescence Correlation Spectroscopy (FCS) method to measure the in vivo bound fractions and residence times for molecules that interact with an immobile substrate.", [["an immobile substrate", "PROBLEM", 160, 181]]], ["We apply this method to measure binding of mutants of the transcription factor VBP (vitellogenin binding protein) to the DNA.", [["VBP", "GENE_OR_GENE_PRODUCT", 79, 82], ["vitellogenin binding protein", "GENE_OR_GENE_PRODUCT", 84, 112], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["transcription factor", "PROTEIN", 58, 78], ["VBP", "PROTEIN", 79, 82], ["vitellogenin binding protein", "PROTEIN", 84, 112], ["this method", "TREATMENT", 9, 20], ["vitellogenin binding protein", "TEST", 84, 112]]], ["Comparison of FCS with FRAP results in comparable estimates of the measured diffusion constants and bound fractions.", [["FRAP", "TEST", 23, 27], ["the measured diffusion constants", "PROBLEM", 63, 95]]], ["However, FCS provides an estimate of the VBP residence time at the DNA, while FRAP does not.", [["DNA", "CELLULAR_COMPONENT", 67, 70]]], ["This limitation in the analysis of VBP is due to the larger photobleaching volume used in FRAP, if compared to the observation volume of an FCS experiment.", [["VBP", "SIMPLE_CHEMICAL", 35, 38], ["VBP", "TEST", 35, 38], ["the larger photobleaching volume", "TREATMENT", 49, 81], ["the observation volume", "TEST", 111, 133], ["an FCS experiment", "TEST", 137, 154], ["larger", "OBSERVATION_MODIFIER", 53, 59], ["photobleaching volume", "OBSERVATION", 60, 81]]], ["Substantial agreement of this method with FRAP is shown.", [["this method with FRAP", "TREATMENT", 25, 46]]], ["However, further validation on tightly bound molecules will be necessary to assess if FRAP and FCS agree in the measurement of residence times.O-173-Imaging and spectroscopy - We have investigated the changes in the mechanical properties of the zona pellucida (ZP), a multilayer glycoprotein coat that surrounds mammalian eggs, that occur after the maturation and fertilization process of the bovine oocyte by using atomic force spectroscopy.", [["ZP", "ANATOMY", 261, 263], ["eggs", "ANATOMY", 322, 326], ["oocyte", "ANATOMY", 400, 406], ["O-173", "CHEMICAL", 143, 148], ["zona pellucida", "MULTI-TISSUE_STRUCTURE", 245, 259], ["ZP", "MULTI-TISSUE_STRUCTURE", 261, 263], ["bovine", "ORGANISM", 393, 399], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 400, 406], ["bovine", "SPECIES", 393, 399], ["further validation", "TEST", 9, 27], ["tightly bound molecules", "PROBLEM", 31, 54], ["FRAP", "TEST", 86, 90], ["Imaging and spectroscopy", "TEST", 149, 173], ["the changes", "PROBLEM", 197, 208], ["the zona pellucida (ZP", "TREATMENT", 241, 263], ["a multilayer glycoprotein coat", "TREATMENT", 266, 296], ["mammalian eggs", "PROBLEM", 312, 326], ["fertilization process", "TREATMENT", 364, 385], ["the bovine oocyte", "TREATMENT", 389, 406], ["atomic force spectroscopy", "TEST", 416, 441], ["zona pellucida", "OBSERVATION", 245, 259], ["mammalian eggs", "OBSERVATION", 312, 326], ["bovine oocyte", "OBSERVATION", 393, 406]]], ["The response of the ZP to mechanical stress has been recovered according to a modified Hertz model.", [["ZP", "MULTI-TISSUE_STRUCTURE", 20, 22], ["mechanical stress", "PROBLEM", 26, 43], ["a modified Hertz model", "TREATMENT", 76, 98], ["mechanical stress", "OBSERVATION", 26, 43]]], ["Zp of immature oocyte's shows a pure elastic behaviour.", [["oocyte", "ANATOMY", 15, 21], ["Zp", "GENE_OR_GENE_PRODUCT", 0, 2], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 15, 21], ["immature oocyte", "OBSERVATION", 6, 21], ["pure elastic behaviour", "OBSERVATION", 32, 54]]], ["Mature and fertilized oocyte's ZPs evidence, instead, a transition from a purely elastic behaviour, which occurs when low stress forces are applied, towards a plastic behaviour has been observed.", [["oocyte", "ANATOMY", 22, 28], ["oocyte", "CELL", 22, 28], ["ZPs", "GENE_OR_GENE_PRODUCT", 31, 34], ["Mature and fertilized oocyte", "PROBLEM", 0, 28], ["a purely elastic behaviour", "PROBLEM", 72, 98], ["low stress forces", "PROBLEM", 118, 135], ["fertilized oocyte", "OBSERVATION", 11, 28]]], ["The high critical force necessary to induce deformations, that well supports the non-covalent long interactions lifetimes of polymers, increase after the cortical reaction.", [["cortical", "ANATOMY", 154, 162], ["deformations", "DISEASE", 44, 56], ["deformations", "PROBLEM", 44, 56], ["polymers", "TREATMENT", 125, 133], ["the cortical reaction", "PROBLEM", 150, 171], ["cortical reaction", "OBSERVATION", 154, 171]]], ["AFM images show that oocytes' ZP surface appear to be composed mainly of a dense, random meshwork of nonuniformly arranged fibril bundles More wrinkled surface characterize marure oocytes with respecto to immature and fertilized oocytes From a mechanical point of view, the transition of the mature ZP membrane toward fertilized ZP, through the hardening process, consists in the recovery of the elasticity of the immature ZP, while maintaining a plastic transition that, however, occurs with a much higher force with respect to that required in mature ZP.P-180Dynamical behavior of ribose and deoxyribose supercooled water solutions S. E. Pagnotta 1 , S. Cerveny 1 , A. Alegria 2 , J. Colmenero 3 1 Centro de Fisica de Materiales, Centro Mixto CSIC-UPV/EHU, San Sebasti\u00e1n, Spain, 2 Departamento de Fisica de Materiales, Universidad del Pais Vasco (UPV/EHU), Facultad de Quimica, San Sebasti\u00e1n, Spain, 3 Donostia International Physics Center, San Sebasti\u00e1n, Spain Ribose and 2'-deoxyribose are probably the most widespread monosaccharides in nature.", [["oocytes", "ANATOMY", 21, 28], ["ZP surface", "ANATOMY", 30, 40], ["surface", "ANATOMY", 152, 159], ["oocytes", "ANATOMY", 180, 187], ["oocytes", "ANATOMY", 229, 236], ["ZP membrane", "ANATOMY", 299, 310], ["ZP", "ANATOMY", 329, 331], ["ZP", "ANATOMY", 423, 425], ["ZP", "ANATOMY", 553, 555], ["ribose", "CHEMICAL", 583, 589], ["deoxyribose", "CHEMICAL", 594, 605], ["Ribose", "CHEMICAL", 964, 970], ["2'-deoxyribose", "CHEMICAL", 975, 989], ["ribose", "CHEMICAL", 583, 589], ["deoxyribose", "CHEMICAL", 594, 605], ["2'-deoxyribose", "CHEMICAL", 975, 989], ["monosaccharides", "CHEMICAL", 1023, 1038], ["oocytes", "CELLULAR_COMPONENT", 21, 28], ["ZP surface", "CELLULAR_COMPONENT", 30, 40], ["fibril bundles", "CELLULAR_COMPONENT", 123, 137], ["wrinkled surface", "CELLULAR_COMPONENT", 143, 159], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 180, 187], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 229, 236], ["ZP membrane", "CELLULAR_COMPONENT", 299, 310], ["ZP", "MULTI-TISSUE_STRUCTURE", 329, 331], ["ZP", "GENE_OR_GENE_PRODUCT", 423, 425], ["ZP", "GENE_OR_GENE_PRODUCT", 553, 555], ["ribose", "SIMPLE_CHEMICAL", 583, 589], ["deoxyribose", "SIMPLE_CHEMICAL", 594, 605], ["Ribose", "SIMPLE_CHEMICAL", 964, 970], ["2'-deoxyribose", "SIMPLE_CHEMICAL", 975, 989], ["monosaccharides", "SIMPLE_CHEMICAL", 1023, 1038], ["nonuniformly arranged fibril bundles", "CELL_LINE", 101, 137], ["marure oocytes", "CELL_TYPE", 173, 187], ["immature ZP", "CELL_TYPE", 414, 425], ["mature ZP", "CELL_TYPE", 546, 555], ["AFM images", "TEST", 0, 10], ["oocytes' ZP surface", "PROBLEM", 21, 40], ["immature and fertilized oocytes", "PROBLEM", 205, 236], ["the mature ZP membrane", "TREATMENT", 288, 310], ["fertilized ZP", "TREATMENT", 318, 331], ["the hardening process", "PROBLEM", 341, 362], ["ribose", "TREATMENT", 583, 589], ["deoxyribose supercooled water solutions", "TREATMENT", 594, 633], ["Spain Ribose", "TREATMENT", 958, 970], ["deoxyribose", "TREATMENT", 978, 989], ["oocytes", "OBSERVATION", 21, 28], ["dense", "OBSERVATION", 75, 80], ["fibril bundles", "OBSERVATION", 123, 137], ["marure oocytes", "OBSERVATION", 173, 187], ["fertilized oocytes", "OBSERVATION", 218, 236], ["ZP membrane", "OBSERVATION", 299, 310], ["fertilized ZP", "OBSERVATION", 318, 331], ["elasticity", "OBSERVATION", 396, 406], ["immature ZP", "OBSERVATION", 414, 425], ["plastic transition", "OBSERVATION", 447, 465]]], ["They can be extensively found in ribonucleic acid (RNA) and 2'-deoxyribonucleic acid (DNA), respectively, where they form, together with a nitrogenous base and a phosphate group, a peculiar building-block structure called nucleotide.", [["ribonucleic acid", "CHEMICAL", 33, 49], ["2'-deoxyribonucleic acid", "CHEMICAL", 60, 84], ["phosphate", "CHEMICAL", 162, 171], ["nucleotide", "CHEMICAL", 222, 232], ["2'-deoxyribonucleic acid", "CHEMICAL", 60, 84], ["phosphate", "CHEMICAL", 162, 171], ["nucleotide", "CHEMICAL", 222, 232], ["ribonucleic acid", "SIMPLE_CHEMICAL", 33, 49], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["phosphate", "SIMPLE_CHEMICAL", 162, 171], ["nucleotide", "SIMPLE_CHEMICAL", 222, 232], ["ribonucleic acid", "RNA", 33, 49], ["peculiar building-block structure", "PROTEIN", 181, 214], ["ribonucleic acid (RNA", "TREATMENT", 33, 54], ["deoxyribonucleic acid (DNA", "TEST", 63, 89], ["a nitrogenous base", "TREATMENT", 137, 155], ["a phosphate group", "TREATMENT", 160, 177], ["nucleotide", "TREATMENT", 222, 232]]], ["In the present work, the relaxation dynamic of ribose and deoxy-ribose water solutions at different concentrations has been studied by broadband dielectric spectroscopy and differential scanning calorimetry in the temperature range of 150-250K.", [["ribose", "CHEMICAL", 47, 53], ["deoxy-ribose", "CHEMICAL", 58, 70], ["ribose", "CHEMICAL", 47, 53], ["deoxy-ribose", "CHEMICAL", 58, 70], ["ribose", "SIMPLE_CHEMICAL", 47, 53], ["deoxy-ribose water", "SIMPLE_CHEMICAL", 58, 76], ["ribose", "TREATMENT", 47, 53], ["deoxy-ribose water solutions", "TREATMENT", 58, 86], ["broadband dielectric spectroscopy", "TEST", 135, 168], ["differential scanning calorimetry", "TEST", 173, 206], ["the temperature range", "TEST", 210, 231]]], ["Two relaxation processes are observed for all the hydration levels; the slower (process I) is related to the relaxation of the whole solution whereas the faster one (process II) is associated with the reorientation of water molecules in the mixture.", [["Two relaxation processes", "PROBLEM", 0, 24], ["all the hydration levels", "TEST", 42, 66], ["the whole solution", "TREATMENT", 123, 141], ["relaxation processes", "OBSERVATION", 4, 24], ["slower", "OBSERVATION_MODIFIER", 72, 78]]], ["As for other polymeric water solutions, dielectric data for process II indicate the existence of a critical water concentration above which water mobility is less restricted.", [["water", "SIMPLE_CHEMICAL", 108, 113], ["other polymeric water solutions", "TREATMENT", 7, 38], ["dielectric data", "TEST", 40, 55], ["a critical water concentration", "TREATMENT", 97, 127]]], ["Moreover, according with these results, ATR-FTIR measurements of the same sugar solutions showed an increment in the intensity of the OH stratching sub-band close to 3200 cm \u22121 as water content increases.P-179The regulation of the formation of cytoskeletal protein complexes by actin-binding proteins M. Nyitrai, A. Vig, T. Kupi, Z. Ujfalusi, S. Bark\u00f3, G. Hild University of P\u00e9cs, Faculty of Medicine, Department of Biophysics, P\u00e9cs, HungaryP-179In living cells various groups of proteins are associated to supramolecular actin filament structures, often in a nucleation factor dependent manner.", [["cytoskeletal", "ANATOMY", 244, 256], ["cells", "ANATOMY", 456, 461], ["OH", "CHEMICAL", 134, 136], ["P-179", "CHEMICAL", 204, 209], ["sugar", "CHEMICAL", 74, 79], ["OH", "CHEMICAL", 134, 136], ["ATR", "SIMPLE_CHEMICAL", 40, 43], ["sugar", "SIMPLE_CHEMICAL", 74, 79], ["OH", "SIMPLE_CHEMICAL", 134, 136], ["water", "SIMPLE_CHEMICAL", 180, 185], ["cytoskeletal", "CELLULAR_COMPONENT", 244, 256], ["actin", "GENE_OR_GENE_PRODUCT", 278, 283], ["cells", "CELL", 456, 461], ["actin", "GENE_OR_GENE_PRODUCT", 522, 527], ["cytoskeletal protein complexes", "PROTEIN", 244, 274], ["actin", "PROTEIN", 278, 283], ["nucleation factor", "PROTEIN", 560, 577], ["ATR-FTIR measurements", "TEST", 40, 61], ["the same sugar solutions", "TEST", 65, 89], ["P", "TEST", 204, 205], ["cytoskeletal protein complexes", "PROBLEM", 244, 274], ["P\u00e9cs", "TEST", 428, 432], ["HungaryP", "TEST", 434, 442], ["increment", "OBSERVATION_MODIFIER", 100, 109], ["3200 cm", "OBSERVATION_MODIFIER", 166, 173], ["cytoskeletal protein complexes", "OBSERVATION", 244, 274], ["supramolecular", "ANATOMY_MODIFIER", 507, 521], ["actin filament", "OBSERVATION", 522, 536]]], ["For example, actin structures associated with formins can bind tropomyosin and profilin, while those polymerised by the nucleation of the Arp2/3 complex bind cofilin and myosin I. The molecular mechanisms underlying the regulation of the formation of these protein complexes is still ambiguous.", [["actin", "GENE_OR_GENE_PRODUCT", 13, 18], ["formins", "GENE_OR_GENE_PRODUCT", 46, 53], ["tropomyosin", "GENE_OR_GENE_PRODUCT", 63, 74], ["profilin", "GENE_OR_GENE_PRODUCT", 79, 87], ["Arp2/3", "GENE_OR_GENE_PRODUCT", 138, 144], ["cofilin", "GENE_OR_GENE_PRODUCT", 158, 165], ["myosin I.", "GENE_OR_GENE_PRODUCT", 170, 179], ["actin", "PROTEIN", 13, 18], ["formins", "PROTEIN", 46, 53], ["tropomyosin", "PROTEIN", 63, 74], ["profilin", "PROTEIN", 79, 87], ["Arp2/3 complex", "PROTEIN", 138, 152], ["cofilin", "PROTEIN", 158, 165], ["myosin I.", "PROTEIN", 170, 179], ["protein complexes", "PROTEIN", 257, 274], ["actin structures", "PROBLEM", 13, 29], ["profilin", "TREATMENT", 79, 87], ["these protein complexes", "TEST", 251, 274], ["protein complexes", "OBSERVATION", 257, 274]]], ["We have shown recently that formins can bind the actin filaments and change their conformational state.", [["filaments", "ANATOMY", 55, 64], ["formins", "GENE_OR_GENE_PRODUCT", 28, 35], ["actin", "GENE_OR_GENE_PRODUCT", 49, 54], ["formins", "PROTEIN", 28, 35], ["actin filaments", "PROTEIN", 49, 64]]], ["Subsequent binding of other actin-binding proteins, such as tropomyosin and myosin, can reverse these changes.", [["actin", "GENE_OR_GENE_PRODUCT", 28, 33], ["tropomyosin", "GENE_OR_GENE_PRODUCT", 60, 71], ["myosin", "GENE_OR_GENE_PRODUCT", 76, 82], ["actin", "PROTEIN", 28, 33], ["binding proteins", "PROTEIN", 34, 50], ["tropomyosin", "PROTEIN", 60, 71], ["myosin", "PROTEIN", 76, 82], ["other actin-binding proteins", "PROBLEM", 22, 50], ["tropomyosin and myosin", "TREATMENT", 60, 82]]], ["It appears that the reversal effect assumes that the actin-binding protein binds the filaments in a well-defined and specific binding site.", [["filaments", "ANATOMY", 85, 94], ["actin", "GENE_OR_GENE_PRODUCT", 53, 58], ["filaments", "CELLULAR_COMPONENT", 85, 94], ["actin", "PROTEIN", 53, 58], ["the reversal effect", "PROBLEM", 16, 35], ["the actin-binding protein", "TEST", 49, 74], ["a well-defined and specific binding site", "PROBLEM", 98, 138], ["reversal effect", "OBSERVATION", 20, 35], ["well-defined", "OBSERVATION_MODIFIER", 100, 112], ["binding site", "OBSERVATION", 126, 138]]], ["The altered conformational state of the actin filaments observed after the binding of these proteins provides a possible explanation for the modified affinity of the filaments for other-actin binding proteins.", [["filaments", "ANATOMY", 46, 55], ["filaments", "ANATOMY", 166, 175], ["actin", "GENE_OR_GENE_PRODUCT", 40, 45], ["actin", "GENE_OR_GENE_PRODUCT", 186, 191], ["actin filaments", "PROTEIN", 40, 55], ["actin binding proteins", "PROTEIN", 186, 208], ["the actin filaments", "PROBLEM", 36, 55], ["other-actin binding proteins", "TREATMENT", 180, 208], ["altered", "OBSERVATION_MODIFIER", 4, 11], ["conformational state", "OBSERVATION", 12, 32]]], ["Based on the results available so far we assume that the affinities are modified differently by different nucleation factors, and the conformational changes introduced to actin by actin nucleation factors can serve as the molecular bases for the regulation of the formation of actin based intracellular protein complexes.", [["intracellular", "ANATOMY", 289, 302], ["actin", "GENE_OR_GENE_PRODUCT", 171, 176], ["actin", "GENE_OR_GENE_PRODUCT", 180, 185], ["actin", "GENE_OR_GENE_PRODUCT", 277, 282], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 289, 302], ["nucleation factors", "PROTEIN", 106, 124], ["actin", "PROTEIN", 171, 176], ["actin nucleation factors", "PROTEIN", 180, 204], ["actin", "PROTEIN", 277, 282], ["intracellular protein complexes", "PROTEIN", 289, 320], ["the conformational changes", "PROBLEM", 130, 156], ["actin by actin nucleation factors", "TREATMENT", 171, 204], ["actin based intracellular protein complexes", "PROBLEM", 277, 320], ["bases", "ANATOMY_MODIFIER", 232, 237], ["protein complexes", "OBSERVATION", 303, 320]]], ["Experiments are currently in progress to test and further corroborate the existence of such regulatory mechanisms in living cells.", [["cells", "ANATOMY", 124, 129], ["cells", "CELL", 124, 129], ["living cells", "CELL_TYPE", 117, 129], ["such regulatory mechanisms in living cells", "PROBLEM", 87, 129]]], ["Correlation between sub-cellular distribution of photoactive drug Hypericin (Hyp), determined by applied delivery systems (Hyp vs Hyp/LDL), and mode of the cell death is addressed in this study.", [["cellular", "ANATOMY", 24, 32], ["cell", "ANATOMY", 156, 160], ["Hypericin", "CHEMICAL", 66, 75], ["death", "DISEASE", 161, 166], ["Hypericin", "CHEMICAL", 66, 75], ["cellular", "CELL", 24, 32], ["Hypericin", "SIMPLE_CHEMICAL", 66, 75], ["Hyp", "SIMPLE_CHEMICAL", 77, 80], ["Hyp", "SIMPLE_CHEMICAL", 123, 126], ["LDL", "GENE_OR_GENE_PRODUCT", 134, 137], ["cell", "CELL", 156, 160], ["LDL", "PROTEIN", 134, 137], ["photoactive drug Hypericin (Hyp)", "TREATMENT", 49, 81], ["delivery systems", "TEST", 105, 121], ["Hyp vs Hyp/LDL)", "TEST", 123, 138], ["the cell death", "PROBLEM", 152, 166], ["this study", "TEST", 183, 193], ["photoactive drug Hypericin", "OBSERVATION", 49, 75], ["LDL", "ANATOMY", 134, 137], ["cell death", "OBSERVATION", 156, 166]]], ["Co-localization of Hyp with mitochondria, lysosomes and Golgi apparatus in U-87 MG glioma cells was determined by confocal laser scanning microscopy in using organelle specific fluorescent dyes as well as by time resolved FRET experiments.", [["mitochondria", "ANATOMY", 28, 40], ["lysosomes", "ANATOMY", 42, 51], ["Golgi apparatus", "ANATOMY", 56, 71], ["U-87 MG glioma cells", "ANATOMY", 75, 95], ["organelle", "ANATOMY", 158, 167], ["glioma", "DISEASE", 83, 89], ["Hyp", "SIMPLE_CHEMICAL", 19, 22], ["mitochondria", "CELLULAR_COMPONENT", 28, 40], ["lysosomes", "CELLULAR_COMPONENT", 42, 51], ["Golgi apparatus", "CELLULAR_COMPONENT", 56, 71], ["U-87 MG glioma cells", "CELL", 75, 95], ["Hyp", "PROTEIN", 19, 22], ["U-87 MG glioma cells", "CELL_LINE", 75, 95], ["Hyp with mitochondria", "PROBLEM", 19, 40], ["Golgi apparatus", "TEST", 56, 71], ["U", "TEST", 75, 76], ["MG glioma cells", "PROBLEM", 80, 95], ["confocal laser scanning microscopy", "TEST", 114, 148], ["organelle specific fluorescent dyes", "PROBLEM", 158, 193], ["Hyp", "OBSERVATION", 19, 22], ["glioma cells", "OBSERVATION", 83, 95]]], ["Flow cytometry experiments were realized to study a photodynamic effect of Hyp (598 nm/4 Jcm \u22121 ) on cells.", [["cells", "ANATOMY", 101, 106], ["Hyp", "SIMPLE_CHEMICAL", 75, 78], ["cells", "CELL", 101, 106], ["Flow cytometry experiments", "TEST", 0, 26], ["a photodynamic effect", "TEST", 50, 71], ["Hyp", "TEST", 75, 78], ["nm", "TEST", 84, 86], ["Jcm", "TEST", 89, 92]]], ["Significant differences in the proportional representation of live, apoptotic and/or necrotic cells were observed for different types of delivery systems of Hyp 24 hours after Hyp (5x10 \u22127 M) photoactivation.", [["necrotic cells", "ANATOMY", 85, 99], ["necrotic", "DISEASE", 85, 93], ["necrotic cells", "CELL", 85, 99], ["Hyp", "SIMPLE_CHEMICAL", 176, 179], ["necrotic cells", "CELL_TYPE", 85, 99], ["Significant differences", "PROBLEM", 0, 23], ["apoptotic and/or necrotic cells", "PROBLEM", 68, 99], ["delivery systems", "TREATMENT", 137, 153], ["Hyp (5x10 \u22127 M) photoactivation", "TREATMENT", 176, 207], ["necrotic cells", "OBSERVATION", 85, 99]]], ["Conclusions: i) Sub-cellular distribution of Hyp depends on using delivery systems, ii) the mode of cell death depends more on concentration of Hyp inside cells, than on different type of delivery systems (for non selective wide-field cell illumination), iii) fluorescence lifetime is sensitive parameter to study sub-cellular distribution of Hyp.", [["cellular", "ANATOMY", 20, 28], ["cell", "ANATOMY", 100, 104], ["cells", "ANATOMY", 155, 160], ["cell", "ANATOMY", 235, 239], ["cellular", "ANATOMY", 318, 326], ["death", "DISEASE", 105, 110], ["cellular", "CELL", 20, 28], ["Hyp", "SIMPLE_CHEMICAL", 45, 48], ["cell", "CELL", 100, 104], ["Hyp", "SIMPLE_CHEMICAL", 144, 147], ["cells", "CELL", 155, 160], ["cell", "CELL", 235, 239], ["cellular", "CELL", 318, 326], ["Hyp.", "GENE_OR_GENE_PRODUCT", 343, 347], ["Hyp inside cells", "CELL_TYPE", 144, 160], ["Hyp depends", "PROBLEM", 45, 56], ["delivery systems", "TREATMENT", 66, 82], ["cell death", "PROBLEM", 100, 110], ["Hyp inside cells", "PROBLEM", 144, 160], ["delivery systems", "TREATMENT", 188, 204], ["non selective wide-field cell illumination", "TREATMENT", 210, 252], ["Hyp", "OBSERVATION", 45, 48], ["cell death", "OBSERVATION", 100, 110]]], ["Novel time-resolved spectroscopic methods have been used to investigate the interactions between a fluorescently-labelled mutant of the peptide melittin and supported lipid bilayers, formed by self-assembly at a silica-water interface via vesicle deposition.", [["lipid bilayers", "ANATOMY", 167, 181], ["vesicle", "ANATOMY", 239, 246], ["silica", "CHEMICAL", 212, 218], ["melittin", "SIMPLE_CHEMICAL", 144, 152], ["lipid bilayers", "SIMPLE_CHEMICAL", 167, 181], ["vesicle", "CELLULAR_COMPONENT", 239, 246], ["spectroscopic methods", "TREATMENT", 20, 41], ["a fluorescently", "TEST", 97, 112], ["the peptide melittin", "TREATMENT", 132, 152], ["lipid bilayers", "TREATMENT", 167, 181], ["lipid bilayers", "OBSERVATION", 167, 181], ["vesicle deposition", "OBSERVATION", 239, 257]]], ["Time-resolved evanescent wave-induced fluorescence spectroscopy (TREWIFS) is a surface-selective technique in which the evanescent field from a pulsed laser source is used to photoexcite fluorescent species at an interface.", [["evanescent wave", "TEST", 14, 29], ["fluorescence spectroscopy", "TEST", 38, 63], ["a surface-selective technique", "TREATMENT", 77, 106], ["a pulsed laser source", "TREATMENT", 142, 163]]], ["The resulting fluorescence decay kinetics, measured using time-correlated single-photon counting, report on the micro-domains experienced by those fluorescent species at an interface.", [["The resulting fluorescence decay kinetics", "PROBLEM", 0, 41], ["the micro-domains", "TEST", 108, 125], ["fluorescent species", "OBSERVATION", 147, 166]]], ["Extending TREWIFS to time-resolved evanescent wave-induced fluorescence anisotropy measurements (EW-TRAMS) provides dynamic rotational information of a fluorescent species, reporting on its mobility at an interface.", [["evanescent wave", "TEST", 35, 50], ["fluorescence anisotropy measurements", "TEST", 59, 95], ["a fluorescent species", "PROBLEM", 150, 171]]], ["Presented here are TREWIFS and EW-TRAMS data obtained from the fluorescence of an Alexa 430-labelled melittin mutant interacting with a dipalmitoylphosphocholine bilayer at room temperature, physiological pH and ionic strength.", [["Alexa 430", "CHEMICAL", 82, 91], ["dipalmitoylphosphocholine", "CHEMICAL", 136, 161], ["Alexa 430", "CHEMICAL", 82, 91], ["dipalmitoylphosphocholine", "CHEMICAL", 136, 161], ["Alexa 430", "SIMPLE_CHEMICAL", 82, 91], ["dipalmitoylphosphocholine", "SIMPLE_CHEMICAL", 136, 161], ["Alexa 430-labelled melittin mutant", "PROTEIN", 82, 116], ["an Alexa", "TEST", 79, 87], ["a dipalmitoylphosphocholine bilayer", "TREATMENT", 134, 169]]], ["The results provide new insights into the conformation, location and motion of cytolytic peptides interacting with cell membranes.", [["cell membranes", "ANATOMY", 115, 129], ["cell membranes", "CELLULAR_COMPONENT", 115, 129], ["cell membranes", "TREATMENT", 115, 129], ["cell membranes", "OBSERVATION", 115, 129]]], ["Optical tweezers are used to controllably apply forces to red blood cells and the resulting chemical and structural changes are monitored using Raman spectroscopy.", [["red blood cells", "ANATOMY", 58, 73], ["red blood cells", "CELL", 58, 73], ["red blood cells", "CELL_TYPE", 58, 73], ["Optical tweezers", "TREATMENT", 0, 16], ["red blood cells", "TEST", 58, 73], ["Raman spectroscopy", "TEST", 144, 162]]], ["The forces are applied in vivo and mimic that which the cell undergoes mechanically as it passes through vessels and smaller capillaries.", [["cell", "ANATOMY", 56, 60], ["vessels", "ANATOMY", 105, 112], ["capillaries", "ANATOMY", 125, 136], ["cell", "CELL", 56, 60], ["vessels", "MULTI-TISSUE_STRUCTURE", 105, 112], ["capillaries", "TISSUE", 125, 136], ["The forces", "TREATMENT", 0, 10], ["forces", "OBSERVATION_MODIFIER", 4, 10], ["vessels", "ANATOMY", 105, 112], ["smaller", "OBSERVATION_MODIFIER", 117, 124], ["capillaries", "OBSERVATION_MODIFIER", 125, 136]]], ["The first result presented will be spectroscopic evidence of a transition between the oxygenation and deoxygenation states of hemoglobin that is caused by the stretching of the red blood cell.", [["red blood cell", "ANATOMY", 177, 191], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 126, 136], ["red blood cell", "CELL", 177, 191], ["hemoglobin", "PROTEIN", 126, 136], ["red blood cell", "CELL_TYPE", 177, 191], ["a transition between the oxygenation", "PROBLEM", 61, 97], ["hemoglobin", "PROBLEM", 126, 136], ["the red blood cell", "TEST", 173, 191], ["oxygenation", "OBSERVATION_MODIFIER", 86, 97], ["red blood cell", "OBSERVATION", 177, 191]]], ["The transition is due to mechanically induced enhancements of hemoglobin-membrane and hemoglobin neighbor-neighbor interactions.", [["membrane", "ANATOMY", 73, 81], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 62, 72], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 86, 96], ["hemoglobin", "PROTEIN", 62, 72], ["hemoglobin", "PROTEIN", 86, 96], ["mechanically induced enhancements of hemoglobin-membrane", "PROBLEM", 25, 81]]], ["The latter, lesser known effect is further studied by modeling the electrostatic binding of two of the protein structures using molecular dynamics methods.", [["lesser", "OBSERVATION_MODIFIER", 12, 18], ["effect", "OBSERVATION_MODIFIER", 25, 31], ["electrostatic binding", "OBSERVATION", 67, 88]]], ["Secondly, polarized Raman spectroscopy is utilized to study the packing and ordering of the hemoglobin proteins in the red blood cell as it is stretched.", [["red blood cell", "ANATOMY", 119, 133], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 92, 102], ["red blood cell", "CELL", 119, 133], ["hemoglobin proteins", "PROTEIN", 92, 111], ["red blood cell", "CELL_TYPE", 119, 133], ["polarized Raman spectroscopy", "TEST", 10, 38], ["the packing", "TREATMENT", 60, 71], ["the hemoglobin proteins", "TEST", 88, 111], ["the red blood cell", "TEST", 115, 133], ["blood cell", "ANATOMY", 123, 133]]], ["Depolarization ratios for a number of heme group modes change, indicating that the applied force additionally packs and orders the proteins inside the cell which further demonstrates the role of cell deformation in the oxygen transport kinetics.", [["cell", "ANATOMY", 151, 155], ["cell", "ANATOMY", 195, 199], ["oxygen", "CHEMICAL", 219, 225], ["heme", "CHEMICAL", 38, 42], ["oxygen", "CHEMICAL", 219, 225], ["cell", "CELL", 151, 155], ["cell", "CELL", 195, 199], ["oxygen", "SIMPLE_CHEMICAL", 219, 225], ["Depolarization ratios", "TEST", 0, 21], ["heme group modes change", "PROBLEM", 38, 61], ["force additionally packs", "TREATMENT", 91, 115], ["cell deformation", "PROBLEM", 195, 211], ["the oxygen transport kinetics", "TREATMENT", 215, 244], ["cell deformation", "OBSERVATION", 195, 211], ["oxygen transport kinetics", "OBSERVATION", 219, 244]]], ["Acknowledgements: This work was supported by MIIN FIS2008-00114 (Spain) and Fundaci\u00f3 Cellex Barcelona FRET microscopy is widely used to study protein-protein interactions in living or fixed specimens.", [["specimens", "ANATOMY", 190, 199], ["FIS2008-00114", "CHEMICAL", 50, 63], ["Barcelona FRET microscopy", "TEST", 92, 117], ["study protein", "TEST", 136, 149], ["protein interactions", "PROBLEM", 150, 170]]], ["Currently, most commonly used visible fluorescent proteins for live-cell FRET studies are the Cerulean and Venus variants of the cyan and yellow fluorescent proteins.", [["cell", "ANATOMY", 68, 72], ["cell", "CELL", 68, 72], ["yellow fluorescent proteins", "GENE_OR_GENE_PRODUCT", 138, 165], ["visible fluorescent proteins", "PROTEIN", 30, 58], ["cyan and yellow fluorescent proteins", "PROTEIN", 129, 165], ["visible fluorescent proteins", "PROBLEM", 30, 58], ["FRET studies", "TEST", 73, 85], ["the cyan", "TEST", 125, 133], ["yellow fluorescent proteins", "PROBLEM", 138, 165]]], ["Even though this FRET pair appears to be ideal for monitoring protein-protein interactions, the most commonly used fixed laser wavelengths do not excite Cerulean at peak absorption.", [["Cerulean", "SIMPLE_CHEMICAL", 153, 161], ["this FRET pair", "PROBLEM", 12, 26], ["monitoring protein-protein interactions", "TREATMENT", 51, 90], ["fixed laser wavelengths", "TREATMENT", 115, 138]]], ["Recently, we characterized an ideal donor, the monomeric teal fluorescent protein (mTFP), which is excitable using the commonly available 457 (8) Opt.", [["teal fluorescent protein (mTFP", "GENE_OR_GENE_PRODUCT", 57, 87], ["monomeric teal fluorescent protein", "PROTEIN", 47, 81], ["mTFP", "PROTEIN", 83, 87]]], ["We used Teal as a donor for various red fluorescent proteins as acceptors including tdTomato, mKO2, mOrange2, mTagRFP, mKate.", [["tdTomato", "GENE_OR_GENE_PRODUCT", 84, 92], ["mKO2", "GENE_OR_GENE_PRODUCT", 94, 98], ["mOrange2", "GENE_OR_GENE_PRODUCT", 100, 108], ["mTagRFP", "GENE_OR_GENE_PRODUCT", 110, 117], ["mKate", "GENE_OR_GENE_PRODUCT", 119, 124], ["red fluorescent proteins", "PROTEIN", 36, 60], ["tdTomato", "PROTEIN", 84, 92], ["mKO2", "PROTEIN", 94, 98], ["mOrange2", "PROTEIN", 100, 108], ["mTagRFP", "PROTEIN", 110, 117], ["mKate", "PROTEIN", 119, 124], ["a donor", "TREATMENT", 16, 23], ["various red fluorescent proteins", "TREATMENT", 28, 60], ["tdTomato", "TREATMENT", 84, 92]]], ["We have employed a \"FRET standard\" genetic construct to minimize variability in separation distances and positioning of the fused donor and acceptor FPs.", [["a \"FRET standard\" genetic construct", "TREATMENT", 17, 52], ["the fused donor and acceptor FPs", "PROBLEM", 120, 152]]], ["Using spectral FRET imaging and fluorescence lifetime measurements in living cells expressing the fused proteins, we have characterized both sensitized acceptor emission and the change in the donor lifetime distribution as a result of quenching for each of the fused FP pairings.Monitoring of oxygenation transition and protein ordering in red blood cells using Raman tweezersOur results indicate that some red FPs are better acceptors than others in terms of quenching the Teal donor and sensitizing the emission of the acceptor indicating a FRET event.Vibrations of DNA with light and heavy counterions in low-frequency Raman spectraS.", [["cells", "ANATOMY", 77, 82], ["red blood cells", "ANATOMY", 340, 355], ["cells", "CELL", 77, 82], ["red blood cells", "CELL", 340, 355], ["DNA", "CELLULAR_COMPONENT", 568, 571], ["fused proteins", "PROTEIN", 98, 112], ["red blood cells", "CELL_TYPE", 340, 355], ["spectral FRET imaging", "TEST", 6, 27], ["fluorescence lifetime measurements", "TEST", 32, 66], ["Monitoring of oxygenation transition", "TEST", 279, 315], ["protein ordering in red blood cells", "TREATMENT", 320, 355], ["some red FPs", "PROBLEM", 402, 414], ["quenching the Teal donor", "TREATMENT", 460, 484], ["a FRET event", "PROBLEM", 541, 553], ["sensitized acceptor emission", "OBSERVATION", 141, 169], ["heavy", "OBSERVATION_MODIFIER", 587, 592], ["counterions", "OBSERVATION", 593, 604], ["low-frequency Raman", "OBSERVATION_MODIFIER", 608, 627]]], ["M. Perepelytsya, S. N. Volkov Bogolyubov Institute for Theoretical Physics, NASU, 14-b Metrologichna str., Kiev, 03680, Ukraine Stability of the DNA double helix is determined by Na + counterions, neutralizing the negatively charged phosphate groups of the macromolecule backbone.", [["Na", "CHEMICAL", 179, 181], ["phosphate", "CHEMICAL", 233, 242], ["Na +", "CHEMICAL", 179, 183], ["phosphate", "CHEMICAL", 233, 242], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["Na + counterions", "SIMPLE_CHEMICAL", 179, 195], ["the DNA double helix", "TREATMENT", 141, 161], ["the macromolecule backbone", "TREATMENT", 253, 279]]], ["But under spatial conditions they may be replaced by much heavier ions, for example Cs + .", [["Cs", "CHEMICAL", 84, 86], ["Cs", "CHEMICAL", 84, 86], ["Cs +", "SIMPLE_CHEMICAL", 84, 88]]], ["To determine the influence of heavy counterions on internal dynamics of the double helix the conformational vibrations of Na-and Cs-DNA are studied.", [["Na-and Cs", "CHEMICAL", 122, 131], ["Cs", "CHEMICAL", 129, 131], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["Na-and Cs-DNA", "DNA", 122, 135], ["the double helix", "TREATMENT", 72, 88]]], ["For this purpose the model of conformational vibrations of DNA with counterions is used [Perepelytsya S.M., Volkov S.N., Eur.Phys.J. E. 24, 261, 2007] .", [["DNA", "CELLULAR_COMPONENT", 59, 62], ["DNA with counterions", "TREATMENT", 59, 79]]], ["As the result the frequencies and amplitudes of vibrations for B -DNA with Na + and Cs + counerions are calculated.", [["Na", "CHEMICAL", 75, 77], ["Cs", "CHEMICAL", 84, 86], ["Na +", "CHEMICAL", 75, 79], ["Cs +", "CHEMICAL", 84, 88], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["Na +", "SIMPLE_CHEMICAL", 75, 79], ["Cs + counerions", "SIMPLE_CHEMICAL", 84, 99], ["B -DNA", "DNA", 63, 69], ["vibrations", "TEST", 48, 58], ["B -DNA", "TEST", 63, 69], ["Na", "TEST", 75, 77], ["Cs", "TEST", 84, 86]]], ["The frequencies of internal modes of the double helix are about 110, 79, 58 and 15 cm \u22121 .", [["internal", "ANATOMY_MODIFIER", 19, 27], ["modes", "ANATOMY_MODIFIER", 28, 33], ["double helix", "OBSERVATION", 41, 53], ["15 cm", "OBSERVATION_MODIFIER", 80, 85]]], ["The frequencies of ion-phosphate modes are about 180 and 110 cm \u22121 for Na-and Cs-DNA respectively.", [["Na-and Cs", "CHEMICAL", 71, 80], ["ion-phosphate", "CHEMICAL", 19, 32], ["Cs", "CHEMICAL", 78, 80], ["ion-phosphate", "SIMPLE_CHEMICAL", 19, 32], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["The frequencies of ion-phosphate modes", "TEST", 0, 38], ["Na-and Cs", "TEST", 71, 80]]], ["The calculated amplitudes of vibrations show that light counterions not disturb the DNA internal dynamics, but heavy counterions make move all structure elements of the double helix.", [["DNA", "CELLULAR_COMPONENT", 84, 87], ["light counterions", "PROBLEM", 50, 67], ["double helix", "OBSERVATION", 169, 181]]], ["Using the valence-optic approach the intensities of the DNA vibrations in Raman spectra are calculated.", [["DNA", "CELLULAR_COMPONENT", 56, 59], ["the valence-optic approach", "TREATMENT", 6, 32], ["the DNA vibrations in Raman spectra", "TEST", 52, 87]]], ["The calculations show that the ion-phosphate mode in Cs-DNA spectra is prominent, in contrast to Na-DNA spectra, where it has very low intensity.", [["ion-phosphate", "CHEMICAL", 31, 44], ["Cs", "CHEMICAL", 53, 55], ["ion-phosphate", "CHEMICAL", 31, 44], ["Cs", "CHEMICAL", 53, 55], ["ion-phosphate", "SIMPLE_CHEMICAL", 31, 44], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["The calculations", "TEST", 0, 16], ["the ion-phosphate mode", "TEST", 27, 49], ["very low intensity", "PROBLEM", 126, 144], ["prominent", "OBSERVATION_MODIFIER", 71, 80], ["very", "OBSERVATION_MODIFIER", 126, 130], ["low intensity", "OBSERVATION_MODIFIER", 131, 144]]], ["Obtained results describe the intensity increase of the band 100 cm \u22121 in Cs-DNA spectra that was observed in [Bulavin L.A., et al., arXiv:0805.0696v1].Coherent white light confocal fluorescence imaging and FLIM for FRETS.", [["Cs", "CHEMICAL", 74, 76], ["Cs", "CHEMICAL", 74, 76], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["Cs", "DNA", 74, 76], ["the band", "TEST", 52, 60], ["DNA spectra", "TEST", 77, 88], ["fluorescence imaging", "TEST", 182, 202], ["intensity", "OBSERVATION_MODIFIER", 30, 39], ["increase", "OBSERVATION_MODIFIER", 40, 48]]], ["Soria 1 , F. Quercioli 3 , R. Mercatelli 3 , F. Bianco 2 , I. Cacciari 2 , G. Righini 2 1 Centro Studi e Ricerche \"E. Fermi\", P. Del Viminale 2, 00184 Rome, Italy, 2 IFAC-CNR, Istituto di Fisica Applicata \"N. Carrara\", Via Madonna del Piano 10, 50019 Sesto Fiorentino (FI), Italy, 3 ISC-CNR, Istituto dei Sistemi Complessi, Via Madonna del Piano 10, 50019 Sesto Fiorentino (FI), ItalyCoherent white light confocal fluorescence imaging and FLIM for FRETWe report on the application of a simple white light source based on the supercontinuum generation from commercial photonic crystal fibres to confocal fluorescence microscopy and fluorescence lifetime imaging (FLIM) microscopy.", [["Soria", "TEST", 0, 5], ["fluorescence imaging", "TEST", 414, 434], ["a simple white light source", "PROBLEM", 484, 511], ["the supercontinuum generation", "TREATMENT", 521, 550], ["confocal fluorescence microscopy", "TEST", 594, 626], ["fluorescence lifetime imaging", "TEST", 631, 660], ["FLIM) microscopy", "TEST", 662, 678]]], ["The coherent white light can be tuned by varying the wavelength and intensity of the pump, a Ti:Sapphire laser.", [["Ti", "CHEMICAL", 93, 95], ["the pump", "TREATMENT", 81, 89], ["a Ti:Sapphire laser", "TREATMENT", 91, 110], ["coherent", "OBSERVATION_MODIFIER", 4, 12], ["white light", "OBSERVATION_MODIFIER", 13, 24]]], ["There are several advantages jn the use of SC sources: spatially coherent white radiation, tuning ranges of approximately 400 nm, high brightness, a robust compact system (potentially all-fibre) and relatively low cost.", [["high brightness", "PROBLEM", 130, 145], ["relatively low cost", "PROBLEM", 199, 218], ["several", "OBSERVATION_MODIFIER", 10, 17], ["advantages", "OBSERVATION", 18, 28], ["high brightness", "OBSERVATION", 130, 145], ["low cost", "OBSERVATION", 210, 218]]], ["Being pulsed, SC sources are suitable for FLIM.", [["FLIM", "PROBLEM", 42, 46]]], ["We have used this system for measuring Foerster Resonance Energy Transfer (FRET) in order to study interactions between ions channels and proteins of membrane within lives cellsP-188Resolving the quaternary structure of plague F1 capsular antigen A. Soliakov 1 , J. R. Harris 1 , M. R. Hicks 2 , A. Rodger 2 , R. Woody 3 , A. Watkinson 4 , J. H. Lakey 1 1 Cell and Molecular biosciences Inst., Newcastle Univ., UK, 2 Chemistry dept., Univ. of Warwick, Coventry, UK, 3 Biochemistry and Molecular Biology dept., Colorado State Univ., USA, 4 PharmAthene UK, Billingham, Cleveland, UK Most Gram-negative pathogens express multi-subunit fibres on their surfaces that mediate host cell attachment, biofilm formation, invasion of host defenses and protection against phagocytosis.", [["membrane", "ANATOMY", 150, 158], ["fibres", "ANATOMY", 632, 638], ["cell", "ANATOMY", 675, 679], ["biofilm", "ANATOMY", 692, 699], ["cellsP-188Resolving", "CHEMICAL", 172, 191], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["Cell", "CELL", 356, 360], ["cell", "CELL", 675, 679], ["multi-subunit fibres", "PROTEIN", 618, 638], ["this system", "TREATMENT", 13, 24], ["Most Gram", "TEST", 581, 590], ["host cell attachment", "PROBLEM", 670, 690], ["biofilm formation", "PROBLEM", 692, 709], ["phagocytosis", "PROBLEM", 760, 772], ["multi-subunit fibres", "OBSERVATION", 618, 638], ["host cell attachment", "OBSERVATION", 670, 690], ["host defenses", "OBSERVATION", 723, 736]]], ["Here we have studied Capsular antigen fraction 1 (or Caf1), secreted through the conserved chaperone/usher pathway by the plague agent Yersinia pestis [1] .", [["Yersinia pestis", "DISEASE", 135, 150], ["Capsular antigen fraction 1", "GENE_OR_GENE_PRODUCT", 21, 48], ["Caf1", "GENE_OR_GENE_PRODUCT", 53, 57], ["Yersinia pestis", "ORGANISM", 135, 150], ["Capsular antigen fraction 1", "PROTEIN", 21, 48], ["Caf1", "PROTEIN", 53, 57], ["chaperone", "PROTEIN", 91, 100], ["Yersinia pestis", "SPECIES", 135, 150], ["Yersinia pestis", "SPECIES", 135, 150], ["Capsular antigen fraction", "TEST", 21, 46]]], ["Caf1 is highly immunogenic and is used in a recombinant subunit vaccine against plague.", [["Caf1", "CHEMICAL", 0, 4], ["plague", "DISEASE", 80, 86], ["Caf1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Caf1", "PROTEIN", 0, 4], ["a recombinant subunit vaccine", "TREATMENT", 42, 71], ["plague", "PROBLEM", 80, 86], ["highly", "OBSERVATION_MODIFIER", 8, 14], ["immunogenic", "OBSERVATION", 15, 26]]], ["Recent immunological studies indicated vaccines containing polymeric Caf1 have higher protective efficacy than vaccines containing its monomeric variant.", [["Caf1", "CHEMICAL", 69, 73], ["Caf1", "GENE_OR_GENE_PRODUCT", 69, 73], ["polymeric Caf1", "PROTEIN", 59, 73], ["Recent immunological studies", "TEST", 0, 28], ["vaccines", "TREATMENT", 39, 47], ["polymeric Caf1", "TREATMENT", 59, 73], ["higher protective efficacy than vaccines", "TREATMENT", 79, 119], ["higher protective", "OBSERVATION_MODIFIER", 79, 96], ["monomeric variant", "OBSERVATION", 135, 152]]], ["This difference in protective efficacy was attributed to the quaternary structure.", [["the quaternary structure", "PROBLEM", 57, 81], ["protective efficacy", "OBSERVATION", 19, 38], ["quaternary structure", "OBSERVATION", 61, 81]]], ["However the quaternary structure of Caf1 has not been characterized [2] .", [["Caf1", "CHEMICAL", 36, 40], ["Caf1", "GENE_OR_GENE_PRODUCT", 36, 40], ["Caf1", "PROTEIN", 36, 40], ["quaternary", "OBSERVATION_MODIFIER", 12, 22], ["Caf1", "OBSERVATION", 36, 40]]], ["In our study we have used transmission electron microscopy of negatively stained specimen and linear dichroism spectroscopy to determine the quaternary structure of recombinant Caf1.", [["specimen", "ANATOMY", 81, 89], ["Caf1", "GENE_OR_GENE_PRODUCT", 177, 181], ["recombinant Caf1", "PROTEIN", 165, 181], ["our study", "TEST", 3, 12], ["transmission electron microscopy", "TEST", 26, 58], ["linear dichroism spectroscopy", "TEST", 94, 123]]], ["Whereas electron microscopy revealed morphology of Caf1 fibres bound to the surface of a carbon coated grid, linear dichroism gave the orientation of subunits in flow aligned Caf1 fibres in solution.", [["Caf1 fibres", "ANATOMY", 51, 62], ["surface", "ANATOMY", 76, 83], ["Caf1 fibres", "ANATOMY", 175, 186], ["carbon", "CHEMICAL", 89, 95], ["Caf1 fibres", "GENE_OR_GENE_PRODUCT", 51, 62], ["surface", "CELLULAR_COMPONENT", 76, 83], ["Caf1", "GENE_OR_GENE_PRODUCT", 175, 179], ["Caf1 fibres", "PROTEIN", 51, 62], ["electron microscopy", "TEST", 8, 27], ["Caf1 fibres bound", "PROBLEM", 51, 68], ["a carbon coated grid", "TREATMENT", 87, 107], ["linear dichroism", "PROBLEM", 109, 125], ["Caf1 fibres", "OBSERVATION", 51, 62], ["surface", "OBSERVATION_MODIFIER", 76, 83], ["carbon coated", "OBSERVATION", 89, 102], ["linear", "OBSERVATION_MODIFIER", 109, 115], ["dichroism", "OBSERVATION", 116, 125], ["flow aligned", "OBSERVATION", 162, 174], ["Caf1 fibres", "OBSERVATION", 175, 186]]], ["Our results show recombinant Caf1 comprises extended linear fibres and circularized fibres, both of which have high degree of conformational freedom.", [["fibres", "ANATOMY", 60, 66], ["fibres", "ANATOMY", 84, 90], ["Caf1", "GENE_OR_GENE_PRODUCT", 29, 33], ["recombinant Caf1", "PROTEIN", 17, 33], ["linear", "OBSERVATION_MODIFIER", 53, 59], ["fibres", "OBSERVATION_MODIFIER", 60, 66], ["circularized fibres", "OBSERVATION", 71, 90], ["high", "OBSERVATION_MODIFIER", 111, 115], ["degree", "OBSERVATION_MODIFIER", 116, 122], ["conformational freedom", "OBSERVATION", 126, 148]]], ["This family of molecules includes most fluorescent molecules, which are very important in biology.", [["most fluorescent molecules", "PROBLEM", 34, 60]]], ["Lambert-Beer law is in fact only valid at very low intensity of incident light and very low concentration of chromophore.", [["very low concentration of chromophore", "TREATMENT", 83, 120]]], ["If the system doesn't meet these conditions, it falls into a nonlinear regime when it is affected by a phenomenon which we call \"dynamic photobleaching\": the depletion of chromophores from the first layers, due to their transition to the excited state, leads to a sub-exponential propagation of light in the medium [1] .", [["a nonlinear regime", "TREATMENT", 59, 77], ["the depletion of chromophores", "TREATMENT", 154, 183]]], ["This phenomenon leads to the necessity of a new formula for the light absorption dynamics which depends on the lifetime of the excited state of the chromophore.", [["This phenomenon", "PROBLEM", 0, 15], ["a new formula", "TREATMENT", 42, 55], ["the light absorption dynamics", "PROBLEM", 60, 89], ["the chromophore", "TREATMENT", 144, 159]]], ["The predictions of the theory were successful in describing the absorption dynamics of azobenzene [2] , but now they have been tested also on a biologically relevant molecule like chlorophyll.", [["azobenzene", "CHEMICAL", 87, 97], ["chlorophyll", "CHEMICAL", 180, 191], ["azobenzene", "CHEMICAL", 87, 97], ["chlorophyll", "CHEMICAL", 180, 191], ["azobenzene [2]", "SIMPLE_CHEMICAL", 87, 101], ["chlorophyll", "SIMPLE_CHEMICAL", 180, 191], ["the absorption dynamics of azobenzene", "TREATMENT", 60, 97]]], ["The results indicate that the absorbance is affected by the intensity of the incident light, and it is therefore a non reliable way of determining, for example, the concentration of the molecule.P-186Annular pupil filter to improve spatial highfrequency signal to noise ratio in linear and non linear microscopy E. Ronzitti 2 , V. Caorsi 1 , A. Diaspro 3 1 LAMBS, MicroSCoBio, Department of Physics, University of Genoa, Genoa, Italy, 2 SEMM, IFOM-IEO, University of Milan, Milan, Italy, 3 Neuroscience and Brain Technologies Department, IIT, Genoa, Italy Shot-noise significantly affects and deteriorates the imaging capabilities of typical two-photon excitation and confocal laser scanning microscope, especially in biological applications where the detected signal can be remarkable slight [1] .", [["P", "DNA", 195, 196], ["the absorbance", "PROBLEM", 26, 40], ["186Annular pupil filter", "TREATMENT", 197, 220], ["spatial highfrequency signal", "PROBLEM", 232, 260], ["noise ratio", "TEST", 264, 275], ["the imaging capabilities", "TEST", 606, 630], ["typical two-photon excitation", "TREATMENT", 634, 663], ["confocal laser scanning microscope", "TEST", 668, 702], ["absorbance", "OBSERVATION", 30, 40]]], ["The insertion of an annular filter on the microscope objective lens in the illumination light pathway is here proposed to retrieve the high frequencies information loss [2] .The electromagnetic interference effect induced by the filter insertion, gives a redistribution of the optical transfer function.", [["an annular filter", "TREATMENT", 17, 34], ["The electromagnetic interference effect", "PROBLEM", 174, 213], ["the filter insertion", "TREATMENT", 225, 245], ["insertion", "OBSERVATION_MODIFIER", 4, 13], ["annular", "OBSERVATION_MODIFIER", 20, 27], ["filter", "OBSERVATION", 28, 34], ["electromagnetic interference", "OBSERVATION", 178, 206], ["filter insertion", "OBSERVATION", 229, 245], ["redistribution", "OBSERVATION_MODIFIER", 255, 269]]], ["In particular, the microscope frequency response in filter scheme exhibits an enhancement of signal to noise ratio at the high frequencies able to recover the high frequencies hampered by shot-noise [3] .", [["the microscope frequency response in filter scheme", "PROBLEM", 15, 65], ["an enhancement of signal to noise ratio", "PROBLEM", 75, 114], ["enhancement", "OBSERVATION_MODIFIER", 78, 89], ["high frequencies", "OBSERVATION_MODIFIER", 122, 138]]], ["The goal of biomarker studies is to develop simple noninvasive tests that identify disease states.", [["biomarker studies", "TEST", 12, 29], ["simple noninvasive tests", "TEST", 44, 68], ["disease states", "PROBLEM", 83, 97]]], ["Focus is beginning to shift from identification of individual biomarkers to identification of biomarker panels comprising multiple targets of different molecular species.", [["individual biomarkers", "TEST", 51, 72], ["biomarker panels", "TEST", 94, 110], ["different molecular species", "PROBLEM", 142, 169], ["multiple", "OBSERVATION_MODIFIER", 122, 130], ["different", "OBSERVATION_MODIFIER", 142, 151], ["molecular species", "OBSERVATION", 152, 169]]], ["There are, however, no current technologies available that allow for a comprehensive and simultaneous analysis of the expression levels of multiple cellular components, i.e. proteins and RNA.", [["cellular", "ANATOMY", 148, 156], ["cellular", "CELL", 148, 156], ["RNA", "RNA", 187, 190], ["simultaneous analysis", "TEST", 89, 110], ["multiple cellular components", "PROBLEM", 139, 167], ["multiple", "OBSERVATION_MODIFIER", 139, 147], ["cellular components", "OBSERVATION", 148, 167]]], ["Surface plasmon resonance (SPR) polaritons are surface electromagnetic waves that propagate in a direction parallel to the interface between a metal surface and an external medium e.g., liquid.", [["Surface plasmon resonance (SPR) polaritons", "TREATMENT", 0, 42], ["surface electromagnetic waves", "PROBLEM", 47, 76], ["a metal surface", "TREATMENT", 141, 156], ["an external medium e.g., liquid", "TREATMENT", 161, 192]]], ["We are utilising the power of SPR to develop technologies that facilitate diagnostic procedures for complex diseases such as Alzheimer's Disease and Chronic Obstructive Pulmonary Disease, through identification and detection of patterns of biomolecules indicative of disease.", [["Pulmonary", "ANATOMY", 169, 178], ["Alzheimer's Disease", "DISEASE", 125, 144], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 149, 186], ["diagnostic procedures", "TREATMENT", 74, 95], ["complex diseases", "PROBLEM", 100, 116], ["Alzheimer's Disease", "PROBLEM", 125, 144], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 149, 186], ["disease", "PROBLEM", 267, 274], ["Chronic", "OBSERVATION_MODIFIER", 149, 156], ["Obstructive", "OBSERVATION_MODIFIER", 157, 168], ["Pulmonary", "ANATOMY", 169, 178], ["Disease", "OBSERVATION", 179, 186], ["disease", "OBSERVATION", 267, 274]]], ["Our approach will facilitate better disease characterisation, improve early detection strategies and aid drug discovery.P-192Surface generated fluorescence detection by supercritical angle confocal microscopy D. Verdes, M. Rabe, S. Seeger Institute of Physical Chemistry, University of Z\u00fcrich, Winterthurerstrasse 190, Z\u00fcrich, Switzerland A two channel confocal microscope for surface and simultaneously in solution fluorescence detection is presented.", [["surface", "ANATOMY", 377, 384], ["surface", "CELLULAR_COMPONENT", 377, 384], ["P", "DNA", 120, 121], ["better disease characterisation", "PROBLEM", 29, 60], ["fluorescence detection", "TEST", 143, 165]]], ["The microscope's core element is a parabolic mirror objective that collects the fluorescence above the critical angles for total internal reflection (TIRF) of the water/glass interface.", [["microscope's core element", "DNA", 4, 29], ["The microscope's core element", "TEST", 0, 29], ["a parabolic mirror objective", "PROBLEM", 33, 61], ["the fluorescence", "TEST", 76, 92], ["the water/glass interface", "TREATMENT", 159, 184], ["angles", "OBSERVATION_MODIFIER", 112, 118], ["total", "OBSERVATION_MODIFIER", 123, 128], ["internal reflection", "OBSERVATION", 129, 148], ["water/glass interface", "OBSERVATION", 163, 184]]], ["An aspheric lens incorporated into the parabolic mirror is used for diffraction limited focusing and collecting the fluorescence at low angles with respect to the optical axis.", [["An aspheric lens", "TREATMENT", 0, 16], ["aspheric lens", "OBSERVATION", 3, 16], ["parabolic mirror", "OBSERVATION", 39, 55], ["low angles", "OBSERVATION_MODIFIER", 132, 142], ["optical axis", "OBSERVATION", 163, 175]]], ["This low angles excitation approach is technically straightforward and gives an advantage over high numerical objectives that require very high angles for TIRF illumination.", [["This low angles excitation approach", "TREATMENT", 0, 35], ["TIRF illumination", "TREATMENT", 155, 172]]], ["By separating the collection of the fluorescence into supercritical and subcritical angles, two detection volumes highly differing in their axial resolution are generated at the interface.", [["two detection volumes", "TEST", 92, 113], ["supercritical", "ANATOMY_MODIFIER", 54, 67], ["subcritical", "ANATOMY_MODIFIER", 72, 83], ["angles", "ANATOMY_MODIFIER", 84, 90], ["two", "OBSERVATION_MODIFIER", 92, 95], ["detection", "OBSERVATION_MODIFIER", 96, 105], ["volumes", "OBSERVATION_MODIFIER", 106, 113], ["highly", "OBSERVATION_MODIFIER", 114, 120], ["differing", "OBSERVATION_MODIFIER", 121, 130], ["axial resolution", "OBSERVATION_MODIFIER", 140, 156]]], ["The surface selectivity of the detection volume is obtained on the basis of the dipole emission profile near a dielectric interface.", [["surface", "ANATOMY", 4, 11], ["the detection volume", "TEST", 27, 47], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["selectivity", "OBSERVATION_MODIFIER", 12, 23], ["dielectric interface", "OBSERVATION", 111, 131]]], ["Its angular distribution is highly anisotropic and consists of a superposition of traveling and evanescent waves, which both are detected using the parabolic mirror objective.", [["angular", "OBSERVATION_MODIFIER", 4, 11], ["distribution", "OBSERVATION_MODIFIER", 12, 24], ["highly", "OBSERVATION_MODIFIER", 28, 34], ["anisotropic", "OBSERVATION_MODIFIER", 35, 46], ["superposition", "OBSERVATION_MODIFIER", 65, 78], ["evanescent waves", "OBSERVATION", 96, 112], ["parabolic mirror", "OBSERVATION", 148, 164]]], ["Unlike with objective TIRF microscopy, the parabolic mirror objective achieves easily diffraction limited excitation/detection volume at the water/glass interface.", [["objective TIRF microscopy", "TEST", 12, 37], ["glass interface", "OBSERVATION", 147, 162]]], ["The objective optical performance is shown by measuring the actin cytoskeleton of cultured cells, FRET energy transfer within adsorbed clustered proteins and single molecules detection.P-191Differential polarization laser scanning microscopy.", [["cytoskeleton", "ANATOMY", 66, 78], ["cells", "ANATOMY", 91, 96], ["actin", "GENE_OR_GENE_PRODUCT", 60, 65], ["cytoskeleton", "CELLULAR_COMPONENT", 66, 78], ["cells", "CELL", 91, 96], ["actin", "PROTEIN", 60, 65], ["cultured cells", "CELL_LINE", 82, 96], ["adsorbed clustered proteins", "PROTEIN", 126, 153], ["The objective optical performance", "TEST", 0, 33], ["single molecules detection", "TEST", 158, 184], ["Differential polarization laser scanning microscopy", "TEST", 190, 241]]], ["Anisotropy in biological samples G. Steinbach 1 , I. Pomozi 2 , G. Garab 1 1 Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary, 2 Pi Vision Bt., Budapest, Hungary Differential polarization (DP) spectroscopy provides unique information on the anisotropic organization of biological samples [Tinoco et al. 1987 Ann Rev Biophys Biophys Chem 16:319].", [["Anisotropy", "TEST", 0, 10], ["DP) spectroscopy", "TEST", 215, 231], ["biological samples", "TEST", 295, 313]]], ["The DP-LSM, constructed in our laboratory enables us to image the main DP quantities: linear and circular dichroisms (LD&CD), also in fluorescence detection ( .", [["linear and circular dichroisms (LD&CD", "PROBLEM", 86, 123], ["fluorescence detection", "TEST", 134, 156], ["DP", "ANATOMY", 4, 6], ["main DP", "ANATOMY", 66, 73], ["linear", "OBSERVATION_MODIFIER", 86, 92], ["circular", "OBSERVATION_MODIFIER", 97, 105], ["dichroisms", "OBSERVATION", 106, 116]]], ["Further applications include: periodic structure of isolated amyloids, anisotropy variations in cell walls related to drought resistance, and strong anisotropy of 'artificial chlorosomes', nanorods of synthetic porphyrins.", [["cell walls", "ANATOMY", 96, 106], ["chlorosomes", "ANATOMY", 175, 186], ["porphyrins", "CHEMICAL", 211, 221], ["cell", "CELL", 96, 100], ["chlorosomes", "SIMPLE_CHEMICAL", 175, 186], ["porphyrins", "SIMPLE_CHEMICAL", 211, 221], ["Further applications", "TREATMENT", 0, 20], ["isolated amyloids", "PROBLEM", 52, 69], ["anisotropy variations in cell walls", "PROBLEM", 71, 106], ["drought resistance", "PROBLEM", 118, 136], ["strong anisotropy of 'artificial chlorosomes'", "TREATMENT", 142, 187], ["synthetic porphyrins", "TREATMENT", 201, 221], ["amyloids", "OBSERVATION", 61, 69], ["anisotropy variations", "OBSERVATION", 71, 92], ["cell walls", "OBSERVATION", 96, 106], ["drought resistance", "OBSERVATION", 118, 136]]], ["DP-LSM might thus represent a novel tool in the better understanding of highly organized molecular macroassemblies.Calyx of Held: STED nanoscopy of a glutamatergic terminalT.", [["glutamatergic terminalT", "PROTEIN", 150, 173], ["DP", "TEST", 0, 2], ["a novel tool", "PROBLEM", 28, 40], ["LSM", "OBSERVATION", 3, 6], ["highly", "OBSERVATION_MODIFIER", 72, 78], ["organized", "OBSERVATION_MODIFIER", 79, 88], ["molecular macroassemblies", "OBSERVATION", 89, 114], ["glutamatergic terminalT", "OBSERVATION", 150, 173]]], ["M. Staudt 2 , P. Bingen 1 , C. Kempf 3 , H. Horstmann 3 , J. Engelhardt 1 , T. Kuner 3 , S. W. Hell 2 1 German Cancer Research Center/ BioQuant, 69120 Heidelberg, Germany, 2 Max Planck Institute for Biophysical Chemistry, 37077 G\u00f6ttingen, Germany, 3 Institute for Anatomy and Cell Biology, University of Heidelberg, 69120 Heidelberg, GermanyCalyx of Held: STED nanoscopy of a glutamatergic terminalThe calyx of Held, a large glutamatergic synaptic terminal in the auditory brainstem circuit has been increasingly employed to study presynaptic mechanisms of neurotransmission in the central nervous system.", [["Cell", "ANATOMY", 276, 280], ["calyx", "ANATOMY", 402, 407], ["glutamatergic synaptic terminal", "ANATOMY", 425, 456], ["auditory brainstem", "ANATOMY", 464, 482], ["central nervous system", "ANATOMY", 582, 604], ["Cancer", "DISEASE", 111, 117], ["glutamatergic synaptic terminal", "CELLULAR_COMPONENT", 425, 456], ["brainstem circuit", "MULTI-TISSUE_STRUCTURE", 473, 490], ["central nervous system", "ANATOMICAL_SYSTEM", 582, 604], ["glutamatergic terminal", "PROTEIN", 376, 398], ["Biophysical Chemistry", "TEST", 199, 220], ["a large glutamatergic synaptic terminal in the auditory brainstem circuit", "TREATMENT", 417, 490], ["Cancer", "OBSERVATION", 111, 117], ["calyx", "ANATOMY_MODIFIER", 402, 407], ["large", "OBSERVATION_MODIFIER", 419, 424], ["glutamatergic synaptic", "OBSERVATION", 425, 447], ["terminal", "OBSERVATION_MODIFIER", 448, 456], ["auditory brainstem", "ANATOMY", 464, 482], ["central", "ANATOMY_MODIFIER", 582, 589], ["nervous system", "ANATOMY", 590, 604]]], ["A highly detailed model of the morphology and distribution of cytoskeleton, synapsin, synaptic vesicles, calcium sensors, mitochondria, the presynaptic membrane and its active zones is derived by colocalization analysis of these different key elements of synaptic transmission in the rat brain.", [["cytoskeleton", "ANATOMY", 62, 74], ["synaptic vesicles", "ANATOMY", 86, 103], ["mitochondria", "ANATOMY", 122, 134], ["presynaptic membrane", "ANATOMY", 140, 160], ["synaptic", "ANATOMY", 255, 263], ["brain", "ANATOMY", 288, 293], ["calcium", "CHEMICAL", 105, 112], ["calcium", "CHEMICAL", 105, 112], ["cytoskeleton", "CELLULAR_COMPONENT", 62, 74], ["synapsin", "GENE_OR_GENE_PRODUCT", 76, 84], ["synaptic vesicles", "CELLULAR_COMPONENT", 86, 103], ["calcium", "SIMPLE_CHEMICAL", 105, 112], ["mitochondria", "CELLULAR_COMPONENT", 122, 134], ["presynaptic membrane", "CELLULAR_COMPONENT", 140, 160], ["synaptic", "MULTI-TISSUE_STRUCTURE", 255, 263], ["rat", "ORGANISM", 284, 287], ["brain", "ORGAN", 288, 293], ["synapsin", "PROTEIN", 76, 84], ["rat", "SPECIES", 284, 287], ["rat", "SPECIES", 284, 287], ["calcium sensors", "TEST", 105, 120], ["mitochondria", "PROBLEM", 122, 134], ["the presynaptic membrane", "PROBLEM", 136, 160], ["colocalization analysis", "TEST", 196, 219], ["synaptic transmission in the rat brain", "PROBLEM", 255, 293], ["synaptic vesicles", "OBSERVATION", 86, 103], ["presynaptic membrane", "OBSERVATION", 140, 160], ["active", "OBSERVATION_MODIFIER", 169, 175], ["synaptic transmission", "OBSERVATION", 255, 276], ["rat", "ANATOMY_MODIFIER", 284, 287], ["brain", "ANATOMY", 288, 293]]], ["The various cellular components are visualized with subdiffraction resolution by stimulated emission depletion (STED) microscopy.", [["cellular", "ANATOMY", 12, 20], ["cellular", "CELL", 12, 20], ["stimulated emission depletion", "TREATMENT", 81, 110], ["microscopy", "TEST", 118, 128], ["various", "OBSERVATION_MODIFIER", 4, 11], ["cellular components", "OBSERVATION", 12, 31], ["resolution", "OBSERVATION_MODIFIER", 67, 77], ["emission depletion", "OBSERVATION", 92, 110]]], ["Imaging individual structural elements exhibit a focal plane resolution of <50 nm inside 3 \u00b5m thick tissue sections.O-189-Imaging and spectroscopy -Towards reconstitution of the interleukin-4 receptors in artificial membranesR.", [["tissue sections", "ANATOMY", 100, 115], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 100, 115], ["interleukin-4 receptors", "GENE_OR_GENE_PRODUCT", 178, 201], ["interleukin-4 receptors", "PROTEIN", 178, 201], ["Imaging", "TEST", 0, 7], ["a focal plane resolution", "PROBLEM", 47, 71], ["thick tissue sections", "PROBLEM", 94, 115], ["Imaging", "TEST", 122, 129], ["spectroscopy", "TEST", 134, 146], ["the interleukin", "TREATMENT", 174, 189], ["focal", "OBSERVATION_MODIFIER", 49, 54], ["plane", "OBSERVATION_MODIFIER", 55, 60], ["resolution", "OBSERVATION_MODIFIER", 61, 71]]], ["Worch, T. Weidemann, P. Schwille Biotec, Biophysics Group, Technische Universit\u00e4t Dresden, GermanyTowards reconstitution of the interleukin-4 receptors in artificial membranesInterleukin-4 (IL-4), a small soluble protein, is a principal regulatory cytokine, playing an important role during the maturation and clonal expansion of antigen specific B-cells in mammals.", [["B-cells", "ANATOMY", 347, 354], ["interleukin-4 receptors", "GENE_OR_GENE_PRODUCT", 128, 151], ["Interleukin-4", "GENE_OR_GENE_PRODUCT", 175, 188], ["IL-4", "GENE_OR_GENE_PRODUCT", 190, 194], ["B-cells", "CELL", 347, 354], ["interleukin-4 receptors", "PROTEIN", 128, 151], ["Interleukin-4 (IL-4", "PROTEIN", 175, 194], ["small soluble protein", "PROTEIN", 199, 220], ["regulatory cytokine", "PROTEIN", 237, 256], ["antigen specific B-cells", "CELL_TYPE", 330, 354], ["the interleukin", "TEST", 124, 139], ["artificial membranes", "TEST", 155, 175], ["Interleukin", "TEST", 175, 186], ["a small soluble protein", "PROBLEM", 197, 220], ["artificial membranes", "ANATOMY", 155, 175], ["small", "OBSERVATION_MODIFIER", 199, 204], ["soluble protein", "OBSERVATION", 205, 220]]], ["At the plasma membrane, IL-4 is recognized by a receptor that consists of two single spanning transmembrane proteins: a high affinity IL-4R alpha chain, and a low affinity IL-2R gamma chain.", [["plasma membrane", "ANATOMY", 7, 22], ["transmembrane", "ANATOMY", 94, 107], ["plasma membrane", "CELLULAR_COMPONENT", 7, 22], ["IL-4", "GENE_OR_GENE_PRODUCT", 24, 28], ["transmembrane", "CELLULAR_COMPONENT", 94, 107], ["IL-4R alpha", "GENE_OR_GENE_PRODUCT", 134, 145], ["IL-2R", "GENE_OR_GENE_PRODUCT", 172, 177], ["IL-4", "PROTEIN", 24, 28], ["transmembrane proteins", "PROTEIN", 94, 116], ["high affinity IL-4R alpha chain", "PROTEIN", 120, 151], ["low affinity IL-2R gamma chain", "PROTEIN", 159, 189], ["a low affinity IL", "TREATMENT", 157, 174], ["plasma membrane", "ANATOMY", 7, 22], ["high affinity", "OBSERVATION_MODIFIER", 120, 133], ["low affinity", "OBSERVATION_MODIFIER", 159, 171]]], ["It is still controversial by which molecular mechanism the signaling complex is fully activated: dimerization of chains, large conformational change upon IL-4 binding or a combination of both.", [["IL-4", "GENE_OR_GENE_PRODUCT", 154, 158], ["signaling complex", "PROTEIN", 59, 76], ["IL", "PROTEIN", 154, 156], ["dimerization of chains", "PROBLEM", 97, 119], ["large conformational change", "PROBLEM", 121, 148], ["IL-4 binding", "TREATMENT", 154, 166], ["chains", "OBSERVATION_MODIFIER", 113, 119], ["large", "OBSERVATION_MODIFIER", 121, 126], ["conformational", "OBSERVATION_MODIFIER", 127, 141], ["change", "OBSERVATION_MODIFIER", 142, 148], ["IL-4 binding", "OBSERVATION_MODIFIER", 154, 166]]], ["Moreover, the influence of the lipid environment in which the activation takes place is poorly characterized.", [["the lipid environment", "TREATMENT", 27, 48], ["poorly characterized", "OBSERVATION_MODIFIER", 88, 108]]], ["To address these issues we aim to reconstitute the receptor component in artificial membrane systems to study the various mutual interactions by means of fluorescence-based techniques, mainly fluorescence correlation spectroscopy.", [["membrane systems", "ANATOMY", 84, 100], ["the receptor component", "TREATMENT", 47, 69], ["artificial membrane systems", "TREATMENT", 73, 100], ["fluorescence correlation spectroscopy", "TEST", 192, 229]]], ["Due to reduced background in a chemically defined system this may provide details not yet accessible in the living cell.Confocal microscopy at high resolution and efficiency by image inversion interferometryK.", [["cell", "ANATOMY", 115, 119], ["cell", "CELL", 115, 119], ["reduced background in a chemically defined system", "PROBLEM", 7, 56], ["Confocal microscopy", "TEST", 120, 139], ["image inversion interferometryK", "TEST", 177, 208], ["reduced", "OBSERVATION_MODIFIER", 7, 14], ["high resolution", "OBSERVATION_MODIFIER", 143, 158]]], ["Wicker, S. Sindbert, R. Heintzmann Randall Division of Cell and Molecular Biophysics, King's College London, SE1 1UL London, U.K.Confocal microscopy at high resolution and efficiency by image inversion interferometryFluorescence confocal microscopy, an indispensable tool of modern biology, allows the imaging of live fluorescent specimen with high lateral as well as axial resolution.", [["Cell", "ANATOMY", 55, 59], ["specimen", "ANATOMY", 330, 338], ["Cell", "CELL", 55, 59], ["Confocal microscopy", "TEST", 129, 148], ["image inversion interferometry", "TEST", 186, 216], ["Fluorescence confocal microscopy", "TEST", 216, 248], ["the imaging", "TEST", 298, 309], ["Cell", "OBSERVATION", 55, 59], ["high resolution", "OBSERVATION_MODIFIER", 152, 167]]], ["Through the introduction of a sufficiently small confocal pinhole, the lateral resolution can be enhanced compared to that of a wide field microscope.", [["a sufficiently small confocal pinhole", "TREATMENT", 28, 65], ["a wide field microscope", "TEST", 126, 149], ["small", "OBSERVATION_MODIFIER", 43, 48], ["confocal pinhole", "OBSERVATION", 49, 65], ["lateral", "OBSERVATION_MODIFIER", 71, 78]]], ["However, this gain in resolution comes at the cost of a decrease in detection efficiency, as light blocked by the pinhole is lost.", [["a decrease in detection efficiency", "PROBLEM", 54, 88], ["decrease", "OBSERVATION_MODIFIER", 56, 64]]], ["We present a method for improving the lateral resolution (extending work of Sandeau et al. [1] ) and detection efficiency of scanning microscopes by adding an interferometer with image inversion in one of its arms to the detection pathway [2] .", [["scanning microscopes", "TEST", 125, 145], ["an interferometer with image inversion", "TREATMENT", 156, 194]]], ["This surpasses the lateral resolution achievable in a conventional confocal microscope (closed pinhole) while increasing the detection efficiency substantially.", [["lateral", "OBSERVATION_MODIFIER", 19, 26], ["resolution", "OBSERVATION_MODIFIER", 27, 37]]], ["Point spread function measurements for a UZ-Interferometer (UZI) are shown.", [["a UZ-Interferometer (UZI)", "TREATMENT", 39, 64]]], ["The light in this setup follows threedimensional U-and Z-shaped paths and relies on reflections off planar surfaces only in order to achieve image inversion.", [["this setup", "TEST", 13, 23], ["threedimensional U", "TEST", 32, 50]]], ["We achieved an interference contrast of 91% for white light, and excellent agreement with theoretical predictions.Blind image restoration in 4Pi microscopy with space-variant point-spread-functionG.", [["an interference contrast", "TEST", 12, 36], ["Blind image restoration", "PROBLEM", 114, 137], ["4Pi microscopy", "TEST", 141, 155], ["space", "TEST", 161, 166]]], ["Vicidomini, A. Sch\u00f6nle, J. Keller, R. Schmidt, C. Von Middendorff, S. W. Hell Max Planck Institute for Biophysical Chemistry, Department of NanoBiophotonics, G\u00f6ttingen, Germany Fluorescence far-field microscopy is a indispensable tool in modern life science.", [["NanoBiophotonics", "TREATMENT", 140, 156], ["field microscopy", "TEST", 194, 210], ["J. Keller", "OBSERVATION", 24, 33]]], ["However, the resolution of its standard variants is limited by diffraction to \u223c200nm in the focal plane and \u223c600nm along the optical axis.", [["focal plane", "ANATOMY", 92, 103], ["resolution", "OBSERVATION_MODIFIER", 13, 23], ["focal", "OBSERVATION_MODIFIER", 92, 97], ["optical axis", "OBSERVATION", 125, 137]]], ["One example is 4Pi microscopy.", [["4Pi microscopy", "TEST", 15, 29], ["4Pi microscopy", "OBSERVATION", 15, 29]]], ["To obtain isotropic resolution, 4Pi uses interference of the wave fronts from two opposing lenses.", [["4Pi", "SIMPLE_CHEMICAL", 32, 35], ["isotropic resolution", "TEST", 10, 30], ["opposing lenses", "OBSERVATION", 82, 97]]], ["The point spread function (PSF) of 4Pi system is characterized by multiple maxima/sidelobes, which replicate the object in the image.", [["multiple maxima/sidelobes", "PROBLEM", 66, 91], ["spread", "OBSERVATION_MODIFIER", 10, 16], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["maxima", "OBSERVATION_MODIFIER", 75, 81], ["sidelobes", "OBSERVATION", 82, 91], ["object", "OBSERVATION_MODIFIER", 113, 119]]], ["Therefore image restoration is mandatory to render unambiguous imaging.", [["unambiguous imaging", "TEST", 51, 70]]], ["The situation is further complicated because the positions and the relative heights of the multiple maxima/sidelobes of the PSF depend on the phase difference (PD) between the two wave fronts at the focus.", [["PSF", "DNA", 124, 127], ["heights", "OBSERVATION_MODIFIER", 76, 83], ["multiple", "OBSERVATION_MODIFIER", 91, 99], ["maxima", "OBSERVATION_MODIFIER", 100, 106], ["two", "OBSERVATION_MODIFIER", 176, 179], ["wave", "OBSERVATION_MODIFIER", 180, 184], ["fronts", "OBSERVATION_MODIFIER", 185, 191]]], ["If the refractive index of the sample varies in space, this PD becomes a function of position and 4Pi image formation process looses its shift invariance.", [["PD", "DISEASE", 60, 62], ["the refractive index", "TEST", 3, 23], ["this PD", "PROBLEM", 55, 62], ["4Pi image formation process", "TREATMENT", 98, 125], ["refractive", "OBSERVATION_MODIFIER", 7, 17], ["index", "OBSERVATION_MODIFIER", 18, 23]]], ["The PD function (PDF) may not even be known a-priori and must then be estimated from the image, leading to a blind image restoration problem.", [["a blind image restoration problem", "PROBLEM", 107, 140]]], ["Here, we propose a maximum a-posteriori based method to solve the problem.", [["a maximum a-posteriori based method", "TREATMENT", 17, 52]]], ["We either assumed a mathematical model for the PDF that depends on a small number of parameters or allowed for an arbitrary PDF but introduced a smoothing constraint.", [["the PDF", "PROBLEM", 43, 50], ["an arbitrary PDF", "TREATMENT", 111, 127], ["a smoothing constraint", "TREATMENT", 143, 165]]], ["Designer multicomponent lipoplexes have recently emerged as especially promising transfection candidates, since they are from 10 to 100 times more efficient than binary complexes usually employed for gene delivery purposes [1] [2] [3] .", [["lipoplexes", "SIMPLE_CHEMICAL", 24, 34], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 223, 234], ["Designer multicomponent lipoplexes", "TREATMENT", 0, 34], ["gene delivery purposes", "TREATMENT", 200, 222], ["lipoplexes", "OBSERVATION", 24, 34]]], ["Here, we show, for the first time, that after internalization binary complexes of lower transfection potency remain in compact perinuclear endosomes, while multicomponent systems have intrinsic endosomal rupture properties that allow plasmid DNA to escape from endosomes with extremely high efficiency [4] .", [["perinuclear endosomes", "ANATOMY", 127, 148], ["endosomal", "ANATOMY", 194, 203], ["plasmid", "ANATOMY", 234, 241], ["endosomes", "ANATOMY", 261, 270], ["perinuclear endosomes", "CELLULAR_COMPONENT", 127, 148], ["endosomal", "CELLULAR_COMPONENT", 194, 203], ["DNA", "CELLULAR_COMPONENT", 242, 245], ["endosomes", "CELLULAR_COMPONENT", 261, 270], ["lower transfection potency", "PROBLEM", 82, 108], ["intrinsic endosomal rupture properties", "PROBLEM", 184, 222], ["plasmid DNA", "TREATMENT", 234, 245], ["extremely high efficiency", "PROBLEM", 276, 301], ["transfection potency", "OBSERVATION", 88, 108], ["perinuclear endosomes", "OBSERVATION", 127, 148], ["endosomal rupture", "OBSERVATION", 194, 211]]], ["Endosomal rupture results in an extraordinarily homogeneous distribution of unbound plasmid DNA throughout the cytoplasm and in the nucleus [4] .", [["plasmid", "ANATOMY", 84, 91], ["cytoplasm", "ANATOMY", 111, 120], ["nucleus", "ANATOMY", 132, 139], ["rupture", "DISEASE", 10, 17], ["plasmid", "CELLULAR_COMPONENT", 84, 91], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["cytoplasm", "ORGANISM_SUBSTANCE", 111, 120], ["nucleus", "CELLULAR_COMPONENT", 132, 139], ["plasmid DNA", "DNA", 84, 95], ["Endosomal rupture", "PROBLEM", 0, 17], ["unbound plasmid DNA", "PROBLEM", 76, 95], ["rupture", "OBSERVATION", 10, 17], ["extraordinarily", "OBSERVATION_MODIFIER", 32, 47], ["homogeneous", "OBSERVATION_MODIFIER", 48, 59], ["unbound plasmid DNA", "OBSERVATION", 76, 95], ["cytoplasm", "OBSERVATION_MODIFIER", 111, 120], ["nucleus", "ANATOMY_MODIFIER", 132, 139]]], ["Fluorescence spectroscopy and stopped-flow technique were utilized for the study of the kinetics of incorporation of hypericin (Hyp), a natural photosensitizing pigment, into lowdensity lipoproteins (LDL).", [["hypericin", "CHEMICAL", 117, 126], ["Hyp", "CHEMICAL", 128, 131], ["hypericin", "CHEMICAL", 117, 126], ["Hyp", "CHEMICAL", 128, 131], ["hypericin", "SIMPLE_CHEMICAL", 117, 126], ["Hyp", "SIMPLE_CHEMICAL", 128, 131], ["lowdensity lipoproteins", "SIMPLE_CHEMICAL", 175, 198], ["LDL", "SIMPLE_CHEMICAL", 200, 203], ["lowdensity lipoproteins", "PROTEIN", 175, 198], ["LDL", "PROTEIN", 200, 203], ["Fluorescence spectroscopy", "TEST", 0, 25], ["stopped-flow technique", "TREATMENT", 30, 52], ["the study", "TEST", 71, 80], ["hypericin (Hyp)", "TREATMENT", 117, 132], ["a natural photosensitizing pigment", "TREATMENT", 134, 168], ["photosensitizing pigment", "OBSERVATION", 144, 168]]], ["Triphasic kinetics of Hyp association with LDL was observed when solutions of Hyp and LDL were mixed together.", [["Hyp", "SIMPLE_CHEMICAL", 22, 25], ["LDL", "SIMPLE_CHEMICAL", 43, 46], ["Hyp", "SIMPLE_CHEMICAL", 78, 81], ["LDL", "SIMPLE_CHEMICAL", 86, 89], ["LDL", "PROTEIN", 43, 46], ["LDL", "PROTEIN", 86, 89], ["Hyp association", "PROBLEM", 22, 37], ["LDL", "TEST", 43, 46], ["Hyp and LDL", "TREATMENT", 78, 89], ["kinetics", "OBSERVATION_MODIFIER", 10, 18], ["Hyp", "OBSERVATION", 22, 25]]], ["The most rapid phase of Hyp incorporation is completed within tens of msec, while the slowest one lasts 10-20 min.", [["Hyp", "SIMPLE_CHEMICAL", 24, 27], ["Hyp incorporation", "TREATMENT", 24, 41], ["most", "OBSERVATION_MODIFIER", 4, 8], ["rapid", "OBSERVATION_MODIFIER", 9, 14], ["phase", "OBSERVATION_MODIFIER", 15, 20], ["Hyp incorporation", "OBSERVATION", 24, 41]]], ["The most of Hyp molecules are incorporated into LDL in the slowest phase.", [["Hyp", "SIMPLE_CHEMICAL", 12, 15], ["LDL", "SIMPLE_CHEMICAL", 48, 51], ["Hyp molecules", "PROTEIN", 12, 25], ["LDL", "PROTEIN", 48, 51], ["Hyp molecules", "PROBLEM", 12, 25], ["Hyp molecules", "OBSERVATION", 12, 25], ["LDL", "OBSERVATION_MODIFIER", 48, 51], ["slowest phase", "OBSERVATION_MODIFIER", 59, 72]]], ["The kinetics of the incorporation of Hyp into LDL particles pre-loaded with Hyp were also investigated.", [["Hyp", "SIMPLE_CHEMICAL", 37, 40], ["LDL", "SIMPLE_CHEMICAL", 46, 49], ["Hyp", "SIMPLE_CHEMICAL", 76, 79], ["Hyp into LDL particles", "TREATMENT", 37, 59], ["Hyp", "PROBLEM", 76, 79], ["kinetics", "OBSERVATION_MODIFIER", 4, 12], ["Hyp", "OBSERVATION", 76, 79]]], ["The observed decrease of the lifetime and total intensity of Hyp fluorescence with the increase of the incubation time of Hyp with Hyp/LDL complex is a sign of the formation of aggregates and the dynamic quenching of singlet excitation state of Hyp inside LDL.", [["Hyp", "SIMPLE_CHEMICAL", 61, 64], ["Hyp", "SIMPLE_CHEMICAL", 122, 125], ["Hyp/LDL complex", "GENE_OR_GENE_PRODUCT", 131, 146], ["Hyp", "SIMPLE_CHEMICAL", 245, 248], ["LDL", "SIMPLE_CHEMICAL", 256, 259], ["Hyp", "PROTEIN", 131, 134], ["LDL complex", "PROTEIN", 135, 146], ["LDL", "PROTEIN", 256, 259], ["Hyp fluorescence", "PROBLEM", 61, 77], ["Hyp with Hyp/LDL complex", "PROBLEM", 122, 146], ["the formation of aggregates", "PROBLEM", 160, 187], ["Hyp inside LDL", "PROBLEM", 245, 259], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["total", "OBSERVATION_MODIFIER", 42, 47], ["intensity", "OBSERVATION_MODIFIER", 48, 57], ["Hyp fluorescence", "OBSERVATION", 61, 77], ["increase", "OBSERVATION_MODIFIER", 87, 95]]], ["To study the kinetics of a transfer of Hyp molecules between LDL particles, the time evolution of the stopped-flow and time-resolved fluorescence experiments were investigated after the mixing of the complex Hyp/LDL=200:1 with appropriate amounts of free LDL.", [["Hyp", "SIMPLE_CHEMICAL", 39, 42], ["LDL", "SIMPLE_CHEMICAL", 61, 64], ["Hyp", "SIMPLE_CHEMICAL", 208, 211], ["LDL", "SIMPLE_CHEMICAL", 212, 215], ["LDL", "SIMPLE_CHEMICAL", 255, 258], ["Hyp molecules", "PROTEIN", 39, 52], ["complex Hyp", "PROTEIN", 200, 211], ["LDL", "PROTEIN", 255, 258], ["Hyp molecules between LDL particles", "TREATMENT", 39, 74], ["fluorescence experiments", "TEST", 133, 157], ["the complex Hyp/LDL", "TEST", 196, 215], ["LDL", "ANATOMY", 212, 215], ["free LDL", "OBSERVATION", 250, 258]]], ["For each final Hyp/LDL ratio the increase of the lifetime and total intensity of Hyp fluorescence was observed.", [["Hyp", "SIMPLE_CHEMICAL", 15, 18], ["LDL", "SIMPLE_CHEMICAL", 19, 22], ["Hyp", "SIMPLE_CHEMICAL", 81, 84], ["LDL", "PROTEIN", 19, 22], ["each final Hyp/LDL ratio", "TEST", 4, 28], ["Hyp fluorescence", "PROBLEM", 81, 97], ["LDL", "OBSERVATION_MODIFIER", 19, 22], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["total", "OBSERVATION_MODIFIER", 62, 67], ["intensity", "OBSERVATION_MODIFIER", 68, 77], ["Hyp fluorescence", "OBSERVATION", 81, 97]]], ["The half-time of this process is similar to that one of the slowest phase of Hyp incorporation into free LDL.Planar patch clamp for neuronal networksA.", [["neuronal networks", "ANATOMY", 132, 149], ["Hyp", "SIMPLE_CHEMICAL", 77, 80], ["LDL", "SIMPLE_CHEMICAL", 105, 108], ["neuronal networks", "MULTI-TISSUE_STRUCTURE", 132, 149], ["LDL", "PROTEIN", 105, 108], ["Hyp incorporation into free LDL", "PROBLEM", 77, 108], ["Planar patch clamp", "TREATMENT", 109, 127], ["free LDL", "OBSERVATION", 100, 108]]], ["Bosca 1 , R. Magrassi 2 , G. Firpo 2 , L. Repetto 2 , C. Boragno 2 , U. Valbusa 2 1 Italian Institute of Technology, Genova, Italy, 2 NanoMed Labs (DIFI-CBA), Genova, ItalyPlanar patch clamp for neuronal networksThe technique of choice to measure the electrophysiological activity of neuronal cells is the so called patch-clamp method because of its precision and sensitivity; this procedure could play a major role also in the investigation of the behavior of a biological neuronal network and so represents an important tool for understanding its functionality and for screening the effects of drugs and compounds on it.", [["neuronal networks", "ANATOMY", 195, 212], ["neuronal cells", "ANATOMY", 284, 298], ["neuronal network", "ANATOMY", 474, 490], ["neuronal networks", "MULTI-TISSUE_STRUCTURE", 195, 212], ["neuronal cells", "CELL", 284, 298], ["neuronal network", "MULTI-TISSUE_STRUCTURE", 474, 490], ["neuronal cells", "CELL_TYPE", 284, 298], ["Bosca", "TEST", 0, 5], ["Labs", "TEST", 142, 146], ["Planar patch clamp", "TREATMENT", 172, 190], ["patch-clamp method", "TREATMENT", 316, 334], ["this procedure", "TREATMENT", 377, 391], ["drugs", "TREATMENT", 596, 601]]], ["The final aim of this project is the development of a planar patch clamp device suited to measure simultaneously the electrical activity of cultured neurons associated in a network.", [["neurons", "ANATOMY", 149, 156], ["neurons", "CELL", 149, 156], ["cultured neurons", "CELL_LINE", 140, 156], ["a planar patch clamp device", "TREATMENT", 52, 79]]], ["This device will be made of polymeric disposable material and will include a microfluidic perfusion system.", [["This device", "TREATMENT", 0, 11], ["polymeric disposable material", "TREATMENT", 28, 57], ["a microfluidic perfusion system", "TREATMENT", 75, 106]]], ["In order to create a smooth micro sized pore in a thin polymeric membrane we exploited the prototyping capabilities of Focused Ion Beam etching and we extended the air moulding technique by combining it with soft moulding, obtaining micro structured substrates with the requested features.", [["pore", "ANATOMY", 40, 44], ["membrane", "ANATOMY", 65, 73], ["a smooth micro sized pore in a thin polymeric membrane", "TREATMENT", 19, 73], ["Focused Ion Beam etching", "TREATMENT", 119, 143], ["the air moulding technique", "TREATMENT", 160, 186], ["soft moulding", "TREATMENT", 208, 221], ["smooth", "OBSERVATION_MODIFIER", 21, 27], ["sized", "OBSERVATION_MODIFIER", 34, 39], ["pore", "OBSERVATION_MODIFIER", 40, 44], ["polymeric membrane", "OBSERVATION", 55, 73], ["air moulding", "OBSERVATION", 164, 176]]], ["We also subjected our substrates to a chemical treatment capable of rendering its surface stable and hydrophilic and we verified that it makes them suitable for neuron culturing.O-197Use of lipoamino acids for nasal delivery of therapeutic proteins C. Bijani 1 , S. Sice 1 , J. Elezgaray 2 , C. Degert 1 , O. Broussaud 1 , E. J. Dufourc 2 1 Physica Pharma, 33600 Pessac, France, 2 UMR 5248 CBMN, CNRS-Universit\u00e9 Bordeaux1, IECB, 33607 Pessac, FranceO-197Most of the therapeutic proteins are clinically administered through an intravenous injection several times a day / week.", [["surface", "ANATOMY", 82, 89], ["neuron", "ANATOMY", 161, 167], ["nasal", "ANATOMY", 210, 215], ["intravenous", "ANATOMY", 526, 537], ["O-197Use of lipoamino acids", "CHEMICAL", 178, 205], ["FranceO-197", "CHEMICAL", 443, 454], ["O-197Use", "CHEMICAL", 178, 186], ["lipoamino acids", "CHEMICAL", 190, 205], ["neuron", "CELL", 161, 167], ["O-197Use", "SIMPLE_CHEMICAL", 178, 186], ["lipoamino acids", "SIMPLE_CHEMICAL", 190, 205], ["nasal", "ORGAN", 210, 215], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 526, 537], ["a chemical treatment", "TREATMENT", 36, 56], ["neuron culturing", "TEST", 161, 177], ["lipoamino acids", "TREATMENT", 190, 205], ["nasal delivery", "TREATMENT", 210, 224], ["therapeutic proteins", "TREATMENT", 228, 248], ["CBMN", "TEST", 390, 394], ["CNRS", "TEST", 396, 400], ["IECB", "TEST", 423, 427], ["Pessac", "TEST", 435, 441], ["FranceO", "TEST", 443, 450], ["the therapeutic proteins", "TREATMENT", 462, 486], ["an intravenous injection", "TREATMENT", 523, 547]]], ["Because the repeated injections are not convenient and cause pain in patients, an alternative route of administration is desirable such as oral or nasal.", [["oral", "ANATOMY", 139, 143], ["nasal", "ANATOMY", 147, 152], ["pain", "DISEASE", 61, 65], ["patients", "ORGANISM", 69, 77], ["oral", "ORGANISM_SUBDIVISION", 139, 143], ["nasal", "ORGANISM_SUBDIVISION", 147, 152], ["patients", "SPECIES", 69, 77], ["the repeated injections", "TREATMENT", 8, 31], ["pain", "PROBLEM", 61, 65], ["an alternative route of administration", "TREATMENT", 79, 117], ["nasal", "ANATOMY", 147, 152]]], ["Unfortunately, proteins are easily degraded by proteolytic enzymes in the gastrointestinal tract and, therefore, have a low bioavailability when administered via oral route.", [["gastrointestinal tract", "ANATOMY", 74, 96], ["oral", "ANATOMY", 162, 166], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 74, 96], ["oral", "ORGANISM_SUBDIVISION", 162, 166], ["proteolytic enzymes", "PROTEIN", 47, 66], ["proteolytic enzymes", "TEST", 47, 66], ["a low bioavailability", "TREATMENT", 118, 139], ["gastrointestinal tract", "ANATOMY", 74, 96]]], ["Physica Pharma has gained experience in forming sprayable solutions combining lipoamino acids (LAA) and Small Therapeutic Organic Compounds with the aim to improve their intranasal absorption.", [["lipoamino acids", "CHEMICAL", 78, 93], ["lipoamino acids", "CHEMICAL", 78, 93], ["lipoamino acids", "SIMPLE_CHEMICAL", 78, 93], ["LAA", "SIMPLE_CHEMICAL", 95, 98], ["forming sprayable solutions", "TREATMENT", 40, 67], ["lipoamino acids", "TREATMENT", 78, 93], ["Small Therapeutic Organic Compounds", "PROBLEM", 104, 139], ["Small", "OBSERVATION_MODIFIER", 104, 109], ["Therapeutic", "OBSERVATION_MODIFIER", 110, 121], ["Organic Compounds", "OBSERVATION", 122, 139]]], ["In the present work we investigated the ability of LAA to complex large molecule such as Human Erythropoietin, Human growth hormone and salmon calcitonin in order to form easily sprayable colloids.", [["calcitonin", "CHEMICAL", 143, 153], ["LAA", "SIMPLE_CHEMICAL", 51, 54], ["Human", "ORGANISM", 89, 94], ["Erythropoietin", "GENE_OR_GENE_PRODUCT", 95, 109], ["Human", "ORGANISM", 111, 116], ["growth hormone", "GENE_OR_GENE_PRODUCT", 117, 131], ["salmon", "ORGANISM", 136, 142], ["calcitonin", "GENE_OR_GENE_PRODUCT", 143, 153], ["Human Erythropoietin", "PROTEIN", 89, 109], ["Human", "SPECIES", 89, 94], ["Human", "SPECIES", 111, 116], ["Human", "SPECIES", 89, 94], ["complex large molecule", "PROBLEM", 58, 80], ["Human Erythropoietin", "TREATMENT", 89, 109], ["Human growth hormone", "TREATMENT", 111, 131], ["salmon calcitonin", "TREATMENT", 136, 153], ["easily sprayable colloids", "TREATMENT", 171, 196]]], ["These three proteins are used respectively to treat anaemia, growth problem and hypercalcemy.", [["anaemia", "DISEASE", 52, 59], ["hypercalcemy", "DISEASE", 80, 92], ["anaemia", "PROBLEM", 52, 59], ["growth problem", "PROBLEM", 61, 75], ["hypercalcemy", "PROBLEM", 80, 92], ["anaemia", "OBSERVATION", 52, 59]]], ["Circular dichroism and dynamic light scattering were used to further characterize the LAA-Protein colloids.", [["Circular dichroism", "TEST", 0, 18], ["dynamic light scattering", "TEST", 23, 47], ["Protein colloids", "TREATMENT", 90, 106]]], ["A specific molar ratio of LAA versus protein was found for wich the proteins keep their secondary structure and have an overall isotropic size slightly increased.", [["LAA", "SIMPLE_CHEMICAL", 26, 29], ["LAA", "PROTEIN", 26, 29], ["A specific molar ratio", "TEST", 0, 22], ["the proteins", "TEST", 64, 76], ["LAA", "ANATOMY", 26, 29], ["secondary structure", "OBSERVATION", 88, 107], ["overall", "OBSERVATION_MODIFIER", 120, 127], ["isotropic", "OBSERVATION_MODIFIER", 128, 137], ["size", "OBSERVATION_MODIFIER", 138, 142], ["slightly", "OBSERVATION_MODIFIER", 143, 151], ["increased", "OBSERVATION_MODIFIER", 152, 161]]], ["Molecular dynamics show that proteins are indeed coated with LAA.", [["LAA", "PROTEIN", 61, 64], ["Molecular dynamics", "TEST", 0, 18], ["LAA", "ANATOMY", 61, 64]]], ["Such a complex is shown to pass very easily through a culture of nasal cells growth at confluence.", [["nasal cells", "ANATOMY", 65, 76], ["nasal cells", "CELL", 65, 76], ["nasal cells", "CELL_TYPE", 65, 76], ["a culture", "TEST", 52, 61], ["nasal cells growth at confluence", "PROBLEM", 65, 97], ["nasal cells", "ANATOMY", 65, 76]]], ["In this study we describe two systems based on soft matter designed for the drug delivery and for the replacement of synovial fluid in osteoarticular pathologies. (i) a new class of temperature sensitive hydrogels PVA/Poly(MA m NiPAAm n ) shaped as microspheres obtained with a water-in-water emulsion photocrosslinking reaction.", [["synovial fluid", "ANATOMY", 117, 131], ["osteoarticular", "ANATOMY", 135, 149], ["osteoarticular pathologies", "DISEASE", 135, 161], ["PVA", "CHEMICAL", 214, 217], ["Poly", "CHEMICAL", 218, 222], ["PVA", "CHEMICAL", 214, 217], ["Poly(MA m NiPAAm n", "CHEMICAL", 218, 236], ["synovial fluid", "ORGANISM_SUBSTANCE", 117, 131], ["osteoarticular pathologies", "PATHOLOGICAL_FORMATION", 135, 161], ["Poly(MA m NiPAAm", "SIMPLE_CHEMICAL", 218, 234], ["this study", "TEST", 3, 13], ["soft matter", "TREATMENT", 47, 58], ["the drug delivery", "TREATMENT", 72, 89], ["the replacement of synovial fluid", "TREATMENT", 98, 131], ["osteoarticular pathologies", "PROBLEM", 135, 161], ["temperature sensitive hydrogels PVA", "TREATMENT", 182, 217], ["Poly(MA m NiPAAm n )", "TREATMENT", 218, 238], ["a water-in-water emulsion photocrosslinking reaction", "TREATMENT", 276, 328], ["soft matter", "OBSERVATION_MODIFIER", 47, 58], ["synovial", "ANATOMY", 117, 125], ["fluid", "OBSERVATION", 126, 131], ["osteoarticular pathologies", "OBSERVATION", 135, 161]]], ["Microparticles of PVA/Poly(MA m NiPAAm n ) with m:n theoretical molar ratios equal to 1:0; 1:4, 1:8 have been studied in terms of average size and responsiveness to temperature characterized by confocal laser scanning microscopy (CLSM), dynamic light scattering (DLS) and differential scanning microcalorimetry (DSC). (ii) a physical network based on hyaluronic acid with a small extent (degree of substitution: 1%) of hydrophobic moiety grafted on the backbone, HYADD4, has been characterized in order to account for the influence of thermal treatment on the stability of the hydrogel.", [["PVA", "CHEMICAL", 18, 21], ["Poly", "CHEMICAL", 22, 26], ["hyaluronic acid", "CHEMICAL", 351, 366], ["HYADD4", "CHEMICAL", 463, 469], ["PVA", "CHEMICAL", 18, 21], ["Poly(MA m NiPAAm n", "CHEMICAL", 22, 40], ["PVA", "SIMPLE_CHEMICAL", 18, 21], ["Poly(MA m NiPAAm", "SIMPLE_CHEMICAL", 22, 38], ["hyaluronic acid", "SIMPLE_CHEMICAL", 351, 366], ["HYADD4", "SIMPLE_CHEMICAL", 463, 469], ["Microparticles", "TEST", 0, 14], ["PVA", "TEST", 18, 21], ["Poly", "TEST", 22, 26], ["theoretical molar ratios", "TEST", 52, 76], ["temperature", "TEST", 165, 176], ["confocal laser scanning microscopy", "TEST", 194, 228], ["CLSM", "TEST", 230, 234], ["dynamic light scattering (DLS", "TEST", 237, 266], ["differential scanning microcalorimetry", "TEST", 272, 310], ["hyaluronic acid", "PROBLEM", 351, 366], ["hydrophobic moiety grafted", "TREATMENT", 419, 445], ["thermal treatment", "TREATMENT", 535, 552], ["the hydrogel", "TREATMENT", 573, 585], ["PVA", "OBSERVATION", 18, 21], ["size", "OBSERVATION_MODIFIER", 138, 142], ["small extent", "OBSERVATION_MODIFIER", 374, 386], ["hydrophobic", "OBSERVATION", 419, 430], ["moiety grafted", "OBSERVATION", 431, 445], ["backbone", "ANATOMY_MODIFIER", 453, 461]]], ["Dynamic light scattering (DLS) and small angle neutron scattering (SANS) have been used for dynamic-structural characterization of HYADD4 hydrogels.", [["HYADD4 hydrogels", "SIMPLE_CHEMICAL", 131, 147], ["small angle neutron scattering (SANS)", "TREATMENT", 35, 72], ["HYADD4 hydrogels", "PROBLEM", 131, 147], ["scattering", "OBSERVATION_MODIFIER", 14, 24], ["small", "OBSERVATION_MODIFIER", 35, 40]]], ["Diffusion of macromolecular probes has been studied by fluorescence recovery after photobleaching (FRAP) to study the mesoscopic texture of the hydrogel and molecular dynamic (MD) simulations were used to approach the time evolution of the physical junction points and of chains clusters.O-203Multi-scale estimation of water soluble diffusivity in polysaccharide gels G. Eisele 1 , S. Bertini 1 , D. Paganini 1 , L. Piazza 2 1 Ronzoni Institute, Milan, Italy, 2 DISTAM, University of Milan, Italy Diffusion properties in gels play important role in food and biotechnological applications.", [["O-203", "CHEMICAL", 288, 293], ["water soluble diffusivity in polysaccharide gels", "TREATMENT", 319, 367], ["Paganini", "TREATMENT", 400, 408], ["Diffusion properties in gels", "TREATMENT", 497, 525], ["biotechnological applications", "TREATMENT", 558, 587], ["macromolecular probes", "OBSERVATION", 13, 34], ["physical junction", "ANATOMY", 240, 257], ["chains clusters", "OBSERVATION", 272, 287]]], ["An attractive goal is to design gels in such a way that the active molecules are delivered by the material according to specific release sequences.", [["the active molecules", "PROBLEM", 56, 76]]], ["The transport of macromolecules within polymeric gels depends: on the obstruction effects of the surrounding gel strands, on the molecular interactions between the gel and the solute, on the interactions between the solute molecules themselves and the interactions between the solute and the solvent.", [["solute", "SIMPLE_CHEMICAL", 277, 283], ["The transport of macromolecules within polymeric gels", "TREATMENT", 0, 53], ["the obstruction effects", "PROBLEM", 66, 89], ["the surrounding gel strands", "PROBLEM", 93, 120], ["the solute molecules", "TREATMENT", 212, 232], ["the solute and the solvent", "TREATMENT", 273, 299], ["obstruction", "OBSERVATION", 70, 81]]], ["Physical polysaccharide gels were evaluated in this work to probe diffusion over both microscopic and macroscopic distance scales.", [["Physical polysaccharide gels", "TREATMENT", 0, 28]]], ["Physical gels from agar and starch were investigated by high and low resolution NMR techniques in order to characterize their structures.", [["starch", "SIMPLE_CHEMICAL", 28, 34]]], ["Obstruction effects of the surrounding gel strands were considered by studying diffusion of glucose.", [["glucose", "CHEMICAL", 92, 99], ["glucose", "CHEMICAL", 92, 99], ["glucose", "SIMPLE_CHEMICAL", 92, 99], ["Obstruction effects", "PROBLEM", 0, 19], ["the surrounding gel strands", "PROBLEM", 23, 50], ["studying diffusion of glucose", "TEST", 70, 99], ["gel strands", "OBSERVATION", 39, 50]]], ["Local diffusion, due to Brownian motion, was quantified by low resolution NMR spectroscopy.", [["Local diffusion", "TEST", 0, 15], ["low resolution NMR spectroscopy", "TEST", 59, 90], ["Brownian motion", "OBSERVATION", 24, 39]]], ["The Fickian diffusion coefficient was measured by modelling experimental concentration-distance curves obtained by means of a two-compartment diffusion-cell.", [["cell", "ANATOMY", 152, 156], ["Fickian", "SIMPLE_CHEMICAL", 4, 11], ["cell", "CELL", 152, 156], ["The Fickian diffusion coefficient", "TEST", 0, 33], ["modelling experimental concentration", "TEST", 50, 86], ["distance curves", "TEST", 87, 102], ["Fickian", "OBSERVATION_MODIFIER", 4, 11], ["diffusion coefficient", "OBSERVATION", 12, 33]]], ["Diffusion coefficients depend on the viscoelastic properties of the gel matrix and on water-polysaccharide interactions.Nanomechanics of Rubella virus shells: How soft viruses are?J. L. Cuellar, G. Koehler, M. Fischlechner, E. Donath Medizinische Institut f\u00fcr Physik und Biophysik, Leipzig, Germany Rather than being just pathogens, from the view point of biotechnology and materials science viruses can be regarded as nanocontainers in which nucleic acids have been enclosed in a protective self assembled protein cage.", [["nucleic acids", "CHEMICAL", 443, 456], ["matrix", "CELLULAR_COMPONENT", 72, 78], ["water", "SIMPLE_CHEMICAL", 86, 91], ["Rubella virus", "ORGANISM", 137, 150], ["nucleic acids", "SIMPLE_CHEMICAL", 443, 456], ["Rubella virus", "SPECIES", 137, 150], ["Rubella virus", "SPECIES", 137, 150], ["Diffusion coefficients", "TEST", 0, 22], ["the gel matrix", "TREATMENT", 64, 78], ["water-polysaccharide interactions", "TREATMENT", 86, 119], ["Rubella virus shells", "PROBLEM", 137, 157], ["soft viruses", "PROBLEM", 163, 175], ["nanocontainers", "TREATMENT", 419, 433], ["nucleic acids", "TEST", 443, 456], ["Rubella virus shells", "OBSERVATION", 137, 157], ["viruses", "OBSERVATION", 168, 175]]], ["In some viruses an additional lipid-protein envelope wraps the capsid shell.", [["an additional lipid-protein envelope", "TREATMENT", 16, 52], ["viruses", "OBSERVATION", 8, 15], ["capsid shell", "OBSERVATION", 63, 75]]], ["The capsid is constituted of several copies of one single protein subunit or just a few, arranged in a regular fashion showing icosahedral symmetry.", [["protein subunit", "PROTEIN", 58, 73], ["capsid", "OBSERVATION", 4, 10], ["icosahedral symmetry", "OBSERVATION", 127, 147]]], ["The mechanical properties of the cage are important for understanding the infection mechanism involving the release of the encaged genome.", [["infection", "DISEASE", 74, 83], ["encaged genome", "DNA", 123, 137], ["The mechanical properties of the cage", "TREATMENT", 0, 37], ["the infection mechanism", "PROBLEM", 70, 93], ["mechanical properties", "OBSERVATION", 4, 25], ["cage", "ANATOMY", 33, 37], ["infection", "OBSERVATION", 74, 83]]], ["By means of Atomic Force Microscopy, it becomes possible to probe such material properties by nanoindentations of single viral particles.", [["Atomic Force Microscopy", "TEST", 12, 35], ["single viral particles", "PROBLEM", 114, 136], ["viral particles", "OBSERVATION", 121, 136]]], ["It is very interesting to learn how strong or brittle a virus can be.", [["brittle a virus", "PROBLEM", 46, 61], ["virus", "OBSERVATION", 56, 61]]], ["Here we have studied the mechanical properties of empty Rubella virus particles (RLPs) due response of external applied forces.", [["Rubella virus", "ORGANISM", 56, 69], ["Rubella virus", "SPECIES", 56, 69], ["Rubella virus", "SPECIES", 56, 69], ["empty Rubella virus particles", "TREATMENT", 50, 79], ["external applied forces", "TREATMENT", 103, 126], ["Rubella virus", "OBSERVATION", 56, 69]]], ["We found that RLPs are extremely soft comparable to that of some rubber materials.", [["RLPs", "SIMPLE_CHEMICAL", 14, 18], ["some rubber materials", "PROBLEM", 60, 81], ["extremely", "OBSERVATION_MODIFIER", 23, 32], ["soft", "OBSERVATION", 33, 37], ["rubber materials", "OBSERVATION", 65, 81]]], ["A peculiarity of the rubella virus is that the capsid is considerably smaller than the surrounding shell filling only a fraction of the lumen provided by the envelope.", [["lumen", "ANATOMY", 136, 141], ["rubella virus", "DISEASE", 21, 34], ["rubella virus", "ORGANISM", 21, 34], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 141], ["rubella virus", "SPECIES", 21, 34], ["the rubella virus", "PROBLEM", 17, 34], ["rubella virus", "OBSERVATION", 21, 34], ["capsid", "OBSERVATION_MODIFIER", 47, 53], ["considerably", "OBSERVATION_MODIFIER", 57, 69], ["smaller", "OBSERVATION_MODIFIER", 70, 77], ["shell", "OBSERVATION_MODIFIER", 99, 104], ["filling", "OBSERVATION", 105, 112], ["fraction", "OBSERVATION_MODIFIER", 120, 128], ["lumen", "ANATOMY_MODIFIER", 136, 141], ["envelope", "OBSERVATION_MODIFIER", 158, 166]]], ["The envelope in Rubella has a distinguishable response on the material properties of the virus.", [["Rubella", "ORGANISM", 16, 23], ["The envelope in Rubella", "PROBLEM", 0, 23], ["the virus", "PROBLEM", 85, 94], ["envelope", "OBSERVATION_MODIFIER", 4, 12], ["Rubella", "OBSERVATION", 16, 23], ["response", "OBSERVATION_MODIFIER", 46, 54], ["virus", "OBSERVATION", 89, 94]]], ["Deformation and fracture of the capsid requires comparatively larger forces.", [["fracture", "DISEASE", 16, 24], ["Deformation", "PROBLEM", 0, 11], ["fracture of the capsid", "PROBLEM", 16, 38], ["fracture", "OBSERVATION", 16, 24], ["capsid", "ANATOMY_MODIFIER", 32, 38], ["comparatively", "OBSERVATION_MODIFIER", 48, 61], ["larger", "OBSERVATION_MODIFIER", 62, 68], ["forces", "OBSERVATION", 69, 75]]], ["Our results indicate that the pH is a major factor influencing on rubella particle material properties.", [["the pH", "PROBLEM", 26, 32], ["rubella particle material properties", "PROBLEM", 66, 102], ["rubella particle", "OBSERVATION", 66, 82]]], ["This can be related to the infection mechanism.", [["infection", "DISEASE", 27, 36], ["the infection mechanism", "PROBLEM", 23, 46], ["can be related to", "UNCERTAINTY", 5, 22], ["infection", "OBSERVATION", 27, 36]]], ["Pentavalent antimony (PA) (Glucantime, Sanofi-Aventis or Glaxo) are the mainstream agents of choice for Leishmaniasis treatment.", [["Pentavalent antimony", "CHEMICAL", 0, 20], ["Glucantime, Sanofi-Aventis", "CHEMICAL", 27, 53], ["Glaxo", "CHEMICAL", 57, 62], ["Leishmaniasis", "DISEASE", 104, 117], ["Glucantime", "CHEMICAL", 27, 37], ["Pentavalent antimony", "SIMPLE_CHEMICAL", 0, 20], ["PA", "SIMPLE_CHEMICAL", 22, 24], ["Glucantime", "SIMPLE_CHEMICAL", 27, 37], ["Sanofi-Aventis", "SIMPLE_CHEMICAL", 39, 53], ["Glaxo", "SIMPLE_CHEMICAL", 57, 62], ["Pentavalent antimony (PA) (Glucantime", "TREATMENT", 0, 37], ["Sanofi-Aventis", "TREATMENT", 39, 53], ["Glaxo", "TREATMENT", 57, 62], ["Leishmaniasis treatment", "TREATMENT", 104, 127]]], ["In therapeutic doses the PA treatment has cardiac side effects like electrocardiographic (ECG) alterations, that include QT segment prolongation, T wave flattening or inversion, inversion of ST segment, P, R and T waves amplitude reductions, torsade de pointes arrhythmias and sudden death by cardiac arrest.", [["cardiac", "ANATOMY", 42, 49], ["cardiac", "ANATOMY", 293, 300], ["torsade de pointes", "DISEASE", 242, 260], ["arrhythmias", "DISEASE", 261, 272], ["sudden death", "DISEASE", 277, 289], ["cardiac arrest", "DISEASE", 293, 307], ["PA", "SIMPLE_CHEMICAL", 25, 27], ["cardiac", "ORGAN", 293, 300], ["the PA treatment", "TREATMENT", 21, 37], ["cardiac side effects", "PROBLEM", 42, 62], ["electrocardiographic (ECG) alterations", "PROBLEM", 68, 106], ["QT segment prolongation", "PROBLEM", 121, 144], ["T wave flattening", "PROBLEM", 146, 163], ["inversion", "PROBLEM", 167, 176], ["inversion of ST segment", "PROBLEM", 178, 201], ["R and T waves amplitude reductions", "PROBLEM", 206, 240], ["torsade de pointes arrhythmias", "PROBLEM", 242, 272], ["sudden death", "PROBLEM", 277, 289], ["cardiac arrest", "PROBLEM", 293, 307], ["segment", "ANATOMY_MODIFIER", 194, 201], ["cardiac", "ANATOMY", 293, 300], ["arrest", "OBSERVATION", 301, 307]]], ["The objective of this study was to characterize the arrhythmogenic potential of PA.", [["PA", "GENE_OR_GENE_PRODUCT", 80, 82], ["this study", "TEST", 17, 27]]], ["We used 30 guinea-pig to assess the chronic effects of PA therapeutic dose on corrected QT interval, QT dispersion, ventricular action potential (AP) amplitude and duration at 30% and 90% of maximal repolarization and survival rate.", [["ventricular", "ANATOMY", 116, 127], ["pig", "ORGANISM", 18, 21], ["PA", "SIMPLE_CHEMICAL", 55, 57], ["ventricular", "MULTI-TISSUE_STRUCTURE", 116, 127], ["guinea-pig", "SPECIES", 11, 21], ["pig", "SPECIES", 18, 21], ["pig", "TREATMENT", 18, 21], ["PA therapeutic dose", "TREATMENT", 55, 74], ["corrected QT interval", "PROBLEM", 78, 99], ["QT dispersion", "PROBLEM", 101, 114], ["AP) amplitude", "TEST", 146, 159], ["duration", "TEST", 164, 172], ["maximal repolarization", "PROBLEM", 191, 213], ["survival rate", "TEST", 218, 231], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["ventricular", "ANATOMY", 116, 127]]], ["Guinea-pig received daily 30mg/kg PA or saline for 15 days.", [["pig", "ORGANISM", 7, 10], ["PA", "SIMPLE_CHEMICAL", 34, 36], ["saline", "SIMPLE_CHEMICAL", 40, 46], ["Guinea-pig", "SPECIES", 0, 10], ["saline", "TREATMENT", 40, 46]]], ["Eight lead ECG were recorded before and in the last treatment day.", [["Eight lead ECG", "TEST", 0, 14]]], ["At the end the animals were killed and the left ventricle papillary muscles excised for AP recording with the intracellular microelectrode technique.", [["left ventricle papillary muscles", "ANATOMY", 43, 75], ["intracellular", "ANATOMY", 110, 123], ["animals", "ORGANISM", 15, 22], ["ventricle papillary muscles", "MULTI-TISSUE_STRUCTURE", 48, 75], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["AP recording", "TEST", 88, 100], ["the intracellular microelectrode technique", "TREATMENT", 106, 148], ["left ventricle", "ANATOMY", 43, 57], ["papillary muscles", "ANATOMY", 58, 75]]], ["Our results of chronic PA treatment showed significant increase of QRS complex duration, QT interval duration, QT dispersion and incidence of T wave flattening or inversion and arrhythmias.", [["arrhythmias", "DISEASE", 177, 188], ["QRS complex", "GENE_OR_GENE_PRODUCT", 67, 78], ["QRS", "PROTEIN", 67, 70], ["chronic PA treatment", "TREATMENT", 15, 35], ["significant increase of QRS complex duration", "PROBLEM", 43, 87], ["QT interval duration", "PROBLEM", 89, 109], ["QT dispersion", "PROBLEM", 111, 124], ["T wave flattening", "PROBLEM", 142, 159], ["inversion", "PROBLEM", 163, 172], ["arrhythmias", "PROBLEM", 177, 188], ["chronic", "OBSERVATION_MODIFIER", 15, 22], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["increase", "OBSERVATION_MODIFIER", 55, 63], ["wave flattening", "OBSERVATION", 144, 159]]], ["The AP analysis demonstrated prolongation at 90% duration.", [["The AP analysis", "TEST", 0, 15], ["prolongation", "PROBLEM", 29, 41], ["prolongation", "OBSERVATION_MODIFIER", 29, 41]]], ["The treatment was lethal in 30% of the animals.", [["The treatment", "TREATMENT", 0, 13]]], ["We concluded that PA is a proarrhythmic drug that upon chronic use may causes arrhythmias and mortality by disturbances in the ventricular repolarization process.Biophysical investigation of PLGA nanoparticles and their interaction with DNAM.", [["ventricular", "ANATOMY", 127, 138], ["arrhythmias", "DISEASE", 78, 89], ["PLGA nanoparticles", "CHEMICAL", 191, 209], ["PLGA", "CHEMICAL", 191, 195], ["PA", "GENE_OR_GENE_PRODUCT", 18, 20], ["ventricular", "MULTI-TISSUE_STRUCTURE", 127, 138], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 191, 209], ["DNAM", "GENE_OR_GENE_PRODUCT", 237, 241], ["DNAM", "PROTEIN", 237, 241], ["a proarrhythmic drug", "PROBLEM", 24, 44], ["arrhythmias", "PROBLEM", 78, 89], ["disturbances in the ventricular repolarization process", "PROBLEM", 107, 161], ["Biophysical investigation", "TEST", 162, 187], ["PLGA nanoparticles", "TREATMENT", 191, 209], ["ventricular", "ANATOMY", 127, 138], ["repolarization process", "OBSERVATION", 139, 161]]], ["M. Khvedelidze 1 , T. J. Mdzinarashvili 2 , T. Partskhaladze 1 , N. Nafee 3 , M. Schneider 4 1 Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia, 2 Institute of Molecular Biology and Biological Physics, Tbilisi, Georgia, 3 Biopharmaceutics and Pharmaceutical Technology, Saarbr\u00fccken, Germany, 4 Pharmaceutical Nanotechnology, Saarbr\u00fccken, GermanyBiophysical investigation of PLGA nanoparticles and their interaction with DNAWe have studied the thermodynamical properties of chitosan-coated nanoparticles (cNP) and non-coated nanoparticles (NP) and have gained some insights about PLGA nanoparticles' properties using supersensitive differential microcalorimetry.", [["PLGA nanoparticles", "CHEMICAL", 388, 406], ["chitosan", "CHEMICAL", 487, 495], ["PLGA nanoparticles", "CHEMICAL", 593, 611], ["PLGA", "CHEMICAL", 388, 392], ["PLGA", "CHEMICAL", 593, 597], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 388, 406], ["chitosan-coated nanoparticles", "SIMPLE_CHEMICAL", 487, 516], ["cNP", "SIMPLE_CHEMICAL", 518, 521], ["non-coated nanoparticles", "SIMPLE_CHEMICAL", 527, 551], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 593, 611], ["Khvedelidze", "TREATMENT", 3, 14], ["Saarbr\u00fccken", "TREATMENT", 339, 350], ["PLGA nanoparticles", "TREATMENT", 388, 406], ["chitosan-coated nanoparticles (cNP) and non-coated nanoparticles (NP)", "TREATMENT", 487, 556], ["PLGA nanoparticles' properties", "TREATMENT", 593, 623], ["supersensitive differential microcalorimetry", "TREATMENT", 630, 674]]], ["The experiments show that in a wide pH interval the changes in transition temperature did not take place.", [["a wide pH interval", "PROBLEM", 29, 47], ["transition temperature", "PROBLEM", 63, 85]]], ["It was shown that such nanoparticles could be used in acidic surrounding for drug transfer.", [["such nanoparticles", "TREATMENT", 18, 36]]], ["Stability and their other properties are less depended on either the particles were in bidistilled or deionized water, or the suspension of particles were located in buffer.Biophysical investigation of PLGA nanoparticles and their interaction with DNATo determine the interaction of PLGA nanoparticles with DNA.", [["PLGA nanoparticles", "CHEMICAL", 202, 220], ["PLGA nanoparticles", "CHEMICAL", 283, 301], ["PLGA", "CHEMICAL", 202, 206], ["PLGA", "CHEMICAL", 283, 287], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 202, 220], ["DNATo", "SIMPLE_CHEMICAL", 248, 253], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 283, 301], ["DNA", "CELLULAR_COMPONENT", 307, 310], ["DNATo", "PROTEIN", 248, 253], ["the suspension of particles", "TREATMENT", 122, 149], ["Biophysical investigation", "TEST", 173, 198], ["PLGA nanoparticles", "TREATMENT", 202, 220], ["PLGA nanoparticles", "TREATMENT", 283, 301], ["DNA", "PROBLEM", 307, 310], ["particles", "OBSERVATION", 140, 149]]], ["In the case of DNA presence in cNP solution the calorimetric experiments show that the heat absorption peak is constricted, what biophysically means that interaction between them takes place.", [["DNA", "CELLULAR_COMPONENT", 15, 18], ["cNP", "SIMPLE_CHEMICAL", 31, 34], ["cNP solution", "TREATMENT", 31, 43], ["the calorimetric experiments", "TEST", 44, 72], ["the heat absorption", "PROBLEM", 83, 102]]], ["For more exact determination the contribution of cNP in spectrum, we have compared the spectra of pure DNA with the spectrum of the same concentration DNA plus cNP.", [["cNP", "SIMPLE_CHEMICAL", 49, 52], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["cNP", "SIMPLE_CHEMICAL", 160, 163], ["cNP", "PROTEIN", 49, 52], ["cNP", "PROTEIN", 160, 163]]], ["The optimal ratio for DNA loading onto the cNP was found to be 7:1.P-207Protein-based \"epoxy-like\" physical hydrogels for stem cell transplantation S. C. Heilshorn, C. Wong Po Foo, J. S. Lee Materials Science and Engineering, Stanford Univ., U.S.A.P-207Stem cell transplantation has emerged as a promising therapy for multiple injuries and diseases; however, cell survival after transplantation is often poor and unpredictable.", [["stem cell", "ANATOMY", 122, 131], ["U.S.A.P-207Stem cell", "ANATOMY", 242, 262], ["cell", "ANATOMY", 359, 363], ["cNP", "CHEMICAL", 43, 46], ["7:1.P-207Protein", "CHEMICAL", 63, 79], ["U.S.A.P-207Stem", "CHEMICAL", 242, 257], ["injuries", "DISEASE", 327, 335], ["epoxy", "CHEMICAL", 87, 92], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["cNP", "SIMPLE_CHEMICAL", 43, 46], ["7:1.P-207Protein", "SIMPLE_CHEMICAL", 63, 79], ["stem cell", "CELL", 122, 131], ["U.S.A.P-207Stem cell", "CELL", 242, 262], ["cell", "CELL", 359, 363], ["DNA loading", "PROBLEM", 22, 33], ["the cNP", "TEST", 39, 46], ["\"epoxy", "TREATMENT", 86, 92], ["physical hydrogels", "TREATMENT", 99, 117], ["stem cell transplantation", "TREATMENT", 122, 147], ["U.S.A.P", "TEST", 242, 249], ["207Stem cell transplantation", "TREATMENT", 250, 278], ["a promising therapy", "TREATMENT", 294, 313], ["multiple injuries", "PROBLEM", 318, 335], ["diseases", "PROBLEM", 340, 348], ["transplantation", "TREATMENT", 379, 394], ["stem cell", "OBSERVATION", 122, 131], ["injuries", "OBSERVATION", 327, 335], ["diseases", "OBSERVATION", 340, 348]]], ["We hypothesize that co-injection of stem cells encapsulated within an optimized physical hydrogel will enhance viability.", [["stem cells", "ANATOMY", 36, 46], ["stem cells", "CELL", 36, 46], ["stem cells", "CELL_TYPE", 36, 46], ["stem cells", "PROBLEM", 36, 46], ["stem cells", "OBSERVATION", 36, 46]]], ["Whereas, current physical hydrogels require a shift in environmental conditions (e.g., pH, temperature) to initiate the sol-gel phase transition during encapsulation, our newly designed molecular-recognition gels do not require environmental triggers.", [["the sol-gel phase transition", "TREATMENT", 116, 144]]], ["Instead, these \"physical epoxy-like\" gels consist of two components that undergo a sol-gel transition upon mixing due to specific hydrogen bonding.", [["epoxy", "CHEMICAL", 25, 30], ["hydrogen", "CHEMICAL", 130, 138], ["a sol-gel transition", "TREATMENT", 81, 101], ["specific hydrogen bonding", "PROBLEM", 121, 146]]], ["The gel viscoelasticity is predictably tuned through precise variation in the molecular-level design of the two components, created using recombinant protein techniques.", [["The gel viscoelasticity", "TREATMENT", 0, 23], ["recombinant protein techniques", "TREATMENT", 138, 168], ["gel viscoelasticity", "OBSERVATION", 4, 23], ["predictably tuned", "OBSERVATION", 27, 44], ["precise", "OBSERVATION_MODIFIER", 53, 60], ["variation", "OBSERVATION_MODIFIER", 61, 70], ["two", "OBSERVATION_MODIFIER", 108, 111], ["components", "OBSERVATION_MODIFIER", 112, 122]]], ["The design of the two components is based on simple polymer physics considerations and utilizes bio-mimimcry.", [["simple polymer physics", "TREATMENT", 45, 67], ["bio-mimimcry", "TREATMENT", 96, 108]]], ["Adult neural stem cells or mesenchymal stem cells are encapsulated within these gels with high viability at constant physiological conditions.", [["neural stem cells", "ANATOMY", 6, 23], ["mesenchymal stem cells", "ANATOMY", 27, 49], ["neural stem cells", "CELL", 6, 23], ["mesenchymal stem cells", "CELL", 27, 49], ["neural stem cells", "CELL_TYPE", 6, 23], ["mesenchymal stem cells", "CELL_TYPE", 27, 49], ["mesenchymal stem cells", "PROBLEM", 27, 49], ["high viability at constant physiological conditions", "PROBLEM", 90, 141], ["neural stem cells", "OBSERVATION", 6, 23], ["mesenchymal stem cells", "OBSERVATION", 27, 49], ["high viability", "OBSERVATION", 90, 104]]], ["The gels promote the growth and differentiation of neural progenitors into neuronal phenotypes, which adopt a 3D-branched morphology.", [["neural progenitors", "ANATOMY", 51, 69], ["neuronal", "ANATOMY", 75, 83], ["neural progenitors", "CELL", 51, 69], ["neuronal", "CELL", 75, 83], ["neural progenitors", "CELL_TYPE", 51, 69], ["The gels", "TREATMENT", 0, 8], ["growth", "OBSERVATION_MODIFIER", 21, 27], ["neural progenitors", "OBSERVATION", 51, 69], ["neuronal phenotypes", "OBSERVATION", 75, 94]]], ["The gels are further optimized for use in the central nervous system by tethering neuroprotective peptides to the gel through molecular-recognition sites.", [["central nervous system", "ANATOMY", 46, 68], ["central nervous system", "ANATOMICAL_SYSTEM", 46, 68], ["molecular-recognition sites", "PROTEIN", 126, 153], ["The gels", "TREATMENT", 0, 8], ["tethering neuroprotective peptides", "TREATMENT", 72, 106], ["central", "ANATOMY_MODIFIER", 46, 53], ["nervous system", "ANATOMY", 54, 68]]], ["These peptides are released-on-demand by cells through the action of proteolytic enzymes.", [["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["proteolytic enzymes", "PROTEIN", 69, 88], ["proteolytic enzymes", "TEST", 69, 88]]], ["We consider the integration of the portal protein of the bacteriophage virus \u03c629 into lipid bilayers of giant unilamellar vesicles (GUVs) membranes with the aim of constructing a functional cargo-device able to transport DNA and later translocate it outwards.", [["lipid bilayers", "ANATOMY", 86, 100], ["giant unilamellar vesicles", "ANATOMY", 104, 130], ["GUVs", "ANATOMY", 132, 136], ["membranes", "ANATOMY", 138, 147], ["unilamellar vesicles", "CELLULAR_COMPONENT", 110, 130], ["GUVs", "CELLULAR_COMPONENT", 132, 136], ["membranes", "CELLULAR_COMPONENT", 138, 147], ["DNA", "CELLULAR_COMPONENT", 221, 224], ["portal protein", "PROTEIN", 35, 49], ["bacteriophage virus \u03c6", "SPECIES", 57, 78], ["bacteriophage virus", "SPECIES", 57, 76], ["the bacteriophage virus", "TREATMENT", 53, 76], ["giant unilamellar vesicles", "PROBLEM", 104, 130], ["a functional cargo-device", "TREATMENT", 177, 202], ["portal", "ANATOMY", 35, 41], ["giant", "OBSERVATION_MODIFIER", 104, 109], ["unilamellar vesicles", "OBSERVATION", 110, 130]]], ["Our nano-engineering plan consists of growing GUVs from bilayer membranes built up from proteoliposomes previously prepared by extrusion.", [["bilayer membranes", "ANATOMY", 56, 73], ["GUVs", "SIMPLE_CHEMICAL", 46, 50], ["bilayer membranes", "CELLULAR_COMPONENT", 56, 73], ["proteoliposomes", "SIMPLE_CHEMICAL", 88, 103], ["growing GUVs", "PROBLEM", 38, 50], ["bilayer membranes", "PROBLEM", 56, 73], ["growing", "OBSERVATION_MODIFIER", 38, 45], ["GUVs", "OBSERVATION", 46, 50], ["bilayer membranes", "OBSERVATION", 56, 73], ["extrusion", "OBSERVATION", 127, 136]]], ["We have designed two alternative chemical routes for integrating the portal protein in the lipid bilayer, the first considering the native protein and the second a mutant modified with a hydrophobic belt made of histidine-tags.", [["lipid bilayer", "ANATOMY", 91, 104], ["histidine", "CHEMICAL", 212, 221], ["histidine", "CHEMICAL", 212, 221], ["lipid bilayer", "CELLULAR_COMPONENT", 91, 104], ["portal protein", "PROTEIN", 69, 83], ["native protein", "PROTEIN", 132, 146], ["a hydrophobic belt", "TREATMENT", 185, 203], ["histidine-tags", "TREATMENT", 212, 226], ["portal protein", "ANATOMY", 69, 83]]], ["In our contribution we will present details on the different nano-engineering strategies and experimental evidence about the integration of the portal protein in the membrane with an orientation adequate to allow for functional DNA translocation.Pyropheophorbide-a-methyl ester: DMPC liposome vectorization and biophysical properties for PDTP.-H. Guelluy 1 , M.-P. Fontaine-Aupart 2 , M. Hoebeke 1 1 Biomedical Spectroscopy, ULg, Belgium, 2 Laboratory of Molecular Photophysics, Univ. of Paris-Sud, France PPME is a second generation photosensitizer (PS), and a promising candidate for photodynamic therapy (PDT) treatment.", [["membrane", "ANATOMY", 166, 174], ["Pyropheophorbide-a-methyl ester", "CHEMICAL", 246, 277], ["DMPC", "CHEMICAL", 279, 283], ["PPME", "CHEMICAL", 506, 510], ["Pyropheophorbide-a-methyl ester", "CHEMICAL", 246, 277], ["DMPC", "CHEMICAL", 279, 283], ["membrane", "CELLULAR_COMPONENT", 166, 174], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["Pyropheophorbide-a-methyl ester", "SIMPLE_CHEMICAL", 246, 277], ["DMPC liposome", "SIMPLE_CHEMICAL", 279, 292], ["PPME", "SIMPLE_CHEMICAL", 506, 510], ["portal protein", "PROTEIN", 144, 158], ["the different nano-engineering strategies", "TREATMENT", 47, 88], ["functional DNA translocation", "PROBLEM", 217, 245], ["Pyropheophorbide", "TREATMENT", 246, 262], ["a-methyl ester", "TREATMENT", 263, 277], ["DMPC liposome vectorization", "TREATMENT", 279, 306], ["biophysical properties", "TREATMENT", 311, 333], ["Biomedical Spectroscopy", "TEST", 400, 423], ["a second generation photosensitizer (PS", "TREATMENT", 514, 553], ["photodynamic therapy (PDT) treatment", "TREATMENT", 586, 622], ["portal protein", "ANATOMY", 144, 158]]], ["We have previously demonstrated that PPME can be easily and efficiently encapsulated in DMPC liposomes, used as PS-vector.", [["PPME", "CHEMICAL", 37, 41], ["PPME", "CHEMICAL", 37, 41], ["DMPC", "CHEMICAL", 88, 92], ["PPME", "SIMPLE_CHEMICAL", 37, 41], ["DMPC liposomes", "SIMPLE_CHEMICAL", 88, 102], ["DMPC liposomes", "TREATMENT", 88, 102]]], ["We therefore compared the photophysical and photochemical properties of free and encapsulated PPME incubated with human carcinoma cells.", [["carcinoma cells", "ANATOMY", 120, 135], ["PPME", "CHEMICAL", 94, 98], ["carcinoma", "DISEASE", 120, 129], ["PPME", "CHEMICAL", 94, 98], ["PPME", "SIMPLE_CHEMICAL", 94, 98], ["human", "ORGANISM", 114, 119], ["carcinoma cells", "CELL", 120, 135], ["PPME", "CELL_LINE", 94, 98], ["human carcinoma cells", "CELL_TYPE", 114, 135], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["free and encapsulated PPME", "TREATMENT", 72, 98], ["human carcinoma cells", "PROBLEM", 114, 135], ["carcinoma cells", "OBSERVATION", 120, 135]]], ["Absorption and fluorescence microspectroscopy as well as FLIM analysis allow evaluating the aggregation state of PPME inside the different cellular organelles and the extracellular medium.", [["cellular organelles", "ANATOMY", 139, 158], ["extracellular", "ANATOMY", 167, 180], ["PPME", "CHEMICAL", 113, 117], ["PPME", "CHEMICAL", 113, 117], ["PPME", "SIMPLE_CHEMICAL", 113, 117], ["cellular organelles", "CELLULAR_COMPONENT", 139, 158], ["extracellular medium", "CELLULAR_COMPONENT", 167, 187], ["fluorescence microspectroscopy", "TEST", 15, 45], ["FLIM analysis", "TEST", 57, 70], ["cellular organelles", "OBSERVATION", 139, 158], ["extracellular medium", "OBSERVATION", 167, 187]]], ["Confocal microscopy established undoubtedly the colocalization of PPME, by robust probabilistic exclusion method, within mitochondrion (central siege of apoptosis).", [["mitochondrion", "ANATOMY", 121, 134], ["PPME", "GENE_OR_GENE_PRODUCT", 66, 70], ["mitochondrion", "CELLULAR_COMPONENT", 121, 134], ["PPME", "PROTEIN", 66, 70], ["Confocal microscopy", "TEST", 0, 19]]], ["After PS activation (4h and 24h), the balance apoptosis-necrosis was double-estimated by FACS device and fluorescence confocal microscopy.", [["necrosis", "DISEASE", 56, 64], ["PS activation", "TEST", 6, 19], ["the balance apoptosis", "PROBLEM", 34, 55], ["necrosis", "PROBLEM", 56, 64], ["fluorescence confocal microscopy", "TEST", 105, 137], ["necrosis", "OBSERVATION", 56, 64]]], ["Quantification of hydroxyl radical was purchased by spin trapping-ESR spectroscopy and quenching technique.", [["hydroxyl", "CHEMICAL", 18, 26], ["hydroxyl", "CHEMICAL", 18, 26], ["hydroxyl radical", "SIMPLE_CHEMICAL", 18, 34], ["hydroxyl radical", "TREATMENT", 18, 34], ["ESR spectroscopy", "TEST", 66, 82], ["quenching technique", "TEST", 87, 106], ["hydroxyl radical", "OBSERVATION", 18, 34]]], ["All these techniques required peculiar settings because of the fluorescence activity of PPME.", [["PPME", "CHEMICAL", 88, 92], ["PPME", "CHEMICAL", 88, 92], ["PPME", "SIMPLE_CHEMICAL", 88, 92], ["PPME", "PROTEIN", 88, 92], ["peculiar settings", "TREATMENT", 30, 47], ["the fluorescence activity of PPME", "PROBLEM", 59, 92]]], ["These results allow to ascertain that the vectorization of PPME affords a better cellular penetration and a monomeric state of PPME.", [["cellular", "ANATOMY", 81, 89], ["PPME", "CHEMICAL", 59, 63], ["PPME", "CHEMICAL", 127, 131], ["PPME", "CHEMICAL", 59, 63], ["PPME", "CHEMICAL", 127, 131], ["PPME", "SIMPLE_CHEMICAL", 59, 63], ["cellular", "CELL", 81, 89], ["PPME", "SIMPLE_CHEMICAL", 127, 131], ["PPME", "PROTEIN", 127, 131], ["the vectorization of PPME", "PROBLEM", 38, 63]]], ["The presence of PPME inside mitochondrion orientated the cellular death in apoptosis 4h following PS-activation.", [["mitochondrion", "ANATOMY", 28, 41], ["cellular", "ANATOMY", 57, 65], ["death", "DISEASE", 66, 71], ["PPME", "SIMPLE_CHEMICAL", 16, 20], ["mitochondrion", "CELLULAR_COMPONENT", 28, 41], ["cellular", "CELL", 57, 65], ["PPME", "PROTEIN", 16, 20], ["PPME inside mitochondrion", "PROBLEM", 16, 41], ["the cellular death", "PROBLEM", 53, 71], ["cellular death", "OBSERVATION", 57, 71]]], ["But necrosis is the major actor 24h after treatment.AbstractsActive substrates to study mechanotransduction J. Le Digabel, P. Hersen, B. Ladoux Laboratoire Mati\u00e8re et Syst\u00e8mes Complexes, Universit\u00e9 Paris Diderot -CNRS, Paris, France Cellular processes imply an important coordination of interactions with the extracellular medium.", [["extracellular", "ANATOMY", 309, 322], ["necrosis", "DISEASE", 4, 12], ["extracellular", "CELLULAR_COMPONENT", 309, 322], ["necrosis", "PROBLEM", 4, 12], ["treatment", "TREATMENT", 42, 51], ["the extracellular medium", "TREATMENT", 305, 329], ["necrosis", "OBSERVATION", 4, 12]]], ["Accumulating evidences demonstrate that cell functions can be modulated by physical factors such as the mechanical forces acting on the cells and the ExtraCellular matrix, as well as the topography or rigidity of the matrix.", [["cell", "ANATOMY", 40, 44], ["cells", "ANATOMY", 136, 141], ["ExtraCellular matrix", "ANATOMY", 150, 170], ["matrix", "ANATOMY", 217, 223], ["rigidity", "DISEASE", 201, 209], ["cell", "CELL", 40, 44], ["cells", "CELL", 136, 141], ["ExtraCellular matrix", "CELLULAR_COMPONENT", 150, 170], ["matrix", "CELLULAR_COMPONENT", 217, 223], ["the mechanical forces", "TREATMENT", 100, 121], ["rigidity of the matrix", "PROBLEM", 201, 223], ["cell functions", "OBSERVATION", 40, 54], ["ExtraCellular matrix", "ANATOMY", 150, 170]]], ["These extracellular signals can be sensed by mechanosensors on the cell surface or in the cell interior to induce various cell responses.", [["extracellular", "ANATOMY", 6, 19], ["cell surface", "ANATOMY", 67, 79], ["cell", "ANATOMY", 90, 94], ["cell", "ANATOMY", 122, 126], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 19], ["cell surface", "CELLULAR_COMPONENT", 67, 79], ["cell interior", "CELLULAR_COMPONENT", 90, 103], ["cell", "CELL", 122, 126], ["the cell surface", "TREATMENT", 63, 79], ["various cell", "OBSERVATION", 114, 126]]], ["We have developed an original approach based on micro-fabricated substrates of PolyDimethylSiloxane (PDMS) to study cell migration.", [["cell", "ANATOMY", 116, 120], ["PolyDimethylSiloxane", "CHEMICAL", 79, 99], ["PolyDimethylSiloxane", "CHEMICAL", 79, 99], ["PDMS", "CHEMICAL", 101, 105], ["PolyDimethylSiloxane", "SIMPLE_CHEMICAL", 79, 99], ["cell", "CELL", 116, 120], ["an original approach", "TREATMENT", 18, 38], ["micro-fabricated substrates of PolyDimethylSiloxane (PDMS)", "TREATMENT", 48, 106], ["cell migration", "OBSERVATION", 116, 130]]], ["We used a closely spaced array of flexible micropillars (diameter\u223c1?m) to map the forces exerted by cells on their substrates.", [["cells", "ANATOMY", 100, 105], ["cells", "CELL", 100, 105], ["a closely spaced array of flexible micropillars (diameter\u223c", "TREATMENT", 8, 66]]], ["In this case, the micropillars act as passive force sensors.", [["micropillars", "ANATOMY", 18, 30], ["micropillars", "CANCER", 18, 30], ["passive force sensors", "TREATMENT", 38, 59]]], ["Here, we propose to analyze the cell response to an external applied stress by a well-controlled actuation of the substrate.", [["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36], ["an external applied stress", "TREATMENT", 49, 75]]], ["Such substrates allow us to modify dynamic adhesion conditions of cells and to better understand the coupling phenomena between mechanical sensing and biochemical activity of a living cell.", [["cells", "ANATOMY", 66, 71], ["cell", "ANATOMY", 184, 188], ["cells", "CELL", 66, 71], ["cell", "CELL", 184, 188], ["dynamic adhesion conditions of cells", "TREATMENT", 35, 71], ["the coupling phenomena", "PROBLEM", 97, 119], ["mechanical sensing", "TREATMENT", 128, 146]]], ["Using polyacrylamide hydrogels doped with ferromagnetic iron oxide particles or ferrofluids, we can make magnetic pillars with diameters of 5 to 10 microns while a magnetic field can be locally applied with a magnetic needle.", [["iron oxide", "CHEMICAL", 56, 66], ["polyacrylamide", "CHEMICAL", 6, 20], ["iron oxide", "CHEMICAL", 56, 66], ["ferromagnetic iron oxide", "SIMPLE_CHEMICAL", 42, 66], ["ferrofluids", "SIMPLE_CHEMICAL", 80, 91], ["polyacrylamide hydrogels", "TREATMENT", 6, 30], ["ferromagnetic iron oxide particles", "TREATMENT", 42, 76], ["ferrofluids", "TREATMENT", 80, 91], ["magnetic pillars with diameters", "TREATMENT", 105, 136], ["a magnetic field", "TREATMENT", 162, 178], ["a magnetic needle", "TREATMENT", 207, 224]]], ["Such a technique will be helpful to study the mechanical response of cells to an external force or to local changes in their microenvironment.P-211Glucose scavenging activities of PAMAM dendrimers M. Labieniec 1 , T. Gabryelak 1 , C. Watala 2 1 University of Lodz, Deptartment of General Biophisics, Lodz, Poland, 2Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, PolandGlycation is a spontaneous, non-enzymatic modification of biomacromolecules with hexoses, mainly glucose.", [["cells", "ANATOMY", 69, 74], ["P-211Glucose", "CHEMICAL", 142, 154], ["PAMAM dendrimers", "CHEMICAL", 180, 196], ["Haemostasis", "DISEASE", 329, 340], ["Haemostatic Disorders", "DISEASE", 345, 366], ["glucose", "CHEMICAL", 499, 506], ["Glucose", "CHEMICAL", 147, 154], ["PAMAM", "CHEMICAL", 180, 185], ["hexoses", "CHEMICAL", 483, 490], ["glucose", "CHEMICAL", 499, 506], ["cells", "CELL", 69, 74], ["Glucose", "SIMPLE_CHEMICAL", 147, 154], ["biomacromolecules", "SIMPLE_CHEMICAL", 460, 477], ["hexoses", "SIMPLE_CHEMICAL", 483, 490], ["glucose", "SIMPLE_CHEMICAL", 499, 506], ["T. Gabryelak 1", "SPECIES", 214, 228], ["a technique", "TREATMENT", 5, 16], ["an external force", "TREATMENT", 78, 95], ["P", "TEST", 142, 143], ["Glucose scavenging", "TEST", 147, 165], ["Labieniec", "TEST", 200, 209], ["Haemostatic Disorders", "PROBLEM", 345, 366], ["Haemostasis", "OBSERVATION", 329, 340]]], ["In terms of its pathophysiological relevance, it targets predominantly proteins, but also nucleotides and phospholipids, and is of major importance to both physiology (ageing) and pathology (diseases with a metabolic background, like diabetes).", [["diabetes", "DISEASE", 234, 242], ["nucleotides", "CHEMICAL", 90, 101], ["phospholipids", "SIMPLE_CHEMICAL", 106, 119], ["nucleotides and phospholipids", "TREATMENT", 90, 119], ["pathology (diseases", "PROBLEM", 180, 199], ["diabetes", "PROBLEM", 234, 242]]], ["Earlier we demonstrated in vivo that the administration of PAMAM G4 to diabetic rats resulted in a significantly reduced blood glucose, as well as the early (HbA 1c ) and late (AGEs) protein glycation products.", [["blood", "ANATOMY", 121, 126], ["PAMAM G4", "CHEMICAL", 59, 67], ["diabetic", "DISEASE", 71, 79], ["glucose", "CHEMICAL", 127, 134], ["PAMAM", "CHEMICAL", 59, 64], ["glucose", "CHEMICAL", 127, 134], ["PAMAM G4", "SIMPLE_CHEMICAL", 59, 67], ["rats", "ORGANISM", 80, 84], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["glucose", "SIMPLE_CHEMICAL", 127, 134], ["HbA 1c", "GENE_OR_GENE_PRODUCT", 158, 164], ["AGEs", "SIMPLE_CHEMICAL", 177, 181], ["rats", "SPECIES", 80, 84], ["PAMAM G4", "TREATMENT", 59, 67], ["diabetic rats", "PROBLEM", 71, 84], ["a significantly reduced blood glucose", "PROBLEM", 97, 134], ["HbA", "TEST", 158, 161], ["late (AGEs) protein glycation products", "TREATMENT", 171, 209], ["glycation products", "OBSERVATION", 191, 209]]], ["In this study we investigated the ability of PAMAM G2 (16 surface NH 2 groups) and G4 (64 NH 2 ) to inhibit glycation of proteins in plasma, and a model protein -BSA.", [["plasma", "ANATOMY", 133, 139], ["PAMAM G2", "CHEMICAL", 45, 53], ["PAMAM", "CHEMICAL", 45, 50], ["NH", "CHEMICAL", 66, 68], ["PAMAM G2", "SIMPLE_CHEMICAL", 45, 53], ["plasma", "ORGANISM_SUBSTANCE", 133, 139], ["BSA", "GENE_OR_GENE_PRODUCT", 162, 165], ["plasma", "CELL_TYPE", 133, 139], ["this study", "TEST", 3, 13], ["plasma", "TEST", 133, 139], ["a model protein", "TEST", 145, 160]]], ["PAMAM G2 and G4 competed chemically with protein NH 2 for the binding of glucose, and hampered protein glycation.", [["PAMAM", "CHEMICAL", 0, 5], ["glucose", "CHEMICAL", 73, 80], ["PAMAM", "CHEMICAL", 0, 5], ["NH 2", "CHEMICAL", 49, 53], ["glucose", "CHEMICAL", 73, 80], ["PAMAM", "SIMPLE_CHEMICAL", 0, 5], ["protein NH 2", "GENE_OR_GENE_PRODUCT", 41, 53], ["glucose", "SIMPLE_CHEMICAL", 73, 80], ["protein NH 2", "PROTEIN", 41, 53], ["protein NH", "TREATMENT", 41, 51], ["glucose", "TEST", 73, 80], ["hampered protein glycation", "PROBLEM", 86, 112], ["protein glycation", "OBSERVATION", 95, 112]]], ["In a high-glucose medium they underwent an excessive glycation themselves.", [["glucose", "CHEMICAL", 10, 17], ["glucose", "SIMPLE_CHEMICAL", 10, 17], ["a high-glucose medium", "TREATMENT", 3, 24], ["an excessive glycation themselves", "TREATMENT", 40, 73], ["excessive", "OBSERVATION_MODIFIER", 43, 52], ["glycation", "OBSERVATION", 53, 62]]], ["This modification was more effective in PAMAM G2, in which surface NH 2 were more mobile and accessible.", [["surface", "ANATOMY", 59, 66], ["PAMAM G2", "CHEMICAL", 40, 48], ["PAMAM", "CHEMICAL", 40, 45], ["NH 2", "CHEMICAL", 67, 71], ["PAMAM G2", "SIMPLE_CHEMICAL", 40, 48], ["This modification", "TREATMENT", 0, 17]]], ["PAMAM modification with glucose rendered these dendrimers less polycationic in aqueous solutions.", [["PAMAM", "CHEMICAL", 0, 5], ["glucose", "CHEMICAL", 24, 31], ["PAMAM", "CHEMICAL", 0, 5], ["glucose", "CHEMICAL", 24, 31], ["PAMAM", "SIMPLE_CHEMICAL", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 24, 31], ["PAMAM modification with glucose", "TREATMENT", 0, 31], ["these dendrimers", "TREATMENT", 41, 57], ["polycationic in aqueous solutions", "TREATMENT", 63, 96]]], ["PAMAMs neither affected BSA conformation nor formed stable complexes with a protein.", [["PAMAMs", "SIMPLE_CHEMICAL", 0, 6], ["BSA", "SIMPLE_CHEMICAL", 24, 27], ["PAMAMs", "PROTEIN", 0, 6], ["stable", "OBSERVATION_MODIFIER", 52, 58]]], ["We conclude that PAMAMs are very effective glucose scavengers.", [["PAMAMs", "CHEMICAL", 17, 23], ["glucose", "CHEMICAL", 43, 50], ["glucose", "CHEMICAL", 43, 50], ["PAMAMs", "SIMPLE_CHEMICAL", 17, 23], ["glucose", "SIMPLE_CHEMICAL", 43, 50], ["glucose scavengers", "TREATMENT", 43, 61]]], ["Thus, even less toxic PAMAMs of lower generations, like G2, may appear useful in further medical applications as the agents attenuating the detrimental effects of sever hyperglycaemia on biomacromolecules.P-210Selective drug delivery and novel drug approaches by polyelectrolytes S. Krol CBM-Cluster in Biomedicine, Area Science Park, S.S. 14, 163.5 km; Trieste, ItalyP-210The use of polyelectrolytes in the past was mainly related to targeted drug delivery and nanoparticle preparations for medical applications.", [["hyperglycaemia", "DISEASE", 169, 183], ["P-210", "CHEMICAL", 205, 210], ["ItalyP-210", "CHEMICAL", 363, 373], ["PAMAMs", "SIMPLE_CHEMICAL", 22, 28], ["further medical applications", "TREATMENT", 81, 109], ["the agents", "TREATMENT", 113, 123], ["sever hyperglycaemia on biomacromolecules", "PROBLEM", 163, 204], ["Selective drug delivery", "TREATMENT", 210, 233], ["novel drug approaches", "TREATMENT", 238, 259], ["ItalyP", "TEST", 363, 369], ["polyelectrolytes", "TREATMENT", 384, 400], ["targeted drug delivery", "TREATMENT", 435, 457], ["nanoparticle preparations", "TREATMENT", 462, 487], ["medical applications", "TREATMENT", 492, 512], ["less", "OBSERVATION_MODIFIER", 11, 15], ["toxic", "OBSERVATION_MODIFIER", 16, 21], ["lower generations", "OBSERVATION_MODIFIER", 32, 49], ["sever", "OBSERVATION_MODIFIER", 163, 168], ["hyperglycaemia", "OBSERVATION", 169, 183]]], ["In our present work we use a special physical feature of cancer cell membranes as a target for a specific polycation.", [["cancer cell membranes", "ANATOMY", 57, 78], ["cancer", "DISEASE", 57, 63], ["cancer cell membranes", "CELL", 57, 78], ["cancer cell membranes", "PROBLEM", 57, 78], ["a specific polycation", "TREATMENT", 95, 116], ["cancer cell membranes", "OBSERVATION", 57, 78]]], ["We found that the polycation is selectively up-taken by cancer cells (leukemia, hepatocarcinoma, cancer stem cells) while normal cells remain unaffected.", [["cancer cells", "ANATOMY", 56, 68], ["leukemia", "ANATOMY", 70, 78], ["hepatocarcinoma", "ANATOMY", 80, 95], ["cancer stem cells", "ANATOMY", 97, 114], ["cells", "ANATOMY", 129, 134], ["polycation", "CHEMICAL", 18, 28], ["cancer", "DISEASE", 56, 62], ["leukemia", "DISEASE", 70, 78], ["hepatocarcinoma", "DISEASE", 80, 95], ["cancer", "DISEASE", 97, 103], ["cancer cells", "CELL", 56, 68], ["leukemia", "CANCER", 70, 78], ["hepatocarcinoma", "CELL", 80, 95], ["cancer stem cells", "CELL", 97, 114], ["cells", "CELL", 129, 134], ["cancer cells", "CELL_TYPE", 56, 68], ["leukemia, hepatocarcinoma, cancer stem cells", "CELL_TYPE", 70, 114], ["normal cells", "CELL_TYPE", 122, 134], ["the polycation", "TREATMENT", 14, 28], ["cancer cells", "PROBLEM", 56, 68], ["leukemia", "PROBLEM", 70, 78], ["hepatocarcinoma", "PROBLEM", 80, 95], ["cancer stem cells", "PROBLEM", 97, 114], ["cancer cells", "OBSERVATION", 56, 68], ["leukemia", "OBSERVATION", 70, 78], ["hepatocarcinoma", "ANATOMY", 80, 95], ["cancer stem cells", "OBSERVATION", 97, 114]]], ["Another interesting application of polyelectrolytes are in form of a multilayer coating on the surface of nanogold particles.", [["surface", "ANATOMY", 95, 102], ["polyelectrolytes", "SIMPLE_CHEMICAL", 35, 51], ["surface", "CELLULAR_COMPONENT", 95, 102], ["nanogold particles", "SIMPLE_CHEMICAL", 106, 124], ["polyelectrolytes", "TREATMENT", 35, 51], ["a multilayer coating on the surface of nanogold particles", "TREATMENT", 67, 124], ["polyelectrolytes", "OBSERVATION", 35, 51], ["multilayer", "OBSERVATION_MODIFIER", 69, 79], ["coating", "OBSERVATION", 80, 87], ["nanogold particles", "OBSERVATION", 106, 124]]], ["For this topic, two new approaches were developed for a drug delivery through the blood brain barrier.", [["blood brain barrier", "ANATOMY", 82, 101], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 82, 101], ["a drug delivery", "TREATMENT", 54, 69], ["the blood brain barrier", "TREATMENT", 78, 101]]], ["In the first case, high amounts of creatine were bound to the gold particles and delivered as protective agents for ischemic stroke (Viota et al., J Colloid Interface Sci.", [["creatine", "CHEMICAL", 35, 43], ["ischemic stroke", "DISEASE", 116, 131], ["creatine", "CHEMICAL", 35, 43], ["creatine", "SIMPLE_CHEMICAL", 35, 43], ["high amounts of creatine", "PROBLEM", 19, 43], ["protective agents", "TREATMENT", 94, 111], ["ischemic stroke", "PROBLEM", 116, 131], ["ischemic", "OBSERVATION_MODIFIER", 116, 124], ["stroke", "OBSERVATION", 125, 131]]], ["In the second case coated multifunctional gold particles were prepared as a drug for neurodegenerative disease on the basis of protein aggregates.", [["neurodegenerative disease", "DISEASE", 85, 110], ["gold particles", "SIMPLE_CHEMICAL", 42, 56], ["the second case coated multifunctional gold particles", "TREATMENT", 3, 56], ["neurodegenerative disease", "PROBLEM", 85, 110], ["protein aggregates", "PROBLEM", 127, 145], ["gold particles", "OBSERVATION", 42, 56]]], ["The use of gold as core for coated nanoparticles offers the possibility to study our systems as \"theranostics\", system which are modified to recognize selectively diseased cells and carry the moieties to treat or destroy the malfunctioning cells.", [["cells", "ANATOMY", 172, 177], ["cells", "ANATOMY", 240, 245], ["gold", "SIMPLE_CHEMICAL", 11, 15], ["cells", "CELL", 172, 177], ["cells", "CELL", 240, 245], ["diseased cells", "CELL_TYPE", 163, 177], ["malfunctioning cells", "CELL_TYPE", 225, 245], ["gold as core for coated nanoparticles", "TREATMENT", 11, 48], ["selectively diseased cells", "PROBLEM", 151, 177], ["the malfunctioning cells", "PROBLEM", 221, 245], ["malfunctioning cells", "OBSERVATION", 225, 245]]], ["Possible treatments can be local hyperthermal therapy by using the particles as amplifier and enhancer or photodynamic therapy with gold as a drug.Study of magnetic PLGA nanospheres containing anticancer drug PaclitaxelM.", [["anticancer", "ANATOMY", 193, 203], ["PLGA nanospheres", "CHEMICAL", 165, 181], ["PaclitaxelM", "CHEMICAL", 209, 220], ["PLGA", "CHEMICAL", 165, 169], ["PaclitaxelM", "CHEMICAL", 209, 220], ["gold", "SIMPLE_CHEMICAL", 132, 136], ["magnetic PLGA nanospheres", "SIMPLE_CHEMICAL", 156, 181], ["anticancer", "CANCER", 193, 203], ["PaclitaxelM", "SIMPLE_CHEMICAL", 209, 220], ["treatments", "TREATMENT", 9, 19], ["local hyperthermal therapy", "TREATMENT", 27, 53], ["the particles as amplifier and enhancer", "TREATMENT", 63, 102], ["photodynamic therapy", "TREATMENT", 106, 126], ["magnetic PLGA nanospheres", "TREATMENT", 156, 181], ["anticancer drug PaclitaxelM", "TREATMENT", 193, 220]]], ["Koneracka 1 , V. Zavisova 1 , M. Muckova 2 , P. Kopcansky 1 , A. Jurikova 1 , N. Tomasovicova 1 , G. Lancz 1 , M. Timko 1 , M. Fabian 3 1 Institute of Experimental Physics, Slovak Academy of Sciences, Ko\u0161ice, Slovakia, 2 Hameln rds a.s., Modra, Slovakia, 3 Institute of Geotechnics, Slovak Academy of Sciences, Ko\u0161ice, SlovakiaStudy of magnetic PLGA nanospheres containing anticancer drug PaclitaxelThe aim of this study was to develop biodegradable and biocompatible Paclitaxel loaded magnetic PLGA nanospheres (NPs) suitable for biomedical applications.", [["anticancer", "ANATOMY", 373, 383], ["PLGA nanospheres", "CHEMICAL", 345, 361], ["Paclitaxel", "CHEMICAL", 389, 399], ["Paclitaxel", "CHEMICAL", 468, 478], ["PLGA nanospheres", "CHEMICAL", 495, 511], ["PLGA", "CHEMICAL", 345, 349], ["Paclitaxel", "CHEMICAL", 389, 399], ["Paclitaxel", "CHEMICAL", 468, 478], ["PLGA", "CHEMICAL", 495, 499], ["magnetic PLGA nanospheres", "SIMPLE_CHEMICAL", 336, 361], ["anticancer", "CANCER", 373, 383], ["Paclitaxel", "SIMPLE_CHEMICAL", 389, 399], ["Paclitaxel", "SIMPLE_CHEMICAL", 468, 478], ["magnetic PLGA nanospheres", "SIMPLE_CHEMICAL", 486, 511], ["NPs", "SIMPLE_CHEMICAL", 513, 516], ["Koneracka", "TREATMENT", 0, 9], ["Zavisova", "TREATMENT", 17, 25], ["Ko\u0161ice", "TREATMENT", 201, 207], ["Modra", "TREATMENT", 238, 243], ["Ko\u0161ice", "TREATMENT", 311, 317], ["magnetic PLGA nanospheres", "TREATMENT", 336, 361], ["anticancer drug Paclitaxel", "TREATMENT", 373, 399], ["this study", "TEST", 410, 420], ["biodegradable and biocompatible Paclitaxel loaded magnetic PLGA nanospheres (NPs", "TREATMENT", 436, 516], ["biomedical applications", "TREATMENT", 531, 554]]], ["Biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA) was used as a capsulation material and the magnetic fluid was used as a magnetic carrier.", [["poly(D,L-lactic-co-glycolic acid", "CHEMICAL", 14, 46], ["PLGA", "CHEMICAL", 49, 53], ["poly(D,L-lactic-co-glycolic acid)", "CHEMICAL", 14, 47], ["PLGA", "CHEMICAL", 49, 53], ["poly(D,L-lactic-co-glycolic acid", "SIMPLE_CHEMICAL", 14, 46], ["PLGA", "SIMPLE_CHEMICAL", 49, 53], ["Biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA)", "TREATMENT", 0, 54], ["a capsulation material", "TREATMENT", 67, 89], ["the magnetic fluid", "TREATMENT", 94, 112], ["a magnetic carrier", "TREATMENT", 125, 143]]], ["Incorporation of magnetic particles and drug in the PLGA polymer matrix was confirmed by infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC).", [["PLGA polymer", "CHEMICAL", 52, 64], ["PLGA", "CHEMICAL", 52, 56], ["Incorporation of magnetic particles", "TREATMENT", 0, 35], ["drug in the PLGA polymer matrix", "TREATMENT", 40, 71], ["infrared spectroscopy", "TEST", 89, 110], ["differential scanning calorimetry", "TEST", 122, 155], ["magnetic particles", "OBSERVATION_MODIFIER", 17, 35]]], ["The release of the drug from the prepared NPs to the surroundings under the different conditions was studied also.", [["NPs", "SIMPLE_CHEMICAL", 42, 45]]], ["The prepared magnetic PLGA NPs with encapsulated Paclitaxel (spherical shape, size 200 -250 nm) have good stability in the presence of high NaCl concentration at 25 \u2022 C, the toxicity of prepared samples declared 3 times higher value of lethal dose LD 50 in comparison with pure Paclitaxel (LD 50 = 33mg/kg) and showed the significant response to external magnetic field which is useful from the point of view to achieve pharmaceutically acceptable drug delivery systems for tumour treatment.", [["samples", "ANATOMY", 195, 202], ["tumour", "ANATOMY", 474, 480], ["PLGA NPs", "CHEMICAL", 22, 30], ["Paclitaxel", "CHEMICAL", 49, 59], ["NaCl", "CHEMICAL", 140, 144], ["toxicity", "DISEASE", 174, 182], ["Paclitaxel", "CHEMICAL", 278, 288], ["tumour", "DISEASE", 474, 480], ["PLGA", "CHEMICAL", 22, 26], ["Paclitaxel", "CHEMICAL", 49, 59], ["NaCl", "CHEMICAL", 140, 144], ["Paclitaxel", "CHEMICAL", 278, 288], ["magnetic PLGA NPs", "SIMPLE_CHEMICAL", 13, 30], ["Paclitaxel", "SIMPLE_CHEMICAL", 49, 59], ["NaCl", "SIMPLE_CHEMICAL", 140, 144], ["Paclitaxel", "SIMPLE_CHEMICAL", 278, 288], ["tumour", "CANCER", 474, 480], ["The prepared magnetic PLGA NPs", "TEST", 0, 30], ["size", "TEST", 78, 82], ["high NaCl concentration", "TREATMENT", 135, 158], ["lethal dose LD", "TREATMENT", 236, 250], ["pure Paclitaxel", "TREATMENT", 273, 288], ["external magnetic field", "TEST", 346, 369], ["pharmaceutically acceptable drug delivery systems", "TREATMENT", 420, 469], ["tumour treatment", "TREATMENT", 474, 490], ["encapsulated", "OBSERVATION_MODIFIER", 36, 48], ["Paclitaxel", "OBSERVATION", 49, 59], ["spherical", "OBSERVATION_MODIFIER", 61, 70], ["shape", "OBSERVATION_MODIFIER", 71, 76], ["size", "OBSERVATION_MODIFIER", 78, 82], ["good", "OBSERVATION_MODIFIER", 101, 105], ["stability", "OBSERVATION_MODIFIER", 106, 115], ["high", "OBSERVATION_MODIFIER", 135, 139], ["NaCl concentration", "OBSERVATION", 140, 158]]], ["Success of human gene therapy depends upon the development of delivery vehicles or vectors, which can selectively deliver therapeutic genes to target cells with efficiency and safety.", [["cells", "ANATOMY", 150, 155], ["human", "ORGANISM", 11, 16], ["cells", "CELL", 150, 155], ["target cells", "CELL_TYPE", 143, 155], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["human gene therapy", "TREATMENT", 11, 29], ["delivery vehicles", "TREATMENT", 62, 79]]], ["Many cationic polymers have been used to condense DNA by electrostatic interaction into small particles (Polyplex), for protecting the DNA from degradation and enhancing uptake via endocytosis.", [["cationic polymers", "SIMPLE_CHEMICAL", 5, 22], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["Polyplex", "SIMPLE_CHEMICAL", 105, 113], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["Many cationic polymers", "TREATMENT", 0, 22], ["the DNA", "PROBLEM", 131, 138], ["enhancing uptake via endocytosis", "PROBLEM", 160, 192], ["cationic polymers", "OBSERVATION", 5, 22], ["small particles", "OBSERVATION_MODIFIER", 88, 103], ["enhancing", "OBSERVATION_MODIFIER", 160, 169], ["uptake", "OBSERVATION", 170, 176], ["endocytosis", "OBSERVATION", 181, 192]]], ["Polyethylenimine (PEI) appears to be one of the most advanced delivery system that can condense DNA efficiently forming PEI-DNA Polyplex complex.", [["Polyethylenimine", "CHEMICAL", 0, 16], ["PEI", "CHEMICAL", 18, 21], ["Polyethylenimine", "CHEMICAL", 0, 16], ["PEI", "CHEMICAL", 18, 21], ["PEI", "CHEMICAL", 120, 123], ["Polyethylenimine", "SIMPLE_CHEMICAL", 0, 16], ["PEI", "SIMPLE_CHEMICAL", 18, 21], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["PEI", "GENE_OR_GENE_PRODUCT", 120, 123], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["PEI-DNA Polyplex complex", "PROTEIN", 120, 144], ["Polyethylenimine (PEI)", "TREATMENT", 0, 22], ["the most advanced delivery system", "TREATMENT", 44, 77], ["DNA Polyplex complex", "PROBLEM", 124, 144], ["Polyplex complex", "OBSERVATION", 128, 144]]], ["The physicochemical properties of different molecular weights of PEI, such as condensation ability, buffer capacity, time kinetics, FTIR and surface charges of the PEI-DNA complexes may be important factors to obtain a higher transfection efficiency of the polycation vectors.", [["surface", "ANATOMY", 141, 148], ["PEI", "CHEMICAL", 65, 68], ["PEI", "CHEMICAL", 164, 167], ["PEI", "CHEMICAL", 65, 68], ["PEI", "CHEMICAL", 164, 167], ["PEI", "SIMPLE_CHEMICAL", 65, 68], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["PEI-DNA complexes", "PROTEIN", 164, 181], ["PEI", "PROBLEM", 65, 68], ["condensation ability", "PROBLEM", 78, 98], ["buffer capacity", "PROBLEM", 100, 115], ["the PEI-DNA complexes", "TREATMENT", 160, 181], ["a higher transfection efficiency of the polycation vectors", "TREATMENT", 217, 275], ["physicochemical properties", "OBSERVATION_MODIFIER", 4, 30], ["different", "OBSERVATION_MODIFIER", 34, 43], ["molecular weights", "OBSERVATION", 44, 61], ["polycation vectors", "OBSERVATION", 257, 275]]], ["Our intent in this study was to characterize PEI-DNA complexes to see whether these physicochemical properties have any influence on their disposition characteristics and cellular uptake process.", [["cellular", "ANATOMY", 171, 179], ["PEI", "CHEMICAL", 45, 48], ["PEI", "CHEMICAL", 45, 48], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["cellular", "CELL", 171, 179], ["PEI-DNA complexes", "PROTEIN", 45, 62], ["this study", "TEST", 14, 24], ["DNA complexes", "PROBLEM", 49, 62], ["cellular uptake process", "PROBLEM", 171, 194], ["cellular", "OBSERVATION", 171, 179], ["uptake process", "OBSERVATION", 180, 194]]], ["We found that PEI-DNA complexes, obtained by the 25 k PEI at N/P ratio > 4, were more stable in the presence of tissue culture medium & serum, and did not dissociate in Nacl easily.", [["tissue", "ANATOMY", 112, 118], ["serum", "ANATOMY", 136, 141], ["PEI", "CHEMICAL", 14, 17], ["PEI", "CHEMICAL", 14, 17], ["PEI", "CHEMICAL", 54, 57], ["PEI", "GENE_OR_GENE_PRODUCT", 14, 17], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["tissue", "TISSUE", 112, 118], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["PEI-DNA complexes", "PROTEIN", 14, 31], ["PEI-DNA complexes", "PROBLEM", 14, 31], ["N/P ratio", "TEST", 61, 70], ["tissue culture medium & serum", "TEST", 112, 141], ["stable", "OBSERVATION_MODIFIER", 86, 92], ["tissue", "ANATOMY", 112, 118]]], ["Key words: Polyethylenimine, Polyplex, Polycations, DNA, transfection, gene delivery.P-215Effect of nanopatterned substrate on neuronal growth cones activityP-215In the last20years an increasing interest has been address to explore, at the level of the single cell, the physical interaction between neurons and micro-and nano-patterned surfaces which mimic the biological environment and can induce specific biological behavior.", [["neuronal", "ANATOMY", 127, 135], ["cell", "ANATOMY", 260, 264], ["neurons", "ANATOMY", 299, 306], ["Polyethylenimine", "CHEMICAL", 11, 27], ["P-215", "CHEMICAL", 85, 90], ["activityP-215", "CHEMICAL", 149, 162], ["Polyethylenimine", "CHEMICAL", 11, 27], ["Polyethylenimine", "SIMPLE_CHEMICAL", 11, 27], ["Polyplex", "SIMPLE_CHEMICAL", 29, 37], ["Polycations", "SIMPLE_CHEMICAL", 39, 50], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["neuronal", "CELL", 127, 135], ["cell", "CELL", 260, 264], ["neurons", "CELL", 299, 306], ["Polyethylenimine", "TREATMENT", 11, 27], ["Polyplex", "TREATMENT", 29, 37], ["Polycations", "TREATMENT", 39, 50], ["DNA", "PROBLEM", 52, 55], ["transfection", "TREATMENT", 57, 69], ["gene delivery", "TREATMENT", 71, 84], ["nanopatterned substrate", "PROBLEM", 100, 123], ["activityP", "TEST", 149, 158]]], ["A consistent number of substrates have been tested (nano-grooves, pillars, GaP nanowires) but the effect of nano-topographical features at subcellular level e.g. branching and pathfinding of growth cones(GC)is still unexplored.", [["subcellular", "ANATOMY", 139, 150], ["GaP", "CHEMICAL", 75, 78], ["nano-grooves, pillars, GaP nanowires", "TREATMENT", 52, 88], ["nano-topographical features", "PROBLEM", 108, 135], ["pillars", "OBSERVATION_MODIFIER", 66, 73], ["growth cones", "OBSERVATION", 191, 203]]], ["Using nanoimprinting lithography we fabricated gratings on glass with grooves of variable pitch, depth and width all in the nm range.", [["nanoimprinting lithography", "TREATMENT", 6, 32], ["variable", "OBSERVATION_MODIFIER", 81, 89], ["pitch", "OBSERVATION_MODIFIER", 90, 95], ["depth", "OBSERVATION_MODIFIER", 97, 102], ["width", "OBSERVATION_MODIFIER", 107, 112], ["nm range", "OBSERVATION", 124, 132]]], ["Embryonic stem cell derived neurons were seeded on nanostructured and on flat control glasses.", [["Embryonic stem cell", "ANATOMY", 0, 19], ["neurons", "ANATOMY", 28, 35], ["Embryonic stem cell derived neurons", "CELL", 0, 35], ["Embryonic stem cell derived neurons", "CELL_TYPE", 0, 35], ["Embryonic stem cell derived neurons", "PROBLEM", 0, 35], ["flat control glasses", "TREATMENT", 73, 93], ["stem cell", "OBSERVATION", 10, 19]]], ["A significant effect on sub-cellular architecture was observed.On nanopatterned substrates72% of GC were branched with a large number of long and thin filopodia(average length and height4.3\u00b5m and 75nm)while on control only34%of GC were branched with an higher percentage of long and thick filopodia (average length and height 6,5\u00b5m and 300nm).", [["cellular", "ANATOMY", 28, 36], ["filopodia", "ANATOMY", 151, 160], ["filopodia", "ANATOMY", 289, 298], ["cellular", "CELL", 28, 36], ["filopodia", "CELLULAR_COMPONENT", 151, 160], ["filopodia", "CELLULAR_COMPONENT", 289, 298], ["A significant effect on sub-cellular architecture", "PROBLEM", 0, 49], ["nanopatterned substrates", "TREATMENT", 66, 90], ["length", "TEST", 169, 175], ["height", "TEST", 180, 186], ["GC", "TEST", 228, 230], ["length", "TEST", 308, 314], ["height", "TEST", 319, 325], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20], ["sub", "OBSERVATION_MODIFIER", 24, 27], ["cellular architecture", "OBSERVATION", 28, 49], ["large", "OBSERVATION_MODIFIER", 121, 126], ["number", "OBSERVATION_MODIFIER", 127, 133], ["long", "OBSERVATION_MODIFIER", 137, 141], ["thin", "OBSERVATION_MODIFIER", 146, 150], ["filopodia", "OBSERVATION_MODIFIER", 151, 160], ["higher", "OBSERVATION_MODIFIER", 253, 259], ["percentage", "OBSERVATION_MODIFIER", 260, 270]]], ["On the contrary we did not observe a significant influence of the nanopatterning on the alignment and elongation of neurites.", [["neurites", "ANATOMY", 116, 124], ["neurites", "CELLULAR_COMPONENT", 116, 124], ["elongation of neurites", "PROBLEM", 102, 124], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["elongation", "OBSERVATION_MODIFIER", 102, 112]]], ["In both cases the distribution of angles between axon and filopodia showed a preferential direction at30 \u2022 .", [["axon", "ANATOMY", 49, 53], ["filopodia", "ANATOMY", 58, 67], ["axon", "CELLULAR_COMPONENT", 49, 53], ["filopodia", "CELLULAR_COMPONENT", 58, 67], ["distribution", "OBSERVATION_MODIFIER", 18, 30], ["angles", "OBSERVATION_MODIFIER", 34, 40]]], ["In conclusion, the tested nanopatterns do not influence the neurite directions but do enhance the GC morphology and explorative activities.P-214Growth enhancement and adhesion control of PC12 on micropatterned ns-TiO 2 thin film C. Lenardi 1 , A. V. Singh 2 , P. Milani 3 1 C.I.Ma.I.Na., Dip. di Scienze Molecolari Applicate ai Biosistemi, Universit\u00e0 di Milano, Italy, 2 C.I.Ma.I.Na., SEMM, European School of Molecular Medicine, Fondazione IFOM, Milano, Italy, 3 C.I.Ma.I.Na., Dip. di Fisica, Universit\u00e0 di Milano, Italy Cluster assembled nanostructured titanium dioxide (ns-TiO 2 ) has been explored as novel substrate for in vitro cell culture.", [["neurite", "ANATOMY", 60, 67], ["PC12", "ANATOMY", 187, 191], ["cell", "ANATOMY", 634, 638], ["P-214", "CHEMICAL", 139, 144], ["titanium dioxide", "CHEMICAL", 555, 571], ["ns-TiO 2", "CHEMICAL", 573, 581], ["TiO 2", "CHEMICAL", 213, 218], ["titanium dioxide", "CHEMICAL", 555, 571], ["ns-TiO 2", "CHEMICAL", 573, 581], ["PC12", "CELL", 187, 191], ["nanostructured titanium dioxide", "SIMPLE_CHEMICAL", 540, 571], ["ns-TiO 2", "SIMPLE_CHEMICAL", 573, 581], ["cell", "CELL", 634, 638], ["PC12", "CELL_LINE", 187, 191], ["in vitro cell culture", "CELL_LINE", 625, 646], ["explorative activities", "TEST", 116, 138], ["P", "TEST", 139, 140], ["adhesion control of PC12", "TREATMENT", 167, 191], ["micropatterned ns", "TREATMENT", 195, 212], ["Italy Cluster assembled nanostructured titanium dioxide (ns-TiO", "TREATMENT", 516, 579], ["vitro cell culture", "TEST", 628, 646], ["Growth enhancement", "OBSERVATION_MODIFIER", 144, 162]]], ["In this work, we report micropatterned ns-TiO 2 thin film as putative microdevice for neuron culture and growth.", [["neuron culture", "ANATOMY", 86, 100], ["TiO 2", "CHEMICAL", 42, 47], ["micropatterned ns-TiO 2 thin film", "TREATMENT", 24, 57], ["putative microdevice", "TREATMENT", 61, 81], ["neuron culture", "TEST", 86, 100]]], ["In additions, we show a simple scheme of molecular patterning of Bovine Serum Albumin (BSA) as cell anti-adherent substrate complementary to ns-TiO 2 micropattern which favors a selective spatially confined adhesion of neurons.", [["cell", "ANATOMY", 95, 99], ["neurons", "ANATOMY", 219, 226], ["ns-TiO 2", "CHEMICAL", 141, 149], ["Bovine", "ORGANISM", 65, 71], ["Serum", "ORGANISM_SUBSTANCE", 72, 77], ["Albumin", "GENE_OR_GENE_PRODUCT", 78, 85], ["BSA", "SIMPLE_CHEMICAL", 87, 90], ["cell", "CELL", 95, 99], ["neurons", "CELL", 219, 226], ["Bovine Serum Albumin", "PROTEIN", 65, 85], ["Bovine", "SPECIES", 65, 71], ["Bovine", "SPECIES", 65, 71], ["Bovine Serum Albumin (BSA", "TEST", 65, 90], ["cell anti-adherent substrate", "TREATMENT", 95, 123], ["ns-TiO 2 micropattern", "TREATMENT", 141, 162], ["a selective spatially confined adhesion of neurons", "PROBLEM", 176, 226], ["selective", "OBSERVATION_MODIFIER", 178, 187], ["adhesion", "OBSERVATION", 207, 215], ["neurons", "ANATOMY", 219, 226]]], ["BSA was drop coated and physisorbed over glass coverslip covered with a thin conducting layer of indium tin oxide (ITO) and then PMMA was spin coated over it using standard protocols.", [["BSA", "CHEMICAL", 0, 3], ["indium tin oxide", "CHEMICAL", 97, 113], ["ITO", "CHEMICAL", 115, 118], ["PMMA", "CHEMICAL", 129, 133], ["indium tin oxide", "CHEMICAL", 97, 113], ["ITO", "CHEMICAL", 115, 118], ["PMMA", "CHEMICAL", 129, 133], ["BSA", "SIMPLE_CHEMICAL", 0, 3], ["indium tin oxide", "SIMPLE_CHEMICAL", 97, 113], ["ITO", "SIMPLE_CHEMICAL", 115, 118], ["PMMA", "SIMPLE_CHEMICAL", 129, 133], ["BSA", "TEST", 0, 3], ["physisorbed over glass coverslip", "TREATMENT", 24, 56], ["a thin conducting layer of indium tin oxide (ITO) and then PMMA", "TREATMENT", 70, 133], ["standard protocols", "TREATMENT", 164, 182], ["drop", "OBSERVATION_MODIFIER", 8, 12], ["coated", "OBSERVATION_MODIFIER", 13, 19], ["physisorbed", "OBSERVATION_MODIFIER", 24, 35]]], ["Later, using combinations of e-beam lithography and pulsed microplasma cluster source (PMCS), a thin layer of ns-TiO 2 was deposited over micropatterned PMMA.", [["PMMA", "CHEMICAL", 153, 157], ["TiO 2", "CHEMICAL", 113, 118], ["PMMA", "CHEMICAL", 153, 157], ["ns-TiO 2", "SIMPLE_CHEMICAL", 110, 118], ["e-beam lithography", "TREATMENT", 29, 47], ["a thin layer of ns-TiO 2", "TREATMENT", 94, 118], ["micropatterned PMMA", "TREATMENT", 138, 157], ["micropatterned PMMA", "OBSERVATION", 138, 157]]], ["Further, lift off process enabled us to generate complementary micropatterns of hydrophobic BSA (cell repellent) and hydrophilic ns-TiO 2 (cell adhesive).", [["cell", "ANATOMY", 97, 101], ["cell", "ANATOMY", 139, 143], ["TiO 2", "CHEMICAL", 132, 137], ["BSA", "SIMPLE_CHEMICAL", 92, 95], ["cell", "CELL", 97, 101], ["cell", "CELL", 139, 143], ["hydrophobic BSA (cell repellent", "TREATMENT", 80, 111], ["hydrophilic ns-TiO 2 (cell adhesive)", "TREATMENT", 117, 153]]], ["Cell culture studies have confirmed that PC12 cells like to grow on ns-TiO 2 substrate and not on BSA layer.", [["Cell", "ANATOMY", 0, 4], ["PC12 cells", "ANATOMY", 41, 51], ["TiO 2", "CHEMICAL", 71, 76], ["Cell", "CELL", 0, 4], ["PC12 cells", "CELL", 41, 51], ["BSA layer", "SIMPLE_CHEMICAL", 98, 107], ["PC12 cells", "CELL_LINE", 41, 51], ["Cell culture studies", "TEST", 0, 20], ["PC12 cells", "PROBLEM", 41, 51], ["ns-TiO 2 substrate", "TREATMENT", 68, 86], ["PC12 cells", "OBSERVATION", 41, 51]]], ["The technique offers a novel approach for neuronal cell assay applications.P-213Gene delivery with chitosan: influence of chain length on intracellular trafficking and dissociation S. L\u00e9lu 1 , C. D. L. Davies 1 , N. Reitan 1 , S. P. Strand 2 1 Department of Physics, NTNU, Trondheim, Norway, 2 Department of Biotechnology, NTNU, Trondheim, Norway Chitosan, a cationic polysaccharide presenting low cytotoxicity, is a promising nonviral gene delivery vector.", [["neuronal cell", "ANATOMY", 42, 55], ["intracellular", "ANATOMY", 138, 151], ["P-213", "CHEMICAL", 75, 80], ["chitosan", "CHEMICAL", 99, 107], ["Chitosan", "CHEMICAL", 347, 355], ["neuronal cell", "CELL", 42, 55], ["chitosan", "SIMPLE_CHEMICAL", 99, 107], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 138, 151], ["Chitosan", "SIMPLE_CHEMICAL", 347, 355], ["P", "DNA", 75, 76], ["C. D. L. Davies 1", "SPECIES", 193, 210], ["a novel approach", "TREATMENT", 21, 37], ["neuronal cell assay applications", "TREATMENT", 42, 74], ["Gene delivery with chitosan", "TREATMENT", 80, 107], ["Trondheim", "TREATMENT", 329, 338], ["Norway Chitosan", "TREATMENT", 340, 355], ["a cationic polysaccharide", "TREATMENT", 357, 382], ["low cytotoxicity", "PROBLEM", 394, 410], ["a promising nonviral gene delivery vector", "TREATMENT", 415, 456], ["low cytotoxicity", "OBSERVATION_MODIFIER", 394, 410]]], ["Chitosan complexes DNA into nanoparticles, and the complexation and cell transfection efficacy are function of the chitosan/DNA ratio and of the intrinsic properties of chitosan, i.e. degree of polymerization DPn, charge density, and molecular structure.", [["cell", "ANATOMY", 68, 72], ["Chitosan", "CHEMICAL", 0, 8], ["chitosan", "CHEMICAL", 115, 123], ["chitosan", "CHEMICAL", 169, 177], ["Chitosan", "SIMPLE_CHEMICAL", 0, 8], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["cell", "CELL", 68, 72], ["chitosan", "SIMPLE_CHEMICAL", 115, 123], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["chitosan", "SIMPLE_CHEMICAL", 169, 177], ["DPn", "SIMPLE_CHEMICAL", 209, 212], ["Chitosan complexes DNA into nanoparticles", "PROBLEM", 0, 41], ["the complexation and cell transfection efficacy", "TREATMENT", 47, 94], ["the chitosan/DNA ratio", "TEST", 111, 133], ["polymerization DPn", "PROBLEM", 194, 212], ["charge density", "PROBLEM", 214, 228], ["cell", "OBSERVATION", 68, 72], ["transfection efficacy", "OBSERVATION", 73, 94], ["polymerization DPn", "OBSERVATION", 194, 212], ["charge density", "OBSERVATION", 214, 228], ["molecular structure", "OBSERVATION", 234, 253]]], ["Nanoparticles formed by shorter chitosan (DPn31-41) mediated higher transgene expression than nanoparticles based on longer chitosans.", [["chitosan", "CHEMICAL", 32, 40], ["DPn31-41", "CHEMICAL", 42, 50], ["chitosans", "CHEMICAL", 124, 133], ["Nanoparticles", "SIMPLE_CHEMICAL", 0, 13], ["chitosan", "SIMPLE_CHEMICAL", 32, 40], ["DPn31-41", "SIMPLE_CHEMICAL", 42, 50], ["chitosans", "SIMPLE_CHEMICAL", 124, 133], ["Nanoparticles", "TREATMENT", 0, 13], ["DPn31", "TEST", 42, 47], ["higher transgene expression than nanoparticles", "TREATMENT", 61, 107], ["longer chitosans", "PROBLEM", 117, 133]]], ["The purpose of this work is to relate the DPn of linear chitosan with the cellular uptake, intracellular trafficking and dissociation of chitosan-pDNA complexes, measured by confocal laser scanning microscopy and fluorescence correlation spectroscopy (FCS).", [["cellular", "ANATOMY", 74, 82], ["intracellular", "ANATOMY", 91, 104], ["chitosan", "CHEMICAL", 56, 64], ["chitosan", "CHEMICAL", 137, 145], ["chitosan", "SIMPLE_CHEMICAL", 56, 64], ["cellular", "CELL", 74, 82], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 104], ["chitosan", "SIMPLE_CHEMICAL", 137, 145], ["pDNA complexes", "PROTEIN", 146, 160], ["the cellular uptake", "PROBLEM", 70, 89], ["dissociation of chitosan-pDNA complexes", "PROBLEM", 121, 160], ["confocal laser scanning microscopy", "TEST", 174, 208], ["fluorescence correlation spectroscopy", "TEST", 213, 250], ["cellular uptake", "OBSERVATION", 74, 89], ["intracellular trafficking", "OBSERVATION", 91, 116]]], ["Cells were incubated with oligomers (DPn 31 and 88) either free or complexed with plasmid-DNA.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["plasmid-DNA", "DNA", 82, 93], ["oligomers", "TEST", 26, 35], ["DPn", "TEST", 37, 40]]], ["Both chitosan oligomers seem to penetrate cell nucleus in association with or free from pDNA.", [["cell nucleus", "ANATOMY", 42, 54], ["chitosan", "CHEMICAL", 5, 13], ["chitosan oligomers", "SIMPLE_CHEMICAL", 5, 23], ["cell nucleus", "CELLULAR_COMPONENT", 42, 54], ["pDNA", "CELLULAR_COMPONENT", 88, 92], ["Both chitosan oligomers", "TREATMENT", 0, 23], ["chitosan oligomers", "OBSERVATION", 5, 23], ["penetrate cell nucleus", "OBSERVATION", 32, 54]]], ["24 hours after incubation, accumulation of oligomers in cell nucleus is similar for free and complexed DPn31, whereas it increases for complexed DPn88 compared to free, indicating a possible delayed dissociation of the complexes based on DPn88 in the nucleus and suggesting a dissociation of pDNA-DPn31 in cytoplasm.", [["cell nucleus", "ANATOMY", 56, 68], ["nucleus", "ANATOMY", 251, 258], ["cytoplasm", "ANATOMY", 306, 315], ["DPn88", "CHEMICAL", 145, 150], ["DPn88", "CHEMICAL", 238, 243], ["DPn31", "CHEMICAL", 103, 108], ["DPn88", "CHEMICAL", 145, 150], ["DPn88", "CHEMICAL", 238, 243], ["cell nucleus", "CELLULAR_COMPONENT", 56, 68], ["DPn31", "SIMPLE_CHEMICAL", 103, 108], ["DPn88", "SIMPLE_CHEMICAL", 145, 150], ["DPn88", "SIMPLE_CHEMICAL", 238, 243], ["nucleus", "CELLULAR_COMPONENT", 251, 258], ["pDNA-DPn31", "SIMPLE_CHEMICAL", 292, 302], ["cytoplasm", "ORGANISM_SUBSTANCE", 306, 315], ["DPn31", "PROTEIN", 103, 108], ["DPn88", "PROTEIN", 238, 243], ["DPn31", "PROTEIN", 297, 302], ["accumulation of oligomers in cell nucleus", "PROBLEM", 27, 68], ["delayed dissociation of the complexes", "PROBLEM", 191, 228], ["a dissociation of pDNA", "PROBLEM", 274, 296], ["oligomers", "OBSERVATION", 43, 52], ["cell nucleus", "OBSERVATION", 56, 68], ["possible", "UNCERTAINTY", 182, 190], ["delayed", "OBSERVATION_MODIFIER", 191, 198], ["dissociation", "OBSERVATION", 199, 211], ["nucleus", "ANATOMY", 251, 258], ["dissociation", "OBSERVATION", 276, 288], ["pDNA", "OBSERVATION", 292, 296]]], ["These data are consistent with previous studies which suggested that longer chitosan chains led to tighter complexes, and hence to a delayed dissociation process and lower transfection efficiencies compared to shorter chitosans.O-212Material surface properties greatly influence DNA purification and PCR yield in microsystems C. Potrich 1 , L. Lunelli 1 , L. Marocchi 1 , L. Pasquardini 1 , G. Guella 2 , D. Vozzi 3 , L. Vanzetti 1 , P. Gasparini 3 , C. Pederzolli 1 1 FBK, Trento, Italy, 2 Univ.Trento, Italy, 3 Univ.Trieste, ItalyO-212Modern microchip platforms integrate DNA purification, target amplification by PCR and DNA detection in a single device.", [["surface", "ANATOMY", 242, 249], ["chitosan", "CHEMICAL", 76, 84], ["O-212", "CHEMICAL", 228, 233], ["chitosans", "CHEMICAL", 218, 227], ["chitosan chains", "SIMPLE_CHEMICAL", 76, 91], ["chitosans", "SIMPLE_CHEMICAL", 218, 227], ["DNA", "CELLULAR_COMPONENT", 279, 282], ["DNA", "CELLULAR_COMPONENT", 574, 577], ["DNA", "CELLULAR_COMPONENT", 624, 627], ["previous studies", "TEST", 31, 47], ["longer chitosan chains", "PROBLEM", 69, 91], ["a delayed dissociation process", "PROBLEM", 131, 161], ["lower transfection efficiencies", "PROBLEM", 166, 197], ["shorter chitosans", "PROBLEM", 210, 227], ["Material surface properties", "TEST", 233, 260], ["DNA purification", "TEST", 279, 295], ["PCR", "TEST", 300, 303], ["Potrich", "TEST", 329, 336], ["P. Gasparini", "TREATMENT", 434, 446], ["microchip platforms", "TREATMENT", 544, 563], ["DNA purification", "TREATMENT", 574, 590], ["PCR", "TEST", 616, 619], ["DNA detection", "TEST", 624, 637], ["a single device", "TREATMENT", 641, 656], ["consistent with", "UNCERTAINTY", 15, 30], ["tighter complexes", "OBSERVATION_MODIFIER", 99, 116], ["lower", "OBSERVATION_MODIFIER", 166, 171], ["transfection efficiencies", "OBSERVATION", 172, 197], ["L. Lunelli", "ANATOMY", 341, 351], ["L. Marocchi", "ANATOMY", 356, 367]]], ["Combination of these processes minimizes sample loss and contamination problems as well as reduces analysis time and costs.", [["sample", "ANATOMY", 41, 47], ["these processes", "PROBLEM", 15, 30], ["sample loss", "PROBLEM", 41, 52], ["contamination problems", "PROBLEM", 57, 79], ["sample loss", "OBSERVATION", 41, 52], ["contamination", "OBSERVATION_MODIFIER", 57, 70]]], ["Different strategies are available to perform DNA extraction on a chip.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["DNA extraction", "TREATMENT", 46, 60], ["a chip", "TREATMENT", 64, 70]]], ["Here we exploited amino-coated materials as a tool for specific binding of DNA through the electrostatic interaction between amine groups and nucleic acids.", [["amine", "CHEMICAL", 125, 130], ["nucleic acids", "CHEMICAL", 142, 155], ["amino", "CHEMICAL", 18, 23], ["amine", "CHEMICAL", 125, 130], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["amine", "SIMPLE_CHEMICAL", 125, 130], ["nucleic acids", "SIMPLE_CHEMICAL", 142, 155], ["amino-coated materials", "TREATMENT", 18, 40], ["DNA", "PROBLEM", 75, 78], ["the electrostatic interaction between amine groups", "TREATMENT", 87, 137], ["nucleic acids", "TREATMENT", 142, 155]]], ["We analyzed the ability of different treated substrates to selectively absorb/desorb the genomic DNA with the aim to purify DNA from unwanted components.", [["DNA", "CELLULAR_COMPONENT", 97, 100], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["genomic DNA", "DNA", 89, 100], ["the genomic DNA", "TREATMENT", 85, 100]]], ["Amino-coated substrates were characterized by AFM, XPS, fluorescence microscopy and absorption spectroscopy to define the surface chemical and morphological properties.", [["surface", "ANATOMY", 122, 129], ["Amino", "CHEMICAL", 0, 5], ["Amino-coated substrates", "TREATMENT", 0, 23], ["fluorescence microscopy", "TEST", 56, 79], ["absorption spectroscopy", "TEST", 84, 107]]], ["The distribution of the DNA adsorbed on materials was homogeneous and the eluted DNA was tested for PCR.", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["eluted DNA", "DNA", 74, 84], ["the DNA adsorbed on materials", "PROBLEM", 20, 49], ["the eluted DNA", "TEST", 70, 84], ["PCR", "TEST", 100, 103], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["DNA", "OBSERVATION", 24, 27], ["homogeneous", "OBSERVATION_MODIFIER", 54, 65]]], ["Same materials were analyzed for their compatibility with PCR and the use of different enzymes and reagents or proper surface treatments was employed.", [["surface", "ANATOMY", 118, 125], ["enzymes", "PROTEIN", 87, 94], ["PCR", "TEST", 58, 61], ["different enzymes", "TREATMENT", 77, 94], ["reagents", "TREATMENT", 99, 107], ["proper surface treatments", "TREATMENT", 111, 136]]], ["We established the best conditions for DNA amplification in silicon/pyrex microdevices depending on the type and the fabrication method used and on the quality of reagents more than on the passivation treatment or increment in standard Taq polymerase concentration.P-219Nanoporous alumina fabricated using unconventional acids for enhanced biomolecular physisorption N. Patra, M. Salerno, R. Losso, R. Cingolani Italian Institute of Technology, Genova, ItalyP-219In the last decades the available porecell sizes of porous alumina have been extended, but operating conditions to obtain some pore diameters still have to be optimized, particularly below the 50 nm limit.", [["porecell", "ANATOMY", 497, 505], ["pore", "ANATOMY", 590, 594], ["silicon", "CHEMICAL", 60, 67], ["pyrex", "CHEMICAL", 68, 73], ["alumina", "CHEMICAL", 281, 288], ["alumina", "CHEMICAL", 522, 529], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 236, 250], ["Taq polymerase", "PROTEIN", 236, 250], ["DNA amplification in silicon/pyrex microdevices", "TREATMENT", 39, 86], ["the fabrication method", "TREATMENT", 113, 135], ["the passivation treatment", "TREATMENT", 185, 210], ["standard Taq polymerase concentration", "TREATMENT", 227, 264], ["Nanoporous alumina fabricated", "TREATMENT", 270, 299], ["unconventional acids", "TREATMENT", 306, 326], ["ItalyP", "TREATMENT", 453, 459], ["porecell sizes of porous alumina", "TREATMENT", 497, 529], ["some pore diameters", "TREATMENT", 585, 604], ["porous alumina", "OBSERVATION", 515, 529]]], ["In this range the use of biocompatible porous alumina thin films could find applications in biosensors, after functionalization by appropriate physisorbed biomolecules.", [["alumina", "CHEMICAL", 46, 53], ["biocompatible porous alumina thin films", "TREATMENT", 25, 64], ["applications in biosensors", "TREATMENT", 76, 102], ["functionalization", "TREATMENT", 110, 127]]], ["While pore ordering and film growth rate are mainly influenced by the electrical parameters of voltage and current, respectively, the typical pore size primarily depends on the electrolyte.", [["pore", "ANATOMY", 6, 10], ["pore", "ANATOMY", 142, 146], ["film growth rate", "TEST", 24, 40], ["the typical pore size", "PROBLEM", 130, 151], ["pore", "OBSERVATION_MODIFIER", 142, 146], ["size", "OBSERVATION_MODIFIER", 147, 151]]], ["In the search for alternative anodization conditions, we have investigated several acids that have never been used before, namely gallic, lactic, propionic, and glycolic acid.", [["gallic", "CHEMICAL", 130, 136], ["propionic", "CHEMICAL", 146, 155], ["glycolic acid", "CHEMICAL", 161, 174], ["gallic, lactic, propionic, and glycolic acid", "CHEMICAL", 130, 174], ["gallic", "SIMPLE_CHEMICAL", 130, 136], ["lactic", "SIMPLE_CHEMICAL", 138, 144], ["propionic", "SIMPLE_CHEMICAL", 146, 155], ["glycolic acid", "SIMPLE_CHEMICAL", 161, 174], ["alternative anodization conditions", "TREATMENT", 18, 52], ["several acids", "TREATMENT", 75, 88], ["gallic", "TEST", 130, 136], ["lactic, propionic", "TREATMENT", 138, 155], ["glycolic acid", "TREATMENT", 161, 174]]], ["The anodizations were carried out in galvanostatic conditions at fixed concentration and durations, by varying the current.", [["The anodizations", "TREATMENT", 0, 16]]], ["Atomic force microscopy was used to test the oxidized surface morphology.", [["surface", "ANATOMY", 54, 61], ["Atomic force microscopy", "TEST", 0, 23]]], ["In particular, lactic and propionic acids demonstrated feasible.", [["propionic acids", "CHEMICAL", 26, 41], ["lactic and propionic acids", "CHEMICAL", 15, 41], ["lactic", "SIMPLE_CHEMICAL", 15, 21], ["propionic acids", "SIMPLE_CHEMICAL", 26, 41], ["lactic and propionic acids", "TEST", 15, 41]]], ["Lactic acid gave best results for \u223c30 mA/cm 2 current density, corresponding to roughly constant \u223c15 V potential, with resulting pore diameter in the 4060 nm range, whereas propionic acid performed best for \u223c5 mA/cm 2 , corresponding to \u223c43 V, resulting in 7090 nm pore diameter.", [["pore", "ANATOMY", 129, 133], ["pore", "ANATOMY", 265, 269], ["Lactic acid", "CHEMICAL", 0, 11], ["propionic acid", "CHEMICAL", 173, 187], ["Lactic acid", "CHEMICAL", 0, 11], ["propionic acid", "CHEMICAL", 173, 187], ["Lactic acid", "SIMPLE_CHEMICAL", 0, 11], ["propionic acid", "SIMPLE_CHEMICAL", 173, 187], ["Lactic acid", "TEST", 0, 11], ["resulting pore diameter", "TEST", 119, 142], ["propionic acid", "TEST", 173, 187], ["density", "OBSERVATION", 54, 61], ["15 V", "OBSERVATION_MODIFIER", 98, 102], ["pore", "OBSERVATION_MODIFIER", 129, 133], ["diameter", "OBSERVATION_MODIFIER", 134, 142], ["43 V", "OBSERVATION_MODIFIER", 238, 242], ["diameter", "OBSERVATION_MODIFIER", 270, 278]]], ["Both kind of films looked lightgray, different from the yellowish oxalic acid porous alumina, which can be a hint of lower ion contamination.P-218Chitosan-arabic gum nanoparticles as potential vehicles for peptide delivery L. Moutinho, S. Rocha, M. Coelho, M. C. Pereira LEPAE, Chemical Engineering Department, Faculty of Engineering, University of Porto, Portugal Chitosan (CS) -arabic gum (GA) nanoparticles were produced by an ion-ion interaction process, using different weight ratios of polysaccharides.", [["oxalic acid", "CHEMICAL", 66, 77], ["P-218Chitosan-arabic gum nanoparticles", "CHEMICAL", 141, 179], ["Chitosan", "CHEMICAL", 365, 373], ["CS) -arabic gum", "CHEMICAL", 375, 390], ["GA", "CHEMICAL", 392, 394], ["oxalic acid", "CHEMICAL", 66, 77], ["alumina", "CHEMICAL", 85, 92], ["oxalic acid", "SIMPLE_CHEMICAL", 66, 77], ["P-218Chitosan-arabic gum nanoparticles", "SIMPLE_CHEMICAL", 141, 179], ["Chitosan", "SIMPLE_CHEMICAL", 365, 373], ["CS) -arabic gum", "SIMPLE_CHEMICAL", 375, 390], ["GA) nanoparticles", "SIMPLE_CHEMICAL", 392, 409], ["ion-ion", "SIMPLE_CHEMICAL", 430, 437], ["films", "TEST", 13, 18], ["lightgray", "PROBLEM", 26, 35], ["the yellowish oxalic acid porous alumina", "PROBLEM", 52, 92], ["lower ion contamination", "PROBLEM", 117, 140], ["P", "TEST", 141, 142], ["Chitosan-arabic gum nanoparticles", "TREATMENT", 146, 179], ["peptide delivery", "TREATMENT", 206, 222], ["an ion-ion interaction process", "TREATMENT", 427, 457], ["different weight ratios of polysaccharides", "TREATMENT", 465, 507], ["acid porous alumina", "OBSERVATION", 73, 92], ["lower ion contamination", "OBSERVATION", 117, 140]]], ["According to zeta potential (ZP) measurements, particles are ionically stable.", [["ionically", "OBSERVATION_MODIFIER", 61, 70], ["stable", "OBSERVATION_MODIFIER", 71, 77]]], ["ZP values ranged from 30 to 70 mV for CS:GA ratios of 1:3.3 and 1:0.8, respectively.", [["ZP", "GENE_OR_GENE_PRODUCT", 0, 2], ["ZP", "PROTEIN", 0, 2], ["ZP values", "TEST", 0, 9], ["CS", "TEST", 38, 40], ["GA ratios", "TEST", 41, 50]]], ["CS:GA 1:5 yielded uncharged nanoparticles and aggregates, showing that, at this ratio, the negative charges of GA neutralize the positive charges of CS.", [["CS", "CHEMICAL", 0, 2], ["GA", "CHEMICAL", 3, 5], ["GA", "CHEMICAL", 111, 113], ["CS", "SIMPLE_CHEMICAL", 0, 2], ["GA", "SIMPLE_CHEMICAL", 3, 5], ["uncharged nanoparticles", "SIMPLE_CHEMICAL", 18, 41], ["GA", "SIMPLE_CHEMICAL", 111, 113], ["GA neutralize", "TREATMENT", 111, 124]]], ["The particle diameters ranged from 300 to 500 nm, as measured by Dynamic Light Scattering (DLS), and displayed a slight tendency for decreasing as the GA concentration increased.", [["GA", "CHEMICAL", 151, 153], ["GA", "SIMPLE_CHEMICAL", 151, 153], ["The particle diameters", "TEST", 0, 22], ["a slight tendency", "PROBLEM", 111, 128], ["particle", "OBSERVATION_MODIFIER", 4, 12], ["diameters", "OBSERVATION_MODIFIER", 13, 22], ["ranged", "OBSERVATION_MODIFIER", 23, 29], ["300 to 500 nm", "OBSERVATION_MODIFIER", 35, 48], ["slight", "OBSERVATION_MODIFIER", 113, 119], ["tendency", "OBSERVATION", 120, 128], ["decreasing", "OBSERVATION_MODIFIER", 133, 143]]], ["Transmission Electron Microscopy (TEM) images showed numerous spherical nanoparticles.", [["Transmission Electron Microscopy (TEM) images", "TEST", 0, 45], ["numerous spherical nanoparticles", "PROBLEM", 53, 85], ["numerous", "OBSERVATION_MODIFIER", 53, 61], ["spherical nanoparticles", "OBSERVATION", 62, 85]]], ["Peptides were encapsulated within the nanoparticles, by mixing them with chitosan solution prior to adding GA.", [["chitosan", "CHEMICAL", 73, 81], ["GA", "CHEMICAL", 107, 109], ["chitosan", "SIMPLE_CHEMICAL", 73, 81], ["GA", "SIMPLE_CHEMICAL", 107, 109], ["chitosan solution", "TREATMENT", 73, 90], ["nanoparticles", "OBSERVATION_MODIFIER", 38, 51]]], ["This system can protect short peptides from rapid metabolization, prolonging their blood half-life.P-217Physical characterization of nanocarriers for drug delivery S. Motta 1 , Y. Gerelli 2 , G. Sandri 3 , E. Ricci 3 , P. Brocca 1 1 Dept. of Chem, Biochem and Biotech for Medicine -University of Milan, Italy, 2 Dept. of Physics -University of Parma, Italy, 3 Dept. of Pharmaceutical Chem -University of Pavia, Italy Nanoparticles used as nanocarriers for pharmaceuticals can improve solubility and bioavailability of problematic drugs and protect labile or toxic molecules.", [["blood", "ANATOMY", 83, 88], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["short peptides", "PROBLEM", 24, 38], ["rapid metabolization", "TREATMENT", 44, 64], ["nanocarriers", "TREATMENT", 133, 145], ["drug delivery", "TREATMENT", 150, 163], ["Italy Nanoparticles", "TREATMENT", 411, 430], ["nanocarriers", "TREATMENT", 439, 451], ["pharmaceuticals", "TREATMENT", 456, 471], ["problematic drugs", "TREATMENT", 518, 535], ["toxic molecules", "PROBLEM", 558, 573], ["Parma", "ANATOMY", 344, 349], ["toxic molecules", "OBSERVATION", 558, 573]]], ["Fundamental parameters like drug encapsulation efficiency and release kinetics are tuned by the physico-chemical features of the drug/carrier complex.", [["carrier complex", "PROTEIN", 134, 149], ["Fundamental parameters", "TEST", 0, 22], ["drug encapsulation efficiency", "TREATMENT", 28, 57], ["the drug/carrier complex", "TREATMENT", 125, 149], ["drug", "OBSERVATION", 28, 32], ["encapsulation efficiency", "OBSERVATION", 33, 57]]], ["A challenging aspect of the pharmaceuticallyoriented issues resides in the relatively low number of molecules allowed to build up nanosystems with different properties and morphology, according to the specific drug and to the intended therapy.", [["the pharmaceuticallyoriented issues", "PROBLEM", 24, 59], ["the intended therapy", "TREATMENT", 222, 242], ["relatively", "OBSERVATION_MODIFIER", 75, 85], ["low", "OBSERVATION_MODIFIER", 86, 89]]], ["We have studied: 1) soybeanlecithine/chitosan nanoparticles for Progesterone and Tamoxifen delivery; 2) solid-lipid nanoparticles (Compritol 888 ATO, Poloxamer 188, Tween 80 and chitosan) for Cyclosporine-A delivery via ophthalmic formulation.", [["soybeanlecithine", "CHEMICAL", 20, 36], ["chitosan nanoparticles", "CHEMICAL", 37, 59], ["Progesterone", "CHEMICAL", 64, 76], ["Tamoxifen", "CHEMICAL", 81, 90], ["Compritol 888 ATO", "CHEMICAL", 131, 148], ["Poloxamer 188, Tween 80 and chitosan", "CHEMICAL", 150, 186], ["Cyclosporine-A", "CHEMICAL", 192, 206], ["soybeanlecithine", "CHEMICAL", 20, 36], ["Progesterone", "CHEMICAL", 64, 76], ["Tamoxifen", "CHEMICAL", 81, 90], ["ATO", "CHEMICAL", 145, 148], ["Poloxamer 188", "CHEMICAL", 150, 163], ["Tween 80", "CHEMICAL", 165, 173], ["Cyclosporine-A", "CHEMICAL", 192, 206], ["soybeanlecithine", "SIMPLE_CHEMICAL", 20, 36], ["chitosan nanoparticles", "SIMPLE_CHEMICAL", 37, 59], ["Progesterone", "SIMPLE_CHEMICAL", 64, 76], ["Tamoxifen", "SIMPLE_CHEMICAL", 81, 90], ["solid-lipid nanoparticles", "SIMPLE_CHEMICAL", 104, 129], ["Compritol 888 ATO", "SIMPLE_CHEMICAL", 131, 148], ["Poloxamer 188", "SIMPLE_CHEMICAL", 150, 163], ["Tween 80", "SIMPLE_CHEMICAL", 165, 173], ["chitosan", "SIMPLE_CHEMICAL", 178, 186], ["Cyclosporine-A", "SIMPLE_CHEMICAL", 192, 206], ["soybeanlecithine/chitosan nanoparticles", "TREATMENT", 20, 59], ["Progesterone", "TREATMENT", 64, 76], ["Tamoxifen delivery", "TREATMENT", 81, 99], ["solid-lipid nanoparticles (Compritol", "TREATMENT", 104, 140], ["Poloxamer", "TREATMENT", 150, 159], ["Cyclosporine", "TREATMENT", 192, 204], ["A delivery via ophthalmic formulation", "TREATMENT", 205, 242]]], ["Both void carriers and drug-loaded nanoparticles have been studied, to understand how the structure of the carriers can be modified by the active molecules.", [["Both void carriers", "TREATMENT", 0, 18], ["drug-loaded nanoparticles", "TREATMENT", 23, 48], ["void", "OBSERVATION_MODIFIER", 5, 9], ["carriers", "OBSERVATION", 10, 18]]], ["Several non-invasive physical techniques have been used to achieve a detailed knowledge of the systems: a) dynamic light scattering for the dimensional distribution of the nanocarriers, b) zeta potential to determine surface charge, c) cryo-Tem for morphological analysis d) X-ray scattering (in small angle configuration) and DSC to access information on the inner structure. .Protein adsorption on PEG brushes studied by neutron reflectometryA.", [["surface", "ANATOMY", 217, 224], ["inner structure", "ANATOMY", 360, 375], ["PEG brushes", "CHEMICAL", 400, 411], ["PEG", "CHEMICAL", 400, 403], ["PEG brushes", "SIMPLE_CHEMICAL", 400, 411], ["cryo", "TEST", 236, 240], ["morphological analysis", "TEST", 249, 271], ["X-ray scattering", "TEST", 275, 291], ["Protein adsorption on PEG brushes", "TREATMENT", 378, 411], ["small angle", "OBSERVATION_MODIFIER", 296, 307], ["inner", "ANATOMY_MODIFIER", 360, 365], ["PEG brushes", "OBSERVATION_MODIFIER", 400, 411]]], ["Schollier 1 , A. Halperin 3 , M. Sferrazza 2 , G. Fragneto 1 1 Institut Laue-Langevin, Grenoble, France, 2 Universite Libre de Bruxelles, Belgium, 3 CNRS-UJF Grenoble, France Protein adsorption on surfaces is responsible of several unwanted effects in technological and pharmaceutical applications: fouling of contact lenses, clotting in blood containing devices, inflammation around artificial organs for instance.", [["blood", "ANATOMY", 338, 343], ["organs", "ANATOMY", 395, 401], ["inflammation", "DISEASE", 364, 376], ["blood", "ORGANISM_SUBSTANCE", 338, 343], ["organs", "ORGAN", 395, 401], ["technological and pharmaceutical applications", "TREATMENT", 252, 297], ["contact lenses", "PROBLEM", 310, 324], ["clotting in blood containing devices", "TREATMENT", 326, 362], ["inflammation", "PROBLEM", 364, 376], ["contact lenses", "OBSERVATION", 310, 324], ["inflammation", "OBSERVATION", 364, 376]]], ["Those phenomena can be repressed with certain types of polymer brushes, in particular PEG (polyethylene glycol) brushes, and a better understanding of the mechanism of adsorption could lead to improvements in the design of biomaterials.", [["PEG", "CHEMICAL", 86, 89], ["polyethylene glycol", "CHEMICAL", 91, 110], ["PEG", "CHEMICAL", 86, 89], ["polyethylene glycol)", "CHEMICAL", 91, 111], ["PEG", "SIMPLE_CHEMICAL", 86, 89], ["polyethylene glycol", "SIMPLE_CHEMICAL", 91, 110], ["polymer brushes", "TREATMENT", 55, 70], ["PEG (polyethylene glycol) brushes", "TREATMENT", 86, 119], ["polymer brushes", "OBSERVATION", 55, 70]]], ["Three cases are predicted: primary adsorption at the grafting surface, secondary adsorption at the outer edge of the brush, and ternary adsorption within the brush itself.", [["surface", "ANATOMY", 62, 69], ["brush", "ANATOMY", 117, 122], ["brush", "ANATOMY", 158, 163], ["brush", "TISSUE", 158, 163], ["primary adsorption at the grafting surface", "TREATMENT", 27, 69], ["secondary adsorption", "PROBLEM", 71, 91], ["primary adsorption", "OBSERVATION", 27, 45], ["grafting", "OBSERVATION", 53, 61], ["secondary adsorption", "OBSERVATION", 71, 91], ["outer", "ANATOMY_MODIFIER", 99, 104], ["edge", "ANATOMY_MODIFIER", 105, 109], ["brush", "ANATOMY_MODIFIER", 117, 122], ["ternary adsorption", "OBSERVATION", 128, 146]]], ["We prepared samples with different grafting densities and different degrees of polymerization and used different protein size and concentrations.", [["samples", "ANATOMY", 12, 19], ["different grafting densities", "TREATMENT", 25, 53], ["polymerization", "TREATMENT", 79, 93], ["different protein size", "TREATMENT", 103, 125], ["grafting", "OBSERVATION", 35, 43], ["different degrees", "OBSERVATION_MODIFIER", 58, 75], ["polymerization", "OBSERVATION_MODIFIER", 79, 93], ["size", "OBSERVATION_MODIFIER", 121, 125]]], ["Neutron reflectivity experiments, able to determine the structure and composition of material interfaces with a fraction of nanometer resolution, were carried out and, by using deuterated proteins (Anti-Freeze Protein, Dihydrofolate Reductase and Myoglobin) on different PEG compositions and grafting densities, it was possible to locate the proteins in the brush and to distinguish between the different kinds of adsorption : primary adsorption is dominant for short brushes and ternary adsorption for long brushes.P-223Effect of powder air polishing on nanocomposite dental materials measured by atomic force microscopy M. Salerno 1 , G. Derchi 2 , A. M. Genovesi 2 , L. Giacomelli 2 1 Italian Institute of Technology, Genova, Italy, 2 Istituto Stomatologico Tirreno, Lido di Camaiore, ItalyP-223In dentistry, airpolishing with glycine and bicarbonate powders is widely used to remove accumulated plaque.", [["brush", "ANATOMY", 358, 363], ["plaque", "ANATOMY", 899, 905], ["PEG", "CHEMICAL", 271, 274], ["P-223", "CHEMICAL", 516, 521], ["ItalyP-223In", "CHEMICAL", 788, 800], ["glycine", "CHEMICAL", 830, 837], ["bicarbonate", "CHEMICAL", 842, 853], ["Dihydrofolate", "CHEMICAL", 219, 232], ["PEG", "CHEMICAL", 271, 274], ["glycine", "CHEMICAL", 830, 837], ["bicarbonate", "CHEMICAL", 842, 853], ["Dihydrofolate Reductase", "SIMPLE_CHEMICAL", 219, 242], ["Myoglobin", "SIMPLE_CHEMICAL", 247, 256], ["brush", "TISSUE", 358, 363], ["glycine", "SIMPLE_CHEMICAL", 830, 837], ["bicarbonate powders", "SIMPLE_CHEMICAL", 842, 861], ["plaque", "PATHOLOGICAL_FORMATION", 899, 905], ["deuterated proteins", "PROTEIN", 177, 196], ["Anti-Freeze Protein", "PROTEIN", 198, 217], ["Dihydrofolate Reductase", "PROTEIN", 219, 242], ["Neutron reflectivity experiments", "TEST", 0, 32], ["Anti-Freeze Protein", "TREATMENT", 198, 217], ["Dihydrofolate Reductase and Myoglobin)", "TREATMENT", 219, 257], ["different PEG compositions", "TREATMENT", 261, 287], ["grafting densities", "TREATMENT", 292, 310], ["short brushes and ternary adsorption", "TREATMENT", 462, 498], ["long brushes", "PROBLEM", 503, 515], ["powder air polishing on nanocomposite dental materials", "TREATMENT", 531, 585], ["Lido di Camaiore", "TREATMENT", 770, 786], ["ItalyP", "TREATMENT", 788, 794], ["glycine and bicarbonate powders", "TREATMENT", 830, 861], ["accumulated plaque", "PROBLEM", 887, 905], ["grafting densities", "OBSERVATION", 292, 310], ["plaque", "OBSERVATION", 899, 905]]], ["However, the resulting teeth and gingival surface roughness, which is a risk factor for further plaque accumulation, has to be considered.", [["teeth", "ANATOMY", 23, 28], ["gingival surface", "ANATOMY", 33, 49], ["plaque", "ANATOMY", 96, 102], ["plaque", "DISEASE", 96, 102], ["teeth", "ORGAN", 23, 28], ["gingival surface", "TISSUE", 33, 49], ["plaque", "PATHOLOGICAL_FORMATION", 96, 102], ["the resulting teeth and gingival surface roughness", "PROBLEM", 9, 59], ["a risk factor", "PROBLEM", 70, 83], ["further plaque accumulation", "PROBLEM", 88, 115], ["teeth", "OBSERVATION", 23, 28], ["gingival", "OBSERVATION_MODIFIER", 33, 41], ["surface", "OBSERVATION_MODIFIER", 42, 49], ["roughness", "OBSERVATION_MODIFIER", 50, 59], ["plaque", "OBSERVATION", 96, 102]]], ["In this in vitro study the effect of the above mentioned technique on the surface of a novel nanocomposite dental material is evaluated by means of Atomic Force Microscopy (AFM).", [["surface", "ANATOMY", 74, 81], ["surface", "CELLULAR_COMPONENT", 74, 81], ["a novel nanocomposite dental material", "PROBLEM", 85, 122], ["Atomic Force Microscopy", "TEST", 148, 171]]], ["Square specimens (0.5\u00d70.5 cm 2 size) were airpolished either with glycine or bicarbonate, using different application times (2, 8, 30 sec) and distances (2, 4, 6 mm) .", [["Square specimens", "ANATOMY", 0, 16], ["glycine", "CHEMICAL", 66, 73], ["bicarbonate", "CHEMICAL", 77, 88], ["glycine", "CHEMICAL", 66, 73], ["bicarbonate", "CHEMICAL", 77, 88], ["glycine", "SIMPLE_CHEMICAL", 66, 73], ["bicarbonate", "SIMPLE_CHEMICAL", 77, 88], ["Square specimens", "TEST", 0, 16], ["glycine", "TREATMENT", 66, 73], ["bicarbonate", "TREATMENT", 77, 88]]], ["Four specimens were evaluated for each timedistance combination, and checked versus untreated specimens (controls).P-223The specimens were imaged with Tappingmode AFM at two different scan sizes (3\u00d73 and 30\u00d730 \u00b5m 2 ) in two different regions for each sample.", [["specimens", "ANATOMY", 5, 14], ["specimens", "ANATOMY", 94, 103], ["specimens", "ANATOMY", 124, 133], ["sample", "ANATOMY", 251, 257], ["specimens", "CELL", 124, 133], ["P-223", "DNA", 115, 120], ["Four specimens", "TEST", 0, 14], ["The specimens", "TEST", 120, 133], ["Tappingmode AFM", "TEST", 151, 166], ["different scan sizes", "TEST", 174, 194], ["each sample", "TEST", 246, 257], ["sizes", "OBSERVATION_MODIFIER", 189, 194]]], ["The surface roughness was measured as the RMS of the feature heights.", [["surface", "ANATOMY", 4, 11], ["The surface roughness", "TEST", 0, 21], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["roughness", "OBSERVATION_MODIFIER", 12, 21], ["RMS", "OBSERVATION_MODIFIER", 42, 45], ["feature heights", "OBSERVATION", 53, 68]]], ["For the 2 sec2 mm group airpolishing resulted in an increased surface roughness as compared to the controls; however, glycine was associated with a lower roughness than bicarbonate (glycine: 238\u00b191 nm; bicarbonate: 436\u00b175 nm; controls: 14\u00b114 nm; p<0.0001 for treated specimens vs controls, p<0.001 for glycine vs bicarbonate, ANOVA test).", [["surface", "ANATOMY", 62, 69], ["specimens", "ANATOMY", 267, 276], ["glycine", "CHEMICAL", 118, 125], ["bicarbonate", "CHEMICAL", 169, 180], ["glycine", "CHEMICAL", 182, 189], ["bicarbonate", "CHEMICAL", 202, 213], ["glycine", "CHEMICAL", 302, 309], ["bicarbonate", "CHEMICAL", 313, 324], ["glycine", "CHEMICAL", 118, 125], ["bicarbonate", "CHEMICAL", 169, 180], ["glycine", "CHEMICAL", 182, 189], ["bicarbonate", "CHEMICAL", 202, 213], ["glycine", "CHEMICAL", 302, 309], ["bicarbonate", "CHEMICAL", 313, 324], ["glycine", "SIMPLE_CHEMICAL", 118, 125], ["bicarbonate", "SIMPLE_CHEMICAL", 169, 180], ["glycine", "SIMPLE_CHEMICAL", 182, 189], ["glycine", "SIMPLE_CHEMICAL", 302, 309], ["bicarbonate", "SIMPLE_CHEMICAL", 313, 324], ["an increased surface roughness", "PROBLEM", 49, 79], ["bicarbonate", "TEST", 202, 213], ["controls", "TEST", 226, 234], ["p", "TEST", 246, 247], ["specimens vs controls", "TEST", 267, 288], ["p", "TEST", 290, 291], ["glycine vs bicarbonate", "TREATMENT", 302, 324], ["ANOVA test", "TEST", 326, 336], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["surface", "OBSERVATION_MODIFIER", 62, 69], ["roughness", "OBSERVATION_MODIFIER", 70, 79]]], ["The work comprises the design of polysaccharide based nanoparticles for drug delivery.", [["polysaccharide based nanoparticles", "SIMPLE_CHEMICAL", 33, 67], ["polysaccharide based nanoparticles", "TREATMENT", 33, 67], ["drug delivery", "TREATMENT", 72, 85]]], ["Chitosan/arabic gum and arabic gum/maltodextrin nanoparticles were prepared by polyelectrolyte complexation and spray drying [1] , respectively.", [["Chitosan", "CHEMICAL", 0, 8], ["arabic gum", "CHEMICAL", 9, 19], ["arabic gum", "CHEMICAL", 24, 34], ["maltodextrin", "CHEMICAL", 35, 47], ["Chitosan", "SIMPLE_CHEMICAL", 0, 8], ["arabic gum", "SIMPLE_CHEMICAL", 9, 19], ["arabic gum", "SIMPLE_CHEMICAL", 24, 34], ["maltodextrin nanoparticles", "SIMPLE_CHEMICAL", 35, 61], ["polyelectrolyte", "SIMPLE_CHEMICAL", 79, 94], ["Chitosan/arabic gum", "TREATMENT", 0, 19], ["arabic gum/maltodextrin nanoparticles", "TREATMENT", 24, 61]]], ["Dynamic light scattering characterization established that arabic gum/maltodextrin nanoparticles are more polydisperse (diameters ranging from 8 to 400 nm) than chitosan/arabic gum particles (diameters of approximately 500 nm).", [["arabic gum", "CHEMICAL", 59, 69], ["maltodextrin", "CHEMICAL", 70, 82], ["chitosan", "CHEMICAL", 161, 169], ["arabic gum", "CHEMICAL", 170, 180], ["arabic gum", "SIMPLE_CHEMICAL", 59, 69], ["maltodextrin nanoparticles", "SIMPLE_CHEMICAL", 70, 96], ["chitosan", "SIMPLE_CHEMICAL", 161, 169], ["Dynamic light scattering characterization", "TEST", 0, 41], ["arabic gum/maltodextrin nanoparticles", "TEST", 59, 96], ["diameters", "TEST", 120, 129], ["chitosan/arabic gum particles", "TEST", 161, 190], ["polydisperse", "OBSERVATION_MODIFIER", 106, 118], ["diameters", "OBSERVATION_MODIFIER", 120, 129]]], ["Scanning electron microscopy measurements demonstrated that the particles are spherical and have a smooth surface.", [["surface", "ANATOMY", 106, 113], ["surface", "CELLULAR_COMPONENT", 106, 113], ["Scanning electron microscopy measurements", "TEST", 0, 41], ["particles", "OBSERVATION_MODIFIER", 64, 73], ["spherical", "OBSERVATION_MODIFIER", 78, 87], ["smooth", "OBSERVATION_MODIFIER", 99, 105], ["surface", "OBSERVATION_MODIFIER", 106, 113]]], ["The systems are highly stable to forces up to 80 nN as observed by atomic force microscopy.", [["atomic force microscopy", "TEST", 67, 90], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["stable", "OBSERVATION", 23, 29]]], ["Due to their nature they are hydrophilic and biodegradable.", [["hydrophilic", "OBSERVATION_MODIFIER", 29, 40], ["biodegradable", "OBSERVATION_MODIFIER", 45, 58]]], ["The nanoparticles were used to entrap short peptide sequences and antioxidants and were proved to be efficient in maintaining the biological activity of the molecules.", [["The nanoparticles", "TREATMENT", 0, 17], ["short peptide sequences", "TEST", 38, 61], ["antioxidants", "TREATMENT", 66, 78]]], ["Kyotorphin (KTP) was found in 1979 in bovine brain.", [["brain", "ANATOMY", 45, 50], ["Kyotorphin", "CHEMICAL", 0, 10], ["KTP", "CHEMICAL", 12, 15], ["Kyotorphin", "CHEMICAL", 0, 10], ["KTP", "CHEMICAL", 12, 15], ["Kyotorphin", "GENE_OR_GENE_PRODUCT", 0, 10], ["KTP", "GENE_OR_GENE_PRODUCT", 12, 15], ["bovine", "ORGANISM", 38, 44], ["brain", "ORGAN", 45, 50], ["bovine", "SPECIES", 38, 44], ["bovine", "SPECIES", 38, 44], ["Kyotorphin (KTP", "TREATMENT", 0, 15], ["brain", "ANATOMY", 45, 50]]], ["Despite revealing remarkable analgesic properties, analgesia was only induced after central delivery.", [["remarkable analgesic properties", "TREATMENT", 18, 49], ["analgesia", "TREATMENT", 51, 60], ["central delivery", "TREATMENT", 84, 100], ["remarkable", "OBSERVATION_MODIFIER", 18, 28], ["analgesic properties", "OBSERVATION", 29, 49]]], ["This limited ability to cross the blood-brain barrier (BBB) combined with the unknown mechanism of action largely confines its pharmacological use.", [["blood-brain barrier", "ANATOMY", 34, 53], ["BBB", "ANATOMY", 55, 58], ["blood-", "MULTI-TISSUE_STRUCTURE", 34, 40], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 40, 53], ["BBB", "MULTI-TISSUE_STRUCTURE", 55, 58], ["brain", "ANATOMY", 40, 45]]], ["To surpass these problems, we designed new KTP derivatives: KTP-RC and KTP-RC-Lipogen.", [["KTP", "CHEMICAL", 43, 46], ["KTP", "CHEMICAL", 60, 63], ["KTP", "CHEMICAL", 71, 74], ["KTP", "CHEMICAL", 43, 46], ["KTP", "CHEMICAL", 60, 63], ["KTP", "CHEMICAL", 71, 74], ["KTP derivatives", "SIMPLE_CHEMICAL", 43, 58], ["KTP-RC", "SIMPLE_CHEMICAL", 60, 66], ["KTP-RC-Lipogen", "SIMPLE_CHEMICAL", 71, 85], ["new KTP derivatives", "TREATMENT", 39, 58], ["KTP", "TREATMENT", 60, 63], ["RC", "TREATMENT", 64, 66], ["KTP", "TREATMENT", 71, 74], ["RC", "TREATMENT", 75, 77], ["Lipogen", "TREATMENT", 78, 85]]], ["Biophysical studies were carried out using fluorescence methodologies to characterize the peptides' interaction with biomembrane model systems.", [["Biophysical studies", "TEST", 0, 19], ["fluorescence methodologies", "TEST", 43, 69], ["biomembrane model systems", "TREATMENT", 117, 142]]], ["Partition coefficient quantification showed a clear preference of the derivatives towards fluid zwitterionic and anionic membranes.", [["membranes", "ANATOMY", 121, 130], ["fluid zwitterionic", "SIMPLE_CHEMICAL", 90, 108], ["anionic membranes", "CELLULAR_COMPONENT", 113, 130], ["Partition coefficient quantification", "TEST", 0, 36], ["the derivatives", "TREATMENT", 66, 81], ["fluid zwitterionic and anionic membranes", "TREATMENT", 90, 130], ["anionic membranes", "OBSERVATION", 113, 130]]], ["Moreover, a relationship between anionic lipid percentage and in-depth insertion in membrane was established.", [["membrane", "ANATOMY", 84, 92], ["membrane", "CELLULAR_COMPONENT", 84, 92], ["anionic lipid percentage", "TREATMENT", 33, 57], ["in-depth insertion in membrane", "TREATMENT", 62, 92], ["lipid", "OBSERVATION_MODIFIER", 41, 46], ["percentage", "OBSERVATION_MODIFIER", 47, 57]]], ["Additionally, studies with fluorescent probe di-8-ANEPPS revealed different membrane-interaction profiles of morphine and KTP-derivatives, suggesting distinct actions between them.", [["membrane", "ANATOMY", 76, 84], ["di-8-", "CHEMICAL", 45, 50], ["morphine", "CHEMICAL", 109, 117], ["KTP", "CHEMICAL", 122, 125], ["morphine", "CHEMICAL", 109, 117], ["KTP", "CHEMICAL", 122, 125], ["di-8-ANEPPS", "SIMPLE_CHEMICAL", 45, 56], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["morphine", "SIMPLE_CHEMICAL", 109, 117], ["KTP-derivatives", "SIMPLE_CHEMICAL", 122, 137], ["studies", "TEST", 14, 21], ["fluorescent probe di-8-ANEPPS", "TEST", 27, 56], ["morphine", "TREATMENT", 109, 117], ["KTP", "TREATMENT", 122, 125], ["derivatives", "TREATMENT", 126, 137], ["different membrane", "OBSERVATION", 66, 84]]], ["The analgesic efficacy of the compounds was studied in vivo after systemic administration in models of acute and tonic pain.", [["acute and tonic pain", "DISEASE", 103, 123], ["The analgesic efficacy", "TREATMENT", 0, 22], ["systemic administration", "TREATMENT", 66, 89], ["acute and tonic pain", "PROBLEM", 103, 123], ["analgesic", "OBSERVATION_MODIFIER", 4, 13], ["acute", "OBSERVATION_MODIFIER", 103, 108]]], ["Unlike KTP, both KTP-RC and KTP-RC-Lipogen displayed high efficacy from doses as low as 1.67 and 0.85 mg/100g, respectively, indicating BBB crossing.", [["KTP", "CHEMICAL", 7, 10], ["KTP", "CHEMICAL", 17, 20], ["KTP", "CHEMICAL", 28, 31], ["Lipogen", "CHEMICAL", 35, 42], ["KTP", "CHEMICAL", 7, 10], ["KTP", "CHEMICAL", 17, 20], ["KTP", "CHEMICAL", 28, 31], ["KTP", "SIMPLE_CHEMICAL", 7, 10], ["KTP-RC", "SIMPLE_CHEMICAL", 17, 23], ["KTP-RC", "SIMPLE_CHEMICAL", 28, 34], ["Lipogen", "SIMPLE_CHEMICAL", 35, 42], ["BBB", "MULTI-TISSUE_STRUCTURE", 136, 139], ["KTP", "TEST", 7, 10], ["KTP", "TEST", 17, 20], ["RC", "TEST", 21, 23], ["KTP", "TEST", 28, 31], ["RC", "TEST", 32, 34], ["Lipogen", "TREATMENT", 35, 42], ["high efficacy", "OBSERVATION", 53, 66], ["BBB", "ANATOMY", 136, 139], ["crossing", "OBSERVATION", 140, 148]]], ["The observed correlation between higher partition/insertion in the membrane and enhanced analgesic action proved the biophysical rationale to be a powerful strategy for early screening in CNS drug development.", [["membrane", "ANATOMY", 67, 75], ["CNS", "ANATOMY", 188, 191], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["CNS", "ANATOMICAL_SYSTEM", 188, 191], ["higher partition/insertion in the membrane", "TREATMENT", 33, 75], ["enhanced analgesic action", "TREATMENT", 80, 105], ["early screening", "TEST", 169, 184]]], ["Metabolic syndrome (MS) is now regarded as a major risk factor for cardiovascular disease.", [["cardiovascular", "ANATOMY", 67, 81], ["Metabolic syndrome", "DISEASE", 0, 18], ["MS", "DISEASE", 20, 22], ["cardiovascular disease", "DISEASE", 67, 89], ["cardiovascular", "ANATOMICAL_SYSTEM", 67, 81], ["Metabolic syndrome", "PROBLEM", 0, 18], ["cardiovascular disease", "PROBLEM", 67, 89], ["syndrome", "OBSERVATION", 10, 18], ["cardiovascular disease", "OBSERVATION", 67, 89]]], ["As prooxidant/antioxidant balance is disturbed in the course of this disorder, it is possible that melatonin may exhibit protective effect against oxidative damage of blood cells.", [["blood cells", "ANATOMY", 167, 178], ["melatonin", "CHEMICAL", 99, 108], ["melatonin", "CHEMICAL", 99, 108], ["melatonin", "SIMPLE_CHEMICAL", 99, 108], ["blood cells", "CELL", 167, 178], ["blood cells", "CELL_TYPE", 167, 178], ["prooxidant/antioxidant balance", "TREATMENT", 3, 33], ["this disorder", "PROBLEM", 64, 77], ["melatonin", "TREATMENT", 99, 108], ["oxidative damage of blood cells", "PROBLEM", 147, 178], ["blood cells", "OBSERVATION", 167, 178]]], ["MS was diagnosed according to International Diabetes Federation definition (2005) .", [["MS", "DISEASE", 0, 2]]], ["The investigated group consisted of patients before and after the melatonin supplementation (5 mg per day for two months) and was compared to control group of healthy individuals on normal diet.", [["melatonin", "CHEMICAL", 66, 75], ["melatonin", "CHEMICAL", 66, 75], ["patients", "ORGANISM", 36, 44], ["melatonin", "SIMPLE_CHEMICAL", 66, 75], ["patients", "SPECIES", 36, 44], ["the melatonin supplementation", "TREATMENT", 62, 91]]], ["Our experiments show that erythrocytes from patient group exhibit significantly higher TBARS and total cholesterol levels whereas the protein thiol concentration, Na + K + ATPase and glutathione peroxidase activities were decreased in comparison to those of healthy volunteers.", [["erythrocytes", "ANATOMY", 26, 38], ["TBARS", "CHEMICAL", 87, 92], ["cholesterol", "CHEMICAL", 103, 114], ["thiol", "CHEMICAL", 142, 147], ["Na", "CHEMICAL", 163, 165], ["K", "CHEMICAL", 168, 169], ["glutathione", "CHEMICAL", 183, 194], ["cholesterol", "CHEMICAL", 103, 114], ["thiol", "CHEMICAL", 142, 147], ["Na +", "CHEMICAL", 163, 167], ["K +", "CHEMICAL", 168, 171], ["glutathione", "CHEMICAL", 183, 194], ["erythrocytes", "CELL", 26, 38], ["patient", "ORGANISM", 44, 51], ["TBARS", "SIMPLE_CHEMICAL", 87, 92], ["cholesterol", "SIMPLE_CHEMICAL", 103, 114], ["thiol", "SIMPLE_CHEMICAL", 142, 147], ["Na + K + ATPase", "GENE_OR_GENE_PRODUCT", 163, 178], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 183, 205], ["volunteers", "ORGANISM", 266, 276], ["erythrocytes", "CELL_TYPE", 26, 38], ["Na + K + ATPase", "PROTEIN", 163, 178], ["glutathione peroxidase", "PROTEIN", 183, 205], ["patient", "SPECIES", 44, 51], ["Our experiments", "TEST", 0, 15], ["erythrocytes", "TEST", 26, 38], ["significantly higher TBARS", "PROBLEM", 66, 92], ["total cholesterol levels", "TEST", 97, 121], ["the protein thiol concentration", "TEST", 130, 161], ["Na", "TEST", 163, 165], ["K", "TEST", 168, 169], ["ATPase", "TEST", 172, 178], ["glutathione peroxidase activities", "TEST", 183, 216], ["decreased", "OBSERVATION_MODIFIER", 222, 231]]], ["After two month melatonin supplementation, TBARS and cholesterol concentrations significantly decreased, whereas the Na + K + ATPase, catalase and glutathione peroxidase activities increased.", [["melatonin", "CHEMICAL", 16, 25], ["TBARS", "CHEMICAL", 43, 48], ["cholesterol", "CHEMICAL", 53, 64], ["Na", "CHEMICAL", 117, 119], ["K", "CHEMICAL", 122, 123], ["glutathione", "CHEMICAL", 147, 158], ["melatonin", "CHEMICAL", 16, 25], ["cholesterol", "CHEMICAL", 53, 64], ["Na +", "CHEMICAL", 117, 121], ["K +", "CHEMICAL", 122, 125], ["glutathione", "CHEMICAL", 147, 158], ["melatonin", "SIMPLE_CHEMICAL", 16, 25], ["TBARS", "SIMPLE_CHEMICAL", 43, 48], ["cholesterol", "SIMPLE_CHEMICAL", 53, 64], ["Na + K + ATPase", "GENE_OR_GENE_PRODUCT", 117, 132], ["catalase", "GENE_OR_GENE_PRODUCT", 134, 142], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 147, 169], ["Na + K + ATPase", "PROTEIN", 117, 132], ["catalase", "PROTEIN", 134, 142], ["glutathione peroxidase", "PROTEIN", 147, 169], ["melatonin supplementation", "TREATMENT", 16, 41], ["TBARS and cholesterol concentrations", "TEST", 43, 79], ["the Na", "TEST", 113, 119], ["K", "TEST", 122, 123], ["ATPase", "TEST", 126, 132], ["catalase", "TEST", 134, 142], ["glutathione peroxidase activities", "TEST", 147, 180]]], ["The glutathione concentration was also higher.", [["glutathione", "CHEMICAL", 4, 15], ["glutathione", "CHEMICAL", 4, 15], ["glutathione", "SIMPLE_CHEMICAL", 4, 15], ["The glutathione concentration", "TREATMENT", 0, 29], ["glutathione concentration", "OBSERVATION", 4, 29], ["higher", "OBSERVATION_MODIFIER", 39, 45]]], ["These results show that melatonin supplementation has a protective effect on erythrocytes of MS patients.P-227Action of ferritin, a nanoparticle model, on ROS formation and glutamate uptake in synaptosomes T. Waseem, A. Alekseenko, S. Fedorovich Institute of Biophysics and Cell Engineering, Minsk, Republic of Belarus Nanoparticles are currently used in medicine as agents for targeted drug delivery and imaging.", [["erythrocytes", "ANATOMY", 77, 89], ["Cell", "ANATOMY", 274, 278], ["melatonin", "CHEMICAL", 24, 33], ["MS", "DISEASE", 93, 95], ["ROS", "CHEMICAL", 155, 158], ["glutamate", "CHEMICAL", 173, 182], ["melatonin", "CHEMICAL", 24, 33], ["glutamate", "CHEMICAL", 173, 182], ["melatonin", "SIMPLE_CHEMICAL", 24, 33], ["erythrocytes", "CELL", 77, 89], ["patients", "ORGANISM", 96, 104], ["ferritin", "GENE_OR_GENE_PRODUCT", 120, 128], ["ROS", "SIMPLE_CHEMICAL", 155, 158], ["glutamate", "SIMPLE_CHEMICAL", 173, 182], ["Cell", "CELL", 274, 278], ["erythrocytes", "CELL_TYPE", 77, 89], ["P", "DNA", 105, 106], ["ferritin", "PROTEIN", 120, 128], ["patients", "SPECIES", 96, 104], ["melatonin supplementation", "TREATMENT", 24, 49], ["P", "TEST", 105, 106], ["ferritin", "TEST", 120, 128], ["a nanoparticle model", "TEST", 130, 150], ["ROS formation", "PROBLEM", 155, 168], ["glutamate uptake", "TEST", 173, 189], ["Cell Engineering", "TREATMENT", 274, 290], ["Belarus Nanoparticles", "TREATMENT", 311, 332], ["targeted drug delivery", "TREATMENT", 378, 400], ["imaging", "TEST", 405, 412]]], ["However it has been demonstrated that nanoparticles induce neurodegeneration in vivo and kill neurons in vitro.", [["neurons", "ANATOMY", 94, 101], ["neurodegeneration", "DISEASE", 59, 76], ["neurons", "CELL", 94, 101], ["neurodegeneration", "PROBLEM", 59, 76], ["neurodegeneration", "OBSERVATION", 59, 76]]], ["The cellular and molecular bases of this phenomenon are still unclear.", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["this phenomenon", "PROBLEM", 36, 51], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["molecular", "ANATOMY_MODIFIER", 17, 26], ["bases", "ANATOMY_MODIFIER", 27, 32], ["phenomenon", "OBSERVATION", 41, 51]]], ["We have used the protein ferritin as a nanoparticle model.", [["ferritin", "GENE_OR_GENE_PRODUCT", 25, 33], ["protein ferritin", "PROTEIN", 17, 33], ["the protein ferritin", "TEST", 13, 33], ["a nanoparticle model", "TREATMENT", 37, 57]]], ["Ferritin contains iron particles (Fe 3+ ) with size 7 nm and a protein shell.", [["iron", "CHEMICAL", 18, 22], ["Fe", "CHEMICAL", 34, 36], ["iron", "CHEMICAL", 18, 22], ["Fe 3+", "CHEMICAL", 34, 39], ["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["iron particles", "SIMPLE_CHEMICAL", 18, 32], ["Fe 3+", "SIMPLE_CHEMICAL", 34, 39], ["Ferritin", "PROTEIN", 0, 8], ["Ferritin", "TEST", 0, 8], ["iron particles", "TEST", 18, 32], ["Fe", "TEST", 34, 36], ["size", "TEST", 47, 51], ["a protein shell", "TREATMENT", 61, 76], ["iron particles", "OBSERVATION_MODIFIER", 18, 32], ["protein shell", "OBSERVATION", 63, 76]]], ["We investigated how ferritin influences uptake and release of [ 14 C]glutamate and free radical formation as monitored by fluorescent dye DCFDA in rat brain synaptosomes.", [["brain synaptosomes", "ANATOMY", 151, 169], ["glutamate", "CHEMICAL", 69, 78], ["DCFDA", "CHEMICAL", 138, 143], ["[ 14 C]glutamate", "CHEMICAL", 62, 78], ["ferritin", "GENE_OR_GENE_PRODUCT", 20, 28], ["[ 14 C]glutamate", "SIMPLE_CHEMICAL", 62, 78], ["free radical", "SIMPLE_CHEMICAL", 83, 95], ["fluorescent dye DCFDA", "SIMPLE_CHEMICAL", 122, 143], ["rat", "ORGANISM", 147, 150], ["brain synaptosomes", "MULTI-TISSUE_STRUCTURE", 151, 169], ["ferritin", "PROTEIN", 20, 28], ["rat", "SPECIES", 147, 150], ["rat", "SPECIES", 147, 150], ["ferritin influences uptake", "PROBLEM", 20, 46], ["glutamate and free radical formation", "TREATMENT", 69, 105]]], ["We found that even a high concentration of ferritin (800 \u00b5g/ml) did not induce spontaneous [ 14 C]glutamate release.", [["glutamate", "CHEMICAL", 98, 107], ["[ 14 C]glutamate", "CHEMICAL", 91, 107], ["ferritin", "GENE_OR_GENE_PRODUCT", 43, 51], ["[ 14 C]glutamate", "SIMPLE_CHEMICAL", 91, 107], ["ferritin", "PROTEIN", 43, 51], ["ferritin", "TEST", 43, 51], ["glutamate release", "TREATMENT", 98, 115]]], ["In contrast the same concentration of this protein inhibited [ 14 C]glutamate uptake two fold.", [["glutamate", "CHEMICAL", 68, 77], ["[ 14 C]glutamate", "CHEMICAL", 61, 77], ["[ 14 C]glutamate", "SIMPLE_CHEMICAL", 61, 77], ["this protein", "TEST", 38, 50], ["glutamate uptake two fold", "PROBLEM", 68, 93]]], ["Furthermore ferritin induced intrasynaptosomal ROS (reactive oxygen species) formation in a dose-dependent manner.", [["ROS", "CHEMICAL", 47, 50], ["oxygen", "CHEMICAL", 61, 67], ["oxygen", "CHEMICAL", 61, 67], ["ferritin", "GENE_OR_GENE_PRODUCT", 12, 20], ["intrasynaptosomal", "SIMPLE_CHEMICAL", 29, 46], ["ROS", "SIMPLE_CHEMICAL", 47, 50], ["reactive oxygen species", "SIMPLE_CHEMICAL", 52, 75], ["ferritin", "PROTEIN", 12, 20], ["ferritin induced intrasynaptosomal ROS", "PROBLEM", 12, 50], ["reactive oxygen species", "TREATMENT", 52, 75], ["reactive", "OBSERVATION_MODIFIER", 52, 60], ["oxygen species", "OBSERVATION", 61, 75]]], ["This process was insensitive to 30 \u00b5M DPI, an inhibitor of NADPH oxidase and to 10 \u00b5M CCCP, a mitochondrial uncoupler.", [["mitochondrial", "ANATOMY", 94, 107], ["DPI", "CHEMICAL", 38, 41], ["NADPH", "CHEMICAL", 59, 64], ["CCCP", "CHEMICAL", 86, 90], ["DPI", "CHEMICAL", 38, 41], ["NADPH", "CHEMICAL", 59, 64], ["CCCP", "CHEMICAL", 86, 90], ["DPI", "SIMPLE_CHEMICAL", 38, 41], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 59, 72], ["CCCP", "SIMPLE_CHEMICAL", 86, 90], ["mitochondrial", "CELLULAR_COMPONENT", 94, 107], ["NADPH oxidase", "PROTEIN", 59, 72], ["DPI", "TREATMENT", 38, 41], ["an inhibitor of NADPH oxidase", "TREATMENT", 43, 72], ["a mitochondrial uncoupler", "TREATMENT", 92, 117]]], ["These results indicate that iron-based nanoparticles can cause ROS synthesis and decrease glutamate uptake, potentially leading to neurodegeneration.", [["iron", "CHEMICAL", 28, 32], ["ROS", "CHEMICAL", 63, 66], ["glutamate", "CHEMICAL", 90, 99], ["neurodegeneration", "DISEASE", 131, 148], ["iron", "CHEMICAL", 28, 32], ["glutamate", "CHEMICAL", 90, 99], ["iron-based nanoparticles", "SIMPLE_CHEMICAL", 28, 52], ["ROS", "SIMPLE_CHEMICAL", 63, 66], ["glutamate", "SIMPLE_CHEMICAL", 90, 99], ["iron-based nanoparticles", "TREATMENT", 28, 52], ["ROS synthesis", "PROBLEM", 63, 76], ["decrease glutamate uptake", "PROBLEM", 81, 106], ["neurodegeneration", "PROBLEM", 131, 148], ["decrease", "OBSERVATION_MODIFIER", 81, 89], ["glutamate uptake", "OBSERVATION", 90, 106], ["potentially leading to", "UNCERTAINTY", 108, 130], ["neurodegeneration", "OBSERVATION", 131, 148]]], ["Functionalized carbon nanotubes 1 (CF-CNTs) have a promising future as vectors for drug delivery 2 and for neuronal cell growth and communications 3 .", [["neuronal cell", "ANATOMY", 107, 120], ["carbon nanotubes", "CHEMICAL", 15, 31], ["CF-CNTs", "CHEMICAL", 35, 42], ["carbon", "CHEMICAL", 15, 21], ["carbon nanotubes 1", "SIMPLE_CHEMICAL", 15, 33], ["CF-CNTs", "SIMPLE_CHEMICAL", 35, 42], ["neuronal cell", "CELL", 107, 120], ["Functionalized carbon nanotubes", "TREATMENT", 0, 31], ["drug delivery", "TREATMENT", 83, 96], ["neuronal cell growth", "PROBLEM", 107, 127], ["neuronal cell", "OBSERVATION", 107, 120]]], ["It has been demonstrated that CNTs can be employed in drug delivery systems.", [["CNTs", "CHEMICAL", 30, 34], ["CNTs", "SIMPLE_CHEMICAL", 30, 34], ["CNTs", "TREATMENT", 30, 34], ["drug delivery systems", "TREATMENT", 54, 75]]], ["The toxicological properties of CNTs result strictly correlated with nanotube solubility 4 .", [["CNTs", "SIMPLE_CHEMICAL", 32, 36], ["nanotube solubility", "TREATMENT", 69, 88]]], ["In this study we focused our attention on multi-walled CNTs (MWCNTs) because they are easy to manipulate and we covalently functionalize them in different ways to increase their solubility..", [["MWCNTs", "CHEMICAL", 61, 67], ["multi-walled CNTs", "SIMPLE_CHEMICAL", 42, 59], ["MWCNTs", "SIMPLE_CHEMICAL", 61, 67], ["this study", "TEST", 3, 13], ["multi-walled CNTs (MWCNTs", "TREATMENT", 42, 67]]], ["We grew different derivatives of a dendrimer on MWCNTs surface with positive charges at the periphery, in order to study the different solubilisation properties and correlate them to the biological activity in gene therapy 5 .P-225Slowdown of 1-40 \u03b2-peptide aggregation by addition of two synthetic biocompatible polymers P. Sciortino 1 , R. Carrotta 1 , G. Cavallaro 2 , D. Bulone 1 , P. L. San Biagio 1 1 IBF-CNR, Palermo, Italy, 2 CTF Dept., University of Palermo, Palermo, Italy Fibril deposit formation of amyloid \u03b2-protein (A\u03b2) in the brain is a hallmark of Alzheimer disease (AD).", [["brain", "ANATOMY", 541, 546], ["MWCNTs", "CHEMICAL", 48, 54], ["5 .P-225Slowdown of 1-40 \u03b2-peptide", "CHEMICAL", 223, 257], ["amyloid \u03b2-protein", "CHEMICAL", 511, 528], ["Alzheimer disease", "DISEASE", 564, 581], ["AD", "DISEASE", 583, 585], ["dendrimer", "SIMPLE_CHEMICAL", 35, 44], ["MWCNTs surface", "SIMPLE_CHEMICAL", 48, 62], [".P-225Slowdown", "SIMPLE_CHEMICAL", 225, 239], ["1-40 \u03b2-peptide", "SIMPLE_CHEMICAL", 243, 257], ["amyloid \u03b2-protein", "GENE_OR_GENE_PRODUCT", 511, 528], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 530, 532], ["brain", "ORGAN", 541, 546], ["amyloid \u03b2-protein", "PROTEIN", 511, 528], ["A\u03b2", "PROTEIN", 530, 532], ["a dendrimer on MWCNTs surface", "TREATMENT", 33, 62], ["gene therapy", "TREATMENT", 210, 222], ["peptide aggregation", "PROBLEM", 250, 269], ["two synthetic biocompatible polymers P. Sciortino", "TREATMENT", 285, 334], ["amyloid \u03b2-protein (A\u03b2) in the brain", "PROBLEM", 511, 546], ["Alzheimer disease", "PROBLEM", 564, 581], ["different derivatives", "OBSERVATION", 8, 29], ["positive charges", "OBSERVATION", 68, 84], ["Fibril deposit", "OBSERVATION", 483, 497], ["amyloid \u03b2-protein", "OBSERVATION", 511, 528], ["brain", "ANATOMY", 541, 546], ["hallmark", "OBSERVATION_MODIFIER", 552, 560], ["Alzheimer disease", "OBSERVATION", 564, 581]]], ["Fibrils formation is triggered by molecular conformational changes and protein-protein interactions involving partially unfolded regions of different A\u03b2 peptide molecules.", [["A\u03b2", "GENE_OR_GENE_PRODUCT", 150, 152], ["unfolded regions", "PROTEIN", 120, 136], ["A\u03b2 peptide molecules", "PROTEIN", 150, 170], ["Fibrils formation", "PROBLEM", 0, 17], ["molecular conformational changes and protein-protein interactions", "PROBLEM", 34, 99], ["partially unfolded regions", "PROBLEM", 110, 136], ["different", "OBSERVATION_MODIFIER", 140, 149], ["peptide molecules", "OBSERVATION", 153, 170]]], ["Increasing evidence suggests that toxicity is linked to diffusible A\u03b2 oligomers, which have been found in soluble brain extracts of AD patients, rather than to the insoluble fibres.", [["brain extracts", "ANATOMY", 114, 128], ["fibres", "ANATOMY", 174, 180], ["toxicity", "DISEASE", 34, 42], ["AD", "DISEASE", 132, 134], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 67, 69], ["brain extracts", "ORGANISM_SUBSTANCE", 114, 128], ["patients", "ORGANISM", 135, 143], ["fibres", "TISSUE", 174, 180], ["patients", "SPECIES", 135, 143], ["toxicity", "PROBLEM", 34, 42], ["A\u03b2 oligomers", "PROBLEM", 67, 79], ["toxicity", "OBSERVATION", 34, 42], ["oligomers", "OBSERVATION", 70, 79], ["brain", "ANATOMY", 114, 119]]], ["New therapeutical approach, based on searching molecules capable of regulating the peptide aggregation, is currently developing.", [["New therapeutical approach", "TREATMENT", 0, 26], ["searching molecules", "TEST", 37, 56], ["the peptide aggregation", "PROBLEM", 79, 102], ["therapeutical approach", "OBSERVATION", 4, 26], ["peptide aggregation", "OBSERVATION", 83, 102]]], ["Here, we study the effects on the aggregation of A\u03b2 1-40 peptide of two different synthetic polymers with structure similar to that of a protein (\u03b1,\u03b2-polyasparthylhydrazide -PAHy and \u03b1,\u03b2-polyasparthylhydrazide-polyethyleneglycol -PAHy-PEG).", [["A\u03b2 1-40 peptide", "CHEMICAL", 49, 64], ["\u03b1,\u03b2-polyasparthylhydrazide -PAHy and \u03b1,\u03b2-polyasparthylhydrazide-polyethyleneglycol -PAHy-PEG", "CHEMICAL", 146, 238], ["\u03b1,\u03b2-polyasparthylhydrazide -PAHy", "CHEMICAL", 146, 178], ["\u03b1,\u03b2-polyasparthylhydrazide-polyethyleneglycol -PAHy", "CHEMICAL", 183, 234], ["PEG", "CHEMICAL", 235, 238], ["A\u03b2 1-40", "SIMPLE_CHEMICAL", 49, 56], ["\u03b1,\u03b2-polyasparthylhydrazide -PAHy", "SIMPLE_CHEMICAL", 146, 178], ["\u03b1", "SIMPLE_CHEMICAL", 183, 184], ["\u03b2-polyasparthylhydrazide-polyethyleneglycol -PAHy-PEG", "SIMPLE_CHEMICAL", 185, 238], ["PAHy", "PROTEIN", 230, 234], ["A\u03b2", "TEST", 49, 51], ["two different synthetic polymers", "TREATMENT", 68, 100], ["a protein", "TEST", 135, 144], ["\u03b2-polyasparthylhydrazide", "TEST", 148, 172], ["PAHy", "TREATMENT", 174, 178], ["\u03b2-polyasparthylhydrazide", "TREATMENT", 185, 209], ["polyethyleneglycol", "TREATMENT", 210, 228], ["PAHy-PEG", "TREATMENT", 230, 238]]], ["Static and Dynamic Light Scattering measurements showed that the aggregation kinetic is slowed down by the presence of both polymers.", [["Dynamic Light Scattering measurements", "TEST", 11, 48], ["the aggregation kinetic", "PROBLEM", 61, 84], ["both polymers", "TREATMENT", 119, 132], ["aggregation kinetic", "OBSERVATION", 65, 84]]], ["Optical Microscopy revealed the presence of aggregates of different dimension in all samples.", [["samples", "ANATOMY", 85, 92], ["Optical Microscopy", "TEST", 0, 18], ["aggregates", "OBSERVATION", 44, 54], ["different", "OBSERVATION_MODIFIER", 58, 67], ["dimension", "OBSERVATION_MODIFIER", 68, 77]]], ["Transmission Electron Microscopy allowed to establish that all aggregates are made of fibers, as confirmed by Fluorescence Spectroscopy measurements on thioflavine binding.Expression of uncoupling proteins (UCPs) during neuronal differentiation and brain developmentA.", [["fibers", "ANATOMY", 86, 92], ["neuronal", "ANATOMY", 220, 228], ["brain", "ANATOMY", 249, 254], ["thioflavine", "CHEMICAL", 152, 163], ["thioflavine", "CHEMICAL", 152, 163], ["fibers", "CELLULAR_COMPONENT", 86, 92], ["thioflavine", "SIMPLE_CHEMICAL", 152, 163], ["uncoupling proteins", "GENE_OR_GENE_PRODUCT", 186, 205], ["UCPs", "GENE_OR_GENE_PRODUCT", 207, 211], ["neuronal", "CELL", 220, 228], ["brain", "ORGAN", 249, 254], ["uncoupling proteins", "PROTEIN", 186, 205], ["UCPs", "PROTEIN", 207, 211], ["Transmission Electron Microscopy", "TEST", 0, 32], ["Fluorescence Spectroscopy measurements", "TEST", 110, 148], ["thioflavine binding", "TREATMENT", 152, 171], ["uncoupling proteins (UCPs", "PROBLEM", 186, 211], ["brain", "ANATOMY", 249, 254], ["developmentA", "OBSERVATION", 255, 267]]], ["Smorodchenko 1 , D. Sittner 1 , A. Rupprecht 1 , J. Goyn 1 , A. Seiler 2 , A. U. Br\u00e4uer 1 , E. E. Pohl 1 1 Institute of Cell Biology and Neurobiology, Charit\u00e9-Universitaetsmedizin, Berlin, Germany, 2 German Federal Institute for Risk Assessment, ZEBET, Berlin, Germany UCP4 is a member of the mitochondrial anion transporter family and one of the three UCPs (UCP2, UCP4 and UCP5) associated with the nervous system.", [["Cell", "ANATOMY", 120, 124], ["mitochondrial", "ANATOMY", 293, 306], ["nervous system", "ANATOMY", 400, 414], ["Cell", "CELL", 120, 124], ["UCP4", "GENE_OR_GENE_PRODUCT", 269, 273], ["mitochondrial", "CELLULAR_COMPONENT", 293, 306], ["UCPs", "GENE_OR_GENE_PRODUCT", 353, 357], ["UCP2", "GENE_OR_GENE_PRODUCT", 359, 363], ["UCP4", "GENE_OR_GENE_PRODUCT", 365, 369], ["UCP5", "GENE_OR_GENE_PRODUCT", 374, 378], ["nervous system", "ANATOMICAL_SYSTEM", 400, 414], ["mitochondrial anion transporter family", "PROTEIN", 293, 331], ["UCPs", "PROTEIN", 353, 357], ["UCP2", "PROTEIN", 359, 363], ["UCP4", "PROTEIN", 365, 369], ["UCP5", "PROTEIN", 374, 378], ["nervous system", "ANATOMY", 400, 414]]], ["In our previous work we have shown that UCP4 appears in brain at embryonic day 14 (E14).", [["brain", "ANATOMY", 56, 61], ["embryonic", "ANATOMY", 65, 74], ["UCP4", "GENE_OR_GENE_PRODUCT", 40, 44], ["brain", "ORGAN", 56, 61], ["UCP4", "PROTEIN", 40, 44], ["brain", "ANATOMY", 56, 61]]], ["We hypothesized that the UCP4 expression can be related to neuronal differentiation.", [["neuronal", "ANATOMY", 59, 67], ["UCP4", "GENE_OR_GENE_PRODUCT", 25, 29], ["neuronal", "CELL", 59, 67], ["UCP4", "PROTEIN", 25, 29], ["can be related to", "UNCERTAINTY", 41, 58], ["neuronal differentiation", "OBSERVATION", 59, 83]]], ["To prove this idea we now investigated protein and mRNA levels in two different systems: (i) mouse embryonic stem cells of line D3 (mESC) and (ii) brains from pre-and postnatal mice.", [["embryonic stem cells", "ANATOMY", 99, 119], ["line D3", "ANATOMY", 123, 130], ["mESC", "ANATOMY", 132, 136], ["brains", "ANATOMY", 147, 153], ["mouse", "ORGANISM", 93, 98], ["embryonic stem cells", "CELL", 99, 119], ["line D3", "CELL", 123, 130], ["mESC", "CELL", 132, 136], ["brains", "ORGAN", 147, 153], ["mice", "ORGANISM", 177, 181], ["mouse embryonic stem cells", "CELL_LINE", 93, 119], ["line D3", "CELL_LINE", 123, 130], ["mESC", "CELL_LINE", 132, 136], ["mouse", "SPECIES", 93, 98], ["mice", "SPECIES", 177, 181], ["mouse", "SPECIES", 93, 98], ["mice", "SPECIES", 177, 181], ["mRNA levels", "TEST", 51, 62], ["mouse embryonic stem cells", "PROBLEM", 93, 119], ["embryonic stem cells", "OBSERVATION", 99, 119]]], ["UCP4 was not present in undifferentiated mESC.", [["mESC", "ANATOMY", 41, 45], ["UCP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["mESC", "CELL", 41, 45], ["UCP4", "PROTEIN", 0, 4], ["undifferentiated mESC", "CELL_TYPE", 24, 45], ["not present", "UNCERTAINTY", 9, 20], ["undifferentiated mESC", "OBSERVATION", 24, 45]]], ["During differentiation of mESC in neurons the expression of neuronal marker MAP2 and UCP4 started at the same time -as early as on day 7 in culture -and were increasing simultaneously. (ii) The comparative analysis of gene transcripts prepared from whole embryos, brains and different brain regions (neocortex, hippocampus, cerebellum) demonstrated that levels of UCP4 mRNA were increasing from E8 till E19, reached an expression peak between E19 and postnatal day 0 (P0) and remained constant in adult animals.", [["mESC", "ANATOMY", 26, 30], ["neurons", "ANATOMY", 34, 41], ["neuronal", "ANATOMY", 60, 68], ["embryos", "ANATOMY", 255, 262], ["brains", "ANATOMY", 264, 270], ["brain regions", "ANATOMY", 285, 298], ["neocortex", "ANATOMY", 300, 309], ["hippocampus", "ANATOMY", 311, 322], ["cerebellum", "ANATOMY", 324, 334], ["mESC", "CELL", 26, 30], ["neurons", "CELL", 34, 41], ["neuronal", "CELL", 60, 68], ["MAP2", "GENE_OR_GENE_PRODUCT", 76, 80], ["UCP4", "GENE_OR_GENE_PRODUCT", 85, 89], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 255, 262], ["brains", "MULTI-TISSUE_STRUCTURE", 264, 270], ["brain regions", "MULTI-TISSUE_STRUCTURE", 285, 298], ["neocortex", "MULTI-TISSUE_STRUCTURE", 300, 309], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 311, 322], ["cerebellum", "ORGAN", 324, 334], ["UCP4", "GENE_OR_GENE_PRODUCT", 364, 368], ["E19", "GENE_OR_GENE_PRODUCT", 403, 406], ["mESC", "CELL_LINE", 26, 30], ["MAP2", "PROTEIN", 76, 80], ["UCP4", "PROTEIN", 85, 89], ["UCP4 mRNA", "RNA", 364, 373], ["neuronal marker MAP2", "TEST", 60, 80], ["UCP4", "TEST", 85, 89], ["culture", "TEST", 140, 147], ["The comparative analysis", "TEST", 190, 214], ["gene transcripts", "TREATMENT", 218, 234], ["levels of UCP4 mRNA", "TEST", 354, 373], ["mESC", "OBSERVATION", 26, 30], ["different", "ANATOMY_MODIFIER", 275, 284], ["brain", "ANATOMY", 285, 290], ["regions", "ANATOMY_MODIFIER", 291, 298], ["neocortex", "ANATOMY", 300, 309], ["hippocampus", "ANATOMY", 311, 322], ["cerebellum", "ANATOMY", 324, 334], ["constant", "OBSERVATION_MODIFIER", 485, 493]]], ["In contrast, expression of UCP5 was increasing permanently until birth, whereas UCP2 expression was invariant in time.", [["UCP5", "GENE_OR_GENE_PRODUCT", 27, 31], ["UCP2", "GENE_OR_GENE_PRODUCT", 80, 84], ["UCP5", "PROTEIN", 27, 31], ["UCP2", "PROTEIN", 80, 84], ["UCP5", "TREATMENT", 27, 31]]], ["Our results suggest that UCP4 contributes to specific neuronal functions.O-231The plant hormone abscisic acid stimulates the proliferation of human hemopoietic progenitors through the second messenger cyclic ADP-ribose S. Scarf\u00ec 1 , C. Fresia 2 , C. Ferraris 1 , S. Bruzzone 2 , F. Fruscione 1 , C. Usai 3 , M. Magnone 2 , M. Podest\u00e0 4 , L. Sturla 2 , L. Guida 2 , G. Damonte 2 , A. Salis 2 , A. de Flora 2 , E. Zocchi 2 1 Advanced Biotechnology Center, Genova, Italy, 2 Dept of Experimental Medicine, Biochemistry Section, and CEBR, University of Genova, Italy;, 3 Institute of Biophysics, CNR, Genova, Italy, 4 Stem Cell Center, S. Martino Hospital, Genova, Italy Abscisic acid (ABA) is a hormone involved in pivotal physiological functions in higher plants.", [["neuronal", "ANATOMY", 54, 62], ["hemopoietic progenitors", "ANATOMY", 148, 171], ["Cell", "ANATOMY", 618, 622], ["UCP4", "CHEMICAL", 25, 29], ["O-231", "CHEMICAL", 73, 78], ["abscisic acid", "CHEMICAL", 96, 109], ["ADP", "CHEMICAL", 208, 211], ["Abscisic acid", "CHEMICAL", 666, 679], ["ABA", "CHEMICAL", 681, 684], ["abscisic acid", "CHEMICAL", 96, 109], ["ADP", "CHEMICAL", 208, 211], ["ribose", "CHEMICAL", 212, 218], ["UCP4", "GENE_OR_GENE_PRODUCT", 25, 29], ["neuronal", "CELL", 54, 62], ["O-231", "SIMPLE_CHEMICAL", 73, 78], ["abscisic acid", "SIMPLE_CHEMICAL", 96, 109], ["human", "ORGANISM", 142, 147], ["hemopoietic progenitors", "CELL", 148, 171], ["ADP", "SIMPLE_CHEMICAL", 208, 211], ["Abscisic acid", "SIMPLE_CHEMICAL", 666, 679], ["ABA", "SIMPLE_CHEMICAL", 681, 684], ["UCP4", "PROTEIN", 25, 29], ["human hemopoietic progenitors", "CELL_TYPE", 142, 171], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["The plant hormone abscisic acid", "TEST", 78, 109], ["human hemopoietic progenitors", "TREATMENT", 142, 171], ["the second messenger cyclic ADP", "TREATMENT", 180, 211], ["Ferraris", "TEST", 250, 258], ["Bruzzone", "TREATMENT", 266, 274], ["Experimental Medicine", "TREATMENT", 479, 500], ["human hemopoietic progenitors", "OBSERVATION", 142, 171], ["Genova", "ANATOMY", 596, 602], ["Abscisic acid", "OBSERVATION", 666, 679], ["higher plants", "OBSERVATION", 746, 759]]], ["Recently, ABA was demonstrated to be produced by human granulocytes, \u03b2 pancreatic cells and mesenchymal stem cells (MSC) and to stimulate cell-specific functions.", [["granulocytes", "ANATOMY", 55, 67], ["\u03b2 pancreatic cells", "ANATOMY", 69, 87], ["mesenchymal stem cells", "ANATOMY", 92, 114], ["MSC", "ANATOMY", 116, 119], ["cell", "ANATOMY", 138, 142], ["ABA", "CHEMICAL", 10, 13], ["ABA", "SIMPLE_CHEMICAL", 10, 13], ["human", "ORGANISM", 49, 54], ["granulocytes", "CELL", 55, 67], ["\u03b2 pancreatic cells", "CELL", 69, 87], ["mesenchymal stem cells", "CELL", 92, 114], ["MSC", "CELL", 116, 119], ["cell", "CELL", 138, 142], ["human granulocytes", "CELL_TYPE", 49, 67], ["\u03b2 pancreatic cells", "CELL_TYPE", 69, 87], ["mesenchymal stem cells", "CELL_TYPE", 92, 114], ["MSC", "CELL_TYPE", 116, 119], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["ABA", "TEST", 10, 13], ["human granulocytes", "TEST", 49, 67], ["mesenchymal stem cells", "PROBLEM", 92, 114], ["pancreatic", "ANATOMY", 71, 81], ["mesenchymal stem cells", "OBSERVATION", 92, 114]]], ["Here we show that ABA expands human hemopoietic progenitors in vitro, through a cADPR-mediated increase of the intracellular calcium concentration.", [["hemopoietic progenitors", "ANATOMY", 36, 59], ["intracellular", "ANATOMY", 111, 124], ["ABA", "CHEMICAL", 18, 21], ["cADPR", "CHEMICAL", 80, 85], ["calcium", "CHEMICAL", 125, 132], ["ABA", "CHEMICAL", 18, 21], ["cADPR", "CHEMICAL", 80, 85], ["calcium", "CHEMICAL", 125, 132], ["ABA", "SIMPLE_CHEMICAL", 18, 21], ["human", "ORGANISM", 30, 35], ["hemopoietic progenitors", "CELL", 36, 59], ["cADPR", "SIMPLE_CHEMICAL", 80, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 124], ["calcium", "SIMPLE_CHEMICAL", 125, 132], ["human hemopoietic progenitors", "CELL_TYPE", 30, 59], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["human hemopoietic progenitors", "TREATMENT", 30, 59], ["a cADPR", "TREATMENT", 78, 85], ["the intracellular calcium concentration", "TREATMENT", 107, 146], ["human hemopoietic progenitors", "OBSERVATION", 30, 59]]], ["Incubation of CD34 + cells with micromolar ABA also induces transcriptional effects, which include NF-\u03baB nuclear translocation and transcription of cytokines encoding genes.", [["CD34 + cells", "ANATOMY", 14, 26], ["nuclear", "ANATOMY", 105, 112], ["ABA", "CHEMICAL", 43, 46], ["ABA", "CHEMICAL", 43, 46], ["CD34", "GENE_OR_GENE_PRODUCT", 14, 18], ["ABA", "SIMPLE_CHEMICAL", 43, 46], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 99, 104], ["CD34 + cells", "CELL_TYPE", 14, 26], ["NF-\u03baB", "PROTEIN", 99, 104], ["cytokines", "PROTEIN", 148, 157], ["micromolar ABA", "TREATMENT", 32, 46], ["transcriptional effects", "PROBLEM", 60, 83]]], ["Stimulated human MSC produce and release ABA at concentrations sufficient to exert growth-stimulatory effects on co-cultured CD34 + cells, as demonstrated by the inhibition of colony growth in the presence of an anti-ABA monoclonal antibody.", [["MSC", "ANATOMY", 17, 20], ["CD34 + cells", "ANATOMY", 125, 137], ["colony", "ANATOMY", 176, 182], ["ABA", "CHEMICAL", 41, 44], ["human", "ORGANISM", 11, 16], ["MSC", "CELL", 17, 20], ["ABA", "SIMPLE_CHEMICAL", 41, 44], ["CD34", "GENE_OR_GENE_PRODUCT", 125, 129], ["anti-ABA", "GENE_OR_GENE_PRODUCT", 212, 220], ["human MSC", "CELL_TYPE", 11, 20], ["co-cultured CD34 + cells", "CELL_LINE", 113, 137], ["anti-ABA monoclonal antibody", "PROTEIN", 212, 240], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["stimulatory effects", "PROBLEM", 90, 109], ["co-cultured CD34 + cells", "PROBLEM", 113, 137], ["colony growth", "PROBLEM", 176, 189], ["an anti-ABA monoclonal antibody", "PROBLEM", 209, 240], ["colony growth", "OBSERVATION", 176, 189], ["monoclonal antibody", "OBSERVATION", 221, 240]]], ["These results provide a remarkable example of conservation of a stress-hormone from plants to humans and identify ABA as a new hemopoietic growth factor involved in the cross-talk between HP and MSC.Spontaneously proliferating and differentiating cells in the culture of new born rat cardiomyocytesT.", [["MSC", "ANATOMY", 195, 198], ["cells", "ANATOMY", 247, 252], ["cardiomyocytes", "ANATOMY", 284, 298], ["ABA", "CHEMICAL", 114, 117], ["humans", "ORGANISM", 94, 100], ["ABA", "GENE_OR_GENE_PRODUCT", 114, 117], ["HP", "CELL", 188, 190], ["MSC", "CELL", 195, 198], ["cells", "CELL", 247, 252], ["rat", "ORGANISM", 280, 283], ["cardiomyocytes", "CELL", 284, 298], ["hemopoietic growth factor", "PROTEIN", 127, 152], ["MSC", "CELL_TYPE", 195, 198], ["Spontaneously proliferating and differentiating cells", "CELL_TYPE", 199, 252], ["rat cardiomyocytes", "CELL_TYPE", 280, 298], ["humans", "SPECIES", 94, 100], ["rat", "SPECIES", 280, 283], ["T.", "SPECIES", 298, 300], ["humans", "SPECIES", 94, 100], ["rat", "SPECIES", 280, 283], ["T.", "SPECIES", 298, 300], ["a stress-hormone", "PROBLEM", 62, 78], ["a new hemopoietic growth factor", "PROBLEM", 121, 152], ["Spontaneously proliferating and differentiating cells", "PROBLEM", 199, 252], ["the culture", "TEST", 256, 267], ["MSC", "ANATOMY", 195, 198], ["proliferating", "OBSERVATION_MODIFIER", 213, 226], ["differentiating cells", "OBSERVATION", 231, 252]]], ["Golovanova, G. B. Belostotskaya Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia A subpopulation of small cells (volume 141\u00b16 \u00b5m 3 ) have been found in the neonatal cardiac myocytes culture whereas the same parameter of the remaining cells was 819\u00b168 \u00b5m 3 on the 1 st day.", [["small cells", "ANATOMY", 169, 180], ["neonatal cardiac myocytes", "ANATOMY", 225, 250], ["cells", "ANATOMY", 303, 308], ["small cells", "CELL", 169, 180], ["cardiac myocytes", "CELL", 234, 250], ["cells", "CELL", 303, 308], ["small cells", "CELL_TYPE", 169, 180], ["small cells", "PROBLEM", 169, 180], ["volume", "TEST", 182, 188], ["the neonatal cardiac myocytes culture", "TEST", 221, 258], ["small cells", "OBSERVATION", 169, 180], ["cardiac myocytes", "ANATOMY", 234, 250], ["remaining cells", "OBSERVATION", 293, 308]]], ["In contrast to main part of hypetrofied cardiomyocytes, the small cells were able to proliferate, form colonies and differentiate spontaneously into cardiac myocytes in the culture.", [["cardiomyocytes", "ANATOMY", 40, 54], ["small cells", "ANATOMY", 60, 71], ["colonies", "ANATOMY", 103, 111], ["cardiac myocytes", "ANATOMY", 149, 165], ["cardiomyocytes", "CELL", 40, 54], ["cells", "CELL", 66, 71], ["cardiac myocytes", "CELL", 149, 165], ["hypetrofied cardiomyocytes", "CELL_TYPE", 28, 54], ["cardiac myocytes", "CELL_TYPE", 149, 165], ["hypetrofied cardiomyocytes", "PROBLEM", 28, 54], ["the small cells", "PROBLEM", 56, 71], ["the culture", "TEST", 169, 180], ["hypetrofied cardiomyocytes", "ANATOMY", 28, 54], ["small cells", "OBSERVATION", 60, 71], ["cardiac myocytes", "ANATOMY", 149, 165]]], ["On the 8 th day there were slight, slow (2-3 beats/min), arrhythmic contractions in the centre of colonies.", [["colonies", "ANATOMY", 98, 106], ["arrhythmic contractions", "DISEASE", 57, 80], ["slight, slow (2-3 beats/min)", "PROBLEM", 27, 55], ["arrhythmic contractions in the centre of colonies", "PROBLEM", 57, 106], ["slight", "OBSERVATION_MODIFIER", 27, 33], ["slow", "OBSERVATION_MODIFIER", 35, 39], ["arrhythmic contractions", "OBSERVATION", 57, 80]]], ["Pulsing cells were not united by common contraction and had individual beating profile.", [["cells", "ANATOMY", 8, 13], ["cells", "CELL", 8, 13], ["Pulsing cells", "CELL_TYPE", 0, 13], ["Pulsing cells", "PROBLEM", 0, 13]]], ["On the 11-12 th days, the colonies displayed comprehensive contractile activity with the pulsation rate 25-28 beats/min and reached 46 beats/min on the 23 d -25 th day and 58 beats/min on the 26-30 th days in the culture.", [["colonies", "ANATOMY", 26, 34], ["the colonies", "TEST", 22, 34], ["the pulsation rate", "TEST", 85, 103], ["the culture", "TEST", 209, 220], ["contractile activity", "OBSERVATION", 59, 79]]], ["It has been shown that receptors of the surface membrane and sarcoplasmic reticulum of colony cells gradually mature.", [["surface membrane", "ANATOMY", 40, 56], ["sarcoplasmic reticulum", "ANATOMY", 61, 83], ["colony cells", "ANATOMY", 87, 99], ["surface membrane", "CELLULAR_COMPONENT", 40, 56], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 61, 83], ["colony cells", "CELL", 87, 99], ["colony cells", "CELL_TYPE", 87, 99], ["the surface membrane", "TEST", 36, 56], ["sarcoplasmic reticulum of colony cells", "PROBLEM", 61, 99], ["surface membrane", "OBSERVATION", 40, 56], ["sarcoplasmic reticulum", "OBSERVATION", 61, 83], ["colony cells", "OBSERVATION", 87, 99], ["gradually", "OBSERVATION_MODIFIER", 100, 109], ["mature", "OBSERVATION_MODIFIER", 110, 116]]], ["By estimating the Ca 2+ transition under the specific agonists action: acetylcholine, KCl and caffeine, we have detected the activity of basic structural and functional elements of excitation-contraction coupling in contractile cells inside colonies.", [["contractile cells", "ANATOMY", 216, 233], ["colonies", "ANATOMY", 241, 249], ["Ca", "CHEMICAL", 18, 20], ["acetylcholine", "CHEMICAL", 71, 84], ["KCl", "CHEMICAL", 86, 89], ["caffeine", "CHEMICAL", 94, 102], ["Ca 2+", "CHEMICAL", 18, 23], ["acetylcholine", "CHEMICAL", 71, 84], ["KCl", "CHEMICAL", 86, 89], ["caffeine", "CHEMICAL", 94, 102], ["acetylcholine", "SIMPLE_CHEMICAL", 71, 84], ["KCl", "SIMPLE_CHEMICAL", 86, 89], ["caffeine", "SIMPLE_CHEMICAL", 94, 102], ["contractile cells", "CELL", 216, 233], ["colonies", "CELL", 241, 249], ["contractile cells", "CELL_TYPE", 216, 233], ["acetylcholine", "TREATMENT", 71, 84], ["KCl", "TREATMENT", 86, 89], ["caffeine", "TREATMENT", 94, 102], ["contraction coupling in contractile cells inside colonies", "PROBLEM", 192, 249], ["contractile cells", "OBSERVATION", 216, 233]]], ["The small cells ability to proliferate and differentiate under the influence of near mature cardiomyocytes allows us to put forward a hypothesis, that they belong to a category of resident stem cells.", [["cells", "ANATOMY", 10, 15], ["cardiomyocytes", "ANATOMY", 92, 106], ["stem cells", "ANATOMY", 189, 199], ["cells", "CELL", 10, 15], ["cardiomyocytes", "CELL", 92, 106], ["stem cells", "CELL", 189, 199], ["mature cardiomyocytes", "CELL_TYPE", 85, 106], ["resident stem cells", "CELL_TYPE", 180, 199], ["The small cells", "PROBLEM", 0, 15], ["near mature cardiomyocytes", "PROBLEM", 80, 106], ["small cells", "OBSERVATION", 4, 15], ["stem cells", "OBSERVATION", 189, 199]]], ["Changes in the gating properties of Na + channels were studied in ES-derived neural stem (NS) cells during in vitro neuronal differentiation with the use of the whole-cell and cell-attached variants of patch-clamp technique.", [["ES-derived neural stem (NS) cells", "ANATOMY", 66, 99], ["neuronal", "ANATOMY", 116, 124], ["whole-cell", "ANATOMY", 161, 171], ["cell", "ANATOMY", 176, 180], ["Na", "CHEMICAL", 36, 38], ["Na +", "CHEMICAL", 36, 40], ["Na +", "SIMPLE_CHEMICAL", 36, 40], ["ES-derived neural stem (NS) cells", "CELL", 66, 99], ["neuronal", "CELL", 116, 124], ["cell", "CELL", 167, 171], ["cell", "CELL", 176, 180], ["Na + channels", "PROTEIN", 36, 49], ["ES-derived neural stem (NS) cells", "CELL_LINE", 66, 99], ["Na + channels", "TREATMENT", 36, 49], ["neural stem (NS) cells", "TREATMENT", 77, 99], ["the whole-cell", "TREATMENT", 157, 171], ["patch-clamp technique", "TREATMENT", 202, 223], ["neural stem", "ANATOMY", 77, 88]]], ["NS cells represent a novel stem cell population remaining stable and highly neurogenic over multiple passages.Voltage-clamp recordings during neuronal differentiation of NS cells indicated significant changes in the key properties of Na + currents.", [["NS cells", "ANATOMY", 0, 8], ["stem cell", "ANATOMY", 27, 36], ["neuronal", "ANATOMY", 142, 150], ["NS cells", "ANATOMY", 170, 178], ["Na", "CHEMICAL", 234, 236], ["Na +", "CHEMICAL", 234, 238], ["NS cells", "CELL", 0, 8], ["stem cell", "CELL", 27, 36], ["neuronal", "CELL", 142, 150], ["NS cells", "CELL", 170, 178], ["Na +", "SIMPLE_CHEMICAL", 234, 238], ["NS cells", "CELL_TYPE", 0, 8], ["novel stem cell population", "CELL_LINE", 21, 47], ["NS cells", "CELL_TYPE", 170, 178], ["Na", "PROTEIN", 234, 236], ["NS cells", "TREATMENT", 0, 8], ["a novel stem cell population", "TREATMENT", 19, 47], ["highly neurogenic", "PROBLEM", 69, 86], ["Voltage", "TEST", 110, 117], ["clamp recordings", "TEST", 118, 134], ["NS cells", "PROBLEM", 170, 178], ["significant changes", "PROBLEM", 189, 208], ["stem cell", "OBSERVATION", 27, 36], ["stable", "OBSERVATION_MODIFIER", 58, 64], ["highly", "OBSERVATION_MODIFIER", 69, 75], ["neurogenic", "OBSERVATION_MODIFIER", 76, 86], ["multiple", "OBSERVATION_MODIFIER", 92, 100], ["passages", "OBSERVATION", 101, 109], ["NS cells", "OBSERVATION", 170, 178], ["significant", "OBSERVATION_MODIFIER", 189, 200]]], ["A voltage-gated and tetrodotoxine-sensitive Na + current,absent under self-renewal conditions, was first recorded following application of differentiative agents.", [["tetrodotoxine", "CHEMICAL", 20, 33], ["Na", "CHEMICAL", 44, 46], ["tetrodotoxine", "CHEMICAL", 20, 33], ["Na +", "CHEMICAL", 44, 48], ["tetrodotoxine", "SIMPLE_CHEMICAL", 20, 33], ["Na +", "SIMPLE_CHEMICAL", 44, 48], ["Na", "PROTEIN", 44, 46], ["A voltage", "TEST", 0, 9], ["tetrodotoxine", "TEST", 20, 33], ["differentiative agents", "TREATMENT", 139, 161]]], ["Current density increased with time of exposure to differentiating conditions.", [["density", "OBSERVATION", 8, 15], ["increased", "OBSERVATION_MODIFIER", 16, 25]]], ["Whole-cell and single channel analysis revealed that the observed increase in current density was due at least in part to changes in steady-state activation and inactivation properties.", [["Whole-cell", "ANATOMY", 0, 10], ["cell", "CELL", 6, 10], ["single channel analysis", "TEST", 15, 38], ["the observed increase in current density", "PROBLEM", 53, 93], ["inactivation properties", "TREATMENT", 161, 184], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["density", "OBSERVATION", 86, 93]]], ["Furthermore, a contribution to the increase in Na + current density could also be given by an enhancement in channel expression, as suggested by an augmentation in the number of single channels per patch area, with increasing neuronal differentiation.", [["patch area", "ANATOMY", 198, 208], ["neuronal", "ANATOMY", 226, 234], ["Na", "CHEMICAL", 47, 49], ["Na +", "CHEMICAL", 47, 51], ["Na +", "SIMPLE_CHEMICAL", 47, 51], ["neuronal", "CELL", 226, 234], ["Na", "PROTEIN", 47, 49], ["the increase in Na + current density", "PROBLEM", 31, 67], ["increasing neuronal differentiation", "PROBLEM", 215, 250], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["density", "OBSERVATION", 60, 67], ["enhancement", "OBSERVATION", 94, 105], ["channel expression", "OBSERVATION", 109, 127], ["augmentation", "OBSERVATION", 148, 160], ["increasing", "OBSERVATION_MODIFIER", 215, 225], ["neuronal differentiation", "OBSERVATION", 226, 250]]], ["Interestingly, those changes in Na + channel activity well correlate with the capability of NS cells to generate action potentials during in vitro neuronal differentiation.Regulation of self-renewal in Cancer Stem CellsA.", [["NS cells", "ANATOMY", 92, 100], ["neuronal", "ANATOMY", 147, 155], ["Cancer Stem CellsA", "ANATOMY", 202, 220], ["Na", "CHEMICAL", 32, 34], ["Cancer", "DISEASE", 202, 208], ["Na +", "CHEMICAL", 32, 36], ["Na + channel", "GENE_OR_GENE_PRODUCT", 32, 44], ["NS cells", "CELL", 92, 100], ["neuronal", "CELL", 147, 155], ["Cancer Stem CellsA", "CANCER", 202, 220], ["Na", "PROTEIN", 32, 34], ["NS cells", "CELL_TYPE", 92, 100], ["Cancer Stem CellsA", "CELL_LINE", 202, 220], ["NS cells", "TREATMENT", 92, 100], ["action potentials", "TEST", 113, 130], ["Cancer Stem CellsA", "OBSERVATION", 202, 220]]], ["Viale, G. Bonizzi, A. Cicalese, F. de Franco, C. Pasi, S. Pece, A. Orleth, P. Di Fiore, P. Pelicci European Institute of Oncology, Milan, ItalyRegulation of self-renewal in Cancer Stem CellsWe are characterizing the biological differences between normal and transformed SCs.", [["Cancer Stem CellsWe", "ANATOMY", 173, 192], ["SCs", "ANATOMY", 270, 273], ["Cancer", "DISEASE", 173, 179], ["Cancer Stem CellsWe", "CELL", 173, 192], ["SCs", "CELL", 270, 273], ["normal and transformed SCs", "CELL_TYPE", 247, 273], ["normal", "OBSERVATION", 247, 253]]], ["SCs are defined by their ability to generate more SCs, termed self-renewal, and to produce cells that differentiate (asymmetric cell division).", [["SCs", "ANATOMY", 0, 3], ["SCs", "ANATOMY", 50, 53], ["cells", "ANATOMY", 91, 96], ["cell", "ANATOMY", 128, 132], ["SCs", "CELL", 0, 3], ["SCs", "CELL", 50, 53], ["cells", "CELL", 91, 96], ["cell", "CELL", 128, 132], ["SCs", "CELL_TYPE", 0, 3], ["SCs", "CELL_TYPE", 50, 53], ["asymmetric cell division", "OBSERVATION", 117, 141]]], ["SCs, however, possess the ability to expand in number (i.e. during development, in adulthood after injury/disease); this increase is not accounted by asymmetric divisions, in which only one daughter cell maintains SC identity.", [["SCs", "ANATOMY", 0, 3], ["daughter cell", "ANATOMY", 190, 203], ["SC", "ANATOMY", 214, 216], ["injury/disease", "DISEASE", 99, 113], ["SCs", "CELL", 0, 3], ["daughter cell", "CELL", 190, 203], ["SC", "CELL", 214, 216], ["SCs", "CELL_TYPE", 0, 3], ["injury", "PROBLEM", 99, 105], ["disease", "PROBLEM", 106, 113], ["disease", "OBSERVATION", 106, 113], ["not accounted", "UNCERTAINTY", 133, 146], ["asymmetric", "OBSERVATION_MODIFIER", 150, 160], ["divisions", "OBSERVATION", 161, 170]]], ["Recent findings in invertebrates indicate that SCs can also generate daughter cells destined to acquire the same fate (symmetric cell division).", [["SCs", "ANATOMY", 47, 50], ["cells", "ANATOMY", 78, 83], ["cell", "ANATOMY", 129, 133], ["SCs", "CELL", 47, 50], ["cells", "CELL", 78, 83], ["cell", "CELL", 129, 133], ["SCs", "CELL_TYPE", 47, 50], ["daughter cells", "CELL_TYPE", 69, 83], ["SCs", "PROBLEM", 47, 50]]], ["On the other hand, SC quiescence is critical to maintain tissue homeostasis after injury.", [["SC", "ANATOMY", 19, 21], ["tissue", "ANATOMY", 57, 63], ["SC", "CELL", 19, 21], ["tissue", "TISSUE", 57, 63], ["injury", "PROBLEM", 82, 88]]], ["Here we show increased symmetric divisions of CSCs in breast tumors (due to inactivation of the p53 tumor suppressor) and dependency of leukemia development on quiescent leukemia SCs (due to transcriptional up-regulation of the cell cycle inhibitor p21 by leukemia-associated fusion proteins).", [["CSCs", "ANATOMY", 46, 50], ["breast tumors", "ANATOMY", 54, 67], ["tumor", "ANATOMY", 100, 105], ["leukemia", "ANATOMY", 136, 144], ["leukemia SCs", "ANATOMY", 170, 182], ["cell", "ANATOMY", 228, 232], ["leukemia", "ANATOMY", 256, 264], ["breast tumors", "DISEASE", 54, 67], ["tumor", "DISEASE", 100, 105], ["leukemia", "DISEASE", 136, 144], ["leukemia", "DISEASE", 170, 178], ["leukemia", "DISEASE", 256, 264], ["CSCs", "CELL", 46, 50], ["breast tumors", "CANCER", 54, 67], ["p53", "GENE_OR_GENE_PRODUCT", 96, 99], ["tumor", "CANCER", 100, 105], ["leukemia", "CANCER", 136, 144], ["quiescent leukemia SCs", "CELL", 160, 182], ["cell", "CELL", 228, 232], ["p21", "GENE_OR_GENE_PRODUCT", 249, 252], ["leukemia", "CANCER", 256, 264], ["-associated fusion proteins", "GENE_OR_GENE_PRODUCT", 264, 291], ["CSCs", "CELL_TYPE", 46, 50], ["p53", "PROTEIN", 96, 99], ["quiescent leukemia SCs", "CELL_TYPE", 160, 182], ["cell cycle inhibitor", "PROTEIN", 228, 248], ["p21", "PROTEIN", 249, 252], ["leukemia-associated fusion proteins", "PROTEIN", 256, 291], ["CSCs in breast tumors", "PROBLEM", 46, 67], ["the p53 tumor suppressor", "TREATMENT", 92, 116], ["leukemia development", "PROBLEM", 136, 156], ["quiescent leukemia SCs", "PROBLEM", 160, 182], ["the cell cycle inhibitor p21", "TREATMENT", 224, 252], ["leukemia", "PROBLEM", 256, 264], ["associated fusion proteins", "TREATMENT", 265, 291], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["symmetric", "OBSERVATION_MODIFIER", 23, 32], ["divisions", "OBSERVATION_MODIFIER", 33, 42], ["CSCs", "OBSERVATION_MODIFIER", 46, 50], ["breast", "ANATOMY", 54, 60], ["tumors", "OBSERVATION", 61, 67], ["leukemia", "OBSERVATION", 136, 144], ["quiescent leukemia SCs", "OBSERVATION", 160, 182]]], ["We suggest that SC asymmetric divisions function as a mechanism of tumor suppression, that SC quiescence is critical to the maintenance of the transformed clone and that symmetric divisions of SCs permit their geometric expansion.Therapeutic plasticity of adult stem cells for neurological diseasesA.", [["tumor", "ANATOMY", 67, 72], ["SC", "ANATOMY", 91, 93], ["clone", "ANATOMY", 155, 160], ["SCs", "ANATOMY", 193, 196], ["adult stem cells", "ANATOMY", 256, 272], ["neurological", "ANATOMY", 277, 289], ["tumor", "DISEASE", 67, 72], ["neurological diseasesA", "DISEASE", 277, 299], ["SC", "CELL", 16, 18], ["tumor", "CANCER", 67, 72], ["SC", "CELL", 91, 93], ["clone", "CELL", 155, 160], ["SCs", "CELL", 193, 196], ["adult stem cells", "CELL", 256, 272], ["transformed clone", "CELL_LINE", 143, 160], ["SCs", "CELL_TYPE", 193, 196], ["adult stem cells", "CELL_TYPE", 256, 272], ["tumor suppression", "PROBLEM", 67, 84], ["the transformed clone", "TREATMENT", 139, 160], ["SCs", "PROBLEM", 193, 196], ["adult stem cells", "TREATMENT", 256, 272], ["neurological diseasesA", "PROBLEM", 277, 299], ["tumor", "OBSERVATION", 67, 72], ["symmetric", "OBSERVATION_MODIFIER", 170, 179], ["adult stem cells", "OBSERVATION", 256, 272]]], ["Uccelli Department of Neurosciences Ophthalmology and Genetics, Genoa, Italy Stem cells are considered as a possible source of cells for tissue repair.", [["Stem cells", "ANATOMY", 77, 87], ["cells", "ANATOMY", 127, 132], ["tissue", "ANATOMY", 137, 143], ["Stem cells", "CELL", 77, 87], ["cells", "CELL", 127, 132], ["tissue", "TISSUE", 137, 143], ["tissue repair", "TREATMENT", 137, 150], ["repair", "OBSERVATION", 144, 150]]], ["In this scenario damaged tissues will be reconstructed by newly formed cells with the result of a recovery of lost functions.", [["tissues", "ANATOMY", 25, 32], ["cells", "ANATOMY", 71, 76], ["tissues", "TISSUE", 25, 32], ["cells", "CELL", 71, 76], ["newly formed cells", "PROBLEM", 58, 76]]], ["Thus, the rationale for utilizing stem cells for the treatment of neurological diseases such as multiple sclerosis (MS) stemmed from the idea that they differentiate in neural cells regenerating the damaged tissues at the basis of irreversibile disability.", [["stem cells", "ANATOMY", 34, 44], ["neurological", "ANATOMY", 66, 78], ["neural cells", "ANATOMY", 169, 181], ["tissues", "ANATOMY", 207, 214], ["neurological diseases", "DISEASE", 66, 87], ["multiple sclerosis", "DISEASE", 96, 114], ["MS", "DISEASE", 116, 118], ["irreversibile disability", "DISEASE", 231, 255], ["stem cells", "CELL", 34, 44], ["neural cells", "CELL", 169, 181], ["tissues", "TISSUE", 207, 214], ["stem cells", "CELL_TYPE", 34, 44], ["neural cells", "CELL_TYPE", 169, 181], ["stem cells", "TREATMENT", 34, 44], ["neurological diseases", "PROBLEM", 66, 87], ["multiple sclerosis (MS)", "PROBLEM", 96, 119], ["neural cells", "PROBLEM", 169, 181], ["irreversibile disability", "PROBLEM", 231, 255], ["multiple", "OBSERVATION_MODIFIER", 96, 104], ["sclerosis", "OBSERVATION", 105, 114], ["neural cells", "OBSERVATION", 169, 181], ["damaged tissues", "OBSERVATION", 199, 214]]], ["However, while multipotential embryonic stem cells may provide in the future an optimal source of cells competent for myelin and axons repair in MS, their use is still far from being exploitable in a clinical setting.", [["embryonic stem cells", "ANATOMY", 30, 50], ["cells", "ANATOMY", 98, 103], ["myelin", "ANATOMY", 118, 124], ["axons", "ANATOMY", 129, 134], ["MS", "DISEASE", 145, 147], ["embryonic stem cells", "CELL", 30, 50], ["cells", "CELL", 98, 103], ["myelin", "GENE_OR_GENE_PRODUCT", 118, 124], ["axons", "MULTI-TISSUE_STRUCTURE", 129, 134], ["multipotential embryonic stem cells", "CELL_TYPE", 15, 50], ["multipotential embryonic stem cells", "TREATMENT", 15, 50], ["myelin", "PROBLEM", 118, 124], ["axons repair", "TREATMENT", 129, 141], ["embryonic stem cells", "OBSERVATION", 30, 50]]], ["Moreover, it is widely accepted that adult stem cells may in vitro transdifferentiate in neural cells but recent experimental data have challenged the biological importance of this event in vivo.", [["adult stem cells", "ANATOMY", 37, 53], ["neural cells", "ANATOMY", 89, 101], ["adult stem cells", "CELL", 37, 53], ["neural cells", "CELL", 89, 101], ["adult stem cells", "CELL_TYPE", 37, 53], ["neural cells", "CELL_TYPE", 89, 101], ["adult stem cells", "PROBLEM", 37, 53], ["stem cells", "OBSERVATION", 43, 53], ["neural cells", "OBSERVATION", 89, 101]]], ["Nevertheless, several experimental studies have provided new evidences supporting the use of adult stem cells derived form different human tissues for the treatment of MS. In the cases of mesenchymal stem cells and neural stem cells current experimental data support an unexpected therapeutic plasticity mediated by diverse paracrine mechanisms including neuroprotection, induction of local neurogenesis and modulation of the immune response.", [["adult stem cells", "ANATOMY", 93, 109], ["tissues", "ANATOMY", 139, 146], ["mesenchymal stem cells", "ANATOMY", 188, 210], ["neural stem cells", "ANATOMY", 215, 232], ["MS", "DISEASE", 168, 170], ["adult stem cells", "CELL", 93, 109], ["human", "ORGANISM", 133, 138], ["tissues", "TISSUE", 139, 146], ["mesenchymal stem cells", "CELL", 188, 210], ["neural stem cells", "CELL", 215, 232], ["adult stem cells", "CELL_TYPE", 93, 109], ["mesenchymal stem cells", "CELL_TYPE", 188, 210], ["neural stem cells", "CELL_TYPE", 215, 232], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["several experimental studies", "TEST", 14, 42], ["adult stem cells", "TREATMENT", 93, 109], ["MS", "PROBLEM", 168, 170], ["mesenchymal stem cells", "PROBLEM", 188, 210], ["neural stem cells", "PROBLEM", 215, 232], ["neuroprotection", "TREATMENT", 355, 370], ["local neurogenesis", "TREATMENT", 385, 403], ["stem cells", "OBSERVATION", 99, 109], ["mesenchymal stem cells", "OBSERVATION", 188, 210], ["neural stem cells", "OBSERVATION", 215, 232], ["immune response", "OBSERVATION", 426, 441]]], ["Therefore, current experimental and clinical studies support the use of stem cells for the treatment of neurological diseases such as MS.AbstractsUnravelling the structure of the water splitting site of photosynthesis and implications for mechanism of catalysis J. Barber Imperial College London, U.K.AbstractsPhotosystem II (PSII) is a multi-subunit membrane protein complex which catalyses the oxidation of water to molecular oxygen and reducing equivalents.", [["stem cells", "ANATOMY", 72, 82], ["neurological", "ANATOMY", 104, 116], ["membrane", "ANATOMY", 351, 359], ["neurological diseases", "DISEASE", 104, 125], ["MS", "DISEASE", 134, 136], ["oxygen", "CHEMICAL", 428, 434], ["oxygen", "CHEMICAL", 428, 434], ["stem cells", "CELL", 72, 82], ["Photosystem II", "GENE_OR_GENE_PRODUCT", 310, 324], ["membrane", "CELLULAR_COMPONENT", 351, 359], ["water", "SIMPLE_CHEMICAL", 409, 414], ["oxygen", "SIMPLE_CHEMICAL", 428, 434], ["stem cells", "CELL_TYPE", 72, 82], ["Photosystem II", "PROTEIN", 310, 324], ["PSII", "PROTEIN", 326, 330], ["multi-subunit membrane protein complex", "PROTEIN", 337, 375], ["clinical studies", "TEST", 36, 52], ["stem cells", "TREATMENT", 72, 82], ["neurological diseases", "PROBLEM", 104, 125], ["MS", "PROBLEM", 134, 136], ["a multi-subunit membrane protein complex", "TREATMENT", 335, 375], ["molecular oxygen", "TREATMENT", 418, 434], ["oxygen", "OBSERVATION_MODIFIER", 428, 434]]], ["The reaction occurs at a catalytic centre composed of 4 Mn ions and a Ca ion, is thermodynamically demanding and generates highly oxidised species.", [["Ca", "CHEMICAL", 70, 72], ["Mn", "CHEMICAL", 56, 58], ["Ca", "CHEMICAL", 70, 72], ["Mn ions", "SIMPLE_CHEMICAL", 56, 63], ["Ca ion", "SIMPLE_CHEMICAL", 70, 76], ["The reaction", "PROBLEM", 0, 12], ["a Ca ion", "TREATMENT", 68, 76], ["thermodynamically demanding", "PROBLEM", 81, 108], ["highly oxidised species", "PROBLEM", 123, 146], ["thermodynamically demanding", "OBSERVATION", 81, 108], ["highly", "OBSERVATION_MODIFIER", 123, 129], ["oxidised species", "OBSERVATION", 130, 146]]], ["Unavoidable side reactions cause detrimental effects on the protein environment leading to the rapid turnover of the reaction centre D1 protein.", [["D1", "GENE_OR_GENE_PRODUCT", 133, 135], ["D1 protein", "PROTEIN", 133, 143], ["Unavoidable side reactions", "PROBLEM", 0, 26], ["detrimental effects", "PROBLEM", 33, 52], ["the protein environment", "TREATMENT", 56, 79]]], ["To understand the mechanisms of water oxidation and D1 turnover structural information is required.", [["water", "SIMPLE_CHEMICAL", 32, 37], ["D1", "SIMPLE_CHEMICAL", 52, 54], ["D1", "PROTEIN", 52, 54], ["water oxidation", "TREATMENT", 32, 47]]], ["Initially the positioning of various protein subunits and their transmembrane helices were determined by electron microscopy.", [["transmembrane helices", "ANATOMY", 64, 85], ["protein subunits", "PROTEIN", 37, 53], ["transmembrane helices", "PROTEIN", 64, 85], ["various protein subunits", "TREATMENT", 29, 53], ["their transmembrane helices", "TREATMENT", 58, 85], ["electron microscopy", "TEST", 105, 124]]], ["More recently a refined structure of the cyanobacterial PSII unit has been elucidated by X-ray crystallography giving details of specific environments of the redox active cofactors.", [["cyanobacterial PSII unit", "PROTEIN", 41, 65], ["X-ray crystallography", "TEST", 89, 110], ["cyanobacterial PSII", "OBSERVATION", 41, 60]]], ["The implications of these structural studies will be discussed in relation to the unique facets of PSII function, particularly the water splitting reaction.", [["PSII", "GENE_OR_GENE_PRODUCT", 99, 103], ["PSII", "PROTEIN", 99, 103], ["these structural studies", "TEST", 20, 44], ["the water splitting reaction", "PROBLEM", 127, 155]]], ["Importantly this new knowledge is providing a blue print for the design of photochemical catalysts which can mimic the photosynthetic water splitting reaction and thus give hope that new technologies will emerge to provide humankind with a sustainable energy supply.O-237Photochemically controlled molecular devices and machines V. Balzani Department of Chemistry \"G. Ciamician\", University of Bologna, ItalyO-237The macroscopic concepts of a device and a machine can be extended to the molecular level.", [["ItalyO-237", "CHEMICAL", 403, 413], ["O-237", "CHEMICAL", 266, 271], ["photochemical catalysts", "TREATMENT", 75, 98], ["the photosynthetic water splitting reaction", "PROBLEM", 115, 158], ["a sustainable energy supply", "TREATMENT", 238, 265], ["Photochemically controlled molecular devices", "TREATMENT", 271, 315], ["ItalyO", "TEST", 403, 409], ["a device", "TREATMENT", 441, 449], ["a machine", "TREATMENT", 454, 463]]], ["Molecular-level devices and machines operate via electronic and/or nuclear rearrangements and, like macroscopic devices and machines, they need energy to operate and signals to communicate with the operator.", [["nuclear", "ANATOMY", 67, 74], ["nuclear", "CELLULAR_COMPONENT", 67, 74], ["Molecular-level devices", "TREATMENT", 0, 23], ["macroscopic devices", "TREATMENT", 100, 119]]], ["The extension of the concepts of a device and a machine to the molecular level is of interest not only for basic research, but also for the growth of nanoscience and the development of nanotechnology.", [["a device", "TREATMENT", 33, 41]]], ["If a molecular device or machine has to work by inputs of chemical energy, it will need addition of fresh reactants (\"fuel\") at any step of its working cycle, with the concomitant formation of waste products that compromise the operation.", [["a molecular device", "TREATMENT", 3, 21], ["fresh reactants", "TREATMENT", 100, 115], ["waste products", "TREATMENT", 193, 207], ["the operation", "TREATMENT", 224, 237], ["waste products", "OBSERVATION", 193, 207], ["operation", "OBSERVATION", 228, 237]]], ["Currently there is an increasing interest in the use of light to power molecular devices and machines.", [["power molecular devices", "TREATMENT", 65, 88], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["interest", "OBSERVATION_MODIFIER", 33, 41]]], ["The lecture will illustrate examples of recent achievements [1, 2, 3] , which include molecular wires, switches, plug-socket systems, extension cables, antennas, and light powered nanomotors.S. A. AliyevaBiophysics Laboratory, Institute of Botany, Azerbaijan National Academy of Sciences, Baku, Azerbaijan It is well known that fast component of induction curves of millisecond delayed chlorophyll fluorescence (ms-DF) originates via radiative recombination of reaction center with product on the donor side of PSII.", [["chlorophyll", "CHEMICAL", 386, 397], ["PSII", "GENE_OR_GENE_PRODUCT", 511, 515], ["PSII", "PROTEIN", 511, 515], ["molecular wires", "TREATMENT", 86, 101], ["plug-socket systems", "TREATMENT", 113, 132], ["extension cables", "TREATMENT", 134, 150], ["antennas", "TREATMENT", 152, 160], ["light powered nanomotors", "TREATMENT", 166, 190], ["millisecond delayed chlorophyll fluorescence", "PROBLEM", 366, 410], ["the donor side of PSII", "TREATMENT", 493, 515], ["molecular wires", "OBSERVATION", 86, 101]]], ["In view of our previous data (J. Photochemistry and Photobiology B: Biology 86, 2007) it was shown that partners for radiative recombination of P 680 Q A \u2212 localized as a hole on the donor side of PSII.", [["PSII", "GENE_OR_GENE_PRODUCT", 197, 201], ["P 680 Q A", "DNA", 144, 153], ["PSII", "PROTEIN", 197, 201], ["a hole on the donor side of PSII", "TREATMENT", 169, 201]]], ["Depending on pH this hole might be on the CaMn 4 -cluster or on Y Z and their recombination with P 680 Q A \u2212 can be monitored by the ms-DF fast component.", [["Y Z", "GENE_OR_GENE_PRODUCT", 64, 67], ["CaMn 4 -cluster", "PROTEIN", 42, 57], ["Y Z", "PROTEIN", 64, 67]]], ["For analysis of site of damages, photoinhibition of PSII particles from spinach at different pH was monitored by ms-DF.", [["PSII", "GENE_OR_GENE_PRODUCT", 52, 56], ["spinach", "ORGANISM_SUBDIVISION", 72, 79], ["damages", "PROBLEM", 24, 31], ["photoinhibition of PSII particles", "TREATMENT", 33, 66], ["damages", "OBSERVATION", 24, 31]]], ["During photoinhibition of PSII (4000 \u00b5mol photons m \u22122 s \u22121 ) the fast component of ms-DF was shown to be more stable at pH 5.5 and ratio of the fast component to the steady-state level of ms-DF was approximately constant, while at pH 8.5 the fast component essentially decreased, the steady-state level increased and ratio of these components rapidly went down.", [["PSII", "PROTEIN", 26, 30], ["photoinhibition of PSII", "TREATMENT", 7, 30], ["the fast component of ms", "PROBLEM", 62, 86], ["DF", "PROBLEM", 87, 89], ["pH", "TEST", 121, 123], ["ratio", "TEST", 132, 137], ["the fast component", "PROBLEM", 141, 159], ["ms", "TEST", 189, 191], ["DF", "PROBLEM", 192, 194], ["pH", "TEST", 232, 234], ["component", "OBSERVATION_MODIFIER", 248, 257], ["essentially", "OBSERVATION_MODIFIER", 258, 269], ["decreased", "OBSERVATION_MODIFIER", 270, 279], ["components", "OBSERVATION_MODIFIER", 333, 343], ["rapidly", "OBSERVATION_MODIFIER", 344, 351]]], ["It is possible concluded that strong light damaged of recombination reaction withS.", [["recombination reaction", "PROBLEM", 54, 76], ["possible concluded", "UNCERTAINTY", 6, 24]]], ["A. AliyevaIn the presence PpBQ -artificial electron acceptor -the protection of PSII from photoinhibition has been observed only at acidic condition.", [["PpBQ", "CHEMICAL", 26, 30], ["PpBQ", "SIMPLE_CHEMICAL", 26, 30], ["electron", "SIMPLE_CHEMICAL", 43, 51], ["PSII", "GENE_OR_GENE_PRODUCT", 80, 84], ["PSII", "PROTEIN", 80, 84], ["artificial electron acceptor", "TREATMENT", 32, 60], ["the protection of PSII", "TREATMENT", 62, 84], ["photoinhibition", "TREATMENT", 90, 105]]], ["Stress factors such as heavy metals, strong light and low temperature were investigated by measurement of transient pictures of ms-DF in intact plants, isolated chloroplasts and pure PSII particles.", [["chloroplasts", "ANATOMY", 161, 173], ["chloroplasts", "CELL", 161, 173], ["pure PSII particles", "CELL_LINE", 178, 197], ["Stress factors", "PROBLEM", 0, 14], ["heavy metals", "PROBLEM", 23, 35], ["low temperature", "PROBLEM", 54, 69], ["transient pictures of ms", "PROBLEM", 106, 130], ["DF", "PROBLEM", 131, 133], ["isolated chloroplasts and pure PSII particles", "TREATMENT", 152, 197], ["low temperature", "OBSERVATION_MODIFIER", 54, 69], ["intact plants", "OBSERVATION", 137, 150], ["PSII particles", "OBSERVATION", 183, 197]]], ["The heavy metals action on PSII was investigated on wheat seedlings.", [["PSII", "SIMPLE_CHEMICAL", 27, 31], ["wheat", "ORGANISM", 52, 57], ["PSII", "PROTEIN", 27, 31], ["wheat", "SPECIES", 52, 57], ["wheat", "SPECIES", 52, 57], ["heavy", "OBSERVATION_MODIFIER", 4, 9], ["metals", "OBSERVATION", 10, 16]]], ["The targets for toxic action of Al, Mn and Co ions were found to be a Q A -Q B acceptor side of PSII.", [["Al", "CHEMICAL", 32, 34], ["Mn", "CHEMICAL", 36, 38], ["Co", "CHEMICAL", 43, 45], ["Al", "CHEMICAL", 32, 34], ["Mn", "CHEMICAL", 36, 38], ["Co", "CHEMICAL", 43, 45], ["Al", "SIMPLE_CHEMICAL", 32, 34], ["Mn", "SIMPLE_CHEMICAL", 36, 38], ["Co ions", "SIMPLE_CHEMICAL", 43, 50], ["PSII", "PROTEIN", 96, 100], ["Co ions", "TEST", 43, 50], ["a Q A -Q B acceptor side of PSII", "TREATMENT", 68, 100]]], ["The damage site for Cd 2+ may be partners for recombination with P680 + -depend on of medium pH -either Y Z or CaMn 4 -cluster.", [["Cd", "CHEMICAL", 20, 22], ["P680", "CHEMICAL", 65, 69], ["Cd 2+", "CHEMICAL", 20, 25], ["Cd 2+", "SIMPLE_CHEMICAL", 20, 25], ["P680 +", "SIMPLE_CHEMICAL", 65, 71], ["P680", "PROTEIN", 65, 69], ["The damage site", "PROBLEM", 0, 15], ["P680", "TEST", 65, 69], ["medium pH", "TEST", 86, 95]]], ["Investigated ions (Mn 2+ , Al 3+ , Cd 2+ and Co 2+ ) have lead to reduction of chlorophyllprotein complexes pigment fund and Cd 2+ and Co 2+ destroyed also an apoproteins, especially of PSII.", [["Mn", "CHEMICAL", 19, 21], ["Al", "CHEMICAL", 27, 29], ["Cd", "CHEMICAL", 35, 37], ["Cd", "CHEMICAL", 125, 127], ["Co", "CHEMICAL", 135, 137], ["Mn 2+", "CHEMICAL", 19, 24], ["Al 3+", "CHEMICAL", 27, 32], ["Cd 2+", "CHEMICAL", 35, 40], ["Co 2+", "CHEMICAL", 45, 50], ["Cd 2+", "CHEMICAL", 125, 130], ["Co 2+", "CHEMICAL", 135, 140], ["ions", "SIMPLE_CHEMICAL", 13, 17], ["Mn 2+", "SIMPLE_CHEMICAL", 19, 24], ["Al 3+", "SIMPLE_CHEMICAL", 27, 32], ["Cd 2+", "SIMPLE_CHEMICAL", 35, 40], ["Co 2+", "SIMPLE_CHEMICAL", 45, 50], ["chlorophyllprotein", "SIMPLE_CHEMICAL", 79, 97], ["Cd 2+", "SIMPLE_CHEMICAL", 125, 130], ["Co 2+", "SIMPLE_CHEMICAL", 135, 140], ["PSII", "GENE_OR_GENE_PRODUCT", 186, 190], ["chlorophyllprotein complexes", "PROTEIN", 79, 107], ["PSII", "PROTEIN", 186, 190], ["Mn", "TEST", 19, 21], ["Cd", "TEST", 35, 37], ["Co", "TEST", 45, 47], ["Cd", "TEST", 125, 127], ["Co", "TEST", 135, 137], ["an apoproteins", "PROBLEM", 156, 170], ["apoproteins", "OBSERVATION", 159, 170]]], ["The photoinhibition of PSII was investigated in intact leaves of barley and maize seedlings at low and normal temperature.", [["leaves", "ANATOMY", 55, 61], ["seedlings", "ANATOMY", 82, 91], ["PSII", "GENE_OR_GENE_PRODUCT", 23, 27], ["leaves", "ORGANISM_SUBDIVISION", 55, 61], ["barley", "ORGANISM_SUBDIVISION", 65, 71], ["PSII", "PROTEIN", 23, 27], ["barley", "SPECIES", 65, 71], ["maize", "SPECIES", 76, 81], ["barley", "SPECIES", 65, 71], ["maize", "SPECIES", 76, 81], ["The photoinhibition of PSII", "TREATMENT", 0, 27], ["normal temperature", "OBSERVATION_MODIFIER", 103, 121]]], ["A very sharp reduction of intensity of ms-DF second fast component, possibly Y Z * P680\u00ffQ A \u2212 radiative recombination of maize seedlings was observed even after short illumination by strong light at 4ms-Delay Fluorescence (ms-DF) as an Indicator of Stress Factors Action on Photosystem II\u2022 C. pH dependence photoinhibition of chloroplasts and pure PSII particles have shown that strong light damaged of CaMn 4 -cluster in great degree than Y Z .", [["chloroplasts", "ANATOMY", 326, 338], ["chloroplasts", "CELLULAR_COMPONENT", 326, 338], ["Y Z", "GENE_OR_GENE_PRODUCT", 440, 443], ["Photosystem II", "PROTEIN", 274, 288], ["chloroplasts", "CELL_TYPE", 326, 338], ["CaMn 4", "PROTEIN", 403, 409], ["maize", "SPECIES", 121, 126], ["A very sharp reduction of intensity of ms", "PROBLEM", 0, 41], ["DF second fast component", "PROBLEM", 42, 66], ["A \u2212 radiative recombination", "TREATMENT", 90, 117], ["maize seedlings", "PROBLEM", 121, 136], ["Stress Factors", "PROBLEM", 249, 263], ["Photosystem II", "TREATMENT", 274, 288], ["pH dependence photoinhibition", "TREATMENT", 293, 322], ["chloroplasts and pure PSII particles", "TREATMENT", 326, 362], ["CaMn", "TEST", 403, 407], ["very", "OBSERVATION_MODIFIER", 2, 6], ["sharp", "OBSERVATION_MODIFIER", 7, 12], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["intensity", "OBSERVATION_MODIFIER", 26, 35], ["great degree", "OBSERVATION_MODIFIER", 422, 434]]], ["Hydrogenases are considered as potential energy sources.", [["Hydrogenases", "TREATMENT", 0, 12]]], ["In particular, the ability of the green alga C . reinhardtii to reduce protons to hydrogen gas upon illumination by means of a [FeFe]-hydrogenase is a phenomenon of great scientific interest, as it would need only light and water to generate energy.", [["hydrogen", "CHEMICAL", 82, 90], ["FeFe", "CHEMICAL", 128, 132], ["hydrogen", "CHEMICAL", 82, 90], ["FeFe", "CHEMICAL", 128, 132], ["green", "ORGANISM", 34, 39], ["alga C . reinhardtii", "ORGANISM", 40, 60], ["protons", "SIMPLE_CHEMICAL", 71, 78], ["hydrogen", "SIMPLE_CHEMICAL", 82, 90], ["[FeFe]-hydrogenase", "PROTEIN", 127, 145], ["C . reinhardtii", "SPECIES", 45, 60], ["green alga C . reinhardtii", "SPECIES", 34, 60], ["hydrogen gas", "PROBLEM", 82, 94], ["a [FeFe]-hydrogenase", "TREATMENT", 125, 145]]], ["However, the catalytic activity is strongly inhibited by the O 2 produced during photosynthesis; furthermore, the protein is expressed at very low levels, only in conditions of strict anaerobiosis.", [["O 2", "CHEMICAL", 61, 64], ["O 2", "GENE_OR_GENE_PRODUCT", 61, 64], ["O 2", "PROTEIN", 61, 64], ["the protein", "TEST", 110, 121], ["strict anaerobiosis", "PROBLEM", 177, 196], ["low levels", "OBSERVATION_MODIFIER", 143, 153], ["strict anaerobiosis", "OBSERVATION", 177, 196]]], ["This mutually exclusive nature of O 2 and H 2 photoproduction represents a crucial problem in the development of H 2 bio-production.", [["O 2", "CHEMICAL", 34, 37], ["H 2", "CHEMICAL", 42, 45], ["H 2", "CHEMICAL", 113, 116], ["O 2", "SIMPLE_CHEMICAL", 34, 37], ["H 2", "SIMPLE_CHEMICAL", 42, 45], ["H 2", "SIMPLE_CHEMICAL", 113, 116], ["a crucial problem", "PROBLEM", 73, 90], ["crucial", "OBSERVATION_MODIFIER", 75, 82], ["problem", "OBSERVATION", 83, 90]]], ["The study of the structurefunction relationship of [FeFe] hydrogenases, which would help to clarify the molecular mechanisms underlying both H 2 production and O 2 sensitivity, requires the characterization of purified native and modified proteins, which can be obtained by site-directed mutagenesis.", [["Fe", "CHEMICAL", 52, 54], ["[FeFe]", "CHEMICAL", 51, 57], ["H 2", "CHEMICAL", 141, 144], ["O 2", "CHEMICAL", 160, 163], ["[FeFe", "SIMPLE_CHEMICAL", 51, 56], ["H 2", "GENE_OR_GENE_PRODUCT", 141, 144], ["O 2", "SIMPLE_CHEMICAL", 160, 163], ["[FeFe] hydrogenases", "PROTEIN", 51, 70], ["purified native and modified proteins", "PROTEIN", 210, 247], ["The study", "TEST", 0, 9], ["FeFe] hydrogenases", "TREATMENT", 52, 70], ["the characterization", "TEST", 186, 206]]], ["We expressed the algal hydrogenase in the cyanobacterium Synechocystis sp.", [["algal hydrogenase", "GENE_OR_GENE_PRODUCT", 17, 34], ["cyanobacterium Synechocystis sp", "ORGANISM", 42, 73], ["algal hydrogenase", "PROTEIN", 17, 34], ["Synechocystis sp", "SPECIES", 57, 73], ["the algal hydrogenase", "PROBLEM", 13, 34], ["the cyanobacterium Synechocystis sp", "PROBLEM", 38, 73], ["algal hydrogenase", "OBSERVATION", 17, 34], ["cyanobacterium Synechocystis", "OBSERVATION", 42, 70]]], ["PCC 6803, which holds a bidirectional [NiFe]-hydrogenase with a well known maturation system (1) .", [["PCC 6803", "CHEMICAL", 0, 8], ["NiFe", "CHEMICAL", 39, 43], ["bidirectional [NiFe]-hydrogenase", "PROTEIN", 24, 56]]], ["We obtained two constructs to stably transform Synechocystis, enabling it to express the C. reinhardtii hydrogenase in an active form.", [["C. reinhardtii", "ORGANISM", 89, 103], ["C. reinhardtii hydrogenase", "PROTEIN", 89, 115], ["C. reinhardtii", "SPECIES", 89, 103], ["C. reinhardtii", "SPECIES", 89, 103], ["the C. reinhardtii hydrogenase", "PROBLEM", 85, 115], ["reinhardtii hydrogenase", "OBSERVATION", 92, 115], ["active", "OBSERVATION", 122, 128]]], ["This suggests that the [NiFe]-hydrogenase maturation pathway is able to drive the biosynthesis of functional [FeFe] enzymes.", [["NiFe", "CHEMICAL", 24, 28], ["[FeFe]", "CHEMICAL", 109, 115], ["hydrogenase", "PROTEIN", 30, 41], ["[FeFe] enzymes", "PROTEIN", 109, 123], ["the [NiFe]-hydrogenase maturation pathway", "TREATMENT", 19, 60], ["functional [FeFe] enzymes", "TREATMENT", 98, 123]]], ["These data open new perspectives about the indispensable presence of HydE, HydF and HydG auxiliary proteins (2, 3) to obtain a correctly folded [FeFe]-hydrogenase.P-241The A2 low energy monomeric chlorophyll of CP29 To investigate the role of low energy spectral forms in energy transfer among chlorophyll protein complexes, we characterized one of the redmost chlorophylls of PSII antenna complexes, the A2 of CP29.", [["FeFe", "CHEMICAL", 145, 149], ["P-241", "CHEMICAL", 163, 168], ["FeFe", "CHEMICAL", 145, 149], ["chlorophyll", "CHEMICAL", 196, 207], ["chlorophyll", "CHEMICAL", 294, 305], ["chlorophylls", "CHEMICAL", 361, 373], ["HydE", "GENE_OR_GENE_PRODUCT", 69, 73], ["HydF", "GENE_OR_GENE_PRODUCT", 75, 79], ["chlorophyll protein", "GENE_OR_GENE_PRODUCT", 294, 313], ["PSII", "GENE_OR_GENE_PRODUCT", 377, 381], ["CP29", "GENE_OR_GENE_PRODUCT", 411, 415], ["HydE", "PROTEIN", 69, 73], ["HydF", "PROTEIN", 75, 79], ["HydG auxiliary proteins", "PROTEIN", 84, 107], ["[FeFe]-hydrogenase", "PROTEIN", 144, 162], ["A2", "PROTEIN", 172, 174], ["CP29", "PROTEIN", 211, 215], ["chlorophyll protein complexes", "PROTEIN", 294, 323], ["PSII antenna complexes", "PROTEIN", 377, 399], ["A2", "PROTEIN", 405, 407], ["CP29", "PROTEIN", 411, 415], ["HydF", "PROBLEM", 75, 79], ["HydG auxiliary proteins", "PROBLEM", 84, 107], ["P", "TEST", 163, 164], ["The A2 low energy monomeric chlorophyll of CP29", "PROBLEM", 168, 215], ["chlorophyll protein complexes", "TREATMENT", 294, 323], ["the redmost chlorophylls of PSII antenna complexes", "TREATMENT", 349, 399]]], ["Pigment stoichiometry of the wild type (CP29wt) and mutant lacking the A2 binding residue (CP29a2) reconstituted complexes confirmed the loss of a chlorophyll a.", [["chlorophyll", "CHEMICAL", 147, 158], ["CP29wt", "GENE_OR_GENE_PRODUCT", 40, 46], ["CP29wt", "PROTEIN", 40, 46], ["A2 binding residue (CP29a2) reconstituted complexes", "PROTEIN", 71, 122], ["Pigment stoichiometry", "PROBLEM", 0, 21], ["mutant lacking the A2 binding residue", "PROBLEM", 52, 89], ["a chlorophyll a.", "TREATMENT", 145, 161], ["stoichiometry", "OBSERVATION", 8, 21]]], ["To exclude the possibility of a marked excitonic interaction of the A2 with other chlorophylls, we quantified the decrease in dipole strength after mutagenesis as a function of the frequency and performed a second derivative analysis of the difference absorption spectrum CP29wt minus CP29a2.", [["chlorophylls", "CHEMICAL", 82, 94], ["A2", "GENE_OR_GENE_PRODUCT", 68, 70], ["chlorophylls", "SIMPLE_CHEMICAL", 82, 94], ["A2", "PROTEIN", 68, 70], ["a marked excitonic interaction of the A2", "PROBLEM", 30, 70], ["other chlorophylls", "TREATMENT", 76, 94], ["the decrease in dipole strength", "PROBLEM", 110, 141], ["mutagenesis", "TREATMENT", 148, 159], ["a second derivative analysis", "TEST", 205, 233], ["exclude the possibility of", "UNCERTAINTY", 3, 29], ["marked", "OBSERVATION_MODIFIER", 32, 38], ["excitonic interaction", "OBSERVATION", 39, 60], ["decrease", "OBSERVATION_MODIFIER", 114, 122], ["dipole strength", "OBSERVATION", 126, 141]]], ["These data, along with circular dichroism spectra of both complexes, support the idea that the A2 is a monomer in CP29, in disagreement with recent suggestion of involvement in an excitonic dimer (Mozzo et al., BBA 2008) .", [["A2", "GENE_OR_GENE_PRODUCT", 95, 97], ["CP29", "SIMPLE_CHEMICAL", 114, 118], ["A2", "PROTEIN", 95, 97], ["These data", "TEST", 0, 10], ["circular dichroism spectra of both complexes", "PROBLEM", 23, 67], ["excitonic dimer", "OBSERVATION", 180, 195]]], ["Chla A2 reorganization energy and inhomogeneous broadening were then determined through a thermal broadening analysis in the 80-285 K temperature range.", [["Chla A2", "GENE_OR_GENE_PRODUCT", 0, 7], ["Chla A2 reorganization energy", "PROBLEM", 0, 29], ["inhomogeneous broadening", "PROBLEM", 34, 58], ["a thermal broadening analysis", "TEST", 88, 117], ["inhomogeneous broadening", "OBSERVATION", 34, 58]]], ["These parameters allowed us to calculate the F\u00f6rster Overlap Integral of the homogeneously broadened A2 bandshape, a fundamental factor for energy transfer rate estimations between chromophores.", [["A2 bandshape", "PROTEIN", 101, 113]]], ["A comparison with FOI of chlorophyll in solution suggests that chla A2 may connect CP29 complex to PSII core favoring energy transfer from CP29 towards other inner antenna low energy chlorophylls.Mechanisms of light harvesting and excess energy dissipation in plants and algaeIn oxygenic photosynthetic organisms, reaction centre complexes catalyze electron transport from water to CO2 using light energy absorbed by tetrapyrrole pigments bound to so called \"antenna proteins\".", [["algae", "ANATOMY", 271, 276], ["chlorophyll", "CHEMICAL", 25, 36], ["CP29", "CHEMICAL", 139, 143], ["CO2", "CHEMICAL", 382, 385], ["tetrapyrrole", "CHEMICAL", 417, 429], ["chlorophyll", "CHEMICAL", 25, 36], ["chla A2", "CHEMICAL", 63, 70], ["CP29", "CHEMICAL", 139, 143], ["chlorophylls", "CHEMICAL", 183, 195], ["CO2", "CHEMICAL", 382, 385], ["tetrapyrrole", "CHEMICAL", 417, 429], ["FOI", "SIMPLE_CHEMICAL", 18, 21], ["chlorophyll", "SIMPLE_CHEMICAL", 25, 36], ["chla A2", "GENE_OR_GENE_PRODUCT", 63, 70], ["CP29", "GENE_OR_GENE_PRODUCT", 83, 87], ["CP29", "SIMPLE_CHEMICAL", 139, 143], ["chlorophylls", "SIMPLE_CHEMICAL", 183, 195], ["algae", "CELL", 271, 276], ["electron", "SIMPLE_CHEMICAL", 349, 357], ["water", "SIMPLE_CHEMICAL", 373, 378], ["CO2", "SIMPLE_CHEMICAL", 382, 385], ["tetrapyrrole pigments", "SIMPLE_CHEMICAL", 417, 438], ["chla A2", "PROTEIN", 63, 70], ["CP29 complex", "PROTEIN", 83, 95], ["PSII", "PROTEIN", 99, 103], ["reaction centre complexes", "PROTEIN", 314, 339], ["antenna proteins", "PROTEIN", 459, 475], ["FOI of chlorophyll in solution", "TREATMENT", 18, 48], ["chla A2", "PROBLEM", 63, 70], ["other inner antenna low energy chlorophylls", "TREATMENT", 152, 195], ["light harvesting", "TREATMENT", 210, 226], ["excess energy dissipation", "PROBLEM", 231, 256], ["oxygenic photosynthetic organisms", "PROBLEM", 279, 312], ["energy chlorophylls", "OBSERVATION", 176, 195], ["light harvesting", "OBSERVATION", 210, 226], ["energy dissipation", "OBSERVATION", 238, 256], ["oxygenic", "OBSERVATION", 279, 287], ["photosynthetic organisms", "OBSERVATION", 288, 312]]], ["A major challenge in performing this type of photosynthesis consists on the difficulty of operating \"one electron\" transport through a multi-step pathway in the chloroplast environment which is the source of oxygen of biosphere.", [["oxygen", "CHEMICAL", 208, 214], ["oxygen", "CHEMICAL", 208, 214], ["electron", "SIMPLE_CHEMICAL", 105, 113], ["oxygen", "SIMPLE_CHEMICAL", 208, 214], ["A major challenge", "TREATMENT", 0, 17], ["a multi-step pathway", "TREATMENT", 133, 153], ["oxygen of biosphere", "TREATMENT", 208, 227], ["chloroplast environment", "OBSERVATION", 161, 184]]], ["In fact, synthesis of ROS, mainly singlet oxygen and superoxide anion and consequent photoinhibition is an intrinsically unavoidable consequence of photosynthesis that must be prevented and/or controlled in order to avoid photodestruction and death.", [["ROS", "CHEMICAL", 22, 25], ["oxygen", "CHEMICAL", 42, 48], ["superoxide", "CHEMICAL", 53, 63], ["death", "DISEASE", 243, 248], ["oxygen", "CHEMICAL", 42, 48], ["superoxide", "CHEMICAL", 53, 63], ["ROS", "SIMPLE_CHEMICAL", 22, 25], ["singlet oxygen", "SIMPLE_CHEMICAL", 34, 48], ["superoxide anion", "SIMPLE_CHEMICAL", 53, 69], ["singlet oxygen", "TREATMENT", 34, 48], ["superoxide anion", "TREATMENT", 53, 69], ["consequent photoinhibition", "TREATMENT", 74, 100], ["photodestruction", "PROBLEM", 222, 238], ["death", "PROBLEM", 243, 248], ["singlet oxygen", "OBSERVATION", 34, 48]]], ["Mechanisms involved include chlorophyll (Chl) triplet quenching, ROS scavenging and controlled heat dissipation of excess Chl singlet excited states.", [["Chl", "CHEMICAL", 41, 44], ["ROS", "CHEMICAL", 65, 68], ["Chl", "CHEMICAL", 122, 125], ["chlorophyll", "CHEMICAL", 28, 39], ["Chl", "CHEMICAL", 41, 44], ["Chl", "CHEMICAL", 122, 125], ["chlorophyll", "SIMPLE_CHEMICAL", 28, 39], ["Chl", "SIMPLE_CHEMICAL", 41, 44], ["ROS", "SIMPLE_CHEMICAL", 65, 68], ["Chl", "SIMPLE_CHEMICAL", 122, 125], ["chlorophyll (Chl) triplet quenching", "TREATMENT", 28, 63], ["ROS scavenging", "PROBLEM", 65, 79], ["controlled heat dissipation of excess", "PROBLEM", 84, 121], ["singlet excited", "OBSERVATION", 126, 141]]], ["Reverse genomics and ultrafast-spectroscopy led to the proposal that the transient formation of carotenoid radical cations, followed by charge recombination might be the underlying mechanism of energy dissipation while three proteins belonging to the LHC superfamily could be the site hosting the reaction.O-239Probing the dark cycle to reveal regulatory networks controlling photosynthetic efficiency The food, fibre and fuel needs of an ever-increasing population are one of the challenges facing current society.", [["carotenoid", "CHEMICAL", 96, 106], ["O-239Probing", "CHEMICAL", 306, 318], ["O-239Probing", "CHEMICAL", 306, 318], ["carotenoid radical cations", "SIMPLE_CHEMICAL", 96, 122], ["LHC", "GENE_OR_GENE_PRODUCT", 251, 254], ["LHC superfamily", "PROTEIN", 251, 266], ["ultrafast-spectroscopy", "TEST", 21, 43], ["carotenoid radical cations", "TREATMENT", 96, 122], ["energy dissipation", "PROBLEM", 194, 212], ["the reaction", "PROBLEM", 293, 305], ["photosynthetic efficiency", "PROBLEM", 376, 401], ["carotenoid", "OBSERVATION", 96, 106], ["radical cations", "OBSERVATION", 107, 122], ["photosynthetic efficiency", "OBSERVATION", 376, 401]]], ["Higher plant photosynthetic efficiency is \u223c1% whereas the theoretical maximum is thought to be \u223c6-8% giving potential for great improvements.", [["Higher plant photosynthetic efficiency", "PROBLEM", 0, 38], ["photosynthetic efficiency", "OBSERVATION", 13, 38], ["thought to be", "UNCERTAINTY", 81, 94]]], ["It is not however clear where in the photosynthetic process the additional losses are occurring.", [["not however", "UNCERTAINTY", 6, 17], ["clear", "OBSERVATION", 18, 23], ["photosynthetic process", "OBSERVATION", 37, 59], ["losses", "OBSERVATION", 75, 81]]], ["We are adopting a systems biology approach to reveal the regulatory networks that control photosynthetic efficiency, the challenge being to make quantitative measurements of the input parameters to models of the network of photosynthetic reactions, and also to identify missing physical parameters and processes.", [["photosynthetic efficiency", "PROBLEM", 90, 115], ["photosynthetic reactions", "PROBLEM", 223, 247], ["photosynthetic efficiency", "OBSERVATION", 90, 115]]], ["We report initial results in this poster from experiments using conventional and novel proteomic methods.", [["conventional and novel proteomic methods", "TREATMENT", 64, 104]]], ["E.g. an optical technique based on a non-linear 2DIR method is being developed for proteomic and metabolomic analysis.", [["an optical technique", "TEST", 5, 25], ["a non-linear 2DIR method", "TREATMENT", 35, 59], ["proteomic and metabolomic analysis", "TEST", 83, 117]]], ["Unlike many conventional proteomic methods, which provide information on the relative levels of various proteins and metabolites, the viability of the 2DIR method as a quantitative, sensitive and high throughput proteomics platform has recently been demonstrated.", [["the 2DIR method", "TEST", 147, 162]]], ["In collaboration with Klug this project will employ 2DIR as a both a proteomic and metabolomic tool.Structural bases for the pH-dependent activation of violaxanthin de-epoxidaseT.", [["violaxanthin de-epoxidaseT", "CHEMICAL", 152, 178], ["violaxanthin", "CHEMICAL", 152, 164], ["violaxanthin de-epoxidaseT", "SIMPLE_CHEMICAL", 152, 178], ["violaxanthin de-epoxidaseT", "PROTEIN", 152, 178], ["the pH", "TEST", 121, 127], ["violaxanthin de-epoxidaseT", "TREATMENT", 152, 178], ["bases", "ANATOMY_MODIFIER", 111, 116], ["violaxanthin de-epoxidaseT", "OBSERVATION", 152, 178]]], ["Morosinotto 1 , P. Arnoux 2 , G. Saga 1 , G. M. Giacometti 1 , R. Bassi 3 , D. Pignol 2 1 Dip. di Biologia, Padova, Italy, 2 CEA, Cadarache, France, 3 Dip. di biotecnologie, Verona, Italy Violaxanthin de-epoxidase (VDE) is the enzyme responsible for zeaxanthin (Z) production.Structural bases for the pH-dependent activation of violaxanthin de-epoxidaseThe synthesis of this carotenoid in plants exposed to high light conditions is an important photoprotection mechanism, enhancing excess energy dissipation and reactive oxygen species scavenging.", [["Violaxanthin", "CHEMICAL", 188, 200], ["VDE", "CHEMICAL", 215, 218], ["zeaxanthin", "CHEMICAL", 250, 260], ["violaxanthin de-epoxidase", "CHEMICAL", 328, 353], ["carotenoid", "CHEMICAL", 375, 385], ["oxygen", "CHEMICAL", 521, 527], ["zeaxanthin", "CHEMICAL", 250, 260], ["violaxanthin", "CHEMICAL", 328, 340], ["oxygen", "CHEMICAL", 521, 527], ["Violaxanthin de-epoxidase", "SIMPLE_CHEMICAL", 188, 213], ["VDE", "SIMPLE_CHEMICAL", 215, 218], ["zeaxanthin", "SIMPLE_CHEMICAL", 250, 260], ["Z", "SIMPLE_CHEMICAL", 262, 263], ["violaxanthin", "SIMPLE_CHEMICAL", 328, 340], ["carotenoid", "SIMPLE_CHEMICAL", 375, 385], ["reactive oxygen species", "SIMPLE_CHEMICAL", 512, 535], ["violaxanthin de-epoxidase", "PROTEIN", 328, 353], ["Italy Violaxanthin de-epoxidase", "TREATMENT", 182, 213], ["the enzyme", "TEST", 223, 233], ["zeaxanthin (Z) production", "PROBLEM", 250, 275], ["the pH", "TEST", 297, 303], ["violaxanthin de-epoxidase", "TREATMENT", 328, 353], ["high light conditions", "PROBLEM", 407, 428], ["enhancing excess energy dissipation", "PROBLEM", 472, 507], ["reactive oxygen species scavenging", "PROBLEM", 512, 546], ["CEA", "ANATOMY", 125, 128], ["bases", "ANATOMY_MODIFIER", 287, 292], ["violaxanthin de-epoxidase", "OBSERVATION", 328, 353], ["high light", "OBSERVATION_MODIFIER", 407, 417], ["reactive", "OBSERVATION_MODIFIER", 512, 520], ["oxygen species scavenging", "OBSERVATION", 521, 546]]], ["The inactive enzyme is normally soluble but, upon activation by low pH, it binds to the thylakoids membrane, where its substrate is found.", [["thylakoids membrane", "ANATOMY", 88, 107], ["thylakoids membrane", "CELLULAR_COMPONENT", 88, 107], ["inactive enzyme", "PROTEIN", 4, 19], ["The inactive enzyme", "TEST", 0, 19], ["low pH", "PROBLEM", 64, 70], ["inactive", "OBSERVATION", 4, 12], ["soluble", "OBSERVATION_MODIFIER", 32, 39], ["low pH", "OBSERVATION_MODIFIER", 64, 70], ["thylakoids membrane", "OBSERVATION", 88, 107]]], ["We present here the first structural data on this enzyme obtained at both acidic and neutral pH.", [["this enzyme", "TEST", 45, 56], ["neutral pH", "OBSERVATION", 85, 95]]], ["At neutral pH, VDE is monomeric with its active site occluded in the lipocalin barrel.", [["VDE", "CHEMICAL", 15, 18], ["VDE", "SIMPLE_CHEMICAL", 15, 18], ["lipocalin", "GENE_OR_GENE_PRODUCT", 69, 78], ["lipocalin barrel", "PROTEIN", 69, 85], ["its active site", "PROBLEM", 37, 52], ["monomeric", "OBSERVATION_MODIFIER", 22, 31], ["active", "OBSERVATION_MODIFIER", 41, 47], ["site", "OBSERVATION_MODIFIER", 48, 52], ["occluded", "OBSERVATION", 53, 61], ["lipocalin barrel", "OBSERVATION", 69, 85]]], ["Upon acidification, the barrel opens up resulting in a functional dimerization of the enzyme.", [["enzyme", "PROTEIN", 86, 92], ["acidification", "PROBLEM", 5, 18], ["the enzyme", "TEST", 82, 92], ["acidification", "OBSERVATION", 5, 18], ["barrel", "OBSERVATION_MODIFIER", 24, 30]]], ["The channel linking the two active sites of the dimer can harbour the entire carotenoid substrate and thus allow the parallel de-epoxidation of the two violaxanthin \u03b2-ionone rings, making VDE an elegant example of the adaptation of an asymmetric enzyme to its symmetric substrate.", [["violaxanthin \u03b2-ionone", "CHEMICAL", 152, 173], ["violaxanthin \u03b2-ionone", "CHEMICAL", 152, 173], ["carotenoid", "SIMPLE_CHEMICAL", 77, 87], ["violaxanthin \u03b2-ionone rings", "SIMPLE_CHEMICAL", 152, 179], ["VDE", "SIMPLE_CHEMICAL", 188, 191], ["dimer", "PROTEIN", 48, 53], ["asymmetric enzyme", "PROTEIN", 235, 252], ["the two violaxanthin \u03b2-ionone rings", "TREATMENT", 144, 179], ["an asymmetric enzyme", "PROBLEM", 232, 252], ["two", "OBSERVATION_MODIFIER", 24, 27], ["active", "OBSERVATION_MODIFIER", 28, 34]]], ["Structural data opened the possibility to investigate deeper this enzyme and further work allowed the identification of its active site, the protein domains responsible of its membrane association as well as key residues involved in the pH dependent conformational change.W. Lubitz Max-Planck-Institut f\u00fcr Bioanorganische Chemie, GermanyHydrogen is considered the fuel of the future if produced from sun light-driven water splitting.", [["membrane", "ANATOMY", 176, 184], ["GermanyHydrogen", "CHEMICAL", 330, 345], ["membrane", "CELLULAR_COMPONENT", 176, 184], ["GermanyHydrogen", "SIMPLE_CHEMICAL", 330, 345], ["water", "SIMPLE_CHEMICAL", 417, 422], ["protein domains", "PROTEIN", 141, 156], ["this enzyme", "TEST", 61, 72], ["its active site", "PROBLEM", 120, 135], ["the protein domains", "PROBLEM", 137, 156], ["the pH dependent conformational change", "PROBLEM", 233, 271], ["pH dependent", "OBSERVATION_MODIFIER", 237, 249], ["conformational change", "OBSERVATION", 250, 271]]], ["A hydrogen economy based on genetically modified organisms, immobilized enzymes or biomimetic synthetic catalysts requires a profound knowledge of the structure and function of the respective enzymes in Nature.", [["hydrogen", "CHEMICAL", 2, 10], ["hydrogen", "CHEMICAL", 2, 10], ["immobilized enzymes", "PROTEIN", 60, 79], ["enzymes", "PROTEIN", 192, 199], ["A hydrogen economy", "TREATMENT", 0, 18], ["genetically modified organisms", "PROBLEM", 28, 58], ["immobilized enzymes", "TEST", 60, 79], ["biomimetic synthetic catalysts", "TREATMENT", 83, 113], ["the respective enzymes", "TEST", 177, 199], ["hydrogen economy", "OBSERVATION", 2, 18]]], ["1 Light-induced water splitting is performed by a tetranuclear manganese cluster located in photosystem (PS) II of oxygenic photosynthesis.", [["manganese", "CHEMICAL", 63, 72], ["manganese", "CHEMICAL", 63, 72], ["manganese", "SIMPLE_CHEMICAL", 63, 72], ["tetranuclear manganese cluster", "PROTEIN", 50, 80], ["photosystem (PS) II", "PROTEIN", 92, 111], ["Light-induced water splitting", "TREATMENT", 2, 31], ["a tetranuclear manganese cluster", "TREATMENT", 48, 80], ["photosystem (PS", "TREATMENT", 92, 107], ["oxygenic photosynthesis", "TREATMENT", 115, 138], ["oxygenic photosynthesis", "OBSERVATION", 115, 138]]], ["The protons generated by PS II can be converted to molecular hydrogen by the enzyme hydrogenase, which is for example found in green algae and cyanobacteria.W. Lubitz Max-Planck-Institut f\u00fcr Bioanorganische Chemie, Germany[NiFe]-and [FeFe]-hydrogenases are the two main classes of this enzyme.", [["PS II", "CHEMICAL", 25, 30], ["FeFe", "CHEMICAL", 234, 238], ["hydrogen", "CHEMICAL", 61, 69], ["FeFe", "CHEMICAL", 234, 238], ["protons", "SIMPLE_CHEMICAL", 4, 11], ["PS II", "GENE_OR_GENE_PRODUCT", 25, 30], ["hydrogen", "SIMPLE_CHEMICAL", 61, 69], ["green algae", "SIMPLE_CHEMICAL", 127, 138], ["Germany[NiFe]-", "SIMPLE_CHEMICAL", 215, 229], ["[FeFe]-hydrogenases", "SIMPLE_CHEMICAL", 233, 252], ["PS II", "PROTEIN", 25, 30], ["enzyme hydrogenase", "PROTEIN", 77, 95], ["[FeFe]-hydrogenases", "PROTEIN", 233, 252], ["enzyme", "PROTEIN", 286, 292], ["the enzyme hydrogenase", "TEST", 73, 95], ["green algae", "PROBLEM", 127, 138], ["cyanobacteria", "PROBLEM", 143, 156], ["FeFe]-hydrogenases", "TREATMENT", 234, 252], ["this enzyme", "TEST", 281, 292], ["green algae", "OBSERVATION", 127, 138]]], ["They contain bridged binuclear transition metal cores, which are tuned by a special ligand environment to efficiently convert protons to hydrogen -or vice versa -via a heterolytic mechanism.", [["hydrogen", "CHEMICAL", 137, 145], ["transition metal", "CHEMICAL", 31, 47], ["hydrogen", "CHEMICAL", 137, 145], ["protons", "SIMPLE_CHEMICAL", 126, 133], ["hydrogen", "SIMPLE_CHEMICAL", 137, 145], ["bridged binuclear transition metal cores", "TREATMENT", 13, 53], ["a special ligand environment", "TREATMENT", 74, 102], ["hydrogen", "TREATMENT", 137, 145], ["a heterolytic mechanism", "TREATMENT", 166, 189], ["bridged", "OBSERVATION_MODIFIER", 13, 20], ["binuclear transition", "OBSERVATION", 21, 41], ["metal cores", "OBSERVATION", 42, 53]]], ["2 Rhodobacter sphaeroides strain A-10 isolated from mineral springs in Armenia produces H 2 with high rate in anaerobic conditions under light.", [["H", "CHEMICAL", 88, 89], ["H 2", "CHEMICAL", 88, 91], ["Rhodobacter sphaeroides", "ORGANISM", 2, 25], ["strain A-10", "ORGANISM", 26, 37], ["Rhodobacter sphaeroides", "SPECIES", 2, 25], ["Rhodobacter sphaeroides strain A-10", "SPECIES", 2, 37], ["Rhodobacter sphaeroides strain A", "PROBLEM", 2, 34], ["high rate in anaerobic conditions", "PROBLEM", 97, 130], ["Rhodobacter sphaeroides", "OBSERVATION", 2, 25], ["mineral springs", "OBSERVATION", 52, 67], ["anaerobic conditions", "OBSERVATION", 110, 130]]], ["In our previous work the inhibition of H 2 production by N,N' -dicyclohexylcarbodiimide (DCCD), the F 0 F 1 -ATPase inhibitor, was shown, and DCCD-inhibited ATPase activity was determined.", [["H 2", "CHEMICAL", 39, 42], ["N,N' -dicyclohexylcarbodiimide", "CHEMICAL", 57, 87], ["DCCD", "CHEMICAL", 89, 93], ["DCCD", "CHEMICAL", 142, 146], ["H 2", "CHEMICAL", 39, 42], ["N,N' -dicyclohexylcarbodiimide", "CHEMICAL", 57, 87], ["DCCD", "CHEMICAL", 89, 93], ["DCCD", "CHEMICAL", 142, 146], ["H 2", "SIMPLE_CHEMICAL", 39, 42], ["N,N' -dicyclohexylcarbodiimide", "SIMPLE_CHEMICAL", 57, 87], ["DCCD", "SIMPLE_CHEMICAL", 89, 93], ["F 0 F 1 -ATPase", "GENE_OR_GENE_PRODUCT", 100, 115], ["DCCD", "SIMPLE_CHEMICAL", 142, 146], ["ATPase", "GENE_OR_GENE_PRODUCT", 157, 163], ["ATPase", "PROTEIN", 157, 163], ["N' -dicyclohexylcarbodiimide (DCCD", "TREATMENT", 59, 93], ["ATPase inhibitor", "TREATMENT", 109, 125], ["DCCD", "TREATMENT", 142, 146], ["ATPase activity", "PROBLEM", 157, 172]]], ["Therefore it is possible to admit a role of this ATPase in H 2 production by R. sphaeroides; otherwise DCCD inhibition of hydrogenase is not ruled out.", [["DCCD", "CHEMICAL", 103, 107], ["H 2", "CHEMICAL", 59, 62], ["DCCD", "CHEMICAL", 103, 107], ["ATPase", "GENE_OR_GENE_PRODUCT", 49, 55], ["H 2", "GENE_OR_GENE_PRODUCT", 59, 62], ["R. sphaeroides", "ORGANISM", 77, 91], ["DCCD", "SIMPLE_CHEMICAL", 103, 107], ["ATPase", "PROTEIN", 49, 55], ["hydrogenase", "PROTEIN", 122, 133], ["R. sphaeroides", "SPECIES", 77, 91], ["R. sphaeroides", "SPECIES", 77, 91], ["DCCD inhibition of hydrogenase", "TREATMENT", 103, 133], ["not ruled", "UNCERTAINTY", 137, 146]]], ["In order to examine the mediatory role of proton-motive force (PMF) or proton ATPase in this process transmembrane electrical potential (\u2206\u03a8) and \u2206pH are determined and the ATPase activity is studied in R. sphaeroides grown under light.", [["transmembrane", "ANATOMY", 101, 114], ["proton ATPase", "GENE_OR_GENE_PRODUCT", 71, 84], ["\u2206pH", "SIMPLE_CHEMICAL", 145, 148], ["ATPase", "GENE_OR_GENE_PRODUCT", 172, 178], ["proton ATPase", "PROTEIN", 71, 84], ["\u2206pH", "PROTEIN", 145, 148], ["ATPase", "PROTEIN", 172, 178], ["R. sphaeroides", "SPECIES", 202, 216], ["R. sphaeroides", "SPECIES", 202, 216], ["proton-motive force", "TREATMENT", 42, 61], ["proton ATPase", "TREATMENT", 71, 84], ["the ATPase activity", "TEST", 168, 187]]], ["PMF was determined under anaerobic conditions in the dark.", [["PMF", "PROBLEM", 0, 3], ["anaerobic conditions", "OBSERVATION", 25, 45]]], ["At pH 7.5 the \u2206\u03a8 was of -94 mV and the reversed \u2206pH was +30 mV, resulting in the PMF of -64 mV.", [["pH", "TEST", 3, 5], ["mV", "TEST", 60, 62], ["the PMF", "TEST", 77, 84]]], ["But \u2206\u03a8 was not affected by DCCD.", [["DCCD", "CHEMICAL", 27, 31], ["DCCD", "CHEMICAL", 27, 31], ["DCCD", "SIMPLE_CHEMICAL", 27, 31], ["\u03a8", "PROTEIN", 5, 6]]], ["Moreover, adenine nucleotide phosphates (ANP) content is essential for cell functioning and may result with ATPase activity.", [["cell", "ANATOMY", 71, 75], ["adenine nucleotide phosphates", "CHEMICAL", 10, 39], ["ANP", "CHEMICAL", 41, 44], ["adenine nucleotide phosphates", "CHEMICAL", 10, 39], ["adenine nucleotide phosphates", "SIMPLE_CHEMICAL", 10, 39], ["ANP", "SIMPLE_CHEMICAL", 41, 44], ["cell", "CELL", 71, 75], ["ATPase", "GENE_OR_GENE_PRODUCT", 108, 114], ["ATPase", "PROTEIN", 108, 114], ["adenine nucleotide phosphates (ANP) content", "TREATMENT", 10, 53], ["cell functioning", "TREATMENT", 71, 87]]], ["The percentage of ATP was calculated from the total quantity of ANP in whole cells, it was 46.6 %.", [["whole cells", "ANATOMY", 71, 82], ["ATP", "CHEMICAL", 18, 21], ["ATP", "CHEMICAL", 18, 21], ["ATP", "SIMPLE_CHEMICAL", 18, 21], ["ANP", "GENE_OR_GENE_PRODUCT", 64, 67], ["cells", "CELL", 77, 82], ["whole cells", "CELL_TYPE", 71, 82], ["ATP", "TEST", 18, 21], ["ANP in whole cells", "TREATMENT", 64, 82], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["ANP", "OBSERVATION", 64, 67], ["whole cells", "OBSERVATION", 71, 82]]], ["A relatively high concentration of ADP (\u223c35 %) and AMP (\u223c18 %) and accordingly low energetic charge were noted; these might be indicative for the ATPase activity, a further study is required.", [["ADP", "CHEMICAL", 35, 38], ["AMP", "CHEMICAL", 51, 54], ["ADP", "CHEMICAL", 35, 38], ["AMP", "CHEMICAL", 51, 54], ["ADP", "SIMPLE_CHEMICAL", 35, 38], ["AMP", "SIMPLE_CHEMICAL", 51, 54], ["ATPase", "GENE_OR_GENE_PRODUCT", 146, 152], ["ATPase", "PROTEIN", 146, 152], ["ADP", "TEST", 35, 38], ["AMP", "TEST", 51, 54], ["accordingly low energetic charge", "PROBLEM", 67, 99], ["the ATPase activity", "PROBLEM", 142, 161], ["a further study", "TEST", 163, 178], ["high", "OBSERVATION_MODIFIER", 13, 17], ["concentration", "OBSERVATION_MODIFIER", 18, 31], ["low", "OBSERVATION_MODIFIER", 79, 82], ["energetic charge", "OBSERVATION", 83, 99], ["might be indicative for", "UNCERTAINTY", 118, 141]]], ["Relationship between H 2 production and ATPase activity by Rh. sphaeroides is suggested; possible mechanisms are discussed.P-243Identification of the sites of Chlorophyll triplet quenching in relation to the structure of LHC-II from higher plants.", [["LHC-II", "CHEMICAL", 221, 227], ["H 2", "CHEMICAL", 21, 24], ["Chlorophyll", "CHEMICAL", 159, 170], ["H 2", "GENE_OR_GENE_PRODUCT", 21, 24], ["ATPase", "GENE_OR_GENE_PRODUCT", 40, 46], ["Rh. sphaeroides", "ORGANISM", 59, 74], ["LHC-II", "GENE_OR_GENE_PRODUCT", 221, 227], ["ATPase", "PROTEIN", 40, 46], ["P", "DNA", 123, 124], ["LHC", "PROTEIN", 221, 224], ["Rh. sphaeroides", "SPECIES", 59, 74], ["Rh. sphaeroides", "SPECIES", 59, 74], ["Chlorophyll triplet quenching", "PROBLEM", 159, 188], ["Chlorophyll triplet", "OBSERVATION", 159, 178], ["LHC", "OBSERVATION", 221, 224], ["higher plants", "OBSERVATION", 233, 246]]], ["Evidence The Chl a molecules involved in the triplet-triplet energy transfer to the central luteins in trimeric LHC-II are identified by time-resolved and pulse EPR techniques.", [["luteins", "CHEMICAL", 92, 99], ["luteins", "SIMPLE_CHEMICAL", 92, 99], ["LHC-II", "GENE_OR_GENE_PRODUCT", 112, 118], ["central luteins", "PROTEIN", 84, 99], ["trimeric LHC-II", "PROTEIN", 103, 118], ["The Chl a molecules", "PROBLEM", 9, 28], ["pulse EPR techniques", "TREATMENT", 155, 175], ["Chl", "OBSERVATION", 13, 16], ["central", "ANATOMY_MODIFIER", 84, 91], ["LHC", "OBSERVATION", 112, 115]]], ["The concept of spin conservation during triplet-triplet energy transfer is exploited.", [["spin conservation", "TREATMENT", 15, 32]]], ["The sites with the highest probability to form triplet states, which are quenched by the central luteins, are Chl603 and Chl612.", [["Chl612", "CHEMICAL", 121, 127], ["luteins", "CHEMICAL", 97, 104], ["Chl603", "CHEMICAL", 110, 116], ["Chl612", "CHEMICAL", 121, 127], ["luteins", "GENE_OR_GENE_PRODUCT", 97, 104], ["Chl603", "GENE_OR_GENE_PRODUCT", 110, 116], ["Chl612", "GENE_OR_GENE_PRODUCT", 121, 127], ["central", "ANATOMY_MODIFIER", 89, 96]]], ["Unquenched Chl triplet states are also produced by photo-excitation in the LHC-II complex.", [["Chl", "CHEMICAL", 11, 14], ["Chl", "CHEMICAL", 11, 14], ["LHC-II", "GENE_OR_GENE_PRODUCT", 75, 81], ["LHC-II complex", "PROTEIN", 75, 89], ["Chl triplet", "OBSERVATION", 11, 22]]], ["Putative sites of these triplet states are Chl614, Chl611, Chla604 and Chl613, since they do not contribute to the formation of the observed carotenoid triplet states.123Fluorescence lifetime spectrum of the plant photosystem II core complex The photosystem II kinetic model (diffusion or trap-limited) is still much debated.", [["carotenoid", "CHEMICAL", 141, 151], ["Chl614", "CHEMICAL", 43, 49], ["Chl611", "CHEMICAL", 51, 57], ["Chla604", "CHEMICAL", 59, 66], ["Chl613", "CHEMICAL", 71, 77], ["Chl614", "GENE_OR_GENE_PRODUCT", 43, 49], ["Chl611", "GENE_OR_GENE_PRODUCT", 51, 57], ["Chla604", "GENE_OR_GENE_PRODUCT", 59, 66], ["Chl613", "AMINO_ACID", 71, 77], ["carotenoid", "SIMPLE_CHEMICAL", 141, 151], ["photosystem II", "GENE_OR_GENE_PRODUCT", 246, 260], ["plant photosystem II core complex", "PROTEIN", 208, 241], ["photosystem II", "PROTEIN", 246, 260], ["Chla604", "TREATMENT", 59, 66], ["Chl613", "TREATMENT", 71, 77], ["the observed carotenoid triplet states", "PROBLEM", 128, 166], ["the plant photosystem II core complex", "TREATMENT", 204, 241], ["The photosystem II kinetic model", "TEST", 242, 274], ["triplet states", "OBSERVATION", 24, 38], ["carotenoid triplet", "OBSERVATION", 141, 159], ["plant photosystem", "OBSERVATION", 208, 225]]], ["There is discussion about whether energy transfer from the core antenna (CP47 and CP43) to the reaction center complex (D1-D2-cyt b559) is rate-limiting (transfer to trap-limited).", [["D1-D2-cyt b559", "CHEMICAL", 120, 134], ["CP47", "PROTEIN", 73, 77], ["CP43", "PROTEIN", 82, 86], ["D1", "PROTEIN", 120, 122], ["D2", "PROTEIN", 123, 125], ["cyt b559", "PROTEIN", 126, 134], ["cyt b", "TEST", 126, 131]]], ["This study investigates this problem in isolated core particles by exploiting the different optical properties of the core antenna and the reaction center complex near 680 nm, due to P680 and an isoenergetic pheophytin.", [["P680", "CHEMICAL", 183, 187], ["pheophytin", "CHEMICAL", 208, 218], ["P680", "CHEMICAL", 183, 187], ["pheophytin", "CHEMICAL", 208, 218], ["P680", "SIMPLE_CHEMICAL", 183, 187], ["pheophytin", "SIMPLE_CHEMICAL", 208, 218], ["reaction center complex", "PROTEIN", 139, 162], ["This study", "TEST", 0, 10], ["an isoenergetic pheophytin", "TREATMENT", 192, 218], ["isoenergetic pheophytin", "OBSERVATION", 195, 218]]], ["This was used as a marker feature for the reaction center complex.", [["the reaction center complex", "PROBLEM", 38, 65]]], ["Such a selective reaction center feature was not observed in fluorescence decay measurements.", [["not observed", "UNCERTAINTY", 45, 57]]], ["Thus, the transfer to the trap-limited model is not supported.P-247Photosynthetic apparatus response under heat stress N. Pshybytko 1 , I. Divak 1 , L. Kabashnikova 1 , E. Lysenko 2 1 Institute of Biophysics and Cell Engineering, National Academy of Sciences of Belarus, Belarus, 2 Institute of Plant Physiology, Russian Academy of Sciences, RussiaP-247The mechanisms of PSII thermoinactivation and adaptation under high temperature impact and participation of hydrogen peroxide at these processes were studied.", [["Cell", "ANATOMY", 212, 216], ["hydrogen peroxide", "CHEMICAL", 461, 478], ["hydrogen peroxide", "CHEMICAL", 461, 478], ["Cell", "CELL", 212, 216], ["PSII", "GENE_OR_GENE_PRODUCT", 371, 375], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 461, 478], ["Photosynthetic apparatus", "TEST", 67, 91], ["Divak", "TREATMENT", 139, 144], ["PSII thermoinactivation", "TREATMENT", 371, 394], ["adaptation under high temperature impact", "TREATMENT", 399, 439], ["hydrogen peroxide", "TREATMENT", 461, 478]]], ["The twice suppression of oxygen evolving activity of thylakoids with simultaneous decrease in D1 protein content and the release of extrinsic 33 kDa polypeptide from WOC after 15-20 min heating at 40 o C were registered.", [["thylakoids", "ANATOMY", 53, 63], ["oxygen", "CHEMICAL", 25, 31], ["oxygen", "CHEMICAL", 25, 31], ["oxygen", "SIMPLE_CHEMICAL", 25, 31], ["thylakoids", "SIMPLE_CHEMICAL", 53, 63], ["D1", "GENE_OR_GENE_PRODUCT", 94, 96], ["D1 protein", "PROTEIN", 94, 104], ["extrinsic 33 kDa polypeptide", "PROTEIN", 132, 160], ["oxygen evolving activity of thylakoids", "PROBLEM", 25, 63], ["simultaneous decrease in D1 protein content", "PROBLEM", 69, 112], ["extrinsic 33 kDa polypeptide", "TREATMENT", 132, 160]]], ["Using inhibitor analysis it was shown that thermoinduced degradation of D1 protein after 20 min heating occurred by proteases.", [["D1", "GENE_OR_GENE_PRODUCT", 72, 74], ["D1 protein", "PROTEIN", 72, 82], ["proteases", "PROTEIN", 116, 125], ["inhibitor analysis", "TEST", 6, 24], ["D1 protein", "TREATMENT", 72, 82]]], ["The participation of FtsH protease in thermoinduced D1 protein degradation was observed.", [["FtsH protease", "GENE_OR_GENE_PRODUCT", 21, 34], ["thermoinduced D1", "GENE_OR_GENE_PRODUCT", 38, 54], ["FtsH protease", "PROTEIN", 21, 34], ["D1 protein", "PROTEIN", 52, 62], ["FtsH protease", "TREATMENT", 21, 34], ["thermoinduced D1 protein degradation", "PROBLEM", 38, 74]]], ["Level of transcription of psbA gene in chloroplast was raised after 20 min heating and was decreased through 1 h.", [["chloroplast", "ANATOMY", 39, 50], ["psbA", "GENE_OR_GENE_PRODUCT", 26, 30], ["chloroplast", "CELLULAR_COMPONENT", 39, 50], ["psbA gene", "DNA", 26, 35], ["transcription of psbA gene in chloroplast", "TREATMENT", 9, 50]]], ["The content of hydrogen peroxide was increased three times after 20 min of heating and was decreased to normal level through 1 h and was raised after 2.5 h again.", [["hydrogen peroxide", "CHEMICAL", 15, 32], ["hydrogen peroxide", "CHEMICAL", 15, 32], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 15, 32], ["hydrogen peroxide", "TREATMENT", 15, 32], ["hydrogen peroxide", "OBSERVATION", 15, 32]]], ["It is interesting that level of peroxidation lipids products was increased after 2.5 h heating only.", [["peroxidation lipids products", "TREATMENT", 32, 60]]], ["Received data indicated that hydrogen peroxide is signal molecular at the photosynthetic apparatus under heat stress.", [["hydrogen peroxide", "CHEMICAL", 29, 46], ["hydrogen peroxide", "CHEMICAL", 29, 46], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 29, 46], ["hydrogen peroxide", "TREATMENT", 29, 46], ["heat stress", "OBSERVATION", 105, 116]]], ["During heating the inactivation of WOC and D1 protein is occurred.", [["WOC", "GENE_OR_GENE_PRODUCT", 35, 38], ["D1", "GENE_OR_GENE_PRODUCT", 43, 45], ["WOC", "PROTEIN", 35, 38], ["D1 protein", "PROTEIN", 43, 53], ["WOC and D1 protein", "TREATMENT", 35, 53]]], ["As result the H 2 O 2 is generated.", [["H 2 O 2", "CHEMICAL", 14, 21]]], ["Hydrogen peroxide as signal molecule activates transcription of psbA.", [["Hydrogen peroxide", "CHEMICAL", 0, 17], ["Hydrogen peroxide", "CHEMICAL", 0, 17], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 0, 17], ["psbA", "GENE_OR_GENE_PRODUCT", 64, 68], ["psbA", "DNA", 64, 68], ["Hydrogen peroxide", "TREATMENT", 0, 17]]], ["Turnover of PSII is occurred.", [["PSII", "GENE_OR_GENE_PRODUCT", 12, 16], ["PSII", "PROTEIN", 12, 16], ["PSII", "OBSERVATION", 12, 16]]], ["More long heating induces degradation of proteins and lipids and H 2 O 2 represents as the destructive agent.Perception of Nod Factors in the Legume-Rhizobia symbiosis: in silico studies on Medicago truncatulaA.", [["H 2 O", "CHEMICAL", 65, 70], ["H 2 O 2", "CHEMICAL", 65, 72], ["lipids", "SIMPLE_CHEMICAL", 54, 60], ["H 2 O 2", "SIMPLE_CHEMICAL", 65, 72], ["Nod", "GENE_OR_GENE_PRODUCT", 123, 126], ["Medicago truncatulaA", "ORGANISM", 190, 210], ["Nod Factors", "PROTEIN", 123, 134], ["Medicago truncatulaA", "SPECIES", 190, 210], ["Medicago truncatulaA", "SPECIES", 190, 210], ["lipids", "TEST", 54, 60], ["the destructive agent", "PROBLEM", 87, 108], ["Nod Factors", "PROBLEM", 123, 134], ["silico studies", "TEST", 172, 186], ["destructive", "OBSERVATION_MODIFIER", 91, 102], ["Rhizobia symbiosis", "OBSERVATION", 149, 167]]], ["Nurisso 1 , M. A. Morando 2 , F. J. Ca\u00f1ada 2 , J. J. Barbero 2 , A. Imberty 1 1 CERMAV-CNRS, Grenoble, France, 2 Centro de Investigaciones Biol\u00f3gicas, Madrid, SpainPerception of Nod Factors in the Legume-Rhizobia symbiosis: in silico studies on Medicago truncatulaThe mechanism of symbiosis between legume plants and Rhizobial bacteria is a relevant topic of interest since it is at the basis of the nitrogen fixation process.", [["nitrogen", "CHEMICAL", 400, 408], ["Medicago truncatula", "ORGANISM", 245, 264], ["legume plants", "ORGANISM", 299, 312], ["Rhizobial bacteria", "ORGANISM", 317, 335], ["nitrogen", "SIMPLE_CHEMICAL", 400, 408], ["Medicago truncatula", "SPECIES", 245, 264], ["Medicago truncatula", "SPECIES", 245, 264], ["Nod Factors", "PROBLEM", 178, 189], ["silico studies", "TEST", 227, 241], ["symbiosis between legume plants", "PROBLEM", 281, 312], ["Rhizobial bacteria", "PROBLEM", 317, 335], ["the nitrogen fixation process", "TREATMENT", 396, 425], ["Rhizobia symbiosis", "OBSERVATION", 204, 222], ["symbiosis", "OBSERVATION", 281, 290], ["legume plants", "OBSERVATION", 299, 312], ["Rhizobial bacteria", "OBSERVATION", 317, 335], ["nitrogen fixation", "OBSERVATION", 400, 417]]], ["This mechanism is strictly related to the production of lipochitooligosaccharides, Nod Factors (NF), which allow the bacterial invasion into the legume host roots.", [["roots", "ANATOMY", 157, 162], ["lipochitooligosaccharides", "SIMPLE_CHEMICAL", 56, 81], ["Nod Factors", "GENE_OR_GENE_PRODUCT", 83, 94], ["NF", "GENE_OR_GENE_PRODUCT", 96, 98], ["roots", "ORGAN", 157, 162], ["lipochitooligosaccharides", "PROTEIN", 56, 81], ["Nod Factors", "PROTEIN", 83, 94], ["NF", "PROTEIN", 96, 98], ["the production of lipochitooligosaccharides", "PROBLEM", 38, 81], ["the bacterial invasion", "PROBLEM", 113, 135], ["strictly related to", "UNCERTAINTY", 18, 37], ["bacterial", "OBSERVATION_MODIFIER", 117, 126], ["invasion", "OBSERVATION", 127, 135], ["legume host roots", "OBSERVATION", 145, 162]]], ["In Medicago truncatula, the recognition of NF from the symbiont Sinorhizobium meliloti requires the NFP gene, able to encode a LysM-motif receptor-like kinase.", [["Medicago truncatula", "ORGANISM", 3, 22], ["NF", "GENE_OR_GENE_PRODUCT", 43, 45], ["Sinorhizobium meliloti", "ORGANISM", 64, 86], ["NFP", "GENE_OR_GENE_PRODUCT", 100, 103], ["LysM-motif receptor-like kinase", "GENE_OR_GENE_PRODUCT", 127, 158], ["NF", "PROTEIN", 43, 45], ["NFP gene", "DNA", 100, 108], ["LysM-motif receptor-like kinase", "PROTEIN", 127, 158], ["Medicago truncatula", "SPECIES", 3, 22], ["Sinorhizobium meliloti", "SPECIES", 64, 86], ["Medicago truncatula", "SPECIES", 3, 22], ["Sinorhizobium meliloti", "SPECIES", 64, 86], ["NF", "PROBLEM", 43, 45], ["the symbiont Sinorhizobium meliloti", "PROBLEM", 51, 86], ["Medicago truncatula", "OBSERVATION", 3, 22]]], ["The extracellular part of this protein is characterized by three LysM motifs: only one of them seems to be involved in the NF recognition.", [["extracellular", "ANATOMY", 4, 17], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["NF", "GENE_OR_GENE_PRODUCT", 123, 125], ["LysM motifs", "PROTEIN", 65, 76]]], ["First of all, the conformational behaviors of a new generation of NF analogues were elucidated by MDs simulation.", [["NF analogues", "SIMPLE_CHEMICAL", 66, 78], ["a new generation of NF analogues", "PROBLEM", 46, 78]]], ["Then, a homology model of the LysM2 domain from M. truncatula was proposed and compared with a model of LysM domain from Pisum sativum: docking calculations of natural NF identified a common binding site in which the carbohydrate portion is the main responsible of the binding.", [["carbohydrate", "CHEMICAL", 217, 229], ["LysM2", "GENE_OR_GENE_PRODUCT", 30, 35], ["M. truncatula", "ORGANISM", 48, 61], ["LysM", "GENE_OR_GENE_PRODUCT", 104, 108], ["Pisum sativum", "ORGANISM", 121, 134], ["NF", "GENE_OR_GENE_PRODUCT", 168, 170], ["LysM2 domain", "PROTEIN", 30, 42], ["LysM domain", "PROTEIN", 104, 115], ["natural NF", "PROTEIN", 160, 170], ["carbohydrate portion", "PROTEIN", 217, 237], ["M. truncatula", "SPECIES", 48, 61], ["Pisum sativum", "SPECIES", 121, 134], ["M. truncatula", "SPECIES", 48, 61], ["Pisum sativum", "SPECIES", 121, 134], ["Pisum sativum", "TEST", 121, 134], ["natural NF", "TREATMENT", 160, 170], ["a common binding site", "PROBLEM", 182, 203], ["main", "OBSERVATION_MODIFIER", 245, 249], ["binding", "OBSERVATION", 269, 276]]], ["Both studies provide support for the idea that the carbohydrate part of NF plays a key role in the interaction with LysM domains, while the lipid moiety modulates ligand specificity probably interacting with a potential second receptor.O-251Interaction between frutalin with biomembrane models and its correlation with cell adhesion propertyO-251Frutalin is a homotetrameric lectin D-Galactose (D-Gal) binding that activates natural killer cells in vitro and leukocyte migration in vivo, being a potent lymphocyte stimulator.", [["cell", "ANATOMY", 319, 323], ["natural killer cells", "ANATOMY", 425, 445], ["leukocyte", "ANATOMY", 459, 468], ["lymphocyte", "ANATOMY", 503, 513], ["frutalin", "CHEMICAL", 261, 269], ["propertyO-251", "CHEMICAL", 333, 346], ["Frutalin", "CHEMICAL", 346, 354], ["D-Galactose", "CHEMICAL", 382, 393], ["D-Gal", "CHEMICAL", 395, 400], ["carbohydrate", "CHEMICAL", 51, 63], ["frutalin", "CHEMICAL", 261, 269], ["propertyO-251", "CHEMICAL", 333, 346], ["Frutalin", "CHEMICAL", 346, 354], ["D-Galactose", "CHEMICAL", 382, 393], ["D-Gal", "CHEMICAL", 395, 400], ["NF", "GENE_OR_GENE_PRODUCT", 72, 74], ["LysM", "GENE_OR_GENE_PRODUCT", 116, 120], ["O-251Interaction", "SIMPLE_CHEMICAL", 236, 252], ["frutalin", "SIMPLE_CHEMICAL", 261, 269], ["cell", "CELL", 319, 323], ["Frutalin", "SIMPLE_CHEMICAL", 346, 354], ["D-Galactose", "SIMPLE_CHEMICAL", 382, 393], ["D-Gal", "SIMPLE_CHEMICAL", 395, 400], ["natural killer cells", "CELL", 425, 445], ["leukocyte", "CELL", 459, 468], ["lymphocyte", "CELL", 503, 513], ["NF", "PROTEIN", 72, 74], ["LysM domains", "PROTEIN", 116, 128], ["natural killer cells", "CELL_TYPE", 425, 445], ["Both studies", "TEST", 0, 12], ["LysM domains", "TREATMENT", 116, 128], ["biomembrane models", "TREATMENT", 275, 293], ["cell adhesion propertyO", "TREATMENT", 319, 342], ["Galactose (D-Gal) binding", "TREATMENT", 384, 409], ["natural killer cells", "TREATMENT", 425, 445], ["vitro and leukocyte migration", "TREATMENT", 449, 478], ["a potent lymphocyte stimulator", "TREATMENT", 494, 524], ["natural killer cells", "OBSERVATION", 425, 445], ["leukocyte migration", "OBSERVATION", 459, 478], ["potent lymphocyte stimulator", "OBSERVATION", 496, 524]]], ["In this study we investigated the interaction of frutalin with different phospho/glyco-lipids using Langmuir monolayers as biomembrane mimetic system.", [["frutalin", "CHEMICAL", 49, 57], ["frutalin", "CHEMICAL", 49, 57], ["phospho", "CHEMICAL", 73, 80], ["frutalin", "SIMPLE_CHEMICAL", 49, 57], ["phospho", "SIMPLE_CHEMICAL", 73, 80], ["glyco-lipids", "SIMPLE_CHEMICAL", 81, 93], ["this study", "TEST", 3, 13], ["frutalin", "TREATMENT", 49, 57], ["different phospho/glyco-lipids", "TREATMENT", 63, 93], ["Langmuir monolayers", "TREATMENT", 100, 119], ["biomembrane mimetic system", "TREATMENT", 123, 149]]], ["The results attest the specificity of the protein for the carbohydrate D-Gal when attached to the biomembrane model.", [["carbohydrate D-Gal", "CHEMICAL", 58, 76], ["carbohydrate D-Gal", "GENE_OR_GENE_PRODUCT", 58, 76], ["carbohydrate D-Gal", "PROTEIN", 58, 76], ["the carbohydrate D-Gal", "TREATMENT", 54, 76], ["the biomembrane model", "TREATMENT", 94, 115]]], ["The adsorption kinetics for frutalin to the mixed monolayers containing glycolipids showed that the interaction depends on the presence of charged groups and on the position of the D-Gal on the polar head of the glycolipid.", [["monolayers", "ANATOMY", 50, 60], ["head", "ANATOMY", 200, 204], ["frutalin", "CHEMICAL", 28, 36], ["D-Gal", "CHEMICAL", 181, 186], ["frutalin", "CHEMICAL", 28, 36], ["D-Gal", "CHEMICAL", 181, 186], ["frutalin", "SIMPLE_CHEMICAL", 28, 36], ["monolayers", "CELL", 50, 60], ["D-Gal", "GENE_OR_GENE_PRODUCT", 181, 186], ["head", "ORGAN", 200, 204], ["D-Gal", "PROTEIN", 181, 186], ["The adsorption kinetics", "TREATMENT", 0, 23], ["frutalin", "TREATMENT", 28, 36], ["the mixed monolayers containing glycolipids", "TREATMENT", 40, 83], ["charged", "OBSERVATION", 139, 146], ["polar", "ANATOMY_MODIFIER", 194, 199], ["head", "ANATOMY", 200, 204]]], ["Using Brewster angle microscopy (BAM), we investigated the morphology of the interface for the binary mixtures containing GalCer, where small domains were formed at high lipid packing, suggesting that frutalin can induce the formation of likelipid rafts domains in vitro.", [["GalCer", "CHEMICAL", 122, 128], ["frutalin", "CHEMICAL", 201, 209], ["GalCer", "CHEMICAL", 122, 128], ["frutalin", "CHEMICAL", 201, 209], ["GalCer", "SIMPLE_CHEMICAL", 122, 128], ["frutalin", "SIMPLE_CHEMICAL", 201, 209], ["GalCer", "PROTEIN", 122, 128], ["likelipid rafts domains", "PROTEIN", 238, 261], ["Brewster angle microscopy", "TEST", 6, 31], ["GalCer", "TREATMENT", 122, 128], ["small domains", "PROBLEM", 136, 149], ["high lipid packing", "TREATMENT", 165, 183], ["frutalin", "TREATMENT", 201, 209], ["small", "OBSERVATION_MODIFIER", 136, 141], ["high", "OBSERVATION_MODIFIER", 165, 169], ["lipid packing", "OBSERVATION", 170, 183], ["likelipid rafts", "OBSERVATION", 238, 253]]], ["The results obtained with the membrane models were associated with those from fibroblast adhesion induction.", [["membrane", "ANATOMY", 30, 38], ["fibroblast", "ANATOMY", 78, 88], ["membrane", "CELLULAR_COMPONENT", 30, 38], ["fibroblast", "CELL", 78, 88], ["the membrane models", "TEST", 26, 45], ["fibroblast adhesion induction", "TREATMENT", 78, 107], ["fibroblast adhesion", "OBSERVATION", 78, 97]]], ["The cell adhesion promoted by frutalin is in accordance with the results observed in Langmuir monolayers, which probes the specificity of the interaction between the lectin and D-Gal on cell-membrane surfaces.", [["cell", "ANATOMY", 4, 8], ["cell-membrane surfaces", "ANATOMY", 186, 208], ["frutalin", "CHEMICAL", 30, 38], ["frutalin", "CHEMICAL", 30, 38], ["D-Gal", "CHEMICAL", 177, 182], ["cell", "CELL", 4, 8], ["frutalin", "SIMPLE_CHEMICAL", 30, 38], ["lectin", "GENE_OR_GENE_PRODUCT", 166, 172], ["D-Gal", "GENE_OR_GENE_PRODUCT", 177, 182], ["cell", "CELL", 186, 190], ["membrane surfaces", "CELLULAR_COMPONENT", 191, 208], ["Langmuir monolayers", "CELL_LINE", 85, 104], ["lectin", "PROTEIN", 166, 172], ["D-Gal", "PROTEIN", 177, 182], ["The cell adhesion", "TREATMENT", 0, 17], ["Langmuir monolayers", "TEST", 85, 104], ["cell adhesion", "OBSERVATION", 4, 17]]], ["Based on these results, frutalin can be considered as a promise biotechnological tool to actuate in tissue engineering regeneration.", [["tissue", "ANATOMY", 100, 106], ["frutalin", "CHEMICAL", 24, 32], ["frutalin", "CHEMICAL", 24, 32], ["frutalin", "SIMPLE_CHEMICAL", 24, 32], ["tissue", "TISSUE", 100, 106], ["frutalin", "TREATMENT", 24, 32], ["tissue engineering regeneration", "PROBLEM", 100, 131], ["tissue", "ANATOMY", 100, 106], ["engineering regeneration", "OBSERVATION", 107, 131]]], ["Supported by FAPESP, CNPq and CAPES Aggregation and glycation processes of proteins are of peculiar interest for several scientific fields.", [["CNPq", "TREATMENT", 21, 25], ["CAPES Aggregation", "TREATMENT", 30, 47]]], ["Serum albumins are widely studied proteins for their ability to self-assemble in aggregates and also to undergo to non enzymatic glycosylation in cases of diabetes.", [["Serum", "ANATOMY", 0, 5], ["diabetes", "DISEASE", 155, 163], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["albumins", "GENE_OR_GENE_PRODUCT", 6, 14], ["Serum albumins", "TEST", 0, 14], ["enzymatic glycosylation", "TREATMENT", 119, 142], ["diabetes", "PROBLEM", 155, 163], ["diabetes", "OBSERVATION", 155, 163]]], ["In this work we report a study on thermal aggregation of glycated bovine serum albumin (BSA) prepared with different concentrations of glucose at pH 7.4.", [["serum", "ANATOMY", 73, 78], ["glucose", "CHEMICAL", 135, 142], ["glucose", "CHEMICAL", 135, 142], ["bovine", "ORGANISM", 66, 72], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["albumin", "SIMPLE_CHEMICAL", 79, 86], ["BSA", "SIMPLE_CHEMICAL", 88, 91], ["glucose", "SIMPLE_CHEMICAL", 135, 142], ["bovine", "SPECIES", 66, 72], ["a study", "TEST", 23, 30], ["thermal aggregation of glycated bovine serum albumin (BSA)", "TREATMENT", 34, 92], ["glucose at pH", "TEST", 135, 148]]], ["Increasing concentration of sugar modulates the effect of different glycation levels on the protein aggregation.", [["sugar", "CHEMICAL", 28, 33], ["sugar", "SIMPLE_CHEMICAL", 28, 33], ["Increasing concentration of sugar modulates", "PROBLEM", 0, 43], ["different glycation levels", "TEST", 58, 84], ["the protein aggregation", "PROBLEM", 88, 111], ["concentration", "OBSERVATION_MODIFIER", 11, 24], ["sugar modulates", "OBSERVATION_MODIFIER", 28, 43], ["glycation levels", "OBSERVATION", 68, 84], ["protein aggregation", "OBSERVATION", 92, 111]]], ["Fluorescence spectroscopy, FTIR absorption, static and dynamic light scattering are used to follow the time evolution of the aggregation process and of protein conformational changes.", [["Fluorescence spectroscopy", "TEST", 0, 25], ["FTIR absorption", "TEST", 27, 42], ["static and dynamic light scattering", "TEST", 44, 79], ["the aggregation process", "PROBLEM", 121, 144], ["protein conformational changes", "PROBLEM", 152, 182], ["aggregation", "OBSERVATION", 125, 136]]], ["Conformational changes of secondary and tertiary structures are measured by FTIR absorption; the kinetics of Amide I, Amide II and Amide II' bands are monitored.", [["Amide I", "CHEMICAL", 109, 116], ["Amide II", "CHEMICAL", 118, 126], ["Amide II", "CHEMICAL", 131, 139], ["Amide I", "GENE_OR_GENE_PRODUCT", 109, 116], ["Amide II", "GENE_OR_GENE_PRODUCT", 118, 126], ["Amide II", "GENE_OR_GENE_PRODUCT", 131, 139], ["Conformational changes of secondary and tertiary structures", "PROBLEM", 0, 59], ["the kinetics of Amide I, Amide II and Amide II' bands", "TREATMENT", 93, 146], ["secondary", "OBSERVATION_MODIFIER", 26, 35], ["tertiary structures", "OBSERVATION", 40, 59]]], ["The kinetics of tryptophans fluorescence give complementary information on the tertiary structure changes and on the polarity modification of the fluorophores environment.", [["tryptophans", "CHEMICAL", 16, 27], ["tryptophans fluorescence", "TREATMENT", 16, 40], ["the fluorophores environment", "TREATMENT", 142, 170]]], ["The aggregates growth is studied by dynamic light scattering measurements and Rayleigh scattering peak.", [["dynamic light scattering measurements", "TEST", 36, 73], ["Rayleigh scattering peak", "TEST", 78, 102], ["aggregates", "OBSERVATION_MODIFIER", 4, 14], ["growth", "OBSERVATION_MODIFIER", 15, 21], ["Rayleigh", "OBSERVATION_MODIFIER", 78, 86], ["scattering peak", "OBSERVATION", 87, 102]]], ["The results show that the partial unfolding of the protein is not affected by the glycation, while the presence of increasing amounts of glycated molecules progressively inhibits the aggregates formation.O-249Solvent occupancy analysis in ligand structure prediction: the case of Galectin-1 S. Di Lella, M. A. Mart\u00ed, D. A. Estrin INQUIMAE-CONICET, Universidad de Buenos Aires, Argentina Formation of protein ligand complexes is a fundamental phenomenum in biochemistry.", [["O-249", "CHEMICAL", 204, 209], ["O-249", "CHEMICAL", 204, 209], ["glycated molecules", "PROTEIN", 137, 155], ["protein ligand complexes", "PROTEIN", 400, 424], ["the partial unfolding of the protein", "PROBLEM", 22, 58], ["increasing amounts of glycated molecules", "PROBLEM", 115, 155], ["the aggregates formation", "PROBLEM", 179, 203], ["Galectin", "TEST", 280, 288], ["protein ligand complexes", "PROBLEM", 400, 424], ["a fundamental phenomenum in biochemistry", "PROBLEM", 428, 468], ["partial", "OBSERVATION_MODIFIER", 26, 33], ["unfolding", "OBSERVATION", 34, 43], ["glycation", "OBSERVATION", 82, 91], ["increasing", "OBSERVATION_MODIFIER", 115, 125], ["amounts", "OBSERVATION_MODIFIER", 126, 133], ["glycated molecules", "OBSERVATION", 137, 155], ["aggregates formation", "OBSERVATION", 183, 203], ["protein ligand complexes", "OBSERVATION", 400, 424], ["fundamental phenomenum", "OBSERVATION", 430, 452]]], ["During the process, significant solvent reorganization is produced along the contact surface.", [["surface", "ANATOMY", 85, 92], ["contact surface", "CELLULAR_COMPONENT", 77, 92], ["significant solvent reorganization", "PROBLEM", 20, 54], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["solvent reorganization", "OBSERVATION", 32, 54], ["contact surface", "OBSERVATION", 77, 92]]], ["Using MD simulations in explicit solvent combined with statistical mechanics analysis, thermodynamic properties of water molecules around proteins can be computed and analyzed in a comparative view.", [["water molecules", "PROTEIN", 115, 130], ["explicit solvent", "TREATMENT", 24, 40], ["statistical mechanics analysis", "TEST", 55, 85]]], ["Based on this idea, we developed a set of analysis tools to link solvation with ligand binding in a key carbohydrate binding protein, human galectin-1 (hGal-1).", [["carbohydrate", "CHEMICAL", 104, 116], ["human", "ORGANISM", 134, 139], ["galectin-1", "GENE_OR_GENE_PRODUCT", 140, 150], ["hGal-1", "GENE_OR_GENE_PRODUCT", 152, 158], ["carbohydrate binding protein", "PROTEIN", 104, 132], ["human galectin-1", "PROTEIN", 134, 150], ["hGal", "PROTEIN", 152, 156], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["ligand binding", "PROBLEM", 80, 94], ["human galectin", "TEST", 134, 148]]], ["Specifically, we defined water sites (WS) in terms of the thermodynamic properties of water molecules strongly bound to protein surfaces.", [["water sites", "OBSERVATION_MODIFIER", 25, 36]]], ["We then succesfully extended the analysis of the role of the surface associated water molecules in the ligand binding and recognition process to many other carbohydrate binding proteins.", [["surface", "ANATOMY", 61, 68], ["carbohydrate", "CHEMICAL", 156, 168], ["surface", "CELLULAR_COMPONENT", 61, 68], ["carbohydrate binding proteins", "GENE_OR_GENE_PRODUCT", 156, 185], ["surface associated water molecules", "PROTEIN", 61, 95], ["carbohydrate binding proteins", "PROTEIN", 156, 185], ["many other carbohydrate binding proteins", "PROBLEM", 145, 185], ["water molecules", "OBSERVATION", 80, 95]]], ["Our results show that the probability of finding water molecules inside the WS, p(v), with respect to the bulk density is directly correlated to the likeliness of finding an oxhydril group of the ligand in the protein-ligand complex.", [["oxhydril", "CHEMICAL", 174, 182], ["oxhydril", "CHEMICAL", 174, 182], ["oxhydril", "SIMPLE_CHEMICAL", 174, 182], ["protein-ligand complex", "PROTEIN", 210, 232], ["the bulk density", "PROBLEM", 102, 118], ["bulk", "OBSERVATION_MODIFIER", 106, 110], ["density", "OBSERVATION", 111, 118], ["ligand complex", "OBSERVATION", 218, 232]]], ["This information can be used to predict possible complex structures when unavailable, and suggest addition of OHcontaining functional groups to displace water from high p(v) WS to enhance drug, specially glycomimetic-drugs, protein affinity and/or specificity.O-248Glyconanoparticles: Nano-biomaterials for application in biotechnology and biomedicine S. Penad\u00e9s Laboratory of GlycoNanotecnology, CICbiomaGUNE -CIBER-BBN, San Sebastian, SpainO-248To study and intervene in carbohydrate interactions our laboratory has developed a chemical strategy (Glyconanotechnology) to produce sugar functionalized gold nanoclusters with multivalent carbohydrate display (glyconanoparticles, GNPs).", [["O-248Glyconanoparticles", "CHEMICAL", 260, 283], ["SpainO-248To", "CHEMICAL", 437, 449], ["O-248Glyconanoparticles", "CHEMICAL", 260, 283], ["carbohydrate", "CHEMICAL", 473, 485], ["sugar", "CHEMICAL", 581, 586], ["carbohydrate", "CHEMICAL", 637, 649], ["O-248Glyconanoparticles", "SIMPLE_CHEMICAL", 260, 283], ["sugar functionalized gold nanoclusters", "SIMPLE_CHEMICAL", 581, 619], ["carbohydrate", "SIMPLE_CHEMICAL", 637, 649], ["glyconanoparticles", "SIMPLE_CHEMICAL", 659, 677], ["GNPs", "SIMPLE_CHEMICAL", 679, 683], ["OHcontaining functional groups", "TREATMENT", 110, 140], ["high p(v) WS", "TREATMENT", 164, 176], ["specially glycomimetic-drugs", "TREATMENT", 194, 222], ["protein affinity", "TEST", 224, 240], ["Nano-biomaterials", "TREATMENT", 285, 302], ["GlycoNanotecnology", "TEST", 377, 395], ["CICbiomaGUNE", "TEST", 397, 409], ["sugar functionalized gold nanoclusters", "PROBLEM", 581, 619]]], ["By combining these tools with biophysical and analytic surface techniques (ITC, AFM, TEM, SPR) we have demonstrated and evaluated Ca 2+ -mediated carbohydratecarbohydrate interactions involved in cell adhesion processes.", [["surface", "ANATOMY", 55, 62], ["cell", "ANATOMY", 196, 200], ["Ca", "CHEMICAL", 130, 132], ["Ca 2+", "CHEMICAL", 130, 135], ["carbohydratecarbohydrate", "CHEMICAL", 146, 170], ["Ca 2+", "SIMPLE_CHEMICAL", 130, 135], ["carbohydratecarbohydrate", "SIMPLE_CHEMICAL", 146, 170], ["cell", "CELL", 196, 200], ["analytic surface techniques", "TEST", 46, 73], ["Ca", "TEST", 130, 132], ["cell adhesion", "OBSERVATION", 196, 209]]], ["The GNP system complements other currently available multivalent systems incorporating carbohydrates and presents some advantages as: 1) exceptionally small core size; 2) high stability in water and physiological buffers; and 3) multivalency and multifunctionality with control over ligands number.", [["GNP", "CHEMICAL", 4, 7], ["carbohydrates", "CHEMICAL", 87, 100], ["carbohydrates", "SIMPLE_CHEMICAL", 87, 100], ["water", "SIMPLE_CHEMICAL", 189, 194], ["exceptionally small core size", "PROBLEM", 137, 166], ["physiological buffers", "TREATMENT", 199, 220], ["size", "OBSERVATION_MODIFIER", 162, 166], ["high stability", "OBSERVATION_MODIFIER", 171, 185]]], ["Specific GNPs have been applied to the inhibition of melanoma metastasis in mice and as inhibitors of HIV-trans infection.", [["melanoma", "ANATOMY", 53, 61], ["GNPs", "CHEMICAL", 9, 13], ["melanoma", "DISEASE", 53, 61], ["HIV-trans infection", "DISEASE", 102, 121], ["GNPs", "SIMPLE_CHEMICAL", 9, 13], ["melanoma", "CANCER", 53, 61], ["mice", "ORGANISM", 76, 80], ["HIV-trans", "ORGANISM", 102, 111], ["mice", "SPECIES", 76, 80], ["HIV-", "SPECIES", 102, 106], ["mice", "SPECIES", 76, 80], ["HIV", "SPECIES", 102, 105], ["Specific GNPs", "TREATMENT", 0, 13], ["melanoma metastasis", "PROBLEM", 53, 72], ["HIV", "PROBLEM", 102, 105], ["trans infection", "PROBLEM", 106, 121], ["melanoma", "OBSERVATION_MODIFIER", 53, 61], ["metastasis", "OBSERVATION", 62, 72], ["infection", "OBSERVATION", 112, 121]]], ["Magnetic GNPs have also been used in cellular labelling and imaging as probes for MRI.", [["cellular", "ANATOMY", 37, 45], ["GNPs", "CHEMICAL", 9, 13], ["Magnetic GNPs", "SIMPLE_CHEMICAL", 0, 13], ["cellular", "CELL", 37, 45], ["Magnetic GNPs", "TEST", 0, 13], ["imaging", "TEST", 60, 67], ["MRI", "TEST", 82, 85]]], ["In this lecture, the Glyconanotechnology strategy will be presented and some application will be highlighted.O-252-Glycobiophysics -AbstractsExpanded ataxin-1 induces membrane mechanical instability: evidences from model systems and cells C. Canale 1 , S. Averaimo 2 , D. Pesci 3 , D. Paulis 2 , V. Fortunati 3 , A. Gliozzi 4 , M. Mazzanti 2 , C. Jodice 3 , A. Relini 4 1 IIT, Genoa, Italy, 2 University of Milan, Italy, 3 University of Tor Vergata, Rome, Italy, 4 University of Genoa, Italy Spinocerebellar ataxia type 1 is a neurodegenerative disorder involving the expansion of a polyglutamine stretch beyond a threshold in the protein ataxin-1, with intracellular deposition of amyloid aggregates.", [["membrane", "ANATOMY", 167, 175], ["cells", "ANATOMY", 233, 238], ["intracellular", "ANATOMY", 654, 667], ["O-252", "CHEMICAL", 109, 114], ["ataxin-1", "CHEMICAL", 150, 158], ["Spinocerebellar ataxia", "DISEASE", 492, 514], ["neurodegenerative disorder", "DISEASE", 527, 553], ["amyloid aggregates", "DISEASE", 682, 700], ["O-252", "CHEMICAL", 109, 114], ["ataxin-1", "GENE_OR_GENE_PRODUCT", 150, 158], ["membrane", "CELLULAR_COMPONENT", 167, 175], ["cells", "CELL", 233, 238], ["ataxin-1", "GENE_OR_GENE_PRODUCT", 639, 647], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 654, 667], ["protein ataxin-1", "PROTEIN", 631, 647], ["Spinocerebellar ataxia type 1", "SPECIES", 492, 521], ["the Glyconanotechnology strategy", "TREATMENT", 17, 49], ["Glycobiophysics", "TEST", 115, 130], ["ataxin", "TEST", 150, 156], ["membrane mechanical instability", "PROBLEM", 167, 198], ["model systems", "TEST", 215, 228], ["cells C. Canale", "TEST", 233, 248], ["Mazzanti", "TREATMENT", 331, 339], ["Spinocerebellar ataxia type 1", "PROBLEM", 492, 521], ["a neurodegenerative disorder", "PROBLEM", 525, 553], ["a polyglutamine stretch", "PROBLEM", 581, 604], ["the protein ataxin", "TEST", 627, 645], ["intracellular deposition of amyloid aggregates", "PROBLEM", 654, 700], ["mechanical instability", "OBSERVATION", 176, 198], ["Spinocerebellar ataxia", "OBSERVATION", 492, 514], ["neurodegenerative", "OBSERVATION_MODIFIER", 527, 544], ["disorder", "OBSERVATION", 545, 553], ["intracellular deposition", "OBSERVATION", 654, 678], ["amyloid aggregates", "OBSERVATION", 682, 700]]], ["Ataxin-1 variants with polyglutamine stretches of pathological length are not associated to disease when the stretch is interrupted by histidines.", [["histidines", "CHEMICAL", 135, 145], ["Ataxin-1", "GENE_OR_GENE_PRODUCT", 0, 8], ["polyglutamine", "AMINO_ACID", 23, 36], ["Ataxin-1 variants", "DNA", 0, 17], ["Ataxin", "TREATMENT", 0, 6], ["polyglutamine stretches of pathological length", "TREATMENT", 23, 69], ["disease", "PROBLEM", 92, 99], ["not associated to", "UNCERTAINTY", 74, 91], ["disease", "OBSERVATION", 92, 99]]], ["Mounting evidence suggests that ataxin-1 aggregates interact with the nuclear membrane.", [["nuclear membrane", "ANATOMY", 70, 86], ["ataxin-1", "GENE_OR_GENE_PRODUCT", 32, 40], ["nuclear membrane", "CELLULAR_COMPONENT", 70, 86], ["ataxin", "PROTEIN", 32, 38], ["ataxin", "TREATMENT", 32, 38], ["nuclear membrane", "ANATOMY", 70, 86]]], ["To get insight into the mechanisms leading to neurological disorders, we studied model lipid membranes containing an expanded pathological form of ataxin-1 or expanded normal forms interrupted by histidines.", [["neurological", "ANATOMY", 46, 58], ["lipid membranes", "ANATOMY", 87, 102], ["neurological disorders", "DISEASE", 46, 68], ["histidines", "CHEMICAL", 196, 206], ["lipid membranes", "CELLULAR_COMPONENT", 87, 102], ["ataxin-1", "GENE_OR_GENE_PRODUCT", 147, 155], ["ataxin-1", "PROTEIN", 147, 155], ["neurological disorders", "PROBLEM", 46, 68], ["model lipid membranes", "TREATMENT", 81, 102], ["ataxin", "TREATMENT", 147, 153], ["lipid membranes", "OBSERVATION", 87, 102], ["normal", "OBSERVATION", 168, 174]]], ["Electrical measurements on planar bilayers showed the occurrence of current steps, much larger for the pathological form, indicating the formation of pore-like structures.", [["pore-like structures", "ANATOMY", 150, 170], ["Electrical measurements on planar bilayers", "TEST", 0, 42], ["pore-like structures", "PROBLEM", 150, 170], ["larger", "OBSERVATION_MODIFIER", 88, 94], ["pore", "OBSERVATION_MODIFIER", 150, 154]]], ["Atomic force microscopy measurements showed that the longer the polyglutamine tract, the smaller was the force required to penetrate the bilayer with the AFM tip.", [["polyglutamine tract", "ANATOMY", 64, 83], ["polyglutamine tract", "ORGANISM_SUBDIVISION", 64, 83], ["Atomic force microscopy measurements", "TEST", 0, 36], ["the longer the polyglutamine tract", "PROBLEM", 49, 83], ["the AFM tip", "TREATMENT", 150, 161], ["polyglutamine tract", "OBSERVATION", 64, 83], ["smaller", "OBSERVATION_MODIFIER", 89, 96]]], ["The smallest penetration force, and then the strongest membrane destabilization, was observed for membranes containing the expanded pathological form.", [["membrane", "ANATOMY", 55, 63], ["membranes", "ANATOMY", 98, 107], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["membranes", "CELLULAR_COMPONENT", 98, 107], ["The smallest penetration force", "PROBLEM", 0, 30], ["the strongest membrane destabilization", "TREATMENT", 41, 79], ["membranes", "PROBLEM", 98, 107], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["penetration force", "OBSERVATION", 13, 30]]], ["Experiments on COS1 cells provided evidence that pathological protein aggregates damage the nuclear membrane eventually causing cell autophagy.O-256Modification by Dopamine adducts links \u03b1synuclein to oxidative stress in Parkinson disease M. Bisaglia 1 , E. Greggio 2 , L. Tosatto 1 , F. Munari 1 , I. Tessari 1 , P. Polverino de Laureto 1 , S. Mammi 1 , M. R. Cookson 2 , L. Bubacco 1 1 University of Padova, Italy, 2 NIH, Bethesda, MD, USA Oxidative stress has been proposed to be involved in the pathogenesis of Parkinson disease (PD).", [["COS1 cells", "ANATOMY", 15, 25], ["nuclear membrane", "ANATOMY", 92, 108], ["cell", "ANATOMY", 128, 132], ["O-256Modification", "CHEMICAL", 143, 160], ["Dopamine", "CHEMICAL", 164, 172], ["\u03b1synuclein", "CHEMICAL", 187, 197], ["Parkinson disease", "DISEASE", 221, 238], ["Parkinson disease", "DISEASE", 515, 532], ["PD", "DISEASE", 534, 536], ["O-256Modification", "CHEMICAL", 143, 160], ["Dopamine", "CHEMICAL", 164, 172], ["COS1 cells", "CELL", 15, 25], ["nuclear membrane", "CELLULAR_COMPONENT", 92, 108], ["cell", "CELL", 128, 132], ["O-256Modification", "SIMPLE_CHEMICAL", 143, 160], ["Dopamine adducts", "SIMPLE_CHEMICAL", 164, 180], ["\u03b1synuclein", "SIMPLE_CHEMICAL", 187, 197], ["COS1 cells", "CELL_LINE", 15, 25], ["pathological protein aggregates damage the nuclear membrane", "PROBLEM", 49, 108], ["cell autophagy", "PROBLEM", 128, 142], ["Dopamine adducts", "TREATMENT", 164, 180], ["oxidative stress in Parkinson disease", "PROBLEM", 201, 238], ["Bisaglia", "TEST", 242, 250], ["Greggio", "TEST", 258, 265], ["Parkinson disease", "PROBLEM", 515, 532], ["nuclear membrane", "ANATOMY", 92, 108], ["cell autophagy", "OBSERVATION", 128, 142], ["Parkinson disease", "OBSERVATION", 221, 238], ["Parkinson disease", "OBSERVATION", 515, 532]]], ["A plausible source of oxidative stress in nigral dopaminergic neurons is the redox reactions that specifically involve dopamine (DA) and produce various toxic molecules, i.e., free radicals and quinone species. \u03b1-Synuclein (\u03b1Syn), a small protein found in Lewy bodies characteristic of PD, is also thought to be involved in the pathogenesis of PD.", [["nigral dopaminergic neurons", "ANATOMY", 42, 69], ["Lewy bodies", "ANATOMY", 256, 267], ["dopamine", "CHEMICAL", 119, 127], ["DA", "CHEMICAL", 129, 131], ["quinone", "CHEMICAL", 194, 201], ["PD", "DISEASE", 286, 288], ["PD", "DISEASE", 344, 346], ["dopamine", "CHEMICAL", 119, 127], ["quinone", "CHEMICAL", 194, 201], ["nigral dopaminergic neurons", "CELL", 42, 69], ["dopamine", "SIMPLE_CHEMICAL", 119, 127], ["DA", "SIMPLE_CHEMICAL", 129, 131], ["free radicals", "SIMPLE_CHEMICAL", 176, 189], ["quinone species", "SIMPLE_CHEMICAL", 194, 209], ["\u03b1-Synuclein", "GENE_OR_GENE_PRODUCT", 211, 222], ["\u03b1Syn", "GENE_OR_GENE_PRODUCT", 224, 228], ["nigral dopaminergic neurons", "CELL_TYPE", 42, 69], ["\u03b1-Synuclein", "PROTEIN", 211, 222], ["\u03b1Syn", "PROTEIN", 224, 228], ["oxidative stress in nigral dopaminergic neurons", "PROBLEM", 22, 69], ["the redox reactions", "PROBLEM", 73, 92], ["dopamine (DA", "TREATMENT", 119, 131], ["various toxic molecules", "PROBLEM", 145, 168], ["free radicals and quinone species", "PROBLEM", 176, 209], ["Synuclein (\u03b1Syn", "TREATMENT", 213, 228], ["a small protein", "PROBLEM", 231, 246], ["PD", "PROBLEM", 286, 288], ["PD", "PROBLEM", 344, 346], ["oxidative stress", "OBSERVATION", 22, 38], ["toxic molecules", "OBSERVATION", 153, 168], ["quinone species", "OBSERVATION", 194, 209], ["small protein", "OBSERVATION_MODIFIER", 233, 246], ["Lewy bodies", "OBSERVATION", 256, 267], ["PD", "OBSERVATION", 286, 288], ["thought to be", "UNCERTAINTY", 298, 311]]], ["To investigate the possibility of a synergistic role of oxidative stress and \u03b1Syn in PD, we analyzed the modulation of DA toxicity by \u03b1Syn overexpression in dopaminergic human neuroblastoma cells.", [["neuroblastoma cells", "ANATOMY", 176, 195], ["PD", "DISEASE", 85, 87], ["DA", "CHEMICAL", 119, 121], ["toxicity", "DISEASE", 122, 130], ["neuroblastoma", "DISEASE", 176, 189], ["\u03b1Syn", "GENE_OR_GENE_PRODUCT", 77, 81], ["DA", "SIMPLE_CHEMICAL", 119, 121], ["\u03b1Syn", "GENE_OR_GENE_PRODUCT", 134, 138], ["human", "ORGANISM", 170, 175], ["neuroblastoma cells", "CELL", 176, 195], ["\u03b1Syn", "PROTEIN", 77, 81], ["\u03b1Syn", "PROTEIN", 134, 138], ["dopaminergic human neuroblastoma cells", "CELL_LINE", 157, 195], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["oxidative stress", "PROBLEM", 56, 72], ["DA toxicity", "PROBLEM", 119, 130], ["dopaminergic human neuroblastoma cells", "PROBLEM", 157, 195], ["dopaminergic human neuroblastoma cells", "OBSERVATION", 157, 195]]], ["Our results indicate that the increased expression of \u03b1Syn enhances the cellular toxicity induced by the accumulation of intracellular DA.", [["cellular", "ANATOMY", 72, 80], ["intracellular", "ANATOMY", 121, 134], ["toxicity", "DISEASE", 81, 89], ["DA", "CHEMICAL", 135, 137], ["\u03b1Syn", "GENE_OR_GENE_PRODUCT", 54, 58], ["cellular", "CELL", 72, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 121, 134], ["DA", "SIMPLE_CHEMICAL", 135, 137], ["\u03b1Syn", "PROTEIN", 54, 58], ["the cellular toxicity", "PROBLEM", 68, 89], ["intracellular DA", "PROBLEM", 121, 137], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["cellular toxicity", "OBSERVATION", 72, 89], ["intracellular DA", "OBSERVATION", 121, 137]]], ["We then correlated our results with the structural modifications induced by the oxidation products of DA on \u03b1Syn by studying two potential pathways for the oxidative chemistry associated with DA.", [["DA", "CHEMICAL", 102, 104], ["DA", "CHEMICAL", 192, 194], ["DA", "SIMPLE_CHEMICAL", 102, 104], ["\u03b1Syn", "GENE_OR_GENE_PRODUCT", 108, 112], ["DA", "SIMPLE_CHEMICAL", 192, 194], ["\u03b1Syn", "PROTEIN", 108, 112], ["the oxidative chemistry", "PROBLEM", 152, 175]]], ["The first one is the auto-oxidation reaction which leads to the concomitant formation of radical and quinone species.", [["quinone", "CHEMICAL", 101, 108], ["quinone", "CHEMICAL", 101, 108], ["radical", "SIMPLE_CHEMICAL", 89, 96], ["quinone species", "SIMPLE_CHEMICAL", 101, 116], ["the auto-oxidation reaction", "PROBLEM", 17, 44], ["radical and quinone species", "PROBLEM", 89, 116], ["auto-oxidation reaction", "OBSERVATION", 21, 44], ["radical", "OBSERVATION_MODIFIER", 89, 96], ["quinone species", "OBSERVATION", 101, 116]]], ["The second is the enzymatic oxidation, mediated by tyrosinase, which leads only to the accumulation of quinones.", [["quinones", "CHEMICAL", 103, 111], ["quinones", "CHEMICAL", 103, 111], ["tyrosinase", "GENE_OR_GENE_PRODUCT", 51, 61], ["quinones", "SIMPLE_CHEMICAL", 103, 111], ["tyrosinase", "PROTEIN", 51, 61], ["the enzymatic oxidation", "TREATMENT", 14, 37], ["enzymatic oxidation", "OBSERVATION", 18, 37]]], ["Our data suggest a link between DA and \u03b1Syn in the progression of PD and provide novel insights on both the mechanisms involved in the oxidative chemistry and the aggregation properties of \u03b1Syn.O-255Dynamic Light Scattering aggregation studies of A\u03b2 (1-40) peptide S. Bertini, R. Beretta, D. Gaudesi, A. Naggi, G. Torri Ronzoni Institute, Milan, Italy Heparan sulfate (HS) proteoglycans play a role in formation of amyloid plaques by facilitating formation of amyloid aggregates.", [["amyloid plaques", "ANATOMY", 415, 430], ["DA", "CHEMICAL", 32, 34], ["PD", "DISEASE", 66, 68], ["A\u03b2 (1-40)", "CHEMICAL", 247, 256], ["Heparan sulfate", "CHEMICAL", 352, 367], ["amyloid plaques", "DISEASE", 415, 430], ["Heparan sulfate", "CHEMICAL", 352, 367], ["DA", "SIMPLE_CHEMICAL", 32, 34], ["\u03b1Syn", "GENE_OR_GENE_PRODUCT", 39, 43], ["A\u03b2 (1-40", "SIMPLE_CHEMICAL", 247, 255], ["Heparan sulfate", "SIMPLE_CHEMICAL", 352, 367], ["HS) proteoglycans", "GENE_OR_GENE_PRODUCT", 369, 386], ["amyloid plaques", "PATHOLOGICAL_FORMATION", 415, 430], ["amyloid aggregates", "SIMPLE_CHEMICAL", 460, 478], ["\u03b1Syn", "PROTEIN", 39, 43], ["Our data", "TEST", 0, 8], ["PD", "TREATMENT", 66, 68], ["the oxidative chemistry", "TEST", 131, 154], ["Scattering aggregation studies", "TEST", 213, 243], ["A\u03b2", "TEST", 247, 249], ["Italy Heparan sulfate (HS) proteoglycans", "TREATMENT", 346, 386], ["amyloid plaques", "PROBLEM", 415, 430], ["amyloid aggregates", "PROBLEM", 460, 478], ["amyloid plaques", "OBSERVATION", 415, 430], ["amyloid aggregates", "OBSERVATION", 460, 478]]], ["Heparins and low-molecular weight heparins which mimic HS sequences could interact with amyloid peptides putatively involved in neurodegenerative processes.", [["Heparins", "CHEMICAL", 0, 8], ["Heparins", "CHEMICAL", 0, 8], ["Heparins", "SIMPLE_CHEMICAL", 0, 8], ["low-molecular weight heparins", "SIMPLE_CHEMICAL", 13, 42], ["amyloid peptides", "GENE_OR_GENE_PRODUCT", 88, 104], ["HS sequences", "DNA", 55, 67], ["Heparins", "TREATMENT", 0, 8], ["low-molecular weight heparins", "TREATMENT", 13, 42], ["HS sequences", "TREATMENT", 55, 67], ["amyloid peptides", "TEST", 88, 104], ["neurodegenerative processes", "PROBLEM", 128, 155], ["low", "OBSERVATION_MODIFIER", 13, 16], ["neurodegenerative processes", "OBSERVATION", 128, 155]]], ["The aim of this work is to study the influence of chain length and structure of heparin oligosaccharides on the aggregation of amyloid.", [["heparin", "CHEMICAL", 80, 87], ["amyloid", "DISEASE", 127, 134], ["heparin oligosaccharides", "SIMPLE_CHEMICAL", 80, 104], ["amyloid", "GENE_OR_GENE_PRODUCT", 127, 134], ["heparin oligosaccharides", "TREATMENT", 80, 104], ["amyloid", "PROBLEM", 127, 134], ["heparin oligosaccharides", "OBSERVATION", 80, 104], ["amyloid", "OBSERVATION", 127, 134]]], ["To this purpose, the interaction with amyloid peptide A\u03b2 1\u221240 with a number of heparin/heparin oligosaccharides had been investigated using dynamic light scattering (DLS) which permits to determine the size and the stability of molecular aggregates in solution.", [["A\u03b2 1\u221240", "CHEMICAL", 54, 61], ["heparin", "CHEMICAL", 79, 86], ["heparin", "CHEMICAL", 87, 94], ["amyloid peptide A\u03b2 1\u221240", "SIMPLE_CHEMICAL", 38, 61], ["heparin", "SIMPLE_CHEMICAL", 79, 86], ["heparin oligosaccharides", "SIMPLE_CHEMICAL", 87, 111], ["amyloid peptide", "TEST", 38, 53], ["heparin/heparin oligosaccharides", "TREATMENT", 79, 111], ["size", "OBSERVATION_MODIFIER", 202, 206], ["stability", "OBSERVATION_MODIFIER", 215, 224], ["molecular aggregates", "OBSERVATION", 228, 248]]], ["As indexes of aggregation in solution, two parameters were chosen, i.e., the area under the autocorrelation function (AF) and the average hydrodynamic ratio (Rh).", [["aggregation in solution", "TREATMENT", 14, 37], ["the autocorrelation function", "TEST", 88, 116], ["AF", "TEST", 118, 120], ["aggregation", "OBSERVATION", 14, 25]]], ["We evaluated the aggregation kinetic of different preparations of A\u03b2 and the pH of solubilization.", [["A\u03b2", "SIMPLE_CHEMICAL", 66, 68], ["A\u03b2", "TREATMENT", 66, 68], ["the pH of solubilization", "TREATMENT", 73, 97]]], ["A clear indication was obtained for the trend of aggregation of the peptide A\u03b2 1\u221240 alone and in the presence of oligosaccharides.", [["aggregation", "DISEASE", 49, 60], ["A\u03b2 1\u221240", "CHEMICAL", 76, 83], ["A\u03b2 1\u221240", "CHEMICAL", 76, 83], ["A\u03b2 1\u221240", "SIMPLE_CHEMICAL", 76, 83], ["the peptide A\u03b2", "TREATMENT", 64, 78], ["oligosaccharides", "PROBLEM", 113, 129], ["clear", "OBSERVATION", 2, 7]]], ["The size of the aggregate in the presence of the tetrasaccharide is definitely lower than for the peptide alone.", [["tetrasaccharide", "CHEMICAL", 49, 64], ["size", "OBSERVATION_MODIFIER", 4, 8], ["aggregate", "OBSERVATION_MODIFIER", 16, 25]]], ["The size of the aggregates increases with increasing size of the oligosaccharides.", [["the aggregates", "PROBLEM", 12, 26], ["increasing size of the oligosaccharides", "PROBLEM", 42, 81], ["size", "OBSERVATION_MODIFIER", 4, 8], ["aggregates", "OBSERVATION_MODIFIER", 16, 26], ["increases", "OBSERVATION_MODIFIER", 27, 36], ["increasing", "OBSERVATION_MODIFIER", 42, 52], ["size", "OBSERVATION_MODIFIER", 53, 57], ["oligosaccharides", "ANATOMY_MODIFIER", 65, 81]]], ["In fact, the octasaccharide promotes further aggregation.", [["octasaccharide", "CHEMICAL", 13, 27], ["octasaccharide", "CHEMICAL", 13, 27], ["octasaccharide", "SIMPLE_CHEMICAL", 13, 27], ["aggregation", "OBSERVATION_MODIFIER", 45, 56]]], ["It is crucial for pharmaceutical protein formulations to have low aggregate content.", [["pharmaceutical protein formulations", "TREATMENT", 18, 53], ["low aggregate content", "PROBLEM", 62, 83], ["low aggregate", "OBSERVATION_MODIFIER", 62, 75]]], ["Using the monoclonal IgG1 antibody Rituximab as a model system, we have studied the mechanisms by which antibodies aggregate at physiological pH when incubated at 52-65 \u2022 C. Light scattering showed two coupled stages: An initial fast stage followed by several hours of exponential growth of the scattered intensity.", [["Rituximab", "CHEMICAL", 35, 44], ["IgG1", "GENE_OR_GENE_PRODUCT", 21, 25], ["monoclonal IgG1 antibody", "PROTEIN", 10, 34], ["antibodies", "PROTEIN", 104, 114], ["the monoclonal IgG1 antibody Rituximab", "TREATMENT", 6, 44], ["physiological pH", "TEST", 128, 144], ["the scattered intensity", "PROBLEM", 291, 314], ["fast stage", "OBSERVATION_MODIFIER", 229, 239], ["exponential", "OBSERVATION_MODIFIER", 269, 280], ["growth", "OBSERVATION_MODIFIER", 281, 287], ["scattered", "OBSERVATION_MODIFIER", 295, 304], ["intensity", "OBSERVATION_MODIFIER", 305, 314]]], ["Data analysis showed the fast formation of a large species, which subsequently increased in size.", [["Data analysis", "TEST", 0, 13], ["a large species", "PROBLEM", 43, 58], ["fast formation", "OBSERVATION", 25, 39], ["large", "OBSERVATION_MODIFIER", 45, 50], ["species", "OBSERVATION", 51, 58], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["The aggregate number density had a maximum suggesting that aggregates increase in size by coagulation.", [["aggregate", "OBSERVATION_MODIFIER", 4, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["density", "OBSERVATION", 21, 28], ["aggregates", "OBSERVATION_MODIFIER", 59, 69], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["size", "OBSERVATION_MODIFIER", 82, 86]]], ["The analysis also predicted the actual underlying increase in aggregate mass to be linear and reach saturation.", [["The analysis", "TEST", 0, 12], ["aggregate mass", "PROBLEM", 62, 76], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["aggregate mass", "OBSERVATION", 62, 76], ["linear", "OBSERVATION_MODIFIER", 83, 89]]], ["This was confirmed by size-exclusion chromatography of incubated samples.", [["samples", "ANATOMY", 65, 72], ["size", "OBSERVATION_MODIFIER", 22, 26]]], ["In an Arrhenius plot the activation energy of the first stage was similar to the unfolding energy of the CH2 domain, suggesting a pivotal role of this domain in the aggregation process.", [["CH2 domain", "PROTEIN", 105, 115], ["the unfolding energy of the CH2 domain", "PROBLEM", 77, 115], ["the aggregation process", "PROBLEM", 161, 184], ["Arrhenius plot", "OBSERVATION", 6, 20], ["aggregation process", "OBSERVATION", 165, 184]]], ["CD and fluorescence showed only minor structural changes in the temperature interval studied.", [["CD and fluorescence", "TEST", 0, 19], ["minor structural changes", "PROBLEM", 32, 56], ["minor", "OBSERVATION_MODIFIER", 32, 37], ["structural changes", "OBSERVATION", 38, 56]]], ["We conclude that coagulation is the main mechanism driving Rituximab aggregation and that aggregation is due to small structural changes.P-253-Condensed colloidal phase in biology: from proteins crystals to amyloid fibrils -Abstracts 123 Solid-state NMR structural studies of Alzheimer's disease amyloid \u03b2(1-42) in lipid bilayers J. D. Gehman 1 , A. K. Mehta 2 , F. Separovic 1 1 School of Chemistry, Bio21 Institute, University of Melbourne, 3010 VIC, Australia, 2 Department of Chemistry, Emory University, 1515 Dickey Dr., 30322 Atlanta, GA, USA Amyloid-\u03b2 peptides are believed to cause loss of nerve cell function in individuals suffering from Alzheimer's disease, where evidence suggests that interaction with the cell membrane correlates strongly with cytotoxicity.", [["nerve cell", "ANATOMY", 598, 608], ["cell membrane", "ANATOMY", 719, 732], ["Rituximab", "CHEMICAL", 59, 68], ["aggregation", "DISEASE", 90, 101], ["P-253", "CHEMICAL", 137, 142], ["Alzheimer's disease", "DISEASE", 276, 295], ["amyloid \u03b2(1-42", "CHEMICAL", 296, 310], ["loss of nerve cell function", "DISEASE", 590, 617], ["Alzheimer's disease", "DISEASE", 648, 667], ["Rituximab", "SIMPLE_CHEMICAL", 59, 68], ["Amyloid-\u03b2 peptides", "GENE_OR_GENE_PRODUCT", 549, 567], ["nerve cell", "CELL", 598, 608], ["cell membrane", "CELLULAR_COMPONENT", 719, 732], ["Rituximab aggregation", "TREATMENT", 59, 80], ["aggregation", "PROBLEM", 90, 101], ["small structural changes", "PROBLEM", 112, 136], ["P", "TEST", 137, 138], ["amyloid fibrils", "TEST", 207, 222], ["structural studies", "TEST", 254, 272], ["Alzheimer's disease", "PROBLEM", 276, 295], ["amyloid \u03b2", "TEST", 296, 305], ["USA Amyloid-\u03b2 peptides", "TREATMENT", 545, 567], ["loss of nerve cell function", "PROBLEM", 590, 617], ["Alzheimer's disease", "PROBLEM", 648, 667], ["cytotoxicity", "PROBLEM", 758, 770], ["small", "OBSERVATION_MODIFIER", 112, 117], ["structural", "OBSERVATION", 118, 128], ["colloidal phase", "OBSERVATION_MODIFIER", 153, 168], ["amyloid fibrils", "OBSERVATION", 207, 222], ["nerve cell function", "OBSERVATION", 598, 617]]], ["Previous studies report a range of different but plausible structures, which depend on the molecular environment of the peptide.", [["Previous studies", "TEST", 0, 16]]], ["This sensitivity to sample preparation suggests that the structure relevant to disease is found in lipid bilayer membranes.", [["lipid bilayer membranes", "ANATOMY", 99, 122], ["lipid bilayer membranes", "CELLULAR_COMPONENT", 99, 122], ["sample preparation", "TEST", 20, 38], ["disease", "PROBLEM", 79, 86], ["lipid bilayer membranes", "OBSERVATION", 99, 122]]], ["While model membrane vesicles are too large to be studied by conventional solution NMR, solid-state NMR is one of the few technologies available to study such systems.", [["membrane vesicles", "ANATOMY", 12, 29], ["membrane vesicles", "CELLULAR_COMPONENT", 12, 29], ["model membrane vesicles", "PROBLEM", 6, 29], ["membrane vesicles", "OBSERVATION", 12, 29], ["too large", "OBSERVATION_MODIFIER", 34, 43]]], ["We present recent measurements which suggest a novel peptide structure in a lipid bilayer environment: (i) rotational-echo double-resonance (REDOR) distance measurements between selectively enriched 13 C-carbonyl and 15 N-amide positions constrain dihedral angles of intervening residues and suggest that at least part of the A\u03b2(1-42) peptide folds into a \u03b2-sheet like conformation, in contrast to the helical and coiled structures in previous reports; and (ii) double quantum filtered DRAWS measurements indicate that the extended strand does not assemble into an in-register parallel sheet as reported for amyloid fibrils.P-260A mutation in APP gene with dominant-negative effect on amyloidogenesis: a light scattering study E. Del Favero 1 , G. Di Fede 2 , F. Tagliavini 2 , M. Salmona 3 , L. Cant\u00f9 1 1 University of Milan, Segrate, Italy, 2 \"Carlo Besta\" National Neurological Institute, Milan, Italy, 3 Istituto di Ricerche Farmacologiche \"Mario Negri\", Milan, ItalyP-260We studied the effect of a single-point mutation (A673V) on the aggregative properties of Alzheimer's peptides A\u03b21\u221240.", [["lipid bilayer", "ANATOMY", 76, 89], ["C-carbonyl", "CHEMICAL", 202, 212], ["N-amide", "CHEMICAL", 220, 227], ["A\u03b2(1-42)", "CHEMICAL", 326, 334], ["amyloid fibrils", "DISEASE", 608, 623], ["amyloidogenesis", "DISEASE", 685, 700], ["\u03b21\u221240", "CHEMICAL", 1088, 1093], ["C-carbonyl and 15 N-amide", "CHEMICAL", 202, 227], ["C-carbonyl", "SIMPLE_CHEMICAL", 202, 212], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 608, 623], ["APP", "GENE_OR_GENE_PRODUCT", 643, 646], ["\u03b21\u221240", "GENE_OR_GENE_PRODUCT", 1088, 1093], ["amyloid fibrils", "PROTEIN", 608, 623], ["P", "DNA", 624, 625], ["APP gene", "DNA", 643, 651], ["a novel peptide structure", "PROBLEM", 45, 70], ["rotational-echo", "TEST", 107, 122], ["distance measurements", "TEST", 148, 169], ["C-carbonyl", "TREATMENT", 202, 212], ["15 N-amide positions", "TREATMENT", 217, 237], ["intervening residues", "PROBLEM", 267, 287], ["a \u03b2-sheet like conformation", "PROBLEM", 354, 381], ["double quantum filtered DRAWS measurements", "TEST", 462, 504], ["the extended strand", "PROBLEM", 519, 538], ["amyloid fibrils", "PROBLEM", 608, 623], ["P", "TEST", 624, 625], ["a light scattering study", "TEST", 702, 726], ["Tagliavini", "TREATMENT", 763, 773], ["Alzheimer's peptides", "TREATMENT", 1066, 1086], ["intervening residues", "OBSERVATION", 267, 287], ["amyloid fibrils", "OBSERVATION", 608, 623]]], ["By laser light scattering it was possible to follow the early stages of aggregation of A\u03b21\u221240 wt and A\u03b21\u221240 mut (within 48 hours after sample preparation), when intermediates in the aggregation pathway, rather than the mature insoluble fibrils, are formed.", [["sample", "ANATOMY", 135, 141], ["fibrils", "ANATOMY", 236, 243], ["aggregation", "DISEASE", 72, 83], ["fibrils", "GENE_OR_GENE_PRODUCT", 236, 243], ["the mature insoluble fibrils", "PROBLEM", 215, 243], ["mature", "OBSERVATION_MODIFIER", 219, 225], ["insoluble fibrils", "OBSERVATION", 226, 243]]], ["Results show that both the kinetics and the extent of aggregation are strongly enhanced by the mutation.", [["aggregation", "PROBLEM", 54, 65], ["the mutation", "PROBLEM", 91, 103], ["kinetics", "OBSERVATION_MODIFIER", 27, 35], ["extent", "OBSERVATION_MODIFIER", 44, 50], ["aggregation", "OBSERVATION", 54, 65], ["enhanced", "OBSERVATION_MODIFIER", 79, 87]]], ["On the reverse, coincubation of mutated and wild-type peptides slows down the aggregation process and results in A\u03b2 aggregates that are much more unstable against dilution.", [["A\u03b2", "GENE_OR_GENE_PRODUCT", 113, 115], ["mutated and wild-type peptides", "PROBLEM", 32, 62], ["the aggregation process", "PROBLEM", 74, 97], ["A\u03b2 aggregates", "PROBLEM", 113, 126]]], ["It is evident that the interaction between mutant and wild-type A\u03b21\u221240 interferes with nucleation or nucleation-dependent polymerization, hindering amyloidogenesis.", [["\u03b21\u221240", "CHEMICAL", 65, 70], ["amyloidogenesis", "DISEASE", 148, 163], ["A\u03b21\u221240", "GENE_OR_GENE_PRODUCT", 64, 70], ["nucleation-dependent polymerization", "TREATMENT", 101, 136], ["hindering amyloidogenesis", "PROBLEM", 138, 163], ["dependent polymerization", "OBSERVATION", 112, 136]]], ["These results account for the highly amyloidogenic effect of the mutation in vitro, if alone, reversely reduced by the mutated-wild type mix.", [["the mutation", "PROBLEM", 61, 73]]], ["This finding may offer grounds for the development of therapeutic strategies, based on modified A\u03b2 peptides or peptido-mimetic compounds, for the potential treatment of Alzheimer's disease.Analysis of physico-chemical parameters affecting collagen I liquid crystal organizationsThe collagen I is the major structural protein of the body and it is found organized in a hierarchical manner in the extra-cellular matrix of several tissues (bone, tendon, cornea and sclera, etc..).", [["body", "ANATOMY", 332, 336], ["extra-cellular matrix", "ANATOMY", 395, 416], ["tissues", "ANATOMY", 428, 435], ["bone", "ANATOMY", 437, 441], ["tendon", "ANATOMY", 443, 449], ["cornea", "ANATOMY", 451, 457], ["sclera", "ANATOMY", 462, 468], ["Alzheimer's disease", "DISEASE", 169, 188], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 96, 98], ["peptido-mimetic compounds", "SIMPLE_CHEMICAL", 111, 136], ["collagen I", "GENE_OR_GENE_PRODUCT", 239, 249], ["collagen I", "GENE_OR_GENE_PRODUCT", 282, 292], ["body", "ORGANISM_SUBDIVISION", 332, 336], ["extra-cellular matrix", "CELLULAR_COMPONENT", 395, 416], ["tissues", "TISSUE", 428, 435], ["bone", "TISSUE", 437, 441], ["tendon", "TISSUE", 443, 449], ["cornea", "TISSUE", 451, 457], ["sclera", "TISSUE", 462, 468], ["collagen I", "PROTEIN", 239, 249], ["collagen I", "PROTEIN", 282, 292], ["therapeutic strategies", "TREATMENT", 54, 76], ["A\u03b2 peptides", "TREATMENT", 96, 107], ["peptido-mimetic compounds", "TREATMENT", 111, 136], ["Alzheimer's disease", "PROBLEM", 169, 188], ["Analysis", "TEST", 189, 197], ["physico", "TEST", 201, 208], ["collagen I liquid crystal organizations", "TREATMENT", 239, 278], ["mimetic compounds", "OBSERVATION", 119, 136], ["Alzheimer", "OBSERVATION", 169, 178], ["collagen", "OBSERVATION", 282, 290], ["protein", "OBSERVATION", 317, 324], ["body", "ANATOMY", 332, 336], ["hierarchical manner", "OBSERVATION", 368, 387], ["extra-cellular", "ANATOMY_MODIFIER", 395, 409], ["matrix", "ANATOMY_MODIFIER", 410, 416], ["several tissues", "ANATOMY", 420, 435], ["bone", "ANATOMY", 437, 441], ["tendon", "ANATOMY", 443, 449], ["cornea", "ANATOMY", 451, 457], ["sclera", "ANATOMY", 462, 468]]], ["It is already known that collagen I is capable of forming cholesteric liquid crystalline phases that once stabilized by a pH increase, lead to collagen matrices that mimic the organization of the organic matrix found in bone [1] .", [["bone", "ANATOMY", 220, 224], ["collagen I", "GENE_OR_GENE_PRODUCT", 25, 35], ["collagen", "GENE_OR_GENE_PRODUCT", 143, 151], ["matrix", "CELLULAR_COMPONENT", 204, 210], ["bone", "TISSUE", 220, 224], ["collagen I", "PROTEIN", 25, 35], ["forming cholesteric liquid crystalline phases", "TREATMENT", 50, 95], ["a pH increase", "PROBLEM", 120, 133], ["collagen matrices", "TREATMENT", 143, 160], ["the organic matrix", "PROBLEM", 192, 210], ["organic matrix", "OBSERVATION", 196, 210], ["bone", "ANATOMY", 220, 224]]], ["We study the effect of collagen concentration, pH (2.6 / 3.6) and acids (hydrochloride acid / acetic acid) over the liquid crystalline order.", [["hydrochloride acid / acetic acid", "CHEMICAL", 73, 105], ["hydrochloride acid", "CHEMICAL", 73, 91], ["acetic acid", "CHEMICAL", 94, 105], ["collagen", "GENE_OR_GENE_PRODUCT", 23, 31], ["hydrochloride acid", "SIMPLE_CHEMICAL", 73, 91], ["acetic acid", "SIMPLE_CHEMICAL", 94, 105], ["collagen", "PROTEIN", 23, 31], ["collagen concentration", "TEST", 23, 45], ["pH", "TEST", 47, 49], ["acids (hydrochloride acid / acetic acid", "TREATMENT", 66, 105], ["the liquid crystalline order", "TREATMENT", 112, 140]]], ["In a original approach, correlation of collagen endofluorescence and SHG signals has enabled us to quantify cholesteric pitch and phase transition as a function of collagen concentration within a gradient.", [["collagen", "GENE_OR_GENE_PRODUCT", 39, 47], ["collagen", "GENE_OR_GENE_PRODUCT", 164, 172], ["collagen", "PROTEIN", 39, 47], ["collagen", "PROTEIN", 164, 172], ["collagen endofluorescence", "TEST", 39, 64], ["SHG signals", "TEST", 69, 80], ["cholesteric pitch and phase transition", "PROBLEM", 108, 146], ["collagen concentration", "TREATMENT", 164, 186]]], ["Cholesteric pitch have proved to be very responsive to physico-chemical conditions.", [["Cholesteric pitch", "PROBLEM", 0, 17]]], ["Indeed, the results allowed us to quantify a I / cholesteric transition as a subsequent transition from cholesteric to a phase hexagonal or colummar.", [["a I / cholesteric transition", "PROBLEM", 43, 71]]], ["Prion diseases are deadly neurodegenerative diseases affecting human and mammalian species.", [["Prion diseases", "DISEASE", 0, 14], ["neurodegenerative diseases", "DISEASE", 26, 52], ["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Prion diseases", "PROBLEM", 0, 14], ["deadly neurodegenerative diseases affecting human and mammalian species", "PROBLEM", 19, 90], ["deadly", "OBSERVATION_MODIFIER", 19, 25], ["mammalian species", "OBSERVATION", 73, 90]]], ["According to the 'protein-only' hypothesis, the key event in the pathogenesis is the conversion of the \u03b1-helix-rich monomer (PrP c ) into a polymeric \u03b2-sheet-rich pathogenic conformer (PrP sc ).", [["PrP c", "GENE_OR_GENE_PRODUCT", 125, 130], ["\u03b1-helix-rich monomer", "PROTEIN", 103, 123], ["PrP c", "PROTEIN", 125, 130], ["polymeric \u03b2-sheet-rich pathogenic conformer", "PROTEIN", 140, 183], ["PrP sc", "PROTEIN", 185, 191], ["the \u03b1-helix-rich monomer (PrP c )", "TREATMENT", 99, 132], ["a polymeric \u03b2-sheet", "TREATMENT", 138, 157]]], ["We have used a combination of biophysical techniques with Molecular Dynamics simulations (MD) to elucidate the molecular mechanisms of PrP c unfolding and polymerization.", [["PrP c", "GENE_OR_GENE_PRODUCT", 135, 140], ["PrP c", "PROTEIN", 135, 140], ["biophysical techniques", "TREATMENT", 30, 52], ["PrP c unfolding", "PROBLEM", 135, 150], ["polymerization", "TREATMENT", 155, 169]]], ["Under well established conditions, three \u03b2-sheet-rich soluble oligomers were generated from the partial unfolding of the monomer, which were found to form in parallel.", [["three \u03b2-sheet-rich soluble oligomers", "TREATMENT", 35, 71], ["partial", "OBSERVATION_MODIFIER", 96, 103], ["unfolding", "OBSERVATION", 104, 113]]], ["To obtain a deeper insight into the molecular events, doublecystein mutants were designed, thus 'locking' different regions of PrP.", [["doublecystein", "GENE_OR_GENE_PRODUCT", 54, 67], ["doublecystein mutants", "PROTEIN", 54, 75], ["doublecystein mutants", "TREATMENT", 54, 75]]], ["Single mutations were also performed, which affected dramatically and selectively the PrP oligomerization pathway.", [["PrP", "GENE_OR_GENE_PRODUCT", 86, 89], ["PrP", "PROTEIN", 86, 89], ["Single mutations", "TEST", 0, 16]]], ["Furthermore, we have now identified the minimal region that leads to the same oligomerization profile as the full-length PrP, namely, H2H3.", [["PrP", "GENE_OR_GENE_PRODUCT", 121, 124], ["PrP", "PROTEIN", 121, 124], ["H2H3", "PROTEIN", 134, 138], ["the full-length PrP", "TREATMENT", 105, 124], ["minimal", "OBSERVATION_MODIFIER", 40, 47]]], ["The existence of at least three distinct oligomerization pathways and the effect of single mutations reveal the conformational diversity of PrP and a possible relationship with prion strain phenomena.", [["PrP", "GENE_OR_GENE_PRODUCT", 140, 143], ["PrP", "PROTEIN", 140, 143], ["single mutations", "PROBLEM", 84, 100], ["PrP", "TREATMENT", 140, 143], ["prion strain phenomena", "PROBLEM", 177, 199], ["at least", "OBSERVATION_MODIFIER", 17, 25], ["distinct", "OBSERVATION_MODIFIER", 32, 40], ["oligomerization", "OBSERVATION", 41, 56]]], ["The identification of domains involved in the conversion process may lead to a better understanding of the effect of mutations or gene polymorphism on the evolution of prion pathology.O-257Investigating toxic protein nanoclusters and their interactions with living cells S. Nag, B. Sahoo, A. Bandyopadhyay, C. Muralidharan, R. Abhyankar, S. Gurav, S. Maiti Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai 400005, India Amyloid protein aggregation is responsible for many neurodegenerative diseases, such as Alzheimer's and Parkinson's.", [["cells", "ANATOMY", 265, 270], ["O-257", "CHEMICAL", 184, 189], ["protein aggregation", "DISEASE", 452, 471], ["neurodegenerative diseases", "DISEASE", 496, 522], ["Alzheimer's and Parkinson's", "DISEASE", 532, 559], ["O-257", "CHEMICAL", 184, 189], ["O-257", "SIMPLE_CHEMICAL", 184, 189], ["cells", "CELL", 265, 270], ["mutations", "PROBLEM", 117, 126], ["gene polymorphism", "PROBLEM", 130, 147], ["prion pathology", "PROBLEM", 168, 183], ["toxic protein nanoclusters", "PROBLEM", 203, 229], ["India Amyloid protein aggregation", "PROBLEM", 438, 471], ["many neurodegenerative diseases", "PROBLEM", 491, 522], ["Alzheimer's", "PROBLEM", 532, 543], ["Parkinson's", "PROBLEM", 548, 559], ["responsible for", "UNCERTAINTY", 475, 490], ["neurodegenerative", "OBSERVATION_MODIFIER", 496, 513], ["diseases", "OBSERVATION", 514, 522]]], ["It appears that quasi-stable small soluble aggregates are the key to amyloid toxicity.", [["toxicity", "DISEASE", 77, 85], ["amyloid", "GENE_OR_GENE_PRODUCT", 69, 76], ["stable small soluble aggregates", "PROBLEM", 22, 53], ["amyloid toxicity", "PROBLEM", 69, 85], ["stable", "OBSERVATION_MODIFIER", 22, 28], ["small", "OBSERVATION_MODIFIER", 29, 34], ["soluble aggregates", "OBSERVATION", 35, 53], ["amyloid toxicity", "OBSERVATION", 69, 85]]], ["Though amyloid aggregation appears to be a nucleation mediated process, simple nucleation theory is unable to explain the stability of these intermediate species.", [["amyloid aggregation", "DISEASE", 7, 26], ["amyloid", "GENE_OR_GENE_PRODUCT", 7, 14], ["amyloid aggregation", "PROBLEM", 7, 26], ["a nucleation mediated process", "PROBLEM", 41, 70], ["simple nucleation theory", "PROBLEM", 72, 96], ["these intermediate species", "PROBLEM", 135, 161], ["amyloid aggregation", "OBSERVATION", 7, 26], ["appears to be", "UNCERTAINTY", 27, 40], ["nucleation", "OBSERVATION", 43, 53], ["simple", "OBSERVATION_MODIFIER", 72, 78], ["nucleation", "OBSERVATION", 79, 89], ["stability", "OBSERVATION_MODIFIER", 122, 131], ["intermediate species", "OBSERVATION", 141, 161]]], ["We investigate this issue with Fluorescence Correlation Spectroscopy in solution and on cell membranes.", [["cell membranes", "ANATOMY", 88, 102], ["cell membranes", "CELLULAR_COMPONENT", 88, 102], ["cell membranes", "TREATMENT", 88, 102], ["cell membranes", "OBSERVATION", 88, 102]]], ["Our initial data, varying the pH and the ionic strength of the solution, show that a charged colloid model can explain the overall stability of these species.", [["Our initial data", "TEST", 0, 16], ["varying the pH", "TEST", 18, 32], ["a charged colloid model", "TREATMENT", 83, 106], ["these species", "PROBLEM", 144, 157], ["stability", "OBSERVATION_MODIFIER", 131, 140]]], ["In addition, this understanding suggests possible ways of modulating the stability of these aggregates in solution.", [["suggests possible", "UNCERTAINTY", 32, 49]]], ["Some of these strategies successfully decimate the stable aggregate population, and also reduce the toxicity of amyloid beta to cultured neurons.O-264AFM studies of artificial amyloid fibrils and filaments P. Mesquida 1 , A. Kurtossy 1 , C. Macphee 2 1 Department of Mechanical Engineering, King's College London, London, U.K., 2 School of Physics, University of Edinburgh, Edinburgh, U.K.O-264Amyloid fibrils are beta-sheet-rich superstructures of peptides or proteins.", [["neurons", "ANATOMY", 137, 144], ["toxicity", "DISEASE", 100, 108], ["amyloid beta", "GENE_OR_GENE_PRODUCT", 112, 124], ["neurons", "CELL", 137, 144], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 176, 191], ["amyloid beta", "PROTEIN", 112, 124], ["cultured neurons", "CELL_LINE", 128, 144], ["the toxicity", "PROBLEM", 96, 108], ["amyloid beta", "TREATMENT", 112, 124], ["AFM studies", "TEST", 150, 161], ["artificial amyloid fibrils", "TREATMENT", 165, 191], ["U.K.O", "TEST", 385, 390], ["proteins", "PROBLEM", 461, 469], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["amyloid fibrils", "OBSERVATION", 176, 191]]], ["Although these aggregates have first been found in connection with protein-misfolding diseases, such as Alzheimer's or Parkinson's Disease, there is evidence that the ability to form fibrils is a generic property of any polypeptide rather than a result of specific, disease-related amino-acid sequences.", [["misfolding diseases", "DISEASE", 75, 94], ["Alzheimer's or Parkinson's Disease", "DISEASE", 104, 138], ["amino-acid", "CHEMICAL", 282, 292], ["amino-acid", "CHEMICAL", 282, 292], ["amino-acid", "SIMPLE_CHEMICAL", 282, 292], ["amino-acid sequences", "PROTEIN", 282, 302], ["protein-misfolding diseases", "PROBLEM", 67, 94], ["Alzheimer's", "PROBLEM", 104, 115], ["Parkinson's Disease", "PROBLEM", 119, 138], ["fibrils", "PROBLEM", 183, 190], ["any polypeptide", "PROBLEM", 216, 231], ["amino-acid sequences", "TEST", 282, 302], ["misfolding diseases", "OBSERVATION", 75, 94]]], ["Fibrils can easily be formed in vitro from nondisease-related proteins and even from synthetic peptides.", [["Fibrils", "SIMPLE_CHEMICAL", 0, 7], ["nondisease-related proteins", "PROTEIN", 43, 70], ["related proteins", "PROBLEM", 54, 70], ["synthetic peptides", "TREATMENT", 85, 103]]], ["These artificial fibrils can thus serve as model systems to investigate the biophysical properties of amyloid fibrils.", [["fibrils", "ANATOMY", 17, 24], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 102, 117], ["These artificial fibrils", "TREATMENT", 0, 24], ["amyloid fibrils", "PROBLEM", 102, 117], ["artificial fibrils", "OBSERVATION", 6, 24], ["amyloid fibrils", "OBSERVATION", 102, 117]]], ["The system presented here is built from the artificial peptide TTR 105\u2212115 , which contains 11 amino-acids and which forms well-defined nanorods of ca 10 nm diameter.", [["TTR 105\u2212115", "CHEMICAL", 63, 74], ["amino-acids", "CHEMICAL", 95, 106], ["amino-acids", "CHEMICAL", 95, 106], ["amino-acids", "SIMPLE_CHEMICAL", 95, 106], ["the artificial peptide TTR", "TEST", 40, 66], ["amino-acids", "TEST", 95, 106]]], ["We present Atomic Force Microscopy (AFM) results of their inner morphology by chemically dissecting the rods into their constituent filaments without completely breaking up the aggregates.", [["filaments", "ANATOMY", 132, 141], ["filaments", "CELLULAR_COMPONENT", 132, 141], ["Atomic Force Microscopy", "TEST", 11, 34]]], ["In contrast to the stiff rods, their constituent filaments of ca 1-2 nm diameter were much more flexible.", [["filaments", "ANATOMY", 49, 58], ["the stiff rods", "TREATMENT", 15, 29], ["ca", "TEST", 62, 64], ["stiff rods", "OBSERVATION", 19, 29], ["filaments", "OBSERVATION_MODIFIER", 49, 58], ["more flexible", "OBSERVATION_MODIFIER", 91, 104]]], ["This shows that the particular way filaments are arranged around each other can massively change the mechanical rigidity of the resulting structures in amyloid fibrils, which could be one cause of the different strains in amyloid diseases.", [["filaments", "ANATOMY", 35, 44], ["amyloid fibrils", "ANATOMY", 152, 167], ["rigidity", "DISEASE", 112, 120], ["amyloid", "DISEASE", 152, 159], ["amyloid diseases", "DISEASE", 222, 238], ["filaments", "CELLULAR_COMPONENT", 35, 44], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 152, 167], ["the mechanical rigidity", "PROBLEM", 97, 120], ["amyloid fibrils", "PROBLEM", 152, 167], ["the different strains in amyloid diseases", "PROBLEM", 197, 238], ["mechanical rigidity", "OBSERVATION", 101, 120], ["amyloid fibrils", "OBSERVATION", 152, 167], ["different", "OBSERVATION_MODIFIER", 201, 210], ["strains", "OBSERVATION", 211, 218], ["amyloid diseases", "OBSERVATION", 222, 238]]], ["The formation of insulin fibrils is characterized by an initial apparent lag-phase, related to the formation of oligomers, protofibrils and aggregation nuclei.", [["nuclei", "ANATOMY", 152, 158], ["aggregation", "DISEASE", 140, 151], ["insulin", "GENE_OR_GENE_PRODUCT", 17, 24], ["nuclei", "CELLULAR_COMPONENT", 152, 158], ["insulin fibrils", "TREATMENT", 17, 32], ["oligomers", "PROBLEM", 112, 121], ["protofibrils and aggregation nuclei", "PROBLEM", 123, 158], ["insulin fibrils", "OBSERVATION", 17, 32], ["oligomers", "OBSERVATION", 112, 121], ["aggregation nuclei", "OBSERVATION", 140, 158]]], ["Afterwards, the aggregation proceeds via fibril elongation, thickening and/or flocculation, and eventual gelation.", [["fibril", "ANATOMY", 41, 47], ["fibril elongation", "PROBLEM", 41, 58], ["thickening", "PROBLEM", 60, 70], ["flocculation", "PROBLEM", 78, 90], ["fibril elongation", "OBSERVATION", 41, 58], ["thickening", "OBSERVATION", 60, 70], ["flocculation", "OBSERVATION", 78, 90]]], ["Here, we focus on the formation of such a gel, made of insulin amyloid fibrils, upon incubation at high temperature and low pH.", [["insulin amyloid fibrils", "GENE_OR_GENE_PRODUCT", 55, 78], ["a gel", "TREATMENT", 40, 45], ["insulin amyloid fibrils", "TREATMENT", 55, 78], ["low pH", "PROBLEM", 120, 126], ["low pH", "OBSERVATION_MODIFIER", 120, 126]]], ["By light scattering and rheological techniques, we monitor the development of the structural, dynamical and mechanical properties of fibrillar aggregates, up to the dynamic arrest of the sample and to the appearance of a non-ergodic behaviour, which marks the onset of gelation.", [["fibrillar aggregates", "ANATOMY", 133, 153], ["sample", "ANATOMY", 187, 193], ["rheological techniques", "TEST", 24, 46], ["fibrillar aggregates", "PROBLEM", 133, 153], ["a non-ergodic behaviour", "PROBLEM", 219, 242], ["fibrillar aggregates", "OBSERVATION", 133, 153]]], ["Our experiments were able to reveal the structural details hidden in the apparent lag-phase, displaying the slow fibril nucleation and elongation.", [["the slow fibril nucleation", "PROBLEM", 104, 130], ["elongation", "PROBLEM", 135, 145], ["slow", "OBSERVATION_MODIFIER", 108, 112], ["fibril nucleation", "OBSERVATION", 113, 130], ["elongation", "OBSERVATION_MODIFIER", 135, 145]]], ["This initial stage is followed by the known exponential growth of structures of different sizes.", [["exponential", "OBSERVATION_MODIFIER", 44, 55], ["growth", "OBSERVATION_MODIFIER", 56, 62], ["different", "OBSERVATION_MODIFIER", 80, 89], ["sizes", "OBSERVATION_MODIFIER", 90, 95]]], ["These two kinetic stages of structural growth are mirrored by the kinetics of the viscoelastic properties and, in particular, by the growth of the elastic modulus.", [["structural growth", "PROBLEM", 28, 45], ["two", "OBSERVATION_MODIFIER", 6, 9], ["kinetic", "OBSERVATION_MODIFIER", 10, 17], ["stages", "OBSERVATION_MODIFIER", 18, 24], ["structural", "OBSERVATION_MODIFIER", 28, 38], ["growth", "OBSERVATION_MODIFIER", 39, 45], ["kinetics", "OBSERVATION_MODIFIER", 66, 74], ["viscoelastic properties", "OBSERVATION", 82, 105], ["growth", "OBSERVATION_MODIFIER", 133, 139], ["elastic modulus", "OBSERVATION", 147, 162]]], ["Our results show that the appearance of a noteworthy elastic network, is associated with the initial fibril nucleation and elongation more than with the formation of large structures, which causes the eventual gelation.P-262Capturing the initial events of In-cubo crystallization of membrane proteins C. V. Kulkarni 3 , O. Ces 1 , S. Iwata 2 , R. H. Templer 1 1 Chemical Biology Centre and Department of Chemistry, Imperial College London, United Kingdom, 2 Division of Molecular Biosciences, Imperial College London, United Kingdom, 3 Institute f\u00fcr Chemie, Heinrichstrasse-28, University of Graz, Austria Lipid based methods for the crystallization of membrane proteins including in-cubo crystallization are becoming popular in recent times.", [["fibril", "ANATOMY", 101, 107], ["membrane", "ANATOMY", 283, 291], ["membrane", "ANATOMY", 653, 661], ["P-262Capturing", "CHEMICAL", 219, 233], ["elastic network", "MULTI-TISSUE_STRUCTURE", 53, 68], ["membrane", "CELLULAR_COMPONENT", 283, 291], ["P", "DNA", 219, 220], ["membrane proteins", "PROTEIN", 283, 300], ["membrane proteins", "PROTEIN", 653, 670], ["the initial fibril nucleation", "PROBLEM", 89, 118], ["Heinrichstrasse", "TEST", 558, 573], ["Austria Lipid based methods", "TREATMENT", 598, 625], ["the crystallization of membrane proteins", "TREATMENT", 630, 670], ["in-cubo crystallization", "TREATMENT", 681, 704], ["noteworthy", "OBSERVATION_MODIFIER", 42, 52], ["elastic network", "OBSERVATION", 53, 68], ["associated with", "UNCERTAINTY", 73, 88], ["fibril nucleation", "OBSERVATION", 101, 118], ["elongation", "OBSERVATION_MODIFIER", 123, 133], ["large", "OBSERVATION_MODIFIER", 166, 171], ["structures", "OBSERVATION", 172, 182], ["eventual", "OBSERVATION_MODIFIER", 201, 209], ["gelation", "OBSERVATION_MODIFIER", 210, 218]]], ["The crystallization of membrane proteins in the lipid cubic phases involves following major steps: removal of membrane proteins from the native membrane using detergentlike molecules, followed by their insertion and equilibration into a lipid bilayer.", [["membrane", "ANATOMY", 23, 31], ["membrane", "ANATOMY", 110, 118], ["membrane", "ANATOMY", 144, 152], ["lipid bilayer", "ANATOMY", 237, 250], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["membrane", "CELLULAR_COMPONENT", 144, 152], ["lipid bilayer", "CELLULAR_COMPONENT", 237, 250], ["membrane proteins", "PROTEIN", 23, 40], ["membrane proteins", "PROTEIN", 110, 127], ["detergentlike molecules", "PROTEIN", 159, 182], ["The crystallization of membrane proteins", "TREATMENT", 0, 40], ["removal of membrane proteins", "TREATMENT", 99, 127], ["detergentlike molecules", "TREATMENT", 159, 182], ["a lipid bilayer", "TREATMENT", 235, 250], ["membrane proteins", "OBSERVATION", 23, 40], ["native membrane", "ANATOMY", 137, 152]]], ["The crystallization itself commences with precipitant induced osmotic dehydration which in turn stimulates the nucleation that subsequently leads to a crystal growth.", [["dehydration", "DISEASE", 70, 81], ["osmotic dehydration", "PROBLEM", 62, 81], ["a crystal growth", "PROBLEM", 149, 165], ["osmotic dehydration", "OBSERVATION", 62, 81]]], ["Using time-resolved X-ray scattering (SAXS) and ultraviolet spectroscopy we have been able to gain new insights into the mechanism behind protein insertion into these complex three dimensional lipid structures including information on the timescales of protein folding relative to crystal growth and the effect of protein insertion on the morphology of the surrounding lipid matrix.", [["lipid matrix", "ANATOMY", 369, 381], ["lipid matrix", "CELLULAR_COMPONENT", 369, 381], ["ultraviolet spectroscopy", "TEST", 48, 72], ["protein insertion", "TREATMENT", 138, 155], ["protein folding", "PROBLEM", 253, 268], ["crystal growth", "PROBLEM", 281, 295], ["protein insertion", "TREATMENT", 314, 331], ["protein insertion", "OBSERVATION", 314, 331], ["lipid matrix", "OBSERVATION", 369, 381]]], ["Several proteins can form amyloid fibrils under given environmental or thermodynamic conditions that affect their native conformation.", [["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 26, 41], ["Several proteins", "PROBLEM", 0, 16], ["amyloid fibrils", "PROBLEM", 26, 41], ["thermodynamic conditions", "PROBLEM", 71, 95], ["amyloid fibrils", "OBSERVATION", 26, 41]]], ["Lysozyme forms amyloid fibrils upon incubation of solutions at acid pH and at about 65 \u2022 C for a few days.", [["Lysozyme", "GENE_OR_GENE_PRODUCT", 0, 8], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 15, 30], ["Lysozyme", "PROTEIN", 0, 8], ["Lysozyme forms amyloid fibrils", "PROBLEM", 0, 30], ["acid pH", "TEST", 63, 70], ["amyloid fibrils", "OBSERVATION", 15, 30]]], ["Differential Scanning Calorimetry experiments confirm that lysozyme is mainly unfolded above 60 \u2022 C at pH 2.", [["lysozyme", "GENE_OR_GENE_PRODUCT", 59, 67], ["lysozyme", "PROTEIN", 59, 67], ["Scanning Calorimetry experiments", "TEST", 13, 45], ["lysozyme", "TEST", 59, 67]]], ["We monitored the growth of aggregate size by Dynamic Light Scattering for some days at different temperatures.", [["growth", "OBSERVATION_MODIFIER", 17, 23], ["size", "OBSERVATION_MODIFIER", 37, 41]]], ["Our results show that the fibrillogenesis is characterized by an initial apparent lag phase and a subsequent growth with quadratic dependence upon time of the scattering intensity.", [["the fibrillogenesis", "PROBLEM", 22, 41], ["an initial apparent lag phase", "PROBLEM", 62, 91], ["a subsequent growth", "PROBLEM", 96, 115], ["quadratic dependence", "PROBLEM", 121, 141], ["the scattering intensity", "PROBLEM", 155, 179], ["scattering", "OBSERVATION_MODIFIER", 159, 169], ["intensity", "OBSERVATION_MODIFIER", 170, 179]]], ["This behaviour recalls a simple kinetic model of nucleation and elongation, with nuclei in equilibrium with monomers.", [["nuclei", "ANATOMY", 81, 87], ["nuclei", "CELLULAR_COMPONENT", 81, 87], ["a simple kinetic model of nucleation", "PROBLEM", 23, 59], ["elongation", "PROBLEM", 64, 74], ["simple kinetic", "OBSERVATION_MODIFIER", 25, 39], ["elongation", "OBSERVATION_MODIFIER", 64, 74]]], ["At the end of the incubation at high temperature, we collected Atomic Force Microscopy images which show fibrils with a diameter of a few tens of nanometers and a length of a few microns, characterized by a periodicity along the elongation axis.", [["Atomic Force Microscopy images", "TEST", 63, 93], ["fibrils", "PROBLEM", 105, 112], ["a periodicity along the elongation axis", "PROBLEM", 205, 244], ["fibrils", "OBSERVATION", 105, 112], ["diameter", "OBSERVATION_MODIFIER", 120, 128], ["few", "OBSERVATION_MODIFIER", 134, 137], ["tens", "OBSERVATION_MODIFIER", 138, 142], ["nanometers", "OBSERVATION_MODIFIER", 146, 156], ["length", "OBSERVATION_MODIFIER", 163, 169], ["few", "OBSERVATION_MODIFIER", 175, 178], ["microns", "OBSERVATION_MODIFIER", 179, 186], ["periodicity", "OBSERVATION_MODIFIER", 207, 218], ["elongation axis", "OBSERVATION", 229, 244]]], ["Interestingly, the fibrils morphology exhibits no branching or thickening.", [["fibrils", "ANATOMY", 19, 26], ["the fibrils morphology", "TEST", 15, 37], ["thickening", "PROBLEM", 63, 73], ["fibrils morphology", "OBSERVATION", 19, 37], ["no", "UNCERTAINTY", 47, 49], ["branching", "OBSERVATION_MODIFIER", 50, 59], ["thickening", "OBSERVATION", 63, 73]]], ["This is consistent with the non-exponential growth observed in light scattering experiments.", [["the non-exponential growth", "PROBLEM", 24, 50], ["consistent with", "UNCERTAINTY", 8, 23], ["growth", "OBSERVATION_MODIFIER", 44, 50], ["scattering experiments", "OBSERVATION", 69, 91]]], ["In order to elicit the role of repulsive electrostatic interaction in protein unfolding and self-assembly we extended our study at different pH.", [["repulsive electrostatic interaction in protein unfolding", "PROBLEM", 31, 87], ["our study", "TEST", 118, 127]]], ["In this work we used AFM to follow the amyloidogenesis pathway of transthyretin (TTR) to form protofilaments.", [["protofilaments", "ANATOMY", 94, 108], ["transthyretin", "GENE_OR_GENE_PRODUCT", 66, 79], ["TTR", "GENE_OR_GENE_PRODUCT", 81, 84], ["transthyretin", "PROTEIN", 66, 79], ["TTR", "PROTEIN", 81, 84], ["transthyretin (TTR", "TREATMENT", 66, 84]]], ["Single-molecule force spectroscopy (SMFS) of native TTR and protofilaments were also compared in order to evaluate dynamic and structural differences.", [["TTR", "GENE_OR_GENE_PRODUCT", 52, 55], ["TTR", "PROTEIN", 52, 55], ["Single-molecule force spectroscopy", "TEST", 0, 34]]], ["We observed that this pathway proceeds through the formation of transient amorphous aggregates, followed by the occurrence of annular oligomers.", [["transient amorphous aggregates", "PROBLEM", 64, 94], ["annular oligomers", "PROBLEM", 126, 143], ["transient", "OBSERVATION_MODIFIER", 64, 73], ["amorphous", "OBSERVATION_MODIFIER", 74, 83], ["aggregates", "OBSERVATION", 84, 94], ["annular", "OBSERVATION_MODIFIER", 126, 133], ["oligomers", "OBSERVATION", 134, 143]]], ["Although implicated in cytoxicity, the role of such oligomers within the amyloidogenesis pathway is poorly understood.", [["such oligomers", "PROBLEM", 47, 61], ["cytoxicity", "OBSERVATION", 23, 33]]], ["We show that the annular species display a tendency to stack, forming tubular-like structures that precede the formation of protofilaments.", [["tubular-like structures", "ANATOMY", 70, 93], ["tubular", "TISSUE", 70, 77], ["the annular species", "PROBLEM", 13, 32], ["a tendency to stack, forming tubular-like structures", "PROBLEM", 41, 93], ["annular", "OBSERVATION_MODIFIER", 17, 24], ["tendency", "OBSERVATION_MODIFIER", 43, 51], ["tubular", "OBSERVATION_MODIFIER", 70, 77], ["-like", "OBSERVATION_MODIFIER", 77, 82], ["protofilaments", "OBSERVATION_MODIFIER", 124, 138]]], ["The protofilament height and pitch resemble those of TTR amyloid reported in previous structural studies.", [["amyloid", "DISEASE", 57, 64], ["TTR amyloid", "GENE_OR_GENE_PRODUCT", 53, 64], ["TTR amyloid", "PROTEIN", 53, 64], ["The protofilament height", "TEST", 0, 24], ["TTR amyloid", "PROBLEM", 53, 64], ["previous structural studies", "TEST", 77, 104]]], ["Upon solvent exchange, we also observed protofilament disassembly that revealed structures reminiscent of the initial TTR annular oligomers.", [["TTR", "GENE_OR_GENE_PRODUCT", 118, 121], ["TTR", "PROTEIN", 118, 121], ["the initial TTR annular oligomers", "PROBLEM", 106, 139]]], ["SMFS of protofilaments showed a time-dependent increase in the length of the manipulated structures, suggesting that associations between monomers stabilize with time.", [["SMFS of protofilaments", "TEST", 0, 22], ["dependent", "OBSERVATION_MODIFIER", 37, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["length", "OBSERVATION_MODIFIER", 63, 69]]], ["Force spectra of native TTR and protofilaments contained transitions spaced by \u223c4 nm, indicative of sequential unfolding of individual \u03b2-strands.", [["TTR", "GENE_OR_GENE_PRODUCT", 24, 27], ["TTR", "PROTEIN", 24, 27], ["protofilaments", "PROTEIN", 32, 46], ["\u03b2-strands", "PROTEIN", 135, 144], ["native TTR and protofilaments", "TREATMENT", 17, 46], ["sequential unfolding of individual \u03b2-strands", "PROBLEM", 100, 144], ["native TTR", "OBSERVATION", 17, 27], ["indicative of", "UNCERTAINTY", 86, 99], ["sequential unfolding", "OBSERVATION", 100, 120]]], ["Based on these results a model of TTR protofilament assembly is proposed.O-267Ability to undergo amyloid aggregation is affected by protein size C. Parrini 1 , H. Ramshini 2 , F. Chiti 2 , A. Relini 1 1 Physics Department, University of Genoa, Italy, 2 Biochemical Sciences Department, University of Florence, Italy Short polypeptide chains, typically between 28 and 253 residues, are generally involved with the conversion from the native state into insoluble fibrillar aggregates.", [["O-267Ability", "CHEMICAL", 73, 85], ["amyloid aggregation", "DISEASE", 97, 116], ["TTR", "GENE_OR_GENE_PRODUCT", 34, 37], ["O-267Ability", "GENE_OR_GENE_PRODUCT", 73, 85], ["amyloid", "GENE_OR_GENE_PRODUCT", 97, 104], ["fibrillar aggregates", "CELLULAR_COMPONENT", 461, 481], ["TTR", "PROTEIN", 34, 37], ["TTR protofilament", "TREATMENT", 34, 51], ["amyloid aggregation", "PROBLEM", 97, 116], ["Short polypeptide chains", "TREATMENT", 316, 340], ["amyloid", "OBSERVATION", 97, 104], ["size", "OBSERVATION_MODIFIER", 140, 144], ["fibrillar aggregates", "OBSERVATION", 461, 481]]], ["The low prevalence of large proteins is disproportionate with their high occurrence in the human proteome.", [["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["large proteins", "PROBLEM", 22, 36], ["low prevalence", "OBSERVATION_MODIFIER", 4, 18], ["large", "OBSERVATION_MODIFIER", 22, 27], ["proteins", "OBSERVATION", 28, 36], ["disproportionate", "OBSERVATION_MODIFIER", 40, 56]]], ["In order to explore the propensity of large proteins to form amyloid-like fibrils, the 486-residue hexokinase-B from Saccharomyces cerevisiae (YHKB) has been induced to aggregate under two separate conditions, at low pH in the presence of salts and at pH 5.5 in the presence of trifluoroethanol.", [["trifluoroethanol", "CHEMICAL", 278, 294], ["trifluoroethanol", "CHEMICAL", 278, 294], ["hexokinase-B", "GENE_OR_GENE_PRODUCT", 99, 111], ["Saccharomyces cerevisiae", "ORGANISM", 117, 141], ["YHKB", "GENE_OR_GENE_PRODUCT", 143, 147], ["salts", "SIMPLE_CHEMICAL", 239, 244], ["trifluoroethanol", "SIMPLE_CHEMICAL", 278, 294], ["amyloid-like fibrils", "PROTEIN", 61, 81], ["486-residue hexokinase-B", "PROTEIN", 87, 111], ["Saccharomyces cerevisiae", "SPECIES", 117, 141], ["Saccharomyces cerevisiae", "SPECIES", 117, 141], ["large proteins", "PROBLEM", 38, 52], ["amyloid", "TEST", 61, 68], ["hexokinase", "TEST", 99, 109], ["Saccharomyces cerevisiae", "TREATMENT", 117, 141], ["low pH", "PROBLEM", 213, 219], ["pH", "TEST", 252, 254], ["trifluoroethanol", "TREATMENT", 278, 294], ["amyloid", "OBSERVATION", 61, 68], ["low pH", "OBSERVATION_MODIFIER", 213, 219]]], ["Such conditions are among the most promising to form amyloid-like fibrils by normally globular proteins.", [["amyloid-like fibrils", "GENE_OR_GENE_PRODUCT", 53, 73], ["amyloid-like fibrils", "PROTEIN", 53, 73], ["globular proteins", "PROTEIN", 86, 103], ["Such conditions", "PROBLEM", 0, 15], ["fibrils", "PROBLEM", 66, 73], ["normally globular proteins", "PROBLEM", 77, 103], ["amyloid", "OBSERVATION", 53, 60], ["globular proteins", "OBSERVATION", 86, 103]]], ["Under both conditions YHKB aggregates very rapidly into species with significant \u03b2-sheet structure, as detected by circular dichroism, and a weak Thioflavin T and Congo red binding.", [["Thioflavin T", "CHEMICAL", 146, 158], ["Thioflavin T", "CHEMICAL", 146, 158], ["Congo red", "CHEMICAL", 163, 172], ["Thioflavin T", "GENE_OR_GENE_PRODUCT", 146, 158], ["\u03b2-sheet structure", "PROTEIN", 81, 98], ["Thioflavin T", "PROTEIN", 146, 158], ["a weak Thioflavin T and Congo red binding", "PROBLEM", 139, 180]]], ["Atomic force microscopy revealed globular aggregates eventually clustering into large amorphous aggregates at low pH, while in the presence of trifluoroethanol ribbon-like structures with distinct morphology from typical amyloid fibrils were observed.", [["trifluoroethanol", "CHEMICAL", 143, 159], ["amyloid", "DISEASE", 221, 228], ["trifluoroethanol", "CHEMICAL", 143, 159], ["trifluoroethanol", "SIMPLE_CHEMICAL", 143, 159], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 221, 236], ["Atomic force microscopy", "TEST", 0, 23], ["globular aggregates", "PROBLEM", 33, 52], ["large amorphous aggregates at low pH", "PROBLEM", 80, 116], ["trifluoroethanol ribbon", "TREATMENT", 143, 166], ["typical amyloid fibrils", "PROBLEM", 213, 236], ["globular aggregates", "OBSERVATION", 33, 52], ["large", "OBSERVATION_MODIFIER", 80, 85], ["amorphous", "OBSERVATION_MODIFIER", 86, 95], ["aggregates", "OBSERVATION", 96, 106], ["low pH", "OBSERVATION_MODIFIER", 110, 116], ["trifluoroethanol ribbon", "OBSERVATION", 143, 166], ["distinct", "OBSERVATION_MODIFIER", 188, 196], ["morphology", "OBSERVATION_MODIFIER", 197, 207], ["typical", "OBSERVATION_MODIFIER", 213, 220], ["amyloid fibrils", "OBSERVATION", 221, 236]]], ["They had irregular width, no twist, and were connected by thinner fibril segments perpendicular to them.", [["irregular width", "PROBLEM", 9, 24], ["twist", "PROBLEM", 29, 34], ["irregular", "OBSERVATION_MODIFIER", 9, 18], ["width", "OBSERVATION_MODIFIER", 19, 24], ["no", "UNCERTAINTY", 26, 28], ["twist", "OBSERVATION", 29, 34]]], ["In general, YHKB aggregates displayed an unusual softness, as they were very easily perturbed by the AFM tip.", [["an unusual softness", "PROBLEM", 38, 57], ["unusual softness", "OBSERVATION", 41, 57]]], ["These results suggest that inability to form amyloid fibrils may prevent large proteins from being associated with protein deposition diseases.P-266The initial stage of proteins aggregation leading to amyloid fibrils: a SAXS study M. G. Ortore 1 , F. Spinozzi 1 , F. Carsughi 1 , T. Narayanan 2 , G. Irace 2 , S. Vilasi 3 , P. Mariani 3 1 Dip.", [["amyloid", "DISEASE", 45, 52], ["P-266", "CHEMICAL", 143, 148], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 45, 60], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 201, 216], ["amyloid fibrils", "PROBLEM", 45, 60], ["large proteins", "PROBLEM", 73, 87], ["protein deposition diseases", "PROBLEM", 115, 142], ["proteins aggregation", "PROBLEM", 169, 189], ["amyloid fibrils", "PROBLEM", 201, 216], ["a SAXS study", "TEST", 218, 230], ["protein deposition", "OBSERVATION", 115, 133], ["amyloid fibrils", "OBSERVATION", 201, 216]]], ["Biofis., II Univ., Napoli, Italy Under some conditions, a protein converts from its soluble form into highly ordered aggregates called amyloid fibrils, which are associated with many human diseases.", [["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 135, 150], ["human", "ORGANISM", 183, 188], ["amyloid fibrils", "PROTEIN", 135, 150], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["amyloid fibrils", "PROBLEM", 135, 150], ["many human diseases", "PROBLEM", 178, 197], ["amyloid fibrils", "OBSERVATION", 135, 150], ["human diseases", "OBSERVATION", 183, 197]]], ["In order to tackle the prevention and treatment of these diseases, we need to understand the mechanism of the pathological aggregation of proteins.", [["treatment", "TREATMENT", 38, 47], ["these diseases", "PROBLEM", 51, 65], ["the pathological aggregation of proteins", "PROBLEM", 106, 146], ["diseases", "OBSERVATION", 57, 65]]], ["In vitro amyloid fibril formation is preceded by the formation of metastable non fibrillar forms, which are responsible for cytotoxicity underlying neurodegeneration.", [["fibril", "ANATOMY", 17, 23], ["neurodegeneration", "DISEASE", 148, 165], ["amyloid fibril", "GENE_OR_GENE_PRODUCT", 9, 23], ["vitro amyloid fibril formation", "PROBLEM", 3, 33], ["metastable non fibrillar forms", "PROBLEM", 66, 96], ["cytotoxicity underlying neurodegeneration", "PROBLEM", 124, 165], ["amyloid fibril formation", "OBSERVATION", 9, 33], ["metastable", "OBSERVATION_MODIFIER", 66, 76], ["non fibrillar", "OBSERVATION_MODIFIER", 77, 90], ["forms", "OBSERVATION_MODIFIER", 91, 96], ["responsible for", "UNCERTAINTY", 108, 123], ["cytotoxicity", "OBSERVATION_MODIFIER", 124, 136], ["neurodegeneration", "OBSERVATION", 148, 165]]], ["The molecular mechanisms leading proteins into prefibrillar aggregates are still unclear.", [["prefibrillar aggregates", "ANATOMY", 47, 70], ["proteins into prefibrillar aggregates", "PROBLEM", 33, 70], ["prefibrillar aggregates", "OBSERVATION", 47, 70]]], ["We present a SAXS study performed at ID02 beamline of ESRF on the apomyoglobin mutant W7FW14F, which at physiological pH, firstly aggregates in prefibrillar forms that are cytotoxic and then forms amyloid fibrils.", [["ESRF", "DISEASE", 54, 58], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 197, 212], ["apomyoglobin mutant W7FW14F", "PROTEIN", 66, 93], ["a SAXS study", "TEST", 11, 23], ["ESRF", "PROBLEM", 54, 58], ["the apomyoglobin mutant", "TEST", 62, 85], ["cytotoxic", "PROBLEM", 172, 181], ["amyloid fibrils", "PROBLEM", 197, 212], ["cytotoxic", "OBSERVATION_MODIFIER", 172, 181], ["amyloid fibrils", "OBSERVATION", 197, 212]]], ["The first stages of W7FW14F oligomerization are induced by a pH jump.", [["W7FW14F", "GENE_OR_GENE_PRODUCT", 20, 27], ["W7FW14F", "PROTEIN", 20, 27], ["a pH jump", "PROBLEM", 59, 68], ["pH jump", "OBSERVATION", 61, 68]]], ["Data show that big changes in W7FW14F in solution happen in less than 100 ms.", [["W7FW14F", "SIMPLE_CHEMICAL", 30, 37], ["W7FW14F", "DNA", 30, 37], ["big changes", "PROBLEM", 15, 26]]], ["Singular Value Decomposition (SVD) of the data yields a set of functions, from which all the scattering curves can be reproduced.", [["Singular Value Decomposition", "PROBLEM", 0, 28]]], ["The major result of our study is the determination of the presence of different oligomers in each step of the process.", [["our study", "TEST", 20, 29], ["different oligomers", "PROBLEM", 70, 89], ["different", "OBSERVATION_MODIFIER", 70, 79], ["oligomers", "OBSERVATION", 80, 89]]], ["Hence, time-resolved SAXS experiments together with the estimation of different oligomers via SVD method, can be a new and useful approach to investigate the first stages of amyloidogenesis.P-265-Condensed colloidal phase in biology: from proteins crystals to amyloid fibrils -AbstractsStudy of structure/toxicity relationship of amyloids by infrared spectroscopy H. P. Ta Amyloid diseases (Alzheimer, Parkinson, type II diabetes, prion) correlate with protein aggregation.", [["amyloidogenesis", "DISEASE", 174, 189], ["P-265", "CHEMICAL", 190, 195], ["toxicity", "DISEASE", 305, 313], ["Amyloid diseases", "DISEASE", 373, 389], ["Alzheimer, Parkinson, type II diabetes", "DISEASE", 391, 429], ["amyloidogenesis", "PROBLEM", 174, 189], ["P", "TEST", 190, 191], ["amyloid fibrils", "PROBLEM", 260, 275], ["structure/toxicity", "PROBLEM", 295, 313], ["amyloids", "PROBLEM", 330, 338], ["infrared spectroscopy", "TEST", 342, 363], ["Ta Amyloid diseases (Alzheimer, Parkinson", "PROBLEM", 370, 411], ["type II diabetes", "PROBLEM", 413, 429], ["protein aggregation", "PROBLEM", 453, 472], ["amyloid fibrils", "OBSERVATION", 260, 275], ["Amyloid diseases", "OBSERVATION", 373, 389]]], ["All the proteins associated with these pathologies aggregate into amyloid fibrils with a common \u00df-cross structure.", [["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 66, 81], ["amyloid fibrils", "PROTEIN", 66, 81], ["these pathologies", "PROBLEM", 33, 50], ["amyloid fibrils", "PROBLEM", 66, 81], ["pathologies", "OBSERVATION", 39, 50], ["amyloid fibrils", "OBSERVATION", 66, 81]]], ["According to many in vitro studies, the toxicity of various amyloids seems to be linked to some intermediates formed during the aggregation pathway and to their interaction with membranes.", [["membranes", "ANATOMY", 178, 187], ["toxicity", "DISEASE", 40, 48], ["membranes", "CELLULAR_COMPONENT", 178, 187], ["vitro studies", "TEST", 21, 34], ["the toxicity of various amyloids", "PROBLEM", 36, 68]]], ["Our aim is to understand the link between structure and toxicity of amyloids by studying their interaction with model membranes.", [["membranes", "ANATOMY", 118, 127], ["toxicity", "DISEASE", 56, 64], ["membranes", "CELLULAR_COMPONENT", 118, 127], ["toxicity of amyloids", "PROBLEM", 56, 76]]], ["For this, we use as an amyloid model, the Prion-Forming Domain PFD218-289 (Wild Type WT) of Het-s, a prion protein of the fungal P. anserina.", [["fungal", "ORGANISM", 122, 128], ["P. anserina", "ORGANISM", 129, 140], ["Prion-Forming Domain PFD218-289", "PROTEIN", 42, 73], ["Wild Type WT", "PROTEIN", 75, 87], ["Het", "PROTEIN", 92, 95], ["prion protein", "PROTEIN", 101, 114], ["P. anserina", "SPECIES", 129, 140], ["P. anserina", "SPECIES", 129, 140], ["an amyloid model", "TEST", 20, 36], ["Domain PFD218", "TEST", 56, 69], ["Het", "TEST", 92, 95], ["a prion protein", "TEST", 99, 114], ["the fungal P. anserina", "PROBLEM", 118, 140]]], ["When expressed in yeast, WT is not toxic whereas one of these mutants, M8 is toxic.", [["yeast", "SPECIES", 18, 23], ["yeast", "SPECIES", 18, 23], ["toxic", "PROBLEM", 77, 82]]], ["In vitro, M8 forms very unusual short amyloid fibers contrary to WT which polymerizes as long fibers.", [["amyloid fibers", "ANATOMY", 38, 52], ["long fibers", "ANATOMY", 89, 100], ["amyloid fibers", "CELLULAR_COMPONENT", 38, 52], ["long fibers", "CELLULAR_COMPONENT", 89, 100], ["very unusual short amyloid fibers", "PROBLEM", 19, 52]]], ["Furthermore, ATR spectra have shown that M8 is essentially assembled into mixed parallel and anti-parallel \u00df-sheets whereas WT displays a predominant parallel organization.", [["ATR", "PROTEIN", 13, 16], ["M8", "PROTEIN", 41, 43], ["anti-parallel \u00df-sheets", "CELL_LINE", 93, 115], ["ATR spectra", "TEST", 13, 24], ["WT", "TEST", 124, 126], ["a predominant parallel organization", "PROBLEM", 136, 171], ["mixed", "OBSERVATION_MODIFIER", 74, 79], ["parallel", "OBSERVATION_MODIFIER", 80, 88], ["predominant", "OBSERVATION_MODIFIER", 138, 149], ["parallel", "OBSERVATION_MODIFIER", 150, 158], ["organization", "OBSERVATION", 159, 171]]], ["We are currently studying the interaction between WT or M8 with lipid Langmuir film by Polarized Modulation-InfraRed Reflexion Absorption Spectroscopy (PM-IRRAS).", [["M8", "PROTEIN", 56, 58], ["lipid Langmuir film", "TEST", 64, 83], ["Polarized Modulation", "TEST", 87, 107], ["InfraRed Reflexion Absorption Spectroscopy", "TEST", 108, 150]]], ["This technique allows determining the secondary structure of proteins and their orientation in the membrane.", [["membrane", "ANATOMY", 99, 107], ["membrane", "CELLULAR_COMPONENT", 99, 107], ["This technique", "TEST", 0, 14], ["membrane", "ANATOMY_MODIFIER", 99, 107]]], ["The study of interactions with different charged phospholipids is following.Temperature and metal ions induced aggregation of human serum albuminA.", [["serum", "ANATOMY", 132, 137], ["metal ions", "SIMPLE_CHEMICAL", 92, 102], ["human", "ORGANISM", 126, 131], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["albuminA", "SIMPLE_CHEMICAL", 138, 146], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["The study", "TEST", 0, 9], ["different charged phospholipids", "TREATMENT", 31, 62], ["Temperature", "TEST", 76, 87], ["metal ions", "PROBLEM", 92, 102], ["human serum albuminA", "TEST", 126, 146], ["metal ions", "OBSERVATION", 92, 102]]], ["Stirpe, M. Pantusa, R. Bartucci, L. Sportelli, R. Guzzi Dipartimento di Fisica, Laboratorio di Biofisica Molecolare & UdR CNISM, Universit\u00e0 della Calabria, Rende (CS), Italy An increasing number of experimental studies is demonstrating that the propensity of forming amyloid fibrils is not limited to proteins related to neurodegenerative diseases but it is a more general phenomenon.", [["amyloid", "DISEASE", 267, 274], ["neurodegenerative diseases", "DISEASE", 321, 347], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 267, 282], ["experimental studies", "TEST", 198, 218], ["amyloid fibrils", "PROBLEM", 267, 282], ["neurodegenerative diseases", "PROBLEM", 321, 347], ["a more general phenomenon", "PROBLEM", 358, 383], ["increasing", "OBSERVATION_MODIFIER", 177, 187], ["amyloid fibrils", "OBSERVATION", 267, 282], ["neurodegenerative", "OBSERVATION_MODIFIER", 321, 338], ["diseases", "OBSERVATION", 339, 347]]], ["We present data on human serum albumin (HSA) aggregation induced by a combination of thermal and metal ions effects investigated by optical density, fluorescence and electron paramagnetic resonance (EPR).", [["serum", "ANATOMY", 25, 30], ["aggregation", "DISEASE", 45, 56], ["human", "ORGANISM", 19, 24], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["albumin", "GENE_OR_GENE_PRODUCT", 31, 38], ["HSA", "SIMPLE_CHEMICAL", 40, 43], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["human serum albumin", "TEST", 19, 38], ["aggregation", "PROBLEM", 45, 56], ["thermal and metal ions effects", "TREATMENT", 85, 115], ["electron paramagnetic resonance", "TEST", 166, 197], ["metal ions", "OBSERVATION", 97, 107]]], ["The turbidity experiments as a function of temperature show that the HSA aggregation starts at about 70 \u2022 C which is higher than the denaturation temperature (\u223c 60 \u2022 C).", [["aggregation", "DISEASE", 73, 84], ["HSA", "SIMPLE_CHEMICAL", 69, 72], ["The turbidity experiments", "PROBLEM", 0, 25], ["the HSA aggregation", "PROBLEM", 65, 84], ["the denaturation temperature", "TEST", 129, 157], ["turbidity", "OBSERVATION", 4, 13], ["higher", "OBSERVATION_MODIFIER", 117, 123]]], ["In the presence of copper and zinc metal ions the onset temperature for protein aggregation is markedly reduced as the metal:protein molar ratio is increased from 1:1 to 10:1.", [["copper", "CHEMICAL", 19, 25], ["zinc", "CHEMICAL", 30, 34], ["copper", "CHEMICAL", 19, 25], ["zinc", "CHEMICAL", 30, 34], ["copper", "SIMPLE_CHEMICAL", 19, 25], ["zinc metal ions", "SIMPLE_CHEMICAL", 30, 45], ["copper and zinc metal ions", "PROBLEM", 19, 45], ["protein aggregation", "PROBLEM", 72, 91], ["markedly reduced", "PROBLEM", 95, 111], ["protein molar ratio", "TEST", 125, 144], ["markedly", "OBSERVATION_MODIFIER", 95, 103], ["reduced", "OBSERVATION_MODIFIER", 104, 111], ["increased", "OBSERVATION_MODIFIER", 148, 157]]], ["Moreover, the copper is more effective in inducing protein aggregation compared to zinc ion.", [["copper", "CHEMICAL", 14, 20], ["zinc", "CHEMICAL", 83, 87], ["copper", "CHEMICAL", 14, 20], ["zinc", "CHEMICAL", 83, 87], ["copper", "SIMPLE_CHEMICAL", 14, 20], ["zinc ion", "SIMPLE_CHEMICAL", 83, 91], ["inducing protein aggregation", "PROBLEM", 42, 70], ["more effective", "OBSERVATION_MODIFIER", 24, 38], ["protein aggregation", "OBSERVATION", 51, 70]]], ["The HSA aggregation analyzed by ThT fluorescence at different incubation temperatures lacks a lag phase and the kinetic traces can be fitted by double exponential functions.", [["HSA", "SIMPLE_CHEMICAL", 4, 7], ["ThT", "SIMPLE_CHEMICAL", 32, 35], ["The HSA aggregation", "TEST", 0, 19], ["ThT fluorescence", "TEST", 32, 48], ["different incubation temperatures", "TEST", 52, 85]]], ["The ThT fluorescence increase evidences the formation of protein aggregates with fibrillar features.", [["fibrillar", "ANATOMY", 81, 90], ["ThT", "SIMPLE_CHEMICAL", 4, 7], ["The ThT fluorescence", "TEST", 0, 20], ["protein aggregates", "PROBLEM", 57, 75], ["fibrillar features", "PROBLEM", 81, 99], ["protein aggregates", "OBSERVATION", 57, 75], ["fibrillar features", "OBSERVATION", 81, 99]]], ["EPR experiments for the Cu(II)-HSA complex show the binding of Cu(II) in the protein native state in a square planar coordination with 4 equatorial N atoms, and is not influenced by the heat treatment of the protein.", [["Cu", "CHEMICAL", 24, 26], ["Cu", "CHEMICAL", 63, 65], ["Cu(II)", "CHEMICAL", 24, 30], ["Cu(II)", "CHEMICAL", 63, 69], ["N", "CHEMICAL", 148, 149], ["Cu(II)", "SIMPLE_CHEMICAL", 63, 69], ["4 equatorial N atoms", "SIMPLE_CHEMICAL", 135, 155], ["Cu(II)-HSA complex", "PROTEIN", 24, 42], ["Cu(II)", "PROTEIN", 63, 69], ["protein native state", "PROTEIN", 77, 97], ["EPR experiments", "TEST", 0, 15], ["the heat treatment", "TREATMENT", 182, 200]]], ["The overall results suggest that HSA aggregation is compatible with a downhill process that does not require the formation of an aggregation nucleus.P-271Protein condensation diseases -a colloid physicists viewpoint P. Schurtenberger Adolphe Merkle Institute, University of Fribourg, CH-1723 Marly 1, Switzerland A broad class of diseases, such as cataract, Alzheimer's disease and sickle-cell disease, involve protein association phenomena as an essential aspect.", [["nucleus", "ANATOMY", 141, 148], ["sickle-cell", "ANATOMY", 382, 393], ["P-271Protein", "CHEMICAL", 149, 161], ["cataract", "DISEASE", 348, 356], ["Alzheimer's disease", "DISEASE", 358, 377], ["sickle-cell disease", "DISEASE", 382, 401], ["HSA", "SIMPLE_CHEMICAL", 33, 36], ["nucleus", "CELLULAR_COMPONENT", 141, 148], ["sickle-cell", "CELL", 382, 393], ["HSA aggregation", "PROBLEM", 33, 48], ["a downhill process", "PROBLEM", 68, 86], ["an aggregation nucleus", "PROBLEM", 126, 148], ["271Protein condensation diseases", "PROBLEM", 151, 183], ["diseases", "PROBLEM", 330, 338], ["cataract", "PROBLEM", 348, 356], ["Alzheimer's disease", "PROBLEM", 358, 377], ["sickle-cell disease", "PROBLEM", 382, 401], ["protein association phenomena", "PROBLEM", 411, 440], ["HSA aggregation", "OBSERVATION", 33, 48], ["compatible with", "UNCERTAINTY", 52, 67], ["aggregation nucleus", "OBSERVATION", 129, 148], ["condensation diseases", "OBSERVATION", 162, 183], ["diseases", "OBSERVATION", 330, 338], ["cataract", "OBSERVATION", 348, 356], ["sickle-cell disease", "OBSERVATION", 382, 401]]], ["The basic element common to all members of this class of molecular condensation diseases is the subtle interplay between protein interactions that produces condensation into dense, frequently insoluble mesoscopic phases.", [["molecular condensation diseases", "PROBLEM", 57, 88], ["protein interactions", "PROBLEM", 121, 141], ["condensation into dense, frequently insoluble mesoscopic phases", "PROBLEM", 156, 219], ["element", "OBSERVATION_MODIFIER", 10, 17], ["common", "OBSERVATION_MODIFIER", 18, 24], ["condensation diseases", "OBSERVATION", 67, 88], ["dense", "OBSERVATION_MODIFIER", 174, 179]]], ["Among this class of diseases, cataract is particularly important as the world's leading cause of blindness.", [["cataract", "DISEASE", 30, 38], ["blindness", "DISEASE", 97, 106], ["diseases", "PROBLEM", 20, 28], ["cataract", "PROBLEM", 30, 38], ["blindness", "PROBLEM", 97, 106], ["diseases", "OBSERVATION", 20, 28], ["cataract", "OBSERVATION", 30, 38], ["blindness", "OBSERVATION", 97, 106]]], ["This disease is most often the consequence of an uncontrolled aggregation (or phase separation) of the proteins in the eye lens that results in a loss of its transparency.", [["eye lens", "ANATOMY", 119, 127], ["eye", "ORGAN", 119, 122], ["This disease", "PROBLEM", 0, 12], ["an uncontrolled aggregation", "PROBLEM", 46, 73], ["the proteins in the eye lens", "PROBLEM", 99, 127], ["a loss of its transparency", "PROBLEM", 144, 170], ["disease", "OBSERVATION", 5, 12], ["uncontrolled", "OBSERVATION_MODIFIER", 49, 61], ["aggregation", "OBSERVATION", 62, 73], ["eye lens", "ANATOMY", 119, 127], ["loss", "OBSERVATION_MODIFIER", 146, 150], ["transparency", "OBSERVATION_MODIFIER", 158, 170]]], ["The high concentration protein mixtures present in the eye lens are normally stable and produce a high refractive index that aids the eye in adaptive focusing of light.", [["eye lens", "ANATOMY", 55, 63], ["eye", "ANATOMY", 134, 137], ["eye", "ORGAN", 55, 58], ["eye", "ORGAN", 134, 137], ["The high concentration protein mixtures", "TEST", 0, 39], ["a high refractive index", "PROBLEM", 96, 119], ["high", "OBSERVATION_MODIFIER", 4, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22], ["protein mixtures", "OBSERVATION", 23, 39], ["eye lens", "ANATOMY", 55, 63], ["normally", "OBSERVATION_MODIFIER", 68, 76], ["stable", "OBSERVATION_MODIFIER", 77, 83], ["high", "OBSERVATION_MODIFIER", 98, 102], ["refractive index", "OBSERVATION", 103, 119], ["eye", "ANATOMY", 134, 137]]], ["Moreover, the proteins themselves exhibit a rich variety of repulsive interactions, attractive interactions, sizes, phase transitions and self-association.", [["repulsive interactions", "OBSERVATION", 60, 82]]], ["These mixtures also exhibit the pathological aggregation and opacification of the cataract disease that has inspired their study.", [["cataract", "DISEASE", 82, 90], ["the pathological aggregation", "PROBLEM", 28, 56], ["opacification of the cataract disease", "PROBLEM", 61, 98], ["their study", "TEST", 117, 128], ["pathological", "OBSERVATION_MODIFIER", 32, 44], ["aggregation", "OBSERVATION", 45, 56], ["opacification", "OBSERVATION", 61, 74], ["cataract disease", "OBSERVATION", 82, 98]]], ["In my presentation I will illustrate how we can use a combination of small-angle neutron and Xray scattering experiments combined with molecular dynamics computer simulations to identify, measure and model the molecular interactions and emergent optical and viscoelastic properties and the phase behavior of the relevant, complex cytoplasmic mixtures.O-270Fluorescence microscopy studies of IAPP fibrillation at model and cellular membranes D. C. Radovan 1 , N. Opitz 2 , R. Winter 1 1 Department of Physical Chemistry I -Biophysical Chemistry, TU Dortmund University, Dortmund, Germany, 2 Max-Planck Institute for Molecular Physiology, Dortmund, Germany Type 2 diabetes mellitus (T2DM) is characterized by islet amyloid deposition and beta cell death, the main culprit being a small 37 a.a. peptide hormone, islet amyloid polypeptide (IAPP), which forms fibrils under pathological conditions.", [["cytoplasmic", "ANATOMY", 330, 341], ["cellular membranes", "ANATOMY", 422, 440], ["islet", "ANATOMY", 707, 712], ["beta cell", "ANATOMY", 736, 745], ["fibrils", "ANATOMY", 855, 862], ["IAPP fibrillation", "DISEASE", 391, 408], ["Type 2 diabetes mellitus", "DISEASE", 655, 679], ["T2DM", "DISEASE", 681, 685], ["O-270", "CHEMICAL", 351, 356], ["cytoplasmic", "ORGANISM_SUBSTANCE", 330, 341], ["IAPP", "GENE_OR_GENE_PRODUCT", 391, 395], ["cellular", "CELL", 422, 430], ["islet", "MULTI-TISSUE_STRUCTURE", 707, 712], ["beta cell", "CELL", 736, 745], ["islet amyloid polypeptide", "GENE_OR_GENE_PRODUCT", 809, 834], ["IAPP", "GENE_OR_GENE_PRODUCT", 836, 840], ["islet amyloid polypeptide", "PROTEIN", 809, 834], ["IAPP", "PROTEIN", 836, 840], ["small-angle neutron", "TREATMENT", 69, 88], ["Xray scattering experiments", "TREATMENT", 93, 120], ["emergent optical and viscoelastic properties", "TREATMENT", 237, 281], ["Fluorescence microscopy studies", "TEST", 356, 387], ["IAPP fibrillation", "PROBLEM", 391, 408], ["Physical Chemistry", "TEST", 500, 518], ["Type 2 diabetes mellitus (T2DM)", "PROBLEM", 655, 686], ["islet amyloid deposition", "PROBLEM", 707, 731], ["beta cell death", "PROBLEM", 736, 751], ["a small 37 a.a. peptide hormone", "PROBLEM", 776, 807], ["islet amyloid polypeptide", "TREATMENT", 809, 834], ["fibrils under pathological conditions", "PROBLEM", 855, 892], ["IAPP fibrillation", "OBSERVATION", 391, 408], ["islet", "OBSERVATION", 707, 712], ["amyloid deposition", "OBSERVATION", 713, 731], ["beta cell death", "OBSERVATION", 736, 751], ["small", "OBSERVATION_MODIFIER", 778, 783]]], ["We studied the interaction of IAPP with giant (GUVs) and large (LUVs) unilamellar vesicles as well as with INS-1E cells.", [["GUVs", "ANATOMY", 47, 51], ["LUVs", "ANATOMY", 64, 68], ["unilamellar vesicles", "ANATOMY", 70, 90], ["INS-1E cells", "ANATOMY", 107, 119], ["IAPP", "GENE_OR_GENE_PRODUCT", 30, 34], ["large (LUVs) unilamellar vesicles", "CELLULAR_COMPONENT", 57, 90], ["INS-1E cells", "CELL", 107, 119], ["IAPP", "PROTEIN", 30, 34], ["INS-1E cells", "CELL_LINE", 107, 119], ["giant (GUVs", "TEST", 40, 51], ["large (LUVs) unilamellar vesicles", "PROBLEM", 57, 90], ["large", "OBSERVATION_MODIFIER", 57, 62], ["unilamellar vesicles", "ANATOMY", 70, 90], ["1E cells", "OBSERVATION", 111, 119]]], ["By using confocal / two-photon excitation fluorescence microscopy and GUVs, we tested the influence of charge (DOPC:DOPG 7:3) and model raft systems, displaying liquid-ordered (l o ) / liquid-disordered (l d ) phase coexistence (such as DOPC:DPPC:cholesterol 1:2:1), respectively, on the kinetics of IAPP fibril formation.", [["raft", "ANATOMY", 136, 140], ["fibril", "ANATOMY", 305, 311], ["DPPC", "CHEMICAL", 242, 246], ["cholesterol", "CHEMICAL", 247, 258], ["DOPC", "CHEMICAL", 111, 115], ["DOPG", "CHEMICAL", 116, 120], ["DOPC", "CHEMICAL", 237, 241], ["DPPC", "CHEMICAL", 242, 246], ["cholesterol", "CHEMICAL", 247, 258], ["DOPC", "SIMPLE_CHEMICAL", 111, 115], ["DOPC:DPPC:cholesterol 1:2:1", "SIMPLE_CHEMICAL", 237, 264], ["IAPP", "GENE_OR_GENE_PRODUCT", 300, 304], ["photon excitation fluorescence microscopy", "TEST", 24, 65], ["model raft systems", "TREATMENT", 130, 148], ["disordered (l d ) phase coexistence", "PROBLEM", 192, 227], ["cholesterol", "TEST", 247, 258], ["IAPP fibril formation", "TREATMENT", 300, 321], ["IAPP fibril", "OBSERVATION", 300, 311]]], ["A preferential partitioning into the l d phase was observed and fibrils grew along with lipid uptake.", [["fibrils", "ANATOMY", 64, 71], ["lipid", "SIMPLE_CHEMICAL", 88, 93], ["fibrils", "PROBLEM", 64, 71], ["lipid uptake", "PROBLEM", 88, 100], ["lipid uptake", "OBSERVATION", 88, 100]]], ["Fluorescence spectroscopy leakage experiments with carboxyfluorescein-filled LUVs and the corresponding ThT kinetics of IAPP fibril formation were carried out as well.", [["carboxyfluorescein", "CHEMICAL", 51, 69], ["carboxyfluorescein", "CHEMICAL", 51, 69], ["carboxyfluorescein", "SIMPLE_CHEMICAL", 51, 69], ["LUVs", "SIMPLE_CHEMICAL", 77, 81], ["IAPP", "GENE_OR_GENE_PRODUCT", 120, 124], ["IAPP", "PROTEIN", 120, 124], ["Fluorescence spectroscopy leakage experiments", "TEST", 0, 45], ["carboxyfluorescein-filled LUVs", "TREATMENT", 51, 81], ["IAPP fibril formation", "PROBLEM", 120, 141], ["IAPP fibril", "OBSERVATION", 120, 131]]], ["Moreover, using the WST-1 reduction assay and fluorescence microscopy, we could show that the red wine compound resveratrol is a potent inhibitor of IAPP fibrillation and its cellular toxicity on INS-1E cells, these findings highlighting the potential role of resveratrol in future clinical applications, i.e., in the treatment of T2DM.", [["cellular", "ANATOMY", 175, 183], ["INS-1E cells", "ANATOMY", 196, 208], ["resveratrol", "CHEMICAL", 112, 123], ["fibrillation", "DISEASE", 154, 166], ["toxicity", "DISEASE", 184, 192], ["resveratrol", "CHEMICAL", 260, 271], ["T2DM", "DISEASE", 331, 335], ["resveratrol", "CHEMICAL", 112, 123], ["resveratrol", "CHEMICAL", 260, 271], ["WST-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["resveratrol", "SIMPLE_CHEMICAL", 112, 123], ["IAPP", "GENE_OR_GENE_PRODUCT", 149, 153], ["cellular", "CELL", 175, 183], ["INS-1E cells", "CELL", 196, 208], ["resveratrol", "SIMPLE_CHEMICAL", 260, 271], ["INS-1E cells", "CELL_LINE", 196, 208], ["the WST", "TEST", 16, 23], ["fluorescence microscopy", "TEST", 46, 69], ["the red wine compound resveratrol", "TREATMENT", 90, 123], ["a potent inhibitor", "TREATMENT", 127, 145], ["IAPP fibrillation", "PROBLEM", 149, 166], ["its cellular toxicity", "PROBLEM", 171, 192], ["resveratrol", "TREATMENT", 260, 271], ["T2DM", "PROBLEM", 331, 335], ["IAPP fibrillation", "OBSERVATION", 149, 166], ["cellular toxicity", "OBSERVATION", 175, 192], ["T2DM", "OBSERVATION", 331, 335]]], ["A remarkably high viscosity has been induced in aqueous solutions of lysozyme by the addition of certain structurally related organic solvents, such as tetramethylurea (TMU), dimethylsulfoxide (DMSO), dimethylformamide (DMF), and hexamethylphosphortriamide.", [["tetramethylurea", "CHEMICAL", 152, 167], ["TMU", "CHEMICAL", 169, 172], ["dimethylsulfoxide", "CHEMICAL", 175, 192], ["DMSO", "CHEMICAL", 194, 198], ["dimethylformamide", "CHEMICAL", 201, 218], ["DMF", "CHEMICAL", 220, 223], ["hexamethylphosphortriamide", "CHEMICAL", 230, 256], ["tetramethylurea", "CHEMICAL", 152, 167], ["TMU", "CHEMICAL", 169, 172], ["dimethylsulfoxide", "CHEMICAL", 175, 192], ["DMSO", "CHEMICAL", 194, 198], ["dimethylformamide", "CHEMICAL", 201, 218], ["DMF", "CHEMICAL", 220, 223], ["hexamethylphosphortriamide", "CHEMICAL", 230, 256], ["lysozyme", "GENE_OR_GENE_PRODUCT", 69, 77], ["tetramethylurea", "SIMPLE_CHEMICAL", 152, 167], ["TMU", "SIMPLE_CHEMICAL", 169, 172], ["dimethylsulfoxide", "SIMPLE_CHEMICAL", 175, 192], ["DMSO", "SIMPLE_CHEMICAL", 194, 198], ["dimethylformamide", "SIMPLE_CHEMICAL", 201, 218], ["DMF", "SIMPLE_CHEMICAL", 220, 223], ["hexamethylphosphortriamide", "SIMPLE_CHEMICAL", 230, 256], ["lysozyme", "PROTEIN", 69, 77], ["A remarkably high viscosity", "PROBLEM", 0, 27], ["lysozyme", "TREATMENT", 69, 77], ["organic solvents", "TREATMENT", 126, 142], ["tetramethylurea (TMU)", "TREATMENT", 152, 173], ["dimethylsulfoxide (DMSO)", "TREATMENT", 175, 199], ["dimethylformamide (DMF)", "TREATMENT", 201, 224], ["hexamethylphosphortriamide", "TREATMENT", 230, 256], ["high viscosity", "OBSERVATION_MODIFIER", 13, 27], ["organic solvents", "OBSERVATION", 126, 142]]], ["DMSO-induced gelation is observed in samples fulfilling the two following requirements: (1.) lysozyme concentration in excess of 5 mM, and (2.) volume fractions of DMSO exceeding 0.7.", [["samples", "ANATOMY", 37, 44], ["DMSO", "CHEMICAL", 0, 4], ["DMSO", "CHEMICAL", 164, 168], ["DMSO", "CHEMICAL", 0, 4], ["DMSO", "CHEMICAL", 164, 168], ["DMSO", "SIMPLE_CHEMICAL", 0, 4], ["lysozyme", "GENE_OR_GENE_PRODUCT", 93, 101], ["DMSO", "SIMPLE_CHEMICAL", 164, 168], ["lysozyme", "PROTEIN", 93, 101], ["DMSO", "TREATMENT", 0, 4], ["induced gelation", "PROBLEM", 5, 21], ["lysozyme concentration", "TREATMENT", 93, 115], ["volume fractions", "TEST", 144, 160], ["DMSO", "TEST", 164, 168]]], ["Based on spectroscopic data, the whole process was characterized as consisting of two mutually independent stages.", [["spectroscopic data", "TEST", 9, 27]]], ["The first involves an extensive transition of the polypeptide backbone, from a predominantly helical to increased random coiled and beta-sheet structures, with the occurrence of non-orthodox protein secondary structures at regions above the solvent critical point.", [["random coiled and beta", "PROTEIN", 114, 136], ["non-orthodox protein", "PROTEIN", 178, 198], ["an extensive transition of the polypeptide backbone", "PROBLEM", 19, 70], ["a predominantly helical to increased random coiled and beta-sheet structures", "PROBLEM", 77, 153], ["non-orthodox protein secondary structures", "PROBLEM", 178, 219], ["extensive", "OBSERVATION_MODIFIER", 22, 31], ["transition", "OBSERVATION", 32, 42], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["random", "OBSERVATION", 114, 120], ["solvent critical point", "OBSERVATION", 241, 263]]], ["The second stage consists of short-lived interchain contacts leading to an entanglement of the macromolecular system as a whole.Sol-gel transition in DMSO/lysozyme/water mixturesHere we present a set of scattering and microrheology experiments that investigate both the structural and dynamic properties of the gels under various experimental conditions.P-274Studying alpha-synuclein aggregation by fluorescence polarization based kinetics L. Tosatto, F. Munari, I. Tessari, G. de Franceschi, M. Pivato, P. Polverino de Laureto, M. Bisaglia, L. Bubacco Universit\u00e0 degli Studi di Padova, Padova, Italy Alpha-synuclein (syn) is linked to Parkinson's disease (PD) by two evidences: the accumulation of amyloid fibrils of the protein and the autosomal dominant forms of the disease (A53T, A30P and E46K mutants).", [["DMSO", "CHEMICAL", 150, 154], ["P-274", "CHEMICAL", 354, 359], ["alpha-synuclein aggregation", "DISEASE", 368, 395], ["Parkinson's disease", "DISEASE", 636, 655], ["PD", "DISEASE", 657, 659], ["DMSO", "CHEMICAL", 150, 154], ["DMSO", "SIMPLE_CHEMICAL", 150, 154], ["lysozyme", "SIMPLE_CHEMICAL", 155, 163], ["alpha-synuclein", "GENE_OR_GENE_PRODUCT", 368, 383], ["Alpha-synuclein", "SIMPLE_CHEMICAL", 601, 616], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 699, 714], ["A30P", "GENE_OR_GENE_PRODUCT", 785, 789], ["E46K", "GENE_OR_GENE_PRODUCT", 794, 798], ["lysozyme", "PROTEIN", 155, 163], ["alpha-synuclein", "PROTEIN", 368, 383], ["amyloid fibrils", "PROTEIN", 699, 714], ["short-lived interchain contacts", "PROBLEM", 29, 60], ["gel transition in DMSO", "TREATMENT", 132, 154], ["lysozyme/water mixtures", "TREATMENT", 155, 178], ["microrheology experiments", "TEST", 218, 243], ["P", "TEST", 354, 355], ["alpha-synuclein aggregation", "PROBLEM", 368, 395], ["fluorescence polarization", "TEST", 399, 424], ["Padova", "TREATMENT", 587, 593], ["Parkinson's disease", "PROBLEM", 636, 655], ["amyloid fibrils of the protein", "PROBLEM", 699, 729], ["the disease", "PROBLEM", 766, 777], ["A53T", "TEST", 779, 783], ["A30P", "TEST", 785, 789], ["short", "OBSERVATION_MODIFIER", 29, 34], ["entanglement", "OBSERVATION", 75, 87], ["macromolecular system", "ANATOMY", 95, 116], ["amyloid fibrils", "OBSERVATION", 699, 714], ["autosomal", "OBSERVATION_MODIFIER", 738, 747], ["dominant", "OBSERVATION_MODIFIER", 748, 756], ["disease", "OBSERVATION", 770, 777]]], ["Protein oligomers seem to be the most toxic species, causing dopaminergic neuronal death, probably disrupting cell membrane (Volles & Lansbury, 2002) .", [["neuronal", "ANATOMY", 74, 82], ["cell membrane", "ANATOMY", 110, 123], ["neuronal death", "DISEASE", 74, 88], ["neuronal", "CELL", 74, 82], ["cell membrane", "CELLULAR_COMPONENT", 110, 123], ["Protein oligomers", "PROBLEM", 0, 17], ["the most toxic species", "PROBLEM", 29, 51], ["dopaminergic neuronal death", "PROBLEM", 61, 88], ["most toxic", "OBSERVATION_MODIFIER", 33, 43], ["dopaminergic neuronal death", "OBSERVATION", 61, 88], ["probably", "UNCERTAINTY", 90, 98], ["disrupting cell membrane", "OBSERVATION", 99, 123]]], ["The aggregation of syn follows a nucleation dependent mechanism, i. e., aggregation is favoured only after the formation of an oligomer composed of a critical number of monomers (Wood et al., 1999) .", [["aggregation", "DISEASE", 72, 83], ["aggregation", "PROBLEM", 72, 83]]], ["As the constitution of the nucleus is a rare event, early aggregation stages are difficult to study.", [["nucleus", "ANATOMY", 27, 34], ["nucleus", "CELLULAR_COMPONENT", 27, 34], ["a rare event", "PROBLEM", 38, 50], ["early aggregation stages", "PROBLEM", 52, 76], ["nucleus", "ANATOMY", 27, 34], ["early", "OBSERVATION_MODIFIER", 52, 57], ["aggregation", "OBSERVATION", 58, 69]]], ["To explore the early stages of the aggregation process a fluorescence polarization (FP) based method (Luk et al., 2007) was applied to study syn oligomerization.", [["a fluorescence polarization (FP)", "TREATMENT", 55, 87]]], ["FP depends on the size of the fluorescent molecule, therefore it is suitable for the detection of oligomers formation.", [["oligomers formation", "PROBLEM", 98, 117], ["size", "OBSERVATION_MODIFIER", 18, 22], ["fluorescent molecule", "OBSERVATION", 30, 50], ["oligomers formation", "OBSERVATION", 98, 117]]], ["We measured aggregation kinetic properties under several different conditions.", [["aggregation kinetic properties", "TREATMENT", 12, 42], ["aggregation kinetic properties", "OBSERVATION", 12, 42], ["several different", "OBSERVATION_MODIFIER", 49, 66]]], ["A 100 to 1 mixture of syn and Oregon Green labelled syn was used to analyze the aggregation behaviour of wild type (wt) and PD mutants.", [["syn", "SIMPLE_CHEMICAL", 22, 25], ["Oregon Green labelled syn", "SIMPLE_CHEMICAL", 30, 55], ["PD", "GENE_OR_GENE_PRODUCT", 124, 126], ["Oregon Green labelled syn", "TREATMENT", 30, 55], ["PD mutants", "PROBLEM", 124, 134]]], ["The wt protein shows the fastest aggregation rate.", [["wt protein", "PROTEIN", 4, 14], ["The wt protein", "TEST", 0, 14], ["the fastest aggregation rate", "PROBLEM", 21, 49], ["fastest", "OBSERVATION_MODIFIER", 25, 32], ["aggregation rate", "OBSERVATION", 33, 49]]], ["This aggregation process is slowed down by the presence of the chaperone 14-3-3eta in wt syn samples.", [["samples", "ANATOMY", 93, 100], ["14-3-3eta", "CHEMICAL", 73, 82], ["14-3", "GENE_OR_GENE_PRODUCT", 73, 77], ["3eta", "GENE_OR_GENE_PRODUCT", 78, 82], ["chaperone 14-3-3eta", "PROTEIN", 63, 82], ["This aggregation process", "PROBLEM", 0, 24], ["the chaperone", "TEST", 59, 72], ["slowed", "OBSERVATION_MODIFIER", 28, 34]]], ["Finally, dimers formed by a disulfide bond at the N-terminus or C-terminus of syn, when tested for their aggregation behaviour, show a different propensity to aggregate.Distribution of pigments in ciliates by multidimensional confocal fluorescence microscopyA.", [["disulfide", "CHEMICAL", 28, 37], ["C", "CHEMICAL", 64, 65], ["N-terminus or C-terminus", "PROTEIN", 50, 74], ["Distribution of pigments in ciliates", "PROBLEM", 169, 205], ["multidimensional confocal fluorescence microscopyA.", "TEST", 209, 260], ["pigments", "OBSERVATION_MODIFIER", 185, 193]]], ["Pardini 1 , R. Bizzarri 2 , A. Diaspro 3 , P. Bianchini 3 , C. Usai 1 , P. Ramoino 3 , G. Checcucci 1 , G. Colombetti 1 1 Istituto di Biofisica, CNR, Italy, 2 a) NEST, SNS, IIT UdR, Pisa, Italy; b) NEST, CNR-INFM, Pisa, Italy, 3 Univiversity of Genova, Genova, ItalyDistribution of pigments in ciliates by multidimensional confocal fluorescence microscopyThe colored ciliates Blepharisma japonicum and Fabrea salina show photomotile responses triggered by endogenous pigments of the hypericin family.", [["hypericin", "CHEMICAL", 483, 492], ["hypericin", "CHEMICAL", 483, 492], ["ciliates", "ORGANISM", 367, 375], ["Blepharisma japonicum", "ORGANISM", 376, 397], ["Fabrea salina", "ORGANISM", 402, 415], ["hypericin", "SIMPLE_CHEMICAL", 483, 492], ["hypericin family", "PROTEIN", 483, 499], ["Blepharisma japonicum", "SPECIES", 376, 397], ["Fabrea salina", "SPECIES", 402, 415], ["Blepharisma japonicum", "SPECIES", 376, 397], ["Fabrea salina", "SPECIES", 402, 415], ["Pardini", "TREATMENT", 0, 7], ["Genova", "TREATMENT", 245, 251], ["Genova", "TREATMENT", 253, 259], ["multidimensional confocal fluorescence microscopy", "TEST", 306, 355], ["The colored ciliates", "TEST", 355, 375], ["photomotile responses", "PROBLEM", 421, 442], ["colored ciliates", "OBSERVATION", 359, 375], ["endogenous pigments", "OBSERVATION", 456, 475]]], ["B. japonicum exists in two forms: the wild one contains red blepharismin; the other one, generated by irradiating the cells with dim visible light, blue blepharismin.", [["cells", "ANATOMY", 118, 123], ["blepharismin", "CHEMICAL", 60, 72], ["blepharismin", "CHEMICAL", 153, 165], ["B. japonicum", "ORGANISM", 0, 12], ["blepharismin", "GENE_OR_GENE_PRODUCT", 60, 72], ["cells", "CELL", 118, 123], ["blue blepharismin", "SIMPLE_CHEMICAL", 148, 165], ["red blepharismin", "PROTEIN", 56, 72], ["B. japonicum", "SPECIES", 0, 12], ["B. japonicum", "SPECIES", 0, 12], ["red blepharismin", "PROBLEM", 56, 72], ["blue blepharismin", "TREATMENT", 148, 165], ["japonicum", "OBSERVATION", 3, 12], ["red blepharismin", "OBSERVATION", 56, 72], ["cells", "ANATOMY", 118, 123]]], ["B. japonicum shows step-up photophobic response, whereas F. salina, that contains fabrein, shows step-down photophobic responses and positive phototaxis.", [["fabrein", "CHEMICAL", 82, 89], ["B. japonicum", "ORGANISM", 0, 12], ["F. salina", "ORGANISM", 57, 66], ["fabrein", "GENE_OR_GENE_PRODUCT", 82, 89], ["B. japonicum", "SPECIES", 0, 12], ["F. salina", "SPECIES", 57, 66], ["B. japonicum", "SPECIES", 0, 12], ["F. salina", "SPECIES", 57, 66], ["B. japonicum", "TEST", 0, 12], ["positive phototaxis", "PROBLEM", 133, 152], ["positive phototaxis", "OBSERVATION", 133, 152]]], ["We showed by confocal microscopy that the pigments are localized not only in pigment granules, but also in the cilia.", [["pigment granules", "ANATOMY", 77, 93], ["cilia", "ANATOMY", 111, 116], ["pigment granules", "CELLULAR_COMPONENT", 77, 93], ["cilia", "CELLULAR_COMPONENT", 111, 116], ["confocal microscopy", "TEST", 13, 32], ["not only", "UNCERTAINTY", 65, 73], ["pigment granules", "OBSERVATION", 77, 93], ["cilia", "ANATOMY_MODIFIER", 111, 116]]], ["This fact implies that the structure of the pigment in the cilia differs from that in the cell body, (pigment granules are too big to fit in the axoneme) and suggests that ciliary pigments might play a decisive role in photoreception.", [["cilia", "ANATOMY", 59, 64], ["cell body", "ANATOMY", 90, 99], ["pigment granules", "ANATOMY", 102, 118], ["axoneme", "ANATOMY", 145, 152], ["ciliary pigments", "ANATOMY", 172, 188], ["cilia", "CELLULAR_COMPONENT", 59, 64], ["cell body", "CELLULAR_COMPONENT", 90, 99], ["pigment granules", "CELLULAR_COMPONENT", 102, 118], ["axoneme", "CELLULAR_COMPONENT", 145, 152], ["ciliary pigments", "PROBLEM", 172, 188], ["pigment", "OBSERVATION_MODIFIER", 44, 51], ["cilia", "ANATOMY_MODIFIER", 59, 64], ["cell", "ANATOMY", 90, 94], ["body", "ANATOMY_MODIFIER", 95, 99], ["pigment", "OBSERVATION_MODIFIER", 102, 109], ["granules", "OBSERVATION_MODIFIER", 110, 118], ["ciliary pigments", "OBSERVATION", 172, 188]]], ["Fluorescence Lifetime Imaging Microscopy (FLIM) shows that there is a spatial distribution of lifetimes, which are shorter for the pigment in the cilia.", [["cilia", "ANATOMY", 146, 151], ["cilia", "CELLULAR_COMPONENT", 146, 151], ["Imaging Microscopy", "TEST", 22, 40], ["spatial", "OBSERVATION_MODIFIER", 70, 77], ["distribution", "OBSERVATION_MODIFIER", 78, 90], ["lifetimes", "OBSERVATION_MODIFIER", 94, 103], ["shorter", "OBSERVATION_MODIFIER", 115, 122], ["cilia", "ANATOMY_MODIFIER", 146, 151]]], ["This might indicate a functional role for these pigments.", [["these pigments", "TREATMENT", 42, 56]]], ["Furthermore, lifetimes for F. salina are always longer than those of Blepharisma.", [["F. salina", "ORGANISM", 27, 36], ["F. salina", "SPECIES", 27, 36], ["F. salina", "SPECIES", 27, 36]]], ["In order to further characterize the structure of ciliary pigments by means of spectroscopic methods, we have also performed spatially resolved static and time-resolved fluorescence anisotropy measurements.P-278Biosensing applications of micro/nano structured silicon Several topics related to porous silicon (PS) biosensing properties were carefully considered in this study.", [["ciliary pigments", "ANATOMY", 50, 66], ["silicon", "CHEMICAL", 301, 308], ["silicon", "CHEMICAL", 260, 267], ["silicon", "CHEMICAL", 301, 308], ["spectroscopic methods", "TEST", 79, 100], ["fluorescence anisotropy measurements", "TEST", 169, 205], ["micro/nano structured silicon", "TREATMENT", 238, 267], ["porous silicon (PS) biosensing properties", "TREATMENT", 294, 335], ["this study", "TEST", 365, 375], ["ciliary pigments", "OBSERVATION", 50, 66]]], ["PS allows the increasing of the immobilised biomolecule number on its surface and the creation of stable covalent bonds due to its controllable chemistry.", [["surface", "ANATOMY", 70, 77], ["surface", "CELLULAR_COMPONENT", 70, 77], ["PS", "TREATMENT", 0, 2], ["the immobilised biomolecule", "TREATMENT", 28, 55], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["stable", "OBSERVATION_MODIFIER", 98, 104], ["covalent bonds", "OBSERVATION", 105, 119]]], ["The experimental results on the fabrication of the PS microstructures such as: (i) protein immobilization and detection using microarray technique; (ii) DNA biomolecule detection by impedance or by fluorescence spectroscopy; (iii) very sensitive SERS biosensors (RAMAN signal of 11-mercaptoundecanoic acid); (iv) sensitive element for neurons in NutMix culture are in detail presented.", [["neurons", "ANATOMY", 335, 342], ["11-mercaptoundecanoic acid", "CHEMICAL", 279, 305], ["11-mercaptoundecanoic acid", "CHEMICAL", 279, 305], ["DNA", "CELLULAR_COMPONENT", 153, 156], ["11-mercaptoundecanoic acid", "SIMPLE_CHEMICAL", 279, 305], ["neurons", "CELL", 335, 342], ["NutMix culture", "CELL_LINE", 346, 360], ["protein immobilization", "TREATMENT", 83, 105], ["microarray technique", "TEST", 126, 146], ["DNA biomolecule detection", "TEST", 153, 178], ["fluorescence spectroscopy", "TEST", 198, 223], ["SERS biosensors", "TEST", 246, 261], ["RAMAN signal", "TEST", 263, 275], ["neurons in NutMix culture", "TEST", 335, 360]]], ["Various characterisation techniques have been used, optical and scanning electron microscopy (SEM), X-ray diffraction, Raman, laser fluorescence and impedance spectroscopy for investigation molecule attachment on the Au/PS structures.", [["Au", "CHEMICAL", 217, 219], ["Au", "CHEMICAL", 217, 219], ["optical and scanning electron microscopy", "TEST", 52, 92], ["X-ray diffraction", "TEST", 100, 117], ["laser fluorescence", "TEST", 126, 144], ["impedance spectroscopy", "TEST", 149, 171], ["investigation molecule attachment", "PROBLEM", 176, 209]]], ["We have demonstrated that different morphologies of PS as-prepared or coated with gold nanoparticles have an important role in biomolecule/cell detection, due to its large internal surface combined with specific optical properties, being in the same time sensing element/support for immobilization of sensing biomolecules as well as transducer for biochemical interactions.", [["cell", "ANATOMY", 139, 143], ["surface", "ANATOMY", 181, 188], ["PS", "SIMPLE_CHEMICAL", 52, 54], ["gold nanoparticles", "SIMPLE_CHEMICAL", 82, 100], ["cell", "CELL", 139, 143], ["gold nanoparticles", "TREATMENT", 82, 100], ["biomolecule/cell detection", "TEST", 127, 153], ["element/support", "TREATMENT", 263, 278], ["immobilization of sensing biomolecules", "TREATMENT", 283, 321], ["large", "OBSERVATION_MODIFIER", 166, 171], ["internal", "OBSERVATION_MODIFIER", 172, 180], ["surface", "OBSERVATION_MODIFIER", 181, 188]]], ["Heterotrimeric G-proteins interact with their G-protein coupled receptors (GPCRs) via key binding elements comprising the C-terminal segment of the \u03b1-subunit and the two lipid anchors at the \u03b1\u2212 and \u03b3\u2212subunit.", [["C", "CHEMICAL", 122, 123], ["Heterotrimeric G-proteins", "GENE_OR_GENE_PRODUCT", 0, 25], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 46, 73], ["\u03b1-subunit", "GENE_OR_GENE_PRODUCT", 148, 157], ["\u03b1\u2212", "GENE_OR_GENE_PRODUCT", 191, 193], ["Heterotrimeric G-proteins", "PROTEIN", 0, 25], ["G-protein coupled receptors", "PROTEIN", 46, 73], ["GPCRs", "PROTEIN", 75, 80], ["C-terminal segment", "PROTEIN", 122, 140], ["\u03b1-subunit", "PROTEIN", 148, 157], ["\u03b1\u2212 and \u03b3\u2212subunit", "PROTEIN", 191, 207], ["Heterotrimeric G-proteins", "PROBLEM", 0, 25], ["terminal segment", "ANATOMY_MODIFIER", 124, 140]]], ["Direct information about diffusion and interaction of GPCRs and their G-proteins is mandatory, as these properties will affect the timing of events in the complex signal transduction cascade.", [["GPCRs", "GENE_OR_GENE_PRODUCT", 54, 59], ["G-proteins", "GENE_OR_GENE_PRODUCT", 70, 80], ["GPCRs", "PROTEIN", 54, 59], ["G-proteins", "PROTEIN", 70, 80], ["GPCRs", "TEST", 54, 59]]], ["In the case of the photoreceptor rhodopsin, receptor packing in the membrane and the related diffusion coefficients are discussed controversially (1, 2).", [["photoreceptor", "ANATOMY", 19, 32], ["membrane", "ANATOMY", 68, 76], ["photoreceptor rhodopsin", "GENE_OR_GENE_PRODUCT", 19, 42], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["photoreceptor rhodopsin", "PROTEIN", 19, 42], ["the photoreceptor rhodopsin", "TREATMENT", 15, 42], ["receptor packing in the membrane", "TREATMENT", 44, 76], ["the related diffusion coefficients", "PROBLEM", 81, 115], ["photoreceptor rhodopsin", "OBSERVATION", 19, 42], ["packing", "OBSERVATION_MODIFIER", 53, 60], ["membrane", "ANATOMY", 68, 76], ["diffusion coefficients", "OBSERVATION", 93, 115]]], ["By using single particle tracking we show that the encounters of rhodopsin with the fluorescently labeled Cterminus of the \u03b1-subunit as well as with the Holo-G-protein transducin change upon rhodopsin light-activation.", [["rhodopsin", "GENE_OR_GENE_PRODUCT", 65, 74], ["\u03b1-subunit", "GENE_OR_GENE_PRODUCT", 123, 132], ["transducin", "GENE_OR_GENE_PRODUCT", 168, 178], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 191, 200], ["rhodopsin", "PROTEIN", 65, 74], ["fluorescently labeled Cterminus", "PROTEIN", 84, 115], ["\u03b1-subunit", "PROTEIN", 123, 132], ["Holo-G-protein transducin", "PROTEIN", 153, 178], ["rhodopsin", "TREATMENT", 65, 74], ["the Holo-G-protein transducin change", "TREATMENT", 149, 185]]], ["Our results indicate confined areas of interaction for the C-terminal segment of the \u03b1-subunit with inactive rhodopsin disk membranes and less restricted diffusion of the receptor-bound Cterminal segment after light-activation.", [["disk membranes", "ANATOMY", 119, 133], ["C", "CHEMICAL", 59, 60], ["\u03b1-subunit", "GENE_OR_GENE_PRODUCT", 85, 94], ["rhodopsin disk membranes", "CELLULAR_COMPONENT", 109, 133], ["C-terminal segment", "PROTEIN", 59, 77], ["\u03b1-subunit", "PROTEIN", 85, 94], ["Cterminal segment", "PROTEIN", 186, 203], ["inactive rhodopsin disk membranes", "PROBLEM", 100, 133], ["interaction", "OBSERVATION", 39, 50], ["terminal segment", "ANATOMY_MODIFIER", 61, 77], ["inactive rhodopsin disk membranes", "OBSERVATION", 100, 133], ["less", "OBSERVATION_MODIFIER", 138, 142], ["restricted", "OBSERVATION_MODIFIER", 143, 153], ["diffusion", "OBSERVATION_MODIFIER", 154, 163], ["bound", "ANATOMY_MODIFIER", 180, 185], ["Cterminal segment", "ANATOMY_MODIFIER", 186, 203]]], ["This suggests dynamic short-range order in rhodopsin packing and specific structures for efficient interaction (3) In vivo, skeletal muscle actively shortens and also resists lengthening, for example when landing after a jump.", [["skeletal muscle", "ANATOMY", 124, 139], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 43, 52], ["skeletal muscle", "TISSUE", 124, 139], ["rhodopsin packing", "TREATMENT", 43, 60], ["dynamic", "OBSERVATION_MODIFIER", 14, 21], ["short", "OBSERVATION_MODIFIER", 22, 27], ["rhodopsin packing", "OBSERVATION", 43, 60], ["skeletal muscle", "ANATOMY", 124, 139]]], ["We study the energy during shortening and during lengthening by measuring the rate of Pi release which results from ATP hydrolysis.", [["Pi", "CHEMICAL", 86, 88], ["ATP", "CHEMICAL", 116, 119], ["ATP", "CHEMICAL", 116, 119], ["Pi", "SIMPLE_CHEMICAL", 86, 88], ["ATP", "SIMPLE_CHEMICAL", 116, 119], ["Pi release", "TREATMENT", 86, 96], ["ATP hydrolysis", "PROBLEM", 116, 130], ["ATP hydrolysis", "OBSERVATION", 116, 130]]], ["We show here the rate of Pi releases in an in vitro protocol that involves muscle stretched followed by muscle shortening.", [["muscle", "ANATOMY", 75, 81], ["muscle", "ANATOMY", 104, 110], ["Pi", "CHEMICAL", 25, 27], ["Pi", "SIMPLE_CHEMICAL", 25, 27], ["muscle", "ORGAN", 75, 81], ["muscle", "ORGAN", 104, 110], ["Pi releases", "TREATMENT", 25, 36], ["an in vitro protocol", "TREATMENT", 40, 60], ["muscle shortening", "PROBLEM", 104, 121], ["muscle", "ANATOMY", 75, 81], ["muscle", "ANATOMY", 104, 110], ["shortening", "OBSERVATION", 111, 121]]], ["It is hypothesised that the magnitude of deceleration of Pi release in the stretch phase is less than the acceleration during the release due the energy input of the motor that is used to apply the length changes.", [["Pi", "CHEMICAL", 57, 59], ["Pi", "SIMPLE_CHEMICAL", 57, 59], ["deceleration of Pi release", "PROBLEM", 41, 67], ["stretch phase", "OBSERVATION_MODIFIER", 75, 88]]], ["Therefore the end point of Pi release is similar to isometric conditions.", [["Pi", "CHEMICAL", 27, 29], ["Pi", "SIMPLE_CHEMICAL", 27, 29], ["Pi release", "TREATMENT", 27, 37], ["Pi release", "OBSERVATION", 27, 37]]], ["Pi release responses to a ramped stretch (5%) followed 100 ms later by a symmetrical release at low velocities (0.5 L 0 /s \u22121 ) were measured in permeabilised fibre bundles of rabbit psoas at 20 \u2022 C. Laser diffraction and high speed video were also recorded to confirm length change.", [["fibre bundles", "ANATOMY", 159, 172], ["psoas", "ANATOMY", 183, 188], ["Pi", "CHEMICAL", 0, 2], ["Pi", "SIMPLE_CHEMICAL", 0, 2], ["fibre bundles", "MULTI-TISSUE_STRUCTURE", 159, 172], ["rabbit", "ORGANISM", 176, 182], ["psoas", "MULTI-TISSUE_STRUCTURE", 183, 188], ["rabbit", "SPECIES", 176, 182], ["rabbit", "SPECIES", 176, 182], ["a ramped stretch", "TREATMENT", 24, 40], ["Laser diffraction", "TEST", 200, 217], ["high speed video", "TEST", 222, 238], ["length change", "PROBLEM", 269, 282], ["rabbit psoas", "ANATOMY", 176, 188]]], ["We show that the rate of Pi release drops during the stretch phase, returns to isometric levels during the length hold phase, and finally accelerates during the ramped release.", [["Pi", "CHEMICAL", 25, 27], ["Pi", "SIMPLE_CHEMICAL", 25, 27], ["Pi release drops", "TREATMENT", 25, 41], ["the stretch phase", "TEST", 49, 66], ["isometric levels", "TEST", 79, 95], ["the ramped release", "TREATMENT", 157, 175]]], ["Tracking of sarcomere length change using video analysis demonstrated that laser diffraction is unreliable at times during stretches due to lack of uniformity of the sarcomere spacing.Monitoring the interaction of single G-proteins with rhodopsin disk membranes upon lightactivationMicrobial rhodopsins: receptors, channels, and pumps from a single design J. L. Spudich, E. Negri-Spudich Center For Membrane Biology, University of Texas, Houston, Texas, U.S.A.Monitoring the interaction of single G-proteins with rhodopsin disk membranes upon lightactivationThe microbial rhodopsin family is comprised of \u223c5000 homologous proteins containing 7 transmembrane helices forming a pocket for the chromophore retinal.", [["sarcomere", "ANATOMY", 12, 21], ["sarcomere", "ANATOMY", 166, 175], ["disk membranes", "ANATOMY", 247, 261], ["disk membranes", "ANATOMY", 523, 537], ["retinal", "ANATOMY", 703, 710], ["G-proteins", "GENE_OR_GENE_PRODUCT", 221, 231], ["rhodopsin disk membranes", "CELLULAR_COMPONENT", 237, 261], ["G-proteins", "GENE_OR_GENE_PRODUCT", 497, 507], ["rhodopsin disk membranes", "CELLULAR_COMPONENT", 513, 537], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 572, 581], ["retinal", "MULTI-TISSUE_STRUCTURE", 703, 710], ["G-proteins", "PROTEIN", 221, 231], ["single G-proteins", "PROTEIN", 490, 507], ["microbial rhodopsin family", "PROTEIN", 562, 588], ["\u223c5000 homologous proteins", "PROTEIN", 605, 630], ["7 transmembrane helices", "PROTEIN", 642, 665], ["sarcomere length change", "PROBLEM", 12, 35], ["video analysis", "TEST", 42, 56], ["laser diffraction", "PROBLEM", 75, 92], ["the sarcomere spacing", "PROBLEM", 162, 183], ["single G-proteins", "TREATMENT", 214, 231], ["rhodopsin disk membranes", "TREATMENT", 237, 261], ["single G-proteins", "TREATMENT", 490, 507], ["rhodopsin disk membranes", "PROBLEM", 513, 537], ["\u223c5000 homologous proteins", "TREATMENT", 605, 630], ["the chromophore retinal", "TREATMENT", 687, 710], ["sarcomere length", "OBSERVATION", 12, 28], ["sarcomere spacing", "OBSERVATION", 166, 183], ["microbial rhodopsin", "OBSERVATION", 562, 581]]], ["Most are lightdriven ion pumps (\"transport rhodopsins\") and others are photosensory receptors (\"sensory rhodopsins\").", [["photosensory receptors", "PROTEIN", 71, 93]]], ["Phylogenetic analysis indicates frequent lateral gene transfer of proton pumps among prokaryotic and unicellular eukaryotic species, followed by coupling of the pump's mechanism to the cell's existing signal transduction machinery to create photosensors.", [["cell", "ANATOMY", 185, 189], ["cell", "CELL", 185, 189], ["Phylogenetic analysis", "TEST", 0, 21], ["proton pumps", "TREATMENT", 66, 78], ["unicellular eukaryotic species", "PROBLEM", 101, 131], ["the pump's mechanism", "TREATMENT", 157, 177], ["frequent", "OBSERVATION_MODIFIER", 32, 40], ["unicellular eukaryotic species", "OBSERVATION", 101, 131]]], ["This evolutionary path is strongly supported by our studies of sensory rhodopsins in various organisms which demonstrate remarkably diverse signaling mechanisms with diverse transducer partners.", [["sensory rhodopsins", "PROTEIN", 63, 81], ["sensory rhodopsins in various organisms", "PROBLEM", 63, 102], ["diverse transducer partners", "TREATMENT", 166, 193], ["diverse signaling", "OBSERVATION", 132, 149]]], ["The best studied are the phototaxis receptors in haloarchaeal prokaryotes (SRI and SRII) and in eukaryotic algae (channelrhodopsins).", [["channelrhodopsins", "GENE_OR_GENE_PRODUCT", 114, 131], ["phototaxis receptors", "PROTEIN", 25, 45], ["haloarchaeal prokaryotes", "PROTEIN", 49, 73], ["SRII", "PROTEIN", 83, 87], ["the phototaxis receptors", "TREATMENT", 21, 45], ["haloarchaeal prokaryotes", "TREATMENT", 49, 73], ["SRII", "TREATMENT", 83, 87]]], ["SRI and SRII transmit signals by protein-protein interaction to control a phosphorylation cascade that modulates motility.", [["SRII", "GENE_OR_GENE_PRODUCT", 8, 12], ["SRI", "PROTEIN", 0, 3], ["SRII", "PROTEIN", 8, 12], ["protein-protein interaction", "TREATMENT", 33, 60], ["a phosphorylation cascade", "TREATMENT", 72, 97]]], ["Channelrhodopsins are light-gated cation channels that depolarize the membrane mediating calcium ion influx into the flagellar axoneme.", [["membrane", "ANATOMY", 70, 78], ["axoneme", "ANATOMY", 127, 134], ["calcium", "CHEMICAL", 89, 96], ["calcium", "CHEMICAL", 89, 96], ["Channelrhodopsins", "SIMPLE_CHEMICAL", 0, 17], ["cation", "SIMPLE_CHEMICAL", 34, 40], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["calcium", "SIMPLE_CHEMICAL", 89, 96], ["flagellar axoneme", "CELLULAR_COMPONENT", 117, 134], ["light-gated cation channels", "PROTEIN", 22, 49], ["Channelrhodopsins", "TREATMENT", 0, 17], ["light-gated cation channels", "TREATMENT", 22, 49], ["the membrane mediating calcium", "TREATMENT", 66, 96]]], ["Crystallography and molecular biophysics have begun to clarify how modifications of the same architecture enable the rhodopsins to carry out their distinctly different molecular functions.", [["Crystallography", "TEST", 0, 15]]], ["Interconversions of their functions by mutation reveal the elegant simplicity by which evolution uses existing genes to create proteins with novel functions.O-282Gold colloids-fluorophore complexes for protein detection assay L. Sironi 1 , S. Freddi 1 , L. D'Alfonso 1 , M. Collini 1 , M. Caccia 1 , G. Tallarida 2 , S. Caprioli 2 , G. Chirico 1 1 Dipartimento di Fisica, Universit\u00e0 di Milano-Bicocca, Italy, 2 Laboratorio Nazionale MDM, Agrate Brianza (MI), Italy Noble metal nanoparticles (NP) are endowed with peculiar optical properties related to the surface plasmon resonances (SPR).", [["MI", "DISEASE", 454, 456], ["Noble metal nanoparticles", "SIMPLE_CHEMICAL", 465, 490], ["Gold colloids-fluorophore complexes", "TREATMENT", 162, 197], ["protein detection", "TEST", 202, 219], ["Laboratorio Nazionale MDM", "TREATMENT", 411, 436], ["Italy Noble metal nanoparticles (NP)", "TREATMENT", 459, 495], ["peculiar optical properties", "TREATMENT", 513, 540]]], ["The interaction of surface plasmons of gold nanoparticles with fluorophores a few nanometers away from the surface modifies their brightness and excited-state lifetime, and this effect can be exploited to obtain nanodevices for proteinprotein recognition.", [["surface", "ANATOMY", 19, 26], ["surface", "ANATOMY", 107, 114], ["gold nanoparticles", "CHEMICAL", 39, 57], ["gold nanoparticles", "SIMPLE_CHEMICAL", 39, 57], ["surface", "CELLULAR_COMPONENT", 107, 114], ["proteinprotein", "SIMPLE_CHEMICAL", 228, 242], ["surface plasmons of gold nanoparticles", "TREATMENT", 19, 57], ["fluorophores", "TREATMENT", 63, 75], ["proteinprotein recognition", "TREATMENT", 228, 254]]], ["We studied different types of constructs based on gold NPs on which derivatives of fluorescein were bound.", [["fluorescein", "CHEMICAL", 83, 94], ["fluorescein", "CHEMICAL", 83, 94], ["gold NPs", "SIMPLE_CHEMICAL", 50, 58], ["fluorescein", "SIMPLE_CHEMICAL", 83, 94], ["gold NPs", "TREATMENT", 50, 58], ["fluorescein", "TREATMENT", 83, 94]]], ["The interaction of this fluorophore with the gold surface plasmon resonances, mainly occurring through quenching, affects its excited-state lifetime, that is measured by fluorescence burst analysis in standard solutions.", [["this fluorophore", "TREATMENT", 19, 35], ["the gold surface plasmon resonances", "TREATMENT", 41, 76], ["fluorescence burst analysis", "TEST", 170, 197]]], ["The binding of proteins to the gold NPs through antigen-antibody recognition further modifies the dye excited-state lifetime.", [["gold NPs", "SIMPLE_CHEMICAL", 31, 39], ["antigen", "GENE_OR_GENE_PRODUCT", 48, 55]]], ["This change can therefore be used to measure the protein concentration.", [["the protein concentration", "TEST", 45, 70]]], ["Streptavidin-functionalized gold NPs of size 5-10 nm are used to bind biotin-fluorescein and biotin-antibodies for specific proteins.", [["biotin-fluorescein", "CHEMICAL", 70, 88], ["biotin", "CHEMICAL", 93, 99], ["biotin", "CHEMICAL", 70, 76], ["fluorescein", "CHEMICAL", 77, 88], ["biotin", "CHEMICAL", 93, 99], ["Streptavidin", "SIMPLE_CHEMICAL", 0, 12], ["gold NPs", "SIMPLE_CHEMICAL", 28, 36], ["biotin-fluorescein", "SIMPLE_CHEMICAL", 70, 88], ["biotin", "SIMPLE_CHEMICAL", 93, 99], ["antibodies", "PROTEIN", 100, 110], ["specific proteins", "PROTEIN", 115, 132], ["Streptavidin", "TEST", 0, 12], ["size", "TEST", 40, 44], ["bind biotin", "TEST", 65, 76], ["fluorescein", "TREATMENT", 77, 88], ["biotin-antibodies", "TEST", 93, 110], ["specific proteins", "PROBLEM", 115, 132]]], ["We have first tested the constructs for bovine serum albumine (BSA) detection.", [["serum", "ANATOMY", 47, 52], ["albumine", "CHEMICAL", 53, 61], ["BSA", "CHEMICAL", 63, 66], ["albumine", "CHEMICAL", 53, 61], ["bovine", "ORGANISM", 40, 46], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["albumine", "SIMPLE_CHEMICAL", 53, 61], ["BSA", "SIMPLE_CHEMICAL", 63, 66], ["bovine", "SPECIES", 40, 46], ["bovine", "SPECIES", 40, 46], ["bovine serum albumine", "TEST", 40, 61]]], ["The data reported here indicate that one can measure the concentration of BSA in solution with an apparent limit of detection of 5\u00b12 pM.", [["BSA", "CHEMICAL", 74, 77], ["BSA", "SIMPLE_CHEMICAL", 74, 77], ["The data", "TEST", 0, 8]]], ["We have then extended the study to the antitumor protein P53 -P53 antibody interaction in standard solution and directly in cellular extracts.P-281Calcium transport and phototransduction in isolated rod outer segments G. Rispoli Dip.", [["antitumor", "ANATOMY", 39, 48], ["cellular extracts", "ANATOMY", 124, 141], ["P-281Calcium", "CHEMICAL", 142, 154], ["Calcium", "CHEMICAL", 147, 154], ["antitumor", "CANCER", 39, 48], ["P53", "GENE_OR_GENE_PRODUCT", 57, 60], ["P53", "GENE_OR_GENE_PRODUCT", 62, 65], ["cellular extracts", "ORGANISM_SUBSTANCE", 124, 141], ["Calcium", "SIMPLE_CHEMICAL", 147, 154], ["antitumor protein", "PROTEIN", 39, 56], ["P53", "PROTEIN", 57, 60], ["P53 antibody", "PROTEIN", 62, 74], ["the study", "TEST", 22, 31], ["the antitumor protein P53", "TEST", 35, 60], ["P", "TEST", 142, 143], ["Calcium transport", "TEST", 147, 164], ["phototransduction in isolated rod outer segments", "TREATMENT", 169, 217], ["Rispoli Dip", "PROBLEM", 221, 232], ["cellular extracts", "OBSERVATION", 124, 141], ["rod", "OBSERVATION_MODIFIER", 199, 202], ["Rispoli Dip", "OBSERVATION", 221, 232]]], ["Biologia ed Evoluzione, Universit\u00e0 di Ferrara, Italy Ca 2+ concentration in photoreceptor rod outer segment (OS) strongly affects the generator potential kinetics and light adaptation.", [["photoreceptor rod outer segment", "ANATOMY", 76, 107], ["Ca", "CHEMICAL", 53, 55], ["Ca 2+", "CHEMICAL", 53, 58], ["Ca 2+", "SIMPLE_CHEMICAL", 53, 58], ["photoreceptor rod outer segment", "MULTI-TISSUE_STRUCTURE", 76, 107], ["Biologia", "TEST", 0, 8], ["concentration in photoreceptor rod outer segment", "TREATMENT", 59, 107], ["photoreceptor rod", "OBSERVATION", 76, 93], ["segment", "ANATOMY_MODIFIER", 100, 107]]], ["Light stimuli may produce voltage changes exceeding 40 mV: since the OS Ca 2+ extrusion is entirely controlled by the Na + :Ca 2+ ,K + exchanger (NCKX), it is important to assess how the NCKX ion transport is affected by voltage and intracellular factors.", [["intracellular", "ANATOMY", 233, 246], ["Ca", "CHEMICAL", 72, 74], ["Na", "CHEMICAL", 118, 120], ["Ca", "CHEMICAL", 124, 126], ["K", "CHEMICAL", 131, 132], ["Ca 2+", "CHEMICAL", 72, 77], ["Na +", "CHEMICAL", 118, 122], ["Ca 2+", "CHEMICAL", 124, 129], ["K +", "CHEMICAL", 131, 134], ["Ca 2+", "SIMPLE_CHEMICAL", 72, 77], ["Na +", "SIMPLE_CHEMICAL", 118, 122], ["Ca 2+", "SIMPLE_CHEMICAL", 124, 129], ["K + exchanger", "GENE_OR_GENE_PRODUCT", 131, 144], ["NCKX", "SIMPLE_CHEMICAL", 146, 150], ["NCKX", "GENE_OR_GENE_PRODUCT", 187, 191], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 233, 246], ["Na + :Ca 2+ ,K + exchanger", "PROTEIN", 118, 144], ["NCKX", "PROTEIN", 146, 150], ["NCKX", "PROTEIN", 187, 191], ["voltage and intracellular factors", "PROTEIN", 221, 254], ["Light stimuli", "TEST", 0, 13], ["voltage changes", "PROBLEM", 26, 41], ["the OS Ca", "TEST", 65, 74], ["extrusion", "PROBLEM", 78, 87], ["the Na", "TEST", 114, 120], ["Ca", "TEST", 124, 126], ["K", "TEST", 131, 132], ["intracellular factors", "OBSERVATION", 233, 254]]], ["The NKCX regulation was investigated in whole-cell recorded OS, using ionic conditions that activated maximally forward and reverse exchange.", [["whole-cell", "ANATOMY", 40, 50], ["NKCX", "GENE_OR_GENE_PRODUCT", 4, 8], ["whole-cell", "CELL", 40, 50], ["NKCX", "PROTEIN", 4, 8], ["The NKCX regulation", "TEST", 0, 19], ["ionic conditions", "TREATMENT", 70, 86]]], ["In all species examined of amphibia and reptilia, the forward (reverse) exchange current increased about linearly for negative (positive) voltages and exhibited outward (inward) rectification for positive (negative) voltages.", [["amphibia", "ANATOMY", 27, 35], ["amphibia", "CELL", 27, 35], ["amphibia and reptilia", "PROBLEM", 27, 48], ["outward (inward) rectification", "PROBLEM", 161, 191], ["positive (negative) voltages", "PROBLEM", 196, 224], ["reptilia", "ANATOMY_MODIFIER", 40, 48]]], ["Since hyperpolarization increases Ca 2+ extrusion rate, the recovery of the dark level of Ca 2+ (and of the generator potential) after light stimuli results accelerated.", [["Ca", "CHEMICAL", 34, 36], ["Ca", "CHEMICAL", 90, 92], ["Ca 2+", "CHEMICAL", 34, 39], ["Ca 2+", "CHEMICAL", 90, 95], ["Ca 2+", "SIMPLE_CHEMICAL", 34, 39], ["Ca 2+", "SIMPLE_CHEMICAL", 90, 95], ["hyperpolarization", "PROBLEM", 6, 23], ["Ca", "TEST", 34, 36], ["extrusion rate", "TEST", 40, 54], ["Ca", "TEST", 90, 92], ["light stimuli", "TEST", 135, 148]]], ["Mg-ATP doubled the size of forward and reverse exchange current without modifying their voltage dependence, indicating that Mg-ATP regulates the number of active exchanger sites and/or the NCKX turnover number.", [["Mg", "CHEMICAL", 0, 2], ["ATP", "CHEMICAL", 3, 6], ["Mg", "CHEMICAL", 124, 126], ["ATP", "CHEMICAL", 127, 130], ["Mg", "CHEMICAL", 0, 2], ["ATP", "CHEMICAL", 3, 6], ["Mg", "CHEMICAL", 124, 126], ["ATP", "CHEMICAL", 127, 130], ["Mg-ATP", "SIMPLE_CHEMICAL", 0, 6], ["Mg-ATP", "SIMPLE_CHEMICAL", 124, 130], ["NCKX", "GENE_OR_GENE_PRODUCT", 189, 193], ["active exchanger sites", "PROTEIN", 155, 177], ["NCKX", "PROTEIN", 189, 193], ["Mg", "TEST", 0, 2], ["ATP", "TREATMENT", 3, 6], ["reverse exchange", "TREATMENT", 39, 55], ["their voltage dependence", "PROBLEM", 82, 106], ["Mg", "TEST", 124, 126], ["active exchanger sites", "PROBLEM", 155, 177], ["size", "OBSERVATION_MODIFIER", 19, 23], ["active", "OBSERVATION_MODIFIER", 155, 161], ["exchanger sites", "OBSERVATION", 162, 177]]], ["Ca 2+ jumps achieved via photolysis of caged-Ca 2+ produced current transients, possibly originating from electrogenic partial reactions.", [["Ca", "CHEMICAL", 0, 2], ["Ca", "CHEMICAL", 45, 47], ["Ca 2+", "CHEMICAL", 0, 5], ["Ca 2+", "CHEMICAL", 45, 50], ["Ca 2+", "SIMPLE_CHEMICAL", 0, 5], ["caged-Ca 2+", "SIMPLE_CHEMICAL", 39, 50], ["Ca", "TEST", 0, 2], ["jumps", "TEST", 6, 11], ["Ca", "TEST", 45, 47], ["electrogenic partial reactions", "PROBLEM", 106, 136], ["possibly originating", "UNCERTAINTY", 80, 100], ["electrogenic", "OBSERVATION", 106, 118], ["partial reactions", "OBSERVATION", 119, 136]]], ["No monovalent cation substituted for Na + at the NCKX binding sites, but Rb + substituted for K + , while Sr 2+ , Ba 2+ , Mg 2+ substituted for Ca 2+ with an apparent permeability ratio of 0.78, 0.20, <0.05:1, respectively.Light perception by phototropin studied with time-resolved infrared spectroscopyA.", [["Na", "CHEMICAL", 37, 39], ["K", "CHEMICAL", 94, 95], ["Ba", "CHEMICAL", 114, 116], ["Mg", "CHEMICAL", 122, 124], ["Ca", "CHEMICAL", 144, 146], ["Na +", "CHEMICAL", 37, 41], ["K +", "CHEMICAL", 94, 97], ["Sr 2+", "CHEMICAL", 106, 111], ["Ba 2+", "CHEMICAL", 114, 119], ["Mg 2+", "CHEMICAL", 122, 127], ["Ca 2+", "CHEMICAL", 144, 149], ["cation", "SIMPLE_CHEMICAL", 14, 20], ["Na +", "SIMPLE_CHEMICAL", 37, 41], ["NCKX", "SIMPLE_CHEMICAL", 49, 53], ["Rb +", "SIMPLE_CHEMICAL", 73, 77], ["K +", "SIMPLE_CHEMICAL", 94, 97], ["Sr 2+", "SIMPLE_CHEMICAL", 106, 111], ["Ba 2+", "SIMPLE_CHEMICAL", 114, 119], ["Mg 2+", "SIMPLE_CHEMICAL", 122, 127], ["Ca 2+", "SIMPLE_CHEMICAL", 144, 149], ["NCKX binding sites", "PROTEIN", 49, 67], ["Rb", "PROTEIN", 73, 75], ["phototropin", "PROTEIN", 243, 254], ["monovalent cation", "TREATMENT", 3, 20], ["Na", "TEST", 37, 39], ["Rb", "TEST", 73, 75], ["K", "TEST", 94, 95], ["Sr", "TEST", 106, 108], ["Ba", "TEST", 114, 116], ["Mg", "TEST", 122, 124], ["Ca", "TEST", 144, 146], ["an apparent permeability ratio", "TEST", 155, 185], ["phototropin studied", "TEST", 243, 262]]], ["Pfeifer 1 , K. Zikihara 2 , S. Tokutomi 2 , J. Heberle 1 , T. Kottke 1 1 Bielefeld University, Bielefeld, Germany, 2 Osaka Prefecture University, Sakai, JapanLight perception by phototropin studied with time-resolved infrared spectroscopyThe blue light receptor phototropin regulates the growth of plants towards the light.", [["phototropin", "CHEMICAL", 178, 189], ["blue light receptor", "GENE_OR_GENE_PRODUCT", 242, 261], ["phototropin", "GENE_OR_GENE_PRODUCT", 262, 273], ["blue light receptor phototropin", "PROTEIN", 242, 273], ["infrared spectroscopy", "TEST", 217, 238], ["The blue light receptor phototropin", "TREATMENT", 238, 273], ["growth", "OBSERVATION_MODIFIER", 288, 294]]], ["It contains two light-, oxygen-, or voltage-sensitive (LOV) domains and a kinase domain.", [["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["voltage-sensitive (LOV) domains", "PROTEIN", 36, 67], ["kinase domain", "PROTEIN", 74, 87], ["oxygen", "TEST", 24, 30], ["a kinase domain", "TEST", 72, 87], ["two", "OBSERVATION_MODIFIER", 12, 15], ["light", "OBSERVATION_MODIFIER", 16, 21]]], ["LOV domains bind noncovalently flavin mononucleotide (FMN) as chromophore.", [["flavin mononucleotide", "CHEMICAL", 31, 52], ["FMN", "CHEMICAL", 54, 57], ["noncovalently flavin mononucleotide", "SIMPLE_CHEMICAL", 17, 52], ["FMN", "SIMPLE_CHEMICAL", 54, 57], ["LOV domains", "PROTEIN", 0, 11], ["LOV domains bind noncovalently flavin mononucleotide (FMN)", "TREATMENT", 0, 58], ["chromophore", "TREATMENT", 62, 73]]], ["Upon illumination, the triplet excited state of flavin reacts within few microseconds with a nearby cysteine under formation of a photoadduct, which represents the signaling state.", [["flavin", "CHEMICAL", 48, 54], ["cysteine", "CHEMICAL", 100, 108], ["flavin", "CHEMICAL", 48, 54], ["cysteine", "CHEMICAL", 100, 108], ["flavin", "SIMPLE_CHEMICAL", 48, 54], ["cysteine", "AMINO_ACID", 100, 108], ["flavin reacts", "PROBLEM", 48, 61], ["signaling state", "OBSERVATION", 164, 179]]], ["In response to adduct formation, a J\u03b1 helix adjacent to the LOV2 domain dissociates and allows for autophosphorylation by the kinase domain.", [["J\u03b1 helix", "PROTEIN", 35, 43], ["LOV2 domain", "PROTEIN", 60, 71], ["kinase domain", "PROTEIN", 126, 139], ["adduct formation", "PROBLEM", 15, 31], ["a J\u03b1 helix", "TREATMENT", 33, 43], ["the LOV2 domain dissociates", "PROBLEM", 56, 83], ["autophosphorylation", "PROBLEM", 99, 118], ["the kinase domain", "TEST", 122, 139], ["adduct formation", "OBSERVATION", 15, 31]]], ["The mechanism of the photoreaction and the signaling pathway from FMN to the J\u03b1 helix are still unclear.", [["FMN", "CHEMICAL", 66, 69], ["FMN", "SIMPLE_CHEMICAL", 66, 69], ["J\u03b1 helix", "GENE_OR_GENE_PRODUCT", 77, 85], ["FMN", "PROTEIN", 66, 69], ["J\u03b1 helix", "PROTEIN", 77, 85], ["the photoreaction", "TREATMENT", 17, 34], ["the signaling pathway", "PROBLEM", 39, 60], ["the J\u03b1 helix", "PROBLEM", 73, 85], ["J\u03b1 helix", "ANATOMY", 77, 85]]], ["We have investigated the LOV2 domain of Arabidopsis phototropin 2 by microsecond FT-infrared spectroscopy.", [["phototropin 2", "GENE_OR_GENE_PRODUCT", 52, 65], ["LOV2 domain", "PROTEIN", 25, 36], ["Arabidopsis phototropin 2", "PROTEIN", 40, 65], ["Arabidopsis phototropin", "TREATMENT", 40, 63], ["infrared spectroscopy", "TEST", 84, 105]]], ["The difference spectrum recorded at 2 \u00b5s provides evidence that the flavin is unprotonated in the triplet excited state.", [["flavin", "CHEMICAL", 68, 74], ["flavin", "CHEMICAL", 68, 74], ["flavin", "SIMPLE_CHEMICAL", 68, 74], ["triplet excited state", "PROTEIN", 98, 119], ["unprotonated", "OBSERVATION", 78, 90]]], ["Therefore, a previously proposed ionic mechanism of bond formation is disfavored.", [["bond formation", "PROBLEM", 52, 66], ["bond formation", "OBSERVATION", 52, 66]]], ["Changes in secondary structure were detected concomitant with adduct formation that relax with a time constant of 120 \u00b5s.", [["adduct", "SIMPLE_CHEMICAL", 62, 68], ["Changes in secondary structure", "PROBLEM", 0, 30], ["adduct formation", "PROBLEM", 62, 78], ["secondary structure", "OBSERVATION", 11, 30], ["adduct formation", "OBSERVATION", 62, 78]]], ["This early adduct intermediate has not been previously characterized.", [["adduct intermediate", "OBSERVATION", 11, 30], ["not been previously characterized", "OBSERVATION_MODIFIER", 35, 68]]], ["The final adduct state is formed in milliseconds by further alterations in secondary structure.", [["further alterations in secondary structure", "PROBLEM", 52, 94], ["adduct", "OBSERVATION", 10, 16], ["secondary structure", "OBSERVATION", 75, 94]]], ["These findings raise the question of whether the early or late adduct intermediate propagate the signal to the J\u03b1 helix.O-279-Photosensory biophysics -AbstractsThe psychostimulant amphetamine increased NO generation measured by EPR as well as amino acid release in the rat brain Nitric oxide (NO) is a novel messenger that modulates many functions of the nervous system.", [["brain", "ANATOMY", 273, 278], ["nervous system", "ANATOMY", 355, 369], ["O-279", "CHEMICAL", 120, 125], ["amphetamine", "CHEMICAL", 180, 191], ["NO", "CHEMICAL", 202, 204], ["amino acid", "CHEMICAL", 243, 253], ["Nitric oxide", "CHEMICAL", 279, 291], ["NO", "CHEMICAL", 293, 295], ["O-279", "CHEMICAL", 120, 125], ["amphetamine", "CHEMICAL", 180, 191], ["NO", "CHEMICAL", 202, 204], ["amino acid", "CHEMICAL", 243, 253], ["Nitric oxide", "CHEMICAL", 279, 291], ["NO", "CHEMICAL", 293, 295], ["amphetamine", "SIMPLE_CHEMICAL", 180, 191], ["NO", "SIMPLE_CHEMICAL", 202, 204], ["amino acid", "AMINO_ACID", 243, 253], ["rat", "ORGANISM", 269, 272], ["brain", "ORGAN", 273, 278], ["Nitric oxide", "SIMPLE_CHEMICAL", 279, 291], ["NO", "SIMPLE_CHEMICAL", 293, 295], ["nervous system", "ANATOMICAL_SYSTEM", 355, 369], ["J\u03b1 helix", "PROTEIN", 111, 119], ["rat", "SPECIES", 269, 272], ["rat", "SPECIES", 269, 272], ["The psychostimulant amphetamine", "TREATMENT", 160, 191], ["amino acid release", "TREATMENT", 243, 261], ["the rat brain Nitric oxide", "TREATMENT", 265, 291], ["raise the question of", "UNCERTAINTY", 15, 36], ["intermediate propagate", "OBSERVATION", 70, 92], ["nervous system", "ANATOMY", 355, 369]]], ["The involvement of NO in brain damage was shown mainly by indirect evidence and the data are controversial.", [["brain", "ANATOMY", 25, 30], ["NO", "CHEMICAL", 19, 21], ["brain damage", "DISEASE", 25, 37], ["NO", "CHEMICAL", 19, 21], ["NO", "SIMPLE_CHEMICAL", 19, 21], ["brain", "ORGAN", 25, 30], ["brain damage", "PROBLEM", 25, 37], ["the data", "TEST", 80, 88], ["NO in", "UNCERTAINTY", 19, 24], ["brain", "ANATOMY", 25, 30], ["damage", "OBSERVATION", 31, 37]]], ["The short half-life of NO makes its direct detection difficult.", [["NO", "CHEMICAL", 23, 25], ["NO", "CHEMICAL", 23, 25], ["NO", "SIMPLE_CHEMICAL", 23, 25]]], ["We measured NO generation using EPR spectroscopy based on determination of the amount of paramagnetic mononitrosyl-iron complexes.", [["NO", "CHEMICAL", 12, 14], ["iron", "CHEMICAL", 115, 119], ["NO", "CHEMICAL", 12, 14], ["mononitrosyl-iron", "CHEMICAL", 102, 119], ["NO", "SIMPLE_CHEMICAL", 12, 14], ["paramagnetic mononitrosyl-iron complexes", "SIMPLE_CHEMICAL", 89, 129], ["paramagnetic mononitrosyl-iron complexes", "PROTEIN", 89, 129], ["EPR spectroscopy", "TEST", 32, 48], ["paramagnetic mononitrosyl-iron complexes", "TREATMENT", 89, 129], ["NO", "UNCERTAINTY", 12, 14]]], ["The aim was to elucidate whether psychostimulant drug amphetamine (AMPH) modulates formation of NO and lipid peroxidation (LPO) products as well as the neurotransmitter release in rat brain.", [["brain", "ANATOMY", 184, 189], ["amphetamine", "CHEMICAL", 54, 65], ["AMPH", "CHEMICAL", 67, 71], ["NO", "CHEMICAL", 96, 98], ["amphetamine", "CHEMICAL", 54, 65], ["AMPH", "CHEMICAL", 67, 71], ["NO", "CHEMICAL", 96, 98], ["amphetamine", "SIMPLE_CHEMICAL", 54, 65], ["AMPH", "SIMPLE_CHEMICAL", 67, 71], ["NO", "SIMPLE_CHEMICAL", 96, 98], ["lipid peroxidation", "SIMPLE_CHEMICAL", 103, 121], ["LPO", "SIMPLE_CHEMICAL", 123, 126], ["rat", "ORGANISM", 180, 183], ["brain", "ORGAN", 184, 189], ["rat", "SPECIES", 180, 183], ["rat", "SPECIES", 180, 183], ["psychostimulant drug amphetamine (AMPH)", "TREATMENT", 33, 72], ["lipid peroxidation (LPO) products", "TREATMENT", 103, 136], ["the neurotransmitter release in rat brain", "PROBLEM", 148, 189], ["brain", "ANATOMY", 184, 189]]], ["The output of glutamate, aspartate, GABA and acetylcholine (ACH) was monitored in striatum by microdialysis with HPLC detection.", [["striatum", "ANATOMY", 82, 90], ["glutamate", "CHEMICAL", 14, 23], ["aspartate", "CHEMICAL", 25, 34], ["GABA", "CHEMICAL", 36, 40], ["acetylcholine", "CHEMICAL", 45, 58], ["ACH", "CHEMICAL", 60, 63], ["glutamate", "CHEMICAL", 14, 23], ["aspartate", "CHEMICAL", 25, 34], ["GABA", "CHEMICAL", 36, 40], ["acetylcholine", "CHEMICAL", 45, 58], ["glutamate", "SIMPLE_CHEMICAL", 14, 23], ["aspartate", "SIMPLE_CHEMICAL", 25, 34], ["GABA", "SIMPLE_CHEMICAL", 36, 40], ["acetylcholine", "SIMPLE_CHEMICAL", 45, 58], ["ACH", "SIMPLE_CHEMICAL", 60, 63], ["striatum", "MULTI-TISSUE_STRUCTURE", 82, 90], ["glutamate", "TREATMENT", 14, 23], ["aspartate", "TEST", 25, 34], ["acetylcholine (ACH)", "TREATMENT", 45, 64], ["HPLC detection", "TEST", 113, 127], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["AMPH produced 2fold elevation of NO generation and LPO formation in brain areas.", [["brain areas", "ANATOMY", 68, 79], ["AMPH", "CHEMICAL", 0, 4], ["NO", "CHEMICAL", 33, 35], ["AMPH", "CHEMICAL", 0, 4], ["NO", "CHEMICAL", 33, 35], ["AMPH", "SIMPLE_CHEMICAL", 0, 4], ["NO", "SIMPLE_CHEMICAL", 33, 35], ["LPO", "SIMPLE_CHEMICAL", 51, 54], ["brain", "ORGAN", 68, 73], ["AMPH", "TEST", 0, 4], ["LPO formation in brain areas", "PROBLEM", 51, 79], ["elevation", "OBSERVATION_MODIFIER", 20, 29], ["NO generation", "OBSERVATION", 33, 46], ["LPO formation", "OBSERVATION", 51, 64], ["brain", "ANATOMY", 68, 73], ["areas", "ANATOMY_MODIFIER", 74, 79]]], ["While AMPH increased the aspartate, GABA and ACH release, the glutamate output was not affected.", [["AMPH", "CHEMICAL", 6, 10], ["aspartate", "CHEMICAL", 25, 34], ["GABA", "CHEMICAL", 36, 40], ["ACH", "CHEMICAL", 45, 48], ["glutamate", "CHEMICAL", 62, 71], ["AMPH", "CHEMICAL", 6, 10], ["aspartate", "CHEMICAL", 25, 34], ["GABA", "CHEMICAL", 36, 40], ["ACH", "CHEMICAL", 45, 48], ["glutamate", "CHEMICAL", 62, 71], ["AMPH", "SIMPLE_CHEMICAL", 6, 10], ["aspartate", "SIMPLE_CHEMICAL", 25, 34], ["GABA", "SIMPLE_CHEMICAL", 36, 40], ["ACH", "SIMPLE_CHEMICAL", 45, 48], ["glutamate", "SIMPLE_CHEMICAL", 62, 71], ["the aspartate", "TEST", 21, 34], ["the glutamate output", "TEST", 58, 78]]], ["Pretreatment with the neuronal NOS inhibitor was highly effective in abating the rise of NO and neurotransmitter levels but failed to influence the LPO intensity elicited by AMPH.", [["neuronal", "ANATOMY", 22, 30], ["NO", "CHEMICAL", 89, 91], ["AMPH", "CHEMICAL", 174, 178], ["NO", "CHEMICAL", 89, 91], ["AMPH", "CHEMICAL", 174, 178], ["neuronal", "CELL", 22, 30], ["NOS", "GENE_OR_GENE_PRODUCT", 31, 34], ["NO", "SIMPLE_CHEMICAL", 89, 91], ["LPO", "SIMPLE_CHEMICAL", 148, 151], ["AMPH", "SIMPLE_CHEMICAL", 174, 178], ["Pretreatment", "TREATMENT", 0, 12], ["the neuronal NOS inhibitor", "TREATMENT", 18, 44], ["neurotransmitter levels", "PROBLEM", 96, 119]]], ["The findings suggest that activation of NO synthesis is a potent factor in the AMPH-induced neurotransmitter release.P-286Light scattering study of DNA over a wide chain length range: comparison with wormlike model P. Baeri, M. Zimbone Dipartimento di Fisica e Astronomia, Universit\u00e0 di Catania, Italy This work reports light scattering measurements on DNA in aqueous solutions (100 mM NaCl ,1mM EDTA and 10 mM Tris-HCl buffer, pH 7.8) over a wide range of molecular weights (10 2 -10 5 base pairs) and shows that, in the above standard solvent, shorter chains ( < 10 4 base pairs) behave as a \"wormlike chain\" and their diffusion coefficient as obtained by dynamic light scattering measurements, confirm the prediction of standard wormlike model, whilst longer chains ( >10 4 base pairs) behave in a different manner.", [["NO", "CHEMICAL", 40, 42], ["AMPH", "CHEMICAL", 79, 83], ["NaCl", "CHEMICAL", 386, 390], ["Tris-HCl", "CHEMICAL", 411, 419], ["NO", "CHEMICAL", 40, 42], ["AMPH", "CHEMICAL", 79, 83], ["NaCl", "CHEMICAL", 386, 390], ["EDTA", "CHEMICAL", 396, 400], ["Tris-HCl", "CHEMICAL", 411, 419], ["NO", "SIMPLE_CHEMICAL", 40, 42], ["AMPH", "SIMPLE_CHEMICAL", 79, 83], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["DNA", "CELLULAR_COMPONENT", 353, 356], ["P", "DNA", 117, 118], ["wormlike chain", "PROTEIN", 595, 609], ["NO synthesis", "PROBLEM", 40, 52], ["scattering study", "TEST", 128, 144], ["DNA", "PROBLEM", 148, 151], ["light scattering measurements", "TEST", 320, 349], ["DNA in aqueous solutions", "TREATMENT", 353, 377], ["NaCl", "TREATMENT", 386, 390], ["1mM EDTA", "TREATMENT", 392, 400], ["Tris", "TEST", 411, 415], ["pH", "TEST", 428, 430], ["molecular weights", "TEST", 457, 474], ["base pairs", "TEST", 487, 497], ["a \"wormlike chain\"", "PROBLEM", 592, 610], ["their diffusion coefficient", "TEST", 615, 642], ["dynamic light scattering measurements", "TEST", 658, 695], ["standard wormlike model", "TREATMENT", 723, 746], ["neurotransmitter release", "OBSERVATION", 92, 116]]], ["Dynamic and static light scattering and SEM analysis indicate that DNA molecules 10 5 base pairs long, condense into compact structures in our solvent condition.", [["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA molecules", "PROTEIN", 67, 80], ["SEM analysis", "TEST", 40, 52], ["DNA molecules", "PROBLEM", 67, 80]]], ["Calculations done using a wormlike model are also presented and discussed in comparison both to our experimental data and to other data reported in the literature.Effects of pH on transport properties and ionic selectivity of amphotericin B-induced channelsA.", [["amphotericin B", "CHEMICAL", 226, 240], ["amphotericin B", "CHEMICAL", 226, 240], ["amphotericin B", "SIMPLE_CHEMICAL", 226, 240], ["channelsA", "SIMPLE_CHEMICAL", 249, 258], ["channelsA", "PROTEIN", 249, 258], ["Calculations", "TEST", 0, 12], ["a wormlike model", "TREATMENT", 24, 40], ["transport properties", "TEST", 180, 200], ["ionic selectivity", "TEST", 205, 222], ["amphotericin B", "TREATMENT", 226, 240]]], ["Carol I no. 11, Iasi, Romania Amphotericin B (AmB) is an antifungal antibiotic which, despite the severe side effects, is still used for the treatment of systemic fungal infections.", [["Amphotericin B", "CHEMICAL", 30, 44], ["AmB", "CHEMICAL", 46, 49], ["fungal infections", "DISEASE", 163, 180], ["Amphotericin B", "CHEMICAL", 30, 44], ["AmB", "CHEMICAL", 46, 49], ["Amphotericin B", "SIMPLE_CHEMICAL", 30, 44], ["AmB", "SIMPLE_CHEMICAL", 46, 49], ["Romania Amphotericin B (AmB)", "TREATMENT", 22, 50], ["an antifungal antibiotic", "TREATMENT", 54, 78], ["the severe side effects", "PROBLEM", 94, 117], ["systemic fungal infections", "PROBLEM", 154, 180], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["side effects", "OBSERVATION_MODIFIER", 105, 117], ["systemic", "OBSERVATION_MODIFIER", 154, 162], ["fungal infections", "OBSERVATION", 163, 180]]], ["In this study we investigated the influence of pH upon the selectivity and the transport properties of AmB channels inserted in reconstituted, ergosterolcontaining zwitterionic lipid membranes.", [["lipid membranes", "ANATOMY", 177, 192], ["AmB", "CHEMICAL", 103, 106], ["AmB", "CHEMICAL", 103, 106], ["AmB", "SIMPLE_CHEMICAL", 103, 106], ["lipid membranes", "CELLULAR_COMPONENT", 177, 192], ["this study", "TEST", 3, 13], ["AmB channels", "TREATMENT", 103, 115], ["ergosterolcontaining zwitterionic lipid membranes", "TREATMENT", 143, 192], ["zwitterionic lipid membranes", "OBSERVATION", 164, 192]]], ["Our electrophysiology experiments carried out on single and multiple AmB channels prove that at pH=2.8 these channels are anion selective, whereas at neutral and alkaline pH's (pH=7 and pH=11) they become cation selective.", [["AmB", "CHEMICAL", 69, 72], ["AmB", "CHEMICAL", 69, 72], ["AmB", "SIMPLE_CHEMICAL", 69, 72], ["anion", "SIMPLE_CHEMICAL", 122, 127], ["cation", "SIMPLE_CHEMICAL", 205, 211], ["Our electrophysiology experiments", "TEST", 0, 33], ["single and multiple AmB channels", "TREATMENT", 49, 81], ["pH", "TEST", 96, 98], ["alkaline pH", "TEST", 162, 173], ["pH", "TEST", 177, 179], ["pH", "TEST", 186, 188]]], ["We attribute this to the pH-dependent ionization state of the carboxyl and amino groups present at the mouth of AmB molecules.", [["amino", "CHEMICAL", 75, 80], ["AmB", "CHEMICAL", 112, 115], ["carboxyl", "CHEMICAL", 62, 70], ["amino", "CHEMICAL", 75, 80], ["AmB", "CHEMICAL", 112, 115], ["carboxyl", "AMINO_ACID", 62, 70], ["amino", "AMINO_ACID", 75, 80], ["AmB molecules", "SIMPLE_CHEMICAL", 112, 125], ["the pH", "PROBLEM", 21, 27], ["the carboxyl and amino groups", "TREATMENT", 58, 87], ["mouth", "ANATOMY", 103, 108]]], ["Surprisingly, our data reveal that the single-molecule ionic conductance of AmB channels varies in a non-monotonic fashion with pH changes, which we attribute to the pH-dependent variation of the surface and dipole membrane potential.", [["surface", "ANATOMY", 196, 203], ["membrane", "ANATOMY", 215, 223], ["AmB", "CHEMICAL", 76, 79], ["AmB", "CHEMICAL", 76, 79], ["AmB", "SIMPLE_CHEMICAL", 76, 79], ["surface", "CELLULAR_COMPONENT", 196, 203], ["our data", "TEST", 14, 22], ["the single-molecule ionic conductance of AmB channels", "TREATMENT", 35, 88], ["pH changes", "PROBLEM", 128, 138], ["the pH", "PROBLEM", 162, 168], ["AmB channels", "OBSERVATION", 76, 88], ["pH changes", "OBSERVATION", 128, 138], ["dependent", "OBSERVATION_MODIFIER", 169, 178], ["variation", "OBSERVATION_MODIFIER", 179, 188], ["surface", "OBSERVATION_MODIFIER", 196, 203], ["dipole membrane potential", "OBSERVATION", 208, 233]]], ["We demonstrate that when added only from one side of the membrane, in symmetrical salt solutions across the membrane and low pH values, AmB channels display a strong rectifying behavior, and their insertion is strongly favored when positive potentials are present on the side of their addition.", [["membrane", "ANATOMY", 57, 65], ["membrane", "ANATOMY", 108, 116], ["AmB", "CHEMICAL", 136, 139], ["AmB", "CHEMICAL", 136, 139], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["membrane", "CELLULAR_COMPONENT", 108, 116], ["AmB", "SIMPLE_CHEMICAL", 136, 139], ["symmetrical salt solutions", "TREATMENT", 70, 96], ["low pH values", "PROBLEM", 121, 134], ["low pH", "OBSERVATION_MODIFIER", 121, 127]]], ["We report a detection method for the redox state of proteins which combines FRET-based fluorescence/confocal microscopy on dye-labeled protein with cyclic voltammetry.", [["FRET", "SIMPLE_CHEMICAL", 76, 80], ["a detection method", "TEST", 10, 28], ["confocal microscopy", "TEST", 100, 119], ["dye-labeled protein", "TEST", 123, 142], ["cyclic voltammetry", "TEST", 148, 166]]], ["By using this combined method, electron transfer properties can be revealed from protein to electrode or from redox enzyme to substrate.", [["electron", "SIMPLE_CHEMICAL", 31, 39], ["redox enzyme", "PROTEIN", 110, 122], ["this combined method", "TREATMENT", 9, 29], ["redox enzyme", "TEST", 110, 122]]], ["We applied the fluorescent detection to azurin, a blue copper protein from the bacterium Ps. aeruginosa, fluorescently labeled on the N-terminus for monitoring the redox state of the protein.", [["copper", "CHEMICAL", 55, 61], ["copper", "CHEMICAL", 55, 61], ["N", "CHEMICAL", 134, 135], ["azurin", "GENE_OR_GENE_PRODUCT", 40, 46], ["Ps. aeruginosa", "ORGANISM", 89, 103], ["azurin", "PROTEIN", 40, 46], ["blue copper protein", "PROTEIN", 50, 69], ["N-terminus", "PROTEIN", 134, 144], ["Ps. aeruginosa", "SPECIES", 89, 103], ["Ps. aeruginosa", "SPECIES", 89, 103], ["azurin", "TREATMENT", 40, 46], ["a blue copper protein", "TEST", 48, 69], ["the bacterium Ps. aeruginosa", "PROBLEM", 75, 103], ["the N-terminus", "TREATMENT", 130, 144]]], ["The dye fluorescence is quenched by energy transfer to the copper in oxidized, but not in reduced azurin.", [["copper", "CHEMICAL", 59, 65], ["copper", "CHEMICAL", 59, 65], ["dye", "SIMPLE_CHEMICAL", 4, 7], ["copper", "SIMPLE_CHEMICAL", 59, 65], ["azurin", "GENE_OR_GENE_PRODUCT", 98, 104], ["The dye fluorescence", "TEST", 0, 20], ["reduced azurin", "PROBLEM", 90, 104], ["dye fluorescence", "OBSERVATION", 4, 20]]], ["Fluorescence results demonstrated that Cy5-labeled wtazurin switched in fluorescence intensity by up to 85% by varying the applied potential.", [["Cy5", "CHEMICAL", 39, 42], ["wtazurin", "CHEMICAL", 51, 59], ["wtazurin", "CHEMICAL", 51, 59], ["Cy5", "SIMPLE_CHEMICAL", 39, 42], ["wtazurin", "SIMPLE_CHEMICAL", 51, 59], ["Fluorescence results", "TEST", 0, 20], ["Cy5", "TEST", 39, 42], ["wtazurin", "TREATMENT", 51, 59]]], ["Labeled zinc-azurin was used as a control sample and did not show any fluorescence switching.", [["zinc-azurin", "CHEMICAL", 8, 19], ["zinc-azurin", "CHEMICAL", 8, 19], ["zinc-azurin", "SIMPLE_CHEMICAL", 8, 19], ["Labeled zinc-azurin", "TREATMENT", 0, 19]]], ["For single molecule studies wt-azurin was labeled with ATTO 655 dye and a mixed SAM was used, with 8-Hydroxy-1octanethiol as a blocking agent to prevent non-specific binding of protein on the surface, and 1,10 decanedithiol for the specific covalent binding to the protein.", [["surface", "ANATOMY", 192, 199], ["ATTO 655 dye", "CHEMICAL", 55, 67], ["8-Hydroxy-1octanethiol", "CHEMICAL", 99, 121], ["1,10 decanedithiol", "CHEMICAL", 205, 223], ["ATTO 655", "CHEMICAL", 55, 63], ["8-Hydroxy-1octanethiol", "CHEMICAL", 99, 121], ["1,10 decanedithiol", "CHEMICAL", 205, 223], ["wt-azurin", "SIMPLE_CHEMICAL", 28, 37], ["ATTO 655 dye", "SIMPLE_CHEMICAL", 55, 67], ["8-Hydroxy-1octanethiol", "SIMPLE_CHEMICAL", 99, 121], ["surface", "CELLULAR_COMPONENT", 192, 199], ["1,10 decanedithiol", "SIMPLE_CHEMICAL", 205, 223], ["single molecule studies", "TEST", 4, 27], ["azurin", "TREATMENT", 31, 37], ["ATTO", "TREATMENT", 55, 59], ["a mixed SAM", "TREATMENT", 72, 83], ["Hydroxy", "TREATMENT", 101, 108], ["1octanethiol", "TREATMENT", 109, 121], ["a blocking agent", "TREATMENT", 125, 141], ["non-specific binding of protein", "PROBLEM", 153, 184]]], ["Preliminary data show that single-molecule fluorescence switching with the potential is indeed possible.P-283-Single molecule biophysics -AbstractsIs there a specific erythrocyte membrane receptor for fibrinogen?", [["erythrocyte membrane", "ANATOMY", 167, 187], ["P-283", "CHEMICAL", 104, 109], ["erythrocyte membrane receptor", "GENE_OR_GENE_PRODUCT", 167, 196], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 201, 211], ["erythrocyte membrane receptor", "PROTEIN", 167, 196], ["fibrinogen", "PROTEIN", 201, 211], ["Preliminary data", "TEST", 0, 16], ["single-molecule fluorescence", "TREATMENT", 27, 55], ["P", "TEST", 104, 105], ["a specific erythrocyte membrane receptor", "TEST", 156, 196], ["fibrinogen", "TEST", 201, 211]]], ["An atomic force microscopy approach F. A. Carvalho 1 , S. Connell 2 , R. A. Ari\u00ebns 2 , N. C. Santos 1 1 Instituto de Medicina Molecular, Univ.", [["An atomic force microscopy", "TEST", 0, 26]]], ["Lisbon, Portugal, 2 University of Leeds, U.K.AbstractsFibrinogen (Fg) contributes to erythrocyte (RBC) hyperaggregation by an increase in.", [["erythrocyte", "ANATOMY", 85, 96], ["RBC", "ANATOMY", 98, 101], ["U.K.AbstractsFibrinogen", "SIMPLE_CHEMICAL", 41, 64], ["Fg", "GENE_OR_GENE_PRODUCT", 66, 68], ["erythrocyte", "CELL", 85, 96], ["RBC", "CELL", 98, 101], ["RBC", "CELL_TYPE", 98, 101], ["erythrocyte (RBC) hyperaggregation", "PROBLEM", 85, 119], ["erythrocyte", "ANATOMY", 85, 96], ["increase", "OBSERVATION_MODIFIER", 126, 134]]], ["RBC-Fb protein binding considered to be non-specific.", [["RBC-Fb", "GENE_OR_GENE_PRODUCT", 0, 6], ["RBC", "CELL_TYPE", 0, 3], ["Fb protein", "PROTEIN", 4, 14], ["RBC", "TEST", 0, 3], ["Fb protein binding", "TEST", 4, 22], ["Fb protein binding", "OBSERVATION", 4, 22], ["considered to be", "UNCERTAINTY", 23, 39], ["non-specific", "OBSERVATION_MODIFIER", 40, 52]]], ["Glycoprotein \u03b1 IIb \u03b2 3 is a specific integrin receptor for fibrinogen on platelets.", [["platelets", "ANATOMY", 73, 82], ["Glycoprotein \u03b1 IIb \u03b2 3", "GENE_OR_GENE_PRODUCT", 0, 22], ["integrin receptor", "GENE_OR_GENE_PRODUCT", 37, 54], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 59, 69], ["platelets", "CELL", 73, 82], ["Glycoprotein \u03b1 IIb \u03b2 3", "PROTEIN", 0, 22], ["integrin receptor", "PROTEIN", 37, 54], ["fibrinogen", "PROTEIN", 59, 69], ["platelets", "CELL_TYPE", 73, 82], ["Glycoprotein \u03b1 IIb", "TREATMENT", 0, 18], ["a specific integrin receptor", "TREATMENT", 26, 54], ["fibrinogen on platelets", "TEST", 59, 82]]], ["We showed that there is a single molecule interaction between Fg and an unknown receptor on RBC membrane, with a lower affinity when compared with platelet binding.", [["RBC membrane", "ANATOMY", 92, 104], ["platelet", "ANATOMY", 147, 155], ["Fg", "GENE_OR_GENE_PRODUCT", 62, 64], ["RBC membrane", "CELLULAR_COMPONENT", 92, 104], ["platelet", "CELL", 147, 155], ["Fg", "PROTEIN", 62, 64], ["a single molecule interaction between Fg", "PROBLEM", 24, 64], ["RBC membrane", "TREATMENT", 92, 104], ["a lower affinity", "PROBLEM", 111, 127], ["platelet binding", "TEST", 147, 163], ["RBC membrane", "OBSERVATION", 92, 104], ["lower affinity", "OBSERVATION_MODIFIER", 113, 127]]], ["We evaluated if RBC-Fg binding is through an integrin-like receptor or not.", [["RBC", "ANATOMY", 16, 19], ["RBC-Fg", "GENE_OR_GENE_PRODUCT", 16, 22], ["integrin-like receptor", "GENE_OR_GENE_PRODUCT", 45, 67], ["RBC", "CELL_TYPE", 16, 19], ["Fg", "PROTEIN", 20, 22], ["integrin-like receptor", "PROTEIN", 45, 67], ["RBC", "TEST", 16, 19], ["Fg binding", "PROBLEM", 20, 30]]], ["Interactions between Fg and platelet/RBC receptors were studied by force spectroscopy.", [["platelet", "ANATOMY", 28, 36], ["RBC", "ANATOMY", 37, 40], ["Fg", "GENE_OR_GENE_PRODUCT", 21, 23], ["platelet", "CELL", 28, 36], ["/RBC receptors", "GENE_OR_GENE_PRODUCT", 36, 50], ["Fg", "PROTEIN", 21, 23], ["platelet/RBC receptors", "PROTEIN", 28, 50], ["Fg", "TEST", 21, 23], ["platelet/RBC receptors", "TEST", 28, 50], ["force spectroscopy", "TEST", 67, 85]]], ["Force curves were performed between Fg-functionalized atomic force microscope tips and RBC or platelets.", [["RBC", "ANATOMY", 87, 90], ["platelets", "ANATOMY", 94, 103], ["RBC", "CELL", 87, 90], ["platelets", "CELL", 94, 103], ["Fg", "PROTEIN", 36, 38], ["RBC", "CELL_TYPE", 87, 90], ["platelets", "CELL_TYPE", 94, 103], ["Force curves", "TEST", 0, 12], ["Fg", "TEST", 36, 38], ["RBC", "TEST", 87, 90], ["platelets", "TEST", 94, 103]]], ["To evaluate if the Fg-RBC binding is calciumdependent, similar studies were performed in the presence of Ca 2+ or EDTA.", [["Ca", "CHEMICAL", 105, 107], ["EDTA", "CHEMICAL", 114, 118], ["Ca 2+", "CHEMICAL", 105, 110], ["EDTA", "CHEMICAL", 114, 118], ["Fg", "GENE_OR_GENE_PRODUCT", 19, 21], ["RBC", "CELL", 22, 25], ["Ca 2+", "SIMPLE_CHEMICAL", 105, 110], ["EDTA", "SIMPLE_CHEMICAL", 114, 118], ["Fg", "PROTEIN", 19, 21], ["RBC", "CELL_TYPE", 22, 25], ["the Fg-RBC binding", "TEST", 15, 33], ["similar studies", "TEST", 55, 70], ["Ca", "TEST", 105, 107], ["EDTA", "PROBLEM", 114, 118]]], ["We also carried out studies in the presence of a \u03b1 IIb \u03b2 3 inhibitor and of methyl-\u00df-cyclodextrin (to disrupt lipid rafts by cholesterol depletion).", [["lipid rafts", "ANATOMY", 110, 121], ["methyl-\u00df-cyclodextrin", "CHEMICAL", 76, 97], ["cholesterol", "CHEMICAL", 125, 136], ["methyl-\u00df-cyclodextrin", "CHEMICAL", 76, 97], ["cholesterol", "CHEMICAL", 125, 136], ["\u03b1 IIb \u03b2 3", "GENE_OR_GENE_PRODUCT", 49, 58], ["methyl-\u00df-cyclodextrin", "SIMPLE_CHEMICAL", 76, 97], ["lipid rafts", "SIMPLE_CHEMICAL", 110, 121], ["cholesterol", "SIMPLE_CHEMICAL", 125, 136], ["studies", "TEST", 20, 27], ["a \u03b1 IIb \u03b2 3 inhibitor", "TREATMENT", 47, 68], ["methyl-\u00df-cyclodextrin", "TREATMENT", 76, 97], ["lipid rafts", "TREATMENT", 110, 121], ["cholesterol depletion", "TREATMENT", 125, 146], ["cholesterol depletion", "OBSERVATION", 125, 146]]], ["RBC-Fg single forces were of 300-380 pN and of 400-480 pN for platelet-Fg binding in presence of calcium.", [["platelet", "ANATOMY", 62, 70], ["calcium", "CHEMICAL", 97, 104], ["calcium", "CHEMICAL", 97, 104], ["RBC-Fg", "GENE_OR_GENE_PRODUCT", 0, 6], ["platelet-Fg", "GENE_OR_GENE_PRODUCT", 62, 73], ["calcium", "SIMPLE_CHEMICAL", 97, 104], ["RBC", "CELL_TYPE", 0, 3], ["Fg", "PROTEIN", 4, 6], ["Fg", "PROTEIN", 71, 73], ["RBC", "TEST", 0, 3], ["platelet", "TEST", 62, 70], ["calcium", "TEST", 97, 104]]], ["A significant decrease of the platelets-Fg force-rupture was obtained in the presence of EDTA or \u03b1 IIb \u03b2 3 inhibitor.", [["platelets", "ANATOMY", 30, 39], ["rupture", "DISEASE", 49, 56], ["EDTA", "CHEMICAL", 89, 93], ["platelets", "CELL", 30, 39], ["Fg", "GENE_OR_GENE_PRODUCT", 40, 42], ["EDTA", "SIMPLE_CHEMICAL", 89, 93], ["\u03b1 IIb \u03b2 3", "GENE_OR_GENE_PRODUCT", 97, 106], ["platelets", "CELL_TYPE", 30, 39], ["Fg", "PROTEIN", 40, 42], ["the platelets", "TEST", 26, 39], ["Fg force", "TEST", 40, 48], ["rupture", "PROBLEM", 49, 56], ["EDTA", "TREATMENT", 89, 93], ["\u03b1 IIb \u03b2", "TREATMENT", 97, 104], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["platelets", "OBSERVATION_MODIFIER", 30, 39], ["rupture", "OBSERVATION", 49, 56]]], ["Significant lower Fg-RBC force value was obtained in the presence of M\u03b2CD, but not in the presence of EDTA.", [["M\u03b2CD", "CHEMICAL", 69, 73], ["M\u03b2CD", "CHEMICAL", 69, 73], ["EDTA", "CHEMICAL", 102, 106], ["Fg", "GENE_OR_GENE_PRODUCT", 18, 20], ["M\u03b2CD", "SIMPLE_CHEMICAL", 69, 73], ["EDTA", "SIMPLE_CHEMICAL", 102, 106], ["Fg", "PROTEIN", 18, 20], ["Significant lower Fg", "PROBLEM", 0, 20], ["RBC force value", "TEST", 21, 36], ["lower", "ANATOMY_MODIFIER", 12, 17], ["EDTA", "OBSERVATION", 102, 106]]], ["Conclusion: Fg-RBC binding seems not to be calcium-dependent but the existence of cholesterol on RBC membrane is important.P-290Nanoscopic and spectroscopic investigation of p53-based complexes at single molecule level A. R. Bizzarri Biophysics and Nanoscience Centre, CNISM, Facolt\u00e0 di Scienze, Universit\u00e0 della Tuscia, Largo dell'Universit\u00e0 -01100 Viterbo, Italy p53 is a transcription factor that plays a widely recognized role in preventing cancer development in response to DNA damage.", [["RBC membrane", "ANATOMY", 97, 109], ["cancer", "ANATOMY", 445, 451], ["calcium", "CHEMICAL", 43, 50], ["cholesterol", "CHEMICAL", 82, 93], ["P-290", "CHEMICAL", 123, 128], ["cancer", "DISEASE", 445, 451], ["calcium", "CHEMICAL", 43, 50], ["cholesterol", "CHEMICAL", 82, 93], ["Fg-RBC", "GENE_OR_GENE_PRODUCT", 12, 18], ["calcium", "SIMPLE_CHEMICAL", 43, 50], ["cholesterol", "SIMPLE_CHEMICAL", 82, 93], ["RBC membrane", "CELLULAR_COMPONENT", 97, 109], ["p53", "GENE_OR_GENE_PRODUCT", 174, 177], ["p53", "GENE_OR_GENE_PRODUCT", 365, 368], ["cancer", "CANCER", 445, 451], ["DNA", "CELLULAR_COMPONENT", 479, 482], ["Fg", "PROTEIN", 12, 14], ["RBC", "CELL_TYPE", 97, 100], ["p53", "PROTEIN", 174, 177], ["p53", "PROTEIN", 365, 368], ["transcription factor", "PROTEIN", 374, 394], ["RBC binding", "PROBLEM", 15, 26], ["calcium", "TEST", 43, 50], ["cholesterol on RBC membrane", "PROBLEM", 82, 109], ["P", "TEST", 123, 124], ["Nanoscopic and spectroscopic investigation", "TEST", 128, 170], ["p53", "TEST", 174, 177], ["DNA damage", "PROBLEM", 479, 489], ["RBC membrane", "OBSERVATION", 97, 109], ["cancer", "OBSERVATION", 445, 451]]], ["The tumor suppressor activity of p53 involves the formation of several complexes whose detection and study, at single molecule level, could be extremely relevant to understand, in detail, the mechanisms governing the cancer defense processes, as well as to develop ultrasensitive biosensors. p53-based complexes, are investigated at molecular level, by combining Atomic Force Microscopy (AFM), Atomic Force Spectroscopy (AFS) and Surface Enhanced Raman Spectroscopy (SERS) with the support of computational docking.", [["tumor", "ANATOMY", 4, 9], ["cancer", "ANATOMY", 217, 223], ["tumor", "DISEASE", 4, 9], ["cancer", "DISEASE", 217, 223], ["tumor", "CANCER", 4, 9], ["p53", "GENE_OR_GENE_PRODUCT", 33, 36], ["cancer", "CANCER", 217, 223], ["p53", "GENE_OR_GENE_PRODUCT", 292, 295], ["p53", "PROTEIN", 33, 36], ["p53", "PROTEIN", 292, 295], ["The tumor suppressor activity of p53", "PROBLEM", 0, 36], ["study", "TEST", 101, 106], ["the cancer defense processes", "PROBLEM", 213, 241], ["ultrasensitive biosensors", "TEST", 265, 290], ["p53", "TEST", 292, 295], ["Atomic Force Microscopy", "TEST", 363, 386], ["Atomic Force Spectroscopy", "TEST", 394, 419], ["AFS", "TEST", 421, 424], ["Surface Enhanced Raman Spectroscopy", "TEST", 430, 465], ["computational docking", "TREATMENT", 493, 514], ["tumor", "OBSERVATION", 4, 9], ["activity", "OBSERVATION_MODIFIER", 21, 29], ["several", "OBSERVATION_MODIFIER", 63, 70], ["cancer", "OBSERVATION", 217, 223], ["based complexes", "OBSERVATION_MODIFIER", 296, 311]]], ["Our attention is mainly devoted to study complexes between p53 and the electron transfer azurin which has been demonstrated to interact with p53, by promoting its stabilization.", [["p53", "GENE_OR_GENE_PRODUCT", 59, 62], ["azurin", "GENE_OR_GENE_PRODUCT", 89, 95], ["p53", "GENE_OR_GENE_PRODUCT", 141, 144], ["p53", "PROTEIN", 59, 62], ["azurin", "PROTEIN", 89, 95], ["p53", "PROTEIN", 141, 144], ["the electron transfer azurin", "TREATMENT", 67, 95], ["stabilization", "OBSERVATION_MODIFIER", 163, 176]]], ["A possible competition between azurin and the cellular oncogene mdm2 is also investigated.O-289Unwinding the DNA helix in force clamp condition P. Bianco 1 , L. Bongini 2 , M. Dolfi 1 , L. Vincenzo 1 1 PhysioLab, DBE, University of Florence, Italy, 2 University of Florence and Centro Interdipartimentale Studio Dinamiche Complesse, Firenze, ItalyO-289We use a dual-laser optical-tweezers (DLOT, Smith et al., Science, 1996) to define the highly cooperative conformational transition in the molecule of DNA, where the natural B-DNA has converted into a new overstretched conformation called S-DNA (Bensimon et al., Phys.", [["cellular", "ANATOMY", 46, 54], ["ItalyO-289We", "CHEMICAL", 342, 354], ["azurin", "GENE_OR_GENE_PRODUCT", 31, 37], ["cellular", "CELL", 46, 54], ["mdm2", "GENE_OR_GENE_PRODUCT", 64, 68], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["DNA", "CELLULAR_COMPONENT", 503, 506], ["DNA", "CELLULAR_COMPONENT", 528, 531], ["DNA", "CELLULAR_COMPONENT", 593, 596], ["azurin", "PROTEIN", 31, 37], ["cellular oncogene mdm2", "DNA", 46, 68], ["natural B-DNA", "DNA", 518, 531], ["azurin", "TREATMENT", 31, 37], ["the cellular oncogene mdm2", "TREATMENT", 42, 68], ["possible", "UNCERTAINTY", 2, 10], ["oncogene mdm2", "OBSERVATION", 55, 68]]], ["Single molecules of double stranded \u03bb-phage DNA (in a solution with 150 mM NaCI, 10 mM tris-HCl, 1 mM EDTA, pH 8.0. and 27 \u2022 C) are stretched either in length clamp or in force clamp mode.", [["NaCI", "CHEMICAL", 75, 79], ["tris-HCl", "CHEMICAL", 87, 95], ["NaCI", "CHEMICAL", 75, 79], ["tris-HCl", "CHEMICAL", 87, 95], ["EDTA", "CHEMICAL", 102, 106], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["NaCI", "SIMPLE_CHEMICAL", 75, 79], ["tris-HCl", "SIMPLE_CHEMICAL", 87, 95], ["EDTA", "SIMPLE_CHEMICAL", 102, 106], ["double stranded \u03bb-phage DNA", "DNA", 20, 47], ["double stranded \u03bb-phage DNA", "TREATMENT", 20, 47], ["150 mM NaCI", "TREATMENT", 68, 79], ["pH", "TEST", 108, 110]]], ["When the DNA molecule is stretched in length clamp mode with a ramp lengthening, it shows the previously described highly cooperative overstretching transition at \u223c60 pN, attributed to unwinding from the B-form to the 1.7 times longer S-form.", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["B", "PROTEIN", 204, 205], ["the DNA molecule", "PROBLEM", 5, 21], ["a ramp lengthening", "TREATMENT", 61, 79], ["stretched", "OBSERVATION_MODIFIER", 25, 34]]], ["Stretching the molecule in force clamp mode with a staircase of force steps at 5 s intervals (step size 1-2 pN, rise time 1-2 ms) shows, for any given clamped force F in the region of the overstretching transition, different amounts of DNA elongation (\u2206L) with exponential time courses.", [["DNA", "CELLULAR_COMPONENT", 236, 239], ["force clamp mode", "TREATMENT", 27, 43], ["a staircase of force steps", "TREATMENT", 49, 75], ["DNA elongation", "PROBLEM", 236, 250], ["exponential time courses", "TREATMENT", 261, 285], ["different", "OBSERVATION_MODIFIER", 215, 224], ["amounts", "OBSERVATION_MODIFIER", 225, 232], ["elongation", "OBSERVATION_MODIFIER", 240, 250]]], ["The analysis of the elongation rates allows to recover all the necessary parameters for an effective two-state model able to reproduce the out-of-equilibrium properties of the system.", [["The analysis", "TEST", 0, 12], ["the elongation rates", "TEST", 16, 36]]], ["The results imply an unwinding cooperativity of 27 bps.", [["an unwinding cooperativity", "TEST", 18, 44], ["bps", "TEST", 51, 54], ["unwinding cooperativity", "OBSERVATION", 21, 44]]], ["This value is significantly lower than that obtained assuming force independent rate constants.", [["This value", "TEST", 0, 10], ["significantly lower", "OBSERVATION_MODIFIER", 14, 33]]], ["Supported by MiUR, Ente Cassa di Risparmio di Firenze and ITB-CNR (Milano).CC/PBSA: Prediction of mutational effects on protein-protein binding affinity and protein stabilityC.", [["CC", "CHEMICAL", 75, 77], ["protein stabilityC", "PROTEIN", 157, 175], ["mutational effects", "PROBLEM", 98, 116], ["protein", "TEST", 120, 127], ["protein binding affinity", "TEST", 128, 152], ["protein stabilityC", "TEST", 157, 175]]], ["M. Becker 1 , A. Benedix 1 , B. L. de Groot 2 , A. Cafisch 3 , R. A. B\u00f6ckmann 1 1 Saarland University, Saarbr\u00fccken, Germany, 2 MPI for Biophysical Chemistry, G\u00f6ttingen, Germany, 3 University of Z\u00fcrich, Z\u00fcrich, SwitzerlandCC/PBSA: Prediction of mutational effects on protein-protein binding affinity and protein stabilityModifying the stability or the binding behavior of the involved proteins by mutation can influence the activity of cellular processes.", [["cellular", "ANATOMY", 435, 443], ["cellular", "CELL", 435, 443], ["Biophysical Chemistry", "TEST", 135, 156], ["mutational effects", "PROBLEM", 244, 262], ["protein-protein binding affinity", "TREATMENT", 266, 298], ["protein stability", "TEST", 303, 320], ["mutation", "PROBLEM", 396, 404]]], ["For an efficient identification of possible mutation-sites a fast calculation of the free energy of proteins is crucial.CC/PBSA: Prediction of mutational effects on protein-protein binding affinity and protein stabilityHere we developed a fast and reliable method (CC/PBSA) [1] for the prediction of the change in stability of proteins and binding affinity of protein-protein complexes upon mutation.", [["CC", "CHEMICAL", 120, 122], ["CC", "CHEMICAL", 265, 267], ["protein-protein complexes", "PROTEIN", 360, 385], ["mutation", "PROBLEM", 44, 52], ["mutational effects", "PROBLEM", 143, 161], ["protein", "TEST", 165, 172], ["protein binding affinity", "TEST", 173, 197], ["protein stability", "TEST", 202, 219], ["the change in stability of proteins", "PROBLEM", 300, 335], ["binding affinity of protein-protein complexes upon mutation", "PROBLEM", 340, 399], ["stability", "OBSERVATION", 314, 323]]], ["The energy function of CC/PBSA is based on gas phase energies, solvation free energies and entropic contributions.", [["CC", "CHEMICAL", 23, 25], ["PBSA", "CHEMICAL", 26, 30], ["CC/PBSA", "TEST", 23, 30], ["entropic contributions", "OBSERVATION", 91, 113]]], ["The protein flexibility is taken into account by generating random conformations based on geometrical constraints only applying the CONCOORD [2] program.", [["The protein flexibility", "TEST", 0, 23]]], ["We applied CC/PBSA on the TEM1-BLIP complex, which is important in bacterial antibiotic resistance.", [["CC", "CHEMICAL", 11, 13], ["PBSA", "CHEMICAL", 14, 18], ["PBSA", "SIMPLE_CHEMICAL", 14, 18], ["TEM1", "GENE_OR_GENE_PRODUCT", 26, 30], ["BLIP", "GENE_OR_GENE_PRODUCT", 31, 35], ["CC", "PROTEIN", 11, 13], ["TEM1", "PROTEIN", 26, 30], ["BLIP complex", "PROTEIN", 31, 43], ["CC/PBSA", "TREATMENT", 11, 18], ["bacterial antibiotic resistance", "TREATMENT", 67, 98], ["bacterial antibiotic resistance", "OBSERVATION", 67, 98]]], ["The results of single-and double-point alanine scanning are used to detect hot spots, cooperative effects, and the corresponding energy distribution.", [["alanine", "CHEMICAL", 39, 46], ["alanine", "CHEMICAL", 39, 46], ["alanine", "AMINO_ACID", 39, 46], ["alanine scanning", "TEST", 39, 55], ["hot spots", "PROBLEM", 75, 84]]], ["CC/PBSA is freely accessible on our web-server: http://ccpbsa.bioinformatik.uni-saarland.de The human recombinase hRad51 is a key protein for the maintenance of genome integrity and for cancer development.", [["cancer", "ANATOMY", 186, 192], ["CC", "CHEMICAL", 0, 2], ["cancer", "DISEASE", 186, 192], ["human", "ORGANISM", 96, 101], ["hRad51", "GENE_OR_GENE_PRODUCT", 114, 120], ["cancer", "CANCER", 186, 192], ["hRad51", "PROTEIN", 114, 120], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["genome integrity", "TREATMENT", 161, 177], ["cancer development", "PROBLEM", 186, 204]]], ["This protein plays a central role is the DNA strand exchange occurring during homologous recombination.", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["the DNA strand exchange", "TREATMENT", 37, 60], ["homologous recombination", "TREATMENT", 78, 102], ["central", "OBSERVATION_MODIFIER", 21, 28], ["DNA strand", "OBSERVATION", 41, 51]]], ["Here we report the polymerization and depolymerization of hRad51 on duplex DNA observed with a new generation of magnetic tweezers, allowing the measurement of DNA twist with a resolution of 5 \u2022 in real time.", [["hRad51", "SIMPLE_CHEMICAL", 58, 64], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["DNA", "CELLULAR_COMPONENT", 160, 163], ["hRad51", "PROTEIN", 58, 64], ["duplex DNA", "DNA", 68, 78], ["the polymerization", "TREATMENT", 15, 33], ["depolymerization of hRad51", "TREATMENT", 38, 64], ["duplex DNA", "PROBLEM", 68, 78], ["magnetic tweezers", "TREATMENT", 113, 130], ["DNA twist", "TREATMENT", 160, 169]]], ["At odds with earlier claims, we show that, after initial deposition of a multimeric nucleus, nucleoprotein filament growth occurs by addition of single proteins, involving DNA twisting steps of 65\u00b15 \u2022 .", [["nucleus", "ANATOMY", 84, 91], ["nucleus", "CELLULAR_COMPONENT", 84, 91], ["DNA", "CELLULAR_COMPONENT", 172, 175], ["single proteins", "PROTEIN", 145, 160], ["a multimeric nucleus", "PROBLEM", 71, 91], ["nucleoprotein filament growth", "PROBLEM", 93, 122], ["single proteins", "TREATMENT", 145, 160], ["multimeric nucleus", "ANATOMY", 73, 91], ["nucleoprotein filament", "OBSERVATION", 93, 115]]], ["Simple numerical simulations support that this mechanism is an efficient way to minimize nucleoprotein filament defects.", [["Simple numerical simulations support", "TREATMENT", 0, 36], ["nucleoprotein filament defects", "PROBLEM", 89, 119], ["nucleoprotein filament defects", "OBSERVATION", 89, 119]]], ["This behavior, consisting of different stoichiometry for nucleation and growth phases, may be instrumental in vivo.", [["nucleation and growth phases", "PROBLEM", 57, 85], ["growth phases", "OBSERVATION_MODIFIER", 72, 85]]], ["Fast growth would permit efficient continuation of strand exchange by Rad51 alone while the limited nucleation would require additional proteins such as Rad52, thus keeping this initiation step under the strict control of regulatory pathways.", [["strand", "CELLULAR_COMPONENT", 51, 57], ["Rad51", "GENE_OR_GENE_PRODUCT", 70, 75], ["Rad52", "GENE_OR_GENE_PRODUCT", 153, 158], ["Rad51", "PROTEIN", 70, 75], ["Rad52", "PROTEIN", 153, 158], ["Fast growth", "PROBLEM", 0, 11], ["strand exchange", "TREATMENT", 51, 66], ["additional proteins", "TREATMENT", 125, 144], ["Rad52", "TREATMENT", 153, 158], ["this initiation step", "TREATMENT", 173, 193]]], ["Besides, our results combined with earlier structural information, suggest that DNA is somewhat less extended (4.5 versus 5.1\u00c5 per bp) and more untwisted (18.2 versus 15 \u2022 per bp) by hRad51 than by RecA, and confirm a stoichiometry of 3-4 bp per protein in the hRad51-dsDNA nucleoprotein filament.O-294Biofunctional micropatterned surfaces to study the spatio-temporal organisation of LFA-1 R. Diez-Ahedo 1 , D. Normanno 1 , C. G. Figdor 2 , A. Cambi 2 , M. F. Garcia-Parajo 1 1 Bionanophotonics, CIBER-BBN and IBEC, Barcelona, Spain, 2 Tumor Immunology, Nijmegen Center for Molecular Life Sciences, The NetherlandsO-294Lymphocyte function associated antigen-1 (LFA-1) adhesion depends on receptor occupancy and lateral organization on the cell membrane.", [["cell membrane", "ANATOMY", 740, 753], ["O-294", "CHEMICAL", 297, 302], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["hRad51", "GENE_OR_GENE_PRODUCT", 183, 189], ["RecA", "GENE_OR_GENE_PRODUCT", 198, 202], ["hRad51", "GENE_OR_GENE_PRODUCT", 261, 267], ["NetherlandsO-294Lymphocyte function associated antigen-1", "GENE_OR_GENE_PRODUCT", 604, 660], ["LFA-1", "GENE_OR_GENE_PRODUCT", 662, 667], ["cell membrane", "CELLULAR_COMPONENT", 740, 753], ["hRad51", "PROTEIN", 183, 189], ["RecA", "PROTEIN", 198, 202], ["hRad51", "PROTEIN", 261, 267], ["NetherlandsO-294Lymphocyte function associated antigen-1 (LFA-1", "PROTEIN", 604, 667], ["DNA", "PROBLEM", 80, 83], ["bp", "TEST", 131, 133], ["bp", "TEST", 176, 178], ["RecA", "TEST", 198, 202], ["a stoichiometry", "TEST", 216, 231], ["study", "TEST", 343, 348], ["the spatio", "TEST", 349, 359], ["LFA", "TEST", 385, 388], ["Diez", "TEST", 394, 398], ["Ahedo", "TEST", 399, 404], ["Figdor", "TEST", 431, 437], ["The NetherlandsO", "TEST", 600, 616], ["antigen", "TEST", 651, 658], ["LFA", "TEST", 662, 665], ["adhesion", "PROBLEM", 669, 677], ["receptor occupancy", "PROBLEM", 689, 707], ["lateral organization on the cell membrane", "PROBLEM", 712, 753], ["LFA", "ANATOMY", 385, 388], ["lateral", "ANATOMY_MODIFIER", 712, 719], ["cell membrane", "OBSERVATION", 740, 753]]], ["However, the signals and mechanisms which dynamically reorganize LFA-1 into high avidity clusters are still a subject of many studies.", [["LFA-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["LFA-1", "PROTEIN", 65, 70], ["LFA", "TEST", 65, 68], ["many studies", "TEST", 121, 133]]], ["To obtain deeper insight on the mechanisms that control and regulate LFA-1 clustering, patterned surfaces of immobilized LFA-1 ligand areas were fabricated using microcontact printing.", [["LFA-1", "GENE_OR_GENE_PRODUCT", 69, 74], ["LFA-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["LFA", "PROTEIN", 69, 72], ["LFA", "PROTEIN", 121, 124], ["LFA", "TEST", 69, 72], ["immobilized LFA", "TREATMENT", 109, 124], ["microcontact printing", "TREATMENT", 162, 183], ["LFA", "ANATOMY", 69, 72]]], ["The diffusion of LFA-1 expressed by monocytes stretched over patterned surfaces was followed in time using single molecule TIRF microscopy.", [["monocytes", "ANATOMY", 36, 45], ["LFA-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["monocytes", "CELL", 36, 45], ["LFA", "PROTEIN", 17, 20], ["monocytes", "CELL_TYPE", 36, 45], ["The diffusion of LFA", "TEST", 0, 20], ["single molecule TIRF microscopy", "TEST", 107, 138], ["monocytes", "OBSERVATION", 36, 45]]], ["Single LFA-1 nanocluster trajectories on individual cells showed an increase of immobile LFA-1 fraction and a slow-down of diffusing LFA-1 on the ligand areas compared to the non-ligand areas.", [["cells", "ANATOMY", 52, 57], ["LFA-1", "GENE_OR_GENE_PRODUCT", 7, 12], ["cells", "CELL", 52, 57], ["LFA-1", "GENE_OR_GENE_PRODUCT", 89, 94], ["LFA-1", "GENE_OR_GENE_PRODUCT", 133, 138], ["LFA", "PROTEIN", 7, 10], ["LFA", "PROTEIN", 89, 92], ["LFA", "PROTEIN", 133, 136], ["Single LFA", "TEST", 0, 10], ["individual cells", "TEST", 41, 57], ["immobile LFA", "TEST", 80, 92], ["a slow-down of diffusing LFA", "PROBLEM", 108, 136], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["immobile", "OBSERVATION", 80, 88], ["slow", "OBSERVATION_MODIFIER", 110, 114]]], ["Moreover, single-cluster intensity analysis indicated a reorganization of LFA-1 nanoclusters in microclusters upon ligand binding.", [["LFA-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["microclusters", "CELLULAR_COMPONENT", 96, 109], ["LFA", "PROTEIN", 74, 77], ["cluster intensity analysis", "TEST", 17, 43], ["a reorganization of LFA", "PROBLEM", 54, 77], ["LFA", "ANATOMY", 74, 77], ["ligand binding", "OBSERVATION", 115, 129]]], ["Finally, single particle motion analysis of LFA-1 trajectories in close neighborhood to the ligand areas showed no assisted diffusion of LFA-1 towards the adhesive regions, consistent with random ligand-encountering and binding.", [["LFA-1", "GENE_OR_GENE_PRODUCT", 44, 49], ["LFA-1", "GENE_OR_GENE_PRODUCT", 137, 142], ["LFA", "PROTEIN", 44, 47], ["LFA", "PROTEIN", 137, 140], ["adhesive regions", "PROTEIN", 155, 171], ["single particle motion analysis", "TEST", 9, 40], ["LFA", "TEST", 44, 47], ["assisted diffusion of LFA", "PROBLEM", 115, 140], ["no", "UNCERTAINTY", 112, 114], ["consistent with", "UNCERTAINTY", 173, 188]]], ["We are currently investigating the effect of cell membrane organizers to regulate the spatio-temporal organization of LFA-1.", [["cell membrane", "ANATOMY", 45, 58], ["cell membrane", "CELLULAR_COMPONENT", 45, 58], ["LFA-1", "GENE_OR_GENE_PRODUCT", 118, 123], ["LFA", "PROTEIN", 118, 121], ["cell membrane organizers", "TREATMENT", 45, 69], ["the spatio", "TEST", 82, 92], ["LFA", "ANATOMY", 118, 121]]], ["R. Diez-Ahedo et al, Small, in press.O-293Optical and electrophysiological detection of single phages across a lipid membrane N. Chiaruttini 1 , P. Boulanger 2 , M. de Frutos 3 , L. Letellier 2 , U. Bockelmann 1 , V. Viasnoff 1 1 Nanobiophysique, ESPCI Paristech, CNRS, Paris, France, 2 IBBMC, Universit\u00e9 Paris XI, CNRS, Orsay, France, 3 LPS, Universit\u00e9 Paris XI, CNRS, Orsay, FranceO-293We present an investigation study of the ejection of single T5 bacteriophages.", [["O-293Optical", "CHEMICAL", 37, 49], ["electrophysiological detection", "TEST", 54, 84], ["single phages", "TREATMENT", 88, 101], ["a lipid membrane N. Chiaruttini", "TREATMENT", 109, 140], ["an investigation study", "TEST", 399, 421], ["single T5 bacteriophages", "TREATMENT", 441, 465], ["Diez", "OBSERVATION", 3, 7], ["Small", "OBSERVATION_MODIFIER", 21, 26]]], ["In vivo studies of DNA ejections from the bacteriophage capsid show that the T5 genome is introduced in the bacterial host in two steps.", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["T5 genome", "DNA", 77, 86], ["DNA ejections", "PROBLEM", 19, 32], ["the bacteriophage capsid", "TREATMENT", 38, 62], ["the T5 genome", "TREATMENT", 73, 86], ["T5", "ANATOMY", 77, 79], ["bacterial host", "OBSERVATION", 108, 122]]], ["First 8% of the genome is ejected then after a pause of a few minutes the rest is internalized.", [["genome", "CELLULAR_COMPONENT", 16, 22], ["ejected", "OBSERVATION", 26, 33]]], ["Bulk in vitro studies showed that various mutants of T5 eject their genome in solution following a single or a multistep process.", [["T5", "DNA", 53, 55], ["Bulk in vitro studies", "TEST", 0, 21], ["various mutants of T5 eject", "PROBLEM", 34, 61], ["T5", "ANATOMY", 53, 55]]], ["By immobilizing single bacteriophages on a surface and following their ejection by fluorescence microscopy we showed that in all cases the ejection occurs in one step, but some mutants seem to have a subpopulation for which the triggering signal of the ejection is transmitted more slowly to the capsid entrance.", [["surface", "ANATOMY", 43, 50], ["surface", "CELLULAR_COMPONENT", 43, 50], ["fluorescence microscopy", "TEST", 83, 106], ["bacteriophages", "OBSERVATION", 23, 37], ["ejection", "OBSERVATION", 139, 147], ["subpopulation", "OBSERVATION", 200, 213], ["ejection", "OBSERVATION", 253, 261], ["capsid entrance", "OBSERVATION", 296, 311]]], ["We then reconstituted the phage receptor FhuA into giant liposomes and followed the ejection of the DNA into the liposome by fluorescence.", [["FhuA", "GENE_OR_GENE_PRODUCT", 41, 45], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["liposome", "SIMPLE_CHEMICAL", 113, 121], ["phage receptor FhuA", "PROTEIN", 26, 45], ["giant liposomes", "TREATMENT", 51, 66], ["giant liposomes", "OBSERVATION", 51, 66], ["liposome", "ANATOMY", 113, 121]]], ["Finally we incorporated FhuA in a suspended bilayer and followed the infection of the phages through the bilayer both by fluorescence labeling and electrophysiological measurements.", [["infection", "DISEASE", 69, 78], ["FhuA", "CHEMICAL", 24, 28], ["FhuA", "GENE_OR_GENE_PRODUCT", 24, 28], ["FhuA", "PROTEIN", 24, 28], ["FhuA", "TREATMENT", 24, 28], ["a suspended bilayer", "TREATMENT", 32, 51], ["the infection of the phages", "PROBLEM", 65, 92], ["fluorescence labeling", "TEST", 121, 142], ["electrophysiological measurements", "TEST", 147, 180], ["infection", "OBSERVATION", 69, 78]]], ["We will discuss the influence of the cross membrane potential on the ejection speed of the DNA.P-292Helixlike pili is a prerequisite of uropathogenic E. coli to adhere to host and withstand urine flow The Gram-negative uropathogenic Escherichia coli (UPEC) bacteria, invades the urinary tract region and cause in some cases severe infections, pyelonephritis, if they can withstand the rinsing action of urine and ascend to the kidney, via the bladder and ureters.", [["membrane", "ANATOMY", 43, 51], ["urine", "ANATOMY", 190, 195], ["urinary tract", "ANATOMY", 279, 292], ["urine", "ANATOMY", 403, 408], ["kidney", "ANATOMY", 427, 433], ["bladder", "ANATOMY", 443, 450], ["ureters", "ANATOMY", 455, 462], ["P-292Helixlike", "CHEMICAL", 95, 109], ["infections", "DISEASE", 331, 341], ["pyelonephritis", "DISEASE", 343, 357], ["E. coli", "ORGANISM", 150, 157], ["urine", "ORGANISM_SUBSTANCE", 190, 195], ["Gram-negative uropathogenic Escherichia coli", "GENE_OR_GENE_PRODUCT", 205, 249], ["urinary tract", "ORGANISM_SUBDIVISION", 279, 292], ["urine", "ORGANISM_SUBSTANCE", 403, 408], ["kidney", "ORGAN", 427, 433], ["bladder", "ORGAN", 443, 450], ["ureters", "ORGAN", 455, 462], ["P", "DNA", 95, 96], ["E. coli", "SPECIES", 150, 157], ["Escherichia coli", "SPECIES", 233, 249], ["P-292Helixlike pili", "SPECIES", 95, 114], ["E. coli", "SPECIES", 150, 157], ["Escherichia coli", "SPECIES", 233, 249], ["UPEC", "SPECIES", 251, 255], ["uropathogenic E. coli", "PROBLEM", 136, 157], ["urine flow", "TEST", 190, 200], ["uropathogenic Escherichia coli (UPEC) bacteria", "PROBLEM", 219, 265], ["the urinary tract region", "PROBLEM", 275, 299], ["some cases severe infections", "PROBLEM", 313, 341], ["pyelonephritis", "PROBLEM", 343, 357], ["the rinsing action of urine", "TEST", 381, 408], ["uropathogenic Escherichia coli", "OBSERVATION", 219, 249], ["urinary tract", "ANATOMY", 279, 292], ["severe", "OBSERVATION_MODIFIER", 324, 330], ["infections", "OBSERVATION", 331, 341], ["pyelonephritis", "OBSERVATION", 343, 357], ["kidney", "ANATOMY", 427, 433], ["bladder", "ANATOMY", 443, 450], ["ureters", "ANATOMY", 455, 462]]], ["To mediate adhesion, UPEC express quaternary surface organelles that are assembled from \u223c10 3 identical subunits into a helix-like coil, with a single adhesin located at the tip.", [["surface organelles", "ANATOMY", 45, 63], ["UPEC", "CELL", 21, 25], ["surface organelles", "CELLULAR_COMPONENT", 45, 63], ["\u223c10 3 identical subunits", "PROTEIN", 88, 112], ["helix-like coil", "PROTEIN", 120, 135], ["adhesin", "PROTEIN", 151, 158], ["UPEC express quaternary surface organelles", "PROBLEM", 21, 63], ["a helix-like coil", "TREATMENT", 118, 135], ["a single adhesin", "TREATMENT", 142, 158], ["adhesion", "OBSERVATION_MODIFIER", 11, 19], ["quaternary", "OBSERVATION_MODIFIER", 34, 44], ["surface", "OBSERVATION_MODIFIER", 45, 52], ["coil", "OBSERVATION", 131, 135], ["tip", "OBSERVATION_MODIFIER", 174, 177]]], ["It is believed that the single adhesin mediate attachment to host cells while the helix-like structures act as shock absorbers to dampen the irregularly shear forces induced by urine flow.", [["cells", "ANATOMY", 66, 71], ["helix-like structures", "ANATOMY", 82, 103], ["urine", "ANATOMY", 177, 182], ["shock", "DISEASE", 111, 116], ["host cells", "CELL", 61, 71], ["urine", "ORGANISM_SUBSTANCE", 177, 182], ["adhesin", "PROTEIN", 31, 38], ["host cells", "CELL_TYPE", 61, 71], ["shock absorbers", "TREATMENT", 111, 126], ["the irregularly shear forces", "PROBLEM", 137, 165], ["urine flow", "TEST", 177, 187], ["host cells", "OBSERVATION", 61, 71], ["helix", "ANATOMY_MODIFIER", 82, 87], ["shock absorbers", "OBSERVATION", 111, 126], ["irregularly", "OBSERVATION_MODIFIER", 141, 152], ["shear forces", "OBSERVATION", 153, 165], ["urine flow", "OBSERVATION", 177, 187]]], ["To unravel the biomechanical properties of such quaternary structures, in particular in terms of their force-elongation and kinetic behavior, Force-Measuring Optical Tweezers (FMOT) have been used.", [["Measuring Optical Tweezers (FMOT)", "TREATMENT", 148, 181], ["biomechanical properties", "OBSERVATION_MODIFIER", 15, 39], ["quaternary structures", "OBSERVATION", 48, 69], ["elongation", "OBSERVATION_MODIFIER", 109, 119], ["kinetic behavior", "OBSERVATION", 124, 140]]], ["A plethora of different types of pili have been identified in the literature and we show, using FMOT, that those dissimilarities might reflect the host environment.", [["pili", "GENE_OR_GENE_PRODUCT", 33, 37], ["pili", "PROTEIN", 33, 37], ["pili", "PROBLEM", 33, 37], ["plethora", "OBSERVATION_MODIFIER", 2, 10], ["different types", "OBSERVATION_MODIFIER", 14, 29], ["host environment", "OBSERVATION", 147, 163]]], ["For example, we have found differences among pili expressed at diverse environment inside the urinary tract, which imply that pili presumably have evolved to resist specific forces under in vivo conditions.", [["urinary tract", "ANATOMY", 94, 107], ["pili", "GENE_OR_GENE_PRODUCT", 45, 49], ["urinary tract", "ORGANISM_SUBDIVISION", 94, 107], ["pili", "GENE_OR_GENE_PRODUCT", 126, 130], ["pili", "PROTEIN", 45, 49], ["pili", "PROTEIN", 126, 130], ["urinary tract", "ANATOMY", 94, 107]]], ["It is thus worth striving for understanding bacterial adhesion in order to figure out alternative to the over-abundance of antibiotics worldwide.", [["bacterial adhesion", "PROBLEM", 44, 62], ["antibiotics", "TREATMENT", 123, 134]]], ["Single molecules studies have probed protein conformational fluctuations and monitored the oscillating activity of enzymes that remained masked in ensemble measurements.", [["enzymes", "PROTEIN", 115, 122], ["Single molecules studies", "TEST", 0, 24], ["protein conformational fluctuations", "PROBLEM", 37, 72], ["the oscillating activity of enzymes", "TEST", 87, 122]]], ["Various statistical models have attempted to connect the conformational motions to the fluctuating activity of enzymes and suggested that they adopt inter-converting conformations each one of them exhibiting different catalytic activity.", [["enzymes", "PROTEIN", 111, 118], ["enzymes", "TEST", 111, 118], ["catalytic activity", "OBSERVATION", 218, 236]]], ["The main drawback of these studies is the non specific interactions that may bias the observed catalytic behavior.", [["these studies", "TEST", 21, 34], ["main", "OBSERVATION_MODIFIER", 4, 8], ["catalytic behavior", "OBSERVATION", 95, 113]]], ["We have developed new innovating tools to study the behavior of single enzymes.", [["single enzymes", "PROTEIN", 64, 78], ["new innovating tools", "PROBLEM", 18, 38], ["single enzymes", "TEST", 64, 78], ["new", "OBSERVATION_MODIFIER", 18, 21]]], ["As a first step we utilized liposomes as scaffold to confine enzymes while keeping them under physiological conditions.", [["liposomes", "SIMPLE_CHEMICAL", 28, 37], ["enzymes", "PROTEIN", 61, 68], ["liposomes", "TREATMENT", 28, 37], ["enzymes", "TEST", 61, 68]]], ["Using this approach we accurately predicted the behavior of single lipases in a highly controlled environment.", [["this approach", "TREATMENT", 6, 19], ["single lipases", "TEST", 60, 74]]], ["We modulated the enzyme's conformational mobility and activity by systematically varying its accessibility to liposomes.", [["liposomes", "SIMPLE_CHEMICAL", 110, 119], ["the enzyme", "TEST", 13, 23]]], ["As we anticipated, that resulted in altering the time the enzyme spends on active conformations.Our results provide new insights on interpreting the behavior of enzymes.P-298Simulations of single-molecule FRET experiments on ribozymes M. Hajdziona, A. Molski Adam Mickiewicz University Laboratory for Dynamics of Physicochemical Processes, Poznan, Poland RNAzymes are important biological molecules and that can catalyze the cleavage of their own nucleotide chains.", [["nucleotide", "CHEMICAL", 447, 457], ["nucleotide", "CHEMICAL", 447, 457], ["enzyme", "PROTEIN", 58, 64], ["enzymes", "PROTEIN", 161, 168], ["P", "DNA", 169, 170], ["the enzyme", "TEST", 54, 64], ["enzymes", "TEST", 161, 168], ["P", "TEST", 169, 170]]], ["There are several methods to to study kinetic properties of ribozymes at the singlemolecule level.", [["ribozymes", "OBSERVATION", 60, 69]]], ["In this work we focus on FRET (F\u00f6rster Resonance Energy Transfer) of single, immobilized molecules.", [["FRET", "SIMPLE_CHEMICAL", 25, 29], ["single, immobilized molecules", "PROBLEM", 69, 98]]], ["Single-molecule fluorescence spectroscopy gives an insight into the behavior of individual molecules rather than the average behavior of an ensemble of molecules, which makes it possible to observe the kinetic heterogeneity.", [["Single-molecule fluorescence spectroscopy", "TEST", 0, 41], ["the kinetic heterogeneity", "PROBLEM", 198, 223], ["kinetic heterogeneity", "OBSERVATION", 202, 223]]], ["We simulated FRET trajectories for single immobilized ribozymes.", [["single immobilized ribozymes", "TREATMENT", 35, 63], ["immobilized ribozymes", "OBSERVATION", 42, 63]]], ["We fitted the histograms of on and off times to recover the kinetic parameters of the models.", [["the histograms", "TEST", 10, 24]]], ["We found that two thresholds give better parameter estimates than one-threshold analysis.", [["one-threshold analysis", "TEST", 66, 88]]], ["References FRAP probes the average dynamical properties of a population of fluorescently labeled molecules whereas SPT obtains these properties from observations of the trajectories of individual molecules tagged with a colloidal particle (the \"bead\").", [["fluorescently labeled molecules", "PROTEIN", 75, 106], ["SPT", "PROTEIN", 115, 118], ["a colloidal particle", "TREATMENT", 218, 238]]], ["When results of FRAP are compared with those of SPT, FRAP yields significantly higher diffusion constants than SPT.", [["FRAP", "SIMPLE_CHEMICAL", 16, 20], ["FRAP", "TEST", 16, 20], ["SPT", "TEST", 48, 51], ["FRAP", "TEST", 53, 57], ["significantly higher diffusion constants", "PROBLEM", 65, 105], ["significantly", "OBSERVATION_MODIFIER", 65, 78], ["higher", "OBSERVATION_MODIFIER", 79, 85], ["diffusion constants", "OBSERVATION", 86, 105]]], ["To understand the origin of this difference, we have developed and tested a model system to evaluate the influence of the bead on the dynamics of a diffusing molecule.", [["a diffusing molecule", "PROBLEM", 146, 166], ["diffusing molecule", "OBSERVATION", 148, 166]]], ["We use a dsDNA tether to attach a bead to a supported lipid bilayer (SLB).", [["lipid bilayer", "ANATOMY", 54, 67], ["lipid bilayer", "CELLULAR_COMPONENT", 54, 67], ["a dsDNA tether", "TREATMENT", 7, 21]]], ["The DNA tether is modified at one end by cholesterol for anchoring to and diffusion in the membrane, and at the other end by biotin for tagging with a bead.P-298With this system, we can vary several parameters: distance between SLB and bead, size and nature of the bead, lipid composition of the SLB, external force.", [["membrane", "ANATOMY", 91, 99], ["cholesterol", "CHEMICAL", 41, 52], ["biotin", "CHEMICAL", 125, 131], ["cholesterol", "CHEMICAL", 41, 52], ["biotin", "CHEMICAL", 125, 131], ["SLB", "CHEMICAL", 228, 231], ["SLB", "CHEMICAL", 296, 299], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["cholesterol", "SIMPLE_CHEMICAL", 41, 52], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["biotin", "SIMPLE_CHEMICAL", 125, 131], ["SLB", "MULTI-TISSUE_STRUCTURE", 228, 231], ["lipid", "SIMPLE_CHEMICAL", 271, 276], ["P", "DNA", 156, 157], ["a bead", "TREATMENT", 149, 155], ["bead", "OBSERVATION_MODIFIER", 236, 240], ["size", "OBSERVATION_MODIFIER", 242, 246], ["SLB", "ANATOMY", 296, 299], ["external force", "OBSERVATION", 301, 315]]], ["We can also model the Brownian motion of the bead and the hydrodynamic flow around it.", [["Brownian motion", "OBSERVATION", 22, 37], ["bead", "OBSERVATION_MODIFIER", 45, 49], ["hydrodynamic flow", "OBSERVATION", 58, 75]]], ["We will present results using \u03c6 = 200 nm neutravidin-coated latex particles attached to an eggPC SLB via a 15 bp to 90 bp DNA tether.P-296Elucidation of the mechanism of the lambda bacteriophage epigenetic switch L. Finzi Physics Department, emory University, 400 dowman Dr, Atlanta, GA 30322, USAP-296The lambda bacteriophage epigenetic switch determines the growth lifestyle of the virus after infection of its host (E. coli ).", [["neutravidin", "CHEMICAL", 41, 52], ["P-296Elucidation", "CHEMICAL", 133, 149], ["GA 30322", "CHEMICAL", 284, 292], ["USAP-296", "CHEMICAL", 294, 302], ["infection", "DISEASE", 396, 405], ["neutravidin", "CHEMICAL", 41, 52], ["SLB", "CHEMICAL", 97, 100], ["neutravidin", "SIMPLE_CHEMICAL", 41, 52], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["E. coli", "ORGANISM", 419, 426], ["90 bp DNA tether", "DNA", 116, 132], ["E. coli", "SPECIES", 419, 426], ["E. coli", "SPECIES", 419, 426], ["nm neutravidin-coated latex particles", "TREATMENT", 38, 75], ["a 15 bp", "TREATMENT", 105, 112], ["P", "TEST", 133, 134], ["the lambda bacteriophage", "TREATMENT", 170, 194], ["USAP", "TEST", 294, 298], ["The lambda bacteriophage epigenetic switch", "TREATMENT", 302, 344], ["the virus", "PROBLEM", 380, 389], ["infection", "PROBLEM", 396, 405], ["E. coli", "PROBLEM", 419, 426], ["lambda bacteriophage", "OBSERVATION", 306, 326], ["growth", "OBSERVATION_MODIFIER", 360, 366], ["E. coli", "OBSERVATION", 419, 426]]], ["It is now clear that the switch consists of a \u223c2.3 kbplong DNA loop mediated by the lambda repressor protein.P-296Using tethered particle microscopy (TPM), magnetic tweezers and AFM, our laboratory has novel, direct evidence of loop formation and breakdown by the repressor, the first characterization of the thermodynamics and kinetics of the looping reaction and its dependence on repressor non-specific binding and DNA supercoiling.", [["P-296Using", "CHEMICAL", 109, 119], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["DNA", "CELLULAR_COMPONENT", 418, 421], ["lambda repressor protein", "PROTEIN", 84, 108], ["P", "DNA", 109, 110], ["a \u223c2.3 kbplong DNA loop", "TREATMENT", 44, 67], ["the lambda repressor protein", "TREATMENT", 80, 108], ["tethered particle microscopy", "TEST", 120, 148], ["loop formation", "PROBLEM", 228, 242], ["breakdown", "PROBLEM", 247, 256], ["the repressor", "TREATMENT", 260, 273], ["the looping reaction", "PROBLEM", 340, 360], ["its dependence", "PROBLEM", 365, 379], ["repressor non-specific binding", "PROBLEM", 383, 413], ["DNA supercoiling", "PROBLEM", 418, 434], ["clear", "OBSERVATION", 10, 15], ["loop formation", "OBSERVATION", 228, 242], ["looping reaction", "OBSERVATION", 344, 360], ["DNA supercoiling", "OBSERVATION", 418, 434]]], ["These in vitro data provide insight into the different possible nucleoprotein complexes and into the lambda repressor-mediated looping mechanism which leads to predictions for that in vivo.", [["lambda", "GENE_OR_GENE_PRODUCT", 101, 107], ["nucleoprotein complexes", "PROTEIN", 64, 87], ["lambda repressor", "PROTEIN", 101, 117], ["the lambda repressor", "TREATMENT", 97, 117], ["mediated looping mechanism", "PROBLEM", 118, 144]]], ["The significance of this work consists not only of the new insight into a paradigmatic epigenetic switch that governs lysogeny vs. lysis, but also the detailed mechanics of regulatory DNA loops mediated by proteins bound to multipartite operators and capable of different levels of oligomerization.", [["DNA", "CELLULAR_COMPONENT", 184, 187], ["lysis", "TREATMENT", 131, 136], ["DNA loops", "OBSERVATION", 184, 193]]], ["Mechanical force at the molecular level is involved in the action of many enzymes.", [["enzymes", "PROTEIN", 74, 81], ["Mechanical force", "TREATMENT", 0, 16], ["many enzymes", "TEST", 69, 81]]], ["For example, the Phi29 DNA polymerase mechanically unwinds the DNA helix as it moves processively along the DNA replicating one strand of the DNA molecule.", [["Phi29", "GENE_OR_GENE_PRODUCT", 17, 22], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["Phi29 DNA polymerase", "PROTEIN", 17, 37], ["DNA molecule", "PROTEIN", 142, 154], ["the Phi29 DNA polymerase", "TREATMENT", 13, 37], ["the DNA helix", "TREATMENT", 59, 72], ["the DNA", "TREATMENT", 104, 111], ["DNA molecule", "OBSERVATION", 142, 154]]], ["Using Optical Tweezers we have developed a single molecule mechanical assay to elucidate the physical mechanism of DNA unwinding by the Phi29 DNA polymerase as the protein replicates the DNA.", [["DNA", "CELLULAR_COMPONENT", 115, 118], ["Phi29", "GENE_OR_GENE_PRODUCT", 136, 141], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["DNA", "CELLULAR_COMPONENT", 187, 190], ["Phi29 DNA polymerase", "PROTEIN", 136, 156], ["a single molecule mechanical assay", "TEST", 41, 75], ["DNA unwinding", "PROBLEM", 115, 128], ["the Phi29 DNA polymerase", "TREATMENT", 132, 156]]], ["A single DNA hairpin is hold between an optical trap and a mobile surface.", [["surface", "ANATOMY", 66, 73], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["surface", "CELLULAR_COMPONENT", 66, 73], ["A single DNA hairpin", "TREATMENT", 0, 20], ["an optical trap", "TREATMENT", 37, 52], ["hairpin", "OBSERVATION", 13, 20]]], ["As a single polymerase works on the DNA hairpin, its replication and unwinding reactions can be measured in real time by measuring the change in extension in the DNA polymer, revealing the fluctuations of its rate in response to the DNA sequence.", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["DNA hairpin", "DNA", 36, 47], ["DNA sequence", "DNA", 233, 245], ["a single polymerase", "TREATMENT", 3, 22], ["the DNA hairpin", "TREATMENT", 32, 47], ["unwinding reactions", "PROBLEM", 69, 88], ["the DNA polymer", "TEST", 158, 173], ["the DNA sequence", "TEST", 229, 245]]], ["Moreover, by gradually pulling on the opposite strands of the DNA hairpin we can promote the controlled mechanical unwinding of the DNA helix and determine the effect of increasing unwinding forces on the polymerization and unwinding rates.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["the DNA hairpin", "TREATMENT", 58, 73], ["the DNA helix", "TREATMENT", 128, 141], ["increasing unwinding forces", "PROBLEM", 170, 197], ["the polymerization", "TREATMENT", 201, 219], ["unwinding rates", "TEST", 224, 239]]], ["The effect of force and DNA sequence on the activities of the wild type and an unwinding-deficient polymerase mutant will allow us to determine the inner workings of this molecular motor.P-302Single centrosome manipulation reveals its electric charge and associated dynamic structure We demonstrate laser manipulation of individual early Drosophila embryo centrosomes in between two microelectrodes to reveal that it is a net negatively-charged organelle with a very low isoelectric region (3.1 \u00b1 0.1).", [["centrosome", "ANATOMY", 199, 209], ["embryo centrosomes", "ANATOMY", 349, 367], ["P-302Single", "CHEMICAL", 187, 198], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["Drosophila", "ORGANISM", 338, 348], ["embryo centrosomes", "MULTI-TISSUE_STRUCTURE", 349, 367], ["organelle", "CELLULAR_COMPONENT", 445, 454], ["unwinding-deficient polymerase mutant", "PROTEIN", 79, 116], ["P", "DNA", 187, 188], ["early Drosophila embryo centrosomes", "CELL_TYPE", 332, 367], ["Drosophila", "SPECIES", 338, 348], ["Drosophila", "SPECIES", 338, 348], ["force and DNA sequence", "TEST", 14, 36], ["an unwinding-deficient polymerase mutant", "PROBLEM", 76, 116], ["302Single centrosome manipulation", "TREATMENT", 189, 222], ["its electric charge", "PROBLEM", 231, 250], ["laser manipulation", "TREATMENT", 299, 317], ["individual early Drosophila embryo centrosomes", "TREATMENT", 321, 367], ["a net negatively-charged organelle", "PROBLEM", 420, 454], ["a very low isoelectric region", "PROBLEM", 460, 489], ["electric charge", "OBSERVATION", 235, 250], ["dynamic structure", "OBSERVATION", 266, 283], ["laser manipulation", "OBSERVATION", 299, 317], ["individual", "OBSERVATION_MODIFIER", 321, 331], ["early", "OBSERVATION_MODIFIER", 332, 337], ["Drosophila embryo centrosomes", "OBSERVATION", 338, 367], ["very", "OBSERVATION_MODIFIER", 462, 466], ["low", "OBSERVATION_MODIFIER", 467, 470]]], ["From this single-organelle electrophoresis, we infer an effective charge smaller or of the order of 10 3 electrons, which corresponds to a surface-charge density significantly smaller than that of microtubules.", [["surface", "ANATOMY", 139, 146], ["microtubules", "ANATOMY", 197, 209], ["microtubules", "CELLULAR_COMPONENT", 197, 209], ["a surface-charge density", "PROBLEM", 137, 161], ["smaller", "OBSERVATION_MODIFIER", 73, 80], ["surface", "OBSERVATION_MODIFIER", 139, 146], ["charge density", "OBSERVATION_MODIFIER", 147, 161], ["significantly", "OBSERVATION_MODIFIER", 162, 175], ["smaller", "OBSERVATION_MODIFIER", 176, 183]]], ["By investigating the centrosome hydrodynamic behavior, we show that its charge has a remarkable influence over its own structure.", [["centrosome", "ANATOMY", 21, 31], ["centrosome", "CELLULAR_COMPONENT", 21, 31], ["centrosome hydrodynamic behavior", "OBSERVATION", 21, 53]]], ["Specifically, we find that the electric field which drains to the centrosome expands its structure to a physiological size a 60% larger than previous electron microscopy determinations, a self-effect which modulates its structural behavior via environmental pH.", [["centrosome", "ANATOMY", 66, 76], ["centrosome", "CELLULAR_COMPONENT", 66, 76], ["the electric field", "TREATMENT", 27, 45], ["drains", "TREATMENT", 52, 58], ["previous electron microscopy determinations", "TEST", 141, 184], ["drains", "OBSERVATION", 52, 58], ["size", "OBSERVATION_MODIFIER", 118, 122], ["larger", "OBSERVATION_MODIFIER", 129, 135]]], ["This methodology further proves useful to study the action of different environmental conditions, such as the presence of Ca 2+ , over the thermally-induced dynamic structure of the centrosome.P-301Magnetic contrast neutron reflectivity delivers significant improvements in resolution for membrane structure analysis Neutron reflection (NR), with its high resolution and use of contrast variation, is a unique tool to gain information on the orientation and structure of lipid bilayers in the z-axis perpendicular to the surface.", [["centrosome", "ANATOMY", 182, 192], ["membrane", "ANATOMY", 289, 297], ["lipid bilayers", "ANATOMY", 471, 485], ["surface", "ANATOMY", 521, 528], ["Ca", "CHEMICAL", 122, 124], ["P-301", "CHEMICAL", 193, 198], ["Ca 2+", "CHEMICAL", 122, 127], ["Ca 2+", "SIMPLE_CHEMICAL", 122, 127], ["centrosome", "CELLULAR_COMPONENT", 182, 192], ["membrane", "CELLULAR_COMPONENT", 289, 297], ["lipid bilayers", "SIMPLE_CHEMICAL", 471, 485], ["surface", "CELLULAR_COMPONENT", 521, 528], ["different environmental conditions", "PROBLEM", 62, 96], ["Ca", "TEST", 122, 124], ["P", "TEST", 193, 194], ["Magnetic contrast neutron reflectivity", "TEST", 198, 236], ["membrane structure analysis", "TEST", 289, 316], ["dynamic structure", "OBSERVATION", 157, 174], ["significant", "OBSERVATION_MODIFIER", 246, 257], ["improvements", "OBSERVATION_MODIFIER", 258, 270], ["lipid bilayers", "OBSERVATION", 471, 485], ["surface", "ANATOMY_MODIFIER", 521, 528]]], ["To improve the use of NR we have used a highly oriented and stable layer of membrane proteins and lipids made possible by self-assembly upon a gold surface.", [["membrane", "ANATOMY", 76, 84], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["lipids", "SIMPLE_CHEMICAL", 98, 104], ["NR", "PROTEIN", 22, 24], ["membrane proteins", "PROTEIN", 76, 93], ["NR", "TREATMENT", 22, 24], ["membrane proteins", "TREATMENT", 76, 93], ["lipids", "TREATMENT", 98, 104]]], ["This also provides a model of the bacterial outer membrane.", [["outer membrane", "ANATOMY", 44, 58], ["outer membrane", "CELLULAR_COMPONENT", 44, 58], ["the bacterial outer membrane", "TREATMENT", 30, 58], ["bacterial", "OBSERVATION_MODIFIER", 34, 43], ["outer membrane", "OBSERVATION", 44, 58]]], ["As the dimensions of the layer can be predicted with accuracy, the system provides a molecular ruler for improvements in methodology and the complexity of the layer structure adds significantly to the modelling challenge.", [["layer", "OBSERVATION_MODIFIER", 159, 164]]], ["Early improvements in resolution were obtained through sample preparation and gold smoothness.P-301Further improvement however required clearer discrimination between similar models.", [["sample", "ANATOMY", 55, 61], ["P-301Further", "CHEMICAL", 94, 106], ["improvements", "OBSERVATION_MODIFIER", 6, 18]]], ["This was achieved using the new approach of magnetic contrast variation which uses a magnetic layer to provide two different scattering length densities for oppositely polarised neutrons.", [["a magnetic layer", "TREATMENT", 83, 99], ["two different scattering length densities", "TREATMENT", 111, 152], ["contrast variation", "OBSERVATION", 53, 71], ["scattering", "OBSERVATION_MODIFIER", 125, 135], ["length", "OBSERVATION_MODIFIER", 136, 142], ["polarised neutrons", "OBSERVATION", 168, 186]]], ["During this data collection the sample is unchanged.", [["this data collection the sample", "TEST", 7, 38], ["unchanged", "OBSERVATION_MODIFIER", 42, 51]]], ["We show that this approach delivers significant improvements in data analysis and resolution of the protein, lipid and solvent structures.", [["lipid", "SIMPLE_CHEMICAL", 109, 114], ["data analysis", "TEST", 64, 77], ["the protein, lipid and solvent structures", "PROBLEM", 96, 137], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["improvements", "OBSERVATION_MODIFIER", 48, 60], ["solvent structures", "OBSERVATION", 119, 137]]], ["The method will provide a new level of understanding of membrane structure and dynamics.P-300Single molecule force spectroscopy and recognition imaging P. Hinterdorfer Institute for Biophysics, Johannes Kepler University of Linz, Altenbergerstr.", [["membrane", "ANATOMY", 56, 64], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["P", "DNA", 88, 89], ["Single molecule force spectroscopy", "TEST", 93, 127], ["recognition imaging", "TEST", 132, 151]]], ["69, A-4040 Linz, AustriaP-300In single molecule force spectroscopy, interaction forces of ligand-containing tips with receptors on probe surfaces are quantified.", [["AustriaP", "TEST", 17, 25], ["single molecule force spectroscopy", "TREATMENT", 32, 66], ["receptors on probe surfaces", "TREATMENT", 118, 145], ["tips", "OBSERVATION_MODIFIER", 108, 112]]], ["Here he attachment of human rhino virus 2 (HRV2) to the cell surface, the first step in infection, was characterized.", [["cell surface", "ANATOMY", 56, 68], ["infection", "DISEASE", 88, 97], ["human", "ORGANISM", 22, 27], ["rhino virus 2", "ORGANISM", 28, 41], ["HRV2", "GENE_OR_GENE_PRODUCT", 43, 47], ["cell surface", "CELLULAR_COMPONENT", 56, 68], ["human", "SPECIES", 22, 27], ["rhino virus", "SPECIES", 28, 39], ["human rhino virus", "SPECIES", 22, 39], ["human rhino virus", "TREATMENT", 22, 39], ["infection", "PROBLEM", 88, 97], ["infection", "OBSERVATION", 88, 97]]], ["Sequential binding of multiple receptors was evident from recordings of characteristic quantized force spectra.", [["multiple receptors", "PROTEIN", 22, 40], ["multiple receptors", "PROBLEM", 22, 40], ["multiple", "OBSERVATION_MODIFIER", 22, 30], ["force spectra", "OBSERVATION", 97, 110]]], ["This suggests that multiple receptors bound to the virus in a timely manner.", [["multiple receptors bound", "PROBLEM", 19, 43], ["the virus", "PROBLEM", 47, 56], ["multiple", "OBSERVATION_MODIFIER", 19, 27]]], ["Unbinding forces required to detach the virus from the cell membrane increased within a time frame of several 100 ms.", [["cell membrane", "ANATOMY", 55, 68], ["cell membrane", "CELLULAR_COMPONENT", 55, 68], ["Unbinding forces", "PROBLEM", 0, 16], ["the virus", "PROBLEM", 36, 45], ["cell membrane", "OBSERVATION", 55, 68]]], ["The number of receptors involved in virus binding was determined and estimates for on-rate, off-rate, and equilibrium binding constant were obtained.", [["virus binding", "PROBLEM", 36, 49]]], ["Furthermore, we show that accurate free energy values of membrane protein unfolding can be obtained from single molecule force measurements.", [["membrane", "ANATOMY", 57, 65], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["membrane protein unfolding", "PROBLEM", 57, 83], ["single molecule force measurements", "TEST", 105, 139]]], ["By applying a statistical theorem developed by Jarzynski, we derived equilibrium unfolding free energies of from unfolding force data acquired at different force loading-rates and temperatures.", [["unfolding force data", "TEST", 113, 133]]], ["Finally, we present a method for the localization of specific binding sites and epitopes with nm positional accuracy.", [["epitopes", "PROTEIN", 80, 88], ["a method", "TREATMENT", 20, 28], ["specific binding sites", "PROBLEM", 53, 75], ["nm positional accuracy", "TEST", 94, 116]]], ["A magnetically driven AFM tip containing a ligand covalently bound via a tether molecule is oscillated at a few nm amplitude, during scanning along the surface.", [["surface", "ANATOMY", 152, 159], ["surface", "CELLULAR_COMPONENT", 152, 159], ["tether molecule", "PROTEIN", 73, 88], ["A magnetically driven AFM tip", "TREATMENT", 0, 29], ["a ligand covalently bound", "PROBLEM", 41, 66], ["a tether molecule", "TREATMENT", 71, 88], ["tether molecule", "OBSERVATION", 73, 88], ["few", "OBSERVATION_MODIFIER", 108, 111], ["nm amplitude", "OBSERVATION", 112, 124], ["surface", "ANATOMY_MODIFIER", 152, 159]]], ["In this way, topography and recognition images on membranes and cell surfaces were obtained simultaneously.", [["membranes", "ANATOMY", 50, 59], ["cell surfaces", "ANATOMY", 64, 77], ["membranes", "CELLULAR_COMPONENT", 50, 59], ["cell surfaces", "CELL", 64, 77], ["topography and recognition images on membranes and cell surfaces", "TEST", 13, 77]]], ["Mapping of the forces acting on biomolecules in cell membranes has spurred the development of effective labels, e.g. organic fluorophores and nanoparticles, to track trajectories of single biomolecules [1] .", [["cell membranes", "ANATOMY", 48, 62], ["cell membranes", "CELLULAR_COMPONENT", 48, 62], ["biomolecules in cell membranes", "TREATMENT", 32, 62], ["organic fluorophores", "TREATMENT", 117, 137], ["nanoparticles", "TREATMENT", 142, 155], ["cell membranes", "OBSERVATION", 48, 62]]], ["Standard methods use particular statistical observables, namely the mean square displacement (MSD), to extract cues on the underlying dynamics.", [["the mean square displacement (MSD)", "PROBLEM", 64, 98]]], ["Yet, MSD is not an appropriate tool to access force fields and becomes easily a biased estimator in the presence of positioning noise.", [["positioning noise", "OBSERVATION", 116, 133]]], ["Here, we introduce general inference methods [2] to fully exploit information hidden in the experimental trajectories, providing sharp estimates for the forces and the diffusion coefficients within membrane microdomains.", [["membrane microdomains", "ANATOMY", 198, 219], ["membrane microdomains", "CELLULAR_COMPONENT", 198, 219], ["the diffusion coefficients", "TEST", 164, 190]]], ["The inference method is then applied to infer forces and potentials acting on the receptor of the \u03b5-toxin labelled by lanthanide-ion nanoparticles.", [["lanthanide", "CHEMICAL", 118, 128], ["lanthanide", "CHEMICAL", 118, 128], ["\u03b5-toxin", "GENE_OR_GENE_PRODUCT", 98, 105], ["lanthanide-ion nanoparticles", "SIMPLE_CHEMICAL", 118, 146], ["\u03b5-toxin", "PROTEIN", 98, 105], ["The inference method", "TREATMENT", 0, 20], ["lanthanide-ion nanoparticles", "TREATMENT", 118, 146]]], ["Results show a constant diffusivity inside a complex force field confining the receptor inside a specific domain.", [["a constant diffusivity", "PROBLEM", 13, 35], ["constant", "OBSERVATION_MODIFIER", 15, 23], ["diffusivity", "OBSERVATION_MODIFIER", 24, 35]]], ["Our scheme is applicable to any labelled biomolecule, and results presented here show its general relevance to the issue of membrane compartmentation and protein motion.", [["membrane", "ANATOMY", 124, 132], ["membrane", "CELLULAR_COMPONENT", 124, 132], ["any labelled biomolecule", "TEST", 28, 52], ["protein motion", "OBSERVATION", 154, 168]]], ["Large scale domain motions are structural rearrangements often adopted by enzymes to achieve their full functionality.", [["enzymes", "PROTEIN", 74, 81], ["Large scale domain motions", "PROBLEM", 0, 26], ["structural rearrangements", "PROBLEM", 31, 56], ["enzymes", "TEST", 74, 81]]], ["Unfortunately, the simulation time required to sample these events by conventional techniques such as plain molecular dynamics, is unfeasible.", [["conventional techniques", "TREATMENT", 70, 93]]], ["Here, the domain motion required by Adenosine kinase (AK) to achieve its (pre-)catalytic conformation was studied using well-tempered metadynamics [Barducci, A. et al. Phys Rev Lett.", [["Adenosine", "CHEMICAL", 36, 45], ["Adenosine", "CHEMICAL", 36, 45], ["Adenosine kinase", "GENE_OR_GENE_PRODUCT", 36, 52], ["AK", "GENE_OR_GENE_PRODUCT", 54, 56], ["Adenosine kinase", "PROTEIN", 36, 52], ["AK", "PROTEIN", 54, 56], ["Adenosine kinase", "TREATMENT", 36, 52], ["Rev Lett", "OBSERVATION", 173, 181]]], ["First, a low energy path for the apo form of the enzyme was obtained, and the potential of mean force along the PCVs was reconstructed.", [["apo", "GENE_OR_GENE_PRODUCT", 33, 36], ["apo form", "PROTEIN", 33, 41], ["enzyme", "PROTEIN", 49, 55], ["PCVs", "PROTEIN", 112, 116], ["a low energy path", "PROBLEM", 7, 24], ["the enzyme", "TEST", 45, 55], ["the PCVs", "TEST", 108, 116]]], ["Then, the large scale movement was simulated in the presence of two inhibitors known to bind to the enzyme in different conformational states.", [["enzyme", "PROTEIN", 100, 106], ["two inhibitors", "TREATMENT", 64, 78], ["the enzyme", "TEST", 96, 106], ["large", "OBSERVATION_MODIFIER", 10, 15], ["scale", "OBSERVATION_MODIFIER", 16, 21], ["movement", "OBSERVATION_MODIFIER", 22, 30]]], ["The adopted approach was proven to be successful both to understand the mechanistic features of the AK domain motion and to provide a picture of the population shift effects upon ligand binding.P-305Force measurement study of the interaction between 23S rRNA and the ribosomal protein L20 Single molecule force measurements enable to probe the complex structure and folding dynamics of RNA molecules and furthermore to investigate the numerous interactions with proteins that affect RNA folding in vivo.", [["ribosomal", "CELLULAR_COMPONENT", 267, 276], ["AK domain", "PROTEIN", 100, 109], ["23S rRNA", "DNA", 250, 258], ["ribosomal protein L20", "PROTEIN", 267, 288], ["RNA molecules", "PROTEIN", 386, 399], ["Force measurement study", "TEST", 199, 222], ["23S rRNA", "TEST", 250, 258], ["the ribosomal protein", "TEST", 263, 284], ["Single molecule force measurements", "TEST", 289, 323], ["folding dynamics of RNA molecules", "PROBLEM", 366, 399]]], ["We use a double optical tweezers setup to study a region of the ribosomal RNA 23S from E.Coli and its interaction with the essential ribosomal protein L20.", [["ribosomal", "ANATOMY", 133, 142], ["ribosomal", "CELLULAR_COMPONENT", 64, 73], ["E.Coli", "GENE_OR_GENE_PRODUCT", 87, 93], ["ribosomal", "CELLULAR_COMPONENT", 133, 142], ["L20", "GENE_OR_GENE_PRODUCT", 151, 154], ["ribosomal RNA 23S", "RNA", 64, 81], ["essential ribosomal protein L20", "PROTEIN", 123, 154], ["a double optical tweezers setup", "TREATMENT", 7, 38], ["the ribosomal RNA 23S", "PROBLEM", 60, 81], ["E.Coli", "PROBLEM", 87, 93], ["ribosomal RNA 23S", "OBSERVATION", 64, 81], ["ribosomal protein L20", "OBSERVATION", 133, 154]]], ["The apparatus permits us to probe the dynamics of the RNA structure with milisecond time-resolution.", [["RNA structure", "OBSERVATION", 54, 67]]], ["First, we pull the RNA and show that it mechanically unfolds in several reproducible steps.", [["several", "OBSERVATION_MODIFIER", 64, 71], ["reproducible steps", "OBSERVATION", 72, 90]]], ["We use these results in combination with structure prediction tools to evaluate the possible structures of the RNA fragment in vitro.", [["RNA fragment", "DNA", 111, 123], ["structure prediction tools", "TEST", 41, 67], ["the RNA fragment", "PROBLEM", 107, 123], ["RNA fragment", "OBSERVATION", 111, 123]]], ["The most probable structure exhibits a unique binding site for L20.", [["L20", "SIMPLE_CHEMICAL", 63, 66], ["L20", "PROTEIN", 63, 66], ["a unique binding site", "PROBLEM", 37, 58], ["most probable", "UNCERTAINTY", 4, 17], ["binding site", "OBSERVATION", 46, 58]]], ["Then, force measurements are done on the RNA in presence of L20.", [["L20", "PROTEIN", 60, 63], ["force measurements", "TEST", 6, 24]]], ["The binding site is recognized with a resolution of a few bases.", [["binding site", "DNA", 4, 16], ["The binding site", "PROBLEM", 0, 16], ["binding site", "OBSERVATION", 4, 16], ["resolution", "OBSERVATION_MODIFIER", 38, 48], ["few", "OBSERVATION_MODIFIER", 54, 57], ["bases", "ANATOMY_MODIFIER", 58, 63]]], ["Finally, two bases are mutated on the RNA fragment.", [["RNA fragment", "DNA", 38, 50], ["mutated on the RNA fragment", "PROBLEM", 23, 50], ["bases", "ANATOMY_MODIFIER", 13, 18], ["mutated", "OBSERVATION", 23, 30], ["RNA fragment", "OBSERVATION", 38, 50]]], ["In presence of these mutations, in vivo and in vitro binding of L20 to 23S RNA is abolished.", [["L20", "GENE_OR_GENE_PRODUCT", 64, 67], ["23S", "GENE_OR_GENE_PRODUCT", 71, 74], ["L20", "PROTEIN", 64, 67], ["23S RNA", "RNA", 71, 78], ["these mutations", "PROBLEM", 15, 30], ["mutations", "OBSERVATION", 21, 30]]], ["The single molecule approach gives an explanation of this result: the force measurements show that the mutated RNA folds differently from the natural one and that it does not bind L20.P-304Control of the translocation of single DNA molecules through alpha-hemolysin nanopores G. Maglia, H. Bayley Department of Chemistry, University of Oxford, OX1 3TA, Oxford, UKP-304The analysis of single nucleic acid molecules by electrophoretic threading through nanopores is under intense investigation as a rapid, low cost platform for DNA sequencing.", [["UKP-304", "CHEMICAL", 361, 368], ["nucleic acid", "CHEMICAL", 391, 403], ["L20", "GENE_OR_GENE_PRODUCT", 180, 183], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["DNA", "CELLULAR_COMPONENT", 526, 529], ["L20", "PROTEIN", 180, 183], ["P-304Control", "DNA", 184, 196], ["the force measurements", "TEST", 66, 88], ["the mutated RNA folds", "PROBLEM", 99, 120], ["single DNA molecules", "TREATMENT", 221, 241], ["UKP", "TEST", 361, 364], ["The analysis", "TEST", 368, 380], ["single nucleic acid molecules", "TREATMENT", 384, 413], ["electrophoretic threading", "TREATMENT", 417, 442], ["intense investigation", "TEST", 470, 491], ["DNA sequencing", "TREATMENT", 526, 540]]], ["Biological nanopores such as staphylococcal alpha-hemolysin (HL) have an added advantage over solid-state nanopores because they can be modified by genetic engineering with atomistic precision.", [["staphylococcal alpha-hemolysin", "GENE_OR_GENE_PRODUCT", 29, 59], ["HL", "CANCER", 61, 63], ["staphylococcal alpha-hemolysin", "PROTEIN", 29, 59], ["HL", "PROTEIN", 61, 63], ["Biological nanopores", "TREATMENT", 0, 20], ["staphylococcal alpha-hemolysin (HL", "TREATMENT", 29, 63]]], ["Although we showed that all four DNA bases can be identified in an immobilized ssDNA molecule (1), the translocation of free DNA is too quick to observe single bases.", [["DNA", "CELLULAR_COMPONENT", 33, 36], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["ssDNA molecule", "PROTEIN", 79, 93], ["all four DNA bases", "PROBLEM", 24, 42], ["an immobilized ssDNA molecule", "PROBLEM", 64, 93], ["the translocation of free DNA", "PROBLEM", 99, 128], ["free DNA", "OBSERVATION", 120, 128]]], ["Here we show that by a small increase of the net internal charge of the HL nanopore (e.g. by introducing a ring of 7 arginine residues), we have augmented the frequency of DNA translocation events through the pore and dramatically lowered the voltage threshold required for DNA translocation (2) .", [["pore", "ANATOMY", 209, 213], ["arginine", "CHEMICAL", 117, 125], ["arginine", "CHEMICAL", 117, 125], ["DNA", "CELLULAR_COMPONENT", 172, 175], ["pore", "CELLULAR_COMPONENT", 209, 213], ["DNA", "CELLULAR_COMPONENT", 274, 277], ["the net internal charge of the HL nanopore", "TREATMENT", 41, 83], ["a ring of 7 arginine residues", "TREATMENT", 105, 134], ["DNA translocation events", "PROBLEM", 172, 196], ["the voltage threshold", "TEST", 239, 260], ["DNA translocation", "PROBLEM", 274, 291], ["small", "OBSERVATION_MODIFIER", 23, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37]]], ["By further increasing the net positive charge of the transmembrane barrel region of the pore (e.g. by introducing 49 extra positive charges) we have also reduced the speed at which DNA translocate the pore by more than two orders of magnitude.", [["transmembrane barrel", "ANATOMY", 53, 73], ["pore", "ANATOMY", 88, 92], ["pore", "ANATOMY", 201, 205], ["pore", "CELLULAR_COMPONENT", 88, 92], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["pore", "CELLULAR_COMPONENT", 201, 205], ["transmembrane barrel region", "PROTEIN", 53, 80], ["increasing", "OBSERVATION_MODIFIER", 11, 21], ["net", "OBSERVATION_MODIFIER", 26, 29], ["positive charge", "OBSERVATION", 30, 45]]], ["These experiments provide a means of controlling DNA translocation with protein nanopores, which might be translated to solid-state nanopores by using chemical surface modification.", [["surface", "ANATOMY", 160, 167], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["DNA translocation with protein nanopores", "TREATMENT", 49, 89], ["chemical surface modification", "TREATMENT", 151, 180]]], ["The atomic force microscope (AFM) is a tool for imaging, measuring and manipulating matter at the nanoscale.", [["The atomic force microscope", "TEST", 0, 27], ["imaging", "TEST", 48, 55]]], ["Single-molecule pulling experiments give information on the thermodynamics and kinetics of biomolecules.", [["Single-molecule pulling experiments", "TREATMENT", 0, 35]]], ["The purpose if this work was to develop software to simulate single-molecule pulling experiments and to analyze singlemolecule pulling data.", [["single-molecule pulling experiments", "TREATMENT", 61, 96]]], ["The long term objective is to asses the accuracy and precision of the parameters recovered from single-molecule pulling data.We carried out simulations for two different models [1, 2, 3] , using a wide range of loading rates.", [["the parameters", "TEST", 66, 80], ["single-molecule pulling data", "TEST", 96, 124], ["a wide range of loading rates", "TREATMENT", 195, 224], ["long term", "OBSERVATION_MODIFIER", 4, 13]]], ["From the simulated force-extension curves we extracted the kinetic parameters and compared them with the values used for simulations.", [["the kinetic parameters", "TEST", 55, 77]]], ["The kinetic parameters were the intrinsic rate coefficient (k 0 Kramers rate), the location of transition state (x ) and the free energy of activation (\u2206G).", [["The kinetic parameters", "TEST", 0, 22], ["Kramers rate", "TEST", 64, 76]]], ["We have found that the loading rates have a small effect on the recovery of the free energy of activation, but have a significant effect on the recovery of the Kramers rate.", [["Kramers", "SIMPLE_CHEMICAL", 160, 167], ["Kramers", "PROTEIN", 160, 167], ["the loading rates", "PROBLEM", 19, 36], ["the Kramers rate", "TEST", 156, 172], ["small", "OBSERVATION_MODIFIER", 44, 49], ["effect", "OBSERVATION_MODIFIER", 50, 56], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["effect", "OBSERVATION_MODIFIER", 130, 136]]], ["We report the tracking of single myosin V molecules in their natural environment, the cell.", [["cell", "ANATOMY", 86, 90], ["myosin V", "GENE_OR_GENE_PRODUCT", 33, 41], ["cell", "CELL", 86, 90], ["myosin V molecules", "PROTEIN", 33, 51], ["single myosin V molecules", "TREATMENT", 26, 51], ["natural environment", "OBSERVATION", 61, 80]]], ["Myosin V molecules, labeled with Quantum Dots, are introduced into the cytoplasm of living HeLa cells and their motion is recorded at the single molecule level with high spatial and temporal resolution.", [["cytoplasm", "ANATOMY", 71, 80], ["HeLa cells", "ANATOMY", 91, 101], ["Myosin V", "GENE_OR_GENE_PRODUCT", 0, 8], ["cytoplasm", "ORGANISM_SUBSTANCE", 71, 80], ["HeLa cells", "CELL", 91, 101], ["Myosin V molecules", "PROTEIN", 0, 18], ["HeLa cells", "CELL_LINE", 91, 101], ["Myosin V molecules", "PROBLEM", 0, 18], ["Quantum Dots", "TREATMENT", 33, 45], ["living HeLa cells", "TREATMENT", 84, 101], ["temporal", "OBSERVATION_MODIFIER", 182, 190], ["resolution", "OBSERVATION_MODIFIER", 191, 201]]], ["We perform intracellular measurements of key parameters of this molecular transporter: velocity, processivity, step size and dwell time.", [["intracellular", "ANATOMY", 11, 24], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["molecular transporter", "PROTEIN", 64, 85], ["intracellular measurements", "TEST", 11, 37], ["size", "OBSERVATION_MODIFIER", 116, 120]]], ["Our experiments bridge the gap between in vitro single molecule assays and the indirect measurements of the motor features deduced from the tracking of organelles in live cells.P-309A mathematical model of neurotransmission at the input stage of the cerebellum T. Nieus 1 , S. Solinas 3 , L. Mapelli 2 , E. D'Angelo 3 1 Dept.", [["organelles", "ANATOMY", 152, 162], ["cells", "ANATOMY", 171, 176], ["organelles", "CELLULAR_COMPONENT", 152, 162], ["cells", "CELL", 171, 176], ["live cells", "CELL_TYPE", 166, 176], ["P", "DNA", 177, 178], ["the motor features", "TEST", 104, 122], ["live cells", "OBSERVATION", 166, 176], ["cerebellum", "ANATOMY", 250, 260]]], ["Neuroscience and Brain Technologies, IIT, Italian Institute of Technology, Genova, Italy, 2 Dept. of Biomolecular Sciences and Biotechnology, Milan, Italy, 3 Dept.", [["Brain", "ANATOMY", 17, 22]]], ["Physiological and Pharmacological Sciences and CNISM, University of Pavia, ItalyP-309The granule cell (GC) of the cerebellum has some peculiar properties compared to other cells of the vertebrate brain.", [["granule cell", "ANATOMY", 89, 101], ["GC", "ANATOMY", 103, 105], ["cerebellum", "ANATOMY", 114, 124], ["cells", "ANATOMY", 172, 177], ["brain", "ANATOMY", 196, 201], ["granule cell", "CELL", 89, 101], ["GC", "CELL", 103, 105], ["cerebellum", "ORGAN", 114, 124], ["cells", "CELL", 172, 177], ["brain", "ORGAN", 196, 201], ["granule cell", "CELL_TYPE", 89, 101], ["ItalyP", "TEST", 75, 81], ["The granule cell", "TEST", 85, 101], ["granule cell", "OBSERVATION", 89, 101], ["cerebellum", "ANATOMY", 114, 124], ["some", "OBSERVATION_MODIFIER", 129, 133], ["peculiar", "OBSERVATION_MODIFIER", 134, 142], ["vertebrate", "ANATOMY_MODIFIER", 185, 195], ["brain", "ANATOMY", 196, 201]]], ["The GC has a small soma (diam=6 microm) and just a few (2 to 6) excitatory and inhibitory inputs (E&I).", [["soma", "ANATOMY", 19, 23], ["small", "OBSERVATION_MODIFIER", 13, 18], ["soma", "OBSERVATION_MODIFIER", 19, 23]]], ["The E&I GC synaptic inputs are formed inside the cerebellar glomerulus, which favors neurotransmitter diffusion between neighboring sites (1) protracting postsynaptic receptor activation and (2) causing cross-tall between E&I synapses through presynaptic receptors.", [["GC synaptic", "ANATOMY", 8, 19], ["cerebellar glomerulus", "ANATOMY", 49, 70], ["E&I synapses", "ANATOMY", 222, 234], ["presynaptic", "ANATOMY", 243, 254], ["cerebellar glomerulus", "MULTI-TISSUE_STRUCTURE", 49, 70], ["E&I synapses", "CELLULAR_COMPONENT", 222, 234], ["postsynaptic receptor", "PROTEIN", 154, 175], ["presynaptic receptors", "PROTEIN", 243, 264], ["The E&I GC synaptic inputs", "TEST", 0, 26], ["neurotransmitter diffusion between neighboring sites", "PROBLEM", 85, 137], ["protracting postsynaptic receptor activation", "PROBLEM", 142, 186], ["cross-tall between E&I synapses", "TREATMENT", 203, 234], ["synaptic inputs", "OBSERVATION", 11, 26], ["cerebellar glomerulus", "ANATOMY", 49, 70], ["neurotransmitter diffusion", "OBSERVATION", 85, 111]]], ["Neurotransmitter release probability (p) can be regulated by long-term plasticity (LTP and LTD at E synapses) and by GABA B and mGlu presynaptic receptors (both at E&I synapses).", [["E&I synapses", "ANATOMY", 164, 176], ["GABA", "CHEMICAL", 117, 121], ["mGlu", "CHEMICAL", 128, 132], ["GABA", "CHEMICAL", 117, 121], ["GABA B", "GENE_OR_GENE_PRODUCT", 117, 123], ["mGlu presynaptic receptors", "GENE_OR_GENE_PRODUCT", 128, 154], ["LTD", "PROTEIN", 91, 94], ["GABA B", "PROTEIN", 117, 123], ["mGlu presynaptic receptors", "PROTEIN", 128, 154], ["long-term plasticity", "TREATMENT", 61, 81], ["LTP and LTD at E synapses", "TREATMENT", 83, 108], ["mGlu presynaptic receptors", "TREATMENT", 128, 154]]], ["To gain insight into the role that p changes might have in computations performed at the cerebellum input stage, we have built detailed biophysical models of the E&I synapses.", [["cerebellum", "ANATOMY", 89, 99], ["E&I synapses", "ANATOMY", 162, 174], ["cerebellum", "MULTI-TISSUE_STRUCTURE", 89, 99], ["E&I synapses", "MULTI-TISSUE_STRUCTURE", 162, 174]]], ["The model has allowed to investigate glomerular processing of high frequency inputs reaching the cerebellum.", [["glomerular", "ANATOMY", 37, 47], ["cerebellum", "ANATOMY", 97, 107], ["glomerular", "TISSUE", 37, 47], ["cerebellum", "ORGAN", 97, 107], ["high frequency inputs", "PROBLEM", 62, 83], ["high frequency", "OBSERVATION_MODIFIER", 62, 76], ["cerebellum", "ANATOMY", 97, 107]]], ["Optimal synaptic transmission through the MFs inputs resulted when GOs inhibited synchronously the GCs.", [["synaptic", "ANATOMY", 8, 16], ["GOs", "ANATOMY", 67, 70], ["GCs", "ANATOMY", 99, 102], ["GOs", "SIMPLE_CHEMICAL", 67, 70], ["GCs", "CELL", 99, 102], ["GOs", "PROTEIN", 67, 70], ["the GCs", "TEST", 95, 102]]], ["The role of feed-forward inhibition onto synaptic transmission is under investigation.P-308Unzipping DNA with a nanopore J. Muzard, N. Chiaruttini, U. Bockelmann, V. Viasnoff CNRS/ESPCI Nanobiophysique, 10 rue Vauquelin, 75005 Paris, FranceP-308The use of proteinaceous or artificial nanometer size pores has become a promising approach for sensing biomolecules at the single molecule level.", [["synaptic", "ANATOMY", 41, 49], ["FranceP-308", "CHEMICAL", 234, 245], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["P-308Unzipping DNA", "DNA", 86, 104], ["V. Viasnoff CNRS/ESPCI Nanobiophysique, 10 rue Vauquelin, 75005 Paris, FranceP-308", "SPECIES", 163, 245], ["Nanobiophysique", "TEST", 186, 201], ["FranceP", "TEST", 234, 241], ["proteinaceous or artificial nanometer size pores", "TREATMENT", 256, 304], ["sensing biomolecules", "PROBLEM", 341, 361], ["proteinaceous", "OBSERVATION_MODIFIER", 256, 269], ["artificial nanometer", "OBSERVATION", 273, 293], ["size", "OBSERVATION_MODIFIER", 294, 298]]], ["It was shown that alphahemolysin, a toxin from staphylococcus aureus, can be employed to sense the translocation of DNA strands through a lipid bilayer.", [["lipid bilayer", "ANATOMY", 138, 151], ["alphahemolysin", "CHEMICAL", 18, 32], ["staphylococcus aureus", "DISEASE", 47, 68], ["alphahemolysin", "SIMPLE_CHEMICAL", 18, 32], ["staphylococcus aureus", "ORGANISM", 47, 68], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["lipid bilayer", "CELLULAR_COMPONENT", 138, 151], ["staphylococcus aureus", "SPECIES", 47, 68], ["staphylococcus aureus", "SPECIES", 47, 68], ["alphahemolysin", "PROBLEM", 18, 32], ["a toxin from staphylococcus aureus", "PROBLEM", 34, 68], ["a lipid bilayer", "TREATMENT", 136, 151]]], ["The pore dimension allows the electrophoretically driven passage of single stranded DNA whereas double stranded structures need to open prior their translocation.", [["pore", "ANATOMY", 4, 8], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["single stranded DNA", "DNA", 68, 87], ["single stranded DNA", "PROBLEM", 68, 87], ["double stranded structures", "PROBLEM", 96, 122], ["pore dimension", "OBSERVATION_MODIFIER", 4, 18]]], ["We study the unzipping process of the double stranded part of DNA both experimentally and theoretically.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["double stranded", "OBSERVATION_MODIFIER", 38, 53]]], ["We then discuss the effect of the pore/DNA interaction on the translocation process.", [["pore", "ANATOMY", 34, 38], ["pore", "CELLULAR_COMPONENT", 34, 38], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["the pore/DNA interaction", "TREATMENT", 30, 54], ["the translocation process", "PROBLEM", 58, 83]]], ["We further characterize the effects of the pore geometry, showing that the pre-confinement of the DNA in the pore vestibule is essential to the unzipping process.", [["pore", "ANATOMY", 43, 47], ["pore vestibule", "ANATOMY", 109, 123], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["pore vestibule", "CELLULAR_COMPONENT", 109, 123], ["the pore geometry", "TEST", 39, 56], ["the DNA", "PROBLEM", 94, 101], ["DNA", "OBSERVATION", 98, 101], ["pore vestibule", "ANATOMY", 109, 123], ["unzipping process", "OBSERVATION", 144, 161]]], ["We eventually discuss the possibility to use this nanopore approach to sequentially probe RNA secondary structures.", [["this nanopore approach", "TREATMENT", 45, 67]]], ["We report on the interaction forces in the range 100 --400 pN determined between pairs of the lectin soybean agglutinin (SBA) and a modified porcine submaxillary mucin (Tn-PSM) using a single-molecule approach.P-308Lectins are carbohydrate-binding proteins with biological activities related to i.e. cellular recognition, adhesion, growth and metastasis.", [["submaxillary mucin", "ANATOMY", 149, 167], ["cellular", "ANATOMY", 300, 308], ["P-308Lectins", "CHEMICAL", 210, 222], ["carbohydrate", "CHEMICAL", 227, 239], ["lectin", "GENE_OR_GENE_PRODUCT", 94, 100], ["SBA", "SIMPLE_CHEMICAL", 121, 124], ["porcine", "ORGANISM", 141, 148], ["submaxillary", "ORGAN", 149, 161], ["mucin", "GENE_OR_GENE_PRODUCT", 162, 167], ["Tn-PSM", "GENE_OR_GENE_PRODUCT", 169, 175], ["P-308Lectins", "SIMPLE_CHEMICAL", 210, 222], ["cellular", "CELL", 300, 308], ["lectin soybean agglutinin", "PROTEIN", 94, 119], ["SBA", "PROTEIN", 121, 124], ["porcine submaxillary mucin", "PROTEIN", 141, 167], ["Tn", "PROTEIN", 169, 171], ["PSM", "PROTEIN", 172, 175], ["P", "DNA", 210, 211], ["308Lectins", "PROTEIN", 212, 222], ["carbohydrate-binding proteins", "PROTEIN", 227, 256], ["soybean", "SPECIES", 101, 108], ["porcine", "SPECIES", 141, 148], ["a modified porcine submaxillary mucin (Tn-PSM", "TREATMENT", 130, 175], ["a single-molecule approach", "TREATMENT", 183, 209], ["cellular recognition", "PROBLEM", 300, 320], ["adhesion", "PROBLEM", 322, 330], ["metastasis", "PROBLEM", 343, 353], ["growth", "OBSERVATION_MODIFIER", 332, 338], ["metastasis", "OBSERVATION", 343, 353]]], ["Here, dynamic force spectroscopy is used to investigate pairs of SBA and Tn-PSM with the aim to understand the mechanisms of binding and cross-linking of multivalent lectins.", [["SBA", "SIMPLE_CHEMICAL", 65, 68], ["Tn-PSM", "GENE_OR_GENE_PRODUCT", 73, 79], ["SBA", "PROTEIN", 65, 68], ["Tn", "PROTEIN", 73, 75], ["PSM", "PROTEIN", 76, 79], ["dynamic force spectroscopy", "TEST", 6, 32], ["SBA", "PROBLEM", 65, 68], ["Tn-PSM", "PROBLEM", 73, 79], ["multivalent lectins", "PROBLEM", 154, 173]]], ["The unbinding force increased from 103 pN to 402 pN with increasing force loading rate and the lifetime of the complex in the absence of applied force was 1.3 -1.9 s.", [["increasing force loading rate", "TREATMENT", 57, 86]]], ["Published kinetic parameters describing the rate of dissociation of other sugar lectin interactions are in the range 3.3 x 10 \u22123 -2.5 x 10 \u22123 s.", [["sugar", "CHEMICAL", 74, 79], ["Published kinetic parameters", "TEST", 0, 28], ["other sugar lectin interactions", "PROBLEM", 68, 99]]], ["The long lifetime of the SBA -TnPSM complex is compatible with a previously proposed \"bind and jump\" mechanism.", [["SBA -TnPSM", "CHEMICAL", 25, 35], ["SBA -TnPSM", "GENE_OR_GENE_PRODUCT", 25, 35], ["SBA", "PROTEIN", 25, 28], ["TnPSM complex", "PROTEIN", 30, 43], ["a previously proposed \"bind", "PROBLEM", 63, 90], ["SBA", "ANATOMY", 25, 28], ["compatible with", "UNCERTAINTY", 47, 62]]], ["This mechanism has also been suggested for lectins binding to multivalent carbohydrates and globular glycoprotein.", [["carbohydrates", "CHEMICAL", 74, 87], ["globular glycoprotein", "GENE_OR_GENE_PRODUCT", 92, 113], ["globular glycoprotein", "PROTEIN", 92, 113], ["lectins binding", "PROBLEM", 43, 58], ["globular glycoprotein", "PROBLEM", 92, 113], ["globular glycoprotein", "OBSERVATION", 92, 113]]], ["The bind and jump mechanism is also similar to that observed for binding of proteins to DNA, and suggest a common conserved binding mechanism of ligands to the two biopolymers and possibly between ligands and all biopolymers, as recently suggested.P-314The rate of topoisomerase II activity correlates with persistence length of DNA Q. Shao 1 , L. Finzi 1 , D. Dunlap 2 1 Dept. of Physics, Emory University, Atlanta, Georgia, U.S.A., 2 Dept. of Cell Biology, Emory Univ.", [["Cell", "ANATOMY", 445, 449], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["topoisomerase II", "GENE_OR_GENE_PRODUCT", 265, 281], ["DNA", "CELLULAR_COMPONENT", 329, 332], ["Cell", "CELL", 445, 449], ["P", "DNA", 248, 249], ["topoisomerase II", "PROTEIN", 265, 281], ["The bind and jump mechanism", "PROBLEM", 0, 27], ["proteins to DNA", "PROBLEM", 76, 91], ["all biopolymers", "TREATMENT", 209, 224], ["P", "TEST", 248, 249], ["topoisomerase II activity", "PROBLEM", 265, 290]]], ["School, Atlanta, Georgia, U.S.A.P-314Type II topoisomerases catalyze the transection of one double helical segment by another to modify the topological state of DNA.", [["P-314Type II", "CHEMICAL", 32, 44], ["314Type II topoisomerases", "GENE_OR_GENE_PRODUCT", 34, 59], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["314Type II topoisomerases", "PROTEIN", 34, 59], ["double helical segment", "PROTEIN", 92, 114], ["the transection", "TREATMENT", 69, 84], ["one double helical segment", "TREATMENT", 88, 114], ["transection", "OBSERVATION", 73, 84], ["DNA", "OBSERVATION", 161, 164]]], ["Reversible 5' linkages to the phosphate-sugar backbones are established on each strand of the \"gate\" segment to create an opening through which the enzyme drives the \"transfer\" segment.", [["phosphate", "CHEMICAL", 30, 39], ["phosphate", "CHEMICAL", 30, 39], ["sugar", "CHEMICAL", 40, 45], ["phosphate-sugar backbones", "SIMPLE_CHEMICAL", 30, 55], ["enzyme", "PROTEIN", 148, 154], ["Reversible 5' linkages", "PROBLEM", 0, 22], ["the phosphate", "TEST", 26, 39], ["sugar backbones", "TREATMENT", 40, 55], ["the enzyme", "TEST", 144, 154], ["opening", "OBSERVATION", 122, 129]]], ["A recent crystal structure shows that the \"gate\" segment bends approximately 150 \u2022 upon binding to the enzyme.", [["enzyme", "PROTEIN", 103, 109], ["A recent crystal structure", "PROBLEM", 0, 26], ["the \"gate\" segment bends", "PROBLEM", 38, 62], ["the enzyme", "TEST", 99, 109]]], ["Bending a stiff polymer like DNA requires considerable energy and could represent the rate limiting step in the catalytic (topological) cycle.", [["DNA", "CELLULAR_COMPONENT", 29, 32], ["Bending a stiff polymer like DNA", "PROBLEM", 0, 32], ["stiff polymer", "OBSERVATION_MODIFIER", 10, 23]]], ["Using modified deoxyribonucleotides in PCR reactions, more rigid DNA fragments have been produced and used as substrates for topoisomerase II-mediated relaxation of plectonemes introduced in single molecules using magnetic tweezers.", [["deoxyribonucleotides", "SIMPLE_CHEMICAL", 15, 35], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["topoisomerase II", "GENE_OR_GENE_PRODUCT", 125, 141], ["plectonemes", "SIMPLE_CHEMICAL", 165, 176], ["DNA fragments", "DNA", 65, 78], ["topoisomerase II", "PROTEIN", 125, 141], ["plectonemes", "PROTEIN", 165, 176], ["modified deoxyribonucleotides in PCR reactions", "TREATMENT", 6, 52], ["more rigid DNA fragments", "PROBLEM", 54, 78], ["topoisomerase II-mediated relaxation of plectonemes", "TREATMENT", 125, 176], ["magnetic tweezers", "TREATMENT", 214, 231]]], ["Before relaxation the persistence lengths were measured by fitting force extension data with the worm-like chain model.", [["fitting force extension data", "TEST", 59, 87], ["persistence", "OBSERVATION_MODIFIER", 22, 33], ["lengths", "OBSERVATION_MODIFIER", 34, 41]]], ["Topoisomerase II was found to release mechanically introduced supercoils more slowly in stiffer DNA suggesting that DNA bending might be a rate limiting step in topoisomerase II activity.In-vitro assembly of Polyoma VP1H.", [["Topoisomerase II", "GENE_OR_GENE_PRODUCT", 0, 16], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["topoisomerase II", "GENE_OR_GENE_PRODUCT", 161, 177], ["Polyoma VP1H", "GENE_OR_GENE_PRODUCT", 208, 220], ["Topoisomerase II", "PROTEIN", 0, 16], ["topoisomerase II", "PROTEIN", 161, 177], ["Polyoma VP1H", "PROTEIN", 208, 220], ["Topoisomerase II", "TREATMENT", 0, 16], ["stiffer DNA", "PROBLEM", 88, 99], ["DNA bending", "PROBLEM", 116, 127], ["Polyoma VP1H", "PROBLEM", 208, 220], ["stiffer DNA", "OBSERVATION_MODIFIER", 88, 99], ["DNA bending", "OBSERVATION", 116, 127], ["Polyoma VP1H", "OBSERVATION", 208, 220]]], ["Seidel 1 , T. Klose 2 , H. Lilie 2 , C. G. H\u00fcbner 1 1 Institute of Physics, Ratzeburger Allee 160, 23538 L\u00fcbeck, Germany, 2 Institute of Biochemistry and Biotechnology, Kurt-Mothes-Str.", [["Ratzeburger Allee 160, 23538", "CHEMICAL", 76, 104]]], ["3, 06120 Halle, GermanyIn-vitro assembly of Polyoma VP1One essential element of a virus is its protein shell, the viral capsid, which encloses the viral genome.", [["3, 06120", "CHEMICAL", 0, 8], ["Polyoma VP1", "ORGANISM", 44, 55], ["Polyoma VP1", "PROTEIN", 44, 55], ["viral capsid", "PROTEIN", 114, 126], ["viral genome", "DNA", 147, 159], ["Polyoma VP1", "SPECIES", 44, 55], ["GermanyIn", "TREATMENT", 16, 25], ["Polyoma VP1", "PROBLEM", 44, 55], ["a virus", "PROBLEM", 80, 87], ["the viral capsid", "PROBLEM", 110, 126], ["Polyoma VP1", "OBSERVATION", 44, 55], ["essential", "OBSERVATION_MODIFIER", 59, 68], ["element", "OBSERVATION_MODIFIER", 69, 76], ["virus", "OBSERVATION", 82, 87], ["protein shell", "OBSERVATION_MODIFIER", 95, 108], ["viral capsid", "OBSERVATION", 114, 126], ["viral genome", "OBSERVATION", 147, 159]]], ["The murine Polyomavirus is a non-enveloped DNA tumor virus with an icosahedral T=7d structure.", [["tumor", "ANATOMY", 47, 52], ["tumor", "DISEASE", 47, 52], ["murine", "ORGANISM", 4, 10], ["DNA tumor", "CANCER", 43, 52], ["murine", "SPECIES", 4, 10], ["a non-enveloped DNA tumor virus", "PROBLEM", 27, 58], ["Polyomavirus", "OBSERVATION", 11, 23], ["non-enveloped", "OBSERVATION_MODIFIER", 29, 42], ["DNA", "OBSERVATION_MODIFIER", 43, 46], ["tumor virus", "OBSERVATION", 47, 58], ["icosahedral", "OBSERVATION_MODIFIER", 67, 78]]], ["The assembly reaction of Polyoma VP1 does not show the typical sigmoidal kinetics in light scattering experiments.", [["Polyoma VP1", "ORGANISM", 25, 36], ["Polyoma VP1", "PROBLEM", 25, 36], ["Polyoma VP1", "OBSERVATION", 25, 36], ["typical", "OBSERVATION_MODIFIER", 55, 62], ["sigmoidal kinetics", "OBSERVATION", 63, 81], ["scattering experiments", "OBSERVATION", 91, 113]]], ["The apparent kinetics is of fourth order, which appears rather unrealistic.", [["kinetics", "OBSERVATION_MODIFIER", 13, 21], ["appears rather", "UNCERTAINTY", 48, 62], ["unrealistic", "OBSERVATION", 63, 74]]], ["In order to gain knowledge on capsid composition during assembly beyond ensemble average, we apply methods of single molecule fluorescence, namely fluorescence correlation spectroscopy (FCS), fluorescence-intensity-distribution-analysis (FIDA), and single-particle-imaging (SPI).", [["single molecule fluorescence", "TEST", 110, 138], ["fluorescence correlation spectroscopy", "TEST", 147, 184]]], ["The molecular brightness and the diffusion time reported by FCS are in agreement with the results from light scattering.", [["The molecular brightness", "PROBLEM", 0, 24], ["the diffusion time", "TEST", 29, 47], ["molecular brightness", "OBSERVATION", 4, 24]]], ["FIDA as well as SPI, moreover, point to a polymerization of subunits to complete capsids along the assembly pathway without pronounced intermediates.", [["FIDA", "SIMPLE_CHEMICAL", 0, 4], ["FIDA", "PROTEIN", 0, 4], ["SPI", "PROTEIN", 16, 19], ["a polymerization of subunits", "TREATMENT", 40, 68], ["complete capsids", "TREATMENT", 72, 88], ["pronounced intermediates", "PROBLEM", 124, 148]]], ["Mixing experiments show that already early in the course of the assembly reaction no exchange of pentamers between capsids occurs, and that the effect of Breathing [2] can be excluded for Polyoma VP1.", [["Polyoma VP1", "ORGANISM", 188, 199], ["Polyoma VP1", "PROTEIN", 188, 199], ["exchange of pentamers between capsids", "TREATMENT", 85, 122], ["Polyoma VP1", "PROBLEM", 188, 199]]], ["Genetic information coded in DNA provides complete instructions to cells regarding metabolism and proper functioning.", [["cells", "ANATOMY", 67, 72], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["cells", "CELL", 67, 72]]], ["A number of endogenous and exogenous sources can damage the genomic DNA.", [["DNA", "CELLULAR_COMPONENT", 68, 71], ["genomic DNA", "DNA", 60, 71], ["the genomic DNA", "PROBLEM", 56, 71], ["endogenous", "OBSERVATION_MODIFIER", 12, 22], ["exogenous sources", "OBSERVATION", 27, 44], ["genomic DNA", "OBSERVATION", 60, 71]]], ["Unrepaired DNA damage can give rise to mutations and may cause cell death.", [["cell", "ANATOMY", 63, 67], ["death", "DISEASE", 68, 73], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["cell", "CELL", 63, 67], ["Unrepaired DNA damage", "PROBLEM", 0, 21], ["mutations", "PROBLEM", 39, 48], ["cell death", "PROBLEM", 63, 73]]], ["Cells have evolved different mechanisms to repair damaged DNA and to protect genetic integrity.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["repair damaged DNA", "TREATMENT", 43, 61], ["repair", "OBSERVATION_MODIFIER", 43, 49], ["damaged DNA", "OBSERVATION", 50, 61]]], ["Uracil in DNA occurs as a result of incorporation of dUMP in the place of dTMP during replication and deamination of cytocine, resulting in U:A and U:G base pairs, respectively.", [["Uracil", "CHEMICAL", 0, 6], ["dUMP", "CHEMICAL", 53, 57], ["dTMP", "CHEMICAL", 74, 78], ["cytocine", "CHEMICAL", 117, 125], ["Uracil", "CHEMICAL", 0, 6], ["dUMP", "CHEMICAL", 53, 57], ["dTMP", "CHEMICAL", 74, 78], ["cytocine", "CHEMICAL", 117, 125], ["Uracil", "SIMPLE_CHEMICAL", 0, 6], ["DNA", "CELLULAR_COMPONENT", 10, 13], ["dUMP", "SIMPLE_CHEMICAL", 53, 57], ["dTMP", "SIMPLE_CHEMICAL", 74, 78], ["cytocine", "SIMPLE_CHEMICAL", 117, 125], ["U:A", "GENE_OR_GENE_PRODUCT", 140, 143], ["U:G", "GENE_OR_GENE_PRODUCT", 148, 151], ["Uracil in DNA", "PROBLEM", 0, 13], ["incorporation of dUMP", "PROBLEM", 36, 57], ["dTMP", "PROBLEM", 74, 78], ["DNA", "OBSERVATION", 10, 13], ["dUMP", "OBSERVATION", 53, 57], ["dTMP", "OBSERVATION", 74, 78]]], ["Uracil-DNA glycosylase (UNG) is a DNA repair protein that searches and removes uracil from DNA.", [["Uracil", "CHEMICAL", 0, 6], ["uracil", "CHEMICAL", 79, 85], ["Uracil", "CHEMICAL", 0, 6], ["uracil", "CHEMICAL", 79, 85], ["Uracil-DNA glycosylase", "GENE_OR_GENE_PRODUCT", 0, 22], ["UNG", "GENE_OR_GENE_PRODUCT", 24, 27], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["uracil", "SIMPLE_CHEMICAL", 79, 85], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["Uracil-DNA glycosylase", "PROTEIN", 0, 22], ["UNG", "PROTEIN", 24, 27], ["DNA repair protein", "PROTEIN", 34, 52], ["Uracil", "TEST", 0, 6], ["DNA glycosylase (UNG)", "TREATMENT", 7, 28], ["a DNA repair protein", "TREATMENT", 32, 52], ["uracil from DNA", "PROBLEM", 79, 94]]], ["UNG removes mismatched base by flipping it out from the base stack into the active site.", [["UNG", "CHEMICAL", 0, 3], ["UNG", "PROTEIN", 0, 3], ["active site", "DNA", 76, 87], ["mismatched", "OBSERVATION_MODIFIER", 12, 22], ["base", "OBSERVATION_MODIFIER", 23, 27], ["base", "ANATOMY_MODIFIER", 56, 60], ["active site", "OBSERVATION", 76, 87]]], ["The exact mechanism by which UNG searches DNA for uracil is unknown.", [["uracil", "CHEMICAL", 50, 56], ["uracil", "CHEMICAL", 50, 56], ["UNG", "GENE_OR_GENE_PRODUCT", 29, 32], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["uracil", "SIMPLE_CHEMICAL", 50, 56], ["UNG", "PROTEIN", 29, 32]]], ["Therefore, in our study we use Atomic Force Microscopy (AFM) to investigate the interaction between single UNG molecules with DNA carrying the U:A or U:G mismatches.", [["UNG", "GENE_OR_GENE_PRODUCT", 107, 110], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["U:A", "GENE_OR_GENE_PRODUCT", 143, 146], ["U:G", "GENE_OR_GENE_PRODUCT", 150, 153], ["UNG molecules", "PROTEIN", 107, 120], ["our study", "TEST", 14, 23], ["Atomic Force Microscopy", "TEST", 31, 54], ["G mismatches", "PROBLEM", 152, 164], ["mismatches", "OBSERVATION", 154, 164]]], ["Furthermore, we study the complexation of DNA and UNG protein.", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["UNG protein", "GENE_OR_GENE_PRODUCT", 50, 61], ["UNG protein", "PROTEIN", 50, 61], ["DNA and UNG protein", "TEST", 42, 61]]], ["AFM images of UNG bound to DNA reveal the structural changes at the level of single complex, e.g. DNA kinking that may occur upon binding of UNG to DNA.", [["UNG", "GENE_OR_GENE_PRODUCT", 14, 17], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["UNG", "GENE_OR_GENE_PRODUCT", 141, 144], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["UNG", "PROTEIN", 14, 17], ["UNG", "PROTEIN", 141, 144], ["AFM images", "TEST", 0, 10], ["UNG bound", "PROBLEM", 14, 23], ["the structural changes", "PROBLEM", 38, 60], ["single complex", "PROBLEM", 77, 91], ["DNA kinking", "PROBLEM", 98, 109], ["UNG to DNA", "PROBLEM", 141, 151], ["DNA kinking", "OBSERVATION", 98, 109]]], ["Imaging of DNAprotein complexes can provide a a new level of understanding of UNG-DNA interaction.", [["DNAprotein", "GENE_OR_GENE_PRODUCT", 11, 21], ["UNG", "GENE_OR_GENE_PRODUCT", 78, 81], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["DNAprotein complexes", "PROTEIN", 11, 31], ["UNG", "PROTEIN", 78, 81], ["Imaging of DNAprotein complexes", "TEST", 0, 31]]], ["Atomic Force Microscopy (AFM) has been a useful device to visualize cellular and molecular structures at a single-molecule resolution.", [["cellular", "ANATOMY", 68, 76], ["cellular", "CELL", 68, 76], ["Atomic Force Microscopy", "TEST", 0, 23], ["a useful device", "TREATMENT", 39, 54]]], ["Especially, AFM imaging under the TREC T M (Topography and RECognition) mode (recognition imaging) can map a specific protein of interest within an AFM image.", [["AFM imaging", "TEST", 12, 23], ["recognition imaging", "TEST", 78, 97], ["an AFM image", "TEST", 145, 157]]], ["In this study, we employed an antibody-coupled AFM cantilever in recognition imaging, and dissected the structural/functional domains of \u03b1 Actinin-4, an actin binding protein that cross-bridges actin filaments and anchors it to Integrin via tailin-vinculin-\u03b1 actinin adaptor-interaction.", [["filaments", "ANATOMY", 200, 209], ["\u03b1 Actinin-4", "GENE_OR_GENE_PRODUCT", 137, 148], ["actin", "GENE_OR_GENE_PRODUCT", 153, 158], ["actin", "GENE_OR_GENE_PRODUCT", 194, 199], ["Integrin", "GENE_OR_GENE_PRODUCT", 228, 236], ["tailin", "GENE_OR_GENE_PRODUCT", 241, 247], ["vinculin", "GENE_OR_GENE_PRODUCT", 248, 256], ["actinin", "GENE_OR_GENE_PRODUCT", 259, 266], ["\u03b1 Actinin-4", "PROTEIN", 137, 148], ["actin binding protein", "PROTEIN", 153, 174], ["actin", "PROTEIN", 194, 199], ["Integrin", "PROTEIN", 228, 236], ["tailin", "PROTEIN", 241, 247], ["vinculin", "PROTEIN", 248, 256], ["\u03b1 actinin adaptor", "PROTEIN", 257, 274], ["this study", "TEST", 3, 13], ["an antibody", "TEST", 27, 38], ["recognition imaging", "TEST", 65, 84], ["\u03b1 Actinin", "TREATMENT", 137, 146], ["an actin binding protein", "TREATMENT", 150, 174], ["bridges actin filaments and anchors", "TREATMENT", 186, 221], ["Integrin via tailin", "TREATMENT", 228, 247], ["vinculin-\u03b1 actinin adaptor", "TREATMENT", 248, 274]]], ["A use of monoclonal anti-\u03b1 actinin-4 antibody enabled us to map its epitope in the amino-terminal actin-binding domain within a single molecule AFM image of \u03b1 Actinin-4.P-318Counting fluorescent molecules by photonantibunching H. Ta, M. Schwering, D. P. Herten BioQuant, Heidelberg University, Germany Information on the stoichiometry of labelled biomolecules is highly desirable.", [["amino-terminal", "CHEMICAL", 83, 97], ["amino", "CHEMICAL", 83, 88], ["anti-\u03b1 actinin-4", "GENE_OR_GENE_PRODUCT", 20, 36], ["actin", "GENE_OR_GENE_PRODUCT", 98, 103], ["monoclonal anti-\u03b1 actinin-4 antibody", "PROTEIN", 9, 45], ["amino-terminal actin-binding domain", "PROTEIN", 83, 118], ["\u03b1 Actinin-4.P-318Counting fluorescent molecules", "PROTEIN", 157, 204], ["monoclonal anti-\u03b1 actinin-4 antibody", "TREATMENT", 9, 45], ["Actinin", "TEST", 159, 166]]], ["A method called photo-antibunching has successfully been used to determine the number of fluorescence emitters in multichromophoric systems.", [["A method called photo", "TREATMENT", 0, 21], ["antibunching", "TREATMENT", 22, 34]]], ["A statistical model to estimate the number of fluorescent molecules in a confocal observation volume is established based on photonantibunching in Time-Correlated Single-Photon Counting (TCSPC) scheme with 4 Avalanche Photon Diodes (APDs) for detection of individual photons.", [["fluorescent molecules", "PROTEIN", 46, 67], ["a confocal observation volume", "TEST", 71, 100], ["Single-Photon Counting (TCSPC) scheme", "TREATMENT", 163, 200], ["4 Avalanche Photon Diodes (APDs", "TREATMENT", 206, 237], ["individual photons", "TREATMENT", 256, 274]]], ["Numerical simulations based on realistic experimental conditions show that the model is able to estimate the number of molecules with moderate errors.", [["Numerical simulations", "TEST", 0, 21], ["moderate errors", "PROBLEM", 134, 149], ["moderate", "OBSERVATION_MODIFIER", 134, 142]]], ["Experiments on immobilized double-strand DNA oligonucleotides with photon stabilizing agents show promising results even when the number of molecules is \u223c 20.", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["immobilized double-strand DNA oligonucleotides", "TREATMENT", 15, 61], ["photon stabilizing agents", "TREATMENT", 67, 92]]], ["The proposed method allows us to monitor labelled single molecules and in the near future we plan to implement it in complex biological systems (cell extracts/live cells).P-317Single molecule AFM force spectroscopy and steered molecular dynamics of contactin-4 protein J. W. Strzelecki, K. Mikulska, A. Balter, W. Nowak Institute of Physics, Nicolaus Copernicus University, Grudziadzka 5, 87-100 Torun, PolandP-317Contactin-4 (CNTN4) is an axonal cell adhesion protein that contains six IgC2 and four FnIII domains and is responsible for creating neural outgrowths.", [["cell extracts", "ANATOMY", 145, 158], ["cells", "ANATOMY", 164, 169], ["axonal cell", "ANATOMY", 440, 451], ["neural outgrowths", "ANATOMY", 547, 564], ["cell extracts", "CELL", 145, 158], ["cells", "CELL", 164, 169], ["PolandP-317Contactin-4", "GENE_OR_GENE_PRODUCT", 403, 425], ["CNTN4", "GENE_OR_GENE_PRODUCT", 427, 432], ["axonal cell", "CELL", 440, 451], ["IgC2", "GENE_OR_GENE_PRODUCT", 487, 491], ["FnIII", "GENE_OR_GENE_PRODUCT", 501, 506], ["neural outgrowths", "TISSUE", 547, 564], ["axonal cell adhesion protein", "PROTEIN", 440, 468], ["IgC2", "PROTEIN", 487, 491], ["FnIII domains", "PROTEIN", 501, 514], ["cell extracts/live cells", "TREATMENT", 145, 169], ["force spectroscopy", "TEST", 196, 214], ["Grudziadzka", "TEST", 374, 385], ["PolandP", "TEST", 403, 410], ["an axonal cell adhesion protein", "PROBLEM", 437, 468], ["creating neural outgrowths", "PROBLEM", 538, 564], ["axonal cell", "OBSERVATION", 440, 451], ["adhesion protein", "OBSERVATION", 452, 468], ["responsible for", "UNCERTAINTY", 522, 537], ["neural outgrowths", "OBSERVATION", 547, 564]]], ["Recent research shows that mutation of CNTN4 gene may be responsible for autism, while its absence in transgenic mice results in lack of smell sense.", [["autism", "DISEASE", 73, 79], ["CNTN4", "GENE_OR_GENE_PRODUCT", 39, 44], ["mice", "ORGANISM", 113, 117], ["CNTN4 gene", "DNA", 39, 49], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["Recent research", "TEST", 0, 15], ["mutation of CNTN4 gene", "PROBLEM", 27, 49], ["autism", "PROBLEM", 73, 79]]], ["We use a homemade AFM single molecule puller and steered molecular dynamics simulation to test its elastic properties through force spectroscopy.", [["a homemade AFM single molecule puller", "TREATMENT", 7, 44], ["force spectroscopy", "TEST", 126, 144]]], ["Stretching experiments show unfolding of FnIII domains while IgC2 domains stay coiled as they are stabilized by disulfide bonds.", [["disulfide", "CHEMICAL", 112, 121], ["FnIII", "GENE_OR_GENE_PRODUCT", 41, 46], ["FnIII domains", "PROTEIN", 41, 54], ["IgC2 domains", "PROTEIN", 61, 73], ["Stretching experiments", "TEST", 0, 22], ["unfolding of FnIII domains", "PROBLEM", 28, 54], ["unfolding", "OBSERVATION_MODIFIER", 28, 37]]], ["Unfolding of Contactin-4 molecule appears to play role of buffer that helps to protect neural contacts from damage when neural cells are subjected to shock or tumor.", [["neural contacts", "ANATOMY", 87, 102], ["neural cells", "ANATOMY", 120, 132], ["tumor", "ANATOMY", 159, 164], ["shock", "DISEASE", 150, 155], ["tumor", "DISEASE", 159, 164], ["Contactin-4", "GENE_OR_GENE_PRODUCT", 13, 24], ["neural cells", "CELL", 120, 132], ["tumor", "CANCER", 159, 164], ["Contactin-4 molecule", "PROTEIN", 13, 33], ["neural cells", "CELL_TYPE", 120, 132], ["Unfolding of Contactin", "PROBLEM", 0, 22], ["neural cells", "PROBLEM", 120, 132], ["shock", "PROBLEM", 150, 155], ["tumor", "PROBLEM", 159, 164], ["tumor", "OBSERVATION", 159, 164]]], ["Single molecule studies of the thermophilic Bacillus PS3 F 1 -ATPase have revealed kinetic and structural information that cannot be discerned using other methods, including the presence of 40 and 80 degree physical substeps (Yasuda et al. 2001 ) and the order and kinetics of chemical substeps.", [["PS3 F 1 -ATPase", "GENE_OR_GENE_PRODUCT", 53, 68], ["thermophilic Bacillus PS3 F 1 -ATPase", "PROTEIN", 31, 68], ["Single molecule studies", "TEST", 0, 23], ["the thermophilic Bacillus PS3 F", "TEST", 27, 58], ["chemical substeps", "TREATMENT", 277, 294], ["kinetic", "OBSERVATION", 83, 90]]], ["We are interested in using single molecule techniques to observe the effects of mgi mutations on enzyme kinetics and torque production in F 1 from the yeast Saccharomyces cerevisiae.", [["mgi", "GENE_OR_GENE_PRODUCT", 80, 83], ["F 1", "GENE_OR_GENE_PRODUCT", 138, 141], ["yeast Saccharomyces cerevisiae", "ORGANISM", 151, 181], ["yeast", "SPECIES", 151, 156], ["Saccharomyces cerevisiae", "SPECIES", 157, 181], ["F 1", "SPECIES", 138, 141], ["yeast", "SPECIES", 151, 156], ["Saccharomyces cerevisiae", "SPECIES", 157, 181], ["single molecule techniques", "TREATMENT", 27, 53], ["mgi mutations", "PROBLEM", 80, 93], ["enzyme kinetics", "TEST", 97, 112], ["Saccharomyces cerevisiae", "OBSERVATION", 157, 181]]], ["Using a high speed imaging camera, we have captured the rotation of wild-type and mutant forms of yeast F 1 -ATPase.", [["yeast F 1 -ATPase", "GENE_OR_GENE_PRODUCT", 98, 115], ["yeast F 1 -ATPase", "PROTEIN", 98, 115], ["yeast", "SPECIES", 98, 103], ["yeast", "SPECIES", 98, 103], ["a high speed imaging camera", "TEST", 6, 33], ["yeast F", "TEST", 98, 105]]], ["Rotation data for the wild-type and preliminary data for some mgi strains will be presented.", [["mgi", "GENE_OR_GENE_PRODUCT", 62, 65], ["Rotation data", "TEST", 0, 13], ["preliminary data", "TEST", 36, 52], ["some mgi strains", "PROBLEM", 57, 73]]], ["We show for the first time that at saturating ATP, wild-type yeast F 1 rotates approximately four times faster than the thermophilic F 1 .", [["ATP", "CHEMICAL", 46, 49], ["ATP", "CHEMICAL", 46, 49], ["ATP", "SIMPLE_CHEMICAL", 46, 49], ["F 1", "GENE_OR_GENE_PRODUCT", 133, 136], ["thermophilic F 1", "PROTEIN", 120, 136], ["yeast", "SPECIES", 61, 66], ["yeast", "SPECIES", 61, 66], ["saturating ATP", "PROBLEM", 35, 49]]], ["Kinetic and substepping behaviour in yeast appears to be similar to that observed in bacterial F 1 .P-315-Single molecule biophysics -123Biophysical characterization of a DNA Gquadruplex formed in the promoter of human MEF2D gene W. Zhou 1 , L. Ying 2 1 Molecular Medicine, National Heart and Lung Institute, Imperial College London, London, SW7 2AZ, UK, 2 Chemical Biology Center, Imperial College London, SW7 2AZ, UK G-quadruplex is believed to be involved in many crucial biological processes, such as the gene regulation and the maintenance of human telomere.", [["Lung", "ANATOMY", 293, 297], ["telomere", "ANATOMY", 554, 562], ["F 1 .P-315", "CHEMICAL", 95, 105], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["human", "ORGANISM", 213, 218], ["Lung", "ORGAN", 293, 297], ["UK", "GENE_OR_GENE_PRODUCT", 416, 418], ["human", "ORGANISM", 548, 553], ["telomere", "CELLULAR_COMPONENT", 554, 562], ["DNA Gquadruplex", "DNA", 171, 186], ["promoter", "DNA", 201, 209], ["human MEF2D gene", "DNA", 213, 229], ["yeast", "SPECIES", 37, 42], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 548, 553], ["yeast", "SPECIES", 37, 42], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 548, 553], ["Kinetic and substepping behaviour in yeast", "PROBLEM", 0, 42], ["Single molecule biophysics", "TEST", 106, 132], ["a DNA Gquadruplex", "PROBLEM", 169, 186], ["the gene regulation", "TREATMENT", 505, 524], ["Heart", "ANATOMY", 283, 288], ["Lung", "ANATOMY", 293, 297], ["human telomere", "OBSERVATION", 548, 562]]], ["MEF2D, a member of MEF2 (myocyte enhancer factor-2) family of transcription factors, regulates the response of heart to cardiac stress signals.", [["heart", "ANATOMY", 111, 116], ["cardiac", "ANATOMY", 120, 127], ["MEF2D", "GENE_OR_GENE_PRODUCT", 0, 5], ["MEF2", "GENE_OR_GENE_PRODUCT", 19, 23], ["myocyte enhancer factor-2", "GENE_OR_GENE_PRODUCT", 25, 50], ["heart", "ORGAN", 111, 116], ["cardiac", "ORGAN", 120, 127], ["MEF2D", "PROTEIN", 0, 5], ["MEF2 (myocyte enhancer factor-2) family", "PROTEIN", 19, 58], ["transcription factors", "PROTEIN", 62, 83], ["MEF2 (myocyte enhancer factor", "TREATMENT", 19, 48], ["transcription factors", "TREATMENT", 62, 83], ["cardiac stress signals", "TEST", 120, 142], ["heart", "ANATOMY", 111, 116]]], ["We found that a G-rich sequence starting at -145bp of MEF2D promoter can form a very stable intramolecular G-quadruplex.", [["MEF2D", "GENE_OR_GENE_PRODUCT", 54, 59], ["G-quadruplex", "SIMPLE_CHEMICAL", 107, 119], ["G-rich sequence", "DNA", 16, 31], ["MEF2D promoter", "DNA", 54, 68], ["intramolecular G-quadruplex", "PROTEIN", 92, 119], ["a G-rich sequence", "PROBLEM", 14, 31], ["bp of MEF2D promoter", "TREATMENT", 48, 68]]], ["Here we present a detailed biophysical characterization of this quadruplex.", [["this quadruplex", "TREATMENT", 59, 74]]], ["We also found that this quadruplex is more stable than its duplex form under physiological conditions by CD melting and single molecular FRET.", [["this quadruplex", "PROBLEM", 19, 34], ["quadruplex", "OBSERVATION", 24, 34], ["more", "OBSERVATION_MODIFIER", 38, 42], ["stable", "OBSERVATION_MODIFIER", 43, 49]]], ["We observed subpopulations in smFRET measurements possibly due to different conformations of the quadruplex.", [["smFRET", "PROTEIN", 30, 36], ["smFRET measurements", "TEST", 30, 49], ["the quadruplex", "TREATMENT", 93, 107], ["subpopulations", "OBSERVATION_MODIFIER", 12, 26]]], ["We characterized its unfolding process by monitoring the change in FRET when it hybridizes to its C-rich complimentary strand.", [["C", "CHEMICAL", 98, 99], ["C-rich complimentary strand", "DNA", 98, 125], ["its unfolding process", "PROBLEM", 17, 38], ["the change in FRET", "PROBLEM", 53, 71], ["unfolding", "OBSERVATION_MODIFIER", 21, 30]]], ["Finally, we proposed several possible structures of this quadruplex based on the smFRET and fluorescence DMS footprinting results.", [["smFRET", "SIMPLE_CHEMICAL", 81, 87], ["this quadruplex", "TREATMENT", 52, 67]]], ["This research is supported by National Heart and Lung Institute Foundation.", [["Lung", "ANATOMY", 49, 53], ["Heart", "ANATOMY", 39, 44], ["Lung", "ANATOMY", 49, 53]]], ["By stretching a polymer in solution using single molecule techniques it is possible to infer about its physical properties.", [["stretching a polymer in solution", "TREATMENT", 3, 35], ["single molecule techniques", "TREATMENT", 42, 68]]], ["AFM stretching experiments allow for a full characterization of the elasto-mechanical properties of the sample under study.", [["AFM stretching experiments", "TEST", 0, 26], ["a full characterization", "TEST", 37, 60], ["the sample under study", "TEST", 100, 122]]], ["In the presented work, single molecule AFM force spectroscopy experiments were used to determine mechanical properties of a peptide obtained from Exon 28 (Ex28) of the human elastin gene.", [["Exon 28", "GENE_OR_GENE_PRODUCT", 146, 153], ["Ex28", "GENE_OR_GENE_PRODUCT", 155, 159], ["human", "ORGANISM", 168, 173], ["elastin", "GENE_OR_GENE_PRODUCT", 174, 181], ["Exon 28", "DNA", 146, 153], ["human elastin gene", "DNA", 168, 186], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["single molecule AFM force spectroscopy experiments", "TEST", 23, 73], ["a peptide", "TEST", 122, 131], ["Exon", "TEST", 146, 150], ["the human elastin gene", "TREATMENT", 164, 186], ["human elastin", "OBSERVATION", 168, 181]]], ["Elastin is a protein with important mechanical properties and, in particular, it shows quasi ideal elastic behavior associated to the presence of many hydrophobic unstructured domains (such as Ex28) into the protein structure.", [["Elastin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Ex28", "GENE_OR_GENE_PRODUCT", 193, 197], ["Elastin", "PROTEIN", 0, 7], ["hydrophobic unstructured domains", "PROTEIN", 151, 183], ["Ex28", "PROTEIN", 193, 197], ["protein structure", "PROTEIN", 208, 225], ["quasi ideal elastic behavior", "PROBLEM", 87, 115], ["many hydrophobic unstructured domains", "PROBLEM", 146, 183], ["mechanical properties", "OBSERVATION_MODIFIER", 36, 57], ["elastic behavior", "OBSERVATION", 99, 115], ["many", "OBSERVATION_MODIFIER", 146, 150], ["hydrophobic", "OBSERVATION_MODIFIER", 151, 162]]], ["Ex28 coded polymer was used as a starting point to obtain bio-materials with specialized elastomechanical functions.", [["Ex28", "SIMPLE_CHEMICAL", 0, 4], ["Ex28", "PROTEIN", 0, 4]]], ["In particular, a mutated polypeptide based on the EX28 sequence was synthesisized with the aim of obtaining a new polymer with the same mechanical and physical properties of the native molecule but with increased aggregation properties, induced by a cross-linking reaction.", [["EX28 sequence", "DNA", 50, 63], ["a mutated polypeptide", "PROBLEM", 15, 36], ["the EX28 sequence", "TEST", 46, 63], ["a new polymer", "TREATMENT", 108, 121], ["increased aggregation properties", "PROBLEM", 203, 235], ["a cross-linking reaction", "PROBLEM", 248, 272], ["native molecule", "OBSERVATION", 178, 193], ["increased", "OBSERVATION_MODIFIER", 203, 212], ["aggregation properties", "OBSERVATION", 213, 235]]], ["AFM stretching experiments were used to verify the mechanical properties of the engineered proteins at a single molecule level.", [["engineered proteins", "PROTEIN", 80, 99], ["AFM stretching experiments", "TEST", 0, 26]]], ["The obtained results allowed not only to address this question, but also to give some insight into the first aggregation steps of the polymer towards the formation of reticulated structures.", [["reticulated structures", "OBSERVATION", 167, 189]]], ["Luminescent lanthanide-ion doped nanoparticles (NPs) are attractive single-biomolecule labels.", [["NPs", "CHEMICAL", 48, 51], ["lanthanide", "CHEMICAL", 12, 22], ["lanthanide-ion doped nanoparticles", "SIMPLE_CHEMICAL", 12, 46], ["NPs", "SIMPLE_CHEMICAL", 48, 51], ["Luminescent lanthanide-ion doped nanoparticles (NPs", "TREATMENT", 0, 51]]], ["They are synthesized directly in water, are highly photostable, and display narrow emission without intermittency.", [["water", "SIMPLE_CHEMICAL", 33, 38]]], ["We coupled Y 0.6 Eu 0.4 VO 4 NPs to \u03b5-toxins produced by Clostridium perfringens, which bind to a specific receptor on MDCK cells.", [["MDCK cells", "ANATOMY", 119, 129], ["Eu", "CHEMICAL", 17, 19], ["Eu", "CHEMICAL", 17, 19], ["VO 4", "CHEMICAL", 24, 28], ["\u03b5-toxins", "CHEMICAL", 36, 44], ["\u03b5-toxins", "SIMPLE_CHEMICAL", 36, 44], ["Clostridium perfringens", "ORGANISM", 57, 80], ["MDCK cells", "CELL", 119, 129], ["MDCK cells", "CELL_LINE", 119, 129], ["Clostridium perfringens", "SPECIES", 57, 80], ["Clostridium perfringens", "SPECIES", 57, 80], ["Clostridium perfringens", "PROBLEM", 57, 80]]], ["Single-molecule tracking experiments using these labels produce long (5 min) uninterrupted trajectories with temporal resolution down to 20 ms or localization precision down to 15 nm.", [["localization precision", "TEST", 146, 168], ["15 nm", "OBSERVATION_MODIFIER", 177, 182]]], ["We found that the toxin receptor exhibits confined motion in cell membrane microdomains.", [["cell membrane microdomains", "ANATOMY", 61, 87], ["toxin receptor", "GENE_OR_GENE_PRODUCT", 18, 32], ["cell membrane microdomains", "CELLULAR_COMPONENT", 61, 87], ["toxin receptor", "PROTEIN", 18, 32], ["the toxin receptor", "TEST", 14, 32], ["confined motion", "OBSERVATION", 42, 57], ["cell membrane microdomains", "OBSERVATION", 61, 87]]], ["To analyze the receptor trajectories, we used a novel approach based on an inference method [1] .", [["a novel approach", "TREATMENT", 46, 62]]], ["From the shape of the confining potential, obtained by mapping the forces inside the domain, we can deduce information about the mechanism of confinement.", [["shape", "OBSERVATION_MODIFIER", 9, 14]]], ["In combination with experiments on cholesterol depletion and cytoskeleton destruction, this technique will shed light into the nature of the membrane micropatterning.", [["cytoskeleton", "ANATOMY", 61, 73], ["membrane", "ANATOMY", 141, 149], ["cholesterol", "CHEMICAL", 35, 46], ["cholesterol", "CHEMICAL", 35, 46], ["cholesterol", "SIMPLE_CHEMICAL", 35, 46], ["cytoskeleton", "CELLULAR_COMPONENT", 61, 73], ["membrane", "CELLULAR_COMPONENT", 141, 149], ["cholesterol depletion", "TREATMENT", 35, 56], ["cytoskeleton destruction", "PROBLEM", 61, 85], ["this technique", "TREATMENT", 87, 101], ["the membrane micropatterning", "TREATMENT", 137, 165], ["cholesterol depletion", "OBSERVATION", 35, 56], ["cytoskeleton destruction", "OBSERVATION", 61, 85], ["membrane micropatterning", "OBSERVATION", 141, 165]]], ["Background: Implantable cardioverter defibrillators (ICDs) are save-life device for patients at risk of sudden cardiac death, and help cardiac patients to avoid slow beat-rate by means of anti-bradichardia pacing (ABP) feature.", [["cardiac", "ANATOMY", 111, 118], ["cardiac", "ANATOMY", 135, 142], ["sudden cardiac death", "DISEASE", 104, 124], ["patients", "ORGANISM", 84, 92], ["cardiac", "ORGAN", 111, 118], ["patients", "ORGANISM", 143, 151], ["anti-bradichardia", "SIMPLE_CHEMICAL", 188, 205], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 143, 151], ["Implantable cardioverter defibrillators", "TREATMENT", 12, 51], ["ICDs)", "TREATMENT", 53, 58], ["save-life device", "TREATMENT", 63, 79], ["sudden cardiac death", "PROBLEM", 104, 124], ["slow beat", "PROBLEM", 161, 170], ["anti-bradichardia pacing", "TREATMENT", 188, 212], ["Implantable", "OBSERVATION", 12, 23], ["cardioverter defibrillators", "OBSERVATION", 24, 51], ["cardiac", "ANATOMY", 111, 118], ["death", "OBSERVATION", 119, 124]]], ["However, recent literature evidenced the presence of ventricular tachyarrhythmias (VTs) immediately following ABP, leading to the hypothesis that ICD devices might be pro-arrhythmic.", [["ventricular", "ANATOMY", 53, 64], ["ventricular tachyarrhythmias", "DISEASE", 53, 81], ["VTs", "DISEASE", 83, 86], ["ventricular", "MULTI-TISSUE_STRUCTURE", 53, 64], ["ventricular tachyarrhythmias", "PROBLEM", 53, 81], ["ABP", "TEST", 110, 113], ["the hypothesis", "PROBLEM", 126, 140], ["ICD devices", "TREATMENT", 146, 157], ["pro-arrhythmic", "PROBLEM", 167, 181], ["ventricular", "ANATOMY", 53, 64], ["tachyarrhythmias", "OBSERVATION", 65, 81], ["ICD", "OBSERVATION", 146, 149]]], ["Aim: Study differences between pacing-associated tachyarrhythmias (PAT) and other spontaneous VTs.", [["tachyarrhythmias", "DISEASE", 49, 65], ["VTs", "DISEASE", 94, 97], ["pacing", "TREATMENT", 31, 37], ["tachyarrhythmias", "PROBLEM", 49, 65], ["other spontaneous VTs", "PROBLEM", 76, 97], ["tachyarrhythmias", "OBSERVATION", 49, 65]]], ["Signals and methods: 165 spontaneous VT episodes are retrieved from 37 patients with ICD.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["spontaneous VT episodes", "PROBLEM", 25, 48], ["ICD", "TREATMENT", 85, 88], ["ICD", "OBSERVATION", 85, 88]]], ["VTs are examined and PAT episodes, classified.", [["VTs", "PROBLEM", 0, 3], ["PAT episodes", "PROBLEM", 21, 33]]], ["Characterization of VTs is based on the analysis of 20 seconds immediately preceding VT-onset quantified by: heart cycle (HC-PreVT), prevalence of premature ventricular contraction (PVCprev) and prevalence of paced beats (Pprev).", [["heart", "ANATOMY", 109, 114], ["ventricular", "ANATOMY", 157, 168], ["premature ventricular contraction", "DISEASE", 147, 180], ["heart", "ORGAN", 109, 114], ["ventricular", "MULTI-TISSUE_STRUCTURE", 157, 168], ["VTs", "PROBLEM", 20, 23], ["the analysis", "TEST", 36, 48], ["VT", "TEST", 85, 87], ["heart cycle", "TEST", 109, 120], ["HC", "TEST", 122, 124], ["premature ventricular contraction", "PROBLEM", 147, 180], ["paced beats", "PROBLEM", 209, 220], ["VTs", "OBSERVATION", 20, 23], ["heart", "ANATOMY", 109, 114], ["premature ventricular contraction", "OBSERVATION", 147, 180], ["paced beats", "OBSERVATION", 209, 220]]], ["Significant differences are evaluated by Student-T or Chi-square tests with p<0.05.", [["Chi-square tests", "TEST", 54, 70]]], ["Results: 20 VT episodes from 8 patients are PAT episodes (12%).", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["20 VT episodes", "PROBLEM", 9, 23], ["PAT episodes", "PROBLEM", 44, 56]]], ["Cardiac activity preceding PATs vs. non-PATs differs: PAT episodes have higher HC-PreVT (p<0.01), greater Pprev (p<0.001), and greater PVCprev (p<0.001).", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac", "ORGAN", 0, 7], ["PAT episodes", "PROBLEM", 54, 66], ["higher HC", "PROBLEM", 72, 81]]], ["Analysis also shows that PAT episode often occur when the paced beat immediately follows a premature contraction.", [["Analysis", "TEST", 0, 8], ["PAT episode", "PROBLEM", 25, 36], ["the paced beat", "TREATMENT", 54, 68], ["a premature contraction", "PROBLEM", 89, 112]]], ["Conclusion: The study indicates that new ICD generations should avoid ABP after premature ventricular contraction.P-325Towards mechanistical understanding of adsorption: combining technologies in situ and in real time P. H. Bj\u00f6\u00f6rn Q-Sense AB, V\u00e4stra Frolunda, Sweden A growing number of researchers in different surface related fields present evidence from more than one analytical technique when detailing their findings.", [["ventricular", "ANATOMY", 90, 101], ["surface", "ANATOMY", 312, 319], ["premature ventricular contraction", "DISEASE", 80, 113], ["ABP", "GENE_OR_GENE_PRODUCT", 70, 73], ["ventricular", "MULTI-TISSUE_STRUCTURE", 90, 101], ["The study", "TEST", 12, 21], ["new ICD generations", "TREATMENT", 37, 56], ["ABP", "TEST", 70, 73], ["premature ventricular contraction", "PROBLEM", 80, 113], ["combining technologies", "TREATMENT", 170, 192], ["new", "OBSERVATION_MODIFIER", 37, 40], ["ICD", "OBSERVATION", 41, 44], ["ventricular contraction", "OBSERVATION", 90, 113], ["growing", "OBSERVATION_MODIFIER", 269, 276], ["number", "OBSERVATION_MODIFIER", 277, 283]]], ["Thus a logic and useful development is to combine technologies for simultaneous measurements on a single sensor surface.", [["simultaneous measurements", "TEST", 67, 92], ["a single sensor surface", "TREATMENT", 96, 119]]], ["To develop a biosensor platform such as an assay fast and accurately, mechanistical understanding of why the platform works is essential.", [["a biosensor platform", "TEST", 11, 31], ["an assay", "TEST", 40, 48]]], ["Quartz Crystal Microbalance-with Dissipation (QCM-D) technology and instrumentation provides an open platform and enable easy and precise quantification of mass, thickness and viscoelastic properties of surface bound molecules.", [["surface", "ANATOMY", 203, 210], ["surface bound molecules", "PROTEIN", 203, 226], ["Quartz Crystal Microbalance", "TEST", 0, 27], ["Dissipation (QCM-D) technology", "TREATMENT", 33, 63], ["instrumentation", "TREATMENT", 68, 83], ["an open platform", "TREATMENT", 93, 109], ["mass", "PROBLEM", 156, 160], ["mass", "OBSERVATION", 156, 160], ["viscoelastic properties", "OBSERVATION", 176, 199], ["surface", "OBSERVATION_MODIFIER", 203, 210], ["bound molecules", "OBSERVATION", 211, 226]]], ["These parameters provide both a reference tool in assay development, but also detecting and identifying your target molecules as the combination of mass and material property info in many cases provide a unique response for a specific molecule.", [["your target molecules", "PROBLEM", 104, 125], ["mass", "PROBLEM", 148, 152], ["mass", "OBSERVATION", 148, 152]]], ["Recent advances will be presented where simultaneous real time and in situ measurements using QCM-D together with electrochemistry, ellipsometry and fluorescence microscopy enables manipulation of films as well as quantification of the variation of water content as a result of conformational changes in immobilized molecules.", [["water", "SIMPLE_CHEMICAL", 249, 254], ["immobilized molecules", "PROTEIN", 304, 325], ["ellipsometry", "TEST", 132, 144], ["fluorescence microscopy", "TEST", 149, 172], ["manipulation of films", "TEST", 181, 202], ["the variation of water content", "PROBLEM", 232, 262], ["conformational changes in immobilized molecules", "PROBLEM", 278, 325], ["water content", "OBSERVATION", 249, 262], ["immobilized molecules", "OBSERVATION", 304, 325]]], ["Examples will include new data from the formation of protein films, polyelectrolyte multilayers and polymer brushes.O-324Intrinsic gravity versus metabolically inert infrastructure and basal metabolic rate in living mass I. R. Bhattacharjee 1 , R. Kashyap 2 , B. Shaptadvipa 2 1 Assam Agricultural University, Jorhat-785013, India, 2 International Institute of Intrinsic Gravitation Biology (i3GB), Jorhat-785013, India 'Self gravitation bio' is an emerging concept in biophysics.", [["O-324Intrinsic", "CHEMICAL", 116, 130], ["Jorhat-785013", "CHEMICAL", 310, 323], ["Jorhat-785013", "CHEMICAL", 399, 412], ["polyelectrolyte multilayers", "SIMPLE_CHEMICAL", 68, 95], ["new data", "TEST", 22, 30], ["protein films", "TEST", 53, 66], ["polyelectrolyte multilayers and polymer brushes", "TREATMENT", 68, 115], ["metabolically inert infrastructure", "PROBLEM", 146, 180], ["basal metabolic rate in living mass", "PROBLEM", 185, 220], ["Jorhat", "TEST", 310, 316], ["Jorhat", "TEST", 399, 405], ["polymer brushes", "OBSERVATION", 100, 115], ["basal", "ANATOMY_MODIFIER", 185, 190], ["metabolic rate", "OBSERVATION", 191, 205]]], ["Intrinsic or 'self' gravitational force might exert when mass increases beyond critical level in biological particle pyramid. (http://en.wikipedia.org/wiki/Biomechanics of intrinsic gravity) 'Metabolically inert infrastructure' (MII) consists of total body mass (body water, dissolved substances, mineral and organic deposits) and serves as storage of nutrients, transport and distribution of these materials.", [["body", "ANATOMY", 252, 256], ["body", "ANATOMY", 263, 267], ["body", "ORGANISM_SUBDIVISION", 252, 256], ["body", "ORGANISM_SUBDIVISION", 263, 267], ["mineral", "SIMPLE_CHEMICAL", 297, 304], ["Intrinsic or 'self' gravitational force", "PROBLEM", 0, 39], ["mass", "PROBLEM", 57, 61], ["total body mass", "PROBLEM", 246, 261], ["dissolved substances", "TREATMENT", 275, 295], ["mineral and organic deposits", "TREATMENT", 297, 325], ["mass", "OBSERVATION", 57, 61], ["particle pyramid", "OBSERVATION", 108, 124], ["total", "OBSERVATION_MODIFIER", 246, 251], ["body", "ANATOMY_MODIFIER", 252, 256], ["mass", "OBSERVATION", 257, 261], ["organic deposits", "OBSERVATION", 309, 325]]], ["To act independently as living body, MII is suggested also to provide structural support to the organism with density-gradient buoyant force against intrinsic and extrinsic gravitational attraction for the biological mass.", [["body", "ANATOMY", 31, 35], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["structural support", "TREATMENT", 70, 88], ["density-gradient buoyant force", "TREATMENT", 110, 140], ["intrinsic and extrinsic gravitational attraction", "PROBLEM", 149, 197], ["the biological mass", "PROBLEM", 202, 221], ["gradient buoyant", "OBSERVATION_MODIFIER", 118, 134], ["gravitational attraction", "OBSERVATION", 173, 197], ["mass", "OBSERVATION", 217, 221]]], ["It is shown that 'amniotic fluid', 'isotonic saline to ailing patient', 'growth factors', 'cultural medium' and other 'medium matrices' act as counter-gravity mechanism for micro to macro living organisms under center-of-biomass reference frame.", [["amniotic fluid", "ANATOMY", 18, 32], ["amniotic fluid", "ORGANISM_SUBSTANCE", 18, 32], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["'amniotic fluid'", "TREATMENT", 17, 33], ["'isotonic saline", "TREATMENT", 35, 51], ["'cultural medium'", "TREATMENT", 90, 107], ["other 'medium matrices", "TREATMENT", 112, 134]]], ["Controversy over relationship between BMR (basal metabolic rate), RMR (resting metabolic rate), PAL (physical activity level), on one hand, and mass of the living organism, on the other, (as described in Rubner's 2/3 law, Kleiber's 3/4 law that continued to be contested by many) can be favorably resolved substituting the concept of self gravitation bio, considering 'mass' as synonym of gravitational force under center-of-biomass reference frame.", [["PAL", "PROTEIN", 96, 99], ["BMR", "TEST", 38, 41], ["basal metabolic rate", "TEST", 43, 63], ["RMR", "TEST", 66, 69], ["resting metabolic rate", "TEST", 71, 93], ["PAL (physical activity level", "TEST", 96, 124], ["self gravitation bio", "TREATMENT", 334, 354], ["'mass'", "PROBLEM", 368, 374], ["mass", "OBSERVATION", 144, 148], ["gravitational force", "OBSERVATION_MODIFIER", 389, 408]]], ["Bioenergetics would be an unequal but opposite entity of self-gravity reinforced by extrinsic gravity.", [["an unequal", "PROBLEM", 23, 33], ["unequal", "OBSERVATION", 26, 33]]], ["Platelet arrest on von Willebrand factor (VWF) occurs transiently via the platelet receptor GPIb.", [["Platelet", "ANATOMY", 0, 8], ["platelet", "ANATOMY", 74, 82], ["Platelet arrest", "DISEASE", 0, 15], ["Platelet", "CELL", 0, 8], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 19, 40], ["VWF", "GENE_OR_GENE_PRODUCT", 42, 45], ["platelet receptor GPIb", "GENE_OR_GENE_PRODUCT", 74, 96], ["von Willebrand factor", "PROTEIN", 19, 40], ["VWF", "PROTEIN", 42, 45], ["platelet receptor GPIb", "PROTEIN", 74, 96], ["Platelet arrest", "PROBLEM", 0, 15], ["the platelet receptor GPIb", "TREATMENT", 70, 96], ["arrest", "OBSERVATION", 9, 15]]], ["Depending on the combination of shear stress and surface density of VWF binding sites the platelets either only adhere, pull tethers or generate microparticles.", [["surface", "ANATOMY", 49, 56], ["platelets", "ANATOMY", 90, 99], ["VWF", "GENE_OR_GENE_PRODUCT", 68, 71], ["platelets", "CELL", 90, 99], ["VWF binding sites", "PROTEIN", 68, 85], ["platelets", "CELL_TYPE", 90, 99], ["shear stress", "PROBLEM", 32, 44], ["VWF binding sites", "PROBLEM", 68, 85], ["surface", "OBSERVATION_MODIFIER", 49, 56], ["density", "OBSERVATION", 57, 64]]], ["These processes are influenced by the properties of the platelet membrane and the cytoskeleton.", [["platelet membrane", "ANATOMY", 56, 73], ["cytoskeleton", "ANATOMY", 82, 94], ["platelet membrane", "CELLULAR_COMPONENT", 56, 73], ["cytoskeleton", "CELLULAR_COMPONENT", 82, 94], ["platelet membrane", "OBSERVATION", 56, 73], ["cytoskeleton", "OBSERVATION_MODIFIER", 82, 94]]], ["Under shear flow conditions these platelet characteristics were examined with reflection interference contrast microscopy and a viscosimeter.", [["platelet", "ANATOMY", 34, 42], ["platelet", "CELL", 34, 42], ["these platelet characteristics", "TEST", 28, 58], ["reflection interference contrast microscopy", "TEST", 78, 121], ["shear flow", "OBSERVATION", 6, 16]]], ["In addition we quantified platelet adhesion energy and tether pulling forces.", [["platelet", "ANATOMY", 26, 34], ["platelet", "CELL", 26, 34], ["platelet adhesion energy", "TREATMENT", 26, 50], ["tether pulling forces", "TREATMENT", 55, 76], ["platelet adhesion energy", "OBSERVATION", 26, 50]]], ["Disrupting platelet F-actin had several effects.", [["platelet", "ANATOMY", 11, 19], ["platelet F-actin", "GENE_OR_GENE_PRODUCT", 11, 27], ["platelet F-actin", "PROTEIN", 11, 27], ["Disrupting platelet F-actin", "TREATMENT", 0, 27], ["platelet F-actin", "OBSERVATION", 11, 27], ["several", "OBSERVATION_MODIFIER", 32, 39], ["effects", "OBSERVATION_MODIFIER", 40, 47]]], ["The tethers were shorter, the membrane contact area was larger, the receptor \u03b1IIb\u03b23 density of the microparticles was depleted and no platelet spreading occurred.", [["membrane contact area", "ANATOMY", 30, 51], ["microparticles", "ANATOMY", 99, 113], ["platelet", "ANATOMY", 134, 142], ["membrane", "CELLULAR_COMPONENT", 30, 38], ["\u03b1IIb\u03b23", "GENE_OR_GENE_PRODUCT", 77, 83], ["platelet", "CELL", 134, 142], ["platelet spreading", "PROBLEM", 134, 152], ["shorter", "OBSERVATION_MODIFIER", 17, 24], ["larger", "OBSERVATION_MODIFIER", 56, 62], ["microparticles", "OBSERVATION_MODIFIER", 99, 113], ["no", "UNCERTAINTY", 131, 133], ["platelet spreading", "OBSERVATION", 134, 152]]], ["Breaking up the microtubular system had different implications.", [["microtubular system", "ANATOMY", 16, 35], ["microtubular system", "ANATOMY", 16, 35], ["different", "OBSERVATION_MODIFIER", 40, 49], ["implications", "OBSERVATION", 50, 62]]], ["The number of severed tethers tripled, the contact area was smaller, microparticle formation was increased and the area of spread platelets was reduced.", [["microparticle", "ANATOMY", 69, 82], ["platelets", "ANATOMY", 130, 139], ["microparticle", "CELLULAR_COMPONENT", 69, 82], ["platelets", "CELL", 130, 139], ["platelets", "CELL_TYPE", 130, 139], ["severed tethers", "PROBLEM", 14, 29], ["microparticle formation", "PROBLEM", 69, 92], ["spread platelets", "PROBLEM", 123, 139], ["severed", "OBSERVATION_MODIFIER", 14, 21], ["tethers", "OBSERVATION_MODIFIER", 22, 29], ["tripled", "OBSERVATION_MODIFIER", 30, 37], ["smaller", "OBSERVATION_MODIFIER", 60, 67], ["microparticle formation", "OBSERVATION", 69, 92], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["area", "OBSERVATION_MODIFIER", 115, 119], ["spread platelets", "OBSERVATION", 123, 139], ["reduced", "OBSERVATION_MODIFIER", 144, 151]]], ["However changes in the membrane elasticity had no effect on the platelets.", [["membrane", "ANATOMY", 23, 31], ["platelets", "ANATOMY", 64, 73], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["platelets", "CELL", 64, 73], ["platelets", "CELL_TYPE", 64, 73], ["changes in the membrane elasticity", "PROBLEM", 8, 42], ["the platelets", "TEST", 60, 73], ["membrane elasticity", "OBSERVATION", 23, 42], ["no", "UNCERTAINTY", 47, 49], ["effect", "OBSERVATION_MODIFIER", 50, 56]]], ["Our results suggest that platelet attachment and adhesion is not only determined by the platelet adhesion receptors and their cytoplasmic linker proteins, but that cytoskeletal structures have also a crucial influence on how platelets interact with thrombogenic surfaces.", [["platelet", "ANATOMY", 25, 33], ["platelet", "ANATOMY", 88, 96], ["cytoplasmic", "ANATOMY", 126, 137], ["cytoskeletal structures", "ANATOMY", 164, 187], ["platelets", "ANATOMY", 225, 234], ["platelet", "CELL", 25, 33], ["platelet adhesion receptors", "GENE_OR_GENE_PRODUCT", 88, 115], ["cytoplasmic", "ORGANISM_SUBSTANCE", 126, 137], ["cytoskeletal structures", "CELLULAR_COMPONENT", 164, 187], ["platelets", "CELL", 225, 234], ["platelet adhesion receptors", "PROTEIN", 88, 115], ["cytoplasmic linker proteins", "PROTEIN", 126, 153], ["platelets", "CELL_TYPE", 225, 234], ["platelet attachment", "PROBLEM", 25, 44], ["adhesion", "PROBLEM", 49, 57], ["the platelet adhesion receptors", "TEST", 84, 115], ["their cytoplasmic linker proteins", "PROBLEM", 120, 153], ["platelet attachment", "OBSERVATION", 25, 44], ["cytoplasmic linker", "OBSERVATION", 126, 144], ["thrombogenic", "OBSERVATION_MODIFIER", 249, 261], ["surfaces", "OBSERVATION_MODIFIER", 262, 270]]], ["Gene expression is orchestrated by a host of regulatory proteins that coordinate the transcription of DNA to RNA.", [["DNA", "CELLULAR_COMPONENT", 102, 105], ["regulatory proteins", "PROTEIN", 45, 64], ["RNA", "RNA", 109, 112]]], ["Regulatory proteins function by locating specific binding sequences of DNA and binding to these sequences to form the transcription initiation complex.", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["Regulatory proteins", "PROTEIN", 0, 19], ["binding sequences", "DNA", 50, 67], ["transcription initiation complex", "PROTEIN", 118, 150], ["DNA", "PROBLEM", 71, 74], ["these sequences", "TEST", 90, 105]]], ["In many instances, these regulatory proteins only have several hundred copies that must efficiently locate target sequences on the genome-length DNA strand.", [["DNA", "CELLULAR_COMPONENT", 145, 148], ["regulatory proteins", "PROTEIN", 25, 44], ["genome-length DNA strand", "DNA", 131, 155]]], ["The non-specific binding of regulatory proteins to random sequences of DNA is believed to permit the protein to slide along the DNA in a stochastic manner.", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["regulatory proteins", "PROTEIN", 28, 47], ["The non-specific binding of regulatory proteins to random sequences of DNA", "PROBLEM", 0, 74], ["non-specific", "OBSERVATION_MODIFIER", 4, 16]]], ["Periodically, a thermal kick or an interaction with another bound protein will disengage the regulatory protein from the DNA surface, leading to three-dimensional diffusion.", [["surface", "ANATOMY", 125, 132], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["surface", "CELLULAR_COMPONENT", 125, 132], ["regulatory protein", "PROTEIN", 93, 111], ["a thermal kick", "PROBLEM", 14, 28], ["another bound protein", "PROBLEM", 52, 73]]], ["Eventually, the protein will reattach to the DNA at some new location that is dictated by both the diffusivity of the protein and the DNA configuration.", [["DNA", "CELLULAR_COMPONENT", 45, 48], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["the DNA", "PROBLEM", 41, 48], ["DNA configuration", "OBSERVATION", 134, 151]]], ["Cycling through these random events constitutes a search strategy for the target site.", [["target site", "DNA", 74, 85], ["a search strategy", "TREATMENT", 48, 65], ["the target site", "PROBLEM", 70, 85]]], ["We build a reaction-diffusion theory of this search process in order to predict the optimal strategy for target site localization.", [["a reaction", "PROBLEM", 9, 19]]], ["The statistical behavior of the DNA strand acts as a necessary input into the theory, and we consider several governing behaviors for the DNA strand.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["DNA strand", "DNA", 32, 42], ["the DNA strand", "PROBLEM", 134, 148]]], ["We explore the impact of DNA configuration and protein occlusion on target site localization in order to predict how protein expression will vary under different experimental conditions.Dynamics of a minimal neural model consisting of an astrocyte, a neuron and an interneuronA.", [["neural", "ANATOMY", 208, 214], ["astrocyte", "ANATOMY", 238, 247], ["neuron", "ANATOMY", 251, 257], ["interneuronA", "ANATOMY", 265, 277], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["astrocyte", "CELL", 238, 247], ["neuron", "CELL", 251, 257], ["astrocyte", "CELL_TYPE", 238, 247], ["DNA configuration", "PROBLEM", 25, 42], ["protein occlusion", "PROBLEM", 47, 64], ["a minimal neural model", "PROBLEM", 198, 220], ["an astrocyte", "PROBLEM", 235, 247], ["DNA configuration", "OBSERVATION", 25, 42], ["protein occlusion", "OBSERVATION", 47, 64], ["minimal neural model", "OBSERVATION", 200, 220], ["astrocyte", "OBSERVATION", 238, 247]]], ["Di Garbo 1 , S. Alloisio 2 , S. Chillemi 1 , M. Nobile 2 1 Istituto di Biofisica CNR, Via G. Moruzzi 1, 56124 Pisa, Italy, 2 Istituto di Biofisica CNR, Via De Marini 6, 16149 Genova, Italy In the nervous system of vertebrates there are more glial cells than neurons: from 10 to 50 times, depending on the animal type.", [["nervous system", "ANATOMY", 196, 210], ["glial cells", "ANATOMY", 241, 252], ["neurons", "ANATOMY", 258, 265], ["nervous system", "ANATOMICAL_SYSTEM", 196, 210], ["glial cells", "CELL", 241, 252], ["neurons", "CELL", 258, 265], ["glial cells", "CELL_TYPE", 241, 252], ["neurons", "CELL_TYPE", 258, 265], ["more", "OBSERVATION_MODIFIER", 236, 240], ["glial cells", "OBSERVATION", 241, 252]]], ["Glial cells are not able to generate action potentials but, nevertheless they play an important role for the functioning of the different brain's area.", [["Glial cells", "ANATOMY", 0, 11], ["brain", "ANATOMY", 138, 143], ["Glial cells", "CELL", 0, 11], ["brain", "ORGAN", 138, 143], ["Glial cells", "CELL_TYPE", 0, 11], ["Glial cells", "PROBLEM", 0, 11], ["brain", "ANATOMY", 138, 143]]], ["The astrocytes are the more abundant cells of the macroglia and through their processes they modulate synaptic activity.", [["astrocytes", "ANATOMY", 4, 14], ["cells", "ANATOMY", 37, 42], ["macroglia", "ANATOMY", 50, 59], ["synaptic", "ANATOMY", 102, 110], ["astrocytes", "CELL", 4, 14], ["cells", "CELL", 37, 42], ["macroglia", "CELL", 50, 59], ["astrocytes", "CELL_TYPE", 4, 14], ["macroglia", "CELL_TYPE", 50, 59], ["astrocytes", "ANATOMY", 4, 14], ["more", "OBSERVATION_MODIFIER", 23, 27], ["abundant cells", "OBSERVATION", 28, 42], ["macroglia", "ANATOMY", 50, 59], ["synaptic activity", "OBSERVATION", 102, 119]]], ["In this contribution a biophysical neural network model consisting of a pyramidal neuron, an interneuron and the astrocyte is studied.", [["neural network", "ANATOMY", 35, 49], ["pyramidal neuron", "ANATOMY", 72, 88], ["interneuron", "ANATOMY", 93, 104], ["astrocyte", "ANATOMY", 113, 122], ["neural network", "MULTI-TISSUE_STRUCTURE", 35, 49], ["pyramidal neuron", "CELL", 72, 88], ["interneuron", "CELL", 93, 104], ["astrocyte", "CELL", 113, 122], ["astrocyte", "CELL_TYPE", 113, 122], ["astrocyte", "ANATOMY", 113, 122]]], ["The corresponding dynamical properties are mainly investigated by using numerical simulations.", [["numerical simulations", "TEST", 72, 93], ["dynamical properties", "OBSERVATION", 18, 38]]], ["The results show that the presence of the ATP and of the interneuron strongly impacts the neural activity.", [["interneuron", "ANATOMY", 57, 68], ["neural", "ANATOMY", 90, 96], ["ATP", "CHEMICAL", 42, 45], ["ATP", "CHEMICAL", 42, 45], ["ATP", "SIMPLE_CHEMICAL", 42, 45], ["interneuron", "CELL", 57, 68], ["the ATP", "PROBLEM", 38, 45], ["neural activity", "OBSERVATION", 90, 105]]], ["Moreover, it is shown that the fluxes of calcium through the cellular membrane strongly affect the modulation of the neural activity arising from the astrocyte.P-328Microscopic origin of the very-low energy vibrational dynamics in proteins G. D'Angelo 1 , V. Conti Nibali 1 , C. Crupi 1 , A. Paciaroni 2 , U. Wanderlingh 1 1 Department of Physics, Faculty of Science, Messina University, Italy, 2 Department of Physics, Faculty of Science, Perugia University, Italy Important functions of biological processes require large atomic rearrangements and conformational fluctuations.", [["cellular membrane", "ANATOMY", 61, 78], ["neural", "ANATOMY", 117, 123], ["astrocyte", "ANATOMY", 150, 159], ["calcium", "CHEMICAL", 41, 48], ["calcium", "CHEMICAL", 41, 48], ["calcium", "SIMPLE_CHEMICAL", 41, 48], ["cellular membrane", "CELLULAR_COMPONENT", 61, 78], ["astrocyte", "CELL", 150, 159], ["astrocyte", "CELL_TYPE", 150, 159], ["P", "DNA", 160, 161], ["the fluxes of calcium", "PROBLEM", 27, 48], ["P", "TEST", 160, 161], ["large atomic rearrangements", "TREATMENT", 518, 545], ["cellular membrane", "OBSERVATION", 61, 78], ["neural activity", "OBSERVATION", 117, 132], ["astrocyte", "ANATOMY", 150, 159], ["large", "OBSERVATION_MODIFIER", 518, 523], ["atomic rearrangements", "OBSERVATION", 524, 545]]], ["For proteins, atoms are mostly displaced along the soft directions identified by the delocalized, low frequency vibrations.", [["proteins", "PROBLEM", 4, 12], ["the delocalized, low frequency vibrations", "PROBLEM", 81, 122], ["atoms", "OBSERVATION_MODIFIER", 14, 19], ["mostly", "OBSERVATION_MODIFIER", 24, 30], ["displaced", "OBSERVATION", 31, 40], ["soft directions", "OBSERVATION_MODIFIER", 51, 66], ["delocalized", "OBSERVATION_MODIFIER", 85, 96], ["low frequency vibrations", "OBSERVATION_MODIFIER", 98, 122]]], ["The study of very low energy vibrational spectrum of proteins is therefore of particular interest.", [["The study", "TEST", 0, 9], ["very low energy vibrational spectrum of proteins", "PROBLEM", 13, 61]]], ["As a step toward understanding their functional role, we have investigated the low frequency vibrational motions (0.03\u00f710 meV) in different proteins by performing inelastic neutron scattering and low temperature (1.5\u00f730 K) specific heat measurements.", [["inelastic neutron scattering", "TREATMENT", 163, 191], ["low temperature", "TEST", 196, 211], ["specific heat measurements", "TEST", 223, 249], ["low temperature", "OBSERVATION_MODIFIER", 196, 211]]], ["For the first time for biological systems, the well-known Boson peak found in neutron scattering spectra at \u223c 3 meV is put in relationship with a clear anomaly of the measured specific heat located at around 7 K. This departure from the Debye-like behavior further expands the analogy of proteins with glassy systems.", [["a clear anomaly", "PROBLEM", 144, 159], ["anomaly", "OBSERVATION", 152, 159]]], ["Quite interestingly, in the very low sub-meV energy range and below \u223c3K, we observe an additional anomalous behaviour, which could be ascribed to the existence of twolevel-systems states.", [["an additional anomalous behaviour", "PROBLEM", 84, 117]]], ["Increasing the hydration degree, the low energy vibrational region is drastically altered, revealing that the addition or removal of the hydrogen bond network around the protein deeply modifies the interatomic forces, affecting the character of the vibrational modes.Watching hemoglobin at work inside intact red blood cells by Time-Resolved Wide Angle X-Ray ScatteringA.", [["red blood cells", "ANATOMY", 309, 324], ["hydrogen", "CHEMICAL", 137, 145], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 276, 286], ["red blood cells", "CELL", 309, 324], ["hemoglobin", "PROTEIN", 276, 286], ["red blood cells", "CELL_TYPE", 309, 324], ["Time-Resolved Wide Angle X-Ray ScatteringA", "PROTEIN", 328, 370], ["Increasing the hydration degree", "PROBLEM", 0, 31], ["the low energy vibrational region", "PROBLEM", 33, 66], ["removal", "TREATMENT", 122, 129], ["the hydrogen bond network", "TREATMENT", 133, 158], ["red blood cells", "TEST", 309, 324], ["hydration degree", "OBSERVATION_MODIFIER", 15, 31], ["low energy", "OBSERVATION_MODIFIER", 37, 47], ["drastically", "OBSERVATION_MODIFIER", 70, 81], ["altered", "OBSERVATION", 82, 89], ["hydrogen bond", "OBSERVATION", 137, 150], ["interatomic forces", "OBSERVATION", 198, 216], ["vibrational modes", "OBSERVATION", 249, 266]]], ["Cupane 1 , M. Levantino 1 , M. Cammarata 2 , G. Schir\u00f2 1 1 Department of Physical and Astronomical Sciences, University of Palermo, Via Archirafi 36, I 90123 Palermo, Italy, 2 European Synchrotron Radiation Facility, Grenoble, France Our efforts in recent years have been to study in great detail the way hemoglobin works in confined geometries [1] [2] [3] .Watching hemoglobin at work inside intact red blood cells by Time-Resolved Wide Angle X-Ray ScatteringTo this aim we have contributed to the development of a new experimental technique, time-resolved wide-angle X-ray scattering (TR-WAXS), that enables one to watch proteins at work in solution [4, 5] .", [["red blood cells", "ANATOMY", 400, 415], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 305, 315], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 367, 377], ["red blood cells", "CELL", 400, 415], ["hemoglobin", "PROTEIN", 305, 315], ["hemoglobin", "PROTEIN", 367, 377], ["red blood cells", "CELL_TYPE", 400, 415], ["Cupane", "TREATMENT", 0, 6], ["red blood cells", "TEST", 400, 415], ["a new experimental technique", "PROBLEM", 514, 542], ["new", "OBSERVATION_MODIFIER", 516, 519]]], ["A very recent and challenging application of this technique is the study of hemoglobin functioning inside intact red blood cells (RBC).", [["red blood cells", "ANATOMY", 113, 128], ["RBC", "ANATOMY", 130, 133], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 76, 86], ["red blood cells", "CELL", 113, 128], ["RBC", "CELL", 130, 133], ["hemoglobin", "PROTEIN", 76, 86], ["red blood cells", "CELL_TYPE", 113, 128], ["RBC", "CELL_TYPE", 130, 133], ["this technique", "TREATMENT", 45, 59], ["the study", "TEST", 63, 72], ["red blood cells", "TEST", 113, 128], ["RBC", "TEST", 130, 133], ["blood cells", "OBSERVATION", 117, 128]]], ["Our preliminary results show that, by using laser pulses of about 150 ns, it is possible to photolyse hemoglobin inside RBCs obtaining about 40% -60% photolysis.", [["RBCs", "ANATOMY", 120, 124], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 102, 112], ["RBCs", "CELL", 120, 124], ["hemoglobin", "PROTEIN", 102, 112], ["RBCs", "CELL_TYPE", 120, 124], ["laser pulses", "TEST", 44, 56], ["ns", "TREATMENT", 70, 72]]], ["Good structural signals from hemoglobin are obtained, with limited radiation damage to the cells: this opens the possibility of studying the conformational transitions of hemoglobin in its \"natural\" environment.", [["cells", "ANATOMY", 91, 96], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 29, 39], ["cells", "CELL", 91, 96], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 171, 181], ["hemoglobin", "PROTEIN", 29, 39], ["hemoglobin", "PROTEIN", 171, 181], ["limited radiation damage to the cells", "PROBLEM", 59, 96], ["the conformational transitions of hemoglobin", "PROBLEM", 137, 181], ["structural signals", "OBSERVATION", 5, 23]]], ["Preliminary results concerning the timing of the R->T quaternary transition inside the RBC and comparison with the behaviour in dilute solution will be discussed.", [["RBC", "ANATOMY", 87, 90], ["RBC", "CELL", 87, 90], ["RBC", "CELL_TYPE", 87, 90], ["the R->T quaternary transition", "PROBLEM", 45, 75], ["dilute solution", "TREATMENT", 128, 143], ["quaternary transition", "OBSERVATION", 54, 75]]], ["Submissions must present significant new results in physics; topics may range from the microscopic to the macroscopic.", [["significant", "OBSERVATION_MODIFIER", 25, 36], ["new", "OBSERVATION_MODIFIER", 37, 40]]], ["All Physical Review journals may be accessed through the website http://publish.aps.org/.P-333Modeling of fibrin gels using confocal microscopy, light scattering and turbidimetry F. Ferri 1 , D. Magatti 1 , B. Cardinali 2 , A. Profumo 2 , M. Rocco 2 1 Dipartimento di Fisica e Matematica, Universit\u00e0 dell'Insubria, Como, Italy, 2 Istituto Nazionale per la Ricerca sul Cancro (IST), Genova, Italy Fibrin gels are biological networks playing a fundamental role in blood coagulation.", [["blood", "ANATOMY", 462, 467], ["blood coagulation", "DISEASE", 462, 479], ["fibrin", "GENE_OR_GENE_PRODUCT", 106, 112], ["blood", "ORGANISM_SUBSTANCE", 462, 467], ["fibrin gels", "TREATMENT", 106, 117], ["confocal microscopy", "TEST", 124, 143], ["light scattering", "TEST", 145, 161], ["turbidimetry", "TEST", 166, 178], ["Ferri", "TEST", 182, 187], ["la Ricerca sul Cancro (IST)", "TREATMENT", 353, 380], ["Genova", "TREATMENT", 382, 388], ["Italy Fibrin gels", "TREATMENT", 390, 407], ["blood coagulation", "TEST", 462, 479]]], ["Confocal microscopy of fibrin gels shows a collection of straight fibers, not uniformly distributed in space, connected together at low-order (3) (4) branching points.", [["fibers", "ANATOMY", 66, 72], ["fibrin", "GENE_OR_GENE_PRODUCT", 23, 29], ["fibers", "CELLULAR_COMPONENT", 66, 72], ["Confocal microscopy of fibrin gels", "TEST", 0, 34], ["a collection of straight fibers", "PROBLEM", 41, 72], ["fibrin gels", "OBSERVATION", 23, 34], ["collection", "OBSERVATION", 43, 53], ["straight fibers", "OBSERVATION_MODIFIER", 57, 72], ["not", "UNCERTAINTY", 74, 77], ["uniformly", "OBSERVATION_MODIFIER", 78, 87], ["distributed", "OBSERVATION_MODIFIER", 88, 99]]], ["Although each fiber is quite straight (mass fractal dimension D m =1), for the overall system D m >1.", [["straight", "OBSERVATION_MODIFIER", 29, 37]]], ["Based on the confocal images, we generated threedimensional (3D) synthetic gels made of cylindrical sticks of diameter d, joined together at randomly distributed nodal points.", [["nodal points", "MULTI-TISSUE_STRUCTURE", 162, 174], ["the confocal images", "TEST", 9, 28], ["threedimensional (3D) synthetic gels", "TREATMENT", 43, 79], ["cylindrical sticks of diameter d", "TREATMENT", 88, 120], ["diameter", "OBSERVATION_MODIFIER", 110, 118], ["nodal points", "OBSERVATION", 162, 174]]], ["The resulting 3D network is no more random but ordered on length scales of the order the average fiber length, and exhibits a fractal morphology with D m \u223c1.", [["3D network", "MULTI-TISSUE_STRUCTURE", 14, 24]]], ["The gel structure is analyzed by means of its 3D correlation function g 3D (r)= x , where n(x) is the gel local density.", [["local", "OBSERVATION_MODIFIER", 106, 111], ["density", "OBSERVATION", 112, 119]]], ["Since the gel is isotropic, g 3D depends on the modulus r=|r| and can be obtained by averaging 2D correlation functions evaluated at different heights of the gel volume.", [["the gel volume", "TEST", 154, 168]]], ["From this analysis we recover the fiber diameter d (FWHM of g 3D ), the fractal dimension D m (power-law decay of g 3D ) and the gel mesh-size \u03be (minimum in g 3D ).", [["fiber", "ANATOMY", 34, 39], ["g 3D", "PROTEIN", 114, 118], ["this analysis", "TEST", 5, 18], ["the gel mesh", "TREATMENT", 125, 137], ["fiber diameter", "OBSERVATION_MODIFIER", 34, 48], ["mesh", "OBSERVATION", 133, 137], ["size", "OBSERVATION_MODIFIER", 138, 142]]], ["Furthermore, the 3D-Fourier transform of g 3D (r) gives the gel power spectrum I(q), which compares quite well with elastic light and multi-wavelength turbidimetry data taken on real gels.O-332A model coupling vibrational and rotational motion for the DNA molecule E. Drigo Filho, J. R. Ruggiero, R. A. D. S. Silva UNESP -Sao Paulo State University, Brazil A largely used mechanical model for vibrational motion of DNA has been proposed by Peyrard and Bishop (PB).", [["O-332A", "CHEMICAL", 188, 194], ["DNA", "CELLULAR_COMPONENT", 252, 255], ["DNA", "CELLULAR_COMPONENT", 415, 418], ["g 3D (r)", "TREATMENT", 41, 49], ["the gel power spectrum I", "TREATMENT", 56, 80], ["multi-wavelength turbidimetry data", "TEST", 134, 168], ["mechanical model for vibrational motion of DNA", "TREATMENT", 372, 418], ["R.", "ANATOMY", 297, 299]]], ["In this model, DNA is represented by a pair of harmonic chains coupled by a nonlinear potential.", [["DNA", "CELLULAR_COMPONENT", 15, 18], ["harmonic chains", "PROTEIN", 47, 62], ["DNA", "PROBLEM", 15, 18], ["harmonic chains", "PROBLEM", 47, 62], ["DNA", "OBSERVATION", 15, 18], ["harmonic chains", "OBSERVATION", 47, 62]]], ["Some extensions of the original model are proposed considering, for example, the helicoidal structure of DNA.", [["DNA", "CELLULAR_COMPONENT", 105, 108], ["the helicoidal structure of DNA", "PROBLEM", 77, 108], ["helicoidal structure", "OBSERVATION", 81, 101], ["DNA", "OBSERVATION", 105, 108]]], ["An important objective for this kind of model is to understand the phenomenon of thermal denaturation and, through this, get some knowledge about other processes such as the genetic transcription and drug intercalation.", [["thermal denaturation", "PROBLEM", 81, 101], ["the genetic transcription", "TREATMENT", 170, 195], ["drug intercalation", "TREATMENT", 200, 218]]], ["It is possible to obtain from this type of model interesting properties, such as the average stretching between base pairs as a function of the temperature using the transfer integral operator.", [["the average stretching between base pairs", "PROBLEM", 81, 122], ["the transfer integral operator", "TREATMENT", 162, 192]]], ["In this work, we extend the original PB model by introducing rotational motions for the nucleotides.", [["nucleotides", "CHEMICAL", 88, 99], ["the original PB model", "TREATMENT", 24, 45], ["the nucleotides", "TREATMENT", 84, 99]]], ["In this way, both the vibrational and rotational motion for each nucleotide are considered.", [["nucleotide", "CHEMICAL", 65, 75], ["nucleotide", "CHEMICAL", 65, 75], ["each nucleotide", "TREATMENT", 60, 75]]], ["The stretch of the base pairs is given by the Morse potential in the same way as in the original PB model.", [["stretch", "OBSERVATION_MODIFIER", 4, 11], ["base", "ANATOMY_MODIFIER", 19, 23]]], ["However, the coupling between the two kinds of motion, rotation and vibration, is obtained through a nonlinear combination of them in the Morse potential.Maximum entropy production principle (MEPP) in generalized Michaelis-Menten kineticsA.", [["rotation and vibration", "TEST", 55, 77], ["Maximum entropy production principle", "TREATMENT", 154, 190], ["generalized Michaelis", "PROBLEM", 201, 222], ["Menten kineticsA", "TREATMENT", 223, 239], ["Morse potential", "OBSERVATION_MODIFIER", 138, 153]]], ["Dobovi\u0161ek 1 , M. Brumen 2 , P.\u017dupanovi\u0107 3 , D. Jureti\u0107 3 1 University of Maribor, Faculty of natural sciences and mathematics, Maribor, Slovenia, 2 Jo\u017eef Stefan Institute, Ljubljana, Slovenia, 3 Faculty of science, University of Split, Split, Croatia MEPP is a physical principle, widely used for quantitative explanation of non equilibrium phenomena in physics, chemistry and biology [1] [2] [3] .", [["P.\u017dupanovi\u0107 3", "CELL", 28, 41], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 385, 396], ["Dobovi\u0161ek", "TREATMENT", 0, 9], ["Maribor", "TREATMENT", 127, 134], ["non equilibrium phenomena", "PROBLEM", 325, 350]]], ["Here, we applied MEPP to study two and three state reversible Michaelis-Menten kinetic schemes of enzymatic reactions.", [["MEPP to study", "TEST", 17, 30], ["enzymatic reactions", "PROBLEM", 98, 117], ["reversible Michaelis", "OBSERVATION", 51, 71], ["enzymatic reactions", "OBSERVATION", 98, 117]]], ["By applying constraints as a diffusional limit for kinetic constants, constant free energy differences between enzymatic states and constant thermodynamic force, we calculated Shannon information entropy and entropy production of the entire reaction system as a function of forward rate constants.", [["kinetic constants", "PROBLEM", 51, 68], ["constant free energy differences between enzymatic states", "PROBLEM", 70, 127], ["entropy production of the entire reaction system", "PROBLEM", 208, 256]]], ["We found maxima in the net steady-state metabolic flux, total entropy production and Shannon entropy for equal values of forward rate constants.", [["total entropy production", "PROBLEM", 56, 80], ["Shannon entropy", "TEST", 85, 100], ["forward rate constants", "PROBLEM", 121, 143], ["maxima", "OBSERVATION_MODIFIER", 9, 15], ["metabolic flux", "OBSERVATION", 40, 54]]], ["Moreover, for these values an analytical expression derived gives a relation between substrate and product concentrations at which enzymes operate in the optimal way.", [["enzymes", "PROTEIN", 131, 138], ["these values", "TEST", 14, 26]]], ["In conclusion, we demonstrated that MEPP is an appropriate selection principle for evolutionary optimization of enzymes.", [["MEPP", "CHEMICAL", 36, 40], ["MEPP", "SIMPLE_CHEMICAL", 36, 40], ["enzymes", "PROTEIN", 112, 119], ["evolutionary optimization of enzymes", "TEST", 83, 119]]], ["Attractive interaction between like-charged lipid surfaces mediated by spherical nanoparticles with spatially distributed charge is theoretically described by using functional density theory and MC simulations.", [["spherical nanoparticles", "SIMPLE_CHEMICAL", 71, 94], ["Attractive interaction", "PROBLEM", 0, 22], ["charged lipid surfaces", "TREATMENT", 36, 58], ["spatially distributed charge", "PROBLEM", 100, 128], ["spherical nanoparticles", "OBSERVATION", 71, 94], ["spatially", "OBSERVATION_MODIFIER", 100, 109], ["distributed charge", "OBSERVATION", 110, 128]]], ["The spatial distribution of charge within a single nanoparticle is considered by two effective charges at a finite distance.", [["spatial", "OBSERVATION_MODIFIER", 4, 11], ["distribution", "OBSERVATION_MODIFIER", 12, 24], ["charge", "OBSERVATION", 28, 34]]], ["The minimization of the free energy is performed to obtain the equilibrium configuration of the system.", [["the free energy", "TEST", 20, 35]]], ["Both, the rigorous solution of the variational problem and the MC simulations show that orientational ordering of nanoparticles subject to the gradient of the electric field gives rise to an attractive interaction between charged lipid surfaces for high enough charge densities of the interacting surfaces and large enough separations between charges within the nanoparticle.", [["the variational problem", "TREATMENT", 31, 54], ["the MC simulations", "TEST", 59, 77], ["charged lipid surfaces", "TREATMENT", 222, 244], ["high enough charge densities", "PROBLEM", 249, 277], ["high enough", "OBSERVATION_MODIFIER", 249, 260], ["charge densities", "OBSERVATION", 261, 277], ["interacting surfaces", "OBSERVATION", 285, 305], ["large", "OBSERVATION_MODIFIER", 310, 315], ["enough", "OBSERVATION_MODIFIER", 316, 322], ["separations", "OBSERVATION_MODIFIER", 323, 334]]], ["Viral genomes encode for a series of membrane proteins which are embedded or attached to the lipid membrane of the host, or penetrate them during the very first step of viral invasion.", [["membrane", "ANATOMY", 37, 45], ["lipid membrane", "ANATOMY", 93, 107], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["lipid membrane", "CELLULAR_COMPONENT", 93, 107], ["Viral genomes", "DNA", 0, 13], ["membrane proteins", "PROTEIN", 37, 54], ["Viral genomes encode", "PROBLEM", 0, 20], ["membrane proteins", "PROBLEM", 37, 54], ["viral invasion", "PROBLEM", 169, 183], ["viral invasion", "OBSERVATION", 169, 183]]], ["We are focussing especially to those of the former which are known to assemble and from channels or pores for small ions or substrates.", [["small ions or substrates", "PROBLEM", 110, 134], ["small", "OBSERVATION_MODIFIER", 110, 115], ["ions", "OBSERVATION", 116, 120]]], ["With these channel forming proteins the virus manipulates the host cell interior for the benefit of its replication.", [["cell", "ANATOMY", 67, 71], ["host cell", "CELL", 62, 71], ["channel forming proteins", "PROTEIN", 11, 35], ["these channel forming proteins", "TREATMENT", 5, 35], ["the virus", "PROBLEM", 36, 45], ["its replication", "TREATMENT", 100, 115], ["virus", "OBSERVATION", 40, 45], ["host cell", "OBSERVATION", 62, 71]]], ["Strategies are developed to answer the question about the assembly process of these proteins based on the 'two stage model' and the substrate flux.", [["these proteins", "TREATMENT", 78, 92], ["the substrate flux", "PROBLEM", 128, 146]]], ["Only few experimental data are available to answer these questions, consequently we stress computational methods to derive the adequate answers.", [["few", "OBSERVATION_MODIFIER", 5, 8]]], ["The methods applied are ab inito molecular dynamics (MD) simulations based on density functional theory (DFT) and conventional MD simulations.", [["The methods", "TREATMENT", 0, 11]]], ["Potential routes for assembly of the three transmembrane domains of 3a protein from SARS-CoV will be outlined and compared with computational data from other viral membrane proteins.", [["transmembrane", "ANATOMY", 43, 56], ["membrane", "ANATOMY", 164, 172], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 84, 92], ["transmembrane domains", "PROTEIN", 43, 64], ["3a protein", "PROTEIN", 68, 78], ["viral membrane proteins", "PROTEIN", 158, 181], ["SARS-CoV", "SPECIES", 84, 92], ["SARS", "PROBLEM", 84, 88], ["CoV", "PROBLEM", 89, 92], ["computational data", "TEST", 128, 146], ["other viral membrane proteins", "PROBLEM", 152, 181]]], ["With a novel pore lining motif suggested for 3a, the dynamics of ions at selected positions within the putative pore will be assessed.P-336Probing the molecular mechanism of antibiotics diffusion through the OmpF channel E. Hajjar 1 , A. Kumar 1 , M. Winterhalter 2 , P. Ruggerone 1 , M. Ceccarelli 1 1 Department of Physics, University of Cagliari, Italy, 2 Jacobs University, Bremen, GermanyP-336In Gram-negative bacteria, the outer membrane porin-F (OmpF) is the preferred entry point of antibiotics.", [["pore lining", "ANATOMY", 13, 24], ["pore", "ANATOMY", 112, 116], ["outer membrane", "ANATOMY", 429, 443], ["P-336Probing", "CHEMICAL", 134, 146], ["pore", "CELLULAR_COMPONENT", 112, 116], ["outer membrane", "CELLULAR_COMPONENT", 429, 443], ["porin-F", "GENE_OR_GENE_PRODUCT", 444, 451], ["OmpF", "GENE_OR_GENE_PRODUCT", 453, 457], ["outer membrane porin", "PROTEIN", 429, 449], ["F", "PROTEIN", 450, 451], ["OmpF", "PROTEIN", 453, 457], ["a novel pore lining motif", "TREATMENT", 5, 30], ["P", "TEST", 134, 135], ["antibiotics diffusion", "TREATMENT", 174, 195], ["Bremen", "TEST", 378, 384], ["GermanyP", "TEST", 386, 394], ["Gram", "TEST", 401, 405], ["the outer membrane porin", "TREATMENT", 425, 449], ["antibiotics", "TREATMENT", 491, 502], ["negative bacteria", "OBSERVATION", 406, 423]]], ["Bacteria can resist to antibiotics by altering the expression and the structures of OmpF.", [["Bacteria", "PROBLEM", 0, 8], ["antibiotics", "TREATMENT", 23, 34]]], ["A key feature in the structure of OmpF is the presence of a constriction zone, characterized by both spatial and electrostatics restrictions.", [["OmpF", "GENE_OR_GENE_PRODUCT", 34, 38], ["OmpF", "PROTEIN", 34, 38], ["a constriction zone", "PROBLEM", 58, 77], ["constriction", "OBSERVATION", 60, 72], ["zone", "OBSERVATION_MODIFIER", 73, 77], ["both", "OBSERVATION_MODIFIER", 96, 100], ["spatial", "OBSERVATION_MODIFIER", 101, 108], ["electrostatics restrictions", "OBSERVATION", 113, 140]]], ["To study the process of antibiotics translocation at a molecular scale, we performed molecular dynamic simulations accelerated with the metadynamics algorithm.", [["antibiotics translocation", "TREATMENT", 24, 49], ["the metadynamics algorithm", "TEST", 132, 158]]], ["We studied the diffusion of antibiotics with different structural and chemical properties through OmpF wild-type and variants.", [["OmpF", "GENE_OR_GENE_PRODUCT", 98, 102], ["OmpF", "PROTEIN", 98, 102], ["antibiotics", "TREATMENT", 28, 39]]], ["The free energy surface suggests faster translocation for the cephalosporins compared to the penicillins antibiotics, and also for OmpF mutants compared to the wild type.", [["cephalosporins", "CHEMICAL", 62, 76], ["penicillins", "CHEMICAL", 93, 104], ["cephalosporins", "CHEMICAL", 62, 76], ["penicillins", "CHEMICAL", 93, 104], ["cephalosporins", "SIMPLE_CHEMICAL", 62, 76], ["penicillins", "SIMPLE_CHEMICAL", 93, 104], ["OmpF", "GENE_OR_GENE_PRODUCT", 131, 135], ["OmpF mutants", "PROTEIN", 131, 143], ["faster translocation", "PROBLEM", 33, 53], ["the cephalosporins", "TREATMENT", 58, 76], ["the penicillins antibiotics", "TREATMENT", 89, 116], ["OmpF mutants", "PROBLEM", 131, 143], ["free", "OBSERVATION_MODIFIER", 4, 8], ["energy surface", "OBSERVATION", 9, 23], ["faster translocation", "OBSERVATION", 33, 53]]], ["Further, the conservation of favored orientation and affinity sites of antibiotics inside the OmpF channel reveal which specific interactions govern translocation.", [["OmpF", "GENE_OR_GENE_PRODUCT", 94, 98], ["OmpF channel", "PROTEIN", 94, 106], ["antibiotics", "TREATMENT", 71, 82]]], ["The calculated energy barriers and rate determining interactions for translocations compared well with the electrophysiology measurements and liposome swelling assays from our collaborators.", [["The calculated energy barriers", "TREATMENT", 0, 30], ["translocations", "PROBLEM", 69, 83], ["the electrophysiology measurements", "TEST", 103, 137], ["liposome swelling assays", "PROBLEM", 142, 166]]], ["This study demonstrates how theory and experiments can be combined to reveal the structural determinants and mechanism of OmpF permeation.", [["OmpF", "GENE_OR_GENE_PRODUCT", 122, 126], ["OmpF", "PROTEIN", 122, 126], ["This study", "TEST", 0, 10]]], ["This will benefit to the design of antibiotics with improved transport properties.Control of DNA replication by anomalous reaction-diffusion kineticsM.", [["DNA", "CELLULAR_COMPONENT", 93, 96], ["antibiotics", "TREATMENT", 35, 46], ["DNA replication", "PROBLEM", 93, 108], ["anomalous reaction", "PROBLEM", 112, 130], ["diffusion kineticsM", "PROBLEM", 131, 150], ["anomalous reaction", "OBSERVATION", 112, 130], ["diffusion kineticsM", "OBSERVATION", 131, 150]]], ["G. Gauthier, J. Bechhoefer Dept. of Physics, Simon Fraser Univ., Burnaby, BC, Canada DNA replication requires two distinct processes: the initiation of pre-licensed replication origins and the propagation of replication forks away from the fired origins.", [["DNA", "CELLULAR_COMPONENT", 85, 88], ["G.", "SPECIES", 0, 2], ["Canada DNA replication", "TREATMENT", 78, 100], ["pre-licensed replication origins", "TREATMENT", 152, 184], ["replication forks", "TREATMENT", 208, 225], ["two distinct", "OBSERVATION_MODIFIER", 110, 122], ["replication forks", "OBSERVATION", 208, 225], ["fired", "OBSERVATION_MODIFIER", 240, 245], ["origins", "OBSERVATION_MODIFIER", 246, 253]]], ["We propose a simple model for the control of DNA replication in which the rate of initiation of replication origins is controlled by the interaction with a population of ratelimiting proteins.", [["DNA", "CELLULAR_COMPONENT", 45, 48], ["ratelimiting proteins", "PROTEIN", 170, 191], ["a simple model", "TREATMENT", 11, 25], ["DNA replication", "TREATMENT", 45, 60], ["ratelimiting proteins", "PROBLEM", 170, 191], ["replication origins", "OBSERVATION", 96, 115]]], ["We find the time set by reaction-diffusion kinetics for such proteins to find, bind to, and trigger a potential origin.", [["such proteins", "PROBLEM", 56, 69]]], ["Analyzing data from Xenopus frog embryos, we find that the initiation rate is reaction limited until nearly the end of replication, when it becomes diffusion limited.", [["embryos", "ANATOMY", 33, 40], ["Xenopus frog", "ORGANISM", 20, 32], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 33, 40], ["Xenopus frog embryos", "TREATMENT", 20, 40], ["the initiation rate", "TEST", 55, 74]]], ["We find that, in order to fit the experimental data, the interaction between DNA and the rate-limiting protein must be subdiffusive.", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["rate-limiting protein", "PROTEIN", 89, 110], ["the interaction between DNA", "PROBLEM", 53, 80], ["the rate", "TEST", 85, 93]]], ["We also find that using a constant nuclear import of the limiting proteins leads to a more accurate description of the experimental data.P. Lecca, A. PalmisanoThe microsoft Research -University of Trento Centre for Computational and Sisytems Biology, Trento, ItalyP.", [["nuclear", "ANATOMY", 35, 42], ["nuclear", "CELLULAR_COMPONENT", 35, 42], ["limiting proteins", "PROTEIN", 57, 74], ["A. Palmisano", "SPECIES", 147, 159]]], ["Lecca, A. PalmisanoWe propose a new method for inferring the structure of a biochemical network from the time-series of the reactant species.", [["a new method", "TREATMENT", 30, 42], ["the reactant species", "PROBLEM", 120, 140], ["reactant species", "OBSERVATION", 124, 140]]], ["It consists of two parts: the first is the quantification of the correlation between the time-series profiles.", [["two", "OBSERVATION_MODIFIER", 15, 18], ["parts", "OBSERVATION_MODIFIER", 19, 24]]], ["Correlation in time series data can be used to reveal dependencies between variables and to infer the graph of connectivity among species.", [["time series data", "TEST", 15, 31], ["dependencies between variables", "PROBLEM", 54, 84]]], ["The cutting of false correlations from the graph is performed through the estimation of the parameters (\"calibration\") of the network.", [["the graph", "TEST", 39, 48]]], ["Based on a new probabilistic model of the variations in reaction concentrations, KInfer infers the values of the kinetic rate constants, their confidence regions and the level of noise in the input data by maximizing the likelihood to obtain the observed variations given the network model.", [["reaction concentrations", "PROBLEM", 56, 79], ["the input data", "TEST", 188, 202], ["new", "OBSERVATION_MODIFIER", 11, 14], ["reaction concentrations", "OBSERVATION", 56, 79]]], ["The a priori knowledge required as input is minimal, as it consists only in the time-series of reactant concentrations.", [["reactant concentrations", "TREATMENT", 95, 118], ["minimal", "OBSERVATION_MODIFIER", 44, 51]]], ["The minimal a priori knowledge and the probabilistic formulation of the calibration method make the accuracy of the predictions strong against experimental, biological and stochastic noise, and allows to use it to cut the null-dynamics edges of the connectivity graph.Determination of root-mean-square pairwise RMSD from experimental B-factorsA.", [["root", "ANATOMY", 285, 289], ["B-factorsA", "GENE_OR_GENE_PRODUCT", 334, 344], ["the calibration method", "TREATMENT", 68, 90], ["root", "TEST", 285, 289], ["experimental B-factorsA", "PROBLEM", 321, 344], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["root", "ANATOMY", 285, 289], ["experimental B", "OBSERVATION", 321, 335]]], ["Kuzmanic, B. Zagrovic Mediterranean Institute for Life Sciences, Split, Croatia Root-mean-square deviation (RMSD) is a measure used to give information on the global structure of macromolecules.", [["Croatia Root", "ANATOMY", 72, 84], ["macromolecules", "OBSERVATION", 179, 193]]], ["For example, pairwise RMSD (pRMSD) is used to assess similarity of the lowest energy NMR structures or for clustering large ensembles of structures.", [["pairwise RMSD (pRMSD)", "PROBLEM", 13, 34], ["clustering large ensembles of structures", "PROBLEM", 107, 147], ["large", "OBSERVATION_MODIFIER", 118, 123], ["ensembles", "OBSERVATION", 124, 133]]], ["On the other hand, to obtain information on the local structure of a macromolecule and its dynamics, root-mean-square fluctuation (RMSF) is often used.", [["root", "ANATOMY", 101, 105]]], ["RMSF can be calculated from MD simulations, but also from experimental X-ray B-factors.", [["RMSF", "DISEASE", 0, 4], ["B-factors", "GENE_OR_GENE_PRODUCT", 77, 86], ["experimental X-ray", "TEST", 58, 76]]], ["First, we provide a mathematical derivation showing that, given a set of conservative assumptions, the RMS is directly related to the RMS and, consequently, experimental B-factors.", [["B-factors", "GENE_OR_GENE_PRODUCT", 170, 179], ["B-factors", "PROTEIN", 170, 179], ["a mathematical derivation", "TEST", 18, 43], ["conservative assumptions", "TREATMENT", 73, 97]]], ["Second, we demonstrate this on structures taken from distributed-computing MD simulations of the native and unfolded state of villin headpiece.", [["villin", "GENE_OR_GENE_PRODUCT", 126, 132], ["villin headpiece", "PROTEIN", 126, 142], ["villin headpiece", "TREATMENT", 126, 142], ["villin headpiece", "OBSERVATION", 126, 142]]], ["Both our analytical and computational results suggest a strong correlation: RMS = [(S-1)/2S] 1/2 RMS , where S is the number of compared structures.Determination of root-mean-square pairwise RMSD from experimental B-factorsFurthermore, if RMS is defined as a generalized radius of gyration in the space of 3D structures and using RMSD as a measure of distance, the following identity holds: RMS = RMS.", [["root", "ANATOMY", 165, 169], ["B-factors", "GENE_OR_GENE_PRODUCT", 214, 223], ["B-factors", "PROTEIN", 214, 223], ["RMS", "PROTEIN", 239, 242], ["root", "TEST", 165, 169], ["a generalized radius of gyration", "PROBLEM", 257, 289], ["root", "ANATOMY", 165, 169], ["generalized", "OBSERVATION_MODIFIER", 259, 270], ["radius", "OBSERVATION", 271, 277], ["gyration", "OBSERVATION", 281, 289]]], ["Our results provide a basis for determining the level of structural diversity of molecular ensembles, as captured by RMS , directly from experiment.", [["molecular ensembles", "OBSERVATION", 81, 100]]], ["Charge migration along DNA helices may be biologically important because extended electronic states could play a role in the processes of sensing of DNA damage and/or DNA repair via long-range charge transfer.", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["DNA", "CELLULAR_COMPONENT", 149, 152], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["Charge migration along DNA helices", "TREATMENT", 0, 34], ["DNA damage", "PROBLEM", 149, 159], ["DNA repair", "TREATMENT", 167, 177], ["long-range charge transfer", "TREATMENT", 182, 208]]], ["We measured conductivity and other physical characteristics of several models of natural and diversely damaged molecules of DNA.", [["DNA", "CELLULAR_COMPONENT", 124, 127], ["natural and diversely damaged molecules of DNA", "PROBLEM", 81, 127], ["conductivity", "OBSERVATION_MODIFIER", 12, 24]]], ["DNA polymers were mimicked by various sequences of 32nucleotide-long double helices with fully Watson-Crick (WC) paired bases, with several central bases mismatched, and also with chemical modifications that included removal of bases from a few central nucleotides (abasic DNA), and neutralization of phosphate charges by their derivatization.", [["phosphate", "CHEMICAL", 301, 310], ["nucleotides", "CHEMICAL", 253, 264], ["phosphate", "CHEMICAL", 301, 310], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["phosphate charges", "SIMPLE_CHEMICAL", 301, 318], ["32nucleotide-long double helices", "DNA", 51, 83], ["Watson-Crick (WC) paired bases", "DNA", 95, 125], ["DNA polymers", "PROBLEM", 0, 12], ["32nucleotide-long double helices", "TREATMENT", 51, 83], ["several central bases mismatched", "PROBLEM", 132, 164], ["chemical modifications", "TREATMENT", 180, 202], ["removal of bases", "TREATMENT", 217, 233], ["a few central nucleotides (abasic DNA", "PROBLEM", 239, 276], ["neutralization of phosphate charges", "TREATMENT", 283, 318], ["their derivatization", "TREATMENT", 322, 342], ["bases", "ANATOMY_MODIFIER", 120, 125], ["central", "ANATOMY_MODIFIER", 140, 147], ["bases", "ANATOMY_MODIFIER", 148, 153], ["mismatched", "OBSERVATION", 154, 164], ["chemical modifications", "OBSERVATION", 180, 202], ["bases", "ANATOMY_MODIFIER", 228, 233], ["few", "OBSERVATION_MODIFIER", 241, 244], ["central nucleotides", "OBSERVATION", 245, 264]]], ["The model DNAs were investigated by scanning tunneling microscopy, time-resolved THz spectroscopy, Raman spectroscopy, circular dichroism, and modeled by molecular dynamics simulations.", [["model DNAs", "DNA", 4, 14], ["scanning tunneling microscopy", "TEST", 36, 65], ["THz spectroscopy", "TEST", 81, 97], ["Raman spectroscopy", "TEST", 99, 117], ["circular dichroism", "TEST", 119, 137], ["DNAs", "OBSERVATION", 10, 14], ["circular dichroism", "OBSERVATION", 119, 137]]], ["DNA has the highest conductivity in its biologically most relevant double helical form with WC base pairs and negatively charged phosphates equilibrated with counterions.", [["WC", "CHEMICAL", 92, 94], ["phosphates", "CHEMICAL", 129, 139], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["phosphates", "SIMPLE_CHEMICAL", 129, 139], ["DNA", "PROBLEM", 0, 3], ["the highest conductivity", "PROBLEM", 8, 32], ["highest conductivity", "OBSERVATION_MODIFIER", 12, 32]]], ["Mismatches and all chemical modifications always lower the conductivity.", [["all chemical modifications", "TREATMENT", 15, 41], ["all", "OBSERVATION_MODIFIER", 15, 18], ["chemical modifications", "OBSERVATION", 19, 41]]], ["The mechanism of charge transfer is consistent with electron or hole hopping between parallel stacked bases.", [["electron", "SIMPLE_CHEMICAL", 52, 60], ["electron or hole hopping between parallel stacked bases", "PROBLEM", 52, 107], ["consistent with", "UNCERTAINTY", 36, 51], ["hole hopping", "OBSERVATION", 64, 76], ["bases", "ANATOMY_MODIFIER", 102, 107]]], ["These observations and data showing that the natural DNA has also the most regular double helical form suggest that the continuous base stacking is critical for charge transfer.", [["DNA", "CELLULAR_COMPONENT", 53, 56], ["These observations and data", "TEST", 0, 27], ["the natural DNA", "PROBLEM", 41, 56], ["the continuous base stacking", "PROBLEM", 116, 144]]], ["To control the passage across the bacterial cell wall nature created a large number of \"nano\"-channels which may act as selective gates for water soluble molecules.", [["cell wall", "ANATOMY", 44, 53], ["water soluble molecules", "PROTEIN", 140, 163], ["\"nano\"-channels", "TREATMENT", 87, 102], ["water soluble molecules", "TREATMENT", 140, 163], ["bacterial cell", "OBSERVATION", 34, 48], ["wall", "ANATOMY_MODIFIER", 49, 53], ["large", "OBSERVATION_MODIFIER", 71, 76], ["number", "OBSERVATION_MODIFIER", 77, 83]]], ["Here we focus on porins from E. coli which control permeation through interactions with the channel surface.", [["channel surface", "ANATOMY", 92, 107], ["porins", "GENE_OR_GENE_PRODUCT", 17, 23], ["E. coli", "ORGANISM", 29, 36], ["channel surface", "CELLULAR_COMPONENT", 92, 107], ["E. coli", "SPECIES", 29, 36], ["E. coli", "SPECIES", 29, 36], ["E. coli", "PROBLEM", 29, 36]]], ["For example, surprisingly modeling OmpF-conductance revealed not only a good agreement with the experiment over a broad range of temperature but also the selectivity for ions.", [["OmpF", "GENE_OR_GENE_PRODUCT", 35, 39], ["OmpF", "PROTEIN", 35, 39]]], ["The primary task of porins is to provide facilitated diffusion.", [["facilitated diffusion", "PROBLEM", 41, 62]]], ["We investigated facilitated diffusion of maltooligosaccharide or antibiotics.", [["maltooligosaccharide", "CHEMICAL", 41, 61], ["maltooligosaccharide", "CHEMICAL", 41, 61], ["maltooligosaccharide", "SIMPLE_CHEMICAL", 41, 61], ["maltooligosaccharide", "TREATMENT", 41, 61], ["antibiotics", "TREATMENT", 65, 76]]], ["Time resolved conductance measurements allows conclusion on the flux and molecular modeling identifies the limiting interactions with the surface, reveal potential barriers and pathways.", [["surface", "ANATOMY", 138, 145], ["surface", "CELLULAR_COMPONENT", 138, 145], ["conductance measurements", "TEST", 14, 38], ["the flux", "TEST", 60, 68]]], ["Exploiting the selectivity of natural or bioengineered channels has promising applications for detecting molecules, characterizing molecular interaction, sequencing DNA, protein folding etc. Traditionally, studies of diffusion-controlled reaction of biological macromolecules have been made in diluted solutions.", [["DNA", "CELLULAR_COMPONENT", 165, 168], ["molecular interaction", "PROBLEM", 131, 152], ["sequencing DNA", "TEST", 154, 168], ["protein folding etc", "PROBLEM", 170, 189], ["diffusion", "TEST", 217, 226], ["biological macromolecules", "TREATMENT", 250, 275], ["diluted solutions", "TREATMENT", 294, 311], ["selectivity", "OBSERVATION_MODIFIER", 15, 26]]], ["However, the high concentration of macromolecules in intracellular environments results into non-specific interactions (macromolecular crowding), which have a great importance on the kinetics and thermodynamics of possible reactions that occur in these systems.", [["intracellular", "ANATOMY", 53, 66], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 66], ["non-specific interactions (macromolecular crowding)", "PROBLEM", 93, 144], ["reactions", "PROBLEM", 223, 232], ["high concentration", "OBSERVATION_MODIFIER", 13, 31], ["non-specific", "OBSERVATION_MODIFIER", 93, 105], ["macromolecular crowding", "OBSERVATION", 120, 143], ["great", "OBSERVATION_MODIFIER", 159, 164]]], ["In the literature there are studies concerning Monte Carlo (MC) simulations, giving results that are satisfactory agreement with experimental data, showing, for example, that the protein diffusion in cell cytoplasm is reduced considerably.", [["cell cytoplasm", "ANATOMY", 200, 214], ["Monte Carlo", "CHEMICAL", 47, 58], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 200, 214], ["experimental data", "TEST", 129, 146], ["the protein diffusion in cell cytoplasm", "PROBLEM", 175, 214], ["cell cytoplasm", "OBSERVATION", 200, 214], ["reduced", "OBSERVATION_MODIFIER", 218, 225], ["considerably", "OBSERVATION_MODIFIER", 226, 238]]], ["In addition, there are MC studies about enzymatic reaction, which predict a temporal dependency of the velocity constant in macromolecular crowding.", [["MC studies", "TEST", 23, 33], ["enzymatic reaction", "PROBLEM", 40, 58], ["a temporal dependency", "PROBLEM", 74, 95], ["macromolecular crowding", "PROBLEM", 124, 147], ["temporal", "OBSERVATION_MODIFIER", 76, 84], ["dependency", "OBSERVATION", 85, 95], ["velocity", "OBSERVATION_MODIFIER", 103, 111], ["constant", "OBSERVATION_MODIFIER", 112, 120], ["macromolecular crowding", "OBSERVATION", 124, 147]]], ["In this work, we try to compare the predicted behavior by MC simulation with the results obtained from the study of the diffusion and reaction of a model protein (alpha-chymotrypsin) using spectroscopic techniques in highly confined media in order to study experimentally the temporal dependence of its diffusion and reaction coefficients.Anomalous dynamical properties of protein hydration water in the picosecond timescaleA.", [["alpha-chymotrypsin", "CHEMICAL", 163, 181], ["alpha-chymotrypsin", "GENE_OR_GENE_PRODUCT", 163, 181], ["model protein", "PROTEIN", 148, 161], ["alpha", "PROTEIN", 163, 168], ["chymotrypsin", "PROTEIN", 169, 181], ["the study", "TEST", 103, 112], ["the diffusion", "TEST", 116, 129], ["a model protein", "TEST", 146, 161], ["alpha-chymotrypsin", "TREATMENT", 163, 181], ["spectroscopic techniques", "TEST", 189, 213], ["protein hydration water in the picosecond timescaleA", "TREATMENT", 373, 425], ["temporal", "OBSERVATION_MODIFIER", 276, 284], ["dependence", "OBSERVATION", 285, 295], ["dynamical properties", "OBSERVATION", 349, 369], ["protein hydration", "OBSERVATION", 373, 390], ["water", "OBSERVATION_MODIFIER", 391, 396], ["picosecond timescaleA", "OBSERVATION", 404, 425]]], ["Paciaroni 1 , A. Orecchini 1 , C. Petrillo 1 , A. de Francesco 2 , F. Sacchetti 1 1 University of Perugia, Italy, 2 CNR-INFM, Genova, ItalyAnomalous dynamical properties of protein hydration water in the picosecond timescaleThe single-particle and collective dynamical properties of protein hydration water have been studied by neutron scattering experiments in a wide temperature and hydration range.", [["Paciaroni", "CHEMICAL", 0, 9], ["Paciaroni", "TREATMENT", 0, 9], ["Genova", "TREATMENT", 126, 132], ["protein hydration water", "TREATMENT", 173, 196], ["the picosecond timescale", "TREATMENT", 200, 224], ["The single-particle and collective dynamical properties of protein hydration water", "TREATMENT", 224, 306], ["a wide temperature and hydration range", "TREATMENT", 362, 400], ["protein hydration", "OBSERVATION", 283, 300]]], ["An unprecedented accuracy has been achieved thanks to the availability of a large amount of fully deuterated protein powder and the use of the high-flux spectrometers IN5 and BRISP.", [["BRISP", "PROTEIN", 175, 180], ["fully deuterated protein powder", "TREATMENT", 92, 123], ["the high-flux spectrometers IN5", "TREATMENT", 139, 170]]], ["The protein under investigation was the Maltose Binding Protein (MBP), which is a well-known and widely studied model of biosensor systems.", [["Maltose", "CHEMICAL", 40, 47], ["Maltose Binding Protein", "GENE_OR_GENE_PRODUCT", 40, 63], ["MBP", "GENE_OR_GENE_PRODUCT", 65, 68], ["Maltose Binding Protein", "PROTEIN", 40, 63], ["MBP", "PROTEIN", 65, 68], ["the Maltose Binding Protein (MBP", "TEST", 36, 68]]], ["We found that the low-temperature single particle dynamics of MBP hydration water shows clear features that can be traced back to amorphous systems.", [["MBP", "CHEMICAL", 62, 65], ["MBP", "SIMPLE_CHEMICAL", 62, 65], ["MBP", "PROTEIN", 62, 65], ["MBP hydration water", "TREATMENT", 62, 81], ["clear features", "PROBLEM", 88, 102], ["low", "OBSERVATION_MODIFIER", 18, 21]]], ["More in detail, its vibrational density of states is simply described as the superposition of the contributions of low-density and high-density amorphous ice.", [["low-density and high-density amorphous ice", "PROBLEM", 115, 157], ["vibrational density", "OBSERVATION", 20, 39], ["low-density", "OBSERVATION_MODIFIER", 115, 126], ["high-density", "OBSERVATION_MODIFIER", 131, 143], ["amorphous ice", "OBSERVATION", 144, 157]]], ["The quasielastic signal, which appears at the higher temperatures, can be excellently described with a fractional power law which may put in relationship with the peculiarities of fractal systems.", [["The quasielastic signal", "TEST", 0, 23], ["quasielastic signal", "OBSERVATION", 4, 23], ["higher temperatures", "OBSERVATION_MODIFIER", 46, 65]]], ["Quite strikingly, there is a strong similarity, on both the qualitative and quantitative point of view, with the behaviour of hydrated proteins.", [["hydrated proteins", "PROTEIN", 126, 143], ["hydrated proteins", "PROBLEM", 126, 143]]], ["The collective dynamics of protein hydration water is characterised by the presence of two modes, whose dispersion curves are reminiscent of those of bulk water.", [["protein hydration water", "TREATMENT", 27, 50]]], ["However, the relevant damping factors suggest a strong similarity with glassy systems.Electron transfer and protein dynamics in photosynthetic reaction centers embedded in sugar glassesM.", [["sugar", "CHEMICAL", 172, 177], ["sugar glassesM", "SIMPLE_CHEMICAL", 172, 186], ["damping factors", "PROTEIN", 22, 37], ["the relevant damping factors", "PROBLEM", 9, 37], ["sugar glassesM", "OBSERVATION", 172, 186]]], ["Malferrari 1 , F. Francia 1 , S. Sacquin-Mora 2 , G. Venturoli 1 1 Universit\u00e0 di Bologna, Bologna, Italy, 2 CNRS UPR 9080, Paris, FranceElectron transfer and protein dynamics in photosynthetic reaction centers embedded in sugar glassesThe coupling between electron transfer and protein dynamics has been compared in reaction centers (RC) from the wild type (wt) and the carotenoid-less mutant R26, by combining Brownian dynamics simulations and the kinetic analysis of charge recombination.", [["sugar", "CHEMICAL", 222, 227], ["electron", "SIMPLE_CHEMICAL", 256, 264], ["carotenoid", "SIMPLE_CHEMICAL", 370, 380], ["mutant R26", "PROTEIN", 386, 396], ["Malferrari", "TEST", 0, 10], ["Francia", "TEST", 18, 25], ["protein dynamics in photosynthetic reaction centers", "TREATMENT", 158, 209], ["the carotenoid", "TEST", 366, 380], ["the kinetic analysis", "TEST", 445, 465], ["charge recombination", "TREATMENT", 469, 489], ["sugar glasses", "OBSERVATION", 222, 235]]], ["Upon incorporation of the RC into a progressively dehydrated trehalose matrix the electron transfer between the primary photoreduced quinone and the photoxidized donor accelerates progressively and becomes broadly distributed.", [["trehalose", "CHEMICAL", 61, 70], ["quinone", "CHEMICAL", 133, 140], ["trehalose", "CHEMICAL", 61, 70], ["quinone", "CHEMICAL", 133, 140], ["trehalose matrix", "CELLULAR_COMPONENT", 61, 77], ["electron", "SIMPLE_CHEMICAL", 82, 90], ["photoreduced quinone", "SIMPLE_CHEMICAL", 120, 140], ["a progressively dehydrated trehalose matrix", "PROBLEM", 34, 77], ["the primary photoreduced quinone", "TREATMENT", 108, 140], ["the photoxidized donor", "TREATMENT", 145, 167], ["progressively", "OBSERVATION_MODIFIER", 36, 49], ["dehydrated", "OBSERVATION", 50, 60], ["trehalose matrix", "OBSERVATION", 61, 77], ["broadly", "OBSERVATION_MODIFIER", 206, 213], ["distributed", "OBSERVATION_MODIFIER", 214, 225]]], ["This behaviour reflects the hindrance of protein relaxation following charge separation and the inhibition of interconversion between conformational substates.", [["protein relaxation", "TREATMENT", 41, 59], ["charge separation", "TREATMENT", 70, 87], ["interconversion between conformational substates", "PROBLEM", 110, 158], ["hindrance", "OBSERVATION_MODIFIER", 28, 37], ["protein relaxation", "OBSERVATION", 41, 59]]], ["In extensively dehydrated matrices the recombination kinetics is two-times faster and three-times more distributed in the wt RC, indicating a larger inhibition of the internal protein dynamics.", [["a larger inhibition of the internal protein dynamics", "PROBLEM", 140, 192], ["dehydrated matrices", "OBSERVATION", 15, 34], ["recombination kinetics", "OBSERVATION", 39, 61], ["larger", "OBSERVATION_MODIFIER", 142, 148], ["internal protein", "ANATOMY", 167, 183]]], ["In line with this findings Brownian dynamics simulations reveal a larger rigidity of the carotenoid-containing structure, in which a cluster of residues close to the quinone acceptors is stiffened as compared to the R26 RC.", [["rigidity", "DISEASE", 73, 81], ["carotenoid", "CHEMICAL", 89, 99], ["quinone", "CHEMICAL", 166, 173], ["quinone", "CHEMICAL", 166, 173], ["carotenoid", "SIMPLE_CHEMICAL", 89, 99], ["quinone", "SIMPLE_CHEMICAL", 166, 173], ["carotenoid-containing structure", "PROTEIN", 89, 120], ["R26 RC", "PROTEIN", 216, 222], ["Brownian dynamics simulations", "TEST", 27, 56], ["a larger rigidity of the carotenoid-containing structure", "PROBLEM", 64, 120], ["a cluster of residues", "PROBLEM", 131, 152], ["the quinone acceptors", "TREATMENT", 162, 183], ["larger", "OBSERVATION_MODIFIER", 66, 72], ["rigidity", "OBSERVATION", 73, 81], ["carotenoid", "ANATOMY", 89, 99], ["structure", "OBSERVATION_MODIFIER", 111, 120], ["cluster", "OBSERVATION_MODIFIER", 133, 140], ["quinone acceptors", "OBSERVATION", 166, 183], ["stiffened", "OBSERVATION", 187, 196]]], ["The in silico and experimental results indicate that the introduction of an internal void in the RC structure has long-range effects on the protein dynamics and that the coupling between the glassy matrix and the RC interior depends markedly on the local mechanical properties of the protein.Nuclear centering in fission yeast mediated by kinesin-8 motor proteinsN.", [["Nuclear", "ANATOMY", 292, 299], ["matrix", "CELLULAR_COMPONENT", 198, 204], ["Nuclear", "CELLULAR_COMPONENT", 292, 299], ["kinesin-8", "GENE_OR_GENE_PRODUCT", 339, 348], ["kinesin-8 motor proteins", "PROTEIN", 339, 363], ["yeast", "SPECIES", 321, 326], ["yeast", "SPECIES", 321, 326], ["an internal void in the RC structure", "PROBLEM", 73, 109], ["the protein dynamics", "TEST", 136, 156], ["the coupling between the glassy matrix", "TREATMENT", 166, 204], ["internal", "OBSERVATION_MODIFIER", 76, 84], ["void", "OBSERVATION", 85, 89], ["RC", "ANATOMY", 97, 99], ["long-range effects", "OBSERVATION_MODIFIER", 114, 132], ["RC", "OBSERVATION_MODIFIER", 213, 215], ["interior", "OBSERVATION_MODIFIER", 216, 224], ["markedly", "OBSERVATION_MODIFIER", 233, 241], ["fission yeast", "OBSERVATION", 313, 326]]], ["Maghelli 1 , V. Krstic 2 , N. Pavin 2 , F. Julicher 2 , I. Tolic-Norrelykke 1 1 MPI-CBG, Dresden, Germany, 2 MPI-PKS, Dresden, Germany In the fission yeast Schizosaccharomyces pombe, the nucleus is positioned at the cell center.", [["nucleus", "ANATOMY", 187, 194], ["cell center", "ANATOMY", 216, 227], ["fission", "CELLULAR_COMPONENT", 142, 149], ["yeast Schizosaccharomyces pombe", "ORGANISM", 150, 181], ["nucleus", "CELLULAR_COMPONENT", 187, 194], ["cell center", "CELLULAR_COMPONENT", 216, 227], ["yeast", "SPECIES", 150, 155], ["Schizosaccharomyces pombe", "SPECIES", 156, 181], ["yeast", "SPECIES", 150, 155], ["Schizosaccharomyces pombe", "SPECIES", 156, 181], ["Maghelli", "TEST", 0, 8], ["Krstic", "TEST", 16, 22], ["CBG", "TEST", 84, 87], ["fission", "OBSERVATION", 142, 149], ["yeast Schizosaccharomyces pombe", "OBSERVATION", 150, 181], ["nucleus", "ANATOMY", 187, 194], ["cell center", "OBSERVATION", 216, 227]]], ["Since the nucleus determines the cell division site, keeping the nucleus at the center is crucial for ensuring symmetrical cell division (1 ) .", [["nucleus", "ANATOMY", 10, 17], ["cell", "ANATOMY", 33, 37], ["nucleus", "ANATOMY", 65, 72], ["cell", "ANATOMY", 123, 127], ["nucleus", "CELLULAR_COMPONENT", 10, 17], ["cell", "CELL", 33, 37], ["nucleus", "CELLULAR_COMPONENT", 65, 72], ["cell", "CELL", 123, 127], ["cell division site", "DNA", 33, 51], ["nucleus", "ANATOMY_MODIFIER", 10, 17], ["cell division", "OBSERVATION", 33, 46], ["nucleus", "OBSERVATION_MODIFIER", 65, 72], ["symmetrical cell division", "OBSERVATION", 111, 136]]], ["Microtubules push against the cell ends and exert force on the nucleus (2 ), but how the cell regulates these forces in order to center the nucleus remains unknown.", [["Microtubules", "ANATOMY", 0, 12], ["cell", "ANATOMY", 30, 34], ["nucleus", "ANATOMY", 63, 70], ["cell", "ANATOMY", 89, 93], ["nucleus", "ANATOMY", 140, 147], ["Microtubules", "CELLULAR_COMPONENT", 0, 12], ["cell", "CELL", 30, 34], ["nucleus", "CELLULAR_COMPONENT", 63, 70], ["cell", "CELL", 89, 93], ["nucleus", "CELLULAR_COMPONENT", 140, 147], ["Microtubules", "TREATMENT", 0, 12], ["cell ends", "OBSERVATION", 30, 39], ["force", "OBSERVATION_MODIFIER", 50, 55], ["nucleus", "ANATOMY", 63, 70], ["nucleus", "ANATOMY", 140, 147]]], ["Here we tackle this problem by using a combination of live cell imaging, cell manipulations by optical tweezers, and a theoretical model.", [["cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 73, 77], ["cell", "CELL", 59, 63], ["cell", "CELL", 73, 77], ["live cell imaging", "TREATMENT", 54, 71], ["cell manipulations", "TREATMENT", 73, 91]]], ["We show that microtubule pushing forces can center the nucleus because of a larger number of contacts between the microtubules and the proximal cell end than the distal one.", [["microtubule", "ANATOMY", 13, 24], ["nucleus", "ANATOMY", 55, 62], ["microtubules", "ANATOMY", 114, 126], ["cell", "ANATOMY", 144, 148], ["microtubule", "CELLULAR_COMPONENT", 13, 24], ["nucleus", "CELLULAR_COMPONENT", 55, 62], ["microtubules", "CELLULAR_COMPONENT", 114, 126], ["cell", "CELLULAR_COMPONENT", 144, 148], ["microtubule", "PROTEIN", 13, 24], ["microtubule pushing forces", "TREATMENT", 13, 39], ["microtubule pushing", "OBSERVATION", 13, 32], ["nucleus", "ANATOMY_MODIFIER", 55, 62], ["larger", "OBSERVATION_MODIFIER", 76, 82], ["number", "OBSERVATION_MODIFIER", 83, 89], ["contacts", "OBSERVATION", 93, 101], ["microtubules", "OBSERVATION_MODIFIER", 114, 126], ["proximal", "ANATOMY_MODIFIER", 135, 143], ["cell", "OBSERVATION", 144, 148], ["end", "OBSERVATION_MODIFIER", 149, 152], ["distal", "OBSERVATION_MODIFIER", 162, 168], ["one", "OBSERVATION_MODIFIER", 169, 172]]], ["Moreover, kinesin-8 motors (Klp5/6) increase the rate of microtubule catastrophe (transition from growth to shrinkage) in a microtubule length-and contact-dependent manner.", [["microtubule", "ANATOMY", 57, 68], ["microtubule", "ANATOMY", 124, 135], ["kinesin-8", "GENE_OR_GENE_PRODUCT", 10, 19], ["Klp5/6", "GENE_OR_GENE_PRODUCT", 28, 34], ["microtubule", "CELLULAR_COMPONENT", 57, 68], ["kinesin-8 motors", "PROTEIN", 10, 26], ["Klp5/6", "PROTEIN", 28, 34], ["microtubule", "PROTEIN", 57, 68], ["microtubule", "PROTEIN", 124, 135], ["kinesin", "TEST", 10, 17], ["microtubule catastrophe", "PROBLEM", 57, 80], ["microtubule catastrophe", "OBSERVATION", 57, 80]]], ["Thus, the motor behavior results in a longer contact between a microtubule and the proximal than the distal cell end.", [["microtubule", "ANATOMY", 63, 74], ["distal cell", "ANATOMY", 101, 112], ["microtubule", "CELLULAR_COMPONENT", 63, 74], ["cell", "CELLULAR_COMPONENT", 108, 112], ["microtubule", "PROTEIN", 63, 74], ["proximal", "ANATOMY_MODIFIER", 83, 91], ["distal", "ANATOMY_MODIFIER", 101, 107], ["cell end", "OBSERVATION", 108, 116]]], ["Taken together, our experimental and theoretical results provide a novel centering mechanism, where kinesin-8 motors increase the efficiency of nuclear centering.", [["nuclear", "ANATOMY", 144, 151], ["kinesin-8", "GENE_OR_GENE_PRODUCT", 100, 109], ["nuclear", "CELLULAR_COMPONENT", 144, 151], ["kinesin-8 motors", "PROTEIN", 100, 116]]], ["Electropermeabilization is a commonly used physical method which can induce a transient permeabilization of the cell membrane allowing the entry of therapeutic molecules into the cell and is thus of great interest in the fields of cancer treatment and gene therapy [1] .", [["cell membrane", "ANATOMY", 112, 125], ["cell", "ANATOMY", 179, 183], ["cancer", "ANATOMY", 231, 237], ["cancer", "DISEASE", 231, 237], ["cell membrane", "CELLULAR_COMPONENT", 112, 125], ["cell", "CELL", 179, 183], ["cancer", "CANCER", 231, 237], ["a transient permeabilization of the cell membrane", "PROBLEM", 76, 125], ["cancer treatment", "TREATMENT", 231, 247], ["gene therapy", "TREATMENT", 252, 264], ["transient", "OBSERVATION_MODIFIER", 78, 87], ["permeabilization", "OBSERVATION", 88, 104], ["cell membrane", "OBSERVATION", 112, 125], ["cancer", "OBSERVATION", 231, 237]]], ["There is clearly some microscopic reorganization of the membrane which is responsible for this change in its transverse transport properties.", [["membrane", "ANATOMY", 56, 64], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["some microscopic reorganization of the membrane", "PROBLEM", 17, 64], ["this change", "PROBLEM", 90, 101], ["some", "OBSERVATION_MODIFIER", 17, 21], ["microscopic", "OBSERVATION_MODIFIER", 22, 33], ["reorganization", "OBSERVATION", 34, 48], ["membrane", "ANATOMY_MODIFIER", 56, 64], ["responsible for", "UNCERTAINTY", 74, 89], ["transverse", "OBSERVATION_MODIFIER", 109, 119]]], ["Rather than studying the change of these transport properties, we adopt a simple strategy based on the use of giant unilamellar vesicles and videomicroscopy, as described below.", [["giant unilamellar vesicles", "ANATOMY", 110, 136], ["unilamellar vesicles", "CELLULAR_COMPONENT", 116, 136], ["a simple strategy", "TREATMENT", 72, 89], ["giant unilamellar vesicles", "TREATMENT", 110, 136], ["videomicroscopy", "TEST", 141, 156]]], ["We apply a series of permeabilizing electric pulses to the liposomes, and we observe a size decrease down to a critical radius beyond which their size no longer changes.", [["liposomes", "SIMPLE_CHEMICAL", 59, 68], ["permeabilizing electric pulses", "TREATMENT", 21, 51], ["a size decrease", "PROBLEM", 85, 100], ["liposomes", "ANATOMY", 59, 68], ["size", "OBSERVATION_MODIFIER", 87, 91], ["decrease", "OBSERVATION_MODIFIER", 92, 100], ["size", "OBSERVATION_MODIFIER", 146, 150], ["no longer", "UNCERTAINTY", 151, 160]]], ["This decrease in size points to the fact that during the physical processes leading to electropermeabilization, lipids are lost from the vesicles.", [["vesicles", "ANATOMY", 137, 145], ["lipids", "SIMPLE_CHEMICAL", 112, 118], ["vesicles", "CELLULAR_COMPONENT", 137, 145], ["electropermeabilization", "TREATMENT", 87, 110], ["lipids", "TREATMENT", 112, 118], ["decrease", "OBSERVATION_MODIFIER", 5, 13], ["size", "OBSERVATION_MODIFIER", 17, 21], ["vesicles", "ANATOMY", 137, 145]]], ["Our results published in [2] suggest different possible modes for lipid loss, which can be small vesicles, pores, or tubules formation.P-349Imaging of brain activation using core techniques as fMRI, PET and synchrotron radiation in parallel C. Poitry-Yamate, G. Margaritondo, R. Gruetter Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne, Switzerland Functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET) and synchrotron x-ray emission imaging form a highly complementary set of imaging core technologies for studying brain function and energy metabolism.", [["vesicles", "ANATOMY", 97, 105], ["pores", "ANATOMY", 107, 112], ["tubules", "ANATOMY", 117, 124], ["brain", "ANATOMY", 151, 156], ["brain", "ANATOMY", 575, 580], ["lipid loss", "DISEASE", 66, 76], ["lipid", "SIMPLE_CHEMICAL", 66, 71], ["vesicles", "CELLULAR_COMPONENT", 97, 105], ["tubules", "TISSUE", 117, 124], ["brain", "ORGAN", 151, 156], ["brain", "ORGAN", 575, 580], ["P", "DNA", 135, 136], ["lipid loss", "PROBLEM", 66, 76], ["small vesicles", "PROBLEM", 91, 105], ["tubules formation", "PROBLEM", 117, 134], ["core techniques", "TREATMENT", 174, 189], ["fMRI", "TEST", 193, 197], ["PET", "TEST", 199, 202], ["synchrotron radiation", "TREATMENT", 207, 228], ["Functional magnetic resonance imaging", "TEST", 342, 379], ["MRI", "TEST", 382, 385], ["magnetic resonance spectroscopy", "TEST", 388, 419], ["positron emission tomography", "TEST", 427, 455], ["synchrotron x-ray emission imaging", "TEST", 466, 500], ["imaging core technologies", "TEST", 536, 561], ["studying brain function", "TEST", 566, 589], ["lipid loss", "OBSERVATION", 66, 76], ["small vesicles", "OBSERVATION", 91, 105], ["pores", "OBSERVATION_MODIFIER", 107, 112], ["tubules formation", "OBSERVATION", 117, 134]]], ["The housing of a 7-Tesla human magnet, 9.4 and 14.1-Tesla animal magnets, an animal PET imaging facility and fully-equipped neurochemistry and RF laboratories has enabled us to develop and perform well-targeted experiments around one research theme.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["an animal PET imaging", "TEST", 74, 95], ["RF laboratories", "TEST", 143, 158]]], ["In parallel, a longterm collaborative project using synchrotron x-ray transmission and emission imaging at Elettra enables us to combine these core technologies towards understanding brain function in vitro and in vivo, from tissue to cells.", [["brain", "ANATOMY", 183, 188], ["tissue", "ANATOMY", 225, 231], ["cells", "ANATOMY", 235, 240], ["brain", "ORGAN", 183, 188], ["tissue", "TISSUE", 225, 231], ["cells", "CELL", 235, 240], ["synchrotron x-ray transmission", "TEST", 52, 82], ["emission imaging", "TEST", 87, 103]]], ["A brief presentation of these methods will be followed by their application in studying the visual system from man to mouse.Insulin protective effects against cell degeneration induced by A-beta amyloidP.", [["cell", "ANATOMY", 159, 163], ["Insulin", "CHEMICAL", 124, 131], ["A-beta amyloidP", "CHEMICAL", 188, 203], ["man", "ORGANISM", 111, 114], ["mouse", "ORGANISM", 118, 123], ["Insulin", "GENE_OR_GENE_PRODUCT", 124, 131], ["cell", "CELL", 159, 163], ["A-beta amyloidP", "SIMPLE_CHEMICAL", 188, 203], ["A-beta amyloidP", "PROTEIN", 188, 203], ["man", "SPECIES", 111, 114], ["mouse", "SPECIES", 118, 123], ["mouse", "SPECIES", 118, 123], ["these methods", "TREATMENT", 24, 37], ["Insulin protective effects", "TREATMENT", 124, 150], ["cell degeneration", "PROBLEM", 159, 176], ["A-beta amyloidP", "PROBLEM", 188, 203], ["against cell degeneration", "OBSERVATION", 151, 176]]], ["Picone 1 , R. Carrotta 2 , D. Giacomazza 2 , M. Di Carlo 3 1 Dip.", [["Picone", "TREATMENT", 0, 6], ["R.", "ANATOMY", 11, 13]]], ["Chimica e Tecnologie Farmaceutiche, Universit\u00e0 di Palermo, Italia, 2 IBF -CNR, Palermo, Italia, 3 IBIM -CNR, Palermo, Italia Diabetes and Alzheimer's disease are connected in a way that still is not completely known.", [["Diabetes", "DISEASE", 125, 133], ["Alzheimer's disease", "DISEASE", 138, 157], ["Chimica", "TEST", 0, 7], ["Italia Diabetes", "PROBLEM", 118, 133], ["Alzheimer's disease", "PROBLEM", 138, 157], ["Italia", "ANATOMY", 118, 124], ["Diabetes", "OBSERVATION", 125, 133], ["Alzheimer", "OBSERVATION", 138, 147]]], ["Diabetes has been implicated as a risk factor for developing Alzheimer's disease.", [["Diabetes", "DISEASE", 0, 8], ["Alzheimer's disease", "DISEASE", 61, 80], ["Diabetes", "PROBLEM", 0, 8], ["developing Alzheimer's disease", "PROBLEM", 50, 80], ["Alzheimer", "OBSERVATION", 61, 70]]], ["Some diabetes drugs appear to decrease the cognitive decline associated with Alzheimer's disease.", [["diabetes", "DISEASE", 5, 13], ["cognitive decline", "DISEASE", 43, 60], ["Alzheimer's disease", "DISEASE", 77, 96], ["Some diabetes drugs", "PROBLEM", 0, 19], ["the cognitive decline", "PROBLEM", 39, 60], ["Alzheimer's disease", "PROBLEM", 77, 96], ["diabetes", "OBSERVATION", 5, 13]]], ["It has been recently demonstrated that extracellular injection of insulin is able to protect neurons against A-beta amyloid cell death.", [["extracellular", "ANATOMY", 39, 52], ["neurons", "ANATOMY", 93, 100], ["A-beta amyloid cell", "ANATOMY", 109, 128], ["death", "DISEASE", 129, 134], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["insulin", "GENE_OR_GENE_PRODUCT", 66, 73], ["neurons", "CELL", 93, 100], ["cell", "CELL", 124, 128], ["insulin", "PROTEIN", 66, 73], ["extracellular injection of insulin", "TREATMENT", 39, 73], ["A-beta amyloid cell death", "PROBLEM", 109, 134], ["amyloid cell death", "OBSERVATION", 116, 134]]], ["One of the proposed theories to explain such an effect is that the hematic glucose levels affect the metabolism of the hippocampus, a part of the brain (associated with memory, emotion and motor skills), which is strongly damaged in Alzheimer's patients.", [["hippocampus", "ANATOMY", 119, 130], ["brain", "ANATOMY", 146, 151], ["glucose", "CHEMICAL", 75, 82], ["Alzheimer", "DISEASE", 233, 242], ["glucose", "CHEMICAL", 75, 82], ["glucose", "SIMPLE_CHEMICAL", 75, 82], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 119, 130], ["brain", "ORGAN", 146, 151], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["the hematic glucose levels", "TEST", 63, 89], ["hippocampus", "ANATOMY", 119, 130], ["brain", "ANATOMY", 146, 151]]], ["The aim of this study is to investigate the effect of insulin on the A-beta induced degeneration and oxidative stress on the neuroblastoma LAN5 cell line.", [["neuroblastoma LAN5 cell line", "ANATOMY", 125, 153], ["insulin", "GENE_OR_GENE_PRODUCT", 54, 61], ["A-beta", "GENE_OR_GENE_PRODUCT", 69, 75], ["neuroblastoma LAN5 cell line", "CELL", 125, 153], ["insulin", "PROTEIN", 54, 61], ["A-beta", "PROTEIN", 69, 75], ["neuroblastoma LAN5 cell line", "CELL_LINE", 125, 153], ["this study", "TEST", 11, 21], ["insulin", "TREATMENT", 54, 61], ["the A-beta induced degeneration", "PROBLEM", 65, 96], ["oxidative stress", "PROBLEM", 101, 117], ["the neuroblastoma LAN5 cell line", "TREATMENT", 121, 153], ["degeneration", "OBSERVATION", 84, 96], ["oxidative stress", "OBSERVATION", 101, 117], ["neuroblastoma", "ANATOMY", 125, 138], ["LAN5 cell line", "OBSERVATION", 139, 153]]], ["In particular, the present study looks into the role of insulin in the inhibition of Abeta specific degenerative apoptotic pathways.", [["insulin", "GENE_OR_GENE_PRODUCT", 56, 63], ["Abeta", "GENE_OR_GENE_PRODUCT", 85, 90], ["insulin", "PROTEIN", 56, 63], ["the present study", "TEST", 15, 32], ["insulin", "TREATMENT", 56, 63], ["Abeta specific degenerative apoptotic pathways", "PROBLEM", 85, 131], ["degenerative", "OBSERVATION_MODIFIER", 100, 112], ["apoptotic pathways", "OBSERVATION", 113, 131]]], ["Preliminary results indicate that insulin dissolved in culture medium in its hexameric form (as tested by absolute scale light scattering) is able to reduce neurodegeneration induced by A-beta amyloid in a dose dependent manner.", [["neurodegeneration", "DISEASE", 157, 174], ["insulin", "GENE_OR_GENE_PRODUCT", 34, 41], ["A-beta amyloid", "GENE_OR_GENE_PRODUCT", 186, 200], ["insulin", "PROTEIN", 34, 41], ["hexameric form", "PROTEIN", 77, 91], ["A-beta amyloid", "PROTEIN", 186, 200], ["insulin", "TREATMENT", 34, 41], ["culture medium", "TEST", 55, 69], ["neurodegeneration", "PROBLEM", 157, 174], ["A-beta amyloid", "PROBLEM", 186, 200], ["amyloid", "OBSERVATION", 193, 200]]], ["The link between diabetes and Alzheimer's disease may provide new targets for future Alzheimer's treatments.", [["diabetes", "DISEASE", 17, 25], ["Alzheimer's disease", "DISEASE", 30, 49], ["Alzheimer", "DISEASE", 85, 94], ["diabetes", "PROBLEM", 17, 25], ["Alzheimer's disease", "PROBLEM", 30, 49], ["future Alzheimer's treatments", "TREATMENT", 78, 107], ["diabetes", "OBSERVATION", 17, 25], ["Alzheimer", "OBSERVATION", 30, 39]]], ["Moreover, due to the increased incidence of diabetes in western countries, a deeper understanding of such a link is relevant in order to control the escalation in the number of people dealing with dementia.Pathways of proteins and RNA mechanical unfolding: an Ising-like modelA.", [["diabetes", "DISEASE", 44, 52], ["dementia", "DISEASE", 197, 205], ["people", "ORGANISM", 177, 183], ["modelA", "PROTEIN", 271, 277], ["people", "SPECIES", 177, 183], ["diabetes", "PROBLEM", 44, 52], ["dementia", "PROBLEM", 197, 205], ["proteins", "TEST", 218, 226], ["RNA mechanical unfolding", "PROBLEM", 231, 255], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["diabetes", "OBSERVATION", 44, 52], ["dementia", "OBSERVATION", 197, 205], ["RNA mechanical unfolding", "OBSERVATION", 231, 255]]], ["Pelizzola Dipartimento di Fisica, Politecnico di Torino, Torino, Italy Many features of protein folding have been shown to be described by an Ising-like model (one-dimensional, with longrange, multispin interactions) whose equilibrium thermodynamics is exactly solvable [1] [2] [3] .Pathways of proteins and RNA mechanical unfolding: an Ising-like modelWe have generalized such a model to the problem of mechanical unfolding.", [["Pelizzola Dipartimento di Fisica", "TREATMENT", 0, 32], ["Politecnico di Torino", "TREATMENT", 34, 55], ["protein folding", "PROBLEM", 88, 103], ["RNA mechanical unfolding", "PROBLEM", 308, 332], ["mechanical unfolding", "PROBLEM", 404, 424], ["protein folding", "OBSERVATION", 88, 103], ["RNA mechanical unfolding", "OBSERVATION", 308, 332], ["mechanical unfolding", "OBSERVATION", 404, 424]]], ["The equilibrium thermodynamics is still exactly solvable, and the characteristic kinetic responses found in force ramp and force clamp experiments are well reproduced [4, 5] .", [["force clamp experiments", "TREATMENT", 123, 146], ["equilibrium thermodynamics", "OBSERVATION", 4, 30]]], ["Unfolding and refolding pathways and intermediates can also be studied, again with good agreement with experiments [6].", [["Unfolding and refolding pathways", "PROBLEM", 0, 32]]], ["Applications to various proteins and RNA fragments will be discussed.", [["RNA fragments", "DNA", 37, 50], ["various proteins", "TREATMENT", 16, 32], ["RNA fragments", "TREATMENT", 37, 50], ["RNA fragments", "OBSERVATION", 37, 50]]], ["[ The key role of water in living systems has been widely studied in Literature, along with its anomalies, consequence of the extensive three-dimensional hydrogen bonding of water molecules.", [["hydrogen", "CHEMICAL", 154, 162], ["water", "SIMPLE_CHEMICAL", 18, 23], ["water molecules", "SIMPLE_CHEMICAL", 174, 189], ["its anomalies", "PROBLEM", 92, 105]]], ["Moreover protein-water interactions take place at protein surface where cell water has been recognized to behave differently from bulky water.", [["surface", "ANATOMY", 58, 65], ["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["Moreover protein-water interactions", "TREATMENT", 0, 35]]], ["The two-states theory of water assumes that water is a mixture of microdomains of different structure and density, the low-density water (LDW) and the high-density water (HDW) domains, and ions partition selectively into LDW or HDW domains.", [["water", "SIMPLE_CHEMICAL", 25, 30], ["water", "SIMPLE_CHEMICAL", 44, 49], ["ions", "SIMPLE_CHEMICAL", 189, 193], ["LDW", "SIMPLE_CHEMICAL", 221, 224], ["high-density water (HDW) domains", "PROTEIN", 151, 183], ["LDW", "PROTEIN", 221, 224], ["HDW domains", "PROTEIN", 228, 239], ["the high-density water (HDW) domains", "TREATMENT", 147, 183], ["different structure", "OBSERVATION_MODIFIER", 82, 101], ["density", "OBSERVATION", 106, 113], ["low-density", "OBSERVATION_MODIFIER", 119, 130], ["density", "OBSERVATION", 156, 163]]], ["The idea developed in this work was to explore the ordered water structure by measuring Delayed Luminescence (DL) from salt aqueous solutions in which water structuring is anticipated.", [["the ordered water structure", "TREATMENT", 47, 74], ["salt aqueous solutions", "TREATMENT", 119, 141]]], ["It appeared that DL signal from salt solutions is significantly relevant when prevalence of LDW domains is foreseen, with a decay time probability distribution function characterized by a broad maximum in the microsecond range.", [["LDW domains", "PROTEIN", 92, 103], ["DL signal from salt solutions", "PROBLEM", 17, 46], ["LDW domains", "PROBLEM", 92, 103], ["DL", "OBSERVATION_MODIFIER", 17, 19], ["salt solutions", "OBSERVATION", 32, 46], ["broad", "OBSERVATION_MODIFIER", 188, 193], ["maximum", "OBSERVATION_MODIFIER", 194, 201]]], ["The obtained results support the ability of DL to reveal the different properties of LDW and HDW domains induced by salt molecules.", [["LDW", "SIMPLE_CHEMICAL", 85, 88], ["salt molecules", "SIMPLE_CHEMICAL", 116, 130], ["LDW and HDW domains", "PROTEIN", 85, 104], ["LDW", "PROBLEM", 85, 88], ["HDW domains", "PROBLEM", 93, 104], ["salt molecules", "OBSERVATION", 116, 130]]], ["Moreover, the results reveal the existence of clusters, whose characteristics strongly depend on the specific ion effects, of surprisingly long lifetimes not observed till now.", [["clusters", "OBSERVATION", 46, 54]]], ["This could give new insight into biological water properties.P-353Self assembly of patchy particles and DNAfunctionalized dendrimers F. Sciortino Dipartimento di Fisica e INFM-CNR-SOFT Universit\u00e0 'La Sapienza', Roma, Italy I will report numerical results on the phase behavior of very simple models of patchy particles with the aim of understanding the interplay between phase separation and selfassembly and how the fraction of surface allowing for attractive interactions controls the collective behavior of the system.", [["surface", "ANATOMY", 429, 436], ["surface", "CELLULAR_COMPONENT", 429, 436], ["patchy particles", "PROBLEM", 83, 99], ["patchy particles", "PROBLEM", 302, 318], ["patchy", "OBSERVATION_MODIFIER", 83, 89]]], ["The case of Janus particles, particles characterized by a surface divided evenly into two areas of different chemical composition, will be discussed.", [["surface", "ANATOMY", 58, 65], ["Janus particles", "SIMPLE_CHEMICAL", 12, 27], ["Janus particles", "OBSERVATION", 12, 27], ["different", "OBSERVATION_MODIFIER", 99, 108], ["chemical composition", "OBSERVATION", 109, 129]]], ["I will also discuss the self-assembly of a simple model for four single strands of DNA tethered to a central core, and show that the model exhibits a rich phase diagram that includes at least four thermodynamically distinct amorphous phases (polyamorphism) in a one-component system.", [["DNA", "CELLULAR_COMPONENT", 83, 86], ["a rich phase diagram", "TEST", 148, 168]]], ["The dense phases consist of a hierarchy of interpenetrating networks, reminiscent of a woven cloth.O-352Peptide dimer motifs in the phospholipid environment -structure, interaction and molecular design P. E. Schneggenburger 1 , A. Beerlink 2 , T. Salditt 2 , U. Diederichsen 1 1 IOBC, Universit\u00e4t G\u00f6ttingen, Germany., 2 IRP, Universit\u00e4t G\u00f6ttingen, Germany.O-352Based on recently reported homodimeric peptide pores with a d,l-alternating configuration a novel double helical hairpin-motif of a membrane active gramicidin A analog was designed.", [["membrane", "ANATOMY", 493, 501], ["O-352Peptide", "CHEMICAL", 99, 111], ["O-352Based", "CHEMICAL", 356, 366], ["gramicidin", "CHEMICAL", 509, 519], ["O-352Peptide", "CHEMICAL", 99, 111], ["O-352Based", "CHEMICAL", 356, 366], ["O-352Peptide", "SIMPLE_CHEMICAL", 99, 111], ["phospholipid", "SIMPLE_CHEMICAL", 132, 144], ["O-352Based", "SIMPLE_CHEMICAL", 356, 366], ["membrane", "CELLULAR_COMPONENT", 493, 501], ["gramicidin A", "SIMPLE_CHEMICAL", 509, 521], ["interpenetrating networks", "PROTEIN", 43, 68], ["O-352Peptide dimer motifs", "PROTEIN", 99, 124], ["a woven cloth", "TREATMENT", 85, 98], ["homodimeric peptide pores", "PROBLEM", 388, 413], ["a d,l-alternating configuration", "PROBLEM", 419, 450], ["a novel double helical hairpin", "TREATMENT", 451, 481], ["a membrane active gramicidin A analog", "TREATMENT", 491, 528], ["dense", "OBSERVATION_MODIFIER", 4, 9], ["phases", "OBSERVATION_MODIFIER", 10, 16], ["interpenetrating networks", "OBSERVATION", 43, 68], ["woven cloth", "OBSERVATION", 87, 98]]], ["[1, 2] The CD spectroscopic analyses of the peptide-lipid complexes revealed the structural preservation and elucidated the importance of a zwitterionic interaction of the peptide termini.", [["The CD spectroscopic analyses", "TEST", 7, 36], ["the peptide-lipid complexes", "TEST", 40, 67], ["the peptide termini", "TREATMENT", 168, 187], ["structural preservation", "OBSERVATION", 81, 104]]], ["[3] The peptide design was enhanced regarding the versatile functionalization with analytical probes as well as molecular recognition moieties like peptide nucleic acids (PNAs) to observe the effects of aggregation and specific organization within model lipid membranes even at high peptide-to-lipid ratios.", [["lipid membranes", "ANATOMY", 254, 269], ["nucleic acids", "CHEMICAL", 156, 169], ["peptide nucleic acids", "SIMPLE_CHEMICAL", 148, 169], ["lipid membranes", "CELLULAR_COMPONENT", 254, 269], ["lipid", "SIMPLE_CHEMICAL", 294, 299], ["The peptide design", "TEST", 4, 22], ["the versatile functionalization", "TREATMENT", 46, 77], ["analytical probes", "TREATMENT", 83, 100], ["peptide nucleic acids (PNAs)", "PROBLEM", 148, 176], ["aggregation", "PROBLEM", 203, 214], ["aggregation", "OBSERVATION", 203, 214], ["lipid membranes", "OBSERVATION", 254, 269]]], ["[3] X-ray reflectivity on lipid bilayer stacks in combination with heavy atom labeling and spectroscopic studies of vesicle systems provides information about the peptide structure and interaction in the native fluid state of the membrane system.", [["lipid bilayer stacks", "ANATOMY", 26, 46], ["vesicle", "ANATOMY", 116, 123], ["membrane system", "ANATOMY", 230, 245], ["membrane", "CELLULAR_COMPONENT", 230, 238], ["X-ray reflectivity", "TEST", 4, 22], ["lipid bilayer stacks", "TREATMENT", 26, 46], ["heavy atom labeling", "TEST", 67, 86], ["spectroscopic studies of vesicle systems", "TEST", 91, 131], ["fluid state", "OBSERVATION", 211, 222], ["membrane system", "ANATOMY", 230, 245]]], ["[2, 3] For this, the Fmoc-diiodo-allylglycine building block was created to serve as a novel iodine label pinpointing at a certain position with respect to the membrane normal.", [["membrane", "ANATOMY", 160, 168], ["Fmoc-diiodo-allylglycine", "CHEMICAL", 21, 45], ["Fmoc-diiodo-allylglycine", "CHEMICAL", 21, 45], ["iodine", "CHEMICAL", 93, 99], ["Fmoc-diiodo-allylglycine", "SIMPLE_CHEMICAL", 21, 45], ["iodine", "SIMPLE_CHEMICAL", 93, 99], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["the Fmoc-diiodo-allylglycine building block", "TREATMENT", 17, 60], ["a novel iodine label", "TREATMENT", 85, 105], ["membrane", "ANATOMY", 160, 168], ["normal", "OBSERVATION", 169, 175]]], ["We study thermal undulations of giant unilamellar vesicles (GUVs) of lipids by flickering spectroscopy.", [["giant unilamellar vesicles", "ANATOMY", 32, 58], ["GUVs", "ANATOMY", 60, 64], ["unilamellar vesicles", "CELLULAR_COMPONENT", 38, 58], ["lipids", "SIMPLE_CHEMICAL", 69, 75], ["giant unilamellar vesicles", "TREATMENT", 32, 58], ["lipids", "TREATMENT", 69, 75], ["flickering spectroscopy", "TEST", 79, 102], ["giant", "OBSERVATION_MODIFIER", 32, 37], ["unilamellar vesicles", "OBSERVATION", 38, 58]]], ["Getting values for the mechanical parameters of lipid bilayers requires the experimental fluctuation spectra to be scrutinized in view of the classical Helfrich's theory.", [["the mechanical parameters of lipid bilayers", "TREATMENT", 19, 62], ["the experimental fluctuation spectra", "TREATMENT", 72, 108]]], ["Pure bending modes are revealed unable in predicting the large fluctuations systematically found at high wavevectors.", [["Pure bending modes", "TEST", 0, 18], ["the large fluctuations systematically", "PROBLEM", 53, 90], ["large", "OBSERVATION_MODIFIER", 57, 62], ["fluctuations", "OBSERVATION", 63, 75]]], ["Hybrid curvature-dilational modes have been invoked as a more efficient mode of motion in producing high curvatures.", [["Hybrid curvature", "PROBLEM", 0, 16], ["dilational modes", "PROBLEM", 17, 33], ["curvature", "OBSERVATION_MODIFIER", 7, 16], ["dilational", "OBSERVATION", 17, 27], ["high curvatures", "OBSERVATION", 100, 115]]], ["A bimodal spectrum of the thermal undulations has been theoretically developed for the shell-like topology.", [["the thermal undulations", "PROBLEM", 22, 45], ["bimodal", "OBSERVATION_MODIFIER", 2, 9], ["spectrum", "OBSERVATION_MODIFIER", 10, 18]]], ["From this new description, two important consequences emerge a priori, the dependence of the fluctuation dynamics on either vesicle size and on bending/compression parameters.", [["vesicle", "ANATOMY", 124, 131], ["vesicle", "CELLULAR_COMPONENT", 124, 131], ["bending/compression parameters", "TEST", 144, 174], ["size", "OBSERVATION_MODIFIER", 132, 136], ["compression", "OBSERVATION", 152, 163]]], ["For POPC and DOPC vesicles containing cholesterol the experimental fluctuation spectra are well described by the new spectrum.", [["DOPC vesicles", "ANATOMY", 13, 26], ["POPC", "CHEMICAL", 4, 8], ["cholesterol", "CHEMICAL", 38, 49], ["POPC", "CHEMICAL", 4, 8], ["DOPC", "CHEMICAL", 13, 17], ["cholesterol", "CHEMICAL", 38, 49], ["POPC", "SIMPLE_CHEMICAL", 4, 8], ["DOPC vesicles", "SIMPLE_CHEMICAL", 13, 26], ["cholesterol", "SIMPLE_CHEMICAL", 38, 49], ["POPC and DOPC vesicles", "TEST", 4, 26], ["cholesterol the experimental fluctuation spectra", "PROBLEM", 38, 86], ["DOPC vesicles", "OBSERVATION", 13, 26], ["cholesterol", "OBSERVATION_MODIFIER", 38, 49], ["experimental", "OBSERVATION_MODIFIER", 54, 66], ["fluctuation spectra", "OBSERVATION", 67, 86]]], ["The new theory opens enormous possibilities for better exploring membrane mechanics in GUV models.", [["membrane", "ANATOMY", 65, 73], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Under normal conditions, platelets circulate in the vascular system having very low interaction with each other and with other cells.", [["platelets", "ANATOMY", 25, 34], ["vascular system", "ANATOMY", 52, 67], ["cells", "ANATOMY", 127, 132], ["platelets", "CELL", 25, 34], ["vascular system", "MULTI-TISSUE_STRUCTURE", 52, 67], ["cells", "CELL", 127, 132], ["platelets", "CELL_TYPE", 25, 34], ["normal conditions", "OBSERVATION", 6, 23], ["vascular system", "ANATOMY", 52, 67], ["very", "OBSERVATION_MODIFIER", 75, 79], ["low", "OBSERVATION", 80, 83]]], ["The platelets become activated when the biological system is disturbed, for instance by vascular damage in which blood gets in contact with collagen.", [["platelets", "ANATOMY", 4, 13], ["vascular", "ANATOMY", 88, 96], ["blood", "ANATOMY", 113, 118], ["vascular damage", "DISEASE", 88, 103], ["platelets", "CELL", 4, 13], ["vascular", "MULTI-TISSUE_STRUCTURE", 88, 96], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["collagen", "GENE_OR_GENE_PRODUCT", 140, 148], ["platelets", "CELL_TYPE", 4, 13], ["collagen", "PROTEIN", 140, 148], ["vascular damage", "PROBLEM", 88, 103], ["vascular", "ANATOMY", 88, 96], ["damage", "OBSERVATION", 97, 103]]], ["Upon activation, different types of receptors/molecules are exposed on the cell membrane to support adhesion, spreading and aggregation of the platelets onto the damaged vessel.", [["cell membrane", "ANATOMY", 75, 88], ["platelets", "ANATOMY", 143, 152], ["vessel", "ANATOMY", 170, 176], ["cell membrane", "CELLULAR_COMPONENT", 75, 88], ["platelets", "CELL", 143, 152], ["vessel", "MULTI-TISSUE_STRUCTURE", 170, 176], ["platelets", "CELL_TYPE", 143, 152], ["receptors/molecules", "TREATMENT", 36, 55], ["the cell membrane", "TREATMENT", 71, 88], ["adhesion", "PROBLEM", 100, 108], ["aggregation of the platelets", "PROBLEM", 124, 152], ["cell membrane", "OBSERVATION", 75, 88], ["adhesion", "OBSERVATION_MODIFIER", 100, 108], ["damaged", "ANATOMY_MODIFIER", 162, 169], ["vessel", "ANATOMY", 170, 176]]], ["The measurement of altered platelet function is particularly important in cardiovascular diseases such as thrombosis.", [["platelet", "ANATOMY", 27, 35], ["cardiovascular", "ANATOMY", 74, 88], ["cardiovascular diseases", "DISEASE", 74, 97], ["thrombosis", "DISEASE", 106, 116], ["platelet", "CELL", 27, 35], ["cardiovascular", "ANATOMICAL_SYSTEM", 74, 88], ["altered platelet function", "PROBLEM", 19, 44], ["cardiovascular diseases", "PROBLEM", 74, 97], ["thrombosis", "PROBLEM", 106, 116], ["altered", "OBSERVATION_MODIFIER", 19, 26], ["platelet function", "OBSERVATION", 27, 44], ["thrombosis", "OBSERVATION", 106, 116]]], ["We are investigating biosensor technologies for the detection of functional properties of platelets.", [["platelets", "ANATOMY", 90, 99], ["platelets", "CELL", 90, 99], ["platelets", "CELL_TYPE", 90, 99], ["the detection", "TEST", 48, 61], ["platelets", "TEST", 90, 99]]], ["An important study is the specific and non-specific stimulation of platelets in a biosensor cartridge.", [["platelets", "ANATOMY", 67, 76], ["platelets", "CELL", 67, 76], ["platelets", "CELL_TYPE", 67, 76], ["An important study", "TEST", 0, 18], ["a biosensor cartridge", "TREATMENT", 80, 101]]], ["We will present experimental results on biosensor platelet activation using the platelet-specific membrane markers P-selectin and GP1b.P-357Multi-joint analysis of locomotion in the first neonatal rats flown in space D. Sulica, J. Vinersan \"Carol Davila\" University of Medicine and Pharmacy, Bucharest, RomaniaP-357The first mammalian neonatal animals in space were the rats flown on the Space Shuttle Endeavor during a 9-day mission, STS-72.", [["platelet", "ANATOMY", 50, 58], ["platelet", "ANATOMY", 80, 88], ["membrane", "ANATOMY", 98, 106], ["RomaniaP-357", "CHEMICAL", 303, 315], ["platelet", "CELL", 50, 58], ["platelet", "CELL", 80, 88], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["P-selectin", "GENE_OR_GENE_PRODUCT", 115, 125], ["GP1b", "GENE_OR_GENE_PRODUCT", 130, 134], ["rats", "ORGANISM", 197, 201], ["animals", "ORGANISM", 344, 351], ["rats", "ORGANISM", 370, 374], ["platelet-specific membrane markers", "PROTEIN", 80, 114], ["P", "PROTEIN", 115, 116], ["selectin", "PROTEIN", 117, 125], ["GP1b", "PROTEIN", 130, 134], ["P", "DNA", 135, 136], ["rats", "SPECIES", 197, 201], ["rats", "SPECIES", 370, 374], ["biosensor platelet activation", "TREATMENT", 40, 69], ["the platelet", "TEST", 76, 88], ["P", "TEST", 135, 136], ["joint analysis", "TEST", 146, 160], ["locomotion", "PROBLEM", 164, 174], ["STS", "TEST", 435, 438], ["joint", "ANATOMY", 146, 151], ["Sulica", "ANATOMY", 220, 226]]], ["The development of locomotion in weightlessness was evaluated using two litters of neonatal rats, launched at postnatal days 7 and 15.", [["rats", "ORGANISM", 92, 96], ["rats", "SPECIES", 92, 96], ["locomotion in weightlessness", "PROBLEM", 19, 47], ["neonatal rats", "TREATMENT", 83, 96], ["locomotion", "OBSERVATION_MODIFIER", 19, 29]]], ["Age-and cage-matched animals were used as ground controls.", [["animals", "ORGANISM", 21, 28], ["cage-matched animals", "TREATMENT", 8, 28]]], ["Although preliminary analysis of walking showed differences in both hindlimb and forelimb joint angles and a hyperextension of the hindlimbs was apparent, the numerical values reached the significance level only for the ankle angle measured at specific moments of the step cycle: foot contact, maximum loading with weight, foot lift and maximum flexion during swing.", [["hindlimb", "ANATOMY", 68, 76], ["forelimb joint", "ANATOMY", 81, 95], ["hindlimbs", "ANATOMY", 131, 140], ["ankle", "ANATOMY", 220, 225], ["foot", "ANATOMY", 280, 284], ["hyperextension", "DISEASE", 109, 123], ["hindlimb", "ORGANISM_SUBDIVISION", 68, 76], ["forelimb joint", "MULTI-TISSUE_STRUCTURE", 81, 95], ["hindlimbs", "ORGAN", 131, 140], ["ankle", "ORGANISM_SUBDIVISION", 220, 225], ["foot", "ORGANISM_SUBDIVISION", 280, 284], ["foot", "ORGANISM_SUBDIVISION", 323, 327], ["preliminary analysis of walking", "TEST", 9, 40], ["differences in both hindlimb and forelimb joint angles", "PROBLEM", 48, 102], ["a hyperextension of the hindlimbs", "PROBLEM", 107, 140], ["the numerical values", "TEST", 155, 175], ["weight", "TEST", 315, 321], ["both", "ANATOMY_MODIFIER", 63, 67], ["hindlimb", "ANATOMY", 68, 76], ["forelimb joint", "ANATOMY", 81, 95], ["hyperextension", "OBSERVATION", 109, 123], ["hindlimbs", "ANATOMY", 131, 140], ["ankle angle", "ANATOMY", 220, 231], ["foot", "ANATOMY", 280, 284], ["foot", "ANATOMY", 323, 327]]], ["We report here on the behavior of all the joints during the whole step cycle, by computing the integral of these angles over the step cycle.", [["joints", "MULTI-TISSUE_STRUCTURE", 42, 48], ["joints", "ANATOMY", 42, 48], ["angles", "ANATOMY_MODIFIER", 113, 119]]], ["We found that, besides the ankle, the knee was also more extended throughout the whole step cycle in both groups of animals.", [["ankle", "ANATOMY", 27, 32], ["knee", "ANATOMY", 38, 42], ["ankle", "ORGANISM_SUBDIVISION", 27, 32], ["knee", "ORGANISM_SUBDIVISION", 38, 42], ["ankle", "ANATOMY", 27, 32], ["knee", "ANATOMY", 38, 42]]], ["Moreover, all the joints (including the toe and the hip) were affected in the same way (hyperextended), since the differences were still significant when we added together these angles.", [["joints", "ANATOMY", 18, 24], ["toe", "ANATOMY", 40, 43], ["hip", "ANATOMY", 52, 55], ["joints", "MULTI-TISSUE_STRUCTURE", 18, 24], ["toe", "ORGANISM_SUBDIVISION", 40, 43], ["hip", "ORGANISM_SUBDIVISION", 52, 55], ["joints", "ANATOMY", 18, 24], ["toe", "ANATOMY", 40, 43], ["hip", "ANATOMY", 52, 55]]], ["The animals recovered slowly, with significant differences remaining after 14 days of readaptation.P-356The effect of Dextran 70 concentration on red blood cell deposit formation J. Strzelecka, B. Grzegorzewski Department of Biophysics, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University 85-067 Bydgoszcz, Poland Red blood cell (RBC) deposit formation was examined by means of an optical method.", [["red blood cell", "ANATOMY", 146, 160], ["Red blood cell", "ANATOMY", 325, 339], ["RBC", "ANATOMY", 341, 344], ["P-356", "CHEMICAL", 99, 104], ["Dextran", "CHEMICAL", 118, 125], ["animals", "ORGANISM", 4, 11], ["Dextran 70", "SIMPLE_CHEMICAL", 118, 128], ["red blood cell", "CELL", 146, 160], ["Red blood cell", "CELL", 325, 339], ["RBC", "CELL", 341, 344], ["Dextran", "TREATMENT", 118, 125], ["red blood cell deposit", "TREATMENT", 146, 168], ["Bydgoszcz", "TEST", 307, 316], ["Red blood cell", "TEST", 325, 339], ["RBC) deposit formation", "PROBLEM", 341, 363], ["an optical method", "TEST", 389, 406], ["slowly", "OBSERVATION_MODIFIER", 22, 28], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["blood cell deposit", "OBSERVATION", 150, 168], ["blood cell", "ANATOMY", 329, 339]]], ["Blood was obtained from healthy donors and measurements were performed at initial hematocrit 40%.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["donors", "ORGANISM", 32, 38], ["Blood", "TEST", 0, 5], ["initial hematocrit", "TEST", 74, 92]]], ["The intensity of scattered light was measured during sedimentation of RBCs suspended in saline -Dextran 70 solutions at different polymer concentrations (2 -6 g/dl).", [["RBCs", "ANATOMY", 70, 74], ["Dextran", "CHEMICAL", 96, 103], ["RBCs", "CELL", 70, 74], ["saline -Dextran 70 solutions", "SIMPLE_CHEMICAL", 88, 116], ["RBCs", "CELL_TYPE", 70, 74], ["sedimentation of RBCs", "TREATMENT", 53, 74], ["saline", "TREATMENT", 88, 94], ["Dextran", "TREATMENT", 96, 103], ["different polymer concentrations", "TREATMENT", 120, 152], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["scattered", "OBSERVATION_MODIFIER", 17, 26], ["light", "OBSERVATION_MODIFIER", 27, 32]]], ["The changes in the intensity of the scattered light manifest RBC aggregate formation, their sedimentation and the process of deposit formation.", [["RBC aggregate", "ANATOMY", 61, 74], ["RBC aggregate", "CELLULAR_COMPONENT", 61, 74], ["RBC", "CELL_TYPE", 61, 64], ["The changes", "PROBLEM", 0, 11], ["the scattered light manifest RBC aggregate formation", "PROBLEM", 32, 84], ["their sedimentation", "PROBLEM", 86, 105], ["deposit formation", "PROBLEM", 125, 142], ["intensity", "OBSERVATION_MODIFIER", 19, 28], ["scattered", "OBSERVATION_MODIFIER", 36, 45], ["light manifest", "OBSERVATION_MODIFIER", 46, 60], ["RBC", "OBSERVATION", 61, 64], ["aggregate formation", "OBSERVATION", 65, 84], ["sedimentation", "OBSERVATION_MODIFIER", 92, 105], ["deposit formation", "OBSERVATION", 125, 142]]], ["The deposit formation curve was determined.", [["The deposit formation curve", "PROBLEM", 0, 27], ["deposit", "OBSERVATION", 4, 11], ["curve", "OBSERVATION_MODIFIER", 22, 27]]], ["It is shown that the concentration of dextran affects the deposit formation.", [["dextran", "CHEMICAL", 38, 45], ["dextran", "SIMPLE_CHEMICAL", 38, 45], ["dextran", "TREATMENT", 38, 45], ["deposit formation", "OBSERVATION", 58, 75]]], ["The parameters of the deposit formation curve as a function of dextran concentration are analyzed.", [["dextran", "CHEMICAL", 63, 70], ["dextran", "SIMPLE_CHEMICAL", 63, 70], ["the deposit formation curve", "TREATMENT", 18, 45], ["dextran concentration", "TREATMENT", 63, 84]]], ["Water is essential to life and a major scientific interest lies in a detailed understanding of how it interacts with biological macromolecules in cells.", [["cells", "ANATOMY", 146, 151], ["cells", "CELL", 146, 151]]], ["We studied water dynamics in whole cells with neutron scattering [1, 2, 3] .", [["whole cells", "ANATOMY", 29, 40], ["cells", "CELL", 35, 40], ["whole cells", "CELL_TYPE", 29, 40], ["neutron scattering", "TREATMENT", 46, 64]]], ["The cellular environment is extremely crowded with macromolecules and water molecules are permanently in close contact to biological interfaces.", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["cellular environment", "OBSERVATION", 4, 24], ["extremely", "OBSERVATION_MODIFIER", 28, 37], ["crowded", "OBSERVATION", 38, 45], ["water molecules", "OBSERVATION_MODIFIER", 70, 85]]], ["We measured water dynamics in E. coli and human Red Blood Cells with neutron scattering [2, 3] .", [["Blood Cells", "ANATOMY", 52, 63], ["E. coli", "ORGANISM", 30, 37], ["human", "ORGANISM", 42, 47], ["Red Blood Cells", "CELL", 48, 63], ["E. coli", "SPECIES", 30, 37], ["human", "SPECIES", 42, 47], ["E. coli", "SPECIES", 30, 37], ["human", "SPECIES", 42, 47], ["water dynamics in E. coli", "TEST", 12, 37], ["human Red Blood Cells", "TEST", 42, 63], ["neutron scattering", "TEST", 69, 87], ["E. coli", "OBSERVATION", 30, 37]]], ["The data revealed two populations of water in the cells: a major fraction which has dynamical properties similar to those of bulk water (relaxation times \u223cps) and a minor fraction in the order of \u223c10% which is interpreted as bound hydration water with significantly slower dynamics (relaxation times >49 ps).", [["cells", "ANATOMY", 50, 55], ["water", "SIMPLE_CHEMICAL", 37, 42], ["cells", "CELL", 50, 55], ["The data", "TEST", 0, 8], ["bulk water (relaxation times \u223cps", "TREATMENT", 125, 157], ["significantly slower dynamics", "PROBLEM", 252, 281], ["two", "OBSERVATION_MODIFIER", 18, 21], ["populations", "OBSERVATION_MODIFIER", 22, 33], ["dynamical properties", "OBSERVATION", 84, 104]]], ["In this contribution we report on investigation of model membrane dynamics by means of Quasi Elastic and Inelastic Incoherent Neutron scattering and on the effect of membrane inserted pore forming peptide Gramicidin.", [["membrane", "ANATOMY", 57, 65], ["membrane", "ANATOMY", 166, 174], ["pore", "ANATOMY", 184, 188], ["Gramicidin", "CHEMICAL", 205, 215], ["Gramicidin", "CHEMICAL", 205, 215], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["membrane", "CELLULAR_COMPONENT", 166, 174], ["Gramicidin", "SIMPLE_CHEMICAL", 205, 215], ["model membrane dynamics", "TREATMENT", 51, 74], ["Quasi Elastic and Inelastic Incoherent Neutron scattering", "TREATMENT", 87, 144], ["membrane inserted pore forming peptide Gramicidin", "TREATMENT", 166, 215], ["Inelastic Incoherent", "OBSERVATION", 105, 125], ["Neutron scattering", "OBSERVATION", 126, 144]]], ["Model membrane are realized by highly oriented, hydrated phospholipid bilayer stacks of DMPC (1,2-dimyristoyl-snglycero-3-phoshatidylcholine) hydrated with D2O in excess of solvent condition.", [["membrane", "ANATOMY", 6, 14], ["DMPC", "CHEMICAL", 88, 92], ["1,2-dimyristoyl-snglycero-3-phoshatidylcholine", "CHEMICAL", 94, 140], ["D2O", "CHEMICAL", 156, 159], ["DMPC", "CHEMICAL", 88, 92], ["1,2-dimyristoyl-snglycero-3-phoshatidylcholine", "CHEMICAL", 94, 140], ["D2O", "CHEMICAL", 156, 159], ["membrane", "CELLULAR_COMPONENT", 6, 14], ["phospholipid", "SIMPLE_CHEMICAL", 57, 69], ["DMPC", "SIMPLE_CHEMICAL", 88, 92], ["1,2-dimyristoyl-snglycero-3-phoshatidylcholine", "SIMPLE_CHEMICAL", 94, 140], ["D2O", "SIMPLE_CHEMICAL", 156, 159], ["hydrated phospholipid bilayer stacks of DMPC", "TREATMENT", 48, 92], ["dimyristoyl", "TREATMENT", 98, 109], ["snglycero", "TREATMENT", 110, 119], ["phoshatidylcholine", "TREATMENT", 122, 140], ["membrane", "OBSERVATION", 6, 14]]], ["The bilayer were supported on mica substrates and prepared at different concentrations of Gramicidin, a 15-residue oligopeptide showing antimicrobial activity by forming pores on the membrane surfaces which allow water and small ions to permeate across the membrane.", [["membrane surfaces", "ANATOMY", 183, 200], ["membrane", "ANATOMY", 257, 265], ["Gramicidin", "CHEMICAL", 90, 100], ["Gramicidin", "CHEMICAL", 90, 100], ["Gramicidin", "SIMPLE_CHEMICAL", 90, 100], ["water", "SIMPLE_CHEMICAL", 213, 218], ["membrane", "CELLULAR_COMPONENT", 257, 265], ["mica substrates", "TREATMENT", 30, 45], ["Gramicidin", "TREATMENT", 90, 100], ["a 15-residue oligopeptide", "TREATMENT", 102, 127], ["antimicrobial activity", "TREATMENT", 136, 158], ["the membrane surfaces", "TREATMENT", 179, 200], ["water and small ions", "TREATMENT", 213, 233], ["antimicrobial activity", "OBSERVATION", 136, 158], ["pores", "OBSERVATION_MODIFIER", 170, 175], ["membrane", "ANATOMY", 257, 265]]], ["Incoherent QENS and INS spectra, measured on IN5 and IN13 spectrometer at ILL, allows to obtaining information on the mean dynamics of the Hydrogen atoms in the system.", [["Hydrogen", "CHEMICAL", 139, 147], ["Hydrogen", "CHEMICAL", 139, 147], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 139, 153], ["Incoherent QENS and INS spectra", "PROBLEM", 0, 31], ["Hydrogen atoms", "OBSERVATION", 139, 153], ["system", "ANATOMY", 161, 167]]], ["Moreover, by proper orientations of the membrane plane respect to the scattering wave vector Q, we were able to derive information on in plane and out of plane motions of the phospholipids.P-360The using of media products for the creating attracted bioenergetic brain rhythmus advertisement V. I. Vlastopulo, V. G. Nikolajev Str.", [["membrane plane", "ANATOMY", 40, 54], ["brain", "ANATOMY", 262, 267], ["P-360", "CHEMICAL", 189, 194], ["phospholipids", "SIMPLE_CHEMICAL", 175, 188], ["brain", "ORGAN", 262, 267], ["the phospholipids", "TREATMENT", 171, 188], ["media products", "TREATMENT", 207, 221], ["brain", "ANATOMY", 262, 267]]], ["44, 65065 Odessa, UkraineP-360The technical efficiency of bioenergetical influence of advertisement is present with assistance of consciousness of memory at revision and hearing of advertisement on TV, radio stations, mobile phones, at supermarkets and other places.", [["UkraineP-360", "CHEMICAL", 18, 30], ["UkraineP", "TEST", 18, 26], ["memory at revision", "TREATMENT", 147, 165]]], ["In a basis of useful model it is put a task to improve the method of creating the attracted advertisement, in which the creation of bioenergetical influence by the oscillation of not less 2 electromagnetic fields or video-images is introduced with their creating as the base on the spatial or flat structure formative macro matrix or matrixes with repeatable structure with the brain \u03b1-rhythm frequency of extreme attention and \u03b4-rhythm frequency of meditation.", [["brain", "ANATOMY", 378, 383], ["matrix", "CELLULAR_COMPONENT", 324, 330], ["brain", "ORGAN", 378, 383], ["video-images", "TEST", 216, 228], ["base", "ANATOMY_MODIFIER", 270, 274], ["macro matrix", "OBSERVATION", 318, 330]]], ["The point of the patent on the device is in the bioenergetical influence increases in addition to the information influence by advertisement of pictures and audio oscillations the bioenergetical influence increases at the consciousness contribution of human memory at the moment of watching or hearing of television, radio stations, working in the Internet, music in the supermarkets, banks, clubs, metro and other places.", [["human", "ORGANISM", 252, 257], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["the device", "TREATMENT", 27, 37], ["audio oscillations the bioenergetical influence", "PROBLEM", 157, 204], ["human memory", "PROBLEM", 252, 264], ["patent", "OBSERVATION", 17, 23]]], ["Cell adhesion and motility are processes involved in fundamental biological phenomena.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell adhesion", "PROBLEM", 0, 13], ["fundamental biological phenomena", "PROBLEM", 53, 85], ["fundamental biological phenomena", "OBSERVATION", 53, 85]]], ["They imply multimolecular scaffolds as anchorage points and actin cytoskeleton filaments to build internal stress and eventually crawl onto the substrate.", [["cytoskeleton filaments", "ANATOMY", 66, 88], ["actin", "GENE_OR_GENE_PRODUCT", 60, 65], ["cytoskeleton filaments", "CELLULAR_COMPONENT", 66, 88], ["actin", "PROTEIN", 60, 65], ["multimolecular scaffolds", "TREATMENT", 11, 35], ["actin cytoskeleton filaments", "PROBLEM", 60, 88], ["multimolecular scaffolds", "OBSERVATION", 11, 35]]], ["These processes, very dynamic by nature are out of equilibrium.", [["very", "OBSERVATION_MODIFIER", 17, 21], ["dynamic", "OBSERVATION_MODIFIER", 22, 29]]], ["We study cell adhesion on micro-patterned substrates where the introduction of a finite distance between the possible anchorage points of the cell modifies drastically the organization of the cytoskeleton and the anchorage point's distribution.", [["cell", "ANATOMY", 9, 13], ["cell", "ANATOMY", 142, 146], ["cytoskeleton", "ANATOMY", 192, 204], ["cell", "CELL", 9, 13], ["cell", "CELL", 142, 146], ["cytoskeleton", "CELLULAR_COMPONENT", 192, 204], ["cell adhesion", "OBSERVATION", 9, 22], ["possible", "UNCERTAINTY", 109, 117], ["anchorage", "OBSERVATION_MODIFIER", 118, 127], ["cell", "OBSERVATION", 142, 146], ["cytoskeleton", "OBSERVATION_MODIFIER", 192, 204], ["anchorage", "OBSERVATION_MODIFIER", 213, 222]]], ["Because statistical quantification shows that some shapes are more likely than other, we believe they represent particular organizations of the system which should minimize the energy dissipation.", [["statistical quantification", "TEST", 8, 34], ["particular organizations of the system", "PROBLEM", 112, 150], ["the energy dissipation", "PROBLEM", 173, 195], ["more likely", "UNCERTAINTY", 62, 73], ["energy dissipation", "OBSERVATION", 177, 195]]], ["We checked this hypothesis by using the Cellular Potts Model.", [["the Cellular Potts Model", "TREATMENT", 36, 60], ["Cellular Potts", "OBSERVATION", 40, 54]]], ["They depend on phenomenological parameters such as interaction between cells and the extra cellular matrix, a line tension and an elastic modulus.", [["cells", "ANATOMY", 71, 76], ["cellular matrix", "ANATOMY", 91, 106], ["cells", "CELL", 71, 76], ["cellular matrix", "CELLULAR_COMPONENT", 91, 106], ["phenomenological parameters", "TEST", 15, 42], ["interaction between cells", "PROBLEM", 51, 76], ["the extra cellular matrix", "PROBLEM", 81, 106], ["a line tension", "PROBLEM", 108, 122], ["an elastic modulus", "PROBLEM", 127, 145], ["cellular matrix", "OBSERVATION", 91, 106], ["line tension", "OBSERVATION", 110, 122], ["elastic modulus", "OBSERVATION", 130, 145]]], ["The aim of this work is to link model parameters to physico-chemical properties of cells and to establish phenomenological relations between relevant biochemical regulators controlling the cytoskeleton organization.Comparative analysis of structural and functional properties of A\u03b2-amyloid aggregated speciesC.", [["cells", "ANATOMY", 83, 88], ["cytoskeleton", "ANATOMY", 189, 201], ["cells", "CELL", 83, 88], ["cytoskeleton", "CELLULAR_COMPONENT", 189, 201], ["A\u03b2-amyloid", "GENE_OR_GENE_PRODUCT", 279, 289], ["biochemical regulators", "PROTEIN", 150, 172], ["A\u03b2", "PROTEIN", 279, 281], ["Comparative analysis", "TEST", 215, 235], ["A\u03b2", "TEST", 279, 281]]], ["Canale, D. Ferrera, F. Benfenati, L. Gasparini The Italian Institute of Technology, 16163 Genova, Italy Alzheimer disease (AD) is characterized by cerebral extracellular deposits of \u03b2-amyloid (A\u03b2) fibrils.", [["cerebral extracellular", "ANATOMY", 147, 169], ["Alzheimer disease", "DISEASE", 104, 121], ["AD", "DISEASE", 123, 125], ["L. Gasparini", "ORGANISM", 34, 46], ["cerebral", "PATHOLOGICAL_FORMATION", 147, 155], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 169], ["\u03b2-amyloid (A\u03b2) fibrils", "GENE_OR_GENE_PRODUCT", 182, 204], ["\u03b2-amyloid (A\u03b2) fibrils", "PROTEIN", 182, 204], ["L. Gasparini", "SPECIES", 34, 46], ["Italy Alzheimer disease", "PROBLEM", 98, 121], ["cerebral extracellular deposits of \u03b2-amyloid (A\u03b2) fibrils", "PROBLEM", 147, 204], ["Alzheimer disease", "OBSERVATION", 104, 121], ["cerebral", "ANATOMY", 147, 155], ["extracellular", "ANATOMY_MODIFIER", 156, 169], ["deposits", "OBSERVATION", 170, 178]]], ["A\u03b2 aggregation is a multi-step process involving the formation of various conformational species including soluble intermediate species (i.e. A\u03b2 oligomers), protofibrils and fibrils.", [["fibrils", "ANATOMY", 174, 181], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 0, 2], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 142, 144], ["fibrils", "CELLULAR_COMPONENT", 174, 181], ["soluble intermediate species", "PROTEIN", 107, 135], ["protofibrils", "PROTEIN", 157, 169], ["A\u03b2 aggregation", "PROBLEM", 0, 14], ["a multi-step process", "PROBLEM", 18, 38], ["various conformational species", "PROBLEM", 66, 96], ["soluble intermediate species", "PROBLEM", 107, 135], ["protofibrils", "PROBLEM", 157, 169], ["fibrils", "PROBLEM", 174, 181], ["aggregation", "OBSERVATION", 3, 14], ["multi-step", "OBSERVATION_MODIFIER", 20, 30], ["various", "OBSERVATION_MODIFIER", 66, 73], ["conformational species", "OBSERVATION", 74, 96], ["intermediate species", "OBSERVATION", 115, 135]]], ["Such aggregates may have various effects on neuronal and glial function and differentially contribute to AD neurodegeneration.", [["neuronal", "ANATOMY", 44, 52], ["glial", "ANATOMY", 57, 62], ["AD", "DISEASE", 105, 107], ["neurodegeneration", "DISEASE", 108, 125], ["neuronal", "CELL", 44, 52], ["glial", "CELL", 57, 62], ["AD neurodegeneration", "PROBLEM", 105, 125], ["glial function", "OBSERVATION", 57, 71], ["neurodegeneration", "OBSERVATION", 108, 125]]], ["Aim of this study was to investigate the structural properties of distinct A\u03b2 aggregated species and dissect out their effects on neuronal viability.", [["neuronal", "ANATOMY", 130, 138], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 75, 77], ["neuronal", "CELL", 130, 138], ["this study", "TEST", 7, 17], ["A\u03b2 aggregated species", "PROBLEM", 75, 96], ["distinct", "OBSERVATION_MODIFIER", 66, 74], ["neuronal viability", "OBSERVATION", 130, 148]]], ["Recombinant A\u03b242 and A\u03b240 peptides were aggregated in vitro in conditions differing by ionic strength, temperature and pH and were analyzed by gel electrophoresis, thioflavin T binding assay and atomic force microscopy (AFM).", [["thioflavin T", "CHEMICAL", 164, 176], ["thioflavin T", "CHEMICAL", 164, 176], ["A\u03b242", "GENE_OR_GENE_PRODUCT", 12, 16], ["A\u03b240 peptides", "GENE_OR_GENE_PRODUCT", 21, 34], ["thioflavin T", "GENE_OR_GENE_PRODUCT", 164, 176], ["A\u03b240 peptides", "PROBLEM", 21, 34], ["pH", "TEST", 119, 121], ["gel electrophoresis", "TEST", 143, 162], ["thioflavin T binding assay", "TEST", 164, 190], ["atomic force microscopy", "TEST", 195, 218]]], ["AFM analysis was performed using both hydrophilic and hydrophobic substrates, to analyze the full spectrum of structural species.", [["AFM analysis", "TEST", 0, 12], ["both hydrophilic and hydrophobic substrates", "TREATMENT", 33, 76], ["structural species", "PROBLEM", 110, 128], ["structural species", "OBSERVATION", 110, 128]]], ["Stable low molecular weight oligomers were obtained when A\u03b242 was incubated at 37 \u2022 C for 5 days in low salt concentration buffer.", [["A\u03b242", "CHEMICAL", 57, 61], ["A\u03b242", "CHEMICAL", 57, 61], ["A\u03b242", "SIMPLE_CHEMICAL", 57, 61], ["salt", "SIMPLE_CHEMICAL", 104, 108], ["low salt concentration buffer", "TREATMENT", 100, 129], ["low molecular", "OBSERVATION_MODIFIER", 7, 20], ["weight oligomers", "OBSERVATION", 21, 37]]], ["Doughnut-shaped conformational species were detected by AFM alongside globular aggregates (1.6-5.2 nm height range).", [["Doughnut-shaped conformational species", "PROTEIN", 0, 38], ["Doughnut-shaped conformational species", "PROBLEM", 0, 38], ["globular aggregates", "TEST", 70, 89], ["shaped", "OBSERVATION_MODIFIER", 9, 15], ["conformational species", "OBSERVATION", 16, 38]]], ["Acidic pH promoted aggregation of A\u03b242 into Thioflavin-positive fibrils and protofibrils.", [["fibrils", "ANATOMY", 64, 71], ["A\u03b242", "CHEMICAL", 34, 38], ["A\u03b242", "CHEMICAL", 34, 38], ["A\u03b242", "SIMPLE_CHEMICAL", 34, 38], ["Thioflavin-positive fibrils", "GENE_OR_GENE_PRODUCT", 44, 71], ["A\u03b242", "PROTEIN", 34, 38], ["Thioflavin-positive fibrils", "PROTEIN", 44, 71], ["Acidic pH", "TEST", 0, 9], ["Thioflavin", "TEST", 44, 54], ["positive fibrils", "TREATMENT", 55, 71], ["protofibrils", "PROBLEM", 76, 88], ["positive fibrils", "OBSERVATION", 55, 71]]], ["Protofibrils appeared as beaded chains having a mean height of 3.65\u00b11.49 nm.", [["Protofibrils", "ANATOMY", 0, 12], ["Protofibrils", "SIMPLE_CHEMICAL", 0, 12], ["a mean height", "TEST", 46, 59], ["beaded", "OBSERVATION_MODIFIER", 25, 31], ["chains", "OBSERVATION_MODIFIER", 32, 38], ["mean height", "OBSERVATION_MODIFIER", 48, 59]]], ["Effects of A\u03b2 on viability of mouse hypppocampal neurons were assessed and correlated with their conformational features.Effect of magnetic nanoparticles on lysozyme amyloid assemblies in vitroA.", [["hypppocampal neurons", "ANATOMY", 36, 56], ["A\u03b2", "CHEMICAL", 11, 13], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 11, 13], ["mouse", "ORGANISM", 30, 35], ["hypppocampal neurons", "CELL", 36, 56], ["magnetic nanoparticles", "SIMPLE_CHEMICAL", 131, 153], ["lysozyme amyloid", "SIMPLE_CHEMICAL", 157, 173], ["vitroA", "SIMPLE_CHEMICAL", 188, 194], ["A\u03b2", "PROTEIN", 11, 13], ["mouse hypppocampal neurons", "CELL_TYPE", 30, 56], ["vitroA", "PROTEIN", 188, 194], ["mouse", "SPECIES", 30, 35], ["mouse", "SPECIES", 30, 35], ["magnetic nanoparticles", "TREATMENT", 131, 153], ["lysozyme amyloid assemblies", "TREATMENT", 157, 184]]], ["Bellova 1 , E. Bystrenova 2 , M. Koneracka 1 , P. Kopcansky 1 , F. Valle 2 , J. Bagelova 1 , F. Biscarini 2 , Z. Gazova 1 1 1 Institute of Experimental Physics, Slovak Academy of Sciences, Kosice, Slovakia, 2 2 ISMN CNR, Bologna, Italy Peptide amyloid aggregation is a hallmark of amyloid diseases including Azheimer's disease or type II diabetes.", [["amyloid aggregation", "DISEASE", 244, 263], ["amyloid diseases", "DISEASE", 281, 297], ["Azheimer's disease", "DISEASE", 308, 326], ["type II diabetes", "DISEASE", 330, 346], ["Bellova", "TREATMENT", 0, 7], ["Kosice", "TREATMENT", 189, 195], ["amyloid aggregation", "PROBLEM", 244, 263], ["amyloid diseases", "PROBLEM", 281, 297], ["Azheimer's disease", "PROBLEM", 308, 326], ["type II diabetes", "PROBLEM", 330, 346], ["amyloid aggregation", "OBSERVATION", 244, 263], ["amyloid diseases", "OBSERVATION", 281, 297]]], ["Recent works have addressed the potential of nanoparticles to affect amyloid aggregation.", [["amyloid aggregation", "DISEASE", 69, 88], ["nanoparticles", "SIMPLE_CHEMICAL", 45, 58], ["amyloid", "GENE_OR_GENE_PRODUCT", 69, 76], ["amyloid aggregation", "PROBLEM", 69, 88], ["amyloid aggregation", "OBSERVATION", 69, 88]]], ["The experimental data are very controversial suggesting that particle characteristics markedly influence the final effect of nanoparticles on the amyloid aggregation (initiation, acceleration or inhibition of amyloid aggregation).", [["amyloid aggregation", "DISEASE", 146, 165], ["amyloid aggregation", "DISEASE", 209, 228], ["nanoparticles", "SIMPLE_CHEMICAL", 125, 138], ["amyloid", "SIMPLE_CHEMICAL", 146, 153], ["amyloid", "GENE_OR_GENE_PRODUCT", 209, 216], ["The experimental data", "TEST", 0, 21], ["nanoparticles", "TREATMENT", 125, 138], ["the amyloid aggregation", "PROBLEM", 142, 165], ["amyloid aggregation", "PROBLEM", 209, 228], ["amyloid aggregation", "OBSERVATION", 146, 165], ["amyloid aggregation", "OBSERVATION", 209, 228]]], ["We investigate the ability of electrostatically stabilized magnetic nanoparticles of Fe 3 O 4 to affect the amyloid aggregation of lysozyme, as a prototype amyloidogenic protein.", [["Fe", "CHEMICAL", 85, 87], ["Fe 3 O 4", "CHEMICAL", 85, 93], ["Fe 3 O 4", "SIMPLE_CHEMICAL", 85, 93], ["amyloid", "SIMPLE_CHEMICAL", 108, 115], ["lysozyme", "GENE_OR_GENE_PRODUCT", 131, 139], ["lysozyme", "PROTEIN", 131, 139], ["amyloidogenic protein", "PROTEIN", 156, 177], ["magnetic nanoparticles of Fe", "TREATMENT", 59, 87], ["the amyloid aggregation of lysozyme", "PROBLEM", 104, 139]]], ["We have used a combination of spectroscopic (ThT fluorescence) and local microscopic techniques (AFM).", [["spectroscopic (ThT fluorescence", "TREATMENT", 30, 61], ["local microscopic techniques", "TEST", 67, 95]]], ["We found, that the ability of magnetic nanoparticles to inhibit formation of amyloid aggregates or destroy pre-formed amyloids exhibit concentrationdependence.", [["magnetic nanoparticles", "TREATMENT", 30, 52], ["amyloid aggregates", "PROBLEM", 77, 95], ["destroy pre-formed amyloids", "PROBLEM", 99, 126], ["amyloid aggregates", "OBSERVATION", 77, 95]]], ["The values of inhibition IC50 and depolymerization DC50 were determined suggesting that nanoparticles interfere with lysozyme aggregation at stoichiometric concentrations.", [["DC50", "SIMPLE_CHEMICAL", 51, 55], ["nanoparticles", "SIMPLE_CHEMICAL", 88, 101], ["lysozyme", "GENE_OR_GENE_PRODUCT", 117, 125], ["lysozyme", "PROTEIN", 117, 125], ["The values", "TEST", 0, 10], ["inhibition IC50", "TREATMENT", 14, 29], ["depolymerization DC50", "TEST", 34, 55], ["lysozyme aggregation", "PROBLEM", 117, 137]]], ["The observed features make magnetic nanoparticles of potential interest as a therapeutical agent against amyloid diseases.", [["amyloid diseases", "DISEASE", 105, 121], ["amyloid", "GENE_OR_GENE_PRODUCT", 105, 112], ["a therapeutical agent", "TREATMENT", 75, 96], ["amyloid diseases", "PROBLEM", 105, 121]]], ["(This work was supported by project of ESF 26220120021 and by Slovak Academy of Sciences in frame of CEX NANOFLUID, VEGA grants 7055, 0056 and 0038 and EU-STRP 0032652 BIODOT.).Glycosyl acridines reducing lysozyme amyloid aggregationA.", [["Glycosyl acridines", "CHEMICAL", 177, 195], ["Glycosyl acridines", "CHEMICAL", 177, 195], ["Glycosyl acridines", "SIMPLE_CHEMICAL", 177, 195], ["lysozyme", "GENE_OR_GENE_PRODUCT", 205, 213], ["lysozyme", "PROTEIN", 205, 213], ["Glycosyl acridines", "TREATMENT", 177, 195], ["lysozyme amyloid aggregationA", "TREATMENT", 205, 234]]], ["Bellova 1 , L. Balogova 2 , B. Chelli 3 , E. Bystrenova 3 , F. Valle 3 , J. Imrich 2 , P. Kristian 2 , L. Drajna 2 , J. Bagelova 1 , F. Biscarini 3 , Z. Gazova 1 1 Institute of Experimental Physics, SAS, Kosice, Slovakia, 2 Faculty of Sciences, P. J. Safarik University, Kosice, Slovakia, 3 ISMN CNR, Bologna, Italy Numerous diseases have been linked to a common pathogenic process called amyloidosis, whereby proteins or peptide clump together to form amyloid aggregates in the body.", [["body", "ANATOMY", 479, 483], ["Numerous diseases", "DISEASE", 316, 333], ["amyloidosis", "DISEASE", 389, 400], ["amyloid aggregates", "DISEASE", 453, 471], ["amyloid", "GENE_OR_GENE_PRODUCT", 453, 460], ["body", "ORGANISM_SUBDIVISION", 479, 483], ["Bellova", "TREATMENT", 0, 7], ["a common pathogenic process", "PROBLEM", 354, 381], ["amyloidosis", "PROBLEM", 389, 400], ["peptide clump", "PROBLEM", 422, 435], ["amyloid aggregates in the body", "PROBLEM", 453, 483], ["diseases", "OBSERVATION", 325, 333], ["amyloidosis", "OBSERVATION", 389, 400], ["amyloid aggregates", "OBSERVATION", 453, 471], ["body", "ANATOMY", 479, 483]]], ["An attractive strategy to develop therapies for these diseases seems to be reduction of polypeptide aggregation.", [["therapies", "TREATMENT", 34, 43], ["these diseases", "PROBLEM", 48, 62], ["polypeptide aggregation", "PROBLEM", 88, 111], ["polypeptide aggregation", "OBSERVATION", 88, 111]]], ["We have tested several acridine derivatives characterized by various glycosyl groups for their potential to affect the lysozyme amyloid aggregation in vitro.", [["acridine", "CHEMICAL", 23, 31], ["amyloid aggregation", "DISEASE", 128, 147], ["acridine", "CHEMICAL", 23, 31], ["glycosyl", "CHEMICAL", 69, 77], ["acridine derivatives", "SIMPLE_CHEMICAL", 23, 43], ["amyloid", "GENE_OR_GENE_PRODUCT", 128, 135], ["several acridine derivatives", "TREATMENT", 15, 43], ["various glycosyl groups", "TREATMENT", 61, 84], ["the lysozyme amyloid aggregation", "PROBLEM", 115, 147], ["lysozyme amyloid aggregation", "OBSERVATION", 119, 147]]], ["The ability of glycosyl acridines to interfere with lysozyme aggregation was investigated by ThT assay.", [["glycosyl acridines", "CHEMICAL", 15, 33], ["glycosyl acridines", "CHEMICAL", 15, 33], ["glycosyl acridines", "SIMPLE_CHEMICAL", 15, 33], ["lysozyme", "GENE_OR_GENE_PRODUCT", 52, 60], ["lysozyme", "PROTEIN", 52, 60], ["glycosyl acridines", "TREATMENT", 15, 33], ["lysozyme aggregation", "TREATMENT", 52, 72]]], ["We found that structure of acridine side chain is factor affecting their anti-aggregation activity significantly.", [["acridine", "CHEMICAL", 27, 35], ["acridine", "CHEMICAL", 27, 35], ["acridine side chain", "SIMPLE_CHEMICAL", 27, 46], ["acridine side chain", "PROBLEM", 27, 46]]], ["For the most effective compounds the values of IC50 and DC50 were obtained.", [["DC50", "SIMPLE_CHEMICAL", 56, 60], ["IC50", "TEST", 47, 51], ["DC50", "TEST", 56, 60]]], ["The reduction of protein aggregation was confirmed by AFM.", [["protein aggregation", "PROBLEM", 17, 36], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["protein aggregation", "OBSERVATION", 17, 36]]], ["To investigate influence of the glycosyl acridines on the cell processes we examined effect of compounds on cell viability.", [["cell", "ANATOMY", 58, 62], ["cell", "ANATOMY", 108, 112], ["glycosyl acridines", "CHEMICAL", 32, 50], ["glycosyl acridines", "CHEMICAL", 32, 50], ["glycosyl acridines", "SIMPLE_CHEMICAL", 32, 50], ["cell", "CELL", 58, 62], ["cell", "CELL", 108, 112], ["the glycosyl acridines", "TREATMENT", 28, 50], ["the cell processes", "TREATMENT", 54, 72], ["compounds on cell viability", "PROBLEM", 95, 122]]], ["We performed glycosyl acridines characterization by high anti-aggregation activity and low toxicity suggesting their possible application for therapeutical purpose.", [["glycosyl acridines", "CHEMICAL", 13, 31], ["toxicity", "DISEASE", 91, 99], ["glycosyl acridines", "CHEMICAL", 13, 31], ["glycosyl acridines", "SIMPLE_CHEMICAL", 13, 31], ["glycosyl acridines characterization", "TREATMENT", 13, 48], ["high anti-aggregation activity", "TREATMENT", 52, 82], ["low toxicity", "PROBLEM", 87, 99]]], ["(This work was supported by project of ESF 26220120021 and by Slovak Academy of Sciences in frame of CEX NANOFLUID and VEGA grants 7055, 0056 and 0038 and EU-STRP 0032652 BIODOT.).Multi-method studies of the membrane spanning domains of proteinsA.", [["membrane", "ANATOMY", 208, 216], ["membrane", "CELLULAR_COMPONENT", 208, 216], ["proteinsA", "GENE_OR_GENE_PRODUCT", 237, 246], ["membrane spanning domains", "PROTEIN", 208, 233], ["proteinsA", "PROTEIN", 237, 246], ["Multi-method studies", "TEST", 180, 200], ["the membrane spanning domains of proteinsA", "PROBLEM", 204, 246]]], ["J. Beevers, A. M. Dixon Department of Chemistry, University of Warwick, UK Due to the immense medical importance of proteins which span the membrane of cells, detailed molecular structural information of these systems is essential.", [["membrane", "ANATOMY", 140, 148], ["cells", "ANATOMY", 152, 157], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["cells", "CELL", 152, 157]]], ["Practical difficulties in employing high-resolution structural elucidation techniques have resulted in a relative paucity of fully resolved membrane protein structures.", [["membrane", "ANATOMY", 140, 148], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["membrane protein structures", "PROTEIN", 140, 167], ["Practical difficulties", "PROBLEM", 0, 22], ["fully resolved membrane protein structures", "PROBLEM", 125, 167], ["paucity", "OBSERVATION_MODIFIER", 114, 121], ["membrane protein structures", "OBSERVATION", 140, 167]]], ["Therefore a variety of lower-resolution techniques are used to determine structural information of the transmembrane (TM) domains of proteins.", [["transmembrane", "ANATOMY", 103, 116], ["transmembrane", "CELLULAR_COMPONENT", 103, 116], ["transmembrane (TM) domains", "PROTEIN", 103, 129], ["lower-resolution techniques", "TREATMENT", 23, 50]]], ["One example of such a membrane protein is ErbB-2, a receptor tyrosine kinase responsible for triggering cell division and which is prone to a mutation in its transmembrane domain resulting in permanent activation and oncogenic effects.", [["membrane", "ANATOMY", 22, 30], ["cell", "ANATOMY", 104, 108], ["transmembrane", "ANATOMY", 158, 171], ["tyrosine", "CHEMICAL", 61, 69], ["tyrosine", "CHEMICAL", 61, 69], ["membrane", "CELLULAR_COMPONENT", 22, 30], ["ErbB-2", "GENE_OR_GENE_PRODUCT", 42, 48], ["tyrosine", "AMINO_ACID", 61, 69], ["cell", "CELL", 104, 108], ["transmembrane", "CELLULAR_COMPONENT", 158, 171], ["membrane protein", "PROTEIN", 22, 38], ["ErbB-2", "PROTEIN", 42, 48], ["receptor tyrosine kinase", "PROTEIN", 52, 76], ["transmembrane domain", "PROTEIN", 158, 178], ["a membrane protein", "TEST", 20, 38], ["ErbB", "TEST", 42, 46], ["a receptor tyrosine kinase", "TEST", 50, 76], ["triggering cell division", "PROBLEM", 93, 117], ["a mutation in its transmembrane domain", "PROBLEM", 140, 178], ["permanent activation", "PROBLEM", 192, 212], ["oncogenic effects", "PROBLEM", 217, 234], ["permanent activation", "OBSERVATION", 192, 212], ["oncogenic effects", "OBSERVATION", 217, 234]]], ["We have predicted an interface for the mutated TM domain dimer using site-specific infrared spectroscopy containing a repeating sequence of Ile, Val and Leu 1 .", [["Ile", "CHEMICAL", 140, 143], ["Val", "CHEMICAL", 145, 148], ["Leu", "CHEMICAL", 153, 156], ["Ile", "AMINO_ACID", 140, 143], ["Leu 1", "GENE_OR_GENE_PRODUCT", 153, 158], ["mutated TM domain dimer", "PROTEIN", 39, 62], ["specific infrared spectroscopy", "TEST", 74, 104], ["a repeating sequence of Ile", "TEST", 116, 143]]], ["Applying the in vivo TOXCAT assay to the TM domain sequence and to specific mutants of it, confirms this proposed interface whilst another proposed interface is discounted.", [["TOXCAT", "PROTEIN", 21, 27], ["TM domain sequence", "DNA", 41, 59], ["the TM domain sequence", "TEST", 37, 59], ["interface", "OBSERVATION", 148, 157]]], ["Current studies are focussing on the effect of the TM mutation to the activation of the ErbB-2 receptor and to any possible change in this interface.", [["TM", "GENE_OR_GENE_PRODUCT", 51, 53], ["ErbB-2 receptor", "GENE_OR_GENE_PRODUCT", 88, 103], ["ErbB-2 receptor", "PROTEIN", 88, 103], ["Current studies", "TEST", 0, 15], ["the TM mutation", "TREATMENT", 47, 62]]], ["Bacteriophages are complex molecular assemblies which multiplication relies on bacteria infection.", [["infection", "DISEASE", 88, 97], ["Bacteriophages", "PROBLEM", 0, 14], ["complex molecular assemblies", "PROBLEM", 19, 47], ["bacteria infection", "PROBLEM", 79, 97], ["complex", "OBSERVATION_MODIFIER", 19, 26], ["molecular assemblies", "OBSERVATION", 27, 47], ["bacteria", "OBSERVATION_MODIFIER", 79, 87], ["infection", "OBSERVATION", 88, 97]]], ["The process starts with the binding of the phage on its specific host receptor and the injection of its genome into the host cytoplasm.", [["cytoplasm", "ANATOMY", 125, 134], ["cytoplasm", "ORGANISM_SUBSTANCE", 125, 134], ["host cytoplasm", "OBSERVATION", 120, 134]]], ["Our work aims to determine the physical mechanisms and forces driving the DNA transfer from the phage capsid.", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["phage capsid", "PROTEIN", 96, 108]]], ["The in vitro DNA ejection has been analyzed by using light scattering and gel electrophoresis measurements for three phages (T5, SPP1 and Lambda) belonging to the same family (Syphoviridae).", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["SPP1", "GENE_OR_GENE_PRODUCT", 129, 133], ["Lambda", "GENE_OR_GENE_PRODUCT", 138, 144], ["Syphoviridae", "CANCER", 176, 188], ["SPP1", "PROTEIN", 129, 133], ["Lambda", "PROTEIN", 138, 144], ["light scattering", "TEST", 53, 69], ["gel electrophoresis measurements", "TEST", 74, 106], ["DNA ejection", "OBSERVATION", 13, 25]]], ["Our results reveal two forces contributing to drive the DNA transfer: the first one is originated from the pressurization due to the strong confinement of DNA into the capsid; the second one comes from a pulling mechanism originated by the presence of condensed DNA outside the capsid.", [["DNA", "CELLULAR_COMPONENT", 56, 59], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["capsid", "CELLULAR_COMPONENT", 168, 174], ["DNA", "CELLULAR_COMPONENT", 262, 265], ["capsid", "CELLULAR_COMPONENT", 278, 284], ["DNA into the capsid", "PROBLEM", 155, 174], ["a pulling mechanism", "TREATMENT", 202, 221], ["condensed DNA", "PROBLEM", 252, 265], ["two forces", "OBSERVATION", 19, 29], ["condensed DNA", "OBSERVATION", 252, 265], ["capsid", "OBSERVATION", 278, 284]]], ["The ejection kinetics was also analysed and the characteristic time of the mechanism was studied as a function of the temperature.", [["The ejection kinetics", "TEST", 0, 21], ["ejection kinetics", "OBSERVATION", 4, 21]]], ["The energy values are close for the different phages, suggesting that the mechanism regulating the ejection is common for a given phage family.", [["phage family", "PROTEIN", 130, 142], ["The energy values", "TEST", 0, 17]]], ["Below these general features, our studies also reveal differences between the three phages.O-368The effect of &beta-amyloid peptide on polymer cushioned membranes S. Dante 1 , R. Steitz 2 , T. Hauss 2 , C. Canale 1 , N. A. Dencher 3 1 Istituto Italiano di Tecnologia, Genova, Italy, 2 BENSC, Helmholtz Center Berlin, Germany, 3 TU-Darmstadt Germany Beta-amyloid (A\u03b2) is a peptide implicated in the neurodegenerative process characteristic of the Alzheimer's disease (AD).", [["O-368", "CHEMICAL", 91, 96], ["&beta-amyloid peptide", "CHEMICAL", 110, 131], ["Beta-amyloid", "CHEMICAL", 349, 361], ["A\u03b2", "CHEMICAL", 363, 365], ["Alzheimer's disease", "DISEASE", 446, 465], ["AD", "DISEASE", 467, 469], ["O-368", "CHEMICAL", 91, 96], ["O-368", "SIMPLE_CHEMICAL", 91, 96], ["&beta-amyloid peptide", "SIMPLE_CHEMICAL", 110, 131], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 363, 365], ["Alzheimer's disease", "CANCER", 446, 465], ["our studies", "TEST", 30, 41], ["&beta", "TEST", 110, 115], ["amyloid peptide", "PROBLEM", 116, 131], ["a peptide", "PROBLEM", 370, 379], ["the Alzheimer's disease", "PROBLEM", 442, 465], ["neurodegenerative", "OBSERVATION", 398, 415], ["Alzheimer", "OBSERVATION", 446, 455]]], ["To clarify its mechanism of action it is crucial to elucidate the interaction of A\u03b2 with the neural membrane.", [["neural membrane", "ANATOMY", 93, 108], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 81, 83], ["neural membrane", "CELLULAR_COMPONENT", 93, 108], ["A\u03b2", "PROTEIN", 81, 83], ["neural membrane", "ANATOMY", 93, 108]]], ["In previous work we demonstrated the capability of A\u03b2 to penetrate and perturb stacked lipid bilayers.", [["lipid bilayers", "ANATOMY", 87, 101], ["A\u03b2", "SIMPLE_CHEMICAL", 51, 53], ["lipid bilayers", "CELLULAR_COMPONENT", 87, 101], ["A\u03b2", "PROTEIN", 51, 53], ["A\u03b2", "TREATMENT", 51, 53], ["lipid bilayers", "OBSERVATION", 87, 101]]], ["In this study we considered polymer cushioned lipid bilayers as a model for neural membranes.", [["neural membranes", "ANATOMY", 76, 92], ["neural membranes", "MULTI-TISSUE_STRUCTURE", 76, 92], ["this study", "TEST", 3, 13], ["polymer cushioned lipid bilayers", "TREATMENT", 28, 60], ["neural membranes", "TREATMENT", 76, 92], ["neural membranes", "OBSERVATION", 76, 92]]], ["The polymer cushion is aimed to preserve the membrane natural fluidity; it is obtained depositing charged polyelectrolites layer-by-layer; the lipid membrane is built on the top of the polymer film by fusion of unilamellar vesicles.", [["membrane", "ANATOMY", 45, 53], ["lipid membrane", "ANATOMY", 143, 157], ["unilamellar vesicles", "ANATOMY", 211, 231], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["lipid membrane", "CELLULAR_COMPONENT", 143, 157], ["unilamellar vesicles", "CELLULAR_COMPONENT", 211, 231], ["The polymer cushion", "TREATMENT", 0, 19], ["the lipid membrane", "TREATMENT", 139, 157], ["fusion of unilamellar vesicles", "TREATMENT", 201, 231], ["polymer cushion", "OBSERVATION", 4, 19], ["layer", "OBSERVATION_MODIFIER", 123, 128], ["layer", "OBSERVATION_MODIFIER", 132, 137], ["lipid membrane", "OBSERVATION", 143, 157], ["top", "OBSERVATION_MODIFIER", 174, 177], ["fusion", "OBSERVATION", 201, 207], ["unilamellar vesicles", "OBSERVATION", 211, 231]]], ["The floating membranes were kept always in contact to the subphase.", [["membranes", "ANATOMY", 13, 22], ["membranes", "CELLULAR_COMPONENT", 13, 22], ["floating membranes", "OBSERVATION", 4, 22]]], ["The kinetics of adsorption of the lipid double layer at the polymer/water interface was monitored by neutron reflectivity; different experimental conditions to obtain the best surface coverage were exploited.", [["surface", "ANATOMY", 176, 183], ["the lipid double layer at the polymer/water interface", "TREATMENT", 30, 83], ["different experimental conditions", "PROBLEM", 123, 156], ["the best surface coverage", "TREATMENT", 167, 192], ["kinetics", "OBSERVATION_MODIFIER", 4, 12], ["adsorption", "OBSERVATION_MODIFIER", 16, 26], ["layer", "OBSERVATION_MODIFIER", 47, 52]]], ["After administration of A\u03b2 to the subphase the lipid membrane still adhered to the polymer cushion, but its structure was modified by the interaction with A\u03b2.", [["lipid membrane", "ANATOMY", 47, 61], ["A\u03b2", "CHEMICAL", 24, 26], ["A\u03b2.", "CHEMICAL", 155, 158], ["A\u03b2.", "CHEMICAL", 155, 158], ["A\u03b2", "SIMPLE_CHEMICAL", 24, 26], ["lipid membrane", "CELLULAR_COMPONENT", 47, 61], ["A\u03b2.", "GENE_OR_GENE_PRODUCT", 155, 158], ["A\u03b2", "PROTEIN", 24, 26], ["A\u03b2", "TREATMENT", 24, 26], ["the subphase the lipid membrane", "TREATMENT", 30, 61], ["the polymer cushion", "TREATMENT", 79, 98], ["lipid membrane", "OBSERVATION", 47, 61]]], ["Neutron reflectivity showed a change of the scattering density profile in the direction perpendicular to the membrane plane, suggesting a penetration of A\u03b2 inside the double layer.", [["membrane plane", "ANATOMY", 109, 123], ["A\u03b2", "CHEMICAL", 153, 155], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["A\u03b2", "SIMPLE_CHEMICAL", 153, 155], ["A\u03b2", "PROTEIN", 153, 155], ["Neutron reflectivity", "TEST", 0, 20], ["a change of the scattering density profile", "PROBLEM", 28, 70], ["change", "OBSERVATION_MODIFIER", 30, 36], ["scattering", "OBSERVATION_MODIFIER", 44, 54], ["density", "OBSERVATION", 55, 62], ["membrane", "ANATOMY_MODIFIER", 109, 117], ["penetration", "OBSERVATION", 138, 149], ["double", "OBSERVATION_MODIFIER", 167, 173], ["layer", "OBSERVATION_MODIFIER", 174, 179]]], ["A change in the surface morphology was detected by AFM imaging; AFM film-rupture experiments showed that A\u03b2 weakens the lipid packing.Assembly and bundling of the bacterial Z-ring protein FtsZX.", [["surface", "ANATOMY", 16, 23], ["A\u03b2", "CHEMICAL", 105, 107], ["surface", "CELLULAR_COMPONENT", 16, 23], ["A\u03b2", "SIMPLE_CHEMICAL", 105, 107], ["lipid", "SIMPLE_CHEMICAL", 120, 125], ["FtsZX", "GENE_OR_GENE_PRODUCT", 188, 193], ["A\u03b2", "PROTEIN", 105, 107], ["bacterial Z-ring protein", "PROTEIN", 163, 187], ["FtsZX", "PROTEIN", 188, 193], ["A change in the surface morphology", "PROBLEM", 0, 34], ["AFM imaging", "TEST", 51, 62], ["AFM film", "TEST", 64, 72], ["rupture experiments", "PROBLEM", 73, 92], ["the lipid packing", "TREATMENT", 116, 133], ["the bacterial Z-ring protein FtsZX", "TREATMENT", 159, 193], ["change", "OBSERVATION_MODIFIER", 2, 8], ["surface", "OBSERVATION_MODIFIER", 16, 23], ["rupture", "OBSERVATION", 73, 80], ["lipid packing", "OBSERVATION", 120, 133]]], ["Cheng 1 , R. Pacheco-Gomez 2 , A. Rodger 1 , H. Matthew 1 , D. I. Roper 1 1 University of Warwick, U.K., 2 University of Birmingham, U.K.Assembly and bundling of the bacterial Z-ring protein FtsZFtsZ, the ancestral homolog of eukaryotic tubulins, is a GT-Pase that assembles into a cytokinetic ring structure (Z ring) essential for cell division in prokaryotic cells.", [["cytokinetic ring", "ANATOMY", 282, 298], ["Z ring", "ANATOMY", 310, 316], ["cell", "ANATOMY", 332, 336], ["cells", "ANATOMY", 361, 366], ["FtsZFtsZ", "GENE_OR_GENE_PRODUCT", 191, 199], ["tubulins", "GENE_OR_GENE_PRODUCT", 237, 245], ["GT-Pase", "GENE_OR_GENE_PRODUCT", 252, 259], ["cell", "CELL", 332, 336], ["cells", "CELL", 361, 366], ["bacterial Z-ring protein", "PROTEIN", 166, 190], ["FtsZFtsZ", "PROTEIN", 191, 199], ["eukaryotic tubulins", "PROTEIN", 226, 245], ["GT", "PROTEIN", 252, 254], ["Pase", "PROTEIN", 255, 259], ["cytokinetic ring structure", "PROTEIN", 282, 308], ["prokaryotic cells", "CELL_TYPE", 349, 366], ["the bacterial Z-ring protein FtsZFtsZ", "TREATMENT", 162, 199], ["a GT-Pase", "TREATMENT", 250, 259], ["a cytokinetic ring structure (Z ring)", "TREATMENT", 280, 317], ["cell division in prokaryotic cells", "PROBLEM", 332, 366], ["ring protein FtsZFtsZ", "OBSERVATION", 178, 199], ["eukaryotic tubulins", "OBSERVATION", 226, 245], ["cytokinetic ring", "OBSERVATION", 282, 298], ["cell division", "OBSERVATION", 332, 345], ["prokaryotic cells", "OBSERVATION", 349, 366]]], ["The Z ring also recruits other proteins (e.g. ZapA, YgfE, ZipA) to the division site, where they participate in formation of the septum that separates the two daughter cells.", [["Z ring", "ANATOMY", 4, 10], ["division site", "ANATOMY", 71, 84], ["septum", "ANATOMY", 129, 135], ["daughter cells", "ANATOMY", 159, 173], ["ZapA", "GENE_OR_GENE_PRODUCT", 46, 50], ["YgfE", "GENE_OR_GENE_PRODUCT", 52, 56], ["ZipA", "GENE_OR_GENE_PRODUCT", 58, 62], ["septum", "CELLULAR_COMPONENT", 129, 135], ["cells", "CELL", 168, 173], ["ZapA", "PROTEIN", 46, 50], ["YgfE", "PROTEIN", 52, 56], ["ZipA", "PROTEIN", 58, 62], ["daughter cells", "CELL_TYPE", 159, 173], ["other proteins", "TEST", 25, 39], ["ZapA", "TEST", 46, 50], ["septum", "ANATOMY", 129, 135]]], ["We have studied FtsZ polymerization and its dynamic behaviour in real time by right angle light scattering.", [["FtsZ", "GENE_OR_GENE_PRODUCT", 16, 20], ["FtsZ", "PROTEIN", 16, 20], ["FtsZ polymerization", "TREATMENT", 16, 35], ["FtsZ polymerization", "OBSERVATION", 16, 35], ["right", "ANATOMY_MODIFIER", 78, 83]]], ["Similar to tubulin, FtsZ polymerizes into dynamic protofilaments in the presence of GTP; polymer assembly is accompanied by GTP hydrolysis.", [["GTP", "CHEMICAL", 84, 87], ["GTP", "CHEMICAL", 124, 127], ["GTP", "CHEMICAL", 84, 87], ["GTP", "CHEMICAL", 124, 127], ["tubulin", "GENE_OR_GENE_PRODUCT", 11, 18], ["FtsZ", "GENE_OR_GENE_PRODUCT", 20, 24], ["GTP", "SIMPLE_CHEMICAL", 84, 87], ["GTP", "SIMPLE_CHEMICAL", 124, 127], ["tubulin", "PROTEIN", 11, 18], ["FtsZ", "PROTEIN", 20, 24], ["tubulin, FtsZ polymerizes", "TREATMENT", 11, 36], ["dynamic protofilaments", "TREATMENT", 42, 64], ["GTP", "PROBLEM", 84, 87], ["GTP hydrolysis", "PROBLEM", 124, 138], ["tubulin", "OBSERVATION", 11, 18], ["FtsZ polymerizes", "OBSERVATION", 20, 36], ["GTP hydrolysis", "OBSERVATION", 124, 138]]], ["The kinetics of inorganic phosphate (P i ) released from the GTP hydrolysis have been studied as well, employing a fast and sensitive colourimetric assay.", [["inorganic phosphate", "CHEMICAL", 16, 35], ["GTP", "CHEMICAL", 61, 64], ["phosphate", "CHEMICAL", 26, 35], ["GTP", "CHEMICAL", 61, 64], ["inorganic phosphate", "SIMPLE_CHEMICAL", 16, 35], ["GTP", "SIMPLE_CHEMICAL", 61, 64], ["inorganic phosphate (P i )", "TREATMENT", 16, 42], ["the GTP hydrolysis", "TREATMENT", 57, 75], ["a fast and sensitive colourimetric assay", "PROBLEM", 113, 153]]], ["At pH 6.5, approximate 90% of the P i was released into the media within 20 minutes of GTP addition.", [["GTP", "CHEMICAL", 87, 90], ["GTP", "CHEMICAL", 87, 90], ["GTP", "SIMPLE_CHEMICAL", 87, 90], ["P i", "DNA", 34, 37], ["pH", "TEST", 3, 5]]], ["The effects of GTP, pH, K + , and Mg 2+ were studied in both cases, and the results were used to build up a model for the mechanism of fibre assembly and disassembly.", [["fibre", "ANATOMY", 135, 140], ["GTP", "CHEMICAL", 15, 18], ["K", "CHEMICAL", 24, 25], ["Mg", "CHEMICAL", 34, 36], ["GTP", "CHEMICAL", 15, 18], ["K +", "CHEMICAL", 24, 27], ["Mg 2+", "CHEMICAL", 34, 39], ["GTP", "SIMPLE_CHEMICAL", 15, 18], ["K +", "SIMPLE_CHEMICAL", 24, 27], ["Mg 2+", "SIMPLE_CHEMICAL", 34, 39], ["fibre", "CELLULAR_COMPONENT", 135, 140], ["GTP", "TEST", 15, 18], ["pH", "TEST", 20, 22], ["K", "TEST", 24, 25], ["Mg", "TEST", 34, 36]]], ["YgfE, a FtsZ accessory protein, is identified as a functional ZapA orthologue.", [["YgfE", "CHEMICAL", 0, 4], ["YgfE", "GENE_OR_GENE_PRODUCT", 0, 4], ["FtsZ", "GENE_OR_GENE_PRODUCT", 8, 12], ["ZapA", "GENE_OR_GENE_PRODUCT", 62, 66], ["YgfE", "PROTEIN", 0, 4], ["FtsZ accessory protein", "PROTEIN", 8, 30], ["ZapA orthologue", "PROTEIN", 62, 77], ["a FtsZ accessory protein", "TEST", 6, 30]]], ["Finally, we have studied the YgfE bundling to FtsZ polymers.", [["YgfE", "CHEMICAL", 29, 33], ["YgfE", "SIMPLE_CHEMICAL", 29, 33], ["FtsZ", "GENE_OR_GENE_PRODUCT", 46, 50], ["YgfE", "PROTEIN", 29, 33], ["FtsZ", "PROTEIN", 46, 50], ["FtsZ polymers", "TREATMENT", 46, 59], ["FtsZ polymers", "OBSERVATION", 46, 59]]], ["It strongly promotes FtsZ bundling and is an inhibitor of the GTPase activity.", [["FtsZ", "GENE_OR_GENE_PRODUCT", 21, 25], ["FtsZ", "PROTEIN", 21, 25], ["GTPase", "PROTEIN", 62, 68], ["FtsZ bundling", "OBSERVATION", 21, 34], ["GTPase activity", "OBSERVATION", 62, 77]]], ["Many genomes of viruses encode small membrane spanning proteins which are proposed to modify membrane permeability for ions and small molecules.", [["membrane", "ANATOMY", 37, 45], ["membrane", "ANATOMY", 93, 101], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["ions", "SIMPLE_CHEMICAL", 119, 123], ["small membrane spanning proteins", "PROTEIN", 31, 63], ["small membrane spanning proteins", "PROBLEM", 31, 63], ["ions and small molecules", "PROBLEM", 119, 143], ["viruses", "OBSERVATION", 16, 23], ["small membrane", "OBSERVATION_MODIFIER", 31, 45], ["small", "OBSERVATION_MODIFIER", 128, 133], ["molecules", "OBSERVATION", 134, 143]]], ["These channel or pore forming proteins are getting into the focus for antiviral therapy since they are essential for some of the viruses.", [["pore", "ANATOMY", 17, 21], ["channel or pore forming proteins", "PROTEIN", 6, 38], ["pore forming proteins", "PROBLEM", 17, 38], ["antiviral therapy", "TREATMENT", 70, 87], ["the viruses", "PROBLEM", 125, 136], ["pore", "OBSERVATION_MODIFIER", 17, 21], ["antiviral therapy", "OBSERVATION", 70, 87], ["viruses", "OBSERVATION", 129, 136]]], ["We present a study on the open reading frame (ORF) 8a membrane protein encoded in structural region of Human Severe Acute Respiratory Syndrome Coronavirus (SARS-CoVs).", [["membrane", "ANATOMY", 54, 62], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 116, 154], ["SARS", "DISEASE", 156, 160], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["Human", "ORGANISM", 103, 108], ["open reading frame", "DNA", 26, 44], ["ORF", "DNA", 46, 49], ["membrane protein", "PROTEIN", 54, 70], ["Human", "SPECIES", 103, 108], ["Human Severe Acute Respiratory Syndrome Coronavirus (SARS-CoVs", "SPECIES", 103, 165], ["a study", "TEST", 11, 18], ["a membrane protein", "TEST", 52, 70], ["Human Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 103, 154], ["Severe", "OBSERVATION_MODIFIER", 109, 115], ["Acute", "OBSERVATION_MODIFIER", 116, 121], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 122, 154]]], ["The full length ORF8a protein is 39 residues long and contains a single transmembrane (TM) domain.", [["transmembrane", "ANATOMY", 72, 85], ["ORF8a", "GENE_OR_GENE_PRODUCT", 16, 21], ["ORF8a protein", "PROTEIN", 16, 29], ["transmembrane (TM) domain", "PROTEIN", 72, 97], ["The full length ORF8a protein", "TEST", 0, 29], ["a single transmembrane (TM) domain", "TREATMENT", 63, 97], ["length", "OBSERVATION_MODIFIER", 9, 15], ["39 residues", "OBSERVATION_MODIFIER", 33, 44], ["long", "OBSERVATION_MODIFIER", 45, 49]]], ["Full length protein is synthesized using solid phase peptide synthesis and reconstituted into artificial lipid bilayers forms cation-selective ion channels.", [["lipid bilayers", "SIMPLE_CHEMICAL", 105, 119], ["cation", "SIMPLE_CHEMICAL", 126, 132], ["cation-selective ion channels", "PROTEIN", 126, 155], ["Full length protein", "TEST", 0, 19], ["solid phase peptide synthesis", "TREATMENT", 41, 70]]], ["The bilayer recordings show cation selection channel activity with a major conductance level of around 8.5 pS also at elevated temperatures (38.5 \u2022 C).", [["cation", "SIMPLE_CHEMICAL", 28, 34], ["The bilayer recordings", "TEST", 0, 22], ["elevated temperatures", "PROBLEM", 118, 139], ["cation selection", "OBSERVATION", 28, 44]]], ["In silico studies with a 22 amino acid TM domain are done to assess conformational space of the monomeric ORF8a helix.", [["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["22 amino acid TM domain", "PROTEIN", 25, 48], ["monomeric ORF8a helix", "PROTEIN", 96, 117], ["silico studies", "TEST", 3, 17], ["a 22 amino acid TM domain", "TREATMENT", 23, 48]]], ["With this monomeric helix homooligomeric helical bundle models are built and embedded in a fully hydrated 1-palmitoyl-2-oleoyl-sn-glycerol-3phosphatidylcholine (POPC) bilayer.", [["1-palmitoyl-2-oleoyl-sn-glycerol-3phosphatidylcholine", "CHEMICAL", 106, 159], ["1-palmitoyl-2-oleoyl-sn-glycerol-3phosphatidylcholine", "CHEMICAL", 106, 159], ["POPC", "CHEMICAL", 161, 165], ["1-palmitoyl-2-oleoyl-sn-glycerol-3phosphatidylcholine", "SIMPLE_CHEMICAL", 106, 159], ["POPC", "SIMPLE_CHEMICAL", 161, 165], ["palmitoyl", "TEST", 108, 117], ["glycerol-3phosphatidylcholine (POPC) bilayer", "TREATMENT", 130, 174]]], ["Results of both experimental channel recordings and computational modeling show SARS ORF8a to act as a channel forming protein.P-365-Biomolecular self-assembly - Microtubules are involved in many vital processes.", [["Microtubules", "ANATOMY", 162, 174], ["P-365", "CHEMICAL", 127, 132], ["ORF8a", "GENE_OR_GENE_PRODUCT", 85, 90], ["Microtubules", "CELLULAR_COMPONENT", 162, 174], ["ORF8a", "PROTEIN", 85, 90], ["channel forming protein", "PROTEIN", 103, 126], ["Microtubules", "PROTEIN", 162, 174], ["both experimental channel recordings", "TEST", 11, 47], ["computational modeling", "TEST", 52, 74], ["SARS", "PROBLEM", 80, 84], ["P", "TEST", 127, 128]]], ["In cells, a sizeable network of microtubule binding proteins control and regulate microtubule dynamics.", [["cells", "ANATOMY", 3, 8], ["microtubule", "ANATOMY", 32, 43], ["microtubule", "ANATOMY", 82, 93], ["cells", "CELL", 3, 8], ["microtubule binding proteins", "GENE_OR_GENE_PRODUCT", 32, 60], ["microtubule", "CELLULAR_COMPONENT", 82, 93], ["microtubule binding proteins", "PROTEIN", 32, 60], ["microtubule", "PROTEIN", 82, 93], ["microtubule binding proteins control", "TREATMENT", 32, 68], ["sizeable", "OBSERVATION_MODIFIER", 12, 20], ["microtubule binding proteins", "OBSERVATION", 32, 60], ["microtubule dynamics", "OBSERVATION", 82, 102]]], ["Alp14 and Dis1 are members of the Dis1/ XMAP215 family that are major players in S.pombe.", [["Alp14", "GENE_OR_GENE_PRODUCT", 0, 5], ["Dis1", "GENE_OR_GENE_PRODUCT", 10, 14], ["Dis1", "GENE_OR_GENE_PRODUCT", 34, 38], ["XMAP215", "GENE_OR_GENE_PRODUCT", 40, 47], ["Alp14", "PROTEIN", 0, 5], ["Dis1", "PROTEIN", 10, 14], ["Dis1", "PROTEIN", 34, 38], ["XMAP215 family", "PROTEIN", 40, 54]]], ["The deletion phenotypes of Alp14 and Dis1 are similar, but nonetheless distinct.", [["Alp14", "GENE_OR_GENE_PRODUCT", 27, 32], ["Dis1", "GENE_OR_GENE_PRODUCT", 37, 41], ["Alp14", "PROTEIN", 27, 32], ["Dis1", "DNA", 37, 41], ["The deletion phenotypes of Alp14", "PROBLEM", 0, 32], ["deletion phenotypes", "OBSERVATION", 4, 23], ["similar", "OBSERVATION_MODIFIER", 46, 53], ["distinct", "OBSERVATION_MODIFIER", 71, 79]]], ["Both are involved in the formation of spindles but Alp14 is also involved in the maintenance of cytosolic microtubules in interphase.", [["spindles", "ANATOMY", 38, 46], ["cytosolic microtubules", "ANATOMY", 96, 118], ["interphase", "ANATOMY", 122, 132], ["spindles", "CELLULAR_COMPONENT", 38, 46], ["Alp14", "GENE_OR_GENE_PRODUCT", 51, 56], ["cytosolic microtubules", "CELLULAR_COMPONENT", 96, 118], ["interphase", "CELLULAR_COMPONENT", 122, 132], ["Alp14", "PROTEIN", 51, 56], ["cytosolic microtubules", "OBSERVATION", 96, 118]]], ["The restrictive temperatures of Alp14-deletion and Dis1-deletion mutants are different.", [["Alp14", "GENE_OR_GENE_PRODUCT", 32, 37], ["Dis1", "GENE_OR_GENE_PRODUCT", 51, 55], ["Alp14-deletion and Dis1-deletion mutants", "DNA", 32, 72], ["The restrictive temperatures", "TEST", 0, 28], ["Alp14", "TEST", 32, 37], ["deletion", "PROBLEM", 38, 46], ["Dis1-deletion mutants", "PROBLEM", 51, 72], ["restrictive", "OBSERVATION_MODIFIER", 4, 15], ["temperatures", "OBSERVATION_MODIFIER", 16, 28], ["different", "OBSERVATION_MODIFIER", 77, 86]]], ["Alp14 interacts with Alp7, a potential member of the TACC protein family.", [["Alp14", "GENE_OR_GENE_PRODUCT", 0, 5], ["Alp7", "GENE_OR_GENE_PRODUCT", 21, 25], ["TACC", "GENE_OR_GENE_PRODUCT", 53, 57], ["Alp14", "PROTEIN", 0, 5], ["Alp7", "PROTEIN", 21, 25], ["TACC protein family", "PROTEIN", 53, 72]]], ["I am working to reconstitute Alp14/Dis1-dependent microtubule dynamics in vitro, using purified S. pombe tubulin.", [["microtubule", "ANATOMY", 50, 61], ["Alp14", "GENE_OR_GENE_PRODUCT", 29, 34], ["Dis1", "GENE_OR_GENE_PRODUCT", 35, 39], ["microtubule", "CELLULAR_COMPONENT", 50, 61], ["S. pombe", "ORGANISM", 96, 104], ["tubulin", "GENE_OR_GENE_PRODUCT", 105, 112], ["Alp14", "PROTEIN", 29, 34], ["Dis1", "PROTEIN", 35, 39], ["microtubule", "PROTEIN", 50, 61], ["S. pombe tubulin", "PROTEIN", 96, 112], ["S. pombe", "SPECIES", 96, 104], ["S. pombe", "SPECIES", 96, 104], ["Alp14", "TREATMENT", 29, 34], ["Dis1", "TREATMENT", 35, 39], ["pombe tubulin", "OBSERVATION", 99, 112]]], ["Both Alp14 and Dis1 express well in insect cells and can be readily purified.", [["cells", "ANATOMY", 43, 48], ["Alp14", "GENE_OR_GENE_PRODUCT", 5, 10], ["Dis1", "GENE_OR_GENE_PRODUCT", 15, 19], ["insect cells", "CELL", 36, 48], ["Alp14", "PROTEIN", 5, 10], ["Dis1", "PROTEIN", 15, 19], ["insect cells", "CELL_TYPE", 36, 48]]], ["Preliminary data show that both proteins bind tubulin at low salt concentrations and that both influence the dynamics of pig brain microtubules.", [["brain microtubules", "ANATOMY", 125, 143], ["salt", "CHEMICAL", 61, 65], ["tubulin", "GENE_OR_GENE_PRODUCT", 46, 53], ["pig", "ORGANISM", 121, 124], ["brain microtubules", "MULTI-TISSUE_STRUCTURE", 125, 143], ["tubulin", "PROTEIN", 46, 53], ["pig", "SPECIES", 121, 124], ["Preliminary data", "TEST", 0, 16], ["both proteins bind tubulin", "PROBLEM", 27, 53], ["bind tubulin", "OBSERVATION", 41, 53], ["pig brain microtubules", "OBSERVATION", 121, 143]]], ["My goal is a complete functional analysis of Alp14 and Dis1, individually and in combination, to test candidate molecular mechanisms for Alp14/Dis1-catalysis of S. pombe microtubule dynamics.", [["microtubule", "ANATOMY", 170, 181], ["Alp14", "GENE_OR_GENE_PRODUCT", 45, 50], ["Dis1", "GENE_OR_GENE_PRODUCT", 55, 59], ["Alp14", "GENE_OR_GENE_PRODUCT", 137, 142], ["Dis1", "GENE_OR_GENE_PRODUCT", 143, 147], ["S. pombe", "ORGANISM", 161, 169], ["Alp14", "PROTEIN", 45, 50], ["Dis1", "PROTEIN", 55, 59], ["Alp14", "PROTEIN", 137, 142], ["Dis1", "PROTEIN", 143, 147], ["microtubule", "PROTEIN", 170, 181], ["S. pombe", "SPECIES", 161, 169], ["S. pombe", "SPECIES", 161, 169], ["Alp14", "TEST", 137, 142], ["microtubule dynamics", "OBSERVATION", 170, 190]]], ["The Syphoviridae coliphage T5 is a well-suited model to study the assembly of large viral capsids.", [["The Syphoviridae coliphage T5", "TREATMENT", 0, 29], ["large viral capsids", "PROBLEM", 78, 97], ["coliphage T5", "OBSERVATION", 17, 29], ["large", "OBSERVATION_MODIFIER", 78, 83], ["viral capsids", "OBSERVATION", 84, 97]]], ["Biochemical and biophysical approaches were used to reconstitute in vitro the assembly pathway of its capsid.", [["capsid", "CELLULAR_COMPONENT", 102, 108], ["biophysical approaches", "TREATMENT", 16, 38]]], ["The T5 structure was recently solved from cryo-EM and image reconstruction.", [["image reconstruction", "TREATMENT", 54, 74], ["T5", "ANATOMY", 4, 6]]], ["Its icosahedral capsid (T = 13) is built from the major head protein (pb8, 775 copies) forming both the pentons and hexons and from the portal protein (pb7, 12 copies) located at one vertex.", [["head", "ORGAN", 56, 60], ["pb8", "GENE_OR_GENE_PRODUCT", 70, 73], ["pentons", "GENE_OR_GENE_PRODUCT", 104, 111], ["hexons", "GENE_OR_GENE_PRODUCT", 116, 122], ["pb7", "GENE_OR_GENE_PRODUCT", 152, 155], ["icosahedral capsid", "PROTEIN", 4, 22], ["major head protein", "PROTEIN", 50, 68], ["pb8", "PROTEIN", 70, 73], ["775 copies", "PROTEIN", 75, 85], ["pentons", "PROTEIN", 104, 111], ["hexons", "PROTEIN", 116, 122], ["portal protein", "PROTEIN", 136, 150], ["pb7", "PROTEIN", 152, 155], ["icosahedral", "OBSERVATION_MODIFIER", 4, 15], ["capsid", "OBSERVATION_MODIFIER", 16, 22], ["head protein", "ANATOMY", 56, 68], ["portal protein", "ANATOMY", 136, 150], ["one vertex", "ANATOMY_MODIFIER", 179, 189]]], ["Its assembly proceeds by steps. pb8 and pb7 first assemble into a precursor structure called prohead I, which is converted to prohead II by proteolysis of pb8 and pb7 by a head maturation protease.", [["head", "ANATOMY", 172, 176], ["pb8", "GENE_OR_GENE_PRODUCT", 32, 35], ["pb7", "GENE_OR_GENE_PRODUCT", 40, 43], ["prohead I", "GENE_OR_GENE_PRODUCT", 93, 102], ["prohead II", "GENE_OR_GENE_PRODUCT", 126, 136], ["pb8", "GENE_OR_GENE_PRODUCT", 155, 158], ["pb7", "GENE_OR_GENE_PRODUCT", 163, 166], ["pb8", "PROTEIN", 32, 35], ["pb7", "PROTEIN", 40, 43], ["prohead I", "PROTEIN", 93, 102], ["prohead II", "PROTEIN", 126, 136], ["pb8", "PROTEIN", 155, 158], ["pb7", "PROTEIN", 163, 166], ["head maturation protease", "PROTEIN", 172, 196], ["pb8", "TEST", 32, 35], ["a head maturation protease", "TREATMENT", 170, 196], ["head", "ANATOMY", 172, 176]]], ["Packaging of the 121 kbp dsDNA is then driven through the portal pore by a molecular motor, the terminase.", [["portal pore", "ANATOMY", 58, 69], ["dsDNA", "CELLULAR_COMPONENT", 25, 30], ["portal pore", "MULTI-TISSUE_STRUCTURE", 58, 69], ["121 kbp dsDNA", "DNA", 17, 30], ["terminase", "PROTEIN", 96, 105], ["Packaging of the 121 kbp dsDNA", "TREATMENT", 0, 30], ["portal", "ANATOMY", 58, 64], ["pore", "ANATOMY_MODIFIER", 65, 69], ["terminase", "OBSERVATION_MODIFIER", 96, 105]]], ["This promotes expansion of prohead II leading to the mature capsid.", [["prohead II", "CHEMICAL", 27, 37], ["prohead II", "GENE_OR_GENE_PRODUCT", 27, 37], ["prohead II", "PROTEIN", 27, 37], ["prohead II", "TREATMENT", 27, 37], ["the mature capsid", "PROBLEM", 49, 66], ["expansion", "OBSERVATION_MODIFIER", 14, 23], ["mature", "OBSERVATION_MODIFIER", 53, 59], ["capsid", "OBSERVATION", 60, 66]]], ["The different assembly steps and the conformational changes accompanying capsid maturation were characterized using Proheads I either self-assembled from the overproduced and purified capsid proteins or isolated from a phage mutant.", [["Proheads I", "PROTEIN", 116, 126], ["overproduced and purified capsid proteins", "PROTEIN", 158, 199], ["the conformational changes", "PROBLEM", 33, 59], ["capsid maturation", "PROBLEM", 73, 90], ["purified capsid proteins", "PROBLEM", 175, 199], ["different", "OBSERVATION_MODIFIER", 4, 13], ["assembly steps", "OBSERVATION", 14, 28]]], ["These precursor capsid structures were analysed by Small Angle X-ray Scattering.", [["Small Angle X-ray Scattering", "TEST", 51, 79], ["capsid structures", "OBSERVATION", 16, 33], ["Small", "OBSERVATION_MODIFIER", 51, 56], ["Angle", "OBSERVATION_MODIFIER", 57, 62]]], ["The 3D structure of prohead II and of the expanded capsid were solved from cryo-EM.", [["prohead II", "CHEMICAL", 20, 30], ["prohead II", "GENE_OR_GENE_PRODUCT", 20, 30], ["prohead II", "PROTEIN", 20, 30], ["expanded capsid", "PROTEIN", 42, 57], ["the expanded capsid", "TREATMENT", 38, 57], ["expanded", "OBSERVATION_MODIFIER", 42, 50], ["capsid", "OBSERVATION", 51, 57]]], ["Our data show that the assembly process of a large icosahedral capsid can be efficiently reconstituted in vitro.P-371Amyloid beta peptide fibril formation modulated by phospholipid membranes E. Hellstrand 1 , E. Sparr 2 , S. Linse 1 1 Lund Univ., Department of biophysical chemistry, Sweden, 2 Lund Univ., Department of physical chemistry, Sweden Disease-causing amyloid fibril formation can be modulated by many factors including interactions with biological lipid membranes.", [["fibril", "ANATOMY", 371, 377], ["lipid membranes", "ANATOMY", 460, 475], ["amyloid fibril", "SIMPLE_CHEMICAL", 363, 377], ["lipid membranes", "CELLULAR_COMPONENT", 460, 475], ["P", "DNA", 112, 113], ["Our data", "TEST", 0, 8], ["a large icosahedral capsid", "PROBLEM", 43, 69], ["P", "TEST", 112, 113], ["371Amyloid beta peptide fibril formation", "TREATMENT", 114, 154], ["Sweden Disease", "PROBLEM", 340, 354], ["amyloid fibril formation", "PROBLEM", 363, 387], ["biological lipid membranes", "TREATMENT", 449, 475], ["large", "OBSERVATION_MODIFIER", 45, 50], ["icosahedral capsid", "OBSERVATION", 51, 69], ["amyloid fibril", "OBSERVATION", 363, 377]]], ["An increasing amount of evidence suggests that the process of fibril formation in vivo and the mechanism of toxicity both involve membrane interactions.", [["fibril", "ANATOMY", 62, 68], ["membrane", "ANATOMY", 130, 138], ["toxicity", "DISEASE", 108, 116], ["fibril", "CELLULAR_COMPONENT", 62, 68], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["fibril formation", "PROBLEM", 62, 78], ["toxicity", "PROBLEM", 108, 116], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["amount", "OBSERVATION_MODIFIER", 14, 20], ["fibril formation", "OBSERVATION", 62, 78]]], ["Alzheimer's is probably the most well-known amyloid disease and the associated amyloid beta peptide originates from the membrane incorporated amyloid precursor protein (APP).", [["membrane", "ANATOMY", 120, 128], ["Alzheimer's", "DISEASE", 0, 11], ["amyloid disease", "DISEASE", 44, 59], ["amyloid beta peptide", "GENE_OR_GENE_PRODUCT", 79, 99], ["membrane", "CELLULAR_COMPONENT", 120, 128], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 142, 167], ["APP", "GENE_OR_GENE_PRODUCT", 169, 172], ["amyloid precursor protein", "PROTEIN", 142, 167], ["APP", "PROTEIN", 169, 172], ["Alzheimer's", "PROBLEM", 0, 11], ["known amyloid disease", "PROBLEM", 38, 59], ["the associated amyloid beta peptide", "PROBLEM", 64, 99], ["amyloid disease", "OBSERVATION", 44, 59], ["amyloid", "OBSERVATION", 79, 86], ["amyloid precursor protein", "OBSERVATION", 142, 167]]], ["We use recombinant Abeta M1-40 and Abeta M1-42 produced in Escherichia coli, which allows us to perform large scale kinetics assays with good statistics where the amyloid formation process is followed in means of thioflavin T fluorescence.", [["amyloid", "DISEASE", 163, 170], ["thioflavin T", "CHEMICAL", 213, 225], ["thioflavin T", "CHEMICAL", 213, 225], ["Abeta M1-40", "GENE_OR_GENE_PRODUCT", 19, 30], ["Abeta M1-42", "GENE_OR_GENE_PRODUCT", 35, 46], ["Escherichia coli", "ORGANISM", 59, 75], ["amyloid", "SIMPLE_CHEMICAL", 163, 170], ["thioflavin T", "GENE_OR_GENE_PRODUCT", 213, 225], ["Abeta M1-42", "PROTEIN", 35, 46], ["Escherichia coli", "SPECIES", 59, 75], ["Escherichia coli", "SPECIES", 59, 75], ["recombinant Abeta M1", "TREATMENT", 7, 27], ["Abeta M1", "TREATMENT", 35, 43], ["Escherichia coli", "PROBLEM", 59, 75], ["large scale kinetics assays", "TEST", 104, 131], ["the amyloid formation process", "PROBLEM", 159, 188], ["Escherichia coli", "OBSERVATION", 59, 75], ["amyloid formation", "OBSERVATION", 163, 180]]], ["The lipid membranes are introduced in the system as large unilamellar vesicles composed of DOPC, DPPC and Sphingomyelin, with and without incorporation of cholesterol.", [["lipid membranes", "ANATOMY", 4, 19], ["unilamellar vesicles", "ANATOMY", 58, 78], ["DOPC, DPPC", "CHEMICAL", 91, 101], ["cholesterol", "CHEMICAL", 155, 166], ["DOPC", "CHEMICAL", 91, 95], ["DPPC", "CHEMICAL", 97, 101], ["Sphingomyelin", "CHEMICAL", 106, 119], ["cholesterol", "CHEMICAL", 155, 166], ["lipid membranes", "CELLULAR_COMPONENT", 4, 19], ["unilamellar vesicles", "CELLULAR_COMPONENT", 58, 78], ["DOPC", "SIMPLE_CHEMICAL", 91, 95], ["DPPC", "SIMPLE_CHEMICAL", 97, 101], ["Sphingomyelin", "SIMPLE_CHEMICAL", 106, 119], ["cholesterol", "SIMPLE_CHEMICAL", 155, 166], ["The lipid membranes", "TREATMENT", 0, 19], ["large unilamellar vesicles", "PROBLEM", 52, 78], ["DOPC, DPPC", "TREATMENT", 91, 101], ["Sphingomyelin", "TREATMENT", 106, 119], ["lipid membranes", "OBSERVATION", 4, 19], ["large", "OBSERVATION_MODIFIER", 52, 57], ["unilamellar vesicles", "OBSERVATION", 58, 78]]], ["We find that the phase behanviour of the membrane in the vesicles has a large effect on the lag time of the amyloid formation process for both Abeta M1-40 and M1-42.", [["membrane", "ANATOMY", 41, 49], ["vesicles", "ANATOMY", 57, 65], ["amyloid", "DISEASE", 108, 115], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["vesicles", "CELLULAR_COMPONENT", 57, 65], ["amyloid", "GENE_OR_GENE_PRODUCT", 108, 115], ["Abeta M1-40", "GENE_OR_GENE_PRODUCT", 143, 154], ["M1-42", "GENE_OR_GENE_PRODUCT", 159, 164], ["Abeta", "PROTEIN", 143, 148], ["the amyloid formation process", "PROBLEM", 104, 133], ["Abeta M1", "TEST", 143, 151], ["vesicles", "ANATOMY", 57, 65], ["large", "OBSERVATION_MODIFIER", 72, 77], ["effect", "OBSERVATION_MODIFIER", 78, 84], ["amyloid formation", "OBSERVATION", 108, 125]]], ["All membranes increase the lagtime to some degree but DPPC has the largest effect.", [["membranes", "ANATOMY", 4, 13], ["DPPC", "CHEMICAL", 54, 58], ["DPPC", "CHEMICAL", 54, 58], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["DPPC", "SIMPLE_CHEMICAL", 54, 58], ["All membranes", "PROBLEM", 0, 13], ["membranes", "OBSERVATION_MODIFIER", 4, 13], ["increase", "OBSERVATION", 14, 22], ["lagtime to some degree", "OBSERVATION_MODIFIER", 27, 49], ["largest", "OBSERVATION_MODIFIER", 67, 74], ["effect", "OBSERVATION_MODIFIER", 75, 81]]], ["By comparing different phases we can conclude that the translational diffusion in the membrane seems to be more important than the acyl chain ordering.", [["membrane", "ANATOMY", 86, 94], ["acyl", "CHEMICAL", 131, 135], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["the translational diffusion in the membrane", "PROBLEM", 51, 94]]], ["Furthermore, electrostatics, concentration dependence and membrane addition at different time points in the amyloid formation process have been investigated.P-370Equilibrium/non-equilibrium transitions in macromolecule interactions P. Dumas 1 , G. Gibrat 2 , S. Bernacchi 1 , E. Ennifar 1 1 IBMC-CNRS, Strasbourg, France, 2 LLB (CEA/CNRS), Saclay, France Usually, so called 'relaxation phenomena' occur on a fast time-scale and 'P-jump' or 'T-jump' techniques are required to follow such events lasting (much) less than 100 ms.", [["membrane", "ANATOMY", 58, 66], ["amyloid", "DISEASE", 108, 115], ["P-370Equilibrium", "CHEMICAL", 157, 173], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["amyloid", "SIMPLE_CHEMICAL", 108, 115], ["concentration dependence", "PROBLEM", 29, 53], ["membrane addition", "PROBLEM", 58, 75], ["the amyloid formation process", "PROBLEM", 104, 133], ["P", "TEST", 157, 158], ["equilibrium transitions", "PROBLEM", 178, 201], ["Dumas", "TEST", 235, 240], ["Gibrat", "TEST", 248, 254], ["'T-jump' techniques", "TREATMENT", 440, 459], ["concentration dependence", "OBSERVATION", 29, 53], ["amyloid formation", "OBSERVATION", 108, 125]]], ["We report that, during stability studies of proteins or nucleic acids, such relaxation events can be observed on astonishing long time-scales.", [["nucleic acids", "CHEMICAL", 56, 69], ["nucleic acids", "SIMPLE_CHEMICAL", 56, 69], ["nucleic acids", "PROBLEM", 56, 69], ["such relaxation events", "PROBLEM", 71, 93]]], ["We first performed 'melting studies' with nucleic-acid duplexes by using linear variations of temperature (T) with time (t).", [["nucleic-acid", "CHEMICAL", 42, 54], ["nucleic-acid", "SIMPLE_CHEMICAL", 42, 54], ["'melting studies", "TEST", 19, 35], ["nucleic-acid duplexes", "TREATMENT", 42, 63]]], ["We observed that even very low rates dT/dt could lead to a frozen state for temperature values below a sharp temperature range, and relaxation to equilibrium beyond that range.", [["dt", "PROBLEM", 40, 42], ["a frozen state", "PROBLEM", 57, 71], ["temperature values", "PROBLEM", 76, 94]]], ["This allows defining a 'relaxation temperature' T r separating the two regimes.", [["a 'relaxation temperature'", "TREATMENT", 21, 47]]], ["Numerical simulations very accurately described the related hysteresis phenomenon observed upon a heating-cooling cycle, which is the hallmark of departure from equilibrium.", [["Numerical simulations", "PROBLEM", 0, 21], ["the related hysteresis phenomenon", "PROBLEM", 48, 81], ["a heating-cooling cycle", "TREATMENT", 96, 119]]], ["Analogous observations were made with protein oligomers submitted to either a variable pressure, or variable concentration in denaturant.", [["protein oligomers", "TREATMENT", 38, 55]]], ["Importantly, a single theoretical frame predicts that the critical relaxation value X r (X standing indifferently for temperature, pressure or denaturant concentration) depends on Ln(dX/dt).", [["temperature", "TEST", 118, 129], ["pressure or denaturant concentration", "TREATMENT", 131, 167], ["Ln", "ANATOMY", 180, 182]]], ["One may ask whether some thermosensor RNAs known for switching on or off genetic expression by 'feeling' a temperature variation, might also 'feel' dT/dt.", [["thermosensor RNAs", "RNA", 25, 42], ["dt", "PROBLEM", 151, 153]]], ["If true, the exact switching temperature would depend on dT/dt and faster temperature changes would increase T r .P-369-Biomolecular self-assembly - The major component of amyloid plaques in the Gerstmann-Str\u00e4ussler-Scheinker disease is a prion peptide fragment from 81-82 to 144-153 residues.", [["P-369", "CHEMICAL", 114, 119], ["amyloid plaques", "DISEASE", 172, 187], ["T r", "GENE_OR_GENE_PRODUCT", 109, 112], ["amyloid plaques", "PATHOLOGICAL_FORMATION", 172, 187], ["the exact switching temperature", "PROBLEM", 9, 40], ["dT/dt", "PROBLEM", 57, 62], ["faster temperature changes", "PROBLEM", 67, 93], ["P", "TEST", 114, 115], ["amyloid plaques", "PROBLEM", 172, 187], ["Scheinker disease", "PROBLEM", 216, 233], ["a prion peptide fragment", "PROBLEM", 237, 261], ["amyloid plaques", "OBSERVATION", 172, 187], ["Gerstmann", "ANATOMY", 195, 204], ["Scheinker disease", "OBSERVATION", 216, 233]]], ["Here, we present a structural study of PrP82-146 in form of oligomers and fibrils by Fourier transform infrared spectroscopy (FTIR) and atomic force microscopy (AFM).", [["PrP82-146", "CHEMICAL", 39, 48], ["PrP82-146", "CHEMICAL", 39, 48], ["PrP82-146", "SIMPLE_CHEMICAL", 39, 48], ["a structural study", "TEST", 17, 35], ["PrP82", "TEST", 39, 44], ["oligomers", "PROBLEM", 60, 69], ["fibrils", "PROBLEM", 74, 81], ["Fourier transform infrared spectroscopy", "TEST", 85, 124], ["atomic force microscopy", "TEST", 136, 159]]], ["After incubation at 37 \u2022 C, the unfolded peptide was found to aggregate into oligomers characterized by intermolecular \u03b2-sheet infrared bands and by a wide distribution of oligomer volumes.", [["the unfolded peptide", "PROBLEM", 28, 48], ["intermolecular \u03b2-sheet infrared bands", "PROBLEM", 104, 141], ["a wide distribution of oligomer volumes", "PROBLEM", 149, 188], ["wide", "OBSERVATION_MODIFIER", 151, 155], ["distribution", "OBSERVATION_MODIFIER", 156, 168], ["oligomer volumes", "OBSERVATION", 172, 188]]], ["After a lag phase, a conformational rearrangement of oligomers into fibrils, with a parallel orientation of the cross \u03b2-sheet structures, was observed.", [["fibrils", "ANATOMY", 68, 75], ["a lag phase", "TEST", 6, 17], ["a conformational rearrangement of oligomers into fibrils", "TREATMENT", 19, 75]]], ["By AFM, different morphologies were also detected for fibrils that displayed high heterogeneity in their twisting periodicity and a complex hierarchical assembly.", [["fibrils", "PROBLEM", 54, 61], ["high heterogeneity in their twisting periodicity", "PROBLEM", 77, 125], ["high", "OBSERVATION_MODIFIER", 77, 81], ["heterogeneity", "OBSERVATION", 82, 95], ["twisting", "OBSERVATION_MODIFIER", 105, 113], ["complex", "OBSERVATION_MODIFIER", 132, 139], ["hierarchical", "OBSERVATION_MODIFIER", 140, 152]]], ["The PrP82-146 peptide was found to undergo several aggregation pathways, whose end products display different structural properties and intermolecular interactions.", [["PrP82-146 peptide", "CHEMICAL", 4, 21], ["PrP82-146 peptide", "CHEMICAL", 4, 21], ["PrP82-146", "GENE_OR_GENE_PRODUCT", 4, 13], ["The PrP82", "TEST", 0, 9], ["several aggregation pathways", "PROBLEM", 43, 71], ["aggregation", "OBSERVATION", 51, 62], ["different", "OBSERVATION_MODIFIER", 100, 109], ["structural properties", "OBSERVATION", 110, 131], ["intermolecular interactions", "OBSERVATION", 136, 163]]], ["These findings underline the high plasticity of the prion peptide, a peculiar feature of prion proteins to overcome species barriers (Natalello et al. J.Mol.Biol.", [["prion proteins", "GENE_OR_GENE_PRODUCT", 89, 103], ["prion proteins", "PROTEIN", 89, 103], ["the prion peptide", "PROBLEM", 48, 65], ["prion proteins", "PROBLEM", 89, 103], ["high plasticity", "OBSERVATION", 29, 44]]], ["2008;381:1349-1361).P-376The role of proline isomerisation in the aggregation process and fibril formation of alpha-synuclein J. Meuvis 1 , M. Gerard 2 , V. Baekelandt 3 , Y. Engelborghs 1 1 Lab.of Biomolecular Dynamics, KU Leuven, Belgium, 2 Lab.of Biochemistry, Campus Kortrijk, Belgium, 3 Lab.for Neurobiology & Gene Therapy, KU Leuven, Belgium Alpha-synuclein (\u03b1-syn) plays a central role in Parkinson's disease.", [["fibril", "ANATOMY", 90, 96], ["2008;381:1349-1361", "CHEMICAL", 0, 18], ["P-376", "CHEMICAL", 20, 25], ["proline", "CHEMICAL", 37, 44], ["\u03b1-syn", "CHEMICAL", 365, 370], ["Parkinson's disease", "DISEASE", 396, 415], ["proline", "CHEMICAL", 37, 44], ["proline", "AMINO_ACID", 37, 44], ["fibril", "CELLULAR_COMPONENT", 90, 96], ["Alpha-synuclein", "GENE_OR_GENE_PRODUCT", 348, 363], ["\u03b1-syn", "GENE_OR_GENE_PRODUCT", 365, 370], ["Parkinson's disease", "CANCER", 396, 415], ["P-376", "DNA", 20, 25], ["proline isomerisation", "PROBLEM", 37, 58], ["the aggregation process", "PROBLEM", 62, 85], ["Parkinson's disease", "PROBLEM", 396, 415], ["proline isomerisation", "OBSERVATION", 37, 58], ["Parkinson", "OBSERVATION", 396, 405]]], ["The aggregation of this protein, which contains five proline residues (P108,P117,P120,P128,P138), is accelerated in vitro by FK506 binding proteins (FKBPs), a family of enzymes with a peptidyl-prolyl cis-trans isomerase activity (PPIase).", [["FK506", "CHEMICAL", 125, 130], ["proline", "CHEMICAL", 53, 60], ["FK506", "CHEMICAL", 125, 130], ["prolyl", "CHEMICAL", 193, 199], ["P138", "GENE_OR_GENE_PRODUCT", 91, 95], ["FK506 binding proteins", "GENE_OR_GENE_PRODUCT", 125, 147], ["FKBPs", "GENE_OR_GENE_PRODUCT", 149, 154], ["peptidyl-prolyl cis-trans isomerase", "GENE_OR_GENE_PRODUCT", 184, 219], ["PPIase", "GENE_OR_GENE_PRODUCT", 230, 236], ["FK506 binding proteins", "PROTEIN", 125, 147], ["FKBPs", "PROTEIN", 149, 154], ["enzymes", "PROTEIN", 169, 176], ["peptidyl-prolyl cis-trans isomerase", "PROTEIN", 184, 219], ["PPIase", "PROTEIN", 230, 236], ["this protein", "TEST", 19, 31], ["five proline residues", "TEST", 48, 69], ["P108", "TEST", 71, 75], ["P117", "TEST", 76, 80], ["P120", "TEST", 81, 85], ["P128", "TEST", 86, 90], ["enzymes", "TEST", 169, 176], ["a peptidyl-prolyl cis-trans isomerase activity", "TREATMENT", 182, 228], ["proline residues", "OBSERVATION", 53, 69]]], ["FKBPs catalyze the cis-trans conformational change of proline, often a rate limiting step in protein folding.", [["proline", "CHEMICAL", 54, 61], ["proline", "CHEMICAL", 54, 61], ["FKBPs", "GENE_OR_GENE_PRODUCT", 0, 5], ["proline", "AMINO_ACID", 54, 61], ["FKBPs", "PROTEIN", 0, 5], ["the cis-trans conformational change of proline", "PROBLEM", 15, 61], ["a rate limiting step in protein folding", "PROBLEM", 69, 108], ["protein folding", "OBSERVATION", 93, 108]]], ["To elucidate the role of the proline residues in aggregation, we constructed a mutant P(108,117,120,128,138)A \u03b1-syn .", [["proline", "CHEMICAL", 29, 36], ["proline", "CHEMICAL", 29, 36], ["\u03b1-syn", "GENE_OR_GENE_PRODUCT", 110, 115], ["the proline residues in aggregation", "PROBLEM", 25, 60]]], ["The kinetics of the aggregation of the mutant were studied with turbidity and Thioflavin T fluorescence (ThT).", [["Thioflavin T", "CHEMICAL", 78, 90], ["Thioflavin T", "SIMPLE_CHEMICAL", 78, 90], ["turbidity", "TREATMENT", 64, 73], ["Thioflavin T fluorescence", "TREATMENT", 78, 103], ["kinetics", "OBSERVATION_MODIFIER", 4, 12]]], ["Turbidity measurements show the formation of early, ThT negative aggregates which is as fast for both WT and mutant.", [["Turbidity measurements", "TEST", 0, 22], ["early", "OBSERVATION_MODIFIER", 45, 50]]], ["Fibril formation however is faster for the proline-deficient mutant.", [["Fibril", "ANATOMY", 0, 6], ["proline", "CHEMICAL", 43, 50], ["proline", "CHEMICAL", 43, 50], ["Fibril", "MULTI-TISSUE_STRUCTURE", 0, 6], ["proline", "AMINO_ACID", 43, 50], ["proline-deficient mutant", "PROTEIN", 43, 67], ["Fibril formation", "PROBLEM", 0, 16], ["the proline-deficient mutant", "PROBLEM", 39, 67]]], ["We also studied the effect of FKBP12 on the aggregation of the mutant.", [["FKBP12", "GENE_OR_GENE_PRODUCT", 30, 36], ["FKBP12", "PROTEIN", 30, 36], ["FKBP12", "TREATMENT", 30, 36]]], ["Although WT \u03b1-syn early aggregate formation is accelerated by the addition of 1 \u00b5M FKBP12, this effect disappears in the mutant.", [["\u03b1-", "GENE_OR_GENE_PRODUCT", 12, 14], ["FKBP12", "GENE_OR_GENE_PRODUCT", 83, 89], ["FKBP12", "PROTEIN", 83, 89], ["WT", "TEST", 9, 11], ["1 \u00b5M FKBP12", "TREATMENT", 78, 89]]], ["Addition of (1pM-1\u00b5M) FKBP12 accelerates the fiber formation of WT \u03b1-syn, which is abolished in the mutant.", [["fiber", "ANATOMY", 45, 50], ["FKBP12", "GENE_OR_GENE_PRODUCT", 22, 28], ["fiber", "CELLULAR_COMPONENT", 45, 50], ["\u03b1-syn", "GENE_OR_GENE_PRODUCT", 67, 72], ["FKBP12", "PROTEIN", 22, 28]]], ["We can conclude that \u03b1-syn fiber formation is accelerated for the proline-deficient mutant, which suggests a role for the proline residues in fiber formation.", [["\u03b1-syn fiber", "ANATOMY", 21, 32], ["fiber", "ANATOMY", 142, 147], ["proline", "CHEMICAL", 66, 73], ["proline", "CHEMICAL", 122, 129], ["proline", "CHEMICAL", 66, 73], ["proline", "CHEMICAL", 122, 129], ["\u03b1-syn fiber", "CELLULAR_COMPONENT", 21, 32], ["proline", "AMINO_ACID", 66, 73], ["fiber", "TISSUE", 142, 147], ["proline-deficient mutant", "PROTEIN", 66, 90], ["\u03b1-syn fiber formation", "TREATMENT", 21, 42], ["the proline-deficient mutant", "PROBLEM", 62, 90], ["the proline residues in fiber formation", "TREATMENT", 118, 157]]], ["Furthermore all accelerating effects of FKBP12 are abolished in the mutant which suggests that the PPIase activity of FKBP12 is responsible for the accelerating effect on the aggregation of WT \u03b1-syn.", [["FKBP12", "GENE_OR_GENE_PRODUCT", 40, 46], ["PPIase", "GENE_OR_GENE_PRODUCT", 99, 105], ["FKBP12", "GENE_OR_GENE_PRODUCT", 118, 124], ["\u03b1-syn", "GENE_OR_GENE_PRODUCT", 193, 198], ["FKBP12", "PROTEIN", 40, 46], ["PPIase", "PROTEIN", 99, 105], ["FKBP12", "PROTEIN", 118, 124], ["FKBP12", "TREATMENT", 40, 46], ["the PPIase activity of FKBP12", "PROBLEM", 95, 124]]], ["Materials used as gene delivery vehicles must be able to condense DNA into small sizes to facilitate transport and crossing various barriers.", [["DNA", "CELLULAR_COMPONENT", 66, 69], ["Materials", "TREATMENT", 0, 9], ["gene delivery vehicles", "TREATMENT", 18, 40], ["small sizes", "OBSERVATION_MODIFIER", 75, 86]]], ["One of the polycations investigated for DNA compaction is chitosan, which has the advantage of being safe and biodegradable.", [["chitosan", "CHEMICAL", 58, 66], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["chitosan", "SIMPLE_CHEMICAL", 58, 66], ["the polycations", "TREATMENT", 7, 22], ["DNA compaction", "TREATMENT", 40, 54]]], ["As a step towards reducing the aggregation behaviour of DNA-chitosan complexes, chitosans were modified by grafting PEG-chains on the backbone.", [["DNA-chitosan", "CHEMICAL", 56, 68], ["chitosans", "CHEMICAL", 80, 89], ["PEG", "CHEMICAL", 116, 119], ["chitosans", "CHEMICAL", 80, 89], ["PEG", "CHEMICAL", 116, 119], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["chitosan complexes", "SIMPLE_CHEMICAL", 60, 78], ["chitosans", "SIMPLE_CHEMICAL", 80, 89], ["PEG-chains", "SIMPLE_CHEMICAL", 116, 126], ["DNA-chitosan complexes", "TREATMENT", 56, 78], ["chitosans", "TREATMENT", 80, 89], ["grafting PEG-chains on the backbone", "TREATMENT", 107, 142], ["backbone", "ANATOMY_MODIFIER", 134, 142]]], ["It is known that the transfection efficacy depends on the chitosan chain length.", [["chitosan", "CHEMICAL", 58, 66], ["chitosan", "SIMPLE_CHEMICAL", 58, 66], ["the transfection efficacy", "PROBLEM", 17, 42], ["transfection efficacy", "OBSERVATION", 21, 42]]], ["Additionally, the degree of pegylation might influence the condensation process.", [["pegylation", "TREATMENT", 28, 38], ["the condensation process", "PROBLEM", 55, 79], ["degree", "OBSERVATION_MODIFIER", 18, 24], ["pegylation", "OBSERVATION", 28, 38], ["condensation process", "OBSERVATION", 59, 79]]], ["Here a systematic biophysical study of pegylated chitosans and how the interplay between chitosan chain length and degree of pegylation affect the compaction of DNA in terms of particle size and structure, stability in PBS and when exposed to serum, and transfection efficacy is presented.", [["particle", "ANATOMY", 177, 185], ["serum", "ANATOMY", 243, 248], ["pegylated chitosans", "CHEMICAL", 39, 58], ["chitosan", "CHEMICAL", 89, 97], ["pegylated chitosans", "CHEMICAL", 39, 58], ["pegylated chitosans", "SIMPLE_CHEMICAL", 39, 58], ["chitosan", "SIMPLE_CHEMICAL", 89, 97], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["serum", "ORGANISM_SUBSTANCE", 243, 248], ["a systematic biophysical study", "TEST", 5, 35], ["pegylated chitosans", "TREATMENT", 39, 58], ["chitosan chain length", "TREATMENT", 89, 110], ["pegylation", "TREATMENT", 125, 135], ["DNA", "PROBLEM", 161, 164], ["serum", "TEST", 243, 248], ["pegylation", "OBSERVATION", 125, 135], ["DNA", "OBSERVATION", 161, 164], ["particle", "OBSERVATION_MODIFIER", 177, 185], ["size", "OBSERVATION_MODIFIER", 186, 190], ["stability", "OBSERVATION_MODIFIER", 206, 215]]], ["Three different chain lengths of chitosans are employed, and for each sample three pegylation degrees are investigated and the properties of the DNA-PEGchitosan complexes compared to complexes formed when employing the original, chitosan for DNA compaction.", [["chitosan", "CHEMICAL", 229, 237], ["chitosans", "CHEMICAL", 33, 42], ["chitosans", "SIMPLE_CHEMICAL", 33, 42], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["chitosan", "SIMPLE_CHEMICAL", 229, 237], ["DNA", "CELLULAR_COMPONENT", 242, 245], ["DNA-PEGchitosan complexes", "PROTEIN", 145, 170], ["Three different chain lengths of chitosans", "TREATMENT", 0, 42], ["each sample three pegylation degrees", "TREATMENT", 65, 101], ["the DNA-PEGchitosan complexes", "PROBLEM", 141, 170], ["DNA compaction", "PROBLEM", 242, 256], ["chain", "OBSERVATION_MODIFIER", 16, 21], ["lengths", "OBSERVATION_MODIFIER", 22, 29]]], ["It is found pegylation of chitosans can be used to increase both the stability of the DNA-chitosan complexes when exposed to serum as well as increase their transfection efficacy in HEK293 cells.I. K\u00f6perMax-Planck Institute for Polymer Research, Mainz, Germany Model membranes mimic the essential function of a natural membrane.", [["serum", "ANATOMY", 125, 130], ["HEK293 cells", "ANATOMY", 182, 194], ["membranes", "ANATOMY", 267, 276], ["membrane", "ANATOMY", 319, 327], ["chitosans", "CHEMICAL", 26, 35], ["chitosan", "CHEMICAL", 90, 98], ["chitosans", "CHEMICAL", 26, 35], ["chitosans", "SIMPLE_CHEMICAL", 26, 35], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["chitosan", "SIMPLE_CHEMICAL", 90, 98], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["HEK293 cells", "CELL", 182, 194], ["membrane", "CELLULAR_COMPONENT", 319, 327], ["DNA-chitosan complexes", "PROTEIN", 86, 108], ["HEK293 cells", "CELL_LINE", 182, 194], ["pegylation of chitosans", "TREATMENT", 12, 35], ["the DNA-chitosan complexes", "TREATMENT", 82, 108], ["Mainz, Germany Model membranes", "TREATMENT", 246, 276], ["pegylation", "OBSERVATION", 12, 22], ["stability", "OBSERVATION_MODIFIER", 69, 78], ["HEK293 cells", "OBSERVATION", 182, 194], ["essential function", "OBSERVATION", 287, 305], ["natural membrane", "OBSERVATION", 311, 327]]], ["However, the complexity is reduced in order to allow the study of fundamental processes.", [["the study", "TEST", 53, 62], ["reduced", "OBSERVATION_MODIFIER", 27, 34]]], ["Tethered membranes consist in principle of a lipid bilayer that is covalently linked to a solid support through a spacer group.", [["membranes", "ANATOMY", 9, 18], ["lipid bilayer", "ANATOMY", 45, 58], ["membranes", "CELLULAR_COMPONENT", 9, 18], ["Tethered membranes", "PROBLEM", 0, 18], ["a lipid bilayer", "TREATMENT", 43, 58], ["a solid support", "TREATMENT", 88, 103], ["a spacer group", "TREATMENT", 112, 126], ["membranes", "OBSERVATION", 9, 18]]], ["This architecture allows the characterization of the membrane itself as well as of incorporated membrane proteins using surface analytical techniques.I. K\u00f6perWe have established a versatile system of various anchor lipids, which allow membrane formation on different surfaces.", [["membrane", "ANATOMY", 53, 61], ["membrane", "ANATOMY", 96, 104], ["surface", "ANATOMY", 120, 127], ["membrane", "ANATOMY", 235, 243], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["lipids", "SIMPLE_CHEMICAL", 215, 221], ["membrane", "CELLULAR_COMPONENT", 235, 243], ["membrane proteins", "PROTEIN", 96, 113], ["surface analytical techniques", "TREATMENT", 120, 149], ["various anchor lipids", "TREATMENT", 200, 221], ["membrane formation", "OBSERVATION", 235, 253], ["surfaces", "OBSERVATION_MODIFIER", 267, 275]]], ["The architectures have been characterized by surface Plasmon techniques, neutron reflectivity and electrochemical methods.", [["neutron reflectivity", "TEST", 73, 93], ["electrochemical methods", "TREATMENT", 98, 121], ["surface", "OBSERVATION_MODIFIER", 45, 52], ["Plasmon", "OBSERVATION_MODIFIER", 53, 60]]], ["The membranes are electrically insulating and allow for the functional incorporation of ion channel proteins.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["ion channel proteins", "PROTEIN", 88, 108], ["ion channel proteins", "TREATMENT", 88, 108]]], ["Polymerizable lipids allow to pattern the membrane and to study lateral diffusion processes.", [["membrane", "ANATOMY", 42, 50], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["Polymerizable lipids", "TREATMENT", 0, 20], ["study lateral diffusion processes", "TEST", 58, 91]]], ["Furthermore, the membranes can be used as a sensing platform, where embedded membrane proteins act as actual sensing units.DNAs or like-charged polyelectrolytes attraction and assemblyA.", [["membranes", "ANATOMY", 17, 26], ["membrane", "ANATOMY", 77, 85], ["membranes", "CELLULAR_COMPONENT", 17, 26], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["DNAs", "CELLULAR_COMPONENT", 123, 127], ["membrane proteins", "PROTEIN", 77, 94], ["a sensing platform", "TREATMENT", 42, 60], ["embedded membrane proteins", "TREATMENT", 68, 94], ["actual sensing units", "TREATMENT", 102, 122], ["DNAs", "PROBLEM", 123, 127], ["charged polyelectrolytes attraction", "TREATMENT", 136, 171], ["polyelectrolytes attraction", "OBSERVATION", 144, 171]]], ["Perico, S. Pietronave, L. Arcesi, C. D'Arrigo Consiglio Nazionale delle Ricerche (CNR), Institute for macromolecular studies (ISMAC)DNAs or like-charged polyelectrolytes attraction and assemblyThe electrostatic free energy (fe) of two parallel rigid likecharged polyelectrolytes (PEs) is given as a function of the separation distance.", [["likecharged polyelectrolytes", "SIMPLE_CHEMICAL", 250, 278], ["C. D'Arrigo Consiglio Nazionale delle Ricerche", "SPECIES", 34, 80], ["macromolecular studies", "TEST", 102, 124], ["(ISMAC)DNAs", "TREATMENT", 125, 136], ["charged polyelectrolytes attraction", "TREATMENT", 145, 180], ["two parallel rigid likecharged polyelectrolytes (PEs)", "TREATMENT", 231, 284], ["L. Arcesi", "OBSERVATION", 23, 32], ["electrostatic", "OBSERVATION_MODIFIER", 197, 210], ["free energy", "OBSERVATION", 211, 222]]], ["1 For high linear charge density, z , the fe shows a minimum due to the increasing of the counterion condensation and condensation volume as the two PEs approach.", [["high linear charge density", "PROBLEM", 6, 32], ["the counterion condensation", "PROBLEM", 86, 113], ["condensation volume", "PROBLEM", 118, 137], ["the two PEs approach", "TREATMENT", 141, 161], ["linear", "OBSERVATION_MODIFIER", 11, 17], ["charge density", "OBSERVATION", 18, 32], ["increasing", "OBSERVATION_MODIFIER", 72, 82], ["counterion condensation", "OBSERVATION", 90, 113], ["condensation volume", "OBSERVATION", 118, 137]]], ["For highly charged PEs (z > z c , like DNA), the PEs attract the stronger the smaller is the counterion valence, because the fe is dominated by the entropic term due to condensation of counterions in a volume displaying a maximum at short distances.", [["DNA", "CELLULAR_COMPONENT", 39, 42], ["highly charged PEs (z > z c , like DNA", "PROBLEM", 4, 42], ["condensation of counterions", "PROBLEM", 169, 196], ["a volume", "TEST", 200, 208], ["maximum", "OBSERVATION_MODIFIER", 222, 229]]], ["For weakly charged PEs (z < z c /2 ) the PEs remain undercritical in the whole separation range and therefore repel.", [["PEs", "SIMPLE_CHEMICAL", 41, 44], ["weakly charged PEs", "PROBLEM", 4, 22], ["the PEs", "PROBLEM", 37, 44]]], ["For moderately charged PEs (z c /2 < z < z c ), the infinitely separated PEs are undercritical but become supercritical as they approach a critical distance and charge condensation and condensation volume expansion start: in these circumstances the PEs may attract if the counterion valence is sufficiently large.", [["PEs", "SIMPLE_CHEMICAL", 73, 76], ["moderately charged PEs", "PROBLEM", 4, 26], ["the infinitely separated PEs", "PROBLEM", 48, 76], ["charge condensation", "PROBLEM", 161, 180], ["condensation volume expansion", "TREATMENT", 185, 214], ["condensation", "OBSERVATION", 185, 197], ["volume expansion", "OBSERVATION", 198, 214], ["PEs", "OBSERVATION", 249, 252], ["large", "OBSERVATION_MODIFIER", 307, 312]]], ["In the case of many DNA rods, hexagonal clusters may be formed.", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["many DNA rods", "PROBLEM", 15, 28], ["DNA rods", "OBSERVATION", 20, 28], ["hexagonal clusters", "OBSERVATION", 30, 48], ["may be", "UNCERTAINTY", 49, 55]]], ["Upon interaction with hydrophobic surfaces, proteins show a tendency to expose regions that are normally buried in the hydrophobic core.", [["a tendency to expose regions", "PROBLEM", 58, 86], ["normally", "OBSERVATION_MODIFIER", 96, 104], ["buried", "OBSERVATION_MODIFIER", 105, 111], ["hydrophobic core", "OBSERVATION_MODIFIER", 119, 135]]], ["Unfolding is generally perceived as an undesired process in studies aimed to anchor functional proteins at surfaces.", [["an undesired process", "PROBLEM", 36, 56]]], ["Upon an upset of perspective the fine control of the unfolding/re-assembly process could be regarded as a strategy to build up molecular nanostructures for the development of organic-inorganic assemblies.", [["the unfolding", "PROBLEM", 49, 62], ["organic-inorganic assemblies", "PROBLEM", 175, 203], ["inorganic assemblies", "OBSERVATION", 183, 203]]], ["We show that molecular layers patterned at the nanoscale, with longrange order properties extending over the microscopic scale, can be obtained upon adsorption of proteins onto the hydrophobic and ordered surface of pyrolytic graphite.", [["surface", "ANATOMY", 205, 212], ["pyrolytic graphite", "CHEMICAL", 216, 234], ["graphite", "CHEMICAL", 226, 234], ["surface", "CELLULAR_COMPONENT", 205, 212], ["molecular layers", "PROBLEM", 13, 29], ["the microscopic scale", "TEST", 105, 126], ["ordered surface of pyrolytic graphite", "TREATMENT", 197, 234], ["molecular", "OBSERVATION_MODIFIER", 13, 22], ["layers", "OBSERVATION_MODIFIER", 23, 29], ["patterned", "OBSERVATION_MODIFIER", 30, 39], ["pyrolytic graphite", "OBSERVATION", 216, 234]]], ["Upon adsorption, proteins lose their native folding and polypeptide chains re-assemble on the surface in a layered fashion, forming a molecular bilayer.", [["surface", "ANATOMY", 94, 101], ["surface", "CELLULAR_COMPONENT", 94, 101], ["polypeptide chains", "PROTEIN", 56, 74], ["polypeptide chains", "TREATMENT", 56, 74], ["native folding", "OBSERVATION", 37, 51], ["polypeptide chains", "OBSERVATION", 56, 74], ["molecular bilayer", "OBSERVATION", 134, 151]]], ["The first layer, in contact with the substrate, and the second molecular layer show corduroy-like nanopatterns of different periodicity, with a relative orientation between the first and second layer patterns of 30 \u2022 .", [["layer", "OBSERVATION_MODIFIER", 10, 15], ["corduroy", "OBSERVATION", 84, 92], ["nanopatterns", "OBSERVATION_MODIFIER", 98, 110], ["different", "OBSERVATION_MODIFIER", 114, 123], ["periodicity", "OBSERVATION_MODIFIER", 124, 135], ["orientation", "OBSERVATION_MODIFIER", 153, 164], ["second layer", "ANATOMY_MODIFIER", 187, 199]]], ["Surface-induced protein unfolding and polypeptide chain reassembly according to a layered ordered structure is a rather general phenomenon since it is observed for different proteins irrespectively of their specific structural properties.", [["Surface", "TEST", 0, 7], ["protein unfolding", "PROBLEM", 16, 33], ["polypeptide chain", "PROBLEM", 38, 55], ["a layered ordered structure", "PROBLEM", 80, 107], ["a rather general phenomenon", "PROBLEM", 111, 138], ["protein unfolding", "OBSERVATION", 16, 33], ["polypeptide chain", "OBSERVATION", 38, 55]]], ["The possibility of using these ordered molecular structures as templates for the subsequent patterned deposition of supramolecular aggregates will be discussed.", [["the subsequent patterned deposition of supramolecular aggregates", "PROBLEM", 77, 141], ["supramolecular aggregates", "OBSERVATION", 116, 141]]], ["Understanding protein-protein interactions and assemblies to control the hierarchical building of well-ordered supramolecular structures is highly relevant to new tailormade biomaterials.", [["protein-protein interactions", "TREATMENT", 14, 42], ["new tailormade biomaterials", "TREATMENT", 159, 186]]], ["We previously evidenced that contrary to native calcium-loaded \u03b1-lactalbumin (holo \u03b1-LA), calcium-depleted form (apo \u03b1-LA) has the ability to selfassemble with lysozyme (LYS) to form different supramolecular structures in temperature-dependent manner.Lactalbumin -Lysozyme interaction as evidenced by fluorescence measurementsIn the present work, the events occurring at molecular scale were explored using fluorescence techniques.", [["calcium", "CHEMICAL", 48, 55], ["\u03b1-lactalbumin", "CHEMICAL", 63, 76], ["holo \u03b1-LA", "CHEMICAL", 78, 87], ["calcium", "CHEMICAL", 90, 97], ["apo \u03b1-LA", "CHEMICAL", 113, 121], ["Lactalbumin", "CHEMICAL", 251, 262], ["calcium", "CHEMICAL", 48, 55], ["\u03b1-lactalbumin", "CHEMICAL", 63, 76], ["holo \u03b1-LA", "CHEMICAL", 78, 87], ["calcium", "CHEMICAL", 90, 97], ["Lactalbumin", "CHEMICAL", 251, 262], ["calcium", "SIMPLE_CHEMICAL", 48, 55], ["\u03b1-lactalbumin", "SIMPLE_CHEMICAL", 63, 76], ["holo \u03b1-LA", "SIMPLE_CHEMICAL", 78, 87], ["calcium", "SIMPLE_CHEMICAL", 90, 97], ["apo \u03b1-LA", "SIMPLE_CHEMICAL", 113, 121], ["lysozyme", "GENE_OR_GENE_PRODUCT", 160, 168], ["LYS", "SIMPLE_CHEMICAL", 170, 173], ["Lactalbumin", "SIMPLE_CHEMICAL", 251, 262], ["Lysozyme", "GENE_OR_GENE_PRODUCT", 264, 272], ["calcium-depleted form", "PROTEIN", 90, 111], ["apo \u03b1-LA", "PROTEIN", 113, 121], ["lysozyme", "PROTEIN", 160, 168], ["LYS", "PROTEIN", 170, 173], ["Lysozyme", "PROTEIN", 264, 272], ["calcium", "TEST", 48, 55], ["\u03b1-lactalbumin", "TEST", 63, 76], ["calcium", "TEST", 90, 97], ["lysozyme (LYS", "TREATMENT", 160, 173], ["Lactalbumin", "TEST", 251, 262], ["fluorescence measurements", "TEST", 301, 326], ["fluorescence techniques", "TEST", 407, 430]]], ["Fluorescence anisotropy and fluorescence lifetime measurements provide a powerful and sensitive mean to measure intermolecular interactions.", [["Fluorescence anisotropy", "TEST", 0, 23], ["fluorescence lifetime measurements", "TEST", 28, 62]]], ["We showed that LYS interacts with both apo \u03b1-LA and holo \u03b1-LA to form oligomers, assumed to be heterodimers, at 10 \u2022 C and 45 \u2022 C. The dissociation constants for dimerization, found to be in the \u00b5M range, were sensitive to the ionic strength.", [["LYS", "CHEMICAL", 15, 18], ["LA", "CHEMICAL", 45, 47], ["LA", "CHEMICAL", 59, 61], ["holo \u03b1-LA", "CHEMICAL", 52, 61], ["LYS", "GENE_OR_GENE_PRODUCT", 15, 18], ["apo \u03b1-LA", "SIMPLE_CHEMICAL", 39, 47], ["holo \u03b1-LA", "SIMPLE_CHEMICAL", 52, 61], ["LYS", "PROTEIN", 15, 18], ["apo \u03b1-LA", "PROTEIN", 39, 47], ["holo \u03b1-LA", "PROTEIN", 52, 61], ["heterodimers", "PROTEIN", 95, 107], ["heterodimers", "TEST", 95, 107], ["The dissociation constants", "PROBLEM", 131, 157], ["dimerization", "PROBLEM", 162, 174]]], ["Correlation time calculations suggest that formed heterodimers holo \u03b1-LA/LYS and apo \u03b1\u2212LA/LYS differed in their shape and/or conformation.", [["LA", "CHEMICAL", 70, 72], ["holo \u03b1-LA", "GENE_OR_GENE_PRODUCT", 63, 72], ["LYS", "GENE_OR_GENE_PRODUCT", 73, 76], ["apo \u03b1\u2212LA", "GENE_OR_GENE_PRODUCT", 81, 89], ["LYS", "GENE_OR_GENE_PRODUCT", 90, 93], ["heterodimers", "PROTEIN", 50, 62], ["LA", "PROTEIN", 70, 72], ["LYS", "PROTEIN", 73, 76], ["apo \u03b1\u2212LA", "PROTEIN", 81, 89], ["LYS", "PROTEIN", 90, 93], ["Correlation time calculations", "TEST", 0, 29], ["apo \u03b1\u2212LA/LYS", "TREATMENT", 81, 93]]], ["Such conformation differences could explain why holo \u03b1-LA/LYS complexes are trapped as heterodimers while the apo \u03b1-LA/LYS complexes have the ability to further self-assemble into previously reported various supramolecular structures.P-378Polyglutamine aggregation and neurodegeneration G. Nicastro, L. Masino, A. Pastore National Institute for Medical Research, The Ridgeway, NW71AA London, U.K.P-378Polyglutamine (polyQ) diseases are rare but dominant misfolding diseases linked to neurodegeneration.", [["LA", "CHEMICAL", 55, 57], ["LA", "CHEMICAL", 116, 118], ["P-378Polyglutamine", "CHEMICAL", 234, 252], ["neurodegeneration", "DISEASE", 269, 286], ["U.K.P-378Polyglutamine", "CHEMICAL", 392, 414], ["polyQ) diseases", "DISEASE", 416, 431], ["misfolding diseases", "DISEASE", 454, 473], ["neurodegeneration", "DISEASE", 484, 501], ["P-378Polyglutamine", "CHEMICAL", 234, 252], ["holo \u03b1-LA", "SIMPLE_CHEMICAL", 48, 57], ["LYS", "GENE_OR_GENE_PRODUCT", 58, 61], ["apo \u03b1-LA", "SIMPLE_CHEMICAL", 110, 118], ["U.K.P-378Polyglutamine", "GENE_OR_GENE_PRODUCT", 392, 414], ["holo \u03b1-LA/LYS complexes", "PROTEIN", 48, 71], ["heterodimers", "PROTEIN", 87, 99], ["apo \u03b1-LA/LYS complexes", "PROTEIN", 110, 132], ["holo \u03b1-LA/LYS complexes", "PROBLEM", 48, 71], ["the apo \u03b1-LA/LYS complexes", "PROBLEM", 106, 132], ["neurodegeneration", "PROBLEM", 269, 286], ["U.K.P", "TEST", 392, 397], ["polyQ) diseases", "PROBLEM", 416, 431], ["dominant misfolding diseases", "PROBLEM", 445, 473], ["neurodegeneration", "PROBLEM", 484, 501], ["dominant", "OBSERVATION_MODIFIER", 445, 453], ["misfolding diseases", "OBSERVATION", 454, 473], ["neurodegeneration", "OBSERVATION", 484, 501]]], ["They are caused by the expansion of CAG codon repeats, which encode polyQ tracts in the corresponding gene products.", [["CAG codon repeats", "DNA", 36, 53], ["CAG codon repeats", "TREATMENT", 36, 53], ["encode polyQ tracts", "PROBLEM", 61, 80], ["polyQ tracts", "OBSERVATION", 68, 80]]], ["Aggregation of polyQ proteins is thought to be triggered by polyQ expansion but be strongly modulated by the protein context.", [["polyQ", "GENE_OR_GENE_PRODUCT", 15, 20], ["polyQ proteins", "PROTEIN", 15, 29], ["Aggregation of polyQ proteins", "PROBLEM", 0, 29], ["polyQ expansion", "PROBLEM", 60, 75], ["polyQ proteins", "OBSERVATION", 15, 29], ["thought to be", "UNCERTAINTY", 33, 46], ["polyQ expansion", "OBSERVATION", 60, 75]]], ["In the attempt of understanding the molecular bases of polyQ diseases, we are studying the structures, interactomes and aggregation properties of selected polyQ proteins.", [["polyQ diseases", "DISEASE", 55, 69], ["polyQ", "GENE_OR_GENE_PRODUCT", 155, 160], ["polyQ proteins", "PROTEIN", 155, 169], ["polyQ diseases", "PROBLEM", 55, 69], ["selected polyQ proteins", "PROBLEM", 146, 169], ["bases", "ANATOMY_MODIFIER", 46, 51], ["polyQ diseases", "OBSERVATION", 55, 69], ["polyQ proteins", "OBSERVATION", 155, 169]]], ["Here, we present recent work on ataxin-3, taken as a representative example of the whole family.", [["ataxin-3", "GENE_OR_GENE_PRODUCT", 32, 40], ["ataxin-3", "PROTEIN", 32, 40]]], ["Ataxin-3 is a ubiquitin specific cysteine protease, involved in the ubiquitinproteasome pathway and known to bind poly-ubiquitin chains of four or more subunits.", [["cysteine", "CHEMICAL", 33, 41], ["Ataxin-3", "GENE_OR_GENE_PRODUCT", 0, 8], ["cysteine", "AMINO_ACID", 33, 41], ["Ataxin-3", "PROTEIN", 0, 8], ["ubiquitin specific cysteine protease", "PROTEIN", 14, 50], ["poly-ubiquitin chains", "PROTEIN", 114, 135], ["Ataxin", "TREATMENT", 0, 6], ["a ubiquitin specific cysteine protease", "TREATMENT", 12, 50], ["the ubiquitinproteasome pathway", "TREATMENT", 64, 95], ["bind poly-ubiquitin chains", "TREATMENT", 109, 135]]], ["The enzymatic site resides in the N-terminal josephin domain of ataxin-3.", [["N", "CHEMICAL", 34, 35], ["ataxin-3", "GENE_OR_GENE_PRODUCT", 64, 72], ["enzymatic site", "DNA", 4, 18], ["N-terminal josephin domain", "PROTEIN", 34, 60], ["ataxin-3", "PROTEIN", 64, 72], ["The enzymatic site", "PROBLEM", 0, 18], ["the N-terminal josephin domain of ataxin", "TREATMENT", 30, 70], ["enzymatic", "OBSERVATION_MODIFIER", 4, 13], ["site", "OBSERVATION_MODIFIER", 14, 18]]], ["We have characterized, using different biophysical techniques, the structure in solution and the aggregation properties of josephin both in isolation and in a ubiquitin complex.", [["josephin", "CHEMICAL", 123, 131], ["josephin", "CHEMICAL", 123, 131], ["josephin", "SIMPLE_CHEMICAL", 123, 131], ["josephin", "PROTEIN", 123, 131], ["ubiquitin complex", "PROTEIN", 159, 176], ["different biophysical techniques", "TREATMENT", 29, 61], ["josephin", "TREATMENT", 123, 131], ["a ubiquitin complex", "TREATMENT", 157, 176], ["ubiquitin complex", "OBSERVATION", 159, 176]]], ["We demonstrate that interaction with ubiquitin strongly modulates the aggregation properties of ataxin-3 and suggest the importance of protein-protein interactions in preventing aggregation.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 37, 46], ["ataxin-3", "GENE_OR_GENE_PRODUCT", 96, 104], ["ubiquitin", "PROTEIN", 37, 46], ["ataxin-3", "PROTEIN", 96, 104], ["ataxin", "TREATMENT", 96, 102], ["protein-protein interactions", "TREATMENT", 135, 163], ["aggregation", "PROBLEM", 178, 189]]], ["Our study also provides new insights into the molecular mechanisms which determine ataxin-3 specificity for poly-ubiquitin chains of the correct length and cross-linking.", [["ataxin-3", "GENE_OR_GENE_PRODUCT", 83, 91], ["ataxin", "PROTEIN", 83, 89], ["poly-ubiquitin chains", "PROTEIN", 108, 129], ["Our study", "TEST", 0, 9], ["ataxin", "TEST", 83, 89], ["poly-ubiquitin chains", "TREATMENT", 108, 129], ["correct length", "OBSERVATION_MODIFIER", 137, 151]]], ["F\u00f6rster Resonant Energy Transfer (FRET) from an optically excited to a non-excited molecule has been widely used to probe molecular interactions in living cells.", [["cells", "ANATOMY", 155, 160], ["cells", "CELL", 155, 160], ["living cells", "CELL_TYPE", 148, 160], ["a non-excited molecule", "TREATMENT", 69, 91]]], ["Changes in the molecular makeup of a cellular region occurring during the acquisition of fluorescence images place tight constraints on the FRET technology and data analysis, which could not be addressed satisfactorily until recently.", [["cellular", "ANATOMY", 37, 45], ["cellular", "CELL", 37, 45], ["a cellular region", "PROBLEM", 35, 52], ["fluorescence images", "TEST", 89, 108], ["the FRET technology", "TEST", 136, 155], ["data analysis", "TEST", 160, 173], ["cellular region", "OBSERVATION", 37, 52]]], ["We will describe a method for imaging protein complex distributions in living cells with sub-cellular spatial resolution, which relies on a spectrally resolved two-photon microscope (Raicu et al, 2009, Nature Photon.", [["cells", "ANATOMY", 78, 83], ["cellular", "ANATOMY", 93, 101], ["cells", "CELL", 78, 83], ["cellular", "CELL", 93, 101], ["protein complex", "PROTEIN", 38, 53], ["living cells", "CELL_TYPE", 71, 83], ["a method", "TEST", 17, 25], ["imaging protein complex distributions in living cells", "PROBLEM", 30, 83], ["cellular spatial resolution", "OBSERVATION", 93, 120]]], ["3: 107-113) and a simple theory of FRET in oligomeric complexes (V. Raicu, 2007, J. Biol.", [["FRET", "SIMPLE_CHEMICAL", 35, 39], ["oligomeric complexes", "PROTEIN", 43, 63]]], ["Then, we will overview recent results on the determination of the supra-molecular structure and distributions in living cells of oligomeric complexes of some G protein-coupled receptors.O-384Observing protein aggregates on surfaces M. Rabe, D. Verdes, S. Seeger Institute of Physical Chemistry, University of Zurich, Switzerland Protein aggregation is an important topic of current protein research as it is associated with several human diseases including Alzheimer's disease, Parkinson's disease, and Type II diabetes.", [["cells", "ANATOMY", 120, 125], ["Protein aggregation", "DISEASE", 329, 348], ["Alzheimer's disease", "DISEASE", 457, 476], ["Parkinson's disease", "DISEASE", 478, 497], ["Type II diabetes", "DISEASE", 503, 519], ["cells", "CELL", 120, 125], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 158, 185], ["human", "ORGANISM", 432, 437], ["oligomeric complexes", "PROTEIN", 129, 149], ["G protein-coupled receptors", "PROTEIN", 158, 185], ["human", "SPECIES", 432, 437], ["human", "SPECIES", 432, 437], ["oligomeric complexes", "PROBLEM", 129, 149], ["Switzerland Protein aggregation", "TREATMENT", 317, 348], ["current protein research", "TREATMENT", 374, 398], ["several human diseases", "PROBLEM", 424, 446], ["Alzheimer's disease", "PROBLEM", 457, 476], ["Parkinson's disease", "PROBLEM", 478, 497], ["Type II diabetes", "PROBLEM", 503, 519], ["supra-molecular structure", "OBSERVATION", 66, 91], ["living cells", "OBSERVATION", 113, 125], ["Type II", "OBSERVATION_MODIFIER", 503, 510], ["diabetes", "OBSERVATION", 511, 519]]], ["Although protein aggregation mechanisms and conditions have been comprehensively investigated, studies on the formation and the fate of protein aggregates in contact with solid interfaces are scarce.", [["protein aggregation mechanisms", "PROBLEM", 9, 39], ["aggregation mechanisms", "OBSERVATION", 17, 39], ["solid interfaces", "OBSERVATION", 171, 187]]], ["We have comprehensively investigated the structure of protein assemblies that form spontaneously upon protein adsorption on solid interfaces using a surface sensitive fluorescence imaging technique based on super critical angle fluorescence (SAF) detection.", [["surface", "ANATOMY", 149, 156], ["fluorescence imaging technique", "TEST", 167, 197]]], ["Combining this technique with FRET we not only succeeded to detect protein aggregates deposited on surfaces but also to characterize their behavior in real time, i.e., their emergence, growth, or spreading.", [["protein aggregates", "PROBLEM", 67, 85]]], ["The model protein BSA, for instance, was found to exhibit a certain tendency for aggregation in the buffer solution.", [["aggregation", "DISEASE", 81, 92], ["BSA", "SIMPLE_CHEMICAL", 18, 21], ["The model protein BSA", "TEST", 0, 21], ["the buffer solution", "TREATMENT", 96, 115], ["protein BSA", "OBSERVATION", 10, 21]]], ["These protein clusters can deposit onto solid surfaces and spread resulting in a large, flat structure after some time.", [["These protein clusters", "PROBLEM", 0, 22], ["a large, flat structure", "PROBLEM", 79, 102], ["solid surfaces", "OBSERVATION_MODIFIER", 40, 54], ["spread", "OBSERVATION_MODIFIER", 59, 65], ["large", "OBSERVATION_MODIFIER", 81, 86], ["flat structure", "OBSERVATION_MODIFIER", 88, 102]]], ["1 A different possibility how protein aggregates emerge on surfaces consists of a direct deposition of protein monomers to pre existing aggregates.", [["protein monomers", "PROTEIN", 103, 119], ["a direct deposition of protein monomers", "TREATMENT", 80, 119], ["protein aggregates", "OBSERVATION", 30, 48]]], ["Such a growth of protein aggregates on the surface has been observed in a model system using the protein \u03b1-synuclein, which is tightly associated with the Parkinson's syndrome.", [["surface", "ANATOMY", 43, 50], ["Parkinson's syndrome", "DISEASE", 155, 175], ["surface", "CELLULAR_COMPONENT", 43, 50], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 105, 116], ["protein \u03b1-synuclein", "PROTEIN", 97, 116], ["a growth of protein aggregates", "PROBLEM", 5, 35], ["the protein \u03b1-synuclein", "TREATMENT", 93, 116], ["the Parkinson's syndrome", "PROBLEM", 151, 175], ["growth", "OBSERVATION_MODIFIER", 7, 13], ["protein aggregates", "OBSERVATION", 17, 35], ["Parkinson's syndrome", "OBSERVATION", 155, 175]]], ["We present the results of a Spectroscopic Ellipsometry (SE) study of the adsorption process of Yeast Cytochrome c (YCC) on gold and graphite substrates, according to methods already applied to study the growth dynamics of organosulphur SAMS on gold [1] .", [["organosulphur SAMS", "CHEMICAL", 222, 240], ["graphite", "CHEMICAL", 132, 140], ["organosulphur", "CHEMICAL", 222, 235], ["Cytochrome c", "GENE_OR_GENE_PRODUCT", 101, 113], ["YCC", "SIMPLE_CHEMICAL", 115, 118], ["gold", "SIMPLE_CHEMICAL", 123, 127], ["organosulphur SAMS", "SIMPLE_CHEMICAL", 222, 240], ["gold [1]", "SIMPLE_CHEMICAL", 244, 252], ["Yeast Cytochrome c", "PROTEIN", 95, 113], ["YCC", "PROTEIN", 115, 118], ["Yeast", "SPECIES", 95, 100], ["a Spectroscopic Ellipsometry (SE) study", "TEST", 26, 65], ["Yeast Cytochrome c (YCC)", "PROBLEM", 95, 119], ["gold and graphite substrates", "TREATMENT", 123, 151], ["Yeast Cytochrome", "OBSERVATION", 95, 111]]], ["SE investigation was carried out both in situ, at room temperature during protein deposition, and ex situ.", [["SE", "DISEASE", 0, 2], ["SE investigation", "TEST", 0, 16], ["protein deposition", "TREATMENT", 74, 92], ["protein deposition", "OBSERVATION", 74, 92]]], ["On gold, SE data demonstrate the formation of an about 3-4 nm thick layer, consistent with the formation of a dense monolayer of YCC molecules, confirmed by AFM inspection.", [["YCC", "CHEMICAL", 129, 132], ["YCC molecules", "SIMPLE_CHEMICAL", 129, 142], ["YCC molecules", "PROTEIN", 129, 142], ["SE data", "TEST", 9, 16], ["4 nm thick layer", "PROBLEM", 57, 73], ["a dense monolayer of YCC molecules", "PROBLEM", 108, 142], ["AFM inspection", "TEST", 157, 171], ["about 3-4 nm", "OBSERVATION_MODIFIER", 49, 61], ["layer", "OBSERVATION_MODIFIER", 68, 73], ["consistent with", "UNCERTAINTY", 75, 90], ["dense", "OBSERVATION_MODIFIER", 110, 115], ["monolayer", "OBSERVATION_MODIFIER", 116, 125], ["YCC molecules", "OBSERVATION", 129, 142]]], ["Both in situ and ex situ measurements were characterized by well defined spectral features related to the Soret band.", [["ex situ measurements", "TEST", 17, 37], ["the Soret band", "PROBLEM", 102, 116], ["situ", "OBSERVATION_MODIFIER", 8, 12], ["ex", "OBSERVATION_MODIFIER", 17, 19], ["situ", "OBSERVATION_MODIFIER", 20, 24], ["Soret band", "OBSERVATION", 106, 116]]], ["Analysis of the fine position of this feature allowed to obtain information on the oxidation state of the iron ion of the heme group.", [["iron", "CHEMICAL", 106, 110], ["iron", "CHEMICAL", 106, 110], ["heme", "CHEMICAL", 122, 126], ["iron", "SIMPLE_CHEMICAL", 106, 110], ["heme", "SIMPLE_CHEMICAL", 122, 126]]], ["SE data suggest that proteins have preserved their native structure.", [["SE", "DISEASE", 0, 2], ["SE data", "TEST", 0, 7], ["native structure", "OBSERVATION", 51, 67]]], ["A completely different adsorption mechanism was observed on highly oriented pyrolytic graphite (HOPG) [2] .", [["HOPG", "CHEMICAL", 96, 100], ["graphite", "CHEMICAL", 86, 94], ["HOPG", "CHEMICAL", 96, 100], ["pyrolytic graphite", "SIMPLE_CHEMICAL", 76, 94], ["HOPG", "SIMPLE_CHEMICAL", 96, 100], ["A completely different adsorption mechanism", "PROBLEM", 0, 43], ["different", "OBSERVATION_MODIFIER", 13, 22], ["adsorption mechanism", "OBSERVATION", 23, 43]]], ["Ex-situ SE data on YCC/HOPG, supported by AFM observations, indicate the formation of an ultrathin molecular layer (\u223c0.7nm) related to complete protein unfolding at the hydrophobic surface.", [["YCC", "SIMPLE_CHEMICAL", 19, 22], ["HOPG", "SIMPLE_CHEMICAL", 23, 27], ["surface", "CELLULAR_COMPONENT", 181, 188], ["YCC/HOPG", "PROBLEM", 19, 27], ["an ultrathin molecular layer", "PROBLEM", 86, 114], ["complete protein unfolding", "PROBLEM", 135, 161], ["protein unfolding", "OBSERVATION", 144, 161], ["hydrophobic surface", "OBSERVATION", 169, 188]]], ["The role of phospholipid anisotropy in the stability of inverted hexagonal phase was considered.", [["phospholipid", "SIMPLE_CHEMICAL", 12, 24], ["phospholipid anisotropy", "TREATMENT", 12, 35], ["phospholipid anisotropy", "OBSERVATION", 12, 35], ["hexagonal phase", "OBSERVATION", 65, 80]]], ["The equilibrium configuration of the system was determined by the minimum of the free energy involving the contribution of the isotropic and deviatoric bending and the interstitial energy of phospholipid monolayers.", [["interstitial", "ANATOMY", 168, 180], ["phospholipid monolayers", "ANATOMY", 191, 214], ["phospholipid monolayers", "CELL", 191, 214], ["the isotropic and deviatoric bending", "PROBLEM", 123, 159], ["the interstitial energy of phospholipid monolayers", "PROBLEM", 164, 214], ["equilibrium configuration", "OBSERVATION", 4, 29], ["free energy", "OBSERVATION", 81, 92], ["deviatoric bending", "OBSERVATION", 141, 159], ["interstitial", "ANATOMY_MODIFIER", 168, 180], ["phospholipid monolayers", "OBSERVATION", 191, 214]]], ["The shape and local interactions of a single lipid molecule were taken into account.", [["a single lipid molecule", "TREATMENT", 36, 59], ["shape", "OBSERVATION_MODIFIER", 4, 9], ["local", "OBSERVATION_MODIFIER", 14, 19]]], ["The minimization with respect to the configuration of the lipid layers was performed by the Monte Carlo simulated annealing method.", [["lipid layers", "ANATOMY", 58, 70], ["lipid layers", "TISSUE", 58, 70], ["the lipid layers", "TREATMENT", 54, 70]]], ["At high enough temperature the lipid molecules attain a shape exhibiting higher intrinsic mean and deviatoric curvatures which fits better into the inverted hexagonal phase than into the lamellar phase.", [["higher intrinsic mean and deviatoric curvatures", "PROBLEM", 73, 120], ["shape", "OBSERVATION_MODIFIER", 56, 61], ["higher", "OBSERVATION_MODIFIER", 73, 79], ["intrinsic mean", "OBSERVATION", 80, 94], ["deviatoric curvatures", "OBSERVATION", 99, 120], ["hexagonal phase", "OBSERVATION_MODIFIER", 157, 172], ["lamellar phase", "OBSERVATION", 187, 201]]], ["For the mathematical model the advanced geometry with non-spherical cross-section of inverted hexagonal phase was calculated, resulting in lower energy in non-spherical cross-section.", [["lower energy in non-spherical cross-section", "PROBLEM", 139, 182], ["hexagonal phase", "OBSERVATION", 94, 109], ["lower energy", "OBSERVATION", 139, 151], ["non-spherical cross-section", "OBSERVATION", 155, 182]]], ["Theoretical results are in a good agreement with the small angle X-ray scattering experimental data.", [["small", "OBSERVATION_MODIFIER", 53, 58]]], ["For a long while the conventional view has been that Alzheimer Disease is brought about by the beta-amyloid fibrils found in the senile plaques, but more recently it has been suggested that the main neurotoxic species would be the soluble oligomeric species, apparently prone to interact with cell structures and macromolecules potentially inducing neuronal dysfunction.", [["plaques", "ANATOMY", 136, 143], ["cell structures", "ANATOMY", 293, 308], ["neuronal", "ANATOMY", 349, 357], ["Alzheimer Disease", "DISEASE", 53, 70], ["senile plaques", "DISEASE", 129, 143], ["neurotoxic", "DISEASE", 199, 209], ["neuronal dysfunction", "DISEASE", 349, 369], ["beta-amyloid fibrils", "GENE_OR_GENE_PRODUCT", 95, 115], ["senile plaques", "PATHOLOGICAL_FORMATION", 129, 143], ["cell structures", "CELLULAR_COMPONENT", 293, 308], ["neuronal", "CELL", 349, 357], ["beta-amyloid fibrils", "PROTEIN", 95, 115], ["Alzheimer Disease", "PROBLEM", 53, 70], ["the beta-amyloid fibrils", "PROBLEM", 91, 115], ["the senile plaques", "PROBLEM", 125, 143], ["the main neurotoxic species", "PROBLEM", 190, 217], ["the soluble oligomeric species", "PROBLEM", 227, 257], ["neuronal dysfunction", "PROBLEM", 349, 369], ["Alzheimer Disease", "OBSERVATION", 53, 70], ["senile", "OBSERVATION_MODIFIER", 129, 135], ["plaques", "OBSERVATION", 136, 143], ["neuronal dysfunction", "OBSERVATION", 349, 369]]], ["Peptide-peptide interactions resulting in self-assembly phenomena of beta-amyloid yielding fibrils can be modulated and influenced by small organic molecules that might also be effective therapeutic tools to ideally target both oligomeric and fibrillar species.", [["beta-amyloid yielding fibrils", "GENE_OR_GENE_PRODUCT", 69, 98], ["oligomeric and fibrillar species", "PROTEIN", 228, 260], ["Peptide-peptide interactions", "PROBLEM", 0, 28], ["beta-amyloid yielding fibrils", "PROBLEM", 69, 98], ["small organic molecules", "PROBLEM", 134, 157], ["both oligomeric and fibrillar species", "PROBLEM", 223, 260], ["small", "OBSERVATION_MODIFIER", 134, 139], ["organic molecules", "OBSERVATION", 140, 157], ["fibrillar species", "OBSERVATION", 243, 260]]], ["In this perspective, polycyclic aromatic molecules are of special interest because they might disrupt the molecular architectures precursors of beta-amyloid fibrils by means of weak, non-covalent aromatic interactions, like stacking interactions.", [["polycyclic aromatic molecules", "SIMPLE_CHEMICAL", 21, 50], ["beta-amyloid fibrils", "GENE_OR_GENE_PRODUCT", 144, 164], ["polycyclic aromatic molecules", "PROBLEM", 21, 50], ["beta-amyloid fibrils", "PROBLEM", 144, 164], ["weak, non-covalent aromatic interactions", "PROBLEM", 177, 217], ["polycyclic", "OBSERVATION", 21, 31], ["aromatic molecules", "OBSERVATION", 32, 50], ["beta-amyloid fibrils", "OBSERVATION", 144, 164], ["aromatic interactions", "OBSERVATION", 196, 217]]], ["We have performed an in vitro spectroscopic study (light scattering, circular dichroism, FTIR and fluorescence) of the effects on beta-amyloid fibrillogenesis of the natural pigment hypericin extracted from Hypericum perforatum.", [["hypericin", "CHEMICAL", 182, 191], ["Hypericum perforatum", "CHEMICAL", 207, 227], ["hypericin", "CHEMICAL", 182, 191], ["beta-amyloid", "GENE_OR_GENE_PRODUCT", 130, 142], ["pigment", "ORGANISM_SUBSTANCE", 174, 181], ["hypericin", "SIMPLE_CHEMICAL", 182, 191], ["Hypericum perforatum", "ORGANISM", 207, 227], ["Hypericum perforatum", "SPECIES", 207, 227], ["Hypericum perforatum", "SPECIES", 207, 227], ["an in vitro spectroscopic study", "TEST", 18, 49], ["circular dichroism", "TEST", 69, 87], ["the effects", "PROBLEM", 115, 126], ["beta-amyloid fibrillogenesis", "TREATMENT", 130, 158], ["the natural pigment hypericin", "TREATMENT", 162, 191], ["Hypericum perforatum", "PROBLEM", 207, 227], ["natural pigment hypericin", "OBSERVATION", 166, 191], ["Hypericum perforatum", "OBSERVATION", 207, 227]]], ["Our results show that, thanks to its structural characteristics and peculiar spectroscopic features, hypericin can be easily used to in vitro monitor the appearance of initial aggregation states of beta-amyloid peptides and, more importantly, that hypericin can interfere with the early stages of polymerization process, playing the role of an aggregation inhibitor.Natural pigments induce perturbation of betaamyloid peptide self assemblyPeptaibols are peculiar peptides produced by fungi associated to plants.", [["hypericin", "CHEMICAL", 101, 110], ["hypericin", "CHEMICAL", 248, 257], ["Peptaibols", "CHEMICAL", 439, 449], ["hypericin", "CHEMICAL", 101, 110], ["hypericin", "CHEMICAL", 248, 257], ["Peptaibols", "CHEMICAL", 439, 449], ["hypericin", "SIMPLE_CHEMICAL", 101, 110], ["beta-amyloid peptides", "GENE_OR_GENE_PRODUCT", 198, 219], ["hypericin", "SIMPLE_CHEMICAL", 248, 257], ["Peptaibols", "SIMPLE_CHEMICAL", 439, 449], ["hypericin", "TREATMENT", 101, 110], ["beta-amyloid peptides", "PROBLEM", 198, 219], ["hypericin", "TREATMENT", 248, 257], ["polymerization process", "PROBLEM", 297, 319], ["an aggregation inhibitor", "TREATMENT", 341, 365], ["Natural pigments", "TREATMENT", 366, 382], ["betaamyloid peptide", "TREATMENT", 406, 425], ["Peptaibols", "TREATMENT", 439, 449], ["peculiar peptides", "PROBLEM", 454, 471], ["fungi", "PROBLEM", 484, 489], ["beta-amyloid peptides", "OBSERVATION", 198, 219], ["polymerization process", "OBSERVATION", 297, 319]]], ["They are composed by 4 to 20 amminoacidic residues and exhibit antibiotic and antifungal properties.", [["20 amminoacidic residues", "TREATMENT", 26, 50], ["antibiotic and antifungal properties", "TREATMENT", 63, 99]]], ["Due to their amphypatic nature, they can form ion channels in biological membranes.", [["membranes", "ANATOMY", 73, 82], ["biological membranes", "CELLULAR_COMPONENT", 62, 82], ["biological membranes", "OBSERVATION", 62, 82]]], ["By making use of experimental models of biological membranes (biomimetic membranes) currently employed in the Laboratory of Bioelectrochemistry, and models of plant membranes (corn seed root), that are used in the International Laboratory of Plant Neurobiology (LINV), we characterized synthetic peptides such as Trichogin GAIV and its shorter homologues (4 and 8 residues).", [["membranes", "ANATOMY", 51, 60], ["membranes", "ANATOMY", 73, 82], ["membranes", "ANATOMY", 165, 174], ["seed root", "ANATOMY", 181, 190], ["Trichogin", "CHEMICAL", 313, 322], ["membranes", "CELLULAR_COMPONENT", 51, 60], ["membranes", "CELLULAR_COMPONENT", 73, 82], ["plant membranes", "CELLULAR_COMPONENT", 159, 174], ["corn seed root", "MULTI-TISSUE_STRUCTURE", 176, 190], ["Trichogin GAIV", "GENE_OR_GENE_PRODUCT", 313, 327], ["Trichogin GAIV", "PROTEIN", 313, 327], ["corn", "SPECIES", 176, 180], ["corn", "SPECIES", 176, 180], ["biological membranes (biomimetic membranes", "TREATMENT", 40, 82], ["plant membranes", "PROBLEM", 159, 174], ["Trichogin GAIV", "TREATMENT", 313, 327], ["plant membranes", "OBSERVATION", 159, 174]]], ["We studied these peptaibols in a dioleoylphosphatidylcholine monolayer supported by Hg using different electrochemical techniques (AC,VC,EIS).", [["peptaibols", "CHEMICAL", 17, 27], ["dioleoylphosphatidylcholine", "CHEMICAL", 33, 60], ["Hg", "CHEMICAL", 84, 86], ["peptaibols", "CHEMICAL", 17, 27], ["dioleoylphosphatidylcholine", "CHEMICAL", 33, 60], ["Hg", "CHEMICAL", 84, 86], ["peptaibols", "SIMPLE_CHEMICAL", 17, 27], ["dioleoylphosphatidylcholine monolayer", "CELL", 33, 70], ["dioleoylphosphatidylcholine monolayer", "CELL_LINE", 33, 70], ["a dioleoylphosphatidylcholine monolayer", "TREATMENT", 31, 70], ["different electrochemical techniques", "TREATMENT", 93, 129]]], ["The experimental technique employed in the LINV (Clark microelectrode coupled to MIFE system) allows to measure oxygen flux in the solution contacting plant cell membranes, after treatment with different peptide concentrations.", [["cell membranes", "ANATOMY", 157, 171], ["oxygen", "CHEMICAL", 112, 118], ["oxygen", "CHEMICAL", 112, 118], ["oxygen", "SIMPLE_CHEMICAL", 112, 118], ["cell membranes", "CELLULAR_COMPONENT", 157, 171], ["The experimental technique", "TREATMENT", 0, 26], ["the LINV (Clark microelectrode", "TREATMENT", 39, 69], ["oxygen flux", "TREATMENT", 112, 123], ["plant cell membranes", "TREATMENT", 151, 171], ["treatment", "TREATMENT", 179, 188], ["different peptide concentrations", "TREATMENT", 194, 226], ["oxygen flux", "OBSERVATION", 112, 123], ["plant cell membranes", "OBSERVATION", 151, 171]]], ["Preliminary results might indicate that short peptides can influence the whole metabolism of the plant and can therefore be used as \"elicitors\" in order to induce an acquired systemic resistance.", [["short peptides", "PROBLEM", 40, 54], ["an acquired systemic resistance", "PROBLEM", 163, 194], ["systemic resistance", "OBSERVATION", 175, 194]]], ["Supported Biomimetic Membranes (SBM) were developed for protein-membrane interactions studies.", [["membrane", "ANATOMY", 64, 72], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["Biomimetic Membranes", "TREATMENT", 10, 30], ["protein-membrane interactions studies", "TEST", 56, 93], ["Biomimetic Membranes", "OBSERVATION", 10, 30]]], ["Phospholipid vesicles were chemically linked onto amine grafted gold or glass surfaces; after an osmotic choc and liposomes fusion a continuous membrane bilayer was formed.", [["Phospholipid vesicles", "ANATOMY", 0, 21], ["membrane bilayer", "ANATOMY", 144, 160], ["amine", "CHEMICAL", 50, 55], ["amine", "CHEMICAL", 50, 55], ["Phospholipid vesicles", "CELLULAR_COMPONENT", 0, 21], ["amine", "SIMPLE_CHEMICAL", 50, 55], ["gold", "SIMPLE_CHEMICAL", 64, 68], ["liposomes", "SIMPLE_CHEMICAL", 114, 123], ["membrane bilayer", "CELLULAR_COMPONENT", 144, 160], ["Phospholipid vesicles", "PROBLEM", 0, 21], ["an osmotic choc and liposomes fusion", "TREATMENT", 94, 130], ["a continuous membrane bilayer", "TREATMENT", 131, 160], ["glass surfaces", "OBSERVATION", 72, 86], ["osmotic choc", "OBSERVATION", 97, 109], ["liposomes fusion", "OBSERVATION", 114, 130]]], ["The anchoring phospholipid molecule (DSPE-PEG-NHS) incorporated into the vesicles allowed the formation of a water-filled compartment between the surface and the bilayer.", [["vesicles", "ANATOMY", 73, 81], ["surface", "ANATOMY", 146, 153], ["DSPE-PEG-NHS", "CHEMICAL", 37, 49], ["DSPE-PEG-NHS", "CHEMICAL", 37, 49], ["phospholipid molecule", "SIMPLE_CHEMICAL", 14, 35], ["DSPE-PEG-NHS", "SIMPLE_CHEMICAL", 37, 49], ["vesicles", "CELLULAR_COMPONENT", 73, 81], ["surface", "CELLULAR_COMPONENT", 146, 153], ["bilayer", "CELLULAR_COMPONENT", 162, 169], ["The anchoring phospholipid molecule (DSPE-PEG-NHS)", "TREATMENT", 0, 50], ["vesicles", "ANATOMY", 73, 81], ["filled compartment", "OBSERVATION", 115, 133], ["surface", "ANATOMY_MODIFIER", 146, 153], ["bilayer", "ANATOMY_MODIFIER", 162, 169]]], ["This first SBM model was used to monitor the membranes binding properties (dependent of calcium) of the adenylate cyclase toxin (CyaA) from Bordetella pertussis.", [["membranes", "ANATOMY", 45, 54], ["calcium", "CHEMICAL", 88, 95], ["Bordetella pertussis", "DISEASE", 140, 160], ["calcium", "CHEMICAL", 88, 95], ["adenylate", "CHEMICAL", 104, 113], ["membranes", "CELLULAR_COMPONENT", 45, 54], ["calcium", "SIMPLE_CHEMICAL", 88, 95], ["adenylate cyclase toxin", "GENE_OR_GENE_PRODUCT", 104, 127], ["CyaA", "GENE_OR_GENE_PRODUCT", 129, 133], ["Bordetella pertussis", "ORGANISM", 140, 160], ["adenylate cyclase toxin", "PROTEIN", 104, 127], ["CyaA", "PROTEIN", 129, 133], ["Bordetella pertussis", "SPECIES", 140, 160], ["Bordetella pertussis", "SPECIES", 140, 160], ["the membranes binding properties", "PROBLEM", 41, 73], ["calcium", "TEST", 88, 95], ["the adenylate cyclase toxin", "TEST", 100, 127], ["Bordetella pertussis", "PROBLEM", 140, 160]]], ["The SBM model was improved in order to study the translocation of the catalytic domain of CyaA across the bilayer.", [["CyaA", "GENE_OR_GENE_PRODUCT", 90, 94], ["bilayer", "CELLULAR_COMPONENT", 106, 113], ["catalytic domain", "PROTEIN", 70, 86], ["CyaA", "PROTEIN", 90, 94], ["The SBM model", "TEST", 0, 13], ["improved", "OBSERVATION_MODIFIER", 18, 26], ["CyaA", "OBSERVATION", 90, 94], ["bilayer", "ANATOMY_MODIFIER", 106, 113]]], ["Naturally, the CyaA catalytic domain, when it reaches the target cell cytosol, associates with intracellular calmodulin (CaM) an activator of the adenylate cyclase activity of CyaA.", [["cell cytosol", "ANATOMY", 65, 77], ["intracellular", "ANATOMY", 95, 108], ["adenylate", "CHEMICAL", 146, 155], ["CyaA", "GENE_OR_GENE_PRODUCT", 15, 19], ["cell cytosol", "CELLULAR_COMPONENT", 65, 77], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["calmodulin", "GENE_OR_GENE_PRODUCT", 109, 119], ["CaM", "GENE_OR_GENE_PRODUCT", 121, 124], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 146, 163], ["CyaA", "GENE_OR_GENE_PRODUCT", 176, 180], ["CyaA catalytic domain", "PROTEIN", 15, 36], ["intracellular calmodulin", "PROTEIN", 95, 119], ["CaM", "PROTEIN", 121, 124], ["adenylate cyclase", "PROTEIN", 146, 163], ["CyaA", "PROTEIN", 176, 180], ["the CyaA catalytic domain", "TEST", 11, 36], ["intracellular calmodulin (CaM", "TREATMENT", 95, 124], ["the adenylate cyclase", "TREATMENT", 142, 163], ["CyaA", "PROBLEM", 176, 180]]], ["To mimic this biological phenomenon, CaM was first immobilized on the surface (gold or glass) and in a second step membrane construction was performed over the CaM layer.", [["surface", "ANATOMY", 70, 77], ["membrane", "ANATOMY", 115, 123], ["CaM", "CHEMICAL", 37, 40], ["CaM", "GENE_OR_GENE_PRODUCT", 37, 40], ["surface", "CELLULAR_COMPONENT", 70, 77], ["gold", "SIMPLE_CHEMICAL", 79, 83], ["membrane", "CELLULAR_COMPONENT", 115, 123], ["CaM", "PROTEIN", 37, 40], ["CaM", "PROTEIN", 160, 163], ["this biological phenomenon", "PROBLEM", 9, 35], ["a second step membrane construction", "TREATMENT", 101, 136]]], ["The formation of the biomimetic membrane onto the CaM layer was monitored by SPR while membrane fluidity and continuity were analysed by fluorescence.", [["membrane", "ANATOMY", 32, 40], ["CaM layer", "ANATOMY", 50, 59], ["membrane", "ANATOMY", 87, 95], ["membrane", "CELLULAR_COMPONENT", 32, 40], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["the biomimetic membrane", "TREATMENT", 17, 40], ["biomimetic membrane", "OBSERVATION", 21, 40], ["CaM", "OBSERVATION_MODIFIER", 50, 53], ["layer", "OBSERVATION_MODIFIER", 54, 59]]], ["Our results demonstrated the potentialities of SBM for the study of protein insertion into and translocation across biological membranes.P-386A multi-resolution approach to the structure and function of integrin \u03b1IIb\u03b23 M. Rocco 1 , C. Rosano 1 , J. W. Weisel 2 , D. Horita 3 , R. R. Hantgan 3 1 Istituto Nazionale per la Ricerca sul Cancro (IST), Genova, Italy, 2 University of Pennsylvania, Philadelphia, PA, USA, 3 Wake Forest University, Winston-Salem, NC, USA.P-386Integrins are heterodimeric transmembrane receptors involved in mechanical anchoring and two-way signaling.", [["membranes", "ANATOMY", 127, 136], ["transmembrane", "ANATOMY", 497, 510], ["membranes", "CELLULAR_COMPONENT", 127, 136], ["integrin", "GENE_OR_GENE_PRODUCT", 203, 211], ["P", "DNA", 137, 138], ["integrin", "PROTEIN", 203, 211], ["P", "DNA", 464, 465], ["386Integrins", "PROTEIN", 466, 478], ["heterodimeric transmembrane receptors", "PROTEIN", 483, 520], ["SBM", "PROBLEM", 47, 50], ["the study", "TEST", 55, 64], ["protein insertion", "TREATMENT", 68, 85], ["translocation across biological membranes", "PROBLEM", 95, 136], ["multi-resolution approach", "TREATMENT", 144, 169], ["heterodimeric transmembrane receptors", "TREATMENT", 483, 520], ["mechanical anchoring", "TREATMENT", 533, 553], ["biological membranes", "OBSERVATION", 116, 136], ["Philadelphia", "OBSERVATION", 392, 404], ["NC", "ANATOMY", 456, 458], ["mechanical anchoring", "OBSERVATION", 533, 553]]], ["Each \u03b1 and \u03b2 subunit has a modular structure with a large extracellular portion, a single transmembrane region, and a cytoplasmic domain.", [["extracellular", "ANATOMY", 58, 71], ["transmembrane", "ANATOMY", 90, 103], ["cytoplasmic", "ANATOMY", 118, 129], ["\u03b1", "GENE_OR_GENE_PRODUCT", 5, 6], ["\u03b2", "GENE_OR_GENE_PRODUCT", 11, 12], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 71], ["cytoplasmic", "ORGANISM_SUBSTANCE", 118, 129], ["\u03b1 and \u03b2 subunit", "PROTEIN", 5, 20], ["extracellular portion", "PROTEIN", 58, 79], ["transmembrane region", "PROTEIN", 90, 110], ["cytoplasmic domain", "PROTEIN", 118, 136], ["a modular structure", "PROBLEM", 25, 44], ["a large extracellular portion", "PROBLEM", 50, 79], ["a single transmembrane region", "PROBLEM", 81, 110], ["a cytoplasmic domain", "PROBLEM", 116, 136], ["modular structure", "OBSERVATION", 27, 44], ["large", "OBSERVATION_MODIFIER", 52, 57], ["extracellular", "OBSERVATION_MODIFIER", 58, 71], ["portion", "OBSERVATION_MODIFIER", 72, 79], ["cytoplasmic domain", "OBSERVATION", 118, 136]]], ["Integrins activation mechanism is regulated by controversial conformational changes: while crystallography revealed similar bent shapes for resting and primed extracellular region constructs, ligand binding-induced large structural rearrangements in smaller constructs suggested extension, \"opening\" and tails separation.", [["extracellular region", "ANATOMY", 159, 179], ["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 172], ["Integrins", "PROTEIN", 0, 9], ["primed extracellular region constructs", "DNA", 152, 190], ["Integrins activation mechanism", "PROBLEM", 0, 30], ["controversial conformational changes", "PROBLEM", 47, 83], ["crystallography", "TEST", 91, 106], ["similar bent shapes", "PROBLEM", 116, 135], ["resting and primed extracellular region constructs", "PROBLEM", 140, 190], ["ligand binding", "PROBLEM", 192, 206], ["large structural rearrangements in smaller constructs", "PROBLEM", 215, 268], ["extension", "PROBLEM", 279, 288], ["large", "OBSERVATION_MODIFIER", 215, 220], ["structural rearrangements", "OBSERVATION", 221, 246], ["smaller constructs", "OBSERVATION", 250, 268], ["tails", "OBSERVATION_MODIFIER", 304, 309], ["separation", "OBSERVATION_MODIFIER", 310, 320]]], ["In a multiresolution approach, we used experimental and computed hydrodynamics to discriminate among \u03b1IIb\u03b23 integrin models built on X-ray, NMR, and EM data.", [["\u03b1IIb\u03b23 integrin", "GENE_OR_GENE_PRODUCT", 101, 116], ["\u03b1IIb\u03b23 integrin", "PROTEIN", 101, 116], ["computed hydrodynamics", "TEST", 56, 78], ["X-ray", "TEST", 133, 138], ["NMR", "TEST", 140, 143], ["EM data", "TEST", 149, 156]]], ["In contrast with Xray data and 3D EM maps, an extension is needed to match the hydrodynamics of full-length, solubilized \u03b1IIb\u03b23; an electron tomography-based model fares better.", [["\u03b1IIb\u03b23", "GENE_OR_GENE_PRODUCT", 121, 127], ["electron", "SIMPLE_CHEMICAL", 132, 140], ["\u03b1IIb\u03b23", "PROTEIN", 121, 127], ["Xray data", "TEST", 17, 26], ["3D EM maps", "TEST", 31, 41], ["an electron tomography", "TEST", 129, 151]]], ["Consistent with that, and with our averaged 2D EM images, a conformational change in the head region (\u03b23 hybrid domain swingout) coupled to a simple transmembrane helices shift matches priming agents-induced frictional changes in full-length \u03b1IIb\u03b23.", [["head region", "ANATOMY", 89, 100], ["transmembrane", "ANATOMY", 149, 162], ["\u03b1IIb\u03b23", "GENE_OR_GENE_PRODUCT", 242, 248], ["head region", "PROTEIN", 89, 100], ["\u03b23 hybrid domain swingout", "PROTEIN", 102, 127], ["transmembrane helices", "PROTEIN", 149, 170], ["\u03b1IIb\u03b23", "PROTEIN", 242, 248], ["our averaged 2D EM images", "TEST", 31, 56], ["a conformational change in the head region", "PROBLEM", 58, 100], ["a simple transmembrane helices shift", "TREATMENT", 140, 176], ["priming agents", "TREATMENT", 185, 199], ["induced frictional changes", "PROBLEM", 200, 226], ["head", "ANATOMY", 89, 93], ["region", "ANATOMY_MODIFIER", 94, 100], ["frictional changes", "OBSERVATION", 208, 226]]], ["Our multi-resolution study thus suggests that in integrins extension and immediate tail separation are uncoupled from head domain rearrangements following activation.O-385-Biomolecular self-assembly -123Stabilizing effects of \u03b1 s1 -casein, a natively unfolded protein, on the aggregation of biomolecules A. Trapani, R. Carrotta, P. L. San Biagio, D. Bulone IBF-CNR Palermo, Italy \u03b1 s1 -casein is one of the four types of caseins, a group of calcium phosphate-binding proteins that, in the form of micellar aggregates, makes up the largest protein component of bovine milk.", [["tail", "ANATOMY", 83, 87], ["head domain", "ANATOMY", 118, 129], ["milk", "ANATOMY", 567, 571], ["O-385", "CHEMICAL", 166, 171], ["\u03b1 s1 -casein", "CHEMICAL", 226, 238], ["calcium phosphate", "CHEMICAL", 441, 458], ["O-385", "CHEMICAL", 166, 171], ["calcium phosphate", "CHEMICAL", 441, 458], ["integrins", "GENE_OR_GENE_PRODUCT", 49, 58], ["\u03b1 s1 -casein", "GENE_OR_GENE_PRODUCT", 226, 238], ["\u03b1 s1 -casein", "GENE_OR_GENE_PRODUCT", 380, 392], ["caseins", "GENE_OR_GENE_PRODUCT", 421, 428], ["calcium", "SIMPLE_CHEMICAL", 441, 448], ["bovine", "ORGANISM", 560, 566], ["milk", "ORGANISM_SUBSTANCE", 567, 571], ["integrins", "PROTEIN", 49, 58], ["\u03b1 s1", "PROTEIN", 226, 230], ["casein", "PROTEIN", 232, 238], ["natively unfolded protein", "PROTEIN", 242, 267], ["\u03b1 s1 -casein", "PROTEIN", 380, 392], ["caseins", "PROTEIN", 421, 428], ["calcium phosphate-binding proteins", "PROTEIN", 441, 475], ["bovine", "SPECIES", 560, 566], ["bovine", "SPECIES", 560, 566], ["Our multi-resolution study", "TEST", 0, 26], ["integrins extension", "PROBLEM", 49, 68], ["immediate tail separation", "PROBLEM", 73, 98], ["a natively unfolded protein", "PROBLEM", 240, 267], ["calcium phosphate-binding proteins", "PROBLEM", 441, 475], ["micellar aggregates", "PROBLEM", 497, 516], ["bovine milk", "TREATMENT", 560, 571], ["tail separation", "OBSERVATION", 83, 98], ["Carrotta", "ANATOMY", 319, 327], ["s1", "ANATOMY", 382, 384], ["one", "OBSERVATION_MODIFIER", 396, 399], ["caseins", "OBSERVATION", 421, 428], ["micellar aggregates", "OBSERVATION", 497, 516], ["bovine milk", "OBSERVATION", 560, 571]]], ["The structure of \u03b1 s1 -casein is that of a triblock polymer with a hydrophilic tract interposed between two hydrophobic blocks.", [["\u03b1 s1 -casein", "SIMPLE_CHEMICAL", 17, 29], ["\u03b1 s1 -casein", "PROTEIN", 17, 29], ["a triblock polymer", "TREATMENT", 41, 59], ["a hydrophilic tract", "TREATMENT", 65, 84], ["two hydrophobic blocks", "TREATMENT", 104, 126], ["s1", "ANATOMY", 19, 21], ["hydrophilic tract", "OBSERVATION", 67, 84], ["hydrophobic blocks", "OBSERVATION", 108, 126]]], ["Due to the lack of a compact folded conformation, this protein can be classified as one of the intrinsically disordered (or natively unfolded) proteins.", [["natively unfolded) proteins", "PROTEIN", 124, 151], ["a compact folded conformation", "PROBLEM", 19, 48], ["natively unfolded) proteins", "PROBLEM", 124, 151]]], ["This class of proteins is known to exert a stabilizing activity on biomolecules through specific interaction with hydrophobic surfaces that partially unfolded molecules may expose to the solvent.", [["hydrophobic surfaces", "TREATMENT", 114, 134], ["partially unfolded molecules", "PROBLEM", 140, 168], ["stabilizing activity", "OBSERVATION", 43, 63], ["unfolded", "OBSERVATION", 150, 158]]], ["Here we present results on \u03b1 s1 -casein effects on the thermally induced aggregation of Gluthathione Stransferase, a ligand-binding anzyme, and 1-40 \u03b2-amyloid peptide involved in Alzheimer's disease.", [["Gluthathione", "CHEMICAL", 88, 100], ["1-40 \u03b2-amyloid peptide", "CHEMICAL", 144, 166], ["Alzheimer's disease", "DISEASE", 179, 198], ["Gluthathione", "CHEMICAL", 88, 100], ["\u03b1 s1 -casein", "SIMPLE_CHEMICAL", 27, 39], ["Gluthathione Stransferase", "SIMPLE_CHEMICAL", 88, 113], ["anzyme", "SIMPLE_CHEMICAL", 132, 138], ["1-40 \u03b2-amyloid peptide", "SIMPLE_CHEMICAL", 144, 166], ["Alzheimer's disease", "CANCER", 179, 198], ["s1", "DNA", 29, 31], ["Gluthathione Stransferase", "PROTEIN", 88, 113], ["Alzheimer's disease", "PROBLEM", 179, 198], ["Alzheimer's disease", "OBSERVATION", 179, 198]]], ["By means of Light Scattering and Circular Dichroism experiments, we attempt to reveal the molecular details of \u03b1 s1 -biomolecules interaction.P-392Bacterial protein self-assembly on surfaces of well-defined chemistry S-layers are one of the most common cell envelope components of prokaryotic organisms and represent the simplest biological membrane developed during evolution.", [["cell", "ANATOMY", 253, 257], ["membrane", "ANATOMY", 341, 349], ["P-392", "CHEMICAL", 142, 147], ["\u03b1 s1", "GENE_OR_GENE_PRODUCT", 111, 115], ["cell", "CELL", 253, 257], ["membrane", "CELLULAR_COMPONENT", 341, 349], ["\u03b1 s1", "PROTEIN", 111, 115], ["Circular Dichroism experiments", "TEST", 33, 63], ["P", "TEST", 142, 143], ["Bacterial protein self", "TEST", 147, 169], ["prokaryotic organisms", "PROBLEM", 281, 302], ["the simplest biological membrane", "PROBLEM", 317, 349], ["prokaryotic organisms", "OBSERVATION", 281, 302], ["biological membrane", "OBSERVATION", 330, 349]]], ["These (glyco)proteins, which can self-assemble into 2-D crystalline nanostructures on lipid films, liposomes, and polymers, play already an important role in nanobiotechnology.", [["2-D crystalline nanostructures", "SIMPLE_CHEMICAL", 52, 82], ["lipid films", "SIMPLE_CHEMICAL", 86, 97], ["liposomes", "SIMPLE_CHEMICAL", 99, 108], ["(glyco)proteins", "PROTEIN", 6, 21], ["These (glyco)proteins", "PROBLEM", 0, 21], ["lipid films", "TREATMENT", 86, 97], ["liposomes", "TREATMENT", 99, 108], ["polymers", "TREATMENT", 114, 122]]], ["In this work, we present new findings concerning the recrystallization of bacterial proteins on substrates with defined chemistry.", [["bacterial proteins", "PROTEIN", 74, 92], ["bacterial proteins", "PROBLEM", 74, 92], ["bacterial proteins", "OBSERVATION", 74, 92]]], ["Manipulation of the protein-sample interaction was carried out by changing the relative height of OH and CH 3 terminated moieties in self-assembled monolayers (SAMs).", [["OH", "CHEMICAL", 98, 100], ["OH", "CHEMICAL", 98, 100], ["CH 3", "CHEMICAL", 105, 109], ["OH", "SIMPLE_CHEMICAL", 98, 100], ["monolayers", "CELL", 148, 158], ["self-assembled monolayers", "CELL_LINE", 133, 158], ["SAMs", "CELL_LINE", 160, 164]]], ["We have found that differences in chain length lead to: i) protein bilayer-protein monolayer transition, ii) preferential protein side adsorption, and iii) increase of the crystal lattice parameters.", [["protein bilayer", "TEST", 59, 74], ["preferential protein side adsorption", "TREATMENT", 109, 145], ["the crystal lattice parameters", "TEST", 168, 198]]], ["Further manipulation of the protein-sample interaction was achieved by using silane chemistry.", [["silane", "CHEMICAL", 77, 83], ["silane", "CHEMICAL", 77, 83], ["silane", "SIMPLE_CHEMICAL", 77, 83], ["silane chemistry", "TEST", 77, 93]]], ["We will show that sample hidrophobicity speeds up recrystallization kinetics and reduces the crystalline domain size (and layer compliance).", [["sample", "ANATOMY", 18, 24], ["sample hidrophobicity", "PROBLEM", 18, 39], ["recrystallization kinetics", "PROBLEM", 50, 76], ["the crystalline domain size", "PROBLEM", 89, 116], ["size", "OBSERVATION_MODIFIER", 112, 116]]], ["The protein-adsorbed mass per unit area on these substrates is reported for the first time.O-391Self-assembly of phenylalanine oligopeptides: insights from experimental and computational studies P. Tamamis 1 , L. Adler-Abramovich 2 , M. Reches 2 , K. Marshall 3 , P. Sikorski 3 , L. Serpell 3 , E. Gazit 2 , G. Archontis 1 1 Dpt. of Physics, Univ. of Cyprus, Cyprus, 2 Dpt. of Molecular Microbiology and Biotechnology, Tel Aviv Univ., Israel, 3 Dpt. of Biochemistry, Univ. of Sussex, U.K.O-391The diphenylalanine peptide (FF) forms well ordered nanotubes and its derivatives form nano-assemblies of various morphologies with promising material applications.", [["O-391Self", "CHEMICAL", 91, 100], ["phenylalanine", "CHEMICAL", 113, 126], [".O-391", "CHEMICAL", 487, 493], ["diphenylalanine", "CHEMICAL", 497, 512], ["O-391Self", "CHEMICAL", 91, 100], ["phenylalanine", "CHEMICAL", 113, 126], ["diphenylalanine peptide", "CHEMICAL", 497, 520], ["phenylalanine", "AMINO_ACID", 113, 126], ["diphenylalanine peptide", "SIMPLE_CHEMICAL", 497, 520], ["U.K.O-391", "SPECIES", 484, 493], ["The protein-adsorbed mass", "PROBLEM", 0, 25], ["phenylalanine oligopeptides", "TREATMENT", 113, 140], ["Tamamis", "TEST", 198, 205], ["The diphenylalanine peptide (FF)", "TREATMENT", 493, 525], ["nanotubes", "TREATMENT", 545, 554], ["its derivatives", "TREATMENT", 559, 574], ["promising material applications", "TREATMENT", 625, 656], ["adsorbed", "OBSERVATION_MODIFIER", 12, 20], ["mass", "OBSERVATION", 21, 25]]], ["We demonstrate for the first time by electron and laser microscopy and FTIR spectroscopy that the related, triphenylalanine peptide (FFF) assembles into rather planar nanostructures, rich in \u03b2-sheet.", [["triphenylalanine", "CHEMICAL", 107, 123], ["triphenylalanine peptide", "CHEMICAL", 107, 131], ["triphenylalanine peptide", "SIMPLE_CHEMICAL", 107, 131], ["laser microscopy", "TEST", 50, 66], ["FTIR spectroscopy", "TEST", 71, 88], ["triphenylalanine peptide (FFF", "TREATMENT", 107, 136]]], ["In addition, we conduct 0.4-\u00b5s replica exchange M.D. simulations of aqueous FF and FFF solutions in implicit solvent.", [["FF", "SIMPLE_CHEMICAL", 76, 78], ["aqueous FF and FFF solutions", "TREATMENT", 68, 96], ["implicit solvent", "TREATMENT", 100, 116]]], ["The peptides coalesce into aggregates and participate frequently in open or ring-like linear networks, as well as elementary and network-containing structures with \u03b2-sheet characteristics.", [["coalesce", "OBSERVATION_MODIFIER", 13, 21], ["aggregates", "OBSERVATION_MODIFIER", 27, 37], ["ring", "OBSERVATION_MODIFIER", 76, 80], ["linear", "OBSERVATION_MODIFIER", 86, 92]]], ["Polar and nonpolar interactions, as well as the surrounding aggregate medium contribute to the network stabilities.", [["nonpolar interactions", "OBSERVATION", 10, 31]]], ["Within a network, consecutive peptides are linked by head-to-tail interactions; the aromatic sidechains of neighbor peptides assume approximately \"T-shaped\" orientations.", [["head", "ANATOMY", 53, 57], ["consecutive peptides", "PROBLEM", 18, 38], ["tail", "ANATOMY", 61, 65]]], ["These features are observed in FF crystals and could characterize early formations, or stabilize the mature nanostructures.", [["early formations", "PROBLEM", 66, 82], ["the mature nanostructures", "PROBLEM", 97, 122], ["early", "OBSERVATION_MODIFIER", 66, 71], ["formations", "OBSERVATION", 72, 82], ["mature", "OBSERVATION_MODIFIER", 101, 107], ["nanostructures", "OBSERVATION_MODIFIER", 108, 122]]], ["The FFF aggregates acquire higher stability and peptide-network propensity compared to the FF aggregates due to energetic contributions 1,2 .", [["higher stability", "OBSERVATION_MODIFIER", 27, 43], ["energetic contributions", "OBSERVATION", 112, 135]]], ["Chlorophyll biosynthesis is light-dependent in angiosperms because the reduction of protochlorophyllide (Pchlide) into chlorophyllide is driven by a photoenzyme, NADPH:Pchlide oxidoreductase (POR).", [["Chlorophyll", "CHEMICAL", 0, 11], ["protochlorophyllide", "CHEMICAL", 84, 103], ["Pchlide", "CHEMICAL", 105, 112], ["chlorophyllide", "CHEMICAL", 119, 133], ["NADPH", "CHEMICAL", 162, 167], ["Chlorophyll", "CHEMICAL", 0, 11], ["protochlorophyllide", "CHEMICAL", 84, 103], ["Pchlide", "CHEMICAL", 105, 112], ["chlorophyllide", "CHEMICAL", 119, 133], ["NADPH", "CHEMICAL", 162, 167], ["Pchlide", "CHEMICAL", 168, 175], ["Chlorophyll", "SIMPLE_CHEMICAL", 0, 11], ["protochlorophyllide", "SIMPLE_CHEMICAL", 84, 103], ["Pchlide", "SIMPLE_CHEMICAL", 105, 112], ["chlorophyllide", "SIMPLE_CHEMICAL", 119, 133], ["NADPH", "SIMPLE_CHEMICAL", 162, 167], ["Pchlide oxidoreductase", "GENE_OR_GENE_PRODUCT", 168, 190], ["POR", "GENE_OR_GENE_PRODUCT", 192, 195], ["NADPH:Pchlide oxidoreductase", "PROTEIN", 162, 190], ["POR", "PROTEIN", 192, 195], ["Chlorophyll biosynthesis", "TREATMENT", 0, 24], ["the reduction of protochlorophyllide (Pchlide) into chlorophyllide", "TREATMENT", 67, 133]]], ["The unique properties of POR are due to its ability to assemble into dimers and oligomers within the prolamellar body (PLB) membranes of etioplasts studied mainly in leaves of dark-grown seedlings under laboratory conditions.", [["prolamellar body (PLB) membranes", "ANATOMY", 101, 133], ["etioplasts", "ANATOMY", 137, 147], ["leaves", "ANATOMY", 166, 172], ["seedlings", "ANATOMY", 187, 196], ["POR", "GENE_OR_GENE_PRODUCT", 25, 28], ["prolamellar body", "CELLULAR_COMPONENT", 101, 117], ["PLB", "GENE_OR_GENE_PRODUCT", 119, 122], ["membranes", "CELLULAR_COMPONENT", 124, 133], ["POR", "PROTEIN", 25, 28], ["etioplasts", "TREATMENT", 137, 147], ["PLB", "ANATOMY", 119, 122], ["grown seedlings", "OBSERVATION", 181, 196]]], ["We extended these studies to plant organs developed in the nature: cabbage heads, leaf primordia inside buds, pericarp-covered regions of sunflower cotyledons, potato tubers and seedlings germinating under the soil.", [["organs", "ANATOMY", 35, 41], ["heads", "ANATOMY", 75, 80], ["leaf primordia", "ANATOMY", 82, 96], ["buds", "ANATOMY", 104, 108], ["pericarp", "ANATOMY", 110, 118], ["cotyledons", "ANATOMY", 148, 158], ["tubers", "ANATOMY", 167, 173], ["organs", "ORGAN", 35, 41], ["leaf primordia", "MULTI-TISSUE_STRUCTURE", 82, 96], ["buds", "ORGANISM_SUBDIVISION", 104, 108], ["pericarp", "TISSUE", 110, 118], ["cotyledons", "ORGANISM_SUBDIVISION", 148, 158], ["tubers", "ORGANISM_SUBDIVISION", 167, 173], ["cabbage", "SPECIES", 67, 74], ["potato", "SPECIES", 160, 166], ["cabbage", "SPECIES", 67, 74], ["potato", "SPECIES", 160, 166], ["these studies", "TEST", 12, 25], ["leaf primordia inside buds", "PROBLEM", 82, 108], ["potato tubers", "TREATMENT", 160, 173], ["leaf primordia", "OBSERVATION", 82, 96], ["pericarp", "ANATOMY", 110, 118], ["sunflower cotyledons", "OBSERVATION", 138, 158], ["potato tubers", "OBSERVATION", 160, 173]]], ["In electron microscopic and fluorescence spectroscopic studies we found in many of these organs poorly developed PLBs in which POR was mainly in monomer state.", [["organs", "ANATOMY", 89, 95], ["organs", "ORGAN", 89, 95], ["PLBs", "SIMPLE_CHEMICAL", 113, 117], ["POR", "GENE_OR_GENE_PRODUCT", 127, 130], ["POR", "PROTEIN", 127, 130], ["fluorescence spectroscopic studies", "TEST", 28, 62]]], ["As a consequence, the chlorophyll accumulation was slow and photo-oxidation processes occurred at illumination.", [["chlorophyll", "CHEMICAL", 22, 33], ["chlorophyll", "CHEMICAL", 22, 33], ["chlorophyll", "SIMPLE_CHEMICAL", 22, 33], ["the chlorophyll accumulation", "PROBLEM", 18, 46], ["slow and photo-oxidation processes", "PROBLEM", 51, 85], ["chlorophyll accumulation", "OBSERVATION", 22, 46]]], ["In vitro we artificially induced the aggregation of POR monomers into oligomers in glycerol and sucrose containing buffers.", [["glycerol", "CHEMICAL", 83, 91], ["sucrose", "CHEMICAL", 96, 103], ["glycerol", "CHEMICAL", 83, 91], ["sucrose", "CHEMICAL", 96, 103], ["POR", "SIMPLE_CHEMICAL", 52, 55], ["glycerol", "SIMPLE_CHEMICAL", 83, 91], ["sucrose", "SIMPLE_CHEMICAL", 96, 103], ["POR monomers", "PROTEIN", 52, 64], ["glycerol and sucrose containing buffers", "TREATMENT", 83, 122]]], ["This resulted in the increase of the photoreduction rate at the expense of photo-oxidation.", [["the photoreduction rate", "TREATMENT", 33, 56], ["photo-oxidation", "TREATMENT", 75, 90], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["These results underline the importance of the self-assembly of POR and the PLBs in chloroplast development and chlorophyll synthesis in nature.Oligomerization of Concanavalin A in live cells detected by fluctuation analysisV.", [["chloroplast", "ANATOMY", 83, 94], ["cells", "ANATOMY", 185, 190], ["chlorophyll", "CHEMICAL", 111, 122], ["POR", "GENE_OR_GENE_PRODUCT", 63, 66], ["PLBs", "GENE_OR_GENE_PRODUCT", 75, 79], ["chloroplast", "CELLULAR_COMPONENT", 83, 94], ["chlorophyll", "SIMPLE_CHEMICAL", 111, 122], ["Concanavalin A", "GENE_OR_GENE_PRODUCT", 162, 176], ["cells", "CELL", 185, 190], ["POR", "PROTEIN", 63, 66], ["PLBs", "PROTEIN", 75, 79], ["Concanavalin A", "PROTEIN", 162, 176], ["the PLBs in chloroplast development", "TREATMENT", 71, 106], ["chlorophyll synthesis", "TREATMENT", 111, 132], ["Concanavalin A in live cells", "PROBLEM", 162, 190], ["chlorophyll synthesis", "OBSERVATION", 111, 132], ["Concanavalin", "OBSERVATION_MODIFIER", 162, 174]]], ["Vetri 1 , G. Ossato 2 , V. Militello 1 , M. A. Digman 2 , M. Leone 1 , E. Gratton 2 1 DSFA, University of Palermo, Palermo, Italy, 2 LFD, University of California, Irvine, CA, USAOligomerization of Concanavalin A in live cells detected by fluctuation analysisWe report an experimental study on ConcanavalinA (ConA) aggregation in live cells.", [["cells", "ANATOMY", 221, 226], ["cells", "ANATOMY", 335, 340], ["Concanavalin A", "CHEMICAL", 198, 212], ["ConcanavalinA", "CHEMICAL", 294, 307], ["ConA", "CHEMICAL", 309, 313], ["ConcanavalinA", "CHEMICAL", 294, 307], ["Concanavalin A", "SIMPLE_CHEMICAL", 198, 212], ["cells", "CELL", 221, 226], ["ConcanavalinA", "SIMPLE_CHEMICAL", 294, 307], ["ConA", "SIMPLE_CHEMICAL", 309, 313], ["cells", "CELL", 335, 340], ["live cells", "CELL_TYPE", 330, 340], ["Vetri", "TEST", 0, 5], ["Ossato", "TEST", 13, 19], ["Militello", "TEST", 27, 36], ["Digman", "TEST", 47, 53], ["Leone", "TEST", 61, 66], ["Concanavalin A in live cells", "TREATMENT", 198, 226], ["an experimental study", "TEST", 269, 290], ["ConcanavalinA (ConA) aggregation in live cells", "TREATMENT", 294, 340]]], ["In vitro, close to physiological temperature, ConA readily forms fibrils involving secondary structure changes leading to \u03b2-aggregate structures.", [["fibrils", "ANATOMY", 65, 72], ["ConA", "SIMPLE_CHEMICAL", 46, 50], ["ConA", "PROTEIN", 46, 50], ["fibrils", "PROBLEM", 65, 72], ["secondary structure changes", "PROBLEM", 83, 110], ["\u03b2-aggregate structures", "PROBLEM", 122, 144], ["secondary structure", "OBSERVATION", 83, 102]]], ["The effect of ConA on cell cultures and formation of protein aggregates were measured by confocal fluorescence microscopy.", [["cell cultures", "ANATOMY", 22, 35], ["ConA", "CHEMICAL", 14, 18], ["ConA", "SIMPLE_CHEMICAL", 14, 18], ["cell cultures", "CELL", 22, 35], ["ConA", "PROTEIN", 14, 18], ["cell cultures", "CELL_LINE", 22, 35], ["ConA on cell cultures", "TEST", 14, 35], ["protein aggregates", "PROBLEM", 53, 71], ["confocal fluorescence microscopy", "TEST", 89, 121], ["ConA", "OBSERVATION_MODIFIER", 14, 18]]], ["In particular, we monitored protein aggregation in live cells by means N&B analysis, Cross-N&B and RICS.", [["cells", "ANATOMY", 56, 61], ["cells", "CELL", 56, 61], ["Cross-N&B", "SIMPLE_CHEMICAL", 85, 94], ["live cells", "CELL_TYPE", 51, 61]]], ["N&B showed the aggregation kinetic and the progressive formation of ConA oligomers at cell surface.", [["cell surface", "ANATOMY", 86, 98], ["N&B", "CHEMICAL", 0, 3], ["N&B", "SIMPLE_CHEMICAL", 0, 3], ["ConA oligomers", "SIMPLE_CHEMICAL", 68, 82], ["cell surface", "CELLULAR_COMPONENT", 86, 98], ["the aggregation kinetic", "PROBLEM", 11, 34], ["ConA oligomers at cell surface", "PROBLEM", 68, 98], ["aggregation kinetic", "OBSERVATION", 15, 34], ["progressive", "OBSERVATION_MODIFIER", 43, 54], ["ConA oligomers", "OBSERVATION", 68, 82], ["cell", "OBSERVATION", 86, 90], ["surface", "OBSERVATION_MODIFIER", 91, 98]]], ["This suggests that, at cell membrane where local concentration is higher, nucleation sites for aggregation are provided.", [["cell membrane", "ANATOMY", 23, 36], ["aggregation", "DISEASE", 95, 106], ["cell membrane", "CELLULAR_COMPONENT", 23, 36], ["local concentration", "PROBLEM", 43, 62], ["aggregation", "PROBLEM", 95, 106], ["cell membrane", "OBSERVATION", 23, 36], ["local", "OBSERVATION_MODIFIER", 43, 48], ["concentration", "OBSERVATION_MODIFIER", 49, 62], ["higher", "OBSERVATION_MODIFIER", 66, 72]]], ["In parallel, the morphology of the cells changes indicating the progressive cell compaction and death.", [["cells", "ANATOMY", 35, 40], ["cell", "ANATOMY", 76, 80], ["death", "DISEASE", 96, 101], ["cells", "CELL", 35, 40], ["cell", "CELL", 76, 80], ["the cells changes", "PROBLEM", 31, 48], ["the progressive cell compaction", "PROBLEM", 60, 91], ["death", "PROBLEM", 96, 101], ["parallel", "OBSERVATION_MODIFIER", 3, 11], ["cells", "OBSERVATION", 35, 40], ["progressive", "OBSERVATION_MODIFIER", 64, 75], ["cell compaction", "OBSERVATION", 76, 91]]], ["Aggregation and binding of small aggregates to the cell surface were assessed by RICS: it is possible to distinguish regions where small aggregates are diffusing and regions where they are bound to the cell.", [["cell surface", "ANATOMY", 51, 63], ["cell", "ANATOMY", 202, 206], ["cell surface", "CELLULAR_COMPONENT", 51, 63], ["cell", "CELL", 202, 206], ["Aggregation", "PROBLEM", 0, 11], ["small aggregates", "PROBLEM", 27, 43], ["small aggregates", "PROBLEM", 131, 147], ["small", "OBSERVATION_MODIFIER", 27, 32], ["aggregates", "OBSERVATION", 33, 43], ["cell surface", "OBSERVATION", 51, 63], ["small", "OBSERVATION_MODIFIER", 131, 136], ["aggregates", "OBSERVATION", 137, 147], ["diffusing", "OBSERVATION_MODIFIER", 152, 161]]], ["Oligomers formation may stimulate non-specific cellular responses due to the exposure of reactive regions of protein structure and of progressive formation of cross\u2212\u03b2 structures.", [["cellular", "ANATOMY", 47, 55], ["Oligomers", "SIMPLE_CHEMICAL", 0, 9], ["cellular", "CELL", 47, 55], ["protein structure", "PROTEIN", 109, 126], ["Oligomers formation", "PROBLEM", 0, 19], ["non-specific cellular responses", "PROBLEM", 34, 65], ["reactive regions of protein structure", "PROBLEM", 89, 126], ["progressive formation of cross\u2212\u03b2 structures", "PROBLEM", 134, 177], ["non-specific", "OBSERVATION_MODIFIER", 34, 46], ["reactive", "OBSERVATION_MODIFIER", 89, 97], ["protein structure", "OBSERVATION", 109, 126], ["progressive", "OBSERVATION_MODIFIER", 134, 145], ["cross\u2212\u03b2 structures", "OBSERVATION", 159, 177]]], ["Moreover, aggregates stoichiometry was measured during the kinetic by Cross-Variance N&B.Oligomerization of Concanavalin A in live cells detected by fluctuation analysisThe two conductive pathways of P2X7 purinergic receptor: different modulation and selectivity R. Barbieri 1 , S. Alloisio 1 , A. Di Garbo 2 , M. Nobile 1 1 Institute of Biophysics, CNR, Via De Marini 6, 16149 Genoa, Italy, 2 Institute of Biophysics, CNR, Via G. Moruzzi 1, 56124 Pisa, Italy The P2X 7 purinoceptor (P2X 7 R) is an ATP-gated cation channel that is able to activate a cell permeabilizing pore.", [["cells", "ANATOMY", 131, 136], ["cell", "ANATOMY", 551, 555], ["pore", "ANATOMY", 571, 575], ["ATP", "CHEMICAL", 499, 502], ["ATP", "CHEMICAL", 499, 502], ["Concanavalin A", "GENE_OR_GENE_PRODUCT", 108, 122], ["cells", "CELL", 131, 136], ["P2X7 purinergic receptor", "GENE_OR_GENE_PRODUCT", 200, 224], ["P2X 7 purinoceptor", "GENE_OR_GENE_PRODUCT", 464, 482], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 484, 491], ["ATP", "SIMPLE_CHEMICAL", 499, 502], ["cation", "SIMPLE_CHEMICAL", 509, 515], ["cell", "CELL", 551, 555], ["pore", "CELLULAR_COMPONENT", 571, 575], ["Concanavalin A", "PROTEIN", 108, 122], ["P2X7 purinergic receptor", "PROTEIN", 200, 224], ["ATP-gated cation channel", "PROTEIN", 499, 523], ["aggregates stoichiometry", "PROBLEM", 10, 34], ["Concanavalin A in live cells", "PROBLEM", 108, 136], ["fluctuation analysis", "TEST", 149, 169], ["purinoceptor (P2X", "TREATMENT", 470, 487], ["an ATP-gated cation channel", "TREATMENT", 496, 523], ["a cell permeabilizing pore", "TREATMENT", 549, 575], ["aggregates stoichiometry", "OBSERVATION", 10, 34]]], ["P2X 7 R cytosolic C-terminal tail is thought to modulate this function.", [["cytosolic", "ANATOMY", 8, 17], ["C", "CHEMICAL", 18, 19], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 0, 7], ["P2X 7 R cytosolic C-terminal tail", "PROTEIN", 0, 33], ["P2X", "TEST", 0, 3], ["terminal", "ANATOMY_MODIFIER", 20, 28], ["tail", "ANATOMY", 29, 33]]], ["This study was aimed to characterise the biophysical properties of P2X 7 R compared to those of the variant lacking the entire C-terminus tail (trP2X 7 R) by measuring whole-cell currents and intracellular Ca 2+ variations.", [["whole-cell", "ANATOMY", 168, 178], ["intracellular", "ANATOMY", 192, 205], ["Ca", "CHEMICAL", 206, 208], ["C", "CHEMICAL", 127, 128], ["Ca 2+", "CHEMICAL", 206, 211], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 67, 74], ["trP2X 7 R", "GENE_OR_GENE_PRODUCT", 144, 153], ["cell", "CELL", 174, 178], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 192, 205], ["Ca 2+", "SIMPLE_CHEMICAL", 206, 211], ["P2X 7 R", "PROTEIN", 67, 74], ["C-terminus tail", "PROTEIN", 127, 142], ["trP2X 7 R", "PROTEIN", 144, 153], ["This study", "TEST", 0, 10], ["intracellular Ca", "TEST", 192, 208], ["terminus tail", "ANATOMY", 129, 142]]], ["In P2X 7 R expressing HEK-293 cells, the potent agonist 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate (BzATP) -evoked ionic currents depending on concentration and frequency of agonist applications.", [["HEK-293 cells", "ANATOMY", 22, 35], ["3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate", "CHEMICAL", 56, 105], ["BzATP", "CHEMICAL", 107, 112], ["3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate", "CHEMICAL", 56, 105], ["BzATP", "CHEMICAL", 107, 112], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 3, 10], ["HEK-293 cells", "CELL", 22, 35], ["3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate", "SIMPLE_CHEMICAL", 56, 105], ["BzATP", "SIMPLE_CHEMICAL", 107, 112], ["P2X 7 R expressing HEK-293 cells", "CELL_LINE", 3, 35], ["P2X", "TEST", 3, 6], ["HEK", "TEST", 22, 25], ["cells", "TEST", 30, 35], ["the potent agonist", "TEST", 37, 55], ["benzoyl", "TREATMENT", 64, 71], ["benzoyl adenosine", "TREATMENT", 72, 89], ["triphosphate (BzATP", "TREATMENT", 93, 112], ["evoked ionic currents", "PROBLEM", 115, 136], ["agonist applications", "TREATMENT", 181, 201]]], ["The currents were strongly inhibited by extracellular Mg 2+ in a noncompetitive way.", [["extracellular", "ANATOMY", 40, 53], ["Mg", "CHEMICAL", 54, 56], ["Mg 2+", "CHEMICAL", 54, 59], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["Mg 2+", "SIMPLE_CHEMICAL", 54, 59]]], ["By contrast, in trP2X 7 R cells, only high BzATP concentrations elicited small currents not affected by Mg 2+ .", [["trP2X 7 R cells", "ANATOMY", 16, 31], ["BzATP", "CHEMICAL", 43, 48], ["Mg", "CHEMICAL", 104, 106], ["BzATP", "CHEMICAL", 43, 48], ["Mg 2+", "CHEMICAL", 104, 109], ["trP2X 7 R cells", "CELL", 16, 31], ["BzATP", "SIMPLE_CHEMICAL", 43, 48], ["Mg 2+", "SIMPLE_CHEMICAL", 104, 109], ["trP2X 7 R cells", "CELL_LINE", 16, 31], ["high BzATP concentrations", "PROBLEM", 38, 63], ["small currents", "PROBLEM", 73, 87], ["Mg", "TEST", 104, 106], ["high", "OBSERVATION_MODIFIER", 38, 42], ["BzATP concentrations", "OBSERVATION", 43, 63], ["small", "OBSERVATION_MODIFIER", 73, 78]]], ["Interestingly, BzATP-induced Ca 2+ influx was present both in P2X 7 R and in trP2X 7 R cells, albeit in the latter the intracellular Ca 2+ elevation was smaller.", [["trP2X 7 R cells", "ANATOMY", 77, 92], ["intracellular", "ANATOMY", 119, 132], ["BzATP", "CHEMICAL", 15, 20], ["Ca", "CHEMICAL", 29, 31], ["Ca", "CHEMICAL", 133, 135], ["BzATP", "CHEMICAL", 15, 20], ["Ca 2+", "CHEMICAL", 29, 34], ["Ca 2+", "CHEMICAL", 133, 138], ["BzATP", "SIMPLE_CHEMICAL", 15, 20], ["Ca 2+", "SIMPLE_CHEMICAL", 29, 34], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 62, 69], ["trP2X 7 R cells", "CELL", 77, 92], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["Ca 2+", "SIMPLE_CHEMICAL", 133, 138], ["P2X 7 R", "PROTEIN", 62, 69], ["trP2X 7 R cells", "CELL_LINE", 77, 92], ["BzATP", "TEST", 15, 20], ["Ca", "TEST", 29, 31], ["influx", "PROBLEM", 35, 41], ["P2X", "TEST", 62, 65], ["elevation", "PROBLEM", 139, 148], ["intracellular", "OBSERVATION_MODIFIER", 119, 132], ["Ca", "OBSERVATION", 133, 135], ["elevation", "OBSERVATION_MODIFIER", 139, 148], ["smaller", "OBSERVATION_MODIFIER", 153, 160]]], ["Importantly, in trP2X 7 R the intracellular Ca 2+ rise maintained a competitive mechanism of Mg 2+ inhibition similar to that observed in P2X 7 R. The experimental data and the modelling findings support the tenet of a functional structure of P2X 7 R possessing two distinct conductive pathways.S. Ayrapetyan UNESCO Chair-Life Sciences International Postgraduate Educational Center, Yerevan, ArmeniaThe review of our data on the effects of physical and chemical weak signals on physicochemical properties of water, cell volume, activity and the number of membrane proteins (receptors, ionic channels and enzymes, Na + /K + pump and Na + /Ca 2+ exchanger), intracellular signal systems in norm and pathology (cancer and nerve disorders) would be presented.", [["intracellular", "ANATOMY", 30, 43], ["cell", "ANATOMY", 515, 519], ["membrane", "ANATOMY", 555, 563], ["intracellular", "ANATOMY", 656, 669], ["cancer", "ANATOMY", 708, 714], ["nerve", "ANATOMY", 719, 724], ["Ca", "CHEMICAL", 44, 46], ["Mg", "CHEMICAL", 93, 95], ["Na", "CHEMICAL", 613, 615], ["K", "CHEMICAL", 619, 620], ["Na", "CHEMICAL", 632, 634], ["Ca", "CHEMICAL", 638, 640], ["cancer and nerve disorders", "DISEASE", 708, 734], ["Ca 2+", "CHEMICAL", 44, 49], ["Mg 2+", "CHEMICAL", 93, 98], ["Na +", "CHEMICAL", 613, 617], ["K +", "CHEMICAL", 619, 622], ["Na +", "CHEMICAL", 632, 636], ["Ca 2+", "CHEMICAL", 638, 643], ["trP2X 7 R", "GENE_OR_GENE_PRODUCT", 16, 25], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["Mg 2+", "SIMPLE_CHEMICAL", 93, 98], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 243, 250], ["water", "SIMPLE_CHEMICAL", 508, 513], ["cell", "CELL", 515, 519], ["membrane", "CELLULAR_COMPONENT", 555, 563], ["Na + /K + pump", "GENE_OR_GENE_PRODUCT", 613, 627], ["Na + /Ca 2+ exchanger", "GENE_OR_GENE_PRODUCT", 632, 653], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 656, 669], ["cancer", "CANCER", 708, 714], ["nerve", "MULTI-TISSUE_STRUCTURE", 719, 724], ["trP2X 7 R", "PROTEIN", 16, 25], ["P2X 7 R", "PROTEIN", 243, 250], ["membrane proteins", "PROTEIN", 555, 572], ["ionic channels", "PROTEIN", 585, 599], ["enzymes", "PROTEIN", 604, 611], ["Na + /K + pump and Na + /Ca 2+ exchanger", "PROTEIN", 613, 653], ["the intracellular Ca", "TEST", 26, 46], ["The experimental data", "TEST", 147, 168], ["our data", "TEST", 413, 421], ["cell volume", "TEST", 515, 526], ["ionic channels", "TEST", 585, 599], ["enzymes", "TEST", 604, 611], ["Na", "TEST", 613, 615], ["K", "TEST", 619, 620], ["pump", "TEST", 623, 627], ["Na", "TEST", 632, 634], ["Ca", "TEST", 638, 640], ["intracellular signal systems", "TEST", 656, 684], ["pathology (cancer and nerve disorders", "PROBLEM", 697, 734], ["distinct", "OBSERVATION_MODIFIER", 266, 274], ["conductive pathways", "OBSERVATION", 275, 294], ["Armenia", "ANATOMY", 392, 399], ["cancer", "OBSERVATION", 708, 714], ["nerve", "ANATOMY", 719, 724]]], ["Light microscopic, cell voltage-and patch-clamp, isotope, standard biochemical and genetic engineering methods were used.", [["cell", "ANATOMY", 19, 23], ["cell", "CELL", 19, 23], ["Light microscopic, cell voltage", "TEST", 0, 31], ["patch-clamp", "TREATMENT", 36, 47], ["isotope", "TREATMENT", 49, 56], ["genetic engineering methods", "TREATMENT", 83, 110], ["cell voltage", "OBSERVATION", 19, 31]]], ["Weak signal-induced effects on cell functional activity (intracellular enzymes activity, the number of functionally active membrane proteins) are realized by changing the physicochemical properties of extra-and intracellular aqua medium.", [["cell", "ANATOMY", 31, 35], ["intracellular", "ANATOMY", 57, 70], ["membrane", "ANATOMY", 123, 131], ["intracellular", "ANATOMY", 211, 224], ["cell", "CELL", 31, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["membrane", "CELLULAR_COMPONENT", 123, 131], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 211, 224], ["intracellular enzymes", "PROTEIN", 57, 78], ["membrane proteins", "PROTEIN", 123, 140], ["Weak signal", "PROBLEM", 0, 11], ["induced effects", "PROBLEM", 12, 27], ["cell functional activity", "PROBLEM", 31, 55], ["intracellular enzymes activity", "TEST", 57, 87], ["intracellular aqua medium", "OBSERVATION", 211, 236]]], ["The latter induces the modulation of Na + /K + pump-induced cell hydration, which serves as a primary mechanism through which the autoregulation of pump and regulation of membrane excitability and chemosensitivity are realized.", [["cell", "ANATOMY", 60, 64], ["membrane", "ANATOMY", 171, 179], ["Na", "CHEMICAL", 37, 39], ["K", "CHEMICAL", 43, 44], ["Na +", "CHEMICAL", 37, 41], ["K +", "CHEMICAL", 43, 46], ["Na + /K + pump", "GENE_OR_GENE_PRODUCT", 37, 51], ["cell", "CELL", 60, 64], ["membrane", "CELLULAR_COMPONENT", 171, 179], ["Na", "TEST", 37, 39], ["K + pump", "TREATMENT", 43, 51], ["induced cell hydration", "TREATMENT", 52, 74], ["the autoregulation of pump", "TREATMENT", 126, 152], ["membrane excitability", "PROBLEM", 171, 192], ["chemosensitivity", "PROBLEM", 197, 213], ["cell hydration", "OBSERVATION", 60, 74], ["membrane excitability", "OBSERVATION", 171, 192]]], ["By genetic engineering method in oocytes it was shown that the correlation between Na + /K + pump and Na + /Ca 2+ exchanger, which is realized through intracellular messenger systems, plays a crucial role in weak signals transduction in cells and determination of aging-induced increase of cell pathology.P-396Listeriolysin pore forming ability in planar lipid membranes at different pH Listeriolysin O (LLO) is a cholesterol-dependent cytolysin secreted by the intracellular pathogen Listeria monocytogenes.", [["oocytes", "ANATOMY", 33, 40], ["intracellular", "ANATOMY", 151, 164], ["cells", "ANATOMY", 237, 242], ["cell", "ANATOMY", 290, 294], ["lipid membranes", "ANATOMY", 355, 370], ["intracellular", "ANATOMY", 462, 475], ["Na", "CHEMICAL", 83, 85], ["K", "CHEMICAL", 89, 90], ["Na", "CHEMICAL", 102, 104], ["Ca", "CHEMICAL", 108, 110], ["P-396Listeriolysin", "CHEMICAL", 305, 323], ["Listeriolysin O", "CHEMICAL", 387, 402], ["cholesterol", "CHEMICAL", 414, 425], ["Na +", "CHEMICAL", 83, 87], ["K +", "CHEMICAL", 89, 92], ["Na +", "CHEMICAL", 102, 106], ["Ca 2+", "CHEMICAL", 108, 113], ["Listeriolysin O", "CHEMICAL", 387, 402], ["cholesterol", "CHEMICAL", 414, 425], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 33, 40], ["Na + /K + pump", "GENE_OR_GENE_PRODUCT", 83, 97], ["Na +", "SIMPLE_CHEMICAL", 102, 106], ["Ca 2+ exchanger", "GENE_OR_GENE_PRODUCT", 108, 123], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 164], ["cells", "CELL", 237, 242], ["cell", "CELL", 290, 294], ["lipid membranes", "CELLULAR_COMPONENT", 355, 370], ["Listeriolysin O", "SIMPLE_CHEMICAL", 387, 402], ["LLO", "GENE_OR_GENE_PRODUCT", 404, 407], ["cholesterol", "SIMPLE_CHEMICAL", 414, 425], ["cytolysin", "GENE_OR_GENE_PRODUCT", 436, 445], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 462, 475], ["pathogen", "ORGANISM", 476, 484], ["Listeria monocytogenes", "ORGANISM", 485, 507], ["oocytes", "CELL_TYPE", 33, 40], ["Na + /K + pump", "PROTEIN", 83, 97], ["Na + /Ca 2+ exchanger", "PROTEIN", 102, 123], ["LLO", "PROTEIN", 404, 407], ["cytolysin", "PROTEIN", 436, 445], ["Listeria monocytogenes", "SPECIES", 485, 507], ["Listeria monocytogenes", "SPECIES", 485, 507], ["Na", "TEST", 83, 85], ["K", "TEST", 89, 90], ["pump", "TEST", 93, 97], ["Na", "TEST", 102, 104], ["Ca", "TEST", 108, 110], ["weak signals transduction in cells", "PROBLEM", 208, 242], ["cell pathology", "PROBLEM", 290, 304], ["planar lipid membranes", "TREATMENT", 348, 370], ["a cholesterol-dependent cytolysin", "TEST", 412, 445], ["the intracellular pathogen Listeria monocytogenes", "PROBLEM", 458, 507], ["cell pathology", "OBSERVATION", 290, 304], ["lipid membranes", "OBSERVATION", 355, 370], ["intracellular pathogen", "OBSERVATION", 462, 484], ["Listeria monocytogenes", "OBSERVATION", 485, 507]]], ["Its main task is to enable escape of bacteria from the phagosomal vacuole into the cytoplasm.", [["phagosomal vacuole", "ANATOMY", 55, 73], ["cytoplasm", "ANATOMY", 83, 92], ["phagosomal vacuole", "CELLULAR_COMPONENT", 55, 73], ["cytoplasm", "ORGANISM_SUBSTANCE", 83, 92], ["bacteria", "PROBLEM", 37, 45], ["main", "OBSERVATION_MODIFIER", 4, 8], ["bacteria", "OBSERVATION", 37, 45], ["phagosomal vacuole", "OBSERVATION", 55, 73], ["cytoplasm", "OBSERVATION_MODIFIER", 83, 92]]], ["LLO exhibits optimal cytolytic activity at low pH but it is still able to bind membranes at physiological or even slightly basic pH values in a cholesterol-dependent fashion.", [["membranes", "ANATOMY", 79, 88], ["cholesterol", "CHEMICAL", 144, 155], ["cholesterol", "CHEMICAL", 144, 155], ["LLO", "GENE_OR_GENE_PRODUCT", 0, 3], ["membranes", "CELLULAR_COMPONENT", 79, 88], ["cholesterol", "SIMPLE_CHEMICAL", 144, 155], ["LLO", "PROTEIN", 0, 3], ["optimal", "OBSERVATION_MODIFIER", 13, 20], ["cytolytic activity", "OBSERVATION", 21, 39], ["low pH", "OBSERVATION_MODIFIER", 43, 49]]], ["High cholesterol concentrations in the membrane restore the low activity of LLO at high pH values.", [["membrane", "ANATOMY", 39, 47], ["cholesterol", "CHEMICAL", 5, 16], ["cholesterol", "CHEMICAL", 5, 16], ["cholesterol", "SIMPLE_CHEMICAL", 5, 16], ["membrane", "CELLULAR_COMPONENT", 39, 47], ["LLO", "GENE_OR_GENE_PRODUCT", 76, 79], ["LLO", "PROTEIN", 76, 79], ["High cholesterol concentrations", "PROBLEM", 0, 31], ["the membrane", "TREATMENT", 35, 47], ["cholesterol", "OBSERVATION", 5, 16], ["concentrations", "OBSERVATION_MODIFIER", 17, 31], ["low activity", "OBSERVATION_MODIFIER", 60, 72]]], ["Based on this broad pH activity we investigated the electrophysiological properties of pores formed by LLO at room temperature and at different pHs using Planar Lipid Bilayer technique.", [["pores", "ANATOMY", 87, 92], ["LLO", "SIMPLE_CHEMICAL", 103, 106], ["LLO", "PROTEIN", 103, 106], ["this broad pH activity", "PROBLEM", 9, 31], ["Planar Lipid Bilayer technique", "TREATMENT", 154, 184]]], ["LLO is able to form pores both at pH 5.5 and 7.5 with a similar permeabilizing ability and similar heterogeneous conductances in the range of picosiemes to nanosiemens.", [["LLO", "GENE_OR_GENE_PRODUCT", 0, 3], ["LLO", "PROTEIN", 0, 3], ["pH", "TEST", 34, 36], ["heterogeneous conductances", "OBSERVATION", 99, 125]]], ["Cholesterol content directly correlates with LLO activity but it does not change the pore characteristics.", [["pore", "ANATOMY", 85, 89], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["LLO", "GENE_OR_GENE_PRODUCT", 45, 48], ["LLO", "PROTEIN", 45, 48], ["Cholesterol content", "TEST", 0, 19], ["LLO activity", "OBSERVATION", 45, 57]]], ["Collectively, our results demonstrate that LLO activity at physiological pH cannot be neglected and that its action at sites distal to cell entry may have important physiological consequences for Listeria pathogenesis.Reconstitution of fluorescent voltage gated ion channels in giant unilamellar vesiclesS.", [["cell", "ANATOMY", 135, 139], ["unilamellar vesiclesS", "ANATOMY", 284, 305], ["LLO", "GENE_OR_GENE_PRODUCT", 43, 46], ["cell", "CELL", 135, 139], ["LLO", "PROTEIN", 43, 46], ["fluorescent voltage gated ion channels", "PROTEIN", 236, 274], ["LLO activity at physiological pH", "PROBLEM", 43, 75], ["Listeria pathogenesis", "PROBLEM", 196, 217], ["fluorescent voltage gated ion channels in giant unilamellar vesiclesS", "PROBLEM", 236, 305], ["LLO activity", "OBSERVATION", 43, 55], ["fluorescent voltage", "OBSERVATION", 236, 255], ["giant", "OBSERVATION_MODIFIER", 278, 283], ["unilamellar vesiclesS", "OBSERVATION", 284, 305]]], ["Aimon, G. Toombes, P. Bassereau Institut Curie, Paris, FranceReconstitution of fluorescent voltage gated ion channels in giant unilamellar vesiclesThe physics of membrane/channel and channel/channel interactions is difficult to investigate in cells where it is nearly impossible to modify relevant parameters to deduce physics laws.", [["giant unilamellar vesicles", "ANATOMY", 121, 147], ["membrane", "ANATOMY", 162, 170], ["cells", "ANATOMY", 243, 248], ["unilamellar vesicles", "MULTI-TISSUE_STRUCTURE", 127, 147], ["membrane", "CELLULAR_COMPONENT", 162, 170], ["cells", "CELL", 243, 248], ["fluorescent voltage gated ion channels", "PROTEIN", 79, 117], ["fluorescent voltage gated ion channels in giant unilamellar vesicles", "PROBLEM", 79, 147], ["channel/channel interactions", "TREATMENT", 183, 211], ["giant", "OBSERVATION_MODIFIER", 121, 126], ["unilamellar vesicles", "OBSERVATION", 127, 147]]], ["To overcome these difficulties we built a model system in which voltage gated ion channels were reconstituted in Giant Unilamellar Vesicles (GUVs) for the first time.", [["Giant Unilamellar Vesicles", "ANATOMY", 113, 139], ["GUVs", "ANATOMY", 141, 145], ["these difficulties", "PROBLEM", 12, 30], ["Giant", "OBSERVATION_MODIFIER", 113, 118], ["Unilamellar Vesicles", "OBSERVATION", 119, 139]]], ["As a first step, we successfully expressed KvAP (a voltage gated potassium channel) in E-coli.", [["potassium", "CHEMICAL", 65, 74], ["potassium", "CHEMICAL", 65, 74], ["KvAP", "GENE_OR_GENE_PRODUCT", 43, 47], ["E-coli", "GENE_OR_GENE_PRODUCT", 87, 93], ["KvAP", "PROTEIN", 43, 47], ["voltage gated potassium channel", "PROTEIN", 51, 82], ["E-coli", "SPECIES", 87, 93], ["a voltage gated potassium channel", "TEST", 49, 82]]], ["The channel was purified, fluorescently labelled and reconstituted in small liposomes.Reconstitution of fluorescent voltage gated ion channels in giant unilamellar vesiclesIts functionality was checked with electrophysiology via fusion of these liposomes into Black Lipid Membranes (BLM).", [["unilamellar", "ANATOMY", 152, 163], ["BLM", "ANATOMY", 283, 286], ["liposomes", "SIMPLE_CHEMICAL", 245, 254], ["BLM", "CELLULAR_COMPONENT", 283, 286], ["fluorescent voltage gated ion channels", "PROTEIN", 104, 142], ["fluorescent voltage gated ion channels in giant unilamellar vesiclesIts functionality", "PROBLEM", 104, 189], ["electrophysiology via fusion of these liposomes", "TREATMENT", 207, 254], ["Black Lipid Membranes", "TREATMENT", 260, 281], ["small liposomes", "OBSERVATION", 70, 85], ["fluorescent voltage", "OBSERVATION", 104, 123], ["giant", "OBSERVATION_MODIFIER", 146, 151], ["unilamellar vesiclesIts", "OBSERVATION", 152, 175], ["Lipid Membranes", "OBSERVATION", 266, 281]]], ["As a second step, GUVs were formed from these small proteoliposomes using electroformation in a buffer containing 100 mM KCl salt.", [["GUVs", "ANATOMY", 18, 22], ["KCl", "CHEMICAL", 121, 124], ["KCl", "CHEMICAL", 121, 124], ["GUVs", "SIMPLE_CHEMICAL", 18, 22], ["KCl salt", "SIMPLE_CHEMICAL", 121, 129], ["a buffer", "TREATMENT", 94, 102], ["100 mM KCl salt", "TREATMENT", 114, 129], ["small proteoliposomes", "OBSERVATION", 46, 67]]], ["The proper incorporation of proteins into GUVs was controlled using confocal microscopy.", [["GUVs", "ANATOMY", 42, 46], ["GUVs", "CELLULAR_COMPONENT", 42, 46], ["confocal microscopy", "TEST", 68, 87]]], ["Functional proteins were detected using the patch clamp technique.", [["Functional proteins", "PROBLEM", 0, 19], ["the patch clamp technique", "TREATMENT", 40, 65]]], ["With our protocol, we are thus able to prepare GUVs containing functional voltage-gated ion channels.", [["GUVs", "SIMPLE_CHEMICAL", 47, 51], ["functional voltage-gated ion channels", "PROTEIN", 63, 100], ["our protocol", "TREATMENT", 5, 17]]], ["One goal is now to study the effect of channel activity on its spatial distribution in these GUVs.O-394RyR activation in cultured SHR cardiomyocytes at the end of the prehypertensive period The rate of [Ca 2+ ] i elevation after the ryanodine receptor (RyR) activation by 4-chloro-m-cresol (4-CmC) and L-type Ca 2+ channels (DHPR) activation by Bay K8644 was studied in cultured (5 days) cardiomyocytes of spontaneously hypertensive (SHR) and normotensive rats (WKY, Wistar) during 6 weeks of postnatal development.", [["GUVs", "ANATOMY", 93, 97], ["SHR cardiomyocytes", "ANATOMY", 130, 148], ["cardiomyocytes", "ANATOMY", 388, 402], ["Ca", "CHEMICAL", 203, 205], ["ryanodine", "CHEMICAL", 233, 242], ["4-chloro-m-cresol", "CHEMICAL", 272, 289], ["4-CmC", "CHEMICAL", 291, 296], ["Ca", "CHEMICAL", 309, 311], ["hypertensive", "DISEASE", 420, 432], ["Ca 2+", "CHEMICAL", 203, 208], ["ryanodine", "CHEMICAL", 233, 242], ["4-chloro-m-cresol", "CHEMICAL", 272, 289], ["4-CmC", "CHEMICAL", 291, 296], ["Ca 2+", "CHEMICAL", 309, 314], ["Bay K8644", "CHEMICAL", 345, 354], ["O-394RyR", "GENE_OR_GENE_PRODUCT", 98, 106], ["SHR cardiomyocytes", "CELL", 130, 148], ["ryanodine receptor", "GENE_OR_GENE_PRODUCT", 233, 251], ["RyR", "GENE_OR_GENE_PRODUCT", 253, 256], ["4-chloro-m-cresol", "SIMPLE_CHEMICAL", 272, 289], ["4-CmC", "SIMPLE_CHEMICAL", 291, 296], ["L-type Ca 2+", "SIMPLE_CHEMICAL", 302, 314], ["DHPR", "GENE_OR_GENE_PRODUCT", 325, 329], ["Bay K8644", "SIMPLE_CHEMICAL", 345, 354], ["cardiomyocytes", "CELL", 388, 402], ["rats", "ORGANISM", 456, 460], ["WKY, Wistar", "ORGANISM", 462, 473], ["394RyR", "PROTEIN", 100, 106], ["cultured SHR cardiomyocytes", "CELL_LINE", 121, 148], ["ryanodine receptor", "PROTEIN", 233, 251], ["RyR", "PROTEIN", 253, 256], ["L-type Ca 2+ channels", "PROTEIN", 302, 323], ["DHPR", "PROTEIN", 325, 329], ["rats", "SPECIES", 456, 460], ["channel activity", "TREATMENT", 39, 55], ["R activation", "PROBLEM", 105, 117], ["cultured SHR cardiomyocytes", "PROBLEM", 121, 148], ["the prehypertensive period", "TREATMENT", 163, 189], ["The rate", "TEST", 190, 198], ["Ca", "TEST", 203, 205], ["i elevation", "PROBLEM", 211, 222], ["the ryanodine receptor", "TREATMENT", 229, 251], ["activation", "TEST", 258, 268], ["chloro", "TEST", 274, 280], ["L-type Ca 2+ channels (DHPR) activation", "TREATMENT", 302, 341], ["cardiomyocytes", "PROBLEM", 388, 402], ["spontaneously hypertensive (SHR)", "PROBLEM", 406, 438], ["normotensive rats", "PROBLEM", 443, 460], ["postnatal development", "PROBLEM", 493, 514]]], ["The differences in DH-PRs and RyRs activities began to be evident after 3 weeks age when CICR formation has finished and became more expressed at the end of prehypertensive period (6 weeks).", [["DH-PRs", "GENE_OR_GENE_PRODUCT", 19, 25], ["RyRs", "SIMPLE_CHEMICAL", 30, 34], ["DH", "PROTEIN", 19, 21], ["CICR formation", "PROBLEM", 89, 103]]], ["In response to 4-CmC (2 mM), a drastic increase in the rate of [Ca 2+ ] i accumulation (2.85\u00b10.8 times) in SHR myocytes was registered after 20 days age versus a decrease in the rates of Ca 2+ efflux from the sarcoplasmic reticulum of Wistar and WKY rat cardiomyocytes.", [["SHR myocytes", "ANATOMY", 107, 119], ["sarcoplasmic reticulum", "ANATOMY", 209, 231], ["cardiomyocytes", "ANATOMY", 254, 268], ["4-CmC", "CHEMICAL", 15, 20], ["Ca", "CHEMICAL", 64, 66], ["Ca", "CHEMICAL", 187, 189], ["4-CmC", "CHEMICAL", 15, 20], ["Ca 2+ ] i", "CHEMICAL", 64, 73], ["Ca 2+", "CHEMICAL", 187, 192], ["4-CmC", "SIMPLE_CHEMICAL", 15, 20], ["SHR myocytes", "CELL", 107, 119], ["Ca 2+", "SIMPLE_CHEMICAL", 187, 192], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 209, 231], ["WKY rat", "ORGANISM", 246, 253], ["cardiomyocytes", "CELL", 254, 268], ["Wistar and WKY rat cardiomyocytes", "CELL_TYPE", 235, 268], ["rat", "SPECIES", 250, 253], ["rat", "SPECIES", 250, 253], ["a drastic increase", "PROBLEM", 29, 47], ["the rate", "TEST", 51, 59], ["Ca 2+ ] i accumulation", "PROBLEM", 64, 86], ["SHR myocytes", "PROBLEM", 107, 119], ["a decrease", "PROBLEM", 160, 170], ["Ca", "TEST", 187, 189], ["efflux", "PROBLEM", 193, 199], ["drastic", "OBSERVATION_MODIFIER", 31, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["SHR myocytes", "ANATOMY", 107, 119], ["decrease", "OBSERVATION_MODIFIER", 162, 170], ["sarcoplasmic reticulum", "ANATOMY", 209, 231], ["cardiomyocytes", "ANATOMY", 254, 268]]], ["BayK (80 \u00b5M) also induced more sharp [Ca 2+ ] i elevation in SHR myocytes (3.35\u00b10.25 times) as compared with Wistar (2.32\u00b10.16 times) and WKY (1.22\u00b10.09 times) ones of the same age.", [["SHR myocytes", "ANATOMY", 61, 73], ["BayK", "CHEMICAL", 0, 4], ["Ca", "CHEMICAL", 38, 40], ["BayK", "CHEMICAL", 0, 4], ["Ca 2+", "CHEMICAL", 38, 43], ["BayK", "SIMPLE_CHEMICAL", 0, 4], ["SHR myocytes", "CELL", 61, 73], ["i elevation in SHR myocytes", "PROBLEM", 46, 73], ["Wistar", "TEST", 109, 115], ["WKY", "TEST", 138, 141], ["SHR myocytes", "ANATOMY", 61, 73]]], ["Our results argue that in SHR and WKY cardiomyocytes, as opposed to normotensive Wistar rats, gradual growth of DHPR activity is observed, which follows in parallel with CICR formation in the excitation-contraction coupling during early postnatal ontogenesis, and drastic activation of RyR2 in SHR myocytes after the process termination.", [["WKY cardiomyocytes", "ANATOMY", 34, 52], ["SHR myocytes", "ANATOMY", 294, 306], ["SHR", "CELL", 26, 29], ["WKY cardiomyocytes", "CELL", 34, 52], ["Wistar rats", "ORGANISM", 81, 92], ["DHPR", "GENE_OR_GENE_PRODUCT", 112, 116], ["CICR", "SIMPLE_CHEMICAL", 170, 174], ["RyR2", "GENE_OR_GENE_PRODUCT", 286, 290], ["SHR myocytes", "CELL", 294, 306], ["SHR and WKY cardiomyocytes", "CELL_LINE", 26, 52], ["DHPR", "PROTEIN", 112, 116], ["RyR2", "PROTEIN", 286, 290], ["rats", "SPECIES", 88, 92], ["WKY", "SPECIES", 34, 37], ["gradual growth of DHPR activity", "PROBLEM", 94, 125], ["contraction coupling", "PROBLEM", 203, 223], ["early postnatal ontogenesis", "PROBLEM", 231, 258], ["drastic activation of RyR2 in SHR myocytes", "PROBLEM", 264, 306], ["cardiomyocytes", "ANATOMY", 38, 52], ["gradual", "OBSERVATION_MODIFIER", 94, 101], ["growth", "OBSERVATION_MODIFIER", 102, 108], ["DHPR activity", "OBSERVATION", 112, 125]]], ["Cytochrome ba 3 from Thermus thermophilus belongs to the large family of structurally related heme-copper oxidases.", [["copper", "CHEMICAL", 99, 105], ["heme", "CHEMICAL", 94, 98], ["copper", "CHEMICAL", 99, 105], ["Cytochrome ba 3", "GENE_OR_GENE_PRODUCT", 0, 15], ["Thermus thermophilus", "ORGANISM", 21, 41], ["heme-copper oxidases", "SIMPLE_CHEMICAL", 94, 114], ["Cytochrome ba 3", "PROTEIN", 0, 15], ["heme", "PROTEIN", 94, 98], ["copper oxidases", "PROTEIN", 99, 114], ["Thermus thermophilus", "SPECIES", 21, 41], ["Thermus thermophilus", "SPECIES", 21, 41], ["Cytochrome ba", "TREATMENT", 0, 13]]], ["It accepts electrons from cytochrome c 552 at the P-side of the membrane and uses them to reduce oxygen to water.", [["membrane", "ANATOMY", 64, 72], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 97, 103], ["cytochrome c 552", "GENE_OR_GENE_PRODUCT", 26, 42], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["water", "SIMPLE_CHEMICAL", 107, 112], ["cytochrome c 552", "PROTEIN", 26, 42], ["oxygen", "TREATMENT", 97, 103]]], ["The energy released in this reaction is used for proton pumping across the membrane to form of an electrochemical proton gradient, used by the cell for formation of ATP.", [["membrane", "ANATOMY", 75, 83], ["cell", "ANATOMY", 143, 147], ["ATP", "CHEMICAL", 165, 168], ["ATP", "CHEMICAL", 165, 168], ["proton", "SIMPLE_CHEMICAL", 49, 55], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["cell", "CELL", 143, 147], ["ATP", "SIMPLE_CHEMICAL", 165, 168], ["this reaction", "PROBLEM", 23, 36], ["proton pumping across the membrane", "TREATMENT", 49, 83], ["an electrochemical proton gradient", "TREATMENT", 95, 129], ["ATP", "PROBLEM", 165, 168], ["proton gradient", "OBSERVATION", 114, 129]]], ["In this work we followed the kinetics of single-electron injection into the oxidized nonrelaxed state (O H \u2192E H ) of cytochrome ba 3 by time-resolved optical spectroscopy.", [["O H \u2192E H", "CHEMICAL", 103, 111], ["cytochrome ba 3", "GENE_OR_GENE_PRODUCT", 117, 132], ["O H \u2192E H", "PROTEIN", 103, 111], ["cytochrome ba 3", "PROTEIN", 117, 132], ["single-electron injection", "TREATMENT", 41, 66], ["cytochrome ba", "TEST", 117, 130], ["optical spectroscopy", "TEST", 150, 170]]], ["Two main phases of electron transfer were resolved.", [["electron", "SIMPLE_CHEMICAL", 19, 27], ["main", "OBSERVATION_MODIFIER", 4, 8], ["phases", "OBSERVATION_MODIFIER", 9, 15]]], ["The first (\u03c4\u223c17 \u00b5s) includes oxidation of Cu A and simultaneous reduction of both low and high spin hemes.", [["Cu", "CHEMICAL", 42, 44], ["Cu A", "CHEMICAL", 42, 46], ["Cu A", "SIMPLE_CHEMICAL", 42, 46], ["simultaneous reduction", "TREATMENT", 51, 73], ["both low and high spin hemes", "PROBLEM", 77, 105], ["both", "OBSERVATION_MODIFIER", 77, 81], ["low", "OBSERVATION_MODIFIER", 82, 85], ["high spin hemes", "OBSERVATION", 90, 105]]], ["The second (\u03c4\u223c420 \u00b5s) reflects reoxidation of both hemes by Cu B .", [["Cu B", "CHEMICAL", 60, 64], ["Cu B", "CHEMICAL", 60, 64], ["hemes", "SIMPLE_CHEMICAL", 51, 56], ["Cu B", "SIMPLE_CHEMICAL", 60, 64], ["hemes", "PROTEIN", 51, 56], ["Cu B", "PROTEIN", 60, 64], ["both hemes", "OBSERVATION", 46, 56]]], ["This is in significant contrast to the O H \u2192E H transition of aa 3 -type oxidases, where the fastest phase is due to transient reduction of the low-spin heme a only.", [["O H", "CHEMICAL", 39, 42], ["H", "CHEMICAL", 46, 47], ["heme", "CHEMICAL", 153, 157], ["aa 3 -type oxidases", "PROTEIN", 62, 81], ["low-spin heme", "PROTEIN", 144, 157], ["transient reduction", "PROBLEM", 117, 136], ["transient", "OBSERVATION_MODIFIER", 117, 126], ["reduction", "OBSERVATION", 127, 136]]], ["On the other hand, the single-electron reduction of the relaxed O state in ba 3 oxidase consisted of only rapid electron transfer from Cu A to heme b, which is similar to that in aa 3 oxidase.", [["Cu", "CHEMICAL", 135, 137], ["O", "CHEMICAL", 64, 65], ["ba 3", "CHEMICAL", 75, 79], ["Cu A", "CHEMICAL", 135, 139], ["heme", "CHEMICAL", 143, 147], ["ba 3 oxidase", "GENE_OR_GENE_PRODUCT", 75, 87], ["electron", "SIMPLE_CHEMICAL", 112, 120], ["Cu A", "SIMPLE_CHEMICAL", 135, 139], ["heme b", "SIMPLE_CHEMICAL", 143, 149], ["aa 3 oxidase", "GENE_OR_GENE_PRODUCT", 179, 191], ["O state", "PROTEIN", 64, 71], ["ba 3 oxidase", "PROTEIN", 75, 87], ["heme b", "PROTEIN", 143, 149], ["aa 3 oxidase", "PROTEIN", 179, 191]]], ["This indicates a functional difference between the relaxed O and the pulsed O H states of cytochrome ba 3 .P-400As opposed to the phospholamban pentamer, sarcolipin forms anion-selective channels in biomembranes L. Becucci 1 , C. B. Karim 3 , D. D. Thomas 3 , G. Veglia 2 , R. Guidelli 1 1 Chemistry Department, Florence University, 50019 Florence,Italy, 2 Chemistry Department, University of Minnesota, Minneapolis, MN 55455, 3 3Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455 Sarcolipin (SLN) and the phospholamban pentamer (PLN) are two membrane proteins that inhibit Ca-ATPase of the sarcoplasmic reticulum at low concentrations.", [["membrane", "ANATOMY", 602, 610], ["sarcoplasmic reticulum", "ANATOMY", 650, 672], [".P-400As", "CHEMICAL", 106, 114], ["sarcolipin", "CHEMICAL", 154, 164], ["Sarcolipin", "CHEMICAL", 540, 550], ["O", "CHEMICAL", 59, 60], ["O H", "CHEMICAL", 76, 79], ["sarcolipin", "CHEMICAL", 154, 164], ["cytochrome ba 3", "GENE_OR_GENE_PRODUCT", 90, 105], ["phospholamban", "GENE_OR_GENE_PRODUCT", 130, 143], ["sarcolipin", "SIMPLE_CHEMICAL", 154, 164], ["anion", "SIMPLE_CHEMICAL", 171, 176], ["phospholamban pentamer", "GENE_OR_GENE_PRODUCT", 565, 587], ["PLN", "GENE_OR_GENE_PRODUCT", 589, 592], ["Ca-ATPase", "GENE_OR_GENE_PRODUCT", 633, 642], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 650, 672], ["cytochrome ba 3 .P-400As", "PROTEIN", 90, 114], ["phospholamban pentamer", "PROTEIN", 130, 152], ["phospholamban pentamer", "PROTEIN", 565, 587], ["PLN", "PROTEIN", 589, 592], ["membrane proteins", "PROTEIN", 602, 619], ["Ca-ATPase", "PROTEIN", 633, 642], ["a functional difference", "PROBLEM", 15, 38], ["cytochrome ba", "TEST", 90, 103], ["the phospholamban pentamer", "TEST", 126, 152], ["anion", "TEST", 171, 176], ["MN", "TREATMENT", 531, 533], ["Sarcolipin (SLN", "TREATMENT", 540, 555], ["the phospholamban pentamer (PLN", "TREATMENT", 561, 592], ["two membrane proteins", "TREATMENT", 598, 619], ["the sarcoplasmic reticulum", "PROBLEM", 646, 672], ["functional difference", "OBSERVATION", 17, 38], ["sarcoplasmic reticulum", "OBSERVATION", 650, 672], ["low concentrations", "OBSERVATION_MODIFIER", 676, 694]]], ["In contrast to PLN, SLN stimulates maximal Ca 2+ uptake rates.", [["PLN", "ANATOMY", 15, 18], ["Ca", "CHEMICAL", 43, 45], ["Ca 2+", "CHEMICAL", 43, 48], ["PLN", "GENE_OR_GENE_PRODUCT", 15, 18], ["Ca 2+", "SIMPLE_CHEMICAL", 43, 48], ["PLN", "PROTEIN", 15, 18], ["SLN", "TEST", 20, 23], ["uptake rates", "TEST", 49, 61], ["PLN", "ANATOMY", 15, 18], ["SLN", "ANATOMY", 20, 23]]], ["SLN and PLN were incorporated in a bilayer lipid membrane (tBLM) tethered to a mercury electrode through a hydrophilic spacer.", [["PLN", "ANATOMY", 8, 11], ["bilayer lipid membrane", "ANATOMY", 35, 57], ["tBLM", "ANATOMY", 59, 63], ["mercury", "CHEMICAL", 79, 86], ["mercury", "CHEMICAL", 79, 86], ["SLN", "MULTI-TISSUE_STRUCTURE", 0, 3], ["PLN", "GENE_OR_GENE_PRODUCT", 8, 11], ["PLN", "PROTEIN", 8, 11], ["SLN", "TREATMENT", 0, 3], ["PLN", "TREATMENT", 8, 11], ["a bilayer lipid membrane", "TREATMENT", 33, 57], ["a mercury electrode", "TREATMENT", 77, 96], ["a hydrophilic spacer", "TREATMENT", 105, 125], ["PLN", "OBSERVATION", 8, 11], ["hydrophilic spacer", "OBSERVATION", 107, 125]]], ["Electrochemical impedance spectroscopy measurements show that SLN forms channels permeable to chloride ion, weakly permeable to phosphate ion and impermeable to inorganic cations such as Na + and K + .", [["chloride", "CHEMICAL", 94, 102], ["phosphate", "CHEMICAL", 128, 137], ["Na", "CHEMICAL", 187, 189], ["K", "CHEMICAL", 196, 197], ["chloride", "CHEMICAL", 94, 102], ["phosphate", "CHEMICAL", 128, 137], ["Na +", "CHEMICAL", 187, 191], ["K +", "CHEMICAL", 196, 199], ["SLN", "SIMPLE_CHEMICAL", 62, 65], ["chloride ion", "SIMPLE_CHEMICAL", 94, 106], ["phosphate ion", "SIMPLE_CHEMICAL", 128, 141], ["inorganic cations", "SIMPLE_CHEMICAL", 161, 178], ["Na +", "SIMPLE_CHEMICAL", 187, 191], ["K +", "SIMPLE_CHEMICAL", 196, 199], ["Electrochemical impedance spectroscopy measurements", "TEST", 0, 51], ["SLN forms channels", "PROBLEM", 62, 80], ["phosphate ion", "TREATMENT", 128, 141], ["inorganic cations", "TREATMENT", 161, 178], ["Na", "TEST", 187, 189], ["K", "TEST", 196, 197]]], ["A relationship between this property of SLN and its regulatory function on Ca-ATPase of sarcoplasmic reticulum is proposed.", [["sarcoplasmic reticulum", "ANATOMY", 88, 110], ["SLN", "MULTI-TISSUE_STRUCTURE", 40, 43], ["Ca-ATPase", "GENE_OR_GENE_PRODUCT", 75, 84], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 88, 110], ["Ca-ATPase", "PROTEIN", 75, 84], ["SLN", "TREATMENT", 40, 43], ["SLN", "OBSERVATION", 40, 43], ["sarcoplasmic reticulum", "OBSERVATION", 88, 110]]], ["ATP increases the permeability of a tBLM incorporating SLN to phosphate ion by associating to SLN with an association constant of 0.1 \u00b5M.", [["ATP", "CHEMICAL", 0, 3], ["phosphate", "CHEMICAL", 62, 71], ["ATP", "CHEMICAL", 0, 3], ["phosphate", "CHEMICAL", 62, 71], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["tBLM", "SIMPLE_CHEMICAL", 36, 40], ["phosphate ion", "SIMPLE_CHEMICAL", 62, 75], ["ATP", "PROBLEM", 0, 3], ["a tBLM incorporating SLN to phosphate ion", "TREATMENT", 34, 75], ["increases", "OBSERVATION_MODIFIER", 4, 13], ["permeability", "OBSERVATION_MODIFIER", 18, 30], ["SLN", "ANATOMY", 94, 97]]], ["SLN can be identified with the \" P i transporter\" described by A.G. Lee et al. Conversely, both electrochemical impedance spectroscopy measurements and molecular dynamics simulations provide strong evidence that the pore of the pentameric form of PLN does not act as a chloride channel.P-399\"Social\" domain organization and dynamics of nicotinic acetylcholine receptor at the cell membrane F. J. Barrantes UNESCO Chair Biophys. & Mol.", [["pore", "ANATOMY", 216, 220], ["cell membrane", "ANATOMY", 376, 389], ["chloride", "CHEMICAL", 269, 277], ["acetylcholine", "CHEMICAL", 346, 359], ["chloride", "CHEMICAL", 269, 277], ["acetylcholine", "CHEMICAL", 346, 359], ["pore", "CELLULAR_COMPONENT", 216, 220], ["PLN", "GENE_OR_GENE_PRODUCT", 247, 250], ["chloride", "SIMPLE_CHEMICAL", 269, 277], ["nicotinic acetylcholine receptor", "GENE_OR_GENE_PRODUCT", 336, 368], ["cell", "CELL", 376, 380], ["P i transporter", "PROTEIN", 33, 48], ["PLN", "PROTEIN", 247, 250], ["P", "DNA", 286, 287], ["nicotinic acetylcholine receptor", "PROTEIN", 336, 368], ["both electrochemical impedance spectroscopy measurements", "TEST", 91, 147], ["molecular dynamics simulations", "TEST", 152, 182], ["nicotinic acetylcholine receptor", "TREATMENT", 336, 368], ["PLN", "OBSERVATION", 247, 250]]], ["Univ.", [["Univ", "TREATMENT", 0, 4]]], ["Nac.", [["Nac", "GENE_OR_GENE_PRODUCT", 0, 3], ["Nac", "PROTEIN", 0, 3], ["Nac", "TREATMENT", 0, 3]]], ["Sur, 8000 B. Blanca, Argentina A combination of experimental techniques (patch-clamp, confocal FRAP and FCS, single-particle tracking, highresolution fluorescence microscopy) has been used to analyze the supramolecular organization of the acetylcholine receptor (AChR), the dynamics of the receptor at the cell surface, and the kinetics of receptor internalization.", [["cell surface", "ANATOMY", 306, 318], ["acetylcholine", "CHEMICAL", 239, 252], ["acetylcholine", "CHEMICAL", 239, 252], ["acetylcholine receptor", "GENE_OR_GENE_PRODUCT", 239, 261], ["AChR", "GENE_OR_GENE_PRODUCT", 263, 267], ["cell surface", "CELLULAR_COMPONENT", 306, 318], ["acetylcholine receptor", "PROTEIN", 239, 261], ["AChR", "PROTEIN", 263, 267], ["experimental techniques (patch-clamp", "TREATMENT", 48, 84], ["FCS", "TREATMENT", 104, 107], ["highresolution fluorescence microscopy", "TEST", 135, 173], ["the acetylcholine receptor", "TREATMENT", 235, 261], ["receptor internalization", "TREATMENT", 340, 364], ["cell surface", "OBSERVATION", 306, 318]]], ["Changes in cholesterol (Chol) content affected muscle and neuronal-type AChR organization and dynamics at the cell surface.", [["muscle", "ANATOMY", 47, 53], ["neuronal", "ANATOMY", 58, 66], ["cell surface", "ANATOMY", 110, 122], ["cholesterol", "CHEMICAL", 11, 22], ["Chol", "CHEMICAL", 24, 28], ["cholesterol", "CHEMICAL", 11, 22], ["Chol", "CHEMICAL", 24, 28], ["cholesterol", "SIMPLE_CHEMICAL", 11, 22], ["Chol", "SIMPLE_CHEMICAL", 24, 28], ["muscle", "ORGAN", 47, 53], ["neuronal", "CELL", 58, 66], ["AChR", "GENE_OR_GENE_PRODUCT", 72, 76], ["cell surface", "CELLULAR_COMPONENT", 110, 122], ["AChR", "PROTEIN", 72, 76], ["Changes in cholesterol (Chol) content affected muscle", "PROBLEM", 0, 53], ["type AChR organization", "PROBLEM", 67, 89], ["muscle", "ANATOMY", 47, 53], ["neuronal", "ANATOMY", 58, 66], ["AChR organization", "OBSERVATION", 72, 89], ["cell", "OBSERVATION_MODIFIER", 110, 114], ["surface", "OBSERVATION_MODIFIER", 115, 122]]], ["Chol depletion produced gain-of-function of single-channel dwell time.", [["Chol", "CHEMICAL", 0, 4], ["Chol", "CHEMICAL", 0, 4], ["Chol", "SIMPLE_CHEMICAL", 0, 4], ["Chol depletion", "PROBLEM", 0, 14], ["single-channel dwell time", "TREATMENT", 44, 69], ["depletion", "OBSERVATION", 5, 14]]], ["Submicron-sized (\u223c250 nm) domains, stable over a period of hours at the cell membrane, could be resolved into AChR \"nano-clusters\" with a peak size distribution of \u223c55 nm by STED microscopy.", [["cell membrane", "ANATOMY", 72, 85], ["cell membrane", "CELLULAR_COMPONENT", 72, 85], ["AChR", "GENE_OR_GENE_PRODUCT", 110, 114], ["AChR", "PROTEIN", 110, 114], ["Submicron", "TEST", 0, 9], ["a peak size distribution", "TEST", 136, 160], ["STED microscopy", "TEST", 174, 189], ["sized", "OBSERVATION_MODIFIER", 10, 15], ["stable", "OBSERVATION_MODIFIER", 35, 41], ["cell membrane", "OBSERVATION", 72, 85], ["peak", "OBSERVATION_MODIFIER", 138, 142], ["size", "OBSERVATION_MODIFIER", 143, 147]]], ["Chol depletion reduced the number of nanoclusters, increasing their size, and changed their supramolecular \"social\" organization on larger scales (0.5-3.5 microns).", [["Chol", "CHEMICAL", 0, 4], ["Chol", "CHEMICAL", 0, 4], ["Chol", "SIMPLE_CHEMICAL", 0, 4], ["Chol depletion", "PROBLEM", 0, 14], ["depletion", "OBSERVATION", 5, 14], ["reduced", "OBSERVATION_MODIFIER", 15, 22], ["number", "OBSERVATION_MODIFIER", 27, 33], ["nanoclusters", "OBSERVATION_MODIFIER", 37, 49], ["increasing", "OBSERVATION_MODIFIER", 51, 61], ["size", "OBSERVATION_MODIFIER", 68, 72], ["supramolecular", "OBSERVATION_MODIFIER", 92, 106], ["\"", "OBSERVATION_MODIFIER", 107, 108], ["social", "OBSERVATION_MODIFIER", 108, 114]]], ["FRAP, FCS and SPT experiments provided information on the dynamics of AChR nanoclusters, disclosing the dependence of their mobility on Chol content and cortical cytoskeleton.", [["cortical cytoskeleton", "ANATOMY", 153, 174], ["Chol", "CHEMICAL", 136, 140], ["Chol", "CHEMICAL", 136, 140], ["AChR", "GENE_OR_GENE_PRODUCT", 70, 74], ["Chol", "SIMPLE_CHEMICAL", 136, 140], ["cortical cytoskeleton", "CELLULAR_COMPONENT", 153, 174], ["FRAP", "TEST", 0, 4], ["SPT experiments", "TEST", 14, 29], ["AChR nanoclusters", "TREATMENT", 70, 87], ["cortical cytoskeleton", "OBSERVATION", 153, 174]]], ["Chol content at the plasmalemma may thus modulate cell-surface organization and dynamics of receptor domains, and fine-tune receptor channel function to temporarily compensate for acute AChR losses from the cell surface.Pirolid protects MCF-7 cancer cells against oxidative stress induced by doxorubicin and paclitaxelM.", [["plasmalemma", "ANATOMY", 20, 31], ["cell", "ANATOMY", 50, 54], ["surface", "ANATOMY", 55, 62], ["cell surface", "ANATOMY", 207, 219], ["MCF-7 cancer cells", "ANATOMY", 237, 255], ["Chol", "CHEMICAL", 0, 4], ["Pirolid", "CHEMICAL", 220, 227], ["cancer", "DISEASE", 243, 249], ["doxorubicin", "CHEMICAL", 292, 303], ["paclitaxelM", "CHEMICAL", 308, 319], ["Chol", "CHEMICAL", 0, 4], ["doxorubicin", "CHEMICAL", 292, 303], ["paclitaxelM", "CHEMICAL", 308, 319], ["Chol", "SIMPLE_CHEMICAL", 0, 4], ["plasmalemma", "CELLULAR_COMPONENT", 20, 31], ["cell", "CELL", 50, 54], ["surface", "CELLULAR_COMPONENT", 55, 62], ["AChR", "GENE_OR_GENE_PRODUCT", 186, 190], ["cell surface", "CELLULAR_COMPONENT", 207, 219], ["Pirolid", "SIMPLE_CHEMICAL", 220, 227], ["MCF-7 cancer cells", "CELL", 237, 255], ["doxorubicin", "SIMPLE_CHEMICAL", 292, 303], ["paclitaxelM", "SIMPLE_CHEMICAL", 308, 319], ["receptor domains", "PROTEIN", 92, 108], ["AChR", "PROTEIN", 186, 190], ["MCF-7 cancer cells", "CELL_LINE", 237, 255], ["MCF-7", "SPECIES", 237, 242], ["Chol content", "PROBLEM", 0, 12], ["receptor domains", "TEST", 92, 108], ["acute AChR losses from the cell surface", "PROBLEM", 180, 219], ["Pirolid protects MCF", "TREATMENT", 220, 240], ["cancer cells", "PROBLEM", 243, 255], ["oxidative stress", "PROBLEM", 264, 280], ["doxorubicin", "TREATMENT", 292, 303], ["paclitaxelM", "TREATMENT", 308, 319], ["plasmalemma", "ANATOMY_MODIFIER", 20, 31], ["may thus", "UNCERTAINTY", 32, 40], ["modulate cell", "OBSERVATION", 41, 54], ["surface", "OBSERVATION_MODIFIER", 55, 62], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["AChR", "OBSERVATION", 186, 190], ["cell surface", "OBSERVATION", 207, 219]]], ["Czaplinska, K. Gwozdzinski, A. Koceva-Chyla Division of Research of Structure of Biopolymers University of Lodz, Lodz, Poland Doxorubicin (DOX) and paclitaxel (PTX) are anticancer drugs commonly used in chemotherapy of breast cancer therapy, however, the use of these drugs is limited by the risk of developing heart failure.", [["anticancer", "ANATOMY", 169, 179], ["breast cancer", "ANATOMY", 219, 232], ["heart", "ANATOMY", 311, 316], ["Doxorubicin", "CHEMICAL", 126, 137], ["DOX", "CHEMICAL", 139, 142], ["paclitaxel", "CHEMICAL", 148, 158], ["PTX", "CHEMICAL", 160, 163], ["breast cancer", "DISEASE", 219, 232], ["heart failure", "DISEASE", 311, 324], ["Doxorubicin", "CHEMICAL", 126, 137], ["DOX", "CHEMICAL", 139, 142], ["paclitaxel", "CHEMICAL", 148, 158], ["PTX", "CHEMICAL", 160, 163], ["Doxorubicin", "SIMPLE_CHEMICAL", 126, 137], ["DOX", "SIMPLE_CHEMICAL", 139, 142], ["paclitaxel", "SIMPLE_CHEMICAL", 148, 158], ["PTX", "SIMPLE_CHEMICAL", 160, 163], ["anticancer", "CANCER", 169, 179], ["breast cancer", "CANCER", 219, 232], ["heart", "ORGAN", 311, 316], ["Gwozdzinski", "TREATMENT", 15, 26], ["Poland Doxorubicin (DOX)", "TREATMENT", 119, 143], ["paclitaxel (PTX", "TREATMENT", 148, 163], ["anticancer drugs", "TREATMENT", 169, 185], ["chemotherapy of breast cancer therapy", "TREATMENT", 203, 240], ["these drugs", "TREATMENT", 262, 273], ["developing heart failure", "PROBLEM", 300, 324], ["breast", "ANATOMY", 219, 225], ["cancer", "OBSERVATION", 226, 232], ["heart", "ANATOMY", 311, 316], ["failure", "OBSERVATION", 317, 324]]], ["Generation of reactive oxygen species contributes to the cardiotoxicity of doxorubicin.", [["oxygen", "CHEMICAL", 23, 29], ["cardiotoxicity", "DISEASE", 57, 71], ["doxorubicin", "CHEMICAL", 75, 86], ["oxygen", "CHEMICAL", 23, 29], ["doxorubicin", "CHEMICAL", 75, 86], ["reactive oxygen species", "SIMPLE_CHEMICAL", 14, 37], ["doxorubicin", "SIMPLE_CHEMICAL", 75, 86], ["reactive oxygen species", "PROBLEM", 14, 37], ["doxorubicin", "TREATMENT", 75, 86], ["reactive", "OBSERVATION_MODIFIER", 14, 22], ["oxygen species", "OBSERVATION", 23, 37]]], ["Nitroxides are low molecular weight, stable free radicals reacting with ROS and they present antioxidant properties.", [["Nitroxides", "CHEMICAL", 0, 10], ["ROS", "CHEMICAL", 72, 75], ["Nitroxides", "CHEMICAL", 0, 10], ["Nitroxides", "SIMPLE_CHEMICAL", 0, 10], ["free radicals", "SIMPLE_CHEMICAL", 44, 57], ["ROS", "SIMPLE_CHEMICAL", 72, 75], ["Nitroxides", "TREATMENT", 0, 10]]], ["The aim of this study was to analyze the effects of Pirolid (PD) on the oxidative stress induced by DOX and taxane in MCF-7 breast cancer cell line.", [["MCF-7 breast cancer cell line", "ANATOMY", 118, 147], ["Pirolid", "CHEMICAL", 52, 59], ["PD", "CHEMICAL", 61, 63], ["DOX", "CHEMICAL", 100, 103], ["taxane", "CHEMICAL", 108, 114], ["breast cancer", "DISEASE", 124, 137], ["Pirolid", "CHEMICAL", 52, 59], ["DOX", "CHEMICAL", 100, 103], ["taxane", "CHEMICAL", 108, 114], ["Pirolid", "SIMPLE_CHEMICAL", 52, 59], ["DOX", "SIMPLE_CHEMICAL", 100, 103], ["taxane", "SIMPLE_CHEMICAL", 108, 114], ["MCF-7 breast cancer cell line", "CELL", 118, 147], ["MCF-7 breast cancer cell line", "CELL_LINE", 118, 147], ["MCF-7", "SPECIES", 118, 123], ["this study", "TEST", 11, 21], ["Pirolid (PD)", "TREATMENT", 52, 64], ["the oxidative stress", "TREATMENT", 68, 88], ["DOX", "TREATMENT", 100, 103], ["taxane in MCF", "TREATMENT", 108, 121], ["breast cancer cell line", "TREATMENT", 124, 147], ["breast", "ANATOMY", 124, 130], ["cancer", "OBSERVATION", 131, 137], ["cell line", "OBSERVATION", 138, 147]]], ["Results from MTT test revealed that PTX is more cytotoxic towards MCF-7 cells than DOX.", [["MCF-7 cells", "ANATOMY", 66, 77], ["PTX", "CHEMICAL", 36, 39], ["DOX", "CHEMICAL", 83, 86], ["MTT", "CHEMICAL", 13, 16], ["PTX", "CHEMICAL", 36, 39], ["DOX", "CHEMICAL", 83, 86], ["PTX", "SIMPLE_CHEMICAL", 36, 39], ["MCF-7 cells", "CELL", 66, 77], ["DOX", "SIMPLE_CHEMICAL", 83, 86], ["MCF-7 cells", "CELL_LINE", 66, 77], ["MTT test", "TEST", 13, 21], ["PTX", "PROBLEM", 36, 39], ["MCF", "TEST", 66, 69], ["DOX", "TEST", 83, 86], ["PTX", "OBSERVATION", 36, 39]]], ["PD alone does not influence cell viability.", [["cell", "ANATOMY", 28, 32], ["PD", "DISEASE", 0, 2], ["cell", "CELL", 28, 32], ["PD", "TREATMENT", 0, 2], ["cell viability", "OBSERVATION", 28, 42]]], ["PD in combination with both drugs did not change viability of cells.", [["cells", "ANATOMY", 62, 67], ["PD", "DISEASE", 0, 2], ["cells", "CELL", 62, 67], ["PD", "TREATMENT", 0, 2], ["both drugs", "TREATMENT", 23, 33]]], ["Both drugs increased the level of carbonyl groups in cells.", [["cells", "ANATOMY", 53, 58], ["carbonyl", "CHEMICAL", 34, 42], ["carbonyl", "CHEMICAL", 34, 42], ["carbonyl", "SIMPLE_CHEMICAL", 34, 42], ["cells", "CELL", 53, 58], ["Both drugs", "TREATMENT", 0, 10], ["carbonyl groups in cells", "TREATMENT", 34, 58], ["drugs", "OBSERVATION", 5, 10], ["carbonyl groups", "OBSERVATION", 34, 49]]], ["The highest level of peroxide was observed in cells incubated with DOX (approx.", [["cells", "ANATOMY", 46, 51], ["peroxide", "CHEMICAL", 21, 29], ["DOX", "CHEMICAL", 67, 70], ["peroxide", "CHEMICAL", 21, 29], ["DOX", "CHEMICAL", 67, 70], ["peroxide", "SIMPLE_CHEMICAL", 21, 29], ["cells", "CELL", 46, 51], ["DOX", "SIMPLE_CHEMICAL", 67, 70], ["DOX", "TREATMENT", 67, 70]]], ["Nitroxide alone did not influence the level of peroxide in the whole range of concentrations.", [["Nitroxide", "CHEMICAL", 0, 9], ["peroxide", "CHEMICAL", 47, 55], ["Nitroxide", "CHEMICAL", 0, 9], ["peroxide", "CHEMICAL", 47, 55], ["Nitroxide", "SIMPLE_CHEMICAL", 0, 9], ["peroxide", "SIMPLE_CHEMICAL", 47, 55], ["Nitroxide", "TREATMENT", 0, 9], ["peroxide", "TREATMENT", 47, 55]]], ["Combination of PD with DOX and PTX reduced the level of carbonyls depending on its concentration.", [["PD", "DISEASE", 15, 17], ["DOX", "CHEMICAL", 23, 26], ["PTX", "CHEMICAL", 31, 34], ["carbonyls", "CHEMICAL", 56, 65], ["DOX", "CHEMICAL", 23, 26], ["PTX", "CHEMICAL", 31, 34], ["carbonyls", "CHEMICAL", 56, 65], ["DOX", "SIMPLE_CHEMICAL", 23, 26], ["PTX", "SIMPLE_CHEMICAL", 31, 34], ["carbonyls", "SIMPLE_CHEMICAL", 56, 65], ["PD", "TREATMENT", 15, 17], ["DOX", "TREATMENT", 23, 26], ["PTX", "TREATMENT", 31, 34], ["carbonyls", "TREATMENT", 56, 65]]], ["PD did not affected on the level of peroxide in cells suspension.", [["cells", "ANATOMY", 48, 53], ["PD", "DISEASE", 0, 2], ["peroxide", "CHEMICAL", 36, 44], ["peroxide", "CHEMICAL", 36, 44], ["peroxide", "SIMPLE_CHEMICAL", 36, 44], ["cells", "CELL", 48, 53], ["PD", "PROBLEM", 0, 2], ["peroxide in cells suspension", "TREATMENT", 36, 64], ["cells suspension", "OBSERVATION", 48, 64]]], ["DOX and PTX increased (2-fold) the level of carbonyls.", [["DOX", "CHEMICAL", 0, 3], ["PTX", "CHEMICAL", 8, 11], ["DOX", "CHEMICAL", 0, 3], ["PTX", "CHEMICAL", 8, 11], ["carbonyls", "CHEMICAL", 44, 53], ["DOX", "SIMPLE_CHEMICAL", 0, 3], ["PTX", "SIMPLE_CHEMICAL", 8, 11], ["carbonyls", "SIMPLE_CHEMICAL", 44, 53], ["DOX", "TEST", 0, 3], ["PTX", "PROBLEM", 8, 11], ["PTX", "OBSERVATION_MODIFIER", 8, 11], ["increased", "OBSERVATION_MODIFIER", 12, 21]]], ["PD decreased the level of peroxides in cells treated with DOX and PTX.", [["cells", "ANATOMY", 39, 44], ["PD", "DISEASE", 0, 2], ["DOX", "CHEMICAL", 58, 61], ["PTX", "CHEMICAL", 66, 69], ["peroxides", "CHEMICAL", 26, 35], ["DOX", "CHEMICAL", 58, 61], ["PTX", "CHEMICAL", 66, 69], ["peroxides", "SIMPLE_CHEMICAL", 26, 35], ["cells", "CELL", 39, 44], ["DOX", "SIMPLE_CHEMICAL", 58, 61], ["PTX", "SIMPLE_CHEMICAL", 66, 69], ["PD", "PROBLEM", 0, 2], ["peroxides in cells", "TREATMENT", 26, 44], ["DOX", "TREATMENT", 58, 61], ["PTX", "PROBLEM", 66, 69], ["peroxides", "OBSERVATION_MODIFIER", 26, 35], ["PTX", "OBSERVATION", 66, 69]]], ["The lowest concentration of peroxide was observed at 50\u00b5M of PD.", [["peroxide", "CHEMICAL", 28, 36], ["PD", "DISEASE", 61, 63], ["peroxide", "CHEMICAL", 28, 36], ["peroxide", "SIMPLE_CHEMICAL", 28, 36], ["The lowest concentration of peroxide", "TREATMENT", 0, 36], ["PD", "TREATMENT", 61, 63]]], ["These results show that PD protect MCF-7 cells against oxidative stress induced by drugs.P-405Open channel structure of MscL from FRET microscopy and simulation Mechanosensitive channels open in response to membrane bilayer deformations occurring in physiological processes such as touch, hearing and osmoregulation.", [["MCF-7 cells", "ANATOMY", 35, 46], ["membrane bilayer", "ANATOMY", 207, 223], ["deformations", "DISEASE", 224, 236], ["MCF-7 cells", "CELL", 35, 46], ["MCF-7 cells", "CELL_LINE", 35, 46], ["P", "DNA", 89, 90], ["MscL", "PROTEIN", 120, 124], ["MCF-7", "SPECIES", 35, 40], ["PD", "TEST", 24, 26], ["MCF", "TEST", 35, 38], ["oxidative stress", "PROBLEM", 55, 71], ["FRET microscopy", "TEST", 130, 145], ["simulation Mechanosensitive channels", "TREATMENT", 150, 186], ["membrane bilayer deformations", "PROBLEM", 207, 236], ["MscL", "ANATOMY", 120, 124], ["Mechanosensitive channels", "OBSERVATION", 161, 186], ["membrane bilayer deformations", "OBSERVATION", 207, 236]]], ["Here, we have determined the likely structure of the open state of the mechanosensitive channel of large conductance from E. coli (MscL) in a natural environment using a combination of patch-clamp studies, FRET spectroscopy, EPR data, molecular and Brownian dynamics simulation.", [["E. coli", "ORGANISM", 122, 129], ["MscL", "GENE_OR_GENE_PRODUCT", 131, 135], ["mechanosensitive channel", "PROTEIN", 71, 95], ["E. coli", "SPECIES", 122, 129], ["E. coli", "SPECIES", 122, 129], ["large conductance", "PROBLEM", 99, 116], ["E. coli", "PROBLEM", 122, 129], ["patch", "TREATMENT", 185, 190], ["clamp studies", "TEST", 191, 204], ["FRET spectroscopy", "TEST", 206, 223], ["EPR data", "TEST", 225, 233], ["large", "OBSERVATION_MODIFIER", 99, 104], ["conductance", "OBSERVATION", 105, 116], ["E. coli", "OBSERVATION", 122, 129], ["Brownian dynamics", "OBSERVATION", 249, 266]]], ["Structural rearrangements of the protein are measured while controlling the state of the pore by modifying lipid bilayer morphology.", [["pore", "ANATOMY", 89, 93], ["lipid bilayer", "ANATOMY", 107, 120], ["pore", "CELLULAR_COMPONENT", 89, 93], ["lipid bilayer", "CELLULAR_COMPONENT", 107, 120], ["rearrangements", "OBSERVATION", 11, 25]]], ["FRET efficiency changes can be related to distance changes using a Monte Carlo analysis program in conjunction with detailed orientational analysis.", [["FRET efficiency changes", "PROBLEM", 0, 23], ["distance changes", "PROBLEM", 42, 58], ["a Monte Carlo analysis program", "TREATMENT", 65, 95], ["detailed orientational analysis", "TEST", 116, 147], ["efficiency", "OBSERVATION", 5, 15]]], ["These measurements are used as restraints in all atom molecular simulations in order to determine the likely structure of the open state, whose probable conductance is derived from Brownian dynamics simulations.P-405Transition to the open state occurs via large rearrangements throughout the protein that create a wide pore nearly 30 A in diameter.", [["P-405Transition", "CHEMICAL", 211, 226], ["P-405Transition", "DNA", 211, 226], ["These measurements", "TEST", 0, 18], ["restraints", "TREATMENT", 31, 41], ["Brownian dynamics simulations", "PROBLEM", 181, 210], ["a wide pore", "TREATMENT", 312, 323], ["Brownian dynamics", "OBSERVATION", 181, 198], ["large", "OBSERVATION_MODIFIER", 256, 261], ["rearrangements", "OBSERVATION", 262, 276], ["wide", "OBSERVATION_MODIFIER", 314, 318]]], ["Both transmembrane helices are found to line part of the pore.", [["transmembrane helices", "ANATOMY", 5, 26], ["pore", "ANATOMY", 57, 61], ["pore", "CELLULAR_COMPONENT", 57, 61], ["transmembrane helices", "PROTEIN", 5, 26], ["Both transmembrane helices", "TREATMENT", 0, 26], ["transmembrane helices", "OBSERVATION", 5, 26], ["pore", "OBSERVATION_MODIFIER", 57, 61]]], ["The N terminal helix is found to lie along the face of the membrane where it can act to sense membrane tension and directly transfer this to the pore lining helices.", [["membrane", "ANATOMY", 59, 67], ["membrane", "ANATOMY", 94, 102], ["pore lining helices", "ANATOMY", 145, 164], ["N", "CHEMICAL", 4, 5], ["membrane", "CELLULAR_COMPONENT", 59, 67], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["N terminal helix", "PROTEIN", 4, 20], ["pore lining helices", "PROTEIN", 145, 164], ["The N terminal helix", "TREATMENT", 0, 20], ["the pore lining helices", "TREATMENT", 141, 164], ["terminal", "OBSERVATION_MODIFIER", 6, 14], ["helix", "OBSERVATION_MODIFIER", 15, 20], ["face", "ANATOMY_MODIFIER", 47, 51], ["membrane", "ANATOMY_MODIFIER", 59, 67]]], ["The method of coupling spectroscopic data with simulations is likely to be of great value for studying conformational changes in a range of membrane proteins.O-404Putative potassium channels in Synechocystis sp.", [["membrane", "ANATOMY", 140, 148], ["O-404Putative potassium", "CHEMICAL", 158, 181], ["O-404Putative potassium", "CHEMICAL", 158, 181], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["O-404Putative potassium", "SIMPLE_CHEMICAL", 158, 181], ["Synechocystis sp", "ORGANISM", 194, 210], ["membrane proteins", "PROTEIN", 140, 157], ["O-404Putative potassium channels", "PROTEIN", 158, 190], ["Synechocystis", "SPECIES", 194, 207], ["coupling spectroscopic data", "TEST", 14, 41], ["conformational changes", "PROBLEM", 103, 125], ["membrane proteins", "PROBLEM", 140, 157], ["Synechocystis sp", "PROBLEM", 194, 210], ["Synechocystis sp", "OBSERVATION", 194, 210]]], ["PCC 6803 V. Checchetto, M. Zanetti, G. M. Giacometti, I. Szab\u00f2, E. Bergantino Department of Biology, University of Padova, ItalyO-404We are interested in the identification and characterization of potassium channels in the cyanobacterium Synechocystis sp.", [["potassium", "CHEMICAL", 197, 206], ["potassium", "CHEMICAL", 197, 206], ["potassium", "SIMPLE_CHEMICAL", 197, 206], ["cyanobacterium Synechocystis sp", "ORGANISM", 223, 254], ["potassium channels", "PROTEIN", 197, 215], ["Synechocystis", "SPECIES", 238, 251], ["the identification", "TEST", 154, 172], ["potassium channels", "TREATMENT", 197, 215]]], ["PCC 6803, an organism which is considered the ancestor of plant chloroplasts.", [["chloroplasts", "ANATOMY", 64, 76], ["PCC 6803", "CHEMICAL", 0, 8], ["plant chloroplasts", "CELL", 58, 76], ["PCC 6803", "SPECIES", 0, 8], ["an organism", "PROBLEM", 10, 21], ["plant chloroplasts", "TREATMENT", 58, 76]]], ["A bioinformatic screening of Synechocystis proteome identified, among others, two proteins on which we focused our attention.", [["A bioinformatic screening", "TEST", 0, 25], ["Synechocystis proteome", "PROBLEM", 29, 51], ["Synechocystis proteome", "OBSERVATION", 29, 51]]], ["The first one (SynCaK) displays sequence homology to MthK, a Ca 2+ -dependent potassium channel from M . thermoautotrophicum.", [["Ca", "CHEMICAL", 61, 63], ["potassium", "CHEMICAL", 78, 87], ["Ca 2+", "CHEMICAL", 61, 66], ["potassium", "CHEMICAL", 78, 87], ["SynCaK", "GENE_OR_GENE_PRODUCT", 15, 21], ["MthK", "GENE_OR_GENE_PRODUCT", 53, 57], ["Ca 2+", "SIMPLE_CHEMICAL", 61, 66], ["potassium", "SIMPLE_CHEMICAL", 78, 87], ["SynCaK", "PROTEIN", 15, 21], ["MthK", "PROTEIN", 53, 57], ["Ca 2+ -dependent potassium channel", "PROTEIN", 61, 95], ["a Ca", "TEST", 59, 63], ["thermoautotrophicum", "PROBLEM", 105, 124]]], ["The second one (SynK) is predicted to contain six transmembrane regions and the typical selectivity filter of all potassium channels.", [["transmembrane", "ANATOMY", 50, 63], ["potassium", "CHEMICAL", 114, 123], ["potassium", "CHEMICAL", 114, 123], ["SynK", "GENE_OR_GENE_PRODUCT", 16, 20], ["potassium", "SIMPLE_CHEMICAL", 114, 123], ["SynK", "PROTEIN", 16, 20], ["transmembrane regions", "PROTEIN", 50, 71], ["potassium channels", "PROTEIN", 114, 132], ["the typical selectivity filter of all potassium channels", "TREATMENT", 76, 132], ["selectivity filter", "OBSERVATION", 88, 106]]], ["Our goal is to understand their roles in the physiology of cyanobacteria.", [["cyanobacteria", "PROBLEM", 59, 72]]], ["We cloned their coding sequences in fusion with GFP and the hybrid proteins were expressed in Chinese hamster ovary cells.", [["hamster ovary cells", "ANATOMY", 102, 121], ["GFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["hamster ovary cells", "CELL", 102, 121], ["GFP", "PROTEIN", 48, 51], ["hybrid proteins", "PROTEIN", 60, 75], ["Chinese hamster ovary cells", "CELL_TYPE", 94, 121], ["Chinese hamster", "SPECIES", 94, 109], ["GFP", "TEST", 48, 51], ["the hybrid proteins", "PROBLEM", 56, 75], ["hamster ovary cells", "OBSERVATION", 102, 121]]], ["We evaluated the presence of both proteins in plasma membrane by fluorescence microscopy and then we proceeded to their functional characterization using patch clamp technique.This analysis will allow us to gain information about channel activity, regulation and pharmacology.", [["plasma membrane", "ANATOMY", 46, 61], ["plasma membrane", "CELLULAR_COMPONENT", 46, 61], ["fluorescence microscopy", "TEST", 65, 88], ["patch clamp technique", "TREATMENT", 154, 175], ["This analysis", "TEST", 176, 189], ["plasma membrane", "ANATOMY", 46, 61]]], ["We also plan to evaluate the importance of SynCaK and SynK channels in photosynthesis.", [["SynCaK", "GENE_OR_GENE_PRODUCT", 43, 49], ["SynK", "GENE_OR_GENE_PRODUCT", 54, 58], ["SynCaK", "PROTEIN", 43, 49], ["SynK channels", "PROTEIN", 54, 67]]], ["To test the hypothesis that they could be involved in regulating this process, we will produce deletion and site-specific mutants in Synechocystis.", [["deletion and site", "PROBLEM", 95, 112], ["specific mutants in Synechocystis", "PROBLEM", 113, 146]]], ["Finally we would also identify the homologous of these channels in the higher plant A. thaliana and obtain some information about their localization and function.Modified valinomycins as sensors in model membranesJ.", [["valinomycins", "CHEMICAL", 171, 183], ["valinomycins", "CHEMICAL", 171, 183], ["A. thaliana", "ORGANISM", 84, 95], ["valinomycins", "SIMPLE_CHEMICAL", 171, 183], ["A. thaliana", "SPECIES", 84, 95], ["A. thaliana", "SPECIES", 84, 95], ["Modified valinomycins", "TREATMENT", 162, 183], ["model membranesJ", "OBSERVATION", 198, 214]]], ["Braunagel Max-Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, GermanyModified valinomycins as sensors in model membranesThe cyclododecadepsipeptide valinomycin is composed of two amino acids (L-Valine and DValine) and two hydroxyl acids (D-\u03b1-Hydroxy-isovaleric acid and L-Lactic acid).", [["membranes", "ANATOMY", 132, 141], ["valinomycins", "CHEMICAL", 99, 111], ["valinomycin", "CHEMICAL", 169, 180], ["amino acids", "CHEMICAL", 200, 211], ["L-Valine", "CHEMICAL", 213, 221], ["DValine", "CHEMICAL", 226, 233], ["hydroxyl acids", "CHEMICAL", 243, 257], ["D-\u03b1-Hydroxy-isovaleric acid", "CHEMICAL", 259, 286], ["L-Lactic acid", "CHEMICAL", 291, 304], ["valinomycins", "CHEMICAL", 99, 111], ["cyclododecadepsipeptide", "CHEMICAL", 145, 168], ["valinomycin", "CHEMICAL", 169, 180], ["amino acids", "CHEMICAL", 200, 211], ["L-Valine", "CHEMICAL", 213, 221], ["DValine", "CHEMICAL", 226, 233], ["hydroxyl acids", "CHEMICAL", 243, 257], ["D-\u03b1-Hydroxy-isovaleric acid", "CHEMICAL", 259, 286], ["L-Lactic acid", "CHEMICAL", 291, 304], ["valinomycins", "SIMPLE_CHEMICAL", 99, 111], ["membranes", "CELLULAR_COMPONENT", 132, 141], ["cyclododecadepsipeptide", "SIMPLE_CHEMICAL", 145, 168], ["valinomycin", "SIMPLE_CHEMICAL", 169, 180], ["amino acids", "AMINO_ACID", 200, 211], ["L-Valine", "SIMPLE_CHEMICAL", 213, 221], ["DValine", "SIMPLE_CHEMICAL", 226, 233], ["hydroxyl acids", "SIMPLE_CHEMICAL", 243, 257], ["D-\u03b1-Hydroxy-isovaleric acid", "SIMPLE_CHEMICAL", 259, 286], ["L-Lactic acid", "SIMPLE_CHEMICAL", 291, 304], ["Ackermannweg", "TREATMENT", 53, 65], ["GermanyModified valinomycins", "TREATMENT", 83, 111], ["The cyclododecadepsipeptide valinomycin", "TREATMENT", 141, 180], ["two amino acids", "TREATMENT", 196, 211], ["L-Valine and DValine)", "TREATMENT", 213, 234], ["two hydroxyl acids", "TREATMENT", 239, 257], ["D-\u03b1-Hydroxy-isovaleric acid", "TREATMENT", 259, 286], ["L-Lactic acid", "TREATMENT", 291, 304]]], ["They form a 36membered ring of alternating amino and hydroxyl acids.", [["amino and hydroxyl acids", "CHEMICAL", 43, 67], ["amino and hydroxyl acids", "CHEMICAL", 43, 67], ["amino", "AMINO_ACID", 43, 48], ["hydroxyl acids", "SIMPLE_CHEMICAL", 53, 67], ["alternating amino and hydroxyl acids", "TREATMENT", 31, 67]]], ["In the cyclic structure, the polar groups are oriented towards the central cavity, whereas the rest of the molecule is relatively nonpolar.", [["cyclic structure", "OBSERVATION", 7, 23], ["polar", "OBSERVATION_MODIFIER", 29, 34], ["oriented", "OBSERVATION_MODIFIER", 46, 54], ["central", "ANATOMY_MODIFIER", 67, 74], ["cavity", "ANATOMY_MODIFIER", 75, 81], ["rest", "ANATOMY_MODIFIER", 95, 99], ["relatively", "OBSERVATION_MODIFIER", 119, 129], ["nonpolar", "OBSERVATION_MODIFIER", 130, 138]]], ["This enables the complexation of ions and valinomycin acts as a selective ion transporter (K + ) in lipid membranes.", [["lipid membranes", "ANATOMY", 100, 115], ["valinomycin", "CHEMICAL", 42, 53], ["K", "CHEMICAL", 91, 92], ["valinomycin", "CHEMICAL", 42, 53], ["ions", "SIMPLE_CHEMICAL", 33, 37], ["valinomycin", "SIMPLE_CHEMICAL", 42, 53], ["K +", "SIMPLE_CHEMICAL", 91, 94], ["lipid membranes", "CELLULAR_COMPONENT", 100, 115], ["selective ion transporter", "PROTEIN", 64, 89], ["the complexation of ions and valinomycin acts", "TREATMENT", 13, 58], ["lipid membranes", "OBSERVATION", 100, 115]]], ["When one of the amino acids is exchanged, e.g one L-Valine by an L-Lysine, selected functionality can be engineered into the depsipeptide while maintaining its ion conducting properties.", [["amino acids", "CHEMICAL", 16, 27], ["L-Lysine", "CHEMICAL", 65, 73], ["amino acids", "CHEMICAL", 16, 27], ["L-Valine", "CHEMICAL", 50, 58], ["L-Lysine", "CHEMICAL", 65, 73], ["depsipeptide", "CHEMICAL", 125, 137], ["amino acids", "AMINO_ACID", 16, 27], ["L-Valine", "SIMPLE_CHEMICAL", 50, 58], ["L-Lysine", "SIMPLE_CHEMICAL", 65, 73], ["the amino acids", "TREATMENT", 12, 27], ["Valine", "TREATMENT", 52, 58], ["an L-Lysine", "TREATMENT", 62, 73], ["the depsipeptide", "TREATMENT", 121, 137]]], ["We induced several modifications into valinomycin, i.e. a Biotin binding unit or a Ferrocene group to induce an electrochemical active center.", [["valinomycin", "CHEMICAL", 38, 49], ["Ferrocene", "CHEMICAL", 83, 92], ["valinomycin", "CHEMICAL", 38, 49], ["Biotin", "CHEMICAL", 58, 64], ["Ferrocene", "CHEMICAL", 83, 92], ["valinomycin", "SIMPLE_CHEMICAL", 38, 49], ["Biotin", "SIMPLE_CHEMICAL", 58, 64], ["Ferrocene", "SIMPLE_CHEMICAL", 83, 92], ["valinomycin", "TREATMENT", 38, 49], ["a Biotin binding unit", "TREATMENT", 56, 77], ["a Ferrocene group", "TREATMENT", 81, 98]]], ["The ion conducting properties of the modified ion carriers have been probed in planar lipid bilayers as well as in solid supported membranes.", [["membranes", "ANATOMY", 131, 140], ["membranes", "CELLULAR_COMPONENT", 131, 140], ["the modified ion carriers", "TREATMENT", 33, 58], ["planar lipid bilayers", "TREATMENT", 79, 100]]], ["The role of the membrane dipole potential (\u03d5 d ) is of a particular interest due to a powerful impact of this potential on the membrane permeability and lipid-protein interactions.", [["membrane", "ANATOMY", 16, 24], ["membrane", "ANATOMY", 127, 135], ["membrane", "CELLULAR_COMPONENT", 16, 24], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["lipid", "SIMPLE_CHEMICAL", 153, 158], ["the membrane permeability", "TREATMENT", 123, 148], ["lipid-protein interactions", "TREATMENT", 153, 179]]], ["Channel forming activity of gramicidin A, alamethicin, syringomycin E, HPA3 peptide, and OmpF porin are influenced by \u03d5 d .", [["gramicidin A", "CHEMICAL", 28, 40], ["alamethicin", "CHEMICAL", 42, 53], ["syringomycin", "CHEMICAL", 55, 67], ["gramicidin A", "CHEMICAL", 28, 40], ["alamethicin", "CHEMICAL", 42, 53], ["syringomycin E", "CHEMICAL", 55, 69], ["HPA3 peptide", "CHEMICAL", 71, 83], ["gramicidin A", "SIMPLE_CHEMICAL", 28, 40], ["alamethicin", "SIMPLE_CHEMICAL", 42, 53], ["syringomycin E", "SIMPLE_CHEMICAL", 55, 69], ["HPA3 peptide", "SIMPLE_CHEMICAL", 71, 83], ["OmpF porin", "GENE_OR_GENE_PRODUCT", 89, 99], ["OmpF porin", "PROTEIN", 89, 99], ["gramicidin A", "TREATMENT", 28, 40], ["alamethicin", "TREATMENT", 42, 53], ["syringomycin E", "TREATMENT", 55, 69], ["HPA3 peptide", "TREATMENT", 71, 83], ["OmpF porin", "TREATMENT", 89, 99]]], ["We have studied the effect of the membrane dipole modifier, phloretin, on the properties of single channels formed by a wild-type alpha-hemolysin in planar lipid bilayers.", [["membrane", "ANATOMY", 34, 42], ["lipid bilayers", "ANATOMY", 156, 170], ["phloretin", "CHEMICAL", 60, 69], ["phloretin", "CHEMICAL", 60, 69], ["membrane", "CELLULAR_COMPONENT", 34, 42], ["phloretin", "SIMPLE_CHEMICAL", 60, 69], ["alpha-hemolysin", "GENE_OR_GENE_PRODUCT", 130, 145], ["planar lipid bilayers", "SIMPLE_CHEMICAL", 149, 170], ["wild-type alpha-hemolysin", "PROTEIN", 120, 145], ["the membrane dipole modifier", "TREATMENT", 30, 58], ["phloretin", "TREATMENT", 60, 69], ["lipid bilayers", "OBSERVATION", 156, 170]]], ["The single channel of a \u223c1000 pS conductance exhibits transitions into a number of low-conductance states as the transmembrane voltage exceeds \u223c130 mV (regardless of the voltage polarity).", [["transmembrane", "ANATOMY", 113, 126], ["transmembrane", "CELLULAR_COMPONENT", 113, 126], ["a \u223c1000 pS conductance", "TREATMENT", 22, 44], ["the transmembrane voltage", "TEST", 109, 134]]], ["The phloretin addition to the bathing solutions (20 \u00b5M) (after the hemolysin channel was formed in the membrane) shifts dramatically the channel voltagedependence.", [["membrane", "ANATOMY", 103, 111], ["phloretin", "CHEMICAL", 4, 13], ["phloretin", "CHEMICAL", 4, 13], ["phloretin", "SIMPLE_CHEMICAL", 4, 13], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["hemolysin channel", "PROTEIN", 67, 84], ["The phloretin", "TREATMENT", 0, 13], ["the bathing solutions", "TREATMENT", 26, 47], ["the hemolysin channel", "TREATMENT", 63, 84]]], ["The effect of the phloretin addition was not observed in the case when it was introduced into the bathing solution before alpha-toxin.", [["phloretin", "CHEMICAL", 18, 27], ["alpha-toxin", "CHEMICAL", 122, 133], ["phloretin", "CHEMICAL", 18, 27], ["phloretin", "SIMPLE_CHEMICAL", 18, 27], ["alpha-toxin", "GENE_OR_GENE_PRODUCT", 122, 133], ["alpha-toxin", "PROTEIN", 122, 133], ["the phloretin addition", "TREATMENT", 14, 36], ["the bathing solution", "TREATMENT", 94, 114], ["alpha-toxin", "TREATMENT", 122, 133]]], ["Since phloretin reduces \u03d5 d , the data may report on the influence of the electric potential profile on the energy of the low-conductance state of the alpha-hemolysin channel.", [["phloretin", "CHEMICAL", 6, 15], ["phloretin", "CHEMICAL", 6, 15], ["phloretin", "SIMPLE_CHEMICAL", 6, 15], ["alpha-hemolysin", "GENE_OR_GENE_PRODUCT", 151, 166], ["alpha-hemolysin channel", "PROTEIN", 151, 174], ["phloretin", "TREATMENT", 6, 15], ["alpha-hemolysin channel", "OBSERVATION", 151, 174]]], ["The alternative explanation of this effect consists in a specific interaction between the phloretin and toxin channel.", [["phloretin", "CHEMICAL", 90, 99], ["phloretin", "CHEMICAL", 90, 99], ["phloretin", "SIMPLE_CHEMICAL", 90, 99], ["toxin channel", "SIMPLE_CHEMICAL", 104, 117], ["toxin channel", "PROTEIN", 104, 117], ["this effect", "PROBLEM", 31, 42], ["the phloretin and toxin channel", "TREATMENT", 86, 117]]], ["The work is supported in part by RFBR (# 09-04-00883), SS (# 1135.2008.4) , and the Program of the RAS \u00abMolecular and Cell Biology\u00bb.P-409Atypical mechanism of conduction in potassium channels C. Domene 1 , S. Furini 1 1 Physical and Theoretical Chemistry Laboratory, Department of Chemistry, University of Oxford, Oxford, U.K., 2 Department of Electronics, Computer Science and Systems, University of Bologna, Bologna, Italy Potassium channels can conduct K + ions with rates of up to \u223c 10 8 ions per second at physiological conditions, and they are selective to these species by a factor of 10 4 over Na + ions.", [["Cell", "ANATOMY", 118, 122], ["potassium", "CHEMICAL", 173, 182], ["Potassium", "CHEMICAL", 425, 434], ["K", "CHEMICAL", 456, 457], ["Na", "CHEMICAL", 602, 604], ["potassium", "CHEMICAL", 173, 182], ["Potassium", "CHEMICAL", 425, 434], ["K +", "CHEMICAL", 456, 459], ["Na +", "CHEMICAL", 602, 606], ["Cell", "CELL", 118, 122], ["K + ions", "SIMPLE_CHEMICAL", 456, 464], ["Na + ions", "SIMPLE_CHEMICAL", 602, 611], ["Potassium channels", "TEST", 425, 443], ["K", "TEST", 456, 457], ["rates", "TEST", 470, 475], ["a factor", "TEST", 580, 588]]], ["Ion conduction has been proposed to involve transitions between two main states, with two or three K + ions occupying the selectivity filter separated by an intervening water molecule.", [["K", "CHEMICAL", 99, 100], ["K +", "CHEMICAL", 99, 102], ["K + ions", "SIMPLE_CHEMICAL", 99, 107], ["Ion conduction", "TREATMENT", 0, 14], ["three K + ions", "TREATMENT", 93, 107], ["the selectivity filter", "TREATMENT", 118, 140], ["an intervening water molecule", "TREATMENT", 154, 183], ["selectivity filter", "OBSERVATION", 122, 140], ["water molecule", "OBSERVATION", 169, 183]]], ["The largest free energy barrier of such a process was reported to be of the order of 2-3kcal mol \u22121 .", [["largest", "OBSERVATION_MODIFIER", 4, 11], ["free", "OBSERVATION_MODIFIER", 12, 16], ["energy barrier", "OBSERVATION", 17, 31]]], ["Here, we present an alternative mechanism for conduction of K + in K + channels where site vacancies are involved, and we propose that coexistence of several ion permeation mechanisms is energetically possible.", [["K", "CHEMICAL", 60, 61], ["K", "CHEMICAL", 67, 68], ["K +", "CHEMICAL", 60, 63], ["K +", "CHEMICAL", 67, 70], ["K +", "SIMPLE_CHEMICAL", 60, 63], ["K +", "SIMPLE_CHEMICAL", 67, 70], ["K + channels", "PROTEIN", 67, 79], ["conduction of K", "TEST", 46, 61], ["several ion permeation mechanisms", "TREATMENT", 150, 183], ["energetically possible", "UNCERTAINTY", 187, 209]]], ["Conduction can be described as a more anarchic phenomenon than previously characterized by the concerted translocations of K + -water-K + .", [["K", "CHEMICAL", 123, 124], ["K", "CHEMICAL", 134, 135], ["K +", "CHEMICAL", 123, 126], ["K +", "CHEMICAL", 134, 137], ["K +", "SIMPLE_CHEMICAL", 123, 126], ["K +", "SIMPLE_CHEMICAL", 134, 137], ["a more anarchic phenomenon", "PROBLEM", 31, 57], ["K", "TEST", 123, 124]]], ["We exploited the Au-deposited self-assembled monolayers of the type: [\u2212S\u2212(CH 2 ) n \u2212CH 3 ] (where n = 4, 9 and 15) with hydrophobically adsorbed redox protein -azurin to verify intrinsic electron transfer mechanisms according to the charge-transfer theory.", [["-azurin", "CHEMICAL", 159, 166], ["[\u2212S\u2212(CH 2 ) n \u2212CH 3 ]", "CHEMICAL", 69, 90], ["-azurin", "CHEMICAL", 159, 166], ["monolayers", "CELL", 45, 55], ["[\u2212S\u2212(CH 2 ) n \u2212CH 3 ]", "SIMPLE_CHEMICAL", 69, 90], ["-azurin", "SIMPLE_CHEMICAL", 159, 166], ["electron", "SIMPLE_CHEMICAL", 187, 195], ["n \u2212CH", "TEST", 81, 86], ["hydrophobically adsorbed redox protein -azurin", "TREATMENT", 120, 166]]], ["The enthalpies and volumes of activation were determined through the variation of temperature (2-50 o C) and pressure (5-150 MPa) and experimental values were compared with those expected on the theoretical grounds.", [["The enthalpies and volumes of activation", "TREATMENT", 0, 40], ["temperature", "TEST", 82, 93], ["pressure", "TEST", 109, 117], ["experimental values", "TEST", 134, 153], ["enthalpies", "OBSERVATION", 4, 14], ["volumes", "OBSERVATION_MODIFIER", 19, 26]]], ["For the case of n = 4 the activation enthalpy definitely contains a large contribution originated from frictional-like dynamics of protein, and the activation volume has a small positive value.", [["the activation volume", "TEST", 144, 165], ["a small positive value", "PROBLEM", 170, 192], ["large", "OBSERVATION_MODIFIER", 68, 73], ["small", "OBSERVATION_MODIFIER", 172, 177], ["positive value", "OBSERVATION", 178, 192]]], ["For n = 15 the value of activation enthalpy directly matches 1/4 of that for the reorganization energy, and the activation volume attains substantially negative value.", [["the activation volume", "TEST", 108, 129]]], ["The whole kinetic pattern is consistent with the smooth changeover between adiabatic and nonadiabatic mechanisms of electron transfer.P-407Two gating modalities in the pore of the miniature K + channel Kcv Kcv is a viral protein that forms functional K + channel in heterologous systems.", [["pore", "ANATOMY", 168, 172], ["P-407", "CHEMICAL", 134, 139], ["K", "CHEMICAL", 190, 191], ["K", "CHEMICAL", 251, 252], ["K +", "CHEMICAL", 190, 193], ["K +", "CHEMICAL", 251, 254], ["electron", "SIMPLE_CHEMICAL", 116, 124], ["K + channel Kcv Kcv", "GENE_OR_GENE_PRODUCT", 190, 209], ["K + channel", "GENE_OR_GENE_PRODUCT", 251, 262], ["miniature K + channel", "PROTEIN", 180, 201], ["Kcv", "PROTEIN", 202, 205], ["Kcv", "PROTEIN", 206, 209], ["viral protein", "PROTEIN", 215, 228], ["K + channel", "PROTEIN", 251, 262], ["a viral protein", "TEST", 213, 228], ["consistent with", "UNCERTAINTY", 29, 44], ["smooth", "OBSERVATION_MODIFIER", 49, 55], ["nonadiabatic mechanisms", "OBSERVATION", 89, 112]]], ["Because of its miniature size (94 amino acids) we use Kcv as a model system to study and manipulate basic properties of the K + channel pore.", [["amino acids", "CHEMICAL", 34, 45], ["K", "CHEMICAL", 124, 125], ["amino acids", "CHEMICAL", 34, 45], ["K +", "CHEMICAL", 124, 127], ["amino acids", "AMINO_ACID", 34, 45], ["Kcv", "GENE_OR_GENE_PRODUCT", 54, 57], ["Kcv", "PROTEIN", 54, 57], ["K + channel pore", "PROTEIN", 124, 140], ["amino acids", "TEST", 34, 45], ["Kcv", "TREATMENT", 54, 57], ["the K + channel pore", "TREATMENT", 120, 140], ["size", "OBSERVATION_MODIFIER", 25, 29]]], ["By analysing single-channel recordings we highlighted two voltage-dependent modalities of gating in Kcv: a slow and a fast gating.", [["Kcv", "GENE_OR_GENE_PRODUCT", 100, 103], ["Kcv", "PROTEIN", 100, 103], ["a slow and a fast gating", "PROBLEM", 105, 129]]], ["The presence of a slow gating is revealed by the very low (in the order of 1-3%) mean open probability.", [["a slow gating", "PROBLEM", 16, 29], ["slow", "OBSERVATION_MODIFIER", 18, 22], ["very", "OBSERVATION_MODIFIER", 49, 53], ["low", "OBSERVATION_MODIFIER", 54, 57]]], ["Slow gating is not related to the presence of a bundle crossing, as shown by accessibility of the cavity to MTS reagents.", [["MTS", "CHEMICAL", 108, 111], ["Slow gating", "PROBLEM", 0, 11], ["a bundle crossing", "PROBLEM", 46, 63], ["MTS reagents", "TREATMENT", 108, 120], ["not related to", "UNCERTAINTY", 15, 29], ["cavity", "OBSERVATION", 98, 104]]], ["Channel opening might involve the transient formation of salt bridges between residues at the N and C termini of the channel, as suggested by mutational experiments inspired by molecular dynamics simulations of Kcv.", [["N", "CHEMICAL", 94, 95], ["C", "CHEMICAL", 100, 101], ["Kcv", "GENE_OR_GENE_PRODUCT", 211, 214], ["N and C termini", "PROTEIN", 94, 109], ["Kcv", "PROTEIN", 211, 214], ["Channel opening", "TREATMENT", 0, 15], ["salt bridges between residues", "PROBLEM", 57, 86], ["Kcv", "TREATMENT", 211, 214], ["transient", "OBSERVATION_MODIFIER", 34, 43], ["formation", "OBSERVATION", 44, 53], ["salt bridges", "OBSERVATION", 57, 69]]], ["Fast gating, analyzed by beta distributions, is responsible for the negative slope conductance in the single-channel I/V curve at extreme potentials and can be explained by depletion-aggravated instability of the filter region.", [["beta", "GENE_OR_GENE_PRODUCT", 25, 29], ["Fast gating", "TEST", 0, 11], ["aggravated instability of the filter region", "PROBLEM", 183, 226], ["depletion", "OBSERVATION", 173, 182], ["filter", "OBSERVATION", 213, 219]]], ["ACA8 is a type 2B CaATPase with a regulatory N-terminus whose autoinhibitory action can be suppressed by binding of calmodulin (CaM).", [["N", "CHEMICAL", 45, 46], ["ACA8", "GENE_OR_GENE_PRODUCT", 0, 4], ["CaATPase", "GENE_OR_GENE_PRODUCT", 18, 26], ["calmodulin", "GENE_OR_GENE_PRODUCT", 116, 126], ["CaM", "GENE_OR_GENE_PRODUCT", 128, 131], ["ACA8", "PROTEIN", 0, 4], ["type 2B CaATPase", "PROTEIN", 10, 26], ["regulatory N-terminus", "PROTEIN", 34, 55], ["calmodulin", "PROTEIN", 116, 126], ["CaM", "PROTEIN", 128, 131], ["a type 2B CaATPase", "PROBLEM", 8, 26], ["a regulatory N-terminus whose autoinhibitory action", "TREATMENT", 32, 83]]], ["ACA8 N-terminus is able to bind a region of the small cytoplasmic loop connecting transmembrane domains 2 and 3.", [["cytoplasmic", "ANATOMY", 54, 65], ["transmembrane", "ANATOMY", 82, 95], ["N", "CHEMICAL", 5, 6], ["cytoplasmic", "ORGANISM_SUBSTANCE", 54, 65], ["transmembrane", "CELLULAR_COMPONENT", 82, 95], ["ACA8 N-terminus", "PROTEIN", 0, 15], ["small cytoplasmic loop", "PROTEIN", 48, 70], ["transmembrane domains 2 and 3", "PROTEIN", 82, 111], ["ACA8 N-terminus", "TREATMENT", 0, 15], ["small", "OBSERVATION_MODIFIER", 48, 53], ["cytoplasmic loop", "OBSERVATION", 54, 70]]], ["To define the role of this interaction in autoinhibition we have analysed a number of single point mutants produced by mutagenesis of ACA8 E252-N345 sequence.", [["ACA8", "GENE_OR_GENE_PRODUCT", 134, 138], ["ACA8 E252-N345 sequence", "DNA", 134, 157]]], ["Mutation to Ala of any of 6 acidic residues (E252, D273, D291, D303, E302, D332) originates an enzyme with normal activity in the presence of CaM, but less CaMstimulated.", [["Ala", "CHEMICAL", 12, 15], ["Ala", "AMINO_ACID", 12, 15], ["CaM", "GENE_OR_GENE_PRODUCT", 142, 145], ["CaM", "PROTEIN", 142, 145], ["an enzyme", "TEST", 92, 101], ["normal activity", "OBSERVATION", 107, 122]]], ["These results highlight the relevance of a negative charge of the surface area of the small cytoplasmic loop in ACA8 autoinhibition.", [["surface area", "ANATOMY", 66, 78], ["cytoplasmic", "ANATOMY", 92, 103], ["cytoplasmic", "ORGANISM_SUBSTANCE", 92, 103], ["ACA8", "GENE_OR_GENE_PRODUCT", 112, 116], ["ACA8", "PROTEIN", 112, 116], ["the small cytoplasmic loop in ACA8 autoinhibition", "PROBLEM", 82, 131], ["negative", "OBSERVATION", 43, 51], ["surface", "OBSERVATION_MODIFIER", 66, 73], ["small", "OBSERVATION_MODIFIER", 86, 91], ["cytoplasmic loop", "OBSERVATION", 92, 108], ["ACA8 autoinhibition", "OBSERVATION", 112, 131]]], ["The most deregulated mutant is D291A ACA8, which is less activated also by controlled proteolysis or by acidic phospholipids; moreover, the phenotype of the D291A mutant is stronger than that of D291N ACA8 suggesting a more direct involvement of this residue in autoinhibition.", [["D291A ACA8", "GENE_OR_GENE_PRODUCT", 31, 41], ["D291A", "GENE_OR_GENE_PRODUCT", 157, 162], ["D291N ACA8", "GENE_OR_GENE_PRODUCT", 195, 205], ["D291A ACA8", "PROTEIN", 31, 41], ["D291A mutant", "PROTEIN", 157, 169], ["D291N ACA8", "PROTEIN", 195, 205], ["acidic phospholipids", "TEST", 104, 124], ["this residue in autoinhibition", "PROBLEM", 246, 276]]], ["Of the other mutants (I284A, N286A, P289A, P322A, V344A, N345A), only P322A ACA8 has a basal activity higher than that of the WT.", [["P322A ACA8", "GENE_OR_GENE_PRODUCT", 70, 80], ["P322A ACA8", "PROTEIN", 70, 80], ["basal", "OBSERVATION_MODIFIER", 87, 92], ["activity", "OBSERVATION_MODIFIER", 93, 101], ["higher", "OBSERVATION_MODIFIER", 102, 108]]], ["These results provide the first evidence that the small cytoplasmic loop of a type 2B CaATPase plays a role in the attainment of the autoinhibited state.", [["cytoplasmic", "ANATOMY", 56, 67], ["cytoplasmic", "ORGANISM_SUBSTANCE", 56, 67], ["type 2B", "GENE_OR_GENE_PRODUCT", 78, 85], ["CaATPase", "GENE_OR_GENE_PRODUCT", 86, 94], ["cytoplasmic loop", "PROTEIN", 56, 72], ["type 2B CaATPase", "PROTEIN", 78, 94], ["the small cytoplasmic loop", "PROBLEM", 46, 72], ["a type 2B CaATPase", "TREATMENT", 76, 94], ["small", "OBSERVATION_MODIFIER", 50, 55], ["cytoplasmic loop", "OBSERVATION", 56, 72]]], ["Complex I, the first member of the respiratory chain, serves as a proton pump catalyzing transfer of two electrons from NADH to ubiquinone coupled with the translocation of four protons across the membrane.", [["membrane", "ANATOMY", 197, 205], ["NADH", "CHEMICAL", 120, 124], ["ubiquinone", "CHEMICAL", 128, 138], ["NADH", "CHEMICAL", 120, 124], ["ubiquinone", "CHEMICAL", 128, 138], ["Complex I", "GENE_OR_GENE_PRODUCT", 0, 9], ["NADH", "SIMPLE_CHEMICAL", 120, 124], ["ubiquinone", "SIMPLE_CHEMICAL", 128, 138], ["protons", "SIMPLE_CHEMICAL", 178, 185], ["membrane", "CELLULAR_COMPONENT", 197, 205], ["Complex I", "PROTEIN", 0, 9], ["respiratory chain", "PROTEIN", 35, 52], ["a proton pump catalyzing", "TREATMENT", 64, 88], ["respiratory chain", "ANATOMY", 35, 52], ["membrane", "ANATOMY", 197, 205]]], ["So far the mechanism of energy transduction by Complex I is unknown.", [["Complex I", "GENE_OR_GENE_PRODUCT", 47, 56], ["Complex I", "PROTEIN", 47, 56]]], ["The NADH-binding cavity of Complex I has a very prominent feature -the presence of two invariant amino acid residues, glutamate and tyrosine, that are exposed to the solvent and located in the vicinity of the FMN, the primary electron acceptor in the enzyme.", [["NADH", "CHEMICAL", 4, 8], ["amino acid", "CHEMICAL", 97, 107], ["glutamate", "CHEMICAL", 118, 127], ["tyrosine", "CHEMICAL", 132, 140], ["NADH", "CHEMICAL", 4, 8], ["amino acid", "CHEMICAL", 97, 107], ["glutamate", "CHEMICAL", 118, 127], ["tyrosine", "CHEMICAL", 132, 140], ["FMN", "CHEMICAL", 209, 212], ["NADH", "SIMPLE_CHEMICAL", 4, 8], ["Complex I", "GENE_OR_GENE_PRODUCT", 27, 36], ["amino acid", "AMINO_ACID", 97, 107], ["glutamate", "SIMPLE_CHEMICAL", 118, 127], ["tyrosine", "AMINO_ACID", 132, 140], ["FMN", "SIMPLE_CHEMICAL", 209, 212], ["electron", "SIMPLE_CHEMICAL", 226, 234], ["NADH", "PROTEIN", 4, 8], ["Complex I", "PROTEIN", 27, 36], ["FMN", "PROTEIN", 209, 212], ["enzyme", "PROTEIN", 251, 257], ["a very prominent feature", "PROBLEM", 41, 65], ["invariant amino acid residues", "TREATMENT", 87, 116], ["glutamate and tyrosine", "TREATMENT", 118, 140], ["the enzyme", "TEST", 247, 257], ["binding cavity", "OBSERVATION", 9, 23], ["very prominent", "OBSERVATION_MODIFIER", 43, 57], ["invariant", "OBSERVATION_MODIFIER", 87, 96], ["amino acid residues", "OBSERVATION", 97, 116], ["FMN", "ANATOMY", 209, 212]]], ["It was suggested that they might be involved in the binding of NADH through interaction with its nicotinamide moiety.", [["NADH", "CHEMICAL", 63, 67], ["nicotinamide", "CHEMICAL", 97, 109], ["NADH", "CHEMICAL", 63, 67], ["nicotinamide", "CHEMICAL", 97, 109], ["NADH", "SIMPLE_CHEMICAL", 63, 67], ["nicotinamide moiety", "SIMPLE_CHEMICAL", 97, 116], ["its nicotinamide moiety", "TREATMENT", 93, 116]]], ["In this work we assessed the function of corresponding Glu95 from the NuoF subunit of E. coli Complex I by mutation for glutamine.", [["glutamine", "CHEMICAL", 120, 129], ["glutamine", "CHEMICAL", 120, 129], ["Glu95", "GENE_OR_GENE_PRODUCT", 55, 60], ["NuoF", "GENE_OR_GENE_PRODUCT", 70, 74], ["E. coli", "ORGANISM", 86, 93], ["Complex I", "GENE_OR_GENE_PRODUCT", 94, 103], ["glutamine", "AMINO_ACID", 120, 129], ["Glu95", "PROTEIN", 55, 60], ["NuoF subunit", "PROTEIN", 70, 82], ["E. coli Complex I", "PROTEIN", 86, 103], ["E. coli", "SPECIES", 86, 93], ["E. coli", "SPECIES", 86, 93], ["E. coli", "PROBLEM", 86, 93], ["glutamine", "TREATMENT", 120, 129]]], ["We showed that the negative charge of glutamate in the catalytic site is needed for the electrostatic repulsion of negatively charged phosphates of nucleotides.", [["glutamate", "CHEMICAL", 38, 47], ["glutamate", "CHEMICAL", 38, 47], ["phosphates", "CHEMICAL", 134, 144], ["nucleotides", "CHEMICAL", 148, 159], ["glutamate", "SIMPLE_CHEMICAL", 38, 47], ["catalytic site", "PROTEIN", 55, 69], ["the negative charge of glutamate in the catalytic site", "PROBLEM", 15, 69], ["nucleotides", "TREATMENT", 148, 159]]], ["This process facilitates release of the product NAD + and, as a result, accelerates turnover of Complex I. We also found that glutamate, as one of the four negatively charged amino acid residues surrounding the isoalloxazine ring of the FMN at a distance of 4-6\u00c5, has a share of 40 mV of the overall 130 mV depression of the midpoint potential of this redox cofactor.Coupling of water and glucose fluxes in epithelial cells expressing sodium-glucose cotransporterL.", [["epithelial cells", "ANATOMY", 407, 423], ["NAD", "CHEMICAL", 48, 51], ["glutamate", "CHEMICAL", 126, 135], ["amino acid", "CHEMICAL", 175, 185], ["isoalloxazine", "CHEMICAL", 211, 224], ["depression", "DISEASE", 307, 317], ["glucose", "CHEMICAL", 389, 396], ["sodium-glucose cotransporterL", "CHEMICAL", 435, 464], ["NAD +", "CHEMICAL", 48, 53], ["glutamate", "CHEMICAL", 126, 135], ["amino acid", "CHEMICAL", 175, 185], ["isoalloxazine", "CHEMICAL", 211, 224], ["FMN", "CHEMICAL", 237, 240], ["glucose", "CHEMICAL", 389, 396], ["sodium-glucose", "CHEMICAL", 435, 449], ["NAD +", "SIMPLE_CHEMICAL", 48, 53], ["glutamate", "SIMPLE_CHEMICAL", 126, 135], ["amino acid", "AMINO_ACID", 175, 185], ["FMN", "SIMPLE_CHEMICAL", 237, 240], ["water", "SIMPLE_CHEMICAL", 379, 384], ["glucose", "SIMPLE_CHEMICAL", 389, 396], ["epithelial cells", "CELL", 407, 423], ["sodium-glucose cotransporterL", "SIMPLE_CHEMICAL", 435, 464], ["FMN", "PROTEIN", 237, 240], ["redox cofactor", "PROTEIN", 352, 366], ["epithelial cells", "CELL_TYPE", 407, 423], ["sodium-glucose cotransporterL", "PROTEIN", 435, 464], ["amino acid residues", "TREATMENT", 175, 194], ["the isoalloxazine ring", "TREATMENT", 207, 229], ["this redox cofactor", "PROBLEM", 347, 366], ["glucose fluxes", "PROBLEM", 389, 403], ["epithelial cells", "TEST", 407, 423], ["sodium", "TEST", 435, 441], ["amino acid", "OBSERVATION", 175, 185], ["isoalloxazine ring", "OBSERVATION", 211, 229], ["130 mV", "OBSERVATION_MODIFIER", 300, 306], ["epithelial cells", "ANATOMY", 407, 423]]], ["Erokhova 1 , P. K\u00fcgler 2 , P. Pohl 1 1 Institute of Biophysics, Johannes Kepler University, Linz, Austria, 2 RICAM, Austrian Academy of Sciences, Linz, AustriaCoupling of water and glucose fluxes in epithelial cells expressing sodium-glucose cotransporterThe mechanism of water transport through epithelia is still under debate.", [["epithelial cells", "ANATOMY", 199, 215], ["epithelia", "ANATOMY", 296, 305], ["glucose", "CHEMICAL", 181, 188], ["sodium-glucose", "CHEMICAL", 227, 241], ["glucose", "CHEMICAL", 181, 188], ["sodium", "CHEMICAL", 227, 233], ["glucose", "CHEMICAL", 234, 241], ["glucose", "SIMPLE_CHEMICAL", 181, 188], ["epithelial cells", "CELL", 199, 215], ["sodium-glucose cotransporter", "SIMPLE_CHEMICAL", 227, 255], ["water", "SIMPLE_CHEMICAL", 272, 277], ["epithelia", "TISSUE", 296, 305], ["epithelial cells", "CELL_TYPE", 199, 215], ["sodium-glucose cotransporter", "PROTEIN", 227, 255], ["Linz", "TREATMENT", 146, 150], ["glucose fluxes", "TEST", 181, 195], ["sodium", "TEST", 227, 233]]], ["In the present work we tested the hypothesis of isosmolal water transport using MDCK cells stably expressing the human sodium-glucose cotransporter (hSGLT1).", [["MDCK cells", "ANATOMY", 80, 90], ["sodium", "CHEMICAL", 119, 125], ["glucose", "CHEMICAL", 126, 133], ["sodium", "CHEMICAL", 119, 125], ["glucose", "CHEMICAL", 126, 133], ["water", "SIMPLE_CHEMICAL", 58, 63], ["MDCK cells", "CELL", 80, 90], ["human", "ORGANISM", 113, 118], ["sodium-glucose cotransporter", "GENE_OR_GENE_PRODUCT", 119, 147], ["hSGLT1", "GENE_OR_GENE_PRODUCT", 149, 155], ["MDCK cells", "CELL_LINE", 80, 90], ["human sodium-glucose cotransporter", "PROTEIN", 113, 147], ["hSGLT1", "PROTEIN", 149, 155], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["isosmolal water transport", "TREATMENT", 48, 73], ["MDCK cells", "TREATMENT", 80, 90], ["the human sodium", "TEST", 109, 125]]], ["Tagging hSGLT1 with EGFP enabled determination of its abundance in the plasma membrane by fluorescence correlation spectroscopy (FCS).", [["plasma membrane", "ANATOMY", 71, 86], ["hSGLT1", "GENE_OR_GENE_PRODUCT", 8, 14], ["EGFP", "GENE_OR_GENE_PRODUCT", 20, 24], ["plasma membrane", "CELLULAR_COMPONENT", 71, 86], ["hSGLT1", "PROTEIN", 8, 14], ["EGFP", "DNA", 20, 24], ["Tagging hSGLT1", "TEST", 0, 14], ["fluorescence correlation spectroscopy", "TEST", 90, 127], ["plasma membrane", "ANATOMY", 71, 86]]], ["By monitoring tiny shifts in the concentration of water-soluble dyes in the vicinity of epithelia, FCS also allowed assessment of the water fluxes through confluent cell monolayers grown on permeable supports.", [["epithelia", "ANATOMY", 88, 97], ["cell monolayers", "ANATOMY", 165, 180], ["epithelia", "TISSUE", 88, 97], ["water", "SIMPLE_CHEMICAL", 134, 139], ["cell monolayers", "CELL", 165, 180], ["confluent cell monolayers", "CELL_LINE", 155, 180], ["tiny shifts", "PROBLEM", 14, 25], ["water-soluble dyes", "TREATMENT", 50, 68], ["assessment", "TEST", 116, 126], ["the water fluxes", "PROBLEM", 130, 146], ["confluent cell monolayers", "PROBLEM", 155, 180], ["permeable supports", "TREATMENT", 190, 208], ["tiny", "OBSERVATION_MODIFIER", 14, 18], ["shifts", "OBSERVATION_MODIFIER", 19, 25], ["confluent", "OBSERVATION_MODIFIER", 155, 164], ["cell monolayers", "OBSERVATION", 165, 180]]], ["Fitting the set of differential equations for the osmotic drift and for the back diffusion to the experimentally determined dye distribution permitted calculation of water flow both in the presence and in the absence of an osmotic gradient.", [["water", "SIMPLE_CHEMICAL", 166, 171], ["differential equations", "TEST", 19, 41], ["the osmotic drift", "PROBLEM", 46, 63], ["the back diffusion", "TEST", 72, 90], ["an osmotic gradient", "PROBLEM", 220, 239], ["osmotic drift", "OBSERVATION", 50, 63], ["water flow", "OBSERVATION", 166, 176], ["osmotic gradient", "OBSERVATION", 223, 239]]], ["From the calorimetric measurements of glucose transported across the cell monolayer, the water:glucose stoichiometry was derived.", [["cell monolayer", "ANATOMY", 69, 83], ["glucose", "CHEMICAL", 38, 45], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 38, 45], ["glucose", "CHEMICAL", 95, 102], ["glucose", "SIMPLE_CHEMICAL", 38, 45], ["cell monolayer", "CELL", 69, 83], ["water", "SIMPLE_CHEMICAL", 89, 94], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["the calorimetric measurements", "TEST", 5, 34], ["glucose", "TEST", 38, 45], ["glucose stoichiometry", "TREATMENT", 95, 116], ["cell monolayer", "OBSERVATION", 69, 83]]], ["Dividing the increment in osmotic water flux due to hSGLT1 expression by the number of hSGLT1 copies in the plasma membrane resulted in a single transporter water permeability p f of 4.6 x 10 \u221214 cm 3 /sec.", [["plasma membrane", "ANATOMY", 108, 123], ["hSGLT1", "GENE_OR_GENE_PRODUCT", 52, 58], ["hSGLT1", "GENE_OR_GENE_PRODUCT", 87, 93], ["plasma membrane", "CELLULAR_COMPONENT", 108, 123], ["hSGLT1", "PROTEIN", 52, 58], ["hSGLT1 copies", "DNA", 87, 100], ["osmotic water flux", "TREATMENT", 26, 44], ["hSGLT1 expression", "PROBLEM", 52, 69], ["increment", "OBSERVATION_MODIFIER", 13, 22], ["water flux", "OBSERVATION", 34, 44], ["plasma membrane", "ANATOMY", 108, 123], ["4.6 x", "OBSERVATION_MODIFIER", 183, 188]]], ["Thus, p f is close to the single channel water permeability of aquaporin-1.", [["aquaporin-1", "GENE_OR_GENE_PRODUCT", 63, 74], ["aquaporin-1", "PROTEIN", 63, 74], ["the single channel water permeability of aquaporin", "TREATMENT", 22, 72]]], ["Consequently, even small osmolyte concentration differences between the cytoplasm and the basolateral buffer solution are sufficient to drive a substantial water flux.The effects of telmisartan on electrical responses of left ventricular papillary muscle in rats with streptozotocin(STZ)-induced diabetes mellitusM.", [["cytoplasm", "ANATOMY", 72, 81], ["left ventricular papillary muscle", "ANATOMY", 221, 254], ["osmolyte", "CHEMICAL", 25, 33], ["telmisartan", "CHEMICAL", 182, 193], ["streptozotocin", "CHEMICAL", 268, 282], ["STZ", "CHEMICAL", 283, 286], ["diabetes mellitusM", "DISEASE", 296, 314], ["telmisartan", "CHEMICAL", 182, 193], ["streptozotocin", "CHEMICAL", 268, 282], ["STZ", "CHEMICAL", 283, 286], ["cytoplasm", "ORGANISM_SUBSTANCE", 72, 81], ["water", "SIMPLE_CHEMICAL", 156, 161], ["telmisartan", "SIMPLE_CHEMICAL", 182, 193], ["left ventricular papillary muscle", "TISSUE", 221, 254], ["rats", "ORGANISM", 258, 262], ["streptozotocin", "SIMPLE_CHEMICAL", 268, 282], ["STZ", "SIMPLE_CHEMICAL", 283, 286], ["rats", "SPECIES", 258, 262], ["small osmolyte concentration differences between the cytoplasm", "PROBLEM", 19, 81], ["the basolateral buffer solution", "TREATMENT", 86, 117], ["a substantial water flux", "TREATMENT", 142, 166], ["telmisartan", "TREATMENT", 182, 193], ["streptozotocin(STZ", "TREATMENT", 268, 286], ["induced diabetes mellitusM", "PROBLEM", 288, 314], ["small", "OBSERVATION_MODIFIER", 19, 24], ["osmolyte concentration", "OBSERVATION", 25, 47], ["cytoplasm", "OBSERVATION_MODIFIER", 72, 81], ["substantial", "OBSERVATION_MODIFIER", 144, 155], ["water flux", "OBSERVATION", 156, 166], ["left ventricular", "ANATOMY", 221, 237], ["papillary muscle", "ANATOMY", 238, 254], ["diabetes mellitusM", "OBSERVATION", 296, 314]]], ["Emre, S. Kavak Cukurova University School of Medicine, Department of Biophysics, Balcali-Adana, TurkeyThe effects of telmisartan on electrical responses of left ventricular papillary muscle in rats with streptozotocin(STZ)-induced diabetes mellitusExperimental studies have shown that the AT1-receptor antagonists telmisartan (Tel) has a PPAR-activating property, but there does not appear to be a class effect.", [["left ventricular papillary muscle", "ANATOMY", 156, 189], ["telmisartan", "CHEMICAL", 117, 128], ["streptozotocin", "CHEMICAL", 203, 217], ["STZ", "CHEMICAL", 218, 221], ["diabetes mellitus", "DISEASE", 231, 248], ["telmisartan", "CHEMICAL", 314, 325], ["Tel", "CHEMICAL", 327, 330], ["telmisartan", "CHEMICAL", 117, 128], ["streptozotocin", "CHEMICAL", 203, 217], ["STZ", "CHEMICAL", 218, 221], ["telmisartan", "CHEMICAL", 314, 325], ["telmisartan", "SIMPLE_CHEMICAL", 117, 128], ["ventricular papillary muscle", "TISSUE", 161, 189], ["rats", "ORGANISM", 193, 197], ["streptozotocin", "SIMPLE_CHEMICAL", 203, 217], ["STZ", "SIMPLE_CHEMICAL", 218, 221], ["AT1-receptor", "GENE_OR_GENE_PRODUCT", 289, 301], ["telmisartan", "SIMPLE_CHEMICAL", 314, 325], ["Tel", "SIMPLE_CHEMICAL", 327, 330], ["PPAR", "GENE_OR_GENE_PRODUCT", 338, 342], ["PPAR", "PROTEIN", 338, 342], ["rats", "SPECIES", 193, 197], ["telmisartan", "TREATMENT", 117, 128], ["left ventricular papillary muscle", "PROBLEM", 156, 189], ["streptozotocin(STZ", "TREATMENT", 203, 221], ["induced diabetes mellitus", "PROBLEM", 223, 248], ["Experimental studies", "TEST", 248, 268], ["the AT1-receptor antagonists telmisartan", "TREATMENT", 285, 325], ["left ventricular", "ANATOMY", 156, 172], ["papillary muscle", "ANATOMY", 173, 189]]], ["To test telmisartan's importance, we investigated its effect on electrical activities (EA) in diabetic (D) rats.", [["telmisartan", "CHEMICAL", 8, 19], ["diabetic", "DISEASE", 94, 102], ["telmisartan", "CHEMICAL", 8, 19], ["telmisartan", "SIMPLE_CHEMICAL", 8, 19], ["rats", "ORGANISM", 107, 111], ["rats", "SPECIES", 107, 111]]], ["The purpose of this study was to investigate the effects of the Tel on EA of diabetic papillary muscle (DPM) with STZ-induced.", [["papillary muscle", "ANATOMY", 86, 102], ["DPM", "ANATOMY", 104, 107], ["diabetic papillary muscle", "DISEASE", 77, 102], ["STZ", "CHEMICAL", 114, 117], ["STZ", "CHEMICAL", 114, 117], ["papillary muscle", "TISSUE", 86, 102], ["STZ", "SIMPLE_CHEMICAL", 114, 117], ["this study", "TEST", 15, 25], ["diabetic papillary muscle", "PROBLEM", 77, 102], ["STZ", "TREATMENT", 114, 117], ["diabetic", "OBSERVATION", 77, 85], ["papillary muscle", "ANATOMY", 86, 102]]], ["In this study, we used four groups: (1) nondiabetic control (NDC) group (C), (2) Tel-treated NDC group (C+Tel), (3) diabetic group (D), and (4) Tel-treated D group (D+Tel).", [["diabetic", "DISEASE", 116, 124], ["Tel-treated D", "SIMPLE_CHEMICAL", 144, 157], ["D+Tel", "SIMPLE_CHEMICAL", 165, 170], ["this study", "TEST", 3, 13], ["nondiabetic control (NDC) group (C), (2) Tel-treated NDC group (C+Tel), (3) diabetic group (D)", "PROBLEM", 40, 134]]], ["Diabetes was induced by a single i.v injection of STZ.", [["Diabetes", "DISEASE", 0, 8], ["STZ", "CHEMICAL", 50, 53], ["STZ", "CHEMICAL", 50, 53], ["STZ", "SIMPLE_CHEMICAL", 50, 53], ["Diabetes", "PROBLEM", 0, 8], ["a single i.v injection of STZ", "TREATMENT", 24, 53]]], ["In the study, membrane potential (MP) and action potential (AP) recorded after the establishment of diabetes.", [["membrane", "ANATOMY", 14, 22], ["diabetes", "DISEASE", 100, 108], ["the study", "TEST", 3, 12], ["diabetes", "PROBLEM", 100, 108], ["diabetes", "OBSERVATION", 100, 108]]], ["1) MP was decreased significantly in both Tel-treated C and D rats (from -71,4\u00b10,7 to -64,7\u00b10,8 mV and from -69,9\u00b10,6 to -63,8\u00b10,7 mV).", [["MP", "GENE_OR_GENE_PRODUCT", 3, 5], ["Tel", "SIMPLE_CHEMICAL", 42, 45], ["C", "CELL", 54, 55], ["D rats", "ORGANISM", 60, 66], ["rats", "SPECIES", 62, 66], ["MP", "TEST", 3, 5], ["mV", "TEST", 96, 98], ["decreased", "OBSERVATION_MODIFIER", 10, 19]]], ["2) AP unchanged in D group, whereas C+Tel and D+Tel groups showed increase in AP compared with C and D groups.", [["AP", "SIMPLE_CHEMICAL", 3, 5], ["D", "SIMPLE_CHEMICAL", 19, 20], ["C+Tel", "SIMPLE_CHEMICAL", 36, 41], ["D+Tel", "SIMPLE_CHEMICAL", 46, 51], ["AP", "SIMPLE_CHEMICAL", 78, 80], ["AP unchanged in D group", "TEST", 3, 26], ["increase in AP", "PROBLEM", 66, 80], ["unchanged", "OBSERVATION_MODIFIER", 6, 15], ["increase", "OBSERVATION_MODIFIER", 66, 74]]], ["3) Repolarization time was prolonged in diabetic rats.", [["diabetic", "DISEASE", 40, 48], ["rats", "ORGANISM", 49, 53], ["rats", "SPECIES", 49, 53], ["Repolarization time", "PROBLEM", 3, 22], ["prolonged in diabetic rats", "PROBLEM", 27, 53], ["prolonged", "OBSERVATION_MODIFIER", 27, 36]]], ["4) In C+Tel and D+Tel groups depolarization rate values increased significantly.", [["C+Tel", "SIMPLE_CHEMICAL", 6, 11], ["D+Tel", "SIMPLE_CHEMICAL", 16, 21], ["Tel groups depolarization rate values", "TEST", 18, 55], ["increased", "OBSERVATION_MODIFIER", 56, 65]]], ["On the other hand, in D group repolarization rate values descreased increased significantly compared to baseline values in Tel solution.", [["D", "SIMPLE_CHEMICAL", 22, 23], ["D group repolarization rate values", "TEST", 22, 56]]], ["As a result, our data suggest that the beneficial effects of Tel-treatment on the EA of the DPM appear to be due to the diminished K + currents.", [["Tel", "CHEMICAL", 61, 64], ["DPM", "CHEMICAL", 92, 95], ["K", "CHEMICAL", 131, 132], ["K +", "CHEMICAL", 131, 134], ["Tel", "SIMPLE_CHEMICAL", 61, 64], ["DPM", "SIMPLE_CHEMICAL", 92, 95], ["K +", "SIMPLE_CHEMICAL", 131, 134], ["our data", "TEST", 13, 21], ["Tel-treatment", "TREATMENT", 61, 74], ["the diminished K + currents", "PROBLEM", 116, 143], ["diminished", "OBSERVATION", 120, 130]]], ["Cytochrome c oxidase is a terminal complex (CcO, Complex IV) of a respiratory chain that is located in an internal membrane of mitochondria or plasma membrane of bacteria.", [["internal membrane", "ANATOMY", 106, 123], ["mitochondria", "ANATOMY", 127, 139], ["plasma membrane", "ANATOMY", 143, 158], ["Cytochrome c oxidase", "GENE_OR_GENE_PRODUCT", 0, 20], ["CcO", "GENE_OR_GENE_PRODUCT", 44, 47], ["Complex IV", "GENE_OR_GENE_PRODUCT", 49, 59], ["internal membrane", "CELLULAR_COMPONENT", 106, 123], ["mitochondria", "CELLULAR_COMPONENT", 127, 139], ["plasma membrane", "CELLULAR_COMPONENT", 143, 158], ["Cytochrome c oxidase", "PROTEIN", 0, 20], ["terminal complex", "PROTEIN", 26, 42], ["CcO", "PROTEIN", 44, 47], ["Complex IV", "PROTEIN", 49, 59], ["respiratory chain", "PROTEIN", 66, 83], ["Cytochrome c oxidase", "TREATMENT", 0, 20], ["a respiratory chain", "PROBLEM", 64, 83], ["plasma membrane of bacteria", "PROBLEM", 143, 170], ["terminal", "OBSERVATION_MODIFIER", 26, 34], ["respiratory chain", "OBSERVATION", 66, 83], ["internal membrane", "ANATOMY", 106, 123], ["plasma membrane", "OBSERVATION", 143, 158], ["bacteria", "OBSERVATION", 162, 170]]], ["CcO is an electron transfer enzyme that reduces O 2 and uses the redox energy of the O 2 reduction for the proton translocation across the membrane.", [["membrane", "ANATOMY", 139, 147], ["CcO", "CHEMICAL", 0, 3], ["CcO", "CHEMICAL", 0, 3], ["O 2", "CHEMICAL", 48, 51], ["O 2", "CHEMICAL", 85, 88], ["CcO", "SIMPLE_CHEMICAL", 0, 3], ["electron", "SIMPLE_CHEMICAL", 10, 18], ["O 2", "SIMPLE_CHEMICAL", 85, 88], ["proton", "SIMPLE_CHEMICAL", 107, 113], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["O 2", "PROTEIN", 48, 51], ["an electron transfer enzyme", "TEST", 7, 34], ["the O 2 reduction", "TREATMENT", 81, 98], ["the proton translocation", "TREATMENT", 103, 127], ["proton translocation", "OBSERVATION", 107, 127], ["membrane", "ANATOMY", 139, 147]]], ["The electron-and proton-transfer generate a transmembrane electrochemical gradient (\u2206\u00b5H + ) that is used for ATP synthesis and all other kinds of work for the cell needs.", [["transmembrane", "ANATOMY", 44, 57], ["cell", "ANATOMY", 159, 163], ["ATP", "CHEMICAL", 109, 112], ["ATP", "CHEMICAL", 109, 112], ["electron", "SIMPLE_CHEMICAL", 4, 12], ["ATP", "SIMPLE_CHEMICAL", 109, 112], ["cell", "CELL", 159, 163], ["a transmembrane electrochemical gradient", "TEST", 42, 82], ["ATP synthesis", "TREATMENT", 109, 122], ["the cell needs", "TREATMENT", 155, 169]]], ["The proton translocation mechanism of CcO requires 'channels' for the H + uptake and expulsion within the enzyme.", [["CcO", "CHEMICAL", 38, 41], ["H", "CHEMICAL", 70, 71], ["CcO", "CHEMICAL", 38, 41], ["H +", "CHEMICAL", 70, 73], ["proton", "SIMPLE_CHEMICAL", 4, 10], ["CcO", "SIMPLE_CHEMICAL", 38, 41], ["H +", "SIMPLE_CHEMICAL", 70, 73], ["CcO", "PROTEIN", 38, 41], ["enzyme", "PROTEIN", 106, 112], ["expulsion", "PROBLEM", 85, 94], ["the enzyme", "TEST", 102, 112]]], ["In order to study the proton transfer in CcO, a flow-flash approach based on a time-resolved FTIR spectroscopy was developed and applied.", [["CcO", "CHEMICAL", 41, 44], ["CcO", "CHEMICAL", 41, 44], ["CcO", "SIMPLE_CHEMICAL", 41, 44], ["a flow-flash approach", "TREATMENT", 46, 67], ["FTIR spectroscopy", "TEST", 93, 110]]], ["Our FTIR flow-flash approach (the measurement of the reaction of CcO with O 2 ) allows to reach a time resolution up to tens milliseconds.", [["CcO", "CHEMICAL", 65, 68], ["O 2", "CHEMICAL", 74, 77], ["Our FTIR flow", "TEST", 0, 13]]], ["With this approach and site-specific mutants of CcO where the catalysis is slowed down, separate steps of the proton transfer were studied.", [["CcO", "CHEMICAL", 48, 51], ["CcO", "CHEMICAL", 48, 51], ["CcO", "SIMPLE_CHEMICAL", 48, 51], ["proton", "SIMPLE_CHEMICAL", 110, 116], ["CcO", "PROTEIN", 48, 51], ["this approach", "TREATMENT", 5, 18], ["the catalysis", "PROBLEM", 58, 71]]], ["The results showed that a unique cross-linked Tyr-280 (in a combination with a time-resolved visible spectroscopy and electrometry) serves as a proton donor for the dioxygen bond cleavage during the O 2 reduction by CcO.", [["Tyr-280", "CHEMICAL", 46, 53], ["dioxygen", "CHEMICAL", 165, 173], ["CcO", "CHEMICAL", 216, 219], ["Tyr-280", "CHEMICAL", 46, 53], ["dioxygen", "CHEMICAL", 165, 173], ["O 2", "CHEMICAL", 199, 202], ["CcO", "CHEMICAL", 216, 219], ["Tyr-280", "SIMPLE_CHEMICAL", 46, 53], ["dioxygen", "SIMPLE_CHEMICAL", 165, 173], ["O 2", "SIMPLE_CHEMICAL", 199, 202], ["CcO", "SIMPLE_CHEMICAL", 216, 219], ["visible spectroscopy", "TEST", 93, 113], ["a proton donor", "TREATMENT", 142, 156], ["the dioxygen bond cleavage", "TREATMENT", 161, 187], ["the O 2 reduction", "TREATMENT", 195, 212]]], ["Furthermore, the protolytic transitions of Glu-278 -a key amino acid in the proton transfer mechanism in CcO -were shown for the first time.P-417Role of Calcium ions in Nickel potentiation of NMDA currents P. Gavazzo, I. Zanardi, P. Guida, C. Marchetti Biophysics Institute ,CNR, Genova, Italy NMDA receptors are glutamate-gated channels distributed throughout the brain in the excitatory synapses and are critical for the nervous system function.", [["brain", "ANATOMY", 365, 370], ["excitatory synapses", "ANATOMY", 378, 397], ["nervous system", "ANATOMY", 423, 437], ["Glu-278", "CHEMICAL", 43, 50], ["amino acid", "CHEMICAL", 58, 68], ["CcO", "CHEMICAL", 105, 108], ["P-417Role", "CHEMICAL", 140, 149], ["Calcium", "CHEMICAL", 153, 160], ["Nickel", "CHEMICAL", 169, 175], ["NMDA", "CHEMICAL", 192, 196], ["NMDA", "CHEMICAL", 294, 298], ["glutamate", "CHEMICAL", 313, 322], ["Glu", "CHEMICAL", 43, 46], ["amino acid", "CHEMICAL", 58, 68], ["CcO", "CHEMICAL", 105, 108], ["Calcium", "CHEMICAL", 153, 160], ["Nickel", "CHEMICAL", 169, 175], ["NMDA", "CHEMICAL", 192, 196], ["NMDA", "CHEMICAL", 294, 298], ["glutamate", "CHEMICAL", 313, 322], ["Glu-278", "SIMPLE_CHEMICAL", 43, 50], ["amino acid", "AMINO_ACID", 58, 68], ["CcO", "SIMPLE_CHEMICAL", 105, 108], ["Calcium ions", "SIMPLE_CHEMICAL", 153, 165], ["Nickel", "SIMPLE_CHEMICAL", 169, 175], ["NMDA", "SIMPLE_CHEMICAL", 192, 196], ["glutamate", "SIMPLE_CHEMICAL", 313, 322], ["brain", "ORGAN", 365, 370], ["excitatory synapses", "CELLULAR_COMPONENT", 378, 397], ["nervous system", "ANATOMICAL_SYSTEM", 423, 437], ["CcO", "PROTEIN", 105, 108], ["glutamate-gated channels", "PROTEIN", 313, 337], ["Glu", "TEST", 43, 46], ["amino acid", "TEST", 58, 68], ["CcO", "TEST", 105, 108], ["P", "TEST", 140, 141], ["Calcium ions", "TREATMENT", 153, 165], ["NMDA currents", "TREATMENT", 192, 205], ["Gavazzo", "TREATMENT", 209, 216], ["brain", "ANATOMY", 365, 370]]], ["They are assembled from two types of subunits, the essential NR1 and at least one NR2(A,B,C,D).", [["NR1", "GENE_OR_GENE_PRODUCT", 61, 64], ["NR2", "GENE_OR_GENE_PRODUCT", 82, 85], ["NR1", "PROTEIN", 61, 64], ["NR2", "PROTEIN", 82, 85], ["A", "PROTEIN", 86, 87], ["B", "PROTEIN", 88, 89], ["C", "PROTEIN", 90, 91], ["D", "PROTEIN", 92, 93], ["subunits", "TREATMENT", 37, 45]]], ["Nickel (Ni) modulates the current flowing through NMDA receptors in a different way depending on the NR2 subunit present.", [["Nickel", "CHEMICAL", 0, 6], ["Ni", "CHEMICAL", 8, 10], ["NMDA", "CHEMICAL", 50, 54], ["Nickel", "CHEMICAL", 0, 6], ["Ni", "CHEMICAL", 8, 10], ["NMDA", "CHEMICAL", 50, 54], ["Nickel", "SIMPLE_CHEMICAL", 0, 6], ["Ni", "SIMPLE_CHEMICAL", 8, 10], ["NMDA", "SIMPLE_CHEMICAL", 50, 54], ["NR2", "GENE_OR_GENE_PRODUCT", 101, 104], ["NMDA receptors", "PROTEIN", 50, 64], ["NR2 subunit", "PROTEIN", 101, 112], ["Nickel (Ni)", "TREATMENT", 0, 11], ["the current flowing through NMDA receptors", "TREATMENT", 22, 64]]], ["We have recently identified several domains of the channel involved in Ni interaction, but many aspects of this modulation remain elusive.", [["Ni", "CHEMICAL", 71, 73], ["Ni", "CHEMICAL", 71, 73], ["Ni", "GENE_OR_GENE_PRODUCT", 71, 73], ["Ni", "PROTEIN", 71, 73], ["this modulation", "PROBLEM", 107, 122]]], ["In this work we intended to determine the role of calcium (Ca) ions in the potentiation induced by Ni on the current through NR1/NR2B recombinant NMDA receptors.", [["calcium", "CHEMICAL", 50, 57], ["Ca", "CHEMICAL", 59, 61], ["Ni", "CHEMICAL", 99, 101], ["NMDA", "CHEMICAL", 146, 150], ["calcium", "CHEMICAL", 50, 57], ["Ca", "CHEMICAL", 59, 61], ["Ni", "CHEMICAL", 99, 101], ["NMDA", "CHEMICAL", 146, 150], ["calcium", "SIMPLE_CHEMICAL", 50, 57], ["Ni", "SIMPLE_CHEMICAL", 99, 101], ["NR1", "GENE_OR_GENE_PRODUCT", 125, 128], ["NR2B", "GENE_OR_GENE_PRODUCT", 129, 133], ["NMDA receptors", "GENE_OR_GENE_PRODUCT", 146, 160], ["NR1", "PROTEIN", 125, 128], ["NR2B recombinant NMDA receptors", "PROTEIN", 129, 160], ["calcium (Ca) ions", "TREATMENT", 50, 67], ["NR1/NR2B recombinant NMDA receptors", "TREATMENT", 125, 160]]], ["When Ni was applied in the presence of the physiological concentration of Ca (1.8 mM) , a voltage-independent potentiation of the current was observed with a Kp of 2.5 \u00b5M.", [["Ni", "CHEMICAL", 5, 7], ["Ca", "CHEMICAL", 74, 76], ["Ni", "CHEMICAL", 5, 7], ["Ca", "CHEMICAL", 74, 76], ["Ni", "SIMPLE_CHEMICAL", 5, 7], ["Ca", "SIMPLE_CHEMICAL", 74, 76], ["Ni", "TREATMENT", 5, 7], ["Ca", "TEST", 74, 76], ["a voltage", "TEST", 88, 97]]], ["This effect was progressively reduced by decreasing Ca concentrations and it was no more detectable with 0.18 mM Ca or in the presence of barium (Ba, 0.3 mM).", [["Ca", "CHEMICAL", 52, 54], ["Ca", "CHEMICAL", 113, 115], ["barium", "CHEMICAL", 138, 144], ["Ba", "CHEMICAL", 146, 148], ["Ca", "CHEMICAL", 52, 54], ["Ca", "CHEMICAL", 113, 115], ["barium", "CHEMICAL", 138, 144], ["Ba", "CHEMICAL", 146, 148], ["Ca", "SIMPLE_CHEMICAL", 52, 54], ["barium", "SIMPLE_CHEMICAL", 138, 144], ["decreasing Ca concentrations", "PROBLEM", 41, 69], ["0.18 mM Ca", "PROBLEM", 105, 115], ["progressively", "OBSERVATION_MODIFIER", 16, 29], ["reduced", "OBSERVATION_MODIFIER", 30, 37], ["decreasing", "OBSERVATION_MODIFIER", 41, 51], ["Ca concentrations", "OBSERVATION_MODIFIER", 52, 69]]], ["In this last case the effect of Ni on NR1/NR2B receptors was mainly inhibitory (Ki(-60mV)=156\u00b5M).", [["Ni", "CHEMICAL", 32, 34], ["Ni", "CHEMICAL", 32, 34], ["NR1", "GENE_OR_GENE_PRODUCT", 38, 41], ["NR2B", "GENE_OR_GENE_PRODUCT", 42, 46], ["NR1/NR2B receptors", "PROTEIN", 38, 56], ["NR1/NR2B receptors", "TREATMENT", 38, 56], ["Ki", "TEST", 80, 82]]], ["Therefore a physiological concentration of Ca is necessary to induce Ni amplification of the current.", [["Ca", "CHEMICAL", 43, 45], ["Ni", "CHEMICAL", 69, 71], ["Ca", "CHEMICAL", 43, 45], ["Ni", "CHEMICAL", 69, 71], ["Ca", "SIMPLE_CHEMICAL", 43, 45], ["a physiological concentration of Ca", "TREATMENT", 10, 45]]], ["Many data in the literature indicate a correlation between Ca ion entrance through the channel, NMDA current facilitation and cytoskeleton; however, in our experiments, the application of the actin perturbing agent cytochalasin-D did not produce major modifications in Ni effect.P-416Heteromerization properties of voltage dependent potassium channels F. Gambale 1 , L. Pedemonte 1 , A. Naso 1 , I. Testa 2 , C. Usai 1 , A. Diaspro 2 , C. Picco 1 1 Istituto di Biofisica, CNR, Genova, Italy, 2 LAMBS-MicroScoBio, Department of Physics, Genova, Italy Voltage-gated potassium channels are either homomeric or heteromeric tetramers composed of four \u03b1-subunits.", [["cytoskeleton", "ANATOMY", 126, 138], ["Ca", "CHEMICAL", 59, 61], ["NMDA", "CHEMICAL", 96, 100], ["cytochalasin-D", "CHEMICAL", 215, 229], ["Ni", "CHEMICAL", 269, 271], ["potassium", "CHEMICAL", 333, 342], ["potassium", "CHEMICAL", 564, 573], ["Ca", "CHEMICAL", 59, 61], ["NMDA", "CHEMICAL", 96, 100], ["cytochalasin-D", "CHEMICAL", 215, 229], ["Ni", "CHEMICAL", 269, 271], ["potassium", "CHEMICAL", 333, 342], ["potassium", "CHEMICAL", 564, 573], ["Ca", "SIMPLE_CHEMICAL", 59, 61], ["NMDA", "SIMPLE_CHEMICAL", 96, 100], ["cytoskeleton", "CELLULAR_COMPONENT", 126, 138], ["actin", "GENE_OR_GENE_PRODUCT", 192, 197], ["cytochalasin-D", "SIMPLE_CHEMICAL", 215, 229], ["actin", "PROTEIN", 192, 197], ["Voltage-gated potassium channels", "PROTEIN", 550, 582], ["heteromeric tetramers", "PROTEIN", 607, 628], ["\u03b1-subunits", "PROTEIN", 646, 656], ["the actin perturbing agent cytochalasin", "TREATMENT", 188, 227], ["P", "TEST", 279, 280], ["voltage dependent potassium channels", "TREATMENT", 315, 351], ["gated potassium channels", "TREATMENT", 558, 582], ["heteromeric tetramers", "TREATMENT", 607, 628], ["Ni effect", "OBSERVATION", 269, 278], ["Genova", "ANATOMY", 477, 483]]], ["In order to bring a contribution to the comprehension of channel heteromerization we have been investigating the properties of two plant voltage-gated K + -channels by using electrophysiological and fluorescence techniques.", [["K", "CHEMICAL", 151, 152], ["K +", "CHEMICAL", 151, 154], ["K +", "SIMPLE_CHEMICAL", 151, 154], ["plant voltage-gated K + -channels", "PROTEIN", 131, 164], ["channel heteromerization", "TREATMENT", 57, 81], ["plant voltage", "TEST", 131, 144], ["electrophysiological and fluorescence techniques", "TEST", 174, 222]]], ["Experiments were focussed on KDC1 and KDC2, coexpressed in Xenopus laevis oocytes.", [["oocytes", "ANATOMY", 74, 81], ["KDC1", "GENE_OR_GENE_PRODUCT", 29, 33], ["KDC2", "GENE_OR_GENE_PRODUCT", 38, 42], ["Xenopus laevis", "ORGANISM", 59, 73], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 74, 81], ["KDC1", "PROTEIN", 29, 33], ["KDC2", "PROTEIN", 38, 42], ["Xenopus laevis", "SPECIES", 59, 73], ["Xenopus laevis", "SPECIES", 59, 73], ["KDC1", "TREATMENT", 29, 33], ["KDC2", "TREATMENT", 38, 42], ["laevis oocytes", "OBSERVATION", 67, 81]]], ["KDC1, the first potassium channel cloned from Daucus carota, belongs to the subfamily of \u03b1-modulatory silent channels as it doesn't form functional homomeric channels by itself.", [["potassium", "CHEMICAL", 16, 25], ["potassium", "CHEMICAL", 16, 25], ["KDC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Daucus carota", "ORGANISM", 46, 59], ["KDC1", "PROTEIN", 0, 4], ["potassium channel", "PROTEIN", 16, 33], ["\u03b1-modulatory silent channels", "PROTEIN", 89, 117], ["homomeric channels", "PROTEIN", 148, 166], ["Daucus carota", "SPECIES", 46, 59], ["Daucus carota", "SPECIES", 46, 59], ["KDC1", "TREATMENT", 0, 4], ["the first potassium channel", "TREATMENT", 6, 33], ["Daucus carota", "OBSERVATION", 46, 59]]], ["On the contrary KDC1 forms functional heteromeric channels when coexpressed with homologous subunits.", [["KDC1", "GENE_OR_GENE_PRODUCT", 16, 20], ["KDC1", "PROTEIN", 16, 20], ["heteromeric channels", "PROTEIN", 38, 58], ["homologous subunits", "PROTEIN", 81, 100], ["homologous subunits", "TREATMENT", 81, 100], ["heteromeric channels", "OBSERVATION", 38, 58]]], ["KDC2, the last K + channel cloned from D. carota, belongs to the KAT1 family and shares an overall identity of 63% with KAT1.", [["K", "CHEMICAL", 15, 16], ["K +", "CHEMICAL", 15, 18], ["KDC2", "GENE_OR_GENE_PRODUCT", 0, 4], ["K + channel", "GENE_OR_GENE_PRODUCT", 15, 26], ["D. carota", "ORGANISM", 39, 48], ["KAT1", "GENE_OR_GENE_PRODUCT", 65, 69], ["KAT1", "GENE_OR_GENE_PRODUCT", 120, 124], ["KDC2", "PROTEIN", 0, 4], ["last K + channel", "PROTEIN", 10, 26], ["KAT1 family", "PROTEIN", 65, 76], ["KAT1", "PROTEIN", 120, 124], ["D. carota", "SPECIES", 39, 48], ["D. carota", "SPECIES", 39, 48], ["KDC2", "TEST", 0, 4], ["KAT1", "TREATMENT", 120, 124], ["carota", "ANATOMY", 42, 48]]], ["To correlate KDC1 functional properties with its localization in oocytes, KDC1 and/or KDC2 subunits were labelled with GFP and their properties investigated by confocal microscopy and voltage-clamp.", [["oocytes", "ANATOMY", 65, 72], ["KDC1", "GENE_OR_GENE_PRODUCT", 13, 17], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 65, 72], ["KDC1", "GENE_OR_GENE_PRODUCT", 74, 78], ["KDC2", "GENE_OR_GENE_PRODUCT", 86, 90], ["GFP", "GENE_OR_GENE_PRODUCT", 119, 122], ["KDC1", "PROTEIN", 13, 17], ["oocytes", "CELL_TYPE", 65, 72], ["KDC1", "PROTEIN", 74, 78], ["KDC2 subunits", "PROTEIN", 86, 99], ["GFP", "PROTEIN", 119, 122], ["KDC1", "TREATMENT", 74, 78], ["KDC2 subunits", "TREATMENT", 86, 99], ["confocal microscopy", "TEST", 160, 179]]], ["We found that the KDC1-EGFP fusion protein is not targeted to the plasma membrane unless it is coexpressed with KDC2.", [["plasma membrane", "ANATOMY", 66, 81], ["KDC1", "GENE_OR_GENE_PRODUCT", 18, 22], ["EGFP", "GENE_OR_GENE_PRODUCT", 23, 27], ["plasma membrane", "CELLULAR_COMPONENT", 66, 81], ["KDC2", "GENE_OR_GENE_PRODUCT", 112, 116], ["KDC1", "PROTEIN", 18, 22], ["EGFP fusion protein", "PROTEIN", 23, 42], ["KDC2", "PROTEIN", 112, 116], ["the KDC1", "TEST", 14, 22], ["EGFP fusion protein", "TEST", 23, 42], ["KDC2", "TREATMENT", 112, 116]]], ["Moreover electrophysiological experiments demonstrated that the heteromeric KDC1-KDC2 channel has altered selectivity and activation properties with respect to homomeric KDC2 channel.", [["KDC1", "GENE_OR_GENE_PRODUCT", 76, 80], ["KDC2", "GENE_OR_GENE_PRODUCT", 81, 85], ["KDC2", "GENE_OR_GENE_PRODUCT", 170, 174], ["KDC1", "PROTEIN", 76, 80], ["KDC2 channel", "PROTEIN", 81, 93], ["homomeric KDC2 channel", "PROTEIN", 160, 182], ["electrophysiological experiments", "TEST", 9, 41], ["the heteromeric KDC1", "TEST", 60, 80], ["selectivity", "OBSERVATION_MODIFIER", 106, 117]]], ["Circulating leukocyte sequestration in pulmonary capillaries is arguably the initiating event of lung injury in Acute Respiratory Distress Syndrome (ARDS) [1] .", [["leukocyte", "ANATOMY", 12, 21], ["pulmonary capillaries", "ANATOMY", 39, 60], ["lung", "ANATOMY", 97, 101], ["lung injury", "DISEASE", 97, 108], ["Acute Respiratory Distress Syndrome", "DISEASE", 112, 147], ["ARDS", "DISEASE", 149, 153], ["leukocyte", "CELL", 12, 21], ["pulmonary capillaries", "MULTI-TISSUE_STRUCTURE", 39, 60], ["lung", "ORGAN", 97, 101], ["Circulating leukocyte sequestration in pulmonary capillaries", "PROBLEM", 0, 60], ["lung injury", "PROBLEM", 97, 108], ["Acute Respiratory Distress Syndrome", "PROBLEM", 112, 147], ["leukocyte sequestration", "OBSERVATION", 12, 35], ["pulmonary capillaries", "ANATOMY", 39, 60], ["lung", "ANATOMY", 97, 101], ["injury", "OBSERVATION", 102, 108], ["Acute", "OBSERVATION_MODIFIER", 112, 117], ["Respiratory Distress Syndrome", "OBSERVATION", 118, 147]]], ["We present a microfluidic investigation of the roles of actin organization and myosin II activity during the different stages of leukocyte trafficking through narrow capillaries using specific drugs.", [["leukocyte", "ANATOMY", 129, 138], ["capillaries", "ANATOMY", 166, 177], ["actin", "GENE_OR_GENE_PRODUCT", 56, 61], ["myosin II", "GENE_OR_GENE_PRODUCT", 79, 88], ["leukocyte", "CELL", 129, 138], ["capillaries", "TISSUE", 166, 177], ["actin", "PROTEIN", 56, 61], ["myosin II", "PROTEIN", 79, 88], ["a microfluidic investigation", "TEST", 11, 39], ["actin organization", "PROBLEM", 56, 74], ["myosin II activity", "PROBLEM", 79, 97], ["leukocyte trafficking", "PROBLEM", 129, 150], ["specific drugs", "TREATMENT", 184, 198], ["actin organization", "OBSERVATION", 56, 74], ["leukocyte trafficking", "OBSERVATION", 129, 150]]], ["The deformation rate during entry reveals that cell stiffness depends strongly on F-actin organization and hardly on myosin II activity, supporting microfilament role in leukocyte sequestration.", [["cell", "ANATOMY", 47, 51], ["microfilament", "ANATOMY", 148, 161], ["leukocyte", "ANATOMY", 170, 179], ["cell", "CELL", 47, 51], ["F-actin", "CELLULAR_COMPONENT", 82, 89], ["myosin II", "GENE_OR_GENE_PRODUCT", 117, 126], ["microfilament", "CELLULAR_COMPONENT", 148, 161], ["leukocyte", "CELL", 170, 179], ["F-actin", "PROTEIN", 82, 89], ["myosin II", "PROTEIN", 117, 126], ["The deformation rate", "TEST", 0, 20], ["cell stiffness", "PROBLEM", 47, 61], ["leukocyte sequestration", "PROBLEM", 170, 193], ["cell stiffness", "OBSERVATION", 47, 61], ["F-actin organization", "OBSERVATION", 82, 102], ["leukocyte sequestration", "OBSERVATION", 170, 193]]], ["In the transit stage, cell friction is influenced by stiffness, demonstrating that the actin network is not completely broken after a forced entry into a capillary.", [["cell", "ANATOMY", 22, 26], ["capillary", "ANATOMY", 154, 163], ["cell", "CELL", 22, 26], ["actin", "GENE_OR_GENE_PRODUCT", 87, 92], ["capillary", "TISSUE", 154, 163], ["actin", "PROTEIN", 87, 92], ["cell friction", "PROBLEM", 22, 35], ["stiffness", "PROBLEM", 53, 62], ["transit stage", "OBSERVATION_MODIFIER", 7, 20], ["cell friction", "OBSERVATION", 22, 35], ["stiffness", "OBSERVATION", 53, 62]]], ["Conversely, membrane unfolding was independent of leukocyte stiffness.", [["membrane", "ANATOMY", 12, 20], ["leukocyte", "ANATOMY", 50, 59], ["membrane", "CELLULAR_COMPONENT", 12, 20], ["leukocyte", "CELL", 50, 59], ["leukocyte stiffness", "PROBLEM", 50, 69], ["membrane unfolding", "OBSERVATION", 12, 30], ["leukocyte stiffness", "OBSERVATION", 50, 69]]], ["The surface area of sequestered leukocytes increased by up to 160% in absence of myosin II activity, showing the major role of molecular motors on microvilli wrinkling and zipping.", [["surface area", "ANATOMY", 4, 16], ["leukocytes", "ANATOMY", 32, 42], ["microvilli", "ANATOMY", 147, 157], ["leukocytes", "CELL", 32, 42], ["myosin II", "GENE_OR_GENE_PRODUCT", 81, 90], ["microvilli", "CELLULAR_COMPONENT", 147, 157], ["sequestered leukocytes", "CELL_TYPE", 20, 42], ["myosin II", "PROTEIN", 81, 90], ["sequestered leukocytes", "PROBLEM", 20, 42], ["microvilli wrinkling", "PROBLEM", 147, 167], ["zipping", "TREATMENT", 172, 179], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["area", "OBSERVATION_MODIFIER", 12, 16], ["sequestered leukocytes", "OBSERVATION", 20, 42], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["myosin II", "OBSERVATION_MODIFIER", 81, 90], ["molecular motors", "OBSERVATION", 127, 143], ["microvilli wrinkling", "OBSERVATION", 147, 167]]], ["Finally, cell shape relaxation was largely independent of both actin organization and myosin II activity, whereas a deformed state was required for normal trafficking through capillary segments [2] .", [["cell", "ANATOMY", 9, 13], ["capillary segments", "ANATOMY", 175, 193], ["cell", "CELL", 9, 13], ["actin", "GENE_OR_GENE_PRODUCT", 63, 68], ["myosin II", "GENE_OR_GENE_PRODUCT", 86, 95], ["capillary", "TISSUE", 175, 184], ["actin", "PROTEIN", 63, 68], ["myosin II", "PROTEIN", 86, 95], ["a deformed state", "PROBLEM", 114, 130], ["cell shape", "OBSERVATION", 9, 19]]], ["[1] G.S. Worthen et al., Science, 245, 183-186 (1989) Excitation-contraction coupling in skeletal and cardiac muscle is tightly regulated by the calcium release channel of the sarcoplasmic reticulum, the ryanodine receptor (RyR).", [["skeletal", "ANATOMY", 89, 97], ["cardiac muscle", "ANATOMY", 102, 116], ["sarcoplasmic reticulum", "ANATOMY", 176, 198], ["calcium", "CHEMICAL", 145, 152], ["ryanodine", "CHEMICAL", 204, 213], ["calcium", "CHEMICAL", 145, 152], ["ryanodine", "CHEMICAL", 204, 213], ["skeletal", "TISSUE", 89, 97], ["cardiac muscle", "TISSUE", 102, 116], ["calcium", "SIMPLE_CHEMICAL", 145, 152], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 176, 198], ["ryanodine receptor", "GENE_OR_GENE_PRODUCT", 204, 222], ["RyR", "GENE_OR_GENE_PRODUCT", 224, 227], ["ryanodine receptor", "PROTEIN", 204, 222], ["RyR", "PROTEIN", 224, 227], ["contraction coupling in skeletal and cardiac muscle", "PROBLEM", 65, 116], ["the ryanodine receptor", "TREATMENT", 200, 222], ["skeletal", "ANATOMY", 89, 97], ["cardiac muscle", "ANATOMY", 102, 116], ["sarcoplasmic reticulum", "ANATOMY", 176, 198]]], ["We could previously show that suramin is a potent activator of the RyR via the calmodulin binding site.", [["suramin", "CHEMICAL", 30, 37], ["suramin", "CHEMICAL", 30, 37], ["suramin", "SIMPLE_CHEMICAL", 30, 37], ["RyR", "GENE_OR_GENE_PRODUCT", 67, 70], ["calmodulin", "GENE_OR_GENE_PRODUCT", 79, 89], ["RyR", "PROTEIN", 67, 70], ["calmodulin binding site", "DNA", 79, 102], ["suramin", "TREATMENT", 30, 37], ["the calmodulin binding site", "PROBLEM", 75, 102], ["calmodulin binding", "OBSERVATION", 79, 97]]], ["Calmodulin shows dualistic action, i.e. activation or inhibition of the ryanodine receptor, depending on the absence or presence of Ca 2+ .", [["ryanodine", "CHEMICAL", 72, 81], ["Ca", "CHEMICAL", 132, 134], ["ryanodine", "CHEMICAL", 72, 81], ["Ca 2+", "CHEMICAL", 132, 137], ["Calmodulin", "GENE_OR_GENE_PRODUCT", 0, 10], ["ryanodine receptor", "GENE_OR_GENE_PRODUCT", 72, 90], ["Ca 2+", "SIMPLE_CHEMICAL", 132, 137], ["Calmodulin", "PROTEIN", 0, 10], ["ryanodine receptor", "PROTEIN", 72, 90], ["Calmodulin", "TREATMENT", 0, 10], ["dualistic action", "TREATMENT", 17, 33], ["the ryanodine receptor", "TREATMENT", 68, 90], ["Ca", "TEST", 132, 134]]], ["Screening of suramin analogues identified NF676 as a use-dependent inhibitor of the skeletal muscle RyR (RyR1).", [["skeletal muscle", "ANATOMY", 84, 99], ["suramin", "CHEMICAL", 13, 20], ["NF676", "CHEMICAL", 42, 47], ["suramin", "CHEMICAL", 13, 20], ["NF676", "CHEMICAL", 42, 47], ["suramin", "SIMPLE_CHEMICAL", 13, 20], ["NF676", "SIMPLE_CHEMICAL", 42, 47], ["skeletal muscle", "ORGAN", 84, 99], ["RyR", "GENE_OR_GENE_PRODUCT", 100, 103], ["RyR1", "GENE_OR_GENE_PRODUCT", 105, 109], ["skeletal muscle RyR", "PROTEIN", 84, 103], ["RyR1", "PROTEIN", 105, 109], ["suramin analogues", "TREATMENT", 13, 30], ["skeletal muscle", "ANATOMY", 84, 99]]], ["Here we show that NF676 inhibits high affinity [ 3 H]ryanodine binding and single channel recordings of the purified RyR1.", [["NF676", "CHEMICAL", 18, 23], ["ryanodine", "CHEMICAL", 53, 62], ["NF676", "CHEMICAL", 18, 23], ["[ 3 H]ryanodine", "CHEMICAL", 47, 62], ["NF676", "SIMPLE_CHEMICAL", 18, 23], ["[ 3 H]ryanodine", "SIMPLE_CHEMICAL", 47, 62], ["RyR1", "GENE_OR_GENE_PRODUCT", 117, 121], ["RyR1", "PROTEIN", 117, 121], ["high affinity", "PROBLEM", 33, 46], ["ryanodine binding", "PROBLEM", 53, 70]]], ["NF676 induced a reduction of open probabilities in a concentration dependent manner, with no effect on current amplitude and unitary conductance.", [["NF676", "CHEMICAL", 0, 5], ["NF676", "CHEMICAL", 0, 5], ["NF676", "SIMPLE_CHEMICAL", 0, 5], ["NF676", "PROTEIN", 0, 5], ["a concentration dependent manner", "TREATMENT", 51, 83], ["reduction", "OBSERVATION_MODIFIER", 16, 25]]], ["Importantly, NF676 triggers flickering episodes of channel openings and closings before the RyR1 is frozen in a complete non-conducting state, which is fully reactivated by the RyR agonist ATP.", [["NF676", "CHEMICAL", 13, 18], ["ATP", "CHEMICAL", 189, 192], ["ATP", "CHEMICAL", 189, 192], ["NF676", "SIMPLE_CHEMICAL", 13, 18], ["RyR1", "GENE_OR_GENE_PRODUCT", 92, 96], ["RyR", "GENE_OR_GENE_PRODUCT", 177, 180], ["ATP", "SIMPLE_CHEMICAL", 189, 192], ["NF676", "PROTEIN", 13, 18], ["RyR1", "PROTEIN", 92, 96], ["RyR", "PROTEIN", 177, 180], ["channel openings", "PROBLEM", 51, 67], ["channel openings", "OBSERVATION", 51, 67]]], ["Moreover, zwitterionic behaviour of NF676 facilitates plasma membrane permeation, which prevented caffeine induced Ca 2+ transients in skeletal muscle cells and cardiomyocytes.", [["plasma membrane", "ANATOMY", 54, 69], ["skeletal muscle cells", "ANATOMY", 135, 156], ["cardiomyocytes", "ANATOMY", 161, 175], ["NF676", "CHEMICAL", 36, 41], ["caffeine", "CHEMICAL", 98, 106], ["Ca", "CHEMICAL", 115, 117], ["NF676", "CHEMICAL", 36, 41], ["caffeine", "CHEMICAL", 98, 106], ["Ca 2+", "CHEMICAL", 115, 120], ["NF676", "SIMPLE_CHEMICAL", 36, 41], ["plasma membrane", "CELLULAR_COMPONENT", 54, 69], ["caffeine", "SIMPLE_CHEMICAL", 98, 106], ["Ca 2+", "SIMPLE_CHEMICAL", 115, 120], ["skeletal muscle cells", "CELL", 135, 156], ["cardiomyocytes", "CELL", 161, 175], ["skeletal muscle cells", "CELL_TYPE", 135, 156], ["cardiomyocytes", "CELL_TYPE", 161, 175], ["plasma membrane permeation", "TREATMENT", 54, 80], ["transients in skeletal muscle cells", "PROBLEM", 121, 156], ["cardiomyocytes", "PROBLEM", 161, 175], ["skeletal muscle", "ANATOMY", 135, 150], ["cardiomyocytes", "ANATOMY", 161, 175]]], ["Conversely, IP 3 mediated Ca 2+ signals were not altered by NF676.", [["Ca", "CHEMICAL", 26, 28], ["NF676", "CHEMICAL", 60, 65], ["Ca 2+", "CHEMICAL", 26, 31], ["NF676", "CHEMICAL", 60, 65], ["IP 3", "GENE_OR_GENE_PRODUCT", 12, 16], ["Ca 2+", "SIMPLE_CHEMICAL", 26, 31], ["NF676", "SIMPLE_CHEMICAL", 60, 65], ["IP 3", "PROTEIN", 12, 16], ["NF676", "PROTEIN", 60, 65]]], ["This work was supported by Herzfelder'sche Familienstiftung and FWF .O-421Beyond steady-state protein dynamics T. Hau\u00df 1 , J. Pieper 3 , A. Buchsteiner 1 , R. E. Lechner 2 , N. A. Dencher 2 1 Helmholtz-Zentrum Berlin f\u00fcr Materialien und Energie, Berlin, Germany, 2 Technische Universit\u00e4t Darmstadt, Germany, 3 Technische Universit\u00e4t Berlin, GermanyO-421To study protein dynamics beyond steady-state experiments we have developed a novel laser-pump:neutron-probe experiment which allows us to monitor temporal changes in protein dynamics during a working cycle of a protein.", [["Herzfelder'sche Familienstiftung", "CELL", 27, 59], ["GermanyO", "TEST", 341, 349], ["a novel laser-pump", "TREATMENT", 429, 447], ["neutron-probe experiment", "TREATMENT", 448, 472], ["temporal changes in protein dynamics", "PROBLEM", 500, 536], ["a protein", "TREATMENT", 563, 572]]], ["Protein dynamics has been extensively studied, but so far, the correlation of internal protein dynamics with the function of proteins was investigated only indirectly in steady-state experiments by variation of external parameters by variation of external parameters like temperature or hydration.", [["Protein dynamics", "TEST", 0, 16], ["internal protein dynamics", "TEST", 78, 103], ["external parameters", "TEST", 211, 230], ["external parameters", "TEST", 247, 266], ["hydration", "TREATMENT", 287, 296]]], ["The method comprises of an in-situ optical activation of a protein and a time-dependent sampling of the dymamic response using quasi-elastic neutron scattering.", [["a protein", "TREATMENT", 57, 66], ["quasi-elastic neutron scattering", "TREATMENT", 127, 159]]], ["With the membrane protein bacteriorhodopsin, a light driven proton pump, we can demonstrate for the first time temporary alterations in the protein dynamics after triggering the working cycle.", [["membrane", "ANATOMY", 9, 17], ["membrane", "CELLULAR_COMPONENT", 9, 17], ["membrane protein bacteriorhodopsin", "PROTEIN", 9, 43], ["the membrane protein bacteriorhodopsin", "TREATMENT", 5, 43], ["a light driven proton pump", "TREATMENT", 45, 71], ["temporary alterations in the protein dynamics", "PROBLEM", 111, 156]]], ["This observation is a direct proof for the functional significance of protein structural flexibility, in connection with the largescale conformational changes in the protein structure occurring during the operation of a \"molecular machine\".", [["protein structure", "PROTEIN", 166, 183], ["protein structural flexibility", "PROBLEM", 70, 100], ["the largescale conformational changes in the protein structure", "PROBLEM", 121, 183], ["the operation", "TREATMENT", 201, 214], ["structural flexibility", "OBSERVATION", 78, 100], ["protein structure", "OBSERVATION", 166, 183]]], ["The Slow Vacuolar (SV) channels are ubiquitous in all tissues of higher plants.", [["tissues", "ANATOMY", 54, 61], ["Slow Vacuolar (SV)", "GENE_OR_GENE_PRODUCT", 4, 22], ["tissues", "TISSUE", 54, 61], ["Slow Vacuolar (SV) channels", "PROTEIN", 4, 31], ["The Slow Vacuolar (SV) channels", "PROBLEM", 0, 31], ["Slow", "OBSERVATION_MODIFIER", 4, 8], ["Vacuolar", "OBSERVATION_MODIFIER", 9, 17], ["all tissues", "OBSERVATION_MODIFIER", 50, 61], ["higher plants", "OBSERVATION", 65, 78]]], ["The SV channel is a non-selective cation channel permeable to both monovalent and divalent cations.", [["cation", "SIMPLE_CHEMICAL", 34, 40], ["cations", "SIMPLE_CHEMICAL", 91, 98], ["SV channel", "PROTEIN", 4, 14], ["a non-selective cation channel permeable", "TREATMENT", 18, 58], ["divalent cations", "TREATMENT", 82, 98], ["SV channel", "ANATOMY", 4, 14], ["non-selective cation", "OBSERVATION", 20, 40], ["divalent cations", "OBSERVATION", 82, 98]]], ["SV currents recorded in a typical patch-clamp experiment require unphysiologically high cytosolic and low vacuolar calcium concentrations for full activation.", [["cytosolic", "ANATOMY", 88, 97], ["vacuolar", "ANATOMY", 106, 114], ["calcium", "CHEMICAL", 115, 122], ["calcium", "CHEMICAL", 115, 122], ["SV", "ORGANISM", 0, 2], ["cytosolic", "ORGANISM_SUBSTANCE", 88, 97], ["vacuolar", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 114], ["calcium", "SIMPLE_CHEMICAL", 115, 122], ["SV currents", "TEST", 0, 11], ["a typical patch", "TREATMENT", 24, 39], ["unphysiologically high cytosolic", "PROBLEM", 65, 97], ["low vacuolar calcium concentrations", "TREATMENT", 102, 137]]], ["We aim at looking for endogenous plant substances which might be able to modify or shift the voltage activation threshold of this channel towards more physiological conditions.", [["endogenous plant substances", "TREATMENT", 22, 49]]], ["Flavonoid Naringenin [Nar] is present in all plant species where it plays a central role in the flavonoid biosynthetic pathway.", [["Naringenin", "CHEMICAL", 10, 20], ["Nar", "CHEMICAL", 22, 25], ["Naringenin", "CHEMICAL", 10, 20], ["Nar", "CHEMICAL", 22, 25], ["flavonoid", "CHEMICAL", 96, 105], ["Flavonoid", "SIMPLE_CHEMICAL", 0, 9], ["Naringenin", "SIMPLE_CHEMICAL", 10, 20], ["Nar", "SIMPLE_CHEMICAL", 22, 25], ["flavonoid", "SIMPLE_CHEMICAL", 96, 105], ["Flavonoid Naringenin", "TREATMENT", 0, 20], ["plant species", "OBSERVATION", 45, 58], ["central", "ANATOMY_MODIFIER", 76, 83], ["flavonoid biosynthetic", "OBSERVATION", 96, 118]]], ["Nar is stored in the vacuoles in glycosylated form called Naringin.", [["vacuoles", "ANATOMY", 21, 29], ["Naringin", "CHEMICAL", 58, 66], ["Nar", "SIMPLE_CHEMICAL", 0, 3], ["vacuoles", "CELLULAR_COMPONENT", 21, 29], ["Naringin", "SIMPLE_CHEMICAL", 58, 66], ["Naringin", "PROTEIN", 58, 66], ["Naringin", "TREATMENT", 58, 66]]], ["When Nar was added to cytosolic bath solution, we recorded a dose-dependent reversible decrease in SV channel activity.", [["cytosolic", "ANATOMY", 22, 31], ["Nar", "CHEMICAL", 5, 8], ["Nar", "SIMPLE_CHEMICAL", 5, 8], ["SV", "GENE_OR_GENE_PRODUCT", 99, 101], ["Nar", "PROTEIN", 5, 8], ["cytosolic bath solution", "TREATMENT", 22, 45], ["dependent reversible decrease in SV channel activity", "PROBLEM", 66, 118], ["reversible", "OBSERVATION_MODIFIER", 76, 86], ["decrease", "OBSERVATION_MODIFIER", 87, 95], ["SV channel activity", "OBSERVATION", 99, 118]]], ["When we investigated the effect of Nar on the voltage dependence of the channel, we observed that the activation threshold of the SV channel is shifted towards more positive voltages.", [["Nar", "CHEMICAL", 35, 38], ["SV channel", "PROTEIN", 130, 140], ["SV channel", "OBSERVATION", 130, 140], ["positive voltages", "OBSERVATION", 165, 182]]], ["Our group has evidences that approximately 10% of the total SV current at high (e.g.> 50 mV) positive voltages is mediated by calcium.", [["calcium", "CHEMICAL", 126, 133], ["calcium", "CHEMICAL", 126, 133], ["calcium", "SIMPLE_CHEMICAL", 126, 133], ["the total SV", "TEST", 50, 62], ["positive voltages", "PROBLEM", 93, 110], ["calcium", "TEST", 126, 133], ["approximately", "OBSERVATION_MODIFIER", 29, 42]]], ["Therefore, in order to verify whether Nar affects both potassium and calcium conductance, we performed experiments by combining the patch clamp technique with fluorescence measurements using the fluorophore fura-2: both SV currents and calcium signals were abolished by 1 mM [Nar].P-419Determination of calcium currents in cation channels using a novel fluorescence/patch-clamp approach P. V. K. Gutla, A. Gradogna, A. Carpaneto Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Via De Marini 6, 16149 Genova, ItalyP-419The patch-clamp technique combined with fura-2 fluorescence detection is suitable to investigate calcium fluxes.", [["potassium", "CHEMICAL", 55, 64], ["calcium", "CHEMICAL", 69, 76], ["fura-2", "CHEMICAL", 207, 213], ["calcium", "CHEMICAL", 236, 243], ["calcium", "CHEMICAL", 303, 310], ["ItalyP-419", "CHEMICAL", 519, 529], ["calcium", "CHEMICAL", 626, 633], ["potassium", "CHEMICAL", 55, 64], ["calcium", "CHEMICAL", 69, 76], ["calcium", "CHEMICAL", 236, 243], ["calcium", "CHEMICAL", 303, 310], ["calcium", "CHEMICAL", 626, 633], ["Nar", "GENE_OR_GENE_PRODUCT", 38, 41], ["potassium", "SIMPLE_CHEMICAL", 55, 64], ["calcium", "SIMPLE_CHEMICAL", 69, 76], ["fura-2", "SIMPLE_CHEMICAL", 207, 213], ["SV", "ORGANISM", 220, 222], ["calcium", "SIMPLE_CHEMICAL", 236, 243], ["calcium", "SIMPLE_CHEMICAL", 303, 310], ["cation", "SIMPLE_CHEMICAL", 323, 329], ["fura-2", "GENE_OR_GENE_PRODUCT", 569, 575], ["calcium", "SIMPLE_CHEMICAL", 626, 633], ["Nar", "PROTEIN", 38, 41], ["cation channels", "PROTEIN", 323, 338], ["potassium", "TEST", 55, 64], ["calcium conductance", "TEST", 69, 88], ["the patch clamp technique", "TREATMENT", 128, 153], ["fluorescence measurements", "TEST", 159, 184], ["the fluorophore fura", "TREATMENT", 191, 211], ["calcium signals", "TEST", 236, 251], ["P", "TEST", 281, 282], ["calcium currents in cation channels", "TREATMENT", 303, 338], ["a novel fluorescence/patch", "TREATMENT", 345, 371], ["The patch-clamp technique", "TREATMENT", 529, 554], ["fura-2 fluorescence detection", "TEST", 569, 598], ["calcium fluxes", "PROBLEM", 626, 640]]], ["We used the excised patch configuration and focused the photomultiplier to the tip of the recording pipette where the fluorescent dye was present (FLuoresence combined with Excised Patch = FLEP).", [["FLEP", "PROTEIN", 189, 193], ["the excised patch configuration", "TREATMENT", 8, 39], ["the photomultiplier", "TREATMENT", 52, 71], ["the fluorescent dye", "PROBLEM", 114, 133], ["tip", "OBSERVATION_MODIFIER", 79, 82]]], ["This configuration has several advantages, i.e. absence of delay in loading the fluorophore, of interference by endogenous calcium buffers and of photobleaching.", [["calcium", "CHEMICAL", 123, 130], ["calcium", "CHEMICAL", 123, 130], ["calcium", "SIMPLE_CHEMICAL", 123, 130], ["loading the fluorophore", "TREATMENT", 68, 91], ["endogenous calcium buffers", "TREATMENT", 112, 138], ["photobleaching", "TREATMENT", 146, 160], ["several", "OBSERVATION_MODIFIER", 23, 30], ["advantages", "OBSERVATION_MODIFIER", 31, 41]]], ["Here we present an application for the determination of fractional calcium currents (Pf) in a plant non-selective cation channel, showing that Pf can be modulated by cytosolic calcium and potassium.", [["cytosolic", "ANATOMY", 166, 175], ["calcium", "CHEMICAL", 67, 74], ["calcium", "CHEMICAL", 176, 183], ["potassium", "CHEMICAL", 188, 197], ["calcium", "CHEMICAL", 67, 74], ["calcium", "CHEMICAL", 176, 183], ["potassium", "CHEMICAL", 188, 197], ["calcium", "SIMPLE_CHEMICAL", 67, 74], ["cation", "SIMPLE_CHEMICAL", 114, 120], ["Pf", "GENE_OR_GENE_PRODUCT", 143, 145], ["calcium", "SIMPLE_CHEMICAL", 176, 183], ["potassium", "SIMPLE_CHEMICAL", 188, 197], ["Pf", "PROTEIN", 143, 145], ["fractional calcium currents", "TREATMENT", 56, 83], ["a plant non-selective cation channel", "TREATMENT", 92, 128], ["Pf", "PROBLEM", 143, 145], ["cytosolic calcium", "TEST", 166, 183], ["potassium", "TEST", 188, 197]]], ["FLEP is very efficient for measuring small calcium currents (<1 pA) of sufficiently long duration; fluorescence signals are amplified by integration in time, as the calcium/fura-2 complex accumulates at the tip of the recording pipette and diffuses slowly.", [["calcium", "CHEMICAL", 43, 50], ["calcium", "CHEMICAL", 165, 172], ["fura-2", "CHEMICAL", 173, 179], ["calcium", "CHEMICAL", 43, 50], ["calcium", "CHEMICAL", 165, 172], ["fura-2", "CHEMICAL", 173, 179], ["FLEP", "SIMPLE_CHEMICAL", 0, 4], ["calcium", "SIMPLE_CHEMICAL", 43, 50], ["calcium", "SIMPLE_CHEMICAL", 165, 172], ["fura-2", "GENE_OR_GENE_PRODUCT", 173, 179], ["calcium/fura-2 complex", "PROTEIN", 165, 187], ["measuring small calcium currents", "TEST", 27, 59], ["fluorescence signals", "TEST", 99, 119], ["the calcium/fura", "TEST", 161, 177], ["tip", "OBSERVATION_MODIFIER", 207, 210], ["diffuses", "OBSERVATION_MODIFIER", 240, 248], ["slowly", "OBSERVATION_MODIFIER", 249, 255]]], ["We propose this technique not only for the study of calcium transport pathways, but also for other transporters of divalent cations as nickel and manganese known to quench fluorescence thus reducing both 340 and 380 nm components.", [["calcium", "CHEMICAL", 52, 59], ["nickel", "CHEMICAL", 135, 141], ["manganese", "CHEMICAL", 146, 155], ["calcium", "CHEMICAL", 52, 59], ["nickel", "CHEMICAL", 135, 141], ["manganese", "CHEMICAL", 146, 155], ["calcium", "SIMPLE_CHEMICAL", 52, 59], ["cations", "SIMPLE_CHEMICAL", 124, 131], ["nickel", "SIMPLE_CHEMICAL", 135, 141], ["manganese", "SIMPLE_CHEMICAL", 146, 155], ["this technique", "TREATMENT", 11, 25], ["the study", "TEST", 39, 48], ["calcium transport pathways", "TREATMENT", 52, 78], ["divalent cations", "TREATMENT", 115, 131], ["quench fluorescence", "TEST", 165, 184]]], ["Moreover, using the appropriate fluorophore the technique may be extended to further ion species, e.g. BCECF for investigating proton transport pathways.", [["BCECF", "SIMPLE_CHEMICAL", 103, 108], ["proton", "SIMPLE_CHEMICAL", 127, 133], ["the appropriate fluorophore the technique", "TREATMENT", 16, 57]]], ["Ref: We introduced an original method for the monitoring of the changes in the electrostatic surface potential, using the quenching of the intrinsic tryptophan fluorescence by acrylamide or iodide.", [["surface", "ANATOMY", 93, 100], ["tryptophan", "CHEMICAL", 149, 159], ["acrylamide or iodide", "CHEMICAL", 176, 196], ["tryptophan", "CHEMICAL", 149, 159], ["acrylamide", "CHEMICAL", 176, 186], ["iodide", "CHEMICAL", 190, 196], ["tryptophan", "SIMPLE_CHEMICAL", 149, 159], ["acrylamide", "SIMPLE_CHEMICAL", 176, 186], ["iodide", "SIMPLE_CHEMICAL", 190, 196], ["an original method", "TREATMENT", 19, 37], ["the monitoring", "TEST", 42, 56]]], ["Our experiments revealed that the conformation of the Na + /K + -ATPase large cytoplasmic loop (C45) in the presence of the ATP (without magnesium) substantially differed from the conformation in the presence of Mg 2+ or MgATP or in the absence of any ligand not only in the sense of geometry but also in the sense of the electrostatic surface potential.", [["cytoplasmic", "ANATOMY", 78, 89], ["surface", "ANATOMY", 336, 343], ["Na", "CHEMICAL", 54, 56], ["K", "CHEMICAL", 60, 61], ["ATP", "CHEMICAL", 124, 127], ["magnesium", "CHEMICAL", 137, 146], ["Mg", "CHEMICAL", 212, 214], ["MgATP", "CHEMICAL", 221, 226], ["Na +", "CHEMICAL", 54, 58], ["K +", "CHEMICAL", 60, 63], ["ATP", "CHEMICAL", 124, 127], ["magnesium", "CHEMICAL", 137, 146], ["Mg 2+", "CHEMICAL", 212, 217], ["MgATP", "CHEMICAL", 221, 226], ["Na + /K + -ATPase", "GENE_OR_GENE_PRODUCT", 54, 71], ["cytoplasmic", "ORGANISM_SUBSTANCE", 78, 89], ["ATP", "SIMPLE_CHEMICAL", 124, 127], ["magnesium", "SIMPLE_CHEMICAL", 137, 146], ["Mg 2+", "SIMPLE_CHEMICAL", 212, 217], ["MgATP", "SIMPLE_CHEMICAL", 221, 226], ["Na + /K + -ATPase", "PROTEIN", 54, 71], ["cytoplasmic loop", "PROTEIN", 78, 94], ["C45", "PROTEIN", 96, 99], ["Our experiments", "TEST", 0, 15], ["the Na", "TEST", 50, 56], ["K", "TEST", 60, 61], ["ATPase large cytoplasmic loop", "PROBLEM", 65, 94], ["the ATP", "PROBLEM", 120, 127], ["magnesium)", "PROBLEM", 137, 147], ["Mg", "TEST", 212, 214], ["MgATP", "PROBLEM", 221, 226], ["large", "OBSERVATION_MODIFIER", 72, 77], ["cytoplasmic loop", "OBSERVATION", 78, 94], ["geometry", "OBSERVATION", 284, 292], ["electrostatic surface", "OBSERVATION", 322, 343]]], ["Moreover, our data indicate that the effect of the ligand binding is not restricted only to the close environment of the binding site and that the information is in fact transmitted also to the distal parts of the molecule.", [["our data", "TEST", 10, 18], ["the ligand binding", "PROBLEM", 47, 65], ["distal", "ANATOMY_MODIFIER", 194, 200], ["molecule", "ANATOMY", 214, 222]]], ["This property could be important for the communication between the cytoplasmic headpiece and the cation binding sites located within the transmembrane domain.", [["cytoplasmic", "ANATOMY", 67, 78], ["transmembrane", "ANATOMY", 137, 150], ["cytoplasmic", "ORGANISM_SUBSTANCE", 67, 78], ["cation", "SIMPLE_CHEMICAL", 97, 103], ["transmembrane", "CELLULAR_COMPONENT", 137, 150], ["cytoplasmic headpiece", "PROTEIN", 67, 88], ["cation binding sites", "PROTEIN", 97, 117], ["transmembrane domain", "PROTEIN", 137, 157], ["the cytoplasmic headpiece", "TREATMENT", 63, 88], ["the cation binding sites", "TREATMENT", 93, 117]]], ["Influx of antibiotics into the periplasm of gram-negative bacteria is facilitated by porins that form channels in the outer membrane.", [["periplasm", "ANATOMY", 31, 40], ["outer membrane", "ANATOMY", 118, 132], ["porins", "GENE_OR_GENE_PRODUCT", 85, 91], ["outer membrane", "CELLULAR_COMPONENT", 118, 132], ["porins", "PROTEIN", 85, 91], ["Influx of antibiotics", "TREATMENT", 0, 21], ["gram", "TEST", 44, 48], ["negative bacteria", "PROBLEM", 49, 66], ["negative bacteria", "OBSERVATION", 49, 66], ["outer membrane", "ANATOMY", 118, 132]]], ["We propose that certain natural antibiotics have been optimized by co-evolution to take advantage of the charge distribution in non-specific porins to achieve binding and thereby facilitating their uptake in bacteria.", [["certain natural antibiotics", "TREATMENT", 16, 43], ["non-specific porins", "PROBLEM", 128, 147], ["their uptake in bacteria", "PROBLEM", 192, 216]]], ["We investigate the permeation pathways of antibiotics into bacteria by reconstitution of a single porin into an artificial lipid bilayer and measuring the binding of antibiotic molecules through the time-resolved modulation of a small ion current.", [["lipid bilayer", "ANATOMY", 123, 136], ["porin", "GENE_OR_GENE_PRODUCT", 98, 103], ["porin", "PROTEIN", 98, 103], ["antibiotics", "TREATMENT", 42, 53], ["bacteria", "PROBLEM", 59, 67], ["a single porin", "TREATMENT", 89, 103], ["an artificial lipid bilayer", "TREATMENT", 109, 136], ["antibiotic molecules", "TREATMENT", 166, 186], ["antibiotic molecules", "OBSERVATION", 166, 186], ["small", "OBSERVATION_MODIFIER", 229, 234]]], ["We have been able to characterize facilitated translocation of several antibiotics through Escherichia coli and Enterobacter aerogenes porins.", [["Escherichia coli", "ORGANISM", 91, 107], ["Enterobacter aerogenes porins", "GENE_OR_GENE_PRODUCT", 112, 141], ["Escherichia coli", "SPECIES", 91, 107], ["Enterobacter aerogenes", "SPECIES", 112, 134], ["Escherichia coli", "SPECIES", 91, 107], ["Enterobacter aerogenes", "SPECIES", 112, 134], ["several antibiotics", "TREATMENT", 63, 82], ["Escherichia coli", "TREATMENT", 91, 107], ["Enterobacter aerogenes porins", "PROBLEM", 112, 141], ["Escherichia coli", "OBSERVATION", 91, 107], ["Enterobacter aerogenes", "OBSERVATION", 112, 134]]], ["Noise analysis of ion currents through a porin in the presence of effective antibiotics revealed binding kinetics at a single molecule level.", [["porin", "GENE_OR_GENE_PRODUCT", 41, 46], ["porin", "PROTEIN", 41, 46], ["Noise analysis", "TEST", 0, 14], ["a porin", "TREATMENT", 39, 46], ["effective antibiotics", "TREATMENT", 66, 87], ["binding kinetics", "PROBLEM", 97, 113], ["binding kinetics", "OBSERVATION", 97, 113]]], ["We report for the first time temperature dependent antibiotic translocation that revealed complete energy profile.", [["temperature dependent antibiotic translocation", "TREATMENT", 29, 75], ["energy profile", "OBSERVATION", 99, 113]]], ["Combining these results with microbiological assays and molecular dynamics simulations, we conclude the molecular mechanism of antibiotic permeation.", [["antibiotic", "SIMPLE_CHEMICAL", 127, 137], ["microbiological assays", "TEST", 29, 51], ["molecular dynamics simulations", "TEST", 56, 86], ["antibiotic permeation", "TREATMENT", 127, 148]]], ["Our approach may contribute to the rational design of new antibiotics against clinical bacterial strains for the most efficient delivery to target sites.P-424Mitochondria regulate Ca 2+ influx and determine patterns of ER Ca 2+ refilling in acinar cel O. Kopach, I. Kruglikov, T. Pivneva, N. Voitenko, N. Fedirko Bogomoletz Institute of Physiology, Kiev, Ukraine Store-operated Ca 2+ entry (SOCE) is mediated by activation of SOC-channels of plasma membrane following the emptying of endoplasmic reticulum (ER) Ca 2+ stores.", [["acinar", "ANATOMY", 241, 247], ["plasma membrane", "ANATOMY", 442, 457], ["endoplasmic reticulum", "ANATOMY", 484, 505], ["ER", "ANATOMY", 507, 509], ["Ca", "CHEMICAL", 180, 182], ["Ca", "CHEMICAL", 222, 224], ["Ca", "CHEMICAL", 378, 380], ["Ca", "CHEMICAL", 511, 513], ["Ca 2+", "CHEMICAL", 180, 185], ["Ca 2+", "CHEMICAL", 222, 227], ["Ca 2+", "CHEMICAL", 378, 383], ["Ca 2+", "CHEMICAL", 511, 516], ["Ca 2+", "SIMPLE_CHEMICAL", 180, 185], ["ER Ca 2", "GENE_OR_GENE_PRODUCT", 219, 226], ["Ca 2+", "SIMPLE_CHEMICAL", 378, 383], ["plasma membrane", "CELLULAR_COMPONENT", 442, 457], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 484, 505], ["ER", "GENE_OR_GENE_PRODUCT", 507, 509], ["P", "DNA", 153, 154], ["SOC-channels", "PROTEIN", 426, 438], ["new antibiotics", "TREATMENT", 54, 69], ["clinical bacterial strains", "PROBLEM", 78, 104], ["P", "TEST", 153, 154], ["Ca", "TEST", 180, 182], ["influx", "PROBLEM", 186, 192], ["Ca", "TEST", 222, 224], ["plasma membrane", "TREATMENT", 442, 457], ["endoplasmic reticulum", "ANATOMY", 484, 505]]], ["The SOCE is required for calcium signaling, secretion of neurotransmitters and proteins, but the mechanisms of natural SOCE regulation are not well understood.", [["calcium", "CHEMICAL", 25, 32], ["calcium", "CHEMICAL", 25, 32], ["calcium", "SIMPLE_CHEMICAL", 25, 32], ["SOCE", "GENE_OR_GENE_PRODUCT", 119, 123], ["SOCE", "PROTEIN", 4, 8], ["calcium signaling", "PROBLEM", 25, 42], ["secretion of neurotransmitters and proteins", "PROBLEM", 44, 87]]], ["We utilized several imaging methods to measure Ca 2+ signals in cytoplasm ( ] Mit transients, observed both in EGTA-and BAPTA-buffering inside solutions.", [["cytoplasm", "ANATOMY", 64, 73], ["Ca", "CHEMICAL", 47, 49], ["EGTA", "CHEMICAL", 111, 115], ["BAPTA", "CHEMICAL", 120, 125], ["Ca 2+", "CHEMICAL", 47, 52], ["EGTA", "CHEMICAL", 111, 115], ["BAPTA", "CHEMICAL", 120, 125], ["cytoplasm", "ORGANISM_SUBSTANCE", 64, 73], ["Mit", "SIMPLE_CHEMICAL", 78, 81], ["EGTA", "SIMPLE_CHEMICAL", 111, 115], ["BAPTA", "SIMPLE_CHEMICAL", 120, 125], ["several imaging methods", "TEST", 12, 35], ["Ca", "TEST", 47, 49], ["Mit transients", "PROBLEM", 78, 92], ["EGTA", "TEST", 111, 115], ["BAPTA", "TREATMENT", 120, 125]]], ["These data suggest that Ca 2+ sequestration by Mit is associated with the formation of microdomains and prevents Ca 2+ -dependent SOCC inactivation.", [["microdomains", "ANATOMY", 87, 99], ["Ca", "CHEMICAL", 24, 26], ["Mit", "CHEMICAL", 47, 50], ["Ca", "CHEMICAL", 113, 115], ["Ca 2+", "CHEMICAL", 24, 29], ["Ca 2+", "CHEMICAL", 113, 118], ["Ca 2+", "SIMPLE_CHEMICAL", 24, 29], ["Mit", "GENE_OR_GENE_PRODUCT", 47, 50], ["microdomains", "CELLULAR_COMPONENT", 87, 99], ["Ca 2+", "SIMPLE_CHEMICAL", 113, 118], ["SOCC", "GENE_OR_GENE_PRODUCT", 130, 134], ["Mit", "PROTEIN", 47, 50], ["SOCC", "PROTEIN", 130, 134], ["These data", "TEST", 0, 10], ["Ca 2+ sequestration", "PROBLEM", 24, 43], ["microdomains", "PROBLEM", 87, 99], ["Ca 2+ -dependent SOCC inactivation", "PROBLEM", 113, 147]]], ["We also found that inhibition of Mit under prolonged cell stimulation resulted in complete inhibition of SOCE as well as decrease and deceleration of ER refilling.", [["cell", "ANATOMY", 53, 57], ["ER", "ANATOMY", 150, 152], ["Mit", "GENE_OR_GENE_PRODUCT", 33, 36], ["cell", "CELL", 53, 57], ["ER", "GENE_OR_GENE_PRODUCT", 150, 152], ["Mit", "PROTEIN", 33, 36], ["ER", "PROTEIN", 150, 152], ["Mit under prolonged cell stimulation", "TREATMENT", 33, 69], ["prolonged cell stimulation", "OBSERVATION", 43, 69], ["decrease", "OBSERVATION_MODIFIER", 121, 129], ["refilling", "OBSERVATION_MODIFIER", 153, 162]]], ["Thus, Mit regulate calcium recycling and maintain the SOCE controlling dynamic interplay between SOCE and sustained ER refilling under prolonged stimulation.", [["ER", "ANATOMY", 116, 118], ["calcium", "CHEMICAL", 19, 26], ["calcium", "CHEMICAL", 19, 26], ["Mit", "GENE_OR_GENE_PRODUCT", 6, 9], ["calcium", "SIMPLE_CHEMICAL", 19, 26], ["SOCE", "SIMPLE_CHEMICAL", 54, 58], ["ER", "GENE_OR_GENE_PRODUCT", 116, 118], ["Mit", "PROTEIN", 6, 9], ["ER", "PROTEIN", 116, 118], ["Mit regulate calcium recycling", "TREATMENT", 6, 36], ["prolonged stimulation", "TREATMENT", 135, 156]]], ["Bioelectrochemical devices composed of Au electrodes coated by self-assembled monolayers (SAMs) of different composition and thickness are ideal systems to probe ET patterns and mechanisms for redox proteins.", [["Au", "CHEMICAL", 39, 41], ["Au", "CHEMICAL", 39, 41], ["monolayers", "CELL", 78, 88], ["self-assembled monolayers", "CELL_LINE", 63, 88], ["redox proteins", "PROTEIN", 193, 207], ["Bioelectrochemical devices", "TREATMENT", 0, 26], ["Au electrodes coated", "TREATMENT", 39, 59], ["self-assembled monolayers (SAMs)", "TREATMENT", 63, 95], ["different composition and thickness", "TREATMENT", 99, 134], ["redox proteins", "PROBLEM", 193, 207], ["Au electrodes", "OBSERVATION", 39, 52]]], ["Representative proteins, cytochrome c and azurin were studied by using the combinations of four different strategies including the variation of SAM thickness ([\u2212S\u2212(CH 2 ) n \u2212\u03c9], with n running over the range 3 to 20, throughout), solution viscosity (varied by adding of the viscose additive -glucose), temperature (0 to 50 o C) and hydrostatic pressure (up to 150 MPa), aiming the identification of different intrinsic ET patterns and interplay between them in the framework of generalized charge-transfer theory.", [["glucose", "CHEMICAL", 292, 299], ["glucose", "CHEMICAL", 292, 299], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 25, 37], ["azurin", "GENE_OR_GENE_PRODUCT", 42, 48], ["glucose", "SIMPLE_CHEMICAL", 292, 299], ["cytochrome c", "PROTEIN", 25, 37], ["azurin", "PROTEIN", 42, 48], ["cytochrome c and azurin", "TREATMENT", 25, 48], ["four different strategies", "TREATMENT", 91, 116], ["SAM thickness", "TEST", 144, 157], ["\u2212S", "TEST", 160, 162], ["the viscose additive", "TREATMENT", 270, 290], ["temperature", "TEST", 302, 313], ["hydrostatic pressure", "TEST", 332, 352], ["pressure", "OBSERVATION_MODIFIER", 344, 352]]], ["We demonstrated the full adiabatic (frictional) control for the case of thinner SAMs, the intermediate (mixed) regime, and the complete changeover to the nonadiabatic mechanism (long-range tunneling) for the case of thick SAMs owing to the variation of electronic coupling, in a nice agreement with theoretical predictions.Mito. bov.", [["the full adiabatic (frictional) control", "TREATMENT", 16, 55], ["thinner SAMs", "TREATMENT", 72, 84], ["the intermediate (mixed) regime", "TREATMENT", 86, 117], ["long-range tunneling", "TREATMENT", 178, 198], ["thick SAMs", "PROBLEM", 216, 226]]], ["ADP/ATP carrier in detergent is predominantly monomeric but also forms multimeric speciesH.", [["ADP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 4, 7], ["ADP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 4, 7], ["ADP", "SIMPLE_CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 4, 7], ["multimeric speciesH", "PROTEIN", 71, 90], ["ADP/ATP carrier", "TREATMENT", 0, 15], ["multimeric speciesH", "PROBLEM", 71, 90]]], ["Nury 1 , F. Manon 1 , B. Arnou 2 , M. Le Maire 2 , E. Pebay-Peyroula 1 , C. Ebel 1 1 Institut De Biologie Structurale (IBS) CEA CNRS UJF Grenoble France, 2 CEA Ibitec CNRS URA2096 Univ.", [["Peyroula", "TEST", 60, 68]]], ["Paris-Sud Gif-sur-YVette France ADP/ATP carriers (AACs) are major and essential constituents of the inner mitochondrial membrane.", [["inner mitochondrial membrane", "ANATOMY", 100, 128], ["ADP", "CHEMICAL", 32, 35], ["ATP", "CHEMICAL", 36, 39], ["ADP", "CHEMICAL", 32, 35], ["ATP", "CHEMICAL", 36, 39], ["ADP", "SIMPLE_CHEMICAL", 32, 35], ["ATP", "SIMPLE_CHEMICAL", 36, 39], ["AACs", "SIMPLE_CHEMICAL", 50, 54], ["inner mitochondrial membrane", "CELLULAR_COMPONENT", 100, 128], ["ADP/ATP carriers (AACs", "TREATMENT", 32, 54], ["essential", "OBSERVATION_MODIFIER", 70, 79], ["constituents", "OBSERVATION", 80, 92], ["inner", "ANATOMY_MODIFIER", 100, 105], ["mitochondrial membrane", "OBSERVATION", 106, 128]]], ["They drive the import of ADP and the export of newly synthesized ATP.", [["ADP", "CHEMICAL", 25, 28], ["ATP", "CHEMICAL", 65, 68], ["ADP", "CHEMICAL", 25, 28], ["ATP", "CHEMICAL", 65, 68], ["ADP", "SIMPLE_CHEMICAL", 25, 28], ["ATP", "SIMPLE_CHEMICAL", 65, 68], ["ADP", "TREATMENT", 25, 28], ["newly synthesized ATP", "TREATMENT", 47, 68]]], ["We aimed to ascertain the published biophysical data claiming that AACs are dimers and to characterize the oligomeric state of the protein before crystallization.", [["AACs", "SIMPLE_CHEMICAL", 67, 71]]], ["Analytical ultracentrifugation sedimentation velocity experiments clearly show that the bovine AAC is a monomer in 3-laurylamido-N,N 2 dimethylpropylaminoxide (LAPAO), whereas in Triton X-100 and reduced Triton X-100, higher molecular mass species can also be identified.", [["AAC", "CHEMICAL", 95, 98], ["3-laurylamido-N,N 2 dimethylpropylaminoxide", "CHEMICAL", 115, 158], ["LAPAO", "CHEMICAL", 160, 165], ["Triton X-100", "CHEMICAL", 179, 191], ["Triton X-100", "CHEMICAL", 204, 216], ["3-laurylamido-N,N 2 dimethylpropylaminoxide", "CHEMICAL", 115, 158], ["LAPAO", "CHEMICAL", 160, 165], ["Triton X-100", "CHEMICAL", 179, 191], ["Triton X-100", "CHEMICAL", 204, 216], ["bovine", "ORGANISM", 88, 94], ["AAC", "SIMPLE_CHEMICAL", 95, 98], ["3-laurylamido-N,N 2 dimethylpropylaminoxide", "SIMPLE_CHEMICAL", 115, 158], ["LAPAO", "SIMPLE_CHEMICAL", 160, 165], ["Triton X-100", "SIMPLE_CHEMICAL", 179, 191], ["Triton X-100", "SIMPLE_CHEMICAL", 204, 216], ["bovine", "SPECIES", 88, 94], ["bovine", "SPECIES", 88, 94], ["Analytical ultracentrifugation sedimentation velocity experiments", "TEST", 0, 65], ["the bovine AAC", "PROBLEM", 84, 98], ["laurylamido", "TREATMENT", 117, 128], ["N 2 dimethylpropylaminoxide (LAPAO)", "TREATMENT", 131, 166], ["higher molecular mass species", "PROBLEM", 218, 247], ["sedimentation velocity", "OBSERVATION", 31, 53], ["bovine AAC", "OBSERVATION", 88, 98], ["mass", "OBSERVATION", 235, 239]]], ["Neutron scattering data for monomeric bovine AAC in LAPAO does not give definite conclusions on the association state, because the large amount of detergent and lipids is imperfectly matched by contrast methods.", [["bovine", "ORGANISM", 38, 44], ["lipids", "SIMPLE_CHEMICAL", 161, 167], ["bovine", "SPECIES", 38, 44], ["Neutron scattering data", "TEST", 0, 23], ["monomeric bovine AAC", "TREATMENT", 28, 48], ["detergent and lipids", "TREATMENT", 147, 167], ["large", "OBSERVATION_MODIFIER", 131, 136], ["amount", "OBSERVATION_MODIFIER", 137, 143]]], ["We discuss a possible way to integrate previously published biochemical evidence in favor of assemblies, the lack of well-defined multimers that we observe, and the information from the high-resolution structures, considering supramolecular organizations of AACs within the mitochondrial membrane.P-429Local anaesthetic binding to Shaker channels: Role of aromatic residues J. Nilsson, H. Ullman, K. Sahlholm, P. Arhem The Nobel Institute for Neurophysiology, Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden Local anaesthetic, antiepileptic and antiarrhythmic drugs acting on Nav and hERG channels have been assumed to bind to aromatic residues in the internal vestibule; to F1764 and Y1771 in Nav (Ragsdale et al., 1996 and to Y652 and F656 in hERG (Mitcheson et al., 2000) .", [["mitochondrial membrane", "ANATOMY", 274, 296], ["internal vestibule", "ANATOMY", 683, 701], ["SE", "DISEASE", 511, 513], ["multimers", "GENE_OR_GENE_PRODUCT", 130, 139], ["AACs", "SIMPLE_CHEMICAL", 258, 262], ["mitochondrial membrane", "CELLULAR_COMPONENT", 274, 296], ["Nav", "GENE_OR_GENE_PRODUCT", 607, 610], ["hERG", "GENE_OR_GENE_PRODUCT", 615, 619], ["vestibule", "ORGAN", 692, 701], ["AACs", "PROTEIN", 258, 262], ["Shaker channels", "PROTEIN", 331, 346], ["Nav and hERG channels", "PROTEIN", 607, 628], ["Local anaesthetic", "TREATMENT", 539, 556], ["antiepileptic", "TREATMENT", 558, 571], ["antiarrhythmic drugs", "TREATMENT", 576, 596], ["Nav and hERG channels", "TREATMENT", 607, 628], ["supramolecular organizations", "OBSERVATION", 226, 254], ["mitochondrial membrane", "OBSERVATION", 274, 296], ["aromatic residues", "OBSERVATION", 356, 373], ["internal vestibule", "ANATOMY", 683, 701]]], ["Despite a lack of such residues in Kv channels, local anaesthetics, antiepileptic and antiarrhythmics bind to Kv channels with a considerable affinity.", [["Kv", "GENE_OR_GENE_PRODUCT", 35, 37], ["Kv", "GENE_OR_GENE_PRODUCT", 110, 112], ["Kv channels", "PROTEIN", 35, 46], ["Kv channels", "PROTEIN", 110, 121], ["Kv channels", "TREATMENT", 35, 46], ["local anaesthetics", "TREATMENT", 48, 66], ["antiepileptic", "TREATMENT", 68, 81], ["antiarrhythmics", "TREATMENT", 86, 101], ["Kv channels", "TREATMENT", 110, 121], ["a considerable affinity", "TREATMENT", 127, 150]]], ["To explore the role of aromatic residues for the binding we investigated the effect of bupivacaine, benzocaine, phenytoin and quinidine on Shaker channels mutated to residues corresponding to the most C-terminal of the two aromatic residues in the S6 segment of the Nav and the hERG channels, (V473Y and P474F respectively).", [["bupivacaine", "CHEMICAL", 87, 98], ["benzocaine", "CHEMICAL", 100, 110], ["phenytoin", "CHEMICAL", 112, 121], ["quinidine", "CHEMICAL", 126, 135], ["bupivacaine", "CHEMICAL", 87, 98], ["benzocaine", "CHEMICAL", 100, 110], ["phenytoin", "CHEMICAL", 112, 121], ["quinidine", "CHEMICAL", 126, 135], ["C", "CHEMICAL", 201, 202], ["bupivacaine", "SIMPLE_CHEMICAL", 87, 98], ["benzocaine", "SIMPLE_CHEMICAL", 100, 110], ["phenytoin", "SIMPLE_CHEMICAL", 112, 121], ["quinidine", "SIMPLE_CHEMICAL", 126, 135], ["Nav", "GENE_OR_GENE_PRODUCT", 266, 269], ["hERG", "GENE_OR_GENE_PRODUCT", 278, 282], ["Shaker channels", "PROTEIN", 139, 154], ["C-terminal", "PROTEIN", 201, 211], ["S6 segment", "PROTEIN", 248, 258], ["Nav", "PROTEIN", 266, 269], ["hERG channels", "PROTEIN", 278, 291], ["V473Y", "PROTEIN", 294, 299], ["P474F", "PROTEIN", 304, 309], ["aromatic residues", "TREATMENT", 23, 40], ["the binding", "PROBLEM", 45, 56], ["bupivacaine", "TREATMENT", 87, 98], ["benzocaine", "TREATMENT", 100, 110], ["phenytoin", "TREATMENT", 112, 121], ["quinidine", "TREATMENT", 126, 135], ["Shaker channels", "TREATMENT", 139, 154], ["aromatic residues", "OBSERVATION", 223, 240], ["S6 segment", "ANATOMY_MODIFIER", 248, 258], ["Nav", "ANATOMY", 266, 269], ["hERG channels", "ANATOMY", 278, 291]]], ["The channels were expressed in Xenopus oocytes and the currents measured with the two-electrode voltage-clamp technique.", [["Xenopus oocytes", "ANATOMY", 31, 46], ["Xenopus", "ORGANISM", 31, 38], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 39, 46], ["Xenopus oocytes", "TREATMENT", 31, 46], ["clamp technique", "TREATMENT", 104, 119], ["Xenopus oocytes", "OBSERVATION", 31, 46]]], ["The results suggest that aromatic residues do not increase the binding affinity of the studied compounds to Kv channels.", [["Kv", "GENE_OR_GENE_PRODUCT", 108, 110], ["Kv channels", "PROTEIN", 108, 119], ["aromatic residues", "PROBLEM", 25, 42], ["aromatic residues", "OBSERVATION", 25, 42]]], ["Rather, the affinity decreases (as reflected in typical K d values for bupivacaine on V473F, P474F and wildtype channels, being 550, 740 and 300 \u00b5M, respectively).", [["bupivacaine", "CHEMICAL", 71, 82], ["bupivacaine", "CHEMICAL", 71, 82], ["bupivacaine", "SIMPLE_CHEMICAL", 71, 82], ["the affinity decreases", "PROBLEM", 8, 30], ["typical K d values", "TEST", 48, 66], ["bupivacaine", "TREATMENT", 71, 82], ["affinity", "OBSERVATION_MODIFIER", 12, 20], ["decreases", "OBSERVATION_MODIFIER", 21, 30]]], ["Thus, aromatic residues seem not to be necessary for high-affinity binding of the studied compounds to Kv channels.", [["Kv", "GENE_OR_GENE_PRODUCT", 103, 105], ["Kv channels", "PROTEIN", 103, 114], ["aromatic residues", "PROBLEM", 6, 23], ["high-affinity binding", "PROBLEM", 53, 74], ["aromatic residues", "OBSERVATION", 6, 23]]], ["How this relates to their suggested roles in the Nav and hERG channels, remains to be evaluated.", [["Nav", "GENE_OR_GENE_PRODUCT", 49, 52], ["hERG", "GENE_OR_GENE_PRODUCT", 57, 61], ["Nav and hERG channels", "PROTEIN", 49, 70]]], ["The occurrence of a similar behavior in other channels points out to clustering and coupled gating as a potentially important drug target to modulate channel activity.", [["similar", "OBSERVATION_MODIFIER", 20, 27], ["behavior", "OBSERVATION_MODIFIER", 28, 36]]], ["We have identified molecular determinants involved in single and coupled channel gating in KcsA.", [["KcsA", "GENE_OR_GENE_PRODUCT", 91, 95], ["KcsA", "PROTEIN", 91, 95]]], ["First, we detected that clustering and coupled gating of KcsA is modulated by anionic lipid.", [["KcsA", "GENE_OR_GENE_PRODUCT", 57, 61], ["anionic lipid", "SIMPLE_CHEMICAL", 78, 91], ["KcsA", "PROTEIN", 57, 61]]], ["Also, a model for the interaction between two KcsA open channels was built.", [["KcsA open channels", "PROTEIN", 46, 64], ["two KcsA open channels", "TREATMENT", 42, 64]]], ["The docking predicts intermolecular sites which includes the non-annular lipid binding site.", [["non-annular lipid binding site", "PROTEIN", 61, 91], ["The docking predicts intermolecular sites", "PROBLEM", 0, 41], ["the non-annular lipid binding site", "PROBLEM", 57, 91], ["intermolecular sites", "OBSERVATION", 21, 41], ["lipid binding", "OBSERVATION", 73, 86]]], ["This explains how an excess of anionic lipid disrupts interactions between channels, destabilizing clustering and coupled gating in KcsA.", [["lipid", "SIMPLE_CHEMICAL", 39, 44], ["KcsA", "GENE_OR_GENE_PRODUCT", 132, 136], ["KcsA", "PROTEIN", 132, 136]]], ["This interaction involves W87, which affects the neighbouring channel through specific interactions in the extracellular mouth stabilizing the selectivity filter in an open conformation.", [["extracellular mouth", "ANATOMY", 107, 126], ["W87", "GENE_OR_GENE_PRODUCT", 26, 29], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 107, 120], ["W87", "PROTEIN", 26, 29], ["the selectivity filter", "TREATMENT", 139, 161], ["selectivity filter", "OBSERVATION", 143, 161]]], ["The coupled gating is also explained since this mechanism affects the opposite channel in a mutual manner.", [["The coupled gating", "PROBLEM", 0, 18]]], ["Finally, mutants KcsA E71A and KcsA W87A disrupt the coupled gating of KcsA, thus, supporting the model.", [["KcsA", "GENE_OR_GENE_PRODUCT", 17, 21], ["KcsA W87A", "GENE_OR_GENE_PRODUCT", 31, 40], ["KcsA", "GENE_OR_GENE_PRODUCT", 71, 75], ["E71A", "PROTEIN", 22, 26], ["KcsA W87A", "PROTEIN", 31, 40], ["KcsA", "PROTEIN", 71, 75], ["KcsA", "TEST", 31, 35], ["KcsA", "TEST", 71, 75]]], ["We think that this coupled gating phenomenon could correspond to the second gate previously detected by fluorescence methods (Blunck, et al, 2006) .", [["this coupled gating phenomenon", "PROBLEM", 14, 44]]], ["Supported by grants from the Spanish BFU2008-00602/BMC and CSD2008-00005.Structural and dynamical properties of OmpF and OmpC porins: a case study on \u03b2-lactamase inhibitorsA.", [["BFU2008-00602", "CHEMICAL", 37, 50], ["CSD2008-00005", "CHEMICAL", 59, 72], ["CSD2008-00005", "CHEMICAL", 59, 72], ["CSD2008-00005", "CELL", 59, 72], ["OmpF", "GENE_OR_GENE_PRODUCT", 112, 116], ["OmpC porins", "GENE_OR_GENE_PRODUCT", 121, 132], ["\u03b2-lactamase inhibitorsA", "SIMPLE_CHEMICAL", 150, 173], ["OmpF", "PROTEIN", 112, 116], ["OmpC porins", "PROTEIN", 121, 132], ["\u03b2-lactamase inhibitorsA", "PROTEIN", 150, 173], ["Spanish BFU2008-00602/BMC and CSD2008-00005", "SPECIES", 29, 72], ["a case study", "TEST", 134, 146], ["\u03b2-lactamase inhibitorsA", "TREATMENT", 150, 173]]], ["Kumar, E. Hajjar, P. Ruggerone, M. Ceccarelli University of Cagliari, Monserrato, ItalyStructural and dynamical properties of OmpF and OmpC porins: a case study on \u03b2-lactamase inhibitorsThe striking presence of outer membrane (OM) in gramnegative bacteria of E.coli represents a strong barrier for any molecule to penetrate inside bacteria.", [["outer membrane", "ANATOMY", 211, 225], ["OM", "ANATOMY", 227, 229], ["OmpF", "GENE_OR_GENE_PRODUCT", 126, 130], ["OmpC porins", "GENE_OR_GENE_PRODUCT", 135, 146], ["\u03b2-lactamase", "GENE_OR_GENE_PRODUCT", 164, 175], ["outer membrane", "CELLULAR_COMPONENT", 211, 225], ["OmpF", "PROTEIN", 126, 130], ["OmpC porins", "PROTEIN", 135, 146], ["\u03b2-lactamase inhibitors", "PROTEIN", 164, 186], ["\u03b2-lactamase inhibitors", "TREATMENT", 164, 186], ["outer membrane (OM) in gramnegative bacteria of E.coli", "PROBLEM", 211, 265], ["any molecule", "PROBLEM", 298, 310], ["outer membrane", "ANATOMY", 211, 225], ["E.coli", "OBSERVATION", 259, 265]]], ["In particular for \u03b2-lactam antibiotics, which have their target located inside the bacteria; the first step towards reaching inner part of bacterium is the cellular uptake.", [["cellular", "ANATOMY", 156, 164], ["\u03b2-lactam", "CHEMICAL", 18, 26], ["\u03b2-lactam", "CHEMICAL", 18, 26], ["\u03b2-lactam antibiotics", "SIMPLE_CHEMICAL", 18, 38], ["inner part", "MULTI-TISSUE_STRUCTURE", 125, 135], ["cellular", "CELL", 156, 164], ["\u03b2-lactam antibiotics", "TREATMENT", 18, 38], ["the bacteria", "PROBLEM", 79, 91], ["bacteria", "OBSERVATION", 83, 91], ["bacterium", "OBSERVATION", 139, 148], ["cellular uptake", "OBSERVATION", 156, 171]]], ["Ubiquitous presence of porins (such as for instance OmpF, OmpC) in the OM, function as a channel facilitating the transport of molecules (such as, for instance antibiotics) across the OM.", [["porins", "GENE_OR_GENE_PRODUCT", 23, 29], ["OmpF", "GENE_OR_GENE_PRODUCT", 52, 56], ["OmpC", "GENE_OR_GENE_PRODUCT", 58, 62], ["porins", "PROTEIN", 23, 29], ["OmpF", "PROTEIN", 52, 56], ["OmpC", "PROTEIN", 58, 62], ["instance antibiotics", "TREATMENT", 151, 171], ["OM", "ANATOMY", 71, 73], ["OM", "ANATOMY", 184, 186]]], ["Bacteria can exhibit resistant towards antibiotics by: (i) decreasing their uptake by under-expressing the porins or/and (ii) production of inactivating enzymes such as \u00df-lactamases.", [["\u00df-lactamases", "GENE_OR_GENE_PRODUCT", 169, 181], ["porins", "PROTEIN", 107, 113], ["inactivating enzymes", "PROTEIN", 140, 160], ["\u00df-lactamases", "PROTEIN", 169, 181], ["Bacteria", "PROBLEM", 0, 8], ["antibiotics", "TREATMENT", 39, 50], ["inactivating enzymes", "PROBLEM", 140, 160], ["\u00df-lactamases", "PROBLEM", 169, 181], ["resistant", "OBSERVATION_MODIFIER", 21, 30]]], ["To combat the latter mechanism \u00df-lactamase inhibitors (such as, sulbactam for instance) are prescribed together with the antibiotics.", [["sulbactam", "CHEMICAL", 64, 73], ["sulbactam", "CHEMICAL", 64, 73], ["\u00df-lactamase", "SIMPLE_CHEMICAL", 31, 42], ["sulbactam", "SIMPLE_CHEMICAL", 64, 73], ["the latter mechanism \u00df-lactamase inhibitors", "TREATMENT", 10, 53], ["sulbactam", "TREATMENT", 64, 73], ["the antibiotics", "TREATMENT", 117, 132]]], ["Like the antibiotics, the inhibitors must penetrate the OM, the main path being through porins.", [["porins", "GENE_OR_GENE_PRODUCT", 88, 94], ["porins", "PROTEIN", 88, 94], ["the antibiotics", "TREATMENT", 5, 20], ["the inhibitors", "TREATMENT", 22, 36], ["OM", "ANATOMY", 56, 58], ["main", "OBSERVATION_MODIFIER", 64, 68]]], ["It is thus evident the biological relevance of investigating the mechanisms by which porins can regulate entry/exit across the OM.", [["OM", "ANATOMY", 127, 129], ["porins", "GENE_OR_GENE_PRODUCT", 85, 91], ["OM", "ANATOMY", 127, 129]]], ["To achieve this goal, molecular dynamics simulations were performed to explore the structure and dynamics of pores formed by OmpF and OmpC porin.", [["pores", "ANATOMY", 109, 114], ["OmpF", "GENE_OR_GENE_PRODUCT", 125, 129], ["OmpC porin", "GENE_OR_GENE_PRODUCT", 134, 144], ["OmpF", "PROTEIN", 125, 129], ["OmpC porin", "PROTEIN", 134, 144], ["molecular dynamics simulations", "TEST", 22, 52], ["OmpF and OmpC porin", "TREATMENT", 125, 144]]], ["From the analysis of data obtained from our simulations, we identified the key residues buried behind the L3 loop, which may play be crucial for porins to exert their biological role.", [["porins", "GENE_OR_GENE_PRODUCT", 145, 151], ["L3 loop", "PROTEIN", 106, 113], ["porins", "PROTEIN", 145, 151], ["L3 loop", "ANATOMY", 106, 113]]], ["As a case study, we report results about the diffusion of sulbactam through the two porins.", [["sulbactam", "CHEMICAL", 58, 67], ["sulbactam", "CHEMICAL", 58, 67], ["sulbactam", "SIMPLE_CHEMICAL", 58, 67], ["a case study", "TEST", 3, 15], ["sulbactam", "TREATMENT", 58, 67]]], ["The pentadecapeptide gramicidin forms a cation-specific ion channel in membrane environment.", [["membrane", "ANATOMY", 71, 79], ["gramicidin", "CHEMICAL", 21, 31], ["pentadecapeptide", "CHEMICAL", 4, 20], ["pentadecapeptide gramicidin", "SIMPLE_CHEMICAL", 4, 31], ["cation", "SIMPLE_CHEMICAL", 40, 46], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["The pentadecapeptide gramicidin", "TREATMENT", 0, 31], ["a cation", "TREATMENT", 38, 46]]], ["The two main conformations are the head-to-head helical dimer (HD) known as the channel conformation and the intertwined double helical form (DH) often referred to as non-channel conformation.", [["head", "ANATOMY", 35, 39], ["head-to-head helical dimer", "PROTEIN", 35, 61], ["HD", "PROTEIN", 63, 65], ["intertwined double helical form", "PROTEIN", 109, 140], ["DH", "PROTEIN", 142, 144], ["main", "OBSERVATION_MODIFIER", 8, 12], ["head", "ANATOMY", 35, 39], ["head", "ANATOMY", 43, 47]]], ["In this comparative study [1] , the energetics of single potassium ion permeation by means of the potential of mean force (PMF) for both gramicidin conformations embedded in a DMPC bilayer has been addressed by molecular dynamics simulations.", [["potassium", "CHEMICAL", 57, 66], ["gramicidin", "CHEMICAL", 137, 147], ["DMPC", "CHEMICAL", 176, 180], ["potassium", "CHEMICAL", 57, 66], ["DMPC", "CHEMICAL", 176, 180], ["potassium ion", "SIMPLE_CHEMICAL", 57, 70], ["gramicidin", "SIMPLE_CHEMICAL", 137, 147], ["this comparative study", "TEST", 3, 25], ["single potassium ion permeation", "TREATMENT", 50, 81], ["both gramicidin conformations", "TREATMENT", 132, 161], ["a DMPC bilayer", "TREATMENT", 174, 188]]], ["A significantly decreased free energy barrier by \u223c25 kJ/mol for potassium ion passage through DH as compared to HD is reported.", [["potassium", "CHEMICAL", 64, 73], ["DH", "CHEMICAL", 94, 96], ["potassium", "CHEMICAL", 64, 73], ["HD", "CHEMICAL", 112, 114], ["potassium ion", "SIMPLE_CHEMICAL", 64, 77], ["DH", "SIMPLE_CHEMICAL", 94, 96], ["A significantly decreased free energy barrier", "TREATMENT", 0, 45], ["potassium ion passage through DH", "TREATMENT", 64, 96], ["HD", "TREATMENT", 112, 114], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["decreased", "OBSERVATION_MODIFIER", 16, 25], ["free", "OBSERVATION_MODIFIER", 26, 30]]], ["Favorable electrostatic side chain-cation interactions in HD are overcompensated by phospholipid-cation interactions in DH.", [["HD", "CHEMICAL", 58, 60], ["cation", "SIMPLE_CHEMICAL", 35, 41], ["phospholipid", "SIMPLE_CHEMICAL", 84, 96], ["cation", "SIMPLE_CHEMICAL", 97, 103], ["DH", "SIMPLE_CHEMICAL", 120, 122], ["Favorable electrostatic side chain", "PROBLEM", 0, 34], ["HD", "TREATMENT", 58, 60], ["electrostatic", "OBSERVATION_MODIFIER", 10, 23], ["side", "OBSERVATION_MODIFIER", 24, 28], ["chain", "OBSERVATION_MODIFIER", 29, 34], ["cation interactions", "OBSERVATION", 35, 54]]], ["The latter are coupled to an increased accessibility of the channel entrance in DH due to distributed tryptophans along the channel axis.", [["tryptophans", "CHEMICAL", 102, 113], ["distributed tryptophans", "PROBLEM", 90, 113], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["accessibility", "OBSERVATION_MODIFIER", 39, 52], ["distributed", "OBSERVATION_MODIFIER", 90, 101], ["tryptophans", "OBSERVATION", 102, 113], ["channel axis", "ANATOMY_MODIFIER", 124, 136]]], ["This result underscores the importance of the lipid environment of this channel not only for the equilibrium between the different conformations but also for their function as cation channels.Molecular dynamics simulations of mechano-gating in the E-coli mechanosensitive channel MscLY.", [["cation", "SIMPLE_CHEMICAL", 176, 182], ["cation channels", "PROTEIN", 176, 191], ["E-coli mechanosensitive channel MscLY", "PROTEIN", 248, 285], ["mechano-gating", "PROBLEM", 226, 240]]], ["Sch.", [["Sch", "CHEMICAL", 0, 3], ["Sch", "TREATMENT", 0, 3]]], ["Med., Nagoya, Japan, 2 ICORP/SORST Cell Mechanosensing, JST, Nagoya, JapanMolecular dynamics simulations of mechano-gating in the E-coli mechanosensitive channel MscLThe bacterial mechanosensitive channel of large conductance MscL is constituted of homopentamer of a subunit with two transmembrane inner and outer \u03b1-helices, and its 3D structure of the closed state has been resolved.", [["Cell", "ANATOMY", 35, 39], ["transmembrane inner", "ANATOMY", 284, 303], ["outer \u03b1-helices", "ANATOMY", 308, 323], ["Cell", "CELL", 35, 39], ["E-coli mechanosensitive channel", "PROTEIN", 130, 161], ["MscLThe bacterial mechanosensitive channel", "PROTEIN", 162, 204], ["large conductance MscL", "PROTEIN", 208, 230], ["homopentamer", "PROTEIN", 249, 261], ["transmembrane inner and outer \u03b1-helices", "PROTEIN", 284, 323], ["mechano-gating", "PROBLEM", 108, 122], ["the E-coli mechanosensitive channel", "TREATMENT", 126, 161], ["large conductance MscL", "PROBLEM", 208, 230], ["two transmembrane inner and outer \u03b1-helices", "TREATMENT", 280, 323], ["mechanosensitive channel", "OBSERVATION", 180, 204], ["large", "OBSERVATION_MODIFIER", 208, 213], ["conductance MscL", "OBSERVATION", 214, 230], ["outer", "ANATOMY_MODIFIER", 308, 313], ["closed", "OBSERVATION", 353, 359], ["resolved", "OBSERVATION_MODIFIER", 375, 383]]], ["The major issue of MscL is to understand the gating mechanism driven by tension in the membrane.", [["membrane", "ANATOMY", 87, 95], ["MscL", "GENE_OR_GENE_PRODUCT", 19, 23], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["MscL", "PROTEIN", 19, 23], ["MscL", "OBSERVATION", 19, 23], ["tension", "OBSERVATION", 72, 79]]], ["Although several models for the opening process have been proposed with Molecular Dynamics (MD) simulations, as they do not include MscLlipid interactions, it remains unclear which amino acids sense membrane tension and how the sensed force induces channel opening.", [["membrane", "ANATOMY", 199, 207], ["amino acids", "CHEMICAL", 181, 192], ["amino acids", "CHEMICAL", 181, 192], ["MscLlipid", "GENE_OR_GENE_PRODUCT", 132, 141], ["amino acids", "AMINO_ACID", 181, 192], ["membrane", "CELLULAR_COMPONENT", 199, 207], ["amino acids sense membrane tension", "PROBLEM", 181, 215]]], ["We performed MD simulations for the mechano-gating of MscL embedded in the lipid bilayer.", [["lipid bilayer", "ANATOMY", 75, 88], ["MscL", "GENE_OR_GENE_PRODUCT", 54, 58], ["lipid bilayer", "CELLULAR_COMPONENT", 75, 88], ["MscL", "PROTEIN", 54, 58], ["the mechano-gating of MscL", "TREATMENT", 32, 58], ["MscL", "ANATOMY", 54, 58]]], ["Upon tension in the bilayer, Phe78 in the outer helix was dragged by lipids, leading to a tilting of the helices.", [["outer helix", "ANATOMY", 42, 53], ["Phe78", "CHEMICAL", 29, 34], ["Phe78", "CHEMICAL", 29, 34], ["Phe78", "SIMPLE_CHEMICAL", 29, 34], ["outer helix", "CELLULAR_COMPONENT", 42, 53], ["lipids", "SIMPLE_CHEMICAL", 69, 75], ["Phe78", "PROTEIN", 29, 34], ["a tilting of the helices", "TREATMENT", 88, 112], ["tension", "OBSERVATION_MODIFIER", 5, 12], ["bilayer", "ANATOMY_MODIFIER", 20, 27], ["outer", "ANATOMY_MODIFIER", 42, 47], ["helix", "ANATOMY_MODIFIER", 48, 53]]], ["Among amino acids in the outer helix facing the bilayer, Phe78 at the water-lipid interface showed the strongest interaction with lipids, thus may work as a major tension sensor.", [["outer helix", "ANATOMY", 25, 36], ["amino acids", "CHEMICAL", 6, 17], ["Phe78", "CHEMICAL", 57, 62], ["amino acids", "CHEMICAL", 6, 17], ["Phe78", "CHEMICAL", 57, 62], ["amino acids", "AMINO_ACID", 6, 17], ["outer helix", "CELLULAR_COMPONENT", 25, 36], ["Phe78", "SIMPLE_CHEMICAL", 57, 62], ["lipids", "SIMPLE_CHEMICAL", 130, 136], ["Among amino acids", "TREATMENT", 0, 17], ["lipids", "TREATMENT", 130, 136]]], ["Neighboring inner helices cross each other in the inner leaflet, forming the most constricted part of the pore.", [["inner helices", "ANATOMY", 12, 25], ["inner leaflet", "ANATOMY", 50, 63], ["pore", "ANATOMY", 106, 110], ["inner leaflet", "CELLULAR_COMPONENT", 50, 63], ["pore", "CELLULAR_COMPONENT", 106, 110], ["Neighboring inner helices", "TREATMENT", 0, 25], ["inner", "ANATOMY_MODIFIER", 12, 17], ["inner", "ANATOMY_MODIFIER", 50, 55], ["leaflet", "ANATOMY_MODIFIER", 56, 63], ["most", "OBSERVATION_MODIFIER", 77, 81], ["constricted", "OBSERVATION", 82, 93], ["pore", "OBSERVATION_MODIFIER", 106, 110]]], ["As tension increases, the crossings move toward the cytoplasm associated with an expansion of the constricted part.", [["cytoplasm", "ANATOMY", 52, 61], ["cytoplasm", "ORGANISM_SUBSTANCE", 52, 61], ["tension increases", "PROBLEM", 3, 20], ["tension", "OBSERVATION_MODIFIER", 3, 10], ["increases", "OBSERVATION_MODIFIER", 11, 20], ["cytoplasm", "OBSERVATION", 52, 61], ["expansion", "OBSERVATION", 81, 90], ["constricted", "OBSERVATION_MODIFIER", 98, 109]]], ["During the movement, a hydrophobic water block environment around the constricted part was broken followed by water penetration and permeation.", [["water", "SIMPLE_CHEMICAL", 110, 115], ["a hydrophobic water block environment", "TREATMENT", 21, 58], ["constricted", "OBSERVATION_MODIFIER", 70, 81]]], ["The K + channel KcsA is an integral membrane protein from S.lividans, used as a model system for studies on ion channels and oligomeric membrane proteins.", [["membrane", "ANATOMY", 36, 44], ["membrane", "ANATOMY", 136, 144], ["K", "CHEMICAL", 4, 5], ["K +", "CHEMICAL", 4, 7], ["K + channel KcsA", "GENE_OR_GENE_PRODUCT", 4, 20], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["K + channel KcsA", "PROTEIN", 4, 20], ["integral membrane protein", "PROTEIN", 27, 52], ["ion channels", "PROTEIN", 108, 120], ["oligomeric membrane proteins", "PROTEIN", 125, 153], ["The K + channel KcsA", "TEST", 0, 20], ["a model system", "TEST", 78, 92], ["oligomeric membrane proteins", "PROBLEM", 125, 153], ["oligomeric membrane proteins", "OBSERVATION", 125, 153]]], ["Its atomic structure has been solved by X-ray diffraction, which shows an assembly of four identical subunits around a central aqueous pore, including the so-called selectivity filter.", [["aqueous pore", "ANATOMY", 127, 139], ["X-ray diffraction", "TEST", 40, 57], ["a central aqueous pore", "TREATMENT", 117, 139], ["the so-called selectivity filter", "TREATMENT", 151, 183], ["atomic structure", "OBSERVATION", 4, 20], ["subunits", "OBSERVATION_MODIFIER", 101, 109], ["central", "OBSERVATION_MODIFIER", 119, 126], ["aqueous pore", "OBSERVATION", 127, 139], ["selectivity filter", "OBSERVATION", 165, 183]]], ["This channel is able to permeate K + at high flux rate and it is blocked by Na + (physiological blocker).", [["K", "CHEMICAL", 33, 34], ["Na", "CHEMICAL", 76, 78], ["K +", "CHEMICAL", 33, 36], ["Na +", "CHEMICAL", 76, 80], ["K +", "SIMPLE_CHEMICAL", 33, 36], ["Na +", "SIMPLE_CHEMICAL", 76, 80], ["K", "TEST", 33, 34], ["Na", "TEST", 76, 78], ["physiological blocker", "TREATMENT", 82, 103]]], ["Fluorescence, circular dichroism and Fourier transform infrared experiments carried out in our laboratory demonstrated that K + and Na + are able to bind to KcsA in a competitive manner.", [["K", "CHEMICAL", 124, 125], ["Na", "CHEMICAL", 132, 134], ["K +", "CHEMICAL", 124, 127], ["Na +", "CHEMICAL", 132, 136], ["K +", "SIMPLE_CHEMICAL", 124, 127], ["Na +", "SIMPLE_CHEMICAL", 132, 136], ["KcsA", "GENE_OR_GENE_PRODUCT", 157, 161], ["KcsA", "PROTEIN", 157, 161], ["Fluorescence", "TEST", 0, 12], ["circular dichroism", "TEST", 14, 32], ["Fourier transform infrared experiments", "TEST", 37, 75], ["K", "TEST", 124, 125], ["Na", "TEST", 132, 134]]], ["This binding is indeed associated with channel conformational changes, which seem to be related to the permeation and blockade processes.", [["channel conformational changes", "PROBLEM", 39, 69], ["the permeation and blockade processes", "TREATMENT", 99, 136]]], ["To further investigate this phenomenon we carried out a detailed study of chemical and thermal denaturation of wild-type and mutant KcsA channels.", [["KcsA", "GENE_OR_GENE_PRODUCT", 132, 136], ["wild-type and mutant KcsA channels", "PROTEIN", 111, 145], ["this phenomenon", "PROBLEM", 23, 38], ["a detailed study", "TEST", 54, 70]]], ["These two types of experiments were in agreement and indicate that both cations are able to stabilize the channel through conformational changes, being K + the more efficient one, even more when lipids are present.", [["K", "CHEMICAL", 152, 153], ["K +", "CHEMICAL", 152, 155], ["cations", "SIMPLE_CHEMICAL", 72, 79], ["K +", "SIMPLE_CHEMICAL", 152, 155], ["lipids", "SIMPLE_CHEMICAL", 195, 201], ["K", "TEST", 152, 153]]], ["Particularly, mutant channels with a structurally altered selectivity filter show that ion and lipid-induced global conformational changes are intimately associated to the conformation of this selectivity filter (conductive and non-conductive forms).P-431Modulation of the voltage-gated sodium channel Nav 1.5 by rCssII, a toxin from the scorpion Centruroides suffusus C. Picco 1 , G. Corzo 2 , L. D. Possani 2 , G. Prestipino 1 1 Institute of Biophysics, CNR, Genova, Italy, 2 Instituto de Biotecnologia, UNAM, Cuernavaca, MexicoP-431The main cardiac voltage-gating sodium channel, Na v 1.5, generates the fast depolarization of the cardiac action potential and plays a key role in cardiac conduction.", [["cardiac", "ANATOMY", 544, 551], ["cardiac", "ANATOMY", 634, 641], ["cardiac", "ANATOMY", 683, 690], ["sodium", "CHEMICAL", 287, 293], ["MexicoP-431", "CHEMICAL", 524, 535], ["sodium", "CHEMICAL", 567, 573], ["Na", "CHEMICAL", 583, 585], ["sodium", "CHEMICAL", 287, 293], ["sodium", "CHEMICAL", 567, 573], ["Na v 1.5", "CHEMICAL", 583, 591], ["lipid", "SIMPLE_CHEMICAL", 95, 100], ["rCssII", "GENE_OR_GENE_PRODUCT", 313, 319], ["cardiac", "ORGAN", 544, 551], ["sodium", "SIMPLE_CHEMICAL", 567, 573], ["Na v 1.5", "GENE_OR_GENE_PRODUCT", 583, 591], ["cardiac", "ORGAN", 634, 641], ["cardiac", "ORGAN", 683, 690], ["mutant channels", "PROTEIN", 14, 29], ["P", "DNA", 250, 251], ["voltage-gated sodium channel Nav 1.5", "PROTEIN", 273, 309], ["rCssII", "PROTEIN", 313, 319], ["Na v 1.5", "PROTEIN", 583, 591], ["Centruroides suffusus", "SPECIES", 347, 368], ["Centruroides suffusus", "SPECIES", 347, 368], ["a structurally altered selectivity filter", "PROBLEM", 35, 76], ["ion and lipid-induced global conformational changes", "PROBLEM", 87, 138], ["this selectivity filter", "TREATMENT", 188, 211], ["P", "TEST", 250, 251], ["the voltage", "TEST", 269, 280], ["gated sodium channel Nav", "TEST", 281, 305], ["rCssII", "TEST", 313, 319], ["a toxin", "TEST", 321, 328], ["Picco", "TEST", 372, 377], ["MexicoP", "TEST", 524, 531], ["The main cardiac voltage", "TEST", 535, 559], ["Na v", "TEST", 583, 587], ["global conformational", "OBSERVATION", 109, 130], ["main", "ANATOMY_MODIFIER", 539, 543], ["cardiac", "ANATOMY", 544, 551], ["voltage", "ANATOMY_MODIFIER", 552, 559], ["fast depolarization", "OBSERVATION", 607, 626], ["cardiac", "ANATOMY", 634, 641], ["cardiac", "ANATOMY", 683, 690], ["conduction", "OBSERVATION", 691, 701]]], ["Its importance for normal cardiac function has been exemplified by the description of numerous naturally occurring genetic variants of the gene SCN5A, which encodes Na v 1.5, that are linked to various cardiac deseases.", [["cardiac", "ANATOMY", 26, 33], ["cardiac", "ANATOMY", 202, 209], ["Na", "CHEMICAL", 165, 167], ["cardiac deseases", "DISEASE", 202, 218], ["cardiac", "ORGAN", 26, 33], ["SCN5A", "GENE_OR_GENE_PRODUCT", 144, 149], ["Na v 1.5", "GENE_OR_GENE_PRODUCT", 165, 173], ["cardiac", "ORGAN", 202, 209], ["SCN5A", "DNA", 144, 149], ["Na v 1.5", "PROTEIN", 165, 173], ["Na v", "TEST", 165, 169], ["various cardiac deseases", "PROBLEM", 194, 218], ["cardiac", "ANATOMY", 26, 33], ["cardiac", "ANATOMY", 202, 209], ["deseases", "OBSERVATION", 210, 218]]], ["Subsequently, studies of this channel localization have led to its identification in immature and denervated skeletal muscle and in the brain neurons.", [["skeletal muscle", "ANATOMY", 109, 124], ["brain neurons", "ANATOMY", 136, 149], ["skeletal muscle", "TISSUE", 109, 124], ["brain neurons", "CELL", 136, 149], ["brain neurons", "CELL_TYPE", 136, 149], ["this channel localization", "TEST", 25, 50], ["denervated", "ANATOMY_MODIFIER", 98, 108], ["skeletal muscle", "ANATOMY", 109, 124], ["brain neurons", "ANATOMY", 136, 149]]], ["In our effort to identify high affinity ligands for this channel, we have investigated the effects of the recombinant CssII (rC-ssII), a four disulfide-bridged scorpion toxin isolated from the venom of the scorpion Centruroides suffusus.", [["venom", "ANATOMY", 193, 198], ["CssII", "CHEMICAL", 118, 123], ["rC-ssII", "CHEMICAL", 125, 132], ["disulfide", "CHEMICAL", 142, 151], ["CssII", "GENE_OR_GENE_PRODUCT", 118, 123], ["rC-ssII", "GENE_OR_GENE_PRODUCT", 125, 132], ["scorpion toxin", "SIMPLE_CHEMICAL", 160, 174], ["venom", "ORGANISM_SUBSTANCE", 193, 198], ["scorpion", "ORGANISM", 206, 214], ["Centruroides suffusus", "ORGANISM", 215, 236], ["recombinant CssII", "PROTEIN", 106, 123], ["rC", "PROTEIN", 125, 127], ["ssII", "PROTEIN", 128, 132], ["disulfide-bridged scorpion toxin", "PROTEIN", 142, 174], ["scorpion", "SPECIES", 206, 214], ["Centruroides suffusus", "SPECIES", 215, 236], ["Centruroides suffusus", "SPECIES", 215, 236], ["high affinity ligands", "PROBLEM", 26, 47], ["the recombinant CssII (rC-ssII", "TREATMENT", 102, 132], ["a four disulfide-bridged scorpion toxin", "TREATMENT", 135, 174], ["venom", "ANATOMY", 193, 198]]], ["Human cardiac sodium channel \u03b1 subunit SCN5a was expressed in CHO cells and macroscopic Na + currents were recorded with patchclamp technique in whole cell configuration.", [["cardiac", "ANATOMY", 6, 13], ["CHO cells", "ANATOMY", 62, 71], ["cell", "ANATOMY", 151, 155], ["sodium", "CHEMICAL", 14, 20], ["Na", "CHEMICAL", 88, 90], ["sodium", "CHEMICAL", 14, 20], ["Na +", "CHEMICAL", 88, 92], ["Human", "ORGANISM", 0, 5], ["cardiac sodium channel \u03b1 subunit", "GENE_OR_GENE_PRODUCT", 6, 38], ["SCN5a", "GENE_OR_GENE_PRODUCT", 39, 44], ["CHO cells", "CELL", 62, 71], ["Na +", "SIMPLE_CHEMICAL", 88, 92], ["cell", "CELL", 151, 155], ["Human cardiac sodium channel \u03b1 subunit", "PROTEIN", 0, 38], ["SCN5a", "PROTEIN", 39, 44], ["CHO cells", "CELL_LINE", 62, 71], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human cardiac sodium channel \u03b1 subunit SCN5a", "TREATMENT", 0, 44], ["macroscopic Na + currents", "TEST", 76, 101], ["patchclamp technique", "TREATMENT", 121, 141], ["SCN5a", "OBSERVATION", 39, 44], ["whole cell configuration", "OBSERVATION", 145, 169]]], ["The electrophysiological experiments have highlighted a strong affinity for the channel at low nanomolar concentration.", [["the channel at low nanomolar concentration", "TREATMENT", 76, 118]]], ["Compared with control conditions, rCssII toxin affects in reversible way the kinetics of activation and inactivation and marked decrease the peak Na + influx.Research supported by International Collaboration between CNR and Mexican CONACyTThe extrusion mechanism of substrates in RND family efflux pumps: a molecular dynamics study A. V The RND transporters of the AcrAB-TolC (E.Coli) and MexAB-OprM (P.Aeruginosa) systems are able to export structurally and chemically different substrates outside bacteria through the membrane, being responsible of multidrug resistance.", [["membrane", "ANATOMY", 520, 528], ["Na", "CHEMICAL", 146, 148], ["Na +", "CHEMICAL", 146, 150], ["rCssII toxin", "GENE_OR_GENE_PRODUCT", 34, 46], ["Na +", "SIMPLE_CHEMICAL", 146, 150], ["AcrAB-TolC", "GENE_OR_GENE_PRODUCT", 365, 375], ["E.Coli", "GENE_OR_GENE_PRODUCT", 377, 383], ["MexAB-OprM", "GENE_OR_GENE_PRODUCT", 389, 399], ["membrane", "CELLULAR_COMPONENT", 520, 528], ["rCssII toxin", "PROTEIN", 34, 46], ["AcrAB", "PROTEIN", 365, 370], ["TolC", "PROTEIN", 371, 375], ["E.Coli", "PROTEIN", 377, 383], ["MexAB", "PROTEIN", 389, 394], ["OprM", "PROTEIN", 395, 399], ["P.Aeruginosa", "PROTEIN", 401, 413], ["rCssII toxin affects", "PROBLEM", 34, 54], ["inactivation", "PROBLEM", 104, 116], ["influx", "PROBLEM", 151, 157], ["the AcrAB", "TEST", 361, 370], ["TolC (E.Coli", "TEST", 371, 383], ["MexAB", "TEST", 389, 394], ["multidrug resistance", "PROBLEM", 551, 571], ["marked", "OBSERVATION_MODIFIER", 121, 127], ["decrease", "OBSERVATION_MODIFIER", 128, 136], ["multidrug resistance", "OBSERVATION", 551, 571]]], ["On the basis of crystallographic information, an extrusion process conceived as a three-cyclic peristaltic pumping has been proposed, but further microscopically well-funded investigations are needed to understand the mechanism.", [["an extrusion process", "PROBLEM", 46, 66], ["a three-cyclic peristaltic pumping", "TREATMENT", 80, 114], ["funded investigations", "TEST", 167, 188], ["extrusion process", "OBSERVATION", 49, 66]]], ["Using different computational methods like adaptive bias force (ABF) and targeted molecular dynamics (TMD), we have investigated the mechanism of substrate uptake and pumping at a molecular level.", [["different computational methods", "TREATMENT", 6, 37], ["substrate uptake", "PROBLEM", 146, 162]]], ["With the first method we have investigated the passage of antibiotics from the periplasm into the internal pore of the pump, while TMD has been used to assess the effect of conformational changes on the extrusion of drugs (which have been located into one of the proposed binding pockets).", [["periplasm", "ANATOMY", 79, 88], ["internal pore", "ANATOMY", 98, 111], ["periplasm", "CELLULAR_COMPONENT", 79, 88], ["antibiotics", "TREATMENT", 58, 69], ["the pump", "TREATMENT", 115, 123], ["conformational changes", "PROBLEM", 173, 195], ["the extrusion of drugs", "TREATMENT", 199, 221], ["internal pore", "ANATOMY_MODIFIER", 98, 111]]], ["Comparison between the active pumps AcrB and MexB (which show different resistance patterns despite their homology) provide insights into the microscopic details of their functioning.", [["AcrB", "GENE_OR_GENE_PRODUCT", 36, 40], ["MexB", "GENE_OR_GENE_PRODUCT", 45, 49], ["AcrB", "PROTEIN", 36, 40], ["MexB", "PROTEIN", 45, 49], ["the active pumps AcrB", "TREATMENT", 19, 40], ["MexB", "TREATMENT", 45, 49], ["different resistance patterns", "PROBLEM", 62, 91]]], ["In Arabidopsis thaliana there are twenty genes, grouped into three subfamilies, encoding for homologues of animal ionotropic glutamate receptors (iGLRs).", [["glutamate", "CHEMICAL", 125, 134], ["glutamate", "CHEMICAL", 125, 134], ["Arabidopsis thaliana", "ORGANISM", 3, 23], ["ionotropic glutamate receptors", "GENE_OR_GENE_PRODUCT", 114, 144], ["iGLRs", "GENE_OR_GENE_PRODUCT", 146, 151], ["animal ionotropic glutamate receptors", "PROTEIN", 107, 144], ["iGLRs", "PROTEIN", 146, 151], ["Arabidopsis thaliana", "SPECIES", 3, 23], ["Arabidopsis thaliana", "SPECIES", 3, 23], ["animal ionotropic glutamate receptors", "TREATMENT", 107, 144], ["Arabidopsis thaliana", "OBSERVATION", 3, 23]]], ["Each protein displays a pore-forming loop, flanked by two conserved helices (plus a third C-terminal helix), a glutamate-binding domain and an N-terminal region.", [["pore", "ANATOMY", 24, 28], ["glutamate", "CHEMICAL", 111, 120], ["C", "CHEMICAL", 90, 91], ["glutamate", "CHEMICAL", 111, 120], ["N", "CHEMICAL", 143, 144], ["glutamate", "SIMPLE_CHEMICAL", 111, 120], ["pore-forming loop", "PROTEIN", 24, 41], ["third C-terminal helix", "PROTEIN", 84, 106], ["glutamate-binding domain", "PROTEIN", 111, 135], ["N-terminal region", "PROTEIN", 143, 160], ["Each protein", "TEST", 0, 12], ["a pore-forming loop", "TREATMENT", 22, 41], ["a third C-terminal helix", "PROBLEM", 82, 106], ["a glutamate-binding domain", "PROBLEM", 109, 135], ["forming loop", "OBSERVATION", 29, 41], ["terminal", "ANATOMY_MODIFIER", 145, 153], ["region", "ANATOMY_MODIFIER", 154, 160]]], ["Through pharmacological and/or genetic approaches, many physiological functions have been attributed to plant GluRs, such as the regulation of cytosolic calcium, photomorphogenesis, water balance and carbon/nitrogen sensing and assimilation.", [["cytosolic", "ANATOMY", 143, 152], ["calcium", "CHEMICAL", 153, 160], ["carbon/nitrogen", "CHEMICAL", 200, 215], ["calcium", "CHEMICAL", 153, 160], ["carbon", "CHEMICAL", 200, 206], ["nitrogen", "CHEMICAL", 207, 215], ["GluRs", "GENE_OR_GENE_PRODUCT", 110, 115], ["calcium", "SIMPLE_CHEMICAL", 153, 160], ["water", "SIMPLE_CHEMICAL", 182, 187], ["carbon", "SIMPLE_CHEMICAL", 200, 206], ["nitrogen", "SIMPLE_CHEMICAL", 207, 215], ["GluRs", "PROTEIN", 110, 115], ["plant GluRs", "PROBLEM", 104, 115], ["cytosolic calcium", "TREATMENT", 143, 160], ["photomorphogenesis", "TREATMENT", 162, 180], ["water balance", "TREATMENT", 182, 195], ["carbon/nitrogen sensing", "TREATMENT", 200, 223]]], ["According to the endosymbiotic theory, the cyanobacteria are considered to represent the precursors of the present chloroplasts.", [["chloroplasts", "ANATOMY", 115, 127], ["chloroplasts", "CELLULAR_COMPONENT", 115, 127], ["the cyanobacteria", "PROBLEM", 39, 56], ["cyanobacteria", "OBSERVATION", 43, 56], ["considered to represent", "UNCERTAINTY", 61, 84]]], ["The first prokaryotic glutamate receptor (GluR0) was identified in the cyanobacterium Synechocystis.", [["glutamate", "CHEMICAL", 22, 31], ["glutamate", "CHEMICAL", 22, 31], ["glutamate receptor", "GENE_OR_GENE_PRODUCT", 22, 40], ["GluR0", "GENE_OR_GENE_PRODUCT", 42, 47], ["cyanobacterium Synechocystis", "ORGANISM", 71, 99], ["prokaryotic glutamate receptor", "PROTEIN", 10, 40], ["GluR0", "PROTEIN", 42, 47], ["cyanobacterium Synechocystis", "SPECIES", 71, 99], ["The first prokaryotic glutamate receptor (GluR0)", "TREATMENT", 0, 48], ["the cyanobacterium Synechocystis", "PROBLEM", 67, 99], ["cyanobacterium Synechocystis", "OBSERVATION", 71, 99]]], ["The putative products of the Atglr3.4 and Atglr3.5 genes display a possible targeting sequence for chloroplast location and show a high degree of homology with GluR0.", [["chloroplast", "ANATOMY", 99, 110], ["Atglr3.4", "GENE_OR_GENE_PRODUCT", 29, 37], ["Atglr3.5", "GENE_OR_GENE_PRODUCT", 42, 50], ["chloroplast", "CELLULAR_COMPONENT", 99, 110], ["GluR0", "GENE_OR_GENE_PRODUCT", 160, 165], ["Atglr3.4 and Atglr3.5 genes", "DNA", 29, 56], ["GluR0", "PROTEIN", 160, 165], ["chloroplast location", "TEST", 99, 119], ["a high degree of homology with GluR0", "PROBLEM", 129, 165], ["high degree", "OBSERVATION_MODIFIER", 131, 142]]], ["Using specific antibodies and confocal microscopy, we have localized the two members of the AtGLR subgroup 3, GLR3.", [["AtGLR subgroup 3", "GENE_OR_GENE_PRODUCT", 92, 108], ["GLR3", "GENE_OR_GENE_PRODUCT", 110, 114], ["AtGLR subgroup 3", "PROTEIN", 92, 108], ["GLR3", "PROTEIN", 110, 114], ["confocal microscopy", "TEST", 30, 49]]], ["4 and GLR3.5 (splicing variant) , to the chloroplast in Arabidopsis and to the inner envelope membrane in spinach.", [["chloroplast", "ANATOMY", 41, 52], ["inner envelope membrane", "ANATOMY", 79, 102], ["spinach", "ANATOMY", 106, 113], ["4", "GENE_OR_GENE_PRODUCT", 0, 1], ["GLR3.5", "GENE_OR_GENE_PRODUCT", 6, 12], ["chloroplast", "CELLULAR_COMPONENT", 41, 52], ["inner envelope membrane", "CELLULAR_COMPONENT", 79, 102], ["spinach", "CELLULAR_COMPONENT", 106, 113], ["GLR3.5", "PROTEIN", 6, 12], ["spinach", "PROTEIN", 106, 113], ["Arabidopsis", "SPECIES", 56, 67], ["the inner envelope membrane in spinach", "TREATMENT", 75, 113], ["inner", "ANATOMY_MODIFIER", 79, 84], ["envelope membrane", "OBSERVATION", 85, 102]]], ["Electrophysiological experiments indicate the presence of an activity which is compatible with that of glutamate receptors.", [["glutamate", "CHEMICAL", 103, 112], ["glutamate", "CHEMICAL", 103, 112], ["glutamate receptors", "GENE_OR_GENE_PRODUCT", 103, 122], ["glutamate receptors", "PROTEIN", 103, 122], ["Electrophysiological experiments", "TEST", 0, 32], ["glutamate receptors", "TREATMENT", 103, 122], ["activity", "OBSERVATION", 61, 69], ["compatible with", "UNCERTAINTY", 79, 94]]], ["Furthermore, oxygen evolution measurements suggest that chloroplast-located glutamate receptors may play a role in the regulation of photosynthesis.", [["oxygen", "CHEMICAL", 13, 19], ["glutamate", "CHEMICAL", 76, 85], ["oxygen", "CHEMICAL", 13, 19], ["glutamate", "CHEMICAL", 76, 85], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["chloroplast", "CELLULAR_COMPONENT", 56, 67], ["glutamate receptors", "GENE_OR_GENE_PRODUCT", 76, 95], ["chloroplast-located glutamate receptors", "PROTEIN", 56, 95], ["oxygen evolution measurements", "TEST", 13, 42], ["chloroplast-located glutamate receptors", "TREATMENT", 56, 95]]], ["Under extreme conditions many cells control their volume responding to osmotic challenges by unloading or loading solutes to recover their original volume.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["osmotic challenges", "TREATMENT", 71, 89], ["unloading or loading solutes", "TREATMENT", 93, 121]]], ["A faster volume regulatory role triggered by membrane tension has been disclosed for aquaporins in kidney proximal tubule cells, where AQP1 is the main water channel, using isolated brush border membranes.", [["membrane", "ANATOMY", 45, 53], ["kidney proximal tubule cells", "ANATOMY", 99, 127], ["brush border membranes", "ANATOMY", 182, 204], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["aquaporins", "GENE_OR_GENE_PRODUCT", 85, 95], ["kidney proximal tubule cells", "CELL", 99, 127], ["AQP1", "GENE_OR_GENE_PRODUCT", 135, 139], ["aquaporins", "PROTEIN", 85, 95], ["kidney proximal tubule cells", "CELL_TYPE", 99, 127], ["AQP1", "PROTEIN", 135, 139], ["A faster volume regulatory role", "PROBLEM", 0, 31], ["membrane tension", "PROBLEM", 45, 61], ["aquaporins in kidney proximal tubule cells", "PROBLEM", 85, 127], ["isolated brush border membranes", "TREATMENT", 173, 204], ["faster", "OBSERVATION_MODIFIER", 2, 8], ["volume regulatory", "OBSERVATION", 9, 26], ["membrane tension", "OBSERVATION", 45, 61], ["kidney", "ANATOMY", 99, 105], ["proximal", "ANATOMY_MODIFIER", 106, 114], ["tubule cells", "OBSERVATION", 115, 127], ["main", "OBSERVATION_MODIFIER", 147, 151], ["water channel", "OBSERVATION", 152, 165]]], ["In conventional osmotic studies in animal cells it is common to disregard internal hydrostatic pressures because they are insignificant compared to osmotic forces.", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47], ["animal cells", "CELL_TYPE", 35, 47], ["conventional osmotic studies", "TEST", 3, 31], ["internal hydrostatic pressures", "PROBLEM", 74, 104], ["hydrostatic pressures", "OBSERVATION", 83, 104], ["insignificant", "OBSERVATION_MODIFIER", 122, 135]]], ["However, by using low osmolarity buffers in small radii vesicles, we detected a rise on the internal pressure that creates surface tension and causes membrane stress, with a negative outcome on aquaporin water permeability.", [["radii vesicles", "ANATOMY", 50, 64], ["surface", "ANATOMY", 123, 130], ["membrane", "ANATOMY", 150, 158], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["aquaporin", "GENE_OR_GENE_PRODUCT", 194, 203], ["low osmolarity buffers in small radii vesicles", "PROBLEM", 18, 64], ["surface tension", "PROBLEM", 123, 138], ["membrane stress", "PROBLEM", 150, 165], ["aquaporin water permeability", "TREATMENT", 194, 222], ["small", "OBSERVATION_MODIFIER", 44, 49], ["radii vesicles", "OBSERVATION", 50, 64], ["rise", "OBSERVATION_MODIFIER", 80, 84], ["internal pressure", "OBSERVATION", 92, 109], ["surface tension", "OBSERVATION", 123, 138], ["membrane stress", "OBSERVATION", 150, 165]]], ["These findings suggested a mechanism for volume regulation in kidney proximal tubule epithelia where massive solute and fluid transport occurs.", [["kidney proximal tubule epithelia", "ANATOMY", 62, 94], ["fluid", "ANATOMY", 120, 125], ["kidney proximal tubule epithelia", "TISSUE", 62, 94], ["fluid", "ORGANISM_SUBSTANCE", 120, 125], ["volume regulation in kidney proximal tubule epithelia", "PROBLEM", 41, 94], ["massive solute and fluid transport", "TREATMENT", 101, 135], ["kidney", "ANATOMY", 62, 68], ["proximal", "ANATOMY_MODIFIER", 69, 77], ["tubule", "ANATOMY_MODIFIER", 78, 84], ["epithelia", "ANATOMY_MODIFIER", 85, 94], ["massive", "OBSERVATION_MODIFIER", 101, 108], ["solute", "OBSERVATION_MODIFIER", 109, 115], ["fluid transport", "OBSERVATION", 120, 135]]], ["To further explore aquaporin regulation by membrane tension, yeast cells were used as a model that could bare surface tension some orders of magnitude higher than animal cells due to the existence of a cell wall.", [["membrane", "ANATOMY", 43, 51], ["yeast cells", "ANATOMY", 61, 72], ["surface", "ANATOMY", 110, 117], ["cells", "ANATOMY", 170, 175], ["cell wall", "ANATOMY", 202, 211], ["aquaporin", "GENE_OR_GENE_PRODUCT", 19, 28], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["yeast cells", "CELL", 61, 72], ["cells", "CELL", 170, 175], ["cell wall", "TISSUE", 202, 211], ["aquaporin", "PROTEIN", 19, 28], ["yeast cells", "CELL_TYPE", 61, 72], ["animal cells", "CELL_TYPE", 163, 175], ["yeast", "SPECIES", 61, 66], ["yeast", "SPECIES", 61, 66], ["aquaporin regulation", "TREATMENT", 19, 39], ["yeast cells", "PROBLEM", 61, 72], ["animal cells", "PROBLEM", 163, 175], ["yeast cells", "OBSERVATION", 61, 72], ["cell", "OBSERVATION", 202, 206], ["wall", "ANATOMY_MODIFIER", 207, 211]]], ["The effect of increasing levels of membrane tension on yeast water channel activity was evaluated.", [["membrane", "ANATOMY", 35, 43], ["membrane", "CELLULAR_COMPONENT", 35, 43], ["yeast", "SPECIES", 55, 60], ["yeast", "SPECIES", 55, 60], ["increasing levels", "PROBLEM", 14, 31], ["membrane tension", "PROBLEM", 35, 51], ["yeast water channel activity", "TREATMENT", 55, 83], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["membrane tension", "OBSERVATION", 35, 51], ["water channel", "OBSERVATION_MODIFIER", 61, 74]]], ["An impairment of aquaporin activity correlated with the increase of membrane tension corroborates the volume regulatory role of aquaporin in different cells.123Deuterium isotope effects on fast gating of the chloride channel ClC-0 G. Zifarelli, A. R. Murgia, P. Soliani, P. Michael Istituto di Biofisica, CNR, Via De Marini, 6, I-16149 Genova, Italy123Gating of the Torpedo Cl \u2212 channel ClC-0 is modulated by intracellular and extracellular pH, but the mechanism responsible for this regulation has remained so far elusive.", [["membrane", "ANATOMY", 68, 76], ["cells", "ANATOMY", 151, 156], ["intracellular", "ANATOMY", 409, 422], ["extracellular", "ANATOMY", 427, 440], ["Deuterium isotope", "CHEMICAL", 160, 177], ["chloride", "CHEMICAL", 208, 216], ["Cl", "CHEMICAL", 374, 376], ["Deuterium", "CHEMICAL", 160, 169], ["chloride", "CHEMICAL", 208, 216], ["Cl", "CHEMICAL", 374, 376], ["aquaporin", "GENE_OR_GENE_PRODUCT", 17, 26], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["aquaporin", "GENE_OR_GENE_PRODUCT", 128, 137], ["cells", "CELL", 151, 156], ["chloride", "SIMPLE_CHEMICAL", 208, 216], ["ClC-0", "GENE_OR_GENE_PRODUCT", 387, 392], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 409, 422], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 427, 440], ["aquaporin", "PROTEIN", 17, 26], ["aquaporin", "PROTEIN", 128, 137], ["Torpedo Cl \u2212 channel ClC-0", "PROTEIN", 366, 392], ["An impairment of aquaporin activity", "PROBLEM", 0, 35], ["membrane tension", "TREATMENT", 68, 84], ["aquaporin in different cells", "TREATMENT", 128, 156], ["Deuterium isotope effects", "PROBLEM", 160, 185], ["the chloride channel ClC", "TREATMENT", 204, 228], ["extracellular pH", "TEST", 427, 443], ["impairment", "OBSERVATION", 3, 13], ["aquaporin activity", "OBSERVATION_MODIFIER", 17, 35], ["membrane tension", "OBSERVATION", 68, 84], ["R.", "ANATOMY", 248, 250], ["extracellular pH", "OBSERVATION", 427, 443]]], ["Using inside-out patch clamp measurements we studied the dependence of the fast gate on pH int and [Cl \u2212 ] int .", [["Cl", "CHEMICAL", 100, 102], ["patch clamp measurements", "TREATMENT", 17, 41]]], ["Only the closing rate, but not the opening rate showed a strong dependence on these intracellular factors.", [["intracellular", "ANATOMY", 84, 97], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["intracellular factors", "PROTEIN", 84, 105], ["the closing rate", "TEST", 5, 21], ["the opening rate", "TEST", 31, 47], ["these intracellular factors", "PROBLEM", 78, 105], ["strong", "OBSERVATION_MODIFIER", 57, 63], ["dependence", "OBSERVATION_MODIFIER", 64, 74], ["intracellular factors", "OBSERVATION", 84, 105]]], ["Using mutagenesis we excluded several candidate residues as mediators of the pH int dependence.", [["mutagenesis", "TREATMENT", 6, 17], ["the pH int dependence", "PROBLEM", 73, 94]]], ["We propose a model in which a proton generated by the dissociation of an intrapore water molecule protonates E166 leading to channel opening.", [["E166", "CHEMICAL", 109, 113], ["E166", "CHEMICAL", 109, 113], ["E166", "SIMPLE_CHEMICAL", 109, 113], ["E166", "PROTEIN", 109, 113], ["a proton", "TREATMENT", 28, 36], ["an intrapore water molecule protonates", "TREATMENT", 70, 108]]], ["Deuterium isotope effects confirm that proton transfer is rate limiting for gate opening and that channel closure depends mostly on [OH \u2212 ].", [["Deuterium", "CHEMICAL", 0, 9], ["[OH \u2212 ]", "CHEMICAL", 132, 139], ["proton", "SIMPLE_CHEMICAL", 39, 45], ["[OH \u2212", "SIMPLE_CHEMICAL", 132, 137], ["Deuterium isotope effects", "PROBLEM", 0, 25], ["proton transfer", "TREATMENT", 39, 54], ["gate opening", "PROBLEM", 76, 88], ["channel closure", "TREATMENT", 98, 113]]], ["The model is in natural agreement with the finding that only the closing rate constant, but not the opening rate constant, depends on pH int and [Cl \u2212 ] int .O-439Deletion of the C-terminus destabilizes phosphorylated Na/K pump state containing 3Na ions N. Vedovato, D. C. Gadsby The Rockefeller University, New York, U.S.A.O-439The Na/K pump's extended C-terminus (compared to the SERCA Ca pump's) links 3 transmembrane helices, and its truncation lowers cytoplasmic Na affinity for forming the occluded E1P(Na 3 ) state.", [["cytoplasmic", "ANATOMY", 456, 467], ["Cl", "CHEMICAL", 146, 148], ["Na", "CHEMICAL", 218, 220], ["K", "CHEMICAL", 221, 222], ["Na", "CHEMICAL", 333, 335], ["K", "CHEMICAL", 336, 337], ["Ca", "CHEMICAL", 388, 390], ["Na", "CHEMICAL", 468, 470], ["Na", "CHEMICAL", 509, 511], ["Cl", "CHEMICAL", 146, 148], ["C", "CHEMICAL", 179, 180], ["Na", "CHEMICAL", 218, 220], ["K", "CHEMICAL", 221, 222], ["Na", "CHEMICAL", 333, 335], ["K", "CHEMICAL", 336, 337], ["C", "CHEMICAL", 354, 355], ["Ca", "CHEMICAL", 388, 390], ["Na", "CHEMICAL", 468, 470], ["Na 3 )", "CHEMICAL", 509, 515], ["Na/K pump", "GENE_OR_GENE_PRODUCT", 218, 227], ["Na/K pump", "GENE_OR_GENE_PRODUCT", 333, 342], ["SERCA Ca pump", "GENE_OR_GENE_PRODUCT", 382, 395], ["cytoplasmic", "ORGANISM_SUBSTANCE", 456, 467], ["C-terminus", "PROTEIN", 179, 189], ["phosphorylated Na/K pump state", "PROTEIN", 203, 233], ["Na/K pump's extended C-terminus", "PROTEIN", 333, 364], ["SERCA", "PROTEIN", 382, 387], ["transmembrane helices", "PROTEIN", 407, 428], ["E1P", "PROTEIN", 505, 508], ["Na 3 ) state", "PROTEIN", 509, 521], ["pH", "TEST", 134, 136], ["Cl", "TEST", 146, 148], ["phosphorylated Na/K pump", "TREATMENT", 203, 227], ["The Na", "TEST", 329, 335], ["the SERCA Ca pump", "TREATMENT", 378, 395], ["3 transmembrane helices", "TREATMENT", 405, 428], ["its truncation lowers cytoplasmic Na affinity", "PROBLEM", 434, 479], ["occluded", "OBSERVATION", 496, 504]]], ["Here we test the effects of C-terminal truncations on interactions with external Na.", [["Na", "CHEMICAL", 81, 83], ["C", "CHEMICAL", 28, 29], ["Na", "CHEMICAL", 81, 83], ["C-terminal truncations", "PROTEIN", 28, 50], ["C-terminal truncations", "PROBLEM", 28, 50]]], ["We deleted the last 2 (YY) or 5 (KESYY) residues in Xenopus \u03b11 \u03b23 pumps made ouabain resistant by mutations Q120R-N131D (RD) or C113Y (C-Y), and then used two-microelectrode voltageclamp recording in Xenopus oocytes to measure pump currents as 10 mM ouabain-sensitive currents while endogenous Na/K pumps were silenced with 1 \u00b5M ouabain.", [["oocytes", "ANATOMY", 208, 215], ["ouabain", "CHEMICAL", 77, 84], ["ouabain", "CHEMICAL", 250, 257], ["Na", "CHEMICAL", 294, 296], ["K", "CHEMICAL", 297, 298], ["ouabain", "CHEMICAL", 329, 336], ["ouabain", "CHEMICAL", 77, 84], ["ouabain", "CHEMICAL", 250, 257], ["Na", "CHEMICAL", 294, 296], ["ouabain", "CHEMICAL", 329, 336], ["Xenopus \u03b11 \u03b23", "GENE_OR_GENE_PRODUCT", 52, 65], ["ouabain", "SIMPLE_CHEMICAL", 77, 84], ["Xenopus", "ORGANISM", 200, 207], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 208, 215], ["ouabain", "SIMPLE_CHEMICAL", 250, 257], ["Na/K pumps", "GENE_OR_GENE_PRODUCT", 294, 304], ["ouabain", "SIMPLE_CHEMICAL", 329, 336], ["Xenopus \u03b11 \u03b23 pumps", "TREATMENT", 52, 71], ["two-microelectrode voltageclamp recording", "TREATMENT", 155, 196], ["Xenopus oocytes", "TREATMENT", 200, 215], ["pump currents", "TEST", 227, 240], ["ouabain", "TEST", 250, 257], ["endogenous Na/K pumps", "TREATMENT", 283, 304]]], ["Inhibition by external Na of steady outward pump current ([K] o =15 mM) at large negative voltages was somewhat weaker in both RD and C-Y pumps than in WT pumps, but was severely impaired in all C-terminal truncated pumps.", [["Na", "CHEMICAL", 23, 25], ["K", "CHEMICAL", 59, 60], ["Na", "CHEMICAL", 23, 25], ["C", "CHEMICAL", 195, 196], ["C-Y pumps", "GENE_OR_GENE_PRODUCT", 134, 143], ["C-terminal truncated pumps", "PROTEIN", 195, 221], ["K] o", "TEST", 59, 63], ["somewhat weaker", "PROBLEM", 103, 118], ["WT pumps", "TREATMENT", 152, 160], ["severely impaired", "PROBLEM", 170, 187], ["terminal truncated pumps", "TREATMENT", 197, 221], ["weaker", "OBSERVATION_MODIFIER", 112, 118], ["severely", "OBSERVATION_MODIFIER", 170, 178], ["impaired", "OBSERVATION", 179, 187], ["terminal", "ANATOMY_MODIFIER", 197, 205], ["truncated pumps", "OBSERVATION", 206, 221]]], ["Consistent with this, the voltage dependence of transient charge movements under Na/Na exchange conditions ([K] o =0 mM) was strongly shifted to more negative potentials in the truncated pumps relative to the parent RD or C-Y pumps, shifts comparable to those seen in WT pumps on decreasing [Na] o several-fold.", [["Na", "CHEMICAL", 81, 83], ["Na", "CHEMICAL", 84, 86], ["K", "CHEMICAL", 109, 110], ["Na", "CHEMICAL", 292, 294], ["Na", "CHEMICAL", 81, 83], ["Na", "CHEMICAL", 84, 86], ["Na", "CHEMICAL", 292, 294], ["C-Y", "GENE_OR_GENE_PRODUCT", 222, 225], ["the voltage dependence", "PROBLEM", 22, 44], ["transient charge movements", "PROBLEM", 48, 74], ["Na/Na exchange conditions", "TEST", 81, 106], ["K] o", "TEST", 109, 113], ["C-Y pumps", "TREATMENT", 222, 231], ["WT pumps", "TREATMENT", 268, 276]]], ["Together, the results suggest that these C-terminal deletions lower the apparent affinity for external Na ions to bind and become occluded in the Na/K pump.", [["Na", "CHEMICAL", 103, 105], ["Na", "CHEMICAL", 146, 148], ["K", "CHEMICAL", 149, 150], ["C", "CHEMICAL", 41, 42], ["Na", "CHEMICAL", 103, 105], ["Na", "CHEMICAL", 146, 148], ["K", "CHEMICAL", 149, 150], ["Na ions", "SIMPLE_CHEMICAL", 103, 110], ["Na/K pump", "GENE_OR_GENE_PRODUCT", 146, 155], ["C-terminal deletions", "DNA", 41, 61], ["these C-terminal deletions", "PROBLEM", 35, 61], ["external Na ions", "TREATMENT", 94, 110], ["the Na/K pump", "TREATMENT", 142, 155], ["occluded", "OBSERVATION", 130, 138]]], ["The C-terminus therefore provides contacts important for stabilizing the occluded E1P(Na 3 ) conformation, regardless of the route of Na ion entry into the binding pocket.", [["Na", "CHEMICAL", 86, 88], ["Na", "CHEMICAL", 134, 136], ["C", "CHEMICAL", 4, 5], ["Na 3 )", "CHEMICAL", 86, 92], ["Na", "CHEMICAL", 134, 136], ["Na ion", "SIMPLE_CHEMICAL", 134, 140], ["C-terminus", "PROTEIN", 4, 14], ["E1P", "PROTEIN", 82, 85], ["Na 3", "PROTEIN", 86, 90], ["Na ion entry", "TREATMENT", 134, 146], ["occluded", "OBSERVATION", 73, 81], ["binding pocket", "OBSERVATION", 156, 170]]], ["Muscle contraction is driven by molecular motors that adapt their energy utilization according to the demands made on them.", [["Muscle", "ANATOMY", 0, 6], ["Muscle", "ORGAN", 0, 6], ["Muscle contraction", "PROBLEM", 0, 18], ["contraction", "OBSERVATION", 7, 18]]], ["We test the hypothesis that rate constants controlling the biochemical steps involved in ATP hydrolysis by myosin ATPase are affected by the force of the muscle.", [["muscle", "ANATOMY", 154, 160], ["ATP", "CHEMICAL", 89, 92], ["ATP", "CHEMICAL", 89, 92], ["ATP", "SIMPLE_CHEMICAL", 89, 92], ["myosin ATPase", "GENE_OR_GENE_PRODUCT", 107, 120], ["muscle", "ORGAN", 154, 160], ["myosin ATPase", "PROTEIN", 107, 120], ["rate constants", "PROBLEM", 28, 42], ["ATP hydrolysis", "TREATMENT", 89, 103], ["ATP hydrolysis", "OBSERVATION", 89, 103], ["muscle", "ANATOMY", 154, 160]]], ["Here we use Fluorescence Lifetime Imaging Microscopy (FLIM) of a fluorescently labelled ATP analogue to investigate changes in the environment of the myosin ATPase, caused by different loads applied to skeletal muscle.", [["skeletal muscle", "ANATOMY", 202, 217], ["ATP", "CHEMICAL", 88, 91], ["ATP", "CHEMICAL", 88, 91], ["ATP", "SIMPLE_CHEMICAL", 88, 91], ["myosin ATPase", "GENE_OR_GENE_PRODUCT", 150, 163], ["skeletal muscle", "TISSUE", 202, 217], ["myosin ATPase", "PROTEIN", 150, 163], ["Imaging Microscopy", "TEST", 34, 52], ["a fluorescently labelled ATP analogue", "TEST", 63, 100], ["the myosin ATPase", "TREATMENT", 146, 163], ["skeletal muscle", "ANATOMY", 202, 217]]], ["Single muscle fibres were subjected to cycles of stretches and releases in the presence of rigor solution and 10 \u00b5M of coumarin-labelled ATP.", [["muscle fibres", "ANATOMY", 7, 20], ["coumarin", "CHEMICAL", 119, 127], ["ATP", "CHEMICAL", 137, 140], ["coumarin", "CHEMICAL", 119, 127], ["ATP", "CHEMICAL", 137, 140], ["muscle fibres", "TISSUE", 7, 20], ["coumarin", "SIMPLE_CHEMICAL", 119, 127], ["ATP", "SIMPLE_CHEMICAL", 137, 140], ["Single muscle fibres", "PROBLEM", 0, 20], ["rigor solution", "TREATMENT", 91, 105], ["coumarin", "TREATMENT", 119, 127], ["labelled ATP", "TREATMENT", 128, 140], ["muscle", "ANATOMY", 7, 13], ["fibres", "OBSERVATION", 14, 20]]], ["FLIM acquisition was synchronised with stretch/release cycles and force measurements, which allow us to investigate the effect of strain on the lifetime of the labelled ATP bound to the actomyosin complex.", [["actomyosin", "ANATOMY", 186, 196], ["ATP", "CHEMICAL", 169, 172], ["ATP", "CHEMICAL", 169, 172], ["ATP", "SIMPLE_CHEMICAL", 169, 172], ["actomyosin", "CELLULAR_COMPONENT", 186, 196], ["actomyosin complex", "PROTEIN", 186, 204], ["FLIM acquisition", "TEST", 0, 16], ["stretch/release cycles", "TREATMENT", 39, 61], ["force measurements", "TEST", 66, 84], ["strain", "PROBLEM", 130, 136]]], ["Characterization of the fluorescence decay by a bi-exponential function resolved the time constant of two populations, namely, free fluorophore (\u03c4 1 = 0.47 \u00b1 0.03 ns; mean \u00b1 S.D.) and fluorescent nucleotide bound to the actomyosin complex (\u03c4 2 = 2.21 \u00b1 0.06 ns at low strain).", [["nucleotide", "CHEMICAL", 196, 206], ["nucleotide", "CHEMICAL", 196, 206], ["actomyosin complex", "PROTEIN", 220, 238], ["a bi-exponential function", "TEST", 46, 71], ["fluorescent nucleotide bound", "PROBLEM", 184, 212]]], ["These experiments showed that while the time constant of the free fluorophore did not change with force, the time constant of the fluorescent nucleotide bound to actomyosin showed a linear dependence with the force applied to the muscle of 0.43 \u00b1 0.05 ps/kPa.P-443Neck linker docking coordinates the kinetics of kinesin\u00b4s heads I. Derenyi, A. Czovek, G. J. Szollosi Department of Biological Physics, Eotvos University, Pazmany P. stny.", [["muscle", "ANATOMY", 230, 236], ["nucleotide", "CHEMICAL", 142, 152], ["P-443Neck", "CHEMICAL", 259, 268], ["nucleotide", "CHEMICAL", 142, 152], ["actomyosin", "CELLULAR_COMPONENT", 162, 172], ["muscle", "ORGAN", 230, 236], ["P", "DNA", 259, 260], ["These experiments", "TEST", 0, 17], ["the free fluorophore", "PROBLEM", 57, 77], ["the fluorescent nucleotide bound", "PROBLEM", 126, 158], ["a linear dependence", "PROBLEM", 180, 199], ["linear dependence", "OBSERVATION", 182, 199], ["muscle", "ANATOMY", 230, 236]]], ["1A, H-1117 Budapest, Hungary Conventional kinesin is a two-headed motor protein, which is able to walk along microtubules processively by hydrolyzing ATP.", [["microtubules", "ANATOMY", 109, 121], ["H-1117", "CHEMICAL", 4, 10], ["ATP", "CHEMICAL", 150, 153], ["ATP", "CHEMICAL", 150, 153], ["kinesin", "GENE_OR_GENE_PRODUCT", 42, 49], ["microtubules", "CELLULAR_COMPONENT", 109, 121], ["ATP", "SIMPLE_CHEMICAL", 150, 153], ["kinesin", "PROTEIN", 42, 49], ["two-headed motor protein", "PROTEIN", 55, 79], ["hydrolyzing ATP", "TREATMENT", 138, 153]]], ["Its neck linkers, which connect the two motor domains and can undergo a docking/undocking transition, are widely believed to play the key role in the coordination of the chemical cycles of the two motor domains and, consequently, in force production and directional stepping.", [["neck", "ANATOMY", 4, 8], ["neck", "ORGAN", 4, 8], ["motor domains", "PROTEIN", 40, 53], ["Its neck linkers", "PROBLEM", 0, 16], ["neck", "ANATOMY", 4, 8], ["linkers", "OBSERVATION", 9, 16]]], ["Although many experiments, often complemented with partial kinetic modeling of specific pathways, support this idea, the ultimate test of the viability of this hypothesis requires the construction of a complete kinetic model.", [["a complete kinetic model", "TREATMENT", 200, 224]]], ["Considering the two neck linkers as entropic springs that are allowed to dock to their head domains and incorporating only the few most relevant kinetic and structural properties of the individual heads, we have developed the first detailed, thermodynamically consistent model of kinesin that can (i) explain the cooperation of the heads during walking and (ii) reproduce much of the available experimental data (speed, dwell time distribution, randomness, processivity, hydrolysis rate, etc.) under a wide range of conditions (nucleotide concentrations, loading force, neck linker length and composition, etc.).", [["neck", "ANATOMY", 20, 24], ["head", "ANATOMY", 87, 91], ["neck", "ANATOMY", 570, 574], ["nucleotide", "CHEMICAL", 528, 538], ["nucleotide", "CHEMICAL", 528, 538], ["head", "ORGANISM_SUBDIVISION", 87, 91], ["kinesin", "GENE_OR_GENE_PRODUCT", 280, 287], ["nucleotide", "SIMPLE_CHEMICAL", 528, 538], ["kinesin", "PROTEIN", 280, 287], ["the two neck linkers", "TREATMENT", 12, 32], ["entropic springs", "TREATMENT", 36, 52], ["hydrolysis rate", "TEST", 471, 486], ["a wide range of conditions", "TREATMENT", 500, 526], ["nucleotide concentrations, loading force", "TREATMENT", 528, 568], ["neck linker length and composition", "TREATMENT", 570, 604], ["neck", "ANATOMY", 570, 574]]], ["Besides revealing the mechanism by which kinesin operates, our model also makes it possible to look into the experimentally inaccessible details of the mechanochemical cycle and predict how certain changes in the protein affect its motion.O-442The positive role of noise on the transport efficiency of Na, K ATPase C.-H. Chang 1 , T. Y. Tsong 2 1 Institute of Physics, National Chiao Tung university & Physics Division, National Center for Theoretical Sciences, Hsinchu, Taiwan, 2 Institute of Physics, Academy of Sciences, Taipei 115, Taiwan Na, K ATPase is a molecular motor which is able to transport ions through cell membranes, even against the transmembrane ion concentration gradient.", [["cell membranes", "ANATOMY", 617, 631], ["transmembrane", "ANATOMY", 650, 663], ["O-442", "CHEMICAL", 239, 244], ["Na", "CHEMICAL", 302, 304], ["K", "CHEMICAL", 306, 307], ["Na", "CHEMICAL", 543, 545], ["K", "CHEMICAL", 547, 548], ["O-442", "CHEMICAL", 239, 244], ["Na", "CHEMICAL", 302, 304], ["Na", "CHEMICAL", 543, 545], ["kinesin", "GENE_OR_GENE_PRODUCT", 41, 48], ["Na, K ATPase", "GENE_OR_GENE_PRODUCT", 543, 555], ["cell membranes", "CELLULAR_COMPONENT", 617, 631], ["transmembrane", "CELLULAR_COMPONENT", 650, 663], ["kinesin", "PROTEIN", 41, 48], ["Taiwan Na, K ATPase", "PROTEIN", 536, 555], ["Na", "TEST", 302, 304], ["mechanochemical cycle", "OBSERVATION", 152, 173]]], ["While in vivo this nanoscale soft machine consumes ATP, it may be driven by external fluctuating electric fields, no matter they are periodic or random.", [["ATP", "CHEMICAL", 51, 54], ["ATP", "CHEMICAL", 51, 54], ["ATP", "SIMPLE_CHEMICAL", 51, 54], ["ATP", "TREATMENT", 51, 54]]], ["Given an oscillating electric field with a slight fluctuation, the Boltzmann distributions of these conformations will change with time.", [["an oscillating electric field", "TREATMENT", 6, 35], ["a slight fluctuation", "PROBLEM", 41, 61], ["slight", "OBSERVATION_MODIFIER", 43, 49], ["fluctuation", "OBSERVATION", 50, 61]]], ["The instantaneous transported ion flux is a functional of the quasi-cyclic trajectory V(t) of this non-autonomous dynamical system.", [["instantaneous", "OBSERVATION_MODIFIER", 4, 17], ["ion flux", "OBSERVATION", 30, 38], ["non-autonomous", "OBSERVATION", 99, 113], ["dynamical system", "OBSERVATION", 114, 130]]], ["Various interesting dynamical properties of this ion pump, including stochastic resonance, can be studied theoretically, some of which have good agreement with recent experimental findings.P-441In situ measurements of the molecular motor of muscle with nanometer-microsecond resolution In a contracting muscle, arrays of the dimeric motor protein myosin II pull the actin filament towards the centre of the sarcomere during cyclical ATP driven interactions.", [["muscle", "ANATOMY", 241, 247], ["muscle", "ANATOMY", 303, 309], ["sarcomere", "ANATOMY", 407, 416], ["ATP", "CHEMICAL", 433, 436], ["ATP", "CHEMICAL", 433, 436], ["muscle", "ORGAN", 241, 247], ["muscle", "ORGAN", 303, 309], ["myosin II", "GENE_OR_GENE_PRODUCT", 347, 356], ["actin", "GENE_OR_GENE_PRODUCT", 366, 371], ["sarcomere", "CELLULAR_COMPONENT", 407, 416], ["ATP", "SIMPLE_CHEMICAL", 433, 436], ["P", "DNA", 189, 190], ["dimeric motor protein", "PROTEIN", 325, 346], ["myosin II", "PROTEIN", 347, 356], ["actin", "PROTEIN", 366, 371], ["this ion pump", "TREATMENT", 44, 57], ["stochastic resonance", "TEST", 69, 89], ["cyclical ATP", "TREATMENT", 424, 436], ["dynamical properties", "OBSERVATION", 20, 40], ["muscle", "ANATOMY", 241, 247], ["contracting muscle", "ANATOMY", 291, 309], ["ATP driven", "OBSERVATION", 433, 443]]], ["When the external load is smaller than the array force, the sarcomere works as a motor, converting metabolic energy into mechanical work; when the external load is larger than the array force, the sarcomere acts as a brake resisting the load with reduced metabolic cost.", [["sarcomere", "ANATOMY", 60, 69], ["sarcomere", "ANATOMY", 197, 206], ["sarcomere", "CELLULAR_COMPONENT", 60, 69], ["sarcomere", "CELLULAR_COMPONENT", 197, 206], ["the external load", "TEST", 143, 160], ["reduced metabolic cost", "PROBLEM", 247, 269], ["smaller", "OBSERVATION_MODIFIER", 26, 33], ["larger", "OBSERVATION", 164, 170], ["metabolic cost", "OBSERVATION", 255, 269]]], ["To investigate the molecular basis of the work production and the braking action of muscle, we use sarcomere-level mechanics and X-ray interferometry in intact single cells from frog skeletal muscle.", [["muscle", "ANATOMY", 84, 90], ["sarcomere", "ANATOMY", 99, 108], ["cells", "ANATOMY", 167, 172], ["skeletal muscle", "ANATOMY", 183, 198], ["muscle", "ORGAN", 84, 90], ["cells", "CELL", 167, 172], ["frog", "ORGANISM", 178, 182], ["skeletal muscle", "TISSUE", 183, 198], ["intact single cells", "CELL_TYPE", 153, 172], ["sarcomere-level mechanics", "TREATMENT", 99, 124], ["X-ray interferometry", "TEST", 129, 149], ["muscle", "ANATOMY", 84, 90], ["skeletal muscle", "ANATOMY", 183, 198]]], ["During isometric contraction, each motor bears a force of about 6 pN.", [["isometric contraction", "OBSERVATION", 7, 28]]], ["During shortening against high and moderate loads, the number of myosin motors attached to actin reduces in proportion to the external load while the force per attached motor is maintained similar to the isometric value (Piazzesi et al., Cell 131, 784-95, 2007) .", [["myosin", "GENE_OR_GENE_PRODUCT", 65, 71], ["actin", "GENE_OR_GENE_PRODUCT", 91, 96], ["myosin motors", "PROTEIN", 65, 78], ["actin", "PROTEIN", 91, 96], ["high and moderate loads", "PROBLEM", 26, 49], ["myosin motors", "TREATMENT", 65, 78], ["the isometric value", "TEST", 200, 219], ["moderate", "OBSERVATION_MODIFIER", 35, 43], ["loads", "OBSERVATION", 44, 49], ["myosin motors", "OBSERVATION", 65, 78]]], ["Rapid stretches of 1-5 nm between each overlapping set of myosin and actin filaments in a muscle sarcomere cause the stiffness of the array of myosin motors to increase up to twice the isometric value within 2 ms (Brunello et al., PNAS USA 104, 20114-19, 2007) , indicating that the high resistance of active muscle to stretch is due to recruitment of the second motor domain of the myosin molecules with the first domain already attached to actin.", [["filaments", "ANATOMY", 75, 84], ["muscle sarcomere", "ANATOMY", 90, 106], ["muscle", "ANATOMY", 309, 315], ["myosin", "GENE_OR_GENE_PRODUCT", 58, 64], ["actin", "GENE_OR_GENE_PRODUCT", 69, 74], ["muscle", "ORGAN", 90, 96], ["myosin", "GENE_OR_GENE_PRODUCT", 143, 149], ["muscle", "ORGAN", 309, 315], ["myosin", "GENE_OR_GENE_PRODUCT", 383, 389], ["actin", "GENE_OR_GENE_PRODUCT", 442, 447], ["myosin", "PROTEIN", 58, 64], ["actin", "PROTEIN", 69, 74], ["myosin motors", "PROTEIN", 143, 156], ["second motor domain", "PROTEIN", 356, 375], ["myosin molecules", "PROTEIN", 383, 399], ["actin", "PROTEIN", 442, 447], ["myosin and actin filaments", "TREATMENT", 58, 84], ["myosin motors", "PROBLEM", 143, 156], ["the isometric value", "TEST", 181, 200], ["PNAS USA", "TEST", 231, 239], ["the high resistance of active muscle to stretch", "PROBLEM", 279, 326], ["actin filaments", "OBSERVATION", 69, 84], ["muscle", "ANATOMY", 90, 96], ["stiffness", "OBSERVATION", 117, 126], ["high resistance", "OBSERVATION", 283, 298], ["muscle", "ANATOMY", 309, 315]]], ["Supported by MiUR and Ente CRF (Italy), NIH (USA), MRC (UK), EMBL, ESRF.", [["CRF", "DISEASE", 27, 30], ["ESRF", "DISEASE", 67, 71], ["ESRF", "PROBLEM", 67, 71], ["ESRF", "OBSERVATION", 67, 71]]], ["Kinesin-1 is a molecular motor that moves cellular cargo along microtubules.", [["cellular cargo", "ANATOMY", 42, 56], ["microtubules", "ANATOMY", 63, 75], ["Kinesin-1", "GENE_OR_GENE_PRODUCT", 0, 9], ["cellular cargo", "CELLULAR_COMPONENT", 42, 56], ["microtubules", "CELLULAR_COMPONENT", 63, 75], ["Kinesin-1", "PROTEIN", 0, 9]]], ["However, the way that many kinesin-1 motor proteins bound to the same cargo move together is not.", [["kinesin-1", "GENE_OR_GENE_PRODUCT", 27, 36], ["kinesin-1 motor proteins", "PROTEIN", 27, 51]]], ["We addressed the structural basis for this phenomenon using video microscopy of single microtubulebound full-length motors and various spectroscopy methods were employed to study synthetic peptides derived from Hinge-1 region.", [["microtubulebound full-length motors", "PROTEIN", 87, 122], ["Hinge-1 region", "DNA", 211, 225], ["this phenomenon", "PROBLEM", 38, 53], ["video microscopy", "TEST", 60, 76], ["various spectroscopy methods", "TEST", 127, 155], ["study synthetic peptides", "TEST", 173, 197]]], ["These Peptides show an unexpected profile of secondary structure forming propensities.", [["These Peptides", "TEST", 0, 14], ["secondary structure forming propensities", "PROBLEM", 45, 85], ["secondary structure", "OBSERVATION", 45, 64], ["propensities", "OBSERVATION_MODIFIER", 73, 85]]], ["Video microscopy of single microtubule-bound full-length motors reveal the sporadic occurrence of high compliance states alternating with longer-lived, low compliance states.", [["microtubule", "ANATOMY", 27, 38], ["microtubule", "CELLULAR_COMPONENT", 27, 38], ["microtubule", "PROTEIN", 27, 38], ["Video microscopy", "TEST", 0, 16], ["high compliance", "OBSERVATION", 98, 113]]], ["The deletion of Hinge-1abolishes transitions to the high compliance state.", [["Hinge", "DNA", 16, 21], ["Hinge-1abolishes", "PROBLEM", 16, 32], ["high compliance", "OBSERVATION_MODIFIER", 52, 67]]], ["From the results we hypothesize that strain accumulated during multiple kinesin motility populates the high compliance state by unfolding helical secondary structure in the central Hinge 1 domain flanked by unordered regions, thereby preventing the motors from interfering with each other in multiple motor situations.", [["kinesin", "GENE_OR_GENE_PRODUCT", 72, 79], ["kinesin", "PROTEIN", 72, 79], ["central Hinge 1 domain", "PROTEIN", 173, 195], ["unordered regions", "PROTEIN", 207, 224], ["strain", "PROBLEM", 37, 43], ["multiple kinesin motility", "TREATMENT", 63, 88], ["unfolding helical secondary structure", "PROBLEM", 128, 165], ["high compliance", "OBSERVATION", 103, 118], ["secondary structure", "OBSERVATION", 146, 165], ["central", "ANATOMY_MODIFIER", 173, 180], ["Hinge", "ANATOMY_MODIFIER", 181, 186]]], ["Titin is a giant protein of vertebrate skeletal and cardiac muscles.", [["skeletal", "ANATOMY", 39, 47], ["cardiac muscles", "ANATOMY", 52, 67], ["Titin", "CHEMICAL", 0, 5], ["Titin", "GENE_OR_GENE_PRODUCT", 0, 5], ["skeletal", "TISSUE", 39, 47], ["cardiac muscles", "TISSUE", 52, 67], ["Titin", "PROTEIN", 0, 5], ["giant", "OBSERVATION_MODIFIER", 11, 16], ["protein", "OBSERVATION", 17, 24], ["vertebrate", "ANATOMY_MODIFIER", 28, 38], ["skeletal", "ANATOMY", 39, 47], ["cardiac muscles", "ANATOMY", 52, 67]]], ["Cardiac titin is expressed in two main isoforms: short N2B (\u223c3000 kDa) and long N2BA (\u223c3400 kDa).", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac titin", "GENE_OR_GENE_PRODUCT", 0, 13], ["titin", "PROTEIN", 8, 13], ["N2B", "PROTEIN", 55, 58], ["\u223c3000 kDa", "PROTEIN", 60, 69], ["N2BA", "PROTEIN", 80, 84], ["short N2B", "PROBLEM", 49, 58], ["titin", "OBSERVATION", 8, 13], ["short N2B", "OBSERVATION_MODIFIER", 49, 58]]], ["We have studied changes of titin isoform composition in myocardium of hibernating ground squirrels and spontaneously hypertensive rats (SHR).", [["myocardium", "ANATOMY", 56, 66], ["hypertensive", "DISEASE", 117, 129], ["titin", "GENE_OR_GENE_PRODUCT", 27, 32], ["myocardium", "ORGAN", 56, 66], ["rats", "ORGANISM", 130, 134], ["titin isoform", "PROTEIN", 27, 40], ["rats", "SPECIES", 130, 134], ["hibernating ground squirrels", "SPECIES", 70, 98], ["titin isoform composition", "TREATMENT", 27, 52], ["spontaneously hypertensive rats", "PROBLEM", 103, 134], ["titin isoform", "OBSERVATION", 27, 40], ["myocardium", "ANATOMY", 56, 66], ["hibernating ground squirrels", "OBSERVATION", 70, 98]]], ["Using electrophoresis we have revealed considerable decrease (by 2-3 times) in the content of titin relative to myosin heavy chains in SHR heart as compared with that for normotensive rats.", [["heart", "ANATOMY", 139, 144], ["titin", "GENE_OR_GENE_PRODUCT", 94, 99], ["myosin heavy chains", "GENE_OR_GENE_PRODUCT", 112, 131], ["SHR", "ORGANISM", 135, 138], ["heart", "ORGAN", 139, 144], ["rats", "ORGANISM", 184, 188], ["titin", "PROTEIN", 94, 99], ["myosin heavy chains", "PROTEIN", 112, 131], ["rats", "SPECIES", 184, 188], ["electrophoresis", "TEST", 6, 21], ["myosin heavy chains in SHR heart", "TREATMENT", 112, 144], ["considerable", "OBSERVATION_MODIFIER", 39, 51], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["heart", "ANATOMY", 139, 144]]], ["Surprisingly that the data of qRT-PCR showed the increase in mRNA content of N2BA and N2B-isoforms in hypertrophic heart more than 2 times in comparison with norm.", [["heart", "ANATOMY", 115, 120], ["N2BA", "GENE_OR_GENE_PRODUCT", 77, 81], ["N2B-isoforms", "GENE_OR_GENE_PRODUCT", 86, 98], ["heart", "ORGAN", 115, 120], ["N2BA", "PROTEIN", 77, 81], ["N2B", "PROTEIN", 86, 89], ["qRT-PCR", "TEST", 30, 37], ["mRNA content", "TEST", 61, 73], ["N2BA", "TEST", 77, 81], ["N2B", "TEST", 86, 89], ["hypertrophic heart", "PROBLEM", 102, 120], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["mRNA content", "OBSERVATION", 61, 73], ["hypertrophic", "OBSERVATION_MODIFIER", 102, 114], ["heart", "ANATOMY", 115, 120]]], ["We suppose that such a result is an effect of depressed translation of mRNAtitin in pathology.", [["depressed", "DISEASE", 46, 55], ["mRNAtitin", "CHEMICAL", 71, 80], ["mRNAtitin", "GENE_OR_GENE_PRODUCT", 71, 80], ["mRNAtitin", "PROTEIN", 71, 80], ["depressed translation of mRNAtitin in pathology", "PROBLEM", 46, 93]]], ["We have observed the decrease (by 1,5 times) of total titin amount in heart of hibernating animals in comparison with that for summer active animals.", [["heart", "ANATOMY", 70, 75], ["titin", "GENE_OR_GENE_PRODUCT", 54, 59], ["heart", "ORGAN", 70, 75], ["titin", "PROTEIN", 54, 59], ["total titin amount", "TREATMENT", 48, 66], ["decrease", "OBSERVATION_MODIFIER", 21, 29], ["heart", "ANATOMY", 70, 75]]], ["However N2BA/N2B ratio in the heart upon hibernation was increased by 2 times.", [["heart", "ANATOMY", 30, 35], ["N2BA", "CHEMICAL", 8, 12], ["N2BA", "GENE_OR_GENE_PRODUCT", 8, 12], ["N2B", "GENE_OR_GENE_PRODUCT", 13, 16], ["heart", "ORGAN", 30, 35], ["N2BA", "PROTEIN", 8, 12], ["N2B", "PROTEIN", 13, 16], ["N2BA/N2B ratio", "TEST", 8, 22], ["N2B", "OBSERVATION", 13, 16], ["heart", "ANATOMY", 30, 35], ["hibernation", "OBSERVATION", 41, 52], ["increased", "OBSERVATION_MODIFIER", 57, 66]]], ["Similar trend was not revealed for the mRNA level of corresponding isoforms, although we have showed the decrease of mRNA of both titin isoforms in heart of hibernating ground squirrels as compared to their content of summer animals.", [["heart", "ANATOMY", 148, 153], ["titin", "GENE_OR_GENE_PRODUCT", 130, 135], ["heart", "ORGAN", 148, 153], ["mRNA", "RNA", 117, 121], ["titin isoforms", "PROTEIN", 130, 144], ["the mRNA level", "TEST", 35, 49], ["decrease", "OBSERVATION_MODIFIER", 105, 113], ["titin isoforms", "OBSERVATION", 130, 144], ["heart", "ANATOMY", 148, 153], ["hibernating", "OBSERVATION", 157, 168], ["ground squirrels", "OBSERVATION", 169, 185]]], ["The decrease in total mRNA level may be explained by repressed transcription or mRNA degradation in the cell during hibernation.", [["cell", "ANATOMY", 104, 108], ["cell", "CELL", 104, 108], ["The decrease in total mRNA level", "PROBLEM", 0, 32], ["mRNA degradation", "PROBLEM", 80, 96], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["total mRNA", "OBSERVATION", 16, 26], ["cell", "OBSERVATION", 104, 108]]], ["These discrepancies in protein and mRNA levels may be considered as the posttranscriptional regulation of titin isoforms expression.", [["titin", "GENE_OR_GENE_PRODUCT", 106, 111], ["titin isoforms", "PROTEIN", 106, 120], ["These discrepancies in protein and mRNA levels", "PROBLEM", 0, 46], ["titin isoforms expression", "PROBLEM", 106, 131], ["titin isoforms", "OBSERVATION", 106, 120]]], ["Actomyosin cross-bridges formed when the globular heads of myosins bind to actin filaments are the molecular engines that drive muscle contraction, fuelled by ATP hydrolysis.", [["filaments", "ANATOMY", 81, 90], ["muscle", "ANATOMY", 128, 134], ["muscle contraction", "DISEASE", 128, 146], ["ATP", "CHEMICAL", 159, 162], ["ATP", "CHEMICAL", 159, 162], ["myosins", "GENE_OR_GENE_PRODUCT", 59, 66], ["actin", "GENE_OR_GENE_PRODUCT", 75, 80], ["muscle", "ORGAN", 128, 134], ["ATP", "SIMPLE_CHEMICAL", 159, 162], ["Actomyosin cross-bridges", "PROTEIN", 0, 24], ["globular heads", "PROTEIN", 41, 55], ["myosins", "PROTEIN", 59, 66], ["actin", "PROTEIN", 75, 80], ["Actomyosin cross-bridges", "TREATMENT", 0, 24], ["ATP hydrolysis", "TREATMENT", 159, 173], ["ATP hydrolysis", "OBSERVATION", 159, 173]]], ["Critical to this process is the change in shape of the cross-bridge and the change in the interactions with actin, in response to force applied to the muscle, and to the status of the nucleotide in the binding pocket.", [["muscle", "ANATOMY", 151, 157], ["nucleotide", "CHEMICAL", 184, 194], ["nucleotide", "CHEMICAL", 184, 194], ["actin", "GENE_OR_GENE_PRODUCT", 108, 113], ["muscle", "ORGAN", 151, 157], ["actin", "PROTEIN", 108, 113], ["the cross-bridge", "TREATMENT", 51, 67], ["actin", "TREATMENT", 108, 113], ["change", "OBSERVATION_MODIFIER", 32, 38], ["shape", "OBSERVATION_MODIFIER", 42, 47], ["change", "OBSERVATION_MODIFIER", 76, 82], ["muscle", "ANATOMY", 151, 157], ["binding pocket", "OBSERVATION", 202, 216]]], ["Although molecular detail is known from X-ray crystallography and biochemistry, understanding of the interplay between cross-bridge shape and chemical state requires studies in muscle fibres generating force.", [["muscle fibres", "ANATOMY", 177, 190], ["muscle fibres", "TISSUE", 177, 190], ["X-ray crystallography", "TEST", 40, 61], ["muscle", "ANATOMY", 177, 183]]], ["We use Fluorescence Life Time Imaging Microscopy (FLIM) as a probe of the cross-bridge environment.With a fluorescent analogue of ATP 1 , fluorescence life-time (FLT) changes when the crossbridge binds to actin.", [["ATP", "CHEMICAL", 130, 133], ["ATP", "CHEMICAL", 130, 133], ["ATP 1", "GENE_OR_GENE_PRODUCT", 130, 135], ["actin", "GENE_OR_GENE_PRODUCT", 205, 210], ["actin", "PROTEIN", 205, 210], ["Imaging Microscopy", "TEST", 30, 48], ["the cross-bridge environment", "TREATMENT", 70, 98], ["a fluorescent analogue of ATP", "PROBLEM", 104, 133]]], ["Now, we show preliminary experiments on the effect of force on FLT.", [["FLT", "CHEMICAL", 63, 66], ["FLT", "SIMPLE_CHEMICAL", 63, 66], ["force on FLT", "TREATMENT", 54, 66]]], ["The Essential Light Chain of myosin (ELC) is a \u223c20 kDa peptide that wraps around a 9nmlong \u03b1-helix of the myosin cross-bridge known as the lever arm which tilts during force generation.", [["myosin", "GENE_OR_GENE_PRODUCT", 29, 35], ["ELC", "GENE_OR_GENE_PRODUCT", 37, 40], ["myosin", "GENE_OR_GENE_PRODUCT", 106, 112], ["myosin", "PROTEIN", 29, 35], ["ELC", "PROTEIN", 37, 40], ["9nmlong \u03b1-helix", "PROTEIN", 83, 98], ["myosin cross-bridge", "PROTEIN", 106, 125], ["a \u223c20 kDa peptide", "TREATMENT", 45, 62], ["the myosin cross-bridge", "TREATMENT", 102, 125], ["Essential", "OBSERVATION_MODIFIER", 4, 13], ["Light Chain", "OBSERVATION_MODIFIER", 14, 25]]], ["Using a recombinant ELC, labelled with a fluorophore at a strategic Cys, we replace the native ELC and introduce the fluorescent ELC in muscle fibres.", [["muscle fibres", "ANATOMY", 136, 149], ["Cys", "CHEMICAL", 68, 71], ["ELC", "GENE_OR_GENE_PRODUCT", 20, 23], ["ELC", "GENE_OR_GENE_PRODUCT", 95, 98], ["ELC", "GENE_OR_GENE_PRODUCT", 129, 132], ["muscle fibres", "TISSUE", 136, 149], ["recombinant ELC", "PROTEIN", 8, 23], ["ELC", "PROTEIN", 95, 98], ["fluorescent ELC", "PROTEIN", 117, 132], ["a recombinant ELC", "TREATMENT", 6, 23], ["a fluorophore", "TREATMENT", 39, 52], ["a strategic Cys", "TREATMENT", 56, 71], ["the native ELC", "TREATMENT", 84, 98], ["the fluorescent ELC in muscle fibres", "TREATMENT", 113, 149], ["muscle fibres", "ANATOMY", 136, 149]]], ["Preliminary experiments demonstrate that the ELC fluorophore also is sensitive to force applied to the muscle fibre.", [["muscle fibre", "ANATOMY", 103, 115], ["muscle fibre", "TISSUE", 103, 115], ["ELC", "PROTEIN", 45, 48], ["Preliminary experiments", "TEST", 0, 23], ["the ELC fluorophore", "PROBLEM", 41, 60], ["muscle", "ANATOMY", 103, 109], ["fibre", "ANATOMY_MODIFIER", 110, 115]]], ["In addition, F\u00f6rster Resonance Energy transfer occurs between the nucleotide and ELC fluorophores, opening the way for studying structural changes in cross-bridges during force generation by FRET.O-445Muscle contraction: Pitfalls in the determination of the contractile response E. Grazi Dipartimento di Biochimica e Biologia Molecolare, Universit\u00e0 di Ferrara, Ferrara, ItalyO-445The contractile response of an active muscle depends on the load.", [["muscle", "ANATOMY", 418, 424], ["nucleotide", "CHEMICAL", 66, 76], ["O-445Muscle", "CHEMICAL", 196, 207], ["ItalyO-445", "CHEMICAL", 370, 380], ["nucleotide", "CHEMICAL", 66, 76], ["O-445Muscle", "CHEMICAL", 196, 207], ["muscle", "ORGAN", 418, 424], ["the nucleotide and ELC fluorophores", "TREATMENT", 62, 97], ["the contractile response", "TEST", 254, 278], ["active muscle", "OBSERVATION", 411, 424]]], ["The load is a force /cross-section.", [["a force /cross-section", "TREATMENT", 12, 34]]], ["There are three fundamental dimensions: the mass, m; the space, l; and the time, t.", [["the mass", "PROBLEM", 40, 48], ["three", "OBSERVATION_MODIFIER", 10, 15], ["fundamental", "OBSERVATION_MODIFIER", 16, 27], ["dimensions", "OBSERVATION_MODIFIER", 28, 38], ["mass", "OBSERVATION", 44, 48], ["l", "ANATOMY_MODIFIER", 64, 65]]], ["From these three dimensions are built up all the physical dimensions.", [["three", "OBSERVATION_MODIFIER", 11, 16], ["dimensions", "OBSERVATION_MODIFIER", 17, 27], ["physical dimensions", "OBSERVATION_MODIFIER", 49, 68]]], ["Once the direction and versus are settled the modulus fully defines the physical effect of the acceleration.", [["the acceleration", "PROBLEM", 91, 107]]], ["At variance with the acceleration, once the direction and versus are settled, the modulus does not define the physical and the biological effects of the force: the same force is generated by an infinite number of mass-acceleration couples that display different physical and biological effects.", [["mass", "OBSERVATION", 213, 217]]], ["Thus defining the load that opposes the contractile force does not define the contractile system.", [["contractile system", "ANATOMY", 78, 96], ["contractile force", "OBSERVATION", 40, 57], ["contractile system", "OBSERVATION", 78, 96]]], ["In the studies on muscle contraction the acceleration of the load is not considered nor it is provided a way to extract this information.", [["muscle", "ANATOMY", 18, 24], ["muscle contraction", "DISEASE", 18, 36], ["muscle", "ORGAN", 18, 24], ["muscle contraction", "PROBLEM", 18, 36], ["muscle", "ANATOMY", 18, 24]]], ["Models of muscle contraction that consider explicitly both the mass and the acceleration of the load show that, at the same load, the decrease of the acceleration of the load significantly delays the pre-steady state of the contraction and decreases the stiffness of the active fibre.Molecular mechanisms underlying force generation in vertebrate neuronsR.", [["muscle", "ANATOMY", 10, 16], ["muscle", "ORGAN", 10, 16], ["fibre", "CELLULAR_COMPONENT", 278, 283], ["neuronsR", "GENE_OR_GENE_PRODUCT", 347, 355], ["muscle contraction", "PROBLEM", 10, 28], ["the mass", "PROBLEM", 59, 67], ["force generation in vertebrate neuronsR", "PROBLEM", 316, 355], ["muscle", "ANATOMY", 10, 16], ["contraction", "OBSERVATION", 17, 28], ["mass", "OBSERVATION", 63, 67], ["decrease", "OBSERVATION_MODIFIER", 134, 142], ["acceleration", "OBSERVATION_MODIFIER", 150, 162], ["contraction", "OBSERVATION", 224, 235], ["stiffness", "OBSERVATION_MODIFIER", 254, 263], ["active fibre", "OBSERVATION", 271, 283], ["force generation", "OBSERVATION", 316, 332], ["vertebrate neuronsR", "OBSERVATION", 336, 355]]], ["Nazionale TASC, Trieste, Italy Polymerization of actin filaments is the main source of motility in lamellipodia and is controlled by many regulatory proteins.", [["lamellipodia", "ANATOMY", 99, 111], ["actin", "GENE_OR_GENE_PRODUCT", 49, 54], ["lamellipodia", "CELLULAR_COMPONENT", 99, 111], ["actin", "PROTEIN", 49, 54], ["regulatory proteins", "PROTEIN", 138, 157], ["Nazionale TASC", "TREATMENT", 0, 14], ["Italy Polymerization of actin filaments", "TREATMENT", 25, 64], ["motility in lamellipodia", "PROBLEM", 87, 111], ["actin filaments", "OBSERVATION", 49, 64], ["motility", "OBSERVATION", 87, 95], ["lamellipodia", "OBSERVATION_MODIFIER", 99, 111]]], ["The underlying molecular mechanisms are only partially understood and now a determination of the dynamical properties of force generation is needed.", [["force generation", "TREATMENT", 121, 137], ["molecular mechanisms", "OBSERVATION", 15, 35]]], ["Using optical tweezers we measured with millisecond temporal resolution and pN sensitivity the force-velocity (Fv) relationship and the power dissipated by lamellipodia of dorsal root ganglia neurons.", [["lamellipodia", "ANATOMY", 156, 168], ["dorsal root ganglia neurons", "ANATOMY", 172, 199], ["lamellipodia", "CELLULAR_COMPONENT", 156, 168], ["dorsal root ganglia neurons", "CELL", 172, 199], ["Fv", "PROTEIN", 111, 113], ["dorsal root ganglia neurons", "CELL_TYPE", 172, 199], ["optical tweezers", "TEST", 6, 22], ["millisecond temporal resolution", "TEST", 40, 71], ["pN sensitivity", "TEST", 76, 90], ["lamellipodia", "OBSERVATION_MODIFIER", 156, 168], ["dorsal", "ANATOMY_MODIFIER", 172, 178], ["root ganglia", "ANATOMY", 179, 191]]], ["When force and velocity are averaged over 3-5 s, Fv relationships can be flat.", [["Fv", "PROTEIN", 49, 51], ["velocity", "TEST", 15, 23], ["velocity", "OBSERVATION_MODIFIER", 15, 23]]], ["On a finer time scale, random occurrence of fast growths and sub-second retractions become predominant.", [["a finer time scale", "TREATMENT", 3, 21], ["fast growths", "PROBLEM", 44, 56], ["sub-second retractions", "PROBLEM", 61, 83], ["fast", "OBSERVATION_MODIFIER", 44, 48], ["growths", "OBSERVATION", 49, 56], ["sub", "OBSERVATION_MODIFIER", 61, 64], ["retractions", "OBSERVATION", 72, 83], ["predominant", "OBSERVATION_MODIFIER", 91, 102]]], ["Maximal power dissipated by lamellipodia over a silica bead with a diameter of 1 \u00b5m is 10 \u221216 W. Due to the presence of adhesion forces, beads in close contact with a lamellipodium can seal on its membrane reducing the amplitude of Brownian fluctuations often by more than 10 times.", [["lamellipodia", "ANATOMY", 28, 40], ["lamellipodium", "ANATOMY", 167, 180], ["membrane", "ANATOMY", 197, 205], ["silica", "CHEMICAL", 48, 54], ["lamellipodia", "CELLULAR_COMPONENT", 28, 40], ["lamellipodium", "CELLULAR_COMPONENT", 167, 180], ["membrane", "CELLULAR_COMPONENT", 197, 205], ["a silica bead", "TREATMENT", 46, 59], ["adhesion forces", "PROBLEM", 120, 135], ["power", "OBSERVATION_MODIFIER", 8, 13], ["lamellipodia", "OBSERVATION_MODIFIER", 28, 40], ["silica bead", "OBSERVATION", 48, 59], ["diameter", "OBSERVATION_MODIFIER", 67, 75], ["adhesion forces", "OBSERVATION", 120, 135], ["beads", "OBSERVATION_MODIFIER", 137, 142], ["amplitude", "OBSERVATION_MODIFIER", 219, 228], ["Brownian fluctuations", "OBSERVATION", 232, 253]]], ["Under these conditions, when lamellipodia grow and push the beads, discrete jumps varying from about 5 to 50 nm are detected.", [["lamellipodia", "ANATOMY", 29, 41], ["lamellipodia", "CELL", 29, 41], ["discrete jumps varying", "PROBLEM", 67, 89], ["beads", "OBSERVATION_MODIFIER", 60, 65], ["discrete", "OBSERVATION_MODIFIER", 67, 75], ["jumps", "OBSERVATION_MODIFIER", 76, 81], ["varying", "OBSERVATION_MODIFIER", 82, 89]]], ["When lamellipodia retract, pulling the beads, no discrete events are observed.", [["lamellipodia", "ANATOMY", 5, 17], ["pulling the beads", "TREATMENT", 27, 44], ["discrete events", "PROBLEM", 49, 64], ["lamellipodia", "OBSERVATION_MODIFIER", 5, 17], ["retract", "OBSERVATION_MODIFIER", 18, 25], ["no", "UNCERTAINTY", 46, 48], ["discrete", "OBSERVATION_MODIFIER", 49, 57]]], ["Our results on the dynamical properties of force generation are: a) force generation is a probabilistic process; b) underlying biological events have a bandwidth up to at least 10 Hz; c) fast growths of lamellipodia leading edge alternate with local retractions; d) force generation is produced in discrete steps with varying amplitude up to 0.2 pN.O-451Pushing on microtubules: dominant spindle centering mechanism in C. elegans embryo?", [["lamellipodia", "ANATOMY", 203, 215], ["microtubules", "ANATOMY", 365, 377], ["spindle", "ANATOMY", 388, 395], ["embryo", "ANATOMY", 430, 436], ["O-451Pushing", "CHEMICAL", 349, 361], ["O-451Pushing", "CHEMICAL", 349, 361], ["O-451Pushing", "GENE_OR_GENE_PRODUCT", 349, 361], ["microtubules", "CELLULAR_COMPONENT", 365, 377], ["spindle", "CELLULAR_COMPONENT", 388, 395], ["C. elegans", "ORGANISM", 419, 429], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 430, 436], ["C. elegans", "SPECIES", 419, 429], ["C. elegans", "SPECIES", 419, 429], ["fast growths of lamellipodia", "PROBLEM", 187, 215], ["local retractions", "PROBLEM", 244, 261], ["varying amplitude", "TEST", 318, 335], ["dominant", "OBSERVATION_MODIFIER", 379, 387], ["spindle centering", "OBSERVATION", 388, 405], ["elegans embryo", "OBSERVATION", 422, 436]]], ["J. Pecreaux, S. Redemann, A. A. Hyman, J. Howard MPI-CBG, PfotenhauerStr 108, 01307 Dresden, Germany Asymmetric cell division, where the content of the two daughter cells -as well as their sizes -differ, is found in many organisms.", [["cell", "ANATOMY", 112, 116], ["cells", "ANATOMY", 165, 170], ["Asymmetric cell", "CELL", 101, 116], ["cells", "CELL", 165, 170], ["daughter cells", "CELL_TYPE", 156, 170], ["CBG", "TEST", 53, 56], ["PfotenhauerStr", "TEST", 58, 72], ["cell division", "OBSERVATION", 112, 125]]], ["Strikingly, the spindle, first centered, starts to be displaced out of the center only in late metaphase.", [["spindle", "ANATOMY", 16, 23], ["spindle", "CELLULAR_COMPONENT", 16, 23], ["metaphase", "CELLULAR_COMPONENT", 95, 104], ["spindle", "OBSERVATION_MODIFIER", 16, 23], ["displaced", "OBSERVATION", 54, 63], ["late metaphase", "OBSERVATION", 90, 104]]], ["In C elegans embryo, the spindle rocks and is posteriorly displaced during anaphase by force generators asymmetrically localized on cell cortex.", [["embryo", "ANATOMY", 13, 19], ["spindle rocks", "ANATOMY", 25, 38], ["cell cortex", "ANATOMY", 132, 143], ["C elegans", "ORGANISM", 3, 12], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 13, 19], ["spindle rocks", "CELLULAR_COMPONENT", 25, 38], ["anaphase", "CELLULAR_COMPONENT", 75, 83], ["cell cortex", "CANCER", 132, 143], ["C elegans", "SPECIES", 3, 12], ["C elegans", "SPECIES", 3, 12], ["C elegans embryo", "TREATMENT", 3, 19], ["posteriorly displaced", "PROBLEM", 46, 67], ["elegans embryo", "OBSERVATION", 5, 19], ["spindle rocks", "OBSERVATION", 25, 38], ["posteriorly", "ANATOMY_MODIFIER", 46, 57], ["cell cortex", "OBSERVATION", 132, 143]]], ["Prior to anaphase onset, the spindle is usually assumed to be centered by the same pulling force.", [["spindle", "ANATOMY", 29, 36], ["anaphase", "CELLULAR_COMPONENT", 9, 17], ["spindle", "CELLULAR_COMPONENT", 29, 36], ["anaphase onset", "PROBLEM", 9, 23]]], ["It thus requires the force generators to be carefully repressed to distribute forces symmetrically.", [["the force generators", "TREATMENT", 17, 37]]], ["On live embryos, we measured positional fluctuations of centrosomes during metaphase with 20 nm accuracy.", [["embryos", "ANATOMY", 8, 15], ["centrosomes", "ANATOMY", 56, 67], ["metaphase", "ANATOMY", 75, 84], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 8, 15], ["centrosomes", "CELLULAR_COMPONENT", 56, 67], ["metaphase", "CELLULAR_COMPONENT", 75, 84], ["positional fluctuations of centrosomes", "PROBLEM", 29, 67], ["positional fluctuations", "OBSERVATION", 29, 52]]], ["Fourier analysis shows an extremely accurate centering respect to the number of force generators and microtubules.", [["microtubules", "ANATOMY", 101, 113], ["microtubules", "CELLULAR_COMPONENT", 101, 113], ["Fourier analysis", "TEST", 0, 16], ["extremely", "OBSERVATION_MODIFIER", 26, 35], ["accurate", "OBSERVATION", 36, 44], ["force generators", "OBSERVATION", 80, 96]]], ["Furthermore, spectrum is close to a Lorentzian, modeled by a spring and a dashpot, suggesting a spindle centering more likely by pushing on microtubules than pulling.", [["spindle", "ANATOMY", 96, 103], ["microtubules", "ANATOMY", 140, 152], ["spindle", "CELLULAR_COMPONENT", 96, 103], ["microtubules", "CELLULAR_COMPONENT", 140, 152]]], ["Deviation at high frequencies indicates a subdominant pulling force.", [["Deviation at high frequencies", "PROBLEM", 0, 29], ["a subdominant pulling force", "PROBLEM", 40, 67], ["high frequencies", "OBSERVATION_MODIFIER", 13, 29], ["subdominant", "OBSERVATION_MODIFIER", 42, 53], ["pulling", "OBSERVATION", 54, 61]]], ["RNAi of gpr-1/2, known to control force generation, increases slightly centering accuracy; this result supports the hypothesis of an independent centering mechanism.", [["gpr-1/2", "GENE_OR_GENE_PRODUCT", 8, 15], ["gpr-1/2", "PROTEIN", 8, 15]]], ["Conversely, zyg-9(RNAi), a microtubule growing factor, decreases centering accuracy, modeled spring stiffness and damping modulus.", [["microtubule", "ANATOMY", 27, 38], ["zyg-9", "CHEMICAL", 12, 17], ["zyg-9", "GENE_OR_GENE_PRODUCT", 12, 17], ["zyg-9", "PROTEIN", 12, 17], ["microtubule growing factor", "PROTEIN", 27, 53], ["a microtubule growing factor", "PROBLEM", 25, 53], ["modeled spring stiffness", "PROBLEM", 85, 109], ["damping modulus", "PROBLEM", 114, 129], ["spring stiffness", "OBSERVATION", 93, 109], ["damping modulus", "OBSERVATION", 114, 129]]], ["Conclusion: first, the spindle centering mechanism is independent of cortical pulling force generator.", [["spindle", "ANATOMY", 23, 30], ["cortical", "ANATOMY", 69, 77], ["spindle", "CELLULAR_COMPONENT", 23, 30], ["cortical pulling force generator", "TREATMENT", 69, 101], ["cortical pulling", "OBSERVATION", 69, 85]]], ["Second, microtubules pushing is likely to center the spindle.", [["microtubules", "ANATOMY", 8, 20], ["spindle", "ANATOMY", 53, 60], ["microtubules", "CELLULAR_COMPONENT", 8, 20], ["spindle", "CELLULAR_COMPONENT", 53, 60], ["microtubules", "PROTEIN", 8, 20], ["microtubules pushing", "OBSERVATION", 8, 28], ["is likely", "UNCERTAINTY", 29, 38], ["spindle", "OBSERVATION", 53, 60]]], ["Mechanical forces are important in the regulation of cellular adhesion and migration.", [["cellular", "ANATOMY", 53, 61], ["cellular", "CELL", 53, 61], ["Mechanical forces", "TREATMENT", 0, 17], ["cellular adhesion", "TREATMENT", 53, 70], ["forces", "OBSERVATION", 11, 17], ["cellular adhesion", "OBSERVATION", 53, 70]]], ["The Focal Adhesion Kinase (FAK) has been suggested to transduce cellular forces and govern cell migration.", [["cellular", "ANATOMY", 64, 72], ["cell", "ANATOMY", 91, 95], ["Focal Adhesion Kinase", "GENE_OR_GENE_PRODUCT", 4, 25], ["FAK", "GENE_OR_GENE_PRODUCT", 27, 30], ["cellular", "CELL", 64, 72], ["cell", "CELL", 91, 95], ["Focal Adhesion Kinase", "PROTEIN", 4, 25], ["FAK", "PROTEIN", 27, 30], ["The Focal Adhesion Kinase (FAK)", "TEST", 0, 31], ["govern cell migration", "TREATMENT", 84, 105], ["Focal", "OBSERVATION_MODIFIER", 4, 9], ["Adhesion Kinase", "OBSERVATION", 10, 25], ["cellular forces", "OBSERVATION", 64, 79], ["govern cell migration", "OBSERVATION", 84, 105]]], ["To obtain more insight in the functioning of FAK, a FRET-based optical biosensor for FAK was designed to relate integrin-mediated conformational changes in its FERM domain to focal adhesion behavior during cell spreading and migration in living cells.", [["cell", "ANATOMY", 206, 210], ["cells", "ANATOMY", 245, 250], ["FAK", "GENE_OR_GENE_PRODUCT", 45, 48], ["FAK", "GENE_OR_GENE_PRODUCT", 85, 88], ["integrin", "GENE_OR_GENE_PRODUCT", 112, 120], ["FERM", "GENE_OR_GENE_PRODUCT", 160, 164], ["cell", "CELL", 206, 210], ["cells", "CELL", 245, 250], ["FAK", "PROTEIN", 45, 48], ["FAK", "PROTEIN", 85, 88], ["integrin", "PROTEIN", 112, 120], ["FERM domain", "PROTEIN", 160, 171], ["living cells", "CELL_TYPE", 238, 250], ["integrin-mediated conformational changes in its FERM domain", "PROBLEM", 112, 171], ["focal adhesion behavior", "PROBLEM", 175, 198], ["cell spreading", "PROBLEM", 206, 220], ["migration in living cells", "TREATMENT", 225, 250], ["focal", "OBSERVATION_MODIFIER", 175, 180], ["adhesion", "OBSERVATION_MODIFIER", 181, 189], ["cell", "OBSERVATION", 206, 210], ["spreading", "OBSERVATION_MODIFIER", 211, 220], ["migration", "OBSERVATION_MODIFIER", 225, 234]]], ["Imaging of the kinetics of FERM-based FAK conformational changes in spreading cells revealed two consecutive stages of focal adhesion activation.", [["cells", "ANATOMY", 78, 83], ["FERM", "GENE_OR_GENE_PRODUCT", 27, 31], ["FAK", "GENE_OR_GENE_PRODUCT", 38, 41], ["cells", "CELL", 78, 83], ["FERM", "PROTEIN", 27, 31], ["FAK", "PROTEIN", 38, 41], ["spreading cells", "CELL_TYPE", 68, 83], ["Imaging", "TEST", 0, 7], ["FERM", "TEST", 27, 31], ["based FAK conformational changes in spreading cells", "PROBLEM", 32, 83], ["focal adhesion activation", "PROBLEM", 119, 144], ["FAK conformational", "OBSERVATION", 38, 56], ["two", "OBSERVATION_MODIFIER", 93, 96], ["consecutive stages", "OBSERVATION_MODIFIER", 97, 115], ["focal", "OBSERVATION_MODIFIER", 119, 124], ["adhesion activation", "OBSERVATION", 125, 144]]], ["Heterogeneous FERM conformational responses were observed in individual focal adhesions of adherent motile cells, with the active FERM conformation being enriched in growing and sliding FAs, but not in stable and shrinking focal adhesions.", [["focal adhesions", "ANATOMY", 72, 87], ["cells", "ANATOMY", 107, 112], ["FAs", "ANATOMY", 186, 189], ["focal adhesions", "ANATOMY", 223, 238], ["FERM", "GENE_OR_GENE_PRODUCT", 14, 18], ["focal adhesions", "CELLULAR_COMPONENT", 72, 87], ["cells", "CELL", 107, 112], ["FERM", "GENE_OR_GENE_PRODUCT", 130, 134], ["FAs", "SIMPLE_CHEMICAL", 186, 189], ["focal adhesions", "CELLULAR_COMPONENT", 223, 238], ["FERM", "PROTEIN", 14, 18], ["adherent motile cells", "CELL_TYPE", 91, 112], ["FERM", "PROTEIN", 130, 134], ["Heterogeneous FERM conformational responses", "PROBLEM", 0, 43], ["individual focal adhesions of adherent motile cells", "PROBLEM", 61, 112], ["the active FERM conformation", "PROBLEM", 119, 147], ["sliding FAs", "TEST", 178, 189], ["shrinking focal adhesions", "PROBLEM", 213, 238], ["individual", "OBSERVATION_MODIFIER", 61, 71], ["focal", "OBSERVATION_MODIFIER", 72, 77], ["adhesions", "OBSERVATION", 78, 87], ["adherent motile cells", "OBSERVATION", 91, 112], ["active", "OBSERVATION_MODIFIER", 123, 129], ["FERM conformation", "OBSERVATION", 130, 147], ["sliding FAs", "OBSERVATION", 178, 189], ["stable", "OBSERVATION_MODIFIER", 202, 208], ["shrinking", "OBSERVATION_MODIFIER", 213, 222], ["focal", "OBSERVATION_MODIFIER", 223, 228], ["adhesions", "OBSERVATION", 229, 238]]], ["Inhibition of the cellular actomyosin system revealed the involvement of Rho-ROCK rather than MLCKinduced tension signaling in the modulation of the FERM response.", [["cellular", "ANATOMY", 18, 26], ["cellular", "CELL", 18, 26], ["Rho-ROCK", "GENE_OR_GENE_PRODUCT", 73, 81], ["MLCKinduced", "GENE_OR_GENE_PRODUCT", 94, 105], ["FERM", "GENE_OR_GENE_PRODUCT", 149, 153], ["Rho-ROCK", "PROTEIN", 73, 81], ["FERM", "PROTEIN", 149, 153], ["the cellular actomyosin system", "TEST", 14, 44], ["MLCKinduced tension signaling", "PROBLEM", 94, 123], ["cellular actomyosin", "OBSERVATION", 18, 37], ["tension signaling", "OBSERVATION", 106, 123], ["FERM response", "OBSERVATION", 149, 162]]], ["Our results place the FERM conformational change of FAK at the interface between integrin and force sensing.O-449The time course of inorganic phosphate release in permeabilized cardiac trabeculae of the rat C. Mansfield, T. West, M. A. Ferenczi Imperial College London, U.K.O-449The rate of P i release was determined in permeabilized rat trabeculae.", [["cardiac trabeculae", "ANATOMY", 177, 195], ["trabeculae", "ANATOMY", 339, 349], ["O-449", "CHEMICAL", 108, 113], ["inorganic phosphate", "CHEMICAL", 132, 151], ["U.K.O-449", "CHEMICAL", 270, 279], ["O-449", "CHEMICAL", 108, 113], ["phosphate", "CHEMICAL", 142, 151], ["FERM", "GENE_OR_GENE_PRODUCT", 22, 26], ["FAK", "GENE_OR_GENE_PRODUCT", 52, 55], ["integrin", "GENE_OR_GENE_PRODUCT", 81, 89], ["inorganic phosphate", "SIMPLE_CHEMICAL", 132, 151], ["cardiac trabeculae", "MULTI-TISSUE_STRUCTURE", 177, 195], ["rat", "ORGANISM", 203, 206], ["rat", "ORGANISM", 335, 338], ["trabeculae", "MULTI-TISSUE_STRUCTURE", 339, 349], ["FERM", "PROTEIN", 22, 26], ["FAK", "PROTEIN", 52, 55], ["integrin", "PROTEIN", 81, 89], ["P", "DNA", 291, 292], ["rat", "SPECIES", 203, 206], ["rat", "SPECIES", 335, 338], ["M. A. Ferenczi Imperial College London, U.K.O-449", "SPECIES", 230, 279], ["rat", "SPECIES", 335, 338], ["the FERM conformational change of FAK", "TREATMENT", 18, 55], ["integrin and force sensing", "TREATMENT", 81, 107], ["inorganic phosphate release", "TREATMENT", 132, 159], ["P i release", "TREATMENT", 291, 302], ["cardiac trabeculae", "ANATOMY", 177, 195], ["rat trabeculae", "OBSERVATION", 335, 349]]], ["Contraction was elicited at 20 \u2022 C by laser-flash photolysis of NPE-caged ATP, and time-resolved P i release was monitored using MDCC-PBP, a coumarin-labelled phosphate binding protein, which increases its fluorescence intensity five-fold upon P i binding.", [["NPE", "CHEMICAL", 64, 67], ["ATP", "CHEMICAL", 74, 77], ["coumarin", "CHEMICAL", 141, 149], ["phosphate", "CHEMICAL", 159, 168], ["ATP", "CHEMICAL", 74, 77], ["coumarin", "CHEMICAL", 141, 149], ["phosphate", "CHEMICAL", 159, 168], ["NPE", "SIMPLE_CHEMICAL", 64, 67], ["ATP", "SIMPLE_CHEMICAL", 74, 77], ["MDCC-PBP", "SIMPLE_CHEMICAL", 129, 137], ["coumarin", "SIMPLE_CHEMICAL", 141, 149], ["phosphate", "SIMPLE_CHEMICAL", 159, 168], ["PBP", "PROTEIN", 134, 137], ["coumarin-labelled phosphate binding protein", "PROTEIN", 141, 184], ["NPE", "PROBLEM", 64, 67], ["caged ATP", "TREATMENT", 68, 77], ["PBP", "TEST", 134, 137], ["a coumarin-labelled phosphate binding protein", "TEST", 139, 184]]], ["The ATPase rate during the first turnover of the total crossbridges (assuming 100 \u00b5M myosin heads) was 23s \u22121 .", [["ATPase", "GENE_OR_GENE_PRODUCT", 4, 10], ["ATPase", "PROTEIN", 4, 10], ["The ATPase rate", "TEST", 0, 15]]], ["The rate decreased to a steady state of 4s \u22121 after the eighth turnover (0.5-0.6s after activation).", [["The rate", "TEST", 0, 8], ["decreased", "OBSERVATION_MODIFIER", 9, 18]]], ["This steady state rate is comparable to published values of 3 -10s \u22121 , made \u223c15s after activation using an NADH-linked enzyme assay of ADP release.", [["NADH", "CHEMICAL", 108, 112], ["ADP", "CHEMICAL", 136, 139], ["NADH", "CHEMICAL", 108, 112], ["ADP", "CHEMICAL", 136, 139], ["NADH", "SIMPLE_CHEMICAL", 108, 112], ["ADP", "SIMPLE_CHEMICAL", 136, 139], ["published values", "TEST", 40, 56], ["an NADH", "TEST", 105, 112], ["enzyme assay", "TEST", 120, 132], ["ADP release", "PROBLEM", 136, 147]]], ["The advantage of using MDCC-PBP is that the control of mechanochemical coupling can be examined from the onset of force production and as it progresses toward the steady state.", [["MDCC-PBP", "GENE_OR_GENE_PRODUCT", 23, 31], ["MDCC", "PROTEIN", 23, 27], ["MDCC-PBP", "TREATMENT", 23, 31], ["mechanochemical coupling", "PROBLEM", 55, 79], ["force production", "PROBLEM", 114, 130]]], ["Force production and P i release were simulated using a seven step scheme.", [["a seven step scheme", "TREATMENT", 54, 73]]], ["Force was attributed to the states in the sequence A.M.ADP.P i \u2194 A.M.ADP \u2194 A.M.ADP, with strain sensitivity incorporated into the isomerisation of A.M.ADP. The A.M.ADP.P i and A.M.ADP states populated rapidly as force was increasing.", [["ADP", "CHEMICAL", 79, 82], ["ADP", "CHEMICAL", 151, 154], ["ADP", "CHEMICAL", 79, 82], ["ADP", "CHEMICAL", 151, 154], ["ADP", "CHEMICAL", 180, 183], ["ADP", "SIMPLE_CHEMICAL", 79, 82], ["ADP", "SIMPLE_CHEMICAL", 151, 154], ["ADP", "SIMPLE_CHEMICAL", 180, 183], ["strain sensitivity", "TEST", 89, 107], ["populated", "OBSERVATION", 191, 200], ["increasing", "OBSERVATION_MODIFIER", 222, 232]]], ["In contrast, the A.M.ADP state accumulated slowly after the force plateau was reached and became the dominant force bearing state at the time of the eighth crossbridge turnover.", [["the force plateau", "TEST", 56, 73], ["slowly", "OBSERVATION_MODIFIER", 43, 49], ["dominant", "OBSERVATION_MODIFIER", 101, 109], ["force bearing", "OBSERVATION", 110, 123]]], ["Experiments are on-going to examine how the distribution of A.M states changes in response to rapid length-changes.AbstractsPulling as a factor in forming the heterophasic structure of immunoglobulin proteins Structure of proteins of immunoglobulin superfamily: human IgG3 Kuc and muscle protein titin, has been investigated by methods of electron microscopy and diffraction with the use synchrotron radiation.", [["muscle", "ANATOMY", 281, 287], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 185, 199], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 234, 248], ["human", "ORGANISM", 262, 267], ["IgG3 Kuc", "GENE_OR_GENE_PRODUCT", 268, 276], ["muscle", "ORGAN", 281, 287], ["titin", "GENE_OR_GENE_PRODUCT", 296, 301], ["immunoglobulin proteins", "PROTEIN", 185, 208], ["immunoglobulin superfamily", "PROTEIN", 234, 260], ["human IgG3 Kuc", "PROTEIN", 262, 276], ["muscle protein titin", "PROTEIN", 281, 301], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 262, 267], ["immunoglobulin proteins", "PROBLEM", 185, 208], ["immunoglobulin superfamily", "TREATMENT", 234, 260], ["human IgG3 Kuc", "TREATMENT", 262, 276], ["muscle protein titin", "TREATMENT", 281, 301], ["electron microscopy", "TEST", 339, 358], ["synchrotron radiation", "TREATMENT", 388, 409]]], ["Super elasticity of titin, the protein of immunoglobulin superfamily, is a key parameter that determines the mechanical properties of muscle.", [["muscle", "ANATOMY", 134, 140], ["titin", "GENE_OR_GENE_PRODUCT", 20, 25], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 42, 56], ["muscle", "ORGAN", 134, 140], ["titin", "PROTEIN", 20, 25], ["immunoglobulin superfamily", "PROTEIN", 42, 68], ["mechanical properties", "OBSERVATION", 109, 130], ["muscle", "ANATOMY", 134, 140]]], ["However, the structural-physical mechanism of titin elasticity under tension remains poorly understood.", [["titin", "GENE_OR_GENE_PRODUCT", 46, 51], ["titin", "PROTEIN", 46, 51], ["titin elasticity", "OBSERVATION", 46, 62]]], ["Here both tension transduction and high elasticity of titin are explained in terms of crystalline polymer physics.", [["titin", "GENE_OR_GENE_PRODUCT", 54, 59], ["titin", "PROTEIN", 54, 59], ["both tension transduction", "TREATMENT", 5, 30], ["high elasticity of titin", "TREATMENT", 35, 59], ["crystalline polymer physics", "TREATMENT", 86, 113], ["tension", "OBSERVATION_MODIFIER", 10, 17], ["high elasticity", "OBSERVATION_MODIFIER", 35, 50]]], ["X-ray data suggest a model of titin as a nanoscale, morphological, aperiodical array of rigid Ig-and Fn3-type domains covalently-connected by conformationally variable short loops.", [["titin", "GENE_OR_GENE_PRODUCT", 30, 35], ["Ig", "GENE_OR_GENE_PRODUCT", 94, 96], ["titin", "PROTEIN", 30, 35], ["Ig", "PROTEIN", 94, 96], ["Fn3", "PROTEIN", 101, 104], ["type domains", "PROTEIN", 105, 117], ["X-ray data", "TEST", 0, 10], ["rigid Ig", "TREATMENT", 88, 96], ["Fn3-type domains covalently", "TREATMENT", 101, 128], ["short loops", "OBSERVATION", 168, 179]]], ["The line group symmetry of the model can be defined as S M with axial translation \u03c4 \u221e .", [["line", "OBSERVATION_MODIFIER", 4, 8], ["group symmetry", "OBSERVATION_MODIFIER", 9, 23]]], ["Homologous domains would have similar stability, but the structure of different domains on stretching is subject to different forces because they have different orientations relative to the axis of the molecule.", [["Homologous domains", "PROBLEM", 0, 18], ["similar", "OBSERVATION_MODIFIER", 30, 37], ["stability", "OBSERVATION", 38, 47], ["different", "OBSERVATION_MODIFIER", 70, 79], ["domains", "OBSERVATION_MODIFIER", 80, 87]]], ["Under the force influence the structure of any domain can become either rigid or flexible depending on its orientation in the titin strand.", [["titin", "GENE_OR_GENE_PRODUCT", 126, 131], ["rigid", "PROBLEM", 72, 77], ["rigid", "OBSERVATION", 72, 77]]], ["Pulling geometry forms an active axial structure from latent isotropic random coil structure of titin strand.", [["titin", "GENE_OR_GENE_PRODUCT", 96, 101], ["an active axial structure", "PROBLEM", 23, 48], ["latent isotropic random coil structure of titin strand", "TREATMENT", 54, 108], ["active", "OBSERVATION_MODIFIER", 26, 32], ["axial structure", "OBSERVATION", 33, 48], ["latent", "OBSERVATION_MODIFIER", 54, 60], ["isotropic", "OBSERVATION_MODIFIER", 61, 70], ["random coil", "OBSERVATION", 71, 82], ["titin strand", "OBSERVATION", 96, 108]]], ["We are suddenly faced with nanophase-separated morphology of IgG3 Kuc.", [["IgG3 Kuc", "GENE_OR_GENE_PRODUCT", 61, 69], ["IgG3 Kuc", "PROTEIN", 61, 69]]], ["Study was supported by RFBR Grant 07-02-01281.O-455Strain response of myosin essential light chain in permeabilized skeletal muscle fibres D. S. Ushakov, D. Ibanez-Garcia, T. G. West, P. M. W. French, M. A. Ferenczi Imperial College London, UK We applied fluorescence lifetime imaging microscopy (FLIM) to investigate the relation between conformation of myosin head and mechanical force in skeletal muscle fibres.", [["skeletal muscle fibres", "ANATOMY", 116, 138], ["head", "ANATOMY", 362, 366], ["skeletal muscle fibres", "ANATOMY", 391, 413], ["myosin essential light chain", "GENE_OR_GENE_PRODUCT", 70, 98], ["skeletal muscle", "TISSUE", 116, 131], ["myosin head", "GENE_OR_GENE_PRODUCT", 355, 366], ["skeletal muscle fibres", "TISSUE", 391, 413], ["myosin essential light chain", "PROTEIN", 70, 98], ["myosin head", "PROTEIN", 355, 366], ["fluorescence lifetime imaging microscopy", "TEST", 255, 295], ["myosin head", "TREATMENT", 355, 366], ["light chain", "OBSERVATION", 87, 98], ["skeletal muscle", "ANATOMY", 116, 131], ["head", "ANATOMY", 362, 366], ["mechanical force", "OBSERVATION", 371, 387], ["skeletal muscle", "ANATOMY", 391, 406]]], ["Recombinant myosin essential light chain (ELC) was expressed in E.coli and labelled at Cys-178 with coumarin.", [["Cys-178", "CHEMICAL", 87, 94], ["coumarin", "CHEMICAL", 100, 108], ["Cys", "CHEMICAL", 87, 90], ["coumarin", "CHEMICAL", 100, 108], ["myosin essential light chain", "GENE_OR_GENE_PRODUCT", 12, 40], ["ELC", "GENE_OR_GENE_PRODUCT", 42, 45], ["E.coli", "CELL", 64, 70], ["Cys-178", "SIMPLE_CHEMICAL", 87, 94], ["coumarin", "SIMPLE_CHEMICAL", 100, 108], ["Recombinant myosin essential light chain", "PROTEIN", 0, 40], ["ELC", "PROTEIN", 42, 45], ["E.coli", "SPECIES", 64, 70], ["E.coli", "PROBLEM", 64, 70], ["Cys", "TEST", 87, 90], ["coumarin", "TREATMENT", 100, 108], ["essential", "OBSERVATION_MODIFIER", 19, 28], ["light chain", "OBSERVATION_MODIFIER", 29, 40], ["E.coli", "ANATOMY", 64, 70]]], ["The labelled ELC was exchanged with native ELC in single permeabilized rabbit m.psoas fibres.", [["m.psoas fibres", "ANATOMY", 78, 92], ["ELC", "GENE_OR_GENE_PRODUCT", 13, 16], ["ELC", "GENE_OR_GENE_PRODUCT", 43, 46], ["rabbit", "ORGANISM", 71, 77], ["m.psoas fibres", "TISSUE", 78, 92], ["ELC", "PROTEIN", 13, 16], ["ELC", "PROTEIN", 43, 46], ["single permeabilized rabbit m.psoas fibres", "CELL_LINE", 50, 92], ["rabbit", "SPECIES", 71, 77], ["rabbit", "SPECIES", 71, 77], ["native ELC", "TREATMENT", 36, 46], ["permeabilized rabbit", "OBSERVATION", 57, 77], ["m.psoas fibres", "OBSERVATION", 78, 92]]], ["Fluorescence lifetime was measured using Leica SP5 upright confocal microscope equipped with Becker & Hickl time-correlated single photon counting module and 63x 1.2 NA Leica PlanApo dipping objective, with the two-photon fluorescence excitation at 856 nm by Sapphire pulsed laser.", [["Fluorescence lifetime", "TEST", 0, 21], ["single photon counting module", "TEST", 124, 153], ["NA", "TEST", 166, 168], ["the two-photon fluorescence excitation", "TREATMENT", 207, 245], ["Sapphire pulsed laser", "TREATMENT", 259, 280]]], ["After acquiring FLIM images of muscle fibres in relaxed state, the solution was changed to Ca-free rigor.", [["muscle fibres", "ANATOMY", 31, 44], ["muscle fibres", "TISSUE", 31, 44], ["FLIM images", "TEST", 16, 27], ["the solution", "TREATMENT", 63, 75], ["muscle", "ANATOMY", 31, 37]]], ["Further images were acquired in rigor with or without 0.5-1% stretch applied by a motor.", [["Further images", "TEST", 0, 14]]], ["Both single and double exponential fluorescence decay analysis showed that the lifetime in rigor was lower compared to relaxed (about 80 ps difference for single exponential fit) and to rigor fibres under strain (about 40 ps).", [["double exponential fluorescence decay analysis", "TEST", 16, 62], ["rigor fibres under strain", "PROBLEM", 186, 211]]], ["These data suggest a change in the microenvironment of coumarin induced by nucleotide binding and strain.", [["coumarin", "CHEMICAL", 55, 63], ["nucleotide", "CHEMICAL", 75, 85], ["coumarin", "CHEMICAL", 55, 63], ["nucleotide", "CHEMICAL", 75, 85], ["coumarin", "SIMPLE_CHEMICAL", 55, 63], ["nucleotide", "SIMPLE_CHEMICAL", 75, 85], ["coumarin", "TREATMENT", 55, 63], ["nucleotide binding", "PROBLEM", 75, 93], ["strain", "PROBLEM", 98, 104], ["change", "OBSERVATION_MODIFIER", 21, 27]]], ["This change is likely to be due to interaction between C-terminal domain of ELC and the N-terminal domain of myosin heavy chain related to the lever arm re-orientation process.", [["C", "CHEMICAL", 55, 56], ["N", "CHEMICAL", 88, 89], ["ELC", "GENE_OR_GENE_PRODUCT", 76, 79], ["myosin heavy chain", "GENE_OR_GENE_PRODUCT", 109, 127], ["C-terminal domain", "PROTEIN", 55, 72], ["ELC", "PROTEIN", 76, 79], ["N-terminal domain", "PROTEIN", 88, 105], ["myosin heavy chain", "PROTEIN", 109, 127], ["interaction between C-terminal domain of ELC", "PROBLEM", 35, 79], ["myosin heavy chain", "TREATMENT", 109, 127], ["the lever arm re-orientation process", "TREATMENT", 139, 175], ["likely to be due to", "UNCERTAINTY", 15, 34]]], ["Supported by BBSRC.P-454Alpha-synuclein and its A30P mutant affects the actin cytoskeleton structure and dynamics V. Sousa 1 , S. Bellani 1 , G. Ronzitti 2 , F. Valtorta 1 , J. Meldolesi 1 , E. Chieregatti 2 1 Department of Neuroscience, HSR, Milano, Italy, 2 Department of Neuroscience, IIT, Genova, Italy Alpha-synuclein (Syn) is a soluble protein abundant in the brain, primarily enriched at pre-synapses.", [["cytoskeleton", "ANATOMY", 78, 90], ["brain", "ANATOMY", 366, 371], ["pre-synapses", "ANATOMY", 395, 407], ["P-454Alpha-synuclein", "CHEMICAL", 19, 39], ["454Alpha-synuclein", "GENE_OR_GENE_PRODUCT", 21, 39], ["A30P", "GENE_OR_GENE_PRODUCT", 48, 52], ["actin", "GENE_OR_GENE_PRODUCT", 72, 77], ["cytoskeleton", "CELLULAR_COMPONENT", 78, 90], ["Alpha-synuclein", "GENE_OR_GENE_PRODUCT", 307, 322], ["Syn", "GENE_OR_GENE_PRODUCT", 324, 327], ["brain", "ORGAN", 366, 371], ["BBSRC", "PROTEIN", 13, 18], ["P-454Alpha-synuclein", "DNA", 19, 39], ["A30P mutant", "PROTEIN", 48, 59], ["actin", "PROTEIN", 72, 77], ["P", "TEST", 19, 20], ["synuclein", "TREATMENT", 30, 39], ["a soluble protein abundant in the brain", "PROBLEM", 332, 371], ["actin cytoskeleton structure", "OBSERVATION", 72, 100], ["brain", "ANATOMY", 366, 371]]], ["Syn overexpression and the expression of its A30P mutant participate in the pathogenesis of Parkinson's disease.", [["Parkinson's disease", "DISEASE", 92, 111], ["Syn", "GENE_OR_GENE_PRODUCT", 0, 3], ["A30P", "GENE_OR_GENE_PRODUCT", 45, 49], ["Parkinson's disease", "CANCER", 92, 111], ["Syn", "PROTEIN", 0, 3], ["A30P mutant", "PROTEIN", 45, 56], ["Parkinson's disease", "PROBLEM", 92, 111], ["Parkinson", "OBSERVATION", 92, 101]]], ["Many roles have been proposed for Syn, including the regulation of synaptic vesicle pools and of neurotransmitter release.", [["synaptic vesicle", "ANATOMY", 67, 83], ["Syn", "GENE_OR_GENE_PRODUCT", 34, 37], ["synaptic vesicle", "CELLULAR_COMPONENT", 67, 83], ["Syn", "PROTEIN", 34, 37], ["Syn", "TREATMENT", 34, 37], ["synaptic vesicle pools", "TREATMENT", 67, 89], ["neurotransmitter release", "TREATMENT", 97, 121]]], ["The actin cytoskeleton regulates many aspects of synaptic function and its dysregulation may be a cause of neurodegeneration.", [["cytoskeleton", "ANATOMY", 10, 22], ["synaptic", "ANATOMY", 49, 57], ["neurodegeneration", "DISEASE", 107, 124], ["actin", "GENE_OR_GENE_PRODUCT", 4, 9], ["cytoskeleton", "CELLULAR_COMPONENT", 10, 22], ["synaptic", "MULTI-TISSUE_STRUCTURE", 49, 57], ["actin", "PROTEIN", 4, 9], ["neurodegeneration", "PROBLEM", 107, 124], ["actin cytoskeleton", "OBSERVATION", 4, 22], ["synaptic function", "OBSERVATION", 49, 66], ["may be a cause of", "UNCERTAINTY", 89, 106], ["neurodegeneration", "OBSERVATION", 107, 124]]], ["Working both in cell-free and in vivo conditions we demonstrate that Syn and the A30P mutant have different effects on the actin cytoskeleton dynamics.", [["cell", "ANATOMY", 16, 20], ["cytoskeleton", "ANATOMY", 129, 141], ["cell", "CELL", 16, 20], ["Syn", "GENE_OR_GENE_PRODUCT", 69, 72], ["A30P", "GENE_OR_GENE_PRODUCT", 81, 85], ["actin", "GENE_OR_GENE_PRODUCT", 123, 128], ["cytoskeleton", "CELLULAR_COMPONENT", 129, 141], ["Syn", "PROTEIN", 69, 72], ["A30P mutant", "PROTEIN", 81, 92], ["actin", "PROTEIN", 123, 128], ["the actin cytoskeleton dynamics", "TEST", 119, 150]]], ["Our results show that Syn binds actin, and decreases actin polymerization rate probably by monomer sequestration.", [["Syn", "GENE_OR_GENE_PRODUCT", 22, 25], ["actin", "GENE_OR_GENE_PRODUCT", 32, 37], ["actin", "GENE_OR_GENE_PRODUCT", 53, 58], ["Syn", "PROTEIN", 22, 25], ["actin", "PROTEIN", 32, 37], ["actin", "PROTEIN", 53, 58], ["Syn binds actin", "PROBLEM", 22, 37], ["actin polymerization rate", "TREATMENT", 53, 78], ["monomer sequestration", "PROBLEM", 91, 112], ["actin polymerization", "OBSERVATION", 53, 73], ["monomer sequestration", "OBSERVATION", 91, 112]]], ["On the contrary, A30P accelerates actin polymerization in vitro and disrupts the cytoskeleton of intact cells.", [["cytoskeleton", "ANATOMY", 81, 93], ["cells", "ANATOMY", 104, 109], ["A30P", "GENE_OR_GENE_PRODUCT", 17, 21], ["actin", "GENE_OR_GENE_PRODUCT", 34, 39], ["cytoskeleton", "CELLULAR_COMPONENT", 81, 93], ["cells", "CELL", 104, 109], ["actin", "PROTEIN", 34, 39], ["intact cells", "CELL_TYPE", 97, 109], ["A30P accelerates actin polymerization in vitro", "PROBLEM", 17, 63], ["actin polymerization", "OBSERVATION", 34, 54], ["intact cells", "OBSERVATION", 97, 109]]], ["In particular, during dynamic cytoskeleton remodeling, A30P induces the assembly of discrete actin-rich foci.", [["cytoskeleton", "ANATOMY", 30, 42], ["actin-rich foci", "ANATOMY", 93, 108], ["cytoskeleton", "CELLULAR_COMPONENT", 30, 42], ["A30P", "GENE_OR_GENE_PRODUCT", 55, 59], ["actin-rich foci", "CELLULAR_COMPONENT", 93, 108], ["A30P", "PROTEIN", 55, 59], ["dynamic cytoskeleton remodeling", "PROBLEM", 22, 53], ["discrete actin-rich foci", "PROBLEM", 84, 108], ["dynamic cytoskeleton remodeling", "OBSERVATION", 22, 53], ["A30P", "OBSERVATION", 55, 59], ["discrete", "OBSERVATION_MODIFIER", 84, 92], ["actin-rich", "OBSERVATION_MODIFIER", 93, 103], ["foci", "OBSERVATION", 104, 108]]], ["Actin trapping and the impairment of filaments reassembly lead to inhibition of cell movement and of the re-establishment of cell-cell contacts.", [["filaments", "ANATOMY", 37, 46], ["cell", "ANATOMY", 80, 84], ["cell-cell contacts", "ANATOMY", 125, 143], ["Actin", "GENE_OR_GENE_PRODUCT", 0, 5], ["filaments", "CELLULAR_COMPONENT", 37, 46], ["cell", "CELL", 80, 84], ["cell-cell contacts", "CELLULAR_COMPONENT", 125, 143], ["Actin", "PROTEIN", 0, 5], ["Actin trapping", "PROBLEM", 0, 14], ["the impairment of filaments", "PROBLEM", 19, 46], ["cell movement", "TREATMENT", 80, 93], ["cell contacts", "OBSERVATION", 130, 143]]], ["In A30P expressing cells cytoskeleton-based processes, such as cell migration and the exo/endocytic traffic are inhibited.", [["cells", "ANATOMY", 19, 24], ["cell", "ANATOMY", 63, 67], ["A30P", "GENE_OR_GENE_PRODUCT", 3, 7], ["cells", "CELL", 19, 24], ["cell", "CELL", 63, 67], ["A30P expressing cells", "CELL_LINE", 3, 24], ["such as cell migration", "PROBLEM", 55, 77], ["cells cytoskeleton", "OBSERVATION", 19, 37], ["cell migration", "OBSERVATION", 63, 77]]], ["Elucidating the dynamics of Syn interaction with actin may contribute to the understanding of its role in neuronal physiology as well as in neurodegeneration.P-453On the physics of muscle contraction M. L. Shur Ural State University, Yekaterinburg, Russian federation Whichever energy source is chosen as an engine, its force will decrease with increasing velocity.", [["neuronal", "ANATOMY", 106, 114], ["muscle", "ANATOMY", 181, 187], ["neurodegeneration", "DISEASE", 140, 157], ["P-453On", "CHEMICAL", 158, 165], ["Syn", "GENE_OR_GENE_PRODUCT", 28, 31], ["actin", "GENE_OR_GENE_PRODUCT", 49, 54], ["neuronal", "CELL", 106, 114], ["muscle", "ORGAN", 181, 187], ["Syn", "PROTEIN", 28, 31], ["actin", "PROTEIN", 49, 54], ["neurodegeneration", "PROBLEM", 140, 157], ["increasing velocity", "PROBLEM", 345, 364], ["neurodegeneration", "OBSERVATION", 140, 157], ["muscle", "ANATOMY", 181, 187], ["increasing", "OBSERVATION_MODIFIER", 345, 355], ["velocity", "OBSERVATION_MODIFIER", 356, 364]]], ["Thus, we state that Hill's formula is a mere sequence of the law of energy conservation.", [["Hill's formula", "TREATMENT", 20, 34]]], ["To derive a mathematical dependence \"force-velocity\", all the means of consumption of fuel energy should be determined -in our case, the energy of the ATP hydrolyze.", [["ATP", "CHEMICAL", 151, 154], ["ATP", "CHEMICAL", 151, 154], ["ATP", "SIMPLE_CHEMICAL", 151, 154], ["the ATP hydrolyze", "TREATMENT", 147, 164]]], ["We state that part of the energy release transforms into the energy of oscillations of myosin proteins; the other part goes into thermal energy of the sarcoplasmic solution.", [["sarcoplasmic", "ANATOMY", 151, 163], ["myosin", "GENE_OR_GENE_PRODUCT", 87, 93], ["sarcoplasmic", "CELLULAR_COMPONENT", 151, 163], ["myosin proteins", "PROTEIN", 87, 102], ["myosin proteins", "PROBLEM", 87, 102], ["the sarcoplasmic solution", "TREATMENT", 147, 172]]], ["Interaction of the oscillating myosin system with the sarcoplasmic solution controls the process of force generation by a muscle.", [["sarcoplasmic", "ANATOMY", 54, 66], ["muscle", "ANATOMY", 122, 128], ["myosin", "GENE_OR_GENE_PRODUCT", 31, 37], ["muscle", "ORGAN", 122, 128], ["the oscillating myosin system", "TREATMENT", 15, 44], ["the sarcoplasmic solution", "TREATMENT", 50, 75], ["muscle", "ANATOMY", 122, 128]]], ["A discussion and constructive critic is especially wanted.P-452-Biological motility and molecular motors - Meiotic nuclear oscillations in the fission yeast Schizosaccharomyces pombe are crucial for proper chromosome pairing and recombination.", [["nuclear", "ANATOMY", 115, 122], ["chromosome", "ANATOMY", 206, 216], ["P-452", "CHEMICAL", 58, 63], ["fission yeast Schizosaccharomyces pombe", "ORGANISM", 143, 182], ["chromosome", "CELLULAR_COMPONENT", 206, 216], ["yeast", "SPECIES", 151, 156], ["Schizosaccharomyces pombe", "SPECIES", 157, 182], ["yeast", "SPECIES", 151, 156], ["Schizosaccharomyces pombe", "SPECIES", 157, 182], ["P", "TEST", 58, 59], ["Meiotic nuclear oscillations", "PROBLEM", 107, 135], ["the fission yeast Schizosaccharomyces pombe", "TREATMENT", 139, 182], ["proper chromosome pairing", "TREATMENT", 199, 224], ["nuclear oscillations", "OBSERVATION", 115, 135], ["yeast Schizosaccharomyces pombe", "OBSERVATION", 151, 182]]], ["We report a mechanism of these oscillations based on collective behavior of dynein motors linking the cell cortex and dynamic microtubules that extend from the spindle pole body in opposite directions.", [["cell cortex", "ANATOMY", 102, 113], ["microtubules", "ANATOMY", 126, 138], ["spindle pole body", "ANATOMY", 160, 177], ["dynein", "GENE_OR_GENE_PRODUCT", 76, 82], ["cell cortex", "CELLULAR_COMPONENT", 102, 113], ["microtubules", "CELLULAR_COMPONENT", 126, 138], ["spindle pole body", "CELLULAR_COMPONENT", 160, 177], ["dynein motors", "PROTEIN", 76, 89], ["these oscillations", "PROBLEM", 25, 43], ["dynein motors", "OBSERVATION", 76, 89], ["cell cortex", "OBSERVATION", 102, 113], ["dynamic microtubules", "OBSERVATION", 118, 138], ["spindle", "ANATOMY_MODIFIER", 160, 167], ["pole", "ANATOMY_MODIFIER", 168, 172], ["body", "ANATOMY_MODIFIER", 173, 177], ["opposite", "ANATOMY_MODIFIER", 181, 189]]], ["By combining quantitative live cell imaging and laser ablation with a theoretical description, we show that dynein dynamically redistributes in the cell in response to load forces, resulting in more dynein attached to the leading than to the trailing microtubules.", [["cell", "ANATOMY", 31, 35], ["cell", "ANATOMY", 148, 152], ["microtubules", "ANATOMY", 251, 263], ["cell", "CELL", 31, 35], ["dynein", "GENE_OR_GENE_PRODUCT", 108, 114], ["cell", "CELL", 148, 152], ["dynein", "GENE_OR_GENE_PRODUCT", 199, 205], ["microtubules", "CELLULAR_COMPONENT", 251, 263], ["dynein", "PROTEIN", 108, 114], ["dynein", "PROTEIN", 199, 205], ["quantitative live cell imaging", "TEST", 13, 43], ["laser ablation", "TREATMENT", 48, 62], ["dynein dynamically redistributes", "PROBLEM", 108, 140], ["load forces", "TREATMENT", 168, 179], ["dynein dynamically", "OBSERVATION", 108, 126], ["redistributes", "OBSERVATION_MODIFIER", 127, 140], ["cell", "OBSERVATION", 148, 152], ["load forces", "OBSERVATION", 168, 179], ["more dynein", "OBSERVATION_MODIFIER", 194, 205]]], ["The redistribution of motors introduces an asymmetry of motor forces pulling in opposite directions, leading to the generation of oscillations.", [["the generation of oscillations", "PROBLEM", 112, 142], ["redistribution", "OBSERVATION_MODIFIER", 4, 18], ["motors", "OBSERVATION", 22, 28], ["asymmetry", "OBSERVATION_MODIFIER", 43, 52], ["motor forces", "OBSERVATION", 56, 68]]], ["Our work provides the first direct in vivo observation of self-organized dynamic dynein distributions, which, due to the intrinsic motor properties, generate regular large-scale movements in the cell (1 )Insights into endothelial cells mechanotransduction from microfluidicsM.", [["cell", "ANATOMY", 195, 199], ["endothelial cells", "ANATOMY", 218, 235], ["dynein", "GENE_OR_GENE_PRODUCT", 81, 87], ["cell", "CELL", 195, 199], ["endothelial cells", "CELL", 218, 235], ["dynein", "PROTEIN", 81, 87], ["endothelial cells", "CELL_TYPE", 218, 235], ["microfluidicsM", "PROBLEM", 261, 275], ["dynein distributions", "OBSERVATION", 81, 101], ["large", "OBSERVATION_MODIFIER", 166, 171], ["cell", "ANATOMY", 195, 199], ["endothelial cells", "ANATOMY", 218, 235]]], ["Versaevel, S. Gabriele, P. Damman University Mons-Hainaut, 7000 Mons, BelgiumInsights into endothelial cells mechanotransduction from microfluidicsThe remodeling of blood vessels in response to changes in blood flow is mainly realized by endothelial cells (ECs) that convert mechanical stimuli from flowing blood into changes in cell signaling through a process called mechanotransduction.", [["endothelial cells", "ANATOMY", 91, 108], ["blood vessels", "ANATOMY", 165, 178], ["blood", "ANATOMY", 205, 210], ["endothelial cells", "ANATOMY", 238, 255], ["ECs", "ANATOMY", 257, 260], ["blood", "ANATOMY", 307, 312], ["cell", "ANATOMY", 329, 333], ["endothelial cells", "CELL", 91, 108], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 165, 178], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["endothelial cells", "CELL", 238, 255], ["ECs", "CELL", 257, 260], ["blood", "ORGANISM_SUBSTANCE", 307, 312], ["cell", "CELL", 329, 333], ["endothelial cells", "CELL_TYPE", 91, 108], ["endothelial cells", "CELL_TYPE", 238, 255], ["ECs", "CELL_TYPE", 257, 260], ["blood flow", "TEST", 205, 215], ["mechanical stimuli", "TEST", 275, 293], ["flowing blood into changes in cell signaling", "PROBLEM", 299, 343], ["endothelial cells", "ANATOMY", 91, 108], ["blood vessels", "ANATOMY", 165, 178], ["blood flow", "OBSERVATION", 205, 215], ["endothelial cells", "OBSERVATION", 238, 255], ["mechanical stimuli", "OBSERVATION", 275, 293], ["cell signaling", "OBSERVATION", 329, 343]]], ["Many of the biological responses to external forces originate at two types of microscale structures: focal adhesions linking cells to their extracellular matrix and adherens junctions that link adjacent cells.", [["focal adhesions", "ANATOMY", 101, 116], ["cells", "ANATOMY", 125, 130], ["extracellular matrix", "ANATOMY", 140, 160], ["adherens junctions", "ANATOMY", 165, 183], ["cells", "ANATOMY", 203, 208], ["focal adhesions", "CELLULAR_COMPONENT", 101, 116], ["cells", "CELL", 125, 130], ["extracellular matrix", "CELLULAR_COMPONENT", 140, 160], ["adherens junctions", "CELLULAR_COMPONENT", 165, 183], ["cells", "CELL", 203, 208], ["adjacent cells", "CELL_TYPE", 194, 208], ["focal adhesions linking cells", "PROBLEM", 101, 130], ["focal", "OBSERVATION_MODIFIER", 101, 106], ["adhesions", "OBSERVATION", 107, 116], ["extracellular matrix", "OBSERVATION", 140, 160], ["adherens junctions", "OBSERVATION", 165, 183], ["adjacent cells", "OBSERVATION", 194, 208]]], ["This study aims to elucidate the role of the cytoskeleton, cell-matrix and cell-cell junctions in transducing fluid shear stress into intracellular signals in ECs.", [["cytoskeleton", "ANATOMY", 45, 57], ["cell", "ANATOMY", 59, 63], ["matrix", "ANATOMY", 64, 70], ["cell-cell junctions", "ANATOMY", 75, 94], ["fluid", "ANATOMY", 110, 115], ["intracellular", "ANATOMY", 134, 147], ["ECs", "ANATOMY", 159, 162], ["cytoskeleton", "CELLULAR_COMPONENT", 45, 57], ["cell-matrix", "CELLULAR_COMPONENT", 59, 70], ["cell-cell junctions", "CELLULAR_COMPONENT", 75, 94], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 147], ["ECs", "CELL", 159, 162], ["ECs", "CELL_TYPE", 159, 162], ["This study", "TEST", 0, 10], ["cell-cell junctions", "TREATMENT", 75, 94], ["transducing fluid shear stress", "TEST", 98, 128], ["cell junctions", "OBSERVATION", 80, 94], ["fluid shear", "OBSERVATION", 110, 121]]], ["By using microcontact printing of proteins, we design substrates with defined adhesive islands in order to control shapes of living cells.", [["cells", "ANATOMY", 132, 137], ["cells", "CELL", 132, 137], ["living cells", "CELL_TYPE", 125, 137], ["microcontact printing of proteins", "TREATMENT", 9, 42], ["defined adhesive islands", "TREATMENT", 70, 94], ["living cells", "OBSERVATION", 125, 137]]], ["This confinement of ECs allows to study the organization and the contractile activity of the cytoskeleton in order to redistribute their intracellular forces in response to externally applied forces.", [["ECs", "ANATOMY", 20, 23], ["cytoskeleton", "ANATOMY", 93, 105], ["intracellular", "ANATOMY", 137, 150], ["ECs", "CELL", 20, 23], ["cytoskeleton", "CELLULAR_COMPONENT", 93, 105], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 137, 150], ["ECs", "CELL_TYPE", 20, 23], ["contractile activity", "OBSERVATION", 65, 85], ["intracellular forces", "OBSERVATION", 137, 157]]], ["We design microfluidic channels with sizes and geometries close to small blood vessels to apply a physiological range of shear stresses on ECs.", [["blood vessels", "ANATOMY", 73, 86], ["ECs", "ANATOMY", 139, 142], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 73, 86], ["ECs", "CELL", 139, 142], ["ECs", "CELL_TYPE", 139, 142], ["microfluidic channels with sizes and geometries", "TREATMENT", 10, 57], ["small blood vessels", "PROBLEM", 67, 86], ["microfluidic channels", "OBSERVATION", 10, 31], ["sizes", "OBSERVATION_MODIFIER", 37, 42], ["small", "OBSERVATION_MODIFIER", 67, 72], ["blood vessels", "OBSERVATION", 73, 86]]], ["Our results indicate that cells deposited on a precisely defined adhesive area inside microchannels and subjected to shear stress reorganize their cytoskeleton, their focal adhesions and adherens junctions in response to blood flow.", [["cells", "ANATOMY", 26, 31], ["cytoskeleton", "ANATOMY", 147, 159], ["focal adhesions", "ANATOMY", 167, 182], ["adherens junctions", "ANATOMY", 187, 205], ["blood", "ANATOMY", 221, 226], ["cells", "CELL", 26, 31], ["cytoskeleton", "CELLULAR_COMPONENT", 147, 159], ["focal adhesions", "CELLULAR_COMPONENT", 167, 182], ["adherens junctions", "CELLULAR_COMPONENT", 187, 205], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["cells deposited", "PROBLEM", 26, 41], ["their focal adhesions", "PROBLEM", 161, 182], ["blood flow", "TEST", 221, 231], ["cells deposited", "OBSERVATION", 26, 41], ["adhesive", "OBSERVATION_MODIFIER", 65, 73], ["area", "OBSERVATION_MODIFIER", 74, 78], ["microchannels", "OBSERVATION_MODIFIER", 86, 99], ["shear stress", "OBSERVATION", 117, 129], ["cytoskeleton", "OBSERVATION_MODIFIER", 147, 159], ["focal", "OBSERVATION_MODIFIER", 167, 172], ["adhesions", "OBSERVATION", 173, 182], ["adherens junctions", "OBSERVATION", 187, 205], ["blood flow", "OBSERVATION", 221, 231]]], ["Drugs interfering with the cytoskeleton are used to underline the role of its different components in the cellular adaptation to the mechanical environment.Gating modifiers of voltage-gated sodium channels as a novel strategy for multiple sclerosis treatmentS.", [["cytoskeleton", "ANATOMY", 27, 39], ["cellular", "ANATOMY", 106, 114], ["sodium", "CHEMICAL", 190, 196], ["multiple sclerosis", "DISEASE", 230, 248], ["sodium", "CHEMICAL", 190, 196], ["cytoskeleton", "CELLULAR_COMPONENT", 27, 39], ["cellular", "CELL", 106, 114], ["sodium", "SIMPLE_CHEMICAL", 190, 196], ["voltage-gated sodium channels", "PROTEIN", 176, 205], ["Drugs", "TREATMENT", 0, 5], ["voltage", "TEST", 176, 183], ["gated sodium channels", "TREATMENT", 184, 205], ["a novel strategy", "TREATMENT", 209, 225], ["multiple sclerosis treatmentS", "TREATMENT", 230, 259], ["mechanical environment", "OBSERVATION", 133, 155], ["sclerosis", "OBSERVATION", 239, 248]]], ["Mahdavi 1 , B. Ranjbar 1 , S. Gharibzadeh 2 , M. Toosi 2 , M. Javan 1 1 Tarbiat Modares University, Tehran, Iran, 2 Amirkabir University of Technology, Tehran, Iran Multiple sclerosis (MS) is the main known pathology of myelinating cells.", [["myelinating cells", "ANATOMY", 220, 237], ["Multiple sclerosis", "DISEASE", 165, 183], ["MS", "DISEASE", 185, 187], ["myelinating cells", "CELL", 220, 237], ["myelinating cells", "CELL_TYPE", 220, 237], ["Mahdavi", "TREATMENT", 0, 7], ["Javan", "TREATMENT", 62, 67], ["Multiple sclerosis (MS)", "PROBLEM", 165, 188], ["myelinating cells", "PROBLEM", 220, 237], ["Multiple", "OBSERVATION_MODIFIER", 165, 173], ["sclerosis", "OBSERVATION", 174, 183], ["pathology", "OBSERVATION", 207, 216], ["myelinating cells", "OBSERVATION", 220, 237]]], ["An autoimmune reaction occurs against myelin sheets of neurons, so action potential (AP) propagation along the affected nerve fibers has been destroyed and it causes various disorders.", [["myelin sheets", "ANATOMY", 38, 51], ["neurons", "ANATOMY", 55, 62], ["nerve fibers", "ANATOMY", 120, 132], ["autoimmune reaction", "DISEASE", 3, 22], ["neurons", "CELL", 55, 62], ["nerve fibers", "TISSUE", 120, 132], ["An autoimmune reaction", "PROBLEM", 0, 22], ["myelin sheets of neurons", "PROBLEM", 38, 62], ["the affected nerve fibers", "PROBLEM", 107, 132], ["various disorders", "PROBLEM", 166, 183], ["autoimmune", "OBSERVATION", 3, 13], ["neurons", "ANATOMY", 55, 62], ["affected nerve", "ANATOMY", 111, 125]]], ["Here, we propose a novel strategy for MS symptoms treatment.", [["a novel strategy", "TREATMENT", 17, 33], ["MS symptoms treatment", "TREATMENT", 38, 59]]], ["We modeled neuron by ORCAD software and simulated the action potential propagation along the axon in normal condition.", [["neuron", "ANATOMY", 11, 17], ["axon", "ANATOMY", 93, 97], ["neuron", "CELL", 11, 17], ["axon", "MULTI-TISSUE_STRUCTURE", 93, 97], ["normal condition", "OBSERVATION", 101, 117]]], ["Our model simulated normal neuronal behavior.", [["neuronal", "ANATOMY", 27, 35], ["neuronal", "CELL", 27, 35], ["normal neuronal behavior", "OBSERVATION", 20, 44]]], ["Then we destroyed the myelin sheet as it occurs in MS and observed destroyed AP propagation as it was reported in MS disease.", [["myelin sheet", "ANATOMY", 22, 34], ["MS", "DISEASE", 51, 53], ["MS disease", "DISEASE", 114, 124], ["myelin", "CELLULAR_COMPONENT", 22, 28], ["MS disease", "CANCER", 114, 124], ["the myelin sheet", "TREATMENT", 18, 34], ["MS", "PROBLEM", 51, 53], ["MS disease", "PROBLEM", 114, 124]]], ["We investigated the effect of changes in the voltage-gated sodium channel (VGSC) threshold on the efficiency of AP propagation.", [["sodium", "CHEMICAL", 59, 65], ["sodium", "CHEMICAL", 59, 65], ["sodium channel", "SIMPLE_CHEMICAL", 59, 73], ["AP", "GENE_OR_GENE_PRODUCT", 112, 114], ["voltage-gated sodium channel", "PROTEIN", 45, 73], ["VGSC", "PROTEIN", 75, 79], ["the voltage", "TEST", 41, 52], ["AP propagation", "TREATMENT", 112, 126]]], ["The results demonstrated that reduction of VGSC threshold improves the propagation of AP by increasing the amount of sodium flux during AP propagation.", [["sodium", "CHEMICAL", 117, 123], ["sodium", "CHEMICAL", 117, 123], ["VGSC", "GENE_OR_GENE_PRODUCT", 43, 47], ["AP", "GENE_OR_GENE_PRODUCT", 86, 88], ["sodium", "SIMPLE_CHEMICAL", 117, 123], ["AP", "SIMPLE_CHEMICAL", 136, 138], ["VGSC", "PROTEIN", 43, 47], ["reduction of VGSC threshold", "PROBLEM", 30, 57], ["sodium flux", "PROBLEM", 117, 128], ["AP propagation", "TREATMENT", 136, 150], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["amount", "OBSERVATION_MODIFIER", 107, 113], ["sodium flux", "OBSERVATION", 117, 128]]], ["Although, some researches have proposed VGSC blocker as MS symptom treatment, our result suggests that the increase of sodium current produced by reduction of VGSC threshold, improves AP propagation and probably cure some MS symptoms.", [["sodium", "CHEMICAL", 119, 125], ["MS", "DISEASE", 222, 224], ["sodium", "CHEMICAL", 119, 125], ["VGSC blocker", "GENE_OR_GENE_PRODUCT", 40, 52], ["sodium", "SIMPLE_CHEMICAL", 119, 125], ["VGSC", "GENE_OR_GENE_PRODUCT", 159, 163], ["VGSC", "PROTEIN", 159, 163], ["VGSC blocker", "TREATMENT", 40, 52], ["MS symptom treatment", "TREATMENT", 56, 76], ["the increase of sodium", "PROBLEM", 103, 125], ["VGSC threshold", "PROBLEM", 159, 173], ["AP propagation", "TEST", 184, 198], ["some MS symptoms", "PROBLEM", 217, 233], ["increase", "OBSERVATION_MODIFIER", 107, 115]]], ["So, we suggest that VGSC gating modifiers can be considered as novel strategy for MS treatment.", [["MS", "DISEASE", 82, 84], ["VGSC", "GENE_OR_GENE_PRODUCT", 20, 24], ["VGSC gating modifiers", "TREATMENT", 20, 41], ["MS treatment", "TREATMENT", 82, 94]]], ["Surely, this results needs to be confirmed by experimental studies.Separate allosteric binding sites for extracellular calcium ions and protons in human CLC-K channelsA.", [["extracellular", "ANATOMY", 105, 118], ["calcium", "CHEMICAL", 119, 126], ["CLC-K", "CHEMICAL", 153, 158], ["calcium", "CHEMICAL", 119, 126], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 118], ["calcium ions", "SIMPLE_CHEMICAL", 119, 131], ["protons", "SIMPLE_CHEMICAL", 136, 143], ["human", "ORGANISM", 147, 152], ["CLC-K channelsA", "GENE_OR_GENE_PRODUCT", 153, 168], ["allosteric binding sites", "PROTEIN", 76, 100], ["human CLC-K channelsA", "PROTEIN", 147, 168], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["experimental studies", "TEST", 46, 66], ["Separate allosteric binding sites", "PROBLEM", 67, 100], ["extracellular calcium ions", "TREATMENT", 105, 131], ["allosteric binding", "OBSERVATION", 76, 94], ["calcium ions", "OBSERVATION", 119, 131]]], ["Gradogna, E. Babini, A. Picollo, M. Pusch Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Via de Marini 6, 16149 Genova, Italy CLC-Ka and CLC-Kb are highly homologous Cl \u2212 channels expressed in the kidney and the inner ear where they mediate transepithelial chloride transport.", [["kidney", "ANATOMY", 209, 215], ["inner ear", "ANATOMY", 224, 233], ["transepithelial", "ANATOMY", 253, 268], ["Cl", "CHEMICAL", 178, 180], ["chloride", "CHEMICAL", 269, 277], ["Cl", "CHEMICAL", 178, 180], ["chloride", "CHEMICAL", 269, 277], ["CLC-Kb", "GENE_OR_GENE_PRODUCT", 149, 155], ["Cl \u2212", "GENE_OR_GENE_PRODUCT", 178, 182], ["kidney", "ORGAN", 209, 215], ["inner", "ORGAN", 224, 229], ["ear", "ORGAN", 230, 233], ["transepithelial", "IMMATERIAL_ANATOMICAL_ENTITY", 253, 268], ["chloride", "SIMPLE_CHEMICAL", 269, 277], ["Cl \u2212 channels", "PROTEIN", 178, 191], ["transepithelial chloride transport", "TREATMENT", 253, 287], ["kidney", "ANATOMY", 209, 215], ["inner ear", "ANATOMY", 224, 233], ["transepithelial chloride", "OBSERVATION", 253, 277]]], ["Both channels heteromerize with the beta subunit barttin.", [["beta subunit barttin", "GENE_OR_GENE_PRODUCT", 36, 56], ["beta subunit barttin", "PROTEIN", 36, 56], ["the beta subunit barttin", "TREATMENT", 32, 56]]], ["Mutations in CLC-Kb and barttin genes lead to Bartter's syndrome.", [["Bartter's syndrome", "DISEASE", 46, 64], ["CLC-Kb", "GENE_OR_GENE_PRODUCT", 13, 19], ["barttin", "GENE_OR_GENE_PRODUCT", 24, 31], ["CLC-Kb and barttin genes", "DNA", 13, 37], ["Mutations in CLC", "PROBLEM", 0, 16], ["Kb and barttin genes", "TREATMENT", 17, 37], ["Bartter's syndrome", "PROBLEM", 46, 64]]], ["We analyzed the modulatory effect of extracellular Ca 2+ and H + on CLC-K channels using the Xenopus oocyte expression system.", [["extracellular", "ANATOMY", 37, 50], ["oocyte", "ANATOMY", 101, 107], ["Ca", "CHEMICAL", 51, 53], ["H", "CHEMICAL", 61, 62], ["Ca 2+", "CHEMICAL", 51, 56], ["H +", "CHEMICAL", 61, 64], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["Ca 2+", "SIMPLE_CHEMICAL", 51, 56], ["H +", "SIMPLE_CHEMICAL", 61, 64], ["CLC-K", "GENE_OR_GENE_PRODUCT", 68, 73], ["Xenopus", "ORGANISM", 93, 100], ["oocyte", "MULTI-TISSUE_STRUCTURE", 101, 107], ["CLC-K channels", "PROTEIN", 68, 82], ["extracellular Ca", "TEST", 37, 53], ["CLC", "TEST", 68, 71], ["K channels", "TREATMENT", 72, 82], ["the Xenopus oocyte expression system", "TREATMENT", 89, 125], ["Ca", "OBSERVATION", 51, 53], ["Xenopus oocyte", "OBSERVATION", 93, 107]]], ["CLC-Ka currents increased with increasing [Ca 2+ ] ext without full saturation for [Ca 2+ ] ext up to 50 mM.", [["Ca", "CHEMICAL", 43, 45], ["Ca", "CHEMICAL", 84, 86], ["Ca 2+ ]", "CHEMICAL", 43, 50], ["Ca 2+ ]", "CHEMICAL", 84, 91], ["[Ca 2+ ] ext", "SIMPLE_CHEMICAL", 83, 95], ["Ca", "TEST", 43, 45], ["full saturation", "TEST", 63, 78], ["Ca", "TEST", 84, 86], ["ext", "ANATOMY", 92, 95], ["50 mM", "OBSERVATION_MODIFIER", 102, 107]]], ["However, in the virtual absence of Ca 2+ , CLC-Ka currents are about 18 % of currents measured in 10 mM [Ca 2+ ] ext , demonstrating that Ca 2+ is not strictly essential for opening.", [["Ca", "CHEMICAL", 35, 37], ["Ca", "CHEMICAL", 105, 107], ["Ca", "CHEMICAL", 138, 140], ["Ca 2+", "CHEMICAL", 35, 40], ["Ca 2+ ]", "CHEMICAL", 105, 112], ["Ca 2+", "CHEMICAL", 138, 143], ["Ca 2+", "SIMPLE_CHEMICAL", 35, 40], ["CLC-Ka", "SIMPLE_CHEMICAL", 43, 49], ["Ca 2+", "SIMPLE_CHEMICAL", 138, 143], ["CLC", "PROTEIN", 43, 46], ["Ca", "TEST", 35, 37], ["CLC", "TEST", 43, 46], ["Ka currents", "TEST", 47, 58], ["currents", "TEST", 77, 85], ["Ca", "TEST", 105, 107], ["Ca", "TEST", 138, 140], ["ext", "ANATOMY", 113, 116]]], ["Vice versa, CLC-Ka was blocked by increasing the [H] + ext with an almost complete block at pH 6.", [["H", "CHEMICAL", 50, 51], ["H", "CHEMICAL", 50, 51], ["CLC-Ka", "SIMPLE_CHEMICAL", 12, 18], ["ext", "ANATOMY", 55, 58]]], ["Among various reaction models tested, the model that best fitted all state-steady data predicts an allosteric regulation of channel opening by separate binding sites for Ca 2+ and H + .", [["Ca", "CHEMICAL", 170, 172], ["H", "CHEMICAL", 180, 181], ["Ca 2+", "CHEMICAL", 170, 175], ["H +", "CHEMICAL", 180, 183], ["Ca 2+", "SIMPLE_CHEMICAL", 170, 175], ["H +", "SIMPLE_CHEMICAL", 180, 183], ["Ca", "TEST", 170, 172]]], ["Moreover, the best fit suggests that one Ca 2+ and two H + bind to the channel.", [["Ca", "CHEMICAL", 41, 43], ["H", "CHEMICAL", 55, 56], ["Ca 2+", "CHEMICAL", 41, 46], ["H +", "CHEMICAL", 55, 58], ["Ca 2+", "SIMPLE_CHEMICAL", 41, 46], ["H +", "SIMPLE_CHEMICAL", 55, 58], ["Ca", "TEST", 41, 43]]], ["Kinetic analysis of current responses upon [Ca 2+ ] ext and pH jumps confirmed the allosteric character of modulation.", [["Ca", "CHEMICAL", 44, 46], ["Ca 2+ ]", "CHEMICAL", 44, 51], ["Kinetic analysis", "TEST", 0, 16], ["Ca", "TEST", 44, 46], ["pH jumps", "TEST", 60, 68], ["ext", "ANATOMY", 52, 55], ["allosteric character", "OBSERVATION", 83, 103], ["modulation", "OBSERVATION", 107, 117]]], ["In support of the presence of two separate binding sites we identified several mutations that selectively altered Ca 2+ or H + sensitivity.", [["Ca", "CHEMICAL", 114, 116], ["H", "CHEMICAL", 123, 124], ["Ca 2+", "CHEMICAL", 114, 119], ["H +", "CHEMICAL", 123, 126], ["Ca 2+", "SIMPLE_CHEMICAL", 114, 119], ["H +", "SIMPLE_CHEMICAL", 123, 126], ["two separate binding sites", "PROBLEM", 30, 56], ["several mutations", "PROBLEM", 71, 88]]], ["Our data represent a first step towards a molecular picture of Ca 2+ and proton regulation of CLC-K channels and suggest that it is of physiological relevance.P-460The extracellular matrix molecule hyaluronic acid modulates L-type voltage-dependent Ca2+ channels E. Dvoretskova 1 , G. Kochlamazashvili 2 , O. Bukalo 2 , C. Henneberger 3 , D. Rusakov 3 , M. Schachner 2 , A. Dityatev 1 1 Italian Institute of Technology, Genova, Italy, 2 Centre for Molecular Neurobiology, Hamburg, Germany, 3 Institute of Neurology, University College London, London, UK We studied the effects of hyaluronic acid (HA), a major extracellular matrix molecule, on activity of L-VDCCs in a heterologous expression system and in hippocampal slices.", [["extracellular", "ANATOMY", 168, 181], ["extracellular matrix", "ANATOMY", 610, 630], ["L-VDCCs", "ANATOMY", 656, 663], ["hippocampal slices", "ANATOMY", 707, 725], ["Ca", "CHEMICAL", 63, 65], ["P-460", "CHEMICAL", 159, 164], ["hyaluronic acid", "CHEMICAL", 198, 213], ["Ca2", "CHEMICAL", 249, 252], ["hyaluronic acid", "CHEMICAL", 580, 595], ["HA", "CHEMICAL", 597, 599], ["Ca 2+", "CHEMICAL", 63, 68], ["Ca2+", "CHEMICAL", 249, 253], ["Ca 2+", "SIMPLE_CHEMICAL", 63, 68], ["proton", "SIMPLE_CHEMICAL", 73, 79], ["CLC-K", "GENE_OR_GENE_PRODUCT", 94, 99], ["extracellular matrix", "CELLULAR_COMPONENT", 168, 188], ["hyaluronic acid", "SIMPLE_CHEMICAL", 198, 213], ["Ca2+", "SIMPLE_CHEMICAL", 249, 253], ["hyaluronic acid", "SIMPLE_CHEMICAL", 580, 595], ["HA", "SIMPLE_CHEMICAL", 597, 599], ["extracellular matrix", "CELLULAR_COMPONENT", 610, 630], ["L-VDCCs", "GENE_OR_GENE_PRODUCT", 656, 663], ["hippocampal slices", "MULTI-TISSUE_STRUCTURE", 707, 725], ["CLC-K channels", "PROTEIN", 94, 108], ["Ca2", "PROTEIN", 249, 252], ["L-VDCCs", "PROTEIN", 656, 663], ["Our data", "TEST", 0, 8], ["Ca", "TEST", 63, 65], ["P", "TEST", 159, 160], ["The extracellular matrix molecule hyaluronic acid modulates", "TEST", 164, 223], ["channels E. Dvoretskova", "TREATMENT", 254, 277], ["Kochlamazashvili", "TREATMENT", 285, 301], ["hyaluronic acid (HA", "TREATMENT", 580, 599], ["a major extracellular matrix molecule", "TREATMENT", 602, 639], ["activity of L-VDCCs", "TREATMENT", 644, 663], ["hyaluronic acid", "OBSERVATION", 198, 213], ["matrix molecule", "OBSERVATION", 624, 639], ["hippocampal", "ANATOMY", 707, 718]]], ["We recorded currents mediated by a major neuronal subtype of L-VDCCs (Ca v 1.2C, \u03b2 1 b, and \u03b1 2 \u03b4 1 ) expressed in CHO cells.", [["neuronal", "ANATOMY", 41, 49], ["L-VDCCs", "ANATOMY", 61, 68], ["CHO cells", "ANATOMY", 115, 124], ["Ca", "CHEMICAL", 70, 72], ["neuronal", "CELL", 41, 49], ["L-VDCCs", "CELL", 61, 68], ["Ca v 1.2C", "GENE_OR_GENE_PRODUCT", 70, 79], ["\u03b2 1 b", "GENE_OR_GENE_PRODUCT", 81, 86], ["\u03b1 2 \u03b4 1", "GENE_OR_GENE_PRODUCT", 92, 99], ["CHO cells", "CELL", 115, 124], ["L-VDCCs", "PROTEIN", 61, 68], ["Ca v 1.2C, \u03b2 1 b", "CELL_LINE", 70, 86], ["\u03b1 2 \u03b4 1", "CELL_LINE", 92, 99], ["CHO cells", "CELL_LINE", 115, 124], ["Ca v", "TEST", 70, 74], ["CHO cells", "OBSERVATION", 115, 124]]], ["A five-minute application of 0.1 mg/ml HA potentiated L-VDCC currents at -20, -10, 0 and +10 mV by approximately 50%.", [["L-VDCC", "ANATOMY", 54, 60], ["HA", "SIMPLE_CHEMICAL", 39, 41], ["L-VDCC", "SIMPLE_CHEMICAL", 54, 60], ["A five-minute application", "TREATMENT", 0, 25], ["L-VDCC currents", "TEST", 54, 69]]], ["Analysis of Boltzmann curves showed that HA increased maximal conductance rather than other parameters (V 0.5 or k ).", [["HA", "SIMPLE_CHEMICAL", 41, 43], ["Analysis of Boltzmann curves", "TEST", 0, 28], ["HA increased maximal conductance", "PROBLEM", 41, 73], ["maximal conductance", "OBSERVATION", 54, 73]]], ["Treatment with hyaluronidase removed endogenous HA in murine hippocampal slices and specifically impaired long-term potentiation (LTP) induced at CA3-CA1 synapses by repetitive theta-burst stimulation.", [["hippocampal slices", "ANATOMY", 61, 79], ["CA3-CA1 synapses", "ANATOMY", 146, 162], ["hyaluronidase", "GENE_OR_GENE_PRODUCT", 15, 28], ["HA", "GENE_OR_GENE_PRODUCT", 48, 50], ["murine", "ORGANISM", 54, 60], ["hippocampal slices", "MULTI-TISSUE_STRUCTURE", 61, 79], ["CA3-CA1 synapses", "CELL", 146, 162], ["theta-burst", "GENE_OR_GENE_PRODUCT", 177, 188], ["theta", "PROTEIN", 177, 182], ["murine", "SPECIES", 54, 60], ["hyaluronidase", "TREATMENT", 15, 28], ["endogenous HA", "PROBLEM", 37, 50], ["murine hippocampal slices", "TREATMENT", 54, 79], ["impaired long-term potentiation", "PROBLEM", 97, 128], ["impaired", "OBSERVATION_MODIFIER", 97, 105], ["long-term potentiation", "OBSERVATION_MODIFIER", 106, 128]]], ["Blockade of L-VDCCs reduced LTP in control slices to the levels seen after hyaluronidase treatment.", [["L-VDCCs", "ANATOMY", 12, 19], ["slices", "ANATOMY", 43, 49], ["hyaluronidase", "CHEMICAL", 75, 88], ["L-VDCCs", "GENE_OR_GENE_PRODUCT", 12, 19], ["hyaluronidase", "SIMPLE_CHEMICAL", 75, 88], ["L-VDCCs", "PROTEIN", 12, 19], ["Blockade of L-VDCCs reduced LTP", "TREATMENT", 0, 31], ["hyaluronidase treatment", "TREATMENT", 75, 98], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["LTP", "OBSERVATION_MODIFIER", 28, 31]]], ["A potentiation of L-VDCCs with Bay K 8644 fully restored LTP after hyaluronidase treatment.", [["Bay K 8644", "CHEMICAL", 31, 41], ["hyaluronidase", "CHEMICAL", 67, 80], ["Bay K 8644", "CHEMICAL", 31, 41], ["L-VDCCs", "SIMPLE_CHEMICAL", 18, 25], ["Bay K 8644", "SIMPLE_CHEMICAL", 31, 41], ["hyaluronidase", "SIMPLE_CHEMICAL", 67, 80], ["hyaluronidase treatment", "TREATMENT", 67, 90]]], ["Removal of HA reduced Ca 2+ transients elicited by backpropagating action potentials in individual dendritic shafts and spines of CA1 pyramidal cells, whereas pretreatment with nifedipine fully occluded this effect.", [["dendritic shafts", "ANATOMY", 99, 115], ["spines", "ANATOMY", 120, 126], ["CA1 pyramidal cells", "ANATOMY", 130, 149], ["Ca", "CHEMICAL", 22, 24], ["nifedipine", "CHEMICAL", 177, 187], ["Ca 2+", "CHEMICAL", 22, 27], ["nifedipine", "CHEMICAL", 177, 187], ["Ca 2+", "SIMPLE_CHEMICAL", 22, 27], ["dendritic shafts", "MULTI-TISSUE_STRUCTURE", 99, 115], ["spines", "CELL", 120, 126], ["CA1 pyramidal cells", "CELL", 130, 149], ["nifedipine", "SIMPLE_CHEMICAL", 177, 187], ["CA1 pyramidal cells", "CELL_TYPE", 130, 149], ["Removal", "TREATMENT", 0, 7], ["HA reduced Ca", "PROBLEM", 11, 24], ["CA1 pyramidal cells", "PROBLEM", 130, 149], ["nifedipine", "TREATMENT", 177, 187], ["HA", "OBSERVATION_MODIFIER", 11, 13], ["reduced", "OBSERVATION_MODIFIER", 14, 21], ["Ca", "OBSERVATION", 22, 24], ["dendritic shafts", "OBSERVATION", 99, 115], ["spines", "ANATOMY", 120, 126], ["CA1 pyramidal", "ANATOMY", 130, 143], ["occluded", "OBSERVATION", 194, 202]]], ["Thus, HA potentiates postsynaptic L-VDCCs and by this way influences use-dependent synaptic plasticity.M. B. A. Djamgoz Imperial College London, UKWhole-cell patch clamp recordings from a variety of human cancer cells showed that functional voltage-gated sodium channel (VGSC) expression occurred specifically with strongly metastatic cells.", [["postsynaptic L-VDCCs", "ANATOMY", 21, 41], ["synaptic", "ANATOMY", 83, 91], ["UKWhole-cell", "ANATOMY", 145, 157], ["cancer cells", "ANATOMY", 205, 217], ["metastatic cells", "ANATOMY", 324, 340], ["HA", "CHEMICAL", 6, 8], ["cancer", "DISEASE", 205, 211], ["sodium", "CHEMICAL", 255, 261], ["sodium", "CHEMICAL", 255, 261], ["HA", "GENE_OR_GENE_PRODUCT", 6, 8], ["synaptic", "MULTI-TISSUE_STRUCTURE", 83, 91], ["UKWhole-cell", "CELL", 145, 157], ["human", "ORGANISM", 199, 204], ["cancer cells", "CELL", 205, 217], ["voltage-gated sodium channel", "GENE_OR_GENE_PRODUCT", 241, 269], ["VGSC", "GENE_OR_GENE_PRODUCT", 271, 275], ["cells", "CELL", 335, 340], ["postsynaptic L-VDCCs", "CELL_TYPE", 21, 41], ["human cancer cells", "CELL_TYPE", 199, 217], ["voltage-gated sodium channel", "PROTEIN", 241, 269], ["VGSC", "PROTEIN", 271, 275], ["metastatic cells", "CELL_TYPE", 324, 340], ["M. B.", "SPECIES", 103, 108], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["HA", "PROBLEM", 6, 8], ["postsynaptic L-VDCCs", "PROBLEM", 21, 41], ["dependent synaptic plasticity", "PROBLEM", 73, 102], ["UKWhole-cell patch clamp recordings", "TREATMENT", 145, 180], ["human cancer cells", "PROBLEM", 199, 217], ["functional voltage", "TEST", 230, 248], ["gated sodium channel (VGSC) expression", "PROBLEM", 249, 287], ["strongly metastatic cells", "PROBLEM", 315, 340], ["synaptic plasticity", "OBSERVATION", 83, 102], ["metastatic cells", "OBSERVATION", 324, 340]]], ["In addition, where studied, this was accompanied by down-regulation of outward (mainly potassium) currents.", [["potassium", "CHEMICAL", 87, 96], ["potassium", "CHEMICAL", 87, 96], ["potassium", "SIMPLE_CHEMICAL", 87, 96]]], ["This has led to the CELEX (\"cellular excitability\") hypothesis of cancer according to which metastatic cell membranes are excitable and this promotes their hyperactivity.", [["cellular", "ANATOMY", 28, 36], ["cancer", "ANATOMY", 66, 72], ["metastatic cell membranes", "ANATOMY", 92, 117], ["cancer", "DISEASE", 66, 72], ["hyperactivity", "DISEASE", 156, 169], ["cellular", "CELL", 28, 36], ["cancer", "CANCER", 66, 72], ["cell membranes", "CELL", 103, 117], ["hypothesis of cancer", "PROBLEM", 52, 72], ["metastatic cell membranes", "PROBLEM", 92, 117], ["their hyperactivity", "PROBLEM", 150, 169], ["cancer", "OBSERVATION", 66, 72], ["metastatic cell membranes", "OBSERVATION", 92, 117], ["hyperactivity", "OBSERVATION", 156, 169]]], ["Importantly, the VGSC genes expressed are embryonic splice variants, which are normally developmentally regulated, hence the phenomenon is 'oncofetal'.", [["embryonic", "ANATOMY", 42, 51], ["VGSC", "GENE_OR_GENE_PRODUCT", 17, 21], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 42, 51], ["oncofetal", "GENE_OR_GENE_PRODUCT", 140, 149], ["VGSC genes", "DNA", 17, 27], ["embryonic splice variants", "PROBLEM", 42, 67], ["VGSC", "ANATOMY", 17, 21], ["embryonic splice variants", "OBSERVATION", 42, 67]]], ["In breast cancer, where the predominant VGSC is Nav1.5 the neonatal and adult forms are significantly different and this is reflected in channel activity whereby the neonatal VGSC has much slower inactivation kinetics.", [["breast cancer", "ANATOMY", 3, 16], ["breast cancer", "DISEASE", 3, 16], ["breast cancer", "CANCER", 3, 16], ["VGSC", "GENE_OR_GENE_PRODUCT", 40, 44], ["Nav1.5", "GENE_OR_GENE_PRODUCT", 48, 54], ["VGSC", "GENE_OR_GENE_PRODUCT", 175, 179], ["VGSC", "PROTEIN", 40, 44], ["Nav1.5", "PROTEIN", 48, 54], ["neonatal VGSC", "PROTEIN", 166, 179], ["breast cancer", "PROBLEM", 3, 16], ["much slower inactivation kinetics", "PROBLEM", 184, 217], ["breast", "ANATOMY", 3, 9], ["cancer", "OBSERVATION", 10, 16], ["predominant", "OBSERVATION_MODIFIER", 28, 39], ["VGSC", "OBSERVATION", 40, 44], ["Nav1.5", "OBSERVATION", 48, 54], ["significantly different", "OBSERVATION_MODIFIER", 88, 111]]], ["The double-charge change at position 211 is critical for this difference.", [["The double-charge change at position", "TREATMENT", 0, 36]]], ["The slow kinetics results in much greater influx of Na + into cells and one consequence of this is activation of protein kinase A. This is a tonic effect and, under steady-state resting conditions, it results in a positive feedback effect promoting post-translational trafficking of VGSC protein to plasma membrane.", [["cells", "ANATOMY", 62, 67], ["plasma membrane", "ANATOMY", 299, 314], ["Na", "CHEMICAL", 52, 54], ["Na +", "CHEMICAL", 52, 56], ["Na +", "SIMPLE_CHEMICAL", 52, 56], ["cells", "CELL", 62, 67], ["protein kinase A.", "GENE_OR_GENE_PRODUCT", 113, 130], ["VGSC", "GENE_OR_GENE_PRODUCT", 283, 287], ["plasma membrane", "CELLULAR_COMPONENT", 299, 314], ["protein kinase A.", "PROTEIN", 113, 130], ["VGSC protein", "PROTEIN", 283, 295], ["The slow kinetics", "PROBLEM", 0, 17], ["protein kinase A.", "PROBLEM", 113, 130], ["a tonic effect", "PROBLEM", 139, 153], ["a positive feedback effect", "PROBLEM", 212, 238]]], ["The unique amino acid sequence of the spliced region has enabled the production of a polyclonal blocking antibody specific to neonatal Nav1.5.", [["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "AMINO_ACID", 11, 21], ["Nav1.5", "GENE_OR_GENE_PRODUCT", 135, 141], ["polyclonal blocking antibody", "PROTEIN", 85, 113], ["neonatal Nav1.5", "PROTEIN", 126, 141], ["The unique amino acid sequence", "TREATMENT", 0, 30], ["a polyclonal blocking antibody", "TREATMENT", 83, 113], ["neonatal Nav1.5", "PROBLEM", 126, 141], ["amino acid", "OBSERVATION", 11, 21]]], ["It is concluded that VGSCs represent novel biophysical targets for clinical management of metastatic disease.Mechanisms of transport coupling in CLC Cl \u2212 /H + antiporters involved in human genetic diseasesM.", [["VGSCs", "ANATOMY", 21, 26], ["metastatic disease", "ANATOMY", 90, 108], ["Cl", "CHEMICAL", 149, 151], ["H", "CHEMICAL", 155, 156], ["Cl", "CHEMICAL", 149, 151], ["H +", "CHEMICAL", 155, 158], ["VGSCs", "CELL", 21, 26], ["metastatic disease", "CANCER", 90, 108], ["CLC Cl \u2212", "SIMPLE_CHEMICAL", 145, 153], ["H +", "SIMPLE_CHEMICAL", 155, 158], ["human", "ORGANISM", 183, 188], ["VGSCs", "CELL_TYPE", 21, 26], ["CLC Cl \u2212 /H + antiporters", "PROTEIN", 145, 170], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["clinical management", "TREATMENT", 67, 86], ["metastatic disease", "PROBLEM", 90, 108], ["metastatic", "OBSERVATION", 90, 100]]], ["Four of the human CLCs are passive plasma membrane Cl \u2212 ion channels.", [["CLCs", "ANATOMY", 18, 22], ["plasma membrane", "ANATOMY", 35, 50], ["Cl", "CHEMICAL", 51, 53], ["Cl", "CHEMICAL", 51, 53], ["human", "ORGANISM", 12, 17], ["CLCs", "CANCER", 18, 22], ["plasma membrane", "CELLULAR_COMPONENT", 35, 50], ["Cl \u2212", "SIMPLE_CHEMICAL", 51, 55], ["human CLCs", "CELL_TYPE", 12, 22], ["Cl \u2212 ion channels", "PROTEIN", 51, 68], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["plasma membrane", "OBSERVATION", 35, 50], ["ion channels", "OBSERVATION", 56, 68]]], ["The other 5 CLCs are expressed in intracellular organelles.", [["intracellular organelles", "ANATOMY", 34, 58], ["CLCs", "GENE_OR_GENE_PRODUCT", 12, 16], ["intracellular organelles", "CELLULAR_COMPONENT", 34, 58], ["CLCs", "PROTEIN", 12, 16], ["intracellular organelles", "OBSERVATION", 34, 58]]], ["ClC-4 and ClC-5, mutations of which lead to Dent's disease, are secondary active Cl \u2212 /H + antiporters, similar to the bacterial ClC-ec1, and with identical 2 Cl \u2212 : 1 H + stoichiometry.", [["Dent's disease", "DISEASE", 44, 58], ["Cl", "CHEMICAL", 81, 83], ["H", "CHEMICAL", 87, 88], ["Cl", "CHEMICAL", 159, 161], ["Cl", "CHEMICAL", 81, 83], ["H +", "CHEMICAL", 87, 90], ["Cl", "CHEMICAL", 159, 161], ["H +", "CHEMICAL", 168, 171], ["ClC-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["ClC-5", "GENE_OR_GENE_PRODUCT", 10, 15], ["Cl \u2212", "SIMPLE_CHEMICAL", 81, 85], ["H +", "SIMPLE_CHEMICAL", 87, 90], ["ClC-ec1", "GENE_OR_GENE_PRODUCT", 129, 136], ["H +", "SIMPLE_CHEMICAL", 168, 171], ["ClC-4 and ClC-5", "DNA", 0, 15], ["Cl \u2212 /H + antiporters", "PROTEIN", 81, 102], ["bacterial ClC", "PROTEIN", 119, 132], ["ec1", "PROTEIN", 133, 136], ["ClC", "TEST", 0, 3], ["ClC", "TEST", 10, 13], ["Dent's disease", "PROBLEM", 44, 58], ["antiporters", "PROBLEM", 91, 102], ["the bacterial ClC", "TEST", 115, 132], ["bacterial ClC", "OBSERVATION", 119, 132]]], ["Cl \u2212 and H + transport activity of the exchanger CLCs depends on two Glut residues.", [["Cl", "CHEMICAL", 0, 2], ["H", "CHEMICAL", 9, 10], ["Cl", "CHEMICAL", 0, 2], ["H +", "CHEMICAL", 9, 12], ["Cl \u2212", "SIMPLE_CHEMICAL", 0, 4], ["H +", "SIMPLE_CHEMICAL", 9, 12], ["exchanger CLCs", "PROTEIN", 39, 53], ["Glut residues", "PROTEIN", 69, 82], ["the exchanger CLCs", "TREATMENT", 35, 53]]], ["Mutating a 'gating glutamate' (E211 in ClC-5) converts the exchanger into anion conductances.", [["glutamate", "CHEMICAL", 19, 28], ["ClC-5", "CHEMICAL", 39, 44], ["glutamate", "CHEMICAL", 19, 28], ["glutamate", "AMINO_ACID", 19, 28], ["anion", "SIMPLE_CHEMICAL", 74, 79]]], ["Neutralizing the 'proton glutamate' (E268), but not its replacement by some other titratable groups, abolishes Cl \u2212 and H + transport.", [["glutamate", "CHEMICAL", 25, 34], ["E268", "CHEMICAL", 37, 41], ["Cl", "CHEMICAL", 111, 113], ["H", "CHEMICAL", 120, 121], ["glutamate", "CHEMICAL", 25, 34], ["Cl", "CHEMICAL", 111, 113], ["H +", "CHEMICAL", 120, 123], ["glutamate", "SIMPLE_CHEMICAL", 25, 34], ["Cl \u2212", "SIMPLE_CHEMICAL", 111, 115], ["H +", "SIMPLE_CHEMICAL", 120, 123], ["Neutralizing the 'proton glutamate'", "TREATMENT", 0, 35], ["its replacement", "TREATMENT", 52, 67]]], ["Noise analysis indicated that ClC-5 switches between silent and transporting states with an apparent unitary conductance of 0.5 pS, indicating a very large transport turnover.", [["ClC-5", "CHEMICAL", 30, 35], ["ClC-5", "CHEMICAL", 30, 35], ["ClC-5", "GENE_OR_GENE_PRODUCT", 30, 35], ["ClC-5", "DNA", 30, 35], ["Noise analysis", "TEST", 0, 14], ["ClC", "TEST", 30, 33], ["an apparent unitary conductance of 0.5 pS", "TREATMENT", 89, 130], ["a very large transport turnover", "PROBLEM", 143, 174]]], ["NO 3 \u2212 uncouples H + transport but mutating the highly conserved S168 to P, as found in the plant NO 3 \u2212 / H + antiporter atClCa, led to coupled NO 3 \u2212 : H + exchange.", [["NO", "CHEMICAL", 0, 2], ["H", "CHEMICAL", 17, 18], ["NO", "CHEMICAL", 98, 100], ["H", "CHEMICAL", 107, 108], ["atClCa", "CHEMICAL", 122, 128], ["NO", "CHEMICAL", 145, 147], ["H", "CHEMICAL", 154, 155], ["NO 3", "CHEMICAL", 0, 4], ["H +", "CHEMICAL", 17, 20], ["NO 3", "CHEMICAL", 98, 102], ["H +", "CHEMICAL", 107, 110], ["NO 3", "CHEMICAL", 145, 149], ["H +", "CHEMICAL", 154, 157], ["NO 3 \u2212", "SIMPLE_CHEMICAL", 0, 6], ["H +", "SIMPLE_CHEMICAL", 17, 20], ["S168", "GENE_OR_GENE_PRODUCT", 65, 69], ["NO 3 \u2212", "SIMPLE_CHEMICAL", 98, 104], ["H + antiporter atClCa", "SIMPLE_CHEMICAL", 107, 128], ["NO 3 \u2212", "SIMPLE_CHEMICAL", 145, 151], ["H +", "SIMPLE_CHEMICAL", 154, 157], ["P", "DNA", 73, 74], ["plant NO 3 \u2212 / H + antiporter", "PROTEIN", 92, 121]]], ["CLC proteins are a fascinating example of how a very similar protein architecture can be used to provide either a passive electrodiffusive permeation pathway or a strictly coupled secondary active ion transporter.", [["CLC proteins", "PROTEIN", 0, 12], ["secondary active ion transporter", "PROTEIN", 180, 212], ["a passive electrodiffusive permeation pathway", "TREATMENT", 112, 157]]], ["(Supported by Telethon Italy -grant GGP08064).O-464The role of ion dynamics in zebrafish fin regeneration The specific and directional ion transport across cell membranes or tissue layers results in differential accumulation of ions and endogenous electric currents.", [["fin", "ANATOMY", 89, 92], ["cell membranes", "ANATOMY", 156, 170], ["tissue layers", "ANATOMY", 174, 187], ["O-464", "CHEMICAL", 46, 51], ["O-464", "CHEMICAL", 46, 51], ["zebrafish", "ORGANISM", 79, 88], ["fin", "ORGANISM_SUBDIVISION", 89, 92], ["cell membranes", "CELLULAR_COMPONENT", 156, 170], ["tissue layers", "TISSUE", 174, 187], ["ions", "SIMPLE_CHEMICAL", 228, 232], ["zebrafish fin regeneration", "TREATMENT", 79, 105], ["directional ion transport across cell membranes", "TREATMENT", 123, 170], ["differential accumulation of ions", "PROBLEM", 199, 232], ["endogenous electric currents", "TREATMENT", 237, 265], ["cell membranes", "OBSERVATION", 156, 170], ["differential", "OBSERVATION_MODIFIER", 199, 211], ["accumulation of ions", "OBSERVATION", 212, 232]]], ["These phenomena have been shown to be important for vertebrate organs regeneration.", [["organs", "ANATOMY", 63, 69], ["organs", "ORGAN", 63, 69], ["vertebrate organs regeneration", "PROBLEM", 52, 82], ["organs", "ANATOMY", 63, 69], ["regeneration", "OBSERVATION", 70, 82]]], ["However, the specific ion nature of such electric currents remains unknown, as well as the role of cellular ion dynamics during regeneration and the molecular signalling pathway that transduces electric cues into cellular responses.O-464We use zebrafish caudal fin as an adult regeneration model to unveil the specific ion composition of the currents associated with wound healing and regeneration, using a non-invasive Ion-Specific Scanning Microprobe setup.", [["cellular", "ANATOMY", 99, 107], ["cellular", "ANATOMY", 213, 221], ["caudal fin", "ANATOMY", 254, 264], ["wound", "ANATOMY", 367, 372], ["O-464We", "CHEMICAL", 232, 239], ["O-464We", "CHEMICAL", 232, 239], ["cellular", "CELL", 99, 107], ["cellular", "CELL", 213, 221], ["O-464We", "GENE_OR_GENE_PRODUCT", 232, 239], ["zebrafish", "ORGANISM", 244, 253], ["caudal fin", "MULTI-TISSUE_STRUCTURE", 254, 264], ["wound", "PATHOLOGICAL_FORMATION", 367, 372], ["such electric currents", "PROBLEM", 36, 58], ["zebrafish caudal fin", "TREATMENT", 244, 264], ["an adult regeneration model", "TREATMENT", 268, 295], ["wound healing", "PROBLEM", 367, 380], ["a non-invasive Ion-Specific Scanning Microprobe setup", "TREATMENT", 405, 458], ["cellular responses", "OBSERVATION", 213, 231], ["wound", "ANATOMY", 367, 372], ["healing", "OBSERVATION", 373, 380]]], ["Our data suggests a role for potassium (K + ), calcium (Ca 2+ ) and protons (H + ) at different stages of the regeneration process.", [["potassium", "CHEMICAL", 29, 38], ["K", "CHEMICAL", 40, 41], ["calcium", "CHEMICAL", 47, 54], ["Ca", "CHEMICAL", 56, 58], ["H", "CHEMICAL", 77, 78], ["potassium", "CHEMICAL", 29, 38], ["K + )", "CHEMICAL", 40, 45], ["calcium", "CHEMICAL", 47, 54], ["Ca 2+ )", "CHEMICAL", 56, 63], ["H +", "CHEMICAL", 77, 80], ["potassium", "SIMPLE_CHEMICAL", 29, 38], ["K +", "SIMPLE_CHEMICAL", 40, 43], ["calcium", "SIMPLE_CHEMICAL", 47, 54], ["Ca 2+", "SIMPLE_CHEMICAL", 56, 61], ["protons", "SIMPLE_CHEMICAL", 68, 75], ["H +", "SIMPLE_CHEMICAL", 77, 80], ["Our data", "TEST", 0, 8], ["potassium", "TEST", 29, 38], ["K", "TEST", 40, 41], ["calcium", "TEST", 47, 54], ["Ca", "TEST", 56, 58], ["the regeneration process", "PROBLEM", 106, 130], ["regeneration process", "OBSERVATION", 110, 130]]], ["K + and Ca 2+ extracellular effluxes have both been detected during the wound healing stage.", [["extracellular", "ANATOMY", 14, 27], ["wound", "ANATOMY", 72, 77], ["K", "CHEMICAL", 0, 1], ["Ca", "CHEMICAL", 8, 10], ["K +", "CHEMICAL", 0, 3], ["Ca 2+", "CHEMICAL", 8, 13], ["K +", "SIMPLE_CHEMICAL", 0, 3], ["Ca 2+", "SIMPLE_CHEMICAL", 8, 13], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["wound", "PATHOLOGICAL_FORMATION", 72, 77], ["K", "TEST", 0, 1], ["Ca", "TEST", 8, 10], ["extracellular effluxes", "PROBLEM", 14, 36], ["the wound healing stage", "PROBLEM", 68, 91], ["effluxes", "OBSERVATION", 28, 36], ["wound", "OBSERVATION_MODIFIER", 72, 77], ["healing", "OBSERVATION_MODIFIER", 78, 85]]], ["H + efflux is triggered during wound healing and is maintained throughout regeneration.", [["wound", "ANATOMY", 31, 36], ["H", "CHEMICAL", 0, 1], ["H +", "CHEMICAL", 0, 3], ["H +", "SIMPLE_CHEMICAL", 0, 3], ["wound", "PATHOLOGICAL_FORMATION", 31, 36], ["efflux", "PROBLEM", 4, 10], ["wound healing", "PROBLEM", 31, 44], ["efflux", "OBSERVATION", 4, 10], ["wound", "ANATOMY", 31, 36], ["healing", "OBSERVATION", 37, 44], ["regeneration", "OBSERVATION_MODIFIER", 74, 86]]], ["We are validating these data with genetic and pharmacological approaches, as well as advanced ion imaging.", [["these data", "TEST", 18, 28], ["advanced ion imaging", "TEST", 85, 105]]], ["Overall, our results suggest ion-driven mechanisms underlie adult tissue regeneration and its comprehension may open way for new therapeutic strategies, both in regenerative and developmental medicine and in cancer therapy.O-463Cardiac effects of anabolic steroids: an electrophysiological approach Anabolic androgenic steroids (AAS) have been used by athletes and non athletes for almost five decades in order to improve performance.", [["adult tissue", "ANATOMY", 60, 72], ["cancer", "ANATOMY", 208, 214], ["cancer", "DISEASE", 208, 214], ["steroids", "CHEMICAL", 256, 264], ["androgenic steroids", "CHEMICAL", 308, 327], ["AAS", "CHEMICAL", 329, 332], ["O-463Cardiac", "CHEMICAL", 223, 235], ["steroids", "CHEMICAL", 256, 264], ["steroids", "CHEMICAL", 319, 327], ["adult tissue", "TISSUE", 60, 72], ["cancer", "CANCER", 208, 214], ["O-463Cardiac", "SIMPLE_CHEMICAL", 223, 235], ["anabolic steroids", "SIMPLE_CHEMICAL", 247, 264], ["Anabolic androgenic steroids", "SIMPLE_CHEMICAL", 299, 327], ["adult tissue regeneration", "PROBLEM", 60, 85], ["new therapeutic strategies", "TREATMENT", 125, 151], ["developmental medicine", "TREATMENT", 178, 200], ["cancer therapy", "TREATMENT", 208, 222], ["anabolic steroids", "TREATMENT", 247, 264], ["an electrophysiological approach", "TREATMENT", 266, 298], ["Anabolic androgenic steroids", "TREATMENT", 299, 327], ["adult tissue regeneration", "OBSERVATION", 60, 85], ["cancer", "OBSERVATION", 208, 214], ["anabolic steroids", "OBSERVATION", 247, 264]]], ["However, the illicit abuse of high-doses of AAS has been attributed as a main cause of several cardiovascular disorders such as arterial hypertension, lipid profile abnormalities, heart failure, hypertrophic cardiomyopathy, arrhythmia and sudden death.", [["cardiovascular", "ANATOMY", 95, 109], ["arterial", "ANATOMY", 128, 136], ["heart", "ANATOMY", 180, 185], ["illicit abuse", "DISEASE", 13, 26], ["AAS", "CHEMICAL", 44, 47], ["cardiovascular disorders", "DISEASE", 95, 119], ["arterial hypertension", "DISEASE", 128, 149], ["heart failure", "DISEASE", 180, 193], ["hypertrophic cardiomyopathy", "DISEASE", 195, 222], ["arrhythmia", "DISEASE", 224, 234], ["sudden death", "DISEASE", 239, 251], ["arterial", "MULTI-TISSUE_STRUCTURE", 128, 136], ["heart", "ORGAN", 180, 185], ["several cardiovascular disorders", "PROBLEM", 87, 119], ["arterial hypertension", "PROBLEM", 128, 149], ["lipid profile abnormalities", "PROBLEM", 151, 178], ["heart failure", "PROBLEM", 180, 193], ["hypertrophic cardiomyopathy", "PROBLEM", 195, 222], ["arrhythmia", "PROBLEM", 224, 234], ["sudden death", "PROBLEM", 239, 251], ["arterial", "ANATOMY", 128, 136], ["hypertension", "OBSERVATION", 137, 149], ["heart", "ANATOMY", 180, 185], ["failure", "OBSERVATION", 186, 193], ["hypertrophic", "OBSERVATION_MODIFIER", 195, 207], ["cardiomyopathy", "OBSERVATION", 208, 222], ["arrhythmia", "OBSERVATION", 224, 234], ["sudden", "OBSERVATION_MODIFIER", 239, 245], ["death", "OBSERVATION", 246, 251]]], ["The aim of this study was to investigate QT interval and transient outward potassium current (I to ) changes in rats treated with nandrolone decanoate (DECA).", [["potassium", "CHEMICAL", 75, 84], ["nandrolone decanoate", "CHEMICAL", 130, 150], ["DECA", "CHEMICAL", 152, 156], ["potassium", "CHEMICAL", 75, 84], ["nandrolone decanoate", "CHEMICAL", 130, 150], ["DECA", "CHEMICAL", 152, 156], ["potassium", "SIMPLE_CHEMICAL", 75, 84], ["rats", "ORGANISM", 112, 116], ["nandrolone decanoate", "SIMPLE_CHEMICAL", 130, 150], ["DECA", "SIMPLE_CHEMICAL", 152, 156], ["rats", "SPECIES", 112, 116], ["this study", "TEST", 11, 21], ["QT interval", "PROBLEM", 41, 52], ["transient outward potassium", "PROBLEM", 57, 84], ["nandrolone decanoate", "TREATMENT", 130, 150]]], ["Male Wistar rats received weekly 10 mg/Kg of DECA (n=10) or vehicle (CONTROL, n=10).", [["DECA", "CHEMICAL", 45, 49], ["DECA", "CHEMICAL", 45, 49], ["Male Wistar rats", "ORGANISM", 0, 16], ["DECA", "SIMPLE_CHEMICAL", 45, 49], ["rats", "SPECIES", 12, 16], ["DECA (n", "TREATMENT", 45, 52]]], ["Electrocardiogram was recorded weekly, and QT interval was measured.", [["Electrocardiogram", "TEST", 0, 17], ["QT interval", "TEST", 43, 54]]], ["After 8 weeks hearts were excised and single myocytes were isolated from the ventricles of animals.", [["hearts", "ANATOMY", 14, 20], ["myocytes", "ANATOMY", 45, 53], ["ventricles", "ANATOMY", 77, 87], ["hearts", "ORGAN", 14, 20], ["myocytes", "CELL", 45, 53], ["ventricles", "MULTI-TISSUE_STRUCTURE", 77, 87], ["single myocytes", "PROBLEM", 38, 53], ["ventricles", "ANATOMY", 77, 87]]], ["I to was recorded by means of the whole cell patch clamp technique.", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44], ["the whole cell patch clamp technique", "TREATMENT", 30, 66]]], ["QT interval was larger in DECA group from 4 th to 8 th week (P <0.01).O-463Analysis of I to showed a decreased current density (P <0.01) in ventricular cardiomyocytes of DECA group, compared to CONTROL group.", [["ventricular cardiomyocytes", "ANATOMY", 140, 166], ["DECA", "ANATOMY", 170, 174], ["DECA", "CANCER", 26, 30], ["ventricular cardiomyocytes", "CELL", 140, 166], ["DECA", "CANCER", 170, 174], ["ventricular cardiomyocytes", "CELL_TYPE", 140, 166], ["QT interval", "TEST", 0, 11], ["a decreased current density", "PROBLEM", 99, 126], ["ventricular cardiomyocytes of DECA group", "PROBLEM", 140, 180], ["larger", "OBSERVATION_MODIFIER", 16, 22], ["decreased", "OBSERVATION_MODIFIER", 101, 110], ["density", "OBSERVATION", 119, 126], ["ventricular cardiomyocytes", "ANATOMY", 140, 166]]], ["In conclusion, our results show that alterations on ventricular repolarizaton may constitute an early consequence of the chronic administration of high doses of anabolic steroids in rats, and demonstrated QT prolongation and I to density reduction, which may constitute an important marker of arrhythmia vulnerability and sudden death.O-462-Ion channels in channelopathies and cancer - Denitrifying bacteria control NO and NO 2 cytosolic levels by regulating the expression of denitrification gene clusters via REDOX signalling of specific transcriptional factors that may act as NO sensors in vivo.", [["ventricular", "ANATOMY", 52, 63], ["cancer", "ANATOMY", 377, 383], ["cytosolic", "ANATOMY", 428, 437], ["ventricular repolarizaton", "DISEASE", 52, 77], ["steroids", "CHEMICAL", 170, 178], ["QT prolongation", "DISEASE", 205, 220], ["arrhythmia", "DISEASE", 293, 303], ["sudden death", "DISEASE", 322, 334], ["O-462", "CHEMICAL", 335, 340], ["channelopathies", "DISEASE", 357, 372], ["cancer", "DISEASE", 377, 383], ["NO", "CHEMICAL", 416, 418], ["NO", "CHEMICAL", 423, 425], ["NO", "CHEMICAL", 580, 582], ["steroids", "CHEMICAL", 170, 178], ["O-462", "CHEMICAL", 335, 340], ["NO", "CHEMICAL", 416, 418], ["NO 2", "CHEMICAL", 423, 427], ["NO", "CHEMICAL", 580, 582], ["ventricular", "ORGAN", 52, 63], ["anabolic steroids", "SIMPLE_CHEMICAL", 161, 178], ["rats", "ORGANISM", 182, 186], ["O-462", "SIMPLE_CHEMICAL", 335, 340], ["cancer", "CANCER", 377, 383], ["NO", "SIMPLE_CHEMICAL", 416, 418], ["NO 2", "GENE_OR_GENE_PRODUCT", 423, 427], ["REDOX", "GENE_OR_GENE_PRODUCT", 511, 516], ["NO", "SIMPLE_CHEMICAL", 580, 582], ["denitrification gene clusters", "DNA", 477, 506], ["REDOX", "PROTEIN", 511, 516], ["transcriptional factors", "PROTEIN", 540, 563], ["rats", "SPECIES", 182, 186], ["ventricular repolarizaton", "TREATMENT", 52, 77], ["anabolic steroids", "TREATMENT", 161, 178], ["QT prolongation", "PROBLEM", 205, 220], ["I to density reduction", "PROBLEM", 225, 247], ["arrhythmia vulnerability", "PROBLEM", 293, 317], ["sudden death", "PROBLEM", 322, 334], ["channelopathies", "PROBLEM", 357, 372], ["cancer", "PROBLEM", 377, 383], ["Denitrifying bacteria control", "TREATMENT", 386, 415], ["2 cytosolic levels", "TEST", 426, 444], ["denitrification gene clusters", "PROBLEM", 477, 506], ["specific transcriptional factors", "PROBLEM", 531, 563], ["chronic", "OBSERVATION_MODIFIER", 121, 128], ["QT prolongation", "OBSERVATION", 205, 220], ["cancer", "OBSERVATION", 377, 383]]], ["A protein belonging to the subclass DNR (dissimilative nitrate respiration regulator) from Pseudomonas aeruginosa has been recently suggested to be a heme containing protein.", [["DNR", "CHEMICAL", 36, 39], ["nitrate", "CHEMICAL", 55, 62], ["nitrate", "CHEMICAL", 55, 62], ["heme", "CHEMICAL", 150, 154], ["DNR", "SIMPLE_CHEMICAL", 36, 39], ["nitrate", "SIMPLE_CHEMICAL", 55, 62], ["Pseudomonas aeruginosa", "ORGANISM", 91, 113], ["subclass DNR", "PROTEIN", 27, 39], ["dissimilative nitrate respiration regulator", "PROTEIN", 41, 84], ["heme containing protein", "PROTEIN", 150, 173], ["Pseudomonas aeruginosa", "SPECIES", 91, 113], ["Pseudomonas aeruginosa", "SPECIES", 91, 113], ["A protein", "TEST", 0, 9], ["the subclass DNR (dissimilative nitrate respiration regulator", "TREATMENT", 23, 84], ["Pseudomonas aeruginosa", "PROBLEM", 91, 113], ["a heme containing protein", "PROBLEM", 148, 173]]], ["Very recently the three dimensional structure of the apo-form of DNR (in the absence of heme) has been determined by X-Ray crystallography, whereas the holo-form (in the presence of heme) has not yet been crystallized.", [["DNR", "CHEMICAL", 65, 68], ["DNR", "CHEMICAL", 65, 68], ["heme", "CHEMICAL", 88, 92], ["heme", "CHEMICAL", 182, 186], ["DNR", "SIMPLE_CHEMICAL", 65, 68], ["heme", "GENE_OR_GENE_PRODUCT", 88, 92], ["heme", "GENE_OR_GENE_PRODUCT", 182, 186], ["DNR", "DNA", 65, 68], ["heme", "PROTEIN", 88, 92], ["holo-form", "PROTEIN", 152, 161], ["heme", "PROTEIN", 182, 186], ["X-Ray crystallography", "TEST", 117, 138]]], ["We have investigated the heme local structure in solution of ferric, ferrous, CO bound and NO bound holo-DNR by X-ray Aborption Spectroscopy (XAS) and we added a kinetic study of the CO bound form by means of a flash photolysis setup using UV-Visible absorption as a spectroscopic probe.", [["ferric", "CHEMICAL", 61, 67], ["ferrous", "CHEMICAL", 69, 76], ["NO", "CHEMICAL", 91, 93], ["heme", "CHEMICAL", 25, 29], ["ferric", "CHEMICAL", 61, 67], ["ferrous", "CHEMICAL", 69, 76], ["CO", "CHEMICAL", 78, 80], ["NO", "CHEMICAL", 91, 93], ["CO", "CHEMICAL", 183, 185], ["ferric", "SIMPLE_CHEMICAL", 61, 67], ["ferrous", "SIMPLE_CHEMICAL", 69, 76], ["CO", "SIMPLE_CHEMICAL", 78, 80], ["NO", "SIMPLE_CHEMICAL", 91, 93], ["holo-DNR", "SIMPLE_CHEMICAL", 100, 108], ["CO", "SIMPLE_CHEMICAL", 183, 185], ["CO bound form", "PROTEIN", 183, 196], ["a kinetic study", "TEST", 160, 175], ["a flash photolysis setup", "TREATMENT", 209, 233], ["UV", "TREATMENT", 240, 242], ["a spectroscopic probe", "TREATMENT", 265, 286], ["heme", "OBSERVATION_MODIFIER", 25, 29], ["local structure", "OBSERVATION", 30, 45]]], ["The combination of Fe K-edge XANES fingerprints and kinetic study reveal a heme pocket able to bind exogenous ligands like NO and CO with increased plasticity, thus supporting its role as the cofactor involved in NO sensing activity.O-468Molecular examination of motifs that lead to the formation of S-nitrosylated proteins I. Alicea, E. R. Schreiter University of Puerto Rico Rio Piedras, San Juan, Puerto RicoO-468Physiologically, a wide range of proteins experience structural and functional modifications after the addition of a nitric oxide (NO) moiety to cysteine thiol.", [["Fe", "CHEMICAL", 19, 21], ["NO", "CHEMICAL", 123, 125], ["NO", "CHEMICAL", 213, 215], ["nitric oxide", "CHEMICAL", 533, 545], ["NO", "CHEMICAL", 547, 549], ["cysteine thiol", "CHEMICAL", 561, 575], ["Fe", "CHEMICAL", 19, 21], ["heme", "CHEMICAL", 75, 79], ["NO", "CHEMICAL", 123, 125], ["CO", "CHEMICAL", 130, 132], ["NO", "CHEMICAL", 213, 215], ["nitric oxide", "CHEMICAL", 533, 545], ["NO", "CHEMICAL", 547, 549], ["cysteine thiol", "CHEMICAL", 561, 575], ["Fe", "SIMPLE_CHEMICAL", 19, 21], ["NO", "SIMPLE_CHEMICAL", 123, 125], ["CO", "SIMPLE_CHEMICAL", 130, 132], ["NO", "SIMPLE_CHEMICAL", 213, 215], ["nitric oxide", "SIMPLE_CHEMICAL", 533, 545], ["NO", "SIMPLE_CHEMICAL", 547, 549], ["cysteine thiol", "SIMPLE_CHEMICAL", 561, 575], ["Fe K-edge XANES fingerprints", "TEST", 19, 47], ["kinetic study", "TEST", 52, 65], ["a heme pocket", "PROBLEM", 73, 86], ["increased plasticity", "PROBLEM", 138, 158], ["468Molecular examination", "TEST", 235, 259], ["a nitric oxide", "TREATMENT", 531, 545], ["cysteine thiol", "TREATMENT", 561, 575], ["heme pocket", "OBSERVATION", 75, 86], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["plasticity", "OBSERVATION", 148, 158], ["functional modifications", "OBSERVATION", 484, 508]]], ["This posttranslational modification, known as S-nitrosylation, regulates a large number of cellular processes like vasodilatation, cell signaling and others, and the products of S-nitrosylation can be involved during the development of different human diseases.", [["cellular", "ANATOMY", 91, 99], ["cell", "ANATOMY", 131, 135], ["cellular", "CELL", 91, 99], ["cell", "CELL", 131, 135], ["human", "ORGANISM", 246, 251], ["human", "SPECIES", 246, 251], ["human", "SPECIES", 246, 251], ["This posttranslational modification", "TREATMENT", 0, 35], ["cellular processes", "PROBLEM", 91, 109], ["vasodilatation", "PROBLEM", 115, 129], ["cell signaling", "PROBLEM", 131, 145], ["S-nitrosylation", "TREATMENT", 178, 193], ["different human diseases", "PROBLEM", 236, 260], ["large", "OBSERVATION_MODIFIER", 75, 80], ["number", "OBSERVATION_MODIFIER", 81, 87], ["cellular processes", "OBSERVATION", 91, 109], ["vasodilatation", "OBSERVATION_MODIFIER", 115, 129], ["cell signaling", "OBSERVATION", 131, 145], ["different human diseases", "OBSERVATION", 236, 260]]], ["However, little is known about the mechanism by which different proteins specifically bind the NO moiety to their cysteine.", [["NO", "CHEMICAL", 95, 97], ["cysteine", "CHEMICAL", 114, 122], ["NO", "CHEMICAL", 95, 97], ["cysteine", "CHEMICAL", 114, 122], ["NO", "SIMPLE_CHEMICAL", 95, 97], ["cysteine", "AMINO_ACID", 114, 122]]], ["Here we show a bio-statistical analysis of some properties of cysteine that are S-nitrosylated in different proteins, including the pK, electrostatic environment, solvent accessibility of the target cysteine and identity of surrounding amino acids.", [["cysteine", "CHEMICAL", 62, 70], ["amino acids", "CHEMICAL", 236, 247], ["cysteine", "CHEMICAL", 62, 70], ["S", "CHEMICAL", 80, 81], ["cysteine", "CHEMICAL", 199, 207], ["amino acids", "CHEMICAL", 236, 247], ["cysteine", "AMINO_ACID", 62, 70], ["cysteine", "AMINO_ACID", 199, 207], ["amino acids", "AMINO_ACID", 236, 247], ["a bio-statistical analysis", "TEST", 13, 39], ["some properties of cysteine", "PROBLEM", 43, 70], ["surrounding amino acids", "PROBLEM", 224, 247], ["cysteine", "OBSERVATION", 62, 70], ["electrostatic environment", "OBSERVATION", 136, 161], ["amino acids", "OBSERVATION", 236, 247]]], ["We also chose model proteins (human thioredoxin and S100 protein) to make specific targeted amino acid substitutions around selected cysteines to alter the properties described above.", [["amino acid", "CHEMICAL", 92, 102], ["amino acid", "CHEMICAL", 92, 102], ["cysteines", "CHEMICAL", 133, 142], ["human", "ORGANISM", 30, 35], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 36, 47], ["S100", "GENE_OR_GENE_PRODUCT", 52, 56], ["amino acid", "AMINO_ACID", 92, 102], ["model proteins", "PROTEIN", 14, 28], ["human thioredoxin", "PROTEIN", 30, 47], ["S100 protein", "PROTEIN", 52, 64], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["model proteins (human thioredoxin and S100 protein)", "TREATMENT", 14, 65], ["specific targeted amino acid substitutions", "TREATMENT", 74, 116]]], ["The reactivity and stability of these mutant proteins towards S-nitrosylation will be examined.P-467Sampling the flexibility of PPAR-\u03b3 S. Aci-S\u00e8che 1 , N. Garnier 1 , D. Genest 1 , S. Bourg 2 , C. Marot 3 , L. Morin-Allory 3 , M. Genest 1 1 UPR CNRS 4301, Orl\u00e9ans, France, 2 FR PCV CNRS 2708, Orl\u00e9ans, France, 3 UMR CNRS 6005, Universit\u00e9 d\u00b4Orl\u00e9ans, FranceP-467A promising approach to consider the flexibility of proteins in docking studies consists in performing multiple rigid docking on a representative set of the receptor conformations.", [["mutant proteins", "PROTEIN", 38, 53], ["P", "DNA", 95, 96], ["PPAR", "PROTEIN", 128, 132], ["these mutant proteins", "PROBLEM", 32, 53], ["S-nitrosylation", "TREATMENT", 62, 77], ["P", "TEST", 95, 96], ["FranceP", "TEST", 349, 356], ["docking studies", "TEST", 424, 439], ["multiple rigid docking", "PROBLEM", 463, 485], ["stability", "OBSERVATION_MODIFIER", 19, 28]]], ["Molecular Dynamic (MD) simulation is one of the best adapted methods for structural sampling, but exploring the conformational diversity of a protein is computationally expensive.", [["structural sampling", "TEST", 73, 92], ["Dynamic", "OBSERVATION_MODIFIER", 10, 17]]], ["We present a protocol for generating a wide range of conformational states of a receptor using restrained MD and a partitioning protocol to select a few representative conformations of the binding site from this MD.", [["a protocol", "TREATMENT", 11, 21], ["a partitioning protocol", "TREATMENT", 113, 136]]], ["We explore a protocol using a distance-dependant permittivity function to represent solvent effect and an ensemble of controlled restraints applied on a subset of specific atoms in order to prevent artefactual structural distortions, but preserving receptor's flexibility.", [["a protocol", "TREATMENT", 11, 21], ["a distance-dependant permittivity function", "TREATMENT", 28, 70], ["solvent effect", "PROBLEM", 84, 98], ["controlled restraints", "TREATMENT", 118, 139], ["a subset of specific atoms", "TREATMENT", 151, 177], ["artefactual structural distortions", "PROBLEM", 198, 232], ["solvent effect", "OBSERVATION", 84, 98], ["artefactual", "OBSERVATION", 198, 209], ["structural distortions", "OBSERVATION", 210, 232]]], ["Ten 100ns simulations have been performed using different sets of parameters and compared to a reference 30ns simulation with explicit solvent.", [["explicit solvent", "TREATMENT", 126, 142]]], ["To select a representative set of conformations, partitioning (k -means algorithm) was applied on the ensemble of simulated conformations.", [["partitioning (k -means algorithm", "TREATMENT", 49, 81]]], ["This methodology was applied to the ligand binding domain of Peroxysome Proliferator-Activated Receptor-\u03b3.", [["Peroxysome Proliferator-Activated Receptor", "GENE_OR_GENE_PRODUCT", 61, 103], ["ligand binding domain", "PROTEIN", 36, 57], ["Peroxysome Proliferator-Activated Receptor", "PROTEIN", 61, 103], ["This methodology", "TREATMENT", 0, 16], ["Peroxysome Proliferator", "TREATMENT", 61, 84]]], ["4 Department of Biomedical Sciences, University of Antwerp, Antwerp, BelgiumLigand migration in human neuroglobin highlights a complex system of interconnected cavitiesThe complex system of cavities identified in human neuroglobin (Ngb) has been postulated to be of functional significance to the putative NO dioxygenase activity of the protein.Ligand migration in human neuroglobin highlights a complex system of interconnected cavitiesThe interconnected hydrophobic cavities may support this catalytic activity by acting as reservoir for reactants and providing preferential pathways assisting product removal from the active site.", [["NO", "CHEMICAL", 306, 308], ["NO", "CHEMICAL", 306, 308], ["human", "ORGANISM", 96, 101], ["neuroglobin", "GENE_OR_GENE_PRODUCT", 102, 113], ["cavities", "MULTI-TISSUE_STRUCTURE", 160, 168], ["human", "ORGANISM", 213, 218], ["neuroglobin", "GENE_OR_GENE_PRODUCT", 219, 230], ["Ngb", "GENE_OR_GENE_PRODUCT", 232, 235], ["NO dioxygenase", "GENE_OR_GENE_PRODUCT", 306, 320], ["human", "ORGANISM", 365, 370], ["neuroglobin", "GENE_OR_GENE_PRODUCT", 371, 382], ["human neuroglobin", "PROTEIN", 213, 230], ["Ngb", "PROTEIN", 232, 235], ["NO dioxygenase", "PROTEIN", 306, 320], ["human neuroglobin", "PROTEIN", 365, 382], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 365, 370], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 365, 370], ["human neuroglobin (Ngb", "PROBLEM", 213, 235], ["The interconnected hydrophobic cavities", "TREATMENT", 437, 476], ["this catalytic activity", "TREATMENT", 489, 512], ["preferential pathways assisting product removal", "TREATMENT", 564, 611], ["interconnected cavities", "OBSERVATION", 145, 168], ["complex", "OBSERVATION_MODIFIER", 172, 179], ["cavities", "OBSERVATION", 190, 198], ["human neuroglobin", "OBSERVATION", 213, 230], ["cavities", "OBSERVATION", 429, 437], ["interconnected", "OBSERVATION_MODIFIER", 441, 455], ["hydrophobic cavities", "OBSERVATION", 456, 476], ["active", "OBSERVATION_MODIFIER", 621, 627], ["site", "OBSERVATION_MODIFIER", 628, 632]]], ["We thus decided to investigate CO rebinding kinetics to Ngb embedded in silica gels to expose ligand migration processes in the geminate phase.", [["CO", "CHEMICAL", 31, 33], ["silica", "CHEMICAL", 72, 78], ["CO", "SIMPLE_CHEMICAL", 31, 33], ["Ngb", "GENE_OR_GENE_PRODUCT", 56, 59], ["silica gels", "SIMPLE_CHEMICAL", 72, 83], ["Ngb", "PROTEIN", 56, 59], ["CO rebinding kinetics", "PROBLEM", 31, 52], ["Ngb embedded in silica gels", "TREATMENT", 56, 83], ["ligand migration", "OBSERVATION", 94, 110], ["geminate phase", "OBSERVATION_MODIFIER", 128, 142]]], ["Encapsulation of the CO complexes of reduced neuroglobin, leads to a slight increase in geminate recombination after nanosecond laser photolysis.", [["neuroglobin", "CHEMICAL", 45, 56], ["CO", "CHEMICAL", 21, 23], ["neuroglobin", "CHEMICAL", 45, 56], ["neuroglobin", "SIMPLE_CHEMICAL", 45, 56], ["geminate", "SIMPLE_CHEMICAL", 88, 96], ["CO complexes", "PROTEIN", 21, 33], ["reduced neuroglobin", "PROBLEM", 37, 56], ["a slight increase in geminate recombination", "PROBLEM", 67, 110], ["nanosecond laser photolysis", "TREATMENT", 117, 144], ["CO complexes", "OBSERVATION_MODIFIER", 21, 33], ["reduced", "OBSERVATION_MODIFIER", 37, 44], ["neuroglobin", "OBSERVATION", 45, 56], ["slight", "OBSERVATION_MODIFIER", 69, 75], ["increase", "OBSERVATION_MODIFIER", 76, 84], ["geminate recombination", "OBSERVATION", 88, 110]]], ["Increasing the viscosity of the medium, by soaking the gels in glycerol, completely inhibits escape of the photodissociated ligand to the solvent, and highlights a complex, multiphasic kinetic pattern.", [["glycerol", "CHEMICAL", 63, 71], ["glycerol", "CHEMICAL", 63, 71], ["glycerol", "SIMPLE_CHEMICAL", 63, 71], ["soaking the gels in glycerol", "TREATMENT", 43, 71], ["a complex, multiphasic kinetic pattern", "PROBLEM", 162, 200], ["viscosity", "OBSERVATION_MODIFIER", 15, 24], ["medium", "OBSERVATION_MODIFIER", 32, 38], ["complex", "OBSERVATION_MODIFIER", 164, 171], ["multiphasic", "OBSERVATION_MODIFIER", 173, 184], ["kinetic pattern", "OBSERVATION", 185, 200]]], ["This finding can be rationalized by assuming the existence of a discrete set of temporary docking sites, capable of trapping the photodissociated ligand for very long times, up to a few ms after photolysis.Inhibition of ion pumps by drugsG.", [["drugsG", "SIMPLE_CHEMICAL", 233, 239], ["temporary docking sites", "PROTEIN", 80, 103], ["temporary docking sites", "TREATMENT", 80, 103], ["ion pumps", "TREATMENT", 220, 229], ["discrete", "OBSERVATION_MODIFIER", 64, 72], ["temporary docking sites", "OBSERVATION", 80, 103], ["ion pumps", "OBSERVATION", 220, 229]]], ["Bartolommei, F. Tadini-Buoninsegni, M. R. Moncelli BioElectroLab -Department of Chemistry, University of Florence, ItalyInhibition of ion pumps by drugsIon pumps are integral membrane proteins devoted to ion transport through a lipid membrane phase.", [["membrane", "ANATOMY", 175, 183], ["lipid membrane", "ANATOMY", 228, 242], ["membrane", "CELLULAR_COMPONENT", 175, 183], ["ion", "SIMPLE_CHEMICAL", 204, 207], ["lipid membrane", "CELLULAR_COMPONENT", 228, 242], ["integral membrane proteins", "PROTEIN", 166, 192], ["ion pumps", "TREATMENT", 134, 143], ["Ion pumps", "TREATMENT", 152, 161], ["integral membrane proteins", "PROBLEM", 166, 192], ["a lipid membrane phase", "TREATMENT", 226, 248]]], ["The ion pumps Ca-ATPase and Na,K-ATPase are prominent members of the P-type ATPases family.", [["Na", "CHEMICAL", 28, 30], ["K", "CHEMICAL", 31, 32], ["Na", "CHEMICAL", 28, 30], ["K", "CHEMICAL", 31, 32], ["Ca-ATPase", "GENE_OR_GENE_PRODUCT", 14, 23], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 28, 39], ["Ca-ATPase", "PROTEIN", 14, 23], ["Na,K-ATPase", "PROTEIN", 28, 39], ["P-type ATPases family", "PROTEIN", 69, 90], ["The ion pumps Ca-ATPase", "TEST", 0, 23], ["Na", "TEST", 28, 30], ["K", "TEST", 31, 32], ["prominent", "OBSERVATION_MODIFIER", 44, 53]]], ["BioElectroLab has a wide expertise in the study of ion transport by these proteins [1] .", [["BioElectroLab", "CHEMICAL", 0, 13], ["ion", "SIMPLE_CHEMICAL", 51, 54], ["wide", "OBSERVATION_MODIFIER", 20, 24]]], ["Our attention has been recently focused on the interaction of these enzymes with molecules of potential pharmacological interest.", [["enzymes", "PROTEIN", 68, 75], ["these enzymes", "TEST", 62, 75]]], ["Frequently, drugs exert an inhibitory action on the transport activity of an ion pump, usually confining it in an inactive conformation.", [["drugs", "TREATMENT", 12, 17], ["an ion pump", "TREATMENT", 74, 85]]], ["Molecules like thapsigargin and cyclopiazonic acid belong to high (nanoM) affinity inhibitors of the Ca-ATPase, whereas clotrimazole and curcumin are medium (microM) affinity inhibitors of both Ca-ATPase and Na,K-ATPase.", [["thapsigargin", "CHEMICAL", 15, 27], ["cyclopiazonic acid", "CHEMICAL", 32, 50], ["clotrimazole", "CHEMICAL", 120, 132], ["curcumin", "CHEMICAL", 137, 145], ["Na", "CHEMICAL", 208, 210], ["thapsigargin", "CHEMICAL", 15, 27], ["cyclopiazonic acid", "CHEMICAL", 32, 50], ["clotrimazole", "CHEMICAL", 120, 132], ["curcumin", "CHEMICAL", 137, 145], ["Na", "CHEMICAL", 208, 210], ["thapsigargin", "SIMPLE_CHEMICAL", 15, 27], ["cyclopiazonic acid", "SIMPLE_CHEMICAL", 32, 50], ["Ca-ATPase", "GENE_OR_GENE_PRODUCT", 101, 110], ["clotrimazole", "SIMPLE_CHEMICAL", 120, 132], ["curcumin", "SIMPLE_CHEMICAL", 137, 145], ["Ca-ATPase", "GENE_OR_GENE_PRODUCT", 194, 203], ["Na", "GENE_OR_GENE_PRODUCT", 208, 210], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 211, 219], ["Ca-ATPase", "PROTEIN", 101, 110], ["Ca-ATPase", "PROTEIN", 194, 203], ["Na", "PROTEIN", 208, 210], ["K-ATPase", "PROTEIN", 211, 219], ["thapsigargin", "PROBLEM", 15, 27], ["cyclopiazonic acid", "TEST", 32, 50], ["affinity inhibitors", "TREATMENT", 74, 93], ["the Ca-ATPase", "TREATMENT", 97, 110], ["clotrimazole and curcumin are medium (microM) affinity inhibitors", "TREATMENT", 120, 185]]], ["Moreover, recent results concerning Ca-ATPase inhibition by clotrimazole analogues will be shown: the relevance of this type of molecules is due to their potential employment as an alternative to traditional drugs against malaria parasite.", [["Ca-", "CHEMICAL", 36, 39], ["clotrimazole", "CHEMICAL", 60, 72], ["malaria parasite", "DISEASE", 222, 238], ["clotrimazole", "CHEMICAL", 60, 72], ["Ca-ATPase", "GENE_OR_GENE_PRODUCT", 36, 45], ["clotrimazole", "SIMPLE_CHEMICAL", 60, 72], ["Ca-ATPase", "PROTEIN", 36, 45], ["Ca-ATPase inhibition", "TREATMENT", 36, 56], ["clotrimazole analogues", "TREATMENT", 60, 82], ["traditional drugs", "TREATMENT", 196, 213], ["malaria parasite", "PROBLEM", 222, 238]]], ["Financial support of Ente Cassa di Risparmio di Firenze and of MIUR (PRIN Project) is gratefully acknowledged.Inhibition of ion pumps by drugs[1] Tadini-Buoninsegni F., Bartolommei G., Moncelli M.R., Fendler K. 2008.", [["ion pumps", "TREATMENT", 124, 133]]], ["476:75-86 (review).Potent flaviviridae inhibitors: targeted finger domain of RdRpS.", [["RdRpS", "GENE_OR_GENE_PRODUCT", 77, 82], ["targeted finger domain", "PROTEIN", 51, 73], ["RdRpS", "PROTEIN", 77, 82], ["Potent flaviviridae inhibitors", "TREATMENT", 19, 49], ["targeted finger domain of RdRpS", "TREATMENT", 51, 82]]], ["Asthana 1 , S. Shukla 1 , G. Giliberti 1 , F. Luliano 1 , M. Ceccarelli 2 , R. Loddu 1 , P. Ruggerone 2 , P. La Colla 1 1 Department of Biomedical Science and Technology, Universit\u00e0 di Cagliari, Cagliari, Italy, 2 Department of Physics, Universit\u00e0 di Cagliari, Cagliari, ItalyPotent flaviviridae inhibitors: targeted finger domain of RdRpStudies of protein-inhibitors interactions are helpful to elucidate the mode of action of ligands and thereby providing clues for rational drug design.", [["targeted finger domain", "PROTEIN", 308, 330], ["Universit\u00e0 di Cagliari", "TREATMENT", 237, 259], ["Cagliari", "TREATMENT", 261, 269], ["ItalyPotent flaviviridae inhibitors", "TREATMENT", 271, 306], ["protein-inhibitors", "TREATMENT", 349, 367]]], ["BVDV, is an important target of drug discovery activities largely because it is essential for viral replication.", [["BVDV", "ORGANISM", 0, 4], ["BVDV", "SPECIES", 0, 4], ["BVDV", "SPECIES", 0, 4], ["BVDV", "PROBLEM", 0, 4], ["viral replication", "PROBLEM", 94, 111]]], ["In BVDV RdRp no specific NNI binding site has been reported till now.", [["BVDV RdRp", "ORGANISM", 3, 12], ["NNI", "GENE_OR_GENE_PRODUCT", 25, 28], ["BVDV RdRp", "PROTEIN", 3, 12], ["NNI binding site", "DNA", 25, 41], ["BVDV RdRp", "SPECIES", 3, 12], ["specific NNI binding site", "PROBLEM", 16, 41], ["BVDV RdRp", "OBSERVATION", 3, 12], ["no", "UNCERTAINTY", 13, 15], ["specific", "OBSERVATION_MODIFIER", 16, 24]]], ["Experimental results have shown that different class of inhibitors (Benzimidazole, Imidazoquinolines and Pyridoxyquinolines), have resistant mutations located in the finger domain of the RdRp.", [["Benzimidazole", "CHEMICAL", 68, 81], ["Imidazoquinolines", "CHEMICAL", 83, 100], ["Pyridoxyquinolines", "CHEMICAL", 105, 123], ["Benzimidazole", "CHEMICAL", 68, 81], ["Imidazoquinolines", "CHEMICAL", 83, 100], ["Pyridoxyquinolines", "CHEMICAL", 105, 123], ["Benzimidazole", "SIMPLE_CHEMICAL", 68, 81], ["Imidazoquinolines", "SIMPLE_CHEMICAL", 83, 100], ["Pyridoxyquinolines", "SIMPLE_CHEMICAL", 105, 123], ["RdRp", "GENE_OR_GENE_PRODUCT", 187, 191], ["finger domain", "PROTEIN", 166, 179], ["RdRp", "PROTEIN", 187, 191], ["inhibitors", "TREATMENT", 56, 66], ["Benzimidazole", "TREATMENT", 68, 81], ["Imidazoquinolines", "TREATMENT", 83, 100], ["Pyridoxyquinolines", "TREATMENT", 105, 123], ["resistant mutations", "PROBLEM", 131, 150], ["resistant mutations", "OBSERVATION", 131, 150], ["finger", "ANATOMY", 166, 172], ["RdRp", "OBSERVATION", 187, 191]]], ["Thereby, indicating that binding sites of NNI's may lie in the finger domain for these different class of inhibitors.Herein, we have utilized docking procedure to investigate binding sites, binding modes as well as binding affinity of different class of inhibitors.We then used all atom molecular dynamics (MD) simulations to investigate the stabilizing interaction between inhibitor-receptor pairs.", [["NNI", "GENE_OR_GENE_PRODUCT", 42, 45], ["NNI", "PROTEIN", 42, 45], ["finger domain", "PROTEIN", 63, 76], ["inhibitor-receptor pairs", "PROTEIN", 374, 398], ["binding sites of NNI's", "PROBLEM", 25, 47], ["docking procedure", "TREATMENT", 142, 159], ["binding sites", "PROBLEM", 175, 188], ["inhibitors", "TREATMENT", 254, 264], ["finger", "ANATOMY", 63, 69]]], ["Thus identifying the binding modes of our inhibitors and mechanism leading to inactivity of the enzyme can help us to build a microscopically well-funded picture of the functioning of these enzymes.", [["enzyme", "PROTEIN", 96, 102], ["enzymes", "PROTEIN", 190, 197], ["our inhibitors", "TREATMENT", 38, 52], ["inactivity of the enzyme", "PROBLEM", 78, 102], ["these enzymes", "TEST", 184, 197]]], ["We present an investigation of the molecular basis of ligand binding and reactivity of heme proteins using computer simulation.", [["heme", "CHEMICAL", 87, 91], ["heme proteins", "GENE_OR_GENE_PRODUCT", 87, 100], ["heme proteins", "PROTEIN", 87, 100], ["computer simulation", "TEST", 107, 126], ["heme proteins", "OBSERVATION", 87, 100]]], ["A combination of classical molecular dynamics and hybrid quantum-classical (QM-MM) calculations are applied to explore distal and proximal effects on diatomic ligand binding to the heme.", [["heme", "CHEMICAL", 181, 185], ["heme", "SIMPLE_CHEMICAL", 181, 185], ["heme", "PROTEIN", 181, 185], ["classical molecular dynamics", "PROBLEM", 17, 45], ["hybrid quantum", "TREATMENT", 50, 64], ["classical (QM-MM) calculations", "TREATMENT", 65, 95], ["distal", "ANATOMY_MODIFIER", 119, 125], ["proximal", "ANATOMY_MODIFIER", 130, 138], ["diatomic ligand", "OBSERVATION", 150, 165], ["heme", "ANATOMY", 181, 185]]], ["Trends in binding energies and in the kinetic constants are illustrated through a number of selected examples.", [["binding energies", "OBSERVATION", 10, 26]]], ["An investigation of the interplay between ligand migration and protein dynamics obtained through classical molecular dynamics techniques in combination with advanced sampling tools is also presented to yield information about free energy profiles and possible secondary docking sites.", [["secondary docking sites", "PROTEIN", 260, 283], ["An investigation", "TEST", 0, 16], ["protein dynamics", "TEST", 63, 79], ["classical molecular dynamics techniques", "TREATMENT", 97, 136], ["advanced sampling tools", "PROBLEM", 157, 180], ["secondary docking sites", "PROBLEM", 260, 283], ["docking sites", "OBSERVATION", 270, 283]]], ["Results for truncated N hemoglobin of Mycobacterium Tuberculosis, presented as an illustrative example, suggest that the truncated hemoglobin N has evolved a dual-path mechanism for selective/distinct migration of O 2 and NO to the heme, to achieve efficient NO detoxification.", [["Mycobacterium Tuberculosis", "DISEASE", 38, 64], ["NO", "CHEMICAL", 222, 224], ["NO", "CHEMICAL", 259, 261], ["O 2", "CHEMICAL", 214, 217], ["NO", "CHEMICAL", 222, 224], ["heme", "CHEMICAL", 232, 236], ["NO", "CHEMICAL", 259, 261], ["truncated N hemoglobin", "GENE_OR_GENE_PRODUCT", 12, 34], ["Mycobacterium Tuberculosis", "ORGANISM", 38, 64], ["hemoglobin N", "GENE_OR_GENE_PRODUCT", 131, 143], ["O 2", "SIMPLE_CHEMICAL", 214, 217], ["NO", "SIMPLE_CHEMICAL", 222, 224], ["heme", "SIMPLE_CHEMICAL", 232, 236], ["NO", "SIMPLE_CHEMICAL", 259, 261], ["truncated N hemoglobin", "PROTEIN", 12, 34], ["truncated hemoglobin N", "PROTEIN", 121, 143], ["Mycobacterium Tuberculosis", "SPECIES", 38, 64], ["truncated N hemoglobin", "TEST", 12, 34], ["Mycobacterium Tuberculosis", "PROBLEM", 38, 64], ["the truncated hemoglobin N", "PROBLEM", 117, 143], ["Mycobacterium Tuberculosis", "OBSERVATION", 38, 64], ["distinct", "OBSERVATION_MODIFIER", 192, 200], ["migration", "OBSERVATION", 201, 210]]], ["Finally, we present also an analysis of the molecular basis of hexacoordination in human neuroglobin, which suggest that the flexibility of the CD plays a key role in determining the ligand binding properties.O-470Thermodynamic bases of nucleoplasmin-histone complexes recognition by the nuclear transport machinery I. Arregi, J. Falces, S. Ba\u00f1uelos, M. A. Urbaneja, S. G. Taneva Unidad de Biof\u00edsica (CSIC/UPV-EHU), Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular, Universidad del Pa\u00eds Vasco, SpainO-470The nuclear transport of the chromatin remodeling (nucleoplasmin) and chromatin building (histones) proteins is mediated by importins.", [["nuclear", "ANATOMY", 288, 295], ["nuclear", "ANATOMY", 507, 514], ["chromatin", "ANATOMY", 532, 541], ["chromatin", "ANATOMY", 573, 582], ["O-470", "CHEMICAL", 209, 214], ["human", "ORGANISM", 83, 88], ["neuroglobin", "GENE_OR_GENE_PRODUCT", 89, 100], ["CD", "GENE_OR_GENE_PRODUCT", 144, 146], ["nucleoplasmin-histone", "GENE_OR_GENE_PRODUCT", 237, 258], ["nuclear", "CELLULAR_COMPONENT", 288, 295], ["nuclear", "CELLULAR_COMPONENT", 507, 514], ["chromatin", "CELLULAR_COMPONENT", 532, 541], ["nucleoplasmin", "GENE_OR_GENE_PRODUCT", 554, 567], ["chromatin", "CELLULAR_COMPONENT", 573, 582], ["importins", "GENE_OR_GENE_PRODUCT", 627, 636], ["human neuroglobin", "PROTEIN", 83, 100], ["nucleoplasmin", "PROTEIN", 237, 250], ["histone complexes", "PROTEIN", 251, 268], ["chromatin", "DNA", 532, 541], ["nucleoplasmin", "PROTEIN", 554, 567], ["chromatin building (histones) proteins", "PROTEIN", 573, 611], ["importins", "PROTEIN", 627, 636], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["S. G. Taneva Unidad de Biof\u00edsica (CSIC/UPV-EHU", "SPECIES", 367, 413], ["an analysis", "TEST", 25, 36], ["hexacoordination in human neuroglobin", "PROBLEM", 63, 100], ["histone complexes recognition", "PROBLEM", 251, 280], ["the chromatin remodeling (nucleoplasmin)", "TREATMENT", 528, 568], ["chromatin building (histones) proteins", "TREATMENT", 573, 611], ["hexacoordination", "OBSERVATION", 63, 79], ["human neuroglobin", "OBSERVATION", 83, 100]]], ["Nucleoplasmin (NP) contains a classical bipartite nuclear localization signal (NLS) that is recognized by importin \u03b1, while histones present multiple sequence elements (NLS-like motifs) for nuclear targeting.", [["nuclear", "ANATOMY", 50, 57], ["nuclear", "ANATOMY", 190, 197], ["Nucleoplasmin", "CHEMICAL", 0, 13], ["Nucleoplasmin", "CHEMICAL", 0, 13], ["Nucleoplasmin", "GENE_OR_GENE_PRODUCT", 0, 13], ["NLS", "GENE_OR_GENE_PRODUCT", 79, 82], ["importin \u03b1", "GENE_OR_GENE_PRODUCT", 106, 116], ["histones", "GENE_OR_GENE_PRODUCT", 124, 132], ["NLS", "GENE_OR_GENE_PRODUCT", 169, 172], ["nuclear", "CELLULAR_COMPONENT", 190, 197], ["Nucleoplasmin", "PROTEIN", 0, 13], ["NP", "PROTEIN", 15, 17], ["classical bipartite nuclear localization signal", "PROTEIN", 30, 77], ["NLS", "PROTEIN", 79, 82], ["importin \u03b1", "PROTEIN", 106, 116], ["histones", "PROTEIN", 124, 132], ["multiple sequence elements", "DNA", 141, 167], ["NLS", "PROTEIN", 169, 172], ["NLS", "TEST", 169, 172]]], ["Besides, ternary importin/NP/histone complexes might represent a putative coimport pathway for nuclear import of linker (H5), nucleosomal core (H2AH2B) histones and their chaperone protein NP, enhancing the histone import efficiency.", [["nuclear", "ANATOMY", 95, 102], ["importin", "GENE_OR_GENE_PRODUCT", 17, 25], ["NP", "GENE_OR_GENE_PRODUCT", 26, 28], ["histone", "GENE_OR_GENE_PRODUCT", 29, 36], ["nuclear", "CELLULAR_COMPONENT", 95, 102], ["nucleosomal core (H2AH2B) histones", "GENE_OR_GENE_PRODUCT", 126, 160], ["histone", "GENE_OR_GENE_PRODUCT", 207, 214], ["ternary importin", "PROTEIN", 9, 25], ["NP", "PROTEIN", 26, 28], ["histone complexes", "PROTEIN", 29, 46], ["linker", "PROTEIN", 113, 119], ["H5", "PROTEIN", 121, 123], ["nucleosomal core (H2AH2B) histones", "PROTEIN", 126, 160], ["chaperone protein NP", "PROTEIN", 171, 191], ["histone", "PROTEIN", 207, 214], ["NP/histone complexes", "TREATMENT", 26, 46], ["nucleosomal core (H2AH2B) histones", "TREATMENT", 126, 160], ["their chaperone protein NP", "TREATMENT", 165, 191], ["import efficiency", "OBSERVATION", 215, 232]]], ["To better understand NP and histone recognition by the transport machinery we studied the thermodynamics of complex formation of importin \u03b1 (a truncated form) and importin \u03b2 with histones and NP, and with NP/histone binary complexes by means of isothermal titration calorimetry.", [["histone", "GENE_OR_GENE_PRODUCT", 28, 35], ["importin \u03b1", "GENE_OR_GENE_PRODUCT", 129, 139], ["importin \u03b2", "GENE_OR_GENE_PRODUCT", 163, 173], ["histones", "CELLULAR_COMPONENT", 179, 187], ["histone", "GENE_OR_GENE_PRODUCT", 208, 215], ["histone", "PROTEIN", 28, 35], ["importin \u03b1", "PROTEIN", 129, 139], ["truncated form", "PROTEIN", 143, 157], ["importin \u03b2", "PROTEIN", 163, 173], ["histones", "PROTEIN", 179, 187], ["NP", "PROTEIN", 192, 194], ["NP", "PROTEIN", 205, 207], ["histone binary complexes", "PROTEIN", 208, 232], ["NP/histone binary complexes", "TREATMENT", 205, 232], ["isothermal titration calorimetry", "TREATMENT", 245, 277]]], ["Data show that importins interact with the two histone types and NP, and that importin and histones can simultaneously bind to NP.", [["importins", "GENE_OR_GENE_PRODUCT", 15, 24], ["histone", "GENE_OR_GENE_PRODUCT", 47, 54], ["importin", "GENE_OR_GENE_PRODUCT", 78, 86], ["histones", "CELLULAR_COMPONENT", 91, 99], ["importins", "PROTEIN", 15, 24], ["histone types", "PROTEIN", 47, 60], ["NP", "PROTEIN", 65, 67], ["importin", "PROTEIN", 78, 86], ["histones", "PROTEIN", 91, 99]]], ["Analysis of the binding energetics reveals an enthalpy driven formation of high affinity binary and ternary complexes.", [["ternary complexes", "PROTEIN", 100, 117], ["the binding energetics", "TEST", 12, 34], ["high affinity binary and ternary complexes", "PROBLEM", 75, 117], ["enthalpy driven", "OBSERVATION", 46, 61], ["high affinity", "OBSERVATION", 75, 88], ["ternary complexes", "OBSERVATION", 100, 117]]], ["We demonstrate that different amount of importin molecules can be loaded on NP/binary complexes dependent on the histone type, linker or core, and the amount of the bound histones.Quantitative analysis of Tau-microtubule interaction using FRETG.", [["microtubule", "ANATOMY", 209, 220], ["importin", "GENE_OR_GENE_PRODUCT", 40, 48], ["histone type", "GENE_OR_GENE_PRODUCT", 113, 125], ["histones", "CELLULAR_COMPONENT", 171, 179], ["Tau-", "GENE_OR_GENE_PRODUCT", 205, 209], ["importin molecules", "PROTEIN", 40, 58], ["histone type, linker or core", "PROTEIN", 113, 141], ["histones", "PROTEIN", 171, 179], ["microtubule", "PROTEIN", 209, 220], ["FRETG", "PROTEIN", 239, 244], ["importin molecules", "TREATMENT", 40, 58], ["NP/binary complexes", "TREATMENT", 76, 95], ["the bound histones", "PROBLEM", 161, 179], ["different", "OBSERVATION_MODIFIER", 20, 29], ["amount", "OBSERVATION_MODIFIER", 30, 36], ["importin molecules", "OBSERVATION", 40, 58], ["amount", "OBSERVATION_MODIFIER", 151, 157], ["bound histones", "OBSERVATION", 165, 179], ["Tau-microtubule", "OBSERVATION", 205, 220]]], ["Breuzard, I. Di Ma\u00efo, P. Barbier, D. Allegro, C. Brault, V. Peyrot CRO2 Inserm U911, UFR de Pharmacie, Marseille, FranceQuantitative analysis of Tau-microtubule interaction using FRETSince a decade, our laboratory has already studied the interaction of tau variant with tubulin (tub) or microtubules (MTs) and phosphorylation process on this interaction.", [["microtubule", "ANATOMY", 149, 160], ["microtubules", "ANATOMY", 287, 299], ["MTs", "ANATOMY", 301, 304], ["Tau-", "GENE_OR_GENE_PRODUCT", 145, 149], ["tau", "GENE_OR_GENE_PRODUCT", 253, 256], ["tubulin (tub)", "GENE_OR_GENE_PRODUCT", 270, 283], ["microtubules", "CELLULAR_COMPONENT", 287, 299], ["MTs", "CELLULAR_COMPONENT", 301, 304], ["microtubule", "PROTEIN", 149, 160], ["tau variant", "PROTEIN", 253, 264], ["tubulin", "PROTEIN", 270, 277], ["tub", "PROTEIN", 279, 282], ["microtubules", "PROTEIN", 287, 299], ["MTs", "PROTEIN", 301, 304], ["tubulin (tub", "TREATMENT", 270, 282], ["microtubules (MTs)", "TREATMENT", 287, 305], ["phosphorylation process", "TREATMENT", 310, 333]]], ["Indeed, FRET assay was a powerful tool to achieve binding parameters between tau and tub in vitro: 1/ with MTs stabilized by fluorescein-coupled taxol (Flutax-2) as donor and rhodamine-labelled tau (rho-tau) as acceptor, and 2/ in living cells by confocal laser scanning microscopy (CLSM) with tau/\u03b1-tub fused to eGFP/mCherry, respectively.", [["MTs", "ANATOMY", 107, 110], ["cells", "ANATOMY", 238, 243], ["fluorescein", "CHEMICAL", 125, 136], ["taxol", "CHEMICAL", 145, 150], ["Flutax-2", "CHEMICAL", 152, 160], ["rhodamine", "CHEMICAL", 175, 184], ["fluorescein", "CHEMICAL", 125, 136], ["taxol", "CHEMICAL", 145, 150], ["Flutax-2", "CHEMICAL", 152, 160], ["rhodamine", "CHEMICAL", 175, 184], ["tau", "GENE_OR_GENE_PRODUCT", 77, 80], ["MTs", "SIMPLE_CHEMICAL", 107, 110], ["fluorescein", "SIMPLE_CHEMICAL", 125, 136], ["taxol", "SIMPLE_CHEMICAL", 145, 150], ["Flutax-2", "SIMPLE_CHEMICAL", 152, 160], ["rhodamine", "SIMPLE_CHEMICAL", 175, 184], ["tau", "GENE_OR_GENE_PRODUCT", 194, 197], ["rho-tau", "GENE_OR_GENE_PRODUCT", 199, 206], ["cells", "CELL", 238, 243], ["tau", "GENE_OR_GENE_PRODUCT", 294, 297], ["\u03b1-tub", "GENE_OR_GENE_PRODUCT", 298, 303], ["eGFP", "GENE_OR_GENE_PRODUCT", 313, 317], ["mCherry", "GENE_OR_GENE_PRODUCT", 318, 325], ["tau", "PROTEIN", 77, 80], ["tau", "PROTEIN", 194, 197], ["rho", "PROTEIN", 199, 202], ["tau", "PROTEIN", 203, 206], ["tau", "PROTEIN", 294, 297], ["\u03b1", "PROTEIN", 298, 299], ["eGFP", "DNA", 313, 317], ["mCherry", "PROTEIN", 318, 325], ["FRET assay", "TEST", 8, 18], ["binding parameters", "TEST", 50, 68], ["taxol (Flutax", "TREATMENT", 145, 158], ["confocal laser scanning microscopy", "TEST", 247, 281], ["CLSM", "TEST", 283, 287], ["tau/\u03b1-tub", "TREATMENT", 294, 303]]], ["Results revealed 47 \u00b1 3 % energy transfer efficiency from Flutax-2 to rho-tau and a donor-to-acceptor distance of 54 \u00b1 1\u00c5.", [["Flutax-2 to rho-tau", "CHEMICAL", 58, 77], ["Flutax-2", "SIMPLE_CHEMICAL", 58, 66], ["rho-tau", "SIMPLE_CHEMICAL", 70, 77], ["Flutax-2 to rho-tau", "PROTEIN", 58, 77], ["Flutax", "TEST", 58, 64]]], ["By titration, the dissociation constant of tau was determined to 1.0 \u00b1 0.5 \u00b5M.", [["tau", "GENE_OR_GENE_PRODUCT", 43, 46], ["tau", "PROTEIN", 43, 46]]], ["A cleavage procedure of \u03b1\u03b2-tub was performed to determine the influence of the C-term tails of \u03b1\u03b2-tub on the tau-MT interaction.", [["\u03b1\u03b2-tub", "SIMPLE_CHEMICAL", 24, 30], ["\u03b1\u03b2-tub", "SIMPLE_CHEMICAL", 95, 101], ["tau", "GENE_OR_GENE_PRODUCT", 109, 112], ["MT", "GENE_OR_GENE_PRODUCT", 113, 115], ["\u03b1\u03b2", "PROTEIN", 24, 26], ["C-term tails", "PROTEIN", 79, 91], ["\u03b1\u03b2-tub", "PROTEIN", 95, 101], ["tau", "PROTEIN", 109, 112], ["MT", "PROTEIN", 113, 115], ["A cleavage procedure", "TREATMENT", 0, 20], ["\u03b1\u03b2-tub", "TREATMENT", 24, 30], ["the C-term tails", "TREATMENT", 75, 91]]], ["No difference in distances and binding parameters was observed.", [["binding parameters", "TEST", 31, 49], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["CLSM images displayed a heightened concentration of fluorescent tau in patches along MTs.", [["MTs", "ANATOMY", 85, 88], ["tau", "GENE_OR_GENE_PRODUCT", 64, 67], ["MTs", "CELLULAR_COMPONENT", 85, 88], ["fluorescent tau", "PROTEIN", 52, 67], ["MTs", "CELL_TYPE", 85, 88], ["CLSM images", "TEST", 0, 11], ["heightened", "OBSERVATION_MODIFIER", 24, 34], ["concentration", "OBSERVATION_MODIFIER", 35, 48], ["fluorescent tau", "OBSERVATION", 52, 67]]], ["FRET experiments revealed in particular higher efficiencies between GFP-tau to mCherry-\u03b1 tub proteins in these locations.", [["GFP-tau", "GENE_OR_GENE_PRODUCT", 68, 75], ["mCherry-\u03b1 tub proteins", "GENE_OR_GENE_PRODUCT", 79, 101], ["GFP", "PROTEIN", 68, 71], ["tau", "PROTEIN", 72, 75], ["mCherry", "PROTEIN", 79, 86], ["\u03b1 tub proteins", "PROTEIN", 87, 101], ["FRET experiments", "TEST", 0, 16], ["particular higher efficiencies", "PROBLEM", 29, 59], ["GFP", "TEST", 68, 71], ["mCherry", "TEST", 79, 86], ["higher efficiencies", "OBSERVATION", 40, 59]]], ["Overall, our results suggested no involvement of the hypervariable and highly acidic C-term tails of tub in MT/tau binding.", [["MT", "GENE_OR_GENE_PRODUCT", 108, 110], ["tau", "GENE_OR_GENE_PRODUCT", 111, 114], ["acidic C-term tails", "PROTEIN", 78, 97], ["MT", "PROTEIN", 108, 110], ["tau", "PROTEIN", 111, 114], ["no", "UNCERTAINTY", 31, 33]]], ["A molecular model is proposed in which Flutax-2 is directly accessible to tau molecules.", [["Flutax-2", "GENE_OR_GENE_PRODUCT", 39, 47], ["tau", "GENE_OR_GENE_PRODUCT", 74, 77], ["tau molecules", "PROTEIN", 74, 87], ["molecular model", "OBSERVATION", 2, 17]]], ["Besides, the modified distribution of fluorescent tau could be implicated in local change of mechanical properties of MTs.Light-enforced antigen dissociation from MHC molecules via photochromic switchesA.", [["MTs", "ANATOMY", 118, 121], ["tau", "GENE_OR_GENE_PRODUCT", 50, 53], ["MTs", "CELLULAR_COMPONENT", 118, 121], ["fluorescent tau", "PROTEIN", 38, 53], ["MTs", "CELL_TYPE", 118, 121], ["MHC molecules", "PROTEIN", 163, 176], ["photochromic switchesA", "PROTEIN", 181, 203], ["fluorescent tau", "PROBLEM", 38, 53], ["enforced antigen dissociation", "PROBLEM", 128, 157], ["photochromic switchesA", "TREATMENT", 181, 203], ["fluorescent tau", "OBSERVATION", 38, 53], ["mechanical properties", "OBSERVATION", 93, 114], ["photochromic switchesA", "OBSERVATION", 181, 203]]], ["Boreham 1 , K. Winkler 1 , C. Gebhard 2 , K. Rueck-Braun 2 , P. Henklein 3 , E. Michalsky 3 , R. Preissner 3 , R. Misselwitz 3 , A. Ziegler 3 , U. Alexiev 1 1 Freie Universit\u00e4t Berlin, Berlin, Germany, 2 Technische Universit\u00e4t Berlin, Berlin, Germany, 3 Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany Peptide presentation by major histocompatibility complex (MHC) molecules is crucial for immune responses.", [["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 330, 362], ["major histocompatibility complex (MHC) molecules", "PROTEIN", 330, 378], ["Boreham", "TEST", 0, 7], ["Winkler", "TEST", 15, 22], ["Gebhard", "TEST", 30, 37]]], ["Photocontrol of peptide dynamics by means of photo-switchable peptide analogs will provide insights in peptide dynamics and its dependence on MHC polymorphism (1) (2) (3) .", [["MHC", "PROTEIN", 142, 145], ["Photocontrol of peptide dynamics", "TREATMENT", 0, 32], ["photo-switchable peptide analogs", "TREATMENT", 45, 77], ["insights in peptide dynamics", "TREATMENT", 91, 119], ["its dependence on MHC polymorphism", "TREATMENT", 124, 158]]], ["We have designed a hemithioindigo (mHTI) photo-switch bearing peptide using the viral epitope RRRWRRLTV (pLMP2) as a template.", [["hemithioindigo", "CHEMICAL", 19, 33], ["hemithioindigo", "CHEMICAL", 19, 33], ["hemithioindigo", "SIMPLE_CHEMICAL", 19, 33], ["pLMP2", "SIMPLE_CHEMICAL", 105, 110], ["viral epitope RRRWRRLTV", "PROTEIN", 80, 103], ["pLMP2", "PROTEIN", 105, 110], ["a hemithioindigo (mHTI) photo", "TREATMENT", 17, 46], ["switch bearing peptide", "TREATMENT", 47, 69], ["the viral epitope RRRWRRLTV (pLMP2", "TREATMENT", 76, 110]]], ["Incorporation of mHTI in the peptide backbone should result only in a minor change of the overall peptide structure given the relaxed conformation of the Zisomer.", [["mHTI", "CHEMICAL", 17, 21], ["Zisomer", "CHEMICAL", 154, 161], ["mHTI", "GENE_OR_GENE_PRODUCT", 17, 21], ["Zisomer", "SIMPLE_CHEMICAL", 154, 161], ["mHTI", "PROTEIN", 17, 21], ["Zisomer", "PROTEIN", 154, 161], ["Incorporation of mHTI in the peptide backbone", "TREATMENT", 0, 45], ["a minor change of the overall peptide structure", "PROBLEM", 68, 115], ["the Zisomer", "TREATMENT", 150, 161], ["overall peptide structure", "OBSERVATION", 90, 115]]], ["Indeed, the human MHC molecule HLA-B2705/mHTI-pLMP2 complex.", [["human", "ORGANISM", 12, 17], ["HLA-B2705", "GENE_OR_GENE_PRODUCT", 31, 40], ["mHTI-pLMP2", "GENE_OR_GENE_PRODUCT", 41, 51], ["human MHC molecule", "PROTEIN", 12, 30], ["HLA", "PROTEIN", 31, 34], ["B2705", "PROTEIN", 35, 40], ["mHTI", "PROTEIN", 41, 45], ["pLMP2 complex", "PROTEIN", 46, 59], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["HLA", "TEST", 31, 34], ["mHTI", "TEST", 41, 45]]], ["Photoswitching from Z \u2192E results in a decrease of HLA-complex stability.", [["Z \u2192E", "CHEMICAL", 20, 24], ["Z \u2192E", "SIMPLE_CHEMICAL", 20, 24], ["Z \u2192E", "PROTEIN", 20, 24], ["HLA", "PROTEIN", 50, 53], ["Photoswitching from Z \u2192E", "TEST", 0, 24], ["decrease", "OBSERVATION_MODIFIER", 38, 46], ["complex", "OBSERVATION_MODIFIER", 54, 61], ["stability", "OBSERVATION", 62, 71]]], ["Based on computer modeling this decrease is due to a reduced interaction of the peptide C-terminus with HLA-B*2705.", [["C", "CHEMICAL", 88, 89], ["peptide C-terminus", "PROTEIN", 80, 98], ["HLA-B*2705", "PROTEIN", 104, 114]]], ["Truncated hemoglobins (trHbs) are heme proteins present in bacteria, unicellular eukaryotes, and higher plants.", [["hemoglobins", "GENE_OR_GENE_PRODUCT", 10, 21], ["trHbs", "GENE_OR_GENE_PRODUCT", 23, 28], ["heme proteins", "GENE_OR_GENE_PRODUCT", 34, 47], ["Truncated hemoglobins", "PROTEIN", 0, 21], ["trHbs", "PROTEIN", 23, 28], ["heme proteins", "PROTEIN", 34, 47], ["Truncated hemoglobins", "TEST", 0, 21], ["trHbs", "TEST", 23, 28], ["heme proteins", "PROBLEM", 34, 47], ["bacteria", "PROBLEM", 59, 67], ["unicellular eukaryotes", "PROBLEM", 69, 91], ["heme proteins", "OBSERVATION", 34, 47], ["bacteria", "OBSERVATION_MODIFIER", 59, 67], ["unicellular eukaryotes", "OBSERVATION", 69, 91], ["higher plants", "OBSERVATION", 97, 110]]], ["Three phylogenetic groups (N, O, and P) have been identified in trHbs.", [["trHbs", "CANCER", 64, 69], ["trHbs", "PROTEIN", 64, 69]]], ["The crystal structure of truncated hemoglobin O of B.subtilis, does not show an evident tunnel/cavity system connecting the protein active site with the solvent, a fact that cannot be easily rationalized considering the very high oxygen association rate.", [["oxygen", "CHEMICAL", 230, 236], ["oxygen", "CHEMICAL", 230, 236], ["hemoglobin O", "SIMPLE_CHEMICAL", 35, 47], ["oxygen", "SIMPLE_CHEMICAL", 230, 236], ["truncated hemoglobin O", "PROTEIN", 25, 47], ["protein active site", "PROTEIN", 124, 143], ["an evident tunnel/cavity system", "PROBLEM", 77, 108], ["the very high oxygen association rate", "PROBLEM", 216, 253], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["truncated hemoglobin", "OBSERVATION", 25, 45], ["tunnel", "OBSERVATION", 88, 94], ["cavity", "OBSERVATION", 95, 101], ["protein", "OBSERVATION", 124, 131], ["active site", "OBSERVATION", 132, 143], ["solvent", "OBSERVATION_MODIFIER", 153, 160]]], ["Moreover, resonant Raman results of the CO bound protein, showed that a complex hydrogen bond network exists in the distal cavity, making it difficult to assign unambiguously the residues involved in the stabilization of the bound ligand.", [["distal cavity", "ANATOMY", 116, 129], ["CO", "CHEMICAL", 40, 42], ["hydrogen", "CHEMICAL", 80, 88], ["CO bound protein", "PROTEIN", 40, 56], ["the CO bound protein", "TEST", 36, 56], ["a complex hydrogen bond network", "PROBLEM", 70, 101], ["complex", "OBSERVATION_MODIFIER", 72, 79], ["hydrogen bond", "OBSERVATION", 80, 93], ["distal", "ANATOMY_MODIFIER", 116, 122], ["cavity", "ANATOMY", 123, 129]]], ["For these reasons we performed classical molecular dynamics simulations of the oxy, carboxy and deoxy protein, and computed the free energy profiles associated with ligand migration to the active site.", [["oxy", "CHEMICAL", 79, 82], ["carboxy", "CHEMICAL", 84, 91], ["deoxy", "CHEMICAL", 96, 101], ["oxy", "SIMPLE_CHEMICAL", 79, 82], ["oxy, carboxy and deoxy protein", "PROTEIN", 79, 109], ["carboxy and deoxy protein", "TEST", 84, 109], ["ligand migration", "TREATMENT", 165, 181], ["active", "OBSERVATION_MODIFIER", 189, 195]]], ["Our results suggest that there is a key residue, GlnE11, that may present an alternate conformation in which a wide ligand migration tunnel is formed, consistently with the kinetic data.", [["GlnE11", "GENE_OR_GENE_PRODUCT", 49, 55], ["a key residue", "PROBLEM", 34, 47], ["a wide ligand migration tunnel", "TREATMENT", 109, 139], ["the kinetic data", "TEST", 169, 185], ["migration tunnel", "OBSERVATION", 123, 139]]], ["The results for the CO and O 2 bound protein show also that GlnE11 is directly involved in the stabilization of the coordinated ligand, playing a similar role as TyrB10, and TrpG8 in other trHbs.", [["CO", "CHEMICAL", 20, 22], ["O 2", "CHEMICAL", 27, 30], ["CO", "SIMPLE_CHEMICAL", 20, 22], ["O 2", "GENE_OR_GENE_PRODUCT", 27, 30], ["GlnE11", "GENE_OR_GENE_PRODUCT", 60, 66], ["TyrB10", "GENE_OR_GENE_PRODUCT", 162, 168], ["TrpG8", "GENE_OR_GENE_PRODUCT", 174, 179], ["trHbs", "GENE_OR_GENE_PRODUCT", 189, 194], ["CO", "PROTEIN", 20, 22], ["O 2 bound protein", "PROTEIN", 27, 44], ["GlnE11", "PROTEIN", 60, 66], ["TyrB10", "PROTEIN", 162, 168], ["TrpG8", "PROTEIN", 174, 179], ["trHbs", "PROTEIN", 189, 194], ["the CO and O 2 bound protein", "TEST", 16, 44]]], ["Our results not only reconcile the structural data with the kinetic information, but also provide additional insight about the general behaviour of trHbs.P-474Patterned functionalization of surfaces for guided transport on molecular motors tracks M. Bhagawati 1 , S. Ghosh 2 , T. Surrey 1 , J. Piehler 2 1 Department of Biophysics, University of Osnabrueck, Osnabrueck, Germany, 2 European Molecular Biology Laboratory, Cell Biology and Biophysics Unit, Heidelberg, Germany Chelator head groups with multiple nitrilotriacetic acid (NTA) moieties have been very well characterized and successfully utilized as high affinity adapters for functional immobilization of oligohistidine tagged proteins to surfaces.", [["P-474Patterned", "CHEMICAL", 154, 168], ["nitrilotriacetic acid", "CHEMICAL", 509, 530], ["NTA", "CHEMICAL", 532, 535], ["oligohistidine", "CHEMICAL", 665, 679], ["P-474Patterned", "CHEMICAL", 154, 168], ["nitrilotriacetic acid", "CHEMICAL", 509, 530], ["NTA", "CHEMICAL", 532, 535], ["oligohistidine", "CHEMICAL", 665, 679], ["trHbs", "SIMPLE_CHEMICAL", 148, 153], ["nitrilotriacetic acid", "SIMPLE_CHEMICAL", 509, 530], ["NTA", "SIMPLE_CHEMICAL", 532, 535], ["oligohistidine", "SIMPLE_CHEMICAL", 665, 679], ["trHbs", "PROTEIN", 148, 153], ["oligohistidine tagged proteins", "PROTEIN", 665, 695], ["functionalization of surfaces", "TREATMENT", 169, 198], ["Germany Chelator head groups", "TREATMENT", 466, 494], ["multiple nitrilotriacetic acid (NTA) moieties", "TREATMENT", 500, 545], ["high affinity adapters", "TREATMENT", 609, 631], ["functional immobilization", "TREATMENT", 636, 661], ["oligohistidine tagged proteins", "TREATMENT", 665, 695]]], ["We have recently established a generic method for patterning NTA functionalized surfaces by selective photodestruction via a light induced Fenton reaction.", [["NTA", "CHEMICAL", 61, 64], ["Fenton", "CHEMICAL", 139, 145], ["NTA", "CHEMICAL", 61, 64], ["NTA", "SIMPLE_CHEMICAL", 61, 64], ["a generic method", "TREATMENT", 29, 45], ["patterning NTA functionalized surfaces", "TREATMENT", 50, 88], ["selective photodestruction", "PROBLEM", 92, 118], ["a light induced Fenton reaction", "TREATMENT", 123, 154]]], ["Efficiency of different transition metal ions for catalyzing this reaction was tested.", [["transition metal", "CHEMICAL", 24, 40], ["metal ions", "SIMPLE_CHEMICAL", 35, 45], ["different transition metal ions", "TREATMENT", 14, 45], ["catalyzing this reaction", "PROBLEM", 50, 74], ["different", "OBSERVATION_MODIFIER", 14, 23], ["transition", "OBSERVATION_MODIFIER", 24, 34], ["metal ions", "OBSERVATION", 35, 45]]], ["Functionality of the patterned protein was confirmed using the interaction between Interferon\u03b12 and its receptor.", [["Interferon\u03b12", "GENE_OR_GENE_PRODUCT", 83, 95], ["patterned protein", "PROTEIN", 21, 38], ["Interferon\u03b12", "PROTEIN", 83, 95], ["Interferon\u03b12 and its receptor", "TREATMENT", 83, 112]]], ["Implementation of this technique in a confocal laser scanning microscope allowed us to control surface density of binding sites, providing the possibility to vary the surface concentration of immobilized proteins in a spatially resolved manner.", [["surface", "ANATOMY", 95, 102], ["surface", "ANATOMY", 167, 174], ["immobilized proteins", "PROTEIN", 192, 212], ["this technique", "TREATMENT", 18, 32], ["a confocal laser scanning microscope", "TEST", 36, 72], ["binding sites", "PROBLEM", 114, 127], ["immobilized proteins", "TREATMENT", 192, 212], ["binding sites", "OBSERVATION", 114, 127]]], ["We also applied this approach for exploring guided transport of microtubules by kinesin selectively immobilized onto TrisNTA patterns.", [["microtubules", "ANATOMY", 64, 76], ["microtubules", "CELLULAR_COMPONENT", 64, 76], ["kinesin", "GENE_OR_GENE_PRODUCT", 80, 87], ["TrisNTA", "GENE_OR_GENE_PRODUCT", 117, 124], ["microtubules", "PROTEIN", 64, 76], ["kinesin", "PROTEIN", 80, 87], ["TrisNTA", "PROTEIN", 117, 124], ["this approach", "TREATMENT", 16, 29], ["exploring guided transport of microtubules", "TREATMENT", 34, 76]]], ["Rheumatoid arthritis (RA) is an autoimmune disorder, leading to pathological damage at the level of joints, associated with the HLA class II allele HLA-DR4.", [["joints", "ANATOMY", 100, 106], ["Rheumatoid arthritis", "DISEASE", 0, 20], ["RA", "DISEASE", 22, 24], ["autoimmune disorder", "DISEASE", 32, 51], ["joints", "MULTI-TISSUE_STRUCTURE", 100, 106], ["HLA-DR4", "GENE_OR_GENE_PRODUCT", 148, 155], ["HLA class II allele HLA-DR4", "DNA", 128, 155], ["Rheumatoid arthritis", "PROBLEM", 0, 20], ["an autoimmune disorder", "PROBLEM", 29, 51], ["pathological damage", "PROBLEM", 64, 83], ["DR4", "PROBLEM", 152, 155], ["arthritis", "OBSERVATION", 11, 20], ["RA", "ANATOMY", 22, 24], ["autoimmune disorder", "OBSERVATION", 32, 51], ["pathological", "OBSERVATION_MODIFIER", 64, 76], ["damage", "OBSERVATION", 77, 83], ["joints", "ANATOMY", 100, 106]]], ["Although etiology of RA is unknown, type II collagen (CII) is a potential antigen candidate and it is believed that T cell responses in collagendependent RA are directed towards the immunodominant pathogenic epitope CII(261-273).", [["T cell", "ANATOMY", 116, 122], ["RA", "DISEASE", 21, 23], ["type II collagen", "GENE_OR_GENE_PRODUCT", 36, 52], ["CII", "GENE_OR_GENE_PRODUCT", 54, 57], ["T cell", "CELL", 116, 122], ["collagendependent RA", "CELL", 136, 156], ["type II collagen", "PROTEIN", 36, 52], ["CII", "PROTEIN", 54, 57], ["CII", "PROTEIN", 216, 219], ["RA", "PROBLEM", 21, 23], ["type II collagen (CII", "PROBLEM", 36, 57], ["T cell responses in collagendependent RA", "PROBLEM", 116, 156], ["RA", "ANATOMY", 21, 23]]], ["Despite recent advances in characterization of class II major histocompatibility complex (MHC) and T-cell receptor (TCR) contacts in this epitope, the atomic details of TCR-CII(261-273)-MHC complex are not known.", [["T-cell", "ANATOMY", 99, 105], ["TCR", "CHEMICAL", 169, 172], ["class II major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 47, 88], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 99, 114], ["TCR", "GENE_OR_GENE_PRODUCT", 116, 119], ["TCR-CII", "GENE_OR_GENE_PRODUCT", 169, 176], ["class II major histocompatibility complex", "PROTEIN", 47, 88], ["MHC", "PROTEIN", 90, 93], ["T-cell receptor", "PROTEIN", 99, 114], ["TCR", "PROTEIN", 116, 119], ["TCR", "PROTEIN", 169, 172], ["CII", "PROTEIN", 173, 176], ["MHC complex", "PROTEIN", 186, 197], ["TCR", "TEST", 169, 172]]], ["Here, homology modeling and molecular docking studies have been used to derive a three-dimensional model of TCR \u03b2 chains, obtained from a DR4+ subject, in complex with CII(261-273)/HLA-DR4.", [["TCR", "CHEMICAL", 108, 111], ["TCR \u03b2 chains", "GENE_OR_GENE_PRODUCT", 108, 120], ["DR4", "GENE_OR_GENE_PRODUCT", 138, 141], ["CII", "GENE_OR_GENE_PRODUCT", 168, 171], ["HLA-DR4", "GENE_OR_GENE_PRODUCT", 181, 188], ["TCR \u03b2 chains", "PROTEIN", 108, 120], ["DR4", "PROTEIN", 138, 141], ["CII", "PROTEIN", 168, 171], ["261-273", "PROTEIN", 172, 179], ["HLA", "PROTEIN", 181, 184], ["DR4", "PROTEIN", 185, 188], ["molecular docking studies", "TEST", 28, 53], ["DR4", "PROBLEM", 185, 188]]], ["The best complex from docking was further refined using molecular dynamics simulations for 20 ns.", [["molecular dynamics simulations", "TREATMENT", 56, 86], ["20 ns", "TREATMENT", 91, 96]]], ["The proposed model represents a reasonable structural basis for understanding CII(261-273)-MHCII complex recognition by TCR and for rational design of inhibitors targeting TCR-pMHC interface.P-480Probing bio-molecular bonds with magnetic force for biosensor applications A. M. de Jong 1 , A. Jacob 1 , X. J. Janssen 1 , J. M. van Noorloos 1 , L. J. van Ijzendoorn 1 , M. W. Prins 2 1 Eindhoven University of Technology, Eindhoven, The Netherlands, 2 Philips Research Laboratories, Eindhoven, The NetherlandsP-480We investigate new technologies to be applied in next generation biosensors, which not only measure biomarker concentrations but also probe bio-molecular interactions.", [["TCR", "CHEMICAL", 120, 123], ["TCR", "CHEMICAL", 172, 175], ["P-480", "CHEMICAL", 191, 196], ["CII", "GENE_OR_GENE_PRODUCT", 78, 81], ["MHCII", "GENE_OR_GENE_PRODUCT", 91, 96], ["TCR", "GENE_OR_GENE_PRODUCT", 120, 123], ["TCR-pMHC", "GENE_OR_GENE_PRODUCT", 172, 180], ["CII", "PROTEIN", 78, 81], ["MHCII complex", "PROTEIN", 91, 104], ["TCR", "PROTEIN", 120, 123], ["TCR", "PROTEIN", 172, 175], ["pMHC", "PROTEIN", 176, 180], ["rational design of inhibitors", "TREATMENT", 132, 161], ["new technologies", "TREATMENT", 527, 543], ["biomarker concentrations", "PROBLEM", 612, 636]]], ["We use functionalized magnetic beads and magnetic fields to apply translational and rotational forces on the molecular bonds.", [["functionalized magnetic beads", "TREATMENT", 7, 36], ["translational and rotational forces", "TREATMENT", 66, 101], ["molecular bonds", "ANATOMY", 109, 124]]], ["In a model experiment, polystyrene surfaces were coated with anti-biotin and beads were coated with biotin.", [["anti-biotin", "CHEMICAL", 61, 72], ["biotin", "CHEMICAL", 100, 106], ["polystyrene", "CHEMICAL", 23, 34], ["anti-biotin", "CHEMICAL", 61, 72], ["biotin", "CHEMICAL", 100, 106], ["polystyrene surfaces", "SIMPLE_CHEMICAL", 23, 43], ["anti-biotin", "SIMPLE_CHEMICAL", 61, 72], ["biotin", "SIMPLE_CHEMICAL", 100, 106], ["a model experiment, polystyrene surfaces", "TREATMENT", 3, 43], ["anti-biotin and beads", "TREATMENT", 61, 82], ["biotin", "TREATMENT", 100, 106], ["polystyrene surfaces", "OBSERVATION", 23, 43]]], ["After incubation, a constant magnetic force was applied to the beads and the number of bound beads was measured as a function of time.", [["a constant magnetic force", "TREATMENT", 18, 43], ["bound beads", "OBSERVATION", 87, 98]]], ["The dissociation rate (k o f f ) is determined for each force and k o f f at zero force is extracted from these data.", [["The dissociation rate", "TEST", 0, 21]]], ["Rotational forces were exerted on protein-G coated beads bound to IgG antibodies immobilized on a surface.", [["surface", "ANATOMY", 98, 105], ["surface", "CELLULAR_COMPONENT", 98, 105], ["protein-G coated beads", "PROTEIN", 34, 56], ["IgG antibodies", "PROTEIN", 66, 80], ["Rotational forces", "TREATMENT", 0, 17], ["protein-G coated beads", "TREATMENT", 34, 56], ["IgG antibodies", "TEST", 66, 80]]], ["Rotating fields revealed an oscillating behavior, which can be understood from the balance between the applied magnetic torque and the torque due to the deformation of the biological bond.P-479Studying interactions between COP1 regulatory protein and HY5 transcription factor D. S. Dalafave The College of New Jersey, Ewing, NJ 18940, USA This work addresses important questions of protein-ligand interactions and selective protein recognition.", [["COP1", "GENE_OR_GENE_PRODUCT", 223, 227], ["HY5", "GENE_OR_GENE_PRODUCT", 251, 254], ["P", "DNA", 188, 189], ["COP1 regulatory protein", "PROTEIN", 223, 246], ["HY5 transcription factor", "PROTEIN", 251, 275], ["Rotating fields", "TEST", 0, 15], ["an oscillating behavior", "PROBLEM", 25, 48], ["selective protein recognition", "TEST", 414, 443], ["oscillating behavior", "OBSERVATION", 28, 48], ["biological bond", "ANATOMY", 172, 187]]], ["Proteinligand bindings are crucial for many cellular processes.", [["cellular", "ANATOMY", 44, 52], ["cellular", "CELL", 44, 52], ["many cellular processes", "PROBLEM", 39, 62], ["cellular processes", "OBSERVATION", 44, 62]]], ["Dependable methods for predicting binding sites would lead to a better understanding of proteins' selective recognition and would, in turn, help research on fighting diseases.", [["predicting binding sites", "PROBLEM", 23, 47], ["fighting diseases", "PROBLEM", 157, 174]]], ["Presented here is a study of interactions between the WD domain found in a regulatory protein COP1 and the motif V-P-E/D-\u03a6-G (\u03a6=hydrophobic residue) found in a transcription factor HY5.", [["COP1", "GENE_OR_GENE_PRODUCT", 94, 98], ["HY5", "GENE_OR_GENE_PRODUCT", 181, 184], ["WD domain", "PROTEIN", 54, 63], ["regulatory protein", "PROTEIN", 75, 93], ["COP1", "PROTEIN", 94, 98], ["motif V-P-E/D-\u03a6-G", "DNA", 107, 124], ["transcription factor", "PROTEIN", 160, 180], ["HY5", "PROTEIN", 181, 184], ["a study", "TEST", 18, 25], ["a regulatory protein COP1", "TEST", 73, 98], ["the motif V", "TEST", 103, 114], ["D", "TEST", 119, 120], ["hydrophobic residue", "PROBLEM", 128, 147]]], ["COP1 and HY5 proteins have opposing roles in developmental regulation.", [["COP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["HY5", "GENE_OR_GENE_PRODUCT", 9, 12], ["COP1", "PROTEIN", 0, 4], ["HY5 proteins", "PROTEIN", 9, 21], ["HY5 proteins", "TEST", 9, 21], ["HY5 proteins", "OBSERVATION", 9, 21], ["developmental regulation", "OBSERVATION", 45, 69]]], ["COP1 can repress HY5 by directly binding with it.", [["COP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["HY5", "GENE_OR_GENE_PRODUCT", 17, 20], ["COP1", "PROTEIN", 0, 4], ["HY5", "PROTEIN", 17, 20]]], ["The repression involves specific interactions between the WD domain and the motif V-P-E/D-\u03a6-G.", [["WD domain", "DNA", 58, 67]]], ["Previous experimental research showed that mutations in the motif's V-P pair resulted in a large decrease in HY5 repression.", [["HY5", "GENE_OR_GENE_PRODUCT", 109, 112], ["motif's V-P pair", "DNA", 60, 76], ["HY5", "PROTEIN", 109, 112], ["mutations", "PROBLEM", 43, 52], ["a large decrease in HY5 repression", "PROBLEM", 89, 123], ["large", "OBSERVATION_MODIFIER", 91, 96], ["decrease", "OBSERVATION_MODIFIER", 97, 105], ["HY5 repression", "OBSERVATION", 109, 123]]], ["To study effects of similar mutations, residues in the motif V-P-E/D-\u03a6-G were systematically substituted with other residues.", [["P", "DNA", 63, 64], ["E", "DNA", 65, 66], ["D", "DNA", 67, 68], ["\u03a6-G", "DNA", 69, 72], ["similar mutations", "PROBLEM", 20, 37], ["the motif V", "TEST", 51, 62]]], ["Interactions between the mutated motif and the WD domain were studied.", [["WD domain", "DNA", 47, 56]]], ["Distributions of binding sites, bond lengths, local shape complementarity, and interaction potentials were modeled for each residue substitution.", [["binding sites", "PROTEIN", 17, 30], ["binding sites", "PROBLEM", 17, 30], ["each residue substitution", "PROBLEM", 119, 144], ["binding sites", "OBSERVATION", 17, 30], ["bond", "OBSERVATION_MODIFIER", 32, 36], ["lengths", "OBSERVATION_MODIFIER", 37, 44], ["local", "OBSERVATION_MODIFIER", 46, 51], ["shape", "OBSERVATION_MODIFIER", 52, 57]]], ["The study identified binding sites critical for the COP1-HY5 binding.", [["COP1", "GENE_OR_GENE_PRODUCT", 52, 56], ["HY5", "GENE_OR_GENE_PRODUCT", 57, 60], ["binding sites", "DNA", 21, 34], ["COP1", "PROTEIN", 52, 56], ["HY5", "PROTEIN", 57, 60], ["The study", "TEST", 0, 9], ["binding sites", "PROBLEM", 21, 34], ["the COP1-HY5 binding", "PROBLEM", 48, 68], ["HY5 binding", "OBSERVATION", 57, 68]]], ["Some HY5 residues in the vicinity of the motif were also found to be important in the binding.", [["HY5", "GENE_OR_GENE_PRODUCT", 5, 8], ["HY5 residues", "PROTEIN", 5, 17], ["Some HY5 residues", "PROBLEM", 0, 17], ["HY5 residues", "OBSERVATION", 5, 17]]], ["The significance of the results for understanding selective protein recognition is discussed.P-478Determination of protein-ligand binding thermodynamics by thermal shift assay P. Cimmperman, A. Zubriene, L. Baranauskiene, E. Kazlauskas, J. Matuliene, D. Matulis Laboratory of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius, Lithuania Thermal shift assay determines the effect of ligand binding on the protein thermal denaturation equilibrium.", [["P", "TEST", 93, 94], ["Vilnius", "TREATMENT", 339, 346], ["Lithuania Thermal shift assay", "TREATMENT", 348, 377], ["ligand binding", "PROBLEM", 403, 417], ["the protein thermal denaturation equilibrium", "PROBLEM", 421, 465]]], ["First, the model describing protein stabilization and destabilization by ligand binding to the native and unfolded states.", [["protein stabilization", "TREATMENT", 28, 49], ["protein stabilization", "OBSERVATION", 28, 49], ["unfolded", "OBSERVATION", 106, 114]]], ["Second, the split of protein melting transitions by tightly binding ligands is presented when the transition of free protein and ligand-bound protein occur separately.", [["ligand-bound protein", "PROTEIN", 129, 149], ["protein melting transitions", "PROBLEM", 21, 48], ["tightly binding ligands", "PROBLEM", 52, 75], ["free protein and ligand-bound protein", "TEST", 112, 149], ["protein melting", "OBSERVATION", 21, 36], ["binding ligands", "OBSERVATION", 60, 75]]], ["Mathematical equations describing the protein unfolding and ligand binding thermodynamic parameters at various temperatures are presented.", [["Mathematical equations", "PROBLEM", 0, 22], ["the protein unfolding", "PROBLEM", 34, 55], ["ligand binding thermodynamic parameters", "TEST", 60, 99]]], ["The protein melting temperature shift can be determined by various techniques such as differential scanning calorimetry, circular dichroism, and intrinsic or extrinsic fluorescence.", [["The protein melting temperature shift", "PROBLEM", 0, 37], ["differential scanning calorimetry", "TEST", 86, 119], ["circular dichroism", "TEST", 121, 139], ["intrinsic or extrinsic fluorescence", "PROBLEM", 145, 180], ["circular dichroism", "OBSERVATION", 121, 139], ["extrinsic fluorescence", "OBSERVATION", 158, 180]]], ["The advantages of fluorescent techniques are presented.", [["fluorescent techniques", "TEST", 18, 40]]], ["The melting temperature shift caused by ligand binding is dependent on the thermodynamic parameters of protein unfolding and ligand binding, including enthalpy, entropy, and heat capacity, thus allowing determination of binding thermodynamics.", [["The melting temperature shift", "PROBLEM", 0, 29], ["protein unfolding and ligand binding", "PROBLEM", 103, 139], ["heat capacity", "TEST", 174, 187], ["binding thermodynamics", "PROBLEM", 220, 242]]], ["Application of the models in the design of Hsp90 chaperone and carbonic anhydrase inhibitors is discussed.", [["Hsp90", "GENE_OR_GENE_PRODUCT", 43, 48], ["carbonic anhydrase", "GENE_OR_GENE_PRODUCT", 63, 81], ["Hsp90 chaperone", "PROTEIN", 43, 58], ["Hsp90 chaperone", "TREATMENT", 43, 58], ["carbonic anhydrase inhibitors", "TREATMENT", 63, 92]]], ["Comparison with isothermal titration calorimetry data is presented.", [["isothermal titration calorimetry data", "TEST", 16, 53]]], ["Recent reports have shown that the bacterial redox protein azurin can enter into cancer cells and induce apoptosis by stabilizing p53.", [["cancer cells", "ANATOMY", 81, 93], ["cancer", "DISEASE", 81, 87], ["azurin", "GENE_OR_GENE_PRODUCT", 59, 65], ["cancer cells", "CELL", 81, 93], ["p53", "GENE_OR_GENE_PRODUCT", 130, 133], ["azurin", "PROTEIN", 59, 65], ["cancer cells", "CELL_TYPE", 81, 93], ["p53", "PROTEIN", 130, 133], ["the bacterial redox protein azurin", "TREATMENT", 31, 65], ["cancer cells", "PROBLEM", 81, 93], ["apoptosis", "PROBLEM", 105, 114], ["cancer cells", "OBSERVATION", 81, 93]]], ["The formation of a complex between the two proteins has been demonstrated, but little is known about binding features.", [["complex", "OBSERVATION_MODIFIER", 19, 26]]], ["For the first time, we show here that azurin binds to the N-terminal region of p53 with a dissociation constant in the 5-10 \u00b5M range.", [["N", "CHEMICAL", 58, 59], ["azurin", "GENE_OR_GENE_PRODUCT", 38, 44], ["p53", "GENE_OR_GENE_PRODUCT", 79, 82], ["azurin", "PROTEIN", 38, 44], ["N-terminal region", "PROTEIN", 58, 75], ["p53", "PROTEIN", 79, 82], ["azurin binds", "PROBLEM", 38, 50], ["a dissociation constant", "PROBLEM", 88, 111], ["terminal", "ANATOMY_MODIFIER", 60, 68]]], ["Trp phosphorescence lifetime measurements revealed conformational changes of azurin induced by the interaction with p53(1-63).", [["p53(1-63", "CHEMICAL", 116, 124], ["Trp", "CHEMICAL", 0, 3], ["p53(1-63", "CHEMICAL", 116, 124], ["Trp", "AMINO_ACID", 0, 3], ["azurin", "GENE_OR_GENE_PRODUCT", 77, 83], ["azurin", "PROTEIN", 77, 83], ["Trp phosphorescence lifetime measurements", "TEST", 0, 41], ["conformational changes of azurin", "PROBLEM", 51, 83]]], ["Acrylamide quenching of Trp phosphorescence also indicated a significant increase of the overall flexibility of azurin upon binding to p53 .", [["Acrylamide", "CHEMICAL", 0, 10], ["Trp", "CHEMICAL", 24, 27], ["Acrylamide", "CHEMICAL", 0, 10], ["Trp", "CHEMICAL", 24, 27], ["Acrylamide", "SIMPLE_CHEMICAL", 0, 10], ["Trp", "AMINO_ACID", 24, 27], ["azurin", "GENE_OR_GENE_PRODUCT", 112, 118], ["p53", "GENE_OR_GENE_PRODUCT", 135, 138], ["azurin", "PROTEIN", 112, 118], ["p53", "PROTEIN", 135, 138], ["Trp phosphorescence", "TEST", 24, 43], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["increase", "OBSERVATION_MODIFIER", 73, 81]]], ["No change of the fluorescence emission of p53(1-63) was detected in the presence of azurin.", [["p53(1-63", "CHEMICAL", 42, 50], ["p53(1-63", "CHEMICAL", 42, 50], ["azurin", "CHEMICAL", 84, 90], ["p53(1-63", "SIMPLE_CHEMICAL", 42, 50], ["azurin", "GENE_OR_GENE_PRODUCT", 84, 90], ["p53(1", "PROTEIN", 42, 47], ["azurin", "PROTEIN", 84, 90], ["the fluorescence emission", "TEST", 13, 38], ["p53(1", "TEST", 42, 47], ["azurin", "TREATMENT", 84, 90], ["change", "OBSERVATION_MODIFIER", 3, 9]]], ["The latter finding suggests that W23 of p53 is not directly involved in domain binding to azurin, indicating that the binding site is distinct from that of MDM2.", [["W23", "GENE_OR_GENE_PRODUCT", 33, 36], ["p53", "GENE_OR_GENE_PRODUCT", 40, 43], ["azurin", "GENE_OR_GENE_PRODUCT", 90, 96], ["MDM2", "GENE_OR_GENE_PRODUCT", 156, 160], ["W23", "PROTEIN", 33, 36], ["p53", "PROTEIN", 40, 43], ["azurin", "PROTEIN", 90, 96], ["MDM2", "PROTEIN", 156, 160], ["azurin", "TREATMENT", 90, 96], ["the binding site", "PROBLEM", 114, 130], ["MDM2", "PROBLEM", 156, 160], ["MDM2", "OBSERVATION", 156, 160]]], ["The present results may assist the design of novel cancer treatments based on p53 stabilization by azurin.Study of HSA-Bilirubin interaction by QCM-D and AFMA.", [["cancer", "ANATOMY", 51, 57], ["cancer", "DISEASE", 51, 57], ["QCM-D", "CHEMICAL", 144, 149], ["Bilirubin", "CHEMICAL", 119, 128], ["cancer", "CANCER", 51, 57], ["p53", "GENE_OR_GENE_PRODUCT", 78, 81], ["azurin", "GENE_OR_GENE_PRODUCT", 99, 105], ["HSA", "SIMPLE_CHEMICAL", 115, 118], ["Bilirubin", "SIMPLE_CHEMICAL", 119, 128], ["QCM-D", "SIMPLE_CHEMICAL", 144, 149], ["AFMA", "SIMPLE_CHEMICAL", 154, 158], ["p53", "PROTEIN", 78, 81], ["azurin", "PROTEIN", 99, 105], ["HSA", "PROTEIN", 115, 118], ["novel cancer treatments", "TREATMENT", 45, 68], ["p53 stabilization", "TREATMENT", 78, 95], ["azurin", "TREATMENT", 99, 105], ["HSA", "TEST", 115, 118], ["Bilirubin interaction", "TEST", 119, 140], ["QCM", "TEST", 144, 147], ["D", "PROBLEM", 148, 149], ["AFMA", "PROBLEM", 154, 158], ["cancer", "OBSERVATION", 51, 57]]], ["Eleta 1 , R. Georgieva 2 , H. B\u00e4umler 2 , J. L. Toca-Herrera 1 1 CIC biomaGUNE, 20009 Donostia-San Sebasti\u00e1n, Spain, 2 Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany Human Serum Albumin (HSA) is the most abundant nonglycosilated plasma protein in the human body.", [["plasma", "ANATOMY", 234, 240], ["body", "ANATOMY", 262, 266], ["Human", "ORGANISM", 171, 176], ["Serum", "ORGANISM_SUBSTANCE", 177, 182], ["Albumin", "GENE_OR_GENE_PRODUCT", 183, 190], ["HSA", "GENE_OR_GENE_PRODUCT", 192, 195], ["plasma", "ORGANISM_SUBSTANCE", 234, 240], ["human", "ORGANISM", 256, 261], ["body", "ORGANISM_SUBDIVISION", 262, 266], ["HSA", "PROTEIN", 192, 195], ["nonglycosilated plasma protein", "PROTEIN", 218, 248], ["Human", "SPECIES", 171, 176], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["Toca", "TEST", 48, 52], ["Herrera", "TEST", 53, 60], ["biomaGUNE", "TEST", 69, 78], ["Germany Human Serum Albumin (HSA", "TEST", 163, 195], ["plasma protein", "OBSERVATION", 234, 248], ["human", "ANATOMY", 256, 261], ["body", "ANATOMY_MODIFIER", 262, 266]]], ["This multifunctional protein has ligand-binding and transport properties, antioxidant functions and enzymatic activity [1] .", [["multifunctional protein", "PROTEIN", 5, 28]]], ["Bilirubin interacts with albumin in order to be transported from the blood to the liver where it is secreted.", [["blood", "ANATOMY", 69, 74], ["liver", "ANATOMY", 82, 87], ["Bilirubin", "CHEMICAL", 0, 9], ["Bilirubin", "CHEMICAL", 0, 9], ["Bilirubin", "SIMPLE_CHEMICAL", 0, 9], ["albumin", "GENE_OR_GENE_PRODUCT", 25, 32], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["liver", "ORGAN", 82, 87], ["albumin", "PROTEIN", 25, 32], ["Bilirubin", "TEST", 0, 9], ["albumin", "TREATMENT", 25, 32], ["liver", "ANATOMY", 82, 87], ["secreted", "OBSERVATION", 100, 108]]], ["The interaction occurs specifically in HSA I-domain of its three domains [2] .", [["HSA I-domain", "PROTEIN", 39, 51]]], ["In our work, we investigate the interaction between HSA and bilirubin by Quartz Crystal Microbalance with Dissipation (QCM-D) and Atomic Force Microscopy (AFM) [1, 3] .", [["bilirubin", "CHEMICAL", 60, 69], ["bilirubin", "CHEMICAL", 60, 69], ["HSA", "SIMPLE_CHEMICAL", 52, 55], ["bilirubin", "SIMPLE_CHEMICAL", 60, 69], ["HSA", "PROTEIN", 52, 55], ["HSA", "TEST", 52, 55], ["bilirubin", "TEST", 60, 69], ["Dissipation (QCM", "TEST", 106, 122], ["Atomic Force Microscopy", "TEST", 130, 153]]], ["Albumin was adsorbed on negatively charged silicon oxide.", [["Albumin", "CHEMICAL", 0, 7], ["silicon oxide", "CHEMICAL", 43, 56], ["silicon oxide", "CHEMICAL", 43, 56], ["Albumin", "GENE_OR_GENE_PRODUCT", 0, 7], ["silicon oxide", "SIMPLE_CHEMICAL", 43, 56], ["Albumin", "TREATMENT", 0, 7], ["negatively charged silicon oxide", "TREATMENT", 24, 56]]], ["However, HSA was removed after rinsing with PBS.", [["HSA", "SIMPLE_CHEMICAL", 9, 12], ["HSA", "PROTEIN", 9, 12], ["PBS", "TREATMENT", 44, 47]]], ["HSA adsorbed on positively charged polyelectrolyte multilayers leads to a stable layer of surface mass density of 272 ng/cm 2 .", [["surface", "ANATOMY", 90, 97], ["HSA", "SIMPLE_CHEMICAL", 0, 3], ["polyelectrolyte multilayers", "SIMPLE_CHEMICAL", 35, 62], ["positively charged polyelectrolyte multilayers", "TREATMENT", 16, 62], ["surface mass density", "PROBLEM", 90, 110], ["polyelectrolyte multilayers", "OBSERVATION", 35, 62], ["stable", "OBSERVATION_MODIFIER", 74, 80], ["layer", "OBSERVATION_MODIFIER", 81, 86], ["surface", "OBSERVATION_MODIFIER", 90, 97], ["mass", "OBSERVATION", 98, 102], ["density", "OBSERVATION_MODIFIER", 103, 110], ["272 ng/cm", "OBSERVATION_MODIFIER", 114, 123]]], ["Cross linked albumin with glutaraldehyde after its adsorption on NH 2 -terminated thiols is also stable reaching surface mass density of 296 ng/cm 2 .", [["surface", "ANATOMY", 113, 120], ["glutaraldehyde", "CHEMICAL", 26, 40], ["NH 2 -terminated thiols", "CHEMICAL", 65, 88], ["glutaraldehyde", "CHEMICAL", 26, 40], ["NH 2", "CHEMICAL", 65, 69], ["thiols", "CHEMICAL", 82, 88], ["albumin", "GENE_OR_GENE_PRODUCT", 13, 20], ["glutaraldehyde", "SIMPLE_CHEMICAL", 26, 40], ["NH 2 -terminated thiols", "SIMPLE_CHEMICAL", 65, 88], ["Cross linked albumin", "TREATMENT", 0, 20], ["glutaraldehyde", "TREATMENT", 26, 40], ["albumin", "OBSERVATION", 13, 20], ["stable", "OBSERVATION_MODIFIER", 97, 103], ["surface", "OBSERVATION_MODIFIER", 113, 120], ["mass", "OBSERVATION", 121, 125], ["density", "OBSERVATION_MODIFIER", 126, 133], ["296 ng/cm", "OBSERVATION_MODIFIER", 137, 146]]], ["A preliminary bilirubin adsorption results on cross linked HSA substrate show that 200 ng/cm 2 is immobilized.", [["bilirubin", "CHEMICAL", 14, 23], ["bilirubin", "CHEMICAL", 14, 23], ["bilirubin", "SIMPLE_CHEMICAL", 14, 23], ["HSA", "SIMPLE_CHEMICAL", 59, 62], ["A preliminary bilirubin adsorption", "TEST", 0, 34], ["cross linked HSA substrate", "TEST", 46, 72]]], ["Taking into account that HSA-bilirubin stoichiometry is 1:1, the outcome demonstrates that the 70% of HSA I-domains remain active.", [["bilirubin", "CHEMICAL", 29, 38], ["bilirubin", "CHEMICAL", 29, 38], ["HSA", "SIMPLE_CHEMICAL", 25, 28], ["bilirubin", "SIMPLE_CHEMICAL", 29, 38], ["HSA", "GENE_OR_GENE_PRODUCT", 102, 105], ["HSA", "PROTEIN", 25, 28], ["HSA I", "PROTEIN", 102, 107], ["HSA", "TEST", 25, 28], ["bilirubin stoichiometry", "TEST", 29, 52], ["active", "OBSERVATION", 123, 129]]], ["Antimicrobial peptides (AMPs) are short positively charged polypeptides.", [["Antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 0, 22], ["Antimicrobial peptides (AMPs)", "TREATMENT", 0, 29], ["short positively charged polypeptides", "PROBLEM", 34, 71]]], ["They are important due to their potential to provide an alternative to conventional therapy against bacterial infections. rBPI 21 is a 21 kDa peptide based on the Nterminal region of the neutrophil bactericidal/permeabilityincreasing protein (BPI).", [["neutrophil", "ANATOMY", 187, 197], ["bacterial infections", "DISEASE", 100, 120], ["neutrophil bactericidal/permeabilityincreasing protein", "GENE_OR_GENE_PRODUCT", 187, 241], ["BPI", "GENE_OR_GENE_PRODUCT", 243, 246], ["Nterminal region", "PROTEIN", 163, 179], ["neutrophil bactericidal/permeabilityincreasing protein", "PROTEIN", 187, 241], ["BPI", "PROTEIN", 243, 246], ["conventional therapy", "TREATMENT", 71, 91], ["bacterial infections", "PROBLEM", 100, 120], ["rBPI", "TEST", 122, 126], ["a 21 kDa peptide", "TREATMENT", 133, 149], ["the neutrophil bactericidal", "TEST", 183, 210], ["BPI", "TEST", 243, 246], ["infections", "OBSERVATION", 110, 120], ["neutrophil bactericidal", "OBSERVATION", 187, 210]]], ["It was shown that this AMP possesses bactericidal effects on Gram-negative bacteria and higher affinity for lipopolysaccharide (LPS), neutralizing its effect.", [["AMP", "CHEMICAL", 23, 26], ["lipopolysaccharide", "CHEMICAL", 108, 126], ["LPS", "CHEMICAL", 128, 131], ["AMP", "CHEMICAL", 23, 26], ["AMP", "SIMPLE_CHEMICAL", 23, 26], ["Gram", "SIMPLE_CHEMICAL", 61, 65], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 108, 126], ["LPS", "SIMPLE_CHEMICAL", 128, 131], ["this AMP possesses bactericidal effects", "PROBLEM", 18, 57], ["Gram", "TEST", 61, 65], ["negative bacteria", "PROBLEM", 66, 83], ["lipopolysaccharide (LPS", "TREATMENT", 108, 131], ["neutralizing its effect", "PROBLEM", 134, 157], ["negative bacteria", "OBSERVATION_MODIFIER", 66, 83]]], ["The peptide use against meningitis, is in Phase III clinical trials.", [["meningitis", "DISEASE", 24, 34], ["meningitis", "PROBLEM", 24, 34], ["meningitis", "OBSERVATION", 24, 34]]], ["Here, we demonstrate that rBPI 21 promotes aggregation of negatively charged large unilamellar vesicles (LUV) and LPS aggregates, by dynamic light scattering, while for zwitterionic phosphatidylcholine (POPC) LUV the size remains unchanged.", [["unilamellar vesicles", "ANATOMY", 83, 103], ["LUV", "ANATOMY", 105, 108], ["rBPI", "CHEMICAL", 26, 30], ["LPS", "CHEMICAL", 114, 117], ["phosphatidylcholine", "CHEMICAL", 182, 201], ["rBPI 21", "CHEMICAL", 26, 33], ["phosphatidylcholine", "CHEMICAL", 182, 201], ["POPC", "CHEMICAL", 203, 207], ["rBPI 21", "GENE_OR_GENE_PRODUCT", 26, 33], ["unilamellar vesicles", "CELLULAR_COMPONENT", 83, 103], ["zwitterionic phosphatidylcholine", "SIMPLE_CHEMICAL", 169, 201], ["POPC", "SIMPLE_CHEMICAL", 203, 207], ["rBPI 21", "PROTEIN", 26, 33], ["rBPI", "TEST", 26, 30], ["negatively charged large unilamellar vesicles", "PROBLEM", 58, 103], ["LPS aggregates", "TEST", 114, 128], ["zwitterionic phosphatidylcholine (POPC)", "TREATMENT", 169, 208], ["large", "OBSERVATION_MODIFIER", 77, 82], ["unilamellar vesicles", "OBSERVATION", 83, 103], ["LPS aggregates", "OBSERVATION_MODIFIER", 114, 128], ["size", "OBSERVATION_MODIFIER", 217, 221], ["unchanged", "OBSERVATION_MODIFIER", 230, 239]]], ["The aggregation increases with peptide concentration until peptide promotes massive aggregation followed by sample flocculation/precipitation.", [["sample", "ANATOMY", 108, 114], ["aggregation", "DISEASE", 84, 95], ["peptide concentration", "TREATMENT", 31, 52], ["massive aggregation", "PROBLEM", 76, 95], ["sample flocculation", "PROBLEM", 108, 127], ["precipitation", "PROBLEM", 128, 141], ["aggregation", "OBSERVATION", 4, 15], ["massive", "OBSERVATION_MODIFIER", 76, 83], ["aggregation", "OBSERVATION", 84, 95]]], ["With the rBPI 21 -lipid interaction there is a progressive change in the zeta-potential of the LUV systems and LPS aggregates.", [["LPS", "CHEMICAL", 111, 114], ["LUV", "GENE_OR_GENE_PRODUCT", 95, 98], ["LPS", "SIMPLE_CHEMICAL", 111, 114], ["the rBPI", "TEST", 5, 13], ["a progressive change", "PROBLEM", 45, 65], ["LPS aggregates", "PROBLEM", 111, 125], ["progressive", "OBSERVATION_MODIFIER", 47, 58], ["change", "OBSERVATION_MODIFIER", 59, 65], ["zeta-potential", "OBSERVATION_MODIFIER", 73, 87], ["LUV systems", "ANATOMY", 95, 106], ["LPS aggregates", "OBSERVATION", 111, 125]]], ["LUV systems composed of phosphatidylglycerol (POPG) and POPC:POPG mixtures have higher zeta-potential variations than POPC LUV.", [["phosphatidylglycerol", "CHEMICAL", 24, 44], ["POPG", "CHEMICAL", 46, 50], ["POPC", "CHEMICAL", 56, 60], ["POPC LUV", "CHEMICAL", 118, 126], ["phosphatidylglycerol", "CHEMICAL", 24, 44], ["POPG", "CHEMICAL", 46, 50], ["POPC", "CHEMICAL", 56, 60], ["POPG", "CHEMICAL", 61, 65], ["POPC", "CHEMICAL", 118, 122], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 24, 44], ["POPG", "SIMPLE_CHEMICAL", 46, 50], ["POPC", "SIMPLE_CHEMICAL", 56, 60], ["POPG", "SIMPLE_CHEMICAL", 61, 65], ["LUV systems", "TEST", 0, 11], ["phosphatidylglycerol (POPG)", "TREATMENT", 24, 51], ["POPG mixtures", "TREATMENT", 61, 74], ["POPC LUV", "TREATMENT", 118, 126], ["zeta-potential variations", "OBSERVATION", 87, 112]]], ["For LPS aggregates, rBPI 21 neutralizes the surface charge and at higher peptide concentrations overcompensates it.", [["surface", "ANATOMY", 44, 51], ["LPS", "CHEMICAL", 4, 7], ["rBPI", "CHEMICAL", 20, 24], ["LPS", "SIMPLE_CHEMICAL", 4, 7], ["rBPI 21", "SIMPLE_CHEMICAL", 20, 27], ["surface", "CELLULAR_COMPONENT", 44, 51], ["LPS aggregates", "TREATMENT", 4, 18], ["rBPI", "TREATMENT", 20, 24], ["the surface charge", "TREATMENT", 40, 58]]], ["Results demonstrate that the interaction of the peptide rBPI 21 with LPS aggregates and LUV systems has electrostatic and hydrophobic contributions.P-482Serratia marcescens heme acquisition system: heme transport and protein:protein interactions M. Delepierre Unit\u00e9 de RMN des Biomol\u00e9cules CNRS URA 2185, Institut Pasteur, Paris, France Heme transport systems in bacteria are required and might be potential target for antibacterial drugs.", [["rBPI", "CHEMICAL", 56, 60], ["LPS", "CHEMICAL", 69, 72], ["P-482Serratia", "CHEMICAL", 148, 161], ["rBPI 21", "CHEMICAL", 56, 63], ["heme", "CHEMICAL", 198, 202], ["LPS aggregates", "SIMPLE_CHEMICAL", 69, 83], ["heme", "SIMPLE_CHEMICAL", 198, 202], ["heme", "PROTEIN", 198, 202], ["482Serratia marcescens", "SPECIES", 150, 172], ["P-482Serratia marcescens", "SPECIES", 148, 172], ["M. Delepierre Unit\u00e9 de RMN des Biomol\u00e9cules CNRS URA 2185", "SPECIES", 246, 303], ["the peptide rBPI", "TEST", 44, 60], ["LPS aggregates", "PROBLEM", 69, 83], ["bacteria", "PROBLEM", 363, 371], ["antibacterial drugs", "TREATMENT", 419, 438], ["electrostatic", "OBSERVATION", 104, 117], ["hydrophobic contributions", "OBSERVATION", 122, 147]]], ["The heme acquisition system, Has, exists in pathogenic as well as in opportunistic bacteria but only for the latter one extensive studies have been conducted, constituting as such a model system.", [["heme", "CHEMICAL", 4, 8], ["The heme acquisition system", "TEST", 0, 27], ["pathogenic", "PROBLEM", 44, 54], ["opportunistic bacteria", "PROBLEM", 69, 91], ["extensive studies", "TEST", 120, 137], ["heme", "OBSERVATION", 4, 8], ["pathogenic", "OBSERVATION", 44, 54], ["opportunistic bacteria", "OBSERVATION", 69, 91]]], ["The outer membrane receptor HasR, the central component of this system, functions in synergy with a secreted high affinity heme binding protein, the hemophore HasA.", [["outer membrane", "ANATOMY", 4, 18], ["outer membrane", "CELLULAR_COMPONENT", 4, 18], ["HasR", "GENE_OR_GENE_PRODUCT", 28, 32], ["outer membrane receptor", "PROTEIN", 4, 27], ["HasR", "PROTEIN", 28, 32], ["secreted high affinity heme binding protein", "PROTEIN", 100, 143], ["hemophore HasA", "PROTEIN", 149, 163], ["outer", "ANATOMY_MODIFIER", 4, 9], ["membrane", "ANATOMY_MODIFIER", 10, 18], ["receptor HasR", "OBSERVATION", 19, 32], ["central", "OBSERVATION_MODIFIER", 38, 45], ["component", "OBSERVATION_MODIFIER", 46, 55]]], ["HasA extracts heme from host hemoproteins and returns it to HasR.", [["HasA", "CHEMICAL", 0, 4], ["heme", "CHEMICAL", 14, 18], ["heme", "SIMPLE_CHEMICAL", 14, 18], ["HasR", "GENE_OR_GENE_PRODUCT", 60, 64], ["HasA", "PROTEIN", 0, 4], ["heme", "PROTEIN", 14, 18], ["HasR", "PROTEIN", 60, 64], ["host hemoproteins", "PROBLEM", 24, 41], ["heme from host hemoproteins", "OBSERVATION_MODIFIER", 14, 41]]], ["Then, the energy given by a protein complex of the inner membrane is used to allow heme entrance across the bacterial membrane and to eject the empty hemophore from the receptor.", [["inner membrane", "ANATOMY", 51, 65], ["membrane", "ANATOMY", 118, 126], ["heme", "CHEMICAL", 83, 87], ["inner membrane", "CELLULAR_COMPONENT", 51, 65], ["bacterial membrane", "CELLULAR_COMPONENT", 108, 126], ["protein complex", "PROTEIN", 28, 43], ["empty hemophore", "PROTEIN", 144, 159], ["inner membrane", "ANATOMY", 51, 65], ["bacterial membrane", "OBSERVATION", 108, 126]]], ["Reconstitution of this heme acquisition system in E coli, overexpression and purification of its various components have allowed us to obtain sufficient amount of protein to perform NMR and biophysical studies to analyse at the molecular level the different steps of heme acquisition by HasR.", [["heme", "CHEMICAL", 23, 27], ["heme", "CHEMICAL", 267, 271], ["heme", "GENE_OR_GENE_PRODUCT", 23, 27], ["E coli", "ORGANISM", 50, 56], ["heme", "SIMPLE_CHEMICAL", 267, 271], ["HasR", "GENE_OR_GENE_PRODUCT", 287, 291], ["heme", "PROTEIN", 23, 27], ["heme", "PROTEIN", 267, 271], ["HasR", "PROTEIN", 287, 291], ["E coli", "SPECIES", 50, 56], ["E coli", "SPECIES", 50, 56], ["this heme acquisition system", "PROBLEM", 18, 46], ["E coli", "PROBLEM", 50, 56], ["overexpression", "PROBLEM", 58, 72], ["purification", "TREATMENT", 77, 89], ["NMR", "TEST", 182, 185], ["biophysical studies", "TEST", 190, 209], ["E coli", "OBSERVATION_MODIFIER", 50, 56]]], ["Protein-protein interactions (PPI) are the central pillar supporting most of biological functional activity on the molecular level.", [["Protein-protein interactions (PPI", "TREATMENT", 0, 33], ["the central pillar", "TREATMENT", 39, 57], ["central", "OBSERVATION_MODIFIER", 43, 50], ["pillar", "OBSERVATION_MODIFIER", 51, 57], ["functional activity", "OBSERVATION", 88, 107]]], ["A binding event between two proteins typically consists of two stages: 1) diffusional search of the binding partners for each other, and 2) specific recognition of the compatible binding surfaces followed by the formation of the complex.", [["binding partners", "PROTEIN", 100, 116], ["A binding event", "PROBLEM", 0, 15], ["the compatible binding surfaces", "PROBLEM", 164, 195], ["binding surfaces", "OBSERVATION", 179, 195]]], ["We focus here on the non-specific component of PPI, which refers to all physico-chemical properties of the binding partners (such as size, charge, isoelectric point, hydrophilicity etc.) that are independent of the exact details of their binding sites, but which could in turn affect their localization or diffusional search for one another.", [["binding sites", "PROTEIN", 238, 251], ["PPI", "TREATMENT", 47, 50], ["PPI", "OBSERVATION", 47, 50]]], ["It is known that proteins co-localize due to segregation into different cellular compartments, sequestration via anchor and scaffold proteins or even chemical modifications.", [["cellular compartments", "ANATOMY", 72, 93], ["cellular", "CELL", 72, 80], ["scaffold proteins", "PROTEIN", 124, 141], ["proteins co-localize", "PROBLEM", 17, 37], ["segregation into different cellular compartments", "PROBLEM", 45, 93], ["anchor and scaffold proteins", "TREATMENT", 113, 141], ["cellular compartments", "OBSERVATION", 72, 93], ["scaffold proteins", "OBSERVATION", 124, 141], ["chemical modifications", "OBSERVATION", 150, 172]]], ["We suggest that the non-specific component of PPI determines in part the co-localization and clustering of the binding partners, which then directly in a non-specific fashion influences their interactions.", [["binding partners", "PROTEIN", 111, 127], ["the non-specific component of PPI", "PROBLEM", 16, 49], ["non-specific", "OBSERVATION_MODIFIER", 20, 32], ["PPI", "OBSERVATION", 46, 49]]], ["We examine the possibility that such signature might be encoded within the experimental 3D structures of a large set of known mutually interacting proteins.", [["interacting proteins", "PROTEIN", 135, 155], ["known mutually interacting proteins", "PROBLEM", 120, 155], ["large", "OBSERVATION_MODIFIER", 107, 112]]], ["We provide preliminary evidence that this indeed may be the case, and corroborate our findings by using different statistical tests to compare those features of the known interacting partners, and ascertain correlations and commonalities between them.P-488A link between hinge-bending domain motions and the temperature dependence of catalysis in IPMDH I. Hajd\u00fa, A. Szil\u00e1gyi, J. Kardos, P. Z\u00e1vodszky Institute of Enzymology, Hung Acad Sci, Budapest, Hungary Enzyme function depends on specific conformational motions.", [["P", "DNA", 251, 252], ["different statistical tests", "TEST", 104, 131], ["A link between hinge-bending domain motions", "PROBLEM", 256, 299], ["the temperature dependence", "PROBLEM", 304, 330], ["Hungary Enzyme function", "TEST", 450, 473]]], ["Since conformational flexibility strongly depends on temperature, temperature dependent enzyme kinetic studies with measurements related to dynamics can give us some insight at atomic level into these functionally relevant motions.", [["temperature", "TEST", 53, 64], ["temperature dependent enzyme kinetic studies", "PROBLEM", 66, 110]]], ["The catalytic efficiency (k cat /K M ) of 3-isopropylmalate dehydrogenase for its substrate (IPM) has unusual temperature dependence, showing a local minimum at 35 \u2022 C. In search of an explanation, we measured the individual constants k cat and K M,IPM as a function of temperature, and found that the van't Hoff plot of K M,IPM shows a sigmoid-like transition in the 20-40 \u2022 C temperature range.", [["3-isopropylmalate", "CHEMICAL", 42, 59], ["K", "CHEMICAL", 321, 322], ["3-isopropylmalate", "CHEMICAL", 42, 59], ["IPM", "CHEMICAL", 93, 96], ["IPM", "CHEMICAL", 249, 252], ["IPM", "CHEMICAL", 325, 328], ["3-isopropylmalate dehydrogenase", "GENE_OR_GENE_PRODUCT", 42, 73], ["isopropylmalate dehydrogenase", "PROTEIN", 44, 73], ["The catalytic efficiency", "TEST", 0, 24], ["k cat /K M )", "TEST", 26, 38], ["unusual temperature dependence", "PROBLEM", 102, 132], ["IPM", "TEST", 325, 328], ["temperature dependence", "OBSERVATION_MODIFIER", 110, 132], ["sigmoid", "ANATOMY", 337, 344]]], ["By means of various measurements including H-D exchange and FRET, we showed that the conformational fluctuations, including hinge-bending domain motions increase more steeply with temperature above 30 \u2022 C. The thermodynamic parameters of ligand binding determined by ITC as a function of temperature were found to be strongly correlated to the conformational fluctuations of the enzyme.", [["H-D", "CHEMICAL", 43, 46], ["H-D", "SIMPLE_CHEMICAL", 43, 46], ["ITC", "SIMPLE_CHEMICAL", 267, 270], ["enzyme", "PROTEIN", 379, 385], ["H-D exchange", "TEST", 43, 55], ["the conformational fluctuations", "PROBLEM", 81, 112], ["hinge-bending domain motions", "PROBLEM", 124, 152], ["temperature", "TEST", 180, 191], ["ligand binding", "PROBLEM", 238, 252], ["the enzyme", "TEST", 375, 385]]], ["Because the binding of IPM is associated with a hinge-bending domain closure, the more intense hinge-bending fluctuations at higher temperatures increasingly interfere with IPM binding, thereby abruptly increasing its dissociation constant and leading to the observed unusual temperature dependence of the catalytic efficiency.P-487A simulation approach to Multiple Sclerosis: study of a peptide with a pharmaceutical potential C. Guardiani 1 , S. Marsili 2 , P. Procacci 2 , R. Livi 3 1 Centro Dinamiche Complesse, Universit\u00e0 di Firenze, Italy, 2 Dipartimento di Chimica, Universit\u00e0 di Firenze, Italy, 3 Dipartimento di Fisica, Universit\u00e0 di Firenze, Italy Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system, leading to premature death.", [["central nervous system", "ANATOMY", 714, 736], ["IPM", "CHEMICAL", 23, 26], ["IPM", "CHEMICAL", 173, 176], ["Sclerosis", "DISEASE", 366, 375], ["Multiple Sclerosis", "DISEASE", 658, 676], ["MS", "DISEASE", 678, 680], ["autoimmune disease of the central nervous system", "DISEASE", 688, 736], ["premature death", "DISEASE", 749, 764], ["IPM", "CHEMICAL", 23, 26], ["IPM", "CHEMICAL", 173, 176], ["IPM", "SIMPLE_CHEMICAL", 173, 176], ["central nervous system", "ANATOMICAL_SYSTEM", 714, 736], ["a hinge-bending domain closure", "TREATMENT", 46, 76], ["the more intense hinge-bending fluctuations", "PROBLEM", 78, 121], ["higher temperatures", "PROBLEM", 125, 144], ["IPM binding", "PROBLEM", 173, 184], ["its dissociation", "PROBLEM", 214, 230], ["the catalytic efficiency", "PROBLEM", 302, 326], ["Multiple Sclerosis", "PROBLEM", 357, 375], ["a peptide", "TREATMENT", 386, 395], ["Multiple Sclerosis (MS)", "PROBLEM", 658, 681], ["an autoimmune disease of the central nervous system", "PROBLEM", 685, 736], ["premature death", "PROBLEM", 749, 764], ["catalytic efficiency", "OBSERVATION", 306, 326], ["Sclerosis", "OBSERVATION", 366, 375], ["Multiple", "OBSERVATION_MODIFIER", 658, 666], ["Sclerosis", "OBSERVATION", 667, 676], ["autoimmune disease", "OBSERVATION", 688, 706], ["central", "ANATOMY_MODIFIER", 714, 721], ["nervous system", "ANATOMY", 722, 736]]], ["One of the potential targets of the autoimmune reaction is the myelin protein MOG that has been crystallized in complex with the 8-18C5 MS-autoantibody.", [["autoimmune reaction", "DISEASE", 36, 55], ["MOG", "GENE_OR_GENE_PRODUCT", 78, 81], ["-18C5", "GENE_OR_GENE_PRODUCT", 130, 135], ["myelin protein MOG", "PROTEIN", 63, 81], ["autoantibody", "PROTEIN", 139, 151], ["the autoimmune reaction", "PROBLEM", 32, 55], ["the myelin protein MOG", "PROBLEM", 59, 81], ["autoimmune", "OBSERVATION", 36, 46]]], ["The analysis of contacts and buried surface area combined with an alanine scanning computation reveals the key role of MOG fragment 101-108 for the interaction with 8-18C5.", [["surface area", "ANATOMY", 36, 48], ["alanine", "CHEMICAL", 66, 73], ["101-108", "CHEMICAL", 132, 139], ["8-18C5", "CHEMICAL", 165, 171], ["alanine", "CHEMICAL", 66, 73], ["8-18C5", "CHEMICAL", 165, 171], ["alanine", "AMINO_ACID", 66, 73], ["8-18C5", "SIMPLE_CHEMICAL", 165, 171], ["MOG fragment 101-108", "PROTEIN", 119, 139], ["buried surface area", "PROBLEM", 29, 48], ["an alanine scanning computation", "TEST", 63, 94], ["MOG fragment", "PROBLEM", 119, 131]]], ["A docking simulation shows that the 101-108 fragment, excised from MOG, and kept in crystal-like conformation, is still capable of fitting into the binding pocket of the antibody.", [["101-108 fragment", "DNA", 36, 52], ["MOG", "PROTEIN", 67, 70], ["A docking simulation", "TEST", 0, 20], ["the 101-108 fragment", "PROBLEM", 32, 52]]], ["We then studied, through Replica Exchange Molecular Dynamics simulations, the structural equilibrium distribution of the free peptide and of a number of analogs stabilized by a disulfide bond.", [["disulfide", "CHEMICAL", 177, 186], ["a disulfide bond", "TREATMENT", 175, 191], ["structural", "OBSERVATION_MODIFIER", 78, 88], ["equilibrium", "OBSERVATION_MODIFIER", 89, 100], ["distribution", "OBSERVATION_MODIFIER", 101, 113], ["free peptide", "OBSERVATION", 121, 133]]], ["We found that the free peptide yields a significant fraction of crystal-like conformations and the proportion of native-like structures is further increased by the disulfide bridge.", [["disulfide", "CHEMICAL", 164, 173], ["disulfide bridge", "PROTEIN", 164, 180], ["the free peptide", "PROBLEM", 14, 30], ["a significant fraction of crystal-like conformations", "PROBLEM", 38, 90], ["native-like structures", "PROBLEM", 113, 135], ["the disulfide bridge", "TREATMENT", 160, 180], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["fraction", "OBSERVATION_MODIFIER", 52, 60], ["crystal", "OBSERVATION_MODIFIER", 64, 71], ["like conformations", "OBSERVATION", 72, 90], ["proportion", "OBSERVATION_MODIFIER", 99, 109], ["native", "OBSERVATION", 113, 119], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["disulfide bridge", "OBSERVATION", 164, 180]]], ["When we tried to dock the centroids of the most populated clusters to 8-18C5, we discovered the existence of a docking funnel whose bottom is populated by stable complexes where the peptide occupies the same spatial region as in the crystal.", [["a docking funnel whose bottom", "PROBLEM", 109, 138], ["stable", "OBSERVATION_MODIFIER", 155, 161], ["crystal", "ANATOMY_MODIFIER", 233, 240]]], ["We therefore conclude that the MOG 101-108 fragment may be used to develop a diagnostic assay or a drug for MS.P-486The Escherichia coli membrane insertase YidC reversibly binds its substrate Pf3 coat protein U. Gerken, S. Winterfeld, A. Kuhn Institute of Microbiology and Molecular Biology, University of Hohenheim, GermanyP-486The membrane insertase YidC of E. coli belongs to the Oxa1 family of mitochondria and plays an essential role in facilitating the insertion and assembly of membrane proteins.", [["membrane", "ANATOMY", 137, 145], ["membrane", "ANATOMY", 333, 341], ["mitochondria", "ANATOMY", 398, 410], ["membrane", "ANATOMY", 485, 493], ["MOG 101-108", "CHEMICAL", 31, 42], ["MS", "DISEASE", 108, 110], ["P-486", "CHEMICAL", 111, 116], ["YidC", "CHEMICAL", 156, 160], ["GermanyP-486", "CHEMICAL", 317, 329], ["Escherichia coli", "GENE_OR_GENE_PRODUCT", 120, 136], ["YidC", "GENE_OR_GENE_PRODUCT", 156, 160], ["membrane", "CELLULAR_COMPONENT", 333, 341], ["E. coli", "ORGANISM", 360, 367], ["Oxa1", "GENE_OR_GENE_PRODUCT", 383, 387], ["mitochondria", "CELLULAR_COMPONENT", 398, 410], ["membrane", "CELLULAR_COMPONENT", 485, 493], ["MOG 101-108 fragment", "DNA", 31, 51], ["Escherichia coli membrane insertase", "PROTEIN", 120, 155], ["YidC", "PROTEIN", 156, 160], ["substrate Pf3 coat protein", "PROTEIN", 182, 208], ["membrane insertase", "PROTEIN", 333, 351], ["YidC", "PROTEIN", 352, 356], ["Oxa1 family", "PROTEIN", 383, 394], ["membrane proteins", "PROTEIN", 485, 502], ["Escherichia coli", "SPECIES", 120, 136], ["E. coli", "SPECIES", 360, 367], ["Escherichia coli", "SPECIES", 120, 136], ["E. coli", "SPECIES", 360, 367], ["the MOG", "TEST", 27, 34], ["a diagnostic assay", "TEST", 75, 93], ["MS", "PROBLEM", 108, 110], ["P", "TEST", 111, 112], ["The Escherichia coli membrane", "TREATMENT", 116, 145], ["GermanyP", "TEST", 317, 325], ["E. coli", "PROBLEM", 360, 367], ["the insertion", "TREATMENT", 455, 468], ["membrane proteins", "PROBLEM", 485, 502], ["E. coli", "OBSERVATION", 360, 367]]], ["We have previously shown with detergent-solubilized (C 12 PC) YidC, labelled with ANS, and Pf3 coat that the initial step of the membrane insertion process, the binding of the substrate Pf3 coat to YidC, is reversible [Biochemistry 47, 6052-6058 (2008) ].", [["membrane", "ANATOMY", 129, 137], ["C 12 PC", "SIMPLE_CHEMICAL", 53, 60], ["YidC", "SIMPLE_CHEMICAL", 62, 66], ["ANS", "GENE_OR_GENE_PRODUCT", 82, 85], ["Pf3", "GENE_OR_GENE_PRODUCT", 91, 94], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["YidC", "GENE_OR_GENE_PRODUCT", 198, 202], ["Pf3 coat", "PROTEIN", 186, 194], ["YidC", "PROTEIN", 198, 202], ["detergent-solubilized (C 12 PC) YidC", "TREATMENT", 30, 66], ["Pf3 coat", "TREATMENT", 91, 99], ["the membrane insertion process", "TREATMENT", 125, 155], ["reversible", "OBSERVATION_MODIFIER", 207, 217]]], ["The dissociation constant K D for that particular system is about 1 \u00b5M.", [["K", "CHEMICAL", 26, 27], ["K D", "SIMPLE_CHEMICAL", 26, 29]]], ["In order to obtain data for the native system we used in this study membrane-reconstituted (DOPC and DOPE/DOPG) YidC.", [["membrane", "ANATOMY", 68, 76], ["DOPE", "CHEMICAL", 101, 105], ["DOPC", "CHEMICAL", 92, 96], ["DOPE", "CHEMICAL", 101, 105], ["DOPG", "CHEMICAL", 106, 110], ["DOPC", "SIMPLE_CHEMICAL", 92, 96], ["DOPE/DOPG) YidC", "SIMPLE_CHEMICAL", 101, 116], ["this study membrane", "TEST", 57, 76], ["YidC", "PROBLEM", 112, 116]]], ["The effect of the initial binding was examined in vitro by fluorescence quenching of the 11 tryptophan (Trp) residues of YidC which are highly sensitive fluorescent probes for changes of the tertiary structure.", [["tryptophan", "CHEMICAL", 92, 102], ["Trp", "CHEMICAL", 104, 107], ["tryptophan", "CHEMICAL", 92, 102], ["Trp", "CHEMICAL", 104, 107], ["YidC", "SIMPLE_CHEMICAL", 121, 125], ["the 11 tryptophan (Trp) residues of YidC", "TREATMENT", 85, 125], ["tertiary structure", "OBSERVATION", 191, 209]]], ["Quenching of the Trp fluorescence after titration with a Trp-free Pf3 mutant indicates a change in the YidCs tertiary structure upon binding to its substrate.", [["Trp", "CHEMICAL", 17, 20], ["Trp", "CHEMICAL", 57, 60], ["Trp", "CHEMICAL", 17, 20], ["Trp", "CHEMICAL", 57, 60], ["YidCs", "CHEMICAL", 103, 108], ["Trp", "AMINO_ACID", 17, 20], ["Pf3", "GENE_OR_GENE_PRODUCT", 66, 69], ["YidCs", "SIMPLE_CHEMICAL", 103, 108], ["Pf3 mutant", "PROTEIN", 66, 76], ["YidCs tertiary structure", "PROTEIN", 103, 127], ["the Trp fluorescence", "TEST", 13, 33], ["a Trp-free Pf3 mutant", "TEST", 55, 76], ["change", "OBSERVATION_MODIFIER", 89, 95]]], ["The binding data show a K D value in the range of 0.5-1.8 \u00b5M.", [["K", "CHEMICAL", 24, 25], ["K D", "SIMPLE_CHEMICAL", 24, 27], ["The binding data", "TEST", 0, 16], ["a K D value", "TEST", 22, 33]]], ["The influence of different environments (lipid membranes, DDM micelles) on the secondary structure of YidC as well as on the YidC large periplasmic domain P1 was investigated by circular dichroism (CD).", [["lipid membranes", "ANATOMY", 41, 56], ["lipid membranes", "MULTI-TISSUE_STRUCTURE", 41, 56], ["YidC", "GENE_OR_GENE_PRODUCT", 102, 106], ["YidC", "PROTEIN", 102, 106], ["YidC large periplasmic domain P1", "PROTEIN", 125, 157], ["different environments (lipid membranes, DDM micelles", "TREATMENT", 17, 70], ["YidC", "PROBLEM", 102, 106], ["the YidC large periplasmic domain P1", "TREATMENT", 121, 157]]], ["The CD data show that the secondary structure of YidC changes upon reconstitution into a membranes when compared to the detergent solubilized state.", [["membranes", "ANATOMY", 89, 98], ["YidC", "SIMPLE_CHEMICAL", 49, 53], ["membranes", "CELLULAR_COMPONENT", 89, 98], ["YidC", "PROTEIN", 49, 53], ["The CD data", "TEST", 0, 11], ["YidC changes", "PROBLEM", 49, 61], ["YidC changes", "OBSERVATION", 49, 61]]], ["Particularly, the P1 domain is considerably affected by the detergent C 12 PC.Reaction pathway analysis for (de)methylation process of histone tailsB.", [["histone tailsB", "GENE_OR_GENE_PRODUCT", 135, 149], ["P1 domain", "PROTEIN", 18, 27], ["histone tailsB", "PROTEIN", 135, 149], ["the detergent C 12 PC", "TREATMENT", 56, 77], ["Reaction pathway analysis", "TEST", 78, 103], ["histone tailsB", "PROBLEM", 135, 149], ["considerably", "OBSERVATION_MODIFIER", 31, 43]]], ["Karasulu, B. Erman, O. Keskin Koc University, Istanbul, Turkey Histone proteins are fundamental to the cells since they are involved in cell regulatory processes, such as chromatin regulation, gene silencing and transcription, cell cycle control, and epigenetics, which are controlled via post-transcriptional modifications of the histone protein tails.", [["cells", "ANATOMY", 103, 108], ["cell", "ANATOMY", 136, 140], ["chromatin", "ANATOMY", 171, 180], ["cell", "ANATOMY", 227, 231], ["cells", "CELL", 103, 108], ["cell", "CELL", 136, 140], ["chromatin", "CELLULAR_COMPONENT", 171, 180], ["cell", "CELL", 227, 231], ["histone", "GENE_OR_GENE_PRODUCT", 331, 338], ["chromatin", "DNA", 171, 180], ["histone protein tails", "PROTEIN", 331, 352], ["cell regulatory processes", "PROBLEM", 136, 161], ["chromatin regulation", "TREATMENT", 171, 191], ["gene silencing", "TREATMENT", 193, 207], ["transcription", "TREATMENT", 212, 225], ["cell cycle control", "TREATMENT", 227, 245], ["the histone protein tails", "TREATMENT", 327, 352], ["cell regulatory processes", "OBSERVATION", 136, 161]]], ["These modifications are categorized under four main groups: methylation, acetylation, ubiquitination, and phosphorylation.", [["methylation, acetylation", "TREATMENT", 60, 84], ["ubiquitination", "TREATMENT", 86, 100], ["phosphorylation", "TREATMENT", 106, 121]]], ["Among them methylation has been very recently proven to be reversible with the discovery of histone demethylase proteins and this modification type has been extensively studied, because the abnormal methylation rates cause the excess proliferation of the cell, which, in turn, triggers the cancer.", [["cell", "ANATOMY", 255, 259], ["cancer", "ANATOMY", 290, 296], ["cancer", "DISEASE", 290, 296], ["histone demethylase", "GENE_OR_GENE_PRODUCT", 92, 111], ["cell", "CELL", 255, 259], ["cancer", "CANCER", 290, 296], ["histone demethylase proteins", "PROTEIN", 92, 120], ["histone demethylase proteins", "PROBLEM", 92, 120], ["the abnormal methylation rates", "PROBLEM", 186, 216], ["the excess proliferation of the cell", "PROBLEM", 223, 259], ["the cancer", "PROBLEM", 286, 296], ["histone demethylase", "OBSERVATION", 92, 111], ["excess proliferation", "OBSERVATION", 227, 247], ["cell", "OBSERVATION", 255, 259], ["cancer", "OBSERVATION", 290, 296]]], ["Therefore, understanding of the details of reaction mechanisms of histone methylation/demethylation dynamics provide the required knowledge basis for preventing the abnormal methylation rates by designing proper inhibitor (drug) molecules.", [["histone", "GENE_OR_GENE_PRODUCT", 66, 73], ["histone", "PROTEIN", 66, 73], ["histone methylation/demethylation dynamics", "TREATMENT", 66, 108], ["the abnormal methylation rates", "PROBLEM", 161, 191]]], ["In this study, we display possible reaction mechanisms (such as amine oxidation via LSD1) for the demethylation of specific histone tail proteins.", [["amine", "CHEMICAL", 64, 69], ["amine", "CHEMICAL", 64, 69], ["amine", "SIMPLE_CHEMICAL", 64, 69], ["LSD1", "GENE_OR_GENE_PRODUCT", 84, 88], ["histone tail proteins", "GENE_OR_GENE_PRODUCT", 124, 145], ["LSD1", "PROTEIN", 84, 88], ["histone tail proteins", "PROTEIN", 124, 145], ["this study", "TEST", 3, 13], ["reaction mechanisms", "PROBLEM", 35, 54], ["amine oxidation via LSD1", "TREATMENT", 64, 88], ["specific histone tail proteins", "PROBLEM", 115, 145], ["possible", "UNCERTAINTY", 26, 34], ["reaction mechanisms", "OBSERVATION", 35, 54]]], ["We try to explain the role/importance of residues that take place in or near to the reaction pocket for the demethylation reaction.", [["the demethylation reaction", "PROBLEM", 104, 130]]], ["We also carry out MD simulations and reaction path (free energy profile) analysis using Free Energy Perturbation (FEP) method for QM/MM hybrid systems in order to compare different possible reaction pathways.", [["QM/MM hybrid systems", "CELL_LINE", 130, 150], ["Free Energy Perturbation (FEP) method", "TREATMENT", 88, 125], ["QM/MM hybrid systems", "TREATMENT", 130, 150], ["reaction pathways", "PROBLEM", 190, 207]]], ["The Sonic Hedgehog (Shh) signalling pathway plays an important role both in embryonic development and in adult stem cell function.", [["embryonic", "ANATOMY", 76, 85], ["adult stem cell", "ANATOMY", 105, 120], ["Sonic Hedgehog", "GENE_OR_GENE_PRODUCT", 4, 18], ["Shh", "GENE_OR_GENE_PRODUCT", 20, 23], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 76, 85], ["adult stem cell", "CELL", 105, 120], ["Sonic Hedgehog", "PROTEIN", 4, 18], ["Shh", "PROTEIN", 20, 23], ["adult stem cell", "CELL_TYPE", 105, 120], ["stem cell function", "OBSERVATION", 111, 129]]], ["Inappropriate regulation of this pathway is often due to dysfunction between two membrane receptors Patched (Ptc) and Smoothened (Smo) , which lead to birth defects, cancer or neurodegenerative diseases.", [["membrane", "ANATOMY", 81, 89], ["cancer", "ANATOMY", 166, 172], ["birth defects", "DISEASE", 151, 164], ["cancer", "DISEASE", 166, 172], ["neurodegenerative diseases", "DISEASE", 176, 202], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["Patched", "GENE_OR_GENE_PRODUCT", 100, 107], ["Ptc", "GENE_OR_GENE_PRODUCT", 109, 112], ["Smoothened", "GENE_OR_GENE_PRODUCT", 118, 128], ["Smo", "GENE_OR_GENE_PRODUCT", 130, 133], ["cancer", "CANCER", 166, 172], ["membrane receptors", "PROTEIN", 81, 99], ["Patched", "PROTEIN", 100, 107], ["Ptc", "PROTEIN", 109, 112], ["Smoothened", "PROTEIN", 118, 128], ["Smo", "PROTEIN", 130, 133], ["dysfunction", "PROBLEM", 57, 68], ["two membrane receptors", "TREATMENT", 77, 99], ["Smoothened (Smo)", "PROBLEM", 118, 134], ["birth defects", "PROBLEM", 151, 164], ["cancer", "PROBLEM", 166, 172], ["neurodegenerative diseases", "PROBLEM", 176, 202], ["defects", "OBSERVATION", 157, 164], ["cancer", "OBSERVATION", 166, 172], ["neurodegenerative", "OBSERVATION_MODIFIER", 176, 193], ["diseases", "OBSERVATION", 194, 202]]], ["However, little is known about Ptc, the receptor of the Shh protein, and the way Ptc regulates Smo, the receptor responsible for the transduction of the signal.", [["Ptc", "GENE_OR_GENE_PRODUCT", 31, 34], ["Shh", "GENE_OR_GENE_PRODUCT", 56, 59], ["Ptc", "GENE_OR_GENE_PRODUCT", 81, 84], ["Smo", "GENE_OR_GENE_PRODUCT", 95, 98], ["Ptc", "PROTEIN", 31, 34], ["Shh protein", "PROTEIN", 56, 67], ["Ptc", "PROTEIN", 81, 84], ["Smo", "PROTEIN", 95, 98], ["the Shh protein", "TEST", 52, 67], ["Smo", "OBSERVATION_MODIFIER", 95, 98]]], ["To develop structure-function studies of these receptors, we expressed human Ptc (hPtc) in the yeast Saccharomyces cerevisiae.", [["human", "ORGANISM", 71, 76], ["Ptc", "GENE_OR_GENE_PRODUCT", 77, 80], ["hPtc", "GENE_OR_GENE_PRODUCT", 82, 86], ["yeast Saccharomyces cerevisiae", "ORGANISM", 95, 125], ["human Ptc", "PROTEIN", 71, 80], ["hPtc", "PROTEIN", 82, 86], ["human", "SPECIES", 71, 76], ["yeast", "SPECIES", 95, 100], ["Saccharomyces cerevisiae", "SPECIES", 101, 125], ["human", "SPECIES", 71, 76], ["yeast", "SPECIES", 95, 100], ["Saccharomyces cerevisiae", "SPECIES", 101, 125], ["human Ptc (hPtc)", "PROBLEM", 71, 87], ["Saccharomyces cerevisiae", "OBSERVATION", 101, 125]]], ["We demonstrated that hPtc expressed in a yeast membrane fraction is able to interact with its purified ligand Shh, indicating that hPtc is produced in yeast in its native conformational state.", [["membrane fraction", "ANATOMY", 47, 64], ["hPtc", "CHEMICAL", 21, 25], ["hPtc", "CHEMICAL", 131, 135], ["hPtc", "GENE_OR_GENE_PRODUCT", 21, 25], ["Shh", "GENE_OR_GENE_PRODUCT", 110, 113], ["hPtc", "GENE_OR_GENE_PRODUCT", 131, 135], ["hPtc", "PROTEIN", 21, 25], ["Shh", "PROTEIN", 110, 113], ["hPtc", "PROTEIN", 131, 135], ["yeast", "SPECIES", 41, 46], ["yeast", "SPECIES", 151, 156], ["yeast", "SPECIES", 41, 46], ["yeast", "SPECIES", 151, 156], ["hPtc", "PROBLEM", 21, 25], ["a yeast membrane fraction", "PROBLEM", 39, 64]]], ["Using Surface Plasmon Resonance technology, we showed that fluorinated surfactants preserve the ability of hPtc to interact with its ligand after purification.", [["fluorinated surfactants", "SIMPLE_CHEMICAL", 59, 82], ["hPtc", "SIMPLE_CHEMICAL", 107, 111], ["hPtc", "PROTEIN", 107, 111], ["fluorinated surfactants", "TREATMENT", 59, 82]]], ["This is the first report on the heterologous expression and the purification of a native and stable conformation of the human receptor Ptc.", [["human", "ORGANISM", 120, 125], ["human receptor", "PROTEIN", 120, 134], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["stable", "OBSERVATION_MODIFIER", 93, 99]]], ["This work will allow the scale-up of hPtc production enabling its biochemical characterization, allowing the development of new therapeutic approaches against diseases induced by Shh signalling dysfunction.P-491Dissecting the colicin translocon C. L. Johnson 1 , A. Solovyova 1 , P. Callow 2 , S. A. Holt 3 , L. A. Clifton 3 , K. Weiss 4 , J. H. Lakey 1 1 Inst. for Cell and Molecular biosciences, Newcastle Univ., UK, 2 Inst.", [["Cell", "ANATOMY", 366, 370], ["hPtc", "SIMPLE_CHEMICAL", 37, 41], ["Shh", "GENE_OR_GENE_PRODUCT", 179, 182], ["Cell", "CELL", 366, 370], ["Shh", "PROTEIN", 179, 182], ["the scale", "TEST", 21, 30], ["diseases", "PROBLEM", 159, 167], ["Shh signalling dysfunction", "PROBLEM", 179, 205], ["the colicin translocon", "TREATMENT", 222, 244]]], ["Laue Langevin, Grenoble, France, 3 ISIS, Rutherford Appleton Lab., Didcot, UK, 4 Oak Ridge National Lab., Centre for Structural Molecular Biology, Oak Ridge, USA Pore-forming colicin N hijacks E. coli outer membrane protein OmpF and exploits it as both a receptor and translocator to cross the outer membrane [1] .", [["outer membrane", "ANATOMY", 294, 308], ["colicin N", "GENE_OR_GENE_PRODUCT", 175, 184], ["E. coli outer membrane protein OmpF", "GENE_OR_GENE_PRODUCT", 193, 228], ["outer membrane", "CELLULAR_COMPONENT", 294, 308], ["colicin N", "PROTEIN", 175, 184], ["E. coli outer membrane protein", "PROTEIN", 193, 223], ["OmpF", "PROTEIN", 224, 228], ["E. coli", "SPECIES", 193, 200], ["E. coli", "SPECIES", 193, 200], ["USA Pore-forming colicin N hijacks E. coli outer membrane protein OmpF", "TREATMENT", 158, 228], ["a receptor and translocator", "TREATMENT", 253, 280], ["Oak Ridge", "OBSERVATION", 147, 156], ["protein OmpF", "OBSERVATION", 216, 228]]], ["It is currently a matter of debate if the translocation route is through the OmpF lumen or the interface between OmpF and the lipid bilayer.", [["lumen", "ANATOMY", 82, 87], ["lipid bilayer", "ANATOMY", 126, 139], ["OmpF lumen", "CELLULAR_COMPONENT", 77, 87], ["OmpF", "GENE_OR_GENE_PRODUCT", 113, 117], ["lipid bilayer", "CELLULAR_COMPONENT", 126, 139], ["OmpF", "PROTEIN", 113, 117], ["the translocation route", "TREATMENT", 38, 61], ["the OmpF lumen", "TREATMENT", 73, 87], ["OmpF and the lipid bilayer", "TREATMENT", 113, 139]]], ["Recent electron microscopy data from our laboratory suggests the latter route for translocation [2] .", [["Recent electron microscopy data", "TEST", 0, 31]]], ["The colicin N/OmpF complex in detergent has been studied by SANS to examine the translocation pathway undertaken by colicin N. By using a combination of deuterated OmpF and hydrogenated colicin we have been able to derive a low resolution structure of individual proteins in the binary complex.", [["colicin N", "GENE_OR_GENE_PRODUCT", 4, 13], ["OmpF", "GENE_OR_GENE_PRODUCT", 14, 18], ["OmpF", "SIMPLE_CHEMICAL", 164, 168], ["hydrogenated colicin", "SIMPLE_CHEMICAL", 173, 193], ["colicin N/OmpF complex", "PROTEIN", 4, 26], ["OmpF", "PROTEIN", 164, 168], ["binary complex", "PROTEIN", 279, 293], ["The colicin N/OmpF complex", "TREATMENT", 0, 26], ["a combination of deuterated OmpF and hydrogenated colicin", "TREATMENT", 136, 193], ["low resolution", "OBSERVATION_MODIFIER", 224, 238]]], ["Low resolution structural studies supplemented by targeted mutagenesis and screening techniques including ITC, potassium efflux assays and AUC have allowed us further our understanding of colicin N translocation.", [["potassium", "CHEMICAL", 111, 120], ["potassium", "CHEMICAL", 111, 120], ["ITC", "CELL", 106, 109], ["potassium", "SIMPLE_CHEMICAL", 111, 120], ["colicin N", "GENE_OR_GENE_PRODUCT", 188, 197], ["colicin N", "PROTEIN", 188, 197], ["screening techniques", "TEST", 75, 95], ["ITC", "TEST", 106, 109], ["potassium efflux assays", "TEST", 111, 134], ["AUC", "TEST", 139, 142], ["colicin N translocation", "PROBLEM", 188, 211]]], ["Dual-color Fluorescence Cross Correlation Spectroscopy (FCCS) has been used to explore the molecular dynamics at immune cell surfaces, with a particular focus towards the regulation mechanisms of natural killer (NK) lymphocytes.", [["immune cell surfaces", "ANATOMY", 113, 133], ["natural killer (NK) lymphocytes", "ANATOMY", 196, 227], ["immune cell", "CELL", 113, 124], ["natural killer (NK) lymphocytes", "CELL", 196, 227], ["natural killer (NK) lymphocytes", "CELL_TYPE", 196, 227], ["Spectroscopy (FCCS)", "TEST", 42, 61], ["immune cell surfaces", "OBSERVATION", 113, 133], ["natural killer", "OBSERVATION", 196, 210]]], ["NK cells are critical mediators of anti-viral immunity and protectors against cancer spread.", [["NK cells", "ANATOMY", 0, 8], ["cancer", "ANATOMY", 78, 84], ["cancer", "DISEASE", 78, 84], ["NK cells", "CELL", 0, 8], ["cancer", "CANCER", 78, 84], ["NK cells", "CELL_TYPE", 0, 8], ["anti-viral immunity and protectors", "TREATMENT", 35, 69], ["cancer spread", "PROBLEM", 78, 91]]], ["Their activity is governed by a fine-tuned balance between inhibitory and activating receptors, where Ly49A and KIR receptors represents the inhibitory ones.", [["Ly49A", "GENE_OR_GENE_PRODUCT", 102, 107], ["KIR", "GENE_OR_GENE_PRODUCT", 112, 115], ["inhibitory and activating receptors", "PROTEIN", 59, 94], ["Ly49A", "PROTEIN", 102, 107], ["KIR receptors", "PROTEIN", 112, 125]]], ["Their ligands are MHC class I receptors.", [["MHC class I receptors", "GENE_OR_GENE_PRODUCT", 18, 39], ["MHC class I receptors", "PROTEIN", 18, 39]]], ["FCS is a technique based on the analysis of intensity fluctuations of fluorescent molecules excited by a focused laser beam.", [["fluorescent molecules", "PROTEIN", 70, 91], ["a technique", "TREATMENT", 7, 18], ["the analysis", "TEST", 28, 40], ["fluorescent molecules", "PROBLEM", 70, 91]]], ["Dual color FCCS expands FCS by correlating the intensity from two different colors.", [["different colors", "OBSERVATION", 66, 82]]], ["By labeling two potential interaction partners with dyes emitting at different wavelengths, the amount of interaction can be determined.P-491Here, we will report on recent FCCS data exploring the interaction between the inhibitory receptors and their ligands, as well as different labeling strategies used to enable these measurements.P-489Effect of osmolytes on the DHFR activity, structure and dynamics B. Legrand 1 , S. Renaud 2 , M. Collen 1 , C. Tascon 3 , S. Bonnassie 2 , E. Gautier 1 , J. Mellet 1 , C. Blanco 2 , E. Le Rumeur 1 , J.-F. Hubert 1 , A. Bondon 1 1 RMN-ILP, 2 DUALS, 3 CBP, UMR CNRS 6026, Univ. de Rennes1, FranceP-489Osmolytes are small molecules accumulated by a wide variety of organisms in response to hyperosmotic stress.", [["P-489Effect of osmolytes", "CHEMICAL", 335, 359], ["DHFR", "GENE_OR_GENE_PRODUCT", 367, 371], ["FranceP-489Osmolytes", "SIMPLE_CHEMICAL", 628, 648], ["inhibitory receptors", "PROTEIN", 220, 240], ["DHFR", "PROTEIN", 367, 371], ["dyes emitting", "TREATMENT", 52, 65], ["recent FCCS data", "TEST", 165, 181], ["different labeling strategies", "TREATMENT", 271, 300], ["these measurements", "TEST", 316, 334], ["P", "TEST", 335, 336], ["osmolytes", "TREATMENT", 350, 359], ["the DHFR activity", "PROBLEM", 363, 380], ["UMR CNRS", "TEST", 595, 603], ["FranceP", "TEST", 628, 635], ["small molecules", "PROBLEM", 653, 668], ["a wide variety of organisms", "PROBLEM", 684, 711], ["hyperosmotic stress", "PROBLEM", 727, 746], ["Le Rumeur", "ANATOMY", 525, 534], ["small molecules", "OBSERVATION", 653, 668], ["hyperosmotic stress", "OBSERVATION", 727, 746]]], ["They contribute to save the cellular integrity and to stabilize the macromolecules from environmental stress.", [["cellular", "ANATOMY", 28, 36], ["cellular", "CELL", 28, 36], ["environmental stress", "PROBLEM", 88, 108], ["cellular integrity", "OBSERVATION", 28, 46], ["environmental stress", "OBSERVATION", 88, 108]]], ["Dihydrofolate reductase activity is inhibited by several osmolytes.", [["Dihydrofolate", "CHEMICAL", 0, 13], ["Dihydrofolate", "CHEMICAL", 0, 13], ["Dihydrofolate reductase", "GENE_OR_GENE_PRODUCT", 0, 23], ["Dihydrofolate reductase", "PROTEIN", 0, 23], ["Dihydrofolate reductase activity", "PROBLEM", 0, 32], ["several osmolytes", "TEST", 49, 66]]], ["We studied the impact of osmolytes on the DHFR structure and dynamics by various techniques.", [["osmolytes", "CHEMICAL", 25, 34], ["osmolytes", "SIMPLE_CHEMICAL", 25, 34], ["DHFR", "GENE_OR_GENE_PRODUCT", 42, 46], ["DHFR", "PROTEIN", 42, 46], ["osmolytes", "TREATMENT", 25, 34], ["the DHFR structure", "TREATMENT", 38, 56]]], ["We observe that substrate (DHF) and cofactor (NADPH) diffusions are quite different in glycerol and betaine despite similar viscosities.", [["DHF", "DISEASE", 27, 30], ["NADPH", "CHEMICAL", 46, 51], ["glycerol", "CHEMICAL", 87, 95], ["betaine", "CHEMICAL", 100, 107], ["NADPH", "CHEMICAL", 46, 51], ["glycerol", "CHEMICAL", 87, 95], ["betaine", "CHEMICAL", 100, 107], ["NADPH", "SIMPLE_CHEMICAL", 46, 51], ["glycerol", "SIMPLE_CHEMICAL", 87, 95], ["betaine", "SIMPLE_CHEMICAL", 100, 107], ["substrate (DHF)", "PROBLEM", 16, 31], ["cofactor (NADPH) diffusions", "PROBLEM", 36, 63], ["glycerol", "TREATMENT", 87, 95]]], ["We demonstrate that the overall structure is maintained at high osmolyte concentrations while no direct interactions can be detected with the enzyme.", [["osmolyte", "CHEMICAL", 64, 72], ["osmolyte", "SIMPLE_CHEMICAL", 64, 72], ["enzyme", "PROTEIN", 142, 148], ["the enzyme", "TEST", 138, 148], ["overall", "OBSERVATION_MODIFIER", 24, 31], ["structure", "OBSERVATION_MODIFIER", 32, 41], ["osmolyte concentrations", "OBSERVATION", 64, 87]]], ["The k o f f of substrate analogues decreases with increasing the osmolyte concentrations.", [["osmolyte", "CHEMICAL", 65, 73], ["osmolyte", "SIMPLE_CHEMICAL", 65, 73], ["substrate analogues", "PROBLEM", 15, 34], ["increasing the osmolyte concentrations", "TREATMENT", 50, 88], ["decreases", "OBSERVATION_MODIFIER", 35, 44], ["osmolyte concentrations", "OBSERVATION", 65, 88]]], ["The enzyme dynamics, in various media, has been compared with the DHFR behaviour in water described in the literature.P-489The osmolyte impact appears only partly conditioned by its viscogenic properties which reduce the molecules diffusion and the k o f f of the product controlled by the M20 loop of the DHFR.", [["P-489", "CHEMICAL", 118, 123], ["DHFR", "GENE_OR_GENE_PRODUCT", 306, 310], ["DHFR", "PROTEIN", 66, 70], ["M20 loop", "PROTEIN", 290, 298], ["DHFR", "PROTEIN", 306, 310], ["The enzyme dynamics", "TEST", 0, 19], ["The osmolyte impact", "TEST", 123, 142], ["the molecules diffusion", "PROBLEM", 217, 240], ["the M20 loop of the DHFR", "TREATMENT", 286, 310]]], ["We suggest that the osmolytes decrease M20 loop mobility.", [["the osmolytes decrease M20 loop mobility", "TREATMENT", 16, 56]]], ["Comparing the results obtained with different osmolytes, we offer a better understanding of the osmolyte nature dependence of the DHFR inhibition.", [["DHFR", "GENE_OR_GENE_PRODUCT", 130, 134], ["DHFR", "PROTEIN", 130, 134], ["different osmolytes", "TEST", 36, 55], ["the DHFR inhibition", "TREATMENT", 126, 145]]], ["Estrogen receptor (ER) is a well characterized member of the nuclear receptor superfamily that modulates the expression of estrogen-responsive target genes in response to estradiol and other natural and synthetic chemicals mimicking the estradiol structure.", [["nuclear", "ANATOMY", 61, 68], ["estrogen", "CHEMICAL", 123, 131], ["estradiol", "CHEMICAL", 171, 180], ["estradiol", "CHEMICAL", 237, 246], ["Estrogen", "CHEMICAL", 0, 8], ["estrogen", "CHEMICAL", 123, 131], ["estradiol", "CHEMICAL", 171, 180], ["estradiol", "CHEMICAL", 237, 246], ["Estrogen receptor", "GENE_OR_GENE_PRODUCT", 0, 17], ["ER", "GENE_OR_GENE_PRODUCT", 19, 21], ["estrogen", "SIMPLE_CHEMICAL", 123, 131], ["estradiol", "SIMPLE_CHEMICAL", 171, 180], ["estradiol", "SIMPLE_CHEMICAL", 237, 246], ["Estrogen receptor", "PROTEIN", 0, 17], ["ER", "PROTEIN", 19, 21], ["nuclear receptor superfamily", "PROTEIN", 61, 89], ["estrogen-responsive target genes", "DNA", 123, 155], ["estradiol", "TREATMENT", 171, 180], ["other natural and synthetic chemicals", "TREATMENT", 185, 222]]], ["In human, two ERs, ER\u03b1 and ER\u03b2, lied on two distinct chromosomes, are known.", [["chromosomes", "ANATOMY", 53, 64], ["human", "ORGANISM", 3, 8], ["ERs", "GENE_OR_GENE_PRODUCT", 14, 17], ["ER\u03b1", "GENE_OR_GENE_PRODUCT", 19, 22], ["ER\u03b2", "GENE_OR_GENE_PRODUCT", 27, 30], ["chromosomes", "CELLULAR_COMPONENT", 53, 64], ["ERs", "PROTEIN", 14, 17], ["ER\u03b1", "PROTEIN", 19, 22], ["ER\u03b2", "PROTEIN", 27, 30], ["chromosomes", "DNA", 53, 64], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8]]], ["ER exhibits several functional domains: two conserved domains, a short domain C involved in DNA-binding and a large domain E/F responsible for ligand-binding and hormone-dependent transcription activation, are linked by a hinge domain D; a poorly conserved A/B domain, at the N terminus, mediating interactions with the general transcription machinery, is involved in hormone-independent transcription activation.", [["N", "CHEMICAL", 276, 277], ["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["A/B", "GENE_OR_GENE_PRODUCT", 257, 260], ["ER", "PROTEIN", 0, 2], ["short domain C", "PROTEIN", 65, 79], ["large domain E/F", "PROTEIN", 110, 126], ["hinge domain D", "PROTEIN", 222, 236], ["B domain", "PROTEIN", 259, 267], ["N terminus", "PROTEIN", 276, 286], ["a short domain C", "PROBLEM", 63, 79], ["DNA-binding", "PROBLEM", 92, 103], ["ligand-binding", "PROBLEM", 143, 157], ["hormone-dependent transcription activation", "TREATMENT", 162, 204], ["a hinge domain D", "PROBLEM", 220, 236], ["a poorly conserved A/B domain", "PROBLEM", 238, 267]]], ["Upon estrogen binding, ERs can specifically bind to a DNA fragment, called estrogen response element ERE, and activate the transcription.", [["estrogen", "CHEMICAL", 5, 13], ["estrogen", "CHEMICAL", 75, 83], ["estrogen", "CHEMICAL", 5, 13], ["estrogen", "CHEMICAL", 75, 83], ["estrogen", "SIMPLE_CHEMICAL", 5, 13], ["ERs", "GENE_OR_GENE_PRODUCT", 23, 26], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["estrogen response element ERE", "GENE_OR_GENE_PRODUCT", 75, 104], ["ERs", "PROTEIN", 23, 26], ["DNA fragment", "DNA", 54, 66], ["estrogen response element ERE", "DNA", 75, 104], ["a DNA fragment", "PROBLEM", 52, 66], ["estrogen binding", "OBSERVATION", 5, 21]]], ["The optimal ERE sequence consists of two six base-pair half-sites, AGGTCA, organized as inverted repeats with a three base-pair spacing.", [["ERE sequence", "DNA", 12, 24], ["base-pair half-sites", "DNA", 45, 65], ["AGGTCA", "DNA", 67, 73], ["inverted repeats", "DNA", 88, 104], ["The optimal ERE sequence", "TEST", 0, 24], ["a three base-pair spacing", "TREATMENT", 110, 135], ["pair spacing", "OBSERVATION", 123, 135]]], ["In this study, we have investigated, by fluorescence methods, the effect of KCl concentrations, on the protein conformational flexibility and the thermodynamic stability of hERs -EREs complexes.", [["KCl", "CHEMICAL", 76, 79], ["KCl", "CHEMICAL", 76, 79], ["KCl", "SIMPLE_CHEMICAL", 76, 79], ["hERs", "GENE_OR_GENE_PRODUCT", 173, 177], ["hERs", "PROTEIN", 173, 177], ["EREs complexes", "PROTEIN", 179, 193], ["this study", "TEST", 3, 13], ["KCl concentrations", "TREATMENT", 76, 94], ["the protein conformational flexibility", "TREATMENT", 99, 137], ["thermodynamic stability", "OBSERVATION", 146, 169]]], ["We show, here, that electrostatic interactions, inside hERs, contribute to its conformational flexibility and its thermal stability.", [["hERs", "GENE_OR_GENE_PRODUCT", 55, 59], ["hERs", "PROTEIN", 55, 59], ["its conformational flexibility", "PROBLEM", 75, 105], ["thermal", "OBSERVATION_MODIFIER", 114, 121], ["stability", "OBSERVATION_MODIFIER", 122, 131]]], ["Moreover, the specific interaction between hERs and EREs is poorly sensitive to changes in ionic strength, in opposite to unspecific complexes.P-495Kinetic and structural explanation for the low enantioselectivity of human 3-phosphoglycerate kinase P. Lallemand 1 , J. Rouhana 1 , L. Chaloin 1 , B. Roy 2 , S. Arold 3 , T. Barman 1 , C. Lionne 1 1 CPBS UMR 5236, 4 bd Henri IV CS69033, 34965 Montpellier cedex 2, France, 2 IBMM UMR 5247, 3 CBS UMR 5048 L-Nucleosides comprise a new class of antiviral and anticancer agents that are converted to pharmacologically active nucleoside triphosphates in vivo.", [["anticancer", "ANATOMY", 505, 515], ["P-495", "CHEMICAL", 143, 148], ["UMR 5048 L-Nucleosides", "CHEMICAL", 444, 466], ["nucleoside triphosphates", "CHEMICAL", 570, 594], ["3-phosphoglycerate", "CHEMICAL", 223, 241], ["L-Nucleosides", "CHEMICAL", 453, 466], ["nucleoside triphosphates", "CHEMICAL", 570, 594], ["hERs", "GENE_OR_GENE_PRODUCT", 43, 47], ["human", "ORGANISM", 217, 222], ["3-phosphoglycerate", "GENE_OR_GENE_PRODUCT", 223, 241], ["anticancer", "CANCER", 505, 515], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 570, 594], ["hERs", "PROTEIN", 43, 47], ["EREs", "DNA", 52, 56], ["phosphoglycerate kinase", "PROTEIN", 225, 248], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 217, 222], ["P", "TEST", 143, 144], ["CBS UMR", "TEST", 440, 447], ["Nucleosides", "TREATMENT", 455, 466], ["antiviral and anticancer agents", "TREATMENT", 491, 522], ["pharmacologically active nucleoside triphosphates", "TREATMENT", 545, 594], ["nucleoside triphosphates", "OBSERVATION", 570, 594]]], ["The last step of the cascade may be catalyzed by 3-phosphoglycerate kinase (PGK), an enzyme that has low specificity for nucleoside diphosphate: NDP + 1,3-bisphosphoglycerate \u2194 NTP + 3-phosphoglycerate.", [["nucleoside diphosphate", "CHEMICAL", 121, 143], ["NDP", "CHEMICAL", 145, 148], ["1,3-bisphosphoglycerate", "CHEMICAL", 151, 174], ["NTP", "CHEMICAL", 177, 180], ["3-phosphoglycerate", "CHEMICAL", 183, 201], ["3-phosphoglycerate", "CHEMICAL", 49, 67], ["nucleoside diphosphate", "CHEMICAL", 121, 143], ["NDP", "CHEMICAL", 145, 148], ["1,3-bisphosphoglycerate", "CHEMICAL", 151, 174], ["NTP", "CHEMICAL", 177, 180], ["3-phosphoglycerate", "CHEMICAL", 183, 201], ["3-phosphoglycerate kinase", "GENE_OR_GENE_PRODUCT", 49, 74], ["PGK", "GENE_OR_GENE_PRODUCT", 76, 79], ["nucleoside diphosphate", "SIMPLE_CHEMICAL", 121, 143], ["NDP + 1,3-bisphosphoglycerate", "SIMPLE_CHEMICAL", 145, 174], ["NTP + 3-phosphoglycerate", "SIMPLE_CHEMICAL", 177, 201], ["phosphoglycerate kinase", "PROTEIN", 51, 74], ["PGK", "PROTEIN", 76, 79], ["an enzyme", "TEST", 82, 91], ["nucleoside diphosphate", "TEST", 121, 143], ["NDP", "TEST", 145, 148], ["bisphosphoglycerate", "TREATMENT", 155, 174], ["NTP", "TEST", 177, 180], ["phosphoglycerate", "TREATMENT", 185, 201]]], ["Here we compare the kinetics of formation of the complexes of human PGK with different D-and their mirror images, L-nucleoside diphosphates, and the effect of 3-phosphoglycerate thereon.", [["L-nucleoside diphosphates", "CHEMICAL", 114, 139], ["3-phosphoglycerate", "CHEMICAL", 159, 177], ["L-nucleoside diphosphates", "CHEMICAL", 114, 139], ["3-phosphoglycerate", "CHEMICAL", 159, 177], ["human", "ORGANISM", 62, 67], ["PGK", "GENE_OR_GENE_PRODUCT", 68, 71], ["L-nucleoside diphosphates", "SIMPLE_CHEMICAL", 114, 139], ["3-phosphoglycerate thereon", "SIMPLE_CHEMICAL", 159, 185], ["human PGK", "PROTEIN", 62, 71], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["human PGK", "TREATMENT", 62, 71], ["L-nucleoside diphosphates", "TREATMENT", 114, 139], ["3-phosphoglycerate thereon", "TREATMENT", 159, 185]]], ["Two types of experiment were carried out: equilibrium experiments allow the estimation of dissociation constants, and stopped-flow experiments the transient kinetics of the interactions.", [["dissociation constants", "PROBLEM", 90, 112], ["transient kinetics", "OBSERVATION_MODIFIER", 147, 165]]], ["In addition, by the rapid-quench-flow technique, we compare the kinetics of the phospho-transfer and product release steps with each D-or L-nucleotide.", [["phospho", "CHEMICAL", 80, 87], ["L-nucleotide", "CHEMICAL", 138, 150], ["D-or L-nucleotide", "SIMPLE_CHEMICAL", 133, 150], ["phospho", "PROTEIN", 80, 87], ["the phospho", "TREATMENT", 76, 87], ["L-nucleotide", "TREATMENT", 138, 150]]], ["Crystallographic and molecular modelling studies allow defining the structural reasons for the low enantioselectivity of PGK.", [["PGK", "GENE_OR_GENE_PRODUCT", 121, 124], ["PGK", "PROTEIN", 121, 124], ["Crystallographic and molecular modelling studies", "TEST", 0, 48], ["the low enantioselectivity of PGK", "PROBLEM", 91, 124]]], ["The aim of this basic work on the mechanism of action of human PGK with non-natural nucleotides is to obtain information for the optimization of therapeutic nucleoside analogues that are poorly phosphorylated by PGK.", [["nucleoside", "CHEMICAL", 157, 167], ["nucleotides", "CHEMICAL", 84, 95], ["nucleoside", "CHEMICAL", 157, 167], ["human", "ORGANISM", 57, 62], ["PGK", "GENE_OR_GENE_PRODUCT", 63, 66], ["nucleoside analogues", "SIMPLE_CHEMICAL", 157, 177], ["PGK", "GENE_OR_GENE_PRODUCT", 212, 215], ["human PGK", "PROTEIN", 57, 66], ["PGK", "PROTEIN", 212, 215], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["human PGK", "TREATMENT", 57, 66], ["non-natural nucleotides", "TREATMENT", 72, 95], ["therapeutic nucleoside analogues", "TREATMENT", 145, 177]]], ["ANRS is gratefully acknowledged for financial support.P-494A new ITC assay for measuring high-and lowaffinity protein-ligand interactions G. Krainer 1 , J. Fangh\u00e4nel 2 , S. Keller 1 1 Leibniz Institute of Molecular Pharmacology (FMP), Berlin, Germany, 2 Bayer Schering Pharma AG, Berlin, Germany Isothermal titration calorimetry (ITC) is the gold standard for the quantitative characterisation of protein-ligand and protein-protein interactions [1] .", [["ITC", "CELL", 65, 68], ["financial support", "TREATMENT", 36, 53], ["P", "TEST", 54, 55], ["new ITC assay", "TEST", 61, 74], ["Krainer", "TEST", 141, 148], ["Germany Isothermal titration calorimetry", "TREATMENT", 288, 328]]], ["However, reliable determination of the dissociation constant (KD) is typically limited to the range 100 \u00b5M > KD >1 nM.", [["the dissociation constant", "PROBLEM", 35, 60], ["dissociation", "OBSERVATION", 39, 51]]], ["Unfortunately, the established competitive ITC assay requires that the high-affinity ligand be soluble at high concentrations in aqueous buffer containing only minimal amounts of organic solvent.", [["ITC", "CELL", 43, 46], ["the high-affinity ligand", "TREATMENT", 67, 91], ["aqueous buffer", "TREATMENT", 129, 143], ["organic solvent", "TREATMENT", 179, 194], ["minimal", "OBSERVATION_MODIFIER", 160, 167], ["amounts", "OBSERVATION_MODIFIER", 168, 175], ["organic solvent", "OBSERVATION", 179, 194]]], ["This poses serious problems when studying protein binding of small-molecule ligands taken from compound libraries dissolved in organic solvents, as is usually the case during screening or drug development.P-494Here we introduce a new ITC competition assay that overcomes this limitation, thus allowing for a precise thermodynamic description of high-and low-affinity protein-ligand interactions involving poorly water-soluble compounds.", [["P-494", "CHEMICAL", 205, 210], ["ITC", "CELL", 234, 237], ["serious problems", "PROBLEM", 11, 27], ["small-molecule ligands", "PROBLEM", 61, 83], ["compound libraries", "PROBLEM", 95, 113], ["organic solvents", "TREATMENT", 127, 143], ["a new ITC competition assay", "TEST", 228, 255], ["small", "OBSERVATION_MODIFIER", 61, 66], ["organic solvents", "OBSERVATION_MODIFIER", 127, 143]]], ["We discuss the theoretical background of the approach and demonstrate some practical applications using examples of both high-affinity (KD <1 nM) and low-affinity (KD >100 \u00b5M) protein-ligand interactions.O-493A molecular dynamics study of the CFTR nucleotide binding domains interaction V. Martorana 1 , R. Noto 1 , O. Moran 2 1 CNR-Istituto di Biofisica, Palermo, Italy, 2 CNR-Istituto di Biofisica, Genova, ItalyO-493The cystic fibrosis transmembrane conductance regulator (CFTR), the dysfunctional protein in cystic fibrosis, contains two transmembrane domains, two nucleotide-binding domains (NBDs), and a regulatory domain.", [["cystic", "ANATOMY", 512, 518], ["transmembrane", "ANATOMY", 542, 555], ["nucleotide", "CHEMICAL", 248, 258], ["ItalyO-493", "CHEMICAL", 409, 419], ["fibrosis", "DISEASE", 430, 438], ["cystic fibrosis", "DISEASE", 512, 527], ["nucleotide", "CHEMICAL", 569, 579], ["O-493A", "CHEMICAL", 204, 210], ["nucleotide", "CHEMICAL", 248, 258], ["nucleotide", "CHEMICAL", 569, 579], ["CFTR", "GENE_OR_GENE_PRODUCT", 243, 247], ["cystic fibrosis transmembrane conductance regulator", "GENE_OR_GENE_PRODUCT", 423, 474], ["CFTR", "GENE_OR_GENE_PRODUCT", 476, 480], ["CFTR nucleotide binding domains", "PROTEIN", 243, 274], ["cystic fibrosis transmembrane conductance regulator", "PROTEIN", 423, 474], ["CFTR", "PROTEIN", 476, 480], ["dysfunctional protein", "PROTEIN", 487, 508], ["transmembrane domains", "PROTEIN", 542, 563], ["nucleotide-binding domains", "PROTEIN", 569, 595], ["NBDs", "PROTEIN", 597, 601], ["regulatory domain", "PROTEIN", 610, 627], ["KD", "TEST", 136, 138], ["low-affinity", "PROBLEM", 150, 162], ["KD", "TEST", 164, 166], ["molecular dynamics study", "TEST", 211, 235], ["The cystic fibrosis transmembrane conductance regulator", "PROBLEM", 419, 474], ["the dysfunctional protein in cystic fibrosis", "PROBLEM", 483, 527], ["two transmembrane domains", "PROBLEM", 538, 563], ["cystic", "OBSERVATION_MODIFIER", 423, 429], ["fibrosis", "OBSERVATION", 430, 438], ["dysfunctional", "OBSERVATION_MODIFIER", 487, 500], ["protein", "OBSERVATION_MODIFIER", 501, 508], ["cystic", "OBSERVATION_MODIFIER", 512, 518], ["fibrosis", "OBSERVATION", 519, 527], ["transmembrane domains", "OBSERVATION", 542, 563]]], ["Opening of the pore have been linked to the ATP-driven tight dimerisation of NBD.", [["pore", "ANATOMY", 15, 19], ["ATP", "CHEMICAL", 44, 47], ["ATP", "CHEMICAL", 44, 47], ["pore", "CELLULAR_COMPONENT", 15, 19], ["ATP", "SIMPLE_CHEMICAL", 44, 47], ["NBD", "SIMPLE_CHEMICAL", 77, 80], ["NBD", "PROTEIN", 77, 80], ["the ATP", "TEST", 40, 47], ["NBD", "OBSERVATION", 77, 80]]], ["We have studied the NBD1-NBD2 interactions on wild type and cystic fibrosis-related mutations by steered molecular dynamics simulations (SMD).", [["cystic", "ANATOMY", 60, 66], ["fibrosis", "DISEASE", 67, 75], ["NBD1", "GENE_OR_GENE_PRODUCT", 20, 24], ["NBD2", "GENE_OR_GENE_PRODUCT", 25, 29], ["NBD1", "PROTEIN", 20, 24], ["NBD2", "PROTEIN", 25, 29], ["cystic fibrosis", "PROBLEM", 60, 75], ["related mutations", "PROBLEM", 76, 93], ["cystic", "OBSERVATION_MODIFIER", 60, 66], ["fibrosis", "OBSERVATION", 67, 75]]], ["A fully solvated dimer, including the two bound ATPs, was separated by pulling one monomer with an external, increasing force.", [["ATPs", "SIMPLE_CHEMICAL", 48, 52], ["ATPs", "PROTEIN", 48, 52], ["A fully solvated dimer", "PROBLEM", 0, 22], ["an external, increasing force", "TREATMENT", 96, 125], ["solvated dimer", "OBSERVATION", 8, 22], ["increasing", "OBSERVATION_MODIFIER", 109, 119], ["force", "OBSERVATION", 120, 125]]], ["Interestingly, the force needed to break the mutated (G511D) dimer is significantly smaller than in the wild type case.", [["mutated (G511D) dimer", "PROTEIN", 45, 66], ["significantly", "OBSERVATION_MODIFIER", 70, 83], ["smaller", "OBSERVATION_MODIFIER", 84, 91]]], ["The effect of a CFTR potentiator, the genistein, has also been tested by repeating the SMD simulations with the small molecule docked at the interface between the two NBD domains.", [["genistein", "CHEMICAL", 38, 47], ["genistein", "CHEMICAL", 38, 47], ["CFTR", "GENE_OR_GENE_PRODUCT", 16, 20], ["genistein", "SIMPLE_CHEMICAL", 38, 47], ["CFTR potentiator", "PROTEIN", 16, 32], ["NBD domains", "PROTEIN", 167, 178], ["a CFTR potentiator", "TREATMENT", 14, 32], ["the SMD simulations", "TEST", 83, 102], ["the small molecule", "PROBLEM", 108, 126], ["small", "OBSERVATION_MODIFIER", 112, 117], ["molecule docked", "OBSERVATION", 118, 133], ["two", "OBSERVATION_MODIFIER", 163, 166], ["NBD", "OBSERVATION", 167, 170]]], ["The amount of distortion on the pulled NBD domain has also been studied.", [["pulled NBD domain", "PROTEIN", 32, 49], ["distortion on the pulled NBD domain", "PROBLEM", 14, 49], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["distortion", "OBSERVATION_MODIFIER", 14, 24]]], ["This work is partially supported by the Italian Cystic Fibrosis Foundation (Prog FFC #2/2008), with the contribution of \"Mille bambini a Via Margutta\"onlus\"Blunotte\", \"Lega Italiana FC Toscana\"P-500Stability and aggregation studies of human septin 3 (SEPT3) J. N. A. Mac\u00eado, R. C. Garratt, A. P. U. Ara\u00fajo Instituto de F\u00edsica de S\u00e3o Carlos, USP, S\u00e3o Carlos, BrazilP-500The septins are a conserved family of nucleotide binding proteins firstly identified in Saccharomyces cerevisae as proteins required for the completion of the cell cycle.", [["cell", "ANATOMY", 528, 532], ["Cystic Fibrosis", "DISEASE", 48, 63], ["nucleotide", "CHEMICAL", 407, 417], ["nucleotide", "CHEMICAL", 407, 417], ["human", "ORGANISM", 235, 240], ["septin 3", "GENE_OR_GENE_PRODUCT", 241, 249], ["septins", "GENE_OR_GENE_PRODUCT", 373, 380], ["Saccharomyces cerevisae", "ORGANISM", 457, 480], ["cell", "CELL", 528, 532], ["septins", "PROTEIN", 373, 380], ["nucleotide binding proteins", "PROTEIN", 407, 434], ["human", "SPECIES", 235, 240], ["Saccharomyces cerevisae", "SPECIES", 457, 480], ["human", "SPECIES", 235, 240], ["Saccharomyces cerevisae", "SPECIES", 457, 480], ["the Italian Cystic Fibrosis", "PROBLEM", 36, 63], ["P", "TEST", 193, 194], ["aggregation studies", "TEST", 212, 231], ["nucleotide binding proteins", "PROBLEM", 407, 434], ["the cell cycle", "TREATMENT", 524, 538], ["Cystic", "OBSERVATION_MODIFIER", 48, 54], ["Fibrosis", "OBSERVATION", 55, 63]]], ["Septins are implicated in several cellular functions such as cytokinesis, vesicle trafficking, exocytosis, cytoeskeletal dynamics, cell polarity and sperm motility.", [["cellular", "ANATOMY", 34, 42], ["vesicle", "ANATOMY", 74, 81], ["cytoeskeletal", "ANATOMY", 107, 120], ["cell", "ANATOMY", 131, 135], ["sperm", "ANATOMY", 149, 154], ["Septins", "GENE_OR_GENE_PRODUCT", 0, 7], ["cellular", "CELL", 34, 42], ["vesicle", "CELLULAR_COMPONENT", 74, 81], ["cell", "CELL", 131, 135], ["sperm", "CELLULAR_COMPONENT", 149, 154], ["Septins", "PROTEIN", 0, 7], ["sperm", "CELL_TYPE", 149, 154], ["cytokinesis", "PROBLEM", 61, 72], ["vesicle trafficking", "PROBLEM", 74, 93], ["exocytosis", "PROBLEM", 95, 105], ["cytoeskeletal dynamics", "PROBLEM", 107, 129], ["sperm motility", "PROBLEM", 149, 163], ["several", "OBSERVATION_MODIFIER", 26, 33], ["cellular functions", "OBSERVATION", 34, 52], ["cytokinesis", "OBSERVATION", 61, 72], ["vesicle trafficking", "OBSERVATION", 74, 93], ["cell polarity", "OBSERVATION", 131, 144], ["sperm motility", "OBSERVATION", 149, 163]]], ["Furthermore, they are associated with Alzheimer's and Parkinson's disease.", [["Alzheimer's and Parkinson's disease", "DISEASE", 38, 73], ["Alzheimer's", "PROBLEM", 38, 49], ["Parkinson's disease", "PROBLEM", 54, 73], ["associated with", "UNCERTAINTY", 22, 37], ["Alzheimer", "OBSERVATION", 38, 47], ["Parkinson's", "OBSERVATION", 54, 65]]], ["SEPT3 was identified in rat brain being highly enriched in presynaptic nerve terminals.", [["brain", "ANATOMY", 28, 33], ["presynaptic nerve terminals", "ANATOMY", 59, 86], ["SEPT3", "GENE_OR_GENE_PRODUCT", 0, 5], ["rat", "ORGANISM", 24, 27], ["brain", "ORGAN", 28, 33], ["nerve terminals", "MULTI-TISSUE_STRUCTURE", 71, 86], ["SEPT3", "PROTEIN", 0, 5], ["rat", "SPECIES", 24, 27], ["rat", "SPECIES", 24, 27], ["rat", "ANATOMY_MODIFIER", 24, 27], ["brain", "ANATOMY", 28, 33], ["highly", "OBSERVATION_MODIFIER", 40, 46], ["enriched", "OBSERVATION", 47, 55], ["presynaptic nerve terminals", "OBSERVATION", 59, 86]]], ["It colocalizes with synaptophysin and dynamin I and is associated with synaptic vesicle.", [["synaptic vesicle", "ANATOMY", 71, 87], ["synaptophysin", "GENE_OR_GENE_PRODUCT", 20, 33], ["dynamin I", "GENE_OR_GENE_PRODUCT", 38, 47], ["synaptic vesicle", "CELLULAR_COMPONENT", 71, 87], ["synaptophysin", "PROTEIN", 20, 33], ["dynamin I", "PROTEIN", 38, 47], ["synaptic vesicle", "PROBLEM", 71, 87], ["synaptophysin", "OBSERVATION", 20, 33], ["associated with", "UNCERTAINTY", 55, 70], ["synaptic vesicle", "OBSERVATION", 71, 87]]], ["In this work, human SEPT3 without its N-terminal domain (SEPT3GC) was expressed in E. coli and purified by affinity and size exclusion cromatographies.", [["N", "CHEMICAL", 38, 39], ["human", "ORGANISM", 14, 19], ["SEPT3", "GENE_OR_GENE_PRODUCT", 20, 25], ["SEPT3GC", "GENE_OR_GENE_PRODUCT", 57, 64], ["E. coli", "ORGANISM", 83, 90], ["human SEPT3", "PROTEIN", 14, 25], ["N-terminal domain", "PROTEIN", 38, 55], ["SEPT3GC", "PROTEIN", 57, 64], ["human", "SPECIES", 14, 19], ["E. coli", "SPECIES", 83, 90], ["human", "SPECIES", 14, 19], ["E. coli", "SPECIES", 83, 90], ["human SEPT3", "TEST", 14, 25], ["E. coli", "PROBLEM", 83, 90], ["size", "OBSERVATION_MODIFIER", 120, 124]]], ["Structural stability studies were performed with recombinant SEPT3GC using circular dichroism spectroscopy (CD), right-angle light scattering, and fluorescence spectroscopy.", [["recombinant SEPT3GC", "PROTEIN", 49, 68], ["Structural stability studies", "TEST", 0, 28], ["recombinant SEPT3GC", "TREATMENT", 49, 68], ["circular dichroism spectroscopy", "TEST", 75, 106], ["right-angle light scattering", "TEST", 113, 141], ["fluorescence spectroscopy", "TEST", 147, 172], ["right", "ANATOMY_MODIFIER", 113, 118]]], ["The SEPT3GC CD spectrum showed a conformational transition from a predominantly \u03b1-helical starting structure to one dominated by \u03b2-sheet, just above physiological temperatures.", [["The SEPT3GC CD spectrum", "TEST", 0, 23], ["a conformational transition", "PROBLEM", 31, 58], ["a predominantly \u03b1-helical starting structure", "PROBLEM", 64, 108], ["conformational transition", "OBSERVATION", 33, 58], ["predominantly", "OBSERVATION_MODIFIER", 66, 79]]], ["The formation of irreversible aggregates, detected by light scattering, and their ability to bind Thioflavin-T suggested that SEPT3 forms amyloidlike structures, as has been previously observed for human septins 2 and 4.", [["amyloidlike structures", "ANATOMY", 138, 160], ["Thioflavin-T", "CHEMICAL", 98, 110], ["SEPT3", "CHEMICAL", 126, 131], ["Thioflavin-T", "GENE_OR_GENE_PRODUCT", 98, 110], ["SEPT3", "GENE_OR_GENE_PRODUCT", 126, 131], ["human", "ORGANISM", 198, 203], ["septins 2", "GENE_OR_GENE_PRODUCT", 204, 213], ["Thioflavin-T", "PROTEIN", 98, 110], ["SEPT3", "PROTEIN", 126, 131], ["human septins 2 and 4", "PROTEIN", 198, 219], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["irreversible aggregates", "PROBLEM", 17, 40], ["SEPT3 forms amyloidlike structures", "PROBLEM", 126, 160], ["human septins", "TEST", 198, 211], ["irreversible", "OBSERVATION_MODIFIER", 17, 29], ["aggregates", "OBSERVATION", 30, 40]]], ["Our data suggest that amyloid formation by isolated septins in vitro may be a general phenomenon whose physiological relevance needs to be further investigated.", [["septins", "ANATOMY", 52, 59], ["amyloid", "DISEASE", 22, 29], ["amyloid", "GENE_OR_GENE_PRODUCT", 22, 29], ["septins", "GENE_OR_GENE_PRODUCT", 52, 59], ["septins", "PROTEIN", 52, 59], ["Our data", "TEST", 0, 8], ["amyloid formation", "PROBLEM", 22, 39], ["isolated septins in vitro", "PROBLEM", 43, 68], ["a general phenomenon", "PROBLEM", 76, 96], ["amyloid formation", "OBSERVATION", 22, 39], ["isolated septins", "OBSERVATION", 43, 59], ["may be", "UNCERTAINTY", 69, 75]]], ["Pln149 is an antimicrobial peptide produced from Lactobacillus plantarum NRIC149.", [["Pln149", "CHEMICAL", 0, 6], ["Lactobacillus plantarum", "CHEMICAL", 49, 72], ["Pln149", "SIMPLE_CHEMICAL", 0, 6], ["Lactobacillus plantarum NRIC149", "ORGANISM", 49, 80], ["Lactobacillus plantarum", "SPECIES", 49, 72], ["Lactobacillus plantarum", "SPECIES", 49, 72], ["an antimicrobial peptide", "TREATMENT", 10, 34], ["Lactobacillus plantarum NRIC149", "TREATMENT", 49, 80]]], ["Analog Pln149 (Pln149a) and a Ser-derived (Pln149S, Tyr to Ser replacement) were synthesized on solid phase and their interactions with biomembrane model systems and inhibitory property on S.aureus and P.aeruginosa were investigated by CD, leakage assays, fluorescence spectroscopy, and differential scanning calorimetry.", [["Pln149a", "CHEMICAL", 15, 22], ["Pln149", "CHEMICAL", 7, 13], ["Tyr", "CHEMICAL", 52, 55], ["Ser", "CHEMICAL", 59, 62], ["Pln149a", "SIMPLE_CHEMICAL", 15, 22], ["Ser", "AMINO_ACID", 59, 62], ["S.aureus", "SIMPLE_CHEMICAL", 189, 197], ["P.aeruginosa", "SIMPLE_CHEMICAL", 202, 214], ["Analog", "TEST", 0, 6], ["a Ser-derived (Pln149S, Tyr to Ser replacement", "TREATMENT", 28, 74], ["biomembrane model systems", "TREATMENT", 136, 161], ["S.aureus", "PROBLEM", 189, 197], ["P.aeruginosa", "PROBLEM", 202, 214], ["leakage assays", "TEST", 240, 254], ["fluorescence spectroscopy", "TEST", 256, 281], ["differential scanning calorimetry", "TEST", 287, 320], ["solid phase", "OBSERVATION_MODIFIER", 96, 107]]], ["Both peptides share the same unordered structure-like CD spectrum in aqueous solution, but a helicoidal induction in the presence of negative vesicles were observed, however Pln149S showed lower helical content than Pln149a.", [["vesicles", "ANATOMY", 142, 150], ["vesicles", "CELLULAR_COMPONENT", 142, 150], ["Pln149S", "GENE_OR_GENE_PRODUCT", 174, 181], ["Pln149S", "PROTEIN", 174, 181], ["aqueous solution", "TREATMENT", 69, 85], ["a helicoidal induction", "TREATMENT", 91, 113], ["negative vesicles", "PROBLEM", 133, 150], ["Pln149S", "TEST", 174, 181], ["lower helical content", "PROBLEM", 189, 210], ["CD spectrum", "OBSERVATION_MODIFIER", 54, 65], ["negative vesicles", "OBSERVATION", 133, 150]]], ["The Ser-derived peptide presented 30% decrease of its leakage activity in different liposome compositions, a threefold increase in the dissociation constant from the liposomes than Pln149a, and close to 40% reduction for the inhibitory activity against P. aeruginosa growth.", [["liposome", "SIMPLE_CHEMICAL", 84, 92], ["liposomes", "SIMPLE_CHEMICAL", 166, 175], ["Pln149a", "SIMPLE_CHEMICAL", 181, 188], ["P. aeruginosa", "ORGANISM", 253, 266], ["P. aeruginosa", "SPECIES", 253, 266], ["P. aeruginosa", "SPECIES", 253, 266], ["The Ser-derived peptide", "TREATMENT", 0, 23], ["its leakage activity", "PROBLEM", 50, 70], ["different liposome compositions", "TREATMENT", 74, 105], ["the dissociation", "PROBLEM", 131, 147], ["P. aeruginosa growth", "PROBLEM", 253, 273], ["30%", "OBSERVATION_MODIFIER", 34, 37], ["decrease", "OBSERVATION_MODIFIER", 38, 46], ["leakage activity", "OBSERVATION", 54, 70], ["different", "OBSERVATION_MODIFIER", 74, 83], ["liposome compositions", "OBSERVATION", 84, 105], ["threefold", "OBSERVATION_MODIFIER", 109, 118], ["increase", "OBSERVATION_MODIFIER", 119, 127], ["dissociation", "OBSERVATION", 135, 147], ["constant", "OBSERVATION_MODIFIER", 148, 156]]], ["We can conclude that besides the electrostatic contacts between the amphipathic &alpha-helix, formed by the cationic residues from Pln149 and negatively charged phospholipids, the Pln149-membrane binding is a process driven for the hydrophobic interactions from non-polar residues.", [["membrane", "ANATOMY", 187, 195], ["Pln149", "CHEMICAL", 180, 186], ["Pln149", "SIMPLE_CHEMICAL", 131, 137], ["phospholipids", "SIMPLE_CHEMICAL", 161, 174], ["membrane", "CELLULAR_COMPONENT", 187, 195], ["amphipathic &alpha-helix", "PROTEIN", 68, 92], ["Pln149", "PROTEIN", 131, 137], ["Pln149", "PROTEIN", 180, 186], ["the electrostatic contacts between the amphipathic &alpha-helix", "PROBLEM", 29, 92], ["the cationic residues", "PROBLEM", 104, 125], ["negatively charged phospholipids", "TREATMENT", 142, 174], ["non-polar residues", "PROBLEM", 262, 280], ["non-polar residues", "OBSERVATION", 262, 280]]], ["In this case, there was a significant contribution of the Tyr residue, which must be allocated in a lipid interface, described as the preferential position to this residue in membrane proteins.", [["membrane", "ANATOMY", 175, 183], ["Tyr", "CHEMICAL", 58, 61], ["Tyr", "AMINO_ACID", 58, 61], ["membrane", "CELLULAR_COMPONENT", 175, 183], ["membrane proteins", "PROTEIN", 175, 192], ["the Tyr residue", "PROBLEM", 54, 69], ["this residue in membrane proteins", "PROBLEM", 159, 192], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["Tyr residue", "OBSERVATION", 58, 69]]], ["Supported: FAPESPP-498Label free detection using deep-UV laser-based fluorescence lifetime imaging microscopy Q. Li, S. Seeger Physikalisch-Chemisches Institut, Universit\u00e4t Z\u00fcrich, Winterthurerstrasse 190, CH-8057 Z\u00fcrich, Switzerland Label free detection based on native fluorescence excited at UV region shows great potential for the life sciences.", [["FAPESPP-498Label", "CHEMICAL", 11, 27], ["Li", "CHEMICAL", 113, 115], ["Winterthurerstrasse 190, CH-8057", "CHEMICAL", 181, 213], ["FAPESPP", "TEST", 11, 18], ["deep-UV laser", "TREATMENT", 49, 62], ["imaging microscopy", "TEST", 91, 109], ["Physikalisch", "TEST", 127, 139], ["Winterthurerstrasse", "TEST", 181, 200]]], ["In this contribution we present a deep UV fluorescence lifetime imaging microscopy system (DUV-FLIM) based on a picosecond deep UV laser using time-correlated single-photon counting method.", [["a picosecond deep UV laser", "TREATMENT", 110, 136]]], ["The described setup is well-suited for biological applications for ultrasensitive detection.", [["ultrasensitive detection", "TEST", 67, 91]]], ["We have showed single UV dye (BMQ) and single protein (Ec\u03b2 Gal ) molecules detection using DUV-FLIM.", [["Ec\u03b2 Gal", "GENE_OR_GENE_PRODUCT", 55, 62], ["Ec\u03b2 Gal ) molecules", "PROTEIN", 55, 74], ["single UV dye", "TREATMENT", 15, 28], ["single protein", "TEST", 39, 53], ["DUV-FLIM", "TREATMENT", 91, 99]]], ["Further, the label free detection of protein interaction between Ec\u03b2 Gal and monoclonal anti-Ec\u03b2 Gal has been demonstrated by means of steady-state and time-resolved fluorescence spectroscopy.", [["Ec\u03b2 Gal", "GENE_OR_GENE_PRODUCT", 65, 72], ["anti-Ec\u03b2", "GENE_OR_GENE_PRODUCT", 88, 96], ["Gal", "GENE_OR_GENE_PRODUCT", 97, 100], ["Ec\u03b2 Gal", "PROTEIN", 65, 72], ["monoclonal anti-Ec\u03b2", "PROTEIN", 77, 96], ["protein interaction", "PROBLEM", 37, 56], ["Ec\u03b2 Gal", "TREATMENT", 65, 72], ["fluorescence spectroscopy", "TEST", 166, 191]]], ["We achieved detection sensitivity for the Ec\u03b2 Gal/ anti-Ec\u03b2 Gal pair down to the nanomolar concentration range.", [["Ec\u03b2 Gal", "GENE_OR_GENE_PRODUCT", 42, 49], ["anti-Ec\u03b2", "GENE_OR_GENE_PRODUCT", 51, 59], ["Gal", "GENE_OR_GENE_PRODUCT", 60, 63], ["Ec\u03b2 Gal", "PROTEIN", 42, 49], ["anti-Ec\u03b2", "PROTEIN", 51, 59], ["detection sensitivity", "TEST", 12, 33], ["Gal pair", "TEST", 60, 68]]], ["We also extended this method to study the interaction of therapeutic drug porphyrin with BSA protein.", [["porphyrin", "CHEMICAL", 74, 83], ["porphyrin", "CHEMICAL", 74, 83], ["porphyrin", "SIMPLE_CHEMICAL", 74, 83], ["BSA", "SIMPLE_CHEMICAL", 89, 92], ["BSA protein", "PROTEIN", 89, 100], ["therapeutic drug porphyrin with BSA protein", "TREATMENT", 57, 100]]], ["Fluorescence resonance energy transfer between protein and Alexa Fluor 350 has been investigated using DUV-FLIM.", [["Alexa Fluor 350", "CHEMICAL", 59, 74], ["Alexa Fluor 350", "SIMPLE_CHEMICAL", 59, 74], ["Alexa Fluor 350", "PROTEIN", 59, 74], ["protein and Alexa Fluor", "TREATMENT", 47, 70]]], ["The intrinsic fluorescence and fluorescence lifetime changes of donor biotin \u03b2-Galactosidase have been measured.", [["biotin \u03b2-Galactosidase", "CHEMICAL", 70, 92], ["biotin", "CHEMICAL", 70, 76], ["biotin \u03b2-Galactosidase", "SIMPLE_CHEMICAL", 70, 92], ["The intrinsic fluorescence", "TEST", 0, 26], ["donor biotin \u03b2-Galactosidase", "TREATMENT", 64, 92], ["intrinsic fluorescence", "OBSERVATION", 4, 26]]], ["Energy transfer efficiency and donor acceptor distance have been obtained.", [["donor acceptor distance", "TREATMENT", 31, 54]]], ["Fluorescence images of acceptor AF 350 due to FRET have been observed when excited at 266 nm.", [["Fluorescence images", "TEST", 0, 19], ["acceptor AF", "TREATMENT", 23, 34]]], ["The monomeric heme-containing indoleamine 2,3dioxygenase (IDO) catalyses the oxidative cleavage of the indole moiety of L-tryptophan (L-Trp).", [["indoleamine", "CHEMICAL", 30, 41], ["indole", "CHEMICAL", 103, 109], ["L-tryptophan", "CHEMICAL", 120, 132], ["L-Trp", "CHEMICAL", 134, 139], ["heme", "CHEMICAL", 14, 18], ["indoleamine", "CHEMICAL", 30, 41], ["indole", "CHEMICAL", 103, 109], ["L-tryptophan", "CHEMICAL", 120, 132], ["L-Trp", "CHEMICAL", 134, 139], ["indoleamine 2,3dioxygenase", "GENE_OR_GENE_PRODUCT", 30, 56], ["IDO", "GENE_OR_GENE_PRODUCT", 58, 61], ["indole", "SIMPLE_CHEMICAL", 103, 109], ["L-tryptophan", "SIMPLE_CHEMICAL", 120, 132], ["L-Trp", "SIMPLE_CHEMICAL", 134, 139], ["monomeric heme", "PROTEIN", 4, 18], ["indoleamine 2,3dioxygenase", "PROTEIN", 30, 56], ["IDO", "PROTEIN", 58, 61], ["The monomeric heme", "TEST", 0, 18], ["indoleamine 2,3dioxygenase (IDO)", "TREATMENT", 30, 62], ["the oxidative cleavage", "TREATMENT", 73, 95], ["L-tryptophan (L-Trp)", "TREATMENT", 120, 140]]], ["Enhanced L-Trp degradation contributes to various physiological disorders including depression or failure of the immuno-regulating system.", [["L-Trp", "CHEMICAL", 9, 14], ["depression", "DISEASE", 84, 94], ["L-Trp", "CHEMICAL", 9, 14], ["L-Trp", "GENE_OR_GENE_PRODUCT", 9, 14], ["Trp degradation", "PROBLEM", 11, 26], ["various physiological disorders", "PROBLEM", 42, 73], ["depression", "PROBLEM", 84, 94], ["failure of the immuno-regulating system", "PROBLEM", 98, 137], ["various physiological disorders", "OBSERVATION", 42, 73], ["failure", "OBSERVATION", 98, 105], ["immuno-regulating", "OBSERVATION", 113, 130]]], ["The regulation of IDO by inhibitors is extensively studied.", [["IDO", "GENE_OR_GENE_PRODUCT", 18, 21], ["IDO", "PROTEIN", 18, 21], ["IDO by inhibitors", "TREATMENT", 18, 35]]], ["However, the catalytic mechanism of IDO on the molecular level is still unknown.", [["IDO", "GENE_OR_GENE_PRODUCT", 36, 39], ["IDO", "PROTEIN", 36, 39], ["the molecular level", "TEST", 43, 62], ["IDO", "OBSERVATION", 36, 39]]], ["In addition to L-Trp, a wide range of substrates are degraded including D-tryptophan, melatonine or tryptamine.", [["L-Trp", "CHEMICAL", 15, 20], ["D-tryptophan", "CHEMICAL", 72, 84], ["melatonine", "CHEMICAL", 86, 96], ["tryptamine", "CHEMICAL", 100, 110], ["L-Trp", "CHEMICAL", 15, 20], ["D-tryptophan", "CHEMICAL", 72, 84], ["melatonine", "CHEMICAL", 86, 96], ["tryptamine", "CHEMICAL", 100, 110], ["L-Trp", "SIMPLE_CHEMICAL", 15, 20], ["D-tryptophan", "SIMPLE_CHEMICAL", 72, 84], ["melatonine", "SIMPLE_CHEMICAL", 86, 96], ["tryptamine", "SIMPLE_CHEMICAL", 100, 110], ["D-tryptophan", "TREATMENT", 72, 84], ["melatonine", "TREATMENT", 86, 96], ["tryptamine", "TREATMENT", 100, 110]]], ["In contrast, indole or histidine do not function as substrates for IDO.", [["indole", "CHEMICAL", 13, 19], ["histidine", "CHEMICAL", 23, 32], ["indole", "CHEMICAL", 13, 19], ["histidine", "CHEMICAL", 23, 32], ["indole", "SIMPLE_CHEMICAL", 13, 19], ["histidine", "AMINO_ACID", 23, 32], ["IDO", "GENE_OR_GENE_PRODUCT", 67, 70], ["IDO", "PROTEIN", 67, 70], ["histidine", "TREATMENT", 23, 32], ["IDO", "PROBLEM", 67, 70]]], ["To understand the determinants for substrate specificity, we investigate the interaction of the heme iron, the heme-bound ligand and the substrate.", [["iron", "CHEMICAL", 101, 105], ["heme iron", "CHEMICAL", 96, 105], ["heme", "CHEMICAL", 111, 115], ["heme iron", "SIMPLE_CHEMICAL", 96, 105], ["heme", "SIMPLE_CHEMICAL", 111, 115], ["heme", "PROTEIN", 111, 115], ["the heme iron", "TREATMENT", 92, 105]]], ["We use (time-resolved) UV/visible and Fourier transform infrared (FTIR) spectroscopy over a wide temperature range (4 -300 K) to monitor the binding of diatomic ligands to the heme iron and the binding of different substrates to COligated IDO.", [["iron", "CHEMICAL", 181, 185], ["heme iron", "CHEMICAL", 176, 185], ["heme iron", "SIMPLE_CHEMICAL", 176, 185], ["IDO", "GENE_OR_GENE_PRODUCT", 239, 242], ["IDO", "PROTEIN", 239, 242], ["a wide temperature range", "TEST", 90, 114], ["the heme iron", "TREATMENT", 172, 185]]], ["Changes in the spectra upon addition of L-Trp are analyzed and compared to those induced by other substrates or inhibitors.P-504Archaeal protoglobin 3D-structure: novel ligand diffusion paths and heme-reactivity modulation Protoglobin (Pgb) from Methanosarcina acetivorans C2A, a strictly anaerobic methanogenic Archaea, is the latest entry in the hemoglobin superfamily.", [["L-Trp", "CHEMICAL", 40, 45], ["P-504Archaeal protoglobin", "CHEMICAL", 123, 148], ["L-Trp", "CHEMICAL", 40, 45], ["heme", "CHEMICAL", 196, 200], ["L-Trp", "GENE_OR_GENE_PRODUCT", 40, 45], ["heme", "SIMPLE_CHEMICAL", 196, 200], ["Protoglobin", "SIMPLE_CHEMICAL", 223, 234], ["Pgb", "SIMPLE_CHEMICAL", 236, 239], ["Methanosarcina acetivorans C2A", "GENE_OR_GENE_PRODUCT", 246, 276], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 348, 358], ["P", "DNA", 123, 124], ["heme", "PROTEIN", 196, 200], ["Protoglobin", "PROTEIN", 223, 234], ["Pgb", "PROTEIN", 236, 239], ["C2A", "PROTEIN", 273, 276], ["hemoglobin superfamily", "PROTEIN", 348, 370], ["Methanosarcina acetivorans", "SPECIES", 246, 272], ["Methanosarcina acetivorans", "SPECIES", 246, 272], ["L-Trp", "TREATMENT", 40, 45], ["inhibitors", "TREATMENT", 112, 122], ["P", "TEST", 123, 124], ["novel ligand diffusion paths", "TEST", 163, 191], ["heme", "TEST", 196, 200], ["Protoglobin", "TEST", 223, 234], ["Methanosarcina acetivorans C2A", "PROBLEM", 246, 276], ["a strictly anaerobic methanogenic Archaea", "PROBLEM", 278, 319], ["methanogenic Archaea", "OBSERVATION", 299, 319]]], ["Our previous crystallographic studies on Pgb have shown that protoglobinspecific loops and a N-terminal extension completely bury the heme within the protein matrix (1) .", [["Pgb", "CHEMICAL", 41, 44], ["N", "CHEMICAL", 93, 94], ["heme", "CHEMICAL", 134, 138], ["Pgb", "GENE_OR_GENE_PRODUCT", 41, 44], ["matrix", "CELLULAR_COMPONENT", 158, 164], ["Pgb", "PROTEIN", 41, 44], ["protoglobinspecific loops", "PROTEIN", 61, 86], ["heme", "PROTEIN", 134, 138], ["Our previous crystallographic studies", "TEST", 0, 37], ["Pgb", "TREATMENT", 41, 44], ["protoglobinspecific loops", "PROBLEM", 61, 86], ["a N-terminal extension", "PROBLEM", 91, 113], ["protoglobinspecific loops", "OBSERVATION", 61, 86], ["terminal", "OBSERVATION_MODIFIER", 95, 103], ["extension", "OBSERVATION_MODIFIER", 104, 113], ["completely", "OBSERVATION_MODIFIER", 114, 124], ["bury", "OBSERVATION_MODIFIER", 125, 129], ["heme", "OBSERVATION_MODIFIER", 134, 138]]], ["Access of O 2 , CO, and NO to the heme is granted by protoglobin-specific apolar tunnels reaching the heme distal site from locations at the B/G and B/E helix interfaces.", [["O 2 , CO", "CHEMICAL", 10, 18], ["NO", "CHEMICAL", 24, 26], ["protoglobin", "CHEMICAL", 53, 64], ["O 2", "CHEMICAL", 10, 13], ["CO", "CHEMICAL", 16, 18], ["NO", "CHEMICAL", 24, 26], ["heme", "CHEMICAL", 34, 38], ["protoglobin", "CHEMICAL", 53, 64], ["heme", "CHEMICAL", 102, 106], ["O 2", "SIMPLE_CHEMICAL", 10, 13], ["CO", "SIMPLE_CHEMICAL", 16, 18], ["NO", "SIMPLE_CHEMICAL", 24, 26], ["heme", "SIMPLE_CHEMICAL", 34, 38], ["protoglobin", "SIMPLE_CHEMICAL", 53, 64], ["heme", "PROTEIN", 34, 38], ["protoglobin", "PROTEIN", 53, 64], ["heme distal site", "DNA", 102, 118], ["B", "PROTEIN", 149, 150], ["CO", "TEST", 16, 18], ["heme", "OBSERVATION", 34, 38], ["apolar tunnels", "OBSERVATION", 74, 88], ["heme", "ANATOMY", 102, 106], ["distal", "ANATOMY_MODIFIER", 107, 113], ["helix", "ANATOMY_MODIFIER", 153, 158]]], ["Here we report structural and kinetic data on Pgb mutants engineered to probe the protein structural and kinetic properties.", [["Pgb", "SIMPLE_CHEMICAL", 46, 49], ["Pgb mutants", "PROTEIN", 46, 57], ["structural and kinetic data", "PROBLEM", 15, 42], ["Pgb mutants", "TREATMENT", 46, 57], ["kinetic properties", "OBSERVATION", 105, 123]]], ["Six crystal structures (Pgb mutants: \u220620 (missing 20 Nter residues), Y(B10)61\u2192A, Y(B10)61\u2192W, F(B12)63\u2192W, F(G7)145\u2192W, I(G11)149\u2192F) show that the mutations engineered essentially restrict access to ligand tunnel 1.", [["Pgb", "GENE_OR_GENE_PRODUCT", 24, 27], ["ligand tunnel 1", "GENE_OR_GENE_PRODUCT", 196, 211], ["Pgb mutants", "PROTEIN", 24, 35], ["Six crystal structures", "TEST", 0, 22], ["Pgb mutants", "TEST", 24, 35], ["B12", "TEST", 95, 98], ["G11", "TEST", 119, 122], ["the mutations engineered", "PROBLEM", 140, 164]]], ["An accurate molecular level description of the signaling mechanism in Ca 2+ transducers necessitates the knowledge of the kinetics and energetics of conformational changes associated with Ca 2+ binding to various calcium binding proteins.", [["Ca", "CHEMICAL", 70, 72], ["Ca", "CHEMICAL", 188, 190], ["calcium", "CHEMICAL", 213, 220], ["Ca 2+", "CHEMICAL", 70, 75], ["Ca 2+", "CHEMICAL", 188, 193], ["calcium", "CHEMICAL", 213, 220], ["Ca 2+", "SIMPLE_CHEMICAL", 70, 75], ["Ca 2+", "SIMPLE_CHEMICAL", 188, 193], ["calcium", "SIMPLE_CHEMICAL", 213, 220], ["calcium binding proteins", "PROTEIN", 213, 237], ["the signaling mechanism", "PROBLEM", 43, 66], ["the kinetics", "PROBLEM", 118, 130], ["conformational changes", "PROBLEM", 149, 171], ["Ca", "TEST", 188, 190], ["various calcium binding proteins", "PROBLEM", 205, 237]]], ["With this in mind, we have developed an approach that combines the laser-induced photolysis of photolabile \"caged\" Ca 2+ compound, DM-nitrophen, with the photothermal beam deflection (PBD) technique to determine thermodynamic profiles associated with the ligand binding to calcium chelator, EDTA, and Ca 2+ sensor, calmodulin.", [["Ca", "CHEMICAL", 115, 117], ["DM-nitrophen", "CHEMICAL", 131, 143], ["calcium", "CHEMICAL", 273, 280], ["EDTA", "CHEMICAL", 291, 295], ["Ca", "CHEMICAL", 301, 303], ["Ca 2+", "CHEMICAL", 115, 120], ["nitrophen", "CHEMICAL", 134, 143], ["calcium", "CHEMICAL", 273, 280], ["EDTA", "CHEMICAL", 291, 295], ["Ca 2+", "CHEMICAL", 301, 306], ["Ca 2+ compound", "SIMPLE_CHEMICAL", 115, 129], ["DM-nitrophen", "SIMPLE_CHEMICAL", 131, 143], ["calcium chelator", "SIMPLE_CHEMICAL", 273, 289], ["EDTA", "SIMPLE_CHEMICAL", 291, 295], ["Ca 2+", "SIMPLE_CHEMICAL", 301, 306], ["calmodulin", "GENE_OR_GENE_PRODUCT", 315, 325], ["calmodulin", "PROTEIN", 315, 325], ["the laser-induced photolysis of photolabile", "TREATMENT", 63, 106], ["DM", "PROBLEM", 131, 133], ["nitrophen", "TREATMENT", 134, 143], ["the photothermal beam deflection (PBD) technique", "TREATMENT", 150, 198], ["the ligand binding", "PROBLEM", 251, 269], ["calcium chelator", "TREATMENT", 273, 289], ["EDTA", "TEST", 291, 295], ["Ca", "TEST", 301, 303]]], ["This approach allows us to monitor time profiles of volume and enthalpy changes on the microsecond to millisecond timescale.", [["volume", "TEST", 52, 58], ["enthalpy changes", "PROBLEM", 63, 79]]], ["The initial PBD study of Ca 2+ photo-relase from Ca 2+ loaded DM-nitrophen reveals the presence of two phases.", [["Ca", "CHEMICAL", 25, 27], ["Ca", "CHEMICAL", 49, 51], ["DM-nitrophen", "CHEMICAL", 62, 74], ["Ca 2+", "CHEMICAL", 25, 30], ["Ca 2+", "CHEMICAL", 49, 54], ["nitrophen", "CHEMICAL", 65, 74], ["Ca 2+", "SIMPLE_CHEMICAL", 25, 30], ["Ca 2+", "SIMPLE_CHEMICAL", 49, 54], ["DM-nitrophen", "SIMPLE_CHEMICAL", 62, 74], ["The initial PBD study", "TEST", 0, 21], ["Ca", "TEST", 25, 27], ["photo", "TEST", 31, 36], ["Ca", "TEST", 49, 51], ["DM", "PROBLEM", 62, 64], ["nitrophen", "TREATMENT", 65, 74]]], ["The first step takes place within first 20 \u00b5s upon and is associated with a volume decrease of -7 mL mol \u22121 and enthalpy change of 66 kcal mol \u22121 .", [["a volume decrease", "TREATMENT", 74, 91]]], ["On the longer timescale (\u03c4 = 200 \u00b5s), the second event with a positive volume change of 7 mL mol \u22121 and enthalpy change of 8 kcal mol \u22121 was detected.", [["a positive volume change", "PROBLEM", 60, 84], ["enthalpy change of 8 kcal mol \u22121", "TREATMENT", 104, 136]]], ["On the other hand, Ca 2+ photorelease in the presence of calmodulin is accompanied with an additional phase with a distinct lifetime and volume and enthalpy changes that reflects the metal binding to calmodulin and concomitant structural changes.P-502Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations Antimicrobial peptides (AMPs) have been intensively studied at micro and macroscopic levels for over twenty years.", [["membrane", "ANATOMY", 312, 320], ["Ca", "CHEMICAL", 19, 21], ["calmodulin", "CHEMICAL", 57, 67], ["Ca 2+", "CHEMICAL", 19, 24], ["Ca 2+", "SIMPLE_CHEMICAL", 19, 24], ["calmodulin", "GENE_OR_GENE_PRODUCT", 57, 67], ["calmodulin", "GENE_OR_GENE_PRODUCT", 200, 210], ["calmodulin", "PROTEIN", 57, 67], ["calmodulin", "PROTEIN", 200, 210], ["Ca", "TEST", 19, 21], ["enthalpy changes", "PROBLEM", 148, 164], ["the metal binding", "PROBLEM", 179, 196], ["concomitant structural changes", "PROBLEM", 215, 245], ["Antimicrobial peptides (AMPs", "TREATMENT", 342, 370], ["macroscopic levels", "TEST", 415, 433], ["calmodulin", "OBSERVATION", 57, 67], ["enthalpy changes", "OBSERVATION", 148, 164], ["metal binding", "OBSERVATION", 183, 196]]], ["Knowledge from these two domains has, however, contributed little to a comprehensive understanding of AMP action; rather, in vivo AMP performance has been only remotely correlated to biophysical properties.", [["AMP", "CHEMICAL", 102, 105], ["AMP", "CHEMICAL", 130, 133], ["AMP", "CHEMICAL", 102, 105], ["AMP", "CHEMICAL", 130, 133], ["AMP", "SIMPLE_CHEMICAL", 102, 105], ["AMP", "SIMPLE_CHEMICAL", 130, 133], ["AMP action", "TREATMENT", 102, 112], ["vivo AMP performance", "TEST", 125, 145]]], ["We focus on the assessment of peptide accumulation on bacterial membranes as an example of this separation: AMP-bilayer interactions have been subject to extensive biophysical characterization, but conversion of that information into educated estimates of in vivo membrane-bound AMP concentrations is lacking.", [["membranes", "ANATOMY", 64, 73], ["membrane", "ANATOMY", 264, 272], ["AMP", "CHEMICAL", 108, 111], ["AMP", "CHEMICAL", 279, 282], ["AMP", "CHEMICAL", 108, 111], ["AMP", "CHEMICAL", 279, 282], ["bacterial membranes", "CELLULAR_COMPONENT", 54, 73], ["AMP", "SIMPLE_CHEMICAL", 108, 111], ["membrane", "CELLULAR_COMPONENT", 264, 272], ["AMP", "SIMPLE_CHEMICAL", 279, 282], ["the assessment", "TEST", 12, 26], ["peptide accumulation", "PROBLEM", 30, 50], ["bacterial membranes", "TREATMENT", 54, 73], ["extensive biophysical characterization", "TEST", 154, 192], ["bound AMP concentrations", "TREATMENT", 273, 297], ["bacterial membranes", "OBSERVATION_MODIFIER", 54, 73]]], ["Using simple partition models we were able to analyze available information on AMP activity and interaction with membranes to show that unexpectedly high membranebound peptide concentrations are likely in vivo and may, in some cases, be required for triggering bacterial death.Mimetic model of the fusion active conformation of gp41 on solid supported lipid bilayersE.", [["membranes", "ANATOMY", 113, 122], ["AMP", "CHEMICAL", 79, 82], ["death", "DISEASE", 271, 276], ["AMP", "CHEMICAL", 79, 82], ["AMP", "SIMPLE_CHEMICAL", 79, 82], ["membranes", "CELLULAR_COMPONENT", 113, 122], ["gp41", "GENE_OR_GENE_PRODUCT", 328, 332], ["gp41", "PROTEIN", 328, 332], ["simple partition models", "TREATMENT", 6, 29], ["AMP activity", "TREATMENT", 79, 91], ["membranes", "TREATMENT", 113, 122], ["triggering bacterial death", "PROBLEM", 250, 276], ["the fusion active conformation of gp41 on solid supported lipid bilayersE", "TREATMENT", 294, 367]]], ["E. Sch\u00e4fer 1 , S. Schuy 2 , A. Janshoff 1 1 Georg August-University G\u00f6ttingen, Germany, 2 Johannes-Gutenberg-University Mainz, GermanyMimetic model of the fusion active conformation of gp41 on solid supported lipid bilayersRetrovirus entry into cells occurs through fusion of the lipid bilayers that surround the virus and the lipid bilayer of the host cell.", [["lipid bilayers", "ANATOMY", 209, 223], ["cells", "ANATOMY", 245, 250], ["lipid bilayers", "ANATOMY", 280, 294], ["lipid bilayer", "ANATOMY", 327, 340], ["cell", "ANATOMY", 353, 357], ["gp41", "GENE_OR_GENE_PRODUCT", 185, 189], ["cells", "CELL", 245, 250], ["lipid bilayers", "CELLULAR_COMPONENT", 280, 294], ["lipid bilayer", "CELLULAR_COMPONENT", 327, 340], ["host cell", "CELL", 348, 357], ["gp41", "PROTEIN", 185, 189], ["host cell", "CELL_TYPE", 348, 357], ["the fusion active conformation of gp41 on solid supported lipid bilayers", "TREATMENT", 151, 223], ["Retrovirus entry into cells", "PROBLEM", 223, 250], ["fusion of the lipid bilayers", "TREATMENT", 266, 294], ["the virus", "PROBLEM", 309, 318], ["fusion", "OBSERVATION", 266, 272], ["lipid", "ANATOMY_MODIFIER", 280, 285], ["bilayers", "ANATOMY_MODIFIER", 286, 294], ["virus", "OBSERVATION", 313, 318], ["lipid", "OBSERVATION_MODIFIER", 327, 332], ["bilayer", "OBSERVATION_MODIFIER", 333, 340], ["host cell", "OBSERVATION", 348, 357]]], ["Fusion proteins, present on the surface of the virus membrane play an essential role in the early stage of virus entry.", [["surface", "ANATOMY", 32, 39], ["membrane", "ANATOMY", 53, 61], ["surface", "CELLULAR_COMPONENT", 32, 39], ["virus membrane", "CELLULAR_COMPONENT", 47, 61], ["Fusion proteins", "PROTEIN", 0, 15], ["Fusion proteins", "PROBLEM", 0, 15], ["the virus membrane", "TREATMENT", 43, 61], ["virus", "OBSERVATION", 47, 52], ["virus", "OBSERVATION", 107, 112]]], ["Understanding of the molecular mechanism is important for the design and function of modern fusion inhibitors.", [["modern fusion inhibitors", "TREATMENT", 85, 109]]], ["In this project we analyze the fusion of active conformation of the envelope gp41 from the human and simian immunodeficiency viruses (HIV and SIV).", [["simian immunodeficiency viruses", "DISEASE", 101, 132], ["human", "ORGANISM", 91, 96], ["simian immunodeficiency viruses", "ORGANISM", 101, 132], ["HIV", "ORGANISM", 134, 137], ["SIV", "ORGANISM", 142, 145], ["envelope gp41", "PROTEIN", 68, 81], ["human", "SPECIES", 91, 96], ["simian immunodeficiency viruses", "SPECIES", 101, 132], ["HIV", "SPECIES", 134, 137], ["human", "SPECIES", 91, 96], ["simian immunodeficiency viruses", "SPECIES", 101, 132], ["HIV", "SPECIES", 134, 137], ["SIV", "SPECIES", 142, 145], ["the fusion", "TREATMENT", 27, 37], ["the envelope gp41", "TREATMENT", 64, 81], ["simian immunodeficiency viruses", "PROBLEM", 101, 132], ["simian immunodeficiency", "OBSERVATION", 101, 124]]], ["During the infection process gp41 undergoes a sequence of conformational changes where the N -terminal NHR develop a trimer pre-hairpin intermediate.", [["infection", "DISEASE", 11, 20], ["N", "CHEMICAL", 91, 92], ["gp41", "PROTEIN", 29, 33], ["N -terminal NHR", "PROTEIN", 91, 106], ["trimer pre-hairpin intermediate", "PROTEIN", 117, 148], ["the infection process gp41", "PROBLEM", 7, 33], ["conformational changes", "PROBLEM", 58, 80], ["the N -terminal NHR", "PROBLEM", 87, 106], ["infection", "OBSERVATION", 11, 20]]], ["Afterwards the three CHR fold back towards the central NHR and a six helix bundle is formed.", [["CHR", "PROTEIN", 21, 24], ["central NHR", "PROTEIN", 47, 58], ["central NHR", "ANATOMY", 47, 58], ["formed", "OBSERVATION", 85, 91]]], ["This rearrangement forces the viral and the host membrane into close contact and fusion pores may induce membrane fusion.", [["membrane", "ANATOMY", 49, 57], ["membrane", "ANATOMY", 105, 113], ["host membrane", "CELLULAR_COMPONENT", 44, 57], ["membrane", "CELLULAR_COMPONENT", 105, 113], ["close contact and fusion pores", "TREATMENT", 63, 93], ["membrane fusion", "PROBLEM", 105, 120], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["host membrane", "OBSERVATION", 44, 57], ["membrane fusion", "OBSERVATION", 105, 120]]], ["This decisive molecular step in retroviral fusion has been modeled by rational design of lipopeptide assemblies that mimic a coiled-coil structure serving as a receptor for potential antagonists.", [["retroviral", "ORGANISM", 32, 42], ["coiled-coil structure", "PROTEIN", 125, 146], ["retroviral fusion", "TREATMENT", 32, 49], ["lipopeptide assemblies", "TREATMENT", 89, 111], ["a coiled-coil structure", "TREATMENT", 123, 146], ["potential antagonists", "TREATMENT", 173, 194], ["retroviral fusion", "OBSERVATION", 32, 49]]], ["For this purpose, SSLBs were functionalized in an in situ coupling reaction with peptides originating from the NHR (N-peptides) of SIV and HIV to monitor the interactions with the specific CHR peptides (C34 and T20).", [["SSLBs", "SIMPLE_CHEMICAL", 18, 23], ["SIV", "ORGANISM", 131, 134], ["HIV", "ORGANISM", 139, 142], ["SIV", "SPECIES", 131, 134], ["HIV", "SPECIES", 139, 142], ["SSLBs", "PROBLEM", 18, 23], ["peptides", "TREATMENT", 81, 89], ["SIV", "PROBLEM", 131, 134], ["HIV", "PROBLEM", 139, 142]]], ["Binding of antagonists to surface confined coiled-coil structures has been quantified by ellipsometry, quartz crystal microbalance and was visualized by atomic force microscopy.Analysis of the interaction between ROS and uncoupling proteins in bilayer membranes and in neuronsA.", [["surface", "ANATOMY", 26, 33], ["bilayer membranes", "ANATOMY", 244, 261], ["ROS", "CHEMICAL", 213, 216], ["quartz", "CHEMICAL", 103, 109], ["ROS", "SIMPLE_CHEMICAL", 213, 216], ["bilayer membranes", "CELLULAR_COMPONENT", 244, 261], ["uncoupling proteins", "PROTEIN", 221, 240], ["antagonists to surface confined coiled-coil structures", "TREATMENT", 11, 65], ["ellipsometry", "TEST", 89, 101], ["quartz crystal microbalance", "TEST", 103, 130], ["atomic force microscopy", "TEST", 153, 176], ["the interaction between ROS", "PROBLEM", 189, 216], ["uncoupling proteins in bilayer membranes", "PROBLEM", 221, 261], ["coil structures", "OBSERVATION", 50, 65], ["bilayer membranes", "ANATOMY", 244, 261]]], ["Rupprecht 1 , E. Sokolenko 2 , E. E. Pohl 1 1 Institute of Cell Biology and Neurobiology, Charit\u00e9 -Universit\u00e4tsmedizin, Berlin, Germany, 2 Frumkin Institute of Physical Chemistry and Electrochemistry Russian Academy of Sciences, Moscow, RussiaAnalysis of the interaction between ROS and uncoupling proteins in bilayer membranes and in neuronsThe production of reactive oxygen species (ROS) in mitochondria is very sensitive to the proton motive force and can be decreased by mild uncoupling, mediated e.g. by uncoupling proteins (UCP) 1 .", [["Cell", "ANATOMY", 59, 63], ["bilayer membranes", "ANATOMY", 310, 327], ["neurons", "ANATOMY", 335, 342], ["mitochondria", "ANATOMY", 393, 405], ["oxygen", "CHEMICAL", 369, 375], ["ROS", "CHEMICAL", 385, 388], ["oxygen", "CHEMICAL", 369, 375], ["Cell", "CELL", 59, 63], ["ROS", "SIMPLE_CHEMICAL", 279, 282], ["bilayer membranes", "CELLULAR_COMPONENT", 310, 327], ["neurons", "CELL", 335, 342], ["reactive oxygen species", "SIMPLE_CHEMICAL", 360, 383], ["ROS", "SIMPLE_CHEMICAL", 385, 388], ["mitochondria", "CELLULAR_COMPONENT", 393, 405], ["UCP) 1", "GENE_OR_GENE_PRODUCT", 530, 536], ["uncoupling proteins", "PROTEIN", 287, 306], ["uncoupling proteins (UCP) 1", "PROTEIN", 509, 536], ["uncoupling proteins in bilayer membranes", "PROBLEM", 287, 327], ["reactive oxygen species", "PROBLEM", 360, 383], ["the proton motive force", "TREATMENT", 427, 450], ["mild uncoupling", "PROBLEM", 475, 490], ["bilayer membranes", "ANATOMY", 310, 327], ["neurons", "ANATOMY", 335, 342], ["reactive", "OBSERVATION_MODIFIER", 360, 368], ["oxygen species", "OBSERVATION", 369, 383]]], ["In contrast, the activation of uncoupling proteins by ROS as a negative feedback loop is a highly controversial hypothesis.", [["ROS", "CHEMICAL", 54, 57], ["ROS", "SIMPLE_CHEMICAL", 54, 57], ["uncoupling proteins", "PROTEIN", 31, 50], ["uncoupling proteins", "PROBLEM", 31, 50], ["a highly controversial hypothesis", "PROBLEM", 89, 122], ["highly", "OBSERVATION_MODIFIER", 91, 97], ["controversial", "OBSERVATION_MODIFIER", 98, 111], ["hypothesis", "OBSERVATION", 112, 122]]], ["UCP activation in mitochondria by 4-hydroxy-2-nonenal (HNE, aldehydic product of lipid peroxidation) was first demonstrated by Echtay et al. 2 .", [["mitochondria", "ANATOMY", 18, 30], ["4-hydroxy-2-nonenal", "CHEMICAL", 34, 53], ["HNE", "CHEMICAL", 55, 58], ["4-hydroxy-2-nonenal", "CHEMICAL", 34, 53], ["HNE", "CHEMICAL", 55, 58], ["aldehydic", "CHEMICAL", 60, 69], ["UCP", "GENE_OR_GENE_PRODUCT", 0, 3], ["mitochondria", "CELLULAR_COMPONENT", 18, 30], ["4-hydroxy-2-nonenal", "SIMPLE_CHEMICAL", 34, 53], ["HNE", "SIMPLE_CHEMICAL", 55, 58], ["aldehydic", "SIMPLE_CHEMICAL", 60, 69], ["lipid", "SIMPLE_CHEMICAL", 81, 86], ["UCP", "PROTEIN", 0, 3], ["UCP activation", "TEST", 0, 14], ["mitochondria", "TEST", 18, 30], ["hydroxy", "TEST", 36, 43], ["aldehydic product of lipid peroxidation", "TREATMENT", 60, 99]]], ["Here we investigate the ability of HNE to activate and/or to regulate the expression of UCP in two different systems: (i) in lipid membranes reconstituted with recombinant UCP and (ii) in primary neuronal cells.", [["lipid membranes", "ANATOMY", 125, 140], ["primary neuronal cells", "ANATOMY", 188, 210], ["HNE", "CHEMICAL", 35, 38], ["HNE", "SIMPLE_CHEMICAL", 35, 38], ["UCP", "GENE_OR_GENE_PRODUCT", 88, 91], ["lipid membranes", "CELLULAR_COMPONENT", 125, 140], ["UCP", "GENE_OR_GENE_PRODUCT", 172, 175], ["neuronal cells", "CELL", 196, 210], ["UCP", "PROTEIN", 88, 91], ["recombinant UCP", "PROTEIN", 160, 175], ["primary neuronal cells", "CELL_TYPE", 188, 210], ["lipid membranes", "TREATMENT", 125, 140], ["recombinant UCP", "PROBLEM", 160, 175], ["neuronal cells", "OBSERVATION", 196, 210]]], ["Total bilayer conductance was enhanced in the presence of HNE, but this effect was independent on UCP1 and UCP2.", [["bilayer", "ANATOMY", 6, 13], ["HNE", "CHEMICAL", 58, 61], ["HNE", "CHEMICAL", 58, 61], ["HNE", "SIMPLE_CHEMICAL", 58, 61], ["UCP1", "GENE_OR_GENE_PRODUCT", 98, 102], ["UCP2", "GENE_OR_GENE_PRODUCT", 107, 111], ["UCP1", "PROTEIN", 98, 102], ["UCP2", "PROTEIN", 107, 111], ["Total bilayer conductance", "TEST", 0, 25], ["UCP2", "TEST", 107, 111], ["bilayer", "OBSERVATION_MODIFIER", 6, 13], ["conductance", "OBSERVATION", 14, 25]]], ["The results concerning the HNE-mediated UCP expression after induction of ROS-production and/or after exogenous addition of HNE are discussed for three brain-associated proteins (UCP2, UCP4, UCP5) in view of their possible functions.", [["brain", "ANATOMY", 152, 157], ["HNE", "CHEMICAL", 27, 30], ["ROS", "CHEMICAL", 74, 77], ["HNE", "CHEMICAL", 124, 127], ["HNE", "CHEMICAL", 124, 127], ["HNE", "SIMPLE_CHEMICAL", 27, 30], ["UCP", "GENE_OR_GENE_PRODUCT", 40, 43], ["ROS", "SIMPLE_CHEMICAL", 74, 77], ["HNE", "SIMPLE_CHEMICAL", 124, 127], ["brain", "ORGAN", 152, 157], ["UCP2", "GENE_OR_GENE_PRODUCT", 179, 183], ["UCP4", "GENE_OR_GENE_PRODUCT", 185, 189], ["UCP5", "GENE_OR_GENE_PRODUCT", 191, 195], ["UCP", "PROTEIN", 40, 43], ["brain-associated proteins", "PROTEIN", 152, 177], ["UCP2", "PROTEIN", 179, 183], ["UCP4", "PROTEIN", 185, 189], ["UCP5", "PROTEIN", 191, 195], ["the HNE", "TEST", 23, 30], ["HNE", "TREATMENT", 124, 127], ["UCP2", "TEST", 179, 183], ["UCP4", "TEST", 185, 189]]], ["Echtay, K. S. et al. 2003 .Interaction of lipidated N-RasGDP and N-RasGTP with a POPC bilayer investigated in silicoT.", [["N-RasGTP", "CHEMICAL", 65, 73], ["N-RasGDP", "CHEMICAL", 52, 60], ["N-RasGTP", "CHEMICAL", 65, 73], ["POPC", "CHEMICAL", 81, 85], ["N-RasGDP", "SIMPLE_CHEMICAL", 52, 60], ["N-RasGTP", "SIMPLE_CHEMICAL", 65, 73], ["POPC", "SIMPLE_CHEMICAL", 81, 85], ["RasGDP", "PROTEIN", 54, 60], ["N", "PROTEIN", 65, 66], ["RasGTP", "PROTEIN", 67, 73], ["silicoT", "PROTEIN", 110, 117], ["lipidated N", "TEST", 42, 53], ["RasGDP", "TEST", 54, 60], ["a POPC bilayer", "TREATMENT", 79, 93]]], ["Rudack, J. Schlitter, K. Gerwert Ruhr University, Department of Biophysics, ND 04 North, 44780 Bochum, GermanyInteraction of lipidated N-RasGDP and N-RasGTP with a POPC bilayer investigated in silicoThe GTPase Ras p21 which is linked to the membrane via a lipid anchor, is a crucial switch in the cellular signal transduction processes that control cell growth and proliferation.", [["membrane", "ANATOMY", 241, 249], ["cellular", "ANATOMY", 297, 305], ["cell", "ANATOMY", 349, 353], ["N-RasGTP", "CHEMICAL", 148, 156], ["N-RasGTP", "CHEMICAL", 148, 156], ["POPC", "CHEMICAL", 164, 168], ["N-RasGDP", "SIMPLE_CHEMICAL", 135, 143], ["N-RasGTP", "SIMPLE_CHEMICAL", 148, 156], ["GTPase Ras p21", "GENE_OR_GENE_PRODUCT", 203, 217], ["membrane", "CELLULAR_COMPONENT", 241, 249], ["cellular", "CELL", 297, 305], ["cell", "CELL", 349, 353], ["GTPase Ras", "PROTEIN", 203, 213], ["p21", "PROTEIN", 214, 217], ["Bochum", "TEST", 95, 101], ["a POPC bilayer", "TREATMENT", 162, 176], ["The GTPase Ras p21", "TEST", 199, 217], ["a lipid anchor", "TREATMENT", 254, 268], ["a crucial switch", "TREATMENT", 273, 289], ["proliferation", "PROBLEM", 365, 378], ["silico", "ANATOMY", 193, 199], ["crucial switch", "OBSERVATION", 275, 289], ["cellular signal transduction processes", "OBSERVATION", 297, 335], ["cell", "OBSERVATION", 349, 353], ["growth", "OBSERVATION_MODIFIER", 354, 360], ["proliferation", "OBSERVATION_MODIFIER", 365, 378]]], ["Docking simulations can be seriously hampered by the great difficulty to accurately estimate the ligand-protein binding affinity constant K, which is usually derived via the computation of the binding free energy \u2206G. Unfortunately, due to the involved logarithmic relationship, errors of less than 1.5 kcal/mol in the computation of \u2206G result in about one order of magnitude inaccuracy on K. This can hinder computational methods from discriminating micromolar from nanomolar compounds.", [["\u2206G", "GENE_OR_GENE_PRODUCT", 333, 335], ["K", "TEST", 389, 390], ["micromolar from nanomolar compounds", "PROBLEM", 450, 485], ["nanomolar compounds", "OBSERVATION", 466, 485]]], ["To improve the reliability of docking prediction, we make use of enhanced sampling methods, ranging from steered molecular dynamics 1 to metadynamics 2 .", [["enhanced sampling methods", "TREATMENT", 65, 90]]], ["We also test several descriptors, such as the recently developed path collective variables 3 , to identify the most suitable reaction coordinates accounting for binding and unbinding processes.", [["binding and unbinding processes", "PROBLEM", 161, 192]]], ["Here, an example of application in drug design is reported.", [["application in drug design", "TREATMENT", 20, 46]]], ["Laio, A. and Parrinello, M.; PNAS 2002, 99 , 12562-6.", [["Laio", "TREATMENT", 0, 4]]], ["Prediction of protein-protein complex structures using Wang-Landau simulations A. Solernou, Barcelona Supercomputing Center, Jordi Girona 29, Barcelona, Spain Protein-protein interactions are essential in the majority of life processes, so they have keen interest in several knowledge areas.", [["protein-protein complex", "PROTEIN", 14, 37], ["Spain Protein", "TEST", 153, 166]]], ["However, experimental data on protein complexes is being produced at a quite low pace in comparison to that of the individual components.", [["protein complexes", "PROTEIN", 30, 47], ["experimental data on protein complexes", "PROBLEM", 9, 47]]], ["A variety of docking protocols have been recently reported, sharing usually the following strategy: fast rigid-body search of the interacting subunits, followed by scoring and refinement of the interfaces.", [["interacting subunits", "PROTEIN", 130, 150], ["docking protocols", "TREATMENT", 13, 30]]], ["Although this kind of strategy has proven some good results in the CAPRI blind test it has two main limitations.", [["the CAPRI blind test", "TEST", 63, 83], ["good", "OBSERVATION_MODIFIER", 47, 51], ["main", "OBSERVATION_MODIFIER", 95, 99]]], ["On the other, the evaluation should be made with free energy calculations instead of using a scoring function.", [["the evaluation", "TEST", 14, 28], ["free energy calculations", "TREATMENT", 49, 73], ["a scoring function", "TEST", 91, 109]]], ["In this work we propose to search the native complex structure in the minimum of the free energy landscape.", [["native complex structure", "PROTEIN", 38, 62], ["free", "OBSERVATION", 85, 89], ["energy landscape", "OBSERVATION", 90, 106]]], ["They are generated changing the dihedral angles, the side chain rotamers, and lastly the mutual orientation using a new sampling protocol we have developed (Rotation-Based Uniform Sampling; RotBUS).", [["a new sampling protocol", "TREATMENT", 114, 137]]], ["Finally, the free energy calculations are performed using an OMP parallelization of the Wang-Landau algorithm.Mystery unveiled: benzimidazole docks different domains in FlaviviridaeS.", [["benzimidazole", "CHEMICAL", 128, 141], ["benzimidazole", "CHEMICAL", 128, 141], ["benzimidazole", "SIMPLE_CHEMICAL", 128, 141], ["FlaviviridaeS", "SIMPLE_CHEMICAL", 169, 182], ["the free energy calculations", "TEST", 9, 37], ["an OMP parallelization", "TREATMENT", 58, 80], ["benzimidazole docks", "TREATMENT", 128, 147], ["FlaviviridaeS", "TREATMENT", 169, 182]]], ["Shukla 1 , S. Asthana 1 , G. Giliberti 1 , F. Luliano 1 , M. Ceccarelli 2 , R. Loddu 1 , P. Ruggerone 2 , P. La Colla 1 1 Department of Biomedical Science and Technology, Universit\u00e0 di Cagliari, Cagliari, Italy, 2 Department of Physics, Universit\u00e0 di Cagliari, Cagliari, ItalyMystery unveiled: benzimidazole docks different domains in FlaviviridaeThe virus encoded RdRp has emerged as a prime target in the search for specific HCV and other Flaviviridae antivirals. recently, the determination of the HCV RdRp structure in complex with certain benzimidazoles has been reported, these NNI's bind to the surface of the thumb domain, thereby disrupting its interaction with the finger domain, which is necessary for catalytic activity.", [["surface", "ANATOMY", 602, 609], ["benzimidazole", "CHEMICAL", 294, 307], ["Flaviviridae", "DISEASE", 335, 347], ["benzimidazoles", "CHEMICAL", 544, 558], ["benzimidazole", "CHEMICAL", 294, 307], ["benzimidazoles", "CHEMICAL", 544, 558], ["benzimidazole", "SIMPLE_CHEMICAL", 294, 307], ["Flaviviridae", "ORGANISM", 335, 347], ["RdRp", "GENE_OR_GENE_PRODUCT", 365, 369], ["HCV", "ORGANISM", 427, 430], ["HCV RdRp", "ORGANISM", 501, 509], ["NNI", "SIMPLE_CHEMICAL", 584, 587], ["surface", "CELLULAR_COMPONENT", 602, 609], ["RdRp", "PROTEIN", 365, 369], ["HCV RdRp structure", "PROTEIN", 501, 519], ["NNI", "PROTEIN", 584, 587], ["thumb domain", "PROTEIN", 617, 629], ["finger domain", "PROTEIN", 675, 688], ["HCV", "SPECIES", 427, 430], ["HCV", "SPECIES", 501, 504], ["benzimidazole docks different domains", "TREATMENT", 294, 331], ["Flaviviridae", "TREATMENT", 335, 347], ["The virus encoded RdRp", "PROBLEM", 347, 369], ["specific HCV", "TREATMENT", 418, 430], ["other Flaviviridae antivirals", "TREATMENT", 435, 464], ["the HCV RdRp structure", "PROBLEM", 497, 519], ["certain benzimidazoles", "TREATMENT", 536, 558], ["virus", "OBSERVATION", 351, 356], ["RdRp", "OBSERVATION_MODIFIER", 365, 369], ["HCV RdRp", "OBSERVATION", 501, 509], ["thumb", "ANATOMY", 617, 622]]], ["On the other hand, we have found that, in BVDV, the mutations conferring resistance to same class of inhibitors lie in the finger domain of RdRp, indicating that the mode of inhibition of Benzimidazole class of compounds is different in both HCV and BVDV RdRp.", [["Benzimidazole", "CHEMICAL", 188, 201], ["Benzimidazole", "CHEMICAL", 188, 201], ["BVDV", "ORGANISM", 42, 46], ["RdRp", "GENE_OR_GENE_PRODUCT", 140, 144], ["Benzimidazole", "SIMPLE_CHEMICAL", 188, 201], ["HCV", "ORGANISM", 242, 245], ["BVDV RdRp", "ORGANISM", 250, 259], ["finger domain", "PROTEIN", 123, 136], ["RdRp", "PROTEIN", 140, 144], ["BVDV RdRp", "PROTEIN", 250, 259], ["BVDV", "SPECIES", 250, 254], ["BVDV", "SPECIES", 42, 46], ["HCV", "SPECIES", 242, 245], ["BVDV RdRp", "SPECIES", 250, 259], ["BVDV", "PROBLEM", 42, 46], ["the mutations", "PROBLEM", 48, 61], ["inhibitors", "TREATMENT", 101, 111], ["RdRp", "PROBLEM", 140, 144], ["Benzimidazole class of compounds", "TREATMENT", 188, 220], ["BVDV RdRp", "PROBLEM", 250, 259], ["finger", "ANATOMY", 123, 129], ["both", "OBSERVATION_MODIFIER", 237, 241], ["HCV", "OBSERVATION", 242, 245], ["BVDV RdRp", "OBSERVATION", 250, 259]]], ["Herein, we have applied docking approaches (binding orientation), Molecular Dynamics (MD) simulations combined with metadynamics to elucidate the microscopic mechanism of the interactions between the ligand and the receptor in order to identify features barely seen in experiment.", [["metadynamics", "TREATMENT", 116, 128]]], ["It mimics the real dynamics of a ligand staying or leaving the receptor and in doing so reconstructs the free energy surface, which in turn gives an idea of the residence time of the inhibitor in the cavity.Finally we identified the binding modes and different mechanism of inhibition of Benzimidazole class of compounds in RdRp of two closely related RNA viruses. .Force distribution analysis (FDA) of the signal transduction of E.Coli chaperone Hsp90 (HtpG)C. Seifert 1 , W. Stacklies 2 , F. Graeter 2 1 Protein Mechanics and Evolution, Bioquant, INF 267 BQ0031, 69120 Heidelberg, Germany, 2 AG Graeter, PICB, 320 Yueyang Lu, Shanghai 200031, China We use a new method that detects force distribution in proteins.", [["Benzimidazole", "CHEMICAL", 288, 301], ["Benzimidazole", "CHEMICAL", 288, 301], ["Benzimidazole", "SIMPLE_CHEMICAL", 288, 301], ["RdRp", "ORGANISM", 324, 328], ["RdRp", "PROTEIN", 324, 328], ["E.Coli chaperone Hsp90", "PROTEIN", 430, 452], ["the binding modes", "TREATMENT", 229, 246], ["Benzimidazole class of compounds", "TREATMENT", 288, 320], ["RdRp", "TREATMENT", 324, 328], ["RNA viruses", "PROBLEM", 352, 363], ["Force distribution analysis", "TEST", 366, 393], ["the signal transduction", "TEST", 403, 426], ["E.Coli chaperone Hsp90", "TEST", 430, 452], ["HtpG", "TEST", 454, 458], ["Seifert", "TEST", 462, 469], ["Stacklies", "TEST", 477, 486], ["a new method", "TREATMENT", 658, 670], ["force distribution in proteins", "PROBLEM", 684, 714], ["cavity", "ANATOMY", 200, 206], ["RNA viruses", "OBSERVATION", 352, 363]]], ["Based on molecular dynamic simulations, changes in inter-atomic forces are calculated, here caused by different ligands.", [["molecular dynamic simulations", "TEST", 9, 38], ["changes in inter-atomic forces", "PROBLEM", 40, 70], ["dynamic simulations", "OBSERVATION", 19, 38], ["inter-atomic forces", "OBSERVATION", 51, 70]]], ["These changes will then be analyzed to detect a signal transfer through a protein initiated by the binding of a ligand to the protein.Force distribution analysis (FDA) of the signal transduction of E.Coli chaperone Hsp90 (HtpG)Chaperones are ubiquitous proteins, which help other proteins to fold into a native conformation.", [["E.Coli chaperone Hsp90", "GENE_OR_GENE_PRODUCT", 198, 220], ["HtpG", "GENE_OR_GENE_PRODUCT", 222, 226], ["E.Coli chaperone Hsp90 (HtpG)Chaperones", "PROTEIN", 198, 237], ["ubiquitous proteins", "PROTEIN", 242, 261], ["a protein", "TREATMENT", 72, 81], ["Force distribution analysis", "TEST", 134, 161], ["the signal transduction", "TEST", 171, 194], ["E.Coli chaperone Hsp90", "TREATMENT", 198, 220], ["ubiquitous proteins", "PROBLEM", 242, 261]]], ["They are able to refold misfolded proteins with a great variety of mechanisms.", [["misfolded proteins", "PROTEIN", 24, 42], ["misfolded proteins", "PROBLEM", 24, 42]]], ["In this project, our group focuses on molecular dynamic simulations of HtpG, an E. Coli homolog of the human Hsp90 (heat shock protein 90kDa).", [["HtpG", "GENE_OR_GENE_PRODUCT", 71, 75], ["E. Coli homolog", "GENE_OR_GENE_PRODUCT", 80, 95], ["human", "ORGANISM", 103, 108], ["Hsp90", "GENE_OR_GENE_PRODUCT", 109, 114], ["heat shock protein 90kDa", "GENE_OR_GENE_PRODUCT", 116, 140], ["HtpG", "PROTEIN", 71, 75], ["E. Coli homolog", "PROTEIN", 80, 95], ["human Hsp90", "PROTEIN", 103, 114], ["heat shock protein 90kDa", "PROTEIN", 116, 140], ["E. Coli", "SPECIES", 80, 87], ["human", "SPECIES", 103, 108], ["E. Coli", "SPECIES", 80, 87], ["human", "SPECIES", 103, 108], ["HtpG", "TREATMENT", 71, 75], ["the human Hsp90", "TEST", 99, 114], ["heat shock protein", "TEST", 116, 134]]], ["The full structure of HtpG was published by Shiau et al. in 2006, but the mechanism of how HtpG performs its function is still not understood.", [["HtpG", "GENE_OR_GENE_PRODUCT", 22, 26], ["HtpG", "GENE_OR_GENE_PRODUCT", 91, 95], ["HtpG", "PROTEIN", 22, 26], ["HtpG", "PROTEIN", 91, 95]]], ["The folding mechanism is an ATP driven reaction cycle, in which the functional entity is a homodimer of HtpG.", [["ATP", "CHEMICAL", 28, 31], ["ATP", "CHEMICAL", 28, 31], ["ATP", "SIMPLE_CHEMICAL", 28, 31], ["HtpG", "GENE_OR_GENE_PRODUCT", 104, 108], ["HtpG", "PROTEIN", 104, 108], ["The folding mechanism", "PROBLEM", 0, 21], ["a homodimer of HtpG", "TREATMENT", 89, 108], ["ATP driven", "OBSERVATION", 28, 38]]], ["We separate the cycle in three main states: apo, ADP-and ATPbound state.", [["ADP", "CHEMICAL", 49, 52], ["ADP", "CHEMICAL", 49, 52], ["apo", "SIMPLE_CHEMICAL", 44, 47], ["ADP", "SIMPLE_CHEMICAL", 49, 52], ["ATPbound", "SIMPLE_CHEMICAL", 57, 65], ["ADP", "TEST", 49, 52]]], ["Conventional molecular dynamics simulations are used to build a stable simulation system and provide structure trajectories and primary information about the behavior of HtpG in its different states of the folding process.", [["HtpG", "GENE_OR_GENE_PRODUCT", 170, 174], ["HtpG", "PROTEIN", 170, 174], ["HtpG", "PROBLEM", 170, 174], ["stable", "OBSERVATION_MODIFIER", 64, 70]]], ["Experiments indicate that the molecular movement is ATP driven.", [["ATP", "CHEMICAL", 52, 55], ["ATP", "CHEMICAL", 52, 55], ["ATP", "SIMPLE_CHEMICAL", 52, 55]]], ["We use force distribution analysis to elucidate how ATP effects HtpG conformation and dynamics.", [["ATP", "CHEMICAL", 52, 55], ["ATP", "CHEMICAL", 52, 55], ["ATP", "SIMPLE_CHEMICAL", 52, 55], ["force distribution analysis", "TEST", 7, 34]]], ["The small size of Myoglobin makes it the preferred candidate to investigate the structure-function paradigm.", [["Myoglobin", "CHEMICAL", 18, 27], ["Myoglobin", "CHEMICAL", 18, 27], ["Myoglobin", "GENE_OR_GENE_PRODUCT", 18, 27], ["Myoglobin", "PROTEIN", 18, 27], ["The small size of Myoglobin", "PROBLEM", 0, 27], ["small", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 10, 14], ["Myoglobin", "OBSERVATION", 18, 27]]], ["In its interior five docking sites have been identified and for long time these Xenon cavities have been classified as packing defects.", [["these Xenon cavities", "TREATMENT", 74, 94], ["packing defects", "PROBLEM", 119, 134], ["interior", "OBSERVATION_MODIFIER", 7, 15], ["five", "OBSERVATION_MODIFIER", 16, 20], ["docking sites", "OBSERVATION", 21, 34], ["packing defects", "OBSERVATION", 119, 134]]], ["However, some questions regarding its role as oxygen carrier NO scavenger remain yet open as well as the microscopic mechanism regulating these biological functions.", [["oxygen", "CHEMICAL", 46, 52], ["NO", "CHEMICAL", 61, 63], ["oxygen", "CHEMICAL", 46, 52], ["NO", "CHEMICAL", 61, 63], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["NO", "SIMPLE_CHEMICAL", 61, 63], ["oxygen carrier", "TREATMENT", 46, 60], ["scavenger", "TREATMENT", 64, 73], ["the microscopic mechanism", "TEST", 101, 126]]], ["In this work we made use of standard MD simulations of solvated myoglobin to characterize internal cavities.", [["myoglobin", "GENE_OR_GENE_PRODUCT", 64, 73], ["solvated myoglobin", "PROBLEM", 55, 73], ["internal cavities", "ANATOMY", 90, 107]]], ["Our principal results is that we have found several secondary cavities showing volume and occurrence at least comparable to that of Xenon cavities.", [["several secondary cavities", "PROBLEM", 44, 70], ["secondary", "OBSERVATION_MODIFIER", 52, 61], ["cavities", "OBSERVATION", 62, 70], ["volume", "OBSERVATION", 79, 85], ["Xenon cavities", "OBSERVATION", 132, 146]]], ["In order to analyze and rationalize internal cavities we applied special cluster-analysis: we classified all cavities with respect to the position, size and occurrence ascribing them to different clusters.", [["size", "OBSERVATION_MODIFIER", 148, 152]]], ["This analysis highlights possible intrinsic migration paths for small ligands within the protein matrix controlled by spontaneous fluctuations of the protein itself.", [["matrix", "CELLULAR_COMPONENT", 97, 103], ["This analysis", "TEST", 0, 13], ["intrinsic migration paths", "PROBLEM", 34, 59], ["small ligands", "PROBLEM", 64, 77], ["the protein matrix", "TREATMENT", 85, 103], ["spontaneous fluctuations of the protein itself", "PROBLEM", 118, 164], ["possible", "UNCERTAINTY", 25, 33], ["intrinsic migration", "OBSERVATION", 34, 53], ["small ligands", "OBSERVATION", 64, 77], ["protein matrix", "OBSERVATION", 89, 103], ["spontaneous fluctuations", "OBSERVATION", 118, 142]]], ["Moreover, we identified some key residues playing a fundamental role in controlling internal pathways.", [["some key residues", "PROBLEM", 24, 41], ["key residues", "OBSERVATION", 29, 41]]], ["Our suggestion that the secondary cavities constitute the preferred path for ligand escape is also supported by explicit metadynamics simulations of ligand escape.Direct kinetic evidence that Lys 215 is involved in the phospho-transfer step of human 3phosphoglycerate kinaseA.", [["Lys 215", "CHEMICAL", 192, 199], ["3phosphoglycerate", "CHEMICAL", 250, 267], ["Lys", "CHEMICAL", 192, 195], ["phospho", "CHEMICAL", 219, 226], ["3phosphoglycerate", "CHEMICAL", 250, 267], ["Lys 215", "AMINO_ACID", 192, 199], ["human", "ORGANISM", 244, 249], ["3phosphoglycerate kinaseA", "GENE_OR_GENE_PRODUCT", 250, 275], ["phospho", "PROTEIN", 219, 226], ["human 3phosphoglycerate kinaseA", "PROTEIN", 244, 275], ["human", "SPECIES", 244, 249], ["human", "SPECIES", 244, 249], ["the secondary cavities", "PROBLEM", 20, 42], ["ligand escape", "PROBLEM", 77, 90], ["the phospho", "TEST", 215, 226], ["human 3phosphoglycerate kinaseA", "TREATMENT", 244, 275], ["secondary cavities", "OBSERVATION", 24, 42], ["ligand escape", "OBSERVATION", 149, 162]]], ["Varga 1 , P. Lallemand 2 , J. Szab\u00f3 1 , P. Z\u00e1vodszky 1 , M. Vas 1 , T. Barman 2 , L. Chaloin 2 , C. Lionne 2 1 Institute of Enzymology, BRC, Hungarian Academy of Sciences, Budapest, Hungary, 2 CNRS-Universit\u00e9 Montpellier 1 -Universit\u00e9 Montpellier 2, Institut de Biologie, UMR5236, Montpellier, France 3-Phosphoglycerate kinase (PGK) is a promising candidate for the activation of nucleotide analogues used in antiviral and anticancer therapies.", [["anticancer", "ANATOMY", 423, 433], ["nucleotide", "CHEMICAL", 380, 390], ["nucleotide", "CHEMICAL", 380, 390], ["Phosphoglycerate kinase", "GENE_OR_GENE_PRODUCT", 303, 326], ["PGK", "GENE_OR_GENE_PRODUCT", 328, 331], ["nucleotide analogues", "SIMPLE_CHEMICAL", 380, 400], ["anticancer", "CANCER", 423, 433], ["Phosphoglycerate kinase", "PROTEIN", 303, 326], ["PGK", "PROTEIN", 328, 331], ["Phosphoglycerate kinase (PGK", "TREATMENT", 303, 331], ["nucleotide analogues", "TREATMENT", 380, 400], ["antiviral and anticancer therapies", "TREATMENT", 409, 443]]], ["PGK is a key enzyme in glycolysis; it catalyses the reversible reaction 1,3-bisphosphoglycerate + ADP \u2194 3-phosphoglycerate + ATP.", [["1,3-bisphosphoglycerate", "CHEMICAL", 72, 95], ["ADP", "CHEMICAL", 98, 101], ["3-phosphoglycerate", "CHEMICAL", 104, 122], ["ATP", "CHEMICAL", 125, 128], ["1,3-bisphosphoglycerate", "CHEMICAL", 72, 95], ["ADP", "CHEMICAL", 98, 101], ["3-phosphoglycerate", "CHEMICAL", 104, 122], ["ATP", "CHEMICAL", 125, 128], ["PGK", "GENE_OR_GENE_PRODUCT", 0, 3], ["1,3-bisphosphoglycerate", "SIMPLE_CHEMICAL", 72, 95], ["ADP \u2194 3-phosphoglycerate + ATP", "SIMPLE_CHEMICAL", 98, 128], ["PGK", "PROTEIN", 0, 3], ["a key enzyme in glycolysis", "PROBLEM", 7, 33], ["the reversible reaction", "PROBLEM", 48, 71], ["bisphosphoglycerate", "TEST", 76, 95], ["ADP", "TEST", 98, 101], ["phosphoglycerate + ATP", "TREATMENT", 106, 128], ["reversible", "OBSERVATION_MODIFIER", 52, 62]]], ["Here we explored the catalytic role in human PGK of the highly conserved Lys 215 that has been proposed to be essential for PGK function, by a transient and equilibrium kinetic study with the active site mutant K215A.", [["Lys 215", "CHEMICAL", 73, 80], ["Lys", "CHEMICAL", 73, 76], ["human", "ORGANISM", 39, 44], ["PGK", "GENE_OR_GENE_PRODUCT", 45, 48], ["Lys 215", "AMINO_ACID", 73, 80], ["PGK", "GENE_OR_GENE_PRODUCT", 124, 127], ["human PGK", "PROTEIN", 39, 48], ["Lys 215", "PROTEIN", 73, 80], ["PGK", "PROTEIN", 124, 127], ["active site mutant K215A", "PROTEIN", 192, 216], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["human PGK", "TEST", 39, 48], ["PGK function", "PROBLEM", 124, 136], ["a transient and equilibrium kinetic study", "TEST", 141, 182]]], ["By the stopped-flow method we show that the kinetics of substrate binding and the associated protein isomerization steps are fast and identical for the wild-type PGK and mutant K215A.", [["PGK", "GENE_OR_GENE_PRODUCT", 162, 165], ["wild-type PGK", "PROTEIN", 152, 165], ["mutant K215A", "PROTEIN", 170, 182], ["the kinetics of substrate binding", "PROBLEM", 40, 73], ["the associated protein isomerization steps", "PROBLEM", 78, 120], ["protein isomerization", "OBSERVATION", 93, 114]]], ["By the use of a chemical sampling method (rapid-quench-flow) under multi and single turnover conditions and in both directions of the reaction, we show that the rate-limiting step with wild type PGK follows product formation, whereas with the mutant it is the phospho-transfer step itself that is rate limiting.", [["phospho", "CHEMICAL", 260, 267], ["PGK", "GENE_OR_GENE_PRODUCT", 195, 198], ["wild type PGK", "PROTEIN", 185, 198], ["phospho", "PROTEIN", 260, 267], ["a chemical sampling method", "TREATMENT", 14, 40], ["the rate", "TEST", 157, 165], ["wild type PGK", "PROBLEM", 185, 198]]], ["These data are supported by SAXS measurements which showed no direct role of Lys 215 in the domain closure of the enzyme i.e. the isomerisation step of the reaction.", [["Lys 215", "CHEMICAL", 77, 84], ["Lys", "CHEMICAL", 77, 80], ["Lys 215", "AMINO_ACID", 77, 84], ["Lys 215", "PROTEIN", 77, 84], ["enzyme", "PROTEIN", 114, 120], ["SAXS measurements", "TEST", 28, 45], ["direct role of Lys", "PROBLEM", 62, 80], ["the enzyme", "TEST", 110, 120], ["the reaction", "PROBLEM", 152, 164]]], ["The results are explained by the structural data of the enzyme.P-516Characterization of different recombinant NRP1 proteins and interactions with heparin K. A. Uniewicz, Y. Ahmed, D. G. Fernig School of Biological Sciences and Centre for Glycobiology, Biosciences Building University of Liverpool, L69 7ZB Liverpool, U.K.P-516Neuropilin-1 (NRP1) is a mammalian membrane glycoprotein involved in tip sprouting processes like angiogenesis and neurogenesis.", [["membrane", "ANATOMY", 361, 369], ["tip", "ANATOMY", 395, 398], ["heparin", "CHEMICAL", 146, 153], ["U.K.P-516Neuropilin-1", "CHEMICAL", 317, 338], ["NRP1", "GENE_OR_GENE_PRODUCT", 110, 114], ["heparin K.", "SIMPLE_CHEMICAL", 146, 156], ["U.K.P-516Neuropilin-1", "GENE_OR_GENE_PRODUCT", 317, 338], ["NRP1", "GENE_OR_GENE_PRODUCT", 340, 344], ["enzyme", "PROTEIN", 56, 62], ["recombinant NRP1 proteins", "PROTEIN", 98, 123], ["NRP1", "PROTEIN", 340, 344], ["mammalian membrane glycoprotein", "PROTEIN", 351, 382], ["K.", "SPECIES", 154, 156], ["the enzyme", "TEST", 52, 62], ["different recombinant NRP1 proteins", "TREATMENT", 88, 123], ["heparin K.", "TREATMENT", 146, 156], ["U.K.P", "TEST", 317, 322], ["a mammalian membrane glycoprotein", "TREATMENT", 349, 382], ["angiogenesis", "PROBLEM", 424, 436], ["neurogenesis", "PROBLEM", 441, 453], ["angiogenesis", "OBSERVATION", 424, 436]]], ["It has been shown that the interaction of NRP1with heparin/heparan sulfate is implicated in its enhancement of growth factor signalling, however the mechanism is not yet known.", [["heparin", "CHEMICAL", 51, 58], ["heparan sulfate", "CHEMICAL", 59, 74], ["NRP1with heparin", "SIMPLE_CHEMICAL", 42, 58], ["heparan sulfate", "SIMPLE_CHEMICAL", 59, 74], ["growth factor", "PROTEIN", 111, 124], ["NRP1with heparin/heparan sulfate", "TREATMENT", 42, 74]]], ["Commercially available extracellular domain of NRP1 is available either as a truncated HIS-tagged human protein (hNRP1) or as the rat protein fused to HIStagged human Fc and expressed as a dimer (FcrNRP1).", [["extracellular", "ANATOMY", 23, 36], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 36], ["NRP1", "GENE_OR_GENE_PRODUCT", 47, 51], ["human", "ORGANISM", 98, 103], ["hNRP1", "GENE_OR_GENE_PRODUCT", 113, 118], ["rat", "ORGANISM", 130, 133], ["human", "ORGANISM", 161, 166], ["Fc", "GENE_OR_GENE_PRODUCT", 167, 169], ["FcrNRP1", "GENE_OR_GENE_PRODUCT", 196, 203], ["extracellular domain", "PROTEIN", 23, 43], ["NRP1", "PROTEIN", 47, 51], ["truncated HIS-tagged human protein", "PROTEIN", 77, 111], ["hNRP1", "PROTEIN", 113, 118], ["rat protein", "PROTEIN", 130, 141], ["HIStagged human Fc", "PROTEIN", 151, 169], ["dimer", "PROTEIN", 189, 194], ["FcrNRP1", "PROTEIN", 196, 203], ["human", "SPECIES", 98, 103], ["rat", "SPECIES", 130, 133], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 161, 166], ["tagged human protein (hNRP1)", "TREATMENT", 91, 119]]], ["Biochemical properties such as kinetics of heparin binding and structural requirements for sugar binding together with biochemical tests of protein properties were performed in order to characterise these commercial proteins.", [["heparin", "CHEMICAL", 43, 50], ["sugar", "CHEMICAL", 91, 96], ["heparin", "SIMPLE_CHEMICAL", 43, 50], ["sugar", "SIMPLE_CHEMICAL", 91, 96], ["commercial proteins", "PROTEIN", 205, 224], ["Biochemical properties", "TREATMENT", 0, 22], ["heparin binding", "TREATMENT", 43, 58], ["sugar binding", "PROBLEM", 91, 104], ["biochemical tests of protein properties", "TEST", 119, 158]]], ["Fc rNRP1 shown high affinity to heparin (Kd=2.5 nM) and required a minimum of dp10 to effectively compete with Fc rNRP1 binding to immobilised heparin.", [["heparin", "CHEMICAL", 32, 39], ["heparin", "CHEMICAL", 143, 150], ["Fc rNRP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["heparin", "SIMPLE_CHEMICAL", 32, 39], ["dp10", "GENE_OR_GENE_PRODUCT", 78, 82], ["Fc rNRP1", "GENE_OR_GENE_PRODUCT", 111, 119], ["heparin", "SIMPLE_CHEMICAL", 143, 150], ["Fc rNRP1", "PROTEIN", 0, 8], ["dp10", "PROTEIN", 78, 82], ["Fc rNRP1", "PROTEIN", 111, 119], ["heparin", "TREATMENT", 32, 39], ["Kd", "TEST", 41, 43], ["a minimum of dp10", "TREATMENT", 65, 82], ["Fc rNRP1 binding", "TREATMENT", 111, 127], ["immobilised heparin", "TREATMENT", 131, 150], ["high affinity", "OBSERVATION_MODIFIER", 15, 28]]], ["Competition experiments with various modified sugars show that interaction of Fc rNRP1 with heparin is highly ionic and dependent on the position of sulfate groups along the heparin chain.", [["heparin", "CHEMICAL", 92, 99], ["heparin", "CHEMICAL", 174, 181], ["sugars", "CHEMICAL", 46, 52], ["sulfate", "CHEMICAL", 149, 156], ["Fc rNRP1", "GENE_OR_GENE_PRODUCT", 78, 86], ["heparin", "SIMPLE_CHEMICAL", 92, 99], ["sulfate", "SIMPLE_CHEMICAL", 149, 156], ["heparin chain", "SIMPLE_CHEMICAL", 174, 187], ["Fc rNRP1", "PROTEIN", 78, 86], ["heparin chain", "PROTEIN", 174, 187], ["various modified sugars", "TREATMENT", 29, 52], ["Fc rNRP1", "TREATMENT", 78, 86], ["heparin", "TREATMENT", 92, 99], ["sulfate groups", "TREATMENT", 149, 163], ["the heparin chain", "TREATMENT", 170, 187], ["highly ionic", "OBSERVATION_MODIFIER", 103, 115], ["heparin chain", "OBSERVATION", 174, 187]]], ["The hNRP1 did not bind to heparin immobilised via NHS-biotin, though it did bind to some heparin affinity chromatography matrices.", [["heparin", "CHEMICAL", 26, 33], ["NHS-biotin", "CHEMICAL", 50, 60], ["heparin", "CHEMICAL", 89, 96], ["biotin", "CHEMICAL", 54, 60], ["hNRP1", "GENE_OR_GENE_PRODUCT", 4, 9], ["heparin", "SIMPLE_CHEMICAL", 26, 33], ["NHS-biotin", "SIMPLE_CHEMICAL", 50, 60], ["heparin", "SIMPLE_CHEMICAL", 89, 96], ["hNRP1", "PROTEIN", 4, 9], ["heparin", "TREATMENT", 26, 33], ["biotin", "TREATMENT", 54, 60], ["some heparin affinity chromatography matrices", "TREATMENT", 84, 129]]], ["Organic compounds of tin are among wide spread environmental pollutants.", [["tin", "CHEMICAL", 21, 24], ["tin", "CHEMICAL", 21, 24], ["tin", "SIMPLE_CHEMICAL", 21, 24], ["wide", "OBSERVATION_MODIFIER", 35, 39], ["spread", "OBSERVATION_MODIFIER", 40, 46], ["environmental pollutants", "OBSERVATION", 47, 71]]], ["Due to physical and/or chemical actions, poly-substituted alkyltins speciate into less substituted, more toxic species.", [["poly-substituted alkyltins", "CHEMICAL", 41, 67], ["poly-substituted alkyltins", "CHEMICAL", 41, 67], ["poly-substituted alkyltins", "SIMPLE_CHEMICAL", 41, 67], ["poly-substituted alkyltins", "PROBLEM", 41, 67], ["more toxic species", "PROBLEM", 100, 118], ["toxic species", "OBSERVATION", 105, 118]]], ["Tetra-or tri-alkyltins show a marked delay in their toxic action with respect to the corresponding di-and mono-alkylated analogs.", [["Tetra-or tri-alkyltins", "CHEMICAL", 0, 22], ["Tetra-or tri-alkyltins", "SIMPLE_CHEMICAL", 0, 22], ["di-and mono-alkylated analogs", "SIMPLE_CHEMICAL", 99, 128], ["Tetra-or tri-alkyltins", "TEST", 0, 22], ["a marked delay", "PROBLEM", 28, 42], ["the corresponding di-and mono-alkylated analogs", "PROBLEM", 81, 128], ["marked", "OBSERVATION_MODIFIER", 30, 36], ["delay", "OBSERVATION_MODIFIER", 37, 42]]], ["It has been hypothesized that the delayed toxicity may results from the progressive dealkylation of alkyltins in more toxic di-and mono-derivatives, which bind and inhibit essential enzymes.", [["toxicity", "DISEASE", 42, 50], ["alkyltins", "CHEMICAL", 100, 109], ["alkyltins", "CHEMICAL", 100, 109], ["di-and mono-derivatives", "CHEMICAL", 124, 147], ["alkyltins", "SIMPLE_CHEMICAL", 100, 109], ["di-and mono-derivatives", "SIMPLE_CHEMICAL", 124, 147], ["essential enzymes", "PROTEIN", 172, 189], ["the delayed toxicity", "PROBLEM", 30, 50], ["the progressive dealkylation of alkyltins", "PROBLEM", 68, 109], ["essential enzymes", "TEST", 172, 189], ["progressive", "OBSERVATION_MODIFIER", 72, 83], ["dealkylation", "OBSERVATION", 84, 96]]], ["It has been proposed that alkyltins preferentially target enzyme sulphydryl groups.", [["alkyltins", "CHEMICAL", 26, 35], ["sulphydryl", "CHEMICAL", 65, 75], ["alkyltins", "CHEMICAL", 26, 35], ["sulphydryl", "CHEMICAL", 65, 75], ["alkyltins", "SIMPLE_CHEMICAL", 26, 35], ["sulphydryl", "SIMPLE_CHEMICAL", 65, 75]]], ["Previously, we showed that a nine amino acid linear peptide (I 1 LGCWCYLR 9 ) containing a CXC motif is able to bind and dealkylate tri-substituted alkyltin compounds into the corresponding dialkyl derivatives.", [["amino acid", "CHEMICAL", 34, 44], ["alkyltin", "CHEMICAL", 148, 156], ["dialkyl", "CHEMICAL", 190, 197], ["amino acid", "CHEMICAL", 34, 44], ["alkyltin", "CHEMICAL", 148, 156], ["dialkyl", "CHEMICAL", 190, 197], ["CXC", "GENE_OR_GENE_PRODUCT", 91, 94], ["dealkylate tri-substituted alkyltin compounds", "SIMPLE_CHEMICAL", 121, 166], ["dialkyl derivatives", "SIMPLE_CHEMICAL", 190, 209], ["CXC motif", "PROTEIN", 91, 100], ["a nine amino acid linear peptide (I 1 LGCWCYLR", "TREATMENT", 27, 73], ["a CXC motif", "TREATMENT", 89, 100], ["the corresponding dialkyl derivatives", "TREATMENT", 172, 209], ["dialkyl derivatives", "OBSERVATION", 190, 209]]], ["Here, we investigated the time dependence of the degradation of the most common alkyltin derivatives by this peptide.", [["alkyltin", "CHEMICAL", 80, 88], ["alkyltin", "CHEMICAL", 80, 88], ["alkyltin derivatives", "SIMPLE_CHEMICAL", 80, 100], ["the most common alkyltin derivatives", "TREATMENT", 64, 100], ["this peptide", "TREATMENT", 104, 116]]], ["We monitored the reaction kinetics using the intrinsic fluorescence of the tryptophan residue in position 5 of the peptide.", [["tryptophan", "CHEMICAL", 75, 85], ["tryptophan", "CHEMICAL", 75, 85], ["tryptophan", "AMINO_ACID", 75, 85], ["the reaction kinetics", "TEST", 13, 34], ["the tryptophan residue", "TREATMENT", 71, 93], ["the peptide", "TREATMENT", 111, 122], ["tryptophan residue", "OBSERVATION", 75, 93]]], ["We found that all of the alkyltins analyzed are progressively degraded to dialkyl derivatives, following a pseudo-enzymatic reaction mechanism.", [["dialkyl", "CHEMICAL", 74, 81], ["alkyltins", "CHEMICAL", 25, 34], ["dialkyl", "CHEMICAL", 74, 81], ["alkyltins", "SIMPLE_CHEMICAL", 25, 34], ["dialkyl derivatives", "SIMPLE_CHEMICAL", 74, 93], ["dialkyl derivatives", "TREATMENT", 74, 93], ["a pseudo-enzymatic reaction mechanism", "PROBLEM", 105, 142], ["dialkyl derivatives", "OBSERVATION", 74, 93], ["enzymatic reaction", "OBSERVATION", 114, 132]]], ["The end-point of the reactions was the formation of a covalent complex between the disubstituted alkyltin and the peptide.", [["alkyltin", "CHEMICAL", 97, 105], ["alkyltin", "CHEMICAL", 97, 105], ["alkyltin", "SIMPLE_CHEMICAL", 97, 105], ["the reactions", "PROBLEM", 17, 30], ["a covalent complex", "TREATMENT", 52, 70], ["the disubstituted alkyltin", "TREATMENT", 79, 105], ["the peptide", "TREATMENT", 110, 121]]], ["These data agree with the speciation profiles proposed for polysubstituted alkyltins in the environment and reveal a possible biotic degradation pathway for these toxic compounds.", [["alkyltins", "CHEMICAL", 75, 84], ["polysubstituted alkyltins", "CHEMICAL", 59, 84], ["polysubstituted alkyltins", "SIMPLE_CHEMICAL", 59, 84], ["biotic degradation pathway", "TREATMENT", 126, 152], ["these toxic compounds", "PROBLEM", 157, 178]]], ["Parkinson's disease (PD) is a multifactorial neurodegenerative condition characterized by the progressive loss of dopaminergic neurons in the substantia nigra and by the presence of intracellular inclusions, composed predominantly of fibrillar alpha-synuclein (aS).", [["dopaminergic neurons", "ANATOMY", 114, 134], ["substantia nigra", "ANATOMY", 142, 158], ["intracellular inclusions", "ANATOMY", 182, 206], ["Parkinson's disease", "DISEASE", 0, 19], ["PD", "DISEASE", 21, 23], ["neurodegenerative condition", "DISEASE", 45, 72], ["loss of dopaminergic neurons", "DISEASE", 106, 134], ["dopaminergic neurons", "CELL", 114, 134], ["substantia nigra", "CELLULAR_COMPONENT", 142, 158], ["intracellular inclusions", "CELLULAR_COMPONENT", 182, 206], ["fibrillar alpha-synuclein", "GENE_OR_GENE_PRODUCT", 234, 259], ["aS", "GENE_OR_GENE_PRODUCT", 261, 263], ["dopaminergic neurons", "CELL_TYPE", 114, 134], ["fibrillar alpha-synuclein", "PROTEIN", 234, 259], ["aS", "PROTEIN", 261, 263], ["Parkinson's disease", "PROBLEM", 0, 19], ["PD", "PROBLEM", 21, 23], ["a multifactorial neurodegenerative condition", "PROBLEM", 28, 72], ["the progressive loss of dopaminergic neurons in the substantia nigra", "PROBLEM", 90, 158], ["intracellular inclusions", "PROBLEM", 182, 206], ["fibrillar alpha-synuclein", "PROBLEM", 234, 259], ["multifactorial", "OBSERVATION_MODIFIER", 30, 44], ["neurodegenerative", "OBSERVATION", 45, 62], ["progressive", "OBSERVATION_MODIFIER", 94, 105], ["loss", "OBSERVATION", 106, 110], ["dopaminergic neurons", "OBSERVATION", 114, 134], ["substantia nigra", "ANATOMY", 142, 158], ["intracellular inclusions", "OBSERVATION", 182, 206], ["fibrillar alpha-synuclein", "OBSERVATION", 234, 259]]], ["Post-mortem studies indicate the presence of oxidative damage in the nigral neurons.", [["nigral neurons", "ANATOMY", 69, 83], ["nigral neurons", "CELL", 69, 83], ["nigral neurons", "CELL_TYPE", 69, 83], ["Post-mortem studies", "TEST", 0, 19], ["oxidative damage in the nigral neurons", "PROBLEM", 45, 83], ["oxidative damage", "OBSERVATION", 45, 61], ["nigral neurons", "ANATOMY", 69, 83]]], ["Dopamine oxidation, which leads to the formation of highly reactive quinones (DAQ), may account for the specificity neurodegeneration observed in PD.", [["Dopamine", "CHEMICAL", 0, 8], ["DAQ", "CHEMICAL", 78, 81], ["neurodegeneration", "DISEASE", 116, 133], ["PD", "DISEASE", 146, 148], ["Dopamine", "CHEMICAL", 0, 8], ["quinones", "CHEMICAL", 68, 76], ["DAQ", "CHEMICAL", 78, 81], ["Dopamine", "SIMPLE_CHEMICAL", 0, 8], ["reactive quinones", "SIMPLE_CHEMICAL", 59, 76], ["DAQ", "SIMPLE_CHEMICAL", 78, 81], ["Dopamine oxidation", "TREATMENT", 0, 18], ["highly reactive quinones", "PROBLEM", 52, 76], ["the specificity neurodegeneration", "PROBLEM", 100, 133], ["PD", "PROBLEM", 146, 148], ["highly", "OBSERVATION_MODIFIER", 52, 58], ["reactive quinones", "OBSERVATION", 59, 76], ["may account for", "UNCERTAINTY", 84, 99], ["neurodegeneration", "OBSERVATION", 116, 133]]], ["DAQ have many potential protein targets for chemical modifications.", [["DAQ", "CHEMICAL", 0, 3], ["DAQ", "SIMPLE_CHEMICAL", 0, 3], ["DAQ", "PROTEIN", 0, 3], ["chemical modifications", "TREATMENT", 44, 66], ["protein targets", "OBSERVATION", 24, 39], ["chemical modifications", "OBSERVATION", 44, 66]]], ["Among them, we focused our attention on DJ-1, of which mutated forms have been found in familial cases of PD.", [["PD", "DISEASE", 106, 108], ["DJ-1", "GENE_OR_GENE_PRODUCT", 40, 44], ["DJ-1", "DNA", 40, 44], ["PD", "PROBLEM", 106, 108]]], ["A possible function of DJ-1 is its redox-dependent chaperone activity that could prevent aS aggregation and fibril formation.", [["fibril", "ANATOMY", 108, 114], ["DJ-1", "GENE_OR_GENE_PRODUCT", 23, 27], ["aS", "SIMPLE_CHEMICAL", 89, 91], ["fibril", "CELLULAR_COMPONENT", 108, 114], ["DJ-1", "PROTEIN", 23, 27], ["aS aggregation", "PROBLEM", 89, 103], ["fibril formation", "PROBLEM", 108, 124], ["possible", "UNCERTAINTY", 2, 10], ["chaperone activity", "OBSERVATION", 51, 69], ["fibril formation", "OBSERVATION", 108, 124]]], ["In the present work, we analyzed the structural and functional modification induced on DJ-1 by DAQ.", [["DJ-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["DAQ", "SIMPLE_CHEMICAL", 95, 98], ["DJ-1", "DNA", 87, 91], ["DJ", "TEST", 87, 89]]], ["15 N-HSQC spectra of DJ-1 were recorded in the presence of different amounts of DAQ and chemical shift perturbations were used to identify the DJ-1 residues target of DAQ and their relative reactivity toward DAQ.", [["DAQ", "CHEMICAL", 80, 83], ["DAQ", "CHEMICAL", 208, 211], ["DAQ", "CHEMICAL", 80, 83], ["DJ-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["DAQ", "SIMPLE_CHEMICAL", 80, 83], ["DJ-1", "GENE_OR_GENE_PRODUCT", 143, 147], ["DAQ", "SIMPLE_CHEMICAL", 167, 170], ["DAQ", "SIMPLE_CHEMICAL", 208, 211], ["DJ", "PROTEIN", 143, 145], ["DAQ", "PROTEIN", 167, 170], ["DAQ", "TREATMENT", 80, 83], ["chemical shift perturbations", "TREATMENT", 88, 116]]], ["Aggregation assays were also performed to evaluate the functional effects of the DAQ modifications on the chaperone activity of DJ-1.", [["DAQ", "CHEMICAL", 81, 84], ["DAQ", "CHEMICAL", 81, 84], ["DAQ", "SIMPLE_CHEMICAL", 81, 84], ["DJ-1", "GENE_OR_GENE_PRODUCT", 128, 132], ["DJ-1", "PROTEIN", 128, 132], ["Aggregation assays", "TEST", 0, 18], ["the DAQ modifications", "TREATMENT", 77, 98]]], ["Rabies Virus (RABV) infects neurons exclusively and causes lethal encephalitis.", [["neurons", "ANATOMY", 28, 35], ["Rabies Virus (RABV) infects neurons", "DISEASE", 0, 35], ["encephalitis", "DISEASE", 66, 78], ["Rabies Virus", "ORGANISM", 0, 12], ["RABV", "ORGANISM", 14, 18], ["neurons", "CELL", 28, 35], ["Rabies Virus", "SPECIES", 0, 12], ["Rabies Virus", "SPECIES", 0, 12], ["RABV", "SPECIES", 14, 18], ["Rabies Virus (RABV) infects neurons", "PROBLEM", 0, 35], ["lethal encephalitis", "PROBLEM", 59, 78], ["lethal", "OBSERVATION_MODIFIER", 59, 65], ["encephalitis", "OBSERVATION", 66, 78]]], ["Pathogenic RABV strains favor neuronal survival, whereas non-pathogen strains lead to neuronal apoptosis.", [["neuronal", "ANATOMY", 30, 38], ["neuronal", "ANATOMY", 86, 94], ["RABV", "ORGANISM", 11, 15], ["neuronal", "CELL", 30, 38], ["neuronal", "CELL", 86, 94], ["RABV", "SPECIES", 11, 15], ["Pathogenic RABV strains", "PROBLEM", 0, 23], ["neuronal survival", "PROBLEM", 30, 47], ["non-pathogen strains", "PROBLEM", 57, 77], ["neuronal apoptosis", "PROBLEM", 86, 104], ["RABV strains", "OBSERVATION", 11, 23], ["neuronal apoptosis", "OBSERVATION", 86, 104]]], ["The use of recombinant RABV showed: 1/ the G protein determined the induction of the survival or death phenotypes; 2/ the last 4 COOH amino acids of the G protein cytoplasmic domain (CytoG) are critical.", [["death", "DISEASE", 97, 102], ["amino acids", "CHEMICAL", 134, 145], ["COOH amino acids", "CHEMICAL", 129, 145], ["recombinant RABV", "ORGANISM", 11, 27], ["G protein", "GENE_OR_GENE_PRODUCT", 43, 52], ["amino acids", "AMINO_ACID", 134, 145], ["G protein", "GENE_OR_GENE_PRODUCT", 153, 162], ["cytoplasmic", "ORGANISM_SUBSTANCE", 163, 174], ["CytoG", "GENE_OR_GENE_PRODUCT", 183, 188], ["G protein", "PROTEIN", 43, 52], ["COOH amino acids", "PROTEIN", 129, 145], ["G protein cytoplasmic domain", "PROTEIN", 153, 181], ["CytoG", "PROTEIN", 183, 188], ["RABV", "SPECIES", 23, 27], ["recombinant RABV", "TEST", 11, 27], ["the G protein", "TEST", 39, 52], ["death phenotypes", "PROBLEM", 97, 113], ["COOH amino acids", "TEST", 129, 145], ["the G protein cytoplasmic domain", "TEST", 149, 181]]], ["These residues form a binding site for PDZ domain (PDZ-BS).", [["PDZ domain", "PROTEIN", 39, 49], ["PDZ", "PROTEIN", 51, 54], ["BS", "PROTEIN", 55, 57], ["These residues", "PROBLEM", 0, 14], ["a binding site", "PROBLEM", 20, 34], ["PDZ domain", "PROBLEM", 39, 49]]], ["One of the 6 amino acid differences between survival and death Gproteins are located in this PDZ-BS.", [["amino acid", "CHEMICAL", 13, 23], ["death", "DISEASE", 57, 62], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "AMINO_ACID", 13, 23], ["Gproteins", "GENE_OR_GENE_PRODUCT", 63, 72], ["PDZ", "GENE_OR_GENE_PRODUCT", 93, 96], ["PDZ", "PROTEIN", 93, 96], ["BS", "PROTEIN", 97, 99], ["the 6 amino acid differences", "PROBLEM", 7, 35], ["death Gproteins", "PROBLEM", 57, 72], ["BS", "ANATOMY", 97, 99]]], ["Results of two-hybrid experiments showed that CytoG survival interacted PDZ domain of Ser/Thr kinases (MAST), while CytoG death interacted also with 3 additional PDZ containing host proteins.", [["death", "DISEASE", 122, 127], ["Ser", "CHEMICAL", 86, 89], ["Thr", "CHEMICAL", 90, 93], ["CytoG", "SIMPLE_CHEMICAL", 46, 51], ["Ser/Thr kinases", "GENE_OR_GENE_PRODUCT", 86, 101], ["MAST", "GENE_OR_GENE_PRODUCT", 103, 107], ["PDZ", "GENE_OR_GENE_PRODUCT", 162, 165], ["CytoG", "PROTEIN", 46, 51], ["PDZ domain", "PROTEIN", 72, 82], ["Ser/Thr kinases", "PROTEIN", 86, 101], ["MAST", "PROTEIN", 103, 107], ["CytoG", "PROTEIN", 116, 121], ["PDZ", "PROTEIN", 162, 165], ["host proteins", "PROTEIN", 177, 190], ["two-hybrid experiments", "TEST", 11, 33], ["CytoG survival", "PROBLEM", 46, 60], ["Ser/Thr kinases", "TEST", 86, 101], ["CytoG death", "PROBLEM", 116, 127], ["3 additional PDZ", "TREATMENT", 149, 165], ["host proteins", "TREATMENT", 177, 190]]], ["To understand the fine structural basis for the specificity of the PDZ-CytoG complexes, we determined the 3D structure and the dynamics of the MAST-CytoG complexes by NMR.", [["PDZ", "GENE_OR_GENE_PRODUCT", 67, 70], ["PDZ", "PROTEIN", 67, 70], ["CytoG complexes", "PROTEIN", 71, 86], ["MAST-CytoG complexes", "PROTEIN", 143, 163], ["MAST", "ANATOMY", 143, 147]]], ["The structures, as well as the affinities and constant kinetics, of the MAST2 PDZ complexes with both CytoG are similar.", [["MAST2 PDZ", "GENE_OR_GENE_PRODUCT", 72, 81], ["CytoG", "GENE_OR_GENE_PRODUCT", 102, 107], ["MAST2 PDZ complexes", "PROTEIN", 72, 91], ["CytoG", "PROTEIN", 102, 107], ["the MAST2 PDZ complexes", "PROBLEM", 68, 91], ["structures", "ANATOMY_MODIFIER", 4, 14], ["constant", "OBSERVATION_MODIFIER", 46, 54], ["kinetics", "OBSERVATION_MODIFIER", 55, 63], ["MAST2 PDZ", "OBSERVATION", 72, 81], ["both CytoG", "OBSERVATION", 97, 107], ["similar", "OBSERVATION_MODIFIER", 112, 119]]], ["We conclude that difference by one aa in the PDZ-BS of the two strains cannot drastically modify the interaction with MAST2-PDZ, in agreement with the two-hybrid data.", [["PDZ", "GENE_OR_GENE_PRODUCT", 45, 48], ["MAST2-PDZ", "GENE_OR_GENE_PRODUCT", 118, 127], ["PDZ", "PROTEIN", 45, 48], ["MAST2", "PROTEIN", 118, 123], ["PDZ", "PROTEIN", 124, 127], ["the two-hybrid data", "TEST", 147, 166]]], ["Preliminary results suggest that the interaction of CytoG death with one additional cellular partner blurs the pro-survival signals engaging the infected cells through apoptotic trails.P-520Functional protein immobilization on glass-type surfaces S. Waichman, M. Bhagawati, Y. Podoplelova, J. Piehler Institute of Biology, Department of Biophysics,University of Osnabr\u00fcck , Barbara st.11 Osnabr\u00fcck, GermanyP-520The immobilization of membrane proteins onto solid supports enables protein interactions and conformational changes to be probed by spectroscopic techniques under highly defined conditions.", [["cellular", "ANATOMY", 84, 92], ["cells", "ANATOMY", 154, 159], ["membrane", "ANATOMY", 433, 441], ["death", "DISEASE", 58, 63], ["P-520", "CHEMICAL", 185, 190], ["GermanyP-520", "CHEMICAL", 399, 411], ["GermanyP-520", "CHEMICAL", 399, 411], ["CytoG", "GENE_OR_GENE_PRODUCT", 52, 57], ["cellular", "CELL", 84, 92], ["cells", "CELL", 154, 159], ["membrane", "CELLULAR_COMPONENT", 433, 441], ["CytoG", "PROTEIN", 52, 57], ["infected cells", "CELL_TYPE", 145, 159], ["P", "DNA", 185, 186], ["membrane proteins", "PROTEIN", 433, 450], ["CytoG death", "PROBLEM", 52, 63], ["the infected cells", "PROBLEM", 141, 159], ["P", "TEST", 185, 186], ["Functional protein immobilization", "TREATMENT", 190, 223], ["GermanyP", "TEST", 399, 407], ["The immobilization of membrane proteins onto solid supports", "TREATMENT", 411, 470], ["conformational changes", "PROBLEM", 504, 526], ["spectroscopic techniques", "TEST", 543, 567], ["infected cells", "OBSERVATION", 145, 159]]], ["Here, we present a novel method for covalent protein immobilization on glass-type surfaces using a bottom-up approach.", [["a novel method", "TREATMENT", 17, 31], ["covalent protein immobilization on glass-type surfaces", "TREATMENT", 36, 90], ["a bottom-up approach", "TREATMENT", 97, 117]]], ["In this approach the 4'phosphopantetheinyl group of coenzyme A (CoA) was transferred to the acyl carrier protein-derived YbbR tag of the target protein by means of the phosphopantetheinyl transferase Sfp.", [["phosphopantetheinyl", "CHEMICAL", 23, 42], ["coenzyme A", "CHEMICAL", 52, 62], ["CoA", "CHEMICAL", 64, 67], ["4'phosphopantetheinyl", "CHEMICAL", 21, 42], ["coenzyme A", "CHEMICAL", 52, 62], ["CoA", "CHEMICAL", 64, 67], ["acyl", "CHEMICAL", 92, 96], ["phosphopantetheinyl", "CHEMICAL", 168, 187], ["4'phosphopantetheinyl", "SIMPLE_CHEMICAL", 21, 42], ["coenzyme A", "SIMPLE_CHEMICAL", 52, 62], ["CoA", "SIMPLE_CHEMICAL", 64, 67], ["YbbR", "GENE_OR_GENE_PRODUCT", 121, 125], ["phosphopantetheinyl transferase", "GENE_OR_GENE_PRODUCT", 168, 199], ["coenzyme A", "PROTEIN", 52, 62], ["CoA", "PROTEIN", 64, 67], ["acyl carrier protein", "PROTEIN", 92, 112], ["YbbR tag", "PROTEIN", 121, 129], ["target protein", "PROTEIN", 137, 151], ["phosphopantetheinyl transferase", "PROTEIN", 168, 199], ["the 4'phosphopantetheinyl group of coenzyme A (CoA)", "TREATMENT", 17, 68], ["the acyl carrier protein", "TEST", 88, 112], ["the phosphopantetheinyl transferase", "TREATMENT", 164, 199]]], ["The glass-support was rendered biocompatible by coating it with an ultrathin layer of PEG (polyethylene glycol), followed by functionalization with CoA through maleimide chemistry.", [["PEG", "CHEMICAL", 86, 89], ["polyethylene glycol", "CHEMICAL", 91, 110], ["CoA", "CHEMICAL", 148, 151], ["maleimide", "CHEMICAL", 160, 169], ["PEG", "CHEMICAL", 86, 89], ["polyethylene glycol", "CHEMICAL", 91, 110], ["CoA", "CHEMICAL", 148, 151], ["maleimide", "CHEMICAL", 160, 169], ["PEG", "SIMPLE_CHEMICAL", 86, 89], ["polyethylene glycol", "SIMPLE_CHEMICAL", 91, 110], ["CoA", "SIMPLE_CHEMICAL", 148, 151], ["maleimide", "SIMPLE_CHEMICAL", 160, 169], ["The glass-support", "TREATMENT", 0, 17], ["an ultrathin layer of PEG (polyethylene glycol)", "TREATMENT", 64, 111], ["CoA through maleimide chemistry", "TREATMENT", 148, 179], ["PEG", "OBSERVATION", 86, 89]]], ["Immobilization of YbbR-tagged proteins in presence of Sfp was followed in real time by label-free detection using reflectance interference spectroscopy.", [["YbbR", "GENE_OR_GENE_PRODUCT", 18, 22], ["Sfp", "GENE_OR_GENE_PRODUCT", 54, 57], ["YbbR", "PROTEIN", 18, 22], ["tagged proteins", "PROTEIN", 23, 38], ["Sfp", "PROTEIN", 54, 57], ["YbbR", "TEST", 18, 22], ["tagged proteins", "PROBLEM", 23, 38], ["reflectance interference spectroscopy", "TEST", 114, 151]]], ["The immobilization procedure was thus systematically optimized by means of binding specificity, enzyme activity and functionality of the immobilized protein.", [["immobilized protein", "PROTEIN", 137, 156], ["The immobilization procedure", "TREATMENT", 0, 28], ["binding specificity", "TEST", 75, 94], ["enzyme activity", "TEST", 96, 111], ["the immobilized protein", "PROBLEM", 133, 156]]], ["This approach was employed for immobilizing the type I interferon IFN\u03b12 in order to probe ligand recognition by ifnar1 and ifnar2 and ligand-induced ternary complex formation.", [["type I interferon IFN\u03b12", "GENE_OR_GENE_PRODUCT", 48, 71], ["ifnar1", "GENE_OR_GENE_PRODUCT", 112, 118], ["ifnar2", "GENE_OR_GENE_PRODUCT", 123, 129], ["type I interferon IFN\u03b12", "PROTEIN", 48, 71], ["ifnar1", "PROTEIN", 112, 118], ["ifnar2", "PROTEIN", 123, 129], ["immobilizing the type I interferon IFN\u03b12", "TREATMENT", 31, 71], ["induced ternary complex formation", "PROBLEM", 141, 174], ["ternary complex", "OBSERVATION", 149, 164]]], ["The versatility of this technique was further enhanced by its combination with photopatterning methods.", [["this technique", "TREATMENT", 19, 33], ["photopatterning methods", "TREATMENT", 79, 102]]], ["This immobilization technique can provide a beneficial tool for bioanalytical and biophysical applications at the single molecule level.Selectivity and interaction of cation and anion modulatory sites in kainate receptorsR.", [["kainate", "CHEMICAL", 204, 211], ["kainate", "CHEMICAL", 204, 211], ["cation", "SIMPLE_CHEMICAL", 167, 173], ["anion", "SIMPLE_CHEMICAL", 178, 183], ["kainate receptorsR", "SIMPLE_CHEMICAL", 204, 222], ["cation and anion modulatory sites", "PROTEIN", 167, 200], ["This immobilization technique", "TREATMENT", 0, 29], ["bioanalytical and biophysical applications", "TREATMENT", 64, 106], ["cation and anion modulatory sites", "TREATMENT", 167, 200]]], ["Vijayan, P. C. Biggin Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK Ionotropic glutamate receptors mediate excitatory synaptic transmission in the brain and are heavily implicated in memory and learning as well as in numerous neuropathological conditions.", [["excitatory synaptic", "ANATOMY", 149, 168], ["brain", "ANATOMY", 189, 194], ["glutamate", "CHEMICAL", 121, 130], ["glutamate", "CHEMICAL", 121, 130], ["UK Ionotropic glutamate receptors", "GENE_OR_GENE_PRODUCT", 107, 140], ["synaptic", "MULTI-TISSUE_STRUCTURE", 160, 168], ["brain", "ORGAN", 189, 194], ["Ionotropic glutamate receptors", "PROTEIN", 110, 140], ["UK Ionotropic glutamate receptors", "TREATMENT", 107, 140], ["brain", "ANATOMY", 189, 194]]], ["One family of iGluRs, the kainate receptors, show unusual sensitivity to changes in external ion species resulting in an apparent requirement for both sodium and chloride ions for activation.", [["kainate", "CHEMICAL", 26, 33], ["sodium", "CHEMICAL", 151, 157], ["chloride", "CHEMICAL", 162, 170], ["kainate", "CHEMICAL", 26, 33], ["sodium", "CHEMICAL", 151, 157], ["chloride", "CHEMICAL", 162, 170], ["iGluRs", "GENE_OR_GENE_PRODUCT", 14, 20], ["kainate", "SIMPLE_CHEMICAL", 26, 33], ["sodium", "SIMPLE_CHEMICAL", 151, 157], ["chloride ions", "SIMPLE_CHEMICAL", 162, 175], ["iGluRs", "PROTEIN", 14, 20], ["kainate receptors", "PROTEIN", 26, 43], ["the kainate receptors", "TEST", 22, 43], ["unusual sensitivity", "PROBLEM", 50, 69], ["external ion species", "PROBLEM", 84, 104], ["both sodium and chloride ions", "TREATMENT", 146, 175]]], ["Our recent work revealed the location and selectivity of the cation binding sites.", [["cation", "SIMPLE_CHEMICAL", 61, 67], ["cation binding sites", "PROTEIN", 61, 81], ["the cation binding sites", "TREATMENT", 57, 81], ["cation binding", "OBSERVATION", 61, 75]]], ["Despite this progress, it is still unclear how the cation binding sites confer sodium selectivity and how apparent affinity for chloride is influenced by the presence of cations.", [["sodium", "CHEMICAL", 79, 85], ["chloride", "CHEMICAL", 128, 136], ["sodium", "CHEMICAL", 79, 85], ["chloride", "CHEMICAL", 128, 136], ["cation", "SIMPLE_CHEMICAL", 51, 57], ["sodium", "SIMPLE_CHEMICAL", 79, 85], ["chloride", "SIMPLE_CHEMICAL", 128, 136], ["cations", "SIMPLE_CHEMICAL", 170, 177], ["cation binding sites", "PROTEIN", 51, 71], ["sodium selectivity", "TEST", 79, 97], ["chloride", "TREATMENT", 128, 136]]], ["We have attempted to address these questions by performing extensive free energy calculations using all-atom molecular dynamics simulations.", [["extensive free energy calculations", "TREATMENT", 59, 93]]], ["The rank order of cation binding obtained from relative binding free energy calculations is in agreement with experimental measurements of apparent affinity.", [["cation", "SIMPLE_CHEMICAL", 18, 24], ["cation binding", "PROBLEM", 18, 32], ["apparent affinity", "PROBLEM", 139, 156]]], ["These calculations also reveal that the pair of cation binding sites in the dimer interface act independently.", [["cation", "SIMPLE_CHEMICAL", 48, 54], ["cation binding sites", "PROTEIN", 48, 68], ["These calculations", "TEST", 0, 18], ["cation binding", "OBSERVATION", 48, 62]]], ["Binding free energy calculations performed using a reduced model of the binding site show that cation selectivity can been attributed to both the rigidity and high charge density of the binding sites.", [["rigidity", "DISEASE", 146, 154], ["cation", "SIMPLE_CHEMICAL", 95, 101], ["binding sites", "PROTEIN", 186, 199], ["Binding free energy calculations", "TEST", 0, 32], ["the rigidity", "PROBLEM", 142, 154], ["high charge density of the binding sites", "PROBLEM", 159, 199], ["rigidity", "OBSERVATION", 146, 154], ["high", "OBSERVATION_MODIFIER", 159, 163], ["charge density", "OBSERVATION", 164, 178], ["binding sites", "OBSERVATION", 186, 199]]], ["Finally, a potential of mean force derived from umbrella sampling simulations indicate that the presence of cations stabilize the anion binding site considerably.P-518The effect of toxins on the inorganic phosphate release during the actin filament formation A. Vig, T. Kupi, G. Hild, M. Nyitrai University of P\u00e9cs, Faculty of Medicine, Department of Biophysics, Szigeti str.", [["P-518", "CHEMICAL", 162, 167], ["inorganic phosphate", "CHEMICAL", 195, 214], ["phosphate", "CHEMICAL", 205, 214], ["cations", "SIMPLE_CHEMICAL", 108, 115], ["anion", "SIMPLE_CHEMICAL", 130, 135], ["inorganic phosphate", "SIMPLE_CHEMICAL", 195, 214], ["actin", "GENE_OR_GENE_PRODUCT", 234, 239], ["anion binding site", "PROTEIN", 130, 148], ["actin", "PROTEIN", 234, 239], ["mean force", "PROBLEM", 24, 34], ["umbrella sampling simulations", "TREATMENT", 48, 77], ["the anion binding site", "PROBLEM", 126, 148], ["toxins", "TREATMENT", 181, 187], ["the inorganic phosphate release", "TREATMENT", 191, 222], ["anion binding", "OBSERVATION", 130, 143]]], ["12, 7624 P\u00e9cs, Hungary Actin can be found in monomeric (G-actin) and filamentous (F-actin) form in eukaryote cells under physiological circumstances.", [["eukaryote cells", "ANATOMY", 99, 114], ["Actin", "GENE_OR_GENE_PRODUCT", 23, 28], ["monomeric (G-actin) and filamentous (F-actin", "GENE_OR_GENE_PRODUCT", 45, 89], ["eukaryote cells", "CELL", 99, 114], ["G-actin", "PROTEIN", 56, 63], ["filamentous (F-actin) form", "PROTEIN", 69, 95], ["eukaryote cells", "CELL_TYPE", 99, 114], ["filamentous (F-actin)", "TREATMENT", 69, 90], ["eukaryote cells", "OBSERVATION", 99, 114]]], ["The first step of actin polymerisation is the formation of actin nuclei by ATP-binding actin monomers.", [["nuclei", "ANATOMY", 65, 71], ["ATP", "CHEMICAL", 75, 78], ["ATP", "CHEMICAL", 75, 78], ["actin", "GENE_OR_GENE_PRODUCT", 18, 23], ["actin", "GENE_OR_GENE_PRODUCT", 59, 64], ["nuclei", "CELLULAR_COMPONENT", 65, 71], ["ATP", "SIMPLE_CHEMICAL", 75, 78], ["-binding actin monomers", "GENE_OR_GENE_PRODUCT", 78, 101], ["actin", "PROTEIN", 18, 23], ["actin", "PROTEIN", 59, 64], ["ATP-binding actin monomers", "PROTEIN", 75, 101], ["actin polymerisation", "TREATMENT", 18, 38], ["actin polymerisation", "OBSERVATION", 18, 38], ["actin nuclei", "OBSERVATION", 59, 71]]], ["The next step in is the elongation when monomers are associated to the previously formed nuclei or to the ends of the growing filaments.", [["nuclei", "ANATOMY", 89, 95], ["filaments", "ANATOMY", 126, 135], ["nuclei", "CELLULAR_COMPONENT", 89, 95], ["filaments", "CELLULAR_COMPONENT", 126, 135], ["elongation", "OBSERVATION_MODIFIER", 24, 34], ["growing", "OBSERVATION_MODIFIER", 118, 125], ["filaments", "OBSERVATION", 126, 135]]], ["After the association of monomers the bound ATP is hydrolysed to ADP.P i , and with first order kinetics the release of inorganic phosphate occures.", [["ATP", "CHEMICAL", 44, 47], ["ADP", "CHEMICAL", 65, 68], ["inorganic phosphate", "CHEMICAL", 120, 139], ["ATP", "CHEMICAL", 44, 47], ["ADP", "CHEMICAL", 65, 68], ["phosphate", "CHEMICAL", 130, 139], ["ATP", "SIMPLE_CHEMICAL", 44, 47], ["ADP", "SIMPLE_CHEMICAL", 65, 68], ["inorganic phosphate", "SIMPLE_CHEMICAL", 120, 139], ["ADP", "TEST", 65, 68], ["inorganic phosphate occures", "TREATMENT", 120, 147]]], ["The rate constant of the release is 0,006 s \u22121 , which is a slower process than the hydrolysis itself (0,02 s \u22121 ).Phalloidin, a cyclic peptide from Amanita phalloides can bind to the filaments and stabilizes their structure.", [["filaments", "ANATOMY", 184, 193], ["cyclic peptide", "CHEMICAL", 129, 143], ["Phalloidin", "CHEMICAL", 115, 125], ["cyclic peptide", "CHEMICAL", 129, 143], ["Phalloidin", "SIMPLE_CHEMICAL", 115, 125], ["cyclic peptide", "SIMPLE_CHEMICAL", 129, 143], ["Amanita phalloides", "ORGANISM", 149, 167], ["filaments", "CELLULAR_COMPONENT", 184, 193], ["Amanita phalloides", "SPECIES", 149, 167], ["Amanita phalloides", "SPECIES", 149, 167], ["The rate", "TEST", 0, 8], ["a slower process", "PROBLEM", 58, 74], ["Phalloidin", "TREATMENT", 115, 125], ["a cyclic peptide", "TREATMENT", 127, 143], ["Amanita phalloides", "PROBLEM", 149, 167], ["constant", "OBSERVATION_MODIFIER", 9, 17], ["slower", "OBSERVATION_MODIFIER", 60, 66], ["process", "OBSERVATION", 67, 74]]], ["Jasplakinolide is another cyclic peptide from marine sponge (Jaspis johnstoni) which binds actin filaments.", [["filaments", "ANATOMY", 97, 106], ["Jasplakinolide", "CHEMICAL", 0, 14], ["Jasplakinolide", "CHEMICAL", 0, 14], ["cyclic peptide", "CHEMICAL", 26, 40], ["Jasplakinolide", "SIMPLE_CHEMICAL", 0, 14], ["Jaspis johnstoni", "ORGANISM", 61, 77], ["actin", "GENE_OR_GENE_PRODUCT", 91, 96], ["filaments", "CELLULAR_COMPONENT", 97, 106], ["actin filaments", "PROTEIN", 91, 106], ["Jaspis johnstoni", "SPECIES", 61, 77], ["Jaspis johnstoni", "SPECIES", 61, 77], ["Jasplakinolide", "TREATMENT", 0, 14], ["another cyclic peptide", "PROBLEM", 18, 40], ["marine sponge (Jaspis johnstoni", "TREATMENT", 46, 77], ["marine sponge", "OBSERVATION", 46, 59]]], ["The aim of this study was to investigate whether the binding of toxins to the newly created filaments has an effect on the kinetics of the inorganic phosphate release or not.", [["filaments", "ANATOMY", 92, 101], ["inorganic phosphate", "CHEMICAL", 139, 158], ["phosphate", "CHEMICAL", 149, 158], ["filaments", "CELLULAR_COMPONENT", 92, 101], ["inorganic phosphate", "SIMPLE_CHEMICAL", 139, 158], ["this study", "TEST", 11, 21], ["the binding of toxins", "PROBLEM", 49, 70], ["the inorganic phosphate release", "TREATMENT", 135, 166]]], ["We used absorption photometry measurements to measure the rate of phosphate release.", [["phosphate", "CHEMICAL", 66, 75], ["phosphate", "CHEMICAL", 66, 75], ["phosphate", "SIMPLE_CHEMICAL", 66, 75], ["absorption photometry measurements", "TEST", 8, 42], ["phosphate release", "TREATMENT", 66, 83]]], ["Phalloidin decreased the rate of the release substantially.", [["Phalloidin", "CHEMICAL", 0, 10], ["Phalloidin", "SIMPLE_CHEMICAL", 0, 10], ["Phalloidin", "TREATMENT", 0, 10]]], ["Although the effect of Jasplakinolide was weaker, the results showed that the binding of these toxins to the actin can modify the rate of the release of inorganic phosphate from the filaments.", [["filaments", "ANATOMY", 182, 191], ["Jasplakinolide", "CHEMICAL", 23, 37], ["inorganic phosphate", "CHEMICAL", 153, 172], ["Jasplakinolide", "CHEMICAL", 23, 37], ["phosphate", "CHEMICAL", 163, 172], ["Jasplakinolide", "SIMPLE_CHEMICAL", 23, 37], ["actin", "GENE_OR_GENE_PRODUCT", 109, 114], ["inorganic phosphate", "SIMPLE_CHEMICAL", 153, 172], ["filaments", "CELLULAR_COMPONENT", 182, 191], ["actin", "PROTEIN", 109, 114], ["Jasplakinolide", "PROBLEM", 23, 37], ["inorganic phosphate", "TREATMENT", 153, 172]]], ["These observations are in agreement with the molecular mechanisms by which these toxins stabilise the actin filamens.", [["filamens", "ANATOMY", 108, 116], ["actin", "GENE_OR_GENE_PRODUCT", 102, 107], ["actin filamens", "PROTEIN", 102, 116], ["actin filamens", "OBSERVATION", 102, 116]]], ["Fluorescent proteins (FPs) are invaluable fluorescent markers in cell biology.", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69], ["Fluorescent proteins", "PROTEIN", 0, 20], ["FPs", "PROTEIN", 22, 25], ["Fluorescent proteins (FPs", "TEST", 0, 25], ["fluorescent markers", "TEST", 42, 61]]], ["However, their use is often limited by photobleaching of the chromophore, notably in single-molecule, time-resolved or super-resolution imaging studies.", [["super-resolution imaging studies", "TEST", 119, 151]]], ["We will present the crystallographic studies at near atomic resolution of a photo-activatable fluorescent protein IrisFP that has been observed in a transient radical state en route to photobleaching.", [["photo-activatable fluorescent protein IrisFP", "PROTEIN", 76, 120], ["the crystallographic studies", "TEST", 16, 44], ["a photo", "TEST", 74, 81], ["activatable fluorescent protein IrisFP", "PROBLEM", 82, 120], ["protein IrisFP", "OBSERVATION", 106, 120]]], ["We took advantage of X-rays to populate the radical, which, under illumination with visible light, presumably forms with low probability from the triplet state.", [["advantage of X-rays", "TREATMENT", 8, 27], ["radical", "OBSERVATION", 44, 51], ["low probability", "OBSERVATION_MODIFIER", 121, 136]]], ["The combined X-ray diffraction and in crystallo spectroscopic data (from UV-Vis and Raman spectroscopies) reveal that radical formation in IrisFP involves strong but reversible distortion of the chromophore, suggesting a transient loss of pi-conjugation.", [["IrisFP", "CHEMICAL", 139, 145], ["IrisFP", "CHEMICAL", 139, 145], ["radical", "SIMPLE_CHEMICAL", 118, 125], ["IrisFP", "SIMPLE_CHEMICAL", 139, 145], ["The combined X-ray diffraction", "TEST", 0, 30], ["crystallo spectroscopic data", "TEST", 38, 66], ["Raman spectroscopies", "TEST", 84, 104], ["radical formation in IrisFP", "PROBLEM", 118, 145], ["reversible distortion of the chromophore", "PROBLEM", 166, 206], ["a transient loss of pi-conjugation", "PROBLEM", 219, 253], ["radical formation", "OBSERVATION", 118, 135], ["reversible", "OBSERVATION_MODIFIER", 166, 176], ["distortion", "OBSERVATION", 177, 187], ["transient", "OBSERVATION_MODIFIER", 221, 230], ["loss", "OBSERVATION_MODIFIER", 231, 235], ["pi-conjugation", "OBSERVATION_MODIFIER", 239, 253]]], ["These results will help unravel the mechanisms of blinking and photobleaching in FPs, which is of importance to rationally design variants of higher photostability.O-524Optimizing photoactivatable fluorescent proteins for live-cell imaging Recently, novel fluorescent proteins (FPs) have been reported which perform spectral changes in response to irradiation with light of a particular wavelength.", [["live-cell", "ANATOMY", 222, 231], ["O-524", "CHEMICAL", 164, 169], ["O-524", "CHEMICAL", 164, 169], ["O-524", "SIMPLE_CHEMICAL", 164, 169], ["cell", "CELL", 227, 231], ["novel fluorescent proteins", "GENE_OR_GENE_PRODUCT", 250, 276], ["photoactivatable fluorescent proteins", "PROTEIN", 180, 217], ["novel fluorescent proteins", "PROTEIN", 250, 276], ["FPs", "PROTEIN", 278, 281], ["blinking", "PROBLEM", 50, 58], ["photobleaching in FPs", "TEST", 63, 84], ["higher photostability", "TREATMENT", 142, 163], ["Optimizing photoactivatable fluorescent proteins", "TEST", 169, 217], ["live-cell imaging", "TEST", 222, 239], ["novel fluorescent proteins (FPs", "TEST", 250, 281], ["higher photostability", "OBSERVATION", 142, 163]]], ["Reversibly photoactivatable proteins switch between a bright and a dim fluorescent state.", [["photoactivatable proteins", "PROTEIN", 11, 36], ["Reversibly photoactivatable proteins", "PROBLEM", 0, 36], ["a dim fluorescent state", "PROBLEM", 65, 88], ["photoactivatable proteins", "OBSERVATION", 11, 36]]], ["This process is accompanied by photoisomerization of the protein chromophore.", [["the protein chromophore", "TREATMENT", 53, 76]]], ["Irreversible photoactivation results from photochemical processes within the protein, e.g., photolysis of an amino acid side chain, or an extension of the alternating \u03c0-electron system of the chromophore by a \u03b2-elimination reaction.", [["amino acid", "CHEMICAL", 109, 119], ["amino acid", "CHEMICAL", 109, 119], ["Irreversible photoactivation", "PROBLEM", 0, 28], ["the protein", "TEST", 73, 84], ["an amino acid side chain", "PROBLEM", 106, 130], ["a \u03b2-elimination reaction", "PROBLEM", 207, 231], ["photochemical processes", "OBSERVATION", 42, 65]]], ["FPs have became valuable tools in live-cell imaging because they allow intracellular protein labeling by using them as fusion tag, and photoactivatable FPs are powerful tools for application in novel subdiffraction imaging techniques.", [["cell", "ANATOMY", 39, 43], ["intracellular", "ANATOMY", 71, 84], ["cell", "CELL", 39, 43], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 71, 84], ["cell imaging", "TEST", 39, 51], ["intracellular protein labeling", "TREATMENT", 71, 101], ["fusion tag", "TREATMENT", 119, 129], ["photoactivatable FPs", "TEST", 135, 155], ["novel subdiffraction imaging techniques", "TEST", 194, 233]]], ["They frequently show a tendency to aggregate or oligomerize, incomplete chromophore maturation, fluctuating emission and low photostability.", [["a tendency to aggregate or oligomerize", "PROBLEM", 21, 59], ["incomplete chromophore maturation", "PROBLEM", 61, 94], ["fluctuating emission", "PROBLEM", 96, 116], ["low photostability", "PROBLEM", 121, 139], ["low photostability", "OBSERVATION_MODIFIER", 121, 139]]], ["Here, we will present our recent progress towards engineering the 'perfect' FP.P-523Simultaneous Intracellular Chloride and pH measurements using GFP-based sensor in LDCV D. Arosio 3 , F. Ricci 1 , L. Marchetti 2 , L. Albertazzi 1 , F. Beltram 2 1 Italian Institute of Technology, UdR Pisa, Italy, 2 NEST, Scuola Normale Superiore, Pisa, Italy, 3 NEST, INFM CNR, Pisa, Italy Chloride ion participates in many physiological functions including control of neuronal resting potential, charge balance during endosome acidification, and regulation of cell volume.", [["neuronal", "ANATOMY", 454, 462], ["endosome", "ANATOMY", 504, 512], ["cell", "ANATOMY", 546, 550], ["Chloride", "CHEMICAL", 111, 119], ["Chloride", "CHEMICAL", 375, 383], ["Chloride", "CHEMICAL", 111, 119], ["Chloride", "CHEMICAL", 375, 383], ["Chloride", "SIMPLE_CHEMICAL", 111, 119], ["GFP", "GENE_OR_GENE_PRODUCT", 146, 149], ["neuronal", "CELL", 454, 462], ["endosome", "CELLULAR_COMPONENT", 504, 512], ["cell", "CELL", 546, 550], ["GFP", "PROTEIN", 146, 149], ["FP.P", "TEST", 76, 80], ["Intracellular Chloride", "TREATMENT", 97, 119], ["pH measurements", "TEST", 124, 139], ["GFP", "TEST", 146, 149], ["Arosio", "TEST", 174, 180], ["endosome acidification", "PROBLEM", 504, 526], ["regulation of cell volume", "TREATMENT", 532, 557], ["Marchetti", "ANATOMY", 201, 210], ["cell volume", "OBSERVATION", 546, 557]]], ["As a consequence dysfunctions in regulating membrane chloride permeability lead to severe diseases including motor disorders, cystic fibrosis and epilepsy.", [["membrane", "ANATOMY", 44, 52], ["cystic", "ANATOMY", 126, 132], ["chloride", "CHEMICAL", 53, 61], ["motor disorders", "DISEASE", 109, 124], ["cystic fibrosis", "DISEASE", 126, 141], ["epilepsy", "DISEASE", 146, 154], ["chloride", "CHEMICAL", 53, 61], ["membrane", "CELLULAR_COMPONENT", 44, 52], ["chloride", "SIMPLE_CHEMICAL", 53, 61], ["a consequence dysfunctions", "PROBLEM", 3, 29], ["regulating membrane chloride permeability", "TREATMENT", 33, 74], ["severe diseases", "PROBLEM", 83, 98], ["motor disorders", "PROBLEM", 109, 124], ["cystic fibrosis", "PROBLEM", 126, 141], ["epilepsy", "PROBLEM", 146, 154], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["diseases", "OBSERVATION", 90, 98], ["motor disorders", "OBSERVATION", 109, 124], ["cystic", "OBSERVATION_MODIFIER", 126, 132], ["fibrosis", "OBSERVATION", 133, 141], ["epilepsy", "OBSERVATION", 146, 154]]], ["At present processes regulating intracellular chloride ion concentrations are still widely unexplored mainly as a consequence of limiting methods to quantify chloride fluxes in living cells.P-523In the present work a highly specific, genetically encoded sensor is developed for detecting simultaneously intracellular pH and chloride concentration.", [["intracellular", "ANATOMY", 32, 45], ["cells", "ANATOMY", 184, 189], ["intracellular", "ANATOMY", 303, 316], ["chloride", "CHEMICAL", 46, 54], ["chloride", "CHEMICAL", 158, 166], ["P-523In", "CHEMICAL", 190, 197], ["chloride", "CHEMICAL", 324, 332], ["chloride", "CHEMICAL", 46, 54], ["chloride", "CHEMICAL", 158, 166], ["chloride", "CHEMICAL", 324, 332], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["chloride", "SIMPLE_CHEMICAL", 46, 54], ["chloride", "SIMPLE_CHEMICAL", 158, 166], ["cells", "CELL", 184, 189], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 303, 316], ["chloride", "SIMPLE_CHEMICAL", 324, 332], ["living cells", "CELL_TYPE", 177, 189], ["P-523In", "DNA", 190, 197], ["intracellular chloride ion concentrations", "TREATMENT", 32, 73], ["chloride fluxes in living cells", "PROBLEM", 158, 189], ["chloride concentration", "TREATMENT", 324, 346], ["intracellular chloride", "OBSERVATION", 32, 54]]], ["The sensor is obtained by fusion of a red fluorescent protein (DsRed-monomer), insensitive to chloride and pH, to a GFP variant containing a specific chloride-binding site (GFP-Chl).", [["chloride", "CHEMICAL", 94, 102], ["chloride", "CHEMICAL", 150, 158], ["chloride", "CHEMICAL", 94, 102], ["chloride", "CHEMICAL", 150, 158], ["Chl", "CHEMICAL", 177, 180], ["DsRed", "GENE_OR_GENE_PRODUCT", 63, 68], ["chloride", "SIMPLE_CHEMICAL", 94, 102], ["GFP", "GENE_OR_GENE_PRODUCT", 116, 119], ["chloride", "SIMPLE_CHEMICAL", 150, 158], ["GFP-Chl", "GENE_OR_GENE_PRODUCT", 173, 180], ["red fluorescent protein", "PROTEIN", 38, 61], ["DsRed", "PROTEIN", 63, 68], ["GFP variant", "PROTEIN", 116, 127], ["chloride-binding site", "PROTEIN", 150, 171], ["GFP", "PROTEIN", 173, 176], ["Chl", "PROTEIN", 177, 180], ["a red fluorescent protein", "TEST", 36, 61], ["chloride", "TEST", 94, 102], ["pH", "TEST", 107, 109], ["a GFP variant", "PROBLEM", 114, 127]]], ["DsRed-GFP-Chl binds the chloride ion following a fluorescence static quenching mechanism, which allows measurements of intracellular pH in a chlorideindependent manner.", [["intracellular", "ANATOMY", 119, 132], ["Chl", "CHEMICAL", 10, 13], ["chloride", "CHEMICAL", 24, 32], ["Chl", "CHEMICAL", 10, 13], ["chloride", "CHEMICAL", 24, 32], ["DsRed-GFP-Chl", "GENE_OR_GENE_PRODUCT", 0, 13], ["chloride ion", "SIMPLE_CHEMICAL", 24, 36], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["DsRed-GFP-Chl", "PROTEIN", 0, 13], ["DsRed-GFP", "TEST", 0, 9], ["the chloride ion", "TREATMENT", 20, 36], ["a fluorescence static quenching mechanism", "TREATMENT", 47, 88]]], ["The sensor has been successfully tested in different living cells, in a pH range 5-8 and chloride concentration up to 200 mM.", [["cells", "ANATOMY", 60, 65], ["5-8 and chloride", "CHEMICAL", 81, 97], ["chloride", "CHEMICAL", 89, 97], ["cells", "CELL", 60, 65], ["chloride", "SIMPLE_CHEMICAL", 89, 97], ["a pH range", "TEST", 70, 80], ["chloride concentration", "TEST", 89, 111], ["200 mM", "OBSERVATION_MODIFIER", 118, 124]]], ["For the first time, to the best of our knowledge, it allowed to measure the chloride concentration of dense core vesicles in the secretory pathway.", [["vesicles", "ANATOMY", 113, 121], ["chloride", "CHEMICAL", 76, 84], ["chloride", "CHEMICAL", 76, 84], ["chloride", "SIMPLE_CHEMICAL", 76, 84], ["core vesicles", "CELLULAR_COMPONENT", 108, 121], ["the chloride concentration", "TREATMENT", 72, 98], ["dense core vesicles", "PROBLEM", 102, 121], ["dense", "OBSERVATION_MODIFIER", 102, 107], ["core vesicles", "OBSERVATION", 108, 121]]], ["Applicability to high-throughput screening, range of validity and accuracy of time-lapse maps will be discussed.", [["throughput screening", "TEST", 22, 42]]], ["We aim to understand the basis of the photophysical changes in fluorescent proteins (FP) induced by reactive oxygen species (ROS).", [["oxygen", "CHEMICAL", 109, 115], ["ROS", "CHEMICAL", 125, 128], ["oxygen", "CHEMICAL", 109, 115], ["reactive oxygen species", "SIMPLE_CHEMICAL", 100, 123], ["ROS", "SIMPLE_CHEMICAL", 125, 128], ["fluorescent proteins", "PROTEIN", 63, 83], ["the photophysical changes", "PROBLEM", 34, 59], ["reactive oxygen species", "PROBLEM", 100, 123], ["reactive", "OBSERVATION_MODIFIER", 100, 108], ["oxygen species", "OBSERVATION", 109, 123]]], ["Indeed, ROS might be involved in photochemistry of FP, leading to their photobleaching or photoconversion.", [["ROS", "CHEMICAL", 8, 11], ["FP", "CHEMICAL", 51, 53], ["ROS", "SIMPLE_CHEMICAL", 8, 11], ["FP", "SIMPLE_CHEMICAL", 51, 53], ["FP", "PROBLEM", 51, 53], ["their photobleaching", "TREATMENT", 66, 86], ["photoconversion", "TREATMENT", 90, 105]]], ["In addition, FP may be used to investigate cellular events like phagocytosis or mitochondrial activity, where ROS are naturally produced.", [["cellular", "ANATOMY", 43, 51], ["mitochondrial", "ANATOMY", 80, 93], ["ROS", "CHEMICAL", 110, 113], ["FP", "SIMPLE_CHEMICAL", 13, 15], ["cellular", "CELL", 43, 51], ["mitochondrial", "CELLULAR_COMPONENT", 80, 93], ["ROS", "SIMPLE_CHEMICAL", 110, 113], ["FP", "TEST", 13, 15], ["cellular events", "PROBLEM", 43, 58], ["phagocytosis", "PROBLEM", 64, 76], ["mitochondrial activity", "PROBLEM", 80, 102], ["phagocytosis", "OBSERVATION", 64, 76], ["mitochondrial activity", "OBSERVATION", 80, 102]]], ["In the latter cases, an accurate analysis of FP's fluorescence signals requires the full knowledge of reactions between ROS and FP.", [["ROS", "CHEMICAL", 120, 123], ["FP", "SIMPLE_CHEMICAL", 45, 47], ["ROS", "SIMPLE_CHEMICAL", 120, 123], ["FP", "SIMPLE_CHEMICAL", 128, 130], ["an accurate analysis", "TEST", 21, 41], ["FP's fluorescence signals", "TEST", 45, 70]]], ["In the future, this work may help in developing either photoresistant or photoswitchable FP and improving their use for imaging under oxidative stress conditions.", [["photoresistant or photoswitchable FP", "PROBLEM", 55, 91], ["imaging", "TEST", 120, 127]]], ["Using \u03b3-radiolysis as a quantitative source of ROS, we investigated the reactions of OH and O 2 \u2212 radicals on the Cyan Fluorescent Protein (CFP) and the modifications of the CFP's photophysical properties by OH radicals were explored in detail (submitted).", [["ROS", "CHEMICAL", 47, 50], ["OH", "CHEMICAL", 85, 87], ["OH", "CHEMICAL", 208, 210], ["OH", "CHEMICAL", 85, 87], ["O 2 \u2212", "CHEMICAL", 92, 97], ["OH", "CHEMICAL", 208, 210], ["ROS", "SIMPLE_CHEMICAL", 47, 50], ["OH", "SIMPLE_CHEMICAL", 85, 87], ["O 2 \u2212 radicals", "SIMPLE_CHEMICAL", 92, 106], ["Cyan Fluorescent Protein", "SIMPLE_CHEMICAL", 114, 138], ["CFP", "SIMPLE_CHEMICAL", 174, 177], ["OH radicals", "SIMPLE_CHEMICAL", 208, 219], ["Cyan Fluorescent Protein", "PROTEIN", 114, 138], ["CFP", "PROTEIN", 140, 143], ["\u03b3-radiolysis", "TREATMENT", 6, 18], ["the Cyan Fluorescent Protein (CFP", "TEST", 110, 143], ["the CFP", "TEST", 170, 177]]], ["In order to address the corresponding chemical changes in the protein, we devised a mild proteolysis protocol that for the first time offers a peptide mass fingerprint almost covering the CFP sequence (Alvarez et al. Biochemistry 2009).", [["CFP sequence", "DNA", 188, 200], ["a mild proteolysis protocol", "TREATMENT", 82, 109], ["a peptide mass fingerprint", "PROBLEM", 141, 167], ["the CFP sequence", "TEST", 184, 200], ["mild", "OBSERVATION_MODIFIER", 84, 88], ["mass", "OBSERVATION", 151, 155]]], ["Then, we achieved the meticulous characterization of the CFP oxidation products by mass spectrometry and proposed a mechanism to account for their formation by pulse radiolysis.", [["the CFP oxidation products", "TREATMENT", 53, 79], ["mass spectrometry", "TEST", 83, 100], ["pulse radiolysis", "TEST", 160, 176]]], ["Since the cloning of the green fluorescent protein from Aequoria victoria, numerous screens have been performed to improve the brightness of this protein, its spectral variants and fluorescent proteins from other species.", [["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 25, 50], ["Aequoria victoria", "ORGANISM", 56, 73], ["green fluorescent protein", "PROTEIN", 25, 50], ["fluorescent proteins", "PROTEIN", 181, 201], ["Aequoria victoria", "SPECIES", 56, 73], ["Aequoria victoria", "SPECIES", 56, 73], ["numerous screens", "TEST", 75, 91], ["this protein", "TEST", 141, 153], ["its spectral variants", "PROBLEM", 155, 176], ["fluorescent proteins from other species", "PROBLEM", 181, 220], ["fluorescent proteins", "OBSERVATION", 181, 201]]], ["The improvement is evaluated by comparing fluorescence intensity of individual bacteria or colonies.", [["colonies", "ANATOMY", 91, 99], ["individual bacteria or colonies", "PROBLEM", 68, 99], ["improvement", "OBSERVATION_MODIFIER", 4, 15]]], ["In this way also expression level, folding and maturation efficiency, and thickness of the bacterial colony contribute.", [["colony", "ANATOMY", 101, 107], ["expression level", "PROBLEM", 17, 33], ["folding and maturation efficiency", "PROBLEM", 35, 68], ["the bacterial colony", "PROBLEM", 87, 107], ["maturation efficiency", "OBSERVATION", 47, 68], ["bacterial colony", "OBSERVATION", 91, 107]]], ["Here we report a screening method that, in addition to fluorescence intensity, quantifies the excited state lifetime of a fluorescent protein, which is independent of intensity or expression level, and provides a direct measure for the quantum efficiency of the fluorescent protein.", [["fluorescent protein", "PROTEIN", 122, 141], ["fluorescent protein", "PROTEIN", 262, 281], ["a screening method", "TEST", 15, 33], ["fluorescence intensity", "TEST", 55, 77], ["a fluorescent protein", "PROBLEM", 120, 141]]], ["The novel approach was used to screen a library of cyan fluorescent protein (CFP) variants randomly mutated at position 65, 148 and 224, yielding an improved bright cyan fluorescent protein named, mPoseidon, with a markedly increased fluorescence lifetime and quantum yield, increased photostability and improved fluorescence intensity in vivo.", [["mPoseidon", "CHEMICAL", 197, 206], ["cyan fluorescent protein", "GENE_OR_GENE_PRODUCT", 51, 75], ["CFP", "GENE_OR_GENE_PRODUCT", 77, 80], ["mPoseidon", "SIMPLE_CHEMICAL", 197, 206], ["cyan fluorescent protein", "PROTEIN", 51, 75], ["CFP", "PROTEIN", 77, 80], ["bright cyan fluorescent protein", "PROTEIN", 158, 189], ["cyan fluorescent protein", "TEST", 51, 75], ["a markedly increased fluorescence lifetime", "PROBLEM", 213, 255], ["increased photostability", "PROBLEM", 275, 299], ["increased", "OBSERVATION_MODIFIER", 275, 284], ["photostability", "OBSERVATION_MODIFIER", 285, 299], ["improved", "OBSERVATION_MODIFIER", 304, 312], ["fluorescence intensity", "OBSERVATION", 313, 335]]], ["It is shown that mPoseidon is the brightest Cyan Fluorescent Protein in mammalian cells.", [["cells", "ANATOMY", 82, 87], ["mPoseidon", "CHEMICAL", 17, 26], ["mPoseidon", "SIMPLE_CHEMICAL", 17, 26], ["mammalian cells", "CELL", 72, 87], ["brightest Cyan Fluorescent Protein", "PROTEIN", 34, 68], ["mammalian cells", "CELL_TYPE", 72, 87], ["the brightest Cyan Fluorescent Protein in mammalian cells", "PROBLEM", 30, 87], ["mammalian cells", "OBSERVATION", 72, 87]]], ["It is demonstrated that three CFP variants can be separated and their distribution quantified in a single detection channel.Photo-switching mechanism of Enhanced Yellow Fluorescent ProteinA.", [["Yellow Fluorescent ProteinA", "SIMPLE_CHEMICAL", 162, 189], ["Enhanced Yellow Fluorescent ProteinA", "PROTEIN", 153, 189], ["three CFP variants", "PROBLEM", 24, 42], ["Photo", "TREATMENT", 124, 129], ["CFP variants", "OBSERVATION", 30, 42], ["Fluorescent ProteinA", "OBSERVATION", 169, 189]]], ["R. Faro 1 , P. Carpentier 2 , D. Bourgeois 3 , E. Rosny 4 1 IRTSV, CEA, UFJ, Grenoble, France, 2 IBS, CEA, CNRS, UFJ, Grenoble, France, 3 IBS, CEA, CNRS, UFJ, Grenoble, France, 4 IBS, CNRS, UFJ, Grenoble, France Enhanced Yellow Fluorescent Protein (EYFP) is extensively used as a fluorescent marker.", [["EYFP", "GENE_OR_GENE_PRODUCT", 249, 253], ["Yellow Fluorescent Protein", "PROTEIN", 221, 247], ["EYFP", "PROTEIN", 249, 253], ["CEA", "TEST", 67, 70], ["CEA", "TEST", 102, 105], ["CNRS", "TEST", 107, 111], ["IBS", "TEST", 138, 141], ["CEA", "TEST", 143, 146], ["CNRS", "TEST", 148, 152], ["CNRS", "TEST", 184, 188], ["a fluorescent marker", "TEST", 278, 298], ["CEA", "ANATOMY", 67, 70], ["CEA", "ANATOMY", 102, 105], ["CEA", "ANATOMY", 143, 146]]], ["Like other Photo Activatable Fluorescence Proteins (PAFP), it exhibits photo-switching properties.", [["Photo Activatable Fluorescence Proteins", "PROTEIN", 11, 50], ["PAFP", "PROTEIN", 52, 56], ["Fluorescence Proteins", "TEST", 29, 50], ["PAFP", "TEST", 52, 56]]], ["However, the mechanism by which fluorescence can be swiched on or off upon light irradiation is not fully understood at the molecular level.", [["light irradiation", "TREATMENT", 75, 92]]], ["The bright to dark conversion involves a protonation step and structural rearrangements of the chromophore, but it is not clear which of these two steps is the triggering event.", [["a protonation step", "TREATMENT", 39, 57], ["dark conversion", "OBSERVATION", 14, 29]]], ["To answer this question, we carried out photo-switching experiments at cryotemperatures.", [["photo", "TREATMENT", 40, 45]]], ["Our data suggest that a photo-induced protonation step (probably in the triplet state) is the primary event in the bright to dark conversion.", [["Our data", "TEST", 0, 8], ["a photo-induced protonation step", "TREATMENT", 22, 54]]], ["Our results may bear relevance to other PAFPs, such as Iris, Eos, Dronpa, Padron or Kaede.", [["PAFPs", "PATHOLOGICAL_FORMATION", 40, 45], ["Eos", "GENE_OR_GENE_PRODUCT", 61, 64], ["other PAFPs", "TEST", 34, 45], ["Kaede", "TREATMENT", 84, 89], ["Iris", "ANATOMY", 55, 59]]], ["How misfolding and aggregation of proteins constitutes a toxic insult to neurons remains largely unknown.", [["neurons", "ANATOMY", 73, 80], ["neurons", "CELL", 73, 80], ["How misfolding and aggregation of proteins", "PROBLEM", 0, 42], ["a toxic insult to neurons", "PROBLEM", 55, 80]]], ["In order to obtain insight into the molecular biology of neurodegenerative disease, we have developed a number of GFP-based biosensors for the detection and quantification of cellular clearing mechanisms for aggregated proteins.", [["cellular", "ANATOMY", 175, 183], ["neurodegenerative disease", "DISEASE", 57, 82], ["GFP", "GENE_OR_GENE_PRODUCT", 114, 117], ["cellular", "CELL", 175, 183], ["GFP", "PROTEIN", 114, 117], ["aggregated proteins", "PROTEIN", 208, 227], ["neurodegenerative disease", "PROBLEM", 57, 82], ["the detection", "TEST", 139, 152], ["cellular clearing mechanisms", "PROBLEM", 175, 203], ["aggregated proteins", "PROBLEM", 208, 227], ["neurodegenerative disease", "OBSERVATION", 57, 82], ["cellular clearing", "OBSERVATION", 175, 192]]], ["The high load on these protein quality control mechanisms, and their failure to meet normal physiological demand ultimately results in a \"de-compensation\" condition from which the nerve cell cannot recover.", [["nerve cell", "ANATOMY", 180, 190], ["nerve cell", "CELL", 180, 190], ["nerve cell", "CELL_TYPE", 180, 190], ["their failure", "PROBLEM", 63, 76], ["a \"de-compensation\" condition", "PROBLEM", 135, 164], ["high load", "OBSERVATION_MODIFIER", 4, 13], ["failure", "OBSERVATION", 69, 76], ["nerve", "ANATOMY", 180, 185]]], ["Our FRET/FLIM-based bioassays visualize protein ubiquitination and degradation; proteasomal activity; foldase activity using a folding-impaired GFP mutant which gains fluorescence conditional on the upregulation of chaperone activity; chaperone binding to unfolded proteins; and autophagosome formation/lysosomal integrity via the targeted and sensitive FRET-based measurement of pH changes.", [["autophagosome", "ANATOMY", 279, 292], ["lysosomal", "ANATOMY", 303, 312], ["foldase", "GENE_OR_GENE_PRODUCT", 102, 109], ["GFP", "GENE_OR_GENE_PRODUCT", 144, 147], ["autophagosome", "CELLULAR_COMPONENT", 279, 292], ["lysosomal", "CELLULAR_COMPONENT", 303, 312], ["GFP mutant", "PROTEIN", 144, 154], ["unfolded proteins", "PROTEIN", 256, 273], ["Our FRET/FLIM", "TEST", 0, 13], ["based bioassays", "TEST", 14, 29], ["protein ubiquitination", "PROBLEM", 40, 62], ["proteasomal activity", "PROBLEM", 80, 100], ["impaired GFP mutant", "PROBLEM", 135, 154], ["chaperone activity", "TREATMENT", 215, 233], ["chaperone binding", "PROBLEM", 235, 252], ["unfolded proteins", "PROBLEM", 256, 273], ["autophagosome formation", "PROBLEM", 279, 302], ["pH changes", "PROBLEM", 380, 390], ["lysosomal integrity", "OBSERVATION", 303, 322]]], ["These sensors are employed in cellular model systems for Parkinson's and Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS) to delineate the molecular pathway of cellular demise, and to gain a mechanistic understanding of the toxicity of protein aggregates and the basis for the vulnerability of neurons.O-526Millisecond photo-switching dynamics of E222Q GFP mutants for sensor and imaging applications M. Collini 1 , V. Quercioli 1 , L. D'Alfonso 1 , G. Baldini 1 , B. Campanini 2 , S. Bettati 2 , G. Chirico 1 1 Dipartimento di Fisica, Universit\u00e0 di Milano Bicocca, Italy, 2 Dipartimento di Biochimica e Biologia Molecolare, Universit\u00e0 di Parma, Parma, Italy E222Q mutants of the Green Fluorescent Protein are known to possess photo-chromic properties: the anionic emission, primed by a pump 488 nm laser beam, can be switched between two levels of different brightness by irradiation with a blue, \u223c = 400 nm, probe laser light.", [["cellular", "ANATOMY", 30, 38], ["cellular", "ANATOMY", 172, 180], ["neurons", "ANATOMY", 306, 313], ["Parkinson's and Alzheimer's disease", "DISEASE", 57, 92], ["Amyotrophic Lateral Sclerosis", "DISEASE", 98, 127], ["ALS", "DISEASE", 129, 132], ["toxicity", "DISEASE", 236, 244], ["O-526", "CHEMICAL", 314, 319], ["cellular", "CELL", 30, 38], ["cellular", "CELL", 172, 180], ["neurons", "CELL", 306, 313], ["GFP", "GENE_OR_GENE_PRODUCT", 365, 368], ["E222Q GFP mutants", "PROTEIN", 359, 376], ["Green Fluorescent Protein", "PROTEIN", 692, 717], ["Parkinson's", "PROBLEM", 57, 68], ["Alzheimer's disease", "PROBLEM", 73, 92], ["Amyotrophic Lateral Sclerosis (ALS)", "PROBLEM", 98, 133], ["cellular demise", "PROBLEM", 172, 187], ["the toxicity of protein aggregates", "PROBLEM", 232, 266], ["the vulnerability of neurons", "PROBLEM", 285, 313], ["Millisecond photo", "TEST", 319, 336], ["imaging applications", "TEST", 392, 412], ["the anionic emission", "TREATMENT", 765, 785], ["a pump", "TREATMENT", 797, 803], ["nm laser beam", "TREATMENT", 808, 821], ["a blue", "TREATMENT", 902, 908], ["Amyotrophic", "OBSERVATION_MODIFIER", 98, 109], ["Lateral", "OBSERVATION_MODIFIER", 110, 117], ["Sclerosis", "OBSERVATION", 118, 127], ["cellular demise", "OBSERVATION", 172, 187], ["neurons", "ANATOMY", 306, 313]]], ["We have studied here the amplitude and the dynamics of the brightness enhancement of the E222Q mutant of GFPMut2.", [["GFPMut2", "GENE_OR_GENE_PRODUCT", 105, 112], ["E222Q mutant", "PROTEIN", 89, 101], ["GFPMut2", "PROTEIN", 105, 112]]], ["The fluorescence emission increases almost threefold, under saturating probe laser excitation, for pump excitation intensity in the linear regime.", [["The fluorescence emission", "TEST", 0, 25], ["saturating probe laser excitation", "TREATMENT", 60, 93], ["pump excitation intensity in the linear regime", "TREATMENT", 99, 145]]], ["Two characteristic activation times, estimated by means of modulated two colour fluorescence correlation spectroscopy, are detected in the 1-30 ms range, independent of solution temperature and viscosity.", [["correlation spectroscopy", "TEST", 93, 117], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["activation times", "OBSERVATION", 19, 35]]], ["The brightness enhancement factor and the characteristic activation times depend markedly on the solution pH.", [["The brightness enhancement factor", "PROBLEM", 0, 33], ["the solution pH", "TEST", 93, 108], ["brightness", "OBSERVATION_MODIFIER", 4, 14], ["enhancement", "OBSERVATION_MODIFIER", 15, 26]]], ["These results indicate that this mutant can be used as a high sensitive intracellular marker for local proton concentration and for modulated excitation imaging.", [["intracellular", "ANATOMY", 72, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["proton", "SIMPLE_CHEMICAL", 103, 109], ["local proton concentration", "TREATMENT", 97, 123], ["modulated excitation imaging", "TEST", 132, 160]]], ["The advent of fluorescent proteins (FP) gave researchers the opportunity to study proteins in situ.", [["fluorescent proteins", "PROTEIN", 14, 34], ["FP", "PROTEIN", 36, 38]]], ["Cell fixation is a commonly used approach when working with microscopy.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell fixation", "TREATMENT", 0, 13], ["microscopy", "TEST", 60, 70], ["fixation", "OBSERVATION", 5, 13]]], ["However, we have found that FRET efficiency (E) in cells transfected with Cerulean and Venus chimeras could not be reproducibly measured after fixation.", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["Cerulean", "CELL", 74, 82], ["Venus chimeras", "ORGANISM", 87, 101], ["FRET efficiency (E) in cells", "PROBLEM", 28, 56], ["Cerulean and Venus chimeras", "TREATMENT", 74, 101], ["fixation", "TREATMENT", 143, 151], ["FRET efficiency", "OBSERVATION", 28, 43], ["Venus chimeras", "OBSERVATION", 87, 101]]], ["To evaluate this problem in detail, we measured E of 3 Cerulean-Venus standard constructs by acceptor photobleaching FRET, intensity-based ratiometric FRET and FLIM-FRET.", [["E of 3 Cerulean-Venus standard constructs", "DNA", 48, 89], ["acceptor photobleaching FRET", "TEST", 93, 121], ["photobleaching FRET", "OBSERVATION", 102, 121], ["ratiometric FRET", "OBSERVATION", 139, 155]]], ["The constructs were produced as standards (Biophys J, 2006, 91, 99) with 43, 38 and 31% E values, comprising donor-acceptor separations of 5, 17 and 32 amino acids, respectively.", [["amino acids", "CHEMICAL", 152, 163], ["amino acids", "CHEMICAL", 152, 163], ["amino acids", "AMINO_ACID", 152, 163], ["donor-acceptor separations", "TEST", 109, 135], ["amino acids", "TEST", 152, 163]]], ["Transient transfection of the fusion plasmids was performed into HeLa cells and E was measured in live and PFA or methanol fixed cells.", [["plasmids", "ANATOMY", 37, 45], ["HeLa cells", "ANATOMY", 65, 75], ["cells", "ANATOMY", 129, 134], ["PFA", "CHEMICAL", 107, 110], ["methanol", "CHEMICAL", 114, 122], ["HeLa cells", "CELL", 65, 75], ["E", "CELL", 80, 81], ["PFA", "SIMPLE_CHEMICAL", 107, 110], ["cells", "CELL", 129, 134], ["fusion plasmids", "DNA", 30, 45], ["HeLa cells", "CELL_LINE", 65, 75], ["methanol fixed cells", "CELL_TYPE", 114, 134], ["the fusion plasmids", "TREATMENT", 26, 45], ["HeLa cells", "TEST", 65, 75], ["methanol fixed cells", "TREATMENT", 114, 134], ["fusion plasmids", "OBSERVATION", 30, 45]]], ["Literature E values were reproduced when measuring live cells.", [["cells", "ANATOMY", 56, 61], ["cells", "CELL", 56, 61], ["live cells", "CELL_TYPE", 51, 61], ["Literature E values", "TEST", 0, 19]]], ["Conversely, cell fixation caused a deviation of E values.", [["cell", "ANATOMY", 12, 16], ["cell", "CELL", 12, 16], ["cell fixation", "TREATMENT", 12, 25], ["a deviation of E values", "PROBLEM", 33, 56], ["cell fixation", "OBSERVATION", 12, 25]]], ["Methanol fixed cells showed E between 1-5% for all the constructs.", [["cells", "ANATOMY", 15, 20], ["Methanol", "CHEMICAL", 0, 8], ["Methanol", "CHEMICAL", 0, 8], ["Methanol", "SIMPLE_CHEMICAL", 0, 8], ["cells", "CELL", 15, 20], ["Methanol fixed cells", "TEST", 0, 20]]], ["The effect of PFA fixation on both fluorescence intensity and FRET varied vastly among independent experiments regardless of the measurement modality.", [["PFA", "CHEMICAL", 14, 17], ["PFA", "SIMPLE_CHEMICAL", 14, 17], ["PFA fixation", "TREATMENT", 14, 26], ["both fluorescence intensity", "TEST", 30, 57], ["the measurement modality", "TEST", 125, 149], ["PFA fixation", "OBSERVATION", 14, 26]]], ["Thus, fixation should be avoided due to the effects it has on FP's fluorescence and consequently on FRET efficiency.", [["FP", "SIMPLE_CHEMICAL", 62, 64], ["fixation", "TREATMENT", 6, 14], ["FP's fluorescence", "TEST", 62, 79], ["fixation", "OBSERVATION", 6, 14]]], ["To explain the improvement in the fluorescence properties of Cerulean when compared to ECFP, we have determined the X-ray crystallographic structures of these two proteins at physiological pH, and performed molecular dynamics simulations.", [["Cerulean", "SIMPLE_CHEMICAL", 61, 69], ["ECFP", "GENE_OR_GENE_PRODUCT", 87, 91], ["ECFP", "PROTEIN", 87, 91], ["the X-ray", "TEST", 112, 121], ["physiological pH", "TEST", 175, 191], ["improvement", "OBSERVATION_MODIFIER", 15, 26]]], ["Both proteins exhibit a structural heterogeneity in the Nterminal half of their seventh strand, which forms a specific set of van der Waals interactions with the chromophore.", [["Nterminal half", "PROTEIN", 56, 70], ["a structural heterogeneity", "PROBLEM", 22, 48], ["the chromophore", "TREATMENT", 158, 173], ["structural", "OBSERVATION_MODIFIER", 24, 34], ["heterogeneity", "OBSERVATION", 35, 48]]], ["The critical H148D mutation present in Cerulean induces a modification of these interactions, and allows the chromophore to be more planar and better packed, albeit only intermittently.", [["Cerulean", "CHEMICAL", 39, 47]]], ["As a consequence, the probability of non-radiative decay is significantly decreased.", [["non-radiative decay", "PROBLEM", 37, 56], ["non-radiative decay", "OBSERVATION", 37, 56], ["significantly", "OBSERVATION_MODIFIER", 60, 73], ["decreased", "OBSERVATION_MODIFIER", 74, 83]]], ["Our results highlight the considerable dynamical flexibility that exists in the vicinity of the tryptophan-based chromophore of these engineered fluorescent proteins, and provide insights which should allow the design of mutants with enhanced optical properties.P-531The fluorescence lifetime of Green Fluorescent Protein G. Jung Biophysical Chemistry, Saarland University, 66123 Saarbruecken, Germany Biotechnological design of the Green Fluorescent Protein (GFP) and the discovery of other proteins boosted the development of the life sciences in the past decade.", [["tryptophan", "CHEMICAL", 96, 106], ["P-531", "CHEMICAL", 262, 267], ["tryptophan", "CHEMICAL", 96, 106], ["tryptophan", "SIMPLE_CHEMICAL", 96, 106], ["Green Fluorescent Protein", "GENE_OR_GENE_PRODUCT", 433, 458], ["GFP", "GENE_OR_GENE_PRODUCT", 460, 463], ["engineered fluorescent proteins", "PROTEIN", 134, 165], ["Green Fluorescent Protein", "PROTEIN", 433, 458], ["GFP", "PROTEIN", 460, 463], ["Green Fluorescent Protein", "TEST", 296, 321], ["the Green Fluorescent Protein", "TEST", 429, 458], ["other proteins", "PROBLEM", 486, 500], ["considerable", "OBSERVATION_MODIFIER", 26, 38], ["dynamical flexibility", "OBSERVATION", 39, 60]]], ["Tracking protein movements and high resolution microscopy are only a few recent applications which were realized by fluorescent protein technology.", [["Tracking protein movements", "TEST", 0, 26], ["high resolution microscopy", "TEST", 31, 57], ["protein movements", "OBSERVATION", 9, 26]]], ["Our aim is to establish fluorescent proteins for bioanalytical fluorescence lifetime measurements.", [["fluorescent proteins", "PROTEIN", 24, 44], ["bioanalytical fluorescence lifetime measurements", "TEST", 49, 97]]], ["Despite the progress in other fields, quantification with GFP still imposes practical problems [1] .", [["GFP", "GENE_OR_GENE_PRODUCT", 58, 61], ["GFP", "PROTEIN", 58, 61], ["GFP", "TEST", 58, 61]]], ["In the past, we observed that the UV-light driven decarboxylation of the nearby aminoacids Glu222 distorts the fluorescence lifetime of GFP [2] .", [["Glu222", "CHEMICAL", 91, 97], ["Glu222", "CHEMICAL", 91, 97], ["nearby aminoacids Glu222", "SIMPLE_CHEMICAL", 73, 97], ["GFP", "GENE_OR_GENE_PRODUCT", 136, 139], ["GFP", "PROTEIN", 136, 139], ["the UV", "TREATMENT", 30, 36], ["the nearby aminoacids", "TREATMENT", 69, 90]]], ["We found out that this chemical reaction also occurs under excitation of the anionic chromophore state with a high quantum yield [3] .", [["this chemical reaction", "PROBLEM", 18, 40]]], ["Suppression of this reaction therefore enables the design of autofluorescent proteins which can be used e.g. for the quantification of ions and which are beneficial as donors in FRET applications.", [["autofluorescent proteins", "PROTEIN", 61, 85], ["this reaction", "PROBLEM", 15, 28], ["autofluorescent proteins", "PROBLEM", 61, 85]]], ["The fluorescent properties of tryptophan residues (W) in proteins are highly dependent on their immediate protein environment.", [["tryptophan", "CHEMICAL", 30, 40], ["tryptophan", "CHEMICAL", 30, 40], ["tryptophan", "AMINO_ACID", 30, 40], ["tryptophan residues (W) in proteins", "PROBLEM", 30, 65], ["tryptophan residues", "OBSERVATION", 30, 49], ["highly", "OBSERVATION_MODIFIER", 70, 76], ["dependent", "OBSERVATION_MODIFIER", 77, 86]]], ["However, the multi exponential decay of single W proteins is not completely understood.", [["single W proteins", "GENE_OR_GENE_PRODUCT", 40, 57], ["W proteins", "PROTEIN", 47, 57], ["single W proteins", "TREATMENT", 40, 57]]], ["The most cited hypothesis contributes a multi exponential decay to the existence of several micro conformations (rotamers) of the W residue within the protein matrix.", [["matrix", "CELLULAR_COMPONENT", 159, 165], ["several micro conformations (rotamers", "TREATMENT", 84, 121], ["the W residue within the protein matrix", "TREATMENT", 126, 165], ["protein matrix", "OBSERVATION", 151, 165]]], ["To determine rotamers we apply a method based on Dead-end elimination (DEE) and molecular dynamics simulations (MD).", [["a method", "TREATMENT", 31, 39]]], ["Low energy rotamers are calculated by DEE while dynamics and further refinement is accomplished using MD.", [["Low energy rotamers", "PROBLEM", 0, 19], ["energy rotamers", "OBSERVATION", 4, 19]]], ["The method was applied on several test cases including the protein mutant Bc-Csp L66E from Bacillus caldolyticus, which contains a solvent exposed W residue.", [["Bacillus caldolyticus", "ORGANISM", 91, 112], ["protein mutant Bc", "PROTEIN", 59, 76], ["Csp L66E", "PROTEIN", 77, 85], ["Bacillus caldolyticus", "SPECIES", 91, 112], ["Bacillus caldolyticus", "SPECIES", 91, 112], ["The method", "TREATMENT", 0, 10], ["several test cases", "TEST", 26, 44], ["the protein mutant Bc", "TEST", 55, 76], ["Csp", "PROBLEM", 77, 80], ["Bacillus caldolyticus", "PROBLEM", 91, 112]]], ["As resolved by X-ray crystallography, this W residue occupies two conformations.", [["X-ray crystallography", "TEST", 15, 36], ["this W residue", "TREATMENT", 38, 52]]], ["Using DEE and MD we were able to retrieve the W conformations found in the X-ray structure.", [["the W conformations", "TREATMENT", 42, 61]]], ["The results demonstrate the ability of the method to obtain valuable W rotamers, both for solvent shielded as exposed residues.", [["valuable W rotamers", "TREATMENT", 60, 79]]], ["The determined conformations were compatible with the findings based on a method using replica exchange simulations.Red-Shifted Fluorescent Protein Variants of eqFP611K.", [["eqFP611K", "GENE_OR_GENE_PRODUCT", 160, 168], ["eqFP611K", "PROTEIN", 160, 168], ["replica exchange simulations", "TREATMENT", 87, 115], ["Fluorescent Protein Variants", "TEST", 128, 156], ["Fluorescent Protein Variants", "OBSERVATION", 128, 156]]], ["Nienhaus 1 , H. Nar 2 , R. Heilker 2 , J. Wiedenmann 3 , G. U. Nienhaus 4 1 Inst. of Biophysics, Universit\u00e4t Ulm, Ulm, Germany, 2 Dept. of Lead Discovery, Boehringer Ingelheim, Biberach/Riss, Germany, 3 National Oceanography Center, University of Southampton, Southampton, UK, 4 Inst. of Applied Physics, Universit\u00e4t Karlsruhe (TH), Karlsruhe, Germany eqFP611 is a red fluorescent protein (RFP) with the chromophore in a co-planar trans orientation, whereas the cis isomer is preferred by most other RFPs.", [["eqFP611", "CHEMICAL", 352, 359], ["red fluorescent protein", "GENE_OR_GENE_PRODUCT", 365, 388], ["RFP", "GENE_OR_GENE_PRODUCT", 390, 393], ["cis isomer", "SIMPLE_CHEMICAL", 462, 472], ["RFPs", "SIMPLE_CHEMICAL", 500, 504], ["red fluorescent protein", "PROTEIN", 365, 388], ["RFP", "PROTEIN", 390, 393], ["RFPs", "PROTEIN", 500, 504], ["Riss", "TREATMENT", 186, 190], ["a red fluorescent protein", "PROBLEM", 363, 388], ["the chromophore", "TREATMENT", 400, 415]]], ["By using X-ray crystallography, we determined the structures of the dimeric variants d1eqFP611 and d2eqFP611 at high resolution (up to 1.1\u00c5).", [["d1eqFP611", "GENE_OR_GENE_PRODUCT", 85, 94], ["d2eqFP611", "AMINO_ACID", 99, 108], ["d2eqFP611", "PROTEIN", 99, 108], ["X-ray crystallography", "TEST", 9, 30]]], ["For d1eqFP611, we had previously seen a redshifted species upon irradiation with 532-nm light.", [["d1eqFP611", "PROTEIN", 4, 13], ["a redshifted species", "PROBLEM", 38, 58]]], ["Concomitant changes in the Raman spectrum were interpreted as evidence of a trans-cis isomerization of the chromophore.", [["Concomitant changes in the Raman spectrum", "PROBLEM", 0, 41], ["the chromophore", "TREATMENT", 103, 118]]], ["Here we have combined X-ray crystallography and site-directed mutagenesis to assess whether we can create a stable fluorescent, red-shifted eqFP611 variant with a cis chromophore.", [["eqFP611", "GENE_OR_GENE_PRODUCT", 140, 147], ["red-shifted eqFP611 variant", "PROTEIN", 128, 155], ["combined X-ray crystallography", "TEST", 13, 43], ["a stable fluorescent, red-shifted eqFP611 variant", "PROBLEM", 106, 155], ["a cis chromophore", "TREATMENT", 161, 178], ["stable", "OBSERVATION_MODIFIER", 108, 114]]], ["In a first step, we introduced the N143S substitution.", [["the N143S substitution", "TREATMENT", 31, 53]]], ["With an additional S158C mutation, the chromophore is found completely in the cis form.", [["S158C", "GENE_OR_GENE_PRODUCT", 19, 24], ["an additional S158C mutation", "TREATMENT", 5, 33]]], ["The variant, RFP639, is highly fluorescent, with excitation and emission maxima at 588 and 639 nm.", [["emission maxima", "TEST", 64, 79]]], ["Still further red shifts appear to be in reach.Structural basis of enhanced photoconversion yield in GFP-like protein Dendra2K.", [["GFP-like protein Dendra2K", "GENE_OR_GENE_PRODUCT", 101, 126], ["GFP", "PROTEIN", 101, 104], ["Dendra2K", "PROTEIN", 118, 126], ["further red shifts", "PROBLEM", 6, 24], ["enhanced photoconversion", "TEST", 67, 91], ["GFP", "TEST", 101, 104], ["red shifts", "OBSERVATION", 14, 24], ["enhanced photoconversion", "OBSERVATION", 67, 91], ["protein Dendra2K", "OBSERVATION", 110, 126]]], ["Nienhaus 1 , V. Adam 2 , D. Bourgeois 2 , G. U. Nienhaus 3 1 of Biophysics, Universit\u00e4t Ulm, Ulm, Germany, 2 ESRF, Grenoble, France, 3 Institute of Applied Physics, Universit\u00e4t Karlsruhe (TH), Karlsruhe, Germany Dendra2 is an engineered, monomeric GFP-like protein that belongs to a sub-class of fluorescent proteins undergoing irreversible photoconversion from a green-to a red-emitting state upon exposure to purple-blue light.", [["GFP", "GENE_OR_GENE_PRODUCT", 248, 251], ["monomeric GFP-like protein", "PROTEIN", 238, 264], ["fluorescent proteins", "PROTEIN", 296, 316], ["monomeric GFP", "TEST", 238, 251], ["fluorescent proteins", "PROBLEM", 296, 316], ["irreversible photoconversion", "TREATMENT", 328, 356], ["irreversible photoconversion", "OBSERVATION", 328, 356], ["blue light", "OBSERVATION_MODIFIER", 418, 428]]], ["This process occurs in the neutral state of the chromophore and is known to result from backbone cleavage accompanied by an extension of the delocalized \u03c0-electron system.", [["backbone cleavage", "PROBLEM", 88, 105], ["an extension of the delocalized \u03c0-electron system", "PROBLEM", 121, 170], ["backbone cleavage", "OBSERVATION", 88, 105], ["delocalized \u03c0-electron", "OBSERVATION", 141, 163]]], ["We have measured the X-ray structure of green Dendra2 and performed a comprehensive characterization of the optical absorption and fluorescence properties of the protein in both its green and red forms.", [["Dendra2", "GENE_OR_GENE_PRODUCT", 46, 53], ["green Dendra2", "PROTEIN", 40, 53], ["green and red forms", "PROTEIN", 182, 201], ["the protein", "TEST", 158, 169], ["green Dendra2", "OBSERVATION", 40, 53]]], ["The structure, which is very similar to those reported for the closely related proteins EosFP and Kaede, revealed a local structural change next to the chromophore, involving mainly Arg66 and a water molecule.", [["Arg66", "CHEMICAL", 182, 187], ["Arg66", "CHEMICAL", 182, 187], ["EosFP", "GENE_OR_GENE_PRODUCT", 88, 93], ["Arg66", "SIMPLE_CHEMICAL", 182, 187], ["EosFP", "PROTEIN", 88, 93], ["Kaede", "PROTEIN", 98, 103], ["Arg66", "PROTEIN", 182, 187], ["a local structural change", "PROBLEM", 114, 139], ["structure", "OBSERVATION_MODIFIER", 4, 13], ["local", "OBSERVATION_MODIFIER", 116, 121], ["structural change", "OBSERVATION", 122, 139], ["water molecule", "OBSERVATION", 194, 208]]], ["We propose that this structural change explains the blue shift of the absorption and emission bands, as well as the markedly higher pKs of the hydroxyphenyl moiety of the chromophore.", [["hydroxyphenyl", "CHEMICAL", 143, 156], ["hydroxyphenyl", "CHEMICAL", 143, 156], ["hydroxyphenyl moiety", "SIMPLE_CHEMICAL", 143, 163], ["this structural change", "PROBLEM", 16, 38], ["emission bands", "TEST", 85, 99], ["the chromophore", "TREATMENT", 167, 182], ["blue shift", "OBSERVATION", 52, 62]]], ["The 20-fold enhancement of the neutral species in Dendra2 at physiological pH accounts for the observed higher photoconversion yield of this protein in comparison to EosFP.O-535Photochromic green fluorescent protein mutants: chromophore states unveiled by Raman spectroscopy S. Luin, V. Voliani, G. Lanza, R. Bizzarri, R. Nifos\u00ec, P. Amat, V. Tozzini, M. Serresi, F. Beltram NEST, Scuola Normale Superiore, CNR-INFM and Italian Institute of Technology, Pisa, ItalyO-535The most widespread genetically-encodable fluorescent markers used for studies in living cells and tissues belong to the green fluorescent protein (GFP) family.", [["cells", "ANATOMY", 557, 562], ["tissues", "ANATOMY", 567, 574], ["Dendra2", "CHEMICAL", 50, 57], ["ItalyO-535", "CHEMICAL", 458, 468], ["EosFP.O-535Photochromic green", "CHEMICAL", 166, 195], ["Dendra2", "SIMPLE_CHEMICAL", 50, 57], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 190, 215], ["cells", "CELL", 557, 562], ["tissues", "TISSUE", 567, 574], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 589, 614], ["GFP", "GENE_OR_GENE_PRODUCT", 616, 619], ["Dendra2", "PROTEIN", 50, 57], ["EosFP.O-535Photochromic green fluorescent protein mutants", "PROTEIN", 166, 223], ["living cells", "CELL_TYPE", 550, 562], ["green fluorescent protein (GFP) family", "PROTEIN", 589, 627], ["the neutral species", "PROBLEM", 27, 46], ["this protein", "TEST", 136, 148], ["EosFP.O", "TEST", 166, 173], ["Raman spectroscopy", "TEST", 256, 274], ["fluorescent markers", "TEST", 510, 529], ["studies", "TEST", 539, 546], ["20-fold", "OBSERVATION_MODIFIER", 4, 11], ["neutral species", "OBSERVATION", 31, 46]]], ["Reversibly switchable fluorescent proteins (RSFPs) were developed that can undergo repeated transitions between different states, e.g. bright and dark forms.", [["Reversibly switchable fluorescent proteins", "GENE_OR_GENE_PRODUCT", 0, 42], ["Reversibly switchable fluorescent proteins", "PROTEIN", 0, 42], ["RSFPs", "PROTEIN", 44, 49], ["Reversibly switchable fluorescent proteins", "PROBLEM", 0, 42], ["RSFPs", "TEST", 44, 49], ["repeated transitions between different states", "PROBLEM", 83, 128], ["fluorescent proteins", "OBSERVATION", 22, 42]]], ["This property makes RSFPs particularly attractive as active labels in biological systems for selective photolabeling applications or subdiffraction imaging.", [["RSFPs", "SIMPLE_CHEMICAL", 20, 25], ["RSFPs", "PROBLEM", 20, 25], ["selective photolabeling applications", "TREATMENT", 93, 129], ["subdiffraction imaging", "TEST", 133, 155]]], ["We shall present pre-resonant Raman results unveiling the photophysical mechanism underlying the observed photochromic behavior.", [["photochromic behavior", "OBSERVATION", 106, 127]]], ["The variation of spectral properties before and after photoconversion of chemically-synthesized isolated chromophores under different protonation and/or isomerization have been analyzed, and compared to results obtained for the case of complete folded proteins comprising the same chromophores.", [["folded proteins", "PROTEIN", 245, 260], ["chemically-synthesized isolated chromophores", "TREATMENT", 73, 117], ["different protonation", "TREATMENT", 124, 145], ["complete folded proteins", "PROBLEM", 236, 260], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["spectral properties", "OBSERVATION_MODIFIER", 17, 36]]], ["These results make it possible to discriminate between the effect of cis-trans isomerization and of diverse protonation states of the chromophore in the photoproducts of these proteins.", [["cis-trans isomerization", "TREATMENT", 69, 92], ["diverse protonation states", "TREATMENT", 100, 126], ["the chromophore", "TREATMENT", 130, 145], ["diverse protonation", "OBSERVATION", 100, 119]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["R. Bizzarri et al., Anal.", [["Anal", "ANATOMY", 20, 24]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["393, 1107 -1122 .O-534A combined study of the interaction of outer membrane proteins with cephalosporin antibiotics M. Lovelle, I. Barroso, M. J. Feio, P. Gameiro REQUIMTE , Fac.", [["outer membrane", "ANATOMY", 61, 75], ["cephalosporin", "CHEMICAL", 90, 103], ["cephalosporin", "CHEMICAL", 90, 103], ["outer membrane", "CELLULAR_COMPONENT", 61, 75], ["cephalosporin", "SIMPLE_CHEMICAL", 90, 103], ["outer membrane proteins", "PROTEIN", 61, 84], ["outer membrane proteins", "TREATMENT", 61, 84], ["cephalosporin antibiotics", "TREATMENT", 90, 115]]], ["Ci\u00eancias, Universidade do Porto, Portugal Gram-negative bacteria characteristically are protected by an outer membrane that serves as a selective permeation barrier.", [["outer membrane", "ANATOMY", 104, 118], ["outer membrane", "CELLULAR_COMPONENT", 104, 118], ["Portugal Gram", "TEST", 33, 46], ["bacteria", "PROBLEM", 56, 64], ["a selective permeation barrier", "TREATMENT", 134, 164], ["bacteria characteristically", "OBSERVATION_MODIFIER", 56, 83]]], ["Most of the \u03b2-lactam antibiotics appear to penetrate the outer membrane through these non-specific channels, and it becomes important to understand the possible interactions between \u03b2-lactams and the porin.", [["outer membrane", "ANATOMY", 57, 71], ["\u03b2-lactam", "CHEMICAL", 12, 20], ["\u03b2-lactam", "CHEMICAL", 12, 20], ["\u03b2-lactam antibiotics", "SIMPLE_CHEMICAL", 12, 32], ["outer membrane", "CELLULAR_COMPONENT", 57, 71], ["\u03b2-lactams", "SIMPLE_CHEMICAL", 182, 191], ["porin", "GENE_OR_GENE_PRODUCT", 200, 205], ["\u03b2-lactams", "PROTEIN", 182, 191], ["porin", "PROTEIN", 200, 205], ["the \u03b2-lactam antibiotics", "TREATMENT", 8, 32], ["the porin", "TREATMENT", 196, 205], ["outer membrane", "ANATOMY", 57, 71]]], ["Fluorescence techniques have been largely used to characterize both the conformation and the dynamic behavior of large biological structures such as membranes and proteins.", [["membranes", "ANATOMY", 149, 158], ["membranes", "CELLULAR_COMPONENT", 149, 158], ["Fluorescence techniques", "TREATMENT", 0, 23], ["large", "OBSERVATION_MODIFIER", 113, 118]]], ["The fluorescence of the tryptophan residues is quenched in the presence of the different cephalosporin antibiotics.", [["tryptophan", "CHEMICAL", 24, 34], ["cephalosporin", "CHEMICAL", 89, 102], ["tryptophan", "CHEMICAL", 24, 34], ["cephalosporin", "CHEMICAL", 89, 102], ["tryptophan", "AMINO_ACID", 24, 34], ["cephalosporin", "SIMPLE_CHEMICAL", 89, 102], ["the tryptophan residues", "TREATMENT", 20, 43], ["the different cephalosporin antibiotics", "TREATMENT", 75, 114], ["tryptophan residues", "OBSERVATION", 24, 43], ["cephalosporin antibiotics", "OBSERVATION", 89, 114]]], ["This reaction between the excited state of the fluorophores and the drug can be described as a formation of a non-fluorescent complex.", [["non-fluorescent complex", "PROTEIN", 110, 133], ["This reaction", "PROBLEM", 0, 13], ["the fluorophores", "TREATMENT", 43, 59], ["a non-fluorescent complex", "PROBLEM", 108, 133]]], ["The dependence of the fluorescence intensity upon quencher concentration for static quenching is proportional to the binding constant for complex formation.", [["quencher", "CHEMICAL", 50, 58], ["the fluorescence intensity", "PROBLEM", 18, 44], ["quencher concentration", "TREATMENT", 50, 72], ["static quenching", "PROBLEM", 77, 93], ["dependence", "OBSERVATION_MODIFIER", 4, 14]]], ["Since \u03b2-lactam susceptibility is closely related to the presence of these non-specific porins, Minimum inhibitory concentration (MIC) by micro-broth dilution in microplate were used to assess the bactericidal activity of cephalosporin antibiotics upon on Escherichia coli strain BL21(DE3 ) and a series of BL21(DE3) mutated in different outer membrane proteins.", [["outer membrane", "ANATOMY", 337, 351], ["\u03b2-lactam", "CHEMICAL", 6, 14], ["cephalosporin", "CHEMICAL", 221, 234], ["\u03b2-lactam", "CHEMICAL", 6, 14], ["cephalosporin", "CHEMICAL", 221, 234], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 6, 14], ["cephalosporin", "SIMPLE_CHEMICAL", 221, 234], ["Escherichia coli", "ORGANISM", 255, 271], ["strain BL21", "ORGANISM", 272, 283], ["DE3", "GENE_OR_GENE_PRODUCT", 284, 287], ["BL21", "GENE_OR_GENE_PRODUCT", 306, 310], ["DE3", "GENE_OR_GENE_PRODUCT", 311, 314], ["outer membrane", "CELLULAR_COMPONENT", 337, 351], ["DE3", "PROTEIN", 284, 287], ["BL21", "PROTEIN", 306, 310], ["DE3", "PROTEIN", 311, 314], ["outer membrane proteins", "PROTEIN", 337, 360], ["Escherichia coli strain BL21", "SPECIES", 255, 283], ["Escherichia coli strain BL21", "SPECIES", 255, 283], ["BL21", "SPECIES", 306, 310], ["DE3", "SPECIES", 311, 314], ["\u03b2-lactam susceptibility", "PROBLEM", 6, 29], ["these non-specific porins", "PROBLEM", 68, 93], ["Minimum inhibitory concentration (MIC)", "TREATMENT", 95, 133], ["micro-broth dilution in microplate", "TREATMENT", 137, 171], ["cephalosporin antibiotics", "TREATMENT", 221, 246], ["Escherichia coli strain BL21", "TREATMENT", 255, 283], ["a series of BL21(DE3", "TREATMENT", 294, 314], ["bactericidal activity", "OBSERVATION", 196, 217], ["membrane proteins", "OBSERVATION", 343, 360]]], ["This combined study of the interactions at single molecular level and at in vivo level provides new insights for a better understanding of the antibiotic translocation.", [["This combined study", "TEST", 0, 19], ["the antibiotic translocation", "TREATMENT", 139, 167]]], ["When used in combination with e.g. a cyan fluorescent protein, Keima offers the unique opportunity to perform dual color fluorescence cross-correlation spectroscopy using a single laser line to excite both fluorophores.", [["cyan fluorescent protein", "PROTEIN", 37, 61], ["dual color fluorescence cross-correlation spectroscopy", "TEST", 110, 164], ["a single laser line", "TREATMENT", 171, 190]]], ["The molecular determinants of the large Stokes shift of mKeima have been characterized structurally by combining X-ray crystallography with in crystallo UV-visible absorption, fluorescence and Raman spectroscopy.", [["mKeima", "PROTEIN", 56, 62], ["the large Stokes", "PROBLEM", 30, 46], ["combining X-ray crystallography", "TEST", 103, 134], ["crystallo UV", "TREATMENT", 143, 155], ["Raman spectroscopy", "TEST", 193, 211], ["large", "OBSERVATION_MODIFIER", 34, 39], ["Stokes", "OBSERVATION", 40, 46]]], ["Our results reveal a pH-dependant \"reverse chromophore protonation\" of mKeima, driven by the key residue Asp157.", [["Asp157", "CHEMICAL", 105, 111], ["Asp", "CHEMICAL", 105, 108], ["Asp157", "AMINO_ACID", 105, 111], ["mKeima", "PROTEIN", 71, 77], ["a pH", "PROBLEM", 19, 23], ["mKeima", "PROBLEM", 71, 77], ["Asp", "TEST", 105, 108], ["chromophore protonation", "OBSERVATION", 43, 66]]], ["Moreover, the chromophore protonation state is shown to be coupled with different chromophore conformations, cis conformation at pH 3.8, and mostly trans conformation at pH 8.0.", [["the chromophore protonation state", "TEST", 10, 43], ["pH", "TEST", 129, 131], ["pH", "TEST", 170, 172]]], ["These results will help unravel the mechanisms of fluorescence in FPs, which is of importance to rationally design and develop new fluorescent markers.", [["fluorescence in FPs", "TEST", 50, 69], ["new fluorescent markers", "PROBLEM", 127, 150]]], ["Recently reversibly switchable fluorescent proteins (RSFPs) have become a new branch of the green fluorescent protein (GFP) like family.", [["reversibly switchable fluorescent proteins", "GENE_OR_GENE_PRODUCT", 9, 51], ["RSFPs", "GENE_OR_GENE_PRODUCT", 53, 58], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 92, 117], ["GFP", "GENE_OR_GENE_PRODUCT", 119, 122], ["reversibly switchable fluorescent proteins", "PROTEIN", 9, 51], ["RSFPs", "PROTEIN", 53, 58], ["green fluorescent protein (GFP) like family", "PROTEIN", 92, 135], ["Recently reversibly switchable fluorescent proteins (RSFPs", "PROBLEM", 0, 58], ["switchable", "OBSERVATION_MODIFIER", 20, 30], ["fluorescent proteins", "OBSERVATION", 31, 51], ["new", "OBSERVATION_MODIFIER", 74, 77], ["branch", "OBSERVATION_MODIFIER", 78, 84]]], ["The RSFPs may be reversibly switched between a fluorescent and a non-fluorescent state by irradiation with light of distinct wavelengths.", [["RSFPs", "SIMPLE_CHEMICAL", 4, 9], ["The RSFPs", "TEST", 0, 9]]], ["The proteins are becoming increasingly important for diverse applications like protein tracking, sub-diffraction resolution microscopy and data storage.", [["diverse applications", "TREATMENT", 53, 73], ["protein tracking", "TEST", 79, 95], ["diffraction resolution microscopy", "TEST", 101, 134], ["data storage", "TEST", 139, 151]]], ["Based on the switching mechanism, we created novel RSFPs with unique and improved characteristics.", [["improved", "OBSERVATION_MODIFIER", 73, 81]]], ["Padron and bs-Dronpa are two of these new switchable proteins.", [["Padron", "CHEMICAL", 0, 6], ["Padron", "CHEMICAL", 0, 6], ["Padron", "SIMPLE_CHEMICAL", 0, 6], ["bs-Dronpa", "SIMPLE_CHEMICAL", 11, 20], ["switchable proteins", "PROTEIN", 42, 61], ["Padron", "TEST", 0, 6], ["bs", "TEST", 11, 13], ["these new switchable proteins", "PROBLEM", 32, 61], ["bs", "ANATOMY", 11, 13], ["new", "OBSERVATION_MODIFIER", 38, 41], ["switchable proteins", "OBSERVATION", 42, 61]]], ["Padron features a reversed switching mechanism as compared to all other green RSFPs known to date while bsDronpa exhibits a very broad absorption spectrum extending into the UV.", [["Padron", "CHEMICAL", 0, 6], ["bsDronpa", "CHEMICAL", 104, 112], ["Padron", "SIMPLE_CHEMICAL", 0, 6], ["bsDronpa", "SIMPLE_CHEMICAL", 104, 112], ["green RSFPs", "PROTEIN", 72, 83], ["bsDronpa", "PROTEIN", 104, 112], ["a reversed switching mechanism", "PROBLEM", 16, 46], ["all other green RSFPs", "PROBLEM", 62, 83], ["a very broad absorption spectrum", "PROBLEM", 122, 154], ["UV", "ANATOMY", 174, 176]]], ["Further, we recently introduced the first monomeric RSFP exhibiting red fluorescence: Using a semi rational mutagenesis approach on the non-switchable mCherry, we generated the switchable monomeric protein rsCherryRev.", [["RSFP", "GENE_OR_GENE_PRODUCT", 52, 56], ["mCherry", "GENE_OR_GENE_PRODUCT", 151, 158], ["rsCherryRev", "GENE_OR_GENE_PRODUCT", 206, 217], ["monomeric RSFP", "PROTEIN", 42, 56], ["switchable monomeric protein", "PROTEIN", 177, 205], ["rsCherryRev", "PROTEIN", 206, 217], ["the switchable monomeric protein rsCherryRev", "TREATMENT", 173, 217]]], ["The use of this protein in single molecule switching microscopy allowed us to record time-lapse live-cell images of the endoplasmic reticulum with sub-diffraction resolution.O-539A spectroscopic approach to the study of chromophoric dissolved organic matter (CDOM) in the sea C. Santinelli, R. Lavezza, L. Nannicini, A. Seritti CNR-IBF, Via Moruzzi 1, 56124 Pisa, Italy Dissolved organic matter (DOM) in the Ocean represents the largest reservoir of reactive carbon on the Earth.", [["cell", "ANATOMY", 101, 105], ["endoplasmic reticulum", "ANATOMY", 120, 141], ["Moruzzi 1, 56124 Pisa", "CHEMICAL", 341, 362], ["DOM", "CHEMICAL", 396, 399], ["O-539A", "CHEMICAL", 174, 180], ["carbon", "CHEMICAL", 459, 465], ["cell", "CELL", 101, 105], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 120, 141], ["chromophoric dissolved organic matter", "SIMPLE_CHEMICAL", 220, 257], ["carbon", "SIMPLE_CHEMICAL", 459, 465], ["this protein", "TREATMENT", 11, 23], ["the study", "TEST", 207, 216], ["chromophoric dissolved organic matter", "PROBLEM", 220, 257], ["endoplasmic reticulum", "ANATOMY", 120, 141], ["sub", "OBSERVATION_MODIFIER", 147, 150], ["organic matter", "OBSERVATION", 243, 257], ["R.", "ANATOMY", 291, 293], ["organic matter", "OBSERVATION", 380, 394], ["largest", "OBSERVATION_MODIFIER", 429, 436], ["reactive carbon", "OBSERVATION", 450, 465]]], ["It is produce at each level of the marine food web and it represents the food for heterotrophic bacteria, which can use the different pools of DOM (labile, semi-labile, refractory) with a large range of turn-over times (from minutes to millennia).", [["DOM", "CHEMICAL", 143, 146], ["DOM", "SIMPLE_CHEMICAL", 143, 146], ["heterotrophic bacteria", "PROBLEM", 82, 104], ["large", "OBSERVATION_MODIFIER", 188, 193]]], ["DOM plays a central role in the global carbon cycle and it has a high ecological significance.", [["DOM", "CHEMICAL", 0, 3], ["carbon", "CHEMICAL", 39, 45], ["central", "OBSERVATION_MODIFIER", 12, 19]]], ["Chromophoric DOM (CDOM) is the fraction of DOM capable of adsorbing light at UV and visible spectral regions.", [["DOM", "CHEMICAL", 13, 16], ["CDOM", "CHEMICAL", 18, 22], ["DOM", "CHEMICAL", 43, 46], ["Chromophoric DOM", "SIMPLE_CHEMICAL", 0, 16], ["CDOM", "SIMPLE_CHEMICAL", 18, 22], ["DOM", "SIMPLE_CHEMICAL", 43, 46], ["Chromophoric DOM (CDOM", "PROBLEM", 0, 22], ["visible", "ANATOMY_MODIFIER", 84, 91], ["spectral", "ANATOMY_MODIFIER", 92, 100], ["regions", "ANATOMY_MODIFIER", 101, 108]]], ["It determines the underwater light availability in open and coastal regions with important implication on primary production and biological activity.", [["open and coastal regions", "TREATMENT", 51, 75], ["primary production", "TREATMENT", 106, 124], ["coastal", "ANATOMY_MODIFIER", 60, 67]]], ["It is photodegraded to CO 2 , CO, with a significant impact on the role of the Ocean as source and/or sink of atmospheric CO 2 and to highly reactive compounds, dangerous for marine organisms.", [["CO 2", "CHEMICAL", 23, 27], ["CO", "CHEMICAL", 30, 32], ["CO 2", "CHEMICAL", 122, 126], ["CO 2", "SIMPLE_CHEMICAL", 23, 27], ["CO", "SIMPLE_CHEMICAL", 30, 32], ["CO", "TEST", 23, 25], ["CO", "TEST", 30, 32], ["atmospheric CO", "TEST", 110, 124], ["highly reactive compounds", "PROBLEM", 134, 159], ["marine organisms", "PROBLEM", 175, 191], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["impact", "OBSERVATION", 53, 59], ["reactive compounds", "OBSERVATION", 141, 159]]], ["In its pool \"humic-like\" and \"protein-like\" fluorophores have been individuated.", [["\"protein-like\" fluorophores", "PROBLEM", 29, 56]]], ["CDOM optical properties (absorption and fluorescence) together with DOC data collected in some key regions of the Mediterranean Sea will be presented and discussed, in order to (i) investigate the powerful of CDOM optical properties to get information on CDOM \"quality\" (i) asses the role of DOM in carbon export at depth, (iii) underline the main unresolved question on DOM and CDOM dynamics in the Ocean, with particular emphasis to their biological lability.P-538Mechanism and applications of photo-and redox-switchable fluorescent proteins S. J. Remington, J. N. Henderson, X. Shu, J. Lohman Institute of Molecular Biology, University of Oregon, U.S.A.P-538Photoswitchable fluorescent proteins have significant advantages over conventional fluorescent labels, and in a revolutionary application, now allow cell biologists to exceed the diffraction limit in light microscopy by a factor of ten.", [["cell", "ANATOMY", 810, 814], ["DOC", "CHEMICAL", 68, 71], ["DOM", "CHEMICAL", 292, 295], ["P-538Mechanism", "CHEMICAL", 461, 475], ["DOC", "CHEMICAL", 68, 71], ["carbon", "CHEMICAL", 299, 305], ["DOC", "SIMPLE_CHEMICAL", 68, 71], ["DOM", "SIMPLE_CHEMICAL", 292, 295], ["carbon", "SIMPLE_CHEMICAL", 299, 305], ["CDOM", "SIMPLE_CHEMICAL", 379, 383], ["cell", "CELL", 810, 814], ["DOC data", "TEST", 68, 76], ["DOM", "PROBLEM", 371, 374], ["P", "TEST", 461, 462], ["photo", "TREATMENT", 496, 501], ["U.S.A.P", "TEST", 650, 657], ["a revolutionary application", "TREATMENT", 771, 798], ["light microscopy", "TEST", 861, 877], ["significant", "OBSERVATION_MODIFIER", 703, 714]]], ["Atomic resolution crystal structures and time resolved spectroscopy of both reversible (mTFP0.7) and irreversible (PA-GFP) photoswitchable fluorescent proteins in the light and dark states explain the long term stability of either state, as well as how illumination at the appropriate wavelength causes the molecules to switch between states.", [["PA-GFP", "GENE_OR_GENE_PRODUCT", 115, 121], ["GFP", "PROTEIN", 118, 121], ["photoswitchable fluorescent proteins", "PROTEIN", 123, 159], ["Atomic resolution crystal structures", "PROBLEM", 0, 36], ["spectroscopy", "TEST", 55, 67], ["both reversible (mTFP0.7) and irreversible (PA-GFP) photoswitchable fluorescent proteins", "PROBLEM", 71, 159], ["resolution", "OBSERVATION_MODIFIER", 7, 17], ["crystal structures", "OBSERVATION", 18, 36], ["both", "OBSERVATION_MODIFIER", 71, 75], ["reversible", "OBSERVATION_MODIFIER", 76, 86], ["irreversible", "OBSERVATION_MODIFIER", 101, 113], ["long term stability", "OBSERVATION_MODIFIER", 201, 220]]], ["The photoswitching mechanisms will be discussed in terms of photochemistry, light induced chromophore isomerization and excited state proton transfer (ESPT).", [["light induced chromophore isomerization", "TREATMENT", 76, 115]]], ["Mutagenesis of ESPT pathways provide insight into the nature of the ratedetermining steps in proton transfer and lead to practical applications, such as redox-sensitive GFP biosensors.STED nanoscopy in living cells using fluorescent proteinsK.", [["cells", "ANATOMY", 209, 214], ["ESPT", "GENE_OR_GENE_PRODUCT", 15, 19], ["proton", "SIMPLE_CHEMICAL", 93, 99], ["GFP", "GENE_OR_GENE_PRODUCT", 169, 172], ["cells", "CELL", 209, 214], ["fluorescent proteinsK", "PROTEIN", 221, 242], ["Mutagenesis of ESPT pathways", "PROBLEM", 0, 28], ["proton transfer", "TREATMENT", 93, 108], ["practical applications", "TREATMENT", 121, 143], ["STED nanoscopy", "TEST", 184, 198], ["fluorescent proteinsK", "TEST", 221, 242]]], ["I. Willig, B. Hein, S. W. Hell Max-Planck-Institute for Biophysical Chemistry, Goettingen, Germany Stimulated Emission Depletion (STED) nanoscopy is a light microscopic technique offering a resolution far beyond the diffraction limit: The excitation beam is overlapped with a doughnut-shaped, red-shifted STED beam, which switches off the ability of the molecules to fluoresce in the outer region of the excitation spot.", [["Germany Stimulated Emission Depletion (STED) nanoscopy", "TREATMENT", 91, 145], ["a light microscopic technique", "TREATMENT", 149, 178], ["a doughnut-shaped, red-shifted STED beam", "TREATMENT", 274, 314], ["shaped", "OBSERVATION_MODIFIER", 285, 291], ["outer", "ANATOMY_MODIFIER", 384, 389], ["excitation spot", "OBSERVATION", 404, 419]]], ["Scanning the nanosized focal spot through the sample renders sub-diffraction images with a sub-second frame rate.", [["sample", "ANATOMY", 46, 52], ["Scanning the nanosized focal spot", "TEST", 0, 33], ["the sample", "TEST", 42, 52], ["diffraction images", "TEST", 65, 83], ["nanosized", "OBSERVATION_MODIFIER", 13, 22], ["focal", "OBSERVATION_MODIFIER", 23, 28]]], ["We used the yellow fluorescent protein Citrine to image individual structural elements of living mammalian cells: Vimentin and the tubular network, structures of the cytoskeleton, were recorded with a lateral (x,y) resolution < 50 nm inside the living cell, corresponding to a 4-fold improvement over that of a confocal microscope.", [["mammalian cells", "ANATOMY", 97, 112], ["tubular network", "ANATOMY", 131, 146], ["structures", "ANATOMY", 148, 158], ["cytoskeleton", "ANATOMY", 166, 178], ["cell", "ANATOMY", 252, 256], ["Citrine", "SIMPLE_CHEMICAL", 39, 46], ["mammalian cells", "CELL", 97, 112], ["Vimentin", "GENE_OR_GENE_PRODUCT", 114, 122], ["tubular network", "MULTI-TISSUE_STRUCTURE", 131, 146], ["cytoskeleton", "CELLULAR_COMPONENT", 166, 178], ["cell", "CELL", 252, 256], ["yellow fluorescent protein", "PROTEIN", 12, 38], ["Citrine", "PROTEIN", 39, 46], ["living mammalian cells", "CELL_TYPE", 90, 112], ["Vimentin", "PROTEIN", 114, 122], ["the yellow fluorescent protein Citrine", "TREATMENT", 8, 46], ["Vimentin", "TREATMENT", 114, 122], ["a confocal microscope", "TEST", 309, 330], ["tubular network", "OBSERVATION", 131, 146], ["cytoskeleton", "ANATOMY_MODIFIER", 166, 178], ["living cell", "OBSERVATION", 245, 256], ["4-fold", "OBSERVATION_MODIFIER", 277, 283]]], ["Also, time lapse STED imaging of dendritic spines of YFPpositive hippocampal neurons in organotypic slices outperforms confocal microscopy in revealing important structural details.STED nanoscopy in living cells using fluorescent proteinsAs an alternative to fluorescent proteins we used a genetically encoded protein tag which can be labelled with modified organic dyes within living samples.", [["dendritic spines", "ANATOMY", 33, 49], ["hippocampal neurons", "ANATOMY", 65, 84], ["organotypic slices", "ANATOMY", 88, 106], ["cells", "ANATOMY", 206, 211], ["samples", "ANATOMY", 385, 392], ["dendritic spines", "MULTI-TISSUE_STRUCTURE", 33, 49], ["YFPpositive hippocampal neurons", "CELL", 53, 84], ["STED", "SIMPLE_CHEMICAL", 181, 185], ["cells", "CELL", 206, 211], ["YFPpositive hippocampal neurons", "CELL_TYPE", 53, 84], ["fluorescent proteins", "PROTEIN", 218, 238], ["fluorescent proteins", "PROTEIN", 259, 279], ["genetically encoded protein tag", "PROTEIN", 290, 321], ["STED imaging", "TEST", 17, 29], ["confocal microscopy", "TEST", 119, 138], ["STED nanoscopy", "TEST", 181, 195], ["fluorescent proteins", "TEST", 218, 238], ["fluorescent proteins", "TEST", 259, 279], ["a genetically encoded protein tag", "TREATMENT", 288, 321], ["modified organic dyes", "TREATMENT", 349, 370], ["dendritic spines", "OBSERVATION", 33, 49], ["hippocampal neurons", "ANATOMY", 65, 84]]], ["Thus nanoscale imaging of structures in the interior of living cells greatly expands the scope of light microscopy in cell biology.O-541Pulling membrane tubes from solid-supported lipid bilayers with atomic force microscopy J. W. Armond 1 , J. V. Macpherson 2 , M. S. Turner 1 1 Department of Physics, University of Warwick, U.K., 2 Department of Chemistry, University of Warwick, U.K.O-541Information on the elastic and dynamic properties of membranes is essential for a thorough understanding of biological processes such as exocytosis, endocytosis, cell division, and pore formation.", [["cells", "ANATOMY", 63, 68], ["cell", "ANATOMY", 118, 122], ["membranes", "ANATOMY", 443, 452], ["cell", "ANATOMY", 552, 556], ["pore", "ANATOMY", 571, 575], ["O-541Pulling", "CHEMICAL", 131, 143], ["U.K.O-541Information", "CHEMICAL", 381, 401], ["O-541Pulling", "CHEMICAL", 131, 143], ["cells", "CELL", 63, 68], ["cell", "CELL", 118, 122], ["membranes", "CELLULAR_COMPONENT", 443, 452], ["cell", "CELL", 552, 556], ["pore", "CELLULAR_COMPONENT", 571, 575], ["nanoscale imaging", "TEST", 5, 22], ["light microscopy", "TEST", 98, 114], ["membrane tubes", "TREATMENT", 144, 158], ["tubes", "OBSERVATION", 153, 158], ["cell division", "OBSERVATION", 552, 565]]], ["We use an atomic force microscope to pull on solid-supported lipid bilayers and observe that an energy barrier must be overcome prior to the formation of membrane tubes.", [["membrane tubes", "ANATOMY", 154, 168], ["lipid bilayers", "SIMPLE_CHEMICAL", 61, 75], ["membrane tubes", "CELLULAR_COMPONENT", 154, 168], ["an atomic force microscope", "TREATMENT", 7, 33], ["solid-supported lipid bilayers", "TREATMENT", 45, 75], ["an energy barrier", "TREATMENT", 93, 110], ["membrane tubes", "TREATMENT", 154, 168], ["membrane tubes", "OBSERVATION", 154, 168]]], ["We have modified elastic models of lipid bilayer vesicles to describe the free energy of a planar lipid bilayer in adhesive contact with a surface.", [["lipid bilayer vesicles", "ANATOMY", 35, 57], ["surface", "ANATOMY", 139, 146], ["surface", "CELLULAR_COMPONENT", 139, 146], ["modified elastic models of lipid bilayer vesicles", "TREATMENT", 8, 57], ["a planar lipid bilayer", "TREATMENT", 89, 111], ["elastic", "OBSERVATION_MODIFIER", 17, 24], ["free energy", "OBSERVATION", 74, 85], ["adhesive contact", "OBSERVATION", 115, 131]]], ["From this model we are able to extract force-distance curves for the formation of a membrane tether, including the associated energy barrier.", [["membrane", "ANATOMY", 84, 92], ["membrane", "CELLULAR_COMPONENT", 84, 92], ["a membrane tether", "TREATMENT", 82, 99]]], ["This work enables the atomic force microscope as a quantitative instrument for measuring membrane pulling mechanics, and in future work will allow two-dimensional mapping of elastic properties under tension.O-545From pores to micelles -a peptide-membrane interaction study T. L. Andresen, J. R. Henriksen Technical University of Denmark, DTU Nanotech, Frederiksborgvej 399, B124, 4000 Roskilde, Denmark.", [["membrane", "ANATOMY", 89, 97], ["membrane", "ANATOMY", 246, 254], ["O-545", "CHEMICAL", 207, 212], ["O-545", "CHEMICAL", 207, 212], ["micelles", "SIMPLE_CHEMICAL", 226, 234], ["T. L.", "SPECIES", 273, 278], ["the atomic force microscope", "TEST", 18, 45], ["measuring membrane pulling mechanics", "TREATMENT", 79, 115], ["elastic properties", "OBSERVATION", 174, 192], ["tension", "OBSERVATION", 199, 206]]], ["Research in the partitioning of peptides into lipid membranes has been intense for several years.", [["lipid membranes", "ANATOMY", 46, 61], ["lipid membranes", "CELLULAR_COMPONENT", 46, 61], ["intense", "OBSERVATION_MODIFIER", 71, 78]]], ["Along with scattering techniques and NMR, isothermal titration calorimetry (ITC) has proven to be a powerful tool for thermodynamic characterization of peptide-membrane interactions.", [["membrane", "ANATOMY", 160, 168], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["scattering techniques", "TEST", 11, 32], ["NMR", "TEST", 37, 40], ["isothermal titration calorimetry", "TEST", 42, 74], ["thermodynamic characterization", "TEST", 118, 148]]], ["We have studied two antimicrobial peptides, mastoparan-X and melittin, and found that these peptides induce a range of structural transitions of POPC and POPC/POPG membrane systems at different peptide-lipid ratios.", [["membrane", "ANATOMY", 164, 172], ["mastoparan", "CHEMICAL", 44, 54], ["melittin", "CHEMICAL", 61, 69], ["POPC", "CHEMICAL", 145, 149], ["POPC", "CHEMICAL", 154, 158], ["mastoparan-X", "SIMPLE_CHEMICAL", 44, 56], ["melittin", "SIMPLE_CHEMICAL", 61, 69], ["POPC", "SIMPLE_CHEMICAL", 145, 149], ["POPC", "SIMPLE_CHEMICAL", 154, 158], ["lipid", "SIMPLE_CHEMICAL", 202, 207], ["two antimicrobial peptides", "TREATMENT", 16, 42], ["mastoparan", "TREATMENT", 44, 54], ["melittin", "TREATMENT", 61, 69], ["these peptides", "PROBLEM", 86, 100], ["POPC", "TEST", 145, 149], ["POPC/POPG membrane systems", "TREATMENT", 154, 180], ["lipid ratios", "TEST", 202, 214]]], ["We have found that ITC can be used to elucidate the threshold where transitions occur, including the threshold for pore formation and micellation.", [["pore", "ANATOMY", 115, 119], ["ITC", "CELL", 19, 22], ["pore", "CELLULAR_COMPONENT", 115, 119]]], ["This has been achieved using a thermodynamic model based on Gouy-Chapman theory, which provides the partitioning constant of the peptide-membrane interaction and thereby the concentration of peptide on the membrane surface.", [["membrane", "ANATOMY", 137, 145], ["membrane surface", "ANATOMY", 206, 222], ["membrane", "CELLULAR_COMPONENT", 137, 145], ["membrane surface", "CELLULAR_COMPONENT", 206, 222], ["the peptide-membrane interaction", "TREATMENT", 125, 157], ["the concentration of peptide on the membrane surface", "TREATMENT", 170, 222]]], ["The structural changes have furthermore been visualized by cryo-TEM.", [["The structural changes", "PROBLEM", 0, 22]]], ["We have further investigated the pore formation in detail and found that the thermodynamic parameters of pore formation can be fully characterized using a system specific temperature where the enthalpy of peptide partitioning becomes zero.", [["pore", "ANATOMY", 33, 37], ["pore", "ANATOMY", 105, 109], ["pore", "CELLULAR_COMPONENT", 33, 37], ["pore", "CELLULAR_COMPONENT", 105, 109], ["the enthalpy of peptide partitioning", "TREATMENT", 189, 225]]], ["This allows for an exclusive study of the pore formation process.", [["pore", "ANATOMY", 42, 46], ["pore", "CELLULAR_COMPONENT", 42, 46], ["an exclusive study", "TEST", 16, 34], ["pore formation", "OBSERVATION", 42, 56]]], ["Lactoferrin is a glycoprotein with two globular lobes, with of two domains each.", [["globular lobes", "ANATOMY", 39, 53], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["Lactoferrin", "PROTEIN", 0, 11], ["glycoprotein", "PROTEIN", 17, 29], ["Lactoferrin", "TREATMENT", 0, 11], ["a glycoprotein with two globular lobes", "TREATMENT", 15, 53], ["globular", "OBSERVATION_MODIFIER", 39, 47], ["lobes", "OBSERVATION_MODIFIER", 48, 53]]], ["Since its discovery, the research on antimicrobial properties has been extended to peptides derived from this protein.", [["antimicrobial properties", "TREATMENT", 37, 61]]], ["The largest family studied so far is known as lactoferricin B, obtained from the protein by digestion with pepsin.", [["lactoferricin B", "CHEMICAL", 46, 61], ["lactoferricin B", "CHEMICAL", 46, 61], ["lactoferricin B", "GENE_OR_GENE_PRODUCT", 46, 61], ["pepsin", "GENE_OR_GENE_PRODUCT", 107, 113], ["lactoferricin B", "PROTEIN", 46, 61], ["pepsin", "PROTEIN", 107, 113], ["lactoferricin B", "TREATMENT", 46, 61], ["pepsin", "TREATMENT", 107, 113], ["largest", "OBSERVATION_MODIFIER", 4, 11]]], ["More recently, a new family of antimicrobial peptides derived from Lactoferrin was discovered by Bolcher et al and named Lactoferrampin (LFampin).", [["Lactoferrampin", "CHEMICAL", 121, 135], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 67, 78], ["Lactoferrampin", "SIMPLE_CHEMICAL", 121, 135], ["LFampin", "SIMPLE_CHEMICAL", 137, 144], ["antimicrobial peptides", "TREATMENT", 31, 53], ["Lactoferrin", "TREATMENT", 67, 78], ["Lactoferrampin (LFampin)", "TREATMENT", 121, 145]]], ["The original sequence of LFampin contained residues 268-284 from the N1 domain of Lactoferrin.", [["LFampin", "CHEMICAL", 25, 32], ["residues 268-284", "CHEMICAL", 43, 59], ["LFampin", "GENE_OR_GENE_PRODUCT", 25, 32], ["268-284", "AMINO_ACID", 52, 59], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 82, 93], ["LFampin", "DNA", 25, 32], ["N1 domain", "PROTEIN", 69, 78], ["Lactoferrin", "PROTEIN", 82, 93], ["Lactoferrin", "TREATMENT", 82, 93]]], ["We studied 3 peptides derived from LFampin obtained by extension and/or truncation at the C-or N-terminal sides, keeping the essential characteristics, in order to unravel the main structural features responsible for antimicrobial action.", [["LFampin", "CHEMICAL", 35, 42], ["C", "CHEMICAL", 90, 91], ["N", "CHEMICAL", 95, 96], ["LFampin", "GENE_OR_GENE_PRODUCT", 35, 42], ["C-or N-terminal sides", "PROTEIN", 90, 111], ["LFampin", "TREATMENT", 35, 42], ["truncation", "PROBLEM", 72, 82], ["antimicrobial action", "TREATMENT", 217, 237]]], ["The peptides were tested against model membranes.", [["membranes", "ANATOMY", 39, 48], ["membranes", "CELLULAR_COMPONENT", 39, 48], ["The peptides", "TREATMENT", 0, 12]]], ["The ability to adopt helical conformation was followed by CD, the perturbation of the membrane phase transition by DSC, the energetics of interaction by Isothermal Titration Calorimetry (ITC), the partition of the peptide to the membrane by TRFS and the importance of charge effects assessed by Zeta Potential measurements.", [["membrane", "ANATOMY", 86, 94], ["membrane", "ANATOMY", 229, 237], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["membrane", "CELLULAR_COMPONENT", 229, 237], ["Isothermal Titration Calorimetry (ITC)", "TREATMENT", 153, 191], ["the partition of the peptide", "TREATMENT", 193, 221]]], ["The results are discussed and compared to the antimicrobial and hemolytic activities obtained by Microbiology techniques.", [["hemolytic", "DISEASE", 64, 73], ["the antimicrobial", "TEST", 42, 59], ["hemolytic activities", "TEST", 64, 84]]], ["Defensins are small cysteine-rich cationic proteins or peptides found in both vertebrates and invertebrates.", [["Defensins", "CHEMICAL", 0, 9], ["cysteine", "CHEMICAL", 20, 28], ["Defensins", "GENE_OR_GENE_PRODUCT", 0, 9], ["cationic proteins", "PROTEIN", 34, 51], ["small cysteine-rich cationic proteins", "PROBLEM", 14, 51], ["peptides", "PROBLEM", 55, 63], ["small", "OBSERVATION_MODIFIER", 14, 19], ["cysteine", "OBSERVATION_MODIFIER", 20, 28], ["rich", "OBSERVATION_MODIFIER", 29, 33], ["cationic proteins", "OBSERVATION", 34, 51], ["both", "ANATOMY_MODIFIER", 73, 77], ["vertebrates", "ANATOMY_MODIFIER", 78, 89], ["invertebrates", "OBSERVATION_MODIFIER", 94, 107]]], ["They can be active against bacteria, fungi and many enveloped and non-enveloped viruses; thus, being also classified as antimicrobial peptides (AMPs).", [["bacteria", "PROBLEM", 27, 35], ["fungi", "PROBLEM", 37, 42], ["non-enveloped viruses", "PROBLEM", 66, 87], ["antimicrobial peptides", "TREATMENT", 120, 142], ["non-enveloped", "OBSERVATION_MODIFIER", 66, 79], ["viruses", "OBSERVATION", 80, 87]]], ["In the present work a comparative study between Psd1 (a plant defensin with antifungic properties obtained from the garden pea Pisum sativum) and Hnp1 (a human neutrophils defensin) was conducted, in order to shed some light on the mechanism of action at the molecular level of these defensins.", [["neutrophils", "ANATOMY", 160, 171], ["Psd1", "CHEMICAL", 48, 52], ["Psd1", "GENE_OR_GENE_PRODUCT", 48, 52], ["defensin", "GENE_OR_GENE_PRODUCT", 62, 70], ["pea Pisum sativum", "ORGANISM", 123, 140], ["Hnp1", "GENE_OR_GENE_PRODUCT", 146, 150], ["human", "ORGANISM", 154, 159], ["neutrophils defensin", "GENE_OR_GENE_PRODUCT", 160, 180], ["defensins", "GENE_OR_GENE_PRODUCT", 284, 293], ["Psd1", "PROTEIN", 48, 52], ["plant defensin", "PROTEIN", 56, 70], ["Hnp1", "PROTEIN", 146, 150], ["human neutrophils defensin", "PROTEIN", 154, 180], ["defensins", "PROTEIN", 284, 293], ["pea", "SPECIES", 123, 126], ["Pisum sativum", "SPECIES", 127, 140], ["human", "SPECIES", 154, 159], ["Pisum sativum", "SPECIES", 127, 140], ["human", "SPECIES", 154, 159], ["a comparative study", "TEST", 20, 39], ["a plant defensin", "TREATMENT", 54, 70], ["antifungic properties", "TREATMENT", 76, 97], ["the garden pea Pisum sativum", "TREATMENT", 112, 140], ["Hnp1", "TREATMENT", 146, 150], ["a human neutrophils defensin", "TREATMENT", 152, 180]]], ["Large unillamelar vesicles with different lipid compositions were used for this purpose as biomembranes model systems; namely, POPC/cholesterol (characteristic of the outer leaflet of vertebrates cell membranes) and POPC/ergosterol (fungal) mixtures.", [["unillamelar vesicles", "ANATOMY", 6, 26], ["outer leaflet", "ANATOMY", 167, 180], ["cell membranes", "ANATOMY", 196, 210], ["POPC", "CHEMICAL", 127, 131], ["cholesterol", "CHEMICAL", 132, 143], ["POPC", "CHEMICAL", 216, 220], ["ergosterol", "CHEMICAL", 221, 231], ["POPC", "CHEMICAL", 127, 131], ["cholesterol", "CHEMICAL", 132, 143], ["POPC", "CHEMICAL", 216, 220], ["ergosterol", "CHEMICAL", 221, 231], ["POPC", "SIMPLE_CHEMICAL", 127, 131], ["cholesterol", "SIMPLE_CHEMICAL", 132, 143], ["outer leaflet", "CELLULAR_COMPONENT", 167, 180], ["cell membranes", "CELLULAR_COMPONENT", 196, 210], ["POPC", "SIMPLE_CHEMICAL", 216, 220], ["ergosterol", "SIMPLE_CHEMICAL", 221, 231], ["Large unillamelar vesicles", "PROBLEM", 0, 26], ["different lipid compositions", "TREATMENT", 32, 60], ["biomembranes model systems", "TEST", 91, 117], ["POPC/cholesterol", "TEST", 127, 143], ["vertebrates cell membranes", "TREATMENT", 184, 210], ["POPC/ergosterol (fungal) mixtures", "TREATMENT", 216, 249], ["unillamelar vesicles", "OBSERVATION", 6, 26], ["different", "OBSERVATION_MODIFIER", 32, 41], ["lipid compositions", "OBSERVATION", 42, 60], ["vertebrates cell membranes", "OBSERVATION", 184, 210]]], ["Changes on the intrinsic fluorescence of the tryptophan residues present in these peptides upon membrane binding/insertion were followed by fluorescence spectroscopy.", [["membrane", "ANATOMY", 96, 104], ["tryptophan", "CHEMICAL", 45, 55], ["tryptophan", "CHEMICAL", 45, 55], ["tryptophan", "AMINO_ACID", 45, 55], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["the tryptophan residues", "TREATMENT", 41, 64], ["membrane binding/insertion", "TREATMENT", 96, 122], ["fluorescence spectroscopy", "TEST", 140, 165], ["tryptophan residues", "OBSERVATION", 45, 64]]], ["Experimental results show the affinity of both defensins for mammalian and fungal sterols.", [["sterols", "CHEMICAL", 82, 89], ["fungal sterols", "SIMPLE_CHEMICAL", 75, 89], ["defensins", "PROTEIN", 47, 56], ["mammalian and fungal sterols", "PROBLEM", 61, 89], ["fungal sterols", "OBSERVATION", 75, 89]]], ["The partitioning behavior of Psd1 showed a high selectivity for ergosterol rich membranes, while Hnp1 has preference for cholesterol rich membranes.P-542Preliminary characterization of atomistic computer models of galactolipid bilayers K. Baczynski, M. Pasenkiewicz-Gierula Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, PolandP-542The main lipid component of thylakoid membranes are galactolipids, which constitute more than 75% of its lipid composition.", [["membranes", "ANATOMY", 80, 89], ["cholesterol rich membranes", "ANATOMY", 121, 147], ["thylakoid membranes", "ANATOMY", 401, 420], ["Psd1", "CHEMICAL", 29, 33], ["ergosterol", "CHEMICAL", 64, 74], ["Hnp1", "CHEMICAL", 97, 101], ["cholesterol", "CHEMICAL", 121, 132], ["PolandP-542", "CHEMICAL", 362, 373], ["ergosterol", "CHEMICAL", 64, 74], ["cholesterol", "CHEMICAL", 121, 132], ["Psd1", "SIMPLE_CHEMICAL", 29, 33], ["ergosterol", "SIMPLE_CHEMICAL", 64, 74], ["membranes", "CELLULAR_COMPONENT", 80, 89], ["Hnp1", "GENE_OR_GENE_PRODUCT", 97, 101], ["cholesterol", "SIMPLE_CHEMICAL", 121, 132], ["membranes", "CELLULAR_COMPONENT", 138, 147], ["thylakoid membranes", "CELLULAR_COMPONENT", 401, 420], ["galactolipids", "SIMPLE_CHEMICAL", 425, 438], ["lipid", "SIMPLE_CHEMICAL", 478, 483], ["Psd1", "PROTEIN", 29, 33], ["Hnp1", "PROTEIN", 97, 101], ["Psd1", "TEST", 29, 33], ["ergosterol rich membranes", "PROBLEM", 64, 89], ["cholesterol rich membranes", "PROBLEM", 121, 147], ["galactolipids", "TREATMENT", 425, 438], ["high selectivity", "OBSERVATION", 43, 59], ["rich membranes", "OBSERVATION", 75, 89], ["main", "OBSERVATION_MODIFIER", 377, 381], ["lipid", "OBSERVATION_MODIFIER", 382, 387], ["component", "OBSERVATION_MODIFIER", 388, 397], ["thylakoid membranes", "OBSERVATION", 401, 420], ["lipid composition", "OBSERVATION", 478, 495]]], ["The most common types of galactolipids found in thylakoid are monogalactosyldiacylglycerol(MGDG), whose headgroup consists of a single molecule of beta-D-galactose and digalactosyldiacylglycerol(DGDG), whose headgroup consists of two galactose molecules: alpha-D-galactose and beta-D-galactose linked by O-glycosidic bond Majorty of thylakoid galactolipid have gamma-linolenic acid both in the sn-1 and sn-2 position.", [["thylakoid", "ANATOMY", 48, 57], ["thylakoid", "ANATOMY", 333, 342], ["monogalactosyldiacylglycerol", "CHEMICAL", 62, 90], ["MGDG", "CHEMICAL", 91, 95], ["beta-D-galactose", "CHEMICAL", 147, 163], ["digalactosyldiacylglycerol", "CHEMICAL", 168, 194], ["DGDG", "CHEMICAL", 195, 199], ["galactose", "CHEMICAL", 234, 243], ["alpha-D-galactose", "CHEMICAL", 255, 272], ["beta-D-galactose", "CHEMICAL", 277, 293], ["gamma-linolenic acid", "CHEMICAL", 361, 381], ["monogalactosyldiacylglycerol", "CHEMICAL", 62, 90], ["MGDG", "CHEMICAL", 91, 95], ["beta-D-galactose", "CHEMICAL", 147, 163], ["digalactosyldiacylglycerol", "CHEMICAL", 168, 194], ["DGDG", "CHEMICAL", 195, 199], ["galactose", "CHEMICAL", 234, 243], ["alpha-D-galactose", "CHEMICAL", 255, 272], ["beta-D-galactose", "CHEMICAL", 277, 293], ["O-glycosidic", "CHEMICAL", 304, 316], ["gamma-linolenic acid", "CHEMICAL", 361, 381], ["galactolipids", "GENE_OR_GENE_PRODUCT", 25, 38], ["thylakoid", "CELLULAR_COMPONENT", 48, 57], ["monogalactosyldiacylglycerol", "SIMPLE_CHEMICAL", 62, 90], ["MGDG", "SIMPLE_CHEMICAL", 91, 95], ["beta-D-galactose", "SIMPLE_CHEMICAL", 147, 163], ["digalactosyldiacylglycerol", "SIMPLE_CHEMICAL", 168, 194], ["DGDG", "SIMPLE_CHEMICAL", 195, 199], ["galactose molecules", "SIMPLE_CHEMICAL", 234, 253], ["alpha-D-galactose", "SIMPLE_CHEMICAL", 255, 272], ["beta-D-galactose", "SIMPLE_CHEMICAL", 277, 293], ["O-glycosidic bond Majorty", "SIMPLE_CHEMICAL", 304, 329], ["thylakoid galactolipid", "SIMPLE_CHEMICAL", 333, 355], ["gamma-linolenic acid", "SIMPLE_CHEMICAL", 361, 381], ["sn-1", "GENE_OR_GENE_PRODUCT", 394, 398], ["sn-2", "GENE_OR_GENE_PRODUCT", 403, 407], ["galactolipids", "TREATMENT", 25, 38], ["galactose", "TREATMENT", 154, 163], ["digalactosyldiacylglycerol(DGDG", "TREATMENT", 168, 199], ["alpha-D", "TEST", 255, 262], ["galactose", "TEST", 263, 272], ["beta-D-galactose", "TEST", 277, 293], ["gamma-linolenic acid", "TREATMENT", 361, 381]]], ["Atomistic computer models of MGDG and DGDG molecules have been constructed and parametrized in the OPLS-AA force field.", [["MGDG", "CHEMICAL", 29, 33], ["MGDG", "CHEMICAL", 29, 33], ["DGDG", "CHEMICAL", 38, 42], ["MGDG", "SIMPLE_CHEMICAL", 29, 33], ["DGDG molecules", "SIMPLE_CHEMICAL", 38, 52], ["MGDG and DGDG molecules", "PROTEIN", 29, 52], ["MGDG and DGDG molecules", "TREATMENT", 29, 52]]], ["The molecules were used to construct three bilayer systems for molecular dynamics (MD) simulations:(1) composed entirely of DGDG molecules,(2) composed entirely of MGDG molecules,(3) composed of a mixture of DGDG and MGDG molecules the ratio 1:2.", [["DGDG", "CHEMICAL", 208, 212], ["DGDG", "CHEMICAL", 124, 128], ["MGDG", "CHEMICAL", 164, 168], ["DGDG", "CHEMICAL", 208, 212], ["MGDG", "CHEMICAL", 217, 221], ["DGDG molecules", "SIMPLE_CHEMICAL", 124, 138], ["MGDG molecules", "SIMPLE_CHEMICAL", 164, 178], ["DGDG", "SIMPLE_CHEMICAL", 208, 212], ["MGDG molecules", "SIMPLE_CHEMICAL", 217, 231], ["DGDG molecules", "PROTEIN", 124, 138], ["MGDG molecules", "PROTEIN", 164, 178], ["DGDG molecules", "PROBLEM", 124, 138], ["MGDG molecules", "PROBLEM", 164, 178], ["DGDG and MGDG molecules", "TREATMENT", 208, 231]]], ["The systems have been MD simulated using the GROMACS 3.3.1 package.", [["the GROMACS 3.3.1 package", "TREATMENT", 41, 66]]], ["The generated trajectories were analysed to determine a number of structural parameters among them: membrane thickness, average area per lipid, electron density profile accross the bilayer, order parameters, organisation of the bilayer/water interface as well as several dynamic parametrers like diffusion coefficients, lifetimes of conformational states, lifetimes od lipid lipid interactions.P-549Single Mixed-Lipid GUV Method Reveals Interaction of Viper venom with Lipid Membranes N. M. Ayvazyan, N. A. Zaqaryan, N. A. Ghazaryan Dpt.", [["membrane", "ANATOMY", 100, 108], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["lipid", "SIMPLE_CHEMICAL", 137, 142], ["electron", "SIMPLE_CHEMICAL", 144, 152], ["venom", "ORGANISM_SUBSTANCE", 458, 463], ["membrane thickness", "TEST", 100, 118], ["electron density profile", "TEST", 144, 168], ["the bilayer/water interface", "TREATMENT", 224, 251], ["lifetimes od lipid lipid interactions", "TREATMENT", 356, 393], ["P", "TEST", 394, 395], ["Lipid GUV Method", "TREATMENT", 412, 428], ["water interface", "OBSERVATION", 236, 251]]], ["Biophysics, Yerevan State University, Armenia Studies on the interaction of snake venom and organized lipid interfaces have been conducted using a variety of systems, including bilayer lipid membranes (BLMs), small and large unilamellar vesicles.", [["venom", "ANATOMY", 82, 87], ["bilayer lipid membranes", "ANATOMY", 177, 200], ["BLMs", "ANATOMY", 202, 206], ["unilamellar vesicles", "ANATOMY", 225, 245], ["snake", "ORGANISM", 76, 81], ["venom", "ORGANISM_SUBSTANCE", 82, 87], ["lipid membranes", "CELLULAR_COMPONENT", 185, 200], ["BLMs", "CELLULAR_COMPONENT", 202, 206], ["unilamellar vesicles", "CELLULAR_COMPONENT", 225, 245], ["Armenia Studies", "TEST", 38, 53], ["snake venom", "TREATMENT", 76, 87], ["organized lipid interfaces", "TREATMENT", 92, 118], ["bilayer lipid membranes", "TEST", 177, 200], ["small and large unilamellar vesicles", "PROBLEM", 209, 245], ["lipid membranes", "OBSERVATION", 185, 200], ["small", "OBSERVATION_MODIFIER", 209, 214], ["large", "OBSERVATION_MODIFIER", 219, 224], ["unilamellar vesicles", "OBSERVATION", 225, 245]]], ["Giant unilamellar vesicles (GUVs) with a mean diameter of 30 \u00b5m have a minimum curvature and mimic cell membranes in this respect.", [["Giant unilamellar vesicles", "ANATOMY", 0, 26], ["GUVs", "ANATOMY", 28, 32], ["cell membranes", "ANATOMY", 99, 113], ["unilamellar vesicles", "MULTI-TISSUE_STRUCTURE", 6, 26], ["GUVs", "CELLULAR_COMPONENT", 28, 32], ["cell membranes", "CELLULAR_COMPONENT", 99, 113], ["Giant unilamellar vesicles", "TEST", 0, 26], ["a mean diameter", "TEST", 39, 54], ["unilamellar vesicles", "OBSERVATION", 6, 26], ["mean diameter", "OBSERVATION_MODIFIER", 41, 54], ["30 \u00b5m", "OBSERVATION_MODIFIER", 58, 63], ["minimum curvature", "OBSERVATION_MODIFIER", 71, 88], ["mimic cell membranes", "OBSERVATION", 93, 113]]], ["GUVs are ideal for studying lipid/lipid and lipid/protein interactions using microscopy techniques with membrane fluorescence probes.", [["membrane", "ANATOMY", 104, 112], ["GUVs", "SIMPLE_CHEMICAL", 0, 4], ["lipid", "SIMPLE_CHEMICAL", 28, 33], ["lipid", "SIMPLE_CHEMICAL", 34, 39], ["lipid", "SIMPLE_CHEMICAL", 44, 49], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["lipid/lipid and lipid/protein interactions", "TREATMENT", 28, 70], ["microscopy techniques", "TEST", 77, 98], ["membrane fluorescence probes", "TREATMENT", 104, 132]]], ["GUVs were formed from the total lipid fraction from bovine brain by the electroformation method, developed by Angelova and Dimitrov (1987) .", [["brain", "ANATOMY", 59, 64], ["GUVs", "SIMPLE_CHEMICAL", 0, 4], ["bovine", "ORGANISM", 52, 58], ["brain", "ORGAN", 59, 64], ["bovine", "SPECIES", 52, 58], ["bovine", "SPECIES", 52, 58], ["bovine brain", "OBSERVATION", 52, 64]]], ["Vipera lebetina obtusa venom was added to the sample chamber before the vesicles were formed.", [["venom", "ANATOMY", 23, 28], ["vesicles", "ANATOMY", 72, 80], ["Vipera lebetina obtusa", "ORGANISM", 0, 22], ["venom", "ORGANISM_SUBSTANCE", 23, 28], ["vesicles", "CELLULAR_COMPONENT", 72, 80], ["Vipera lebetina obtusa", "SPECIES", 0, 22], ["Vipera lebetina", "SPECIES", 0, 15], ["Vipera lebetina obtusa venom", "TREATMENT", 0, 28], ["obtusa venom", "OBSERVATION", 16, 28], ["vesicles", "ANATOMY", 72, 80]]], ["The membrane fluorescence probes, ANS and pyrene, were used to assess the state of the membrane and specifically mark the phospholipid domains.", [["membrane", "ANATOMY", 4, 12], ["membrane", "ANATOMY", 87, 95], ["pyrene", "CHEMICAL", 42, 48], ["pyrene", "CHEMICAL", 42, 48], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["ANS", "SIMPLE_CHEMICAL", 34, 37], ["pyrene", "SIMPLE_CHEMICAL", 42, 48], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["phospholipid domains", "PROTEIN", 122, 142], ["The membrane fluorescence probes", "TEST", 0, 32], ["ANS and pyrene", "TREATMENT", 34, 48]]], ["ANS and pyrene allows us to quantify the fluidity changes in the membrane by measuring of the fluorescence intensity.", [["membrane", "ANATOMY", 65, 73], ["pyrene", "CHEMICAL", 8, 14], ["pyrene", "CHEMICAL", 8, 14], ["ANS", "SIMPLE_CHEMICAL", 0, 3], ["pyrene", "SIMPLE_CHEMICAL", 8, 14], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["the fluidity changes", "PROBLEM", 37, 57], ["the fluorescence intensity", "TEST", 90, 116]]], ["The presence of viper venom in GUVs media reveals a noticable decreasing of membrane fluidity compare the control, while the binding of fluorophores with GUVs modified by venom lead to appearance of channel activity.", [["membrane", "ANATOMY", 76, 84], ["venom", "ANATOMY", 171, 176], ["viper", "ORGANISM", 16, 21], ["venom", "ORGANISM_SUBSTANCE", 22, 27], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["GUVs", "SIMPLE_CHEMICAL", 154, 158], ["venom", "ORGANISM_SUBSTANCE", 171, 176], ["viper venom in GUVs media", "TEST", 16, 41], ["membrane fluidity", "TREATMENT", 76, 93], ["GUVs", "TREATMENT", 154, 158], ["viper venom", "OBSERVATION", 16, 27], ["decreasing", "OBSERVATION_MODIFIER", 62, 72], ["membrane fluidity", "OBSERVATION", 76, 93], ["channel activity", "OBSERVATION", 199, 215]]], ["It was recognized early that the vipers' venom components preferred an organized lipid substrate near the lipid's phase transition and were particularly active against micellar lipids.", [["venom", "ANATOMY", 41, 46], ["venom", "ORGANISM_SUBSTANCE", 41, 46], ["lipid substrate", "CELLULAR_COMPONENT", 81, 96], ["lipid", "SIMPLE_CHEMICAL", 106, 111], ["micellar lipids", "SIMPLE_CHEMICAL", 168, 183], ["the vipers' venom components", "TREATMENT", 29, 57], ["micellar lipids", "TREATMENT", 168, 183]]], ["These studies also emphasize the importance of a membrane surface curvature for its interaction with enzymatic components of venom.", [["membrane surface", "ANATOMY", 49, 65], ["venom", "ANATOMY", 125, 130], ["membrane surface", "CELLULAR_COMPONENT", 49, 65], ["venom", "ORGANISM_SUBSTANCE", 125, 130], ["These studies", "TEST", 0, 13], ["a membrane surface curvature", "TREATMENT", 47, 75], ["enzymatic components of venom", "TREATMENT", 101, 130], ["venom", "ANATOMY", 125, 130]]], ["The attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy is ideal for highly absorbing samples such as water suspensions or even bulk water due to the small light penetration depth.", [["samples", "ANATOMY", 113, 120], ["highly absorbing samples", "PROBLEM", 96, 120], ["water suspensions", "TREATMENT", 129, 146], ["the small light penetration depth", "PROBLEM", 173, 206], ["attenuated", "OBSERVATION_MODIFIER", 4, 14], ["total", "OBSERVATION_MODIFIER", 15, 20], ["small", "OBSERVATION_MODIFIER", 177, 182], ["light penetration", "OBSERVATION", 183, 200]]], ["It is also suited for experiments on lipid membranes in excess water.", [["lipid membranes", "ANATOMY", 37, 52], ["lipid membranes", "CELLULAR_COMPONENT", 37, 52], ["lipid membranes", "TREATMENT", 37, 52]]], ["For example, we have studied the hydrogen bonding (H-bonding) between cholesterol (CH) and phosphatidylcholine (PC) or sphingomyelin (SM), which could be important for the stabilization of the cholesterol-rich lipid domains.", [["H", "CHEMICAL", 51, 52], ["cholesterol", "CHEMICAL", 70, 81], ["CH", "CHEMICAL", 83, 85], ["phosphatidylcholine", "CHEMICAL", 91, 110], ["sphingomyelin", "CHEMICAL", 119, 132], ["cholesterol", "CHEMICAL", 193, 204], ["hydrogen", "CHEMICAL", 33, 41], ["H", "CHEMICAL", 51, 52], ["cholesterol", "CHEMICAL", 70, 81], ["CH", "CHEMICAL", 83, 85], ["phosphatidylcholine", "CHEMICAL", 91, 110], ["sphingomyelin", "CHEMICAL", 119, 132], ["cholesterol", "CHEMICAL", 193, 204], ["hydrogen", "SIMPLE_CHEMICAL", 33, 41], ["H", "SIMPLE_CHEMICAL", 51, 52], ["cholesterol", "SIMPLE_CHEMICAL", 70, 81], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 91, 110], ["PC", "SIMPLE_CHEMICAL", 112, 114], ["sphingomyelin", "SIMPLE_CHEMICAL", 119, 132], ["SM", "SIMPLE_CHEMICAL", 134, 136], ["cholesterol", "SIMPLE_CHEMICAL", 193, 204], ["cholesterol-rich lipid domains", "PROTEIN", 193, 223], ["the hydrogen bonding (H-bonding) between cholesterol (CH)", "TREATMENT", 29, 86], ["phosphatidylcholine (PC)", "TREATMENT", 91, 115], ["sphingomyelin (SM)", "TREATMENT", 119, 137], ["the cholesterol", "TEST", 189, 204]]], ["The ATR-FTIR method enabled comparison of the carbonyl band shape for PC/CH samples in excess H 2 O or D 2 O, and has confirmed similar behavior for both [1] .", [["carbonyl", "CHEMICAL", 46, 54], ["carbonyl", "CHEMICAL", 46, 54], ["CH", "CHEMICAL", 73, 75], ["H 2 O", "CHEMICAL", 94, 99], ["D 2 O", "CHEMICAL", 103, 108], ["ATR", "SIMPLE_CHEMICAL", 4, 7], ["carbonyl", "SIMPLE_CHEMICAL", 46, 54], ["H 2 O", "SIMPLE_CHEMICAL", 94, 99], ["D 2 O", "SIMPLE_CHEMICAL", 103, 108], ["The ATR", "TEST", 0, 7], ["the carbonyl band shape", "TREATMENT", 42, 65], ["PC/CH samples", "TREATMENT", 70, 83]]], ["Secondly, we were able to analyze the amide II band for SM/CH samples in excess H 2 O. The observations confirm the presence of H-bonds between CH and N-H group in SM [2] .", [["amide II", "CHEMICAL", 38, 46], ["H", "CHEMICAL", 128, 129], ["N-H", "CHEMICAL", 151, 154], ["amide", "CHEMICAL", 38, 43], ["CH", "CHEMICAL", 59, 61], ["H", "CHEMICAL", 128, 129], ["CH", "CHEMICAL", 144, 146], ["N-H", "CHEMICAL", 151, 154], ["H-bonds", "SIMPLE_CHEMICAL", 128, 135], ["N-H", "SIMPLE_CHEMICAL", 151, 154], ["SM [2]", "SIMPLE_CHEMICAL", 164, 170], ["amide II band", "PROTEIN", 38, 51], ["SM", "PROTEIN", 56, 58], ["the amide II band", "TREATMENT", 34, 51], ["SM/CH samples", "TEST", 56, 69], ["The observations", "TEST", 87, 103]]], ["Another example is the study of the interlamellar water structure, which could influence the water-mediated phenomena in membranes.", [["membranes", "ANATOMY", 121, 130], ["water", "SIMPLE_CHEMICAL", 93, 98], ["membranes", "CELLULAR_COMPONENT", 121, 130], ["the study", "TEST", 19, 28], ["the water-mediated phenomena in membranes", "PROBLEM", 89, 130], ["interlamellar", "ANATOMY_MODIFIER", 36, 49], ["water-mediated", "OBSERVATION_MODIFIER", 93, 107], ["phenomena", "OBSERVATION", 108, 117]]], ["H-bonds in interlamellar water in partially hydrated lipid multibilayers are stronger with respect to bulk water.", [["H", "CHEMICAL", 0, 1], ["H", "CHEMICAL", 0, 1], ["H-bonds", "SIMPLE_CHEMICAL", 0, 7], ["interlamellar water", "SIMPLE_CHEMICAL", 11, 30], ["lipid multibilayers", "SIMPLE_CHEMICAL", 53, 72], ["H-bonds in interlamellar water in partially hydrated lipid multibilayers", "TREATMENT", 0, 72], ["interlamellar", "ANATOMY_MODIFIER", 11, 24], ["lipid multibilayers", "OBSERVATION", 53, 72]]], ["In contrast, we show by ATR-FTIR spectroscopy that the H-bonds are weaker in multibilayers in excess water [3] .", [["H", "CHEMICAL", 55, 56], ["H", "CHEMICAL", 55, 56], ["H-bonds", "SIMPLE_CHEMICAL", 55, 62], ["multibilayers", "SIMPLE_CHEMICAL", 77, 90], ["weaker", "OBSERVATION_MODIFIER", 67, 73]]], ["The bactericidal activity of antimicrobial peptides is linked to their ability to perturb the permeability of bacterial cells.", [["cells", "ANATOMY", 120, 125], ["cells", "CELL", 120, 125], ["bacterial cells", "CELL_TYPE", 110, 125], ["antimicrobial peptides", "TREATMENT", 29, 51], ["bacterial cells", "PROBLEM", 110, 125], ["bactericidal", "OBSERVATION_MODIFIER", 4, 16], ["activity", "OBSERVATION_MODIFIER", 17, 25], ["bacterial cells", "OBSERVATION", 110, 125]]], ["They often show \u03b1-helical conformation, and many peptides have a kink in the middle of this structure, caused by Pro or Gly.", [["Pro", "CHEMICAL", 113, 116], ["Gly", "CHEMICAL", 120, 123], ["Gly", "AMINO_ACID", 120, 123], ["kink", "OBSERVATION", 65, 69], ["middle", "ANATOMY_MODIFIER", 77, 83]]], ["In order to understand the role of the kink we designed various analogues of P5, in which the central Pro residue was moved from its central position, or removed altogether (in analogue P5F).", [["Pro", "CHEMICAL", 102, 105], ["P5", "SIMPLE_CHEMICAL", 77, 79], ["various analogues of P5", "TREATMENT", 56, 79], ["the central Pro residue", "TREATMENT", 90, 113], ["central", "OBSERVATION_MODIFIER", 133, 140], ["position", "OBSERVATION_MODIFIER", 141, 149]]], ["Displacement of the Pro residue caused a decrease of the antimicrobial activity, and an increase in the toxicity against erythrocytes, with the less active and more toxic peptide being P5F.", [["erythrocytes", "ANATOMY", 121, 133], ["Pro", "CHEMICAL", 20, 23], ["toxicity", "DISEASE", 104, 112], ["Pro", "CHEMICAL", 20, 23], ["erythrocytes", "CELL", 121, 133], ["P5F", "SIMPLE_CHEMICAL", 185, 188], ["erythrocytes", "CELL_TYPE", 121, 133], ["P5F", "PROTEIN", 185, 188], ["the Pro residue", "PROBLEM", 16, 31], ["a decrease of the antimicrobial activity", "PROBLEM", 39, 79], ["the toxicity against erythrocytes", "PROBLEM", 100, 133], ["Pro residue", "OBSERVATION", 20, 31], ["decrease", "OBSERVATION_MODIFIER", 41, 49], ["antimicrobial activity", "OBSERVATION", 57, 79], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["less", "OBSERVATION_MODIFIER", 144, 148], ["active", "OBSERVATION_MODIFIER", 149, 155], ["toxic", "OBSERVATION_MODIFIER", 165, 170]]], ["Fluorescence studies suggest that both P5 and P5F bind on the membrane surface.", [["membrane surface", "ANATOMY", 62, 78], ["P5", "GENE_OR_GENE_PRODUCT", 39, 41], ["P5F", "GENE_OR_GENE_PRODUCT", 46, 49], ["membrane surface", "CELLULAR_COMPONENT", 62, 78], ["P5", "DNA", 39, 41], ["P5F", "PROTEIN", 46, 49], ["Fluorescence studies", "TEST", 0, 20], ["membrane", "ANATOMY_MODIFIER", 62, 70]]], ["Fluorescence experiments show that the activities of the two analogues correlate with their affinity for different kinds of lipid bilayers: the kinked P5 peptide has a dramatically higher affinity for negatively charged vesicles (mimicking the composition of bacterial membranes) than for neutral liposomes (similar to mammalian cells), while analogue P5F exhibits comparable affinities for both membranes.", [["vesicles", "ANATOMY", 220, 228], ["membranes", "ANATOMY", 269, 278], ["cells", "ANATOMY", 329, 334], ["membranes", "ANATOMY", 396, 405], ["P5F", "CHEMICAL", 352, 355], ["lipid bilayers", "SIMPLE_CHEMICAL", 124, 138], ["vesicles", "CELLULAR_COMPONENT", 220, 228], ["membranes", "CELLULAR_COMPONENT", 269, 278], ["neutral liposomes", "SIMPLE_CHEMICAL", 289, 306], ["mammalian cells", "CELL", 319, 334], ["P5F", "SIMPLE_CHEMICAL", 352, 355], ["membranes", "CELLULAR_COMPONENT", 396, 405], ["mammalian cells", "CELL_TYPE", 319, 334], ["P5F", "PROTEIN", 352, 355], ["Fluorescence experiments", "TEST", 0, 24], ["lipid bilayers", "TREATMENT", 124, 138], ["the kinked P5 peptide", "PROBLEM", 140, 161], ["negatively charged vesicles", "PROBLEM", 201, 228], ["bacterial membranes", "PROBLEM", 259, 278], ["neutral liposomes", "PROBLEM", 289, 306], ["bacterial membranes", "OBSERVATION", 259, 278]]], ["Therefore, our data suggest that the central Pro-induced kink is involved in selectivity, inhibiting peptide binding to the membranes of eukaryotic cells.C-Polycystin-2 and its specific interaction partnersD.", [["membranes", "ANATOMY", 124, 133], ["cells", "ANATOMY", 148, 153], ["membranes", "CELLULAR_COMPONENT", 124, 133], ["cells", "CELL", 148, 153], ["C-Polycystin-2", "GENE_OR_GENE_PRODUCT", 154, 168], ["central Pro-induced kink", "PROTEIN", 37, 61], ["eukaryotic cells", "CELL_TYPE", 137, 153], ["partnersD", "PROTEIN", 198, 207], ["our data", "TEST", 11, 19], ["the central Pro-induced kink", "PROBLEM", 33, 61], ["central", "OBSERVATION_MODIFIER", 37, 44], ["Pro-induced kink", "OBSERVATION", 45, 61], ["eukaryotic cells", "OBSERVATION", 137, 153]]], ["Behn 1 , H. Hoffmeister 2 , R. Witzgall 2 , C. Steinem 1 1 Institute for Organic and Biomolecular Chemistry, University of G\u00f6ttingen, Germany, 2 Institute for Molecular and Cellular Anatomy, University of Regensburg, GermanyC-Polycystin-2 and its specific interaction partnersPolycystin-2, encoded by PKD2, is an integral membrane protein with a size of 110 kDa and 968 amino acids.", [["membrane", "ANATOMY", 322, 330], ["amino acids", "CHEMICAL", 370, 381], ["amino acids", "CHEMICAL", 370, 381], ["Polycystin-2", "GENE_OR_GENE_PRODUCT", 226, 238], ["Polycystin-2", "GENE_OR_GENE_PRODUCT", 276, 288], ["PKD2", "GENE_OR_GENE_PRODUCT", 301, 305], ["membrane", "CELLULAR_COMPONENT", 322, 330], ["amino acids", "AMINO_ACID", 370, 381], ["PKD2", "PROTEIN", 301, 305], ["integral membrane protein", "PROTEIN", 313, 338], ["Regensburg", "TEST", 205, 215], ["GermanyC", "TEST", 217, 225], ["Polycystin", "TREATMENT", 226, 236], ["Polycystin", "TEST", 276, 286], ["amino acids", "TEST", 370, 381], ["Cellular Anatomy", "OBSERVATION", 173, 189], ["size", "OBSERVATION_MODIFIER", 346, 350]]], ["The protein, which is known to be a Ca 2+ permeable, non selective cation channel, interacts with several proteins such as Polycystin-1, PIGEA14 or PACS-1/-2 etc. The interaction takes place through a proposed coiled-coil domain of Polycystin-2 located at the C-terminus of the protein.If mutation of either PKD2 or PKD1 (gene product of Polycystin-1) occurs, the interaction between the proteins is disturbed leading to increased formation of renal cysts.", [["renal cysts", "ANATOMY", 444, 455], ["Ca", "CHEMICAL", 36, 38], ["renal cysts", "DISEASE", 444, 455], ["Ca 2+", "CHEMICAL", 36, 41], ["C", "CHEMICAL", 260, 261], ["cation", "SIMPLE_CHEMICAL", 67, 73], ["Polycystin-1", "GENE_OR_GENE_PRODUCT", 123, 135], ["PIGEA14", "GENE_OR_GENE_PRODUCT", 137, 144], ["PACS-1", "GENE_OR_GENE_PRODUCT", 148, 154], ["-2", "GENE_OR_GENE_PRODUCT", 155, 157], ["Polycystin-2", "GENE_OR_GENE_PRODUCT", 232, 244], ["PKD2", "GENE_OR_GENE_PRODUCT", 308, 312], ["PKD1", "GENE_OR_GENE_PRODUCT", 316, 320], ["Polycystin-1", "GENE_OR_GENE_PRODUCT", 338, 350], ["renal cysts", "CANCER", 444, 455], ["cation channel", "PROTEIN", 67, 81], ["Polycystin-1", "PROTEIN", 123, 135], ["PIGEA14", "PROTEIN", 137, 144], ["PACS-1/-2 etc", "PROTEIN", 148, 161], ["coiled-coil domain", "PROTEIN", 210, 228], ["Polycystin-2", "PROTEIN", 232, 244], ["C-terminus", "PROTEIN", 260, 270], ["PKD2", "PROTEIN", 308, 312], ["PKD1", "PROTEIN", 316, 320], ["Polycystin-1", "PROTEIN", 338, 350], ["The protein", "TEST", 0, 11], ["Polycystin", "TREATMENT", 123, 133], ["PIGEA14", "TREATMENT", 137, 144], ["PACS", "TEST", 148, 152], ["a proposed coiled-coil domain of Polycystin", "TREATMENT", 199, 242], ["mutation", "PROBLEM", 289, 297], ["PKD2", "PROBLEM", 308, 312], ["PKD1 (gene product of Polycystin", "TREATMENT", 316, 348], ["renal cysts", "PROBLEM", 444, 455], ["known to be", "UNCERTAINTY", 22, 33], ["protein", "ANATOMY", 278, 285], ["increased", "OBSERVATION_MODIFIER", 421, 430], ["renal", "ANATOMY", 444, 449], ["cysts", "OBSERVATION", 450, 455]]], ["This autosomal polycystic kidney disease (ADPKD) is one of the most common genetic diseases causing renal failure due to the enormous cyst formation.", [["polycystic kidney", "ANATOMY", 15, 32], ["renal", "ANATOMY", 100, 105], ["cyst", "ANATOMY", 134, 138], ["autosomal polycystic kidney disease", "DISEASE", 5, 40], ["ADPKD", "DISEASE", 42, 47], ["renal failure", "DISEASE", 100, 113], ["kidney", "ORGAN", 26, 32], ["renal", "ORGAN", 100, 105], ["cyst", "PATHOLOGICAL_FORMATION", 134, 138], ["This autosomal polycystic kidney disease", "PROBLEM", 0, 40], ["ADPKD", "PROBLEM", 42, 47], ["genetic diseases", "PROBLEM", 75, 91], ["renal failure", "PROBLEM", 100, 113], ["the enormous cyst formation", "PROBLEM", 121, 148], ["autosomal", "OBSERVATION_MODIFIER", 5, 14], ["polycystic", "OBSERVATION_MODIFIER", 15, 25], ["kidney", "ANATOMY", 26, 32], ["disease", "OBSERVATION", 33, 40], ["most common", "OBSERVATION_MODIFIER", 63, 74], ["diseases", "OBSERVATION", 83, 91], ["renal", "ANATOMY", 100, 105], ["failure", "OBSERVATION", 106, 113], ["enormous", "OBSERVATION_MODIFIER", 125, 133], ["cyst", "OBSERVATION", 134, 138]]], ["In this study, the interaction of the C-terminus of Polycystin-2 with its postulated specific interaction partners has been investigated in terms of its biological relevance.", [["Polycystin-2", "GENE_OR_GENE_PRODUCT", 52, 64], ["C-terminus", "PROTEIN", 38, 48], ["Polycystin-2", "PROTEIN", 52, 64], ["this study", "TEST", 3, 13], ["Polycystin", "TREATMENT", 52, 62]]], ["Binding affinities as well as kinetic parameters of the interaction were determined.", [["Binding affinities", "PROBLEM", 0, 18]]], ["In particular, the interaction of C-Polycystin-1 and PIGEA14 immobilized on solid supported membranes with C-Polycystin-2 has been quantified by means of the quartz crystal microbalance (QCM) method.", [["membranes", "ANATOMY", 92, 101], ["C-Polycystin-1", "CHEMICAL", 34, 48], ["PIGEA14", "CHEMICAL", 53, 60], ["C-Polycystin-2", "CHEMICAL", 107, 121], ["C-Polycystin-1", "CHEMICAL", 34, 48], ["PIGEA14", "CHEMICAL", 53, 60], ["quartz", "CHEMICAL", 158, 164], ["C-Polycystin-1", "GENE_OR_GENE_PRODUCT", 34, 48], ["PIGEA14", "SIMPLE_CHEMICAL", 53, 60], ["membranes", "CELLULAR_COMPONENT", 92, 101], ["C-Polycystin-2", "SIMPLE_CHEMICAL", 107, 121], ["C-Polycystin-1", "PROTEIN", 34, 48], ["PIGEA14", "PROTEIN", 53, 60], ["C-Polycystin", "TEST", 34, 46], ["PIGEA14", "TREATMENT", 53, 60], ["solid supported membranes", "TREATMENT", 76, 101], ["C-Polycystin-2", "TREATMENT", 107, 121], ["the quartz crystal microbalance (QCM) method", "TREATMENT", 154, 198]]], ["A dissociation constant of about 100 nM was obtained.", [["A dissociation constant", "TEST", 0, 23]]], ["The results are compared with those obtained by surface plasmon resonance (SPR) technique using a different immobilization strategy.P-552Correlation of the lateral structure of lipid bilayers and monolayers using two photon excitation fluorescence microscopy L. A. Bagatolli Membrane Biophysics and Biophotonics group/MEMPHYS -Center for Biomembrane Physics, BMB, University of Southern DenmarkP-552Most of the reported fluorescence microscopy applications on Langmuir lipid films are focused in obtaining fluorescence intensity images using particular fluorescence probes.", [["lateral structure", "ANATOMY", 156, 173], ["lipid bilayers", "ANATOMY", 177, 191], ["monolayers", "ANATOMY", 196, 206], ["monolayers", "CELL", 196, 206], ["P", "DNA", 132, 133], ["a different immobilization strategy", "TREATMENT", 96, 131], ["P", "TEST", 132, 133], ["lipid bilayers", "TREATMENT", 177, 191], ["two photon excitation fluorescence microscopy", "TEST", 213, 258], ["fluorescence microscopy", "TEST", 420, 443], ["Langmuir lipid films", "TEST", 460, 480], ["fluorescence intensity images", "TEST", 506, 535], ["particular fluorescence probes", "TEST", 542, 572], ["lateral", "ANATOMY_MODIFIER", 156, 163], ["lipid bilayers", "OBSERVATION", 177, 191]]], ["In this type of experiments the probes are generally utilized to obtain \"contrast\" between membrane regions (lipid domains) displaying dissimilar physical properties.", [["membrane", "ANATOMY", 91, 99], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["membrane regions", "PROTEIN", 91, 107], ["lipid domains", "PROTEIN", 109, 122]]], ["The obtained information largely depends on the partition of the fluorescent probes for the lipid domains and the obtained fluorescence intensity pictures are not providing any information about the local physical properties of the lipid film.", [["lipid film", "MULTI-TISSUE_STRUCTURE", 232, 242], ["lipid domains", "PROTEIN", 92, 105], ["the fluorescent probes", "TREATMENT", 61, 83], ["the lipid domains", "TEST", 88, 105], ["the lipid film", "TEST", 228, 242]]], ["However these fluorescent probe's properties are almost unexplored in this type of experiments.", [["these fluorescent probe's properties", "TREATMENT", 8, 44]]], ["This presentation will focus in describing a new experimental setup that includes a specially designed film balance on top of a custom built multiphoton excitation fluorescence microscope.", [["a new experimental setup", "PROBLEM", 43, 67], ["a specially designed film balance", "PROBLEM", 82, 115]]], ["This setup allows obtaining LAUR-DAN GP images (1) Many studies on phase separations of lipids in bilayers and their leaflet asymmetry make use of fluorescence techniques.", [["lipids", "SIMPLE_CHEMICAL", 88, 94], ["LAUR-DAN GP images", "TEST", 28, 46], ["Many studies", "TEST", 51, 63], ["phase separations of lipids in bilayers", "TREATMENT", 67, 106], ["fluorescence techniques", "TEST", 147, 170], ["leaflet asymmetry", "OBSERVATION", 117, 134]]], ["We used a dithionite assay, steady-state fluorescence anisotropy and fluorescence resonance energy transfer (FRET) for characterization.", [["dithionite", "CHEMICAL", 10, 20], ["dithionite", "CHEMICAL", 10, 20], ["dithionite", "SIMPLE_CHEMICAL", 10, 20], ["a dithionite assay", "TEST", 8, 26]]], ["Dithionite assay was performed to measure the fluorophore distribution in the inner and outer leaflets of symmetric membranes.", [["inner", "ANATOMY", 78, 83], ["outer leaflets", "ANATOMY", 88, 102], ["membranes", "ANATOMY", 116, 125], ["Dithionite", "CHEMICAL", 0, 10], ["Dithionite", "CHEMICAL", 0, 10], ["Dithionite", "SIMPLE_CHEMICAL", 0, 10], ["inner", "TISSUE", 78, 83], ["outer leaflets", "CELLULAR_COMPONENT", 88, 102], ["membranes", "CELLULAR_COMPONENT", 116, 125], ["Dithionite assay", "TEST", 0, 16], ["fluorophore distribution", "OBSERVATION", 46, 70], ["inner", "ANATOMY_MODIFIER", 78, 83], ["outer leaflets", "ANATOMY", 88, 102], ["symmetric membranes", "OBSERVATION", 106, 125]]], ["For low concentrations, the fluorophore is distributed almost homogeneously, whereas for concentrations > 0.5 mol % it accumulates in the outer leaflet.", [["outer leaflet", "ANATOMY", 138, 151], ["outer leaflet", "CELLULAR_COMPONENT", 138, 151], ["low concentrations", "PROBLEM", 4, 22], ["the fluorophore", "TREATMENT", 24, 39], ["concentrations", "TEST", 89, 103], ["low concentrations", "OBSERVATION_MODIFIER", 4, 22], ["homogeneously", "OBSERVATION_MODIFIER", 62, 75], ["outer leaflet", "ANATOMY", 138, 151]]], ["We discuss these effects taking into account the presence of multilamellar liposomes and dynamic effects produced by higher local bending elasticities.", [["multilamellar liposomes", "SIMPLE_CHEMICAL", 61, 84], ["multilamellar liposomes", "TREATMENT", 61, 84], ["higher local bending elasticities", "PROBLEM", 117, 150], ["multilamellar liposomes", "OBSERVATION", 61, 84], ["higher", "OBSERVATION_MODIFIER", 117, 123], ["local bending", "OBSERVATION", 124, 137]]], ["The results point out possible artifacts in the use of fluorophores to characterize bilayers under the assumption of their homogeneous distribution.", [["artifacts", "PROBLEM", 31, 40], ["fluorophores", "TREATMENT", 55, 67], ["homogeneous", "OBSERVATION_MODIFIER", 123, 134], ["distribution", "OBSERVATION_MODIFIER", 135, 147]]], ["Dithionite relative bilayer permeability is discussed.", [["Dithionite", "CHEMICAL", 0, 10], ["Dithionite", "CHEMICAL", 0, 10], ["Dithionite", "SIMPLE_CHEMICAL", 0, 10], ["Dithionite relative bilayer permeability", "PROBLEM", 0, 40], ["bilayer permeability", "OBSERVATION", 20, 40]]], ["The results won by FRET and steady-state fluorescence anisotropy regarding lipid phase transitions are in good coincidence to each other and to results reported in the literature.", [["lipid phase transitions", "PROBLEM", 75, 98]]], ["The photosensitizing properties of three chlorins are compared in solution and when incorporated in dioleoylphosphatidylcholine vesicules.", [["chlorins", "CHEMICAL", 41, 49], ["dioleoylphosphatidylcholine", "CHEMICAL", 100, 127], ["chlorins", "CHEMICAL", 41, 49], ["dioleoylphosphatidylcholine", "CHEMICAL", 100, 127], ["chlorins", "SIMPLE_CHEMICAL", 41, 49], ["dioleoylphosphatidylcholine vesicules", "SIMPLE_CHEMICAL", 100, 137], ["The photosensitizing properties of three chlorins", "TREATMENT", 0, 49], ["dioleoylphosphatidylcholine vesicules", "OBSERVATION", 100, 137]]], ["In solution, they possess a similar efficacy to generate singlet oxygen and a similar ability to induce the peroxidation.", [["oxygen", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 65, 71], ["singlet oxygen", "SIMPLE_CHEMICAL", 57, 71], ["singlet oxygen", "TREATMENT", 57, 71], ["singlet oxygen", "OBSERVATION", 57, 71]]], ["However, the role of the photosensitizer localization within the lipidic bilayer is strongly highlighted, when chlorins are incorporated in liposomes, both by the changes in order of peroxidation efficacy but by the measurements of the photoinduced permeation of the liposomes.", [["lipidic bilayer", "ANATOMY", 65, 80], ["chlorins", "CHEMICAL", 111, 119], ["chlorins", "CHEMICAL", 111, 119], ["chlorins", "SIMPLE_CHEMICAL", 111, 119], ["liposomes", "SIMPLE_CHEMICAL", 140, 149], ["liposomes", "SIMPLE_CHEMICAL", 267, 276], ["the photosensitizer localization", "TEST", 21, 53], ["peroxidation efficacy", "TREATMENT", 183, 204], ["the photoinduced permeation of the liposomes", "TREATMENT", 232, 276], ["lipidic bilayer", "OBSERVATION", 65, 80], ["liposomes", "ANATOMY", 267, 276]]], ["The results are discussed in relation with the technology of photochemical internalization, PCI.", [["photochemical internalization", "TREATMENT", 61, 90], ["PCI", "TREATMENT", 92, 95]]], ["Then, using Giant unilamellar vesicles, we asymmetrically oxidize the membranes.", [["Giant unilamellar vesicles", "ANATOMY", 12, 38], ["membranes", "ANATOMY", 70, 79], ["membranes", "CELLULAR_COMPONENT", 70, 79], ["Giant unilamellar vesicles", "TREATMENT", 12, 38], ["unilamellar vesicles", "OBSERVATION", 18, 38], ["asymmetrically oxidize", "OBSERVATION", 43, 65], ["membranes", "OBSERVATION_MODIFIER", 70, 79]]], ["We observed different shape transitions, such as budding, typical of membrane curvature modifications.", [["membrane", "ANATOMY", 69, 77], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["different shape transitions", "PROBLEM", 12, 39], ["membrane curvature modifications", "PROBLEM", 69, 101], ["different shape", "OBSERVATION_MODIFIER", 12, 27], ["transitions", "OBSERVATION_MODIFIER", 28, 39], ["membrane curvature", "OBSERVATION", 69, 87]]], ["The asymmetry of the shape transitions are in accordance to a lowered effective spontaneous curvature of the leaflet targeted.", [["leaflet", "CELLULAR_COMPONENT", 109, 116], ["a lowered effective spontaneous curvature of the leaflet", "TREATMENT", 60, 116], ["asymmetry", "OBSERVATION_MODIFIER", 4, 13], ["shape", "OBSERVATION_MODIFIER", 21, 26], ["transitions", "OBSERVATION_MODIFIER", 27, 38], ["lowered", "OBSERVATION_MODIFIER", 62, 69], ["effective", "OBSERVATION_MODIFIER", 70, 79], ["spontaneous", "OBSERVATION_MODIFIER", 80, 91], ["curvature", "OBSERVATION_MODIFIER", 92, 101], ["leaflet", "ANATOMY_MODIFIER", 109, 116]]], ["This effect is interpreted as a decreased preferred area of the targeted leaflet compared to the other, due to the secondary products of oxidation.", [["leaflet", "CELLULAR_COMPONENT", 73, 80], ["the secondary products of oxidation", "PROBLEM", 111, 146], ["decreased", "OBSERVATION_MODIFIER", 32, 41], ["targeted leaflet", "OBSERVATION", 64, 80]]], ["Permeabilization of GUV by photooxidation is interpret as the opening of a pore above a critical membrane tension due to the budding of vesicles.", [["pore", "ANATOMY", 75, 79], ["membrane", "ANATOMY", 97, 105], ["vesicles", "ANATOMY", 136, 144], ["GUV", "CHEMICAL", 20, 23], ["GUV", "SIMPLE_CHEMICAL", 20, 23], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["vesicles", "CELLULAR_COMPONENT", 136, 144], ["Permeabilization", "TREATMENT", 0, 16], ["photooxidation", "TREATMENT", 27, 41], ["a critical membrane tension", "TREATMENT", 86, 113], ["the budding of vesicles", "PROBLEM", 121, 144], ["membrane tension", "OBSERVATION", 97, 113], ["vesicles", "ANATOMY", 136, 144]]], ["The effective spontaneous curvature of photosensitized vesicle at lysis was estimated.", [["vesicle", "ANATOMY", 55, 62], ["vesicle", "CELLULAR_COMPONENT", 55, 62], ["The effective spontaneous curvature of photosensitized vesicle at lysis", "TREATMENT", 0, 71], ["effective", "OBSERVATION_MODIFIER", 4, 13], ["spontaneous", "OBSERVATION_MODIFIER", 14, 25], ["curvature", "OBSERVATION_MODIFIER", 26, 35], ["photosensitized vesicle", "OBSERVATION", 39, 62], ["lysis", "OBSERVATION", 66, 71]]], ["Additionally photooxidation was shown to be fusogenic.P-557Influence of polyphenol extracts from fruits on biological and model membranes D. Bonarska-Kujawa, H. Pruchnik, J. Sarapuk, J. Oszmia\u0144ski, H. Kleszczy\u0144ska Univ. of Environmental and Life Sciences, Wroc law, Poland Biological activity of polyphenol extracts from apple, strawberry and chokeberry was studied.", [["extracts", "ANATOMY", 83, 91], ["fruits", "ANATOMY", 97, 103], ["extracts", "ANATOMY", 307, 315], ["P-557Influence of polyphenol", "CHEMICAL", 54, 82], ["polyphenol", "CHEMICAL", 296, 306], ["chokeberry", "CHEMICAL", 343, 353], ["polyphenol", "CHEMICAL", 72, 82], ["polyphenol", "CHEMICAL", 296, 306], ["polyphenol extracts", "ORGANISM_SUBSTANCE", 72, 91], ["fruits", "ORGANISM_SUBDIVISION", 97, 103], ["polyphenol extracts", "ORGANISM_SUBSTANCE", 296, 315], ["apple", "ORGANISM_SUBDIVISION", 321, 326], ["strawberry", "ORGANISM_SUBDIVISION", 328, 338], ["chokeberry", "SIMPLE_CHEMICAL", 343, 353], ["apple", "SPECIES", 321, 326], ["strawberry", "SPECIES", 328, 338], ["apple", "SPECIES", 321, 326], ["strawberry", "SPECIES", 328, 338], ["photooxidation", "TREATMENT", 13, 27], ["fusogenic", "PROBLEM", 44, 53], ["P", "TEST", 54, 55], ["polyphenol extracts", "TREATMENT", 72, 91], ["polyphenol extracts", "TREATMENT", 296, 315], ["shown to be", "UNCERTAINTY", 32, 43], ["fusogenic", "OBSERVATION", 44, 53]]], ["Polyphenols were shown to be good antioxidants and to act as antyhemolytic agents.", [["Polyphenols", "CHEMICAL", 0, 11], ["Polyphenols", "CHEMICAL", 0, 11], ["Polyphenols", "SIMPLE_CHEMICAL", 0, 11], ["Polyphenols", "TREATMENT", 0, 11], ["antyhemolytic agents", "TREATMENT", 61, 81]]], ["Both the activities are the result of polyphenols incorporation into biological membranes.", [["membranes", "ANATOMY", 80, 89], ["polyphenols", "CHEMICAL", 38, 49], ["polyphenols", "SIMPLE_CHEMICAL", 38, 49], ["membranes", "CELLULAR_COMPONENT", 80, 89], ["polyphenols incorporation into biological membranes", "PROBLEM", 38, 89], ["biological membranes", "OBSERVATION", 69, 89]]], ["To check potential changes they induce in membranes some experiments were performed with the use of erythrocytes, and lipid membranes.", [["membranes", "ANATOMY", 42, 51], ["erythrocytes", "ANATOMY", 100, 112], ["lipid membranes", "ANATOMY", 118, 133], ["membranes", "CELLULAR_COMPONENT", 42, 51], ["erythrocytes", "CELL", 100, 112], ["lipid membranes", "CELLULAR_COMPONENT", 118, 133], ["erythrocytes", "CELL_TYPE", 100, 112], ["erythrocytes", "TREATMENT", 100, 112], ["lipid membranes", "TREATMENT", 118, 133], ["lipid membranes", "OBSERVATION", 118, 133]]], ["It was found that the extracts studied induced shape transitions of erythrocytes.", [["extracts", "ANATOMY", 22, 30], ["erythrocytes", "ANATOMY", 68, 80], ["extracts", "ORGANISM_SUBSTANCE", 22, 30], ["erythrocytes", "CELL", 68, 80], ["erythrocytes", "CELL_TYPE", 68, 80], ["the extracts", "PROBLEM", 18, 30], ["shape transitions of erythrocytes", "PROBLEM", 47, 80], ["shape", "OBSERVATION_MODIFIER", 47, 52], ["erythrocytes", "ANATOMY", 68, 80]]], ["Strawberry extract induced mainly discocytes and discoechinocytes.", [["extract", "ANATOMY", 11, 18], ["discocytes", "ANATOMY", 34, 44], ["discoechinocytes", "ANATOMY", 49, 65], ["Strawberry extract", "CHEMICAL", 0, 18], ["discoechinocytes", "CELL_TYPE", 49, 65], ["Strawberry extract", "TEST", 0, 18], ["mainly discocytes and discoechinocytes", "PROBLEM", 27, 65], ["mainly discocytes", "OBSERVATION", 27, 44]]], ["Populations of discocytes, echinocytes and some discoechinocytes were found on applying apple extract, while chokeberry induced mainly the formation of echinocytes and spheroechinocytes.", [["discocytes", "ANATOMY", 15, 25], ["echinocytes", "ANATOMY", 27, 38], ["discoechinocytes", "ANATOMY", 48, 64], ["extract", "ANATOMY", 94, 101], ["echinocytes", "ANATOMY", 152, 163], ["spheroechinocytes", "ANATOMY", 168, 185], ["apple extract", "CHEMICAL", 88, 101], ["chokeberry", "CHEMICAL", 109, 119], ["discocytes", "CELL", 15, 25], ["echinocytes", "CELL", 27, 38], ["chokeberry", "SIMPLE_CHEMICAL", 109, 119], ["echinocytes", "CELL", 152, 163], ["discocytes", "CELL_TYPE", 15, 25], ["echinocytes", "CELL_TYPE", 27, 38], ["echinocytes", "CELL_TYPE", 152, 163], ["spheroechinocytes", "CELL_TYPE", 168, 185], ["apple", "SPECIES", 88, 93], ["discocytes", "PROBLEM", 15, 25], ["echinocytes", "PROBLEM", 27, 38], ["some discoechinocytes", "PROBLEM", 43, 64], ["echinocytes", "PROBLEM", 152, 163], ["spheroechinocytes", "PROBLEM", 168, 185], ["discocytes", "OBSERVATION", 15, 25], ["some", "OBSERVATION_MODIFIER", 43, 47], ["discoechinocytes", "OBSERVATION", 48, 64], ["echinocytes", "OBSERVATION", 152, 163]]], ["The results evidence that the polyphenols incorporate into the external monolayer of lipid bilayer of the erythrocyte membrane.", [["monolayer", "ANATOMY", 72, 81], ["lipid bilayer", "ANATOMY", 85, 98], ["erythrocyte membrane", "ANATOMY", 106, 126], ["polyphenols", "CHEMICAL", 30, 41], ["polyphenols", "SIMPLE_CHEMICAL", 30, 41], ["monolayer", "CELL", 72, 81], ["lipid bilayer", "CELLULAR_COMPONENT", 85, 98], ["erythrocyte membrane", "CELLULAR_COMPONENT", 106, 126], ["the polyphenols", "PROBLEM", 26, 41], ["polyphenols", "OBSERVATION", 30, 41], ["external", "ANATOMY_MODIFIER", 63, 71], ["monolayer", "ANATOMY_MODIFIER", 72, 81], ["lipid bilayer", "OBSERVATION", 85, 98], ["erythrocyte membrane", "OBSERVATION", 106, 126]]], ["The results of the fluorimetric experiments showed that all the extracts changed fluidity in the hydrophilic part of RBC membrane.", [["extracts", "ANATOMY", 64, 72], ["RBC membrane", "ANATOMY", 117, 129], ["extracts", "ORGANISM_SUBSTANCE", 64, 72], ["RBC membrane", "CELLULAR_COMPONENT", 117, 129], ["RBC", "CELL_TYPE", 117, 120], ["the fluorimetric experiments", "TEST", 15, 43], ["hydrophilic", "ANATOMY_MODIFIER", 97, 108], ["RBC membrane", "OBSERVATION", 117, 129]]], ["The changes observed were biggest for chokeberry extract and smallest for strawberry one.", [["chokeberry extract", "CHEMICAL", 38, 56], ["chokeberry extract", "PROBLEM", 38, 56], ["smallest", "OBSERVATION_MODIFIER", 61, 69]]], ["Incorporation was also followed by changes in electrical resistance of black lipid membranes and in shifting the temperatures of main transition (T m ) and pretransition (T p ) in liposomes.", [["lipid membranes", "ANATOMY", 77, 92], ["lipid membranes", "CELLULAR_COMPONENT", 77, 92], ["liposomes", "SIMPLE_CHEMICAL", 180, 189], ["black lipid membranes", "PROBLEM", 71, 92], ["pretransition (T p ) in liposomes", "TREATMENT", 156, 189], ["electrical resistance", "OBSERVATION", 46, 67], ["black lipid membranes", "OBSERVATION", 71, 92]]], ["This work was sponsored by Ministry of Science and Education, scientific project no. N N305 337034.Perturbation of lipid membranes by HIV-1 TatA.", [["lipid membranes", "ANATOMY", 115, 130], ["N N305 337034", "CHEMICAL", 85, 98], ["N N305 337034", "CHEMICAL", 85, 98], ["lipid membranes", "CELLULAR_COMPONENT", 115, 130], ["HIV-1 TatA", "GENE_OR_GENE_PRODUCT", 134, 144], ["HIV-1", "SPECIES", 134, 139], ["HIV-1", "SPECIES", 134, 139], ["Perturbation of lipid membranes", "TREATMENT", 99, 130], ["lipid membranes", "OBSERVATION", 115, 130]]], ["Boll 1 , N. Czudnochowski 2 , M. Geyer 2 , C. Steinem 1 1 Institue of Organic and Biomolecular Chemistry, University of G\u00f6ttingen, Germany, 2 MPI for Molecular Physiology, Dortmund, Germany HIV-1 Tat belongs to the accessory proteins of HIV and has regulatory functions.", [["HIV-1", "ORGANISM", 190, 195], ["Tat", "ORGANISM", 196, 199], ["HIV", "ORGANISM", 237, 240], ["Tat", "PROTEIN", 196, 199], ["accessory proteins", "PROTEIN", 215, 233], ["HIV-1", "SPECIES", 190, 195], ["HIV", "SPECIES", 237, 240], ["HIV-1", "SPECIES", 190, 195], ["HIV", "SPECIES", 237, 240], ["Boll", "TEST", 0, 4], ["Geyer", "TEST", 33, 38], ["HIV", "PROBLEM", 237, 240], ["HIV", "OBSERVATION", 237, 240]]], ["Tat is concentrated in the nucleus and nucleolus of infected cells.", [["nucleus", "ANATOMY", 27, 34], ["nucleolus", "ANATOMY", 39, 48], ["cells", "ANATOMY", 61, 66], ["Tat", "GENE_OR_GENE_PRODUCT", 0, 3], ["nucleus", "CELLULAR_COMPONENT", 27, 34], ["nucleolus", "CELLULAR_COMPONENT", 39, 48], ["cells", "CELL", 61, 66], ["Tat", "PROTEIN", 0, 3], ["infected cells", "CELL_TYPE", 52, 66], ["infected cells", "PROBLEM", 52, 66], ["concentrated", "OBSERVATION_MODIFIER", 7, 19], ["nucleus", "ANATOMY", 27, 34], ["nucleolus", "OBSERVATION_MODIFIER", 39, 48], ["infected cells", "OBSERVATION", 52, 66]]], ["The protein is composed of 86 amino acids with a molecular weight of 11 kDa.", [["amino acids", "CHEMICAL", 30, 41], ["amino acids", "CHEMICAL", 30, 41], ["amino acids", "AMINO_ACID", 30, 41], ["The protein", "TEST", 0, 11], ["amino acids", "TEST", 30, 41]]], ["Tat is a transcriptional activator protein, which stimulates RNA polymerase II-mediated transcription elongation.", [["Tat", "GENE_OR_GENE_PRODUCT", 0, 3], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 61, 78], ["Tat", "PROTEIN", 0, 3], ["transcriptional activator protein", "PROTEIN", 9, 42], ["RNA polymerase II", "PROTEIN", 61, 78], ["a transcriptional activator protein", "TREATMENT", 7, 42], ["elongation", "OBSERVATION_MODIFIER", 102, 112]]], ["Therefore, Tat interacts with Cyclin T1 and binds to the TAR RNA element.", [["Tat", "GENE_OR_GENE_PRODUCT", 11, 14], ["Cyclin T1", "GENE_OR_GENE_PRODUCT", 30, 39], ["Tat", "PROTEIN", 11, 14], ["Cyclin T1", "PROTEIN", 30, 39], ["TAR RNA element", "DNA", 57, 72], ["Cyclin T1", "TREATMENT", 30, 39], ["TAR RNA element", "OBSERVATION", 57, 72]]], ["Tat has different domains.", [["Tat", "GENE_OR_GENE_PRODUCT", 0, 3], ["Tat", "PROTEIN", 0, 3], ["different", "OBSERVATION_MODIFIER", 8, 17], ["domains", "OBSERVATION_MODIFIER", 18, 25]]], ["With respect to the interaction with lipid membranes, the most important structural motif is its basic region, including 6 arginine and 2 lysine residues.", [["lipid membranes", "ANATOMY", 37, 52], ["arginine", "CHEMICAL", 123, 131], ["arginine", "CHEMICAL", 123, 131], ["lysine", "CHEMICAL", 138, 144], ["lipid membranes", "CELLULAR_COMPONENT", 37, 52], ["arginine", "AMINO_ACID", 123, 131], ["basic region", "PROTEIN", 97, 109], ["lipid membranes", "TREATMENT", 37, 52], ["6 arginine and 2 lysine residues", "TREATMENT", 121, 153], ["lipid membranes", "OBSERVATION", 37, 52]]], ["The peptide derived from this basic region belongs to the cell-penetrating peptides and is able to translocate through lipid membranes.", [["cell", "ANATOMY", 58, 62], ["lipid membranes", "ANATOMY", 119, 134], ["cell", "CELL", 58, 62], ["lipid membranes", "CELLULAR_COMPONENT", 119, 134], ["The peptide", "TEST", 0, 11], ["penetrating peptides", "OBSERVATION", 63, 83], ["lipid membranes", "OBSERVATION", 119, 134]]], ["The major aim of this study is to investigate the influence of full length HIV-1 Tat on artificial lipid membranes.", [["lipid membranes", "ANATOMY", 99, 114], ["HIV-1", "ORGANISM", 75, 80], ["Tat", "GENE_OR_GENE_PRODUCT", 81, 84], ["lipid membranes", "CELLULAR_COMPONENT", 99, 114], ["full length HIV-1 Tat", "PROTEIN", 63, 84], ["HIV-1", "SPECIES", 75, 80], ["HIV-1", "SPECIES", 75, 80], ["this study", "TEST", 17, 27], ["artificial lipid membranes", "TREATMENT", 88, 114], ["lipid membranes", "OBSERVATION", 99, 114]]], ["As a starting point solid-supported membranes composed of 1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholine (POPC) immobilized on silicon dioxide were used.", [["membranes", "ANATOMY", 36, 45], ["1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholine", "CHEMICAL", 58, 105], ["POPC", "CHEMICAL", 107, 111], ["silicon dioxide", "CHEMICAL", 128, 143], ["1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholine", "CHEMICAL", 58, 105], ["POPC", "CHEMICAL", 107, 111], ["silicon dioxide", "CHEMICAL", 128, 143], ["membranes", "CELLULAR_COMPONENT", 36, 45], ["1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholine", "SIMPLE_CHEMICAL", 58, 105], ["POPC", "SIMPLE_CHEMICAL", 107, 111], ["silicon dioxide", "SIMPLE_CHEMICAL", 128, 143], ["palmitoyl", "TEST", 60, 69], ["sn-glycero-3phosphocholine (POPC)", "TREATMENT", 79, 112], ["silicon dioxide", "TREATMENT", 128, 143]]], ["The influence of the lipid head groups on the interaction with Tat was analysed by using membranes composed of the negatively charged lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-L-serine] (POPS) in a mixture with POPC.", [["membranes", "ANATOMY", 89, 98], ["1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-L-serine", "CHEMICAL", 140, 191], ["POPS", "CHEMICAL", 194, 198], ["POPC", "CHEMICAL", 218, 222], ["1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-L-serine]", "CHEMICAL", 140, 192], ["POPS", "CHEMICAL", 194, 198], ["POPC", "CHEMICAL", 218, 222], ["Tat", "GENE_OR_GENE_PRODUCT", 63, 66], ["membranes", "CELLULAR_COMPONENT", 89, 98], ["lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-L-serine]", "SIMPLE_CHEMICAL", 134, 192], ["POPS", "SIMPLE_CHEMICAL", 194, 198], ["POPC", "SIMPLE_CHEMICAL", 218, 222], ["Tat", "PROTEIN", 63, 66], ["the negatively charged lipid", "TREATMENT", 111, 139], ["palmitoyl", "TEST", 142, 151], ["oleoyl", "TREATMENT", 154, 160], ["glycero", "TREATMENT", 164, 171], ["phospho-L-serine] (POPS", "TREATMENT", 175, 198], ["POPC", "TREATMENT", 218, 222]]], ["Fluorescently labelled Tat was used to localise the protein in the membrane.", [["membrane", "ANATOMY", 67, 75], ["Tat", "GENE_OR_GENE_PRODUCT", 23, 26], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["Tat", "PROTEIN", 23, 26], ["Tat", "TEST", 23, 26], ["membrane", "ANATOMY_MODIFIER", 67, 75]]], ["The impact of Tat on lipid membranes was investigated by fluorescence and atomic force microscopy, showing that it is capable of perturbing lipid membranes.Different action mechanisms of antimicrobial peptides: fluorescence experiments and MD simulationsG.", [["lipid membranes", "ANATOMY", 21, 36], ["lipid membranes", "ANATOMY", 140, 155], ["Tat", "GENE_OR_GENE_PRODUCT", 14, 17], ["lipid membranes", "CELLULAR_COMPONENT", 21, 36], ["lipid membranes", "CELLULAR_COMPONENT", 140, 155], ["Tat", "PROTEIN", 14, 17], ["Tat on lipid membranes", "TREATMENT", 14, 36], ["atomic force microscopy", "TEST", 74, 97], ["perturbing lipid membranes", "PROBLEM", 129, 155], ["lipid membranes", "OBSERVATION", 140, 155]]], ["Bocchinfuso 1 , A. Palleschi 1 , B. Orioni 1 , G. Grande 1 , F. Formaggio 2 , C. Toniolo 2 , Y. Park 3 , K. S. Hahm 3 , L. Stella 1 1 Univ. of Rome Tor Vergata, Dept. of Chemistry, Italy, 2 Dept. of Chemistry, Univ. of Padova and CNR, Italy, 3 Chosun Univ., RCPM, South Korea.Different action mechanisms of antimicrobial peptides: fluorescence experiments and MD simulationsMost antimicrobial peptides exert their activity by perturbing the permeability of bacterial membranes, but the molecular details of this process are still debated.", [["membranes", "ANATOMY", 467, 476], ["bacterial membranes", "CELLULAR_COMPONENT", 457, 476], ["Formaggio", "TEST", 64, 73], ["Chemistry", "TEST", 199, 208], ["Padova", "TREATMENT", 219, 225], ["Most antimicrobial peptides", "TREATMENT", 374, 401], ["bacterial membranes", "PROBLEM", 457, 476], ["bacterial membranes", "OBSERVATION", 457, 476]]], ["Here, we compare fluorescence experiments and molecular dynamics simulations regarding the interaction of two antimicrobial peptides (PMAP-23 and trichogin GA IV) with lipid membranes, showing that their mechanisms of bilayer perturbation are significantly different.", [["lipid membranes", "ANATOMY", 168, 183], ["PMAP-23 and trichogin GA IV", "CHEMICAL", 134, 161], ["trichogin GA IV", "CHEMICAL", 146, 161], ["PMAP-23", "SIMPLE_CHEMICAL", 134, 141], ["trichogin GA IV", "SIMPLE_CHEMICAL", 146, 161], ["lipid membranes", "CELLULAR_COMPONENT", 168, 183], ["fluorescence experiments", "TEST", 17, 41], ["two antimicrobial peptides", "TREATMENT", 106, 132], ["PMAP", "TEST", 134, 138], ["trichogin GA IV", "TREATMENT", 146, 161], ["lipid membranes", "TREATMENT", 168, 183], ["bilayer perturbation", "PROBLEM", 218, 238], ["lipid membranes", "ANATOMY", 168, 183], ["bilayer perturbation", "OBSERVATION", 218, 238], ["significantly", "OBSERVATION_MODIFIER", 243, 256], ["different", "OBSERVATION_MODIFIER", 257, 266]]], ["PMAP-23, a cationic peptide member of the cathelicidin family, associates to the membrane close to its surface and parallel to it, and in this arrangement it causes a severe perturbation to the bilayer, both regarding its surface tension and lipid order.", [["membrane", "ANATOMY", 81, 89], ["surface", "ANATOMY", 103, 110], ["surface", "ANATOMY", 222, 229], ["PMAP-23", "CHEMICAL", 0, 7], ["PMAP-23", "CHEMICAL", 0, 7], ["PMAP-23", "SIMPLE_CHEMICAL", 0, 7], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 42, 54], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["surface", "CELLULAR_COMPONENT", 103, 110], ["lipid", "SIMPLE_CHEMICAL", 242, 247], ["cathelicidin family", "PROTEIN", 42, 61], ["PMAP", "TEST", 0, 4], ["a severe perturbation to the bilayer", "PROBLEM", 165, 201], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["perturbation", "OBSERVATION", 174, 186]]], ["On the other hand, trichogin GA IV, a neutral peptide member of the peptaibol family, undergoes a transition from a surface-bound state to an inserted orientation.", [["surface", "ANATOMY", 116, 123], ["trichogin", "CHEMICAL", 19, 28], ["GA IV", "CHEMICAL", 29, 34], ["trichogin GA IV", "CHEMICAL", 19, 34], ["trichogin GA IV", "SIMPLE_CHEMICAL", 19, 34], ["peptaibol", "GENE_OR_GENE_PRODUCT", 68, 77], ["trichogin GA IV", "PROTEIN", 19, 34], ["peptaibol family", "PROTEIN", 68, 84], ["trichogin GA IV", "TREATMENT", 19, 34]]], ["In the first arrangement it does not cause any strong membrane perturbation, while in the second orientation it may span the bilayer from one side to the other, despite its relatively short length, by causing a significant thinning of the membrane.", [["membrane", "ANATOMY", 54, 62], ["membrane", "ANATOMY", 239, 247], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["membrane", "CELLULAR_COMPONENT", 239, 247], ["any strong membrane perturbation", "PROBLEM", 43, 75], ["a significant thinning of the membrane", "PROBLEM", 209, 247], ["does not cause", "UNCERTAINTY", 28, 42], ["strong", "OBSERVATION_MODIFIER", 47, 53], ["membrane", "OBSERVATION_MODIFIER", 54, 62], ["perturbation", "OBSERVATION", 63, 75], ["short length", "OBSERVATION_MODIFIER", 184, 196], ["significant", "OBSERVATION_MODIFIER", 211, 222], ["thinning", "OBSERVATION", 223, 231], ["membrane", "ANATOMY_MODIFIER", 239, 247]]], ["Lipopolysaccharide (LPS) is the main component of the outer membrane of Gram negative bacteria.", [["outer membrane", "ANATOMY", 54, 68], ["Lipopolysaccharide", "CHEMICAL", 0, 18], ["LPS", "CHEMICAL", 20, 23], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 0, 18], ["LPS", "SIMPLE_CHEMICAL", 20, 23], ["outer membrane", "CELLULAR_COMPONENT", 54, 68], ["Gram", "GENE_OR_GENE_PRODUCT", 72, 76], ["Lipopolysaccharide (LPS", "TEST", 0, 23], ["Gram negative bacteria", "PROBLEM", 72, 94], ["main", "OBSERVATION_MODIFIER", 32, 36], ["component", "OBSERVATION_MODIFIER", 37, 46], ["outer membrane", "ANATOMY", 54, 68], ["Gram negative bacteria", "OBSERVATION", 72, 94]]], ["LPS is also known as endotoxin because of its potency to induce sepsis, a serious source of mortality in many clinical cases.", [["LPS", "CHEMICAL", 0, 3], ["sepsis", "DISEASE", 64, 70], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS", "TEST", 0, 3], ["endotoxin", "TREATMENT", 21, 30], ["sepsis", "PROBLEM", 64, 70], ["sepsis", "OBSERVATION", 64, 70]]], ["Among LPS-neutralizing agents, polymyxin B (PxB) is considered as the \"gold standard\" due to its high efficiency of binding and detoxification of endotoxin.", [["LPS", "CHEMICAL", 6, 9], ["polymyxin B", "CHEMICAL", 31, 42], ["PxB", "CHEMICAL", 44, 47], ["endotoxin", "CHEMICAL", 146, 155], ["polymyxin B", "CHEMICAL", 31, 42], ["PxB", "CHEMICAL", 44, 47], ["LPS", "SIMPLE_CHEMICAL", 6, 9], ["polymyxin B", "SIMPLE_CHEMICAL", 31, 42], ["PxB", "SIMPLE_CHEMICAL", 44, 47], ["endotoxin", "SIMPLE_CHEMICAL", 146, 155], ["endotoxin", "PROTEIN", 146, 155], ["LPS", "TEST", 6, 9], ["neutralizing agents", "TREATMENT", 10, 29], ["polymyxin B (PxB", "TREATMENT", 31, 47], ["its high efficiency of binding", "PROBLEM", 93, 123], ["endotoxin", "TREATMENT", 146, 155]]], ["In this work, we have further explored the interaction of PxB to LPS from the rough mutant of Salmonella minnesota (Re-LPS) both in the gel and in the liquid crystalline phase, using isothermal titration calorimetry (ITC) and fluorescence based techniques.", [["PxB", "CHEMICAL", 58, 61], ["LPS", "CHEMICAL", 65, 68], ["LPS", "CHEMICAL", 119, 122], ["PxB", "CHEMICAL", 58, 61], ["PxB", "SIMPLE_CHEMICAL", 58, 61], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["Salmonella minnesota", "ORGANISM", 94, 114], ["Re-LPS", "SIMPLE_CHEMICAL", 116, 122], ["PxB", "PROTEIN", 58, 61], ["Salmonella minnesota", "SPECIES", 94, 114], ["Salmonella minnesota", "SPECIES", 94, 114], ["LPS", "TREATMENT", 65, 68], ["Salmonella minnesota (Re-LPS)", "TREATMENT", 94, 123], ["isothermal titration calorimetry", "TREATMENT", 183, 215], ["fluorescence based techniques", "TEST", 226, 255]]], ["The effect of PxB binding on LPS-membrane integrity was determined with a fluorescence quenching assay treating vesicles of LPS labeled with NBD-PE with dithionite.", [["membrane", "ANATOMY", 33, 41], ["vesicles", "ANATOMY", 112, 120], ["PxB", "CHEMICAL", 14, 17], ["LPS", "CHEMICAL", 29, 32], ["LPS", "CHEMICAL", 124, 127], ["NBD-PE", "CHEMICAL", 141, 147], ["dithionite", "CHEMICAL", 153, 163], ["PxB", "CHEMICAL", 14, 17], ["NBD-PE", "CHEMICAL", 141, 147], ["dithionite", "CHEMICAL", 153, 163], ["PxB", "SIMPLE_CHEMICAL", 14, 17], ["LPS", "SIMPLE_CHEMICAL", 29, 32], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["NBD-PE", "SIMPLE_CHEMICAL", 141, 147], ["dithionite", "SIMPLE_CHEMICAL", 153, 163], ["PxB", "PROTEIN", 14, 17], ["PxB binding", "PROBLEM", 14, 25], ["LPS", "TEST", 29, 32], ["a fluorescence quenching assay", "TEST", 72, 102], ["NBD", "PROBLEM", 141, 144], ["PE", "PROBLEM", 145, 147], ["dithionite", "TREATMENT", 153, 163], ["PE", "OBSERVATION", 145, 147]]], ["Thermodynamic parameters associated with the binding process as well as binding stoichiometry were obtained from ITC experiments.", [["Thermodynamic parameters", "TEST", 0, 24], ["the binding process", "PROBLEM", 41, 60], ["binding stoichiometry", "PROBLEM", 72, 93]]], ["Finally, ITC was conducted with Enterococcus faecalis and Salmonella typhimurium, as representative examples of a Gram negative and a Gram positive bacterium respectively.P-561Pressure jumps -an accessible trigger for biomolecular transformations High pressure can be used to induce many structural changes in biological systems: from triggering phase changes in model membranes to causing protein unfolding, in fact any change involving a volume reduction is promoted by pressure.", [["ITC", "ANATOMY", 9, 12], ["membranes", "ANATOMY", 369, 378], ["ITC", "CELL", 9, 12], ["Enterococcus faecalis", "ORGANISM", 32, 53], ["Salmonella typhimurium", "ORGANISM", 58, 80], ["Gram", "GENE_OR_GENE_PRODUCT", 114, 118], ["membranes", "CELLULAR_COMPONENT", 369, 378], ["Enterococcus faecalis", "SPECIES", 32, 53], ["Salmonella typhimurium", "SPECIES", 58, 80], ["Enterococcus faecalis", "SPECIES", 32, 53], ["Salmonella typhimurium", "SPECIES", 58, 80], ["ITC", "TREATMENT", 9, 12], ["Enterococcus faecalis", "PROBLEM", 32, 53], ["Salmonella typhimurium", "PROBLEM", 58, 80], ["a Gram", "TEST", 112, 118], ["a Gram positive bacterium", "PROBLEM", 132, 157], ["biomolecular transformations", "PROBLEM", 218, 246], ["High pressure", "TREATMENT", 247, 260], ["many structural changes in biological systems", "PROBLEM", 283, 328], ["triggering phase changes in model membranes", "PROBLEM", 335, 378], ["protein unfolding", "PROBLEM", 390, 407], ["a volume reduction", "TREATMENT", 438, 456], ["Enterococcus faecalis", "OBSERVATION", 32, 53], ["biomolecular transformations", "OBSERVATION", 218, 246], ["model membranes", "OBSERVATION", 363, 378], ["protein unfolding", "OBSERVATION", 390, 407], ["volume reduction", "OBSERVATION", 440, 456], ["pressure", "OBSERVATION_MODIFIER", 472, 480]]], ["As well as being broadly applicable, pressure changes can be applied very quickly both up and down in contrast to other structure change triggers such as temperature jumps.", [["pressure changes", "TREATMENT", 37, 53]]], ["Fast pressure jumps allow the trigger to be decoupled from structural changes, so with fast structure probe techniques such as time resolved X-ray diffraction, the out-of-equilibrium evolution of these systems can be monitored.", [["Fast pressure jumps", "PROBLEM", 0, 19], ["fast structure probe techniques", "TREATMENT", 87, 118], ["pressure jumps", "OBSERVATION", 5, 19]]], ["Despite great advantages, high pressure remains under-utilised primarily due to its technical difficulty.", [["high pressure", "TREATMENT", 26, 39], ["its technical difficulty", "PROBLEM", 80, 104], ["high pressure", "OBSERVATION", 26, 39]]], ["In response to this technology vacuum a high pressure user facility based around a pressure jump cell for small and wide angle X-ray diffraction has been commissioned at beamline I22, Diamond Light Source, UK and will be freely available to the user community.", [["cell", "ANATOMY", 97, 101], ["cell", "CELL", 97, 101], ["this technology vacuum a high pressure user facility", "TREATMENT", 15, 67], ["a pressure jump cell", "TREATMENT", 81, 101], ["small and wide angle X-ray diffraction", "TREATMENT", 106, 144], ["jump cell", "OBSERVATION", 92, 101], ["small", "OBSERVATION_MODIFIER", 106, 111]]], ["The cell is highly robust requiring virtually no user intervention during an experiment and the pressure system is computer controlled with a graphical user interface and is integrated with the beamline.", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["user intervention", "TREATMENT", 49, 66], ["the pressure system", "TEST", 92, 111], ["the beamline", "TREATMENT", 190, 202], ["cell", "OBSERVATION", 4, 8]]], ["Pressures between 0 and 0.5 GPa are accessible and jumps can be carried out in approximately 5 ms at temperatures from -10 to 120 \u2022 C. Sample changing has been made simple and fast with a dedicated sample loading port and modular sample holders allow optimisation for a broad range of samples.P-560The transformation of vesicle and lateral distribution of mobile membrane inclusions B. Bozic Institute of Biophysics, Faculty of Medicine, University of Ljubljana, Lipi\u010deva 2, SI-1000 Ljubljana, Slovenia Membrane inclusions such as membrane embedded peptides or proteins exhibit curvature dependent interaction with the surrounding lipid matrix due to the mismatch between their intrinsic curvature and the local membrane curvature.", [["sample", "ANATOMY", 198, 204], ["samples", "ANATOMY", 285, 292], ["vesicle", "ANATOMY", 320, 327], ["membrane", "ANATOMY", 363, 371], ["membrane", "ANATOMY", 531, 539], ["lipid matrix", "ANATOMY", 631, 643], ["membrane", "ANATOMY", 712, 720], ["P-560", "CHEMICAL", 293, 298], ["samples", "CANCER", 285, 292], ["vesicle", "CELLULAR_COMPONENT", 320, 327], ["membrane", "CELLULAR_COMPONENT", 363, 371], ["membrane", "CELLULAR_COMPONENT", 531, 539], ["lipid matrix", "CELLULAR_COMPONENT", 631, 643], ["membrane", "CELLULAR_COMPONENT", 712, 720], ["Pressures", "TEST", 0, 9], ["temperatures", "TEST", 101, 113], ["a dedicated sample loading port", "TREATMENT", 186, 217], ["modular sample holders", "TREATMENT", 222, 244], ["P", "TEST", 293, 294], ["Lipi\u010deva", "TREATMENT", 463, 471], ["Slovenia Membrane inclusions", "TREATMENT", 494, 522], ["membrane embedded peptides", "TREATMENT", 531, 557], ["curvature dependent interaction", "PROBLEM", 578, 609], ["the surrounding lipid matrix", "TREATMENT", 615, 643], ["vesicle", "ANATOMY", 320, 327], ["lateral", "OBSERVATION_MODIFIER", 332, 339], ["mobile membrane", "OBSERVATION", 356, 371], ["curvature", "OBSERVATION_MODIFIER", 578, 587], ["mismatch", "OBSERVATION", 655, 663], ["intrinsic curvature", "OBSERVATION", 678, 697], ["local", "OBSERVATION_MODIFIER", 706, 711], ["membrane curvature", "OBSERVATION", 712, 730]]], ["This interaction causes an inhomogeneous lateral distribution of the inclusions and a corresponding adjustment of the vesicle shape.", [["vesicle", "ANATOMY", 118, 125], ["vesicle", "CELLULAR_COMPONENT", 118, 125], ["the inclusions", "PROBLEM", 65, 79], ["a corresponding adjustment of the vesicle shape", "PROBLEM", 84, 131], ["inhomogeneous", "OBSERVATION_MODIFIER", 27, 40], ["lateral", "OBSERVATION_MODIFIER", 41, 48], ["distribution", "OBSERVATION_MODIFIER", 49, 61], ["inclusions", "OBSERVATION", 69, 79], ["vesicle shape", "OBSERVATION", 118, 131]]], ["By taking into consideration that the membrane free energy includes elastic energy of the lipid bilayer and a contribution due to an inclusion-membrane interaction, the configurations of lipid vesicles with mobile inclusions have been studied theoretically.", [["membrane", "ANATOMY", 38, 46], ["lipid bilayer", "ANATOMY", 90, 103], ["membrane", "ANATOMY", 143, 151], ["lipid vesicles", "ANATOMY", 187, 201], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["lipid bilayer", "CELLULAR_COMPONENT", 90, 103], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["lipid vesicles", "CELLULAR_COMPONENT", 187, 201], ["the membrane free energy", "PROBLEM", 34, 58], ["an inclusion-membrane interaction", "PROBLEM", 130, 163], ["lipid vesicles", "PROBLEM", 187, 201], ["mobile inclusions", "PROBLEM", 207, 224], ["membrane interaction", "OBSERVATION", 143, 163], ["lipid vesicles", "OBSERVATION", 187, 201], ["mobile inclusions", "OBSERVATION", 207, 224]]], ["The variational problem to calculate equilibrium vesicle shapes is solved by applying a Ritz method based on an expansion in spherical harmonics.", [["vesicle", "ANATOMY", 49, 56], ["The variational problem", "PROBLEM", 0, 23], ["a Ritz method", "TREATMENT", 86, 99], ["an expansion in spherical harmonics", "TREATMENT", 109, 144], ["variational problem", "OBSERVATION", 4, 23], ["expansion", "OBSERVATION_MODIFIER", 112, 121], ["spherical harmonics", "OBSERVATION", 125, 144]]], ["In general, vesicle shapes adjust to the presence of inclusions by increasing regions with favorable curvature and decreasing regions of unfavorable curvature in such a way that the lateral distribution of inclusions becomes inhomogeneous.", [["vesicle", "ANATOMY", 12, 19], ["vesicle", "CELLULAR_COMPONENT", 12, 19], ["favorable curvature", "PROBLEM", 91, 110], ["unfavorable curvature", "PROBLEM", 137, 158], ["vesicle shapes", "OBSERVATION", 12, 26], ["inclusions", "OBSERVATION", 53, 63], ["increasing", "OBSERVATION_MODIFIER", 67, 77], ["favorable", "OBSERVATION_MODIFIER", 91, 100], ["curvature", "OBSERVATION_MODIFIER", 101, 110], ["decreasing", "OBSERVATION_MODIFIER", 115, 125], ["regions", "OBSERVATION_MODIFIER", 126, 133], ["unfavorable curvature", "OBSERVATION", 137, 158], ["lateral", "OBSERVATION_MODIFIER", 182, 189], ["inclusions", "OBSERVATION", 206, 216], ["inhomogeneous", "OBSERVATION_MODIFIER", 225, 238]]], ["If the number of inclusions or the inclusion-membrane interaction exceeds a certain value, the prolate shapes become globally stable.P-559Investigating the structure of pores formed by antimicrobial peptides using EPR spectroscopy M. Bortolus 1 , K.-S. Hahm 2 , A. L. Maniero 1 1 Universita' di Padova, Padova, Italy, 2 Chosun University, Kwangju, South Korea Spin label Electron Paramagnetic Resonance (EPR) is a spectroscopical technique effective to study the molecular mobility of membrane components and the membranepeptide interactions, as the timescale of EPR is optimally matched to the rotational motions of lipids in membranes.", [["membrane", "ANATOMY", 45, 53], ["pores", "ANATOMY", 169, 174], ["membrane components", "ANATOMY", 485, 504], ["membranes", "ANATOMY", 627, 636], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["membrane components", "CELLULAR_COMPONENT", 485, 504], ["membranepeptide", "SIMPLE_CHEMICAL", 513, 528], ["lipids", "SIMPLE_CHEMICAL", 617, 623], ["membranes", "CELLULAR_COMPONENT", 627, 636], ["P", "DNA", 133, 134], ["P", "TEST", 133, 134], ["antimicrobial peptides", "TREATMENT", 185, 207], ["EPR spectroscopy", "TEST", 214, 230], ["Bortolus", "TEST", 234, 242], ["Padova", "TREATMENT", 303, 309], ["a spectroscopical technique", "TREATMENT", 412, 439], ["the membranepeptide interactions", "TREATMENT", 509, 541], ["inclusions", "OBSERVATION", 17, 27], ["globally", "OBSERVATION_MODIFIER", 117, 125], ["stable", "OBSERVATION_MODIFIER", 126, 132]]], ["We applied EPR to study the pore-forming mechanism of two antimicrobial peptides (AMP) that create pores of different dimensions when interacting with liposomes.", [["pore", "ANATOMY", 28, 32], ["AMP", "CHEMICAL", 82, 85], ["AMP", "SIMPLE_CHEMICAL", 82, 85], ["liposomes", "SIMPLE_CHEMICAL", 151, 160], ["EPR", "TREATMENT", 11, 14], ["two antimicrobial peptides", "TREATMENT", 54, 80], ["AMP)", "TREATMENT", 82, 86], ["different dimensions", "OBSERVATION_MODIFIER", 108, 128]]], ["HP (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) is derived from the N-terminus of Helicobacter pylori ribosomal protein L1, and HPA3 is an HP (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) analogue where Gln and Asp at positions 17 and 19 were substituted by Trp.", [["Gln", "CHEMICAL", 286, 289], ["Asp", "CHEMICAL", 294, 297], ["HP (2) (3) (4)", "CHEMICAL", 0, 14], ["Gln", "CHEMICAL", 286, 289], ["Asp", "CHEMICAL", 294, 297], ["HP (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20)", "SIMPLE_CHEMICAL", 0, 89], ["Helicobacter pylori", "ORGANISM", 124, 143], ["ribosomal protein L1", "GENE_OR_GENE_PRODUCT", 144, 164], ["HPA3", "SIMPLE_CHEMICAL", 170, 174], ["5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) analogue", "SIMPLE_CHEMICAL", 197, 279], ["Gln", "AMINO_ACID", 286, 289], ["Asp", "AMINO_ACID", 294, 297], ["Helicobacter pylori ribosomal protein L1", "PROTEIN", 124, 164], ["HPA3", "PROTEIN", 170, 174], ["Helicobacter pylori", "SPECIES", 124, 143], ["Helicobacter pylori", "SPECIES", 124, 143], ["HP (2) (3) (4) (5) (6) (7) (8) (9", "TEST", 0, 33], ["Helicobacter pylori ribosomal protein L1", "TEST", 124, 164], ["HPA3", "TEST", 170, 174], ["an HP", "TEST", 178, 183], ["analogue", "TEST", 271, 279], ["Gln", "TEST", 286, 289], ["Asp at positions", "TEST", 294, 310], ["Helicobacter pylori", "OBSERVATION", 124, 143], ["protein L1", "OBSERVATION", 154, 164], ["HP", "OBSERVATION", 181, 183]]], ["We studied the interaction of the two AMP with zwitterionic and negatively charged vesicles, doped with phospholipids spin labelled in the lipid head or at the C5 or C10 positions; the different phospholipids allow us to study the peptide-membrane interaction at different depths relative to the membrane surface.", [["vesicles", "ANATOMY", 83, 91], ["lipid head", "ANATOMY", 139, 149], ["membrane", "ANATOMY", 239, 247], ["membrane surface", "ANATOMY", 296, 312], ["AMP", "CHEMICAL", 38, 41], ["AMP", "CHEMICAL", 38, 41], ["AMP", "SIMPLE_CHEMICAL", 38, 41], ["zwitterionic", "SIMPLE_CHEMICAL", 47, 59], ["vesicles", "CELLULAR_COMPONENT", 83, 91], ["phospholipids", "SIMPLE_CHEMICAL", 195, 208], ["membrane", "CELLULAR_COMPONENT", 239, 247], ["membrane surface", "CELLULAR_COMPONENT", 296, 312], ["the two AMP with zwitterionic and negatively charged vesicles", "TREATMENT", 30, 91], ["phospholipids spin", "TEST", 104, 122], ["C5", "ANATOMY_MODIFIER", 160, 162], ["C10", "ANATOMY", 166, 169], ["membrane surface", "OBSERVATION", 296, 312]]], ["We studied the interaction of the AMP with vesicles following the influence of AMP on label mobility as a function of temperature and membrane depth.", [["vesicles", "ANATOMY", 43, 51], ["membrane", "ANATOMY", 134, 142], ["AMP", "CHEMICAL", 34, 37], ["AMP", "CHEMICAL", 79, 82], ["AMP", "CHEMICAL", 34, 37], ["AMP", "CHEMICAL", 79, 82], ["AMP", "SIMPLE_CHEMICAL", 34, 37], ["vesicles", "CELLULAR_COMPONENT", 43, 51], ["AMP", "SIMPLE_CHEMICAL", 79, 82], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["the AMP with vesicles", "TREATMENT", 30, 51], ["AMP on label mobility", "TREATMENT", 79, 100]]], ["We also prepared spin-labelled DMPC/DHPC bicelles, doped with lanthanide ions (Dy 3+ /Tm 3+ ) that allow us to macroscopically orient the system using the magnetic field of the EPR spectrometer.", [["DMPC", "CHEMICAL", 31, 35], ["DMPC", "CHEMICAL", 31, 35], ["DHPC", "CHEMICAL", 36, 40], ["lanthanide", "CHEMICAL", 62, 72], ["Dy 3+", "CHEMICAL", 79, 84], ["DMPC", "SIMPLE_CHEMICAL", 31, 35], ["DHPC bicelles", "SIMPLE_CHEMICAL", 36, 49], ["lanthanide ions", "SIMPLE_CHEMICAL", 62, 77], ["Dy 3+", "SIMPLE_CHEMICAL", 79, 84], ["Tm 3+", "SIMPLE_CHEMICAL", 86, 91], ["labelled DMPC/DHPC bicelles", "TREATMENT", 22, 49], ["lanthanide ions", "TREATMENT", 62, 77]]], ["We studied the interaction of AMP with the oriented bicellar system monitoring the effect of AMP on the order parameter of the phase.Organization and dynamics of the serotonin-1A receptor in live cells using fluorescence microscopyA.", [["cells", "ANATOMY", 196, 201], ["AMP", "CHEMICAL", 30, 33], ["AMP", "CHEMICAL", 93, 96], ["serotonin", "CHEMICAL", 166, 175], ["AMP", "CHEMICAL", 30, 33], ["AMP", "CHEMICAL", 93, 96], ["serotonin", "CHEMICAL", 166, 175], ["AMP", "SIMPLE_CHEMICAL", 30, 33], ["AMP", "SIMPLE_CHEMICAL", 93, 96], ["serotonin-1A receptor", "GENE_OR_GENE_PRODUCT", 166, 187], ["cells", "CELL", 196, 201], ["serotonin-1A receptor", "PROTEIN", 166, 187], ["live cells", "CELL_TYPE", 191, 201], ["AMP", "TREATMENT", 30, 33], ["the oriented bicellar system", "TREATMENT", 39, 67], ["AMP", "TREATMENT", 93, 96], ["the serotonin", "TEST", 162, 175], ["fluorescence microscopyA", "TEST", 208, 232]]], ["Chattopadhyay Centre for Cellular and Molecular Biology, Hyderabad, IndiaOrganization and dynamics of the serotonin-1A receptor in live cells using fluorescence microscopyWe addressed the organization and dynamics of the human serotonin 1A receptor fused to enhanced yellow fluorescent protein (serotonin 1A R-EYFP) expressed in CHO cells.", [["cells", "ANATOMY", 136, 141], ["CHO cells", "ANATOMY", 329, 338], ["serotonin", "CHEMICAL", 106, 115], ["serotonin", "CHEMICAL", 227, 236], ["serotonin", "CHEMICAL", 295, 304], ["serotonin", "CHEMICAL", 106, 115], ["serotonin", "CHEMICAL", 227, 236], ["serotonin", "CHEMICAL", 295, 304], ["serotonin-1A receptor", "GENE_OR_GENE_PRODUCT", 106, 127], ["cells", "CELL", 136, 141], ["human", "ORGANISM", 221, 226], ["serotonin 1A receptor", "GENE_OR_GENE_PRODUCT", 227, 248], ["yellow fluorescent protein", "GENE_OR_GENE_PRODUCT", 267, 293], ["serotonin 1A R-EYFP", "GENE_OR_GENE_PRODUCT", 295, 314], ["CHO cells", "CELL", 329, 338], ["serotonin-1A receptor", "PROTEIN", 106, 127], ["live cells", "CELL_TYPE", 131, 141], ["human serotonin 1A receptor", "PROTEIN", 221, 248], ["yellow fluorescent protein", "PROTEIN", 267, 293], ["serotonin 1A R", "PROTEIN", 295, 309], ["EYFP", "PROTEIN", 310, 314], ["CHO cells", "CELL_LINE", 329, 338], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["the serotonin", "TEST", 102, 115], ["fluorescence microscopy", "TEST", 148, 171], ["enhanced yellow fluorescent protein", "PROBLEM", 258, 293], ["serotonin", "TEST", 295, 304], ["CHO cells", "OBSERVATION", 329, 338]]], ["Serotonin 1A receptors are prototypical members of the Gprotein coupled receptor superfamily and represent a prime target for therapeutic actions of several anxiolytic and antidepressant drugs.", [["Serotonin", "CHEMICAL", 0, 9], ["antidepressant", "CHEMICAL", 172, 186], ["Serotonin", "CHEMICAL", 0, 9], ["Serotonin 1A receptors", "GENE_OR_GENE_PRODUCT", 0, 22], ["Gprotein coupled receptor", "GENE_OR_GENE_PRODUCT", 55, 80], ["Serotonin 1A receptors", "PROTEIN", 0, 22], ["Gprotein coupled receptor superfamily", "PROTEIN", 55, 92], ["Serotonin 1A receptors", "TREATMENT", 0, 22], ["several anxiolytic", "TREATMENT", 149, 167], ["antidepressant drugs", "TREATMENT", 172, 192]]], ["Interestingly, we observed significant retention in fluorescence of serotonin 1A receptors upon Triton X-100 treatment of intact cells at low temperature demonstrating their detergent insolubility.", [["cells", "ANATOMY", 129, 134], ["serotonin", "CHEMICAL", 68, 77], ["Triton X-100", "CHEMICAL", 96, 108], ["serotonin", "CHEMICAL", 68, 77], ["Triton X-100", "CHEMICAL", 96, 108], ["serotonin 1A receptors", "GENE_OR_GENE_PRODUCT", 68, 90], ["Triton X-100", "SIMPLE_CHEMICAL", 96, 108], ["cells", "CELL", 129, 134], ["serotonin 1A receptors", "PROTEIN", 68, 90], ["intact cells", "CELL_TYPE", 122, 134], ["significant retention", "PROBLEM", 27, 48], ["serotonin 1A receptors", "TREATMENT", 68, 90], ["Triton X", "TREATMENT", 96, 104], ["intact cells", "PROBLEM", 122, 134], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["retention", "OBSERVATION_MODIFIER", 39, 48], ["intact cells", "OBSERVATION", 122, 134], ["low temperature", "OBSERVATION_MODIFIER", 138, 153]]], ["We analyzed the role of cholesterol in the plasma membrane organization of the serotonin 1A receptor by fluorescence recovery after photobleaching (FRAP) measurements with varying bleach spot sizes.", [["plasma membrane", "ANATOMY", 43, 58], ["cholesterol", "CHEMICAL", 24, 35], ["serotonin", "CHEMICAL", 79, 88], ["cholesterol", "CHEMICAL", 24, 35], ["serotonin", "CHEMICAL", 79, 88], ["cholesterol", "SIMPLE_CHEMICAL", 24, 35], ["plasma membrane", "CELLULAR_COMPONENT", 43, 58], ["serotonin 1A receptor", "GENE_OR_GENE_PRODUCT", 79, 100], ["serotonin 1A receptor", "PROTEIN", 79, 100], ["photobleaching (FRAP) measurements", "TEST", 132, 166], ["varying bleach spot sizes", "PROBLEM", 172, 197], ["sizes", "OBSERVATION_MODIFIER", 192, 197]]], ["Our results show that lateral diffusion parameters of serotonin 1A receptors are altered in cholesterol-depleted cells in a manner that is consistent with dynamic confinement of serotonin 1A receptors in the plasma membrane.", [["cells", "ANATOMY", 113, 118], ["plasma membrane", "ANATOMY", 208, 223], ["serotonin", "CHEMICAL", 54, 63], ["cholesterol", "CHEMICAL", 92, 103], ["serotonin", "CHEMICAL", 178, 187], ["serotonin", "CHEMICAL", 54, 63], ["cholesterol", "CHEMICAL", 92, 103], ["serotonin", "CHEMICAL", 178, 187], ["serotonin 1A receptors", "GENE_OR_GENE_PRODUCT", 54, 76], ["cholesterol", "SIMPLE_CHEMICAL", 92, 103], ["cells", "CELL", 113, 118], ["serotonin 1A receptors", "GENE_OR_GENE_PRODUCT", 178, 200], ["plasma membrane", "CELLULAR_COMPONENT", 208, 223], ["serotonin 1A receptors", "PROTEIN", 54, 76], ["cholesterol-depleted cells", "CELL_TYPE", 92, 118], ["serotonin 1A receptors", "PROTEIN", 178, 200], ["lateral diffusion parameters", "TEST", 22, 50], ["serotonin 1A receptors", "PROBLEM", 54, 76], ["depleted cells", "PROBLEM", 104, 118], ["lateral", "OBSERVATION_MODIFIER", 22, 29], ["depleted cells", "OBSERVATION", 104, 118], ["consistent with", "UNCERTAINTY", 139, 154], ["dynamic confinement", "OBSERVATION", 155, 174], ["serotonin 1A", "OBSERVATION", 178, 190], ["plasma membrane", "ANATOMY", 208, 223]]], ["Interestingly, results from FRAP measurements performed under conditions of mild cytoskeletal destabilization suggest that receptor signaling is correlated with receptor mobility, in agreement with the 'mobile receptor hypothesis'.", [["cytoskeletal", "ANATOMY", 81, 93], ["FRAP measurements", "TEST", 28, 45], ["mild cytoskeletal destabilization", "PROBLEM", 76, 109], ["receptor signaling", "PROBLEM", 123, 141], ["mild", "OBSERVATION_MODIFIER", 76, 80], ["cytoskeletal destabilization", "OBSERVATION", 81, 109]]], ["Our current work is focused on exploring the oligomerization of the receptor using photobleaching anisotropy measurements and indicates the presence of constitutive oligomers of the serotonin 1A receptor in live cells.O-565Expression and reconstitution of Connexin43 in pore-suspending membranes C. Carnarius 1 , S. Kaufmann 2 , M. Tanaka 2 , C. Steinem 1 1 Institute of Organic and Biomolecular Chemistry, University of G\u00f6ttingen, TammannstraSSe 2, 37077 G\u00f6ttingen, Germany, 2 Institute of Physical Chemistry, University of Heidelberg, Im Neuenheimer Feld 253, Heidelberg, GermanyO-565The intercellular communication and electronic coupling between adjacent cells of vertebrates are mediated by gap junctions.", [["cells", "ANATOMY", 212, 217], ["pore", "ANATOMY", 270, 274], ["membranes", "ANATOMY", 286, 295], ["intercellular", "ANATOMY", 590, 603], ["cells", "ANATOMY", 659, 664], ["gap junctions", "ANATOMY", 696, 709], ["serotonin", "CHEMICAL", 182, 191], ["O-565", "CHEMICAL", 218, 223], ["GermanyO-565", "CHEMICAL", 574, 586], ["serotonin", "CHEMICAL", 182, 191], ["serotonin 1A receptor", "GENE_OR_GENE_PRODUCT", 182, 203], ["cells", "CELL", 212, 217], ["Connexin43", "GENE_OR_GENE_PRODUCT", 256, 266], ["cells", "CELL", 659, 664], ["gap junctions", "CELLULAR_COMPONENT", 696, 709], ["serotonin 1A receptor", "PROTEIN", 182, 203], ["live cells", "CELL_TYPE", 207, 217], ["Connexin43", "PROTEIN", 256, 266], ["photobleaching anisotropy measurements", "TEST", 83, 121], ["constitutive oligomers", "PROBLEM", 152, 174], ["Connexin43 in pore-suspending membranes", "TREATMENT", 256, 295], ["Carnarius", "TEST", 299, 308], ["Kaufmann", "TREATMENT", 316, 324], ["GermanyO", "TEST", 574, 582], ["The intercellular communication", "TREATMENT", 586, 617], ["electronic coupling between adjacent cells of vertebrates", "TREATMENT", 622, 679], ["constitutive oligomers", "OBSERVATION", 152, 174], ["gap junctions", "OBSERVATION", 696, 709]]], ["These proteins are composed of two connexon hemichannels, whereas each connexon consists of six connexin subunits.", [["connexon", "GENE_OR_GENE_PRODUCT", 35, 43], ["connexin", "GENE_OR_GENE_PRODUCT", 96, 104], ["connexon hemichannels", "PROTEIN", 35, 56], ["connexon", "PROTEIN", 71, 79], ["connexin subunits", "PROTEIN", 96, 113], ["two connexon hemichannels", "TREATMENT", 31, 56], ["six connexin subunits", "TREATMENT", 92, 113]]], ["Each subunit is characterized by two conserved motives: two extracellular loops and four transmembrane \u03b1-helices.", [["extracellular", "ANATOMY", 60, 73], ["transmembrane", "ANATOMY", 89, 102], ["extracellular loops", "CELLULAR_COMPONENT", 60, 79], ["extracellular loops", "PROTEIN", 60, 79], ["transmembrane \u03b1-helices", "PROTEIN", 89, 112], ["loops", "OBSERVATION", 74, 79]]], ["In this study, we focused on Cx43.", [["Cx43", "GENE_OR_GENE_PRODUCT", 29, 33], ["Cx43", "PROTEIN", 29, 33], ["this study", "TEST", 3, 13]]], ["To obtain large amounts of this protein, we expressed Cx43 and Cx43+GFP in a rather new expression system: Dictyostelium discoideum.", [["Cx43", "GENE_OR_GENE_PRODUCT", 54, 58], ["Cx43", "GENE_OR_GENE_PRODUCT", 63, 67], ["GFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["Dictyostelium discoideum", "ORGANISM", 107, 131], ["Cx43", "PROTEIN", 54, 58], ["Cx43", "PROTEIN", 63, 67], ["GFP", "PROTEIN", 68, 71], ["Dictyostelium discoideum", "SPECIES", 107, 131], ["Dictyostelium discoideum", "SPECIES", 107, 131], ["this protein", "TEST", 27, 39], ["Cx43", "TEST", 54, 58], ["Cx43", "TEST", 63, 67], ["GFP", "TEST", 68, 71], ["Dictyostelium discoideum", "PROBLEM", 107, 131], ["large", "OBSERVATION_MODIFIER", 10, 15], ["Dictyostelium discoideum", "OBSERVATION", 107, 131]]], ["In contrast to human tissue cultures, the system allows for high cell densities up to 30 million cells per mL and the cells can be cultivated by fermentation.", [["tissue cultures", "ANATOMY", 21, 36], ["cell", "ANATOMY", 65, 69], ["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 118, 123], ["human", "ORGANISM", 15, 20], ["tissue cultures", "CELL", 21, 36], ["cell", "CELL", 65, 69], ["cells", "CELL", 97, 102], ["cells", "CELL", 118, 123], ["human tissue cultures", "CELL_LINE", 15, 36], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["human tissue cultures", "TEST", 15, 36], ["the system", "TEST", 38, 48], ["high cell densities", "PROBLEM", 60, 79], ["human tissue", "OBSERVATION_MODIFIER", 15, 27], ["high cell densities", "OBSERVATION", 60, 79]]], ["Cx43+GFP was successfully visualized in D. discoideum by confocal laser scanning microscopy, where it was preferentially found in the plasma membrane.After the cells were harvested, plasma membranes were prepared and both proteins (Cx43 and Cx43+GFP) were verified by western blot analysis.", [["plasma membrane", "ANATOMY", 134, 149], ["cells", "ANATOMY", 160, 165], ["plasma membranes", "ANATOMY", 182, 198], ["Cx43", "GENE_OR_GENE_PRODUCT", 0, 4], ["GFP", "GENE_OR_GENE_PRODUCT", 5, 8], ["D. discoideum", "CELL", 40, 53], ["plasma membrane", "CELLULAR_COMPONENT", 134, 149], ["cells", "CELL", 160, 165], ["plasma", "ORGANISM_SUBSTANCE", 182, 188], ["membranes", "CELLULAR_COMPONENT", 189, 198], ["Cx43", "GENE_OR_GENE_PRODUCT", 232, 236], ["Cx43", "GENE_OR_GENE_PRODUCT", 241, 245], ["GFP", "GENE_OR_GENE_PRODUCT", 246, 249], ["Cx43", "PROTEIN", 0, 4], ["GFP", "PROTEIN", 5, 8], ["Cx43", "PROTEIN", 232, 236], ["Cx43", "PROTEIN", 241, 245], ["GFP", "PROTEIN", 246, 249], ["D. discoideum", "SPECIES", 40, 53], ["D. discoideum", "SPECIES", 40, 53], ["Cx43", "TEST", 0, 4], ["GFP", "TEST", 5, 8], ["confocal laser scanning microscopy", "TEST", 57, 91], ["plasma membranes", "TEST", 182, 198], ["Cx43", "TEST", 232, 236], ["Cx43+GFP", "TEST", 241, 249], ["blot analysis", "TEST", 276, 289], ["plasma membrane", "OBSERVATION", 134, 149]]], ["The proteins were solubilized by addition of 5% n-octyl-\u03b2-D-glucopyranoside and purified by ion metal chelate affinity chromatography.", [["n-octyl-\u03b2-D-glucopyranoside", "CHEMICAL", 48, 75], ["n-octyl-\u03b2-D-glucopyranoside", "CHEMICAL", 48, 75], ["n-octyl-\u03b2-D-glucopyranoside", "SIMPLE_CHEMICAL", 48, 75], ["ion metal chelate", "SIMPLE_CHEMICAL", 92, 109], ["5% n-octyl", "TREATMENT", 45, 55], ["D-glucopyranoside", "TREATMENT", 58, 75]]], ["The activities of both proteins were confirmed by a cytochrome C assay.", [["cytochrome C", "GENE_OR_GENE_PRODUCT", 52, 64], ["cytochrome C", "PROTEIN", 52, 64], ["a cytochrome C assay", "TEST", 50, 70]]], ["After the purification of both proteins, they were reconstituted in \u00b5m-sized pore-suspending membranes.", [["membranes", "ANATOMY", 93, 102], ["membranes", "CELLULAR_COMPONENT", 93, 102], ["sized", "OBSERVATION_MODIFIER", 71, 76], ["pore", "OBSERVATION_MODIFIER", 77, 81], ["suspending membranes", "OBSERVATION", 82, 102]]], ["In the near future, we plan to determine the mobility of Cx43 and Cx43+GFP in these membranes by fluorescence recovery after photobleaching.Inhibition of the surface activity of DPPC films by smooth lipopolysaccharide.", [["membranes", "ANATOMY", 84, 93], ["surface", "ANATOMY", 158, 165], ["DPPC", "CHEMICAL", 178, 182], ["lipopolysaccharide", "CHEMICAL", 199, 217], ["DPPC", "CHEMICAL", 178, 182], ["Cx43", "GENE_OR_GENE_PRODUCT", 57, 61], ["Cx43", "GENE_OR_GENE_PRODUCT", 66, 70], ["GFP", "GENE_OR_GENE_PRODUCT", 71, 74], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["DPPC films", "SIMPLE_CHEMICAL", 178, 188], ["smooth lipopolysaccharide", "SIMPLE_CHEMICAL", 192, 217], ["Cx43", "PROTEIN", 57, 61], ["Cx43", "PROTEIN", 66, 70], ["GFP", "PROTEIN", 71, 74], ["Cx43", "TEST", 57, 61], ["Cx43", "TEST", 66, 70], ["the surface activity of DPPC films", "TREATMENT", 154, 188]]], ["Effect of SP-AO.", [["SP-AO.", "CHEMICAL", 10, 16], ["SP", "PROTEIN", 10, 12]]], ["Biochemistry and molecular Biology I, and CIBER enfermedades Respiratorias, Complutense University of Madrid, Madrid, Spain Inhaled bacterial lipopolysaccharide (LPS) may incorporate into the lung surfactant monolayer.", [["lung surfactant monolayer", "ANATOMY", 192, 217], ["lipopolysaccharide", "CHEMICAL", 142, 160], ["LPS", "CHEMICAL", 162, 165], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 142, 160], ["LPS", "SIMPLE_CHEMICAL", 162, 165], ["lung surfactant monolayer", "CELL", 192, 217], ["Spain Inhaled bacterial lipopolysaccharide (LPS", "TREATMENT", 118, 165], ["the lung surfactant monolayer", "TREATMENT", 188, 217], ["bacterial lipopolysaccharide", "OBSERVATION", 132, 160], ["lung", "ANATOMY", 192, 196], ["surfactant monolayer", "OBSERVATION", 197, 217]]], ["In this study, the effect of smooth LPS (s-LPS) on the surface activity of lung surfactant was evaluated.", [["surface", "ANATOMY", 55, 62], ["lung", "ANATOMY", 75, 79], ["LPS", "CHEMICAL", 36, 39], ["s-LPS", "CHEMICAL", 41, 46], ["smooth LPS", "SIMPLE_CHEMICAL", 29, 39], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["lung", "ORGAN", 75, 79], ["this study", "TEST", 3, 13], ["smooth LPS", "TEST", 29, 39], ["lung surfactant", "TREATMENT", 75, 90], ["smooth", "OBSERVATION_MODIFIER", 29, 35], ["LPS", "OBSERVATION_MODIFIER", 36, 39], ["lung", "ANATOMY", 75, 79], ["surfactant", "OBSERVATION", 80, 90]]], ["To that end we investigated the behavior of DPPC films containing s-LPS, with and without surfactant protein A (SP-A) in the subphase, using epifluorescence microscopy combined with a surface balance.", [["surface", "ANATOMY", 184, 191], ["DPPC", "CHEMICAL", 44, 48], ["s-LPS", "CHEMICAL", 66, 71], ["SP-A", "CHEMICAL", 112, 116], ["DPPC", "CHEMICAL", 44, 48], ["DPPC films", "SIMPLE_CHEMICAL", 44, 54], ["LPS", "SIMPLE_CHEMICAL", 68, 71], ["surfactant protein A", "SIMPLE_CHEMICAL", 90, 110], ["SP-A", "SIMPLE_CHEMICAL", 112, 116], ["surfactant protein A", "PROTEIN", 90, 110], ["SP", "PROTEIN", 112, 114], ["DPPC films", "TEST", 44, 54], ["epifluorescence microscopy", "TEST", 141, 167], ["a surface balance", "TEST", 182, 199]]], ["Our data show that s-LPS injected into the subphase incorporated into DPPC films forming mixed DPPC/s-LPS monolayers.", [["monolayers", "ANATOMY", 106, 116], ["LPS", "CHEMICAL", 21, 24], ["DPPC", "CHEMICAL", 70, 74], ["DPPC", "CHEMICAL", 95, 99], ["DPPC", "CHEMICAL", 70, 74], ["DPPC", "CHEMICAL", 95, 99], ["s-", "SIMPLE_CHEMICAL", 19, 21], ["LPS", "SIMPLE_CHEMICAL", 21, 24], ["DPPC films", "SIMPLE_CHEMICAL", 70, 80], ["DPPC", "SIMPLE_CHEMICAL", 95, 99], ["monolayers", "CELL", 106, 116], ["Our data", "TEST", 0, 8], ["LPS", "PROBLEM", 21, 24], ["DPPC films", "TEST", 70, 80], ["mixed DPPC", "TEST", 89, 99], ["LPS monolayers", "PROBLEM", 102, 116]]], ["Cospread s-LPS fluidized the DPPC monolayer as demonstrated by epifluorescence images and changes in the compressibility modulus of the monolayer as a function of s-LPS molar fraction (X s\u2212LPS ).", [["DPPC monolayer", "ANATOMY", 29, 43], ["monolayer", "ANATOMY", 136, 145], ["DPPC", "CHEMICAL", 29, 33], ["DPPC", "CHEMICAL", 29, 33], ["DPPC monolayer", "CELL", 29, 43], ["monolayer", "CELL", 136, 145], ["X s\u2212LPS", "SIMPLE_CHEMICAL", 185, 192], ["Cospread s-LPS fluidized the DPPC monolayer", "TEST", 0, 43], ["epifluorescence images", "TEST", 63, 85], ["the compressibility modulus", "TEST", 101, 128], ["LPS molar fraction", "PROBLEM", 165, 183], ["LPS fluidized", "OBSERVATION", 11, 24], ["DPPC monolayer", "OBSERVATION", 29, 43], ["compressibility modulus", "OBSERVATION", 105, 128], ["monolayer", "OBSERVATION_MODIFIER", 136, 145]]], ["The presence of low amounts of s-LPS in the monolayer promoted early collapse, preventing high surface pressures to be reached.", [["monolayer", "ANATOMY", 44, 53], ["surface", "ANATOMY", 95, 102], ["LPS", "CHEMICAL", 33, 36], ["LPS", "SIMPLE_CHEMICAL", 33, 36], ["monolayer", "CELL", 44, 53], ["s-LPS", "TREATMENT", 31, 36], ["early collapse", "PROBLEM", 63, 77], ["high surface pressures", "TREATMENT", 90, 112], ["low", "OBSERVATION_MODIFIER", 16, 19], ["amounts", "OBSERVATION_MODIFIER", 20, 27], ["s-LPS", "OBSERVATION_MODIFIER", 31, 36], ["early", "OBSERVATION_MODIFIER", 63, 68], ["collapse", "OBSERVATION", 69, 77], ["high", "OBSERVATION_MODIFIER", 90, 94], ["surface pressures", "OBSERVATION", 95, 112]]], ["Moreover, s-LPS hampered the re-spreading of DPPC molecules during dynamic compression at s-LPS concentrations as small as X s\u2212LPS = 0.02.", [["LPS", "CHEMICAL", 12, 15], ["DPPC", "CHEMICAL", 45, 49], ["LPS", "CHEMICAL", 92, 95], ["DPPC", "CHEMICAL", 45, 49], ["s-LPS", "SIMPLE_CHEMICAL", 10, 15], ["DPPC", "SIMPLE_CHEMICAL", 45, 49], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["LPS", "TEST", 12, 15], ["DPPC molecules", "PROBLEM", 45, 59], ["dynamic compression", "TEST", 67, 86], ["LPS concentrations", "TEST", 92, 110], ["s\u2212LPS", "TEST", 125, 130], ["compression", "OBSERVATION", 75, 86], ["small", "OBSERVATION_MODIFIER", 114, 119]]], ["Such inhibitory effects could not be relieved by repeated compression-expansion cycles or by adding surfactant protein A. However, SP-A facilitated the squeeze-out of s-LPS from DPPC/s-LPS mixed monolayers, suggesting that SP-A is an s-LPS scavenger.P-563Cholesterol displaces ceramide from its tight packing with sphingomyelin in the absence of ld phase J. V. Busto, J. Sot, J. Requejo-Isidro, F. M. Go\u00f1i, A. Alonso Unidad de Biof\u00edsica (CSIC-UPV/EHU) and Departamento de Bioqu\u00edmica, U. Pa\u00eds Vasco (UPV/EHU), Spain A set of biophysical approaches have been applied to study the phase behaviour of palmitoylsphingomyelin (pSM)/cholesterol (Chol) model membranes upon palmitoylceramide (pCer) addition.", [["monolayers", "ANATOMY", 195, 205], ["membranes", "ANATOMY", 651, 660], ["SP-A", "CHEMICAL", 131, 135], ["s-LPS", "CHEMICAL", 167, 172], ["DPPC/s-LPS", "CHEMICAL", 178, 188], ["SP-A", "CHEMICAL", 223, 227], ["P-563", "CHEMICAL", 250, 255], ["ceramide", "CHEMICAL", 277, 285], ["sphingomyelin", "CHEMICAL", 314, 327], ["palmitoylsphingomyelin", "CHEMICAL", 597, 619], ["cholesterol", "CHEMICAL", 626, 637], ["Chol", "CHEMICAL", 639, 643], ["palmitoylceramide", "CHEMICAL", 666, 683], ["pCer", "CHEMICAL", 685, 689], ["DPPC", "CHEMICAL", 178, 182], ["Cholesterol", "CHEMICAL", 255, 266], ["ceramide", "CHEMICAL", 277, 285], ["sphingomyelin", "CHEMICAL", 314, 327], ["palmitoylsphingomyelin", "CHEMICAL", 597, 619], ["cholesterol", "CHEMICAL", 626, 637], ["Chol", "CHEMICAL", 639, 643], ["palmitoylceramide", "CHEMICAL", 666, 683], ["pCer", "CHEMICAL", 685, 689], ["SP-A", "SIMPLE_CHEMICAL", 131, 135], ["LPS", "SIMPLE_CHEMICAL", 169, 172], ["DPPC", "SIMPLE_CHEMICAL", 178, 182], ["LPS", "SIMPLE_CHEMICAL", 185, 188], ["monolayers", "CELL", 195, 205], ["SP-A", "SIMPLE_CHEMICAL", 223, 227], ["LPS", "SIMPLE_CHEMICAL", 236, 239], ["P-563", "SIMPLE_CHEMICAL", 250, 255], ["Cholesterol", "SIMPLE_CHEMICAL", 255, 266], ["ceramide", "SIMPLE_CHEMICAL", 277, 285], ["sphingomyelin", "SIMPLE_CHEMICAL", 314, 327], ["palmitoylsphingomyelin", "SIMPLE_CHEMICAL", 597, 619], ["pSM", "SIMPLE_CHEMICAL", 621, 624], ["cholesterol", "SIMPLE_CHEMICAL", 626, 637], ["Chol", "SIMPLE_CHEMICAL", 639, 643], ["membranes", "CELLULAR_COMPONENT", 651, 660], ["palmitoylceramide", "SIMPLE_CHEMICAL", 666, 683], ["pCer", "SIMPLE_CHEMICAL", 685, 689], ["SP", "PROTEIN", 131, 133], ["A. Alonso Unidad de Biof\u00edsica (CSIC-UPV/EHU", "SPECIES", 407, 450], ["repeated compression-expansion cycles", "TREATMENT", 49, 86], ["surfactant protein A.", "TREATMENT", 100, 121], ["the squeeze", "TEST", 148, 159], ["DPPC/s", "TEST", 178, 184], ["LPS mixed monolayers", "PROBLEM", 185, 205], ["an s-LPS scavenger", "TREATMENT", 231, 249], ["P", "TEST", 250, 251], ["Cholesterol displaces ceramide", "PROBLEM", 255, 285], ["its tight packing", "TREATMENT", 291, 308], ["biophysical approaches", "TREATMENT", 524, 546], ["palmitoylsphingomyelin (pSM)/cholesterol (Chol) model membranes", "TREATMENT", 597, 660], ["palmitoylceramide (pCer)", "TREATMENT", 666, 690], ["expansion cycles", "OBSERVATION", 70, 86], ["tight packing", "OBSERVATION_MODIFIER", 295, 308]]], ["Fluorescence spectroscopy of di-4-ANEPPDHQ-stained pSM/Chol vesicles reveals no segregation of large liquid-ordered (l o ) microdomains.", [["pSM/Chol vesicles", "ANATOMY", 51, 68], ["di-4-ANEPPDHQ", "CHEMICAL", 29, 42], ["di-4-ANEPPDHQ", "CHEMICAL", 29, 42], ["Chol", "CHEMICAL", 55, 59], ["di-4-ANEPPDHQ", "SIMPLE_CHEMICAL", 29, 42], ["pSM", "SIMPLE_CHEMICAL", 51, 54], ["Chol", "SIMPLE_CHEMICAL", 55, 59], ["di-4", "PROTEIN", 29, 33], ["ANEPPDHQ", "PROTEIN", 34, 42], ["pSM", "PROTEIN", 51, 54], ["Fluorescence spectroscopy", "TEST", 0, 25], ["di-4", "TEST", 29, 33], ["ANEPPDHQ", "TEST", 34, 42], ["stained pSM/Chol vesicles", "TEST", 43, 68], ["segregation of large liquid", "PROBLEM", 80, 107], ["microdomains", "PROBLEM", 123, 135], ["no", "UNCERTAINTY", 77, 79], ["large", "OBSERVATION_MODIFIER", 95, 100], ["liquid", "OBSERVATION", 101, 107]]], ["In contrast, the formation of disperse, compositionally homogeneous l o pSM/Chol (3:1) nanodomains over a pSM gel (L \u03b2 ) phase is proposed.", [["Chol", "CHEMICAL", 76, 80], ["l o pSM", "CHEMICAL", 68, 75], ["Chol", "CHEMICAL", 76, 80], ["l o pSM/Chol (3:1) nanodomains", "SIMPLE_CHEMICAL", 68, 98], ["a pSM gel (L \u03b2 ) phase", "TREATMENT", 104, 126], ["homogeneous", "OBSERVATION_MODIFIER", 56, 67]]], ["DSC measurements show that pCer addition to vesicles with coexisting l o and L \u03b2 phases (low [Chol] ) induces the formation of large gel-like pSM/pCer microdomains, coexisting with a l o pSM/Chol phase.", [["vesicles", "ANATOMY", 44, 52], ["pCer", "CHEMICAL", 27, 31], ["Chol", "CHEMICAL", 94, 98], ["Chol", "CHEMICAL", 191, 195], ["pCer", "CHEMICAL", 27, 31], ["Chol", "CHEMICAL", 94, 98], ["Chol", "CHEMICAL", 191, 195], ["pCer", "GENE_OR_GENE_PRODUCT", 27, 31], ["vesicles", "CELLULAR_COMPONENT", 44, 52], ["pSM", "GENE_OR_GENE_PRODUCT", 142, 145], ["pCer", "GENE_OR_GENE_PRODUCT", 146, 150], ["pCer", "PROTEIN", 27, 31], ["pSM", "PROTEIN", 142, 145], ["pCer microdomains", "PROTEIN", 146, 163], ["DSC measurements", "TEST", 0, 16], ["coexisting l o and L \u03b2 phases", "TEST", 58, 87], ["large gel-like pSM/pCer microdomains", "PROBLEM", 127, 163], ["a l o pSM/Chol phase", "TREATMENT", 181, 201], ["large", "OBSERVATION_MODIFIER", 127, 132], ["Chol phase", "OBSERVATION", 191, 201]]], ["The \u2206H for the pSM/pCer phase at high pSM/(Chol+pCer) ratio is close to that of the binary mixture in the absence of Chol, supporting immiscibility, but no displacement, between Chol and pCer-rich phases.", [["Chol", "CHEMICAL", 43, 47], ["Chol", "CHEMICAL", 117, 121], ["Chol", "CHEMICAL", 178, 182], ["pCer", "CHEMICAL", 187, 191], ["Chol", "CHEMICAL", 43, 47], ["Cer", "CHEMICAL", 49, 52], ["Chol", "CHEMICAL", 117, 121], ["Chol", "CHEMICAL", 178, 182], ["pCer", "CHEMICAL", 187, 191], ["Chol+pCer", "SIMPLE_CHEMICAL", 43, 52], ["Chol", "SIMPLE_CHEMICAL", 117, 121], ["Chol", "SIMPLE_CHEMICAL", 178, 182], ["pCer", "SIMPLE_CHEMICAL", 187, 191], ["\u2206H", "PROTEIN", 4, 6], ["pSM", "PROTEIN", 15, 18], ["pCer", "PROTEIN", 187, 191], ["the pSM/pCer phase", "TEST", 11, 29], ["displacement", "PROBLEM", 156, 168], ["Chol", "OBSERVATION", 117, 121], ["no", "UNCERTAINTY", 153, 155], ["displacement", "OBSERVATION_MODIFIER", 156, 168]]], ["On the contrary, both confocal microscopy of GUVs and the DSC data coincide in showing that a rise in pCer increases the gel-like phase to a lower extent than in the pure pSM/pCer mixture, revealing some Cholinduced restriction.", [["pCer", "CHEMICAL", 102, 106], ["pSM", "CHEMICAL", 171, 174], ["pCer", "GENE_OR_GENE_PRODUCT", 102, 106], ["pSM", "SIMPLE_CHEMICAL", 171, 174], ["pCer", "GENE_OR_GENE_PRODUCT", 175, 179], ["pCer", "PROTEIN", 102, 106], ["pSM", "PROTEIN", 171, 174], ["both confocal microscopy of GUVs", "TEST", 17, 49], ["the DSC data", "TEST", 54, 66], ["a rise in pCer", "PROBLEM", 92, 106], ["some Cholinduced restriction", "TREATMENT", 199, 227], ["rise", "OBSERVATION_MODIFIER", 94, 98], ["lower extent", "OBSERVATION_MODIFIER", 141, 153], ["Cholinduced restriction", "OBSERVATION", 204, 227]]], ["In the presence of a pure l o pSM/Chol phase (high [Chol] ), pCer addition is unable to induce the formation of large pSM/pCer microdomains.", [["Chol", "CHEMICAL", 34, 38], ["Chol", "CHEMICAL", 52, 56], ["pCer", "CHEMICAL", 61, 65], ["l o pSM", "CHEMICAL", 26, 33], ["Chol", "CHEMICAL", 34, 38], ["Chol", "CHEMICAL", 52, 56], ["pCer", "CHEMICAL", 61, 65], ["Chol", "SIMPLE_CHEMICAL", 34, 38], ["high [Chol", "SIMPLE_CHEMICAL", 46, 56], ["pCer", "SIMPLE_CHEMICAL", 61, 65], ["pSM", "GENE_OR_GENE_PRODUCT", 118, 121], ["pCer", "GENE_OR_GENE_PRODUCT", 122, 126], ["pCer", "PROTEIN", 61, 65], ["pSM", "PROTEIN", 118, 121], ["pCer", "PROTEIN", 122, 126], ["a pure l o pSM/Chol phase", "TEST", 19, 44], ["large pSM/pCer microdomains", "PROBLEM", 112, 139], ["Chol phase", "OBSERVATION_MODIFIER", 34, 44], ["large", "OBSERVATION_MODIFIER", 112, 117], ["pSM", "OBSERVATION", 118, 121], ["pCer microdomains", "OBSERVATION", 122, 139]]], ["The present data support the role of Chol as the key determinant in controlling its own displacement from l o domains by ceramide.P-562Hydroquinones modifying lipid membrane morphology C. Di Vitta 1 , L. Marzorati 1 , V. Rebbin 2 , S. S. Funari 2 1 IQUSP, University of S\u00e3o Paulo, S\u00e3o Paulo, Brasil, 2 HASYLAB, Hamburg, Germany Quinones are important molecules in cells.P-562Flavina, ubiquinone and coenzyme Q, CoQ, are associated with electron transfer.", [["membrane", "ANATOMY", 165, 173], ["cells", "ANATOMY", 364, 369], ["Chol", "CHEMICAL", 37, 41], ["ceramide", "CHEMICAL", 121, 129], ["P-562Hydroquinones", "CHEMICAL", 130, 148], ["P-562Flavina", "CHEMICAL", 370, 382], ["ubiquinone", "CHEMICAL", 384, 394], ["CoQ", "CHEMICAL", 411, 414], ["Chol", "CHEMICAL", 37, 41], ["ceramide", "CHEMICAL", 121, 129], ["P-562Hydroquinones", "CHEMICAL", 130, 148], ["P-562Flavina", "CHEMICAL", 370, 382], ["ubiquinone", "CHEMICAL", 384, 394], ["coenzyme Q", "CHEMICAL", 399, 409], ["CoQ", "CHEMICAL", 411, 414], ["Chol", "SIMPLE_CHEMICAL", 37, 41], ["ceramide", "SIMPLE_CHEMICAL", 121, 129], ["P-562Hydroquinones", "SIMPLE_CHEMICAL", 130, 148], ["cells", "CELL", 364, 369], ["P-562Flavina", "SIMPLE_CHEMICAL", 370, 382], ["ubiquinone", "SIMPLE_CHEMICAL", 384, 394], ["coenzyme Q", "SIMPLE_CHEMICAL", 399, 409], ["CoQ", "SIMPLE_CHEMICAL", 411, 414], ["electron", "SIMPLE_CHEMICAL", 436, 444], ["S. S.", "SPECIES", 232, 237], ["P", "TEST", 130, 131], ["562Hydroquinones modifying lipid membrane morphology", "TREATMENT", 132, 184], ["P", "TEST", 370, 371], ["ubiquinone", "TREATMENT", 384, 394], ["coenzyme", "TREATMENT", 399, 407]]], ["CoQ, having a hydrophobic tail, is soluble in the internal lipid membrane of mitochondria.", [["lipid membrane", "ANATOMY", 59, 73], ["mitochondria", "ANATOMY", 77, 89], ["CoQ", "CHEMICAL", 0, 3], ["CoQ", "CHEMICAL", 0, 3], ["CoQ", "SIMPLE_CHEMICAL", 0, 3], ["lipid membrane", "CELLULAR_COMPONENT", 59, 73], ["mitochondria", "CELLULAR_COMPONENT", 77, 89], ["hydrophobic tail", "PROTEIN", 14, 30], ["a hydrophobic tail", "PROBLEM", 12, 30], ["hydrophobic tail", "OBSERVATION_MODIFIER", 14, 30], ["soluble", "OBSERVATION_MODIFIER", 35, 42], ["internal", "ANATOMY_MODIFIER", 50, 58], ["lipid membrane", "OBSERVATION", 59, 73], ["mitochondria", "OBSERVATION", 77, 89]]], ["Their reduction leads to the equivalent hydroquinones.", [["hydroquinones", "CHEMICAL", 40, 53], ["hydroquinones", "CHEMICAL", 40, 53], ["hydroquinones", "SIMPLE_CHEMICAL", 40, 53], ["reduction", "OBSERVATION_MODIFIER", 6, 15], ["equivalent", "OBSERVATION_MODIFIER", 29, 39], ["hydroquinones", "OBSERVATION", 40, 53]]], ["We synthesized novel alkylthioquinones ATHs, to investigate their interaction with phospholipids.", [["alkylthioquinones", "CHEMICAL", 21, 38], ["alkylthioquinones", "CHEMICAL", 21, 38], ["alkylthioquinones", "SIMPLE_CHEMICAL", 21, 38], ["ATHs", "SIMPLE_CHEMICAL", 39, 43], ["phospholipids", "SIMPLE_CHEMICAL", 83, 96], ["novel alkylthioquinones ATHs", "TREATMENT", 15, 43], ["phospholipids", "TREATMENT", 83, 96]]], ["One or more long hydrophobic chains attached to the quinone ring alter their hydrophobicity and electron availability.", [["quinone", "CHEMICAL", 52, 59], ["quinone", "CHEMICAL", 52, 59], ["quinone ring", "SIMPLE_CHEMICAL", 52, 64], ["electron", "SIMPLE_CHEMICAL", 96, 104], ["more long hydrophobic chains", "TREATMENT", 7, 35], ["the quinone ring", "TREATMENT", 48, 64], ["quinone ring", "OBSERVATION", 52, 64]]], ["We aimed at their influence on the structure of membranes.", [["membranes", "ANATOMY", 48, 57], ["membranes", "CELLULAR_COMPONENT", 48, 57]]], ["Different pHs highlights the charge/polarity effect on the interaction and on the morphology of the bilayer.", [["bilayer", "CELLULAR_COMPONENT", 100, 107], ["Different pHs", "PROBLEM", 0, 13], ["polarity effect", "OBSERVATION_MODIFIER", 36, 51], ["bilayer", "ANATOMY_MODIFIER", 100, 107]]], ["For that, POPE and POPC, lipids with different charges, but identical chains were selected.", [["POPC", "CHEMICAL", 19, 23], ["POPE", "CHEMICAL", 10, 14], ["POPC", "CHEMICAL", 19, 23], ["POPE", "SIMPLE_CHEMICAL", 10, 14], ["POPC", "SIMPLE_CHEMICAL", 19, 23], ["lipids", "SIMPLE_CHEMICAL", 25, 31], ["POPE and POPC, lipids", "TREATMENT", 10, 31], ["different charges", "TREATMENT", 37, 54]]], ["X-rays diffraction on POPE/2,6BATH, 100/1 at different temperatures and pH, showed cubic phases coexisting with the usual phases formed by simply hydrated POPE, at different pHs.", [["POPE", "CHEMICAL", 155, 159], ["2,6BATH", "CHEMICAL", 27, 34], ["POPE", "CHEMICAL", 155, 159], ["POPE", "SIMPLE_CHEMICAL", 155, 159], ["X-rays diffraction", "TEST", 0, 18], ["pH", "TEST", 72, 74], ["cubic phases", "PROBLEM", 83, 95]]], ["For investigation of the charge/polarity, we turned to the POPC/2,6BATH system (smaller charge/polarity).", [["POPC", "CHEMICAL", 59, 63], ["2,6BATH", "CHEMICAL", 64, 71], ["POPC", "SIMPLE_CHEMICAL", 59, 63], ["the charge/polarity", "TREATMENT", 21, 40], ["the POPC/2,6BATH system", "TREATMENT", 55, 78], ["smaller charge/polarity", "TREATMENT", 80, 103]]], ["Despite decrease in temperature of phase transition and dimensions of the lattice, the structures were the same as in hydrated lipid, illustrating a less significant effect than on the similar lipid POPE.", [["lipid", "SIMPLE_CHEMICAL", 127, 132], ["decrease in temperature of phase transition", "PROBLEM", 8, 51], ["decrease", "OBSERVATION_MODIFIER", 8, 16], ["temperature", "OBSERVATION_MODIFIER", 20, 31], ["less significant", "OBSERVATION_MODIFIER", 149, 165], ["effect", "OBSERVATION_MODIFIER", 166, 172]]], ["Another additive, 2,5ATH, mixed with POPE showed the effect of multiple thioalky chains.", [["2,5ATH", "CHEMICAL", 18, 24], ["POPE", "CHEMICAL", 37, 41], ["2,5ATH", "SIMPLE_CHEMICAL", 18, 24], ["POPE", "SIMPLE_CHEMICAL", 37, 41], ["thioalky chains", "SIMPLE_CHEMICAL", 72, 87], ["thioalky chains", "PROTEIN", 72, 87], ["multiple thioalky chains", "PROBLEM", 63, 87], ["multiple", "OBSERVATION_MODIFIER", 63, 71], ["thioalky chains", "OBSERVATION", 72, 87]]], ["No morphology change was seen, compared to pure lipid.", [["morphology change", "PROBLEM", 3, 20], ["morphology", "OBSERVATION_MODIFIER", 3, 13], ["change", "OBSERVATION", 14, 20]]], ["Interestingly, despite both additives differ by one thioalkyl chain only, their influence on the POPE matrix is so different.P-569Cross-linking of phospholipid membranes by calcium-sensitive synaptotagmins Synaptotagmins are vesicular proteins implicated in many membrane trafficking events.", [["POPE matrix", "ANATOMY", 97, 108], ["phospholipid membranes", "ANATOMY", 147, 169], ["vesicular", "ANATOMY", 225, 234], ["membrane", "ANATOMY", 263, 271], ["thioalkyl", "CHEMICAL", 52, 61], ["P-569Cross", "CHEMICAL", 125, 135], ["calcium", "CHEMICAL", 173, 180], ["thioalkyl", "CHEMICAL", 52, 61], ["calcium", "CHEMICAL", 173, 180], ["matrix", "CELLULAR_COMPONENT", 102, 108], ["phospholipid membranes", "CELLULAR_COMPONENT", 147, 169], ["calcium", "SIMPLE_CHEMICAL", 173, 180], ["synaptotagmins Synaptotagmins", "SIMPLE_CHEMICAL", 191, 220], ["membrane", "CELLULAR_COMPONENT", 263, 271], ["P", "DNA", 125, 126], ["Synaptotagmins", "PROTEIN", 206, 220], ["vesicular proteins", "PROTEIN", 225, 243], ["P", "TEST", 125, 126], ["phospholipid membranes", "TREATMENT", 147, 169], ["calcium", "TEST", 173, 180], ["vesicular proteins", "PROBLEM", 225, 243], ["many membrane trafficking events", "PROBLEM", 258, 290], ["vesicular proteins", "OBSERVATION", 225, 243], ["many", "OBSERVATION_MODIFIER", 258, 262], ["membrane trafficking", "OBSERVATION", 263, 283]]], ["They are highly conserved in evolution and the mammalian family contains 16 isoforms.", [["16 isoforms", "PROTEIN", 73, 84]]], ["We now show that the tandem C2 domains of several calcium-sensitive synaptotagmin isoforms tested, including Drosophila synaptotagmin, rapidly cross-link phospholipid membranes.", [["phospholipid membranes", "ANATOMY", 154, 176], ["calcium", "CHEMICAL", 50, 57], ["calcium", "CHEMICAL", 50, 57], ["calcium", "SIMPLE_CHEMICAL", 50, 57], ["synaptotagmin", "GENE_OR_GENE_PRODUCT", 68, 81], ["synaptotagmin", "GENE_OR_GENE_PRODUCT", 120, 133], ["phospholipid membranes", "CELLULAR_COMPONENT", 154, 176], ["tandem C2 domains", "PROTEIN", 21, 38], ["synaptotagmin isoforms", "PROTEIN", 68, 90], ["Drosophila synaptotagmin", "PROTEIN", 109, 133], ["Drosophila", "SPECIES", 109, 119], ["Drosophila", "SPECIES", 109, 119], ["the tandem C2 domains", "TEST", 17, 38], ["several calcium", "TEST", 42, 57], ["Drosophila synaptotagmin", "TEST", 109, 133], ["phospholipid membranes", "OBSERVATION", 154, 176]]], ["In contrast to the tandem structure, individual C2 domains failed to trigger membrane cross-linking in several novel assays.", [["membrane", "ANATOMY", 77, 85], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["C2 domains", "PROTEIN", 48, 58], ["individual C2 domains", "PROBLEM", 37, 58], ["C2", "OBSERVATION_MODIFIER", 48, 50]]], ["Large-scale liposomal aggregation driven by tandem C2 domains in response to calcium was confirmed by the following techniques: turbidity assay, dynamic lightscattering and both confocal and negative stain electron microscopy.", [["aggregation", "DISEASE", 22, 33], ["calcium", "CHEMICAL", 77, 84], ["calcium", "CHEMICAL", 77, 84], ["liposomal", "SIMPLE_CHEMICAL", 12, 21], ["calcium", "SIMPLE_CHEMICAL", 77, 84], ["tandem C2 domains", "PROTEIN", 44, 61], ["Large-scale liposomal aggregation", "PROBLEM", 0, 33], ["calcium", "TEST", 77, 84], ["turbidity assay", "TEST", 128, 143], ["-scale", "OBSERVATION_MODIFIER", 5, 11], ["liposomal aggregation", "OBSERVATION", 12, 33]]], ["High-resolution cryo-electron microscopy revealed that membrane cross-linking by tandem C2 domains results in a constant distance of approximately 9 nm between the apposed membranes.", [["membrane", "ANATOMY", 55, 63], ["membranes", "ANATOMY", 172, 181], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["membranes", "CELLULAR_COMPONENT", 172, 181], ["tandem C2 domains", "PROTEIN", 81, 98], ["High-resolution cryo-electron microscopy", "TEST", 0, 40], ["membrane cross-linking", "PROBLEM", 55, 77], ["membrane cross-linking", "OBSERVATION", 55, 77], ["9 nm", "OBSERVATION_MODIFIER", 147, 151], ["apposed membranes", "OBSERVATION", 164, 181]]], ["Our findings show the conserved nature of this important property of synaptotagmin, demonstrate the significance of the tandem C2 domain structure and provide a plausible explanation for the accelerating effect of synaptotagmins on membrane fusion.", [["membrane", "ANATOMY", 232, 240], ["synaptotagmin", "GENE_OR_GENE_PRODUCT", 69, 82], ["synaptotagmins", "SIMPLE_CHEMICAL", 214, 228], ["membrane", "CELLULAR_COMPONENT", 232, 240], ["synaptotagmin", "PROTEIN", 69, 82], ["C2 domain structure", "PROTEIN", 127, 146], ["synaptotagmins", "PROTEIN", 214, 228], ["the tandem C2 domain structure", "PROBLEM", 116, 146], ["synaptotagmins on membrane fusion", "TREATMENT", 214, 247], ["membrane fusion", "OBSERVATION", 232, 247]]], ["Membrane proteins can be challenging samples to work with and as such often require the use of multiple techniques.", [["Membrane", "ANATOMY", 0, 8], ["samples", "ANATOMY", 37, 44], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["Membrane proteins", "PROTEIN", 0, 17], ["Membrane proteins", "PROBLEM", 0, 17], ["multiple techniques", "TREATMENT", 95, 114]]], ["Here we present an insight into the structure of the antimicrobial peptide melittin in lipid membranes using various techniques.", [["lipid membranes", "ANATOMY", 87, 102], ["melittin", "SIMPLE_CHEMICAL", 75, 83], ["lipid membranes", "CELLULAR_COMPONENT", 87, 102], ["the antimicrobial peptide melittin in lipid membranes", "TREATMENT", 49, 102], ["various techniques", "TREATMENT", 109, 127], ["antimicrobial peptide melittin", "OBSERVATION", 53, 83], ["lipid membranes", "OBSERVATION", 87, 102]]], ["We explore the conformational changes of membrane-bound melittin and its interaction with model membrane lipid systems with a series of spectroscopic methods that can be used in parallel.", [["membrane", "ANATOMY", 41, 49], ["membrane", "ANATOMY", 96, 104], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["melittin", "SIMPLE_CHEMICAL", 56, 64], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["membrane-bound melittin", "TREATMENT", 41, 64], ["model membrane lipid systems", "TREATMENT", 90, 118], ["spectroscopic methods", "TREATMENT", 136, 157]]], ["The techniques used include linear dichroism and FT-IR for orientation information and circular dichroism for conformation information.", [["linear dichroism", "TEST", 28, 44]]], ["We use dynamic light scattering for molecular sizing, fluorescence emission for information on peptide environment, thin-layer chromatography for lipid identification, analytical ultracentrifugation to identify oligomerisation state and calorimetry to investigate the thermodynamics.", [["peptide environment", "TREATMENT", 95, 114], ["thin-layer chromatography", "TEST", 116, 141], ["lipid identification", "TEST", 146, 166], ["analytical ultracentrifugation", "TREATMENT", 168, 198], ["calorimetry", "TEST", 237, 248]]], ["We observe how the physical properties of both the peptide and the membranes affect the insertion kinetics of the peptide in the membrane.P-567Phospholipid membranes dynamics: molecular dynamics vs neutron scattering V. Conti Nibali 1 , M. Tarek 2 , U. Wanderlingh 1 , G. D'Angelo 1 1 Department of Physics, Faculty of Science, University of Messina, Italy, 2 Unit\u00e9 mixte de recherche CNRS/UHP 7565, Universit\u00e9 Henri Poincar\u00e9, Nancy, FranceP-567Collective dynamics and single-particle dynamics of hydrated multilamellar phospholipid bilayers (1,2-dimyristoylsn-glycero-3-phosphatidylcholine, DMPC) have been studied by means of all-atom molecular dynamics simulations.", [["membranes", "ANATOMY", 67, 76], ["membrane", "ANATOMY", 129, 137], ["1,2-dimyristoylsn-glycero-3-phosphatidylcholine", "CHEMICAL", 543, 590], ["DMPC", "CHEMICAL", 592, 596], ["1,2-dimyristoylsn-glycero-3-phosphatidylcholine", "CHEMICAL", 543, 590], ["DMPC", "CHEMICAL", 592, 596], ["membranes", "CELLULAR_COMPONENT", 67, 76], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["multilamellar phospholipid bilayers", "SIMPLE_CHEMICAL", 506, 541], ["1,2-dimyristoylsn-glycero-3-phosphatidylcholine", "SIMPLE_CHEMICAL", 543, 590], ["DMPC", "SIMPLE_CHEMICAL", 592, 596], ["UHP", "TEST", 390, 393], ["FranceP", "TEST", 434, 441], ["single-particle dynamics of hydrated multilamellar phospholipid bilayers", "TREATMENT", 469, 541], ["dimyristoylsn", "TREATMENT", 547, 560], ["glycero", "TREATMENT", 561, 568], ["phosphatidylcholine", "TREATMENT", 571, 590], ["DMPC", "TREATMENT", 592, 596], ["membrane", "ANATOMY", 129, 137]]], ["Here we report results of a gel phase bilayer at 283 K and of a liquid crystal phase bilayer at 303 K. Coherent and incoherent dynamic structure factors and meansquare displacements have been calculated from the trajectories for both the inplane and out-of-plane lipid dynamics.", [["structure factors", "PROTEIN", 135, 152], ["a gel phase bilayer", "TEST", 26, 45], ["a liquid crystal phase bilayer", "TEST", 62, 92], ["incoherent dynamic structure factors", "PROBLEM", 116, 152], ["meansquare displacements", "PROBLEM", 157, 181], ["dynamic structure", "OBSERVATION", 127, 144]]], ["Moreover, the results have been compared to recent quasi-elastic and inelastic neutron scattering data.", [["recent quasi-elastic", "TEST", 44, 64], ["inelastic neutron scattering data", "TEST", 69, 102]]], ["Optical tweezers allow trapping of particles of different types in a wide range of sizes [1] .", [["Optical tweezers", "TREATMENT", 0, 16]]], ["Among these, unilamellar vesicles are of interest as they are known to be effective vectors in drug delivery and they are also studied as models for cell membranes.", [["unilamellar vesicles", "ANATOMY", 13, 33], ["cell membranes", "ANATOMY", 149, 163], ["unilamellar vesicles", "SIMPLE_CHEMICAL", 13, 33], ["cell membranes", "CELLULAR_COMPONENT", 149, 163], ["drug delivery", "TREATMENT", 95, 108], ["cell membranes", "PROBLEM", 149, 163], ["cell membranes", "OBSERVATION", 149, 163]]], ["This work focuses on the interactions between optically confined unilamellar vesicles and their cross-linking by proteins [2] .", [["unilamellar vesicles", "ANATOMY", 65, 85], ["unilamellar vesicles", "CELLULAR_COMPONENT", 65, 85]]], ["Synaptotagmins are vesicular proteins implicated in many membrane trafficking events having an accelerating effect on the membrane fusion.", [["vesicular", "ANATOMY", 19, 28], ["membrane", "ANATOMY", 57, 65], ["membrane", "ANATOMY", 122, 130], ["Synaptotagmins", "GENE_OR_GENE_PRODUCT", 0, 14], ["vesicular", "MULTI-TISSUE_STRUCTURE", 19, 28], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["membrane", "CELLULAR_COMPONENT", 122, 130], ["Synaptotagmins", "PROTEIN", 0, 14], ["vesicular proteins", "PROTEIN", 19, 37], ["vesicular proteins", "PROBLEM", 19, 37], ["many membrane trafficking events", "PROBLEM", 52, 84], ["the membrane fusion", "TREATMENT", 118, 137], ["vesicular proteins", "OBSERVATION", 19, 37], ["many", "OBSERVATION_MODIFIER", 52, 56], ["membrane trafficking", "OBSERVATION", 57, 77], ["membrane fusion", "OBSERVATION", 122, 137]]], ["Calcium-sensitive synaptotagmins are thought to confer calcium sensitivity to the fusion of secretory vesicles with target membranes [3] .", [["secretory vesicles", "ANATOMY", 92, 110], ["membranes", "ANATOMY", 123, 132], ["Calcium", "CHEMICAL", 0, 7], ["calcium", "CHEMICAL", 55, 62], ["Calcium", "CHEMICAL", 0, 7], ["calcium", "CHEMICAL", 55, 62], ["Calcium", "SIMPLE_CHEMICAL", 0, 7], ["synaptotagmins", "GENE_OR_GENE_PRODUCT", 18, 32], ["calcium", "SIMPLE_CHEMICAL", 55, 62], ["secretory vesicles", "CELLULAR_COMPONENT", 92, 110], ["membranes", "CELLULAR_COMPONENT", 123, 132], ["Calcium-sensitive synaptotagmins", "PROTEIN", 0, 32], ["Calcium", "TEST", 0, 7], ["synaptotagmins", "TREATMENT", 18, 32], ["calcium sensitivity", "TEST", 55, 74]]], ["The novel optical assay reported here allowed us to visualize the cross-linking of 600 nm liposomes mediated by synaptotagmin and calcium.", [["calcium", "CHEMICAL", 130, 137], ["calcium", "CHEMICAL", 130, 137], ["synaptotagmin", "GENE_OR_GENE_PRODUCT", 112, 125], ["calcium", "SIMPLE_CHEMICAL", 130, 137], ["synaptotagmin", "PROTEIN", 112, 125], ["The novel optical assay", "TEST", 0, 23], ["calcium", "TEST", 130, 137]]], ["The use of the optical tweezers approach to investigate the function of other fusogenic proteins related to exocytosis (i.e., SNARE proteins) is discussed as well.", [["SNARE", "GENE_OR_GENE_PRODUCT", 126, 131], ["fusogenic proteins", "PROTEIN", 78, 96], ["SNARE proteins", "PROTEIN", 126, 140], ["the optical tweezers approach", "TREATMENT", 11, 40], ["other fusogenic proteins", "PROBLEM", 72, 96], ["exocytosis", "PROBLEM", 108, 118]]], ["Antimicrobial peptides (AMPs) have received increasing interest as the search for new potential antibiotics has become imperative due to increasing bacterial multiresistance.", [["Antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 0, 22], ["Antimicrobial peptides (AMPs)", "TREATMENT", 0, 29], ["new potential antibiotics", "TREATMENT", 82, 107], ["increasing bacterial multiresistance", "PROBLEM", 137, 173], ["increasing", "OBSERVATION_MODIFIER", 137, 147], ["bacterial multiresistance", "OBSERVATION", 148, 173]]], ["Acylating the natural occurring Polymyxin B (PMB) significantly enhances antibacterial activity towards two representative Gram-negative bacteria E. coli and K. pneumonia compared to the nonacylated PMB.", [["Polymyxin B", "CHEMICAL", 32, 43], ["PMB", "CHEMICAL", 45, 48], ["pneumonia", "DISEASE", 161, 170], ["PMB", "CHEMICAL", 199, 202], ["Polymyxin B", "CHEMICAL", 32, 43], ["PMB", "CHEMICAL", 45, 48], ["PMB", "CHEMICAL", 199, 202], ["Polymyxin B", "SIMPLE_CHEMICAL", 32, 43], ["PMB", "SIMPLE_CHEMICAL", 45, 48], ["Gram", "GENE_OR_GENE_PRODUCT", 123, 127], ["E. coli", "ORGANISM", 146, 153], ["PMB", "SIMPLE_CHEMICAL", 199, 202], ["E. coli", "SPECIES", 146, 153], ["K. pneumonia", "SPECIES", 158, 170], ["E. coli", "SPECIES", 146, 153], ["K. pneumonia", "SPECIES", 158, 170], ["Acylating", "TREATMENT", 0, 9], ["Polymyxin B (PMB", "TREATMENT", 32, 48], ["enhances antibacterial activity", "PROBLEM", 64, 95], ["representative Gram", "TEST", 108, 127], ["negative bacteria E. coli", "PROBLEM", 128, 153], ["K. pneumonia", "PROBLEM", 158, 170], ["the nonacylated PMB", "TREATMENT", 183, 202], ["antibacterial activity", "OBSERVATION", 73, 95], ["negative bacteria", "OBSERVATION_MODIFIER", 128, 145], ["E. coli", "OBSERVATION", 146, 153], ["pneumonia", "OBSERVATION", 161, 170]]], ["The aim of the presented work was to study various biophysical parameters, such as partitioning coefficients, zeta potentials and effective charges of a selected AMP, mastoparan-X (MPX) and a propanoylated (PAMPX) and octanoylated (OAMPX) analogue, respectively.", [["AMP", "CHEMICAL", 162, 165], ["mastoparan-X", "CHEMICAL", 167, 179], ["MPX", "CHEMICAL", 181, 184], ["propanoylated", "CHEMICAL", 192, 205], ["PAMPX", "CHEMICAL", 207, 212], ["octanoylated", "CHEMICAL", 218, 230], ["OAMPX", "CHEMICAL", 232, 237], ["AMP", "CHEMICAL", 162, 165], ["mastoparan-X", "CHEMICAL", 167, 179], ["MPX", "CHEMICAL", 181, 184], ["propanoylated", "CHEMICAL", 192, 205], ["PAMPX", "CHEMICAL", 207, 212], ["octanoylated", "CHEMICAL", 218, 230], ["OAMPX", "CHEMICAL", 232, 237], ["AMP", "SIMPLE_CHEMICAL", 162, 165], ["mastoparan-X", "SIMPLE_CHEMICAL", 167, 179], ["MPX", "SIMPLE_CHEMICAL", 181, 184], ["propanoylated", "SIMPLE_CHEMICAL", 192, 205], ["PAMPX", "SIMPLE_CHEMICAL", 207, 212], ["octanoylated", "SIMPLE_CHEMICAL", 218, 230], ["OAMPX", "SIMPLE_CHEMICAL", 232, 237], ["zeta potentials", "TREATMENT", 110, 125], ["a selected AMP", "TREATMENT", 151, 165], ["mastoparan-X (MPX)", "TREATMENT", 167, 185], ["a propanoylated (PAMPX)", "TREATMENT", 190, 213], ["octanoylated (OAMPX) analogue", "TREATMENT", 218, 247]]], ["Fluorescence spectroscopy, isothermal titration calorimetry and \u03b6-potential measurements were the main techniques used for the measurements.", [["Fluorescence spectroscopy", "TEST", 0, 25], ["isothermal titration calorimetry", "TEST", 27, 59], ["\u03b6-potential measurements", "TEST", 64, 88], ["the measurements", "TEST", 123, 139]]], ["We employed 2 different LUV model systems; a partially charged (POPG/POPC 1:3) and a neutral system (POPC).", [["POPC", "CHEMICAL", 69, 73], ["POPC", "CHEMICAL", 101, 105], ["2 different LUV model systems", "TREATMENT", 12, 41], ["a partially charged (POPG/POPC", "TREATMENT", 43, 73], ["a neutral system (POPC", "TREATMENT", 83, 105]]], ["For the neutral LUVs there was an increase in partitioning with increasing length of the acyl chain, whereas partioning into the partially charged LUVs was governed by a balance of hydrophobic and electrostatic contributions.", [["acyl", "CHEMICAL", 89, 93], ["acyl", "CHEMICAL", 89, 93], ["LUVs", "SIMPLE_CHEMICAL", 16, 20], ["LUVs", "SIMPLE_CHEMICAL", 147, 151], ["acyl chain", "PROTEIN", 89, 99], ["the neutral LUVs", "TEST", 4, 20], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["increasing", "OBSERVATION_MODIFIER", 64, 74], ["length", "OBSERVATION_MODIFIER", 75, 81], ["acyl chain", "OBSERVATION", 89, 99], ["charged LUVs", "OBSERVATION", 139, 151], ["electrostatic contributions", "OBSERVATION", 197, 224]]], ["The selectivity for the partially charged LUVs over the neutral LUVs was in the order PAMPX, MPX and OAMPX.", [["MPX", "CHEMICAL", 93, 96], ["OAMPX", "CHEMICAL", 101, 106], ["PAMPX", "CHEMICAL", 86, 91], ["MPX", "CHEMICAL", 93, 96], ["OAMPX", "CHEMICAL", 101, 106], ["LUVs", "SIMPLE_CHEMICAL", 42, 46], ["LUVs", "SIMPLE_CHEMICAL", 64, 68], ["PAMPX", "SIMPLE_CHEMICAL", 86, 91], ["MPX", "SIMPLE_CHEMICAL", 93, 96], ["OAMPX", "SIMPLE_CHEMICAL", 101, 106], ["the neutral LUVs", "TREATMENT", 52, 68], ["MPX", "TREATMENT", 93, 96], ["OAMPX", "TREATMENT", 101, 106]]], ["The modeled effective charge for the peptide followed the same trend as the partitioning coefficient for the three peptides for the respective LUV systems.P-572Does the lysosomal membrane need triglycerides?", [["lysosomal membrane", "ANATOMY", 169, 187], ["triglycerides", "CHEMICAL", 193, 206], ["lysosomal membrane", "CELLULAR_COMPONENT", 169, 187], ["triglycerides", "SIMPLE_CHEMICAL", 193, 206], ["P", "DNA", 155, 156], ["the peptide", "TREATMENT", 33, 44], ["triglycerides", "TEST", 193, 206], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["lysosomal membrane", "OBSERVATION", 169, 187]]], ["A spectroscopic study of a simple model membrane L. Duelund 1 , K. Pakkanen 2 , M. Vuento 2 , J. H. Ipsen 1 1 MEMPHYS -Center for Biomembrane Physics, University of Southern Denmark, Odense, Denmark, 2 Nanoscience Center, University of Jyv\u00e4skyl\u00e4, Jyv\u00e4skyl\u00e4, FinlandP-572Lysosomes are intracellular organelles in which proteins and other macromolecules are degraded.", [["intracellular organelles", "ANATOMY", 284, 308], ["FinlandP-572Lysosomes", "SIMPLE_CHEMICAL", 258, 279], ["intracellular organelles", "CELLULAR_COMPONENT", 284, 308], ["A spectroscopic study", "TEST", 0, 21], ["Jyv\u00e4skyl\u00e4", "TEST", 236, 245], ["Jyv\u00e4skyl\u00e4", "TEST", 247, 256], ["FinlandP", "TEST", 258, 266], ["intracellular organelles", "PROBLEM", 284, 308]]], ["Morphological and functional changes in different compartments of the endocytic pathway are connected to several diseases.", [["endocytic", "ANATOMY", 70, 79], ["Morphological and functional changes", "PROBLEM", 0, 36], ["several diseases", "PROBLEM", 105, 121], ["functional changes", "OBSERVATION", 18, 36], ["different", "OBSERVATION_MODIFIER", 40, 49], ["compartments", "OBSERVATION_MODIFIER", 50, 62], ["endocytic pathway", "OBSERVATION", 70, 87], ["several", "OBSERVATION_MODIFIER", 105, 112], ["diseases", "OBSERVATION", 113, 121]]], ["A crucial step in understanding biogenesis of lysosomes and their role in disease conditions, is to characterise the properties of the lysosomal membrane.", [["lysosomes", "ANATOMY", 46, 55], ["lysosomal membrane", "ANATOMY", 135, 153], ["lysosomes", "CELLULAR_COMPONENT", 46, 55], ["lysosomal membrane", "CELLULAR_COMPONENT", 135, 153], ["disease conditions", "PROBLEM", 74, 92], ["lysosomal membrane", "OBSERVATION", 135, 153]]], ["By the use of TLC we have found that lysosomes contain non-neglible amounts of triglycerides (TG).", [["lysosomes", "ANATOMY", 37, 46], ["TG", "DISEASE", 94, 96], ["triglycerides", "CHEMICAL", 79, 92], ["lysosomes", "CELLULAR_COMPONENT", 37, 46], ["triglycerides", "SIMPLE_CHEMICAL", 79, 92], ["TG", "SIMPLE_CHEMICAL", 94, 96], ["TLC", "TREATMENT", 14, 17], ["triglycerides", "TEST", 79, 92]]], ["To investigate how the presence of TGs could influence the lysosomal membrane, we have investigated the properties of a mixture of POPC and triolein, as a simple model for the lysosomal membrane.", [["lysosomal membrane", "ANATOMY", 59, 77], ["lysosomal membrane", "ANATOMY", 176, 194], ["POPC", "CHEMICAL", 131, 135], ["triolein", "CHEMICAL", 140, 148], ["TGs", "CHEMICAL", 35, 38], ["POPC", "CHEMICAL", 131, 135], ["triolein", "CHEMICAL", 140, 148], ["TGs", "SIMPLE_CHEMICAL", 35, 38], ["lysosomal membrane", "CELLULAR_COMPONENT", 59, 77], ["POPC", "SIMPLE_CHEMICAL", 131, 135], ["triolein", "SIMPLE_CHEMICAL", 140, 148], ["lysosomal membrane", "CELLULAR_COMPONENT", 176, 194], ["TGs", "PROBLEM", 35, 38], ["POPC and triolein", "TREATMENT", 131, 148], ["the lysosomal membrane", "TREATMENT", 172, 194], ["lysosomal membrane", "OBSERVATION", 59, 77], ["lysosomal membrane", "OBSERVATION", 176, 194]]], ["We found the system to form two types of POPC-rich membranes.", [["membranes", "ANATOMY", 51, 60], ["POPC", "CHEMICAL", 41, 45], ["POPC", "CHEMICAL", 41, 45], ["POPC", "SIMPLE_CHEMICAL", 41, 45], ["membranes", "CELLULAR_COMPONENT", 51, 60], ["rich membranes", "OBSERVATION", 46, 60]]], ["By using EPR and fluorescence spectroscopy the physical properties, including order, fluidity and water penetration, of these phases were found to differ markedly despite of their almost identical composition.", [["water", "SIMPLE_CHEMICAL", 98, 103], ["fluorescence spectroscopy", "TEST", 17, 42], ["fluidity and water penetration", "TREATMENT", 85, 115]]], ["The results suggest that presence of TGs on lysosomal membranes could have a crucial effect in the barrier functions and thus, the integrity of the organelle.", [["lysosomal membranes", "ANATOMY", 44, 63], ["organelle", "ANATOMY", 148, 157], ["TGs", "CHEMICAL", 37, 40], ["TGs", "SIMPLE_CHEMICAL", 37, 40], ["lysosomal membranes", "CELLULAR_COMPONENT", 44, 63], ["organelle", "CELLULAR_COMPONENT", 148, 157], ["TGs on lysosomal membranes", "PROBLEM", 37, 63], ["TGs", "OBSERVATION", 37, 40], ["lysosomal membranes", "OBSERVATION", 44, 63], ["crucial", "OBSERVATION_MODIFIER", 77, 84], ["effect", "OBSERVATION_MODIFIER", 85, 91]]], ["Model membranes with the capacity to align in magnetic fields such as bicelles and magnetically sensitive vesicles are of high interest, since their macroscopically alignment allows for the determination of structure, dynamics and topology of molecules within the membrane [1] .", [["membranes", "ANATOMY", 6, 15], ["bicelles", "ANATOMY", 70, 78], ["vesicles", "ANATOMY", 106, 114], ["membrane", "ANATOMY", 264, 272], ["membranes", "CELLULAR_COMPONENT", 6, 15], ["vesicles", "CELLULAR_COMPONENT", 106, 114], ["membrane", "CELLULAR_COMPONENT", 264, 272], ["Model membranes", "PROBLEM", 0, 15], ["the capacity", "PROBLEM", 21, 33], ["membranes", "OBSERVATION", 6, 15], ["high interest", "OBSERVATION_MODIFIER", 122, 135]]], ["We performed 31 P solid state NMR on a magnetically sensitive lipid possessing a large positive magnetic anisotropy introduced in form of a biphenyl unit during lipid synthesis in one of its acyl chains (1-tetradecanoyl-2-(4-(4biphenyl) butanoyl)-snglycero-3-phosphocholine (TBBPC)).", [["biphenyl", "CHEMICAL", 140, 148], ["1-tetradecanoyl-2-(4-(4biphenyl) butanoyl)-snglycero-3-phosphocholine", "CHEMICAL", 204, 273], ["TBBPC", "CHEMICAL", 275, 280], ["biphenyl", "CHEMICAL", 140, 148], ["acyl", "CHEMICAL", 191, 195], ["1-tetradecanoyl-2-(4-(4biphenyl) butanoyl)-snglycero-3-phosphocholine", "CHEMICAL", 204, 273], ["TBBPC", "CHEMICAL", 275, 280], ["lipid", "SIMPLE_CHEMICAL", 161, 166], ["acyl chains (1-tetradecanoyl-2-(4-(4biphenyl) butanoyl)-snglycero-3-phosphocholine", "SIMPLE_CHEMICAL", 191, 273], ["TBBPC", "SIMPLE_CHEMICAL", 275, 280], ["a large positive magnetic anisotropy", "TREATMENT", 79, 115], ["a biphenyl unit during lipid synthesis", "TREATMENT", 138, 176], ["its acyl chains", "TREATMENT", 187, 202], ["tetradecanoyl-2", "TREATMENT", 206, 221], ["4biphenyl) butanoyl", "TREATMENT", 226, 245], ["snglycero", "TREATMENT", 247, 256], ["phosphocholine (TBBPC)", "TREATMENT", 259, 281], ["large", "OBSERVATION_MODIFIER", 81, 86], ["positive", "OBSERVATION", 87, 95]]], ["The phosphorus lineshapes of TBBPC MLVs studied at various magnetic fields (7.1T, 9.4T, 11.7T, 16.4T), revealed a drastic change in shape upon exposure to fields > 9.4 Tesla: resonances resulting from phospholipid molecules oriented perpendicular to the magnetic field decrease whereas resonances resulting from parallel oriented molecules increase.", [["phosphorus", "CHEMICAL", 4, 14], ["TBBPC", "CHEMICAL", 29, 34], ["phosphorus", "CHEMICAL", 4, 14], ["TBBPC", "CHEMICAL", 29, 34], ["phosphorus", "SIMPLE_CHEMICAL", 4, 14], ["phospholipid molecules", "SIMPLE_CHEMICAL", 201, 223], ["phospholipid molecules", "PROTEIN", 201, 223], ["The phosphorus lineshapes", "TEST", 0, 25], ["TBBPC MLVs", "TEST", 29, 39], ["a drastic change in shape", "PROBLEM", 112, 137], ["phospholipid molecules", "PROBLEM", 201, 223], ["parallel oriented molecules", "PROBLEM", 312, 339], ["drastic", "OBSERVATION_MODIFIER", 114, 121], ["change", "OBSERVATION", 122, 128], ["shape", "OBSERVATION_MODIFIER", 132, 137]]], ["This is a sign for magnetically induced vesicle deformation from vesicle to oblate ellipsoid shape.", [["vesicle", "ANATOMY", 40, 47], ["vesicle", "ANATOMY", 65, 72], ["vesicle", "CELLULAR_COMPONENT", 40, 47], ["vesicle", "CELLULAR_COMPONENT", 65, 72], ["magnetically induced vesicle deformation", "PROBLEM", 19, 59], ["vesicle deformation", "OBSERVATION", 40, 59], ["vesicle", "ANATOMY", 65, 72], ["oblate", "OBSERVATION_MODIFIER", 76, 82], ["ellipsoid shape", "OBSERVATION", 83, 98]]], ["Factors influencing this drastic deformation, such as magnetic anisotropy, membrane elasticity, lipid chain length and field dependency are discussed based on existing theories [2] .", [["membrane", "ANATOMY", 75, 83], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["this drastic deformation", "PROBLEM", 20, 44], ["magnetic anisotropy", "TEST", 54, 73], ["lipid chain length and field dependency", "PROBLEM", 96, 135], ["drastic deformation", "OBSERVATION", 25, 44], ["membrane elasticity", "OBSERVATION", 75, 94], ["lipid", "OBSERVATION", 96, 101], ["chain length", "OBSERVATION_MODIFIER", 102, 114]]], ["Hepatitis G virus (GBV-C/HGV) is an enveloped viruses belonging to the Flaviviridae family.", [["Hepatitis G", "DISEASE", 0, 11], ["Hepatitis G virus", "ORGANISM", 0, 17], ["GBV-C/HGV", "ORGANISM", 19, 28], ["Hepatitis G virus", "SPECIES", 0, 17], ["Hepatitis G virus", "SPECIES", 0, 17], ["GBV", "SPECIES", 19, 22], ["HGV", "SPECIES", 25, 28], ["Hepatitis G virus", "PROBLEM", 0, 17], ["GBV", "TEST", 19, 22], ["HGV", "PROBLEM", 25, 28], ["an enveloped viruses", "PROBLEM", 33, 53], ["viruses", "OBSERVATION", 46, 53]]], ["Clinical findings have suggested that in people co-infected with GBV-C/HGV and human immunodeficiency virus (HIV), delayed progression of AIDS has been observed (1).", [["human immunodeficiency virus (HIV)", "DISEASE", 79, 113], ["AIDS", "DISEASE", 138, 142], ["people", "ORGANISM", 41, 47], ["GBV-C/HGV", "ORGANISM", 65, 74], ["human immunodeficiency virus", "ORGANISM", 79, 107], ["HIV", "ORGANISM", 109, 112], ["people", "SPECIES", 41, 47], ["human", "SPECIES", 79, 84], ["immunodeficiency virus (HIV", "SPECIES", 85, 112], ["HGV", "SPECIES", 71, 74], ["human immunodeficiency virus", "SPECIES", 79, 107], ["HIV", "SPECIES", 109, 112], ["GBV", "TEST", 65, 68], ["C/HGV", "PROBLEM", 69, 74], ["human immunodeficiency virus", "PROBLEM", 79, 107], ["HIV", "PROBLEM", 109, 112], ["delayed progression of AIDS", "PROBLEM", 115, 142]]], ["The mechanism by which this virus may inhibit the progression of AIDS remain to be elucidated.", [["AIDS", "DISEASE", 65, 69], ["this virus", "PROBLEM", 23, 33], ["AIDS", "PROBLEM", 65, 69]]], ["Enveloped viruses acquire their lipid membranes by budding through host cellular membranes (2) , in this process; fusion peptides play an important role.", [["lipid membranes", "ANATOMY", 32, 47], ["cellular membranes", "ANATOMY", 72, 90], ["lipid membranes", "CELLULAR_COMPONENT", 32, 47], ["cellular membranes", "CELLULAR_COMPONENT", 72, 90], ["Enveloped viruses", "PROBLEM", 0, 17], ["their lipid membranes", "TREATMENT", 26, 47], ["fusion peptides", "TREATMENT", 114, 129], ["viruses", "OBSERVATION", 10, 17], ["lipid membranes", "OBSERVATION", 32, 47], ["host cellular membranes", "OBSERVATION", 67, 90]]], ["Study of the interaction of HGV-C peptides with lipid membranes could lead us useful information about the mechanism that takes place.", [["lipid membranes", "ANATOMY", 48, 63], ["HGV-C peptides", "GENE_OR_GENE_PRODUCT", 28, 42], ["lipid membranes", "CELLULAR_COMPONENT", 48, 63], ["HGV-C peptides", "TREATMENT", 28, 42], ["lipid membranes", "TREATMENT", 48, 63]]], ["In this work we present a study on the effects of E1 peptides on the fluidity of and polarizability of model membranes (DMPC and DPPC liposomes) by DSC and fluorescence polarization.", [["membranes", "ANATOMY", 109, 118], ["DMPC", "CHEMICAL", 120, 124], ["DPPC", "CHEMICAL", 129, 133], ["E1 peptides", "GENE_OR_GENE_PRODUCT", 50, 61], ["membranes", "CELLULAR_COMPONENT", 109, 118], ["DMPC", "SIMPLE_CHEMICAL", 120, 124], ["DPPC liposomes", "SIMPLE_CHEMICAL", 129, 143], ["a study", "TEST", 24, 31], ["E1 peptides", "TREATMENT", 50, 61], ["polarizability of model membranes (DMPC and DPPC liposomes", "TREATMENT", 85, 143], ["fluorescence polarization", "TEST", 156, 181], ["fluorescence polarization", "OBSERVATION", 156, 181]]], ["Both techniques showed that the presence of the studied sequences in phospholipid mixtures already affected the thermotropic properties of the gel to liquid-crystalline phase transition.", [["phospholipid", "SIMPLE_CHEMICAL", 69, 81], ["the studied sequences in phospholipid mixtures", "TEST", 44, 90], ["the gel to liquid-crystalline phase transition", "TREATMENT", 139, 185], ["crystalline phase", "OBSERVATION", 157, 174]]], ["Systems were thermodynamically charac- Small angle neutron scattering (SANS) studies have been performed to study the structural changes induced in membranes of vesicles prepared from phospholipid and mixed phospholipid-sterol mixtures, in the presence of different concentrations of the anti-fungal drug, amphotericin B (AmB).The vesicles, sonicated to a mean size\u223c100nm, were prepared using dimyristoylphosphatidylcholine(DMPC) or DMPC-cholesterol or DMPC-ergosterol mixtures -with both of the mixed systems involving 30mol% sterol.", [["membranes", "ANATOMY", 148, 157], ["vesicles", "ANATOMY", 161, 169], ["vesicles", "ANATOMY", 331, 339], ["amphotericin B", "CHEMICAL", 306, 320], ["AmB", "CHEMICAL", 322, 325], ["dimyristoylphosphatidylcholine", "CHEMICAL", 393, 423], ["DMPC", "CHEMICAL", 424, 428], ["DMPC", "CHEMICAL", 433, 437], ["cholesterol", "CHEMICAL", 438, 449], ["DMPC-ergosterol", "CHEMICAL", 453, 468], ["sterol", "CHEMICAL", 527, 533], ["sterol", "CHEMICAL", 220, 226], ["amphotericin B", "CHEMICAL", 306, 320], ["AmB", "CHEMICAL", 322, 325], ["dimyristoylphosphatidylcholine", "CHEMICAL", 393, 423], ["DMPC", "CHEMICAL", 424, 428], ["DMPC", "CHEMICAL", 433, 437], ["cholesterol", "CHEMICAL", 438, 449], ["DMPC", "CHEMICAL", 453, 457], ["ergosterol", "CHEMICAL", 458, 468], ["sterol", "CHEMICAL", 527, 533], ["membranes", "CELLULAR_COMPONENT", 148, 157], ["vesicles", "CELLULAR_COMPONENT", 161, 169], ["phospholipid", "SIMPLE_CHEMICAL", 184, 196], ["phospholipid", "SIMPLE_CHEMICAL", 207, 219], ["sterol", "SIMPLE_CHEMICAL", 220, 226], ["amphotericin B", "SIMPLE_CHEMICAL", 306, 320], ["AmB", "SIMPLE_CHEMICAL", 322, 325], ["vesicles", "CELLULAR_COMPONENT", 331, 339], ["dimyristoylphosphatidylcholine", "SIMPLE_CHEMICAL", 393, 423], ["DMPC", "SIMPLE_CHEMICAL", 424, 428], ["DMPC-cholesterol", "SIMPLE_CHEMICAL", 433, 449], ["DMPC-ergosterol mixtures", "SIMPLE_CHEMICAL", 453, 477], ["sterol", "SIMPLE_CHEMICAL", 527, 533], ["phospholipid and mixed phospholipid-sterol mixtures", "TREATMENT", 184, 235], ["the anti-fungal drug", "TREATMENT", 284, 304], ["amphotericin B (AmB)", "TREATMENT", 306, 326], ["dimyristoylphosphatidylcholine(DMPC", "TREATMENT", 393, 428], ["DMPC-cholesterol", "TREATMENT", 433, 449], ["DMPC-ergosterol mixtures", "TREATMENT", 453, 477], ["Small", "OBSERVATION_MODIFIER", 39, 44], ["angle", "OBSERVATION_MODIFIER", 45, 50], ["sterol mixtures", "OBSERVATION", 220, 235], ["anti-fungal drug", "OBSERVATION", 288, 304], ["vesicles", "ANATOMY", 331, 339], ["size", "OBSERVATION_MODIFIER", 361, 365]]], ["Analysis of the SANS data show that when the concentration of AmB added is just above the drug's cmc (\u223c1\u00b5M) there is an increase in the membrane thickness of both the DMPC-chol and DMPC-erg vesicles (both cases + 4\u00c5), but the thickness of the pure DMPC vesicle membranes remains the same as in the absence of AmB.", [["membrane", "ANATOMY", 136, 144], ["DMPC-erg vesicles", "ANATOMY", 181, 198], ["DMPC vesicle membranes", "ANATOMY", 248, 270], ["AmB", "CHEMICAL", 62, 65], ["DMPC-chol", "CHEMICAL", 167, 176], ["DMPC", "CHEMICAL", 181, 185], ["AmB", "CHEMICAL", 62, 65], ["DMPC", "CHEMICAL", 167, 171], ["chol", "CHEMICAL", 172, 176], ["DMPC", "CHEMICAL", 181, 185], ["DMPC", "CHEMICAL", 248, 252], ["AmB", "SIMPLE_CHEMICAL", 62, 65], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["DMPC-chol", "SIMPLE_CHEMICAL", 167, 176], ["DMPC-erg vesicles", "SIMPLE_CHEMICAL", 181, 198], ["the SANS data", "TEST", 12, 25], ["AmB", "TREATMENT", 62, 65], ["an increase", "PROBLEM", 117, 128], ["the DMPC", "TEST", 163, 171], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["membrane thickness", "OBSERVATION", 136, 154], ["erg vesicles", "ANATOMY", 186, 198], ["pure DMPC", "OBSERVATION", 243, 252], ["vesicle membranes", "OBSERVATION", 253, 270]]], ["When AmB is added at a concentration in excess of its cmc (\u223c10\u00b5M), the mixed-sterol vesicles show the same changes in membrane thickness as observed with the lower AmB concentration, and the pure DMPC vesicles again remain unaffected.", [["membrane", "ANATOMY", 118, 126], ["DMPC vesicles", "ANATOMY", 196, 209], ["AmB", "CHEMICAL", 5, 8], ["AmB", "CHEMICAL", 164, 167], ["AmB", "CHEMICAL", 5, 8], ["sterol", "CHEMICAL", 77, 83], ["AmB", "CHEMICAL", 164, 167], ["DMPC", "CHEMICAL", 196, 200], ["AmB", "SIMPLE_CHEMICAL", 5, 8], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["AmB", "SIMPLE_CHEMICAL", 164, 167], ["DMPC", "SIMPLE_CHEMICAL", 196, 200], ["the same changes in membrane thickness", "PROBLEM", 98, 136], ["the lower AmB concentration", "TREATMENT", 154, 181], ["the pure DMPC vesicles", "PROBLEM", 187, 209], ["cmc", "ANATOMY", 54, 57], ["sterol vesicles", "ANATOMY", 77, 92], ["membrane thickness", "OBSERVATION", 118, 136], ["unaffected", "OBSERVATION", 223, 233]]], ["On the basis of these studies, therefore, there appears to be no difference in the structural changes induced by the insertion of AmB into the model fungal cell membranes (mimicked by DMPC-erg vesicles and those resulting from its insertion into the model mammalian cell membranes (mimicked by DMPC-chol vesicles).", [["cell membranes", "ANATOMY", 156, 170], ["cell membranes", "ANATOMY", 266, 280], ["DMPC-chol vesicles", "ANATOMY", 294, 312], ["AmB", "CHEMICAL", 130, 133], ["DMPC-erg", "CHEMICAL", 184, 192], ["DMPC-chol", "CHEMICAL", 294, 303], ["AmB", "CHEMICAL", 130, 133], ["DMPC", "CHEMICAL", 184, 188], ["DMPC", "CHEMICAL", 294, 298], ["AmB", "SIMPLE_CHEMICAL", 130, 133], ["cell membranes", "CELLULAR_COMPONENT", 156, 170], ["cell membranes", "CELLULAR_COMPONENT", 266, 280], ["these studies", "TEST", 16, 29], ["the structural changes", "PROBLEM", 79, 101], ["the insertion of AmB", "TREATMENT", 113, 133], ["the model fungal cell membranes", "PROBLEM", 139, 170], ["erg vesicles", "PROBLEM", 189, 201], ["DMPC-chol vesicles", "TREATMENT", 294, 312], ["appears to be", "UNCERTAINTY", 48, 61], ["fungal cell membranes", "OBSERVATION", 149, 170], ["erg vesicles", "OBSERVATION", 189, 201], ["mammalian cell membranes", "OBSERVATION", 256, 280], ["chol vesicles", "ANATOMY", 299, 312]]], ["The third transmembrane helix of bacteriorhodopsin, also known as pHLIP, is a unique model system for studying the interactions of a natural transmembrane domain with lipid membranes: depending on pH, the water-soluble peptide either adsorbs superficially or inserts as a transmembrane helix on addition of lipid vesicles [1] .", [["transmembrane", "ANATOMY", 10, 23], ["transmembrane", "ANATOMY", 141, 154], ["lipid membranes", "ANATOMY", 167, 182], ["transmembrane", "ANATOMY", 272, 285], ["lipid vesicles", "ANATOMY", 307, 321], ["bacteriorhodopsin", "AMINO_ACID", 33, 50], ["pHLIP", "GENE_OR_GENE_PRODUCT", 66, 71], ["lipid membranes", "CELLULAR_COMPONENT", 167, 182], ["lipid vesicles", "CELLULAR_COMPONENT", 307, 321], ["bacteriorhodopsin", "PROTEIN", 33, 50], ["pHLIP", "PROTEIN", 66, 71], ["natural transmembrane domain", "PROTEIN", 133, 161], ["transmembrane helix", "PROTEIN", 272, 291], ["The third transmembrane helix of bacteriorhodopsin", "TREATMENT", 0, 50], ["a natural transmembrane domain with lipid membranes", "TREATMENT", 131, 182], ["pH", "TEST", 197, 199], ["the water-soluble peptide", "TREATMENT", 201, 226], ["a transmembrane helix", "TREATMENT", 270, 291], ["lipid vesicles", "TREATMENT", 307, 321]]], ["Published values for the free energies of these processes were based on a stoichiometric model invoking two distinct sets of binding sites [2] .", [["binding sites", "PROTEIN", 125, 138], ["a stoichiometric model", "TREATMENT", 72, 94]]], ["However, discrepancies between data obtained from different experimental techniques and inconsistencies between experimental and expected temperature dependencies suggest that these values should be taken with caution.", [["discrepancies between data", "PROBLEM", 9, 35], ["inconsistencies between experimental and expected temperature dependencies", "PROBLEM", 88, 162], ["these values", "TEST", 176, 188]]], ["We therefore reassessed membrane interactions of pHLIP using titration calorimetry and fluorescence spectroscopy.", [["membrane", "ANATOMY", 24, 32], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["pHLIP", "SIMPLE_CHEMICAL", 49, 54], ["pHLIP", "PROTEIN", 49, 54], ["titration calorimetry", "TREATMENT", 61, 82], ["fluorescence spectroscopy", "TEST", 87, 112]]], ["If electrostatic effects at the membrane surface are taken into account, the data can be described quantitatively by a partition equilibrium, but not by a stoichiometric binding model.", [["membrane surface", "ANATOMY", 32, 48], ["membrane surface", "CELLULAR_COMPONENT", 32, 48], ["electrostatic effects at the membrane surface", "PROBLEM", 3, 48], ["electrostatic effects", "OBSERVATION", 3, 24]]], ["The thermodynamics of membrane partitioning differ substantially from those determined previously [2] and draw a different picture of peptide-lipid interactions.", [["membrane", "ANATOMY", 22, 30], ["membrane", "CELLULAR_COMPONENT", 22, 30], ["lipid", "SIMPLE_CHEMICAL", 142, 147]]], ["Beyond deepening our insights into the first step of the two-stage model of membrane protein folding, this also sheds light on the ability of pHLIP to drag cargo molecules across lipid membranes.", [["membrane", "ANATOMY", 76, 84], ["lipid membranes", "ANATOMY", 179, 194], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["pHLIP", "SIMPLE_CHEMICAL", 142, 147], ["lipid membranes", "CELLULAR_COMPONENT", 179, 194], ["pHLIP", "PROTEIN", 142, 147], ["membrane protein folding", "PROBLEM", 76, 100], ["membrane protein folding", "OBSERVATION", 76, 100], ["lipid membranes", "OBSERVATION", 179, 194]]], ["Adsorption of monolysine and polylysines at the surface of lipid membranes of varied composition was studied by two methods.", [["surface", "ANATOMY", 48, 55], ["lipid membranes", "ANATOMY", 59, 74], ["monolysine", "CHEMICAL", 14, 24], ["polylysines", "CHEMICAL", 29, 40], ["monolysine", "CHEMICAL", 14, 24], ["polylysines", "CHEMICAL", 29, 40], ["monolysine", "SIMPLE_CHEMICAL", 14, 24], ["polylysines", "SIMPLE_CHEMICAL", 29, 40], ["surface", "CELLULAR_COMPONENT", 48, 55], ["lipid membranes", "CELLULAR_COMPONENT", 59, 74], ["monolysine", "TREATMENT", 14, 24], ["polylysines", "TREATMENT", 29, 40], ["lipid membranes", "TREATMENT", 59, 74], ["lipid membranes", "OBSERVATION", 59, 74]]], ["Both methods -the electrokinetic one, measured the surface potential of liposomes, and the Intramembranouse Field Compensation sensitive to boundary potential of planar bilayer lipid membranes -detected the positive changes of the potentials for membranes with negatively charged component (cardiolipin, CL).", [["surface", "ANATOMY", 51, 58], ["bilayer lipid membranes", "ANATOMY", 169, 192], ["membranes", "ANATOMY", 246, 255], ["cardiolipin", "CHEMICAL", 291, 302], ["liposomes", "SIMPLE_CHEMICAL", 72, 81], ["membranes", "CELLULAR_COMPONENT", 246, 255], ["cardiolipin", "SIMPLE_CHEMICAL", 291, 302], ["CL", "SIMPLE_CHEMICAL", 304, 306], ["planar bilayer lipid membranes", "TEST", 162, 192], ["membranes", "PROBLEM", 246, 255], ["liposomes", "OBSERVATION", 72, 81], ["lipid membranes", "OBSERVATION", 177, 192], ["positive", "OBSERVATION", 207, 215]]], ["Neither monolysine, nor polylysines adsorbed at neutral membranes (phosphatidylcholine, PC).", [["membranes", "ANATOMY", 56, 65], ["monolysine", "CHEMICAL", 8, 18], ["polylysines", "CHEMICAL", 24, 35], ["phosphatidylcholine", "CHEMICAL", 67, 86], ["monolysine", "CHEMICAL", 8, 18], ["polylysines", "CHEMICAL", 24, 35], ["phosphatidylcholine", "CHEMICAL", 67, 86], ["monolysine", "SIMPLE_CHEMICAL", 8, 18], ["polylysines", "SIMPLE_CHEMICAL", 24, 35], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 67, 86], ["PC", "SIMPLE_CHEMICAL", 88, 90], ["monolysine", "TREATMENT", 8, 18], ["phosphatidylcholine, PC)", "TREATMENT", 67, 91]]], ["Pentalysine show the difference between these potentials for the membranes composed from CL/PC mixtures.", [["membranes", "ANATOMY", 65, 74], ["Pentalysine", "CHEMICAL", 0, 11], ["Pentalysine", "CHEMICAL", 0, 11], ["Pentalysine", "SIMPLE_CHEMICAL", 0, 11], ["membranes", "CELLULAR_COMPONENT", 65, 74], ["CL", "SIMPLE_CHEMICAL", 89, 91], ["Pentalysine", "TREATMENT", 0, 11], ["the membranes", "PROBLEM", 61, 74], ["CL/PC mixtures", "TREATMENT", 89, 103]]], ["This difference is attributed to dipole part of boundary potential and indicates the changes in lipid packing.", [["lipid", "SIMPLE_CHEMICAL", 96, 101], ["lipid packing", "TREATMENT", 96, 109], ["lipid packing", "OBSERVATION", 96, 109]]], ["Polylysines show high affinity to the membrane and saturation with plateau.", [["membrane", "ANATOMY", 38, 46], ["Polylysines", "CHEMICAL", 0, 11], ["Polylysines", "CHEMICAL", 0, 11], ["Polylysines", "SIMPLE_CHEMICAL", 0, 11], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["Polylysines", "TEST", 0, 11], ["high affinity", "PROBLEM", 17, 30], ["high affinity", "OBSERVATION", 17, 30], ["plateau", "ANATOMY", 67, 74]]], ["These saturation levels correspond to surface charge densities 0.005 and 0.016 C/m 2 for oligomers with 5 and 12 units, and 0.032 C/m 2 for polymers with 130 and 1435 units.", [["surface", "ANATOMY", 38, 45], ["These saturation levels", "TEST", 0, 23], ["surface charge densities", "PROBLEM", 38, 62], ["oligomers", "TEST", 89, 98], ["polymers", "TEST", 140, 148]]], ["These values do not depend on the ionic strength of background electrolyte but proportional to the content of negatively charged components in the lipid bilayer.", [["lipid bilayer", "ANATOMY", 147, 160], ["lipid bilayer", "CELLULAR_COMPONENT", 147, 160], ["These values", "TEST", 0, 12], ["negatively", "OBSERVATION_MODIFIER", 110, 120], ["charged", "OBSERVATION", 121, 128]]], ["The polylysine layer at the mica surface was studied by atomic-force microscope (AFM) technique.", [["polylysine", "CHEMICAL", 4, 14], ["polylysine", "CHEMICAL", 4, 14], ["The polylysine layer", "TREATMENT", 0, 20], ["polylysine", "OBSERVATION_MODIFIER", 4, 14], ["layer", "OBSERVATION_MODIFIER", 15, 20]]], ["It was shown that pentalysine molecules cover the surface by the layer of 0.8 nm thickness and polylysines of high molecular weight by the layer up to 4 nm.P-574Effects of lysolipids on the mechanical stability of lipid membranes J. R. Henriksen 1 , L. Feldborg 1 , J. H. Ipsen 2 , T. L. Andresen 1 1 Technical University of Denmark, DTU Nanotech, Frederiksborgvej 399, B124, 4000 Roskilde, Denmark., 2 University of Southern Denmark, Department of physics and chemistry, Memphys Center, Campusvej 55, 5230 Odense M, Denmark Lysolipids (LPCs) and fatty acids (FAs) are the natural products formed by the hydrolysis of phospholipids.", [["surface", "ANATOMY", 50, 57], ["lipid membranes", "ANATOMY", 214, 229], ["pentalysine", "CHEMICAL", 18, 29], ["fatty acids", "CHEMICAL", 547, 558], ["FAs", "CHEMICAL", 560, 563], ["pentalysine", "CHEMICAL", 18, 29], ["fatty acids", "CHEMICAL", 547, 558], ["pentalysine molecules", "SIMPLE_CHEMICAL", 18, 39], ["surface", "CELLULAR_COMPONENT", 50, 57], ["lysolipids", "SIMPLE_CHEMICAL", 172, 182], ["Denmark Lysolipids", "SIMPLE_CHEMICAL", 517, 535], ["fatty acids", "SIMPLE_CHEMICAL", 547, 558], ["FAs", "SIMPLE_CHEMICAL", 560, 563], ["phospholipids", "SIMPLE_CHEMICAL", 618, 631], ["pentalysine molecules", "PROTEIN", 18, 39], ["pentalysine molecules", "TREATMENT", 18, 39], ["high molecular weight", "PROBLEM", 110, 131], ["P", "TEST", 156, 157], ["lysolipids", "TREATMENT", 172, 182], ["Campusvej", "TEST", 488, 497], ["Denmark Lysolipids (LPCs", "TREATMENT", 517, 541], ["fatty acids (FAs)", "TREATMENT", 547, 564], ["the natural products", "TREATMENT", 569, 589], ["the hydrolysis of phospholipids", "TREATMENT", 600, 631], ["surface", "OBSERVATION_MODIFIER", 50, 57], ["layer", "OBSERVATION_MODIFIER", 65, 70], ["high molecular", "OBSERVATION_MODIFIER", 110, 124], ["lipid membranes", "OBSERVATION", 214, 229]]], ["LPCs and FAs form micelles in solution and thus act as detergents in the presence of lipid membranes.", [["LPCs", "ANATOMY", 0, 4], ["lipid membranes", "ANATOMY", 85, 100], ["FAs", "CHEMICAL", 9, 12], ["LPCs", "SIMPLE_CHEMICAL", 0, 4], ["FAs", "SIMPLE_CHEMICAL", 9, 12], ["micelles", "SIMPLE_CHEMICAL", 18, 26], ["lipid membranes", "CELLULAR_COMPONENT", 85, 100], ["LPCs", "CELL_TYPE", 0, 4], ["LPCs", "TEST", 0, 4], ["lipid membranes", "PROBLEM", 85, 100], ["micelles", "OBSERVATION_MODIFIER", 18, 26], ["lipid membranes", "OBSERVATION", 85, 100]]], ["In the present study we investigate the detergent strength of a homologous series of lysolipids (LPCs) on POPC lipid membranes by use of Isothermal Titration Calorimetry (ITC) and Vesicle Fluctuation Analysis (VFA).", [["LPCs", "ANATOMY", 97, 101], ["lipid membranes", "ANATOMY", 111, 126], ["lysolipids", "CHEMICAL", 85, 95], ["POPC", "CHEMICAL", 106, 110], ["lysolipids", "SIMPLE_CHEMICAL", 85, 95], ["LPCs", "SIMPLE_CHEMICAL", 97, 101], ["POPC", "SIMPLE_CHEMICAL", 106, 110], ["a homologous series of lysolipids (LPCs", "TREATMENT", 62, 101], ["POPC lipid membranes", "TREATMENT", 106, 126], ["Isothermal Titration Calorimetry", "TREATMENT", 137, 169], ["Vesicle Fluctuation Analysis", "TEST", 180, 208], ["VFA", "TEST", 210, 213]]], ["The membrane partition coefficient (K) and critical micelle concentration (CMC) are determined and found to obey an inverse proportionality relation (CMC x K \u223c constant).", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["The membrane partition", "TEST", 0, 22], ["critical micelle concentration (CMC)", "TEST", 43, 79]]], ["The partition coefficient and critical micelle concentration are used for the analysis of LPC's effect on the membrane bending rigidity.", [["membrane", "ANATOMY", 110, 118], ["LPC", "CHEMICAL", 90, 93], ["rigidity", "DISEASE", 127, 135], ["LPC", "CHEMICAL", 90, 93], ["LPC", "SIMPLE_CHEMICAL", 90, 93], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["critical micelle concentration", "TREATMENT", 30, 60], ["the analysis", "TEST", 74, 86], ["LPC's effect", "TREATMENT", 90, 102], ["the membrane bending rigidity", "PROBLEM", 106, 135]]], ["The dependence of the bending rigidity on the LPC membrane coverage has been analyzed in terms a phenomenological model based on continuum elastic theory which yield information about the curvature inducing properties of the LPC molecule.", [["membrane", "ANATOMY", 50, 58], ["rigidity", "DISEASE", 30, 38], ["LPC", "CHEMICAL", 46, 49], ["LPC", "CHEMICAL", 225, 228], ["LPC", "CHEMICAL", 46, 49], ["LPC", "CHEMICAL", 225, 228], ["LPC molecule", "SIMPLE_CHEMICAL", 225, 237], ["the bending rigidity", "PROBLEM", 18, 38], ["the LPC membrane coverage", "TREATMENT", 42, 67], ["dependence", "OBSERVATION_MODIFIER", 4, 14], ["bending", "OBSERVATION_MODIFIER", 22, 29], ["rigidity", "OBSERVATION_MODIFIER", 30, 38], ["LPC membrane", "OBSERVATION", 46, 58], ["LPC molecule", "OBSERVATION", 225, 237]]], ["The results reveal: (I) an increase in the partition coefficient with LPC acyl-chain length and (II) the degree in acyl chain mismatch between LPC and POPC determines the magnitude of the membrane mechanical perturbation per LPC molecule on the membrane.", [["membrane", "ANATOMY", 188, 196], ["membrane", "ANATOMY", 245, 253], ["LPC acyl", "CHEMICAL", 70, 78], ["acyl", "CHEMICAL", 115, 119], ["LPC", "CHEMICAL", 143, 146], ["POPC", "CHEMICAL", 151, 155], ["LPC", "CHEMICAL", 225, 228], ["acyl", "CHEMICAL", 74, 78], ["acyl", "CHEMICAL", 115, 119], ["LPC", "CHEMICAL", 143, 146], ["POPC", "CHEMICAL", 151, 155], ["LPC", "CHEMICAL", 225, 228], ["LPC", "SIMPLE_CHEMICAL", 70, 73], ["acyl chain", "SIMPLE_CHEMICAL", 115, 125], ["LPC", "SIMPLE_CHEMICAL", 143, 146], ["POPC", "SIMPLE_CHEMICAL", 151, 155], ["membrane", "CELLULAR_COMPONENT", 188, 196], ["membrane", "CELLULAR_COMPONENT", 245, 253], ["LPC acyl-chain length", "TREATMENT", 70, 91], ["acyl chain mismatch", "PROBLEM", 115, 134], ["LPC and POPC", "TREATMENT", 143, 155], ["the membrane mechanical perturbation", "TREATMENT", 184, 220], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["chain length", "OBSERVATION_MODIFIER", 79, 91], ["acyl", "OBSERVATION", 115, 119], ["chain mismatch", "OBSERVATION", 120, 134], ["LPC", "OBSERVATION_MODIFIER", 143, 146], ["membrane mechanical perturbation", "OBSERVATION", 188, 220], ["LPC molecule", "OBSERVATION", 225, 237]]], ["Patch clamp electrophysiology remains the gold-standard for ion channel research because of the information richness of the data produced.", [["Patch clamp electrophysiology", "TREATMENT", 0, 29], ["ion channel research", "TREATMENT", 60, 80]]], ["Automated planar patch clamp devices, with their higher throughput and high data information content, have made the technique accessible to a wider audience.", [["Automated planar patch clamp devices", "TREATMENT", 0, 36], ["patch", "OBSERVATION_MODIFIER", 17, 22], ["clamp devices", "OBSERVATION", 23, 36]]], ["Nanion Technologies offers two planar patch clamp workstations combining higher throughput with high data quality.", [["two planar patch clamp workstations", "TREATMENT", 27, 62]]], ["The Port-a-Patch records from a single cell at a time and the Patchliner from up to 8 cells simultaneously with high success rates (typically 60-80%).", [["cell", "ANATOMY", 39, 43], ["cells", "ANATOMY", 86, 91], ["cell", "CELL", 39, 43], ["cells", "CELL", 86, 91], ["the Patchliner", "TEST", 58, 72]]], ["Both, the Port-a-Patch and the Patchliner are bench top patch clamp rigs which uses a planar borosilicate glass chip for obtaining a giga-seal for electrophysiological recordings.", [["borosilicate", "CHEMICAL", 93, 105], ["Patchliner", "DNA", 31, 41], ["the Port-a-Patch", "TREATMENT", 6, 22], ["the Patchliner", "TREATMENT", 27, 41], ["bench top patch clamp rigs", "TREATMENT", 46, 72], ["a planar borosilicate glass chip", "TREATMENT", 84, 116], ["a giga-seal", "TREATMENT", 131, 142], ["electrophysiological recordings", "TEST", 147, 178]]], ["Suction applied from the underside of the chip is used to attract a single cell to the recording site without the need for optical visualization.", [["cell", "ANATOMY", 75, 79], ["cell", "CELL", 75, 79], ["Suction", "TREATMENT", 0, 7], ["optical visualization", "TEST", 123, 144]]], ["Both workstations have been successfully used for whole cell, perforated patch, and cell attached recordings as well as for GUV-bilayer recordings.", [["whole cell", "ANATOMY", 50, 60], ["cell", "ANATOMY", 84, 88], ["cell", "CELL", 56, 60], ["cell", "CELL", 84, 88], ["GUV", "PROTEIN", 124, 127], ["whole cell, perforated patch", "TREATMENT", 50, 78], ["cell attached recordings", "TEST", 84, 108], ["GUV-bilayer recordings", "TEST", 124, 146]]], ["Due to the versatility of Nanion`s products it is possible to study a wide variety of ion channels including NaV, KV, CaV, ligandgated, hERG or reconstituted proteins such as KscA, Cx26, OmpC.", [["Nanion", "CHEMICAL", 26, 32], ["Nanion", "SIMPLE_CHEMICAL", 26, 32], ["NaV", "GENE_OR_GENE_PRODUCT", 109, 112], ["KV", "GENE_OR_GENE_PRODUCT", 114, 116], ["CaV", "GENE_OR_GENE_PRODUCT", 118, 121], ["ligandgated", "GENE_OR_GENE_PRODUCT", 123, 134], ["hERG", "GENE_OR_GENE_PRODUCT", 136, 140], ["KscA", "GENE_OR_GENE_PRODUCT", 175, 179], ["Cx26", "GENE_OR_GENE_PRODUCT", 181, 185], ["ion channels", "PROTEIN", 86, 98], ["NaV", "PROTEIN", 109, 112], ["KV", "PROTEIN", 114, 116], ["CaV", "PROTEIN", 118, 121], ["ligandgated", "PROTEIN", 123, 134], ["hERG", "PROTEIN", 136, 140], ["reconstituted proteins", "PROTEIN", 144, 166], ["KscA", "PROTEIN", 175, 179], ["Cx26", "PROTEIN", 181, 185], ["OmpC.", "PROTEIN", 187, 192], ["Nanion`s products", "TREATMENT", 26, 43], ["KscA", "TEST", 175, 179], ["CaV", "ANATOMY", 118, 121]]], ["Special features unique to Nanion products, including but not limited to internal solution exchange and temperature control, expand the experimental possibilities.P-580Waves on lipid monolayers J. Griesbauer, S. Boessinger, A. Wixforth, S. F. Matthias Univiversity of Augsburg, Experimental Physics I, Biological Physics Group, Augsburg, Germany \" For the sake of illustration we shall try to provide a physical basis for the equations, but must emphasize that the interpretation given is unlikely to provide a correct picture of the membrane.\"", [["membrane", "ANATOMY", 534, 542], ["membrane", "CELLULAR_COMPONENT", 534, 542], ["Nanion products", "PROTEIN", 27, 42], ["Nanion products", "TREATMENT", 27, 42], ["internal solution exchange", "TREATMENT", 73, 99], ["temperature control", "TREATMENT", 104, 123], ["P", "TEST", 163, 164]]], ["[ Hodgkin&Huxley, 1952 ] To explain the occurrence of reversible heat production during nerve pulse propagation it has been suggested by multiple authors [Wilke,Kaufmann,Heimburg] that travelling sound waves and not ion channels may offer a better explanation than the Hodgkin&Huxley theory.", [["nerve", "ANATOMY", 88, 93], ["reversible heat production", "PROBLEM", 54, 80], ["nerve pulse propagation", "TREATMENT", 88, 111], ["reversible", "OBSERVATION_MODIFIER", 54, 64], ["heat production", "OBSERVATION", 65, 80]]], ["Therefore, if sound waves are an essential feature of the nerve membrane they should also appear on lipid monolayers where ion conductivity is evidently absent.", [["nerve membrane", "ANATOMY", 58, 72], ["lipid monolayers", "ANATOMY", 100, 116], ["nerve membrane", "MULTI-TISSUE_STRUCTURE", 58, 72], ["lipid monolayers", "CELL", 100, 116], ["ion", "SIMPLE_CHEMICAL", 123, 126], ["sound waves", "PROBLEM", 14, 25], ["the nerve membrane", "PROBLEM", 54, 72], ["nerve membrane", "ANATOMY", 58, 72], ["ion conductivity", "OBSERVATION_MODIFIER", 123, 139]]], ["Here we demonstrate that sound waves can be excited on a lipid monolayer by using a set of planar electrodes incorporated into the monolayer and driven by an alternating voltage.", [["lipid monolayer", "ANATOMY", 57, 72], ["monolayer", "ANATOMY", 131, 140], ["lipid monolayer", "CELL", 57, 72], ["monolayer", "CELL", 131, 140], ["a lipid monolayer", "TREATMENT", 55, 72], ["a set of planar electrodes", "TREATMENT", 82, 108]]], ["Not only do our results indicate propagating waves on lipid monolayers in accordance with their thermodynamic predictions, but importantly, no significant attenuation is detected proposing an adiabatic phenomenon.", [["lipid monolayers", "ANATOMY", 54, 70], ["lipid monolayers", "CELL", 54, 70], ["propagating waves on lipid monolayers", "PROBLEM", 33, 70], ["significant attenuation", "PROBLEM", 143, 166], ["an adiabatic phenomenon", "PROBLEM", 189, 212], ["lipid monolayers", "OBSERVATION_MODIFIER", 54, 70], ["significant", "OBSERVATION_MODIFIER", 143, 154], ["attenuation", "OBSERVATION", 155, 166], ["adiabatic phenomenon", "OBSERVATION", 192, 212]]], ["In order to provide evidence that our physical explanation provides a correct picture of the membrane, direct detection of the waves was done, whereas a clear transduction of signals was shown.", [["membrane", "ANATOMY", 93, 101], ["membrane", "CELLULAR_COMPONENT", 93, 101]]], ["Finally, the impact of toxins, neuropharmaca and anaesthetics needs to be integrated in our physical picture of the nerve membranes, what can easily be done now and could deliver a new approach for understanding their physical mechanism.", [["nerve membranes", "ANATOMY", 116, 131], ["neuropharmaca", "SIMPLE_CHEMICAL", 31, 44], ["nerve membranes", "MULTI-TISSUE_STRUCTURE", 116, 131], ["toxins", "TREATMENT", 23, 29], ["neuropharmaca", "TREATMENT", 31, 44], ["anaesthetics", "TREATMENT", 49, 61], ["a new approach", "TREATMENT", 179, 193], ["nerve membranes", "ANATOMY", 116, 131]]], ["Our earlier studies showed that organometallic compounds (OTC) in the presence of UVC radiation enhanced the degree of phosphatidylcholine (PC) liposome oxidation, whereas quercetin effectively protected the membrane.", [["membrane", "ANATOMY", 208, 216], ["OTC", "CHEMICAL", 58, 61], ["UVC", "CHEMICAL", 82, 85], ["phosphatidylcholine", "CHEMICAL", 119, 138], ["PC", "CHEMICAL", 140, 142], ["quercetin", "CHEMICAL", 172, 181], ["UVC", "CHEMICAL", 82, 85], ["phosphatidylcholine", "CHEMICAL", 119, 138], ["quercetin", "CHEMICAL", 172, 181], ["organometallic compounds", "SIMPLE_CHEMICAL", 32, 56], ["OTC", "SIMPLE_CHEMICAL", 58, 61], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 119, 138], ["PC", "SIMPLE_CHEMICAL", 140, 142], ["liposome", "SIMPLE_CHEMICAL", 144, 152], ["quercetin", "SIMPLE_CHEMICAL", 172, 181], ["membrane", "CELLULAR_COMPONENT", 208, 216], ["Our earlier studies", "TEST", 0, 19], ["organometallic compounds (OTC", "PROBLEM", 32, 61], ["UVC radiation", "TREATMENT", 82, 95], ["phosphatidylcholine (PC) liposome oxidation", "TREATMENT", 119, 162], ["quercetin", "TREATMENT", 172, 181], ["organometallic compounds", "OBSERVATION", 32, 56], ["UVC radiation", "OBSERVATION", 82, 95]]], ["The present investigation is concerned with the effect of UVB and OTC (chlorides of diphenyl-and dibutyltin, triphenyl-and tributyltin), both in combined action and separately, on oxidation of erythrocyte proteins, PC liposome and albumin.", [["erythrocyte", "ANATOMY", 193, 204], ["UVB", "CHEMICAL", 58, 61], ["OTC", "CHEMICAL", 66, 69], ["chlorides of diphenyl-and dibutyltin, triphenyl-and tributyltin", "CHEMICAL", 71, 134], ["OTC", "CHEMICAL", 66, 69], ["chlorides", "CHEMICAL", 71, 80], ["diphenyl", "CHEMICAL", 84, 92], ["dibutyltin", "CHEMICAL", 97, 107], ["triphenyl", "CHEMICAL", 109, 118], ["tributyltin", "CHEMICAL", 123, 134], ["UVB", "SIMPLE_CHEMICAL", 58, 61], ["OTC", "SIMPLE_CHEMICAL", 66, 69], ["chlorides", "SIMPLE_CHEMICAL", 71, 80], ["diphenyl", "SIMPLE_CHEMICAL", 84, 92], ["dibutyltin", "SIMPLE_CHEMICAL", 97, 107], ["triphenyl", "SIMPLE_CHEMICAL", 109, 118], ["tributyltin", "SIMPLE_CHEMICAL", 123, 134], ["erythrocyte", "CELL", 193, 204], ["PC liposome", "SIMPLE_CHEMICAL", 215, 226], ["albumin", "GENE_OR_GENE_PRODUCT", 231, 238], ["erythrocyte proteins", "PROTEIN", 193, 213], ["albumin", "PROTEIN", 231, 238], ["UVB", "TREATMENT", 58, 61], ["OTC (chlorides", "TREATMENT", 66, 80], ["diphenyl", "TREATMENT", 84, 92], ["dibutyltin", "TREATMENT", 97, 107], ["triphenyl", "TREATMENT", 109, 118], ["tributyltin", "TREATMENT", 123, 134], ["erythrocyte proteins", "TREATMENT", 193, 213], ["PC liposome", "TREATMENT", 215, 226], ["albumin", "TREATMENT", 231, 238]]], ["The degree of oxidation of proteins and liposomes induced by OTC and radiation, also in the presence of selected antioxidants (trolox, quercetin) was determined on the basis of changes in the number of sulfhydryl groups, carbonyl groups and malone dialdehyde, respectively.", [["OTC", "CHEMICAL", 61, 64], ["trolox", "CHEMICAL", 127, 133], ["quercetin", "CHEMICAL", 135, 144], ["sulfhydryl", "CHEMICAL", 202, 212], ["carbonyl", "CHEMICAL", 221, 229], ["malone dialdehyde", "CHEMICAL", 241, 258], ["trolox", "CHEMICAL", 127, 133], ["quercetin", "CHEMICAL", 135, 144], ["sulfhydryl", "CHEMICAL", 202, 212], ["carbonyl", "CHEMICAL", 221, 229], ["malone dialdehyde", "CHEMICAL", 241, 258], ["liposomes", "SIMPLE_CHEMICAL", 40, 49], ["OTC", "SIMPLE_CHEMICAL", 61, 64], ["trolox", "SIMPLE_CHEMICAL", 127, 133], ["quercetin", "SIMPLE_CHEMICAL", 135, 144], ["sulfhydryl", "SIMPLE_CHEMICAL", 202, 212], ["carbonyl", "SIMPLE_CHEMICAL", 221, 229], ["malone dialdehyde", "SIMPLE_CHEMICAL", 241, 258], ["oxidation of proteins and liposomes", "PROBLEM", 14, 49], ["OTC", "TREATMENT", 61, 64], ["radiation", "TREATMENT", 69, 78], ["selected antioxidants (trolox", "TREATMENT", 104, 133], ["quercetin", "TREATMENT", 135, 144], ["carbonyl groups and malone dialdehyde", "TREATMENT", 221, 258], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["oxidation", "OBSERVATION", 14, 23]]], ["The studies indicate that UVB induces PC liposome and erythrocyte oxidation, whereas in the case of albumin it causes both an increase in the number of C=O groups and free SH groups (most probably, braking sulphonic bridges).", [["PC liposome", "ANATOMY", 38, 49], ["erythrocyte", "ANATOMY", 54, 65], ["UVB", "CHEMICAL", 26, 29], ["C=O", "CHEMICAL", 152, 155], ["SH", "CHEMICAL", 172, 174], ["UVB", "SIMPLE_CHEMICAL", 26, 29], ["PC liposome", "SIMPLE_CHEMICAL", 38, 49], ["erythrocyte", "CELL", 54, 65], ["albumin", "GENE_OR_GENE_PRODUCT", 100, 107], ["C=O groups", "SIMPLE_CHEMICAL", 152, 162], ["The studies", "TEST", 0, 11], ["UVB induces PC liposome", "TREATMENT", 26, 49], ["erythrocyte oxidation", "PROBLEM", 54, 75], ["albumin", "TREATMENT", 100, 107], ["an increase", "PROBLEM", 123, 134], ["braking sulphonic bridges", "TREATMENT", 198, 223], ["PC liposome", "OBSERVATION", 38, 49], ["erythrocyte oxidation", "OBSERVATION", 54, 75], ["increase", "OBSERVATION_MODIFIER", 126, 134]]], ["OTC compounds interact with membrane biomolecules both as weak pro-and antioxidants, also in combined action (UVB plus OTC).", [["membrane", "ANATOMY", 28, 36], ["UVB", "CHEMICAL", 110, 113], ["OTC", "SIMPLE_CHEMICAL", 0, 3], ["membrane", "CELLULAR_COMPONENT", 28, 36], ["UVB", "SIMPLE_CHEMICAL", 110, 113], ["UVB plus OTC", "TREATMENT", 110, 122]]], ["The prooxidative effects are markedly diminished by application of antioxidants.", [["markedly diminished", "PROBLEM", 29, 48], ["antioxidants", "TREATMENT", 67, 79], ["markedly", "OBSERVATION_MODIFIER", 29, 37], ["diminished", "OBSERVATION_MODIFIER", 38, 48]]], ["The action of quercetin results from its ability to incorporate into membranes and formation of complexes with OTC (liposome>erythrocyte>albumine).", [["membranes", "ANATOMY", 69, 78], ["quercetin", "CHEMICAL", 14, 23], ["albumine", "CHEMICAL", 137, 145], ["quercetin", "CHEMICAL", 14, 23], ["albumine", "CHEMICAL", 137, 145], ["quercetin", "SIMPLE_CHEMICAL", 14, 23], ["membranes", "CELLULAR_COMPONENT", 69, 78], ["OTC", "SIMPLE_CHEMICAL", 111, 114], ["liposome", "SIMPLE_CHEMICAL", 116, 124], ["erythrocyte", "SIMPLE_CHEMICAL", 125, 136], ["albumine", "SIMPLE_CHEMICAL", 137, 145], ["quercetin", "TREATMENT", 14, 23], ["OTC (liposome>erythrocyte>albumine", "TREATMENT", 111, 145]]], ["A phospholipase C/ sphingomyelinase from Pseudomonas aeruginosa has been assayed on giant unilamellar vesicles (GUV) consisting of phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, and cholesterol, at equimolar ratios.", [["giant unilamellar vesicles", "ANATOMY", 84, 110], ["GUV", "ANATOMY", 112, 115], ["phosphatidylcholine", "CHEMICAL", 131, 150], ["sphingomyelin", "CHEMICAL", 152, 165], ["phosphatidylethanolamine", "CHEMICAL", 167, 191], ["cholesterol", "CHEMICAL", 197, 208], ["phosphatidylcholine", "CHEMICAL", 131, 150], ["sphingomyelin", "CHEMICAL", 152, 165], ["phosphatidylethanolamine", "CHEMICAL", 167, 191], ["cholesterol", "CHEMICAL", 197, 208], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 2, 17], ["sphingomyelinase", "GENE_OR_GENE_PRODUCT", 19, 35], ["Pseudomonas aeruginosa", "ORGANISM", 41, 63], ["unilamellar vesicles", "MULTI-TISSUE_STRUCTURE", 90, 110], ["GUV", "SIMPLE_CHEMICAL", 112, 115], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 131, 150], ["sphingomyelin", "SIMPLE_CHEMICAL", 152, 165], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 167, 191], ["cholesterol", "SIMPLE_CHEMICAL", 197, 208], ["phospholipase C", "PROTEIN", 2, 17], ["sphingomyelinase", "PROTEIN", 19, 35], ["Pseudomonas aeruginosa", "SPECIES", 41, 63], ["Pseudomonas aeruginosa", "SPECIES", 41, 63], ["A phospholipase C/ sphingomyelinase", "TEST", 0, 35], ["Pseudomonas aeruginosa", "PROBLEM", 41, 63], ["giant unilamellar vesicles", "PROBLEM", 84, 110], ["phosphatidylcholine, sphingomyelin", "TREATMENT", 131, 165], ["phosphatidylethanolamine", "TREATMENT", 167, 191], ["cholesterol", "TEST", 197, 208], ["unilamellar vesicles", "OBSERVATION", 90, 110]]], ["The enzyme activity modifies the chemical composition, thus the physical properties of the bilayer, and conversely the latter influence the enzyme activity.", [["bilayer", "CELLULAR_COMPONENT", 91, 98], ["The enzyme activity", "TEST", 0, 19], ["activity", "OBSERVATION_MODIFIER", 11, 19], ["chemical composition", "OBSERVATION_MODIFIER", 33, 53]]], ["Biochemical assays of enzyme activity, together with confocal fluorescence microscopy examination of GUV provide novel information about the system.", [["Biochemical assays", "TEST", 0, 18], ["enzyme activity", "TEST", 22, 37], ["confocal fluorescence microscopy examination", "TEST", 53, 97]]], ["The original lipid composition in the absence of enzyme gives rise to lateral phase separation of liquid-ordered and liquid-disordered domains in the GUV.", [["enzyme", "PROTEIN", 49, 55], ["liquid-ordered and liquid-disordered domains", "PROTEIN", 98, 142], ["GUV", "PROTEIN", 150, 153], ["enzyme", "TEST", 49, 55], ["lateral phase separation of liquid", "TREATMENT", 70, 104], ["disordered domains in the GUV", "PROBLEM", 124, 153], ["lipid composition", "OBSERVATION", 13, 30]]], ["The two enzyme end-products, diacylglycerol and ceramide, have opposite effects on the bilayer physical properties, the former abolishes lateral phase separation, while the latter generates a new gel phase.", [["diacylglycerol", "CHEMICAL", 29, 43], ["ceramide", "CHEMICAL", 48, 56], ["diacylglycerol", "CHEMICAL", 29, 43], ["ceramide", "CHEMICAL", 48, 56], ["diacylglycerol", "SIMPLE_CHEMICAL", 29, 43], ["ceramide", "SIMPLE_CHEMICAL", 48, 56], ["diacylglycerol and ceramide", "TREATMENT", 29, 56]]], ["Morphological examination of individual GUV shows that the enzyme binds preferentially the more fluid (or more disordered) domains, and that, in most cases, it causes the fluidification (disordering) of the other domains..", [["GUV", "PROTEIN", 40, 43], ["enzyme", "PROTEIN", 59, 65], ["Morphological examination", "TEST", 0, 25], ["individual GUV", "TEST", 29, 43], ["the enzyme binds", "PROBLEM", 55, 71], ["the fluidification (disordering) of the other domains", "PROBLEM", 167, 220], ["more", "OBSERVATION_MODIFIER", 91, 95], ["fluid", "OBSERVATION", 96, 101]]], ["Cholesterol incorporation into lipid bilayers, in the form of multilamellar vesicles or extruded large unilamellar vesicles, has been quantitated.", [["lipid bilayers", "ANATOMY", 31, 45], ["multilamellar vesicles", "ANATOMY", 62, 84], ["unilamellar vesicles", "ANATOMY", 103, 123], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["lipid bilayers", "SIMPLE_CHEMICAL", 31, 45], ["multilamellar vesicles", "CELLULAR_COMPONENT", 62, 84], ["unilamellar vesicles", "CELLULAR_COMPONENT", 103, 123], ["Cholesterol incorporation into lipid bilayers", "PROBLEM", 0, 45], ["multilamellar vesicles", "PROBLEM", 62, 84], ["extruded large unilamellar vesicles", "PROBLEM", 88, 123], ["lipid bilayers", "OBSERVATION", 31, 45], ["multilamellar vesicles", "OBSERVATION", 62, 84], ["extruded", "OBSERVATION_MODIFIER", 88, 96], ["large", "OBSERVATION_MODIFIER", 97, 102], ["unilamellar vesicles", "OBSERVATION", 103, 123]]], ["To this aim, the cholesterol contents of bilayers prepared from phospholipid:cholesterol mixtures (33-75 mol% cholesterol) have been measured and compared with the original mixture before lipid hydration.", [["cholesterol", "CHEMICAL", 17, 28], ["cholesterol", "CHEMICAL", 77, 88], ["cholesterol", "CHEMICAL", 110, 121], ["cholesterol", "CHEMICAL", 17, 28], ["cholesterol", "CHEMICAL", 77, 88], ["cholesterol", "CHEMICAL", 110, 121], ["cholesterol", "SIMPLE_CHEMICAL", 17, 28], ["phospholipid", "SIMPLE_CHEMICAL", 64, 76], ["cholesterol", "SIMPLE_CHEMICAL", 77, 88], ["cholesterol", "SIMPLE_CHEMICAL", 110, 121], ["lipid", "SIMPLE_CHEMICAL", 188, 193], ["the cholesterol contents", "TEST", 13, 37], ["phospholipid:cholesterol mixtures", "TREATMENT", 64, 97], ["lipid hydration", "TREATMENT", 188, 203]]], ["There is a great diversity of cases, but under most conditions the actual cholesterol proportion present in the bilayers is much lower than expected.", [["cholesterol", "CHEMICAL", 74, 85], ["cholesterol", "CHEMICAL", 74, 85], ["cholesterol", "SIMPLE_CHEMICAL", 74, 85], ["great", "OBSERVATION_MODIFIER", 11, 16], ["diversity", "OBSERVATION_MODIFIER", 17, 26], ["cholesterol", "OBSERVATION", 74, 85], ["bilayers", "ANATOMY_MODIFIER", 112, 120], ["much", "OBSERVATION_MODIFIER", 124, 128], ["lower", "OBSERVATION_MODIFIER", 129, 134]]], ["The maximum solubility of Chol in bilayers containing saturated PC or PC with less than four unsaturations is 50-60mol%, while in polyunsaturated PC, e. g. diC18:4, and in sphingomyelin the maximum Chol contents is 23mol%.", [["Chol", "CHEMICAL", 26, 30], ["sphingomyelin", "CHEMICAL", 172, 185], ["Chol", "CHEMICAL", 198, 202], ["Chol", "CHEMICAL", 26, 30], ["polyunsaturated PC", "CHEMICAL", 130, 148], ["diC18:4", "CHEMICAL", 156, 163], ["sphingomyelin", "CHEMICAL", 172, 185], ["Chol", "CHEMICAL", 198, 202], ["Chol", "SIMPLE_CHEMICAL", 26, 30], ["saturated PC", "SIMPLE_CHEMICAL", 54, 66], ["PC", "SIMPLE_CHEMICAL", 70, 72], ["polyunsaturated PC", "SIMPLE_CHEMICAL", 130, 148], ["diC18:4", "SIMPLE_CHEMICAL", 156, 163], ["sphingomyelin", "SIMPLE_CHEMICAL", 172, 185], ["Chol", "SIMPLE_CHEMICAL", 198, 202], ["The maximum solubility of Chol in bilayers containing saturated PC", "TREATMENT", 0, 66], ["PC", "TREATMENT", 70, 72], ["sphingomyelin the maximum Chol contents", "TEST", 172, 211], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["solubility", "OBSERVATION_MODIFIER", 12, 22], ["Chol", "OBSERVATION", 26, 30]]], ["A quantitative analysis of the vesicles is thus required before any experimental study is undertaken.P-584Membrane fusion assay based on poresuspending lipid bilayers I. H\u00f6fer, C. Steinem Institute of Organic and Biomolecular Chemistry, University of G\u00f6ttingen, Germany Membrane fusion has attracted significant interest due to its biological relevance.", [["vesicles", "ANATOMY", 31, 39], ["P-584", "CHEMICAL", 101, 106], ["vesicles", "CELLULAR_COMPONENT", 31, 39], ["P", "DNA", 101, 102], ["A quantitative analysis", "TEST", 0, 23], ["the vesicles", "PROBLEM", 27, 39], ["any experimental study", "TEST", 64, 86], ["P", "TEST", 101, 102], ["Membrane fusion assay", "TEST", 106, 127], ["Germany Membrane fusion", "TREATMENT", 262, 285], ["vesicles", "ANATOMY", 31, 39]]], ["Thus in recent years a great variety of fusion assays has been developed.", [["fusion assays", "PROBLEM", 40, 53], ["great", "OBSERVATION_MODIFIER", 23, 28], ["variety", "OBSERVATION_MODIFIER", 29, 36], ["fusion", "OBSERVATION", 40, 46]]], ["Since the process of membrane fusion is not yet fully understood, our aim is to develop a new fusion assay based on pore-spanning membranes, which have been proven mechanically stable, highly insulating and rather tension free.", [["membrane", "ANATOMY", 21, 29], ["pore-spanning membranes", "ANATOMY", 116, 139], ["membrane", "CELLULAR_COMPONENT", 21, 29], ["membranes", "CELLULAR_COMPONENT", 130, 139], ["membrane fusion", "TREATMENT", 21, 36], ["a new fusion assay", "TEST", 88, 106], ["membrane fusion", "OBSERVATION", 21, 36], ["new", "OBSERVATION_MODIFIER", 90, 93], ["fusion", "OBSERVATION", 94, 100], ["mechanically", "OBSERVATION_MODIFIER", 164, 176], ["stable", "OBSERVATION_MODIFIER", 177, 183], ["tension", "OBSERVATION_MODIFIER", 214, 221], ["free", "OBSERVATION_MODIFIER", 222, 226]]], ["The application of these so-called micro-BLMs should allow simultaneous monitoring of lipid mixing, content release as well as electrical readouts.", [["lipid", "SIMPLE_CHEMICAL", 86, 91], ["lipid mixing", "TREATMENT", 86, 98], ["content release", "TREATMENT", 100, 115], ["electrical readouts", "TEST", 127, 146]]], ["Furthermore both membrane sides can be addressed individually to apply transmembrane potential or fusion modulating compounds.", [["membrane sides", "ANATOMY", 17, 31], ["transmembrane", "ANATOMY", 71, 84], ["transmembrane potential", "TREATMENT", 71, 94], ["fusion modulating compounds", "TREATMENT", 98, 125]]], ["First results show that the micro-BLMs provide the opportunity to investigate lipid bilayer fusion by means of fluorescence microscopy.", [["lipid bilayer", "ANATOMY", 78, 91], ["lipid bilayer fusion", "TREATMENT", 78, 98], ["fluorescence microscopy", "TEST", 111, 134]]], ["The formation of porespanning membranes is achieved by the painting technique of DPhPC doped with Oregon Green DHPE dissolved in ndecane.", [["porespanning membranes", "ANATOMY", 17, 39], ["DPhPC", "CHEMICAL", 81, 86], ["Oregon Green DHPE", "CHEMICAL", 98, 115], ["ndecane", "CHEMICAL", 129, 136], ["DPhPC", "CHEMICAL", 81, 86], ["ndecane", "CHEMICAL", 129, 136], ["DPhPC", "SIMPLE_CHEMICAL", 81, 86], ["Oregon Green DHPE", "SIMPLE_CHEMICAL", 98, 115], ["ndecane", "SIMPLE_CHEMICAL", 129, 136], ["porespanning membranes", "PROBLEM", 17, 39], ["porespanning membranes", "OBSERVATION", 17, 39]]], ["The addition of large unilamellar vesicles doped with Texas Red DHPE allows direct observation of single fusion events.", [["unilamellar vesicles", "ANATOMY", 22, 42], ["Texas Red DHPE", "CHEMICAL", 54, 68], ["unilamellar vesicles", "SIMPLE_CHEMICAL", 22, 42], ["Texas Red DHPE", "SIMPLE_CHEMICAL", 54, 68], ["large unilamellar vesicles", "PROBLEM", 16, 42], ["single fusion events", "PROBLEM", 98, 118], ["large", "OBSERVATION_MODIFIER", 16, 21], ["unilamellar vesicles", "OBSERVATION", 22, 42]]], ["Lipid mixing during fusion leads to a decrease of the donor fluorescence (Oregon Green) and an increase in acceptor fluorescence intensity (Texas Red) in the plane of the planar bilayer due to FRET.", [["Texas Red", "CHEMICAL", 140, 149], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["Lipid mixing during fusion", "TREATMENT", 0, 26], ["the donor fluorescence", "PROBLEM", 50, 72], ["an increase in acceptor fluorescence intensity", "PROBLEM", 92, 138], ["decrease", "OBSERVATION_MODIFIER", 38, 46], ["increase", "OBSERVATION_MODIFIER", 95, 103], ["acceptor fluorescence", "OBSERVATION", 107, 128], ["intensity", "OBSERVATION_MODIFIER", 129, 138]]], ["In future work simultaneous monitoring of lipid-mixing and content release combined with electrical measurements are planned to gain further insight into different intermediate steps of membrane fusion.P-583The kinetics of membrane-peptide folding and orientation M. R. Hicks Department of Chemistry, University of Warwick, UK.P-583Understanding interactions of peptides with lipid membranes is essential if we are to be able to design new and better antibiotic peptides.", [["membrane", "ANATOMY", 186, 194], ["membrane", "ANATOMY", 223, 231], ["lipid membranes", "ANATOMY", 376, 391], ["P-583", "CHEMICAL", 202, 207], ["P-583Understanding", "CHEMICAL", 327, 345], ["lipid", "SIMPLE_CHEMICAL", 42, 47], ["membrane", "CELLULAR_COMPONENT", 186, 194], ["membrane", "CELLULAR_COMPONENT", 223, 231], ["lipid membranes", "CELLULAR_COMPONENT", 376, 391], ["lipid-mixing and content release", "TREATMENT", 42, 74], ["electrical measurements", "TEST", 89, 112], ["membrane fusion", "TREATMENT", 186, 201], ["P", "TEST", 202, 203], ["peptides with lipid membranes", "TREATMENT", 362, 391], ["better antibiotic peptides", "TREATMENT", 444, 470], ["membrane fusion", "OBSERVATION", 186, 201]]], ["There are different steps in these interactions and following the kinetics of these processes requires that we combine the information from different biophysical techniques.", [["different", "OBSERVATION_MODIFIER", 10, 19], ["steps", "OBSERVATION_MODIFIER", 20, 25]]], ["Here we present data on the kinetics of peptidemembrane interactions using circular dichroism to report on conformation and linear dichroism to report on orientation of the peptides in/on membranes.", [["membranes", "ANATOMY", 188, 197], ["peptidemembrane", "CHEMICAL", 40, 55], ["peptidemembrane", "SIMPLE_CHEMICAL", 40, 55], ["membranes", "CELLULAR_COMPONENT", 188, 197], ["peptidemembrane interactions", "PROBLEM", 40, 68]]], ["These are combined with other techniques such as dynamic light scattering and fluorescence spectroscopy to elucidate the mechanisms of action of the peptides.", [["dynamic light scattering", "TEST", 49, 73], ["fluorescence spectroscopy", "TEST", 78, 103], ["the peptides", "TREATMENT", 145, 157]]], ["One of the most important aspects of membrane-active peptide design is that of specificity.", [["membrane", "ANATOMY", 37, 45], ["membrane", "CELLULAR_COMPONENT", 37, 45]]], ["We investigate specificity for different types of membranes by using libraries of lipids with different properties of charge, chain saturation and curvature stress.", [["membranes", "ANATOMY", 50, 59], ["membranes", "CELLULAR_COMPONENT", 50, 59], ["lipids", "SIMPLE_CHEMICAL", 82, 88], ["different types of membranes", "PROBLEM", 31, 59], ["libraries of lipids", "TREATMENT", 69, 88], ["chain saturation", "TEST", 126, 142], ["curvature stress", "PROBLEM", 147, 163]]], ["In this way one can test for effects of e.g. negatively charged head groups found in bacterial membranes or cholesterol found in animal and human membranes.", [["head", "ANATOMY", 64, 68], ["membranes", "ANATOMY", 95, 104], ["membranes", "ANATOMY", 146, 155], ["cholesterol", "CHEMICAL", 108, 119], ["cholesterol", "CHEMICAL", 108, 119], ["bacterial membranes", "CELLULAR_COMPONENT", 85, 104], ["cholesterol", "SIMPLE_CHEMICAL", 108, 119], ["human", "ORGANISM", 140, 145], ["membranes", "CELLULAR_COMPONENT", 146, 155], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["bacterial membranes", "PROBLEM", 85, 104], ["cholesterol", "TEST", 108, 119], ["bacterial membranes", "OBSERVATION", 85, 104], ["human membranes", "ANATOMY", 140, 155]]], ["Using these approaches it is proposed that we will be able to modify peptide sequences, test what part of the kinetic processes are affected and subsequently use this information to design new and better antibiotics.Influence of lipid oxidation on membrane electroporationK.", [["membrane", "ANATOMY", 248, 256], ["lipid", "SIMPLE_CHEMICAL", 229, 234], ["membrane", "CELLULAR_COMPONENT", 248, 256], ["these approaches", "TREATMENT", 6, 22], ["peptide sequences", "TEST", 69, 86], ["better antibiotics", "TREATMENT", 197, 215], ["lipid oxidation on membrane electroporationK", "TREATMENT", 229, 273], ["lipid oxidation", "OBSERVATION", 229, 244]]], ["Kubica, H. Misiak Wroclaw University of Technology, Wroclaw, Poland Reversible membrane electroporation, that can be observed as a effect of electric field influence on biological membranes, finds application in cell delivery of biologically active compounds.", [["membrane", "ANATOMY", 79, 87], ["membranes", "ANATOMY", 180, 189], ["cell", "ANATOMY", 212, 216], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["membranes", "CELLULAR_COMPONENT", 180, 189], ["cell", "CELL", 212, 216], ["Poland Reversible membrane electroporation", "TREATMENT", 61, 103], ["electric field influence", "TREATMENT", 141, 165], ["biological membranes", "TREATMENT", 169, 189], ["application in cell delivery", "TREATMENT", 197, 225], ["membrane electroporation", "OBSERVATION", 79, 103]]], ["The membrane susceptibility for creation of stable pores, depends on electric field parameters applied to the membrane as well as on the membrane environment (ionic strength, pH, temperature) and membrane molecular composition.", [["membrane", "ANATOMY", 4, 12], ["membrane", "ANATOMY", 110, 118], ["membrane", "ANATOMY", 137, 145], ["membrane", "ANATOMY", 196, 204], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["membrane", "CELLULAR_COMPONENT", 137, 145], ["membrane", "CELLULAR_COMPONENT", 196, 204], ["The membrane susceptibility", "PROBLEM", 0, 27], ["creation of stable pores", "TREATMENT", 32, 56], ["electric field parameters", "TREATMENT", 69, 94], ["membrane molecular composition", "PROBLEM", 196, 226], ["membrane susceptibility", "OBSERVATION", 4, 27], ["stable", "OBSERVATION_MODIFIER", 44, 50], ["pores", "OBSERVATION_MODIFIER", 51, 56]]], ["We have already shown that the changes of van der Waals lipid chain interaction effect the process of pore formation.", [["pore", "ANATOMY", 102, 106], ["pore", "CELLULAR_COMPONENT", 102, 106], ["van der Waals lipid chain", "TREATMENT", 42, 67], ["pore formation", "OBSERVATION", 102, 116]]], ["There are known factors which increase or decrease the membrane respond to electric field.", [["membrane", "ANATOMY", 55, 63], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["known factors", "PROBLEM", 10, 23], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["decrease", "OBSERVATION_MODIFIER", 42, 50], ["membrane", "OBSERVATION_MODIFIER", 55, 63]]], ["Because pores appear in lipid membrane matrix it make sense to study this phenomenon using model planar lipid membranes.", [["pores", "ANATOMY", 8, 13], ["lipid membrane matrix", "ANATOMY", 24, 45], ["lipid membranes", "ANATOMY", 104, 119], ["lipid", "CELLULAR_COMPONENT", 24, 29], ["membrane matrix", "CELLULAR_COMPONENT", 30, 45], ["lipid membranes", "CELLULAR_COMPONENT", 104, 119], ["lipid membrane matrix", "TREATMENT", 24, 45], ["this phenomenon", "PROBLEM", 69, 84], ["model planar lipid membranes", "TREATMENT", 91, 119], ["lipid membrane matrix", "OBSERVATION", 24, 45], ["lipid membranes", "OBSERVATION", 104, 119]]], ["As lipids are very receptive on oxidizing factors we decided to study the relation between lipid oxidation and membrane reaction on electric field.", [["membrane", "ANATOMY", 111, 119], ["lipids", "SIMPLE_CHEMICAL", 3, 9], ["lipid", "SIMPLE_CHEMICAL", 91, 96], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["oxidizing factors", "PROTEIN", 32, 49], ["lipid oxidation", "TREATMENT", 91, 106], ["membrane reaction", "PROBLEM", 111, 128], ["lipid oxidation", "OBSERVATION", 91, 106], ["membrane reaction", "OBSERVATION", 111, 128]]], ["With the use of four electrode galvanostat we are examining the influence of factors initiating lipid oxidation (UV, Fe 2+ ) and the efficiency of some antioxidant compounds of lipid protection on electric properties of lipid membrane.", [["lipid membrane", "ANATOMY", 220, 234], ["Fe", "CHEMICAL", 117, 119], ["galvanostat", "CHEMICAL", 31, 42], ["Fe 2+", "CHEMICAL", 117, 122], ["lipid", "SIMPLE_CHEMICAL", 96, 101], ["Fe 2+", "SIMPLE_CHEMICAL", 117, 122], ["lipid", "SIMPLE_CHEMICAL", 177, 182], ["lipid membrane", "CELLULAR_COMPONENT", 220, 234], ["four electrode galvanostat", "TREATMENT", 16, 42], ["lipid oxidation", "TREATMENT", 96, 111], ["UV, Fe", "TREATMENT", 113, 119], ["lipid protection", "TREATMENT", 177, 193], ["electric properties of lipid membrane", "TREATMENT", 197, 234], ["antioxidant compounds", "OBSERVATION", 152, 173], ["lipid protection", "OBSERVATION", 177, 193], ["lipid membrane", "OBSERVATION", 220, 234]]], ["The product of lipid oxidation is determined by characteristic reaction with tiobarbituric acid.", [["tiobarbituric acid", "CHEMICAL", 77, 95], ["tiobarbituric acid", "CHEMICAL", 77, 95], ["lipid", "SIMPLE_CHEMICAL", 15, 20], ["tiobarbituric acid", "SIMPLE_CHEMICAL", 77, 95], ["lipid oxidation", "TREATMENT", 15, 30], ["tiobarbituric acid", "TREATMENT", 77, 95], ["lipid oxidation", "OBSERVATION", 15, 30]]], ["We want to determine the role of polyunsaturated fatty acids on membrane properties also.", [["membrane", "ANATOMY", 64, 72], ["polyunsaturated fatty acids", "CHEMICAL", 33, 60], ["polyunsaturated fatty acids", "CHEMICAL", 33, 60], ["polyunsaturated fatty acids", "SIMPLE_CHEMICAL", 33, 60], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["polyunsaturated fatty acids on membrane properties", "TREATMENT", 33, 83]]], ["Results of our work will be useful in optimization of medicine distribution, aided by electric field, into cells.P-589Budding of giant phospholipid vesicles induced by \u03b22-glycoprotein I J. Kovacic, B. Bozic, S. Svetina Institute of Biophysics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia \u03b2 2 -glycoprotein I (\u03b2 2 GPI) is classified among amphitropic proteins: in its inactive form it is dissolved in plasma and in its active form it is bound to membrane.", [["cells", "ANATOMY", 107, 112], ["giant phospholipid vesicles", "ANATOMY", 129, 156], ["plasma", "ANATOMY", 427, 433], ["membrane", "ANATOMY", 472, 480], ["P-589Budding", "CHEMICAL", 113, 125], ["cells", "CELL", 107, 112], ["phospholipid vesicles", "CELLULAR_COMPONENT", 135, 156], ["2 -glycoprotein I", "GENE_OR_GENE_PRODUCT", 317, 334], ["\u03b2 2 GPI", "GENE_OR_GENE_PRODUCT", 336, 343], ["plasma", "ORGANISM_SUBSTANCE", 427, 433], ["membrane", "CELLULAR_COMPONENT", 472, 480], ["P", "DNA", 113, 114], ["\u03b22", "PROTEIN", 168, 170], ["glycoprotein I", "PROTEIN", 320, 334], ["\u03b2 2 GPI", "PROTEIN", 336, 343], ["amphitropic proteins", "PROTEIN", 365, 385], ["P", "TEST", 113, 114], ["giant phospholipid vesicles", "PROBLEM", 129, 156], ["glycoprotein I (\u03b2 2 GPI", "TREATMENT", 320, 343]]], ["In comparison to other amphitropic proteins it exhibits a distinct membrane interaction behavior.", [["membrane", "ANATOMY", 67, 75], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["amphitropic proteins", "PROTEIN", 23, 43], ["other amphitropic proteins", "TEST", 17, 43], ["a distinct membrane interaction behavior", "PROBLEM", 56, 96], ["distinct", "OBSERVATION_MODIFIER", 58, 66], ["membrane interaction", "OBSERVATION", 67, 87]]], ["A patch of positively charged amino acid residues contacts anionic phospholipids via electrostatic interactions, and a hydrophobic loop anchores the protein into the outer leaflet of the membrane via hydrophobic interactions.", [["outer leaflet", "ANATOMY", 166, 179], ["membrane", "ANATOMY", 187, 195], ["amino acid", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 30, 40], ["amino acid", "AMINO_ACID", 30, 40], ["anionic phospholipids", "SIMPLE_CHEMICAL", 59, 80], ["outer leaflet", "CELLULAR_COMPONENT", 166, 179], ["membrane", "CELLULAR_COMPONENT", 187, 195], ["hydrophobic loop", "PROTEIN", 119, 135], ["A patch", "TREATMENT", 0, 7], ["positively charged amino acid residues", "TREATMENT", 11, 49], ["anionic phospholipids", "TREATMENT", 59, 80], ["a hydrophobic loop", "TREATMENT", 117, 135], ["amino acid", "OBSERVATION", 30, 40], ["electrostatic interactions", "OBSERVATION", 85, 111], ["outer", "ANATOMY_MODIFIER", 166, 171], ["leaflet", "ANATOMY_MODIFIER", 172, 179], ["membrane", "ANATOMY_MODIFIER", 187, 195], ["hydrophobic interactions", "OBSERVATION", 200, 224]]], ["The binding constant depends on physical properties of the membrane such as membrane lipid composition, surface potential, lipid packing density and curvature.", [["membrane", "ANATOMY", 59, 67], ["membrane", "ANATOMY", 76, 84], ["surface", "ANATOMY", 104, 111], ["membrane", "CELLULAR_COMPONENT", 59, 67], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["lipid", "SIMPLE_CHEMICAL", 85, 90], ["lipid", "SIMPLE_CHEMICAL", 123, 128], ["The binding", "PROBLEM", 0, 11], ["membrane lipid composition", "TREATMENT", 76, 102], ["lipid packing density", "TREATMENT", 123, 144], ["constant", "OBSERVATION_MODIFIER", 12, 20], ["lipid", "OBSERVATION", 123, 128], ["packing density", "OBSERVATION", 129, 144], ["curvature", "OBSERVATION_MODIFIER", 149, 158]]], ["The binding of an amphitropic protein alters the membrane's spontaneous curvature as well as the difference between the equilibrium areas of membrane leaflets.", [["membrane", "ANATOMY", 49, 57], ["membrane leaflets", "ANATOMY", 141, 158], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["membrane leaflets", "CELLULAR_COMPONENT", 141, 158], ["amphitropic protein", "PROTEIN", 18, 37], ["an amphitropic protein", "TREATMENT", 15, 37], ["spontaneous curvature", "OBSERVATION", 60, 81], ["membrane leaflets", "ANATOMY", 141, 158]]], ["Theoretical model has been developed to predict vesicles shape transformations realized by the formation of buds.", [["vesicles", "ANATOMY", 48, 56], ["buds", "ANATOMY", 108, 112], ["vesicles", "CELLULAR_COMPONENT", 48, 56], ["buds", "TISSUE", 108, 112], ["shape", "OBSERVATION_MODIFIER", 57, 62]]], ["It was shown that the effects are stronger for flaccid vesicles which were therefore chosen for our experimental investigations.", [["flaccid vesicles", "ANATOMY", 47, 63], ["flaccid vesicles", "PROBLEM", 47, 63], ["our experimental investigations", "TEST", 96, 127]]], ["Vesicles were composed of 20 % POPS and 80 % POPC, and flaccidity was achieved by an osmotic adjustment.", [["Vesicles", "ANATOMY", 0, 8], ["POPC", "CHEMICAL", 45, 49], ["POPC", "CHEMICAL", 45, 49], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["POPS", "SIMPLE_CHEMICAL", 31, 35], ["POPC", "SIMPLE_CHEMICAL", 45, 49], ["POPC", "TEST", 45, 49], ["flaccidity", "PROBLEM", 55, 65], ["an osmotic adjustment", "TREATMENT", 82, 103], ["osmotic adjustment", "OBSERVATION", 85, 103]]], ["The solution containing \u03b2 2 GPI was subsequently injected to a chamber with flaccid vesicles by a syringe pump.", [["flaccid vesicles", "ANATOMY", 76, 92], ["\u03b2 2 GPI", "CHEMICAL", 24, 31], ["\u03b2 2 GPI", "SIMPLE_CHEMICAL", 24, 31], ["\u03b2 2 GPI", "PROTEIN", 24, 31], ["The solution containing \u03b2 2 GPI", "TREATMENT", 0, 31], ["flaccid vesicles", "PROBLEM", 76, 92], ["a syringe pump", "TREATMENT", 96, 110], ["flaccid vesicles", "ANATOMY", 76, 92], ["syringe pump", "OBSERVATION", 98, 110]]], ["Experiments showed a concentration dependent occurrence of buds.", [["buds", "ANATOMY", 59, 63], ["buds", "ORGANISM_SUBDIVISION", 59, 63], ["a concentration dependent occurrence of buds", "PROBLEM", 19, 63], ["concentration dependent", "OBSERVATION_MODIFIER", 21, 44]]], ["Their number and size were related to the degree of vesicle flaccidness.P-588The interplay between detergent cohesion and peptide adsorption on the structure and dynamics of a Glycophorin A TM-detergent complex J. Khao, J.-P. Duneau, J. N. Sturgis LISM, CNRS -Aix Marseille University, Marseille, FranceP-588In spite of the major interest of membrane proteins at functional, genomic and therapeutic scales, their biochemical and structural study remain challenging as they require, solubilization in detergent micelles.", [["vesicle", "ANATOMY", 52, 59], ["membrane", "ANATOMY", 342, 350], ["flaccidness", "DISEASE", 60, 71], ["P-588", "CHEMICAL", 72, 77], ["vesicle", "CELLULAR_COMPONENT", 52, 59], ["membrane", "CELLULAR_COMPONENT", 342, 350], ["detergent micelles", "SIMPLE_CHEMICAL", 500, 518], ["membrane proteins", "PROTEIN", 342, 359], ["vesicle flaccidness", "PROBLEM", 52, 71], ["detergent cohesion", "TREATMENT", 99, 117], ["peptide adsorption", "PROBLEM", 122, 140], ["FranceP", "TEST", 297, 304], ["membrane proteins", "PROBLEM", 342, 359], ["therapeutic scales", "TREATMENT", 387, 405], ["structural study", "TEST", 429, 445], ["solubilization in detergent micelles", "TREATMENT", 482, 518], ["size", "OBSERVATION_MODIFIER", 17, 21], ["vesicle flaccidness", "OBSERVATION", 52, 71]]], ["The complexity of this task arises from the structural dependence of membrane proteins on their anisotropic environment and in particular by a delicate balance between different physico-chemical properties.", [["membrane", "ANATOMY", 69, 77], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["membrane proteins", "PROTEIN", 69, 86], ["complexity", "OBSERVATION_MODIFIER", 4, 14], ["structural", "OBSERVATION_MODIFIER", 44, 54], ["dependence", "OBSERVATION_MODIFIER", 55, 65], ["membrane proteins", "OBSERVATION", 69, 86]]], ["In order to study these properties in a small protein detergent complex, we have used molecular dynamics simulations on the transmembrane part of Glycophorin A (GpAtm) solubilized in micelles of the detergent di-hexanoyl-phosphatidylcholine(D6PC).", [["transmembrane", "ANATOMY", 124, 137], ["Glycophorin A", "CHEMICAL", 146, 159], ["di-hexanoyl-phosphatidylcholine", "CHEMICAL", 209, 240], ["D6PC", "CHEMICAL", 241, 245], ["Glycophorin A", "CHEMICAL", 146, 159], ["di-hexanoyl-phosphatidylcholine", "CHEMICAL", 209, 240], ["D6PC", "CHEMICAL", 241, 245], ["Glycophorin A", "SIMPLE_CHEMICAL", 146, 159], ["GpAtm", "SIMPLE_CHEMICAL", 161, 166], ["detergent di-hexanoyl-phosphatidylcholine", "SIMPLE_CHEMICAL", 199, 240], ["D6PC", "SIMPLE_CHEMICAL", 241, 245], ["protein detergent complex", "PROTEIN", 46, 71], ["Glycophorin A", "PROTEIN", 146, 159], ["GpAtm", "PROTEIN", 161, 166], ["a small protein detergent complex", "TREATMENT", 38, 71], ["Glycophorin A (GpAtm)", "TREATMENT", 146, 167], ["the detergent di-hexanoyl-phosphatidylcholine(D6PC)", "TREATMENT", 195, 246]]], ["We show that the molecular aggregates organizes to give distinct populations of detergent molecules.", [["detergent molecules", "PROTEIN", 80, 99]]], ["Those molecules which loosely interact with the peptide are preferentially involved in highly cohesive inter-detergent interactions that impose a global bilayer structure to the micelle.", [["global", "OBSERVATION_MODIFIER", 146, 152], ["bilayer structure", "OBSERVATION", 153, 170]]], ["Interaction profiles of other detergents with GpAtm depend upon the nature of residues along the surface of the peptide.", [["surface", "ANATOMY", 97, 104], ["GpAtm", "CHEMICAL", 46, 51], ["GpAtm", "SIMPLE_CHEMICAL", 46, 51], ["surface", "CELLULAR_COMPONENT", 97, 104], ["GpAtm", "PROTEIN", 46, 51], ["other detergents", "TREATMENT", 24, 40], ["GpAtm", "TREATMENT", 46, 51]]], ["This topology dependence leads to different modes and strength of interactions that ultimately constrain the orientation of the micelles around the peptide.", [["micelles", "SIMPLE_CHEMICAL", 128, 136]]], ["This simple model illustrates how differential detergent selectivity for faces and strong constraints coming from purely environmental features could influence transmembrane helix packing, membrane protein structure and assembly.", [["transmembrane", "ANATOMY", 160, 173], ["membrane", "ANATOMY", 189, 197], ["membrane", "CELLULAR_COMPONENT", 189, 197], ["faces", "PROBLEM", 73, 78], ["strong constraints", "PROBLEM", 83, 101], ["transmembrane helix packing", "TREATMENT", 160, 187], ["membrane protein structure", "OBSERVATION", 189, 215]]], ["In this paper we present a study of a new family of bolaamphiphiles.", [["bolaamphiphiles", "CHEMICAL", 52, 67], ["bolaamphiphiles", "SIMPLE_CHEMICAL", 52, 67], ["a study", "TEST", 25, 32], ["bolaamphiphiles", "TREATMENT", 52, 67]]], ["These amphiphiles are unsymmetrical bolalipids having one sugar polar head and the second glycine betaine polar head.", [["head", "ANATOMY", 70, 74], ["head", "ANATOMY", 112, 116], ["glycine betaine", "CHEMICAL", 90, 105], ["sugar", "CHEMICAL", 58, 63], ["glycine betaine", "CHEMICAL", 90, 105], ["bolalipids", "SIMPLE_CHEMICAL", 36, 46], ["head", "ORGANISM_SUBDIVISION", 70, 74], ["glycine", "AMINO_ACID", 90, 97], ["betaine", "SIMPLE_CHEMICAL", 98, 105], ["head", "ORGANISM_SUBDIVISION", 112, 116], ["polar", "ANATOMY_MODIFIER", 64, 69], ["head", "ANATOMY", 70, 74], ["polar", "ANATOMY_MODIFIER", 106, 111], ["head", "ANATOMY", 112, 116]]], ["They are potentially useful for pharmaceutical or cosmetics applications as vectors for drugs.", [["pharmaceutical or cosmetics applications", "TREATMENT", 32, 72], ["drugs", "TREATMENT", 88, 93]]], ["The chemical variations that we introduced in this new family concern the length of the main chain that connects two polar heads as well as the length of the side chain placed on the position 1 of the sugar moiety.", [["sugar", "CHEMICAL", 201, 206], ["sugar moiety", "SIMPLE_CHEMICAL", 201, 213], ["side chain", "PROTEIN", 158, 168], ["the side chain", "TREATMENT", 154, 168], ["the sugar moiety", "TREATMENT", 197, 213], ["chemical variations", "OBSERVATION", 4, 23]]], ["Another variation concerns the introduction of a diacetylenic unit into the main chain in order to rigidify it.", [["diacetylenic", "CHEMICAL", 49, 61], ["diacetylenic unit", "DNA", 49, 66], ["a diacetylenic unit", "TREATMENT", 47, 66], ["main", "OBSERVATION_MODIFIER", 76, 80], ["chain", "OBSERVATION_MODIFIER", 81, 86]]], ["We have performed the SAXS (Small Angle X-ray Scattering) measurements on the dehydrated compounds as a function of temperature and observed the lamellar liquid crystalline structures.", [["the SAXS", "TEST", 18, 26], ["Small Angle X-ray Scattering", "TEST", 28, 56], ["the dehydrated compounds", "PROBLEM", 74, 98], ["Small", "OBSERVATION_MODIFIER", 28, 33], ["lamellar", "OBSERVATION", 145, 153], ["liquid crystalline", "OBSERVATION", 154, 172]]], ["We also measured the SAXS spectra of aqueous solutions of these compounds that have shown lamellar L \u03b1 structure in all cases.", [["lamellar L \u03b1 structure", "PROTEIN", 90, 112], ["aqueous solutions", "TREATMENT", 37, 54], ["these compounds", "PROBLEM", 58, 73], ["lamellar L \u03b1 structure in all cases", "PROBLEM", 90, 125], ["lamellar", "OBSERVATION_MODIFIER", 90, 98], ["L", "OBSERVATION_MODIFIER", 99, 100], ["\u03b1 structure", "OBSERVATION", 101, 112]]], ["These measurements are compared with polarised optical microscopy measurements that confirmed our interpretation.O-586Formation of membrane tubular structures induced by phase separation in giant vesicles Y. Li, R. Lipowsky, R. Dimova Max Planck Institute of Colloids and Interfaces, Science Park Golm, 14424 Potsdam, Germany Tubular membrane structures (also known as tethers) exist widely in eukaryotes.", [["membrane tubular structures", "ANATOMY", 131, 158], ["giant vesicles", "ANATOMY", 190, 204], ["Tubular membrane structures", "ANATOMY", 326, 353], ["O-586Formation", "CHEMICAL", 113, 127], ["O-586Formation", "CHEMICAL", 113, 127], ["membrane tubular structures", "TISSUE", 131, 158], ["These measurements", "TEST", 0, 18], ["polarised optical microscopy measurements", "TEST", 37, 78], ["membrane tubular structures", "PROBLEM", 131, 158], ["tubular structures", "OBSERVATION", 140, 158], ["phase", "OBSERVATION_MODIFIER", 170, 175], ["separation", "OBSERVATION_MODIFIER", 176, 186], ["giant", "OBSERVATION_MODIFIER", 190, 195], ["Li", "ANATOMY", 208, 210], ["Tubular membrane", "OBSERVATION", 326, 342]]], ["Abundant work has been done on tube extrusion from cells and model membranes under the application of external forces.", [["tube", "ANATOMY", 31, 35], ["cells", "ANATOMY", 51, 56], ["membranes", "ANATOMY", 67, 76], ["tube", "TISSUE", 31, 35], ["cells", "CELL", 51, 56], ["membranes", "CELLULAR_COMPONENT", 67, 76], ["tube extrusion", "TREATMENT", 31, 45], ["model membranes", "TREATMENT", 61, 76], ["external forces", "OBSERVATION", 102, 117]]], ["We present a novel system allowing tube formation in the absence of external forces.", [["tube", "ANATOMY", 35, 39], ["tube", "TISSUE", 35, 39], ["a novel system", "TREATMENT", 11, 25], ["tube formation", "TREATMENT", 35, 49], ["tube formation", "OBSERVATION", 35, 49], ["external forces", "OBSERVATION", 68, 83]]], ["Aqueous solutions of two chemically dissimilar polymers, polyethylene glycol (PEG) and dextran are encapsulated in giant vesicles, a cell-size model system.", [["giant vesicles", "ANATOMY", 115, 129], ["cell", "ANATOMY", 133, 137], ["polyethylene glycol", "CHEMICAL", 57, 76], ["PEG", "CHEMICAL", 78, 81], ["dextran", "CHEMICAL", 87, 94], ["polyethylene glycol", "CHEMICAL", 57, 76], ["PEG", "CHEMICAL", 78, 81], ["polyethylene glycol", "SIMPLE_CHEMICAL", 57, 76], ["PEG", "SIMPLE_CHEMICAL", 78, 81], ["dextran", "SIMPLE_CHEMICAL", 87, 94], ["vesicles", "ORGANISM_SUBSTANCE", 121, 129], ["cell", "CELL", 133, 137], ["Aqueous solutions", "TREATMENT", 0, 17], ["two chemically dissimilar polymers", "TREATMENT", 21, 55], ["polyethylene glycol (PEG)", "TREATMENT", 57, 82], ["dextran", "TREATMENT", 87, 94], ["polyethylene glycol", "OBSERVATION", 57, 76], ["giant vesicles", "OBSERVATION", 115, 129], ["size", "OBSERVATION_MODIFIER", 138, 142], ["model system", "OBSERVATION", 143, 155]]], ["The exposure of vesicles to hypertonic solutions induces phase separation of the internal aqueous polymer solution.", [["vesicles", "ANATOMY", 16, 24], ["vesicles", "CELLULAR_COMPONENT", 16, 24], ["hypertonic solutions", "TREATMENT", 28, 48], ["phase separation", "TREATMENT", 57, 73], ["the internal aqueous polymer solution", "TREATMENT", 77, 114], ["internal", "ANATOMY_MODIFIER", 81, 89]]], ["The excess membrane area created by this vesicle deflation, engages in the formation of tubular structures.", [["membrane area", "ANATOMY", 11, 24], ["vesicle", "ANATOMY", 41, 48], ["tubular structures", "ANATOMY", 88, 106], ["membrane area", "CELLULAR_COMPONENT", 11, 24], ["vesicle", "CELLULAR_COMPONENT", 41, 48], ["tubular structures", "TISSUE", 88, 106], ["The excess membrane area", "PROBLEM", 0, 24], ["this vesicle deflation", "TREATMENT", 36, 58], ["excess", "OBSERVATION_MODIFIER", 4, 10], ["membrane", "OBSERVATION_MODIFIER", 11, 19], ["area", "OBSERVATION_MODIFIER", 20, 24], ["vesicle deflation", "OBSERVATION", 41, 58], ["tubular", "ANATOMY_MODIFIER", 88, 95]]], ["Membrane tube formation and phase separation are coupled processes.", [["Membrane tube", "ANATOMY", 0, 13], ["Membrane tube", "TISSUE", 0, 13], ["Membrane tube formation", "TREATMENT", 0, 23], ["phase separation", "TREATMENT", 28, 44], ["tube formation", "OBSERVATION", 9, 23], ["phase separation", "OBSERVATION", 28, 44]]], ["Hydrodynamic flows and changes in the membrane spontaneous curvature during phase separation might be the driving forces for tube formation.", [["membrane", "ANATOMY", 38, 46], ["tube", "ANATOMY", 125, 129], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["tube", "TISSUE", 125, 129], ["Hydrodynamic flows", "PROBLEM", 0, 18], ["the membrane spontaneous curvature during phase separation", "TREATMENT", 34, 92], ["tube formation", "TREATMENT", 125, 139], ["flows", "OBSERVATION", 13, 18], ["membrane", "OBSERVATION_MODIFIER", 38, 46], ["spontaneous", "OBSERVATION_MODIFIER", 47, 58], ["curvature", "OBSERVATION_MODIFIER", 59, 68]]], ["The tubes are rather stable: without external perturbation, they can exist for several days.", [["tubes", "ANATOMY", 4, 9], ["tubes", "TISSUE", 4, 9], ["The tubes", "TREATMENT", 0, 9], ["external perturbation", "PROBLEM", 37, 58], ["tubes", "OBSERVATION", 4, 9], ["stable", "OBSERVATION_MODIFIER", 21, 27], ["perturbation", "OBSERVATION", 46, 58]]], ["They prefer to be located in the PEG-rich phase at low polymer concentration.", [["PEG", "CHEMICAL", 33, 36], ["PEG", "CHEMICAL", 33, 36], ["the PEG-rich phase at low polymer concentration", "TREATMENT", 29, 76]]], ["At high concentration, they are absorbed at the interface of the liquid phases to lower the surface energy of the system by decreasing the contact area between the liquid phases.", [["surface", "ANATOMY", 92, 99], ["high concentration", "OBSERVATION_MODIFIER", 3, 21], ["contact area", "OBSERVATION", 139, 151], ["liquid phases", "OBSERVATION", 164, 177]]], ["The membrane tubes can be retracted back to the vesicle surface by increasing the membrane tension via vesicle aspiration.", [["membrane tubes", "ANATOMY", 4, 18], ["vesicle surface", "ANATOMY", 48, 63], ["membrane", "ANATOMY", 82, 90], ["vesicle", "ANATOMY", 103, 110], ["membrane tubes", "CELLULAR_COMPONENT", 4, 18], ["vesicle surface", "CELLULAR_COMPONENT", 48, 63], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["vesicle", "CELLULAR_COMPONENT", 103, 110], ["The membrane tubes", "TREATMENT", 0, 18], ["the membrane tension", "PROBLEM", 78, 98], ["vesicle aspiration", "PROBLEM", 103, 121], ["membrane tubes", "OBSERVATION", 4, 18], ["vesicle", "ANATOMY_MODIFIER", 48, 55], ["surface", "ANATOMY_MODIFIER", 56, 63], ["increasing", "OBSERVATION_MODIFIER", 67, 77], ["membrane tension", "OBSERVATION", 82, 98], ["vesicle", "OBSERVATION_MODIFIER", 103, 110], ["aspiration", "OBSERVATION", 111, 121]]], ["Membrane tubes, which can form and be retracted easily, might be relevant to lipid storage in cells.P-593Insight into the antimicrobial mechanism of a de novo auto-assembling peptide B. Legrand 1 , M. Laurencin 2 , E. Duval 3 , C. Zatylny 3 , J. Henry 3 , M. Baudy-Floc\u00b4h 2 , A. Bondon 1 1 RMN-ILP, UMR CNRS 6026 -Univ. de Rennes1, France, 2 ICMV, UMR CNRS 6226 -Univ. de Rennes1, France, 3 PEMM, UMR IFREMER 100 -Univ. de Caen, France A short (14 residues) de novo antimicrobial peptide (K4) composed of a cationic polar head and a hydrophobic tail was studied.", [["Membrane tubes", "ANATOMY", 0, 14], ["cells", "ANATOMY", 94, 99], ["head", "ANATOMY", 522, 526], ["tail", "ANATOMY", 545, 549], ["P-593Insight", "CHEMICAL", 100, 112], ["Membrane tubes", "CELLULAR_COMPONENT", 0, 14], ["lipid", "SIMPLE_CHEMICAL", 77, 82], ["cells", "CELL", 94, 99], ["head", "ORGANISM_SUBDIVISION", 522, 526], ["P-593Insight", "DNA", 100, 112], ["hydrophobic tail", "PROTEIN", 533, 549], ["Membrane tubes", "TREATMENT", 0, 14], ["a de novo auto-assembling peptide B. Legrand", "TREATMENT", 149, 193], ["A short (14 residues) de novo antimicrobial peptide (K4)", "TREATMENT", 436, 492], ["a cationic polar head", "TREATMENT", 505, 526], ["tubes", "OBSERVATION", 9, 14], ["polar", "ANATOMY_MODIFIER", 516, 521], ["head", "ANATOMY", 522, 526], ["hydrophobic tail", "ANATOMY", 533, 549]]], ["It exhibits a broad spectrum of antimicrobial activity on bacteria.", [["antimicrobial activity", "PROBLEM", 32, 54], ["bacteria", "PROBLEM", 58, 66], ["broad", "OBSERVATION_MODIFIER", 14, 19], ["antimicrobial activity", "OBSERVATION", 32, 54]]], ["No haemolytic activity or cytotoxicity on eukaryotic cells are observed at MIC.", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["eukaryotic cells", "CELL_TYPE", 42, 58], ["haemolytic activity", "PROBLEM", 3, 22], ["cytotoxicity on eukaryotic cells", "PROBLEM", 26, 58], ["haemolytic", "OBSERVATION_MODIFIER", 3, 13], ["activity", "OBSERVATION_MODIFIER", 14, 22], ["cytotoxicity", "OBSERVATION_MODIFIER", 26, 38], ["eukaryotic cells", "OBSERVATION", 42, 58]]], ["When bacteria are lysed by the K4, spherical objects are observed on the SEM micrograph.", [["K4", "GENE_OR_GENE_PRODUCT", 31, 33], ["K4", "PROTEIN", 31, 33], ["bacteria", "PROBLEM", 5, 13], ["the SEM micrograph", "TEST", 69, 87], ["spherical objects", "OBSERVATION", 35, 52]]], ["K4 was structurally studied using various membrane mimetic media such as different micelles and small unilamellar vesicles (SUV) of different composition.", [["membrane", "ANATOMY", 42, 50], ["unilamellar vesicles", "ANATOMY", 102, 122], ["K4", "GENE_OR_GENE_PRODUCT", 0, 2], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["unilamellar vesicles", "SIMPLE_CHEMICAL", 102, 122], ["K4", "PROTEIN", 0, 2], ["various membrane mimetic media", "TREATMENT", 34, 64], ["small unilamellar vesicles", "PROBLEM", 96, 122], ["small", "OBSERVATION_MODIFIER", 96, 101], ["unilamellar vesicles", "OBSERVATION", 102, 122], ["different", "OBSERVATION_MODIFIER", 132, 141], ["composition", "OBSERVATION_MODIFIER", 142, 153]]], ["CD revealed that K4 adopt various structures (random, \u03b2-turn, \u03b1-helix) in the presence or the absence of detergents or phospholipids.", [["K4", "GENE_OR_GENE_PRODUCT", 17, 19], ["\u03b1-helix", "SIMPLE_CHEMICAL", 62, 69], ["phospholipids", "SIMPLE_CHEMICAL", 119, 132], ["K4", "PROTEIN", 17, 19], ["phospholipids", "TREATMENT", 119, 132]]], ["NMR structures confirmed the \u03b1-helical structure of K4 hydrophobic tail in presence of SDS.", [["SDS", "CHEMICAL", 87, 90], ["K4 hydrophobic tail", "PROTEIN", 52, 71], ["NMR structures", "TEST", 0, 14], ["SDS", "PROBLEM", 87, 90], ["hydrophobic tail", "OBSERVATION", 55, 71], ["SDS", "OBSERVATION", 87, 90]]], ["K4 self-assembles at high concentration as observed by SEM and DLS.", [["K4", "GENE_OR_GENE_PRODUCT", 0, 2], ["K4", "PROTEIN", 0, 2]]], ["We suggest that K4 may act as a surfactant building mixed microsomes composed of peptide and lipids.", [["microsomes", "ANATOMY", 58, 68], ["K4", "GENE_OR_GENE_PRODUCT", 16, 18], ["lipids", "SIMPLE_CHEMICAL", 93, 99], ["K4", "PROTEIN", 16, 18], ["a surfactant building mixed microsomes", "TREATMENT", 30, 68], ["peptide and lipids", "TREATMENT", 81, 99]]], ["This destabilization mechanism of the bacterial membrane support the \"detergent like model\" previously described in the literature.P-592Oxidative stress and the membrane dipole potential; modulation with tocopherol S. Le-Nen-Davey 1 , B. M. Davis 2 , J. L. Richens 2 , K. A. Vere 2 , M. W. Tilley 2 , P. G. Petrov 1 , C. P. Winlove 1 , P. O'Shea 2 1 Biomedical Physics Group, University of Exeter, UK, 2 Cell Biophysics Group, University of Nottingham, UK Tocopherol, a component of vitamin E well know for its antioxidant properties, has recently been thought also to influence the structure of cellular membranes.", [["membrane", "ANATOMY", 48, 56], ["membrane", "ANATOMY", 161, 169], ["cellular membranes", "ANATOMY", 596, 614], ["P-592Oxidative", "CHEMICAL", 131, 145], ["tocopherol", "CHEMICAL", 204, 214], ["Tocopherol", "CHEMICAL", 456, 466], ["vitamin E", "CHEMICAL", 483, 492], ["tocopherol", "CHEMICAL", 204, 214], ["vitamin E", "CHEMICAL", 483, 492], ["bacterial membrane", "CELLULAR_COMPONENT", 38, 56], ["membrane", "CELLULAR_COMPONENT", 161, 169], ["UK", "SIMPLE_CHEMICAL", 453, 455], ["Tocopherol", "SIMPLE_CHEMICAL", 456, 466], ["vitamin E", "SIMPLE_CHEMICAL", 483, 492], ["cellular membranes", "CELLULAR_COMPONENT", 596, 614], ["the bacterial membrane", "TREATMENT", 34, 56], ["the membrane dipole potential", "TREATMENT", 157, 186], ["tocopherol S.", "TREATMENT", 204, 217], ["Tocopherol", "TREATMENT", 456, 466], ["a component of vitamin E", "TREATMENT", 468, 492], ["bacterial membrane", "OBSERVATION", 38, 56], ["cellular membranes", "OBSERVATION", 596, 614]]], ["Tocopherol treatment reduces hyperglycaemia induced oxidative stress and the associated endothelial dysfunction which is a precursor to the vascular complications of diabetes.", [["endothelial", "ANATOMY", 88, 99], ["vascular", "ANATOMY", 140, 148], ["Tocopherol", "CHEMICAL", 0, 10], ["hyperglycaemia", "DISEASE", 29, 43], ["endothelial dysfunction", "DISEASE", 88, 111], ["diabetes", "DISEASE", 166, 174], ["Tocopherol", "CHEMICAL", 0, 10], ["Tocopherol", "SIMPLE_CHEMICAL", 0, 10], ["endothelial", "TISSUE", 88, 99], ["vascular", "MULTI-TISSUE_STRUCTURE", 140, 148], ["Tocopherol treatment", "TREATMENT", 0, 20], ["hyperglycaemia induced oxidative stress", "PROBLEM", 29, 68], ["the associated endothelial dysfunction", "PROBLEM", 73, 111], ["the vascular complications", "PROBLEM", 136, 162], ["diabetes", "PROBLEM", 166, 174], ["oxidative stress", "OBSERVATION", 52, 68], ["endothelial dysfunction", "OBSERVATION", 88, 111], ["vascular", "ANATOMY", 140, 148], ["complications", "OBSERVATION", 149, 162], ["diabetes", "OBSERVATION", 166, 174]]], ["Tocopherol and insulin interactions are also modified by hyperglycaemia.", [["Tocopherol", "CHEMICAL", 0, 10], ["hyperglycaemia", "DISEASE", 57, 71], ["Tocopherol", "CHEMICAL", 0, 10], ["Tocopherol", "SIMPLE_CHEMICAL", 0, 10], ["insulin", "GENE_OR_GENE_PRODUCT", 15, 22], ["Tocopherol", "TREATMENT", 0, 10], ["insulin interactions", "TREATMENT", 15, 35], ["hyperglycaemia", "PROBLEM", 57, 71]]], ["It is unclear whether these clinically important effects arise from the anti-oxidant and/or structural properties of tocopherol.", [["tocopherol", "CHEMICAL", 117, 127], ["tocopherol", "CHEMICAL", 117, 127], ["tocopherol", "SIMPLE_CHEMICAL", 117, 127], ["the anti-oxidant", "TREATMENT", 68, 84], ["tocopherol", "TREATMENT", 117, 127], ["unclear whether", "UNCERTAINTY", 6, 21]]], ["We have therefore measured the dipole and surface potentials of phosphatidylcholine vesicles containing different amounts of cholesterol, ketocholesterol and tocopherol.", [["surface", "ANATOMY", 42, 49], ["phosphatidylcholine vesicles", "ANATOMY", 64, 92], ["phosphatidylcholine", "CHEMICAL", 64, 83], ["cholesterol", "CHEMICAL", 125, 136], ["ketocholesterol", "CHEMICAL", 138, 153], ["tocopherol", "CHEMICAL", 158, 168], ["phosphatidylcholine", "CHEMICAL", 64, 83], ["cholesterol", "CHEMICAL", 125, 136], ["ketocholesterol", "CHEMICAL", 138, 153], ["tocopherol", "CHEMICAL", 158, 168], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 64, 83], ["cholesterol", "SIMPLE_CHEMICAL", 125, 136], ["ketocholesterol", "SIMPLE_CHEMICAL", 138, 153], ["tocopherol", "SIMPLE_CHEMICAL", 158, 168], ["phosphatidylcholine vesicles", "TREATMENT", 64, 92], ["cholesterol", "TREATMENT", 125, 136], ["ketocholesterol", "TREATMENT", 138, 153], ["tocopherol", "TREATMENT", 158, 168], ["phosphatidylcholine vesicles", "OBSERVATION", 64, 92]]], ["We have also investigated the effects of hyperglycaemia, ketocholesterol and tocopherol, alone and in combination, on microdomain formation and interactions of insulin within the membranes of cultured endothelial cells.", [["microdomain", "ANATOMY", 118, 129], ["membranes", "ANATOMY", 179, 188], ["endothelial cells", "ANATOMY", 201, 218], ["hyperglycaemia", "DISEASE", 41, 55], ["ketocholesterol", "CHEMICAL", 57, 72], ["tocopherol", "CHEMICAL", 77, 87], ["ketocholesterol", "CHEMICAL", 57, 72], ["tocopherol", "CHEMICAL", 77, 87], ["ketocholesterol", "SIMPLE_CHEMICAL", 57, 72], ["tocopherol", "SIMPLE_CHEMICAL", 77, 87], ["microdomain", "CELLULAR_COMPONENT", 118, 129], ["insulin", "GENE_OR_GENE_PRODUCT", 160, 167], ["membranes", "CELLULAR_COMPONENT", 179, 188], ["endothelial cells", "CELL", 201, 218], ["insulin", "PROTEIN", 160, 167], ["cultured endothelial cells", "CELL_LINE", 192, 218], ["hyperglycaemia", "PROBLEM", 41, 55], ["ketocholesterol", "TREATMENT", 57, 72], ["tocopherol", "TREATMENT", 77, 87], ["microdomain formation", "TREATMENT", 118, 139], ["insulin", "TREATMENT", 160, 167], ["hyperglycaemia", "OBSERVATION", 41, 55], ["endothelial cells", "OBSERVATION", 201, 218]]], ["Both sets of experiments indicate that tocopherol causes significant modifications of the membrane dipole and surface potentials.", [["membrane", "ANATOMY", 90, 98], ["surface", "ANATOMY", 110, 117], ["tocopherol", "CHEMICAL", 39, 49], ["tocopherol", "CHEMICAL", 39, 49], ["tocopherol", "SIMPLE_CHEMICAL", 39, 49], ["membrane", "CELLULAR_COMPONENT", 90, 98], ["tocopherol", "TREATMENT", 39, 49], ["significant modifications of the membrane dipole", "PROBLEM", 57, 105], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["modifications", "OBSERVATION", 69, 82], ["membrane dipole", "OBSERVATION", 90, 105], ["surface potentials", "OBSERVATION", 110, 128]]], ["The physiological significance of these changes will be discussed.Cell Penetrating Peptide interactions with membranes on nanoporous supportsT.", [["Cell", "ANATOMY", 66, 70], ["membranes", "ANATOMY", 109, 118], ["Cell", "CELL", 66, 70], ["membranes", "CELLULAR_COMPONENT", 109, 118], ["T.", "SPECIES", 141, 143], ["these changes", "PROBLEM", 34, 47], ["membranes on nanoporous supports", "TREATMENT", 109, 141]]], ["D. Lazzara 1 , A. Janshoff 2 , C. Steinem 1 1 Georg-August University G\u00f6ttingen, Institute for organic and biomolecular chemistry, Tammannstr.", [["D. Lazzara", "TREATMENT", 0, 10], ["Tammannstr", "TREATMENT", 131, 141]]], ["2, 37077, Germany, 2 Georg-August University G\u00f6ttingen, Institute for physical chemistry, Tammannstr.", [["physical chemistry", "TEST", 70, 88], ["Tammannstr", "TREATMENT", 90, 100]]], ["6, 37077, Germany Cell penetrating peptides (CPP) have been shown to penetrate cellular membranes.", [["Cell", "ANATOMY", 18, 22], ["cellular membranes", "ANATOMY", 79, 97], ["Cell penetrating peptides", "GENE_OR_GENE_PRODUCT", 18, 43], ["cellular membranes", "CELLULAR_COMPONENT", 79, 97], ["Germany Cell penetrating peptides", "TEST", 10, 43], ["CPP", "TEST", 45, 48], ["cellular membranes", "OBSERVATION", 79, 97]]], ["They have been of interest for their ability to translocate not only themselves through cellular membranes, but also carry along with them, cargo as large as iron nanoparticles.", [["cellular membranes", "ANATOMY", 88, 106], ["iron", "CHEMICAL", 158, 162], ["iron", "CHEMICAL", 158, 162], ["cellular membranes", "CELLULAR_COMPONENT", 88, 106], ["iron nanoparticles", "SIMPLE_CHEMICAL", 158, 176], ["iron nanoparticles", "TREATMENT", 158, 176]]], ["The exact entry mechanism remains unclear, but has been shown to vary with peptide sequence.", [["peptide sequence", "TEST", 75, 91]]], ["Their translocation properties have been demonstrated through different experiments involving vesicles, cells and living animals.", [["vesicles", "ANATOMY", 94, 102], ["cells", "ANATOMY", 104, 109], ["vesicles", "CELLULAR_COMPONENT", 94, 102], ["cells", "CELL", 104, 109]]], ["We plan on using nano-black lipid membranes (nano-BLM), which span the pores of nanoporous materials as a model system to study the interaction between CPP and lipid membranes.", [["lipid membranes", "ANATOMY", 160, 175], ["nano-BLM", "SIMPLE_CHEMICAL", 45, 53], ["CPP", "SIMPLE_CHEMICAL", 152, 155], ["lipid membranes", "CELLULAR_COMPONENT", 160, 175], ["nano-black lipid membranes", "TREATMENT", 17, 43], ["nano-BLM)", "TREATMENT", 45, 54], ["CPP", "TEST", 152, 155], ["lipid membranes", "PROBLEM", 160, 175], ["lipid membranes", "OBSERVATION", 160, 175]]], ["The nanopores can be used as cellular containers whose interior surface can be functionalized with receptors for biotin-streptavidin recognition.", [["cellular", "ANATOMY", 29, 37], ["interior surface", "ANATOMY", 55, 71], ["biotin", "CHEMICAL", 113, 119], ["biotin", "CHEMICAL", 113, 119], ["cellular", "CELL", 29, 37], ["biotin", "SIMPLE_CHEMICAL", 113, 119], ["streptavidin", "SIMPLE_CHEMICAL", 120, 132], ["The nanopores", "TREATMENT", 0, 13], ["cellular containers", "TREATMENT", 29, 48], ["biotin-streptavidin recognition", "TREATMENT", 113, 144]]], ["We hope that this system will provide greater control over experimental variables, such as the type of CPP and lipid used, as well as provide kinetic data that can be used to evaluate CPP activity and the kinetics of cargo transport.", [["CPP", "SIMPLE_CHEMICAL", 103, 106], ["lipid", "SIMPLE_CHEMICAL", 111, 116], ["this system", "TREATMENT", 13, 24], ["CPP", "TEST", 103, 106], ["kinetic data", "TEST", 142, 154]]], ["Ethanol induces phospholipid acyl chain interdigitation.", [["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "CHEMICAL", 0, 7], ["acyl", "CHEMICAL", 29, 33], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["phospholipid", "SIMPLE_CHEMICAL", 16, 28], ["Ethanol induces phospholipid acyl chain interdigitation", "TREATMENT", 0, 55], ["phospholipid acyl", "OBSERVATION", 16, 33], ["chain interdigitation", "OBSERVATION", 34, 55]]], ["While much is known, important issues remain unclear, such as the role of lipid domains.", [["lipid domains", "PROTEIN", 74, 87]]], ["The main purpose of this study was to follow, in real time, the changes induced by ethanol on supported lipid bilayers with nano to microdomains by in situ Atomic Force Microscopy.", [["lipid bilayers", "ANATOMY", 104, 118], ["microdomains", "ANATOMY", 132, 144], ["ethanol", "CHEMICAL", 83, 90], ["ethanol", "CHEMICAL", 83, 90], ["ethanol", "SIMPLE_CHEMICAL", 83, 90], ["lipid bilayers", "SIMPLE_CHEMICAL", 104, 118], ["this study", "TEST", 20, 30], ["supported lipid bilayers", "TREATMENT", 94, 118], ["nano to microdomains", "TREATMENT", 124, 144], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["To this goal, a pure lipid in the fluid phase (DOPC), a pure lipid in the gel phase (DPPC), binary phospholipid mixtures with gel/fluid phase coexistence, and cholesterol-containing, raft -forming mixtures (DOPC/DPPC/cholesterol and DOPC/sphingomyelin/cholesterol) were investigated.", [["raft", "ANATOMY", 183, 187], ["DPPC", "CHEMICAL", 85, 89], ["cholesterol", "CHEMICAL", 159, 170], ["DOPC/DPPC", "CHEMICAL", 207, 216], ["cholesterol", "CHEMICAL", 217, 228], ["DOPC", "CHEMICAL", 233, 237], ["sphingomyelin", "CHEMICAL", 238, 251], ["cholesterol", "CHEMICAL", 252, 263], ["DOPC", "CHEMICAL", 47, 51], ["DPPC", "CHEMICAL", 85, 89], ["cholesterol", "CHEMICAL", 159, 170], ["DOPC", "CHEMICAL", 207, 211], ["DPPC", "CHEMICAL", 212, 216], ["cholesterol", "CHEMICAL", 217, 228], ["DOPC", "CHEMICAL", 233, 237], ["sphingomyelin", "CHEMICAL", 238, 251], ["cholesterol", "CHEMICAL", 252, 263], ["lipid", "SIMPLE_CHEMICAL", 21, 26], ["DOPC", "SIMPLE_CHEMICAL", 47, 51], ["DPPC", "SIMPLE_CHEMICAL", 85, 89], ["phospholipid", "SIMPLE_CHEMICAL", 99, 111], ["cholesterol", "SIMPLE_CHEMICAL", 159, 170], ["DOPC/DPPC/cholesterol", "SIMPLE_CHEMICAL", 207, 228], ["DOPC", "SIMPLE_CHEMICAL", 233, 237], ["sphingomyelin", "SIMPLE_CHEMICAL", 238, 251], ["cholesterol", "SIMPLE_CHEMICAL", 252, 263], ["a pure lipid in the fluid phase (DOPC", "TREATMENT", 14, 51], ["a pure lipid in the gel phase (DPPC)", "TREATMENT", 54, 90], ["binary phospholipid mixtures", "TREATMENT", 92, 120], ["gel/fluid phase coexistence", "TEST", 126, 153], ["cholesterol", "TEST", 159, 170], ["raft -forming mixtures", "TREATMENT", 183, 205], ["DOPC/DPPC/cholesterol and DOPC/sphingomyelin/cholesterol)", "TREATMENT", 207, 264], ["fluid phase", "OBSERVATION", 130, 141]]], ["From the height differences observed upon ethanol addition to pure lipids (DPPC and DOPC), and to DOPC/DPPC mixtures, it is shown that in the binary system the interdigitation of the fluid phase occurs prior to the gel phase.", [["ethanol", "CHEMICAL", 42, 49], ["DPPC", "CHEMICAL", 75, 79], ["DOPC", "CHEMICAL", 84, 88], ["DOPC", "CHEMICAL", 98, 102], ["DPPC", "CHEMICAL", 103, 107], ["ethanol", "CHEMICAL", 42, 49], ["DPPC", "CHEMICAL", 75, 79], ["DOPC", "CHEMICAL", 84, 88], ["DOPC", "CHEMICAL", 98, 102], ["DPPC", "CHEMICAL", 103, 107], ["ethanol", "SIMPLE_CHEMICAL", 42, 49], ["DPPC", "SIMPLE_CHEMICAL", 75, 79], ["DOPC", "SIMPLE_CHEMICAL", 84, 88], ["DOPC", "SIMPLE_CHEMICAL", 98, 102], ["DPPC", "SIMPLE_CHEMICAL", 103, 107], ["pure lipids (DPPC and DOPC)", "TREATMENT", 62, 89], ["DOPC/DPPC mixtures", "TREATMENT", 98, 116], ["the fluid phase", "TEST", 179, 194], ["the gel phase", "TEST", 211, 224], ["interdigitation", "OBSERVATION_MODIFIER", 160, 175], ["fluid phase", "OBSERVATION", 183, 194]]], ["However, for the lipid rafts mixtures the simultaneous interdigitation of both raft and non raft portions of the membrane is observed both in mica and silicon substrates.", [["lipid rafts", "ANATOMY", 17, 28], ["raft", "ANATOMY", 79, 83], ["non raft portions", "ANATOMY", 88, 105], ["membrane", "ANATOMY", 113, 121], ["silicon", "CHEMICAL", 151, 158], ["raft", "CELLULAR_COMPONENT", 79, 83], ["membrane", "CELLULAR_COMPONENT", 113, 121], ["the lipid rafts mixtures", "TREATMENT", 13, 37], ["simultaneous interdigitation", "OBSERVATION", 42, 70], ["both", "ANATOMY_MODIFIER", 74, 78], ["raft", "ANATOMY_MODIFIER", 79, 83], ["non raft", "ANATOMY_MODIFIER", 88, 96], ["silicon substrates", "OBSERVATION", 151, 169]]], ["For all compositions studied, domain formation or rearrangement accompanied by lipid bilayer expansion occurs as a consequence of interdigitation.", [["lipid bilayer", "ANATOMY", 79, 92], ["lipid bilayer", "CELLULAR_COMPONENT", 79, 92], ["domain formation", "PROBLEM", 30, 46], ["lipid bilayer expansion", "PROBLEM", 79, 102], ["interdigitation", "PROBLEM", 130, 145], ["lipid", "OBSERVATION", 79, 84], ["bilayer expansion", "OBSERVATION", 85, 102]]], ["These results show the ability of ethanol to influence the bilayer properties in different ways according to membrane composition.", [["bilayer", "ANATOMY", 59, 66], ["membrane", "ANATOMY", 109, 117], ["ethanol", "CHEMICAL", 34, 41], ["ethanol", "CHEMICAL", 34, 41], ["ethanol", "SIMPLE_CHEMICAL", 34, 41], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["the bilayer properties", "TREATMENT", 55, 77]]], ["Ethanol may exert its biological effects by reducing bilayer thickness, and also by changing membrane proteins conformation and lateral distribution, as a consequence of the altered properties of the lipid bilayer.O-597Interactions between non-steroidal anti-inflammatory drugs and a PC/cholesterol bilayer M. Markiewicz 1 , T. Librowski 2 , P. Serda 3 , M. Pasenkiewicz-Gierula 1 1 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University \" 2 Department of Pharmacodynamics, Medical College, Jagiellonian University \" 3 Regional Laboratory, Jagiellonian University, Krakow, Poland.O-597The non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed and used drugs [1] .", [["bilayer", "ANATOMY", 53, 60], ["membrane", "ANATOMY", 93, 101], ["lipid bilayer", "ANATOMY", 200, 213], ["Ethanol", "CHEMICAL", 0, 7], ["O-597", "CHEMICAL", 214, 219], ["cholesterol", "CHEMICAL", 287, 298], ["O-597", "CHEMICAL", 604, 609], ["NSAIDs", "CHEMICAL", 652, 658], ["Ethanol", "CHEMICAL", 0, 7], ["O-597", "CHEMICAL", 214, 219], ["cholesterol", "CHEMICAL", 287, 298], ["O-597", "CHEMICAL", 604, 609], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["lipid bilayer", "CELLULAR_COMPONENT", 200, 213], ["O-597", "SIMPLE_CHEMICAL", 214, 219], ["non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 240, 277], ["PC", "SIMPLE_CHEMICAL", 284, 286], ["non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 613, 650], ["NSAIDs", "SIMPLE_CHEMICAL", 652, 658], ["membrane proteins", "PROTEIN", 93, 110], ["Ethanol", "TREATMENT", 0, 7], ["non-steroidal anti-inflammatory drugs", "TREATMENT", 240, 277], ["a PC/cholesterol bilayer M. Markiewicz", "TREATMENT", 282, 320], ["The non-steroidal anti-inflammatory drugs", "TREATMENT", 609, 650], ["NSAIDs)", "TREATMENT", 652, 659], ["lateral", "OBSERVATION_MODIFIER", 128, 135], ["non-steroidal", "OBSERVATION_MODIFIER", 613, 626], ["anti-inflammatory drugs", "OBSERVATION", 627, 650]]], ["There are several side effects connected with frequent use of NSAID, mainly gastrointestinal ulcers and bleedings.", [["gastrointestinal", "ANATOMY", 76, 92], ["gastrointestinal ulcers", "DISEASE", 76, 99], ["bleedings", "DISEASE", 104, 113], ["NSAID", "SIMPLE_CHEMICAL", 62, 67], ["gastrointestinal ulcers", "PATHOLOGICAL_FORMATION", 76, 99], ["several side effects", "PROBLEM", 10, 30], ["NSAID", "TREATMENT", 62, 67], ["mainly gastrointestinal ulcers", "PROBLEM", 69, 99], ["bleedings", "PROBLEM", 104, 113], ["several", "OBSERVATION_MODIFIER", 10, 17], ["side effects", "OBSERVATION_MODIFIER", 18, 30], ["gastrointestinal", "ANATOMY", 76, 92], ["ulcers", "OBSERVATION", 93, 99], ["bleedings", "OBSERVATION", 104, 113]]], ["A plausible molecular mechanism of these effects are direct interactions of NSAIDs with gastric phospholipids [2, 3] .", [["gastric", "ANATOMY", 88, 95], ["NSAIDs", "CHEMICAL", 76, 82], ["NSAIDs", "SIMPLE_CHEMICAL", 76, 82], ["gastric phospholipids", "SIMPLE_CHEMICAL", 88, 109], ["NSAIDs", "TREATMENT", 76, 82], ["gastric phospholipids", "TREATMENT", 88, 109]]], ["The influence of three well-known non-steroidal antiinflammatory drugs with a diverse gastric toxicity (aspirin, ketoprofen and piroxicam) and three newly-synthesized xanthone derivatives (belonging to the NSAIDs) on the structure and dynamics of lipid bilayers was studied using small angle X-ray scattering and molecular dynamics simulations.", [["gastric", "ANATOMY", 86, 93], ["gastric toxicity", "DISEASE", 86, 102], ["aspirin", "CHEMICAL", 104, 111], ["ketoprofen", "CHEMICAL", 113, 123], ["piroxicam", "CHEMICAL", 128, 137], ["xanthone", "CHEMICAL", 167, 175], ["NSAIDs", "CHEMICAL", 206, 212], ["aspirin", "CHEMICAL", 104, 111], ["ketoprofen", "CHEMICAL", 113, 123], ["piroxicam", "CHEMICAL", 128, 137], ["xanthone", "CHEMICAL", 167, 175], ["gastric", "ORGAN", 86, 93], ["aspirin", "SIMPLE_CHEMICAL", 104, 111], ["ketoprofen", "SIMPLE_CHEMICAL", 113, 123], ["piroxicam", "SIMPLE_CHEMICAL", 128, 137], ["xanthone derivatives", "SIMPLE_CHEMICAL", 167, 187], ["NSAIDs", "SIMPLE_CHEMICAL", 206, 212], ["lipid bilayers", "SIMPLE_CHEMICAL", 247, 261], ["non-steroidal antiinflammatory drugs", "TREATMENT", 34, 70], ["a diverse gastric toxicity", "PROBLEM", 76, 102], ["aspirin", "TREATMENT", 104, 111], ["ketoprofen", "TREATMENT", 113, 123], ["piroxicam", "TREATMENT", 128, 137], ["newly-synthesized xanthone derivatives", "TREATMENT", 149, 187], ["the NSAIDs", "TREATMENT", 202, 212], ["lipid bilayers", "TREATMENT", 247, 261], ["small angle X-ray scattering", "TREATMENT", 280, 308], ["gastric", "ANATOMY", 86, 93], ["small", "OBSERVATION_MODIFIER", 280, 285]]], ["The results showed some correlation between NSAID toxicity and its binding to the lipid polar groups.", [["toxicity", "DISEASE", 50, 58], ["NSAID", "SIMPLE_CHEMICAL", 44, 49], ["NSAID toxicity", "PROBLEM", 44, 58], ["NSAID toxicity", "OBSERVATION", 44, 58]]], ["This binding increases membrane fluidity by reducing its density due to an increased membrane surface area.", [["membrane", "ANATOMY", 23, 31], ["membrane surface area", "ANATOMY", 85, 106], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["membrane surface area", "CELLULAR_COMPONENT", 85, 106], ["This binding increases membrane fluidity", "PROBLEM", 0, 40], ["its density", "PROBLEM", 53, 64], ["an increased membrane surface area", "PROBLEM", 72, 106], ["increases", "OBSERVATION_MODIFIER", 13, 22], ["membrane fluidity", "OBSERVATION", 23, 40], ["density", "OBSERVATION", 57, 64], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["membrane", "OBSERVATION_MODIFIER", 85, 93], ["surface", "OBSERVATION_MODIFIER", 94, 101]]], ["A reduced lipid packing in the membrane most likely increases gastric mucosa permeability, which can result in a decreased resistance of the gastric mucosa to luminal acid.", [["membrane", "ANATOMY", 31, 39], ["gastric mucosa", "ANATOMY", 62, 76], ["gastric mucosa", "ANATOMY", 141, 155], ["luminal", "ANATOMY", 159, 166], ["luminal acid", "CHEMICAL", 159, 171], ["lipid", "SIMPLE_CHEMICAL", 10, 15], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 62, 76], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 141, 155], ["luminal acid", "SIMPLE_CHEMICAL", 159, 171], ["A reduced lipid packing in the membrane", "TREATMENT", 0, 39], ["gastric mucosa permeability", "PROBLEM", 62, 89], ["a decreased resistance of the gastric mucosa", "PROBLEM", 111, 155], ["reduced", "OBSERVATION_MODIFIER", 2, 9], ["lipid packing", "OBSERVATION", 10, 23], ["membrane", "ANATOMY_MODIFIER", 31, 39], ["most likely", "UNCERTAINTY", 40, 51], ["increases", "OBSERVATION_MODIFIER", 52, 61], ["gastric mucosa permeability", "OBSERVATION", 62, 89], ["decreased", "OBSERVATION_MODIFIER", 113, 122], ["resistance", "OBSERVATION", 123, 133], ["gastric mucosa", "ANATOMY", 141, 155], ["luminal", "ANATOMY_MODIFIER", 159, 166], ["acid", "OBSERVATION_MODIFIER", 167, 171]]], ["We studied the partition of the anionic amphiphile 1pyrenesulfonate (PSA) into MLV and LUV (produced by extrusion), composed by zwitterionic POPC and zwitterionic/anionic mixtures with POPS (until 10 mol %).", [["amphiphile 1pyrenesulfonate", "CHEMICAL", 40, 67], ["LUV", "CHEMICAL", 87, 90], ["POPC", "CHEMICAL", 141, 145], ["POPS", "CHEMICAL", 185, 189], ["1pyrenesulfonate", "CHEMICAL", 51, 67], ["PSA", "CHEMICAL", 69, 72], ["LUV", "CHEMICAL", 87, 90], ["POPC", "CHEMICAL", 141, 145], ["POPS", "CHEMICAL", 185, 189], ["anionic amphiphile 1pyrenesulfonate", "SIMPLE_CHEMICAL", 32, 67], ["PSA", "SIMPLE_CHEMICAL", 69, 72], ["MLV", "ORGANISM", 79, 82], ["LUV", "SIMPLE_CHEMICAL", 87, 90], ["zwitterionic POPC", "SIMPLE_CHEMICAL", 128, 145], ["zwitterionic/anionic mixtures", "SIMPLE_CHEMICAL", 150, 179], ["POPS", "SIMPLE_CHEMICAL", 185, 189], ["PSA", "PROTEIN", 69, 72], ["the anionic amphiphile 1pyrenesulfonate (PSA", "TREATMENT", 28, 72], ["zwitterionic POPC", "TREATMENT", 128, 145], ["zwitterionic/anionic mixtures", "TREATMENT", 150, 179], ["LUV", "ANATOMY", 87, 90]]], ["PSA is an anionic amphiphile that mimics several xenobiotics (e.g. pharmaceuticals, pesticides) and endogenous substrates that interact with biological membranes.", [["membranes", "ANATOMY", 152, 161], ["PSA", "GENE_OR_GENE_PRODUCT", 0, 3], ["membranes", "CELLULAR_COMPONENT", 152, 161], ["PSA", "PROTEIN", 0, 3], ["PSA", "TEST", 0, 3], ["an anionic amphiphile", "TREATMENT", 7, 28], ["endogenous substrates", "PROBLEM", 100, 121], ["anionic amphiphile", "OBSERVATION", 10, 28]]], ["We found increasingMimicking and quantifying cell-cell and cellvirus interactions via colloidal probe microscopyB.", [["cell", "ANATOMY", 45, 49], ["cell", "ANATOMY", 50, 54], ["cellvirus", "ANATOMY", 59, 68], ["cell", "CELL", 45, 49], ["cell", "CELL", 50, 54], ["cellvirus", "CELL", 59, 68], ["increasingMimicking", "PROBLEM", 9, 28], ["cellvirus interactions", "PROBLEM", 59, 81], ["colloidal probe microscopyB", "TREATMENT", 86, 113], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["cell-cell", "OBSERVATION", 45, 54]]], ["Lorenz, S. Schuy, A. Janshoff Georg August University, G\u00f6ttingen, GermanyMimicking and quantifying cell-cell and cellvirus interactions via colloidal probe microscopyCell-cell and cell-virus interactions are ubiquitous in living organisms.", [["cell", "ANATOMY", 99, 103], ["cell", "ANATOMY", 104, 108], ["cellvirus", "ANATOMY", 113, 122], ["Cell", "ANATOMY", 166, 170], ["cell", "ANATOMY", 171, 175], ["cell", "ANATOMY", 180, 184], ["cell", "CELL", 99, 103], ["cell", "CELL", 104, 108], ["cellvirus", "CELL", 113, 122], ["Cell", "CELL", 166, 170], ["cell", "CELL", 171, 175], ["cell", "CELL", 180, 184], ["cellvirus interactions", "PROBLEM", 113, 135], ["colloidal probe microscopy", "TEST", 140, 166], ["cell-virus interactions", "PROBLEM", 180, 203], ["quantifying cell", "OBSERVATION", 87, 103], ["cell", "OBSERVATION", 104, 108], ["cell", "OBSERVATION", 171, 175], ["cell", "OBSERVATION", 180, 184]]], ["The analysis of the forces acting between two cells or a cell and a virus gives insight into details of these interaction processes such as their stochastics, cooperativity, reversibility, and energy landscape.", [["cells", "ANATOMY", 46, 51], ["cell", "ANATOMY", 57, 61], ["cells", "CELL", 46, 51], ["cell", "CELL", 57, 61], ["The analysis", "TEST", 0, 12], ["two cells", "PROBLEM", 42, 51], ["a cell", "PROBLEM", 55, 61], ["a virus", "PROBLEM", 66, 73], ["these interaction processes", "PROBLEM", 104, 131], ["energy landscape", "OBSERVATION", 193, 209]]], ["Using colloidal probe microscopy in conjunction with solid-supported lipid bilayer techniques, we mimic the contact between two membranous compounds displaying sponge glycolipids or viral peptides on their surfaces.Mimicking and quantifying cell-cell and cellvirus interactions via colloidal probe microscopyAfter spreading functionalized lipid bilayers on both -a colloidal probe and a silicon wafer surface -the molecular interactions are quantified by means of force-distance curves.", [["cell", "ANATOMY", 241, 245], ["cell", "ANATOMY", 246, 250], ["cellvirus", "ANATOMY", 255, 264], ["silicon", "CHEMICAL", 387, 394], ["silicon", "CHEMICAL", 387, 394], ["cell", "CELL", 241, 245], ["cell", "CELL", 246, 250], ["cellvirus", "CELL", 255, 264], ["lipid bilayers", "SIMPLE_CHEMICAL", 339, 353], ["colloidal probe microscopy", "TEST", 6, 32], ["solid-supported lipid bilayer techniques", "TREATMENT", 53, 93], ["two membranous compounds", "TREATMENT", 124, 148], ["sponge glycolipids", "TREATMENT", 160, 178], ["viral peptides", "TREATMENT", 182, 196], ["colloidal probe microscopy", "TEST", 282, 308], ["spreading functionalized lipid bilayers", "TREATMENT", 314, 353], ["both -a colloidal probe", "TREATMENT", 357, 380], ["a silicon wafer surface", "TREATMENT", 385, 408], ["viral peptides", "OBSERVATION", 182, 196], ["lipid bilayers", "OBSERVATION", 339, 353]]], ["By probing the dynamic interaction strength between the viral peptides N36 and C34 we aim for a deeper understanding of the role of these peptides in the complex process of the formation of the prehairpin intermediate as the key step in retroviral fusion.", [["prehairpin", "GENE_OR_GENE_PRODUCT", 194, 204], ["retroviral", "ORGANISM", 237, 247], ["prehairpin intermediate", "PROTEIN", 194, 217], ["the viral peptides", "TEST", 52, 70], ["these peptides", "TREATMENT", 132, 146], ["the prehairpin intermediate", "TREATMENT", 190, 217], ["retroviral fusion", "TREATMENT", 237, 254], ["retroviral fusion", "OBSERVATION", 237, 254]]], ["As far as the cellular interaction of marine sponge cells is concerned, we intend to investigate the strength, specificity, and the Ca 2+ dependency of the self-recognition between sponge glycans.Mimicking and quantifying cell-cell and cellvirus interactions via colloidal probe microscopyThe systems advantages are the flexibility of the membrane composition and the control over the distribution of receptor molecules in the membranes.", [["cellular", "ANATOMY", 14, 22], ["sponge cells", "ANATOMY", 45, 57], ["cell", "ANATOMY", 222, 226], ["cell", "ANATOMY", 227, 231], ["cellvirus", "ANATOMY", 236, 245], ["membrane", "ANATOMY", 339, 347], ["membranes", "ANATOMY", 427, 436], ["Ca", "CHEMICAL", 132, 134], ["Ca 2+", "CHEMICAL", 132, 137], ["cellular", "CELL", 14, 22], ["marine sponge cells", "CELL", 38, 57], ["cell", "CELL", 222, 226], ["cell", "CELL", 227, 231], ["cellvirus", "CELL", 236, 245], ["membrane", "CELLULAR_COMPONENT", 339, 347], ["membranes", "CELLULAR_COMPONENT", 427, 436], ["marine sponge cells", "CELL_TYPE", 38, 57], ["receptor molecules", "PROTEIN", 401, 419], ["sponge glycans", "TREATMENT", 181, 195], ["colloidal probe microscopy", "TEST", 263, 289], ["the membrane composition", "TREATMENT", 335, 359], ["receptor molecules", "OBSERVATION", 401, 419]]], ["Since adhesion in biological systems relies heavily on cluster formation within the biomembrane, we plan to mimic the clustering by \"printing\" interaction domains and comparing the results to homogeneous samples.P-594Development of video-rate imaging microscope using laurdan and its applications to lipid raft T. Ohba, K.-I. Muto, T. Kiuchi, K. Ohki Department of Physics, Graduate School of Science, Aobaku, Sendai, Japan 980-8578, ohki@bio.phys.tohoku.ac.jp Various biological functions are located on cell membranes, and the biomembranes maintain heterogeneity as microdomain even in its dynamic structure.", [["samples", "ANATOMY", 204, 211], ["cell membranes", "ANATOMY", 505, 519], ["microdomain", "ANATOMY", 568, 579], ["P-594", "CHEMICAL", 212, 217], ["P-594", "CHEMICAL", 212, 217], ["samples", "CANCER", 204, 211], ["cell membranes", "CELLULAR_COMPONENT", 505, 519], ["biomembranes", "CELLULAR_COMPONENT", 529, 541], ["microdomain", "CELLULAR_COMPONENT", 568, 579], ["interaction domains", "PROTEIN", 143, 162], ["P", "DNA", 212, 213], ["adhesion in biological systems", "PROBLEM", 6, 36], ["video-rate imaging microscope", "TEST", 232, 261], ["laurdan", "TREATMENT", 268, 275], ["cell membranes", "TREATMENT", 505, 519], ["cell membranes", "OBSERVATION", 505, 519], ["heterogeneity", "OBSERVATION", 551, 564], ["microdomain", "OBSERVATION_MODIFIER", 568, 579]]], ["Existence of such domain was reported as phase-separated 'rafts' in a cell.", [["rafts", "ANATOMY", 58, 63], ["cell", "ANATOMY", 70, 74], ["rafts", "CELLULAR_COMPONENT", 58, 63], ["cell", "CELL", 70, 74], ["such domain", "PROBLEM", 13, 24]]], ["And the bio-functions of membrane protein are affected by physical property of its surrounding lipid bilayers.", [["membrane", "ANATOMY", 25, 33], ["lipid bilayers", "ANATOMY", 95, 109], ["membrane", "CELLULAR_COMPONENT", 25, 33], ["lipid bilayers", "CELLULAR_COMPONENT", 95, 109], ["membrane protein", "PROTEIN", 25, 41], ["membrane protein", "PROBLEM", 25, 41], ["membrane protein", "OBSERVATION", 25, 41], ["lipid bilayers", "OBSERVATION", 95, 109]]], ["Laurdan is a useful fluorescence dye to monitor membrane fluidity, and we have developed an instrument to image spatial and temporal change in membrane fluidity by use of laurdan.", [["membrane", "ANATOMY", 48, 56], ["membrane", "ANATOMY", 143, 151], ["Laurdan", "CHEMICAL", 0, 7], ["Laurdan", "SIMPLE_CHEMICAL", 0, 7], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["membrane fluidity", "TEST", 48, 65], ["temporal change in membrane fluidity", "PROBLEM", 124, 160], ["laurdan", "TREATMENT", 171, 178], ["instrument", "OBSERVATION", 92, 102], ["temporal", "OBSERVATION_MODIFIER", 124, 132], ["change", "OBSERVATION", 133, 139], ["membrane fluidity", "OBSERVATION", 143, 160]]], ["In order to examine role of 'micro-domain' in biomembrane, we applied this imaging instrument to a giant liposome, CHO cells and PC12D cells.", [["giant liposome", "ANATOMY", 99, 113], ["CHO cells", "ANATOMY", 115, 124], ["PC12D cells", "ANATOMY", 129, 140], ["CHO cells", "CELL", 115, 124], ["PC12D cells", "CELL", 129, 140], ["CHO cells", "CELL_LINE", 115, 124], ["PC12D cells", "CELL_LINE", 129, 140], ["this imaging instrument", "TEST", 70, 93], ["a giant liposome, CHO cells and PC12D cells", "TREATMENT", 97, 140]]], ["Fluorescence microscope was equipped with a home-build dual-view optical unit.", [["Fluorescence microscope", "TEST", 0, 23]]], ["Microscopic image of membranes stained with laurdan is separated into an image at 440 nm and an image at 490 nm by the combination of monochromatic filters and dichroic mirrors.", [["membranes", "ANATOMY", 21, 30], ["membranes", "CELLULAR_COMPONENT", 21, 30], ["laurdan", "PROTEIN", 44, 51], ["Microscopic image of membranes", "TEST", 0, 30], ["an image", "TEST", 93, 101], ["monochromatic filters", "TREATMENT", 134, 155], ["dichroic mirrors", "TREATMENT", 160, 176], ["monochromatic filters", "OBSERVATION", 134, 155]]], ["And generalized polarization (G.P.) image is calculated from those images by personal computer according to the definition of G.P. The G.P. imaging at video rate was applied to a giant liposome of composed of DMPC and DMPE in order to observe phase separation.", [["DMPC", "CHEMICAL", 209, 213], ["DMPE", "CHEMICAL", 218, 222], ["DMPC", "CHEMICAL", 209, 213], ["DMPE", "CHEMICAL", 218, 222], ["DMPC", "SIMPLE_CHEMICAL", 209, 213], ["DMPE", "SIMPLE_CHEMICAL", 218, 222], ["G.P.", "SPECIES", 126, 130], ["The G.P. imaging", "TEST", 131, 147], ["video rate", "TEST", 151, 161], ["a giant liposome", "TREATMENT", 177, 193], ["DMPC and DMPE", "TREATMENT", 209, 222], ["generalized", "OBSERVATION_MODIFIER", 4, 15], ["polarization", "OBSERVATION_MODIFIER", 16, 28]]], ["It was also examined that specific interaction of sphingomyelin and cholesterol in living CHO cells and neuritis protrusion from raft region of PC12D cells stimulated by neuron growth factor.P-601Current fluctuations in biological lipid membranes from human cell lines S. Nuschele, A. Wixforth, M. F. Schneider University of Augsburg, Experimental Physics 1, Univer-sit\u00e4tsstraSSe 1, D -86159 Augsburg, Germany Lipid Membranes can undergo phase transitions at physiological temperatures.", [["CHO cells", "ANATOMY", 90, 99], ["raft region", "ANATOMY", 129, 140], ["PC12D cells", "ANATOMY", 144, 155], ["lipid membranes", "ANATOMY", 231, 246], ["cell lines", "ANATOMY", 258, 268], ["sphingomyelin", "CHEMICAL", 50, 63], ["cholesterol", "CHEMICAL", 68, 79], ["neuritis", "DISEASE", 104, 112], ["sphingomyelin", "CHEMICAL", 50, 63], ["cholesterol", "CHEMICAL", 68, 79], ["sphingomyelin", "SIMPLE_CHEMICAL", 50, 63], ["cholesterol", "SIMPLE_CHEMICAL", 68, 79], ["CHO cells", "CELL", 90, 99], ["PC12D cells", "CELL", 144, 155], ["neuron growth factor", "GENE_OR_GENE_PRODUCT", 170, 190], ["lipid membranes", "CELLULAR_COMPONENT", 231, 246], ["human", "ORGANISM", 252, 257], ["cell lines", "CELL", 258, 268], ["D -86159", "SIMPLE_CHEMICAL", 383, 391], ["CHO cells", "CELL_LINE", 90, 99], ["PC12D cells", "CELL_LINE", 144, 155], ["neuron growth factor", "PROTEIN", 170, 190], ["human cell lines", "CELL_LINE", 252, 268], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["sphingomyelin and cholesterol in living CHO cells", "TREATMENT", 50, 99], ["neuritis protrusion", "PROBLEM", 104, 123], ["raft region of PC12D cells", "TREATMENT", 129, 155], ["P", "TEST", 191, 192], ["biological lipid membranes", "TREATMENT", 220, 246], ["phase transitions", "PROBLEM", 438, 455], ["neuritis protrusion", "OBSERVATION", 104, 123], ["lipid membranes", "OBSERVATION", 231, 246], ["cell lines", "OBSERVATION", 258, 268]]], ["Not only do single lipid component membranes show melting behaviour but also biological lipid membranes from eukaryotes as well as from prokaryotes.", [["lipid component membranes", "ANATOMY", 19, 44], ["lipid membranes", "ANATOMY", 88, 103], ["membranes", "CELLULAR_COMPONENT", 35, 44], ["lipid membranes", "CELLULAR_COMPONENT", 88, 103], ["melting behaviour", "PROBLEM", 50, 67], ["membranes", "OBSERVATION", 35, 44], ["melting", "OBSERVATION", 50, 57], ["lipid membranes", "OBSERVATION", 88, 103]]], ["Performing calorimetric and monolayer studies we are able to detect phase transitions in extracted membranes from different human cell lines (e.g. keratinocytes and melanoma cells).", [["membranes", "ANATOMY", 99, 108], ["cell lines", "ANATOMY", 130, 140], ["keratinocytes", "ANATOMY", 147, 160], ["melanoma cells", "ANATOMY", 165, 179], ["melanoma", "DISEASE", 165, 173], ["monolayer", "CELL", 28, 37], ["membranes", "CELLULAR_COMPONENT", 99, 108], ["human", "ORGANISM", 124, 129], ["cell lines", "CELL", 130, 140], ["keratinocytes", "CELL", 147, 160], ["melanoma cells", "CELL", 165, 179], ["human cell lines", "CELL_LINE", 124, 140], ["keratinocytes", "CELL_TYPE", 147, 160], ["melanoma cells", "CELL_TYPE", 165, 179], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129], ["Performing calorimetric and monolayer studies", "TEST", 0, 45], ["phase transitions", "PROBLEM", 68, 85], ["extracted membranes", "PROBLEM", 89, 108], ["different human cell lines", "TREATMENT", 114, 140], ["keratinocytes and melanoma cells", "TREATMENT", 147, 179], ["human cell lines", "OBSERVATION", 124, 140], ["melanoma cells", "OBSERVATION", 165, 179]]], ["Close to and in the melting transition regime we measured distinct channel like current fluctuations.", [["the melting transition regime", "TREATMENT", 16, 45]]], ["The opening times of these current fluctuations can be predicted based on the lateral compressibility measured from the monolayer isotherm and agree well with the experimental data [*].", [["the lateral compressibility", "TEST", 74, 101]]], ["The applied method of extraction excludes the presence of functional proteins in the membrane rendering the lipid bilayer as the source of the observed current fluctuations.", [["membrane", "ANATOMY", 85, 93], ["lipid bilayer", "ANATOMY", 108, 121], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["lipid bilayer", "CELLULAR_COMPONENT", 108, 121], ["functional proteins", "PROTEIN", 58, 77], ["extraction", "TREATMENT", 22, 32], ["functional proteins", "PROBLEM", 58, 77], ["functional proteins", "OBSERVATION", 58, 77]]], ["The molecules are composed of single hydrophobic tail and two hydrophilic aldonamide-type groupings (gluconyl C12-DGA or lactobionyl C12-DLA) linked by the propylene chain at the nitrogen atom.P-601The micellization processes of C12-DGA and C12-DLA were studied by means of ITC.", [["aldonamide", "CHEMICAL", 74, 84], ["gluconyl C12-DGA", "CHEMICAL", 101, 117], ["lactobionyl C12-DLA", "CHEMICAL", 121, 140], ["propylene", "CHEMICAL", 156, 165], ["P-601", "CHEMICAL", 193, 198], ["C12-DGA", "CHEMICAL", 229, 236], ["C12-DLA", "CHEMICAL", 241, 248], ["aldonamide", "CHEMICAL", 74, 84], ["gluconyl C12-DGA", "CHEMICAL", 101, 117], ["lactobionyl C12-DLA", "CHEMICAL", 121, 140], ["propylene", "CHEMICAL", 156, 165], ["nitrogen", "CHEMICAL", 179, 187], ["C12-DGA", "CHEMICAL", 229, 236], ["C12-DLA", "CHEMICAL", 241, 248], ["gluconyl C12-DGA", "SIMPLE_CHEMICAL", 101, 117], ["lactobionyl C12-DLA", "SIMPLE_CHEMICAL", 121, 140], ["propylene chain", "SIMPLE_CHEMICAL", 156, 171], ["nitrogen atom", "SIMPLE_CHEMICAL", 179, 192], ["C12-DGA", "SIMPLE_CHEMICAL", 229, 236], ["C12-DLA", "SIMPLE_CHEMICAL", 241, 248], ["ITC", "CELL", 274, 277], ["hydrophobic tail", "PROTEIN", 37, 53], ["single hydrophobic tail", "PROBLEM", 30, 53], ["gluconyl C12", "TREATMENT", 101, 113], ["lactobionyl C12", "TREATMENT", 121, 136], ["the propylene chain", "TREATMENT", 152, 171], ["P", "TEST", 193, 194], ["The micellization processes", "TEST", 198, 225], ["C12", "TEST", 229, 232], ["hydrophobic tail", "OBSERVATION_MODIFIER", 37, 53], ["hydrophilic", "OBSERVATION_MODIFIER", 62, 73], ["C12", "ANATOMY", 229, 232], ["C12", "ANATOMY", 241, 244], ["DLA", "ANATOMY", 245, 248]]], ["The critical micelle concentrations, the enthalpies (\u2206H m ) and the entropies (\u2206S m ) of micellization as well as the contributions of the headgroups to the Gibbs free energies (\u2206G m 0 (hy)) were calculated.", [["The critical micelle concentrations", "TREATMENT", 0, 35], ["the enthalpies (\u2206H m )", "TREATMENT", 37, 59], ["the entropies", "TREATMENT", 64, 77], ["micellization", "TREATMENT", 89, 102], ["micelle concentrations", "OBSERVATION", 13, 35]]], ["QSPR analysis was also used to predict CMC of studied compounds.", [["QSPR analysis", "TEST", 0, 13]]], ["The interactions of C12-DGA and C12-DLA with model membranes (DPPC and DPPC/chol. bilayers) were studied by means of DSC.", [["membranes", "ANATOMY", 51, 60], ["C12-DGA", "CHEMICAL", 20, 27], ["C12-DLA", "CHEMICAL", 32, 39], ["DPPC", "CHEMICAL", 62, 66], ["DPPC/chol", "CHEMICAL", 71, 80], ["C12-DGA", "CHEMICAL", 20, 27], ["C12-DLA", "CHEMICAL", 32, 39], ["DPPC", "CHEMICAL", 62, 66], ["DPPC", "CHEMICAL", 71, 75], ["chol", "CHEMICAL", 76, 80], ["C12-DGA", "SIMPLE_CHEMICAL", 20, 27], ["C12-DLA", "SIMPLE_CHEMICAL", 32, 39], ["DPPC", "SIMPLE_CHEMICAL", 62, 66], ["DPPC/chol", "SIMPLE_CHEMICAL", 71, 80], ["C12", "TEST", 20, 23], ["model membranes", "TREATMENT", 45, 60], ["DPPC/chol", "TREATMENT", 71, 80], ["C12", "ANATOMY", 32, 35], ["DLA", "ANATOMY", 36, 39]]], ["Obtained results were compared with those for analogical compounds with single head groups, e.g. with also synthesised by us N-alkanoyl-Nmethyllactitolamines (C n MeLA) and common sugar-based surfactants C 12 Gluc and MEGA-10.", [["head", "ANATOMY", 79, 83], ["N-alkanoyl-Nmethyllactitolamines", "CHEMICAL", 125, 157], ["N-alkanoyl-Nmethyllactitolamines", "CHEMICAL", 125, 157], ["C n MeLA", "CHEMICAL", 159, 167], ["sugar", "CHEMICAL", 180, 185], ["N-alkanoyl-Nmethyllactitolamines", "SIMPLE_CHEMICAL", 125, 157], ["C n MeLA", "SIMPLE_CHEMICAL", 159, 167], ["sugar-based surfactants C 12 Gluc", "SIMPLE_CHEMICAL", 180, 213], ["MEGA-10", "SIMPLE_CHEMICAL", 218, 225], ["analogical compounds", "PROBLEM", 46, 66], ["alkanoyl", "TREATMENT", 127, 135], ["Nmethyllactitolamines (C n MeLA)", "TREATMENT", 136, 168], ["common sugar", "TEST", 173, 185], ["surfactants", "TEST", 192, 203], ["Gluc", "TEST", 209, 213], ["MEGA", "TEST", 218, 222]]], ["Enfuvirtide (T-20) was the first HIV-1 fusion inhibitor peptide approved for clinical use.", [["Enfuvirtide", "CHEMICAL", 0, 11], ["T-20", "CHEMICAL", 13, 17], ["Enfuvirtide", "CHEMICAL", 0, 11], ["Enfuvirtide", "SIMPLE_CHEMICAL", 0, 11], ["T-20", "GENE_OR_GENE_PRODUCT", 13, 17], ["HIV-1", "ORGANISM", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["Enfuvirtide", "TREATMENT", 0, 11], ["the first HIV-1 fusion inhibitor peptide", "TREATMENT", 23, 63]]], ["T-1249 is an inhibitor still under evaluation.", [["T-1249", "CHEMICAL", 0, 6], ["T-1249", "CHEMICAL", 0, 6], ["T-1249", "GENE_OR_GENE_PRODUCT", 0, 6], ["T-1249", "SPECIES", 0, 6], ["T", "TEST", 0, 1], ["an inhibitor", "TREATMENT", 10, 22], ["evaluation", "TEST", 35, 45]]], ["Previous studies, based on tryptophan intrinsic fluorescence, showed that the peptides interact differentially with membrane model systems (LUV) with different lipid compositions.", [["membrane", "ANATOMY", 116, 124], ["tryptophan", "CHEMICAL", 27, 37], ["tryptophan", "CHEMICAL", 27, 37], ["tryptophan", "SIMPLE_CHEMICAL", 27, 37], ["membrane", "CELLULAR_COMPONENT", 116, 124], ["lipid", "SIMPLE_CHEMICAL", 160, 165], ["Previous studies", "TEST", 0, 16], ["tryptophan intrinsic fluorescence", "TEST", 27, 60], ["different lipid compositions", "TREATMENT", 150, 178], ["lipid compositions", "OBSERVATION", 160, 178]]], ["Studies with human blood cells were necessary to further establish the role of membranes on these peptides mode of action.", [["blood cells", "ANATOMY", 19, 30], ["membranes", "ANATOMY", 79, 88], ["human", "ORGANISM", 13, 18], ["blood cells", "CELL", 19, 30], ["membranes", "CELLULAR_COMPONENT", 79, 88], ["human blood cells", "CELL_TYPE", 13, 30], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["human blood cells", "TEST", 13, 30], ["these peptides", "TREATMENT", 92, 106]]], ["An experimental strategy was applied based on the membrane dipole potential, as measured by the fluorescent probe di-8-ANEPPS.", [["membrane", "ANATOMY", 50, 58], ["di-8-ANEPPS", "CHEMICAL", 114, 125], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["An experimental strategy", "TREATMENT", 0, 24]]], ["Human erythrocytes and peripheral blood mononuclear cells (PBMC) were successfully labeled.", [["erythrocytes", "ANATOMY", 6, 18], ["peripheral blood mononuclear cells", "ANATOMY", 23, 57], ["PBMC", "ANATOMY", 59, 63], ["Human", "ORGANISM", 0, 5], ["erythrocytes", "CELL", 6, 18], ["peripheral blood mononuclear cells", "CELL", 23, 57], ["PBMC", "CELL", 59, 63], ["Human erythrocytes", "CELL_TYPE", 0, 18], ["peripheral blood mononuclear cells", "CELL_TYPE", 23, 57], ["PBMC", "CELL_TYPE", 59, 63], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human erythrocytes", "TEST", 0, 18], ["peripheral blood mononuclear cells (PBMC)", "TREATMENT", 23, 64], ["peripheral", "ANATOMY_MODIFIER", 23, 33], ["blood", "ANATOMY", 34, 39], ["mononuclear cells", "OBSERVATION", 40, 57]]], ["For both systems, a fusion inhibitor concentration-dependent decrease on di-8-ANEPPS fluorescence excitation ratio (a measure of the spectral shift and dipole potential) was observed.", [["di-8-ANEPPS", "SIMPLE_CHEMICAL", 73, 84], ["ANEPPS", "PROTEIN", 78, 84], ["a fusion inhibitor concentration", "TREATMENT", 18, 50], ["dependent decrease", "PROBLEM", 51, 69], ["fusion", "OBSERVATION", 20, 26], ["dependent", "OBSERVATION_MODIFIER", 51, 60], ["decrease", "OBSERVATION_MODIFIER", 61, 69]]], ["The quantitative analysis of these variations indicated that T-1249 has an approximately ten-fold higher affinity towards erythrocyte and PBMC, when compared with enfuvirtide.", [["erythrocyte", "ANATOMY", 122, 133], ["PBMC", "ANATOMY", 138, 142], ["T-1249", "CHEMICAL", 61, 67], ["enfuvirtide", "CHEMICAL", 163, 174], ["T-1249", "CHEMICAL", 61, 67], ["enfuvirtide", "CHEMICAL", 163, 174], ["T-1249", "GENE_OR_GENE_PRODUCT", 61, 67], ["erythrocyte", "CELL", 122, 133], ["PBMC", "CELL", 138, 142], ["enfuvirtide", "SIMPLE_CHEMICAL", 163, 174], ["erythrocyte", "CELL_TYPE", 122, 133], ["PBMC", "CELL_TYPE", 138, 142], ["T-1249", "SPECIES", 61, 67], ["The quantitative analysis", "TEST", 0, 25], ["these variations", "TEST", 29, 45], ["T", "TEST", 61, 62], ["an approximately ten-fold higher affinity", "PROBLEM", 72, 113], ["PBMC", "TEST", 138, 142], ["enfuvirtide", "TREATMENT", 163, 174]]], ["This is in agreement with the previously known adsorption of T-1249 on cholesterol-rich membrane domains and with its higher partition constants.", [["membrane", "ANATOMY", 88, 96], ["T-1249", "CHEMICAL", 61, 67], ["cholesterol", "CHEMICAL", 71, 82], ["T-1249", "CHEMICAL", 61, 67], ["cholesterol", "CHEMICAL", 71, 82], ["T-1249", "SIMPLE_CHEMICAL", 61, 67], ["cholesterol", "SIMPLE_CHEMICAL", 71, 82], ["cholesterol-rich membrane domains", "PROTEIN", 71, 104], ["cholesterol-rich membrane domains", "TREATMENT", 71, 104]]], ["HIV associates with erythrocytes in vivo, which can constitute a route to deliver peptide to the viral membranes (also rich in cholesterol).", [["erythrocytes", "ANATOMY", 20, 32], ["membranes", "ANATOMY", 103, 112], ["cholesterol", "CHEMICAL", 127, 138], ["cholesterol", "CHEMICAL", 127, 138], ["HIV", "ORGANISM", 0, 3], ["erythrocytes", "CELL", 20, 32], ["cholesterol", "SIMPLE_CHEMICAL", 127, 138], ["erythrocytes", "CELL_TYPE", 20, 32], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3], ["erythrocytes in vivo", "PROBLEM", 20, 40], ["a route to deliver peptide", "TREATMENT", 63, 89], ["viral membranes", "OBSERVATION", 97, 112]]], ["Lymphocyte membranes can concentrate and accelerate the drug interactions with its molecular target, gp41 in its exposed conformation.", [["Lymphocyte membranes", "ANATOMY", 0, 20], ["Lymphocyte membranes", "CELLULAR_COMPONENT", 0, 20], ["gp41", "GENE_OR_GENE_PRODUCT", 101, 105], ["gp41", "PROTEIN", 101, 105], ["Lymphocyte membranes", "PROBLEM", 0, 20]]], ["Oxidation of low density lipoprotein (LDL) is known to be a key step in atherogenesis, leading to inflammation, proliferation and apoptosis of cells of the arterial wall.", [["cells", "ANATOMY", 143, 148], ["arterial wall", "ANATOMY", 156, 169], ["atherogenesis", "DISEASE", 72, 85], ["inflammation", "DISEASE", 98, 110], ["low density lipoprotein", "GENE_OR_GENE_PRODUCT", 13, 36], ["LDL", "SIMPLE_CHEMICAL", 38, 41], ["cells", "CELL", 143, 148], ["arterial wall", "MULTI-TISSUE_STRUCTURE", 156, 169], ["low density lipoprotein", "PROTEIN", 13, 36], ["LDL", "PROTEIN", 38, 41], ["Oxidation of low density lipoprotein (LDL)", "PROBLEM", 0, 42], ["a key step in atherogenesis", "PROBLEM", 58, 85], ["inflammation", "PROBLEM", 98, 110], ["proliferation", "PROBLEM", 112, 125], ["apoptosis of cells of the arterial wall", "PROBLEM", 130, 169], ["low density", "OBSERVATION_MODIFIER", 13, 24], ["lipoprotein", "OBSERVATION", 25, 36], ["known to be", "UNCERTAINTY", 46, 57], ["atherogenesis", "OBSERVATION", 72, 85], ["leading to", "UNCERTAINTY", 87, 97], ["inflammation", "OBSERVATION", 98, 110], ["proliferation", "OBSERVATION_MODIFIER", 112, 125], ["apoptosis", "OBSERVATION_MODIFIER", 130, 139], ["arterial", "ANATOMY", 156, 164], ["wall", "ANATOMY_MODIFIER", 165, 169]]], ["These effects are largely exerted by oxidatively fragmented phospholipids, which are highly exchangeable between cells, tissues and lipoproteins.", [["cells", "ANATOMY", 113, 118], ["tissues", "ANATOMY", 120, 127], ["phospholipids", "SIMPLE_CHEMICAL", 60, 73], ["cells", "CELL", 113, 118], ["tissues", "TISSUE", 120, 127], ["lipoproteins", "PROTEIN", 132, 144], ["oxidatively fragmented phospholipids", "PROBLEM", 37, 73], ["oxidatively", "OBSERVATION_MODIFIER", 37, 48], ["fragmented", "OBSERVATION_MODIFIER", 49, 59], ["phospholipids", "OBSERVATION_MODIFIER", 60, 73], ["highly", "OBSERVATION_MODIFIER", 85, 91], ["exchangeable", "OBSERVATION_MODIFIER", 92, 104], ["lipoproteins", "OBSERVATION_MODIFIER", 132, 144]]], ["In particular, PGPC has been identified in minimally modified LDL and has been reported to elicit a wide range of pathophysiological responses in vascular cells, e.g. the activation of apoptotic signaling pathways.", [["vascular cells", "ANATOMY", 146, 160], ["PGPC", "CHEMICAL", 15, 19], ["PGPC", "GENE_OR_GENE_PRODUCT", 15, 19], ["LDL", "GENE_OR_GENE_PRODUCT", 62, 65], ["vascular cells", "CELL", 146, 160], ["PGPC", "PROTEIN", 15, 19], ["LDL", "PROTEIN", 62, 65], ["vascular cells", "CELL_TYPE", 146, 160], ["PGPC", "TEST", 15, 19], ["pathophysiological responses in vascular cells", "PROBLEM", 114, 160], ["vascular cells", "ANATOMY", 146, 160]]], ["We investigated here the behavior of the fluorescent oxidized PGPE-Alexa647 compared to DHPE-Bodipy in artificial supported lipid bilayers with different cholesterol contents.", [["lipid bilayers", "ANATOMY", 124, 138], ["PGPE", "CHEMICAL", 62, 66], ["Alexa647", "CHEMICAL", 67, 75], ["DHPE-Bodipy", "CHEMICAL", 88, 99], ["cholesterol", "CHEMICAL", 154, 165], ["PGPE-Alexa647", "CHEMICAL", 62, 75], ["DHPE", "CHEMICAL", 88, 92], ["cholesterol", "CHEMICAL", 154, 165], ["PGPE-Alexa647", "SIMPLE_CHEMICAL", 62, 75], ["DHPE-Bodipy", "SIMPLE_CHEMICAL", 88, 99], ["lipid bilayers", "SIMPLE_CHEMICAL", 124, 138], ["cholesterol", "SIMPLE_CHEMICAL", 154, 165], ["the fluorescent oxidized PGPE", "TEST", 37, 66], ["DHPE", "TEST", 88, 92], ["artificial supported lipid bilayers", "TREATMENT", 103, 138], ["lipid bilayers", "OBSERVATION", 124, 138], ["cholesterol contents", "OBSERVATION", 154, 174]]], ["The two labeled lipids differ in the type of membrane insertion: while DHPE-Bodipy is anchored to the membrane via two fatty acids, PGPE is incorporated with only one fatty acid.", [["membrane", "ANATOMY", 45, 53], ["membrane", "ANATOMY", 102, 110], ["DHPE", "CHEMICAL", 71, 75], ["fatty acids", "CHEMICAL", 119, 130], ["PGPE", "CHEMICAL", 132, 136], ["DHPE-Bodipy", "CHEMICAL", 71, 82], ["fatty acids", "CHEMICAL", 119, 130], ["PGPE", "CHEMICAL", 132, 136], ["fatty acid", "CHEMICAL", 167, 177], ["lipids", "SIMPLE_CHEMICAL", 16, 22], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["DHPE", "SIMPLE_CHEMICAL", 71, 75], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["fatty acids", "SIMPLE_CHEMICAL", 119, 130], ["PGPE", "SIMPLE_CHEMICAL", 132, 136], ["fatty acid", "SIMPLE_CHEMICAL", 167, 177], ["PGPE", "PROTEIN", 132, 136], ["two fatty acids", "TEST", 115, 130], ["PGPE", "TEST", 132, 136], ["fatty acids", "OBSERVATION", 119, 130], ["fatty acid", "OBSERVATION", 167, 177]]], ["The second chain is an acyl fragment in sn-2 position, which represents the oxidation product of an unsaturated acyl chain.", [["acyl", "CHEMICAL", 23, 27], ["acyl", "CHEMICAL", 23, 27], ["unsaturated acyl", "CHEMICAL", 100, 116], ["sn-2 position", "PROTEIN", 40, 53], ["an acyl fragment", "PROBLEM", 20, 36], ["an unsaturated acyl chain", "PROBLEM", 97, 122], ["second", "OBSERVATION_MODIFIER", 4, 10], ["chain", "OBSERVATION_MODIFIER", 11, 16], ["acyl fragment", "OBSERVATION", 23, 36], ["sn-2 position", "OBSERVATION_MODIFIER", 40, 53], ["oxidation product", "OBSERVATION", 76, 93], ["unsaturated", "OBSERVATION_MODIFIER", 100, 111], ["acyl chain", "OBSERVATION", 112, 122]]], ["With increasing cholesterol content we observed a decrease in the diffusion coefficient for both lipids.", [["cholesterol", "CHEMICAL", 16, 27], ["cholesterol", "CHEMICAL", 16, 27], ["cholesterol", "SIMPLE_CHEMICAL", 16, 27], ["increasing cholesterol content", "PROBLEM", 5, 35], ["a decrease in the diffusion coefficient", "PROBLEM", 48, 87], ["both lipids", "TREATMENT", 92, 103], ["increasing", "OBSERVATION_MODIFIER", 5, 15], ["cholesterol content", "OBSERVATION", 16, 35], ["decrease", "OBSERVATION_MODIFIER", 50, 58]]], ["Interestingly, the diffusion of the oxidized lipid was reduced in a higher degree compared to that of the non-oxidized lipid.", [["lipid", "SIMPLE_CHEMICAL", 119, 124], ["the non-oxidized lipid", "TREATMENT", 102, 124], ["oxidized lipid", "OBSERVATION", 36, 50], ["reduced", "OBSERVATION_MODIFIER", 55, 62], ["higher degree", "OBSERVATION_MODIFIER", 68, 81]]], ["The calculated ratios of the diffusion constants of PGPE-Alexa647 and DHPE-Bodipy suggest a different type of interaction with cholesterol.", [["PGPE", "CHEMICAL", 52, 56], ["Alexa647", "CHEMICAL", 57, 65], ["DHPE", "CHEMICAL", 70, 74], ["cholesterol", "CHEMICAL", 127, 138], ["PGPE-Alexa647", "CHEMICAL", 52, 65], ["DHPE-Bodipy", "CHEMICAL", 70, 81], ["cholesterol", "CHEMICAL", 127, 138], ["PGPE-Alexa647", "SIMPLE_CHEMICAL", 52, 65], ["DHPE-Bodipy", "SIMPLE_CHEMICAL", 70, 81], ["cholesterol", "SIMPLE_CHEMICAL", 127, 138], ["The calculated ratios", "TEST", 0, 21], ["PGPE", "TEST", 52, 56], ["DHPE", "TEST", 70, 74], ["ratios", "OBSERVATION_MODIFIER", 15, 21], ["different type", "OBSERVATION_MODIFIER", 92, 106]]], ["Membrane proteins account for a third of all proteins encoded for by the human genome, and play a vital role in a number of cellular processes.", [["Membrane", "ANATOMY", 0, 8], ["cellular", "ANATOMY", 124, 132], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["human", "ORGANISM", 73, 78], ["cellular", "CELL", 124, 132], ["Membrane proteins", "PROTEIN", 0, 17], ["human genome", "DNA", 73, 85], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["Membrane proteins", "TEST", 0, 17], ["cellular processes", "OBSERVATION", 124, 142]]], ["Few membrane protein structures have been determined to date in comparison to soluble proteins.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["soluble proteins", "PROTEIN", 78, 94], ["Few membrane protein structures", "PROBLEM", 0, 31], ["membrane", "OBSERVATION_MODIFIER", 4, 12], ["protein", "OBSERVATION", 13, 20]]], ["This discrepancy is due to experimental difficulties in preparing membrane protein samples for structural analysis.", [["membrane protein samples", "ANATOMY", 66, 90], ["membrane", "CELLULAR_COMPONENT", 66, 74], ["experimental difficulties in preparing membrane protein samples", "PROBLEM", 27, 90], ["structural analysis", "TEST", 95, 114]]], ["Traditional techniques for studying membrane proteins by X-ray crystallography or solution NMR use detergent solubilised proteins which can differ from their native confirmations.", [["membrane", "ANATOMY", 36, 44], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["membrane proteins", "PROTEIN", 36, 53], ["detergent solubilised proteins", "PROTEIN", 99, 129], ["Traditional techniques", "TREATMENT", 0, 22], ["studying membrane proteins", "TEST", 27, 53], ["X-ray crystallography", "TEST", 57, 78], ["detergent solubilised proteins", "TREATMENT", 99, 129]]], ["Solid-state NMR allows the study of transmembrane proteins in lipid bilayers, representing a more native like environment in which to obtain biologically relevant structural information.", [["transmembrane", "ANATOMY", 36, 49], ["lipid bilayers", "ANATOMY", 62, 76], ["transmembrane", "CELLULAR_COMPONENT", 36, 49], ["lipid bilayers", "CELLULAR_COMPONENT", 62, 76], ["transmembrane proteins", "PROTEIN", 36, 58], ["the study", "TEST", 23, 32], ["transmembrane proteins in lipid bilayers", "PROBLEM", 36, 76]]], ["We have been working on the development of reliable methods for reconstitution of transmembrane peptide into liposomes using Glycophorin A as a model TM protein.Development of Solid State NMR Methods forUsing reconstitution methods based on the removal of detergent by bio-beads, we have used Electron Microscopy to screen the ideal conditions for insertion of GpA into liposomes in preparation for MAS NMR experiments.", [["transmembrane", "ANATOMY", 82, 95], ["Glycophorin A", "CHEMICAL", 125, 138], ["GpA", "CHEMICAL", 361, 364], ["GpA", "CHEMICAL", 361, 364], ["liposomes", "SIMPLE_CHEMICAL", 109, 118], ["Glycophorin A", "GENE_OR_GENE_PRODUCT", 125, 138], ["TM", "GENE_OR_GENE_PRODUCT", 150, 152], ["GpA", "SIMPLE_CHEMICAL", 361, 364], ["liposomes", "SIMPLE_CHEMICAL", 370, 379], ["Glycophorin A", "PROTEIN", 125, 138], ["TM protein", "PROTEIN", 150, 160], ["GpA", "PROTEIN", 361, 364], ["reconstitution of transmembrane peptide into liposomes", "TREATMENT", 64, 118], ["Glycophorin A", "TREATMENT", 125, 138], ["a model TM protein", "TREATMENT", 142, 160], ["reconstitution methods", "TREATMENT", 209, 231], ["the removal of detergent", "TREATMENT", 241, 265], ["Electron Microscopy", "TEST", 293, 312], ["insertion of GpA into liposomes", "TREATMENT", 348, 379], ["MAS NMR experiments", "TEST", 399, 418], ["Solid", "OBSERVATION_MODIFIER", 176, 181]]], ["EM has allowed us to identify conditions favourable for insertion of peptide into lipid vesicles and those that result in aggregation.", [["lipid vesicles", "ANATOMY", 82, 96], ["lipid vesicles", "CELLULAR_COMPONENT", 82, 96], ["insertion of peptide into lipid vesicles", "TREATMENT", 56, 96], ["aggregation", "PROBLEM", 122, 133], ["aggregation", "OBSERVATION", 122, 133]]], ["In order to confirm the secondary structure and insertion of GpA into lipid vesicles, techniques such as CD, OCD, FTIR and DLS have been used to provide quantitative information in addition to the visual results from EM.", [["lipid vesicles", "ANATOMY", 70, 84], ["OCD", "DISEASE", 109, 112], ["GpA", "SIMPLE_CHEMICAL", 61, 64], ["lipid vesicles", "CELLULAR_COMPONENT", 70, 84], ["GpA", "PROTEIN", 61, 64], ["insertion of GpA into lipid vesicles", "TREATMENT", 48, 84], ["OCD", "PROBLEM", 109, 112], ["secondary structure", "OBSERVATION", 24, 43], ["lipid vesicles", "ANATOMY", 70, 84]]], ["Nonesterified fatty acids regulate a broad spectrum of metabolic activities and are involved in many physiological, pathological and/or pharmacological processes in living cells.", [["cells", "ANATOMY", 172, 177], ["fatty acids", "CHEMICAL", 14, 25], ["Nonesterified fatty acids", "CHEMICAL", 0, 25], ["Nonesterified fatty acids", "SIMPLE_CHEMICAL", 0, 25], ["cells", "CELL", 172, 177], ["living cells", "CELL_TYPE", 165, 177], ["Nonesterified fatty acids", "TEST", 0, 25], ["many physiological, pathological and/or pharmacological processes in living cells", "PROBLEM", 96, 177], ["fatty acids", "OBSERVATION", 14, 25], ["metabolic activities", "OBSERVATION", 55, 75]]], ["They spontaneously transfer between donors and acceptors such as fatty acid binding proteins and lipid membranes.", [["lipid membranes", "ANATOMY", 97, 112], ["fatty acid", "CHEMICAL", 65, 75], ["fatty acid", "CHEMICAL", 65, 75], ["fatty acid binding proteins", "GENE_OR_GENE_PRODUCT", 65, 92], ["lipid membranes", "CELLULAR_COMPONENT", 97, 112], ["fatty acid binding proteins", "PROTEIN", 65, 92], ["donors and acceptors", "TREATMENT", 36, 56], ["fatty acid binding proteins", "PROBLEM", 65, 92], ["lipid membranes", "TREATMENT", 97, 112], ["lipid membranes", "OBSERVATION", 97, 112]]], ["We focus on protein-lipid dispersions of human serum albumin (HSA) and sterically stabilized liposomes (SSL) composed of DPPC and appropriate amount of PEG:2000-DPPE in which stearic acids (SA) are inserted either in the protein or in the SSL.", [["serum", "ANATOMY", 47, 52], ["DPPC", "CHEMICAL", 121, 125], ["PEG:2000-DPPE", "CHEMICAL", 152, 165], ["stearic acids", "CHEMICAL", 175, 188], ["SA", "CHEMICAL", 190, 192], ["DPPC", "CHEMICAL", 121, 125], ["PEG:2000-DPPE", "CHEMICAL", 152, 165], ["stearic acids", "CHEMICAL", 175, 188], ["human", "ORGANISM", 41, 46], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["albumin", "SIMPLE_CHEMICAL", 53, 60], ["HSA", "SIMPLE_CHEMICAL", 62, 65], ["sterically stabilized liposomes", "SIMPLE_CHEMICAL", 71, 102], ["SSL", "SIMPLE_CHEMICAL", 104, 107], ["DPPC", "SIMPLE_CHEMICAL", 121, 125], ["PEG", "SIMPLE_CHEMICAL", 152, 155], ["2000-DPPE", "SIMPLE_CHEMICAL", 156, 165], ["stearic acids", "SIMPLE_CHEMICAL", 175, 188], ["SA", "SIMPLE_CHEMICAL", 190, 192], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["protein-lipid dispersions", "TREATMENT", 12, 37], ["human serum albumin", "TEST", 41, 60], ["sterically stabilized liposomes (SSL)", "TREATMENT", 71, 108], ["DPPC", "TREATMENT", 121, 125], ["PEG", "TREATMENT", 152, 155], ["DPPE in which stearic acids (SA)", "TREATMENT", 161, 193], ["SSL", "ANATOMY", 239, 242]]], ["Exploiting the fact that HSA has a single tryptophan residue and that the intrinsic Trp-fluorescence emission signal is quenced by the presence of SA, the kinetics of SA transport between HSA and PEG:2000-grafted DPPC membranes is studied by means of fluorescence.", [["DPPC membranes", "ANATOMY", 213, 227], ["tryptophan", "CHEMICAL", 42, 52], ["Trp", "CHEMICAL", 84, 87], ["SA", "CHEMICAL", 167, 169], ["PEG", "CHEMICAL", 196, 199], ["DPPC", "CHEMICAL", 213, 217], ["tryptophan", "CHEMICAL", 42, 52], ["Trp", "CHEMICAL", 84, 87], ["PEG", "CHEMICAL", 196, 199], ["DPPC", "CHEMICAL", 213, 217], ["HSA", "GENE_OR_GENE_PRODUCT", 25, 28], ["tryptophan", "AMINO_ACID", 42, 52], ["SA", "SIMPLE_CHEMICAL", 167, 169], ["HSA", "SIMPLE_CHEMICAL", 188, 191], ["PEG:2000-grafted DPPC membranes", "SIMPLE_CHEMICAL", 196, 227], ["HSA", "PROTEIN", 25, 28], ["a single tryptophan residue", "PROBLEM", 33, 60], ["the intrinsic Trp-fluorescence emission signal", "TEST", 70, 116], ["SA", "PROBLEM", 147, 149], ["SA transport between HSA and PEG", "TREATMENT", 167, 199], ["grafted DPPC membranes", "TREATMENT", 205, 227]]], ["It is found that the transfer of SA between HSA and SSL is a first-order process and the kinetics of transfer depends on the type of donor and acceptor matrix, on the temperature (i.e., on the physical state of the lipid bilayers), and on the grafting density of the PEG-lipids at the protein/lipid interface.", [["PEG-lipids", "CHEMICAL", 267, 277], ["PEG", "CHEMICAL", 267, 270], ["SA", "SIMPLE_CHEMICAL", 33, 35], ["HSA", "SIMPLE_CHEMICAL", 44, 47], ["matrix", "CELLULAR_COMPONENT", 152, 158], ["PEG-lipids", "SIMPLE_CHEMICAL", 267, 277], ["SA between HSA", "TREATMENT", 33, 47], ["donor and acceptor matrix", "TREATMENT", 133, 158], ["the grafting density", "TREATMENT", 239, 259], ["the PEG-lipids at the protein/lipid interface", "TREATMENT", 263, 308], ["grafting", "OBSERVATION", 243, 251], ["PEG", "OBSERVATION", 267, 270], ["lipid interface", "OBSERVATION", 293, 308]]], ["Indeed, in the absence of polymer-lipids, the rate of transfer increases with temperature in both directions of transfer and it is faster for the passage from DPPC bilayers to HSA.", [["DPPC", "CHEMICAL", 159, 163], ["DPPC", "CHEMICAL", 159, 163], ["DPPC bilayers", "SIMPLE_CHEMICAL", 159, 172], ["HSA", "SIMPLE_CHEMICAL", 176, 179], ["polymer-lipids", "TREATMENT", 26, 40], ["the passage from DPPC bilayers", "TREATMENT", 142, 172]]], ["The presence of polymer-lipids reduces the rate of transfer both in the mushroom and in the brush regime of the polymer-chains, especially for lipid membranes in the fluid phase.Curvature of pore-suspending membranes influenced by Shiga ToxinA.", [["mushroom", "ANATOMY", 72, 80], ["lipid membranes", "ANATOMY", 143, 158], ["pore-suspending membranes", "ANATOMY", 191, 216], ["polymer-lipids", "CHEMICAL", 16, 30], ["Shiga ToxinA", "CHEMICAL", 231, 243], ["polymer-lipids", "SIMPLE_CHEMICAL", 16, 30], ["lipid membranes", "CELLULAR_COMPONENT", 143, 158], ["Shiga ToxinA", "GENE_OR_GENE_PRODUCT", 231, 243], ["Shiga ToxinA", "PROTEIN", 231, 243], ["polymer-lipids", "TREATMENT", 16, 30], ["the polymer-chains", "TREATMENT", 108, 126], ["lipid membranes in the fluid phase", "TEST", 143, 177], ["Curvature of pore-suspending membranes", "TREATMENT", 178, 216], ["mushroom", "ANATOMY", 72, 80], ["fluid phase", "OBSERVATION", 166, 177], ["Shiga ToxinA", "OBSERVATION", 231, 243]]], ["Orth 1 , W. R\u00f6mer 2 , L. Johannes 2 , C. Steinem 1 1 Institute for Organic and Biomolecular Chemistry, University of Goettingen, Germany, 2 Laboratoire Trafic et Signalisation, Institut Curie, Paris, France Shiga Toxin (STx) from Shigella dysenteriae is an AB 5 -class bacterial toxin.", [["Shiga Toxin", "CHEMICAL", 207, 218], ["STx", "CHEMICAL", 220, 223], ["Shiga Toxin", "SIMPLE_CHEMICAL", 207, 218], ["Shigella dysenteriae", "ORGANISM", 230, 250], ["Shigella dysenteriae", "SPECIES", 230, 250], ["Shigella dysenteriae", "SPECIES", 230, 250], ["Biomolecular Chemistry", "TEST", 79, 101], ["France Shiga Toxin (STx", "TEST", 200, 223], ["Shigella dysenteriae", "PROBLEM", 230, 250]]], ["Infections with STx lead to the haemolyticuraemic syndrome, which is known to be a major cause for renal failure at an early age.", [["renal", "ANATOMY", 99, 104], ["Infections", "DISEASE", 0, 10], ["STx", "DISEASE", 16, 19], ["haemolyticuraemic syndrome", "DISEASE", 32, 58], ["renal failure", "DISEASE", 99, 112], ["renal", "ORGAN", 99, 104], ["Infections", "PROBLEM", 0, 10], ["STx", "PROBLEM", 16, 19], ["the haemolyticuraemic syndrome", "PROBLEM", 28, 58], ["renal failure", "PROBLEM", 99, 112], ["haemolyticuraemic syndrome", "OBSERVATION", 32, 58], ["renal", "ANATOMY", 99, 104], ["failure", "OBSERVATION", 105, 112]]], ["The interaction of the homopentameric B-subunit (STxB), which is responsible for binding and intracellular transport of the holotoxin, with its cellular receptor, the glycosphingolipid Gb 3 , is the first step for endocytosis of the toxin.", [["intracellular", "ANATOMY", 93, 106], ["cellular", "ANATOMY", 144, 152], ["homopentameric B-subunit", "GENE_OR_GENE_PRODUCT", 23, 47], ["STxB", "GENE_OR_GENE_PRODUCT", 49, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 93, 106], ["holotoxin", "GENE_OR_GENE_PRODUCT", 124, 133], ["cellular", "CELL", 144, 152], ["glycosphingolipid Gb 3", "GENE_OR_GENE_PRODUCT", 167, 189], ["homopentameric B-subunit", "PROTEIN", 23, 47], ["STxB", "PROTEIN", 49, 53], ["holotoxin", "PROTEIN", 124, 133], ["cellular receptor", "PROTEIN", 144, 161], ["glycosphingolipid Gb 3", "PROTEIN", 167, 189], ["toxin", "PROTEIN", 233, 238], ["the holotoxin", "TREATMENT", 120, 133], ["the glycosphingolipid Gb", "TEST", 163, 187], ["the toxin", "PROBLEM", 229, 238], ["glycosphingolipid Gb", "ANATOMY", 167, 187]]], ["One B-subunit can bind up to 15 Gb 3 -molecules to form STxB-Gb 3 -clusters causing negative curvature of a membrane.", [["membrane", "ANATOMY", 108, 116], ["B-subunit", "GENE_OR_GENE_PRODUCT", 4, 13], ["membrane", "CELLULAR_COMPONENT", 108, 116], ["B-subunit", "PROTEIN", 4, 13], ["STxB", "PROTEIN", 56, 60], ["STxB", "TEST", 56, 60], ["Gb", "ANATOMY", 61, 63], ["negative curvature", "OBSERVATION", 84, 102]]], ["The binding of STxB to giant unilamellar vesicles, composed of DOPC, cholesterol and Gb 3 induces tubular membrane invaginations, which were also found in experiments with energy-depleted HeLa-cells.", [["giant unilamellar vesicles", "ANATOMY", 23, 49], ["tubular membrane invaginations", "ANATOMY", 98, 128], ["HeLa-cells", "ANATOMY", 188, 198], ["DOPC", "CHEMICAL", 63, 67], ["cholesterol", "CHEMICAL", 69, 80], ["DOPC", "CHEMICAL", 63, 67], ["cholesterol", "CHEMICAL", 69, 80], ["STxB", "GENE_OR_GENE_PRODUCT", 15, 19], ["unilamellar vesicles", "CELLULAR_COMPONENT", 29, 49], ["DOPC", "SIMPLE_CHEMICAL", 63, 67], ["cholesterol", "SIMPLE_CHEMICAL", 69, 80], ["Gb 3", "GENE_OR_GENE_PRODUCT", 85, 89], ["tubular membrane invaginations", "CELLULAR_COMPONENT", 98, 128], ["HeLa-cells", "CELL", 188, 198], ["STxB", "PROTEIN", 15, 19], ["HeLa-cells", "CELL_TYPE", 188, 198], ["giant unilamellar vesicles", "PROBLEM", 23, 49], ["DOPC", "TEST", 63, 67], ["cholesterol", "TEST", 69, 80], ["tubular membrane invaginations", "PROBLEM", 98, 128], ["giant", "OBSERVATION_MODIFIER", 23, 28], ["unilamellar vesicles", "OBSERVATION", 29, 49], ["Gb", "ANATOMY", 85, 87], ["tubular membrane invaginations", "OBSERVATION", 98, 128], ["depleted", "OBSERVATION", 179, 187]]], ["In recent studies, protein and lipid reorganization processes after attaching STxB to solid supported membranes, composed of DOPC/sphingomyelin/cholesterol/Gb 3 have been investigated.", [["membranes", "ANATOMY", 102, 111], ["STxB", "CHEMICAL", 78, 82], ["DOPC", "CHEMICAL", 125, 129], ["sphingomyelin", "CHEMICAL", 130, 143], ["cholesterol", "CHEMICAL", 144, 155], ["STxB", "CHEMICAL", 78, 82], ["DOPC", "CHEMICAL", 125, 129], ["sphingomyelin", "CHEMICAL", 130, 143], ["cholesterol", "CHEMICAL", 144, 155], ["lipid", "SIMPLE_CHEMICAL", 31, 36], ["STxB", "SIMPLE_CHEMICAL", 78, 82], ["membranes", "CELLULAR_COMPONENT", 102, 111], ["DOPC", "SIMPLE_CHEMICAL", 125, 129], ["sphingomyelin", "SIMPLE_CHEMICAL", 130, 143], ["cholesterol", "SIMPLE_CHEMICAL", 144, 155], ["Gb 3", "GENE_OR_GENE_PRODUCT", 156, 160], ["STxB", "PROTEIN", 78, 82], ["recent studies", "TEST", 3, 17], ["lipid reorganization processes", "PROBLEM", 31, 61], ["attaching STxB to solid supported membranes", "PROBLEM", 68, 111], ["DOPC/sphingomyelin/cholesterol/Gb", "TREATMENT", 125, 158], ["lipid reorganization", "OBSERVATION", 31, 51], ["Gb", "ANATOMY", 156, 158]]], ["The compaction of Gb 3 -molecules led to an additional STxB-Gb 3 -enriched phase, which was also observed in lipid monolayers at the air/water interface.", [["lipid monolayers", "ANATOMY", 109, 125], ["lipid monolayers", "CELL", 109, 125], ["STxB", "PROTEIN", 55, 59], ["an additional STxB", "TEST", 41, 59], ["Gb", "ANATOMY", 18, 20], ["Gb 3 -enriched phase", "OBSERVATION_MODIFIER", 60, 80], ["lipid monolayers", "OBSERVATION", 109, 125], ["air", "ANATOMY", 133, 136], ["water interface", "OBSERVATION", 137, 152]]], ["In this study, the influence of STxB on model membranes will be investigated combining the advantages of free-standing lipid membranes with those of SSMs.", [["membranes", "ANATOMY", 46, 55], ["lipid membranes", "ANATOMY", 119, 134], ["STxB", "CHEMICAL", 32, 36], ["STxB", "CHEMICAL", 32, 36], ["STxB", "SIMPLE_CHEMICAL", 32, 36], ["membranes", "CELLULAR_COMPONENT", 46, 55], ["lipid membranes", "MULTI-TISSUE_STRUCTURE", 119, 134], ["STxB", "PROTEIN", 32, 36], ["this study", "TEST", 3, 13], ["STxB on model membranes", "TREATMENT", 32, 55], ["free-standing lipid membranes", "TREATMENT", 105, 134]]], ["The impact of STxB on pore-suspending membranes will be followed by confocal laser scanning mi croscopy and atomic force microscopy.Characterization of phosphatidylcholine chlorohydrins and their effects on the erythrocyteA.", [["pore-suspending membranes", "ANATOMY", 22, 47], ["STxB", "CHEMICAL", 14, 18], ["phosphatidylcholine chlorohydrins", "CHEMICAL", 152, 185], ["phosphatidylcholine chlorohydrins", "CHEMICAL", 152, 185], ["STxB", "SIMPLE_CHEMICAL", 14, 18], ["phosphatidylcholine chlorohydrins", "SIMPLE_CHEMICAL", 152, 185], ["erythrocyteA", "SIMPLE_CHEMICAL", 211, 223], ["STxB", "PROTEIN", 14, 18], ["STxB on pore-suspending membranes", "TREATMENT", 14, 47], ["confocal laser scanning mi croscopy", "TEST", 68, 103], ["atomic force microscopy", "TEST", 108, 131], ["phosphatidylcholine chlorohydrins", "TREATMENT", 152, 185], ["the erythrocyteA", "TREATMENT", 207, 223], ["phosphatidylcholine chlorohydrins", "OBSERVATION", 152, 185]]], ["Robaszkiewicz 1 , C. Spickett 2 , P. Sicinska 1 , G. Bartosz 1 , M. Soszynski 1 1 Department of Molecular Biophysics, University of Lodz, Lodz, Poland, 2 Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, U.K.Characterization of phosphatidylcholine chlorohydrins and their effects on the erythrocyteHypochlorite generated in vivo under pathological conditions is a known oxidant, able to initiate lipid peroxidation process, which affects the stability of biological membranes.", [["erythrocyte", "ANATOMY", 305, 316], ["membranes", "ANATOMY", 484, 493], ["phosphatidylcholine chlorohydrins", "CHEMICAL", 246, 279], ["Hypochlorite", "CHEMICAL", 316, 328], ["phosphatidylcholine chlorohydrins", "CHEMICAL", 246, 279], ["Hypochlorite", "CHEMICAL", 316, 328], ["phosphatidylcholine chlorohydrins", "SIMPLE_CHEMICAL", 246, 279], ["erythrocyte", "CELL", 305, 316], ["Hypochlorite", "SIMPLE_CHEMICAL", 316, 328], ["lipid", "SIMPLE_CHEMICAL", 414, 419], ["membranes", "CELLULAR_COMPONENT", 484, 493], ["Robaszkiewicz", "TREATMENT", 0, 13], ["phosphatidylcholine chlorohydrins", "TREATMENT", 246, 279], ["the erythrocyte", "TEST", 301, 316], ["Hypochlorite", "TREATMENT", 316, 328], ["lipid peroxidation process", "PROBLEM", 414, 440], ["phosphatidylcholine chlorohydrins", "OBSERVATION", 246, 279], ["stability", "OBSERVATION_MODIFIER", 460, 469], ["biological membranes", "OBSERVATION", 473, 493]]], ["The aim of this study was the analysis of the products formed during the reaction of hypochlorite with phosphatidylcholines containing unsuturated fatty acid residues (1-stearoyl-2-oleoyl-, 1-stearoyl-2-linoleoyl-, 1stearoyl-2-arachidonylphosphatidylcholine) and their effects on the human erythrocytes.", [["erythrocytes", "ANATOMY", 290, 302], ["hypochlorite", "CHEMICAL", 85, 97], ["phosphatidylcholines", "CHEMICAL", 103, 123], ["fatty acid", "CHEMICAL", 147, 157], ["1-stearoyl-2-oleoyl-, 1-stearoyl-2-linoleoyl-, 1stearoyl-2-arachidonylphosphatidylcholine", "CHEMICAL", 168, 257], ["hypochlorite", "CHEMICAL", 85, 97], ["phosphatidylcholines", "CHEMICAL", 103, 123], ["fatty acid", "CHEMICAL", 147, 157], ["1-stearoyl-2-oleoyl-, 1-stearoyl-2-linoleoyl-, 1stearoyl-2-arachidonylphosphatidylcholine", "CHEMICAL", 168, 257], ["hypochlorite", "SIMPLE_CHEMICAL", 85, 97], ["phosphatidylcholines", "SIMPLE_CHEMICAL", 103, 123], ["unsuturated fatty acid", "SIMPLE_CHEMICAL", 135, 157], ["1-stearoyl-2-oleoyl-, 1-stearoyl-2-linoleoyl-, 1stearoyl-2-arachidonylphosphatidylcholine", "SIMPLE_CHEMICAL", 168, 257], ["human", "ORGANISM", 284, 289], ["erythrocytes", "CELL", 290, 302], ["human erythrocytes", "CELL_TYPE", 284, 302], ["human", "SPECIES", 284, 289], ["human", "SPECIES", 284, 289], ["this study", "TEST", 11, 21], ["the analysis", "TEST", 26, 38], ["hypochlorite", "TREATMENT", 85, 97], ["phosphatidylcholines", "TREATMENT", 103, 123], ["unsuturated fatty acid residues", "TREATMENT", 135, 166], ["stearoyl", "TEST", 170, 178], ["oleoyl", "TEST", 181, 187], ["stearoyl", "TEST", 192, 200], ["linoleoyl", "TREATMENT", 203, 212], ["1stearoyl", "TREATMENT", 215, 224], ["arachidonylphosphatidylcholine", "TREATMENT", 227, 257], ["the human erythrocytes", "PROBLEM", 280, 302], ["fatty acid residues", "OBSERVATION", 147, 166], ["human erythrocytes", "ANATOMY", 284, 302]]], ["Using electrospray mass spectrometry we observed complete conversion of the lipids into chlorohydrins, which resulted in the decrease of the rotational correlation time and rotational motion freedom of liposomes estimated by EPR using spin probes (16-and 5doxylstearic acid).", [["chlorohydrins", "CHEMICAL", 88, 101], ["16-and 5doxylstearic acid", "CHEMICAL", 248, 273], ["chlorohydrins", "CHEMICAL", 88, 101], ["16-and 5doxylstearic acid", "CHEMICAL", 248, 273], ["lipids", "SIMPLE_CHEMICAL", 76, 82], ["chlorohydrins", "SIMPLE_CHEMICAL", 88, 101], ["liposomes", "SIMPLE_CHEMICAL", 202, 211], ["5doxylstearic acid", "SIMPLE_CHEMICAL", 255, 273], ["electrospray mass spectrometry", "TREATMENT", 6, 36], ["the lipids into chlorohydrins", "TREATMENT", 72, 101], ["rotational motion freedom of liposomes", "TREATMENT", 173, 211], ["spin probes", "TEST", 235, 246], ["5doxylstearic acid)", "TREATMENT", 255, 274], ["decrease", "OBSERVATION_MODIFIER", 125, 133]]], ["Unilamellar chlorohydrin liposomes had lower diffusion coefficient for calcein than liposomes made of parent lipids.", [["chlorohydrin", "CHEMICAL", 12, 24], ["calcein", "CHEMICAL", 71, 78], ["calcein", "CHEMICAL", 71, 78], ["Unilamellar chlorohydrin liposomes", "SIMPLE_CHEMICAL", 0, 34], ["calcein", "SIMPLE_CHEMICAL", 71, 78], ["liposomes", "SIMPLE_CHEMICAL", 84, 93], ["Unilamellar chlorohydrin liposomes", "TREATMENT", 0, 34], ["lower diffusion coefficient", "PROBLEM", 39, 66], ["calcein than liposomes", "TREATMENT", 71, 93], ["parent lipids", "TREATMENT", 102, 115]]], ["Flow cytometry demonstrated fast incorporation of uni-and multilamellar chlorohydrin liposomes labeled with NBD-PE into erythrocytes.", [["erythrocytes", "ANATOMY", 120, 132], ["NBD-PE", "CHEMICAL", 108, 114], ["chlorohydrin", "CHEMICAL", 72, 84], ["uni-and multilamellar chlorohydrin liposomes", "SIMPLE_CHEMICAL", 50, 94], ["NBD-PE", "SIMPLE_CHEMICAL", 108, 114], ["erythrocytes", "CELL", 120, 132], ["NBD", "PROTEIN", 108, 111], ["erythrocytes", "CELL_TYPE", 120, 132], ["Flow cytometry", "TEST", 0, 14], ["uni-and multilamellar chlorohydrin liposomes", "TREATMENT", 50, 94], ["NBD", "PROBLEM", 108, 111], ["PE into erythrocytes", "PROBLEM", 112, 132], ["fast incorporation", "OBSERVATION", 28, 46], ["PE", "OBSERVATION", 112, 114]]], ["This effect was accompanied by the formation of the erythrocyte subpopulations of higher volume, decrease of the rate of fluorescein diacetate hydrolysis, estimated by flow cytometry, and increase of affinity and maximal velocity of the membrane enzyme acetylcholinesterase.P-609Extensive bilayer perforation coupled with the phase transition region of an anionic phospholipid K. A. Riske 1 , L. Q. Amaral 2 , M. T. Lamy 2 1 Depto.", [["erythrocyte", "ANATOMY", 52, 63], ["membrane", "ANATOMY", 237, 245], ["fluorescein diacetate", "CHEMICAL", 121, 142], ["P-609", "CHEMICAL", 274, 279], ["fluorescein diacetate", "CHEMICAL", 121, 142], ["P-609", "CHEMICAL", 274, 279], ["erythrocyte", "CELL", 52, 63], ["fluorescein diacetate", "SIMPLE_CHEMICAL", 121, 142], ["membrane", "CELLULAR_COMPONENT", 237, 245], ["acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 253, 273], ["erythrocyte subpopulations", "CELL_TYPE", 52, 78], ["membrane enzyme", "PROTEIN", 237, 252], ["acetylcholinesterase", "PROTEIN", 253, 273], ["the erythrocyte subpopulations", "PROBLEM", 48, 78], ["higher volume", "PROBLEM", 82, 95], ["fluorescein diacetate hydrolysis", "TREATMENT", 121, 153], ["flow cytometry", "TEST", 168, 182], ["increase of affinity", "PROBLEM", 188, 208], ["the membrane enzyme acetylcholinesterase", "TREATMENT", 233, 273], ["P", "TEST", 274, 275], ["Extensive bilayer perforation", "PROBLEM", 279, 308], ["erythrocyte subpopulations", "OBSERVATION", 52, 78], ["higher volume", "OBSERVATION", 82, 95], ["decrease", "OBSERVATION_MODIFIER", 97, 105], ["fluorescein diacetate hydrolysis", "OBSERVATION", 121, 153], ["flow cytometry", "OBSERVATION", 168, 182], ["increase", "OBSERVATION_MODIFIER", 188, 196], ["Extensive", "OBSERVATION_MODIFIER", 279, 288], ["bilayer", "OBSERVATION_MODIFIER", 289, 296], ["perforation", "OBSERVATION", 297, 308]]], ["Biofisica, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 2 Instituto de Fisica, Universidade de Sao Paulo, Sao Paulo, Brazil At low ionic strength dimyristoylphosphatidylglycerol (DMPG) exhibits a broad phase transition region characterized by several superimposed calorimetric peaks.", [["dimyristoylphosphatidylglycerol", "CHEMICAL", 155, 186], ["DMPG", "CHEMICAL", 188, 192], ["dimyristoylphosphatidylglycerol", "CHEMICAL", 155, 186], ["DMPG", "CHEMICAL", 188, 192], ["dimyristoylphosphatidylglycerol", "SIMPLE_CHEMICAL", 155, 186], ["DMPG", "SIMPLE_CHEMICAL", 188, 192], ["Brazil At low ionic strength dimyristoylphosphatidylglycerol (DMPG)", "TREATMENT", 126, 193], ["a broad phase transition region", "TREATMENT", 203, 234], ["several superimposed calorimetric peaks", "PROBLEM", 252, 291], ["broad phase", "OBSERVATION_MODIFIER", 205, 216], ["calorimetric peaks", "OBSERVATION", 273, 291]]], ["Peculiar properties, such as sample transparency, are observed only in the transition region.", [["transparency", "OBSERVATION_MODIFIER", 36, 48]]], ["We use differential scanning calorimetry, turbidity and optical microscopy to study the narrowing of the transition region with the increase of ionic strength.", [["differential scanning calorimetry", "TEST", 7, 40], ["optical microscopy", "TEST", 56, 74], ["the transition region", "PROBLEM", 101, 122], ["narrowing", "OBSERVATION", 88, 97], ["increase", "OBSERVATION_MODIFIER", 132, 140], ["ionic strength", "OBSERVATION", 144, 158]]], ["Upon addition of salt, the temperature extension of the transition region is reduced and the number of calorimetric peaks decreases until a single cooperative event is observed in the presence of 500 mM NaCl.", [["NaCl", "CHEMICAL", 203, 207], ["NaCl", "CHEMICAL", 203, 207], ["salt", "TREATMENT", 17, 21], ["the transition region", "PROBLEM", 52, 73], ["calorimetric peaks", "PROBLEM", 103, 121], ["500 mM NaCl", "TREATMENT", 196, 207], ["reduced", "OBSERVATION_MODIFIER", 77, 84], ["peaks", "OBSERVATION_MODIFIER", 116, 121], ["decreases", "OBSERVATION_MODIFIER", 122, 131]]], ["The transition region is always coupled with a decrease in turbidity, but a transparent region is detected within the melting process only in the presence of up to 20 mM NaCl.", [["NaCl", "CHEMICAL", 170, 174], ["NaCl", "CHEMICAL", 170, 174], ["The transition region", "PROBLEM", 0, 21], ["a decrease in turbidity", "PROBLEM", 45, 68], ["a transparent region", "PROBLEM", 74, 94], ["20 mM NaCl", "TREATMENT", 164, 174], ["decrease", "OBSERVATION_MODIFIER", 47, 55], ["turbidity", "OBSERVATION", 59, 68], ["transparent", "OBSERVATION_MODIFIER", 76, 87], ["melting", "OBSERVATION_MODIFIER", 118, 125]]], ["Optical microscopy of giant vesicles shows that bilayers first rupture when the transition region is reached and subsequently lose optical contrast.", [["giant vesicles", "ANATOMY", 22, 36], ["vesicles", "CELLULAR_COMPONENT", 28, 36], ["Optical microscopy", "TEST", 0, 18], ["giant vesicles", "PROBLEM", 22, 36], ["bilayers first rupture", "PROBLEM", 48, 70], ["giant vesicles", "OBSERVATION", 22, 36], ["bilayers", "OBSERVATION_MODIFIER", 48, 56], ["first", "OBSERVATION_MODIFIER", 57, 62], ["rupture", "OBSERVATION", 63, 70]]], ["Fluorescence microscopy reveals a blurry image in the transparent region, suggesting a different lipid self-assembly.", [["lipid", "SIMPLE_CHEMICAL", 97, 102], ["Fluorescence microscopy", "TEST", 0, 23], ["a blurry image in the transparent region", "PROBLEM", 32, 72], ["transparent", "ANATOMY_MODIFIER", 54, 65], ["region", "ANATOMY_MODIFIER", 66, 72], ["different", "OBSERVATION_MODIFIER", 87, 96], ["lipid self", "OBSERVATION", 97, 107]]], ["Overall sample turbidity can be related to the bilayer optical contrast.", [["Overall sample turbidity", "TEST", 0, 24], ["the bilayer optical contrast", "TEST", 43, 71], ["turbidity", "OBSERVATION", 15, 24]]], ["Our observations are discussed in terms of the bilayer being perforated along the transition region.", [["Our observations", "TEST", 0, 16], ["perforated", "OBSERVATION", 61, 71]]], ["In the transparent region the perforation is extensive and the bilayer completely loses the optical contrast.", [["perforation", "DISEASE", 30, 41], ["the perforation", "PROBLEM", 26, 41], ["transparent", "OBSERVATION_MODIFIER", 7, 18], ["region", "OBSERVATION_MODIFIER", 19, 25], ["perforation", "OBSERVATION", 30, 41], ["extensive", "OBSERVATION_MODIFIER", 45, 54], ["bilayer", "OBSERVATION_MODIFIER", 63, 70], ["completely", "OBSERVATION_MODIFIER", 71, 81]]], ["Financial Support: Fapesp.P-608Label-free imaging of biological membranes using surface imaging techniques J. L. Richens, K.-A. Vere, P. O'Shea Cell Biophysics Group, University of Nottingham, Nottingham, UK Surface plasmon resonance (SPR) is a detection technique traditionally used for specific protein detection, which is now exploited routinely as a generic label-free sensor.", [["membranes", "ANATOMY", 64, 73], ["surface", "ANATOMY", 80, 87], ["P-608Label", "CHEMICAL", 26, 36], ["P", "TEST", 26, 27], ["free imaging", "TEST", 37, 49], ["surface imaging", "TEST", 80, 95], ["a detection technique", "TEST", 243, 264], ["specific protein detection", "TEST", 288, 314]]], ["SPR responds to changes on a metal surface conditioned to sense the binding of analytes.", [["a metal surface conditioned", "TREATMENT", 27, 54]]], ["Thus, the composition of the external medium and metal surface will be fundamental to the signal output.", [["the external medium and metal surface", "TREATMENT", 25, 62], ["the signal output", "TEST", 86, 103], ["external", "OBSERVATION_MODIFIER", 29, 37], ["medium", "OBSERVATION_MODIFIER", 38, 44], ["metal surface", "OBSERVATION", 49, 62], ["signal output", "OBSERVATION", 90, 103]]], ["Here we use a model phospholipid membrane system to investigate the effect of altered buffer and surface compositions on SPR signals.", [["phospholipid membrane", "ANATOMY", 20, 41], ["surface", "ANATOMY", 97, 104], ["a model phospholipid membrane system", "TREATMENT", 12, 48], ["altered buffer", "PROBLEM", 78, 92], ["SPR signals", "TEST", 121, 132]]], ["Comparisons are undertaken between continuous gold surfaces and gold nanoparticles.", [["gold nanoparticles", "SIMPLE_CHEMICAL", 64, 82], ["continuous gold surfaces and gold nanoparticles", "TREATMENT", 35, 82], ["gold nanoparticles", "OBSERVATION", 64, 82]]], ["We demonstrate that surface electrostatics and the salt composition and molarity of a buffer all have significant impacts on SPR output.Effect of cholesterol on the structure of phospholipid and non-phospholipid membranesThe association of respiratory syncytial virus matrix protein with membrane microdomainsEffect of cholesterol on the structure of phospholipid and non-phospholipid membranesThe association of the matrix protein from respiratory syncytical virus with membranes has been characterised by tensiometry, Brewster angle microscopy, and atomic force microscopy following deposition of Langmuir monolayers onto modified silica substrates.", [["surface", "ANATOMY", 20, 27], ["non-phospholipid membranes", "ANATOMY", 195, 221], ["membrane microdomains", "ANATOMY", 288, 309], ["non-phospholipid membranes", "ANATOMY", 368, 394], ["membranes", "ANATOMY", 471, 480], ["cholesterol", "CHEMICAL", 146, 157], ["cholesterol", "CHEMICAL", 319, 330], ["silica", "CHEMICAL", 633, 639], ["cholesterol", "CHEMICAL", 146, 157], ["cholesterol", "CHEMICAL", 319, 330], ["silica", "CHEMICAL", 633, 639], ["salt", "SIMPLE_CHEMICAL", 51, 55], ["cholesterol", "SIMPLE_CHEMICAL", 146, 157], ["phospholipid", "SIMPLE_CHEMICAL", 178, 190], ["non-phospholipid membranes", "CELLULAR_COMPONENT", 195, 221], ["respiratory syncytial virus matrix protein", "GENE_OR_GENE_PRODUCT", 240, 282], ["membrane microdomains", "CELLULAR_COMPONENT", 288, 309], ["cholesterol", "SIMPLE_CHEMICAL", 319, 330], ["phospholipid", "SIMPLE_CHEMICAL", 351, 363], ["non-phospholipid membranes", "CELLULAR_COMPONENT", 368, 394], ["matrix", "CELLULAR_COMPONENT", 417, 423], ["respiratory syncytical virus", "ORGANISM", 437, 465], ["membranes", "CELLULAR_COMPONENT", 471, 480], ["silica substrates", "SIMPLE_CHEMICAL", 633, 650], ["respiratory syncytial virus matrix protein", "PROTEIN", 240, 282], ["matrix protein", "PROTEIN", 417, 431], ["respiratory syncytial virus", "SPECIES", 240, 267], ["respiratory syncytial virus", "SPECIES", 240, 267], ["respiratory syncytical virus", "SPECIES", 437, 465], ["surface electrostatics", "TREATMENT", 20, 42], ["the salt composition", "TREATMENT", 47, 67], ["a buffer", "TREATMENT", 84, 92], ["SPR output", "TEST", 125, 135], ["cholesterol", "TEST", 146, 157], ["phospholipid and non-phospholipid membranes", "TREATMENT", 178, 221], ["respiratory syncytial virus matrix protein", "PROBLEM", 240, 282], ["membrane microdomains", "PROBLEM", 288, 309], ["cholesterol", "TEST", 319, 330], ["phospholipid and non-phospholipid membranes", "TREATMENT", 351, 394], ["the matrix protein", "PROBLEM", 413, 431], ["respiratory syncytical virus", "PROBLEM", 437, 465], ["Brewster angle microscopy", "TEST", 520, 545], ["atomic force microscopy", "TEST", 551, 574], ["deposition of Langmuir monolayers onto modified silica substrates", "TREATMENT", 585, 650], ["surface", "OBSERVATION_MODIFIER", 20, 27], ["electrostatics", "OBSERVATION", 28, 42], ["salt", "OBSERVATION_MODIFIER", 51, 55], ["composition", "OBSERVATION_MODIFIER", 56, 67], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["impacts", "OBSERVATION", 114, 121], ["SPR output", "OBSERVATION", 125, 135], ["cholesterol", "OBSERVATION", 146, 157], ["non-phospholipid membranes", "ANATOMY", 195, 221], ["respiratory syncytial virus", "OBSERVATION", 240, 267], ["membrane microdomains", "OBSERVATION", 288, 309], ["cholesterol", "OBSERVATION", 319, 330], ["non-phospholipid membranes", "ANATOMY", 368, 394], ["respiratory syncytical virus", "OBSERVATION", 437, 465], ["silica substrates", "OBSERVATION", 633, 650]]], ["Association of the protein with monolayers containing phosphocholines and cholesterol leads to the formation of materials with new properties that differ from those of either of the pure components.", [["monolayers", "ANATOMY", 32, 42], ["phosphocholines", "CHEMICAL", 54, 69], ["cholesterol", "CHEMICAL", 74, 85], ["phosphocholines", "CHEMICAL", 54, 69], ["cholesterol", "CHEMICAL", 74, 85], ["monolayers", "CELL", 32, 42], ["phosphocholines", "SIMPLE_CHEMICAL", 54, 69], ["cholesterol", "SIMPLE_CHEMICAL", 74, 85], ["the protein with monolayers containing phosphocholines", "PROBLEM", 15, 69], ["cholesterol", "TREATMENT", 74, 85], ["new", "OBSERVATION_MODIFIER", 127, 130], ["pure", "OBSERVATION_MODIFIER", 182, 186], ["components", "OBSERVATION_MODIFIER", 187, 197]]], ["The behaviour of the protein in monolayers rich in cholesterol and sphingomyelin exhibits a significant concentration dependence.", [["monolayers", "ANATOMY", 32, 42], ["cholesterol", "CHEMICAL", 51, 62], ["sphingomyelin", "CHEMICAL", 67, 80], ["cholesterol", "CHEMICAL", 51, 62], ["sphingomyelin", "CHEMICAL", 67, 80], ["monolayers", "CELL", 32, 42], ["cholesterol", "SIMPLE_CHEMICAL", 51, 62], ["sphingomyelin", "SIMPLE_CHEMICAL", 67, 80], ["a significant concentration dependence", "PROBLEM", 90, 128], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["concentration dependence", "OBSERVATION", 104, 128]]], ["At low concentrations, the protein exhibits a simple partioning behaviour.", [["the protein", "TEST", 23, 34], ["low concentrations", "OBSERVATION_MODIFIER", 3, 21]]], ["At higher concentrations, lipids are extruded from the monolayer below a critical surface area.", [["monolayer", "ANATOMY", 55, 64], ["surface area", "ANATOMY", 82, 94], ["lipids", "SIMPLE_CHEMICAL", 26, 32], ["monolayer", "CELL", 55, 64], ["lipids", "TREATMENT", 26, 32], ["monolayer", "OBSERVATION_MODIFIER", 55, 64], ["critical", "OBSERVATION_MODIFIER", 73, 81], ["surface", "OBSERVATION_MODIFIER", 82, 89]]], ["These findings are discussed in relation to the recently published structure of the protein (PNAS, 2009, 106, 4441-4446) , the documented formation of viral filaments during key stages of the infection cycle and the isolation of the protein from detergent-resistant membrane fractions.P-613Structure and dynamics of closed melting membranes V. M. Rondelli 1 , S. Santorsola 1 , P. Brocca 1 , E. Del Favero 1 , L. Cant\u00f9 1 , M. Zimbone 2 1 Dep. of Chemistry, Biochemistry and Biotechnologies for Medicine, University of Milan, Segrate, Italy., 2 Dep.", [["filaments", "ANATOMY", 157, 166], ["membrane fractions", "ANATOMY", 266, 284], ["infection", "DISEASE", 192, 201], ["P-613Structure", "CHEMICAL", 285, 299], ["membrane", "CELLULAR_COMPONENT", 266, 274], ["P", "DNA", 285, 286], ["PNAS", "TEST", 93, 97], ["viral filaments", "PROBLEM", 151, 166], ["the infection cycle", "PROBLEM", 188, 207], ["the protein", "TEST", 229, 240], ["resistant membrane fractions", "PROBLEM", 256, 284], ["P", "TEST", 285, 286], ["closed melting membranes", "TREATMENT", 316, 340], ["viral filaments", "OBSERVATION", 151, 166], ["infection", "OBSERVATION", 192, 201], ["resistant membrane fractions", "OBSERVATION", 256, 284]]], ["Of Physics, University of Catania, Catania, Italy.P-613We studied the dynamical and structural properties of large unilamellar vesicles (\u2248 120 nm LUVs) of phospholipids (DMPC, DC 15 PC and DMPC : DC 15 PC = 1 : 1 molar mixture) in the temperature range around the chain-melting transition, \u2248 3 \u2022 C wide, with 0.1 \u2022 C resolution and 0.01 \u2022 C accuracy.", [["unilamellar vesicles", "ANATOMY", 115, 135], ["DC", "ANATOMY", 176, 178], ["DC", "ANATOMY", 196, 198], ["P-613We", "CHEMICAL", 50, 57], ["DMPC", "CHEMICAL", 170, 174], ["DMPC", "CHEMICAL", 170, 174], ["DMPC", "CHEMICAL", 189, 193], ["unilamellar vesicles", "SIMPLE_CHEMICAL", 115, 135], ["phospholipids", "SIMPLE_CHEMICAL", 155, 168], ["DMPC", "SIMPLE_CHEMICAL", 170, 174], ["DMPC", "SIMPLE_CHEMICAL", 189, 193], ["P-613We", "DNA", 50, 57], ["large unilamellar vesicles", "PROBLEM", 109, 135], ["nm LUVs", "TEST", 143, 150], ["phospholipids (DMPC", "TREATMENT", 155, 174], ["DC 15 PC", "TREATMENT", 176, 184], ["DC 15 PC", "TREATMENT", 196, 204], ["large", "OBSERVATION_MODIFIER", 109, 114], ["unilamellar vesicles", "OBSERVATION", 115, 135]]], ["Small-Angle (SAXS) and Wide-Angle X-ray Scattering (WAXS) measurements show that across the transition the vesicle behaves as an 'evolving membrane', passing through several different states, each of them being characterized by different proportions of coexisting fluid-and gelchains molecules.", [["vesicle", "ANATOMY", 107, 114], ["membrane", "ANATOMY", 139, 147], ["vesicle", "CELLULAR_COMPONENT", 107, 114], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["gelchains molecules", "SIMPLE_CHEMICAL", 274, 293], ["fluid-and gelchains molecules", "PROTEIN", 264, 293], ["Small-Angle (SAXS", "TEST", 0, 17], ["Wide-Angle X-ray Scattering (WAXS) measurements", "TEST", 23, 70], ["an 'evolving membrane'", "PROBLEM", 126, 148], ["coexisting fluid-and gelchains molecules", "PROBLEM", 253, 293], ["-Angle", "OBSERVATION_MODIFIER", 5, 11], ["vesicle", "OBSERVATION", 107, 114], ["membrane'", "OBSERVATION", 139, 148], ["several different", "OBSERVATION_MODIFIER", 166, 183], ["different", "OBSERVATION_MODIFIER", 228, 237], ["proportions", "OBSERVATION_MODIFIER", 238, 249], ["coexisting", "OBSERVATION_MODIFIER", 253, 263], ["fluid", "OBSERVATION", 264, 269]]], ["Noteworthy, no kinetics has been detected.", [["kinetics", "PROBLEM", 15, 23], ["no", "UNCERTAINTY", 12, 14], ["kinetics", "OBSERVATION", 15, 23]]], ["On the same samples, a unique and very sensitive laser light scattering technique allows to determine the characteristic times of thermally induced shape fluctuations, connected to the elastic properties of the membranes.", [["samples", "ANATOMY", 12, 19], ["membranes", "ANATOMY", 211, 220], ["membranes", "CELLULAR_COMPONENT", 211, 220], ["thermally induced shape fluctuations", "PROBLEM", 130, 166], ["shape", "OBSERVATION_MODIFIER", 148, 153], ["fluctuations", "OBSERVATION", 154, 166], ["elastic", "ANATOMY_MODIFIER", 185, 192], ["membranes", "ANATOMY_MODIFIER", 211, 220]]], ["Results indicate a clear softening of the membranes in correspondence to the chain-melting transition, as indicated by a manifold increase of the corresponding fluctuation characteristic time.", [["membranes", "ANATOMY", 42, 51], ["membranes", "CELLULAR_COMPONENT", 42, 51], ["a clear softening of the membranes", "PROBLEM", 17, 51], ["clear", "OBSERVATION_MODIFIER", 19, 24], ["softening", "OBSERVATION", 25, 34], ["membranes", "OBSERVATION_MODIFIER", 42, 51], ["chain", "OBSERVATION_MODIFIER", 77, 82], ["melting transition", "OBSERVATION", 83, 101], ["increase", "OBSERVATION_MODIFIER", 130, 138]]], ["Meanwhile the overall size of the vesicle is not sensibly changed.", [["vesicle", "ANATOMY", 34, 41], ["vesicle", "CELLULAR_COMPONENT", 34, 41], ["overall", "OBSERVATION_MODIFIER", 14, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["vesicle", "ANATOMY", 34, 41], ["not", "UNCERTAINTY", 45, 48], ["sensibly", "OBSERVATION_MODIFIER", 49, 57], ["changed", "OBSERVATION", 58, 65]]], ["This softening is likely to be due to the presence of structural defects, eventually driving to local morphological modifications.P-612Thermodynamics characterization of isolated lung surfactant assembled as lamellar bodies E. X. Rodriguez 1 , R. Alvarez 1 , R. Barrio 2 , C. Irles 3 , A. Ortega 1 1 Biochemistry Depto., School of Medicine, 2 Inst. of Physics UNAM, 3 Nat.", [["lung", "ANATOMY", 179, 183], ["lung", "ORGAN", 179, 183], ["structural defects", "PROBLEM", 54, 72], ["Thermodynamics characterization", "TEST", 135, 166], ["isolated lung surfactant", "TREATMENT", 170, 194], ["lamellar bodies", "TEST", 208, 223], ["Rodriguez", "TEST", 230, 239], ["Alvarez", "TEST", 247, 254], ["Barrio", "TEST", 262, 268], ["likely to be due to", "UNCERTAINTY", 18, 37], ["structural defects", "OBSERVATION", 54, 72], ["lung", "ANATOMY", 179, 183], ["surfactant", "OBSERVATION", 184, 194]]], ["Inst. of Perinatology, Mexico City, MexicoP-612Lungs are a large extension of \u223c80m 2 of one layer cells, which is structured as compacted sacs called alveoli, where lung function takes place: the gas exchange.", [["layer cells", "ANATOMY", 92, 103], ["sacs", "ANATOMY", 138, 142], ["alveoli", "ANATOMY", 150, 157], ["lung", "ANATOMY", 165, 169], ["MexicoP-612Lungs", "CELL", 36, 52], ["layer cells", "CELL", 92, 103], ["sacs", "TISSUE", 138, 142], ["alveoli", "MULTI-TISSUE_STRUCTURE", 150, 157], ["lung", "ORGAN", 165, 169], ["MexicoP", "TEST", 36, 43], ["the gas exchange", "TEST", 192, 208], ["large", "OBSERVATION_MODIFIER", 59, 64], ["layer cells", "OBSERVATION", 92, 103], ["alveoli", "ANATOMY_MODIFIER", 150, 157], ["lung", "ANATOMY", 165, 169], ["gas exchange", "OBSERVATION", 196, 208]]], ["Alveolar endotelium is formed by two kinds of cells: Neumocyte type I (NTI), which covers \u223c97% of the alveolar surface where gas exchange occurs and, NTII where lung surfactant (LS) is produced.", [["Alveolar endotelium", "ANATOMY", 0, 19], ["cells", "ANATOMY", 46, 51], ["alveolar surface", "ANATOMY", 102, 118], ["lung", "ANATOMY", 161, 165], ["Alveolar endotelium", "CANCER", 0, 19], ["cells", "CELL", 46, 51], ["Neumocyte type I", "GENE_OR_GENE_PRODUCT", 53, 69], ["alveolar surface", "MULTI-TISSUE_STRUCTURE", 102, 118], ["lung", "ORGAN", 161, 165], ["Neumocyte type I", "PROTEIN", 53, 69], ["Alveolar endotelium", "PROBLEM", 0, 19], ["Neumocyte type I", "PROBLEM", 53, 69], ["gas exchange", "TEST", 125, 137], ["lung surfactant", "TREATMENT", 161, 176], ["two kinds", "OBSERVATION_MODIFIER", 33, 42], ["alveolar", "ANATOMY", 102, 110], ["surface", "ANATOMY_MODIFIER", 111, 118], ["gas exchange", "OBSERVATION", 125, 137], ["lung", "ANATOMY", 161, 165], ["surfactant", "OBSERVATION", 166, 176]]], ["LS are a mixture that lay over a water film in the luminal surface of the alveoli and it is thought to decrease the surface tension to avoid alveolar collapse during expiration.", [["luminal surface", "ANATOMY", 51, 66], ["alveoli", "ANATOMY", 74, 81], ["surface", "ANATOMY", 116, 123], ["alveolar", "ANATOMY", 141, 149], ["luminal", "CHEMICAL", 51, 58], ["luminal surface", "CELLULAR_COMPONENT", 51, 66], ["alveoli", "MULTI-TISSUE_STRUCTURE", 74, 81], ["alveolar", "MULTI-TISSUE_STRUCTURE", 141, 149], ["a water film", "TEST", 31, 43], ["alveolar collapse", "PROBLEM", 141, 158], ["luminal", "ANATOMY_MODIFIER", 51, 58], ["surface", "ANATOMY_MODIFIER", 59, 66], ["alveoli", "ANATOMY", 74, 81], ["thought to", "UNCERTAINTY", 92, 102], ["decrease", "OBSERVATION_MODIFIER", 103, 111], ["surface tension", "OBSERVATION", 116, 131], ["avoid", "UNCERTAINTY", 135, 140], ["alveolar", "ANATOMY_MODIFIER", 141, 149], ["collapse", "OBSERVATION", 150, 158]]], ["LS are made of phospholipids and proteins, which are determinant for the structure of LS under particular conditions of pressure and temperature.", [["phospholipids", "SIMPLE_CHEMICAL", 15, 28], ["phospholipids", "TEST", 15, 28], ["proteins", "TEST", 33, 41], ["pressure", "OBSERVATION_MODIFIER", 120, 128]]], ["LS inside the cell is packed in organelles called lamellar bodies (LB), and is released to the water/air interphase in other conformation.", [["cell", "ANATOMY", 14, 18], ["organelles", "ANATOMY", 32, 42], ["lamellar bodies", "ANATOMY", 50, 65], ["cell", "CELL", 14, 18], ["organelles", "CELLULAR_COMPONENT", 32, 42], ["lamellar bodies", "CELLULAR_COMPONENT", 50, 65], ["cell", "OBSERVATION", 14, 18], ["packed", "OBSERVATION_MODIFIER", 22, 28], ["lamellar", "ANATOMY_MODIFIER", 50, 58], ["bodies", "ANATOMY_MODIFIER", 59, 65], ["air interphase", "OBSERVATION", 101, 115]]], ["In the present study we isolate LB from pig's lung and study LB thermodynamic characteristics by microcalorimetry in the presence and in the absence of structural proteins.", [["lung", "ANATOMY", 46, 50], ["pig", "ORGANISM", 40, 43], ["lung", "ORGAN", 46, 50], ["structural proteins", "PROTEIN", 152, 171], ["pig", "SPECIES", 40, 43], ["pig", "SPECIES", 40, 43], ["pig's lung", "TEST", 40, 50], ["microcalorimetry", "TEST", 97, 113], ["structural proteins", "PROBLEM", 152, 171], ["lung", "ANATOMY", 46, 50], ["structural proteins", "OBSERVATION", 152, 171]]], ["Phase transition profile of LB with and without proteins is basically the same; while LS in the alveolar lumen have a higher transition temperature (Tm).", [["alveolar lumen", "ANATOMY", 96, 110], ["alveolar lumen", "MULTI-TISSUE_STRUCTURE", 96, 110], ["Phase transition profile of LB", "PROBLEM", 0, 30], ["without", "UNCERTAINTY", 40, 47], ["alveolar lumen", "ANATOMY", 96, 110], ["higher", "OBSERVATION_MODIFIER", 118, 124], ["transition temperature", "OBSERVATION_MODIFIER", 125, 147]]], ["Mayor changes in Tm are observed between LB and LS from alveolar lumen.", [["alveolar lumen", "ANATOMY", 56, 70], ["alveolar lumen", "MULTI-TISSUE_STRUCTURE", 56, 70], ["Mayor changes in Tm", "PROBLEM", 0, 19], ["LS", "ANATOMY_MODIFIER", 48, 50], ["alveolar", "ANATOMY", 56, 64], ["lumen", "ANATOMY_MODIFIER", 65, 70]]], ["Although LS lipid composition in and outside the cell is assumed to be the same, the ground for the differences in Tm under these two conditions is unknown.Molecular basis of translocation of novel nucleolar-targetting peptidesM.", [["cell", "ANATOMY", 49, 53], ["nucleolar", "ANATOMY", 198, 207], ["cell", "CELL", 49, 53], ["nucleolar", "CELLULAR_COMPONENT", 198, 207], ["novel nucleolar-targetting peptidesM", "PROTEIN", 192, 228], ["novel nucleolar", "PROBLEM", 192, 207]]], ["Rodrigues 1 , G. R\u00e1dis-Baptista 3 , B. G. de la Torre 2 , M. Castanho 1 , D. Andreu 2 , N. C. Santos 1 1 Instituto de Medicina Molecular, Portugal, 2 Pompeu Fabra University, Spain, 3 Federal University of Cear\u00e0, Brasil Nucleolar-targeting peptides (NrTPs) have been recently designed by structural dissection of crotamine, a toxin from the venom of a South America rattlesnake (Radis-Baptista et al. 2008.", [["venom", "ANATOMY", 341, 346], ["crotamine", "CHEMICAL", 313, 322], ["crotamine", "CHEMICAL", 313, 322], ["crotamine", "SIMPLE_CHEMICAL", 313, 322], ["venom", "ORGANISM_SUBSTANCE", 341, 346], ["America rattlesnake", "SPECIES", 358, 377], ["Rodrigues", "TEST", 0, 9], ["crotamine", "TREATMENT", 313, 322], ["a toxin", "TEST", 324, 331], ["Brasil Nucleolar", "OBSERVATION", 213, 229], ["dissection", "OBSERVATION", 299, 309]]], ["J Med Chem 51:7041) .", [["Med", "ANATOMY", 2, 5]]], ["At \u00b5M concentration, NrTPs penetrate different cell types and exhibit exquisite nucleolar localization.", [["cell", "ANATOMY", 47, 51], ["nucleolar", "ANATOMY", 80, 89], ["NrTPs", "SIMPLE_CHEMICAL", 21, 26], ["cell", "CELL", 47, 51], ["nucleolar", "CELLULAR_COMPONENT", 80, 89], ["NrTPs", "PROTEIN", 21, 26], ["NrTPs", "TREATMENT", 21, 26], ["cell types", "OBSERVATION", 47, 57], ["exquisite", "OBSERVATION_MODIFIER", 70, 79], ["nucleolar localization", "OBSERVATION", 80, 102]]], ["The aim of this work is to decipher the molecular mechanism for the translocation of NrTPs into cells.", [["cells", "ANATOMY", 96, 101], ["NrTPs", "GENE_OR_GENE_PRODUCT", 85, 90], ["cells", "CELL", 96, 101], ["NrTPs", "PROTEIN", 85, 90], ["the translocation of NrTPs into cells", "PROBLEM", 64, 101]]], ["Quantification of partition into membranes was carried out, based on intrinsic tyrosine fluorescence.", [["membranes", "ANATOMY", 33, 42], ["tyrosine", "CHEMICAL", 79, 87], ["tyrosine", "CHEMICAL", 79, 87], ["membranes", "CELLULAR_COMPONENT", 33, 42], ["tyrosine", "AMINO_ACID", 79, 87], ["partition into membranes", "PROBLEM", 18, 42], ["intrinsic tyrosine fluorescence", "TEST", 69, 100], ["tyrosine fluorescence", "OBSERVATION", 79, 100]]], ["The role of the bilayer phase, anionic lipids, reducing agents and peptide concentration on the extent and kinetics of partition were studied.", [["anionic lipids", "SIMPLE_CHEMICAL", 31, 45], ["anionic lipids", "TREATMENT", 31, 45], ["reducing agents", "TREATMENT", 47, 62], ["peptide concentration", "TREATMENT", 67, 88]]], ["Both NrTP1 and NrTP2 exhibited high partition to POPC (neutral) lipid vesicles (K p \u22483\u00d710 3 ), which was enhanced by the anionic lipid POPG for NrTP1, but not NrTP2.", [["lipid vesicles", "ANATOMY", 64, 78], ["POPC", "CHEMICAL", 49, 53], ["NrTP1", "GENE_OR_GENE_PRODUCT", 5, 10], ["NrTP2", "GENE_OR_GENE_PRODUCT", 15, 20], ["POPC", "SIMPLE_CHEMICAL", 49, 53], ["NrTP1", "GENE_OR_GENE_PRODUCT", 144, 149], ["NrTP2", "GENE_OR_GENE_PRODUCT", 159, 164], ["NrTP1", "PROTEIN", 5, 10], ["NrTP2", "PROTEIN", 15, 20], ["NrTP1", "PROTEIN", 144, 149], ["NrTP2", "PROTEIN", 159, 164], ["Both NrTP1", "TEST", 0, 10], ["NrTP2", "TEST", 15, 20], ["POPC", "TEST", 49, 53], ["lipid vesicles", "TEST", 64, 78], ["K p \u2248", "TEST", 80, 85], ["the anionic lipid POPG", "TEST", 117, 139], ["NrTP1", "TEST", 144, 149]]], ["The peptides showed a decrease in partition for POPC:cholesterol (liquid ordered state) or DPPC (gel) membranes.Molecular basis of translocation of novel nucleolar-targetting peptidesDepending on the lipid composition, the peptides either increased or decreased their quantum yield upon membrane insertion.", [["membranes", "ANATOMY", 102, 111], ["nucleolar", "ANATOMY", 154, 163], ["membrane", "ANATOMY", 287, 295], ["cholesterol", "CHEMICAL", 53, 64], ["DPPC", "CHEMICAL", 91, 95], ["POPC", "CHEMICAL", 48, 52], ["cholesterol", "CHEMICAL", 53, 64], ["DPPC", "CHEMICAL", 91, 95], ["POPC", "SIMPLE_CHEMICAL", 48, 52], ["cholesterol", "SIMPLE_CHEMICAL", 53, 64], ["DPPC", "SIMPLE_CHEMICAL", 91, 95], ["nucleolar", "CELLULAR_COMPONENT", 154, 163], ["lipid", "SIMPLE_CHEMICAL", 200, 205], ["membrane", "CELLULAR_COMPONENT", 287, 295], ["The peptides", "TEST", 0, 12], ["cholesterol (liquid ordered state", "TREATMENT", 53, 86], ["DPPC (gel) membranes", "TREATMENT", 91, 111], ["novel nucleolar-targetting peptides", "PROBLEM", 148, 183], ["the lipid composition", "TEST", 196, 217], ["membrane insertion", "TREATMENT", 287, 305], ["decrease", "OBSERVATION_MODIFIER", 22, 30], ["increased", "OBSERVATION_MODIFIER", 239, 248], ["decreased", "OBSERVATION_MODIFIER", 252, 261], ["membrane insertion", "OBSERVATION", 287, 305]]], ["Quenching experiments with acrylamide showed no peptide aggregation in solution.", [["acrylamide", "CHEMICAL", 27, 37], ["acrylamide", "CHEMICAL", 27, 37], ["acrylamide", "SIMPLE_CHEMICAL", 27, 37], ["Quenching experiments", "TEST", 0, 21], ["acrylamide", "TREATMENT", 27, 37], ["peptide aggregation in solution", "PROBLEM", 48, 79]]], ["Once the translocation mechanism is fully understood we will test NrTPs as carriers of relevant cellular cargos, evaluating their potential clinical application in drug delivery or gene therapy among other applications.The effect of TRANS unsaturation on molecular organization in a phospholipid bilayerThe ingestion of trans fatty acids (TFA) formed during the partial hydrogenation of vegetable oils has been linked to a detrimental impact on health by an, as yet, unknown mechanism.", [["cellular", "ANATOMY", 96, 104], ["phospholipid bilayer", "ANATOMY", 283, 303], ["vegetable oils", "ANATOMY", 387, 401], ["TRANS unsaturation", "CHEMICAL", 233, 251], ["trans fatty acids", "CHEMICAL", 320, 337], ["TFA", "CHEMICAL", 339, 342], ["vegetable oils", "CHEMICAL", 387, 401], ["trans fatty acids", "CHEMICAL", 320, 337], ["TFA", "CHEMICAL", 339, 342], ["NrTPs", "SIMPLE_CHEMICAL", 66, 71], ["cellular", "CELL", 96, 104], ["TRANS", "SIMPLE_CHEMICAL", 233, 238], ["trans fatty acids", "SIMPLE_CHEMICAL", 320, 337], ["TFA", "SIMPLE_CHEMICAL", 339, 342], ["NrTPs", "PROTEIN", 66, 71], ["drug delivery", "TREATMENT", 164, 177], ["gene therapy", "TREATMENT", 181, 193], ["TRANS unsaturation", "PROBLEM", 233, 251], ["a phospholipid bilayer", "TREATMENT", 281, 303], ["trans fatty acids (TFA)", "TREATMENT", 320, 343], ["the partial hydrogenation of vegetable oils", "TREATMENT", 358, 401]]], ["We synthesized deuterated analogs of 1-elaidoyl-2-stearoylphosphatidylcholine (t18:1-18:0PC) that contains a single \"unnatural\" trans double bond and 1-oleoyl-2-stearoylphosphatidylcholine (c18:1-18:0PC) that contains a single \"natural\" cis double bond.", [["1-elaidoyl-2-stearoylphosphatidylcholine", "CHEMICAL", 37, 77], ["t18:1-18:0PC", "CHEMICAL", 79, 91], ["1-oleoyl-2-stearoylphosphatidylcholine", "CHEMICAL", 150, 188], ["c18:1-18:0PC", "CHEMICAL", 190, 202], ["1-elaidoyl-2-stearoylphosphatidylcholine", "CHEMICAL", 37, 77], ["t18:1-18:0PC", "CHEMICAL", 79, 91], ["1-oleoyl-2-stearoylphosphatidylcholine", "CHEMICAL", 150, 188], ["c18:1-18:0PC", "CHEMICAL", 190, 202], ["1-elaidoyl-2-stearoylphosphatidylcholine", "SIMPLE_CHEMICAL", 37, 77], ["t18:1-18:0PC", "SIMPLE_CHEMICAL", 79, 91], ["trans double bond", "SIMPLE_CHEMICAL", 128, 145], ["1-oleoyl-2-stearoylphosphatidylcholine", "SIMPLE_CHEMICAL", 150, 188], ["c18:1-18:0PC", "SIMPLE_CHEMICAL", 190, 202], ["cis double bond", "SIMPLE_CHEMICAL", 237, 252], ["elaidoyl", "TEST", 39, 47]]], ["Solid state 2 H NMR, complemented by molecular dynamics (MD) simulations, was then employed to compare molecular organization in model membranes prepared from these isomeric molecules.", [["membranes", "ANATOMY", 135, 144], ["2 H", "CHEMICAL", 12, 15], ["membranes", "CELLULAR_COMPONENT", 135, 144], ["model membranes", "OBSERVATION", 129, 144], ["isomeric molecules", "OBSERVATION", 165, 183]]], ["Analysis of spectra recorded as a function of temperature reveals a higher chain melting temperature for the trans isomer, indicating tighter molecular packing in the gel state.", [["Analysis of spectra", "TEST", 0, 19], ["a function of temperature", "TEST", 32, 57], ["a higher chain melting temperature", "PROBLEM", 66, 100], ["tighter", "OBSERVATION_MODIFIER", 134, 141], ["molecular packing", "OBSERVATION", 142, 159]]], ["In the liquid crystalline, however, the difference between the trans and cis isomers is subtle.", [["cis isomers", "SIMPLE_CHEMICAL", 73, 84], ["liquid crystalline", "OBSERVATION_MODIFIER", 7, 25], ["subtle", "OBSERVATION_MODIFIER", 88, 94]]], ["Order as probed by the perdeuterated [ 2 H 31 ]18:0 sn-2 chain, and corroborated by computer simulation, coincides within <5%.", [["[ 2 H 31 ]18:0", "CHEMICAL", 37, 51]]], ["Only in the conformation of the double bond is an appreciable difference implied.", [["appreciable", "OBSERVATION_MODIFIER", 50, 61], ["difference", "OBSERVATION", 62, 72]]], ["Thus, our results contradict the conventional view that TFA resemble saturated fatty acids, which is >20% more ordered.", [["TFA", "CHEMICAL", 56, 59], ["fatty acids", "CHEMICAL", 79, 90], ["TFA", "CHEMICAL", 56, 59], ["saturated fatty acids", "CHEMICAL", 69, 90], ["TFA", "SIMPLE_CHEMICAL", 56, 59], ["saturated fatty acids", "SIMPLE_CHEMICAL", 69, 90], ["fatty acids", "TEST", 79, 90]]], ["(Supported by ACS, PRF 43281-AC7.)P-617Photooxidation and lateral membrane diffusion of dipole molecules V. S. Sokolov 1 , E. A. Sokolenko 1 , A. A. Lents 2 , P. Pohl 2 1 A.N Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Science, Moscow, Russia, 2 Institut fuer Biophysik, Johannes Kepler Universitaet Linz, AustriaP-617The photodynamic oxidation of phloridzin, of the styryl dye di-8-Anepps and of unsaturated lipids was monitored \"online\" by measuring the collapse of the dipole potential which has been introduced to the membrane by these molecules.", [["lateral membrane", "ANATOMY", 58, 74], ["membrane", "ANATOMY", 559, 567], ["ACS", "DISEASE", 14, 17], ["P-617", "CHEMICAL", 34, 39], ["AustriaP-617", "CHEMICAL", 343, 355], ["phloridzin", "CHEMICAL", 385, 395], ["styryl", "CHEMICAL", 404, 410], ["di-8-Anepps", "CHEMICAL", 415, 426], ["phloridzin", "CHEMICAL", 385, 395], ["styryl", "CHEMICAL", 404, 410], ["di-8-Anepps", "CHEMICAL", 415, 426], ["phloridzin", "SIMPLE_CHEMICAL", 385, 395], ["styryl dye di-8-Anepps", "SIMPLE_CHEMICAL", 404, 426], ["unsaturated lipids", "SIMPLE_CHEMICAL", 434, 452], ["membrane", "CELLULAR_COMPONENT", 559, 567], ["P", "TEST", 34, 35], ["Photooxidation", "TREATMENT", 39, 53], ["lateral membrane diffusion", "TEST", 58, 84], ["The photodynamic oxidation of phloridzin", "TREATMENT", 355, 395], ["the styryl dye", "TEST", 400, 414], ["unsaturated lipids", "TEST", 434, 452], ["collapse", "OBSERVATION", 493, 501], ["dipole potential", "OBSERVATION_MODIFIER", 509, 525]]], ["Their photodamage occurred at different rates when the target molecules and the singlet oxygen generating photosensitizer (phthalocyanin) were adsorbed to the same or to opposite sides of the planar lipid bilayer.", [["oxygen", "CHEMICAL", 88, 94], ["phthalocyanin", "CHEMICAL", 123, 136], ["oxygen", "CHEMICAL", 88, 94], ["phthalocyanin", "CHEMICAL", 123, 136], ["oxygen", "SIMPLE_CHEMICAL", 88, 94], ["photosensitizer", "SIMPLE_CHEMICAL", 106, 121], ["phthalocyanin", "SIMPLE_CHEMICAL", 123, 136], ["Their photodamage", "PROBLEM", 0, 17], ["the singlet oxygen generating photosensitizer (phthalocyanin", "TREATMENT", 76, 136], ["photodamage", "OBSERVATION", 6, 17]]], ["The difference in the oxidation rates were attribute to singlet oxygen transport through lipid bilayer and therefore we were able to estimate the permeability of lipid bilayers to singlet oxygen.", [["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 188, 194], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 188, 194], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["lipid bilayers", "SIMPLE_CHEMICAL", 162, 176], ["singlet oxygen", "SIMPLE_CHEMICAL", 180, 194], ["the oxidation rates", "TREATMENT", 18, 37], ["singlet oxygen transport through lipid bilayer", "TREATMENT", 56, 102], ["lipid bilayers", "TREATMENT", 162, 176], ["singlet oxygen", "TREATMENT", 180, 194], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["singlet oxygen", "OBSERVATION", 56, 70], ["singlet oxygen", "OBSERVATION", 180, 194]]], ["However, the apparent permeabilities derived from experiments with different targets were differ from each other.", [["the apparent permeabilities", "PROBLEM", 9, 36]]], ["Therefore, we tested the hypothesis that the lateral membrane diffusion of target molecules and oxidation product may have biased our analysis.", [["lateral membrane", "ANATOMY", 45, 61], ["lateral membrane", "MULTI-TISSUE_STRUCTURE", 45, 61], ["our analysis", "TEST", 130, 142]]], ["In line with this anticipation we found that the apparent permeability is dependent on the size of the planar bilayer.", [["the apparent permeability", "PROBLEM", 45, 70], ["permeability", "OBSERVATION", 58, 70], ["dependent", "OBSERVATION_MODIFIER", 74, 83], ["size", "OBSERVATION_MODIFIER", 91, 95], ["planar", "ANATOMY_MODIFIER", 103, 109], ["bilayer", "ANATOMY_MODIFIER", 110, 117]]], ["The development of a new mathematical model, which takes the mobility of all reacting species in the aqueous and lipid environments into account, allowed estimation of the real membrane permeability to singlet oxygen.", [["membrane", "ANATOMY", 177, 185], ["oxygen", "CHEMICAL", 210, 216], ["oxygen", "CHEMICAL", 210, 216], ["aqueous", "SIMPLE_CHEMICAL", 101, 108], ["membrane", "CELLULAR_COMPONENT", 177, 185], ["singlet oxygen", "SIMPLE_CHEMICAL", 202, 216], ["a new mathematical model", "PROBLEM", 19, 43], ["all reacting species", "PROBLEM", 73, 93], ["singlet oxygen", "TREATMENT", 202, 216], ["new", "OBSERVATION_MODIFIER", 21, 24], ["mathematical model", "OBSERVATION", 25, 43], ["mobility", "OBSERVATION_MODIFIER", 61, 69], ["reacting species", "OBSERVATION", 77, 93], ["singlet oxygen", "OBSERVATION", 202, 216]]], ["It appeared to be very close to that of oxygen in the ground state.", [["oxygen", "CHEMICAL", 40, 46], ["oxygen", "CHEMICAL", 40, 46], ["oxygen", "SIMPLE_CHEMICAL", 40, 46]]], ["A number of complex three-dimensional lyotropic liquid crystal phases are already known, such as the bicontinuous cubic phases, but so far only a single example has been found -a cubic phase of spacegroup Fd3m -of a structure based upon a complex close packing of inverse micelles (1) .", [["Fd3m", "PROTEIN", 205, 209], ["complex three-dimensional lyotropic liquid crystal phases", "TREATMENT", 12, 69], ["the bicontinuous cubic phases", "TEST", 97, 126], ["a complex close packing of inverse micelles", "TREATMENT", 237, 280], ["complex", "OBSERVATION_MODIFIER", 12, 19]]], ["We now report the discovery (2) of a novel lyotropic liquid crystal phase, of space group, P6 3 /mmc, whose structure is based upon a hexagonal close packing of identical quasi-spherical inverse micelles.", [["mmc", "PROTEIN", 97, 100], ["a novel lyotropic liquid crystal phase", "TREATMENT", 35, 73], ["space group, P6", "TREATMENT", 78, 93], ["a hexagonal close packing", "TREATMENT", 132, 157], ["inverse micelles", "OBSERVATION", 187, 203]]], ["The model membrane system consists of a hydrated mixture of dioleoylphosphatidylcholine, dioleoylglycerol, and cholesterol.", [["membrane system", "ANATOMY", 10, 25], ["dioleoylphosphatidylcholine", "CHEMICAL", 60, 87], ["dioleoylglycerol", "CHEMICAL", 89, 105], ["cholesterol", "CHEMICAL", 111, 122], ["dioleoylphosphatidylcholine", "CHEMICAL", 60, 87], ["dioleoylglycerol", "CHEMICAL", 89, 105], ["cholesterol", "CHEMICAL", 111, 122], ["dioleoylphosphatidylcholine", "SIMPLE_CHEMICAL", 60, 87], ["dioleoylglycerol", "SIMPLE_CHEMICAL", 89, 105], ["cholesterol", "SIMPLE_CHEMICAL", 111, 122], ["a hydrated mixture of dioleoylphosphatidylcholine", "TREATMENT", 38, 87], ["dioleoylglycerol", "TREATMENT", 89, 105], ["cholesterol", "TREATMENT", 111, 122], ["membrane system", "OBSERVATION", 10, 25]]], ["Firstly, it is the only known self-assembled lyotropic phase whose structure consists of a periodic close packing of identical inverse micelles.", [["lyotropic phase", "OBSERVATION_MODIFIER", 45, 60], ["periodic", "OBSERVATION_MODIFIER", 91, 99], ["close packing", "OBSERVATION_MODIFIER", 100, 113], ["inverse micelles", "OBSERVATION", 127, 143]]], ["Secondly, it is stable in excess aqueous solution, which is very important for potential biological or biomedical applications.", [["excess aqueous solution", "TREATMENT", 26, 49], ["biomedical applications", "TREATMENT", 103, 126], ["stable", "OBSERVATION_MODIFIER", 16, 22]]], ["Dystrophin is a rod-shaped muscular subsarcolemal protein.P-617Its deficiency is one of the root causes of Duchenne muscular dystrophy.", [["muscular subsarcolemal", "ANATOMY", 27, 49], ["root", "ANATOMY", 92, 96], ["Duchenne muscular", "ANATOMY", 107, 124], ["P-617Its", "CHEMICAL", 58, 66], ["Duchenne muscular dystrophy", "DISEASE", 107, 134], ["Dystrophin", "GENE_OR_GENE_PRODUCT", 0, 10], ["muscular subsarcolemal", "CANCER", 27, 49], ["P-617Its", "GENE_OR_GENE_PRODUCT", 58, 66], ["muscular", "ORGAN", 116, 124], ["Dystrophin", "PROTEIN", 0, 10], ["rod-shaped muscular subsarcolemal protein", "PROTEIN", 16, 57], ["P", "DNA", 58, 59], ["Dystrophin", "PROBLEM", 0, 10], ["a rod-shaped muscular subsarcolemal protein", "PROBLEM", 14, 57], ["deficiency", "PROBLEM", 67, 77], ["Duchenne muscular dystrophy", "PROBLEM", 107, 134], ["shaped", "OBSERVATION_MODIFIER", 20, 26], ["muscular", "OBSERVATION_MODIFIER", 27, 35], ["subsarcolemal protein", "OBSERVATION", 36, 57], ["root", "ANATOMY", 92, 96], ["Duchenne muscular dystrophy", "OBSERVATION", 107, 134]]], ["Dystrophin rod domain contains 24 homologous repeats, where the sub-domain constituted by the repeats 11 to 15 (R11-15) was reported to bind actin and membrane lipids.", [["membrane lipids", "ANATOMY", 151, 166], ["Dystrophin", "GENE_OR_GENE_PRODUCT", 0, 10], ["actin", "GENE_OR_GENE_PRODUCT", 141, 146], ["membrane lipids", "CELLULAR_COMPONENT", 151, 166], ["Dystrophin rod domain", "PROTEIN", 0, 21], ["sub-domain", "PROTEIN", 64, 74], ["repeats 11 to 15 (R11-15", "DNA", 94, 118], ["actin", "PROTEIN", 141, 146], ["Dystrophin rod domain", "PROBLEM", 0, 21], ["homologous repeats", "TEST", 34, 52], ["the repeats", "TEST", 90, 101], ["R11", "TEST", 112, 115], ["24 homologous", "OBSERVATION_MODIFIER", 31, 44]]], ["We analyzed the interaction of R11-15 with lipid monolayers.", [["lipid monolayers", "ANATOMY", 43, 59], ["R11-15", "CHEMICAL", 31, 37], ["R11-15", "SIMPLE_CHEMICAL", 31, 37], ["lipid monolayers", "CELL", 43, 59], ["R11", "PROTEIN", 31, 34], ["R11", "TEST", 31, 34], ["lipid monolayers", "TREATMENT", 43, 59]]], ["To better understand the assembly mechanism of this protein with lipids, we studied its adsorption behavior at the air-liquid and lipid/liquid interface using ellipsometry, surface pressure, and atomic Force Microscopy (AFM).", [["air-liquid", "ANATOMY", 115, 125], ["surface", "ANATOMY", 173, 180], ["lipids", "SIMPLE_CHEMICAL", 65, 71], ["lipid", "SIMPLE_CHEMICAL", 130, 135], ["lipids", "TREATMENT", 65, 71], ["lipid/liquid interface", "TREATMENT", 130, 152], ["ellipsometry", "TEST", 159, 171], ["surface pressure", "TEST", 173, 189], ["atomic Force Microscopy", "TEST", 195, 218]]], ["Using two different mixtures of phospholipids, ellipsometry and pressure surface data show that R11-15 interacts with the lipid monolayers, but is inserted into the monolayer formed by DOPC-DOPS while it lies below the monolayer of DOPC-DOPE.", [["lipid monolayers", "ANATOMY", 122, 138], ["monolayer", "ANATOMY", 165, 174], ["monolayer", "ANATOMY", 219, 228], ["R11-15", "CHEMICAL", 96, 102], ["DOPC-DOPS", "CHEMICAL", 185, 194], ["DOPC-DOPE", "CHEMICAL", 232, 241], ["R11-15", "CHEMICAL", 96, 102], ["DOPC", "CHEMICAL", 185, 189], ["DOPS", "CHEMICAL", 190, 194], ["DOPC", "CHEMICAL", 232, 236], ["DOPE", "CHEMICAL", 237, 241], ["phospholipids", "SIMPLE_CHEMICAL", 32, 45], ["R11-15", "SIMPLE_CHEMICAL", 96, 102], ["lipid monolayers", "CELL", 122, 138], ["monolayer", "CELL", 165, 174], ["DOPC-DOPS", "SIMPLE_CHEMICAL", 185, 194], ["monolayer", "CELL", 219, 228], ["DOPC-DOPE", "SIMPLE_CHEMICAL", 232, 241], ["R11-15", "PROTEIN", 96, 102], ["phospholipids", "TREATMENT", 32, 45], ["ellipsometry and pressure surface data", "TEST", 47, 85], ["R11", "TEST", 96, 99], ["the lipid monolayers", "TREATMENT", 118, 138], ["DOPC", "TEST", 185, 189]]], ["This indicates that R11-15 interacts more strongly with DOPC-DOPS than with DOPC-DOPE.", [["R11-15", "CHEMICAL", 20, 26], ["DOPC-DOPS", "CHEMICAL", 56, 65], ["DOPC-DOPE", "CHEMICAL", 76, 85], ["R11-15", "CHEMICAL", 20, 26], ["DOPC", "CHEMICAL", 56, 60], ["DOPS", "CHEMICAL", 61, 65], ["DOPC", "CHEMICAL", 76, 80], ["DOPE", "CHEMICAL", 81, 85], ["R11-15", "SIMPLE_CHEMICAL", 20, 26], ["DOPC-DOPS", "SIMPLE_CHEMICAL", 56, 65], ["DOPC-DOPE", "SIMPLE_CHEMICAL", 76, 85], ["R11", "TEST", 20, 23], ["DOPC", "TEST", 56, 60], ["DOPC", "TEST", 76, 80]]], ["AFM images show that the pressure of lipid monolayer influences the organization of R11-15.", [["lipid monolayer", "ANATOMY", 37, 52], ["R11-15", "CHEMICAL", 84, 90], ["R11", "PROTEIN", 84, 87], ["AFM images", "TEST", 0, 10], ["the pressure of lipid monolayer", "TEST", 21, 52], ["R11", "TEST", 84, 87], ["pressure", "OBSERVATION_MODIFIER", 25, 33], ["lipid monolayer", "OBSERVATION", 37, 52]]], ["When the lipid surface pressure is 30mN/m, R11-15 forms a striking network, indicating a protein-protein interaction in addition to the protein-lipid interaction.", [["lipid surface", "ANATOMY", 9, 22], ["R11-15", "PROTEIN", 43, 49], ["the lipid surface pressure", "TEST", 5, 31], ["a protein-protein interaction", "PROBLEM", 87, 116], ["the protein", "TEST", 132, 143]]], ["This unique behavior of one part of the central domain of dystrophin may explain its key role in muscle cell.", [["muscle cell", "ANATOMY", 97, 108], ["dystrophin", "GENE_OR_GENE_PRODUCT", 58, 68], ["muscle cell", "CELL", 97, 108], ["central domain", "PROTEIN", 40, 54], ["dystrophin", "PROTEIN", 58, 68], ["muscle cell", "CELL_TYPE", 97, 108], ["dystrophin", "OBSERVATION", 58, 68], ["muscle cell", "OBSERVATION", 97, 108]]], ["Studies on polyphenol extracts from Helichrysum L., Fagopyrum Mill., Crataegus L. and Hypericum L. were performed in order to find if they may be applied as a natural free radical scavengers protecting biological membranes against peroxidation.", [["extracts", "ANATOMY", 22, 30], ["membranes", "ANATOMY", 213, 222], ["polyphenol", "CHEMICAL", 11, 21], ["Helichrysum L., Fagopyrum Mill., Crataegus L.", "CHEMICAL", 36, 81], ["polyphenol", "CHEMICAL", 11, 21], ["polyphenol extracts", "ORGANISM_SUBSTANCE", 11, 30], ["Helichrysum L.", "ORGANISM", 36, 50], ["Fagopyrum Mill.", "ORGANISM", 52, 67], ["Crataegus L.", "ORGANISM", 69, 81], ["Hypericum L.", "ORGANISM", 86, 98], ["Helichrysum L.", "SPECIES", 36, 50], ["Fagopyrum Mill.", "SPECIES", 52, 67], ["Crataegus L.", "SPECIES", 69, 81], ["Hypericum L.", "SPECIES", 86, 98], ["Helichrysum L.", "SPECIES", 36, 50], ["Fagopyrum Mill.", "SPECIES", 52, 67], ["Crataegus L.", "SPECIES", 69, 81], ["Hypericum L.", "SPECIES", 86, 98], ["Studies", "TEST", 0, 7], ["polyphenol extracts", "TEST", 11, 30], ["Crataegus L.", "TEST", 69, 81], ["Hypericum L.", "TEST", 86, 98], ["a natural free radical scavengers", "TREATMENT", 157, 190], ["Fagopyrum Mill.", "OBSERVATION", 52, 67], ["Crataegus", "OBSERVATION_MODIFIER", 69, 78], ["Hypericum", "OBSERVATION_MODIFIER", 86, 95]]], ["Ghosts erythrocytes were used in the experiments.", [["erythrocytes", "ANATOMY", 7, 19], ["Ghosts erythrocytes", "CELL", 0, 19], ["Ghosts erythrocytes", "CELL_TYPE", 0, 19], ["Ghosts erythrocytes", "PROBLEM", 0, 19]]], ["They were suspended in Tris-EDTA solution, pH 7,4, then.irradiated with a bactericidal lamp without (control) or with a proper amount of the extracts studied.", [["extracts", "ANATOMY", 141, 149], ["Tris-EDTA", "CHEMICAL", 23, 32], ["Tris-EDTA", "CHEMICAL", 23, 32], ["Tris-EDTA", "SIMPLE_CHEMICAL", 23, 32], ["extracts", "ORGANISM_SUBSTANCE", 141, 149], ["pH", "TEST", 43, 45], ["a bactericidal lamp", "TREATMENT", 72, 91]]], ["The product of lipid peroxidation was malonic dialdehyde (MA).", [["malonic dialdehyde", "CHEMICAL", 38, 56], ["MA", "CHEMICAL", 58, 60], ["malonic dialdehyde", "CHEMICAL", 38, 56], ["lipid", "SIMPLE_CHEMICAL", 15, 20], ["malonic dialdehyde", "SIMPLE_CHEMICAL", 38, 56], ["MA", "SIMPLE_CHEMICAL", 58, 60], ["lipid peroxidation", "PROBLEM", 15, 33], ["lipid peroxidation", "OBSERVATION", 15, 33], ["malonic dialdehyde", "OBSERVATION", 38, 56]]], ["The colour reaction of MA with thiobarbituric acid (TBA) enables to determine the concentration of MA spectrophotometrically.", [["MA", "CHEMICAL", 23, 25], ["thiobarbituric acid", "CHEMICAL", 31, 50], ["TBA", "CHEMICAL", 52, 55], ["thiobarbituric acid", "CHEMICAL", 31, 50], ["TBA", "CHEMICAL", 52, 55], ["MA", "SIMPLE_CHEMICAL", 23, 25], ["thiobarbituric acid", "SIMPLE_CHEMICAL", 31, 50], ["TBA", "SIMPLE_CHEMICAL", 52, 55], ["MA", "GENE_OR_GENE_PRODUCT", 99, 101], ["thiobarbituric acid (TBA)", "TREATMENT", 31, 56]]], ["It was found that peroxidation increased with the irradiation time.", [["peroxidation", "PROBLEM", 18, 30], ["the irradiation time", "TREATMENT", 46, 66], ["peroxidation", "OBSERVATION_MODIFIER", 18, 30], ["increased", "OBSERVATION_MODIFIER", 31, 40]]], ["However, it significantly decreased when concentrations of poliphenols increased.", [["poliphenols", "CHEMICAL", 59, 70], ["poliphenols", "CHEMICAL", 59, 70], ["poliphenols", "SIMPLE_CHEMICAL", 59, 70], ["poliphenols", "TREATMENT", 59, 70], ["significantly", "OBSERVATION_MODIFIER", 12, 25], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["increased", "OBSERVATION_MODIFIER", 71, 80]]], ["The best antioxidtive property was found for Hypericum L. The antioxidative efficiency sequence of the plant extracts studied was the following: Hypericum L. > Crataegus L. > Fagopyrum Mill. > Helichrysum L. The results obtained indicate that polyphenol extracts exhibit excelent antioxidative properties that make them good free radical scavengers for efficient protection of biological membranes.", [["extracts", "ANATOMY", 109, 117], ["extracts", "ANATOMY", 254, 262], ["membranes", "ANATOMY", 388, 397], ["Hypericum L.", "CHEMICAL", 45, 57], ["polyphenol", "CHEMICAL", 243, 253], ["polyphenol", "CHEMICAL", 243, 253], ["Hypericum L.", "ORGANISM", 45, 57], ["extracts", "ORGANISM_SUBSTANCE", 109, 117], ["Hypericum L.", "ORGANISM", 145, 157], ["Crataegus L.", "ORGANISM", 160, 172], ["Fagopyrum Mill", "ORGANISM", 175, 189], ["Helichrysum L.", "ORGANISM", 193, 207], ["polyphenol extracts", "ORGANISM_SUBSTANCE", 243, 262], ["membranes", "CELLULAR_COMPONENT", 388, 397], ["Hypericum L.", "SPECIES", 45, 57], ["Hypericum L.", "SPECIES", 145, 157], ["Crataegus L.", "SPECIES", 160, 172], ["Hypericum L.", "SPECIES", 45, 57], ["Hypericum L.", "SPECIES", 145, 157], ["Crataegus L.", "SPECIES", 160, 172], ["Helichrysum L.", "SPECIES", 193, 207], ["Hypericum L.", "PROBLEM", 45, 57], ["the plant extracts", "TEST", 99, 117], ["Hypericum L.", "TEST", 145, 157], ["polyphenol extracts", "TREATMENT", 243, 262], ["antioxidative properties", "TREATMENT", 280, 304], ["radical scavengers", "TREATMENT", 330, 348], ["biological membranes", "TREATMENT", 377, 397], ["Fagopyrum Mill", "OBSERVATION", 175, 189], ["biological membranes", "OBSERVATION", 377, 397]]], ["This work was sponsored by Ministry of Science and Education, scientific project no. N N305 337034.P-621Interaction of cationic porphyrins with neutral and negatively charged liposomes I. Voszka 1 , G. Corradi 2 , P. Maillard 3 , H.-J. Steinhoff 4 , G. Cs\u00edk 1 1 Institute of Biophysics and Radiation Biology, Semmelweis University Budapest, Hungary, 2 Research Institute for Solid State Physics and Optics, Hungarian Academy of Sciences, Budapest, Hungary, 3 Institute Curie, Section de Biologie, Orsay, France, 4 Fachbereich Physik, Universitat Osnabr\u00fcck, Germany Porphyrin derivatives are used in photodynamic therapy of tumors.", [["tumors", "ANATOMY", 623, 629], ["N", "CHEMICAL", 85, 86], ["N305 337034.P-621Interaction", "CHEMICAL", 87, 115], ["Porphyrin", "CHEMICAL", 565, 574], ["tumors", "DISEASE", 623, 629], ["porphyrins", "CHEMICAL", 128, 138], ["cationic porphyrins", "SIMPLE_CHEMICAL", 119, 138], ["tumors", "CANCER", 623, 629], ["cationic porphyrins", "TREATMENT", 119, 138], ["neutral and negatively charged liposomes", "TREATMENT", 144, 184], ["Universitat Osnabr\u00fcck", "TREATMENT", 534, 555], ["Germany Porphyrin derivatives", "TREATMENT", 557, 586], ["photodynamic therapy", "TREATMENT", 599, 619], ["tumors", "PROBLEM", 623, 629], ["tumors", "OBSERVATION", 623, 629]]], ["The knowledge of the photosensitizer location within the cell is important.", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["photosensitizer location", "OBSERVATION", 21, 45], ["cell", "OBSERVATION", 57, 61]]], ["The effect of porphyrin derivatives containing cationic side groups was examined on neutral and negatively charged liposomes by ESR.", [["porphyrin", "CHEMICAL", 14, 23], ["porphyrin", "CHEMICAL", 14, 23], ["porphyrin derivatives", "SIMPLE_CHEMICAL", 14, 35], ["cationic side groups", "SIMPLE_CHEMICAL", 47, 67], ["liposomes", "SIMPLE_CHEMICAL", 115, 124], ["ESR", "PROTEIN", 128, 131], ["porphyrin derivatives containing cationic side groups", "TREATMENT", 14, 67], ["porphyrin derivatives", "OBSERVATION", 14, 35]]], ["The ESR signal was first examined as a function of temperature and porphyrin concentration in the dark.", [["porphyrin", "CHEMICAL", 67, 76], ["porphyrin", "CHEMICAL", 67, 76], ["porphyrin", "SIMPLE_CHEMICAL", 67, 76], ["ESR", "PROTEIN", 4, 7], ["The ESR signal", "TEST", 0, 14], ["porphyrin concentration", "TEST", 67, 90]]], ["A significant change related to the appearance of quasi free spin labels was obtained for spin probes at the 12 th carbon atom and was more expressed for the asymmetrical derivative.", [["carbon", "CHEMICAL", 115, 121], ["A significant change", "PROBLEM", 0, 20], ["spin probes at the 12 th carbon atom", "TREATMENT", 90, 126], ["the asymmetrical derivative", "PROBLEM", 154, 181], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["change", "OBSERVATION", 14, 20]]], ["Illuminating the samples the ESR amplitude decreased for all positions of the spin probe but to different extent.", [["samples", "ANATOMY", 17, 24], ["the samples", "TEST", 13, 24], ["the ESR amplitude", "TEST", 25, 42], ["all positions", "OBSERVATION_MODIFIER", 57, 70], ["different extent", "OBSERVATION_MODIFIER", 96, 112]]], ["The effect was more expressed in case of the symmetrical derivative, especially for label positions 5 and 12.", [["the symmetrical derivative", "TREATMENT", 41, 67]]], ["For the asymmetrical derivative the effect changed from moderate to weak from the 5 th to the 16 th position.", [["the asymmetrical derivative the effect", "PROBLEM", 4, 42], ["asymmetrical", "OBSERVATION_MODIFIER", 8, 20], ["derivative", "OBSERVATION_MODIFIER", 21, 31], ["moderate", "OBSERVATION_MODIFIER", 56, 64], ["weak", "OBSERVATION_MODIFIER", 68, 72]]], ["This indicates that the asymmetrical derivative is incorporated nearer to the lipid head groups while the symmetrical one may be located deeper in the membrane.", [["lipid head", "ANATOMY", 78, 88], ["membrane", "ANATOMY", 151, 159], ["membrane", "CELLULAR_COMPONENT", 151, 159], ["the asymmetrical derivative", "PROBLEM", 20, 47], ["asymmetrical", "OBSERVATION_MODIFIER", 24, 36], ["derivative", "OBSERVATION_MODIFIER", 37, 47], ["symmetrical", "OBSERVATION_MODIFIER", 106, 117], ["may be", "UNCERTAINTY", 122, 128], ["membrane", "ANATOMY_MODIFIER", 151, 159]]], ["Under oxygen-free conditions both derivatives showed weaker but still pronounced effects..P-620Single channel recording of \u03b1-Hemolysin in nanopore-spanning tethered bilayer lipid membranes N. T. Thet 1 , I. Pfeiffer 2 , W. Knoll 1 , I. K\u00f6per 1 1 Max Planck Institute for Polymer Research (MPI-P), Ackermannweg 10, 55128 Mainz, 2 Austrian Research Centers GmbH -ARC, Tech Gate Vienna, 1220 Vienna, Austria Artificial lipid bilayer membranes mimic biological cell membranes in many aspects and can be used to study functional processes such as ion channeling, signal transducing, transport of nutrients etc. As most of the functions of a cell are accomplished by membrane proteins, research has been ongoing in studying and characterization of membrane proteins embedded in model lipid bilayer membranes.", [["lipid bilayer membranes", "ANATOMY", 416, 439], ["cell membranes", "ANATOMY", 457, 471], ["cell", "ANATOMY", 636, 640], ["membrane", "ANATOMY", 661, 669], ["membrane", "ANATOMY", 742, 750], ["lipid bilayer membranes", "ANATOMY", 778, 801], ["oxygen", "CHEMICAL", 6, 12], ["\u03b1-Hemolysin", "CHEMICAL", 123, 134], ["oxygen", "CHEMICAL", 6, 12], ["oxygen", "SIMPLE_CHEMICAL", 6, 12], ["\u03b1-Hemolysin", "GENE_OR_GENE_PRODUCT", 123, 134], ["cell membranes", "CELLULAR_COMPONENT", 457, 471], ["cell", "CELL", 636, 640], ["membrane", "CELLULAR_COMPONENT", 661, 669], ["membrane", "CELLULAR_COMPONENT", 742, 750], ["lipid bilayer membranes", "CELLULAR_COMPONENT", 778, 801], ["P", "DNA", 90, 91], ["\u03b1-Hemolysin", "PROTEIN", 123, 134], ["membrane proteins", "PROTEIN", 661, 678], ["membrane proteins", "PROTEIN", 742, 759], ["weaker", "PROBLEM", 53, 59], ["P", "TEST", 90, 91], ["\u03b1-Hemolysin in nanopore", "TREATMENT", 123, 146], ["spanning tethered bilayer lipid membranes", "TREATMENT", 147, 188], ["Austria Artificial lipid bilayer membranes", "TREATMENT", 397, 439], ["membrane proteins", "PROBLEM", 742, 759], ["model lipid bilayer membranes", "TREATMENT", 772, 801], ["biological cell membranes", "OBSERVATION", 446, 471], ["lipid bilayer membranes", "OBSERVATION", 778, 801]]], ["Black lipid membranes (BLMs) were studied for decades but their potential for practical applications is hindered, mainly due to their lack of stability and limited lifespan.", [["lipid membranes", "ANATOMY", 6, 21], ["BLMs", "ANATOMY", 23, 27], ["lipid membranes", "CELLULAR_COMPONENT", 6, 21], ["BLMs", "CELLULAR_COMPONENT", 23, 27], ["Black lipid membranes", "PROBLEM", 0, 21], ["practical applications", "TREATMENT", 78, 100], ["lipid membranes", "OBSERVATION", 6, 21], ["stability", "OBSERVATION", 142, 151]]], ["Recently, tethered bilayer lipid membranes (tBLMs) proved to have long life span of up to several months without significant changes in membrane resistance and capacitance.", [["bilayer lipid membranes", "ANATOMY", 19, 42], ["tBLMs", "ANATOMY", 44, 49], ["membrane", "ANATOMY", 136, 144], ["lipid membranes", "CELLULAR_COMPONENT", 27, 42], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["tethered bilayer lipid membranes", "PROBLEM", 10, 42], ["significant changes in membrane resistance", "PROBLEM", 113, 155], ["lipid membranes", "OBSERVATION", 27, 42], ["membrane resistance", "OBSERVATION", 136, 155]]], ["In order to combine advantages of BLMs and tBLMs, we have designed a membrane system which is freely spanned across a single nanopore in a silicon nitride membrane.", [["membrane system", "ANATOMY", 69, 84], ["silicon nitride", "CHEMICAL", 139, 154], ["silicon nitride", "CHEMICAL", 139, 154], ["BLMs", "SIMPLE_CHEMICAL", 34, 38], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["BLMs", "CELL_TYPE", 34, 38], ["BLMs and tBLMs", "PROBLEM", 34, 48], ["a membrane system", "TREATMENT", 67, 84], ["a single nanopore in a silicon nitride membrane", "TREATMENT", 116, 163], ["silicon nitride", "OBSERVATION", 139, 154]]], ["This system not only mimics cell membranes, but also it allows control over the chemical composition of buffer with unlimited ionic reservoirs on both sides of the membrane.", [["cell membranes", "ANATOMY", 28, 42], ["membrane", "ANATOMY", 164, 172], ["cell membranes", "CELLULAR_COMPONENT", 28, 42], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["unlimited ionic reservoirs", "TREATMENT", 116, 142], ["mimics cell membranes", "OBSERVATION", 21, 42], ["ionic reservoirs", "OBSERVATION", 126, 142], ["membrane", "ANATOMY", 164, 172]]], ["This freestanding tBLM maintains structural stability and lifetime of up to 120 hours without significant decrease in its structural integrity and electrical sealing.", [["significant decrease in its structural integrity", "PROBLEM", 94, 142], ["structural stability", "OBSERVATION", 33, 53], ["significant", "OBSERVATION_MODIFIER", 94, 105], ["decrease", "OBSERVATION", 106, 114], ["structural integrity", "OBSERVATION", 122, 142], ["electrical sealing", "OBSERVATION", 147, 165]]], ["For the validation of the tBLM formation, we have inserted well known \u03b1-HL pores.", [["tBLM", "CANCER", 26, 30], ["the tBLM formation", "PROBLEM", 22, 40]]], ["We are able to control the amount of \u03b1-HL pores insertion and measure single channel ion transport across the tBLM by \u03b1-HL pores using a capacitor feedback amplifier.P-619The language of shape: biological reactions are dramatically affected by the shape of lipid membrane D. Stamou University of Copenhagen, Copenhagen, Denmark A plethora of biological process are taking place on the surface of lipid membranes.", [["surface", "ANATOMY", 385, 392], ["lipid membranes", "ANATOMY", 396, 411], ["P-619", "CHEMICAL", 166, 171], ["surface", "CELLULAR_COMPONENT", 385, 392], ["lipid membranes", "CELLULAR_COMPONENT", 396, 411], ["tBLM", "PROTEIN", 110, 114], ["\u03b1-HL pores insertion", "TREATMENT", 37, 57], ["single channel ion transport", "TREATMENT", 70, 98], ["a capacitor feedback amplifier", "TREATMENT", 135, 165], ["biological reactions", "PROBLEM", 194, 214], ["lipid membranes", "OBSERVATION", 396, 411]]], ["As a rule membranes in vivo are curved in a variety of complex geometries.", [["membranes", "ANATOMY", 10, 19], ["membranes", "CELLULAR_COMPONENT", 10, 19], ["a rule membranes", "PROBLEM", 3, 19], ["rule membranes", "OBSERVATION", 5, 19], ["complex geometries", "OBSERVATION", 55, 73]]], ["Here I will present a quantitave study on the influence of membrane curvature on protein-membrane and membrane-membrane interactions.", [["membrane", "ANATOMY", 59, 67], ["membrane", "ANATOMY", 89, 97], ["membrane", "ANATOMY", 102, 110], ["membrane", "ANATOMY", 111, 119], ["membrane", "CELLULAR_COMPONENT", 59, 67], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["membrane-membrane", "CELLULAR_COMPONENT", 102, 119], ["a quantitave study", "TEST", 20, 38], ["protein-membrane", "TREATMENT", 81, 97], ["membrane-membrane interactions", "TREATMENT", 102, 132]]], ["To gain systematic access to a continuum of membrane curvatures we immobilized liposomes on a surface at dilute densities.", [["membrane", "ANATOMY", 44, 52], ["surface", "ANATOMY", 94, 101], ["membrane", "CELLULAR_COMPONENT", 44, 52], ["liposomes", "SIMPLE_CHEMICAL", 79, 88], ["a continuum of membrane curvatures", "TREATMENT", 29, 63], ["a surface at dilute densities", "TREATMENT", 92, 121], ["membrane curvatures", "OBSERVATION", 44, 63], ["immobilized liposomes", "OBSERVATION", 67, 88]]], ["Using confocal fluorescence microscopy we imaged single liposomes of different size, and therefore different curvature, and monitored their interaction with a binding partner (proteins or other liposomes).", [["liposomes", "SIMPLE_CHEMICAL", 194, 203], ["confocal fluorescence microscopy", "TEST", 6, 38], ["different", "OBSERVATION_MODIFIER", 69, 78], ["size", "OBSERVATION_MODIFIER", 79, 83], ["different", "OBSERVATION_MODIFIER", 99, 108], ["curvature", "OBSERVATION_MODIFIER", 109, 118]]], ["I will discuss unpublished data on two important classes of biomolecular interactions that exhibited dramatic curvature dependence: A) SNARE-mediated docking and fusion B) anchoring of peripheral proteins.P-619The following references provide partial information on the single-liposome assay:RNA-lipid interaction at the air-liquid interfaceA.", [["P-619", "CHEMICAL", 205, 210], ["SNARE", "GENE_OR_GENE_PRODUCT", 135, 140], ["SNARE", "PROTEIN", 135, 140], ["fusion B", "PROTEIN", 162, 170], ["peripheral proteins", "PROTEIN", 185, 204], ["P-619", "DNA", 205, 210], ["biomolecular interactions", "PROBLEM", 60, 85], ["dramatic curvature dependence", "PROBLEM", 101, 130], ["A) SNARE-mediated docking and fusion B) anchoring of peripheral proteins", "TREATMENT", 132, 204], ["peripheral proteins", "ANATOMY", 185, 204]]], ["Zettergren, C. Gudmundsson, T. Nylander, E. Sparr Physical Chemistry1, Lund University, 22100 Lund, SwedenRNA-lipid interaction at the air-liquid interfaceThere is accumulating evidence of substantial amounts of phospholipids in the cell nuclei 1 , although the function of these lipids is still not fully understood.", [["cell nuclei", "ANATOMY", 233, 244], ["SwedenRNA", "SIMPLE_CHEMICAL", 100, 109], ["phospholipids", "SIMPLE_CHEMICAL", 212, 225], ["cell nuclei 1", "CELL", 233, 246], ["Zettergren", "TREATMENT", 0, 10], ["substantial amounts of phospholipids in the cell nuclei", "PROBLEM", 189, 244], ["substantial", "OBSERVATION_MODIFIER", 189, 200], ["amounts", "OBSERVATION_MODIFIER", 201, 208], ["phospholipids", "OBSERVATION_MODIFIER", 212, 225], ["cell nuclei", "OBSERVATION", 233, 244]]], ["It has been shown that the chromatin complex composed of DNA, RNA and proteins also includes phospholipids, and that RNA colocalize with these 2 .", [["chromatin", "ANATOMY", 27, 36], ["chromatin", "CELLULAR_COMPONENT", 27, 36], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["phospholipids", "SIMPLE_CHEMICAL", 93, 106], ["chromatin complex", "PROTEIN", 27, 44], ["RNA", "RNA", 62, 65], ["RNA", "RNA", 117, 120], ["the chromatin complex", "PROBLEM", 23, 44], ["DNA, RNA and proteins", "PROBLEM", 57, 78], ["phospholipids", "TREATMENT", 93, 106], ["chromatin complex", "OBSERVATION", 27, 44]]], ["Although the RNA-phospholipid interactions may have important implications to biological function, in gene therapy and in medicine, very little work has been dedicated to the characterization of RNA interaction with phospholipids.", [["phospholipid", "SIMPLE_CHEMICAL", 17, 29], ["phospholipids", "SIMPLE_CHEMICAL", 216, 229], ["gene therapy", "TREATMENT", 102, 114], ["phospholipids", "TREATMENT", 216, 229]]], ["The objective of this work is to investigate the adsorption behavior of short single stranded 10 bases long RNA (ssRNA 10 ) molecules (similar to miRNA) to lipid monolayers at the air-water interface as well as to study how the presence of RNA affect the domain formation in the monolayers using fluorescence microscopy.", [["lipid monolayers", "ANATOMY", 156, 172], ["monolayers", "ANATOMY", 279, 289], ["lipid monolayers", "CELL", 156, 172], ["monolayers", "CELL", 279, 289], ["long RNA", "RNA", 103, 111], ["ssRNA 10 ) molecules", "PROTEIN", 113, 133], ["miRNA", "PROTEIN", 146, 151], ["short single stranded 10 bases long RNA (ssRNA 10 ) molecules", "PROBLEM", 72, 133], ["RNA affect", "PROBLEM", 240, 250], ["the domain formation", "PROBLEM", 251, 271], ["fluorescence microscopy", "TEST", 296, 319]]], ["Monolayer studies have shown adsorption of ssRNA 10 to monolayers consisting of zwitterionic DPPC as well as to monolayers consisting of cationic DODAB.", [["monolayers", "ANATOMY", 112, 122], ["zwitterionic DPPC", "CHEMICAL", 80, 97], ["DODAB", "CHEMICAL", 146, 151], ["DPPC", "CHEMICAL", 93, 97], ["DODAB", "CHEMICAL", 146, 151], ["monolayers", "CELL", 55, 65], ["zwitterionic DPPC", "SIMPLE_CHEMICAL", 80, 97], ["monolayers", "CELL", 112, 122], ["cationic DODAB", "SIMPLE_CHEMICAL", 137, 151], ["Monolayer studies", "TEST", 0, 17], ["ssRNA", "PROBLEM", 43, 48], ["zwitterionic DPPC", "TREATMENT", 80, 97], ["cationic DODAB", "TREATMENT", 137, 151]]], ["The adsorption behavior of these very short nucleic acids differ significantly from the adsorption process for longer nucleic acids as for example a 2000 base pairs long ds DNA (dsDNA 2000 ) which has been used as a reference system 3 .", [["nucleic acids", "CHEMICAL", 44, 57], ["nucleic acids", "CHEMICAL", 118, 131], ["nucleic acids", "SIMPLE_CHEMICAL", 118, 131], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["2000 base pairs long ds DNA", "DNA", 149, 176], ["these very short nucleic acids", "PROBLEM", 27, 57], ["longer nucleic acids", "TREATMENT", 111, 131], ["a 2000 base pairs long ds DNA (dsDNA", "TREATMENT", 147, 183]]], ["The presence of ssRNA 10 significantly changes the compression isotherm of both DPPC and DODAB monolayers.", [["DODAB monolayers", "ANATOMY", 89, 105], ["DPPC", "CHEMICAL", 80, 84], ["DPPC", "CHEMICAL", 80, 84], ["DODAB", "CHEMICAL", 89, 94], ["DPPC", "SIMPLE_CHEMICAL", 80, 84], ["DODAB monolayers", "CELL", 89, 105], ["DODAB monolayers", "CELL_LINE", 89, 105], ["ssRNA", "PROBLEM", 16, 21], ["the compression isotherm", "TEST", 47, 71], ["ssRNA 10 significantly", "OBSERVATION_MODIFIER", 16, 38], ["compression isotherm", "OBSERVATION", 51, 71], ["DODAB monolayers", "OBSERVATION", 89, 105]]], ["Plant defensins are cysteine-rich antimicrobial peptides found in various plant species.", [["cysteine", "CHEMICAL", 20, 28], ["cysteine", "AMINO_ACID", 20, 28], ["Plant defensins", "TREATMENT", 0, 15], ["cysteine-rich antimicrobial peptides", "TREATMENT", 20, 56], ["various plant species", "PROBLEM", 66, 87], ["defensins", "OBSERVATION_MODIFIER", 6, 15], ["rich", "OBSERVATION_MODIFIER", 29, 33], ["antimicrobial peptides", "OBSERVATION", 34, 56], ["plant species", "OBSERVATION", 74, 87]]], ["They share a common threedimensional structure, stabilized by eight disulphide-linked cysteines consisting of three antiparallel \u03b2-strands and one \u03b1-helix.", [["disulphide", "CHEMICAL", 68, 78], ["cysteines", "CHEMICAL", 86, 95], ["disulphide-linked cysteines", "PROTEIN", 68, 95], ["antiparallel \u03b2-strands", "PROTEIN", 116, 138], ["\u03b1-helix", "PROTEIN", 147, 154]]], ["Most plant defensins show antifungal activity with no effect on mammalian and plant cells.", [["cells", "ANATOMY", 84, 89], ["mammalian", "CELL", 64, 73], ["plant cells", "CELL", 78, 89], ["mammalian and plant cells", "CELL_TYPE", 64, 89], ["antifungal activity", "TREATMENT", 26, 45], ["effect on mammalian and plant cells", "PROBLEM", 54, 89], ["defensins", "OBSERVATION", 11, 20], ["antifungal activity", "OBSERVATION", 26, 45], ["plant cells", "OBSERVATION", 78, 89]]], ["Expression of these peptides in plant tissue is induced by pathogen infection.", [["tissue", "ANATOMY", 38, 44], ["pathogen infection", "DISEASE", 59, 77], ["plant tissue", "TISSUE", 32, 44], ["these peptides in plant tissue", "PROBLEM", 14, 44], ["pathogen infection", "PROBLEM", 59, 77], ["plant tissue", "OBSERVATION", 32, 44], ["pathogen", "OBSERVATION_MODIFIER", 59, 67], ["infection", "OBSERVATION", 68, 77]]], ["The mechanism of defensin action is based on membrane permeabilization.", [["membrane", "ANATOMY", 45, 53], ["defensin", "GENE_OR_GENE_PRODUCT", 17, 25], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["defensin", "PROTEIN", 17, 25], ["defensin action", "TREATMENT", 17, 32], ["membrane permeabilization", "TREATMENT", 45, 70], ["defensin", "OBSERVATION", 17, 25]]], ["This occurs through an interaction with high affinity binding sites on fungal membranes, resulting in alteration of membrane potential.", [["membranes", "ANATOMY", 78, 87], ["membrane", "ANATOMY", 116, 124], ["fungal membranes", "CELLULAR_COMPONENT", 71, 87], ["membrane", "CELLULAR_COMPONENT", 116, 124], ["high affinity binding sites", "PROTEIN", 40, 67], ["high affinity binding sites", "PROBLEM", 40, 67], ["fungal membranes", "TREATMENT", 71, 87], ["alteration of membrane potential", "PROBLEM", 102, 134], ["fungal membranes", "OBSERVATION", 71, 87], ["membrane potential", "OBSERVATION", 116, 134]]], ["The genes encoding for a peach PpDfn1 and a grape VvAMP defensins were expressed in E. coli and purified to homogeneity.", [["PpDfn1", "GENE_OR_GENE_PRODUCT", 31, 37], ["VvAMP", "GENE_OR_GENE_PRODUCT", 50, 55], ["E. coli", "ORGANISM", 84, 91], ["peach PpDfn1", "DNA", 25, 37], ["grape VvAMP defensins", "PROTEIN", 44, 65], ["E. coli", "SPECIES", 84, 91], ["peach", "SPECIES", 25, 30], ["E. coli", "SPECIES", 84, 91], ["a peach PpDfn1", "TREATMENT", 23, 37], ["a grape VvAMP defensins", "TREATMENT", 42, 65], ["E. coli", "PROBLEM", 84, 91]]], ["They were tested for antimicrobial activity against some fungi and showed to have an inhibitory effect on the spore germination.", [["spore", "ANATOMY", 110, 115], ["antimicrobial activity", "TEST", 21, 43], ["some fungi", "PROBLEM", 52, 62], ["an inhibitory effect", "PROBLEM", 82, 102], ["inhibitory effect", "OBSERVATION", 85, 102], ["spore germination", "OBSERVATION", 110, 127]]], ["Biophysical analysis showed that defensins were able to interact with artificial membranes.", [["membranes", "ANATOMY", 81, 90], ["defensins", "GENE_OR_GENE_PRODUCT", 33, 42], ["membranes", "CELLULAR_COMPONENT", 81, 90], ["defensins", "PROTEIN", 33, 42], ["Biophysical analysis", "TEST", 0, 20], ["defensins", "PROBLEM", 33, 42], ["artificial membranes", "TREATMENT", 70, 90], ["artificial membranes", "OBSERVATION", 70, 90]]], ["Binding of defensins to membranes was dependent on lipid composition, increasing with the sphingolipids content.", [["membranes", "ANATOMY", 24, 33], ["sphingolipids", "CHEMICAL", 90, 103], ["defensins", "GENE_OR_GENE_PRODUCT", 11, 20], ["membranes", "CELLULAR_COMPONENT", 24, 33], ["lipid", "SIMPLE_CHEMICAL", 51, 56], ["sphingolipids", "SIMPLE_CHEMICAL", 90, 103], ["defensins", "PROTEIN", 11, 20], ["Binding of defensins to membranes", "PROBLEM", 0, 33], ["lipid composition", "TREATMENT", 51, 68], ["defensins to membranes", "OBSERVATION_MODIFIER", 11, 33], ["lipid composition", "OBSERVATION_MODIFIER", 51, 68]]], ["Interaction between peptides and sphingolipids could lead to insertion of the defensins into the membrane resulting in its destabilization.", [["membrane", "ANATOMY", 97, 105], ["sphingolipids", "CHEMICAL", 33, 46], ["sphingolipids", "SIMPLE_CHEMICAL", 33, 46], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["defensins", "PROTEIN", 78, 87], ["peptides", "TREATMENT", 20, 28], ["sphingolipids", "TREATMENT", 33, 46], ["insertion of the defensins into the membrane", "TREATMENT", 61, 105], ["its destabilization", "PROBLEM", 119, 138], ["membrane", "ANATOMY_MODIFIER", 97, 105], ["destabilization", "OBSERVATION", 123, 138]]], ["Extracts of the plant Perilla frutescens have many uses in the Asian kitchen, e.g. as a popular garnish used in sushi.", [["Extracts", "ANATOMY", 0, 8], ["Perilla frutescens", "ORGANISM", 22, 40], ["Perilla frutescens", "SPECIES", 22, 40], ["Perilla frutescens", "SPECIES", 22, 40], ["plant", "OBSERVATION_MODIFIER", 16, 21], ["Perilla frutescens", "OBSERVATION", 22, 40]]], ["The plant is also employed in eastern traditional medicine to treat a variety of ailments including colds, food allergy and depression.", [["colds", "DISEASE", 100, 105], ["food allergy", "DISEASE", 107, 119], ["depression", "DISEASE", 124, 134], ["colds", "PROBLEM", 100, 105], ["food allergy", "PROBLEM", 107, 119], ["depression", "PROBLEM", 124, 134]]], ["Two of the main constituents of the plant are limonene and perilla aldehyde.", [["limonene", "CHEMICAL", 46, 54], ["perilla aldehyde", "CHEMICAL", 59, 75], ["limonene", "CHEMICAL", 46, 54], ["perilla aldehyde", "CHEMICAL", 59, 75], ["limonene", "SIMPLE_CHEMICAL", 46, 54], ["perilla aldehyde", "SIMPLE_CHEMICAL", 59, 75], ["main", "OBSERVATION_MODIFIER", 11, 15], ["limonene", "OBSERVATION", 46, 54], ["perilla aldehyde", "OBSERVATION", 59, 75]]], ["By bio-oxidation, these molecules can be converted to perillic alcohol and perillic acid.", [["perillic alcohol", "CHEMICAL", 54, 70], ["perillic acid", "CHEMICAL", 75, 88], ["perillic alcohol", "CHEMICAL", 54, 70], ["perillic acid", "CHEMICAL", 75, 88], ["perillic alcohol", "SIMPLE_CHEMICAL", 54, 70], ["perillic acid", "SIMPLE_CHEMICAL", 75, 88], ["perillic acid", "TREATMENT", 75, 88]]], ["These cyclic terpenes possess antibacterial and anticarcinogenic properties.", [["cyclic terpenes", "CHEMICAL", 6, 21], ["cyclic terpenes", "CHEMICAL", 6, 21], ["cyclic terpenes", "SIMPLE_CHEMICAL", 6, 21], ["These cyclic terpenes", "TREATMENT", 0, 21], ["antibacterial and anticarcinogenic properties", "TREATMENT", 30, 75], ["antibacterial", "OBSERVATION_MODIFIER", 30, 43], ["anticarcinogenic properties", "OBSERVATION", 48, 75]]], ["The modes of action for these compounds are at present not understood, but their remarkably diverse pharmacological properties suggest that they might target the phospholipid matrix of the cellular lipid membrane.", [["phospholipid matrix", "ANATOMY", 162, 181], ["cellular lipid membrane", "ANATOMY", 189, 212], ["phospholipid matrix", "CELLULAR_COMPONENT", 162, 181], ["cellular lipid membrane", "CELLULAR_COMPONENT", 189, 212], ["these compounds", "PROBLEM", 24, 39], ["phospholipid matrix", "OBSERVATION", 162, 181], ["cellular lipid membrane", "OBSERVATION", 189, 212]]], ["Indeed, the cyclic terpenes can bind to, and alter the physiochemical properties of the lipid bilayer of the membrane, the effects of which can cascade down to several essential cellular processes.", [["membrane", "ANATOMY", 109, 117], ["cellular", "ANATOMY", 178, 186], ["cyclic terpenes", "CHEMICAL", 12, 27], ["cyclic terpenes", "CHEMICAL", 12, 27], ["cyclic terpenes", "SIMPLE_CHEMICAL", 12, 27], ["lipid bilayer", "CELLULAR_COMPONENT", 88, 101], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["cellular", "CELL", 178, 186], ["the cyclic terpenes", "TREATMENT", 8, 27], ["cellular processes", "OBSERVATION", 178, 196]]], ["Here, we use molecular dynamics (MD) simulations to investigate the effect of limonene and its derivatives on the properties of lipid bilayers including the changes in acyl chain order parameters, bilayer thickness and the area per lipid.", [["limonene", "CHEMICAL", 78, 86], ["limonene", "CHEMICAL", 78, 86], ["acyl", "CHEMICAL", 168, 172], ["limonene", "SIMPLE_CHEMICAL", 78, 86], ["lipid bilayers", "SIMPLE_CHEMICAL", 128, 142], ["lipid", "SIMPLE_CHEMICAL", 232, 237], ["limonene", "TREATMENT", 78, 86], ["its derivatives", "TREATMENT", 91, 106], ["lipid bilayers", "TREATMENT", 128, 142], ["the changes in acyl chain order parameters", "TREATMENT", 153, 195], ["bilayer thickness", "TREATMENT", 197, 214]]], ["MD can afford molecular-scale dynamic information, often not easily accessible from experimental measurements.", [["experimental measurements", "TEST", 84, 109]]], ["This information can be used to interpret existing experimental data obtained by e.g. isothermal titration calorimetry, electron paramagnetic spectroscopy and differential scanning calorimetry.P-623Catalysis in the membrane: Interfacial mechanism of Phospholipase A2 H. P. Wacklin 1 , R. K. Thomas 2 1 Institut Laue Langevin, Grenoble, France, 2 Physical and Theoretical Chemistry Laboratory, Oxford University, U.K.P-623Phospholipase A2 cleaves the sn-2 acyl chains of membrane phospholipids and performs a range of physiological functions.", [["membrane", "ANATOMY", 215, 223], ["membrane phospholipids", "ANATOMY", 470, 492], ["P-623Catalysis", "CHEMICAL", 193, 207], ["sn-2 acyl", "CHEMICAL", 450, 459], ["acyl", "CHEMICAL", 455, 459], ["membrane", "CELLULAR_COMPONENT", 215, 223], ["U.K.P-623Phospholipase A2", "GENE_OR_GENE_PRODUCT", 412, 437], ["sn-2", "GENE_OR_GENE_PRODUCT", 450, 454], ["membrane phospholipids", "CELLULAR_COMPONENT", 470, 492], ["P-623Catalysis", "DNA", 193, 207], ["sn-2 acyl chains", "PROTEIN", 450, 466], ["isothermal titration calorimetry", "TEST", 86, 118], ["electron paramagnetic spectroscopy", "TEST", 120, 154], ["differential scanning calorimetry", "TEST", 159, 192], ["U.K.P", "TEST", 412, 417], ["membrane phospholipids", "TREATMENT", 470, 492]]], ["One of the least well understood aspects of the its mechanism is how its activity is regulated by the interaction with the substrate membrane.", [["membrane", "ANATOMY", 133, 141], ["substrate membrane", "CELLULAR_COMPONENT", 123, 141]]], ["We have used neutron reflection to monitor changes in membrane structure during lipid hydrolysis [1, 2] .", [["membrane", "ANATOMY", 54, 62], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["lipid", "SIMPLE_CHEMICAL", 80, 85], ["neutron reflection", "TREATMENT", 13, 31], ["changes in membrane structure during lipid hydrolysis", "TREATMENT", 43, 96]]], ["The penetration depth of PLA2 depends on lipid packing and increases during the lag phase of porcine pancreatic PLA2.", [["pancreatic", "ANATOMY", 101, 111], ["PLA2", "GENE_OR_GENE_PRODUCT", 25, 29], ["lipid", "SIMPLE_CHEMICAL", 41, 46], ["porcine", "ORGANISM", 93, 100], ["pancreatic PLA2", "GENE_OR_GENE_PRODUCT", 101, 116], ["PLA2", "PROTEIN", 25, 29], ["porcine pancreatic PLA2", "PROTEIN", 93, 116], ["porcine", "SPECIES", 93, 100], ["The penetration depth of PLA2", "PROBLEM", 0, 29], ["lipid packing", "TREATMENT", 41, 54], ["porcine pancreatic PLA2", "TREATMENT", 93, 116], ["penetration", "OBSERVATION_MODIFIER", 4, 15], ["depth", "OBSERVATION_MODIFIER", 16, 21], ["lipid packing", "OBSERVATION_MODIFIER", 41, 54], ["pancreatic", "ANATOMY", 101, 111], ["PLA2", "OBSERVATION", 112, 116]]], ["By using a selectively deuterated lipid substrate, d31-POPC, we determined the relative membrane-water partitioning of the lipid products in-situ.", [["membrane", "ANATOMY", 88, 96], ["d31-POPC", "CHEMICAL", 51, 59], ["d31-POPC", "CHEMICAL", 51, 59], ["d31-POPC", "SIMPLE_CHEMICAL", 51, 59], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["water", "SIMPLE_CHEMICAL", 97, 102], ["a selectively deuterated lipid substrate", "TREATMENT", 9, 49], ["d31-POPC", "TREATMENT", 51, 59], ["the lipid products", "TREATMENT", 119, 137], ["water partitioning", "OBSERVATION", 97, 115], ["lipid products", "OBSERVATION", 123, 137]]], ["The lyso-lipid product partitions into the solution phase, while fatty acid accumulates in the membrane and increases the affinity of PLA2 [2] .", [["membrane", "ANATOMY", 95, 103], ["fatty acid", "CHEMICAL", 65, 75], ["fatty acid", "CHEMICAL", 65, 75], ["lyso", "SIMPLE_CHEMICAL", 4, 8], ["fatty acid", "SIMPLE_CHEMICAL", 65, 75], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["PLA2", "GENE_OR_GENE_PRODUCT", 134, 138], ["PLA2", "PROTEIN", 134, 138], ["The lyso-lipid product partitions", "TREATMENT", 0, 33], ["the solution phase", "TEST", 39, 57], ["fatty acid accumulates in the membrane", "PROBLEM", 65, 103], ["membrane", "ANATOMY_MODIFIER", 95, 103]]], ["PLA2 is inhibited at pH 5, which is consistent with protonation of the catalytic histidine.", [["histidine", "CHEMICAL", 81, 90], ["histidine", "CHEMICAL", 81, 90], ["PLA2", "GENE_OR_GENE_PRODUCT", 0, 4], ["histidine", "AMINO_ACID", 81, 90], ["PLA2", "PROTEIN", 0, 4], ["PLA2", "TEST", 0, 4], ["the catalytic histidine", "TREATMENT", 67, 90], ["consistent with", "UNCERTAINTY", 36, 51]]], ["However, irrespective of pH, PLA2 is fully activated by Me-betacyclodextrin, which facilitates the release of the lyso-lipid from the enzyme-substrate complex.", [["Me-betacyclodextrin", "CHEMICAL", 56, 75], ["Me-betacyclodextrin", "CHEMICAL", 56, 75], ["lyso", "CHEMICAL", 114, 118], ["PLA2", "GENE_OR_GENE_PRODUCT", 29, 33], ["Me-betacyclodextrin", "SIMPLE_CHEMICAL", 56, 75], ["lyso-lipid", "SIMPLE_CHEMICAL", 114, 124], ["PLA2", "PROTEIN", 29, 33], ["enzyme-substrate complex", "PROTEIN", 134, 158], ["PLA2", "TEST", 29, 33], ["Me-betacyclodextrin", "TREATMENT", 56, 75], ["the enzyme", "TEST", 130, 140]]], ["Me-beta-cyclodextrin does not interact directly with the membrane surface or the substrate lipids, indicating that product release occurs outside the immediate membrane-water interface.", [["membrane surface", "ANATOMY", 57, 73], ["membrane", "ANATOMY", 160, 168], ["Me-beta-cyclodextrin", "CHEMICAL", 0, 20], ["Me-beta-cyclodextrin", "CHEMICAL", 0, 20], ["Me-beta-cyclodextrin", "SIMPLE_CHEMICAL", 0, 20], ["membrane surface", "CELLULAR_COMPONENT", 57, 73], ["lipids", "SIMPLE_CHEMICAL", 91, 97], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["Me-beta-cyclodextrin", "TREATMENT", 0, 20]]], ["Diffraction limits resolution in optical microscopy, but many interesting biological problems occur on shorter (molecular) length scales.", [["optical microscopy", "TEST", 33, 51], ["many interesting biological problems", "PROBLEM", 57, 93], ["resolution", "OBSERVATION_MODIFIER", 19, 29]]], ["Fluorescence photoactivation localization microscopy (FPALM) uses activation of many small subsets of photoactivatable or photoswitchable fluorescent probes (PAFPs) to generate images with effective resolution in the tens of nanometers.", [["PAFPs", "DNA", 158, 163], ["Fluorescence photoactivation localization microscopy", "TEST", 0, 52], ["photoactivatable", "TREATMENT", 102, 118], ["photoswitchable fluorescent probes (PAFPs", "TREATMENT", 122, 163]]], ["PAFP molecules are photoactivated, imaged, localized, and photobleached in small numbers.", [["PAFP", "SIMPLE_CHEMICAL", 0, 4], ["PAFP molecules", "PROTEIN", 0, 14], ["small", "OBSERVATION_MODIFIER", 75, 80], ["numbers", "OBSERVATION_MODIFIER", 81, 88]]], ["The positions of all localized molecules are used to construct an image of the sample with resolution limited not by diffraction, but by the localization precision and molecular density.", [["sample", "ANATOMY", 79, 85], ["molecular", "OBSERVATION_MODIFIER", 168, 177], ["density", "OBSERVATION", 178, 185]]], ["Results will be shown from a variety of biological systems, including live and fixed cells expressing a variety of PAFP-tagged proteins.", [["cells", "ANATOMY", 85, 90], ["cells", "CELL", 85, 90], ["PAFP", "GENE_OR_GENE_PRODUCT", 115, 119], ["PAFP", "PROTEIN", 115, 119], ["tagged proteins", "PROTEIN", 120, 135]]], ["Bi-plane FPALM can image in three dimensions with demonstrated resolution of 30 nm x 30 nm x 70 nm.", [["FPALM", "PROTEIN", 9, 14]]], ["Polarization FPALM can image both molecular positions and anisotropies simultaneously with lateral resolution of \u223c20-30 nm.", [["Polarization FPALM", "TEST", 0, 18], ["lateral resolution", "TEST", 91, 109], ["\u223c", "TEST", 113, 114]]], ["Using these powerful capabilities, many potentially interesting biological problems can be addressed.O-630Binding of the HIV-1 NCp7 on oligonucleotides at the single-molecule level J. Godet, P. Didier, A. Jouonang, Y. Arntz, Y. M\u00e9ly Laboratory of Biophotonics and Pharmacology, UMR CNRS 7213, University of Strasbourg, FranceO-630The nucleocapsid protein (NCp7) of the HIV-1 is a small basic protein which plays key functions in the viral life cycle.", [["O-630", "CHEMICAL", 101, 106], ["O-630", "CHEMICAL", 101, 106], ["HIV-1", "ORGANISM", 121, 126], ["NCp7", "ORGANISM", 127, 131], ["nucleocapsid protein (NCp7", "GENE_OR_GENE_PRODUCT", 334, 360], ["HIV-1", "ORGANISM", 369, 374], ["HIV-1 NCp7", "PROTEIN", 121, 131], ["nucleocapsid protein", "PROTEIN", 334, 354], ["NCp7", "PROTEIN", 356, 360], ["small basic protein", "PROTEIN", 380, 399], ["HIV-1", "SPECIES", 121, 126], ["HIV-1", "SPECIES", 369, 374], ["HIV-1", "SPECIES", 121, 126], ["HIV-1", "SPECIES", 369, 374], ["oligonucleotides", "TREATMENT", 135, 151], ["UMR CNRS", "TEST", 278, 286], ["FranceO", "TEST", 319, 326], ["The nucleocapsid protein", "TEST", 330, 354], ["NCp", "TEST", 356, 359], ["the HIV", "TEST", 365, 372], ["a small basic protein", "PROBLEM", 378, 399], ["small", "OBSERVATION_MODIFIER", 380, 385]]], ["The activity of NCp7 mainly rely on its potent RNA-and DNA-chaperone activities that direct the rearrangement of numerous nucleic acid molecules into their most stable conformation.", [["nucleic acid", "CHEMICAL", 122, 134], ["NCp7", "GENE_OR_GENE_PRODUCT", 16, 20], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["NCp7", "PROTEIN", 16, 20], ["nucleic acid molecules", "PROTEIN", 122, 144], ["NCp7", "TREATMENT", 16, 20], ["its potent RNA", "TEST", 36, 50], ["numerous nucleic acid molecules", "TREATMENT", 113, 144]]], ["Two main features of NC's chaperone activity are its abilities to aggregate and destabilize nucleic acids.", [["nucleic acids", "CHEMICAL", 92, 105], ["NC", "GENE_OR_GENE_PRODUCT", 21, 23], ["nucleic acids", "SIMPLE_CHEMICAL", 92, 105], ["nucleic acids", "TREATMENT", 92, 105], ["main", "OBSERVATION_MODIFIER", 4, 8], ["NC", "OBSERVATION", 21, 23]]], ["In addition, the rapid kinetics of NCp7 interaction with nucleic acids was recently proposed as another major component of NC's chaperone function based on the apparent correlation between an indirect measurement of the nucleic acid dissociation kinetics of NCp7 and its overall chaperone activity.", [["nucleic acids", "CHEMICAL", 57, 70], ["nucleic acid", "CHEMICAL", 220, 232], ["NCp7", "GENE_OR_GENE_PRODUCT", 35, 39], ["nucleic acids", "SIMPLE_CHEMICAL", 57, 70], ["NC", "GENE_OR_GENE_PRODUCT", 123, 125], ["NCp7", "GENE_OR_GENE_PRODUCT", 258, 262], ["NCp7", "PROTEIN", 35, 39], ["NCp7", "PROTEIN", 258, 262], ["nucleic acids", "TREATMENT", 57, 70], ["the nucleic acid dissociation kinetics", "PROBLEM", 216, 254], ["NCp7", "TREATMENT", 258, 262], ["chaperone activity", "OBSERVATION", 279, 297]]], ["But so far, no direct measurement of the on/off rates of NCp7 binding to oligonucleotides was performed.", [["NCp7", "GENE_OR_GENE_PRODUCT", 57, 61], ["NCp7", "PROTEIN", 57, 61], ["direct measurement", "TEST", 15, 33], ["NCp7 binding to oligonucleotides", "TREATMENT", 57, 89]]], ["In the present work, we realized single molecule fluorescence resonance energy transfer (smFRET) measurements to probe the transient interactions of a TMR-labelled NCp7 with a short Cy5-labelled DNA oligonucleotide confined into nanovesicles.", [["nanovesicles", "ANATOMY", 229, 241], ["TMR", "SIMPLE_CHEMICAL", 151, 154], ["NCp7", "GENE_OR_GENE_PRODUCT", 164, 168], ["Cy5", "SIMPLE_CHEMICAL", 182, 185], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["nanovesicles", "CANCER", 229, 241], ["TMR-labelled NCp7", "PROTEIN", 151, 168], ["nanovesicles", "CELL_TYPE", 229, 241], ["a TMR", "TEST", 149, 154], ["a short Cy5-labelled DNA oligonucleotide", "TREATMENT", 174, 214], ["nanovesicles", "ANATOMY", 229, 241]]], ["After confirming the efficiency of the NCp7/ODN complex encapsulation into the nanovesicles by FCS, the vesicles were tethered to the surface for immobilization.", [["vesicles", "ANATOMY", 104, 112], ["surface", "ANATOMY", 134, 141], ["ODN", "CHEMICAL", 44, 47], ["NCp7", "GENE_OR_GENE_PRODUCT", 39, 43], ["ODN", "SIMPLE_CHEMICAL", 44, 47], ["nanovesicles", "SIMPLE_CHEMICAL", 79, 91], ["FCS", "SIMPLE_CHEMICAL", 95, 98], ["vesicles", "CELLULAR_COMPONENT", 104, 112], ["surface", "CELLULAR_COMPONENT", 134, 141], ["NCp7", "PROTEIN", 39, 43], ["the NCp7/ODN complex encapsulation", "TREATMENT", 35, 69], ["the vesicles", "PROBLEM", 100, 112], ["immobilization", "TREATMENT", 146, 160], ["encapsulation", "OBSERVATION_MODIFIER", 56, 69], ["nanovesicles", "OBSERVATION_MODIFIER", 79, 91], ["vesicles", "ANATOMY", 104, 112], ["surface", "OBSERVATION_MODIFIER", 134, 141], ["immobilization", "OBSERVATION", 146, 160]]], ["Integrity of the entrapping vesicles attached on the surface was confirmed by AFM.", [["entrapping vesicles", "ANATOMY", 17, 36], ["surface", "ANATOMY", 53, 60], ["vesicles", "CELLULAR_COMPONENT", 28, 36], ["surface", "CELLULAR_COMPONENT", 53, 60], ["the entrapping vesicles", "TREATMENT", 13, 36], ["entrapping vesicles", "OBSERVATION", 17, 36], ["surface", "OBSERVATION_MODIFIER", 53, 60]]], ["Finally, the association and dissociation constants retrieved from these smFRET measurements were discussed in the context of the DNA-chaperoning activity of the protein.P-629High-resolution spatiotemporal organization of the integrin LFA-1 M. F. Garcia-Parajo 1 , T. S. van Zanten 1 , G.-J. Bakker 1 , R. Diez-Ahedo 1 , A. Cambi 2 , C. G. Figdor 2 1 Bionanophotonics group; IBEC, Barcelona, Spain, 2 Tumour Immunology Dept; NCMLS, Nijmegen, The Netherlands LFA-1 is a leukocyte-specific integrin involved in different steps of the immune response.", [["leukocyte", "ANATOMY", 469, 478], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["integrin", "GENE_OR_GENE_PRODUCT", 226, 234], ["LFA-1", "GENE_OR_GENE_PRODUCT", 458, 463], ["leukocyte", "CELL", 469, 478], ["integrin", "GENE_OR_GENE_PRODUCT", 488, 496], ["smFRET", "PROTEIN", 73, 79], ["P", "DNA", 170, 171], ["integrin LFA", "PROTEIN", 226, 238], ["integrin", "PROTEIN", 488, 496], ["dissociation constants", "PROBLEM", 29, 51], ["these smFRET measurements", "TEST", 67, 92], ["P", "TEST", 170, 171], ["the integrin LFA", "TEST", 222, 238], ["The Netherlands LFA", "TEST", 442, 461], ["a leukocyte", "TEST", 467, 478], ["integrin LFA", "ANATOMY", 226, 238], ["leukocyte", "ANATOMY", 469, 478], ["immune response", "OBSERVATION", 532, 547]]], ["On monocytes, LFA-1 plays a key role in the regulation of monocyte-endothelial interaction during rolling, arrest and extravasation into the underlying tissue.", [["monocytes", "ANATOMY", 3, 12], ["monocyte", "ANATOMY", 58, 66], ["endothelial", "ANATOMY", 67, 78], ["tissue", "ANATOMY", 152, 158], ["monocytes", "CELL", 3, 12], ["LFA-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["monocyte", "CELL", 58, 66], ["endothelial", "CELL", 67, 78], ["tissue", "TISSUE", 152, 158], ["monocytes", "CELL_TYPE", 3, 12], ["LFA-1", "PROTEIN", 14, 19], ["monocytes", "TEST", 3, 12], ["LFA", "TEST", 14, 17], ["arrest", "PROBLEM", 107, 113], ["extravasation into the underlying tissue", "PROBLEM", 118, 158], ["monocytes", "OBSERVATION", 3, 12], ["LFA", "ANATOMY", 14, 17], ["monocyte", "OBSERVATION", 58, 66], ["endothelial", "ANATOMY", 67, 78], ["extravasation", "OBSERVATION", 118, 131], ["underlying tissue", "ANATOMY", 141, 158]]], ["I n-vivo experiments showed that blood borne lymphocytes can 'switch' within seconds from rolling to arrest.", [["blood", "ANATOMY", 33, 38], ["lymphocytes", "ANATOMY", 45, 56], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["lymphocytes", "CELL", 45, 56], ["blood borne lymphocytes", "CELL_TYPE", 33, 56], ["blood borne lymphocytes", "PROBLEM", 33, 56], ["arrest", "PROBLEM", 101, 107]]], ["Furthermore, TEM observations of pro-active, ligandindependent nanoclusters confirmed that affinity and clustering are complementary processes required in adhesion.", [["ligandindependent nanoclusters", "TREATMENT", 45, 75], ["complementary processes", "PROBLEM", 119, 142]]], ["In our group, we used a combination of single molecule fluorescence techniques to study the spatiotemporal organization of LFA-1 on monocytes.", [["monocytes", "ANATOMY", 132, 141], ["LFA-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["monocytes", "CELL", 132, 141], ["LFA-1", "PROTEIN", 123, 128], ["monocytes", "CELL_TYPE", 132, 141], ["single molecule fluorescence techniques", "TREATMENT", 39, 78], ["LFA", "TEST", 123, 126], ["monocytes", "TEST", 132, 141], ["LFA", "ANATOMY", 123, 126]]], ["We performed optical nanoimaging of LFA-1 nanoclusters in relation to membrane rafts with a resolution of 70nm and accuracy of \u223c3nm.", [["membrane rafts", "ANATOMY", 70, 84], ["LFA-1 nanoclusters", "SIMPLE_CHEMICAL", 36, 54], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["LFA", "PROTEIN", 36, 39], ["optical nanoimaging of LFA", "TEST", 13, 39], ["membrane rafts", "TREATMENT", 70, 84]]], ["In quiescent cells, LFA-1 nanoclusters do not associate with membrane rafts and diffuse freely on the membrane.", [["cells", "ANATOMY", 13, 18], ["membrane rafts", "ANATOMY", 61, 75], ["membrane", "ANATOMY", 102, 110], ["cells", "CELL", 13, 18], ["LFA-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["membrane rafts", "CELLULAR_COMPONENT", 61, 75], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["LFA", "PROTEIN", 20, 23], ["LFA", "TEST", 20, 23], ["membrane rafts", "PROBLEM", 61, 75], ["diffuse freely on the membrane", "PROBLEM", 80, 110], ["quiescent cells", "OBSERVATION", 3, 18], ["LFA", "ANATOMY", 20, 23], ["membrane rafts", "OBSERVATION", 61, 75], ["diffuse", "OBSERVATION_MODIFIER", 80, 87], ["membrane", "ANATOMY_MODIFIER", 102, 110]]], ["Binding of the integrin to its ligand ICAM-1 induces the formation of microclusters that further associate with rafts and exhibit reduced mobility, consistent with cytoskeleton interactions.", [["microclusters", "ANATOMY", 70, 83], ["rafts", "ANATOMY", 112, 117], ["cytoskeleton", "ANATOMY", 164, 176], ["integrin", "GENE_OR_GENE_PRODUCT", 15, 23], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 38, 44], ["microclusters", "CELLULAR_COMPONENT", 70, 83], ["rafts", "CELLULAR_COMPONENT", 112, 117], ["cytoskeleton", "CELLULAR_COMPONENT", 164, 176], ["integrin", "PROTEIN", 15, 23], ["ICAM-1", "PROTEIN", 38, 44], ["microclusters", "PROBLEM", 70, 83], ["reduced mobility", "PROBLEM", 130, 146], ["cytoskeleton interactions", "PROBLEM", 164, 189], ["reduced", "OBSERVATION_MODIFIER", 130, 137], ["mobility", "OBSERVATION", 138, 146], ["consistent with", "UNCERTAINTY", 148, 163], ["cytoskeleton interactions", "OBSERVATION", 164, 189]]], ["Our work highlights the markedly different spatiotemporal organization of LFA-1 that might explain its concerted action to form larger and stable platforms on the cell surface required for rapid and effective cell adhesion.HIV1 TAT peptides translocate efficiently into giant unilamellar vesiclesC.", [["cell surface", "ANATOMY", 163, 175], ["cell", "ANATOMY", 209, 213], ["unilamellar", "ANATOMY", 276, 287], ["LFA-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["cell surface", "CELLULAR_COMPONENT", 163, 175], ["cell", "CELL", 209, 213], ["HIV1 TAT peptides", "GENE_OR_GENE_PRODUCT", 223, 240], ["unilamellar vesiclesC", "SIMPLE_CHEMICAL", 276, 297], ["LFA", "PROTEIN", 74, 77], ["HIV1", "SPECIES", 223, 227], ["the cell surface", "TREATMENT", 159, 175], ["rapid and effective cell adhesion", "TREATMENT", 189, 222], ["HIV1 TAT peptides", "TREATMENT", 223, 240], ["giant unilamellar vesiclesC", "PROBLEM", 270, 297], ["markedly", "OBSERVATION_MODIFIER", 24, 32], ["different", "OBSERVATION_MODIFIER", 33, 42], ["spatiotemporal", "OBSERVATION_MODIFIER", 43, 57], ["LFA", "ANATOMY", 74, 77], ["larger", "OBSERVATION_MODIFIER", 128, 134], ["stable", "OBSERVATION_MODIFIER", 139, 145], ["effective cell adhesion", "OBSERVATION", 199, 222]]], ["Ciobanasu, U. Kubitscheck Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn, Germany Cell penetrating peptides like the HIV1 TAT peptide have the property to rapidly translocate the cell membranes and the capability to deliver a wide range of cargoes.", [["Cell", "ANATOMY", 82, 86], ["cell membranes", "ANATOMY", 179, 193], ["Cell", "CELL", 82, 86], ["HIV1 TAT peptide", "GENE_OR_GENE_PRODUCT", 117, 133], ["cell membranes", "CELLULAR_COMPONENT", 179, 193], ["U. Kubitscheck Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn, Germany", "SPECIES", 11, 81], ["Cell penetrating peptides", "TREATMENT", 82, 107], ["the HIV1 TAT peptide", "PROBLEM", 113, 133], ["a wide range of cargoes", "TREATMENT", 224, 247], ["cell membranes", "OBSERVATION", 179, 193]]], ["The mechanism of the membrane translocation is still under investigation and object of considerable controversy.", [["membrane", "ANATOMY", 21, 29], ["membrane", "CELLULAR_COMPONENT", 21, 29], ["the membrane translocation", "PROBLEM", 17, 43], ["membrane translocation", "OBSERVATION", 21, 43]]], ["We applied and single-molecule and confocal laser scanning microscopy (LSM) to study peptide-membrane interactions.", [["membrane", "ANATOMY", 93, 101], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["single-molecule", "TREATMENT", 15, 30], ["confocal laser scanning microscopy", "TEST", 35, 69], ["study peptide", "TEST", 79, 92]]], ["Electron-multiplying CCD cameras yield images of single fluorescent molecules with a time resolution in the range of a few milliseconds only, which allows the tracking of fluorescently labelled peptides and lipids at bio-interfaces in realtime with a localization precision of a few nanometers.", [["lipids", "SIMPLE_CHEMICAL", 207, 213], ["Electron", "TEST", 0, 8], ["a few nanometers", "TREATMENT", 277, 293]]], ["We formed giant unilamellar vesicles (GUVs) from different lipid mixtures and examined their interaction with fluorescently labeled TAT peptides.", [["giant unilamellar vesicles", "ANATOMY", 10, 36], ["GUVs", "ANATOMY", 38, 42], ["unilamellar vesicles", "MULTI-TISSUE_STRUCTURE", 16, 36], ["GUVs", "SIMPLE_CHEMICAL", 38, 42], ["TAT", "GENE_OR_GENE_PRODUCT", 132, 135], ["giant unilamellar vesicles", "PROBLEM", 10, 36], ["different lipid mixtures", "TREATMENT", 49, 73], ["fluorescently labeled TAT peptides", "TREATMENT", 110, 144], ["giant", "OBSERVATION_MODIFIER", 10, 15], ["unilamellar vesicles", "OBSERVATION", 16, 36]]], ["We found that the passive peptide internalization process depends on lipid composition, charge of the lipid bilayer, and the ionic properties of the medium.", [["lipid bilayer", "ANATOMY", 102, 115], ["lipid", "SIMPLE_CHEMICAL", 69, 74], ["the passive peptide internalization process", "PROBLEM", 14, 57], ["lipid composition", "TREATMENT", 69, 86], ["the lipid bilayer", "TREATMENT", 98, 115], ["the ionic properties of the medium", "TREATMENT", 121, 155], ["passive peptide internalization", "OBSERVATION", 18, 49], ["lipid composition", "OBSERVATION_MODIFIER", 69, 86]]], ["A translocation of cationic TAT peptides was observed in membranes containing at least 20 mol% of lipids with a phosphatidyl ethanolamine or a high mol fraction of the phosphatidyl serine head group.", [["membranes", "ANATOMY", 57, 66], ["phosphatidyl ethanolamine", "CHEMICAL", 112, 137], ["phosphatidyl serine", "CHEMICAL", 168, 187], ["phosphatidyl ethanolamine", "CHEMICAL", 112, 137], ["phosphatidyl serine", "CHEMICAL", 168, 187], ["TAT", "GENE_OR_GENE_PRODUCT", 28, 31], ["membranes", "CELLULAR_COMPONENT", 57, 66], ["lipids", "SIMPLE_CHEMICAL", 98, 104], ["phosphatidyl ethanolamine", "SIMPLE_CHEMICAL", 112, 137], ["phosphatidyl serine head", "SIMPLE_CHEMICAL", 168, 192], ["A translocation of cationic TAT peptides", "TREATMENT", 0, 40], ["lipids", "TREATMENT", 98, 104], ["a phosphatidyl ethanolamine", "TREATMENT", 110, 137], ["a high mol fraction", "TREATMENT", 141, 160], ["high mol fraction", "OBSERVATION_MODIFIER", 143, 160]]], ["In salt-free solution TAT efficiently bound to GUVs, however, in a physiological NaCl solution TAT binding was completely abrogated, but the peptides efficiently equilibrated across the GUV membrane.P-627New approaches to measure interactions in the live cell plasma membrane G. J. Sch\u00fctz Biophysics Institute, Johannes Kepler University Linz, Austria In my lecture, I will show examples how to obtain insights into the organization of the cellular Nanocosm by single molecule experiments.", [["GUV membrane", "ANATOMY", 186, 198], ["cell plasma membrane", "ANATOMY", 255, 275], ["cellular", "ANATOMY", 440, 448], ["NaCl", "CHEMICAL", 81, 85], ["NaCl", "CHEMICAL", 81, 85], ["salt-free solution TAT", "SIMPLE_CHEMICAL", 3, 25], ["GUVs", "SIMPLE_CHEMICAL", 47, 51], ["TAT", "SIMPLE_CHEMICAL", 95, 98], ["GUV membrane", "CELLULAR_COMPONENT", 186, 198], ["cell", "CELL", 255, 259], ["cellular", "CELL", 440, 448], ["TAT", "PROTEIN", 22, 25], ["TAT", "PROTEIN", 95, 98], ["salt-free solution TAT", "TREATMENT", 3, 25], ["a physiological NaCl solution TAT binding", "TREATMENT", 65, 106], ["GUV membrane", "ANATOMY", 186, 198]]], ["Brightness and single molecule colocalization analysis allows us to study stable or transient molecular associations in vivo.", [["single molecule colocalization analysis", "TEST", 15, 54]]], ["In particular, I will present results on the interaction between antigen-loaded MHC and the T cell receptor directly in the interface region of a T cell with a surrogate antigenpresenting cell.", [["T cell", "ANATOMY", 92, 98], ["T cell", "ANATOMY", 146, 152], ["antigenpresenting cell", "ANATOMY", 170, 192], ["antigen", "GENE_OR_GENE_PRODUCT", 65, 72], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 92, 107], ["T cell", "CELL", 146, 152], ["cell", "CELL", 188, 192], ["antigen-loaded MHC", "PROTEIN", 65, 83], ["T cell receptor", "PROTEIN", 92, 107], ["T cell", "CELL_TYPE", 146, 152], ["surrogate antigenpresenting cell", "CELL_TYPE", 160, 192], ["antigen-loaded MHC", "TREATMENT", 65, 83], ["the T cell receptor", "TREATMENT", 88, 107], ["T cell", "OBSERVATION", 146, 152]]], ["In addition, we developed a method for in vivo micropatterning of plasma membrane proteins to measure molecular interactions.", [["plasma membrane", "ANATOMY", 66, 81], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["plasma membrane proteins", "PROTEIN", 66, 90], ["a method", "TREATMENT", 26, 34], ["plasma membrane proteins", "TREATMENT", 66, 90]]], ["The method allows identifying and characterizing interactions between an arbitrary fluorescence labeled protein (\"prey\") and a membrane protein (\"bait\") directly in living cells.", [["membrane", "ANATOMY", 127, 135], ["cells", "ANATOMY", 172, 177], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["cells", "CELL", 172, 177], ["arbitrary fluorescence labeled protein", "PROTEIN", 73, 111], ["membrane protein", "PROTEIN", 127, 143], ["living cells", "CELL_TYPE", 165, 177], ["a membrane protein (\"bait\"", "TREATMENT", 125, 151]]], ["Cells transfected with a fluorescent fusion protein of the prey are plated on micropatterned surfaces functionalized with specific antibodies to the extracellular domain of the bait; the fluorescence copatterning is used as readout for the interaction.", [["Cells", "ANATOMY", 0, 5], ["extracellular", "ANATOMY", 149, 162], ["Cells", "CELL", 0, 5], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 149, 162], ["fluorescent fusion protein", "PROTEIN", 25, 51], ["specific antibodies", "PROTEIN", 122, 141], ["extracellular domain", "PROTEIN", 149, 169], ["a fluorescent fusion protein", "TEST", 23, 51], ["micropatterned surfaces functionalized", "TREATMENT", 78, 116], ["specific antibodies", "TREATMENT", 122, 141], ["the fluorescence copatterning", "TREATMENT", 183, 212]]], ["We applied this tool for the study of the interaction between CD4 -the major coreceptor for T cell activation -and Lck, an important tyrosine kinase in early T cell signaling.", [["T cell", "ANATOMY", 92, 98], ["T cell", "ANATOMY", 158, 164], ["tyrosine", "CHEMICAL", 133, 141], ["tyrosine", "CHEMICAL", 133, 141], ["CD4", "GENE_OR_GENE_PRODUCT", 62, 65], ["T cell", "CELL", 92, 98], ["Lck", "GENE_OR_GENE_PRODUCT", 115, 118], ["tyrosine", "AMINO_ACID", 133, 141], ["T cell", "CELL", 158, 164], ["CD4", "PROTEIN", 62, 65], ["Lck", "PROTEIN", 115, 118], ["tyrosine kinase", "PROTEIN", 133, 148], ["the study", "TEST", 25, 34], ["CD4", "TEST", 62, 65], ["T cell activation", "TEST", 92, 109], ["an important tyrosine kinase", "PROBLEM", 120, 148], ["tyrosine kinase", "OBSERVATION", 133, 148], ["cell signaling", "OBSERVATION", 160, 174]]], ["In addition to the well-known zinc-clasp structure, we found strong contributions of Lck membrane anchorage for the binding of the two proteins.O-638Developing a fluorescent redox sensor for monitoring metal-ion mediated catalysis in biosystems A. Rybina 1 , A. Kiel 1 , B. Thaler 2 , A. Spr\u00f6defeld 2 , R. Kr\u00e4mer 2 , D. P. Herten 1 1 BioQuant and, 2 Department of Inorganic Chemistry, Heidelberg University, Germany A fluorescent redox sensor is an electron photo-switching device that can be used for the characterization of the redox state of a given environment.", [["membrane", "ANATOMY", 89, 97], ["zinc", "CHEMICAL", 30, 34], ["O-638Developing", "CHEMICAL", 144, 159], ["zinc", "CHEMICAL", 30, 34], ["zinc", "SIMPLE_CHEMICAL", 30, 34], ["Lck", "GENE_OR_GENE_PRODUCT", 85, 88], ["O-638Developing", "SIMPLE_CHEMICAL", 144, 159], ["zinc-clasp structure", "PROTEIN", 30, 50], ["Lck", "PROTEIN", 85, 88], ["the well-known zinc-clasp structure", "PROBLEM", 15, 50], ["Lck membrane anchorage", "TREATMENT", 85, 107], ["monitoring metal-ion mediated catalysis", "TREATMENT", 191, 230], ["an electron photo-switching device", "TREATMENT", 446, 480], ["clasp structure", "OBSERVATION", 35, 50], ["strong", "OBSERVATION_MODIFIER", 61, 67], ["Lck membrane anchorage", "OBSERVATION", 85, 107]]], ["It combines a fluorescent fragment with a redox-active unit that senses the media by a redox reaction and controls the light emitting properties of the fluorophore.", [["a fluorescent fragment", "PROBLEM", 12, 34], ["a redox-active unit", "TREATMENT", 40, 59], ["a redox reaction", "PROBLEM", 85, 101], ["the fluorophore", "TREATMENT", 148, 163], ["fluorescent fragment", "OBSERVATION", 14, 34], ["active", "OBSERVATION_MODIFIER", 48, 54]]], ["Such reversible sensor can help to examine the electrochemical state and changes in biological systems during biochemical processes in real time.", [["Such reversible sensor", "PROBLEM", 0, 22], ["changes in biological systems", "PROBLEM", 73, 102]]], ["Recently a new fluorescent molecular sensor with a redox-active hydroquinoneunit covalently linked to fluorophore Rhodamine B was developed.", [["hydroquinoneunit", "CHEMICAL", 64, 80], ["Rhodamine B", "CHEMICAL", 114, 125], ["hydroquinoneunit", "CHEMICAL", 64, 80], ["Rhodamine B", "CHEMICAL", 114, 125], ["hydroquinoneunit", "SIMPLE_CHEMICAL", 64, 80], ["fluorophore Rhodamine B", "SIMPLE_CHEMICAL", 102, 125], ["a new fluorescent molecular sensor", "PROBLEM", 9, 43], ["a redox-active hydroquinoneunit covalently", "TREATMENT", 49, 91], ["fluorophore Rhodamine B", "TREATMENT", 102, 125]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["The reduced hydroquinone-form of the sensor is fluorescent while its oxidation to benzoquinone-derivative leads to a significant decrease of the fluorescence.", [["hydroquinone", "CHEMICAL", 12, 24], ["benzoquinone", "CHEMICAL", 82, 94], ["hydroquinone", "CHEMICAL", 12, 24], ["benzoquinone", "CHEMICAL", 82, 94], ["hydroquinone", "SIMPLE_CHEMICAL", 12, 24], ["benzoquinone-derivative", "SIMPLE_CHEMICAL", 82, 105], ["The reduced hydroquinone", "TREATMENT", 0, 24], ["its oxidation to benzoquinone-derivative", "TREATMENT", 65, 105], ["a significant decrease of the fluorescence", "PROBLEM", 115, 157], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["hydroquinone", "OBSERVATION", 12, 24], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["decrease", "OBSERVATION_MODIFIER", 129, 137]]], ["Although the above method shows great promise for applications in biological systems, the exact mechanism of this process is not fully understood yet.", [["the above method", "TEST", 9, 25], ["great", "OBSERVATION_MODIFIER", 32, 37]]], ["We use fluorescence spectroscopy to investigate oxidation reactions on the ensemble and single-molecule level and study kinetic rates.", [["fluorescence spectroscopy", "TEST", 7, 32], ["oxidation reactions", "PROBLEM", 48, 67], ["single-molecule level", "TEST", 88, 109], ["study kinetic rates", "TEST", 114, 133]]], ["The proposed strategy is to use Cu (II) complex as oxidation mediator immobilized on surface via DNA linker to examine the oxidation mechanism.P-637Fluorescently labeled ATP as a probe of the outer mitochondrial membrane barrier: role of VDAC Fluorescence correlation spectroscopy (FCS) was applied for studying the distribution of fluorescently labeled ATP (Bodipy-ATP) in isolated mitochondria.", [["surface", "ANATOMY", 85, 92], ["mitochondrial membrane", "ANATOMY", 198, 220], ["mitochondria", "ANATOMY", 383, 395], ["Cu", "CHEMICAL", 32, 34], ["P-637", "CHEMICAL", 143, 148], ["ATP", "CHEMICAL", 170, 173], ["ATP", "CHEMICAL", 354, 357], ["Bodipy-ATP", "CHEMICAL", 359, 369], ["Cu (II)", "CHEMICAL", 32, 39], ["P-637", "CHEMICAL", 143, 148], ["ATP", "CHEMICAL", 170, 173], ["ATP", "CHEMICAL", 354, 357], ["Bodipy", "CHEMICAL", 359, 365], ["ATP", "CHEMICAL", 366, 369], ["surface", "CELLULAR_COMPONENT", 85, 92], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["ATP", "SIMPLE_CHEMICAL", 170, 173], ["outer", "CELLULAR_COMPONENT", 192, 197], ["mitochondrial", "CELLULAR_COMPONENT", 198, 211], ["membrane barrier", "CELLULAR_COMPONENT", 212, 228], ["VDAC", "SIMPLE_CHEMICAL", 238, 242], ["ATP", "SIMPLE_CHEMICAL", 354, 357], ["Bodipy-ATP", "SIMPLE_CHEMICAL", 359, 369], ["mitochondria", "CELLULAR_COMPONENT", 383, 395], ["Cu (II) complex", "PROTEIN", 32, 47], ["VDAC", "PROTEIN", 238, 242], ["Cu (II) complex as oxidation mediator", "TREATMENT", 32, 69], ["DNA linker", "TREATMENT", 97, 107], ["the oxidation mechanism", "TREATMENT", 119, 142], ["Fluorescently labeled ATP", "TREATMENT", 148, 173], ["the outer mitochondrial membrane barrier", "TREATMENT", 188, 228]]], ["The setup and peak intensity analysis (PIA) was described in our recent paper (Perevoshchikova et al. 2008 Biochim.Biophys.Acta 1778 :2182 .", [["The setup and peak intensity analysis", "TEST", 0, 37]]], ["The binding of Bodipy-ATP to mitochondria was maximal in the non-energized state, whereas the addition of succinate (respiratoty substrate) or atractyloside (adenine nucleotide translocase inhibitor) led to a decrease in the binding.", [["mitochondria", "ANATOMY", 29, 41], ["ATP", "CHEMICAL", 22, 25], ["succinate", "CHEMICAL", 106, 115], ["atractyloside", "CHEMICAL", 143, 156], ["adenine nucleotide", "CHEMICAL", 158, 176], ["ATP", "CHEMICAL", 22, 25], ["succinate", "CHEMICAL", 106, 115], ["atractyloside", "CHEMICAL", 143, 156], ["adenine", "CHEMICAL", 158, 165], ["Bodipy-ATP", "SIMPLE_CHEMICAL", 15, 25], ["mitochondria", "CELLULAR_COMPONENT", 29, 41], ["succinate", "SIMPLE_CHEMICAL", 106, 115], ["respiratoty substrate", "SIMPLE_CHEMICAL", 117, 138], ["atractyloside", "SIMPLE_CHEMICAL", 143, 156], ["adenine nucleotide", "SIMPLE_CHEMICAL", 158, 176], ["ATP", "TREATMENT", 22, 25], ["succinate (respiratoty substrate", "TREATMENT", 106, 138], ["atractyloside (adenine nucleotide translocase inhibitor", "TREATMENT", 143, 198], ["a decrease in the binding", "PROBLEM", 207, 232], ["decrease", "OBSERVATION_MODIFIER", 209, 217]]], ["NADH reduced the FCS signal from Bodipy-ATP added to non-energized mitochondria more than NAD+ did under the same conditions suggesting the control of nucleotide transport through voltage-dependent anion channel (VDAC) residing in the outer membrane.", [["mitochondria", "ANATOMY", 67, 79], ["outer membrane", "ANATOMY", 235, 249], ["NADH", "CHEMICAL", 0, 4], ["ATP", "CHEMICAL", 40, 43], ["NAD", "CHEMICAL", 90, 93], ["nucleotide", "CHEMICAL", 151, 161], ["NADH", "CHEMICAL", 0, 4], ["ATP", "CHEMICAL", 40, 43], ["NAD+", "CHEMICAL", 90, 94], ["nucleotide", "CHEMICAL", 151, 161], ["NADH", "SIMPLE_CHEMICAL", 0, 4], ["Bodipy-ATP", "SIMPLE_CHEMICAL", 33, 43], ["mitochondria", "CELLULAR_COMPONENT", 67, 79], ["NAD+", "SIMPLE_CHEMICAL", 90, 94], ["nucleotide", "SIMPLE_CHEMICAL", 151, 161], ["voltage-dependent anion channel", "GENE_OR_GENE_PRODUCT", 180, 211], ["VDAC", "GENE_OR_GENE_PRODUCT", 213, 217], ["outer membrane", "CELLULAR_COMPONENT", 235, 249], ["voltage-dependent anion channel", "PROTEIN", 180, 211], ["VDAC", "PROTEIN", 213, 217], ["NADH", "PROBLEM", 0, 4], ["the FCS signal", "TEST", 13, 27], ["Bodipy", "TEST", 33, 39], ["ATP", "PROBLEM", 40, 43], ["non-energized mitochondria", "PROBLEM", 53, 79], ["NAD", "PROBLEM", 90, 93], ["dependent anion channel (VDAC", "TREATMENT", 188, 217], ["dependent", "OBSERVATION_MODIFIER", 188, 197], ["anion channel", "OBSERVATION", 198, 211], ["outer membrane", "ANATOMY", 235, 249]]], ["Konig's polyanion also decreased the Bodipy-ATP binding to mitochondria with the effect being reduced by alamethicin or digitonin.", [["mitochondria", "ANATOMY", 59, 71], ["polyanion", "CHEMICAL", 8, 17], ["Bodipy", "CHEMICAL", 37, 43], ["ATP", "CHEMICAL", 44, 47], ["alamethicin", "CHEMICAL", 105, 116], ["digitonin", "CHEMICAL", 120, 129], ["ATP", "CHEMICAL", 44, 47], ["alamethicin", "CHEMICAL", 105, 116], ["digitonin", "CHEMICAL", 120, 129], ["Konig's polyanion", "SIMPLE_CHEMICAL", 0, 17], ["Bodipy", "SIMPLE_CHEMICAL", 37, 43], ["ATP", "SIMPLE_CHEMICAL", 44, 47], ["mitochondria", "CELLULAR_COMPONENT", 59, 71], ["alamethicin", "SIMPLE_CHEMICAL", 105, 116], ["digitonin", "SIMPLE_CHEMICAL", 120, 129], ["Konig's polyanion", "TREATMENT", 0, 17], ["the Bodipy", "TREATMENT", 33, 43], ["ATP binding", "PROBLEM", 44, 55], ["alamethicin", "TREATMENT", 105, 116], ["digitonin", "TREATMENT", 120, 129], ["decreased", "OBSERVATION_MODIFIER", 23, 32]]], ["Control experiments showed that Bodipy-ATP did not bind to liposomes showing minor role of unspecific binding.", [["Bodipy", "CHEMICAL", 32, 38], ["ATP", "CHEMICAL", 39, 42], ["ATP", "CHEMICAL", 39, 42], ["Bodipy-ATP", "SIMPLE_CHEMICAL", 32, 42], ["liposomes", "SIMPLE_CHEMICAL", 59, 68], ["Bodipy-ATP", "TEST", 32, 42], ["unspecific binding", "PROBLEM", 91, 109]]], ["It was suggested that Bodipy-ATP in combination with FCS can be used to monitor the functional state of mitochondrial VDAC which is considered to be a principal regulator of mitochondrial function.P-636Fluorescence correlation spectroscopy studies of lysozyme partition to phospholipid vesicles A. M. Melo 2 , A. Coutinho 2 , M. Prieto 1 1 CQFM and IN, IST, 1049-001 Lisboa, Portugal, 2 DQB, FCUL, 1749-016, Lisboa, Portugal Binding to membrane lipids has been increasingly recognized as an important step in the aggregation and cytotoxicity of several amyloidogenic proteins [1] .", [["mitochondrial", "ANATOMY", 104, 117], ["mitochondrial", "ANATOMY", 174, 187], ["membrane lipids", "ANATOMY", 436, 451], ["ATP", "CHEMICAL", 29, 32], ["FCUL, 1749-016", "CHEMICAL", 392, 406], ["ATP", "CHEMICAL", 29, 32], ["Bodipy-ATP", "SIMPLE_CHEMICAL", 22, 32], ["mitochondrial", "CELLULAR_COMPONENT", 104, 117], ["VDAC", "GENE_OR_GENE_PRODUCT", 118, 122], ["mitochondrial", "CELLULAR_COMPONENT", 174, 187], ["lysozyme", "GENE_OR_GENE_PRODUCT", 251, 259], ["mitochondrial VDAC", "PROTEIN", 104, 122], ["lysozyme", "PROTEIN", 251, 259], ["amyloidogenic proteins", "PROTEIN", 553, 575], ["Bodipy-ATP", "TREATMENT", 22, 32], ["FCS", "TREATMENT", 53, 56], ["Fluorescence correlation spectroscopy studies", "TEST", 202, 247], ["lysozyme partition", "TREATMENT", 251, 269], ["Prieto", "TEST", 329, 335], ["DQB", "TEST", 387, 390], ["FCUL", "TEST", 392, 396], ["several amyloidogenic proteins", "PROBLEM", 545, 575], ["mitochondrial VDAC", "OBSERVATION", 104, 122], ["mitochondrial function", "OBSERVATION", 174, 196]]], ["In addition, it has been recently reported that membranes containing negatively-charged phospholipids can also trigger rapid amyloid-like fiber formation by a variety of several nonamyloidogenic proteins, such as cytochrome c and lysozyme [2] .", [["membranes", "ANATOMY", 48, 57], ["fiber", "ANATOMY", 138, 143], ["membranes", "CELLULAR_COMPONENT", 48, 57], ["phospholipids", "SIMPLE_CHEMICAL", 88, 101], ["fiber", "CELLULAR_COMPONENT", 138, 143], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 213, 225], ["lysozyme [2]", "GENE_OR_GENE_PRODUCT", 230, 242], ["nonamyloidogenic proteins", "PROTEIN", 178, 203], ["cytochrome c", "PROTEIN", 213, 225], ["lysozyme", "PROTEIN", 230, 238], ["rapid amyloid", "PROBLEM", 119, 132], ["several nonamyloidogenic proteins", "PROBLEM", 170, 203], ["cytochrome c and lysozyme", "TREATMENT", 213, 238], ["rapid", "OBSERVATION_MODIFIER", 119, 124], ["amyloid", "OBSERVATION", 125, 132], ["fiber formation", "OBSERVATION", 138, 153]]], ["Our study aims to elucidate the factors that govern the formation of these lipid-protein complexes.", [["lipid-protein complexes", "PROTEIN", 75, 98], ["Our study", "TEST", 0, 9], ["the factors", "PROBLEM", 28, 39], ["protein complexes", "OBSERVATION", 81, 98]]], ["Given the importance of electrostatic interactions between the proteins and the acidic phospholipids in the putative membrane-induced protein misfolding step, it is essential to first characterize quantitatively the protein partition behavior towards liposomes prepared with variable anionic lipid content.", [["membrane", "ANATOMY", 117, 125], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["liposomes", "SIMPLE_CHEMICAL", 251, 260], ["lipid", "SIMPLE_CHEMICAL", 292, 297], ["electrostatic interactions", "PROBLEM", 24, 50], ["the proteins", "TREATMENT", 59, 71], ["the acidic phospholipids", "TREATMENT", 76, 100], ["protein misfolding step", "PROBLEM", 134, 157], ["variable anionic lipid content", "PROBLEM", 275, 305], ["protein misfolding", "OBSERVATION", 134, 152], ["lipid content", "OBSERVATION", 292, 305]]], ["In this study, lysozyme was chosen as a model protein and fluorescence correlation spectroscopy (FCS) was used to monitor its binding to liposomes after its conjugation to Alexa Fluor 488.", [["Alexa Fluor 488", "CHEMICAL", 172, 187], ["Alexa Fluor 488", "CHEMICAL", 172, 187], ["lysozyme", "GENE_OR_GENE_PRODUCT", 15, 23], ["liposomes", "SIMPLE_CHEMICAL", 137, 146], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 172, 187], ["lysozyme", "PROTEIN", 15, 23], ["Alexa Fluor 488", "PROTEIN", 172, 187], ["this study", "TEST", 3, 13], ["lysozyme", "TREATMENT", 15, 23], ["fluorescence correlation spectroscopy", "TEST", 58, 95], ["FCS", "TEST", 97, 100]]], ["Most organic dyes labelling techniques produce a mixture of populations of molecules labelled with a different number of fluorophores.", [["Most organic dyes labelling techniques", "TREATMENT", 0, 38], ["populations of molecules", "PROBLEM", 60, 84]]], ["The influence of this poli-dispersity of labelled molecules on the protein partition behaviour will be explored, namely the ability of the FCS technique to detect the production of non-competent membrane-binding species.Determination of dissociation constants in live cells and organisms by SW-FCCST.", [["membrane", "ANATOMY", 195, 203], ["cells", "ANATOMY", 268, 273], ["membrane", "CELLULAR_COMPONENT", 195, 203], ["cells", "CELL", 268, 273], ["non-competent membrane-binding species", "PROTEIN", 181, 219], ["live cells", "CELL_TYPE", 263, 273], ["labelled molecules", "PROBLEM", 41, 59], ["the FCS technique", "TEST", 135, 152], ["non-competent membrane-binding species", "PROBLEM", 181, 219], ["dissociation constants in live cells", "PROBLEM", 237, 273], ["binding species", "OBSERVATION", 204, 219], ["dissociation constants", "OBSERVATION", 237, 259]]], ["Univ., 2 Medical Biology Inst., Singapore, 3 Molecular & Cell Biology Inst., Singapore Biomolecular interactions have been measured mostly under in vitro conditions because of higher accuracy and ease of measurement.", [["Cell", "ANATOMY", 57, 61]]], ["However, it has become clear that the cellular environment has an important influence on these interactions.", [["cellular", "ANATOMY", 38, 46], ["cellular", "CELL", 38, 46], ["clear", "OBSERVATION", 23, 28], ["cellular environment", "OBSERVATION", 38, 58]]], ["It was therefore necessary to develop new tools to allow the measurement of interactions in cells and organisms.", [["cells", "ANATOMY", 92, 97], ["cells", "CELL", 92, 97], ["new tools", "PROBLEM", 38, 47], ["interactions in cells", "PROBLEM", 76, 97]]], ["Recently, we have developed a modality of fluorescence cross-correlation spectroscopy (FCCS) called single wavelength FCCS (SW-FCCS), which uses one-photon excitation to excite two fluorophores with overlapping absorption but separable emission spectra.", [["fluorescence cross-correlation spectroscopy", "TEST", 42, 85], ["single wavelength FCCS", "TREATMENT", 100, 122], ["one-photon excitation", "TREATMENT", 145, 166], ["two fluorophores", "TREATMENT", 177, 193]]], ["SW-FCCS has been used to determine e.g. dimer fractions of proteins in live cells.Determination of dissociation constants in live cells and organisms by SW-FCCSHere we aim to extend the use of SW-FCCS to cells and organisms.", [["cells", "ANATOMY", 76, 81], ["cells", "ANATOMY", 130, 135], ["cells", "ANATOMY", 204, 209], ["cells", "CELL", 76, 81], ["cells", "CELL", 130, 135], ["SW-FCCS", "CELL", 193, 200], ["cells", "CELL", 204, 209], ["FCCS", "PROTEIN", 3, 7], ["live cells", "CELL_TYPE", 71, 81], ["live cells", "CELL_TYPE", 125, 135], ["proteins in live cells", "PROBLEM", 59, 81], ["dissociation constants in live cells", "PROBLEM", 99, 135], ["dissociation", "OBSERVATION", 99, 111]]], ["In the first part we determine the dissociation constants of a small Rho-GTPase (Cdc42) with an effector domain (CRIB) and two effectors (N-WASP or IRSp53).", [["Rho-", "CHEMICAL", 69, 73], ["Cdc42", "GENE_OR_GENE_PRODUCT", 81, 86], ["N-WASP", "GENE_OR_GENE_PRODUCT", 138, 144], ["IRSp53", "GENE_OR_GENE_PRODUCT", 148, 154], ["Rho-GTPase", "PROTEIN", 69, 79], ["Cdc42", "PROTEIN", 81, 86], ["effector domain", "PROTEIN", 96, 111], ["CRIB", "PROTEIN", 113, 117], ["N", "PROTEIN", 138, 139], ["WASP", "PROTEIN", 140, 144], ["IRSp53", "PROTEIN", 148, 154], ["the dissociation constants", "PROBLEM", 31, 57], ["a small Rho-GTPase (Cdc42", "PROBLEM", 61, 86], ["an effector domain", "PROBLEM", 93, 111], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["In the second part we measure the binding between Cdc42 and a scaffolding protein (IQGAP1) in dependence of their expression levels in CHO cells and in live zebrafish embryos.", [["CHO cells", "ANATOMY", 135, 144], ["embryos", "ANATOMY", 167, 174], ["Cdc42", "GENE_OR_GENE_PRODUCT", 50, 55], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 83, 89], ["CHO cells", "CELL", 135, 144], ["zebrafish", "ORGANISM", 157, 166], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 167, 174], ["Cdc42", "PROTEIN", 50, 55], ["scaffolding protein", "PROTEIN", 62, 81], ["IQGAP1", "PROTEIN", 83, 89], ["CHO cells", "CELL_LINE", 135, 144], ["a scaffolding protein (IQGAP1", "TREATMENT", 60, 89], ["CHO cells", "TREATMENT", 135, 144], ["CHO cells", "OBSERVATION", 135, 144]]], ["By using GFP/mRFP fusion proteins we can excite both fluorophores at 514 nm and detect them separately in two different wavelength channels.", [["GFP", "GENE_OR_GENE_PRODUCT", 9, 12], ["mRFP", "GENE_OR_GENE_PRODUCT", 13, 17], ["GFP", "PROTEIN", 9, 12], ["mRFP fusion proteins", "PROTEIN", 13, 33], ["GFP/mRFP fusion proteins", "TREATMENT", 9, 33]]], ["We quantitatively determine the dissociation constants and compare their differences in vitro, in cells, and in embryos.", [["cells", "ANATOMY", 98, 103], ["embryos", "ANATOMY", 112, 119], ["cells", "CELL", 98, 103], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 112, 119], ["the dissociation constants", "PROBLEM", 28, 54]]], ["These experiments demonstrate that SW-FCCS is a powerful biophysical tool for the quantitation of biomolecular interactions in cells and organisms.O-644Addressing plasma membrane structure at the nanoscopic length-scale S. Wieser, M. Axmann, G. J. Sch\u00fctz Biophysics Institute, Johannes Kepler University Linz, Altenbergerstr.69, A-4040 Linz, Austria There is increasing interest in a detailed understanding of the structure and dynamics of the cellular plasma membrane, primarily based on recognizing its essential role for controlling cellular signaling processes.", [["cells", "ANATOMY", 127, 132], ["plasma membrane", "ANATOMY", 163, 178], ["cellular plasma membrane", "ANATOMY", 444, 468], ["cellular", "ANATOMY", 536, 544], ["O-644Addressing", "CHEMICAL", 147, 162], ["O-644Addressing", "CHEMICAL", 147, 162], ["cells", "CELL", 127, 132], ["plasma", "ORGANISM_SUBSTANCE", 163, 169], ["membrane", "CELLULAR_COMPONENT", 170, 178], ["cellular", "CELLULAR_COMPONENT", 444, 452], ["plasma membrane", "CELLULAR_COMPONENT", 453, 468], ["cellular", "CELL", 536, 544], ["biomolecular interactions in cells", "PROBLEM", 98, 132], ["plasma membrane structure", "PROBLEM", 163, 188], ["controlling cellular signaling processes", "PROBLEM", 524, 564], ["increasing", "OBSERVATION_MODIFIER", 359, 369], ["interest", "OBSERVATION_MODIFIER", 370, 378], ["cellular plasma membrane", "OBSERVATION", 444, 468], ["signaling processes", "OBSERVATION", 545, 564]]], ["We employed single molecule fluorescence microscopy to study diffusion of CD59, a GPI-anchored protein, in the plasma membrane of living T24 cells at sub-wavelength resolution, both on the cell body and on tunneling nanotubules connecting cells.", [["plasma membrane", "ANATOMY", 111, 126], ["T24 cells", "ANATOMY", 137, 146], ["cell body", "ANATOMY", 189, 198], ["cells", "ANATOMY", 239, 244], ["CD59", "GENE_OR_GENE_PRODUCT", 74, 78], ["plasma membrane", "CELLULAR_COMPONENT", 111, 126], ["T24 cells", "CELL", 137, 146], ["cell body", "CELLULAR_COMPONENT", 189, 198], ["cells", "CELL", 239, 244], ["CD59", "PROTEIN", 74, 78], ["GPI-anchored protein", "PROTEIN", 82, 102], ["T24 cells", "CELL_LINE", 137, 146], ["single molecule fluorescence microscopy", "TEST", 12, 51], ["CD59", "TEST", 74, 78], ["a GPI", "TEST", 80, 85], ["anchored protein", "PROBLEM", 86, 102], ["tunneling nanotubules connecting cells", "TREATMENT", 206, 244], ["T24 cells", "OBSERVATION", 137, 146], ["wavelength", "OBSERVATION_MODIFIER", 154, 164], ["resolution", "OBSERVATION_MODIFIER", 165, 175], ["cell body", "OBSERVATION", 189, 198]]], ["The lateral motion of this single fluorescence labeled molecule was imaged on a millisecond time scale.", [["a millisecond time scale", "TREATMENT", 78, 102], ["lateral", "OBSERVATION_MODIFIER", 4, 11]]], ["Within the experimental errors, no indications for confined diffusion for CD59 on the cell body in T24 cells have been found.", [["cell body", "ANATOMY", 86, 95], ["T24 cells", "ANATOMY", 99, 108], ["CD59", "GENE_OR_GENE_PRODUCT", 74, 78], ["cell body", "CELLULAR_COMPONENT", 86, 95], ["T24 cells", "CELL", 99, 108], ["CD59", "PROTEIN", 74, 78], ["T24 cells", "CELL_LINE", 99, 108], ["confined diffusion", "TEST", 51, 69], ["CD59", "PROBLEM", 74, 78], ["the cell body in T24 cells", "TEST", 82, 108]]], ["Furthermore by separating longitudinal and transversal mobility, we found isotropic diffusion behavior on the surface of tunneling nanotubules.", [["surface", "ANATOMY", 110, 117], ["surface", "CELLULAR_COMPONENT", 110, 117], ["isotropic diffusion behavior", "PROBLEM", 74, 102], ["transversal mobility", "OBSERVATION_MODIFIER", 43, 63], ["isotropic", "OBSERVATION_MODIFIER", 74, 83], ["diffusion behavior", "OBSERVATION", 84, 102], ["tunneling nanotubules", "OBSERVATION", 121, 142]]], ["In both studies we analyzed the mean square displacement as a function of the time-lag and the distribution of displacement steps.", [["the mean square displacement", "PROBLEM", 28, 56], ["displacement steps", "PROBLEM", 111, 129], ["displacement steps", "OBSERVATION", 111, 129]]], ["However, a closed analytical theory for these analysis is only available for the simplest models.", [["these analysis", "TEST", 40, 54]]], ["To address a suspected diffusion process we reasoned that a full analytical description may not be required; it may well be sufficient to compare the experimental data with Monte Carlo simulations of the process.", [["a suspected diffusion process", "PROBLEM", 11, 40]]], ["We demonstrated the working principle for this simulation based analysis for free diffusion, hop diffusion and transient binding of the tracer molecule to slowly moving receptors.Investigating the early stages of sheep PrP oligomerization using SAXS and MD simulationsN.", [["sheep", "ORGANISM", 213, 218], ["PrP", "GENE_OR_GENE_PRODUCT", 219, 222], ["PrP", "PROTEIN", 219, 222], ["sheep", "SPECIES", 213, 218], ["sheep", "SPECIES", 213, 218], ["this simulation based analysis", "TEST", 42, 72], ["free diffusion", "PROBLEM", 77, 91], ["hop diffusion", "PROBLEM", 93, 106], ["the tracer molecule", "PROBLEM", 132, 151], ["sheep PrP oligomerization", "TREATMENT", 213, 238], ["tracer molecule", "OBSERVATION", 136, 151]]], ["Chakroun 1 , F. Fraternali 1 , M. Malfois 2 , H. Rezaei 3 , C. A. Dreiss 1 1 King's College London, U.K., 2 Diamond Light Source, Didcot, Oxfordshire, U.K., 3 INRA, Jouy-en-Josas, France Prion(PrP) diseases are fatal neurodegenerative diseases affecting mammals including Human and sheep.They are characterized by the accumulation of extracellular \u03b2rich fibrillar deposits of a structurally modified form (PrP sc ) of the cellular PrP c .Despite the increasing interest for PrP diseases,the mechanism of PrP c /PrP sc conversion is still unknown.Studies on PrP diseases suggest that neurotoxicity arises from small pre-fibrillar oligomers.We have used a range of biophysical techniques combined with Molecular Dynamics simulations (MD) to resolve the oligomerization pathways of sheep PrP (sPrP).We have shown that under well established conditions, sPrP oligomerizes into three oligomers, which form in parallel.In addition, we have now identified the minimal region of sPrP leading to the same oligomerization profile of the entire sPrP,namely H2H3.Low resolution shapes of sPrP, H2H3 and resulting oligomers have been determined by Small-Angle X-ray Scattering.Time-resolved studies have been used to follow the oligomerization of sPrP and H2H3 monomers into the oligomers.The conversion of sPrP sc at the molecular scale was studied by MD.Simulations of the H2H3 region recreating experimental conditions revealed a complete unfolding of H2 helix followed by H3 helix.These crucial steps are followed by the formation of \u03b2-sheet structures leading to a stable \u03b2rich double hairpin structure.P-648Single-molecule force spectroscopy investigation of the conformational equilibria of alphasynuclein M. Brucale 1 , A. Rampioni 1 , M. Sandal 1 , I. Tessari 2 , L. Tosatto 2 , L. Bubacco 2 , B. Samor\u00ec 1 1 Istituto di Biochimica G.Moruzzi, Universit\u00e0 di Bologna (Italy), 2 Dipartimento di Biologia, Universit\u00e0 di Padova (Italy) Alpha-synuclein (aSyn) is an abundant Intrinsically Disordered Protein (IDP) primarily located at presynaptic terminals.", [["extracellular", "ANATOMY", 334, 347], ["cellular", "ANATOMY", 422, 430], ["presynaptic terminals", "ANATOMY", 2024, 2045], ["Prion(PrP) diseases", "DISEASE", 187, 206], ["neurodegenerative diseases", "DISEASE", 217, 243], ["PrP diseases", "DISEASE", 474, 486], ["PrP diseases", "DISEASE", 557, 569], ["neurotoxicity", "DISEASE", 583, 596], ["P-648Single", "CHEMICAL", 1595, 1606], ["sPrP", "CHEMICAL", 850, 854], ["H2H3", "CHEMICAL", 1082, 1086], ["H2H3", "CHEMICAL", 1243, 1247], ["H2", "CHEMICAL", 1442, 1444], ["Human", "ORGANISM", 272, 277], ["sheep", "ORGANISM", 282, 287], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 334, 347], ["PrP sc )", "GENE_OR_GENE_PRODUCT", 406, 414], ["cellular PrP c", "GENE_OR_GENE_PRODUCT", 422, 436], ["PrP", "GENE_OR_GENE_PRODUCT", 474, 477], ["PrP c", "GENE_OR_GENE_PRODUCT", 504, 509], ["PrP", "GENE_OR_GENE_PRODUCT", 511, 514], ["PrP", "GENE_OR_GENE_PRODUCT", 557, 560], ["sheep", "ORGANISM", 779, 784], ["PrP", "GENE_OR_GENE_PRODUCT", 785, 788], ["sPrP", "SIMPLE_CHEMICAL", 850, 854], ["sPrP", "GENE_OR_GENE_PRODUCT", 971, 975], ["sPrP", "GENE_OR_GENE_PRODUCT", 1034, 1038], ["sPrP", "SIMPLE_CHEMICAL", 1076, 1080], ["H2H3", "SIMPLE_CHEMICAL", 1082, 1086], ["sPrP", "SIMPLE_CHEMICAL", 1234, 1238], ["H2H3 monomers", "SIMPLE_CHEMICAL", 1243, 1256], ["sPrP sc", "SIMPLE_CHEMICAL", 1294, 1301], ["H3 helix", "GENE_OR_GENE_PRODUCT", 1463, 1471], ["Alpha-synuclein", "GENE_OR_GENE_PRODUCT", 1926, 1941], ["aSyn", "GENE_OR_GENE_PRODUCT", 1943, 1947], ["presynaptic terminals", "CELLULAR_COMPONENT", 2024, 2045], ["PrP sc", "PROTEIN", 406, 412], ["cellular PrP c", "PROTEIN", 422, 436], ["PrP c", "PROTEIN", 504, 509], ["PrP", "PROTEIN", 511, 514], ["sheep PrP", "PROTEIN", 779, 788], ["PrP", "PROTEIN", 791, 794], ["sPrP", "PROTEIN", 850, 854], ["sPrP", "PROTEIN", 971, 975], ["sPrP", "PROTEIN", 1034, 1038], ["H2H3", "PROTEIN", 1046, 1050], ["sPrP", "PROTEIN", 1076, 1080], ["H2H3", "PROTEIN", 1082, 1086], ["sPrP", "PROTEIN", 1234, 1238], ["H2H3 monomers", "PROTEIN", 1243, 1256], ["sPrP", "PROTEIN", 1294, 1298], ["H2H3 region", "DNA", 1362, 1373], ["H2 helix", "PROTEIN", 1442, 1450], ["H3 helix", "PROTEIN", 1463, 1471], ["\u03b2rich double hairpin structure", "PROTEIN", 1564, 1594], ["Intrinsically Disordered Protein", "PROTEIN", 1964, 1996], ["IDP", "PROTEIN", 1998, 2001], ["Human", "SPECIES", 272, 277], ["sheep", "SPECIES", 282, 287], ["sheep", "SPECIES", 779, 784], ["sheep", "SPECIES", 282, 287], ["sheep", "SPECIES", 779, 784], ["INRA", "TEST", 159, 163], ["Jouy", "TEST", 165, 169], ["France Prion(PrP) diseases", "TREATMENT", 180, 206], ["fatal neurodegenerative diseases", "PROBLEM", 211, 243], ["extracellular \u03b2rich fibrillar deposits", "PROBLEM", 334, 372], ["the cellular PrP c", "TREATMENT", 418, 436], ["PrP diseases", "PROBLEM", 474, 486], ["PrP c /PrP sc conversion", "TREATMENT", 504, 528], ["PrP diseases", "TEST", 557, 569], ["neurotoxicity", "PROBLEM", 583, 596], ["small pre-fibrillar oligomers", "PROBLEM", 609, 638], ["biophysical techniques", "TREATMENT", 663, 685], ["sheep PrP (sPrP)", "TREATMENT", 779, 795], ["Low resolution shapes of sPrP", "PROBLEM", 1051, 1080], ["resulting oligomers", "PROBLEM", 1091, 1110], ["sPrP and H2H3 monomers", "TREATMENT", 1234, 1256], ["sPrP sc", "TREATMENT", 1294, 1301], ["the H2H3 region", "TREATMENT", 1358, 1373], ["a complete unfolding of H2 helix", "PROBLEM", 1418, 1450], ["a stable \u03b2rich double hairpin structure", "PROBLEM", 1555, 1594], ["P", "TEST", 1595, 1596], ["molecule force spectroscopy investigation", "TEST", 1607, 1648], ["alphasynuclein M. Brucale", "TREATMENT", 1685, 1710], ["Universit\u00e0 di Padova", "TREATMENT", 1897, 1917], ["Alpha-synuclein (aSyn", "TREATMENT", 1926, 1947], ["Disordered Protein (IDP)", "PROBLEM", 1978, 2002], ["fatal", "OBSERVATION_MODIFIER", 211, 216], ["neurodegenerative diseases", "OBSERVATION", 217, 243], ["accumulation", "OBSERVATION_MODIFIER", 318, 330], ["extracellular \u03b2rich", "OBSERVATION", 334, 353], ["fibrillar deposits", "OBSERVATION", 354, 372], ["cellular PrP", "OBSERVATION", 422, 434], ["small", "OBSERVATION_MODIFIER", 609, 614], ["pre-fibrillar oligomers", "OBSERVATION", 615, 638], ["minimal", "OBSERVATION_MODIFIER", 953, 960], ["resolution", "OBSERVATION_MODIFIER", 1055, 1065], ["shapes", "OBSERVATION_MODIFIER", 1066, 1072], ["Small", "OBSERVATION_MODIFIER", 1135, 1140], ["H2 helix", "OBSERVATION", 1442, 1450], ["crucial steps", "OBSERVATION", 1478, 1491], ["stable", "OBSERVATION_MODIFIER", 1557, 1563], ["hairpin structure", "OBSERVATION", 1577, 1594]]], ["Mutations in the gene encoding aSyn have been linked to early-onset Parkinson's disease (PD).", [["Parkinson's disease", "DISEASE", 68, 87], ["PD", "DISEASE", 89, 91], ["aSyn", "GENE_OR_GENE_PRODUCT", 31, 35], ["aSyn", "PROTEIN", 31, 35], ["Mutations", "PROBLEM", 0, 9], ["Parkinson's disease", "PROBLEM", 68, 87]]], ["By means of single molecule force spectroscopy (SMFS) experiment, we show how the conformational equilibrium of monomeric wild type (WT) aSyn shifts toward more compact structures in several unrelated conditions linked to PD pathogenicity [1] .", [["PD", "DISEASE", 222, 224], ["aSyn", "GENE_OR_GENE_PRODUCT", 137, 141], ["single molecule force spectroscopy", "TEST", 12, 46], ["PD pathogenicity", "PROBLEM", 222, 238]]], ["The conformational heterogeneity of pathological alpha-Syn mutants A30P, A53T and E46K has also been characterized, revealing marked differences in the conformational behaviors of the mutants with respect to WT aSyn [2] .", [["alpha-Syn", "GENE_OR_GENE_PRODUCT", 49, 58], ["A30P", "GENE_OR_GENE_PRODUCT", 67, 71], ["E46K", "AMINO_ACID", 82, 86], ["Syn [2]", "GENE_OR_GENE_PRODUCT", 212, 219], ["pathological alpha-Syn mutants", "PROTEIN", 36, 66], ["A53T", "PROTEIN", 73, 77], ["E46K", "PROTEIN", 82, 86], ["Syn [2]", "PROTEIN", 212, 219], ["marked", "OBSERVATION_MODIFIER", 126, 132], ["differences", "OBSERVATION_MODIFIER", 133, 144]]], ["All the mutants show a distinctively higher propensity, with respect to WT, to acquire a monomeric compact conformation that is compatible with the acquiring of beta structure.", [["beta", "GENE_OR_GENE_PRODUCT", 161, 165], ["beta structure", "PROTEIN", 161, 175], ["a monomeric compact conformation", "PROBLEM", 87, 119], ["distinctively", "OBSERVATION_MODIFIER", 23, 36], ["higher propensity", "OBSERVATION_MODIFIER", 37, 54], ["compatible with", "UNCERTAINTY", 128, 143], ["beta structure", "OBSERVATION", 161, 175]]], ["The same SMFS experimental methodology is then used to characterize the conformational behavior of WT and mutant aSyn in a variety of conditions, in an attempt to gain insight about the multiple and contrasting parameters controlling the equilibrium.", [["aSyn", "CHEMICAL", 113, 117], ["mutant aSyn", "PROTEIN", 106, 117]]], ["In vitro protein folding studies using chemical denaturants have contributed tremendously to our understanding of the folding thermodynamics and kinetics of water-soluble proteins.", [["water-soluble proteins", "PROTEIN", 157, 179], ["chemical denaturants", "TREATMENT", 39, 59], ["water-soluble proteins", "TREATMENT", 157, 179]]], ["This is not the case for integral membrane proteins, which constitute about one third of all eukaryotic proteins and more than half of all validated and potential drug targets.", [["membrane", "ANATOMY", 34, 42], ["membrane", "CELLULAR_COMPONENT", 34, 42], ["integral membrane proteins", "PROTEIN", 25, 51], ["eukaryotic proteins", "PROTEIN", 93, 112], ["integral membrane proteins", "PROBLEM", 25, 51]]], ["Fully reversible denaturant-induced unfolding remains limited to a few \u03b2-barrel porins, whereas the much larger and more relevant class of \u03b1-helical membrane proteins has thus far evaded this approach.", [["membrane", "ANATOMY", 149, 157], ["denaturant", "CHEMICAL", 17, 27], ["\u03b2-barrel porins", "GENE_OR_GENE_PRODUCT", 71, 86], ["\u03b2-barrel porins", "PROTEIN", 71, 86], ["\u03b1-helical membrane proteins", "PROTEIN", 139, 166], ["Fully reversible denaturant-induced unfolding", "PROBLEM", 0, 45], ["a few \u03b2-barrel porins", "PROBLEM", 65, 86], ["\u03b1-helical membrane proteins", "PROBLEM", 139, 166], ["reversible", "OBSERVATION_MODIFIER", 6, 16], ["denaturant", "OBSERVATION", 17, 27], ["unfolding", "OBSERVATION", 36, 45], ["larger", "OBSERVATION_MODIFIER", 105, 111]]], ["We report here the first example of an \u03b1-helical membrane protein that can be unfolded completely and reversibly by a chemical denaturant: Mistic, a 110-residue protein from Bacillus subtilis [1] , dissociates from detergent micelles or lipid vesicles and assumes an unfolded monomeric state on titration with urea.", [["\u03b1-helical membrane", "ANATOMY", 39, 57], ["lipid vesicles", "ANATOMY", 237, 251], ["Mistic", "CHEMICAL", 139, 145], ["urea", "CHEMICAL", 310, 314], ["urea", "CHEMICAL", 310, 314], ["Mistic", "SIMPLE_CHEMICAL", 139, 145], ["Bacillus subtilis", "ORGANISM", 174, 191], ["detergent micelles", "SIMPLE_CHEMICAL", 215, 233], ["lipid vesicles", "CELLULAR_COMPONENT", 237, 251], ["urea", "SIMPLE_CHEMICAL", 310, 314], ["\u03b1-helical membrane protein", "PROTEIN", 39, 65], ["Bacillus subtilis", "SPECIES", 174, 191], ["Bacillus subtilis", "SPECIES", 174, 191], ["an \u03b1-helical membrane protein", "PROBLEM", 36, 65], ["Bacillus subtilis", "PROBLEM", 174, 191], ["detergent micelles", "TREATMENT", 215, 233], ["lipid vesicles", "PROBLEM", 237, 251], ["an unfolded monomeric state", "PROBLEM", 264, 291], ["titration with urea", "TREATMENT", 295, 314], ["lipid vesicles", "ANATOMY", 237, 251], ["unfolded", "OBSERVATION_MODIFIER", 267, 275], ["monomeric state", "OBSERVATION", 276, 291]]], ["Using spectroscopic and microcalorimetric techniques, we exploited this unique property to provide (i) a quantitative comparison of membrane protein stability in different membrane-mimetic systems; (ii) an experimental test of controversial predictions [2] regarding the folding core of Mistic; and (iii) a convenient setup to study the spontaneous, translocon-independent membrane insertion of this unusual membrane protein.", [["membrane", "ANATOMY", 132, 140], ["membrane", "ANATOMY", 172, 180], ["translocon", "ANATOMY", 350, 360], ["membrane", "ANATOMY", 373, 381], ["membrane", "ANATOMY", 408, 416], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["membrane", "CELLULAR_COMPONENT", 172, 180], ["membrane", "CELLULAR_COMPONENT", 373, 381], ["membrane", "CELLULAR_COMPONENT", 408, 416], ["unusual membrane protein", "PROTEIN", 400, 424], ["spectroscopic and microcalorimetric techniques", "TREATMENT", 6, 52], ["membrane protein stability", "PROBLEM", 132, 158], ["an experimental test", "TEST", 203, 223], ["translocon-independent membrane insertion", "TREATMENT", 350, 391]]], ["The mechanical functioning of biological tissues is important from many viewpoints such as diseases, clothing and even food.", [["tissues", "ANATOMY", 41, 48], ["tissues", "TISSUE", 41, 48], ["mechanical functioning", "OBSERVATION", 4, 26], ["biological tissues", "OBSERVATION", 30, 48]]], ["The protein collagen makes up the greater part of these tissues, and is remarkable for its many uses in the body, however there are at least two other major components.", [["tissues", "ANATOMY", 56, 63], ["body", "ANATOMY", 108, 112], ["collagen", "GENE_OR_GENE_PRODUCT", 12, 20], ["tissues", "TISSUE", 56, 63], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["protein collagen", "PROTEIN", 4, 20], ["The protein collagen", "TREATMENT", 0, 20], ["protein collagen", "OBSERVATION", 4, 20], ["greater", "OBSERVATION_MODIFIER", 34, 41], ["these tissues", "ANATOMY", 50, 63], ["body", "ANATOMY_MODIFIER", 108, 112], ["at least", "OBSERVATION_MODIFIER", 132, 140], ["two", "OBSERVATION_MODIFIER", 141, 144], ["major", "OBSERVATION_MODIFIER", 151, 156], ["components", "OBSERVATION_MODIFIER", 157, 167]]], ["One of the most interesting properties of these tissues is their non-linear behavior under stress.", [["tissues", "ANATOMY", 48, 55], ["tissues", "TISSUE", 48, 55], ["most interesting", "OBSERVATION_MODIFIER", 11, 27], ["tissues", "OBSERVATION", 48, 55]]], ["This behavior is essential to prevent a catastrophic failure such as an aneurysm.", [["aneurysm", "ANATOMY", 72, 80], ["aneurysm", "DISEASE", 72, 80], ["aneurysm", "PATHOLOGICAL_FORMATION", 72, 80], ["a catastrophic failure", "PROBLEM", 38, 60], ["an aneurysm", "PROBLEM", 69, 80], ["catastrophic", "OBSERVATION_MODIFIER", 40, 52], ["failure", "OBSERVATION", 53, 60], ["aneurysm", "OBSERVATION", 72, 80]]], ["In order to determine a correct description of the mechanical structure of the tissue we have been using cutting edge technological solutions to address the single molecules within the extra cellular matrix.", [["tissue", "ANATOMY", 79, 85], ["cellular matrix", "ANATOMY", 191, 206], ["tissue", "TISSUE", 79, 85], ["extra cellular matrix", "CELLULAR_COMPONENT", 185, 206], ["cutting edge technological solutions", "TREATMENT", 105, 141], ["mechanical structure", "OBSERVATION", 51, 71], ["extra cellular matrix", "OBSERVATION", 185, 206]]], ["This technique combines optical methods with single molecule force spectroscopy, allowing stiffness measurements over the nanoscale as well as determining the individual protein tensions within the extra cellular matrix.", [["cellular matrix", "ANATOMY", 204, 219], ["cellular matrix", "CELLULAR_COMPONENT", 204, 219], ["single molecule force spectroscopy", "TEST", 45, 79], ["stiffness measurements over the nanoscale", "TEST", 90, 131], ["protein tensions", "OBSERVATION", 170, 186], ["extra cellular matrix", "OBSERVATION", 198, 219]]], ["The results show that this method can be used to determine the network properties even in the complicated aortic wall enabling better understanding of disease states, which in this case include Marfan's syndrome and ascending aortic aneurysms.P-648Beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than Abeta1-42 C. D'Arrigo 1 , M. Tabaton 2 , A. Perico 1 1 Institute for Macromolecular Studies, National Research Council, 16149 Genova, Italy, 2 Department of Neurosciences, University of Genova, 16132 Genova, ItalyP-648We test directly the differences in the aggregation kinetics of three important beta amyloid peptides, the full-length Abeta1-42 and the two N-terminal truncated and pyroglutamil modified Abetapy3-42 and Abetapy11-42, found in different relative concentrations in the brains in normal aging and in Alzheimer disease.", [["aortic wall", "ANATOMY", 106, 117], ["ascending aortic aneurysms", "ANATOMY", 216, 242], ["brains", "ANATOMY", 808, 814], ["Marfan's syndrome", "DISEASE", 194, 211], ["ascending aortic aneurysms", "DISEASE", 216, 242], ["P-648Beta", "CHEMICAL", 243, 252], ["Abetapy3-42", "CHEMICAL", 269, 280], ["Alzheimer disease", "DISEASE", 838, 855], ["Abetapy3-42", "CHEMICAL", 269, 280], ["N", "CHEMICAL", 681, 682], ["pyroglutamil", "CHEMICAL", 706, 718], ["Abetapy11-42", "CHEMICAL", 744, 756], ["aortic wall", "MULTI-TISSUE_STRUCTURE", 106, 117], ["aortic aneurysms", "PATHOLOGICAL_FORMATION", 226, 242], ["beta amyloid peptides", "GENE_OR_GENE_PRODUCT", 620, 641], ["Abeta1-42", "GENE_OR_GENE_PRODUCT", 659, 668], ["pyroglutamil", "SIMPLE_CHEMICAL", 706, 718], ["Abetapy3-42", "GENE_OR_GENE_PRODUCT", 728, 739], ["Abetapy11-42", "GENE_OR_GENE_PRODUCT", 744, 756], ["brains", "ORGAN", 808, 814], ["Alzheimer disease", "CANCER", 838, 855], ["P", "DNA", 243, 244], ["Abeta1", "PROTEIN", 659, 665], ["N-terminal truncated", "PROTEIN", 681, 701], ["Abetapy3", "PROTEIN", 728, 736], ["Abetapy11", "PROTEIN", 744, 753], ["this method", "TREATMENT", 22, 33], ["the complicated aortic wall", "PROBLEM", 90, 117], ["disease states", "PROBLEM", 151, 165], ["Marfan's syndrome", "PROBLEM", 194, 211], ["ascending aortic aneurysms", "PROBLEM", 216, 242], ["P", "TEST", 243, 244], ["amyloid peptide Abetapy3", "TEST", 253, 277], ["a faster aggregation kinetics", "PROBLEM", 287, 316], ["Abeta1", "TEST", 322, 328], ["Abeta1", "TEST", 659, 665], ["terminal truncated", "TREATMENT", 683, 701], ["pyroglutamil modified Abetapy3", "TREATMENT", 706, 736], ["Abetapy11", "TREATMENT", 744, 753], ["Alzheimer disease", "PROBLEM", 838, 855], ["aortic", "ANATOMY", 106, 112], ["wall", "ANATOMY_MODIFIER", 113, 117], ["disease", "OBSERVATION", 151, 158], ["Marfan", "OBSERVATION", 194, 200], ["ascending", "ANATOMY_MODIFIER", 216, 225], ["aortic", "ANATOMY", 226, 232], ["aneurysms", "OBSERVATION", 233, 242], ["brains", "ANATOMY", 808, 814], ["normal aging", "OBSERVATION", 818, 830], ["Alzheimer disease", "OBSERVATION", 838, 855]]], ["1 We find by following the CD signal and the ThT fluorescence of the solution in phosphate buffer, a substantial faster aggregation kinetics for Abetapy3-42.", [["phosphate", "CHEMICAL", 81, 90], ["Abetapy3-42", "CHEMICAL", 145, 156], ["phosphate", "CHEMICAL", 81, 90], ["Abetapy3-42", "CHEMICAL", 145, 156], ["phosphate", "SIMPLE_CHEMICAL", 81, 90], ["Abetapy3-42", "SIMPLE_CHEMICAL", 145, 156], ["the CD signal", "TEST", 23, 36], ["the solution in phosphate buffer", "TREATMENT", 65, 97], ["a substantial faster aggregation kinetics", "TREATMENT", 99, 140], ["Abetapy3", "TEST", 145, 153]]], ["This behavior is due to the particular sequence of this peptide which is also responsible of the specific oligomeric aggregation states, found by TEM, during the fibrillization process which are very different from those of Abeta1-42, more prone to fibril formation.", [["fibril", "ANATOMY", 249, 255], ["Abeta1-42", "CHEMICAL", 224, 233], ["Abeta1-42", "CHEMICAL", 224, 233], ["Abeta1-42", "SIMPLE_CHEMICAL", 224, 233], ["fibril", "CELLULAR_COMPONENT", 249, 255], ["Abeta1", "PROTEIN", 224, 230], ["the fibrillization process", "PROBLEM", 158, 184], ["Abeta1", "TEST", 224, 230], ["oligomeric aggregation", "OBSERVATION", 106, 128], ["very", "OBSERVATION_MODIFIER", 195, 199], ["different", "OBSERVATION_MODIFIER", 200, 209]]], ["In addition Abetapy3-42 is found here to have an inhibitory effect on Abeta1-42 fibrillogenesis, coherently with its known greater infective power.", [["Abetapy3-42", "CHEMICAL", 12, 23], ["Abetapy3-42", "CHEMICAL", 12, 23], ["Abetapy3-42", "SIMPLE_CHEMICAL", 12, 23], ["Abeta1-42", "GENE_OR_GENE_PRODUCT", 70, 79], ["Abeta1", "PROTEIN", 70, 76], ["Abetapy3", "TEST", 12, 20], ["an inhibitory effect", "PROBLEM", 46, 66], ["Abeta1", "TEST", 70, 76], ["greater", "OBSERVATION_MODIFIER", 123, 130], ["infective power", "OBSERVATION", 131, 146]]], ["This is an indication of the important role of this peptide in the aggregation process of beta-peptides in Alzheimer disease.", [["Alzheimer disease", "DISEASE", 107, 124], ["beta-peptides", "SIMPLE_CHEMICAL", 90, 103], ["Alzheimer disease", "CANCER", 107, 124], ["beta-peptides", "PROTEIN", 90, 103], ["this peptide", "TREATMENT", 47, 59], ["Alzheimer disease", "PROBLEM", 107, 124], ["Alzheimer disease", "OBSERVATION", 107, 124]]], ["The puzzle of the anomalously long denaturation kinetics of Green Fluorescent Protein (GFP) mutants still is largely unveiled.", [["Green Fluorescent Protein", "GENE_OR_GENE_PRODUCT", 60, 85], ["GFP", "GENE_OR_GENE_PRODUCT", 87, 90], ["Green Fluorescent Protein (GFP) mutants", "PROTEIN", 60, 99], ["the anomalously long denaturation kinetics", "PROBLEM", 14, 56], ["Green Fluorescent Protein (GFP", "TEST", 60, 90], ["anomalously", "OBSERVATION_MODIFIER", 18, 29], ["long denaturation", "OBSERVATION_MODIFIER", 30, 47], ["Green Fluorescent Protein", "OBSERVATION", 60, 85]]], ["In this study we have followed the effect of mutation H148G on the stability of GFPMut2 (Mut2G) in the presence of guanidinium hydrochloride (GdnHCl).", [["guanidinium hydrochloride", "CHEMICAL", 115, 140], ["GdnHCl", "CHEMICAL", 142, 148], ["guanidinium hydrochloride", "CHEMICAL", 115, 140], ["GdnHCl", "CHEMICAL", 142, 148], ["GFPMut2", "GENE_OR_GENE_PRODUCT", 80, 87], ["guanidinium hydrochloride", "SIMPLE_CHEMICAL", 115, 140], ["GdnHCl", "SIMPLE_CHEMICAL", 142, 148], ["GFPMut2", "PROTEIN", 80, 87], ["Mut2G", "PROTEIN", 89, 94], ["this study", "TEST", 3, 13], ["mutation H148G", "PROBLEM", 45, 59], ["GFPMut2 (Mut2G)", "TREATMENT", 80, 95], ["guanidinium hydrochloride (GdnHCl", "TREATMENT", 115, 148]]], ["Different techniques of fluorescence spectroscopy have been employed in order to obtain information concerning the unfolding event: time resolved fluorescence, fluorescence correlation spectroscopy (FCS), and fluorescence anisotropy.", [["fluorescence spectroscopy", "TEST", 24, 49], ["fluorescence correlation spectroscopy", "TEST", 160, 197], ["FCS", "TEST", 199, 202], ["fluorescence anisotropy", "TEST", 209, 232]]], ["The substitution of the histidine with glycine affects protein stability versus pH: in particular Mut2G kinetics is not pH dependent and at basic pH values the protein is less stable.", [["histidine", "CHEMICAL", 24, 33], ["glycine", "CHEMICAL", 39, 46], ["histidine", "CHEMICAL", 24, 33], ["glycine", "CHEMICAL", 39, 46], ["histidine", "AMINO_ACID", 24, 33], ["glycine", "AMINO_ACID", 39, 46], ["Mut2G", "SIMPLE_CHEMICAL", 98, 103], ["the histidine", "TREATMENT", 20, 33], ["glycine affects protein stability", "PROBLEM", 39, 72], ["pH", "TEST", 80, 82], ["pH dependent", "PROBLEM", 120, 132], ["basic pH", "TEST", 140, 148], ["the protein", "TEST", 156, 167], ["pH dependent", "OBSERVATION_MODIFIER", 120, 132], ["less", "OBSERVATION_MODIFIER", 171, 175], ["stable", "OBSERVATION_MODIFIER", 176, 182]]], ["The fluorescence properties (quantum yield, lifetime) and the rotational correlation time are unchanged during the unfolding dynamics, while the number of fluorescent proteins decreases exponentially.", [["fluorescent proteins", "PROTEIN", 155, 175], ["the unfolding dynamics", "PROBLEM", 111, 133], ["fluorescent proteins", "TEST", 155, 175], ["unchanged", "OBSERVATION_MODIFIER", 94, 103], ["decreases", "OBSERVATION_MODIFIER", 176, 185], ["exponentially", "OBSERVATION_MODIFIER", 186, 199]]], ["An extrinsic probe, bound to cysteine 48, has been employed in order to gain more insights on the unfolding process, monitoring the stability of a different region of the protein.", [["cysteine 48", "CHEMICAL", 29, 40], ["cysteine", "CHEMICAL", 29, 37], ["An extrinsic probe", "TEST", 0, 18], ["extrinsic probe", "OBSERVATION", 3, 18]]], ["In particular, it has been found that a softer region is present around cysteine 48 in both GFP variants, showing that the unfolding process does not follow a simple two step mechanism.", [["cysteine", "CHEMICAL", 72, 80], ["cysteine", "CHEMICAL", 72, 80], ["cysteine", "AMINO_ACID", 72, 80], ["GFP", "GENE_OR_GENE_PRODUCT", 92, 95], ["GFP variants", "PROTEIN", 92, 104], ["a softer region", "PROBLEM", 38, 53], ["the unfolding process", "PROBLEM", 119, 140], ["softer", "OBSERVATION_MODIFIER", 40, 46], ["GFP variants", "OBSERVATION", 92, 104]]], ["Recently, negatively-charged membranes were reported to catalyze amyloid fiber formation by amyloidogenic peptides/proteins and also to induce formation of \"amyloidlike\" fibrils by nonamyloidogenic proteins.", [["membranes", "ANATOMY", 29, 38], ["amyloid fiber", "ANATOMY", 65, 78], ["fibrils", "ANATOMY", 170, 177], ["membranes", "CELLULAR_COMPONENT", 29, 38], ["amyloid fiber", "CELLULAR_COMPONENT", 65, 78], ["nonamyloidogenic proteins", "PROTEIN", 181, 206], ["amyloidogenic peptides/proteins", "PROBLEM", 92, 123], ["\"amyloidlike\" fibrils", "PROBLEM", 156, 177], ["nonamyloidogenic proteins", "PROBLEM", 181, 206]]], ["Here, we used an approach which combines steady-state and time-resolved fluorescence measurements to obtain structural information about these supramolecular assemblies and to gain insights about the factors that control their formation.", [["an approach", "TREATMENT", 14, 25], ["fluorescence measurements", "TEST", 72, 97]]], ["By exploring a wide range of lipid concentrations, the interaction of Alexa488-lysozyme with phosphatidylserine-containing membranes was found to be a complex multi-step process, critically dependent upon the protein-to-lipid molar ratio (P/L) used.", [["membranes", "ANATOMY", 123, 132], ["Alexa488", "CHEMICAL", 70, 78], ["phosphatidylserine", "CHEMICAL", 93, 111], ["Alexa488", "CHEMICAL", 70, 78], ["phosphatidylserine", "CHEMICAL", 93, 111], ["lipid", "SIMPLE_CHEMICAL", 29, 34], ["Alexa488-lysozyme", "SIMPLE_CHEMICAL", 70, 87], ["phosphatidylserine", "SIMPLE_CHEMICAL", 93, 111], ["membranes", "CELLULAR_COMPONENT", 123, 132], ["lysozyme", "PROTEIN", 79, 87], ["a wide range of lipid concentrations", "TREATMENT", 13, 49], ["Alexa488-lysozyme", "TREATMENT", 70, 87], ["phosphatidylserine-containing membranes", "TREATMENT", 93, 132], ["a complex multi-step process", "PROBLEM", 149, 177], ["critically dependent", "PROBLEM", 179, 199], ["the protein", "TEST", 205, 216], ["lipid molar ratio", "TREATMENT", 220, 237], ["P/L)", "TREATMENT", 239, 243], ["multi-step process", "OBSERVATION", 159, 177]]], ["Upon increasing the total lipid concentration in solution, there was a balance between an increased overall protein binding to the lipid vesicles and a progressive protein dilution on the membrane surface.", [["lipid vesicles", "ANATOMY", 131, 145], ["membrane surface", "ANATOMY", 188, 204], ["lipid", "SIMPLE_CHEMICAL", 26, 31], ["lipid vesicles", "CELLULAR_COMPONENT", 131, 145], ["membrane surface", "CELLULAR_COMPONENT", 188, 204], ["the total lipid concentration in solution", "TREATMENT", 16, 57], ["an increased overall protein binding", "PROBLEM", 87, 123], ["a progressive protein dilution on the membrane surface", "PROBLEM", 150, 204], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["protein binding", "OBSERVATION", 108, 123], ["lipid vesicles", "ANATOMY", 131, 145], ["progressive", "OBSERVATION_MODIFIER", 152, 163], ["protein dilution", "OBSERVATION", 164, 180], ["membrane", "OBSERVATION_MODIFIER", 188, 196], ["surface", "OBSERVATION_MODIFIER", 197, 204]]], ["As the surface potential of the vesicles decreased upon increasing the protein interfacial coverage of the liposomes, the protein binding mode was found to switch from a peripheral binding of lysozyme to the anionic headgroups (at low to intermediate P/L) to a partial insertion of the basic protein into the hydrophobic core of the membrane (at a high P/L).", [["surface", "ANATOMY", 7, 14], ["vesicles", "ANATOMY", 32, 40], ["membrane", "ANATOMY", 333, 341], ["vesicles", "CELLULAR_COMPONENT", 32, 40], ["liposomes", "SIMPLE_CHEMICAL", 107, 116], ["lysozyme", "GENE_OR_GENE_PRODUCT", 192, 200], ["anionic headgroups", "SIMPLE_CHEMICAL", 208, 226], ["membrane", "CELLULAR_COMPONENT", 333, 341], ["lysozyme", "PROTEIN", 192, 200], ["basic protein", "PROTEIN", 286, 299], ["the vesicles", "PROBLEM", 28, 40], ["increasing the protein interfacial coverage of the liposomes", "TREATMENT", 56, 116], ["the protein binding mode", "PROBLEM", 118, 142], ["a peripheral binding of lysozyme", "TREATMENT", 168, 200], ["the anionic headgroups", "TREATMENT", 204, 226], ["a partial insertion of the basic protein", "TREATMENT", 259, 299], ["surface", "OBSERVATION_MODIFIER", 7, 14], ["vesicles", "OBSERVATION_MODIFIER", 32, 40], ["decreased", "OBSERVATION_MODIFIER", 41, 50], ["increasing", "OBSERVATION_MODIFIER", 56, 66], ["liposomes", "ANATOMY", 107, 116], ["hydrophobic core", "ANATOMY_MODIFIER", 309, 325], ["membrane", "ANATOMY_MODIFIER", 333, 341]]], ["It is hypothesized that disruption of the protein tertiary structure might be a stepwise process beginning with loosening of the structure caused by its deeper insertion in the membrane bilayer.P-650Unexpected scaling laws in the mechanical unfolding of single protein molecules M. Clusel, E. I. Corwin, H. Lannon, J. Brujic Center for Soft Matter Research, Physics Department, New York University, New York, NY, USA It is a question of fundamental importance to understand the response of proteins to a stretching force, particularly in the case of mechanically active proteins, such as those in muscle fibers.", [["membrane bilayer", "ANATOMY", 177, 193], ["muscle fibers", "ANATOMY", 597, 610], ["membrane bilayer", "CELLULAR_COMPONENT", 177, 193], ["muscle fibers", "TISSUE", 597, 610], ["the protein tertiary structure", "PROBLEM", 38, 68], ["a stepwise process", "PROBLEM", 78, 96], ["loosening of the structure", "PROBLEM", 112, 138], ["Unexpected scaling laws", "PROBLEM", 199, 222], ["a stretching force", "TREATMENT", 502, 520], ["mechanically active proteins", "PROBLEM", 550, 578], ["protein", "OBSERVATION", 42, 49], ["tertiary structure", "OBSERVATION", 50, 68], ["stepwise", "OBSERVATION", 80, 88], ["loosening", "OBSERVATION", 112, 121], ["deeper", "OBSERVATION_MODIFIER", 153, 159], ["insertion", "OBSERVATION_MODIFIER", 160, 169], ["membrane", "ANATOMY_MODIFIER", 177, 185], ["bilayer", "ANATOMY_MODIFIER", 186, 193], ["mechanical unfolding", "OBSERVATION_MODIFIER", 230, 250], ["muscle", "ANATOMY", 597, 603]]], ["We aim to understand how the structure and topology of a protein affect its resilience to external forces and presumably its function.", [["a protein affect", "PROBLEM", 55, 71]]], ["Owing to recent advances in single molecule force-clamp spectroscopy using the Atomic Force Microscope (AFM), we are now able to probe the structure and dynamics of single proteins under a constant stretching force by measuring their end-to-end length over time.", [["single molecule force", "TREATMENT", 28, 49], ["clamp spectroscopy", "TREATMENT", 50, 68], ["the Atomic Force Microscope", "TEST", 75, 102], ["a constant stretching force", "TREATMENT", 187, 214]]], ["The probability distribution of unfolding times at a given force allows us to estimate the strength of the protein in terms of a characteristic energy barrier, while the shape of the distribution provides a window into the microscopic mechanism by which the protein breaks apart.", [["a characteristic energy barrier", "TREATMENT", 127, 158], ["probability", "OBSERVATION_MODIFIER", 4, 15], ["distribution", "OBSERVATION_MODIFIER", 16, 28], ["unfolding", "OBSERVATION", 32, 41], ["energy barrier", "OBSERVATION", 144, 158], ["protein breaks", "OBSERVATION", 258, 272]]], ["Here we show a novel scaling of the unfolding kinetics with the stretching force, which deviates significantly from the currently accepted Bell model.", [["the unfolding kinetics", "PROBLEM", 32, 54], ["the stretching force", "PROBLEM", 60, 80], ["scaling", "OBSERVATION_MODIFIER", 21, 28], ["unfolding kinetics", "OBSERVATION", 36, 54], ["stretching force", "OBSERVATION", 64, 80], ["Bell model", "OBSERVATION", 139, 149]]], ["Instead, we propose a physical picture for forced unfolding that is analogous to the mechanics of fracture.Structural Arrangements that Support Lipid Transfer in the Cholesteryl-ester Transfer Protein (CETP)V. Garc\u00eda-Gonz\u00e1lez, J. Mas-Oliva Instituto de Fisiolog\u00eda Celular.Structural Arrangements that Support Lipid Transfer in the Cholesteryl-ester Transfer Protein (CETP)Universidad Nacional Aut\u00f3noma de M\u00e9xico.", [["fracture", "DISEASE", 98, 106], ["Cholesteryl-ester", "CHEMICAL", 166, 183], ["Cholesteryl-ester", "CHEMICAL", 331, 348], ["Cholesteryl-ester", "CHEMICAL", 166, 183], ["Cholesteryl-ester", "CHEMICAL", 331, 348], ["Lipid", "SIMPLE_CHEMICAL", 144, 149], ["Cholesteryl-ester", "SIMPLE_CHEMICAL", 166, 183], ["Lipid", "SIMPLE_CHEMICAL", 309, 314], ["Cholesteryl-ester", "SIMPLE_CHEMICAL", 331, 348], ["forced unfolding", "PROBLEM", 43, 59], ["fracture", "PROBLEM", 98, 106], ["fracture", "OBSERVATION", 98, 106]]], ["04510 M\u00e9xico, D.F. M\u00e9xico.Structural Arrangements that Support Lipid Transfer in the Cholesteryl-ester Transfer Protein (CETP)Studies focused on the thermodynamic and kinetic analysis have demonstrated that transfer of neutral lipids such as cholesterol esters through an aqueous phase is a highly costly biophysical event.", [["Cholesteryl-ester", "CHEMICAL", 85, 102], ["cholesterol esters", "CHEMICAL", 242, 260], ["Cholesteryl-ester", "CHEMICAL", 85, 102], ["cholesterol esters", "CHEMICAL", 242, 260], ["Lipid", "SIMPLE_CHEMICAL", 63, 68], ["Cholesteryl-ester", "SIMPLE_CHEMICAL", 85, 102], ["CETP", "SIMPLE_CHEMICAL", 121, 125], ["cholesterol esters", "SIMPLE_CHEMICAL", 242, 260], ["CETP", "PROTEIN", 121, 125], ["the thermodynamic and kinetic analysis", "TEST", 145, 183], ["neutral lipids", "TREATMENT", 219, 233], ["cholesterol esters", "TEST", 242, 260]]], ["Therefore, nature has developed a series of lipid transfer proteins such as the cholesterylester transfer protein (CETP) designed to efficiently lower the energy barrier for transfer of cholesterol-esters between lipoproteins through an aqueous environment.", [["cholesterol-esters", "CHEMICAL", 186, 204], ["cholesterylester", "CHEMICAL", 80, 96], ["cholesterol", "CHEMICAL", 186, 197], ["esters", "CHEMICAL", 198, 204], ["cholesterylester transfer protein", "GENE_OR_GENE_PRODUCT", 80, 113], ["CETP", "GENE_OR_GENE_PRODUCT", 115, 119], ["cholesterol-esters", "SIMPLE_CHEMICAL", 186, 204], ["lipoproteins", "SIMPLE_CHEMICAL", 213, 225], ["lipid transfer proteins", "PROTEIN", 44, 67], ["cholesterylester transfer protein", "PROTEIN", 80, 113], ["CETP", "PROTEIN", 115, 119], ["lipoproteins", "PROTEIN", 213, 225], ["lipid transfer proteins", "TREATMENT", 44, 67], ["the cholesterylester transfer protein (CETP)", "TREATMENT", 76, 120], ["aqueous environment", "OBSERVATION", 237, 256]]], ["Employing circular dichroism we evaluated the secondary structure stability of a small peptide derived from the carboxy-end of CETP (Helix Y ) in a wide range of pH's.", [["carboxy", "CHEMICAL", 112, 119], ["CETP", "SIMPLE_CHEMICAL", 127, 131], ["carboxy-end", "PROTEIN", 112, 123], ["CETP", "PROTEIN", 127, 131], ["Helix Y", "PROTEIN", 133, 140], ["a small peptide", "PROBLEM", 79, 94], ["the carboxy-end of CETP (Helix Y", "TREATMENT", 108, 140], ["small", "OBSERVATION_MODIFIER", 81, 86]]], ["The percentage of \u03b1-helix is diminished only at extreme temperatures and acidic pH's in a reversible way.", [["\u03b1-helix", "GENE_OR_GENE_PRODUCT", 18, 25], ["\u03b1-helix", "PROTEIN", 18, 25], ["diminished", "PROBLEM", 29, 39], ["acidic pH", "TEST", 73, 82], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["diminished", "OBSERVATION", 29, 39]]], ["We report that while a mixture of phosphatidylcholine/cholesteryl-ester forms large aggregated particles independently of pH, inclusion of helix Y to the mixtures close to neutral pH's allows the formation of small micellar-like structures confirmed by dynamic light scattering and electron microscopy.", [["phosphatidylcholine", "CHEMICAL", 34, 53], ["cholesteryl-ester", "CHEMICAL", 54, 71], ["phosphatidylcholine", "CHEMICAL", 34, 53], ["cholesteryl-ester", "CHEMICAL", 54, 71], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 34, 53], ["cholesteryl-ester", "SIMPLE_CHEMICAL", 54, 71], ["helix Y", "PROTEIN", 139, 146], ["phosphatidylcholine/cholesteryl-ester forms", "TREATMENT", 34, 77], ["large aggregated particles", "PROBLEM", 78, 104], ["helix Y to the mixtures", "TREATMENT", 139, 162], ["neutral pH's", "TEST", 172, 184], ["small micellar-like structures", "PROBLEM", 209, 239], ["electron microscopy", "TEST", 282, 301], ["small micellar", "OBSERVATION", 209, 223]]], ["These results suggest that helix Y when close to physiological pH values presents the ability to organize a micellar structure around itself.", [["helix Y", "PROTEIN", 27, 34], ["helix Y", "TREATMENT", 27, 34], ["physiological pH values", "TEST", 49, 72], ["micellar structure", "OBSERVATION", 108, 126]]], ["This type of organization allows the process to dramatically lower the energetic barrier for lipid transfer through aqueous media, phenomenon directly related with the facilitation of lipid transfer between lipoproteins.P-656Mimicking metastasis by a novel microfluidic approach There is increasing evidence that cancer metastasis shares commonalities with thrombosis.", [["cancer", "ANATOMY", 313, 319], ["P-656Mimicking", "CHEMICAL", 220, 234], ["cancer metastasis", "DISEASE", 313, 330], ["thrombosis", "DISEASE", 357, 367], ["lipid", "SIMPLE_CHEMICAL", 93, 98], ["lipid", "SIMPLE_CHEMICAL", 184, 189], ["cancer", "CANCER", 313, 319], ["lipoproteins", "PROTEIN", 207, 219], ["P", "DNA", 220, 221], ["lipid transfer through aqueous media", "TREATMENT", 93, 129], ["phenomenon", "PROBLEM", 131, 141], ["lipid transfer between lipoproteins", "TREATMENT", 184, 219], ["metastasis", "PROBLEM", 235, 245], ["a novel microfluidic approach", "TREATMENT", 249, 278], ["cancer metastasis", "PROBLEM", 313, 330], ["thrombosis", "PROBLEM", 357, 367], ["metastasis", "OBSERVATION", 235, 245], ["increasing", "OBSERVATION_MODIFIER", 288, 298], ["cancer", "OBSERVATION_MODIFIER", 313, 319], ["metastasis", "OBSERVATION", 320, 330], ["thrombosis", "OBSERVATION", 357, 367]]], ["The von-Willebrand-Factor (vWF), a mechanical active blood clotting protein appears to be a particular potent candidate to bridge the gap between clotting and cancer extravasation.", [["blood", "ANATOMY", 53, 58], ["cancer", "ANATOMY", 159, 165], ["cancer", "DISEASE", 159, 165], ["von-Willebrand-Factor", "GENE_OR_GENE_PRODUCT", 4, 25], ["vWF", "GENE_OR_GENE_PRODUCT", 27, 30], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["cancer", "CANCER", 159, 165], ["von-Willebrand-Factor", "PROTEIN", 4, 25], ["blood clotting protein", "PROTEIN", 53, 75], ["a mechanical active blood clotting protein", "PROBLEM", 33, 75], ["the gap between clotting", "PROBLEM", 130, 154], ["cancer extravasation", "PROBLEM", 159, 179], ["clotting", "OBSERVATION", 146, 154], ["cancer", "OBSERVATION", 159, 165]]], ["Modeling the crucial physiological conditions of the blood circulatory system, for an in situ study of blood clotting-metastasis connections is not only, absolutely necessary, but also a challenging task.", [["blood", "ANATOMY", 53, 58], ["blood", "ANATOMY", 103, 108], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["an in situ study", "TEST", 83, 99], ["blood clotting", "PROBLEM", 103, 117], ["metastasis", "PROBLEM", 118, 128], ["crucial physiological conditions", "OBSERVATION", 13, 45], ["blood circulatory", "ANATOMY", 53, 70], ["metastasis", "OBSERVATION", 118, 128]]], ["Here, we present acoustically driven flow as a novel microfluidics method for mimicking the blood flow.", [["blood", "ANATOMY", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["a novel microfluidics method", "TREATMENT", 45, 73], ["the blood flow", "TEST", 88, 102]]], ["This method enjoys very beneficial advantages of possibility of handling very little volumes of fluids, together with freedom to model most of the geometries present in our microcirculatory system.", [["microcirculatory system", "MULTI-TISSUE_STRUCTURE", 173, 196], ["microcirculatory system", "ANATOMY", 173, 196]]], ["One technologically challenging, yet physiologically important factor, is the hydrodynamic condition in a bifurcated vessel, where complex shear profiles arise.", [["vessel", "ANATOMY", 117, 123], ["vessel", "MULTI-TISSUE_STRUCTURE", 117, 123], ["the hydrodynamic condition", "PROBLEM", 74, 100], ["complex shear profiles", "TEST", 131, 153], ["hydrodynamic condition", "OBSERVATION", 78, 100], ["bifurcated", "ANATOMY_MODIFIER", 106, 116], ["vessel", "ANATOMY", 117, 123]]], ["We present a model to mimic these conditions and discuss the impact of hydrodynamics on vWF mediated cancer cell adhesion in bifurcated vessels of our microcirculatory system.P-655Protein structural changes occurring in flows Stresses inherent to viscous fluid flow have previously been associated with protein unfolding, although structural changes have not been well documented as a function of relevant hydrodynamic parameters.P-655We have used Raman Spectroscopy to monitor the structure of various protein solutions in situ for multiple flow scenarios within a concentric cylinder fluidic device (1) .", [["cancer cell", "ANATOMY", 101, 112], ["vessels", "ANATOMY", 136, 143], ["microcirculatory system", "ANATOMY", 151, 174], ["fluid", "ANATOMY", 255, 260], ["cancer", "DISEASE", 101, 107], ["P-655", "CHEMICAL", 175, 180], ["P-655We", "CHEMICAL", 430, 437], ["vWF", "GENE_OR_GENE_PRODUCT", 88, 91], ["cancer cell", "CELL", 101, 112], ["bifurcated vessels", "MULTI-TISSUE_STRUCTURE", 125, 143], ["microcirculatory system", "MULTI-TISSUE_STRUCTURE", 151, 174], ["fluid", "ORGANISM_SUBSTANCE", 255, 260], ["vWF", "PROTEIN", 88, 91], ["P-655We", "DNA", 430, 437], ["vWF mediated cancer cell adhesion", "TREATMENT", 88, 121], ["P", "TEST", 175, 176], ["Protein structural changes", "PROBLEM", 180, 206], ["viscous fluid flow", "TEST", 247, 265], ["protein unfolding", "PROBLEM", 303, 320], ["Raman Spectroscopy", "TEST", 448, 466], ["various protein solutions", "TREATMENT", 495, 520], ["multiple flow scenarios", "PROBLEM", 533, 556], ["a concentric cylinder fluidic device", "TREATMENT", 564, 600], ["cancer cell adhesion", "OBSERVATION", 101, 121], ["bifurcated", "ANATOMY_MODIFIER", 125, 135], ["vessels", "ANATOMY", 136, 143], ["microcirculatory system", "ANATOMY", 151, 174], ["flows Stresses", "OBSERVATION", 220, 234], ["viscous", "OBSERVATION_MODIFIER", 247, 254], ["fluid flow", "OBSERVATION", 255, 265], ["protein unfolding", "OBSERVATION", 303, 320], ["multiple", "OBSERVATION_MODIFIER", 533, 541], ["flow scenarios", "OBSERVATION", 542, 556]]], ["The flows, which ranged from circular Couette to wavy Taylor-Couette flow, were characterised experimentally using Particle Image Velocimetry.", [["The flows", "TEST", 0, 9], ["Particle Image Velocimetry", "TEST", 115, 141], ["flows", "OBSERVATION_MODIFIER", 4, 9], ["circular", "OBSERVATION_MODIFIER", 29, 37], ["Couette", "OBSERVATION_MODIFIER", 38, 45], ["wavy", "OBSERVATION_MODIFIER", 49, 53], ["Taylor", "OBSERVATION_MODIFIER", 54, 60], ["Couette flow", "OBSERVATION", 61, 73]]], ["Several proteins were observed to change conformation when exposed to these flows, although the nature of these changes was protein specific.", [["Several proteins", "PROBLEM", 0, 16], ["these flows", "TEST", 70, 81]]], ["Shearing hen egg white lysozyme in water altered the protein backbone structure, while similar shear rates in a 95% glycerol, 5% water solution affected the solvent exposure of the side chain residues near the exterior of the \u03b1-domain.", [["glycerol", "CHEMICAL", 116, 124], ["glycerol", "CHEMICAL", 116, 124], ["lysozyme", "GENE_OR_GENE_PRODUCT", 23, 31], ["water", "SIMPLE_CHEMICAL", 35, 40], ["glycerol", "SIMPLE_CHEMICAL", 116, 124], ["hen egg white lysozyme", "PROTEIN", 9, 31], ["\u03b1-domain", "PROTEIN", 226, 234], ["hen", "SPECIES", 9, 12], ["Shearing hen egg white lysozyme", "TEST", 0, 31], ["the protein backbone structure", "PROBLEM", 49, 79], ["a 95% glycerol", "TREATMENT", 110, 124], ["5% water solution", "TREATMENT", 126, 143], ["exterior", "ANATOMY_MODIFIER", 210, 218]]], ["The solventdependent response may be due to the flow topology, viscous stress, or the surface hydration properties.", [["surface", "ANATOMY", 86, 93], ["the flow topology", "PROBLEM", 44, 61], ["viscous stress", "PROBLEM", 63, 77], ["the surface hydration properties", "TREATMENT", 82, 114], ["may be due to", "UNCERTAINTY", 30, 43], ["flow topology", "OBSERVATION", 48, 61]]], ["Comparison of spectra acquired at different time points, including before and after flow, confirmed that the observed changes are reversible and independent of fluid stress exposure time.A. A. DenizThe Scripps Research Institute, La Jolla, CA, USA.A. A. DenizIntrinsically disordered proteins are increasingly found to play major roles in cell biology and disease.", [["fluid", "ANATOMY", 160, 165], ["cell", "ANATOMY", 339, 343], ["cell", "CELL", 339, 343], ["fluid stress exposure", "TREATMENT", 160, 181], ["disordered proteins", "PROBLEM", 273, 292], ["disease", "PROBLEM", 356, 363], ["reversible", "OBSERVATION_MODIFIER", 130, 140], ["fluid stress", "OBSERVATION", 160, 172]]], ["We are utilizing single-molecule fluorescence methods to probe these complex and highly dynamic molecules, allowing more direct measurements of structural distributions and dynamics, while avoiding loss of information due to ensemble averaging.", [["single-molecule fluorescence methods", "TREATMENT", 17, 53]]], ["In one example, we investigated the structural dynamics of Sup35-NM, whose regulatable amyloid formation is believed to have functional significance in yeast.", [["Sup35", "GENE_OR_GENE_PRODUCT", 59, 64], ["amyloid", "GENE_OR_GENE_PRODUCT", 87, 94], ["Sup35", "PROTEIN", 59, 64], ["NM", "PROTEIN", 65, 67], ["yeast", "SPECIES", 152, 157], ["yeast", "SPECIES", 152, 157], ["whose regulatable amyloid formation", "PROBLEM", 69, 104], ["functional significance in yeast", "PROBLEM", 125, 157], ["amyloid formation", "OBSERVATION", 87, 104]]], ["Using a combination of single-molecule FRET as a molecular ruler, coincidence to interrogate intermolecular interactions, and correlation analysis to probe conformational dynamics, we showed that the monomeric protein populates an ensemble of compact and rapidly interconverting conformations.", [["monomeric protein", "PROTEIN", 200, 217], ["single-molecule FRET", "TREATMENT", 23, 43], ["correlation analysis", "TEST", 126, 146], ["conformational dynamics", "TEST", 156, 179], ["the monomeric protein populates", "PROBLEM", 196, 227]]], ["A particularly interesting feature of intrinsically disordered proteins is that they are relatively unstructured in isolation, but can gain stable structure by interaction with binding partners.", [["intrinsically disordered proteins", "PROTEIN", 38, 71], ["intrinsically disordered proteins", "PROBLEM", 38, 71], ["relatively", "OBSERVATION_MODIFIER", 89, 99], ["unstructured", "OBSERVATION", 100, 112]]], ["In this context, we used single-molecule fluorescence to characterize the complex folding pathway for the Parkinson's-related IDP alpha-synuclein induced by binding to a lipid-mimic.", [["alpha-synuclein", "GENE_OR_GENE_PRODUCT", 130, 145], ["IDP alpha-synuclein", "PROTEIN", 126, 145], ["single-molecule fluorescence", "TREATMENT", 25, 53], ["the Parkinson's", "PROBLEM", 102, 117], ["IDP alpha-synuclein", "PROBLEM", 126, 145]]], ["This combined single-molecule fluorescence methodology provides a powerful approach for detailed studies of the coupling of folding and dynamics with interactions and biology of this important class of proteins.Molecular dynamics study of amyloid betapeptide unfoldingM.", [["amyloid betapeptide", "SIMPLE_CHEMICAL", 239, 258], ["amyloid betapeptide unfoldingM", "PROTEIN", 239, 269], ["detailed studies", "TEST", 88, 104], ["Molecular dynamics study", "TEST", 211, 235], ["amyloid betapeptide unfoldingM", "PROBLEM", 239, 269]]], ["Ito 1 , J. Johansson 2 , R. Stromberg 1 , L. Nilsson 1 1 Department of Biosciences and Nutrirtion, Karolinska Institutet, Huddinge, Sweden, 2 Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, the Biomedical Centre, Uppsala, Sweden Amyloid \u03b2-peptide (A\u03b2) is a 39-42 amino acid polypeptide and known to aggregate and form insoluble amyloid fibril, which is regarded as a primary cause of Alzheimer's disease (AD).", [["Amyloid \u03b2-peptide", "CHEMICAL", 278, 295], ["A\u03b2", "CHEMICAL", 297, 299], ["Alzheimer's disease", "DISEASE", 433, 452], ["AD", "DISEASE", 454, 456], ["amino acid", "CHEMICAL", 312, 322], ["Amyloid \u03b2-peptide", "GENE_OR_GENE_PRODUCT", 278, 295], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 297, 299], ["amyloid fibril", "CELLULAR_COMPONENT", 377, 391], ["Alzheimer's disease", "CANCER", 433, 452], ["amino acid polypeptide", "TREATMENT", 312, 334], ["insoluble amyloid fibril", "PROBLEM", 367, 391], ["Alzheimer's disease", "PROBLEM", 433, 452], ["amyloid fibril", "OBSERVATION", 377, 391], ["Alzheimer", "OBSERVATION", 433, 442]]], ["The discovery of practical and effective treatments and drugs for AD has been waited eagerly.", [["AD", "DISEASE", 66, 68], ["practical and effective treatments", "TREATMENT", 17, 51], ["drugs", "TREATMENT", 56, 61]]], ["In a recent experimental study, it was suggested that stabilization of the helical conformation of the A\u03b2 middle region, which strongly favors collapsed coil formation in the extracellular environment, would reduce the A\u03b2 fibril formation.", [["A\u03b2 middle region", "ANATOMY", 103, 119], ["extracellular", "ANATOMY", 175, 188], ["A\u03b2 fibril", "ANATOMY", 219, 228], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 175, 188], ["A\u03b2 fibril", "CELLULAR_COMPONENT", 219, 228], ["A\u03b2 middle region", "PROTEIN", 103, 119], ["a recent experimental study", "TEST", 3, 30], ["collapsed coil formation", "PROBLEM", 143, 167], ["the A\u03b2 fibril formation", "PROBLEM", 215, 238], ["middle", "ANATOMY_MODIFIER", 106, 112], ["collapsed coil", "OBSERVATION", 143, 157], ["fibril formation", "OBSERVATION", 222, 238]]], ["Based on the experimental evidence, inhibition of the unfolding of the A\u03b2 \u03b1-helix can be a forceful strategy to repress the A\u03b2 fibril formation resulting in prevention of AD.", [["A\u03b2 fibril", "ANATOMY", 124, 133], ["AD", "DISEASE", 171, 173], ["A\u03b2 \u03b1-helix", "GENE_OR_GENE_PRODUCT", 71, 81], ["A\u03b2 fibril", "GENE_OR_GENE_PRODUCT", 124, 133], ["A\u03b2 \u03b1-helix", "PROTEIN", 71, 81], ["a forceful strategy", "TREATMENT", 89, 108], ["the A\u03b2 fibril formation", "TREATMENT", 120, 143], ["AD", "PROBLEM", 171, 173]]], ["However, the detailed mechanism of the unfolding of the A\u03b2 \u03b1-helix has remained unclear, because the X-ray or the NMR structure of the A\u03b2 \u03b1-helix in aqueous solution has not been reported due to its instability.", [["A\u03b2", "GENE_OR_GENE_PRODUCT", 56, 58], ["A\u03b2 \u03b1-helix", "SIMPLE_CHEMICAL", 135, 145], ["A\u03b2 \u03b1-helix", "PROTEIN", 56, 66], ["A\u03b2 \u03b1-helix", "PROTEIN", 135, 145], ["the unfolding of the A\u03b2 \u03b1-helix", "PROBLEM", 35, 66], ["the X-ray", "TEST", 97, 106], ["the NMR structure", "TEST", 110, 127], ["its instability", "PROBLEM", 195, 210], ["unfolding", "OBSERVATION", 39, 48], ["instability", "OBSERVATION", 199, 210]]], ["The aim of this study is to find effective ways to inhibit the unfolding of the A\u03b2 middle region, which is a prerequisite for the A\u03b2 fibril formation.", [["A\u03b2 fibril", "ANATOMY", 130, 139], ["A\u03b2 fibril", "GENE_OR_GENE_PRODUCT", 130, 139], ["A\u03b2 middle region", "PROTEIN", 80, 96], ["this study", "TEST", 11, 21], ["the A\u03b2 fibril formation", "TREATMENT", 126, 149], ["unfolding", "OBSERVATION", 63, 72], ["middle", "ANATOMY_MODIFIER", 83, 89], ["fibril formation", "OBSERVATION", 133, 149]]], ["In this study, we attempted to elucidate the molecular mechanism of the A\u03b2 unfolding by molecular modeling and molecular dynamics (MD) simulations.", [["A\u03b2", "GENE_OR_GENE_PRODUCT", 72, 74], ["A\u03b2", "PROTEIN", 72, 74], ["this study", "TEST", 3, 13]]], ["The MD simulations were performed for \u03b1-helical structures of a wild-type A\u03b2(13-26) model and a mutant A\u03b2(13-26) model.P-660Linker average hydrophilicity as a tool to discriminate between extended and non-extended calcium binding proteins A. Isvoran 1 , E. Quiniou 2 , C. Craescu 2 , L. Mouawad 2 1 West University of Timisoara, Department of Chemistry, Pestalozzi 16, 300115 Timisoara, Romania, 2 Inserm U759, Centre Universitaire Paris-Sud, B\u00e2timent 112, 91405 Orsay, FranceP-660The EF-hand calcium binding proteins (CaBPs) may exist either in an extended or a compact conformation, sometimes correlated with their functions.", [["A\u03b2(13-26", "CHEMICAL", 103, 111], ["calcium", "CHEMICAL", 214, 221], ["FranceP-660", "CHEMICAL", 470, 481], ["calcium", "CHEMICAL", 493, 500], ["calcium", "CHEMICAL", 214, 221], ["calcium", "CHEMICAL", 493, 500], ["calcium", "SIMPLE_CHEMICAL", 214, 221], ["EF-hand calcium binding proteins", "GENE_OR_GENE_PRODUCT", 485, 517], ["CaBPs", "GENE_OR_GENE_PRODUCT", 519, 524], ["P", "DNA", 119, 120], ["non-extended calcium binding proteins", "PROTEIN", 201, 238], ["EF-hand calcium binding proteins", "PROTEIN", 485, 517], ["CaBPs", "PROTEIN", 519, 524], ["The MD simulations", "TEST", 0, 18], ["a mutant A\u03b2", "TEST", 94, 105], ["Pestalozzi", "TEST", 354, 364], ["FranceP", "TEST", 470, 477], ["The EF", "TEST", 481, 487], ["hand calcium binding proteins", "PROBLEM", 488, 517], ["CaBPs", "TEST", 519, 524]]], ["For the CaBPs with know structure and function, calcium sensors are usually extended and calcium buffers compact, hence the interest to predict the form of the protein starting from its sequence.", [["calcium", "CHEMICAL", 48, 55], ["calcium", "CHEMICAL", 89, 96], ["calcium", "CHEMICAL", 48, 55], ["calcium", "CHEMICAL", 89, 96], ["CaBPs", "SIMPLE_CHEMICAL", 8, 13], ["calcium", "SIMPLE_CHEMICAL", 48, 55], ["calcium", "SIMPLE_CHEMICAL", 89, 96], ["CaBPs", "PROTEIN", 8, 13], ["the CaBPs", "TEST", 4, 13], ["calcium sensors", "TEST", 48, 63], ["calcium buffers compact", "TREATMENT", 89, 112]]], ["In this study we used two different procedures, the SOSUIdumbbell algorithm and a novel procedure that is based on the linker average hydrophilicity (LAH).", [["this study", "TEST", 3, 13], ["two different procedures", "TREATMENT", 22, 46], ["the SOSUIdumbbell algorithm", "TREATMENT", 48, 75], ["a novel procedure", "TREATMENT", 80, 97]]], ["The two procedures were tested on 17 known-structure CaBPs and then applied to 59 unknown-structure centrins.", [["centrins", "GENE_OR_GENE_PRODUCT", 100, 108], ["CaBPs", "PROTEIN", 53, 58], ["59 unknown-structure centrins", "PROTEIN", 79, 108]]], ["The SO-SUIdumbbell algorithm yielded the right conformations for 15 of the 17 known-structure proteins and predicted that all centrins should are compact.", [["centrins", "GENE_OR_GENE_PRODUCT", 126, 134], ["17 known-structure proteins", "PROTEIN", 75, 102], ["centrins", "PROTEIN", 126, 134], ["right", "ANATOMY_MODIFIER", 41, 46]]], ["The LAH procedure discriminated well between the extended and non-extended forms of all the known-structure CaBPs and it reflected well the phylogenetic classification of centrins being a simple and powerful means to discriminate between extended and nonextended forms of CaBPs.", [["CaBPs", "GENE_OR_GENE_PRODUCT", 108, 113], ["centrins", "GENE_OR_GENE_PRODUCT", 171, 179], ["CaBPs", "GENE_OR_GENE_PRODUCT", 272, 277], ["CaBPs", "PROTEIN", 108, 113], ["CaBPs", "PROTEIN", 272, 277], ["The LAH procedure", "TREATMENT", 0, 17], ["CaBPs", "TEST", 272, 277]]], ["Only few residues that constitute the linker are responsible for the form of the CaBP, showing that this form is mainly governed by short-range interactions. (http://u759.curie.u-psud.fr/modelisation/LAH)P-659Lipid and protein organization of Hepatitis B antigen characterized by fluorescence spectroscopy V. Greiner 1 , C. Egel\u00e9 1 , S. Oncul 1 , F. Ronzon 2 , C. Manin 2 , A. Klymchenko 1 , Y. M\u00e9ly 1 1 Laboratoire de Biophotonique et Pharmacologie, UMR 7213 CNRS, Facult\u00e9 de pharmacie, Universit\u00e9 de Strasbourg, France, 2 Sanofi pasteur, 1541 av.", [["CaBP", "GENE_OR_GENE_PRODUCT", 81, 85], ["Hepatitis B antigen", "GENE_OR_GENE_PRODUCT", 243, 262], ["CaBP", "PROTEIN", 81, 85], ["Hepatitis B antigen", "PROTEIN", 243, 262], ["few residues", "PROBLEM", 5, 17], ["the CaBP", "TEST", 77, 85], ["protein organization", "TEST", 219, 239], ["Hepatitis B antigen", "TEST", 243, 262], ["fluorescence spectroscopy", "TEST", 280, 305], ["Greiner", "TEST", 309, 316], ["Egel\u00e9", "TEST", 324, 329], ["few", "OBSERVATION_MODIFIER", 5, 8], ["residues", "OBSERVATION", 9, 17], ["Hepatitis", "OBSERVATION", 243, 252]]], ["Marcel m\u00e9rieux, 69290 Marcy l'\u00e9toile, France.P-659Hepatitis B surface antigen (HBsAg) particles are 20 nm lipoprotein particles, mainly composed of the major S surface viral protein containing 13 Trp residues and yeast-derived lipids.", [["P-659Hepatitis B surface antigen", "CHEMICAL", 45, 77], ["HBsAg", "CHEMICAL", 79, 84], ["Trp", "CHEMICAL", 196, 199], ["P-659Hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 45, 77], ["HBsAg", "GENE_OR_GENE_PRODUCT", 79, 84], ["HBsAg", "PROTEIN", 79, 84], ["major S surface viral protein", "PROTEIN", 152, 181], ["13 Trp residues", "PROTEIN", 193, 208], ["yeast", "SPECIES", 213, 218], ["Marcel m\u00e9rieux, 69290 Marcy l'\u00e9toile", "SPECIES", 0, 36], ["P-659Hepatitis B", "SPECIES", 45, 61], ["yeast", "SPECIES", 213, 218], ["P", "TEST", 45, 46], ["B surface antigen", "TEST", 60, 77], ["HBsAg", "TEST", 79, 84], ["nm lipoprotein particles", "TEST", 103, 127], ["viral protein", "TEST", 168, 181], ["Trp residues", "TEST", 196, 208], ["yeast", "TEST", 213, 218]]], ["Since the structure of these particles is still missing, we further characterized them by fluorescence techniques.", [["fluorescence techniques", "TEST", 90, 113], ["particles", "OBSERVATION", 29, 38]]], ["FCS indicated that the particles diffuse mainly as monomers and contain about 80 proteins per particle.", [["the particles diffuse", "PROBLEM", 19, 40], ["particles", "OBSERVATION_MODIFIER", 23, 32], ["diffuse", "OBSERVATION_MODIFIER", 33, 40]]], ["Fluorescence quenching and time-resolved fluorescence experiments showed that the fluorescence signal is largely dominated by the Trp residues at the protein surface.", [["Trp", "CHEMICAL", 130, 133], ["Trp", "CHEMICAL", 130, 133], ["surface", "CELLULAR_COMPONENT", 158, 165], ["Fluorescence quenching", "TEST", 0, 22], ["fluorescence experiments", "TEST", 41, 65], ["the fluorescence signal", "TEST", 78, 101], ["largely", "OBSERVATION_MODIFIER", 105, 112], ["dominated", "OBSERVATION", 113, 122], ["Trp residues", "OBSERVATION", 130, 142], ["surface", "OBSERVATION_MODIFIER", 158, 165]]], ["Moreover, time-resolved anisotropy measurements indicate that the protein motion is restricted and that the surface Trp residues exhibit both local and segmental motions.", [["surface", "ANATOMY", 108, 115], ["Trp", "CHEMICAL", 116, 119], ["anisotropy measurements", "TEST", 24, 47], ["the protein motion", "PROBLEM", 62, 80], ["the surface Trp residues", "TEST", 104, 128], ["protein motion", "OBSERVATION", 66, 80], ["both", "OBSERVATION_MODIFIER", 137, 141], ["local", "OBSERVATION_MODIFIER", 142, 147], ["segmental motions", "OBSERVATION", 152, 169]]], ["The lipid part of the particles has been studied by environment sensitive 3-hydroxyflavone probes and viscosity-sensitive DPHbased probes, and compared to lipid bilayers and low density lipoproteins (LDLs), taken as models.", [["lipid bilayers", "ANATOMY", 155, 169], ["3-hydroxyflavone", "CHEMICAL", 74, 90], ["3-hydroxyflavone", "CHEMICAL", 74, 90], ["3-hydroxyflavone", "SIMPLE_CHEMICAL", 74, 90], ["lipid bilayers", "SIMPLE_CHEMICAL", 155, 169], ["low density lipoproteins", "SIMPLE_CHEMICAL", 174, 198], ["LDLs", "SIMPLE_CHEMICAL", 200, 204], ["low density lipoproteins", "PROTEIN", 174, 198], ["LDLs", "CELL_TYPE", 200, 204], ["hydroxyflavone probes", "TREATMENT", 76, 97], ["viscosity", "TEST", 102, 111], ["sensitive DPHbased probes", "PROBLEM", 112, 137], ["lipid bilayers", "TEST", 155, 169], ["particles", "OBSERVATION", 22, 31], ["low density", "OBSERVATION_MODIFIER", 174, 185]]], ["The results suggest that the lipid part of HBsAg is closer to LDLs than to model lipid bilayers.", [["lipid bilayers", "ANATOMY", 81, 95], ["HBsAg", "CHEMICAL", 43, 48], ["HBsAg", "GENE_OR_GENE_PRODUCT", 43, 48], ["LDLs", "SIMPLE_CHEMICAL", 62, 66], ["HBsAg", "PROTEIN", 43, 48], ["LDLs", "CELL_TYPE", 62, 66], ["HBsAg", "TEST", 43, 48], ["lipid bilayers", "OBSERVATION", 81, 95]]], ["We present an extensive calorimetric study of bovine alphalactalbumin for various Ca++ content.", [["alphalactalbumin", "CHEMICAL", 53, 69], ["Ca", "CHEMICAL", 82, 84], ["alphalactalbumin", "CHEMICAL", 53, 69], ["Ca++", "CHEMICAL", 82, 86], ["bovine", "ORGANISM", 46, 52], ["alphalactalbumin", "SIMPLE_CHEMICAL", 53, 69], ["Ca++", "SIMPLE_CHEMICAL", 82, 86], ["bovine", "SPECIES", 46, 52], ["bovine", "SPECIES", 46, 52], ["an extensive calorimetric study", "TEST", 11, 42], ["bovine alphalactalbumin", "TREATMENT", 46, 69], ["various Ca", "TEST", 74, 84]]], ["Equilibrium DSC raw data are analyzed and the melting temperature Tm, the specific heat jump DeltaCp, the heat of unfolding DeltaHm are directly extracted.", [["DeltaHm", "GENE_OR_GENE_PRODUCT", 124, 131], ["DeltaHm", "PROTEIN", 124, 131], ["Equilibrium DSC raw data", "TEST", 0, 24], ["the melting temperature", "TEST", 42, 65], ["the specific heat jump DeltaCp", "TREATMENT", 70, 100], ["unfolding DeltaHm", "TREATMENT", 114, 131]]], ["The binding of calcium on the native (N) state greatly stabilizes the protein, essentially by the enthalpic difference between the unfolded (U) and N states.", [["calcium", "CHEMICAL", 15, 22], ["calcium", "CHEMICAL", 15, 22], ["calcium", "SIMPLE_CHEMICAL", 15, 22], ["native (N) state", "PROTEIN", 30, 46], ["unfolded", "OBSERVATION_MODIFIER", 131, 139]]], ["We show that subsequent addition of calcium in the mM range stabilizes further the N state.", [["calcium", "CHEMICAL", 36, 43], ["calcium", "CHEMICAL", 36, 43], ["calcium", "SIMPLE_CHEMICAL", 36, 43], ["calcium", "TEST", 36, 43]]], ["The equilibrium calorimetric measurements are completed with out of equilibrium stopped flow refolding kinetics by CD spectroscopy performed at different temperature and Ca++ concentrations.", [["Ca", "CHEMICAL", 170, 172], ["Ca++", "CHEMICAL", 170, 174], ["Ca++", "SIMPLE_CHEMICAL", 170, 174], ["The equilibrium calorimetric measurements", "TEST", 0, 41], ["CD spectroscopy", "TEST", 115, 130], ["different temperature", "TEST", 144, 165], ["Ca", "TEST", 170, 172]]], ["We discuss the possible stabilization mechanisms compatible with our measurements.O-657Protein unfolding/refolding in cellular compartments: application of luciferase constructs Our studies show that a reporter enzyme, firefly luciferase, can be used for evaluation of the stress-induced proteotoxicity within different cellular compartments such as the nucleus, cytoplasm or mitochondria.", [["cellular compartments", "ANATOMY", 118, 139], ["cellular compartments", "ANATOMY", 320, 341], ["nucleus", "ANATOMY", 354, 361], ["cytoplasm", "ANATOMY", 363, 372], ["mitochondria", "ANATOMY", 376, 388], ["O-657Protein", "CHEMICAL", 82, 94], ["O-657Protein", "CHEMICAL", 82, 94], ["O-657Protein", "GENE_OR_GENE_PRODUCT", 82, 94], ["cellular", "CELL", 118, 126], ["luciferase", "GENE_OR_GENE_PRODUCT", 156, 166], ["luciferase", "GENE_OR_GENE_PRODUCT", 227, 237], ["cellular", "CELL", 320, 328], ["nucleus", "CELLULAR_COMPONENT", 354, 361], ["cytoplasm", "ORGANISM_SUBSTANCE", 363, 372], ["mitochondria", "CELLULAR_COMPONENT", 376, 388], ["luciferase constructs", "DNA", 156, 177], ["luciferase", "PROTEIN", 227, 237], ["our measurements", "TEST", 65, 81], ["application of luciferase constructs", "TREATMENT", 141, 177], ["Our studies", "TEST", 178, 189], ["a reporter enzyme", "TEST", 200, 217], ["firefly luciferase", "TEST", 219, 237], ["evaluation", "TEST", 255, 265], ["the stress-induced proteotoxicity", "PROBLEM", 269, 302], ["mitochondria", "PROBLEM", 376, 388], ["cellular compartments", "OBSERVATION", 320, 341], ["nucleus", "ANATOMY", 354, 361]]], ["In transfected mammalian cells, firefly luciferase is localized in microsomes.", [["cells", "ANATOMY", 25, 30], ["microsomes", "ANATOMY", 67, 77], ["mammalian cells", "CELL", 15, 30], ["firefly", "GENE_OR_GENE_PRODUCT", 32, 39], ["luciferase", "GENE_OR_GENE_PRODUCT", 40, 50], ["microsomes", "TISSUE", 67, 77], ["transfected mammalian cells", "CELL_LINE", 3, 30], ["luciferase", "PROTEIN", 40, 50], ["firefly luciferase", "TEST", 32, 50], ["mammalian cells", "OBSERVATION", 15, 30]]], ["We engineered plasmid constructs encoding luciferase with inserted specific sequences that ensure its cytoplasmic or intranuclear, or intramitochondrial localization.", [["plasmid", "ANATOMY", 14, 21], ["cytoplasmic", "ANATOMY", 102, 113], ["intranuclear", "ANATOMY", 117, 129], ["luciferase", "GENE_OR_GENE_PRODUCT", 42, 52], ["cytoplasmic", "ORGANISM_SUBSTANCE", 102, 113], ["intranuclear", "CELLULAR_COMPONENT", 117, 129], ["plasmid constructs", "DNA", 14, 32], ["luciferase", "PROTEIN", 42, 52], ["inserted specific sequences", "TEST", 58, 85], ["plasmid constructs", "OBSERVATION", 14, 32], ["intramitochondrial localization", "OBSERVATION", 134, 165]]], ["In addition, we fused luciferase to the green fluorescent protein (GFP) that enables to visualize patterns of the compartment-targeted product.", [["compartment", "ANATOMY", 114, 125], ["luciferase", "GENE_OR_GENE_PRODUCT", 22, 32], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 40, 65], ["GFP", "GENE_OR_GENE_PRODUCT", 67, 70], ["luciferase", "PROTEIN", 22, 32], ["green fluorescent protein", "PROTEIN", 40, 65], ["GFP", "PROTEIN", 67, 70], ["compartment", "ANATOMY", 114, 125]]], ["Using such GFP-labeled constructs we had a possibility to monitor protein unfolding, aggregation and refolding in the cytoplasm, nucleus and mitochondria of transfectants exposed to either stressful conditions.", [["cytoplasm", "ANATOMY", 118, 127], ["nucleus", "ANATOMY", 129, 136], ["mitochondria", "ANATOMY", 141, 153], ["transfectants", "ANATOMY", 157, 170], ["GFP", "GENE_OR_GENE_PRODUCT", 11, 14], ["cytoplasm", "ORGANISM_SUBSTANCE", 118, 127], ["nucleus", "CELLULAR_COMPONENT", 129, 136], ["mitochondria", "CELLULAR_COMPONENT", 141, 153], ["transfectants", "CELL", 157, 170], ["GFP-labeled constructs", "DNA", 11, 33], ["protein unfolding", "PROBLEM", 66, 83], ["aggregation", "PROBLEM", 85, 96], ["nucleus", "ANATOMY", 129, 136]]], ["GFP-luciferase expressed in mammalian cells behaves as a relatively labile protein which can undergo reversible unfolding and aggregation in response to heat shock, ATP depletion or action of toxic agents.", [["mammalian cells", "ANATOMY", 28, 43], ["shock", "DISEASE", 158, 163], ["ATP", "CHEMICAL", 165, 168], ["ATP", "CHEMICAL", 165, 168], ["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["mammalian cells", "CELL", 28, 43], ["ATP", "SIMPLE_CHEMICAL", 165, 168], ["GFP", "PROTEIN", 0, 3], ["luciferase", "PROTEIN", 4, 14], ["mammalian cells", "CELL_TYPE", 28, 43], ["GFP", "TEST", 0, 3], ["a relatively labile protein", "PROBLEM", 55, 82], ["reversible unfolding", "PROBLEM", 101, 121], ["aggregation", "PROBLEM", 126, 137], ["heat shock", "TREATMENT", 153, 163], ["ATP depletion", "TREATMENT", 165, 178], ["toxic agents", "TREATMENT", 192, 204], ["mammalian cells", "OBSERVATION", 28, 43], ["reversible", "OBSERVATION_MODIFIER", 101, 111], ["unfolding", "OBSERVATION", 112, 121]]], ["In the case of cell recovery, refolding of denatured luciferase is carried out at the chaperone machine.", [["cell", "ANATOMY", 15, 19], ["cell", "CELL", 15, 19], ["luciferase", "GENE_OR_GENE_PRODUCT", 53, 63], ["luciferase", "PROTEIN", 53, 63], ["cell recovery", "TREATMENT", 15, 28], ["denatured luciferase", "PROBLEM", 43, 63], ["cell recovery", "OBSERVATION", 15, 28]]], ["We explored unfolding/refolding of GFP-luciferase in the cytoplasm, nucleus and mitochondria of ischemia-stressed rat cardiac cells and in several cancer cell lines treated with hyperthermia or some chemotherapeutic drugs.", [["cytoplasm", "ANATOMY", 57, 66], ["nucleus", "ANATOMY", 68, 75], ["mitochondria", "ANATOMY", 80, 92], ["cardiac cells", "ANATOMY", 118, 131], ["cancer cell lines", "ANATOMY", 147, 164], ["ischemia", "DISEASE", 96, 104], ["cancer", "DISEASE", 147, 153], ["hyperthermia", "DISEASE", 178, 190], ["GFP", "GENE_OR_GENE_PRODUCT", 35, 38], ["luciferase", "GENE_OR_GENE_PRODUCT", 39, 49], ["cytoplasm", "ORGANISM_SUBSTANCE", 57, 66], ["nucleus", "CELLULAR_COMPONENT", 68, 75], ["mitochondria", "CELLULAR_COMPONENT", 80, 92], ["rat", "ORGANISM", 114, 117], ["cardiac cells", "CELL", 118, 131], ["cancer cell lines", "CELL", 147, 164], ["GFP", "PROTEIN", 35, 38], ["luciferase", "PROTEIN", 39, 49], ["ischemia-stressed rat cardiac cells", "CELL_TYPE", 96, 131], ["cancer cell lines", "CELL_LINE", 147, 164], ["rat", "SPECIES", 114, 117], ["GFP", "TEST", 35, 38], ["ischemia", "PROBLEM", 96, 104], ["stressed rat cardiac cells", "PROBLEM", 105, 131], ["several cancer cell lines", "TREATMENT", 139, 164], ["hyperthermia", "PROBLEM", 178, 190], ["some chemotherapeutic drugs", "TREATMENT", 194, 221], ["nucleus", "ANATOMY", 68, 75], ["ischemia", "OBSERVATION", 96, 104], ["cardiac cells", "ANATOMY", 118, 131], ["several", "OBSERVATION_MODIFIER", 139, 146], ["cancer cell lines", "OBSERVATION", 147, 164], ["chemotherapeutic drugs", "OBSERVATION", 199, 221]]], ["The results obtained have revealed intriguing correlations between the proteotoxic impact within either compartment and the viability of treated cells.P-664Amyloidogenic and conformational properties of ProIAPP and IAPP in the presence of lipid bilayers S. Jha 1 , D. Sellin 1 , R. Seidel 2 , R. Winter 1 1 Biophysical Chemistry, Department of Chemistry, TU Dortmund University, Otto-Hahn Str.", [["cells", "ANATOMY", 145, 150], ["ProIAPP", "CHEMICAL", 203, 210], ["ProIAPP", "CHEMICAL", 203, 210], ["cells", "CELL", 145, 150], ["ProIAPP", "SIMPLE_CHEMICAL", 203, 210], ["IAPP", "GENE_OR_GENE_PRODUCT", 215, 219], ["treated cells", "CELL_LINE", 137, 150], ["ProIAPP", "PROTEIN", 203, 210], ["IAPP", "PROTEIN", 215, 219], ["the proteotoxic impact", "PROBLEM", 67, 89], ["P", "TEST", 151, 152], ["ProIAPP", "TREATMENT", 203, 210], ["IAPP", "TEST", 215, 219], ["lipid bilayers S. Jha", "TEST", 239, 260], ["proteotoxic impact", "OBSERVATION", 71, 89], ["treated cells", "OBSERVATION", 137, 150]]], ["11, D-44227, Dortmund, GermanyP-664The islet amyloid polypeptide (IAPP), which is considered as the primary culprit for \u03b2-cell loss in type 2 diabetes mellitus patients, is synthesized in the \u03b2-cells of the pancreas from its precursor, the pro-islet amyloid polypeptide (proIAPP).", [["\u03b2-cell", "ANATOMY", 120, 126], ["\u03b2-cells", "ANATOMY", 192, 199], ["pancreas", "ANATOMY", 207, 215], ["GermanyP-664", "CHEMICAL", 23, 35], ["type 2 diabetes mellitus", "DISEASE", 135, 159], ["GermanyP-664", "CHEMICAL", 23, 35], ["islet amyloid polypeptide", "GENE_OR_GENE_PRODUCT", 39, 64], ["IAPP", "GENE_OR_GENE_PRODUCT", 66, 70], ["\u03b2-cell", "CELL", 120, 126], ["patients", "ORGANISM", 160, 168], ["\u03b2-cells", "CANCER", 192, 199], ["pancreas", "ORGAN", 207, 215], ["pro-islet amyloid polypeptide", "GENE_OR_GENE_PRODUCT", 240, 269], ["proIAPP", "GENE_OR_GENE_PRODUCT", 271, 278], ["islet amyloid polypeptide", "PROTEIN", 39, 64], ["IAPP", "PROTEIN", 66, 70], ["pro-islet amyloid polypeptide", "PROTEIN", 240, 269], ["proIAPP", "PROTEIN", 271, 278], ["patients", "SPECIES", 160, 168], ["GermanyP", "TEST", 23, 31], ["The islet amyloid polypeptide (IAPP", "TEST", 35, 70], ["\u03b2-cell loss", "PROBLEM", 120, 131], ["type 2 diabetes mellitus", "PROBLEM", 135, 159], ["the pro-islet amyloid polypeptide", "TREATMENT", 236, 269], ["cell loss", "OBSERVATION", 122, 131], ["diabetes mellitus", "OBSERVATION", 142, 159], ["pancreas", "ANATOMY", 207, 215]]], ["ProIAPP is co-processed in the secretory granules and co-secreted to the extracellular matrix together with insulin as IAPP.", [["secretory granules", "ANATOMY", 31, 49], ["extracellular matrix", "ANATOMY", 73, 93], ["ProIAPP", "CHEMICAL", 0, 7], ["ProIAPP", "SIMPLE_CHEMICAL", 0, 7], ["secretory", "CELLULAR_COMPONENT", 31, 40], ["granules", "ORGANISM_SUBSTANCE", 41, 49], ["extracellular matrix", "CELLULAR_COMPONENT", 73, 93], ["insulin", "GENE_OR_GENE_PRODUCT", 108, 115], ["IAPP", "GENE_OR_GENE_PRODUCT", 119, 123], ["ProIAPP", "PROTEIN", 0, 7], ["insulin", "PROTEIN", 108, 115], ["IAPP", "PROTEIN", 119, 123], ["the secretory granules", "PROBLEM", 27, 49], ["insulin", "TREATMENT", 108, 115], ["secretory granules", "OBSERVATION", 31, 49]]], ["Here, we compare the amyloidogenic and conformational properties of proIAPP and IAPP in the presence of lipid membranes, which have been discussed as loci of initiation of the fibrillation reaction.", [["lipid membranes", "ANATOMY", 104, 119], ["fibrillation", "DISEASE", 176, 188], ["proIAPP", "SIMPLE_CHEMICAL", 68, 75], ["IAPP", "GENE_OR_GENE_PRODUCT", 80, 84], ["lipid membranes", "CELLULAR_COMPONENT", 104, 119], ["proIAPP", "PROTEIN", 68, 75], ["IAPP", "PROTEIN", 80, 84], ["proIAPP", "TREATMENT", 68, 75], ["IAPP", "TREATMENT", 80, 84], ["lipid membranes", "PROBLEM", 104, 119], ["the fibrillation reaction", "PROBLEM", 172, 197], ["lipid membranes", "OBSERVATION", 104, 119], ["fibrillation", "OBSERVATION", 176, 188]]], ["The two peptides show an enhanced amyloidogenic propensity in the presence of negatively charged membranes and similar secondary structural properties.", [["membranes", "ANATOMY", 97, 106], ["membranes", "CELLULAR_COMPONENT", 97, 106], ["The two peptides", "TEST", 0, 16], ["an enhanced amyloidogenic propensity", "PROBLEM", 22, 58], ["negatively charged membranes", "PROBLEM", 78, 106], ["enhanced", "OBSERVATION_MODIFIER", 25, 33], ["amyloidogenic propensity", "OBSERVATION", 34, 58], ["negatively", "OBSERVATION_MODIFIER", 78, 88], ["charged membranes", "OBSERVATION", 89, 106], ["secondary structural properties", "OBSERVATION", 119, 150]]], ["However, proIAPP shows a much less amyloidogenic propensity, probably due to the increased net charge on proIAPP, compared to IAPP.", [["proIAPP", "CHEMICAL", 9, 16], ["proIAPP", "CHEMICAL", 9, 16], ["proIAPP", "CHEMICAL", 105, 112], ["proIAPP", "SIMPLE_CHEMICAL", 9, 16], ["proIAPP", "SIMPLE_CHEMICAL", 105, 112], ["IAPP", "GENE_OR_GENE_PRODUCT", 126, 130], ["proIAPP", "PROTEIN", 9, 16], ["proIAPP", "PROTEIN", 105, 112], ["IAPP", "PROTEIN", 126, 130], ["a much less amyloidogenic propensity", "PROBLEM", 23, 59], ["the increased net charge", "PROBLEM", 77, 101], ["proIAPP", "TREATMENT", 105, 112], ["IAPP", "TEST", 126, 130], ["much less", "OBSERVATION_MODIFIER", 25, 34], ["amyloidogenic propensity", "OBSERVATION", 35, 59], ["probably due to", "UNCERTAINTY", 61, 76], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["net charge", "OBSERVATION", 91, 101]]], ["Unlike IAPP, proIAPP forms small oligomeric structures at the lipid interface, having heights of \u223c3.5 nm.", [["IAPP", "GENE_OR_GENE_PRODUCT", 7, 11], ["proIAPP", "GENE_OR_GENE_PRODUCT", 13, 20], ["IAPP", "PROTEIN", 7, 11], ["proIAPP", "PROTEIN", 13, 20], ["IAPP", "TEST", 7, 11], ["small oligomeric structures at the lipid interface", "PROBLEM", 27, 77], ["heights", "TEST", 86, 93], ["small", "OBSERVATION_MODIFIER", 27, 32], ["oligomeric structures", "OBSERVATION", 33, 54], ["lipid interface", "OBSERVATION", 62, 77]]], ["This morphological distinction can be attributed to the presence of the pro-region, flanking the amyloidogenic IAPP.", [["IAPP", "GENE_OR_GENE_PRODUCT", 111, 115], ["amyloidogenic IAPP", "PROTEIN", 97, 115], ["the pro-region", "PROBLEM", 68, 82], ["flanking the amyloidogenic IAPP", "PROBLEM", 84, 115], ["amyloidogenic IAPP", "OBSERVATION", 97, 115]]], ["The addition of proIAPP to IAPP marginally delays IAPP fibrillation, probably by interfering with the interaction between amyloidogenic IAPP cores of distinct IAPP molecules.", [["proIAPP", "CHEMICAL", 16, 23], ["fibrillation", "DISEASE", 55, 67], ["proIAPP", "SIMPLE_CHEMICAL", 16, 23], ["IAPP", "GENE_OR_GENE_PRODUCT", 27, 31], ["IAPP", "GENE_OR_GENE_PRODUCT", 50, 54], ["IAPP", "GENE_OR_GENE_PRODUCT", 136, 140], ["IAPP", "GENE_OR_GENE_PRODUCT", 159, 163], ["proIAPP", "PROTEIN", 16, 23], ["IAPP", "PROTEIN", 27, 31], ["amyloidogenic IAPP cores", "PROTEIN", 122, 146], ["IAPP molecules", "PROTEIN", 159, 173], ["proIAPP to IAPP", "TREATMENT", 16, 31], ["IAPP fibrillation", "PROBLEM", 50, 67], ["distinct IAPP molecules", "PROBLEM", 150, 173], ["IAPP fibrillation", "OBSERVATION", 50, 67], ["distinct", "OBSERVATION_MODIFIER", 150, 158], ["IAPP molecules", "OBSERVATION", 159, 173]]], ["Thus, it appears reasonable to speculate that the pro-region of the proIAPP could serve to delay the fibrillogenesis of IAPP at negatively charged lipid bilayers.P-663The role of transmembrane domain interactions in the kinetics and folding of CPT 1 Z. A. Jenei 1 , K. Borthwick 2 , V. A. Zammit 2 , A. M. Dixon 1 1 Chemistry Dept., Univ.P-663of Warwick, Coventry, UK, 2 Clinical\u0203Sciences\u0203Res.\u0203Inst., Warwick Univ., Coventry, UK Carnitine palmitoyltransferase I (CPT 1) enzymes are polytopic integral membrane proteins in the outer membrane of mitochondria (OMM).", [["transmembrane", "ANATOMY", 179, 192], ["membrane", "ANATOMY", 501, 509], ["outer membrane", "ANATOMY", 526, 540], ["mitochondria", "ANATOMY", 544, 556], ["OMM", "ANATOMY", 558, 561], ["proIAPP", "CHEMICAL", 68, 75], ["P-663", "CHEMICAL", 162, 167], ["Univ.P-663of", "CHEMICAL", 333, 345], ["Carnitine", "CHEMICAL", 429, 438], ["Carnitine", "CHEMICAL", 429, 438], ["proIAPP", "GENE_OR_GENE_PRODUCT", 68, 75], ["IAPP", "GENE_OR_GENE_PRODUCT", 120, 124], ["lipid bilayers", "CELLULAR_COMPONENT", 147, 161], ["Carnitine palmitoyltransferase I", "GENE_OR_GENE_PRODUCT", 429, 461], ["CPT 1", "GENE_OR_GENE_PRODUCT", 463, 468], ["outer membrane", "CELLULAR_COMPONENT", 526, 540], ["mitochondria", "CELLULAR_COMPONENT", 544, 556], ["OMM", "CELLULAR_COMPONENT", 558, 561], ["proIAPP", "PROTEIN", 68, 75], ["IAPP", "PROTEIN", 120, 124], ["P-663", "DNA", 162, 167], ["transmembrane domain", "PROTEIN", 179, 199], ["Carnitine palmitoyltransferase I (CPT 1) enzymes", "PROTEIN", 429, 477], ["polytopic integral membrane proteins", "PROTEIN", 482, 518], ["the fibrillogenesis of IAPP", "TREATMENT", 97, 124], ["transmembrane domain interactions", "PROBLEM", 179, 212], ["Univ.P", "TEST", 333, 339], ["UK Carnitine palmitoyltransferase I (CPT 1) enzymes", "TREATMENT", 426, 477], ["polytopic integral membrane proteins", "PROBLEM", 482, 518], ["membrane proteins", "OBSERVATION", 501, 518], ["outer membrane", "ANATOMY", 526, 540]]], ["CPT 1 controls the rate of entry of long-chain fatty acids into the mitochondrial matrix for \u03b2oxidation.", [["mitochondrial matrix", "ANATOMY", 68, 88], ["fatty acids", "CHEMICAL", 47, 58], ["fatty acids", "CHEMICAL", 47, 58], ["CPT 1", "GENE_OR_GENE_PRODUCT", 0, 5], ["long-chain fatty acids", "SIMPLE_CHEMICAL", 36, 58], ["mitochondrial matrix", "CELLULAR_COMPONENT", 68, 88], ["CPT", "TEST", 0, 3], ["long-chain fatty acids", "TREATMENT", 36, 58], ["mitochondrial matrix", "ANATOMY", 68, 88]]], ["The two catalytically active isoforms, CPT 1A and CPT 1B, are different in their inhibitor binding kinetics and structure (interaction between N-and C-segments, interactions of transmembrane domains (TMD)).", [["N", "CHEMICAL", 143, 144], ["CPT 1A", "GENE_OR_GENE_PRODUCT", 39, 45], ["CPT 1B", "GENE_OR_GENE_PRODUCT", 50, 56], ["catalytically active isoforms", "PROTEIN", 8, 37], ["CPT 1A", "PROTEIN", 39, 45], ["CPT 1B", "PROTEIN", 50, 56], ["N-and C-segments", "PROTEIN", 143, 159], ["transmembrane domains", "PROTEIN", 177, 198], ["TMD", "PROTEIN", 200, 203], ["CPT 1B", "TREATMENT", 50, 56], ["N", "TEST", 143, 144], ["catalytically", "OBSERVATION_MODIFIER", 8, 21], ["active isoforms", "OBSERVATION", 22, 37]]], ["It has been suggested that inter-and intramolecular TMDs interactions are important for CPT 1A, but not for CPT 1B function.", [["CPT 1A", "GENE_OR_GENE_PRODUCT", 88, 94], ["CPT 1B", "GENE_OR_GENE_PRODUCT", 108, 114], ["CPT 1A", "PROTEIN", 88, 94]]], ["CPT 1A has also been implicated in formation of oligomeric complexes through its TM segments.", [["CPT", "CHEMICAL", 0, 3], ["CPT 1A", "GENE_OR_GENE_PRODUCT", 0, 6], ["CPT 1A", "PROTEIN", 0, 6], ["oligomeric complexes", "PROTEIN", 48, 68], ["TM segments", "PROTEIN", 81, 92], ["oligomeric complexes", "OBSERVATION", 48, 68]]], ["The study of TM helix-helix interactions in CPT 1 isoforms could lead to a better understanding of their function and inhibitor binding kinetics, and will contribute towards the design of pharmacological strategies aimed at modulating the activities of CPT 1 enzymes in conditions such as diabetes.", [["diabetes", "DISEASE", 289, 297], ["CPT 1", "GENE_OR_GENE_PRODUCT", 44, 49], ["CPT 1", "GENE_OR_GENE_PRODUCT", 253, 258], ["CPT 1 isoforms", "PROTEIN", 44, 58], ["CPT 1 enzymes", "PROTEIN", 253, 266], ["The study", "TEST", 0, 9], ["TM helix", "TREATMENT", 13, 21], ["pharmacological strategies", "TREATMENT", 188, 214], ["CPT 1 enzymes", "TREATMENT", 253, 266], ["diabetes", "PROBLEM", 289, 297]]], ["To investigate the ability of the TMD in CPT 1 to self-associate and the order of any oligomers formed, several biochemical and biophysical techniques have been used.", [["TMD", "DISEASE", 34, 37], ["CPT 1", "GENE_OR_GENE_PRODUCT", 41, 46], ["CPT", "TEST", 41, 44], ["any oligomers", "TREATMENT", 82, 95], ["biophysical techniques", "TREATMENT", 128, 150]]], ["We found the self-association of rCPT 1A TMDs (TM1, TM2) to be different as measured using the in vivo TOX-CAT assay.", [["rCPT 1A", "GENE_OR_GENE_PRODUCT", 33, 40], ["rCPT 1A TMDs", "PROTEIN", 33, 45], ["TM1", "PROTEIN", 47, 50], ["TM2", "PROTEIN", 52, 55], ["TOX", "PROTEIN", 103, 106], ["CAT", "PROTEIN", 107, 110], ["the in vivo TOX", "TEST", 91, 106]]], ["Chemical cross-linking and analytical ultracentrifugation studies demonstrated formation of both trimers and hexamers by the rCPT 1A TM2 peptide.", [["Chemical cross-linking", "TREATMENT", 0, 22], ["analytical ultracentrifugation studies", "TEST", 27, 65], ["hexamers", "TREATMENT", 109, 117], ["both trimers", "OBSERVATION", 92, 104]]], ["These results provide further evidence that TM2 plays role in formation of a channel in the OMM.P-662Self-assembly of transmembrane domains in CPT1: Role of GXXXG(A) motif in possible channel formation Z. A. Jenei 1 , K. Borthwick 2 , V. A. Zammit 2 , A. M. Dixon 1 1 Department of Chemistry and, 2 Warwick Medical School, University of Warwick, Coventry, UK Carnitine palmitoyltransferase 1A (CPT1A), a membrane protein that controls the rate of oxidation of long-chain fatty acids, is of key importance in diabetes and has recently been reported to exist as an oligomer in vivo.", [["OMM", "ANATOMY", 92, 95], ["transmembrane", "ANATOMY", 118, 131], ["membrane", "ANATOMY", 404, 412], ["Carnitine", "CHEMICAL", 359, 368], ["fatty acids", "CHEMICAL", 471, 482], ["diabetes", "DISEASE", 508, 516], ["Carnitine", "CHEMICAL", 359, 368], ["fatty acids", "CHEMICAL", 471, 482], ["TM2", "GENE_OR_GENE_PRODUCT", 44, 47], ["OMM", "CELLULAR_COMPONENT", 92, 95], ["CPT1", "GENE_OR_GENE_PRODUCT", 143, 147], ["Carnitine palmitoyltransferase 1A", "GENE_OR_GENE_PRODUCT", 359, 392], ["CPT1A", "GENE_OR_GENE_PRODUCT", 394, 399], ["membrane", "CELLULAR_COMPONENT", 404, 412], ["long-chain fatty acids", "SIMPLE_CHEMICAL", 460, 482], ["TM2", "PROTEIN", 44, 47], ["P", "DNA", 96, 97], ["662Self", "DNA", 98, 105], ["transmembrane domains", "PROTEIN", 118, 139], ["CPT1: Role of GXXXG(A) motif", "PROTEIN", 143, 171], ["Carnitine palmitoyltransferase 1A", "PROTEIN", 359, 392], ["CPT1A", "PROTEIN", 394, 399], ["membrane protein", "PROTEIN", 404, 420], ["P", "TEST", 96, 97], ["a membrane protein", "TREATMENT", 402, 420], ["long-chain fatty acids", "TREATMENT", 460, 482], ["diabetes", "PROBLEM", 508, 516], ["CPT1", "ANATOMY", 143, 147], ["diabetes", "OBSERVATION", 508, 516]]], ["We have investigated full-length CPT1A and find that the protein exists as a hexamer in liver mitochondria.", [["liver mitochondria", "ANATOMY", 88, 106], ["CPT1A", "GENE_OR_GENE_PRODUCT", 33, 38], ["liver mitochondria", "MULTI-TISSUE_STRUCTURE", 88, 106], ["CPT1A", "PROTEIN", 33, 38], ["liver", "ANATOMY", 88, 93]]], ["Using mutants of CPT1A expressed in yeast mitochondria, we have localised key protein interactions in the hexamer to the transmembrane (TM) domains of the protein.", [["mitochondria", "ANATOMY", 42, 54], ["transmembrane", "ANATOMY", 121, 134], ["CPT1A", "GENE_OR_GENE_PRODUCT", 17, 22], ["yeast mitochondria", "CELLULAR_COMPONENT", 36, 54], ["transmembrane", "CELLULAR_COMPONENT", 121, 134], ["CPT1A", "PROTEIN", 17, 22], ["transmembrane (TM) domains", "PROTEIN", 121, 147], ["yeast", "SPECIES", 36, 41], ["yeast", "SPECIES", 36, 41]]], ["Detailed study of the TM domains in isolation, in both E.Coli membranes and detergent micelles, demonstrated that while TM1 shows little self-assembly, TM2 displayed significant self-association.", [["E.Coli membranes", "ANATOMY", 55, 71], ["TM1", "GENE_OR_GENE_PRODUCT", 120, 123], ["TM2", "AMINO_ACID", 152, 155], ["TM domains", "PROTEIN", 22, 32], ["TM1", "PROTEIN", 120, 123], ["TM2", "PROTEIN", 152, 155], ["Detailed study", "TEST", 0, 14], ["the TM domains", "TEST", 18, 32], ["detergent micelles", "TREATMENT", 76, 94], ["TM1", "TEST", 120, 123], ["E.Coli membranes", "OBSERVATION", 55, 71], ["significant", "OBSERVATION_MODIFIER", 166, 177]]], ["Biophysical analyses of a TM2-derived synthetic peptide revealed oligomerization behaviour identical to native CPT1A in mitochondria, providing a strong link between TM2 helixhelix interactions and CPT1A hexamer formation.", [["mitochondria", "ANATOMY", 120, 132], ["CPT1A", "GENE_OR_GENE_PRODUCT", 111, 116], ["mitochondria", "CELLULAR_COMPONENT", 120, 132], ["TM2", "GENE_OR_GENE_PRODUCT", 166, 169], ["CPT1A", "GENE_OR_GENE_PRODUCT", 198, 203], ["TM2", "PROTEIN", 26, 29], ["CPT1A", "PROTEIN", 111, 116], ["TM2", "PROTEIN", 166, 169], ["CPT1A", "PROTEIN", 198, 203], ["Biophysical analyses", "TEST", 0, 20], ["a TM2-derived synthetic peptide", "TEST", 24, 55], ["oligomerization behaviour", "PROBLEM", 65, 90], ["TM2 helixhelix interactions", "TREATMENT", 166, 193], ["CPT1A hexamer formation", "TREATMENT", 198, 221]]], ["This is significant in light of a recent suggestion that CPT1A oligomerization may lead to formation of a channel in the mitochondrial outer membrane through which acylcarnitine gains access to the inter-membrane space.", [["mitochondrial outer membrane", "ANATOMY", 121, 149], ["inter-membrane space", "ANATOMY", 198, 218], ["acylcarnitine", "CHEMICAL", 164, 177], ["acylcarnitine", "CHEMICAL", 164, 177], ["CPT1A", "GENE_OR_GENE_PRODUCT", 57, 62], ["mitochondrial", "CELLULAR_COMPONENT", 121, 134], ["outer membrane", "CELLULAR_COMPONENT", 135, 149], ["acylcarnitine", "SIMPLE_CHEMICAL", 164, 177], ["CPT1A", "PROTEIN", 57, 62], ["CPT1A oligomerization", "PROBLEM", 57, 78], ["a channel in the mitochondrial outer membrane", "PROBLEM", 104, 149], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["mitochondrial outer membrane", "ANATOMY", 121, 149]]], ["Our data supports this new theory, and we go on to demonstrate experimentally the structural determinants of hexamer (channel) formation, specifically GXXXG(A) motifs in the TM domain which pack favourably in the hexamer and stabilize the oligomer.P-662Investigation of flexible loop role in structure and thermodynamic stability of firefly luciferase P. Maghami, B. Ranjbar, S. Hosseinkhani Department of Biochemistry and Biophysics, Faculty of Basic Sciences, Tarbiat Modares University, Tehran, Iran Protein folding, like any chemical process, consists of two fundamental components, thermodynamics and kinetics, which determine the stability of the folded state and the pathway of folding, respectively.", [["luciferase", "GENE_OR_GENE_PRODUCT", 341, 351], ["GXXXG(A) motifs", "PROTEIN", 151, 166], ["TM domain", "PROTEIN", 174, 183], ["P", "DNA", 248, 249], ["the TM domain", "TREATMENT", 170, 183], ["flexible loop role in structure", "TREATMENT", 270, 301], ["Iran Protein folding", "PROBLEM", 498, 518], ["any chemical process", "PROBLEM", 525, 545], ["flexible loop", "OBSERVATION", 270, 283], ["thermodynamic stability", "OBSERVATION", 306, 329], ["stability", "OBSERVATION_MODIFIER", 636, 645], ["folded state", "OBSERVATION", 653, 665]]], ["Experimental evidence is required to simplify the problem via protein engineering .In this research, the wild type firefly luciferase (Photinus pyralis) and some of its mutants were over expressed and purified.", [["luciferase", "GENE_OR_GENE_PRODUCT", 123, 133], ["Photinus pyralis", "ORGANISM", 135, 151], ["wild type firefly luciferase", "PROTEIN", 105, 133], ["Photinus pyralis", "PROTEIN", 135, 151], ["Photinus pyralis", "SPECIES", 135, 151], ["Photinus pyralis", "SPECIES", 135, 151], ["protein engineering", "TREATMENT", 62, 81]]], ["Then their unfolding thermodynamics were examined, using circular dichroism and conventional fluorescence measurements.", [["circular dichroism", "TEST", 57, 75], ["conventional fluorescence measurements", "TEST", 80, 118]]], ["The unfolding equilibrium constant were measured over a complete rang of denaturant conditions.", [["The unfolding equilibrium constant", "PROBLEM", 0, 34], ["unfolding", "OBSERVATION_MODIFIER", 4, 13], ["equilibrium", "OBSERVATION_MODIFIER", 14, 25], ["constant", "OBSERVATION_MODIFIER", 26, 34]]], ["The measurements were shown structural and physico-chemical changes between wild-type and mutant proteins.P-668Exploring intrinsic disorder of unstructured membrane proteins by surface polymer physics Intrinsically unstructured proteins (IUPs) are considered as a separate class within the protein world because they lack a well-defined folded structure.", [["membrane", "ANATOMY", 156, 164], ["disorder", "DISEASE", 131, 139], ["membrane", "CELLULAR_COMPONENT", 156, 164], ["wild-type and mutant proteins", "PROTEIN", 76, 105], ["P", "DNA", 106, 107], ["unstructured membrane proteins", "PROTEIN", 143, 173], ["unstructured proteins", "PROTEIN", 215, 236], ["IUPs", "PROTEIN", 238, 242], ["The measurements", "TEST", 0, 16], ["structural and physico-chemical changes", "PROBLEM", 28, 67], ["P", "TEST", 106, 107], ["intrinsic disorder", "PROBLEM", 121, 139], ["unstructured membrane proteins", "PROBLEM", 143, 173], ["surface polymer physics", "TEST", 177, 200], ["a well-defined folded structure", "PROBLEM", 322, 353], ["disorder", "OBSERVATION", 131, 139], ["well-defined", "OBSERVATION_MODIFIER", 324, 336], ["folded structure", "OBSERVATION", 337, 353]]], ["Because IUP's function is indeed directly linked to structural disorder, they are assumed to be natively unfolded.", [["disorder", "DISEASE", 63, 71], ["IUP", "GENE_OR_GENE_PRODUCT", 8, 11], ["IUP", "PROTEIN", 8, 11], ["IUP's function", "TEST", 8, 22], ["structural disorder", "PROBLEM", 52, 71], ["assumed to be", "UNCERTAINTY", 82, 95], ["unfolded", "OBSERVATION", 105, 113]]], ["Several physicochemical techniques are available to discriminate the degree of disorder.", [["disorder", "DISEASE", 79, 87], ["Several physicochemical techniques", "TREATMENT", 0, 34], ["disorder", "PROBLEM", 79, 87], ["disorder", "OBSERVATION", 79, 87]]], ["However a clear structural classification is still lacking.", [["clear", "OBSERVATION_MODIFIER", 10, 15], ["structural", "OBSERVATION_MODIFIER", 16, 26], ["classification", "OBSERVATION", 27, 41]]], ["In this context, polymer physics emerges as a powerful tool for getting inside on the conformational abilities directly related to structural disordered of IUPs.", [["IUPs", "GENE_OR_GENE_PRODUCT", 156, 160], ["IUPs", "PROTEIN", 156, 160], ["structural disordered of IUPs", "PROBLEM", 131, 160]]], ["In the present contribution, surface pressure and ellipsometry experiments in conjunction with polymer physics have been used to infer structural data in terms of molecular conformation and flexibility of a membrane protein essential for bacterial division, ZipA.", [["surface", "ANATOMY", 29, 36], ["membrane", "ANATOMY", 207, 215], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["ZipA", "GENE_OR_GENE_PRODUCT", 258, 262], ["membrane protein", "PROTEIN", 207, 223], ["ZipA", "PROTEIN", 258, 262], ["surface pressure", "TREATMENT", 29, 45], ["ellipsometry experiments", "TEST", 50, 74], ["polymer physics", "TREATMENT", 95, 110], ["a membrane protein", "TEST", 205, 223], ["bacterial division", "PROBLEM", 238, 256], ["ZipA", "TREATMENT", 258, 262], ["surface", "OBSERVATION_MODIFIER", 29, 36], ["pressure", "OBSERVATION_MODIFIER", 37, 45]]], ["This protein has been pointed to posses a high molecular flexibility and to adopt a random coil conformation.O-667Folding dynamics of peptides studied by timeresolved infrared spectroscopy C. Krejtschi 1 , O. Ridderbusch 1 , R. Huang 2 , L. Wu 2 , T. A. Keiderling 2 , K. Hauser 1 1 Institute of Biophysics, University of Frankfurt, Germany, 2 Department of Chemistry, University of Illinois at Chicago, USA Peptides are ideal model systems to study protein folding mechanisms.", [["O-667", "CHEMICAL", 109, 114], ["O-667", "CHEMICAL", 109, 114], ["a high molecular flexibility", "PROBLEM", 40, 68], ["a random coil conformation", "TREATMENT", 82, 108], ["high", "OBSERVATION_MODIFIER", 42, 46], ["molecular flexibility", "OBSERVATION", 47, 68]]], ["IR techniques provide both the necessary time resolution as well as the structural sensitivity.", [["IR techniques", "TREATMENT", 0, 13], ["the structural sensitivity", "TEST", 68, 94]]], ["We initiate rapid heating by laser-excited ns temperature jumps (\u223c10 \u2022 C) and study fast ns-to-\u00b5s relaxation dynamics [1] .", [["rapid heating", "TREATMENT", 12, 25], ["excited ns temperature jumps", "TREATMENT", 35, 63]]], ["The dynamics of the \u03b1-helix to random coil transition of polyglutamic acid was analyzed under reversible folding/refolding pH-conditions.", [["polyglutamic acid", "CHEMICAL", 57, 74], ["polyglutamic acid", "CHEMICAL", 57, 74], ["\u03b1-helix", "SIMPLE_CHEMICAL", 20, 27], ["polyglutamic acid", "SIMPLE_CHEMICAL", 57, 74], ["random coil transition of polyglutamic acid", "TREATMENT", 31, 74], ["reversible folding", "OBSERVATION", 94, 112]]], ["The observed relaxation kinetics allowed separation of the folding and unfolding process with additional use of FTIR measurements in thermal equilibrium.", [["The observed relaxation kinetics", "PROBLEM", 0, 32], ["unfolding process", "PROBLEM", 71, 88], ["FTIR measurements", "TEST", 112, 129], ["relaxation kinetics", "OBSERVATION", 13, 32], ["separation", "OBSERVATION_MODIFIER", 41, 51]]], ["Sitespecific dynamics were monitored by use of isotopic labeling for a \u03b2-hairpin peptide whose conformation is stabilized by a hydrophobic core.", [["isotopic labeling", "TREATMENT", 47, 64], ["a \u03b2-hairpin peptide", "TREATMENT", 69, 88]]], ["The isotope-edited kinetics show variations in local structural stability of the hairpin backbone.", [["the hairpin backbone", "TREATMENT", 77, 97], ["variations", "OBSERVATION_MODIFIER", 33, 43], ["local structural stability", "OBSERVATION", 47, 73], ["hairpin backbone", "OBSERVATION", 81, 97]]], ["Our data support a multistate dynamic behavior, and the site-specific kinetics are consistent with a hydrophobic collapse hypothesis for hairpin folding [2] .", [["Our data", "TEST", 0, 8], ["a hydrophobic collapse hypothesis", "PROBLEM", 99, 132], ["hairpin folding", "PROBLEM", 137, 152], ["consistent with", "UNCERTAINTY", 83, 98], ["hydrophobic collapse", "OBSERVATION", 101, 121]]], ["Small heat shock protein Hsp22 was predicted to belong to the family of intrinsically disordered proteins.", [["Small heat shock protein Hsp22", "GENE_OR_GENE_PRODUCT", 0, 30], ["Small heat shock protein", "PROTEIN", 0, 24], ["Hsp22", "PROTEIN", 25, 30], ["intrinsically disordered proteins", "PROTEIN", 72, 105], ["Small heat shock protein Hsp22", "PROBLEM", 0, 30], ["intrinsically disordered proteins", "PROBLEM", 72, 105], ["heat", "OBSERVATION_MODIFIER", 6, 10], ["shock protein", "OBSERVATION", 11, 24]]], ["One of the features of these proteins is that they do not demonstrate cooperative thermal transitions on heating.", [["cooperative thermal transitions", "PROBLEM", 70, 101]]], ["We applied different methods (DSC, FTIR and intrinsic tryptophan fluorescence) to investigate the thermal unfolding of Hsp22.", [["tryptophan", "CHEMICAL", 54, 64], ["tryptophan", "CHEMICAL", 54, 64], ["tryptophan", "SIMPLE_CHEMICAL", 54, 64], ["Hsp22", "GENE_OR_GENE_PRODUCT", 119, 124], ["Hsp22", "PROTEIN", 119, 124], ["different methods (DSC", "TREATMENT", 11, 33], ["intrinsic tryptophan fluorescence", "TREATMENT", 44, 77], ["the thermal unfolding of Hsp22", "PROBLEM", 94, 124]]], ["DSC results have shown that thermal denaturation of Hsp22 begins from 25 o C and occurs, with very low cooperativity, within a broad temperature region (up to 80 o C and above).", [["Hsp22", "CHEMICAL", 52, 57], ["Hsp22", "GENE_OR_GENE_PRODUCT", 52, 57], ["Hsp22", "PROTEIN", 52, 57], ["DSC", "TEST", 0, 3], ["thermal denaturation of Hsp22", "PROBLEM", 28, 57], ["very low cooperativity", "PROBLEM", 94, 116], ["a broad temperature region", "PROBLEM", 125, 151], ["thermal", "OBSERVATION_MODIFIER", 28, 35], ["denaturation", "OBSERVATION", 36, 48]]], ["The thermal unfolding of Hsp22 is fully reversible.", [["Hsp22", "CHEMICAL", 25, 30], ["Hsp22", "GENE_OR_GENE_PRODUCT", 25, 30], ["Hsp22", "PROTEIN", 25, 30], ["The thermal unfolding of Hsp22", "PROBLEM", 0, 30], ["thermal", "OBSERVATION_MODIFIER", 4, 11], ["unfolding", "OBSERVATION", 12, 21], ["reversible", "OBSERVATION_MODIFIER", 40, 50]]], ["The FTIR data show that heating of Hsp22 from 20 to 70 o C results in complete disappearance of \u03b1-helices (from 8-12% to 0) and the decrease in \u03b2-sheets content from 42 to 30%.", [["Hsp22", "CHEMICAL", 35, 40], ["Hsp22", "CHEMICAL", 35, 40], ["\u03b1-helices", "SIMPLE_CHEMICAL", 96, 105], ["Hsp22", "PROTEIN", 35, 40], ["\u03b2", "PROTEIN", 144, 145], ["The FTIR data", "TEST", 0, 13], ["Hsp22", "TEST", 35, 40], ["\u03b1-helices", "TEST", 96, 105], ["decrease", "OBSERVATION_MODIFIER", 132, 140]]], ["Studies on the temperature dependences of tryptophan fluorescence have shown a significant red shift of the spectrum.", [["tryptophan", "CHEMICAL", 42, 52], ["tryptophan", "CHEMICAL", 42, 52], ["tryptophan", "SIMPLE_CHEMICAL", 42, 52], ["the temperature dependences", "TEST", 11, 38], ["tryptophan fluorescence", "TEST", 42, 65], ["a significant red shift of the spectrum", "PROBLEM", 77, 116], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["red shift", "OBSERVATION", 91, 100]]], ["These changes occurred within temperature region from 30 to 80 o C with midpoint at \u223c56 o C. Probably, this transition can be explained by destruction of \u03b2-sheets around Trp96, the only Trp residue of the \u03b1-crystallin domain of Hsp22 (other 3 Trp residues of Hsp22 are localized in the N-terminal domain).", [["Trp", "CHEMICAL", 186, 189], ["Trp", "CHEMICAL", 243, 246], ["N", "CHEMICAL", 286, 287], ["Trp96", "GENE_OR_GENE_PRODUCT", 170, 175], ["Hsp22", "GENE_OR_GENE_PRODUCT", 228, 233], ["Hsp22", "GENE_OR_GENE_PRODUCT", 259, 264], ["\u03b2-sheets", "PROTEIN", 154, 162], ["Trp96", "PROTEIN", 170, 175], ["\u03b1-crystallin domain", "PROTEIN", 205, 224], ["Hsp22", "PROTEIN", 228, 233], ["3 Trp residues", "PROTEIN", 241, 255], ["Hsp22", "PROTEIN", 259, 264], ["N-terminal domain", "PROTEIN", 286, 303], ["These changes", "PROBLEM", 0, 13], ["destruction of \u03b2-sheets", "PROBLEM", 139, 162], ["Hsp22", "TEST", 228, 233], ["Trp residues", "TEST", 243, 255], ["Hsp22", "TEST", 259, 264], ["destruction", "OBSERVATION", 139, 150]]], ["The data obtained confirm the suggestion that Hsp22 is a protein, whose significant part is intrinsically disordered.", [["Hsp22", "GENE_OR_GENE_PRODUCT", 46, 51], ["Hsp22", "PROTEIN", 46, 51], ["The data", "TEST", 0, 8], ["Hsp22", "TEST", 46, 51], ["a protein", "TEST", 55, 64]]], ["We propose that, on heating, the \u03b1-crystallin domain containing \u03b2-sheets melts at higher temperature than the N-terminal domain containing the most of \u03b1-helices.Immobilization of encapsulated single protein molecules: A tool to study protein foldingT.", [["N", "CHEMICAL", 110, 111], ["\u03b1-helices", "GENE_OR_GENE_PRODUCT", 151, 160], ["\u03b1-crystallin domain", "PROTEIN", 33, 52], ["N-terminal domain", "PROTEIN", 110, 127], ["\u03b1-helices", "PROTEIN", 151, 160], ["protein molecules", "PROTEIN", 199, 216], ["T.", "SPECIES", 249, 251], ["heating", "TREATMENT", 20, 27], ["the \u03b1-crystallin domain", "TREATMENT", 29, 52], ["\u03b2-sheets melts", "TREATMENT", 64, 78], ["the N-terminal domain", "TREATMENT", 106, 127]]], ["Rosenkranz 1 , A. Katranidis 1 , D. Atta 1 , J. Enderlein 2 , I. Gregor 2 , M. Grzelakowski 3 , P. Rigler 3 , W. Meier 3 , J. Fitter 1 1 ISB-2: Molecular Biophysics, Research Centre J\u00fclich, Germany, 2 Institute of Physics, Biophysics/Complex Systems, Georg August University, G\u00f6ttingen, Germany, 3 Institut f\u00fcr Physikalische Chemie; Universit\u00e4t Basel, Basel, SwizerlandImmobilization of encapsulated single protein molecules: A tool to study protein foldingThe protein folding mechanism is the missing link in the biological flow of information from the DNA to its specific function.", [["DNA", "CELLULAR_COMPONENT", 554, 557], ["protein molecules", "PROTEIN", 407, 424], ["Chemie", "TEST", 325, 331], ["study protein folding", "TREATMENT", 436, 457], ["The protein folding mechanism", "PROBLEM", 457, 486]]], ["Since most of proteins within a cell consist of more than one domain studies on this protein class are of major importance.", [["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36]]], ["It is a common feature of multidomain proteins to aggregate under refolding conditions, which hinders a refolding.", [["multidomain proteins", "PROTEIN", 26, 46], ["multidomain proteins", "PROBLEM", 26, 46]]], ["Molecular encapsulation of single molecules prevents aggregation.", [["aggregation", "PROBLEM", 53, 64], ["encapsulation", "OBSERVATION", 10, 23], ["single molecules", "OBSERVATION", 27, 43], ["prevents", "UNCERTAINTY", 44, 52], ["aggregation", "OBSERVATION_MODIFIER", 53, 64]]], ["By immobilizing the nanocapsule the observation period in a wide field microscope will be extended, so that slow or rare folding events can be detected.", [["a wide field microscope", "TREATMENT", 58, 81], ["slow or rare folding events", "PROBLEM", 108, 135]]], ["A major goal of this study is to investigate polymeric vesicles with respect to their suitability for protein folding studies [1] .", [["vesicles", "ANATOMY", 55, 63], ["this study", "TEST", 16, 26], ["polymeric vesicles", "PROBLEM", 45, 63], ["protein folding studies", "TEST", 102, 125]]], ["Polymer vesicles maintain their structural integrity even under harsh unfolding conditions.", [["vesicles", "ANATOMY", 8, 16], ["Polymer vesicles", "PROBLEM", 0, 16], ["structural integrity", "OBSERVATION", 32, 52]]], ["Furthermore the nanocontainer proved to be permeable to guanidinium hydrochloride.", [["guanidinium hydrochloride", "CHEMICAL", 56, 81], ["guanidinium hydrochloride", "CHEMICAL", 56, 81], ["nanocontainer", "SIMPLE_CHEMICAL", 16, 29], ["guanidinium hydrochloride", "SIMPLE_CHEMICAL", 56, 81], ["guanidinium hydrochloride", "TREATMENT", 56, 81]]], ["Using encapsulated phoshoglycerate kinase, labeled with ATTO-655, a dye which experiences fluorescence quenching by photo-induced electron transfer (PET) with tryptophans, we demonstrate the remarkable properties of polymeric nanocontainers.", [["phoshoglycerate", "CHEMICAL", 19, 34], ["ATTO-655", "CHEMICAL", 56, 64], ["phoshoglycerate", "CHEMICAL", 19, 34], ["ATTO-655", "CHEMICAL", 56, 64], ["tryptophans", "CHEMICAL", 159, 170], ["phoshoglycerate", "SIMPLE_CHEMICAL", 19, 34], ["ATTO-655", "SIMPLE_CHEMICAL", 56, 64], ["electron", "SIMPLE_CHEMICAL", 130, 138], ["polymeric nanocontainers", "SIMPLE_CHEMICAL", 216, 240], ["phoshoglycerate kinase", "PROTEIN", 19, 41], ["ATTO", "TEST", 56, 60], ["a dye", "TREATMENT", 66, 71], ["fluorescence quenching", "TEST", 90, 112], ["tryptophans", "TREATMENT", 159, 170], ["polymeric nanocontainers", "TREATMENT", 216, 240], ["polymeric nanocontainers", "OBSERVATION", 216, 240]]], ["Applying PET as a folding probe we detected multiple unfolding/refolding transitions of single proteins.", [["single proteins", "PROTEIN", 88, 103], ["PET", "TREATMENT", 9, 12], ["a folding probe", "TREATMENT", 16, 31], ["multiple unfolding", "PROBLEM", 44, 62], ["single proteins", "PROBLEM", 88, 103], ["multiple", "OBSERVATION_MODIFIER", 44, 52], ["unfolding", "OBSERVATION", 53, 62]]], ["Proteins frequently become irreversibly modified by carbonylation, a process of introducing the carbonyl group (carbon monoxide) in a reaction with reactive oxygen species (ROS) such as superoxide, peroxide or ozone.", [["carbon monoxide", "CHEMICAL", 112, 127], ["oxygen", "CHEMICAL", 157, 163], ["ROS", "CHEMICAL", 173, 176], ["superoxide", "CHEMICAL", 186, 196], ["ozone", "CHEMICAL", 210, 215], ["carbonyl", "CHEMICAL", 96, 104], ["carbon monoxide", "CHEMICAL", 112, 127], ["oxygen", "CHEMICAL", 157, 163], ["superoxide", "CHEMICAL", 186, 196], ["peroxide", "CHEMICAL", 198, 206], ["ozone", "CHEMICAL", 210, 215], ["carbonyl", "SIMPLE_CHEMICAL", 96, 104], ["carbon monoxide", "SIMPLE_CHEMICAL", 112, 127], ["reactive oxygen species", "SIMPLE_CHEMICAL", 148, 171], ["ROS", "SIMPLE_CHEMICAL", 173, 176], ["superoxide", "SIMPLE_CHEMICAL", 186, 196], ["peroxide", "SIMPLE_CHEMICAL", 198, 206], ["ozone", "SIMPLE_CHEMICAL", 210, 215], ["the carbonyl group (carbon monoxide", "TREATMENT", 92, 127], ["a reaction", "PROBLEM", 132, 142], ["reactive oxygen species", "TREATMENT", 148, 171], ["superoxide, peroxide", "TREATMENT", 186, 206], ["irreversibly", "OBSERVATION_MODIFIER", 27, 39], ["reactive", "OBSERVATION_MODIFIER", 148, 156], ["oxygen species", "OBSERVATION", 157, 171]]], ["The main targets for carbonylation in proteins are amino-acid side chains of lysine, arginine and proline.", [["amino-acid", "CHEMICAL", 51, 61], ["lysine", "CHEMICAL", 77, 83], ["arginine", "CHEMICAL", 85, 93], ["proline", "CHEMICAL", 98, 105], ["amino-acid", "CHEMICAL", 51, 61], ["lysine", "CHEMICAL", 77, 83], ["arginine", "CHEMICAL", 85, 93], ["proline", "CHEMICAL", 98, 105], ["amino-acid", "SIMPLE_CHEMICAL", 51, 61], ["lysine", "AMINO_ACID", 77, 83], ["arginine", "AMINO_ACID", 85, 93], ["proline", "AMINO_ACID", 98, 105], ["carbonylation in proteins", "TREATMENT", 21, 46], ["amino-acid side chains of lysine", "TREATMENT", 51, 83], ["arginine and proline", "TREATMENT", 85, 105], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Products of carbonylation are aminoadipic semialdehyde from lysine (ASA) and glutamic semialdehyde (GSA) from arginine and proline.", [["aminoadipic semialdehyde", "CHEMICAL", 30, 54], ["lysine", "CHEMICAL", 60, 66], ["ASA", "CHEMICAL", 68, 71], ["glutamic semialdehyde", "CHEMICAL", 77, 98], ["arginine", "CHEMICAL", 110, 118], ["proline", "CHEMICAL", 123, 130], ["aminoadipic semialdehyde", "CHEMICAL", 30, 54], ["lysine", "CHEMICAL", 60, 66], ["ASA", "CHEMICAL", 68, 71], ["glutamic semialdehyde", "CHEMICAL", 77, 98], ["GSA", "CHEMICAL", 100, 103], ["arginine", "CHEMICAL", 110, 118], ["proline", "CHEMICAL", 123, 130], ["aminoadipic semialdehyde", "SIMPLE_CHEMICAL", 30, 54], ["lysine", "SIMPLE_CHEMICAL", 60, 66], ["ASA", "SIMPLE_CHEMICAL", 68, 71], ["glutamic semialdehyde", "SIMPLE_CHEMICAL", 77, 98], ["GSA", "SIMPLE_CHEMICAL", 100, 103], ["arginine", "AMINO_ACID", 110, 118], ["proline", "AMINO_ACID", 123, 130], ["carbonylation", "TREATMENT", 12, 25], ["aminoadipic semialdehyde from lysine (ASA", "TREATMENT", 30, 71], ["glutamic semialdehyde", "TEST", 77, 98], ["arginine and proline", "TREATMENT", 110, 130]]], ["Importantly, carbonylated proteins are marked for proteolysis by the proteasome, but can escape degradation and form aggregates that can be cytotoxic.", [["carbonylated proteins", "PROTEIN", 13, 34], ["proteasome", "PROTEIN", 69, 79], ["carbonylated proteins", "TEST", 13, 34], ["proteolysis", "PROBLEM", 50, 61], ["the proteasome", "TREATMENT", 65, 79]]], ["Carbonylation increases with the age of cells and it is associated with ageing and age related disorders such as Alzheimer's disease, Parkinson's disease and cancer.", [["cells", "ANATOMY", 40, 45], ["cancer", "ANATOMY", 158, 164], ["Alzheimer's disease", "DISEASE", 113, 132], ["Parkinson's disease", "DISEASE", 134, 153], ["cancer", "DISEASE", 158, 164], ["cells", "CELL", 40, 45], ["cancer", "CANCER", 158, 164], ["Carbonylation", "TREATMENT", 0, 13], ["age related disorders", "PROBLEM", 83, 104], ["Alzheimer's disease", "PROBLEM", 113, 132], ["Parkinson's disease", "PROBLEM", 134, 153], ["cancer", "PROBLEM", 158, 164], ["cancer", "OBSERVATION", 158, 164]]], ["We have used the molecular dynamics method to study the stability of carbonylated proteins villin headpiece and ubiquitin.", [["villin headpiece", "GENE_OR_GENE_PRODUCT", 91, 107], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 112, 121], ["carbonylated proteins", "PROTEIN", 69, 90], ["villin headpiece", "PROTEIN", 91, 107], ["ubiquitin", "PROTEIN", 112, 121], ["carbonylated proteins villin headpiece", "TREATMENT", 69, 107]]], ["Simulations were run after mutations of arginine, proline and lysine into GSA and ASA had been performed.", [["arginine", "CHEMICAL", 40, 48], ["proline", "CHEMICAL", 50, 57], ["lysine", "CHEMICAL", 62, 68], ["ASA", "CHEMICAL", 82, 85], ["arginine", "CHEMICAL", 40, 48], ["proline", "CHEMICAL", 50, 57], ["lysine", "CHEMICAL", 62, 68], ["ASA", "CHEMICAL", 82, 85], ["arginine", "AMINO_ACID", 40, 48], ["proline", "AMINO_ACID", 50, 57], ["lysine", "AMINO_ACID", 62, 68], ["GSA", "SIMPLE_CHEMICAL", 74, 77], ["ASA", "SIMPLE_CHEMICAL", 82, 85], ["mutations of arginine, proline and lysine into GSA", "TREATMENT", 27, 77], ["ASA", "TREATMENT", 82, 85]]], ["In addition, we have used thermodynamic integration on lysine, arginine, proline, ASA and GSA residues in order to estimate their solvation free energy (related to relative hydrophobicity and hydrophilicity).", [["lysine", "CHEMICAL", 55, 61], ["arginine", "CHEMICAL", 63, 71], ["proline", "CHEMICAL", 73, 80], ["ASA", "CHEMICAL", 82, 85], ["lysine", "CHEMICAL", 55, 61], ["arginine", "CHEMICAL", 63, 71], ["proline", "CHEMICAL", 73, 80], ["ASA", "CHEMICAL", 82, 85], ["lysine", "SIMPLE_CHEMICAL", 55, 61], ["arginine", "SIMPLE_CHEMICAL", 63, 71], ["proline", "AMINO_ACID", 73, 80], ["ASA", "SIMPLE_CHEMICAL", 82, 85], ["GSA", "SIMPLE_CHEMICAL", 90, 93], ["thermodynamic integration on lysine", "TREATMENT", 26, 61], ["arginine", "TREATMENT", 63, 71], ["proline", "TREATMENT", 73, 80], ["ASA", "TREATMENT", 82, 85], ["GSA residues", "TREATMENT", 90, 102], ["relative hydrophobicity and hydrophilicity", "PROBLEM", 164, 206]]], ["Our results suggest that carbonylation markedly decreases the overall stability of proteins, and that one potential reason for that may be a disruption of the balance between hydrophilic and hydrophobic regions in the protein.Structural characterisation and epitope binding activity of three meningococcal vaccine componentsA.", [["hydrophilic and hydrophobic regions", "PROTEIN", 175, 210], ["a disruption of the balance between hydrophilic and hydrophobic regions in the protein", "PROBLEM", 139, 225], ["three meningococcal vaccine components", "TREATMENT", 286, 324], ["carbonylation", "OBSERVATION", 25, 38], ["stability", "OBSERVATION_MODIFIER", 70, 79], ["disruption", "OBSERVATION", 141, 151], ["epitope binding", "OBSERVATION", 258, 273]]], ["Martino, D. Crane, I. M. Feavers, B. Bolgiano Division of Bacteriology, National Institute for Biological Standards and Control, Potters Bar, UKStructural characterisation and epitope binding activity of three meningococcal vaccine componentsThe sensitivity to protein's secondary structure and progress in computational calculations have made Circular Dichroism (CD) an attractive technique to explore the optical properties of three promising vaccine candidates to Neisseria meningitidis.", [["Neisseria meningitidis", "DISEASE", 467, 489], ["Neisseria meningitidis", "ORGANISM", 467, 489], ["Neisseria meningitidis", "SPECIES", 467, 489], ["Neisseria meningitidis", "SPECIES", 467, 489], ["Biological Standards", "TREATMENT", 95, 115], ["three meningococcal vaccine components", "TREATMENT", 204, 242], ["The sensitivity", "TEST", 242, 257], ["computational calculations", "TEST", 307, 333], ["Circular Dichroism", "PROBLEM", 344, 362], ["an attractive technique", "TREATMENT", 368, 391], ["Neisseria meningitidis", "PROBLEM", 467, 489]]], ["Clinical batches of a C-term deleted form of NadA (Genome-derived Neisseria Antigen -GNA1994) and the fusion proteins GNA2132-1030 (FP-1) and GNA2091-1870 (FP-2) were therefore studied.", [["NadA", "GENE_OR_GENE_PRODUCT", 45, 49], ["Genome-derived Neisseria Antigen -GNA1994", "GENE_OR_GENE_PRODUCT", 51, 92], ["FP-1", "GENE_OR_GENE_PRODUCT", 132, 136], ["FP-2", "GENE_OR_GENE_PRODUCT", 156, 160], ["C-term deleted form", "DNA", 22, 41], ["NadA", "PROTEIN", 45, 49], ["GNA1994", "PROTEIN", 85, 92], ["fusion proteins", "PROTEIN", 102, 117], ["GNA2132", "PROTEIN", 118, 125], ["NadA", "PROBLEM", 45, 49], ["Neisseria Antigen", "TEST", 66, 83], ["the fusion proteins GNA2132", "TEST", 98, 125], ["FP", "TEST", 132, 134], ["GNA2091", "TEST", 142, 149], ["FP", "TEST", 156, 158]]], ["Increases in temperature and denaturant concentration on secondary structures and folding/unfolding profile were monitored by CD in the far and near UV regions and complemented by Trp fluorescence spectroscopy data.", [["denaturant", "CHEMICAL", 29, 39], ["Trp", "CHEMICAL", 180, 183], ["Increases in temperature", "PROBLEM", 0, 24], ["denaturant concentration on secondary structures", "PROBLEM", 29, 77], ["folding/unfolding profile", "PROBLEM", 82, 107], ["Trp fluorescence spectroscopy data", "TEST", 180, 214], ["temperature", "OBSERVATION_MODIFIER", 13, 24], ["denaturant concentration", "OBSERVATION_MODIFIER", 29, 53]]], ["Furthermore, epitope conformational changes on binding activities to immune-sera were investigated.", [["sera", "ANATOMY", 76, 80], ["sera", "ORGANISM_SUBSTANCE", 76, 80], ["epitope conformational changes", "PROBLEM", 13, 43], ["immune-sera", "TREATMENT", 69, 80]]], ["The calculated secondary structure content was in broad agreement with the available predicted or solved protein structures.", [["The calculated secondary structure content", "PROBLEM", 0, 42], ["secondary", "OBSERVATION_MODIFIER", 15, 24], ["structure content", "OBSERVATION", 25, 42]]], ["Upon temperature incubation, a structural transition from a highly \u03b1-helical NadA to a more unordered conformation, with a mid point at \u223c40 \u2022 C, was observed.", [["NadA", "GENE_OR_GENE_PRODUCT", 77, 81], ["\u03b1-helical NadA", "PROTEIN", 67, 81], ["a structural transition", "PROBLEM", 29, 52]]], ["FP-1 and FP-2 maintained their conformation up to 50 \u2022 C or 6M GuHCl in the case of FP-1.", [["GuHCl", "CHEMICAL", 63, 68], ["FP-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["FP-2", "GENE_OR_GENE_PRODUCT", 9, 13], ["6M GuHCl", "SIMPLE_CHEMICAL", 60, 68], ["FP-1", "GENE_OR_GENE_PRODUCT", 84, 88], ["FP-1 and FP-2", "DNA", 0, 13], ["FP", "TEST", 0, 2], ["FP", "TEST", 9, 11], ["FP", "TEST", 84, 86]]], ["Unfolding was not always reversible.", [["not always", "UNCERTAINTY", 14, 24]]], ["Reductions in binding to monoclonal Ab titrated along with increasing unfolding.", [["monoclonal Ab", "PROTEIN", 25, 38], ["monoclonal Ab", "TREATMENT", 25, 38], ["increasing unfolding", "PROBLEM", 59, 79], ["increasing", "OBSERVATION_MODIFIER", 59, 69], ["unfolding", "OBSERVATION", 70, 79]]], ["Folding/unfolding studies have proven useful in better understanding the solution behaviour and extent of folding of proteins.P-670Cold denaturation of Yfh1 offers the clue to understand the effect of alcohols on protein stability S. R. Martin 1 , V. Esposito 1 , P. de los Rios 2 , A. Pastore 1 , P. A. Temussi 3 1 National Institute for Medical Research, The Ridgeway, NW7 1AA London, U.K., 2 Laboratoire de Biophysique Statistique, SB/ITP, Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland, 3 Dipartimento di Chimica, Universit\u00e0 di Napoli Federico II, Via Cinthia, I-80126 Napoli, ItalyP-670Although alcohols are well known to be protein denaturants when present at high concentrations, their effect on proteins at low concentrations is much less well characterized.", [["P-670", "CHEMICAL", 126, 131], ["Yfh1", "CHEMICAL", 152, 156], ["alcohols", "CHEMICAL", 201, 209], ["ITP", "DISEASE", 438, 441], ["ItalyP-670Although alcohols", "CHEMICAL", 614, 641], ["alcohols", "CHEMICAL", 201, 209], ["ItalyP-670Although alcohols", "CHEMICAL", 614, 641], ["Yfh1", "GENE_OR_GENE_PRODUCT", 152, 156], ["alcohols", "SIMPLE_CHEMICAL", 201, 209], ["ItalyP-670Although alcohols", "SIMPLE_CHEMICAL", 614, 641], ["Yfh1", "PROTEIN", 152, 156], ["Folding/unfolding studies", "TEST", 0, 25], ["folding of proteins", "PROBLEM", 106, 125], ["Cold denaturation of Yfh1", "PROBLEM", 131, 156], ["ItalyP", "TEST", 614, 620], ["protein denaturants", "PROBLEM", 663, 682], ["proteins at low concentrations", "PROBLEM", 736, 766], ["ITP", "OBSERVATION", 438, 441], ["low concentrations", "OBSERVATION_MODIFIER", 748, 766], ["much less well characterized", "OBSERVATION_MODIFIER", 770, 798]]], ["Here we present a study of the effects of alcohols on protein stability using Yfh1.", [["alcohols", "CHEMICAL", 42, 50], ["alcohols", "CHEMICAL", 42, 50], ["alcohols", "SIMPLE_CHEMICAL", 42, 50], ["Yfh1", "GENE_OR_GENE_PRODUCT", 78, 82], ["Yfh1", "PROTEIN", 78, 82], ["a study", "TEST", 16, 23]]], ["Exploiting the unusual property of this protein of undergoing cold denaturation around 0 \u2022 C without any ad hoc destabilization, we determined the stability curve on the basis of both high and low temperature unfolding in the presence of three commonly used alcohols: trifluoroethanol,ethanol methanol.", [["trifluoroethanol", "CHEMICAL", 268, 284], ["ethanol methanol", "CHEMICAL", 285, 301], ["alcohols", "CHEMICAL", 258, 266], ["trifluoroethanol", "CHEMICAL", 268, 284], ["ethanol methanol", "CHEMICAL", 285, 301], ["0 \u2022 C", "SIMPLE_CHEMICAL", 87, 92], ["alcohols", "SIMPLE_CHEMICAL", 258, 266], ["trifluoroethanol", "SIMPLE_CHEMICAL", 268, 284], ["ethanol methanol", "SIMPLE_CHEMICAL", 285, 301], ["cold denaturation", "PROBLEM", 62, 79], ["any ad hoc destabilization", "PROBLEM", 101, 127], ["both high and low temperature unfolding", "PROBLEM", 179, 218], ["trifluoroethanol", "TREATMENT", 268, 284], ["ethanol methanol", "TREATMENT", 285, 301], ["low temperature", "OBSERVATION_MODIFIER", 193, 208]]], ["In all cases, we observed an extended temperature range of protein stability as determined by a modest increase of the high temperature of unfolding but an appreciable decrease in the low temperature of unfolding.", [["the high temperature of unfolding", "PROBLEM", 115, 148], ["an appreciable decrease", "PROBLEM", 153, 176], ["the low temperature of unfolding", "PROBLEM", 180, 212], ["modest", "OBSERVATION_MODIFIER", 96, 102], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["high temperature", "OBSERVATION_MODIFIER", 119, 135], ["appreciable", "OBSERVATION_MODIFIER", 156, 167], ["decrease", "OBSERVATION_MODIFIER", 168, 176], ["low temperature", "OBSERVATION_MODIFIER", 184, 199]]], ["We suggest that alcohols, at low concentration and physiological pH, stabilize proteins by greatly widening the range of temperatures over which the protein is stable.", [["alcohols", "CHEMICAL", 16, 24], ["alcohols", "CHEMICAL", 16, 24], ["alcohols", "SIMPLE_CHEMICAL", 16, 24], ["alcohols", "TREATMENT", 16, 24], ["physiological pH", "TEST", 51, 67], ["the protein", "TEST", 145, 156], ["widening", "OBSERVATION_MODIFIER", 99, 107], ["stable", "OBSERVATION_MODIFIER", 160, 166]]], ["Our results also clarify the molecular mechanism of the interaction and validate the current theoretical interpretation of the mechanism of cold denaturation.", [["cold denaturation", "PROBLEM", 140, 157], ["cold denaturation", "OBSERVATION", 140, 157]]]], "6805a99a3c5a410c7729fc088e03c8c8f3ba8571": [["Letter to the Editor in Response to article: \"Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)Dear editor, We recently published an article highlighting the special concerns while managing patients with diabetes in the times of COVID-19 pandemic i .", [["diabetes", "DISEASE", 88, 96], ["diabetes", "DISEASE", 250, 258], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 236, 244], ["diabetes", "PROBLEM", 88, 96], ["COVID", "TEST", 109, 114], ["diabetes", "PROBLEM", 250, 258], ["COVID", "TEST", 275, 280]]], ["There have been some concerns about the use of Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), which were not clarified in our publication ii .", [["Angiotensin", "CHEMICAL", 47, 58], ["Angiotensin", "CHEMICAL", 98, 109], ["Angiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 47, 76], ["ACE", "GENE_OR_GENE_PRODUCT", 78, 81], ["Angiotensin Receptor Blockers", "SIMPLE_CHEMICAL", 98, 127], ["ARBs", "SIMPLE_CHEMICAL", 129, 133], ["Angiotensin Converting Enzyme (ACE) inhibitors", "TREATMENT", 47, 93], ["Angiotensin Receptor Blockers", "TREATMENT", 98, 127], ["ARBs", "TREATMENT", 129, 133]]], ["We are summarising the current evidence in this regard and will try to arrive at a reasonable conclusion.Letter to the Editor in Response to article: \"Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)In the absence of a vaccine and an antiviral drug for the COVID-19 infection, several therapeutic approaches are being studied.", [["diabetes", "DISEASE", 193, 201], ["infection", "DISEASE", 313, 322], ["patients", "ORGANISM", 179, 187], ["COVID-19", "ORGANISM", 304, 312], ["patients", "SPECIES", 179, 187], ["COVID-19", "SPECIES", 304, 312], ["diabetes", "PROBLEM", 193, 201], ["COVID", "TEST", 214, 219], ["a vaccine", "TREATMENT", 264, 273], ["an antiviral drug", "TREATMENT", 278, 295], ["the COVID-19 infection", "PROBLEM", 300, 322], ["several therapeutic approaches", "TREATMENT", 324, 354], ["infection", "OBSERVATION", 313, 322]]], ["One such approach is the use of inhibitors of the renin angiotensin system, namely ACE inhibitors and ARBs.", [["angiotensin", "CHEMICAL", 56, 67], ["renin angiotensin", "GENE_OR_GENE_PRODUCT", 50, 67], ["ACE", "GENE_OR_GENE_PRODUCT", 83, 86], ["ARBs", "SIMPLE_CHEMICAL", 102, 106], ["renin", "PROTEIN", 50, 55], ["inhibitors", "TREATMENT", 32, 42], ["the renin angiotensin system", "TREATMENT", 46, 74], ["ACE inhibitors", "TREATMENT", 83, 97], ["ARBs", "TREATMENT", 102, 106]]], ["On the other hand, some concern has been raised about the fact that patients on these agents might be at an increased risk of infection by Severe Acute Respiratory Syndrome coronavirus-2 (SARS CoV-2).Letter to the Editor in Response to article: \"Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)Angiotensin converting enzyme-2 (ACE-2) is the receptor for SARS CoV-2 as well as other coronaviruses and is expressed in type 2 alveolar epithelial cells and endothelium.", [["type 2 alveolar epithelial cells", "ANATOMY", 463, 495], ["endothelium", "ANATOMY", 500, 511], ["infection", "DISEASE", 126, 135], ["Acute Respiratory Syndrome coronavirus", "DISEASE", 146, 184], ["diabetes", "DISEASE", 288, 296], ["Angiotensin", "CHEMICAL", 341, 352], ["patients", "ORGANISM", 68, 76], ["Severe Acute Respiratory Syndrome coronavirus-2", "ORGANISM", 139, 186], ["patients", "ORGANISM", 274, 282], ["Angiotensin converting enzyme-2", "GENE_OR_GENE_PRODUCT", 341, 372], ["ACE-2", "GENE_OR_GENE_PRODUCT", 374, 379], ["SARS CoV-2", "GENE_OR_GENE_PRODUCT", 401, 411], ["coronaviruses", "ORGANISM", 429, 442], ["type 2 alveolar epithelial cells", "CELL", 463, 495], ["endothelium", "TISSUE", 500, 511], ["Angiotensin converting enzyme-2", "PROTEIN", 341, 372], ["ACE", "PROTEIN", 374, 377], ["type 2 alveolar epithelial cells", "CELL_TYPE", 463, 495], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 274, 282], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 139, 184], ["these agents", "TREATMENT", 80, 92], ["infection", "PROBLEM", 126, 135], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 139, 184], ["SARS CoV", "TEST", 188, 196], ["diabetes", "PROBLEM", 288, 296], ["COVID", "TEST", 309, 314], ["Angiotensin converting enzyme-2", "TREATMENT", 341, 372], ["ACE", "TEST", 374, 377], ["SARS CoV", "TEST", 401, 409], ["other coronaviruses", "PROBLEM", 423, 442], ["type 2 alveolar epithelial cells", "PROBLEM", 463, 495], ["infection", "OBSERVATION", 126, 135], ["Severe", "OBSERVATION_MODIFIER", 139, 145], ["Acute", "OBSERVATION_MODIFIER", 146, 151], ["Respiratory Syndrome coronavirus", "OBSERVATION", 152, 184], ["coronaviruses", "OBSERVATION", 429, 442], ["alveolar", "ANATOMY_MODIFIER", 470, 478], ["epithelial cells", "OBSERVATION", 479, 495], ["endothelium", "ANATOMY", 500, 511]]], ["The Sglycoprotein on the surface of coronavirus binds to ACE2.", [["surface", "ANATOMY", 25, 32], ["Sglycoprotein", "GENE_OR_GENE_PRODUCT", 4, 17], ["surface", "CELLULAR_COMPONENT", 25, 32], ["coronavirus", "ORGANISM", 36, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["Sglycoprotein", "PROTEIN", 4, 17], ["ACE2", "PROTEIN", 57, 61], ["The Sglycoprotein", "TREATMENT", 0, 17]]], ["This leads to a conformational change in the S-glycoprotein and allows proteolytic digestion by host cell proteases (TMPRSS2) ultimately leading to internalization of the virion iii .", [["cell", "ANATOMY", 101, 105], ["S-glycoprotein", "GENE_OR_GENE_PRODUCT", 45, 59], ["host cell proteases", "GENE_OR_GENE_PRODUCT", 96, 115], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 117, 124], ["S-glycoprotein", "PROTEIN", 45, 59], ["host cell proteases", "PROTEIN", 96, 115], ["TMPRSS2", "PROTEIN", 117, 124], ["a conformational change in the S-glycoprotein", "PROBLEM", 14, 59], ["proteolytic digestion", "TREATMENT", 71, 92], ["host cell proteases", "TREATMENT", 96, 115], ["host cell", "OBSERVATION", 96, 105], ["virion iii", "OBSERVATION", 171, 181]]], ["Viral S-glycoprotein, TMPRSS2 and ACE-2 inhibition are potential targets of therapy and possibly vaccine development.Letter to the Editor in Response to article: \"Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)As ACE-2 is essential to coronavirus infection, its blockade is thought to be beneficial in preventing/treating this infection.", [["diabetes", "DISEASE", 205, 213], ["coronavirus infection", "DISEASE", 283, 304], ["infection", "DISEASE", 375, 384], ["Viral", "ORGANISM", 0, 5], ["S-glycoprotein", "GENE_OR_GENE_PRODUCT", 6, 20], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 22, 29], ["ACE-2", "GENE_OR_GENE_PRODUCT", 34, 39], ["patients", "ORGANISM", 191, 199], ["ACE-2", "GENE_OR_GENE_PRODUCT", 261, 266], ["coronavirus", "ORGANISM", 283, 294], ["Viral S-glycoprotein", "PROTEIN", 0, 20], ["TMPRSS2", "PROTEIN", 22, 29], ["ACE", "PROTEIN", 34, 37], ["ACE", "PROTEIN", 261, 264], ["patients", "SPECIES", 191, 199], ["coronavirus", "SPECIES", 283, 294], ["Viral S-glycoprotein", "TREATMENT", 0, 20], ["TMPRSS2", "TREATMENT", 22, 29], ["ACE-2 inhibition", "TREATMENT", 34, 50], ["therapy", "TREATMENT", 76, 83], ["vaccine development", "TREATMENT", 97, 116], ["diabetes", "PROBLEM", 205, 213], ["COVID", "TEST", 226, 231], ["ACE", "TEST", 261, 264], ["coronavirus infection", "PROBLEM", 283, 304], ["its blockade", "TREATMENT", 306, 318], ["this infection", "PROBLEM", 370, 384], ["coronavirus", "OBSERVATION_MODIFIER", 283, 294], ["infection", "OBSERVATION", 295, 304], ["infection", "OBSERVATION", 375, 384]]], ["A retrospective analysis found reduced rates of death and endotracheal intubation in patients with viral pneumonia who were continued on ACE inhibitors iv .", [["endotracheal", "ANATOMY", 58, 70], ["death", "DISEASE", 48, 53], ["viral pneumonia", "DISEASE", 99, 114], ["ACE inhibitors", "CHEMICAL", 137, 151], ["patients", "ORGANISM", 85, 93], ["ACE", "GENE_OR_GENE_PRODUCT", 137, 140], ["patients", "SPECIES", 85, 93], ["A retrospective analysis", "TEST", 0, 24], ["reduced rates of death", "PROBLEM", 31, 53], ["endotracheal intubation", "TREATMENT", 58, 81], ["viral pneumonia", "PROBLEM", 99, 114], ["ACE inhibitors iv", "TREATMENT", 137, 154], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["endotracheal intubation", "OBSERVATION", 58, 81], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["pneumonia", "OBSERVATION", 105, 114]]], ["Mice with coronavirus induced lung injury showed improvement when treated with losartan v .", [["lung", "ANATOMY", 30, 34], ["coronavirus", "DISEASE", 10, 21], ["lung injury", "DISEASE", 30, 41], ["losartan", "CHEMICAL", 79, 87], ["losartan", "CHEMICAL", 79, 87], ["Mice", "ORGANISM", 0, 4], ["coronavirus", "ORGANISM", 10, 21], ["lung", "ORGAN", 30, 34], ["losartan", "SIMPLE_CHEMICAL", 79, 87], ["Mice", "SPECIES", 0, 4], ["coronavirus", "SPECIES", 10, 21], ["coronavirus induced lung injury", "PROBLEM", 10, 41], ["losartan v", "TREATMENT", 79, 89], ["coronavirus", "OBSERVATION", 10, 21], ["lung", "ANATOMY", 30, 34], ["injury", "OBSERVATION", 35, 41], ["improvement", "OBSERVATION_MODIFIER", 49, 60]]], ["As far as CVID-19 infection is concerned, the data on RAS activation or the effect of its blockade is limited at present.", [["CVID", "DISEASE", 10, 14], ["infection", "DISEASE", 18, 27], ["RAS", "GENE_OR_GENE_PRODUCT", 54, 57], ["CVID", "PROBLEM", 10, 14], ["infection", "PROBLEM", 18, 27], ["RAS activation", "TREATMENT", 54, 68], ["its blockade", "TREATMENT", 86, 98], ["infection", "OBSERVATION", 18, 27]]], ["Hypokalaemia could be a marker of RAS activation and high incidence of hypokalaemia has been reported in patients with COVID-19 infection vi .Letter to the Editor in Response to article: \"Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)Despite these small studies suggesting the benefit of drugs acting on RAS, there is some data, albeit scarce, from animal models and human studies that treatment with ACE inhibitors and ARB could cause up regulation of ACE2 vii .", [["Hypokalaemia", "DISEASE", 0, 12], ["hypokalaemia", "DISEASE", 71, 83], ["COVID-19", "CHEMICAL", 119, 127], ["infection", "DISEASE", 128, 137], ["diabetes", "DISEASE", 230, 238], ["ACE inhibitors", "CHEMICAL", 450, 464], ["ARB", "CHEMICAL", 469, 472], ["RAS", "GENE_OR_GENE_PRODUCT", 34, 37], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 216, 224], ["RAS", "GENE_OR_GENE_PRODUCT", 353, 356], ["human", "ORGANISM", 416, 421], ["ACE", "GENE_OR_GENE_PRODUCT", 450, 453], ["ARB", "SIMPLE_CHEMICAL", 469, 472], ["ACE2", "GENE_OR_GENE_PRODUCT", 502, 506], ["RAS", "PROTEIN", 34, 37], ["ACE2", "PROTEIN", 502, 506], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 216, 224], ["human", "SPECIES", 416, 421], ["human", "SPECIES", 416, 421], ["Hypokalaemia", "PROBLEM", 0, 12], ["RAS activation", "PROBLEM", 34, 48], ["hypokalaemia", "PROBLEM", 71, 83], ["COVID", "TEST", 119, 124], ["infection vi", "PROBLEM", 128, 140], ["diabetes", "PROBLEM", 230, 238], ["COVID", "TEST", 251, 256], ["these small studies", "TEST", 291, 310], ["drugs", "TREATMENT", 337, 342], ["human studies", "TEST", 416, 429], ["ACE inhibitors", "TREATMENT", 450, 464], ["ARB", "TREATMENT", 469, 472], ["high", "OBSERVATION_MODIFIER", 53, 57], ["hypokalaemia", "OBSERVATION", 71, 83], ["infection", "OBSERVATION", 128, 137]]], ["Ibuprofen and thiazolidinediones have also been shown to do the same viii,ix .", [["Ibuprofen", "CHEMICAL", 0, 9], ["thiazolidinediones", "CHEMICAL", 14, 32], ["Ibuprofen", "CHEMICAL", 0, 9], ["thiazolidinediones", "CHEMICAL", 14, 32], ["Ibuprofen", "SIMPLE_CHEMICAL", 0, 9], ["thiazolidinediones", "SIMPLE_CHEMICAL", 14, 32], ["Ibuprofen", "TREATMENT", 0, 9], ["thiazolidinediones", "TREATMENT", 14, 32]]], ["Increased expression of ACE2 could theoretically increase the risk of infection with SARS CoV-2.", [["infection", "DISEASE", 70, 79], ["SARS", "DISEASE", 85, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["CoV-2", "GENE_OR_GENE_PRODUCT", 90, 95], ["ACE2", "PROTEIN", 24, 28], ["SARS CoV", "SPECIES", 85, 93], ["ACE2", "PROBLEM", 24, 28], ["infection", "PROBLEM", 70, 79], ["SARS CoV", "TEST", 85, 93], ["infection", "OBSERVATION", 70, 79]]], ["This could be a concern in people with diabetes who are at already elevated risk of infections because of many other factors.", [["diabetes", "DISEASE", 39, 47], ["infections", "DISEASE", 84, 94], ["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["diabetes", "PROBLEM", 39, 47], ["infections", "PROBLEM", 84, 94], ["infections", "OBSERVATION", 84, 94]]], ["However, currently, there is no evidence to support this hypothesis.", [["this hypothesis", "PROBLEM", 52, 67], ["no evidence to", "UNCERTAINTY", 29, 43]]], ["In view of lack of robust evidence for either benefit or harm, it is reasonable for patients to continue using ACE inhibitors and ARB, as recommended by European Society of Cardiology Council on Hypertension and European Society of Hypertension. x,xi .Ritesh GuptaFortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India Correspondence to: riteshgupta72@gmail.com", [["ACE inhibitors", "CHEMICAL", 111, 125], ["ARB", "CHEMICAL", 130, 133], ["Hypertension", "DISEASE", 195, 207], ["Hypertension", "DISEASE", 232, 244], ["Diabetes", "DISEASE", 289, 297], ["patients", "ORGANISM", 84, 92], ["ACE", "GENE_OR_GENE_PRODUCT", 111, 114], ["ARB", "SIMPLE_CHEMICAL", 130, 133], ["patients", "SPECIES", 84, 92], ["ACE inhibitors", "TREATMENT", 111, 125], ["ARB", "TREATMENT", 130, 133], ["Hypertension", "PROBLEM", 195, 207], ["Hypertension", "PROBLEM", 232, 244], ["Diabetes", "PROBLEM", 289, 297], ["Hypertension", "OBSERVATION", 195, 207], ["Hypertension", "OBSERVATION", 232, 244]]]], "62a1f5bb2940b4c4c29338c8f9fc47fd431aed28": [["Avian Influenza AThe identification of transmission clusters is irrelevant in flu as the virus is transmitted so rapidly and so frequently that it is highly unlikely that transmission pairs will be sampled.", [["Avian", "ORGANISM", 0, 5], ["Avian Influenza", "SPECIES", 0, 15], ["transmission clusters", "PROBLEM", 39, 60], ["flu", "PROBLEM", 78, 81], ["the virus", "PROBLEM", 85, 94], ["transmission pairs", "PROBLEM", 171, 189], ["highly unlikely", "UNCERTAINTY", 150, 165]]], ["Instead, we have used the CP to down sample a dataset of sequences while maintaining its full genetic diversity.", [["the CP", "PROBLEM", 22, 28]]], ["This might be useful for downstream analyses in BEAST [3] , or to investigate the effects of sampling.", [["downstream analyses", "TEST", 25, 44]]], ["In the present analysis, the CP was run with the aim of downsizing the dataset from 2989 sequences to ~150.", [["the CP", "PROBLEM", 25, 31]]], ["All PB2 avian influenza A sequences were downloaded from NCBI Influenza Virus Resource [4] , duplicate sequences were removed, and a phylogenetic tree reconstructed in FastTree.", [["PB2 avian influenza A", "ORGANISM", 4, 25], ["PB2 avian influenza A sequences", "DNA", 4, 35], ["FastTree", "DNA", 168, 176], ["PB2 avian influenza", "SPECIES", 4, 23], ["PB2 avian influenza A", "SPECIES", 4, 25], ["All PB2 avian influenza A sequences", "PROBLEM", 0, 35], ["duplicate sequences", "TEST", 93, 112]]], ["The CP was run with a series of thresholds (using the command line version) until we found a threshold which maximized inclusion of sequences in ~150 clusters.", [["The CP", "PROBLEM", 0, 6], ["the command line version", "TREATMENT", 50, 74], ["a threshold", "PROBLEM", 91, 102]]], ["70% bootstrap and 6% genetic distance thresholds yielded 158 clusters containing 98% of sequences.", [["bootstrap", "TEST", 4, 13], ["genetic distance thresholds", "TEST", 21, 48]]], ["A single sequence from each cluster was selected for further analysis (L. Lu, manuscript in preparation).Figure S1.2: Example Avian Influenza clustersWe used the CP in a BEAST Maximum Clade Credibility (MCC) [3] tree comprising 492 full genome H1N1 human pandemic sequences (segments concatenated, excluding PB1), mostly from the Spring and Fall waves of the pandemic (2009-2010).", [["human", "ORGANISM", 249, 254], ["PB1", "DNA", 308, 311], ["H1N1", "SPECIES", 244, 248], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["A single sequence", "TEST", 0, 17], ["further analysis", "TEST", 53, 69], ["the CP", "PROBLEM", 158, 164], ["full genome H1N1 human pandemic sequences", "TREATMENT", 232, 273], ["PB1", "TEST", 308, 311]]], ["Details of the sequences and BEAST tree models can be found in the original publication [5] .", [["the sequences", "TEST", 11, 24]]], ["The BEAST MCC tree was generated with Tree Annotator (distributed with BEAST) in the extended nexus format, and was converted into a newick format with the posterior probabilities encoded as support values at the nodes using an R script MCC_to_NWK.R (see the Tutorial files).", [["BEAST MCC tree", "DNA", 4, 18], ["MCC tree", "OBSERVATION", 10, 18], ["nodes", "OBSERVATION", 213, 218]]], ["Initial and main support thresholds of 0.7 were used together with a genetic distance threshold of 2%.", [["a genetic distance threshold", "TEST", 67, 95]]], ["These resulted in three large clusters, broadly corresponding to the initial clades present in the USA at the start of the pandemic as determined by hand on a maximum likelihood tree on USA only data [6] .", [["hand", "ORGANISM_SUBDIVISION", 149, 153], ["the initial clades", "PROBLEM", 65, 83], ["large", "OBSERVATION_MODIFIER", 24, 29], ["clusters", "OBSERVATION", 30, 38]]], ["The largest of these clusters (Cluster3, purple) corresponds to \"Global Clade 7\", which became dominant in Wave 2 of the pandemic.", [["the pandemic", "PROBLEM", 117, 129], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["clusters", "OBSERVATION_MODIFIER", 21, 29], ["purple", "OBSERVATION_MODIFIER", 41, 47], ["Global", "OBSERVATION_MODIFIER", 65, 71], ["Clade", "OBSERVATION_MODIFIER", 72, 77], ["dominant", "OBSERVATION_MODIFIER", 95, 103], ["Wave", "OBSERVATION_MODIFIER", 107, 111], ["pandemic", "OBSERVATION_MODIFIER", 121, 129]]], ["A data set comprising 1027 H3N2 human seasonal influenza full length haemagglutinin sequences, from 2004 -2012 was obtained from the NCBI Influenza Virus Resource [4] .", [["Influenza Virus", "DISEASE", 138, 153], ["1027 H3N2", "ORGANISM", 22, 31], ["human", "ORGANISM", 32, 37], ["1027 H3N2 human seasonal influenza full length haemagglutinin sequences", "DNA", 22, 93], ["H3N2", "SPECIES", 27, 31], ["human", "SPECIES", 32, 37], ["seasonal influenza", "SPECIES", 38, 56], ["human", "SPECIES", 32, 37], ["A data", "TEST", 0, 6], ["H3N2 human seasonal influenza full length haemagglutinin sequences", "TEST", 27, 93]]], ["Sequences from each isolate were classified by global region (North, Tropical and South), continent and year, similar to the H3N2 Global Migration Dynamics study by Bedford et al [7] .", [["Sequences from each isolate", "TEST", 0, 27]]], ["Time resolved trees were generated using BEAST with the SRD06 nucleotide model, the relaxed lognormal uncorrelated clock and constant population size.", [["nucleotide", "CHEMICAL", 62, 72], ["the SRD06 nucleotide model", "TREATMENT", 52, 78], ["uncorrelated clock", "OBSERVATION", 102, 120], ["constant", "OBSERVATION_MODIFIER", 125, 133], ["population", "OBSERVATION_MODIFIER", 134, 144], ["size", "OBSERVATION_MODIFIER", 145, 149]]], ["Two independent runs of 500,000,000 MCMC samples (step 10,000) were combined, and the final MCC tree was converted to newick format (using MCC_to_NWK.R).", [["samples", "ANATOMY", 41, 48], ["R", "GENE_OR_GENE_PRODUCT", 150, 151], ["MCC_to_NWK", "TREATMENT", 139, 149]]], ["The CP was used with initial and main support thresholds of 0.7, and genetic distance threshold of 2% to reveal 93 clusters, including 76% of the sequences.", [["genetic distance threshold", "TEST", 69, 95], ["the sequences", "TEST", 142, 155]]], ["The composition of the clusters was analyzed with the CM.", [["CM", "DISEASE", 54, 56]]], ["We found that on average 76% of the sequences in a large cluster (>= 20 sequences) were isolated in the same year, 72% of them were isolated in the same global region (North, Tropical, South) but only 66% in the same continent.", [["the sequences", "TEST", 32, 45], ["large", "OBSERVATION_MODIFIER", 51, 56], ["global", "ANATOMY_MODIFIER", 153, 159], ["region", "ANATOMY_MODIFIER", 160, 166], ["North", "OBSERVATION_MODIFIER", 168, 173]]]], "8584d403a7d4378257a8805ab67454ad1e902dfc": [["IntroductionThe food market demands new technologies, which are essential to keep market leadership in the food processing industry to produce fresh, authentic, convenient, and flavorful food products, prolonging the product's shelf life and freshness with improved quality food (Alfadul and Elneshwy 2010) .", [["flavorful food products", "TREATMENT", 177, 200]]], ["The new materials, products, and applications are anticipated to bring lots of advancements and improvements to the food and relevant sectors, impacting agriculture and food production, food processing, distribution, storage, nanoadditives, cleaning, and sensors for the detection of contaminants and developments of innovative products.", [["nanoadditives", "TREATMENT", 226, 239], ["cleaning", "TREATMENT", 241, 249], ["the detection", "TEST", 267, 280], ["contaminants", "PROBLEM", 284, 296], ["innovative products", "TREATMENT", 317, 336], ["new", "OBSERVATION_MODIFIER", 4, 7], ["materials", "OBSERVATION_MODIFIER", 8, 17]]], ["Nanotechnology is an area of rising attention and unwraps new possibilities for the food industry.", [["rising attention", "PROBLEM", 29, 45], ["area", "OBSERVATION_MODIFIER", 21, 25], ["rising", "OBSERVATION_MODIFIER", 29, 35]]], ["There are suggestions that consumers should remain cautious about using nanofoods.", [["nanofoods", "SIMPLE_CHEMICAL", 72, 81], ["nanofoods", "TREATMENT", 72, 81]]], ["Food undergoes a variety of modifications in postharvest and processing that are likely to affect its biological and biochemical features, and here, nanotechnology developments could eventually also influence the food industry.IntroductionAccording to a definition in a report by the European Nanotechnology Gateway, a food is called nanofood when nanoparticles, or nanotechnology techniques, are used during cultivation, production, processing, or packaging of the food (Nanowerk 2019).", [["modifications in postharvest", "TREATMENT", 28, 56], ["nanoparticles", "TREATMENT", 348, 361], ["nanotechnology techniques", "TREATMENT", 366, 391], ["variety", "OBSERVATION_MODIFIER", 17, 24]]], ["It should be made clear here that it does not mean that it is atomically modified food or produced by nanomachines.IntroductionApplications of nano include smart packaging, on-demand preservatives, and interactive foods.", [["smart packaging", "TREATMENT", 156, 171], ["demand preservatives", "TREATMENT", 176, 196]]], ["There are many positive impacts of nanotechnology in the food industry, and these are expected to grow in the near future.", [["many", "OBSERVATION_MODIFIER", 10, 14], ["positive", "OBSERVATION_MODIFIER", 15, 23], ["impacts", "OBSERVATION_MODIFIER", 24, 31]]], ["Applications of nanomaterials will continue to affect the food industry commercially because of their unique and novel properties.", [["nanomaterials", "TREATMENT", 16, 29]]], ["New nanomaterials are developed that will make not only a difference in the taste of food but also safety and the health benefits that food is bound to deliver.", [["New nanomaterials", "PROBLEM", 0, 17], ["nanomaterials", "OBSERVATION", 4, 17]]], ["Therefore, nanotechnology may play a potential role in promoting the food industry.Applications of Food NanotechnologyNanotechnology is the science of very small materials, and it can have a big impact in the food industry.", [["very small materials", "PROBLEM", 151, 171]]], ["Nanotechnology possesses a great potential in ensuring modification of color and flavor and nutritional values, increasing the shelf life of food, and monitoring the integrity of food via barcodes such as cold chain, i.e., whenever there is a slight change in food storage conditions because of its submicroscopic nature (Aigbogun et al. 2017) .", [["a slight change in food storage conditions", "PROBLEM", 241, 283], ["great potential", "OBSERVATION_MODIFIER", 27, 42], ["slight", "OBSERVATION_MODIFIER", 243, 249], ["change", "OBSERVATION_MODIFIER", 250, 256]]], ["It is an emerging area of science with potentials to generate radical new products and processes in the food sector.", [["radical new products", "TREATMENT", 62, 82]]], ["It is commonly distinguished between two forms of nanofood applications:Applications of Food Nanotechnology\u2022 Food additives (nano inside) \u2022 Food packaging (nano outside) Concepts in nanotechnology provide a sound framework for better understanding of the interactions and assembly behavior of food components into microstructures, which is likely to affect food structure, rheology, and functional properties at the submicroscopic scale (Sanguansri and Augustin 2006) .", [["likely to", "UNCERTAINTY", 340, 349]]], ["It can also modify permeation of materials by the incorporation of synthesized nanoparticles (zinc, silver, gold, etc.) for improved packaging system ( Fig. 24.1 ).Food ProcessingFood processing deals with transformation of agricultural/animal products into food.", [["zinc, silver", "CHEMICAL", 94, 106], ["zinc", "CHEMICAL", 94, 98], ["silver", "CHEMICAL", 100, 106], ["nanoparticles", "SIMPLE_CHEMICAL", 79, 92], ["zinc", "SIMPLE_CHEMICAL", 94, 98], ["silver", "SIMPLE_CHEMICAL", 100, 106], ["gold", "SIMPLE_CHEMICAL", 108, 112], ["permeation of materials", "TREATMENT", 19, 42], ["the incorporation of synthesized nanoparticles (zinc, silver, gold", "TREATMENT", 46, 112], ["agricultural/animal products", "TREATMENT", 224, 252]]], ["It also includes many forms of processing foods ranging from grinding grain to make raw flour for home cooking to complex industrial methods used to make convenience foods.", [["processing foods", "PROBLEM", 31, 47]]], ["Food processing can be improved much in the aspects of smart delivery of nutrients, nanoencapsulation of nutraceuticals, bioseparation of proteins, rapid sampling of biological and chemical contaminants, solubilization, delivery, and color in food systems.", [["smart delivery of nutrients", "TREATMENT", 55, 82], ["nanoencapsulation of nutraceuticals", "TREATMENT", 84, 119], ["bioseparation of proteins", "PROBLEM", 121, 146], ["biological and chemical contaminants", "TREATMENT", 166, 202], ["solubilization", "TREATMENT", 204, 218], ["delivery", "TREATMENT", 220, 228], ["improved", "OBSERVATION_MODIFIER", 23, 31], ["chemical contaminants", "OBSERVATION", 181, 202]]], ["Nanotechnology can assist in the development of functional or interactive foods, which respond to requirements of the human body and can deliver these nutrients more efficiently.", [["body", "ANATOMY", 124, 128], ["human", "ORGANISM", 118, 123], ["body", "ORGANISM_SUBDIVISION", 124, 128], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 118, 123], ["the human body", "TREATMENT", 114, 128]]], ["Various research groups are also developing new on-demand foods, which will remain dormant in the body and deliver nutrients to cells as and when needed.", [["body", "ANATOMY", 98, 102], ["cells", "ANATOMY", 128, 133], ["body", "ORGANISM_SUBDIVISION", 98, 102], ["cells", "CELL", 128, 133], ["new", "OBSERVATION_MODIFIER", 44, 47], ["body", "ANATOMY", 98, 102]]], ["The concept is that thousands of nanocapsules containing flavor or color enhancers, or added nutritional elements (such as vitamins), would remain dormant in the food and these will be released only, when triggered by the consumer (Amin et al. 2015) .", [["nanocapsules", "SIMPLE_CHEMICAL", 33, 45], ["vitamins", "SIMPLE_CHEMICAL", 123, 131], ["nanocapsules containing flavor", "TREATMENT", 33, 63], ["color enhancers", "PROBLEM", 67, 82], ["vitamins)", "TREATMENT", 123, 132]]], ["A key element in this sector is the development of nanocapsules that can be incorporated into food to deliver nutrients timely.", [["nanocapsules", "SIMPLE_CHEMICAL", 51, 63], ["nanocapsules", "TREATMENT", 51, 63], ["element", "OBSERVATION_MODIFIER", 6, 13], ["nanocapsules", "OBSERVATION", 51, 63]]], ["Other developments in food processing include the addition of nanoparticles to existing foods to enable increased absorption of nutrients.", [["nanoparticles", "TREATMENT", 62, 75], ["increased absorption of nutrients", "TREATMENT", 104, 137]]], ["One of the bakeries in Western Australia is quite successful in incorporating tuna fish oil (a source of omega-3 fatty acids) in nanocapsules in their top-selling product \"Tip-Top\" Up bread (Bund 2008) .", [["oil", "ANATOMY", 88, 91], ["omega-3 fatty acids", "CHEMICAL", 105, 124], ["omega-3 fatty acids", "CHEMICAL", 105, 124], ["fish", "ORGANISM", 83, 87], ["oil", "ORGANISM_SUBSTANCE", 88, 91], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 105, 124], ["nanocapsules", "SIMPLE_CHEMICAL", 129, 141], ["omega-3 fatty acids", "TREATMENT", 105, 124]]], ["The microcapsules are designed to break open only when they have reached the stomach, thus avoiding the unpleasant taste of the fish oil.Food ProcessingIn this aspect, food and cosmetic companies are already working together to develop newer mechanisms to deliver vitamins directly to the skin.", [["stomach", "ANATOMY", 77, 84], ["oil", "ANATOMY", 133, 136], ["skin", "ANATOMY", 289, 293], ["stomach", "ORGAN", 77, 84], ["fish", "ORGANISM", 128, 132], ["oil", "ORGANISM_SUBSTANCE", 133, 136], ["vitamins", "SIMPLE_CHEMICAL", 264, 272], ["skin", "ORGAN", 289, 293], ["The microcapsules", "TREATMENT", 0, 17], ["the fish oil", "TREATMENT", 124, 136], ["vitamins", "TREATMENT", 264, 272], ["stomach", "ANATOMY", 77, 84], ["skin", "ANATOMY", 289, 293]]], ["Nestl\u00e9, having 49% stake in L'Or\u00e9al, is developing transparent sun creams so that vitamin E is delivered directly to the skin.", [["skin", "ANATOMY", 121, 125], ["vitamin E", "CHEMICAL", 82, 91], ["vitamin E", "CHEMICAL", 82, 91], ["vitamin E", "SIMPLE_CHEMICAL", 82, 91], ["skin", "ORGAN", 121, 125], ["transparent sun creams", "TREATMENT", 51, 73], ["vitamin E", "TREATMENT", 82, 91], ["skin", "ANATOMY", 121, 125]]], ["The major objective is to manufacture a cream which is first absorbed by the skin and then releases vitamin E slowly, apart from providing protection against UV.", [["skin", "ANATOMY", 77, 81], ["vitamin E", "CHEMICAL", 100, 109], ["vitamin E", "CHEMICAL", 100, 109], ["skin", "ORGAN", 77, 81], ["vitamin E", "SIMPLE_CHEMICAL", 100, 109], ["a cream", "TREATMENT", 38, 45], ["vitamin E", "TREATMENT", 100, 109], ["skin", "ANATOMY", 77, 81]]], ["While Est\u00e9e Lauder is manufacturing antiaging formulations making use of nanoparticles (Joseph and Morrison 2006) , Unilever is developing ice creams with low fat by decreasing the size of emulsion particles, which is responsible for its texture.", [["fat", "ANATOMY", 159, 162], ["Est\u00e9e", "CHEMICAL", 6, 11], ["fat", "TISSUE", 159, 162], ["ice creams", "TREATMENT", 139, 149], ["low fat", "OBSERVATION_MODIFIER", 155, 162], ["size", "OBSERVATION_MODIFIER", 181, 185], ["emulsion particles", "OBSERVATION", 189, 207]]], ["It is hoped that up to 90% less of the emulsion will be used and that will decrease fat content from 16% to about 1% (Verma and Gupta 2017).NanosensorsNanosensors are devices that can measure physical quantities and convert those quantities to respective signals that can be detected and analyzed.", [["fat", "ANATOMY", 84, 87], ["fat", "TISSUE", 84, 87], ["fat content", "TEST", 84, 95], ["NanosensorsNanosensors are devices", "TREATMENT", 140, 174]]], ["These nanosensors are diagnostic devices to monitor the quality of food processes and also safety of food.", [["diagnostic devices", "TREATMENT", 22, 40]]], ["Such nanosensors are used for the detection of very minute amounts of any chemical pollutant, virus, or bacteria in food systems.", [["the detection", "TEST", 30, 43], ["any chemical pollutant, virus", "PROBLEM", 70, 99], ["bacteria in food systems", "PROBLEM", 104, 128]]], ["There is a possibility of combining biology with nanoscale technology in fabrication of sensors with a great potential of higher sensitivity and reduced response time.", [["nanoscale technology", "TREATMENT", 49, 69], ["fabrication of sensors", "TREATMENT", 73, 95], ["higher sensitivity", "PROBLEM", 122, 140]]], ["Nanoparticles may selectively attach themselves to food pathogens, and even traces of harmful pathogens could be detected with sensors using either infrared light or magnetic materials.", [["Nanoparticles", "TREATMENT", 0, 13], ["harmful pathogens", "PROBLEM", 86, 103]]], ["It is advantageous that numerous nanoparticles can be placed on a single nanosensor so as to detect the presence of different bacteria and pathogens rapidly and accurately also.", [["numerous nanoparticles", "TREATMENT", 24, 46], ["different bacteria", "PROBLEM", 116, 134], ["pathogens", "PROBLEM", 139, 148], ["different", "OBSERVATION_MODIFIER", 116, 125], ["bacteria", "OBSERVATION", 126, 134]]], ["Another advantage is that nanosensors can gain access into the tiny crevices because of its small size, where the pathogens often used to hide, and nanotechnology will reduce the time taken for this detection from days to a few hours, minutes, or even seconds (Choudhury and Goswami 2012) .", [["the tiny crevices", "PROBLEM", 59, 76], ["its small size", "PROBLEM", 88, 102], ["the pathogens", "PROBLEM", 110, 123], ["this detection", "TEST", 194, 208], ["tiny", "OBSERVATION_MODIFIER", 63, 67], ["small", "OBSERVATION_MODIFIER", 92, 97], ["size", "OBSERVATION_MODIFIER", 98, 102]]], ["Nanotechnology utilizes biological molecules like sugars or proteins as target-recognition groups for nanostructures as biosensors (Charych et al. 1996) .", [["sugars", "CHEMICAL", 50, 56], ["sugars", "SIMPLE_CHEMICAL", 50, 56]]], ["These biosensors could serve as detectors of food pathogens and other contaminants and also to track food products.NanosensorsNanosensors may play a significant role in detection of any traces of pesticide available in various food products, providing a potent solution to food safety.", [["food pathogens", "PROBLEM", 45, 59], ["NanosensorsNanosensors", "TREATMENT", 115, 137], ["a potent solution", "TREATMENT", 252, 269]]], ["These are of significant importance as such devices are capable for finding out and detect very minute quantity of organic compounds, very low concentration of pathogens, and other harmful chemicals.", [["such devices", "TREATMENT", 39, 51], ["organic compounds", "PROBLEM", 115, 132], ["pathogens", "PROBLEM", 160, 169], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["organic compounds", "OBSERVATION", 115, 132], ["low concentration", "OBSERVATION_MODIFIER", 139, 156]]], ["These devices show extraordinary sensitivity, quick response, and rescue Yalcin and Otles 2010) .", [["extraordinary", "OBSERVATION_MODIFIER", 19, 32]]], ["Mostly, nanosensors are used in recognition of pesticide as organophosphate in plants, fruits, and aquatics.", [["fruits", "ANATOMY", 87, 93], ["organophosphate", "CHEMICAL", 60, 75], ["organophosphate", "CHEMICAL", 60, 75], ["organophosphate", "SIMPLE_CHEMICAL", 60, 75], ["fruits", "ORGANISM_SUBDIVISION", 87, 93], ["nanosensors", "TREATMENT", 8, 19]]], ["There is significant importance in analysis of residue of highly sensitive pollutants (Mclaren et al. 2009 ).", [["highly sensitive pollutants", "PROBLEM", 58, 85], ["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["Nanosensors devices have benefits over other techniques like gas/liquid chromatography and mass spectroscopy, because they contain high surface to volume ratios, primarily loading of more antibody/enzymes (great sensitivity interface), less recognition limits, exceptional selectivity with small size, and quick response.", [["surface", "ANATOMY", 136, 143], ["antibody", "PROTEIN", 188, 196], ["enzymes", "PROTEIN", 197, 204], ["Nanosensors devices", "TREATMENT", 0, 19], ["other techniques", "TEST", 39, 55], ["gas/liquid chromatography", "TEST", 61, 86], ["mass spectroscopy", "TEST", 91, 108], ["volume ratios", "TEST", 147, 160], ["more antibody/enzymes", "TEST", 183, 204], ["high", "OBSERVATION_MODIFIER", 131, 135], ["surface", "OBSERVATION_MODIFIER", 136, 143], ["small", "OBSERVATION_MODIFIER", 290, 295], ["size", "OBSERVATION_MODIFIER", 296, 300]]], ["It has been known that the use of these nanosized materials is likely to enhance the sensitive transducer indication or signals.", [["these nanosized materials", "TREATMENT", 34, 59], ["nanosized materials", "OBSERVATION", 40, 59], ["is likely", "UNCERTAINTY", 60, 69]]], ["Carbon nanotubes semiconductor and metal nanostructures have exceptional electrical or optical characteristics (Hwang et al. 2011 ).", [["Carbon nanotubes", "CHEMICAL", 0, 16], ["Carbon", "CHEMICAL", 0, 6], ["Carbon nanotubes semiconductor", "TREATMENT", 0, 30], ["metal nanostructures", "TREATMENT", 35, 55], ["nanotubes semiconductor", "OBSERVATION", 7, 30]]], ["Intelligent packing is another aspect, where covering a nano-biosensor makes these to fluoresce in various colors on interaction with different pathogens of food materials.", [["Intelligent packing", "TREATMENT", 0, 19], ["packing", "OBSERVATION", 12, 19]]], ["Various types of devices have been developed to identify contaminants, chemicals, and pathogens in food materials.", [["devices", "TREATMENT", 17, 24], ["pathogens in food materials", "PROBLEM", 86, 113], ["devices", "OBSERVATION", 17, 24]]], ["Such device is highly sensitive in identifying E. coli and Salmonella (Chen et al. 2008) .NanosensorsTraditional methods to screen food to find disease-causing microbes can take as long a day, which are normally very slow so that they may or may not be able to efficiently catch tainted products.", [["E. coli", "ORGANISM", 47, 54], ["E. coli", "SPECIES", 47, 54], ["E. coli", "SPECIES", 47, 54], ["Such device", "TREATMENT", 0, 11], ["E. coli", "PROBLEM", 47, 54], ["Salmonella", "PROBLEM", 59, 69], ["disease", "PROBLEM", 144, 151]]], ["However, some faster methods are known, but they have their own limitations.", [["faster", "OBSERVATION_MODIFIER", 14, 20]]], ["Magnetic resonance can detect extremely low levels of bacteria, but it is almost ineffective at higher bacteria concentrations, while fluorescence is opposite.", [["Magnetic resonance", "TEST", 0, 18], ["extremely low levels of bacteria", "PROBLEM", 30, 62], ["higher bacteria concentrations", "PROBLEM", 96, 126], ["low levels", "OBSERVATION_MODIFIER", 40, 50], ["bacteria", "OBSERVATION", 54, 62], ["ineffective", "OBSERVATION_MODIFIER", 81, 92], ["bacteria concentrations", "OBSERVATION", 103, 126]]], ["A hybrid nanosensor incorporating magnetic resonance and fluorescence has been developed to rapidly detect the presence of E. coli (Banerjee et al. 2016) .", [["E. coli", "ORGANISM", 123, 130], ["E. coli", "SPECIES", 123, 130], ["E. coli", "SPECIES", 123, 130], ["A hybrid nanosensor", "TREATMENT", 0, 19], ["magnetic resonance", "TEST", 34, 52], ["E. coli", "PROBLEM", 123, 130], ["E. coli", "OBSERVATION", 123, 130]]], ["It has been reported that detector could sense different concentrations of a pathogenic strain of E. coli known as O157: H7 during test of milk in less than an hour.", [["milk", "ANATOMY", 139, 143], ["O157: H7", "CHEMICAL", 115, 123], ["E. coli", "ORGANISM", 98, 105], ["O157: H7", "ORGANISM", 115, 123], ["milk", "ORGANISM_SUBSTANCE", 139, 143], ["E. coli", "SPECIES", 98, 105], ["E. coli", "SPECIES", 98, 105], ["O157: H7", "SPECIES", 115, 123], ["a pathogenic strain of E. coli", "PROBLEM", 75, 105], ["E. coli", "OBSERVATION_MODIFIER", 98, 105]]], ["Such sensors will find the use in detecting environmental contamination control in the food sectors.Interactive \"Smart\" Food Using EncapsulationNanoencapsulation is a technology to pack substances in miniature using techniques like nanocomposite, nanoemulsification, and nanostructuration providing final product functionality that includes controlled release of the core (Sekhon 2010) .", [["nanoemulsification", "PROBLEM", 247, 265]]], ["Nanocapsules can be incorporated into food to deliver any nutrient.", [["Nanocapsules", "CHEMICAL", 0, 12], ["Nanocapsules", "SIMPLE_CHEMICAL", 0, 12], ["Nanocapsules", "TREATMENT", 0, 12]]], ["Addition of nanoparticles to existing food can also enable increased absorption of these nutrients (Jampilek et al. 2019) .", [["nanoparticles", "TREATMENT", 12, 25], ["these nutrients", "TREATMENT", 83, 98]]], ["Nanoparticle additives could easily be absorbed by the body, and these could increase shelf life of the product.", [["body", "ANATOMY", 55, 59], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["Nanoparticle additives", "TREATMENT", 0, 22]]], ["Nanosized dispersions, emulsions, and filled micelles have an advantage that they are not subjected to sedimentation resulting in better life span and storage of the product.", [["emulsions", "TREATMENT", 23, 32], ["dispersions", "OBSERVATION_MODIFIER", 10, 21], ["emulsions", "OBSERVATION_MODIFIER", 23, 32]]], ["As size of these nanoadditives is much smaller as compared to wavelength of light, they can be easily incorporated even in clear and transparent foods without causing problems of colors.", [["problems of colors", "PROBLEM", 167, 185], ["size", "OBSERVATION_MODIFIER", 3, 7], ["nanoadditives", "OBSERVATION", 17, 30], ["much", "OBSERVATION_MODIFIER", 34, 38], ["smaller", "OBSERVATION_MODIFIER", 39, 46]]], ["Substances, which are difficult to dissolve by the body, can more easily be absorbed in nanoscale size, because of their larger surface area.", [["body", "ANATOMY", 51, 55], ["surface area", "ANATOMY", 128, 140], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["size", "OBSERVATION_MODIFIER", 98, 102], ["larger", "OBSERVATION_MODIFIER", 121, 127], ["surface", "OBSERVATION_MODIFIER", 128, 135]]], ["If any active substance is to be protected during storage or its passage through the intestines, the nanotechnology can provide perfect protective layers.", [["intestines", "ANATOMY", 85, 95], ["intestines", "ORGAN", 85, 95], ["layers", "TISSUE", 147, 153], ["active", "OBSERVATION_MODIFIER", 7, 13], ["substance", "OBSERVATION", 14, 23], ["intestines", "ANATOMY", 85, 95]]], ["It is also possible to tailor these protective layers so as to release active substances in an intelligent way (caused by a change of pH value).Interactive \"Smart\" Food Using EncapsulationIt may also be useful in protection against environmental factors and used in the design of food ingredients flavors and antioxidants (Imafidon and Spanier 1994) .", [["Imafidon", "SIMPLE_CHEMICAL", 323, 331], ["antioxidants", "TREATMENT", 309, 321], ["may also be", "UNCERTAINTY", 191, 202]]], ["The main aim is to improve the functionality of such ingredients and keeping their concentration minimum.", [["such ingredients", "TREATMENT", 48, 64], ["main", "OBSERVATION_MODIFIER", 4, 8], ["functionality", "OBSERVATION_MODIFIER", 31, 44]]], ["As the requirement of novel ingredients into foods is gaining popularity, better delivery and controlled release systems for nutraceuticals will be needed (Haruyama 2003; Lawrence and Rees 2000) .Interactive \"Smart\" Food Using EncapsulationBioactives, like coenzyme Q10 (CoQ10), vitamins, iron, calcium, curcumin, etc., have been widely tested in nanodelivery systems (He and Hwang 2016) .", [["coenzyme Q10", "CHEMICAL", 257, 269], ["CoQ10", "CHEMICAL", 271, 276], ["vitamins", "CHEMICAL", 279, 287], ["iron", "CHEMICAL", 289, 293], ["calcium", "CHEMICAL", 295, 302], ["curcumin", "CHEMICAL", 304, 312], ["coenzyme Q10", "CHEMICAL", 257, 269], ["CoQ10", "CHEMICAL", 271, 276], ["vitamins", "CHEMICAL", 279, 287], ["iron", "CHEMICAL", 289, 293], ["calcium", "CHEMICAL", 295, 302], ["curcumin", "CHEMICAL", 304, 312], ["coenzyme Q10", "SIMPLE_CHEMICAL", 257, 269], ["CoQ10", "SIMPLE_CHEMICAL", 271, 276], ["vitamins", "SIMPLE_CHEMICAL", 279, 287], ["iron", "SIMPLE_CHEMICAL", 289, 293], ["calcium", "SIMPLE_CHEMICAL", 295, 302], ["curcumin", "SIMPLE_CHEMICAL", 304, 312], ["controlled release systems", "TREATMENT", 94, 120], ["nutraceuticals", "TREATMENT", 125, 139], ["EncapsulationBioactives", "TREATMENT", 227, 250], ["coenzyme Q10 (CoQ10)", "TREATMENT", 257, 277], ["vitamins", "TREATMENT", 279, 287], ["iron", "TREATMENT", 289, 293], ["calcium", "TREATMENT", 295, 302], ["curcumin", "TREATMENT", 304, 312]]], ["Different nanodelivery vehicles have been developed such as association colloids, lipid-based nanoencapsulators/nanocarriers, nanoemulsions, biopolymeric nanoparticles, nanolaminates, nanofibers, etc. These nanodelivery systems can increase the bioavailability of bioactives by different pathways.", [["lipid-based nanoencapsulators", "SIMPLE_CHEMICAL", 82, 111], ["nanoemulsions", "SIMPLE_CHEMICAL", 126, 139], ["biopolymeric nanoparticles", "SIMPLE_CHEMICAL", 141, 167], ["nanolaminates", "SIMPLE_CHEMICAL", 169, 182], ["bioactives", "SIMPLE_CHEMICAL", 264, 274], ["Different nanodelivery vehicles", "TREATMENT", 0, 31], ["lipid-based nanoencapsulators/nanocarriers", "TREATMENT", 82, 124], ["nanoemulsions", "TREATMENT", 126, 139], ["biopolymeric nanoparticles", "TREATMENT", 141, 167], ["nanolaminates", "TREATMENT", 169, 182], ["nanofibers", "TREATMENT", 184, 194], ["These nanodelivery systems", "TREATMENT", 201, 227]]], ["Nanoencapsulation can enhance bioavailability of bioactive compounds after oral administration through targeted delivery systems.", [["oral", "ANATOMY", 75, 79], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["Nanoencapsulation", "TREATMENT", 0, 17], ["bioactive compounds", "TREATMENT", 49, 68], ["oral administration", "TREATMENT", 75, 94], ["targeted delivery systems", "TREATMENT", 103, 128], ["bioactive compounds", "OBSERVATION", 49, 68]]], ["Such nanoencapsulation enables to control the release of flavors at the desired time and also to protect the degradation of these flavors during processing and storage .Interactive \"Smart\" Food Using EncapsulationNowadays people are requiring more nutritional supplements because of the fact that many nutrients in food are being destroyed in the digestive tract.", [["digestive tract", "ANATOMY", 347, 362], ["people", "ORGANISM", 222, 228], ["digestive tract", "ORGANISM_SUBDIVISION", 347, 362], ["people", "SPECIES", 222, 228], ["nutritional supplements", "TREATMENT", 248, 271], ["digestive tract", "ANATOMY", 347, 362]]], ["Each part presents a completely different environment, from oral cavity to the colon.", [["oral cavity", "ANATOMY", 60, 71], ["colon", "ANATOMY", 79, 84], ["oral", "ORGANISM_SUBDIVISION", 60, 64], ["cavity", "ORGANISM_SUBDIVISION", 65, 71], ["colon", "ORGAN", 79, 84], ["colon", "ANATOMY", 79, 84]]], ["In other words, there are a number of factors which decide the absorption of food in the body for infants, children, adults, old people, and those who are suffering from any type of gastrointestinal diseases.", [["body", "ANATOMY", 89, 93], ["gastrointestinal", "ANATOMY", 182, 198], ["gastrointestinal diseases", "DISEASE", 182, 207], ["body", "ORGANISM_SUBDIVISION", 89, 93], ["infants", "ORGANISM", 98, 105], ["children", "ORGANISM", 107, 115], ["people", "ORGANISM", 129, 135], ["gastrointestinal", "ORGAN", 182, 198], ["infants", "SPECIES", 98, 105], ["children", "SPECIES", 107, 115], ["people", "SPECIES", 129, 135], ["gastrointestinal diseases", "PROBLEM", 182, 207], ["gastrointestinal", "ANATOMY", 182, 198], ["diseases", "OBSERVATION", 199, 207]]], ["A nutrition delivery system is a system or nanocarrier that delivers nutrition to specific places.", [["A nutrition delivery system", "TREATMENT", 0, 27]]], ["Chitosan is such a nanocarrier (Maestrelli et al. 2006) .", [["Chitosan", "CHEMICAL", 0, 8], ["Chitosan", "SIMPLE_CHEMICAL", 0, 8], ["Chitosan", "TREATMENT", 0, 8]]], ["Although a delivery system has numerous functions, one of them is to transport a functional ingredient to its desired site.", [["a delivery system", "TREATMENT", 9, 26], ["a functional ingredient", "TREATMENT", 79, 102]]], ["Just like taste, texture, and shelf life, major functions of a delivery system for a food product are that it should protect an ingredient from chemical or biological degradation, such as oxidation, and controlling the rate of release of functional ingredient under specific environmental conditions.", [["a delivery system", "TREATMENT", 61, 78], ["functional ingredient", "TREATMENT", 238, 259], ["texture", "OBSERVATION_MODIFIER", 17, 24]]], ["Nanodispersions and nanocapsules are ideal mechanisms for delivery of functional ingredients because they can effectively perform all these tasks.Interactive \"Smart\" Food Using EncapsulationOne of important part of the food industry is extracting nutrition from raw materials.", [["nanocapsules", "SIMPLE_CHEMICAL", 20, 32], ["Nanodispersions", "TREATMENT", 0, 15], ["nanocapsules", "TREATMENT", 20, 32], ["delivery of functional ingredients", "TREATMENT", 58, 92]]], ["Conventional methods for food processing are being replaced by newer techniques like nanotechnology, which will play a major role here.", [["Conventional methods", "TREATMENT", 0, 20], ["food processing", "TREATMENT", 25, 40]]], ["Nutrition delivery systems must be prepared with biodegradable materials to prevent adverse effects on health of consumers.", [["Nutrition delivery systems", "TREATMENT", 0, 26], ["biodegradable materials", "TREATMENT", 49, 72]]], ["Some of the nanodelivery vehicles are as follows.Association ColloidsA colloid system of a substance contains small particles dispersed throughout.", [["small particles", "PROBLEM", 110, 125], ["colloid system", "OBSERVATION", 71, 85], ["small", "OBSERVATION_MODIFIER", 110, 115], ["particles", "OBSERVATION_MODIFIER", 116, 125], ["dispersed", "OBSERVATION_MODIFIER", 126, 135]]], ["An association colloid is the colloid, when particles are made up of even smaller molecules.", [["colloid", "OBSERVATION", 15, 22], ["smaller", "OBSERVATION_MODIFIER", 74, 81], ["molecules", "OBSERVATION", 82, 91]]], ["It is already used to deliver polar, nonpolar, and amphiphilic functional ingredients (Golding and Sein 2004) .", [["polar, nonpolar", "TREATMENT", 30, 45], ["amphiphilic functional ingredients", "TREATMENT", 51, 85]]], ["The size of association colloids ranges between 5 and 100 nm, and there are usually transparent solutions.", [["size", "OBSERVATION_MODIFIER", 4, 8], ["colloids ranges", "OBSERVATION", 24, 39]]], ["Vesicles, bilayers, micelles, reverse micelles, and liquid crystals are some of the examples of association colloids.", [["Vesicles", "ANATOMY", 0, 8], ["bilayers", "ANATOMY", 10, 18], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["micelles", "SIMPLE_CHEMICAL", 20, 28], ["liquid crystals", "PROBLEM", 52, 67], ["association colloids", "TREATMENT", 96, 116], ["bilayers", "ANATOMY_MODIFIER", 10, 18], ["liquid crystals", "OBSERVATION", 52, 67]]], ["The major disadvantages of such colloids are that they may compromise with the flavor of the ingredients and these can spontaneously dissociate on dilution.NanoemulsionsAn emulsion is a mixture of two or more liquids (such as oil and water) that are immiscible and, as such, do not easily combine.", [["oil", "ANATOMY", 226, 229], ["oil", "ORGANISM_SUBSTANCE", 226, 229], ["water", "SIMPLE_CHEMICAL", 234, 239], ["such colloids", "TREATMENT", 27, 40]]], ["A nanoemulsion is an emulsion, when the diameters of the dispersed droplets is about 500 nm or even less than that.", [["nanoemulsion", "OBSERVATION_MODIFIER", 2, 14], ["emulsion", "OBSERVATION", 21, 29]]], ["Nanoemulsions can encapsulate functional ingredients within their droplets facilitating a reduction in their chemical degradation (McClements and Decker 2000) .", [["Nanoemulsions", "SIMPLE_CHEMICAL", 0, 13], ["Nanoemulsions", "TREATMENT", 0, 13], ["a reduction", "TREATMENT", 88, 99]]], ["Different types of nanoemulsions having more complex properties such as nanostructured multiple emulsions or nanostructured multilayer emulsions have multiple encapsulating abilities from a single delivery system that can carry several functional components.", [["nanoemulsions", "CHEMICAL", 19, 32], ["nanoemulsions", "SIMPLE_CHEMICAL", 19, 32], ["nanostructured multilayer emulsions", "SIMPLE_CHEMICAL", 109, 144], ["nanoemulsions", "TREATMENT", 19, 32], ["nanostructured multiple emulsions", "TREATMENT", 72, 105], ["nanostructured multilayer emulsions", "TREATMENT", 109, 144], ["multiple encapsulating abilities", "PROBLEM", 150, 182], ["a single delivery system", "TREATMENT", 188, 212], ["nanoemulsions", "OBSERVATION", 19, 32], ["more complex", "OBSERVATION_MODIFIER", 40, 52], ["properties", "OBSERVATION_MODIFIER", 53, 63], ["multiple", "OBSERVATION_MODIFIER", 87, 95], ["emulsions", "OBSERVATION", 96, 105], ["multiple", "OBSERVATION_MODIFIER", 150, 158], ["encapsulating abilities", "OBSERVATION", 159, 182], ["several", "OBSERVATION_MODIFIER", 228, 235], ["functional", "OBSERVATION_MODIFIER", 236, 246], ["components", "OBSERVATION_MODIFIER", 247, 257]]], ["Here, a functional component is encased within one component of a particular multiple emulsion system, which could be released in response to a specific environmental trigger.Biopolymeric NanoparticlesFood-grade biopolymers like polysaccharides or proteins can be used to produce nanosized particles (Tak et al. 2015) .", [["polysaccharides", "SIMPLE_CHEMICAL", 229, 244], ["Biopolymeric NanoparticlesFood-grade biopolymers like polysaccharides", "TREATMENT", 175, 244], ["proteins", "TREATMENT", 248, 256], ["functional", "OBSERVATION_MODIFIER", 8, 18], ["component", "OBSERVATION_MODIFIER", 19, 28], ["encased", "OBSERVATION", 32, 39], ["one component", "OBSERVATION_MODIFIER", 47, 60], ["multiple", "OBSERVATION_MODIFIER", 77, 85], ["emulsion system", "OBSERVATION", 86, 101]]], ["A single biopolymer separates into smaller nanoparticles with aggregative (net attraction) or segregative (net repulsion) interactions.", [["A single biopolymer separates into smaller nanoparticles", "TREATMENT", 0, 56], ["aggregative (net attraction", "TREATMENT", 62, 89], ["segregative (net repulsion)", "TREATMENT", 94, 121], ["smaller", "OBSERVATION_MODIFIER", 35, 42], ["aggregative", "OBSERVATION_MODIFIER", 62, 73]]], ["Nanoparticles can then be used to encapsulate functional ingredients and release them in response to particular environmental triggers.", [["Nanoparticles", "TREATMENT", 0, 13], ["functional ingredients", "TREATMENT", 46, 68]]], ["Most common components used biodegradable biopolymeric nanoparticles such as polylactic acid (PLA).", [["polylactic acid", "CHEMICAL", 77, 92], ["PLA", "CHEMICAL", 94, 97], ["polylactic acid", "CHEMICAL", 77, 92], ["PLA", "CHEMICAL", 94, 97], ["biopolymeric nanoparticles", "SIMPLE_CHEMICAL", 42, 68], ["polylactic acid", "SIMPLE_CHEMICAL", 77, 92], ["PLA", "SIMPLE_CHEMICAL", 94, 97], ["biodegradable biopolymeric nanoparticles", "TREATMENT", 28, 68], ["polylactic acid (PLA", "TREATMENT", 77, 97]]], ["PLA is quite commonly used to encapsulate and deliver drugs, vaccines, and proteins, but it has certain limitations:Biopolymeric Nanoparticles\u2022 It is quickly removed from the bloodstream. \u2022 It remains isolated in the liver and kidneys.", [["bloodstream", "ANATOMY", 175, 186], ["liver", "ANATOMY", 217, 222], ["kidneys", "ANATOMY", 227, 234], ["PLA", "CHEMICAL", 0, 3], ["PLA", "CHEMICAL", 0, 3], ["PLA", "SIMPLE_CHEMICAL", 0, 3], ["liver", "ORGAN", 217, 222], ["kidneys", "ORGAN", 227, 234], ["drugs", "TREATMENT", 54, 59], ["vaccines", "TREATMENT", 61, 69], ["Biopolymeric Nanoparticles", "TREATMENT", 116, 142], ["bloodstream", "ANATOMY", 175, 186], ["isolated", "OBSERVATION", 201, 209], ["liver", "ANATOMY", 217, 222], ["kidneys", "ANATOMY", 227, 234]]], ["Therefore, PLA needs an associative compound such as polyethylene glycol to be successful in delivering active components to other areas of the body (Taylor et al. 2005) .NanolaminatesApart from nanodispersions and nanocapsules, nanolaminate is also a nanoscale technique, which is commercially used in the food industry.", [["body", "ANATOMY", 144, 148], ["PLA", "CHEMICAL", 11, 14], ["polyethylene glycol", "CHEMICAL", 53, 72], ["nanolaminate", "CHEMICAL", 229, 241], ["PLA", "CHEMICAL", 11, 14], ["polyethylene glycol", "CHEMICAL", 53, 72], ["PLA", "SIMPLE_CHEMICAL", 11, 14], ["polyethylene glycol", "SIMPLE_CHEMICAL", 53, 72], ["body", "ORGANISM_SUBDIVISION", 144, 148], ["nanocapsules", "SIMPLE_CHEMICAL", 215, 227], ["nanolaminate", "SIMPLE_CHEMICAL", 229, 241], ["an associative compound", "PROBLEM", 21, 44], ["polyethylene glycol", "TREATMENT", 53, 72], ["Nanolaminates", "TREATMENT", 171, 184], ["nanocapsules", "TREATMENT", 215, 227], ["nanolaminate", "TREATMENT", 229, 241], ["a nanoscale technique", "TREATMENT", 250, 271], ["polyethylene glycol", "OBSERVATION", 53, 72], ["body", "ANATOMY", 144, 148], ["nanodispersions", "OBSERVATION_MODIFIER", 195, 210], ["nanocapsules", "OBSERVATION_MODIFIER", 215, 227]]], ["It consists of two or more layers of material with nano-dimensions, and it is an extremely thin foodgrade film (1-100 nm per layer), which has physically bonded or chemically bonded dimensions (Ravichandran 2010) .", [["an extremely thin foodgrade film", "PROBLEM", 78, 110], ["two", "OBSERVATION_MODIFIER", 15, 18], ["more", "OBSERVATION_MODIFIER", 22, 26], ["layers", "OBSERVATION_MODIFIER", 27, 33], ["nano-dimensions", "OBSERVATION_MODIFIER", 51, 66], ["extremely", "OBSERVATION_MODIFIER", 81, 90], ["thin", "OBSERVATION_MODIFIER", 91, 95], ["bonded", "OBSERVATION_MODIFIER", 154, 160], ["chemically bonded", "OBSERVATION_MODIFIER", 164, 181]]], ["A nanolaminate has a number of important applications in the food industry due to these advantages in the preparation of edible films.", [["nanolaminate", "CHEMICAL", 2, 14], ["edible films", "TEST", 121, 133]]], ["Such edible films are present on wide range of foods such as chocolate, candies, fruits, vegetables, meats, baked goods, French fries, etc. (Pavlath and Orts 2009 ).", [["fruits", "ANATOMY", 81, 87], ["vegetables", "ANATOMY", 89, 99], ["meats", "ANATOMY", 101, 106], ["chocolate, candies, fruits, vegetables", "CHEMICAL", 61, 99], ["chocolate", "ORGANISM_SUBDIVISION", 61, 70], ["candies", "ORGANISM_SUBDIVISION", 72, 79], ["fruits", "ORGANISM_SUBDIVISION", 81, 87], ["vegetables", "ORGANISM_SUBDIVISION", 89, 99], ["meats", "ORGANISM_SUBDIVISION", 101, 106], ["fries", "SPECIES", 128, 133], ["Such edible films", "TEST", 0, 17]]], ["These films protect foods from gases, humidity, and lipids.", [["lipids", "SIMPLE_CHEMICAL", 52, 58], ["These films", "TEST", 0, 11], ["humidity", "TREATMENT", 38, 46], ["lipids", "TREATMENT", 52, 58]]], ["They can also improve the textural properties of foods and serve as carriers of colors, flavors, nutrients, antioxidants, and antimicrobials.NanolaminatesPresently, these edible nanolaminates are prepared from polysaccharides, proteins, and lipids.", [["nanolaminates", "SIMPLE_CHEMICAL", 178, 191], ["polysaccharides", "SIMPLE_CHEMICAL", 210, 225], ["lipids", "SIMPLE_CHEMICAL", 241, 247], ["antioxidants", "TREATMENT", 108, 120], ["antimicrobials", "TREATMENT", 126, 140], ["Nanolaminates", "TREATMENT", 141, 154], ["these edible nanolaminates", "TREATMENT", 165, 191], ["polysaccharides", "TREATMENT", 210, 225], ["lipids", "TREATMENT", 241, 247]]], ["Polysaccharide and protein-based films provide good protection against oxygen and carbon dioxide, but these are poor to protect against moisture.", [["Polysaccharide", "CHEMICAL", 0, 14], ["oxygen", "CHEMICAL", 71, 77], ["carbon dioxide", "CHEMICAL", 82, 96], ["oxygen", "CHEMICAL", 71, 77], ["carbon dioxide", "CHEMICAL", 82, 96], ["Polysaccharide", "SIMPLE_CHEMICAL", 0, 14], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["carbon dioxide", "SIMPLE_CHEMICAL", 82, 96], ["Polysaccharide", "TEST", 0, 14], ["protein-based films", "TEST", 19, 38], ["oxygen", "TREATMENT", 71, 77], ["carbon dioxide", "TREATMENT", 82, 96]]], ["While lipid-based nanolaminates are significantly good to protect food from moisture, they have limited resistance to gases and show poor mechanical strength.", [["lipid", "SIMPLE_CHEMICAL", 6, 11], ["nanolaminates", "SIMPLE_CHEMICAL", 18, 31], ["poor mechanical strength", "PROBLEM", 133, 157], ["mechanical strength", "OBSERVATION", 138, 157]]], ["Neither polysaccharides and proteins nor lipids provide all the properties in an edible coating and identify additives.", [["polysaccharides", "SIMPLE_CHEMICAL", 8, 23], ["lipids", "SIMPLE_CHEMICAL", 41, 47], ["an edible coating", "TREATMENT", 78, 95]]], ["Newer additives are searched that can improve these properties, e.g., polyols.", [["polyols", "CHEMICAL", 70, 77], ["polyols", "SIMPLE_CHEMICAL", 70, 77], ["Newer additives", "TREATMENT", 0, 15]]], ["Foods can be coated with nanolaminates either by dipping them into a series of solutions containing substances or by spraying substances onto the food surface (Shit and Shah 2014) .", [["nanolaminates", "TREATMENT", 25, 38], ["a series of solutions containing substances", "TREATMENT", 67, 110]]], ["The degree of adsorption of any substance depends on the nature of surface of food as well as on the nature of the adsorbing substance.", [["surface", "ANATOMY", 67, 74], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["adsorption", "OBSERVATION_MODIFIER", 14, 24]]], ["Various adsorbing substances can form different layers of a nanolaminate; some of these are polyelectrolytes (proteins and polysaccharides), charged lipids, and colloidal particles.", [["polysaccharides", "SIMPLE_CHEMICAL", 123, 138], ["lipids", "SIMPLE_CHEMICAL", 149, 155], ["colloidal particles", "SIMPLE_CHEMICAL", 161, 180], ["Various adsorbing substances", "TREATMENT", 0, 28], ["a nanolaminate", "TREATMENT", 58, 72], ["polyelectrolytes (proteins and polysaccharides", "TREATMENT", 92, 138], ["charged lipids", "TREATMENT", 141, 155], ["colloidal particles", "TREATMENT", 161, 180], ["adsorbing substances", "OBSERVATION", 8, 28], ["different layers", "OBSERVATION_MODIFIER", 38, 54], ["colloidal particles", "OBSERVATION", 161, 180]]], ["Different nanolaminates include varying functional agents such as flavors, colors, antimicrobials, anti-browning agents, antioxidants, enzymes, etc.Nanofibers and NanotubesNanotechnology has two more materials, which are likely to have an impact on the food industry.", [["Nanotubes", "CHEMICAL", 163, 172], ["anti-browning agents", "SIMPLE_CHEMICAL", 99, 119], ["enzymes", "PROTEIN", 135, 142], ["Different nanolaminates", "TREATMENT", 0, 23], ["varying functional agents", "TREATMENT", 32, 57], ["antimicrobials", "TREATMENT", 83, 97], ["anti-browning agents", "TREATMENT", 99, 119], ["antioxidants", "TREATMENT", 121, 133], ["enzymes", "TEST", 135, 142], ["Nanofibers", "TREATMENT", 148, 158], ["NanotubesNanotechnology", "TREATMENT", 163, 186], ["more materials", "OBSERVATION_MODIFIER", 195, 209]]], ["These are nanofibers and nanotubes.", [["nanofibers and nanotubes", "TREATMENT", 10, 34], ["nanofibers", "OBSERVATION", 10, 20], ["nanotubes", "OBSERVATION_MODIFIER", 25, 34]]], ["Nanofibers are usually not composed of food-grade substances; therefore, nanofibers have only fewer applications in the food industry.", [["Nanofibers", "SIMPLE_CHEMICAL", 0, 10], ["Nanofibers", "TREATMENT", 0, 10], ["nanofibers", "TREATMENT", 73, 83]]], ["Nanofibers have small diameters in the size from 10 to 1000 nm, which makes them ideal to serve as a platform for bacterial cultures (Guo 2015) .", [["Nanofibers", "TREATMENT", 0, 10], ["small diameters in the size", "PROBLEM", 16, 43], ["bacterial cultures", "TEST", 114, 132], ["small", "OBSERVATION_MODIFIER", 16, 21], ["diameters", "OBSERVATION_MODIFIER", 22, 31], ["size", "OBSERVATION_MODIFIER", 39, 43], ["10 to 1000 nm", "OBSERVATION_MODIFIER", 49, 62]]], ["These could also serve as the structural matrix for artificial foods and food packaging material, which are eco-friendly.", [["matrix", "CELLULAR_COMPONENT", 41, 47], ["artificial foods", "TREATMENT", 52, 68]]], ["As the efforts are growing in the area of producing nanofibers from food-grade materials, their use is likely to increase in the future.", [["growing", "OBSERVATION_MODIFIER", 19, 26]]], ["Similar to nanofibers, the use of nanotubes is mainly for nonfood applications.", [["nanofibers", "TREATMENT", 11, 21], ["nanotubes", "TREATMENT", 34, 43], ["nonfood applications", "TREATMENT", 58, 78]]], ["Carbon nanotubes are commonly used as low-resistance conductors and catalytic reaction vessels.", [["vessels", "ANATOMY", 87, 94], ["Carbon nanotubes", "CHEMICAL", 0, 16], ["Carbon", "CHEMICAL", 0, 6], ["Carbon nanotubes", "SIMPLE_CHEMICAL", 0, 16], ["vessels", "MULTI-TISSUE_STRUCTURE", 87, 94], ["Carbon nanotubes", "TREATMENT", 0, 16], ["low-resistance conductors", "TREATMENT", 38, 63], ["catalytic reaction vessels", "PROBLEM", 68, 94], ["reaction vessels", "OBSERVATION", 78, 94]]], ["Certain globular milk proteins can self-assemble into similarly structured nanotubes in some appropriate environmental conditions (Graveland-Bikker and de Kruif 2006).Antimicrobial PropertiesMicrobial contamination is there due to pathogenic infections and poor nutrition associated with major types of food, but in particular weaning foods.", [["milk", "ANATOMY", 17, 21], ["Microbial contamination", "DISEASE", 191, 214], ["infections", "DISEASE", 242, 252], ["milk", "ORGANISM_SUBSTANCE", 17, 21], ["globular milk proteins", "PROTEIN", 8, 30], ["Certain globular milk proteins", "PROBLEM", 0, 30], ["Antimicrobial PropertiesMicrobial contamination", "PROBLEM", 167, 214], ["pathogenic infections", "PROBLEM", 231, 252], ["poor nutrition", "PROBLEM", 257, 271], ["Microbial contamination", "OBSERVATION", 191, 214], ["pathogenic", "OBSERVATION_MODIFIER", 231, 241], ["infections", "OBSERVATION", 242, 252]]], ["Bacterial deterioration is one of the most discussed subjects as far as the production, processing, transport, and storing of food are concerned.", [["Bacterial deterioration", "PROBLEM", 0, 23], ["deterioration", "OBSERVATION", 10, 23], ["one of the most", "OBSERVATION_MODIFIER", 27, 42]]], ["A number of metal and metal oxide nanomaterials have been reported to be effective as antimicrobials.", [["metal oxide", "CHEMICAL", 22, 33], ["metal oxide", "CHEMICAL", 22, 33], ["metal", "SIMPLE_CHEMICAL", 12, 17], ["metal oxide nanomaterials", "SIMPLE_CHEMICAL", 22, 47], ["metal and metal oxide nanomaterials", "TREATMENT", 12, 47], ["antimicrobials", "TREATMENT", 86, 100]]], ["Their physicochemical properties are considered responsible for excessive formation of reactive oxygen species (ROS), which leads to oxidative stress and subsequent cell damage (Fu et al. 2014; Wu et al. 2014) .Antimicrobial PropertiesRelease of metal ions at all the places can affect cellular structure or function, whether it is outside the cell, at the cell surface, or within the cell.", [["cell", "ANATOMY", 165, 169], ["cellular", "ANATOMY", 286, 294], ["cell", "ANATOMY", 344, 348], ["cell surface", "ANATOMY", 357, 369], ["cell", "ANATOMY", 385, 389], ["oxygen", "CHEMICAL", 96, 102], ["ROS", "CHEMICAL", 112, 115], ["oxygen", "CHEMICAL", 96, 102], ["reactive oxygen species", "SIMPLE_CHEMICAL", 87, 110], ["ROS", "SIMPLE_CHEMICAL", 112, 115], ["cell", "CELL", 165, 169], ["metal ions", "SIMPLE_CHEMICAL", 246, 256], ["cellular", "CELL", 286, 294], ["cell", "CELL", 344, 348], ["cell surface", "CELLULAR_COMPONENT", 357, 369], ["cell", "CELL", 385, 389], ["reactive oxygen species", "PROBLEM", 87, 110], ["oxidative stress", "PROBLEM", 133, 149], ["subsequent cell damage", "PROBLEM", 154, 176], ["Antimicrobial PropertiesRelease of metal ions", "TREATMENT", 211, 256], ["reactive", "OBSERVATION_MODIFIER", 87, 95], ["oxygen species", "OBSERVATION", 96, 110], ["cell damage", "OBSERVATION", 165, 176], ["metal ions", "OBSERVATION", 246, 256], ["cellular structure", "OBSERVATION", 286, 304], ["cell", "OBSERVATION_MODIFIER", 357, 361], ["surface", "OBSERVATION_MODIFIER", 362, 369], ["cell", "ANATOMY", 385, 389]]], ["Metal or metal oxide-based nanocomposites are used in food packaging and coating or sometimes even as ingredients of food.", [["Metal", "CHEMICAL", 0, 5], ["metal oxide", "CHEMICAL", 9, 20], ["metal oxide", "CHEMICAL", 9, 20], ["Metal", "SIMPLE_CHEMICAL", 0, 5], ["metal oxide", "SIMPLE_CHEMICAL", 9, 20], ["Metal or metal oxide-based nanocomposites", "TREATMENT", 0, 41], ["metal oxide", "OBSERVATION", 9, 20]]], ["Silver nanoparticles and its nanocomposites are most commonly used nanomaterials as antimicrobials in the food industry (He and Hwang 2016) .", [["Silver nanoparticles", "CHEMICAL", 0, 20], ["Silver", "CHEMICAL", 0, 6], ["Silver nanoparticles", "SIMPLE_CHEMICAL", 0, 20], ["Silver nanoparticles", "TREATMENT", 0, 20], ["its nanocomposites", "TREATMENT", 25, 43]]], ["The use of a number of silver-containing zeolites or similar substances as food contact materials has been approved by the USFDA for the purpose of disinfection (Duncan 2011) .", [["silver", "CHEMICAL", 23, 29], ["silver", "CHEMICAL", 23, 29], ["zeolites", "CHEMICAL", 41, 49], ["silver", "SIMPLE_CHEMICAL", 23, 29], ["zeolites", "SIMPLE_CHEMICAL", 41, 49], ["a number of silver-containing zeolites", "TREATMENT", 11, 49]]], ["These nanoparticles are used as a source of Ag + ions, which binds to membrane proteins, forming pits and/or causing other morphological changes (Morones et al. 2005) .", [["membrane", "ANATOMY", 70, 78], ["pits", "ANATOMY", 97, 101], ["Ag", "CHEMICAL", 44, 46], ["Ag +", "CHEMICAL", 44, 48], ["Ag + ions", "SIMPLE_CHEMICAL", 44, 53], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["pits", "CELLULAR_COMPONENT", 97, 101], ["Ag", "PROTEIN", 44, 46], ["membrane proteins", "PROTEIN", 70, 87], ["These nanoparticles", "TREATMENT", 0, 19], ["Ag + ions", "PROBLEM", 44, 53], ["membrane proteins", "TEST", 70, 87], ["other morphological changes", "PROBLEM", 117, 144]]], ["These also catalyze the generation of ROS in bacterial cells, which, in turn, leads to cell death through oxidative stress (Kim et al. 2007 ).", [["cells", "ANATOMY", 55, 60], ["cell", "ANATOMY", 87, 91], ["ROS", "CHEMICAL", 38, 41], ["death", "DISEASE", 92, 97], ["ROS", "SIMPLE_CHEMICAL", 38, 41], ["bacterial cells", "CELL", 45, 60], ["cell", "CELL", 87, 91], ["bacterial cells", "CELL_TYPE", 45, 60], ["ROS in bacterial cells", "PROBLEM", 38, 60], ["bacterial cells", "OBSERVATION", 45, 60]]], ["It has been suggested that silver nanocomposites are quite safe for packaging of food, as no detectable or negligible levels of silver nanoparticles are released, which migrate from containers to actual food samples and food stimulants (Ntim et al. 2015) .", [["silver", "CHEMICAL", 27, 33], ["silver", "CHEMICAL", 128, 134], ["silver", "CHEMICAL", 27, 33], ["silver", "CHEMICAL", 128, 134], ["silver nanocomposites", "SIMPLE_CHEMICAL", 27, 48], ["silver nanoparticles", "SIMPLE_CHEMICAL", 128, 148], ["silver nanocomposites", "TREATMENT", 27, 48], ["negligible levels of silver nanoparticles", "PROBLEM", 107, 148]]], ["Nanocomposites have an advantage of enhanced stability, which is very much required for sustaining antimicrobial activity and reducing the possibility of migration of metal ions into stored foods.", [["metal ions", "SIMPLE_CHEMICAL", 167, 177], ["Nanocomposites", "TREATMENT", 0, 14], ["sustaining antimicrobial activity", "TREATMENT", 88, 121], ["migration of metal ions", "TREATMENT", 154, 177], ["enhanced", "OBSERVATION_MODIFIER", 36, 44], ["stability", "OBSERVATION", 45, 54]]], ["Some polymers are designed to form nanocomposites with metal/metal oxide nanomaterials for various applications in food science.", [["metal oxide", "CHEMICAL", 61, 72], ["metal oxide", "CHEMICAL", 61, 72], ["metal/metal oxide", "SIMPLE_CHEMICAL", 55, 72], ["Some polymers", "PROBLEM", 0, 13], ["metal/metal oxide nanomaterials", "TREATMENT", 55, 86]]], ["Polymers most widely used in nanocomposites include gelatin, polylactic acid, isotactic polypropylene, and low-density polyethylene (LDPE).", [["gelatin, polylactic acid", "CHEMICAL", 52, 76], ["isotactic polypropylene", "CHEMICAL", 78, 101], ["LDPE", "CHEMICAL", 133, 137], ["polylactic acid", "CHEMICAL", 61, 76], ["polypropylene", "CHEMICAL", 88, 101], ["polyethylene", "CHEMICAL", 119, 131], ["LDPE", "CHEMICAL", 133, 137], ["gelatin", "SIMPLE_CHEMICAL", 52, 59], ["polylactic acid", "SIMPLE_CHEMICAL", 61, 76], ["isotactic polypropylene", "SIMPLE_CHEMICAL", 78, 101], ["low-density polyethylene", "SIMPLE_CHEMICAL", 107, 131], ["LDPE", "SIMPLE_CHEMICAL", 133, 137], ["Polymers", "TREATMENT", 0, 8], ["gelatin", "TREATMENT", 52, 59], ["polylactic acid", "TREATMENT", 61, 76], ["isotactic polypropylene", "TREATMENT", 78, 101], ["low-density polyethylene (LDPE", "TREATMENT", 107, 137], ["isotactic polypropylene", "OBSERVATION", 78, 101], ["low-density polyethylene", "OBSERVATION_MODIFIER", 107, 131]]], ["Nanocomposites of LDPE with metals (Ag/LDPE) and metal oxide (CuO/LDPE, TiO 2 /LDPE, and ZnO/LDPE) are used in some food applications.", [["LDPE", "CHEMICAL", 18, 22], ["metals", "CHEMICAL", 28, 34], ["Ag", "CHEMICAL", 36, 38], ["metal oxide", "CHEMICAL", 49, 60], ["CuO", "CHEMICAL", 62, 65], ["TiO 2 /LDPE", "CHEMICAL", 72, 83], ["ZnO", "CHEMICAL", 89, 92], ["LDPE", "CHEMICAL", 93, 97], ["Ag", "CHEMICAL", 36, 38], ["LDPE", "CHEMICAL", 39, 43], ["metal oxide", "CHEMICAL", 49, 60], ["CuO", "CHEMICAL", 62, 65], ["LDPE", "CHEMICAL", 66, 70], ["TiO 2", "CHEMICAL", 72, 77], ["LDPE", "CHEMICAL", 79, 83], ["ZnO", "CHEMICAL", 89, 92], ["LDPE", "CHEMICAL", 93, 97], ["LDPE", "SIMPLE_CHEMICAL", 18, 22], ["metals", "SIMPLE_CHEMICAL", 28, 34], ["Ag/LDPE", "SIMPLE_CHEMICAL", 36, 43], ["metal oxide", "SIMPLE_CHEMICAL", 49, 60], ["CuO/LDPE", "SIMPLE_CHEMICAL", 62, 70], ["TiO 2 /LDPE", "SIMPLE_CHEMICAL", 72, 83], ["ZnO/LDPE", "SIMPLE_CHEMICAL", 89, 97], ["Ag", "PROTEIN", 36, 38], ["metals (Ag/LDPE)", "TREATMENT", 28, 44], ["metal oxide (CuO/LDPE, TiO 2 /LDPE", "TREATMENT", 49, 83], ["ZnO/LDPE)", "TREATMENT", 89, 98], ["LDPE", "OBSERVATION_MODIFIER", 18, 22]]], ["Apart from these ZnO/gelatin, ZnO/polylactic acid, and ZnO/graphene oxide/polylactic acid, ZnO/polycarbonate, ZnO/isotactic polypropylene, Ag/OMteLDPE, and Ag/poly(3-hydroxybutyrate-co-18 mol%-3-hydroxyvalerate) are also used specifically for food packaging applications (He and Hwang 2016) .", [["ZnO", "CHEMICAL", 17, 20], ["gelatin", "CHEMICAL", 21, 28], ["ZnO", "CHEMICAL", 30, 33], ["polylactic acid", "CHEMICAL", 34, 49], ["ZnO", "CHEMICAL", 55, 58], ["graphene oxide", "CHEMICAL", 59, 73], ["polylactic acid", "CHEMICAL", 74, 89], ["ZnO", "CHEMICAL", 91, 94], ["ZnO", "CHEMICAL", 110, 113], ["isotactic polypropylene", "CHEMICAL", 114, 137], ["Ag", "CHEMICAL", 139, 141], ["OMteLDPE", "CHEMICAL", 142, 150], ["Ag", "CHEMICAL", 156, 158], ["poly(3-hydroxybutyrate-co-18 mol%-3-hydroxyvalerate", "CHEMICAL", 159, 210], ["ZnO", "CHEMICAL", 17, 20], ["ZnO", "CHEMICAL", 30, 33], ["polylactic acid", "CHEMICAL", 34, 49], ["ZnO", "CHEMICAL", 55, 58], ["graphene oxide", "CHEMICAL", 59, 73], ["polylactic acid", "CHEMICAL", 74, 89], ["ZnO", "CHEMICAL", 91, 94], ["polycarbonate", "CHEMICAL", 95, 108], ["ZnO", "CHEMICAL", 110, 113], ["polypropylene", "CHEMICAL", 124, 137], ["Ag", "CHEMICAL", 139, 141], ["OMteLDPE", "CHEMICAL", 142, 150], ["Ag", "CHEMICAL", 156, 158], ["poly(3-hydroxybutyrate-co-18 mol%-3-hydroxyvalerate", "CHEMICAL", 159, 210], ["ZnO", "SIMPLE_CHEMICAL", 17, 20], ["gelatin", "SIMPLE_CHEMICAL", 21, 28], ["ZnO/polylactic acid", "SIMPLE_CHEMICAL", 30, 49], ["ZnO/graphene oxide", "SIMPLE_CHEMICAL", 55, 73], ["polylactic acid", "SIMPLE_CHEMICAL", 74, 89], ["ZnO/polycarbonate", "SIMPLE_CHEMICAL", 91, 108], ["ZnO", "SIMPLE_CHEMICAL", 110, 113], ["isotactic polypropylene", "SIMPLE_CHEMICAL", 114, 137], ["Ag/OMteLDPE", "SIMPLE_CHEMICAL", 139, 150], ["Ag/poly(3-hydroxybutyrate-co-18 mol%-3-hydroxyvalerate", "SIMPLE_CHEMICAL", 156, 210], ["Ag", "PROTEIN", 139, 141], ["Ag", "PROTEIN", 156, 158], ["these ZnO/gelatin", "TREATMENT", 11, 28], ["ZnO/polylactic acid", "TREATMENT", 30, 49], ["ZnO/graphene oxide", "TREATMENT", 55, 73], ["polylactic acid", "TREATMENT", 74, 89], ["ZnO", "TREATMENT", 91, 94], ["polycarbonate", "TREATMENT", 95, 108], ["ZnO", "TREATMENT", 110, 113], ["isotactic polypropylene", "TREATMENT", 114, 137], ["OMteLDPE", "TREATMENT", 142, 150], ["Ag/poly", "TREATMENT", 156, 163], ["hydroxybutyrate", "TEST", 166, 181], ["co", "TEST", 182, 184], ["hydroxyvalerate", "TREATMENT", 195, 210]]], ["Polystyrene, polyvinylpyrrolidone, and poly(vinyl chloride) are also reported along with chitosan, as nanocomposite films, which binds to Cu or ZnO nanomaterials to control the growth of food pathogens or inactivate these ).AntioxidantsAs some metal/metal oxide nanomaterials cause oxidative stress through the formation of ROS (Manke et al. 2013) , therefore, efforts were made to develop less reactive nanomaterials so that they can act as antioxidant carriers.", [["Polystyrene", "CHEMICAL", 0, 11], ["polyvinylpyrrolidone", "CHEMICAL", 13, 33], ["poly(vinyl chloride", "CHEMICAL", 39, 58], ["chitosan", "CHEMICAL", 89, 97], ["Cu", "CHEMICAL", 138, 140], ["ZnO", "CHEMICAL", 144, 147], ["AntioxidantsAs", "CHEMICAL", 224, 238], ["metal oxide", "CHEMICAL", 250, 261], ["ROS", "CHEMICAL", 324, 327], ["Polystyrene", "CHEMICAL", 0, 11], ["polyvinylpyrrolidone", "CHEMICAL", 13, 33], ["poly(vinyl chloride)", "CHEMICAL", 39, 59], ["Cu", "CHEMICAL", 138, 140], ["ZnO", "CHEMICAL", 144, 147], ["metal oxide", "CHEMICAL", 250, 261], ["Polystyrene", "SIMPLE_CHEMICAL", 0, 11], ["polyvinylpyrrolidone", "SIMPLE_CHEMICAL", 13, 33], ["poly(vinyl chloride", "SIMPLE_CHEMICAL", 39, 58], ["chitosan", "SIMPLE_CHEMICAL", 89, 97], ["Cu", "SIMPLE_CHEMICAL", 138, 140], ["ZnO nanomaterials", "SIMPLE_CHEMICAL", 144, 161], ["AntioxidantsAs", "SIMPLE_CHEMICAL", 224, 238], ["metal/metal oxide", "SIMPLE_CHEMICAL", 244, 261], ["ROS", "SIMPLE_CHEMICAL", 324, 327], ["Polystyrene", "TREATMENT", 0, 11], ["polyvinylpyrrolidone", "TREATMENT", 13, 33], ["poly(vinyl chloride)", "TREATMENT", 39, 59], ["chitosan", "TREATMENT", 89, 97], ["nanocomposite films", "TEST", 102, 121], ["ZnO nanomaterials", "TREATMENT", 144, 161], ["AntioxidantsAs", "TREATMENT", 224, 238], ["some metal/metal oxide nanomaterials", "TREATMENT", 239, 275], ["oxidative stress", "PROBLEM", 282, 298], ["less reactive nanomaterials", "PROBLEM", 390, 417], ["oxidative stress", "OBSERVATION", 282, 298], ["reactive nanomaterials", "OBSERVATION", 395, 417]]], ["Polymeric nanoparticles are considered suitable for the encapsulation of bioactive compounds such as flavonoids and vitamins, which are released in the stomach having acidic environments (Pool et al. 2012) .", [["stomach", "ANATOMY", 152, 159], ["vitamins", "CHEMICAL", 116, 124], ["flavonoids", "CHEMICAL", 101, 111], ["vitamins", "CHEMICAL", 116, 124], ["Polymeric nanoparticles", "SIMPLE_CHEMICAL", 0, 23], ["flavonoids", "SIMPLE_CHEMICAL", 101, 111], ["vitamins", "SIMPLE_CHEMICAL", 116, 124], ["stomach", "ORGAN", 152, 159], ["Polymeric nanoparticles", "TREATMENT", 0, 23], ["the encapsulation of bioactive compounds", "TREATMENT", 52, 92], ["flavonoids", "TREATMENT", 101, 111], ["vitamins", "TREATMENT", 116, 124], ["nanoparticles", "OBSERVATION", 10, 23], ["bioactive compounds", "OBSERVATION", 73, 92], ["stomach", "ANATOMY", 152, 159]]], ["SiO 2 -gallic acid nanoparticles were also developed, and these were tested as antioxidant with its scavenging capacity of DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals (Deligiannakis et al. 2012 ).", [["SiO 2 -gallic acid", "CHEMICAL", 0, 18], ["DPPH", "CHEMICAL", 123, 127], ["2,2-diphenyl-1-picrylhydrazyl", "CHEMICAL", 129, 158], ["SiO 2 -gallic acid", "CHEMICAL", 0, 18], ["DPPH (2,2-diphenyl-1-picrylhydrazyl)", "CHEMICAL", 123, 159], ["SiO 2 -gallic acid nanoparticles", "SIMPLE_CHEMICAL", 0, 32], ["DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals", "SIMPLE_CHEMICAL", 123, 168], ["SiO 2 -gallic acid nanoparticles", "TREATMENT", 0, 32], ["DPPH", "TEST", 123, 127], ["diphenyl", "TREATMENT", 133, 141]]], ["Browning of fresh-cut fruits is another problem, which can be controlled by the application of antioxidant treatments in association with edible coating, because browning of fresh-cut fruits is an undesirable effect due to conversion of phenolic compounds into some dark-colored pigments in the presence of oxygen (air), during storage and marketing (Garcia and Barrett 2019) .", [["fruits", "ANATOMY", 22, 28], ["fruits", "ANATOMY", 184, 190], ["oxygen", "CHEMICAL", 307, 313], ["oxygen", "CHEMICAL", 307, 313], ["fruits", "ORGANISM_SUBDIVISION", 22, 28], ["fruits", "ORGANISM_SUBDIVISION", 184, 190], ["phenolic compounds", "SIMPLE_CHEMICAL", 237, 255], ["oxygen", "SIMPLE_CHEMICAL", 307, 313], ["fresh-cut fruits", "PROBLEM", 12, 28], ["antioxidant treatments", "TREATMENT", 95, 117], ["edible coating", "TREATMENT", 138, 152], ["fresh-cut fruits", "PROBLEM", 174, 190], ["phenolic compounds", "PROBLEM", 237, 255], ["some dark-colored pigments", "PROBLEM", 261, 287], ["fresh", "OBSERVATION_MODIFIER", 12, 17], ["cut fruits", "OBSERVATION", 18, 28], ["phenolic compounds", "OBSERVATION", 237, 255], ["colored pigments", "OBSERVATION", 271, 287], ["oxygen", "OBSERVATION_MODIFIER", 307, 313]]], ["But only some applications of nanomaterials directly as anti-browning agents have been known.", [["anti-browning agents", "SIMPLE_CHEMICAL", 56, 76], ["nanomaterials", "TREATMENT", 30, 43], ["anti-browning agents", "TREATMENT", 56, 76]]], ["The shelf life of Fuji apples (as a fresh-cut product) was enhanced using nano-ZnO-coated active packaging (Li et al. 2011 ).Color AdditivesA wide range of nanoscale color additives has been prepared and studied.", [["Fuji apples", "CHEMICAL", 18, 29], ["nano-ZnO", "CHEMICAL", 74, 82], ["ZnO", "CHEMICAL", 79, 82], ["Fuji apples", "ORGANISM", 18, 29], ["nano-ZnO", "SIMPLE_CHEMICAL", 74, 82], ["Fuji apples", "TREATMENT", 18, 29], ["a fresh-cut product", "TREATMENT", 34, 53], ["nano-ZnO-coated active packaging", "TREATMENT", 74, 106], ["Color", "TEST", 125, 130], ["nanoscale color additives", "TREATMENT", 156, 181], ["wide", "OBSERVATION_MODIFIER", 142, 146], ["range", "OBSERVATION_MODIFIER", 147, 152]]], ["These additives must be approved by the Office of Cosmetics and Colors in the Center for Food Safety and Applied Nutrition and the USFDA and used only for approved purpose, specifications, and of course restrictions (He and Hwang 2016) .", [["Nutrition", "TREATMENT", 113, 122], ["the USFDA", "TREATMENT", 127, 136]]], ["Certain such nanomaterial products have been duly approved to be used as food color additives.", [["Certain such nanomaterial products", "TREATMENT", 0, 34]]], ["TiO 2 is approved as a food color additive with the limit that it should not exceed 1% w/w (Shi et al. 2013 ).", [["TiO 2", "CHEMICAL", 0, 5], ["TiO 2", "CHEMICAL", 0, 5], ["TiO 2", "SIMPLE_CHEMICAL", 0, 5]]], ["It has also been permitted to use color additive mixtures made with TiO 2 containing SiO 2 and/or Al 2 O 3 as dispersing aids, but their limit should not be more than 2% of the total.FlavorsFlavors provide sensory perception of taste along with smell to stimulate appetite and eating experience, and therefore, it is one of the most important parts of the food system.", [["TiO 2", "CHEMICAL", 68, 73], ["TiO 2", "CHEMICAL", 68, 73], ["SiO 2", "CHEMICAL", 85, 90], ["Al 2 O 3", "CHEMICAL", 98, 106], ["TiO 2", "SIMPLE_CHEMICAL", 68, 73], ["SiO 2", "SIMPLE_CHEMICAL", 85, 90], ["Al 2 O 3", "SIMPLE_CHEMICAL", 98, 106], ["color additive mixtures", "TREATMENT", 34, 57], ["TiO 2 containing SiO", "TREATMENT", 68, 88]]], ["Nanoencapsulation technique has been quite commonly used to improve release and retention of flavor and to deliver dietary balance (Nakagawa 2014) .", [["Nanoencapsulation technique", "TREATMENT", 0, 27], ["retention of flavor", "TREATMENT", 80, 99]]], ["SiO 2 nanomaterials can also act as carriers of these fragrances or flavors in food as well as nonfood products (Dekkers et al. 2011) .Anticaking AgentsSiO 2 is also used for thickening of pastes (as an anticaking agent) so as to maintain flow properties in powdered products along with as a carrier of fragrances or flavors in food and nonfood products.", [["SiO 2 nanomaterials", "CHEMICAL", 0, 19], ["AgentsSiO", "CHEMICAL", 146, 155], ["SiO 2", "CHEMICAL", 0, 5], ["AgentsSiO 2", "CHEMICAL", 146, 157], ["SiO 2", "SIMPLE_CHEMICAL", 0, 5], ["SiO 2 nanomaterials", "TREATMENT", 0, 19], ["Anticaking AgentsSiO", "TREATMENT", 135, 155], ["thickening of pastes", "PROBLEM", 175, 195], ["an anticaking agent", "TREATMENT", 200, 219], ["flow properties in powdered products", "TREATMENT", 239, 275], ["a carrier of fragrances", "TREATMENT", 290, 313], ["nonfood products", "TREATMENT", 337, 353], ["thickening", "OBSERVATION", 175, 185]]], ["As a result, it has been used in food products and is registered within the EU as a food additive E551.", [["E551", "CHEMICAL", 98, 102]]], ["However, still there is a debate regarding the health and safety issues related to the use of such engineered nanoparticles in consumer products (Athinarayanan et al. 2014 ).Packaging and Food SafetyFood is a perishable item.", [["such engineered nanoparticles", "TREATMENT", 94, 123], ["Packaging", "TREATMENT", 174, 183]]], ["The process may be chemical, physical, or biological.", [["may be", "UNCERTAINTY", 12, 18]]], ["The introduction/ presence of any pathogen in food can result in its poisoning, which can be deadly.", [["poisoning", "DISEASE", 69, 78], ["any pathogen in food", "PROBLEM", 30, 50], ["its poisoning", "PROBLEM", 65, 78]]], ["A good-quality packaging material is thus required, which is safe, nontoxic, and costeffective.", [["good", "OBSERVATION_MODIFIER", 2, 6], ["-quality", "OBSERVATION_MODIFIER", 6, 14], ["packaging material", "OBSERVATION", 15, 33], ["nontoxic", "OBSERVATION_MODIFIER", 67, 75]]], ["Packaging using nanomaterial controls pH, temperature, moisture, and freshness of the material kept inside the packet.", [["Packaging", "TREATMENT", 0, 9]]], ["It provides smart packaging and extends the shelf life of a product so that food material can be transported to a long distance also.", [["smart packaging", "TREATMENT", 12, 27]]], ["Nanosensors are developed for smart packaging so as to detect spoilage of food and release nanoantimicrobials as and when required, to extend shelf life.", [["smart packaging", "TREATMENT", 30, 45], ["nanoantimicrobials", "TREATMENT", 91, 109]]], ["There is a great demand for nano-enabled packaging for food, beverage, and pharmaceutical industries due to the regularly changing consumption patterns.", [["nano-enabled packaging", "TREATMENT", 28, 50], ["pharmaceutical industries", "TREATMENT", 75, 100], ["great", "OBSERVATION_MODIFIER", 11, 16]]], ["Such nanopackaging systems can repair small losses like holes/tears because of environmental conditions (temperature and moisture) and make the customer alert if the food is being contaminated due to some or the other reasons.", [["Such nanopackaging systems", "PROBLEM", 0, 26], ["small losses like holes/tears", "PROBLEM", 38, 67], ["environmental conditions", "PROBLEM", 79, 103], ["small", "OBSERVATION_MODIFIER", 38, 43], ["losses", "OBSERVATION", 44, 50], ["tears", "OBSERVATION", 62, 67]]], ["Nanoscience can provide solutions for such problems, change in permeation behavior of foils, enhancing barrier properties (like thermal, chemical, mechanical, and microbial), improving upon mechanical and heat resistance properties, introducing active antimicrobial and antifungal surfaces, and sensing/signaling any microbiological and biochemical changes that have occurred (Alfadul and Elneshwy 2010) .", [["such problems", "PROBLEM", 38, 51], ["enhancing barrier properties", "TREATMENT", 93, 121], ["mechanical and heat resistance properties", "TREATMENT", 190, 231], ["active antimicrobial", "TREATMENT", 245, 265], ["antifungal surfaces", "TREATMENT", 270, 289]]], ["Not only this, the cost of food additive ingredients can be lowered and the shelf life of food products can be increased using this technology.", [["this technology", "TREATMENT", 127, 142]]], ["It has been estimated that advancement in nanotechnology supported by increased global investments has thrusted the nano-enabled packaging market all over the world in the past few years (Nano-enabled Packaging Market 2019).Packaging and Food SafetyAbout 400 companies and more than 400,000 scientists in the world are developing different nanotechnology applications in food and food packaging (Neethirajan and Jayas 2011) .", [["Packaging", "TREATMENT", 224, 233], ["advancement", "OBSERVATION_MODIFIER", 27, 38], ["increased", "OBSERVATION_MODIFIER", 70, 79]]], ["Here, smart packaging industry is growing relatively faster than predicted and is reaching maturity.", [["growing", "OBSERVATION_MODIFIER", 34, 41], ["relatively", "OBSERVATION_MODIFIER", 42, 52], ["faster", "OBSERVATION_MODIFIER", 53, 59]]], ["The demand of consumer today is much more from packaging, particularly from protecting the quality, freshness, and safety of foods as well as convenience.Packaging and Food SafetySeveral organizations have developed smart packaging systems.", [["Packaging", "TREATMENT", 154, 163]]], ["Researchers of Rutgers University have developed an electronic tongue for inclusion in packaging for Kraft Foods, which consists of an array of nanosensors extremely sensitive to gases released by spoiling food.", [["tongue", "ANATOMY", 63, 69], ["tongue", "ORGANISM_SUBDIVISION", 63, 69], ["Kraft Foods", "TREATMENT", 101, 112], ["tongue", "ANATOMY", 63, 69]]], ["They make sensor strip to change its color giving a clear signal, whether the food is fresh or not (World Bank 2017).", [["sensor strip", "PROBLEM", 10, 22]]], ["A packaging film was developed by the Durethan KU2-2601, which is relatively lighter, stronger, and more heat resistant than those available currently in the market (Rani et al. 2017; Hamad et al. 2018) .", [["Durethan KU2-2601", "CHEMICAL", 38, 55], ["Durethan KU2-2601", "SPECIES", 38, 55], ["A packaging film", "TEST", 0, 16], ["relatively", "OBSERVATION_MODIFIER", 66, 76], ["lighter", "OBSERVATION_MODIFIER", 77, 84]]], ["The main purpose of these food packaging films is to protect contents from drying out, moisture and oxygen.", [["oxygen", "CHEMICAL", 100, 106], ["oxygen", "CHEMICAL", 100, 106], ["oxygen", "SIMPLE_CHEMICAL", 100, 106], ["these food packaging films", "TREATMENT", 20, 46], ["moisture and oxygen", "TREATMENT", 87, 106], ["main", "OBSERVATION_MODIFIER", 4, 8], ["oxygen", "OBSERVATION_MODIFIER", 100, 106]]], ["Such film is known as a hybrid system that contains number of silicate nanoparticles, thus reducing the entrance of oxygen and other gases and the exit of moisture, preventing food from spoiling.Packaging and Food SafetyPlastic bottles are normally used by breweries in shipping of beer, as these bottles are lighter than glass and low cost than metal cans.", [["silicate nanoparticles", "CHEMICAL", 62, 84], ["oxygen", "CHEMICAL", 116, 122], ["silicate", "CHEMICAL", 62, 70], ["oxygen", "CHEMICAL", 116, 122], ["silicate nanoparticles", "SIMPLE_CHEMICAL", 62, 84], ["oxygen", "SIMPLE_CHEMICAL", 116, 122], ["Such film", "TEST", 0, 9], ["a hybrid system", "PROBLEM", 22, 37], ["silicate nanoparticles", "TREATMENT", 62, 84], ["oxygen", "TREATMENT", 116, 122], ["other gases", "TEST", 127, 138], ["Packaging", "TREATMENT", 195, 204], ["Food SafetyPlastic bottles", "TREATMENT", 209, 235], ["silicate nanoparticles", "OBSERVATION", 62, 84], ["entrance", "OBSERVATION_MODIFIER", 104, 112], ["oxygen", "OBSERVATION_MODIFIER", 116, 122]]], ["But, alcohol in beer reacts with the plastic of the bottles, which shortens the shelf life of alcohol to a great extent.", [["alcohol", "CHEMICAL", 5, 12], ["alcohol", "CHEMICAL", 94, 101], ["alcohol", "CHEMICAL", 5, 12], ["alcohol", "CHEMICAL", 94, 101], ["alcohol", "SIMPLE_CHEMICAL", 5, 12], ["beer", "SIMPLE_CHEMICAL", 16, 20], ["alcohol", "SIMPLE_CHEMICAL", 94, 101], ["great extent", "OBSERVATION_MODIFIER", 107, 119]]], ["Voridan has developed a nanocomposite in association with Nanocor, containing clay nanoparticles and named as Imperm (Srinivas 2016) .", [["Voridan", "CHEMICAL", 0, 7], ["Nanocor", "CHEMICAL", 58, 65], ["clay nanoparticles", "CHEMICAL", 78, 96], ["Voridan", "SIMPLE_CHEMICAL", 0, 7], ["Nanocor", "SIMPLE_CHEMICAL", 58, 65], ["clay nanoparticles", "SIMPLE_CHEMICAL", 78, 96], ["Nanocor", "TREATMENT", 58, 65], ["clay nanoparticles", "TREATMENT", 78, 96]]], ["These bottles are having both the qualities; these are lighter and stronger than glass and also less likely to shatter.", [["lighter", "OBSERVATION", 55, 62]]], ["It has been suggested that such nanocomposites structure minimizes the loss of carbon dioxide from the beer and the ingress of oxygen to the bottle, so as to keep the beer fresh up to a 6-month shelf life (Lua and Bowles 2013) .", [["carbon dioxide", "CHEMICAL", 79, 93], ["oxygen", "CHEMICAL", 127, 133], ["carbon dioxide", "CHEMICAL", 79, 93], ["oxygen", "CHEMICAL", 127, 133], ["carbon dioxide", "SIMPLE_CHEMICAL", 79, 93], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["such nanocomposites structure", "PROBLEM", 27, 56], ["carbon dioxide", "TREATMENT", 79, 93], ["nanocomposites structure", "OBSERVATION", 32, 56], ["loss", "OBSERVATION_MODIFIER", 71, 75], ["carbon dioxide", "OBSERVATION", 79, 93]]], ["Antimicrobial coatings and dirt repellent plastic bags are used ensuring the safety and security of packaged food.", [["Antimicrobial coatings", "TREATMENT", 0, 22], ["dirt repellent plastic bags", "TREATMENT", 27, 54], ["plastic bags", "OBSERVATION", 42, 54]]], ["This will solve food shortage crises by ensuring that food reaches to masses in time and with good qualities (Hamad et al. 2018) .Packaging and Food SafetyNanosensors used in different food packaging industries include time-temperature integrator and gas detector (Pradhan et al. 2015) .", [["Packaging", "TREATMENT", 130, 139], ["SafetyNanosensors", "TREATMENT", 149, 166], ["gas detector", "TEST", 251, 263], ["masses", "OBSERVATION", 70, 76]]], ["Nanoparticle in solution, nanoparticle-based sensors, array biosensors, electronic noses, nano-test strips, and nanocantilevers are among the different types of nanosensors used (Tang et al. 2009 ).", [["Nanoparticle in solution", "TREATMENT", 0, 24], ["nanoparticle-based sensors", "TREATMENT", 26, 52], ["array biosensors", "TREATMENT", 54, 70], ["electronic noses", "TREATMENT", 72, 88], ["nano-test strips", "TREATMENT", 90, 106], ["nanocantilevers", "TREATMENT", 112, 127]]], ["Electronic noses are the type of sensor, which uses several chemical sensors attached to a data processing system (Vidhyalakshmi et al. 2009 ).", [["several chemical sensors", "TREATMENT", 52, 76]]], ["Such sensor behaves just like our human nose, and therefore, this sensor is termed as electronic nose (e-nose).", [["nose", "ANATOMY", 40, 44], ["human", "ORGANISM", 34, 39], ["nose", "ORGANISM_SUBDIVISION", 40, 44], ["nose", "ORGANISM_SUBDIVISION", 97, 101], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39]]], ["There are also reports of electronic tongue (e-tongue) sensors that are based on the principle of an electronic nose.", [["tongue", "ANATOMY", 37, 43], ["tongue", "ORGANISM_SUBDIVISION", 37, 43], ["nose", "ORGANISM_SUBDIVISION", 112, 116], ["electronic tongue (e-tongue) sensors", "PROBLEM", 26, 62], ["tongue", "ANATOMY", 37, 43]]], ["The color is changed in contact with any sign of spoilage in the food material indicating that the food does not remain fit for consumption (Yuan et al. 2008) .", [["spoilage in the food material", "PROBLEM", 49, 78], ["changed", "OBSERVATION", 13, 20], ["spoilage", "OBSERVATION", 49, 57]]], ["Packaging with such nanosensors can identify conditions of food and containers (internal and external) throughout the supply chain.", [["Packaging", "TREATMENT", 0, 9], ["such nanosensors", "TREATMENT", 15, 31], ["internal and external) throughout the supply chain", "TREATMENT", 80, 130]]], ["Nanosensors can also detect gases in food, spoiled in plastic packaging, where a change in color of packaging alerts the consumer.Packaging and Food SafetyA number of types of packaging materials are used in food sectors, which include active packaging, smart/intelligent packaging, edible coating, and biobased (biodegradable) polymeric films (Rai et al. 2018) .", [["Packaging", "TREATMENT", 130, 139], ["packaging materials", "TREATMENT", 176, 195], ["active packaging", "TREATMENT", 236, 252], ["smart/intelligent packaging", "TREATMENT", 254, 281], ["edible coating", "TREATMENT", 283, 297], ["biobased (biodegradable) polymeric films", "TREATMENT", 303, 343], ["packaging materials", "OBSERVATION", 176, 195]]], ["Nanotechnology-driven food packaging has been categorized as follows.Active PackagingActive packaging means the use of active nanomaterials like antimicrobials and oxygen scavenging materials.", [["oxygen", "CHEMICAL", 164, 170], ["oxygen", "CHEMICAL", 164, 170], ["oxygen", "SIMPLE_CHEMICAL", 164, 170], ["Active Packaging", "TREATMENT", 69, 85], ["active nanomaterials", "TREATMENT", 119, 139], ["antimicrobials", "TREATMENT", 145, 159], ["oxygen scavenging materials", "TREATMENT", 164, 191], ["Packaging", "OBSERVATION", 76, 85], ["Active packaging", "OBSERVATION", 85, 101], ["active", "OBSERVATION_MODIFIER", 119, 125], ["nanomaterials", "OBSERVATION", 126, 139], ["antimicrobials", "OBSERVATION_MODIFIER", 145, 159], ["oxygen scavenging", "OBSERVATION", 164, 181]]], ["The use of such nanomaterials is beneficial to interact directly with food to provide better protection to the product.", [["such nanomaterials", "TREATMENT", 11, 29]]], ["Some nanomaterials can provide antimicrobial properties to food packaging.", [["Some nanomaterials", "PROBLEM", 0, 18], ["antimicrobial properties", "TREATMENT", 31, 55], ["food packaging", "TREATMENT", 59, 73], ["nanomaterials", "OBSERVATION", 5, 18]]], ["Some of them are nanosilver, nano-titanium dioxide, nano-magnesium oxide, nano-copper oxide, carbon nanotubes, etc. Active packaging utilizes the packaging materials, which interact with the environment, and food also and plays an active role in increasing the shelf life of products.", [["nanosilver", "CHEMICAL", 17, 27], ["titanium dioxide", "CHEMICAL", 34, 50], ["magnesium oxide", "CHEMICAL", 57, 72], ["nano-copper oxide", "CHEMICAL", 74, 91], ["carbon nanotubes", "CHEMICAL", 93, 109], ["nanosilver", "CHEMICAL", 17, 27], ["titanium dioxide", "CHEMICAL", 34, 50], ["magnesium oxide", "CHEMICAL", 57, 72], ["copper oxide", "CHEMICAL", 79, 91], ["carbon", "CHEMICAL", 93, 99], ["nanosilver", "SIMPLE_CHEMICAL", 17, 27], ["nano-titanium dioxide", "SIMPLE_CHEMICAL", 29, 50], ["nano-magnesium oxide", "SIMPLE_CHEMICAL", 52, 72], ["nano-copper oxide", "SIMPLE_CHEMICAL", 74, 91], ["carbon nanotubes", "SIMPLE_CHEMICAL", 93, 109], ["nanosilver", "TREATMENT", 17, 27], ["nano-titanium dioxide", "TREATMENT", 29, 50], ["nano-magnesium oxide", "TREATMENT", 52, 72], ["nano-copper oxide", "TREATMENT", 74, 91], ["carbon nanotubes", "TREATMENT", 93, 109], ["Active packaging", "TREATMENT", 116, 132], ["the packaging materials", "TREATMENT", 142, 165], ["carbon nanotubes", "OBSERVATION", 93, 109], ["packaging", "OBSERVATION", 123, 132]]], ["Advances made in active packaging leads to delayed oxidation, controlled respiration rate, microbial growth, and moisture migration (Brody 2006) .Active PackagingThese packaging technologies include absorbers of carbon dioxide, odor, and ethylene and emitters of CO 2 and aroma.", [["carbon dioxide", "CHEMICAL", 212, 226], ["ethylene", "CHEMICAL", 238, 246], ["carbon dioxide", "CHEMICAL", 212, 226], ["ethylene", "CHEMICAL", 238, 246], ["CO 2", "CHEMICAL", 263, 267], ["carbon dioxide", "SIMPLE_CHEMICAL", 212, 226], ["ethylene", "SIMPLE_CHEMICAL", 238, 246], ["CO 2", "SIMPLE_CHEMICAL", 263, 267], ["active packaging", "TREATMENT", 17, 33], ["delayed oxidation", "TREATMENT", 43, 60], ["microbial growth", "PROBLEM", 91, 107], ["Active Packaging", "TREATMENT", 146, 162], ["carbon dioxide", "TREATMENT", 212, 226], ["odor", "PROBLEM", 228, 232], ["ethylene and emitters of CO", "TREATMENT", 238, 265], ["carbon dioxide", "OBSERVATION", 212, 226], ["aroma", "ANATOMY", 272, 277]]], ["But purging moisture control and oxygen removal remain prominent in active packaging, and out of these, purge control has been most successful on commercial scale.", [["oxygen", "CHEMICAL", 33, 39], ["oxygen", "CHEMICAL", 33, 39], ["oxygen", "SIMPLE_CHEMICAL", 33, 39], ["purging moisture control", "TREATMENT", 4, 28], ["oxygen removal", "TREATMENT", 33, 47], ["active packaging", "TREATMENT", 68, 84], ["purge control", "TREATMENT", 104, 117], ["oxygen removal", "OBSERVATION", 33, 47], ["prominent", "OBSERVATION_MODIFIER", 55, 64], ["active packaging", "OBSERVATION", 68, 84]]], ["Best example is the use of drip-absorbing pad in the poultry industry (Suppakul et al. 2003) .", [["pad", "TISSUE", 42, 45], ["drip", "TREATMENT", 27, 31]]], ["Active packaging technology also involves change in permselectivity (selective permeation) of package materials to different gases.", [["Active packaging technology", "TREATMENT", 0, 27], ["permselectivity (selective permeation) of package materials", "TREATMENT", 52, 111], ["different gases", "TEST", 115, 130]]], ["Some nanocomposite materials have been used in active packaging so as to prevent oxygen, carbon dioxide, and moisture from reaching the food (Brody et al. 2008 ).", [["oxygen", "CHEMICAL", 81, 87], ["carbon dioxide", "CHEMICAL", 89, 103], ["oxygen", "CHEMICAL", 81, 87], ["carbon dioxide", "CHEMICAL", 89, 103], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["carbon dioxide", "SIMPLE_CHEMICAL", 89, 103], ["Some nanocomposite materials", "TREATMENT", 0, 28], ["active packaging", "TREATMENT", 47, 63], ["oxygen, carbon dioxide", "TREATMENT", 81, 103], ["nanocomposite materials", "OBSERVATION", 5, 28], ["carbon dioxide", "OBSERVATION", 89, 103]]], ["An active system involving moisture scavenging has been quite commonly used particularly for packaging of dried and moisture-sensitive foods, while oxygen scavengers are normally inserted into the package in the form of small sachets just to reduce the oxygen level within the package, because an environment free from oxygen prevents oxidation of food as well as the growth of aerobic bacteria and mold.", [["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 253, 259], ["oxygen", "CHEMICAL", 319, 325], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 253, 259], ["oxygen", "CHEMICAL", 319, 325], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["oxygen", "SIMPLE_CHEMICAL", 253, 259], ["oxygen", "SIMPLE_CHEMICAL", 319, 325], ["moisture scavenging", "TREATMENT", 27, 46], ["oxygen scavengers", "TREATMENT", 148, 165], ["small sachets", "TREATMENT", 220, 233], ["the oxygen level", "TEST", 249, 265], ["oxygen prevents oxidation of food", "TREATMENT", 319, 352], ["aerobic bacteria", "PROBLEM", 378, 394], ["active", "OBSERVATION_MODIFIER", 3, 9], ["moisture scavenging", "OBSERVATION", 27, 46], ["small", "OBSERVATION_MODIFIER", 220, 225], ["sachets", "OBSERVATION", 226, 233]]], ["Ethylene-absorbing material is incorporated in packaging materials with the object of slowing the process of ripening and senescence of fruits and vegetables triggered by ethylene (Brody 2009) .Active PackagingDifferent antimicrobial agents are also incorporated in packaging so as to prevent the growth of spoilage and pathogenic microorganisms, which can directly influence the shelf life of products.", [["fruits", "ANATOMY", 136, 142], ["vegetables", "ANATOMY", 147, 157], ["Ethylene", "CHEMICAL", 0, 8], ["ethylene", "CHEMICAL", 171, 179], ["Ethylene", "CHEMICAL", 0, 8], ["ethylene", "CHEMICAL", 171, 179], ["Ethylene", "SIMPLE_CHEMICAL", 0, 8], ["fruits", "ORGANISM_SUBDIVISION", 136, 142], ["vegetables", "ORGANISM_SUBDIVISION", 147, 157], ["ethylene", "SIMPLE_CHEMICAL", 171, 179], ["Ethylene-absorbing material", "TREATMENT", 0, 27], ["Active Packaging", "TREATMENT", 194, 210], ["Different antimicrobial agents", "TREATMENT", 210, 240], ["spoilage", "PROBLEM", 307, 315], ["pathogenic microorganisms", "PROBLEM", 320, 345], ["absorbing material", "OBSERVATION_MODIFIER", 9, 27], ["antimicrobial agents", "OBSERVATION", 220, 240]]], ["It is more advantageous compared to direct addition of some antimicrobial agents onto foods either by sprays or drips.", [["some antimicrobial agents", "TREATMENT", 55, 80], ["drips", "TREATMENT", 112, 117], ["more advantageous", "OBSERVATION_MODIFIER", 6, 23]]], ["This packaging permits slow but a continuous release of antimicrobial agent from this packaging material to food surfaces, so that a high concentration of these agents is not there over a long period (Quintavalla and Vicini 2002) .", [["a continuous release of antimicrobial agent", "TREATMENT", 32, 75], ["this packaging material", "TREATMENT", 81, 104], ["slow", "OBSERVATION_MODIFIER", 23, 27]]], ["Different enzymes, bacteriocins, essential oils, anhydrides, and weak organic acids have also been investigated in terms of antimicrobial activity of food packaging systems (Corrales et al. 2014) .Active PackagingImproved packaging by nanomaterials involves mixing them into the polymer matrix, so as to improve the gas barrier properties and also resistance of the packaging against temperature and humidity.", [["organic acids", "CHEMICAL", 70, 83], ["anhydrides", "CHEMICAL", 49, 59], ["anhydrides", "SIMPLE_CHEMICAL", 49, 59], ["organic acids", "SIMPLE_CHEMICAL", 70, 83], ["Different enzymes", "TEST", 0, 17], ["bacteriocins", "TEST", 19, 31], ["anhydrides", "TREATMENT", 49, 59], ["weak organic acids", "PROBLEM", 65, 83], ["Active Packaging", "TREATMENT", 197, 213], ["the gas barrier properties", "TREATMENT", 312, 338], ["the packaging", "TREATMENT", 362, 375], ["Packaging", "OBSERVATION_MODIFIER", 204, 213], ["Improved packaging", "OBSERVATION", 213, 231], ["polymer matrix", "OBSERVATION_MODIFIER", 279, 293]]], ["The US Food and Drug Administration has also approved the use of these nanocomposites in contact with food.Smart/Intelligent PackagingSmart packaging is designed to sense any microbial or biochemical changes in the food products as it can detect the growth of any pathogens in the food.", [["Drug Administration", "TREATMENT", 16, 35], ["these nanocomposites", "TREATMENT", 65, 85], ["Intelligent PackagingSmart packaging", "TREATMENT", 113, 149]]], ["Some such smart packaging has been developed to be used as a tracking device for food safety.", [["Some such smart packaging", "TREATMENT", 0, 25], ["a tracking device", "TREATMENT", 59, 76], ["smart packaging", "OBSERVATION", 10, 25]]], ["Presently, British Airways, MonoPrix supermarket, and Nestl\u00e9 are using chemical sensors, which can quickly detect any color change (Pehanich 2006) .", [["chemical sensors", "TEST", 71, 87], ["Airways", "ANATOMY", 19, 26]]], ["Nanotechnology has been used to manufacture a \"smart\" packaging, which can extend the shelf life of food dramatically, which permits it to be transported to a longer distance.", [["a \"smart\" packaging", "TREATMENT", 44, 63]]], ["Intelligent or smart packaging has been designed to monitor and communicate information about quality of food.", [["smart packaging", "TREATMENT", 15, 30]]], ["It includes time-temperature indicators (TTIs), ripeness indicators, biosensors, and radio frequency identification.", [["radio frequency identification", "TEST", 85, 115]]], ["Such smart devices may be either incorporated in package materials itself or these are attached inside or outside of a package (Kerry et al. 2006; Yam et al. 2005; Kerry and Butler 2008) .", [["Such smart devices", "TREATMENT", 0, 18], ["smart devices", "OBSERVATION", 5, 18]]], ["Smart packaging either responds to change in environmental conditions, repairs, or alerts the consumer about such contamination and/or the presence of some harmful pathogens.", [["Smart packaging", "TREATMENT", 0, 15], ["repairs", "TREATMENT", 71, 78], ["such contamination", "PROBLEM", 109, 127], ["some harmful pathogens", "PROBLEM", 151, 173], ["harmful", "OBSERVATION_MODIFIER", 156, 163], ["pathogens", "OBSERVATION", 164, 173]]], ["It is capable of detecting spoilage of food and release nanoantimicrobes to extend shelf life of food, so that supermarkets can keep their food materials even for a longer time periods before it is sold.", [["nanoantimicrobes", "SIMPLE_CHEMICAL", 56, 72], ["nanoantimicrobes", "TREATMENT", 56, 72]]], ["Nanosensors are used as tiny chips invisible to the human eye, embedded into food products that act as electronic barcodes (Sekhon 2010) .Smart/Intelligent PackagingIntelligent packaging is also developed, with specific preservative, which starts releasing preservatives as soon as food starts spoiling.", [["eye", "ANATOMY", 58, 61], ["human", "ORGANISM", 52, 57], ["eye", "ORGAN", 58, 61], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["Nanosensors", "TREATMENT", 0, 11], ["Smart/Intelligent PackagingIntelligent packaging", "TREATMENT", 138, 186], ["human eye", "ANATOMY", 52, 61], ["Intelligent packaging", "OBSERVATION", 165, 186]]], ["Such \"release on command\" preservative packaging is based on a bio-switch.", [["preservative packaging", "TREATMENT", 26, 48]]], ["These are \"smart\" food packaging, which will warn, when oxygen has got inside or if food is being spoiled.", [["oxygen", "CHEMICAL", 56, 62], ["oxygen", "CHEMICAL", 56, 62], ["oxygen", "SIMPLE_CHEMICAL", 56, 62], ["oxygen", "TREATMENT", 56, 62], ["food packaging", "OBSERVATION", 18, 32]]], ["These packaging are already in use in brewing and dairy industries.", [["These packaging", "TREATMENT", 0, 15]]], ["These consist of nanofilters, which can filter microorganisms and sometime even viruses.", [["nanofilters", "TREATMENT", 17, 28]]], ["In some experiments, color was successfully removed from beetroot juice, but the flavor is not affected.", [["beetroot juice", "ANATOMY", 57, 71], ["beetroot juice", "ORGANISM_SUBSTANCE", 57, 71], ["beetroot juice", "OBSERVATION", 57, 71], ["not", "UNCERTAINTY", 91, 94], ["affected", "OBSERVATION", 95, 103]]], ["Similarly red wine was turned into colorless or white in color.", [["red wine", "OBSERVATION", 10, 18], ["white", "OBSERVATION_MODIFIER", 48, 53]]], ["Lactose can also be filtered from milk, and it is replaced with some other sugar so that milk can be used by the lactose intolerant also.", [["milk", "ANATOMY", 34, 38], ["milk", "ANATOMY", 89, 93], ["Lactose", "CHEMICAL", 0, 7], ["lactose", "CHEMICAL", 113, 120], ["Lactose", "CHEMICAL", 0, 7], ["sugar", "CHEMICAL", 75, 80], ["lactose", "CHEMICAL", 113, 120], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["milk", "ORGANISM_SUBSTANCE", 34, 38], ["sugar", "SIMPLE_CHEMICAL", 75, 80], ["milk", "ORGANISM_SUBSTANCE", 89, 93], ["lactose", "SIMPLE_CHEMICAL", 113, 120], ["Lactose", "TREATMENT", 0, 7], ["the lactose intolerant", "TREATMENT", 109, 131], ["lactose intolerant", "OBSERVATION", 113, 131]]], ["Nanoceramic particles are used for clustering of dirt molecules, so as to keep cooking oil fresh (Llobet et al. 2007; Wooster 2010) .", [["dirt molecules", "PROTEIN", 49, 63], ["Nanoceramic particles", "TREATMENT", 0, 21], ["dirt molecules", "PROBLEM", 49, 63]]], ["Nanotechnology has proved it worth in food safety by developing highly sensitive and low-cost nanosensors, which can respond to changes in environmental conditions during storage, degradation products, or contamination by microbes.", [["highly sensitive and low-cost nanosensors", "PROBLEM", 64, 105], ["degradation products", "TREATMENT", 180, 200]]], ["Such nanosensors can be effectively used in packaging materials (Bouwmeester et al. 2014; Liao et al. 2005) .Smart/Intelligent PackagingTime-temperature indicators (TTIs nanosensors) have been designed to monitor, record, and translate the safety of food.", [["Such nanosensors", "TREATMENT", 0, 16], ["Intelligent Packaging", "TREATMENT", 115, 136]]], ["They also allow manufacturers to locate their foods along the supply line.", [["supply line", "OBSERVATION", 62, 73]]], ["A system based on gold nanoparticles for chilled foods has been developed by Timestrip.", [["gold nanoparticles", "CHEMICAL", 18, 36], ["gold nanoparticles", "SIMPLE_CHEMICAL", 18, 36], ["A system", "TREATMENT", 0, 8], ["gold nanoparticles", "TREATMENT", 18, 36], ["chilled foods", "PROBLEM", 41, 54]]], ["The system looks red above freezing temperature, but red color is lost because of agglomeration of the gold nanoparticles, when accidental freezing occurs (Robinson and Morrison 2010) .Smart/Intelligent PackagingGas sensors are also used for identification and quantification of various microorganisms, because they emit gas.", [["gold nanoparticles", "SIMPLE_CHEMICAL", 103, 121], ["freezing temperature", "PROBLEM", 27, 47], ["red color", "TEST", 53, 62], ["agglomeration", "PROBLEM", 82, 95], ["the gold nanoparticles", "TREATMENT", 99, 121], ["Intelligent PackagingGas sensors", "TREATMENT", 191, 223], ["various microorganisms", "PROBLEM", 279, 301], ["above freezing", "OBSERVATION_MODIFIER", 21, 35], ["temperature", "OBSERVATION_MODIFIER", 36, 47], ["agglomeration", "OBSERVATION", 82, 95], ["Gas sensors", "OBSERVATION", 212, 223]]], ["Metal oxide gas nanosensor is most commonly used due to their high sensitivity and stability (Setkus 2002) .", [["Metal oxide", "CHEMICAL", 0, 11], ["Metal oxide", "CHEMICAL", 0, 11], ["Metal oxide", "SIMPLE_CHEMICAL", 0, 11], ["Metal oxide gas nanosensor", "TREATMENT", 0, 26], ["their high sensitivity", "PROBLEM", 56, 78], ["stability", "OBSERVATION_MODIFIER", 83, 92]]], ["Conducting polymers based nanosensors are also used because of their capability for identification and quantification of such microorganisms based on their gas emissions (Ahuja et al. 2007 ).", [["Conducting polymers based nanosensors", "TREATMENT", 0, 37], ["such microorganisms", "PROBLEM", 121, 140], ["their gas emissions", "TEST", 150, 169]]], ["Nontoxic and irreversible oxygen sensors were developed to assure the absence of oxygen in oxygen-free food packaging systems.", [["oxygen", "CHEMICAL", 26, 32], ["oxygen", "CHEMICAL", 81, 87], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "CHEMICAL", 26, 32], ["oxygen", "CHEMICAL", 81, 87], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 26, 32], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["Nontoxic and irreversible oxygen sensors", "PROBLEM", 0, 40], ["oxygen in oxygen", "TREATMENT", 81, 97], ["irreversible", "OBSERVATION_MODIFIER", 13, 25], ["oxygen sensors", "OBSERVATION", 26, 40]]], ["Here, a UV-activated oxygen indicator was used, which is almost colorless on UV exposure, but blue color is restored in the presence of oxygen (Lee et al. 2002) .", [["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 136, 142], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 136, 142], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 136, 142], ["a UV-activated oxygen indicator", "TREATMENT", 6, 37], ["UV exposure", "TREATMENT", 77, 88], ["blue color", "TEST", 94, 104], ["colorless", "OBSERVATION_MODIFIER", 64, 73], ["UV exposure", "OBSERVATION", 77, 88], ["blue color", "OBSERVATION", 94, 104], ["oxygen", "OBSERVATION_MODIFIER", 136, 142]]], ["Rapid, sensitive, and relatively low-cost diagnostic methods for detection of pathogens are being developed making use of unique magnetic, electrical, luminescent, and catalytic properties of nanomaterials (Merkoci 2010; Ayala-Zavala et al. 2014 ).Smart/Intelligent PackagingAn electronic tongue or nose device has been fabricated, which consists of an array of nanosensors.", [["tongue", "ANATOMY", 289, 295], ["tongue", "ORGAN", 289, 295], ["nose", "ORGAN", 299, 303], ["pathogens", "PROBLEM", 78, 87], ["Smart/Intelligent Packaging", "TREATMENT", 248, 275], ["nose device", "TREATMENT", 299, 310], ["an array of nanosensors", "TREATMENT", 350, 373], ["pathogens", "OBSERVATION", 78, 87], ["Intelligent Packaging", "OBSERVATION", 254, 275], ["tongue", "ANATOMY", 289, 295], ["nose", "ANATOMY", 299, 303]]], ["Electronic nose (e-nose) has been developed for detecting freshness of fish (Oconnell et al. 2001) , dairy products (off-flavor and rancidity of milk) (Ampuero and Bosset 2003; Marsili 1999 Marsili , 2000 Capone et al. 2001 ), spoilage of red wine (Berna et al. 2008) , red meat (El Barbri et al. 2008; L\u00e4ngkvist et al. 2013; Musatov et al. 2010) , wine aging (Lozano et al. 2008 ), classification of different brands of coffee (Pardo et al. 2000) , etc. These are extremely sensitive to gases released by spoiling microorganisms and produce change in color, indicating that the food is deteriorated.", [["milk", "ANATOMY", 145, 149], ["red meat", "ANATOMY", 270, 278], ["nose", "MULTI-TISSUE_STRUCTURE", 11, 15], ["fish", "ORGANISM", 71, 75], ["milk", "ORGANISM_SUBDIVISION", 145, 149], ["meat", "ORGANISM_SUBDIVISION", 274, 278], ["red wine", "SPECIES", 239, 247], ["spoiling microorganisms", "PROBLEM", 506, 529], ["change in color", "PROBLEM", 542, 557], ["nose", "ANATOMY", 11, 15], ["change", "OBSERVATION_MODIFIER", 542, 548], ["deteriorated", "OBSERVATION_MODIFIER", 587, 599]]], ["Such nanosensors could be placed directly into the packaging material (Liu et al. 2007; Lange et al. 2002 ).", [["Such nanosensors", "TREATMENT", 0, 16]]], ["An electronic tongue developed by Kraft Foods (Smart Packaging systems, Glenview, IL, USA) may be incorporated in packaging.", [["tongue", "ANATOMY", 14, 20], ["tongue", "ORGAN", 14, 20], ["An electronic tongue", "PROBLEM", 0, 20], ["Smart Packaging systems", "TREATMENT", 47, 70], ["tongue", "ANATOMY", 14, 20], ["Kraft Foods", "OBSERVATION", 34, 45]]], ["It also consists of an array of nanosensors, which are sensitive to gases released by spoiling food, and in that case, the sensor changes its color, giving a visible signal about freshness or adulteration of food (Momin et al. 2013) .", [["the sensor changes its color", "PROBLEM", 119, 147]]], ["Electronic tongue (e-tongue) has been fabricated for determination of concentration of nitrite, nitrate, and chloride in minced meat (Campos et al. 2010) , ripening of grapes (Campos et al. 2013) , quality of tea (Kumar et al. 2016) , polyphenols in wine (Andrei et al. 2016; Cet\u00f3 et al. 2012; Magro et al. 2016) , etc.Smart/Intelligent PackagingSilicate nanoparticles-packed films can control flow of oxygen into the pack as well as leakage of moisture out of the packings.", [["tongue", "ANATOMY", 11, 17], ["meat", "ANATOMY", 128, 132], ["nitrite", "CHEMICAL", 87, 94], ["nitrate", "CHEMICAL", 96, 103], ["chloride", "CHEMICAL", 109, 117], ["polyphenols", "CHEMICAL", 235, 246], ["oxygen", "CHEMICAL", 402, 408], ["nitrite", "CHEMICAL", 87, 94], ["nitrate", "CHEMICAL", 96, 103], ["chloride", "CHEMICAL", 109, 117], ["polyphenols", "CHEMICAL", 235, 246], ["oxygen", "CHEMICAL", 402, 408], ["tongue", "ORGAN", 11, 17], ["nitrite", "SIMPLE_CHEMICAL", 87, 94], ["nitrate", "SIMPLE_CHEMICAL", 96, 103], ["chloride", "SIMPLE_CHEMICAL", 109, 117], ["grapes", "ORGANISM_SUBDIVISION", 168, 174], ["tea", "ORGANISM_SUBDIVISION", 209, 212], ["polyphenols", "SIMPLE_CHEMICAL", 235, 246], ["PackagingSilicate nanoparticles", "SIMPLE_CHEMICAL", 337, 368], ["oxygen", "SIMPLE_CHEMICAL", 402, 408], ["concentration of nitrite", "TREATMENT", 70, 94], ["nitrate", "TREATMENT", 96, 103], ["chloride", "TREATMENT", 109, 117], ["Smart/Intelligent PackagingSilicate nanoparticles", "TREATMENT", 319, 368], ["packed films", "TREATMENT", 369, 381], ["oxygen into the pack", "TREATMENT", 402, 422], ["the packings", "TREATMENT", 461, 473], ["tongue", "ANATOMY", 11, 17], ["leakage", "OBSERVATION", 434, 441], ["moisture", "OBSERVATION_MODIFIER", 445, 453], ["packings", "OBSERVATION", 465, 473]]], ["It protects the package from being spoiled.", [["package", "OBSERVATION", 16, 23]]], ["The amount of packaging waste associated with processed food can also be reduced by using nanotechnology assisting in the preservation of fresh food.Carbon NanotubesFood packaging materials are available ranging from films, carbon nanotubes, to waxy nano-coatings.", [["carbon nanotubes", "CHEMICAL", 224, 240], ["Carbon", "CHEMICAL", 149, 155], ["carbon", "CHEMICAL", 224, 230], ["carbon nanotubes", "SIMPLE_CHEMICAL", 224, 240], ["packaging waste", "TREATMENT", 14, 29], ["nanotechnology", "TREATMENT", 90, 104], ["Carbon NanotubesFood packaging materials", "TREATMENT", 149, 189], ["carbon nanotubes", "TREATMENT", 224, 240], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["packaging waste", "OBSERVATION", 14, 29], ["reduced", "OBSERVATION_MODIFIER", 73, 80]]], ["Carbon nanotubes (CNTs) are available in both forms, singlewalled nanotube (SWCNT) and multiwalled nanotube (MWCNT).", [["Carbon nanotubes", "CHEMICAL", 0, 16], ["CNTs", "CHEMICAL", 18, 22], ["SWCNT", "CHEMICAL", 76, 81], ["multiwalled nanotube", "CHEMICAL", 87, 107], ["MWCNT", "CHEMICAL", 109, 114], ["Carbon", "CHEMICAL", 0, 6], ["Carbon nanotubes", "SIMPLE_CHEMICAL", 0, 16], ["singlewalled nanotube", "SIMPLE_CHEMICAL", 53, 74], ["SWCNT", "SIMPLE_CHEMICAL", 76, 81], ["multiwalled nanotube", "SIMPLE_CHEMICAL", 87, 107], ["Carbon nanotubes (CNTs)", "TREATMENT", 0, 23], ["singlewalled nanotube (SWCNT) and multiwalled nanotube (MWCNT)", "TREATMENT", 53, 115]]], ["SWCNT is generally one atom thick, while MWCNT comprises of several concentric tubes with very high aspect ratios and elastic modulus.", [["SWCNT", "CHEMICAL", 0, 5], ["MWCNT", "CHEMICAL", 41, 46], ["SWCNT", "SIMPLE_CHEMICAL", 0, 5], ["MWCNT", "SIMPLE_CHEMICAL", 41, 46], ["several concentric tubes", "TREATMENT", 60, 84], ["very high aspect ratios", "PROBLEM", 90, 113], ["elastic modulus", "PROBLEM", 118, 133], ["one atom thick", "OBSERVATION_MODIFIER", 19, 33], ["several", "OBSERVATION_MODIFIER", 60, 67], ["concentric tubes", "OBSERVATION", 68, 84], ["very", "OBSERVATION_MODIFIER", 90, 94], ["high", "OBSERVATION_MODIFIER", 95, 99], ["elastic modulus", "OBSERVATION", 118, 133]]], ["Asgari et al. (2014) reported that CNTs infused with polyethylene films can be used for the packaging of Mazafati dates, which can prevent fungal invasion up to 90 days.", [["CNTs", "CHEMICAL", 35, 39], ["polyethylene films", "CHEMICAL", 53, 71], ["polyethylene", "CHEMICAL", 53, 65], ["CNTs", "SIMPLE_CHEMICAL", 35, 39], ["polyethylene films", "SIMPLE_CHEMICAL", 53, 71], ["Mazafati", "ORGANISM", 105, 113], ["polyethylene films", "TREATMENT", 53, 71], ["Mazafati dates", "TREATMENT", 105, 119], ["fungal invasion", "PROBLEM", 139, 154], ["fungal invasion", "OBSERVATION", 139, 154]]], ["Carbon nanotubes have also been developed in packaging to pump out carbon dioxide or absorb undesirable flavors (Sinha et al. 2006) .", [["Carbon nanotubes", "CHEMICAL", 0, 16], ["carbon dioxide", "CHEMICAL", 67, 81], ["Carbon", "CHEMICAL", 0, 6], ["carbon dioxide", "CHEMICAL", 67, 81], ["Carbon nanotubes", "SIMPLE_CHEMICAL", 0, 16], ["carbon dioxide", "SIMPLE_CHEMICAL", 67, 81], ["Carbon nanotubes", "TREATMENT", 0, 16], ["carbon dioxide", "TREATMENT", 67, 81]]], ["It has been known that CNTs also have antibacterial properties, which may be due to their direct penetration through microbial cells (Sharma et al. 2017) .", [["cells", "ANATOMY", 127, 132], ["CNTs", "SIMPLE_CHEMICAL", 23, 27], ["microbial cells", "CELL", 117, 132], ["microbial cells", "CELL_TYPE", 117, 132], ["antibacterial properties", "TREATMENT", 38, 62], ["their direct penetration through microbial cells", "PROBLEM", 84, 132], ["antibacterial properties", "OBSERVATION", 38, 62], ["may be due to", "UNCERTAINTY", 70, 83]]], ["It has been reported that antimicrobial activity of silver nanoparticles against E. coli and B. cereus spores is significantly enhanced in combination with titanium dioxide and carbon nanotubes, respectively (Krishna et al. 2005) .", [["spores", "ANATOMY", 103, 109], ["silver nanoparticles", "CHEMICAL", 52, 72], ["titanium dioxide", "CHEMICAL", 156, 172], ["carbon nanotubes", "CHEMICAL", 177, 193], ["silver", "CHEMICAL", 52, 58], ["titanium dioxide", "CHEMICAL", 156, 172], ["carbon", "CHEMICAL", 177, 183], ["silver nanoparticles", "SIMPLE_CHEMICAL", 52, 72], ["E. coli", "ORGANISM", 81, 88], ["B. cereus spores", "ORGANISM", 93, 109], ["titanium dioxide", "SIMPLE_CHEMICAL", 156, 172], ["carbon nanotubes", "SIMPLE_CHEMICAL", 177, 193], ["E. coli", "SPECIES", 81, 88], ["B. cereus", "SPECIES", 93, 102], ["E. coli", "SPECIES", 81, 88], ["B. cereus", "SPECIES", 93, 102], ["antimicrobial activity of silver nanoparticles", "TREATMENT", 26, 72], ["E. coli", "PROBLEM", 81, 88], ["B. cereus spores", "PROBLEM", 93, 109], ["titanium dioxide and carbon nanotubes", "TREATMENT", 156, 193], ["antimicrobial", "OBSERVATION_MODIFIER", 26, 39], ["significantly", "OBSERVATION_MODIFIER", 113, 126], ["enhanced", "OBSERVATION_MODIFIER", 127, 135], ["carbon nanotubes", "OBSERVATION", 177, 193]]], ["Ionic nanocomposites of carbon ceramic electrode with multiwalled carbon nanotubes may be used for the electrochemical determination of the adulterants in food and beverages such as food dyes, like sunset yellow, tartrazine, etc. In addition, carbon nanotubes have many other properties that may be exploited later on to develop the next generation of nanosensors.", [["carbon ceramic", "CHEMICAL", 24, 38], ["multiwalled carbon nanotubes", "CHEMICAL", 54, 82], ["tartrazine", "CHEMICAL", 213, 223], ["carbon nanotubes", "CHEMICAL", 243, 259], ["carbon", "CHEMICAL", 24, 30], ["carbon", "CHEMICAL", 66, 72], ["tartrazine", "CHEMICAL", 213, 223], ["carbon", "CHEMICAL", 243, 249], ["multiwalled carbon nanotubes", "SIMPLE_CHEMICAL", 54, 82], ["tartrazine", "SIMPLE_CHEMICAL", 213, 223], ["carbon nanotubes", "SIMPLE_CHEMICAL", 243, 259], ["Ionic nanocomposites of carbon ceramic electrode", "TREATMENT", 0, 48], ["multiwalled carbon nanotubes", "TREATMENT", 54, 82], ["tartrazine", "TREATMENT", 213, 223], ["carbon nanotubes", "TREATMENT", 243, 259], ["carbon ceramic", "OBSERVATION", 24, 38]]], ["An important role is played by CNTs in food packaging and processing, but there may be some pitfalls, like these may migrate into food and contaminate it and can lead to toxic effects in human beings.", [["CNTs", "SIMPLE_CHEMICAL", 31, 35], ["human", "ORGANISM", 187, 192], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 187, 192], ["some pitfalls", "PROBLEM", 87, 100], ["toxic effects in human beings", "PROBLEM", 170, 199]]], ["The toxicity levels of CNTs are considerably high, and therefore, their use is limited.Biobased PackagingNanotechnology can also be used for improving plastic substance barrier, incorporation of bioactive, sensing and signaling of important information about the food, for the change of the pervasion action of foils, growing different barrier characters (microbial, chemical, thermal, and mechanical), enhancing heat resistance and also mechanical characters (Berekaa 2015) .", [["toxicity", "DISEASE", 4, 12], ["CNTs", "SIMPLE_CHEMICAL", 23, 27], ["The toxicity levels of CNTs", "TEST", 0, 27], ["Biobased Packaging", "TREATMENT", 87, 105], ["improving plastic substance barrier", "TREATMENT", 141, 176], ["the pervasion action of foils", "TREATMENT", 287, 316], ["enhancing heat resistance", "PROBLEM", 403, 428], ["heat resistance", "OBSERVATION", 413, 428]]], ["It may also decrease the environmental contamination by making use of decomposable packaging based on biodegradable plastics.Biobased PackagingThese biodegradable plastics are basically polymeric materials, where at least one step in the degradation process is through metabolic process in the presence of some naturally occurring organisms.", [["the environmental contamination", "PROBLEM", 21, 52], ["decomposable packaging", "TREATMENT", 70, 92], ["biodegradable plastics", "TREATMENT", 102, 124], ["Biobased Packaging", "TREATMENT", 125, 143], ["These biodegradable plastics", "TREATMENT", 143, 171], ["the degradation process", "PROBLEM", 234, 257], ["metabolic process", "PROBLEM", 269, 286], ["some naturally occurring organisms", "PROBLEM", 306, 340], ["environmental", "OBSERVATION_MODIFIER", 25, 38], ["contamination", "OBSERVATION", 39, 52], ["biodegradable plastics", "OBSERVATION", 149, 171], ["polymeric materials", "OBSERVATION", 186, 205], ["metabolic process", "OBSERVATION", 269, 286]]], ["Disintegration or fragmentation of the plastics leads to biodegradation under desired conditions of moisture, temperature, and oxygen availability, without producing toxic or environmentally harmful materials (Chandra and Rustgi 1998) .", [["oxygen", "CHEMICAL", 127, 133], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["the plastics", "TREATMENT", 35, 47], ["oxygen availability", "TEST", 127, 146], ["fragmentation", "OBSERVATION", 18, 31]]], ["Such biodegradable polymers can be classified depending upon their source:Biobased Packaging\u2022 Polymers, which are directly extracted or removed from biomass (i.e., polysaccharides, polypeptides, proteins, polynucleotides, etc.) \u2022 Polymers, which are produced by classical chemical synthesis using some renewable biobased monomers or mixed sources of biomass and petroleum (polylactic acid or biopolyester) \u2022 Polymers, which are produced by microorganism or genetically modified bacteria (polyhydroxybutyrate, bacterial cellulose, xanthan, curdian, pullan)Biobased PackagingVarious kinds of biodegradable polymer nanocomposites have been prepared with desired properties for a wide range of applications (Ray and Bousmina 2005) .", [["polylactic acid", "CHEMICAL", 373, 388], ["biopolyester", "CHEMICAL", 392, 404], ["polyhydroxybutyrate", "CHEMICAL", 488, 507], ["xanthan, curdian", "CHEMICAL", 530, 546], ["petroleum", "CHEMICAL", 362, 371], ["polylactic acid", "CHEMICAL", 373, 388], ["biopolyester", "CHEMICAL", 392, 404], ["polyhydroxybutyrate", "CHEMICAL", 488, 507], ["biomass", "SIMPLE_CHEMICAL", 350, 357], ["petroleum", "SIMPLE_CHEMICAL", 362, 371], ["polylactic acid", "SIMPLE_CHEMICAL", 373, 388], ["biopolyester", "SIMPLE_CHEMICAL", 392, 404], ["polyhydroxybutyrate", "SIMPLE_CHEMICAL", 488, 507], ["bacterial cellulose", "SIMPLE_CHEMICAL", 509, 528], ["xanthan", "SIMPLE_CHEMICAL", 530, 537], ["curdian", "SIMPLE_CHEMICAL", 539, 546], ["pullan", "SIMPLE_CHEMICAL", 548, 554], ["biodegradable polymer nanocomposites", "SIMPLE_CHEMICAL", 590, 626], ["Such biodegradable polymers", "TREATMENT", 0, 27], ["Biobased Packaging\u2022 Polymers", "TREATMENT", 74, 102], ["polysaccharides", "TREATMENT", 164, 179], ["polypeptides, proteins", "TREATMENT", 181, 203], ["polynucleotides", "TREATMENT", 205, 220], ["classical chemical synthesis", "PROBLEM", 262, 290], ["some renewable biobased monomers", "TREATMENT", 297, 329], ["petroleum (polylactic acid", "TREATMENT", 362, 388], ["Polymers", "TREATMENT", 408, 416], ["microorganism", "PROBLEM", 440, 453], ["genetically modified bacteria", "PROBLEM", 457, 486], ["polyhydroxybutyrate", "TREATMENT", 488, 507], ["bacterial cellulose, xanthan", "TREATMENT", 509, 537], ["curdian", "TREATMENT", 539, 546], ["pullan", "TREATMENT", 548, 554], ["Biobased Packaging", "TREATMENT", 555, 573], ["biodegradable polymer nanocomposites", "TREATMENT", 590, 626], ["petroleum", "OBSERVATION_MODIFIER", 362, 371], ["biodegradable polymer nanocomposites", "OBSERVATION", 590, 626]]], ["At present, the most commonly used biodegradable nanocomposites include starch and derivatives, polylactic acid (PLA), polybutylene succinate (PBS), polyhydroxybutyrate (PHB), and aliphatic polyester polycaprolactone, which are suitable for packaging purpose.Starch and Their DerivativesStarch is a potential raw material, because it is available from many plants.", [["starch", "CHEMICAL", 72, 78], ["polylactic acid", "CHEMICAL", 96, 111], ["PLA", "CHEMICAL", 113, 116], ["polybutylene succinate", "CHEMICAL", 119, 141], ["polyhydroxybutyrate", "CHEMICAL", 149, 168], ["PHB", "CHEMICAL", 170, 173], ["polycaprolactone", "CHEMICAL", 200, 216], ["Starch", "CHEMICAL", 259, 265], ["Starch", "CHEMICAL", 287, 293], ["polylactic acid", "CHEMICAL", 96, 111], ["PLA", "CHEMICAL", 113, 116], ["polybutylene succinate", "CHEMICAL", 119, 141], ["polyhydroxybutyrate", "CHEMICAL", 149, 168], ["PHB", "CHEMICAL", 170, 173], ["aliphatic polyester polycaprolactone", "CHEMICAL", 180, 216], ["starch", "SIMPLE_CHEMICAL", 72, 78], ["derivatives", "SIMPLE_CHEMICAL", 83, 94], ["polylactic acid", "SIMPLE_CHEMICAL", 96, 111], ["PLA", "SIMPLE_CHEMICAL", 113, 116], ["polybutylene succinate", "SIMPLE_CHEMICAL", 119, 141], ["PBS", "SIMPLE_CHEMICAL", 143, 146], ["polyhydroxybutyrate", "SIMPLE_CHEMICAL", 149, 168], ["PHB", "SIMPLE_CHEMICAL", 170, 173], ["aliphatic polyester polycaprolactone", "SIMPLE_CHEMICAL", 180, 216], ["Starch", "SIMPLE_CHEMICAL", 259, 265], ["Starch", "SIMPLE_CHEMICAL", 287, 293], ["biodegradable nanocomposites", "TREATMENT", 35, 63], ["starch and derivatives", "TREATMENT", 72, 94], ["polylactic acid (PLA)", "TREATMENT", 96, 117], ["polybutylene succinate (PBS)", "TREATMENT", 119, 147], ["polyhydroxybutyrate (PHB)", "TREATMENT", 149, 174], ["aliphatic polyester polycaprolactone", "TREATMENT", 180, 216], ["Starch", "TREATMENT", 259, 265], ["Their DerivativesStarch", "TREATMENT", 270, 293]]], ["Its large production may fulfill current requirements, and it is low cost (Gonera and Cornillon 2002) , but it cannot form films with appropriate mechanical strength for a packaging material.", [["a packaging material", "TREATMENT", 170, 190], ["large", "OBSERVATION_MODIFIER", 4, 9], ["production", "OBSERVATION", 10, 20], ["low", "OBSERVATION_MODIFIER", 65, 68]]], ["It is converted to a thermoplastic material on treating in an extruder by application of both thermal and mechanical energy.", [["a thermoplastic material", "PROBLEM", 19, 43], ["both thermal and mechanical energy", "TREATMENT", 89, 123], ["thermoplastic material", "OBSERVATION", 21, 43], ["mechanical energy", "OBSERVATION", 106, 123]]], ["Plasticizers play an important role in efficiently reducing intramolecular hydrogen bonds and also provide stability to properties of product, when thermoplastic starches are produced.", [["hydrogen", "CHEMICAL", 75, 83], ["Plasticizers", "SIMPLE_CHEMICAL", 0, 12], ["Plasticizers", "TREATMENT", 0, 12], ["intramolecular hydrogen bonds", "TREATMENT", 60, 89], ["thermoplastic starches", "TREATMENT", 148, 170]]], ["Hence, there are ample opportunities that thermoplastic starches may be used as packaging material (Kim and Pometto 1994) .Polylactic Acid (PLA)A wide range of biopolyesters can be prepared by conventional chemical synthesis.", [["Polylactic Acid", "CHEMICAL", 123, 138], ["PLA", "CHEMICAL", 140, 143], ["Polylactic Acid", "CHEMICAL", 123, 138], ["PLA", "CHEMICAL", 140, 143], ["Polylactic Acid", "SIMPLE_CHEMICAL", 123, 138], ["PLA", "SIMPLE_CHEMICAL", 140, 143], ["biopolyesters", "SIMPLE_CHEMICAL", 160, 173], ["thermoplastic starches", "TREATMENT", 42, 64], ["Polylactic Acid (PLA", "PROBLEM", 123, 143], ["A wide range of biopolyesters", "TREATMENT", 144, 173]]], ["Presently, polylactic acid is the polymer, which has the highest potential as renewable packaging material, and it is commercially produced on major scale because lactic acid, a monomer of PLA, is easily produced by fermentation of carbohydrate feedstock (biomass).", [["polylactic acid", "CHEMICAL", 11, 26], ["lactic acid", "CHEMICAL", 163, 174], ["PLA", "CHEMICAL", 189, 192], ["polylactic acid", "CHEMICAL", 11, 26], ["lactic acid", "CHEMICAL", 163, 174], ["PLA", "CHEMICAL", 189, 192], ["carbohydrate", "CHEMICAL", 232, 244], ["polylactic acid", "SIMPLE_CHEMICAL", 11, 26], ["lactic acid", "SIMPLE_CHEMICAL", 163, 174], ["PLA", "SIMPLE_CHEMICAL", 189, 192], ["carbohydrate", "SIMPLE_CHEMICAL", 232, 244], ["lactic acid", "PROBLEM", 163, 174], ["polylactic acid", "OBSERVATION", 11, 26], ["highest potential", "OBSERVATION_MODIFIER", 57, 74], ["renewable packaging material", "OBSERVATION", 78, 106], ["PLA", "ANATOMY", 189, 192]]], ["This feedstock can be obtained from a variety of agricultural products like wheat, maize, molasses, and whey.", [["wheat, maize, molasses", "CHEMICAL", 76, 98], ["wheat", "ORGANISM_SUBDIVISION", 76, 81], ["maize", "ORGANISM_SUBDIVISION", 83, 88], ["whey", "ORGANISM_SUBSTANCE", 104, 108], ["wheat", "SPECIES", 76, 81], ["maize", "SPECIES", 83, 88], ["wheat", "SPECIES", 76, 81], ["maize", "SPECIES", 83, 88], ["This feedstock", "TREATMENT", 0, 14], ["agricultural products", "TREATMENT", 49, 70]]], ["Biodegradable polylactic acid (PLA) polymer was evaluated for its use as a material for antimicrobial food packaging (Jin and Zhang 2008) .", [["polylactic acid", "CHEMICAL", 14, 29], ["PLA", "CHEMICAL", 31, 34], ["polylactic acid", "CHEMICAL", 14, 29], ["PLA", "CHEMICAL", 31, 34], ["Biodegradable polylactic acid", "SIMPLE_CHEMICAL", 0, 29], ["PLA", "SIMPLE_CHEMICAL", 31, 34], ["Biodegradable polylactic acid (PLA) polymer", "TREATMENT", 0, 43], ["antimicrobial food packaging", "TREATMENT", 88, 116], ["polylactic acid", "OBSERVATION", 14, 29]]], ["They incorporated nisin in PLA films for controlling foodborne pathogens.", [["nisin", "CHEMICAL", 18, 23], ["PLA", "CHEMICAL", 27, 30], ["foodborne pathogens", "DISEASE", 53, 72], ["PLA", "CHEMICAL", 27, 30], ["nisin", "SIMPLE_CHEMICAL", 18, 23], ["PLA films", "SIMPLE_CHEMICAL", 27, 36], ["nisin in PLA films", "TREATMENT", 18, 36], ["controlling foodborne pathogens", "PROBLEM", 41, 72]]], ["Antimicrobial activity of PLA/nisin films was evaluated in liquid foods (orange juice and liquid egg white) against Listeria monocytogenes, Escherichia coli O157:H7, and Salmonella Enteritidis.", [["orange juice", "ANATOMY", 73, 85], ["PLA/nisin", "CHEMICAL", 26, 35], ["PLA", "CHEMICAL", 26, 29], ["PLA/nisin films", "SIMPLE_CHEMICAL", 26, 41], ["orange juice", "ORGANISM_SUBSTANCE", 73, 85], ["egg", "ORGANISM_SUBDIVISION", 97, 100], ["Listeria monocytogenes", "ORGANISM", 116, 138], ["Escherichia coli", "ORGANISM", 140, 156], ["O157:H7", "ORGANISM", 157, 164], ["Salmonella Enteritidis", "ORGANISM", 170, 192], ["Listeria monocytogenes", "SPECIES", 116, 138], ["Escherichia coli O157", "SPECIES", 140, 161], ["Salmonella Enteritidis", "SPECIES", 170, 192], ["Listeria monocytogenes", "SPECIES", 116, 138], ["Escherichia coli O157:H7", "SPECIES", 140, 164], ["Salmonella Enteritidis", "SPECIES", 170, 192], ["PLA/nisin films", "TREATMENT", 26, 41], ["Listeria monocytogenes", "PROBLEM", 116, 138], ["Escherichia coli", "PROBLEM", 140, 156], ["H7", "PROBLEM", 162, 164], ["Salmonella Enteritidis", "PROBLEM", 170, 192], ["Escherichia coli", "OBSERVATION", 140, 156], ["Salmonella Enteritidis", "OBSERVATION", 170, 192]]], ["Ramos et al. (2014) prepared nano-biocomposite films based on polylactic acid by incorporating thymol (as the active additive) and modified montmorillonite (D43B) at two different concentrations.", [["polylactic acid", "CHEMICAL", 62, 77], ["thymol", "CHEMICAL", 95, 101], ["montmorillonite", "CHEMICAL", 140, 155], ["D43B", "CHEMICAL", 157, 161], ["polylactic acid", "CHEMICAL", 62, 77], ["thymol", "CHEMICAL", 95, 101], ["montmorillonite", "CHEMICAL", 140, 155], ["D43B", "CHEMICAL", 157, 161], ["polylactic acid", "SIMPLE_CHEMICAL", 62, 77], ["thymol", "SIMPLE_CHEMICAL", 95, 101], ["montmorillonite", "SIMPLE_CHEMICAL", 140, 155], ["D43B", "SIMPLE_CHEMICAL", 157, 161], ["nano-biocomposite films", "TREATMENT", 29, 52], ["polylactic acid", "TREATMENT", 62, 77], ["incorporating thymol", "TREATMENT", 81, 101], ["modified montmorillonite (D43B)", "TREATMENT", 131, 162]]], ["It was observed that thermal stability was not significantly affected by the addition of thymol, but the incorporation of D43B improved its mechanical properties and reduced the oxygen transmission rate by the formation of intercalated structures.", [["thymol", "CHEMICAL", 89, 95], ["D43B", "CHEMICAL", 122, 126], ["oxygen", "CHEMICAL", 178, 184], ["thymol", "CHEMICAL", 89, 95], ["D43B", "CHEMICAL", 122, 126], ["oxygen", "CHEMICAL", 178, 184], ["thymol", "SIMPLE_CHEMICAL", 89, 95], ["D43B", "SIMPLE_CHEMICAL", 122, 126], ["oxygen", "SIMPLE_CHEMICAL", 178, 184], ["thermal stability", "PROBLEM", 21, 38], ["thymol", "TREATMENT", 89, 95], ["D43B", "TREATMENT", 122, 126], ["the oxygen transmission rate", "TREATMENT", 174, 202], ["thermal", "OBSERVATION_MODIFIER", 21, 28], ["stability", "OBSERVATION", 29, 38], ["mechanical properties", "OBSERVATION", 140, 161], ["oxygen transmission", "OBSERVATION", 178, 197]]], ["It was suggested that the formulated nano-biocomposites could be considered a potential antioxidant active packaging material.Polyhydroxybutyrate (PHB)Polylactic acid and polyhydroxybutyrate both offer a lot of opportunities in food packaging applications, because they are compatible with many foods, including dairy products, beverage, ready meals, and fresh meat products.", [["meat", "ANATOMY", 361, 365], ["Polyhydroxybutyrate", "CHEMICAL", 126, 145], ["PHB", "CHEMICAL", 147, 150], ["Polylactic acid", "CHEMICAL", 151, 166], ["polyhydroxybutyrate", "CHEMICAL", 171, 190], ["Polyhydroxybutyrate", "CHEMICAL", 126, 145], ["PHB", "CHEMICAL", 147, 150], ["Polylactic acid", "CHEMICAL", 151, 166], ["polyhydroxybutyrate", "CHEMICAL", 171, 190], ["nano-biocomposites", "SIMPLE_CHEMICAL", 37, 55], ["Polyhydroxybutyrate", "SIMPLE_CHEMICAL", 126, 145], ["PHB", "SIMPLE_CHEMICAL", 147, 150], ["Polylactic acid", "SIMPLE_CHEMICAL", 151, 166], ["polyhydroxybutyrate", "SIMPLE_CHEMICAL", 171, 190], ["the formulated nano-biocomposites", "TREATMENT", 22, 55], ["a potential antioxidant active packaging material", "TREATMENT", 76, 125], ["Polyhydroxybutyrate (PHB)Polylactic acid", "TREATMENT", 126, 166], ["polyhydroxybutyrate", "TREATMENT", 171, 190], ["fresh meat products", "TREATMENT", 355, 374], ["packaging material", "OBSERVATION", 107, 125]]], ["It is accumulated by a large number of bacteria in the form of energy and carbon reserves.", [["carbon", "CHEMICAL", 74, 80], ["carbon", "SIMPLE_CHEMICAL", 74, 80], ["bacteria", "PROBLEM", 39, 47], ["carbon reserves", "TREATMENT", 74, 89], ["large", "OBSERVATION_MODIFIER", 23, 28], ["number", "OBSERVATION_MODIFIER", 29, 35], ["bacteria", "OBSERVATION", 39, 47], ["carbon reserves", "OBSERVATION", 74, 89]]], ["This biopolyester may also find industrial applications easily because of its biodegradability and biocompatibility (Van der Walle et al. 2001) .", [["biopolyester", "CHEMICAL", 5, 17], ["biopolyester", "SIMPLE_CHEMICAL", 5, 17]]], ["Poly(lactic acid) and poly(hydroxybutyrate) were blended and plasticized by Arrieta et al. (2014) with a natural terpene D-limonene (LIM) so as to increase PLA crystallinity and to also obtain flexible films for food packaging applications.", [["Poly(lactic acid", "CHEMICAL", 0, 16], ["poly(hydroxybutyrate", "CHEMICAL", 22, 42], ["terpene D-limonene", "CHEMICAL", 113, 131], ["PLA", "CHEMICAL", 156, 159], ["Poly(lactic acid)", "CHEMICAL", 0, 17], ["poly(hydroxybutyrate)", "CHEMICAL", 22, 43], ["terpene D-limonene", "CHEMICAL", 113, 131], ["LIM", "CHEMICAL", 133, 136], ["PLA", "CHEMICAL", 156, 159], ["Poly(lactic acid", "SIMPLE_CHEMICAL", 0, 16], ["poly(hydroxybutyrate", "SIMPLE_CHEMICAL", 22, 42], ["terpene D-limonene", "SIMPLE_CHEMICAL", 113, 131], ["PLA", "SIMPLE_CHEMICAL", 156, 159], ["Poly(lactic acid)", "TREATMENT", 0, 17], ["poly(hydroxybutyrate)", "TREATMENT", 22, 43], ["a natural terpene D-limonene (LIM)", "TREATMENT", 103, 137], ["PLA crystallinity", "TREATMENT", 156, 173], ["flexible films", "TEST", 193, 207], ["food packaging applications", "TREATMENT", 212, 239]]], ["As-prepared materials were melt-blended and processed in transparent films.", [["transparent films", "TEST", 57, 74]]], ["Disintegrability under composting conditions was also worked out, and it was reported that PHB delays the PLA disintegrability, but on the contrary, D-limonene speeds it up.", [["PHB", "CHEMICAL", 91, 94], ["PLA", "CHEMICAL", 106, 109], ["D-limonene", "CHEMICAL", 149, 159], ["PHB", "CHEMICAL", 91, 94], ["PLA", "CHEMICAL", 106, 109], ["D-limonene", "CHEMICAL", 149, 159], ["PHB", "SIMPLE_CHEMICAL", 91, 94], ["D-limonene", "SIMPLE_CHEMICAL", 149, 159]]], ["Ma et al. (2018) developed poly(lactic acid)-poly(hydroxybutyrate) (PLA-PHB) based films containing bioactive elements and prepared seven formulations containing different contents of plasticizers (mono-caprylin glycerate (GMC) or glycerol monolaurate (GML)).", [["poly(lactic acid)-poly(hydroxybutyrate", "CHEMICAL", 27, 65], ["PLA-PHB", "CHEMICAL", 68, 75], ["mono-caprylin glycerate", "CHEMICAL", 198, 221], ["GMC", "CHEMICAL", 223, 226], ["glycerol monolaurate", "CHEMICAL", 231, 251], ["poly(lactic acid)", "CHEMICAL", 27, 44], ["poly(hydroxybutyrate)", "CHEMICAL", 45, 66], ["PLA", "CHEMICAL", 68, 71], ["PHB", "CHEMICAL", 72, 75], ["mono-caprylin glycerate", "CHEMICAL", 198, 221], ["GMC", "CHEMICAL", 223, 226], ["glycerol monolaurate", "CHEMICAL", 231, 251], ["poly(lactic acid", "SIMPLE_CHEMICAL", 27, 43], ["poly(hydroxybutyrate)", "SIMPLE_CHEMICAL", 45, 66], ["PLA-PHB", "SIMPLE_CHEMICAL", 68, 75], ["plasticizers", "SIMPLE_CHEMICAL", 184, 196], ["mono-caprylin glycerate", "SIMPLE_CHEMICAL", 198, 221], ["GMC", "SIMPLE_CHEMICAL", 223, 226], ["glycerol monolaurate", "SIMPLE_CHEMICAL", 231, 251], ["GML", "SIMPLE_CHEMICAL", 253, 256], ["poly(lactic acid", "TEST", 27, 43], ["poly(hydroxybutyrate)", "TREATMENT", 45, 66], ["PLA-PHB)", "TREATMENT", 68, 76], ["based films", "TEST", 77, 88], ["bioactive elements", "TREATMENT", 100, 118], ["prepared seven formulations", "TREATMENT", 123, 150], ["different contents of plasticizers (mono-caprylin glycerate (GMC)", "TREATMENT", 162, 227], ["glycerol monolaurate", "TREATMENT", 231, 251], ["bioactive elements", "OBSERVATION", 100, 118]]], ["Two formulations (PLA-PHB-based films with 0.5% GMC or GML) were selected, and 5% cinnamaldehyde was added into each of these.", [["PLA-PHB", "CHEMICAL", 18, 25], ["cinnamaldehyde", "CHEMICAL", 82, 96], ["PLA", "CHEMICAL", 18, 21], ["PHB", "CHEMICAL", 22, 25], ["cinnamaldehyde", "CHEMICAL", 82, 96], ["PLA-PHB", "SIMPLE_CHEMICAL", 18, 25], ["GMC", "SIMPLE_CHEMICAL", 48, 51], ["GML", "SIMPLE_CHEMICAL", 55, 58], ["cinnamaldehyde", "SIMPLE_CHEMICAL", 82, 96], ["Two formulations", "TREATMENT", 0, 16], ["PLA", "TEST", 18, 21], ["films", "TEST", 32, 37], ["5% cinnamaldehyde", "TREATMENT", 79, 96]]], ["It was revealed that PLA-PHB-based films possessed better mechanical properties and better active properties on application to high lipid food simulant.", [["PLA-PHB", "CHEMICAL", 21, 28], ["PLA", "CHEMICAL", 21, 24], ["PHB", "CHEMICAL", 25, 28], ["PLA-PHB", "SIMPLE_CHEMICAL", 21, 28], ["PLA", "TEST", 21, 24], ["PHB", "TEST", 25, 28], ["based films", "TEST", 29, 40], ["mechanical properties", "TREATMENT", 58, 79], ["high lipid", "OBSERVATION_MODIFIER", 127, 137]]], ["This study showed that it is possible to use biodegradable active packing as an alternative to replace nonbiodegradable packaging for chilled salmon.Polycaprolactone (PCL)It is a biodegradable polyester having a low melting point around 60 \u00b0C only.", [["Polycaprolactone", "CHEMICAL", 149, 165], ["PCL", "CHEMICAL", 167, 170], ["Polycaprolactone", "CHEMICAL", 149, 165], ["PCL", "CHEMICAL", 167, 170], ["polyester", "CHEMICAL", 193, 202], ["Polycaprolactone", "SIMPLE_CHEMICAL", 149, 165], ["PCL", "SIMPLE_CHEMICAL", 167, 170], ["chilled salmon", "SPECIES", 134, 148], ["This study", "TEST", 0, 10], ["biodegradable active packing", "TREATMENT", 45, 73], ["nonbiodegradable packaging", "TREATMENT", 103, 129], ["Polycaprolactone (PCL", "TREATMENT", 149, 170], ["a biodegradable polyester", "TREATMENT", 177, 202], ["low melting", "OBSERVATION_MODIFIER", 212, 223]]], ["It has some interesting applications in the fields of medical and agricultural areas (Nakayama et al. 1997) .", [["some", "OBSERVATION_MODIFIER", 7, 11], ["interesting", "OBSERVATION_MODIFIER", 12, 23], ["applications", "OBSERVATION", 24, 36], ["fields", "OBSERVATION_MODIFIER", 44, 50]]], ["It has high elongation at break and low modulus.", [["high elongation at break and low modulus", "PROBLEM", 7, 47], ["high", "OBSERVATION_MODIFIER", 7, 11], ["elongation", "OBSERVATION_MODIFIER", 12, 22], ["low modulus", "OBSERVATION_MODIFIER", 36, 47]]], ["Apart from it, its physical properties and availability on commercial scale made it very attractive material for commodity applications.", [["commercial scale", "TREATMENT", 59, 75]]], ["An antimicrobial nanopackaging was developed by Ahmed et al. (2019) for food application by incorporating zinc oxide nanoparticles and clove essential oil (CEO) into polylactide/polyethylene glycol polycaprolactone (PLA/PEG/PCL) blend.", [["zinc oxide", "CHEMICAL", 106, 116], ["polylactide/polyethylene glycol polycaprolactone", "CHEMICAL", 166, 214], ["PLA/PEG/PCL", "CHEMICAL", 216, 227], ["zinc oxide", "CHEMICAL", 106, 116], ["polylactide", "CHEMICAL", 166, 177], ["polyethylene glycol polycaprolactone", "CHEMICAL", 178, 214], ["PLA", "CHEMICAL", 216, 219], ["PEG", "CHEMICAL", 220, 223], ["PCL", "CHEMICAL", 224, 227], ["zinc oxide nanoparticles", "SIMPLE_CHEMICAL", 106, 130], ["clove essential oil", "SIMPLE_CHEMICAL", 135, 154], ["CEO", "SIMPLE_CHEMICAL", 156, 159], ["polylactide", "SIMPLE_CHEMICAL", 166, 177], ["polyethylene glycol polycaprolactone", "SIMPLE_CHEMICAL", 178, 214], ["PLA/PEG/PCL", "SIMPLE_CHEMICAL", 216, 227], ["An antimicrobial nanopackaging", "TREATMENT", 0, 30], ["incorporating zinc oxide nanoparticles", "TREATMENT", 92, 130], ["clove essential oil (CEO)", "TREATMENT", 135, 160], ["polylactide/polyethylene glycol polycaprolactone", "TREATMENT", 166, 214], ["PLA/PEG/PCL) blend", "TREATMENT", 216, 234], ["antimicrobial", "OBSERVATION_MODIFIER", 3, 16], ["PCL", "ANATOMY", 224, 227]]], ["Here, CEO acts as an efficient plasticizer, which facilitates the chain mobility in the blend, as evident from tensile and thermal properties.", [["CEO", "CHEMICAL", 6, 9], ["CEO", "SIMPLE_CHEMICAL", 6, 9], ["an efficient plasticizer", "TREATMENT", 18, 42], ["the chain mobility in the blend", "PROBLEM", 62, 93], ["thermal properties", "OBSERVATION_MODIFIER", 123, 141]]], ["The efficacy of these composite films was confirmed by using Staphylococcus aureus and Escherichia coli inoculated in scrambled egg.", [["egg", "ANATOMY", 128, 131], ["Staphylococcus aureus", "ORGANISM", 61, 82], ["Escherichia coli", "ORGANISM", 87, 103], ["egg", "ORGANISM_SUBSTANCE", 128, 131], ["Staphylococcus aureus", "SPECIES", 61, 82], ["Escherichia coli", "SPECIES", 87, 103], ["Staphylococcus aureus", "SPECIES", 61, 82], ["Escherichia coli", "SPECIES", 87, 103], ["these composite films", "TEST", 16, 37], ["Staphylococcus aureus", "PROBLEM", 61, 82], ["Escherichia coli", "PROBLEM", 87, 103], ["Staphylococcus aureus", "OBSERVATION", 61, 82], ["Escherichia coli", "OBSERVATION", 87, 103], ["scrambled egg", "OBSERVATION", 118, 131]]], ["It was indicated that the PLA/PEG/PCL/ZnO/CEO film exhibited the highest antibacterial activity during 21 days storage at 4 \u00b0C. Cesur et al. (2018) prepared antimicrobial and biodegradable food packaging films with polycaprolactone (PCL).", [["PLA", "CHEMICAL", 26, 29], ["PEG", "CHEMICAL", 30, 33], ["PCL", "CHEMICAL", 34, 37], ["ZnO", "CHEMICAL", 38, 41], ["polycaprolactone", "CHEMICAL", 215, 231], ["PCL", "CHEMICAL", 233, 236], ["PLA", "CHEMICAL", 26, 29], ["PEG", "CHEMICAL", 30, 33], ["PCL", "CHEMICAL", 34, 37], ["ZnO", "CHEMICAL", 38, 41], ["CEO", "CHEMICAL", 42, 45], ["polycaprolactone", "CHEMICAL", 215, 231], ["PCL", "CHEMICAL", 233, 236], ["PLA", "SIMPLE_CHEMICAL", 26, 29], ["PEG/PCL", "SIMPLE_CHEMICAL", 30, 37], ["ZnO", "SIMPLE_CHEMICAL", 38, 41], ["CEO film", "SIMPLE_CHEMICAL", 42, 50], ["polycaprolactone", "SIMPLE_CHEMICAL", 215, 231], ["PCL", "SIMPLE_CHEMICAL", 233, 236], ["the PLA/PEG/PCL/ZnO/CEO film", "TREATMENT", 22, 50], ["antimicrobial and biodegradable food packaging films", "TREATMENT", 157, 209], ["polycaprolactone (PCL)", "TREATMENT", 215, 237], ["antibacterial activity", "OBSERVATION", 73, 95]]], ["The 0.4 wt% of organo nanoclay (C) and 25, 50, 75 wt% chitosan (K) and glycerol monooleate (GMO) or oleic acid (OA) as a plastifier (5, 10, 20, and 30 wt%) were added, and 12 polymeric composite films were prepared.", [["organo nanoclay", "CHEMICAL", 15, 30], ["chitosan", "CHEMICAL", 54, 62], ["K", "CHEMICAL", 64, 65], ["glycerol monooleate", "CHEMICAL", 71, 90], ["GMO", "CHEMICAL", 92, 95], ["oleic acid", "CHEMICAL", 100, 110], ["OA", "CHEMICAL", 112, 114], ["glycerol monooleate", "CHEMICAL", 71, 90], ["oleic acid", "CHEMICAL", 100, 110], ["organo nanoclay", "SIMPLE_CHEMICAL", 15, 30], ["C", "SIMPLE_CHEMICAL", 32, 33], ["chitosan (K)", "SIMPLE_CHEMICAL", 54, 66], ["glycerol monooleate", "SIMPLE_CHEMICAL", 71, 90], ["GMO", "SIMPLE_CHEMICAL", 92, 95], ["oleic acid", "SIMPLE_CHEMICAL", 100, 110], ["OA", "SIMPLE_CHEMICAL", 112, 114], ["organo nanoclay (C)", "TREATMENT", 15, 34], ["glycerol monooleate (GMO", "TREATMENT", 71, 95], ["oleic acid (OA", "TREATMENT", 100, 114], ["12 polymeric composite films", "TREATMENT", 172, 200]]], ["The samples were coded as PCL (P), organo nanoclay (C), oleic acid (O), and glycerol monooleate (G).", [["samples", "ANATOMY", 4, 11], ["PCL", "CHEMICAL", 26, 29], ["oleic acid", "CHEMICAL", 56, 66], ["glycerol monooleate", "CHEMICAL", 76, 95], ["PCL", "CHEMICAL", 26, 29], ["oleic acid", "CHEMICAL", 56, 66], ["O", "CHEMICAL", 68, 69], ["glycerol monooleate", "CHEMICAL", 76, 95], ["organo nanoclay", "SIMPLE_CHEMICAL", 35, 50], ["C", "SIMPLE_CHEMICAL", 52, 53], ["oleic acid", "SIMPLE_CHEMICAL", 56, 66], ["O)", "SIMPLE_CHEMICAL", 68, 70], ["glycerol monooleate", "SIMPLE_CHEMICAL", 76, 95], ["G", "SIMPLE_CHEMICAL", 97, 98], ["The samples", "TEST", 0, 11], ["PCL", "TEST", 26, 29], ["organo nanoclay (C), oleic acid", "TREATMENT", 35, 66], ["glycerol monooleate", "TREATMENT", 76, 95]]], ["The antimicrobial properties of these films were evaluated against Escherichia coli, Pseudomonas aeruginosa, Bacillus cereus, and Candida albicans.", [["Escherichia coli", "ORGANISM", 67, 83], ["Pseudomonas aeruginosa", "ORGANISM", 85, 107], ["Bacillus cereus", "ORGANISM", 109, 124], ["Candida albicans", "ORGANISM", 130, 146], ["Escherichia coli", "SPECIES", 67, 83], ["Pseudomonas aeruginosa", "SPECIES", 85, 107], ["Bacillus cereus", "SPECIES", 109, 124], ["Candida albicans", "SPECIES", 130, 146], ["Escherichia coli", "SPECIES", 67, 83], ["Pseudomonas aeruginosa", "SPECIES", 85, 107], ["Bacillus cereus", "SPECIES", 109, 124], ["Candida albicans", "SPECIES", 130, 146], ["these films", "TEST", 32, 43], ["Escherichia coli", "PROBLEM", 67, 83], ["Pseudomonas aeruginosa", "PROBLEM", 85, 107], ["Bacillus cereus", "PROBLEM", 109, 124], ["Candida albicans", "PROBLEM", 130, 146], ["Bacillus cereus", "OBSERVATION", 109, 124], ["Candida albicans", "OBSERVATION", 130, 146]]], ["Polycaprolactone (PCL)/starch/ pomegranate rind (PR) hybrids were developed by Khalid et al. (2018) for antimicrobial packaging applications.", [["Polycaprolactone", "CHEMICAL", 0, 16], ["PCL", "CHEMICAL", 18, 21], ["starch/ pomegranate rind", "CHEMICAL", 23, 47], ["Polycaprolactone", "CHEMICAL", 0, 16], ["PCL", "CHEMICAL", 18, 21], ["Polycaprolactone", "SIMPLE_CHEMICAL", 0, 16], ["PCL", "SIMPLE_CHEMICAL", 18, 21], ["starch", "SIMPLE_CHEMICAL", 23, 29], ["pomegranate", "ORGANISM", 31, 42], ["pomegranate rind (PR) hybrids", "CELL_LINE", 31, 60], ["pomegranate", "SPECIES", 31, 42], ["Polycaprolactone (PCL)/starch/ pomegranate rind (PR) hybrids", "TREATMENT", 0, 60], ["antimicrobial packaging applications", "TREATMENT", 104, 140]]], ["PR was used as an antimicrobial compound, and it was incorporated directly in PCL matrix, without the extraction of any active compound from the fruit rind.", [["PCL matrix", "ANATOMY", 78, 88], ["fruit rind", "ANATOMY", 145, 155], ["PR", "GENE_OR_GENE_PRODUCT", 0, 2], ["PR", "PROTEIN", 0, 2], ["an antimicrobial compound", "TREATMENT", 15, 40], ["the extraction", "TREATMENT", 98, 112], ["PCL matrix", "OBSERVATION", 78, 88], ["active", "OBSERVATION_MODIFIER", 120, 126], ["compound", "OBSERVATION", 127, 135], ["fruit rind", "OBSERVATION", 145, 155]]], ["It was revealed that PCL/PR films show reasonably good antimicrobial activity at higher concentrations.", [["PCL", "CHEMICAL", 21, 24], ["PCL", "SIMPLE_CHEMICAL", 21, 24], ["PR", "PROTEIN", 25, 27], ["PCL/PR films", "TEST", 21, 33], ["good", "OBSERVATION_MODIFIER", 50, 54], ["antimicrobial activity", "OBSERVATION", 55, 77]]], ["Addition of starch was found to enhance the antimicrobial activity of PR.", [["starch", "CHEMICAL", 12, 18], ["starch", "SIMPLE_CHEMICAL", 12, 18], ["PR", "GENE_OR_GENE_PRODUCT", 70, 72], ["PR", "PROTEIN", 70, 72], ["starch", "TREATMENT", 12, 18]]], ["As all the materials used here are biodegradable and food contactable, it has been suggested that the as-developed material could be used as food-grade antimicrobial packaging material.Polycaprolactone (PCL)Newer and newer nanomaterials have also been regularly developed, so that their physical and mechanical properties of packaging are improved, particularly in terms of tensile strength, water resistance, gas permeability, rigidity, flame resistance, etc. Due to such interesting properties, polymer nanocomposites are emerging as promising materials with a large capability for their applications in the active food packaging industry (Youssef 2013) .Types of Nanomaterials in FoodNanoparticles present in foods can be easily categorized based on their composition, (organic or inorganic), as this factor has a major impact on their gastrointestinal fate and potential toxicity (McClements and Xiao 2017).Inorganic NanoparticlesA number of nanoparticles used in food materials are mainly composed of some or the other inorganic materials, such as silver, silicon dioxide, iron oxide, titanium dioxide, or zinc oxide (Pietroiusti et al. 2016 ).", [["gastrointestinal", "ANATOMY", 839, 855], ["Polycaprolactone", "CHEMICAL", 185, 201], ["PCL", "CHEMICAL", 203, 206], ["rigidity", "DISEASE", 428, 436], ["FoodNanoparticles", "CHEMICAL", 683, 700], ["inorganic", "CHEMICAL", 784, 793], ["toxicity", "DISEASE", 875, 883], ["silver", "CHEMICAL", 1053, 1059], ["silicon dioxide", "CHEMICAL", 1061, 1076], ["iron oxide", "CHEMICAL", 1078, 1088], ["titanium dioxide", "CHEMICAL", 1090, 1106], ["zinc oxide", "CHEMICAL", 1111, 1121], ["Polycaprolactone", "CHEMICAL", 185, 201], ["PCL", "CHEMICAL", 203, 206], ["silver", "CHEMICAL", 1053, 1059], ["silicon dioxide", "CHEMICAL", 1061, 1076], ["iron oxide", "CHEMICAL", 1078, 1088], ["titanium dioxide", "CHEMICAL", 1090, 1106], ["zinc oxide", "CHEMICAL", 1111, 1121], ["Polycaprolactone", "SIMPLE_CHEMICAL", 185, 201], ["polymer nanocomposites", "SIMPLE_CHEMICAL", 497, 519], ["FoodNanoparticles", "SIMPLE_CHEMICAL", 683, 700], ["inorganic", "SIMPLE_CHEMICAL", 784, 793], ["gastrointestinal", "ORGAN", 839, 855], ["silver", "SIMPLE_CHEMICAL", 1053, 1059], ["silicon dioxide", "SIMPLE_CHEMICAL", 1061, 1076], ["iron oxide", "SIMPLE_CHEMICAL", 1078, 1088], ["titanium dioxide", "SIMPLE_CHEMICAL", 1090, 1106], ["zinc oxide", "SIMPLE_CHEMICAL", 1111, 1121], ["food-grade antimicrobial packaging material", "TREATMENT", 141, 184], ["Polycaprolactone (PCL)", "TREATMENT", 185, 207], ["Newer and newer nanomaterials", "TREATMENT", 207, 236], ["gas permeability", "PROBLEM", 410, 426], ["rigidity", "PROBLEM", 428, 436], ["flame resistance", "PROBLEM", 438, 454], ["polymer nanocomposites", "TREATMENT", 497, 519], ["potential toxicity", "PROBLEM", 865, 883], ["Inorganic Nanoparticles", "TREATMENT", 911, 934], ["A number of nanoparticles", "TREATMENT", 934, 959], ["silver, silicon dioxide", "TREATMENT", 1053, 1076], ["iron oxide", "TREATMENT", 1078, 1088], ["titanium dioxide", "TREATMENT", 1090, 1106], ["zinc oxide", "TREATMENT", 1111, 1121], ["antimicrobial packaging material", "OBSERVATION", 152, 184], ["improved", "OBSERVATION_MODIFIER", 339, 347], ["tensile strength", "OBSERVATION", 374, 390], ["water resistance", "OBSERVATION", 392, 408], ["gas permeability", "OBSERVATION", 410, 426], ["flame resistance", "OBSERVATION", 438, 454], ["Nanomaterials", "OBSERVATION", 666, 679], ["gastrointestinal", "ANATOMY", 839, 855], ["Nanoparticles", "OBSERVATION", 921, 934]]], ["These may be spherical or nonspherical with different surface characteristics and sizes depending on precursor materials and conditions of preparation while these were fabricated.", [["surface", "ANATOMY", 54, 61], ["precursor materials", "TREATMENT", 101, 120], ["may be", "UNCERTAINTY", 6, 12], ["spherical", "OBSERVATION_MODIFIER", 13, 22], ["nonspherical", "OBSERVATION_MODIFIER", 26, 38], ["different", "OBSERVATION_MODIFIER", 44, 53], ["surface", "OBSERVATION_MODIFIER", 54, 61], ["sizes", "OBSERVATION_MODIFIER", 82, 87]]], ["Such inorganic nanoparticles have different tendencies to dissolve under specific solution conditions (pH and ionic strength) and also chemical reactivities, which have a major impact on their gastrointestinal fate and toxicity.Silver NanoparticlesSilver nanoparticles (AgNPs) are commonly used as antimicrobial agents in food packaging, chopping boards, storage containers, refrigerators, and health supplements.", [["gastrointestinal", "ANATOMY", 193, 209], ["toxicity", "DISEASE", 219, 227], ["Silver", "CHEMICAL", 228, 234], ["NanoparticlesSilver nanoparticles", "CHEMICAL", 235, 268], ["AgNPs", "CHEMICAL", 270, 275], ["Silver", "CHEMICAL", 228, 234], ["inorganic nanoparticles", "SIMPLE_CHEMICAL", 5, 28], ["gastrointestinal", "ORGANISM_SUBDIVISION", 193, 209], ["Silver NanoparticlesSilver nanoparticles", "SIMPLE_CHEMICAL", 228, 268], ["AgNPs", "SIMPLE_CHEMICAL", 270, 275], ["Such inorganic nanoparticles", "TREATMENT", 0, 28], ["different tendencies", "PROBLEM", 34, 54], ["Silver NanoparticlesSilver nanoparticles (AgNPs)", "TREATMENT", 228, 276], ["antimicrobial agents", "TREATMENT", 298, 318], ["chemical reactivities", "OBSERVATION", 135, 156], ["gastrointestinal", "ANATOMY", 193, 209]]], ["Silver nanoparticles are used for their antimicrobial effects in certain types of food containers by some manufacturer in the United States such as Kinetic Go Green basic nanosilver food storage container, Oso fresh food storage container, and FresherLonger\u2122 Plastic Storage bags.", [["Silver", "CHEMICAL", 0, 6], ["Silver", "CHEMICAL", 0, 6], ["Silver nanoparticles", "SIMPLE_CHEMICAL", 0, 20], ["Silver nanoparticles", "TREATMENT", 0, 20], ["their antimicrobial effects", "TREATMENT", 34, 61], ["Kinetic Go Green basic nanosilver food storage container", "TREATMENT", 148, 204], ["Plastic Storage bags", "TREATMENT", 259, 279]]], ["It is also possible that some of these silver nanoparticles may migrate into foods from these containers and they could be ingested by humans (Echegoyen and Nerin 2013) .", [["silver", "CHEMICAL", 39, 45], ["silver", "CHEMICAL", 39, 45], ["silver nanoparticles", "SIMPLE_CHEMICAL", 39, 59], ["humans", "ORGANISM", 135, 141], ["humans", "SPECIES", 135, 141], ["humans", "SPECIES", 135, 141], ["these silver nanoparticles", "TREATMENT", 33, 59], ["also possible", "UNCERTAINTY", 6, 19]]], ["Emamifar et al. (2011) prepared nanocomposite LDPE films containing Ag and ZnO nanoparticles via melt mixing in a twin screw extruder.", [["Ag", "CHEMICAL", 68, 70], ["ZnO nanoparticles", "CHEMICAL", 75, 92], ["Ag", "CHEMICAL", 68, 70], ["ZnO", "CHEMICAL", 75, 78], ["nanocomposite LDPE films", "SIMPLE_CHEMICAL", 32, 56], ["Ag", "SIMPLE_CHEMICAL", 68, 70], ["ZnO nanoparticles", "SIMPLE_CHEMICAL", 75, 92], ["prepared nanocomposite LDPE films", "TREATMENT", 23, 56], ["Ag and ZnO nanoparticles via melt mixing", "TREATMENT", 68, 108], ["a twin screw extruder", "TREATMENT", 112, 133], ["screw extruder", "OBSERVATION", 119, 133]]], ["Orange juice was sterilized and then inoculated with 8.5 log cfu/mL of Lactobacillus plantarum.", [["Orange juice", "ANATOMY", 0, 12], ["Lactobacillus plantarum", "CHEMICAL", 71, 94], ["Orange juice", "ORGANISM_SUBSTANCE", 0, 12], ["Lactobacillus plantarum", "ORGANISM", 71, 94], ["Lactobacillus plantarum", "SPECIES", 71, 94], ["Lactobacillus plantarum", "SPECIES", 71, 94], ["Orange juice", "TREATMENT", 0, 12], ["Lactobacillus plantarum", "TREATMENT", 71, 94], ["Lactobacillus plantarum", "ANATOMY", 71, 94]]], ["They filled packages prepared from nanocomposite films with orange juice and then stored at 4 \u00b0C. Microbial stability of the juice was evaluated after 7, 28, 56, 84, and 112 days of storage.", [["juice", "ANATOMY", 67, 72], ["juice", "ANATOMY", 125, 130], ["juice", "ORGANISM_SUBSTANCE", 67, 72], ["juice", "ORGANISM_SUBSTANCE", 125, 130], ["orange juice", "TREATMENT", 60, 72], ["stability", "OBSERVATION_MODIFIER", 108, 117]]], ["It was reported that microbial growth rate significantly reduced on using this nanocomposite packaging material.", [["microbial growth rate", "PROBLEM", 21, 42], ["this nanocomposite packaging material", "TREATMENT", 74, 111], ["microbial", "OBSERVATION_MODIFIER", 21, 30], ["growth", "OBSERVATION_MODIFIER", 31, 37]]], ["A potential role of quantum sensors (QS) in food spoilage and food safety has been indicated (Naik and Kowshik 2014) .", [["quantum sensors (QS)", "TREATMENT", 20, 40]]], ["Anti-QS materials like ATNPs were proposed as efficient models for controlling spoilage of food.", [["ATNPs", "CHEMICAL", 23, 28], ["ATNPs", "SIMPLE_CHEMICAL", 23, 28], ["Anti-QS materials", "TREATMENT", 0, 17]]], ["Incorporation of ATNPs in food packaging materials could play an important role in preservation of food and ensure its safety by prolonging their shelf life.", [["ATNPs", "CHEMICAL", 17, 22], ["ATNPs", "SIMPLE_CHEMICAL", 17, 22], ["Incorporation of ATNPs in food packaging materials", "TREATMENT", 0, 50]]], ["They proposed ATNPs as QS inhibitors with their potential use as an antipathogenic but nontoxic bioactive material.", [["ATNPs", "SIMPLE_CHEMICAL", 14, 19], ["QS inhibitors", "TREATMENT", 23, 36], ["an antipathogenic but nontoxic bioactive material", "PROBLEM", 65, 114], ["nontoxic", "OBSERVATION_MODIFIER", 87, 95], ["bioactive material", "OBSERVATION", 96, 114]]], ["Ag/TiO 2 -SiO 2 -coated food packaging film was developed also (Peter et al. 2015) .", [["Ag", "CHEMICAL", 0, 2], ["TiO 2 -SiO 2", "CHEMICAL", 3, 15], ["Ag", "CHEMICAL", 0, 2], ["TiO 2 -SiO 2", "CHEMICAL", 3, 15], ["TiO 2 -SiO 2", "SIMPLE_CHEMICAL", 3, 15], ["Ag", "PROTEIN", 0, 2], ["Ag/TiO 2 -SiO 2 -coated food packaging film", "TREATMENT", 0, 43]]], ["Its ability to inactivate Botrytis cinerea was evaluated during the storage of fresh lettuce.", [["Botrytis cinerea", "CHEMICAL", 26, 42], ["Botrytis cinerea", "ORGANISM", 26, 42], ["lettuce", "ORGANISM_SUBDIVISION", 85, 92], ["Botrytis cinerea", "SPECIES", 26, 42], ["Botrytis cinerea", "SPECIES", 26, 42], ["lettuce", "SPECIES", 85, 92], ["Botrytis cinerea", "PROBLEM", 26, 42], ["fresh lettuce", "OBSERVATION", 79, 92]]], ["Packaging film was prepared by coating the Ag/TiO 2 -SiO 2 ethanol suspension on polyethylene film.", [["Ag", "CHEMICAL", 43, 45], ["TiO 2 -SiO 2 ethanol", "CHEMICAL", 46, 66], ["polyethylene", "CHEMICAL", 81, 93], ["Ag", "CHEMICAL", 43, 45], ["TiO 2 -SiO 2", "CHEMICAL", 46, 58], ["ethanol", "CHEMICAL", 59, 66], ["polyethylene", "CHEMICAL", 81, 93], ["TiO 2 -SiO 2 ethanol", "SIMPLE_CHEMICAL", 46, 66], ["polyethylene film", "SIMPLE_CHEMICAL", 81, 98], ["Ag", "PROTEIN", 43, 45], ["Packaging film", "TREATMENT", 0, 14], ["the Ag/TiO 2 -SiO 2 ethanol suspension on polyethylene film", "TREATMENT", 39, 98]]], ["As-prepared packaging film was used for storage of green lettuce in a vegetation room.", [["green lettuce", "CHEMICAL", 51, 64], ["lettuce", "ORGANISM_SUBDIVISION", 57, 64], ["green lettuce", "SPECIES", 51, 64], ["packaging film", "TEST", 12, 26]]], ["It was revealed that the shelf life of the lettuce stored in single-and double-layer film modified with TiO 2 was extended by 4 and 2 days, respectively.", [["lettuce", "ANATOMY", 43, 50], ["TiO 2", "CHEMICAL", 104, 109], ["TiO 2", "CHEMICAL", 104, 109], ["lettuce", "ORGANISM_SUBDIVISION", 43, 50], ["TiO 2", "SIMPLE_CHEMICAL", 104, 109], ["lettuce", "SPECIES", 43, 50], ["double-layer film", "TREATMENT", 72, 89]]], ["It was revealed that the spoilage of the lettuce in double-layer film modified with Ag/TiO 2 -SiO 2 was lower after 5 days of storage than that of the lettuce stored in film modified with ethanol and unmodified film.", [["Ag", "CHEMICAL", 84, 86], ["TiO 2 -SiO 2", "CHEMICAL", 87, 99], ["ethanol", "CHEMICAL", 188, 195], ["Ag", "CHEMICAL", 84, 86], ["TiO 2 -SiO 2", "CHEMICAL", 87, 99], ["ethanol", "CHEMICAL", 188, 195], ["lettuce", "ORGANISM_SUBDIVISION", 41, 48], ["Ag/TiO 2 -SiO 2", "SIMPLE_CHEMICAL", 84, 99], ["ethanol", "SIMPLE_CHEMICAL", 188, 195], ["Ag", "PROTEIN", 84, 86], ["lettuce", "SPECIES", 41, 48], ["lettuce", "SPECIES", 151, 158], ["the lettuce", "TREATMENT", 37, 48], ["double-layer film", "TREATMENT", 52, 69], ["Ag/TiO 2 -SiO 2", "TREATMENT", 84, 99], ["ethanol and unmodified film", "TREATMENT", 188, 215], ["lettuce", "OBSERVATION_MODIFIER", 41, 48]]], ["Microbiological and chemical characteristics of white bread during storage in paper packages modified with Ag/TiO 2 -SiO 2 , Ag/N-TiO 2 , or Au/TiO 2 have been investigated (Peter et al. 2016) .", [["Ag", "CHEMICAL", 107, 109], ["TiO 2 -SiO", "CHEMICAL", 110, 120], ["Ag", "CHEMICAL", 125, 127], ["N-TiO 2", "CHEMICAL", 128, 135], ["Au", "CHEMICAL", 141, 143], ["Ag", "CHEMICAL", 107, 109], ["TiO 2 -SiO 2", "CHEMICAL", 110, 122], ["Ag", "CHEMICAL", 125, 127], ["N-TiO 2", "CHEMICAL", 128, 135], ["Au", "CHEMICAL", 141, 143], ["TiO 2", "CHEMICAL", 144, 149], ["bread", "ORGANISM_SUBDIVISION", 54, 59], ["TiO 2 -SiO 2", "SIMPLE_CHEMICAL", 110, 122], ["Ag/N-TiO 2", "SIMPLE_CHEMICAL", 125, 135], ["Au/TiO 2", "SIMPLE_CHEMICAL", 141, 149], ["Ag", "PROTEIN", 107, 109], ["Ag", "PROTEIN", 125, 127], ["white bread", "PROBLEM", 48, 59], ["Ag/TiO", "TREATMENT", 107, 113], ["Ag/N-TiO 2", "TREATMENT", 125, 135], ["Au/TiO 2", "TREATMENT", 141, 149], ["chemical characteristics", "OBSERVATION_MODIFIER", 20, 44]]], ["The whiteness and the water retention of the modified packages were found to be slightly superior.", [["The whiteness", "PROBLEM", 0, 13], ["the water retention", "TREATMENT", 18, 37], ["the modified packages", "TREATMENT", 41, 62], ["whiteness", "OBSERVATION_MODIFIER", 4, 13], ["water", "OBSERVATION_MODIFIER", 22, 27], ["retention", "OBSERVATION_MODIFIER", 28, 37], ["slightly", "OBSERVATION_MODIFIER", 80, 88], ["superior", "OBSERVATION_MODIFIER", 89, 97]]], ["The water retention was also observed to be very good, especially for the Ag/TiO 2 -SiO 2 paper.", [["Ag", "CHEMICAL", 74, 76], ["TiO 2 -SiO", "CHEMICAL", 77, 87], ["Ag", "CHEMICAL", 74, 76], ["TiO 2 -SiO 2", "CHEMICAL", 77, 89], ["water", "SIMPLE_CHEMICAL", 4, 9], ["Ag", "PROTEIN", 74, 76], ["The water retention", "PROBLEM", 0, 19], ["the Ag/TiO 2 -SiO 2 paper", "TREATMENT", 70, 95], ["water retention", "OBSERVATION", 4, 19]]], ["These improvements can be associated with the high specific surface area and with the low agglomeration tendency of Ag nanoparticles in comparison with the Au ones.", [["surface", "ANATOMY", 60, 67], ["Ag", "CHEMICAL", 116, 118], ["Ag", "CHEMICAL", 116, 118], ["Au", "CHEMICAL", 156, 158], ["Ag nanoparticles", "SIMPLE_CHEMICAL", 116, 132], ["the high specific surface area", "PROBLEM", 42, 72], ["the low agglomeration tendency of Ag nanoparticles", "PROBLEM", 82, 132], ["high", "OBSERVATION_MODIFIER", 46, 50], ["specific", "OBSERVATION_MODIFIER", 51, 59], ["surface", "OBSERVATION_MODIFIER", 60, 67], ["low agglomeration", "OBSERVATION_MODIFIER", 86, 103], ["Ag nanoparticles", "OBSERVATION", 116, 132]]], ["Their use extends the shelf life of bread by 2 days except Au/TiO 2 as compared with the unmodified paper package.Zinc and Zinc Oxide NanoparticlesZinc and zinc oxide nanoparticles may be used as an additive in supplements and functional foods for nutrition, because this is an essential trace element required to maintain human health and well-being.", [["Au", "CHEMICAL", 59, 61], ["Zinc", "CHEMICAL", 114, 118], ["Zinc", "CHEMICAL", 123, 127], ["zinc oxide", "CHEMICAL", 156, 166], ["Au", "CHEMICAL", 59, 61], ["TiO 2", "CHEMICAL", 62, 67], ["Zinc", "CHEMICAL", 114, 118], ["Zinc Oxide", "CHEMICAL", 123, 133], ["zinc oxide", "CHEMICAL", 156, 166], ["bread", "ORGANISM_SUBDIVISION", 36, 41], ["Zinc", "SIMPLE_CHEMICAL", 114, 118], ["Zinc Oxide NanoparticlesZinc", "SIMPLE_CHEMICAL", 123, 151], ["zinc oxide nanoparticles", "SIMPLE_CHEMICAL", 156, 180], ["human", "ORGANISM", 323, 328], ["human", "SPECIES", 323, 328], ["human", "SPECIES", 323, 328], ["Au/TiO 2", "TREATMENT", 59, 67], ["Zinc", "TREATMENT", 114, 118], ["Zinc Oxide NanoparticlesZinc", "TREATMENT", 123, 151], ["zinc oxide nanoparticles", "TREATMENT", 156, 180], ["an additive in supplements", "TREATMENT", 196, 222], ["nutrition", "TREATMENT", 248, 257], ["an essential trace element", "PROBLEM", 275, 301], ["Zinc Oxide", "OBSERVATION", 123, 133], ["trace element", "OBSERVATION", 288, 301]]], ["ZnO nanoparticles can also be used in food packaging as antimicrobial agents so that contamination of foods with harmful bacteria can be prevented (Sirelkhatim et al. 2015) .", [["ZnO nanoparticles", "CHEMICAL", 0, 17], ["ZnO", "CHEMICAL", 0, 3], ["ZnO nanoparticles", "SIMPLE_CHEMICAL", 0, 17], ["ZnO nanoparticles", "TREATMENT", 0, 17], ["antimicrobial agents", "TREATMENT", 56, 76], ["harmful bacteria", "PROBLEM", 113, 129]]], ["These are also used as ultraviolet (UV) light absorbers to protect foods from UV light exposure, if food is sensitive toward it.", [["ultraviolet (UV) light absorbers", "TREATMENT", 23, 55]]], ["The preparation of ZnO nanoparticles loaded starch-coated polyethylene film was reported (Tankhiwale and Bajpai 2012) .", [["ZnO nanoparticles", "CHEMICAL", 19, 36], ["starch-coated polyethylene film", "CHEMICAL", 44, 75], ["ZnO", "CHEMICAL", 19, 22], ["polyethylene", "CHEMICAL", 58, 70], ["ZnO nanoparticles", "SIMPLE_CHEMICAL", 19, 36], ["starch", "SIMPLE_CHEMICAL", 44, 50], ["polyethylene film", "SIMPLE_CHEMICAL", 58, 75], ["The preparation of ZnO nanoparticles loaded starch", "TREATMENT", 0, 50], ["coated polyethylene film", "TREATMENT", 51, 75]]], ["This ZnO-loaded film was tested for its biocidal action against E. coli.", [["ZnO", "CHEMICAL", 5, 8], ["ZnO", "CHEMICAL", 5, 8], ["ZnO", "SIMPLE_CHEMICAL", 5, 8], ["E. coli", "ORGANISM", 64, 71], ["E. coli", "SPECIES", 64, 71], ["E. coli", "SPECIES", 64, 71], ["This ZnO-loaded film", "TEST", 0, 20], ["E. coli", "PROBLEM", 64, 71], ["coli", "OBSERVATION", 67, 71]]], ["As-developed material has a great potential to be used as food packaging material to prevent foodstuff from bacterial contamination.", [["material", "PROBLEM", 13, 21], ["food packaging material", "TREATMENT", 58, 81], ["bacterial contamination", "PROBLEM", 108, 131], ["bacterial contamination", "OBSERVATION", 108, 131]]], ["TiO 2 and ZnO are biocompatible nanomaterials, and their biocompatibility was established through toxicity studies on cell lines (Venkatasubbu et al. 2016) .", [["cell lines", "ANATOMY", 118, 128], ["TiO 2", "CHEMICAL", 0, 5], ["ZnO", "CHEMICAL", 10, 13], ["toxicity", "DISEASE", 98, 106], ["TiO 2", "CHEMICAL", 0, 5], ["ZnO", "CHEMICAL", 10, 13], ["TiO 2", "SIMPLE_CHEMICAL", 0, 5], ["ZnO", "SIMPLE_CHEMICAL", 10, 13], ["cell lines", "CELL", 118, 128], ["cell lines", "CELL_LINE", 118, 128], ["biocompatible nanomaterials", "PROBLEM", 18, 45], ["toxicity studies", "TEST", 98, 114], ["cell lines", "TREATMENT", 118, 128], ["biocompatible", "OBSERVATION_MODIFIER", 18, 31], ["nanomaterials", "OBSERVATION", 32, 45]]], ["Titanium dioxide and zinc oxide nanoparticle were synthesized by wet chemical process.", [["Titanium dioxide", "CHEMICAL", 0, 16], ["zinc oxide", "CHEMICAL", 21, 31], ["Titanium dioxide", "CHEMICAL", 0, 16], ["zinc oxide", "CHEMICAL", 21, 31], ["Titanium dioxide", "SIMPLE_CHEMICAL", 0, 16], ["zinc oxide nanoparticle", "SIMPLE_CHEMICAL", 21, 44], ["Titanium dioxide", "TREATMENT", 0, 16], ["zinc oxide nanoparticle", "TREATMENT", 21, 44]]], ["The antibacterial activities of these materials were evaluated as food preservatives against Salmonella typhi, Klebsiella pneumoniae, and Shigella flexneri, and it was indicated that TiO 2 and ZnO nanoparticles inhibited the growth of Salmonella, Klebsiella, and Shigella.", [["TiO 2", "CHEMICAL", 183, 188], ["ZnO nanoparticles", "CHEMICAL", 193, 210], ["TiO 2", "CHEMICAL", 183, 188], ["ZnO", "CHEMICAL", 193, 196], ["Salmonella typhi", "ORGANISM", 93, 109], ["Klebsiella pneumoniae", "ORGANISM", 111, 132], ["Shigella flexneri", "ORGANISM", 138, 155], ["TiO 2", "SIMPLE_CHEMICAL", 183, 188], ["ZnO nanoparticles", "SIMPLE_CHEMICAL", 193, 210], ["Shigella.", "ORGANISM", 263, 272], ["Salmonella typhi", "SPECIES", 93, 109], ["Klebsiella pneumoniae", "SPECIES", 111, 132], ["Shigella flexneri", "SPECIES", 138, 155], ["Salmonella typhi", "SPECIES", 93, 109], ["Klebsiella pneumoniae", "SPECIES", 111, 132], ["Shigella flexneri", "SPECIES", 138, 155], ["Salmonella", "SPECIES", 235, 245], ["food preservatives", "TREATMENT", 66, 84], ["Salmonella typhi", "PROBLEM", 93, 109], ["Klebsiella pneumoniae", "PROBLEM", 111, 132], ["Shigella flexneri", "PROBLEM", 138, 155], ["TiO 2 and ZnO nanoparticles", "PROBLEM", 183, 210], ["Salmonella", "PROBLEM", 235, 245], ["Klebsiella", "PROBLEM", 247, 257], ["Shigella", "PROBLEM", 263, 271], ["antibacterial", "OBSERVATION_MODIFIER", 4, 17], ["Klebsiella pneumoniae", "OBSERVATION", 111, 132], ["Salmonella", "OBSERVATION", 235, 245], ["Klebsiella", "OBSERVATION", 247, 257]]], ["It was revealed that the mode of their action is through generation of ROS in the case of Salmonella and Klebsiella, but it is still unclear in the case of Shigella.Titanium Dioxide NanoparticlesTiO 2 nanoparticles are used as ingredients in foods to provide its characteristic optical properties, so that lightness and brightness are enhanced (Weir et al. 2012) .", [["ROS", "CHEMICAL", 71, 74], ["Klebsiella", "CHEMICAL", 105, 115], ["Titanium Dioxide", "CHEMICAL", 165, 181], ["NanoparticlesTiO 2 nanoparticles", "CHEMICAL", 182, 214], ["Titanium Dioxide NanoparticlesTiO 2", "CHEMICAL", 165, 200], ["ROS", "SIMPLE_CHEMICAL", 71, 74], ["Titanium Dioxide NanoparticlesTiO 2 nanoparticles", "SIMPLE_CHEMICAL", 165, 214], ["Salmonella", "SPECIES", 90, 100], ["ROS", "PROBLEM", 71, 74], ["Salmonella", "PROBLEM", 90, 100], ["Klebsiella", "PROBLEM", 105, 115], ["Shigella", "PROBLEM", 156, 164], ["Titanium Dioxide NanoparticlesTiO 2 nanoparticles", "TREATMENT", 165, 214], ["Klebsiella", "OBSERVATION", 105, 115], ["Shigella", "OBSERVATION", 156, 164]]], ["It is widely used as food additive and antimicrobial agent for food packaging and storage containers.", [["antimicrobial agent", "TREATMENT", 39, 58], ["food packaging", "TREATMENT", 63, 77]]], ["TiO 2 ingredients utilized in the food industry as lightening agents should have particle sizes in the range of 100-300 nanometers, so that their lightscattering properties are increased.", [["TiO 2 ingredients", "CHEMICAL", 0, 17], ["TiO 2", "CHEMICAL", 0, 5], ["TiO 2 ingredients", "TREATMENT", 0, 17], ["lightening agents", "TREATMENT", 51, 68], ["sizes", "OBSERVATION_MODIFIER", 90, 95], ["increased", "OBSERVATION_MODIFIER", 177, 186]]], ["Six different coating suspensions were prepared, through mixing TiO 2 (Aeroxide\u00aeP-25) nanoparticles (NPs) with three different types of binders [Shellac (A), polyuretahne (B), and polycrylic (C)] at a 1:4 to 1:16 NP to binder weight ratio (Yemmireddy and Hung 2015) .", [["TiO 2", "CHEMICAL", 64, 69], ["Aeroxide\u00aeP-25) nanoparticles", "CHEMICAL", 71, 99], ["NPs", "CHEMICAL", 101, 104], ["Shellac", "CHEMICAL", 145, 152], ["polyuretahne", "CHEMICAL", 158, 170], ["TiO 2", "CHEMICAL", 64, 69], ["Aeroxide\u00aeP-25", "CHEMICAL", 71, 84], ["Shellac", "CHEMICAL", 145, 152], ["polyuretahne", "CHEMICAL", 158, 170], ["polycrylic (C)", "CHEMICAL", 180, 194], ["TiO 2 (Aeroxide\u00aeP-25) nanoparticles", "SIMPLE_CHEMICAL", 64, 99], ["NPs", "SIMPLE_CHEMICAL", 101, 104], ["Shellac (A)", "SIMPLE_CHEMICAL", 145, 156], ["polyuretahne", "SIMPLE_CHEMICAL", 158, 170], ["B)", "SIMPLE_CHEMICAL", 172, 174], ["polycrylic (C)", "SIMPLE_CHEMICAL", 180, 194], ["Six different coating suspensions", "TREATMENT", 0, 33], ["mixing TiO 2 (Aeroxide\u00aeP-25) nanoparticles (NPs", "TREATMENT", 57, 104], ["binders", "TREATMENT", 136, 143], ["Shellac (A), polyuretahne (B)", "TREATMENT", 145, 174], ["polycrylic (C)", "TREATMENT", 180, 194], ["coating suspensions", "OBSERVATION", 14, 33]]], ["They evaluated bactericidal activity of these TiO 2 coatings against Escherichia coli O157:H7 at three different UV-A light intensities.", [["TiO 2", "CHEMICAL", 46, 51], ["TiO 2 coatings", "SIMPLE_CHEMICAL", 46, 60], ["Escherichia coli", "ORGANISM", 69, 85], ["O157:H7", "ORGANISM", 86, 93], ["Escherichia coli O157", "SPECIES", 69, 90], ["Escherichia coli O157:H7", "SPECIES", 69, 93], ["these TiO 2 coatings", "TREATMENT", 40, 60], ["Escherichia coli", "PROBLEM", 69, 85], ["H7", "PROBLEM", 91, 93], ["light intensities", "OBSERVATION_MODIFIER", 118, 135]]], ["TiO 2 coatings with binder polyuretahne showed highest adhesion strength and scratch hardness as compared to coatings with other binders.", [["polyuretahne", "CHEMICAL", 27, 39], ["TiO 2", "CHEMICAL", 0, 5], ["polyuretahne", "CHEMICAL", 27, 39], ["TiO 2", "SIMPLE_CHEMICAL", 0, 5], ["binder polyuretahne", "SIMPLE_CHEMICAL", 20, 39], ["TiO 2 coatings with binder polyuretahne", "TREATMENT", 0, 39], ["highest adhesion strength", "PROBLEM", 47, 72], ["scratch hardness", "PROBLEM", 77, 93], ["other binders", "TREATMENT", 123, 136], ["highest", "OBSERVATION_MODIFIER", 47, 54], ["adhesion strength", "OBSERVATION", 55, 72], ["scratch hardness", "OBSERVATION", 77, 93]]], ["It was found that TiO 2 coatings with binder polycrylic were found to be physically more stable and able to retain their original bactericidal property on repeated use experiments (1, 3, 5, and 10 times).Silicon Dioxide NanoparticlesSilicon dioxide nanoparticles are used in certain powdered foods as anticaking agents.", [["TiO", "CHEMICAL", 18, 21], ["Silicon Dioxide", "CHEMICAL", 204, 219], ["NanoparticlesSilicon dioxide", "CHEMICAL", 220, 248], ["TiO 2", "CHEMICAL", 18, 23], ["Silicon Dioxide NanoparticlesSilicon dioxide", "CHEMICAL", 204, 248], ["TiO 2 coatings", "SIMPLE_CHEMICAL", 18, 32], ["binder polycrylic", "SIMPLE_CHEMICAL", 38, 55], ["Silicon Dioxide NanoparticlesSilicon dioxide nanoparticles", "SIMPLE_CHEMICAL", 204, 262], ["TiO 2 coatings", "TREATMENT", 18, 32], ["binder polycrylic", "TREATMENT", 38, 55], ["Silicon Dioxide NanoparticlesSilicon dioxide nanoparticles", "TREATMENT", 204, 262], ["anticaking agents", "TREATMENT", 301, 318], ["bactericidal", "OBSERVATION_MODIFIER", 130, 142]]], ["Silicon dioxide and carbon having particle size in the range of a few hundred nm are used as food additives and for food packaging.Organic NanoparticlesThese nanoparticles are basically composed of organic substances, like carbohydrates, proteins, or lipids.", [["Silicon dioxide", "CHEMICAL", 0, 15], ["carbon", "CHEMICAL", 20, 26], ["Silicon dioxide", "CHEMICAL", 0, 15], ["carbon", "CHEMICAL", 20, 26], ["carbohydrates", "CHEMICAL", 223, 236], ["Silicon dioxide", "SIMPLE_CHEMICAL", 0, 15], ["carbon", "SIMPLE_CHEMICAL", 20, 26], ["organic substances", "SIMPLE_CHEMICAL", 198, 216], ["carbohydrates", "SIMPLE_CHEMICAL", 223, 236], ["lipids", "SIMPLE_CHEMICAL", 251, 257], ["Silicon dioxide", "TREATMENT", 0, 15], ["carbon having particle size", "TREATMENT", 20, 47], ["food packaging", "TREATMENT", 116, 130], ["Organic NanoparticlesThese nanoparticles", "TREATMENT", 131, 171], ["organic substances", "TREATMENT", 198, 216], ["lipids", "TREATMENT", 251, 257], ["size", "OBSERVATION_MODIFIER", 43, 47]]], ["These substances are liquids, semisolids, or solids (crystalline or amorphous) at ambient temperatures, which depends on their composition and processing conditions.Lipid NanoparticlesLipid nanoparticles are present in a wide range within many commercial food products.", [["semisolids", "SIMPLE_CHEMICAL", 30, 40], ["Lipid NanoparticlesLipid nanoparticles", "SIMPLE_CHEMICAL", 165, 203], ["Lipid NanoparticlesLipid nanoparticles", "TREATMENT", 165, 203], ["food products", "OBSERVATION", 255, 268]]], ["These lipids and lipid nanoparticles are mostly used as oral delivery systems for different drugs and other active ingredients.", [["oral", "ANATOMY", 56, 60], ["lipids", "SIMPLE_CHEMICAL", 6, 12], ["lipid nanoparticles", "SIMPLE_CHEMICAL", 17, 36], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["These lipids and lipid nanoparticles", "TREATMENT", 0, 36], ["oral delivery systems", "TREATMENT", 56, 77], ["different drugs", "TREATMENT", 82, 97], ["other active ingredients", "TREATMENT", 102, 126]]], ["Lipids usually increase drug absorption in the gastrointestinal tract (GIT).", [["gastrointestinal tract", "ANATOMY", 47, 69], ["GIT", "ANATOMY", 71, 74], ["Lipids", "SIMPLE_CHEMICAL", 0, 6], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 47, 69], ["GIT", "ORGAN", 71, 74], ["Lipids", "TREATMENT", 0, 6], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["drug absorption", "OBSERVATION", 24, 39], ["gastrointestinal tract", "ANATOMY", 47, 69], ["GIT", "ANATOMY", 71, 74]]], ["These molecules in the form of nanoparticles improve mucosal adhesion because of their small particle size and increase their residence time in GIT.", [["mucosal", "ANATOMY", 53, 60], ["GIT", "ANATOMY", 144, 147], ["mucosal", "MULTI-TISSUE_STRUCTURE", 53, 60], ["GIT", "CANCER", 144, 147], ["nanoparticles", "TREATMENT", 31, 44], ["mucosal adhesion", "PROBLEM", 53, 69], ["their small particle size", "PROBLEM", 81, 106], ["mucosal adhesion", "OBSERVATION", 53, 69], ["small", "OBSERVATION_MODIFIER", 87, 92], ["particle", "OBSERVATION_MODIFIER", 93, 101], ["size", "OBSERVATION_MODIFIER", 102, 106], ["increase", "OBSERVATION_MODIFIER", 111, 119]]], ["Lipid nanoparticles will also protect the loaded drugs from different degradations (chemical as well as enzymatic) and release drug molecules from the lipid matrix gradually into blood, thus resulting in enhanced therapeutic profiles as compared to free drug (Severino et al. 2012) .Protein NanoparticlesProtein nanoparticles and other protein assemblies have shown a great potential recently in the field of catalysis, materials synthesis, drug and gene delivery, and bio-imaging (Rong et al. 2011) .", [["lipid matrix", "ANATOMY", 151, 163], ["blood", "ANATOMY", 179, 184], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 0, 19], ["lipid matrix", "CELLULAR_COMPONENT", 151, 163], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["Lipid nanoparticles", "TREATMENT", 0, 19], ["the loaded drugs", "TREATMENT", 38, 54], ["different degradations", "PROBLEM", 60, 82], ["release drug molecules", "TREATMENT", 119, 141], ["the lipid matrix", "TREATMENT", 147, 163], ["enhanced therapeutic profiles", "PROBLEM", 204, 233], ["Protein Nanoparticles", "TREATMENT", 283, 304], ["Protein nanoparticles", "TEST", 304, 325], ["other protein assemblies", "TEST", 330, 354], ["materials synthesis", "TREATMENT", 420, 439], ["gene delivery", "TREATMENT", 450, 463], ["bio-imaging", "TEST", 469, 480], ["great potential", "OBSERVATION_MODIFIER", 368, 383]]], ["Protein nanoparticles are also found in foods in the form of casein micelles, which are available in bovine milk and other dairy products.", [["milk", "ANATOMY", 108, 112], ["casein micelles", "SIMPLE_CHEMICAL", 61, 76], ["bovine", "ORGANISM", 101, 107], ["milk", "ORGANISM_SUBSTANCE", 108, 112], ["bovine", "SPECIES", 101, 107], ["bovine", "SPECIES", 101, 107], ["Protein nanoparticles", "TREATMENT", 0, 21], ["casein micelles", "TREATMENT", 61, 76], ["bovine milk", "TREATMENT", 101, 112], ["other dairy products", "TREATMENT", 117, 137], ["casein micelles", "OBSERVATION", 61, 76]]], ["These are nothing but small clusters of casein molecules and calcium phosphate ions.Carbohydrate NanoparticlesCarbohydrate nanoparticles are either digestible or indigestible polysaccharides, like starch, cellulose, xanthan, carrageenan, alginate, and pectin.Complex NanoparticlesNanoparticles utilized in foods are many a time fabricated using combinations of these three ingredients, such as lipids, proteins, and carbohydrates.", [["calcium phosphate", "CHEMICAL", 61, 78], ["starch, cellulose, xanthan, carrageenan, alginate, and pectin", "CHEMICAL", 197, 258], ["calcium phosphate", "CHEMICAL", 61, 78], ["Carbohydrate", "CHEMICAL", 84, 96], ["Carbohydrate", "CHEMICAL", 110, 122], ["carbohydrates", "CHEMICAL", 416, 429], ["casein molecules", "SIMPLE_CHEMICAL", 40, 56], ["calcium phosphate ions", "SIMPLE_CHEMICAL", 61, 83], ["Carbohydrate NanoparticlesCarbohydrate nanoparticles", "SIMPLE_CHEMICAL", 84, 136], ["starch", "SIMPLE_CHEMICAL", 197, 203], ["cellulose", "SIMPLE_CHEMICAL", 205, 214], ["xanthan", "SIMPLE_CHEMICAL", 216, 223], ["carrageenan", "SIMPLE_CHEMICAL", 225, 236], ["alginate", "SIMPLE_CHEMICAL", 238, 246], ["pectin", "SIMPLE_CHEMICAL", 252, 258], ["lipids", "SIMPLE_CHEMICAL", 394, 400], ["carbohydrates", "SIMPLE_CHEMICAL", 416, 429], ["casein molecules", "PROTEIN", 40, 56], ["small clusters of casein molecules", "PROBLEM", 22, 56], ["calcium phosphate ions", "TREATMENT", 61, 83], ["Carbohydrate NanoparticlesCarbohydrate nanoparticles", "TREATMENT", 84, 136], ["indigestible polysaccharides", "PROBLEM", 162, 190], ["cellulose, xanthan", "TREATMENT", 205, 223], ["carrageenan", "TREATMENT", 225, 236], ["alginate", "TREATMENT", 238, 246], ["pectin", "TREATMENT", 252, 258], ["Complex NanoparticlesNanoparticles", "TREATMENT", 259, 293], ["these three ingredients", "TREATMENT", 361, 384], ["lipids, proteins", "TREATMENT", 394, 410], ["carbohydrates", "TREATMENT", 416, 429], ["small", "OBSERVATION_MODIFIER", 22, 27], ["clusters", "OBSERVATION_MODIFIER", 28, 36], ["casein molecules", "OBSERVATION", 40, 56], ["NanoparticlesNanoparticles", "OBSERVATION", 267, 293]]], ["Coacervates are formed by electrostatic complexation of oppositely charged proteins and polysaccharides.Role in Tracking, Tracing, Nanolithography, and Brand ProtectionNanotechnology is also helping food industries in providing authentication and track and trace features of a food product so that adulteration and diversion of products can be prevented (Nam et al. 2003) .", [["Coacervates", "SIMPLE_CHEMICAL", 0, 11], ["oppositely charged proteins", "PROTEIN", 56, 83], ["oppositely charged proteins", "PROBLEM", 56, 83], ["diversion of products", "TREATMENT", 315, 336], ["electrostatic complexation", "OBSERVATION", 26, 52]]], ["It is simply done by generating some complex invisible nanobarcodes with desired information, and it can be encrypted onto the food products and packaging.", [["packaging", "TREATMENT", 145, 154]]], ["Such a nanobarcode detection system was created by Li et al. (2005) that produced fluorescence on exposure to ultraviolet light in a combination of color, which can be read by a computer scanner.", [["a nanobarcode detection system", "TREATMENT", 5, 35], ["ultraviolet light", "TREATMENT", 110, 127]]], ["This system has been tested on the food and some biological samples containing various pathogens like E. coli, anthrax, tularemia bacteria, and Ebola SARS viruses.", [["samples", "ANATOMY", 60, 67], ["anthrax", "DISEASE", 111, 118], ["tularemia", "DISEASE", 120, 129], ["Ebola SARS viruses", "DISEASE", 144, 162], ["E. coli", "ORGANISM", 102, 109], ["anthrax", "ORGANISM", 111, 118], ["tularemia bacteria", "ORGANISM", 120, 138], ["Ebola SARS viruses", "ORGANISM", 144, 162], ["E. coli", "SPECIES", 102, 109], ["Ebola", "SPECIES", 144, 149], ["E. coli", "SPECIES", 102, 109], ["Ebola SARS viruses", "SPECIES", 144, 162], ["some biological samples", "PROBLEM", 44, 67], ["various pathogens", "PROBLEM", 79, 96], ["E. coli", "PROBLEM", 102, 109], ["anthrax", "PROBLEM", 111, 118], ["tularemia bacteria", "PROBLEM", 120, 138], ["Ebola SARS viruses", "PROBLEM", 144, 162], ["E. coli", "OBSERVATION", 102, 109], ["tularemia bacteria", "OBSERVATION", 120, 138]]], ["These are also clearly indicated simultaneously by different color codes.", [["color codes", "OBSERVATION", 61, 72]]], ["Different codes can be created in the technology by altering the stripe orders, where every food item is assigned brand so that food batches can be traced.Implication and Safety ConcernsAlthough there had been a rapid development in food nanotechnology using nanoparticles, little is known about the toxicity due to nanoparticles.", [["toxicity", "DISEASE", 300, 308], ["nanoparticles", "TREATMENT", 259, 272], ["the toxicity", "PROBLEM", 296, 308], ["rapid", "OBSERVATION_MODIFIER", 212, 217]]], ["Nanomaterials have some unique properties like high surface area, which makes them more active chemically than their bulk counterparts, and therefore, they could participate in most of the biological reaction having harmful effects on human health and/or environment.", [["surface area", "ANATOMY", 52, 64], ["human", "ORGANISM", 235, 240], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 235, 240], ["the biological reaction", "PROBLEM", 185, 208], ["high", "OBSERVATION_MODIFIER", 47, 51], ["surface", "OBSERVATION_MODIFIER", 52, 59]]], ["But these unique properties may occasionally lead to dangerous side effects to ecosystems and even in people.", [["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["dangerous side effects", "PROBLEM", 53, 75]]], ["There are two main safety concerns on using nanoparticles, and these are allergies and heavy metal release.", [["nanoparticles", "TREATMENT", 44, 57], ["heavy metal release", "TREATMENT", 87, 106], ["two", "OBSERVATION_MODIFIER", 10, 13], ["main", "OBSERVATION_MODIFIER", 14, 18]]], ["It is necessary to take extra care while using nanomaterials as they may have potential toxic effects and their use in food science is increasing day by day.", [["nanomaterials", "TREATMENT", 47, 60]]], ["A report by the British Royal Society notes that we may face a nanotoxicity crisis in the future (Amini et al. 2014) .", [["a nanotoxicity crisis", "PROBLEM", 61, 82], ["nanotoxicity crisis", "OBSERVATION", 63, 82]]], ["Only with a proper detailed understanding of the properties of nanomaterials like size, solubility, surface chemistry, composition, etc., we will be in a position to find useful and safe food products.", [["surface", "ANATOMY", 100, 107], ["size", "OBSERVATION_MODIFIER", 82, 86]]], ["Of course, some of these unique properties of nanomaterials are making them wonderful materials, but sidewise, their use is also questionable at some or the other side.SizeThe size of nanoparticles is a very important feature for its unique properties as the surface area of nanoparticles depends upon its size.", [["surface area", "ANATOMY", 259, 271], ["nanomaterials", "OBSERVATION", 46, 59], ["size", "OBSERVATION_MODIFIER", 176, 180], ["nanoparticles", "OBSERVATION", 184, 197], ["surface", "OBSERVATION_MODIFIER", 259, 266], ["area", "OBSERVATION_MODIFIER", 267, 271], ["nanoparticles", "OBSERVATION", 275, 288], ["size", "OBSERVATION_MODIFIER", 306, 310]]], ["The effect of surface area on the respiration has been known as some nanoparticles are reported to cause pulmonary inflammation (Qiao et al. 2015) .", [["surface area", "ANATOMY", 14, 26], ["pulmonary", "ANATOMY", 105, 114], ["pulmonary inflammation", "DISEASE", 105, 127], ["pulmonary", "ORGAN", 105, 114], ["surface area", "PROBLEM", 14, 26], ["some nanoparticles", "PROBLEM", 64, 82], ["pulmonary inflammation", "PROBLEM", 105, 127], ["surface", "OBSERVATION_MODIFIER", 14, 21], ["area", "OBSERVATION_MODIFIER", 22, 26], ["pulmonary", "ANATOMY", 105, 114], ["inflammation", "OBSERVATION", 115, 127]]], ["The toxicity of these nanoparticles not only depends on its chemical component, but it also depends on the quantity as well as position of the deposition.", [["toxicity", "DISEASE", 4, 12], ["The toxicity of these nanoparticles", "PROBLEM", 0, 35]]], ["The size of particles is an important factor, which can be deciding for observing dermal-cell cytotoxicity in vitro.", [["dermal-cell", "ANATOMY", 82, 93], ["dermal-cell", "CELL", 82, 93], ["dermal-cell cytotoxicity", "TREATMENT", 82, 106], ["size", "OBSERVATION_MODIFIER", 4, 8], ["particles", "OBSERVATION", 12, 21], ["cell cytotoxicity", "OBSERVATION", 89, 106]]], ["Such absorbed nanoparticles in different absorption routes could trigger an immune system response.", [["immune system", "ANATOMY", 76, 89], ["Such absorbed nanoparticles", "PROBLEM", 0, 27]]], ["The smaller size of these nanoparticles permits them to pass through different biological barriers.", [["these nanoparticles", "TREATMENT", 20, 39], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["nanoparticles", "OBSERVATION", 26, 39]]], ["They can then settle in tissues like the central nervous system (CNS).", [["tissues", "ANATOMY", 24, 31], ["central nervous system", "ANATOMY", 41, 63], ["CNS", "ANATOMY", 65, 68], ["tissues", "TISSUE", 24, 31], ["central nervous system", "ANATOMICAL_SYSTEM", 41, 63], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["central", "ANATOMY_MODIFIER", 41, 48], ["nervous system", "ANATOMY", 49, 63]]], ["Thus, the size of the nanoparticles is very important for safety purpose, whether such nanomaterials can be used in food and food-related industries or not.Chemical CompositionReagents used in the production of nanoparticles may be toxic.", [["Chemical CompositionReagents", "TREATMENT", 156, 184], ["the production of nanoparticles", "TREATMENT", 193, 224], ["toxic", "PROBLEM", 232, 237], ["size", "OBSERVATION_MODIFIER", 10, 14], ["nanoparticles", "OBSERVATION", 22, 35], ["toxic", "OBSERVATION_MODIFIER", 232, 237]]], ["Some may remain in the final product and result in exposure to toxins that are unrelated to the nanomaterials themselves.", [["toxins", "PROBLEM", 63, 69]]], ["For instance, some observed toxic effects of carbon nanotubes and semiconductor nanoparticles are related to residual reagents during synthesis.", [["carbon nanotubes", "CHEMICAL", 45, 61], ["carbon", "CHEMICAL", 45, 51], ["carbon nanotubes", "SIMPLE_CHEMICAL", 45, 61], ["semiconductor nanoparticles", "SIMPLE_CHEMICAL", 66, 93], ["carbon nanotubes", "TREATMENT", 45, 61], ["semiconductor nanoparticles", "TREATMENT", 66, 93], ["residual reagents during synthesis", "PROBLEM", 109, 143], ["toxic", "OBSERVATION_MODIFIER", 28, 33], ["carbon nanotubes", "OBSERVATION", 45, 61]]], ["The remaining reagents and impurities may hinder our understanding of possible side effects of carbon nanotubes.", [["carbon nanotubes", "CHEMICAL", 95, 111], ["carbon", "CHEMICAL", 95, 101], ["carbon nanotubes", "SIMPLE_CHEMICAL", 95, 111], ["carbon nanotubes", "TREATMENT", 95, 111], ["carbon nanotubes", "OBSERVATION", 95, 111]]], ["Iron ions and impurities can accelerate the oxidative stress in cells.", [["cells", "ANATOMY", 64, 69], ["Iron ions", "CHEMICAL", 0, 9], ["Iron", "CHEMICAL", 0, 4], ["Iron ions", "SIMPLE_CHEMICAL", 0, 9], ["cells", "CELL", 64, 69], ["Iron ions", "TREATMENT", 0, 9], ["the oxidative stress in cells", "PROBLEM", 40, 69], ["oxidative stress", "OBSERVATION", 44, 60]]], ["Crystallinity is another important aspect of chemical composition.", [["Crystallinity", "TREATMENT", 0, 13], ["chemical composition", "OBSERVATION", 45, 65]]], ["Titanium oxide has three different levels of crystallinity that each has different cytotoxic effects (Suker and Albadran 2013).Surface StructureCytotoxicity may also be affected from surfaces of nanostructures.", [["Titanium oxide", "CHEMICAL", 0, 14], ["Titanium oxide", "CHEMICAL", 0, 14], ["Titanium oxide", "SIMPLE_CHEMICAL", 0, 14], ["Titanium oxide", "TREATMENT", 0, 14], ["crystallinity", "TREATMENT", 45, 58], ["different cytotoxic effects", "PROBLEM", 73, 100], ["Surface StructureCytotoxicity", "TREATMENT", 127, 156], ["three different", "OBSERVATION_MODIFIER", 19, 34], ["cytotoxic effects", "OBSERVATION", 83, 100], ["StructureCytotoxicity", "OBSERVATION", 135, 156], ["may also be", "UNCERTAINTY", 157, 168], ["surfaces", "OBSERVATION_MODIFIER", 183, 191], ["nanostructures", "OBSERVATION_MODIFIER", 195, 209]]], ["Roughness, charge, hydrophobicity, and surface chemistry are the major factors that could affect the toxicological nature of absorbed nanoparticles in the human body (Kirchner et al. 2005) .", [["surface", "ANATOMY", 39, 46], ["body", "ANATOMY", 161, 165], ["Roughness", "DISEASE", 0, 9], ["human", "ORGANISM", 155, 160], ["body", "ORGANISM_SUBDIVISION", 161, 165], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["hydrophobicity", "PROBLEM", 19, 33], ["surface chemistry", "TEST", 39, 56], ["hydrophobicity", "OBSERVATION_MODIFIER", 19, 33], ["human body", "ANATOMY", 155, 165]]], ["The toxic effects of nanoparticles can be controlled to some extent by coating nanoparticles with hydrophilic polymer like polyethylene glycol (PEG).", [["polyethylene glycol", "CHEMICAL", 123, 142], ["PEG", "CHEMICAL", 144, 147], ["polyethylene glycol", "CHEMICAL", 123, 142], ["PEG", "CHEMICAL", 144, 147], ["nanoparticles", "SIMPLE_CHEMICAL", 21, 34], ["hydrophilic polymer like polyethylene glycol", "SIMPLE_CHEMICAL", 98, 142], ["PEG", "SIMPLE_CHEMICAL", 144, 147], ["nanoparticles", "TREATMENT", 21, 34], ["coating nanoparticles", "TREATMENT", 71, 92], ["hydrophilic polymer like polyethylene glycol (PEG", "TREATMENT", 98, 147], ["toxic", "OBSERVATION_MODIFIER", 4, 9], ["polyethylene glycol", "OBSERVATION", 123, 142]]], ["It was indicated that positively charged nanoparticles were found to be more toxic as compared to negative or neutral nanoparticles.SolubilitySolubility is also important in the toxicity of nanoparticles.", [["toxicity", "DISEASE", 178, 186], ["positively charged nanoparticles", "PROBLEM", 22, 54], ["SolubilitySolubility", "TREATMENT", 132, 152], ["the toxicity of nanoparticles", "TREATMENT", 174, 203]]], ["Soluble titanium oxide nanoparticles (hydrophilic) are more toxic as compared to insoluble titanium oxide nanoparticles (Oberd\u00f6rster 2001) .", [["titanium oxide", "CHEMICAL", 8, 22], ["titanium oxide", "CHEMICAL", 91, 105], ["titanium oxide", "CHEMICAL", 8, 22], ["titanium oxide", "CHEMICAL", 91, 105], ["titanium oxide nanoparticles", "SIMPLE_CHEMICAL", 8, 36], ["titanium oxide nanoparticles", "SIMPLE_CHEMICAL", 91, 119], ["Soluble titanium oxide nanoparticles (hydrophilic", "TREATMENT", 0, 49], ["insoluble titanium oxide nanoparticles", "TREATMENT", 81, 119], ["titanium oxide", "OBSERVATION", 8, 22], ["more toxic", "OBSERVATION_MODIFIER", 55, 65]]], ["Solubility of the toxicity of oxide nanoparticles has also been reported (Brunner et al. 2006) .Routes of Nanoparticle ExposureThere are different entry routes on exposure to nanoparticles such as dermal, respiratory, and digestive routes.", [["dermal", "ANATOMY", 197, 203], ["respiratory", "ANATOMY", 205, 216], ["digestive", "ANATOMY", 222, 231], ["toxicity", "DISEASE", 18, 26], ["oxide nanoparticles", "CHEMICAL", 30, 49], ["oxide", "CHEMICAL", 30, 35], ["oxide nanoparticles", "SIMPLE_CHEMICAL", 30, 49], ["dermal", "TISSUE", 197, 203], ["digestive", "ORGAN", 222, 231], ["the toxicity of oxide nanoparticles", "TREATMENT", 14, 49], ["Nanoparticle ExposureThere", "TREATMENT", 106, 132], ["nanoparticles", "TREATMENT", 175, 188], ["respiratory", "ANATOMY", 205, 216]]], ["These nanoparticles may enter the bloodstream after absorption and settle in different tissues like the brain or trigger some immune responses.", [["bloodstream", "ANATOMY", 34, 45], ["tissues", "ANATOMY", 87, 94], ["brain", "ANATOMY", 104, 109], ["tissues", "TISSUE", 87, 94], ["brain", "ORGAN", 104, 109], ["These nanoparticles", "TREATMENT", 0, 19], ["bloodstream", "ANATOMY", 34, 45], ["brain", "ANATOMY", 104, 109]]], ["Some genetic alteration has been also reported due to nanoparticles in food or nanoengineering of food (Bowman and Fitzharris 2007) .", [["Some genetic alteration", "PROBLEM", 0, 23], ["genetic", "OBSERVATION_MODIFIER", 5, 12], ["alteration", "OBSERVATION", 13, 23]]], ["Although there had been a long debate and it will go on, nanotechnology has entered into food packaging and food processing, so some safety measures are also required from governments and food producers.Routes of Nanoparticle ExposureSome nanoparticles may be dispersed in the air during the production of nanoparticles used in food and related industries.", [["Nanoparticle ExposureSome nanoparticles", "SIMPLE_CHEMICAL", 213, 252], ["some safety measures", "TREATMENT", 128, 148], ["Nanoparticle ExposureSome nanoparticles", "TREATMENT", 213, 252], ["the production of nanoparticles", "TREATMENT", 288, 319], ["air", "OBSERVATION", 277, 280]]], ["This should be taken into consideration, and workers' health must be protected from respiratory tract uptake of nanoparticles.", [["respiratory tract", "ANATOMY", 84, 101], ["respiratory tract", "ORGANISM_SUBDIVISION", 84, 101], ["respiratory tract uptake of nanoparticles", "PROBLEM", 84, 125]]], ["The digestive path is another major route of uptake of nanoparticles.", [["digestive", "ANATOMY", 4, 13], ["digestive", "ORGAN", 4, 13], ["uptake of nanoparticles", "PROBLEM", 45, 68], ["digestive", "ANATOMY", 4, 13]]], ["Some nanoparticles may also enter in the respiratory tract and then the digestive system through mucociliary clearance.", [["respiratory tract", "ANATOMY", 41, 58], ["digestive system", "ANATOMY", 72, 88], ["mucociliary", "ANATOMY", 97, 108], ["respiratory tract", "ORGANISM_SUBDIVISION", 41, 58], ["digestive system", "ANATOMICAL_SYSTEM", 72, 88], ["mucociliary", "ORGAN", 97, 108], ["Some nanoparticles", "PROBLEM", 0, 18], ["nanoparticles", "OBSERVATION", 5, 18], ["respiratory tract", "ANATOMY", 41, 58]]], ["The skin is an alternate main route of contact between human and nanomaterials.Routes of Nanoparticle ExposureThere are several diseases that are associated with exposure to nanoparticles due to their accumulation or contact with cells and its internal parts like the mitochondrion, nucleus, cytoplasm, membrane, and lipid vesicle (Buzea et al. 2007Emerging Challenges and Potential SolutionsWith the developments in nanotechnology, its applicability to the food industry is likely to increase in the future.", [["skin", "ANATOMY", 4, 8], ["cells", "ANATOMY", 230, 235], ["mitochondrion", "ANATOMY", 268, 281], ["nucleus", "ANATOMY", 283, 290], ["cytoplasm", "ANATOMY", 292, 301], ["membrane", "ANATOMY", 303, 311], ["lipid vesicle", "ANATOMY", 317, 330], ["skin", "ORGAN", 4, 8], ["human", "ORGANISM", 55, 60], ["cells", "CELL", 230, 235], ["mitochondrion", "CELLULAR_COMPONENT", 268, 281], ["nucleus", "CELLULAR_COMPONENT", 283, 290], ["cytoplasm", "ORGANISM_SUBSTANCE", 292, 301], ["membrane", "CELLULAR_COMPONENT", 303, 311], ["lipid vesicle", "CELLULAR_COMPONENT", 317, 330], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["Nanoparticle ExposureThere", "TREATMENT", 89, 115], ["several diseases", "PROBLEM", 120, 136], ["nanoparticles", "TREATMENT", 174, 187], ["their accumulation", "PROBLEM", 195, 213], ["contact with cells", "PROBLEM", 217, 235], ["skin", "ANATOMY", 4, 8], ["Nanoparticle ExposureThere", "OBSERVATION", 89, 115], ["several", "OBSERVATION_MODIFIER", 120, 127], ["diseases", "OBSERVATION", 128, 136], ["internal", "ANATOMY_MODIFIER", 244, 252], ["nucleus", "ANATOMY", 283, 290], ["cytoplasm", "OBSERVATION_MODIFIER", 292, 301], ["lipid vesicle", "OBSERVATION", 317, 330]]], ["Various nanostructured materials (NSMs) ranging from inorganic metal, metal oxides, and their nanocomposites to nano-organic materials with bioactive agents have been applied in a wide range of food materials (Bajpai et al. 2018) .", [["metal oxides", "CHEMICAL", 70, 82], ["NSMs", "SIMPLE_CHEMICAL", 34, 38], ["inorganic metal", "SIMPLE_CHEMICAL", 53, 68], ["metal oxides", "SIMPLE_CHEMICAL", 70, 82], ["Various nanostructured materials (NSMs)", "PROBLEM", 0, 39], ["inorganic metal, metal oxides", "TREATMENT", 53, 82], ["their nanocomposites to nano-organic materials", "TREATMENT", 88, 134], ["bioactive agents", "TREATMENT", 140, 156], ["nanostructured materials", "OBSERVATION", 8, 32], ["bioactive agents", "OBSERVATION", 140, 156]]], ["Human exposure to these nanomaterials is regularly increasing, and its impact on health of the human and environment has become a point of public concern and interest.", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 95, 100], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["increasing", "OBSERVATION_MODIFIER", 51, 61]]], ["Although huge benefits are being offered by nanotechnology, the accumulation of nanostructured materials in human bodies and also in the environment has aroused several health and safety issues.", [["human", "ORGANISM", 108, 113], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["the accumulation of nanostructured materials in human bodies", "PROBLEM", 60, 120], ["nanostructured materials", "OBSERVATION", 80, 104], ["human bodies", "OBSERVATION", 108, 120]]], ["Different preparation technology could produce nanoparticles with different physical properties for their application in food.", [["Different preparation technology", "TREATMENT", 0, 32], ["nanoparticles", "TREATMENT", 47, 60]]], ["It has been reported that these nanomaterials can improve food safety by increasing the efficacy of food packaging, shelf life, and nutritional value of food using additives without affecting the taste and physical characteristics of food products.Emerging Challenges and Potential SolutionsNanotechnology is regularly gaining momentum; thus, it has become a very important tool for the food and bioprocessing industry to meet demands of increasing population growth all over the world.", [["food packaging", "TREATMENT", 100, 114], ["Potential Solutions", "TREATMENT", 272, 291], ["bioprocessing industry", "TREATMENT", 396, 418], ["increasing population growth", "PROBLEM", 438, 466], ["increasing", "OBSERVATION_MODIFIER", 438, 448], ["population", "OBSERVATION", 449, 459]]], ["It is also important to ascertain the toxicity of nanoparticles and the possible environmental and health hazards it may cause.", [["toxicity", "DISEASE", 38, 46], ["the toxicity of nanoparticles", "PROBLEM", 34, 63]]], ["Improvement in inorganic nanosubstance and microfluid manufacturing has permitted the preparation of effective and competent sensors to quickly detect/identify pathogens, microbes, or pesticides.", [["inorganic nanosubstance", "CHEMICAL", 15, 38], ["inorganic nanosubstance", "SIMPLE_CHEMICAL", 15, 38], ["microfluid", "SIMPLE_CHEMICAL", 43, 53], ["inorganic nanosubstance", "TREATMENT", 15, 38], ["microfluid manufacturing", "TREATMENT", 43, 67], ["pathogens", "PROBLEM", 160, 169], ["inorganic nanosubstance", "OBSERVATION", 15, 38], ["microfluid manufacturing", "OBSERVATION", 43, 67]]], ["The nanosensor or nanobiosensor should also be used in environmental contamination control in the food sectors.", [["The nanosensor", "TREATMENT", 0, 14], ["nanobiosensor", "TREATMENT", 18, 31]]], ["Functionalized food and nanosubstance should improve food value and protection as flavor and nutrient transporter.Emerging Challenges and Potential SolutionsIt is still challenging to develop a healthy and sustainable food industry making use of nanoparticles in some or other forms.", [["nanosubstance", "SIMPLE_CHEMICAL", 24, 37], ["nutrient transporter", "PROTEIN", 93, 113], ["nanosubstance", "TREATMENT", 24, 37], ["Potential Solutions", "TREATMENT", 138, 157], ["nanoparticles", "TREATMENT", 246, 259]]], ["A large strength of the public is having a fear in using food engineered and genetically modified materials.", [["large", "OBSERVATION_MODIFIER", 2, 7], ["strength", "OBSERVATION_MODIFIER", 8, 16]]], ["Of course, one should be cautious in using nano-based materials in food science and the food industry but not afraid of its application.", [["nano-based materials", "TREATMENT", 43, 63]]], ["Although the fate and potential toxicity of nanomaterials are not fully known at this stage and such concerns require the education of public, ultimate success of such products will depend on acceptance by consumer.", [["toxicity", "DISEASE", 32, 40], ["potential toxicity of nanomaterials", "PROBLEM", 22, 57], ["such products", "TREATMENT", 163, 176]]]], "PMC7286130": [["Introduction\u201cThe risk from viruses is an unanswered question.\u201d is such a meaningful quote with multi-directional implications.", [["viruses", "PROBLEM", 27, 34], ["viruses", "OBSERVATION", 27, 34]]], ["The enormous genetic diversity of existing viruses and unpredictability of viral behavior complemented by inadequacy of knowledge about global virome database always poses potential threats over the entire living world to acquire infection from any emerging or re-emerging viruses.", [["viral behavior", "DISEASE", 75, 89], ["infection", "DISEASE", 230, 239], ["existing viruses", "PROBLEM", 34, 50], ["viral behavior", "PROBLEM", 75, 89], ["infection", "PROBLEM", 230, 239], ["enormous", "OBSERVATION_MODIFIER", 4, 12], ["genetic", "OBSERVATION_MODIFIER", 13, 20], ["diversity", "OBSERVATION_MODIFIER", 21, 30], ["viruses", "OBSERVATION", 43, 50], ["viral behavior", "OBSERVATION", 75, 89], ["infection", "OBSERVATION", 230, 239]]], ["Rapid climate change, increased traveling in the era of globalization and frequent mingling of sylvatic and urban lifecycle have also potentiated the viruses for genetic undulation, emergence and re-emergence to become pandemic at occasions (Devaux, 2012).", [["Rapid climate change", "PROBLEM", 0, 20], ["frequent mingling of sylvatic", "PROBLEM", 74, 103], ["the viruses", "PROBLEM", 146, 157], ["genetic undulation", "PROBLEM", 162, 180], ["pandemic", "PROBLEM", 219, 227], ["climate change", "OBSERVATION", 6, 20], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["viruses", "OBSERVATION", 150, 157]]], ["Keen introspection regarding the virus-host interaction is a primordial aspect to reduce the knowledge gap and prepare the answer for the upcoming viral outbreaks.", [["the virus", "PROBLEM", 29, 38], ["the upcoming viral outbreaks", "PROBLEM", 134, 162]]], ["Exploitation of the highly specific nature of the virus-host interaction as well as the virus-cell interaction which are key for completion of viral life cycle and their transmission can offer crucial information to combat emerging viral infections.", [["cell", "ANATOMY", 94, 98], ["viral infections", "DISEASE", 232, 248], ["cell", "CELL", 94, 98], ["the virus-cell interaction", "PROBLEM", 84, 110], ["viral life cycle", "TREATMENT", 143, 159], ["emerging viral infections", "PROBLEM", 223, 248], ["virus", "OBSERVATION", 50, 55]]], ["The fundamental cellular components required for viral replication and the host restriction factors to counter them can be of immense value to decide the checkpoints and therapeutic targets for customizing effective anti-viral mechanisms (Lassen, 2011).", [["cellular", "ANATOMY", 16, 24], ["cellular", "CELL", 16, 24], ["host restriction factors", "PROTEIN", 75, 99], ["viral replication", "TREATMENT", 49, 66], ["the host restriction factors", "TREATMENT", 71, 99], ["customizing effective anti-viral mechanisms", "TREATMENT", 194, 237], ["fundamental", "OBSERVATION_MODIFIER", 4, 15], ["cellular components", "OBSERVATION", 16, 35], ["viral replication", "OBSERVATION", 49, 66]]], ["Single cell omics tools although in its budding age, still have enough penetration and resolution to introspect at the cellular and sub-cellular level for elucidation of such useful information.", [["cell", "ANATOMY", 7, 11], ["cellular", "ANATOMY", 119, 127], ["cellular", "ANATOMY", 136, 144], ["cell", "CELL", 7, 11], ["cellular", "CELL", 119, 127], ["cellular", "CELL", 136, 144], ["Single cell omics tools", "TEST", 0, 23], ["penetration", "OBSERVATION", 71, 82]]], ["Progress in this arena is going on apace which will enable to explore the changing pattern of the viral interactions in cellular heterogeneity under variable ecosystem and host subjects.", [["cellular", "ANATOMY", 120, 128], ["cellular", "CELL", 120, 128], ["the viral interactions", "PROBLEM", 94, 116], ["viral interactions", "OBSERVATION", 98, 116], ["cellular heterogeneity", "OBSERVATION", 120, 142]]], ["Suitable theranostics and effective vaccine of broad host specificity by unveiling the common pathways of viral interaction are the need of the hour to counter the ever-ending viral heterogeneity and future pandemics.", [["Suitable theranostics", "TREATMENT", 0, 21], ["effective vaccine", "TREATMENT", 26, 43], ["viral interaction", "PROBLEM", 106, 123], ["viral heterogeneity", "PROBLEM", 176, 195], ["viral", "OBSERVATION", 106, 111]]], ["The security of \u201cOne Health\u201d concept in current scenario depends immensely on symbiotic development and convergence of several high throughput techniques such as but not limited to single cell omics, nanotechnology, artificial intelligence and various computational platforms (Minakshi et al., 2019a).", [["cell", "ANATOMY", 188, 192], ["cell", "CELL", 188, 192]]], ["The present review will focus toward various developments in single cell metabolomics tools and their few existing and mostly the probable future applications in unveiling the host virus interactions to acquire new armory in the arsenal for combating the emerging viral diseases.Single Cell Metabolomics (SCM)\u201cOmics\u201d technologies pertain to the entire sets of molecules expressed at cellular or tissue level, or within an organism under specific set of condition.", [["cell", "ANATOMY", 68, 72], ["Cell", "ANATOMY", 286, 290], ["cellular", "ANATOMY", 383, 391], ["tissue", "ANATOMY", 395, 401], ["viral diseases", "DISEASE", 264, 278], ["single cell", "CELL", 61, 72], ["Cell", "CELL", 286, 290], ["cellular", "CELL", 383, 391], ["tissue", "TISSUE", 395, 401], ["the host virus interactions", "TREATMENT", 172, 199], ["the emerging viral diseases", "PROBLEM", 251, 278], ["Single Cell Metabolomics", "TEST", 279, 303], ["viral diseases", "OBSERVATION", 264, 278]]], ["However cellular heterogeneity in multicellular organisms is often masked in pooled analyses.", [["cellular", "ANATOMY", 8, 16], ["cellular", "CELL", 8, 16], ["cellular heterogeneity in multicellular organisms", "PROBLEM", 8, 57], ["cellular", "OBSERVATION_MODIFIER", 8, 16], ["heterogeneity", "OBSERVATION", 17, 30], ["multicellular organisms", "OBSERVATION", 34, 57]]], ["There the importance of single cell omics can be apprehended because it holds the potential to identify several targets expressed within a single individual cell or a cell population of interest individually at a specified time, or analyze handful of parameters in the same cells over time (Minakshi et al., 2019a).", [["cell", "ANATOMY", 31, 35], ["cell", "ANATOMY", 157, 161], ["cell", "ANATOMY", 167, 171], ["cells", "ANATOMY", 274, 279], ["cell", "CELL", 31, 35], ["cell", "CELL", 157, 161], ["cell", "CELL", 167, 171], ["cells", "CELL", 274, 279], ["single cell omics", "TREATMENT", 24, 41]]], ["The enormous utility and popularity of omics tools have left almost no stone untouched in any of the biological research arena; the case is also not unlike in unveiling virus host interaction.", [["stone", "PROBLEM", 71, 76], ["enormous", "OBSERVATION_MODIFIER", 4, 12], ["stone", "OBSERVATION", 71, 76]]], ["As single cell omics tools are mostly in its na\u00efve stage, thus ample evidences of their application at virus host interface is currently lacking but surely not too far in future which can be easily predicted from the bulk of omics interventions in terms of genomics, transcriptomics, proteomics, metabolomics and interactomics in the current perspective.", [["cell", "ANATOMY", 10, 14], ["cell", "CELL", 10, 14], ["single cell omics tools", "TEST", 3, 26], ["omics interventions", "TREATMENT", 225, 244], ["proteomics", "TEST", 284, 294], ["metabolomics", "TEST", 296, 308]]], ["Other single cell omics techniques have been employed to explore virus-host interaction in recent years (Dhillon and Li, 2015; Labont\u00e9 et al., 2015; Drayman et al., 2017, 2019; Zanini et al., 2018; Rosenwasser et al., 2019; Russell et al., 2019; Wang S. et al., 2019).", [["cell", "ANATOMY", 13, 17], ["cell", "CELL", 13, 17], ["Li", "ANATOMY", 117, 119]]], ["However SCM techniques are yet to start contributing significantly in understanding virus-host interaction.Single Cell Metabolomics (SCM)Metabolites are smaller molecules, usually of lesser than 1.5 kD in size reflecting various cellular pathways which include sugar, lipids, glycolytic products (pyruvate, lactate, etc.), phosphate compounds (AMP, ADP, and ATP etc.), xenobiotics etc., but generally excludes nucleic acids, minerals, and salts (Minakshi et al., 2019a, b).", [["Cell", "ANATOMY", 114, 118], ["cellular", "ANATOMY", 229, 237], ["pyruvate", "CHEMICAL", 297, 305], ["lactate", "CHEMICAL", 307, 314], ["phosphate", "CHEMICAL", 323, 332], ["AMP", "CHEMICAL", 344, 347], ["ADP", "CHEMICAL", 349, 352], ["ATP", "CHEMICAL", 358, 361], ["nucleic acids", "CHEMICAL", 410, 423], ["sugar", "CHEMICAL", 261, 266], ["pyruvate", "CHEMICAL", 297, 305], ["lactate", "CHEMICAL", 307, 314], ["phosphate", "CHEMICAL", 323, 332], ["AMP", "CHEMICAL", 344, 347], ["ADP", "CHEMICAL", 349, 352], ["ATP", "CHEMICAL", 358, 361], ["Cell", "CELL", 114, 118], ["cellular", "CELL", 229, 237], ["sugar", "SIMPLE_CHEMICAL", 261, 266], ["lipids", "SIMPLE_CHEMICAL", 268, 274], ["pyruvate", "SIMPLE_CHEMICAL", 297, 305], ["lactate", "SIMPLE_CHEMICAL", 307, 314], ["phosphate compounds", "SIMPLE_CHEMICAL", 323, 342], ["AMP", "SIMPLE_CHEMICAL", 344, 347], ["ADP", "SIMPLE_CHEMICAL", 349, 352], ["ATP", "SIMPLE_CHEMICAL", 358, 361], ["nucleic acids", "SIMPLE_CHEMICAL", 410, 423], ["minerals", "SIMPLE_CHEMICAL", 425, 433], ["salts", "SIMPLE_CHEMICAL", 439, 444], ["Single Cell Metabolomics", "TEST", 107, 131], ["smaller molecules", "PROBLEM", 153, 170], ["various cellular pathways", "PROBLEM", 221, 246], ["sugar", "TEST", 261, 266], ["lipids", "TEST", 268, 274], ["glycolytic products", "TREATMENT", 276, 295], ["pyruvate", "TEST", 297, 305], ["lactate", "TEST", 307, 314], ["phosphate compounds", "TREATMENT", 323, 342], ["AMP, ADP", "TREATMENT", 344, 352], ["ATP", "TREATMENT", 358, 361], ["xenobiotics", "TREATMENT", 369, 380], ["smaller", "OBSERVATION_MODIFIER", 153, 160], ["molecules", "OBSERVATION_MODIFIER", 161, 170], ["lesser", "OBSERVATION_MODIFIER", 183, 189], ["size", "OBSERVATION_MODIFIER", 205, 209], ["various cellular pathways", "OBSERVATION", 221, 246]]], ["They are arguably the terminal product of the basic central dogma process and provide the most nascent information about the phenotype.", [["central dogma", "OBSERVATION", 52, 65]]], ["Metabolomics refers to the study of entire set of metabolites at a specific time-point.", [["the study", "TEST", 23, 32]]], ["It can yield a snap shot of dynamic and vulnerable host metabolites in response to its viral counterpart modulating each pathways at a particular infection stage.", [["infection", "DISEASE", 146, 155], ["a snap shot of dynamic and vulnerable host metabolites", "PROBLEM", 13, 67], ["a particular infection stage", "PROBLEM", 133, 161], ["host metabolites", "OBSERVATION", 51, 67], ["infection", "OBSERVATION", 146, 155]]], ["A recent flush of literature in metabolomics targeting virus-host interaction vividly justifies the utility of such analysis in current context (Table 1).", [["A recent flush of literature", "TREATMENT", 0, 28], ["such analysis", "TEST", 111, 124], ["flush", "OBSERVATION", 9, 14]]], ["Precise sampling methods accompanied by robust and high throughput analytical platforms such as nuclear magnetic resonance (NMR), receptive separation-based methods such as capillary electrophoresis (CE) or liquid chromatography (LC) and gas chromatography (GC) coupled with mass spectrometry (MS), and fluorescence-based techniques have delivered significant precision to \u201cmetabolomics.\u201d", [["capillary", "TISSUE", 173, 182], ["Precise sampling methods", "TEST", 0, 24], ["robust and high throughput analytical platforms", "PROBLEM", 40, 87], ["nuclear magnetic resonance", "TEST", 96, 122], ["receptive separation-based methods", "PROBLEM", 130, 164], ["capillary electrophoresis", "TEST", 173, 198], ["liquid chromatography", "TEST", 207, 228], ["gas chromatography", "TEST", 238, 256], ["mass spectrometry", "PROBLEM", 275, 292], ["robust", "OBSERVATION_MODIFIER", 40, 46], ["high", "OBSERVATION_MODIFIER", 51, 55]]], ["Parallel progress in metabolite databases and bioinformatics programs have also assisted to generate an array of valuable information in a single go to match the expectations (Minakshi et al., 2019a).", [["bioinformatics programs", "TREATMENT", 46, 69]]], ["However single cell metabolomics (SCM) is obviously beneficial over population study alike other omics techniques to obtain specific temporal information regarding cell differentiation and division, communication, interaction with surroundings, stress responses including stage-specific metabolomic changes during viral infection (Strzelecka et al., 2018).Single Cell Metabolomics (SCM)Research related to virus host interaction and information regarding susceptibility, virulence, mechanisms of gene regulation and metabolic pathway modulation under variable environmental factors such as temperature, humidity, light color, intensity and also radiation etc. are mostly lacking that may be useful to combat the incidences of outbreaks from novel viral emergence.", [["cell", "ANATOMY", 15, 19], ["cell", "ANATOMY", 164, 168], ["Cell", "ANATOMY", 363, 367], ["viral infection", "DISEASE", 314, 329], ["single cell", "CELL", 8, 19], ["cell", "CELL", 164, 168], ["Cell", "CELL", 363, 367], ["single cell metabolomics", "TEST", 8, 32], ["population study", "TEST", 68, 84], ["stress responses", "PROBLEM", 245, 261], ["stage-specific metabolomic changes", "PROBLEM", 272, 306], ["viral infection", "PROBLEM", 314, 329], ["virulence", "PROBLEM", 471, 480], ["gene regulation", "TREATMENT", 496, 511], ["metabolic pathway modulation", "TREATMENT", 516, 544], ["light color", "TEST", 613, 624], ["outbreaks", "PROBLEM", 726, 735], ["novel viral emergence", "PROBLEM", 741, 762], ["cell differentiation", "OBSERVATION", 164, 184], ["viral infection", "OBSERVATION", 314, 329]]], ["Although metabolomics has found its value in virology research but mostly in population study whereas SCM intervention is almost yet to be started to introspect virus-host interaction and is reached upto the level of cell lines only, may be due to the hardship of SCM in terms of single cell isolation and handling, structural diversity and rapid metabolite turnover, lack of amplification opportunity, sensitivity and repeatability of the analytical platforms etc. (Table 1; Minakshi et al., 2019a).", [["cell lines", "ANATOMY", 217, 227], ["cell", "ANATOMY", 287, 291], ["cell lines", "CELL", 217, 227], ["cell", "CELL", 287, 291], ["cell lines", "CELL_LINE", 217, 227], ["population study", "TEST", 77, 93], ["SCM intervention", "TREATMENT", 102, 118], ["the hardship of SCM", "PROBLEM", 248, 267], ["single cell isolation", "TREATMENT", 280, 301], ["rapid metabolite turnover", "PROBLEM", 341, 366], ["sensitivity", "TEST", 403, 414], ["the analytical platforms", "TEST", 436, 460], ["cell lines", "OBSERVATION", 217, 227], ["SCM", "OBSERVATION", 264, 267], ["cell isolation", "OBSERVATION", 287, 301], ["rapid", "OBSERVATION_MODIFIER", 341, 346], ["metabolite turnover", "OBSERVATION", 347, 366]]], ["However it\u2019s not tough predictions that no longer will SCM be left incumbent considering the worth of information it generates and its ample application in the current context will be reflected in near future.Sample Preparation Methods for Single Cell Isolation for SCM AnalysisThe most common hurdle in SCM analyses is the isolation of single target cell followed by its careful handling and delivery to the downstream analytical platforms because it is directly reflected over the precision of SCM data.", [["Cell", "ANATOMY", 247, 251], ["cell", "ANATOMY", 351, 355], ["Cell", "CELL", 247, 251], ["cell", "CELL", 351, 355], ["Single Cell Isolation", "TREATMENT", 240, 261], ["SCM Analysis", "TEST", 266, 278], ["single target cell", "TREATMENT", 337, 355], ["delivery", "TREATMENT", 393, 401], ["SCM data", "TEST", 496, 504], ["most common", "OBSERVATION_MODIFIER", 282, 293], ["SCM", "OBSERVATION", 304, 307]]], ["Limiting dilutions, manual cell-picking by micromanipulator and laser micro dissection are the common manual methods having relatively low throughput yet applied for single cell analyses where as fluorescence-based cell sorting, high-density microarrays and microfluidics are the most popular automatic high throughput single-cell isolation techniques employed for SCM (Gross et al., 2015; Minakshi et al., 2019b; Figure 1 and Table 2).", [["cell", "ANATOMY", 27, 31], ["cell", "ANATOMY", 173, 177], ["cell", "ANATOMY", 215, 219], ["cell", "ANATOMY", 326, 330], ["cell", "CELL", 27, 31], ["cell", "CELL", 173, 177], ["cell", "CELL", 215, 219], ["cell", "CELL", 326, 330], ["manual cell", "TREATMENT", 20, 31], ["laser micro dissection", "TREATMENT", 64, 86], ["single cell analyses", "TEST", 166, 186], ["fluorescence", "TEST", 196, 208], ["based cell sorting", "TEST", 209, 227], ["high-density microarrays", "TREATMENT", 229, 253], ["microfluidics", "TEST", 258, 271], ["single-cell isolation techniques", "TREATMENT", 319, 351], ["manual cell", "OBSERVATION", 20, 31], ["dissection", "OBSERVATION", 76, 86], ["density microarrays", "OBSERVATION_MODIFIER", 234, 253]]], ["High cost involvement is a major limitation associated with all of these high end techniques.Sample Preparation Methods for Single Cell Isolation for SCM AnalysisFluorescence-activated cell sorting isolates the target cells specifically labeled with antibody coupled with a fluorescent tags.", [["Cell", "ANATOMY", 131, 135], ["cell", "ANATOMY", 185, 189], ["cells", "ANATOMY", 218, 223], ["Cell", "CELL", 131, 135], ["cell", "CELL", 185, 189], ["cells", "CELL", 218, 223], ["target cells", "CELL_TYPE", 211, 223], ["antibody", "PROTEIN", 250, 258], ["High cost involvement", "PROBLEM", 0, 21], ["Single Cell Isolation", "TREATMENT", 124, 145], ["SCM AnalysisFluorescence", "TREATMENT", 150, 174], ["activated cell sorting", "TREATMENT", 175, 197], ["a fluorescent tags", "TEST", 272, 290], ["cost", "OBSERVATION", 5, 9]]], ["This technique prefers the samples that are naturally suspended in liquid media, such as blood, bone marrow cells, semen, ovum, secretions, yeast, protoplast, bacteria, and viruses (Ciuffi et al., 2016; Khalil et al., 2017; Janssens et al., 2018; Singh, 2019).", [["samples", "ANATOMY", 27, 34], ["blood", "ANATOMY", 89, 94], ["bone marrow cells", "ANATOMY", 96, 113], ["semen", "ANATOMY", 115, 120], ["ovum", "ANATOMY", 122, 126], ["secretions", "ANATOMY", 128, 138], ["protoplast", "ANATOMY", 147, 157], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["bone marrow cells", "CELL", 96, 113], ["semen", "ORGANISM_SUBSTANCE", 115, 120], ["ovum", "MULTI-TISSUE_STRUCTURE", 122, 126], ["secretions", "ORGANISM_SUBSTANCE", 128, 138], ["protoplast", "CELL", 147, 157], ["blood, bone marrow cells", "CELL_TYPE", 89, 113], ["yeast", "SPECIES", 140, 145], ["yeast", "SPECIES", 140, 145], ["This technique", "TREATMENT", 0, 14], ["liquid media", "TREATMENT", 67, 79], ["blood, bone marrow cells", "TEST", 89, 113], ["semen, ovum", "PROBLEM", 115, 126], ["secretions", "PROBLEM", 128, 138], ["yeast", "PROBLEM", 140, 145], ["protoplast", "PROBLEM", 147, 157], ["bacteria", "PROBLEM", 159, 167], ["viruses", "PROBLEM", 173, 180], ["blood", "ANATOMY", 89, 94], ["bone", "ANATOMY", 96, 100], ["marrow cells", "OBSERVATION", 101, 113]]], ["Time-lapse fluorescence imaging is a similar type of fluorescence based single cell analysis technique used for monitoring of cell virus interaction (Drayman et al., 2017).Sample Preparation Methods for Single Cell Isolation for SCM AnalysisImmune-magnetic separation using antibody-coated magnetic beads or attached with other ligands for capturing the target cells is also an important single cell isolation method.", [["cell", "ANATOMY", 79, 83], ["cell", "ANATOMY", 126, 130], ["Cell", "ANATOMY", 210, 214], ["cells", "ANATOMY", 361, 366], ["cell", "ANATOMY", 395, 399], ["cell", "CELL", 79, 83], ["cell", "CELL", 126, 130], ["Cell", "CELL", 210, 214], ["cells", "CELL", 361, 366], ["cell", "CELL", 395, 399], ["antibody", "PROTEIN", 274, 282], ["target cells", "CELL_TYPE", 354, 366], ["fluorescence imaging", "TEST", 11, 31], ["single cell analysis technique", "TEST", 72, 102], ["Single Cell Isolation", "TREATMENT", 203, 224], ["SCM AnalysisImmune", "TREATMENT", 229, 247], ["magnetic separation", "TREATMENT", 248, 267], ["antibody-coated magnetic beads", "TREATMENT", 274, 304]]], ["Dynabeads or MACS (Dynabeads Magnetic Separation Technology) employs such isolation principle (Miltenyi et al., 1990).Sample Preparation Methods for Single Cell Isolation for SCM AnalysisAptamer-based cell isolation relies upon the precise binding of aptamers (single-stranded oligonucleotides, DNA or RNA) to its target using structural conformation and ease the isolation of single cells (Guo et al., 2006; Hu et al., 2016; Delley et al., 2018; Chen, 2019; Kacherovsky et al., 2019).", [["Cell", "ANATOMY", 156, 160], ["cell", "ANATOMY", 201, 205], ["cells", "ANATOMY", 384, 389], ["Dynabeads", "ORGANISM_SUBSTANCE", 0, 9], ["Cell", "CELL", 156, 160], ["cell", "CELL", 201, 205], ["DNA", "CELLULAR_COMPONENT", 295, 298], ["cells", "CELL", 384, 389], ["single cells", "CELL_TYPE", 377, 389], ["Single Cell Isolation", "TREATMENT", 149, 170], ["SCM AnalysisAptamer", "TREATMENT", 175, 194], ["based cell isolation", "TREATMENT", 195, 215], ["single-stranded oligonucleotides", "TREATMENT", 261, 293], ["DNA or RNA", "TREATMENT", 295, 305]]], ["Fluorescent nanodiamonds (FNDs) are diamond nano-crystals which have also been used for single cell labeling for cell tracking and illuminating the cellular processes under different conditions (Prabhakar et al., 2017; Claveau et al., 2018).Sample Preparation Methods for Single Cell Isolation for SCM AnalysisSingle-cell printing technique like \u201cBlock-Cell-Printing\u201d is another example of high throughput single cell isolation technique yet to find ample application (Gross et al., 2013; Zhang et al., 2014; Schoendube et al., 2015).Sample Preparation Methods for Single Cell Isolation for SCM AnalysisMicrofluidics or Lab-on-a-Chip devices provide excellent opportunity for simultaneous isolation of target single cells along with its handling and manipulation followed by SCM suitable platforms with high end automation (Warrick et al., 2016).", [["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 113, 117], ["cellular", "ANATOMY", 148, 156], ["Cell", "ANATOMY", 279, 283], ["cell", "ANATOMY", 413, 417], ["Cell", "ANATOMY", 572, 576], ["cells", "ANATOMY", 716, 721], ["diamond", "CHEMICAL", 36, 43], ["nanodiamonds", "SIMPLE_CHEMICAL", 12, 24], ["FNDs", "SIMPLE_CHEMICAL", 26, 30], ["single cell", "CELL", 88, 99], ["cell", "CELL", 113, 117], ["cellular", "CELL", 148, 156], ["Cell", "CELL", 279, 283], ["cell", "CELL", 413, 417], ["Cell", "CELL", 572, 576], ["cells", "CELL", 716, 721], ["target single cells", "CELL_TYPE", 702, 721], ["Fluorescent nanodiamonds (FNDs)", "TREATMENT", 0, 31], ["diamond nano-crystals", "TREATMENT", 36, 57], ["single cell labeling", "TREATMENT", 88, 108], ["cell tracking", "TEST", 113, 126], ["Single Cell Isolation", "TREATMENT", 272, 293], ["SCM AnalysisSingle-cell printing technique", "TREATMENT", 298, 340], ["single cell isolation technique", "TREATMENT", 406, 437], ["Single Cell Isolation", "TREATMENT", 565, 586], ["a-Chip devices", "TREATMENT", 627, 641], ["simultaneous isolation of target single cells", "TREATMENT", 676, 721], ["manipulation", "TREATMENT", 750, 762], ["cellular processes", "OBSERVATION", 148, 166]]], ["Several analytical platforms such as electrophoresis, optical spectroscopy, fluorescence based imaging, or mass spectrometry are compatible with microfluidics based cell isolation.", [["cell", "ANATOMY", 165, 169], ["cell", "CELL", 165, 169], ["Several analytical platforms", "TEST", 0, 28], ["electrophoresis", "TEST", 37, 52], ["optical spectroscopy", "TEST", 54, 74], ["fluorescence based imaging", "TEST", 76, 102], ["mass spectrometry", "PROBLEM", 107, 124], ["microfluidics based cell isolation", "TREATMENT", 145, 179], ["compatible with", "UNCERTAINTY", 129, 144], ["cell isolation", "OBSERVATION", 165, 179]]], ["Soft lithographic fabrication onto polydimethylsiloxane (PDMS), glass or silicon chips provides the base of microfluidic devices and hydrodynamic or gravity-driven flow of cells are used to capture the target cells.", [["cells", "ANATOMY", 172, 177], ["cells", "ANATOMY", 209, 214], ["polydimethylsiloxane", "CHEMICAL", 35, 55], ["silicon", "CHEMICAL", 73, 80], ["polydimethylsiloxane", "CHEMICAL", 35, 55], ["PDMS", "CHEMICAL", 57, 61], ["silicon", "CHEMICAL", 73, 80], ["polydimethylsiloxane", "SIMPLE_CHEMICAL", 35, 55], ["cells", "CELL", 172, 177], ["cells", "CELL", 209, 214], ["target cells", "CELL_TYPE", 202, 214], ["Soft lithographic fabrication onto polydimethylsiloxane (PDMS)", "TREATMENT", 0, 62], ["glass or silicon chips", "TREATMENT", 64, 86], ["microfluidic devices", "TREATMENT", 108, 128], ["hydrodynamic or gravity-driven flow of cells", "TREATMENT", 133, 177], ["lithographic fabrication", "OBSERVATION", 5, 29], ["microfluidic devices", "OBSERVATION", 108, 128], ["target cells", "OBSERVATION", 202, 214]]], ["Microfluidics device installed on a fluorescence microscope has yielded valuable information regarding the kinetics of viral infection in single cells and variability of cellular factors regulating the viral replication (Guo et al., 2017).", [["cells", "ANATOMY", 145, 150], ["cellular", "ANATOMY", 170, 178], ["viral infection", "DISEASE", 119, 134], ["cells", "CELL", 145, 150], ["cellular", "CELL", 170, 178], ["single cells", "CELL_TYPE", 138, 150], ["cellular factors", "PROTEIN", 170, 186], ["Microfluidics device", "TREATMENT", 0, 20], ["a fluorescence microscope", "TEST", 34, 59], ["viral infection in single cells", "PROBLEM", 119, 150], ["cellular factors", "PROBLEM", 170, 186], ["the viral replication", "TREATMENT", 198, 219], ["viral infection", "OBSERVATION", 119, 134], ["cellular factors", "OBSERVATION", 170, 186], ["viral replication", "OBSERVATION", 202, 219]]], ["Hybrid microfluidics using either active or passive approaches or their combination, integration of nano- and microfluidics, digital or virtual microfluidics are the emerging microfluidic platforms which are being recently introduced for high throughput and continuous single cell isolation avoiding the general limitations of the existing technique (Xu et al., 2016; Yan et al., 2016; Wang et al., 2017; Vanderpoorten et al., 2019).Sample Preparation Methods for Single Cell Isolation for SCM AnalysisDirect sampling through nano-electrospray ionization tips followed by mass spectrometric analyses method is gaining popularity in recent times due to its minimum sample requirement and processing along with high throughput data generation.", [["cell", "ANATOMY", 276, 280], ["Cell", "ANATOMY", 471, 475], ["cell", "CELL", 276, 280], ["Cell", "CELL", 471, 475], ["Hybrid microfluidics", "TREATMENT", 0, 20], ["passive approaches", "TREATMENT", 44, 62], ["nano- and microfluidics", "TREATMENT", 100, 123], ["virtual microfluidics", "TREATMENT", 136, 157], ["continuous single cell isolation", "TREATMENT", 258, 290], ["Single Cell Isolation", "TREATMENT", 464, 485], ["SCM AnalysisDirect sampling", "TREATMENT", 490, 517], ["nano-electrospray ionization tips", "TREATMENT", 526, 559], ["mass spectrometric analyses", "TEST", 572, 599], ["its minimum sample requirement", "PROBLEM", 652, 682]]], ["Pipette tip column electrospray ionization (PTC-ESI) or ballpoint electrospray ionization (BP-ESI) followed by simultaneous mass spectrometry or live single-cell video-mass spectrometry are the SCM platforms where the technique has been used (Tsuyama et al., 2008; Huang et al., 2012; Ji et al., 2016; Pu et al., 2018).Analytical Platforms for Single Cell MetabolomicsThe precision and coverage of SCM analysis depends upon the \u201cresolution\u201d and \u201csensitivity\u201d of the analytical platform.", [["Cell", "ANATOMY", 351, 355], ["Cell", "CELL", 351, 355], ["Pipette tip column electrospray ionization", "TREATMENT", 0, 42], ["PTC", "TEST", 44, 47], ["ballpoint electrospray ionization", "TREATMENT", 56, 89], ["BP", "TEST", 91, 93], ["simultaneous mass spectrometry", "TEST", 111, 141], ["Single Cell Metabolomics", "TEST", 344, 368], ["SCM analysis", "TEST", 398, 410], ["the analytical platform", "TEST", 462, 485]]], ["Although theoretically SCM analyze the entire set of cellular metabolites but more often it is restricted to qualitative or quantitative analysis of a cluster of metabolites under certain condition.", [["cellular", "ANATOMY", 53, 61], ["cellular", "CELL", 53, 61], ["quantitative analysis", "TEST", 124, 145], ["a cluster of metabolites under certain condition", "PROBLEM", 149, 197], ["cellular metabolites", "OBSERVATION", 53, 73]]], ["\u201cTargeted\u201d for acquiring information regarding specific metabolite(s) or \u201cuntargeted\u201d SCM approach for obtaining the maximum coverage can be chosen according to the requirement and selection of the analytical platform should be done accordingly.", [["the maximum coverage", "TREATMENT", 113, 133], ["the analytical platform", "TEST", 194, 217]]], ["Mass Spectrometry Imaging (MSI)-based methods are arguably the most sensitive and thus preferred SCM platform.", [["Mass Spectrometry", "TEST", 0, 17], ["Imaging (MSI)", "TEST", 18, 31]]], ["However, the compromised reliability, restricted quantitation option, and poor resolution for structural characterization are the certain limitations need to be taken care of.", [["restricted quantitation option", "TREATMENT", 38, 68], ["structural characterization", "TEST", 94, 121], ["compromised", "OBSERVATION_MODIFIER", 13, 24], ["reliability", "OBSERVATION_MODIFIER", 25, 36]]], ["Other SCM platforms include but not limited to separation-based methods like capillary electrophoresis (CE), liquid chromatography (LC), or gas chromatography (GC) combined with MS or fluorescent tagging approach which are mostly used for \u201ctargeted SCM\u201d due to the sensitivity issue (Minakshi et al., 2019a; Table 2).Separation-Based Methods Coupled With Mass SpectrometryCapillary electrophoresis coupled with electrospray ionization and mass spectrometry (CE-\u03bcESI-MS) has been employed to analyze single 8-cell embryo of Xenopus laevis to depict more than 80 metabolites (Onjiko et al., 2015).", [["embryo", "ANATOMY", 513, 519], ["Xenopus laevis", "ANATOMY", 523, 537], ["capillary", "TISSUE", 77, 86], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 513, 519], ["Xenopus laevis", "ORGANISM", 523, 537], ["Xenopus laevis", "SPECIES", 523, 537], ["Xenopus laevis", "SPECIES", 523, 537], ["capillary electrophoresis", "TEST", 77, 102], ["liquid chromatography", "TEST", 109, 130], ["gas chromatography", "TEST", 140, 158], ["MS", "PROBLEM", 178, 180], ["fluorescent tagging approach", "TREATMENT", 184, 212], ["Separation", "TEST", 317, 327], ["Mass SpectrometryCapillary electrophoresis", "PROBLEM", 355, 397], ["electrospray ionization", "TREATMENT", 411, 434], ["mass spectrometry", "TEST", 439, 456], ["CE", "TEST", 458, 460], ["Xenopus laevis", "TREATMENT", 523, 537]]], ["Similarly CE-ESI-TOF-MS has explored over 300 metabolites from the neuronal cell of sea slug Aplysia californica (Nemes et al., 2013).", [["neuronal cell", "ANATOMY", 67, 80], ["CE", "CHEMICAL", 10, 12], ["neuronal cell", "CELL", 67, 80], ["Aplysia californica", "ORGANISM", 93, 112], ["neuronal cell", "CELL_TYPE", 67, 80], ["Aplysia californica", "SPECIES", 93, 112], ["Aplysia californica", "SPECIES", 93, 112], ["CE", "TEST", 10, 12], ["ESI", "TEST", 13, 16], ["TOF", "TEST", 17, 20], ["MS", "PROBLEM", 21, 23], ["neuronal cell", "OBSERVATION", 67, 80], ["slug Aplysia", "OBSERVATION", 88, 100]]], ["CE-ESI-MS has quantitatively characterized over 15 anionic metabolites (nucleotides and derivatives) from Aplysia sensory neuron with the detection limits in <22 nM range (Liu et al., 2014).", [["sensory neuron", "ANATOMY", 114, 128], ["CE", "CHEMICAL", 0, 2], ["nucleotides", "CHEMICAL", 72, 83], ["Aplysia sensory neuron", "CELL", 106, 128], ["CE", "TEST", 0, 2], ["ESI", "TEST", 3, 6], ["nucleotides and derivatives", "TREATMENT", 72, 99], ["the detection", "TEST", 134, 147]]], ["High-Resolution Mass Spectrometry (CE-ESI-HRMS) analyses of a single 16-cell stage embryo of Xenopuslaevishasrevealed438 non-redundant protein groups by label-free quantification with a detection limit of \u223c75 attomol (\u223c11 nm) (Lombard-Banek et al., 2016).", [["embryo", "ANATOMY", 83, 89], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 83, 89], ["Resolution Mass Spectrometry", "TEST", 5, 33], ["CE", "TEST", 35, 37], ["a detection limit", "TEST", 184, 201], ["Resolution", "OBSERVATION_MODIFIER", 5, 15], ["Mass", "OBSERVATION", 16, 20]]], ["Targeted automated SCM analysis of neuronal cell by a microchip electrophoresis-mass spectrometric method (MCE-MS) has quantitatively measured dopamine and glutamic acid content within individual cell with detection limits 8.3 and 15.6 nM for the metabolites, respectively.", [["neuronal cell", "ANATOMY", 35, 48], ["cell", "ANATOMY", 196, 200], ["dopamine", "CHEMICAL", 143, 151], ["glutamic acid", "CHEMICAL", 156, 169], ["dopamine", "CHEMICAL", 143, 151], ["glutamic acid", "CHEMICAL", 156, 169], ["neuronal cell", "CELL", 35, 48], ["dopamine", "SIMPLE_CHEMICAL", 143, 151], ["glutamic acid", "SIMPLE_CHEMICAL", 156, 169], ["cell", "CELL", 196, 200], ["neuronal cell", "CELL_TYPE", 35, 48], ["Targeted automated SCM analysis", "TEST", 0, 31], ["neuronal cell", "PROBLEM", 35, 48], ["a microchip electrophoresis", "TEST", 52, 79], ["mass spectrometric method", "PROBLEM", 80, 105], ["MCE", "TEST", 107, 110], ["dopamine", "TEST", 143, 151], ["glutamic acid content", "TEST", 156, 177], ["detection limits", "TEST", 206, 222], ["the metabolites", "TEST", 243, 258], ["neuronal cell", "OBSERVATION", 35, 48], ["glutamic acid", "OBSERVATION", 156, 169]]], ["Although the introduction of this platform in virus-host interaction arena is pending but the mentioned evidences has clearly suggested about its potential in SCM analysis.Separation-Based Methods Coupled With Mass SpectrometryNano-flow liquid chromatography-electro spray ionization mass spectrometry (LC-ESI-MS) based analysis has yielded 5 anthocyanins from 2-4picolitervolume of individual Torenia hybrida petal cell (Kajiyama et al., 2006).", [["petal cell", "ANATOMY", 410, 420], ["anthocyanins", "CHEMICAL", 343, 355], ["anthocyanins", "SIMPLE_CHEMICAL", 343, 355], ["Torenia hybrida petal cell", "CELL", 394, 420], ["Torenia hybrida", "SPECIES", 394, 409], ["Torenia hybrida", "SPECIES", 394, 409], ["SCM analysis", "TEST", 159, 171], ["Separation", "TREATMENT", 172, 182], ["Mass Spectrometry", "PROBLEM", 210, 227], ["Nano-flow liquid chromatography", "TEST", 227, 258], ["electro spray ionization mass spectrometry", "TEST", 259, 301], ["LC", "TEST", 303, 305], ["based analysis", "TEST", 314, 328], ["anthocyanins", "TEST", 343, 355], ["hybrida petal cell", "OBSERVATION", 402, 420]]], ["Gas chromatography Time-of-Flight mass spectrometry (GC-TOF-MS) analyses of Mesembryanthemum crystallinum epidermal bladder cells has identified 194 known and 722 overall molecular features which generate significant pathway information regarding metabolic alterations in salty environment (Barkla and Vera-Estrella, 2015).", [["epidermal bladder cells", "ANATOMY", 106, 129], ["Mesembryanthemum crystallinum epidermal bladder cells", "CELL", 76, 129], ["Mesembryanthemum crystallinum epidermal bladder cells", "CELL_LINE", 76, 129], ["Mesembryanthemum crystallinum", "SPECIES", 76, 105], ["Mesembryanthemum crystallinum", "SPECIES", 76, 105], ["Gas chromatography", "TEST", 0, 18], ["Time", "TEST", 19, 23], ["Flight mass spectrometry", "TEST", 27, 51], ["GC", "TEST", 53, 55], ["TOF", "TEST", 56, 59], ["Mesembryanthemum crystallinum epidermal bladder cells", "TEST", 76, 129], ["overall molecular features", "PROBLEM", 163, 189], ["metabolic alterations in salty environment", "PROBLEM", 247, 289], ["bladder cells", "ANATOMY", 116, 129]]], ["Thus chromatographic methods have great potential for SCM analyses in combination with MS platforms.", [["chromatographic methods", "TREATMENT", 5, 28], ["SCM analyses", "TEST", 54, 66], ["MS platforms", "TREATMENT", 87, 99]]], ["Although not in single cell level but GC/MS based metabolomics technique has already been applied for introspection of fatty acid biosynthesis and cholesterol metabolism in A549 and AGS cell lines infected with influenza A virus yielding valuable information regarding susceptibility and cell differentiation in association with viral replication (Lin et al., 2010).", [["cell", "ANATOMY", 23, 27], ["A549", "ANATOMY", 173, 177], ["AGS cell lines", "ANATOMY", 182, 196], ["cell", "ANATOMY", 288, 292], ["fatty acid", "CHEMICAL", 119, 129], ["cholesterol", "CHEMICAL", 147, 158], ["influenza A virus", "DISEASE", 211, 228], ["fatty acid", "CHEMICAL", 119, 129], ["cholesterol", "CHEMICAL", 147, 158], ["cell", "CELL", 23, 27], ["fatty acid", "SIMPLE_CHEMICAL", 119, 129], ["cholesterol", "SIMPLE_CHEMICAL", 147, 158], ["A549", "CELL", 173, 177], ["AGS cell lines", "CELL", 182, 196], ["influenza A virus", "ORGANISM", 211, 228], ["cell", "CELL", 288, 292], ["A549", "CELL_LINE", 173, 177], ["AGS cell lines", "CELL_LINE", 182, 196], ["influenza A virus", "SPECIES", 211, 228], ["influenza A virus", "SPECIES", 211, 228], ["single cell level", "TEST", 16, 33], ["GC/MS based metabolomics technique", "PROBLEM", 38, 72], ["fatty acid biosynthesis", "PROBLEM", 119, 142], ["cholesterol metabolism in A549", "PROBLEM", 147, 177], ["AGS cell lines", "PROBLEM", 182, 196], ["influenza A virus", "PROBLEM", 211, 228], ["viral replication", "TREATMENT", 329, 346], ["fatty acid", "OBSERVATION", 119, 129], ["AGS cell lines", "OBSERVATION", 182, 196], ["cell differentiation", "OBSERVATION", 288, 308]]], ["Ultra-high-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry (UHPLC-QTOF-MS) analyses has depicted significant changes in 305 metabolites during infection of DF-1 cells with the Herts/33 strain of New Castle Disease Virus (Liu et al., 2019).", [["DF-1 cells", "ANATOMY", 193, 203], ["infection", "DISEASE", 180, 189], ["DF-1 cells", "CELL", 193, 203], ["Herts/33 strain", "ORGANISM", 213, 228], ["New Castle Disease Virus", "ORGANISM", 232, 256], ["DF-1", "SPECIES", 193, 197], ["New Castle Disease Virus", "SPECIES", 232, 256], ["Ultra", "TEST", 0, 5], ["quadrupole time", "TEST", 45, 60], ["flight tandem mass spectrometry", "TEST", 64, 95], ["UHPLC", "TEST", 97, 102], ["QTOF-MS) analyses", "TEST", 103, 120], ["significant changes in 305 metabolites during infection of DF", "PROBLEM", 134, 195], ["the Herts", "TEST", 209, 218], ["New Castle Disease Virus", "PROBLEM", 232, 256], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["New", "OBSERVATION_MODIFIER", 232, 235], ["Castle Disease", "OBSERVATION", 236, 250]]], ["Gut metabolomic analyses of rhesus monkeys by GC-MS and LC-MS during gut virome alteration has been correlated with gut microbiome and the underlying role of metabolites like tryptophan, arginine, and quinine (Li et al., 2019).", [["Gut", "ANATOMY", 0, 3], ["gut", "ANATOMY", 69, 72], ["gut microbiome", "ANATOMY", 116, 130], ["tryptophan", "CHEMICAL", 175, 185], ["arginine", "CHEMICAL", 187, 195], ["quinine", "CHEMICAL", 201, 208], ["Li", "CHEMICAL", 210, 212], ["tryptophan", "CHEMICAL", 175, 185], ["arginine", "CHEMICAL", 187, 195], ["quinine", "CHEMICAL", 201, 208], ["Li", "CHEMICAL", 210, 212], ["Gut", "MULTI-TISSUE_STRUCTURE", 0, 3], ["rhesus", "ORGANISM", 28, 34], ["monkeys", "ORGANISM", 35, 42], ["gut virome", "MULTI-TISSUE_STRUCTURE", 69, 79], ["gut", "ORGANISM_SUBDIVISION", 116, 119], ["tryptophan", "SIMPLE_CHEMICAL", 175, 185], ["arginine", "SIMPLE_CHEMICAL", 187, 195], ["quinine", "SIMPLE_CHEMICAL", 201, 208], ["rhesus monkeys", "SPECIES", 28, 42], ["rhesus monkeys", "SPECIES", 28, 42], ["LC", "TEST", 56, 58], ["MS", "PROBLEM", 59, 61], ["gut virome alteration", "PROBLEM", 69, 90], ["arginine", "TREATMENT", 187, 195], ["quinine", "TREATMENT", 201, 208]]], ["Although the penetration upto the single cell level is yet to be reached but the evidences are enough to ensure the utility and future of this platform for metabolomic analyses in virology research.Mass Spectrometry ImagingExtreme sensitivity, vast coverage and the opportunity of label-free analysis has rendered MSI as one of the most preferred method of SCM analysis, particularly for untargeted approach.", [["cell", "ANATOMY", 41, 45], ["cell", "CELL", 41, 45], ["the penetration", "PROBLEM", 9, 24], ["this platform", "TEST", 138, 151], ["metabolomic analyses", "TEST", 156, 176], ["Mass Spectrometry", "TEST", 198, 215], ["Imaging", "TEST", 216, 223], ["Extreme sensitivity", "PROBLEM", 223, 242], ["vast coverage", "TREATMENT", 244, 257], ["label-free analysis", "TEST", 281, 300], ["MSI", "PROBLEM", 314, 317], ["SCM analysis", "TEST", 357, 369]]], ["Improvement in resolution is going on in terms of reducing the laser spot area by lowering the diameter of optical fiber along with providing multiplexing option by integration of multiple mass analyzers.", [["the laser spot area", "PROBLEM", 59, 78], ["multiplexing option", "TREATMENT", 142, 161], ["multiple mass analyzers", "TEST", 180, 203], ["resolution", "OBSERVATION_MODIFIER", 15, 25], ["laser", "OBSERVATION_MODIFIER", 63, 68], ["spot", "OBSERVATION_MODIFIER", 69, 73], ["area", "OBSERVATION_MODIFIER", 74, 78], ["multiple", "OBSERVATION_MODIFIER", 180, 188], ["mass", "OBSERVATION", 189, 193]]], ["Matrix-Assisted Laser Desorption Ionization (MALDI)-MSI and Electrospray Ionization (ESI)-MSI are the two conventional platforms applied for SCM analyses (Figure 1).Mass Spectrometry ImagingPolarity-switching option is lacking in MALDI-MSI, it can be run in either ion mode at a time, multiplexing can be added subsequently for increasing the coverage.", [["Matrix-Assisted Laser Desorption Ionization (MALDI)", "TREATMENT", 0, 51], ["MSI and Electrospray Ionization (ESI)", "TREATMENT", 52, 89], ["MSI", "TREATMENT", 90, 93], ["SCM analyses", "TEST", 141, 153], ["Mass Spectrometry", "TEST", 165, 182], ["Imaging", "TEST", 183, 190], ["increasing the coverage", "TREATMENT", 328, 351]]], ["However, introduction of advanced matrices, such as 9-AA or silver, gold, or titanium and grapheme oxide nanoparticles, have increased the sensitivity by reducing background noise.", [["9-AA", "CHEMICAL", 52, 56], ["silver", "CHEMICAL", 60, 66], ["titanium", "CHEMICAL", 77, 85], ["grapheme oxide", "CHEMICAL", 90, 104], ["9-AA", "CHEMICAL", 52, 56], ["silver", "CHEMICAL", 60, 66], ["titanium", "CHEMICAL", 77, 85], ["grapheme oxide", "CHEMICAL", 90, 104], ["9-AA", "SIMPLE_CHEMICAL", 52, 56], ["silver", "SIMPLE_CHEMICAL", 60, 66], ["gold", "SIMPLE_CHEMICAL", 68, 72], ["grapheme oxide nanoparticles", "SIMPLE_CHEMICAL", 90, 118], ["advanced matrices", "TREATMENT", 25, 42], ["9-AA or silver, gold, or titanium and grapheme oxide nanoparticles", "TREATMENT", 52, 118]]], ["Multiplex MSI platforms are equipped to directly explore individual intracellular metabolites, even their sub-cellular location irrespective of chromatographic separation.", [["intracellular", "ANATOMY", 68, 81], ["cellular", "ANATOMY", 110, 118], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 81], ["cellular", "CELL", 110, 118], ["Multiplex MSI platforms", "TEST", 0, 23], ["individual intracellular metabolites", "TEST", 57, 93], ["chromatographic separation", "PROBLEM", 144, 170], ["sub", "OBSERVATION_MODIFIER", 106, 109], ["cellular location", "OBSERVATION", 110, 127], ["chromatographic separation", "OBSERVATION", 144, 170]]], ["SCM analysis of by MALDI-MS operated in negative ion mode has revealed several metabolites such as ADP, ATP, GTP, and UDP-Glucose etc. from Closterium acerosum (Amantonico et al., 2010).", [["ADP", "CHEMICAL", 99, 102], ["ATP", "CHEMICAL", 104, 107], ["GTP", "CHEMICAL", 109, 112], ["UDP-Glucose", "CHEMICAL", 118, 129], ["ADP", "CHEMICAL", 99, 102], ["ATP", "CHEMICAL", 104, 107], ["GTP", "CHEMICAL", 109, 112], ["UDP", "CHEMICAL", 118, 121], ["Glucose", "CHEMICAL", 122, 129], ["ADP", "SIMPLE_CHEMICAL", 99, 102], ["ATP", "SIMPLE_CHEMICAL", 104, 107], ["GTP", "SIMPLE_CHEMICAL", 109, 112], ["UDP-Glucose", "SIMPLE_CHEMICAL", 118, 129], ["Closterium acerosum", "ORGANISM", 140, 159], ["Closterium acerosum", "SPECIES", 140, 159], ["Closterium acerosum", "SPECIES", 140, 159], ["SCM analysis", "TEST", 0, 12], ["MALDI", "TEST", 19, 24], ["ADP", "TEST", 99, 102], ["ATP", "TEST", 104, 107], ["GTP", "TEST", 109, 112], ["UDP", "TEST", 118, 121], ["Glucose etc", "TEST", 122, 133]]], ["Metabolic analysis of single Yeast cell by coupling microscale sampling and MALDI-MS at negative ion mode detection has elucidated information regarding some valuable metabolites such as ADP, GDP, ATP, GTP, and acetyl-CoA.", [["Yeast cell", "ANATOMY", 29, 39], ["ADP", "CHEMICAL", 187, 190], ["GDP", "CHEMICAL", 192, 195], ["ATP", "CHEMICAL", 197, 200], ["GTP", "CHEMICAL", 202, 205], ["acetyl-CoA", "CHEMICAL", 211, 221], ["ADP", "CHEMICAL", 187, 190], ["GDP", "CHEMICAL", 192, 195], ["ATP", "CHEMICAL", 197, 200], ["GTP", "CHEMICAL", 202, 205], ["acetyl-CoA", "CHEMICAL", 211, 221], ["Yeast cell", "CELL", 29, 39], ["ADP", "SIMPLE_CHEMICAL", 187, 190], ["GDP", "SIMPLE_CHEMICAL", 192, 195], ["ATP", "SIMPLE_CHEMICAL", 197, 200], ["GTP", "SIMPLE_CHEMICAL", 202, 205], ["acetyl-CoA", "SIMPLE_CHEMICAL", 211, 221], ["Yeast cell", "CELL_LINE", 29, 39], ["Yeast", "SPECIES", 29, 34], ["Metabolic analysis", "TEST", 0, 18], ["single Yeast cell", "PROBLEM", 22, 39], ["microscale sampling", "TEST", 52, 71], ["MALDI", "TEST", 76, 81], ["ADP", "TEST", 187, 190], ["GDP", "PROBLEM", 192, 195], ["ATP", "PROBLEM", 197, 200], ["GTP", "PROBLEM", 202, 205], ["Yeast cell", "OBSERVATION", 29, 39], ["CoA", "ANATOMY", 218, 221]]], ["The detection limit ranged from 5 to 12 attomoles (Amantonico et al., 2008).", [["The detection limit", "TEST", 0, 19]]], ["Pressure probe sampling (in picoliters) coupled with UV-MALDI MS has been applied for shotgun metabolite profiling of organic compounds live single plant cell (Gholipour et al., 2012).", [["cell", "ANATOMY", 154, 158], ["cell", "CELL", 154, 158], ["Pressure probe sampling", "TEST", 0, 23], ["UV-MALDI MS", "TREATMENT", 53, 64], ["shotgun metabolite profiling", "TEST", 86, 114], ["organic compounds", "PROBLEM", 118, 135], ["organic compounds", "OBSERVATION", 118, 135], ["plant cell", "OBSERVATION", 148, 158]]], ["High spatial resolution MSI analysis of Maize root epidermal and cortex cell has elucidated several TCA cycle metabolites including their localization with spatial resolution improved to \u223c5 \u03bcm (Hansen and Lee, 2018).", [["root epidermal", "ANATOMY", 46, 60], ["cortex cell", "ANATOMY", 65, 76], ["TCA", "CHEMICAL", 100, 103], ["root epidermal", "CELL", 46, 60], ["cortex cell", "CELL", 65, 76], ["TCA", "SIMPLE_CHEMICAL", 100, 103], ["Maize root epidermal and cortex cell", "CELL_LINE", 40, 76], ["Maize", "SPECIES", 40, 45], ["High spatial resolution MSI analysis", "TEST", 0, 36], ["Maize root epidermal and cortex cell", "PROBLEM", 40, 76], ["several TCA cycle metabolites", "PROBLEM", 92, 121], ["root", "ANATOMY_MODIFIER", 46, 50], ["epidermal", "ANATOMY", 51, 60], ["cortex cell", "OBSERVATION", 65, 76], ["spatial", "OBSERVATION_MODIFIER", 156, 163], ["resolution", "OBSERVATION_MODIFIER", 164, 174], ["improved", "OBSERVATION_MODIFIER", 175, 183]]], ["Turkey gut microbiome has been introspected using MALDI-MS platform operated in positive ion mode with nanoparticle microarray and organic matrices (Hansen et al., 2018).", [["gut microbiome", "ANATOMY", 7, 21], ["gut", "ORGANISM_SUBDIVISION", 7, 10]]], ["Metabolomics variability during virus host interaction in bloom-forming alga Emiliania huxleyi has been evaluated by Plaque assay combined with several MSI techniques (Flow-probe-MSI, MALDI-MSI, UPLC-q-TOF MS, and LC-MS/MC for lipidomics, GC-MS for fatty acid methyl esters) (Schleyer et al., 2019).", [["fatty acid methyl esters", "CHEMICAL", 249, 273], ["fatty acid methyl esters", "CHEMICAL", 249, 273], ["alga Emiliania huxleyi", "ORGANISM", 72, 94], ["fatty acid methyl esters", "SIMPLE_CHEMICAL", 249, 273], ["Emiliania huxleyi", "SPECIES", 77, 94], ["Emiliania huxleyi", "SPECIES", 77, 94], ["Metabolomics variability", "PROBLEM", 0, 24], ["Plaque assay", "TEST", 117, 129], ["several MSI techniques", "TEST", 144, 166], ["Flow", "TEST", 168, 172], ["MSI", "TEST", 179, 182], ["MALDI", "TEST", 184, 189], ["MSI", "TEST", 190, 193], ["UPLC", "TEST", 195, 199], ["MS", "TEST", 206, 208], ["LC", "TEST", 214, 216], ["MS", "TEST", 217, 219], ["lipidomics", "TEST", 227, 237], ["GC", "TEST", 239, 241], ["fatty acid methyl esters", "TREATMENT", 249, 273]]], ["Fluorescence in situ hybridization (FISH) microscopy combined with high-resolution atmospheric pressure-MALDI-MSI of Bathymodiolus puteoserpensis epithelial cells has also been used to understand host-microbe symbiosis (Geier et al., 2019).", [["epithelial cells", "ANATOMY", 146, 162], ["Bathymodiolus puteoserpensis epithelial cells", "CELL", 117, 162], ["Bathymodiolus puteoserpensis epithelial cells", "CELL_LINE", 117, 162], ["Bathymodiolus puteoserpensis", "SPECIES", 117, 145], ["Bathymodiolus puteoserpensis", "SPECIES", 117, 145], ["Fluorescence", "TEST", 0, 12], ["microscopy", "TEST", 42, 52], ["high-resolution atmospheric pressure", "TREATMENT", 67, 103], ["Bathymodiolus puteoserpensis", "TREATMENT", 117, 145], ["epithelial cells", "PROBLEM", 146, 162], ["epithelial cells", "OBSERVATION", 146, 162]]], ["Lipidomics profile of infected Aedes albopictus cells during Zika virus infection has been investigated using MALDI-MS platform to identify thirteen infection-specific lipid markers in the mosquitoes (Melo et al., 2016).", [["cells", "ANATOMY", 48, 53], ["infection", "DISEASE", 72, 81], ["infection", "DISEASE", 149, 158], ["Aedes albopictus", "ORGANISM", 31, 47], ["cells", "CELL", 48, 53], ["Zika virus", "ORGANISM", 61, 71], ["lipid markers", "PROTEIN", 168, 181], ["Aedes albopictus", "SPECIES", 31, 47], ["Zika virus", "SPECIES", 61, 71], ["Aedes albopictus", "SPECIES", 31, 47], ["Zika virus", "SPECIES", 61, 71], ["Lipidomics profile", "TEST", 0, 18], ["infected Aedes albopictus cells", "PROBLEM", 22, 53], ["Zika virus infection", "PROBLEM", 61, 81], ["MALDI-MS platform", "TREATMENT", 110, 127], ["thirteen infection", "PROBLEM", 140, 158], ["infected", "OBSERVATION", 22, 30], ["albopictus cells", "OBSERVATION", 37, 53], ["infection", "OBSERVATION", 149, 158]]], ["Thus the mentioned evidences easily suggest about the utility and potential of MALDI-MSI based platform for SCM analyses and can be predicted more often application to evaluate host-virus interaction at single cell level.Mass Spectrometry ImagingAlike MALDI, Electrospray Ionization (ESI) is another important soft ionization technique where the analytes after ionization, evaluated by MS to facilitate metabolite characterization.", [["cell", "ANATOMY", 210, 214], ["single cell", "CELL", 203, 214], ["MALDI", "TEST", 79, 84], ["SCM analyses", "TEST", 108, 120], ["host-virus interaction", "PROBLEM", 177, 199], ["Mass Spectrometry", "TEST", 221, 238], ["Imaging", "TEST", 239, 246], ["Electrospray Ionization (ESI", "TREATMENT", 259, 287], ["soft ionization technique", "TREATMENT", 310, 335], ["metabolite characterization", "TEST", 403, 430]]], ["ESI-MS is equipped with simultaneous detection at both positive and negative ion mode yielding enormous sensitivity.", [["ESI", "TEST", 0, 3], ["simultaneous detection", "TEST", 24, 46], ["enormous sensitivity", "PROBLEM", 95, 115]]], ["Live nano-ESI-LTQ-MS analyses of Pelargonium zonale leaf cell has depicted over16 metabolites from 1to 5pL of sample (Tejedor et al., 2009).", [["leaf cell", "ANATOMY", 52, 61], ["Pelargonium zonale leaf cell", "CELL", 33, 61], ["Pelargonium zonale", "SPECIES", 33, 51], ["Pelargonium zonale", "SPECIES", 33, 51], ["Live nano", "TEST", 0, 9], ["ESI", "TEST", 10, 13], ["MS analyses", "TEST", 18, 29], ["Pelargonium zonale leaf cell", "PROBLEM", 33, 61], ["leaf cell", "OBSERVATION", 52, 61]]], ["Probe ESI mass spectrometry (PESI-MS) with tungsten probe of 1 \u03bcM diameter has detected several metabolites including 6 fructans, 4 lipids and 8 flavone derivatives in single Allium cepa cell (Gong et al., 2014).", [["cepa cell", "ANATOMY", 182, 191], ["flavone", "CHEMICAL", 145, 152], ["tungsten", "CHEMICAL", 43, 51], ["flavone", "CHEMICAL", 145, 152], ["fructans", "SIMPLE_CHEMICAL", 120, 128], ["4 lipids", "SIMPLE_CHEMICAL", 130, 138], ["flavone derivatives", "SIMPLE_CHEMICAL", 145, 164], ["Allium cepa cell", "CELL", 175, 191], ["Allium cepa", "SPECIES", 175, 186], ["Allium cepa", "SPECIES", 175, 186], ["Probe ESI mass spectrometry", "TEST", 0, 27], ["PESI", "TEST", 29, 33], ["tungsten probe", "TEST", 43, 57], ["fructans", "TEST", 120, 128], ["lipids", "TREATMENT", 132, 138], ["8 flavone derivatives", "TREATMENT", 143, 164], ["several", "OBSERVATION_MODIFIER", 88, 95], ["metabolites", "OBSERVATION_MODIFIER", 96, 107], ["cepa cell", "OBSERVATION", 182, 191]]], ["ESI-Q-TOF-MS operated in either positive or negative-ion mode has yielded status regarding several metabolites such as tryptophan, creatinine, dopamine, and glycine, and cofactors such as lactate and pyruvate to link energy metabolism and immunodeficiency in microgravity (Chakraborty et al., 2018).Mass Spectrometry ImagingLaser ablation electrospray ionization (LAESI) employs mid-infrared (mid-IR) laser to generate gas phase metabolites.", [["tryptophan", "CHEMICAL", 119, 129], ["creatinine", "CHEMICAL", 131, 141], ["dopamine", "CHEMICAL", 143, 151], ["glycine", "CHEMICAL", 157, 164], ["lactate", "CHEMICAL", 188, 195], ["pyruvate", "CHEMICAL", 200, 208], ["immunodeficiency", "DISEASE", 239, 255], ["tryptophan", "CHEMICAL", 119, 129], ["creatinine", "CHEMICAL", 131, 141], ["dopamine", "CHEMICAL", 143, 151], ["glycine", "CHEMICAL", 157, 164], ["lactate", "CHEMICAL", 188, 195], ["pyruvate", "CHEMICAL", 200, 208], ["tryptophan", "SIMPLE_CHEMICAL", 119, 129], ["creatinine", "SIMPLE_CHEMICAL", 131, 141], ["dopamine", "SIMPLE_CHEMICAL", 143, 151], ["glycine", "SIMPLE_CHEMICAL", 157, 164], ["lactate", "SIMPLE_CHEMICAL", 188, 195], ["pyruvate", "SIMPLE_CHEMICAL", 200, 208], ["ESI", "TEST", 0, 3], ["several metabolites", "PROBLEM", 91, 110], ["tryptophan", "TEST", 119, 129], ["creatinine", "TEST", 131, 141], ["dopamine", "TREATMENT", 143, 151], ["glycine", "TREATMENT", 157, 164], ["lactate", "TEST", 188, 195], ["immunodeficiency in microgravity", "PROBLEM", 239, 271], ["Mass Spectrometry ImagingLaser ablation electrospray ionization (LAESI) employs mid-infrared (mid-IR) laser", "TREATMENT", 299, 406], ["gas phase", "OBSERVATION", 419, 428]]], ["Large plant cells or cluster of animal cells are preferred subjects for this platform but high sensitivity, little chemical background and a direct sample delivery to MS platform has made it a desired choice for SCM analysis.", [["cells", "ANATOMY", 12, 17], ["cells", "ANATOMY", 39, 44], ["sample", "ANATOMY", 148, 154], ["plant cells", "CELL", 6, 17], ["cells", "CELL", 39, 44], ["animal cells", "CELL_TYPE", 32, 44], ["Large plant cells", "PROBLEM", 0, 17], ["animal cells", "PROBLEM", 32, 44], ["this platform", "TEST", 72, 85], ["high sensitivity", "PROBLEM", 90, 106], ["a direct sample delivery", "TREATMENT", 139, 163], ["SCM analysis", "TEST", 212, 224], ["plant cells", "OBSERVATION", 6, 17], ["cluster", "OBSERVATION_MODIFIER", 21, 28], ["animal cells", "OBSERVATION", 32, 44]]], ["Metabolites from single cells or cluster of Allium cepa and Narcissus pseudonarcissus bulb epidermis and single eggs from Lytechinus pictus has been evaluated through LAESI to detect 35 prominent metabolites including anthocyanidins, flavonoids, and their glucosides depicting its potential in SCM analysis (Shrestha and Vertes, 2009).", [["cells", "ANATOMY", 24, 29], ["pseudonarcissus bulb epidermis", "ANATOMY", 70, 100], ["eggs", "ANATOMY", 112, 116], ["anthocyanidins", "CHEMICAL", 218, 232], ["flavonoids", "CHEMICAL", 234, 244], ["anthocyanidins", "CHEMICAL", 218, 232], ["flavonoids", "CHEMICAL", 234, 244], ["glucosides", "CHEMICAL", 256, 266], ["cells", "CELL", 24, 29], ["Allium cepa", "ORGANISM", 44, 55], ["Narcissus pseudonarcissus", "ORGANISM", 60, 85], ["bulb epidermis", "TISSUE", 86, 100], ["eggs", "ORGANISM_SUBSTANCE", 112, 116], ["Lytechinus pictus", "ORGANISM", 122, 139], ["anthocyanidins", "SIMPLE_CHEMICAL", 218, 232], ["flavonoids", "SIMPLE_CHEMICAL", 234, 244], ["glucosides", "SIMPLE_CHEMICAL", 256, 266], ["Allium cepa", "SPECIES", 44, 55], ["Narcissus pseudonarcissus", "SPECIES", 60, 85], ["Lytechinus pictus", "SPECIES", 122, 139], ["Allium cepa", "SPECIES", 44, 55], ["Narcissus pseudonarcissus", "SPECIES", 60, 85], ["Lytechinus pictus", "SPECIES", 122, 139], ["single cells", "PROBLEM", 17, 29], ["Allium cepa", "TREATMENT", 44, 55], ["Narcissus pseudonarcissus bulb epidermis", "PROBLEM", 60, 100], ["single eggs", "PROBLEM", 105, 116], ["Lytechinus pictus", "PROBLEM", 122, 139], ["anthocyanidins", "TREATMENT", 218, 232], ["flavonoids", "TREATMENT", 234, 244], ["their glucosides", "TREATMENT", 250, 266], ["SCM analysis", "TEST", 294, 306], ["single cells", "OBSERVATION", 17, 29], ["cluster", "OBSERVATION_MODIFIER", 33, 40], ["Allium cepa", "OBSERVATION", 44, 55], ["Narcissus pseudonarcissus", "OBSERVATION", 60, 85], ["bulb", "ANATOMY_MODIFIER", 86, 90], ["epidermis", "ANATOMY", 91, 100], ["Lytechinus pictus", "OBSERVATION", 122, 139]]], ["LAESI-MS coupled with ion mobility separation (IMS) has been described as capable of direct profiling and imaging of several biomolecules including metabolites from biological tissues and single cells (Etalo et al., 2018; Paglia and Astarita, 2020).", [["tissues", "ANATOMY", 176, 183], ["cells", "ANATOMY", 195, 200], ["LAESI", "CHEMICAL", 0, 5], ["tissues", "TISSUE", 176, 183], ["single cells", "CELL", 188, 200], ["single cells", "CELL_TYPE", 188, 200], ["ion mobility separation", "PROBLEM", 22, 45], ["direct profiling", "TEST", 85, 101], ["imaging", "TEST", 106, 113], ["several biomolecules", "PROBLEM", 117, 137]]], ["LAESI coupled with a 21 tesla Fourier transform ion cyclotron resonance (21T-FTICR) has capable of elucidating isotopic fine structure of the biomolecules by direct MS analysis and imaging (Stopka et al., 2019).Mass Spectrometry ImagingLive Single-Cell Video-Mass Spectrometry using micro sampling method by video microscopy and micromanipulator guided gold-coated glass capillary nano-ESI tip along with Nano-ESI-Q-TOF platform has demonstrated good potential for SCM analysis (Lapainis et al., 2009; Hiyama et al., 2015).Non-Mass Spectrometric MethodsNext to mass spectrometry, NMR is a major tool for metabolite analyses.", [["cyclotron resonance", "TEST", 52, 71], ["direct MS analysis", "TEST", 158, 176], ["imaging", "TEST", 181, 188], ["Mass Spectrometry", "TEST", 211, 228], ["ImagingLive", "TEST", 229, 240], ["Mass", "PROBLEM", 259, 263], ["micro sampling method", "TEST", 283, 304], ["video microscopy", "TEST", 308, 324], ["micromanipulator guided gold-coated glass capillary nano-ESI tip", "TREATMENT", 329, 393], ["Nano-ESI", "TREATMENT", 405, 413], ["SCM analysis", "TEST", 465, 477], ["Mass Spectrometric Methods", "PROBLEM", 527, 553], ["mass spectrometry", "TEST", 561, 578], ["metabolite analyses", "TEST", 604, 623], ["isotopic fine structure", "OBSERVATION", 111, 134], ["Mass", "OBSERVATION", 259, 263]]], ["It is even robust and requires less sample processing than the other metabolomics tools.", [["robust", "OBSERVATION_MODIFIER", 11, 17]]], ["However requirement of large sample volume and the issue of sensitivity render it imperfect for SCM analyses rather it is preferred for tissue sample and biofluid introspection.", [["tissue sample", "ANATOMY", 136, 149], ["tissue", "TISSUE", 136, 142], ["large sample volume", "TREATMENT", 23, 42], ["SCM analyses", "PROBLEM", 96, 108], ["tissue sample", "TEST", 136, 149], ["biofluid introspection", "TEST", 154, 176], ["large", "OBSERVATION_MODIFIER", 23, 28], ["sample volume", "OBSERVATION_MODIFIER", 29, 42]]], ["For example continuous in vivo metabolism has been followed by using NMR (CIVM-NMR) coupled with high-resolution-magic angle spinning to elucidate branched-chain amino acid metabolism in human chronic lymphoid leukemia cells (Judge et al., 2019).Non-Mass Spectrometric MethodsFluorescence-based sensors are also being applied in targeted SCM analyses.", [["chronic lymphoid leukemia cells", "ANATOMY", 193, 224], ["amino acid", "CHEMICAL", 162, 172], ["chronic lymphoid leukemia", "DISEASE", 193, 218], ["branched-chain amino acid", "CHEMICAL", 147, 172], ["amino acid", "AMINO_ACID", 162, 172], ["human", "ORGANISM", 187, 192], ["chronic lymphoid leukemia cells", "CELL", 193, 224], ["human chronic lymphoid leukemia cells", "CELL_LINE", 187, 224], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 187, 192], ["NMR", "TEST", 69, 72], ["branched-chain amino acid metabolism in human chronic lymphoid leukemia cells", "PROBLEM", 147, 224], ["Mass Spectrometric MethodsFluorescence", "TREATMENT", 250, 288], ["based sensors", "TREATMENT", 289, 302], ["acid metabolism", "OBSERVATION", 168, 183], ["human", "ANATOMY", 187, 192], ["chronic lymphoid leukemia cells", "OBSERVATION", 193, 224], ["Mass", "OBSERVATION", 250, 254]]], ["CE with laser-induced fluorescence (LIF) detection has been employed for detection of chiral amino acids and neurotransmitters from mouse brain and neuron cells (Jak\u00f3 et al., 2014; Qi et al., 2017).", [["brain", "ANATOMY", 138, 143], ["neuron cells", "ANATOMY", 148, 160], ["CE", "CHEMICAL", 0, 2], ["amino acids", "CHEMICAL", 93, 104], ["amino acids", "CHEMICAL", 93, 104], ["amino acids", "AMINO_ACID", 93, 104], ["mouse", "ORGANISM", 132, 137], ["brain", "CELL", 138, 143], ["neuron cells", "CELL", 148, 160], ["LIF", "PROTEIN", 36, 39], ["neuron cells", "CELL_TYPE", 148, 160], ["mouse", "SPECIES", 132, 137], ["mouse", "SPECIES", 132, 137], ["CE", "TEST", 0, 2], ["chiral amino acids", "TEST", 86, 104], ["neurotransmitters from mouse brain and neuron cells", "PROBLEM", 109, 160], ["brain", "ANATOMY", 138, 143], ["neuron cells", "ANATOMY", 148, 160]]], ["Capillary micro sampling MS with fluorescence microscopy has successfully identified 29 metabolites and 54 lipids from Human HepG2/C3Acancer cells (Zhang et al., 2018).", [["HepG2/C3Acancer cells", "ANATOMY", 125, 146], ["Human", "ORGANISM", 119, 124], ["HepG2/C3Acancer cells", "CELL", 125, 146], ["Human HepG2/C3Acancer cells", "CELL_LINE", 119, 146], ["Human", "SPECIES", 119, 124], ["Human HepG2/C3Acancer", "SPECIES", 119, 140], ["Capillary micro sampling MS", "TEST", 0, 27], ["fluorescence microscopy", "TEST", 33, 56], ["metabolites", "TEST", 88, 99], ["lipids", "TEST", 107, 113], ["Human HepG2/C3Acancer cells", "TREATMENT", 119, 146], ["HepG2", "ANATOMY", 125, 130]]], ["Microchip electrophoresis coupled with LIF detection have been employed for identifying ethanol induced metabolite change in mice liver cells to depict elevated hydrogen peroxide along with depleted glutathione and cysteine level in the target cells (Li et al., 2016).", [["liver cells", "ANATOMY", 130, 141], ["cells", "ANATOMY", 244, 249], ["ethanol", "CHEMICAL", 88, 95], ["hydrogen peroxide", "CHEMICAL", 161, 178], ["glutathione", "CHEMICAL", 199, 210], ["cysteine", "CHEMICAL", 215, 223], ["ethanol", "CHEMICAL", 88, 95], ["hydrogen peroxide", "CHEMICAL", 161, 178], ["glutathione", "CHEMICAL", 199, 210], ["cysteine", "CHEMICAL", 215, 223], ["ethanol", "SIMPLE_CHEMICAL", 88, 95], ["mice", "ORGANISM", 125, 129], ["liver cells", "CELL", 130, 141], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 161, 178], ["glutathione", "SIMPLE_CHEMICAL", 199, 210], ["cysteine", "AMINO_ACID", 215, 223], ["cells", "CELL", 244, 249], ["LIF", "PROTEIN", 39, 42], ["mice liver cells", "CELL_TYPE", 125, 141], ["target cells", "CELL_TYPE", 237, 249], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 125, 129], ["Microchip electrophoresis", "TEST", 0, 25], ["LIF detection", "TEST", 39, 52], ["ethanol induced metabolite change in mice liver cells", "PROBLEM", 88, 141], ["elevated hydrogen peroxide", "TREATMENT", 152, 178], ["depleted glutathione", "TREATMENT", 190, 210], ["cysteine level", "TEST", 215, 229], ["liver", "ANATOMY", 130, 135], ["hydrogen peroxide", "OBSERVATION", 161, 178]]], ["However limited multiplexing option has restricted its application mostly within targeted approach.Non-Mass Spectrometric MethodsSurface Enhanced Raman Scattering (SERS) employs laser in the visible, near-infrared, or near-ultraviolet range for label free detection of the metabolites within the cells (Shalabaeva et al., 2017).", [["cells", "ANATOMY", 296, 301], ["cells", "CELL", 296, 301], ["limited multiplexing option", "TREATMENT", 8, 35], ["Non-Mass", "PROBLEM", 99, 107], ["Enhanced Raman Scattering (SERS) employs laser", "TREATMENT", 137, 183], ["Mass", "OBSERVATION", 103, 107]]], ["SERS has been applied for fast, label-free detection of Chlamydia trahomatis and Neisseria gonorrheoae along with associated extra-cellular metabolite changes (Chen et al., 2018).", [["Chlamydia trahomatis", "DISEASE", 56, 76], ["Chlamydia trahomatis", "ORGANISM", 56, 76], ["Neisseria gonorrheoae", "ORGANISM", 81, 102], ["Chlamydia trahomatis", "SPECIES", 56, 76], ["Neisseria gonorrheoae", "SPECIES", 81, 102], ["Chlamydia trahomatis", "SPECIES", 56, 76], ["Neisseria gonorrheoae", "SPECIES", 81, 102], ["Chlamydia trahomatis", "PROBLEM", 56, 76], ["Neisseria gonorrheoae", "PROBLEM", 81, 102], ["associated extra-cellular metabolite changes", "PROBLEM", 114, 158], ["Chlamydia trahomatis", "OBSERVATION", 56, 76], ["extra-cellular metabolite", "OBSERVATION", 125, 150]]], ["Raman spectroscopy is a non-destructive method for metabolite analysis but only few functional groups emit detectable Raman signals reducing the applicability of the method for SCM analyses (Smith et al., 2016).", [["Raman spectroscopy", "TEST", 0, 18], ["a non-destructive method", "TEST", 22, 46], ["metabolite analysis", "TEST", 51, 70], ["SCM analyses", "TEST", 177, 189]]], ["Recently, Raman micro-spectroscopy using graded X-ray doses has successfully uncovered several nucleus and cytoplasmic specific metabolic features from single SH-SY5Y human cancer cells (Delfino et al., 2019).Future SCM TechniquesSecondary Ion Mass Spectrometry Imaging with spatial resolution capacity at the range of 50\u2013100 nm is a potential future tool for SCM as well as sub-cellular metabolite analyses (Svatos, 2011; Kollmer et al., 2012; Gilmore et al., 2019).", [["nucleus", "ANATOMY", 95, 102], ["cytoplasmic", "ANATOMY", 107, 118], ["SH-SY5Y human cancer cells", "ANATOMY", 159, 185], ["cellular", "ANATOMY", 379, 387], ["cancer", "DISEASE", 173, 179], ["nucleus", "CELLULAR_COMPONENT", 95, 102], ["cytoplasmic", "ORGANISM_SUBSTANCE", 107, 118], ["SH-SY5Y human cancer cells", "CELL", 159, 185], ["cellular", "CELL", 379, 387], ["SH-SY5Y human cancer cells", "CELL_LINE", 159, 185], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["Raman micro-spectroscopy", "TEST", 10, 34], ["graded X-ray doses", "TREATMENT", 41, 59], ["several nucleus", "PROBLEM", 87, 102], ["cytoplasmic specific metabolic features", "PROBLEM", 107, 146], ["Future SCM Techniques", "TREATMENT", 209, 230], ["Secondary Ion Mass Spectrometry", "TEST", 230, 261], ["Imaging", "TEST", 262, 269], ["spatial resolution capacity", "TEST", 275, 302], ["SCM", "PROBLEM", 360, 363], ["several nucleus", "ANATOMY", 87, 102], ["cytoplasmic specific", "OBSERVATION", 107, 127], ["metabolic features", "OBSERVATION", 128, 146], ["cancer cells", "OBSERVATION", 173, 185], ["Mass", "OBSERVATION", 244, 248]]], ["The matrix-free laser desorption ionization (LDI) methods include Desorption Ionization on Silicon (DIOS)-MSI which is a variant of surface-assisted laser desorption ionization (SALDI), both use soft ionization of analytes followed by MS analyses.", [["Silicon", "CHEMICAL", 91, 98], ["Silicon", "CHEMICAL", 91, 98], ["Silicon", "SIMPLE_CHEMICAL", 91, 98], ["The matrix-free laser desorption ionization (LDI) methods", "TREATMENT", 0, 57], ["Desorption Ionization on Silicon (DIOS)", "TREATMENT", 66, 105], ["surface-assisted laser desorption ionization", "TREATMENT", 132, 176], ["soft ionization of analytes", "TREATMENT", 195, 222], ["MS analyses", "TEST", 235, 246]]], ["LDI-MS platform employing HR-MS along with Orbitrap FT-MS has been used for SCM analysis of microalgae, marine diatoms and freshwater chlorophytes (Baumeister et al., 2019).", [["LDI", "TEST", 0, 3], ["MS platform", "PROBLEM", 4, 15], ["HR", "TEST", 26, 28], ["MS", "PROBLEM", 29, 31], ["Orbitrap FT", "TEST", 43, 54], ["MS", "PROBLEM", 55, 57], ["SCM analysis", "TEST", 76, 88]]], ["Matrix-free nanophotonic ionization of analytes on Silicon Nanopost Array chip followed by MSI offers an effective platform for detection of small metabolites at single cell level (Walker et al., 2012; Korte et al., 2016).", [["cell", "ANATOMY", 169, 173], ["Silicon", "CHEMICAL", 51, 58], ["cell", "CELL", 169, 173], ["free nanophotonic ionization of analytes", "TREATMENT", 7, 47], ["Silicon Nanopost Array chip", "TREATMENT", 51, 78], ["small metabolites", "PROBLEM", 141, 158], ["small", "OBSERVATION_MODIFIER", 141, 146]]], ["Desorption Electrospray Ionization is another soft ionization technique having capability to ionize wide variable molecules however poor spatial resolution is a limitation of this technique which can be improved further for SCM analyses.", [["Desorption Electrospray Ionization", "TREATMENT", 0, 34], ["another soft ionization technique", "TREATMENT", 38, 71], ["wide variable molecules", "PROBLEM", 100, 123], ["this technique", "TREATMENT", 175, 189], ["SCM analyses", "TEST", 224, 236]]], ["MS coupled with Microfluidic chips or microarray systems and 3D MALDI Mass Spectrometry Imaging are the other potential SCM techniques which can be used for analyzing virus-host interaction in near future.", [["MS", "PROBLEM", 0, 2], ["Microfluidic chips", "TREATMENT", 16, 34], ["microarray systems", "TEST", 38, 56], ["3D MALDI Mass Spectrometry", "TEST", 61, 87], ["Imaging", "TEST", 88, 95], ["analyzing virus", "PROBLEM", 157, 172]]], ["Single-Molecule Array which resembles the digital ELISA format may also be employed for targeted SCM by using specific tagged antibody against the target metabolite(s) (Minakshi et al., 2019a).Metabolomic Insight at Virus-Host Interface to Combat Emerging VirusesZika virus, Dengu virus, Chikungunya virus, HIV, avian influenza, Nipah (NiV) viruses, Ebola and Marburg filoviruses, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome coronavirus (MERS CoV) are the emerging viruses as evidenced in recent times (Afrough et al., 2019).", [["SCM", "ANATOMY", 97, 100], ["Chikungunya virus", "DISEASE", 288, 305], ["avian influenza", "DISEASE", 312, 327], ["Nipah (NiV) viruses", "DISEASE", 329, 348], ["Ebola", "DISEASE", 350, 355], ["Marburg filoviruses", "DISEASE", 360, 379], ["acute respiratory syndrome", "DISEASE", 388, 414], ["SARS", "DISEASE", 416, 420], ["Middle East respiratory syndrome coronavirus", "DISEASE", 426, 470], ["SCM", "CANCER", 97, 100], ["VirusesZika virus", "ORGANISM", 256, 273], ["Dengu virus", "ORGANISM", 275, 286], ["Chikungunya virus", "ORGANISM", 288, 305], ["HIV", "ORGANISM", 307, 310], ["avian influenza", "ORGANISM", 312, 327], ["Nipah (NiV) viruses", "ORGANISM", 329, 348], ["Ebola", "ORGANISM", 350, 355], ["Marburg filoviruses", "ORGANISM", 360, 379], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 426, 470], ["MERS CoV", "ORGANISM", 472, 480], ["tagged antibody", "PROTEIN", 119, 134], ["Dengu virus", "SPECIES", 275, 286], ["Chikungunya virus", "SPECIES", 288, 305], ["HIV", "SPECIES", 307, 310], ["avian influenza", "SPECIES", 312, 327], ["Nipah", "SPECIES", 329, 334], ["Ebola", "SPECIES", 350, 355], ["VirusesZika virus", "SPECIES", 256, 273], ["Dengu virus", "SPECIES", 275, 286], ["Chikungunya virus", "SPECIES", 288, 305], ["HIV", "SPECIES", 307, 310], ["NiV", "SPECIES", 336, 339], ["Marburg filoviruses", "SPECIES", 360, 379], ["Middle East respiratory syndrome coronavirus", "SPECIES", 426, 470], ["MERS CoV", "SPECIES", 472, 480], ["Metabolomic Insight at Virus", "PROBLEM", 193, 221], ["Emerging VirusesZika virus", "PROBLEM", 247, 273], ["Dengu virus", "PROBLEM", 275, 286], ["Chikungunya virus", "PROBLEM", 288, 305], ["HIV", "PROBLEM", 307, 310], ["avian influenza", "PROBLEM", 312, 327], ["Nipah (NiV) viruses", "TREATMENT", 329, 348], ["Ebola", "PROBLEM", 350, 355], ["Marburg filoviruses", "PROBLEM", 360, 379], ["severe acute respiratory syndrome", "PROBLEM", 381, 414], ["SARS)", "PROBLEM", 416, 421], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 426, 470], ["the emerging viruses", "PROBLEM", 486, 506], ["Chikungunya virus", "OBSERVATION", 288, 305], ["Marburg filoviruses", "OBSERVATION", 360, 379], ["severe", "OBSERVATION_MODIFIER", 381, 387], ["acute", "OBSERVATION_MODIFIER", 388, 393], ["respiratory syndrome", "OBSERVATION", 394, 414], ["Middle", "ANATOMY_MODIFIER", 426, 432], ["respiratory syndrome", "OBSERVATION", 438, 458], ["viruses", "OBSERVATION", 499, 506]]], ["Several of them are having zoonotic importance and emerge from viral spill over from the sylvatic cycle infecting multiple hosts.", [["viral spill", "PROBLEM", 63, 74], ["viral spill", "OBSERVATION", 63, 74]]], ["Metabolomic intervention can trace out some common metabolic pathway(s) in different host range which are also essential for viral replication (Passalacqua et al., 2018; Mayer et al., 2019).", [["Metabolomic intervention", "TREATMENT", 0, 24], ["essential for", "UNCERTAINTY", 111, 124], ["viral replication", "OBSERVATION", 125, 142]]], ["For Example, Progression of human cytomegalovirus (HCMV) infection has increased the metabolite flux through glycolysis, citric acid cycle, and pyrimidine nucleotide biosynthesis in human fibroblasts, probably to meet the energy demand for viral replication and supply of macromolecular precursors (Munger et al., 2008).", [["fibroblasts", "ANATOMY", 188, 199], ["human cytomegalovirus (HCMV) infection", "DISEASE", 28, 66], ["citric acid", "CHEMICAL", 121, 132], ["pyrimidine nucleotide", "CHEMICAL", 144, 165], ["citric acid", "CHEMICAL", 121, 132], ["pyrimidine nucleotide", "CHEMICAL", 144, 165], ["human", "ORGANISM", 28, 33], ["cytomegalovirus", "ORGANISM", 34, 49], ["HCMV", "ORGANISM", 51, 55], ["citric acid", "SIMPLE_CHEMICAL", 121, 132], ["pyrimidine nucleotide", "SIMPLE_CHEMICAL", 144, 165], ["human", "ORGANISM", 182, 187], ["fibroblasts", "CELL", 188, 199], ["human fibroblasts", "CELL_TYPE", 182, 199], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 182, 187], ["human cytomegalovirus", "SPECIES", 28, 49], ["HCMV", "SPECIES", 51, 55], ["human", "SPECIES", 182, 187], ["human cytomegalovirus (HCMV) infection", "PROBLEM", 28, 66], ["the metabolite flux through glycolysis", "PROBLEM", 81, 119], ["citric acid cycle", "TREATMENT", 121, 138], ["pyrimidine nucleotide biosynthesis", "TREATMENT", 144, 178], ["human fibroblasts", "PROBLEM", 182, 199], ["viral replication", "TREATMENT", 240, 257], ["Progression", "OBSERVATION_MODIFIER", 13, 24], ["human cytomegalovirus", "OBSERVATION", 28, 49], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["metabolite flux", "OBSERVATION", 85, 100]]], ["HCMV mediated metabolic reprogramming also includes enhanced lipogenesis through mTOR-sterol regulatory element-binding protein (SREBP)-regulated and other pathways inducing several enzymes such as acetyl-CoA carboxylase, fatty acid synthase, fatty acid elongases etc. The synthesized very long chain and long chain fatty acids are essential for viral envelope production, because inhibition of such pathways result into impaired viral replication.", [["acetyl-Co", "CHEMICAL", 198, 207], ["fatty acid", "CHEMICAL", 222, 232], ["fatty acid", "CHEMICAL", 243, 253], ["fatty acids", "CHEMICAL", 316, 327], ["impaired viral replication", "DISEASE", 421, 447], ["sterol", "CHEMICAL", 86, 92], ["acetyl-CoA", "CHEMICAL", 198, 208], ["fatty acid", "CHEMICAL", 222, 232], ["fatty acid", "CHEMICAL", 243, 253], ["fatty acids", "CHEMICAL", 316, 327], ["HCMV", "ORGANISM", 0, 4], ["mTOR-sterol regulatory element-binding protein", "GENE_OR_GENE_PRODUCT", 81, 127], ["SREBP", "GENE_OR_GENE_PRODUCT", 129, 134], ["acetyl-CoA carboxylase", "GENE_OR_GENE_PRODUCT", 198, 220], ["fatty acid synthase", "GENE_OR_GENE_PRODUCT", 222, 241], ["fatty acid", "SIMPLE_CHEMICAL", 243, 253], ["long chain fatty acids", "SIMPLE_CHEMICAL", 305, 327], ["mTOR", "PROTEIN", 81, 85], ["sterol regulatory element-binding protein", "PROTEIN", 86, 127], ["SREBP", "PROTEIN", 129, 134], ["acetyl-CoA carboxylase", "PROTEIN", 198, 220], ["fatty acid synthase", "PROTEIN", 222, 241], ["HCMV", "SPECIES", 0, 4], ["HCMV mediated metabolic reprogramming", "PROBLEM", 0, 37], ["enhanced lipogenesis", "PROBLEM", 52, 72], ["several enzymes", "TEST", 174, 189], ["acetyl", "TEST", 198, 204], ["A carboxylase", "TEST", 207, 220], ["fatty acid synthase", "TREATMENT", 222, 241], ["fatty acid elongases", "TREATMENT", 243, 263], ["The synthesized very long chain and long chain fatty acids", "PROBLEM", 269, 327], ["viral envelope production", "PROBLEM", 346, 371], ["inhibition of such pathways", "PROBLEM", 381, 408], ["impaired viral replication", "PROBLEM", 421, 447], ["metabolic reprogramming", "OBSERVATION", 14, 37], ["very", "OBSERVATION_MODIFIER", 285, 289], ["long chain", "OBSERVATION_MODIFIER", 290, 300], ["viral replication", "OBSERVATION", 430, 447]]], ["Similarly other DNA viruses such as herpes simplex virus-1 (HSV-1), Kaposi\u2019s sarcoma-associated herpes virus (KSHV), vaccinia virus (VACV) are also found to modulate glycolysis, glutamine metabolism and fatty acid synthesis as common pathways.", [["herpes simplex virus", "DISEASE", 36, 56], ["Kaposi\u2019s sarcoma-associated herpes virus", "DISEASE", 68, 108], ["glutamine", "CHEMICAL", 178, 187], ["fatty acid", "CHEMICAL", 203, 213], ["glutamine", "CHEMICAL", 178, 187], ["fatty acid", "CHEMICAL", 203, 213], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["herpes simplex virus-1", "ORGANISM", 36, 58], ["HSV-1", "ORGANISM", 60, 65], ["Kaposi\u2019s sarcoma-associated herpes virus", "ORGANISM", 68, 108], ["KSHV", "ORGANISM", 110, 114], ["vaccinia virus", "ORGANISM", 117, 131], ["VACV", "ORGANISM", 133, 137], ["glutamine", "AMINO_ACID", 178, 187], ["fatty acid", "SIMPLE_CHEMICAL", 203, 213], ["herpes simplex virus-1", "SPECIES", 36, 58], ["HSV-1", "SPECIES", 60, 65], ["Kaposi\u2019s sarcoma-associated herpes virus", "SPECIES", 68, 108], ["vaccinia virus", "SPECIES", 117, 131], ["herpes simplex virus-1", "SPECIES", 36, 58], ["HSV-1", "SPECIES", 60, 65], ["Kaposi\u2019s sarcoma-associated herpes virus", "SPECIES", 68, 108], ["KSHV", "SPECIES", 110, 114], ["vaccinia virus", "SPECIES", 117, 131], ["VACV", "SPECIES", 133, 137], ["Similarly other DNA viruses", "PROBLEM", 0, 27], ["herpes simplex virus", "TEST", 36, 56], ["HSV", "TEST", 60, 63], ["Kaposi\u2019s sarcoma", "PROBLEM", 68, 84], ["herpes virus (KSHV", "PROBLEM", 96, 114], ["vaccinia virus", "PROBLEM", 117, 131], ["modulate glycolysis", "PROBLEM", 157, 176], ["glutamine metabolism", "PROBLEM", 178, 198], ["fatty acid synthesis", "PROBLEM", 203, 223], ["DNA viruses", "OBSERVATION", 16, 27], ["Kaposi", "ANATOMY", 68, 74], ["sarcoma", "OBSERVATION", 77, 84], ["herpes virus", "OBSERVATION", 96, 108], ["glutamine metabolism", "OBSERVATION", 178, 198], ["fatty acid", "OBSERVATION", 203, 213]]], ["Thus any substrate analog (e.g., glucose analog 2-deoxyglucose) or enzyme inhibitor which prevents such virus-induced host metabolic reprogramming can be effective against multiple viruses.", [["glucose", "CHEMICAL", 33, 40], ["2-deoxyglucose", "CHEMICAL", 48, 62], ["glucose", "CHEMICAL", 33, 40], ["2-deoxyglucose", "CHEMICAL", 48, 62], ["glucose", "SIMPLE_CHEMICAL", 33, 40], ["2-deoxyglucose", "SIMPLE_CHEMICAL", 48, 62], ["any substrate analog", "PROBLEM", 5, 25], ["glucose analog", "TREATMENT", 33, 47], ["deoxyglucose)", "TREATMENT", 50, 63], ["enzyme inhibitor", "TREATMENT", 67, 83], ["such virus", "PROBLEM", 99, 109], ["host metabolic reprogramming", "TREATMENT", 118, 146], ["multiple viruses", "PROBLEM", 172, 188], ["metabolic reprogramming", "OBSERVATION", 123, 146], ["viruses", "OBSERVATION", 181, 188]]], ["Although RNA viruses like rhinovirus, hepatitis C virus and several emerging arboviruses such as Zika virus, Dengu virus, Chikungunya virus etc. modulate host metabolic pathways in a little different manner but glycolysis, glutamine metabolism and fatty acid synthesis remain as the prime targets.", [["rhinovirus, hepatitis C virus", "DISEASE", 26, 55], ["Chikungunya virus", "DISEASE", 122, 139], ["glutamine", "CHEMICAL", 223, 232], ["fatty acid", "CHEMICAL", 248, 258], ["glutamine", "CHEMICAL", 223, 232], ["fatty acid", "CHEMICAL", 248, 258], ["rhinovirus", "ORGANISM", 26, 36], ["hepatitis C virus", "ORGANISM", 38, 55], ["Zika virus", "ORGANISM", 97, 107], ["Dengu virus", "ORGANISM", 109, 120], ["Chikungunya virus etc", "ORGANISM", 122, 143], ["glutamine", "AMINO_ACID", 223, 232], ["fatty acid", "SIMPLE_CHEMICAL", 248, 258], ["rhinovirus", "SPECIES", 26, 36], ["hepatitis C virus", "SPECIES", 38, 55], ["Zika virus", "SPECIES", 97, 107], ["Dengu virus", "SPECIES", 109, 120], ["Chikungunya virus", "SPECIES", 122, 139], ["hepatitis C virus", "SPECIES", 38, 55], ["Zika virus", "SPECIES", 97, 107], ["Dengu virus", "SPECIES", 109, 120], ["Chikungunya virus", "SPECIES", 122, 139], ["RNA viruses", "PROBLEM", 9, 20], ["rhinovirus", "PROBLEM", 26, 36], ["hepatitis C virus", "PROBLEM", 38, 55], ["several emerging arboviruses", "PROBLEM", 60, 88], ["Zika virus", "PROBLEM", 97, 107], ["Dengu virus", "PROBLEM", 109, 120], ["Chikungunya virus etc", "PROBLEM", 122, 143], ["modulate host metabolic pathways", "PROBLEM", 145, 177], ["glycolysis", "TEST", 211, 221], ["glutamine metabolism", "TEST", 223, 243], ["fatty acid synthesis", "PROBLEM", 248, 268], ["RNA viruses", "OBSERVATION", 9, 20], ["rhinovirus", "OBSERVATION", 26, 36], ["hepatitis", "OBSERVATION", 38, 47], ["host metabolic pathways", "OBSERVATION", 154, 177], ["little different", "OBSERVATION_MODIFIER", 183, 199]]], ["Similar host enzyme machineries are being exploited by these RNA viruses too.", [["Similar host enzyme machineries", "TREATMENT", 0, 31]]], ["These common metabolic pathway nodes can be exploited for preventive, diagnostic and therapeutic management of emerging viral infections.", [["metabolic pathway nodes", "ANATOMY", 13, 36], ["viral infections", "DISEASE", 120, 136], ["These common metabolic pathway nodes", "PROBLEM", 0, 36], ["therapeutic management", "TREATMENT", 85, 107], ["emerging viral infections", "PROBLEM", 111, 136], ["pathway nodes", "OBSERVATION", 23, 36], ["viral infections", "OBSERVATION", 120, 136]]], ["Further, such exploration can be of interest for therapeutic repurposing of existing drugs to combat any emerging viral outbreak.", [["such exploration", "TEST", 9, 25], ["existing drugs", "TREATMENT", 76, 90], ["any emerging viral outbreak", "PROBLEM", 101, 128]]], ["For example, Remdesivir (GS-5734) is a novel nucleoside analog antiviral prodrug, actually developed for the treatment of single stranded RNA containing Ebola virus disease and Marburg virus infections, has now been suggested as therapeutic option against recent SARS-CoV-2 pandemic.", [["Remdesivir", "CHEMICAL", 13, 23], ["GS-5734", "CHEMICAL", 25, 32], ["nucleoside", "CHEMICAL", 45, 55], ["Ebola virus disease", "DISEASE", 153, 172], ["Marburg virus infections", "DISEASE", 177, 201], ["SARS-CoV-2 pandemic", "DISEASE", 263, 282], ["Remdesivir", "CHEMICAL", 13, 23], ["GS-5734", "CHEMICAL", 25, 32], ["nucleoside", "CHEMICAL", 45, 55], ["Remdesivir", "SIMPLE_CHEMICAL", 13, 23], ["GS-5734", "SIMPLE_CHEMICAL", 25, 32], ["nucleoside", "SIMPLE_CHEMICAL", 45, 55], ["Ebola virus", "ORGANISM", 153, 164], ["Marburg virus", "ORGANISM", 177, 190], ["SARS-CoV-2", "ORGANISM", 263, 273], ["Ebola virus", "SPECIES", 153, 164], ["Marburg virus", "SPECIES", 177, 190], ["Ebola virus", "SPECIES", 153, 164], ["Marburg virus", "SPECIES", 177, 190], ["Remdesivir (GS", "TEST", 13, 27], ["a novel nucleoside analog antiviral prodrug", "TREATMENT", 37, 80], ["the treatment", "TREATMENT", 105, 118], ["single stranded RNA containing Ebola virus disease", "PROBLEM", 122, 172], ["Marburg virus infections", "PROBLEM", 177, 201], ["recent SARS", "PROBLEM", 256, 267], ["pandemic", "PROBLEM", 274, 282], ["stranded RNA", "OBSERVATION", 129, 141], ["Ebola virus disease", "OBSERVATION", 153, 172]]], ["SARS-CoV-2 is also having positive-sense single-stranded RNA genome and Remdesivir gets incorporated into the nascent viral RNA chains leading to inhibition of viral replication through premature termination of RNA transcription (Centers for Disease Control and Prevention, 2020; Liu et al., 2020).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 72, 82], ["positive-sense single-stranded RNA genome", "DNA", 26, 67], ["nascent viral RNA chains", "PROTEIN", 110, 134], ["positive-sense single-stranded RNA genome", "PROBLEM", 26, 67], ["Remdesivir", "TREATMENT", 72, 82], ["the nascent viral RNA chains", "TREATMENT", 106, 134], ["viral replication", "TREATMENT", 160, 177], ["RNA transcription", "TREATMENT", 211, 228], ["Disease Control", "TREATMENT", 242, 257], ["viral RNA chains", "OBSERVATION", 118, 134], ["viral replication", "OBSERVATION", 160, 177]]], ["However, the toxic effects of such substrate analogs or pathway inhibitors on host cells should be critically analyzed prior to their extensive application.", [["cells", "ANATOMY", 83, 88], ["host cells", "CELL", 78, 88], ["host cells", "CELL_TYPE", 78, 88], ["such substrate analogs", "TREATMENT", 30, 52], ["pathway inhibitors", "TREATMENT", 56, 74], ["host cells", "TREATMENT", 78, 88], ["toxic", "OBSERVATION_MODIFIER", 13, 18]]], ["Recently, traditional anti-parasitic drug ivermectin has also found to exhibit in vitro antiviral activity against SARS-CoV-2 infection and warrants rapid further in vivo introspection to combat current COVID-19 pandemic.", [["ivermectin", "CHEMICAL", 42, 52], ["SARS-CoV-2 infection", "DISEASE", 115, 135], ["ivermectin", "CHEMICAL", 42, 52], ["ivermectin", "SIMPLE_CHEMICAL", 42, 52], ["SARS-CoV-2", "ORGANISM", 115, 125], ["COVID-19", "ORGANISM", 203, 211], ["CoV-2", "SPECIES", 120, 125], ["SARS-CoV-2", "SPECIES", 115, 125], ["traditional anti-parasitic drug ivermectin", "TREATMENT", 10, 52], ["vitro antiviral activity", "TREATMENT", 82, 106], ["SARS", "PROBLEM", 115, 119], ["CoV-2 infection", "PROBLEM", 120, 135], ["current COVID", "TEST", 195, 208], ["pandemic", "PROBLEM", 212, 220], ["infection", "OBSERVATION", 126, 135]]], ["This is also an example of drug repurposing relying upon the virus-exploited common pathways.", [["the virus", "PROBLEM", 57, 66]]], ["Because in earlier research, ivermectin has depicted efficacy against multiple RNA viruses such as DENV 1-4, West Nile Virus, influenza virus, Venezuelan equine encephalitis virus (VEEV) and human immunodeficiency virus-1 (HIV-1) by destabilizing the importin (IMP) \u03b1/\u03b21 heterodimer and blocking IMP \u03b1/\u03b21-mediated nuclear import of viral proteins (Caly et al., 2020).Metabolomic Insight at Virus-Host Interface to Combat Emerging VirusesMetabolite profiling can also provide an idea about the disease severity and predictive outcome of the viral infection.", [["nuclear", "ANATOMY", 314, 321], ["ivermectin", "CHEMICAL", 29, 39], ["influenza virus", "DISEASE", 126, 141], ["Venezuelan equine encephalitis", "DISEASE", 143, 173], ["human immunodeficiency virus", "DISEASE", 191, 219], ["IMP", "CHEMICAL", 296, 299], ["viral infection", "DISEASE", 540, 555], ["ivermectin", "CHEMICAL", 29, 39], ["ivermectin", "SIMPLE_CHEMICAL", 29, 39], ["DENV 1-4", "ORGANISM", 99, 107], ["West Nile Virus", "ORGANISM", 109, 124], ["influenza virus", "ORGANISM", 126, 141], ["Venezuelan equine encephalitis virus", "ORGANISM", 143, 179], ["VEEV", "ORGANISM", 181, 185], ["human immunodeficiency virus-1", "ORGANISM", 191, 221], ["HIV-1", "ORGANISM", 223, 228], ["importin (IMP) \u03b1/\u03b21", "GENE_OR_GENE_PRODUCT", 251, 270], ["IMP \u03b1", "GENE_OR_GENE_PRODUCT", 296, 301], ["\u03b21", "GENE_OR_GENE_PRODUCT", 302, 304], ["nuclear", "CELLULAR_COMPONENT", 314, 321], ["importin (IMP) \u03b1", "PROTEIN", 251, 267], ["\u03b21 heterodimer", "PROTEIN", 268, 282], ["IMP \u03b1", "PROTEIN", 296, 301], ["\u03b21", "PROTEIN", 302, 304], ["viral proteins", "PROTEIN", 332, 346], ["West Nile Virus", "SPECIES", 109, 124], ["influenza virus", "SPECIES", 126, 141], ["Venezuelan equine encephalitis virus", "SPECIES", 143, 179], ["human immunodeficiency virus-1", "SPECIES", 191, 221], ["HIV-1", "SPECIES", 223, 228], ["DENV 1-4", "SPECIES", 99, 107], ["West Nile Virus", "SPECIES", 109, 124], ["Venezuelan equine encephalitis virus", "SPECIES", 143, 179], ["VEEV", "SPECIES", 181, 185], ["human immunodeficiency virus-1", "SPECIES", 191, 221], ["HIV-1", "SPECIES", 223, 228], ["ivermectin", "TREATMENT", 29, 39], ["multiple RNA viruses", "PROBLEM", 70, 90], ["DENV", "PROBLEM", 99, 103], ["West Nile Virus", "PROBLEM", 109, 124], ["influenza virus", "PROBLEM", 126, 141], ["Venezuelan equine encephalitis virus", "PROBLEM", 143, 179], ["human immunodeficiency virus", "PROBLEM", 191, 219], ["Metabolomic Insight at Virus", "PROBLEM", 367, 395], ["the disease severity", "PROBLEM", 489, 509], ["the viral infection", "PROBLEM", 536, 555], ["RNA viruses", "OBSERVATION", 79, 90], ["viral", "OBSERVATION_MODIFIER", 540, 545], ["infection", "OBSERVATION", 546, 555]]], ["Serum metabolite analyses of H7N9 infected subjects have revealed that increase in palmitic acid, erucic acid, and phytal level is related to virus-induced repression of fatty acid metabolism and negatively correlated with the disease outcome (Sun et al., 2018).Metabolomic Insight at Virus-Host Interface to Combat Emerging VirusesIn arboviral infections, metabolic reprogramming in arthropod vector and vertebrate host takes place in different manner.", [["Serum", "ANATOMY", 0, 5], ["palmitic acid", "CHEMICAL", 83, 96], ["erucic acid", "CHEMICAL", 98, 109], ["phytal", "CHEMICAL", 115, 121], ["fatty acid", "CHEMICAL", 170, 180], ["arboviral infections", "DISEASE", 335, 355], ["palmitic acid", "CHEMICAL", 83, 96], ["erucic acid", "CHEMICAL", 98, 109], ["fatty acid", "CHEMICAL", 170, 180], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["palmitic acid", "SIMPLE_CHEMICAL", 83, 96], ["erucic acid", "SIMPLE_CHEMICAL", 98, 109], ["phytal", "SIMPLE_CHEMICAL", 115, 121], ["fatty acid", "SIMPLE_CHEMICAL", 170, 180], ["Viruses", "ORGANISM", 325, 332], ["H7N9", "SPECIES", 29, 33], ["Serum metabolite analyses", "TEST", 0, 25], ["H7N9 infected subjects", "PROBLEM", 29, 51], ["palmitic acid", "TEST", 83, 96], ["erucic acid, and phytal level", "PROBLEM", 98, 127], ["virus", "PROBLEM", 142, 147], ["fatty acid metabolism", "PROBLEM", 170, 191], ["the disease outcome", "PROBLEM", 223, 242], ["Metabolomic Insight at Virus", "PROBLEM", 262, 290], ["arboviral infections", "PROBLEM", 335, 355], ["metabolic reprogramming in arthropod vector", "TREATMENT", 357, 400], ["vertebrate host", "TREATMENT", 405, 420], ["increase", "OBSERVATION_MODIFIER", 71, 79], ["palmitic acid", "OBSERVATION", 83, 96], ["fatty acid", "OBSERVATION", 170, 180], ["Viruses", "OBSERVATION", 325, 332], ["arboviral", "OBSERVATION_MODIFIER", 335, 344], ["infections", "OBSERVATION", 345, 355], ["metabolic reprogramming", "OBSERVATION", 357, 380], ["vertebrate host", "OBSERVATION", 405, 420]]], ["Zika virus (ZIKV) induced metabolic reprogramming of human foreskin fibroblast cells (HFF-1) shapes differently from C6/36 cells of Aedes albopictus mosquito which serves as the vector of ZIKV infection.", [["foreskin fibroblast cells", "ANATOMY", 59, 84], ["HFF-1", "ANATOMY", 86, 91], ["C6/36 cells", "ANATOMY", 117, 128], ["infection", "DISEASE", 193, 202], ["Zika virus", "ORGANISM", 0, 10], ["human", "ORGANISM", 53, 58], ["foreskin fibroblast cells", "CELL", 59, 84], ["HFF-1", "CELL", 86, 91], ["C6/36 cells", "CELL", 117, 128], ["Aedes albopictus mosquito", "ORGANISM", 132, 157], ["ZIKV", "ORGANISM", 188, 192], ["human foreskin fibroblast cells", "CELL_TYPE", 53, 84], ["C6/36 cells", "CELL_LINE", 117, 128], ["Zika virus", "SPECIES", 0, 10], ["human", "SPECIES", 53, 58], ["Aedes albopictus", "SPECIES", 132, 148], ["Zika virus", "SPECIES", 0, 10], ["ZIKV", "SPECIES", 12, 16], ["human", "SPECIES", 53, 58], ["Aedes albopictus", "SPECIES", 132, 148], ["ZIKV", "SPECIES", 188, 192], ["Zika virus", "PROBLEM", 0, 10], ["human foreskin fibroblast cells", "PROBLEM", 53, 84], ["HFF", "TEST", 86, 89], ["Aedes albopictus mosquito", "PROBLEM", 132, 157], ["ZIKV infection", "PROBLEM", 188, 202], ["metabolic reprogramming", "OBSERVATION", 26, 49], ["human foreskin", "ANATOMY", 53, 67], ["fibroblast cells", "OBSERVATION", 68, 84], ["ZIKV infection", "OBSERVATION", 188, 202]]], ["Glucose influx has been increased through glycolysis in both the cases, however, it is mainly diverted toward tricarboxylic acid (TCA) cycle and amino acid synthesis in human cells whereas glucose contribution to TCA cycle gets reduced to augment the intermediates of pentose phosphate pathway in mosquito cells.", [["cells", "ANATOMY", 175, 180], ["cells", "ANATOMY", 306, 311], ["Glucose", "CHEMICAL", 0, 7], ["tricarboxylic acid", "CHEMICAL", 110, 128], ["TCA", "CHEMICAL", 130, 133], ["amino acid", "CHEMICAL", 145, 155], ["glucose", "CHEMICAL", 189, 196], ["TCA", "CHEMICAL", 213, 216], ["pentose phosphate", "CHEMICAL", 268, 285], ["Glucose", "CHEMICAL", 0, 7], ["tricarboxylic acid", "CHEMICAL", 110, 128], ["TCA", "CHEMICAL", 130, 133], ["amino acid", "CHEMICAL", 145, 155], ["glucose", "CHEMICAL", 189, 196], ["TCA", "CHEMICAL", 213, 216], ["pentose phosphate", "CHEMICAL", 268, 285], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 110, 128], ["TCA", "SIMPLE_CHEMICAL", 130, 133], ["amino acid", "AMINO_ACID", 145, 155], ["human", "ORGANISM", 169, 174], ["cells", "CELL", 175, 180], ["glucose", "SIMPLE_CHEMICAL", 189, 196], ["TCA", "SIMPLE_CHEMICAL", 213, 216], ["pentose", "SIMPLE_CHEMICAL", 268, 275], ["mosquito cells", "CELL", 297, 311], ["human cells", "CELL_TYPE", 169, 180], ["mosquito cells", "CELL_TYPE", 297, 311], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 169, 174], ["Glucose influx", "TEST", 0, 14], ["tricarboxylic acid (TCA) cycle", "TREATMENT", 110, 140], ["amino acid synthesis in human cells", "TREATMENT", 145, 180], ["glucose", "TEST", 189, 196], ["TCA cycle", "PROBLEM", 213, 222], ["pentose phosphate pathway", "TREATMENT", 268, 293], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["mosquito cells", "OBSERVATION", 297, 311]]], ["Further, ZIKV infection depletes ATP level in HFF-1 cells leading to elevated AMPK phosphorylation and increased caspase-mediated cell death whereas neither such increase in AMP/ATP and ADP/ATP ratios as well as AMPK phosphorylation nor decreased cell viability has been evidenced in infected C6/36 mosquito cells.", [["HFF-1 cells", "ANATOMY", 46, 57], ["cell", "ANATOMY", 130, 134], ["cell", "ANATOMY", 247, 251], ["C6/36 mosquito cells", "ANATOMY", 293, 313], ["infection", "DISEASE", 14, 23], ["ATP", "CHEMICAL", 33, 36], ["death", "DISEASE", 135, 140], ["AMP", "CHEMICAL", 174, 177], ["ATP", "CHEMICAL", 178, 181], ["ADP", "CHEMICAL", 186, 189], ["ATP", "CHEMICAL", 190, 193], ["ATP", "CHEMICAL", 33, 36], ["AMP", "CHEMICAL", 174, 177], ["ATP", "CHEMICAL", 178, 181], ["ADP", "CHEMICAL", 186, 189], ["ATP", "CHEMICAL", 190, 193], ["ZIKV", "GENE_OR_GENE_PRODUCT", 9, 13], ["ATP", "SIMPLE_CHEMICAL", 33, 36], ["HFF-1 cells", "CELL", 46, 57], ["AMPK", "GENE_OR_GENE_PRODUCT", 78, 82], ["caspase", "GENE_OR_GENE_PRODUCT", 113, 120], ["cell", "CELL", 130, 134], ["AMP", "SIMPLE_CHEMICAL", 174, 177], ["ATP", "SIMPLE_CHEMICAL", 178, 181], ["ADP", "SIMPLE_CHEMICAL", 186, 189], ["ATP", "SIMPLE_CHEMICAL", 190, 193], ["AMPK", "GENE_OR_GENE_PRODUCT", 212, 216], ["cell", "CELL", 247, 251], ["C6/36 mosquito cells", "CELL", 293, 313], ["HFF-1 cells", "CELL_LINE", 46, 57], ["AMPK", "PROTEIN", 78, 82], ["caspase", "PROTEIN", 113, 120], ["AMPK", "PROTEIN", 212, 216], ["infected C6/36 mosquito cells", "CELL_LINE", 284, 313], ["ZIKV", "SPECIES", 9, 13], ["ZIKV infection depletes", "PROBLEM", 9, 32], ["ATP level", "TEST", 33, 42], ["HFF", "TEST", 46, 49], ["elevated AMPK phosphorylation", "PROBLEM", 69, 98], ["increased caspase", "PROBLEM", 103, 120], ["mediated cell death", "PROBLEM", 121, 140], ["AMP/ATP", "TEST", 174, 181], ["ADP/ATP ratios", "TEST", 186, 200], ["AMPK phosphorylation", "TEST", 212, 232], ["decreased cell viability", "PROBLEM", 237, 261], ["infected C6/36 mosquito cells", "PROBLEM", 284, 313], ["AMPK phosphorylation", "OBSERVATION", 78, 98], ["cell death", "OBSERVATION", 130, 140], ["decreased cell viability", "OBSERVATION", 237, 261], ["infected", "OBSERVATION_MODIFIER", 284, 292], ["C6", "ANATOMY", 293, 295], ["mosquito cells", "OBSERVATION", 299, 313]]], ["Such difference in cell viability may be contributed by both altered pentose phosphate pathway and AMPK activation (Thaker et al., 2019).", [["cell", "ANATOMY", 19, 23], ["pentose phosphate", "CHEMICAL", 69, 86], ["pentose phosphate", "CHEMICAL", 69, 86], ["cell", "CELL", 19, 23], ["pentose", "SIMPLE_CHEMICAL", 69, 76], ["AMPK", "GENE_OR_GENE_PRODUCT", 99, 103], ["AMPK", "PROTEIN", 99, 103], ["Such difference in cell viability", "PROBLEM", 0, 33], ["both altered pentose phosphate pathway", "PROBLEM", 56, 94], ["cell viability", "OBSERVATION", 19, 33], ["pentose phosphate", "OBSERVATION", 69, 86]]], ["So metabolic introspection is not only capable of elucidating virus-host interaction but also provides information regarding maintenance and propagation of virus through their arthropod vectors.", [["virus through their arthropod vectors", "TREATMENT", 156, 193]]], ["Understanding of lifecycle of such viruses exploiting metabolic pathways within arthropod vectors can assist to design strategies for preventing their transmission in vertebrate hosts.Metabolomic Insight at Virus-Host Interface to Combat Emerging VirusesConsiderable numbers of researches have followed such path providing metabolomic insight at virus-host interface.", [["such viruses", "PROBLEM", 30, 42], ["arthropod vectors", "TREATMENT", 80, 97], ["design strategies", "TREATMENT", 112, 129], ["Metabolomic Insight at Virus", "PROBLEM", 184, 212], ["host interface", "OBSERVATION", 352, 366]]], ["Chromatography (LC/GC) coupled with tandem mass spectrometry (MS/MS) is the most common method employed for metabolomics introspection followed by NMR, FTIR and fluorescence based methods (Table 1).", [["Chromatography", "TEST", 0, 14], ["LC/GC)", "TEST", 16, 22], ["tandem mass spectrometry", "PROBLEM", 36, 60], ["MS/MS", "PROBLEM", 62, 67], ["metabolomics introspection", "TEST", 108, 134], ["NMR", "TEST", 147, 150], ["FTIR", "TEST", 152, 156]]], ["Most of these experiments have reached upto the level of cell line but significant penetration at single cell level is yet to be achieved in terms of SCM analysis in the context of virus-host interaction.", [["cell line", "ANATOMY", 57, 66], ["cell", "ANATOMY", 105, 109], ["cell line", "CELL", 57, 66], ["single cell", "CELL", 98, 109], ["cell line", "CELL_LINE", 57, 66], ["cell line", "TREATMENT", 57, 66], ["significant penetration at single cell level", "PROBLEM", 71, 115], ["SCM analysis", "TEST", 150, 162], ["cell line", "OBSERVATION", 57, 66], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["penetration", "OBSERVATION", 83, 94]]], ["But single-cell analysis may elucidate far precise information regarding viral replication and infection kinetics which is beyond the capacity of population study (Guo et al., 2017).", [["cell", "ANATOMY", 11, 15], ["infection", "DISEASE", 95, 104], ["single-cell analysis", "TEST", 4, 24], ["viral replication", "PROBLEM", 73, 90], ["infection kinetics", "PROBLEM", 95, 113], ["population study", "TEST", 146, 162], ["infection", "OBSERVATION", 95, 104]]], ["A high-throughput, microfluidics-based platform has been devised to perform kinetic analysis of green fluorescence protein (GFP) tagged polio virus (PV) infections in individual HeLa S3 cells.", [["HeLa S3 cells", "ANATOMY", 178, 191], ["infections", "DISEASE", 153, 163], ["green fluorescence protein", "GENE_OR_GENE_PRODUCT", 96, 122], ["GFP", "GENE_OR_GENE_PRODUCT", 124, 127], ["polio virus", "ORGANISM", 136, 147], ["HeLa S3 cells", "CELL", 178, 191], ["green fluorescence protein", "PROTEIN", 96, 122], ["GFP", "PROTEIN", 124, 127], ["HeLa S3 cells", "CELL_LINE", 178, 191], ["polio virus", "SPECIES", 136, 147], ["polio virus", "SPECIES", 136, 147], ["PV", "SPECIES", 149, 151], ["kinetic analysis", "TEST", 76, 92], ["green fluorescence protein", "TEST", 96, 122], ["GFP", "TEST", 124, 127], ["tagged polio virus (PV) infections in individual HeLa S3 cells", "PROBLEM", 129, 191], ["high", "OBSERVATION_MODIFIER", 2, 6], ["HeLa S3 cells", "OBSERVATION", 178, 191]]], ["Monitoring of fluorescence intensity has revealed marked variation in viral replication and infection cycle in each of the GFP-PV infected cells which are uniquely and independently controlled by viral as well as the cellular factors.", [["cells", "ANATOMY", 139, 144], ["cellular", "ANATOMY", 217, 225], ["infection", "DISEASE", 92, 101], ["GFP", "GENE_OR_GENE_PRODUCT", 123, 126], ["cells", "CELL", 139, 144], ["cellular", "CELL", 217, 225], ["GFP-PV infected cells", "CELL_LINE", 123, 144], ["cellular factors", "PROTEIN", 217, 233], ["PV", "SPECIES", 127, 129], ["Monitoring of fluorescence intensity", "TEST", 0, 36], ["marked variation", "PROBLEM", 50, 66], ["viral replication", "TREATMENT", 70, 87], ["infection cycle", "PROBLEM", 92, 107], ["the GFP", "TEST", 119, 126], ["PV infected cells", "PROBLEM", 127, 144], ["marked", "OBSERVATION_MODIFIER", 50, 56], ["variation", "OBSERVATION_MODIFIER", 57, 66], ["viral replication", "OBSERVATION", 70, 87], ["infection", "OBSERVATION", 92, 101], ["PV", "ANATOMY", 127, 129], ["infected cells", "OBSERVATION", 130, 144]]], ["The time of onset of viral replication varied significantly among the individual infected cells.", [["cells", "ANATOMY", 90, 95], ["cells", "CELL", 90, 95], ["infected cells", "CELL_TYPE", 81, 95], ["viral replication", "PROBLEM", 21, 38], ["the individual infected cells", "PROBLEM", 66, 95], ["viral replication", "OBSERVATION", 21, 38], ["infected cells", "OBSERVATION", 81, 95]]], ["Similar cellular-factor regulated variable pattern has continued to follow throughout the viral infection cycle upto the cell lysis.", [["cellular", "ANATOMY", 8, 16], ["cell", "ANATOMY", 121, 125], ["infection", "DISEASE", 96, 105], ["cellular", "CELL", 8, 16], ["cell", "CELL", 121, 125], ["cellular-factor", "PROTEIN", 8, 23], ["the viral infection cycle", "PROBLEM", 86, 111], ["the cell lysis", "TREATMENT", 117, 131], ["factor regulated", "OBSERVATION", 17, 33], ["variable", "OBSERVATION_MODIFIER", 34, 42], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["infection", "OBSERVATION", 96, 105], ["cell lysis", "OBSERVATION", 121, 131]]], ["The analysis at single cell level has unearthed plethora of valuable information regarding virulence determinants and mechanisms of drug action which have been escaped in population methods (Guo et al., 2017).", [["cell", "ANATOMY", 23, 27], ["single cell", "CELL", 16, 27], ["The analysis", "TEST", 0, 12], ["virulence determinants", "PROBLEM", 91, 113], ["drug action", "PROBLEM", 132, 143]]], ["The mentioned evidence is extremely useful to justify the value of single cell techniques over population measurements and several such SCM introspection at virus-host interface may follow the path in near future.", [["cell", "ANATOMY", 74, 78], ["cell", "CELL", 74, 78], ["single cell techniques", "TREATMENT", 67, 89], ["population measurements", "TEST", 95, 118]]], ["It will not only surmount the heterogeneity issue of samples otherwise succumb to superimposed results but also help to identify the effect of mutation both in virus as well as host, virus homing affinity toward cell types, post-infection survival, progression of disease etc. Although SCM analyses have its own advantage but it must be complemented by the bulk metabolomic analyses of the infected tissue or organ because cell-to-cell communication may have crucial effect in virus infection cycle which may not be reflected in SCM analyses.", [["samples", "ANATOMY", 53, 60], ["cell", "ANATOMY", 212, 216], ["tissue", "ANATOMY", 399, 405], ["organ", "ANATOMY", 409, 414], ["cell", "ANATOMY", 423, 427], ["cell", "ANATOMY", 431, 435], ["infection", "DISEASE", 483, 492], ["samples", "CANCER", 53, 60], ["cell", "CELL", 212, 216], ["tissue", "TISSUE", 399, 405], ["organ", "ORGAN", 409, 414], ["cell", "CELL", 423, 427], ["cell", "CELL", 431, 435], ["mutation both in virus", "PROBLEM", 143, 165], ["disease etc", "PROBLEM", 264, 275], ["SCM analyses", "PROBLEM", 286, 298], ["the bulk metabolomic analyses", "TEST", 353, 382], ["the infected tissue", "PROBLEM", 386, 405], ["crucial effect in virus infection cycle", "PROBLEM", 459, 498], ["disease", "OBSERVATION", 264, 271], ["infected", "OBSERVATION", 390, 398], ["virus infection", "OBSERVATION", 477, 492], ["may not be", "UNCERTAINTY", 505, 515]]], ["Thus a combinatorial approach is more beneficial over a standalone SCM introspection so that the real reflection of cellular heterogeneity at virus-host interface as well as the influence of cell communication can be elucidated precisely.", [["cellular", "ANATOMY", 116, 124], ["cell", "ANATOMY", 191, 195], ["cellular", "CELL", 116, 124], ["cell", "CELL", 191, 195], ["a combinatorial approach", "TREATMENT", 5, 29], ["a standalone SCM introspection", "TREATMENT", 54, 84], ["cellular heterogeneity at virus-host interface", "PROBLEM", 116, 162], ["cell communication", "TREATMENT", 191, 209], ["cellular", "OBSERVATION_MODIFIER", 116, 124], ["heterogeneity", "OBSERVATION", 125, 138], ["host interface", "OBSERVATION", 148, 162], ["cell communication", "OBSERVATION", 191, 209]]], ["The specific information extracted from such analyses like mutation study along with computational modeling may assist in future vaccine formulation, mapping of virus evolution strategy to identify the potential hot-spots of novel viral emergence, their virulence and putative contentment recipes.Metabolomic Insight at Virus-Host Interface to Combat Emerging VirusesHowever, the inherent challenges of SCM techniques require to be surmounted with diligence and passion for proper utilization of the potential of single-cell analyses.", [["cell", "ANATOMY", 520, 524], ["cell", "CELL", 520, 524], ["such analyses", "TEST", 40, 53], ["mutation study", "TEST", 59, 73], ["computational modeling", "TREATMENT", 85, 107], ["future vaccine formulation", "TREATMENT", 122, 148], ["virus evolution strategy", "TREATMENT", 161, 185], ["novel viral emergence", "PROBLEM", 225, 246], ["putative contentment recipes", "TREATMENT", 268, 296], ["Emerging Viruses", "PROBLEM", 351, 367], ["SCM techniques", "TREATMENT", 403, 417], ["single-cell analyses", "TEST", 513, 533], ["Viruses", "OBSERVATION", 360, 367]]], ["The difficulty in single cell isolation along with rapid turnover, transport and degradation of the cellular metabolites are the key challenges of SCM analyses.", [["cell", "ANATOMY", 25, 29], ["cellular", "ANATOMY", 100, 108], ["cell", "CELL", 25, 29], ["cellular", "CELL", 100, 108], ["single cell isolation", "TREATMENT", 18, 39], ["rapid turnover", "PROBLEM", 51, 65], ["the cellular metabolites", "PROBLEM", 96, 120], ["SCM analyses", "TEST", 147, 159]]], ["Rapid metabolite turnover can produce random noise which may create analytical error and difficulty in differentiating infected cells from the healthy one.", [["cells", "ANATOMY", 128, 133], ["cells", "CELL", 128, 133], ["infected cells", "CELL_TYPE", 119, 133], ["Rapid metabolite turnover", "PROBLEM", 0, 25], ["random noise", "PROBLEM", 38, 50], ["analytical error", "PROBLEM", 68, 84], ["difficulty in differentiating infected cells", "PROBLEM", 89, 133], ["infected cells", "OBSERVATION", 119, 133]]], ["Thus normalization of such random error must be performed during the experimental set-up for SCM data acquisition to differentiate the deterministic effects from the stochastic one.", [["such random error", "PROBLEM", 22, 39], ["SCM data acquisition", "TEST", 93, 113]]], ["Similar type of random fluorescence noise normalization has been performed by Guo et al. (2017) during GFP-PV infected single-cell analyses.", [["cell", "ANATOMY", 126, 130], ["GFP", "GENE_OR_GENE_PRODUCT", 103, 106], ["single-cell", "CELL", 119, 130], ["PV", "SPECIES", 107, 109], ["random fluorescence noise", "TEST", 16, 41], ["GFP", "TEST", 103, 106], ["PV", "ANATOMY", 107, 109], ["infected", "OBSERVATION", 110, 118], ["cell", "OBSERVATION", 126, 130]]], ["Further dealing with minute sample volume, diverse types of metabolites and their femto-molar range concentration demands high sensitivity and throughput of the analytical platform which is essential particularly for SCM analyses.", [["sample", "ANATOMY", 28, 34], ["minute sample volume", "TEST", 21, 41], ["metabolites", "TEST", 60, 71], ["high sensitivity", "PROBLEM", 122, 138], ["the analytical platform", "TEST", 157, 180], ["SCM analyses", "TEST", 217, 229]]], ["For example, NMR is extremely robust, reliable, requiring minimal sample processing and commonly employed metabolomics analysis platform for population study but low sensitivity has limited the utility of the technique for SCM analyses.", [["minimal sample processing", "TEST", 58, 83], ["metabolomics analysis", "TEST", 106, 127], ["population study", "TEST", 141, 157], ["low sensitivity", "PROBLEM", 162, 177], ["the technique", "TEST", 205, 218], ["SCM analyses", "TEST", 223, 235], ["extremely", "OBSERVATION_MODIFIER", 20, 29], ["robust", "OBSERVATION_MODIFIER", 30, 36]]], ["Proper analyses of SCM data is another crucial challenge which has been eased out significantly with recent advances in bioinformatics tools and growing metabolite database (Minakshi et al., 2019a).", [["bioinformatics tools", "TEST", 120, 140]]], ["Moreover, integration of SCM with single-cell proteomics, transcriptomics, genomics and interactomics can provide a whole-some image of the life processes which may assist to explore the biological missing links regarding virus infection and transmission cycle.ConclusionRapid development in single cell isolation and handling methods, persistent improvement in sensitivity and resolution of the analytical platforms along with growing database and data interpretation programs are smoothening the hurdles of SCM to introduce it at the virus-host interface as early as possible.", [["cell", "ANATOMY", 41, 45], ["cell", "ANATOMY", 299, 303], ["infection", "DISEASE", 228, 237], ["cell", "CELL", 41, 45], ["cell", "CELL", 299, 303], ["single-cell proteomics", "TREATMENT", 34, 56], ["virus infection", "PROBLEM", 222, 237], ["single cell isolation", "TREATMENT", 292, 313], ["handling methods", "TREATMENT", 318, 334], ["sensitivity", "TEST", 362, 373], ["the analytical platforms", "TEST", 392, 416], ["growing database", "TEST", 428, 444], ["SCM", "ANATOMY", 25, 28], ["single cell isolation", "OBSERVATION", 292, 313], ["persistent", "OBSERVATION_MODIFIER", 336, 346], ["improvement", "OBSERVATION_MODIFIER", 347, 358]]], ["The SCM derived precise information regarding the altered metabolism of infected cell over the healthy cells may assist to investigate the virulence, survival, and progression of diseases.", [["cell", "ANATOMY", 81, 85], ["cells", "ANATOMY", 103, 108], ["cell", "CELL", 81, 85], ["cells", "CELL", 103, 108], ["infected cell", "CELL_TYPE", 72, 85], ["healthy cells", "CELL_TYPE", 95, 108], ["infected cell", "PROBLEM", 72, 85], ["the virulence", "PROBLEM", 135, 148], ["diseases", "PROBLEM", 179, 187], ["infected cell", "OBSERVATION", 72, 85], ["progression", "OBSERVATION_MODIFIER", 164, 175], ["diseases", "OBSERVATION", 179, 187]]], ["The exploration of cellular heterogeneity can illuminate the aspects which remain concealed in population study.", [["cellular", "ANATOMY", 19, 27], ["cellular", "CELL", 19, 27], ["cellular heterogeneity", "PROBLEM", 19, 41], ["population study", "TEST", 95, 111], ["cellular heterogeneity", "OBSERVATION", 19, 41]]], ["Thus SCM holds the promise as a key tool of future to introspect virus-host interaction and assist in efficient management of emerging viral disease.Author ContributionsMP and MG conceptualized the manuscript.", [["viral disease", "DISEASE", 135, 148], ["emerging viral disease", "PROBLEM", 126, 148], ["viral disease", "OBSERVATION", 135, 148]]], ["MP critically analyzed and improved the manuscript.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["MP", "GENE_OR_GENE_PRODUCT", 0, 2], ["improved", "OBSERVATION_MODIFIER", 27, 35]]]], "6715010f2a6cffd895f81a69598772b840d26fd5": [["25To better understand the genetic diversity, host association and evolution of coronaviruses 26 (CoVs) in China we analyzed a total of 696 rodents encompassing 16 different species 27 sampled from Zhejiang and Yunnan provinces.", [["coronaviruses 26", "ORGANISM", 80, 96], ["coronaviruses", "PROBLEM", 80, 93]]], ["Based on the reverse transcriptase PCR-based 28 CoV screening CoVs of fecal samples and subsequent sequence analysis of the RdRp gene, 29 we identified CoVs in diverse rodent species, comprising Apodemus agrarius, Apodemus 30 latronum, Bandicota indica, Eothenomys miletus, E. eleusis, Rattus andamanesis, Rattus 31 norvegicus, and R. tanezumi.", [["fecal samples", "ANATOMY", 70, 83], ["fecal samples", "CANCER", 70, 83], ["CoVs", "GENE_OR_GENE_PRODUCT", 152, 156], ["Apodemus agrarius", "ORGANISM", 195, 212], ["Apodemus 30 latronum", "ORGANISM", 214, 234], ["Bandicota indica", "ORGANISM", 236, 252], ["Eothenomys miletus", "ORGANISM", 254, 272], ["E. eleusis", "ORGANISM", 274, 284], ["Rattus andamanesis", "ORGANISM", 286, 304], ["Rattus 31 norvegicus", "ORGANISM", 306, 326], ["R. tanezumi", "ORGANISM", 332, 343], ["reverse transcriptase", "PROTEIN", 13, 34], ["CoVs", "DNA", 62, 66], ["RdRp gene", "DNA", 124, 133], ["CoVs", "DNA", 152, 156], ["rodent", "SPECIES", 168, 174], ["Apodemus agrarius", "SPECIES", 195, 212], ["Apodemus 30 latronum", "SPECIES", 214, 234], ["Bandicota indica", "SPECIES", 236, 252], ["Eothenomys miletus", "SPECIES", 254, 272], ["E. eleusis", "SPECIES", 274, 284], ["Rattus andamanesis", "SPECIES", 286, 304], ["Rattus 31 norvegicus", "SPECIES", 306, 326], ["R. tanezumi", "SPECIES", 332, 343], ["CoV", "SPECIES", 48, 51], ["Apodemus agrarius", "SPECIES", 195, 212], ["Apodemus 30 latronum", "SPECIES", 214, 234], ["Bandicota indica", "SPECIES", 236, 252], ["Eothenomys miletus", "SPECIES", 254, 272], ["E. eleusis", "SPECIES", 274, 284], ["Rattus andamanesis", "SPECIES", 286, 304], ["Rattus 31 norvegicus", "SPECIES", 306, 326], ["R. tanezumi", "SPECIES", 332, 343], ["the reverse transcriptase PCR", "TEST", 9, 38], ["CoV screening CoVs", "TEST", 48, 66], ["fecal samples", "TEST", 70, 83], ["subsequent sequence analysis", "TEST", 88, 116], ["CoVs in diverse rodent species", "PROBLEM", 152, 182], ["E. eleusis", "PROBLEM", 274, 284], ["Rattus andamanesis", "PROBLEM", 286, 304], ["fecal", "ANATOMY", 70, 75], ["diverse rodent species", "OBSERVATION", 160, 182], ["Apodemus agrarius", "OBSERVATION", 195, 212], ["tanezumi", "ANATOMY", 335, 343]]], ["Apodemus chevrieri was a particularly rich host, harboring 25 32 rodent CoVs.", [["Apodemus chevrieri", "ORGANISM", 0, 18], ["CoVs", "CANCER", 72, 76], ["Apodemus chevrieri", "SPECIES", 0, 18], ["rodent", "SPECIES", 65, 71], ["Apodemus chevrieri", "SPECIES", 0, 18]]], ["Genetic and phylogenetic analysis revealed the presence of three groups of 33 CoVs carried by a range of rodents that were closely related to the Lucheng Rn rat 34 coronavirus (LRNV), China Rattus coronavirus HKU24 (ChRCoV_HKU24) and Longquan 35 Rl rat coronavirus (LRLV) identified previously.", [["CoVs", "GENE_OR_GENE_PRODUCT", 78, 82], ["rodents", "ORGANISM", 105, 112], ["Lucheng Rn rat 34 coronavirus", "ORGANISM", 146, 175], ["LRNV", "ORGANISM", 177, 181], ["China", "ORGANISM", 184, 189], ["Rattus coronavirus", "ORGANISM", 190, 208], ["HKU24", "ORGANISM", 209, 214], ["ChRCoV_HKU24", "GENE_OR_GENE_PRODUCT", 216, 228], ["Longquan 35 Rl rat coronavirus", "ORGANISM", 234, 264], ["LRLV", "CANCER", 266, 270], ["CoVs", "DNA", 78, 82], ["rat", "SPECIES", 157, 160], ["34 coronavirus", "SPECIES", 161, 175], ["Rattus coronavirus", "SPECIES", 190, 208], ["rat", "SPECIES", 249, 252], ["coronavirus", "SPECIES", 253, 264], ["Lucheng Rn rat 34 coronavirus", "SPECIES", 146, 175], ["LRNV", "SPECIES", 177, 181], ["China Rattus coronavirus", "SPECIES", 184, 208], ["Longquan 35 Rl rat coronavirus", "SPECIES", 234, 264], ["LRLV", "SPECIES", 266, 270], ["phylogenetic analysis", "TEST", 12, 33], ["33 CoVs", "PROBLEM", 75, 82], ["coronavirus", "PROBLEM", 164, 175], ["China Rattus coronavirus", "TEST", 184, 208], ["Longquan", "TEST", 234, 242]]], ["One newly identified A. 36 chevrieri-associated virus closely related to LRNV lacked an NS2 gene.", [["A. 36 chevrieri", "ORGANISM", 21, 36], ["LRNV", "CANCER", 73, 77], ["NS2", "GENE_OR_GENE_PRODUCT", 88, 91], ["LRNV", "DNA", 73, 77], ["NS2 gene", "DNA", 88, 96], ["A. 36 chevrieri", "SPECIES", 21, 36], ["A. 36 chevrieri", "SPECIES", 21, 36], ["LRNV", "SPECIES", 73, 77], ["A. 36 chevrieri-associated virus", "PROBLEM", 21, 53], ["LRNV", "TREATMENT", 73, 77], ["virus", "OBSERVATION", 48, 53], ["NS2 gene", "OBSERVATION", 88, 96]]], ["This virus had a 37 similar genetic organization to AcCoV-JC34, recently discovered in the same rodent species 38 in Yunnan, suggesting that it represents a new viral subtype.", [["AcCoV-JC34", "GENE_OR_GENE_PRODUCT", 52, 62], ["AcCoV", "DNA", 52, 57], ["JC34", "DNA", 58, 62], ["This virus", "PROBLEM", 0, 10], ["a new viral subtype", "PROBLEM", 155, 174], ["suggesting that it represents", "UNCERTAINTY", 125, 154], ["new", "OBSERVATION_MODIFIER", 157, 160], ["viral subtype", "OBSERVATION", 161, 174]]], ["Introduction played a key role in coronavirus evolution and emergence.", [["coronavirus", "ORGANISM", 34, 45], ["coronavirus", "OBSERVATION", 34, 45]]], ["77 Zhejiang province is located in the southern part of the Yangtze River Delta on the 78 southeast coast of China, from where rodent CoVs have previously been reported (Wang et al. 79 2015; Lin et al. 2017) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 134, 138], ["rodent", "SPECIES", 127, 133]]], ["A 81 previous study from Yunnan provide identified a novel SARS-like CoV, 82 Rs-betacoronavirus/Yunnan2013, whose ORF8 was nearly identical to ORF8 of SARS-CoVs 83 (98% nt sequence identities) (Wu et al. 2016 The best-fit model of nucleotide substitution was determined using jModelTest version 0.ResultsLijiang city, Ruili city, Yunnan province and Longquan city, Wenzhou city, Zhejiang province ( Figure 1 and three species of rodent-borne coronavirus.", [["SARS", "DISEASE", 59, 63], ["SARS", "DISEASE", 151, 155], ["nucleotide", "CHEMICAL", 231, 241], ["rodent-borne coronavirus", "DISEASE", 429, 453], ["nucleotide", "CHEMICAL", 231, 241], ["SARS-like CoV", "ORGANISM", 59, 72], ["Rs-betacoronavirus", "ORGANISM", 77, 95], ["Yunnan2013", "GENE_OR_GENE_PRODUCT", 96, 106], ["ORF8", "GENE_OR_GENE_PRODUCT", 114, 118], ["ORF8", "GENE_OR_GENE_PRODUCT", 143, 147], ["rodent-borne coronavirus", "ORGANISM", 429, 453], ["betacoronavirus", "DNA", 80, 95], ["Yunnan2013", "DNA", 96, 106], ["ORF8", "DNA", 114, 118], ["ORF8", "DNA", 143, 147], ["SARS-CoVs 83", "DNA", 151, 163], ["rodent-borne coronavirus", "SPECIES", 429, 453], ["SARS-CoVs 83", "SPECIES", 151, 163], ["rodent-borne coronavirus", "SPECIES", 429, 453], ["previous study", "TEST", 5, 19], ["a novel SARS-like CoV", "PROBLEM", 51, 72], ["Rs", "TEST", 77, 79], ["SARS", "TEST", 151, 155], ["CoVs", "TEST", 156, 160], ["nt sequence identities", "TEST", 169, 191], ["nucleotide substitution", "TREATMENT", 231, 254], ["jModel", "TREATMENT", 276, 282], ["Test version", "TEST", 282, 294]]], ["This is in contrast to previous studies in which 193 individual CoVs were associated with a single species or genera, including Carollia, 194 Eptesicus, Miniopterus, Scotophilus, and Rhinolipus bats (Anthony et al.2013; Drexler et 195 al.2010; Fischer et al.2016; Wacharapluesadee et al. 2015) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 64, 68], ["Rhinolipus bats", "ORGANISM", 183, 198], ["Rhinolipus bats", "SPECIES", 183, 198], ["previous studies", "TEST", 23, 39], ["individual CoVs", "PROBLEM", 53, 68], ["a single species", "PROBLEM", 90, 106], ["genera", "PROBLEM", 110, 116], ["Carollia", "PROBLEM", 128, 136], ["Rhinolipus bats", "OBSERVATION", 183, 198]]], ["RtClan-CoV/GZ2015 and RtMruf-CoV-1/JL2014 and contains two putative non-structural 218 proteins -NS2 and NS2blocated between the ORF1ab and S gene.", [["RtClan-CoV", "GENE_OR_GENE_PRODUCT", 0, 10], ["GZ2015", "GENE_OR_GENE_PRODUCT", 11, 17], ["RtMruf-CoV-1", "GENE_OR_GENE_PRODUCT", 22, 34], ["NS2", "GENE_OR_GENE_PRODUCT", 105, 108], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 129, 135], ["RtClan-CoV", "PROTEIN", 0, 10], ["GZ2015", "PROTEIN", 11, 17], ["RtMruf", "PROTEIN", 22, 28], ["CoV", "PROTEIN", 29, 32], ["JL2014", "DNA", 35, 41], ["non-structural 218 proteins", "PROTEIN", 68, 95], ["NS2", "PROTEIN", 97, 100], ["NS2", "PROTEIN", 105, 108], ["ORF1ab and S gene", "DNA", 129, 146], ["RtClan-CoV", "TEST", 0, 10], ["RtMruf", "TEST", 22, 28], ["CoV", "TEST", 29, 32], ["NS2", "TREATMENT", 97, 100], ["NS2", "TREATMENT", 105, 108]]], ["The putative NS2 gene 219 of the third variant is 828 nt in length, with 82.9-88.9% sequence identity.", [["NS2 gene 219", "DNA", 13, 25], ["length", "TEST", 60, 66]]], ["Similarly, the 220 putative NS2b has a gene length of 462 nt and exhibits 77.5-96.3% sequence identity among 221 these three viruses.", [["NS2b", "GENE_OR_GENE_PRODUCT", 28, 32], ["220 putative NS2b", "DNA", 15, 32], ["a gene length", "TEST", 37, 50], ["nt", "TEST", 58, 60]]], ["Strikingly, a blastp search reveals that the NS2b encodes a putative 222 nonstructural protein of 153 amino acid residues in length that has no amino acid sequence 223 similarity to other coronaviruses; rather, this sequence exhibits ~43% amino acid identity to 224 the C-type lectin-like protein within the rodent Microtus ochrogaster genome.", [["amino acid", "CHEMICAL", 102, 112], ["amino acid", "CHEMICAL", 144, 154], ["amino acid", "CHEMICAL", 239, 249], ["amino acid", "CHEMICAL", 102, 112], ["amino acid", "CHEMICAL", 144, 154], ["amino acid", "CHEMICAL", 239, 249], ["NS2b", "GENE_OR_GENE_PRODUCT", 45, 49], ["amino acid", "AMINO_ACID", 102, 112], ["amino acid", "AMINO_ACID", 144, 154], ["amino acid", "AMINO_ACID", 239, 249], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 270, 283], ["Microtus ochrogaster", "ORGANISM", 315, 335], ["NS2b", "DNA", 45, 49], ["222 nonstructural protein", "PROTEIN", 69, 94], ["C-type lectin-like protein", "PROTEIN", 270, 296], ["rodent Microtus ochrogaster genome", "DNA", 308, 342], ["rodent", "SPECIES", 308, 314], ["Microtus ochrogaster", "SPECIES", 315, 335], ["Microtus ochrogaster", "SPECIES", 315, 335], ["a blastp search", "TEST", 12, 27], ["nonstructural protein", "TEST", 73, 94], ["amino acid residues in length", "PROBLEM", 102, 131], ["amino acid sequence", "TEST", 144, 163], ["other coronaviruses", "PROBLEM", 182, 201], ["this sequence", "TEST", 211, 224], ["amino acid identity", "TEST", 239, 258], ["the C-type lectin", "TEST", 266, 283], ["rodent Microtus", "OBSERVATION", 308, 323], ["ochrogaster genome", "OBSERVATION", 324, 342]]], ["Hence, this 225 pattern suggests that the NS2b gene may have originally been acquired from the host genome 226 during evolutionary history.", [["NS2b", "GENE_OR_GENE_PRODUCT", 42, 46], ["NS2b gene", "DNA", 42, 51], ["host genome 226", "DNA", 95, 110]]], ["Moreover, the amino acid sequence identity between Lijiang-170, 227 Lijiang-71, Ruian-83 and LRNV was greater than 90% in RdRp, E, and M genes (as expected 228 from members of the same species), but only 70%-88% in ADRP, 3CLpro, ORF1ab and S 229 ( Table 2 ).", [["amino acid", "CHEMICAL", 14, 24], ["Lijiang-170, 227 Lijiang-71, Ruian-83", "CHEMICAL", 51, 88], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["Ruian-83", "GENE_OR_GENE_PRODUCT", 80, 88], ["LRNV", "GENE_OR_GENE_PRODUCT", 93, 97], ["E", "GENE_OR_GENE_PRODUCT", 128, 129], ["ADRP", "GENE_OR_GENE_PRODUCT", 215, 219], ["RdRp, E, and M genes", "DNA", 122, 142], ["ADRP", "PROTEIN", 215, 219], ["3CLpro", "PROTEIN", 221, 227], ["ORF1ab", "PROTEIN", 229, 235], ["S 229", "PROTEIN", 240, 245], ["Lijiang-170", "SPECIES", 51, 62], ["Ruian-83", "SPECIES", 80, 88], ["the amino acid sequence identity", "TEST", 10, 42], ["Lijiang", "TEST", 51, 58], ["Lijiang", "TEST", 68, 75], ["Ruian", "TEST", 80, 85], ["LRNV", "TEST", 93, 97], ["RdRp", "TEST", 122, 126], ["ADRP", "TEST", 215, 219], ["3CLpro", "TEST", 221, 227], ["ORF1ab", "TEST", 229, 235], ["S", "TEST", 240, 241]]], ["Further analysis of the characteristics of Lijiang-170, for which a complete genome 230 sequence is available, shows that it has similar transcription regulatory sequence (TRS) to 231 AcCoV-JC34 (Table 3) .", [["Lijiang-170", "CHEMICAL", 43, 54], ["Lijiang-170", "GENE_OR_GENE_PRODUCT", 43, 54], ["Lijiang-170", "DNA", 43, 54], ["genome 230 sequence", "DNA", 77, 96], ["transcription regulatory sequence", "DNA", 137, 170], ["JC34", "DNA", 190, 194], ["Lijiang-170", "SPECIES", 43, 54], ["Further analysis", "TEST", 0, 16], ["Lijiang", "TEST", 43, 50], ["a complete genome 230 sequence", "TEST", 66, 96], ["AcCoV", "TEST", 184, 189]]], ["Hence, Lijiang-170 and AcCoV-JC34 may represent a novel subtype 232 of LRNV that exhibits marked differences to the prototype strain Lucheng-19.", [["Lijiang-170", "CHEMICAL", 7, 18], ["Lucheng-19", "CHEMICAL", 133, 143], ["Lijiang-170", "ORGANISM", 7, 18], ["AcCoV-JC34", "ORGANISM", 23, 33], ["LRNV", "CANCER", 71, 75], ["Lucheng-19", "ORGANISM", 133, 143], ["Lijiang-170", "SPECIES", 7, 18], ["Lucheng-19", "SPECIES", 133, 143], ["Lijiang", "TEST", 7, 14], ["LRNV", "TREATMENT", 71, 75], ["marked", "OBSERVATION_MODIFIER", 90, 96]]], ["Mi-Ba tCoV_ HKU8 L o n g q u a n -3 3 8", [["HKU8", "PROTEIN", 12, 16]]]], "2ab7c15271a9a80bd7ac4617b211afbf832e6a1a": [["| INTRODUCTIONInvestigation of cytologic specimens obtained by fine-needle aspiration (FNA) is the least invasive approach to obtain a diagnosis of disease.", [["cytologic specimens", "ANATOMY", 31, 50], ["cytologic specimens", "CANCER", 31, 50], ["cytologic specimens", "TEST", 31, 50], ["fine-needle aspiration", "TEST", 63, 85], ["disease", "PROBLEM", 148, 155], ["disease", "OBSERVATION", 148, 155]]], ["[1] [2] [3] Cytomorphology, however, can provide only limited insights into the biology of a neoplastic disorder or the etiology of an infectious process.", [["neoplastic", "ANATOMY", 93, 103], ["neoplastic disorder", "DISEASE", 93, 112], ["[3] Cytomorphology", "TEST", 8, 26], ["a neoplastic disorder", "PROBLEM", 91, 112], ["an infectious process", "PROBLEM", 132, 153], ["neoplastic", "OBSERVATION", 93, 103], ["infectious", "OBSERVATION", 135, 145]]], ["It may be necessary to combine cytomorphology with specific disease markers to elucidate the underlying disease and collect predictive data.", [["specific disease markers", "TEST", 51, 75], ["the underlying disease", "PROBLEM", 89, 111], ["collect predictive data", "TEST", 116, 139]]], ["2 In contrast to histologic investigations, which allow for multiple tissue sections that can examine individual cells, repetitive impression smears and FNA of the same tissue can by no means reproduce the same composition of cells and tissue components.", [["tissue sections", "ANATOMY", 69, 84], ["cells", "ANATOMY", 113, 118], ["tissue", "ANATOMY", 169, 175], ["cells", "ANATOMY", 226, 231], ["tissue", "ANATOMY", 236, 242], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 69, 84], ["cells", "CELL", 113, 118], ["tissue", "TISSUE", 169, 175], ["cells", "CELL", 226, 231], ["tissue", "TISSUE", 236, 242], ["histologic investigations", "TEST", 17, 42], ["multiple tissue sections", "TEST", 60, 84], ["individual cells", "PROBLEM", 102, 118], ["repetitive impression smears", "TEST", 120, 148], ["FNA", "TEST", 153, 156]]], ["2 In addition to these technologic limitations, the type and distribution of a lesion can pose essential limitations to its holistic cytologic characterization.", [["lesion", "ANATOMY", 79, 85], ["lesion", "CANCER", 79, 85], ["a lesion", "PROBLEM", 77, 85], ["its holistic cytologic characterization", "TEST", 120, 159], ["lesion", "OBSERVATION", 79, 85]]], ["Thus, detectability is compromised if the lesion is (a) poorly exfoliative and of low cellularity; (b) affecting tissues that are difficult to access (eg, the central nervous system (c) has atypical cells and pathogens that are poorly dense or scantly distributed; and (d) has cells that are highly vulnerable to shearing stress.| INTRODUCTIONTo detect changes in samples with low cellularity, multiple investigations should be carried out on the same slide rather than single investigations on multiple slides with variable cell numbers.| INTRODUCTIONThe simplest secondary procedures use conventional stains to highlight microorganisms, chemical compounds, matrix components, and subcellular structures with histochemistry after a destaining procedure.", [["lesion", "ANATOMY", 42, 48], ["tissues", "ANATOMY", 113, 120], ["central nervous system", "ANATOMY", 159, 181], ["cells", "ANATOMY", 199, 204], ["cells", "ANATOMY", 277, 282], ["samples", "ANATOMY", 364, 371], ["cell", "ANATOMY", 525, 529], ["matrix", "ANATOMY", 659, 665], ["subcellular structures", "ANATOMY", 682, 704], ["tissues", "TISSUE", 113, 120], ["central nervous system", "ANATOMICAL_SYSTEM", 159, 181], ["atypical cells", "CELL", 190, 204], ["cells", "CELL", 277, 282], ["cell", "CELL", 525, 529], ["matrix", "CELLULAR_COMPONENT", 659, 665], ["atypical cells", "CELL_TYPE", 190, 204], ["the lesion", "PROBLEM", 38, 48], ["low cellularity", "PROBLEM", 82, 97], ["atypical cells", "PROBLEM", 190, 204], ["pathogens", "PROBLEM", 209, 218], ["poorly dense", "PROBLEM", 228, 240], ["changes in samples", "PROBLEM", 353, 371], ["low cellularity", "PROBLEM", 377, 392], ["multiple investigations", "TEST", 394, 417], ["single investigations", "TEST", 470, 491], ["conventional stains", "TEST", 590, 609], ["microorganisms", "PROBLEM", 623, 637], ["chemical compounds, matrix components", "PROBLEM", 639, 676], ["a destaining procedure", "TREATMENT", 731, 753], ["lesion", "OBSERVATION", 42, 48], ["low cellularity", "OBSERVATION_MODIFIER", 82, 97], ["central", "ANATOMY_MODIFIER", 159, 166], ["nervous system", "ANATOMY", 167, 181], ["atypical cells", "OBSERVATION", 190, 204], ["pathogens", "OBSERVATION_MODIFIER", 209, 218], ["poorly", "OBSERVATION_MODIFIER", 228, 234], ["dense", "OBSERVATION_MODIFIER", 235, 240], ["low cellularity", "OBSERVATION_MODIFIER", 377, 392], ["chemical compounds", "OBSERVATION", 639, 657]]], ["With the advancement of panoptic stains, special stains have mainly focused on the assessment of microbial and fungal organisms (eg, Ziehl-Neelsen, Fite-Faraco, Gram, Fontana-Masson), mucins and polysaccharides (eg, Alcian blue, Periodic acid-Schiff), iron pigments, and melanin (eg, Prussian blue reaction, Nile blue A, Fontana-Masson).", [["Alcian blue", "CHEMICAL", 216, 227], ["acid-Schiff", "CHEMICAL", 238, 249], ["iron", "CHEMICAL", 252, 256], ["melanin", "CHEMICAL", 271, 278], ["Prussian blue", "CHEMICAL", 284, 297], ["Alcian blue", "CHEMICAL", 216, 227], ["acid-Schiff", "CHEMICAL", 238, 249], ["iron", "CHEMICAL", 252, 256], ["Prussian blue", "CHEMICAL", 284, 297], ["Gram", "SIMPLE_CHEMICAL", 161, 165], ["Fontana-Masson", "SIMPLE_CHEMICAL", 167, 181], ["mucins", "GENE_OR_GENE_PRODUCT", 184, 190], ["polysaccharides", "SIMPLE_CHEMICAL", 195, 210], ["Alcian blue", "SIMPLE_CHEMICAL", 216, 227], ["Periodic acid-Schiff", "SIMPLE_CHEMICAL", 229, 249], ["iron pigments", "SIMPLE_CHEMICAL", 252, 265], ["melanin", "SIMPLE_CHEMICAL", 271, 278], ["Prussian blue", "SIMPLE_CHEMICAL", 284, 297], ["Nile blue A", "SPECIES", 308, 319], ["panoptic stains", "TEST", 24, 39], ["special stains", "TEST", 41, 55], ["the assessment", "TEST", 79, 93], ["microbial and fungal organisms", "PROBLEM", 97, 127], ["Ziehl", "TEST", 133, 138], ["Faraco", "TREATMENT", 153, 159], ["Fontana", "TREATMENT", 167, 174], ["mucins and polysaccharides", "TREATMENT", 184, 210], ["Alcian blue", "TREATMENT", 216, 227], ["Periodic acid-Schiff)", "TREATMENT", 229, 250], ["iron pigments", "TREATMENT", 252, 265], ["melanin (eg, Prussian blue reaction", "TREATMENT", 271, 306], ["fungal organisms", "OBSERVATION", 111, 127]]], ["2 As cellular identification is rarely needed in these situations, ancillary staining often can be conducted on spare slides.", [["cellular", "ANATOMY", 5, 13], ["cellular", "CELL", 5, 13], ["ancillary staining", "TEST", 67, 85]]], ["2 Other infectious diseases and tumor cell antigens, however, could require preselection and cytomorphologic characterization of the cells to be stained.", [["tumor cell", "ANATOMY", 32, 42], ["cells", "ANATOMY", 133, 138], ["infectious diseases", "DISEASE", 8, 27], ["tumor", "DISEASE", 32, 37], ["tumor cell antigens", "CELL", 32, 51], ["cells", "CELL", 133, 138], ["tumor cell antigens", "PROTEIN", 32, 51], ["Other infectious diseases", "PROBLEM", 2, 27], ["tumor cell antigens", "TEST", 32, 51], ["cytomorphologic characterization", "TEST", 93, 125], ["the cells", "PROBLEM", 129, 138], ["infectious", "OBSERVATION_MODIFIER", 8, 18], ["tumor cell antigens", "OBSERVATION", 32, 51]]], ["2, 3 This holds true, in particular, for advanced tumor diagnoses.", [["tumor", "ANATOMY", 50, 55], ["tumor", "DISEASE", 50, 55], ["tumor", "CANCER", 50, 55], ["advanced tumor diagnoses", "PROBLEM", 41, 65], ["tumor", "OBSERVATION", 50, 55]]], ["3, 4 Immunocytochemistry (ICC) on Romansky-stained (prestained) slides (poststaining ICC, PSICC) could help identify the histogenetic origin of tumors or cell types, characterize cells that cannot be identified with conventional stains, and obtain further prognostic and predictive information.", [["tumors", "ANATOMY", 144, 150], ["cell", "ANATOMY", 154, 158], ["cells", "ANATOMY", 179, 184], ["tumors", "DISEASE", 144, 150], ["tumors", "CANCER", 144, 150], ["cell", "CELL", 154, 158], ["cells", "CELL", 179, 184], ["Romansky", "TEST", 34, 42], ["tumors", "PROBLEM", 144, 150], ["cell types", "PROBLEM", 154, 164], ["conventional stains", "TEST", 216, 235], ["tumors", "OBSERVATION", 144, 150], ["cell types", "OBSERVATION", 154, 164]]], ["3, [5] [6] [7] [8] For infectious diseases, PSICC is a promising tool for the intracellular detection of viral proteins.", [["intracellular", "ANATOMY", 78, 91], ["infectious diseases", "DISEASE", 23, 42], ["[5] [6] [7] [8", "SIMPLE_CHEMICAL", 3, 17], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["viral proteins", "PROTEIN", 105, 119], ["infectious diseases", "PROBLEM", 23, 42], ["the intracellular detection", "TEST", 74, 101], ["viral proteins", "PROBLEM", 105, 119], ["viral proteins", "OBSERVATION", 105, 119]]], ["One of the most common situations is in the detection of feline coronavirus (FCoV) for the diagnosis of feline infectious peritonitis (FIP), in which the presence of intracellular viral antigens in macrophages must be demonstrated.", [["intracellular", "ANATOMY", 166, 179], ["macrophages", "ANATOMY", 198, 209], ["feline coronavirus", "DISEASE", 57, 75], ["feline infectious peritonitis", "DISEASE", 104, 133], ["FIP", "DISEASE", 135, 138], ["feline coronavirus", "ORGANISM", 57, 75], ["FCoV", "CANCER", 77, 81], ["feline", "ORGANISM", 104, 110], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 166, 179], ["macrophages", "CELL", 198, 209], ["intracellular viral antigens", "PROTEIN", 166, 194], ["macrophages", "CELL_TYPE", 198, 209], ["feline coronavirus", "SPECIES", 57, 75], ["feline", "SPECIES", 104, 110], ["feline coronavirus", "SPECIES", 57, 75], ["FCoV", "SPECIES", 77, 81], ["feline coronavirus", "PROBLEM", 57, 75], ["feline infectious peritonitis", "PROBLEM", 104, 133], ["intracellular viral antigens in macrophages", "PROBLEM", 166, 209], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["feline", "OBSERVATION_MODIFIER", 104, 110], ["infectious", "OBSERVATION_MODIFIER", 111, 121], ["peritonitis", "OBSERVATION", 122, 133], ["intracellular", "OBSERVATION_MODIFIER", 166, 179], ["viral", "OBSERVATION", 180, 185], ["macrophages", "OBSERVATION", 198, 209]]], ["9, 10 This approach requires preservation of both the target antigen and host cell morphology.| INTRODUCTIONHistorically, PSICC methodology was tailored to individual cases.", [["cell", "ANATOMY", 78, 82], ["host cell", "CELL", 73, 82], ["This approach", "TREATMENT", 6, 19], ["preservation", "TREATMENT", 29, 41], ["PSICC methodology", "TREATMENT", 122, 139], ["host cell morphology", "OBSERVATION", 73, 93]]], ["Therefore, systematic studies on the reproducibility, efficacy, and reliability of immunostaining are rare.", [["systematic studies", "TEST", 11, 29], ["the reproducibility", "TEST", 33, 52], ["immunostaining", "TEST", 83, 97]]], ["1, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Hence, the present study aimed to fill this gap by establishing reproducible guidelines for PSICC labeling of selected cellular and viral antigens in tissue imprints, FNA, and cytocentrifuged fluids with the focus specifically on antigen preservation and retrieval.", [["cellular", "ANATOMY", 192, 200], ["tissue", "ANATOMY", 223, 229], ["FNA", "ANATOMY", 240, 243], ["[11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23", "CHEMICAL", 3, 66], ["1, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22]", "CHEMICAL", 0, 62], ["[11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 3, 72], ["PSICC", "SIMPLE_CHEMICAL", 165, 170], ["cellular", "CELL", 192, 200], ["tissue", "TISSUE", 223, 229], ["cellular and viral antigens", "PROTEIN", 192, 219], ["the present study", "TEST", 80, 97], ["PSICC labeling", "TREATMENT", 165, 179], ["selected cellular and viral antigens in tissue imprints", "PROBLEM", 183, 238], ["FNA", "TEST", 240, 243], ["cytocentrifuged fluids", "TREATMENT", 249, 271], ["antigen preservation", "TREATMENT", 303, 323], ["viral antigens", "OBSERVATION", 205, 219]]], ["Target antigen selection was driven by our daily neurocytologic specimen caseload various mammalian species with possible inflammatory and infectious CNS diseases.| Study designThis study investigated (a) the ability to apply ICC to prestained cytologic specimens, (b) whether coverslipping could be used to preserve antigenicity, and (c) whether microwave treatment (MWT) enhanced immunodetection in prestained smears.", [["neurocytologic specimen", "ANATOMY", 49, 72], ["CNS", "ANATOMY", 150, 153], ["cytologic specimens", "ANATOMY", 244, 263], ["CNS diseases", "DISEASE", 150, 162], ["antigen", "GENE_OR_GENE_PRODUCT", 7, 14], ["CNS", "ANATOMICAL_SYSTEM", 150, 153], ["Target antigen selection", "PROBLEM", 0, 24], ["inflammatory and infectious CNS diseases", "PROBLEM", 122, 162], ["This study", "TEST", 177, 187], ["cytologic specimens", "TEST", 244, 263], ["microwave treatment", "TREATMENT", 347, 366], ["MWT) enhanced immunodetection", "TEST", 368, 397], ["mammalian species", "OBSERVATION", 90, 107], ["possible", "UNCERTAINTY", 113, 121], ["inflammatory", "OBSERVATION_MODIFIER", 122, 134], ["infectious", "OBSERVATION_MODIFIER", 139, 149]]], ["Therefore, ICC staining quality was evaluated on smears after prestaining with a modified Wright's stain (modWS), destaining with hydrochloric acid (HCl), and then comparing the now unstained samples with and without coverslipping and MWT.", [["samples", "ANATOMY", 192, 199], ["hydrochloric acid", "CHEMICAL", 130, 147], ["HCl", "CHEMICAL", 149, 152], ["hydrochloric acid", "CHEMICAL", 130, 147], ["HCl", "CHEMICAL", 149, 152], ["hydrochloric acid", "SIMPLE_CHEMICAL", 130, 147], ["HCl", "SIMPLE_CHEMICAL", 149, 152], ["ICC staining quality", "TEST", 11, 31], ["smears", "TEST", 49, 55], ["a modified Wright's stain", "TEST", 79, 104], ["hydrochloric acid (HCl", "TREATMENT", 130, 152]]], ["The effects were evaluated for a set of cellular antigens with a distinct subcellular distribution (study A) and intracellular FCoV proteins (study B| Study A-cellular antigensWe tested the impact of individual pretreatments on the immunostaining of nuclear, cytoplasmic, and membrane antigens.", [["cellular", "ANATOMY", 40, 48], ["subcellular", "ANATOMY", 74, 85], ["intracellular", "ANATOMY", 113, 126], ["nuclear", "ANATOMY", 250, 257], ["cytoplasmic", "ANATOMY", 259, 270], ["membrane", "ANATOMY", 276, 284], ["cellular", "CELL", 40, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 126], ["nuclear", "CELLULAR_COMPONENT", 250, 257], ["cytoplasmic", "ORGANISM_SUBSTANCE", 259, 270], ["membrane", "CELLULAR_COMPONENT", 276, 284], ["cellular antigens", "PROTEIN", 40, 57], ["intracellular FCoV proteins", "PROTEIN", 113, 140], ["B|", "PROTEIN", 148, 150], ["A-cellular antigens", "PROTEIN", 157, 176], ["nuclear, cytoplasmic, and membrane antigens", "PROTEIN", 250, 293], ["intracellular FCoV proteins", "TEST", 113, 140], ["Study A-cellular antigens", "TEST", 151, 176], ["individual pretreatments", "TREATMENT", 200, 224], ["the immunostaining", "TEST", 228, 246], ["subcellular distribution", "OBSERVATION", 74, 98]]], ["Therefore, this systematic evaluation employed distinct methodologic trials, as illustrated in Figure 1 and Table 1.", [["this systematic evaluation", "TEST", 11, 37]]], ["A series of 122 impression smears and 64 FNA preparations were taken from the brain and lymph nodes of a cat and a pig during postmortem examination (<1/2 hour after euthanasia) for reasons unrelated to the study's purpose.", [["FNA", "ANATOMY", 41, 44], ["brain", "ANATOMY", 78, 83], ["lymph nodes", "ANATOMY", 88, 99], ["brain", "ORGAN", 78, 83], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 88, 99], ["cat", "ORGANISM", 105, 108], ["pig", "ORGANISM", 115, 118], ["cat", "SPECIES", 105, 108], ["pig", "SPECIES", 115, 118], ["pig", "SPECIES", 115, 118], ["122 impression smears", "TEST", 12, 33], ["FNA preparations", "TEST", 41, 57], ["postmortem examination", "TEST", 126, 148], ["the study's purpose", "TEST", 203, 222], ["brain", "ANATOMY", 78, 83], ["lymph nodes", "OBSERVATION", 88, 99]]], ["CNS cells were obtained from the postcruciate gyrus of the brain after extensive craniectomy, encephalectomy, and trimming, as described elsewhere.", [["CNS cells", "ANATOMY", 0, 9], ["postcruciate gyrus", "ANATOMY", 33, 51], ["brain", "ANATOMY", 59, 64], ["CNS cells", "CELL", 0, 9], ["postcruciate gyrus", "MULTI-TISSUE_STRUCTURE", 33, 51], ["brain", "ORGAN", 59, 64], ["CNS cells", "CELL_TYPE", 0, 9], ["CNS cells", "TEST", 0, 9], ["extensive craniectomy", "TREATMENT", 71, 92], ["encephalectomy", "TREATMENT", 94, 108], ["trimming", "TREATMENT", 114, 122], ["postcruciate gyrus", "ANATOMY", 33, 51], ["brain", "ANATOMY", 59, 64], ["extensive", "OBSERVATION_MODIFIER", 71, 80], ["craniectomy", "OBSERVATION", 81, 92], ["encephalectomy", "OBSERVATION", 94, 108]]], ["25, 26 Lymphocyte-enriched samples were collected from the superficial cervical and para-aortic lymph nodes via FNA using a 22-gauge syringe.", [["Lymphocyte", "ANATOMY", 7, 17], ["samples", "ANATOMY", 27, 34], ["superficial cervical", "ANATOMY", 59, 79], ["para-aortic lymph nodes", "ANATOMY", 84, 107], ["Lymphocyte", "CELL", 7, 17], ["samples", "CANCER", 27, 34], ["superficial cervical", "MULTI-TISSUE_STRUCTURE", 59, 79], ["para-aortic lymph nodes", "MULTI-TISSUE_STRUCTURE", 84, 107], ["Lymphocyte", "TEST", 7, 17], ["FNA", "TEST", 112, 115], ["a 22-gauge syringe", "TREATMENT", 122, 140], ["superficial", "ANATOMY_MODIFIER", 59, 70], ["cervical", "ANATOMY", 71, 79], ["para-aortic", "ANATOMY", 84, 95], ["lymph nodes", "OBSERVATION", 96, 107]]], ["All preparations were air-dried immediately.", [["air", "OBSERVATION", 22, 25]]], ["3) plus the additive effects of additional coverslipping-decoverslipping cycles (SDS-CDC, 36 slides) (trial 4) were investigated with another 60 slides.", [["additional coverslipping-decoverslipping cycles", "TREATMENT", 32, 79], ["SDS", "TEST", 81, 84]]], ["These trials were compared to the 36 CDC-treated slides (trial 5) and to a series of 24 slides not subjected to any treatment, which served as the gold standard (trial 6) ( Table 1 ).", [["any treatment", "TREATMENT", 112, 125]]], ["All samples were stored for up to 3 months.| Study A-cellular antigensAll slides except those from trial 6 were subjected to the laboratory treatments mentioned above, which preceded ICC.", [["samples", "ANATOMY", 4, 11], ["A-cellular antigens", "PROTEIN", 51, 70], ["All samples", "TEST", 0, 11], ["Study A-cellular antigens", "TEST", 45, 70]]], ["Coverslipped samples from trials 2, 4, and 5 were immersed in xylene to achieve liquefaction of the mounting medium until the coverslips slipped off.| Study A-cellular antigensThereafter, the slides were put through a graded ethanol series (2 \u00d7 100%, 1 \u00d7 96%, 1 \u00d7 70%; 5 minutes each) and immersed in distilled water.| Study A-cellular antigensPrestained and decoverslipped slides (trials 2 and 4) and those left uncovered after the modWS method (trial 3) were immersed in 1% HCl until the color had completely faded as identified with microscopy.", [["samples", "ANATOMY", 13, 20], ["xylene", "CHEMICAL", 62, 68], ["ethanol", "CHEMICAL", 225, 232], ["HCl", "CHEMICAL", 476, 479], ["xylene", "CHEMICAL", 62, 68], ["ethanol", "CHEMICAL", 225, 232], ["HCl", "CHEMICAL", 476, 479], ["xylene", "SIMPLE_CHEMICAL", 62, 68], ["ethanol", "SIMPLE_CHEMICAL", 225, 232], ["HCl", "SIMPLE_CHEMICAL", 476, 479], ["A-cellular antigens", "PROTEIN", 157, 176], ["A-cellular antigens", "PROTEIN", 325, 344], ["trials", "TEST", 26, 32], ["the coverslips slipped", "TREATMENT", 122, 144], ["the slides", "TEST", 188, 198], ["Study A-cellular antigens", "TEST", 319, 344], ["trials", "TEST", 382, 388], ["the modWS method", "TREATMENT", 429, 445], ["microscopy", "TEST", 536, 546], ["left", "ANATOMY_MODIFIER", 408, 412]]], ["Freshly destained slides (trials 2, 3, and 4) and nonstained decoverslipped slides from trial 5 were immersed in distilled water until ICC was performed ( Figure 1 , Table 1 ).| Study A-cellular antigensBefore performing ICC, one set of slides from each trial (trials 2, 3, and 6: n = 12 each; trials 4 and 5: n = 18 each; Figure 1 and Table 1 ) was subjected to the MWT-based antigen retrieval.", [["A-cellular antigens", "PROTEIN", 184, 203], ["trials", "TEST", 261, 267], ["trials", "TEST", 294, 300], ["the MWT", "TREATMENT", 363, 370], ["based antigen retrieval", "TREATMENT", 371, 394]]], ["For this F I G U R E 1 Schematic illustration of the staining trials.", [["the staining trials", "TREATMENT", 49, 68]]], ["These slides were used for cytomorphologic evaluations.", [["cytomorphologic evaluations", "TEST", 27, 54]]], ["Trial 2: The procedure included staining, coverslipping, and microwave treatments of the slides.", [["The procedure", "TREATMENT", 9, 22], ["staining", "TEST", 32, 40], ["coverslipping", "TREATMENT", 42, 55], ["microwave treatments", "TREATMENT", 61, 81], ["the slides", "TEST", 85, 95]]], ["After storage and directly before immunocytochemistry, these specimens were decoverslipped and destained, and half of the slides were microwave-treated again.", [["specimens", "ANATOMY", 61, 70], ["immunocytochemistry", "TEST", 34, 53], ["these specimens", "TEST", 55, 70]]], ["Trial 3: Slides were only stained and stored before immunocytochemistry, at which time the slides were destained, and half were microwave treated.", [["immunocytochemistry", "TEST", 52, 71], ["the slides", "TEST", 87, 97]]], ["After storage and directly before immunocytochemistry, they were decoverslipped and destained, and half of them were microwave treated.", [["immunocytochemistry", "TEST", 34, 53]]], ["Trial 5: This procedure included only the coverslipping of the slides.", [["This procedure", "TREATMENT", 9, 23]]], ["Before immunocytochemistry, the slides were decoverslipped, and half were microwave treated.", [["immunocytochemistry", "TEST", 7, 26], ["the slides", "TEST", 28, 38]]], ["Trial 6: No pretreatment was carried out with these specimens, and they were stored frozen.", [["specimens", "ANATOMY", 52, 61], ["pretreatment", "TREATMENT", 12, 24], ["these specimens", "TEST", 46, 61]]], ["Only half of the slides were pretreated in the microwave before immunocytochemistry.", [["immunocytochemistry", "TEST", 64, 83]]], ["These unstained and untreated slides served as the gold standard for the study procedure, the slides were transferred to a cuvette containing 0.01 mol/L of a citrate buffer solution (pH 6).", [["citrate", "CHEMICAL", 158, 165], ["citrate", "CHEMICAL", 158, 165], ["citrate", "SIMPLE_CHEMICAL", 158, 165], ["the study procedure", "TREATMENT", 69, 88], ["a cuvette", "TREATMENT", 121, 130], ["a citrate buffer solution", "TREATMENT", 156, 181]]], ["Based on our immunohistochemical protocol, MWT was carried out for 5 minutes/800 W followed by 20 minutes/250 W. The slides were left in citrate buffer for 30 minutes to cool down to room temperature.", [["citrate", "CHEMICAL", 137, 144], ["citrate", "CHEMICAL", 137, 144], ["citrate", "SIMPLE_CHEMICAL", 137, 144], ["our immunohistochemical protocol", "TEST", 9, 41], ["MWT", "TEST", 43, 46], ["citrate buffer", "TREATMENT", 137, 151]]], ["All further steps except for the primary antibody (pAB) incubations were carried out at room temperature.| Study A-cellular antigensThe MWT slides and those kept in distilled water (destained and unstained slides without MWT, Table 1 Upon removal of the nonimmune serum, lymph node FNAs were incubated with an anti-CD3 antibody for detection of the corresponding T cell antigen.", [["serum", "ANATOMY", 264, 269], ["lymph node FNAs", "ANATOMY", 271, 286], ["T cell", "ANATOMY", 363, 369], ["pAB", "SIMPLE_CHEMICAL", 51, 54], ["nonimmune", "ORGANISM", 254, 263], ["serum", "ORGANISM_SUBSTANCE", 264, 269], ["lymph node", "MULTI-TISSUE_STRUCTURE", 271, 281], ["FNAs", "MULTI-TISSUE_STRUCTURE", 282, 286], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 310, 318], ["T cell antigen", "GENE_OR_GENE_PRODUCT", 363, 377], ["primary antibody", "PROTEIN", 33, 49], ["pAB", "PROTEIN", 51, 54], ["A-cellular antigens", "PROTEIN", 113, 132], ["anti-CD3 antibody", "PROTEIN", 310, 327], ["T cell antigen", "PROTEIN", 363, 377], ["the primary antibody (pAB) incubations", "TREATMENT", 29, 67], ["Study A-cellular antigens", "TEST", 107, 132], ["The MWT slides", "TREATMENT", 132, 146], ["removal", "TREATMENT", 239, 246], ["the nonimmune serum", "TEST", 250, 269], ["lymph node FNAs", "TEST", 271, 286], ["an anti-CD3 antibody", "TEST", 307, 327], ["the corresponding T cell antigen", "PROBLEM", 345, 377], ["lymph node", "OBSERVATION", 271, 281]]], ["Other markers, specifically, NeuN and GFAP, were used on separate brain smears ( Table 2) .", [["brain", "ANATOMY", 66, 71], ["NeuN", "GENE_OR_GENE_PRODUCT", 29, 33], ["GFAP", "GENE_OR_GENE_PRODUCT", 38, 42], ["brain", "ORGAN", 66, 71], ["NeuN", "PROTEIN", 29, 33], ["GFAP", "PROTEIN", 38, 42], ["Other markers", "TEST", 0, 13], ["GFAP", "TEST", 38, 42], ["brain", "ANATOMY", 66, 71]]], ["Each run contained site-matched slides in which a pAB was replaced by an antibody diluent, serving as a negative control (altogether n = 12).", [["pAB", "GENE_OR_GENE_PRODUCT", 50, 53], ["pAB", "PROTEIN", 50, 53], ["a pAB", "TREATMENT", 48, 53], ["an antibody diluent", "TREATMENT", 70, 89], ["site", "OBSERVATION_MODIFIER", 19, 23], ["pAB", "ANATOMY", 50, 53]]], ["Incubation was carried out for 18 hours at 4\u00b0C (39.2\u00b0F).| Study A-cellular antigensAfter repeated wash steps with PBS, the slides were mounted with biotinylated goat anti-rabbit/mouse IgG antibodies (both DAKO, Glostrup, Denmark) for 1 hour.", [["goat", "ORGANISM", 161, 165], ["mouse", "ORGANISM", 178, 183], ["A-cellular antigens", "PROTEIN", 64, 83], ["biotinylated goat anti-rabbit/mouse IgG antibodies", "PROTEIN", 148, 198], ["DAKO", "PROTEIN", 205, 209], ["goat", "SPECIES", 161, 165], ["anti-rabbit", "SPECIES", 166, 177], ["mouse", "SPECIES", 178, 183], ["goat", "SPECIES", 161, 165], ["mouse", "SPECIES", 178, 183], ["Incubation", "TREATMENT", 0, 10], ["Study A-cellular antigens", "TEST", 58, 83], ["PBS", "TREATMENT", 114, 117], ["the slides", "TEST", 119, 129], ["biotinylated goat anti-rabbit/mouse IgG antibodies", "TREATMENT", 148, 198]]], ["Bound pAB was subsequently visualized using an ABC amplification kit (Vectastain; Vector Laboratory Inc, Burlingame, CA, USA) using diaminobenzidine tetrahydrochloride (DAB) as the chromagen.", [["diaminobenzidine tetrahydrochloride", "CHEMICAL", 132, 167], ["DAB", "CHEMICAL", 169, 172], ["diaminobenzidine tetrahydrochloride", "CHEMICAL", 132, 167], ["DAB", "CHEMICAL", 169, 172], ["pAB", "GENE_OR_GENE_PRODUCT", 6, 9], ["diaminobenzidine tetrahydrochloride", "SIMPLE_CHEMICAL", 132, 167], ["DAB", "SIMPLE_CHEMICAL", 169, 172], ["pAB", "PROTEIN", 6, 9], ["Bound pAB", "TREATMENT", 0, 9], ["an ABC amplification kit", "TEST", 44, 68], ["diaminobenzidine tetrahydrochloride", "TREATMENT", 132, 167], ["the chromagen", "TREATMENT", 177, 190], ["pAB", "OBSERVATION", 6, 9]]], ["The enzyme reaction was blocked with PBS rinses.", [["The enzyme reaction", "PROBLEM", 0, 19], ["PBS rinses", "TREATMENT", 37, 47]]], ["Then, the slides were counterstained with Mayer's hematoxylin (AppliChem GmbH, Darmstadt, Germany), underwent an ascending ethanol series, and were coverslipped as described above.| Study A-cellular antigensCell yields and preservation were assessed with bright field microscopy by two different clinical pathologists.", [["Cell", "ANATOMY", 207, 211], ["ethanol", "CHEMICAL", 123, 130], ["hematoxylin", "CHEMICAL", 50, 61], ["ethanol", "CHEMICAL", 123, 130], ["hematoxylin", "SIMPLE_CHEMICAL", 50, 61], ["ethanol", "SIMPLE_CHEMICAL", 123, 130], ["Cell", "CELL", 207, 211], ["A-cellular antigens", "PROTEIN", 188, 207], ["an ascending ethanol series", "TREATMENT", 110, 137], ["Study A-cellular antigens", "TEST", 182, 207], ["bright field microscopy", "TEST", 255, 278], ["ascending", "ANATOMY_MODIFIER", 113, 122]]], ["In separate sessions, these observers, who were blinded to the smear origins, the pretreatment types, and the pAB type, evaluated the ICC outcomes.| Study A-cellular antigensICC quality determinants were (a) cell type specificity, (b) intensity of cellular staining, (c) the presence/absence of acellular background activity, and (d) nonspecific staining.", [["A-cellular", "ANATOMY", 155, 165], ["cell", "ANATOMY", 208, 212], ["cellular", "ANATOMY", 248, 256], ["cell", "CELL", 208, 212], ["cellular", "CELL", 248, 256], ["acellular", "TISSUE", 295, 304], ["a) cell type specificity", "TEST", 205, 229], ["cellular staining", "PROBLEM", 248, 265], ["acellular background activity", "PROBLEM", 295, 324], ["(d) nonspecific staining", "PROBLEM", 330, 354], ["cellular staining", "OBSERVATION", 248, 265], ["acellular", "OBSERVATION_MODIFIER", 295, 304], ["background activity", "OBSERVATION", 305, 324], ["nonspecific", "OBSERVATION_MODIFIER", 334, 345], ["staining", "OBSERVATION", 346, 354]]], ["In the event of intraobserver disagreement, the slides were reviewed on a T A B L E 1 Different pretreatments applied before performing the immunocytochemistry trials (Trials 1-6) Germany), and mean values were newly assigned.| Study A-cellular antigensFor statistical evaluations, the final scores were compared between the different procedures using nonparametric statistical algorithms.", [["A-cellular antigens", "PROTEIN", 234, 253], ["a T A B L E", "TREATMENT", 72, 83], ["Different pretreatments", "TREATMENT", 86, 109], ["the immunocytochemistry trials", "TEST", 136, 166], ["Trials", "TEST", 168, 174], ["mean values", "TEST", 194, 205], ["statistical evaluations", "TEST", 257, 280], ["the different procedures", "TEST", 321, 345], ["nonparametric statistical algorithms", "TEST", 352, 388]]], ["A P of \u2264 0.05 indicated statistical significance.| Study B-viral antigensThis study evaluated the impact of pretreatment on FCoV antigen immunolabeling.| Study B-viral antigensStudy B was conducted on pleural (n = 6) and abdominal (n = 16) effusions of FIP cases confirmed with histopathology and FCoV antigen-positive immunohistochemistry.", [["pleural", "ANATOMY", 201, 208], ["abdominal", "ANATOMY", 221, 230], ["effusions", "ANATOMY", 240, 249], ["effusions", "DISEASE", 240, 249], ["FIP", "DISEASE", 253, 256], ["B-viral antigens", "GENE_OR_GENE_PRODUCT", 57, 73], ["FCoV antigen", "GENE_OR_GENE_PRODUCT", 124, 136], ["pleural", "MULTI-TISSUE_STRUCTURE", 201, 208], ["abdominal", "ORGAN", 221, 230], ["FIP", "ORGANISM", 253, 256], ["FCoV antigen", "GENE_OR_GENE_PRODUCT", 297, 309], ["viral antigens", "PROTEIN", 59, 73], ["FCoV antigen", "PROTEIN", 124, 136], ["FCoV antigen", "PROTEIN", 297, 309], ["A P", "TEST", 0, 3], ["Study", "TEST", 51, 56], ["This study", "TEST", 73, 83], ["Study B", "TEST", 154, 161], ["viral antigensStudy", "TEST", 162, 181], ["pleural (n", "TREATMENT", 201, 211], ["abdominal (n = 16) effusions of FIP cases", "PROBLEM", 221, 262], ["histopathology", "TEST", 278, 292], ["FCoV antigen", "TEST", 297, 309], ["pleural", "ANATOMY", 201, 208], ["abdominal", "ANATOMY", 221, 230], ["effusions", "OBSERVATION", 240, 249]]], ["9 These effusions were collected using conventional thoracentesis or abdominocentesis procedures.| Study B-viral antigensHarvested fluids were mounted onto uncoated standard slides (Langenbrinck, Emmendingen, Germany) using a cytocentrifuge (Hettich Universal 16, Adelsried, Germany).", [["effusions", "ANATOMY", 8, 17], ["effusions", "DISEASE", 8, 17], ["viral antigens", "PROTEIN", 107, 121], ["These effusions", "PROBLEM", 2, 17], ["conventional thoracentesis", "TREATMENT", 39, 65], ["abdominocentesis procedures", "TREATMENT", 69, 96], ["Study", "TEST", 99, 104], ["viral antigensHarvested fluids", "TREATMENT", 107, 137], ["a cytocentrifuge (Hettich Universal", "TREATMENT", 224, 259], ["effusions", "OBSERVATION", 8, 17]]], ["According to our in-house protocol for effusions, centrifugation chambers were spun for 5 minutes at 250g, after which the supernatant was removed, and the coated slides were centrifuged for 1 minute at 416g.", [["effusions", "ANATOMY", 39, 48], ["supernatant", "ANATOMY", 123, 134], ["effusions", "DISEASE", 39, 48], ["effusions", "PROBLEM", 39, 48], ["centrifugation chambers", "TREATMENT", 50, 73], ["the coated slides", "TREATMENT", 152, 169], ["effusions", "OBSERVATION", 39, 48]]], ["Then, the slides were air-dried and stored at \u221220\u00b0C (\u22124\u00b0F) until further processing.| Study B-viral antigensTo evaluate the preservation and antigenicity of viral antigens, the samples underwent trials 3, 4, 5, and 6 (with and without MWT), as described in study A. ICC was performed using a mouse monoclonal antibody directed against the coronavirus nucleocapsid (clone FIPV3-70; Table 2 ).", [["samples", "ANATOMY", 177, 184], ["B-viral antigens", "GENE_OR_GENE_PRODUCT", 92, 108], ["mouse", "ORGANISM", 292, 297], ["coronavirus nucleocapsid", "ORGANISM", 339, 363], ["viral antigens", "PROTEIN", 94, 108], ["viral antigens", "PROTEIN", 157, 171], ["mouse monoclonal antibody", "PROTEIN", 292, 317], ["coronavirus nucleocapsid", "PROTEIN", 339, 363], ["FIPV3", "PROTEIN", 371, 376], ["mouse", "SPECIES", 292, 297], ["coronavirus", "SPECIES", 339, 350], ["mouse", "SPECIES", 292, 297], ["Study", "TEST", 86, 91], ["viral antigens", "PROBLEM", 157, 171], ["trials", "TEST", 195, 201], ["a mouse monoclonal antibody", "TREATMENT", 290, 317], ["the coronavirus nucleocapsid", "PROBLEM", 335, 363], ["clone FIPV3", "TEST", 365, 376]]], ["Incubation and subsequent steps were identical to those applied for NeuN labeling (see above) using the ABC enhancer and DAB.| Study B-viral antigensThe ICC signal was re-evaluated by both observers concerning cellular and subcellular localization, intensity, specificity, and background, as described above.| Study A-cell-specific antigensTo evaluate cell preservation, the slides were microscopically assessed.", [["cellular", "ANATOMY", 210, 218], ["subcellular", "ANATOMY", 223, 234], ["cell", "ANATOMY", 318, 322], ["cell", "ANATOMY", 352, 356], ["NeuN", "GENE_OR_GENE_PRODUCT", 68, 72], ["ABC", "GENE_OR_GENE_PRODUCT", 104, 107], ["DAB", "GENE_OR_GENE_PRODUCT", 121, 124], ["B-viral antigens", "GENE_OR_GENE_PRODUCT", 133, 149], ["cellular", "CELL", 210, 218], ["A-cell", "CELL", 316, 322], ["cell", "CELL", 352, 356], ["NeuN", "PROTEIN", 68, 72], ["ABC enhancer", "DNA", 104, 116], ["viral antigens", "PROTEIN", 135, 149], ["A-cell-specific antigens", "PROTEIN", 316, 340], ["Incubation", "TREATMENT", 0, 10], ["NeuN labeling", "TEST", 68, 81], ["Study", "TEST", 127, 132], ["Study A-cell", "TEST", 310, 322], ["cell preservation", "TREATMENT", 352, 369], ["the slides", "TEST", 371, 381], ["cellular", "OBSERVATION_MODIFIER", 210, 218], ["subcellular localization", "OBSERVATION", 223, 247], ["intensity", "OBSERVATION_MODIFIER", 249, 258], ["cell preservation", "OBSERVATION", 352, 369]]], ["ModWS-stained slides revealed a representative cell yield, with fewer than 5% of cells suffering crush artifact and fewer than F I G U R E 2 The outcome of immunocytochemical staining for cellular antigens (blue arrows: specific positive staining; black arrows: immunonegative cells).", [["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 81, 86], ["cellular", "ANATOMY", 188, 196], ["cells", "ANATOMY", 277, 282], ["ModWS", "SIMPLE_CHEMICAL", 0, 5], ["cell", "CELL", 47, 51], ["cells", "CELL", 81, 86], ["cellular antigens", "GENE_OR_GENE_PRODUCT", 188, 205], ["cells", "CELL", 277, 282], ["ModWS", "PROTEIN", 0, 5], ["cellular antigens", "PROTEIN", 188, 205], ["immunonegative cells", "CELL_TYPE", 262, 282], ["stained slides", "TEST", 6, 20], ["crush artifact", "PROBLEM", 97, 111], ["immunocytochemical staining", "TEST", 156, 183], ["cellular antigens", "TEST", 188, 205], ["blue arrows", "TEST", 207, 218], ["specific positive staining", "PROBLEM", 220, 246], ["immunonegative cells", "PROBLEM", 262, 282], ["crush artifact", "OBSERVATION", 97, 111], ["immunonegative cells", "OBSERVATION", 262, 282]]], ["Counterstaining with Mayer's hematoxylin.", [["hematoxylin", "CHEMICAL", 29, 40], ["hematoxylin", "SIMPLE_CHEMICAL", 29, 40], ["Mayer's hematoxylin", "TREATMENT", 21, 40]]], ["A, Immunocytochemistry on unstained and untreated films served as the gold standard, and which illustrates optimal staining results.", [["untreated films", "TEST", 40, 55]]], ["The CD3 signal was strongest in the periphery of the lymphocyte cytoplasm close to the membrane.", [["lymphocyte cytoplasm", "ANATOMY", 53, 73], ["membrane", "ANATOMY", 87, 95], ["CD3", "GENE_OR_GENE_PRODUCT", 4, 7], ["lymphocyte", "CELLULAR_COMPONENT", 53, 63], ["cytoplasm", "ORGANISM_SUBSTANCE", 64, 73], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["CD3", "PROTEIN", 4, 7], ["The CD3 signal", "TEST", 0, 14], ["CD3 signal", "OBSERVATION", 4, 14], ["strongest", "OBSERVATION_MODIFIER", 19, 28], ["periphery", "ANATOMY_MODIFIER", 36, 45], ["lymphocyte cytoplasm", "OBSERVATION", 53, 73], ["membrane", "ANATOMY_MODIFIER", 87, 95]]], ["NeuN immunoreactivity was restricted to neuronal nuclei, while GFAP diffusely stained the soma and fragmented processes of astrocytes (procedure depicted in trial 6 without microwave treatment).", [["neuronal nuclei", "ANATOMY", 40, 55], ["soma", "ANATOMY", 90, 94], ["astrocytes", "ANATOMY", 123, 133], ["NeuN", "GENE_OR_GENE_PRODUCT", 0, 4], ["neuronal nuclei", "CELLULAR_COMPONENT", 40, 55], ["GFAP", "GENE_OR_GENE_PRODUCT", 63, 67], ["soma", "CELLULAR_COMPONENT", 90, 94], ["astrocytes", "CELL", 123, 133], ["GFAP", "PROTEIN", 63, 67], ["astrocytes", "CELL_TYPE", 123, 133], ["NeuN immunoreactivity", "TEST", 0, 21], ["fragmented processes of astrocytes", "PROBLEM", 99, 133], ["procedure", "TREATMENT", 135, 144], ["microwave treatment", "TREATMENT", 173, 192], ["neuronal nuclei", "ANATOMY", 40, 55], ["soma", "OBSERVATION_MODIFIER", 90, 94], ["fragmented", "OBSERVATION_MODIFIER", 99, 109], ["astrocytes", "ANATOMY", 123, 133]]], ["B, The impact of xylene-based coverslipping and decoverslipping appeared negligible.", [["xylene", "CHEMICAL", 17, 23], ["xylene", "CHEMICAL", 17, 23], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["xylene", "SIMPLE_CHEMICAL", 17, 23], ["xylene-based coverslipping", "TREATMENT", 17, 43], ["negligible", "OBSERVATION_MODIFIER", 73, 83]]], ["Hence, microwave treatment was not necessary (procedure depicted in trial 5 without microwave treatment).", [["microwave treatment", "TREATMENT", 7, 26], ["procedure", "TREATMENT", 46, 55], ["microwave treatment", "TREATMENT", 84, 103]]], ["C, Prestaining with Wright's stain and then bleaching with hydrogen chloride abolished the specific immunostaining of all markers (blue arrow), if the slides were left uncoverslipped (procedure depicted in trial 3 without microwave treatment).", [["hydrogen chloride", "CHEMICAL", 59, 76], ["hydrogen chloride", "CHEMICAL", 59, 76], ["C", "SIMPLE_CHEMICAL", 0, 1], ["hydrogen chloride", "SIMPLE_CHEMICAL", 59, 76], ["Wright's stain", "TEST", 20, 34], ["hydrogen chloride", "TREATMENT", 59, 76], ["the slides", "TEST", 147, 157], ["procedure", "TREATMENT", 184, 193], ["microwave treatment", "TREATMENT", 222, 241]]], ["D, Coverslipping after prestaining with a Wright's stain appeared superior in being able to preserve antigenicities and specific staining intensities (procedure depicted in trial 4 without microwave treatment).", [["a Wright's stain", "TEST", 40, 56], ["specific staining intensities", "PROBLEM", 120, 149], ["procedure", "TREATMENT", 151, 160], ["microwave treatment", "TREATMENT", 189, 208]]], ["E, Microwave treatment completely rescued the compromising effects of staining/destaining and coverslipping/ decoverslipping (procedure depicted in trial 4 with microwave treatment).", [["Microwave treatment", "TREATMENT", 3, 22], ["staining/destaining", "TREATMENT", 70, 89], ["coverslipping/ decoverslipping (procedure", "TREATMENT", 94, 135], ["microwave treatment", "TREATMENT", 161, 180]]], ["NeuN = neuronal nuclei, GFAP = glial fibrillary acidic protein, CD3 = T cell marker.", [["neuronal nuclei", "ANATOMY", 7, 22], ["T cell", "ANATOMY", 70, 76], ["NeuN", "GENE_OR_GENE_PRODUCT", 0, 4], ["neuronal nuclei", "CELLULAR_COMPONENT", 7, 22], ["GFAP", "GENE_OR_GENE_PRODUCT", 24, 28], ["glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 31, 62], ["CD3", "GENE_OR_GENE_PRODUCT", 64, 67], ["NeuN", "PROTEIN", 0, 4], ["GFAP", "PROTEIN", 24, 28], ["glial fibrillary acidic protein", "PROTEIN", 31, 62], ["CD3", "PROTEIN", 64, 67], ["T cell marker", "PROTEIN", 70, 83], ["GFAP", "TEST", 24, 28], ["glial fibrillary acidic protein", "TEST", 31, 62], ["CD3", "TEST", 64, 67], ["T cell marker", "TEST", 70, 83], ["neuronal nuclei", "ANATOMY", 7, 22]]], ["The wave image depicts microwave treatment, the upside down y image depict antibody treatment, the coverslip indicates the coverslipping/decoverslipping technique D\u00d6RFELT ET AL.| Study A-cell-specific antigens| 103 (GFAP: score 1.5 \u00b1 0.58) (Figure 2A ; Table 3 ).", [["cell", "ANATOMY", 187, 191], ["A-cell", "CELL", 185, 191], ["GFAP", "GENE_OR_GENE_PRODUCT", 216, 220], ["A-cell-specific antigens", "PROTEIN", 185, 209], ["GFAP", "PROTEIN", 216, 220], ["The wave image", "TEST", 0, 14], ["microwave treatment", "TREATMENT", 23, 42], ["antibody treatment", "TREATMENT", 75, 93], ["the coverslip", "TREATMENT", 95, 108], ["the coverslipping/decoverslipping technique", "TREATMENT", 119, 162], ["Study A-cell", "TEST", 179, 191], ["specific antigens", "TEST", 192, 209], ["GFAP", "TEST", 216, 220], ["score", "TEST", 222, 227]]], ["For GFAP only, a background with brownish, cloudy, sometimes flocculent low-intensity staining was evident in all specimens (4/4) ( Table 3 ).", [["specimens", "ANATOMY", 114, 123], ["GFAP", "GENE_OR_GENE_PRODUCT", 4, 8], ["GFAP", "PROTEIN", 4, 8], ["GFAP", "TEST", 4, 8], ["brownish, cloudy, sometimes flocculent low-intensity staining", "PROBLEM", 33, 94], ["all specimens", "TEST", 110, 123], ["brownish", "OBSERVATION_MODIFIER", 33, 41], ["cloudy", "OBSERVATION_MODIFIER", 43, 49], ["flocculent", "OBSERVATION_MODIFIER", 61, 71], ["low-intensity", "OBSERVATION_MODIFIER", 72, 85], ["all specimens", "OBSERVATION_MODIFIER", 110, 123]]], ["However, this background did not interfere with the distinctive staining of astrocyte somata.", [["astrocyte somata", "ANATOMY", 76, 92], ["astrocyte somata", "CELLULAR_COMPONENT", 76, 92], ["the distinctive staining of astrocyte somata", "PROBLEM", 48, 92], ["distinctive", "OBSERVATION_MODIFIER", 52, 63], ["staining", "OBSERVATION", 64, 72], ["astrocyte somata", "OBSERVATION", 76, 92]]], ["Regarding the subcellular distribution of ICC on these plain slides, the CD3 signal was strongest in the periphery of the lymphocyte cytoplasm close to the membrane.", [["subcellular", "ANATOMY", 14, 25], ["lymphocyte cytoplasm", "ANATOMY", 122, 142], ["membrane", "ANATOMY", 156, 164], ["CD3", "GENE_OR_GENE_PRODUCT", 73, 76], ["lymphocyte", "CELLULAR_COMPONENT", 122, 132], ["cytoplasm", "ORGANISM_SUBSTANCE", 133, 142], ["membrane", "CELLULAR_COMPONENT", 156, 164], ["ICC", "PROTEIN", 42, 45], ["CD3", "PROTEIN", 73, 76], ["these plain slides", "TEST", 49, 67], ["the CD3 signal", "TEST", 69, 83], ["subcellular", "OBSERVATION_MODIFIER", 14, 25], ["distribution", "OBSERVATION_MODIFIER", 26, 38], ["ICC", "OBSERVATION_MODIFIER", 42, 45], ["strongest", "OBSERVATION_MODIFIER", 88, 97], ["periphery", "ANATOMY_MODIFIER", 105, 114], ["lymphocyte cytoplasm", "OBSERVATION", 122, 142], ["membrane", "ANATOMY_MODIFIER", 156, 164]]], ["NeuN immunoreactivity was restricted to neuronal nuclei, while GFAP diffusely stained the soma and fragmented processes of astrocytes.| Study A-cell-specific antigensEven after coverslipping and decoverslipping (CDC only, trial 5), ICC permitted the identification of all three cell types ( Figure 2B ).| Study A-cell-specific antigensHowever, both the staining intensity and cell specificity of the CD3| Study A-cell-specific antigensand NeuN specimens were significantly lower than those observed in trial 6 (P \u2264 0.04), while GFAP background staining was stronger (P = 0.02) (Tables 3 and 4 ).| Study A-cell-specific antigensThe SDS (trial 3) did not interfere with immunolabeling if ICC was performed within a few days after the Romanowsky staining.| Study A-cell-specific antigensHowever, a delay of 1-2 weeks abolished immunolabeling significantly ( Figure 2C ).", [["neuronal nuclei", "ANATOMY", 40, 55], ["soma", "ANATOMY", 90, 94], ["astrocytes", "ANATOMY", 123, 133], ["cell", "ANATOMY", 144, 148], ["cell", "ANATOMY", 278, 282], ["cell", "ANATOMY", 313, 317], ["cell", "ANATOMY", 376, 380], ["cell", "ANATOMY", 413, 417], ["NeuN specimens", "ANATOMY", 439, 453], ["cell", "ANATOMY", 605, 609], ["cell", "ANATOMY", 762, 766], ["NeuN", "GENE_OR_GENE_PRODUCT", 0, 4], ["neuronal nuclei", "CELLULAR_COMPONENT", 40, 55], ["GFAP", "GENE_OR_GENE_PRODUCT", 63, 67], ["soma", "CELLULAR_COMPONENT", 90, 94], ["astrocytes", "CELL", 123, 133], ["A-cell", "CELL", 142, 148], ["cell", "CELL", 278, 282], ["A-cell", "CELL", 311, 317], ["cell", "CELL", 376, 380], ["CD3", "GENE_OR_GENE_PRODUCT", 400, 403], ["A-cell", "CELL", 411, 417], ["NeuN", "GENE_OR_GENE_PRODUCT", 439, 443], ["GFAP", "GENE_OR_GENE_PRODUCT", 528, 532], ["A-cell", "CELL", 603, 609], ["A-cell", "CELL", 760, 766], ["NeuN", "PROTEIN", 0, 4], ["GFAP", "PROTEIN", 63, 67], ["astrocytes", "CELL_TYPE", 123, 133], ["A-cell-specific antigens", "PROTEIN", 142, 166], ["A-cell-specific antigens", "PROTEIN", 311, 335], ["CD3", "PROTEIN", 400, 403], ["GFAP", "PROTEIN", 528, 532], ["A-cell-specific antigens", "PROTEIN", 603, 627], ["A-cell-specific antigens", "PROTEIN", 760, 784], ["NeuN immunoreactivity", "TEST", 0, 21], ["Study A-cell", "TEST", 136, 148], ["Study A-cell", "TEST", 305, 317], ["the staining intensity", "TEST", 349, 371], ["Study A-cell", "TEST", 405, 417], ["NeuN specimens", "TEST", 439, 453], ["GFAP background staining", "TEST", 528, 552], ["P", "TEST", 567, 568], ["Study A-cell", "TEST", 597, 609], ["The SDS", "TEST", 627, 634], ["ICC", "TEST", 686, 689], ["Study A-cell", "TEST", 754, 766], ["immunolabeling", "PROBLEM", 824, 838], ["neuronal nuclei", "ANATOMY", 40, 55], ["soma", "OBSERVATION_MODIFIER", 90, 94], ["fragmented", "OBSERVATION_MODIFIER", 99, 109], ["astrocytes", "ANATOMY", 123, 133], ["cell types", "OBSERVATION", 278, 288]]], ["Hence, the detectability of all markers was severely compromised (cell specificity: P = 0.013; intensity: Tables 3 and 5 ).", [["cell", "ANATOMY", 66, 70], ["cell", "CELL", 66, 70], ["all markers", "TEST", 28, 39], ["severely compromised", "PROBLEM", 44, 64], ["P", "TEST", 84, 85]]], ["Weak cellular staining was seen in isolated lymphocytes and astrocytes only, while the majority of cells in all specimens remained immunonegative.| Study A-cell-specific antigensEarly coverslipping of modWS-stained specimens (trials 2 and 4)| Study A-cell-specific antigensrescued the antigenicity of all three antigens compared with the prestained, noncoverslipped slides in trial 3 (intensity and cell specificity: Figure 2D ; Tables 5 and 6 ).", [["cellular", "ANATOMY", 5, 13], ["lymphocytes", "ANATOMY", 44, 55], ["astrocytes", "ANATOMY", 60, 70], ["cells", "ANATOMY", 99, 104], ["specimens", "ANATOMY", 112, 121], ["cell", "ANATOMY", 156, 160], ["specimens", "ANATOMY", 215, 224], ["A-cell", "ANATOMY", 249, 255], ["cell", "ANATOMY", 399, 403], ["cellular", "CELL", 5, 13], ["lymphocytes", "CELL", 44, 55], ["astrocytes", "CELL", 60, 70], ["cells", "CELL", 99, 104], ["A-cell", "CELL", 154, 160], ["A-cell", "CELL", 249, 255], ["cell", "CELL", 399, 403], ["isolated lymphocytes", "CELL_TYPE", 35, 55], ["astrocytes", "CELL_TYPE", 60, 70], ["A-cell-specific antigens", "PROTEIN", 154, 178], ["modWS", "PROTEIN", 201, 206], ["antigens", "PROTEIN", 311, 319], ["Weak cellular staining", "PROBLEM", 0, 22], ["isolated lymphocytes and astrocytes", "PROBLEM", 35, 70], ["all specimens", "TEST", 108, 121], ["Study A-cell", "TEST", 148, 160], ["Early coverslipping of modWS", "PROBLEM", 178, 206], ["Study A-cell", "TEST", 243, 255], ["cellular", "OBSERVATION_MODIFIER", 5, 13], ["staining", "OBSERVATION", 14, 22], ["isolated lymphocytes", "OBSERVATION", 35, 55], ["astrocytes", "ANATOMY", 60, 70]]], ["A specific signal was obtained on these slides, with a median signal intensity (SI) of 1.0-1.5 (Table 6 ).", [["A specific signal", "TEST", 0, 17], ["these slides", "TEST", 34, 46], ["a median signal intensity", "TEST", 53, 78]]], ["Nonspecific background staining was restricted mostly to GFAP slides (10/10) but remained distinct from cellular chromagen enrichment, as seen in Figure 2D ( Table 6) .", [["cellular", "ANATOMY", 104, 112], ["GFAP", "GENE_OR_GENE_PRODUCT", 57, 61], ["cellular", "CELL", 104, 112], ["GFAP", "PROTEIN", 57, 61], ["Nonspecific background staining", "PROBLEM", 0, 31], ["GFAP slides", "TEST", 57, 68], ["cellular chromagen enrichment", "PROBLEM", 104, 133], ["staining", "OBSERVATION", 23, 31], ["distinct", "OBSERVATION_MODIFIER", 90, 98], ["cellular chromagen enrichment", "OBSERVATION", 104, 133]]], ["Notably, SDS/CDC affected the subcellular distribution of immunostaining; the CD3 signal extended throughout the lymphocyte cytoplasm rather than accentuating the periphery, while GFAP staining in astrocytes leaked into the nucleus.", [["subcellular", "ANATOMY", 30, 41], ["lymphocyte cytoplasm", "ANATOMY", 113, 133], ["astrocytes", "ANATOMY", 197, 207], ["nucleus", "ANATOMY", 224, 231], ["CD3", "GENE_OR_GENE_PRODUCT", 78, 81], ["lymphocyte", "CELLULAR_COMPONENT", 113, 123], ["cytoplasm", "ORGANISM_SUBSTANCE", 124, 133], ["GFAP", "GENE_OR_GENE_PRODUCT", 180, 184], ["astrocytes", "CELL", 197, 207], ["nucleus", "CELLULAR_COMPONENT", 224, 231], ["CD3", "PROTEIN", 78, 81], ["GFAP", "PROTEIN", 180, 184], ["astrocytes", "CELL_TYPE", 197, 207], ["SDS/CDC", "PROBLEM", 9, 16], ["the CD3 signal", "TEST", 74, 88], ["the lymphocyte cytoplasm", "TEST", 109, 133], ["GFAP staining", "TEST", 180, 193], ["subcellular", "OBSERVATION_MODIFIER", 30, 41], ["distribution", "OBSERVATION_MODIFIER", 42, 54], ["immunostaining", "OBSERVATION", 58, 72], ["CD3 signal", "OBSERVATION", 78, 88], ["lymphocyte cytoplasm", "OBSERVATION", 113, 133], ["periphery", "ANATOMY_MODIFIER", 163, 172], ["astrocytes leaked", "OBSERVATION", 197, 214], ["nucleus", "ANATOMY", 224, 231]]], ["NeuN staining was still mainly confined to neuronal nuclei; however, the signal was patchy and did not encompass the entire nuclear area ( Figure 2D) .", [["neuronal nuclei", "ANATOMY", 43, 58], ["nuclear area", "ANATOMY", 124, 136], ["NeuN", "GENE_OR_GENE_PRODUCT", 0, 4], ["neuronal nuclei", "CELLULAR_COMPONENT", 43, 58], ["NeuN", "PROTEIN", 0, 4], ["NeuN staining", "TEST", 0, 13], ["patchy", "PROBLEM", 84, 90], ["neuronal nuclei", "ANATOMY", 43, 58], ["patchy", "OBSERVATION_MODIFIER", 84, 90]]], ["The positive effect of MWT was restricted to coverslipped slides.| Study A-cell-specific antigensThe omission of coverslipping in trial 3 failed to rescue antigenicity.| Study B-FCoV antigenAll types of chemical pretreatments (trials 3, 4, and 5) completely abolished immunostaining of the FCoV nucleocapsid ( Figure 3A and B; Table 7 ).", [["cell", "ANATOMY", 75, 79], ["A-cell", "CELL", 73, 79], ["A-cell-specific antigens", "PROTEIN", 73, 97], ["FCoV nucleocapsid", "PROTEIN", 290, 307], ["Figure 3A and B; Table 7", "PROTEIN", 310, 334], ["MWT", "PROBLEM", 23, 26], ["Study A-cell", "TEST", 67, 79], ["coverslipping in trial", "TREATMENT", 113, 135], ["Study", "TEST", 170, 175], ["chemical pretreatments (trials", "TREATMENT", 203, 233], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["FCoV", "OBSERVATION", 178, 182], ["FCoV nucleocapsid", "OBSERVATION", 290, 307]]], ["Therefore, in contrast to the immunodetection of cellular antigens, coverslipping did not protect viral antigenicity on stained slides (Table 7) .", [["cellular", "ANATOMY", 49, 57], ["cellular", "CELL", 49, 57], ["cellular antigens", "PROTEIN", 49, 66]]], ["Likewise, MWT precluded immunostaining on plain slides from trial 6 and, hence, failed to rescue antigen labeling on the pretreated slides. contamination, and differences in yield and cell composition among consecutive samples.", [["cell", "ANATOMY", 184, 188], ["samples", "ANATOMY", 219, 226], ["cell", "CELL", 184, 188], ["plain slides", "TEST", 42, 54], ["contamination", "PROBLEM", 140, 153], ["consecutive samples", "TEST", 207, 226]]], ["2, 29, 30 Traditionally, MWT is used in immunohistochemistry with formalin-fixed tissues for antigen recovery from the cross-linking of aldehyde bridges.", [["tissues", "ANATOMY", 81, 88], ["aldehyde", "CHEMICAL", 136, 144], ["formalin", "CHEMICAL", 66, 74], ["aldehyde", "CHEMICAL", 136, 144], ["tissues", "TISSUE", 81, 88], ["aldehyde", "SIMPLE_CHEMICAL", 136, 144], ["formalin-fixed tissues", "TREATMENT", 66, 88], ["antigen recovery", "TREATMENT", 93, 109], ["the cross-linking of aldehyde bridges", "TREATMENT", 115, 152], ["aldehyde bridges", "OBSERVATION", 136, 152]]], ["37, 38 Similarly, MWT has proven useful for antigen demasking in cytologic specimens after fixation with ethanol and formalin 37 and after cytologic staining.", [["cytologic specimens", "ANATOMY", 65, 84], ["ethanol", "CHEMICAL", 105, 112], ["ethanol", "CHEMICAL", 105, 112], ["formalin", "CHEMICAL", 117, 125], ["cytologic specimens", "CANCER", 65, 84], ["ethanol", "SIMPLE_CHEMICAL", 105, 112], ["antigen demasking", "PROBLEM", 44, 61], ["cytologic specimens", "TEST", 65, 84], ["fixation", "TREATMENT", 91, 99], ["ethanol and formalin", "TREATMENT", 105, 125], ["cytologic staining", "TEST", 139, 157]]], ["1 However, MWT failed to recover viral antigen detectability in this study.", [["viral antigen detectability", "PROBLEM", 33, 60], ["this study", "TEST", 64, 74]]], ["Instead, MWT alone effectively abolished the immunolabeling of FCoV in untreated and unstained films; furthermore, it was not possible to reestablish immunostaining after antecedent cytologic staining and coverslipping.", [["MWT", "CHEMICAL", 9, 12], ["FCoV", "GENE_OR_GENE_PRODUCT", 63, 67], ["FCoV", "PROTEIN", 63, 67], ["unstained films", "TEST", 85, 100], ["antecedent cytologic staining", "TEST", 171, 200], ["coverslipping", "PROBLEM", 205, 218], ["FCoV", "OBSERVATION", 63, 67]]], ["Thus, this FCoV epitope appears to be much more vulnerable to changes induced by physicochemical factors than the other cellular proteins investigated in this study.| DISCUSSIONWhether viral antigen preservation can be achieved by prior fixation of a smear, as described for other microbial antigens, such as Chlamydia, 39 is currently under investigation.| DISCUSSIONOther studies have proposed that fixation by formalin or ethanol can improve ICC results.", [["cellular", "ANATOMY", 120, 128], ["Chlamydia", "DISEASE", 309, 318], ["formalin", "CHEMICAL", 413, 421], ["ethanol", "CHEMICAL", 425, 432], ["formalin", "CHEMICAL", 413, 421], ["ethanol", "CHEMICAL", 425, 432], ["FCoV", "GENE_OR_GENE_PRODUCT", 11, 15], ["cellular", "CELL", 120, 128], ["formalin", "SIMPLE_CHEMICAL", 413, 421], ["ethanol", "SIMPLE_CHEMICAL", 425, 432], ["FCoV epitope", "PROTEIN", 11, 23], ["physicochemical factors", "PROTEIN", 81, 104], ["cellular proteins", "PROTEIN", 120, 137], ["microbial antigens", "PROTEIN", 281, 299], ["this FCoV epitope", "PROBLEM", 6, 23], ["the other cellular proteins", "PROBLEM", 110, 137], ["this study", "TEST", 154, 164], ["viral antigen preservation", "TREATMENT", 185, 211], ["prior fixation", "TREATMENT", 231, 245], ["a smear", "TEST", 249, 256], ["other microbial antigens", "PROBLEM", 275, 299], ["Chlamydia", "PROBLEM", 309, 318], ["DISCUSSIONOther studies", "TEST", 358, 381], ["fixation", "TREATMENT", 401, 409], ["ethanol", "TREATMENT", 425, 432]]], ["1, 11, 13, 14, 26, 36, 37, 39 for FCoV detection in air-dried prestained films.ACKNOWLEDG EMENTSWe are grateful to the head technician of our Neuropathology & Cytology Lab, Mrs. Karin Stingl, for excellent technical assistance.DISCLOSUREThe authors have indicated that they have no affiliations or financial involvement with any organization or entity with a financial interest in, or in financial competition with, the subject matter or materials discussed in this article.", [["head", "ANATOMY", 119, 123], ["Neuropathology", "DISEASE", 142, 156], ["FCoV", "SIMPLE_CHEMICAL", 34, 38], ["head", "ORGANISM_SUBDIVISION", 119, 123], ["FCoV detection", "TEST", 34, 48], ["air-dried prestained films", "TEST", 52, 78]]]], "PMC7398604": [["IntroductionMetabolic surgery improves functional impairment and cardiovascular disease and reduces cancer risk and mortality related to obesity and type 2 diabetes (T2DM) [1, 2].", [["cardiovascular", "ANATOMY", 65, 79], ["cancer", "ANATOMY", 100, 106], ["functional impairment", "DISEASE", 39, 60], ["cardiovascular disease", "DISEASE", 65, 87], ["cancer", "DISEASE", 100, 106], ["obesity", "DISEASE", 137, 144], ["type 2 diabetes", "DISEASE", 149, 164], ["T2DM", "DISEASE", 166, 170], ["cardiovascular", "ANATOMICAL_SYSTEM", 65, 79], ["cancer", "CANCER", 100, 106], ["IntroductionMetabolic surgery", "TREATMENT", 0, 29], ["functional impairment", "PROBLEM", 39, 60], ["cardiovascular disease", "PROBLEM", 65, 87], ["reduces cancer risk", "PROBLEM", 92, 111], ["obesity", "PROBLEM", 137, 144], ["type 2 diabetes (T2DM)", "PROBLEM", 149, 171], ["cardiovascular disease", "OBSERVATION", 65, 87], ["obesity", "OBSERVATION", 137, 144]]], ["The recent coronavirus pandemic has proven to have poorer outcomes for persons with obesity [3] which has brought focus to the provision of weight management services [4].", [["coronavirus pandemic", "DISEASE", 11, 31], ["obesity", "DISEASE", 84, 91], ["coronavirus", "ORGANISM", 11, 22], ["persons", "ORGANISM", 71, 78], ["persons", "SPECIES", 71, 78], ["The recent coronavirus pandemic", "PROBLEM", 0, 31], ["obesity", "PROBLEM", 84, 91], ["weight management services", "TREATMENT", 140, 166], ["coronavirus", "OBSERVATION", 11, 22]]], ["The National Institute for Health and Clinical Excellence\u2019s (NICE) guidelines for metabolic surgery in 2014 [5] recommends metabolic surgery for patients with a body mass index (BMI) > 40 kg/m2 or 35\u201340 kg/m2 with a \u201csignificant disease that could be improved if they lost weight\u201d or BMI 30\u201335 kg/m2 with recent-onset T2DM.", [["body", "ANATOMY", 161, 165], ["T2DM", "DISEASE", 318, 322], ["patients", "ORGANISM", 145, 153], ["body", "ORGANISM_SUBDIVISION", 161, 165], ["patients", "SPECIES", 145, 153], ["metabolic surgery", "TREATMENT", 82, 99], ["metabolic surgery", "TREATMENT", 123, 140], ["a body mass index", "TEST", 159, 176], ["a \u201csignificant disease", "PROBLEM", 214, 236], ["recent-onset T2DM", "PROBLEM", 305, 322], ["significant", "OBSERVATION_MODIFIER", 217, 228], ["disease", "OBSERVATION", 229, 236], ["T2DM", "OBSERVATION", 318, 322]]], ["The guidelines are similar across Europe as well as internationally from the National Institutes of Health (USA) [6, 7].IntroductionThe rates of metabolic surgery in the National Health Service have increased 20-fold (approximately 250/year to 5500/year) between 2000 and 2016 [8, 9], but these are limited understanding of the provision of metabolic related to the number of individuals eligible.", [["metabolic surgery", "TREATMENT", 145, 162], ["metabolic surgery", "OBSERVATION", 145, 162]]], ["The aim of this study was to determine the proportion of the English population that are potentially eligible for metabolic surgery using national guidance and compare this to the delivery of metabolic surgery within regions of England.Data Sampling ::: MethodsThe Health Survey for England (HSE) versions for 2010 to 2014 were used to estimate the population potentially eligible for metabolic surgery.", [["this study", "TEST", 11, 21], ["metabolic surgery", "TREATMENT", 114, 131], ["national guidance", "TREATMENT", 138, 155], ["metabolic surgery", "TREATMENT", 192, 209], ["Data Sampling", "TEST", 236, 249], ["Methods", "TREATMENT", 254, 261], ["metabolic surgery", "TREATMENT", 385, 402], ["metabolic surgery", "OBSERVATION", 192, 209]]], ["Information was collected via trained interviewers who administered the interview face-to-face in participants\u2019 households.Data Collection ::: MethodsValid BMI was calculated and coded into groups: < 35 kg/m2, 35\u201340 kg/m2, and > 40 kg/m2.", [["participants", "SPECIES", 98, 110], ["MethodsValid BMI", "TEST", 143, 159]]], ["Data were collected on the obesity-related comorbidities T2DM, hypertension, stroke, ischaemic heart disease and osteoarthritis.", [["heart", "ANATOMY", 95, 100], ["obesity", "DISEASE", 27, 34], ["T2DM", "DISEASE", 57, 61], ["hypertension", "DISEASE", 63, 75], ["stroke", "DISEASE", 77, 83], ["ischaemic heart disease", "DISEASE", 85, 108], ["osteoarthritis", "DISEASE", 113, 127], ["heart", "ORGAN", 95, 100], ["the obesity", "PROBLEM", 23, 34], ["T2DM", "PROBLEM", 57, 61], ["hypertension", "PROBLEM", 63, 75], ["stroke", "PROBLEM", 77, 83], ["ischaemic heart disease", "PROBLEM", 85, 108], ["osteoarthritis", "PROBLEM", 113, 127], ["hypertension", "OBSERVATION", 63, 75], ["stroke", "OBSERVATION", 77, 83], ["ischaemic", "OBSERVATION_MODIFIER", 85, 94], ["heart", "ANATOMY", 95, 100], ["disease", "OBSERVATION", 101, 108], ["osteoarthritis", "OBSERVATION", 113, 127]]], ["Data was also collected on age, gender, ethnicity (White/Black/Asian/mixed/other), highest educational qualification (school/further-education/university/none), social class (managerial and profession/intermediate/routine-manual/other) and which of the 10 English regions they resided in.Study Outcomes ::: MethodsThe primary outcome for the study was to define the eligible population for metabolic surgery within the HSE respondent population.", [["Methods", "TREATMENT", 307, 314], ["the study", "TEST", 338, 347], ["metabolic surgery", "TREATMENT", 390, 407]]], ["Secondarily, the study compared the delivery of metabolic surgery with the potentially eligible population by region in England.", [["the study", "TEST", 13, 22], ["metabolic surgery", "TREATMENT", 48, 65], ["metabolic surgery", "OBSERVATION", 48, 65]]], ["Using the current NICE criteria, eligibility for metabolic surgery was defined as BMI > 40 kg/m2, BMI 35\u201340 kg/m2 with an obesity-related comorbidity or BMI 30\u201335 kg/m2 with a diagnosis of type 2 diabetes.", [["obesity", "DISEASE", 122, 129], ["type 2 diabetes", "DISEASE", 189, 204], ["metabolic surgery", "TREATMENT", 49, 66], ["BMI", "TEST", 82, 85], ["BMI", "TEST", 98, 101], ["an obesity", "PROBLEM", 119, 129], ["comorbidity", "PROBLEM", 138, 149], ["type 2 diabetes", "PROBLEM", 189, 204], ["obesity", "OBSERVATION", 122, 129], ["diabetes", "OBSERVATION", 196, 204]]], ["People with recent-onset T2DM and Asian ethnicity are also eligible with BMI 27.5 kg/m2.", [["T2DM", "DISEASE", 25, 29], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["recent-onset T2DM", "PROBLEM", 12, 29], ["BMI", "TEST", 73, 76], ["T2DM", "OBSERVATION", 25, 29]]], ["Comorbidity reports from HSE respondents did not define type of diabetes.", [["diabetes", "DISEASE", 64, 72], ["diabetes", "PROBLEM", 64, 72], ["diabetes", "OBSERVATION", 64, 72]]], ["Therefore, based on previous HSE analyses, the study estimated 90% of the respondents stating they had diabetes had type 2 diabetes mellitus.", [["diabetes", "DISEASE", 103, 111], ["type 2 diabetes mellitus", "DISEASE", 116, 140], ["previous HSE analyses", "TEST", 20, 41], ["the study", "TEST", 43, 52], ["diabetes", "PROBLEM", 103, 111], ["type 2 diabetes mellitus", "PROBLEM", 116, 140], ["diabetes mellitus", "OBSERVATION", 123, 140]]], ["Additionally, to define the \u201crecently diagnosed patient with type 2 diabetes\u201d identified as eligible in NICE guidance, data was secured on duration of type 2 diabetes for patients with BMI 30\u201335 kg/m2 from the National Diabetes Audit.", [["type 2 diabetes", "DISEASE", 61, 76], ["diabetes", "DISEASE", 158, 166], ["Diabetes", "DISEASE", 219, 227], ["patient", "ORGANISM", 48, 55], ["patients", "ORGANISM", 171, 179], ["patient", "SPECIES", 48, 55], ["patients", "SPECIES", 171, 179], ["type 2 diabetes", "PROBLEM", 61, 76], ["type 2 diabetes", "PROBLEM", 151, 166]]], ["Recent onset was defined as less than 10 years in agreement with NICE guidance.Metabolic Surgery Volume ::: MethodsThe volume of metabolic surgery performed in England was calculated using Hospital Episode Statistics from NHS Digital through the publicly available Statistics on Obesity, Physical Activity and Diet [11] from 2014 to 2019.", [["Obesity", "DISEASE", 279, 286], ["Methods", "TREATMENT", 108, 115], ["metabolic surgery", "TREATMENT", 129, 146], ["Obesity", "PROBLEM", 279, 286], ["volume", "OBSERVATION_MODIFIER", 119, 125], ["metabolic surgery", "OBSERVATION", 129, 146]]], ["Finished consultant episodes (FCE) with a primary diagnosis of obesity (E66) and procedure codes for metabolic surgery were included (appendix).Statistical Analysis ::: MethodsStatistical analysis was performed using SPSS version 26.0 software (Statistical Package for the Social Sciences software, Version 22, SPSS Chicago (IL), USA).", [["obesity", "DISEASE", 63, 70], ["appendix", "ORGAN", 134, 142], ["obesity", "PROBLEM", 63, 70], ["procedure codes", "TREATMENT", 81, 96], ["metabolic surgery", "TREATMENT", 101, 118], ["MethodsStatistical analysis", "TEST", 169, 196], ["SPSS version", "TEST", 217, 229], ["obesity", "OBSERVATION", 63, 70], ["appendix", "ANATOMY", 134, 142]]], ["Multivariable logistic regression analyses were performed to evaluate the associations with meeting NICE criteria for metabolic surgery with the HSE respondent population.", [["Multivariable logistic regression analyses", "TEST", 0, 42], ["metabolic surgery", "TREATMENT", 118, 135]]], ["All statistical tests were two-sided, with the threshold of significance set at a P value of less than 0.05.Metabolic Surgery\u2014Eligible Population ::: ResultsFollowing survey weightings, 7.3% of the community-dwelling population in England have fulfilled the NICE guidance for metabolic surgery.", [["All statistical tests", "TEST", 0, 21], ["a P value", "TEST", 80, 89], ["Metabolic Surgery", "TREATMENT", 108, 125], ["survey weightings", "TEST", 167, 184], ["metabolic surgery", "TREATMENT", 276, 293], ["metabolic surgery", "OBSERVATION", 276, 293]]], ["(2.6%: BMI > 40 kg/m2, 2.1%: BMI 35\u201340 kg/m2 with an obesity-related comorbidity, and, after adjustment with the NDA data, 2.6%: BMI 30\u201335 kg/m2 with presumed recent-onset T2DM).", [["obesity", "DISEASE", 53, 60], ["T2DM", "DISEASE", 172, 176], ["BMI", "TEST", 7, 10], ["BMI", "TEST", 29, 32], ["an obesity", "PROBLEM", 50, 60], ["comorbidity", "PROBLEM", 69, 80], ["the NDA data", "TEST", 109, 121], ["recent-onset T2DM", "PROBLEM", 159, 176], ["obesity", "OBSERVATION", 53, 60]]], ["Using the mid-2018 adult English population estimate (44.02million), this would indicate a potentially eligible population of 3.21million.Variation by English Region ::: ResultsThere was variation between 6.1 and 9.7% in the proportion of the population potentially eligible for metabolic surgery between English regions (Fig. 2).", [["variation", "TEST", 187, 196], ["metabolic surgery", "TREATMENT", 279, 296], ["metabolic surgery", "OBSERVATION", 279, 296]]], ["From 2013 to 2019, there were 39,253 metabolic surgery FCEs (mean 6542 FCEs annually).", [["metabolic surgery", "TREATMENT", 37, 54]]], ["This equates to 0.20% of potentially eligible patients undergoing metabolic surgery annually.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["metabolic surgery", "TREATMENT", 66, 83], ["metabolic surgery", "OBSERVATION", 66, 83]]], ["The rates in English regions varied between 0.08 and 0.41% (Fig. 3).Factors Associated with Metabolic Surgery Eligibility ::: ResultsThe association of sociodemographic variables with eligibility for metabolic surgery is shown in Table 1.", [["The rates", "TEST", 0, 9], ["metabolic surgery", "TREATMENT", 200, 217], ["rates", "OBSERVATION_MODIFIER", 4, 9]]], ["Intermediate and other social classes were associated with reduced metabolic surgery eligibility compared with managerial and professional classes.", [["reduced metabolic surgery", "TREATMENT", 59, 84]]], ["Ethnicity was not associated with metabolic surgery eligibility.DiscussionThis study has uniquely demonstrated that 7.3% of adults in England are potentially eligible for metabolic surgery according to NICE guidance.", [["adults", "ORGANISM", 124, 130], ["metabolic surgery", "TREATMENT", 34, 51], ["This study", "TEST", 74, 84], ["metabolic surgery", "TREATMENT", 171, 188], ["not associated with", "UNCERTAINTY", 14, 33]]], ["Eligible adults were more likely to be female, older and have a lower educational attainment and higher social deprivation.", [["adults", "ORGANISM", 9, 15]]], ["Considering the annual 6500 metabolic surgery procedure volume, this equates to 0.20% of the potentially eligible English population undergoing metabolic surgery per year.", [["the annual 6500 metabolic surgery procedure volume", "TREATMENT", 12, 62], ["metabolic surgery", "TREATMENT", 144, 161], ["metabolic surgery", "OBSERVATION", 144, 161]]], ["This extends previous work showing proportionally higher need for and lower delivery of metabolic surgery in the UK compared with Europe based on average national BMI rates [6].DiscussionThere are several potential explanations for the poor implementation of metabolic surgery despite NICE guidance.", [["metabolic surgery", "TREATMENT", 88, 105], ["metabolic surgery", "TREATMENT", 259, 276], ["NICE guidance", "TREATMENT", 285, 298]]], ["First, at the patient level, this study has shown that eligible adults are more likely to have poorer educational attainment and higher deprivation indicating a form of inverse care law.", [["patient", "ORGANISM", 14, 21], ["adults", "ORGANISM", 64, 70], ["patient", "SPECIES", 14, 21], ["this study", "TEST", 29, 39]]], ["Second, stigma surrounding obesity treatment and willingness or ability to meet strict criteria for accessing weight management services, or indeed capacity within these services, in England may present a barrier to uptake [12, 13].", [["obesity", "DISEASE", 27, 34], ["obesity treatment", "TREATMENT", 27, 44], ["accessing weight management services", "TREATMENT", 100, 136], ["obesity", "OBSERVATION", 27, 34]]], ["Third, studies on primary care practitioners in the UK suggest there is limited awareness of the role of metabolic surgery and perhaps even a level of bias against the provision of this treatment to patients who are obese [14].DiscussionThere are some important limitations.", [["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["metabolic surgery", "TREATMENT", 105, 122], ["this treatment", "TREATMENT", 181, 195], ["obese", "PROBLEM", 216, 221]]], ["The disadvantages of routine collected data, such as HES, have been described in detail elsewhere [15].", [["routine collected data", "TEST", 21, 43]]], ["However, the HES dataset has been used previously for the reporting of the provision of NHS public-funded bariatric surgery in England.", [["funded bariatric surgery", "TREATMENT", 99, 123], ["bariatric surgery", "OBSERVATION", 106, 123]]], ["With regard to the HSE dataset, a proportion of respondents did not have a BMI available for analysis because of refusal or invalid weight recording.", [["HSE dataset", "DNA", 19, 30], ["a BMI", "TEST", 73, 78], ["analysis", "TEST", 93, 101], ["invalid weight recording", "TEST", 124, 148]]], ["Additionally, the self-reported comorbid conditions rely on patient recall.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["comorbid conditions", "PROBLEM", 32, 51]]], ["However, not all of these comorbidities could be included as the HSE did not provide data about some obesity-related comorbidities such as non-alcoholic steatohepatitis and obstructive sleep apnoea.", [["obesity", "DISEASE", 101, 108], ["non-alcoholic steatohepatitis", "DISEASE", 139, 168], ["obstructive sleep apnoea", "DISEASE", 173, 197], ["these comorbidities", "PROBLEM", 20, 39], ["some obesity", "PROBLEM", 96, 108], ["related comorbidities", "PROBLEM", 109, 130], ["non-alcoholic steatohepatitis", "PROBLEM", 139, 168], ["obstructive sleep apnoea", "PROBLEM", 173, 197], ["obesity", "OBSERVATION", 101, 108], ["non-alcoholic steatohepatitis", "OBSERVATION", 139, 168], ["obstructive", "OBSERVATION_MODIFIER", 173, 184], ["sleep apnoea", "OBSERVATION", 185, 197]]], ["Extrapolating this national level data from a comparatively moderate sample size from several non-linked datasets may introduce a margin of error in the study estimates.", [["a comparatively moderate sample size", "PROBLEM", 44, 80], ["several non-linked datasets", "PROBLEM", 86, 113], ["the study estimates", "TEST", 149, 168], ["size", "OBSERVATION_MODIFIER", 76, 80], ["several", "OBSERVATION_MODIFIER", 86, 93], ["non-linked datasets", "OBSERVATION", 94, 113], ["margin", "OBSERVATION_MODIFIER", 130, 136]]], ["However, the HSE data were weighted for non-response, and the HSE was specifically designed to be representative of private households.", [["the HSE data", "TEST", 9, 21]]], ["Additionally, the study used surrogate data extrapolation from the National Diabetes Audit to define recent-onset type 2 diabetes.", [["Diabetes", "DISEASE", 76, 84], ["type 2 diabetes", "DISEASE", 114, 129], ["the study", "TEST", 14, 23], ["type 2 diabetes", "PROBLEM", 114, 129], ["diabetes", "OBSERVATION", 121, 129]]], ["Finally, the HSE dataset prevented derivation of those patients who would not wish to proceed with metabolic surgery or who would be unfit to do so.DiscussionThe current eligibility rate for metabolic surgery far exceeds current service delivery, which has both financial and workforce resource implications for the NHS.", [["patients", "ORGANISM", 55, 63], ["HSE dataset", "DNA", 13, 24], ["patients", "SPECIES", 55, 63], ["metabolic surgery", "TREATMENT", 99, 116], ["metabolic surgery", "TREATMENT", 191, 208], ["current service delivery", "TREATMENT", 221, 245]]], ["In England, with the decision to move the commissioning of metabolic surgery from a national perspective to a more locally delivered version through Clinical Commissioning Groups (CCG) [16], there is the risk that metabolic surgery access has become less uniform and that these current study findings of 5-fold regional variation between the East of England and London mask more extensive variation at the smaller CCG level.", [["metabolic surgery", "TREATMENT", 59, 76], ["metabolic surgery access", "TREATMENT", 214, 238], ["these current study", "TEST", 272, 291], ["5-fold regional variation", "PROBLEM", 304, 329], ["less uniform", "OBSERVATION_MODIFIER", 250, 262], ["regional variation", "OBSERVATION", 311, 329], ["extensive", "OBSERVATION_MODIFIER", 379, 388], ["variation", "OBSERVATION_MODIFIER", 389, 398], ["smaller", "OBSERVATION_MODIFIER", 406, 413], ["CCG", "OBSERVATION_MODIFIER", 414, 417]]], ["Coupled with the socio-demographic characteristics of those meeting eligibility criteria, any service change needs to ensure equitable access to metabolic surgery on the basis of need.", [["metabolic surgery", "TREATMENT", 145, 162]]], ["Further exploration of the equity of access to metabolic surgery at local and regional levels is urgently required.ConclusionThe limited current volume of bariatric surgery provided in England only benefits a tiny fraction of the general population who are eligible for it; this failing is compounded by marked regional variation.", [["Further exploration", "TEST", 0, 19], ["metabolic surgery", "TREATMENT", 47, 64], ["bariatric surgery", "TREATMENT", 155, 172], ["marked regional variation", "PROBLEM", 304, 329], ["tiny", "OBSERVATION_MODIFIER", 209, 213], ["marked", "OBSERVATION_MODIFIER", 304, 310], ["regional variation", "OBSERVATION", 311, 329]]], ["The approximately 6500 operations performed annually in England contrast markedly with up to 3.21million eligible patients (before adjustment for fitness and desire for surgery).", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["surgery", "TREATMENT", 169, 176]]], ["Possible solutions include (a) reducing stigma around surgery; (b) continuing to publicize the personal and societal benefits of metabolic surgery with the public, primary care and the cardiovascular and metabolic physician community and (c) encouraging more funding and commissioning of metabolic surgical services.", [["cardiovascular", "ANATOMY", 185, 199], ["a) reducing stigma around surgery", "TREATMENT", 28, 61], ["metabolic surgery", "TREATMENT", 129, 146], ["metabolic surgical services", "TREATMENT", 288, 315]]]], "PMC7107499": [["In Silico Design of the Immunogen and Generation of rAd5 Vaccines ::: MATERIALS AND METHODSThe fusion gene was designed and codon-optimized to express a secreted and CD40-targeted consensus MERS-CoV S1 subunit (amino acids 1\u2013747).", [["amino acids 1\u2013747", "CHEMICAL", 211, 228], ["amino acids", "CHEMICAL", 211, 222], ["rAd5", "ORGANISM", 52, 56], ["CD40", "GENE_OR_GENE_PRODUCT", 166, 170], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 190, 201], ["amino acids", "AMINO_ACID", 211, 222], ["1\u2013747", "AMINO_ACID", 223, 228], ["METHODSThe fusion gene", "DNA", 84, 106], ["CD40", "PROTEIN", 166, 170], ["consensus MERS-CoV S1 subunit", "PROTEIN", 180, 209], ["amino acids 1\u2013747", "PROTEIN", 211, 228], ["the Immunogen", "TREATMENT", 20, 33], ["rAd5 Vaccines", "TREATMENT", 52, 65], ["METHODSThe fusion gene", "TREATMENT", 84, 106], ["CoV S1 subunit (amino acids", "TREATMENT", 195, 222]]], ["In brief, all available MERS-CoV S sequences were downloaded from the GenBank database, and the dataset was filtered by removing sequences containing ambiguous amino acid codes (BJOUXZ).", [["amino acid", "CHEMICAL", 160, 170], ["amino acid", "CHEMICAL", 160, 170], ["amino acid", "AMINO_ACID", 160, 170], ["MERS-CoV S sequences", "DNA", 24, 44], ["all available MERS-CoV S sequences", "TEST", 10, 44], ["the GenBank database", "TEST", 66, 86], ["ambiguous amino acid codes", "TREATMENT", 150, 176]]], ["The final dataset was multiply aligned using CLUSTALW, the Shannon entropy for each position was determined, and the consensus S1 subunit sequence was obtained.", [["consensus S1 subunit sequence", "DNA", 117, 146], ["the consensus S1 subunit sequence", "TEST", 113, 146]]], ["The signal peptide from the MERS-CoV S protein was maintained at the N-terminus to secrete the fusion protein from rAd5-infected cells.", [["cells", "ANATOMY", 129, 134], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 28, 38], ["rAd5", "GENE_OR_GENE_PRODUCT", 115, 119], ["cells", "CELL", 129, 134], ["MERS-CoV S protein", "PROTEIN", 28, 46], ["N-terminus", "PROTEIN", 69, 79], ["fusion protein", "PROTEIN", 95, 109], ["rAd5", "PROTEIN", 115, 119], ["infected cells", "CELL_TYPE", 120, 134], ["MERS-CoV", "SPECIES", 28, 36], ["The signal peptide", "TEST", 0, 18], ["CoV S protein", "TEST", 33, 46], ["the N-terminus", "TREATMENT", 65, 79], ["the fusion protein", "TEST", 91, 109], ["infected cells", "PROBLEM", 120, 134], ["infected cells", "OBSERVATION", 120, 134]]], ["The synthetic fusion gene was synthesized by linking the coding region of MERS-CoV S1 to a histidine tag coding sequence, followed by coding region for the fibritin trimerization motif [37] connected via a nonpolar amino acid linker to the ectodomain of CD40L (amino acids 117\u2013260) coding region to express the fusion protein S1/F/CD40L.", [["amino acid", "CHEMICAL", 215, 225], ["amino acids 117\u2013260", "CHEMICAL", 261, 280], ["histidine", "CHEMICAL", 91, 100], ["amino acid", "CHEMICAL", 215, 225], ["amino acids", "CHEMICAL", 261, 272], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 74, 85], ["amino acid", "AMINO_ACID", 215, 225], ["CD40L", "GENE_OR_GENE_PRODUCT", 254, 259], ["amino acids 117\u2013260", "AMINO_ACID", 261, 280], ["S1/F", "GENE_OR_GENE_PRODUCT", 326, 330], ["CD40L", "GENE_OR_GENE_PRODUCT", 331, 336], ["synthetic fusion gene", "DNA", 4, 25], ["MERS-CoV S1", "DNA", 74, 85], ["histidine tag coding sequence", "DNA", 91, 120], ["fibritin trimerization motif", "PROTEIN", 156, 184], ["nonpolar amino acid linker", "PROTEIN", 206, 232], ["CD40L", "PROTEIN", 254, 259], ["amino acids 117\u2013260", "PROTEIN", 261, 280], ["fusion protein", "PROTEIN", 311, 325], ["S1", "PROTEIN", 326, 328], ["F", "PROTEIN", 329, 330], ["CD40L", "PROTEIN", 331, 336], ["MERS-CoV", "SPECIES", 74, 82], ["The synthetic fusion gene", "TREATMENT", 0, 25], ["a histidine tag coding sequence", "TREATMENT", 89, 120], ["the fibritin trimerization motif", "TREATMENT", 152, 184], ["a nonpolar amino acid linker", "TREATMENT", 204, 232], ["amino acids", "TEST", 261, 272]]], ["The fusion gene was then used to generate the proposed rAd5 construct (rAd5-S1/F/CD40L) in addition to rAd5 vaccines expressing secreted and consensus S1 protein alone (rAd5-S1) and a vector control expressing Green Fluorescent Protein (rAd5-GFP) as shown in Figure 1.Cells and MERS-CoV Virus ::: MATERIALS AND METHODSVero E6 and Huh7.5 cells were cultured and maintained in complete Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum.", [["Cells", "ANATOMY", 268, 273], ["Huh7.5 cells", "ANATOMY", 330, 342], ["fetal bovine serum", "ANATOMY", 465, 483], ["rAd5", "GENE_OR_GENE_PRODUCT", 55, 59], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 71, 78], ["CD40L", "GENE_OR_GENE_PRODUCT", 81, 86], ["rAd5", "GENE_OR_GENE_PRODUCT", 103, 107], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 169, 176], ["Green Fluorescent Protein", "GENE_OR_GENE_PRODUCT", 210, 235], ["rAd5-GFP", "GENE_OR_GENE_PRODUCT", 237, 245], ["Cells", "CELL", 268, 273], ["MERS-CoV Virus", "ORGANISM", 278, 292], ["METHODSVero E6", "CELL", 311, 325], ["Huh7.5 cells", "CELL", 330, 342], ["bovine", "ORGANISM", 471, 477], ["serum", "ORGANISM_SUBSTANCE", 478, 483], ["fusion gene", "DNA", 4, 15], ["rAd5 construct", "DNA", 55, 69], ["rAd5", "PROTEIN", 71, 75], ["S1", "PROTEIN", 76, 78], ["F", "PROTEIN", 79, 80], ["CD40L", "PROTEIN", 81, 86], ["consensus S1 protein", "PROTEIN", 141, 161], ["rAd5", "PROTEIN", 169, 173], ["S1", "PROTEIN", 174, 176], ["Green Fluorescent Protein", "PROTEIN", 210, 235], ["rAd5", "PROTEIN", 237, 241], ["GFP", "PROTEIN", 242, 245], ["METHODSVero E6", "CELL_LINE", 311, 325], ["Huh7.5 cells", "CELL_LINE", 330, 342], ["bovine", "SPECIES", 471, 477], ["MERS-CoV Virus", "SPECIES", 278, 292], ["bovine", "SPECIES", 471, 477], ["The fusion gene", "TREATMENT", 0, 15], ["the proposed rAd5 construct", "TREATMENT", 42, 69], ["rAd5-S1/F/CD40L)", "TREATMENT", 71, 87], ["rAd5 vaccines", "TREATMENT", 103, 116], ["a vector control", "TREATMENT", 182, 198], ["Green Fluorescent Protein", "TEST", 210, 235], ["METHODSVero E6", "TREATMENT", 311, 325], ["fetal bovine serum", "TEST", 465, 483], ["fusion", "OBSERVATION", 4, 10]]], ["MERS-CoV-EMC/2012 was provided by Heinz Feldmann (National Institutes of Health [NIH], National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, Hamilton, Montana) and Ron A. Fouchier (Erasmus Medical Center, Rotterdam, Netherlands).", [["Allergy and Infectious Diseases", "DISEASE", 109, 140]]], ["MERS-CoV titration was done in Vero E6 cells using Median Tissue Culture Infectious Dose (TCID50) assay as previously described [11].", [["Vero E6 cells", "ANATOMY", 31, 44], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["Vero E6 cells", "CELL", 31, 44], ["Vero E6 cells", "CELL_LINE", 31, 44], ["Vero E6", "SPECIES", 31, 38], ["CoV titration", "TREATMENT", 5, 18], ["Vero E6 cells", "TREATMENT", 31, 44], ["Median Tissue Culture", "TREATMENT", 51, 72]]], ["All work involving infectious MERS-CoV was conducted within approved biosafety level 3 (BSL-3) at the Galveston National Laboratory (GNL) at the University of Texas Medical Branch (UTMB) in Galveston.Animal Experiments ::: MATERIALS AND METHODSThe immunogenicity and the protective efficacy of the rAd5-based vaccine candidates were evaluated against MERS-CoV infection in the hDPP4 Tg+ mouse model.", [["rAd5", "CHEMICAL", 298, 302], ["MERS-CoV infection", "DISEASE", 351, 369], ["MERS-CoV", "ORGANISM", 30, 38], ["rAd5", "SIMPLE_CHEMICAL", 298, 302], ["MERS-CoV", "ORGANISM", 351, 359], ["hDPP4", "GENE_OR_GENE_PRODUCT", 377, 382], ["mouse", "ORGANISM", 387, 392], ["rAd5", "PROTEIN", 298, 302], ["mouse", "SPECIES", 387, 392], ["MERS-CoV", "SPECIES", 30, 38], ["MERS-CoV", "SPECIES", 351, 359], ["mouse", "SPECIES", 387, 392], ["BSL", "TEST", 88, 91], ["METHODSThe immunogenicity", "TREATMENT", 237, 262], ["the rAd5-based vaccine", "TREATMENT", 294, 316], ["MERS", "PROBLEM", 351, 355], ["CoV infection", "PROBLEM", 356, 369], ["infectious", "OBSERVATION", 19, 29], ["infection", "OBSERVATION", 360, 369]]], ["A total of 45 hDPP4 Tg+ mice aged 4\u20135 months were used (15 mice/group).", [["hDPP4", "GENE_OR_GENE_PRODUCT", 14, 19], ["mice", "ORGANISM", 24, 28], ["mice", "ORGANISM", 59, 63], ["hDPP4 Tg", "PROTEIN", 14, 22], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 24, 28]]], ["Mice were intramuscularly immunized twice, 28 days apart, with 109 of rAd5 vaccine candidates (Figure 2).", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["rAd5 vaccine candidates", "TREATMENT", 70, 93]]], ["Blood samples were collected 3 weeks after each immunization via retro-orbital bleeding.", [["Blood samples", "ANATOMY", 0, 13], ["retro-orbital", "ANATOMY", 65, 78], ["retro-orbital bleeding", "DISEASE", 65, 87], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["retro-orbital", "ORGANISM_SUBDIVISION", 65, 78], ["Blood samples", "TEST", 0, 13], ["each immunization", "TREATMENT", 43, 60], ["retro-orbital bleeding", "PROBLEM", 65, 87], ["retro-orbital", "ANATOMY", 65, 78], ["bleeding", "OBSERVATION", 79, 87]]], ["Four weeks after the second immunization, mice were intranasally challenged with 103 TCID50 (~100 Median Lethal Dose [LD50]) of MERS-CoV.", [["mice", "ORGANISM", 42, 46], ["MERS-CoV", "ORGANISM", 128, 136], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["MERS-CoV", "SPECIES", 128, 136], ["the second immunization", "TREATMENT", 17, 40]]], ["On days 3 and 6 postinfection, 4 mice from each group were killed to assess the virus titer and lung pathology.", [["lung", "ANATOMY", 96, 100], ["mice", "ORGANISM", 33, 37], ["lung", "ORGAN", 96, 100], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["the virus titer", "TEST", 76, 91], ["lung pathology", "PROBLEM", 96, 110], ["lung", "ANATOMY", 96, 100], ["pathology", "OBSERVATION", 101, 110]]], ["The remaining mice were monitored for morbidity and mortality on a daily basis for up to 18 days.", [["mice", "ORGANISM", 14, 18], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["morbidity", "PROBLEM", 38, 47]]], ["All animal studies involving infectious MERS-CoV were conducted within approved animal BSL-3 laboratories at GNL in accordance with the Guide for the Care and Use of Laboratory Animals of the NIH and Association for Assessment and Accreditation of Laboratory Animal Care, and with institutional animal protocol approval from UTMB.", [["MERS-CoV", "ORGANISM", 40, 48], ["MERS-CoV", "SPECIES", 40, 48], ["All animal studies", "TEST", 0, 18], ["animal BSL", "TEST", 80, 90], ["Assessment", "TEST", 216, 226], ["infectious", "OBSERVATION", 29, 39]]], ["Animals were housed in on-site animal facilities under a 12:12 light:dark cycle with room temperature and humidity kept between 21\u00b0C and 25\u00b0C and 31%\u201347%, respectively, with ad libitum access to food and water.Lung Pathology ::: MATERIALS AND METHODSAt day 3 and 6 after challenge, 4 mice in each group were euthanized and their lungs were collected and examined for pathological changes after immunization and viral challenge.", [["Lung", "ANATOMY", 210, 214], ["lungs", "ANATOMY", 329, 334], ["Animals", "ORGANISM", 0, 7], ["Lung", "ORGAN", 210, 214], ["mice", "ORGANISM", 284, 288], ["lungs", "ORGAN", 329, 334], ["mice", "SPECIES", 284, 288], ["mice", "SPECIES", 284, 288], ["humidity", "TREATMENT", 106, 114], ["Lung Pathology", "TEST", 210, 224], ["pathological changes", "PROBLEM", 367, 387], ["immunization", "TREATMENT", 394, 406], ["viral challenge", "TREATMENT", 411, 426], ["Pathology", "OBSERVATION", 215, 224], ["lungs", "ANATOMY", 329, 334]]], ["In brief, lung tissues were fixed in 10% buffered formalin for 72 hours, transferred to 70% ethanol, and later paraffin embedded.", [["lung tissues", "ANATOMY", 10, 22], ["formalin", "CHEMICAL", 50, 58], ["ethanol", "CHEMICAL", 92, 99], ["formalin", "CHEMICAL", 50, 58], ["ethanol", "CHEMICAL", 92, 99], ["paraffin", "CHEMICAL", 111, 119], ["lung tissues", "TISSUE", 10, 22], ["formalin", "SIMPLE_CHEMICAL", 50, 58], ["ethanol", "SIMPLE_CHEMICAL", 92, 99], ["lung tissues", "ANATOMY", 10, 22]]], ["Histopathological evaluation was performed on deparaffinized sections stained by routine hematoxylin and eosin staining.", [["sections", "ANATOMY", 61, 69], ["hematoxylin", "CHEMICAL", 89, 100], ["eosin", "CHEMICAL", 105, 110], ["hematoxylin", "SIMPLE_CHEMICAL", 89, 100], ["Histopathological evaluation", "TEST", 0, 28], ["deparaffinized sections", "TEST", 46, 69], ["routine hematoxylin", "TEST", 81, 100], ["eosin staining", "TEST", 105, 119]]], ["Evaluations for histopathology were done by pathologists who were blinded to each specimen source.", [["Evaluations", "TEST", 0, 11], ["histopathology", "TEST", 16, 30]]], ["Numeric scores were assigned to assess the extent of pathological damage as follows: 0, no observed pathology (undetectable infiltration); 1, mild pathology (up to 5% infiltration); 2, moderate pathology (up to 20% infiltration); 3, severe pathology (>20% infiltration).Viral Titration by TCID50 ::: MATERIALS AND METHODSLungs collected from challenged mice on day 3 postchallenge were used to determine viral titer by TCID50.", [["mice", "ORGANISM", 353, 357], ["mice", "SPECIES", 353, 357], ["mice", "SPECIES", 353, 357], ["Numeric scores", "TEST", 0, 14], ["pathological damage", "PROBLEM", 53, 72], ["observed pathology (undetectable infiltration", "PROBLEM", 91, 136], ["mild pathology", "PROBLEM", 142, 156], ["moderate pathology", "PROBLEM", 185, 203], ["severe pathology", "PROBLEM", 233, 249], ["Viral Titration", "TREATMENT", 270, 285], ["METHODSLungs", "TEST", 314, 326], ["pathological", "OBSERVATION_MODIFIER", 53, 65], ["damage", "OBSERVATION", 66, 72], ["no observed", "UNCERTAINTY", 88, 99], ["pathology", "OBSERVATION", 100, 109], ["undetectable", "OBSERVATION_MODIFIER", 111, 123], ["infiltration", "OBSERVATION", 124, 136], ["mild", "OBSERVATION_MODIFIER", 142, 146], ["pathology", "OBSERVATION", 147, 156], ["moderate", "OBSERVATION_MODIFIER", 185, 193], ["pathology", "OBSERVATION", 194, 203], ["severe", "OBSERVATION_MODIFIER", 233, 239], ["pathology", "OBSERVATION", 240, 249]]], ["In brief, pieces of collected lung tissue were weighed and homogenized in phosphate-buffered saline containing 2% fetal calf serum with a TissueLyser (Qiagen).", [["lung tissue", "ANATOMY", 30, 41], ["fetal calf serum", "ANATOMY", 114, 130], ["phosphate", "CHEMICAL", 74, 83], ["phosphate", "CHEMICAL", 74, 83], ["lung tissue", "TISSUE", 30, 41], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 74, 99], ["fetal calf", "ORGANISM_SUBSTANCE", 114, 124], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["calf", "SPECIES", 120, 124], ["collected lung tissue", "PROBLEM", 20, 41], ["phosphate-buffered saline", "TREATMENT", 74, 99], ["a TissueLyser (Qiagen)", "TREATMENT", 136, 158], ["lung tissue", "ANATOMY", 30, 41]]], ["After clarification of the cellular and tissue debris by centrifugation, the titers of infectious virus in the suspensions of infected tissues were determined using TCID50 assay.", [["cellular", "ANATOMY", 27, 35], ["tissue debris", "ANATOMY", 40, 53], ["tissues", "ANATOMY", 135, 142], ["cellular", "CELL", 27, 35], ["tissue debris", "TISSUE", 40, 53], ["tissues", "TISSUE", 135, 142], ["the cellular and tissue debris", "PROBLEM", 23, 53], ["centrifugation", "TREATMENT", 57, 71], ["infectious virus", "PROBLEM", 87, 103], ["infected tissues", "PROBLEM", 126, 142], ["TCID50 assay", "TEST", 165, 177], ["tissue", "ANATOMY", 40, 46], ["debris", "OBSERVATION", 47, 53], ["infectious", "OBSERVATION_MODIFIER", 87, 97], ["infected tissues", "OBSERVATION", 126, 142]]], ["The virus titers of individual samples were expressed as log10 TCID50 per gram of tissue and the minimal detectable level of virus was 2.5 log10 TCID50 as determined by lung size.Viral Titration by Reverse-Transcription Quantitative Polymerase Chain Reaction ::: MATERIALS AND METHODSLung samples from each group of mice (n = 4 per group) were transferred to individual vials containing RNAlater solution and subsequently homogenized and subjected to total RNA isolation using TRIzol Reagent.", [["samples", "ANATOMY", 31, 38], ["tissue", "ANATOMY", 82, 88], ["lung", "ANATOMY", 169, 173], ["METHODSLung samples", "ANATOMY", 277, 296], ["tissue", "TISSUE", 82, 88], ["lung", "ORGAN", 169, 173], ["METHODSLung samples", "CANCER", 277, 296], ["mice", "ORGANISM", 316, 320], ["mice", "SPECIES", 316, 320], ["mice", "SPECIES", 316, 320], ["The virus titers", "TEST", 0, 16], ["individual samples", "TEST", 20, 38], ["the minimal detectable level of virus", "PROBLEM", 93, 130], ["Viral Titration", "TREATMENT", 179, 194], ["METHODSLung samples", "TEST", 277, 296], ["RNAlater solution", "TREATMENT", 387, 404], ["total RNA isolation", "TREATMENT", 451, 470], ["TRIzol Reagent", "TREATMENT", 477, 491], ["lung", "ANATOMY", 169, 173], ["size", "OBSERVATION_MODIFIER", 174, 178]]], ["To determine the viral titer in the lung, MERS-CoV-specific upstream E gene (upE) and endogenous control gene (mouse \u03b2-actin) were quantified using 1-step reverse-transcription quantitative polymerase chain reaction (RT-qPCR).", [["lung", "ANATOMY", 36, 40], ["lung", "ORGAN", 36, 40], ["MERS-CoV-specific upstream E gene", "GENE_OR_GENE_PRODUCT", 42, 75], ["upE", "GENE_OR_GENE_PRODUCT", 77, 80], ["mouse", "ORGANISM", 111, 116], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 117, 124], ["MERS-CoV-specific upstream E gene", "DNA", 42, 75], ["upE", "DNA", 77, 80], ["endogenous control gene", "DNA", 86, 109], ["mouse \u03b2-actin", "DNA", 111, 124], ["mouse", "SPECIES", 111, 116], ["mouse", "SPECIES", 111, 116], ["the viral titer", "TEST", 13, 28], ["MERS-CoV", "TEST", 42, 50], ["endogenous control gene (mouse \u03b2-actin)", "TREATMENT", 86, 125], ["quantitative polymerase chain reaction", "PROBLEM", 177, 215], ["viral titer", "OBSERVATION", 17, 28], ["lung", "ANATOMY", 36, 40]]], ["Cycle threshold (Ct) values for each sample were analyzed against Ct values from a standard curve of MERS-CoV messenger RNA (mRNA) copy number.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 101, 109], ["MERS-CoV messenger RNA", "RNA", 101, 123], ["mRNA", "RNA", 125, 129], ["MERS-CoV", "SPECIES", 101, 109], ["Cycle threshold", "TEST", 0, 15], ["Ct) values", "TEST", 17, 27], ["each sample", "TEST", 32, 43], ["Ct values", "TEST", 66, 75], ["a standard curve", "TEST", 81, 97]]], ["Relative MERS-CoV upE mRNA expression value was calculated for each replicate and expressed as the equivalent of log10 equivalents per gram (TCID eq/g) of the tissue by the standard Ct (\u2206\u2206Ct) method using Bio-Rad CFX Manager 3.0 software.Enzyme-Linked Immunosorbent Assay ::: MATERIALS AND METHODSThe end-point titers of anti-S1 total immunoglobulin G (IgG) as well as its isotypes including IgG1, IgG2a, and IgG2b from immunized mice were determined by enzyme-linked immunosorbent assay as described previously [11].", [["tissue", "ANATOMY", 159, 165], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["tissue", "TISSUE", 159, 165], ["anti-S1", "GENE_OR_GENE_PRODUCT", 321, 328], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 335, 351], ["IgG", "GENE_OR_GENE_PRODUCT", 353, 356], ["IgG1", "GENE_OR_GENE_PRODUCT", 392, 396], ["IgG2a", "GENE_OR_GENE_PRODUCT", 398, 403], ["IgG2b", "GENE_OR_GENE_PRODUCT", 409, 414], ["mice", "ORGANISM", 430, 434], ["MERS-CoV upE mRNA", "RNA", 9, 26], ["anti-S1", "PROTEIN", 321, 328], ["immunoglobulin G", "PROTEIN", 335, 351], ["IgG", "PROTEIN", 353, 356], ["IgG1", "PROTEIN", 392, 396], ["IgG2a", "PROTEIN", 398, 403], ["IgG2b", "PROTEIN", 409, 414], ["mice", "SPECIES", 430, 434], ["mice", "SPECIES", 430, 434], ["Relative MERS", "TEST", 0, 13], ["CoV upE mRNA expression value", "TEST", 14, 43], ["the standard Ct", "TEST", 169, 184], ["Enzyme", "TEST", 238, 244], ["METHODSThe", "TEST", 290, 300], ["titers", "TEST", 311, 317], ["anti-S1 total immunoglobulin G (IgG)", "TREATMENT", 321, 357], ["IgG1", "TEST", 392, 396], ["IgG2a", "TEST", 398, 403], ["IgG2b", "TREATMENT", 409, 414], ["enzyme", "TEST", 454, 460], ["immunosorbent assay", "TEST", 468, 487], ["MERS", "OBSERVATION", 9, 13], ["tissue", "ANATOMY", 159, 165]]], ["Serum samples were tested in a 2-fold serial dilution starting from 1:100.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["Serum samples", "TEST", 0, 13]]], ["End-point titers were determined and expressed as the reciprocals of the highest dilution that gave an optical density signal higher than the cutoff value, defined as the mean of prebleed samples plus 3 standard deviations (SD).MERS-Pseudotyped Neutralization Assay ::: MATERIALS AND METHODSMERS-pseudotyped viral particles (MERSpp) were produced and titrated using the Huh7.5 cell line as described previously [39].", [["samples", "ANATOMY", 188, 195], ["Huh7.5 cell line", "ANATOMY", 370, 386], ["pseudotyped", "ORGANISM", 296, 307], ["Huh7.5 cell line", "CELL", 370, 386], ["Huh7.5 cell line", "CELL_LINE", 370, 386], ["End-point titers", "TEST", 0, 16], ["an optical density signal", "TEST", 100, 125], ["METHODSMERS", "TEST", 284, 295], ["pseudotyped viral particles (MERSpp)", "TREATMENT", 296, 332], ["the Huh7.5 cell line", "TREATMENT", 366, 386], ["highest dilution", "OBSERVATION", 73, 89], ["optical density", "OBSERVATION", 103, 118], ["higher", "OBSERVATION_MODIFIER", 126, 132], ["cell line", "OBSERVATION", 377, 386]]], ["Plasmids for generating MERSpp were kindly provided by Dr Nigel Temperton at the University of Kent, United Kingdom.", [["MERSpp", "DNA", 24, 30], ["Plasmids", "TREATMENT", 0, 8]]], ["Heat-inactivated serum samples were prepared in a 3-fold serial dilution starting from 1:20 and tested in duplicates in 96-well Nunc white plates.", [["serum samples", "ANATOMY", 17, 30], ["serum samples", "ORGANISM_SUBSTANCE", 17, 30], ["serum samples", "TEST", 17, 30], ["a 3-fold serial dilution", "TREATMENT", 48, 72]]], ["A standard amount of MERSpp (~200 000 Relative Light Units) was added to each well and plates were incubated for 1 hour at 37\u00b0C. Then, approximately 10 000 Huh7.5 cells were added to each well and incubated for 48 hours.", [["Huh7.5 cells", "ANATOMY", 156, 168], ["MERSpp", "CHEMICAL", 21, 27], ["Huh7.5 cells", "CELL", 156, 168], ["Huh7.5 cells", "CELL_LINE", 156, 168], ["A standard amount of MERSpp", "TREATMENT", 0, 27]]], ["Cells only and cells with MERSpp only were included in quadruplicate as controls in all plates.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 15, 20], ["Cells", "CELL", 0, 5], ["cells", "CELL", 15, 20], ["MERSpp", "TEST", 26, 32]]], ["Following incubation, cells were lysed and luciferase activity was developed and measured using the Bright-Glo Luciferase Assay System (Promega) according to the manufacturer\u2019s instructions.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["luciferase", "GENE_OR_GENE_PRODUCT", 43, 53], ["luciferase", "PROTEIN", 43, 53], ["cells", "TREATMENT", 22, 27], ["luciferase activity", "TEST", 43, 62], ["the Bright-Glo Luciferase Assay System (Promega)", "TREATMENT", 96, 144]]], ["Log10 Median Inhibitory Concentration (IC50) neutralization titers were calculated for each serum sample using GraphPad Prism software.Live Virus Microneutralization Assay ::: MATERIALS AND METHODSThe standard live virus microneutralization (MN) assay was used as previously described [11].", [["serum sample", "ANATOMY", 92, 104], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["Log10 Median Inhibitory Concentration (IC50) neutralization titers", "TREATMENT", 0, 66], ["each serum sample", "TEST", 87, 104], ["METHODSThe standard live virus microneutralization (MN)", "TREATMENT", 190, 245]]], ["In brief, starting at a dilution of 1:10, 60 \u03bcL volumes of serial 2-fold dilutions of heat-inactivated sera were mixed with equal volume of media containing 120 TCID50 of MERS-CoV.", [["sera", "ANATOMY", 103, 107], ["sera", "ORGANISM_SUBSTANCE", 103, 107], ["MERS-CoV", "ORGANISM", 171, 179], ["MERS-CoV", "SPECIES", 171, 179], ["serial 2-fold dilutions of heat", "TREATMENT", 59, 90], ["equal volume of media", "TREATMENT", 124, 145]]], ["Each dilution was tested in duplicate in 96-well plates.", [["Each dilution", "TEST", 0, 13]]], ["The antibody-virus mixtures were incubated for 1 hour at 37\u00b0C before transfer of 100 \u03bcL into confluent Vero E6 cell monolayers in 96-well plates.", [["cell monolayers", "ANATOMY", 111, 126], ["Vero E6 cell monolayers", "CELL", 103, 126], ["confluent Vero E6 cell monolayers", "CELL_LINE", 93, 126], ["Vero E6", "SPECIES", 103, 110], ["The antibody-virus mixtures", "TEST", 0, 27], ["confluent Vero E6 cell monolayers", "TEST", 93, 126], ["E6 cell monolayers", "OBSERVATION", 108, 126]]], ["Vero E6 cells cultured with DMEM medium with or without virus were included as positive and negative controls, respectively.", [["cells", "ANATOMY", 8, 13], ["Vero E6 cells", "CELL", 0, 13], ["Vero E6 cells", "CELL_LINE", 0, 13], ["Vero E6", "SPECIES", 0, 7], ["Vero E6 cells", "TEST", 0, 13], ["DMEM medium", "PROBLEM", 28, 39], ["virus", "PROBLEM", 56, 61], ["E6 cells", "OBSERVATION", 5, 13]]], ["After 72 hours of incubation, the nAb titer of each serum sample was determined as the reciprocal of the highest dilution capable of completely preventing virus-induced cytopathic effect in 50% of the wells (MN50).Data Analysis ::: MATERIALS AND METHODSStatistical analysis was conducted using 1-way or 2-way analysis of variance with Bonferroni posttest to adjust for multiple comparisons between groups using GraphPad Prism software.Targeting MERS-CoV S1 via CD40L Enhances Circulating S1-Specific IgG and Its Isotypes ::: RESULTSTo evaluate the immunogenicity of the generated rAd5 vector-based MERS vaccines, we immunized mice intramuscularly with 2 doses of individual vaccines and measured the levels of circulating S1-specific IgG and its isotypes before and at 3 weeks after each immunization.", [["serum sample", "ANATOMY", 52, 64], ["intramuscularly", "ANATOMY", 631, 646], ["nAb", "GENE_OR_GENE_PRODUCT", 34, 37], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 445, 456], ["CD40L", "GENE_OR_GENE_PRODUCT", 461, 466], ["Circulating S1", "GENE_OR_GENE_PRODUCT", 476, 490], ["IgG", "GENE_OR_GENE_PRODUCT", 500, 503], ["rAd5", "GENE_OR_GENE_PRODUCT", 580, 584], ["mice", "ORGANISM", 626, 630], ["S1", "GENE_OR_GENE_PRODUCT", 722, 724], ["IgG", "GENE_OR_GENE_PRODUCT", 734, 737], ["nAb", "PROTEIN", 34, 37], ["MERS-CoV S1", "PROTEIN", 445, 456], ["CD40L", "PROTEIN", 461, 466], ["Circulating S1", "PROTEIN", 476, 490], ["IgG", "PROTEIN", 500, 503], ["Isotypes", "PROTEIN", 512, 520], ["rAd5 vector", "DNA", 580, 591], ["S1", "PROTEIN", 722, 724], ["IgG", "PROTEIN", 734, 737], ["mice", "SPECIES", 626, 630], ["MERS-CoV", "SPECIES", 445, 453], ["mice", "SPECIES", 626, 630], ["incubation", "TREATMENT", 18, 28], ["the nAb titer", "TEST", 30, 43], ["each serum sample", "TEST", 47, 64], ["virus", "PROBLEM", 155, 160], ["induced cytopathic effect", "PROBLEM", 161, 186], ["Data Analysis", "TEST", 214, 227], ["METHODSStatistical analysis", "TEST", 246, 273], ["MERS", "TEST", 445, 449], ["Circulating S1", "TEST", 476, 490], ["Specific IgG", "TEST", 491, 503], ["rAd5 vector", "TREATMENT", 580, 591], ["based MERS vaccines", "TREATMENT", 592, 611], ["individual vaccines", "TREATMENT", 663, 682], ["each immunization", "TREATMENT", 783, 800], ["cytopathic", "OBSERVATION_MODIFIER", 169, 179]]], ["Here, we observed that both rAd5-S1/F/CD40L and rAd5-S1 induced S1-specific Abs from all isotypes in hDPP4 Tg+ mice after primary or secondary immunization (Figure 3).", [["rAd5-S1", "GENE_OR_GENE_PRODUCT", 28, 35], ["F", "GENE_OR_GENE_PRODUCT", 36, 37], ["CD40L", "GENE_OR_GENE_PRODUCT", 38, 43], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 48, 55], ["S1", "GENE_OR_GENE_PRODUCT", 64, 66], ["Abs", "GENE_OR_GENE_PRODUCT", 76, 79], ["hDPP4 Tg+ mice", "ORGANISM", 101, 115], ["rAd5", "PROTEIN", 28, 32], ["S1", "PROTEIN", 33, 35], ["F", "PROTEIN", 36, 37], ["CD40L", "PROTEIN", 38, 43], ["rAd5", "PROTEIN", 48, 52], ["S1", "PROTEIN", 53, 55], ["S1", "PROTEIN", 64, 66], ["Abs", "PROTEIN", 76, 79], ["hDPP4 Tg", "PROTEIN", 101, 109], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["rAd5", "TEST", 28, 32], ["CD40L", "TEST", 38, 43], ["rAd5", "TEST", 48, 52], ["specific Abs", "PROBLEM", 67, 79], ["all isotypes", "PROBLEM", 85, 97]]], ["As expected, control vector (rAd5-GFP) failed to elicit any S1-specific Ab response.", [["rAd5-GFP", "GENE_OR_GENE_PRODUCT", 29, 37], ["S1", "GENE_OR_GENE_PRODUCT", 60, 62], ["Ab", "GENE_OR_GENE_PRODUCT", 72, 74], ["control vector", "DNA", 13, 27], ["rAd5", "DNA", 29, 33], ["GFP", "PROTEIN", 34, 37], ["S1", "PROTEIN", 60, 62], ["Ab response", "OBSERVATION", 72, 83]]], ["Notably, a single dose or 2 doses of rAd5-S1/F/CD40L consistently elicited significantly higher levels of total IgG as well as IgG1, IgG2a, and IgG2b isotypes compared with the control group immunized with rAd5-GFP (Figure 3), whereas immunization with a single dose of rAd5-S1 induced significant titers of total IgG, IgG1, and IgG2a but not IgG2b compared to the control group, with a second dose of rAd5-S1 eventually inducing significantly higher levels of IgG2b compared to the control group.", [["rAd5-S1", "GENE_OR_GENE_PRODUCT", 37, 44], ["F", "GENE_OR_GENE_PRODUCT", 45, 46], ["CD40L", "GENE_OR_GENE_PRODUCT", 47, 52], ["IgG", "GENE_OR_GENE_PRODUCT", 112, 115], ["IgG1", "GENE_OR_GENE_PRODUCT", 127, 131], ["IgG2a", "GENE_OR_GENE_PRODUCT", 133, 138], ["IgG2b", "GENE_OR_GENE_PRODUCT", 144, 149], ["rAd5-GFP", "GENE_OR_GENE_PRODUCT", 206, 214], ["Figure 3", "ORGANISM", 216, 224], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 270, 277], ["IgG", "GENE_OR_GENE_PRODUCT", 314, 317], ["IgG1", "GENE_OR_GENE_PRODUCT", 319, 323], ["IgG2a", "GENE_OR_GENE_PRODUCT", 329, 334], ["IgG2b", "GENE_OR_GENE_PRODUCT", 343, 348], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 402, 409], ["IgG2b", "GENE_OR_GENE_PRODUCT", 461, 466], ["rAd5", "PROTEIN", 37, 41], ["S1", "PROTEIN", 42, 44], ["F", "PROTEIN", 45, 46], ["CD40L", "PROTEIN", 47, 52], ["IgG", "PROTEIN", 112, 115], ["IgG1", "PROTEIN", 127, 131], ["IgG2a", "PROTEIN", 133, 138], ["IgG2b isotypes", "PROTEIN", 144, 158], ["rAd5", "PROTEIN", 206, 210], ["GFP", "PROTEIN", 211, 214], ["rAd5", "PROTEIN", 270, 274], ["S1", "PROTEIN", 275, 277], ["total IgG", "PROTEIN", 308, 317], ["IgG1", "PROTEIN", 319, 323], ["IgG2a", "PROTEIN", 329, 334], ["IgG2b", "PROTEIN", 343, 348], ["rAd5", "PROTEIN", 402, 406], ["IgG2b", "PROTEIN", 461, 466], ["rAd5", "TREATMENT", 37, 41], ["total IgG", "TEST", 106, 115], ["IgG1", "TEST", 127, 131], ["IgG2b isotypes", "PROBLEM", 144, 158], ["immunization", "TREATMENT", 235, 247], ["rAd5", "TREATMENT", 270, 274], ["total IgG", "TEST", 308, 317], ["IgG1", "TEST", 319, 323], ["IgG2a", "TREATMENT", 329, 334], ["IgG2b", "PROBLEM", 343, 348], ["significantly higher levels of IgG2b", "PROBLEM", 430, 466], ["IgG2b isotypes", "OBSERVATION", 144, 158]]], ["Interestingly, immunizing mice with a second dose of rAd5-S1/F/CD40L enhanced the levels of circulatory IgG and all tested isotypes compared with the rAd5-S1\u2013vaccinated group.", [["mice", "ORGANISM", 26, 30], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 53, 60], ["F", "GENE_OR_GENE_PRODUCT", 61, 62], ["CD40L", "GENE_OR_GENE_PRODUCT", 63, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 104, 107], ["rAd5", "PROTEIN", 53, 57], ["S1", "PROTEIN", 58, 60], ["F", "PROTEIN", 61, 62], ["CD40L", "PROTEIN", 63, 68], ["circulatory IgG", "PROTEIN", 92, 107], ["rAd5", "PROTEIN", 150, 154], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["rAd5-S1/F/CD40L", "TREATMENT", 53, 68], ["circulatory IgG", "TEST", 92, 107], ["all tested isotypes", "TREATMENT", 112, 131], ["circulatory IgG", "ANATOMY", 92, 107]]], ["Furthermore, 2 doses of rAd5-S1 only enhanced IgG2b significantly compared to 1 dose, with mean IgG1:IgG2a ratios being 3.8 (SD, 3.2) and 3.9 (SD, 3.2) after priming and boosting, respectively.", [["rAd5-S1", "CHEMICAL", 24, 31], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 24, 31], ["IgG2b", "GENE_OR_GENE_PRODUCT", 46, 51], ["IgG1", "GENE_OR_GENE_PRODUCT", 96, 100], ["IgG2a", "GENE_OR_GENE_PRODUCT", 101, 106], ["rAd5", "PROTEIN", 24, 28], ["IgG2b", "PROTEIN", 46, 51], ["IgG1", "PROTEIN", 96, 100], ["IgG2a", "PROTEIN", 101, 106], ["rAd5", "TEST", 24, 28], ["IgG2b", "TEST", 46, 51], ["mean IgG1", "TEST", 91, 100], ["IgG2a ratios", "TEST", 101, 113], ["SD", "TEST", 125, 127], ["SD", "TEST", 143, 145]]], ["In contrast, boosting with a second dose of rAd5-S1/F/CD40L resulted in a significant increase in total IgG, particularly in IgG2a and IgG2b isotypes but not IgG1, compared with a single dose of rAd5-S1/F/CD40L, suggesting a bias toward Th1 response as demonstrated by mean IgG1:IgG2a ratios of 3.4 (SD, 2.4) and 1.8 (SD, 1.4) after priming and boosting, respectively.", [["rAd5-S1", "GENE_OR_GENE_PRODUCT", 44, 51], ["F", "GENE_OR_GENE_PRODUCT", 52, 53], ["CD40L", "GENE_OR_GENE_PRODUCT", 54, 59], ["IgG", "GENE_OR_GENE_PRODUCT", 104, 107], ["IgG2a", "GENE_OR_GENE_PRODUCT", 125, 130], ["IgG2b", "GENE_OR_GENE_PRODUCT", 135, 140], ["IgG1", "GENE_OR_GENE_PRODUCT", 158, 162], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 195, 202], ["F", "GENE_OR_GENE_PRODUCT", 203, 204], ["CD40L", "GENE_OR_GENE_PRODUCT", 205, 210], ["Th1", "GENE_OR_GENE_PRODUCT", 237, 240], ["IgG1", "GENE_OR_GENE_PRODUCT", 274, 278], ["IgG2a", "GENE_OR_GENE_PRODUCT", 279, 284], ["rAd5", "PROTEIN", 44, 48], ["S1", "PROTEIN", 49, 51], ["F", "PROTEIN", 52, 53], ["CD40L", "PROTEIN", 54, 59], ["IgG", "PROTEIN", 104, 107], ["IgG2a", "PROTEIN", 125, 130], ["IgG2b isotypes", "PROTEIN", 135, 149], ["IgG1", "PROTEIN", 158, 162], ["rAd5", "PROTEIN", 195, 199], ["S1", "PROTEIN", 200, 202], ["F", "PROTEIN", 203, 204], ["CD40L", "PROTEIN", 205, 210], ["IgG1", "PROTEIN", 274, 278], ["IgG2a", "PROTEIN", 279, 284], ["rAd5-S1/F/CD40L", "TREATMENT", 44, 59], ["a significant increase in total IgG", "PROBLEM", 72, 107], ["IgG2b isotypes", "PROBLEM", 135, 149], ["mean IgG1", "TEST", 269, 278], ["IgG2a ratios", "TEST", 279, 291], ["SD", "TEST", 300, 302], ["SD", "TEST", 318, 320], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["total IgG", "OBSERVATION", 98, 107], ["IgG2b isotypes", "OBSERVATION", 135, 149]]], ["Together, these data showed that targeting the secreted S1 to CD40-expressing APCs via CD40L (rAd5-S1/F/CD40L) not only enhanced S1-specific IgG Abs levels but also boosted Th1 responses, as demonstrated by markedly elevated titers of S1-specific IgG2a and IgG2b antibodies, especially after boosting.A Single Dose of CD40-Targeted MERS-CoV S1 Induces High Levels of nAbs in Immunized Mice ::: RESULTSTo extend our analysis and to evaluate the effector function of induced Abs, we measured their neutralizing activities before and after each immunization.", [["APCs", "ANATOMY", 78, 82], ["S1", "GENE_OR_GENE_PRODUCT", 56, 58], ["CD40", "GENE_OR_GENE_PRODUCT", 62, 66], ["APCs", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD40L", "GENE_OR_GENE_PRODUCT", 87, 92], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 94, 101], ["CD40L", "GENE_OR_GENE_PRODUCT", 104, 109], ["S1", "GENE_OR_GENE_PRODUCT", 129, 131], ["IgG Abs", "GENE_OR_GENE_PRODUCT", 141, 148], ["S1", "GENE_OR_GENE_PRODUCT", 235, 237], ["IgG2a", "GENE_OR_GENE_PRODUCT", 247, 252], ["IgG2b", "GENE_OR_GENE_PRODUCT", 257, 262], ["CD40", "GENE_OR_GENE_PRODUCT", 318, 322], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 332, 343], ["nAbs", "GENE_OR_GENE_PRODUCT", 367, 371], ["Mice", "ORGANISM", 385, 389], ["S1", "PROTEIN", 56, 58], ["CD40", "PROTEIN", 62, 66], ["APCs", "CELL_TYPE", 78, 82], ["CD40L", "PROTEIN", 87, 92], ["rAd5", "PROTEIN", 94, 98], ["S1", "PROTEIN", 99, 101], ["F", "PROTEIN", 102, 103], ["CD40L", "PROTEIN", 104, 109], ["S1", "PROTEIN", 129, 131], ["IgG Abs", "PROTEIN", 141, 148], ["S1", "PROTEIN", 235, 237], ["IgG2a", "PROTEIN", 247, 252], ["IgG2b antibodies", "PROTEIN", 257, 273], ["CD40", "PROTEIN", 318, 322], ["Targeted MERS-CoV S1", "PROTEIN", 323, 343], ["nAbs", "PROTEIN", 367, 371], ["induced Abs", "PROTEIN", 465, 476], ["Mice", "SPECIES", 385, 389], ["these data", "TEST", 10, 20], ["CD40", "TEST", 62, 66], ["APCs", "TEST", 78, 82], ["CD40L", "TEST", 87, 92], ["rAd5", "TEST", 94, 98], ["S1/F/CD40L", "TEST", 99, 109], ["IgG Abs levels", "TEST", 141, 155], ["markedly elevated titers of S1", "PROBLEM", 207, 237], ["IgG2b antibodies", "TEST", 257, 273], ["CD40", "TREATMENT", 318, 322], ["our analysis", "TEST", 411, 423], ["induced Abs", "PROBLEM", 465, 476], ["each immunization", "TREATMENT", 537, 554], ["markedly", "OBSERVATION_MODIFIER", 207, 215], ["elevated", "OBSERVATION", 216, 224], ["IgG2b antibodies", "OBSERVATION", 257, 273]]], ["As expected, all immunized mice from all groups showed no detectable levels of nAbs in samples collected before immunization.", [["samples", "ANATOMY", 87, 94], ["mice", "ORGANISM", 27, 31], ["nAbs", "GENE_OR_GENE_PRODUCT", 79, 83], ["nAbs", "PROTEIN", 79, 83], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["detectable levels of nAbs in samples", "PROBLEM", 58, 94], ["immunization", "TREATMENT", 112, 124], ["nAbs", "OBSERVATION", 79, 83]]], ["As shown in Figure 4, a single dose of either rAd5-S1/F/CD40L or rAd5-S1 elicited high levels of nAbs compared to the control group (rAd5-GFP), with rAd5-S1/F/CD40L, but not rAd5-S1, being consistently capable of inducing significantly higher levels of nAbs against both live and pseudotyped MERS-CoV virus, suggesting that rAd5-S1/F/CD40L is better than rAd-S1 vaccine in promoting strong humoral response and neutralizing activity against MERS-CoV.", [["rAd5-S1", "GENE_OR_GENE_PRODUCT", 46, 53], ["CD40L", "GENE_OR_GENE_PRODUCT", 56, 61], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 65, 72], ["nAbs", "GENE_OR_GENE_PRODUCT", 97, 101], ["rAd5-GFP", "GENE_OR_GENE_PRODUCT", 133, 141], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 149, 156], ["F", "GENE_OR_GENE_PRODUCT", 157, 158], ["CD40L", "GENE_OR_GENE_PRODUCT", 159, 164], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 174, 181], ["nAbs", "GENE_OR_GENE_PRODUCT", 253, 257], ["pseudotyped MERS-CoV virus", "ORGANISM", 280, 306], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 324, 331], ["F", "GENE_OR_GENE_PRODUCT", 332, 333], ["CD40L", "GENE_OR_GENE_PRODUCT", 334, 339], ["rAd-S1", "ORGANISM", 355, 361], ["MERS-CoV", "ORGANISM", 441, 449], ["rAd5", "PROTEIN", 46, 50], ["S1", "PROTEIN", 51, 53], ["F", "PROTEIN", 54, 55], ["CD40L", "PROTEIN", 56, 61], ["rAd5", "PROTEIN", 65, 69], ["S1", "PROTEIN", 70, 72], ["nAbs", "PROTEIN", 97, 101], ["rAd5", "PROTEIN", 133, 137], ["GFP", "PROTEIN", 138, 141], ["rAd5", "PROTEIN", 149, 153], ["S1", "PROTEIN", 154, 156], ["F", "PROTEIN", 157, 158], ["CD40L", "PROTEIN", 159, 164], ["rAd5", "PROTEIN", 174, 178], ["S1", "PROTEIN", 179, 181], ["nAbs", "PROTEIN", 253, 257], ["rAd5", "PROTEIN", 324, 328], ["S1", "PROTEIN", 329, 331], ["F", "PROTEIN", 332, 333], ["CD40L", "PROTEIN", 334, 339], ["MERS-CoV", "PROTEIN", 441, 449], ["MERS-CoV virus", "SPECIES", 292, 306], ["MERS-CoV virus", "SPECIES", 292, 306], ["MERS-CoV", "SPECIES", 441, 449], ["high levels of nAbs", "PROBLEM", 82, 101], ["rAd5", "TEST", 149, 153], ["S1/F/CD40L", "TEST", 154, 164], ["significantly higher levels of nAbs", "PROBLEM", 222, 257], ["pseudotyped MERS", "PROBLEM", 280, 296], ["CoV virus", "PROBLEM", 297, 306], ["rAd5", "TEST", 324, 328], ["CD40L", "TREATMENT", 334, 339], ["S1 vaccine", "TREATMENT", 359, 369], ["nAbs", "OBSERVATION", 97, 101], ["S1", "ANATOMY", 179, 181], ["nAbs", "OBSERVATION", 253, 257], ["humoral response", "OBSERVATION", 390, 406], ["neutralizing activity", "OBSERVATION", 411, 432]]], ["However, after boosting once, all rAd5-S1/F/CD40L\u2013 and rAd5-S1\u2013immunized animals elicited robust and significant levels of nAbs, indicating that at least 2 doses of rAd-S1 are required to induce nAb levels similar to those obtained by a single dose of rAd5-S1/F/CD40L.", [["rAd5-S1", "GENE_OR_GENE_PRODUCT", 34, 41], ["F", "GENE_OR_GENE_PRODUCT", 42, 43], ["CD40L", "GENE_OR_GENE_PRODUCT", 44, 49], ["rAd5", "GENE_OR_GENE_PRODUCT", 55, 59], ["nAbs", "GENE_OR_GENE_PRODUCT", 123, 127], ["rAd-S1", "GENE_OR_GENE_PRODUCT", 165, 171], ["nAb", "GENE_OR_GENE_PRODUCT", 195, 198], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 252, 259], ["F", "GENE_OR_GENE_PRODUCT", 260, 261], ["CD40L", "GENE_OR_GENE_PRODUCT", 262, 267], ["rAd5", "PROTEIN", 34, 38], ["CD40L", "PROTEIN", 44, 49], ["rAd5", "PROTEIN", 55, 59], ["nAbs", "PROTEIN", 123, 127], ["rAd", "PROTEIN", 165, 168], ["nAb", "PROTEIN", 195, 198], ["rAd5", "PROTEIN", 252, 256], ["S1", "PROTEIN", 257, 259], ["F", "PROTEIN", 260, 261], ["CD40L", "PROTEIN", 262, 267], ["rAd5", "TREATMENT", 55, 59], ["significant levels of nAbs", "PROBLEM", 101, 127], ["rAd-S1", "TREATMENT", 165, 171], ["nAb levels", "PROBLEM", 195, 205], ["nAbs", "OBSERVATION", 123, 127]]], ["These findings clearly confirm that incorporation of CD40L as molecular adjuvant could effectively enhance the immunogenicity of S1-based vaccines and may represent a very promising vaccine platform to induce protective immunity with a single dose.MERS-CoV S1-Based Vaccines Protect hDPP4 Tg+ Mice From MERS-CoV Challenge ::: RESULTSHaving demonstrated that CD40-targeted vaccine was superior in eliciting immune responses in hDPP4 Tg+ mice, we next investigated if these S1-based vaccines could effectively protect these highly MERS-CoV permissive mice from viral challenge.", [["CD40L", "GENE_OR_GENE_PRODUCT", 53, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 248, 256], ["Mice", "ORGANISM", 293, 297], ["CD40", "GENE_OR_GENE_PRODUCT", 358, 362], ["hDPP4 Tg+ mice", "ORGANISM", 426, 440], ["S1", "GENE_OR_GENE_PRODUCT", 472, 474], ["MERS-CoV", "ORGANISM", 529, 537], ["mice", "ORGANISM", 549, 553], ["CD40L", "PROTEIN", 53, 58], ["S1", "PROTEIN", 129, 131], ["CD40", "PROTEIN", 358, 362], ["S1", "PROTEIN", 472, 474], ["Mice", "SPECIES", 293, 297], ["mice", "SPECIES", 436, 440], ["mice", "SPECIES", 549, 553], ["mice", "SPECIES", 436, 440], ["MERS-CoV", "SPECIES", 529, 537], ["mice", "SPECIES", 549, 553], ["CD40L as molecular adjuvant", "TREATMENT", 53, 80], ["S1-based vaccines", "TREATMENT", 129, 146], ["a very promising vaccine platform", "TREATMENT", 165, 198], ["CoV S1-Based Vaccines", "TREATMENT", 253, 274], ["CD40-targeted vaccine", "TREATMENT", 358, 379], ["these S1-based vaccines", "TREATMENT", 466, 489], ["viral challenge", "TREATMENT", 559, 574], ["may represent", "UNCERTAINTY", 151, 164]]], ["To this end, the vaccinated mice were challenged with 100 LD50 of MERS-CoV and subsequently monitored for 3 weeks.", [["mice", "ORGANISM", 28, 32], ["MERS-CoV", "ORGANISM", 66, 74], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["MERS-CoV", "SPECIES", 66, 74], ["the vaccinated mice", "TREATMENT", 13, 32]]], ["It was clear that mice immunized twice with either rAd5-S1 or rAd5-S1/F/CD40L were completely protected based on clinical signs of disease (weight loss) and mortality (Figure 5), whereas rAd5-GFP\u2013immunized animals expectedly succumbed to lethal infection within days, likely due to encephalitis [28, 40].", [["weight loss", "DISEASE", 140, 151], ["infection", "DISEASE", 245, 254], ["encephalitis", "DISEASE", 282, 294], ["mice", "ORGANISM", 18, 22], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 51, 58], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 62, 69], ["F", "GENE_OR_GENE_PRODUCT", 70, 71], ["CD40L", "GENE_OR_GENE_PRODUCT", 72, 77], ["rAd5", "GENE_OR_GENE_PRODUCT", 187, 191], ["animals", "ORGANISM", 206, 213], ["rAd5", "PROTEIN", 51, 55], ["S1", "PROTEIN", 56, 58], ["rAd5", "PROTEIN", 62, 66], ["S1", "PROTEIN", 67, 69], ["F", "PROTEIN", 70, 71], ["CD40L", "PROTEIN", 72, 77], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["CD40L", "TREATMENT", 72, 77], ["disease", "PROBLEM", 131, 138], ["weight loss)", "PROBLEM", 140, 152], ["lethal infection", "PROBLEM", 238, 254], ["encephalitis", "PROBLEM", 282, 294], ["disease", "OBSERVATION", 131, 138], ["likely due to", "UNCERTAINTY", 268, 281], ["encephalitis", "OBSERVATION", 282, 294]]], ["These findings suggest that both rAd5-S1 and rAd5-S1/F/CD40L vaccines are protective in this mouse model.MERS-CoV S1-Based Vaccines Inhibit Pulmonary Viral Replication in hDPP4 Tg+ Mice ::: RESULTSTo further confirm that immunized hDPP4 Tg+ mice were protected from MERS-CoV infection after challenge, we measured lung viral titer, both infectious progeny virus and viral RNA, on day 3 postchallenge by Vero E6-based infectivity assay and RT-qPCR, respectively.", [["lung", "ANATOMY", 314, 318], ["infection", "DISEASE", 275, 284], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 33, 40], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 45, 52], ["F", "GENE_OR_GENE_PRODUCT", 53, 54], ["CD40L", "GENE_OR_GENE_PRODUCT", 55, 60], ["mouse", "ORGANISM", 93, 98], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["hDPP4 Tg", "ORGANISM", 171, 179], ["Mice", "ORGANISM", 181, 185], ["hDPP4 Tg+ mice", "ORGANISM", 231, 245], ["MERS-CoV", "ORGANISM", 266, 274], ["lung", "ORGAN", 314, 318], ["E6", "GENE_OR_GENE_PRODUCT", 408, 410], ["rAd5", "PROTEIN", 33, 37], ["S1", "PROTEIN", 38, 40], ["rAd5", "PROTEIN", 45, 49], ["S1", "PROTEIN", 50, 52], ["F", "PROTEIN", 53, 54], ["CD40L", "PROTEIN", 55, 60], ["hDPP4 Tg", "PROTEIN", 231, 239], ["viral RNA", "RNA", 366, 375], ["mouse", "SPECIES", 93, 98], ["Mice", "SPECIES", 181, 185], ["mice", "SPECIES", 241, 245], ["mouse", "SPECIES", 93, 98], ["mice", "SPECIES", 241, 245], ["MERS-CoV", "SPECIES", 266, 274], ["Vero E6", "SPECIES", 403, 410], ["rAd5", "TEST", 33, 37], ["rAd5-S1/F/CD40L vaccines", "TREATMENT", 45, 69], ["MERS", "TEST", 105, 109], ["CoV S1-Based Vaccines", "TREATMENT", 110, 131], ["Pulmonary Viral Replication", "TREATMENT", 140, 167], ["CoV infection", "PROBLEM", 271, 284], ["lung viral titer", "PROBLEM", 314, 330], ["both infectious progeny virus", "PROBLEM", 332, 361], ["viral RNA", "PROBLEM", 366, 375], ["Vero E6", "TEST", 403, 410], ["infectivity assay", "TEST", 417, 434], ["RT-qPCR", "TEST", 439, 446], ["Pulmonary", "ANATOMY", 140, 149], ["Viral Replication", "OBSERVATION", 150, 167], ["CoV", "OBSERVATION_MODIFIER", 271, 274], ["infection", "OBSERVATION", 275, 284], ["lung", "ANATOMY", 314, 318], ["viral titer", "OBSERVATION", 319, 330], ["infectious", "OBSERVATION_MODIFIER", 337, 347], ["viral RNA", "OBSERVATION", 366, 375]]], ["Analysis of infectious viral titer revealed that immunization with both vaccines significantly protected against viral replication to undetectable levels compared with rAd5-GFP\u2013immunized and \u2013challenged mice (Figure 6).", [["mice", "ORGANISM", 203, 207], ["rAd5", "PROTEIN", 168, 172], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 203, 207], ["infectious viral titer", "TEST", 12, 34], ["immunization", "TREATMENT", 49, 61], ["both vaccines", "TREATMENT", 67, 80], ["viral replication", "PROBLEM", 113, 130], ["rAd5", "TEST", 168, 172], ["infectious", "OBSERVATION_MODIFIER", 12, 22]]], ["These results were further confirmed by an average of 3- to 4-log reduction in pulmonary viral RNA, compared to that of the rAd5-GFP\u2013immunized group (Figure 6).", [["pulmonary", "ANATOMY", 79, 88], ["pulmonary", "ORGAN", 79, 88], ["pulmonary viral RNA", "RNA", 79, 98], ["rAd5", "PROTEIN", 124, 128], ["pulmonary viral RNA", "PROBLEM", 79, 98], ["pulmonary", "ANATOMY", 79, 88], ["viral RNA", "OBSERVATION", 89, 98]]], ["It should be mentioned that, albeit not statistically significant, rAd5-S1/F/CD40L\u2013immunized animals had a viral RNA load lower by 1 log compared with the rAd5-S1 group, consistent with the overall stronger immune response we observed in this group.CD40-Targeted MERS-CoV S1 Prevents Vaccine-Associated Lung Pathology in Virally Challenged hDPP4 Tg+ Mice ::: RESULTSFinally, investigations were carried out to assess safety of these vaccine candidates to rule out any vaccine-associated pulmonary injuries as observed with some vaccines against other coronaviruses.", [["Lung", "ANATOMY", 303, 307], ["pulmonary", "ANATOMY", 487, 496], ["pulmonary injuries", "DISEASE", 487, 505], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 67, 74], ["F", "GENE_OR_GENE_PRODUCT", 75, 76], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 155, 162], ["CD40", "GENE_OR_GENE_PRODUCT", 249, 253], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 263, 271], ["Lung", "ORGAN", 303, 307], ["Mice", "ORGANISM", 350, 354], ["pulmonary", "ORGAN", 487, 496], ["coronaviruses", "ORGANISM", 551, 564], ["rAd5", "PROTEIN", 67, 71], ["rAd5", "PROTEIN", 155, 159], ["CD40", "PROTEIN", 249, 253], ["Mice", "SPECIES", 350, 354], ["rAd5", "TEST", 67, 71], ["a viral RNA load", "TEST", 105, 121], ["CD40", "TEST", 249, 253], ["CoV S1 Prevents Vaccine", "TREATMENT", 268, 291], ["investigations", "TEST", 375, 389], ["these vaccine candidates", "TREATMENT", 427, 451], ["any vaccine", "PROBLEM", 464, 475], ["pulmonary injuries", "PROBLEM", 487, 505], ["some vaccines", "TREATMENT", 523, 536], ["other coronaviruses", "PROBLEM", 545, 564], ["viral RNA", "OBSERVATION", 107, 116], ["consistent with", "UNCERTAINTY", 170, 185], ["Lung", "ANATOMY", 303, 307], ["Pathology", "OBSERVATION", 308, 317], ["pulmonary", "ANATOMY", 487, 496], ["injuries", "OBSERVATION", 497, 505]]], ["Evaluation of lung pathology in immunized and challenged mice showed up to 15% multiple monocytic and lymphocytic infiltrations (moderate pathology) in the lungs of the rAd5-GFP group 3 and 6 days postchallenge compared to other groups, which showed minimal to no inflammatory infiltration (Figure 7).", [["lung", "ANATOMY", 14, 18], ["monocytic", "ANATOMY", 88, 97], ["lymphocytic", "ANATOMY", 102, 113], ["lungs", "ANATOMY", 156, 161], ["lung", "ORGAN", 14, 18], ["mice", "ORGANISM", 57, 61], ["monocytic", "CELL", 88, 97], ["lymphocytic infiltrations", "PATHOLOGICAL_FORMATION", 102, 127], ["lungs", "ORGAN", 156, 161], ["rAd5-GFP", "GENE_OR_GENE_PRODUCT", 169, 177], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["Evaluation of lung pathology", "TEST", 0, 28], ["multiple monocytic and lymphocytic infiltrations", "PROBLEM", 79, 127], ["moderate pathology", "PROBLEM", 129, 147], ["inflammatory infiltration", "PROBLEM", 264, 289], ["lung", "ANATOMY", 14, 18], ["pathology", "OBSERVATION", 19, 28], ["multiple", "OBSERVATION_MODIFIER", 79, 87], ["monocytic", "OBSERVATION_MODIFIER", 88, 97], ["lymphocytic infiltrations", "OBSERVATION", 102, 127], ["moderate", "OBSERVATION_MODIFIER", 129, 137], ["pathology", "OBSERVATION", 138, 147], ["lungs", "ANATOMY", 156, 161], ["minimal", "OBSERVATION_MODIFIER", 250, 257], ["no", "UNCERTAINTY", 261, 263], ["inflammatory", "OBSERVATION_MODIFIER", 264, 276], ["infiltration", "OBSERVATION", 277, 289]]], ["Surprisingly, although rAd5-S1 immunization protected animals from death and weight loss and prevented the lung infiltration similar to rAd5-S1/F/CD40L, we observed perivascular hemorrhage in the whole lung of all examined mice immunized with rAd5-S1 but not those vaccinated with rAd5-S1/F/CD40L (Figure 7).", [["lung", "ANATOMY", 107, 111], ["perivascular", "ANATOMY", 165, 177], ["lung", "ANATOMY", 202, 206], ["death", "DISEASE", 67, 72], ["weight loss", "DISEASE", 77, 88], ["perivascular hemorrhage", "DISEASE", 165, 188], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 23, 30], ["animals", "ORGANISM", 54, 61], ["lung", "ORGAN", 107, 111], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 136, 143], ["F", "GENE_OR_GENE_PRODUCT", 144, 145], ["CD40L", "GENE_OR_GENE_PRODUCT", 146, 151], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 165, 177], ["lung", "ORGAN", 202, 206], ["mice", "ORGANISM", 223, 227], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 243, 250], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 281, 288], ["CD40L", "GENE_OR_GENE_PRODUCT", 291, 296], ["rAd5", "PROTEIN", 23, 27], ["rAd5", "PROTEIN", 136, 140], ["S1", "PROTEIN", 141, 143], ["F", "PROTEIN", 144, 145], ["CD40L", "PROTEIN", 146, 151], ["rAd5", "PROTEIN", 243, 247], ["rAd5", "PROTEIN", 281, 285], ["S1", "PROTEIN", 286, 288], ["F", "PROTEIN", 289, 290], ["CD40L", "PROTEIN", 291, 296], ["mice", "SPECIES", 223, 227], ["mice", "SPECIES", 223, 227], ["rAd5-S1 immunization", "TREATMENT", 23, 43], ["death", "PROBLEM", 67, 72], ["weight loss", "PROBLEM", 77, 88], ["the lung infiltration", "PROBLEM", 103, 124], ["perivascular hemorrhage", "PROBLEM", 165, 188], ["rAd5", "TEST", 281, 285], ["lung", "ANATOMY", 107, 111], ["infiltration", "OBSERVATION", 112, 124], ["perivascular", "ANATOMY_MODIFIER", 165, 177], ["hemorrhage", "OBSERVATION", 178, 188], ["whole", "ANATOMY_MODIFIER", 196, 201], ["lung", "ANATOMY", 202, 206]]], ["Together, these results suggest that although S1 alone could protect the animals from viral infection, it may inadvertently induce lung pathology, and that using CD40L as targeting molecule and molecular adjuvant does not only enhance immunogenicity and protective efficacy but also prevents vaccine-associated pulmonary pathology.DISCUSSIONThe rapid spread and persistence of MERS-CoV in the Arabian Peninsula, in addition to the associated high mortality rates, represent a serious global public health concern, particularly that the elimination of the zoonotic reservoir is extremely unlikely at the current setting.", [["lung", "ANATOMY", 131, 135], ["pulmonary", "ANATOMY", 311, 320], ["viral infection", "DISEASE", 86, 101], ["S1", "GENE_OR_GENE_PRODUCT", 46, 48], ["lung", "ORGAN", 131, 135], ["CD40L", "GENE_OR_GENE_PRODUCT", 162, 167], ["pulmonary", "ORGAN", 311, 320], ["MERS-CoV", "ORGANISM", 377, 385], ["S1", "PROTEIN", 46, 48], ["CD40L", "PROTEIN", 162, 167], ["MERS-CoV", "SPECIES", 377, 385], ["viral infection", "PROBLEM", 86, 101], ["lung pathology", "PROBLEM", 131, 145], ["CD40L", "TREATMENT", 162, 167], ["molecular adjuvant", "TREATMENT", 194, 212], ["pulmonary pathology", "PROBLEM", 311, 330], ["The rapid spread", "PROBLEM", 341, 357], ["the zoonotic reservoir", "PROBLEM", 551, 573], ["viral", "OBSERVATION_MODIFIER", 86, 91], ["infection", "OBSERVATION", 92, 101], ["lung", "ANATOMY", 131, 135], ["pathology", "OBSERVATION", 136, 145], ["pulmonary", "ANATOMY", 311, 320], ["pathology", "OBSERVATION", 321, 330], ["rapid", "OBSERVATION_MODIFIER", 345, 350], ["spread", "OBSERVATION_MODIFIER", 351, 357], ["persistence", "OBSERVATION_MODIFIER", 362, 373], ["Arabian Peninsula", "ANATOMY", 393, 410], ["serious", "OBSERVATION_MODIFIER", 476, 483], ["zoonotic", "OBSERVATION_MODIFIER", 555, 563], ["reservoir", "OBSERVATION", 564, 573]]], ["This threat is further complicated by the absence of prophylactic or therapeutic measures.", [["prophylactic or therapeutic measures", "TREATMENT", 53, 89]]], ["Therefore, development of an effective and safe vaccine is urgently needed to prevent or contain MERS-CoV.", [["MERS-CoV", "ORGANISM", 97, 105], ["MERS-CoV", "SPECIES", 97, 105], ["an effective and safe vaccine", "TREATMENT", 26, 55], ["effective", "OBSERVATION_MODIFIER", 29, 38]]], ["Several groups have investigated various MERS-CoV vaccine platforms in several animal models [9\u201318, 28].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["MERS-CoV", "SPECIES", 41, 49], ["various MERS", "PROBLEM", 33, 45], ["CoV vaccine platforms", "TREATMENT", 46, 67]]], ["However, serious safety concerns are associated with vaccines for several coronaviruses including MERS-CoV and need to be elucidated and better understood [19\u201328].DISCUSSIONWe showed in this study that although rAd5 expressing S1 or CD40-targeted S1 were both capable of inducing significant levels of IgG and nAbs specific to MERS-CoV in immunized mice, incorporation of CD40L substantially enhances the immunogenicity of S1, as demonstrated by the effectiveness of a single immunization dose, which was sufficient to elicit stronger and robust immune responses compared to control groups, consistent with our previous reports [37, 38].", [["coronaviruses", "ORGANISM", 74, 87], ["MERS-CoV", "ORGANISM", 98, 106], ["rAd5", "GENE_OR_GENE_PRODUCT", 211, 215], ["S1", "GENE_OR_GENE_PRODUCT", 227, 229], ["CD40", "GENE_OR_GENE_PRODUCT", 233, 237], ["S1", "GENE_OR_GENE_PRODUCT", 247, 249], ["IgG", "GENE_OR_GENE_PRODUCT", 302, 305], ["nAbs", "GENE_OR_GENE_PRODUCT", 310, 314], ["MERS-CoV", "ORGANISM", 327, 335], ["mice", "ORGANISM", 349, 353], ["CD40L", "GENE_OR_GENE_PRODUCT", 372, 377], ["S1", "GENE_OR_GENE_PRODUCT", 423, 425], ["rAd5", "PROTEIN", 211, 215], ["S1", "PROTEIN", 227, 229], ["CD40", "PROTEIN", 233, 237], ["S1", "PROTEIN", 247, 249], ["IgG", "PROTEIN", 302, 305], ["nAbs", "PROTEIN", 310, 314], ["CD40L", "PROTEIN", 372, 377], ["S1", "PROTEIN", 423, 425], ["mice", "SPECIES", 349, 353], ["MERS-CoV", "SPECIES", 98, 106], ["MERS-CoV", "SPECIES", 327, 335], ["mice", "SPECIES", 349, 353], ["vaccines", "TREATMENT", 53, 61], ["several coronaviruses", "PROBLEM", 66, 87], ["this study", "TEST", 186, 196], ["CD40", "TEST", 233, 237], ["IgG", "TEST", 302, 305], ["MERS", "TEST", 327, 331], ["CoV in immunized mice", "TREATMENT", 332, 353], ["incorporation of CD40L", "TREATMENT", 355, 377], ["a single immunization dose", "TREATMENT", 467, 493]]], ["Importantly, both S1 and CD40-targeted S1 vaccines provided complete protection, prevented virus replication significantly, and prevented monocytic and lymphocytic lung infiltration as compared to control group.", [["monocytic", "ANATOMY", 138, 147], ["lymphocytic lung", "ANATOMY", 152, 168], ["CD40", "GENE_OR_GENE_PRODUCT", 25, 29], ["monocytic", "CELL", 138, 147], ["lung", "ORGAN", 164, 168], ["S1", "PROTEIN", 18, 20], ["CD40", "PROTEIN", 25, 29], ["targeted S1 vaccines", "TREATMENT", 30, 50], ["complete protection", "TREATMENT", 60, 79], ["virus replication", "TREATMENT", 91, 108], ["monocytic and lymphocytic lung infiltration", "PROBLEM", 138, 181], ["S1", "ANATOMY", 18, 20], ["CD40", "ANATOMY", 25, 29], ["prevented", "UNCERTAINTY", 128, 137], ["monocytic", "OBSERVATION_MODIFIER", 138, 147], ["lymphocytic", "OBSERVATION_MODIFIER", 152, 163], ["lung", "ANATOMY", 164, 168], ["infiltration", "OBSERVATION", 169, 181]]], ["However, the non-CD40-targeted vaccine (rAd5-S1) uniformly induced varying degrees of severe perivascular hemorrhage within the lungs of all examined mice following viral challenge, regardless of the exhibited full protection against lethal MERS-CoV challenge.", [["perivascular", "ANATOMY", 93, 105], ["lungs", "ANATOMY", 128, 133], ["perivascular hemorrhage", "DISEASE", 93, 116], ["non-CD40", "GENE_OR_GENE_PRODUCT", 13, 21], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 40, 47], ["perivascular hemorrhage", "PATHOLOGICAL_FORMATION", 93, 116], ["lungs", "ORGAN", 128, 133], ["mice", "ORGANISM", 150, 154], ["MERS-CoV", "ORGANISM", 241, 249], ["non-CD40", "PROTEIN", 13, 21], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 150, 154], ["MERS-CoV", "SPECIES", 241, 249], ["the non-CD40-targeted vaccine", "TREATMENT", 9, 38], ["severe perivascular hemorrhage", "PROBLEM", 86, 116], ["viral challenge", "TREATMENT", 165, 180], ["CoV challenge", "TREATMENT", 246, 259], ["varying", "OBSERVATION_MODIFIER", 67, 74], ["degrees", "OBSERVATION_MODIFIER", 75, 82], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["perivascular", "ANATOMY_MODIFIER", 93, 105], ["hemorrhage", "OBSERVATION", 106, 116], ["lungs", "ANATOMY", 128, 133]]], ["While these data suggest that there might be yet to be explained lung pathology associated with rAd5 vector\u2013 and/or MERS-CoV S1\u2013based vaccines, our results clearly show that including CD40L as a fusion protein of S1-based MERS-CoV vaccine could prevent or at least mitigate the safety concern of undesirable immunopathology while affording complete protection in hDPP4 Tg+ mice.DISCUSSIONAt least 3 groups have developed different rAd-vectored MERS-CoV vaccines [14, 41, 42].", [["lung", "ANATOMY", 65, 69], ["immunopathology", "DISEASE", 308, 323], ["lung", "ORGAN", 65, 69], ["rAd5", "GENE_OR_GENE_PRODUCT", 96, 100], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 116, 124], ["CD40L", "GENE_OR_GENE_PRODUCT", 184, 189], ["S1", "GENE_OR_GENE_PRODUCT", 213, 215], ["MERS-CoV", "ORGANISM", 222, 230], ["hDPP4 Tg+ mice", "ORGANISM", 363, 377], ["MERS-CoV", "ORGANISM", 444, 452], ["CD40L", "PROTEIN", 184, 189], ["fusion protein", "PROTEIN", 195, 209], ["S1", "PROTEIN", 213, 215], ["mice", "SPECIES", 373, 377], ["MERS-CoV", "SPECIES", 116, 124], ["MERS-CoV", "SPECIES", 222, 230], ["mice", "SPECIES", 373, 377], ["MERS-CoV", "SPECIES", 444, 452], ["lung pathology", "PROBLEM", 65, 79], ["rAd5 vector\u2013", "TREATMENT", 96, 108], ["CoV S1\u2013based vaccines", "TREATMENT", 121, 142], ["CD40L", "TREATMENT", 184, 189], ["a fusion protein", "TEST", 193, 209], ["CoV vaccine", "TREATMENT", 227, 238], ["undesirable immunopathology", "PROBLEM", 296, 323], ["CoV vaccines", "TREATMENT", 449, 461], ["lung", "ANATOMY", 65, 69], ["pathology", "OBSERVATION", 70, 79]]], ["However, these studies have mainly focused on the immunogenicity and/or the protective efficacy, and may have overlooked any possible vaccine-associated pathology, especially after viral challenge.", [["these studies", "TEST", 9, 22], ["associated pathology", "PROBLEM", 142, 162], ["viral challenge", "TREATMENT", 181, 196], ["pathology", "OBSERVATION", 153, 162]]], ["Our finding that rAd5-S1 immunized animals were completely protected despite the observed pathology is reminiscent of the immunopathology documented using WIV for MERS-CoV, SARS-CoV, and respiratory syncytial virus after viral challenge [19\u201328, 43\u201345].", [["respiratory syncytial virus", "DISEASE", 187, 214], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 17, 24], ["animals", "ORGANISM", 35, 42], ["MERS-CoV", "ORGANISM", 163, 171], ["SARS-CoV", "ORGANISM", 173, 181], ["respiratory syncytial virus", "ORGANISM", 187, 214], ["rAd5", "PROTEIN", 17, 21], ["respiratory syncytial virus", "SPECIES", 187, 214], ["WIV", "SPECIES", 155, 158], ["MERS-CoV", "SPECIES", 163, 171], ["SARS-CoV", "SPECIES", 173, 181], ["respiratory syncytial virus", "SPECIES", 187, 214], ["the immunopathology", "PROBLEM", 118, 137], ["MERS", "PROBLEM", 163, 167], ["CoV", "TEST", 168, 171], ["SARS", "PROBLEM", 173, 177], ["CoV", "TEST", 178, 181], ["respiratory syncytial virus", "PROBLEM", 187, 214], ["viral challenge", "TEST", 221, 236], ["respiratory syncytial", "ANATOMY", 187, 208]]], ["It is of note that lung pathology was also observed in some previous studies involving rhesus macaques immunized with high doses of DNA vaccines expressing MERS-CoV S protein [16], as well as in mouse models vaccinated with RBD or vectored vaccines encoding S protein [46\u201348].", [["lung", "ANATOMY", 19, 23], ["RBD", "DISEASE", 224, 227], ["lung", "ORGAN", 19, 23], ["rhesus", "ORGANISM", 87, 93], ["macaques", "ORGANISM", 94, 102], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 156, 166], ["mouse", "ORGANISM", 195, 200], ["MERS-CoV S protein", "PROTEIN", 156, 174], ["RBD", "PROTEIN", 224, 227], ["S protein", "PROTEIN", 258, 267], ["rhesus macaques", "SPECIES", 87, 102], ["mouse", "SPECIES", 195, 200], ["rhesus macaques", "SPECIES", 87, 102], ["MERS-CoV", "SPECIES", 156, 164], ["mouse", "SPECIES", 195, 200], ["lung pathology", "PROBLEM", 19, 33], ["rhesus macaques", "TREATMENT", 87, 102], ["DNA vaccines", "TREATMENT", 132, 144], ["CoV S protein", "TEST", 161, 174], ["RBD", "PROBLEM", 224, 227], ["vectored vaccines", "TREATMENT", 231, 248], ["lung", "ANATOMY", 19, 23], ["pathology", "OBSERVATION", 24, 33]]], ["Nevertheless, this is the first report of vaccine-associated severe pulmonary perivascular hemorrhage after viral challenge.", [["pulmonary perivascular", "ANATOMY", 68, 90], ["pulmonary perivascular hemorrhage", "DISEASE", 68, 101], ["pulmonary", "PATHOLOGICAL_FORMATION", 68, 77], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 90], ["vaccine", "TREATMENT", 42, 49], ["severe pulmonary perivascular hemorrhage", "PROBLEM", 61, 101], ["viral challenge", "TREATMENT", 108, 123], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["pulmonary", "ANATOMY", 68, 77], ["perivascular", "ANATOMY_MODIFIER", 78, 90], ["hemorrhage", "OBSERVATION", 91, 101], ["viral challenge", "OBSERVATION", 108, 123]]], ["Although the exact molecular mechanisms underlying such vaccine-induced pulmonary injury associated with rAd5-S1 vaccination remain to be determined, several factors could have been involved.", [["pulmonary", "ANATOMY", 72, 81], ["pulmonary injury", "DISEASE", 72, 88], ["pulmonary", "ORGAN", 72, 81], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 105, 112], ["rAd5", "PROTEIN", 105, 109], ["such vaccine", "TREATMENT", 51, 63], ["pulmonary injury", "PROBLEM", 72, 88], ["rAd5-S1 vaccination", "TREATMENT", 105, 124], ["pulmonary", "ANATOMY", 72, 81], ["injury", "OBSERVATION", 82, 88]]], ["Specifically, the likely higher levels of residual infectious viruses in rAd5-S1\u2013immunized mice as detected by RT-qPCR, and the quantitative and perhaps qualitative difference of specific antibody and T-cell responses, as evidenced by the lower levels of Ig2a and IgG2b found in this group, could have played a role.", [["T-cell", "ANATOMY", 201, 207], ["rAd5-S1\u2013immunized mice", "ORGANISM", 73, 95], ["T-cell", "CELL", 201, 207], ["Ig2a", "GENE_OR_GENE_PRODUCT", 255, 259], ["IgG2b", "GENE_OR_GENE_PRODUCT", 264, 269], ["Ig2a", "PROTEIN", 255, 259], ["IgG2b", "PROTEIN", 264, 269], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["residual infectious viruses", "PROBLEM", 42, 69], ["RT-qPCR", "TEST", 111, 118], ["specific antibody", "TEST", 179, 196], ["the lower levels of Ig2a", "PROBLEM", 235, 259], ["IgG2b", "PROBLEM", 264, 269], ["likely", "UNCERTAINTY", 18, 24], ["higher", "OBSERVATION_MODIFIER", 25, 31], ["levels", "OBSERVATION_MODIFIER", 32, 38], ["residual", "OBSERVATION_MODIFIER", 42, 50], ["infectious", "OBSERVATION_MODIFIER", 51, 61], ["viruses", "OBSERVATION", 62, 69], ["lower", "ANATOMY_MODIFIER", 239, 244]]], ["Therefore, future studies should include systematic analyses of T-cell responses as we have previously conducted [37, 38], to fully explore the mechanisms of immunization-induced hemorrhage of the lungs.", [["T-cell", "ANATOMY", 64, 70], ["lungs", "ANATOMY", 197, 202], ["hemorrhage", "DISEASE", 179, 189], ["T-cell", "CELL", 64, 70], ["lungs", "ORGAN", 197, 202], ["future studies", "TEST", 11, 25], ["systematic analyses", "TEST", 41, 60], ["immunization", "TREATMENT", 158, 170], ["hemorrhage of the lungs", "PROBLEM", 179, 202], ["hemorrhage", "OBSERVATION", 179, 189], ["lungs", "ANATOMY", 197, 202]]], ["Collectively, these previous data, along with our report here, indicate that viral components (ie, within the S protein) could be involved in inadvertent adverse reactions similar to those associated with the different S-based SARS vaccines [19\u201328].DISCUSSIONOur study suggests that although rAd5-S1 could be a potential vaccine candidate, it might be associated with severe lung pathology upon viral challenge or infection.", [["lung", "ANATOMY", 375, 379], ["SARS", "DISEASE", 227, 231], ["infection", "DISEASE", 414, 423], ["rAd5-S1", "GENE_OR_GENE_PRODUCT", 292, 299], ["lung", "ORGAN", 375, 379], ["S protein", "PROTEIN", 110, 119], ["rAd5", "PROTEIN", 292, 296], ["S1", "PROTEIN", 297, 299], ["these previous data", "TEST", 14, 33], ["viral components", "PROBLEM", 77, 93], ["inadvertent adverse reactions", "PROBLEM", 142, 171], ["the different S-based SARS vaccines", "TREATMENT", 205, 240], ["DISCUSSIONOur study", "TEST", 249, 268], ["severe lung pathology", "PROBLEM", 368, 389], ["viral challenge", "PROBLEM", 395, 410], ["infection", "PROBLEM", 414, 423], ["viral", "OBSERVATION", 77, 82], ["might be associated with", "UNCERTAINTY", 343, 367], ["severe", "OBSERVATION_MODIFIER", 368, 374], ["lung", "ANATOMY", 375, 379], ["pathology", "OBSERVATION", 380, 389], ["viral", "OBSERVATION_MODIFIER", 395, 400], ["infection", "OBSERVATION", 414, 423]]], ["These findings are of great importance in order to develop safe and effective human MERS-CoV vaccine.", [["human", "ORGANISM", 78, 83], ["MERS-CoV", "ORGANISM", 84, 92], ["human", "SPECIES", 78, 83], ["human MERS-CoV", "SPECIES", 78, 92], ["CoV vaccine", "TREATMENT", 89, 100]]], ["Moreover, there is a huge gap in our understanding of the correlates of protection in camels, and the waning nature of nAbs in these animals [49, 50] might hinder the \u201cOne Health\u201d approach in tackling the MERS epidemic.", [["nAbs", "GENE_OR_GENE_PRODUCT", 119, 123], ["a huge gap", "PROBLEM", 19, 29], ["huge", "OBSERVATION_MODIFIER", 21, 25], ["gap", "OBSERVATION", 26, 29], ["MERS", "OBSERVATION", 205, 209]]], ["Therefore, it is critical to better understand and elucidate any safety concerns that might be associated with MERS-CoV vaccine to develop a safe and effective human vaccine.", [["MERS-CoV", "ORGANISM", 111, 119], ["human", "ORGANISM", 160, 165], ["human", "SPECIES", 160, 165], ["MERS-CoV", "SPECIES", 111, 119], ["human", "SPECIES", 160, 165], ["MERS-CoV vaccine", "TREATMENT", 111, 127], ["a safe and effective human vaccine", "TREATMENT", 139, 173]]], ["Our previous studies have mainly focused on the development of candidate universal influenza vaccines using vectored vaccines by targeting antigens to CD40-expressing cells via CD40L.", [["cells", "ANATOMY", 167, 172], ["CD40", "GENE_OR_GENE_PRODUCT", 151, 155], ["cells", "CELL", 167, 172], ["CD40L", "GENE_OR_GENE_PRODUCT", 177, 182], ["CD40", "PROTEIN", 151, 155], ["expressing cells", "CELL_TYPE", 156, 172], ["CD40L", "PROTEIN", 177, 182], ["Our previous studies", "TEST", 0, 20], ["universal influenza vaccines", "TREATMENT", 73, 101], ["vectored vaccines", "TREATMENT", 108, 125], ["CD40", "TEST", 151, 155]]], ["This platform was modified, optimized, and utilized to generate an immunogenic, protective, and safe MERS-CoV vaccine based on the S1 subunit of the MERS-CoV S protein, thus representing a promising platform for vaccine development against a broad range of pathogens.", [["MERS-CoV", "ORGANISM", 101, 109], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 149, 159], ["S1 subunit", "PROTEIN", 131, 141], ["MERS-CoV S protein", "PROTEIN", 149, 167], ["MERS-CoV", "SPECIES", 101, 109], ["MERS-CoV", "SPECIES", 149, 157], ["safe MERS-CoV vaccine", "TREATMENT", 96, 117], ["CoV S protein", "TEST", 154, 167], ["vaccine", "TREATMENT", 212, 219], ["pathogens", "PROBLEM", 257, 266]]]]}